diff --git "a/oms/vec_who_2/storage_nodes/docstore.json" "b/oms/vec_who_2/storage_nodes/docstore.json"
deleted file mode 100644--- "a/oms/vec_who_2/storage_nodes/docstore.json"
+++ /dev/null
@@ -1 +0,0 @@
-{"docstore/data": {"4131d99d-1dab-4e76-bcd5-465cf5e89648": {"__data__": {"id_": "4131d99d-1dab-4e76-bcd5-465cf5e89648", "embedding": null, "metadata": {"page_label": "1", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido que podr\u00eda estar relacionado:\n\n### Resumen del Contexto\nEl documento mencionado es el \"WHO - Technical Report Series 957\", que forma parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica, y recomendaciones para pr\u00e1cticas de salud a nivel global. Sin embargo, en este caso espec\u00edfico, no se proporciona contenido detallado en el texto extra\u00eddo.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los principales temas o \u00e1reas de enfoque abordados en el informe t\u00e9cnico de la OMS en la serie 957?**\n   - Esta pregunta busca identificar los temas espec\u00edficos que se discuten en el informe, que podr\u00edan incluir enfermedades, pol\u00edticas de salud, o recomendaciones para la pr\u00e1ctica m\u00e9dica.\n\n2. **\u00bfQu\u00e9 recomendaciones espec\u00edficas se hacen en el informe WHO TRS 957 para mejorar la salud p\u00fablica a nivel global?**\n   - Esta pregunta se centra en las recomendaciones pr\u00e1cticas que la OMS podr\u00eda ofrecer en el informe, que son cruciales para la implementaci\u00f3n de pol\u00edticas de salud efectivas.\n\n3. **\u00bfC\u00f3mo se compara el contenido del informe WHO TRS 957 con otros informes anteriores de la serie t\u00e9cnica de la OMS?**\n   - Esta pregunta busca establecer un contexto comparativo que podr\u00eda revelar tendencias en la investigaci\u00f3n y las recomendaciones de la OMS a lo largo del tiempo.\n\nEstas preguntas est\u00e1n dise\u00f1adas para obtener informaci\u00f3n espec\u00edfica que probablemente no se encuentre f\u00e1cilmente en otros documentos o fuentes, dado que se centran en el contenido particular del informe t\u00e9cnico mencionado.", "excerpt_keywords": "Keywords: OMS, salud p\u00fablica, informe t\u00e9cnico, recomendaciones, investigaci\u00f3n m\u00e9dica"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e6d5325e-bdd2-47ab-b611-6aa0165f3552", "node_type": "4", "metadata": {"page_label": "1", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "441f993a-a697-4ca8-a84e-800acc7a1abf": {"__data__": {"id_": "441f993a-a697-4ca8-a84e-800acc7a1abf", "embedding": null, "metadata": {"page_label": "2", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO\u2019s constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.\n\nThe Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization\u2019s priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO\u2019s Member countries and the collaboration of world leaders in public health and the biomedical sciences.\n\nTo ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO\u2019s books contribute to achieving the Organization\u2019s principal objective \u2014 the attainment by all people of the highest possible level of health.\n\n----\n\nThe *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about six such reports, costs CHF/US$ 188.00 (CHF/US$ 143.00 in developing countries). For further information, please contact WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int; order online at http://www.who.int/bookorders).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nLa Organizaci\u00f3n Mundial de la Salud (OMS) fue establecida en 1948 como una agencia especializada de las Naciones Unidas, con el objetivo de ser la autoridad coordinadora en asuntos de salud internacional y salud p\u00fablica. La OMS tiene la responsabilidad de proporcionar informaci\u00f3n objetiva y confiable en el campo de la salud humana, lo que realiza a trav\u00e9s de una amplia gama de publicaciones. Estas publicaciones buscan apoyar las estrategias de salud nacionales y abordar preocupaciones de salud p\u00fablica a nivel global, ofreciendo manuales, gu\u00edas, an\u00e1lisis de pol\u00edticas y recomendaciones t\u00e9cnicas. La serie de informes t\u00e9cnicos de la OMS presenta hallazgos de grupos de expertos que brindan asesoramiento cient\u00edfico y t\u00e9cnico sobre diversos temas de salud. La OMS tambi\u00e9n se esfuerza por asegurar la distribuci\u00f3n internacional de sus publicaciones y fomentar su traducci\u00f3n y adaptaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los tipos de publicaciones que la OMS ofrece para apoyar a los trabajadores de la salud y a los pa\u00edses en desarrollo?**\n   - La OMS publica manuales pr\u00e1cticos, gu\u00edas internacionales, an\u00e1lisis de pol\u00edticas y programas, y reportes de consenso que ofrecen recomendaciones t\u00e9cnicas.\n\n2. **\u00bfQu\u00e9 costo tiene una suscripci\u00f3n anual a la *Serie de Informes T\u00e9cnicos de la OMS* y c\u00f3mo var\u00eda seg\u00fan el nivel de desarrollo del pa\u00eds?**\n   - Una suscripci\u00f3n anual cuesta CHF/US$ 188.00, y CHF/US$ 143.00 en pa\u00edses en desarrollo.\n\n3. **\u00bfC\u00f3mo asegura la OMS la disponibilidad de informaci\u00f3n y gu\u00edas sobre salud a nivel internacional?**\n   - La OMS asegura la amplia distribuci\u00f3n internacional de sus publicaciones y fomenta su traducci\u00f3n y adaptaci\u00f3n para alcanzar una mayor disponibilidad de informaci\u00f3n autorizada sobre salud.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 957\" es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque el contenido espec\u00edfico no est\u00e1 disponible en el extracto proporcionado, se pueden inferir algunos temas clave y entidades relevantes:\n\n#### Temas Clave\n1. **Salud P\u00fablica**: El informe probablemente aborda cuestiones relacionadas con la salud p\u00fablica a nivel global, incluyendo enfermedades, prevenci\u00f3n y control de epidemias.\n2. **Investigaci\u00f3n M\u00e9dica**: Es posible que se discutan avances en la investigaci\u00f3n m\u00e9dica y su aplicaci\u00f3n en pol\u00edticas de salud.\n3. **Recomendaciones de Salud**: El informe podr\u00eda incluir recomendaciones para mejorar pr\u00e1cticas de salud y pol\u00edticas en diferentes contextos.\n\n#### Entidades\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la publicaci\u00f3n del informe, que se dedica a coordinar esfuerzos internacionales en salud p\u00fablica.\n- **Informe T\u00e9cnico**: El documento en s\u00ed, que forma parte de una serie m\u00e1s amplia de informes t\u00e9cnicos que la OMS publica regularmente.\n\nEste resumen proporciona una visi\u00f3n general de los posibles temas y entidades que podr\u00edan estar presentes en el informe, a pesar de la falta de contenido espec\u00edfico en el extracto.", "excerpt_keywords": "Keywords: World Health Organization, public health, technical reports, health publications, disease prevention"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6c5e5cef-722b-4ab8-aa76-f7735b954206", "node_type": "4", "metadata": {"page_label": "2", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO\u2019s constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.\n\nThe Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization\u2019s priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO\u2019s Member countries and the collaboration of world leaders in public health and the biomedical sciences.\n\nTo ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO\u2019s books contribute to achieving the Organization\u2019s principal objective \u2014 the attainment by all people of the highest possible level of health.\n\n----\n\nThe *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about six such reports, costs CHF/US$ 188.00 (CHF/US$ 143.00 in developing countries). For further information, please contact WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int; order online at http://www.who.int/bookorders).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "f9693d97a57d649ca61cf7cffed718fe05d86bb77c3a15c9701c7eda0fc78d36", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO\u2019s constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.\n\nThe Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization\u2019s priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO\u2019s Member countries and the collaboration of world leaders in public health and the biomedical sciences.\n\nTo ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO\u2019s books contribute to achieving the Organization\u2019s principal objective \u2014 the attainment by all people of the highest possible level of health.\n\n----\n\nThe *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about six such reports, costs CHF/US$ 188.00 (CHF/US$ 143.00 in developing countries). For further information, please contact WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int; order online at http://www.who.int/bookorders).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2820, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "49eeb952-0fe1-4ced-a73a-c8be3173b2b1": {"__data__": {"id_": "49eeb952-0fe1-4ced-a73a-c8be3173b2b1", "embedding": null, "metadata": {"page_label": "3", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido:\n\n### Resumen del Contexto\nEl documento mencionado es el \"WHO - Technical Report Series 957\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica y recomendaciones para pr\u00e1cticas de salud a nivel global. Sin embargo, en este caso espec\u00edfico, no se proporciona contenido detallado en el texto extra\u00eddo.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los principales temas o \u00e1reas de enfoque abordados en el informe t\u00e9cnico de la OMS, \"Technical Report Series 957\"?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el contenido del informe, que podr\u00eda incluir temas de salud p\u00fablica, pol\u00edticas de salud, o investigaciones relevantes.\n\n2. **\u00bfQu\u00e9 recomendaciones o directrices espec\u00edficas se presentan en el \"Technical Report Series 957\" para mejorar la salud p\u00fablica a nivel global?**\n   - Aqu\u00ed se indaga sobre las posibles recomendaciones que la OMS podr\u00eda haber hecho en este informe, lo que podr\u00eda ser \u00fatil para profesionales de la salud y responsables de pol\u00edticas.\n\n3. **\u00bfC\u00f3mo se relaciona el \"Technical Report Series 957\" con otros informes de la OMS en t\u00e9rminos de continuidad de investigaci\u00f3n o evoluci\u00f3n de pol\u00edticas de salud?**\n   - Esta pregunta busca establecer conexiones entre este informe y otros documentos de la OMS, lo que podr\u00eda ayudar a entender la evoluci\u00f3n de las recomendaciones y pol\u00edticas de salud a lo largo del tiempo.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que podr\u00eda no estar disponible en otros documentos o fuentes, dado que el contenido del informe no se ha proporcionado en el contexto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**:\n   - Establecida en 1948 como agencia especializada de las Naciones Unidas.\n   - Funci\u00f3n principal: autoridad coordinadora en asuntos de salud internacional y salud p\u00fablica.\n\n2. **Publicaciones de la OMS**:\n   - Proporciona informaci\u00f3n objetiva y confiable en salud humana.\n   - Tipos de publicaciones:\n     - Manuales pr\u00e1cticos y material de capacitaci\u00f3n para trabajadores de la salud.\n     - Gu\u00edas y est\u00e1ndares internacionalmente aplicables.\n     - An\u00e1lisis de pol\u00edticas y programas de salud.\n     - Reportes de consenso con recomendaciones t\u00e9cnicas.\n\n3. **Objetivos de las Publicaciones**:\n   - Apoyar estrategias de salud nacionales.\n   - Abordar preocupaciones de salud p\u00fablica global.\n   - Promover la prevenci\u00f3n de enfermedades y el desarrollo de sistemas de salud equitativos.\n\n4. **Distribuci\u00f3n y Accesibilidad**:\n   - Asegura la distribuci\u00f3n internacional de sus publicaciones.\n   - Fomenta la traducci\u00f3n y adaptaci\u00f3n de materiales para mayor disponibilidad.\n\n5. **Serie de Informes T\u00e9cnicos de la OMS**:\n   - Presenta hallazgos de grupos de expertos en temas de salud.\n   - Suscripci\u00f3n anual: CHF/US$ 188.00 (CHF/US$ 143.00 en pa\u00edses en desarrollo).\n\n6. **Contacto**:\n   - Informaci\u00f3n de contacto para suscripciones y consultas: WHO Press, Ginebra, Suiza.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**\n- **Naciones Unidas**\n- **Expertos internacionales en salud p\u00fablica**\n- **Pa\u00edses en desarrollo** \n\nEste resumen destaca la misi\u00f3n de la OMS, la variedad de sus publicaciones y su compromiso con la salud global, as\u00ed como detalles sobre la suscripci\u00f3n a su serie de informes t\u00e9cnicos.", "excerpt_keywords": "Keywords: OMS, salud p\u00fablica, informes t\u00e9cnicos, recomendaciones, pol\u00edticas de salud"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8d0b0a58-a1d8-4779-a673-b12be1a022ac", "node_type": "4", "metadata": {"page_label": "3", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "19793f11-d73e-435d-9bd8-7a245690f691": {"__data__": {"id_": "19793f11-d73e-435d-9bd8-7a245690f691", "embedding": null, "metadata": {"page_label": "4", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# WHO Library Cataloguing-in-Publication Data\n\nForty-fourth report of the WHO Expert Committee on specifications for pharmaceutical preparations.\n\n(WHO technical report series; no. 957)\n\n1. Pharmaceutical preparations \u2014 standards. 2. Technology, Pharmaceuticals \u2014 standards. 3. Drug industry \u2014 legislation. 4. Quality control. I. World Health Organization. II. Series.\n\nISBN 978 92 4 120957 1  \nISSN 0512-3054  \n(NLM classification: QV 771)\n\n----\n\n\u00a9 World Health Organization 2010\n\nAll rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications\u2014whether for sale or for noncommercial distribution\u2014should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).\n\nThe designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.\n\nThe mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.\n\nAll reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.\n\nThis publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.\n\n*Typeset in Switzerland*  \n*Printed in Switzerland*", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es el \"Cuarenta y cuarto informe del Comit\u00e9 de Expertos de la OMS sobre especificaciones para preparaciones farmac\u00e9uticas\", publicado en la serie de informes t\u00e9cnicos de la OMS (n\u00famero 957). Este informe aborda est\u00e1ndares para preparaciones farmac\u00e9uticas, tecnolog\u00eda farmac\u00e9utica, legislaci\u00f3n en la industria farmac\u00e9utica y control de calidad. Se menciona que la publicaci\u00f3n contiene las opiniones colectivas de un grupo internacional de expertos y no necesariamente representa las decisiones o pol\u00edticas de la OMS. Adem\u00e1s, se incluyen detalles sobre derechos de autor, contacto para pedidos y permisos, y una declaraci\u00f3n de responsabilidad sobre la informaci\u00f3n presentada.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los temas principales abordados en el informe del Comit\u00e9 de Expertos de la OMS sobre especificaciones para preparaciones farmac\u00e9uticas?**\n   - Respuesta: Los temas principales incluyen est\u00e1ndares para preparaciones farmac\u00e9uticas, tecnolog\u00eda farmac\u00e9utica, legislaci\u00f3n en la industria farmac\u00e9utica y control de calidad.\n\n2. **\u00bfQu\u00e9 advertencias se hacen sobre la informaci\u00f3n contenida en la publicaci\u00f3n y la responsabilidad del lector?**\n   - Respuesta: Se advierte que la informaci\u00f3n se distribuye sin garant\u00eda de ning\u00fan tipo y que la responsabilidad de la interpretaci\u00f3n y uso del material recae en el lector. La OMS no ser\u00e1 responsable de da\u00f1os derivados del uso de la informaci\u00f3n.\n\n3. **\u00bfQu\u00e9 se indica sobre la menci\u00f3n de productos o empresas espec\u00edficas en el informe?**\n   - Respuesta: La menci\u00f3n de productos o empresas no implica que sean respaldados o recomendados por la OMS en preferencia a otros productos similares que no se mencionan. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no ser f\u00e1cilmente accesible en otros documentos o fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento mencionado, \"WHO - Technical Report Series 957\", es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque el contenido espec\u00edfico no est\u00e1 disponible en el texto extra\u00eddo, se pueden inferir algunos temas y entidades clave:\n\n#### Temas Clave\n1. **Salud P\u00fablica**: El informe probablemente aborda cuestiones relevantes para la salud p\u00fablica a nivel global, incluyendo pol\u00edticas, pr\u00e1cticas y recomendaciones.\n2. **Investigaci\u00f3n M\u00e9dica**: Es posible que el documento incluya hallazgos de investigaciones recientes en el campo de la salud.\n3. **Recomendaciones de la OMS**: Se espera que el informe contenga directrices o recomendaciones para mejorar la salud p\u00fablica y guiar a los profesionales de la salud.\n\n#### Entidades\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la publicaci\u00f3n del informe, que se dedica a coordinar esfuerzos internacionales en salud p\u00fablica.\n- **Technical Report Series**: La serie a la que pertenece este informe, que incluye m\u00faltiples documentos t\u00e9cnicos sobre diversos temas de salud.\n\nEste resumen proporciona una visi\u00f3n general de los posibles temas y entidades relevantes en el contexto del informe, a pesar de la falta de contenido espec\u00edfico en el texto extra\u00eddo.", "excerpt_keywords": "Pharmaceutical preparations, Quality control, WHO Expert Committee, Drug industry legislation, Technical report series"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "12fadc77-0e2f-4907-8a90-9ae6f59152a3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# WHO Library Cataloguing-in-Publication Data\n\nForty-fourth report of the WHO Expert Committee on specifications for pharmaceutical preparations.\n\n(WHO technical report series; no. 957)\n\n1. Pharmaceutical preparations \u2014 standards. 2. Technology, Pharmaceuticals \u2014 standards. 3. Drug industry \u2014 legislation. 4. Quality control. I. World Health Organization. II. Series.\n\nISBN 978 92 4 120957 1  \nISSN 0512-3054  \n(NLM classification: QV 771)\n\n----\n\n\u00a9 World Health Organization 2010\n\nAll rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications\u2014whether for sale or for noncommercial distribution\u2014should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).\n\nThe designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.\n\nThe mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.\n\nAll reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.\n\nThis publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.\n\n*Typeset in Switzerland*  \n*Printed in Switzerland*", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a4507689b7e1477321200822a53a7da734ca35bb62a3f841b20ab4e6bc4aa1af", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# WHO Library Cataloguing-in-Publication Data\n\nForty-fourth report of the WHO Expert Committee on specifications for pharmaceutical preparations.\n\n(WHO technical report series; no. 957)\n\n1. Pharmaceutical preparations \u2014 standards. 2. Technology, Pharmaceuticals \u2014 standards. 3. Drug industry \u2014 legislation. 4. Quality control. I. World Health Organization. II. Series.\n\nISBN 978 92 4 120957 1  \nISSN 0512-3054  \n(NLM classification: QV 771)\n\n----\n\n\u00a9 World Health Organization 2010\n\nAll rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications\u2014whether for sale or for noncommercial distribution\u2014should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).\n\nThe designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.\n\nThe mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.\n\nAll reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.\n\nThis publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.\n\n*Typeset in Switzerland*  \n*Printed in Switzerland*", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2399, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "975f072c-b766-4ceb-8b61-0d754f1bf738": {"__data__": {"id_": "975f072c-b766-4ceb-8b61-0d754f1bf738", "embedding": null, "metadata": {"page_label": "5", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Contents\n\n1. **Introduction**  \n   1\n\n2. **General policy**  \n   3  \n   2.1 International collaboration  \n   3  \n   2.1.1 International organizations, agencies and nongovernmental organizations  \n   3  \n   - European Directorate for the Quality of Medicines and HealthCare  \n     3  \n   - European Medicines Agency  \n     4  \n   - The Global Fund to Fight AIDS, Tuberculosis and Malaria  \n     4  \n   - Groupement International de la R\u00e9partition Pharmaceutique \u2014 European Association of Pharmaceutical Full-line Wholesalers  \n     4  \n   - International Federation of Pharmaceutical Manufacturers and Associations  \n     5  \n   - International Generic Pharmaceutical Alliance  \n     5  \n   - International Pharmaceutical Federation  \n     6  \n   - United Nations Children\u2019s Fund  \n     6  \n   2.1.2 Pharmacopoeial Discussion Group  \n   7  \n   2.1.3 International Conference on Harmonisation  \n   8  \n   2.1.4 International Conference of Drug Regulatory Authorities  \n   8  \n   2.2 Cross-cutting issues in pharmaceuticals \u2014 quality assurance issues  \n   9  \n   2.2.1 Herbal medicines  \n   9  \n   2.2.2 Biologicals and vaccines  \n   10  \n   2.2.3 Blood products  \n   11  \n   2.2.4 Essential medicines  \n   11  \n   2.2.5 Regulatory support  \n   13  \n   2.2.6 HIV-related activities  \n   14  \n   2.3 Counterfeit medicines  \n   14  \n\n3. **Quality control \u2014 specifications and tests**  \n   16  \n   3.1 *The International Pharmacopoeia*  \n   16  \n   3.2 Current work plan and future work programme  \n   19  \n   3.3 Specifications for medicines, including children\u2019s medicines  \n   23  \n   3.3.1 Medicines for HIV and related conditions  \n   23  \n   3.3.2 Antimalarial medicines  \n   23  \n   3.3.3 Antituberculosis medicines  \n   24  \n   3.3.4 Other medicines  \n   25  \n   3.4 Revision of texts of *The International Pharmacopoeia*  \n   26  \n   3.4.1 Antimalarials: artemisinin derivatives  \n   26  \n   3.4.2 Antibiotics  \n   27  \n   3.4.3 Other medicines  \n   28  \n   3.4.4 Heparin  \n   28  \n   3.5 Review of published general monographs for dosage forms  \n   29  \n   3.6 General policy topics and general revision issues  \n   30  \n   3.7 Radiopharmaceuticals  \n   33  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a generar preguntas m\u00e1s espec\u00edficas:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 957\" aborda temas relacionados con la pol\u00edtica general en el \u00e1mbito farmac\u00e9utico, la colaboraci\u00f3n internacional, y la calidad y control de medicamentos. Se discuten diversas organizaciones internacionales y su papel en la regulaci\u00f3n y aseguramiento de la calidad de los medicamentos, as\u00ed como cuestiones espec\u00edficas como medicamentos esenciales, productos biol\u00f3gicos, y la lucha contra medicamentos falsificados. Tambi\u00e9n se detalla el trabajo en curso y los planes futuros para la elaboraci\u00f3n de especificaciones y pruebas de calidad, incluyendo la revisi\u00f3n de textos de la Farmacopea Internacional.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 papel desempe\u00f1an las organizaciones internacionales mencionadas en el documento en la regulaci\u00f3n de medicamentos y c\u00f3mo se coordinan entre s\u00ed?**\n   - Esta pregunta busca una respuesta detallada sobre la colaboraci\u00f3n y las funciones espec\u00edficas de las organizaciones como la EMA, el Global Fund, y otras, en el contexto de la regulaci\u00f3n farmac\u00e9utica.\n\n2. **\u00bfCu\u00e1les son los principales desaf\u00edos en la garant\u00eda de calidad de los medicamentos esenciales seg\u00fan el informe, y qu\u00e9 estrategias se proponen para abordarlos?**\n   - Esta pregunta se centra en los problemas espec\u00edficos que enfrenta la calidad de los medicamentos esenciales y las soluciones sugeridas en el documento.\n\n3. **\u00bfQu\u00e9 avances se han logrado en la revisi\u00f3n de textos de *La Farmacopea Internacional* y cu\u00e1les son las \u00e1reas prioritarias para futuras revisiones?**\n   - Esta pregunta busca informaci\u00f3n sobre el progreso en la actualizaci\u00f3n de la Farmacopea Internacional, as\u00ed como las \u00e1reas que requieren atenci\u00f3n inmediata, como los derivados de artemisinina y los antibi\u00f3ticos.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y detallada que probablemente no se encuentre f\u00e1cilmente en otras fuentes, bas\u00e1ndose en el contenido del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Est\u00e1ndares para Preparaciones Farmac\u00e9uticas:** El informe aborda las especificaciones y est\u00e1ndares necesarios para la calidad de las preparaciones farmac\u00e9uticas.\n2. **Tecnolog\u00eda Farmac\u00e9utica:** Se discuten las tecnolog\u00edas aplicadas en la industria farmac\u00e9utica y su estandarizaci\u00f3n.\n3. **Legislaci\u00f3n en la Industria Farmac\u00e9utica:** Se examinan las normativas y leyes que rigen la industria farmac\u00e9utica.\n4. **Control de Calidad:** Se enfatiza la importancia del control de calidad en la producci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos.\n\n**Entidades:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad responsable de la publicaci\u00f3n y del contenido del informe.\n- **Comit\u00e9 de Expertos de la OMS:** Grupo internacional de expertos que contribuye con sus opiniones y recomendaciones en el informe.\n- **WHO Press:** Entidad encargada de la distribuci\u00f3n de las publicaciones de la OMS.\n\n**Otros Detalles:**\n- **ISBN y ISSN:** Identificadores de la publicaci\u00f3n.\n- **Derechos de Autor:** Se menciona que todos los derechos est\u00e1n reservados y se proporcionan detalles de contacto para pedidos y permisos.\n- **Advertencias sobre la Informaci\u00f3n:** Se aclara que la informaci\u00f3n se distribuye sin garant\u00eda y que la responsabilidad de su uso recae en el lector. \n\nEste resumen proporciona una visi\u00f3n general de los temas tratados en el informe y las entidades involucradas en su creaci\u00f3n y distribuci\u00f3n.", "excerpt_keywords": "Keywords: pharmaceuticals, quality assurance, international collaboration, counterfeit medicines, pharmacopoeia"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "30fe9bc0-caf8-4f11-913f-90cc73eec111", "node_type": "4", "metadata": {"page_label": "5", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Contents\n\n1. **Introduction**  \n   1\n\n2. **General policy**  \n   3  \n   2.1 International collaboration  \n   3  \n   2.1.1 International organizations, agencies and nongovernmental organizations  \n   3  \n   - European Directorate for the Quality of Medicines and HealthCare  \n     3  \n   - European Medicines Agency  \n     4  \n   - The Global Fund to Fight AIDS, Tuberculosis and Malaria  \n     4  \n   - Groupement International de la R\u00e9partition Pharmaceutique \u2014 European Association of Pharmaceutical Full-line Wholesalers  \n     4  \n   - International Federation of Pharmaceutical Manufacturers and Associations  \n     5  \n   - International Generic Pharmaceutical Alliance  \n     5  \n   - International Pharmaceutical Federation  \n     6  \n   - United Nations Children\u2019s Fund  \n     6  \n   2.1.2 Pharmacopoeial Discussion Group  \n   7  \n   2.1.3 International Conference on Harmonisation  \n   8  \n   2.1.4 International Conference of Drug Regulatory Authorities  \n   8  \n   2.2 Cross-cutting issues in pharmaceuticals \u2014 quality assurance issues  \n   9  \n   2.2.1 Herbal medicines  \n   9  \n   2.2.2 Biologicals and vaccines  \n   10  \n   2.2.3 Blood products  \n   11  \n   2.2.4 Essential medicines  \n   11  \n   2.2.5 Regulatory support  \n   13  \n   2.2.6 HIV-related activities  \n   14  \n   2.3 Counterfeit medicines  \n   14  \n\n3. **Quality control \u2014 specifications and tests**  \n   16  \n   3.1 *The International Pharmacopoeia*  \n   16  \n   3.2 Current work plan and future work programme  \n   19  \n   3.3 Specifications for medicines, including children\u2019s medicines  \n   23  \n   3.3.1 Medicines for HIV and related conditions  \n   23  \n   3.3.2 Antimalarial medicines  \n   23  \n   3.3.3 Antituberculosis medicines  \n   24  \n   3.3.4 Other medicines  \n   25  \n   3.4 Revision of texts of *The International Pharmacopoeia*  \n   26  \n   3.4.1 Antimalarials: artemisinin derivatives  \n   26  \n   3.4.2 Antibiotics  \n   27  \n   3.4.3 Other medicines  \n   28  \n   3.4.4 Heparin  \n   28  \n   3.5 Review of published general monographs for dosage forms  \n   29  \n   3.6 General policy topics and general revision issues  \n   30  \n   3.7 Radiopharmaceuticals  \n   33  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "17036837ec45ccd28230f4d033f57273ec118670e831dcc21b37d8934304cb4e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Contents\n\n1. **Introduction**  \n   1\n\n2. **General policy**  \n   3  \n   2.1 International collaboration  \n   3  \n   2.1.1 International organizations, agencies and nongovernmental organizations  \n   3  \n   - European Directorate for the Quality of Medicines and HealthCare  \n     3  \n   - European Medicines Agency  \n     4  \n   - The Global Fund to Fight AIDS, Tuberculosis and Malaria  \n     4  \n   - Groupement International de la R\u00e9partition Pharmaceutique \u2014 European Association of Pharmaceutical Full-line Wholesalers  \n     4  \n   - International Federation of Pharmaceutical Manufacturers and Associations  \n     5  \n   - International Generic Pharmaceutical Alliance  \n     5  \n   - International Pharmaceutical Federation  \n     6  \n   - United Nations Children\u2019s Fund  \n     6  \n   2.1.2 Pharmacopoeial Discussion Group  \n   7  \n   2.1.3 International Conference on Harmonisation  \n   8  \n   2.1.4 International Conference of Drug Regulatory Authorities  \n   8  \n   2.2 Cross-cutting issues in pharmaceuticals \u2014 quality assurance issues  \n   9  \n   2.2.1 Herbal medicines  \n   9  \n   2.2.2 Biologicals and vaccines  \n   10  \n   2.2.3 Blood products  \n   11  \n   2.2.4 Essential medicines  \n   11  \n   2.2.5 Regulatory support  \n   13  \n   2.2.6 HIV-related activities  \n   14  \n   2.3 Counterfeit medicines  \n   14  \n\n3. **Quality control \u2014 specifications and tests**  \n   16  \n   3.1 *The International Pharmacopoeia*  \n   16  \n   3.2 Current work plan and future work programme  \n   19  \n   3.3 Specifications for medicines, including children\u2019s medicines  \n   23  \n   3.3.1 Medicines for HIV and related conditions  \n   23  \n   3.3.2 Antimalarial medicines  \n   23  \n   3.3.3 Antituberculosis medicines  \n   24  \n   3.3.4 Other medicines  \n   25  \n   3.4 Revision of texts of *The International Pharmacopoeia*  \n   26  \n   3.4.1 Antimalarials: artemisinin derivatives  \n   26  \n   3.4.2 Antibiotics  \n   27  \n   3.4.3 Other medicines  \n   28  \n   3.4.4 Heparin  \n   28  \n   3.5 Review of published general monographs for dosage forms  \n   29  \n   3.6 General policy topics and general revision issues  \n   30  \n   3.7 Radiopharmaceuticals  \n   33", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2162, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "28b5a7f5-5d41-4cc9-b27b-137bb0fab6a5": {"__data__": {"id_": "28b5a7f5-5d41-4cc9-b27b-137bb0fab6a5", "embedding": null, "metadata": {"page_label": "6", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\n4. Quality control \u2014 international reference materials  \n   (International Chemical Reference Substances and  \n   International Infrared Reference Spectra)  \n   4.1 Annual report of the WHO Collaborating Centre 36  \n   4.2 Adoption of new International Chemical Reference Substances 36  \n   4.3 New institution for the establishment of international reference materials 36  \n\n5. Quality control \u2014 national laboratories  \n   5.1 External Quality Assurance Assessment Scheme 37  \n   5.2 WHO good practices for quality control laboratories 39  \n   5.3 WHO good practices for pharmaceutical microbiology laboratories 42  \n\n6. Quality assurance \u2014 good manufacturing practices  \n   6.1 WHO good manufacturing practices: main principles  \n       for pharmaceutical products 42  \n   6.2 WHO good manufacturing practices for active  \n       pharmaceutical ingredients 43  \n   6.3 WHO good manufacturing practices for pharmaceutical  \n       products containing hazardous substances 44  \n   6.4 WHO good manufacturing practices for sterile  \n       pharmaceutical products 44  \n   6.5 Updates of other WHO good manufacturing practices texts 45  \n   6.6 Good manufacturing practices for blood establishments 45  \n\n7. Quality assurance \u2014 new approaches  \n   7.1 Risk analysis 47  \n   7.2 WHO guidelines on technology transfer 48  \n\n8. Quality assurance \u2014 distribution and trade of pharmaceuticals  \n   8.1 WHO Certification Scheme on the quality of pharmaceutical  \n       products moving in international commerce 49  \n   8.2 WHO good distribution practices for pharmaceutical products 50  \n   8.3 Regulatory oversight on pharmaceutical cold chain management 51  \n\n9. Prequalification of priority essential medicines  \n   9.1 Prequalification Programme managed by WHO 52  \n   9.2 Guidelines on requalification of prequalified dossiers 57  \n   9.3 Guidelines for the preparation of a contract research  \n       organization master file 58  \n\n10. Nomenclature, terminology and databases  \n    10.1 Quality assurance terminology 59  \n    10.2 International nonproprietary names 61  \n    10.3 Pharmacopoeial references 61  \n\n11. Miscellaneous  \n    11.1 WHO Model List of Essential Medicines 62  \n    11.2 Update on stability 62  \n    11.3 Diethylene glycol 64  \n\n12. Summary and recommendations 65  \n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 957\" aborda diversos aspectos de la calidad y el control en la producci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos. Se centra en la calidad de los materiales de referencia internacionales, las buenas pr\u00e1cticas de fabricaci\u00f3n, la evaluaci\u00f3n de la calidad en laboratorios nacionales, y la precalificaci\u00f3n de medicamentos esenciales. Tambi\u00e9n se discuten nuevas aproximaciones en la garant\u00eda de calidad, incluyendo el an\u00e1lisis de riesgos y la transferencia de tecnolog\u00eda. Adem\u00e1s, se abordan temas de nomenclatura y bases de datos relevantes para la industria farmac\u00e9utica.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son los principales principios de las buenas pr\u00e1cticas de fabricaci\u00f3n seg\u00fan la OMS para productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en el apartado 6.1 del documento, que detalla los principios fundamentales que deben seguirse en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 incluye el esquema de evaluaci\u00f3n externa de aseguramiento de calidad para laboratorios nacionales mencionado en el documento?**\n   - Esta pregunta se relaciona con el apartado 5.1, que describe el esquema de evaluaci\u00f3n y c\u00f3mo se implementa en los laboratorios nacionales.\n\n3. **\u00bfCu\u00e1les son las pautas para la preparaci\u00f3n de un archivo maestro de organizaci\u00f3n de investigaci\u00f3n por contrato seg\u00fan el documento?**\n   - Esta pregunta se refiere al apartado 9.3, que proporciona directrices espec\u00edficas sobre c\u00f3mo preparar un archivo maestro para organizaciones de investigaci\u00f3n que trabajan en la precalificaci\u00f3n de medicamentos esenciales. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y detallada que no se puede encontrar f\u00e1cilmente en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 957\" aborda varios temas fundamentales relacionados con la pol\u00edtica farmac\u00e9utica y la calidad de los medicamentos. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas en la secci\u00f3n:\n\n#### Temas Clave\n\n1. **Introducci\u00f3n**: Presenta el contexto general del informe y su relevancia en el \u00e1mbito de la salud p\u00fablica y la regulaci\u00f3n farmac\u00e9utica.\n\n2. **Pol\u00edtica General**:\n   - **Colaboraci\u00f3n Internacional**: Se discute la importancia de la cooperaci\u00f3n entre diversas organizaciones para mejorar la regulaci\u00f3n y la calidad de los medicamentos.\n   - **Cuestiones Transversales en Farmac\u00e9uticos**: Incluye temas como la garant\u00eda de calidad, medicamentos esenciales, productos biol\u00f3gicos, y la lucha contra medicamentos falsificados.\n\n3. **Control de Calidad**:\n   - **Especificaciones y Pruebas**: Se detalla el trabajo en curso y los planes futuros para la elaboraci\u00f3n de especificaciones de calidad, incluyendo la revisi\u00f3n de textos de *La Farmacopea Internacional*.\n\n#### Entidades Mencionadas\n\n- **Organizaciones Internacionales**:\n  - **European Directorate for the Quality of Medicines and HealthCare**\n  - **European Medicines Agency (EMA)**\n  - **The Global Fund to Fight AIDS, Tuberculosis and Malaria**\n  - **International Federation of Pharmaceutical Manufacturers and Associations**\n  - **International Generic Pharmaceutical Alliance**\n  - **International Pharmaceutical Federation**\n  - **United Nations Children\u2019s Fund (UNICEF)**\n\n- **Grupos de Discusi\u00f3n y Conferencias**:\n  - **Pharmacopoeial Discussion Group**\n  - **International Conference on Harmonisation**\n  - **International Conference of Drug Regulatory Authorities**\n\n#### Conclusi\u00f3n\n\nEl documento enfatiza la necesidad de colaboraci\u00f3n internacional y el establecimiento de est\u00e1ndares de calidad para garantizar la seguridad y eficacia de los medicamentos. Se abordan desaf\u00edos espec\u00edficos en la regulaci\u00f3n de medicamentos esenciales y se delinean planes para la revisi\u00f3n y actualizaci\u00f3n de las especificaciones de calidad en la Farmacopea Internacional.", "excerpt_keywords": "Keywords: quality control, good manufacturing practices, pharmaceutical microbiology, prequalification, international reference materials"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "88e4382f-b126-4d2b-9c9f-e955378d9fc7", "node_type": "4", "metadata": {"page_label": "6", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\n4. Quality control \u2014 international reference materials  \n   (International Chemical Reference Substances and  \n   International Infrared Reference Spectra)  \n   4.1 Annual report of the WHO Collaborating Centre 36  \n   4.2 Adoption of new International Chemical Reference Substances 36  \n   4.3 New institution for the establishment of international reference materials 36  \n\n5. Quality control \u2014 national laboratories  \n   5.1 External Quality Assurance Assessment Scheme 37  \n   5.2 WHO good practices for quality control laboratories 39  \n   5.3 WHO good practices for pharmaceutical microbiology laboratories 42  \n\n6. Quality assurance \u2014 good manufacturing practices  \n   6.1 WHO good manufacturing practices: main principles  \n       for pharmaceutical products 42  \n   6.2 WHO good manufacturing practices for active  \n       pharmaceutical ingredients 43  \n   6.3 WHO good manufacturing practices for pharmaceutical  \n       products containing hazardous substances 44  \n   6.4 WHO good manufacturing practices for sterile  \n       pharmaceutical products 44  \n   6.5 Updates of other WHO good manufacturing practices texts 45  \n   6.6 Good manufacturing practices for blood establishments 45  \n\n7. Quality assurance \u2014 new approaches  \n   7.1 Risk analysis 47  \n   7.2 WHO guidelines on technology transfer 48  \n\n8. Quality assurance \u2014 distribution and trade of pharmaceuticals  \n   8.1 WHO Certification Scheme on the quality of pharmaceutical  \n       products moving in international commerce 49  \n   8.2 WHO good distribution practices for pharmaceutical products 50  \n   8.3 Regulatory oversight on pharmaceutical cold chain management 51  \n\n9. Prequalification of priority essential medicines  \n   9.1 Prequalification Programme managed by WHO 52  \n   9.2 Guidelines on requalification of prequalified dossiers 57  \n   9.3 Guidelines for the preparation of a contract research  \n       organization master file 58  \n\n10. Nomenclature, terminology and databases  \n    10.1 Quality assurance terminology 59  \n    10.2 International nonproprietary names 61  \n    10.3 Pharmacopoeial references 61  \n\n11. Miscellaneous  \n    11.1 WHO Model List of Essential Medicines 62  \n    11.2 Update on stability 62  \n    11.3 Diethylene glycol 64  \n\n12. Summary and recommendations 65  \n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "3b114ad458541f4133c14bfafdb4dad7bbf74ab27a0e8bae48af4c588fe0b48c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "4. Quality control \u2014 international reference materials  \n   (International Chemical Reference Substances and  \n   International Infrared Reference Spectra)  \n   4.1 Annual report of the WHO Collaborating Centre 36  \n   4.2 Adoption of new International Chemical Reference Substances 36  \n   4.3 New institution for the establishment of international reference materials 36  \n\n5. Quality control \u2014 national laboratories  \n   5.1 External Quality Assurance Assessment Scheme 37  \n   5.2 WHO good practices for quality control laboratories 39  \n   5.3 WHO good practices for pharmaceutical microbiology laboratories 42  \n\n6. Quality assurance \u2014 good manufacturing practices  \n   6.1 WHO good manufacturing practices: main principles  \n       for pharmaceutical products 42  \n   6.2 WHO good manufacturing practices for active  \n       pharmaceutical ingredients 43  \n   6.3 WHO good manufacturing practices for pharmaceutical  \n       products containing hazardous substances 44  \n   6.4 WHO good manufacturing practices for sterile  \n       pharmaceutical products 44  \n   6.5 Updates of other WHO good manufacturing practices texts 45  \n   6.6 Good manufacturing practices for blood establishments 45  \n\n7. Quality assurance \u2014 new approaches  \n   7.1 Risk analysis 47  \n   7.2 WHO guidelines on technology transfer 48  \n\n8. Quality assurance \u2014 distribution and trade of pharmaceuticals  \n   8.1 WHO Certification Scheme on the quality of pharmaceutical  \n       products moving in international commerce 49  \n   8.2 WHO good distribution practices for pharmaceutical products 50  \n   8.3 Regulatory oversight on pharmaceutical cold chain management 51  \n\n9. Prequalification of priority essential medicines  \n   9.1 Prequalification Programme managed by WHO 52  \n   9.2 Guidelines on requalification of prequalified dossiers 57  \n   9.3 Guidelines for the preparation of a contract research  \n       organization master file 58  \n\n10. Nomenclature, terminology and databases  \n    10.1 Quality assurance terminology 59  \n    10.2 International nonproprietary names 61  \n    10.3 Pharmacopoeial references 61  \n\n11. Miscellaneous  \n    11.1 WHO Model List of Essential Medicines 62  \n    11.2 Update on stability 62  \n    11.3 Diethylene glycol 64  \n\n12. Summary and recommendations 65", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2284, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e44d2700-8361-410f-934c-6e2571538d92": {"__data__": {"id_": "e44d2700-8361-410f-934c-6e2571538d92", "embedding": null, "metadata": {"page_label": "7", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\nAnnex 1  \nWHO good practices for pharmaceutical quality control laboratories  81\n\nAnnex 2  \nWHO good manufacturing practices for active pharmaceutical ingredients  130\n\nAnnex 3  \nWHO good manufacturing practices for pharmaceutical products containing hazardous substances  192\n\nAnnex 4  \nWHO good manufacturing practices for sterile pharmaceutical products  209\n\nAnnex 5  \nWHO good distribution practices for pharmaceutical products  235\n\nAnnex 6  \nGuidelines on the requalification of prequalified dossiers  265\n\nAnnex 7  \nGuidelines for the preparation of a contract research organization master file  271\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 957\" incluye varios anexos que abordan buenas pr\u00e1cticas y directrices relacionadas con la calidad y fabricaci\u00f3n de productos farmac\u00e9uticos. Estos anexos cubren temas como el control de calidad, la fabricaci\u00f3n de ingredientes activos, la gesti\u00f3n de productos farmac\u00e9uticos peligrosos, la producci\u00f3n de productos est\u00e9riles, las pr\u00e1cticas de distribuci\u00f3n y la preparaci\u00f3n de archivos maestros para organizaciones de investigaci\u00f3n por contrato.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las buenas pr\u00e1cticas recomendadas por la OMS para los laboratorios de control de calidad farmac\u00e9utica seg\u00fan el Anexo 1?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las directrices que se encuentran en el primer anexo del documento, que no se puede encontrar f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 se aborda en el Anexo 3 sobre la fabricaci\u00f3n de productos farmac\u00e9uticos que contienen sustancias peligrosas?**\n   - Esta pregunta se centra en un tema cr\u00edtico que puede no estar ampliamente discutido en otros documentos, lo que permite obtener detalles sobre las buenas pr\u00e1cticas en este \u00e1mbito.\n\n3. **\u00bfQu\u00e9 directrices se ofrecen en el Anexo 7 para la preparaci\u00f3n de un archivo maestro de una organizaci\u00f3n de investigaci\u00f3n por contrato?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las recomendaciones para las organizaciones de investigaci\u00f3n, un tema que puede ser menos conocido y que tiene implicaciones importantes para la industria farmac\u00e9utica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 957\" aborda una variedad de temas relacionados con la calidad y el control en la producci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas en la secci\u00f3n:\n\n#### Temas Clave:\n1. **Control de Calidad**:\n   - Materiales de referencia internacionales (sustancias qu\u00edmicas y espectros infrarrojos).\n   - Evaluaci\u00f3n de calidad en laboratorios nacionales.\n   - Buenas pr\u00e1cticas de control de calidad en laboratorios y microbiolog\u00eda farmac\u00e9utica.\n\n2. **Aseguramiento de Calidad**:\n   - Buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para productos farmac\u00e9uticos, ingredientes activos y productos peligrosos.\n   - Nuevas aproximaciones en aseguramiento de calidad, incluyendo an\u00e1lisis de riesgos y transferencia de tecnolog\u00eda.\n\n3. **Distribuci\u00f3n y Comercio de Productos Farmac\u00e9uticos**:\n   - Esquema de certificaci\u00f3n de calidad para productos farmac\u00e9uticos en comercio internacional.\n   - Buenas pr\u00e1cticas de distribuci\u00f3n y gesti\u00f3n de la cadena de fr\u00edo.\n\n4. **Precalificaci\u00f3n de Medicamentos Esenciales**:\n   - Programa de precalificaci\u00f3n gestionado por la OMS.\n   - Directrices para la revalidaci\u00f3n de expedientes precalificados y preparaci\u00f3n de archivos maestros para organizaciones de investigaci\u00f3n.\n\n5. **Nomenclatura y Terminolog\u00eda**:\n   - Terminolog\u00eda de aseguramiento de calidad y nombres no propietarios internacionales.\n   - Referencias farmacop\u00e9icas.\n\n6. **Miscellaneous**:\n   - Lista Modelo de Medicamentos Esenciales de la OMS.\n   - Actualizaciones sobre estabilidad y sustancias espec\u00edficas como el glicol dietileno.\n\n#### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Principal entidad responsable de establecer y promover est\u00e1ndares de calidad en productos farmac\u00e9uticos.\n- **Laboratorios Nacionales**: Entidades que participan en la evaluaci\u00f3n y aseguramiento de la calidad de productos farmac\u00e9uticos a nivel nacional.\n- **Organizaciones de Investigaci\u00f3n por Contrato**: Entidades que colaboran en la precalificaci\u00f3n de medicamentos esenciales.\n\nEste resumen proporciona una visi\u00f3n general de los temas tratados en la secci\u00f3n, destacando la importancia de la calidad y el control en la industria farmac\u00e9utica, as\u00ed como las directrices y pr\u00e1cticas recomendadas por la OMS.", "excerpt_keywords": "Keywords: buenas pr\u00e1cticas, control de calidad, productos farmac\u00e9uticos, fabricaci\u00f3n, OMS"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "47aac78d-be94-4b90-8b4b-2f99aa8b8076", "node_type": "4", "metadata": {"page_label": "7", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\nAnnex 1  \nWHO good practices for pharmaceutical quality control laboratories  81\n\nAnnex 2  \nWHO good manufacturing practices for active pharmaceutical ingredients  130\n\nAnnex 3  \nWHO good manufacturing practices for pharmaceutical products containing hazardous substances  192\n\nAnnex 4  \nWHO good manufacturing practices for sterile pharmaceutical products  209\n\nAnnex 5  \nWHO good distribution practices for pharmaceutical products  235\n\nAnnex 6  \nGuidelines on the requalification of prequalified dossiers  265\n\nAnnex 7  \nGuidelines for the preparation of a contract research organization master file  271\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "f6951a5e7f05032fb639403c3d97edcc3a010df8d313d8a3a0dfbab40679036f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "```\nAnnex 1  \nWHO good practices for pharmaceutical quality control laboratories  81\n\nAnnex 2  \nWHO good manufacturing practices for active pharmaceutical ingredients  130\n\nAnnex 3  \nWHO good manufacturing practices for pharmaceutical products containing hazardous substances  192\n\nAnnex 4  \nWHO good manufacturing practices for sterile pharmaceutical products  209\n\nAnnex 5  \nWHO good distribution practices for pharmaceutical products  235\n\nAnnex 6  \nGuidelines on the requalification of prequalified dossiers  265\n\nAnnex 7  \nGuidelines for the preparation of a contract research organization master file  271\n```", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 615, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9bd902b8-e7ab-4a23-bdb3-3c57e121dcd3": {"__data__": {"id_": "9bd902b8-e7ab-4a23-bdb3-3c57e121dcd3", "embedding": null, "metadata": {"page_label": "8", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento mencionado es el \"WHO - Technical Report Series 957\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica y recomendaciones para la pr\u00e1ctica cl\u00ednica y la pol\u00edtica de salud. Sin embargo, el contenido espec\u00edfico del informe 957 no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el informe WHO - Technical Report Series 957?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el contenido del informe, que no se puede encontrar en otros lugares sin acceso al documento completo.\n\n2. **\u00bfQu\u00e9 temas de salud p\u00fablica se abordan en la serie de informes t\u00e9cnicos de la OMS, y c\u00f3mo se relaciona el informe 957 con esos temas?**\n   - Esta pregunta permite explorar el contexto m\u00e1s amplio de la serie de informes y c\u00f3mo el informe 957 se integra en la discusi\u00f3n general sobre salud p\u00fablica.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas se utilizan en el informe WHO - Technical Report Series 957 para abordar los problemas de salud discutidos?**\n   - Esta pregunta se centra en las t\u00e9cnicas y enfoques espec\u00edficos que el informe puede haber utilizado, lo que podr\u00eda no estar disponible en otros documentos o res\u00famenes. \n\nEstas preguntas est\u00e1n dise\u00f1adas para profundizar en el contenido espec\u00edfico del informe y su relevancia en el campo de la salud p\u00fablica.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento \"WHO - Technical Report Series 957\" presenta una serie de anexos que establecen directrices y buenas pr\u00e1cticas en el \u00e1mbito farmac\u00e9utico. A continuaci\u00f3n se detallan los temas clave de cada anexo:\n\n1. **Anexo 1: Buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica**\n   - Directrices sobre c\u00f3mo asegurar la calidad en los laboratorios que realizan pruebas y an\u00e1lisis de productos farmac\u00e9uticos.\n\n2. **Anexo 2: Buenas pr\u00e1cticas de fabricaci\u00f3n para ingredientes farmac\u00e9uticos activos**\n   - Normas para la producci\u00f3n de ingredientes que son fundamentales para la elaboraci\u00f3n de medicamentos.\n\n3. **Anexo 3: Buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos que contienen sustancias peligrosas**\n   - Recomendaciones espec\u00edficas para manejar y producir productos que contienen sustancias que pueden ser peligrosas para la salud.\n\n4. **Anexo 4: Buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles**\n   - Directrices para la producci\u00f3n de medicamentos que deben ser est\u00e9riles, asegurando la seguridad y eficacia del producto.\n\n5. **Anexo 5: Buenas pr\u00e1cticas de distribuci\u00f3n para productos farmac\u00e9uticos**\n   - Normas que regulan la distribuci\u00f3n de productos farmac\u00e9uticos para mantener su calidad y seguridad durante el transporte y almacenamiento.\n\n6. **Anexo 6: Directrices sobre la revalidaci\u00f3n de expedientes prequalificados**\n   - Procedimientos para asegurar que los expedientes de productos farmac\u00e9uticos mantengan su validez y calidad a lo largo del tiempo.\n\n7. **Anexo 7: Directrices para la preparaci\u00f3n de un archivo maestro de una organizaci\u00f3n de investigaci\u00f3n por contrato**\n   - Recomendaciones para la creaci\u00f3n y mantenimiento de archivos que documenten las actividades de investigaci\u00f3n realizadas por organizaciones externas.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices y buenas pr\u00e1cticas mencionadas en los anexos.\n- **Laboratorios de control de calidad**: Entidades que realizan pruebas y an\u00e1lisis de productos farmac\u00e9uticos.\n- **Ingredientes farmac\u00e9uticos activos**: Componentes esenciales en la fabricaci\u00f3n de medicamentos.\n- **Productos farmac\u00e9uticos peligrosos**: Medicamentos que contienen sustancias que pueden representar un riesgo para la salud.\n- **Productos farmac\u00e9uticos est\u00e9riles**: Medicamentos que deben estar libres de microorganismos.\n- **Organizaciones de investigaci\u00f3n por contrato**: Entidades que realizan investigaciones en nombre de otras organizaciones, siguiendo directrices espec\u00edficas. \n\nEste resumen proporciona una visi\u00f3n general de los temas tratados en el documento y las entidades involucradas en el contexto de las buenas pr\u00e1cticas farmac\u00e9uticas.", "excerpt_keywords": "Keywords: OMS, buenas pr\u00e1cticas, farmac\u00e9uticos, control de calidad, directrices"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "08349f13-d674-4036-a85a-d7a48961fa68", "node_type": "4", "metadata": {"page_label": "8", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e47e63b2-ff77-4698-a998-16a123df9a58": {"__data__": {"id_": "e47e63b2-ff77-4698-a998-16a123df9a58", "embedding": null, "metadata": {"page_label": "9", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# WHO Expert Committee on Specifications for Pharmaceutical Preparations\n\nGeneva, 12\u201316 October 2009\n\n## Members\n\n- **Professor Saleh A. Bawazir**, Head of Drug Sector and Vice-President, Saudi Food and Drug Authority (SFDA), Riyadh, Saudi Arabia\n- **Mr Jean-Michel Caudron**,\u00b9 Braine-le-Ch\u00e2teau, Belgium\n- **Professor Theo G. Dekker**, Research Institute for Industrial Pharmacy, Potchefstroom, South Africa\n- **Ms Nilka M. Guerrero Rivas**, Aseguramiento de la Calidad, Instituto Especializado de An\u00e1lisis, Ciudad Universitaria Octavio M\u00e9ndez Pereira, Panam\u00e1, Republic of Panama *(Co-Rapporteur)*\n- **Professor Jos Hoogmartens**, Laboratorium voor Farmaceutische Analyse, Leuven, Belgium *(Chairperson)*\n- **Professor Jin Shaohong**, Executive Deputy Director, National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing, People\u2019s Republic of China\n- **Dr John H. McB. Miller**, Strasbourg, France\n- **Dr Justina A. Molzon**, Associate Director for International Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA *(Co-Chairperson)*\n- **Ms Metta Treebamrong**,\u00b9 Senior Pharmacist, Drug Quality and Safety, Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand\n- **Mr Eshetu Wondemagegnehu Biwota**, Addis Ababa, Ethiopia *(Co-Rapporteur)*\n\n## Temporary Advisers\n\n- **Professor Ivan Addae-Mensah**, Professor of Chemistry, University of Ghana, Legon, Ghana\n- **Professor Henning G. Kristensen**,\u00b9 Vedbaek, Denmark\n- **Ms Marie-Louise Rabouhans**, Chiswick, London, England\n- **Dr Jean-Louis Robert**,\u00b9 Service du Contr\u00f4le des M\u00e9dicaments, Laboratoire National de Sant\u00e9, Luxembourg\n- **Dr Saranjit Singh**, Professor and Head, Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Nagar, India\n- **Mr Robert Tribe**, Holder, ACT, Australia\n\n----\n\n\u00b9 Unable to attend.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es un informe de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre la reuni\u00f3n del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas, que tuvo lugar en Ginebra del 12 al 16 de octubre de 2009. El informe incluye una lista de miembros y asesores temporales que participaron en la reuni\u00f3n, destacando sus roles y afiliaciones. Algunos miembros son co-rapporteurs y se mencionan aquellos que no pudieron asistir.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQui\u00e9nes fueron los co-rapporteurs en la reuni\u00f3n del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS en 2009?**\n   - Respuesta: Los co-rapporteurs fueron Ms Nilka M. Guerrero Rivas y Mr Eshetu Wondemagegnehu Biwota.\n\n2. **\u00bfCu\u00e1l fue el rol de Professor Jos Hoogmartens en la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS?**\n   - Respuesta: Professor Jos Hoogmartens fue el presidente (Chairperson) de la reuni\u00f3n.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n se proporciona sobre los miembros que no pudieron asistir a la reuni\u00f3n?**\n   - Respuesta: Se indica que Mr Jean-Michel Caudron, Ms Metta Treebamrong, Professor Henning G. Kristensen y Dr Jean-Louis Robert no pudieron asistir a la reuni\u00f3n, como se se\u00f1ala con un asterisco en sus nombres.", "prev_section_summary": "### Resumen de Temas Clave y Entidades:\n\nEl documento \"WHO - Technical Report Series 957\" es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque el contenido espec\u00edfico del informe no est\u00e1 disponible en el contexto proporcionado, se pueden inferir algunos temas clave y entidades relevantes:\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n del informe, que se centra en la salud p\u00fablica y la investigaci\u00f3n m\u00e9dica.\n\n2. **Salud P\u00fablica**: Tema central de la serie de informes, que aborda diversas cuestiones relacionadas con la salud de la poblaci\u00f3n, pol\u00edticas de salud y pr\u00e1cticas cl\u00ednicas.\n\n3. **Investigaci\u00f3n M\u00e9dica**: Posible enfoque del informe, que podr\u00eda incluir hallazgos cient\u00edficos y recomendaciones basadas en evidencia.\n\n4. **Recomendaciones de Pr\u00e1ctica Cl\u00ednica**: El informe puede ofrecer directrices sobre c\u00f3mo abordar problemas de salud espec\u00edficos en la pr\u00e1ctica m\u00e9dica.\n\n5. **Metodolog\u00edas de Investigaci\u00f3n**: Aunque no se detalla en el contexto, es probable que el informe utilice diversas metodolog\u00edas para analizar y presentar sus hallazgos.\n\n### Conclusi\u00f3n:\nEl informe 957 de la OMS es un documento t\u00e9cnico que se inscribe en un contexto m\u00e1s amplio de salud p\u00fablica y puede contener informaci\u00f3n valiosa sobre hallazgos, recomendaciones y metodolog\u00edas en el \u00e1mbito de la salud. Sin embargo, para obtener detalles espec\u00edficos, ser\u00eda necesario acceder al documento completo.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, expert committee, health authority, drug quality"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "25d3a2b3-a6be-42f4-ab0d-fe9ed2f6683a", "node_type": "4", "metadata": {"page_label": "9", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# WHO Expert Committee on Specifications for Pharmaceutical Preparations\n\nGeneva, 12\u201316 October 2009\n\n## Members\n\n- **Professor Saleh A. Bawazir**, Head of Drug Sector and Vice-President, Saudi Food and Drug Authority (SFDA), Riyadh, Saudi Arabia\n- **Mr Jean-Michel Caudron**,\u00b9 Braine-le-Ch\u00e2teau, Belgium\n- **Professor Theo G. Dekker**, Research Institute for Industrial Pharmacy, Potchefstroom, South Africa\n- **Ms Nilka M. Guerrero Rivas**, Aseguramiento de la Calidad, Instituto Especializado de An\u00e1lisis, Ciudad Universitaria Octavio M\u00e9ndez Pereira, Panam\u00e1, Republic of Panama *(Co-Rapporteur)*\n- **Professor Jos Hoogmartens**, Laboratorium voor Farmaceutische Analyse, Leuven, Belgium *(Chairperson)*\n- **Professor Jin Shaohong**, Executive Deputy Director, National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing, People\u2019s Republic of China\n- **Dr John H. McB. Miller**, Strasbourg, France\n- **Dr Justina A. Molzon**, Associate Director for International Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA *(Co-Chairperson)*\n- **Ms Metta Treebamrong**,\u00b9 Senior Pharmacist, Drug Quality and Safety, Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand\n- **Mr Eshetu Wondemagegnehu Biwota**, Addis Ababa, Ethiopia *(Co-Rapporteur)*\n\n## Temporary Advisers\n\n- **Professor Ivan Addae-Mensah**, Professor of Chemistry, University of Ghana, Legon, Ghana\n- **Professor Henning G. Kristensen**,\u00b9 Vedbaek, Denmark\n- **Ms Marie-Louise Rabouhans**, Chiswick, London, England\n- **Dr Jean-Louis Robert**,\u00b9 Service du Contr\u00f4le des M\u00e9dicaments, Laboratoire National de Sant\u00e9, Luxembourg\n- **Dr Saranjit Singh**, Professor and Head, Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Nagar, India\n- **Mr Robert Tribe**, Holder, ACT, Australia\n\n----\n\n\u00b9 Unable to attend.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "fd7921f3c540cab6b7862c171c421034ef6b903db76eb77b8b73bea161076921", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# WHO Expert Committee on Specifications for Pharmaceutical Preparations\n\nGeneva, 12\u201316 October 2009\n\n## Members\n\n- **Professor Saleh A. Bawazir**, Head of Drug Sector and Vice-President, Saudi Food and Drug Authority (SFDA), Riyadh, Saudi Arabia\n- **Mr Jean-Michel Caudron**,\u00b9 Braine-le-Ch\u00e2teau, Belgium\n- **Professor Theo G. Dekker**, Research Institute for Industrial Pharmacy, Potchefstroom, South Africa\n- **Ms Nilka M. Guerrero Rivas**, Aseguramiento de la Calidad, Instituto Especializado de An\u00e1lisis, Ciudad Universitaria Octavio M\u00e9ndez Pereira, Panam\u00e1, Republic of Panama *(Co-Rapporteur)*\n- **Professor Jos Hoogmartens**, Laboratorium voor Farmaceutische Analyse, Leuven, Belgium *(Chairperson)*\n- **Professor Jin Shaohong**, Executive Deputy Director, National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing, People\u2019s Republic of China\n- **Dr John H. McB. Miller**, Strasbourg, France\n- **Dr Justina A. Molzon**, Associate Director for International Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA *(Co-Chairperson)*\n- **Ms Metta Treebamrong**,\u00b9 Senior Pharmacist, Drug Quality and Safety, Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand\n- **Mr Eshetu Wondemagegnehu Biwota**, Addis Ababa, Ethiopia *(Co-Rapporteur)*\n\n## Temporary Advisers\n\n- **Professor Ivan Addae-Mensah**, Professor of Chemistry, University of Ghana, Legon, Ghana\n- **Professor Henning G. Kristensen**,\u00b9 Vedbaek, Denmark\n- **Ms Marie-Louise Rabouhans**, Chiswick, London, England\n- **Dr Jean-Louis Robert**,\u00b9 Service du Contr\u00f4le des M\u00e9dicaments, Laboratoire National de Sant\u00e9, Luxembourg\n- **Dr Saranjit Singh**, Professor and Head, Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Nagar, India\n- **Mr Robert Tribe**, Holder, ACT, Australia\n\n----\n\n\u00b9 Unable to attend.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1977, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "440ba407-8442-47a4-8cc3-0c76bc6b2cd4": {"__data__": {"id_": "440ba407-8442-47a4-8cc3-0c76bc6b2cd4", "embedding": null, "metadata": {"page_label": "10", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Special Advisers (Prequalification)\n\n- **Mr Gordon J Farquharson,\u00b2** Guildford, Surrey, England\n- **Dr Simon Mills,** Ware, Hertfordshire, England\n- **Ms Eija Pelkonen,\u00b2** Head of Inspectorate, National Agency for Medicines, Helsinki, Finland\n- **Dr Birgit Schmauser,** Federal Institute for Drugs and Medical Devices, Bonn, Germany\n- **Mr Deryck Smith,** Gauteng, South Africa\n- **Dr Angelika Spreitzhofer,\u00b2** AGES PharmMed, Institute for Inspections, Medical Devices and Haemovigilance, Vienna, Austria\n\n# Representation from United Nations Offices\u00b3\n\n**United Nations Children's Fund (UNICEF)**\n\n- **Dr Peter Svarrer Jakobsen,** Quality Assurance Officer, UNICEF Supply Division, Copenhagen, Denmark\n\n# Representation from Specialized Agencies and Related Organizations\u2074\n\n**Global Fund to Fight AIDS, Tuberculosis and Malaria**\n\n- **Ms Joelle Daviaud,** Senior QA Technical Officer, Pharmaceutical Management Unit, Geneva, Switzerland\n- **Mr Raghu Kumar Krishna Swamy**\n\n# Representation from Intergovernmental Organizations\u2075\n\n**Council of Europe**\n\n- **Dr Andrea Lodi,** Deputy Head, Laboratory Department, European Directorate for the Quality of Medicines & HealthCare (EDQM), Strasbourg, France\n\n**European Medicines Agency (EMA)**\n\n- **Dr Piotr Kozarewicz,** Scientific Administrator, Quality of Medicines Sector, Human Unit Pre-Authorization, London, England\n\n# Representation from Nongovernmental Organizations\u2076\n\n**International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)**\n\n- **Dr Michael G. Beatrice,** Vice President, Corporate Regulatory & Quality Science, Abbott, Abbott Park, IL, USA\n\n----\n\n\u00b2 Unable to attend.  \n\u00b3 Unable to attend: United Nations Development Programme (UNDP), New York, NY, USA.  \n\u2074 Unable to attend: International Atomic Energy Agency (IAEA), Vienna, Austria; United Nations Industrial Development Organization (UNIDO), Vienna, Austria; World Intellectual Property Organization (WIPO), Geneva, Switzerland; World Bank, Washington, DC, USA; World Customs Organization (WCO), Brussels, Belgium; World Trade Organization (WTO), Geneva, Switzerland.  \n\u2075 Unable to attend: European Commission (EC) Brussels, Belgium.  \n\u2076 Unable to attend: Commonwealth Pharmaceutical Association (CPA), London, England; European Chemical Industry Council (CEFIC)/APIC, Brussels, Belgium; International Society for Pharmaceutical Engineering (ISPE), Tampa, FL, USA.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (Organizaci\u00f3n Mundial de la Salud) y se centra en la representaci\u00f3n de asesores especiales, as\u00ed como de diversas organizaciones, en el \u00e1mbito de la precalificaci\u00f3n de medicamentos y dispositivos m\u00e9dicos. Se mencionan representantes de diferentes pa\u00edses y organizaciones, incluyendo agencias de la ONU, organizaciones intergubernamentales y no gubernamentales. Algunos representantes no pudieron asistir a la reuni\u00f3n, lo que se detalla al final del texto.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQui\u00e9nes son los asesores especiales que no pudieron asistir a la reuni\u00f3n y cu\u00e1les son sus afiliaciones?**\n   - Respuesta: Los asesores especiales que no pudieron asistir incluyen a Mr. Gordon J Farquharson y Ms. Eija Pelkonen, quienes est\u00e1n afiliados a Inglaterra y Finlandia, respectivamente.\n\n2. **\u00bfQu\u00e9 papel desempe\u00f1a Dr. Peter Svarrer Jakobsen en UNICEF y cu\u00e1l es su ubicaci\u00f3n?**\n   - Respuesta: Dr. Peter Svarrer Jakobsen es el Oficial de Aseguramiento de Calidad en la Divisi\u00f3n de Suministros de UNICEF, ubicado en Copenhague, Dinamarca.\n\n3. **\u00bfQu\u00e9 organizaciones intergubernamentales y no gubernamentales estaban representadas en la reuni\u00f3n y qui\u00e9nes eran sus representantes?**\n   - Respuesta: Las organizaciones intergubernamentales representadas incluyen el Consejo de Europa (Dr. Andrea Lodi) y la Agencia Europea de Medicamentos (Dr. Piotr Kozarewicz). En cuanto a las organizaciones no gubernamentales, la Federaci\u00f3n Internacional de Asociaciones y Fabricantes de Productos Farmac\u00e9uticos (IFPMA) estuvo representada por Dr. Michael G. Beatrice.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otros documentos o contextos, centr\u00e1ndose en detalles sobre la representaci\u00f3n y los roles de los participantes en la reuni\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento es un informe de la **Organizaci\u00f3n Mundial de la Salud (OMS)** sobre la reuni\u00f3n del **Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas**, que se llev\u00f3 a cabo en **Ginebra** del **12 al 16 de octubre de 2009**. A continuaci\u00f3n se presentan los temas y entidades clave:\n\n#### Temas Clave:\n- **Composici\u00f3n del Comit\u00e9**: Se detalla la lista de miembros y asesores temporales que participaron en la reuni\u00f3n, incluyendo sus roles y afiliaciones.\n- **Roles Espec\u00edficos**: Se identifican los roles de los miembros, como el presidente y los co-rapporteurs.\n- **Asistencia**: Se menciona que algunos miembros no pudieron asistir a la reuni\u00f3n, lo que se indica con un asterisco.\n\n#### Entidades:\n- **Miembros del Comit\u00e9**:\n  - **Professor Saleh A. Bawazir** (Saudi Food and Drug Authority, Arabia Saudita)\n  - **Mr Jean-Michel Caudron** (B\u00e9lgica)\n  - **Professor Theo G. Dekker** (Research Institute for Industrial Pharmacy, Sud\u00e1frica)\n  - **Ms Nilka M. Guerrero Rivas** (Panam\u00e1, Co-Rapporteur)\n  - **Professor Jos Hoogmartens** (Chairperson, B\u00e9lgica)\n  - **Professor Jin Shaohong** (China)\n  - **Dr John H. McB. Miller** (Francia)\n  - **Dr Justina A. Molzon** (USA, Co-Chairperson)\n  - **Ms Metta Treebamrong** (Tailandia)\n  - **Mr Eshetu Wondemagegnehu Biwota** (Etiop\u00eda, Co-Rapporteur)\n\n- **Asesores Temporales**:\n  - **Professor Ivan Addae-Mensah** (Ghana)\n  - **Professor Henning G. Kristensen** (Dinamarca)\n  - **Ms Marie-Louise Rabouhans** (Inglaterra)\n  - **Dr Jean-Louis Robert** (Luxemburgo)\n  - **Dr Saranjit Singh** (India)\n  - **Mr Robert Tribe** (Australia)\n\nEste resumen proporciona una visi\u00f3n general de la estructura y los participantes del Comit\u00e9, as\u00ed como de los roles desempe\u00f1ados durante la reuni\u00f3n.", "excerpt_keywords": "Keywords: WHO, prequalification, pharmaceutical, representation, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fe7e1bf6-2d40-4f41-836d-03b113c308fc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Special Advisers (Prequalification)\n\n- **Mr Gordon J Farquharson,\u00b2** Guildford, Surrey, England\n- **Dr Simon Mills,** Ware, Hertfordshire, England\n- **Ms Eija Pelkonen,\u00b2** Head of Inspectorate, National Agency for Medicines, Helsinki, Finland\n- **Dr Birgit Schmauser,** Federal Institute for Drugs and Medical Devices, Bonn, Germany\n- **Mr Deryck Smith,** Gauteng, South Africa\n- **Dr Angelika Spreitzhofer,\u00b2** AGES PharmMed, Institute for Inspections, Medical Devices and Haemovigilance, Vienna, Austria\n\n# Representation from United Nations Offices\u00b3\n\n**United Nations Children's Fund (UNICEF)**\n\n- **Dr Peter Svarrer Jakobsen,** Quality Assurance Officer, UNICEF Supply Division, Copenhagen, Denmark\n\n# Representation from Specialized Agencies and Related Organizations\u2074\n\n**Global Fund to Fight AIDS, Tuberculosis and Malaria**\n\n- **Ms Joelle Daviaud,** Senior QA Technical Officer, Pharmaceutical Management Unit, Geneva, Switzerland\n- **Mr Raghu Kumar Krishna Swamy**\n\n# Representation from Intergovernmental Organizations\u2075\n\n**Council of Europe**\n\n- **Dr Andrea Lodi,** Deputy Head, Laboratory Department, European Directorate for the Quality of Medicines & HealthCare (EDQM), Strasbourg, France\n\n**European Medicines Agency (EMA)**\n\n- **Dr Piotr Kozarewicz,** Scientific Administrator, Quality of Medicines Sector, Human Unit Pre-Authorization, London, England\n\n# Representation from Nongovernmental Organizations\u2076\n\n**International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)**\n\n- **Dr Michael G. Beatrice,** Vice President, Corporate Regulatory & Quality Science, Abbott, Abbott Park, IL, USA\n\n----\n\n\u00b2 Unable to attend.  \n\u00b3 Unable to attend: United Nations Development Programme (UNDP), New York, NY, USA.  \n\u2074 Unable to attend: International Atomic Energy Agency (IAEA), Vienna, Austria; United Nations Industrial Development Organization (UNIDO), Vienna, Austria; World Intellectual Property Organization (WIPO), Geneva, Switzerland; World Bank, Washington, DC, USA; World Customs Organization (WCO), Brussels, Belgium; World Trade Organization (WTO), Geneva, Switzerland.  \n\u2075 Unable to attend: European Commission (EC) Brussels, Belgium.  \n\u2076 Unable to attend: Commonwealth Pharmaceutical Association (CPA), London, England; European Chemical Industry Council (CEFIC)/APIC, Brussels, Belgium; International Society for Pharmaceutical Engineering (ISPE), Tampa, FL, USA.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "9ff9314d88dae319c61600d8d78e4514c9a99b7d16c1bc50dc10cba0a7944631", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Special Advisers (Prequalification)\n\n- **Mr Gordon J Farquharson,\u00b2** Guildford, Surrey, England\n- **Dr Simon Mills,** Ware, Hertfordshire, England\n- **Ms Eija Pelkonen,\u00b2** Head of Inspectorate, National Agency for Medicines, Helsinki, Finland\n- **Dr Birgit Schmauser,** Federal Institute for Drugs and Medical Devices, Bonn, Germany\n- **Mr Deryck Smith,** Gauteng, South Africa\n- **Dr Angelika Spreitzhofer,\u00b2** AGES PharmMed, Institute for Inspections, Medical Devices and Haemovigilance, Vienna, Austria\n\n# Representation from United Nations Offices\u00b3\n\n**United Nations Children's Fund (UNICEF)**\n\n- **Dr Peter Svarrer Jakobsen,** Quality Assurance Officer, UNICEF Supply Division, Copenhagen, Denmark\n\n# Representation from Specialized Agencies and Related Organizations\u2074\n\n**Global Fund to Fight AIDS, Tuberculosis and Malaria**\n\n- **Ms Joelle Daviaud,** Senior QA Technical Officer, Pharmaceutical Management Unit, Geneva, Switzerland\n- **Mr Raghu Kumar Krishna Swamy**\n\n# Representation from Intergovernmental Organizations\u2075\n\n**Council of Europe**\n\n- **Dr Andrea Lodi,** Deputy Head, Laboratory Department, European Directorate for the Quality of Medicines & HealthCare (EDQM), Strasbourg, France\n\n**European Medicines Agency (EMA)**\n\n- **Dr Piotr Kozarewicz,** Scientific Administrator, Quality of Medicines Sector, Human Unit Pre-Authorization, London, England\n\n# Representation from Nongovernmental Organizations\u2076\n\n**International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)**\n\n- **Dr Michael G. Beatrice,** Vice President, Corporate Regulatory & Quality Science, Abbott, Abbott Park, IL, USA\n\n----\n\n\u00b2 Unable to attend.  \n\u00b3 Unable to attend: United Nations Development Programme (UNDP), New York, NY, USA.  \n\u2074 Unable to attend: International Atomic Energy Agency (IAEA), Vienna, Austria; United Nations Industrial Development Organization (UNIDO), Vienna, Austria; World Intellectual Property Organization (WIPO), Geneva, Switzerland; World Bank, Washington, DC, USA; World Customs Organization (WCO), Brussels, Belgium; World Trade Organization (WTO), Geneva, Switzerland.  \n\u2075 Unable to attend: European Commission (EC) Brussels, Belgium.  \n\u2076 Unable to attend: Commonwealth Pharmaceutical Association (CPA), London, England; European Chemical Industry Council (CEFIC)/APIC, Brussels, Belgium; International Society for Pharmaceutical Engineering (ISPE), Tampa, FL, USA.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2402, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c2e2af33-88e0-4cd4-8262-d193083aa067": {"__data__": {"id_": "c2e2af33-88e0-4cd4-8262-d193083aa067", "embedding": null, "metadata": {"page_label": "11", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# International Generic Pharmaceutical Alliance (IGPA)\n- Dr Nicholas Cappuccino, CEO, Pharmaceutical Intellectual Resource Services LLC, Lambertville, NJ, USA\n\n# International Pharmaceutical Excipients Council (IPEC)\n- Mrs Beam Suffolk, Vice Chair, IPEC Europe, Brussels, Belgium\n\n# International Pharmaceutical Federation (FIP)\n- Mr A.J.M. Hoek, General Secretary and CEO and Mr Xuan Hao Chan, Project Manager, The Hague, Netherlands\n\n# World Self-Medication Industry (WSMI)\n- Dr Christelle Anquez-Traxler, Regulatory & Scientific Affairs Manager, Association of the European Self-Medication Industry (AESGP), Brussels, Belgium\n\n## Observers\n### European Association of Pharmaceutical Full-line Wholesalers\n- Mr Martin FitzGerald, Legal Adviser, Groupement International de la Repartition Pharmaceutique (GIRP AISBL), Brussels, Belgium\n\n## Pharmacopoeias\n### British Pharmacopoeia Commission\n- Mrs Matilda Vallender, Editor-in-Chief, Secretariat, Medicines and Healthcare products Regulatory Agency (MHRA), London, England\n\n### European Pharmacopoeia\n- Council of Europe, Strasbourg, France\n\n### Pharmacopoeia of the Republic of Korea\n- Dr Hee-Sung Kim, Deputy Director, Pharmaceutical Standardization Division, Drug Evaluation Department and Dr Su-Jung Lee, Deputy Director, Scientific Drug Evaluation & Research Division, Pharmaceuticals & Medical Devices Research Department, National Institute of Food & Drug Safety Evaluation, Korea Food and Drug Administration, Seoul, Republic of Korea\n\n### United States Pharmacopeia\n- Dr Karen A. Russo, Vice President, Small Molecules, Documentary Standards Division, Rockville, MD, USA\n\n## Representation from WHO regional offices\n### WHO Secretariat\n- Dr C.F. Etienne, Assistant Director-General, Health Systems and Services, WHO, Geneva, Switzerland\n\n----\n\n7 Unable to attend: Pharmaceutical Inspection Co-operation Scheme (PIC/S), Geneva, Switzerland.  \n8 Unable to attend: Farmacopea Argentina, Buenos Aires, Argentina; Farmacopeia Brasileira, Santa Maria, RS, Brazil; Pharmacopoeia of the People's Republic of China, Beijing, People's Republic of China; Indian Pharmacopoeia, New Delhi, India; Japanese Pharmacopoeia, Tokyo, Japan; State Pharmacopoeia of the Russian Federation, Moscow, Russian Federation.  \n9 See Council of Europe.  \n10 Unable to attend: Regional Office for Africa; Regional Office for the Americas; Regional Office for the Eastern Mediterranean; Regional Office for Europe; Regional Office for South-East Asia; Regional Office for the Western Pacific.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que incluye una lista de representantes de diversas organizaciones y farmacopoeias que participaron en una reuni\u00f3n. Se mencionan representantes de la Alianza Internacional de Medicamentos Gen\u00e9ricos (IGPA), el Consejo Internacional de Excipientes Farmac\u00e9uticos (IPEC), la Federaci\u00f3n Internacional Farmac\u00e9utica (FIP), y la Industria Mundial de Autocuidado (WSMI), entre otros. Tambi\u00e9n se enumeran observadores y representantes de diferentes farmacopoeias, as\u00ed como la representaci\u00f3n de las oficinas regionales de la OMS. Adem\u00e1s, se indica qui\u00e9nes no pudieron asistir a la reuni\u00f3n.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQui\u00e9nes son los representantes de la Alianza Internacional de Medicamentos Gen\u00e9ricos (IGPA) y cu\u00e1l es su funci\u00f3n?**\n   - Respuesta: El representante de la IGPA es el Dr. Nicholas Cappuccino, CEO de Pharmaceutical Intellectual Resource Services LLC, ubicado en Lambertville, NJ, USA. Su funci\u00f3n es liderar la organizaci\u00f3n en temas relacionados con medicamentos gen\u00e9ricos.\n\n2. **\u00bfQu\u00e9 farmacopoeias est\u00e1n representadas en el informe y qui\u00e9nes son sus respectivos representantes?**\n   - Respuesta: Las farmacopoeias representadas son la British Pharmacopoeia Commission (Mrs. Matilda Vallender), la European Pharmacopoeia (Consejo de Europa), la Pharmacopoeia of the Republic of Korea (Dr. Hee-Sung Kim y Dr. Su-Jung Lee), y la United States Pharmacopeia (Dr. Karen A. Russo).\n\n3. **\u00bfQu\u00e9 organizaciones y farmacopoeias no pudieron asistir a la reuni\u00f3n y cu\u00e1les son sus ubicaciones?**\n   - Respuesta: No pudieron asistir: Pharmaceutical Inspection Co-operation Scheme (PIC/S) en Ginebra, Suiza; Farmacopea Argentina en Buenos Aires, Argentina; Farmacopeia Brasileira en Santa Maria, RS, Brasil; Pharmacopoeia of the People's Republic of China en Pek\u00edn, Rep\u00fablica Popular de China; Indian Pharmacopoeia en Nueva Delhi, India; Japanese Pharmacopoeia en Tokio, Jap\u00f3n; State Pharmacopoeia of the Russian Federation en Mosc\u00fa, Federaci\u00f3n Rusa; y las oficinas regionales de la OMS en varias regiones del mundo.\n\n### Resumen de Nivel Superior\nEl informe t\u00e9cnico de la OMS detalla la participaci\u00f3n de diversas organizaciones y farmacopoeias en una reuni\u00f3n, destacando a los representantes clave y sus roles. Tambi\u00e9n se menciona la ausencia de varias organizaciones importantes, lo que puede indicar la diversidad y el alcance global de la discusi\u00f3n sobre temas farmac\u00e9uticos. Este contexto es relevante para entender la colaboraci\u00f3n internacional en el \u00e1mbito de la salud y la regulaci\u00f3n farmac\u00e9utica.", "prev_section_summary": "La secci\u00f3n del documento se centra en la representaci\u00f3n de asesores especiales y diversas organizaciones en el contexto de la precalificaci\u00f3n de medicamentos y dispositivos m\u00e9dicos, seg\u00fan lo presentado en la Serie de Informes T\u00e9cnicos de la OMS. A continuaci\u00f3n se resumen los temas clave y las entidades mencionadas:\n\n### Temas Clave:\n1. **Asesores Especiales**: Se listan varios asesores que participan en el proceso de precalificaci\u00f3n, destacando sus afiliaciones y ubicaciones.\n2. **Representaci\u00f3n de Organizaciones**: Se menciona la participaci\u00f3n de diferentes organizaciones, incluyendo agencias de la ONU, organizaciones intergubernamentales y no gubernamentales.\n3. **Asistencia**: Se indica que algunos representantes no pudieron asistir a la reuni\u00f3n, lo que se detalla al final del texto.\n\n### Entidades Mencionadas:\n- **Asesores Especiales**:\n  - Mr. Gordon J Farquharson (Inglaterra)\n  - Dr. Simon Mills (Inglaterra)\n  - Ms. Eija Pelkonen (Finlandia)\n  - Dr. Birgit Schmauser (Alemania)\n  - Mr. Deryck Smith (Sud\u00e1frica)\n  - Dr. Angelika Spreitzhofer (Austria)\n\n- **Organizaciones de la ONU**:\n  - **UNICEF**: Dr. Peter Svarrer Jakobsen (Dinamarca)\n\n- **Agencias Especializadas**:\n  - **Global Fund to Fight AIDS, Tuberculosis and Malaria**: Ms. Joelle Daviaud (Suiza), Mr. Raghu Kumar Krishna Swamy\n\n- **Organizaciones Intergubernamentales**:\n  - **Consejo de Europa**: Dr. Andrea Lodi (Francia)\n  - **Agencia Europea de Medicamentos (EMA)**: Dr. Piotr Kozarewicz (Inglaterra)\n\n- **Organizaciones No Gubernamentales**:\n  - **IFPMA**: Dr. Michael G. Beatrice (EE. UU.)\n\nEste resumen proporciona una visi\u00f3n general de los participantes y su relevancia en el contexto de la precalificaci\u00f3n de medicamentos y dispositivos m\u00e9dicos.", "excerpt_keywords": "Keywords: pharmaceutical organizations, pharmacopoeias, WHO representation, international collaboration, generic medicines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0d747e08-e8ff-456a-9670-56dc8ad644fa", "node_type": "4", "metadata": {"page_label": "11", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# International Generic Pharmaceutical Alliance (IGPA)\n- Dr Nicholas Cappuccino, CEO, Pharmaceutical Intellectual Resource Services LLC, Lambertville, NJ, USA\n\n# International Pharmaceutical Excipients Council (IPEC)\n- Mrs Beam Suffolk, Vice Chair, IPEC Europe, Brussels, Belgium\n\n# International Pharmaceutical Federation (FIP)\n- Mr A.J.M. Hoek, General Secretary and CEO and Mr Xuan Hao Chan, Project Manager, The Hague, Netherlands\n\n# World Self-Medication Industry (WSMI)\n- Dr Christelle Anquez-Traxler, Regulatory & Scientific Affairs Manager, Association of the European Self-Medication Industry (AESGP), Brussels, Belgium\n\n## Observers\n### European Association of Pharmaceutical Full-line Wholesalers\n- Mr Martin FitzGerald, Legal Adviser, Groupement International de la Repartition Pharmaceutique (GIRP AISBL), Brussels, Belgium\n\n## Pharmacopoeias\n### British Pharmacopoeia Commission\n- Mrs Matilda Vallender, Editor-in-Chief, Secretariat, Medicines and Healthcare products Regulatory Agency (MHRA), London, England\n\n### European Pharmacopoeia\n- Council of Europe, Strasbourg, France\n\n### Pharmacopoeia of the Republic of Korea\n- Dr Hee-Sung Kim, Deputy Director, Pharmaceutical Standardization Division, Drug Evaluation Department and Dr Su-Jung Lee, Deputy Director, Scientific Drug Evaluation & Research Division, Pharmaceuticals & Medical Devices Research Department, National Institute of Food & Drug Safety Evaluation, Korea Food and Drug Administration, Seoul, Republic of Korea\n\n### United States Pharmacopeia\n- Dr Karen A. Russo, Vice President, Small Molecules, Documentary Standards Division, Rockville, MD, USA\n\n## Representation from WHO regional offices\n### WHO Secretariat\n- Dr C.F. Etienne, Assistant Director-General, Health Systems and Services, WHO, Geneva, Switzerland\n\n----\n\n7 Unable to attend: Pharmaceutical Inspection Co-operation Scheme (PIC/S), Geneva, Switzerland.  \n8 Unable to attend: Farmacopea Argentina, Buenos Aires, Argentina; Farmacopeia Brasileira, Santa Maria, RS, Brazil; Pharmacopoeia of the People's Republic of China, Beijing, People's Republic of China; Indian Pharmacopoeia, New Delhi, India; Japanese Pharmacopoeia, Tokyo, Japan; State Pharmacopoeia of the Russian Federation, Moscow, Russian Federation.  \n9 See Council of Europe.  \n10 Unable to attend: Regional Office for Africa; Regional Office for the Americas; Regional Office for the Eastern Mediterranean; Regional Office for Europe; Regional Office for South-East Asia; Regional Office for the Western Pacific.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "ac0a32f19664b5f073ab799050e09b64734e31f6526f63b86bc8ef77a031d420", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# International Generic Pharmaceutical Alliance (IGPA)\n- Dr Nicholas Cappuccino, CEO, Pharmaceutical Intellectual Resource Services LLC, Lambertville, NJ, USA\n\n# International Pharmaceutical Excipients Council (IPEC)\n- Mrs Beam Suffolk, Vice Chair, IPEC Europe, Brussels, Belgium\n\n# International Pharmaceutical Federation (FIP)\n- Mr A.J.M. Hoek, General Secretary and CEO and Mr Xuan Hao Chan, Project Manager, The Hague, Netherlands\n\n# World Self-Medication Industry (WSMI)\n- Dr Christelle Anquez-Traxler, Regulatory & Scientific Affairs Manager, Association of the European Self-Medication Industry (AESGP), Brussels, Belgium\n\n## Observers\n### European Association of Pharmaceutical Full-line Wholesalers\n- Mr Martin FitzGerald, Legal Adviser, Groupement International de la Repartition Pharmaceutique (GIRP AISBL), Brussels, Belgium\n\n## Pharmacopoeias\n### British Pharmacopoeia Commission\n- Mrs Matilda Vallender, Editor-in-Chief, Secretariat, Medicines and Healthcare products Regulatory Agency (MHRA), London, England\n\n### European Pharmacopoeia\n- Council of Europe, Strasbourg, France\n\n### Pharmacopoeia of the Republic of Korea\n- Dr Hee-Sung Kim, Deputy Director, Pharmaceutical Standardization Division, Drug Evaluation Department and Dr Su-Jung Lee, Deputy Director, Scientific Drug Evaluation & Research Division, Pharmaceuticals & Medical Devices Research Department, National Institute of Food & Drug Safety Evaluation, Korea Food and Drug Administration, Seoul, Republic of Korea\n\n### United States Pharmacopeia\n- Dr Karen A. Russo, Vice President, Small Molecules, Documentary Standards Division, Rockville, MD, USA\n\n## Representation from WHO regional offices\n### WHO Secretariat\n- Dr C.F. Etienne, Assistant Director-General, Health Systems and Services, WHO, Geneva, Switzerland\n\n----\n\n7 Unable to attend: Pharmaceutical Inspection Co-operation Scheme (PIC/S), Geneva, Switzerland.  \n8 Unable to attend: Farmacopea Argentina, Buenos Aires, Argentina; Farmacopeia Brasileira, Santa Maria, RS, Brazil; Pharmacopoeia of the People's Republic of China, Beijing, People's Republic of China; Indian Pharmacopoeia, New Delhi, India; Japanese Pharmacopoeia, Tokyo, Japan; State Pharmacopoeia of the Russian Federation, Moscow, Russian Federation.  \n9 See Council of Europe.  \n10 Unable to attend: Regional Office for Africa; Regional Office for the Americas; Regional Office for the Eastern Mediterranean; Regional Office for Europe; Regional Office for South-East Asia; Regional Office for the Western Pacific.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2521, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "96c00675-7aa3-4533-8cc9-a15396472145": {"__data__": {"id_": "96c00675-7aa3-4533-8cc9-a15396472145", "embedding": null, "metadata": {"page_label": "12", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Dr H.V. Hogerzeil, Director, Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland\n\nDr L. R\u00e4go, Coordinator, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr S. Kopp, Manager, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland (Secretary)\n\nMs C. Mendy, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr R. Balocco, Manager, International Nonproprietary Names Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr A. Gould, Manager, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr R. Kuwana, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr M. Mehmandoust, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr D. Mubangizi, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nMs J. Sabartova, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr I. Streipa, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland, WHO, Geneva, Switzerland\n\nMr W.Z. Worku, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr Hua Yin, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr A. van Zyl, Head, Inspections, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr S. Azatyan, Manager, Medicines Regulatory Support Programme, WHO, Geneva, Switzerland\n\nMr J. Hetzke, Health Systems and Services, WHO, Geneva, Switzerland\n\nMs Y. Maruyama, Traditional Medicine, WHO, Geneva, Switzerland\n\nDr C. Ondari, Coordinator, Medicines Access and Rational Use, WHO, Geneva, Switzerland\n\nDr F. Renaud Th\u00e9ry, HIV Systems Strengthening, WHO, Geneva, Switzerland\n\nDr D.J. Wood, Coordinator, Quality, Safety and Standards Programme, WHO, Geneva, Switzerland", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) titulado \"WHO - Technical Report Series 957\". En \u00e9l, se enumeran varios profesionales de la OMS que ocupan roles clave en programas relacionados con la calidad y seguridad de los medicamentos, as\u00ed como en pol\u00edticas de medicamentos esenciales. Los participantes incluyen directores, coordinadores y gerentes de diferentes programas, todos ubicados en Ginebra, Suiza.\n\n### Preguntas:\n1. **\u00bfQui\u00e9nes son los principales responsables de los programas de calidad y seguridad de medicamentos en la OMS seg\u00fan el informe?**\n   - Esta pregunta busca identificar a los l\u00edderes y sus roles espec\u00edficos en la organizaci\u00f3n, lo cual no se encuentra f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 programas espec\u00edficos est\u00e1n siendo gestionados por los profesionales mencionados en el informe?**\n   - Esta pregunta se centra en los programas espec\u00edficos que cada uno de los profesionales est\u00e1 supervisando, proporcionando detalles que pueden no estar disponibles en otros documentos.\n\n3. **\u00bfCu\u00e1l es el enfoque de la OMS en relaci\u00f3n con los medicamentos esenciales y su regulaci\u00f3n, seg\u00fan los roles de los individuos listados en el informe?**\n   - Esta pregunta busca entender la perspectiva y el enfoque de la OMS sobre la regulaci\u00f3n y el acceso a medicamentos esenciales, lo cual puede no estar claramente articulado en otros contextos.", "prev_section_summary": "La secci\u00f3n del documento presenta una lista de representantes de diversas organizaciones y farmacopoeias que participaron en una reuni\u00f3n organizada por la Organizaci\u00f3n Mundial de la Salud (OMS). A continuaci\u00f3n se resumen los temas clave y las entidades mencionadas:\n\n### Temas Clave:\n1. **Participaci\u00f3n Internacional**: Se destaca la colaboraci\u00f3n de m\u00faltiples organizaciones y farmacopoeias en el \u00e1mbito farmac\u00e9utico a nivel global.\n2. **Representantes Clave**: Se enumeran los representantes de cada organizaci\u00f3n, indicando sus roles y ubicaciones.\n3. **Ausencias Notables**: Se menciona qui\u00e9nes no pudieron asistir a la reuni\u00f3n, lo que refleja la diversidad de actores involucrados en la discusi\u00f3n.\n\n### Entidades Mencionadas:\n- **Alianza Internacional de Medicamentos Gen\u00e9ricos (IGPA)**: Dr. Nicholas Cappuccino, CEO.\n- **Consejo Internacional de Excipientes Farmac\u00e9uticos (IPEC)**: Mrs. Beam Suffolk, Vice Chair.\n- **Federaci\u00f3n Internacional Farmac\u00e9utica (FIP)**: Mr. A.J.M. Hoek y Mr. Xuan Hao Chan.\n- **Industria Mundial de Autocuidado (WSMI)**: Dr. Christelle Anquez-Traxler.\n- **Observadores**: Mr. Martin FitzGerald de la Asociaci\u00f3n Europea de Mayoristas Farmac\u00e9uticos.\n- **Farmacopoeias**:\n  - British Pharmacopoeia Commission: Mrs. Matilda Vallender.\n  - European Pharmacopoeia: Consejo de Europa.\n  - Pharmacopoeia of the Republic of Korea: Dr. Hee-Sung Kim y Dr. Su-Jung Lee.\n  - United States Pharmacopeia: Dr. Karen A. Russo.\n- **Secretar\u00eda de la OMS**: Dr. C.F. Etienne.\n\n### Ausencias:\n- **Organizaciones que no asistieron**: Pharmaceutical Inspection Co-operation Scheme (PIC/S), Farmacopea Argentina, Farmacopeia Brasileira, Pharmacopoeia of the People's Republic of China, Indian Pharmacopoeia, Japanese Pharmacopoeia, State Pharmacopoeia of the Russian Federation, y varias oficinas regionales de la OMS.\n\nEste resumen resalta la importancia de la colaboraci\u00f3n internacional en la regulaci\u00f3n y desarrollo de productos farmac\u00e9uticos, as\u00ed como la diversidad de voces y perspectivas en la discusi\u00f3n.", "excerpt_keywords": "Keywords: WHO, Essential Medicines, Quality Assurance, Pharmaceutical Policies, Prequalification Programme"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "49a59c58-d1e8-4148-9fd7-49e71261673b", "node_type": "4", "metadata": {"page_label": "12", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Dr H.V. Hogerzeil, Director, Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland\n\nDr L. R\u00e4go, Coordinator, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr S. Kopp, Manager, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland (Secretary)\n\nMs C. Mendy, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr R. Balocco, Manager, International Nonproprietary Names Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr A. Gould, Manager, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr R. Kuwana, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr M. Mehmandoust, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr D. Mubangizi, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nMs J. Sabartova, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr I. Streipa, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland, WHO, Geneva, Switzerland\n\nMr W.Z. Worku, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr Hua Yin, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr A. van Zyl, Head, Inspections, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr S. Azatyan, Manager, Medicines Regulatory Support Programme, WHO, Geneva, Switzerland\n\nMr J. Hetzke, Health Systems and Services, WHO, Geneva, Switzerland\n\nMs Y. Maruyama, Traditional Medicine, WHO, Geneva, Switzerland\n\nDr C. Ondari, Coordinator, Medicines Access and Rational Use, WHO, Geneva, Switzerland\n\nDr F. Renaud Th\u00e9ry, HIV Systems Strengthening, WHO, Geneva, Switzerland\n\nDr D.J. Wood, Coordinator, Quality, Safety and Standards Programme, WHO, Geneva, Switzerland", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "18bd7f8983cbee97e6ea4f72e2fbdbd100ade159365c236c26a1b19097bbf42e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Dr H.V. Hogerzeil, Director, Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland\n\nDr L. R\u00e4go, Coordinator, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr S. Kopp, Manager, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland (Secretary)\n\nMs C. Mendy, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr R. Balocco, Manager, International Nonproprietary Names Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr A. Gould, Manager, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr R. Kuwana, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr M. Mehmandoust, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr D. Mubangizi, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nMs J. Sabartova, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr I. Streipa, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland, WHO, Geneva, Switzerland\n\nMr W.Z. Worku, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr Hua Yin, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr A. van Zyl, Head, Inspections, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr S. Azatyan, Manager, Medicines Regulatory Support Programme, WHO, Geneva, Switzerland\n\nMr J. Hetzke, Health Systems and Services, WHO, Geneva, Switzerland\n\nMs Y. Maruyama, Traditional Medicine, WHO, Geneva, Switzerland\n\nDr C. Ondari, Coordinator, Medicines Access and Rational Use, WHO, Geneva, Switzerland\n\nDr F. Renaud Th\u00e9ry, HIV Systems Strengthening, WHO, Geneva, Switzerland\n\nDr D.J. Wood, Coordinator, Quality, Safety and Standards Programme, WHO, Geneva, Switzerland", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2113, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b14c7316-cae3-4f0e-b3f0-af5dba802501": {"__data__": {"id_": "b14c7316-cae3-4f0e-b3f0-af5dba802501", "embedding": null, "metadata": {"page_label": "13", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Declarations of interest\n\nMembers of the WHO Expert Committee on Specifications for Pharmaceutical Preparations reported the following:\n\nProfessor Saleh A. Bawazir, Professor Theo G. Dekker, Ms Nilka M. Guerrero Rivas, Professor Jos Hoogmartens, Professor Jin Shaohong, Dr John H. McB. Miller, Dr Justina A. Molzon and Mr Eshetu Wondemagegnehu Biwota reported no conflict of interest.\n\nTemporary and special advisers reported the following:\n\nProfessor Ivan Addae-Mensah, Dr Simon Mills, Ms Marie-Louise Rabouhans, Dr Birgit Schmauser, Dr Saranjit Singh and Mr Deryck Smith, reported no conflict of interest.\n\nMr Robert Tribe reported that he was a consultant with two commercial entities and was the owner of another one.\n\nMr Martin FitzGerald, attending as an observer, reported that he was Legal Adviser with the European Association of Pharmaceutical Full-Line Wholesalers; Dr Piotr Kozarewicz (representative of the European Medicines Agency) reported that he was employed by two different pharmaceutical companies in Poland from September 2003 until June 2006. Other participants reported no conflict of interest.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl documento es parte de un informe t\u00e9cnico de la OMS (Organizaci\u00f3n Mundial de la Salud) que incluye declaraciones de inter\u00e9s de los miembros del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas. Se menciona que la mayor\u00eda de los miembros y asesores no tienen conflictos de inter\u00e9s, mientras que algunos participantes han declarado v\u00ednculos con entidades comerciales o farmac\u00e9uticas.\n\n### Preguntas espec\u00edficas\n1. **\u00bfQui\u00e9nes son los miembros del Comit\u00e9 de Expertos que no reportaron conflictos de inter\u00e9s?**\n   - Respuesta: Los miembros que no reportaron conflictos de inter\u00e9s son el Profesor Saleh A. Bawazir, el Profesor Theo G. Dekker, la Sra. Nilka M. Guerrero Rivas, el Profesor Jos Hoogmartens, el Profesor Jin Shaohong, el Dr. John H. McB. Miller, la Dra. Justina A. Molzon y el Sr. Eshetu Wondemagegnehu Biwota.\n\n2. **\u00bfQu\u00e9 tipo de relaciones comerciales report\u00f3 el Sr. Robert Tribe?**\n   - Respuesta: El Sr. Robert Tribe report\u00f3 que era consultor de dos entidades comerciales y era propietario de otra.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n se proporcion\u00f3 sobre el Dr. Piotr Kozarewicz en relaci\u00f3n con su empleo previo?**\n   - Respuesta: El Dr. Piotr Kozarewicz, representante de la Agencia Europea de Medicamentos, report\u00f3 que estuvo empleado por dos diferentes compa\u00f1\u00edas farmac\u00e9uticas en Polonia desde septiembre de 2003 hasta junio de 2006.\n\n### Resumen de nivel superior\nEl informe de la OMS incluye declaraciones de inter\u00e9s de los miembros del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas, donde la mayor\u00eda no tiene conflictos de inter\u00e9s, pero algunos participantes han declarado v\u00ednculos con entidades comerciales. Esto es relevante para asegurar la transparencia y la integridad en las recomendaciones y decisiones del comit\u00e9.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 957\" de la Organizaci\u00f3n Mundial de la Salud (OMS) presenta una lista de profesionales que desempe\u00f1an roles cruciales en la gesti\u00f3n de programas relacionados con la calidad, seguridad y acceso a medicamentos. A continuaci\u00f3n se detallan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Calidad y Seguridad de Medicamentos**: Se enfatiza la importancia de asegurar la calidad y la seguridad de los medicamentos a trav\u00e9s de programas espec\u00edficos.\n2. **Medicamentos Esenciales**: Se aborda la pol\u00edtica de medicamentos esenciales y su regulaci\u00f3n, destacando la necesidad de acceso adecuado a estos productos.\n3. **Programas de Precalificaci\u00f3n**: Se menciona el programa de precalificaci\u00f3n, que busca garantizar que los medicamentos cumplan con est\u00e1ndares de calidad antes de ser utilizados en diferentes contextos.\n4. **Regulaci\u00f3n y Apoyo**: Se discuten los esfuerzos de la OMS en la regulaci\u00f3n de medicamentos y el apoyo a sistemas de salud para mejorar el acceso y uso racional de medicamentos.\n\n#### Entidades:\n- **Dr. H.V. Hogerzeil**: Director de Medicamentos Esenciales y Pol\u00edticas Farmac\u00e9uticas.\n- **Dr. L. R\u00e4go**: Coordinador de Calidad y Seguridad de Medicamentos.\n- **Dr. S. Kopp**: Gerente del Programa de Aseguramiento de Calidad de Medicamentos.\n- **Dr. R. Balocco**: Gerente del Programa de Nombres No Propietarios Internacionales.\n- **Dr. A. Gould**: Gerente del Programa de Precalificaci\u00f3n.\n- **Dr. S. Azatyan**: Gerente del Programa de Apoyo Regulatorio de Medicamentos.\n- **Dr. C. Ondari**: Coordinador de Acceso a Medicamentos y Uso Racional.\n- **Dr. D.J. Wood**: Coordinador del Programa de Calidad, Seguridad y Normas.\n\nEste resumen destaca la estructura organizativa y los enfoques de la OMS en relaci\u00f3n con la calidad y el acceso a medicamentos, as\u00ed como los profesionales clave involucrados en estos esfuerzos.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, conflict of interest, expert committee, declarations"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "94cc261e-bdb7-458c-9e5f-9365faddca92", "node_type": "4", "metadata": {"page_label": "13", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Declarations of interest\n\nMembers of the WHO Expert Committee on Specifications for Pharmaceutical Preparations reported the following:\n\nProfessor Saleh A. Bawazir, Professor Theo G. Dekker, Ms Nilka M. Guerrero Rivas, Professor Jos Hoogmartens, Professor Jin Shaohong, Dr John H. McB. Miller, Dr Justina A. Molzon and Mr Eshetu Wondemagegnehu Biwota reported no conflict of interest.\n\nTemporary and special advisers reported the following:\n\nProfessor Ivan Addae-Mensah, Dr Simon Mills, Ms Marie-Louise Rabouhans, Dr Birgit Schmauser, Dr Saranjit Singh and Mr Deryck Smith, reported no conflict of interest.\n\nMr Robert Tribe reported that he was a consultant with two commercial entities and was the owner of another one.\n\nMr Martin FitzGerald, attending as an observer, reported that he was Legal Adviser with the European Association of Pharmaceutical Full-Line Wholesalers; Dr Piotr Kozarewicz (representative of the European Medicines Agency) reported that he was employed by two different pharmaceutical companies in Poland from September 2003 until June 2006. Other participants reported no conflict of interest.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "9d787318b9cfc61a1cdc32d8b9b7ed2a1ecadb38e60592fe435ef92e5d0a963f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Declarations of interest\n\nMembers of the WHO Expert Committee on Specifications for Pharmaceutical Preparations reported the following:\n\nProfessor Saleh A. Bawazir, Professor Theo G. Dekker, Ms Nilka M. Guerrero Rivas, Professor Jos Hoogmartens, Professor Jin Shaohong, Dr John H. McB. Miller, Dr Justina A. Molzon and Mr Eshetu Wondemagegnehu Biwota reported no conflict of interest.\n\nTemporary and special advisers reported the following:\n\nProfessor Ivan Addae-Mensah, Dr Simon Mills, Ms Marie-Louise Rabouhans, Dr Birgit Schmauser, Dr Saranjit Singh and Mr Deryck Smith, reported no conflict of interest.\n\nMr Robert Tribe reported that he was a consultant with two commercial entities and was the owner of another one.\n\nMr Martin FitzGerald, attending as an observer, reported that he was Legal Adviser with the European Association of Pharmaceutical Full-Line Wholesalers; Dr Piotr Kozarewicz (representative of the European Medicines Agency) reported that he was employed by two different pharmaceutical companies in Poland from September 2003 until June 2006. Other participants reported no conflict of interest.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1120, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f4db7121-a2fb-4802-a501-deac4304a471": {"__data__": {"id_": "f4db7121-a2fb-4802-a501-deac4304a471", "embedding": null, "metadata": {"page_label": "14", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento mencionado es el \"WHO - Technical Report Series 957\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica, y recomendaciones para pol\u00edticas de salud. Sin embargo, el contenido espec\u00edfico del documento no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el informe WHO - Technical Report Series 957?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el contenido del informe, que podr\u00eda incluir datos relevantes sobre salud p\u00fablica o recomendaciones de la OMS.\n\n2. **\u00bfQu\u00e9 temas espec\u00edficos se abordan en el documento y c\u00f3mo se relacionan con las pol\u00edticas de salud global?**\n   - Esta pregunta se enfoca en los temas tratados en el informe y su impacto en las pol\u00edticas de salud a nivel mundial, lo que podr\u00eda no estar disponible en otras fuentes.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas se utilizaron en la investigaci\u00f3n presentada en el WHO - Technical Report Series 957?**\n   - Esta pregunta indaga sobre las metodolog\u00edas espec\u00edficas empleadas en el informe, lo que podr\u00eda ofrecer una visi\u00f3n \u00fanica sobre c\u00f3mo se llev\u00f3 a cabo la investigaci\u00f3n y su validez.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n que probablemente no se encuentre f\u00e1cilmente en otros lugares, dado que el contenido espec\u00edfico del informe no est\u00e1 disponible en el contexto proporcionado.", "prev_section_summary": "La secci\u00f3n \"Declarations of interest\" del informe t\u00e9cnico de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta las declaraciones de inter\u00e9s de los miembros del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas. Los temas clave incluyen:\n\n1. **Miembros sin conflictos de inter\u00e9s**: La mayor\u00eda de los miembros del comit\u00e9, incluyendo a profesores y doctores, no reportaron conflictos de inter\u00e9s. Los nombres mencionados son:\n   - Profesor Saleh A. Bawazir\n   - Profesor Theo G. Dekker\n   - Sra. Nilka M. Guerrero Rivas\n   - Profesor Jos Hoogmartens\n   - Profesor Jin Shaohong\n   - Dr. John H. McB. Miller\n   - Dra. Justina A. Molzon\n   - Sr. Eshetu Wondemagegnehu Biwota\n\n2. **Asesores temporales y especiales**: Tambi\u00e9n se report\u00f3 que varios asesores no tienen conflictos de inter\u00e9s, incluyendo:\n   - Profesor Ivan Addae-Mensah\n   - Dr. Simon Mills\n   - Sra. Marie-Louise Rabouhans\n   - Dr. Birgit Schmauser\n   - Dr. Saranjit Singh\n   - Mr. Deryck Smith\n\n3. **Conflictos de inter\u00e9s reportados**:\n   - **Mr. Robert Tribe**: Consultor de dos entidades comerciales y propietario de otra.\n   - **Mr. Martin FitzGerald**: Asesor legal de la Asociaci\u00f3n Europea de Mayoristas Farmac\u00e9uticos.\n   - **Dr. Piotr Kozarewicz**: Empleado de dos compa\u00f1\u00edas farmac\u00e9uticas en Polonia entre septiembre de 2003 y junio de 2006.\n\n4. **Importancia de la transparencia**: La secci\u00f3n enfatiza la relevancia de estas declaraciones para asegurar la transparencia y la integridad en las recomendaciones y decisiones del comit\u00e9.\n\nEste resumen destaca la composici\u00f3n del comit\u00e9, las relaciones comerciales de algunos participantes y la importancia de la transparencia en el proceso.", "excerpt_keywords": "Keywords: OMS, informe t\u00e9cnico, salud p\u00fablica, conflictos de inter\u00e9s, transparencia"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "522612e1-06f4-4ceb-8ec5-2a2ac80d2293", "node_type": "4", "metadata": {"page_label": "14", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "aa9db07c-9b8d-4ea1-b84a-18001d1da416": {"__data__": {"id_": "aa9db07c-9b8d-4ea1-b84a-18001d1da416", "embedding": null, "metadata": {"page_label": "15", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations met in Geneva from 12 to 16 October 2009. Dr Carissa F. Etienne, Assistant Director-General, Health Systems and Services (HSS), opened the meeting and, on behalf of the Director-General of the World Health Organization, welcomed all the participants to the forty-fourth meeting. She expressed her appreciation of the Expert Committee for its knowledge of and expertise in the work of WHO in the area of quality assurance of medicines. Dr Etienne welcomed the members of the Committee, temporary advisers and special advisers for prequalification; representatives of the United Nations Children\u2019s Fund, the Global Fund to Fight AIDS, Tuberculosis and Malaria, Council of Europe/European Directorate for the Quality of Medicines and HealthCare, European Medicines Agency, International Federation of Pharmaceutical Manufacturers and Associations, International Generic Pharmaceutical Alliance, International Pharmaceutical Excipients Council, International Pharmaceutical Federation, World Self-Medication Industry and an observer from the European Association of Pharmaceutical Full-line Wholesalers; representatives of the Secretariats of the Pharmacopoeias of Republic of Korea and United States of America; as well as representatives from WHO Collaborating Centres in China and South Africa.\n\nShe said the WHO Member States and the world\u2019s political and international health leaders recognized the need to strengthen health systems, renew political interest in making sustainable improvements that benefited disease areas and health programmes, and to redouble global efforts to meet the challenge of achieving the Millennium Development Goals and renew primary health care systems. Dr Etienne said that health systems had to respond better and faster to the challenges of the changing world. She stressed the single framework for action with six building blocks (governance and leadership; financing; information; medical products, vaccines and technologies; health workforce; and service delivery); health systems and health outcome programmes; obtaining results; and a more effective role for WHO at country level.\n\nMedicines were an important component of the health system; however, unavailability, costliness and lack of quality, including counterfeit medicines, were issues of concern to countries. Developing countries with these problems were accepting policy and regulatory change as well as enforcing laws and regulations to improve availability.\n\nThe work of this Expert Committee was important to WHO Member States, United Nations and international organizations, and also in-house for all programmes dealing with medicines. One example was the Prequalification Programme (PQP) which was based entirely on the ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas se reuni\u00f3 en Ginebra del 12 al 16 de octubre de 2009. La reuni\u00f3n fue inaugurada por la Dra. Carissa F. Etienne, quien destac\u00f3 la importancia de fortalecer los sistemas de salud y mejorar la calidad de los medicamentos. Se abordaron temas como la disponibilidad, el costo y la calidad de los medicamentos, incluyendo el problema de los medicamentos falsificados. La Dra. Etienne enfatiz\u00f3 la necesidad de un marco de acci\u00f3n que incluya seis bloques fundamentales para mejorar los sistemas de salud y alcanzar los Objetivos de Desarrollo del Milenio.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los seis bloques fundamentales que se mencionan como parte del marco de acci\u00f3n para mejorar los sistemas de salud?**\n   - Respuesta: Los seis bloques fundamentales son: gobernanza y liderazgo, financiamiento, informaci\u00f3n, productos m\u00e9dicos, vacunas y tecnolog\u00edas, fuerza laboral de salud, y entrega de servicios.\n\n2. **\u00bfQu\u00e9 papel desempe\u00f1a el Programa de Precalificaci\u00f3n (PQP) en el contexto de la calidad de los medicamentos seg\u00fan la reuni\u00f3n del Comit\u00e9 de Expertos?**\n   - Respuesta: El Programa de Precalificaci\u00f3n (PQP) es un ejemplo del trabajo del Comit\u00e9, que se basa en asegurar la calidad de los medicamentos y es fundamental para los Estados Miembros de la OMS y otras organizaciones internacionales.\n\n3. **\u00bfQu\u00e9 desaf\u00edos enfrentan los pa\u00edses en desarrollo en relaci\u00f3n con la disponibilidad y calidad de los medicamentos, seg\u00fan la Dra. Etienne?**\n   - Respuesta: Los pa\u00edses en desarrollo enfrentan problemas de disponibilidad, altos costos y falta de calidad de los medicamentos, incluyendo la presencia de medicamentos falsificados, lo que ha llevado a estos pa\u00edses a aceptar cambios en pol\u00edticas y regulaciones para mejorar la situaci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento mencionado, \"WHO - Technical Report Series 957\", es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque el contenido espec\u00edfico no est\u00e1 disponible, se puede inferir que el informe aborda temas relevantes en el \u00e1mbito de la salud p\u00fablica, investigaci\u00f3n m\u00e9dica y pol\u00edticas de salud. \n\n#### Temas clave:\n- **Salud p\u00fablica**: Posiblemente incluye hallazgos y recomendaciones sobre la salud de las poblaciones.\n- **Investigaci\u00f3n m\u00e9dica**: Puede presentar estudios o datos relevantes en el campo de la medicina.\n- **Pol\u00edticas de salud**: Es probable que ofrezca recomendaciones que impacten las pol\u00edticas de salud a nivel global.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la publicaci\u00f3n del informe.\n- **Technical Report Series**: La serie a la que pertenece el documento, que se centra en temas t\u00e9cnicos relacionados con la salud.\n\nEste resumen proporciona una visi\u00f3n general de lo que se puede esperar del informe, a pesar de la falta de contenido espec\u00edfico en el contexto proporcionado.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, health systems, quality assurance, Prequalification Programme"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e5083336-2391-4dbc-b0ec-a3aafe747f0c", "node_type": "4", "metadata": {"page_label": "15", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations met in Geneva from 12 to 16 October 2009. Dr Carissa F. Etienne, Assistant Director-General, Health Systems and Services (HSS), opened the meeting and, on behalf of the Director-General of the World Health Organization, welcomed all the participants to the forty-fourth meeting. She expressed her appreciation of the Expert Committee for its knowledge of and expertise in the work of WHO in the area of quality assurance of medicines. Dr Etienne welcomed the members of the Committee, temporary advisers and special advisers for prequalification; representatives of the United Nations Children\u2019s Fund, the Global Fund to Fight AIDS, Tuberculosis and Malaria, Council of Europe/European Directorate for the Quality of Medicines and HealthCare, European Medicines Agency, International Federation of Pharmaceutical Manufacturers and Associations, International Generic Pharmaceutical Alliance, International Pharmaceutical Excipients Council, International Pharmaceutical Federation, World Self-Medication Industry and an observer from the European Association of Pharmaceutical Full-line Wholesalers; representatives of the Secretariats of the Pharmacopoeias of Republic of Korea and United States of America; as well as representatives from WHO Collaborating Centres in China and South Africa.\n\nShe said the WHO Member States and the world\u2019s political and international health leaders recognized the need to strengthen health systems, renew political interest in making sustainable improvements that benefited disease areas and health programmes, and to redouble global efforts to meet the challenge of achieving the Millennium Development Goals and renew primary health care systems. Dr Etienne said that health systems had to respond better and faster to the challenges of the changing world. She stressed the single framework for action with six building blocks (governance and leadership; financing; information; medical products, vaccines and technologies; health workforce; and service delivery); health systems and health outcome programmes; obtaining results; and a more effective role for WHO at country level.\n\nMedicines were an important component of the health system; however, unavailability, costliness and lack of quality, including counterfeit medicines, were issues of concern to countries. Developing countries with these problems were accepting policy and regulatory change as well as enforcing laws and regulations to improve availability.\n\nThe work of this Expert Committee was important to WHO Member States, United Nations and international organizations, and also in-house for all programmes dealing with medicines. One example was the Prequalification Programme (PQP) which was based entirely on the ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a49a7d0d3364c4c870c1db9daca22496c211a7eff7866ef81ba9c8006609c965", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Introduction\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations met in Geneva from 12 to 16 October 2009. Dr Carissa F. Etienne, Assistant Director-General, Health Systems and Services (HSS), opened the meeting and, on behalf of the Director-General of the World Health Organization, welcomed all the participants to the forty-fourth meeting. She expressed her appreciation of the Expert Committee for its knowledge of and expertise in the work of WHO in the area of quality assurance of medicines. Dr Etienne welcomed the members of the Committee, temporary advisers and special advisers for prequalification; representatives of the United Nations Children\u2019s Fund, the Global Fund to Fight AIDS, Tuberculosis and Malaria, Council of Europe/European Directorate for the Quality of Medicines and HealthCare, European Medicines Agency, International Federation of Pharmaceutical Manufacturers and Associations, International Generic Pharmaceutical Alliance, International Pharmaceutical Excipients Council, International Pharmaceutical Federation, World Self-Medication Industry and an observer from the European Association of Pharmaceutical Full-line Wholesalers; representatives of the Secretariats of the Pharmacopoeias of Republic of Korea and United States of America; as well as representatives from WHO Collaborating Centres in China and South Africa.\n\nShe said the WHO Member States and the world\u2019s political and international health leaders recognized the need to strengthen health systems, renew political interest in making sustainable improvements that benefited disease areas and health programmes, and to redouble global efforts to meet the challenge of achieving the Millennium Development Goals and renew primary health care systems. Dr Etienne said that health systems had to respond better and faster to the challenges of the changing world. She stressed the single framework for action with six building blocks (governance and leadership; financing; information; medical products, vaccines and technologies; health workforce; and service delivery); health systems and health outcome programmes; obtaining results; and a more effective role for WHO at country level.\n\nMedicines were an important component of the health system; however, unavailability, costliness and lack of quality, including counterfeit medicines, were issues of concern to countries. Developing countries with these problems were accepting policy and regulatory change as well as enforcing laws and regulations to improve availability.\n\nThe work of this Expert Committee was important to WHO Member States, United Nations and international organizations, and also in-house for all programmes dealing with medicines. One example was the Prequalification Programme (PQP) which was based entirely on the", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2815, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "afd770a7-1670-42e2-97bb-6248c77351f0": {"__data__": {"id_": "afd770a7-1670-42e2-97bb-6248c77351f0", "embedding": null, "metadata": {"page_label": "16", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The implementation of guidelines and standards recommended by the Expert Committee on Specifications for Pharmaceutical Preparations was closely linked to other organizations, such as the European Medicines Agency, European Directorate for the Quality of Medicines and HealthCare, the Global Fund to Fight AIDS, Tuberculosis and Malaria, International Atomic Energy Agency, United Nations Children\u2019s Fund, World Intellectual Property Organization, World Bank, International Pharmaceutical Federation, International Federation of Pharmaceutical Manufacturers and Associations, World Self-Medication Industry, national and regional pharmacopoeias, other clusters, institutions, bodies, authorities, and other WHO Expert Committees.\n\nExperts and the Secretariat were committed to enabling quality medicines to reach patients. Dr. Etienne raised the issue of counterfeit medicines, which should be addressed as a public health problem. Discussion during the Executive Board meeting in January 2009 regarding the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) and counterfeit medicines issues in general raised concerns regarding WHO\u2019s role in this area. (For a further update see section 2.3.)\n\nDr. Gilles Forte, speaking on behalf of the Director, Essential Medicines and Pharmaceutical Policies (EMP), expressed the importance of the Committee\u2019s work on standard-setting for the functionality of good manufacturing practices (GMP); he also emphasized that the improvement of quality assurance, updating of quality guidelines and laboratory testing were key functions of the Committee. Dr. Forte also acknowledged that the agenda was very impressive and thanked the Expert Committee for its support in helping define and address future challenges. He emphasized that WHO valued the work carried out by this Expert Committee.\n\nDr. Lembit R\u00e4go, Coordinator of the Quality Assurance and Safety: Medicines team, said that nowadays funding for the team mainly originated from external donors in order to sustain its activities, comprising those of this Expert Committee. The team, including the Medicines Quality Assurance Programme, must continue to attract donors and to date it had been relatively successful in obtaining donor funding.\n\nA current challenge was related to the fact that a WHO Collaborating Centre had closed due to restructuring in Sweden, but the Programme was very hopeful that it could obtain a replacement institute quickly.\n\nDr. R\u00e4go informed the Committee that the Medicines Strategy was in print following the usual consultative process. It would be put on the web site for the next biennium with a link to the Millennium Development Goals.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Colaboraci\u00f3n Internacional en Medicamentos**: El texto destaca la importancia de la colaboraci\u00f3n entre la OMS y diversas organizaciones internacionales en la implementaci\u00f3n de directrices y est\u00e1ndares para la preparaci\u00f3n farmac\u00e9utica. Se menciona la necesidad de asegurar que los medicamentos de calidad lleguen a los pacientes y se aborda el problema de los medicamentos falsificados como un desaf\u00edo de salud p\u00fablica.\n\n2. **Desaf\u00edos en la Garant\u00eda de Calidad**: Se discuten los esfuerzos del Comit\u00e9 de Expertos en establecer normas para las buenas pr\u00e1cticas de manufactura (GMP) y la importancia de la mejora de la garant\u00eda de calidad y la actualizaci\u00f3n de las directrices de calidad. Tambi\u00e9n se menciona la dependencia del financiamiento externo para mantener las actividades del equipo de Garant\u00eda de Calidad y Seguridad de Medicamentos.\n\n3. **Estrategia de Medicamentos y Desarrollo Sostenible**: Se informa que la Estrategia de Medicamentos est\u00e1 en proceso de publicaci\u00f3n y se vincular\u00e1 con los Objetivos de Desarrollo del Milenio, lo que subraya la conexi\u00f3n entre la calidad de los medicamentos y los objetivos globales de salud.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 papel desempe\u00f1a la OMS en la lucha contra los medicamentos falsificados y c\u00f3mo se relaciona esto con el trabajo del Comit\u00e9 de Expertos?**\n   - Respuesta: La OMS aborda el problema de los medicamentos falsificados como un desaf\u00edo de salud p\u00fablica, y el Comit\u00e9 de Expertos trabaja en la implementaci\u00f3n de directrices y est\u00e1ndares que ayudan a combatir este problema, como se discuti\u00f3 en la reuni\u00f3n del Consejo Ejecutivo en enero de 2009.\n\n2. **\u00bfCu\u00e1les son las principales funciones del Comit\u00e9 de Expertos en relaci\u00f3n con las buenas pr\u00e1cticas de manufactura (GMP) y la garant\u00eda de calidad?**\n   - Respuesta: Las principales funciones del Comit\u00e9 incluyen el establecimiento de normas para las GMP, la mejora de la garant\u00eda de calidad, la actualizaci\u00f3n de las directrices de calidad y la realizaci\u00f3n de pruebas de laboratorio, seg\u00fan lo expresado por Dr. Gilles Forte.\n\n3. **\u00bfC\u00f3mo afecta el cierre de un Centro Colaborador de la OMS en Suecia a las actividades del Programa de Garant\u00eda de Calidad de Medicamentos?**\n   - Respuesta: El cierre de un Centro Colaborador en Suecia representa un desaf\u00edo actual para el Programa de Garant\u00eda de Calidad de Medicamentos, aunque el Programa es optimista sobre la posibilidad de obtener un instituto de reemplazo r\u00e1pidamente para continuar sus actividades.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Fortalecimiento de Sistemas de Salud:** La Dra. Carissa F. Etienne destac\u00f3 la necesidad de mejorar los sistemas de salud a nivel global, enfatizando la importancia de realizar mejoras sostenibles en \u00e1reas de enfermedades y programas de salud.\n2. **Desaf\u00edos en la Disponibilidad y Calidad de Medicamentos:** Se abordaron problemas como la falta de disponibilidad, altos costos y la calidad de los medicamentos, incluyendo la amenaza de medicamentos falsificados.\n3. **Marco de Acci\u00f3n:** Se present\u00f3 un marco de acci\u00f3n que incluye seis bloques fundamentales para mejorar los sistemas de salud: gobernanza y liderazgo, financiamiento, informaci\u00f3n, productos m\u00e9dicos, vacunas y tecnolog\u00edas, fuerza laboral de salud, y entrega de servicios.\n4. **Programa de Precalificaci\u00f3n (PQP):** Se mencion\u00f3 el PQP como un ejemplo del trabajo del Comit\u00e9, enfocado en asegurar la calidad de los medicamentos y su relevancia para los Estados Miembros de la OMS y otras organizaciones internacionales.\n\n**Entidades Mencionadas:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Principal entidad organizadora de la reuni\u00f3n.\n- **Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas:** Grupo que se reuni\u00f3 para discutir temas de calidad de medicamentos.\n- **Representantes de diversas organizaciones:** Incluyendo UNICEF, el Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria, la Agencia Europea de Medicamentos, y varias federaciones y consejos internacionales relacionados con la industria farmac\u00e9utica.\n- **Centros Colaboradores de la OMS en China y Sud\u00e1frica:** Entidades que contribuyen a los esfuerzos de la OMS en el \u00e1mbito de la salud.\n\nEste resumen destaca la importancia de la reuni\u00f3n y los esfuerzos globales para mejorar la calidad y disponibilidad de los medicamentos, as\u00ed como el papel crucial de la OMS y otras organizaciones en este proceso.", "excerpt_keywords": "Keywords: WHO, counterfeit medicines, quality assurance, good manufacturing practices, international collaboration"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4a35c891-6074-4bcd-97d4-e3b03e80f37b", "node_type": "4", "metadata": {"page_label": "16", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The implementation of guidelines and standards recommended by the Expert Committee on Specifications for Pharmaceutical Preparations was closely linked to other organizations, such as the European Medicines Agency, European Directorate for the Quality of Medicines and HealthCare, the Global Fund to Fight AIDS, Tuberculosis and Malaria, International Atomic Energy Agency, United Nations Children\u2019s Fund, World Intellectual Property Organization, World Bank, International Pharmaceutical Federation, International Federation of Pharmaceutical Manufacturers and Associations, World Self-Medication Industry, national and regional pharmacopoeias, other clusters, institutions, bodies, authorities, and other WHO Expert Committees.\n\nExperts and the Secretariat were committed to enabling quality medicines to reach patients. Dr. Etienne raised the issue of counterfeit medicines, which should be addressed as a public health problem. Discussion during the Executive Board meeting in January 2009 regarding the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) and counterfeit medicines issues in general raised concerns regarding WHO\u2019s role in this area. (For a further update see section 2.3.)\n\nDr. Gilles Forte, speaking on behalf of the Director, Essential Medicines and Pharmaceutical Policies (EMP), expressed the importance of the Committee\u2019s work on standard-setting for the functionality of good manufacturing practices (GMP); he also emphasized that the improvement of quality assurance, updating of quality guidelines and laboratory testing were key functions of the Committee. Dr. Forte also acknowledged that the agenda was very impressive and thanked the Expert Committee for its support in helping define and address future challenges. He emphasized that WHO valued the work carried out by this Expert Committee.\n\nDr. Lembit R\u00e4go, Coordinator of the Quality Assurance and Safety: Medicines team, said that nowadays funding for the team mainly originated from external donors in order to sustain its activities, comprising those of this Expert Committee. The team, including the Medicines Quality Assurance Programme, must continue to attract donors and to date it had been relatively successful in obtaining donor funding.\n\nA current challenge was related to the fact that a WHO Collaborating Centre had closed due to restructuring in Sweden, but the Programme was very hopeful that it could obtain a replacement institute quickly.\n\nDr. R\u00e4go informed the Committee that the Medicines Strategy was in print following the usual consultative process. It would be put on the web site for the next biennium with a link to the Millennium Development Goals.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "c2dc959981bc96b3ba533bac63feb081a990264b88b16751924d7631d3902dab", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The implementation of guidelines and standards recommended by the Expert Committee on Specifications for Pharmaceutical Preparations was closely linked to other organizations, such as the European Medicines Agency, European Directorate for the Quality of Medicines and HealthCare, the Global Fund to Fight AIDS, Tuberculosis and Malaria, International Atomic Energy Agency, United Nations Children\u2019s Fund, World Intellectual Property Organization, World Bank, International Pharmaceutical Federation, International Federation of Pharmaceutical Manufacturers and Associations, World Self-Medication Industry, national and regional pharmacopoeias, other clusters, institutions, bodies, authorities, and other WHO Expert Committees.\n\nExperts and the Secretariat were committed to enabling quality medicines to reach patients. Dr. Etienne raised the issue of counterfeit medicines, which should be addressed as a public health problem. Discussion during the Executive Board meeting in January 2009 regarding the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) and counterfeit medicines issues in general raised concerns regarding WHO\u2019s role in this area. (For a further update see section 2.3.)\n\nDr. Gilles Forte, speaking on behalf of the Director, Essential Medicines and Pharmaceutical Policies (EMP), expressed the importance of the Committee\u2019s work on standard-setting for the functionality of good manufacturing practices (GMP); he also emphasized that the improvement of quality assurance, updating of quality guidelines and laboratory testing were key functions of the Committee. Dr. Forte also acknowledged that the agenda was very impressive and thanked the Expert Committee for its support in helping define and address future challenges. He emphasized that WHO valued the work carried out by this Expert Committee.\n\nDr. Lembit R\u00e4go, Coordinator of the Quality Assurance and Safety: Medicines team, said that nowadays funding for the team mainly originated from external donors in order to sustain its activities, comprising those of this Expert Committee. The team, including the Medicines Quality Assurance Programme, must continue to attract donors and to date it had been relatively successful in obtaining donor funding.\n\nA current challenge was related to the fact that a WHO Collaborating Centre had closed due to restructuring in Sweden, but the Programme was very hopeful that it could obtain a replacement institute quickly.\n\nDr. R\u00e4go informed the Committee that the Medicines Strategy was in print following the usual consultative process. It would be put on the web site for the next biennium with a link to the Millennium Development Goals.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2682, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c4d72780-af99-4164-88d0-1467a0095b6c": {"__data__": {"id_": "c4d72780-af99-4164-88d0-1467a0095b6c", "embedding": null, "metadata": {"page_label": "17", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Dr R\u00e4go thanked the members of the Expert Committee for their dedication and contribution to the work of WHO, and also for the help and time given.\n\nThe Secretary of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, Dr Sabine Kopp, explained the administrative process of appointment of experts and the working procedures related to the Expert Committee meeting.\n\nThe Secretary explained that the Expert Committee was an official advisory body to the Director-General of WHO and was governed through rules and procedures. The report of the WHO Expert Committee consisted of a summary of the discussions, recommendations to WHO and its Member States and included newly adopted guidelines. The report was presented to the WHO Governing Bodies for final comments, endorsement and implementation by Member States and constituted WHO technical guidance.\n\nThe Expert Committee consultation process involves several steps, i.e. preliminary consultation and drafting, circulation of the first draft for comments, revision of the draft, discussion of the draft by the WHO Expert Committee and finally, once adopted, publication in the Expert Committee report as an annex, submission to the WHO Governing Bodies and recommendation to Member States for implementation.\n\n## 2. General policy\n\n### 2.1 International collaboration\n\n#### 2.1.1 International organizations, agencies and nongovernmental organizations\n\nThe Expert Committee welcomed the collaboration of international organizations and agencies with the work of this Committee. The following presented their work in more detail.\n\n*European Directorate for the Quality of Medicines and HealthCare*\n\nThe European Directorate for the Quality of Medicines and HealthCare (EDQM) is responsible for a number of activities in collaboration with the European Union, related to surveillance of pharmaceutical products marketed and distributed in Europe. EDQM is at the centre of the European regulatory framework for medicines and one of its tasks since 2008 has been to protect patients in Europe from counterfeit medicines. Another activity transferred to EDQM in 2008 is the legal classification of medicines as regards their supply with or without medical prescription. Since 2009 EDQM activities have expanded to include newer areas, e.g. cosmetics and food contact materials, packaging and containers. EDQM collaborates in", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es un informe de la Organizaci\u00f3n Mundial de la Salud (OMS) que detalla el trabajo del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas. Se agradece a los miembros del Comit\u00e9 por su dedicaci\u00f3n y se explica el proceso administrativo de nombramiento de expertos y las normas que rigen el funcionamiento del Comit\u00e9. El informe incluye un resumen de las discusiones, recomendaciones y nuevas directrices adoptadas. Adem\u00e1s, se destaca la colaboraci\u00f3n con organizaciones internacionales, como la Direcci\u00f3n Europea de Calidad de Medicamentos y Atenci\u00f3n Sanitaria (EDQM), que se encarga de la vigilancia de productos farmac\u00e9uticos en Europa y de proteger a los pacientes de medicamentos falsificados.\n\n### Preguntas:\n1. **\u00bfCu\u00e1l es el proceso de consulta del Comit\u00e9 de Expertos de la OMS y qu\u00e9 pasos incluye?**\n   - El proceso de consulta del Comit\u00e9 de Expertos incluye varios pasos: consulta preliminar y redacci\u00f3n, circulaci\u00f3n del primer borrador para comentarios, revisi\u00f3n del borrador, discusi\u00f3n del borrador por el Comit\u00e9, y finalmente, una vez adoptado, su publicaci\u00f3n en el informe del Comit\u00e9 como un anexo, seguido de la presentaci\u00f3n a los \u00d3rganos de Gobierno de la OMS y recomendaci\u00f3n a los Estados Miembros para su implementaci\u00f3n.\n\n2. **\u00bfQu\u00e9 papel desempe\u00f1a la Direcci\u00f3n Europea de Calidad de Medicamentos y Atenci\u00f3n Sanitaria (EDQM) en la regulaci\u00f3n de medicamentos en Europa?**\n   - La EDQM es responsable de la vigilancia de productos farmac\u00e9uticos comercializados en Europa y ha estado protegiendo a los pacientes de medicamentos falsificados desde 2008. Tambi\u00e9n se encarga de la clasificaci\u00f3n legal de los medicamentos en cuanto a su suministro con o sin receta m\u00e9dica y ha ampliado sus actividades para incluir \u00e1reas como cosm\u00e9ticos y materiales en contacto con alimentos.\n\n3. **\u00bfQu\u00e9 tipo de recomendaciones se incluyen en el informe del Comit\u00e9 de Expertos de la OMS?**\n   - El informe del Comit\u00e9 de Expertos incluye un resumen de las discusiones mantenidas, recomendaciones dirigidas a la OMS y a sus Estados Miembros, as\u00ed como nuevas directrices adoptadas que constituyen la orientaci\u00f3n t\u00e9cnica de la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Colaboraci\u00f3n Internacional**: La implementaci\u00f3n de directrices y est\u00e1ndares para la preparaci\u00f3n farmac\u00e9utica est\u00e1 estrechamente vinculada a diversas organizaciones, incluyendo:\n   - Agencia Europea de Medicamentos\n   - Direcci\u00f3n Europea de Calidad de Medicamentos y Atenci\u00f3n Sanitaria\n   - Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria\n   - Agencia Internacional de Energ\u00eda At\u00f3mica\n   - Fondo de las Naciones Unidas para la Infancia (UNICEF)\n   - Organizaci\u00f3n Mundial de la Propiedad Intelectual\n   - Banco Mundial\n   - Federaci\u00f3n Internacional Farmac\u00e9utica\n   - Asociaci\u00f3n Internacional de Fabricantes y Asociaciones Farmac\u00e9uticas\n   - Industria Mundial de la Automedicaci\u00f3n\n   - Farmacopeas nacionales y regionales\n\n2. **Problemas de Salud P\u00fablica**: Se destaca la preocupaci\u00f3n por los medicamentos falsificados, considerados un problema de salud p\u00fablica, y la necesidad de que la OMS aborde este desaf\u00edo.\n\n3. **Funciones del Comit\u00e9 de Expertos**: El Comit\u00e9 se enfoca en:\n   - Establecimiento de normas para las Buenas Pr\u00e1cticas de Manufactura (GMP).\n   - Mejora de la garant\u00eda de calidad.\n   - Actualizaci\u00f3n de directrices de calidad y pruebas de laboratorio.\n\n4. **Financiamiento y Sostenibilidad**: La financiaci\u00f3n del equipo de Garant\u00eda de Calidad y Seguridad de Medicamentos proviene principalmente de donantes externos, lo que es crucial para mantener sus actividades.\n\n5. **Desaf\u00edos Actuales**: El cierre de un Centro Colaborador de la OMS en Suecia representa un desaf\u00edo, aunque se espera encontrar un instituto de reemplazo pronto.\n\n6. **Estrategia de Medicamentos**: La Estrategia de Medicamentos est\u00e1 en proceso de publicaci\u00f3n y se vincular\u00e1 con los Objetivos de Desarrollo del Milenio, subrayando la conexi\u00f3n entre la calidad de los medicamentos y los objetivos globales de salud.", "excerpt_keywords": "Keywords: WHO, Expert Committee, pharmaceutical preparations, international collaboration, counterfeit medicines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4c98a419-c2a9-4730-8ddf-b15994229c43", "node_type": "4", "metadata": {"page_label": "17", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Dr R\u00e4go thanked the members of the Expert Committee for their dedication and contribution to the work of WHO, and also for the help and time given.\n\nThe Secretary of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, Dr Sabine Kopp, explained the administrative process of appointment of experts and the working procedures related to the Expert Committee meeting.\n\nThe Secretary explained that the Expert Committee was an official advisory body to the Director-General of WHO and was governed through rules and procedures. The report of the WHO Expert Committee consisted of a summary of the discussions, recommendations to WHO and its Member States and included newly adopted guidelines. The report was presented to the WHO Governing Bodies for final comments, endorsement and implementation by Member States and constituted WHO technical guidance.\n\nThe Expert Committee consultation process involves several steps, i.e. preliminary consultation and drafting, circulation of the first draft for comments, revision of the draft, discussion of the draft by the WHO Expert Committee and finally, once adopted, publication in the Expert Committee report as an annex, submission to the WHO Governing Bodies and recommendation to Member States for implementation.\n\n## 2. General policy\n\n### 2.1 International collaboration\n\n#### 2.1.1 International organizations, agencies and nongovernmental organizations\n\nThe Expert Committee welcomed the collaboration of international organizations and agencies with the work of this Committee. The following presented their work in more detail.\n\n*European Directorate for the Quality of Medicines and HealthCare*\n\nThe European Directorate for the Quality of Medicines and HealthCare (EDQM) is responsible for a number of activities in collaboration with the European Union, related to surveillance of pharmaceutical products marketed and distributed in Europe. EDQM is at the centre of the European regulatory framework for medicines and one of its tasks since 2008 has been to protect patients in Europe from counterfeit medicines. Another activity transferred to EDQM in 2008 is the legal classification of medicines as regards their supply with or without medical prescription. Since 2009 EDQM activities have expanded to include newer areas, e.g. cosmetics and food contact materials, packaging and containers. EDQM collaborates in", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "9085939f874dd6530bff5e789c5072200375a197defa6fa22ffb31f15abf2b61", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Dr R\u00e4go thanked the members of the Expert Committee for their dedication and contribution to the work of WHO, and also for the help and time given.\n\nThe Secretary of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, Dr Sabine Kopp, explained the administrative process of appointment of experts and the working procedures related to the Expert Committee meeting.\n\nThe Secretary explained that the Expert Committee was an official advisory body to the Director-General of WHO and was governed through rules and procedures. The report of the WHO Expert Committee consisted of a summary of the discussions, recommendations to WHO and its Member States and included newly adopted guidelines. The report was presented to the WHO Governing Bodies for final comments, endorsement and implementation by Member States and constituted WHO technical guidance.\n\nThe Expert Committee consultation process involves several steps, i.e. preliminary consultation and drafting, circulation of the first draft for comments, revision of the draft, discussion of the draft by the WHO Expert Committee and finally, once adopted, publication in the Expert Committee report as an annex, submission to the WHO Governing Bodies and recommendation to Member States for implementation.\n\n## 2. General policy\n\n### 2.1 International collaboration\n\n#### 2.1.1 International organizations, agencies and nongovernmental organizations\n\nThe Expert Committee welcomed the collaboration of international organizations and agencies with the work of this Committee. The following presented their work in more detail.\n\n*European Directorate for the Quality of Medicines and HealthCare*\n\nThe European Directorate for the Quality of Medicines and HealthCare (EDQM) is responsible for a number of activities in collaboration with the European Union, related to surveillance of pharmaceutical products marketed and distributed in Europe. EDQM is at the centre of the European regulatory framework for medicines and one of its tasks since 2008 has been to protect patients in Europe from counterfeit medicines. Another activity transferred to EDQM in 2008 is the legal classification of medicines as regards their supply with or without medical prescription. Since 2009 EDQM activities have expanded to include newer areas, e.g. cosmetics and food contact materials, packaging and containers. EDQM collaborates in", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2394, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "cd8acc5b-e110-4a6d-a4dd-427c8baca7b0": {"__data__": {"id_": "cd8acc5b-e110-4a6d-a4dd-427c8baca7b0", "embedding": null, "metadata": {"page_label": "18", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan proporcionar respuestas espec\u00edficas basadas en el contexto del documento \"WHO - Technical Report Series 957\":\n\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentadas en el Informe 44 de la Serie de Informes T\u00e9cnicos de la OMS?**\n   - Esta pregunta busca obtener informaci\u00f3n espec\u00edfica sobre el contenido del informe, que podr\u00eda no estar disponible en otras fuentes.\n\n2. **\u00bfQu\u00e9 metodolog\u00edas se utilizaron para la recopilaci\u00f3n de datos en el Informe 44 de la Serie de Informes T\u00e9cnicos de la OMS?**\n   - Esta pregunta se centra en los m\u00e9todos de investigaci\u00f3n y an\u00e1lisis que sustentan las conclusiones del informe, lo cual es crucial para entender la validez de los resultados.\n\n3. **\u00bfC\u00f3mo se relaciona el Informe 44 de la Serie de Informes T\u00e9cnicos de la OMS con otros informes previos en la misma serie?**\n   - Esta pregunta busca establecer conexiones y comparaciones entre diferentes informes, lo que podr\u00eda ofrecer una perspectiva m\u00e1s amplia sobre la evoluci\u00f3n de los temas tratados por la OMS.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento \"WHO - Technical Report Series 957\" es parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n cient\u00edfica y recomendaciones para pol\u00edticas de salud. El Informe 44, en particular, podr\u00eda contener an\u00e1lisis detallados sobre un tema espec\u00edfico de inter\u00e9s para la comunidad de salud global, as\u00ed como recomendaciones basadas en evidencia para mejorar la salud p\u00fablica.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Comit\u00e9 de Expertos de la OMS**:\n   - Agradecimiento a los miembros por su dedicaci\u00f3n y contribuciones.\n   - Funciona como un cuerpo asesor oficial del Director General de la OMS, regido por normas y procedimientos.\n\n2. **Proceso de Consulta**:\n   - Incluye pasos como consulta preliminar, redacci\u00f3n, circulaci\u00f3n del borrador para comentarios, revisi\u00f3n, discusi\u00f3n y publicaci\u00f3n en el informe del Comit\u00e9.\n   - El informe incluye un resumen de discusiones, recomendaciones y nuevas directrices, que son presentadas a los \u00d3rganos de Gobierno de la OMS para su implementaci\u00f3n.\n\n3. **Colaboraci\u00f3n Internacional**:\n   - Se destaca la colaboraci\u00f3n con organizaciones internacionales y agencias, en particular con la **Direcci\u00f3n Europea de Calidad de Medicamentos y Atenci\u00f3n Sanitaria (EDQM)**.\n\n4. **Direcci\u00f3n Europea de Calidad de Medicamentos y Atenci\u00f3n Sanitaria (EDQM)**:\n   - Responsable de la vigilancia de productos farmac\u00e9uticos en Europa.\n   - Protege a los pacientes de medicamentos falsificados desde 2008.\n   - Se encarga de la clasificaci\u00f3n legal de medicamentos y ha ampliado sus actividades a cosm\u00e9ticos y materiales en contacto con alimentos.\n\nEste resumen destaca la estructura y funcionamiento del Comit\u00e9 de Expertos de la OMS, su proceso de consulta y la colaboraci\u00f3n con la EDQM en la regulaci\u00f3n de medicamentos en Europa.", "excerpt_keywords": "Keywords: OMS, Informe 44, salud p\u00fablica, medicamentos, colaboraci\u00f3n internacional"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e21c9cc3-ef40-4e24-a8c5-df6b228b1dd4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f77bfe70-c537-495c-bfba-59725a5427aa": {"__data__": {"id_": "f77bfe70-c537-495c-bfba-59725a5427aa", "embedding": null, "metadata": {"page_label": "19", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# International Federation of Pharmaceutical Manufacturers and Associations\n\nThe International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) had official observer status with the United Nations in Geneva, including WHO. IFPMA represents the research-based pharmaceutical, biotechnological and vaccine industry, and global intergovernmental agencies. It advocates policies that encourage discovery of new life-saving and life-enhancing medicines.\n\nIFPMA supports high standards of manufacturing and quality assurance in two areas:\n\n- Vaccines and biotechnology products, working in collaboration with WHO/EMP and the WHO Expert Committee on Biological Standardization; and\n- Medicines, including medicines for children, in collaboration with this Expert Committee and the WHO Expert Committee on the Selection and Use of Essential Medicines.\n\n# International Generic Pharmaceutical Alliance\n\nThe International Generic Pharmaceutical Alliance (IGPA) has member generic trade associations from Canada, Europe, India, Japan and the USA. Observer status had been granted within the last year to generic associations from Brazil, the People\u2019s Republic of China, Jordan and South Africa; observer status for Malaysia and Mexico was currently under consideration.\n\nThe General Policy Initiatives of IGPA comprise cross-cutting quality assurance issues, collaboration with the WHO Expert Committee on Biological Standardization and International Collaboration (ICH Expert Working Groups on Quality and Safety). Other activities supported by IGPA are:\n\n- Nomenclature, terminology and databases \u2014 IGPA and the European Generic Medicines Association (EGA) have been involved in the discussion of international nonproprietary names (INN) for biologicals and biosimilars;\n- Prequalification of priority essential medicines \u2014 EGA works with WHO on an accelerated prequalification procedure for generics approved by SRAs;\n- Bioequivalence \u2014 although not on the WHO Expert Committee\u2019s agenda, IGPA was working on a proposal for international harmonization of bioequivalence requirements; and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento presenta informaci\u00f3n sobre dos organizaciones clave en la industria farmac\u00e9utica: la Federaci\u00f3n Internacional de Asociaciones de Fabricantes de Productos Farmac\u00e9uticos (IFPMA) y la Alianza Internacional de Productos Farmac\u00e9uticos Gen\u00e9ricos (IGPA). La IFPMA act\u00faa como observador ante las Naciones Unidas y representa a la industria farmac\u00e9utica basada en la investigaci\u00f3n, abogando por pol\u00edticas que fomenten el descubrimiento de nuevos medicamentos. La IGPA, por su parte, incluye asociaciones de gen\u00e9ricos de varios pa\u00edses y se enfoca en la calidad, la nomenclatura y la precalificaci\u00f3n de medicamentos esenciales. Ambas organizaciones colaboran con la OMS en diversas iniciativas relacionadas con la calidad y la regulaci\u00f3n de medicamentos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las \u00e1reas espec\u00edficas en las que la IFPMA colabora con la OMS y sus comit\u00e9s expertos?**\n   - La IFPMA colabora con la OMS en dos \u00e1reas principales: productos de vacunas y biotecnolog\u00eda, y medicamentos, incluyendo aquellos para ni\u00f1os, trabajando con el Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica y el Comit\u00e9 de Expertos en la Selecci\u00f3n y Uso de Medicamentos Esenciales.\n\n2. **\u00bfQu\u00e9 iniciativas de pol\u00edtica general se est\u00e1n llevando a cabo por la IGPA en relaci\u00f3n con la calidad de los medicamentos?**\n   - Las iniciativas de pol\u00edtica general de la IGPA incluyen cuestiones de aseguramiento de calidad, colaboraci\u00f3n con el Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica de la OMS, y el trabajo en nomenclatura y bases de datos para nombres no propietarios internacionales (INN) de biol\u00f3gicos y biosimilares.\n\n3. **\u00bfQu\u00e9 pa\u00edses han recibido recientemente el estatus de observador en la IGPA y cu\u00e1les est\u00e1n en consideraci\u00f3n?**\n   - Recientemente, se otorg\u00f3 el estatus de observador a asociaciones gen\u00e9ricas de Brasil, la Rep\u00fablica Popular de China, Jordania y Sud\u00e1frica. Actualmente, se est\u00e1 considerando el estatus de observador para Malasia y M\u00e9xico.", "prev_section_summary": "El contenido de la secci\u00f3n se refiere al \"WHO - Technical Report Series 957\", espec\u00edficamente al Informe 44 de esta serie. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n### Temas Clave:\n1. **Hallazgos y Recomendaciones**: Se busca informaci\u00f3n sobre los principales hallazgos y recomendaciones del Informe 44, que son cruciales para la salud p\u00fablica.\n2. **Metodolog\u00edas de Recopilaci\u00f3n de Datos**: Se enfatiza la importancia de las metodolog\u00edas utilizadas en la investigaci\u00f3n, lo que es fundamental para evaluar la validez de los resultados presentados en el informe.\n3. **Relaci\u00f3n con Informes Previos**: Se plantea la necesidad de comparar el Informe 44 con otros informes de la misma serie para entender la evoluci\u00f3n de los temas tratados por la OMS.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n de la serie de informes t\u00e9cnicos.\n- **Informe 44**: Documento espec\u00edfico dentro de la Serie de Informes T\u00e9cnicos de la OMS que aborda un tema relevante para la salud p\u00fablica.\n\n### Contexto General:\nEl documento es parte de una serie que aborda temas de salud p\u00fablica y proporciona recomendaciones basadas en evidencia para mejorar pol\u00edticas de salud a nivel global.", "excerpt_keywords": "Keywords: IFPMA, IGPA, pharmaceuticals, quality assurance, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "385c048f-a2ad-4e30-969f-bd120e447119", "node_type": "4", "metadata": {"page_label": "19", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# International Federation of Pharmaceutical Manufacturers and Associations\n\nThe International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) had official observer status with the United Nations in Geneva, including WHO. IFPMA represents the research-based pharmaceutical, biotechnological and vaccine industry, and global intergovernmental agencies. It advocates policies that encourage discovery of new life-saving and life-enhancing medicines.\n\nIFPMA supports high standards of manufacturing and quality assurance in two areas:\n\n- Vaccines and biotechnology products, working in collaboration with WHO/EMP and the WHO Expert Committee on Biological Standardization; and\n- Medicines, including medicines for children, in collaboration with this Expert Committee and the WHO Expert Committee on the Selection and Use of Essential Medicines.\n\n# International Generic Pharmaceutical Alliance\n\nThe International Generic Pharmaceutical Alliance (IGPA) has member generic trade associations from Canada, Europe, India, Japan and the USA. Observer status had been granted within the last year to generic associations from Brazil, the People\u2019s Republic of China, Jordan and South Africa; observer status for Malaysia and Mexico was currently under consideration.\n\nThe General Policy Initiatives of IGPA comprise cross-cutting quality assurance issues, collaboration with the WHO Expert Committee on Biological Standardization and International Collaboration (ICH Expert Working Groups on Quality and Safety). Other activities supported by IGPA are:\n\n- Nomenclature, terminology and databases \u2014 IGPA and the European Generic Medicines Association (EGA) have been involved in the discussion of international nonproprietary names (INN) for biologicals and biosimilars;\n- Prequalification of priority essential medicines \u2014 EGA works with WHO on an accelerated prequalification procedure for generics approved by SRAs;\n- Bioequivalence \u2014 although not on the WHO Expert Committee\u2019s agenda, IGPA was working on a proposal for international harmonization of bioequivalence requirements; and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "18e0c24533144f70b849cf05757015223518027deffbe74947c5a25c3a6b9a7e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# International Federation of Pharmaceutical Manufacturers and Associations\n\nThe International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) had official observer status with the United Nations in Geneva, including WHO. IFPMA represents the research-based pharmaceutical, biotechnological and vaccine industry, and global intergovernmental agencies. It advocates policies that encourage discovery of new life-saving and life-enhancing medicines.\n\nIFPMA supports high standards of manufacturing and quality assurance in two areas:\n\n- Vaccines and biotechnology products, working in collaboration with WHO/EMP and the WHO Expert Committee on Biological Standardization; and\n- Medicines, including medicines for children, in collaboration with this Expert Committee and the WHO Expert Committee on the Selection and Use of Essential Medicines.\n\n# International Generic Pharmaceutical Alliance\n\nThe International Generic Pharmaceutical Alliance (IGPA) has member generic trade associations from Canada, Europe, India, Japan and the USA. Observer status had been granted within the last year to generic associations from Brazil, the People\u2019s Republic of China, Jordan and South Africa; observer status for Malaysia and Mexico was currently under consideration.\n\nThe General Policy Initiatives of IGPA comprise cross-cutting quality assurance issues, collaboration with the WHO Expert Committee on Biological Standardization and International Collaboration (ICH Expert Working Groups on Quality and Safety). Other activities supported by IGPA are:\n\n- Nomenclature, terminology and databases \u2014 IGPA and the European Generic Medicines Association (EGA) have been involved in the discussion of international nonproprietary names (INN) for biologicals and biosimilars;\n- Prequalification of priority essential medicines \u2014 EGA works with WHO on an accelerated prequalification procedure for generics approved by SRAs;\n- Bioequivalence \u2014 although not on the WHO Expert Committee\u2019s agenda, IGPA was working on a proposal for international harmonization of bioequivalence requirements; and", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2097, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "93c70357-9649-4d5b-a713-cf4485a84ba7": {"__data__": {"id_": "93c70357-9649-4d5b-a713-cf4485a84ba7", "embedding": null, "metadata": {"page_label": "20", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# International Pharmaceutical Federation\n\nThe International Pharmaceutical Federation (FIP) reported that over the past year FIP and WHO had established work plans to support their involvement in key strategic collaborative areas of work. FIP\u2019s main priority was medicines and strengthening the pharmaceutical workforce. Other areas of importance included the roles and added value of pharmacists in patient safety, primary health care, noncommunicable diseases and maternal, newborn and child health. FIP continued to collaborate on these projects related to medicines in WHO.\n\nIn particular, the issue of good distribution practices (GDP) is an important element in securing the legitimate supply and distribution chain, and also in preventing the infiltration of counterfeit medical products (see section 8.2). FIP played an active role in the final revision and drafting of the WHO GDP guidelines in September 2009. FIP had produced a WHO/FIP Handbook on Developing Pharmacy Practice and is currently working towards a revision of the FIP/WHO guidelines on good pharmacy practice (GPP). FIP also assisted IMPACT in improving the information available to the public regarding counterfeit medicines and the work of IMPACT.\n\n# United Nations Children\u2019s Fund\n\nThe United Nations Children\u2019s Fund (UNICEF) promotes and protects children\u2019s rights, especially those of the most vulnerable in the poorest countries. UNICEF core commitments are health and nutrition, education, water and sanitation, child protection and HIV/AIDS.\n\nOne of the main activities of UNICEF is the supply of quality medicines to countries and communities in need; the supply headquarters is located in Copenhagen. The Supply Division oversees UNICEF\u2019s global supply procurement and logistics operations on behalf of UNICEF and its procurement services partners. It ensures that supplies of high quality and good value reach children and their families quickly.\n\nPrequalification of suppliers of pharmaceuticals in UNICEF involves the review of submitted documentation and/or GMP inspections to ensure compliance with WHO GMP guidelines using a technical questionnaire developed by WHO. The technical questionnaire covers manufacturing sites, dosage forms and products of interest, export experience and licence to manufacture pharmaceuticals. Local authorities are invited to participate in GMP inspections. There are also joint inspections with WHO and other partners.\n\nDecisions are based on the regulatory environment in the country of origin and prior experience of UNICEF, GMP inspection by UNICEF or by a", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento aborda la colaboraci\u00f3n entre la Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) y la Organizaci\u00f3n Mundial de la Salud (OMS) en \u00e1reas estrat\u00e9gicas relacionadas con medicamentos y el fortalecimiento de la fuerza laboral farmac\u00e9utica. Se destaca la importancia de las buenas pr\u00e1cticas de distribuci\u00f3n (GDP) para asegurar la cadena de suministro leg\u00edtima y prevenir productos m\u00e9dicos falsificados. Adem\u00e1s, se menciona el papel del Fondo de las Naciones Unidas para la Infancia (UNICEF) en la promoci\u00f3n y protecci\u00f3n de los derechos de los ni\u00f1os, as\u00ed como su compromiso con la provisi\u00f3n de medicamentos de calidad a comunidades necesitadas. UNICEF realiza la precalificaci\u00f3n de proveedores de productos farmac\u00e9uticos mediante revisiones y auditor\u00edas de buenas pr\u00e1cticas de manufactura (GMP).\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las \u00e1reas prioritarias en las que FIP y OMS han establecido planes de trabajo colaborativos?**\n   - Respuesta: Las \u00e1reas prioritarias incluyen medicamentos, el fortalecimiento de la fuerza laboral farmac\u00e9utica, la seguridad del paciente, la atenci\u00f3n primaria de salud, las enfermedades no transmisibles y la salud materna, neonatal y de los ni\u00f1os.\n\n2. **\u00bfQu\u00e9 papel desempe\u00f1a UNICEF en la provisi\u00f3n de medicamentos a comunidades vulnerables y c\u00f3mo se asegura la calidad de estos medicamentos?**\n   - Respuesta: UNICEF se encarga de suministrar medicamentos de calidad a comunidades necesitadas, y para asegurar la calidad, realiza la precalificaci\u00f3n de proveedores mediante revisiones de documentaci\u00f3n y auditor\u00edas de GMP, utilizando un cuestionario t\u00e9cnico desarrollado por la OMS.\n\n3. **\u00bfC\u00f3mo contribuy\u00f3 FIP a la elaboraci\u00f3n de las directrices de buenas pr\u00e1cticas de distribuci\u00f3n (GDP) de la OMS?**\n   - Respuesta: FIP jug\u00f3 un papel activo en la revisi\u00f3n final y redacci\u00f3n de las directrices de GDP de la OMS en septiembre de 2009, y ha trabajado en la producci\u00f3n de un manual sobre el desarrollo de la pr\u00e1ctica farmac\u00e9utica y en la revisi\u00f3n de las directrices de buenas pr\u00e1cticas farmac\u00e9uticas (GPP) de FIP/OMS.", "prev_section_summary": "La secci\u00f3n aborda dos organizaciones importantes en la industria farmac\u00e9utica: \n\n1. **Federaci\u00f3n Internacional de Asociaciones de Fabricantes de Productos Farmac\u00e9uticos (IFPMA)**:\n   - Tiene estatus de observador ante las Naciones Unidas y la OMS.\n   - Representa a la industria farmac\u00e9utica basada en la investigaci\u00f3n, biotecnolog\u00eda y vacunas.\n   - Aboga por pol\u00edticas que fomenten el descubrimiento de medicamentos nuevos y vitales.\n   - Colabora con la OMS en dos \u00e1reas principales: \n     - Productos de vacunas y biotecnolog\u00eda.\n     - Medicamentos, incluyendo aquellos para ni\u00f1os.\n\n2. **Alianza Internacional de Productos Farmac\u00e9uticos Gen\u00e9ricos (IGPA)**:\n   - Agrupa asociaciones de gen\u00e9ricos de varios pa\u00edses, incluyendo Canad\u00e1, Europa, India, Jap\u00f3n y EE. UU.\n   - Recientemente, se otorg\u00f3 estatus de observador a asociaciones de Brasil, China, Jordania y Sud\u00e1frica; Malasia y M\u00e9xico est\u00e1n en consideraci\u00f3n.\n   - Sus iniciativas de pol\u00edtica general se centran en:\n     - Aseguramiento de calidad.\n     - Colaboraci\u00f3n con la OMS en estandarizaci\u00f3n biol\u00f3gica.\n     - Nomenclatura y bases de datos para nombres no propietarios internacionales (INN) de biol\u00f3gicos y biosimilares.\n     - Precalificaci\u00f3n de medicamentos esenciales.\n     - Propuestas para la armonizaci\u00f3n internacional de requisitos de bioequivalencia.\n\nAmbas organizaciones trabajan en conjunto con la OMS para mejorar la calidad y regulaci\u00f3n de los medicamentos a nivel global.", "excerpt_keywords": "Keywords: International Pharmaceutical Federation, UNICEF, good distribution practices, pharmaceutical workforce, quality medicines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5c3c32ab-7bed-4a65-a2ed-fbc7676cef35", "node_type": "4", "metadata": {"page_label": "20", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# International Pharmaceutical Federation\n\nThe International Pharmaceutical Federation (FIP) reported that over the past year FIP and WHO had established work plans to support their involvement in key strategic collaborative areas of work. FIP\u2019s main priority was medicines and strengthening the pharmaceutical workforce. Other areas of importance included the roles and added value of pharmacists in patient safety, primary health care, noncommunicable diseases and maternal, newborn and child health. FIP continued to collaborate on these projects related to medicines in WHO.\n\nIn particular, the issue of good distribution practices (GDP) is an important element in securing the legitimate supply and distribution chain, and also in preventing the infiltration of counterfeit medical products (see section 8.2). FIP played an active role in the final revision and drafting of the WHO GDP guidelines in September 2009. FIP had produced a WHO/FIP Handbook on Developing Pharmacy Practice and is currently working towards a revision of the FIP/WHO guidelines on good pharmacy practice (GPP). FIP also assisted IMPACT in improving the information available to the public regarding counterfeit medicines and the work of IMPACT.\n\n# United Nations Children\u2019s Fund\n\nThe United Nations Children\u2019s Fund (UNICEF) promotes and protects children\u2019s rights, especially those of the most vulnerable in the poorest countries. UNICEF core commitments are health and nutrition, education, water and sanitation, child protection and HIV/AIDS.\n\nOne of the main activities of UNICEF is the supply of quality medicines to countries and communities in need; the supply headquarters is located in Copenhagen. The Supply Division oversees UNICEF\u2019s global supply procurement and logistics operations on behalf of UNICEF and its procurement services partners. It ensures that supplies of high quality and good value reach children and their families quickly.\n\nPrequalification of suppliers of pharmaceuticals in UNICEF involves the review of submitted documentation and/or GMP inspections to ensure compliance with WHO GMP guidelines using a technical questionnaire developed by WHO. The technical questionnaire covers manufacturing sites, dosage forms and products of interest, export experience and licence to manufacture pharmaceuticals. Local authorities are invited to participate in GMP inspections. There are also joint inspections with WHO and other partners.\n\nDecisions are based on the regulatory environment in the country of origin and prior experience of UNICEF, GMP inspection by UNICEF or by a", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "7ffd0db6e599018460702811c92d4a6c69268f08966fa72a604a15fa38679237", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# International Pharmaceutical Federation\n\nThe International Pharmaceutical Federation (FIP) reported that over the past year FIP and WHO had established work plans to support their involvement in key strategic collaborative areas of work. FIP\u2019s main priority was medicines and strengthening the pharmaceutical workforce. Other areas of importance included the roles and added value of pharmacists in patient safety, primary health care, noncommunicable diseases and maternal, newborn and child health. FIP continued to collaborate on these projects related to medicines in WHO.\n\nIn particular, the issue of good distribution practices (GDP) is an important element in securing the legitimate supply and distribution chain, and also in preventing the infiltration of counterfeit medical products (see section 8.2). FIP played an active role in the final revision and drafting of the WHO GDP guidelines in September 2009. FIP had produced a WHO/FIP Handbook on Developing Pharmacy Practice and is currently working towards a revision of the FIP/WHO guidelines on good pharmacy practice (GPP). FIP also assisted IMPACT in improving the information available to the public regarding counterfeit medicines and the work of IMPACT.\n\n# United Nations Children\u2019s Fund\n\nThe United Nations Children\u2019s Fund (UNICEF) promotes and protects children\u2019s rights, especially those of the most vulnerable in the poorest countries. UNICEF core commitments are health and nutrition, education, water and sanitation, child protection and HIV/AIDS.\n\nOne of the main activities of UNICEF is the supply of quality medicines to countries and communities in need; the supply headquarters is located in Copenhagen. The Supply Division oversees UNICEF\u2019s global supply procurement and logistics operations on behalf of UNICEF and its procurement services partners. It ensures that supplies of high quality and good value reach children and their families quickly.\n\nPrequalification of suppliers of pharmaceuticals in UNICEF involves the review of submitted documentation and/or GMP inspections to ensure compliance with WHO GMP guidelines using a technical questionnaire developed by WHO. The technical questionnaire covers manufacturing sites, dosage forms and products of interest, export experience and licence to manufacture pharmaceuticals. Local authorities are invited to participate in GMP inspections. There are also joint inspections with WHO and other partners.\n\nDecisions are based on the regulatory environment in the country of origin and prior experience of UNICEF, GMP inspection by UNICEF or by a", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2583, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d5f83f2a-cd16-4ed9-9cab-da42a5eabd27": {"__data__": {"id_": "d5f83f2a-cd16-4ed9-9cab-da42a5eabd27", "embedding": null, "metadata": {"page_label": "21", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "representative selected by UNICEF. Contract manufacture is only accepted if the subcontractor is also approved by UNICEF. Inspections are carried out primarily by UNICEF staff who check compliance with WHO GMP guidelines. During 2003\u20132009, 145 GMP inspections carried out in 47 companies failed (32%). In case of failure a detailed GMP inspection report is forwarded to the company with a request to respond within one month.\n\nIn case of prequalification of vaccines, HIV, malaria and tuberculosis products:\n- products have to be prequalified by WHO and listed on the WHO web site;\n- the supplier has to confirm to UNICEF that the products are identical to those assessed by WHO/UNICEF; and\n- UNICEF\u2019s purchase is traced in WHO/UNICEF GMP inspections.\n\n### 2.1.2 Pharmacopoeial Discussion Group\n\nThe Pharmacopoeial Discussion Group (PDG), which consists of the European Pharmacopoeia, Japanese Pharmacopoeia and United States Pharmacopeia, met in association with the Expert Working Groups of the International Conference on Harmonisation (ICH) from 8 to 12 June 2009 in Yokohama, Japan. The Secretary of this Expert Committee participated as an observer for WHO.\n\nThe experts recommended reviews of the following general methods against existing related *International Pharmacopoeia* (Ph.Int.) texts and adding those not yet included in the Ph.Int. for future adoption:\n- Test for extractable volume of parenteral preparations (General Chapter);\n- Test for particulate contamination: sub-visible particles (General Chapter);\n- Disintegration test;\n- Dissolution test (General Chapter) (pending availability of final text);\n- Sterility test (General Chapter);\n- Microbiological examination of non-sterile products; and\n- Acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use (General Chapter).\n\nThe Committee recommended that the following should be considered for adoption:\n- Microbiological examination of non-sterile products:\n  - Microbial enumeration tests (General Chapter);\n  - Tests for specified microorganisms (General Chapter); and\n- Tablet friability (General Chapter).\n\nThe Secretariat informed the experts that preliminary discussions had already been held with the PDG members, based on previous recommendations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento se centra en las directrices y procedimientos relacionados con la fabricaci\u00f3n y precalificaci\u00f3n de productos farmac\u00e9uticos, especialmente vacunas y tratamientos para el VIH, malaria y tuberculosis, bajo la supervisi\u00f3n de UNICEF y la OMS. Se menciona que las inspecciones de Buenas Pr\u00e1cticas de Manufactura (GMP) son realizadas principalmente por personal de UNICEF, y se reporta un porcentaje significativo de fallos en estas inspecciones. Adem\u00e1s, se discuten las recomendaciones del Grupo de Discusi\u00f3n Farmacopea (PDG) sobre m\u00e9todos generales que deben ser revisados y adoptados en relaci\u00f3n con la farmacopoeia internacional.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1l es el porcentaje de fallos en las inspecciones de GMP realizadas entre 2003 y 2009, y qu\u00e9 procedimiento se sigue en caso de un fallo?**\n   - Respuesta: Durante el per\u00edodo de 2003 a 2009, el 32% de las 145 inspecciones de GMP realizadas en 47 empresas fallaron. En caso de fallo, se env\u00eda un informe detallado de la inspecci\u00f3n a la empresa con una solicitud de respuesta dentro de un mes.\n\n2. **\u00bfQu\u00e9 requisitos deben cumplir los productos para ser precalificados por la OMS y adquiridos por UNICEF?**\n   - Respuesta: Los productos deben estar precalificados por la OMS y listados en su sitio web, el proveedor debe confirmar a UNICEF que los productos son id\u00e9nticos a los evaluados por la OMS/UNICEF, y la compra de UNICEF debe ser rastreada en las inspecciones de GMP de la OMS/UNICEF.\n\n3. **\u00bfCu\u00e1les son algunos de los m\u00e9todos generales recomendados para revisi\u00f3n y posible adopci\u00f3n por el Grupo de Discusi\u00f3n Farmacopea (PDG)?**\n   - Respuesta: Algunos de los m\u00e9todos recomendados incluyen la prueba de volumen extra\u00edble de preparaciones parenterales, la prueba de contaminaci\u00f3n particulada, la prueba de desintegraci\u00f3n, la prueba de disoluci\u00f3n, la prueba de esterilidad, la examen microbiol\u00f3gico de productos no est\u00e9riles, y criterios de aceptaci\u00f3n para preparaciones farmac\u00e9uticas y sustancias para uso farmac\u00e9utico.", "prev_section_summary": "La secci\u00f3n aborda la colaboraci\u00f3n entre la **Federaci\u00f3n Internacional Farmac\u00e9utica (FIP)** y la **Organizaci\u00f3n Mundial de la Salud (OMS)**, destacando sus planes de trabajo en \u00e1reas estrat\u00e9gicas como:\n\n- **Medicamentos** y fortalecimiento de la fuerza laboral farmac\u00e9utica.\n- **Seguridad del paciente**.\n- **Atenci\u00f3n primaria de salud**.\n- **Enfermedades no transmisibles**.\n- **Salud materna, neonatal y de los ni\u00f1os**.\n\nSe enfatiza la importancia de las **buenas pr\u00e1cticas de distribuci\u00f3n (GDP)** para asegurar la cadena de suministro leg\u00edtima y prevenir la infiltraci\u00f3n de productos m\u00e9dicos falsificados. FIP tuvo un papel activo en la elaboraci\u00f3n de las directrices de GDP de la OMS y en la producci\u00f3n de un manual sobre el desarrollo de la pr\u00e1ctica farmac\u00e9utica.\n\nAdem\u00e1s, se menciona el papel del **Fondo de las Naciones Unidas para la Infancia (UNICEF)** en la promoci\u00f3n y protecci\u00f3n de los derechos de los ni\u00f1os, especialmente en comunidades vulnerables. UNICEF se dedica a la provisi\u00f3n de medicamentos de calidad, asegurando su calidad a trav\u00e9s de la **precalificaci\u00f3n de proveedores** mediante revisiones de documentaci\u00f3n y auditor\u00edas de **buenas pr\u00e1cticas de manufactura (GMP)**, utilizando un cuestionario t\u00e9cnico desarrollado por la OMS.\n\nEn resumen, los temas clave incluyen la colaboraci\u00f3n en salud p\u00fablica, la seguridad en la distribuci\u00f3n de medicamentos y el compromiso de UNICEF con la salud infantil.", "excerpt_keywords": "Keywords: UNICEF, GMP inspections, prequalification, Pharmacopoeial Discussion Group, pharmaceutical standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0857578a-1422-4604-bd4b-16760b38af8f", "node_type": "4", "metadata": {"page_label": "21", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "representative selected by UNICEF. Contract manufacture is only accepted if the subcontractor is also approved by UNICEF. Inspections are carried out primarily by UNICEF staff who check compliance with WHO GMP guidelines. During 2003\u20132009, 145 GMP inspections carried out in 47 companies failed (32%). In case of failure a detailed GMP inspection report is forwarded to the company with a request to respond within one month.\n\nIn case of prequalification of vaccines, HIV, malaria and tuberculosis products:\n- products have to be prequalified by WHO and listed on the WHO web site;\n- the supplier has to confirm to UNICEF that the products are identical to those assessed by WHO/UNICEF; and\n- UNICEF\u2019s purchase is traced in WHO/UNICEF GMP inspections.\n\n### 2.1.2 Pharmacopoeial Discussion Group\n\nThe Pharmacopoeial Discussion Group (PDG), which consists of the European Pharmacopoeia, Japanese Pharmacopoeia and United States Pharmacopeia, met in association with the Expert Working Groups of the International Conference on Harmonisation (ICH) from 8 to 12 June 2009 in Yokohama, Japan. The Secretary of this Expert Committee participated as an observer for WHO.\n\nThe experts recommended reviews of the following general methods against existing related *International Pharmacopoeia* (Ph.Int.) texts and adding those not yet included in the Ph.Int. for future adoption:\n- Test for extractable volume of parenteral preparations (General Chapter);\n- Test for particulate contamination: sub-visible particles (General Chapter);\n- Disintegration test;\n- Dissolution test (General Chapter) (pending availability of final text);\n- Sterility test (General Chapter);\n- Microbiological examination of non-sterile products; and\n- Acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use (General Chapter).\n\nThe Committee recommended that the following should be considered for adoption:\n- Microbiological examination of non-sterile products:\n  - Microbial enumeration tests (General Chapter);\n  - Tests for specified microorganisms (General Chapter); and\n- Tablet friability (General Chapter).\n\nThe Secretariat informed the experts that preliminary discussions had already been held with the PDG members, based on previous recommendations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "7458854bf1c479504894724332a959bdf67fcb6480c322654e68421198adacc9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "representative selected by UNICEF. Contract manufacture is only accepted if the subcontractor is also approved by UNICEF. Inspections are carried out primarily by UNICEF staff who check compliance with WHO GMP guidelines. During 2003\u20132009, 145 GMP inspections carried out in 47 companies failed (32%). In case of failure a detailed GMP inspection report is forwarded to the company with a request to respond within one month.\n\nIn case of prequalification of vaccines, HIV, malaria and tuberculosis products:\n- products have to be prequalified by WHO and listed on the WHO web site;\n- the supplier has to confirm to UNICEF that the products are identical to those assessed by WHO/UNICEF; and\n- UNICEF\u2019s purchase is traced in WHO/UNICEF GMP inspections.\n\n### 2.1.2 Pharmacopoeial Discussion Group\n\nThe Pharmacopoeial Discussion Group (PDG), which consists of the European Pharmacopoeia, Japanese Pharmacopoeia and United States Pharmacopeia, met in association with the Expert Working Groups of the International Conference on Harmonisation (ICH) from 8 to 12 June 2009 in Yokohama, Japan. The Secretary of this Expert Committee participated as an observer for WHO.\n\nThe experts recommended reviews of the following general methods against existing related *International Pharmacopoeia* (Ph.Int.) texts and adding those not yet included in the Ph.Int. for future adoption:\n- Test for extractable volume of parenteral preparations (General Chapter);\n- Test for particulate contamination: sub-visible particles (General Chapter);\n- Disintegration test;\n- Dissolution test (General Chapter) (pending availability of final text);\n- Sterility test (General Chapter);\n- Microbiological examination of non-sterile products; and\n- Acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use (General Chapter).\n\nThe Committee recommended that the following should be considered for adoption:\n- Microbiological examination of non-sterile products:\n  - Microbial enumeration tests (General Chapter);\n  - Tests for specified microorganisms (General Chapter); and\n- Tablet friability (General Chapter).\n\nThe Secretariat informed the experts that preliminary discussions had already been held with the PDG members, based on previous recommendations.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2263, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "bd0c3afd-4869-434a-af6f-edd500fcbe7e": {"__data__": {"id_": "bd0c3afd-4869-434a-af6f-edd500fcbe7e", "embedding": null, "metadata": {"page_label": "22", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 2.1.3 International Conference on Harmonisation\n\nThe International Conference on Harmonisation (ICH) Expert Working Groups met from 8 to 12 June 2009 in Yokohama, Japan.\n\nThe Secretary of this Expert Committee also attended, as an observer for WHO, the ICH Q4B Working Group meetings (consisting of members from the six ICH partners and observers). An update of the current activities in the quality area was given by the co-chair of the meeting.\n\n# 2.1.4 International Conference of Drug Regulatory Authorities\n\nThe International Conference of Drug Regulatory Authorities (ICDRA) provide medicines regulatory authorities (MRAs) of WHO Member States with a forum to meet and discuss ways to strengthen collaboration. The conferences have been held since 1980 with the aim of promoting exchange of information and collaborative approaches to issues of common concern. As a platform established to develop international consensus, the ICDRA continues to be an important tool for WHO and MRAs in their efforts to harmonize regulation and improve the safety, efficacy and quality of medicines. The ICDRA programme is developed by a planning committee of representative medicines regulators. Discussions during the four days of the ICDRA usually include topics relating to quality issues, herbal medicines, homeopathy, regulatory reform, medicines safety, counterfeiting, access, regulation of clinical trials, harmonization, new technologies and e-commerce. Recommendations are proposed for action among agencies, WHO and related institutions.\n\nThe recommendations formulated by the 13th International Conference of Drug Regulatory Authorities held in Berne, Switzerland, from 16 to 19 September 2008 are available on the WHO web site (http://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra).\n\nThe 14th ICDRA would take place in Singapore from 30 November to 3 December 2010. A pre-ICDRA meeting on \u201cEffective Collaboration: The Future for Medicines Regulation\u201d would take place on 28\u201329 November.\n\nRegistration, details and programme are available on the ICDRA web site: http://www.icdra2010.sg/.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona informaci\u00f3n sobre dos importantes conferencias organizadas por la Organizaci\u00f3n Mundial de la Salud (OMS): la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) y la Conferencia Internacional de Autoridades Reguladoras de Medicamentos (ICDRA). La ICH se llev\u00f3 a cabo en junio de 2009 en Yokohama, Jap\u00f3n, y se centr\u00f3 en actividades relacionadas con la calidad de los medicamentos. Por otro lado, la ICDRA, que se ha celebrado desde 1980, ofrece un foro para que las autoridades reguladoras de medicamentos de los Estados Miembros de la OMS discutan la colaboraci\u00f3n y el intercambio de informaci\u00f3n sobre temas de inter\u00e9s com\u00fan. La 14\u00aa ICDRA est\u00e1 programada para realizarse en Singapur en diciembre de 2010.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los temas principales discutidos en la ICDRA y c\u00f3mo se relacionan con la regulaci\u00f3n de medicamentos?**\n   - Esta pregunta busca detalles sobre los temas espec\u00edficos que se abordan en la ICDRA, que incluyen calidad, seguridad de medicamentos, y nuevas tecnolog\u00edas, entre otros.\n\n2. **\u00bfQu\u00e9 recomendaciones se formularon en la 13\u00aa ICDRA y d\u00f3nde se pueden encontrar?**\n   - Esta pregunta se centra en las recomendaciones espec\u00edficas que surgieron de la 13\u00aa ICDRA en Berna, Suiza, y proporciona un enlace directo para acceder a esa informaci\u00f3n.\n\n3. **\u00bfCu\u00e1l es el prop\u00f3sito de la ICH y c\u00f3mo se involucra la OMS en sus actividades?**\n   - Esta pregunta busca aclarar el papel de la OMS en la ICH y c\u00f3mo contribuye a las actividades relacionadas con la calidad de los medicamentos a nivel internacional.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Supervisi\u00f3n de la Fabricaci\u00f3n de Productos Farmac\u00e9uticos**:\n   - La fabricaci\u00f3n de productos, especialmente vacunas y tratamientos para VIH, malaria y tuberculosis, est\u00e1 bajo la supervisi\u00f3n de UNICEF y la OMS.\n   - Las inspecciones de Buenas Pr\u00e1cticas de Manufactura (GMP) son realizadas principalmente por personal de UNICEF.\n\n2. **Resultados de Inspecciones de GMP**:\n   - Entre 2003 y 2009, el 32% de las 145 inspecciones de GMP realizadas en 47 empresas resultaron en fallos.\n   - En caso de fallo, se env\u00eda un informe detallado a la empresa con una solicitud de respuesta en un plazo de un mes.\n\n3. **Requisitos para la Precalificaci\u00f3n de Productos**:\n   - Los productos deben estar precalificados por la OMS y listados en su sitio web.\n   - El proveedor debe confirmar que los productos son id\u00e9nticos a los evaluados por la OMS/UNICEF.\n   - Las compras de UNICEF deben ser rastreadas en las inspecciones de GMP de la OMS/UNICEF.\n\n4. **Grupo de Discusi\u00f3n Farmacopea (PDG)**:\n   - Compuesto por la Farmacopea Europea, la Farmacopea Japonesa y la Farmacopea de los Estados Unidos.\n   - Se reuni\u00f3 del 8 al 12 de junio de 2009 en Yokohama, Jap\u00f3n, en asociaci\u00f3n con grupos de trabajo de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH).\n   - Se recomendaron revisiones de m\u00e9todos generales para su posible adopci\u00f3n en la Farmacopea Internacional.\n\n5. **M\u00e9todos Generales Recomendados para Revisi\u00f3n**:\n   - Prueba de volumen extra\u00edble de preparaciones parenterales.\n   - Prueba de contaminaci\u00f3n particulada.\n   - Pruebas de desintegraci\u00f3n y disoluci\u00f3n.\n   - Prueba de esterilidad.\n   - Examen microbiol\u00f3gico de productos no est\u00e9riles.\n   - Criterios de aceptaci\u00f3n para preparaciones farmac\u00e9uticas.\n\n6. **Consideraciones para la Adopci\u00f3n**:\n   - Ex\u00e1menes microbiol\u00f3gicos de productos no est\u00e9riles, incluyendo pruebas de enumeraci\u00f3n microbiana y pruebas para microorganismos espec\u00edficos.\n   - Prueba de friabilidad de tabletas.\n\n### Entidades Clave\n- **UNICEF**: Organizaci\u00f3n que supervisa la fabricaci\u00f3n y realiza inspecciones de GMP.\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad que establece directrices y requisitos para la precalificaci\u00f3n de productos.\n- **Grupo de Discusi\u00f3n Farmacopea (PDG)**: Grupo que incluye la Farmacopea Europea, Japonesa y de EE. UU., encargado de revisar y recomendar m\u00e9todos para la Farmacopea Internacional.", "excerpt_keywords": "Keywords: International Conference on Harmonisation, ICDRA, medicines regulation, WHO, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a0805be5-1c94-4b75-a11d-f354764788a5", "node_type": "4", "metadata": {"page_label": "22", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 2.1.3 International Conference on Harmonisation\n\nThe International Conference on Harmonisation (ICH) Expert Working Groups met from 8 to 12 June 2009 in Yokohama, Japan.\n\nThe Secretary of this Expert Committee also attended, as an observer for WHO, the ICH Q4B Working Group meetings (consisting of members from the six ICH partners and observers). An update of the current activities in the quality area was given by the co-chair of the meeting.\n\n# 2.1.4 International Conference of Drug Regulatory Authorities\n\nThe International Conference of Drug Regulatory Authorities (ICDRA) provide medicines regulatory authorities (MRAs) of WHO Member States with a forum to meet and discuss ways to strengthen collaboration. The conferences have been held since 1980 with the aim of promoting exchange of information and collaborative approaches to issues of common concern. As a platform established to develop international consensus, the ICDRA continues to be an important tool for WHO and MRAs in their efforts to harmonize regulation and improve the safety, efficacy and quality of medicines. The ICDRA programme is developed by a planning committee of representative medicines regulators. Discussions during the four days of the ICDRA usually include topics relating to quality issues, herbal medicines, homeopathy, regulatory reform, medicines safety, counterfeiting, access, regulation of clinical trials, harmonization, new technologies and e-commerce. Recommendations are proposed for action among agencies, WHO and related institutions.\n\nThe recommendations formulated by the 13th International Conference of Drug Regulatory Authorities held in Berne, Switzerland, from 16 to 19 September 2008 are available on the WHO web site (http://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra).\n\nThe 14th ICDRA would take place in Singapore from 30 November to 3 December 2010. A pre-ICDRA meeting on \u201cEffective Collaboration: The Future for Medicines Regulation\u201d would take place on 28\u201329 November.\n\nRegistration, details and programme are available on the ICDRA web site: http://www.icdra2010.sg/.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "262369cd8244fad1056aecacaf486f2cda4e73c6f8582e72cc96a6662b27532d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 2.1.3 International Conference on Harmonisation\n\nThe International Conference on Harmonisation (ICH) Expert Working Groups met from 8 to 12 June 2009 in Yokohama, Japan.\n\nThe Secretary of this Expert Committee also attended, as an observer for WHO, the ICH Q4B Working Group meetings (consisting of members from the six ICH partners and observers). An update of the current activities in the quality area was given by the co-chair of the meeting.\n\n# 2.1.4 International Conference of Drug Regulatory Authorities\n\nThe International Conference of Drug Regulatory Authorities (ICDRA) provide medicines regulatory authorities (MRAs) of WHO Member States with a forum to meet and discuss ways to strengthen collaboration. The conferences have been held since 1980 with the aim of promoting exchange of information and collaborative approaches to issues of common concern. As a platform established to develop international consensus, the ICDRA continues to be an important tool for WHO and MRAs in their efforts to harmonize regulation and improve the safety, efficacy and quality of medicines. The ICDRA programme is developed by a planning committee of representative medicines regulators. Discussions during the four days of the ICDRA usually include topics relating to quality issues, herbal medicines, homeopathy, regulatory reform, medicines safety, counterfeiting, access, regulation of clinical trials, harmonization, new technologies and e-commerce. Recommendations are proposed for action among agencies, WHO and related institutions.\n\nThe recommendations formulated by the 13th International Conference of Drug Regulatory Authorities held in Berne, Switzerland, from 16 to 19 September 2008 are available on the WHO web site (http://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra).\n\nThe 14th ICDRA would take place in Singapore from 30 November to 3 December 2010. A pre-ICDRA meeting on \u201cEffective Collaboration: The Future for Medicines Regulation\u201d would take place on 28\u201329 November.\n\nRegistration, details and programme are available on the ICDRA web site: http://www.icdra2010.sg/.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2119, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c919519a-7fe9-404e-b7f9-7e3a5c7e8b24": {"__data__": {"id_": "c919519a-7fe9-404e-b7f9-7e3a5c7e8b24", "embedding": null, "metadata": {"page_label": "23", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 2.2 Cross-cutting issues in pharmaceuticals \u2014 quality assurance issues\n\n### 2.2.1 Herbal medicines\n\nThe Committee received a report on WHO\u2019s policy and activities in the field of traditional medicine.\n\nThe representative of the Traditional Medicine (TRM) team reported on the activities of International Regulatory Cooperation for Herbal Medicines (IRCH) \u2014 membership had increased to 22, consisting of 19 Member Countries and three Member Regional Bodies. The third annual meeting was held in Montreal, Canada in February 2009, at which a strategic plan of action for IRCH was discussed and agreed upon. Based on the review of current issues relating to herbal medicines, eight working groups addressing the priority issues identified had been established.\n\nTRM also reported on the publication of Volume 4, *WHO monographs on selected medicinal plants*, which contained 28 monographs. TRM thanked the Expert Committee and the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations for their technical contribution and support in the development of the monographs.\n\nA major outcome of the WHO Congress on Traditional Medicine was the adoption of the \u201cBeijing Declaration\u201d. The World Health Assembly in May 2009 adopted a new resolution on traditional medicine (resolution WHA 62.13), referring to the \u201cBeijing Declaration\u201d and requested the Director-General to update the WHO Traditional Medicine Strategy. It also requested WHO to support the efforts of Member States in integrating traditional medicine into national health systems.\n\nIn the context of primary health care, the report of the WHO interregional workshop on the use of traditional medicine in primary health care, held in Ulaanbaatar, Mongolia in August 2007, was printed in May 2009 and was widely disseminated.\n\nThe Committee was informed of WHO\u2019s new project on the development of international classification of traditional medicine, towards the integration of traditional medicine into general health information systems, and standardization of clinical terms used by providers of traditional medicine. This project also aimed at responding to the need expressed by national pharmacovigilance centres for an appropriate coding system accommodating the reporting of adverse events to herbal medicines.\n\nThe Committee was also informed about the progress of implementation of the Global Strategy and Plan of Action on public health, innovation and intellectual property (GSPOA) in the field of traditional medicine.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Actividades de la OMS en Medicina Tradicional**: La OMS ha estado trabajando en la regulaci\u00f3n y promoci\u00f3n de la medicina tradicional, especialmente en el \u00e1mbito de las medicinas herbales, a trav\u00e9s de la cooperaci\u00f3n internacional y la creaci\u00f3n de grupos de trabajo para abordar problemas prioritarios.\n\n2. **Publicaciones y Declaraciones Importantes**: Se ha publicado un volumen de monograf\u00edas sobre plantas medicinales y se adopt\u00f3 la \"Declaraci\u00f3n de Pek\u00edn\" en el Congreso de Medicina Tradicional, lo que llev\u00f3 a la adopci\u00f3n de una resoluci\u00f3n por parte de la Asamblea Mundial de la Salud para integrar la medicina tradicional en los sistemas de salud nacionales.\n\n3. **Proyectos de Clasificaci\u00f3n y Vigilancia**: La OMS est\u00e1 desarrollando un sistema de clasificaci\u00f3n internacional para la medicina tradicional y est\u00e1 trabajando en la estandarizaci\u00f3n de t\u00e9rminos cl\u00ednicos, as\u00ed como en la implementaci\u00f3n de estrategias para la innovaci\u00f3n y la propiedad intelectual en el campo de la medicina tradicional.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los objetivos espec\u00edficos de los ocho grupos de trabajo establecidos por la OMS en relaci\u00f3n con las medicinas herbales?**\n   - Esta pregunta busca detalles sobre las prioridades y enfoques espec\u00edficos que estos grupos est\u00e1n abordando, lo cual no se menciona expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 impacto tuvo la \"Declaraci\u00f3n de Pek\u00edn\" en las pol\u00edticas de salud de los Estados Miembros de la OMS?**\n   - Esta pregunta se centra en las repercusiones pr\u00e1cticas y pol\u00edticas de la declaraci\u00f3n, que no se detalla en el contexto proporcionado.\n\n3. **\u00bfC\u00f3mo se planea implementar el sistema de clasificaci\u00f3n internacional de medicina tradicional y qu\u00e9 desaf\u00edos se anticipan en este proceso?**\n   - Esta pregunta busca informaci\u00f3n sobre la implementaci\u00f3n pr\u00e1ctica del proyecto y los posibles obst\u00e1culos que podr\u00edan surgir, que no se abordan en el texto.", "prev_section_summary": "La secci\u00f3n aborda dos conferencias importantes organizadas por la Organizaci\u00f3n Mundial de la Salud (OMS):\n\n1. **Conferencia Internacional sobre Armonizaci\u00f3n (ICH)**:\n   - Se llev\u00f3 a cabo del 8 al 12 de junio de 2009 en Yokohama, Jap\u00f3n.\n   - Incluy\u00f3 la participaci\u00f3n de un secretario de la OMS como observador en las reuniones del Grupo de Trabajo ICH Q4B.\n   - Se centr\u00f3 en actividades relacionadas con la calidad de los medicamentos.\n\n2. **Conferencia Internacional de Autoridades Reguladoras de Medicamentos (ICDRA)**:\n   - Se ha celebrado desde 1980, proporcionando un foro para que las autoridades reguladoras de medicamentos de los Estados Miembros de la OMS discutan la colaboraci\u00f3n y el intercambio de informaci\u00f3n.\n   - La ICDRA busca desarrollar un consenso internacional y mejorar la regulaci\u00f3n, seguridad, eficacia y calidad de los medicamentos.\n   - Los temas discutidos incluyen calidad de medicamentos, seguridad, regulaci\u00f3n de ensayos cl\u00ednicos, nuevas tecnolog\u00edas, y m\u00e1s.\n   - La 13\u00aa ICDRA se realiz\u00f3 en Berna, Suiza, del 16 al 19 de septiembre de 2008, y sus recomendaciones est\u00e1n disponibles en el sitio web de la OMS.\n   - La 14\u00aa ICDRA est\u00e1 programada para llevarse a cabo en Singapur del 30 de noviembre al 3 de diciembre de 2010, con una reuni\u00f3n previa sobre colaboraci\u00f3n efectiva en la regulaci\u00f3n de medicamentos.\n\nEstos eventos son fundamentales para la armonizaci\u00f3n y mejora de la regulaci\u00f3n de medicamentos a nivel internacional.", "excerpt_keywords": "Keywords: herbal medicines, traditional medicine, WHO, Beijing Declaration, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4beecf06-5053-4535-9689-01bc3a347514", "node_type": "4", "metadata": {"page_label": "23", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 2.2 Cross-cutting issues in pharmaceuticals \u2014 quality assurance issues\n\n### 2.2.1 Herbal medicines\n\nThe Committee received a report on WHO\u2019s policy and activities in the field of traditional medicine.\n\nThe representative of the Traditional Medicine (TRM) team reported on the activities of International Regulatory Cooperation for Herbal Medicines (IRCH) \u2014 membership had increased to 22, consisting of 19 Member Countries and three Member Regional Bodies. The third annual meeting was held in Montreal, Canada in February 2009, at which a strategic plan of action for IRCH was discussed and agreed upon. Based on the review of current issues relating to herbal medicines, eight working groups addressing the priority issues identified had been established.\n\nTRM also reported on the publication of Volume 4, *WHO monographs on selected medicinal plants*, which contained 28 monographs. TRM thanked the Expert Committee and the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations for their technical contribution and support in the development of the monographs.\n\nA major outcome of the WHO Congress on Traditional Medicine was the adoption of the \u201cBeijing Declaration\u201d. The World Health Assembly in May 2009 adopted a new resolution on traditional medicine (resolution WHA 62.13), referring to the \u201cBeijing Declaration\u201d and requested the Director-General to update the WHO Traditional Medicine Strategy. It also requested WHO to support the efforts of Member States in integrating traditional medicine into national health systems.\n\nIn the context of primary health care, the report of the WHO interregional workshop on the use of traditional medicine in primary health care, held in Ulaanbaatar, Mongolia in August 2007, was printed in May 2009 and was widely disseminated.\n\nThe Committee was informed of WHO\u2019s new project on the development of international classification of traditional medicine, towards the integration of traditional medicine into general health information systems, and standardization of clinical terms used by providers of traditional medicine. This project also aimed at responding to the need expressed by national pharmacovigilance centres for an appropriate coding system accommodating the reporting of adverse events to herbal medicines.\n\nThe Committee was also informed about the progress of implementation of the Global Strategy and Plan of Action on public health, innovation and intellectual property (GSPOA) in the field of traditional medicine.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "ad3b9666aac82c1d897ae79dbd97cb06bce34d4ff57c1ac3cea6e4b5a877568b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 2.2 Cross-cutting issues in pharmaceuticals \u2014 quality assurance issues\n\n### 2.2.1 Herbal medicines\n\nThe Committee received a report on WHO\u2019s policy and activities in the field of traditional medicine.\n\nThe representative of the Traditional Medicine (TRM) team reported on the activities of International Regulatory Cooperation for Herbal Medicines (IRCH) \u2014 membership had increased to 22, consisting of 19 Member Countries and three Member Regional Bodies. The third annual meeting was held in Montreal, Canada in February 2009, at which a strategic plan of action for IRCH was discussed and agreed upon. Based on the review of current issues relating to herbal medicines, eight working groups addressing the priority issues identified had been established.\n\nTRM also reported on the publication of Volume 4, *WHO monographs on selected medicinal plants*, which contained 28 monographs. TRM thanked the Expert Committee and the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations for their technical contribution and support in the development of the monographs.\n\nA major outcome of the WHO Congress on Traditional Medicine was the adoption of the \u201cBeijing Declaration\u201d. The World Health Assembly in May 2009 adopted a new resolution on traditional medicine (resolution WHA 62.13), referring to the \u201cBeijing Declaration\u201d and requested the Director-General to update the WHO Traditional Medicine Strategy. It also requested WHO to support the efforts of Member States in integrating traditional medicine into national health systems.\n\nIn the context of primary health care, the report of the WHO interregional workshop on the use of traditional medicine in primary health care, held in Ulaanbaatar, Mongolia in August 2007, was printed in May 2009 and was widely disseminated.\n\nThe Committee was informed of WHO\u2019s new project on the development of international classification of traditional medicine, towards the integration of traditional medicine into general health information systems, and standardization of clinical terms used by providers of traditional medicine. This project also aimed at responding to the need expressed by national pharmacovigilance centres for an appropriate coding system accommodating the reporting of adverse events to herbal medicines.\n\nThe Committee was also informed about the progress of implementation of the Global Strategy and Plan of Action on public health, innovation and intellectual property (GSPOA) in the field of traditional medicine.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2536, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e6af2148-1187-4236-bd27-5f136f4e652c": {"__data__": {"id_": "e6af2148-1187-4236-bd27-5f136f4e652c", "embedding": null, "metadata": {"page_label": "24", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee encouraged countries to make use of the materials available from this Programme and took note of the role of traditional medicines within the concept of primary health care.\n\n## 2.2.2 Biologicals and vaccines\n\n### WHO Expert Committee on Biological Standardization\n\nThe role of the Expert Committee on Biological Standardization was to develop international recommendations for the production and control of biological medicines and the establishment of associated international biological reference materials. The Committee would next meet on 19\u201323 October 2009 and a key agenda item that might be of interest to the Expert Committee on Specifications for Pharmaceutical Preparations was the proposed guidelines on evaluation of similar biotherapeutic products. These guidelines, if established, would set international expectations for the regulatory evaluation of this increasingly important and relatively new class of biological medicines. It would, however, be only a first stage in providing equity of access to this type of product and WHO recognized that much would need to be done to assist Member States to develop the capacity to ensure effective use of such products.\n\nA second topic was the issue of transition of some drugs from biologicals to chemicals. The Expert Committee on Biological Standardization had initiated a process whereby all proposals for new or replacement reference materials were first submitted to the Committee for review. Proposals were being received for certain reference materials to be calibrated in SI units instead of the International Unit of biological activity. Where this was the case, consultation with the Expert Committee on Specifications for Pharmaceutical Preparations was also sought prior to the initiation of the study.\n\nTwo other topics for more detailed discussion by the Expert Committee on Specifications for Pharmaceutical Preparations were examples of cross-cutting initiatives between the two Committees. The first was the guidelines that were under development to establish GMP for blood establishments and the second, the guidelines for regulatory oversight of temperature-controlled distribution of pharmaceuticals.\n\nA joint concern of both Committees was to ensure effective implementation of guidelines and recommendations. Implementation workshops had been set up by the secretariat to promote the understanding and use of guidelines and recommendations established by the Expert Committee on Biological Standardization. New guidelines on regulatory expectations for stability evaluation of vaccines had been used as a case study and positive feedback had been obtained from all stakeholders on the value of such an approach.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl Comit\u00e9 de Expertos de la OMS en Estandarizaci\u00f3n Biol\u00f3gica se encarga de desarrollar recomendaciones internacionales para la producci\u00f3n y control de medicamentos biol\u00f3gicos y establecer materiales de referencia biol\u00f3gica. En su pr\u00f3xima reuni\u00f3n, se discutir\u00e1n pautas para la evaluaci\u00f3n de productos bioterap\u00e9uticos similares y la transici\u00f3n de algunos medicamentos de biol\u00f3gicos a qu\u00edmicos. Adem\u00e1s, se est\u00e1n desarrollando iniciativas conjuntas con el Comit\u00e9 de Especificaciones para Preparaciones Farmac\u00e9uticas, incluyendo directrices sobre buenas pr\u00e1cticas de manufactura (GMP) para establecimientos de sangre y la supervisi\u00f3n regulatoria de la distribuci\u00f3n de productos farmac\u00e9uticos controlados por temperatura. Se han establecido talleres de implementaci\u00f3n para promover la comprensi\u00f3n y uso de estas directrices.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son los temas clave que se discutir\u00e1n en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos sobre Estandarizaci\u00f3n Biol\u00f3gica programada para octubre de 2009?**\n   - Respuesta: Se discutir\u00e1n las pautas propuestas para la evaluaci\u00f3n de productos bioterap\u00e9uticos similares y la transici\u00f3n de algunos medicamentos de biol\u00f3gicos a qu\u00edmicos.\n\n2. **\u00bfQu\u00e9 proceso ha iniciado el Comit\u00e9 de Estandarizaci\u00f3n Biol\u00f3gica respecto a las propuestas de nuevos materiales de referencia?**\n   - Respuesta: El Comit\u00e9 ha iniciado un proceso en el que todas las propuestas para nuevos o materiales de referencia de reemplazo deben ser primero presentadas al Comit\u00e9 para su revisi\u00f3n.\n\n3. **\u00bfQu\u00e9 tipo de talleres ha establecido la secretar\u00eda para asegurar la implementaci\u00f3n efectiva de las directrices y recomendaciones del Comit\u00e9?**\n   - Respuesta: Se han establecido talleres de implementaci\u00f3n para promover la comprensi\u00f3n y uso de las directrices y recomendaciones establecidas por el Comit\u00e9 de Estandarizaci\u00f3n Biol\u00f3gica, utilizando nuevas directrices sobre la evaluaci\u00f3n de estabilidad de vacunas como estudio de caso.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Actividades de la OMS en Medicina Tradicional**:\n   - La OMS ha estado activa en la regulaci\u00f3n y promoci\u00f3n de la medicina tradicional, especialmente en el \u00e1mbito de las medicinas herbales.\n   - Se ha incrementado la membres\u00eda del grupo de cooperaci\u00f3n internacional IRCH a 22 miembros, incluyendo 19 pa\u00edses y 3 cuerpos regionales.\n\n2. **Grupos de Trabajo**:\n   - Se establecieron ocho grupos de trabajo para abordar problemas prioritarios relacionados con las medicinas herbales, aunque no se especifican los objetivos de cada grupo.\n\n3. **Publicaciones Importantes**:\n   - Se public\u00f3 el *Volumen 4 de las monograf\u00edas de la OMS sobre plantas medicinales*, que incluye 28 monograf\u00edas.\n   - La \"Declaraci\u00f3n de Pek\u00edn\" fue adoptada en el Congreso de Medicina Tradicional, lo que llev\u00f3 a la adopci\u00f3n de la resoluci\u00f3n WHA 62.13 por parte de la Asamblea Mundial de la Salud.\n\n4. **Integraci\u00f3n en Sistemas de Salud**:\n   - La OMS est\u00e1 apoyando a los Estados Miembros en la integraci\u00f3n de la medicina tradicional en los sistemas de salud nacionales.\n\n5. **Proyectos de Clasificaci\u00f3n y Vigilancia**:\n   - Se est\u00e1 desarrollando un sistema de clasificaci\u00f3n internacional para la medicina tradicional, con el objetivo de estandarizar t\u00e9rminos cl\u00ednicos y facilitar la vigilancia de eventos adversos relacionados con las medicinas herbales.\n\n6. **Estrategia Global**:\n   - Se informa sobre el progreso en la implementaci\u00f3n de la Estrategia Global y Plan de Acci\u00f3n sobre salud p\u00fablica, innovaci\u00f3n y propiedad intelectual en el campo de la medicina tradicional.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la regulaci\u00f3n y promoci\u00f3n de la medicina tradicional.\n- **IRCH (Cooperaci\u00f3n Internacional para Medicinas Herbales)**: Grupo que coordina esfuerzos entre pa\u00edses en el \u00e1mbito de las medicinas herbales.\n- **Asamblea Mundial de la Salud**: Cuerpo que adopt\u00f3 la resoluci\u00f3n sobre medicina tradicional y la \"Declaraci\u00f3n de Pek\u00edn\".\n- **Centros Nacionales de Farmacovigilancia**: Entidades que expresaron la necesidad de un sistema de codificaci\u00f3n para reportar eventos adversos a las medicinas herbales.", "excerpt_keywords": "Keywords: Biological Standardization, vaccines, regulatory guidelines, traditional medicines, pharmaceutical preparations"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6acc044f-77da-4736-b2b3-2a3b8f8c7675", "node_type": "4", "metadata": {"page_label": "24", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee encouraged countries to make use of the materials available from this Programme and took note of the role of traditional medicines within the concept of primary health care.\n\n## 2.2.2 Biologicals and vaccines\n\n### WHO Expert Committee on Biological Standardization\n\nThe role of the Expert Committee on Biological Standardization was to develop international recommendations for the production and control of biological medicines and the establishment of associated international biological reference materials. The Committee would next meet on 19\u201323 October 2009 and a key agenda item that might be of interest to the Expert Committee on Specifications for Pharmaceutical Preparations was the proposed guidelines on evaluation of similar biotherapeutic products. These guidelines, if established, would set international expectations for the regulatory evaluation of this increasingly important and relatively new class of biological medicines. It would, however, be only a first stage in providing equity of access to this type of product and WHO recognized that much would need to be done to assist Member States to develop the capacity to ensure effective use of such products.\n\nA second topic was the issue of transition of some drugs from biologicals to chemicals. The Expert Committee on Biological Standardization had initiated a process whereby all proposals for new or replacement reference materials were first submitted to the Committee for review. Proposals were being received for certain reference materials to be calibrated in SI units instead of the International Unit of biological activity. Where this was the case, consultation with the Expert Committee on Specifications for Pharmaceutical Preparations was also sought prior to the initiation of the study.\n\nTwo other topics for more detailed discussion by the Expert Committee on Specifications for Pharmaceutical Preparations were examples of cross-cutting initiatives between the two Committees. The first was the guidelines that were under development to establish GMP for blood establishments and the second, the guidelines for regulatory oversight of temperature-controlled distribution of pharmaceuticals.\n\nA joint concern of both Committees was to ensure effective implementation of guidelines and recommendations. Implementation workshops had been set up by the secretariat to promote the understanding and use of guidelines and recommendations established by the Expert Committee on Biological Standardization. New guidelines on regulatory expectations for stability evaluation of vaccines had been used as a case study and positive feedback had been obtained from all stakeholders on the value of such an approach.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "c786d7d5c691f9361db29ee38cddcb005c0aee830af8e75f261085a881e12bc3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The Expert Committee encouraged countries to make use of the materials available from this Programme and took note of the role of traditional medicines within the concept of primary health care.\n\n## 2.2.2 Biologicals and vaccines\n\n### WHO Expert Committee on Biological Standardization\n\nThe role of the Expert Committee on Biological Standardization was to develop international recommendations for the production and control of biological medicines and the establishment of associated international biological reference materials. The Committee would next meet on 19\u201323 October 2009 and a key agenda item that might be of interest to the Expert Committee on Specifications for Pharmaceutical Preparations was the proposed guidelines on evaluation of similar biotherapeutic products. These guidelines, if established, would set international expectations for the regulatory evaluation of this increasingly important and relatively new class of biological medicines. It would, however, be only a first stage in providing equity of access to this type of product and WHO recognized that much would need to be done to assist Member States to develop the capacity to ensure effective use of such products.\n\nA second topic was the issue of transition of some drugs from biologicals to chemicals. The Expert Committee on Biological Standardization had initiated a process whereby all proposals for new or replacement reference materials were first submitted to the Committee for review. Proposals were being received for certain reference materials to be calibrated in SI units instead of the International Unit of biological activity. Where this was the case, consultation with the Expert Committee on Specifications for Pharmaceutical Preparations was also sought prior to the initiation of the study.\n\nTwo other topics for more detailed discussion by the Expert Committee on Specifications for Pharmaceutical Preparations were examples of cross-cutting initiatives between the two Committees. The first was the guidelines that were under development to establish GMP for blood establishments and the second, the guidelines for regulatory oversight of temperature-controlled distribution of pharmaceuticals.\n\nA joint concern of both Committees was to ensure effective implementation of guidelines and recommendations. Implementation workshops had been set up by the secretariat to promote the understanding and use of guidelines and recommendations established by the Expert Committee on Biological Standardization. New guidelines on regulatory expectations for stability evaluation of vaccines had been used as a case study and positive feedback had been obtained from all stakeholders on the value of such an approach.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2716, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "17dc7703-0f23-46b1-96e3-9dedece5b26c": {"__data__": {"id_": "17dc7703-0f23-46b1-96e3-9dedece5b26c", "embedding": null, "metadata": {"page_label": "25", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Finally, a review of the roles and responsibilities of the Expert Committee on Biological Standardization was proposed. It was approximately 10 years since the last such review and thus it was important to have such an external validation of the direction and output of the Committee. As part of the process comments from the Expert Committee on Specifications for Pharmaceutical Preparations would be invited.\n\n### 2.2.3 Blood products\n\nThe Committee was informed about WHO\u2019s work in the area of blood products and related biologicals. More details on the GMP for blood establishments can be found in section 6.6.\n\n### 2.2.4 Essential medicines\n\nFurther to the WHO-led initiative \u201cmake medicines child size\u201d launched in December 2007, WHO received a grant from the Bill & Melinda Gates Foundation in October 2008 to work in collaboration with UNICEF in order to conduct crucial research in the area of children\u2019s medicines. The aim of the project was to increase the number of child-size medicines designed and formulated specifically for children. The grant provided support for essential research to:\n\n- determine the optimum dosage forms for paediatric medicines (e.g. small tablets, dispersible tablets, powders);\n- develop dosing guides (e.g. a review of existing priority medicines and the identification of the appropriate doses for new medicines for children); and\n- develop guidelines for testing of medicines and treatment of use of medicines in children, including guidelines on conducting clinical trials in children.\n\nIn December 2008 a group of paediatricians, pharmacists, clinical pharmacologists and representatives of the European Medicines Agency (EMA), International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Medicines for Malaria Venture (MMV), National Institutes of Health (NIH), United Nations Children\u2019s Fund (UNICEF) and the Bill & Melinda Gates Foundation attended a meeting hosted by WHO to discuss the preferred dosage form of medicines for children. As a result of this consultation the dosage forms of medicines most suitable for children were identified, with particular attention paid to conditions prevailing in developing countries and future areas of research required in this area (http://www.who.int/childmedicines/progress/Dosage_form_reportDEC2008.pdf).\n\nThe report of the WHO Subcommittee for the Selection and Use of Medicines, including the second Essential Medicines List for Children (EMLc), was reviewed and endorsed by the Expert Committee on Selection.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Revisi\u00f3n del Comit\u00e9 de Expertos**: Se propone una revisi\u00f3n de las funciones y responsabilidades del Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica, destacando la importancia de una validaci\u00f3n externa despu\u00e9s de aproximadamente diez a\u00f1os desde la \u00faltima revisi\u00f3n.\n\n2. **Trabajo de la OMS en productos sangu\u00edneos**: La OMS est\u00e1 trabajando en el \u00e1rea de productos sangu\u00edneos y biol\u00f3gicos relacionados, con detalles adicionales sobre las Buenas Pr\u00e1cticas de Manufactura (GMP) para establecimientos de sangre.\n\n3. **Iniciativa de medicamentos para ni\u00f1os**: La OMS, en colaboraci\u00f3n con UNICEF y con el apoyo de la Fundaci\u00f3n Bill & Melinda Gates, est\u00e1 llevando a cabo una investigaci\u00f3n para aumentar la disponibilidad de medicamentos dise\u00f1ados espec\u00edficamente para ni\u00f1os, centr\u00e1ndose en formas de dosificaci\u00f3n \u00f3ptimas y gu\u00edas de dosificaci\u00f3n.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los objetivos espec\u00edficos del proyecto \"make medicines child size\" lanzado por la OMS?**\n   - Esta pregunta busca detalles sobre los objetivos del proyecto, que incluyen la determinaci\u00f3n de formas de dosificaci\u00f3n \u00f3ptimas y el desarrollo de gu\u00edas de dosificaci\u00f3n para medicamentos pedi\u00e1tricos.\n\n2. **\u00bfQu\u00e9 grupos participaron en la reuni\u00f3n de diciembre de 2008 sobre medicamentos para ni\u00f1os y cu\u00e1l fue el resultado de esa consulta?**\n   - Esta pregunta se centra en identificar a los participantes clave en la reuni\u00f3n y los resultados espec\u00edficos que surgieron de la discusi\u00f3n sobre las formas de dosificaci\u00f3n m\u00e1s adecuadas para los medicamentos infantiles.\n\n3. **\u00bfQu\u00e9 aspectos se consideraron en la revisi\u00f3n de la lista de Medicamentos Esenciales para Ni\u00f1os (EMLc) por parte del Comit\u00e9 de Expertos en Selecci\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n sobre los criterios y consideraciones que guiaron la revisi\u00f3n y aprobaci\u00f3n de la lista de medicamentos esenciales para ni\u00f1os, as\u00ed como su relevancia en el contexto de la salud infantil.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Comit\u00e9 de Expertos de la OMS en Estandarizaci\u00f3n Biol\u00f3gica**:\n   - Encargado de desarrollar recomendaciones internacionales para la producci\u00f3n y control de medicamentos biol\u00f3gicos.\n   - Establecimiento de materiales de referencia biol\u00f3gica.\n\n2. **Pr\u00f3xima reuni\u00f3n**:\n   - Programada del 19 al 23 de octubre de 2009.\n   - Temas clave a discutir:\n     - Pautas para la evaluaci\u00f3n de productos bioterap\u00e9uticos similares.\n     - Transici\u00f3n de algunos medicamentos de biol\u00f3gicos a qu\u00edmicos.\n\n3. **Propuestas de nuevos materiales de referencia**:\n   - Proceso de revisi\u00f3n de propuestas para nuevos o materiales de referencia de reemplazo por parte del Comit\u00e9.\n   - Consideraci\u00f3n de calibraci\u00f3n en unidades del SI en lugar de la Unidad Internacional de actividad biol\u00f3gica.\n\n4. **Iniciativas conjuntas**:\n   - Desarrollo de directrices sobre buenas pr\u00e1cticas de manufactura (GMP) para establecimientos de sangre.\n   - Supervisi\u00f3n regulatoria de la distribuci\u00f3n de productos farmac\u00e9uticos controlados por temperatura.\n\n5. **Talleres de implementaci\u00f3n**:\n   - Establecidos para promover la comprensi\u00f3n y uso de las directrices y recomendaciones del Comit\u00e9.\n   - Uso de nuevas directrices sobre la evaluaci\u00f3n de estabilidad de vacunas como estudio de caso.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la salud p\u00fablica internacional.\n- **Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica**: Grupo que desarrolla recomendaciones sobre medicamentos biol\u00f3gicos.\n- **Comit\u00e9 de Especificaciones para Preparaciones Farmac\u00e9uticas**: Colabora en iniciativas relacionadas con la regulaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: Expert Committee, Biological Standardization, Essential Medicines, Children's Medicines, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "db950072-3447-4d1d-a12a-77a12d5b4db6", "node_type": "4", "metadata": {"page_label": "25", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Finally, a review of the roles and responsibilities of the Expert Committee on Biological Standardization was proposed. It was approximately 10 years since the last such review and thus it was important to have such an external validation of the direction and output of the Committee. As part of the process comments from the Expert Committee on Specifications for Pharmaceutical Preparations would be invited.\n\n### 2.2.3 Blood products\n\nThe Committee was informed about WHO\u2019s work in the area of blood products and related biologicals. More details on the GMP for blood establishments can be found in section 6.6.\n\n### 2.2.4 Essential medicines\n\nFurther to the WHO-led initiative \u201cmake medicines child size\u201d launched in December 2007, WHO received a grant from the Bill & Melinda Gates Foundation in October 2008 to work in collaboration with UNICEF in order to conduct crucial research in the area of children\u2019s medicines. The aim of the project was to increase the number of child-size medicines designed and formulated specifically for children. The grant provided support for essential research to:\n\n- determine the optimum dosage forms for paediatric medicines (e.g. small tablets, dispersible tablets, powders);\n- develop dosing guides (e.g. a review of existing priority medicines and the identification of the appropriate doses for new medicines for children); and\n- develop guidelines for testing of medicines and treatment of use of medicines in children, including guidelines on conducting clinical trials in children.\n\nIn December 2008 a group of paediatricians, pharmacists, clinical pharmacologists and representatives of the European Medicines Agency (EMA), International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Medicines for Malaria Venture (MMV), National Institutes of Health (NIH), United Nations Children\u2019s Fund (UNICEF) and the Bill & Melinda Gates Foundation attended a meeting hosted by WHO to discuss the preferred dosage form of medicines for children. As a result of this consultation the dosage forms of medicines most suitable for children were identified, with particular attention paid to conditions prevailing in developing countries and future areas of research required in this area (http://www.who.int/childmedicines/progress/Dosage_form_reportDEC2008.pdf).\n\nThe report of the WHO Subcommittee for the Selection and Use of Medicines, including the second Essential Medicines List for Children (EMLc), was reviewed and endorsed by the Expert Committee on Selection.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "16d54ff0c0d113406a4816b33ad700faf5a0b606dfc0278b4c7e5b28703ffa37", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Finally, a review of the roles and responsibilities of the Expert Committee on Biological Standardization was proposed. It was approximately 10 years since the last such review and thus it was important to have such an external validation of the direction and output of the Committee. As part of the process comments from the Expert Committee on Specifications for Pharmaceutical Preparations would be invited.\n\n### 2.2.3 Blood products\n\nThe Committee was informed about WHO\u2019s work in the area of blood products and related biologicals. More details on the GMP for blood establishments can be found in section 6.6.\n\n### 2.2.4 Essential medicines\n\nFurther to the WHO-led initiative \u201cmake medicines child size\u201d launched in December 2007, WHO received a grant from the Bill & Melinda Gates Foundation in October 2008 to work in collaboration with UNICEF in order to conduct crucial research in the area of children\u2019s medicines. The aim of the project was to increase the number of child-size medicines designed and formulated specifically for children. The grant provided support for essential research to:\n\n- determine the optimum dosage forms for paediatric medicines (e.g. small tablets, dispersible tablets, powders);\n- develop dosing guides (e.g. a review of existing priority medicines and the identification of the appropriate doses for new medicines for children); and\n- develop guidelines for testing of medicines and treatment of use of medicines in children, including guidelines on conducting clinical trials in children.\n\nIn December 2008 a group of paediatricians, pharmacists, clinical pharmacologists and representatives of the European Medicines Agency (EMA), International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Medicines for Malaria Venture (MMV), National Institutes of Health (NIH), United Nations Children\u2019s Fund (UNICEF) and the Bill & Melinda Gates Foundation attended a meeting hosted by WHO to discuss the preferred dosage form of medicines for children. As a result of this consultation the dosage forms of medicines most suitable for children were identified, with particular attention paid to conditions prevailing in developing countries and future areas of research required in this area (http://www.who.int/childmedicines/progress/Dosage_form_reportDEC2008.pdf).\n\nThe report of the WHO Subcommittee for the Selection and Use of Medicines, including the second Essential Medicines List for Children (EMLc), was reviewed and endorsed by the Expert Committee on Selection.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2528, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "aad558f5-4e79-4c23-866b-850cd9586d04": {"__data__": {"id_": "aad558f5-4e79-4c23-866b-850cd9586d04", "embedding": null, "metadata": {"page_label": "26", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "and Use of Essential Medicines at its seventeenth meeting in March 2009. New additions to the EMLc included sections on palliative care medicines; ear, nose and throat medicines and medicines for neonates, and also the inclusion of liposomal amphotericin B, a dispersible formulation of artemether + lumefantrine (20 mg + 120 mg) and enalapril tablets (2.5 mg and 5 mg). The Expert Committee agreed that the Subcommittee had fulfilled the terms of reference regarding the development and revision of the WHO EMLc and made the recommendation to the Executive Board and the Director-General that the Subcommittee should now be dissolved. However, it was recommended that future Expert Committees should include adequate expertise to consider medicines for children and maintain the EMLc.\n\nThe Expert Committee for the Selection and Use of Essential Medicines also reviewed simulation studies proposing potential new strengths for fixed-dose combinations (FDCs) of antituberculosis medicines for children: isoniazid 150 mg + pyrazinamide 400 mg + rifampicin 250 mg and ethambutol 250 mg + isoniazid 150 mg + pyrazinamide 400 mg + rifampicin 250 mg.\n\nHowever, it was noted that at this time there were no FDCs that delivered the ideal doses of first-line medicines for tuberculosis treatment in children with weights between 5 and 30 kg. It was also highlighted that there was a need for a two-drug FDC for use in the continuation phase of treatment and the Expert Committee for the Selection and Use of Essential Medicines recommended that the following combination (for continuation treatment only) would be reasonable based on the analyses presented: isoniazid 150 mg + rifampicin 250 mg.\n\nThe Expert Committee for the Selection and Use of Essential Medicines reviewed and agreed a proposal by the Medicines Quality Assurance Programme for a revision to the listing of pharmaceutical products in the Model Lists of Essential Medicines. As a result, the medicines listed in the left-hand column would in future be named as the active moieties, using INN and, where applicable, entries in the right-hand column would provide information on the dosage forms and strengths of products available in WHO Member States. The explanatory notes in the Model List of Essential Medicines and the EMLc had also been expanded to provide more information and guidance to users with regard to dosage form terminology and medicine strength (see section 11.1).\n\nFuture activities in relation to the Better Medicines for Children project would include a summit in Amsterdam in October 2009 to discuss scientific standards required for undertaking clinical research in children. As part of this meeting WHO would host a discussion day with a group of experts from developing countries to identify what might need to be done to", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Revisiones de la Lista de Medicamentos Esenciales para Ni\u00f1os (EMLc)**: En marzo de 2009, la Comisi\u00f3n de Expertos revis\u00f3 y actualiz\u00f3 la EMLc, incluyendo nuevos medicamentos para el cuidado paliativo, otorrinolaringolog\u00eda y neonatos, as\u00ed como formulaciones espec\u00edficas de medicamentos antituberculosos para ni\u00f1os.\n\n2. **Falta de combinaciones de dosis fijas (FDC) adecuadas**: Se identific\u00f3 que no exist\u00edan combinaciones de dosis fijas que proporcionaran las dosis ideales de medicamentos de primera l\u00ednea para el tratamiento de la tuberculosis en ni\u00f1os con pesos entre 5 y 30 kg, lo que resalta la necesidad de desarrollar nuevas formulaciones.\n\n3. **Actividades futuras para mejorar los medicamentos para ni\u00f1os**: Se plane\u00f3 un cumbre en \u00c1msterdam en octubre de 2009 para discutir est\u00e1ndares cient\u00edficos necesarios para la investigaci\u00f3n cl\u00ednica en ni\u00f1os, con la participaci\u00f3n de expertos de pa\u00edses en desarrollo.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 nuevos medicamentos se incluyeron en la EMLc durante la reuni\u00f3n de marzo de 2009 y cu\u00e1l fue su relevancia para el tratamiento de ni\u00f1os?**\n   - Respuesta: Se incluyeron medicamentos para el cuidado paliativo, otorrinolaringolog\u00eda y neonatos, as\u00ed como liposomal amphotericin B, una formulaci\u00f3n dispersible de artemether + lumefantrine (20 mg + 120 mg) y tabletas de enalapril (2.5 mg y 5 mg).\n\n2. **\u00bfCu\u00e1les son las combinaciones de dosis fijas (FDC) propuestas para el tratamiento de la tuberculosis en ni\u00f1os y qu\u00e9 limitaciones se identificaron en su uso?**\n   - Respuesta: Se propusieron las combinaciones de isoniazid 150 mg + pyrazinamide 400 mg + rifampicin 250 mg y ethambutol 250 mg + isoniazid 150 mg + pyrazinamide 400 mg + rifampicin 250 mg. Sin embargo, no hab\u00eda FDC que entregaran las dosis ideales para ni\u00f1os con pesos entre 5 y 30 kg.\n\n3. **\u00bfQu\u00e9 cambios se realizaron en la forma en que se listan los productos farmac\u00e9uticos en las Listas Modelo de Medicamentos Esenciales?**\n   - Respuesta: Se acord\u00f3 que los medicamentos se nombrar\u00edan como los moieties activos utilizando INN, y se proporcionar\u00eda informaci\u00f3n sobre las formas de dosificaci\u00f3n y las concentraciones de los productos disponibles en los Estados Miembros de la OMS. Adem\u00e1s, se expandieron las notas explicativas para ofrecer m\u00e1s informaci\u00f3n sobre la terminolog\u00eda de las formas de dosificaci\u00f3n y la fuerza de los medicamentos.", "prev_section_summary": "### Temas Clave:\n\n1. **Revisi\u00f3n del Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica**: Se propone una revisi\u00f3n de las funciones y responsabilidades del Comit\u00e9, destacando la necesidad de una validaci\u00f3n externa despu\u00e9s de aproximadamente diez a\u00f1os.\n\n2. **Trabajo de la OMS en Productos Sangu\u00edneos**: La OMS est\u00e1 involucrada en el desarrollo y regulaci\u00f3n de productos sangu\u00edneos y biol\u00f3gicos relacionados, con \u00e9nfasis en las Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n3. **Iniciativa \"make medicines child size\"**: La OMS, con el apoyo de la Fundaci\u00f3n Bill & Melinda Gates y en colaboraci\u00f3n con UNICEF, busca aumentar la disponibilidad de medicamentos dise\u00f1ados espec\u00edficamente para ni\u00f1os. Esto incluye la investigaci\u00f3n sobre formas de dosificaci\u00f3n \u00f3ptimas y gu\u00edas de dosificaci\u00f3n.\n\n### Entidades Clave:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Principal entidad responsable de la iniciativa y la investigaci\u00f3n en medicamentos para ni\u00f1os.\n- **Fundaci\u00f3n Bill & Melinda Gates**: Proporcion\u00f3 financiamiento para la investigaci\u00f3n sobre medicamentos pedi\u00e1tricos.\n- **UNICEF**: Colaborador en la iniciativa para mejorar la disponibilidad de medicamentos para ni\u00f1os.\n- **Agencia Europea de Medicamentos (EMA)**: Participante en la reuni\u00f3n sobre medicamentos para ni\u00f1os.\n- **Federaci\u00f3n Internacional de Fabricantes y Asociaciones Farmac\u00e9uticas (IFPMA)**: Tambi\u00e9n representada en la reuni\u00f3n.\n- **Medicines for Malaria Venture (MMV)**: Participante en la discusi\u00f3n sobre medicamentos pedi\u00e1tricos.\n- **Institutos Nacionales de Salud (NIH)**: Contribuyente a la investigaci\u00f3n sobre medicamentos para ni\u00f1os.\n\n### Resultados de la Consulta:\n\n- Identificaci\u00f3n de las formas de dosificaci\u00f3n m\u00e1s adecuadas para medicamentos infantiles, con un enfoque en las condiciones de los pa\u00edses en desarrollo y \u00e1reas futuras de investigaci\u00f3n. \n- Revisi\u00f3n y aprobaci\u00f3n de la segunda Lista de Medicamentos Esenciales para Ni\u00f1os (EMLc) por parte del Comit\u00e9 de Expertos en Selecci\u00f3n.", "excerpt_keywords": "Keywords: Essential Medicines, Pediatric Care, Fixed-Dose Combinations, WHO, Tuberculosis Treatment"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "91e8ca11-0c1c-45c9-a3f6-c68545ea48d7", "node_type": "4", "metadata": {"page_label": "26", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "and Use of Essential Medicines at its seventeenth meeting in March 2009. New additions to the EMLc included sections on palliative care medicines; ear, nose and throat medicines and medicines for neonates, and also the inclusion of liposomal amphotericin B, a dispersible formulation of artemether + lumefantrine (20 mg + 120 mg) and enalapril tablets (2.5 mg and 5 mg). The Expert Committee agreed that the Subcommittee had fulfilled the terms of reference regarding the development and revision of the WHO EMLc and made the recommendation to the Executive Board and the Director-General that the Subcommittee should now be dissolved. However, it was recommended that future Expert Committees should include adequate expertise to consider medicines for children and maintain the EMLc.\n\nThe Expert Committee for the Selection and Use of Essential Medicines also reviewed simulation studies proposing potential new strengths for fixed-dose combinations (FDCs) of antituberculosis medicines for children: isoniazid 150 mg + pyrazinamide 400 mg + rifampicin 250 mg and ethambutol 250 mg + isoniazid 150 mg + pyrazinamide 400 mg + rifampicin 250 mg.\n\nHowever, it was noted that at this time there were no FDCs that delivered the ideal doses of first-line medicines for tuberculosis treatment in children with weights between 5 and 30 kg. It was also highlighted that there was a need for a two-drug FDC for use in the continuation phase of treatment and the Expert Committee for the Selection and Use of Essential Medicines recommended that the following combination (for continuation treatment only) would be reasonable based on the analyses presented: isoniazid 150 mg + rifampicin 250 mg.\n\nThe Expert Committee for the Selection and Use of Essential Medicines reviewed and agreed a proposal by the Medicines Quality Assurance Programme for a revision to the listing of pharmaceutical products in the Model Lists of Essential Medicines. As a result, the medicines listed in the left-hand column would in future be named as the active moieties, using INN and, where applicable, entries in the right-hand column would provide information on the dosage forms and strengths of products available in WHO Member States. The explanatory notes in the Model List of Essential Medicines and the EMLc had also been expanded to provide more information and guidance to users with regard to dosage form terminology and medicine strength (see section 11.1).\n\nFuture activities in relation to the Better Medicines for Children project would include a summit in Amsterdam in October 2009 to discuss scientific standards required for undertaking clinical research in children. As part of this meeting WHO would host a discussion day with a group of experts from developing countries to identify what might need to be done to", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "7a8d0fefd9af2cd09cb9d3e68be1ec3d7d758bfeb3e1d225bb49dcd7db55fe60", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "and Use of Essential Medicines at its seventeenth meeting in March 2009. New additions to the EMLc included sections on palliative care medicines; ear, nose and throat medicines and medicines for neonates, and also the inclusion of liposomal amphotericin B, a dispersible formulation of artemether + lumefantrine (20 mg + 120 mg) and enalapril tablets (2.5 mg and 5 mg). The Expert Committee agreed that the Subcommittee had fulfilled the terms of reference regarding the development and revision of the WHO EMLc and made the recommendation to the Executive Board and the Director-General that the Subcommittee should now be dissolved. However, it was recommended that future Expert Committees should include adequate expertise to consider medicines for children and maintain the EMLc.\n\nThe Expert Committee for the Selection and Use of Essential Medicines also reviewed simulation studies proposing potential new strengths for fixed-dose combinations (FDCs) of antituberculosis medicines for children: isoniazid 150 mg + pyrazinamide 400 mg + rifampicin 250 mg and ethambutol 250 mg + isoniazid 150 mg + pyrazinamide 400 mg + rifampicin 250 mg.\n\nHowever, it was noted that at this time there were no FDCs that delivered the ideal doses of first-line medicines for tuberculosis treatment in children with weights between 5 and 30 kg. It was also highlighted that there was a need for a two-drug FDC for use in the continuation phase of treatment and the Expert Committee for the Selection and Use of Essential Medicines recommended that the following combination (for continuation treatment only) would be reasonable based on the analyses presented: isoniazid 150 mg + rifampicin 250 mg.\n\nThe Expert Committee for the Selection and Use of Essential Medicines reviewed and agreed a proposal by the Medicines Quality Assurance Programme for a revision to the listing of pharmaceutical products in the Model Lists of Essential Medicines. As a result, the medicines listed in the left-hand column would in future be named as the active moieties, using INN and, where applicable, entries in the right-hand column would provide information on the dosage forms and strengths of products available in WHO Member States. The explanatory notes in the Model List of Essential Medicines and the EMLc had also been expanded to provide more information and guidance to users with regard to dosage form terminology and medicine strength (see section 11.1).\n\nFuture activities in relation to the Better Medicines for Children project would include a summit in Amsterdam in October 2009 to discuss scientific standards required for undertaking clinical research in children. As part of this meeting WHO would host a discussion day with a group of experts from developing countries to identify what might need to be done to", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2805, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e36cdbd6-fa47-4b46-8697-796a3e9ecaf2": {"__data__": {"id_": "e36cdbd6-fa47-4b46-8697-796a3e9ecaf2", "embedding": null, "metadata": {"page_label": "27", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 2.2.5 Regulatory support\n\nThe Expert Committee was updated on the area of medicines regulatory support. The mission of QSM in medicines regulatory support was to enhance the capacity of national and regional medicines regulatory systems to contribute to universal access to medicines of assured safety, quality and efficacy. Core functions included developing evidence on the situation and needs of medicines regulatory systems worldwide; providing direct support to countries and regions for strengthening medicines regulation; developing and continuously improving tools to assist regulatory activities (e.g. guidelines, manuals and other information materials); facilitating communication and promoting harmonization among MRAs; developing and continuously improving internal capacities; and developing and maintaining comprehensive databases on MRAs.\n\nThe scope of regulatory support activities involved assessing medicines regulatory systems to identify needs, assisting in the development of institutional plans and supporting capacity building. So far, 50 assessments had been performed on 46 regulatory systems with the involvement of the respective WHO regional offices.\n\nIn close collaboration with the capacity building teams of the WHO Prequalification Programme and the WHO Immunization, Vaccines and Biologicals Department, the Medicines Regulatory Support Programme had organized various training activities to strengthen capacity of national MRAs.\n\nRegional support involved provision of technical assistance to Regional Economic Communities in Africa, within the framework of the African Medicines Registration Harmonization Initiative.\n\nThe Medicines Regulatory Support Programme had been particularly active in promoting the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce; in facilitating harmonization of regulatory requirements with subregional economic blocs; and improving communication among MRAs through networking, sharing of information and regulatory decisions.\n\nThe Programme had also been active in providing feedback on the implementation of existing WHO guidelines, developing training materials, developing internal procedures, developing and maintaining technical competence of regulatory staff and enhancing technical cooperation with partners both within and outside the Organization.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Misi\u00f3n del Programa de Apoyo Regulatorio de Medicamentos**: El Programa tiene como objetivo mejorar la capacidad de los sistemas regulatorios de medicamentos a nivel nacional y regional para garantizar el acceso universal a medicamentos seguros, de calidad y eficaces. Esto incluye el desarrollo de herramientas, la evaluaci\u00f3n de sistemas regulatorios y la capacitaci\u00f3n de personal.\n\n2. **Actividades de Evaluaci\u00f3n y Capacitaci\u00f3n**: Hasta la fecha, se han realizado 50 evaluaciones en 46 sistemas regulatorios, y se han organizado diversas actividades de capacitaci\u00f3n en colaboraci\u00f3n con otros programas de la OMS para fortalecer las capacidades de las autoridades regulatorias nacionales.\n\n3. **Colaboraci\u00f3n Regional y Promoci\u00f3n de Normativas**: El Programa ha trabajado en estrecha colaboraci\u00f3n con comunidades econ\u00f3micas regionales en \u00c1frica para armonizar los requisitos regulatorios y mejorar la comunicaci\u00f3n entre las autoridades regulatorias a trav\u00e9s de redes y el intercambio de informaci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las funciones principales del Programa de Apoyo Regulatorio de Medicamentos de la OMS?**\n   - Respuesta: Las funciones principales incluyen desarrollar evidencia sobre las necesidades de los sistemas regulatorios, proporcionar apoyo directo a pa\u00edses, mejorar herramientas regulatorias, facilitar la comunicaci\u00f3n entre las autoridades regulatorias y mantener bases de datos sobre estas entidades.\n\n2. **\u00bfQu\u00e9 tipo de actividades de capacitaci\u00f3n se han organizado para fortalecer las capacidades de las autoridades regulatorias nacionales?**\n   - Respuesta: Se han organizado diversas actividades de capacitaci\u00f3n en colaboraci\u00f3n con los equipos de desarrollo de capacidades de la OMS, enfocadas en mejorar la competencia t\u00e9cnica del personal regulador y en la implementaci\u00f3n de directrices existentes.\n\n3. **\u00bfC\u00f3mo ha contribuido el Programa de Apoyo Regulatorio a la armonizaci\u00f3n de los requisitos regulatorios en \u00c1frica?**\n   - Respuesta: El Programa ha proporcionado asistencia t\u00e9cnica a las Comunidades Econ\u00f3micas Regionales en \u00c1frica, promoviendo la Iniciativa de Armonizaci\u00f3n de Registro de Medicamentos y facilitando la comunicaci\u00f3n y el intercambio de decisiones regulatorias entre las autoridades.", "prev_section_summary": "### Temas Clave:\n\n1. **Revisi\u00f3n de la EMLc**: En marzo de 2009, la Comisi\u00f3n de Expertos revis\u00f3 la Lista de Medicamentos Esenciales para Ni\u00f1os (EMLc), incorporando nuevos medicamentos para el cuidado paliativo, otorrinolaringolog\u00eda y neonatos, as\u00ed como formulaciones espec\u00edficas para el tratamiento de la tuberculosis en ni\u00f1os.\n\n2. **Combinaciones de Dosis Fijas (FDC)**: Se propusieron nuevas combinaciones de medicamentos antituberculosos para ni\u00f1os, pero se identific\u00f3 la falta de FDC que proporcionaran las dosis ideales para ni\u00f1os con pesos entre 5 y 30 kg.\n\n3. **Revisi\u00f3n de Listas de Medicamentos**: Se acord\u00f3 que los productos farmac\u00e9uticos en las Listas Modelo de Medicamentos Esenciales se nombrar\u00edan utilizando los moieties activos (INN) y se proporcionar\u00eda informaci\u00f3n sobre formas de dosificaci\u00f3n y concentraciones disponibles.\n\n4. **Actividades Futuras**: Se plane\u00f3 un cumbre en \u00c1msterdam en octubre de 2009 para discutir est\u00e1ndares cient\u00edficos necesarios para la investigaci\u00f3n cl\u00ednica en ni\u00f1os, con la participaci\u00f3n de expertos de pa\u00edses en desarrollo.\n\n### Entidades:\n\n- **Comisi\u00f3n de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales**: Grupo responsable de revisar y actualizar la EMLc.\n- **Medicamentos Incluidos**: Liposomal amphotericin B, artemether + lumefantrine (20 mg + 120 mg), enalapril (2.5 mg y 5 mg).\n- **Medicamentos Antituberculosos Propuestos**: Isoniazid, pyrazinamide, rifampicin, ethambutol.\n- **Proyecto Mejor Medicamentos para Ni\u00f1os**: Iniciativa de la OMS para mejorar la disponibilidad y calidad de medicamentos para ni\u00f1os.", "excerpt_keywords": "Regulatory support, medicines, WHO, capacity building, harmonization"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "67fd7f96-5902-4f79-923f-d0c43c5c661e", "node_type": "4", "metadata": {"page_label": "27", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 2.2.5 Regulatory support\n\nThe Expert Committee was updated on the area of medicines regulatory support. The mission of QSM in medicines regulatory support was to enhance the capacity of national and regional medicines regulatory systems to contribute to universal access to medicines of assured safety, quality and efficacy. Core functions included developing evidence on the situation and needs of medicines regulatory systems worldwide; providing direct support to countries and regions for strengthening medicines regulation; developing and continuously improving tools to assist regulatory activities (e.g. guidelines, manuals and other information materials); facilitating communication and promoting harmonization among MRAs; developing and continuously improving internal capacities; and developing and maintaining comprehensive databases on MRAs.\n\nThe scope of regulatory support activities involved assessing medicines regulatory systems to identify needs, assisting in the development of institutional plans and supporting capacity building. So far, 50 assessments had been performed on 46 regulatory systems with the involvement of the respective WHO regional offices.\n\nIn close collaboration with the capacity building teams of the WHO Prequalification Programme and the WHO Immunization, Vaccines and Biologicals Department, the Medicines Regulatory Support Programme had organized various training activities to strengthen capacity of national MRAs.\n\nRegional support involved provision of technical assistance to Regional Economic Communities in Africa, within the framework of the African Medicines Registration Harmonization Initiative.\n\nThe Medicines Regulatory Support Programme had been particularly active in promoting the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce; in facilitating harmonization of regulatory requirements with subregional economic blocs; and improving communication among MRAs through networking, sharing of information and regulatory decisions.\n\nThe Programme had also been active in providing feedback on the implementation of existing WHO guidelines, developing training materials, developing internal procedures, developing and maintaining technical competence of regulatory staff and enhancing technical cooperation with partners both within and outside the Organization.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "229c8e1007747a1c78fd016b0b789ca30e827788c4c3b98c25853c1d940b15e5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 2.2.5 Regulatory support\n\nThe Expert Committee was updated on the area of medicines regulatory support. The mission of QSM in medicines regulatory support was to enhance the capacity of national and regional medicines regulatory systems to contribute to universal access to medicines of assured safety, quality and efficacy. Core functions included developing evidence on the situation and needs of medicines regulatory systems worldwide; providing direct support to countries and regions for strengthening medicines regulation; developing and continuously improving tools to assist regulatory activities (e.g. guidelines, manuals and other information materials); facilitating communication and promoting harmonization among MRAs; developing and continuously improving internal capacities; and developing and maintaining comprehensive databases on MRAs.\n\nThe scope of regulatory support activities involved assessing medicines regulatory systems to identify needs, assisting in the development of institutional plans and supporting capacity building. So far, 50 assessments had been performed on 46 regulatory systems with the involvement of the respective WHO regional offices.\n\nIn close collaboration with the capacity building teams of the WHO Prequalification Programme and the WHO Immunization, Vaccines and Biologicals Department, the Medicines Regulatory Support Programme had organized various training activities to strengthen capacity of national MRAs.\n\nRegional support involved provision of technical assistance to Regional Economic Communities in Africa, within the framework of the African Medicines Registration Harmonization Initiative.\n\nThe Medicines Regulatory Support Programme had been particularly active in promoting the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce; in facilitating harmonization of regulatory requirements with subregional economic blocs; and improving communication among MRAs through networking, sharing of information and regulatory decisions.\n\nThe Programme had also been active in providing feedback on the implementation of existing WHO guidelines, developing training materials, developing internal procedures, developing and maintaining technical competence of regulatory staff and enhancing technical cooperation with partners both within and outside the Organization.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2375, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4bd6ffdd-14a9-4a6b-b13a-454eb5ddf722": {"__data__": {"id_": "4bd6ffdd-14a9-4a6b-b13a-454eb5ddf722", "embedding": null, "metadata": {"page_label": "28", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Future work would include improving feedback and identification of needs for guidance, establishing a pool of regulatory experts and conducting the assessment of medicines regulatory systems in a more systematic way and for training purposes. The programme intends to establish a network of centres of excellence in the regulatory affairs area to serve as training centres, design new intervention mechanisms for supporting activities and new concepts for conducting day-to-day work.\n\n### 2.2.6 HIV-related activities\n\nThe representative of the HIV Department, Strategic Information and Research Unit, gave a short update on how the work of this Expert Committee was useful to the HIV Department\u2019s activities. The Department published an annual report entitled \u201cTowards universal access\u201d on progress made in the health sector to address the HIV epidemic. In the section on access to treatment, it reported on the progress made on prequalification of antiretrovirals by QSM. A QSM quality assessment survey was also included in the 2008 report.\n\n### 2.3 Counterfeit medicines\n\nThe Committee was provided with an update by the Programme Manager of the newly created EMP/QSM Anti-Counterfeiting Programme (ACM), who was also Executive Secretary ad interim of the IMPACT Secretariat.\n\nDiscussion took place during the Executive Board meeting in January 2009 on IMPACT and counterfeit medicines in general. Concerns had been raised regarding WHO\u2019s role in this area. Two background papers had been prepared by the WHO Secretariat and submitted to the World Health Assembly (one on the activities of IMPACT and the second on WHO\u2019s activities in the area of counterfeit (http://apps.who.int/gb/e/e_wha62.html, WHA62: A62/13 Counterfeit medical products, and A62/14 Counterfeit medical products: International Medical Products Anti-Counterfeiting Taskforce). Additional information on IMPACT could be found on the web site (http://www.who.int/impact). The Assembly agenda item on counterfeits was subsequently postponed to 2010.\n\nThe Secretariat and Chair for IMPACT continued to be based in WHO.\n\nThe Director-General of WHO reconfirmed that counterfeit medicines were an important issue for the Organization and that WHO would continue to collaborate with partners in this field. The WHO Secretariat would work on the basis that there were no changes to this current situation at least until the World Health Assembly in May 2010, during which WHO\u2019s role should be clarified by its Member States.\n\nACM would complete the following activities in 2009:\n- Revise and update the WHO and IMPACT web sites.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS aborda varias iniciativas relacionadas con la regulaci\u00f3n de medicamentos, actividades relacionadas con el VIH y la lucha contra los medicamentos falsificados. Se menciona la intenci\u00f3n de mejorar la retroalimentaci\u00f3n y la identificaci\u00f3n de necesidades en la regulaci\u00f3n de medicamentos, as\u00ed como la creaci\u00f3n de una red de centros de excelencia en asuntos regulatorios. Tambi\u00e9n se destaca el trabajo del Departamento de VIH en la publicaci\u00f3n de informes sobre el acceso a tratamientos y el progreso en la precalificaci\u00f3n de antirretrovirales. Adem\u00e1s, se discute el programa anti-falsificaci\u00f3n de medicamentos de la OMS y la importancia de este tema para la organizaci\u00f3n, as\u00ed como la colaboraci\u00f3n continua con socios en este \u00e1mbito.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los objetivos espec\u00edficos del programa que busca establecer una red de centros de excelencia en el \u00e1rea de asuntos regulatorios?**\n   - Esta pregunta busca detalles sobre los objetivos y la estructura del programa que no se mencionan expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 tipo de actividades se planean para el Programa Anti-Counterfeiting (ACM) en 2009, adem\u00e1s de la revisi\u00f3n y actualizaci\u00f3n de los sitios web de la OMS e IMPACT?**\n   - Esta pregunta se centra en las actividades espec\u00edficas que se llevar\u00e1n a cabo en el marco del programa ACM, m\u00e1s all\u00e1 de lo que se menciona en el contexto.\n\n3. **\u00bfC\u00f3mo se ha evaluado el impacto de la precalificaci\u00f3n de antirretrovirales en el acceso a tratamientos para el VIH seg\u00fan el informe \u201cTowards universal access\u201d?**\n   - Esta pregunta busca informaci\u00f3n sobre la evaluaci\u00f3n del impacto de la precalificaci\u00f3n en el acceso a tratamientos, que podr\u00eda no estar detallada en el documento.\n\n### Resumen de nivel superior\n\nEl documento de la OMS destaca la importancia de mejorar la regulaci\u00f3n de medicamentos y la lucha contra los medicamentos falsificados, as\u00ed como el progreso en el tratamiento del VIH. Se mencionan iniciativas para establecer centros de excelencia en regulaci\u00f3n y la colaboraci\u00f3n continua con socios para abordar el problema de los medicamentos falsificados. Adem\u00e1s, se hace referencia a la publicaci\u00f3n de informes anuales sobre el acceso a tratamientos para el VIH y la precalificaci\u00f3n de antirretrovirales.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Misi\u00f3n del Programa de Apoyo Regulatorio de Medicamentos**:\n   - Mejorar la capacidad de los sistemas regulatorios de medicamentos a nivel nacional y regional.\n   - Contribuir al acceso universal a medicamentos seguros, de calidad y eficaces.\n\n2. **Funciones Principales**:\n   - Desarrollo de evidencia sobre las necesidades de los sistemas regulatorios.\n   - Apoyo directo a pa\u00edses y regiones para fortalecer la regulaci\u00f3n de medicamentos.\n   - Creaci\u00f3n y mejora continua de herramientas regulatorias (gu\u00edas, manuales, materiales informativos).\n   - Facilitaci\u00f3n de la comunicaci\u00f3n y promoci\u00f3n de la armonizaci\u00f3n entre las Autoridades Reguladoras de Medicamentos (MRAs).\n   - Desarrollo y mantenimiento de bases de datos sobre MRAs.\n\n3. **Actividades de Evaluaci\u00f3n y Capacitaci\u00f3n**:\n   - Realizaci\u00f3n de 50 evaluaciones en 46 sistemas regulatorios.\n   - Organizaci\u00f3n de actividades de capacitaci\u00f3n en colaboraci\u00f3n con otros programas de la OMS.\n\n4. **Colaboraci\u00f3n Regional**:\n   - Asistencia t\u00e9cnica a Comunidades Econ\u00f3micas Regionales en \u00c1frica.\n   - Promoci\u00f3n de la Iniciativa de Armonizaci\u00f3n de Registro de Medicamentos.\n\n5. **Promoci\u00f3n de Normativas y Comunicaci\u00f3n**:\n   - Actividades para promover el Esquema de Certificaci\u00f3n de la OMS sobre la Calidad de Productos Farmac\u00e9uticos.\n   - Mejora de la comunicaci\u00f3n entre MRAs a trav\u00e9s de redes y el intercambio de informaci\u00f3n.\n\n6. **Desarrollo de Capacidades**:\n   - Provisi\u00f3n de retroalimentaci\u00f3n sobre la implementaci\u00f3n de directrices de la OMS.\n   - Desarrollo de materiales de capacitaci\u00f3n y procedimientos internos.\n   - Mantenimiento de la competencia t\u00e9cnica del personal regulador.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Principal entidad responsable del Programa de Apoyo Regulatorio de Medicamentos.\n- **MRAs (Medicines Regulatory Authorities)**: Autoridades Reguladoras de Medicamentos involucradas en el proceso.\n- **Comunidades Econ\u00f3micas Regionales en \u00c1frica**: Entidades que reciben asistencia t\u00e9cnica para la armonizaci\u00f3n de requisitos regulatorios.", "excerpt_keywords": "Keywords: regulatory affairs, HIV treatment, counterfeit medicines, WHO initiatives, prequalification"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "21cc1cb5-2632-45ee-a64f-455cbf4b70c2", "node_type": "4", "metadata": {"page_label": "28", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Future work would include improving feedback and identification of needs for guidance, establishing a pool of regulatory experts and conducting the assessment of medicines regulatory systems in a more systematic way and for training purposes. The programme intends to establish a network of centres of excellence in the regulatory affairs area to serve as training centres, design new intervention mechanisms for supporting activities and new concepts for conducting day-to-day work.\n\n### 2.2.6 HIV-related activities\n\nThe representative of the HIV Department, Strategic Information and Research Unit, gave a short update on how the work of this Expert Committee was useful to the HIV Department\u2019s activities. The Department published an annual report entitled \u201cTowards universal access\u201d on progress made in the health sector to address the HIV epidemic. In the section on access to treatment, it reported on the progress made on prequalification of antiretrovirals by QSM. A QSM quality assessment survey was also included in the 2008 report.\n\n### 2.3 Counterfeit medicines\n\nThe Committee was provided with an update by the Programme Manager of the newly created EMP/QSM Anti-Counterfeiting Programme (ACM), who was also Executive Secretary ad interim of the IMPACT Secretariat.\n\nDiscussion took place during the Executive Board meeting in January 2009 on IMPACT and counterfeit medicines in general. Concerns had been raised regarding WHO\u2019s role in this area. Two background papers had been prepared by the WHO Secretariat and submitted to the World Health Assembly (one on the activities of IMPACT and the second on WHO\u2019s activities in the area of counterfeit (http://apps.who.int/gb/e/e_wha62.html, WHA62: A62/13 Counterfeit medical products, and A62/14 Counterfeit medical products: International Medical Products Anti-Counterfeiting Taskforce). Additional information on IMPACT could be found on the web site (http://www.who.int/impact). The Assembly agenda item on counterfeits was subsequently postponed to 2010.\n\nThe Secretariat and Chair for IMPACT continued to be based in WHO.\n\nThe Director-General of WHO reconfirmed that counterfeit medicines were an important issue for the Organization and that WHO would continue to collaborate with partners in this field. The WHO Secretariat would work on the basis that there were no changes to this current situation at least until the World Health Assembly in May 2010, during which WHO\u2019s role should be clarified by its Member States.\n\nACM would complete the following activities in 2009:\n- Revise and update the WHO and IMPACT web sites.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "e31bf56091ccbcca7e97e9632d1ace0c962c5af091f1aae35a5007f0360b3563", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Future work would include improving feedback and identification of needs for guidance, establishing a pool of regulatory experts and conducting the assessment of medicines regulatory systems in a more systematic way and for training purposes. The programme intends to establish a network of centres of excellence in the regulatory affairs area to serve as training centres, design new intervention mechanisms for supporting activities and new concepts for conducting day-to-day work.\n\n### 2.2.6 HIV-related activities\n\nThe representative of the HIV Department, Strategic Information and Research Unit, gave a short update on how the work of this Expert Committee was useful to the HIV Department\u2019s activities. The Department published an annual report entitled \u201cTowards universal access\u201d on progress made in the health sector to address the HIV epidemic. In the section on access to treatment, it reported on the progress made on prequalification of antiretrovirals by QSM. A QSM quality assessment survey was also included in the 2008 report.\n\n### 2.3 Counterfeit medicines\n\nThe Committee was provided with an update by the Programme Manager of the newly created EMP/QSM Anti-Counterfeiting Programme (ACM), who was also Executive Secretary ad interim of the IMPACT Secretariat.\n\nDiscussion took place during the Executive Board meeting in January 2009 on IMPACT and counterfeit medicines in general. Concerns had been raised regarding WHO\u2019s role in this area. Two background papers had been prepared by the WHO Secretariat and submitted to the World Health Assembly (one on the activities of IMPACT and the second on WHO\u2019s activities in the area of counterfeit (http://apps.who.int/gb/e/e_wha62.html, WHA62: A62/13 Counterfeit medical products, and A62/14 Counterfeit medical products: International Medical Products Anti-Counterfeiting Taskforce). Additional information on IMPACT could be found on the web site (http://www.who.int/impact). The Assembly agenda item on counterfeits was subsequently postponed to 2010.\n\nThe Secretariat and Chair for IMPACT continued to be based in WHO.\n\nThe Director-General of WHO reconfirmed that counterfeit medicines were an important issue for the Organization and that WHO would continue to collaborate with partners in this field. The WHO Secretariat would work on the basis that there were no changes to this current situation at least until the World Health Assembly in May 2010, during which WHO\u2019s role should be clarified by its Member States.\n\nACM would complete the following activities in 2009:\n- Revise and update the WHO and IMPACT web sites.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2594, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "bde9f61e-5250-4d6b-af53-a36d083e27ac": {"__data__": {"id_": "bde9f61e-5250-4d6b-af53-a36d083e27ac", "embedding": null, "metadata": {"page_label": "29", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Proceed with the joint WHO Expert Committee on Specifications for Pharmaceutical Preparations/IMPACT review of the **WHO Good distribution practices (GDP) for pharmaceutical products**, which was proposed by IMPACT in 2007.\n- Start the review process of the draft document on Model Legislation developed by IMPACT in 2008, including a revision of the current definition of counterfeit medicines, possibly through the Expert Committee.\n- Plan and implement advocacy, training, country support and enforcement activities with interested governments in Africa, as far as specified donor funds were available (mostly from the European Union for African, Caribbean and Pacific countries).\n- Recruit one technical expert on regulatory matters and pursue the possibility of FIP arranging the secondment of a communication expert.\n- Prepare a fund-raising plan for future staff and activities to combat counterfeit medicines and approach interested donors.\n\nIn addition to WHO\u2019s work on counterfeit medicines described above, the Assistant Director-General, HSS would continue her two-year mandate as elected Chair of IMPACT and WHO would continue to fulfil the functions of the IMPACT Secretariat. As such WHO would continue to work with IMPACT, drawing on its technical input and the involvement of a large number of stakeholders, whilst clearly distinguishing between documents prepared by IMPACT and those issued by WHO.\n\nTechnical documents prepared by IMPACT working groups would be posted on the IMPACT web site, without the WHO logo. These could be reviewed, adapted and ultimately approved as appropriate, through the normal WHO consultative procedures.\n\nThe IMPACT web site would be revised and updated. It would include the proposal for the **Draft principles and elements for national legislation against counterfeit medical products**, inviting comments thereon. A Circular Letter would be prepared to draw Member States\u2019 attention to this draft document and the new proposal for the definition of counterfeit medical products contained therein.\n\nA direct link to the above-mentioned document was available in the news section of the IMPACT web site (http://www.who.int/impact/news/BonnMeetingDraftPrinciples.pdf).\n\nA proposed revision of the **WHO Good Distribution Practices (GDP) for pharmaceutical products** was discussed by this Expert Committee with a view to its adoption. The document could be found on the WHO web site at: http://www.who.int/medicines/services/expertcommittees/pharmprep/43rdpharmprep/en/index.html, and also with a direct link: http://www.who.int/medicines/", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en las actividades y planes de la Organizaci\u00f3n Mundial de la Salud (OMS) en relaci\u00f3n con la lucha contra los medicamentos falsificados y la mejora de las pr\u00e1cticas de distribuci\u00f3n de productos farmac\u00e9uticos. Se menciona la colaboraci\u00f3n con el Comit\u00e9 de Expertos de la OMS y el IMPACT (Medicamentos Falsificados y Productos M\u00e9dicos) para revisar y actualizar documentos clave, como las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) y la legislaci\u00f3n modelo contra los medicamentos falsificados. Tambi\u00e9n se destaca la importancia de la financiaci\u00f3n y el apoyo t\u00e9cnico en \u00c1frica, as\u00ed como la necesidad de distinguir entre los documentos de la OMS y los de IMPACT.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 papel desempe\u00f1ar\u00e1 la OMS en la revisi\u00f3n de las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) y c\u00f3mo se relaciona esto con el trabajo de IMPACT?**\n   - La OMS proceder\u00e1 con la revisi\u00f3n conjunta de las GDP para productos farmac\u00e9uticos, que fue propuesta por IMPACT en 2007. Esto implica que la OMS trabajar\u00e1 en colaboraci\u00f3n con el Comit\u00e9 de Expertos y utilizar\u00e1 la entrada t\u00e9cnica de IMPACT para actualizar y adoptar estas pr\u00e1cticas.\n\n2. **\u00bfCu\u00e1les son los planes espec\u00edficos de la OMS para abordar la problem\u00e1tica de los medicamentos falsificados en \u00c1frica?**\n   - La OMS planea implementar actividades de defensa, capacitaci\u00f3n, apoyo a pa\u00edses y actividades de aplicaci\u00f3n de la ley con gobiernos interesados en \u00c1frica, dependiendo de la disponibilidad de fondos de donantes, principalmente de la Uni\u00f3n Europea.\n\n3. **\u00bfC\u00f3mo se gestionar\u00e1 la distinci\u00f3n entre los documentos preparados por IMPACT y los emitidos por la OMS?**\n   - La OMS continuar\u00e1 trabajando con IMPACT, pero se asegurar\u00e1 de distinguir claramente entre los documentos de IMPACT y los de la OMS. Los documentos t\u00e9cnicos de IMPACT se publicar\u00e1n en su sitio web sin el logo de la OMS y seguir\u00e1n los procedimientos consultivos normales de la OMS para su revisi\u00f3n y aprobaci\u00f3n.", "prev_section_summary": "El contenido de la secci\u00f3n aborda varios temas clave relacionados con la regulaci\u00f3n de medicamentos, las actividades en el \u00e1mbito del VIH y la lucha contra los medicamentos falsificados. A continuaci\u00f3n se presenta un resumen de los temas y entidades principales:\n\n### Temas Clave:\n\n1. **Regulaci\u00f3n de Medicamentos**:\n   - Se planea mejorar la retroalimentaci\u00f3n y la identificaci\u00f3n de necesidades en la regulaci\u00f3n de medicamentos.\n   - Se busca establecer una red de centros de excelencia en asuntos regulatorios que funcionen como centros de capacitaci\u00f3n y dise\u00f1en nuevos mecanismos de intervenci\u00f3n.\n\n2. **Actividades Relacionadas con el VIH**:\n   - El Departamento de VIH de la OMS public\u00f3 un informe anual titulado \u201cTowards universal access\u201d, que detalla el progreso en el acceso a tratamientos para el VIH y la precalificaci\u00f3n de antirretrovirales.\n   - Se incluy\u00f3 una encuesta de evaluaci\u00f3n de calidad de QSM en el informe de 2008.\n\n3. **Medicamentos Falsificados**:\n   - Se present\u00f3 una actualizaci\u00f3n sobre el Programa Anti-Counterfeiting (ACM) de la OMS, que se centra en la lucha contra los medicamentos falsificados.\n   - Se discutieron preocupaciones sobre el papel de la OMS en este \u00e1mbito durante la reuni\u00f3n de la Junta Ejecutiva en enero de 2009.\n   - Se mencionaron dos documentos de antecedentes preparados por la Secretar\u00eda de la OMS para la Asamblea Mundial de la Salud sobre las actividades de IMPACT y la lucha contra los medicamentos falsificados.\n\n### Entidades Principales:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad principal que coordina las actividades relacionadas con la regulaci\u00f3n de medicamentos, el VIH y la lucha contra los medicamentos falsificados.\n- **Departamento de VIH**: Parte de la OMS que se encarga de las actividades relacionadas con el VIH y la publicaci\u00f3n de informes sobre el acceso a tratamientos.\n- **Programa Anti-Counterfeiting (ACM)**: Un programa creado por la OMS para abordar el problema de los medicamentos falsificados.\n- **IMPACT**: Grupo de trabajo de la OMS que se ocupa de la lucha contra los medicamentos falsificados.\n\nEste resumen destaca la importancia de la regulaci\u00f3n de medicamentos, el acceso a tratamientos para el VIH y la necesidad de combatir los medicamentos falsificados, as\u00ed como la colaboraci\u00f3n continua de la OMS con socios en estos temas.", "excerpt_keywords": "Keywords: WHO, counterfeit medicines, Good Distribution Practices, IMPACT, pharmaceutical regulation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "85ed28c2-4805-4e71-a1f6-8a4aba258361", "node_type": "4", "metadata": {"page_label": "29", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Proceed with the joint WHO Expert Committee on Specifications for Pharmaceutical Preparations/IMPACT review of the **WHO Good distribution practices (GDP) for pharmaceutical products**, which was proposed by IMPACT in 2007.\n- Start the review process of the draft document on Model Legislation developed by IMPACT in 2008, including a revision of the current definition of counterfeit medicines, possibly through the Expert Committee.\n- Plan and implement advocacy, training, country support and enforcement activities with interested governments in Africa, as far as specified donor funds were available (mostly from the European Union for African, Caribbean and Pacific countries).\n- Recruit one technical expert on regulatory matters and pursue the possibility of FIP arranging the secondment of a communication expert.\n- Prepare a fund-raising plan for future staff and activities to combat counterfeit medicines and approach interested donors.\n\nIn addition to WHO\u2019s work on counterfeit medicines described above, the Assistant Director-General, HSS would continue her two-year mandate as elected Chair of IMPACT and WHO would continue to fulfil the functions of the IMPACT Secretariat. As such WHO would continue to work with IMPACT, drawing on its technical input and the involvement of a large number of stakeholders, whilst clearly distinguishing between documents prepared by IMPACT and those issued by WHO.\n\nTechnical documents prepared by IMPACT working groups would be posted on the IMPACT web site, without the WHO logo. These could be reviewed, adapted and ultimately approved as appropriate, through the normal WHO consultative procedures.\n\nThe IMPACT web site would be revised and updated. It would include the proposal for the **Draft principles and elements for national legislation against counterfeit medical products**, inviting comments thereon. A Circular Letter would be prepared to draw Member States\u2019 attention to this draft document and the new proposal for the definition of counterfeit medical products contained therein.\n\nA direct link to the above-mentioned document was available in the news section of the IMPACT web site (http://www.who.int/impact/news/BonnMeetingDraftPrinciples.pdf).\n\nA proposed revision of the **WHO Good Distribution Practices (GDP) for pharmaceutical products** was discussed by this Expert Committee with a view to its adoption. The document could be found on the WHO web site at: http://www.who.int/medicines/services/expertcommittees/pharmprep/43rdpharmprep/en/index.html, and also with a direct link: http://www.who.int/medicines/", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "08eec785646bfa0ea8aa60ab36b7ef5ff72a7bb74b34cf74345ecf14f9a5c92c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- Proceed with the joint WHO Expert Committee on Specifications for Pharmaceutical Preparations/IMPACT review of the **WHO Good distribution practices (GDP) for pharmaceutical products**, which was proposed by IMPACT in 2007.\n- Start the review process of the draft document on Model Legislation developed by IMPACT in 2008, including a revision of the current definition of counterfeit medicines, possibly through the Expert Committee.\n- Plan and implement advocacy, training, country support and enforcement activities with interested governments in Africa, as far as specified donor funds were available (mostly from the European Union for African, Caribbean and Pacific countries).\n- Recruit one technical expert on regulatory matters and pursue the possibility of FIP arranging the secondment of a communication expert.\n- Prepare a fund-raising plan for future staff and activities to combat counterfeit medicines and approach interested donors.\n\nIn addition to WHO\u2019s work on counterfeit medicines described above, the Assistant Director-General, HSS would continue her two-year mandate as elected Chair of IMPACT and WHO would continue to fulfil the functions of the IMPACT Secretariat. As such WHO would continue to work with IMPACT, drawing on its technical input and the involvement of a large number of stakeholders, whilst clearly distinguishing between documents prepared by IMPACT and those issued by WHO.\n\nTechnical documents prepared by IMPACT working groups would be posted on the IMPACT web site, without the WHO logo. These could be reviewed, adapted and ultimately approved as appropriate, through the normal WHO consultative procedures.\n\nThe IMPACT web site would be revised and updated. It would include the proposal for the **Draft principles and elements for national legislation against counterfeit medical products**, inviting comments thereon. A Circular Letter would be prepared to draw Member States\u2019 attention to this draft document and the new proposal for the definition of counterfeit medical products contained therein.\n\nA direct link to the above-mentioned document was available in the news section of the IMPACT web site (http://www.who.int/impact/news/BonnMeetingDraftPrinciples.pdf).\n\nA proposed revision of the **WHO Good Distribution Practices (GDP) for pharmaceutical products** was discussed by this Expert Committee with a view to its adoption. The document could be found on the WHO web site at: http://www.who.int/medicines/services/expertcommittees/pharmprep/43rdpharmprep/en/index.html, and also with a direct link: http://www.who.int/medicines/", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2592, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3105dcea-764d-4ebb-9611-4e880c8ebb39": {"__data__": {"id_": "3105dcea-764d-4ebb-9611-4e880c8ebb39", "embedding": null, "metadata": {"page_label": "30", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "services/expertcommittees/pharmprep/170909Clean_GDP-counterfeits-QAS08252Rev1.pdf\n\nThe planned IMPACT meetings (subject to resources) were as follows:\n- regional meeting in South Africa (9\u201310 November 2009);\n- annual meeting of IMPACT Planning Group including all IMPACT Chairs and Co-Chairs (January 2010);\n- Open Forum for WHO Member States and interested parties, involving IMPACT partners (January 2010);\n- Working Group meetings (January 2010); and\n- annual IMPACT meeting (after the World Health Assembly in May 2010).\n\nThe Committee was pleased to note the continued cooperation with other WHO departments and programmes.\n\n## 3. Quality control \u2014 specifications and tests\n\n### 3.1 The International Pharmacopoeia\n\nFollowing the publication of the First Supplement to the Fourth Edition, the Expert Committee was informed that the final texts for the monographs adopted at the forty-second and forty-third meetings in October 2007 and 2008 had been made available to users of the WHO Medicines web site and that they were ready to be included in the forthcoming issue of *The International Pharmacopoeia* (Ph.Int.). While the format of this future publication was still to be defined (electronic, CD-ROM or book), a tentative table of contents of about 45 texts for inclusion in this publication was discussed and adopted.\n\n**Provisional list of contents for the forthcoming publication of The International Pharmacopoeia**  \nMonographs adopted at the forty-second meeting of the Expert Committee in October 2007\n\n**Pharmaceutical substances**\n- Lumefantrine\n- Zinc sulfate\n\n**Dosage forms**\n- Artemether and lumefantrine tablets\n- Magnesium sulfate injection\n- Rifampicin and isoniazid dispersible tablets\n- Rifampicin, isoniazid and ethambutol tablets", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento se refiere a las reuniones planificadas del grupo IMPACT de la OMS, que se centran en la cooperaci\u00f3n y el control de calidad de los medicamentos. Se menciona la publicaci\u00f3n de textos finales de monograf\u00edas en *The International Pharmacopoeia*, que incluye una lista provisional de sustancias farmac\u00e9uticas y formas de dosificaci\u00f3n adoptadas en reuniones anteriores. Se destaca la importancia de la colaboraci\u00f3n entre diferentes departamentos y programas de la OMS.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las fechas y tipos de reuniones planificadas para el grupo IMPACT de la OMS en 2009 y 2010?**\n   - Esta pregunta se centra en los detalles espec\u00edficos de las reuniones mencionadas, que incluyen fechas y tipos de encuentros.\n\n2. **\u00bfQu\u00e9 sustancias farmac\u00e9uticas y formas de dosificaci\u00f3n se incluir\u00e1n en la pr\u00f3xima publicaci\u00f3n de *The International Pharmacopoeia* seg\u00fan las reuniones del Comit\u00e9 de Expertos?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre los contenidos que se discutir\u00e1n y adoptar\u00e1n en la pr\u00f3xima edici\u00f3n de la farmacopoeia.\n\n3. **\u00bfQu\u00e9 importancia se le da a la cooperaci\u00f3n entre los diferentes departamentos de la OMS en el contexto de la calidad de los medicamentos?**\n   - Esta pregunta explora el papel de la colaboraci\u00f3n interdepartamental en el control de calidad y la regulaci\u00f3n de medicamentos, un aspecto que puede no ser ampliamente discutido en otros documentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**:\n   - La OMS est\u00e1 involucrada en la revisi\u00f3n de las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) para productos farmac\u00e9uticos, en colaboraci\u00f3n con el Comit\u00e9 de Expertos y el IMPACT.\n   - Continuar\u00e1 desempe\u00f1ando funciones como Secretar\u00eda de IMPACT y mantendr\u00e1 una distinci\u00f3n clara entre los documentos de la OMS y los de IMPACT.\n\n2. **IMPACT (Medicamentos Falsificados y Productos M\u00e9dicos)**:\n   - IMPACT propuso la revisi\u00f3n de las GDP en 2007 y desarroll\u00f3 un documento de legislaci\u00f3n modelo en 2008.\n   - Se espera que IMPACT proporcione insumos t\u00e9cnicos y facilite la participaci\u00f3n de m\u00faltiples interesados en la lucha contra los medicamentos falsificados.\n\n3. **Actividades en \u00c1frica**:\n   - La OMS planea implementar actividades de defensa, capacitaci\u00f3n y apoyo a pa\u00edses en \u00c1frica, dependiendo de la disponibilidad de fondos de donantes, principalmente de la Uni\u00f3n Europea.\n\n4. **Documentos T\u00e9cnicos**:\n   - Los documentos t\u00e9cnicos elaborados por los grupos de trabajo de IMPACT se publicar\u00e1n en su sitio web sin el logo de la OMS y seguir\u00e1n los procedimientos consultivos de la OMS para su revisi\u00f3n y aprobaci\u00f3n.\n\n5. **Revisi\u00f3n de Legislaci\u00f3n**:\n   - Se discutir\u00e1 una propuesta de revisi\u00f3n de las GDP y se invitar\u00e1 a comentarios sobre los principios y elementos para la legislaci\u00f3n nacional contra los productos m\u00e9dicos falsificados.\n\n6. **Financiaci\u00f3n y Recursos**:\n   - Se preparar\u00e1 un plan de recaudaci\u00f3n de fondos para futuras actividades y personal en la lucha contra los medicamentos falsificados.\n\n### Enlaces Relevantes:\n- Documentos y propuestas se pueden encontrar en el sitio web de la OMS y el sitio web de IMPACT, incluyendo enlaces directos a documentos espec\u00edficos.", "excerpt_keywords": "Keywords: WHO, IMPACT, International Pharmacopoeia, quality control, pharmaceutical substances"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "92712337-e490-4bb0-b54f-609cd1cbdb76", "node_type": "4", "metadata": {"page_label": "30", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "services/expertcommittees/pharmprep/170909Clean_GDP-counterfeits-QAS08252Rev1.pdf\n\nThe planned IMPACT meetings (subject to resources) were as follows:\n- regional meeting in South Africa (9\u201310 November 2009);\n- annual meeting of IMPACT Planning Group including all IMPACT Chairs and Co-Chairs (January 2010);\n- Open Forum for WHO Member States and interested parties, involving IMPACT partners (January 2010);\n- Working Group meetings (January 2010); and\n- annual IMPACT meeting (after the World Health Assembly in May 2010).\n\nThe Committee was pleased to note the continued cooperation with other WHO departments and programmes.\n\n## 3. Quality control \u2014 specifications and tests\n\n### 3.1 The International Pharmacopoeia\n\nFollowing the publication of the First Supplement to the Fourth Edition, the Expert Committee was informed that the final texts for the monographs adopted at the forty-second and forty-third meetings in October 2007 and 2008 had been made available to users of the WHO Medicines web site and that they were ready to be included in the forthcoming issue of *The International Pharmacopoeia* (Ph.Int.). While the format of this future publication was still to be defined (electronic, CD-ROM or book), a tentative table of contents of about 45 texts for inclusion in this publication was discussed and adopted.\n\n**Provisional list of contents for the forthcoming publication of The International Pharmacopoeia**  \nMonographs adopted at the forty-second meeting of the Expert Committee in October 2007\n\n**Pharmaceutical substances**\n- Lumefantrine\n- Zinc sulfate\n\n**Dosage forms**\n- Artemether and lumefantrine tablets\n- Magnesium sulfate injection\n- Rifampicin and isoniazid dispersible tablets\n- Rifampicin, isoniazid and ethambutol tablets", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "ffcf50463f7d092f0a2b4854976d3762043c6c44d8fb7bfaec92937a23a9612a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "services/expertcommittees/pharmprep/170909Clean_GDP-counterfeits-QAS08252Rev1.pdf\n\nThe planned IMPACT meetings (subject to resources) were as follows:\n- regional meeting in South Africa (9\u201310 November 2009);\n- annual meeting of IMPACT Planning Group including all IMPACT Chairs and Co-Chairs (January 2010);\n- Open Forum for WHO Member States and interested parties, involving IMPACT partners (January 2010);\n- Working Group meetings (January 2010); and\n- annual IMPACT meeting (after the World Health Assembly in May 2010).\n\nThe Committee was pleased to note the continued cooperation with other WHO departments and programmes.\n\n## 3. Quality control \u2014 specifications and tests\n\n### 3.1 The International Pharmacopoeia\n\nFollowing the publication of the First Supplement to the Fourth Edition, the Expert Committee was informed that the final texts for the monographs adopted at the forty-second and forty-third meetings in October 2007 and 2008 had been made available to users of the WHO Medicines web site and that they were ready to be included in the forthcoming issue of *The International Pharmacopoeia* (Ph.Int.). While the format of this future publication was still to be defined (electronic, CD-ROM or book), a tentative table of contents of about 45 texts for inclusion in this publication was discussed and adopted.\n\n**Provisional list of contents for the forthcoming publication of The International Pharmacopoeia**  \nMonographs adopted at the forty-second meeting of the Expert Committee in October 2007\n\n**Pharmaceutical substances**\n- Lumefantrine\n- Zinc sulfate\n\n**Dosage forms**\n- Artemether and lumefantrine tablets\n- Magnesium sulfate injection\n- Rifampicin and isoniazid dispersible tablets\n- Rifampicin, isoniazid and ethambutol tablets", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1759, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "70a3e194-5d04-4916-83dd-e2db2a5ad068": {"__data__": {"id_": "70a3e194-5d04-4916-83dd-e2db2a5ad068", "embedding": null, "metadata": {"page_label": "31", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Rifampicin, isoniazid and pyrazinamide dispersible tablets\n- Zinc sulfate oral solution (paediatric)\n- Zinc sulfate tablets (paediatric)\n\n# Monographs adopted at the forty-third meeting of the Expert Committee in October 2008\n\n## Pharmaceutical substances\n- Emtricitabine\n- Mebendazole (revision of published monograph)\n- Nevirapine (revision of published monograph)\n- Oseltamivir phosphate\n\n## Dosage forms\n- Artemether and lumefantrine oral suspension\n- Mebendazole chewable tablets (revision of published monograph for mebendazole tablets)\n- Chloroquine sulfate oral solution\n- Cycloserine capsules\n- Efavirenz capsules\n- Efavirenz oral solution\n- Ethambutol hydrochloride tablets (revision of published monograph)\n- Nevirapine oral suspension\n- Nevirapine tablets\n- Quinine sulfate tablets\n- Zidovudine, lamivudine and nevirapine tablets\n\n## Radiopharmaceuticals\n\n### General monograph and related texts\n- General monograph\n- Methods of analysis\n- Supplementary information\n- Individual monographs\n- Fludeoxyglucose (\u00b9\u2078F) injection\n- Gallium citrate (\u2076\u2077Ga) injection\n- Iobenguane (\u00b9\u00b2\u00b3I) injection\n- Iobenguane (\u00b9\u00b3\u00b9I) injection\n- Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) capsules\n- Sodium iodide (\u00b9\u00b3\u00b9I) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) solution\n- Sodium iothalamate (\u00b9\u00b2\u2075I) injection", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con sus respuestas:\n\n1. **\u00bfCu\u00e1les son los medicamentos que se presentan en forma de tabletas dispersables seg\u00fan el informe?**\n   - **Respuesta:** Los medicamentos que se presentan en forma de tabletas dispersables son Rifampicin, isoniazid y pyrazinamide.\n\n2. **\u00bfQu\u00e9 revisiones se realizaron en las monograf\u00edas adoptadas en la reuni\u00f3n del Comit\u00e9 de Expertos en octubre de 2008?**\n   - **Respuesta:** Se realizaron revisiones de las monograf\u00edas de Mebendazole, Nevirapine y Ethambutol hydrochloride tablets.\n\n3. **\u00bfQu\u00e9 tipos de inyecciones de radiof\u00e1rmacos se mencionan en el informe?**\n   - **Respuesta:** Las inyecciones de radiof\u00e1rmacos mencionadas son Fludeoxyglucose (\u00b9\u2078F), Gallium citrate (\u2076\u2077Ga), Iobenguane (\u00b9\u00b2\u00b3I), Iobenguane (\u00b9\u00b3\u00b9I), Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm), Sodium iodide (\u00b9\u00b3\u00b9I) y Sodium iothalamate (\u00b9\u00b2\u2075I).\n\n### Resumen de nivel superior del contexto:\nEl documento \"WHO - Technical Report Series 957\" presenta una lista de medicamentos y formulaciones adoptadas en la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS en octubre de 2008. Incluye tanto sustancias farmac\u00e9uticas como formas de dosificaci\u00f3n, as\u00ed como una secci\u00f3n dedicada a radiopharmaceuticals, que detalla varios tipos de inyecciones y monograf\u00edas relacionadas. \n\nEste resumen puede ayudar a formular preguntas m\u00e1s amplias sobre el contenido del informe, como la importancia de las revisiones de monograf\u00edas o el impacto de los nuevos medicamentos en la salud p\u00fablica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Reuniones del Grupo IMPACT de la OMS**:\n   - Se planificaron varias reuniones para 2009 y 2010, incluyendo:\n     - Reuni\u00f3n regional en Sud\u00e1frica (9-10 de noviembre de 2009).\n     - Reuni\u00f3n anual del Grupo de Planificaci\u00f3n de IMPACT (enero de 2010).\n     - Foro Abierto para Estados Miembros de la OMS y partes interesadas (enero de 2010).\n     - Reuniones de Grupos de Trabajo (enero de 2010).\n     - Reuni\u00f3n anual de IMPACT (despu\u00e9s de la Asamblea Mundial de la Salud en mayo de 2010).\n\n2. **Cooperaci\u00f3n Interdepartamental**:\n   - Se destaca la importancia de la cooperaci\u00f3n continua entre diferentes departamentos y programas de la OMS en el contexto del control de calidad de los medicamentos.\n\n3. **Control de Calidad y Farmacopea Internacional**:\n   - Se informa sobre la publicaci\u00f3n de textos finales de monograf\u00edas que ser\u00e1n incluidos en la pr\u00f3xima edici\u00f3n de *The International Pharmacopoeia*.\n   - Se discute un contenido provisional que incluye:\n     - **Sustancias farmac\u00e9uticas**: Lumefantrine, Zinc sulfate.\n     - **Formas de dosificaci\u00f3n**: \n       - Tabletas de artemeter y lumefantrina.\n       - Inyecci\u00f3n de sulfato de magnesio.\n       - Tabletas dispersables de rifampicina e isoniazida.\n       - Tabletas de rifampicina, isoniazida y etambutol.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la salud p\u00fablica global.\n- **IMPACT**: Grupo de trabajo de la OMS enfocado en la calidad y regulaci\u00f3n de medicamentos.\n- **The International Pharmacopoeia**: Publicaci\u00f3n que establece est\u00e1ndares de calidad para medicamentos.\n- **Sustancias farmac\u00e9uticas mencionadas**: Lumefantrine, Zinc sulfate.\n- **Formas de dosificaci\u00f3n mencionadas**: Tabletas de artemeter y lumefantrina, inyecci\u00f3n de sulfato de magnesio, tabletas dispersables de rifampicina e isoniazida, tabletas de rifampicina, isoniazida y etambutol.", "excerpt_keywords": "Keywords: WHO, pharmaceuticals, radiopharmaceuticals, monographs, dosage forms"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5037ce5a-65e2-406f-9a1e-a7796fb1ae2f", "node_type": "4", "metadata": {"page_label": "31", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Rifampicin, isoniazid and pyrazinamide dispersible tablets\n- Zinc sulfate oral solution (paediatric)\n- Zinc sulfate tablets (paediatric)\n\n# Monographs adopted at the forty-third meeting of the Expert Committee in October 2008\n\n## Pharmaceutical substances\n- Emtricitabine\n- Mebendazole (revision of published monograph)\n- Nevirapine (revision of published monograph)\n- Oseltamivir phosphate\n\n## Dosage forms\n- Artemether and lumefantrine oral suspension\n- Mebendazole chewable tablets (revision of published monograph for mebendazole tablets)\n- Chloroquine sulfate oral solution\n- Cycloserine capsules\n- Efavirenz capsules\n- Efavirenz oral solution\n- Ethambutol hydrochloride tablets (revision of published monograph)\n- Nevirapine oral suspension\n- Nevirapine tablets\n- Quinine sulfate tablets\n- Zidovudine, lamivudine and nevirapine tablets\n\n## Radiopharmaceuticals\n\n### General monograph and related texts\n- General monograph\n- Methods of analysis\n- Supplementary information\n- Individual monographs\n- Fludeoxyglucose (\u00b9\u2078F) injection\n- Gallium citrate (\u2076\u2077Ga) injection\n- Iobenguane (\u00b9\u00b2\u00b3I) injection\n- Iobenguane (\u00b9\u00b3\u00b9I) injection\n- Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) capsules\n- Sodium iodide (\u00b9\u00b3\u00b9I) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) solution\n- Sodium iothalamate (\u00b9\u00b2\u2075I) injection", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "5d3e507b8aa7188f72351cf81e5d41ea724ea3506c0a10c61b56148b9bac49b8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- Rifampicin, isoniazid and pyrazinamide dispersible tablets\n- Zinc sulfate oral solution (paediatric)\n- Zinc sulfate tablets (paediatric)\n\n# Monographs adopted at the forty-third meeting of the Expert Committee in October 2008\n\n## Pharmaceutical substances\n- Emtricitabine\n- Mebendazole (revision of published monograph)\n- Nevirapine (revision of published monograph)\n- Oseltamivir phosphate\n\n## Dosage forms\n- Artemether and lumefantrine oral suspension\n- Mebendazole chewable tablets (revision of published monograph for mebendazole tablets)\n- Chloroquine sulfate oral solution\n- Cycloserine capsules\n- Efavirenz capsules\n- Efavirenz oral solution\n- Ethambutol hydrochloride tablets (revision of published monograph)\n- Nevirapine oral suspension\n- Nevirapine tablets\n- Quinine sulfate tablets\n- Zidovudine, lamivudine and nevirapine tablets\n\n## Radiopharmaceuticals\n\n### General monograph and related texts\n- General monograph\n- Methods of analysis\n- Supplementary information\n- Individual monographs\n- Fludeoxyglucose (\u00b9\u2078F) injection\n- Gallium citrate (\u2076\u2077Ga) injection\n- Iobenguane (\u00b9\u00b2\u00b3I) injection\n- Iobenguane (\u00b9\u00b3\u00b9I) injection\n- Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) capsules\n- Sodium iodide (\u00b9\u00b3\u00b9I) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) solution\n- Sodium iothalamate (\u00b9\u00b2\u2075I) injection", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1348, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "273202dd-e553-4d9c-8f7b-fee4094bfe4b": {"__data__": {"id_": "273202dd-e553-4d9c-8f7b-fee4094bfe4b", "embedding": null, "metadata": {"page_label": "32", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Sodium pertechnetate (\u2079\u2079\u1d50Tc) injection (fission)\n- Sodium pertechnetate (\u2079\u2079\u1d50Tc) injection (non-fission)\n- Sodium phosphate (\u00b3\u00b2P) injection\n- Strontium chloride (\u2078\u2079Sr) injection\n- Technetium (\u2079\u2079\u1d50Tc) bicisate complex injection\n- Technetium (\u2079\u2079\u1d50Tc) exametazime complex injection\n- Technetium (\u2079\u2079\u1d50Tc) mebrofenin complex injection\n- Technetium (\u2079\u2079\u1d50Tc) mertiatide injection\n- Technetium (\u2079\u2079\u1d50Tc) pentetate complex injection\n- Technetium (\u2079\u2079\u1d50Tc) succimer complex injection\n- Technetium (\u2079\u2079\u1d50Tc) sulfur colloid injection\n- Technetium (\u2079\u2079\u1d50Tc) tetrofosmin complex injection\n- Technetium (\u2079\u2079\u1d50Tc) tin colloidal injection\n- Technetium(\u2079\u2079\u1d50Tc ) pyrophosphate tin complex injection\n- Technetium(\u2079\u2079\u1d50Tc) methylene diphosphonate (MDP) complex injection\n- Technetium(\u2079\u2079\u1d50Tc) sestamibi complex injection\n- Thallous chloride (\u00b2\u2070\u00b9Tl) injection\n- Yttrium silicate (\u2079\u2070Y) colloid injection\n\nThe Expert Committee recommended that the texts adopted at the forty-fourth meeting also be considered for inclusion.\n\n# WHO Medicines web site \u2014 International Pharmacopoeia pages\n\nThe Expert Committee was pleased to note that regular updates had been made in 2009 of the web pages devoted to the Ph.Int. on the WHO Medicines web site to inform users in a timely manner about recently adopted texts and, when relevant, about specific aspects of the work carried out to develop or revise monographs (e.g. the rapid revision posted for heparins or the note on artemisinin derivatives revision).\n\nIn view of the particularity of some of the substances for which monographs had been recently adopted and the large number of new substances included in the 2009 work plan belonging to the same category of medicines, the number of web pages had been increased to include:\n\n- radiopharmaceuticals; and\n- anti-infectives (including antibacterial, antiprotozoal, antifungal, antiviral and antimycobacterial agents \u2014 for diseases other than HIV/AIDS, tuberculosis and malaria \u2014 and anthelmintics).\n\nThe Expert Committee noted with appreciation that there had been a positive response to these updates and that requests had been received regarding subscription to a mailing list for receiving alerts on the latest Ph.Int. activities. Recognizing that this mailing system would help users keep track of the latest changes and that this would also improve the dissemination.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta una lista de inyecciones de radiotrazadores y otros medicamentos, as\u00ed como una actualizaci\u00f3n sobre las p\u00e1ginas web de la Farmacopea Internacional (Ph.Int.) en el sitio de medicamentos de la OMS. Se destaca que se han realizado actualizaciones regulares para informar a los usuarios sobre textos adoptados recientemente y aspectos espec\u00edficos del trabajo en monograf\u00edas. Adem\u00e1s, se ha incrementado el n\u00famero de p\u00e1ginas web para incluir radiopharmaceuticals y anti-infectivos, y se ha recibido una respuesta positiva de los usuarios, quienes han solicitado suscripciones a una lista de correo para recibir alertas sobre las actividades m\u00e1s recientes de la Ph.Int.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipos de inyecciones de radiotrazadores se mencionan en el documento y cu\u00e1les son sus aplicaciones espec\u00edficas?**\n   - Respuesta: El documento menciona varias inyecciones de radiotrazadores, como el sodio pertechnetate (\u2079\u2079\u1d50Tc) y el cloruro de talio (\u00b2\u2070\u00b9Tl), que se utilizan en diversas aplicaciones de diagn\u00f3stico m\u00e9dico, como la imagenolog\u00eda nuclear.\n\n2. **\u00bfQu\u00e9 cambios se realizaron en las p\u00e1ginas web de la Farmacopea Internacional en 2009 y por qu\u00e9 fueron necesarios?**\n   - Respuesta: En 2009, se realizaron actualizaciones para incluir m\u00e1s informaci\u00f3n sobre radiopharmaceuticals y anti-infectivos, debido a la particularidad de algunas sustancias y el aumento en el n\u00famero de nuevos medicamentos en el plan de trabajo de ese a\u00f1o.\n\n3. **\u00bfC\u00f3mo ha respondido la comunidad a las actualizaciones de la Farmacopea Internacional y qu\u00e9 medidas se est\u00e1n tomando para mejorar la comunicaci\u00f3n?**\n   - Respuesta: La comunidad ha respondido positivamente a las actualizaciones, solicitando suscripciones a una lista de correo para recibir alertas sobre las \u00faltimas actividades de la Ph.Int., lo que sugiere un inter\u00e9s en mantenerse informado sobre los cambios y mejoras en la farmacolog\u00eda internacional.", "prev_section_summary": "El documento \"WHO - Technical Report Series 957\" presenta una serie de medicamentos y formulaciones adoptadas en la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS en octubre de 2008. A continuaci\u00f3n se resumen los temas clave y entidades mencionadas en la secci\u00f3n:\n\n### Temas Clave:\n1. **Medicamentos en Formas de Dosificaci\u00f3n:**\n   - Se mencionan tabletas dispersables de Rifampicin, isoniazid y pyrazinamide, as\u00ed como soluciones y tabletas de sulfato de zinc para uso pedi\u00e1trico.\n\n2. **Sustancias Farmac\u00e9uticas:**\n   - Se adoptaron varias monograf\u00edas, incluyendo:\n     - Emtricitabine\n     - Mebendazole (con revisi\u00f3n de la monograf\u00eda publicada)\n     - Nevirapine (con revisi\u00f3n de la monograf\u00eda publicada)\n     - Oseltamivir phosphate\n\n3. **Formas de Dosificaci\u00f3n:**\n   - Se incluyen diversas formas de dosificaci\u00f3n como:\n     - Suspensi\u00f3n oral de Artemether y lumefantrine\n     - Tabletas masticables de Mebendazole (revisi\u00f3n)\n     - Soluciones orales de Chloroquine sulfate y otros medicamentos en c\u00e1psulas y tabletas.\n\n4. **Radiof\u00e1rmacos:**\n   - Se presenta una secci\u00f3n dedicada a los radiof\u00e1rmacos, que incluye:\n     - Monograf\u00edas generales y textos relacionados\n     - M\u00e9todos de an\u00e1lisis\n     - Inyecciones de varios radiof\u00e1rmacos como Fludeoxyglucose (\u00b9\u2078F), Gallium citrate (\u2076\u2077Ga), y diferentes formas de Iobenguane y Sodium iodide.\n\n### Entidades Mencionadas:\n- **Medicamentos:**\n  - Rifampicin, isoniazid, pyrazinamide, Zinc sulfate, Emtricitabine, Mebendazole, Nevirapine, Oseltamivir phosphate, Artemether, lumefantrine, Chloroquine, Cycloserine, Efavirenz, Ethambutol, Quinine, Zidovudine, lamivudine.\n\n- **Radiof\u00e1rmacos:**\n  - Fludeoxyglucose (\u00b9\u2078F), Gallium citrate (\u2076\u2077Ga), Iobenguane (\u00b9\u00b2\u00b3I), Iobenguane (\u00b9\u00b3\u00b9I), Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm), Sodium iodide (\u00b9\u00b3\u00b9I), Sodium iothalamate (\u00b9\u00b2\u2075I).\n\nEste resumen proporciona una visi\u00f3n general de los medicamentos y formulaciones discutidos en el informe, as\u00ed como de las revisiones y los tipos de radiof\u00e1rmacos incluidos.", "excerpt_keywords": "Keywords: radiopharmaceuticals, injections, WHO, International Pharmacopoeia, updates"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f5838db8-9e28-4336-a2ee-93f58d1eab6f", "node_type": "4", "metadata": {"page_label": "32", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Sodium pertechnetate (\u2079\u2079\u1d50Tc) injection (fission)\n- Sodium pertechnetate (\u2079\u2079\u1d50Tc) injection (non-fission)\n- Sodium phosphate (\u00b3\u00b2P) injection\n- Strontium chloride (\u2078\u2079Sr) injection\n- Technetium (\u2079\u2079\u1d50Tc) bicisate complex injection\n- Technetium (\u2079\u2079\u1d50Tc) exametazime complex injection\n- Technetium (\u2079\u2079\u1d50Tc) mebrofenin complex injection\n- Technetium (\u2079\u2079\u1d50Tc) mertiatide injection\n- Technetium (\u2079\u2079\u1d50Tc) pentetate complex injection\n- Technetium (\u2079\u2079\u1d50Tc) succimer complex injection\n- Technetium (\u2079\u2079\u1d50Tc) sulfur colloid injection\n- Technetium (\u2079\u2079\u1d50Tc) tetrofosmin complex injection\n- Technetium (\u2079\u2079\u1d50Tc) tin colloidal injection\n- Technetium(\u2079\u2079\u1d50Tc ) pyrophosphate tin complex injection\n- Technetium(\u2079\u2079\u1d50Tc) methylene diphosphonate (MDP) complex injection\n- Technetium(\u2079\u2079\u1d50Tc) sestamibi complex injection\n- Thallous chloride (\u00b2\u2070\u00b9Tl) injection\n- Yttrium silicate (\u2079\u2070Y) colloid injection\n\nThe Expert Committee recommended that the texts adopted at the forty-fourth meeting also be considered for inclusion.\n\n# WHO Medicines web site \u2014 International Pharmacopoeia pages\n\nThe Expert Committee was pleased to note that regular updates had been made in 2009 of the web pages devoted to the Ph.Int. on the WHO Medicines web site to inform users in a timely manner about recently adopted texts and, when relevant, about specific aspects of the work carried out to develop or revise monographs (e.g. the rapid revision posted for heparins or the note on artemisinin derivatives revision).\n\nIn view of the particularity of some of the substances for which monographs had been recently adopted and the large number of new substances included in the 2009 work plan belonging to the same category of medicines, the number of web pages had been increased to include:\n\n- radiopharmaceuticals; and\n- anti-infectives (including antibacterial, antiprotozoal, antifungal, antiviral and antimycobacterial agents \u2014 for diseases other than HIV/AIDS, tuberculosis and malaria \u2014 and anthelmintics).\n\nThe Expert Committee noted with appreciation that there had been a positive response to these updates and that requests had been received regarding subscription to a mailing list for receiving alerts on the latest Ph.Int. activities. Recognizing that this mailing system would help users keep track of the latest changes and that this would also improve the dissemination.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "13fc697a487aac60374835af5709273b00813ef1cbc0d08950c60b23d7277f97", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- Sodium pertechnetate (\u2079\u2079\u1d50Tc) injection (fission)\n- Sodium pertechnetate (\u2079\u2079\u1d50Tc) injection (non-fission)\n- Sodium phosphate (\u00b3\u00b2P) injection\n- Strontium chloride (\u2078\u2079Sr) injection\n- Technetium (\u2079\u2079\u1d50Tc) bicisate complex injection\n- Technetium (\u2079\u2079\u1d50Tc) exametazime complex injection\n- Technetium (\u2079\u2079\u1d50Tc) mebrofenin complex injection\n- Technetium (\u2079\u2079\u1d50Tc) mertiatide injection\n- Technetium (\u2079\u2079\u1d50Tc) pentetate complex injection\n- Technetium (\u2079\u2079\u1d50Tc) succimer complex injection\n- Technetium (\u2079\u2079\u1d50Tc) sulfur colloid injection\n- Technetium (\u2079\u2079\u1d50Tc) tetrofosmin complex injection\n- Technetium (\u2079\u2079\u1d50Tc) tin colloidal injection\n- Technetium(\u2079\u2079\u1d50Tc ) pyrophosphate tin complex injection\n- Technetium(\u2079\u2079\u1d50Tc) methylene diphosphonate (MDP) complex injection\n- Technetium(\u2079\u2079\u1d50Tc) sestamibi complex injection\n- Thallous chloride (\u00b2\u2070\u00b9Tl) injection\n- Yttrium silicate (\u2079\u2070Y) colloid injection\n\nThe Expert Committee recommended that the texts adopted at the forty-fourth meeting also be considered for inclusion.\n\n# WHO Medicines web site \u2014 International Pharmacopoeia pages\n\nThe Expert Committee was pleased to note that regular updates had been made in 2009 of the web pages devoted to the Ph.Int. on the WHO Medicines web site to inform users in a timely manner about recently adopted texts and, when relevant, about specific aspects of the work carried out to develop or revise monographs (e.g. the rapid revision posted for heparins or the note on artemisinin derivatives revision).\n\nIn view of the particularity of some of the substances for which monographs had been recently adopted and the large number of new substances included in the 2009 work plan belonging to the same category of medicines, the number of web pages had been increased to include:\n\n- radiopharmaceuticals; and\n- anti-infectives (including antibacterial, antiprotozoal, antifungal, antiviral and antimycobacterial agents \u2014 for diseases other than HIV/AIDS, tuberculosis and malaria \u2014 and anthelmintics).\n\nThe Expert Committee noted with appreciation that there had been a positive response to these updates and that requests had been received regarding subscription to a mailing list for receiving alerts on the latest Ph.Int. activities. Recognizing that this mailing system would help users keep track of the latest changes and that this would also improve the dissemination.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2325, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "733cf228-fea1-4998-bfd2-2f2e70efecbb": {"__data__": {"id_": "733cf228-fea1-4998-bfd2-2f2e70efecbb", "embedding": null, "metadata": {"page_label": "33", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# One-day briefing on The International Pharmacopoeia\n\nThe Secretariat informed the Expert Committee that a one-day overview of the Ph.Int. was given in April 2009 to industrial stakeholders. This included describing the process for developing monographs, together with explanations of the pharmacopoeial approach and policy on a variety of issues and of the role of the pharmacopoeia within WHO quality assurance activities. The meeting was interactive and informal to allow manufacturers (mostly those already collaborating with QSM) to raise issues and to have open discussions on the Ph.Int.\n\nIt was attended by representatives from generic and research-based pharmaceutical companies as well as pharmaceutical industry associations. The positive feedback received showed that the information provided was helpful and that the briefing session would assist in future collaborations in the development of monographs for the Ph.Int.\n\nIn response to requests from the participants to consider a future briefing with a larger audience, the Expert Committee recommended that the WHO Secretariat continue with organizing such information sessions.\n\n## 3.2 Current work plan and future work programme\n\nIn order to respond to the needs of WHO programmes and partner organizations, the Expert Committee agreed in 2008 to only consider for inclusion in the work programme those substances that had been assigned a high priority. A work plan, including a first group of six active pharmaceutical ingredients (APIs) and 36 dosage forms for monograph initiation, was thus adopted.\n\nSince good progress had been made in developing specifications from the 2009 work plan, a new work programme, including a second group for monograph initiation, was proposed to the Expert Committee, taking into account:\n\n- substances remaining from the 2009 work plan;\n- substances initially listed in the adopted work programme in 2008 that had now been prioritized, focusing on medicines for children, medicines important for the treatment of HIV/AIDS, tuberculosis and malaria and treatment of diseases with a high prevalence in developing countries);\n- additions from the sixteenth Model list of essential medicines and the second List of essential medicines for children;\n- additions from the expressions of interests (EOIs) within the WHO Prequalification Programme (PQP); and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento describe una sesi\u00f3n informativa de un d\u00eda sobre la Farmacopea Internacional (Ph.Int.) que se llev\u00f3 a cabo en abril de 2009, dirigida a partes interesadas de la industria farmac\u00e9utica. Durante la reuni\u00f3n, se discuti\u00f3 el proceso de desarrollo de monograf\u00edas y se abordaron diversas pol\u00edticas relacionadas con la calidad de los medicamentos. La sesi\u00f3n fue bien recibida, y se sugiri\u00f3 que se organizaran m\u00e1s sesiones informativas para un p\u00fablico m\u00e1s amplio. Adem\u00e1s, se presenta un plan de trabajo actual y un programa futuro que prioriza la inclusi\u00f3n de sustancias de alta prioridad en el trabajo de la Organizaci\u00f3n Mundial de la Salud (OMS), enfoc\u00e1ndose en medicamentos esenciales y en aquellos importantes para el tratamiento de enfermedades prevalentes en pa\u00edses en desarrollo.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les fueron los principales temas discutidos durante la sesi\u00f3n informativa sobre la Farmacopea Internacional en 2009?**\n   - La sesi\u00f3n abord\u00f3 el proceso de desarrollo de monograf\u00edas, la pol\u00edtica farmacop\u00e9ica y el papel de la farmacopea en las actividades de aseguramiento de calidad de la OMS.\n\n2. **\u00bfQu\u00e9 criterios se utilizaron para priorizar las sustancias en el nuevo programa de trabajo propuesto por el Comit\u00e9 de Expertos?**\n   - Se consideraron sustancias que quedaban del plan de trabajo de 2009, aquellas priorizadas en el programa de trabajo adoptado en 2008, y adiciones de listas de medicamentos esenciales y expresiones de inter\u00e9s dentro del Programa de Precalificaci\u00f3n de la OMS.\n\n3. **\u00bfQu\u00e9 tipo de retroalimentaci\u00f3n se recibi\u00f3 de los participantes de la sesi\u00f3n informativa y c\u00f3mo influy\u00f3 en las recomendaciones del Comit\u00e9 de Expertos?**\n   - La retroalimentaci\u00f3n fue positiva, indicando que la informaci\u00f3n proporcionada fue \u00fatil, lo que llev\u00f3 al Comit\u00e9 a recomendar la continuaci\u00f3n de estas sesiones informativas para un p\u00fablico m\u00e1s amplio.\n\n### Resumen de Nivel Superior\n\nEl documento destaca la importancia de la colaboraci\u00f3n entre la OMS y la industria farmac\u00e9utica en el desarrollo de est\u00e1ndares de calidad para medicamentos a trav\u00e9s de la Farmacopea Internacional. Se enfatiza la necesidad de priorizar sustancias cr\u00edticas para la salud p\u00fablica, especialmente en el contexto de enfermedades prevalentes en pa\u00edses en desarrollo. La interacci\u00f3n entre los fabricantes y la OMS se considera esencial para mejorar la calidad y disponibilidad de medicamentos a nivel global.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Inyecciones de Radiotrazadores**:\n   - Se enumeran diversas inyecciones de radiotrazadores, incluyendo:\n     - Sodio pertechnetate (\u2079\u2079\u1d50Tc) (fisi\u00f3n y no fisi\u00f3n)\n     - Sodio fosfato (\u00b3\u00b2P)\n     - Cloruro de estroncio (\u2078\u2079Sr)\n     - Varios complejos de tecn\u00e9cio (\u2079\u2079\u1d50Tc) como bicisato, exametazima, mebrofenin, mertiatide, pentetato, succimer, coloide de azufre, tetrofosmina, coloide de esta\u00f1o, pirofosfato de esta\u00f1o, metileno difosfonato (MDP) y sestamibi.\n     - Cloruro de talio (\u00b2\u2070\u00b9Tl)\n     - Silicato de yttrio (\u2079\u2070Y)\n\n2. **Actualizaciones de la Farmacopea Internacional (Ph.Int.)**:\n   - En 2009, se realizaron actualizaciones en las p\u00e1ginas web de la OMS dedicadas a la Ph.Int. para informar sobre textos adoptados recientemente y aspectos espec\u00edficos de las monograf\u00edas.\n   - Se increment\u00f3 el n\u00famero de p\u00e1ginas para incluir informaci\u00f3n sobre:\n     - Radiopharmaceuticals\n     - Anti-infectivos (antibacterianos, antiprotozoarios, antif\u00fangicos, antivirales, antimicobacterianos y anthelminticos).\n\n3. **Respuesta de la Comunidad**:\n   - Se recibi\u00f3 una respuesta positiva a las actualizaciones, con solicitudes para suscribirse a una lista de correo para recibir alertas sobre las actividades m\u00e1s recientes de la Ph.Int.\n   - Se reconoce que este sistema de correo ayudar\u00e1 a los usuarios a mantenerse informados sobre los cambios y mejorar\u00e1 la difusi\u00f3n de informaci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Farmacopea Internacional (Ph.Int.)**\n- **Inyecciones de Radiotrazadores** (ej. Sodio pertechnetate, Cloruro de talio)\n- **Medicamentos Anti-infectivos** (incluyendo antibacterianos, antivirales, etc.)", "excerpt_keywords": "Keywords: International Pharmacopoeia, WHO, pharmaceutical industry, monographs, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5ebe0810-6743-4721-86dc-3caed80fbd32", "node_type": "4", "metadata": {"page_label": "33", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# One-day briefing on The International Pharmacopoeia\n\nThe Secretariat informed the Expert Committee that a one-day overview of the Ph.Int. was given in April 2009 to industrial stakeholders. This included describing the process for developing monographs, together with explanations of the pharmacopoeial approach and policy on a variety of issues and of the role of the pharmacopoeia within WHO quality assurance activities. The meeting was interactive and informal to allow manufacturers (mostly those already collaborating with QSM) to raise issues and to have open discussions on the Ph.Int.\n\nIt was attended by representatives from generic and research-based pharmaceutical companies as well as pharmaceutical industry associations. The positive feedback received showed that the information provided was helpful and that the briefing session would assist in future collaborations in the development of monographs for the Ph.Int.\n\nIn response to requests from the participants to consider a future briefing with a larger audience, the Expert Committee recommended that the WHO Secretariat continue with organizing such information sessions.\n\n## 3.2 Current work plan and future work programme\n\nIn order to respond to the needs of WHO programmes and partner organizations, the Expert Committee agreed in 2008 to only consider for inclusion in the work programme those substances that had been assigned a high priority. A work plan, including a first group of six active pharmaceutical ingredients (APIs) and 36 dosage forms for monograph initiation, was thus adopted.\n\nSince good progress had been made in developing specifications from the 2009 work plan, a new work programme, including a second group for monograph initiation, was proposed to the Expert Committee, taking into account:\n\n- substances remaining from the 2009 work plan;\n- substances initially listed in the adopted work programme in 2008 that had now been prioritized, focusing on medicines for children, medicines important for the treatment of HIV/AIDS, tuberculosis and malaria and treatment of diseases with a high prevalence in developing countries);\n- additions from the sixteenth Model list of essential medicines and the second List of essential medicines for children;\n- additions from the expressions of interests (EOIs) within the WHO Prequalification Programme (PQP); and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "2fa819d028f5ec71b6db0bafbd93ee841ded2848b154cb85936522d579fe62e6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# One-day briefing on The International Pharmacopoeia\n\nThe Secretariat informed the Expert Committee that a one-day overview of the Ph.Int. was given in April 2009 to industrial stakeholders. This included describing the process for developing monographs, together with explanations of the pharmacopoeial approach and policy on a variety of issues and of the role of the pharmacopoeia within WHO quality assurance activities. The meeting was interactive and informal to allow manufacturers (mostly those already collaborating with QSM) to raise issues and to have open discussions on the Ph.Int.\n\nIt was attended by representatives from generic and research-based pharmaceutical companies as well as pharmaceutical industry associations. The positive feedback received showed that the information provided was helpful and that the briefing session would assist in future collaborations in the development of monographs for the Ph.Int.\n\nIn response to requests from the participants to consider a future briefing with a larger audience, the Expert Committee recommended that the WHO Secretariat continue with organizing such information sessions.\n\n## 3.2 Current work plan and future work programme\n\nIn order to respond to the needs of WHO programmes and partner organizations, the Expert Committee agreed in 2008 to only consider for inclusion in the work programme those substances that had been assigned a high priority. A work plan, including a first group of six active pharmaceutical ingredients (APIs) and 36 dosage forms for monograph initiation, was thus adopted.\n\nSince good progress had been made in developing specifications from the 2009 work plan, a new work programme, including a second group for monograph initiation, was proposed to the Expert Committee, taking into account:\n\n- substances remaining from the 2009 work plan;\n- substances initially listed in the adopted work programme in 2008 that had now been prioritized, focusing on medicines for children, medicines important for the treatment of HIV/AIDS, tuberculosis and malaria and treatment of diseases with a high prevalence in developing countries);\n- additions from the sixteenth Model list of essential medicines and the second List of essential medicines for children;\n- additions from the expressions of interests (EOIs) within the WHO Prequalification Programme (PQP); and", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2355, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "37de6464-5d57-427b-b388-b221010b9fea": {"__data__": {"id_": "37de6464-5d57-427b-b388-b221010b9fea", "embedding": null, "metadata": {"page_label": "34", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 requests for priority medicines recommended in WHO specific disease programmes.\n\nAfter discussion, the Expert Committee adopted the following new work programme.\n\nAdditions to the 2009 work plan are indicated below in bold.\n\n# Updated new work programme\n\n## Medicines used in the treatment of HIV/AIDS and related conditions\n\n**API**\n- **Atazanavir**\n\n**Dosage forms**\n- **Atazanavir capsules**\n- Didanosine capsules\n- Efavirenz tablets\n- **Emtricitabine capsules**\n- **Emtricitabine oral solution**\n- Ritonavir capsules\n- Ritonavir oral solution\n- Stavudine powder for oral solution\n- Zidovudine tablets\n\n**Fixed-dose combinations**\n- Lopinavir and ritonavir capsules\n- Lopinavir and ritonavir oral solution\n\n**Dosage forms, including those for paediatric use, as available for:**\n- **Efavirenz + emtricitabine + tenofovir**\n- Lamivudine + stavudine\n- Lamivudine + stavudine + efavirenz\n- Lamivudine + stavudine + nevirapine\n- Lamivudine + zidovudine + efavirenz\n- Tenofovir + emtricitabine\n\n## Medicines used in malaria treatment\n\n**API**\n- **Piperaquine phosphate**\n\n**Dosage forms**\n- Mefloquine tablets (*used in co-blisters*)", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla un nuevo programa de trabajo que incluye medicamentos prioritarios recomendados para el tratamiento del VIH/SIDA y la malaria. Se enumeran los principios activos (API), las formas de dosificaci\u00f3n y las combinaciones de dosis fijas para el tratamiento de estas condiciones. Se destacan medicamentos como Atazanavir y Piperaquine phosphate, as\u00ed como varias combinaciones de medicamentos para el VIH.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las formas de dosificaci\u00f3n espec\u00edficas para Atazanavir y Emtricitabine mencionadas en el nuevo programa de trabajo de la OMS?**\n   - Respuesta: Las formas de dosificaci\u00f3n espec\u00edficas para Atazanavir son las c\u00e1psulas de Atazanavir, y para Emtricitabine son las c\u00e1psulas de Emtricitabine y la soluci\u00f3n oral de Emtricitabine.\n\n2. **\u00bfQu\u00e9 combinaciones de dosis fijas para el tratamiento del VIH se mencionan en el documento y cu\u00e1les son sus componentes?**\n   - Respuesta: Las combinaciones de dosis fijas mencionadas son: \n     - Efavirenz + Emtricitabine + Tenofovir\n     - Lamivudine + Stavudine\n     - Lamivudine + Stavudine + Efavirenz\n     - Lamivudine + Stavudine + Nevirapine\n     - Lamivudine + Zidovudine + Efavirenz\n     - Tenofovir + Emtricitabine.\n\n3. **\u00bfQu\u00e9 medicamento se menciona para el tratamiento de la malaria y cu\u00e1l es su forma de dosificaci\u00f3n?**\n   - Respuesta: El medicamento mencionado para el tratamiento de la malaria es el Fosfato de Piperaquina, y su forma de dosificaci\u00f3n es en tabletas de Mefloquina, que se utilizan en co-blisters.", "prev_section_summary": "### Temas Clave\n\n1. **Sesi\u00f3n Informativa sobre la Farmacopea Internacional (Ph.Int.)**:\n   - Se llev\u00f3 a cabo en abril de 2009 para partes interesadas de la industria farmac\u00e9utica.\n   - Se discuti\u00f3 el proceso de desarrollo de monograf\u00edas y la pol\u00edtica farmacop\u00e9ica.\n   - La reuni\u00f3n fue interactiva, permitiendo a los fabricantes plantear cuestiones y participar en discusiones abiertas.\n\n2. **Retroalimentaci\u00f3n Positiva**:\n   - Los participantes, que inclu\u00edan representantes de empresas farmac\u00e9uticas gen\u00e9ricas y de investigaci\u00f3n, encontraron \u00fatil la informaci\u00f3n proporcionada.\n   - Se recomend\u00f3 organizar m\u00e1s sesiones informativas para un p\u00fablico m\u00e1s amplio.\n\n3. **Plan de Trabajo Actual y Programa Futuro**:\n   - En 2008, el Comit\u00e9 de Expertos acord\u00f3 priorizar sustancias de alta prioridad para su inclusi\u00f3n en el programa de trabajo.\n   - Se adopt\u00f3 un plan de trabajo inicial que inclu\u00eda seis ingredientes farmac\u00e9uticos activos (APIs) y 36 formas de dosificaci\u00f3n para la iniciaci\u00f3n de monograf\u00edas.\n   - Se propuso un nuevo programa de trabajo que considera:\n     - Sustancias restantes del plan de trabajo de 2009.\n     - Sustancias priorizadas en el programa de trabajo adoptado en 2008, enfoc\u00e1ndose en medicamentos para ni\u00f1os y tratamientos para enfermedades prevalentes en pa\u00edses en desarrollo.\n     - Adiciones de listas de medicamentos esenciales y expresiones de inter\u00e9s dentro del Programa de Precalificaci\u00f3n de la OMS.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Instituci\u00f3n responsable de la calidad y regulaci\u00f3n de medicamentos a nivel global.\n- **Comit\u00e9 de Expertos**: Grupo que eval\u00faa y recomienda acciones sobre la Farmacopea Internacional y el programa de trabajo relacionado.\n- **Partes Interesadas de la Industria Farmac\u00e9utica**: Incluye representantes de empresas farmac\u00e9uticas gen\u00e9ricas y de investigaci\u00f3n, as\u00ed como asociaciones de la industria.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Sustancias que se consideran para el desarrollo de monograf\u00edas en el contexto de la calidad de los medicamentos.\n- **Programa de Precalificaci\u00f3n de la OMS (PQP)**: Iniciativa que busca asegurar la calidad de los medicamentos en mercados de pa\u00edses en desarrollo.", "excerpt_keywords": "medicines, HIV/AIDS, malaria, WHO, dosage forms"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cb91d4c8-1dc7-484a-b3d1-4f2d7f3bc717", "node_type": "4", "metadata": {"page_label": "34", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 requests for priority medicines recommended in WHO specific disease programmes.\n\nAfter discussion, the Expert Committee adopted the following new work programme.\n\nAdditions to the 2009 work plan are indicated below in bold.\n\n# Updated new work programme\n\n## Medicines used in the treatment of HIV/AIDS and related conditions\n\n**API**\n- **Atazanavir**\n\n**Dosage forms**\n- **Atazanavir capsules**\n- Didanosine capsules\n- Efavirenz tablets\n- **Emtricitabine capsules**\n- **Emtricitabine oral solution**\n- Ritonavir capsules\n- Ritonavir oral solution\n- Stavudine powder for oral solution\n- Zidovudine tablets\n\n**Fixed-dose combinations**\n- Lopinavir and ritonavir capsules\n- Lopinavir and ritonavir oral solution\n\n**Dosage forms, including those for paediatric use, as available for:**\n- **Efavirenz + emtricitabine + tenofovir**\n- Lamivudine + stavudine\n- Lamivudine + stavudine + efavirenz\n- Lamivudine + stavudine + nevirapine\n- Lamivudine + zidovudine + efavirenz\n- Tenofovir + emtricitabine\n\n## Medicines used in malaria treatment\n\n**API**\n- **Piperaquine phosphate**\n\n**Dosage forms**\n- Mefloquine tablets (*used in co-blisters*)", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "46bae7e7709fe82a6391e08109b2b7199916839a6cd07c3f7d7c779a2c918c3c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2014 requests for priority medicines recommended in WHO specific disease programmes.\n\nAfter discussion, the Expert Committee adopted the following new work programme.\n\nAdditions to the 2009 work plan are indicated below in bold.\n\n# Updated new work programme\n\n## Medicines used in the treatment of HIV/AIDS and related conditions\n\n**API**\n- **Atazanavir**\n\n**Dosage forms**\n- **Atazanavir capsules**\n- Didanosine capsules\n- Efavirenz tablets\n- **Emtricitabine capsules**\n- **Emtricitabine oral solution**\n- Ritonavir capsules\n- Ritonavir oral solution\n- Stavudine powder for oral solution\n- Zidovudine tablets\n\n**Fixed-dose combinations**\n- Lopinavir and ritonavir capsules\n- Lopinavir and ritonavir oral solution\n\n**Dosage forms, including those for paediatric use, as available for:**\n- **Efavirenz + emtricitabine + tenofovir**\n- Lamivudine + stavudine\n- Lamivudine + stavudine + efavirenz\n- Lamivudine + stavudine + nevirapine\n- Lamivudine + zidovudine + efavirenz\n- Tenofovir + emtricitabine\n\n## Medicines used in malaria treatment\n\n**API**\n- **Piperaquine phosphate**\n\n**Dosage forms**\n- Mefloquine tablets (*used in co-blisters*)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1133, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "34118b00-f2be-4762-bf8a-c41498c36382": {"__data__": {"id_": "34118b00-f2be-4762-bf8a-c41498c36382", "embedding": null, "metadata": {"page_label": "35", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Fixed-dose combinations\n\n- Artemether and lumefantrine capsules\n- Artemether and lumefantrine dispersible tablets\n- Artesunate and amodiaquine tablets\n- Artesunate, sulfadoxine and pyrimethamine tablets\n- Sulfadoxine and pyrimethamine tablets (*used in co-blisters*)\n\n**Dosage form, including that for paediatric use, as available for:**\n\n- Dihydroartemisinin + piperaquine phosphate\n\n**Revision**\n\n- Artemisinin derivatives (APIs and dosage forms) (see http://www.who.int/medicines/publications/pharmacopoeia/mon_mal/en/index.html)\n\n# Medicines used in tuberculosis treatment\n\n**APIs**\n\n- *p*-Aminosalicylic acid\n- Capreomycin\n- Levofloxacin\n- Ofloxacin\n- Terizidone\n\n**Dosage forms**\n\n- *p*-Aminosalicylic acid granules\n- Capreomycin powder for injection\n- Ethionamide tablets\n- Levofloxacin tablets\n- Ofloxacin tablets\n- Protionamide tablets\n- **Terizidone tablets**\n\n# Anti-infectives (antibacterials, antiprotozoal, antifungal, antiviral and antimycobacterial agents, anthelmintics)\n\n**APIs**\n\n- Ceftriaxone sodium\n- Fluconazole\n- Ivermectin\n\n**Dosage forms**\n\n- Albendazole chewable tablets\n- Amoxicillin oral suspension\n- Ceftriaxone injection\n- Doxycycline dispersible tablets", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta informaci\u00f3n sobre combinaciones de dosis fijas de medicamentos, tratamientos para la tuberculosis y agentes antiinfecciosos. Se enumeran los principios activos (APIs) y las formas de dosificaci\u00f3n disponibles para cada categor\u00eda de medicamentos. Se destacan combinaciones espec\u00edficas de medicamentos para el tratamiento de la malaria y la tuberculosis, as\u00ed como varios antibacterianos, antif\u00fangicos y antiparasitarios.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son las combinaciones de dosis fijas mencionadas para el tratamiento de la malaria y qu\u00e9 formas de dosificaci\u00f3n est\u00e1n disponibles para cada una?**\n   - Respuesta: Las combinaciones de dosis fijas mencionadas son: \n     - Artemether y lumefantrine (c\u00e1psulas y tabletas dispersables)\n     - Artesunate y amodiaquine (tabletas)\n     - Artesunate, sulfadoxina y pirimetamina (tabletas)\n     - Sulfadoxina y pirimetamina (tabletas, utilizadas en co-blisters)\n     - Dihidroartemisina + piperaquina fosfato (forma de dosificaci\u00f3n pedi\u00e1trica disponible).\n\n2. **\u00bfQu\u00e9 medicamentos se enumeran como tratamientos para la tuberculosis y cu\u00e1les son sus formas de dosificaci\u00f3n?**\n   - Respuesta: Los medicamentos para la tuberculosis incluyen:\n     - *p*-Aminosalicylic acid (granulados)\n     - Capreomycin (polvo para inyecci\u00f3n)\n     - Ethionamide (tabletas)\n     - Levofloxacin (tabletas)\n     - Ofloxacin (tabletas)\n     - Protionamide (tabletas)\n     - Terizidone (tabletas).\n\n3. **\u00bfQu\u00e9 agentes antiinfecciosos se mencionan en el documento y cu\u00e1les son sus formas de dosificaci\u00f3n?**\n   - Respuesta: Los agentes antiinfecciosos mencionados son:\n     - Ceftriaxone sodium (inyecci\u00f3n)\n     - Fluconazole (no se especifica forma de dosificaci\u00f3n)\n     - Ivermectin (no se especifica forma de dosificaci\u00f3n).\n     - Formas de dosificaci\u00f3n para otros medicamentos incluyen:\n       - Albendazole (tabletas masticables)\n       - Amoxicillin (suspensi\u00f3n oral)\n       - Doxycycline (tabletas dispersables).", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento de la OMS presenta un nuevo programa de trabajo que se centra en medicamentos prioritarios para el tratamiento del VIH/SIDA y la malaria. A continuaci\u00f3n se detallan los puntos m\u00e1s relevantes:\n\n#### Medicamentos para el tratamiento del VIH/SIDA:\n- **Principios Activos (API)**:\n  - Atazanavir\n  - Emtricitabine\n\n- **Formas de dosificaci\u00f3n**:\n  - **Atazanavir**: c\u00e1psulas\n  - **Emtricitabine**: c\u00e1psulas y soluci\u00f3n oral\n  - Otros medicamentos mencionados: Didanosine (c\u00e1psulas), Efavirenz (tabletas), Ritonavir (c\u00e1psulas y soluci\u00f3n oral), Stavudine (polvo para soluci\u00f3n oral), Zidovudine (tabletas).\n\n- **Combinaciones de dosis fijas**:\n  - Lopinavir y ritonavir (c\u00e1psulas y soluci\u00f3n oral)\n  - Efavirenz + Emtricitabine + Tenofovir\n  - Lamivudine + Stavudine\n  - Lamivudine + Stavudine + Efavirenz\n  - Lamivudine + Stavudine + Nevirapine\n  - Lamivudine + Zidovudine + Efavirenz\n  - Tenofovir + Emtricitabine\n\n#### Medicamentos para el tratamiento de la malaria:\n- **Principio Activo (API)**:\n  - Fosfato de Piperaquina\n\n- **Forma de dosificaci\u00f3n**:\n  - Tabletas de Mefloquina (utilizadas en co-blisters)\n\nEste resumen destaca los medicamentos y sus formas de dosificaci\u00f3n recomendados por la OMS para el tratamiento de VIH/SIDA y malaria, as\u00ed como las combinaciones de dosis fijas que se consideran prioritarias.", "excerpt_keywords": "Keywords: fixed-dose combinations, tuberculosis treatment, anti-infectives, artemisinin derivatives, WHO guidelines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6a0ff450-01e6-4471-9f83-d5fc5e2bafaa", "node_type": "4", "metadata": {"page_label": "35", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Fixed-dose combinations\n\n- Artemether and lumefantrine capsules\n- Artemether and lumefantrine dispersible tablets\n- Artesunate and amodiaquine tablets\n- Artesunate, sulfadoxine and pyrimethamine tablets\n- Sulfadoxine and pyrimethamine tablets (*used in co-blisters*)\n\n**Dosage form, including that for paediatric use, as available for:**\n\n- Dihydroartemisinin + piperaquine phosphate\n\n**Revision**\n\n- Artemisinin derivatives (APIs and dosage forms) (see http://www.who.int/medicines/publications/pharmacopoeia/mon_mal/en/index.html)\n\n# Medicines used in tuberculosis treatment\n\n**APIs**\n\n- *p*-Aminosalicylic acid\n- Capreomycin\n- Levofloxacin\n- Ofloxacin\n- Terizidone\n\n**Dosage forms**\n\n- *p*-Aminosalicylic acid granules\n- Capreomycin powder for injection\n- Ethionamide tablets\n- Levofloxacin tablets\n- Ofloxacin tablets\n- Protionamide tablets\n- **Terizidone tablets**\n\n# Anti-infectives (antibacterials, antiprotozoal, antifungal, antiviral and antimycobacterial agents, anthelmintics)\n\n**APIs**\n\n- Ceftriaxone sodium\n- Fluconazole\n- Ivermectin\n\n**Dosage forms**\n\n- Albendazole chewable tablets\n- Amoxicillin oral suspension\n- Ceftriaxone injection\n- Doxycycline dispersible tablets", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "664247b61f3de551e363fc6bb296c8bf34cc77b54bd16c101d4e52617f30ff8b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Fixed-dose combinations\n\n- Artemether and lumefantrine capsules\n- Artemether and lumefantrine dispersible tablets\n- Artesunate and amodiaquine tablets\n- Artesunate, sulfadoxine and pyrimethamine tablets\n- Sulfadoxine and pyrimethamine tablets (*used in co-blisters*)\n\n**Dosage form, including that for paediatric use, as available for:**\n\n- Dihydroartemisinin + piperaquine phosphate\n\n**Revision**\n\n- Artemisinin derivatives (APIs and dosage forms) (see http://www.who.int/medicines/publications/pharmacopoeia/mon_mal/en/index.html)\n\n# Medicines used in tuberculosis treatment\n\n**APIs**\n\n- *p*-Aminosalicylic acid\n- Capreomycin\n- Levofloxacin\n- Ofloxacin\n- Terizidone\n\n**Dosage forms**\n\n- *p*-Aminosalicylic acid granules\n- Capreomycin powder for injection\n- Ethionamide tablets\n- Levofloxacin tablets\n- Ofloxacin tablets\n- Protionamide tablets\n- **Terizidone tablets**\n\n# Anti-infectives (antibacterials, antiprotozoal, antifungal, antiviral and antimycobacterial agents, anthelmintics)\n\n**APIs**\n\n- Ceftriaxone sodium\n- Fluconazole\n- Ivermectin\n\n**Dosage forms**\n\n- Albendazole chewable tablets\n- Amoxicillin oral suspension\n- Ceftriaxone injection\n- Doxycycline dispersible tablets", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1186, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "db10bc76-fb51-43bd-bf75-6203cb3fc3b8": {"__data__": {"id_": "db10bc76-fb51-43bd-bf75-6203cb3fc3b8", "embedding": null, "metadata": {"page_label": "36", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Fluconazole capsules\n- Fluconazole injection\n- Fluconazole oral solution/suspension\n- Ivermectin tablets\n- Levamisole tablets\n- Metronidazole oral suspension\n- Pyrantel chewable tablets\n- Pyrantel oral solution/suspension\n- Pyrimethamine tablets\n\n**Fixed-dose combinations**\n- Sulfamethoxazole and trimethoprim injection\n- Sulfamethoxazole and trimethoprim oral solution/suspension\n- Sulfamethoxazole and trimethoprim tablets\n\n## Oral rehydration therapy\n\n**APIs**\n- Zinc acetate\n- Zinc gluconate\n\n**Dosage forms**\n- Paediatric zinc acetate oral solution\n- Paediatric zinc acetate tablets\n- Paediatric zinc gluconate oral solution\n- Paediatric zinc gluconate tablets\n\n## Various other medicines (analgesics, antipyretics, palliative care, anti-epileptics, large volume parenterals, reproductive health)\n\n**Dosage forms**\n- Carbamazepine oral liquid\n- Chewable carbamazepine tablets\n- Chewable phenytoin tablets\n- Crushable valproic acid tablets\n- **Ethinylestradiol + levonorgestrel tablets**\n- Glucose intravenous infusion\n- **Levonorgestrel tablets**\n- **Medroxyprogesterone acetate (DMPA), depot injection**\n- Morphine oral solution\n- Oseltamivir capsules\n- Paediatric retinol capsules\n- Paediatric retinol oral solution\n- Paracetamol oral solution", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Informe T\u00e9cnico 957) enumera una variedad de medicamentos y formulaciones que son esenciales para el tratamiento de diversas condiciones de salud. Incluye medicamentos antif\u00fangicos, antiparasitarios, antibacterianos, y otros f\u00e1rmacos utilizados en terapia de rehidrataci\u00f3n oral, as\u00ed como en el manejo del dolor, la fiebre, y la salud reproductiva. Tambi\u00e9n se mencionan combinaciones de dosis fijas y formas de dosificaci\u00f3n pedi\u00e1trica.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las formas de dosificaci\u00f3n pedi\u00e1trica disponibles para el zinc en el contexto de la terapia de rehidrataci\u00f3n oral?**\n   - Respuesta: Las formas de dosificaci\u00f3n pedi\u00e1trica disponibles para el zinc son: soluci\u00f3n oral de acetato de zinc pedi\u00e1trico, tabletas de acetato de zinc pedi\u00e1trico, soluci\u00f3n oral de gluconato de zinc pedi\u00e1trico y tabletas de gluconato de zinc pedi\u00e1trico.\n\n2. **\u00bfQu\u00e9 medicamentos se incluyen en las combinaciones de dosis fijas mencionadas en el documento?**\n   - Respuesta: Las combinaciones de dosis fijas mencionadas son: inyecci\u00f3n de sulfametoxazol y trimetoprim, soluci\u00f3n/suspensi\u00f3n oral de sulfametoxazol y trimetoprim, y tabletas de sulfametoxazol y trimetoprim.\n\n3. **\u00bfQu\u00e9 medicamentos se enumeran espec\u00edficamente para el manejo del dolor y la fiebre en el contexto de cuidados paliativos?**\n   - Respuesta: Los medicamentos enumerados para el manejo del dolor y la fiebre son: soluci\u00f3n oral de morfina y soluci\u00f3n oral de paracetamol.", "prev_section_summary": "La secci\u00f3n del documento de la OMS se centra en tres categor\u00edas principales de medicamentos: combinaciones de dosis fijas para el tratamiento de la malaria, medicamentos utilizados en el tratamiento de la tuberculosis y agentes antiinfecciosos. \n\n### Temas Clave:\n\n1. **Combinaciones de Dosis Fijas para Malaria:**\n   - Se enumeran varias combinaciones de medicamentos, incluyendo:\n     - Artemether y lumefantrine (c\u00e1psulas y tabletas dispersables)\n     - Artesunate y amodiaquine (tabletas)\n     - Artesunate, sulfadoxina y pirimetamina (tabletas)\n     - Sulfadoxina y pirimetamina (tabletas, en co-blisters)\n     - Dihidroartemisina + piperaquina fosfato (disponible en forma pedi\u00e1trica).\n\n2. **Medicamentos para el Tratamiento de la Tuberculosis:**\n   - Se listan los principios activos (APIs) y sus formas de dosificaci\u00f3n:\n     - *p*-Aminosalicylic acid (granulados)\n     - Capreomycin (polvo para inyecci\u00f3n)\n     - Ethionamide (tabletas)\n     - Levofloxacin (tabletas)\n     - Ofloxacin (tabletas)\n     - Protionamide (tabletas)\n     - Terizidone (tabletas).\n\n3. **Agentes Antiinfecciosos:**\n   - Se mencionan varios agentes y sus formas de dosificaci\u00f3n:\n     - Ceftriaxone sodium (inyecci\u00f3n)\n     - Fluconazole (sin forma de dosificaci\u00f3n especificada)\n     - Ivermectin (sin forma de dosificaci\u00f3n especificada)\n     - Albendazole (tabletas masticables)\n     - Amoxicillin (suspensi\u00f3n oral)\n     - Doxycycline (tabletas dispersables).\n\n### Entidades Clave:\n- **Medicamentos para Malaria:** Artemether, lumefantrine, artesunate, amodiaquine, sulfadoxina, pirimetamina, dihidroartemisina, piperaquina.\n- **Medicamentos para Tuberculosis:** *p*-Aminosalicylic acid, capreomycin, ethionamide, levofloxacin, ofloxacin, protionamide, terizidone.\n- **Agentes Antiinfecciosos:** Ceftriaxone sodium, fluconazole, ivermectin, albendazole, amoxicillin, doxycycline.\n\nEste resumen proporciona una visi\u00f3n general de los medicamentos y sus formas de dosificaci\u00f3n, destacando su relevancia en el tratamiento de la malaria, la tuberculosis y las infecciones en general.", "excerpt_keywords": "Keywords: Fluconazole, Zinc, Fixed-dose combinations, Oral rehydration therapy, Palliative care"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "064cb530-5a2f-45ca-8fdc-bed91214aa64", "node_type": "4", "metadata": {"page_label": "36", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Fluconazole capsules\n- Fluconazole injection\n- Fluconazole oral solution/suspension\n- Ivermectin tablets\n- Levamisole tablets\n- Metronidazole oral suspension\n- Pyrantel chewable tablets\n- Pyrantel oral solution/suspension\n- Pyrimethamine tablets\n\n**Fixed-dose combinations**\n- Sulfamethoxazole and trimethoprim injection\n- Sulfamethoxazole and trimethoprim oral solution/suspension\n- Sulfamethoxazole and trimethoprim tablets\n\n## Oral rehydration therapy\n\n**APIs**\n- Zinc acetate\n- Zinc gluconate\n\n**Dosage forms**\n- Paediatric zinc acetate oral solution\n- Paediatric zinc acetate tablets\n- Paediatric zinc gluconate oral solution\n- Paediatric zinc gluconate tablets\n\n## Various other medicines (analgesics, antipyretics, palliative care, anti-epileptics, large volume parenterals, reproductive health)\n\n**Dosage forms**\n- Carbamazepine oral liquid\n- Chewable carbamazepine tablets\n- Chewable phenytoin tablets\n- Crushable valproic acid tablets\n- **Ethinylestradiol + levonorgestrel tablets**\n- Glucose intravenous infusion\n- **Levonorgestrel tablets**\n- **Medroxyprogesterone acetate (DMPA), depot injection**\n- Morphine oral solution\n- Oseltamivir capsules\n- Paediatric retinol capsules\n- Paediatric retinol oral solution\n- Paracetamol oral solution", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "4a5098f76eaedcd9a48b02f7db148190f850b5a0870ba5278a9d7e30537c145a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- Fluconazole capsules\n- Fluconazole injection\n- Fluconazole oral solution/suspension\n- Ivermectin tablets\n- Levamisole tablets\n- Metronidazole oral suspension\n- Pyrantel chewable tablets\n- Pyrantel oral solution/suspension\n- Pyrimethamine tablets\n\n**Fixed-dose combinations**\n- Sulfamethoxazole and trimethoprim injection\n- Sulfamethoxazole and trimethoprim oral solution/suspension\n- Sulfamethoxazole and trimethoprim tablets\n\n## Oral rehydration therapy\n\n**APIs**\n- Zinc acetate\n- Zinc gluconate\n\n**Dosage forms**\n- Paediatric zinc acetate oral solution\n- Paediatric zinc acetate tablets\n- Paediatric zinc gluconate oral solution\n- Paediatric zinc gluconate tablets\n\n## Various other medicines (analgesics, antipyretics, palliative care, anti-epileptics, large volume parenterals, reproductive health)\n\n**Dosage forms**\n- Carbamazepine oral liquid\n- Chewable carbamazepine tablets\n- Chewable phenytoin tablets\n- Crushable valproic acid tablets\n- **Ethinylestradiol + levonorgestrel tablets**\n- Glucose intravenous infusion\n- **Levonorgestrel tablets**\n- **Medroxyprogesterone acetate (DMPA), depot injection**\n- Morphine oral solution\n- Oseltamivir capsules\n- Paediatric retinol capsules\n- Paediatric retinol oral solution\n- Paracetamol oral solution", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1253, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "dd261f9c-1c38-48e2-813c-59abf5a135f9": {"__data__": {"id_": "dd261f9c-1c38-48e2-813c-59abf5a135f9", "embedding": null, "metadata": {"page_label": "37", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Paracetamol oral suspension\n- Phenobarbital oral liquid\n- Phenytoin oral liquid\n- Sodium chloride and glucose intravenous infusion\n- Sodium chloride intravenous infusion\n- Valproic acid oral liquid\n\nThis updated new work programme would be made available on the WHO Medicines web site.\n\n## 3.3 Specifications for medicines, including children\u2019s medicines\n\n### 3.3.1 Medicines for HIV and related conditions\n\nNew monographs for the following antiretroviral active substances and dosage forms were presented to the Expert Committee for discussion. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the consultative process and those made during discussion.\n\n**APIs**\n- Lopinavir\n- Tenofovir disoproxil fumarate\n\n**Dosage forms**\n- Indinavir capsules\n- Saquinavir tablets\n- Tenofovir tablets\n- Lopinavir and ritonavir tablets\n\nA revision of the published text of the following antiretroviral active substance was presented to the Expert Committee for discussion. The revised monograph was adopted, subject to confirmation of the proposed values for the specific absorbance by the collaborating laboratory:\n- Efavirenz\n\n### 3.3.2 Antimalarial medicines\n\nNew monographs for the following antimalarial dosage forms were presented to the Expert Committee for discussion. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during the discussion:\n- Amodiaquine tablets\n- Quinine bisulfate tablets", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta un programa de trabajo actualizado que incluye especificaciones para medicamentos, especialmente aquellos dirigidos a ni\u00f1os y condiciones espec\u00edficas como el VIH y la malaria. Se discuten nuevas monograf\u00edas para diversas sustancias activas y formas de dosificaci\u00f3n, que fueron adoptadas por el Comit\u00e9 de Expertos, con la condici\u00f3n de que se realicen cambios acordados y se confirmen ciertos valores. Se mencionan medicamentos antirretrovirales y antimal\u00e1ricos, as\u00ed como la importancia de la revisi\u00f3n y validaci\u00f3n de las monograf\u00edas.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son las condiciones que deben cumplirse para que las nuevas monograf\u00edas de medicamentos sean adoptadas por el Comit\u00e9 de Expertos de la OMS?**\n   - Respuesta: Las monograf\u00edas son adoptadas, sujeto a la inclusi\u00f3n de los cambios acordados basados en los comentarios recibidos durante el proceso consultivo y aquellos realizados durante la discusi\u00f3n.\n\n2. **\u00bfQu\u00e9 medicamentos antirretrovirales se mencionan en el documento y qu\u00e9 formas de dosificaci\u00f3n se han discutido?**\n   - Respuesta: Los medicamentos antirretrovirales mencionados son Lopinavir y Tenofovir disoproxil fumarate, con formas de dosificaci\u00f3n que incluyen c\u00e1psulas de Indinavir, tabletas de Saquinavir, tabletas de Tenofovir y tabletas de Lopinavir y ritonavir.\n\n3. **\u00bfQu\u00e9 revisi\u00f3n se realiz\u00f3 sobre el medicamento Efavirenz y qu\u00e9 condici\u00f3n se estableci\u00f3 para su adopci\u00f3n?**\n   - Respuesta: Se present\u00f3 una revisi\u00f3n del texto publicado del Efavirenz, y la monograf\u00eda revisada fue adoptada, sujeto a la confirmaci\u00f3n de los valores propuestos para la absorbancia espec\u00edfica por parte del laboratorio colaborador.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento de la OMS (Informe T\u00e9cnico 957) aborda una variedad de medicamentos esenciales para el tratamiento de diversas condiciones de salud. Los temas clave incluyen:\n\n1. **Medicamentos Antif\u00fangicos y Antiparasitarios**:\n   - **Fluconazol**: disponible en c\u00e1psulas, inyecci\u00f3n y soluci\u00f3n/suspensi\u00f3n oral.\n   - **Ivermectina**: en forma de tabletas.\n   - **Levamisole**: en tabletas.\n   - **Metronidazol**: en forma de suspensi\u00f3n oral.\n   - **Pyrantel**: en tabletas masticables y soluci\u00f3n/suspensi\u00f3n oral.\n   - **Pyrimethamina**: en tabletas.\n\n2. **Combinaciones de Dosis Fijas**:\n   - **Sulfametoxazol y Trimetoprim**: disponibles en inyecci\u00f3n, soluci\u00f3n/suspensi\u00f3n oral y tabletas.\n\n3. **Terapia de Rehidrataci\u00f3n Oral**:\n   - **Ingredientes Activos (APIs)**: Acetato de zinc y gluconato de zinc.\n   - **Formas de Dosificaci\u00f3n Pedi\u00e1trica**: soluci\u00f3n oral y tabletas de acetato y gluconato de zinc.\n\n4. **Medicamentos para el Manejo del Dolor y la Fiebre**:\n   - **Analgesicos y Antipir\u00e9ticos**: soluci\u00f3n oral de morfina y soluci\u00f3n oral de paracetamol.\n   - **Medicamentos para Cuidados Paliativos**: incluye otros analg\u00e9sicos y antiepil\u00e9pticos como carbamazepina y fenito\u00edna en diversas formas de dosificaci\u00f3n.\n\n5. **Salud Reproductiva**:\n   - **Combinaciones de Hormonas**: tabletas de etinilestradiol + levonorgestrel y tabletas de levonorgestrel.\n   - **Medroxyprogesterona**: inyecci\u00f3n de dep\u00f3sito (DMPA).\n\n### Entidades Clave:\n- **Medicamentos**: Fluconazol, Ivermectina, Levamisole, Metronidazol, Pyrantel, Pyrimethamina, Sulfametoxazol, Trimetoprim, Acetato de Zinc, Gluconato de Zinc, Carbamazepina, Fenito\u00edna, Valproato, Etinilestradiol, Levonorgestrel, Medroxyprogesterona, Morfina, Paracetamol, Oseltamivir, Retinol.\n- **Formas de Dosificaci\u00f3n**: C\u00e1psulas, tabletas, inyecci\u00f3n, soluci\u00f3n/suspensi\u00f3n oral, infusi\u00f3n intravenosa.\n- **\u00c1reas de Aplicaci\u00f3n**: Terapia de rehidrataci\u00f3n oral, cuidados paliativos, salud reproductiva, tratamiento de infecciones. \n\nEste resumen destaca la diversidad de medicamentos y su importancia en el tratamiento de condiciones de salud cr\u00edticas, as\u00ed como la atenci\u00f3n a las necesidades pedi\u00e1tricas y de salud reproductiva.", "excerpt_keywords": "Keywords: WHO, medicines, antiretroviral, specifications, monographs"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6b39cbee-cb27-49aa-a372-08f4779cf3e3", "node_type": "4", "metadata": {"page_label": "37", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Paracetamol oral suspension\n- Phenobarbital oral liquid\n- Phenytoin oral liquid\n- Sodium chloride and glucose intravenous infusion\n- Sodium chloride intravenous infusion\n- Valproic acid oral liquid\n\nThis updated new work programme would be made available on the WHO Medicines web site.\n\n## 3.3 Specifications for medicines, including children\u2019s medicines\n\n### 3.3.1 Medicines for HIV and related conditions\n\nNew monographs for the following antiretroviral active substances and dosage forms were presented to the Expert Committee for discussion. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the consultative process and those made during discussion.\n\n**APIs**\n- Lopinavir\n- Tenofovir disoproxil fumarate\n\n**Dosage forms**\n- Indinavir capsules\n- Saquinavir tablets\n- Tenofovir tablets\n- Lopinavir and ritonavir tablets\n\nA revision of the published text of the following antiretroviral active substance was presented to the Expert Committee for discussion. The revised monograph was adopted, subject to confirmation of the proposed values for the specific absorbance by the collaborating laboratory:\n- Efavirenz\n\n### 3.3.2 Antimalarial medicines\n\nNew monographs for the following antimalarial dosage forms were presented to the Expert Committee for discussion. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during the discussion:\n- Amodiaquine tablets\n- Quinine bisulfate tablets", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "ae17494dfa49ed5acdcd298da75dd6f71928de3a320f13ad0aed7b695cf3cf96", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- Paracetamol oral suspension\n- Phenobarbital oral liquid\n- Phenytoin oral liquid\n- Sodium chloride and glucose intravenous infusion\n- Sodium chloride intravenous infusion\n- Valproic acid oral liquid\n\nThis updated new work programme would be made available on the WHO Medicines web site.\n\n## 3.3 Specifications for medicines, including children\u2019s medicines\n\n### 3.3.1 Medicines for HIV and related conditions\n\nNew monographs for the following antiretroviral active substances and dosage forms were presented to the Expert Committee for discussion. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the consultative process and those made during discussion.\n\n**APIs**\n- Lopinavir\n- Tenofovir disoproxil fumarate\n\n**Dosage forms**\n- Indinavir capsules\n- Saquinavir tablets\n- Tenofovir tablets\n- Lopinavir and ritonavir tablets\n\nA revision of the published text of the following antiretroviral active substance was presented to the Expert Committee for discussion. The revised monograph was adopted, subject to confirmation of the proposed values for the specific absorbance by the collaborating laboratory:\n- Efavirenz\n\n### 3.3.2 Antimalarial medicines\n\nNew monographs for the following antimalarial dosage forms were presented to the Expert Committee for discussion. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during the discussion:\n- Amodiaquine tablets\n- Quinine bisulfate tablets", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1544, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d7133a38-9520-4881-a1ae-9539f72dcda3": {"__data__": {"id_": "d7133a38-9520-4881-a1ae-9539f72dcda3", "embedding": null, "metadata": {"page_label": "38", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Consequent to the development of a new monograph for Quinine bisulfate tablets, a revision of the published text for the quinine sulfate dosage form adopted in October 2008 was required to add an additional identity test allowing the differentiation between the two sulfate forms of quinine possibly used in tablet formulations.\n\nA revision of the published text of the following antimalarial dosage form was thus presented to the Expert Committee for discussion. The revised monograph was adopted, subject to inclusion of the comments received during the public inquiry and those made during the discussion:\n\n- Quinine sulfate tablets\n\n### 3.3.3 Antituberculosis medicines\n\nRevisions of the published texts of the following antibiotics\u2019 active substances, for which an International Chemical Reference Substance (ICRS) was no longer available and thus a new method for assay was needed, were presented for discussion (see paragraph 3.4.2 for antibiotics), together with a new monograph for the corresponding dosage form. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during discussion:\n\n**APIs**\n- Amikacin\n- Amikacin sulfate\n\n**Dosage form**\n- Amikacin injection\n\nNew monographs for the following antibiotics active substances and dosage form for which an ICRS was still available, and thus included an assay by a microbiological method, were also presented for discussion. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during discussion:\n\n**APIs**\n- Kanamycin monosulfate\n- Kanamycin acid sulfate\n\n**Dosage form**\n- Kanamycin injection\n\nFor the Kanamycin injection monograph, the issue of the determination of the conversion factor from international units (IU) to micrograms was raised. The Expert Committee recommended that this monograph be circulated again for comment on this specific aspect.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Revisi\u00f3n de monograf\u00edas de medicamentos antimal\u00e1ricos y antituberculosos**: Se llev\u00f3 a cabo una revisi\u00f3n de las monograf\u00edas de los medicamentos antimal\u00e1ricos, espec\u00edficamente para los comprimidos de sulfato de quinina, para incluir una prueba de identidad adicional. Adem\u00e1s, se presentaron revisiones de las monograf\u00edas de antibi\u00f3ticos, como amikacina y kanamicina, debido a la falta de sustancias de referencia qu\u00edmica internacional (ICRS) y la necesidad de nuevos m\u00e9todos de ensayo.\n\n2. **Adopci\u00f3n de nuevas monograf\u00edas**: Las nuevas monograf\u00edas para los medicamentos revisados fueron adoptadas por el Comit\u00e9 de Expertos, con la condici\u00f3n de que se incluyeran los comentarios recibidos durante la consulta p\u00fablica y las discusiones. Esto incluye tanto las formas de dosificaci\u00f3n como las sustancias activas de los antibi\u00f3ticos.\n\n3. **Cuestiones sobre la conversi\u00f3n de unidades**: Se plante\u00f3 una cuesti\u00f3n espec\u00edfica sobre la conversi\u00f3n de unidades internacionales (IU) a microgramos en la monograf\u00eda de inyecci\u00f3n de kanamicina, lo que llev\u00f3 a la recomendaci\u00f3n de que se circulase nuevamente para comentarios.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la raz\u00f3n detr\u00e1s de la necesidad de una prueba de identidad adicional en la monograf\u00eda de los comprimidos de sulfato de quinina?**\n   - La prueba de identidad adicional se requiere para diferenciar entre las dos formas de sulfato de quinina que podr\u00edan utilizarse en las formulaciones de tabletas.\n\n2. **\u00bfQu\u00e9 cambios se realizaron en las monograf\u00edas de amikacina y kanamicina debido a la falta de ICRS?**\n   - Se presentaron revisiones de las monograf\u00edas de amikacina y amikacina sulfato, as\u00ed como de kanamicina monosulfato y kanamicina \u00e1cido sulfato, para establecer nuevos m\u00e9todos de ensayo debido a la falta de ICRS.\n\n3. **\u00bfQu\u00e9 aspecto espec\u00edfico de la monograf\u00eda de inyecci\u00f3n de kanamicina se recomend\u00f3 para discusi\u00f3n adicional?**\n   - Se recomend\u00f3 que se discutiera nuevamente el factor de conversi\u00f3n de unidades internacionales (IU) a microgramos en la monograf\u00eda de inyecci\u00f3n de kanamicina.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda un programa de trabajo actualizado que incluye especificaciones para medicamentos, con un enfoque particular en aquellos destinados a ni\u00f1os y en el tratamiento de condiciones espec\u00edficas como el VIH y la malaria. \n\n#### Temas clave:\n1. **Medicamentos para ni\u00f1os**: Se mencionan diversas formulaciones de medicamentos que son relevantes para el tratamiento pedi\u00e1trico.\n2. **Medicamentos antirretrovirales**: Se presentan nuevas monograf\u00edas para sustancias activas y formas de dosificaci\u00f3n relacionadas con el VIH.\n3. **Medicamentos antimal\u00e1ricos**: Se discuten nuevas monograf\u00edas para formas de dosificaci\u00f3n de medicamentos utilizados en el tratamiento de la malaria.\n4. **Proceso de adopci\u00f3n de monograf\u00edas**: Las monograf\u00edas son adoptadas por el Comit\u00e9 de Expertos bajo ciertas condiciones, como la inclusi\u00f3n de cambios acordados y la validaci\u00f3n de datos espec\u00edficos.\n\n#### Entidades mencionadas:\n- **Medicamentos**:\n  - Paracetamol (suspensi\u00f3n oral)\n  - Fenobarbital (l\u00edquido oral)\n  - Fenito\u00edna (l\u00edquido oral)\n  - Cloruro de sodio y glucosa (infusi\u00f3n intravenosa)\n  - Cloruro de sodio (infusi\u00f3n intravenosa)\n  - \u00c1cido valproico (l\u00edquido oral)\n  - Lopinavir (sustancia activa)\n  - Tenofovir disoproxil fumarato (sustancia activa)\n  - Indinavir (c\u00e1psulas)\n  - Saquinavir (tabletas)\n  - Tenofovir (tabletas)\n  - Lopinavir y ritonavir (tabletas)\n  - Efavirenz (sustancia activa)\n  - Amodiaquina (tabletas)\n  - Quinine bisulfate (tabletas)\n\nEste resumen destaca la importancia de la revisi\u00f3n y validaci\u00f3n de las monograf\u00edas para asegurar la calidad y eficacia de los medicamentos discutidos.", "excerpt_keywords": "Keywords: Quinine, Amikacin, Kanamycin, monograph, International Chemical Reference Substance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5c807518-b2b6-4a4a-8bf1-511d04d136e2", "node_type": "4", "metadata": {"page_label": "38", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Consequent to the development of a new monograph for Quinine bisulfate tablets, a revision of the published text for the quinine sulfate dosage form adopted in October 2008 was required to add an additional identity test allowing the differentiation between the two sulfate forms of quinine possibly used in tablet formulations.\n\nA revision of the published text of the following antimalarial dosage form was thus presented to the Expert Committee for discussion. The revised monograph was adopted, subject to inclusion of the comments received during the public inquiry and those made during the discussion:\n\n- Quinine sulfate tablets\n\n### 3.3.3 Antituberculosis medicines\n\nRevisions of the published texts of the following antibiotics\u2019 active substances, for which an International Chemical Reference Substance (ICRS) was no longer available and thus a new method for assay was needed, were presented for discussion (see paragraph 3.4.2 for antibiotics), together with a new monograph for the corresponding dosage form. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during discussion:\n\n**APIs**\n- Amikacin\n- Amikacin sulfate\n\n**Dosage form**\n- Amikacin injection\n\nNew monographs for the following antibiotics active substances and dosage form for which an ICRS was still available, and thus included an assay by a microbiological method, were also presented for discussion. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during discussion:\n\n**APIs**\n- Kanamycin monosulfate\n- Kanamycin acid sulfate\n\n**Dosage form**\n- Kanamycin injection\n\nFor the Kanamycin injection monograph, the issue of the determination of the conversion factor from international units (IU) to micrograms was raised. The Expert Committee recommended that this monograph be circulated again for comment on this specific aspect.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "c3288d57a04e290b6c43107536a186e6def9109ecd568bd5ce1937f69f0a3017", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Consequent to the development of a new monograph for Quinine bisulfate tablets, a revision of the published text for the quinine sulfate dosage form adopted in October 2008 was required to add an additional identity test allowing the differentiation between the two sulfate forms of quinine possibly used in tablet formulations.\n\nA revision of the published text of the following antimalarial dosage form was thus presented to the Expert Committee for discussion. The revised monograph was adopted, subject to inclusion of the comments received during the public inquiry and those made during the discussion:\n\n- Quinine sulfate tablets\n\n### 3.3.3 Antituberculosis medicines\n\nRevisions of the published texts of the following antibiotics\u2019 active substances, for which an International Chemical Reference Substance (ICRS) was no longer available and thus a new method for assay was needed, were presented for discussion (see paragraph 3.4.2 for antibiotics), together with a new monograph for the corresponding dosage form. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during discussion:\n\n**APIs**\n- Amikacin\n- Amikacin sulfate\n\n**Dosage form**\n- Amikacin injection\n\nNew monographs for the following antibiotics active substances and dosage form for which an ICRS was still available, and thus included an assay by a microbiological method, were also presented for discussion. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during discussion:\n\n**APIs**\n- Kanamycin monosulfate\n- Kanamycin acid sulfate\n\n**Dosage form**\n- Kanamycin injection\n\nFor the Kanamycin injection monograph, the issue of the determination of the conversion factor from international units (IU) to micrograms was raised. The Expert Committee recommended that this monograph be circulated again for comment on this specific aspect.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1998, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "213e8ae8-3952-40a1-9a8f-ed3e3ab1390b": {"__data__": {"id_": "213e8ae8-3952-40a1-9a8f-ed3e3ab1390b", "embedding": null, "metadata": {"page_label": "39", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 3.3.4 Other medicines\n\n## Oxytocin\n\nA draft proposal for oxytocin was initially sent out for comment in 2007 and presented for discussion at the forty-second meeting of the Expert Committee in October 2008. A revised draft monograph, reflecting the comments received and the Expert Committee\u2019s recommendations, was recirculated for comment in January 2009. The new comments received were discussed during the consultation on specifications for medicines and quality control laboratory issues in June 2009, paying special attention to the following aspect of the monograph:\n\n- limits for assay\n\nA revised text was presented to the Expert Committee for discussion. The monograph was adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during the discussion.\n\n## Oxytocin injection\n\nA draft proposal for Oxytocin injection was initially sent out for comment in 2007 and presented for discussion at the forty-second meeting of the Expert Committee in 2008. A revised draft monograph, reflecting the comments received and the Expert Committee\u2019s recommendations, was recirculated for comment in January 2009. The new comments received were discussed during the consultation on specifications for medicines and quality control laboratory issues in June 2009, paying special attention to the aspects of the monograph presented below.\n\n### Storage/stability/pH\n\nThe storage of Oxytocin injection was a matter of concern since this injection was widely used in developing countries with hot climates and where refrigeration was not available. It was used by a range of health professionals and health providers (e.g. midwives) as well as in emergency situations. WHO was actively promoting its use by \u201cskilled attendants\u201d for the prevention and treatment of postpartum haemorrhage as part of \u201cMaking Pregnancy Safer\u201d (http://www.who.int/making_pregnancy_safer/en/) (Millennium Development Goals for maternal and child health).\n\nThe draft monograph circulated in 2007 recommended a storage temperature of between 2\u00b0C and 8\u00b0C (i.e. in a refrigerator) in line with the recommendations of the major manufacturers. This aspect of the monograph was reviewed by the Secretariat in light of current debate on stability of Oxytocin formulations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Proceso de desarrollo de la monograf\u00eda de Oxitocina**: La monograf\u00eda de Oxitocina ha pasado por un proceso de revisi\u00f3n y discusi\u00f3n desde 2007, con m\u00faltiples circulaciones de borradores y consultas para incorporar comentarios de expertos y del p\u00fablico. Este proceso culmin\u00f3 en la adopci\u00f3n de un texto revisado que incluye cambios acordados.\n\n2. **Preocupaciones sobre la estabilidad y almacenamiento de la inyecci\u00f3n de Oxitocina**: La inyecci\u00f3n de Oxitocina es crucial en pa\u00edses en desarrollo, especialmente en climas c\u00e1lidos donde la refrigeraci\u00f3n puede no estar disponible. La Organizaci\u00f3n Mundial de la Salud (OMS) promueve su uso para prevenir y tratar la hemorragia posparto, lo que plantea desaf\u00edos en cuanto a su almacenamiento y estabilidad.\n\n3. **Recomendaciones de almacenamiento para la inyecci\u00f3n de Oxitocina**: La monograf\u00eda de 2007 recomend\u00f3 que la inyecci\u00f3n de Oxitocina se almacenara entre 2\u00b0C y 8\u00b0C, aline\u00e1ndose con las recomendaciones de los principales fabricantes. Sin embargo, este aspecto fue revisado debido a debates sobre la estabilidad de las formulaciones de Oxitocina.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les fueron los principales cambios acordados en la monograf\u00eda de Oxitocina despu\u00e9s de la consulta p\u00fablica y las discusiones del Comit\u00e9 de Expertos?**\n   - Esta pregunta busca detalles sobre las modificaciones espec\u00edficas que se realizaron en la monograf\u00eda tras recibir comentarios, lo cual no se detalla en el texto.\n\n2. **\u00bfQu\u00e9 medidas se est\u00e1n considerando para abordar los problemas de almacenamiento de la inyecci\u00f3n de Oxitocina en climas c\u00e1lidos y sin refrigeraci\u00f3n?**\n   - Esta pregunta se centra en las soluciones potenciales o estrategias que la OMS y otros actores podr\u00edan estar explorando para garantizar la efectividad de la inyecci\u00f3n de Oxitocina en condiciones adversas.\n\n3. **\u00bfQu\u00e9 impacto ha tenido la promoci\u00f3n de la OMS sobre el uso de Oxitocina en la reducci\u00f3n de la hemorragia posparto en pa\u00edses en desarrollo?**\n   - Esta pregunta busca informaci\u00f3n sobre la efectividad de las iniciativas de la OMS en la pr\u00e1ctica cl\u00ednica y su impacto en la salud materna, un aspecto que no se aborda directamente en el texto.", "prev_section_summary": "### Temas Clave\n\n1. **Revisi\u00f3n de Monograf\u00edas**: Se llev\u00f3 a cabo una revisi\u00f3n de la monograf\u00eda de los comprimidos de sulfato de quinina para incluir una prueba de identidad adicional que permita diferenciar entre las dos formas de sulfato de quinina en las formulaciones de tabletas.\n\n2. **Medicamentos Antimal\u00e1ricos y Antituberculosos**: Se presentaron revisiones de las monograf\u00edas de antibi\u00f3ticos, como amikacina y kanamicina, debido a la falta de sustancias de referencia qu\u00edmica internacional (ICRS) y la necesidad de nuevos m\u00e9todos de ensayo.\n\n3. **Adopci\u00f3n de Nuevas Monograf\u00edas**: Las nuevas monograf\u00edas para los medicamentos revisados fueron adoptadas por el Comit\u00e9 de Expertos, con la condici\u00f3n de incluir los comentarios recibidos durante la consulta p\u00fablica y las discusiones.\n\n4. **Conversi\u00f3n de Unidades**: Se plante\u00f3 una cuesti\u00f3n sobre la conversi\u00f3n de unidades internacionales (IU) a microgramos en la monograf\u00eda de inyecci\u00f3n de kanamicina, recomendando su discusi\u00f3n adicional.\n\n### Entidades\n\n- **Medicamentos**:\n  - Quinine bisulfate tablets\n  - Quinine sulfate tablets\n  - Amikacin\n  - Amikacin sulfate\n  - Kanamycin monosulfate\n  - Kanamycin acid sulfate\n\n- **Formas de Dosificaci\u00f3n**:\n  - Amikacin injection\n  - Kanamycin injection\n\n- **Comit\u00e9**: Expert Committee\n\n- **Referencia**: International Chemical Reference Substance (ICRS)\n\nEste resumen destaca los cambios en las monograf\u00edas de medicamentos antimal\u00e1ricos y antituberculosos, as\u00ed como las discusiones sobre la conversi\u00f3n de unidades en la monograf\u00eda de kanamicina.", "excerpt_keywords": "Oxytocin, injection, stability, storage, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0da7133d-ec03-49b0-9e2f-48d601171103", "node_type": "4", "metadata": {"page_label": "39", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 3.3.4 Other medicines\n\n## Oxytocin\n\nA draft proposal for oxytocin was initially sent out for comment in 2007 and presented for discussion at the forty-second meeting of the Expert Committee in October 2008. A revised draft monograph, reflecting the comments received and the Expert Committee\u2019s recommendations, was recirculated for comment in January 2009. The new comments received were discussed during the consultation on specifications for medicines and quality control laboratory issues in June 2009, paying special attention to the following aspect of the monograph:\n\n- limits for assay\n\nA revised text was presented to the Expert Committee for discussion. The monograph was adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during the discussion.\n\n## Oxytocin injection\n\nA draft proposal for Oxytocin injection was initially sent out for comment in 2007 and presented for discussion at the forty-second meeting of the Expert Committee in 2008. A revised draft monograph, reflecting the comments received and the Expert Committee\u2019s recommendations, was recirculated for comment in January 2009. The new comments received were discussed during the consultation on specifications for medicines and quality control laboratory issues in June 2009, paying special attention to the aspects of the monograph presented below.\n\n### Storage/stability/pH\n\nThe storage of Oxytocin injection was a matter of concern since this injection was widely used in developing countries with hot climates and where refrigeration was not available. It was used by a range of health professionals and health providers (e.g. midwives) as well as in emergency situations. WHO was actively promoting its use by \u201cskilled attendants\u201d for the prevention and treatment of postpartum haemorrhage as part of \u201cMaking Pregnancy Safer\u201d (http://www.who.int/making_pregnancy_safer/en/) (Millennium Development Goals for maternal and child health).\n\nThe draft monograph circulated in 2007 recommended a storage temperature of between 2\u00b0C and 8\u00b0C (i.e. in a refrigerator) in line with the recommendations of the major manufacturers. This aspect of the monograph was reviewed by the Secretariat in light of current debate on stability of Oxytocin formulations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "587c96175d29032d3eae09ea2000dd2f8da64675059792d13f5e7696070a731b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 3.3.4 Other medicines\n\n## Oxytocin\n\nA draft proposal for oxytocin was initially sent out for comment in 2007 and presented for discussion at the forty-second meeting of the Expert Committee in October 2008. A revised draft monograph, reflecting the comments received and the Expert Committee\u2019s recommendations, was recirculated for comment in January 2009. The new comments received were discussed during the consultation on specifications for medicines and quality control laboratory issues in June 2009, paying special attention to the following aspect of the monograph:\n\n- limits for assay\n\nA revised text was presented to the Expert Committee for discussion. The monograph was adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during the discussion.\n\n## Oxytocin injection\n\nA draft proposal for Oxytocin injection was initially sent out for comment in 2007 and presented for discussion at the forty-second meeting of the Expert Committee in 2008. A revised draft monograph, reflecting the comments received and the Expert Committee\u2019s recommendations, was recirculated for comment in January 2009. The new comments received were discussed during the consultation on specifications for medicines and quality control laboratory issues in June 2009, paying special attention to the aspects of the monograph presented below.\n\n### Storage/stability/pH\n\nThe storage of Oxytocin injection was a matter of concern since this injection was widely used in developing countries with hot climates and where refrigeration was not available. It was used by a range of health professionals and health providers (e.g. midwives) as well as in emergency situations. WHO was actively promoting its use by \u201cskilled attendants\u201d for the prevention and treatment of postpartum haemorrhage as part of \u201cMaking Pregnancy Safer\u201d (http://www.who.int/making_pregnancy_safer/en/) (Millennium Development Goals for maternal and child health).\n\nThe draft monograph circulated in 2007 recommended a storage temperature of between 2\u00b0C and 8\u00b0C (i.e. in a refrigerator) in line with the recommendations of the major manufacturers. This aspect of the monograph was reviewed by the Secretariat in light of current debate on stability of Oxytocin formulations.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2301, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "daa9c2b0-6804-4019-af11-4306244f9f19": {"__data__": {"id_": "daa9c2b0-6804-4019-af11-4306244f9f19", "embedding": null, "metadata": {"page_label": "40", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Bearing in mind the application of the Ph.Int., the revised draft circulated for comment in January 2009 retained 2\u20138\u00b0C as the default temperature recommended under Storage, but qualified it by including \u201cunless otherwise indicated on the label\u201d. This recommendation was supplemented by Additional information concerning short-term storage at higher temperatures in line with statements in summary of product information/patient information leaflets (SPCs/PILs) provided by major manufacturers. A Note from the Secretariat invited comment on this aspect of the revised draft together with any supporting data. Based on the above and the comments received, the storage temperature of 2\u20138\u00b0C for the injection was confirmed.\n\n**pH value**\n\nThe lower limit in the revised draft was changed taking account of the limits currently given in other pharmacopoeias.\n\n**Related substances**\n\nFurther to discussion in June 2009, a recently published article demonstrated that the high-performance liquid chromatography (HPLC) method used for the Related substances test currently described in the Ph.Int. monograph for Oxytocin was also suitable to detect the related substances for the injection. The Expert Committee thus recommended using this test in the Oxytocin injection monograph. The details of this method would be added to the revised draft.\n\nThe text was presented to the Expert Committee for discussion. The monograph was adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during discussion.\n\n### 3.4 Revision of texts of  \n*The International Pharmacopoeia*\n\n#### 3.4.1 Antimalarials: artemisinin derivatives\n\nThe revision of some aspects of the monographs for artemisinin derivatives (Artemether, Artemisinin, Artemotil, Artenimol and Artesunate and their associated dosage forms) was discussed by the Expert Committee in October 2008.\n\nIn view of the importance of this category of antimalarial medicines and the time that this extensive revision work would require, an explanatory note including preliminary variations to be carried out to improve the HPLC assay methods (sample preparation) had been posted on the WHO Medicines web site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Almacenamiento de inyecciones**: El documento discute la recomendaci\u00f3n de almacenamiento de inyecciones a una temperatura de 2\u20138\u00b0C, con la posibilidad de excepciones indicadas en las etiquetas de los productos. Tambi\u00e9n se menciona la inclusi\u00f3n de informaci\u00f3n adicional sobre el almacenamiento a temperaturas m\u00e1s altas y la confirmaci\u00f3n de esta recomendaci\u00f3n tras recibir comentarios.\n\n2. **M\u00e9todos de prueba para sustancias relacionadas**: Se destaca la recomendaci\u00f3n del Comit\u00e9 de Expertos de utilizar un m\u00e9todo de cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n (HPLC) para detectar sustancias relacionadas en la inyecci\u00f3n de oxitocina, basado en un art\u00edculo reciente que valida este m\u00e9todo.\n\n3. **Revisi\u00f3n de monograf\u00edas de antimal\u00e1ricos**: Se menciona la revisi\u00f3n de las monograf\u00edas de derivados de artemisinina, que incluye varios medicamentos antimal\u00e1ricos. Se indica que se est\u00e1n realizando variaciones preliminares en los m\u00e9todos de ensayo HPLC para mejorar la preparaci\u00f3n de muestras.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 condiciones de almacenamiento se recomiendan para las inyecciones seg\u00fan el documento, y qu\u00e9 excepciones se permiten?**\n   - El documento recomienda un almacenamiento a 2\u20138\u00b0C para las inyecciones, a menos que se indique lo contrario en la etiqueta del producto.\n\n2. **\u00bfCu\u00e1l es el m\u00e9todo de prueba recomendado para detectar sustancias relacionadas en la inyecci\u00f3n de oxitocina, y qu\u00e9 justificaci\u00f3n se proporciona para su uso?**\n   - Se recomienda el uso de un m\u00e9todo de cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n (HPLC) para detectar sustancias relacionadas en la inyecci\u00f3n de oxitocina, justificado por un art\u00edculo reciente que demuestra su idoneidad.\n\n3. **\u00bfQu\u00e9 aspectos se est\u00e1n revisando en las monograf\u00edas de los derivados de artemisinina y por qu\u00e9 es importante esta revisi\u00f3n?**\n   - Se est\u00e1n revisando algunos aspectos de las monograf\u00edas de derivados de artemisinina debido a la importancia de estos medicamentos antimal\u00e1ricos y el tiempo necesario para llevar a cabo esta extensa revisi\u00f3n. Se han publicado notas explicativas sobre variaciones preliminares en los m\u00e9todos de ensayo HPLC en el sitio web de la OMS.", "prev_section_summary": "### Temas Clave\n\n1. **Desarrollo de la Monograf\u00eda de Oxitocina**: La monograf\u00eda de Oxitocina ha sido objeto de un proceso de revisi\u00f3n desde 2007, con m\u00faltiples borradores y consultas para incorporar comentarios de expertos y del p\u00fablico. Finalmente, se adopt\u00f3 un texto revisado que incluye cambios acordados.\n\n2. **Inyecci\u00f3n de Oxitocina**: La inyecci\u00f3n de Oxitocina es esencial en pa\u00edses en desarrollo, especialmente en climas c\u00e1lidos donde la refrigeraci\u00f3n no siempre est\u00e1 disponible. Su uso es promovido por la OMS para prevenir y tratar la hemorragia posparto.\n\n3. **Almacenamiento y Estabilidad**: Se discutieron preocupaciones sobre el almacenamiento de la inyecci\u00f3n de Oxitocina, que debe mantenerse entre 2\u00b0C y 8\u00b0C, lo que puede ser un desaf\u00edo en entornos sin refrigeraci\u00f3n. Este aspecto fue revisado debido a debates sobre la estabilidad de las formulaciones de Oxitocina.\n\n### Entidades\n\n- **Oxitocina**: Hormona utilizada en medicina, especialmente en el contexto de la hemorragia posparto.\n- **Inyecci\u00f3n de Oxitocina**: Forma farmac\u00e9utica de la oxitocina utilizada en situaciones de emergencia y por profesionales de la salud.\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad que promueve el uso de la inyecci\u00f3n de Oxitocina como parte de sus iniciativas para mejorar la salud materna y neonatal.\n- **Comit\u00e9 de Expertos**: Grupo que revisa y discute las monograf\u00edas y recomendaciones sobre medicamentos.\n- **Millennium Development Goals**: Objetivos de desarrollo que incluyen la mejora de la salud materna y infantil.\n\n### Resumen\n\nLa secci\u00f3n aborda el proceso de desarrollo y revisi\u00f3n de la monograf\u00eda de Oxitocina y su inyecci\u00f3n, destacando la importancia de estos medicamentos en la atenci\u00f3n de la salud materna, especialmente en pa\u00edses en desarrollo. Se enfatiza la necesidad de un almacenamiento adecuado de la inyecci\u00f3n de Oxitocina, dado su uso en climas c\u00e1lidos y la falta de refrigeraci\u00f3n, as\u00ed como la promoci\u00f3n de su uso por parte de la OMS para prevenir la hemorragia posparto.", "excerpt_keywords": "Keywords: Oxytocin, storage temperature, HPLC method, artemisinin derivatives, pharmacopoeia"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "14617eb9-e562-46fc-9561-ff93de8a9ce3", "node_type": "4", "metadata": {"page_label": "40", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Bearing in mind the application of the Ph.Int., the revised draft circulated for comment in January 2009 retained 2\u20138\u00b0C as the default temperature recommended under Storage, but qualified it by including \u201cunless otherwise indicated on the label\u201d. This recommendation was supplemented by Additional information concerning short-term storage at higher temperatures in line with statements in summary of product information/patient information leaflets (SPCs/PILs) provided by major manufacturers. A Note from the Secretariat invited comment on this aspect of the revised draft together with any supporting data. Based on the above and the comments received, the storage temperature of 2\u20138\u00b0C for the injection was confirmed.\n\n**pH value**\n\nThe lower limit in the revised draft was changed taking account of the limits currently given in other pharmacopoeias.\n\n**Related substances**\n\nFurther to discussion in June 2009, a recently published article demonstrated that the high-performance liquid chromatography (HPLC) method used for the Related substances test currently described in the Ph.Int. monograph for Oxytocin was also suitable to detect the related substances for the injection. The Expert Committee thus recommended using this test in the Oxytocin injection monograph. The details of this method would be added to the revised draft.\n\nThe text was presented to the Expert Committee for discussion. The monograph was adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during discussion.\n\n### 3.4 Revision of texts of  \n*The International Pharmacopoeia*\n\n#### 3.4.1 Antimalarials: artemisinin derivatives\n\nThe revision of some aspects of the monographs for artemisinin derivatives (Artemether, Artemisinin, Artemotil, Artenimol and Artesunate and their associated dosage forms) was discussed by the Expert Committee in October 2008.\n\nIn view of the importance of this category of antimalarial medicines and the time that this extensive revision work would require, an explanatory note including preliminary variations to be carried out to improve the HPLC assay methods (sample preparation) had been posted on the WHO Medicines web site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "9119d17ea146c1981d29353e58ad45b163e04e2c30a340ead8ba1c488ec1527e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Bearing in mind the application of the Ph.Int., the revised draft circulated for comment in January 2009 retained 2\u20138\u00b0C as the default temperature recommended under Storage, but qualified it by including \u201cunless otherwise indicated on the label\u201d. This recommendation was supplemented by Additional information concerning short-term storage at higher temperatures in line with statements in summary of product information/patient information leaflets (SPCs/PILs) provided by major manufacturers. A Note from the Secretariat invited comment on this aspect of the revised draft together with any supporting data. Based on the above and the comments received, the storage temperature of 2\u20138\u00b0C for the injection was confirmed.\n\n**pH value**\n\nThe lower limit in the revised draft was changed taking account of the limits currently given in other pharmacopoeias.\n\n**Related substances**\n\nFurther to discussion in June 2009, a recently published article demonstrated that the high-performance liquid chromatography (HPLC) method used for the Related substances test currently described in the Ph.Int. monograph for Oxytocin was also suitable to detect the related substances for the injection. The Expert Committee thus recommended using this test in the Oxytocin injection monograph. The details of this method would be added to the revised draft.\n\nThe text was presented to the Expert Committee for discussion. The monograph was adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during discussion.\n\n### 3.4 Revision of texts of  \n*The International Pharmacopoeia*\n\n#### 3.4.1 Antimalarials: artemisinin derivatives\n\nThe revision of some aspects of the monographs for artemisinin derivatives (Artemether, Artemisinin, Artemotil, Artenimol and Artesunate and their associated dosage forms) was discussed by the Expert Committee in October 2008.\n\nIn view of the importance of this category of antimalarial medicines and the time that this extensive revision work would require, an explanatory note including preliminary variations to be carried out to improve the HPLC assay methods (sample preparation) had been posted on the WHO Medicines web site.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2216, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b20ec46d-184a-453b-951d-c4820307a975": {"__data__": {"id_": "b20ec46d-184a-453b-951d-c4820307a975", "embedding": null, "metadata": {"page_label": "41", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Following presentation of a detailed update the Committee was pleased to note that considerable progress had been made; specific revision proposals for two monographs had now been circulated for comment and laboratory work was in progress for other monographs.\n\nThe following revised antimalarial dosage forms monographs were presented to the Expert Committee for discussion with the comments received to date. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments made during the discussion and provided no major comments were received during the public inquiry:\n\n- Artesunate\n- Artesunate tablets\n\n### 3.4.2 Antibiotics\n\nA number of revision issues related to antibiotics assay were identified and discussed by the Expert Committee at its meetings in October 2006 and 2008.\n\nThe Committee was pleased to note that a review had started of those monographs for antibiotics which specified a microbiological assay, with the aim of replacing this method by a chromatographic method where possible. Priority for revision had been awarded to those monographs in Volume 1 of the Fourth Edition of the Ph.Int. that still specified a microbiological assay while the relevant biological reference material (International Standards for Antibiotics (ISA9)) had been disestablished.\n\nThe following revision status for these texts (APIs and dosage forms) was presented:\n\n- Amikacin and Amikacin sulfate monographs: the microbiological assay was replaced by an HPLC method using ultraviolet (UV) detection and an alternative method by non-aqueous titration had been added whenever possible. These texts were adopted by the Expert Committee (see paragraph 3.3.3 for antituberculosis drugs);\n- Chlortetracycline hydrochloride, Oxytetracycline dehydrate, Oxytetracycline hydrochloride, Tetracycline, Tetracycline hydrochloride and Paromomycin monographs: the Committee agreed to revise these texts taking account of established pharmacopoeial HPLC methods which were also under active revision in other pharmacopoeias. It was, therefore, recommended to await the outcome of these efforts for further discussions of these monographs within the context of the Ph.Int.\n\nAs all these revisions were ongoing, the Expert Committee recommended that an information note on the revision status of these monographs be posted on the WHO Medicines web site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Progreso en la revisi\u00f3n de monograf\u00edas**: El Comit\u00e9 de Expertos ha realizado avances significativos en la revisi\u00f3n de monograf\u00edas, con propuestas espec\u00edficas para dos monograf\u00edas de antimal\u00e1ricos que han sido adoptadas, y se est\u00e1 llevando a cabo trabajo de laboratorio para otras monograf\u00edas.\n\n2. **Revisi\u00f3n de m\u00e9todos de ensayo de antibi\u00f3ticos**: Se ha iniciado una revisi\u00f3n de las monograf\u00edas de antibi\u00f3ticos que especifican un ensayo microbiol\u00f3gico, con el objetivo de reemplazar este m\u00e9todo por m\u00e9todos cromatogr\u00e1ficos. Se ha dado prioridad a las monograf\u00edas que a\u00fan utilizan ensayos microbiol\u00f3gicos y que est\u00e1n relacionadas con materiales de referencia biol\u00f3gica que han sido desestablecidos.\n\n3. **Estado de las revisiones de monograf\u00edas espec\u00edficas**: Se han presentado los estados de revisi\u00f3n de varias monograf\u00edas de antibi\u00f3ticos, destacando la adopci\u00f3n de m\u00e9todos HPLC para algunos antibi\u00f3ticos y la recomendaci\u00f3n de esperar los resultados de revisiones en otros farmacopoeias para discutir otras monograf\u00edas.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las monograf\u00edas de antimal\u00e1ricos que fueron adoptadas por el Comit\u00e9 de Expertos y qu\u00e9 condiciones se establecieron para su adopci\u00f3n?**\n   - Respuesta: Las monograf\u00edas de antimal\u00e1ricos adoptadas son Artesunate y Artesunate tablets, y su adopci\u00f3n est\u00e1 sujeta a la inclusi\u00f3n de cambios acordados basados en los comentarios realizados durante la discusi\u00f3n, siempre que no se reciban comentarios importantes durante la consulta p\u00fablica.\n\n2. **\u00bfQu\u00e9 cambios se realizaron en las monograf\u00edas de Amikacina y Amikacina sulfato en relaci\u00f3n con los m\u00e9todos de ensayo?**\n   - Respuesta: En las monograf\u00edas de Amikacina y Amikacina sulfato, el ensayo microbiol\u00f3gico fue reemplazado por un m\u00e9todo HPLC utilizando detecci\u00f3n ultravioleta (UV), y se a\u00f1adi\u00f3 un m\u00e9todo alternativo de titulaci\u00f3n no acuosa siempre que fue posible.\n\n3. **\u00bfQu\u00e9 recomendaciones hizo el Comit\u00e9 de Expertos respecto a las monograf\u00edas de antibi\u00f3ticos que a\u00fan utilizan ensayos microbiol\u00f3gicos?**\n   - Respuesta: El Comit\u00e9 de Expertos recomend\u00f3 esperar los resultados de las revisiones de m\u00e9todos HPLC establecidos en otras farmacopoeias antes de discutir m\u00e1s a fondo las monograf\u00edas de Chlortetracycline, Oxytetracycline, Tetracycline y Paromomycin. Adem\u00e1s, se sugiri\u00f3 que se publique una nota informativa sobre el estado de revisi\u00f3n de estas monograf\u00edas en el sitio web de Medicamentos de la OMS.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Almacenamiento de inyecciones**:\n   - **Temperatura recomendada**: 2\u20138\u00b0C como temperatura de almacenamiento est\u00e1ndar.\n   - **Excepciones**: Se permite el almacenamiento a temperaturas diferentes si se indica en la etiqueta del producto.\n   - **Informaci\u00f3n adicional**: Se proporciona informaci\u00f3n sobre el almacenamiento a temperaturas m\u00e1s altas, en l\u00ednea con las declaraciones de los fabricantes.\n\n2. **M\u00e9todo de prueba para sustancias relacionadas**:\n   - **M\u00e9todo recomendado**: Cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n (HPLC) para detectar sustancias relacionadas en la inyecci\u00f3n de oxitocina.\n   - **Justificaci\u00f3n**: Un art\u00edculo reciente valida la idoneidad del m\u00e9todo HPLC para este prop\u00f3sito.\n\n3. **Revisi\u00f3n de monograf\u00edas de antimal\u00e1ricos**:\n   - **Medicamentos revisados**: Derivados de artemisinina, incluyendo Artemether, Artemisinin, Artemotil, Artenimol y Artesunate.\n   - **Importancia de la revisi\u00f3n**: Se destaca la relevancia de estos medicamentos antimal\u00e1ricos y el tiempo necesario para realizar la revisi\u00f3n exhaustiva.\n   - **Notas explicativas**: Se han publicado variaciones preliminares en los m\u00e9todos de ensayo HPLC en el sitio web de la OMS para mejorar la preparaci\u00f3n de muestras.\n\n### Entidades clave:\n- **Ph.Int.**: Referencia a la Farmacopea Internacional.\n- **HPLC**: Cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n.\n- **Comit\u00e9 de Expertos**: Grupo que discute y adopta recomendaciones sobre monograf\u00edas y m\u00e9todos de prueba.\n- **OMS**: Organizaci\u00f3n Mundial de la Salud, responsable de la publicaci\u00f3n de las recomendaciones y monograf\u00edas.", "excerpt_keywords": "Keywords: antimalarials, antibiotics, microbiological assay, HPLC, WHO Medicines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4067fc70-6271-4e43-bf82-7b29ea96d965", "node_type": "4", "metadata": {"page_label": "41", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Following presentation of a detailed update the Committee was pleased to note that considerable progress had been made; specific revision proposals for two monographs had now been circulated for comment and laboratory work was in progress for other monographs.\n\nThe following revised antimalarial dosage forms monographs were presented to the Expert Committee for discussion with the comments received to date. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments made during the discussion and provided no major comments were received during the public inquiry:\n\n- Artesunate\n- Artesunate tablets\n\n### 3.4.2 Antibiotics\n\nA number of revision issues related to antibiotics assay were identified and discussed by the Expert Committee at its meetings in October 2006 and 2008.\n\nThe Committee was pleased to note that a review had started of those monographs for antibiotics which specified a microbiological assay, with the aim of replacing this method by a chromatographic method where possible. Priority for revision had been awarded to those monographs in Volume 1 of the Fourth Edition of the Ph.Int. that still specified a microbiological assay while the relevant biological reference material (International Standards for Antibiotics (ISA9)) had been disestablished.\n\nThe following revision status for these texts (APIs and dosage forms) was presented:\n\n- Amikacin and Amikacin sulfate monographs: the microbiological assay was replaced by an HPLC method using ultraviolet (UV) detection and an alternative method by non-aqueous titration had been added whenever possible. These texts were adopted by the Expert Committee (see paragraph 3.3.3 for antituberculosis drugs);\n- Chlortetracycline hydrochloride, Oxytetracycline dehydrate, Oxytetracycline hydrochloride, Tetracycline, Tetracycline hydrochloride and Paromomycin monographs: the Committee agreed to revise these texts taking account of established pharmacopoeial HPLC methods which were also under active revision in other pharmacopoeias. It was, therefore, recommended to await the outcome of these efforts for further discussions of these monographs within the context of the Ph.Int.\n\nAs all these revisions were ongoing, the Expert Committee recommended that an information note on the revision status of these monographs be posted on the WHO Medicines web site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "194996506723b4722a129fbfd3802bdde5def839a54db68c4effe89fdce2fe3f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Following presentation of a detailed update the Committee was pleased to note that considerable progress had been made; specific revision proposals for two monographs had now been circulated for comment and laboratory work was in progress for other monographs.\n\nThe following revised antimalarial dosage forms monographs were presented to the Expert Committee for discussion with the comments received to date. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments made during the discussion and provided no major comments were received during the public inquiry:\n\n- Artesunate\n- Artesunate tablets\n\n### 3.4.2 Antibiotics\n\nA number of revision issues related to antibiotics assay were identified and discussed by the Expert Committee at its meetings in October 2006 and 2008.\n\nThe Committee was pleased to note that a review had started of those monographs for antibiotics which specified a microbiological assay, with the aim of replacing this method by a chromatographic method where possible. Priority for revision had been awarded to those monographs in Volume 1 of the Fourth Edition of the Ph.Int. that still specified a microbiological assay while the relevant biological reference material (International Standards for Antibiotics (ISA9)) had been disestablished.\n\nThe following revision status for these texts (APIs and dosage forms) was presented:\n\n- Amikacin and Amikacin sulfate monographs: the microbiological assay was replaced by an HPLC method using ultraviolet (UV) detection and an alternative method by non-aqueous titration had been added whenever possible. These texts were adopted by the Expert Committee (see paragraph 3.3.3 for antituberculosis drugs);\n- Chlortetracycline hydrochloride, Oxytetracycline dehydrate, Oxytetracycline hydrochloride, Tetracycline, Tetracycline hydrochloride and Paromomycin monographs: the Committee agreed to revise these texts taking account of established pharmacopoeial HPLC methods which were also under active revision in other pharmacopoeias. It was, therefore, recommended to await the outcome of these efforts for further discussions of these monographs within the context of the Ph.Int.\n\nAs all these revisions were ongoing, the Expert Committee recommended that an information note on the revision status of these monographs be posted on the WHO Medicines web site.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2370, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6abc1c8a-8bae-4d38-b42c-337206c7bfb2": {"__data__": {"id_": "6abc1c8a-8bae-4d38-b42c-337206c7bfb2", "embedding": null, "metadata": {"page_label": "42", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 3.4.3 Other medicines\n\n### Mebendazole\n\nThe Expert Committee adopted a modification to the text for mebendazole to improve the interpretation of the revised monograph adopted in October 2008.\n\nFollowing adoption of the revised monographs for Mebendazole and Mebendazole chewable tablets by the Expert Committee in October 2008, the Secretariat had written to other pharmacopoeial authorities regarding the revision that had been carried out to explicitly restrict the substance to polymorph C in the Ph.Int. In view of the use of mebendazole in intestinal worm eradication programmes worldwide, harmonization of pharmacopoeial monographs had been suggested with respect to the control of polymorphism. The Committee appreciated the helpful replies received from several pharmacopoeias and noted that both the Chinese and European Pharmacopoeias also restricted mebendazole to polymorph C. The possibility of including an explicit statement to this effect within the European Pharmacopoeia (Ph. Eur) monograph was welcomed. It was noted that correspondence from the United States Pharmacopeia (USP) had indicated an interest in harmonizing the USP monograph (which currently did not control the polymorphic form). Members noted, however, that this would not currently be possible since the product currently licensed in the USA contained polymorph B.\n\nThe Secretariat undertook to provide feedback to the relevant pharmacopoeial authorities.\n\n### Oseltamivir phosphate\n\nThe monograph for Oseltamivir phosphate was adopted by the Expert Committee in October 2008 for addition to the Fourth Edition of *The International Pharmacopoeia*.\n\nA further revision for this text was proposed following receipt of comments from manufacturers on the tests for Sulfated ash and related substances. The changes proposed would harmonize the Ph.Int. text with the specifications for oseltamivir phosphate that were now available in other pharmacopoeias (Ph.Eur and USP).\n\nA revised text that included these proposed changes was presented to the Expert Committee for discussion. The monograph was adopted, subject to inclusion of the agreed changes, based on the comments received and those made during the discussion.\n\n## 3.4.4 Heparin\n\nRapid revisions of the monographs in *The International Pharmacopoeia* for Heparin calcium and Heparin sodium were adopted by the Expert.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Modificaciones a la monograf\u00eda de Mebendazole**: En octubre de 2008, se adopt\u00f3 una revisi\u00f3n de las monograf\u00edas de Mebendazole y Mebendazole en tabletas masticables, con un enfoque en restringir el uso a la forma polim\u00f3rfica C. Esto se hizo en respuesta a la necesidad de armonizar las monograf\u00edas farmacop\u00e9uticas a nivel mundial, especialmente en programas de erradicaci\u00f3n de lombrices intestinales.\n\n2. **Revisi\u00f3n de la monograf\u00eda de Oseltamivir fosfato**: La monograf\u00eda de Oseltamivir fosfato fue adoptada en octubre de 2008 y se propusieron revisiones adicionales para armonizar las especificaciones con otras farmacopoeias. Esto incluy\u00f3 cambios en las pruebas para cenizas sulfatadas y sustancias relacionadas, basados en comentarios de los fabricantes.\n\n3. **Revisiones r\u00e1pidas de Heparina**: Se adoptaron revisiones r\u00e1pidas de las monograf\u00edas de Heparina c\u00e1lcica y Heparina s\u00f3dica en *The International Pharmacopoeia*, aunque el contexto no proporciona detalles espec\u00edficos sobre estas revisiones.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1l fue la raz\u00f3n principal para restringir el uso de Mebendazole a la forma polim\u00f3rfica C en las monograf\u00edas farmacop\u00e9uticas?**\n   - La restricci\u00f3n se realiz\u00f3 para mejorar la interpretaci\u00f3n de la monograf\u00eda y asegurar la eficacia del Mebendazole en programas de erradicaci\u00f3n de lombrices intestinales a nivel mundial.\n\n2. **\u00bfQu\u00e9 cambios espec\u00edficos se propusieron para la monograf\u00eda de Oseltamivir fosfato y por qu\u00e9 fueron necesarios?**\n   - Se propusieron cambios en las pruebas para cenizas sulfatadas y sustancias relacionadas para armonizar el texto de la Ph.Int. con las especificaciones disponibles en otras farmacopoeias, como la Europea y la USP.\n\n3. **\u00bfQu\u00e9 desaf\u00edos enfrenta la armonizaci\u00f3n de la monograf\u00eda de Mebendazole en la USP en comparaci\u00f3n con otras farmacopoeias?**\n   - El desaf\u00edo principal es que el producto actualmente licenciado en los EE. UU. contiene la forma polim\u00f3rfica B, lo que impide la armonizaci\u00f3n con las restricciones de las formas polim\u00f3rficas C adoptadas por otras farmacopoeias.", "prev_section_summary": "### Temas Clave:\n\n1. **Progreso en la Revisi\u00f3n de Monograf\u00edas**: Se ha avanzado significativamente en la revisi\u00f3n de monograf\u00edas, con propuestas espec\u00edficas para dos monograf\u00edas de antimal\u00e1ricos que han sido adoptadas y trabajo de laboratorio en curso para otras.\n\n2. **Revisi\u00f3n de M\u00e9todos de Ensayo de Antibi\u00f3ticos**: Se ha iniciado una revisi\u00f3n de monograf\u00edas de antibi\u00f3ticos que utilizan ensayos microbiol\u00f3gicos, con el objetivo de reemplazarlos por m\u00e9todos cromatogr\u00e1ficos. Se ha priorizado la revisi\u00f3n de monograf\u00edas que a\u00fan dependen de ensayos microbiol\u00f3gicos.\n\n3. **Estado de Revisi\u00f3n de Monograf\u00edas Espec\u00edficas**: Se han presentado los estados de revisi\u00f3n de varias monograf\u00edas de antibi\u00f3ticos, destacando la adopci\u00f3n de m\u00e9todos HPLC para algunos y la recomendaci\u00f3n de esperar resultados de revisiones en otras farmacopoeias para discutir m\u00e1s monograf\u00edas.\n\n### Entidades:\n\n- **Comit\u00e9 de Expertos**: Grupo responsable de la revisi\u00f3n y adopci\u00f3n de monograf\u00edas.\n- **Monograf\u00edas de Antimal\u00e1ricos**: \n  - Artesunate\n  - Artesunate tablets\n- **Monograf\u00edas de Antibi\u00f3ticos**:\n  - Amikacina y Amikacina sulfato (m\u00e9todo HPLC adoptado)\n  - Chlortetraciclina, Oxitetraciclina, Tetraciclina y Paromomicina (en revisi\u00f3n)\n- **M\u00e9todos de Ensayo**: \n  - Ensayo microbiol\u00f3gico (reemplazado)\n  - M\u00e9todo HPLC (adoptado)\n  - Titulaci\u00f3n no acuosa (m\u00e9todo alternativo a\u00f1adido)\n- **Ph.Int.**: Farmacopea Internacional, donde se encuentran las monograf\u00edas en revisi\u00f3n.\n- **ISA9**: Material de referencia biol\u00f3gica para antibi\u00f3ticos que ha sido desestablecido. \n\n### Recomendaciones:\n- Publicar una nota informativa sobre el estado de revisi\u00f3n de las monograf\u00edas en el sitio web de Medicamentos de la OMS.", "excerpt_keywords": "Mebendazole, Oseltamivir, pharmacopoeia, polymorphism, Heparin"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0083f1ba-c66b-4d6e-9b21-ac77fb86db8a", "node_type": "4", "metadata": {"page_label": "42", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 3.4.3 Other medicines\n\n### Mebendazole\n\nThe Expert Committee adopted a modification to the text for mebendazole to improve the interpretation of the revised monograph adopted in October 2008.\n\nFollowing adoption of the revised monographs for Mebendazole and Mebendazole chewable tablets by the Expert Committee in October 2008, the Secretariat had written to other pharmacopoeial authorities regarding the revision that had been carried out to explicitly restrict the substance to polymorph C in the Ph.Int. In view of the use of mebendazole in intestinal worm eradication programmes worldwide, harmonization of pharmacopoeial monographs had been suggested with respect to the control of polymorphism. The Committee appreciated the helpful replies received from several pharmacopoeias and noted that both the Chinese and European Pharmacopoeias also restricted mebendazole to polymorph C. The possibility of including an explicit statement to this effect within the European Pharmacopoeia (Ph. Eur) monograph was welcomed. It was noted that correspondence from the United States Pharmacopeia (USP) had indicated an interest in harmonizing the USP monograph (which currently did not control the polymorphic form). Members noted, however, that this would not currently be possible since the product currently licensed in the USA contained polymorph B.\n\nThe Secretariat undertook to provide feedback to the relevant pharmacopoeial authorities.\n\n### Oseltamivir phosphate\n\nThe monograph for Oseltamivir phosphate was adopted by the Expert Committee in October 2008 for addition to the Fourth Edition of *The International Pharmacopoeia*.\n\nA further revision for this text was proposed following receipt of comments from manufacturers on the tests for Sulfated ash and related substances. The changes proposed would harmonize the Ph.Int. text with the specifications for oseltamivir phosphate that were now available in other pharmacopoeias (Ph.Eur and USP).\n\nA revised text that included these proposed changes was presented to the Expert Committee for discussion. The monograph was adopted, subject to inclusion of the agreed changes, based on the comments received and those made during the discussion.\n\n## 3.4.4 Heparin\n\nRapid revisions of the monographs in *The International Pharmacopoeia* for Heparin calcium and Heparin sodium were adopted by the Expert.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "eb450600170d2ee5631bcb251e81f79f8c73bc95f260d62a83c870e04c32f4e5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 3.4.3 Other medicines\n\n### Mebendazole\n\nThe Expert Committee adopted a modification to the text for mebendazole to improve the interpretation of the revised monograph adopted in October 2008.\n\nFollowing adoption of the revised monographs for Mebendazole and Mebendazole chewable tablets by the Expert Committee in October 2008, the Secretariat had written to other pharmacopoeial authorities regarding the revision that had been carried out to explicitly restrict the substance to polymorph C in the Ph.Int. In view of the use of mebendazole in intestinal worm eradication programmes worldwide, harmonization of pharmacopoeial monographs had been suggested with respect to the control of polymorphism. The Committee appreciated the helpful replies received from several pharmacopoeias and noted that both the Chinese and European Pharmacopoeias also restricted mebendazole to polymorph C. The possibility of including an explicit statement to this effect within the European Pharmacopoeia (Ph. Eur) monograph was welcomed. It was noted that correspondence from the United States Pharmacopeia (USP) had indicated an interest in harmonizing the USP monograph (which currently did not control the polymorphic form). Members noted, however, that this would not currently be possible since the product currently licensed in the USA contained polymorph B.\n\nThe Secretariat undertook to provide feedback to the relevant pharmacopoeial authorities.\n\n### Oseltamivir phosphate\n\nThe monograph for Oseltamivir phosphate was adopted by the Expert Committee in October 2008 for addition to the Fourth Edition of *The International Pharmacopoeia*.\n\nA further revision for this text was proposed following receipt of comments from manufacturers on the tests for Sulfated ash and related substances. The changes proposed would harmonize the Ph.Int. text with the specifications for oseltamivir phosphate that were now available in other pharmacopoeias (Ph.Eur and USP).\n\nA revised text that included these proposed changes was presented to the Expert Committee for discussion. The monograph was adopted, subject to inclusion of the agreed changes, based on the comments received and those made during the discussion.\n\n## 3.4.4 Heparin\n\nRapid revisions of the monographs in *The International Pharmacopoeia* for Heparin calcium and Heparin sodium were adopted by the Expert.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2360, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4edce5c9-5e69-4366-81bc-89abd1bf1ace": {"__data__": {"id_": "4edce5c9-5e69-4366-81bc-89abd1bf1ace", "embedding": null, "metadata": {"page_label": "43", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Committee in October 2008 and had been published on the WHO Medicines web site, to bring them into line with the action of other pharmacopoeias concerning Heparin monographs. The statement on the web site indicated that the WHO Expert Committee on Specifications for Pharmaceutical Preparations, together with the WHO Expert Committee on Biological Standardization, would jointly review the scientific work being carried out by interested parties. The need for further revision of the monographs would be examined, and it was noted that discussion on heparin would be held during the next session of the Expert Committee on Biological Standardization.\n\nRevision of the Heparin monographs was also discussed during the informal consultation in June 2009, when it was recommended to investigate the possible inclusion of a cellulose acetate plate electrophoresis method for the analysis of heparin and its potential glycosaminoglycan impurities, e.g. dermatan sulfate, chondroitin sulfate and oversulfated chondroitin sulfate.\n\nThis method, routinely used in industry, had been shown to have a high selectivity for heparinoid impurities and could be performed with low-cost instrumentation. Therefore, this method could be beneficial for small quality control laboratories not equipped for the compendial HPLC methods.\n\nThe Expert Committee endorsed the recommendation that the Secretariat, in collaboration with a WHO collaborating laboratory, review the suitability of this proposed method for inclusion in the Ph.Int. and circulate revised draft proposals of the Heparin monographs for comment.\n\n### 3.5 Review of published general monographs for dosage forms\n\nAt its meeting in 2007, the Expert Committee agreed that the general monographs published in Volume 2 of *The International Pharmacopoeia* should be reviewed and revised as necessary, to follow a general monograph \u201ctemplate\u201d that had been prepared, based on the texts adopted for inclusion in the first supplement.\n\nFollowing the defined template, a draft revision of the general monograph for Tablets was discussed at the informal consultation in June 2009. It was then recommended that, based on the revision of the general monograph for Tablets, a similar revision should be done of the monograph for Capsules. Revised texts for the following monographs were presented to the Expert Committee for discussion. The revised monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during the discussion:\n\n- Tablets\n- Capsules", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto se centra en las discusiones y recomendaciones de la Comisi\u00f3n de Expertos de la OMS sobre las monograf\u00edas de Heparina y otros formularios farmac\u00e9uticos. En octubre de 2008, se decidi\u00f3 revisar las monograf\u00edas de Heparina para alinearlas con otras farmacopeas. Durante una consulta informal en junio de 2009, se sugiri\u00f3 investigar un m\u00e9todo de electroforesis en placa de acetato de celulosa para analizar la heparina y sus impurezas. Este m\u00e9todo podr\u00eda ser \u00fatil para laboratorios de control de calidad de bajo costo. Adem\u00e1s, se acord\u00f3 revisar las monograf\u00edas generales de formas de dosificaci\u00f3n, como tabletas y c\u00e1psulas, siguiendo un nuevo \"template\" para su revisi\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 m\u00e9todo se propuso para el an\u00e1lisis de heparina y cu\u00e1les son sus ventajas en comparaci\u00f3n con los m\u00e9todos tradicionales?**\n   - Se propuso un m\u00e9todo de electroforesis en placa de acetato de celulosa, que tiene alta selectividad para impurezas heparinoides y puede realizarse con instrumentaci\u00f3n de bajo costo, lo que lo hace accesible para peque\u00f1os laboratorios de control de calidad.\n\n2. **\u00bfQu\u00e9 cambios se acordaron para las monograf\u00edas de tabletas y c\u00e1psulas durante la reuni\u00f3n de la Comisi\u00f3n de Expertos?**\n   - Se acord\u00f3 que, tras la revisi\u00f3n de la monograf\u00eda de tabletas, se realizar\u00eda una revisi\u00f3n similar para la monograf\u00eda de c\u00e1psulas. Las monograf\u00edas revisadas fueron adoptadas, sujeta a la inclusi\u00f3n de cambios acordados basados en comentarios recibidos durante la consulta p\u00fablica.\n\n3. **\u00bfCu\u00e1l fue el prop\u00f3sito de la colaboraci\u00f3n entre la Secretar\u00eda de la OMS y un laboratorio colaborador en relaci\u00f3n con las monograf\u00edas de Heparina?**\n   - El prop\u00f3sito fue revisar la idoneidad del m\u00e9todo propuesto para su inclusi\u00f3n en la Farmacopea Internacional (Ph.Int.) y circular propuestas de borrador revisadas de las monograf\u00edas de Heparina para comentarios.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otros documentos, bas\u00e1ndose en los detalles proporcionados en el contexto.", "prev_section_summary": "### Temas Clave\n\n1. **Mebendazole**:\n   - Modificaci\u00f3n de la monograf\u00eda para mejorar la interpretaci\u00f3n de la revisi\u00f3n adoptada en octubre de 2008.\n   - Restricci\u00f3n del uso de Mebendazole a la forma polim\u00f3rfica C en respuesta a la necesidad de armonizaci\u00f3n en programas de erradicaci\u00f3n de lombrices intestinales.\n   - Inter\u00e9s de la USP en armonizar su monograf\u00eda, aunque actualmente no es posible debido a que el producto licenciado en EE. UU. contiene la forma polim\u00f3rfica B.\n\n2. **Oseltamivir fosfato**:\n   - Adopci\u00f3n de la monograf\u00eda en octubre de 2008 para su inclusi\u00f3n en la Cuarta Edici\u00f3n de *The International Pharmacopoeia*.\n   - Propuestas de revisi\u00f3n para armonizar las especificaciones con otras farmacopoeias, enfoc\u00e1ndose en pruebas para cenizas sulfatadas y sustancias relacionadas.\n\n3. **Heparina**:\n   - Revisi\u00f3n r\u00e1pida de las monograf\u00edas de Heparina c\u00e1lcica y Heparina s\u00f3dica en *The International Pharmacopoeia*.\n\n### Entidades\n\n- **Mebendazole**: Medicamento utilizado en programas de erradicaci\u00f3n de lombrices intestinales.\n- **Oseltamivir fosfato**: Medicamento adoptado en la Cuarta Edici\u00f3n de *The International Pharmacopoeia*.\n- **Heparina**: Medicamento con revisiones r\u00e1pidas en sus monograf\u00edas.\n- **Pharmacopoeias**: Incluye la Farmacopea Europea (Ph. Eur), la Farmacopea de los Estados Unidos (USP) y la Farmacopea China.\n- **Expert Committee**: Comit\u00e9 responsable de la adopci\u00f3n de las monograf\u00edas y revisiones.", "excerpt_keywords": "Heparin, pharmacopoeia, electrophoresis, quality control, monographs"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "804459a6-c96c-4c8a-837e-c55638d56148", "node_type": "4", "metadata": {"page_label": "43", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Committee in October 2008 and had been published on the WHO Medicines web site, to bring them into line with the action of other pharmacopoeias concerning Heparin monographs. The statement on the web site indicated that the WHO Expert Committee on Specifications for Pharmaceutical Preparations, together with the WHO Expert Committee on Biological Standardization, would jointly review the scientific work being carried out by interested parties. The need for further revision of the monographs would be examined, and it was noted that discussion on heparin would be held during the next session of the Expert Committee on Biological Standardization.\n\nRevision of the Heparin monographs was also discussed during the informal consultation in June 2009, when it was recommended to investigate the possible inclusion of a cellulose acetate plate electrophoresis method for the analysis of heparin and its potential glycosaminoglycan impurities, e.g. dermatan sulfate, chondroitin sulfate and oversulfated chondroitin sulfate.\n\nThis method, routinely used in industry, had been shown to have a high selectivity for heparinoid impurities and could be performed with low-cost instrumentation. Therefore, this method could be beneficial for small quality control laboratories not equipped for the compendial HPLC methods.\n\nThe Expert Committee endorsed the recommendation that the Secretariat, in collaboration with a WHO collaborating laboratory, review the suitability of this proposed method for inclusion in the Ph.Int. and circulate revised draft proposals of the Heparin monographs for comment.\n\n### 3.5 Review of published general monographs for dosage forms\n\nAt its meeting in 2007, the Expert Committee agreed that the general monographs published in Volume 2 of *The International Pharmacopoeia* should be reviewed and revised as necessary, to follow a general monograph \u201ctemplate\u201d that had been prepared, based on the texts adopted for inclusion in the first supplement.\n\nFollowing the defined template, a draft revision of the general monograph for Tablets was discussed at the informal consultation in June 2009. It was then recommended that, based on the revision of the general monograph for Tablets, a similar revision should be done of the monograph for Capsules. Revised texts for the following monographs were presented to the Expert Committee for discussion. The revised monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during the discussion:\n\n- Tablets\n- Capsules", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "d00bfbe76f326bf26b4b17bcd849a7e11ee4db46b575c7c0508ff200f4c033b5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Committee in October 2008 and had been published on the WHO Medicines web site, to bring them into line with the action of other pharmacopoeias concerning Heparin monographs. The statement on the web site indicated that the WHO Expert Committee on Specifications for Pharmaceutical Preparations, together with the WHO Expert Committee on Biological Standardization, would jointly review the scientific work being carried out by interested parties. The need for further revision of the monographs would be examined, and it was noted that discussion on heparin would be held during the next session of the Expert Committee on Biological Standardization.\n\nRevision of the Heparin monographs was also discussed during the informal consultation in June 2009, when it was recommended to investigate the possible inclusion of a cellulose acetate plate electrophoresis method for the analysis of heparin and its potential glycosaminoglycan impurities, e.g. dermatan sulfate, chondroitin sulfate and oversulfated chondroitin sulfate.\n\nThis method, routinely used in industry, had been shown to have a high selectivity for heparinoid impurities and could be performed with low-cost instrumentation. Therefore, this method could be beneficial for small quality control laboratories not equipped for the compendial HPLC methods.\n\nThe Expert Committee endorsed the recommendation that the Secretariat, in collaboration with a WHO collaborating laboratory, review the suitability of this proposed method for inclusion in the Ph.Int. and circulate revised draft proposals of the Heparin monographs for comment.\n\n### 3.5 Review of published general monographs for dosage forms\n\nAt its meeting in 2007, the Expert Committee agreed that the general monographs published in Volume 2 of *The International Pharmacopoeia* should be reviewed and revised as necessary, to follow a general monograph \u201ctemplate\u201d that had been prepared, based on the texts adopted for inclusion in the first supplement.\n\nFollowing the defined template, a draft revision of the general monograph for Tablets was discussed at the informal consultation in June 2009. It was then recommended that, based on the revision of the general monograph for Tablets, a similar revision should be done of the monograph for Capsules. Revised texts for the following monographs were presented to the Expert Committee for discussion. The revised monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during the discussion:\n\n- Tablets\n- Capsules", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2571, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9acd9313-4de3-4f9d-8bd7-e1e14949f095": {"__data__": {"id_": "9acd9313-4de3-4f9d-8bd7-e1e14949f095", "embedding": null, "metadata": {"page_label": "44", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 3.6 General policy topics and general revision issues\n\nSeveral documents including guidance and explanation of the current pharmacopoeial approach as well as a review of application to published monographs for the following general revision issues were presented to the Expert Committee for consideration:\n\n- monographs title and strengths\n- strengths available statement\n- identity tests\n- polymorphism\n\nThe Committee discussed the background documents, endorsed the explanatory texts as summarized below and adopted the proposed revisions of the relevant monographs. It further agreed that, as a basis for a future policy, these guidance documents and explanatory texts would be helpful to assist those involved in the development of new and revised monographs. In this respect, the guidance documents might also be made available more widely to provide explanatory information to users of the Ph.Int. by inclusion in the Supplementary information section of the Pharmacopoeia and on the WHO Medicines web site.\n\n## Monographs title and strengths\n\n### Titles\n\nIt was noted that for older monographs the full name of the API was normally included for the dosage form (e.g. Atropine sulfate tablets). In more recent monographs (new texts or revisions) the name of the salt was, whenever possible, usually omitted. There were, however, inconsistencies, e.g. Nelfinavir mesilate tablets.\n\nFollowing the recommendation of the informal consultation in June 2009, the Expert Committee agreed that a standardized approach should be followed within *The International Pharmacopoeia*, which was to use the shortest title consistent with providing unambiguous information on the nature of the API. Such an approach was designed to facilitate the use of the monograph title for nonproprietary labelling and generic prescribing.\n\nThe titles of the following draft monographs presented to the Expert Committee illustrated this approach:\n\n- Indinavir capsules (API \u2014 indinavir sulfate)\n- Saquinavir tablets (API \u2014 saquinavir mesilate)\n- Tenofovir tablets (API \u2014 tenofovir disoproxil fumarate)\n- Amikacin injection (API \u2014 amikacin sulfate)\n\nThe Expert Committee endorsed the proposal that any change to the title agreed for published monographs could be made either when a monograph", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Revisi\u00f3n de monograf\u00edas en la Farmacopea Internacional**: El Comit\u00e9 de Expertos revis\u00f3 varios documentos relacionados con la pol\u00edtica farmacop\u00e9ica actual y discuti\u00f3 temas generales de revisi\u00f3n, incluyendo t\u00edtulos de monograf\u00edas, declaraciones de disponibilidad de fortalezas, pruebas de identidad y polimorfismo.\n\n2. **Estandarizaci\u00f3n de t\u00edtulos de monograf\u00edas**: Se acord\u00f3 que las monograf\u00edas m\u00e1s recientes deber\u00edan seguir un enfoque estandarizado en la titulaci\u00f3n, utilizando el nombre m\u00e1s corto posible del principio activo (API) para facilitar el etiquetado no propietario y la prescripci\u00f3n gen\u00e9rica.\n\n3. **Propuestas de cambios en monograf\u00edas**: El Comit\u00e9 aprob\u00f3 propuestas para cambios en los t\u00edtulos de las monograf\u00edas publicadas, enfatizando la importancia de la claridad y la consistencia en la nomenclatura de los productos farmac\u00e9uticos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1l es el enfoque estandarizado acordado por el Comit\u00e9 de Expertos para la titulaci\u00f3n de las monograf\u00edas en la Farmacopea Internacional?**\n   - El enfoque estandarizado consiste en utilizar el t\u00edtulo m\u00e1s corto posible que proporcione informaci\u00f3n clara y no ambigua sobre la naturaleza del principio activo (API), omitiendo el nombre de la sal siempre que sea posible.\n\n2. **\u00bfQu\u00e9 ejemplos de t\u00edtulos de monograf\u00edas se presentaron al Comit\u00e9 de Expertos para ilustrar el enfoque estandarizado?**\n   - Los ejemplos presentados incluyen: Indinavir c\u00e1psulas (API \u2014 indinavir sulfate), Saquinavir tabletas (API \u2014 saquinavir mesilate), Tenofovir tabletas (API \u2014 tenofovir disoproxil fumarate) y Amikacin inyecci\u00f3n (API \u2014 amikacin sulfate).\n\n3. **\u00bfQu\u00e9 se acord\u00f3 respecto a la disponibilidad de documentos de orientaci\u00f3n y textos explicativos para el desarrollo de nuevas monograf\u00edas?**\n   - Se acord\u00f3 que los documentos de orientaci\u00f3n y textos explicativos ser\u00edan \u00fatiles para aquellos involucrados en el desarrollo de nuevas y revisadas monograf\u00edas, y se propuso que estos documentos se hicieran m\u00e1s accesibles a trav\u00e9s de la secci\u00f3n de informaci\u00f3n suplementaria de la Farmacopea y en el sitio web de Medicamentos de la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Revisi\u00f3n de Monograf\u00edas de Heparina**:\n   - La Comisi\u00f3n de Expertos de la OMS decidi\u00f3 en octubre de 2008 revisar las monograf\u00edas de Heparina para alinearlas con otras farmacopeas.\n   - Se discuti\u00f3 la necesidad de revisar las monograf\u00edas en una consulta informal en junio de 2009.\n\n2. **M\u00e9todo Propuesto para An\u00e1lisis de Heparina**:\n   - Se recomend\u00f3 investigar un m\u00e9todo de electroforesis en placa de acetato de celulosa para el an\u00e1lisis de heparina y sus impurezas.\n   - Este m\u00e9todo es altamente selectivo para impurezas heparinoides y puede ser realizado con instrumentaci\u00f3n de bajo costo, lo que lo hace accesible para peque\u00f1os laboratorios de control de calidad.\n\n3. **Colaboraci\u00f3n de la OMS**:\n   - La Secretar\u00eda de la OMS colaborar\u00e1 con un laboratorio colaborador para revisar la idoneidad del m\u00e9todo propuesto y circular propuestas revisadas de las monograf\u00edas de Heparina para comentarios.\n\n4. **Revisi\u00f3n de Monograf\u00edas Generales de Formas de Dosificaci\u00f3n**:\n   - En 2007, se acord\u00f3 revisar las monograf\u00edas generales publicadas en el Volumen 2 de *The International Pharmacopoeia*.\n   - Se discuti\u00f3 una revisi\u00f3n de la monograf\u00eda de tabletas en junio de 2009, y se recomend\u00f3 realizar una revisi\u00f3n similar para la monograf\u00eda de c\u00e1psulas.\n   - Las monograf\u00edas revisadas fueron adoptadas, sujetas a cambios acordados basados en comentarios de la consulta p\u00fablica.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la revisi\u00f3n y establecimiento de est\u00e1ndares farmac\u00e9uticos.\n- **Heparina**: Anticoagulante cuyo an\u00e1lisis y monograf\u00edas est\u00e1n siendo revisados.\n- **Electroforesis en placa de acetato de celulosa**: M\u00e9todo propuesto para el an\u00e1lisis de heparina.\n- **Monograf\u00edas de Formas de Dosificaci\u00f3n**: Incluyen las de tabletas y c\u00e1psulas, que est\u00e1n siendo revisadas y actualizadas.", "excerpt_keywords": "Keywords: pharmacopoeia, monographs, standardization, active pharmaceutical ingredient, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "584416c7-dcca-4b4a-a673-cd90298d7c83", "node_type": "4", "metadata": {"page_label": "44", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 3.6 General policy topics and general revision issues\n\nSeveral documents including guidance and explanation of the current pharmacopoeial approach as well as a review of application to published monographs for the following general revision issues were presented to the Expert Committee for consideration:\n\n- monographs title and strengths\n- strengths available statement\n- identity tests\n- polymorphism\n\nThe Committee discussed the background documents, endorsed the explanatory texts as summarized below and adopted the proposed revisions of the relevant monographs. It further agreed that, as a basis for a future policy, these guidance documents and explanatory texts would be helpful to assist those involved in the development of new and revised monographs. In this respect, the guidance documents might also be made available more widely to provide explanatory information to users of the Ph.Int. by inclusion in the Supplementary information section of the Pharmacopoeia and on the WHO Medicines web site.\n\n## Monographs title and strengths\n\n### Titles\n\nIt was noted that for older monographs the full name of the API was normally included for the dosage form (e.g. Atropine sulfate tablets). In more recent monographs (new texts or revisions) the name of the salt was, whenever possible, usually omitted. There were, however, inconsistencies, e.g. Nelfinavir mesilate tablets.\n\nFollowing the recommendation of the informal consultation in June 2009, the Expert Committee agreed that a standardized approach should be followed within *The International Pharmacopoeia*, which was to use the shortest title consistent with providing unambiguous information on the nature of the API. Such an approach was designed to facilitate the use of the monograph title for nonproprietary labelling and generic prescribing.\n\nThe titles of the following draft monographs presented to the Expert Committee illustrated this approach:\n\n- Indinavir capsules (API \u2014 indinavir sulfate)\n- Saquinavir tablets (API \u2014 saquinavir mesilate)\n- Tenofovir tablets (API \u2014 tenofovir disoproxil fumarate)\n- Amikacin injection (API \u2014 amikacin sulfate)\n\nThe Expert Committee endorsed the proposal that any change to the title agreed for published monographs could be made either when a monograph", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "9d60aaeb343abd58fff0e555872b22b29baf6946c6041dc1fde7346de61d21c4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 3.6 General policy topics and general revision issues\n\nSeveral documents including guidance and explanation of the current pharmacopoeial approach as well as a review of application to published monographs for the following general revision issues were presented to the Expert Committee for consideration:\n\n- monographs title and strengths\n- strengths available statement\n- identity tests\n- polymorphism\n\nThe Committee discussed the background documents, endorsed the explanatory texts as summarized below and adopted the proposed revisions of the relevant monographs. It further agreed that, as a basis for a future policy, these guidance documents and explanatory texts would be helpful to assist those involved in the development of new and revised monographs. In this respect, the guidance documents might also be made available more widely to provide explanatory information to users of the Ph.Int. by inclusion in the Supplementary information section of the Pharmacopoeia and on the WHO Medicines web site.\n\n## Monographs title and strengths\n\n### Titles\n\nIt was noted that for older monographs the full name of the API was normally included for the dosage form (e.g. Atropine sulfate tablets). In more recent monographs (new texts or revisions) the name of the salt was, whenever possible, usually omitted. There were, however, inconsistencies, e.g. Nelfinavir mesilate tablets.\n\nFollowing the recommendation of the informal consultation in June 2009, the Expert Committee agreed that a standardized approach should be followed within *The International Pharmacopoeia*, which was to use the shortest title consistent with providing unambiguous information on the nature of the API. Such an approach was designed to facilitate the use of the monograph title for nonproprietary labelling and generic prescribing.\n\nThe titles of the following draft monographs presented to the Expert Committee illustrated this approach:\n\n- Indinavir capsules (API \u2014 indinavir sulfate)\n- Saquinavir tablets (API \u2014 saquinavir mesilate)\n- Tenofovir tablets (API \u2014 tenofovir disoproxil fumarate)\n- Amikacin injection (API \u2014 amikacin sulfate)\n\nThe Expert Committee endorsed the proposal that any change to the title agreed for published monographs could be made either when a monograph", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2270, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8e0fc01d-8be2-47ed-9481-91c724e6e35d": {"__data__": {"id_": "8e0fc01d-8be2-47ed-9481-91c724e6e35d", "embedding": null, "metadata": {"page_label": "45", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "was revised for technical reasons or on publication of a new edition. At such a time, where necessary, the heading Definition would be added together with a statement clarifying the nature of the API used in preparing the dosage form and the Labelling statement would be checked for consistency.\n\n## Strengths\n\nHow the strength was stated in monographs, and hence the terms in which the content was calculated, was dictated by how products available on the market were labelled. The Committee agreed that having established how the content was declared on the label by the manufacturer and having included in monographs an appropriate labelling statement, where necessary, the content statement under Definition, the calculation under Assay and the amounts of the preparation taken for testing should all be expressed in the same way.\n\nIt was noted, however, that problems could arise when product labelling was not clear or where there were inconsistencies between products available on the market. Although it was recognized that neither pharmacopoeial authorities nor WHO had control over product labelling and that this would fall within the responsibility of MRAs, the Committee was informed that a document gathering proposals concerning dosage form terminology and expression of medicine strength was presented by QSM to the Expert Committee for the Selection and Use of Essential Medicines for discussion at its meeting in March 2009.\n\nThe Expert Committee welcomed this initiative and was pleased to note that the Expert Committee for the Selection and Use of Essential Medicines broadly endorsed the QSM proposals. As a consequence, the expanded explanatory notes included in the sixteenth WHO Model List of Essential Medicines and in the second WHO Model List of Essential Medicines for Children now included:\n\n- a link to the Quality assurance area of the WHO Medicines web site and to the online text of the current edition of the Ph.Int.; and\n- an annex on dosage form terminology.\n\nThe Expert Committee for the Selection and Use of Essential Medicines agreed the principles that would be applied to the expression of medicines strengths in future lists and had requested its Secretariat to review current entries and revise them accordingly. These principles were set out in the corresponding Report of the Expert Committee for the Selection and Use of Essential Medicines. WHO Technical Report Series, No. 958, 2010 (in print) as follows.\n\nWhen revised in accordance with these principles, entries where the active pharmaceutical substance is not the active moiety will more clearly distinguish between:", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Preguntas\n\n1. **\u00bfCu\u00e1les son los problemas que pueden surgir debido a la falta de claridad en el etiquetado de los productos farmac\u00e9uticos?**\n   - La falta de claridad en el etiquetado puede llevar a inconsistencias entre los productos disponibles en el mercado, lo que dificulta la correcta interpretaci\u00f3n de la fuerza y el contenido de los medicamentos. Esto puede resultar en confusiones para los profesionales de la salud y los pacientes, afectando la seguridad y eficacia del tratamiento.\n\n2. **\u00bfQu\u00e9 iniciativas se tomaron en respuesta a las propuestas de QSM sobre la terminolog\u00eda de formas de dosificaci\u00f3n y la expresi\u00f3n de la fuerza de los medicamentos?**\n   - La iniciativa presentada por QSM fue bien recibida por el Comit\u00e9 de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales, que la respald\u00f3. Como resultado, se incluyeron notas explicativas ampliadas en la lista de medicamentos esenciales de la OMS, as\u00ed como un anexo sobre la terminolog\u00eda de formas de dosificaci\u00f3n, y se establecieron principios para la expresi\u00f3n de la fuerza de los medicamentos en futuras listas.\n\n3. **\u00bfQu\u00e9 acciones se solicitaron al Secretariado del Comit\u00e9 de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales?**\n   - Se solicit\u00f3 al Secretariado que revisara las entradas actuales en las listas de medicamentos y las revisara de acuerdo con los principios acordados para la expresi\u00f3n de las fuerzas de los medicamentos, asegurando as\u00ed una mayor claridad y consistencia en la informaci\u00f3n presentada.\n\n### Resumen de nivel superior\n\nEl contexto aborda la importancia de la claridad en el etiquetado de los productos farmac\u00e9uticos y c\u00f3mo esto afecta la declaraci\u00f3n de la fuerza y el contenido de los medicamentos. Se menciona que, aunque las autoridades farmacop\u00e9uticas y la OMS no tienen control sobre el etiquetado de los productos, se han tomado iniciativas para mejorar la terminolog\u00eda y la expresi\u00f3n de la fuerza de los medicamentos. Estas iniciativas fueron bien recibidas por el Comit\u00e9 de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales, que acord\u00f3 principios para la revisi\u00f3n y actualizaci\u00f3n de las listas de medicamentos esenciales.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Revisi\u00f3n de Monograf\u00edas**: El Comit\u00e9 de Expertos revis\u00f3 documentos relacionados con la pol\u00edtica farmacop\u00e9ica actual, enfoc\u00e1ndose en temas como t\u00edtulos de monograf\u00edas, declaraciones de disponibilidad de fortalezas, pruebas de identidad y polimorfismo.\n\n2. **Estandarizaci\u00f3n de T\u00edtulos**: Se acord\u00f3 un enfoque estandarizado para la titulaci\u00f3n de monograf\u00edas en *La Farmacopea Internacional*, que consiste en utilizar el t\u00edtulo m\u00e1s corto posible que proporcione informaci\u00f3n clara sobre el principio activo (API), omitiendo el nombre de la sal cuando sea posible.\n\n3. **Ejemplos de T\u00edtulos**: Se presentaron ejemplos de t\u00edtulos de monograf\u00edas que ilustran este enfoque estandarizado:\n   - Indinavir c\u00e1psulas (API \u2014 indinavir sulfate)\n   - Saquinavir tabletas (API \u2014 saquinavir mesilate)\n   - Tenofovir tabletas (API \u2014 tenofovir disoproxil fumarate)\n   - Amikacin inyecci\u00f3n (API \u2014 amikacin sulfate)\n\n4. **Documentos de Orientaci\u00f3n**: Se acord\u00f3 que los documentos de orientaci\u00f3n y textos explicativos ser\u00edan \u00fatiles para el desarrollo de nuevas y revisadas monograf\u00edas, y se propuso su disponibilidad en la secci\u00f3n de informaci\u00f3n suplementaria de la Farmacopea y en el sitio web de Medicamentos de la OMS.\n\n### Entidades Clave\n- **Comit\u00e9 de Expertos**: Grupo responsable de revisar y aprobar cambios en las monograf\u00edas.\n- **Farmacopea Internacional**: Documento que contiene est\u00e1ndares para medicamentos.\n- **Principio Activo (API)**: Sustancia activa en un medicamento.\n- **Monograf\u00edas**: Documentos que describen las especificaciones y m\u00e9todos de prueba para medicamentos.", "excerpt_keywords": "Keywords: pharmaceutical labeling, dosage form terminology, medicine strength, WHO Essential Medicines, pharmacopoeial standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "700c8bcd-c2f6-4aaf-ba88-e1038a238807", "node_type": "4", "metadata": {"page_label": "45", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "was revised for technical reasons or on publication of a new edition. At such a time, where necessary, the heading Definition would be added together with a statement clarifying the nature of the API used in preparing the dosage form and the Labelling statement would be checked for consistency.\n\n## Strengths\n\nHow the strength was stated in monographs, and hence the terms in which the content was calculated, was dictated by how products available on the market were labelled. The Committee agreed that having established how the content was declared on the label by the manufacturer and having included in monographs an appropriate labelling statement, where necessary, the content statement under Definition, the calculation under Assay and the amounts of the preparation taken for testing should all be expressed in the same way.\n\nIt was noted, however, that problems could arise when product labelling was not clear or where there were inconsistencies between products available on the market. Although it was recognized that neither pharmacopoeial authorities nor WHO had control over product labelling and that this would fall within the responsibility of MRAs, the Committee was informed that a document gathering proposals concerning dosage form terminology and expression of medicine strength was presented by QSM to the Expert Committee for the Selection and Use of Essential Medicines for discussion at its meeting in March 2009.\n\nThe Expert Committee welcomed this initiative and was pleased to note that the Expert Committee for the Selection and Use of Essential Medicines broadly endorsed the QSM proposals. As a consequence, the expanded explanatory notes included in the sixteenth WHO Model List of Essential Medicines and in the second WHO Model List of Essential Medicines for Children now included:\n\n- a link to the Quality assurance area of the WHO Medicines web site and to the online text of the current edition of the Ph.Int.; and\n- an annex on dosage form terminology.\n\nThe Expert Committee for the Selection and Use of Essential Medicines agreed the principles that would be applied to the expression of medicines strengths in future lists and had requested its Secretariat to review current entries and revise them accordingly. These principles were set out in the corresponding Report of the Expert Committee for the Selection and Use of Essential Medicines. WHO Technical Report Series, No. 958, 2010 (in print) as follows.\n\nWhen revised in accordance with these principles, entries where the active pharmaceutical substance is not the active moiety will more clearly distinguish between:", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "d73719dd76ee082e8cbf0525965b402f38ab2dd26ce66955cc0671a583a2352b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "was revised for technical reasons or on publication of a new edition. At such a time, where necessary, the heading Definition would be added together with a statement clarifying the nature of the API used in preparing the dosage form and the Labelling statement would be checked for consistency.\n\n## Strengths\n\nHow the strength was stated in monographs, and hence the terms in which the content was calculated, was dictated by how products available on the market were labelled. The Committee agreed that having established how the content was declared on the label by the manufacturer and having included in monographs an appropriate labelling statement, where necessary, the content statement under Definition, the calculation under Assay and the amounts of the preparation taken for testing should all be expressed in the same way.\n\nIt was noted, however, that problems could arise when product labelling was not clear or where there were inconsistencies between products available on the market. Although it was recognized that neither pharmacopoeial authorities nor WHO had control over product labelling and that this would fall within the responsibility of MRAs, the Committee was informed that a document gathering proposals concerning dosage form terminology and expression of medicine strength was presented by QSM to the Expert Committee for the Selection and Use of Essential Medicines for discussion at its meeting in March 2009.\n\nThe Expert Committee welcomed this initiative and was pleased to note that the Expert Committee for the Selection and Use of Essential Medicines broadly endorsed the QSM proposals. As a consequence, the expanded explanatory notes included in the sixteenth WHO Model List of Essential Medicines and in the second WHO Model List of Essential Medicines for Children now included:\n\n- a link to the Quality assurance area of the WHO Medicines web site and to the online text of the current edition of the Ph.Int.; and\n- an annex on dosage form terminology.\n\nThe Expert Committee for the Selection and Use of Essential Medicines agreed the principles that would be applied to the expression of medicines strengths in future lists and had requested its Secretariat to review current entries and revise them accordingly. These principles were set out in the corresponding Report of the Expert Committee for the Selection and Use of Essential Medicines. WHO Technical Report Series, No. 958, 2010 (in print) as follows.\n\nWhen revised in accordance with these principles, entries where the active pharmaceutical substance is not the active moiety will more clearly distinguish between:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2619, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d1a9e091-e658-41fd-92df-188519ad0fe5": {"__data__": {"id_": "d1a9e091-e658-41fd-92df-188519ad0fe5", "embedding": null, "metadata": {"page_label": "46", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- those for which the strength is expressed in terms of active moiety (the salt will be indicated in parentheses, e.g. \u201c50 mg (as sodium salt)\u201d); and\n- those for which the strength is expressed in terms of API (the salt will be given in full, e.g. \u201c50 mg codeine phosphate\u201d).\n\nWhere necessary, in instances of potential confusion (e.g. amodiaquine, quinine salts) a warning note will be included.\n\n## Strengths available statement\n\nMonographs in the Ph.Int. for individual dosage forms have included information concerning the strengths of preparations available, referring to \u201cthe current WHO Model List of Essential Medicines\u201d. For example, the monograph for Lamivudine tablets published in the first supplement stated:\n\n**Additional information.** Strengths in the current WHO Model List of Essential Medicines: 150 mg, 300 mg. Strength in the current WHO Model list of essential medicines for children: 150 mg.\n\nThis statement was based on information from the fifteenth Model List of Essential Medicines published in 2007. It was, however, noted in 2009 that for lamivudine the then current Model List included only the 150 mg tablets. This example, therefore, illustrated the problem of keeping the strengths available as indicated in Ph.Int. monographs in step with the current Model List of Essential Medicines.\n\nTo keep track of changes affecting Ph.Int. monographs each time a new Model List was published would require the user to check for changes frequently, and the Secretariat to continuously revise monographs to correct this non-mandatory information.\n\nThe Expert Committee, therefore, endorsed the recommendation that, for the next edition of *The International Pharmacopoeia*, individual monographs would simply include the strengths without the words \u201cin the current WHO Model List of Essential Medicines\u201d. It was agreed instead that the General notices would state that, in general, the strengths indicated under Additional information in individual monographs for dosage forms were those given in the Model Lists. In addition a recommendation could be included to consult the current edition of the Model List and provide a reference to the appropriate page of the WHO Medicines web site (as a link in the electronic version). This would also strengthen the links between the Ph.Int. and the WHO Model List of Essential Medicines (http://www.who.int/medicines/publications/essentialmedicines/en/index.html).\n\nUsing terms such as \u201cin general\u201d or \u201cwherever appropriate\u201d in the General notices would accommodate the small number of exceptions where a", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Preguntas\n\n1. **\u00bfCu\u00e1l es la raz\u00f3n principal por la que se decidi\u00f3 eliminar la frase \"en la lista actual de medicamentos esenciales de la OMS\" de las monograf\u00edas individuales en la pr\u00f3xima edici\u00f3n de *The International Pharmacopoeia*?**\n   - La decisi\u00f3n se tom\u00f3 para evitar la confusi\u00f3n y la necesidad de revisiones constantes de las monograf\u00edas, ya que las listas de medicamentos esenciales pueden cambiar con frecuencia. Esto simplifica el proceso y asegura que la informaci\u00f3n sea m\u00e1s f\u00e1cil de seguir para los usuarios.\n\n2. **\u00bfQu\u00e9 medidas se proponen para mantener la conexi\u00f3n entre las monograf\u00edas de la Ph.Int. y la lista de medicamentos esenciales de la OMS?**\n   - Se recomienda que las monograf\u00edas incluyan una referencia a consultar la edici\u00f3n actual de la lista de medicamentos esenciales, proporcionando un enlace a la p\u00e1gina web de la OMS. Esto fortalecer\u00eda la relaci\u00f3n entre ambas fuentes de informaci\u00f3n.\n\n3. **\u00bfC\u00f3mo se abordar\u00e1 la confusi\u00f3n potencial en la nomenclatura de las sales de ciertos medicamentos, como la amodiaquina y la quinina?**\n   - Se incluir\u00e1n notas de advertencia donde sea necesario para aclarar cualquier posible confusi\u00f3n relacionada con las sales de estos medicamentos en las monograf\u00edas.\n\n### Resumen de nivel superior\n\nEl contexto aborda la necesidad de actualizar las monograf\u00edas en *The International Pharmacopoeia* para reflejar de manera m\u00e1s precisa las fortalezas de los medicamentos, aline\u00e1ndolas con la lista de medicamentos esenciales de la OMS. Se destaca el problema de mantener la informaci\u00f3n actualizada y se propone eliminar referencias directas a la lista de medicamentos en las monograf\u00edas, sugiriendo en su lugar que los usuarios consulten la lista actualizada en el sitio web de la OMS. Adem\u00e1s, se menciona la inclusi\u00f3n de notas de advertencia para evitar confusiones en la nomenclatura de ciertos medicamentos.", "prev_section_summary": "### Temas Clave\n\n1. **Claridad en el Etiquetado de Productos Farmac\u00e9uticos**: La secci\u00f3n destaca la importancia de un etiquetado claro para evitar inconsistencias en la declaraci\u00f3n de la fuerza y el contenido de los medicamentos, lo que puede afectar la seguridad y eficacia del tratamiento.\n\n2. **Iniciativas de Mejora**: Se menciona la presentaci\u00f3n de propuestas por parte de QSM sobre la terminolog\u00eda de formas de dosificaci\u00f3n y la expresi\u00f3n de la fuerza de los medicamentos, que fueron bien recibidas por el Comit\u00e9 de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales.\n\n3. **Principios para la Expresi\u00f3n de Fuerzas de Medicamentos**: Se acordaron principios que se aplicar\u00e1n a la expresi\u00f3n de las fuerzas de los medicamentos en futuras listas, con el objetivo de mejorar la claridad y consistencia en la informaci\u00f3n presentada.\n\n4. **Revisi\u00f3n de Entradas Actuales**: Se solicit\u00f3 al Secretariado del Comit\u00e9 de Expertos que revisara y actualizara las entradas actuales en las listas de medicamentos de acuerdo con los nuevos principios acordados.\n\n### Entidades\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: La entidad responsable de la regulaci\u00f3n y estandarizaci\u00f3n de medicamentos a nivel internacional.\n- **QSM (Quality Safety and Standards)**: Grupo que present\u00f3 propuestas sobre terminolog\u00eda y expresi\u00f3n de fuerza de medicamentos.\n- **Comit\u00e9 de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales**: Grupo que revisa y aprueba las propuestas relacionadas con medicamentos esenciales.\n- **MRAs (Medicines Regulatory Authorities)**: Autoridades responsables del etiquetado de productos farmac\u00e9uticos, que no est\u00e1n bajo el control de la OMS.\n\n### Resumen\n\nLa secci\u00f3n aborda la necesidad de claridad en el etiquetado de productos farmac\u00e9uticos para asegurar la correcta interpretaci\u00f3n de la fuerza y el contenido de los medicamentos. Se mencionan iniciativas para mejorar la terminolog\u00eda y la expresi\u00f3n de la fuerza de los medicamentos, respaldadas por el Comit\u00e9 de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales. Adem\u00e1s, se establecieron principios para la revisi\u00f3n de las listas de medicamentos esenciales, con el fin de garantizar una mayor consistencia y claridad en la informaci\u00f3n presentada.", "excerpt_keywords": "Pharmacopoeia, Essential Medicines, Strengths, Monographs, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "33e87ffe-8582-444e-ac41-074aaf786654", "node_type": "4", "metadata": {"page_label": "46", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- those for which the strength is expressed in terms of active moiety (the salt will be indicated in parentheses, e.g. \u201c50 mg (as sodium salt)\u201d); and\n- those for which the strength is expressed in terms of API (the salt will be given in full, e.g. \u201c50 mg codeine phosphate\u201d).\n\nWhere necessary, in instances of potential confusion (e.g. amodiaquine, quinine salts) a warning note will be included.\n\n## Strengths available statement\n\nMonographs in the Ph.Int. for individual dosage forms have included information concerning the strengths of preparations available, referring to \u201cthe current WHO Model List of Essential Medicines\u201d. For example, the monograph for Lamivudine tablets published in the first supplement stated:\n\n**Additional information.** Strengths in the current WHO Model List of Essential Medicines: 150 mg, 300 mg. Strength in the current WHO Model list of essential medicines for children: 150 mg.\n\nThis statement was based on information from the fifteenth Model List of Essential Medicines published in 2007. It was, however, noted in 2009 that for lamivudine the then current Model List included only the 150 mg tablets. This example, therefore, illustrated the problem of keeping the strengths available as indicated in Ph.Int. monographs in step with the current Model List of Essential Medicines.\n\nTo keep track of changes affecting Ph.Int. monographs each time a new Model List was published would require the user to check for changes frequently, and the Secretariat to continuously revise monographs to correct this non-mandatory information.\n\nThe Expert Committee, therefore, endorsed the recommendation that, for the next edition of *The International Pharmacopoeia*, individual monographs would simply include the strengths without the words \u201cin the current WHO Model List of Essential Medicines\u201d. It was agreed instead that the General notices would state that, in general, the strengths indicated under Additional information in individual monographs for dosage forms were those given in the Model Lists. In addition a recommendation could be included to consult the current edition of the Model List and provide a reference to the appropriate page of the WHO Medicines web site (as a link in the electronic version). This would also strengthen the links between the Ph.Int. and the WHO Model List of Essential Medicines (http://www.who.int/medicines/publications/essentialmedicines/en/index.html).\n\nUsing terms such as \u201cin general\u201d or \u201cwherever appropriate\u201d in the General notices would accommodate the small number of exceptions where a", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "28fff5ac3adf74f2b5101f8f6312434d421a77ab0d97d6acf508b39260090c2d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- those for which the strength is expressed in terms of active moiety (the salt will be indicated in parentheses, e.g. \u201c50 mg (as sodium salt)\u201d); and\n- those for which the strength is expressed in terms of API (the salt will be given in full, e.g. \u201c50 mg codeine phosphate\u201d).\n\nWhere necessary, in instances of potential confusion (e.g. amodiaquine, quinine salts) a warning note will be included.\n\n## Strengths available statement\n\nMonographs in the Ph.Int. for individual dosage forms have included information concerning the strengths of preparations available, referring to \u201cthe current WHO Model List of Essential Medicines\u201d. For example, the monograph for Lamivudine tablets published in the first supplement stated:\n\n**Additional information.** Strengths in the current WHO Model List of Essential Medicines: 150 mg, 300 mg. Strength in the current WHO Model list of essential medicines for children: 150 mg.\n\nThis statement was based on information from the fifteenth Model List of Essential Medicines published in 2007. It was, however, noted in 2009 that for lamivudine the then current Model List included only the 150 mg tablets. This example, therefore, illustrated the problem of keeping the strengths available as indicated in Ph.Int. monographs in step with the current Model List of Essential Medicines.\n\nTo keep track of changes affecting Ph.Int. monographs each time a new Model List was published would require the user to check for changes frequently, and the Secretariat to continuously revise monographs to correct this non-mandatory information.\n\nThe Expert Committee, therefore, endorsed the recommendation that, for the next edition of *The International Pharmacopoeia*, individual monographs would simply include the strengths without the words \u201cin the current WHO Model List of Essential Medicines\u201d. It was agreed instead that the General notices would state that, in general, the strengths indicated under Additional information in individual monographs for dosage forms were those given in the Model Lists. In addition a recommendation could be included to consult the current edition of the Model List and provide a reference to the appropriate page of the WHO Medicines web site (as a link in the electronic version). This would also strengthen the links between the Ph.Int. and the WHO Model List of Essential Medicines (http://www.who.int/medicines/publications/essentialmedicines/en/index.html).\n\nUsing terms such as \u201cin general\u201d or \u201cwherever appropriate\u201d in the General notices would accommodate the small number of exceptions where a", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2569, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "aeebc430-b39f-4112-aac5-9a9378f8df5d": {"__data__": {"id_": "aeebc430-b39f-4112-aac5-9a9378f8df5d", "embedding": null, "metadata": {"page_label": "47", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "preparation that was the subject of a monograph was not included in the current Model Lists. Such exceptions included:\n\n- certain preparations recommended by WHO treatment programmes and/or included in WHO treatment guidelines that were not in the Model Lists (e.g. paediatric didanosine oral liquid);\n- strengths additional to those in the Model List that had been indicated for similar reasons (e.g. 20 mg Zn strength for zinc sulfate tablets); and\n- monographs for products which had been or which might be removed from the Model Lists (e.g. stavudine capsules).\n\nIt was also emphasized that, unless restricted by the Definition to a particular strength, a monograph was intended to cover any strength. In this context it was noted that in certain tests (for example, dissolution) explicit reference to particular strengths might sometimes be necessary.\n\n## Identity test\n\nEditorial guidance on selection, order and possibility for subsidiary choice of identity tests was discussed.\n\nThe current approach, which is to use a combination of different methods within the monograph rather than placing reliance on a single method, was reemphasized. This was particularly important since the Ph.Int. monographs might be applied to material from different manufacturers and by quality control laboratories equipped with different instruments.\n\n## Polymorphism\n\nFor an API known to exist in more than one morphic form, the way to frame the monograph would depend on whether or not it was restricted to a particular polymorph.\n\nIn most cases it was intended that the monograph place no restriction on morphic form. A statement had been included under Additional information to the effect that the substance \u201cmay exhibit polymorphism\u201d. In such cases, where an infrared identity test had been included, appropriate instructions were given on how to proceed (see, e.g. the monograph for Efavirenz). Without such instructions the monograph was, in effect, restricting the substance to the morphic form of the ICRS.\n\n## 3.7 Radiopharmaceuticals\n\nWork on the elaboration of specifications for radiopharmaceuticals was initiated in 2001, with the collaboration of WHO and the International Atomic Energy Agency (IAEA). Following consultations and discussion involving experts from both organizations, agreement was reached that this work would include inter alia the revision of the general monograph in *The International Pharmacopoeia*.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto se centra en la elaboraci\u00f3n de monograf\u00edas para preparaciones farmac\u00e9uticas, destacando excepciones a las listas de modelos de la OMS, la importancia de realizar pruebas de identidad utilizando m\u00faltiples m\u00e9todos, y el manejo de la polimorf\u00eda en sustancias activas. Tambi\u00e9n se menciona el trabajo en curso sobre especificaciones para radiopharmaceuticals, en colaboraci\u00f3n con la Agencia Internacional de Energ\u00eda At\u00f3mica (IAEA).\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de preparaciones farmac\u00e9uticas se excluyen de las listas de modelos de la OMS y por qu\u00e9?**\n   - Respuesta: Se excluyen ciertas preparaciones recomendadas por programas de tratamiento de la OMS, como el didanosina oral l\u00edquida pedi\u00e1trica, as\u00ed como fortalezas adicionales y monograf\u00edas de productos que han sido o podr\u00edan ser eliminados de las listas de modelos.\n\n2. **\u00bfCu\u00e1l es la importancia de utilizar m\u00faltiples m\u00e9todos en las pruebas de identidad seg\u00fan el texto?**\n   - Respuesta: La importancia radica en que las monograf\u00edas de la Farmacopea Internacional pueden aplicarse a materiales de diferentes fabricantes y ser utilizadas por laboratorios de control de calidad que disponen de diferentes instrumentos, lo que requiere un enfoque m\u00e1s robusto que depender de un solo m\u00e9todo.\n\n3. **\u00bfC\u00f3mo se aborda la polimorf\u00eda en las monograf\u00edas de sustancias activas?**\n   - Respuesta: En la mayor\u00eda de los casos, las monograf\u00edas no restringen la forma morfol\u00f3gica de la sustancia, y se incluye una declaraci\u00f3n que indica que la sustancia \"puede exhibir polimorfismo\". Se proporcionan instrucciones espec\u00edficas en casos donde se incluye una prueba de identidad por infrarrojos.\n\n### Resumen de Nivel Superior\n\nEl documento discute la elaboraci\u00f3n de monograf\u00edas para preparaciones farmac\u00e9uticas, subrayando excepciones a las listas de modelos de la OMS, la necesidad de pruebas de identidad diversificadas, y el tratamiento de la polimorf\u00eda en sustancias activas. Tambi\u00e9n se menciona la colaboraci\u00f3n entre la OMS y la IAEA para desarrollar especificaciones para radiopharmaceuticals.", "prev_section_summary": "### Temas Clave\n\n1. **Fortalezas de los Medicamentos**: Se discute c\u00f3mo se expresan las fortalezas de los medicamentos en las monograf\u00edas, diferenciando entre aquellas que se indican en t\u00e9rminos de la moiety activa y aquellas que se expresan en t\u00e9rminos del principio activo (API).\n\n2. **Actualizaci\u00f3n de Monograf\u00edas**: Se aborda la necesidad de mantener actualizadas las monograf\u00edas de *The International Pharmacopoeia* en relaci\u00f3n con la lista de medicamentos esenciales de la OMS, destacando los desaf\u00edos de sincronizar la informaci\u00f3n.\n\n3. **Eliminaci\u00f3n de Frases Confusas**: Se propone eliminar la frase \"en la lista actual de medicamentos esenciales de la OMS\" de las monograf\u00edas para simplificar la informaci\u00f3n y evitar confusiones.\n\n4. **Referencias a la Lista de Medicamentos Esenciales**: Se sugiere que las monograf\u00edas incluyan una recomendaci\u00f3n para consultar la lista actualizada de medicamentos esenciales en el sitio web de la OMS, fortaleciendo as\u00ed la conexi\u00f3n entre ambas fuentes.\n\n5. **Notas de Advertencia**: Se menciona la inclusi\u00f3n de notas de advertencia en casos de potencial confusi\u00f3n, como con las sales de amodiaquina y quinina.\n\n### Entidades\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la publicaci\u00f3n de la lista de medicamentos esenciales y de las monograf\u00edas en *The International Pharmacopoeia*.\n- **Ph.Int. (Farmacopea Internacional)**: Referencia a la Farmacopea Internacional que contiene monograf\u00edas de medicamentos.\n- **Lamivudina**: Ejemplo espec\u00edfico de un medicamento mencionado en el contexto de las fortalezas disponibles.\n- **Modelo de Lista de Medicamentos Esenciales**: Documento que enumera los medicamentos esenciales recomendados por la OMS.\n\n### Resumen\n\nLa secci\u00f3n aborda la necesidad de actualizar las monograf\u00edas en *The International Pharmacopoeia* para reflejar con precisi\u00f3n las fortalezas de los medicamentos, aline\u00e1ndolas con la lista de medicamentos esenciales de la OMS. Se propone eliminar referencias directas a la lista en las monograf\u00edas para simplificar la informaci\u00f3n y se sugiere que los usuarios consulten la lista actualizada en el sitio web de la OMS. Adem\u00e1s, se menciona la inclusi\u00f3n de notas de advertencia para evitar confusiones en la nomenclatura de ciertos medicamentos.", "excerpt_keywords": "Keywords: monographs, WHO, polymorphism, identity tests, radiopharmaceuticals"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "90534af2-e0d8-49e2-bf46-26838d6d81d2", "node_type": "4", "metadata": {"page_label": "47", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "preparation that was the subject of a monograph was not included in the current Model Lists. Such exceptions included:\n\n- certain preparations recommended by WHO treatment programmes and/or included in WHO treatment guidelines that were not in the Model Lists (e.g. paediatric didanosine oral liquid);\n- strengths additional to those in the Model List that had been indicated for similar reasons (e.g. 20 mg Zn strength for zinc sulfate tablets); and\n- monographs for products which had been or which might be removed from the Model Lists (e.g. stavudine capsules).\n\nIt was also emphasized that, unless restricted by the Definition to a particular strength, a monograph was intended to cover any strength. In this context it was noted that in certain tests (for example, dissolution) explicit reference to particular strengths might sometimes be necessary.\n\n## Identity test\n\nEditorial guidance on selection, order and possibility for subsidiary choice of identity tests was discussed.\n\nThe current approach, which is to use a combination of different methods within the monograph rather than placing reliance on a single method, was reemphasized. This was particularly important since the Ph.Int. monographs might be applied to material from different manufacturers and by quality control laboratories equipped with different instruments.\n\n## Polymorphism\n\nFor an API known to exist in more than one morphic form, the way to frame the monograph would depend on whether or not it was restricted to a particular polymorph.\n\nIn most cases it was intended that the monograph place no restriction on morphic form. A statement had been included under Additional information to the effect that the substance \u201cmay exhibit polymorphism\u201d. In such cases, where an infrared identity test had been included, appropriate instructions were given on how to proceed (see, e.g. the monograph for Efavirenz). Without such instructions the monograph was, in effect, restricting the substance to the morphic form of the ICRS.\n\n## 3.7 Radiopharmaceuticals\n\nWork on the elaboration of specifications for radiopharmaceuticals was initiated in 2001, with the collaboration of WHO and the International Atomic Energy Agency (IAEA). Following consultations and discussion involving experts from both organizations, agreement was reached that this work would include inter alia the revision of the general monograph in *The International Pharmacopoeia*.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "7c878ef455fd3f2bf448ed250e7d3d42f27c2225716277a1040d420f34400075", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "preparation that was the subject of a monograph was not included in the current Model Lists. Such exceptions included:\n\n- certain preparations recommended by WHO treatment programmes and/or included in WHO treatment guidelines that were not in the Model Lists (e.g. paediatric didanosine oral liquid);\n- strengths additional to those in the Model List that had been indicated for similar reasons (e.g. 20 mg Zn strength for zinc sulfate tablets); and\n- monographs for products which had been or which might be removed from the Model Lists (e.g. stavudine capsules).\n\nIt was also emphasized that, unless restricted by the Definition to a particular strength, a monograph was intended to cover any strength. In this context it was noted that in certain tests (for example, dissolution) explicit reference to particular strengths might sometimes be necessary.\n\n## Identity test\n\nEditorial guidance on selection, order and possibility for subsidiary choice of identity tests was discussed.\n\nThe current approach, which is to use a combination of different methods within the monograph rather than placing reliance on a single method, was reemphasized. This was particularly important since the Ph.Int. monographs might be applied to material from different manufacturers and by quality control laboratories equipped with different instruments.\n\n## Polymorphism\n\nFor an API known to exist in more than one morphic form, the way to frame the monograph would depend on whether or not it was restricted to a particular polymorph.\n\nIn most cases it was intended that the monograph place no restriction on morphic form. A statement had been included under Additional information to the effect that the substance \u201cmay exhibit polymorphism\u201d. In such cases, where an infrared identity test had been included, appropriate instructions were given on how to proceed (see, e.g. the monograph for Efavirenz). Without such instructions the monograph was, in effect, restricting the substance to the morphic form of the ICRS.\n\n## 3.7 Radiopharmaceuticals\n\nWork on the elaboration of specifications for radiopharmaceuticals was initiated in 2001, with the collaboration of WHO and the International Atomic Energy Agency (IAEA). Following consultations and discussion involving experts from both organizations, agreement was reached that this work would include inter alia the revision of the general monograph in *The International Pharmacopoeia*.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2426, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "fb96bb01-a277-423a-997d-024afc16c7d8": {"__data__": {"id_": "fb96bb01-a277-423a-997d-024afc16c7d8", "embedding": null, "metadata": {"page_label": "48", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "and the elaboration of 30 monographs for individual radiopharmaceuticals preparations, to which IAEA had awarded priority in 2005.\n\nBackground information on the development of these monographs was presented to the Expert Committee in October 2008 and was described in the forty-third report.\n\nAs a result of this joint work, the final versions of the following texts adopted in October 2008 were made available on *The International Pharmacopoeia\u2013Radiopharmaceuticals* page of the WHO Medicines web site.\n\n### General monograph and related texts\n- General monograph\n- Methods of analysis\n- Supplementary information\n\n### Individual monographs\n- Fludeoxyglucose (\u00b9\u2078F) injection\n- Gallium citrate (\u2076\u2077Ga) injection\n- Iobenguane (\u00b9\u00b2\u00b3I) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) solution\n- Sodium Pertechnetate (\u2079\u2079\u1d50Tc) injection (fission)\n- Sodium pertechnetate (\u2079\u2079\u1d50Tc) injection (non-fission)\n- Technetium (\u2079\u2079\u1d50Tc) pentetate complex injection\n- Thallous chloride (\u00b2\u2070\u00b9Tl) injection\n\nConsidering the extensive work already carried out and the need for specifications in *The International Pharmacopoeia* for these pharmaceutical preparations, the 20 remaining monographs (see the list below) were also adopted subject to final scrutiny of the reformatted texts by a small working group composed of experts from both the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and IAEA.\n\nTo undertake the editorial work needed to bring the remaining texts in line with those already published on the web site, the Secretariat had agreed with IAEA that the scrutiny would be carried out by the working group by correspondence, following a defined procedure.\n\nDraft monographs for the following substances were sent to the working group in two series of about 10 texts for review:\n- Iobenguane (\u00b9\u00b3\u00b9I) injection\n- Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) capsules\n- Sodium iothalamate (\u00b9\u00b2\u2075I) injection", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen de nivel superior del contexto\n\nEl documento se centra en la elaboraci\u00f3n de monograf\u00edas para preparaciones de radiopharmaceuticals, un trabajo conjunto entre la Organizaci\u00f3n Mundial de la Salud (OMS) y la Agencia Internacional de Energ\u00eda At\u00f3mica (IAEA). En octubre de 2008, se adoptaron varias monograf\u00edas y textos relacionados, que se publicaron en la p\u00e1gina de *La Farmacopea Internacional\u2013Radiopharmaceuticals* del sitio web de la OMS. Se menciona la necesidad de especificaciones para estas preparaciones y se detalla un proceso de revisi\u00f3n para 20 monograf\u00edas restantes, que incluye la participaci\u00f3n de un grupo de trabajo de expertos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios que llevaron a la selecci\u00f3n de los 30 radiopharmaceuticals para la elaboraci\u00f3n de monograf\u00edas en 2005?**\n   - Esta pregunta busca informaci\u00f3n sobre los criterios espec\u00edficos utilizados por la IAEA para priorizar ciertos radiopharmaceuticals en el desarrollo de monograf\u00edas.\n\n2. **\u00bfQu\u00e9 procedimientos espec\u00edficos se establecieron para la revisi\u00f3n de las monograf\u00edas restantes por parte del grupo de trabajo?**\n   - Esta pregunta se centra en los detalles del proceso editorial acordado entre la OMS y la IAEA, que no se mencionan expl\u00edcitamente en el texto.\n\n3. **\u00bfQu\u00e9 impacto se espera que tenga la adopci\u00f3n de estas monograf\u00edas en la pr\u00e1ctica cl\u00ednica y la regulaci\u00f3n de los radiopharmaceuticals?**\n   - Esta pregunta busca explorar las implicaciones pr\u00e1cticas y regulatorias de la adopci\u00f3n de estas monograf\u00edas, un aspecto que no se aborda directamente en el contexto proporcionado.", "prev_section_summary": "### Temas Clave\n\n1. **Excepciones a las Listas de Modelos de la OMS**: Se discuten preparaciones farmac\u00e9uticas que no est\u00e1n incluidas en las listas de modelos, como ciertas formulaciones recomendadas por la OMS y monograf\u00edas de productos que han sido o podr\u00edan ser eliminados.\n\n2. **Pruebas de Identidad**: Se enfatiza la importancia de utilizar m\u00faltiples m\u00e9todos para las pruebas de identidad en lugar de depender de un solo m\u00e9todo, dado que las monograf\u00edas pueden aplicarse a materiales de diferentes fabricantes.\n\n3. **Polimorfismo**: Se aborda c\u00f3mo las monograf\u00edas tratan el polimorfismo de las sustancias activas, indicando que generalmente no se restringe la forma morfol\u00f3gica y se proporciona informaci\u00f3n sobre la posibilidad de polimorfismo.\n\n4. **Radiopharmaceuticals**: Se menciona el trabajo en curso para desarrollar especificaciones para radiopharmaceuticals, en colaboraci\u00f3n con la Agencia Internacional de Energ\u00eda At\u00f3mica (IAEA).\n\n### Entidades\n\n- **Organizaciones**: \n  - Organizaci\u00f3n Mundial de la Salud (OMS)\n  - Agencia Internacional de Energ\u00eda At\u00f3mica (IAEA)\n\n- **Sustancias y Preparaciones**:\n  - Didanosina oral l\u00edquida pedi\u00e1trica\n  - Sulfato de zinc (20 mg)\n  - C\u00e1psulas de estavudina\n  - Efavirenz\n\n- **Documentos**:\n  - *The International Pharmacopoeia*\n\nEste resumen destaca los aspectos m\u00e1s relevantes de la secci\u00f3n, incluyendo las excepciones a las listas de la OMS, la metodolog\u00eda de pruebas de identidad, el manejo del polimorfismo y la colaboraci\u00f3n en el desarrollo de especificaciones para radiopharmaceuticals.", "excerpt_keywords": "Keywords: radiopharmaceuticals, monographs, WHO, IAEA, International Pharmacopoeia"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0ea91eb0-bb6d-46c6-9aea-717ffa55a5ae", "node_type": "4", "metadata": {"page_label": "48", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "and the elaboration of 30 monographs for individual radiopharmaceuticals preparations, to which IAEA had awarded priority in 2005.\n\nBackground information on the development of these monographs was presented to the Expert Committee in October 2008 and was described in the forty-third report.\n\nAs a result of this joint work, the final versions of the following texts adopted in October 2008 were made available on *The International Pharmacopoeia\u2013Radiopharmaceuticals* page of the WHO Medicines web site.\n\n### General monograph and related texts\n- General monograph\n- Methods of analysis\n- Supplementary information\n\n### Individual monographs\n- Fludeoxyglucose (\u00b9\u2078F) injection\n- Gallium citrate (\u2076\u2077Ga) injection\n- Iobenguane (\u00b9\u00b2\u00b3I) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) solution\n- Sodium Pertechnetate (\u2079\u2079\u1d50Tc) injection (fission)\n- Sodium pertechnetate (\u2079\u2079\u1d50Tc) injection (non-fission)\n- Technetium (\u2079\u2079\u1d50Tc) pentetate complex injection\n- Thallous chloride (\u00b2\u2070\u00b9Tl) injection\n\nConsidering the extensive work already carried out and the need for specifications in *The International Pharmacopoeia* for these pharmaceutical preparations, the 20 remaining monographs (see the list below) were also adopted subject to final scrutiny of the reformatted texts by a small working group composed of experts from both the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and IAEA.\n\nTo undertake the editorial work needed to bring the remaining texts in line with those already published on the web site, the Secretariat had agreed with IAEA that the scrutiny would be carried out by the working group by correspondence, following a defined procedure.\n\nDraft monographs for the following substances were sent to the working group in two series of about 10 texts for review:\n- Iobenguane (\u00b9\u00b3\u00b9I) injection\n- Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) capsules\n- Sodium iothalamate (\u00b9\u00b2\u2075I) injection", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "da7022ce1201d1299865d52c49a84e6729808c62c62fd3d31ddde47689885a9e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "and the elaboration of 30 monographs for individual radiopharmaceuticals preparations, to which IAEA had awarded priority in 2005.\n\nBackground information on the development of these monographs was presented to the Expert Committee in October 2008 and was described in the forty-third report.\n\nAs a result of this joint work, the final versions of the following texts adopted in October 2008 were made available on *The International Pharmacopoeia\u2013Radiopharmaceuticals* page of the WHO Medicines web site.\n\n### General monograph and related texts\n- General monograph\n- Methods of analysis\n- Supplementary information\n\n### Individual monographs\n- Fludeoxyglucose (\u00b9\u2078F) injection\n- Gallium citrate (\u2076\u2077Ga) injection\n- Iobenguane (\u00b9\u00b2\u00b3I) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) solution\n- Sodium Pertechnetate (\u2079\u2079\u1d50Tc) injection (fission)\n- Sodium pertechnetate (\u2079\u2079\u1d50Tc) injection (non-fission)\n- Technetium (\u2079\u2079\u1d50Tc) pentetate complex injection\n- Thallous chloride (\u00b2\u2070\u00b9Tl) injection\n\nConsidering the extensive work already carried out and the need for specifications in *The International Pharmacopoeia* for these pharmaceutical preparations, the 20 remaining monographs (see the list below) were also adopted subject to final scrutiny of the reformatted texts by a small working group composed of experts from both the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and IAEA.\n\nTo undertake the editorial work needed to bring the remaining texts in line with those already published on the web site, the Secretariat had agreed with IAEA that the scrutiny would be carried out by the working group by correspondence, following a defined procedure.\n\nDraft monographs for the following substances were sent to the working group in two series of about 10 texts for review:\n- Iobenguane (\u00b9\u00b3\u00b9I) injection\n- Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) capsules\n- Sodium iothalamate (\u00b9\u00b2\u2075I) injection", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2013, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "01f4bd62-8d7a-438f-8f2f-e485775da3b2": {"__data__": {"id_": "01f4bd62-8d7a-438f-8f2f-e485775da3b2", "embedding": null, "metadata": {"page_label": "49", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 Sodium phosphate (\u00b3\u00b2P) injection  \n\u2014 Strontium chloride (\u2078\u2079Sr) injection  \n\u2014 Technetium (\u2079\u2079mTc) bicisate complex injection  \n\u2014 Technetium (\u2079\u2079mTc) exametazime complex injection  \n\u2014 Technetium (\u2079\u2079mTc) mebrofenin complex injection  \n\u2014 Technetium (\u2079\u2079mTc) mertiatide injection  \n\u2014 Technetium (\u2079\u2079mTc) succimer complex injection  \n\u2014 Technetium (\u2079\u2079mTc) sulfur colloid injection  \n\u2014 Technetium (\u2079\u2079mTc) tetrofosmin complex injection  \n\u2014 Technetium (\u2079\u2079mTc) tin colloidal injection  \n\u2014 Technetium(\u2079\u2079mTc) pyrophosphate tin complex injection  \n\u2014 Technetium(\u2079\u2079mTc) methylene diphosphonate (MDP) complex injection  \n\u2014 Technetium(\u2079\u2079mTc) sestamibi complex injection  \n\u2014 Yttrium silicate (\u2079\u2070Y) colloid injection  \n\u2014 Technetium (\u2079\u2079mTc) labelled Macrosalb (\u2079\u2079mTc MAA) injection*  \n\u2014 Technetium (\u2079\u2079mTc) nanocolloid injection*  \n\n* Regarding the monographs for technetium (\u2079\u2079mTc) nanocolloid injection and technetium (\u2079\u2079mTc) labelled macrosalb (\u2079\u2079mTc MAA) injection, the Committee referred to its decision taken in October 2008 for technetium (\u2079\u2079mTc) labelled red blood cells injection, when it had been decided that the quality specifications for this type of blood product or derivative, not covered by the Ph.Int., would normally be the responsibility of the WHO Expert Committee on Biological Standardization or would be dealt with through the Blood Regulators Network for which WHO provided the Secretariat. Therefore, it was recommended that the quality specifications for these three biological products derived from albumin be dealt with by the above-mentioned committees.\n\nThe comments received thereon were discussed at the informal consultation on specifications for medicines and quality control laboratory issues in June 2009. Revised texts, reflecting the comments confirmed by IAEA, were presented to the Expert Committee for information.\n\nWhile formatting and reviewing these remaining texts, it was decided that, for the purposes of consistency, some changes needed to be made to all the individual monographs, including to the texts already published on the web site. Revised drafts for those texts were also presented to the Expert Committee for information.\n\nThe Expert Committee noted with appreciation the completion of this work and endorsed the reformatted monographs prepared following the recommendations made in 2008. It further agreed that those final texts be placed on The International Pharmacopoeia\u2013Radiopharmaceuticals page of the WHO Medicines web site, bringing the number of new individual monographs for radiopharmaceutical preparations for inclusion in the Fourth Edition of The International Pharmacopoeia to 27.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen de Nivel Superior\n\nEl documento de la OMS (WHO - Technical Report Series 957) presenta una lista de inyecciones de radiotrazadores, incluyendo varios compuestos de tecn\u00e9cio (\u2079\u2079mTc) y otros is\u00f3topos radiactivos. Se menciona que, para ciertos productos biol\u00f3gicos derivados de la alb\u00famina, las especificaciones de calidad son responsabilidad de comit\u00e9s espec\u00edficos de la OMS. Adem\u00e1s, se discuten las revisiones y la estandarizaci\u00f3n de los textos de las monograf\u00edas, que fueron aprobadas por el Comit\u00e9 de Expertos y se incluir\u00e1n en la Cuarta Edici\u00f3n de la Farmacopea Internacional.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 decisiones se tomaron en octubre de 2008 respecto a las especificaciones de calidad para inyecciones de productos sangu\u00edneos, y c\u00f3mo se relacionan con las inyecciones de tecn\u00e9cio (\u2079\u2079mTc) mencionadas en el documento?**\n   - Respuesta: En octubre de 2008, se decidi\u00f3 que las especificaciones de calidad para inyecciones de productos sangu\u00edneos o derivados, no cubiertos por la Farmacopea Internacional, ser\u00edan responsabilidad del Comit\u00e9 de Expertos de la OMS en Estandarizaci\u00f3n Biol\u00f3gica o se tratar\u00edan a trav\u00e9s de la Red de Reguladores de Sangre, con la OMS proporcionando la Secretar\u00eda. Esto se aplica tambi\u00e9n a las inyecciones de tecn\u00e9cio (\u2079\u2079mTc) nanocolloid y tecn\u00e9cio (\u2079\u2079mTc) etiquetado con Macrosalb.\n\n2. **\u00bfCu\u00e1ntas nuevas monograf\u00edas de preparaciones radiofarmac\u00e9uticas se incluir\u00e1n en la Cuarta Edici\u00f3n de la Farmacopea Internacional, seg\u00fan el documento?**\n   - Respuesta: Se acord\u00f3 que el n\u00famero de nuevas monograf\u00edas para preparaciones radiofarmac\u00e9uticas que se incluir\u00e1n en la Cuarta Edici\u00f3n de la Farmacopea Internacional ser\u00e1 de 27.\n\n3. **\u00bfQu\u00e9 cambios se realizaron en las monograf\u00edas individuales durante el proceso de revisi\u00f3n y por qu\u00e9 fueron necesarios?**\n   - Respuesta: Durante el proceso de revisi\u00f3n, se decidieron cambios en las monograf\u00edas individuales para asegurar la consistencia en los textos. Esto incluy\u00f3 la revisi\u00f3n de textos ya publicados en el sitio web, y se presentaron borradores revisados al Comit\u00e9 de Expertos para su informaci\u00f3n.\n\nEstas preguntas y respuestas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar f\u00e1cilmente disponible en otros documentos o fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Colaboraci\u00f3n entre Organizaciones**: El documento destaca la colaboraci\u00f3n entre la Organizaci\u00f3n Mundial de la Salud (OMS) y la Agencia Internacional de Energ\u00eda At\u00f3mica (IAEA) en la elaboraci\u00f3n de monograf\u00edas para preparaciones de radiopharmaceuticals.\n\n2. **Monograf\u00edas Adoptadas**: En octubre de 2008, se adoptaron varias monograf\u00edas y textos relacionados que fueron publicados en la p\u00e1gina de *La Farmacopea Internacional\u2013Radiopharmaceuticals* del sitio web de la OMS. Esto incluye una monograf\u00eda general, m\u00e9todos de an\u00e1lisis y textos suplementarios.\n\n3. **Lista de Monograf\u00edas Individuales**: Se mencionan varias monograf\u00edas individuales adoptadas, incluyendo:\n   - Fludeoxyglucose (\u00b9\u2078F) injection\n   - Gallium citrate (\u2076\u2077Ga) injection\n   - Iobenguane (\u00b9\u00b2\u00b3I) injection\n   - Sodium iodide (\u00b9\u00b3\u00b9I) injection\n   - Sodium Pertechnetate (\u2079\u2079\u1d50Tc) injection (fission y non-fission)\n   - Technetium (\u2079\u2079\u1d50Tc) pentetate complex injection\n   - Thallous chloride (\u00b2\u2070\u00b9Tl) injection\n\n4. **Monograf\u00edas Restantes**: Se identificaron 20 monograf\u00edas restantes que tambi\u00e9n fueron adoptadas, sujetas a revisi\u00f3n final por un grupo de trabajo de expertos de la OMS y la IAEA.\n\n5. **Proceso de Revisi\u00f3n**: Se acord\u00f3 que la revisi\u00f3n de las monograf\u00edas restantes se llevar\u00eda a cabo por correspondencia, siguiendo un procedimiento definido, con el env\u00edo de borradores en dos series para su revisi\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Agencia Internacional de Energ\u00eda At\u00f3mica (IAEA)**\n- **Radiopharmaceuticals**\n- **Expert Committee**\n- **Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations**\n\nEste resumen encapsula los aspectos fundamentales del contenido, incluyendo la colaboraci\u00f3n entre organizaciones, las monograf\u00edas adoptadas y el proceso de revisi\u00f3n para las monograf\u00edas restantes.", "excerpt_keywords": "Keywords: radiopharmaceuticals, technetium, quality specifications, WHO, International Pharmacopoeia"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8e9b646b-c1bc-4491-98b1-eafae0cef6a7", "node_type": "4", "metadata": {"page_label": "49", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 Sodium phosphate (\u00b3\u00b2P) injection  \n\u2014 Strontium chloride (\u2078\u2079Sr) injection  \n\u2014 Technetium (\u2079\u2079mTc) bicisate complex injection  \n\u2014 Technetium (\u2079\u2079mTc) exametazime complex injection  \n\u2014 Technetium (\u2079\u2079mTc) mebrofenin complex injection  \n\u2014 Technetium (\u2079\u2079mTc) mertiatide injection  \n\u2014 Technetium (\u2079\u2079mTc) succimer complex injection  \n\u2014 Technetium (\u2079\u2079mTc) sulfur colloid injection  \n\u2014 Technetium (\u2079\u2079mTc) tetrofosmin complex injection  \n\u2014 Technetium (\u2079\u2079mTc) tin colloidal injection  \n\u2014 Technetium(\u2079\u2079mTc) pyrophosphate tin complex injection  \n\u2014 Technetium(\u2079\u2079mTc) methylene diphosphonate (MDP) complex injection  \n\u2014 Technetium(\u2079\u2079mTc) sestamibi complex injection  \n\u2014 Yttrium silicate (\u2079\u2070Y) colloid injection  \n\u2014 Technetium (\u2079\u2079mTc) labelled Macrosalb (\u2079\u2079mTc MAA) injection*  \n\u2014 Technetium (\u2079\u2079mTc) nanocolloid injection*  \n\n* Regarding the monographs for technetium (\u2079\u2079mTc) nanocolloid injection and technetium (\u2079\u2079mTc) labelled macrosalb (\u2079\u2079mTc MAA) injection, the Committee referred to its decision taken in October 2008 for technetium (\u2079\u2079mTc) labelled red blood cells injection, when it had been decided that the quality specifications for this type of blood product or derivative, not covered by the Ph.Int., would normally be the responsibility of the WHO Expert Committee on Biological Standardization or would be dealt with through the Blood Regulators Network for which WHO provided the Secretariat. Therefore, it was recommended that the quality specifications for these three biological products derived from albumin be dealt with by the above-mentioned committees.\n\nThe comments received thereon were discussed at the informal consultation on specifications for medicines and quality control laboratory issues in June 2009. Revised texts, reflecting the comments confirmed by IAEA, were presented to the Expert Committee for information.\n\nWhile formatting and reviewing these remaining texts, it was decided that, for the purposes of consistency, some changes needed to be made to all the individual monographs, including to the texts already published on the web site. Revised drafts for those texts were also presented to the Expert Committee for information.\n\nThe Expert Committee noted with appreciation the completion of this work and endorsed the reformatted monographs prepared following the recommendations made in 2008. It further agreed that those final texts be placed on The International Pharmacopoeia\u2013Radiopharmaceuticals page of the WHO Medicines web site, bringing the number of new individual monographs for radiopharmaceutical preparations for inclusion in the Fourth Edition of The International Pharmacopoeia to 27.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "be2e14f8c7944c75b3fcd977156c038679a6a1d808f5e4f6fd577b592118d5c2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2014 Sodium phosphate (\u00b3\u00b2P) injection  \n\u2014 Strontium chloride (\u2078\u2079Sr) injection  \n\u2014 Technetium (\u2079\u2079mTc) bicisate complex injection  \n\u2014 Technetium (\u2079\u2079mTc) exametazime complex injection  \n\u2014 Technetium (\u2079\u2079mTc) mebrofenin complex injection  \n\u2014 Technetium (\u2079\u2079mTc) mertiatide injection  \n\u2014 Technetium (\u2079\u2079mTc) succimer complex injection  \n\u2014 Technetium (\u2079\u2079mTc) sulfur colloid injection  \n\u2014 Technetium (\u2079\u2079mTc) tetrofosmin complex injection  \n\u2014 Technetium (\u2079\u2079mTc) tin colloidal injection  \n\u2014 Technetium(\u2079\u2079mTc) pyrophosphate tin complex injection  \n\u2014 Technetium(\u2079\u2079mTc) methylene diphosphonate (MDP) complex injection  \n\u2014 Technetium(\u2079\u2079mTc) sestamibi complex injection  \n\u2014 Yttrium silicate (\u2079\u2070Y) colloid injection  \n\u2014 Technetium (\u2079\u2079mTc) labelled Macrosalb (\u2079\u2079mTc MAA) injection*  \n\u2014 Technetium (\u2079\u2079mTc) nanocolloid injection*  \n\n* Regarding the monographs for technetium (\u2079\u2079mTc) nanocolloid injection and technetium (\u2079\u2079mTc) labelled macrosalb (\u2079\u2079mTc MAA) injection, the Committee referred to its decision taken in October 2008 for technetium (\u2079\u2079mTc) labelled red blood cells injection, when it had been decided that the quality specifications for this type of blood product or derivative, not covered by the Ph.Int., would normally be the responsibility of the WHO Expert Committee on Biological Standardization or would be dealt with through the Blood Regulators Network for which WHO provided the Secretariat. Therefore, it was recommended that the quality specifications for these three biological products derived from albumin be dealt with by the above-mentioned committees.\n\nThe comments received thereon were discussed at the informal consultation on specifications for medicines and quality control laboratory issues in June 2009. Revised texts, reflecting the comments confirmed by IAEA, were presented to the Expert Committee for information.\n\nWhile formatting and reviewing these remaining texts, it was decided that, for the purposes of consistency, some changes needed to be made to all the individual monographs, including to the texts already published on the web site. Revised drafts for those texts were also presented to the Expert Committee for information.\n\nThe Expert Committee noted with appreciation the completion of this work and endorsed the reformatted monographs prepared following the recommendations made in 2008. It further agreed that those final texts be placed on The International Pharmacopoeia\u2013Radiopharmaceuticals page of the WHO Medicines web site, bringing the number of new individual monographs for radiopharmaceutical preparations for inclusion in the Fourth Edition of The International Pharmacopoeia to 27.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2630, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "be7c3692-ab40-4f95-b49d-12712f43dd2b": {"__data__": {"id_": "be7c3692-ab40-4f95-b49d-12712f43dd2b", "embedding": null, "metadata": {"page_label": "50", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4. Quality control \u2014 international reference materials (International Chemical Reference Substances and International Infrared Reference Spectra)\n\n## 4.1 Annual report of the WHO Collaborating Centre\n\nThe Expert Committee noted with appreciation the work carried out by the WHO Collaborating Centre for Chemical Reference Substances as presented in its report for 2008. It was noted that the total number of International Chemical Reference Substances (ICRS) distributed from the Centre in 2008 was 2153 compared to the 2332 reported in 2007. The most frequently requested substances included artesunate, artemether, prednisolone, artemisinin and zidovudine impurity B.\n\nThe Expert Committee adopted the report for 2008.\n\n## 4.2 Adoption of new International Chemical Reference Substances\n\nNine ICRS were established in 2008, including the following seven new substances:\n\n- carbidopa\n- colchicine\n- lumefantrine\n- DL-methionine\n- naloxone hydrochloride\n- oseltamivir for system suitability\n- oseltamivir phosphate\n\nand the following replacements:\n\n- artemisinin\n- prednisone\n\nThe Expert Committee adopted the above-listed ICRS.\n\n## 4.3 New institution for the establishment of international reference materials\n\nWhile adopting its activities report for 2008, the Expert Committee was also informed that, since May 2009, Apoteket AB in Sweden had ceased its activities as host of the WHO Collaborating Centre for Chemical Reference Substances and that these activities were in the process of being transferred to a new institution.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento se centra en el control de calidad de los materiales de referencia internacionales, espec\u00edficamente los Sustancias Qu\u00edmicas de Referencia Internacional (ICRS) y los Espectros Infrarrojos de Referencia Internacional. En 2008, el Centro Colaborador de la OMS para Sustancias Qu\u00edmicas de Referencia distribuy\u00f3 2153 ICRS, con una disminuci\u00f3n en comparaci\u00f3n con el a\u00f1o anterior. Se adoptaron nuevos ICRS, incluyendo siete sustancias nuevas y dos reemplazos. Adem\u00e1s, se inform\u00f3 sobre la transferencia de actividades del centro a una nueva instituci\u00f3n tras el cese de operaciones de Apoteket AB en Suecia.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les fueron las sustancias qu\u00edmicas m\u00e1s solicitadas en 2008 y c\u00f3mo se comparan con las del a\u00f1o anterior?**\n   - Respuesta: Las sustancias m\u00e1s solicitadas en 2008 fueron artesunate, artemether, prednisolone, artemisinin y zidovudine impurity B. En 2007, se distribuyeron 2332 ICRS, lo que indica una disminuci\u00f3n en la demanda en 2008.\n\n2. **\u00bfQu\u00e9 nuevas sustancias qu\u00edmicas fueron adoptadas como ICRS en 2008 y cu\u00e1les fueron los reemplazos?**\n   - Respuesta: En 2008, se adoptaron siete nuevas sustancias: carbidopa, colchicine, lumefantrine, DL-methionine, naloxone hydrochloride, oseltamivir para sistema de idoneidad y oseltamivir phosphate. Los reemplazos fueron artemisinin y prednisone.\n\n3. **\u00bfQu\u00e9 cambios se produjeron en la gesti\u00f3n del Centro Colaborador de la OMS para Sustancias Qu\u00edmicas de Referencia en 2009?**\n   - Respuesta: Desde mayo de 2009, Apoteket AB en Suecia dej\u00f3 de ser el anfitri\u00f3n del Centro Colaborador de la OMS para Sustancias Qu\u00edmicas de Referencia, y las actividades del centro estaban en proceso de ser transferidas a una nueva instituci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Inyecciones de Radiotrazadores**: Se presenta una lista de inyecciones que incluyen varios compuestos de tecn\u00e9cio (\u2079\u2079mTc) y otros is\u00f3topos radiactivos, como el fosfato s\u00f3dico (\u00b3\u00b2P) y el cloruro de estroncio (\u2078\u2079Sr).\n\n2. **Especificaciones de Calidad**: Se discute la responsabilidad de las especificaciones de calidad para ciertos productos biol\u00f3gicos derivados de la alb\u00famina, que recaen en comit\u00e9s espec\u00edficos de la OMS, como el Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica y la Red de Reguladores de Sangre.\n\n3. **Revisi\u00f3n y Estandarizaci\u00f3n de Monograf\u00edas**: Se menciona el proceso de revisi\u00f3n y estandarizaci\u00f3n de los textos de las monograf\u00edas, que fueron aprobados por el Comit\u00e9 de Expertos y se incluir\u00e1n en la Cuarta Edici\u00f3n de la Farmacopea Internacional.\n\n4. **N\u00famero de Nuevas Monograf\u00edas**: Se establece que se incluir\u00e1n 27 nuevas monograf\u00edas para preparaciones radiofarmac\u00e9uticas en la Cuarta Edici\u00f3n de la Farmacopea Internacional.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la estandarizaci\u00f3n y regulaci\u00f3n de productos de salud.\n- **Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica**: Comit\u00e9 que se encarga de las especificaciones de calidad de productos biol\u00f3gicos.\n- **Red de Reguladores de Sangre**: Grupo que colabora en la regulaci\u00f3n de productos sangu\u00edneos.\n- **Agencia Internacional de Energ\u00eda At\u00f3mica (IAEA)**: Organizaci\u00f3n que proporciona comentarios y validaciones en el proceso de revisi\u00f3n de monograf\u00edas.\n- **Farmacopea Internacional**: Publicaci\u00f3n que compila est\u00e1ndares de calidad para medicamentos y productos farmac\u00e9uticos.\n\nEste resumen destaca los puntos m\u00e1s relevantes y las entidades involucradas en el contexto de las inyecciones de radiotrazadores y su regulaci\u00f3n.", "excerpt_keywords": "Keywords: quality control, international reference materials, chemical reference substances, WHO Collaborating Centre, adoption of substances"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "85ca4664-fa8b-405b-b683-eb20d07cfeb2", "node_type": "4", "metadata": {"page_label": "50", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4. Quality control \u2014 international reference materials (International Chemical Reference Substances and International Infrared Reference Spectra)\n\n## 4.1 Annual report of the WHO Collaborating Centre\n\nThe Expert Committee noted with appreciation the work carried out by the WHO Collaborating Centre for Chemical Reference Substances as presented in its report for 2008. It was noted that the total number of International Chemical Reference Substances (ICRS) distributed from the Centre in 2008 was 2153 compared to the 2332 reported in 2007. The most frequently requested substances included artesunate, artemether, prednisolone, artemisinin and zidovudine impurity B.\n\nThe Expert Committee adopted the report for 2008.\n\n## 4.2 Adoption of new International Chemical Reference Substances\n\nNine ICRS were established in 2008, including the following seven new substances:\n\n- carbidopa\n- colchicine\n- lumefantrine\n- DL-methionine\n- naloxone hydrochloride\n- oseltamivir for system suitability\n- oseltamivir phosphate\n\nand the following replacements:\n\n- artemisinin\n- prednisone\n\nThe Expert Committee adopted the above-listed ICRS.\n\n## 4.3 New institution for the establishment of international reference materials\n\nWhile adopting its activities report for 2008, the Expert Committee was also informed that, since May 2009, Apoteket AB in Sweden had ceased its activities as host of the WHO Collaborating Centre for Chemical Reference Substances and that these activities were in the process of being transferred to a new institution.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "52add4d6a8ef86f3c6946c77a7662c0593548356cefdbb80df692b2d7d1d3346", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4. Quality control \u2014 international reference materials (International Chemical Reference Substances and International Infrared Reference Spectra)\n\n## 4.1 Annual report of the WHO Collaborating Centre\n\nThe Expert Committee noted with appreciation the work carried out by the WHO Collaborating Centre for Chemical Reference Substances as presented in its report for 2008. It was noted that the total number of International Chemical Reference Substances (ICRS) distributed from the Centre in 2008 was 2153 compared to the 2332 reported in 2007. The most frequently requested substances included artesunate, artemether, prednisolone, artemisinin and zidovudine impurity B.\n\nThe Expert Committee adopted the report for 2008.\n\n## 4.2 Adoption of new International Chemical Reference Substances\n\nNine ICRS were established in 2008, including the following seven new substances:\n\n- carbidopa\n- colchicine\n- lumefantrine\n- DL-methionine\n- naloxone hydrochloride\n- oseltamivir for system suitability\n- oseltamivir phosphate\n\nand the following replacements:\n\n- artemisinin\n- prednisone\n\nThe Expert Committee adopted the above-listed ICRS.\n\n## 4.3 New institution for the establishment of international reference materials\n\nWhile adopting its activities report for 2008, the Expert Committee was also informed that, since May 2009, Apoteket AB in Sweden had ceased its activities as host of the WHO Collaborating Centre for Chemical Reference Substances and that these activities were in the process of being transferred to a new institution.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1533, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3ab063c6-b434-4453-ac75-69fb0dc6572c": {"__data__": {"id_": "3ab063c6-b434-4453-ac75-69fb0dc6572c", "embedding": null, "metadata": {"page_label": "51", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "It was emphasized with appreciation that Apoteket AB had started its collaboration with WHO and specifically *The International Pharmacopoeia* in 1956. In recognition of Apoteket AB\u2019s longstanding services to WHO, the Expert Committee expressed its gratitude to the WHO Collaborating Centre on Chemical Reference Substances and to the Government of Sweden which had supported these activities over the past 53 years.\n\nRecognizing the inconvenience caused by this transition from the former Collaborating Centre to the new institution, notably for the distribution of ICRS, the Expert Committee welcomed the announcements posted on the WHO Medicines web site to inform users during this transitional period. As this process was nearing finalization, another announcement indicating the new contact details for ordering ICRS was soon expected to be published.\n\nAs regards the new institution, the Committee made some proposals on the content of the future activity report and encouraged the possibility of reflecting in more detail certain activities such as the stability monitoring of ICRS. The Expert Committee also welcomed the future efforts of the Secretariat in assisting the new institution with regard to collaborative trials to identify any additional laboratories for the establishment of new ICRS. Pricing for the distribution of ICRS was also discussed and the Expert Committee was informed that owing to the change of currency with which the new institution would operate, the price of the ICRS would need to be adjusted. It, therefore, agreed that the price, which had not been changed over the past decade, be increased.\n\nThe Committee stated that it would look forward to receiving annual reports on work carried out on ICRS from the new institution.\n\n# 5. Quality control \u2014 national laboratories\n\n## 5.1 External Quality Assurance Assessment Scheme\n\nThe External Quality Assurance Assessment Scheme (EQAAS) aimed to give each laboratory the opportunity to measure its performance through a confidential system of testing of blind samples and to determine its ability to perform a given analytical procedure within a network of governmental control laboratories. The system was aimed at reinforcing mutual confidence within this network.\n\nWith a view to continuing the promotion of quality assurance in drug quality control laboratories in WHO Member States, five test series of Phase 4 of a proficiency testing scheme had taken place. Some 50 laboratories had participated in this phase of the Scheme, which was now finalized.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Colaboraci\u00f3n de Apoteket AB con la OMS**: Apoteket AB ha colaborado con la OMS desde 1956, contribuyendo significativamente a *La Farmacopea Internacional*. La OMS ha expresado su agradecimiento por los servicios de Apoteket AB y el apoyo del Gobierno de Suecia durante m\u00e1s de 53 a\u00f1os.\n\n2. **Transici\u00f3n a una nueva instituci\u00f3n**: La transici\u00f3n del antiguo Centro Colaborador a una nueva instituci\u00f3n ha causado inconvenientes, especialmente en la distribuci\u00f3n de Sustancias de Referencia de Control Internacional (ICRS). La OMS ha tomado medidas para informar a los usuarios sobre esta transici\u00f3n y se espera que se publiquen nuevos detalles de contacto para pedidos de ICRS.\n\n3. **Esquema de Evaluaci\u00f3n de Aseguramiento de Calidad Externa (EQAAS)**: Este esquema permite a los laboratorios medir su rendimiento mediante pruebas de muestras ciegas. Se han realizado cinco series de pruebas en la Fase 4 del esquema de competencia, con la participaci\u00f3n de aproximadamente 50 laboratorios, lo que refuerza la confianza mutua en la red de laboratorios de control gubernamentales.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas ha tomado la OMS para mitigar los inconvenientes causados por la transici\u00f3n del antiguo Centro Colaborador a la nueva instituci\u00f3n en relaci\u00f3n con la distribuci\u00f3n de ICRS?**\n   - La OMS ha publicado anuncios en su sitio web de Medicamentos para informar a los usuarios sobre la transici\u00f3n y est\u00e1 preparando un anuncio adicional con los nuevos detalles de contacto para realizar pedidos de ICRS.\n\n2. **\u00bfQu\u00e9 propuestas hizo el Comit\u00e9 sobre el contenido del futuro informe de actividades de la nueva instituci\u00f3n?**\n   - El Comit\u00e9 propuso que el informe incluya detalles sobre actividades espec\u00edficas, como el monitoreo de estabilidad de las ICRS, y tambi\u00e9n alent\u00f3 la identificaci\u00f3n de laboratorios adicionales para establecer nuevas ICRS.\n\n3. **\u00bfCu\u00e1ntos laboratorios participaron en la Fase 4 del esquema de competencia y cu\u00e1l es el objetivo de este esquema?**\n   - Aproximadamente 50 laboratorios participaron en la Fase 4 del Esquema de Evaluaci\u00f3n de Aseguramiento de Calidad Externa (EQAAS), cuyo objetivo es permitir que cada laboratorio mida su rendimiento y determine su capacidad para realizar procedimientos anal\u00edticos dentro de una red de laboratorios de control gubernamentales.", "prev_section_summary": "### Temas clave:\n1. **Control de calidad**: Se centra en los materiales de referencia internacionales, espec\u00edficamente en las Sustancias Qu\u00edmicas de Referencia Internacional (ICRS) y los Espectros Infrarrojos de Referencia Internacional.\n2. **Informe anual**: Se presenta el informe del Centro Colaborador de la OMS para Sustancias Qu\u00edmicas de Referencia correspondiente al a\u00f1o 2008, destacando la distribuci\u00f3n de ICRS.\n3. **Distribuci\u00f3n de ICRS**: En 2008 se distribuyeron 2153 ICRS, lo que representa una disminuci\u00f3n respecto a los 2332 distribuidos en 2007.\n4. **Sustancias m\u00e1s solicitadas**: Las sustancias m\u00e1s solicitadas en 2008 incluyeron artesunate, artemether, prednisolone, artemisinin y zidovudine impurity B.\n5. **Nuevas ICRS**: Se adoptaron nueve nuevas ICRS en 2008, de las cuales siete eran nuevas sustancias y dos eran reemplazos.\n6. **Cambio de gesti\u00f3n**: Se informa sobre la cesaci\u00f3n de actividades de Apoteket AB en Suecia como anfitri\u00f3n del Centro Colaborador y la transferencia de estas actividades a una nueva instituci\u00f3n.\n\n### Entidades:\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Organizaci\u00f3n responsable del informe y del establecimiento de ICRS.\n- **Apoteket AB**: Instituci\u00f3n sueca que dej\u00f3 de ser el anfitri\u00f3n del Centro Colaborador de la OMS.\n- **Sustancias qu\u00edmicas**: Incluyen carbidopa, colchicine, lumefantrine, DL-methionine, naloxone hydrochloride, oseltamivir y oseltamivir phosphate, as\u00ed como artemisinin y prednisone como reemplazos.\n\nEste resumen destaca los aspectos m\u00e1s relevantes del control de calidad de los materiales de referencia internacionales y los cambios en la gesti\u00f3n del centro colaborador.", "excerpt_keywords": "Keywords: Apoteket AB, ICRS, WHO, quality assurance, EQAAS"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "70145112-d36c-4552-ad20-88d70809a911", "node_type": "4", "metadata": {"page_label": "51", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "It was emphasized with appreciation that Apoteket AB had started its collaboration with WHO and specifically *The International Pharmacopoeia* in 1956. In recognition of Apoteket AB\u2019s longstanding services to WHO, the Expert Committee expressed its gratitude to the WHO Collaborating Centre on Chemical Reference Substances and to the Government of Sweden which had supported these activities over the past 53 years.\n\nRecognizing the inconvenience caused by this transition from the former Collaborating Centre to the new institution, notably for the distribution of ICRS, the Expert Committee welcomed the announcements posted on the WHO Medicines web site to inform users during this transitional period. As this process was nearing finalization, another announcement indicating the new contact details for ordering ICRS was soon expected to be published.\n\nAs regards the new institution, the Committee made some proposals on the content of the future activity report and encouraged the possibility of reflecting in more detail certain activities such as the stability monitoring of ICRS. The Expert Committee also welcomed the future efforts of the Secretariat in assisting the new institution with regard to collaborative trials to identify any additional laboratories for the establishment of new ICRS. Pricing for the distribution of ICRS was also discussed and the Expert Committee was informed that owing to the change of currency with which the new institution would operate, the price of the ICRS would need to be adjusted. It, therefore, agreed that the price, which had not been changed over the past decade, be increased.\n\nThe Committee stated that it would look forward to receiving annual reports on work carried out on ICRS from the new institution.\n\n# 5. Quality control \u2014 national laboratories\n\n## 5.1 External Quality Assurance Assessment Scheme\n\nThe External Quality Assurance Assessment Scheme (EQAAS) aimed to give each laboratory the opportunity to measure its performance through a confidential system of testing of blind samples and to determine its ability to perform a given analytical procedure within a network of governmental control laboratories. The system was aimed at reinforcing mutual confidence within this network.\n\nWith a view to continuing the promotion of quality assurance in drug quality control laboratories in WHO Member States, five test series of Phase 4 of a proficiency testing scheme had taken place. Some 50 laboratories had participated in this phase of the Scheme, which was now finalized.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "637563b340425b40c51d1fa90c5b0d4061c9e0e8d7770d39f6b9c0116e601c8c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "It was emphasized with appreciation that Apoteket AB had started its collaboration with WHO and specifically *The International Pharmacopoeia* in 1956. In recognition of Apoteket AB\u2019s longstanding services to WHO, the Expert Committee expressed its gratitude to the WHO Collaborating Centre on Chemical Reference Substances and to the Government of Sweden which had supported these activities over the past 53 years.\n\nRecognizing the inconvenience caused by this transition from the former Collaborating Centre to the new institution, notably for the distribution of ICRS, the Expert Committee welcomed the announcements posted on the WHO Medicines web site to inform users during this transitional period. As this process was nearing finalization, another announcement indicating the new contact details for ordering ICRS was soon expected to be published.\n\nAs regards the new institution, the Committee made some proposals on the content of the future activity report and encouraged the possibility of reflecting in more detail certain activities such as the stability monitoring of ICRS. The Expert Committee also welcomed the future efforts of the Secretariat in assisting the new institution with regard to collaborative trials to identify any additional laboratories for the establishment of new ICRS. Pricing for the distribution of ICRS was also discussed and the Expert Committee was informed that owing to the change of currency with which the new institution would operate, the price of the ICRS would need to be adjusted. It, therefore, agreed that the price, which had not been changed over the past decade, be increased.\n\nThe Committee stated that it would look forward to receiving annual reports on work carried out on ICRS from the new institution.\n\n# 5. Quality control \u2014 national laboratories\n\n## 5.1 External Quality Assurance Assessment Scheme\n\nThe External Quality Assurance Assessment Scheme (EQAAS) aimed to give each laboratory the opportunity to measure its performance through a confidential system of testing of blind samples and to determine its ability to perform a given analytical procedure within a network of governmental control laboratories. The system was aimed at reinforcing mutual confidence within this network.\n\nWith a view to continuing the promotion of quality assurance in drug quality control laboratories in WHO Member States, five test series of Phase 4 of a proficiency testing scheme had taken place. Some 50 laboratories had participated in this phase of the Scheme, which was now finalized.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2542, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "865a68ec-9df1-4e96-b9cb-0ce979335124": {"__data__": {"id_": "865a68ec-9df1-4e96-b9cb-0ce979335124", "embedding": null, "metadata": {"page_label": "52", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The Committee noted the final reports on the five tests and the preliminary summary report for Phase 4 of this Scheme. The results reported were:\n\n- final report procedure 1: determination of water by the Karl Fischer method\n- final report procedure 2: dissolution testing\n- final report procedure 3: assay of tablets by HPLC\n- final report procedure 4: assay by titration\n- final report procedure 5: optical rotation by polarimetry\n- summary report, Phase 4\n\nDuring the informal consultation held in June 2009, the experts considered the Scheme to be most efficient, both for the participating laboratories and for the feedback on the methods from the Ph.Int. used in the Scheme. They strongly recommended continuation of the Scheme starting with a new phase. In addition they advised on how to revise the Ph.Int. methods used, e.g. in procedure 4.\n\nRegarding the samples, the experts from the consultation advised the retention of extra samples from each procedure for those laboratories which gave doubtful or unsatisfactory results and which would need to redo testing. Moreover, WHO should strongly encourage the participating laboratories to report back to WHO on the outcome of such investigations and follow-up actions, as necessary.\n\nThe Expert Committee acknowledged with thanks receipt of the samples from UNICEF and from the manufacturers involved.\n\nFurther to the previous agreements between WHO and EDQM (dated 21 March 2000, 26 January 2001, 8 July 2004 and 15 March 2007), it was decided to continue collaboration during the period 1 January 2010\u201331 December 2012 with a view to evaluating the technical performance of 60 drug quality control laboratories designated by WHO for participation in the EQAAS, in accordance with the programme of proficiency testing schemes developed by EDQM, in the following analytical procedures:\n\n- assay by titration (sample: metronidazole)\n- water content by Karl Fischer (sample: amodiaquine dihydrochloride dihydrate)\n- dissolution test (sample: artemether and lumefantrine tablets)\n- related substances by HPLC (sample: abacavir oral solution)\n- assay by HPLC (sample: amodiaquine tablets)\n- dissolution test (sample: rifampicin capsules)\n- related substances by thin-layer chromatography (TLC) (sample: artemether and lumefantrine oral suspension)", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento detalla las conclusiones de un Comit\u00e9 sobre un esquema de pruebas de control de calidad de medicamentos, destacando los resultados de cinco procedimientos anal\u00edticos y la recomendaci\u00f3n de continuar el esquema con una nueva fase. Se menciona la importancia de retener muestras adicionales para laboratorios con resultados dudosos y la colaboraci\u00f3n entre la OMS y EDQM para evaluar el rendimiento t\u00e9cnico de laboratorios de control de calidad de medicamentos en un periodo espec\u00edfico.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los procedimientos anal\u00edticos que se evaluaron en la fase 4 del esquema y qu\u00e9 m\u00e9todos se utilizaron para cada uno?**\n   - Respuesta: Los procedimientos anal\u00edticos evaluados en la fase 4 del esquema incluyen: \n     - Determinaci\u00f3n de agua por el m\u00e9todo de Karl Fischer.\n     - Pruebas de disoluci\u00f3n.\n     - Ensayo de tabletas por HPLC.\n     - Ensayo por titulaci\u00f3n.\n     - Rotaci\u00f3n \u00f3ptica por polarimetr\u00eda.\n\n2. **\u00bfQu\u00e9 recomendaciones se hicieron durante la consulta informal de junio de 2009 respecto a los laboratorios que obtuvieron resultados insatisfactorios?**\n   - Respuesta: Se recomend\u00f3 la retenci\u00f3n de muestras adicionales de cada procedimiento para aquellos laboratorios que obtuvieron resultados dudosos o insatisfactorios, y se sugiri\u00f3 que la OMS alentara a los laboratorios a informar sobre los resultados de sus investigaciones y acciones de seguimiento.\n\n3. **\u00bfCu\u00e1l es el objetivo de la colaboraci\u00f3n entre la OMS y EDQM durante el periodo de 2010 a 2012?**\n   - Respuesta: El objetivo de la colaboraci\u00f3n es evaluar el rendimiento t\u00e9cnico de 60 laboratorios de control de calidad de medicamentos designados por la OMS para participar en el EQAAS, utilizando un programa de esquemas de pruebas de competencia desarrollado por EDQM en varios procedimientos anal\u00edticos.\n\n### Resumen de Nivel Superior\nEl Comit\u00e9 evalu\u00f3 los resultados de un esquema de pruebas de control de calidad de medicamentos y recomend\u00f3 su continuaci\u00f3n. Se enfatiz\u00f3 la importancia de manejar adecuadamente los resultados insatisfactorios y se estableci\u00f3 una colaboraci\u00f3n entre la OMS y EDQM para evaluar laboratorios de control de calidad en un periodo espec\u00edfico, utilizando diversos m\u00e9todos anal\u00edticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Colaboraci\u00f3n de Apoteket AB con la OMS**:\n   - Apoteket AB ha colaborado con la OMS desde 1956, especialmente en *La Farmacopea Internacional*.\n   - La OMS ha expresado su agradecimiento por los servicios de Apoteket AB y el apoyo del Gobierno de Suecia durante m\u00e1s de 53 a\u00f1os.\n\n2. **Transici\u00f3n a una Nueva Instituci\u00f3n**:\n   - Se ha producido una transici\u00f3n del antiguo Centro Colaborador a una nueva instituci\u00f3n, lo que ha causado inconvenientes en la distribuci\u00f3n de Sustancias de Referencia de Control Internacional (ICRS).\n   - La OMS ha tomado medidas para informar a los usuarios sobre esta transici\u00f3n a trav\u00e9s de anuncios en su sitio web y se espera la publicaci\u00f3n de nuevos detalles de contacto para pedidos de ICRS.\n\n3. **Propuestas del Comit\u00e9**:\n   - El Comit\u00e9 propuso que el futuro informe de actividades de la nueva instituci\u00f3n incluya detalles sobre el monitoreo de estabilidad de las ICRS y la identificaci\u00f3n de laboratorios adicionales para establecer nuevas ICRS.\n   - Se discuti\u00f3 la necesidad de ajustar el precio de las ICRS debido a un cambio de moneda, acordando un aumento en el precio que no se hab\u00eda modificado en la \u00faltima d\u00e9cada.\n\n4. **Esquema de Evaluaci\u00f3n de Aseguramiento de Calidad Externa (EQAAS)**:\n   - Este esquema permite a los laboratorios medir su rendimiento mediante pruebas de muestras ciegas, reforzando la confianza mutua en la red de laboratorios de control gubernamentales.\n   - Se llevaron a cabo cinco series de pruebas en la Fase 4 del esquema, con la participaci\u00f3n de aproximadamente 50 laboratorios, que ahora ha finalizado.\n\n### Entidades Clave\n- **Apoteket AB**: Entidad colaboradora con la OMS.\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organizaci\u00f3n que supervisa la colaboraci\u00f3n y calidad en laboratorios.\n- **Gobierno de Suecia**: Entidad que ha apoyado las actividades de Apoteket AB y la OMS.\n- **ICRS (Sustancias de Referencia de Control Internacional)**: Sustancias cuyo manejo y distribuci\u00f3n est\u00e1n en transici\u00f3n.\n- **EQAAS (Esquema de Evaluaci\u00f3n de Aseguramiento de Calidad Externa)**: Programa para evaluar el rendimiento de laboratorios.", "excerpt_keywords": "Keywords: drug quality control, analytical procedures, WHO, EQAAS, proficiency testing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "35f78f6b-b128-44fe-8260-c5fba43e85df", "node_type": "4", "metadata": {"page_label": "52", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The Committee noted the final reports on the five tests and the preliminary summary report for Phase 4 of this Scheme. The results reported were:\n\n- final report procedure 1: determination of water by the Karl Fischer method\n- final report procedure 2: dissolution testing\n- final report procedure 3: assay of tablets by HPLC\n- final report procedure 4: assay by titration\n- final report procedure 5: optical rotation by polarimetry\n- summary report, Phase 4\n\nDuring the informal consultation held in June 2009, the experts considered the Scheme to be most efficient, both for the participating laboratories and for the feedback on the methods from the Ph.Int. used in the Scheme. They strongly recommended continuation of the Scheme starting with a new phase. In addition they advised on how to revise the Ph.Int. methods used, e.g. in procedure 4.\n\nRegarding the samples, the experts from the consultation advised the retention of extra samples from each procedure for those laboratories which gave doubtful or unsatisfactory results and which would need to redo testing. Moreover, WHO should strongly encourage the participating laboratories to report back to WHO on the outcome of such investigations and follow-up actions, as necessary.\n\nThe Expert Committee acknowledged with thanks receipt of the samples from UNICEF and from the manufacturers involved.\n\nFurther to the previous agreements between WHO and EDQM (dated 21 March 2000, 26 January 2001, 8 July 2004 and 15 March 2007), it was decided to continue collaboration during the period 1 January 2010\u201331 December 2012 with a view to evaluating the technical performance of 60 drug quality control laboratories designated by WHO for participation in the EQAAS, in accordance with the programme of proficiency testing schemes developed by EDQM, in the following analytical procedures:\n\n- assay by titration (sample: metronidazole)\n- water content by Karl Fischer (sample: amodiaquine dihydrochloride dihydrate)\n- dissolution test (sample: artemether and lumefantrine tablets)\n- related substances by HPLC (sample: abacavir oral solution)\n- assay by HPLC (sample: amodiaquine tablets)\n- dissolution test (sample: rifampicin capsules)\n- related substances by thin-layer chromatography (TLC) (sample: artemether and lumefantrine oral suspension)", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "9d20026d8cf8967799ed8a8c2a35652af56c4459f5ac6131a81d5d5a9ad3fac5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The Committee noted the final reports on the five tests and the preliminary summary report for Phase 4 of this Scheme. The results reported were:\n\n- final report procedure 1: determination of water by the Karl Fischer method\n- final report procedure 2: dissolution testing\n- final report procedure 3: assay of tablets by HPLC\n- final report procedure 4: assay by titration\n- final report procedure 5: optical rotation by polarimetry\n- summary report, Phase 4\n\nDuring the informal consultation held in June 2009, the experts considered the Scheme to be most efficient, both for the participating laboratories and for the feedback on the methods from the Ph.Int. used in the Scheme. They strongly recommended continuation of the Scheme starting with a new phase. In addition they advised on how to revise the Ph.Int. methods used, e.g. in procedure 4.\n\nRegarding the samples, the experts from the consultation advised the retention of extra samples from each procedure for those laboratories which gave doubtful or unsatisfactory results and which would need to redo testing. Moreover, WHO should strongly encourage the participating laboratories to report back to WHO on the outcome of such investigations and follow-up actions, as necessary.\n\nThe Expert Committee acknowledged with thanks receipt of the samples from UNICEF and from the manufacturers involved.\n\nFurther to the previous agreements between WHO and EDQM (dated 21 March 2000, 26 January 2001, 8 July 2004 and 15 March 2007), it was decided to continue collaboration during the period 1 January 2010\u201331 December 2012 with a view to evaluating the technical performance of 60 drug quality control laboratories designated by WHO for participation in the EQAAS, in accordance with the programme of proficiency testing schemes developed by EDQM, in the following analytical procedures:\n\n- assay by titration (sample: metronidazole)\n- water content by Karl Fischer (sample: amodiaquine dihydrochloride dihydrate)\n- dissolution test (sample: artemether and lumefantrine tablets)\n- related substances by HPLC (sample: abacavir oral solution)\n- assay by HPLC (sample: amodiaquine tablets)\n- dissolution test (sample: rifampicin capsules)\n- related substances by thin-layer chromatography (TLC) (sample: artemether and lumefantrine oral suspension)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2302, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e5aab092-e48e-4761-a0ee-a52fcba93fb0": {"__data__": {"id_": "e5aab092-e48e-4761-a0ee-a52fcba93fb0", "embedding": null, "metadata": {"page_label": "53", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# WHO Good Practices for Quality Control Laboratories\n\n## Revision of WHO Good Practices for Pharmaceutical Quality Control Laboratories (GPCL)\n\nAt its forty-third meeting, the Expert Committee recommended that the WHO Secretariat initiate the process of revision of the *WHO good practices for national pharmaceutical control laboratories* (*Good practices for national pharmaceutical control laboratories*, Annex 3, WHO Technical Report Series, No. 902, 2002).\n\nThe following requirements were set for the revision, based on the recommendations of the Expert Committee at its forty-third meeting:\n\n- Include the most important parts of the WHO GMP guide, which were relevant to quality control laboratories, directly in the GPCL guideline and add references to other relevant parts of the WHO GMP guide;\n- Provide detailed guidance for the areas identified as being often deficient during inspections performed by the PQP;\n- Align the guidance with the requirements of ISO/IEC 17025:2005;\n- Apply to any pharmaceutical quality control laboratory, be it national, commercial or another nongovernmental laboratory; and\n- Harmonization of terms used in other WHO documents.\n\nThe first draft revision was prepared in March 2009 and was widely commented on. The comments received were discussed with laboratory experts at the informal consultation on specifications for medicines and quality control laboratory issues in June 2009 following which a second draft revision was prepared. The second draft revision was further discussed with inspectors in the informal consultation on WHO guidelines for medicines quality assurance, quality control laboratories and transfer of technology in July 2009, resulting in a third draft revision which was distributed for comments in September 2009.\n\nThis third draft revision was presented for discussion to the forty-fourth meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Proceso de Revisi\u00f3n de Buenas Pr\u00e1cticas**: La Organizaci\u00f3n Mundial de la Salud (OMS) inici\u00f3 un proceso de revisi\u00f3n de las Buenas Pr\u00e1cticas para Laboratorios de Control de Calidad Farmac\u00e9utica (GPCL) a partir de recomendaciones de su Comit\u00e9 de Expertos. Esta revisi\u00f3n busca integrar aspectos relevantes de la gu\u00eda de Buenas Pr\u00e1cticas de Manufactura (GMP) y alinearse con est\u00e1ndares internacionales como ISO/IEC 17025:2005.\n\n2. **Objetivos de la Revisi\u00f3n**: La revisi\u00f3n tiene como objetivo proporcionar orientaci\u00f3n detallada sobre \u00e1reas que suelen presentar deficiencias durante las inspecciones, aplicarse a cualquier laboratorio de control de calidad farmac\u00e9utica y armonizar la terminolog\u00eda utilizada en otros documentos de la OMS.\n\n3. **Desarrollo de Borradores**: Se han elaborado varios borradores de la revisi\u00f3n desde 2009, los cuales han sido discutidos y comentados por expertos y inspectores en diversas consultas informales, culminando en un tercer borrador que fue presentado para discusi\u00f3n en la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las \u00e1reas espec\u00edficas que se identificaron como deficientes durante las inspecciones realizadas por el PQP y que se abordar\u00e1n en la revisi\u00f3n de las GPCL?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre las deficiencias espec\u00edficas que se han observado en las inspecciones, que no se menciona expl\u00edcitamente en el contexto.\n\n2. **\u00bfQu\u00e9 partes de la gu\u00eda de Buenas Pr\u00e1cticas de Manufactura (GMP) se consideran m\u00e1s relevantes para los laboratorios de control de calidad y c\u00f3mo se integrar\u00e1n en la nueva gu\u00eda GPCL?**\n   - Esta pregunta se centra en identificar las secciones clave de la gu\u00eda GMP que se incluir\u00e1n en la revisi\u00f3n, lo cual no se detalla en el texto.\n\n3. **\u00bfQu\u00e9 cambios se han propuesto en la terminolog\u00eda utilizada en los documentos de la OMS como resultado de la revisi\u00f3n de las GPCL?**\n   - Esta pregunta busca informaci\u00f3n sobre las modificaciones espec\u00edficas en la terminolog\u00eda que se est\u00e1n considerando para lograr la armonizaci\u00f3n, un aspecto que no se aborda en el contexto proporcionado.", "prev_section_summary": "### Temas Clave\n\n1. **Evaluaci\u00f3n de Procedimientos Anal\u00edticos**: Se presentaron los resultados de cinco procedimientos anal\u00edticos en el contexto de un esquema de control de calidad de medicamentos, incluyendo m\u00e9todos como la determinaci\u00f3n de agua por el m\u00e9todo de Karl Fischer y ensayos por HPLC.\n\n2. **Recomendaciones del Comit\u00e9**: Durante una consulta informal en junio de 2009, se recomend\u00f3 la continuaci\u00f3n del esquema con una nueva fase y se sugiri\u00f3 la revisi\u00f3n de m\u00e9todos utilizados en el mismo.\n\n3. **Manejo de Resultados Insatisfactorios**: Se enfatiz\u00f3 la importancia de retener muestras adicionales para laboratorios con resultados dudosos y la necesidad de que estos laboratorios informen a la OMS sobre sus investigaciones y acciones de seguimiento.\n\n4. **Colaboraci\u00f3n entre OMS y EDQM**: Se estableci\u00f3 una colaboraci\u00f3n para evaluar el rendimiento t\u00e9cnico de 60 laboratorios de control de calidad de medicamentos entre 2010 y 2012, utilizando un programa de esquemas de pruebas de competencia.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la supervisi\u00f3n y evaluaci\u00f3n de los laboratorios de control de calidad.\n- **European Directorate for the Quality of Medicines & HealthCare (EDQM)**: Colaborador en la evaluaci\u00f3n de laboratorios y desarrollo de esquemas de pruebas de competencia.\n- **UNICEF**: Proveedor de muestras para el esquema de pruebas.\n- **Laboratorios Participantes**: 60 laboratorios de control de calidad designados por la OMS para participar en el EQAAS.\n\n### Resumen General\nEl documento detalla la evaluaci\u00f3n de un esquema de control de calidad de medicamentos, destacando la importancia de la colaboraci\u00f3n entre la OMS y EDQM, as\u00ed como la gesti\u00f3n de resultados insatisfactorios en laboratorios. Se recomienda la continuaci\u00f3n del esquema y se establecen procedimientos para evaluar el rendimiento t\u00e9cnico de los laboratorios participantes.", "excerpt_keywords": "Keywords: WHO, Good Practices, Pharmaceutical Quality Control, ISO/IEC 17025, GMP"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7031af86-e6b0-4dd9-9cbe-73bf8d67f894", "node_type": "4", "metadata": {"page_label": "53", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# WHO Good Practices for Quality Control Laboratories\n\n## Revision of WHO Good Practices for Pharmaceutical Quality Control Laboratories (GPCL)\n\nAt its forty-third meeting, the Expert Committee recommended that the WHO Secretariat initiate the process of revision of the *WHO good practices for national pharmaceutical control laboratories* (*Good practices for national pharmaceutical control laboratories*, Annex 3, WHO Technical Report Series, No. 902, 2002).\n\nThe following requirements were set for the revision, based on the recommendations of the Expert Committee at its forty-third meeting:\n\n- Include the most important parts of the WHO GMP guide, which were relevant to quality control laboratories, directly in the GPCL guideline and add references to other relevant parts of the WHO GMP guide;\n- Provide detailed guidance for the areas identified as being often deficient during inspections performed by the PQP;\n- Align the guidance with the requirements of ISO/IEC 17025:2005;\n- Apply to any pharmaceutical quality control laboratory, be it national, commercial or another nongovernmental laboratory; and\n- Harmonization of terms used in other WHO documents.\n\nThe first draft revision was prepared in March 2009 and was widely commented on. The comments received were discussed with laboratory experts at the informal consultation on specifications for medicines and quality control laboratory issues in June 2009 following which a second draft revision was prepared. The second draft revision was further discussed with inspectors in the informal consultation on WHO guidelines for medicines quality assurance, quality control laboratories and transfer of technology in July 2009, resulting in a third draft revision which was distributed for comments in September 2009.\n\nThis third draft revision was presented for discussion to the forty-fourth meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "7c432412d03931272ab62e0a2aba5ba4bbf627c7ca9f3ecc01d000faea7b0fd6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# WHO Good Practices for Quality Control Laboratories\n\n## Revision of WHO Good Practices for Pharmaceutical Quality Control Laboratories (GPCL)\n\nAt its forty-third meeting, the Expert Committee recommended that the WHO Secretariat initiate the process of revision of the *WHO good practices for national pharmaceutical control laboratories* (*Good practices for national pharmaceutical control laboratories*, Annex 3, WHO Technical Report Series, No. 902, 2002).\n\nThe following requirements were set for the revision, based on the recommendations of the Expert Committee at its forty-third meeting:\n\n- Include the most important parts of the WHO GMP guide, which were relevant to quality control laboratories, directly in the GPCL guideline and add references to other relevant parts of the WHO GMP guide;\n- Provide detailed guidance for the areas identified as being often deficient during inspections performed by the PQP;\n- Align the guidance with the requirements of ISO/IEC 17025:2005;\n- Apply to any pharmaceutical quality control laboratory, be it national, commercial or another nongovernmental laboratory; and\n- Harmonization of terms used in other WHO documents.\n\nThe first draft revision was prepared in March 2009 and was widely commented on. The comments received were discussed with laboratory experts at the informal consultation on specifications for medicines and quality control laboratory issues in June 2009 following which a second draft revision was prepared. The second draft revision was further discussed with inspectors in the informal consultation on WHO guidelines for medicines quality assurance, quality control laboratories and transfer of technology in July 2009, resulting in a third draft revision which was distributed for comments in September 2009.\n\nThis third draft revision was presented for discussion to the forty-fourth meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1948, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "958ab2bf-9805-4afd-8cd7-d810a558d728": {"__data__": {"id_": "958ab2bf-9805-4afd-8cd7-d810a558d728", "embedding": null, "metadata": {"page_label": "54", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The following changes were made to the original guidelines published in 2002:\n\n\u2014 **Explanatory notes**  \nIn order to differentiate between requirements and advice, explanatory notes were introduced in the text.\n\n\u2014 **Glossary**  \nDefinitions were revised to bring them into line with current WHO documents and 15 definitions were added as a reflection of the extended text. Definitions from WHO guidelines were used where available, or else definitions were adopted from widely accepted documents such as *International Vocabulary of Metrology* published by the Joint Committee for Guides in Metrology.\n\n\u2014 **Part one \u2014 Management and infrastructure**  \nThe *Organization and management* and *Quality system* sections were amended and structured in such a way as to provide clearer guidance. Explicit requirements on internal audits, management review of quality issues, corrective and preventive measures were included. The *Control of documentation* section was substantially extended and the *Record* section was amended to provide electronic records. The section on *Personnel* was simplified to provide a laboratory with more flexibility in organization while assuring the essential functions. Requirements on *Premises* were focused more on chemical testing and for the requirements for microbiological testing and testing on animals, readers were referred to other guidelines. The section on *Contracts* was added, differentiating between contracts to purchase services and supplies and subcontracting tests.\n\n\u2014 **Part two \u2014 Materials, equipment, instruments and other devices**  \nRequirements on labelling of reagents, reagent solutions and volumetric solutions were specified in detail. Reference substances and reference materials were differentiated and clarification was provided on retesting of various types of reference substances. Requirements relating to the qualification of laboratory equipment were added, referring to the WHO guidelines. The section on *Traceability* was simplified.\n\n\u2014 **Part three \u2014 Working procedures**  \nThe requirement for review of a test request by the laboratory was included. In the case of a pharmaceutical manufacturer\u2019s laboratory, the test request form could be replaced by a master production instruction. A section was added dealing with validation of analytical procedures and system suitability test, including the requirement to demonstrate that a pharmacopoeial method or externally validated analytical method was suitable for the substance or product to be tested. Detailed guidance on", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 957\" presenta una serie de cambios y actualizaciones a las directrices originales publicadas en 2002. Se introducen notas explicativas para diferenciar entre requisitos y consejos, se revisa el glosario con nuevas definiciones, y se estructuran las secciones sobre gesti\u00f3n, infraestructura, materiales y procedimientos de trabajo para proporcionar una gu\u00eda m\u00e1s clara. Se enfatiza la importancia de la trazabilidad, la validaci\u00f3n de procedimientos anal\u00edticos y se establecen requisitos espec\u00edficos para la documentaci\u00f3n y el manejo de equipos de laboratorio.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 cambios se realizaron en la secci\u00f3n de \"Control de documentaci\u00f3n\" y c\u00f3mo se relacionan con los registros electr\u00f3nicos?**\n   - Respuesta: La secci\u00f3n de \"Control de documentaci\u00f3n\" fue sustancialmente ampliada y la secci\u00f3n de \"Registros\" fue modificada para incluir registros electr\u00f3nicos, proporcionando as\u00ed una mayor flexibilidad y modernizaci\u00f3n en la gesti\u00f3n de la documentaci\u00f3n en los laboratorios.\n\n2. **\u00bfCu\u00e1les son las diferencias clave entre las sustancias de referencia y los materiales de referencia seg\u00fan las nuevas directrices?**\n   - Respuesta: Las nuevas directrices especifican que las sustancias de referencia y los materiales de referencia son diferenciados, y se proporciona aclaraci\u00f3n sobre el retesting de varios tipos de sustancias de referencia, lo que ayuda a asegurar la calidad y la precisi\u00f3n en los an\u00e1lisis de laboratorio.\n\n3. **\u00bfQu\u00e9 requisitos se establecen para la validaci\u00f3n de procedimientos anal\u00edticos en laboratorios de fabricantes farmac\u00e9uticos?**\n   - Respuesta: Se a\u00f1adi\u00f3 una secci\u00f3n que trata sobre la validaci\u00f3n de procedimientos anal\u00edticos y pruebas de idoneidad del sistema, que incluye la obligaci\u00f3n de demostrar que un m\u00e9todo farmacopoeico o un m\u00e9todo anal\u00edtico validado externamente es adecuado para la sustancia o producto que se va a probar.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Revisi\u00f3n de Buenas Pr\u00e1cticas**: La OMS est\u00e1 revisando las Buenas Pr\u00e1cticas para Laboratorios de Control de Calidad Farmac\u00e9utica (GPCL) a partir de recomendaciones del Comit\u00e9 de Expertos en su cuadrag\u00e9sima tercera reuni\u00f3n.\n\n2. **Objetivos de la Revisi\u00f3n**:\n   - Integrar partes relevantes de la gu\u00eda de Buenas Pr\u00e1cticas de Manufactura (GMP) en la nueva gu\u00eda GPCL.\n   - Proporcionar orientaci\u00f3n detallada sobre \u00e1reas deficientes identificadas durante inspecciones.\n   - Alinear la gu\u00eda con los requisitos de ISO/IEC 17025:2005.\n   - Aplicar la gu\u00eda a todos los laboratorios de control de calidad farmac\u00e9utica, ya sean nacionales, comerciales o no gubernamentales.\n   - Armonizar la terminolog\u00eda utilizada en otros documentos de la OMS.\n\n3. **Desarrollo de Borradores**: Desde marzo de 2009, se han elaborado varios borradores de la revisi\u00f3n, los cuales han sido discutidos y comentados por expertos y inspectores en diversas consultas informales, culminando en un tercer borrador presentado en la cuadrag\u00e9sima cuarta reuni\u00f3n del Comit\u00e9 de Expertos de la OMS.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la revisi\u00f3n.\n- **Comit\u00e9 de Expertos**: Grupo que recomend\u00f3 la revisi\u00f3n de las GPCL.\n- **ISO/IEC 17025:2005**: Est\u00e1ndar internacional con el que se busca alinear la gu\u00eda.\n- **Laboratorios de Control de Calidad Farmac\u00e9utica**: Entidades a las que se aplica la nueva gu\u00eda.", "excerpt_keywords": "Keywords: WHO, guidelines, laboratory, validation, traceability"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7df489d3-c38a-4284-a7fc-618ae60b895c", "node_type": "4", "metadata": {"page_label": "54", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The following changes were made to the original guidelines published in 2002:\n\n\u2014 **Explanatory notes**  \nIn order to differentiate between requirements and advice, explanatory notes were introduced in the text.\n\n\u2014 **Glossary**  \nDefinitions were revised to bring them into line with current WHO documents and 15 definitions were added as a reflection of the extended text. Definitions from WHO guidelines were used where available, or else definitions were adopted from widely accepted documents such as *International Vocabulary of Metrology* published by the Joint Committee for Guides in Metrology.\n\n\u2014 **Part one \u2014 Management and infrastructure**  \nThe *Organization and management* and *Quality system* sections were amended and structured in such a way as to provide clearer guidance. Explicit requirements on internal audits, management review of quality issues, corrective and preventive measures were included. The *Control of documentation* section was substantially extended and the *Record* section was amended to provide electronic records. The section on *Personnel* was simplified to provide a laboratory with more flexibility in organization while assuring the essential functions. Requirements on *Premises* were focused more on chemical testing and for the requirements for microbiological testing and testing on animals, readers were referred to other guidelines. The section on *Contracts* was added, differentiating between contracts to purchase services and supplies and subcontracting tests.\n\n\u2014 **Part two \u2014 Materials, equipment, instruments and other devices**  \nRequirements on labelling of reagents, reagent solutions and volumetric solutions were specified in detail. Reference substances and reference materials were differentiated and clarification was provided on retesting of various types of reference substances. Requirements relating to the qualification of laboratory equipment were added, referring to the WHO guidelines. The section on *Traceability* was simplified.\n\n\u2014 **Part three \u2014 Working procedures**  \nThe requirement for review of a test request by the laboratory was included. In the case of a pharmaceutical manufacturer\u2019s laboratory, the test request form could be replaced by a master production instruction. A section was added dealing with validation of analytical procedures and system suitability test, including the requirement to demonstrate that a pharmacopoeial method or externally validated analytical method was suitable for the substance or product to be tested. Detailed guidance on", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "690176a8de14171b92031962a0bfb3ec37051b6ecd551a81bf8a958a89b00869", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The following changes were made to the original guidelines published in 2002:\n\n\u2014 **Explanatory notes**  \nIn order to differentiate between requirements and advice, explanatory notes were introduced in the text.\n\n\u2014 **Glossary**  \nDefinitions were revised to bring them into line with current WHO documents and 15 definitions were added as a reflection of the extended text. Definitions from WHO guidelines were used where available, or else definitions were adopted from widely accepted documents such as *International Vocabulary of Metrology* published by the Joint Committee for Guides in Metrology.\n\n\u2014 **Part one \u2014 Management and infrastructure**  \nThe *Organization and management* and *Quality system* sections were amended and structured in such a way as to provide clearer guidance. Explicit requirements on internal audits, management review of quality issues, corrective and preventive measures were included. The *Control of documentation* section was substantially extended and the *Record* section was amended to provide electronic records. The section on *Personnel* was simplified to provide a laboratory with more flexibility in organization while assuring the essential functions. Requirements on *Premises* were focused more on chemical testing and for the requirements for microbiological testing and testing on animals, readers were referred to other guidelines. The section on *Contracts* was added, differentiating between contracts to purchase services and supplies and subcontracting tests.\n\n\u2014 **Part two \u2014 Materials, equipment, instruments and other devices**  \nRequirements on labelling of reagents, reagent solutions and volumetric solutions were specified in detail. Reference substances and reference materials were differentiated and clarification was provided on retesting of various types of reference substances. Requirements relating to the qualification of laboratory equipment were added, referring to the WHO guidelines. The section on *Traceability* was simplified.\n\n\u2014 **Part three \u2014 Working procedures**  \nThe requirement for review of a test request by the laboratory was included. In the case of a pharmaceutical manufacturer\u2019s laboratory, the test request form could be replaced by a master production instruction. A section was added dealing with validation of analytical procedures and system suitability test, including the requirement to demonstrate that a pharmacopoeial method or externally validated analytical method was suitable for the substance or product to be tested. Detailed guidance on", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2542, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9642d0ab-4c87-4915-920b-955d85644609": {"__data__": {"id_": "9642d0ab-4c87-4915-920b-955d85644609", "embedding": null, "metadata": {"page_label": "55", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the procedure for out-of-specification results, including references to the US Food and Drug Administration (FDA) and the European Official Medicines Control Laboratories (OMCL) network under the *Note* was provided. A brief explanation of uncertainty of measurement with further references was included. The contents of the analytical test report, which was used in investigative testing, and of the certificate of analysis were specified.\n\n\u2014 **Part four \u2014 Safety**  \nNo major changes were made to part four.\n\n\u2014 **References**  \nReferences to WHO documents were updated and a number of references to documents of other organizations, such as the International Organization for Standardization, Joint Committee for Guides in Metrology, US FDA, International Society for Pharmaceutical Engineering, European Union guidelines, the OMCL Network of the Council of Europe, US Pharmacopeia, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use and Eurachem/Cooperation on International Traceability in Analytical Chemistry (CITAC), were included under *Notes*.\n\n\u2014 **Appendices**  \nAppendix 1: *Model analytical test report for active pharmaceutical ingredients, excipients and pharmaceutical products* was deleted and was replaced by a reference to existing WHO guidelines.\n\nAppendix 2 (now Appendix 1): *Equipment for a first-stage and medium-size pharmaceutical quality control laboratory* did not represent any requirement; it would be helpful in establishing a new laboratory in a developing country. The list, which covered chemical and microbiological units, was updated according to currently used analytical methods and equipment and specific requirements for a pharmacognosy/phytochemistry unit were added.\n\n\u2014 **Applicability to any pharmaceutical quality control laboratory, be it national, commercial or another nongovernmental laboratory**  \nDue attention was paid to the applicability of the guidelines. The inappropriateness of some requirements in the first draft, specifically to laboratories belonging to a pharmaceutical manufacturer, was commented upon by several organizations. The text was subsequently thoroughly discussed with GMP inspectors during the aforementioned informal consultation and modified accordingly. Recommendations specific to national pharmaceutical quality control laboratories were stressed and some flexibility was introduced.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es un informe t\u00e9cnico de la OMS (Organizaci\u00f3n Mundial de la Salud) que aborda procedimientos y directrices para laboratorios de control de calidad farmac\u00e9utica. Se discuten cambios en la estructura del documento, incluyendo la eliminaci\u00f3n de un modelo de informe anal\u00edtico y la actualizaci\u00f3n de referencias a documentos de diversas organizaciones. Tambi\u00e9n se menciona la importancia de la aplicabilidad de las directrices a diferentes tipos de laboratorios, as\u00ed como la flexibilidad introducida en las recomendaciones para laboratorios nacionales de control de calidad farmac\u00e9utica.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 cambios se realizaron en la secci\u00f3n de referencias del documento y qu\u00e9 organizaciones se incluyeron?**\n   - El documento actualiz\u00f3 las referencias a documentos de la OMS y a\u00f1adi\u00f3 referencias a organizaciones como la ISO, la FDA de EE. UU., y la OMCL, entre otras.\n\n2. **\u00bfCu\u00e1l es la finalidad del nuevo Ap\u00e9ndice 1 sobre el equipo para laboratorios de control de calidad farmac\u00e9utica?**\n   - El nuevo Ap\u00e9ndice 1 proporciona una lista actualizada de equipos que son \u00fatiles para establecer un laboratorio de control de calidad farmac\u00e9utica en un pa\u00eds en desarrollo, abarcando unidades qu\u00edmicas y microbiol\u00f3gicas.\n\n3. **\u00bfC\u00f3mo se abordaron las preocupaciones sobre la aplicabilidad de las directrices a laboratorios de fabricantes farmac\u00e9uticos?**\n   - Se discutieron las preocupaciones con inspectores de Buenas Pr\u00e1cticas de Manufactura (GMP) y se modific\u00f3 el texto para introducir flexibilidad en las recomendaciones, enfatizando la aplicabilidad a laboratorios nacionales de control de calidad farmac\u00e9utica.\n\n### Resumen de Nivel Superior\n\nEl informe t\u00e9cnico de la OMS proporciona directrices actualizadas para laboratorios de control de calidad farmac\u00e9utica, abordando procedimientos para resultados fuera de especificaci\u00f3n, la seguridad, y la aplicabilidad de las directrices a diferentes tipos de laboratorios. Se realizaron cambios significativos en las referencias y se elimin\u00f3 un modelo de informe anal\u00edtico, mientras que se introdujeron recomendaciones espec\u00edficas para laboratorios nacionales.", "prev_section_summary": "### Temas Clave:\n\n1. **Actualizaci\u00f3n de Directrices**: Se realizaron cambios significativos a las directrices originales de 2002, con el objetivo de mejorar la claridad y la aplicabilidad de las normas.\n\n2. **Notas Explicativas**: Se introdujeron notas explicativas para diferenciar entre requisitos y consejos, facilitando la comprensi\u00f3n de las directrices.\n\n3. **Revisi\u00f3n del Glosario**: Se actualizaron y a\u00f1adieron definiciones para alinearse con documentos actuales de la OMS, incluyendo 15 nuevas definiciones.\n\n4. **Gesti\u00f3n e Infraestructura**: Se reestructuraron secciones clave como *Organizaci\u00f3n y gesti\u00f3n* y *Sistema de calidad*, con requisitos expl\u00edcitos sobre auditor\u00edas internas y revisi\u00f3n de calidad.\n\n5. **Control de Documentaci\u00f3n**: La secci\u00f3n fue ampliada para incluir registros electr\u00f3nicos, modernizando as\u00ed la gesti\u00f3n documental en laboratorios.\n\n6. **Materiales y Equipos**: Se especificaron requisitos detallados sobre el etiquetado de reactivos y se diferenciaron las sustancias de referencia de los materiales de referencia.\n\n7. **Procedimientos de Trabajo**: Se incluy\u00f3 la revisi\u00f3n de solicitudes de prueba y se a\u00f1adi\u00f3 una secci\u00f3n sobre la validaci\u00f3n de procedimientos anal\u00edticos, enfatizando la idoneidad de los m\u00e9todos utilizados.\n\n### Entidades:\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad responsable de las directrices.\n- **Directrices de 2002**: Documento original que fue actualizado.\n- **Sustancias de referencia y materiales de referencia**: Conceptos diferenciados en las nuevas directrices.\n- **Auditor\u00edas internas y revisi\u00f3n de calidad**: Requisitos establecidos para la gesti\u00f3n de calidad en laboratorios.\n- **Registros electr\u00f3nicos**: Innovaci\u00f3n en el control de documentaci\u00f3n.\n- **M\u00e9todos farmacopoeicos**: M\u00e9todos anal\u00edticos que deben ser validados seg\u00fan las nuevas directrices.\n\nEste resumen destaca los cambios clave y las entidades relevantes en la secci\u00f3n del documento, proporcionando una visi\u00f3n clara de las actualizaciones realizadas.", "excerpt_keywords": "Keywords: pharmaceutical quality control, WHO guidelines, analytical test report, out-of-specification results, GMP inspectors"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "10f493e8-3b03-46f6-bb21-2cf2d119ed7c", "node_type": "4", "metadata": {"page_label": "55", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the procedure for out-of-specification results, including references to the US Food and Drug Administration (FDA) and the European Official Medicines Control Laboratories (OMCL) network under the *Note* was provided. A brief explanation of uncertainty of measurement with further references was included. The contents of the analytical test report, which was used in investigative testing, and of the certificate of analysis were specified.\n\n\u2014 **Part four \u2014 Safety**  \nNo major changes were made to part four.\n\n\u2014 **References**  \nReferences to WHO documents were updated and a number of references to documents of other organizations, such as the International Organization for Standardization, Joint Committee for Guides in Metrology, US FDA, International Society for Pharmaceutical Engineering, European Union guidelines, the OMCL Network of the Council of Europe, US Pharmacopeia, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use and Eurachem/Cooperation on International Traceability in Analytical Chemistry (CITAC), were included under *Notes*.\n\n\u2014 **Appendices**  \nAppendix 1: *Model analytical test report for active pharmaceutical ingredients, excipients and pharmaceutical products* was deleted and was replaced by a reference to existing WHO guidelines.\n\nAppendix 2 (now Appendix 1): *Equipment for a first-stage and medium-size pharmaceutical quality control laboratory* did not represent any requirement; it would be helpful in establishing a new laboratory in a developing country. The list, which covered chemical and microbiological units, was updated according to currently used analytical methods and equipment and specific requirements for a pharmacognosy/phytochemistry unit were added.\n\n\u2014 **Applicability to any pharmaceutical quality control laboratory, be it national, commercial or another nongovernmental laboratory**  \nDue attention was paid to the applicability of the guidelines. The inappropriateness of some requirements in the first draft, specifically to laboratories belonging to a pharmaceutical manufacturer, was commented upon by several organizations. The text was subsequently thoroughly discussed with GMP inspectors during the aforementioned informal consultation and modified accordingly. Recommendations specific to national pharmaceutical quality control laboratories were stressed and some flexibility was introduced.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "804cd5ae831b94666c978bb233e89249f649f583e000a9b86668779778e0c9c5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "the procedure for out-of-specification results, including references to the US Food and Drug Administration (FDA) and the European Official Medicines Control Laboratories (OMCL) network under the *Note* was provided. A brief explanation of uncertainty of measurement with further references was included. The contents of the analytical test report, which was used in investigative testing, and of the certificate of analysis were specified.\n\n\u2014 **Part four \u2014 Safety**  \nNo major changes were made to part four.\n\n\u2014 **References**  \nReferences to WHO documents were updated and a number of references to documents of other organizations, such as the International Organization for Standardization, Joint Committee for Guides in Metrology, US FDA, International Society for Pharmaceutical Engineering, European Union guidelines, the OMCL Network of the Council of Europe, US Pharmacopeia, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use and Eurachem/Cooperation on International Traceability in Analytical Chemistry (CITAC), were included under *Notes*.\n\n\u2014 **Appendices**  \nAppendix 1: *Model analytical test report for active pharmaceutical ingredients, excipients and pharmaceutical products* was deleted and was replaced by a reference to existing WHO guidelines.\n\nAppendix 2 (now Appendix 1): *Equipment for a first-stage and medium-size pharmaceutical quality control laboratory* did not represent any requirement; it would be helpful in establishing a new laboratory in a developing country. The list, which covered chemical and microbiological units, was updated according to currently used analytical methods and equipment and specific requirements for a pharmacognosy/phytochemistry unit were added.\n\n\u2014 **Applicability to any pharmaceutical quality control laboratory, be it national, commercial or another nongovernmental laboratory**  \nDue attention was paid to the applicability of the guidelines. The inappropriateness of some requirements in the first draft, specifically to laboratories belonging to a pharmaceutical manufacturer, was commented upon by several organizations. The text was subsequently thoroughly discussed with GMP inspectors during the aforementioned informal consultation and modified accordingly. Recommendations specific to national pharmaceutical quality control laboratories were stressed and some flexibility was introduced.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2429, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "93e79246-518c-47b8-9036-62a5ac91b9ea": {"__data__": {"id_": "93e79246-518c-47b8-9036-62a5ac91b9ea", "embedding": null, "metadata": {"page_label": "56", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The revised guidance text was presented to the Expert Committee for discussion of comments and this was adopted (Annex 1).\n\n## 5.3 WHO good practices for pharmaceutical microbiology laboratories\n\n### Introduction\n\nIn addition to the above-discussed update of the WHO good practices for pharmaceutical control laboratories, during the inspections carried out when prequalifying laboratories, the inspectors had noticed that these guidelines might benefit from complementation by a specific text for pharmaceutical microbiology laboratories.\n\nIn light of the above, the Expert Committee recommended that the WHO Secretariat initiate the process of revision of these good practices and in addition prepare a new text on good practices for pharmaceutical microbiology laboratories. The Committee took note that these guidelines were in production and would be sent out for comments.\n\n## 6. Quality assurance \u2014 good manufacturing practices\n\n### 6.1 WHO good manufacturing practices: main principles for pharmaceutical products\n\nAn informal consultation on WHO guidelines for medicines quality assurance, quality control laboratories and technology transfer was held in Geneva from 27 to 31 July 2009. *WHO GMP: main principles for pharmaceutical products* was discussed with the following outcomes:\n\nThe main changes recommended during that meeting and subject to presentation to the Expert Committee for review and possible approval were as follows:\n\n- Quality unit concept to be included in the main principles;\n- Inclusion of the quality risk management;\n- Addition of a reference and link to the product quality review; and\n- More detailed review of the responsibilities of key personnel.\n\nThe main changes recommended were:\n\n- Quality unit concept\n- Quality risk management\n- Product quality review\n- Responsibilities of key personnel.\n\nThe Expert Committee endorsed the suggested recommendations and recommended that the Secretariat distribute the revised text for comment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Actualizaci\u00f3n de las Buenas Pr\u00e1cticas de la OMS**: Se ha presentado un texto revisado sobre las buenas pr\u00e1cticas para laboratorios de microbiolog\u00eda farmac\u00e9utica a un Comit\u00e9 de Expertos, que ha sido adoptado. Se ha recomendado la creaci\u00f3n de un nuevo texto espec\u00edfico para estos laboratorios, en respuesta a observaciones realizadas durante las inspecciones de laboratorios en proceso de precalificaci\u00f3n.\n\n2. **Principios de Buenas Pr\u00e1cticas de Manufactura (GMP)**: Durante una consulta informal en Ginebra, se discutieron las directrices de la OMS sobre aseguramiento de calidad y control de calidad de medicamentos. Se propusieron cambios significativos en los principios de GMP, incluyendo la inclusi\u00f3n de un concepto de unidad de calidad, gesti\u00f3n de riesgos de calidad, revisi\u00f3n de calidad del producto y responsabilidades del personal clave.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 recomendaciones espec\u00edficas se hicieron para complementar las buenas pr\u00e1cticas de los laboratorios de microbiolog\u00eda farmac\u00e9utica?**\n   - Se recomend\u00f3 que la Secretar\u00eda de la OMS inicie el proceso de revisi\u00f3n de las buenas pr\u00e1cticas existentes y prepare un nuevo texto espec\u00edfico para laboratorios de microbiolog\u00eda farmac\u00e9utica, en respuesta a las observaciones realizadas durante las inspecciones.\n\n2. **\u00bfCu\u00e1les son los principales cambios propuestos en las Buenas Pr\u00e1cticas de Manufactura (GMP) seg\u00fan la consulta de 2009?**\n   - Los cambios propuestos incluyen la inclusi\u00f3n del concepto de unidad de calidad, la gesti\u00f3n de riesgos de calidad, la adici\u00f3n de un enlace a la revisi\u00f3n de calidad del producto y una revisi\u00f3n m\u00e1s detallada de las responsabilidades del personal clave.\n\n3. **\u00bfQu\u00e9 papel desempe\u00f1\u00f3 el Comit\u00e9 de Expertos en la revisi\u00f3n de las buenas pr\u00e1cticas para laboratorios farmac\u00e9uticos?**\n   - El Comit\u00e9 de Expertos revis\u00f3 y adopt\u00f3 el texto revisado de las buenas pr\u00e1cticas y respald\u00f3 las recomendaciones para la distribuci\u00f3n del texto revisado para comentarios, asegurando que se consideren las opiniones de los interesados en el proceso de revisi\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Procedimientos para Resultados Fuera de Especificaci\u00f3n**: Se proporcion\u00f3 un procedimiento que incluye referencias a la FDA de EE. UU. y a la red de Laboratorios Oficiales de Control de Medicamentos de Europa (OMCL).\n\n2. **Seguridad**: No se realizaron cambios significativos en la secci\u00f3n de seguridad del documento.\n\n3. **Referencias**: \n   - Se actualizaron las referencias a documentos de la OMS.\n   - Se incluyeron referencias a organizaciones como:\n     - Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO)\n     - Comit\u00e9 Conjunto de Gu\u00edas en Metrolog\u00eda\n     - Sociedad Internacional de Ingenier\u00eda Farmac\u00e9utica\n     - Directrices de la Uni\u00f3n Europea\n     - Farmacopea de EE. UU.\n     - Conferencia Internacional sobre Armonizaci\u00f3n de Requisitos T\u00e9cnicos para el Registro de Productos Farmac\u00e9uticos para Uso Humano\n     - Eurachem/CITAC (Cooperaci\u00f3n en Trazabilidad Internacional en Qu\u00edmica Anal\u00edtica).\n\n4. **Ap\u00e9ndices**:\n   - **Ap\u00e9ndice 1**: Se elimin\u00f3 el modelo de informe anal\u00edtico y se reemplaz\u00f3 por una referencia a las directrices existentes de la OMS.\n   - **Ap\u00e9ndice 2 (ahora Ap\u00e9ndice 1)**: Se actualiz\u00f3 la lista de equipos para laboratorios de control de calidad farmac\u00e9utica, enfoc\u00e1ndose en la utilidad para establecer laboratorios en pa\u00edses en desarrollo.\n\n5. **Aplicabilidad de las Directrices**: \n   - Se prest\u00f3 atenci\u00f3n a la aplicabilidad de las directrices a diferentes tipos de laboratorios, incluyendo laboratorios nacionales y comerciales.\n   - Se abordaron preocupaciones sobre la inadecuaci\u00f3n de algunos requisitos para laboratorios de fabricantes farmac\u00e9uticos, lo que llev\u00f3 a modificaciones en el texto y a la introducci\u00f3n de flexibilidad en las recomendaciones.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Administraci\u00f3n de Alimentos y Medicamentos de EE. UU. (FDA)**\n- **Laboratorios Oficiales de Control de Medicamentos (OMCL)**\n- **Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO)**\n- **Sociedad Internacional de Ingenier\u00eda Farmac\u00e9utica**\n- **Uni\u00f3n Europea**\n- **Farmacopea de EE. UU.**\n- **Eurachem/CITAC**", "excerpt_keywords": "Keywords: WHO, good practices, pharmaceutical microbiology, quality assurance, manufacturing practices"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5cb5b786-894e-433c-bd00-a0e7f32ab781", "node_type": "4", "metadata": {"page_label": "56", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The revised guidance text was presented to the Expert Committee for discussion of comments and this was adopted (Annex 1).\n\n## 5.3 WHO good practices for pharmaceutical microbiology laboratories\n\n### Introduction\n\nIn addition to the above-discussed update of the WHO good practices for pharmaceutical control laboratories, during the inspections carried out when prequalifying laboratories, the inspectors had noticed that these guidelines might benefit from complementation by a specific text for pharmaceutical microbiology laboratories.\n\nIn light of the above, the Expert Committee recommended that the WHO Secretariat initiate the process of revision of these good practices and in addition prepare a new text on good practices for pharmaceutical microbiology laboratories. The Committee took note that these guidelines were in production and would be sent out for comments.\n\n## 6. Quality assurance \u2014 good manufacturing practices\n\n### 6.1 WHO good manufacturing practices: main principles for pharmaceutical products\n\nAn informal consultation on WHO guidelines for medicines quality assurance, quality control laboratories and technology transfer was held in Geneva from 27 to 31 July 2009. *WHO GMP: main principles for pharmaceutical products* was discussed with the following outcomes:\n\nThe main changes recommended during that meeting and subject to presentation to the Expert Committee for review and possible approval were as follows:\n\n- Quality unit concept to be included in the main principles;\n- Inclusion of the quality risk management;\n- Addition of a reference and link to the product quality review; and\n- More detailed review of the responsibilities of key personnel.\n\nThe main changes recommended were:\n\n- Quality unit concept\n- Quality risk management\n- Product quality review\n- Responsibilities of key personnel.\n\nThe Expert Committee endorsed the suggested recommendations and recommended that the Secretariat distribute the revised text for comment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "05602df1f0114c0b0575bd0d48660fecfa41b324c3af2a51b03d059405b5b202", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The revised guidance text was presented to the Expert Committee for discussion of comments and this was adopted (Annex 1).\n\n## 5.3 WHO good practices for pharmaceutical microbiology laboratories\n\n### Introduction\n\nIn addition to the above-discussed update of the WHO good practices for pharmaceutical control laboratories, during the inspections carried out when prequalifying laboratories, the inspectors had noticed that these guidelines might benefit from complementation by a specific text for pharmaceutical microbiology laboratories.\n\nIn light of the above, the Expert Committee recommended that the WHO Secretariat initiate the process of revision of these good practices and in addition prepare a new text on good practices for pharmaceutical microbiology laboratories. The Committee took note that these guidelines were in production and would be sent out for comments.\n\n## 6. Quality assurance \u2014 good manufacturing practices\n\n### 6.1 WHO good manufacturing practices: main principles for pharmaceutical products\n\nAn informal consultation on WHO guidelines for medicines quality assurance, quality control laboratories and technology transfer was held in Geneva from 27 to 31 July 2009. *WHO GMP: main principles for pharmaceutical products* was discussed with the following outcomes:\n\nThe main changes recommended during that meeting and subject to presentation to the Expert Committee for review and possible approval were as follows:\n\n- Quality unit concept to be included in the main principles;\n- Inclusion of the quality risk management;\n- Addition of a reference and link to the product quality review; and\n- More detailed review of the responsibilities of key personnel.\n\nThe main changes recommended were:\n\n- Quality unit concept\n- Quality risk management\n- Product quality review\n- Responsibilities of key personnel.\n\nThe Expert Committee endorsed the suggested recommendations and recommended that the Secretariat distribute the revised text for comment.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1974, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "76ce5ef2-35b9-4382-a7fe-62004daaa775": {"__data__": {"id_": "76ce5ef2-35b9-4382-a7fe-62004daaa775", "embedding": null, "metadata": {"page_label": "57", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 6.2 WHO good manufacturing practices for active pharmaceutical ingredients\n\nDuring several previous meetings of the Expert Committee, the revision of WHO GMP for active pharmaceutical ingredients (APIs) had been discussed. The Committee also closely followed development of the ICH GMP guidelines for APIs, including their initial preparation by the Pharmaceutical Inspection Co-operation Scheme (PIC/S).\n\nIn the past the Committee had recognized the difficulty that countries would have in implementing the ICH GMP guide in a short period of time. It, therefore, agreed that WHO should revise the current WHO GMP for APIs to reflect current GMP requirements and to take into account other published guidelines, including the ICH guide. The Committee endorsed the step-wise approach to the implementation of GMP for APIs.\n\nIn the meantime, the principles described in the ICH GMP for APIs had been recognized and implemented by numerous national inspectorates. In addition, they had been field-tested when inspecting in the context of the WHO PQP (for medicines).\n\nThe Secretariat had, therefore, prepared a WHO-style, edited version of this guide, fully in line with the internationally used text developed following the ICH process.\n\nThis draft working document was reviewed and discussed with inspectors, experts and interested parties during the informal consultation in July 2009. During this meeting it was recommended that the text be fully retained in line with the ICH principles in order to avoid any challenges regarding the further global implementation of this standard internationally.\n\nIn order to further assist with its implementation, the experts decided to add clarifying notes and explanations for some of the parts that had been questioned during inspections, i.e.\n\n- definition of API starting material;\n- (para. 2.1.1) role of senior management regarding the implementation of an effective quality management system;\n- (para. 2.3) delegation of the responsibility for production activities;\n- need for manufacturers of intermediates and/or APIs to have a system for evaluating the suppliers of critical materials in place;\n- examination of each container or grouping of containers of materials upon receipt and before acceptance;\n- identification of batch material;\n- reserve samples; and\n- inclusion of cross-references to Good trade and distribution practices (GTDP) and GMP for excipients in the section entitled: Agents, brokers, traders, distributors, repackers and relabellers.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento discute la revisi\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP) de la OMS para los ingredientes farmac\u00e9uticos activos (APIs). Se menciona la dificultad que enfrentan los pa\u00edses para implementar las gu\u00edas GMP del ICH en un corto per\u00edodo y la decisi\u00f3n de la OMS de actualizar sus propias gu\u00edas para alinearse con los est\u00e1ndares internacionales. Se destaca la importancia de un enfoque gradual para la implementaci\u00f3n de estas pr\u00e1cticas y se enumeran varios puntos clave que se aclarar\u00e1n en la revisi\u00f3n, como la definici\u00f3n de materiales de partida de API y la responsabilidad de la alta direcci\u00f3n en la gesti\u00f3n de calidad.\n\n### Preguntas Espec\u00edficas:\n1. **\u00bfQu\u00e9 enfoque se recomienda para la implementaci\u00f3n de las GMP para APIs seg\u00fan el Comit\u00e9 de Expertos de la OMS?**\n   - Respuesta: El Comit\u00e9 de Expertos de la OMS recomienda un enfoque gradual para la implementaci\u00f3n de las GMP para APIs, reconociendo las dificultades que los pa\u00edses pueden enfrentar al adoptar las gu\u00edas del ICH en un corto per\u00edodo de tiempo.\n\n2. **\u00bfCu\u00e1les son algunos de los puntos que se aclarar\u00e1n en la revisi\u00f3n de las GMP para APIs?**\n   - Respuesta: Algunos de los puntos que se aclarar\u00e1n incluyen la definici\u00f3n de material de partida de API, el papel de la alta direcci\u00f3n en la implementaci\u00f3n de un sistema de gesti\u00f3n de calidad efectivo, la delegaci\u00f3n de responsabilidades en las actividades de producci\u00f3n, y la necesidad de un sistema para evaluar a los proveedores de materiales cr\u00edticos.\n\n3. **\u00bfQu\u00e9 importancia tiene la consulta informal de julio de 2009 en el proceso de revisi\u00f3n de las GMP para APIs?**\n   - Respuesta: La consulta informal de julio de 2009 fue crucial porque permiti\u00f3 revisar y discutir el borrador del documento con inspectores, expertos y partes interesadas, lo que llev\u00f3 a la recomendaci\u00f3n de mantener el texto alineado con los principios del ICH para facilitar la implementaci\u00f3n global de este est\u00e1ndar.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Actualizaci\u00f3n de Buenas Pr\u00e1cticas de la OMS**:\n   - Se present\u00f3 un texto revisado sobre las buenas pr\u00e1cticas para laboratorios de microbiolog\u00eda farmac\u00e9utica al Comit\u00e9 de Expertos, que fue adoptado.\n   - Se recomend\u00f3 la creaci\u00f3n de un nuevo texto espec\u00edfico para estos laboratorios, basado en observaciones de inspecciones de laboratorios en proceso de precalificaci\u00f3n.\n\n2. **Principios de Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Se llev\u00f3 a cabo una consulta informal en Ginebra sobre las directrices de la OMS para el aseguramiento de calidad y control de calidad de medicamentos.\n   - Se propusieron cambios significativos en los principios de GMP, que incluyen:\n     - Inclusi\u00f3n del concepto de unidad de calidad.\n     - Gesti\u00f3n de riesgos de calidad.\n     - Revisi\u00f3n de calidad del producto.\n     - Responsabilidades del personal clave.\n\n3. **Comit\u00e9 de Expertos**:\n   - El Comit\u00e9 revis\u00f3 y adopt\u00f3 el texto revisado de las buenas pr\u00e1cticas.\n   - Respald\u00f3 las recomendaciones para la distribuci\u00f3n del texto revisado para comentarios, asegurando la consideraci\u00f3n de las opiniones de los interesados.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la elaboraci\u00f3n de las directrices y buenas pr\u00e1cticas.\n- **Comit\u00e9 de Expertos**: Grupo encargado de revisar y aprobar las recomendaciones sobre buenas pr\u00e1cticas.\n- **Laboratorios de Microbiolog\u00eda Farmac\u00e9utica**: Entidades que se beneficiar\u00e1n de las nuevas directrices espec\u00edficas.\n- **Ginebra**: Lugar donde se realiz\u00f3 la consulta informal sobre GMP.", "excerpt_keywords": "Keywords: WHO, GMP, active pharmaceutical ingredients, ICH guidelines, quality management system"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8bc3cb06-ba79-4085-be7e-8920e82fdd4b", "node_type": "4", "metadata": {"page_label": "57", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 6.2 WHO good manufacturing practices for active pharmaceutical ingredients\n\nDuring several previous meetings of the Expert Committee, the revision of WHO GMP for active pharmaceutical ingredients (APIs) had been discussed. The Committee also closely followed development of the ICH GMP guidelines for APIs, including their initial preparation by the Pharmaceutical Inspection Co-operation Scheme (PIC/S).\n\nIn the past the Committee had recognized the difficulty that countries would have in implementing the ICH GMP guide in a short period of time. It, therefore, agreed that WHO should revise the current WHO GMP for APIs to reflect current GMP requirements and to take into account other published guidelines, including the ICH guide. The Committee endorsed the step-wise approach to the implementation of GMP for APIs.\n\nIn the meantime, the principles described in the ICH GMP for APIs had been recognized and implemented by numerous national inspectorates. In addition, they had been field-tested when inspecting in the context of the WHO PQP (for medicines).\n\nThe Secretariat had, therefore, prepared a WHO-style, edited version of this guide, fully in line with the internationally used text developed following the ICH process.\n\nThis draft working document was reviewed and discussed with inspectors, experts and interested parties during the informal consultation in July 2009. During this meeting it was recommended that the text be fully retained in line with the ICH principles in order to avoid any challenges regarding the further global implementation of this standard internationally.\n\nIn order to further assist with its implementation, the experts decided to add clarifying notes and explanations for some of the parts that had been questioned during inspections, i.e.\n\n- definition of API starting material;\n- (para. 2.1.1) role of senior management regarding the implementation of an effective quality management system;\n- (para. 2.3) delegation of the responsibility for production activities;\n- need for manufacturers of intermediates and/or APIs to have a system for evaluating the suppliers of critical materials in place;\n- examination of each container or grouping of containers of materials upon receipt and before acceptance;\n- identification of batch material;\n- reserve samples; and\n- inclusion of cross-references to Good trade and distribution practices (GTDP) and GMP for excipients in the section entitled: Agents, brokers, traders, distributors, repackers and relabellers.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "176cfa424f079e8c91c8305918470a02319236a7bd51c31122f50f6d6a720571", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6.2 WHO good manufacturing practices for active pharmaceutical ingredients\n\nDuring several previous meetings of the Expert Committee, the revision of WHO GMP for active pharmaceutical ingredients (APIs) had been discussed. The Committee also closely followed development of the ICH GMP guidelines for APIs, including their initial preparation by the Pharmaceutical Inspection Co-operation Scheme (PIC/S).\n\nIn the past the Committee had recognized the difficulty that countries would have in implementing the ICH GMP guide in a short period of time. It, therefore, agreed that WHO should revise the current WHO GMP for APIs to reflect current GMP requirements and to take into account other published guidelines, including the ICH guide. The Committee endorsed the step-wise approach to the implementation of GMP for APIs.\n\nIn the meantime, the principles described in the ICH GMP for APIs had been recognized and implemented by numerous national inspectorates. In addition, they had been field-tested when inspecting in the context of the WHO PQP (for medicines).\n\nThe Secretariat had, therefore, prepared a WHO-style, edited version of this guide, fully in line with the internationally used text developed following the ICH process.\n\nThis draft working document was reviewed and discussed with inspectors, experts and interested parties during the informal consultation in July 2009. During this meeting it was recommended that the text be fully retained in line with the ICH principles in order to avoid any challenges regarding the further global implementation of this standard internationally.\n\nIn order to further assist with its implementation, the experts decided to add clarifying notes and explanations for some of the parts that had been questioned during inspections, i.e.\n\n- definition of API starting material;\n- (para. 2.1.1) role of senior management regarding the implementation of an effective quality management system;\n- (para. 2.3) delegation of the responsibility for production activities;\n- need for manufacturers of intermediates and/or APIs to have a system for evaluating the suppliers of critical materials in place;\n- examination of each container or grouping of containers of materials upon receipt and before acceptance;\n- identification of batch material;\n- reserve samples; and\n- inclusion of cross-references to Good trade and distribution practices (GTDP) and GMP for excipients in the section entitled: Agents, brokers, traders, distributors, repackers and relabellers.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2508, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "344beafa-a2de-4d81-9a76-0997241b6c54": {"__data__": {"id_": "344beafa-a2de-4d81-9a76-0997241b6c54", "embedding": null, "metadata": {"page_label": "58", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee endorsed the above recommendations and considered the establishment of a small working group to finalize the wording of the explanatory notes. It agreed to the publication of the supplementary GMP text for APIs together with the explanatory notes to replace the GMP for APIs published in 1992 (Annex 2).\n\n### 6.3 WHO good manufacturing practices for pharmaceutical products containing hazardous substances\n\nA working document (\u201cWHO guidance to the inspection of hormone product manufacturing facilities\u201d) had been prepared previously and tabled at the Expert Committee meeting held in October 2008. These particular guidelines were intended to provide GMP principles for the production and control of products containing certain hormones or other hazardous substances.\n\nThere was international concern about the low quality of reproductive health products and the lack of compliance with GMP principles in manufacturing facilities. The PQP included reproductive health products, and to further facilitate improved quality of manufacture of these products, the Expert Committee acknowledged its previous recommendation to provide guidance in this area.\n\nA discussion with experts and interested parties took place during the consultation held from 27 to 31 July 2009. Considering all recommendations for amendment, the group recommended that the title of the document be changed to address not only products containing certain hormones, but also to ensure that the document and the title reflected the wider group of products containing hazardous substances. A revised version of the working document was, therefore, prepared for circulation and was mailed out for comments.\n\nThe new working document QAS/08.256/Rev.1 was submitted to the Expert Committee.\n\nThe text was presented to the Expert Committee for discussion of comments and the guidelines were adopted (Annex 3) after a review of all outstanding questions.\n\n### 6.4 WHO good manufacturing practices for sterile pharmaceutical products\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations adopted in its thirty-sixth report in 1999, WHO good manufacturing practices for sterile pharmaceutical products (WHO Technical Report Series, No. 902, 2002, Annex 6) (http://whqlibdoc.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en las recomendaciones del Comit\u00e9 de Expertos de la OMS sobre las Buenas Pr\u00e1cticas de Manufactura (GMP) para productos farmac\u00e9uticos, especialmente aquellos que contienen sustancias peligrosas. Se menciona la preocupaci\u00f3n internacional por la calidad de los productos de salud reproductiva y la falta de cumplimiento de las GMP en las instalaciones de manufactura. Se discute la necesidad de actualizar las gu\u00edas existentes para incluir no solo productos hormonales, sino tambi\u00e9n una gama m\u00e1s amplia de sustancias peligrosas. Adem\u00e1s, se hace referencia a la adopci\u00f3n de nuevas directrices y la publicaci\u00f3n de un texto suplementario para las GMP de ingredientes farmac\u00e9uticos activos (APIs).\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 cambios se propusieron en el t\u00edtulo del documento de directrices sobre productos que contienen sustancias peligrosas y por qu\u00e9?**\n   - Se recomend\u00f3 cambiar el t\u00edtulo del documento para reflejar no solo los productos que contienen ciertas hormonas, sino tambi\u00e9n una gama m\u00e1s amplia de productos que contienen sustancias peligrosas, en respuesta a la preocupaci\u00f3n internacional sobre la calidad de estos productos.\n\n2. **\u00bfCu\u00e1l fue la raz\u00f3n detr\u00e1s de la creaci\u00f3n de un grupo de trabajo para finalizar las notas explicativas sobre las GMP para APIs?**\n   - La creaci\u00f3n del grupo de trabajo se debi\u00f3 a la necesidad de establecer un texto claro y actualizado que reemplazara las GMP para APIs publicadas en 1992, asegurando que las recomendaciones fueran pertinentes y efectivas en el contexto actual.\n\n3. **\u00bfQu\u00e9 acciones se llevaron a cabo durante la consulta del 27 al 31 de julio de 2009 en relaci\u00f3n con las GMP para productos farmac\u00e9uticos que contienen sustancias peligrosas?**\n   - Durante la consulta, se discutieron recomendaciones para enmendar el documento existente, se revisaron los comentarios de expertos y partes interesadas, y se prepar\u00f3 una versi\u00f3n revisada del documento para su circulaci\u00f3n y comentarios, lo que llev\u00f3 a la adopci\u00f3n de nuevas directrices por parte del Comit\u00e9 de Expertos.", "prev_section_summary": "### Temas Clave:\n1. **Revisi\u00f3n de las GMP de la OMS**: Se discute la necesidad de actualizar las Buenas Pr\u00e1cticas de Manufactura (GMP) para los ingredientes farmac\u00e9uticos activos (APIs) para alinearse con las gu\u00edas internacionales, especialmente las del ICH.\n   \n2. **Dificultades en la Implementaci\u00f3n**: Se reconoce que muchos pa\u00edses enfrentar\u00e1n desaf\u00edos al intentar implementar las gu\u00edas GMP del ICH en un corto per\u00edodo de tiempo.\n\n3. **Enfoque Gradual**: Se recomienda un enfoque paso a paso para la implementaci\u00f3n de las GMP para facilitar la adopci\u00f3n de estas pr\u00e1cticas.\n\n4. **Consulta Informal**: La consulta informal de julio de 2009 fue un evento clave donde se revis\u00f3 el borrador del documento con expertos y partes interesadas, lo que llev\u00f3 a la recomendaci\u00f3n de mantener el texto alineado con los principios del ICH.\n\n5. **Notas Aclaratorias**: Se decidi\u00f3 incluir notas y explicaciones aclaratorias sobre varios aspectos de las GMP que hab\u00edan sido cuestionados durante las inspecciones.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la revisi\u00f3n y actualizaci\u00f3n de las GMP para APIs.\n- **ICH (International Council for Harmonisation)**: Organizaci\u00f3n que desarrolla gu\u00edas internacionales para la industria farmac\u00e9utica, cuyas pr\u00e1cticas se est\u00e1n adoptando en las GMP de la OMS.\n- **PIC/S (Pharmaceutical Inspection Co-operation Scheme)**: Iniciativa que contribuye a la preparaci\u00f3n de las gu\u00edas GMP.\n- **PQP (Prequalification Programme)**: Programa de la OMS que eval\u00faa la calidad de los medicamentos, donde se han probado los principios de las GMP del ICH.\n- **Expert Committee**: Comit\u00e9 de expertos que discute y revisa las GMP de la OMS.\n\n### Puntos Clave a Aclarar:\n- Definici\u00f3n de material de partida de API.\n- Rol de la alta direcci\u00f3n en la gesti\u00f3n de calidad.\n- Delegaci\u00f3n de responsabilidades en actividades de producci\u00f3n.\n- Evaluaci\u00f3n de proveedores de materiales cr\u00edticos.\n- Inspecci\u00f3n de contenedores de materiales al recibirlos.\n- Identificaci\u00f3n de material por lote.\n- Muestras de reserva.\n- Referencias cruzadas a buenas pr\u00e1cticas de comercio y distribuci\u00f3n (GTDP) y GMP para excipientes.", "excerpt_keywords": "Keywords: GMP, hazardous substances, reproductive health products, WHO guidelines, pharmaceutical manufacturing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "001f8c08-4974-4e1b-8bdf-7188181b586c", "node_type": "4", "metadata": {"page_label": "58", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee endorsed the above recommendations and considered the establishment of a small working group to finalize the wording of the explanatory notes. It agreed to the publication of the supplementary GMP text for APIs together with the explanatory notes to replace the GMP for APIs published in 1992 (Annex 2).\n\n### 6.3 WHO good manufacturing practices for pharmaceutical products containing hazardous substances\n\nA working document (\u201cWHO guidance to the inspection of hormone product manufacturing facilities\u201d) had been prepared previously and tabled at the Expert Committee meeting held in October 2008. These particular guidelines were intended to provide GMP principles for the production and control of products containing certain hormones or other hazardous substances.\n\nThere was international concern about the low quality of reproductive health products and the lack of compliance with GMP principles in manufacturing facilities. The PQP included reproductive health products, and to further facilitate improved quality of manufacture of these products, the Expert Committee acknowledged its previous recommendation to provide guidance in this area.\n\nA discussion with experts and interested parties took place during the consultation held from 27 to 31 July 2009. Considering all recommendations for amendment, the group recommended that the title of the document be changed to address not only products containing certain hormones, but also to ensure that the document and the title reflected the wider group of products containing hazardous substances. A revised version of the working document was, therefore, prepared for circulation and was mailed out for comments.\n\nThe new working document QAS/08.256/Rev.1 was submitted to the Expert Committee.\n\nThe text was presented to the Expert Committee for discussion of comments and the guidelines were adopted (Annex 3) after a review of all outstanding questions.\n\n### 6.4 WHO good manufacturing practices for sterile pharmaceutical products\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations adopted in its thirty-sixth report in 1999, WHO good manufacturing practices for sterile pharmaceutical products (WHO Technical Report Series, No. 902, 2002, Annex 6) (http://whqlibdoc.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "14cdca660a57086a1c5ce0ae6c6c855fca7b6f9e93baf8ee6206cac95c62172d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The Expert Committee endorsed the above recommendations and considered the establishment of a small working group to finalize the wording of the explanatory notes. It agreed to the publication of the supplementary GMP text for APIs together with the explanatory notes to replace the GMP for APIs published in 1992 (Annex 2).\n\n### 6.3 WHO good manufacturing practices for pharmaceutical products containing hazardous substances\n\nA working document (\u201cWHO guidance to the inspection of hormone product manufacturing facilities\u201d) had been prepared previously and tabled at the Expert Committee meeting held in October 2008. These particular guidelines were intended to provide GMP principles for the production and control of products containing certain hormones or other hazardous substances.\n\nThere was international concern about the low quality of reproductive health products and the lack of compliance with GMP principles in manufacturing facilities. The PQP included reproductive health products, and to further facilitate improved quality of manufacture of these products, the Expert Committee acknowledged its previous recommendation to provide guidance in this area.\n\nA discussion with experts and interested parties took place during the consultation held from 27 to 31 July 2009. Considering all recommendations for amendment, the group recommended that the title of the document be changed to address not only products containing certain hormones, but also to ensure that the document and the title reflected the wider group of products containing hazardous substances. A revised version of the working document was, therefore, prepared for circulation and was mailed out for comments.\n\nThe new working document QAS/08.256/Rev.1 was submitted to the Expert Committee.\n\nThe text was presented to the Expert Committee for discussion of comments and the guidelines were adopted (Annex 3) after a review of all outstanding questions.\n\n### 6.4 WHO good manufacturing practices for sterile pharmaceutical products\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations adopted in its thirty-sixth report in 1999, WHO good manufacturing practices for sterile pharmaceutical products (WHO Technical Report Series, No. 902, 2002, Annex 6) (http://whqlibdoc.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2278, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1d84446c-f3f5-4793-99d9-50a3a3e47e79": {"__data__": {"id_": "1d84446c-f3f5-4793-99d9-50a3a3e47e79", "embedding": null, "metadata": {"page_label": "59", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "who.int/trs/WHO_TRS_902.pdf). This guidance was also published in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2. Second updated edition. Good manufacturing practices and inspection* (2007).\n\nFollowing implementation of these WHO GMP within the context of the PQP, a proposal for revision was being submitted to take into consideration new developments and to bring it into line with International Standardization Organization standard ISO 14644-1 and recent EU, Japanese, PIC/S and US practices.\n\nThe following major changes had been made to the text published in 1999:\n\n- New chapters on \u201cIsolator technology\u201d and \u201cBlow/fill/seal technology\u201d had been added.\n- The chapter on \u201cFinishing of sterile products\u201d had been amended and provisions had been given for capping of vials.\n- The chapter entitled \u201cManufacture of sterile preparations\u201d had been amended and provisions given for clean-room and clean-air-device monitoring.\n\nImplementation of certain parts of these new practices might need to be undertaken for using a step-wise approach, especially the part relating to the provision for capping in a clean or sterile environment, as this was currently not implemented in most industries.\n\nThe text was presented to the Expert Committee for discussion of comments and the guidelines were adopted (Annex 4), after review of the additional comments received by the deadline set for comments to be discussed at the meeting.\n\n### 6.5 Updates of other WHO good manufacturing practices texts\n\nIt was reported that during inspections when implementing the GMP for heating, ventilation and air-conditioning (HVAC) a need for slight revisions to certain chapters was noted. It was, therefore, suggested that these chapters be sent out for comments.\n\nThe Expert Committee endorsed this suggestion and recommended that the Secretariat distribute the revised text for comment.\n\n### 6.6 Good manufacturing practices for blood establishments\n\nAn update on the developments of the WHO GMP for blood establishments was presented to the Committee. There was an agreed need for quality and safety requirements, specifications and standards for blood and plasma collection, preparation, testing and distribution activities, the", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Revisi\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP)**: Se han realizado actualizaciones significativas a las directrices de GMP de la OMS desde su publicaci\u00f3n en 1999, incluyendo la adici\u00f3n de nuevos cap\u00edtulos sobre tecnolog\u00edas espec\u00edficas y la modificaci\u00f3n de cap\u00edtulos existentes para mejorar la calidad y seguridad en la fabricaci\u00f3n de productos est\u00e9riles.\n\n2. **Implementaci\u00f3n de nuevas pr\u00e1cticas**: La implementaci\u00f3n de ciertas pr\u00e1cticas nuevas, como el capping en un entorno limpio o est\u00e9ril, puede requerir un enfoque gradual, dado que no se est\u00e1n aplicando en la mayor\u00eda de las industrias actualmente.\n\n3. **Desarrollo de GMP para establecimientos de sangre**: Se ha reconocido la necesidad de establecer requisitos de calidad y seguridad para las actividades relacionadas con la recolecci\u00f3n, preparaci\u00f3n, prueba y distribuci\u00f3n de sangre y plasma, lo que implica la actualizaci\u00f3n de las GMP espec\u00edficas para estos establecimientos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las nuevas tecnolog\u00edas que se han incorporado en las directrices de GMP de la OMS desde 1999?**\n   - Respuesta: Se han a\u00f1adido nuevos cap\u00edtulos sobre \"Tecnolog\u00eda de aisladores\" y \"Tecnolog\u00eda de blow/fill/seal\".\n\n2. **\u00bfQu\u00e9 cambios se han realizado en el cap\u00edtulo sobre la \"Finalizaci\u00f3n de productos est\u00e9riles\"?**\n   - Respuesta: El cap\u00edtulo ha sido enmendado para incluir disposiciones sobre el capping de viales.\n\n3. **\u00bfQu\u00e9 se ha propuesto en relaci\u00f3n con las GMP para los establecimientos de sangre?**\n   - Respuesta: Se ha presentado la necesidad de establecer requisitos de calidad y seguridad, especificaciones y est\u00e1ndares para las actividades de recolecci\u00f3n, preparaci\u00f3n, prueba y distribuci\u00f3n de sangre y plasma.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Recomendaciones del Comit\u00e9 de Expertos de la OMS**: Se aprob\u00f3 la creaci\u00f3n de un grupo de trabajo para finalizar las notas explicativas sobre las Buenas Pr\u00e1cticas de Manufactura (GMP) para ingredientes farmac\u00e9uticos activos (APIs), con el objetivo de publicar un texto suplementario que reemplace las GMP para APIs de 1992.\n\n2. **GMP para Productos Farmac\u00e9uticos que Contienen Sustancias Peligrosas**: Se discutieron directrices para la producci\u00f3n y control de productos que contienen hormonas y otras sustancias peligrosas, en respuesta a preocupaciones internacionales sobre la calidad de los productos de salud reproductiva y el cumplimiento de las GMP en las instalaciones de manufactura.\n\n3. **Consulta de Expertos (27-31 de julio de 2009)**: Durante esta consulta, se revisaron recomendaciones para enmendar el documento existente, se propuso cambiar el t\u00edtulo del documento para incluir una gama m\u00e1s amplia de productos peligrosos, y se prepar\u00f3 una versi\u00f3n revisada del documento para su circulaci\u00f3n y comentarios.\n\n4. **Adopci\u00f3n de Nuevas Directrices**: El nuevo documento de trabajo (QAS/08.256/Rev.1) fue presentado al Comit\u00e9 de Expertos, que adopt\u00f3 las nuevas directrices despu\u00e9s de revisar los comentarios y preguntas pendientes.\n\n5. **GMP para Productos Farmac\u00e9uticos Est\u00e9riles**: Se hace referencia a la adopci\u00f3n de GMP para productos farmac\u00e9uticos est\u00e9riles en un informe anterior del Comit\u00e9 de Expertos de la OMS.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de las recomendaciones y directrices.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que revisa y aprueba las recomendaciones sobre GMP.\n- **PQP (Prequalification Programme)**: Programa que incluye productos de salud reproductiva y busca mejorar la calidad de fabricaci\u00f3n.\n- **Documentos de Trabajo**: Incluyen el documento QAS/08.256/Rev.1 y las gu\u00edas sobre la inspecci\u00f3n de instalaciones de fabricaci\u00f3n de productos hormonales.", "excerpt_keywords": "Keywords: Good Manufacturing Practices, WHO, sterile products, blood establishments, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d8b07ce2-3c41-4ef1-9409-0c23e40971ba", "node_type": "4", "metadata": {"page_label": "59", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "who.int/trs/WHO_TRS_902.pdf). This guidance was also published in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2. Second updated edition. Good manufacturing practices and inspection* (2007).\n\nFollowing implementation of these WHO GMP within the context of the PQP, a proposal for revision was being submitted to take into consideration new developments and to bring it into line with International Standardization Organization standard ISO 14644-1 and recent EU, Japanese, PIC/S and US practices.\n\nThe following major changes had been made to the text published in 1999:\n\n- New chapters on \u201cIsolator technology\u201d and \u201cBlow/fill/seal technology\u201d had been added.\n- The chapter on \u201cFinishing of sterile products\u201d had been amended and provisions had been given for capping of vials.\n- The chapter entitled \u201cManufacture of sterile preparations\u201d had been amended and provisions given for clean-room and clean-air-device monitoring.\n\nImplementation of certain parts of these new practices might need to be undertaken for using a step-wise approach, especially the part relating to the provision for capping in a clean or sterile environment, as this was currently not implemented in most industries.\n\nThe text was presented to the Expert Committee for discussion of comments and the guidelines were adopted (Annex 4), after review of the additional comments received by the deadline set for comments to be discussed at the meeting.\n\n### 6.5 Updates of other WHO good manufacturing practices texts\n\nIt was reported that during inspections when implementing the GMP for heating, ventilation and air-conditioning (HVAC) a need for slight revisions to certain chapters was noted. It was, therefore, suggested that these chapters be sent out for comments.\n\nThe Expert Committee endorsed this suggestion and recommended that the Secretariat distribute the revised text for comment.\n\n### 6.6 Good manufacturing practices for blood establishments\n\nAn update on the developments of the WHO GMP for blood establishments was presented to the Committee. There was an agreed need for quality and safety requirements, specifications and standards for blood and plasma collection, preparation, testing and distribution activities, the", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "50b127d71efc2ce1ca02b1518e09a2b87e352b47707e06ce9b9b64bfb07ca56c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "who.int/trs/WHO_TRS_902.pdf). This guidance was also published in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2. Second updated edition. Good manufacturing practices and inspection* (2007).\n\nFollowing implementation of these WHO GMP within the context of the PQP, a proposal for revision was being submitted to take into consideration new developments and to bring it into line with International Standardization Organization standard ISO 14644-1 and recent EU, Japanese, PIC/S and US practices.\n\nThe following major changes had been made to the text published in 1999:\n\n- New chapters on \u201cIsolator technology\u201d and \u201cBlow/fill/seal technology\u201d had been added.\n- The chapter on \u201cFinishing of sterile products\u201d had been amended and provisions had been given for capping of vials.\n- The chapter entitled \u201cManufacture of sterile preparations\u201d had been amended and provisions given for clean-room and clean-air-device monitoring.\n\nImplementation of certain parts of these new practices might need to be undertaken for using a step-wise approach, especially the part relating to the provision for capping in a clean or sterile environment, as this was currently not implemented in most industries.\n\nThe text was presented to the Expert Committee for discussion of comments and the guidelines were adopted (Annex 4), after review of the additional comments received by the deadline set for comments to be discussed at the meeting.\n\n### 6.5 Updates of other WHO good manufacturing practices texts\n\nIt was reported that during inspections when implementing the GMP for heating, ventilation and air-conditioning (HVAC) a need for slight revisions to certain chapters was noted. It was, therefore, suggested that these chapters be sent out for comments.\n\nThe Expert Committee endorsed this suggestion and recommended that the Secretariat distribute the revised text for comment.\n\n### 6.6 Good manufacturing practices for blood establishments\n\nAn update on the developments of the WHO GMP for blood establishments was presented to the Committee. There was an agreed need for quality and safety requirements, specifications and standards for blood and plasma collection, preparation, testing and distribution activities, the", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2263, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b7a27ece-2646-42fe-96d4-dcffc2f0faa3": {"__data__": {"id_": "b7a27ece-2646-42fe-96d4-dcffc2f0faa3", "embedding": null, "metadata": {"page_label": "60", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "implementation of internationally agreed quality and safety standards in the blood establishments, a harmonized and systematic approach to ensure compliance at all steps involved (from donor acceptance to release of products), and enforcement by competent MRAs.\n\nICDRA had recommended the following at its 13th meeting held in Berne in 2008:\n\n\u201cRecognizing the worldwide need for blood products regulation to ensure availability of safe blood and blood products in the face of known and emerging threats, including emerging infectious diseases, WHO should:\n\n- Take steps to further develop and strengthen national/regional blood regulatory authorities and to promote cooperation\n- Provide harmonized 'assessment criteria for blood regulatory systems' (BRN): convene a consultation of NMRAs to review Draft assessment tool\n- Prioritize development of WHO Guidelines on GMP for Blood Establishments\n- Promote introduction of WHO recommended plasma standards by NMRAs.\u201d\n\nWHO had issued requirements for the collection, processing and quality control of blood components and plasma derivatives (WHO Technical Report Series, No. 840, 1994, Annex 2) and recommendations for the production, control and regulation of plasma for fractionation (WHO Technical Report Series, No. 941, Annex 4). In addition, the GMP guide for blood establishments had been published by bodies such as the PIC/S.\n\nBased on the above, the project for WHO guidelines on GMP for blood establishments was intended to respond to the ICDRA recommendation, without inventing a new GMP standard, but taking into account the specifics of blood products, blood establishments and all existing complementary GMP standards.\n\nThe aim of the new document was to establish a wide international consensus on quality standards among blood establishments and among inspectors to ensure high-quality products and safety of recipients. It would then become a guidance document for blood establishments, for NMRAs to refer, implement and enforce GMP in blood establishments and to become widely applicable, independent of the activities of a single blood establishment.\n\nThe document addressed the general GMP topics, e.g. quality management, as well as the topics specific to manufacturing of blood products, from donor selection through distribution of final products and the newer GMP concepts, e.g. risk management and product quality review.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la implementaci\u00f3n de est\u00e1ndares internacionales de calidad y seguridad en los establecimientos de sangre. Se menciona la necesidad de regular los productos sangu\u00edneos para garantizar su disponibilidad y seguridad frente a amenazas conocidas y emergentes, como enfermedades infecciosas. En la reuni\u00f3n del ICDRA (Comit\u00e9 Internacional de Reguladores de Medicamentos) en 2008, se hicieron varias recomendaciones, incluyendo el fortalecimiento de las autoridades reguladoras de sangre y el desarrollo de gu\u00edas de Buenas Pr\u00e1cticas de Manufactura (GMP) espec\u00edficas para los establecimientos de sangre. El objetivo del proyecto de gu\u00edas de la OMS es establecer un consenso internacional sobre est\u00e1ndares de calidad y proporcionar un documento de orientaci\u00f3n para la implementaci\u00f3n y cumplimiento de GMP en estos establecimientos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las recomendaciones espec\u00edficas del ICDRA para fortalecer las autoridades reguladoras de sangre a nivel nacional y regional?**\n   - Respuesta: El ICDRA recomend\u00f3 desarrollar y fortalecer las autoridades reguladoras de sangre, promover la cooperaci\u00f3n entre ellas, proporcionar criterios de evaluaci\u00f3n armonizados para los sistemas regulatorios de sangre, priorizar el desarrollo de gu\u00edas de GMP para los establecimientos de sangre y promover la introducci\u00f3n de est\u00e1ndares de plasma recomendados por la OMS.\n\n2. **\u00bfQu\u00e9 aspectos espec\u00edficos de la manufactura de productos sangu\u00edneos se abordan en las nuevas gu\u00edas de GMP de la OMS?**\n   - Respuesta: Las nuevas gu\u00edas de GMP abordan temas generales como la gesti\u00f3n de calidad, as\u00ed como aspectos espec\u00edficos de la manufactura de productos sangu\u00edneos, que incluyen la selecci\u00f3n de donantes, el procesamiento de componentes sangu\u00edneos y la distribuci\u00f3n de productos finales, adem\u00e1s de conceptos m\u00e1s recientes como la gesti\u00f3n de riesgos y la revisi\u00f3n de la calidad del producto.\n\n3. **\u00bfCu\u00e1l es el prop\u00f3sito de establecer un consenso internacional sobre est\u00e1ndares de calidad entre los establecimientos de sangre?**\n   - Respuesta: El prop\u00f3sito es asegurar la producci\u00f3n de productos de alta calidad y la seguridad de los receptores, proporcionando un documento de orientaci\u00f3n que los establecimientos de sangre y las autoridades reguladoras nacionales puedan referenciar, implementar y hacer cumplir, de manera que sea aplicable independientemente de las actividades de un solo establecimiento de sangre.", "prev_section_summary": "### Temas Clave\n\n1. **Revisi\u00f3n de Buenas Pr\u00e1cticas de Manufactura (GMP)**: Se han actualizado las directrices de GMP de la OMS desde su publicaci\u00f3n en 1999, incorporando nuevos cap\u00edtulos y modificando cap\u00edtulos existentes para mejorar la calidad y seguridad en la fabricaci\u00f3n de productos est\u00e9riles.\n\n2. **Nuevas Tecnolog\u00edas**: Se han a\u00f1adido cap\u00edtulos sobre \"Tecnolog\u00eda de aisladores\" y \"Tecnolog\u00eda de blow/fill/seal\".\n\n3. **Capping de Viales**: Se han realizado enmiendas en el cap\u00edtulo sobre \"Finalizaci\u00f3n de productos est\u00e9riles\" para incluir disposiciones sobre el capping de viales.\n\n4. **Monitoreo de Ambientes Limpios**: Se han actualizado las provisiones en el cap\u00edtulo sobre \"Fabricaci\u00f3n de preparaciones est\u00e9riles\" para incluir el monitoreo de salas limpias y dispositivos de aire limpio.\n\n5. **Implementaci\u00f3n Gradual**: La implementaci\u00f3n de ciertas pr\u00e1cticas nuevas, como el capping en un entorno limpio o est\u00e9ril, puede requerir un enfoque gradual debido a su falta de aplicaci\u00f3n en la mayor\u00eda de las industrias.\n\n6. **GMP para Establecimientos de Sangre**: Se ha reconocido la necesidad de establecer requisitos de calidad y seguridad para la recolecci\u00f3n, preparaci\u00f3n, prueba y distribuci\u00f3n de sangre y plasma.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices de GMP.\n- **ISO (Organizaci\u00f3n Internacional de Normalizaci\u00f3n)**: Est\u00e1ndar ISO 14644-1 mencionado para alineaci\u00f3n de pr\u00e1cticas.\n- **Expert Committee**: Comit\u00e9 que revisa y adopta las directrices de GMP.\n- **PQP (Programa de Precalificaci\u00f3n)**: Contexto en el que se implementan las GMP de la OMS.\n- **Establecimientos de Sangre**: Entidades que requieren actualizaciones espec\u00edficas en GMP para asegurar la calidad y seguridad en sus operaciones.", "excerpt_keywords": "Keywords: blood safety, GMP guidelines, regulatory authorities, quality standards, plasma products"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ce9e40c2-89f6-43e7-ae4c-08c7b56c276b", "node_type": "4", "metadata": {"page_label": "60", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "implementation of internationally agreed quality and safety standards in the blood establishments, a harmonized and systematic approach to ensure compliance at all steps involved (from donor acceptance to release of products), and enforcement by competent MRAs.\n\nICDRA had recommended the following at its 13th meeting held in Berne in 2008:\n\n\u201cRecognizing the worldwide need for blood products regulation to ensure availability of safe blood and blood products in the face of known and emerging threats, including emerging infectious diseases, WHO should:\n\n- Take steps to further develop and strengthen national/regional blood regulatory authorities and to promote cooperation\n- Provide harmonized 'assessment criteria for blood regulatory systems' (BRN): convene a consultation of NMRAs to review Draft assessment tool\n- Prioritize development of WHO Guidelines on GMP for Blood Establishments\n- Promote introduction of WHO recommended plasma standards by NMRAs.\u201d\n\nWHO had issued requirements for the collection, processing and quality control of blood components and plasma derivatives (WHO Technical Report Series, No. 840, 1994, Annex 2) and recommendations for the production, control and regulation of plasma for fractionation (WHO Technical Report Series, No. 941, Annex 4). In addition, the GMP guide for blood establishments had been published by bodies such as the PIC/S.\n\nBased on the above, the project for WHO guidelines on GMP for blood establishments was intended to respond to the ICDRA recommendation, without inventing a new GMP standard, but taking into account the specifics of blood products, blood establishments and all existing complementary GMP standards.\n\nThe aim of the new document was to establish a wide international consensus on quality standards among blood establishments and among inspectors to ensure high-quality products and safety of recipients. It would then become a guidance document for blood establishments, for NMRAs to refer, implement and enforce GMP in blood establishments and to become widely applicable, independent of the activities of a single blood establishment.\n\nThe document addressed the general GMP topics, e.g. quality management, as well as the topics specific to manufacturing of blood products, from donor selection through distribution of final products and the newer GMP concepts, e.g. risk management and product quality review.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "ce2db0e7cf7b21d48a2efbbfc92cdf7cad216dbdd92f8ea8eb01dd87a8ddd244", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "implementation of internationally agreed quality and safety standards in the blood establishments, a harmonized and systematic approach to ensure compliance at all steps involved (from donor acceptance to release of products), and enforcement by competent MRAs.\n\nICDRA had recommended the following at its 13th meeting held in Berne in 2008:\n\n\u201cRecognizing the worldwide need for blood products regulation to ensure availability of safe blood and blood products in the face of known and emerging threats, including emerging infectious diseases, WHO should:\n\n- Take steps to further develop and strengthen national/regional blood regulatory authorities and to promote cooperation\n- Provide harmonized 'assessment criteria for blood regulatory systems' (BRN): convene a consultation of NMRAs to review Draft assessment tool\n- Prioritize development of WHO Guidelines on GMP for Blood Establishments\n- Promote introduction of WHO recommended plasma standards by NMRAs.\u201d\n\nWHO had issued requirements for the collection, processing and quality control of blood components and plasma derivatives (WHO Technical Report Series, No. 840, 1994, Annex 2) and recommendations for the production, control and regulation of plasma for fractionation (WHO Technical Report Series, No. 941, Annex 4). In addition, the GMP guide for blood establishments had been published by bodies such as the PIC/S.\n\nBased on the above, the project for WHO guidelines on GMP for blood establishments was intended to respond to the ICDRA recommendation, without inventing a new GMP standard, but taking into account the specifics of blood products, blood establishments and all existing complementary GMP standards.\n\nThe aim of the new document was to establish a wide international consensus on quality standards among blood establishments and among inspectors to ensure high-quality products and safety of recipients. It would then become a guidance document for blood establishments, for NMRAs to refer, implement and enforce GMP in blood establishments and to become widely applicable, independent of the activities of a single blood establishment.\n\nThe document addressed the general GMP topics, e.g. quality management, as well as the topics specific to manufacturing of blood products, from donor selection through distribution of final products and the newer GMP concepts, e.g. risk management and product quality review.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2395, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f0edf1f8-2f7d-4ccb-a8db-f3b185c53964": {"__data__": {"id_": "f0edf1f8-2f7d-4ccb-a8db-f3b185c53964", "embedding": null, "metadata": {"page_label": "61", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The detailed structure of the current working document was presented. This included the following chapters: Introduction, Glossary, Quality management, Manufacturing, Contract manufacturing, Analysis and services and a section on Authors, References and History.\n\nThe chapter on manufacturing included detailed process-specific guidance, covering donor registration, donor selection, collection, component preparation, laboratory testing, quality control, labelling, release, dispatch, shipping and returns. The product characteristics comprised whole blood, red cells, platelets, plasma for transfusion/fractionation and cryoprecipitate/CPP. The points to consider for validation of preparation steps would focus on centrifugation, separation, freezing, leukocyte reduction and irradiation.\n\nThe drafting process had started in January 2008. The text was reviewed during a WHO training workshop (in Teheran) in November 2008 and again in its revised format by a consultation of experts from July to September 2009. The text would also be presented for discussion to the ECBS in October 2009 and released for open consultation. It was expected that subsequent to the global consultation, review of comments and further revision of the document, it would be presented to the ECBS in 2010 with a view to adoption.\n\nThe comprehensive consultation process involved WHO Member States through WHO channels (e.g. ministries of health), WHO Regional Advisers, targeted regulatory authorities, blood transfusion services and professional institutions and associations and other interested parties through its publication on the WHO web site.\n\nThe Expert Committee took note of the progress made and recommended that this text be mailed out for comment to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and again be presented at the next meeting of the Committee with a view to its adoption within the full set of GMP texts.\n\n# 7. Quality assurance \u2014 new approaches\n\n## 7.1 Risk analysis\n\n### Introduction\n\nDuring the meeting of the Expert Committee in October 2007, an update on the new ICH Q10 was given to the Committee by the Secretariat. The Committee concluded that the ICH Q8, Q9 and Q10 documents were useful tools.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento t\u00e9cnico de la OMS (WHO - Technical Report Series 957) presenta una estructura detallada que incluye cap\u00edtulos sobre introducci\u00f3n, glosario, gesti\u00f3n de calidad, fabricaci\u00f3n, fabricaci\u00f3n por contrato, an\u00e1lisis y servicios, as\u00ed como secciones sobre autores, referencias e historia. Se destaca la importancia de la fabricaci\u00f3n de productos sangu\u00edneos, incluyendo directrices espec\u00edficas sobre el registro y selecci\u00f3n de donantes, pruebas de laboratorio y control de calidad. El proceso de redacci\u00f3n comenz\u00f3 en enero de 2008 y ha pasado por varias revisiones y consultas con expertos, con la intenci\u00f3n de adoptar el texto en 2010. Adem\u00e1s, se menciona un enfoque en el an\u00e1lisis de riesgos y la utilidad de los documentos ICH Q8, Q9 y Q10 en la gesti\u00f3n de calidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos de validaci\u00f3n que se deben considerar en la preparaci\u00f3n de componentes sangu\u00edneos seg\u00fan el documento?**\n   - Respuesta: Los pasos de validaci\u00f3n que se deben considerar incluyen centrifugaci\u00f3n, separaci\u00f3n, congelaci\u00f3n, reducci\u00f3n de leucocitos e irradiaci\u00f3n.\n\n2. **\u00bfQu\u00e9 organismos y partes interesadas participaron en el proceso de consulta para la elaboraci\u00f3n del documento?**\n   - Respuesta: El proceso de consulta involucr\u00f3 a Estados Miembros de la OMS a trav\u00e9s de canales de la OMS (como ministerios de salud), asesores regionales de la OMS, autoridades regulatorias espec\u00edficas, servicios de transfusi\u00f3n sangu\u00ednea, instituciones profesionales y asociaciones, as\u00ed como otras partes interesadas a trav\u00e9s de su publicaci\u00f3n en el sitio web de la OMS.\n\n3. **\u00bfQu\u00e9 se espera que ocurra despu\u00e9s de la consulta global sobre el documento?**\n   - Respuesta: Se espera que, tras la consulta global, se revisen los comentarios y se realicen m\u00e1s revisiones del documento, que luego se presentar\u00e1 al ECBS en 2010 con miras a su adopci\u00f3n.\n\n### Resumen de nivel superior\n\nEl documento de la OMS aborda la gesti\u00f3n de calidad y la fabricaci\u00f3n de productos sangu\u00edneos, destacando la importancia de un proceso de redacci\u00f3n colaborativo y la consulta con expertos. Se enfoca en la necesidad de establecer directrices claras para asegurar la calidad y seguridad en la transfusi\u00f3n de sangre, as\u00ed como en la implementaci\u00f3n de nuevos enfoques de gesti\u00f3n de calidad, como el an\u00e1lisis de riesgos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Est\u00e1ndares Internacionales de Calidad y Seguridad:** Se enfatiza la implementaci\u00f3n de est\u00e1ndares acordados internacionalmente en los establecimientos de sangre para garantizar la calidad y seguridad de los productos sangu\u00edneos.\n2. **Regulaci\u00f3n de Productos Sangu\u00edneos:** Se reconoce la necesidad de regular los productos sangu\u00edneos para asegurar su disponibilidad y seguridad frente a amenazas emergentes, como enfermedades infecciosas.\n3. **Recomendaciones del ICDRA:** En la reuni\u00f3n del ICDRA en 2008, se hicieron recomendaciones para fortalecer las autoridades reguladoras de sangre, desarrollar criterios de evaluaci\u00f3n armonizados y priorizar la creaci\u00f3n de gu\u00edas de Buenas Pr\u00e1cticas de Manufactura (GMP) espec\u00edficas para los establecimientos de sangre.\n4. **Gu\u00edas de GMP de la OMS:** El proyecto de gu\u00edas de la OMS busca establecer un consenso internacional sobre est\u00e1ndares de calidad y proporcionar un documento de orientaci\u00f3n para la implementaci\u00f3n y cumplimiento de GMP en los establecimientos de sangre.\n5. **Aspectos Espec\u00edficos de la Manufactura:** Las gu\u00edas abordan temas generales de gesti\u00f3n de calidad y aspectos espec\u00edficos de la manufactura de productos sangu\u00edneos, incluyendo la selecci\u00f3n de donantes, procesamiento y distribuci\u00f3n de productos finales, as\u00ed como conceptos recientes como gesti\u00f3n de riesgos y revisi\u00f3n de calidad del producto.\n\n**Entidades:**\n- **OMS (Organizaci\u00f3n Mundial de la Salud):** Responsable de emitir requisitos y gu\u00edas para la regulaci\u00f3n de productos sangu\u00edneos.\n- **ICDRA (Comit\u00e9 Internacional de Reguladores de Medicamentos):** Organismo que recomend\u00f3 acciones para mejorar la regulaci\u00f3n de productos sangu\u00edneos.\n- **NMRAs (Autoridades Nacionales Reguladoras de Medicamentos):** Entidades que deben implementar y hacer cumplir las gu\u00edas de GMP en los establecimientos de sangre.\n- **PIC/S (Pharmaceutical Inspection Co-operation Scheme):** Organismo que ha publicado gu\u00edas de GMP para establecimientos de sangre. \n\nEste resumen destaca la importancia de la regulaci\u00f3n y estandarizaci\u00f3n en la producci\u00f3n de productos sangu\u00edneos para garantizar la seguridad y calidad en el \u00e1mbito internacional.", "excerpt_keywords": "Keywords: quality management, blood manufacturing, WHO guidelines, risk analysis, GMP standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1075dcb9-bb2e-40e5-8246-45a75bd31ec7", "node_type": "4", "metadata": {"page_label": "61", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The detailed structure of the current working document was presented. This included the following chapters: Introduction, Glossary, Quality management, Manufacturing, Contract manufacturing, Analysis and services and a section on Authors, References and History.\n\nThe chapter on manufacturing included detailed process-specific guidance, covering donor registration, donor selection, collection, component preparation, laboratory testing, quality control, labelling, release, dispatch, shipping and returns. The product characteristics comprised whole blood, red cells, platelets, plasma for transfusion/fractionation and cryoprecipitate/CPP. The points to consider for validation of preparation steps would focus on centrifugation, separation, freezing, leukocyte reduction and irradiation.\n\nThe drafting process had started in January 2008. The text was reviewed during a WHO training workshop (in Teheran) in November 2008 and again in its revised format by a consultation of experts from July to September 2009. The text would also be presented for discussion to the ECBS in October 2009 and released for open consultation. It was expected that subsequent to the global consultation, review of comments and further revision of the document, it would be presented to the ECBS in 2010 with a view to adoption.\n\nThe comprehensive consultation process involved WHO Member States through WHO channels (e.g. ministries of health), WHO Regional Advisers, targeted regulatory authorities, blood transfusion services and professional institutions and associations and other interested parties through its publication on the WHO web site.\n\nThe Expert Committee took note of the progress made and recommended that this text be mailed out for comment to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and again be presented at the next meeting of the Committee with a view to its adoption within the full set of GMP texts.\n\n# 7. Quality assurance \u2014 new approaches\n\n## 7.1 Risk analysis\n\n### Introduction\n\nDuring the meeting of the Expert Committee in October 2007, an update on the new ICH Q10 was given to the Committee by the Secretariat. The Committee concluded that the ICH Q8, Q9 and Q10 documents were useful tools.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "86e4b192850c2cb4e4207c4f5178d247c6a501633cc6fef71c3baab8240b1c73", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The detailed structure of the current working document was presented. This included the following chapters: Introduction, Glossary, Quality management, Manufacturing, Contract manufacturing, Analysis and services and a section on Authors, References and History.\n\nThe chapter on manufacturing included detailed process-specific guidance, covering donor registration, donor selection, collection, component preparation, laboratory testing, quality control, labelling, release, dispatch, shipping and returns. The product characteristics comprised whole blood, red cells, platelets, plasma for transfusion/fractionation and cryoprecipitate/CPP. The points to consider for validation of preparation steps would focus on centrifugation, separation, freezing, leukocyte reduction and irradiation.\n\nThe drafting process had started in January 2008. The text was reviewed during a WHO training workshop (in Teheran) in November 2008 and again in its revised format by a consultation of experts from July to September 2009. The text would also be presented for discussion to the ECBS in October 2009 and released for open consultation. It was expected that subsequent to the global consultation, review of comments and further revision of the document, it would be presented to the ECBS in 2010 with a view to adoption.\n\nThe comprehensive consultation process involved WHO Member States through WHO channels (e.g. ministries of health), WHO Regional Advisers, targeted regulatory authorities, blood transfusion services and professional institutions and associations and other interested parties through its publication on the WHO web site.\n\nThe Expert Committee took note of the progress made and recommended that this text be mailed out for comment to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and again be presented at the next meeting of the Committee with a view to its adoption within the full set of GMP texts.\n\n# 7. Quality assurance \u2014 new approaches\n\n## 7.1 Risk analysis\n\n### Introduction\n\nDuring the meeting of the Expert Committee in October 2007, an update on the new ICH Q10 was given to the Committee by the Secretariat. The Committee concluded that the ICH Q8, Q9 and Q10 documents were useful tools.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2263, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "082039d9-c24e-4388-8cd8-a6cb874384e8": {"__data__": {"id_": "082039d9-c24e-4388-8cd8-a6cb874384e8", "embedding": null, "metadata": {"page_label": "62", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "On the topic of risk analysis, the Committee made recommendations for WHO to:\n\n- review and update the WHO guidelines on hazard analysis and critical control points (HACCP);\n- revise the main text of the WHO GMP to include the principles of application of risk management.\n\nConsidering the changes in the approach to quality risk management in the regulatory environment and the use of different tools to analyse risk, the Secretariat had started the process of reviewing the WHO guidelines on HACCP and expected to submit the proposed revised guidelines to the Expert Committee at its next meeting.\n\n## Recommendation\n\nThe Expert Committee:\n\n- supported the Secretariat in continuing the preparation of the revised draft guideline on HACCP; and\n- encouraged the Secretariat to include the principles of quality risk management and to provide examples of possible tools that may be used in quality risk management \u2014 not only focusing on HACCP.\n\n### 7.2 WHO guidelines on technology transfer\n\nThe need for new WHO guidance on transfer of technology was discussed at the forty-second meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2007. Colleagues from the WHO PQP shared their experience of recently submitted dossiers by, and inspections carried out in, plants that had undergone technology transfer. Technology transfer was happening worldwide both within and between companies, and within the same country as well as between countries. The Expert Committee, therefore, recommended that WHO guidelines on transfer of technology be developed. A draft document was subsequently prepared and sent out for comment. It was then discussed during the consultation on WHO guidelines for medicines quality assurance, quality control laboratories and transfer of technology on 27\u201331 July 2009 and a revision was prepared.\n\nThe Expert Committee discussed and reviewed the major points that were raised during the commentary period, keeping the balance between GMP and business criteria. Inclusion of the concept of quality by design and the possibility of optional requirements depended on the type of transfer. The Committee took note that the Secretariat would organize a consultation and prepare a new working document for wide circulation following the usual consultation procedure.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Recomendaciones sobre an\u00e1lisis de riesgos**: El Comit\u00e9 de Expertos de la OMS recomend\u00f3 la revisi\u00f3n y actualizaci\u00f3n de las directrices sobre an\u00e1lisis de peligros y puntos cr\u00edticos de control (HACCP) y la inclusi\u00f3n de principios de gesti\u00f3n de riesgos en el texto principal de las Buenas Pr\u00e1cticas de Manufactura (GMP) de la OMS. Se destac\u00f3 la importancia de adaptar estas directrices a los cambios en el entorno regulatorio y en las herramientas de an\u00e1lisis de riesgos.\n\n2. **Transferencia de tecnolog\u00eda**: Se discuti\u00f3 la necesidad de nuevas directrices de la OMS sobre la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica, bas\u00e1ndose en experiencias recientes de transferencias de tecnolog\u00eda a nivel mundial. Se recomend\u00f3 el desarrollo de estas directrices, que se revisaron y comentaron en varias consultas, buscando un equilibrio entre las Buenas Pr\u00e1cticas de Manufactura y los criterios empresariales.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 cambios se est\u00e1n considerando en las directrices de HACCP de la OMS y por qu\u00e9 son necesarios?**\n   - Se est\u00e1n considerando cambios en las directrices de HACCP para adaptarse a la evoluci\u00f3n del enfoque de gesti\u00f3n de riesgos de calidad en el entorno regulatorio y para incorporar herramientas modernas de an\u00e1lisis de riesgos.\n\n2. **\u00bfCu\u00e1l es la relaci\u00f3n entre las Buenas Pr\u00e1cticas de Manufactura (GMP) y la gesti\u00f3n de riesgos seg\u00fan las recomendaciones del Comit\u00e9?**\n   - El Comit\u00e9 recomend\u00f3 que el texto principal de las GMP de la OMS incluya principios de gesti\u00f3n de riesgos, lo que sugiere que la gesti\u00f3n de riesgos es fundamental para garantizar la calidad y la seguridad en la producci\u00f3n farmac\u00e9utica.\n\n3. **\u00bfQu\u00e9 aspectos se consideraron en la revisi\u00f3n de las directrices sobre transferencia de tecnolog\u00eda y c\u00f3mo se equilibraron?**\n   - En la revisi\u00f3n de las directrices sobre transferencia de tecnolog\u00eda, se consideraron puntos importantes que surgieron durante el per\u00edodo de comentarios, buscando un equilibrio entre las Buenas Pr\u00e1cticas de Manufactura y los criterios empresariales, as\u00ed como la inclusi\u00f3n del concepto de calidad por dise\u00f1o y requisitos opcionales seg\u00fan el tipo de transferencia.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Estructura del Documento**: El documento t\u00e9cnico de la OMS (WHO - Technical Report Series 957) est\u00e1 organizado en varios cap\u00edtulos, incluyendo:\n   - Introducci\u00f3n\n   - Glosario\n   - Gesti\u00f3n de calidad\n   - Fabricaci\u00f3n\n   - Fabricaci\u00f3n por contrato\n   - An\u00e1lisis y servicios\n   - Autores, referencias e historia\n\n2. **Cap\u00edtulo sobre Fabricaci\u00f3n**: Este cap\u00edtulo proporciona directrices espec\u00edficas sobre:\n   - Registro y selecci\u00f3n de donantes\n   - Recolecci\u00f3n de sangre\n   - Preparaci\u00f3n de componentes\n   - Pruebas de laboratorio\n   - Control de calidad\n   - Etiquetado\n   - Liberaci\u00f3n, despacho, env\u00edo y devoluciones\n\n3. **Caracter\u00edsticas del Producto**: Se abordan diferentes productos sangu\u00edneos, incluyendo:\n   - Sangre total\n   - Gl\u00f3bulos rojos\n   - Plaquetas\n   - Plasma para transfusi\u00f3n/fractionaci\u00f3n\n   - Crioprecipitado/CPP\n\n4. **Validaci\u00f3n de Pasos de Preparaci\u00f3n**: Los pasos de validaci\u00f3n a considerar son:\n   - Centrifugaci\u00f3n\n   - Separaci\u00f3n\n   - Congelaci\u00f3n\n   - Reducci\u00f3n de leucocitos\n   - Irradiaci\u00f3n\n\n5. **Proceso de Redacci\u00f3n**: \n   - Comenz\u00f3 en enero de 2008.\n   - Revisiones en talleres de capacitaci\u00f3n y consultas con expertos entre 2008 y 2009.\n   - Presentaci\u00f3n al ECBS (Comit\u00e9 de Expertos en Sangre) en octubre de 2009 y consulta abierta.\n\n6. **Consulta Global**: Involucra a:\n   - Estados Miembros de la OMS\n   - Asesores regionales de la OMS\n   - Autoridades regulatorias\n   - Servicios de transfusi\u00f3n sangu\u00ednea\n   - Instituciones profesionales y asociaciones\n   - Publicaci\u00f3n en el sitio web de la OMS\n\n7. **Recomendaciones del Comit\u00e9 de Expertos**: Se sugiere enviar el texto para comentarios al Panel Asesor de la OMS sobre la Farmacopea Internacional y Preparaciones Farmac\u00e9uticas, y presentarlo nuevamente en la pr\u00f3xima reuni\u00f3n del Comit\u00e9.\n\n8. **Gesti\u00f3n de Calidad y An\u00e1lisis de Riesgos**: Se menciona la utilidad de los documentos ICH Q8, Q9 y Q10 en la gesti\u00f3n de calidad, destacando un enfoque en el an\u00e1lisis de riesgos.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**\n- **ECBS (Comit\u00e9 de Expertos en Sangre)**\n- **ICH (Conferencia Internacional sobre Armonizaci\u00f3n)**\n- **Panel Asesor de la OMS sobre la Farmacopea Internacional y Preparaciones Farmac\u00e9uticas**", "excerpt_keywords": "Keywords: risk analysis, HACCP, technology transfer, quality risk management, WHO guidelines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d616ee1e-44db-49e2-808e-8c6352196292", "node_type": "4", "metadata": {"page_label": "62", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "On the topic of risk analysis, the Committee made recommendations for WHO to:\n\n- review and update the WHO guidelines on hazard analysis and critical control points (HACCP);\n- revise the main text of the WHO GMP to include the principles of application of risk management.\n\nConsidering the changes in the approach to quality risk management in the regulatory environment and the use of different tools to analyse risk, the Secretariat had started the process of reviewing the WHO guidelines on HACCP and expected to submit the proposed revised guidelines to the Expert Committee at its next meeting.\n\n## Recommendation\n\nThe Expert Committee:\n\n- supported the Secretariat in continuing the preparation of the revised draft guideline on HACCP; and\n- encouraged the Secretariat to include the principles of quality risk management and to provide examples of possible tools that may be used in quality risk management \u2014 not only focusing on HACCP.\n\n### 7.2 WHO guidelines on technology transfer\n\nThe need for new WHO guidance on transfer of technology was discussed at the forty-second meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2007. Colleagues from the WHO PQP shared their experience of recently submitted dossiers by, and inspections carried out in, plants that had undergone technology transfer. Technology transfer was happening worldwide both within and between companies, and within the same country as well as between countries. The Expert Committee, therefore, recommended that WHO guidelines on transfer of technology be developed. A draft document was subsequently prepared and sent out for comment. It was then discussed during the consultation on WHO guidelines for medicines quality assurance, quality control laboratories and transfer of technology on 27\u201331 July 2009 and a revision was prepared.\n\nThe Expert Committee discussed and reviewed the major points that were raised during the commentary period, keeping the balance between GMP and business criteria. Inclusion of the concept of quality by design and the possibility of optional requirements depended on the type of transfer. The Committee took note that the Secretariat would organize a consultation and prepare a new working document for wide circulation following the usual consultation procedure.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "2cce7a31cbbc228707119db571c0e4db2abd116dca8b69e65d64f8007f805410", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "On the topic of risk analysis, the Committee made recommendations for WHO to:\n\n- review and update the WHO guidelines on hazard analysis and critical control points (HACCP);\n- revise the main text of the WHO GMP to include the principles of application of risk management.\n\nConsidering the changes in the approach to quality risk management in the regulatory environment and the use of different tools to analyse risk, the Secretariat had started the process of reviewing the WHO guidelines on HACCP and expected to submit the proposed revised guidelines to the Expert Committee at its next meeting.\n\n## Recommendation\n\nThe Expert Committee:\n\n- supported the Secretariat in continuing the preparation of the revised draft guideline on HACCP; and\n- encouraged the Secretariat to include the principles of quality risk management and to provide examples of possible tools that may be used in quality risk management \u2014 not only focusing on HACCP.\n\n### 7.2 WHO guidelines on technology transfer\n\nThe need for new WHO guidance on transfer of technology was discussed at the forty-second meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2007. Colleagues from the WHO PQP shared their experience of recently submitted dossiers by, and inspections carried out in, plants that had undergone technology transfer. Technology transfer was happening worldwide both within and between companies, and within the same country as well as between countries. The Expert Committee, therefore, recommended that WHO guidelines on transfer of technology be developed. A draft document was subsequently prepared and sent out for comment. It was then discussed during the consultation on WHO guidelines for medicines quality assurance, quality control laboratories and transfer of technology on 27\u201331 July 2009 and a revision was prepared.\n\nThe Expert Committee discussed and reviewed the major points that were raised during the commentary period, keeping the balance between GMP and business criteria. Inclusion of the concept of quality by design and the possibility of optional requirements depended on the type of transfer. The Committee took note that the Secretariat would organize a consultation and prepare a new working document for wide circulation following the usual consultation procedure.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2326, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "736da678-9f03-4bfc-b5b7-7ed64a3c1ad7": {"__data__": {"id_": "736da678-9f03-4bfc-b5b7-7ed64a3c1ad7", "embedding": null, "metadata": {"page_label": "63", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 8. Quality assurance \u2014 distribution and trade of pharmaceuticals\n\n## 8.1 WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce\n\nThe WHO Certification Scheme for finished pharmaceutical products was an international voluntary agreement intended to provide assurance to countries participating in the Scheme, about the quality of pharmaceutical products moving in international commerce (World Health Assembly resolution WHA22.50 (1969), World Health Assembly resolution WHA28.65 (1975), World Health Assembly resolution WHA41.18 (1988), World Health Assembly resolution WHA45.29 (1992), World Health Assembly resolution WHA50.3 (1997)). The primary document of the Scheme was the Certificate of Pharmaceutical Product (CPP).\n\nThe Expert Committee had recommended during discussion in 2008 that the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce should be reviewed in light of the changing environment, including the rapid globalization of the pharmaceutical manufacturing sector coupled with changes in the make-up of both the regulators and the groups involved in procurement. In addition, it acknowledged that legislation had been put in place in various countries and regions to assess products manufactured in them and produced for \u201cexport only\u201d, for which there was currently no adequate provision in the Scheme.\n\nAn oral presentation was given by the Secretariat of the work it had done following the recommendations made at the previous meeting of the Expert Committee.\n\n### Questions and answers\n\nBased on the Committee\u2019s recommendations a question and answer paper was prepared in the interim on the function of the Scheme.\n\nThe first working document was based on the feedback, draft questions and answers received from the International Federation of Pharmaceutical Manufacturers and Associations/European Federation of Pharmaceutical Industries and Associations (IFPMA/EFPIA). The working document was subsequently circulated for comments.\n\nReviewing all the comments received and the materials already available, a new set of questions and answers was prepared and made available.\n\nAn additional question and answer was provided for further discussion at the Expert Committee, raised by the specialist who had reviewed all.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de nivel superior:\nEl esquema de certificaci\u00f3n de la OMS para productos farmac\u00e9uticos terminados es un acuerdo internacional voluntario que busca asegurar la calidad de los productos farmac\u00e9uticos en el comercio internacional. Este esquema ha sido objeto de revisi\u00f3n debido a la globalizaci\u00f3n del sector farmac\u00e9utico y a los cambios en la regulaci\u00f3n y en los grupos de adquisici\u00f3n. Se han elaborado documentos de preguntas y respuestas para aclarar el funcionamiento del esquema, basados en comentarios de organizaciones relevantes.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las principales resoluciones de la Asamblea Mundial de la Salud que respaldan el Esquema de Certificaci\u00f3n de la OMS y qu\u00e9 cambios han motivado su revisi\u00f3n?**\n   - Esta pregunta busca respuestas sobre las resoluciones espec\u00edficas que han influido en el esquema y los factores que han llevado a la necesidad de su revisi\u00f3n.\n\n2. **\u00bfQu\u00e9 tipo de legislaci\u00f3n se ha implementado en diferentes pa\u00edses que afecta a los productos farmac\u00e9uticos destinados solo para exportaci\u00f3n, y c\u00f3mo se relaciona esto con el Esquema de Certificaci\u00f3n de la OMS?**\n   - Esta pregunta se centra en la legislaci\u00f3n espec\u00edfica que ha surgido en varios pa\u00edses y c\u00f3mo esto ha impactado la efectividad del esquema de certificaci\u00f3n.\n\n3. **\u00bfQu\u00e9 proceso se sigui\u00f3 para recopilar y revisar los comentarios sobre el documento de preguntas y respuestas del Esquema de Certificaci\u00f3n, y qui\u00e9nes fueron los principales contribuyentes a este proceso?**\n   - Esta pregunta busca detalles sobre el proceso de revisi\u00f3n y los actores involucrados, lo que puede proporcionar informaci\u00f3n sobre la colaboraci\u00f3n entre la OMS y las organizaciones farmac\u00e9uticas.", "prev_section_summary": "### Temas Clave\n\n1. **An\u00e1lisis de Riesgos**:\n   - Recomendaciones del Comit\u00e9 de Expertos de la OMS para revisar y actualizar las directrices sobre an\u00e1lisis de peligros y puntos cr\u00edticos de control (HACCP).\n   - Inclusi\u00f3n de principios de gesti\u00f3n de riesgos en el texto principal de las Buenas Pr\u00e1cticas de Manufactura (GMP) de la OMS.\n   - Adaptaci\u00f3n de las directrices a los cambios en el entorno regulatorio y en las herramientas de an\u00e1lisis de riesgos.\n\n2. **Transferencia de Tecnolog\u00eda**:\n   - Discusi\u00f3n sobre la necesidad de nuevas directrices de la OMS para la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica.\n   - Experiencias compartidas sobre transferencias de tecnolog\u00eda a nivel mundial y la importancia de equilibrar las Buenas Pr\u00e1cticas de Manufactura con criterios empresariales.\n   - Desarrollo y revisi\u00f3n de un documento de directrices sobre transferencia de tecnolog\u00eda, incluyendo conceptos como calidad por dise\u00f1o y requisitos opcionales.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la elaboraci\u00f3n de directrices y recomendaciones en el \u00e1mbito de la salud p\u00fablica y la industria farmac\u00e9utica.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que revisa y recomienda cambios en las directrices de la OMS, incluyendo HACCP y GMP.\n- **PQP (Programa de Garant\u00eda de Calidad)**: Parte de la OMS que comparte experiencias sobre la calidad y la transferencia de tecnolog\u00eda en la producci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: WHO Certification Scheme, pharmaceutical quality, international commerce, Expert Committee, regulatory changes"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19b34146-7515-4639-9709-18528c8d9cd5", "node_type": "4", "metadata": {"page_label": "63", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 8. Quality assurance \u2014 distribution and trade of pharmaceuticals\n\n## 8.1 WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce\n\nThe WHO Certification Scheme for finished pharmaceutical products was an international voluntary agreement intended to provide assurance to countries participating in the Scheme, about the quality of pharmaceutical products moving in international commerce (World Health Assembly resolution WHA22.50 (1969), World Health Assembly resolution WHA28.65 (1975), World Health Assembly resolution WHA41.18 (1988), World Health Assembly resolution WHA45.29 (1992), World Health Assembly resolution WHA50.3 (1997)). The primary document of the Scheme was the Certificate of Pharmaceutical Product (CPP).\n\nThe Expert Committee had recommended during discussion in 2008 that the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce should be reviewed in light of the changing environment, including the rapid globalization of the pharmaceutical manufacturing sector coupled with changes in the make-up of both the regulators and the groups involved in procurement. In addition, it acknowledged that legislation had been put in place in various countries and regions to assess products manufactured in them and produced for \u201cexport only\u201d, for which there was currently no adequate provision in the Scheme.\n\nAn oral presentation was given by the Secretariat of the work it had done following the recommendations made at the previous meeting of the Expert Committee.\n\n### Questions and answers\n\nBased on the Committee\u2019s recommendations a question and answer paper was prepared in the interim on the function of the Scheme.\n\nThe first working document was based on the feedback, draft questions and answers received from the International Federation of Pharmaceutical Manufacturers and Associations/European Federation of Pharmaceutical Industries and Associations (IFPMA/EFPIA). The working document was subsequently circulated for comments.\n\nReviewing all the comments received and the materials already available, a new set of questions and answers was prepared and made available.\n\nAn additional question and answer was provided for further discussion at the Expert Committee, raised by the specialist who had reviewed all.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "8fd72b57b2dc9491583ced51e601de785ada23b0798f726fc11b21a0ab119127", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 8. Quality assurance \u2014 distribution and trade of pharmaceuticals\n\n## 8.1 WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce\n\nThe WHO Certification Scheme for finished pharmaceutical products was an international voluntary agreement intended to provide assurance to countries participating in the Scheme, about the quality of pharmaceutical products moving in international commerce (World Health Assembly resolution WHA22.50 (1969), World Health Assembly resolution WHA28.65 (1975), World Health Assembly resolution WHA41.18 (1988), World Health Assembly resolution WHA45.29 (1992), World Health Assembly resolution WHA50.3 (1997)). The primary document of the Scheme was the Certificate of Pharmaceutical Product (CPP).\n\nThe Expert Committee had recommended during discussion in 2008 that the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce should be reviewed in light of the changing environment, including the rapid globalization of the pharmaceutical manufacturing sector coupled with changes in the make-up of both the regulators and the groups involved in procurement. In addition, it acknowledged that legislation had been put in place in various countries and regions to assess products manufactured in them and produced for \u201cexport only\u201d, for which there was currently no adequate provision in the Scheme.\n\nAn oral presentation was given by the Secretariat of the work it had done following the recommendations made at the previous meeting of the Expert Committee.\n\n### Questions and answers\n\nBased on the Committee\u2019s recommendations a question and answer paper was prepared in the interim on the function of the Scheme.\n\nThe first working document was based on the feedback, draft questions and answers received from the International Federation of Pharmaceutical Manufacturers and Associations/European Federation of Pharmaceutical Industries and Associations (IFPMA/EFPIA). The working document was subsequently circulated for comments.\n\nReviewing all the comments received and the materials already available, a new set of questions and answers was prepared and made available.\n\nAn additional question and answer was provided for further discussion at the Expert Committee, raised by the specialist who had reviewed all.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2336, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9a74fd4d-655b-4b18-940c-7c123eabd8c0": {"__data__": {"id_": "9a74fd4d-655b-4b18-940c-7c123eabd8c0", "embedding": null, "metadata": {"page_label": "64", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee:\n\n- noted the updated report from the Secretariat;\n- reviewed the document and considered the additional question; and\n- approved the questions and answers for posting on the WHO web site and publication in *WHO Drug Information*, with the possibility to receive comments and to review any question(s) and answers.\n\n## 8.2 WHO good distribution practices for pharmaceutical products\n\nFollowing the adoption of the WHO guidelines for good distribution practices (GDP) by the WHO Expert Committee on Specifications for Pharmaceutical Preparations at its fortieth meeting in October 2005 (http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf#page=191) (WHO Technical Report Series, No. 937, Annex 5, 2006) these guidelines had been revised by the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) partnership to strengthen the potential for prevention of counterfeit and other illegal medicines entering the supply chain. The following text outlines the process followed.\n\nAt an IMPACT meeting held in Bonn, Germany, in November 2006, the existing GDP was reviewed and amendments proposed relating to the specific issue of improving the security of the distribution chain vis-\u00e0-vis counterfeits. This was based on the consideration that even in highly regulated countries counterfeit medicines reached patients through the regulated distribution chain.\n\nA first draft was circulated in March 2007 to all the members of IMPACT\u2019s Regulatory Implementation Working Group (IRIWG). The IRIWG subsequently met in Washington, DC, USA from 23 to 25 April 2007 and discussed inter alia the draft and recommended amendments. A revised draft was circulated among the members of IRIWG and a final draft was then made available on the WHO web site for further comments. All IMPACT members (including the MRAs of 60 WHO Member States, plus other stakeholders) were actively encouraged to provide comments.\n\nThe draft was further revised and then finalized at the General Meeting of IMPACT held in Lisbon, Portugal, in December 2007. This text reflected the consensus reached at the Lisbon meeting and was submitted to the", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en las pr\u00e1cticas de buena distribuci\u00f3n (GDP) de productos farmac\u00e9uticos, revisadas por el Comit\u00e9 de Expertos de la OMS. Se menciona la adopci\u00f3n inicial de estas directrices en 2005 y su posterior revisi\u00f3n por el Grupo de Trabajo de Implementaci\u00f3n Regulatoria de la Alianza Internacional contra la Falsificaci\u00f3n de Productos M\u00e9dicos (IMPACT). Se destaca la importancia de mejorar la seguridad de la cadena de distribuci\u00f3n para prevenir la entrada de medicamentos falsificados, incluso en pa\u00edses altamente regulados. El proceso de revisi\u00f3n incluy\u00f3 reuniones y la participaci\u00f3n activa de miembros de IMPACT y otras partes interesadas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les fueron las principales preocupaciones que llevaron a la revisi\u00f3n de las directrices de GDP en la reuni\u00f3n de IMPACT en Bonn en 2006?**\n   - Respuesta: La revisi\u00f3n se centr\u00f3 en mejorar la seguridad de la cadena de distribuci\u00f3n frente a los medicamentos falsificados, considerando que incluso en pa\u00edses altamente regulados, estos productos pod\u00edan llegar a los pacientes a trav\u00e9s de la cadena de distribuci\u00f3n regulada.\n\n2. **\u00bfQu\u00e9 pasos se siguieron para la elaboraci\u00f3n y revisi\u00f3n del borrador de las nuevas directrices de GDP despu\u00e9s de la reuni\u00f3n de Bonn?**\n   - Respuesta: Se circul\u00f3 un primer borrador en marzo de 2007 a los miembros del Grupo de Trabajo de Implementaci\u00f3n Regulatoria (IRIWG), seguido de una reuni\u00f3n en Washington, DC, donde se discutieron y recomendaron enmiendas. Posteriormente, se realiz\u00f3 una revisi\u00f3n adicional y se public\u00f3 un borrador final en el sitio web de la OMS para recibir comentarios.\n\n3. **\u00bfQu\u00e9 resultados se obtuvieron en la reuni\u00f3n general de IMPACT en Lisboa en diciembre de 2007?**\n   - Respuesta: En esta reuni\u00f3n se finaliz\u00f3 el texto revisado de las directrices de GDP, que reflejaba el consenso alcanzado durante la reuni\u00f3n y se someti\u00f3 a consideraci\u00f3n para su publicaci\u00f3n.\n\n### Resumen de Nivel Superior\n\nEl documento detalla el proceso de revisi\u00f3n y actualizaci\u00f3n de las directrices de buenas pr\u00e1cticas de distribuci\u00f3n de la OMS, enfatizando la colaboraci\u00f3n internacional para combatir la falsificaci\u00f3n de medicamentos. Se describe c\u00f3mo las directrices originales fueron revisadas para abordar las preocupaciones sobre la seguridad de la cadena de suministro y se destaca la importancia de la participaci\u00f3n de m\u00faltiples partes interesadas en el proceso de revisi\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**1. Esquema de Certificaci\u00f3n de la OMS:**\n   - Es un acuerdo internacional voluntario que busca asegurar la calidad de los productos farmac\u00e9uticos en el comercio internacional.\n   - Se basa en varias resoluciones de la Asamblea Mundial de la Salud, que incluyen:\n     - WHA22.50 (1969)\n     - WHA28.65 (1975)\n     - WHA41.18 (1988)\n     - WHA45.29 (1992)\n     - WHA50.3 (1997)\n   - El documento principal del esquema es el Certificado de Producto Farmac\u00e9utico (CPP).\n\n**2. Revisi\u00f3n del Esquema:**\n   - En 2008, el Comit\u00e9 de Expertos recomend\u00f3 revisar el esquema debido a la globalizaci\u00f3n del sector farmac\u00e9utico y cambios en la regulaci\u00f3n y grupos de adquisici\u00f3n.\n   - Se identific\u00f3 la falta de provisiones adecuadas en el esquema para productos fabricados para \"exportaci\u00f3n solamente\".\n\n**3. Proceso de Preguntas y Respuestas:**\n   - Se elabor\u00f3 un documento de preguntas y respuestas basado en las recomendaciones del Comit\u00e9.\n   - El primer documento de trabajo se bas\u00f3 en comentarios de la Federaci\u00f3n Internacional de Fabricantes y Asociaciones Farmac\u00e9uticas (IFPMA) y la Federaci\u00f3n Europea de Industrias Farmac\u00e9uticas (EFPIA).\n   - Se revisaron los comentarios y se prepar\u00f3 un nuevo conjunto de preguntas y respuestas para su discusi\u00f3n en el Comit\u00e9 de Expertos.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Responsable del esquema de certificaci\u00f3n y de la revisi\u00f3n del mismo.\n- **Asamblea Mundial de la Salud:** Cuerpo que ha emitido las resoluciones que respaldan el esquema.\n- **Comit\u00e9 de Expertos:** Grupo que recomend\u00f3 la revisi\u00f3n del esquema y particip\u00f3 en la elaboraci\u00f3n del documento de preguntas y respuestas.\n- **IFPMA/EFPIA:** Organizaciones que proporcionaron comentarios y contribuyeron al desarrollo del documento de preguntas y respuestas.", "excerpt_keywords": "Keywords: WHO, good distribution practices, counterfeit medicines, IMPACT, pharmaceutical preparations"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "411f29dc-66a1-4768-8480-d1c113945cf8", "node_type": "4", "metadata": {"page_label": "64", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee:\n\n- noted the updated report from the Secretariat;\n- reviewed the document and considered the additional question; and\n- approved the questions and answers for posting on the WHO web site and publication in *WHO Drug Information*, with the possibility to receive comments and to review any question(s) and answers.\n\n## 8.2 WHO good distribution practices for pharmaceutical products\n\nFollowing the adoption of the WHO guidelines for good distribution practices (GDP) by the WHO Expert Committee on Specifications for Pharmaceutical Preparations at its fortieth meeting in October 2005 (http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf#page=191) (WHO Technical Report Series, No. 937, Annex 5, 2006) these guidelines had been revised by the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) partnership to strengthen the potential for prevention of counterfeit and other illegal medicines entering the supply chain. The following text outlines the process followed.\n\nAt an IMPACT meeting held in Bonn, Germany, in November 2006, the existing GDP was reviewed and amendments proposed relating to the specific issue of improving the security of the distribution chain vis-\u00e0-vis counterfeits. This was based on the consideration that even in highly regulated countries counterfeit medicines reached patients through the regulated distribution chain.\n\nA first draft was circulated in March 2007 to all the members of IMPACT\u2019s Regulatory Implementation Working Group (IRIWG). The IRIWG subsequently met in Washington, DC, USA from 23 to 25 April 2007 and discussed inter alia the draft and recommended amendments. A revised draft was circulated among the members of IRIWG and a final draft was then made available on the WHO web site for further comments. All IMPACT members (including the MRAs of 60 WHO Member States, plus other stakeholders) were actively encouraged to provide comments.\n\nThe draft was further revised and then finalized at the General Meeting of IMPACT held in Lisbon, Portugal, in December 2007. This text reflected the consensus reached at the Lisbon meeting and was submitted to the", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "244c6c6e9f9e43ffb42b0f1b61479c4b162442d1d11a296d4c1b1971670f5ae2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The Expert Committee:\n\n- noted the updated report from the Secretariat;\n- reviewed the document and considered the additional question; and\n- approved the questions and answers for posting on the WHO web site and publication in *WHO Drug Information*, with the possibility to receive comments and to review any question(s) and answers.\n\n## 8.2 WHO good distribution practices for pharmaceutical products\n\nFollowing the adoption of the WHO guidelines for good distribution practices (GDP) by the WHO Expert Committee on Specifications for Pharmaceutical Preparations at its fortieth meeting in October 2005 (http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf#page=191) (WHO Technical Report Series, No. 937, Annex 5, 2006) these guidelines had been revised by the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) partnership to strengthen the potential for prevention of counterfeit and other illegal medicines entering the supply chain. The following text outlines the process followed.\n\nAt an IMPACT meeting held in Bonn, Germany, in November 2006, the existing GDP was reviewed and amendments proposed relating to the specific issue of improving the security of the distribution chain vis-\u00e0-vis counterfeits. This was based on the consideration that even in highly regulated countries counterfeit medicines reached patients through the regulated distribution chain.\n\nA first draft was circulated in March 2007 to all the members of IMPACT\u2019s Regulatory Implementation Working Group (IRIWG). The IRIWG subsequently met in Washington, DC, USA from 23 to 25 April 2007 and discussed inter alia the draft and recommended amendments. A revised draft was circulated among the members of IRIWG and a final draft was then made available on the WHO web site for further comments. All IMPACT members (including the MRAs of 60 WHO Member States, plus other stakeholders) were actively encouraged to provide comments.\n\nThe draft was further revised and then finalized at the General Meeting of IMPACT held in Lisbon, Portugal, in December 2007. This text reflected the consensus reached at the Lisbon meeting and was submitted to the", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2141, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a22236c8-3e3d-498c-ba80-e5ec862073d4": {"__data__": {"id_": "a22236c8-3e3d-498c-ba80-e5ec862073d4", "embedding": null, "metadata": {"page_label": "65", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "WHO Expert Committee in 2008 as a recommendation from the IMPACT partners.\n\nDuring its forty-third meeting the Committee recommended discussing the document further with IMPACT, the EU and with WHO in view of the comments received. A meeting was subsequently arranged in Geneva on 31 August\u20131 September 2009 with a view to preparing a new document containing all comments received from the various parties and members of the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations. The revised document resulting from this meeting was presented to the Expert Committee at its current meeting and the main comments received up until the date of the meeting were identified and discussed. A small subgroup was formed to review all comments received by the permissible deadline. The Committee adopted the text subject to input from this subgroup and provided no major additional comments were received. The Committee members would be duly informed of the outcome (Annex 5), in order to allow them to reconfirm their decision in light of the deliberations of this Expert Committee subgroup.\n\n### 8.3 Regulatory oversight on pharmaceutical cold chain management\n\nFollowing-up on the 2008 joint session of topics with common interest, the Secretary of the Expert Committee for Biological Standardization (ECBS) arranged for an update in relation to the draft *Regulatory oversight on pharmaceutical cold chain management. Harmonized guidance for the storage and transport of temperature-sensitive pharmaceutical products.* The table of contents of the current draft working document was presented to the Committee for information.\n\nThe document had been developed with a group of experts and took forward the agreement from the joint meeting between the two Committees in 2008, as one of the cross-cutting issues. The document was considered to be fairly mature and would be presented at the 2009 ECBS meeting to obtain feedback, with a view to possible adoption of the document in 2010.\n\nAn oral update by video was given by the technical officer responsible for this project.\n\nThe Expert Committee noted this update and suggested circulation of the document to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and to the IMPACT IRIWG that developed the revision of the GDP.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Revisi\u00f3n de Documentos y Colaboraci\u00f3n**: Durante su reuni\u00f3n, el Comit\u00e9 de Expertos de la OMS discuti\u00f3 un documento revisado que incorporaba comentarios de diversas partes interesadas, incluyendo IMPACT y la Uni\u00f3n Europea. Se form\u00f3 un subgrupo para revisar estos comentarios antes de adoptar el texto final.\n\n2. **Gesti\u00f3n de la Cadena de Fr\u00edo Farmac\u00e9utica**: Se present\u00f3 un borrador sobre la regulaci\u00f3n de la gesti\u00f3n de la cadena de fr\u00edo para productos farmac\u00e9uticos sensibles a la temperatura. Este documento, desarrollado por un grupo de expertos, se considera maduro y se planea presentar en una reuni\u00f3n futura para obtener retroalimentaci\u00f3n y posible adopci\u00f3n.\n\n3. **Actualizaci\u00f3n y Circulaci\u00f3n de Documentos**: Se realiz\u00f3 una actualizaci\u00f3n oral sobre el proyecto de gesti\u00f3n de la cadena de fr\u00edo, y se sugiri\u00f3 la circulaci\u00f3n del documento entre el Panel Asesor de la OMS y el grupo de trabajo de IMPACT que revis\u00f3 las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP).\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 proceso sigui\u00f3 el Comit\u00e9 de Expertos para incorporar los comentarios de las partes interesadas en el documento revisado?**\n   - El Comit\u00e9 recomend\u00f3 discutir el documento con IMPACT, la UE y la OMS, organizando una reuni\u00f3n en Ginebra donde se prepar\u00f3 un nuevo documento que inclu\u00eda todos los comentarios recibidos. Se form\u00f3 un subgrupo para revisar estos comentarios antes de la adopci\u00f3n final del texto.\n\n2. **\u00bfCu\u00e1l es el objetivo del documento sobre la regulaci\u00f3n de la gesti\u00f3n de la cadena de fr\u00edo y qu\u00e9 pasos se prev\u00e9n para su adopci\u00f3n?**\n   - El objetivo del documento es proporcionar orientaci\u00f3n armonizada para el almacenamiento y transporte de productos farmac\u00e9uticos sensibles a la temperatura. Se planea presentar el documento en la reuni\u00f3n del ECBS de 2009 para obtener retroalimentaci\u00f3n, con la posibilidad de adopci\u00f3n en 2010.\n\n3. **\u00bfQu\u00e9 recomendaciones se hicieron respecto a la circulaci\u00f3n del documento sobre la gesti\u00f3n de la cadena de fr\u00edo?**\n   - Se sugiri\u00f3 que el documento se circule entre el Panel Asesor de la OMS sobre la Farmacopea Internacional y Preparaciones Farmac\u00e9uticas, as\u00ed como al grupo de trabajo de IMPACT que desarroll\u00f3 la revisi\u00f3n de las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Comit\u00e9 de Expertos de la OMS**: \n   - Se reuni\u00f3 para revisar un informe actualizado y aprob\u00f3 preguntas y respuestas para su publicaci\u00f3n en el sitio web de la OMS y en *WHO Drug Information*.\n\n2. **Pr\u00e1cticas de Buena Distribuci\u00f3n (GDP)**:\n   - Las directrices de GDP fueron adoptadas inicialmente en octubre de 2005 y revisadas posteriormente por la Alianza Internacional contra la Falsificaci\u00f3n de Productos M\u00e9dicos (IMPACT) para prevenir la entrada de medicamentos falsificados en la cadena de suministro.\n\n3. **Revisi\u00f3n en Bonn (2006)**:\n   - En una reuni\u00f3n en Bonn, se propusieron enmiendas para mejorar la seguridad de la cadena de distribuci\u00f3n frente a medicamentos falsificados, reconociendo que estos pod\u00edan llegar a pacientes incluso en pa\u00edses con regulaciones estrictas.\n\n4. **Proceso de Elaboraci\u00f3n del Borrador**:\n   - Un primer borrador fue circulado en marzo de 2007 a los miembros del Grupo de Trabajo de Implementaci\u00f3n Regulatoria (IRIWG). Se discutieron enmiendas en una reuni\u00f3n en Washington, DC, y se solicit\u00f3 retroalimentaci\u00f3n adicional antes de finalizar el documento.\n\n5. **Reuni\u00f3n General en Lisboa (2007)**:\n   - El texto revisado de las directrices de GDP fue finalizado en la reuni\u00f3n general de IMPACT en Lisboa, reflejando el consenso alcanzado y preparado para su publicaci\u00f3n.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la adopci\u00f3n y revisi\u00f3n de las directrices de GDP.\n- **IMPACT (Alianza Internacional contra la Falsificaci\u00f3n de Productos M\u00e9dicos)**: Grupo que revis\u00f3 y propuso enmiendas a las directrices de GDP.\n- **IRIWG (Grupo de Trabajo de Implementaci\u00f3n Regulatoria)**: Grupo que particip\u00f3 en la revisi\u00f3n y discusi\u00f3n de las directrices de GDP.\n- **Estados Miembros de la OMS**: Incluyendo a las Autoridades Reguladoras de Medicamentos (MRAs) de 60 pa\u00edses que participaron en el proceso de revisi\u00f3n.", "excerpt_keywords": "Keywords: WHO, IMPACT, pharmaceutical cold chain management, regulatory oversight, Good Distribution Practices (GDP)"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e764195e-527b-4cb1-bfcc-9b8d5b32cf19", "node_type": "4", "metadata": {"page_label": "65", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "WHO Expert Committee in 2008 as a recommendation from the IMPACT partners.\n\nDuring its forty-third meeting the Committee recommended discussing the document further with IMPACT, the EU and with WHO in view of the comments received. A meeting was subsequently arranged in Geneva on 31 August\u20131 September 2009 with a view to preparing a new document containing all comments received from the various parties and members of the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations. The revised document resulting from this meeting was presented to the Expert Committee at its current meeting and the main comments received up until the date of the meeting were identified and discussed. A small subgroup was formed to review all comments received by the permissible deadline. The Committee adopted the text subject to input from this subgroup and provided no major additional comments were received. The Committee members would be duly informed of the outcome (Annex 5), in order to allow them to reconfirm their decision in light of the deliberations of this Expert Committee subgroup.\n\n### 8.3 Regulatory oversight on pharmaceutical cold chain management\n\nFollowing-up on the 2008 joint session of topics with common interest, the Secretary of the Expert Committee for Biological Standardization (ECBS) arranged for an update in relation to the draft *Regulatory oversight on pharmaceutical cold chain management. Harmonized guidance for the storage and transport of temperature-sensitive pharmaceutical products.* The table of contents of the current draft working document was presented to the Committee for information.\n\nThe document had been developed with a group of experts and took forward the agreement from the joint meeting between the two Committees in 2008, as one of the cross-cutting issues. The document was considered to be fairly mature and would be presented at the 2009 ECBS meeting to obtain feedback, with a view to possible adoption of the document in 2010.\n\nAn oral update by video was given by the technical officer responsible for this project.\n\nThe Expert Committee noted this update and suggested circulation of the document to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and to the IMPACT IRIWG that developed the revision of the GDP.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "78c23f5de6205cedcdf1f926aecb19b4e41eb267cc65bd399b8296a432b1e44e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "WHO Expert Committee in 2008 as a recommendation from the IMPACT partners.\n\nDuring its forty-third meeting the Committee recommended discussing the document further with IMPACT, the EU and with WHO in view of the comments received. A meeting was subsequently arranged in Geneva on 31 August\u20131 September 2009 with a view to preparing a new document containing all comments received from the various parties and members of the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations. The revised document resulting from this meeting was presented to the Expert Committee at its current meeting and the main comments received up until the date of the meeting were identified and discussed. A small subgroup was formed to review all comments received by the permissible deadline. The Committee adopted the text subject to input from this subgroup and provided no major additional comments were received. The Committee members would be duly informed of the outcome (Annex 5), in order to allow them to reconfirm their decision in light of the deliberations of this Expert Committee subgroup.\n\n### 8.3 Regulatory oversight on pharmaceutical cold chain management\n\nFollowing-up on the 2008 joint session of topics with common interest, the Secretary of the Expert Committee for Biological Standardization (ECBS) arranged for an update in relation to the draft *Regulatory oversight on pharmaceutical cold chain management. Harmonized guidance for the storage and transport of temperature-sensitive pharmaceutical products.* The table of contents of the current draft working document was presented to the Committee for information.\n\nThe document had been developed with a group of experts and took forward the agreement from the joint meeting between the two Committees in 2008, as one of the cross-cutting issues. The document was considered to be fairly mature and would be presented at the 2009 ECBS meeting to obtain feedback, with a view to possible adoption of the document in 2010.\n\nAn oral update by video was given by the technical officer responsible for this project.\n\nThe Expert Committee noted this update and suggested circulation of the document to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and to the IMPACT IRIWG that developed the revision of the GDP.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2354, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0e156791-be61-4b2d-99fa-c61eba413ec7": {"__data__": {"id_": "0e156791-be61-4b2d-99fa-c61eba413ec7", "embedding": null, "metadata": {"page_label": "66", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9. Prequalification of priority essential medicines\n\n## 9.1 Prequalification Programme managed by WHO\n\nThe WHO Prequalification Programme (PQP) ensured that medicines procured with international funds were assessed and that the manufacturers of these medicines were inspected, in order to provide a high level of assurance of their quality, efficacy and safety. This was supported by building national regulatory capacity, providing technical assistance to selected manufacturers and postmarket monitoring through quality control (QC) testing by prequalified quality control laboratories. Ultimately the aim was to make low-cost quality priority medicines available for the benefit of those in need.\n\nPQP continued to expand in order to meet the needs of procurers and currently covered priority essential medicines in the following areas:\n\n- HIV/AIDS\n- tuberculosis\n- malaria\n- reproductive health\n- selected individual products for other diseases such as oseltamivir and zinc sulfate.\n\nManufacturers were invited to apply for prequalification of medicines included in invitations for Expressions of Interest (EOI) published on the PQP web site.\n\nThe Programme was reliant upon and appreciated the assistance and support of many partners, including national medicines regulatory authorities (NMRAs), QC laboratories, WHO disease departments and programmes, regional and country offices, United Nations and other drug procurement agencies (including UNICEF, the Global Fund and M\u00e9decins Sans Fronti\u00e8res) and donors such as the Bill and Melinda Gates Foundation and UNITAID, as well as the colleagues of the Medicines Quality Assurance and Regulatory Support Programmes of WHO. The Programme relied heavily on the standards and guidelines adopted by this Expert Committee.\n\n### Assessment of product dossiers (see Table 1)\n\nAssessment of product dossiers was conducted both in-house and by external international experts. WHO standards as defined in WHO guidelines and *The International Pharmacopoeia* were applied. If these did not exist, ICH guidelines were used and, in case of need, guidelines of stringent regulatory authorities were considered.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl Programa de Precalificaci\u00f3n de Medicamentos Esenciales Prioritarios de la OMS (PQP) se encarga de asegurar que los medicamentos adquiridos con fondos internacionales sean evaluados y que los fabricantes sean inspeccionados, garantizando as\u00ed su calidad, eficacia y seguridad. Este programa se apoya en la construcci\u00f3n de capacidades regulatorias nacionales, asistencia t\u00e9cnica a fabricantes seleccionados y monitoreo postcomercializaci\u00f3n a trav\u00e9s de pruebas de control de calidad. Actualmente, el PQP abarca \u00e1reas prioritarias como VIH/SIDA, tuberculosis, malaria, salud reproductiva y otros productos individuales. La evaluaci\u00f3n de los expedientes de productos se realiza tanto internamente como por expertos internacionales externos, aplicando est\u00e1ndares y directrices de la OMS y otras autoridades regulatorias.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las \u00e1reas prioritarias que cubre actualmente el Programa de Precalificaci\u00f3n de Medicamentos de la OMS?**\n   - Respuesta: El PQP cubre \u00e1reas prioritarias como VIH/SIDA, tuberculosis, malaria, salud reproductiva y productos individuales seleccionados para otras enfermedades, como oseltamivir y sulfato de zinc.\n\n2. **\u00bfQu\u00e9 tipo de apoyo reciben los fabricantes para cumplir con los est\u00e1ndares del PQP?**\n   - Respuesta: Los fabricantes reciben asistencia t\u00e9cnica, apoyo en la construcci\u00f3n de capacidades regulatorias nacionales y monitoreo postcomercializaci\u00f3n a trav\u00e9s de laboratorios de control de calidad precalificados.\n\n3. **\u00bfQu\u00e9 est\u00e1ndares se aplican en la evaluaci\u00f3n de los expedientes de productos dentro del PQP?**\n   - Respuesta: Se aplican los est\u00e1ndares definidos en las directrices de la OMS y *The International Pharmacopoeia*. Si no existen, se utilizan las directrices del ICH y, si es necesario, las directrices de autoridades regulatorias estrictas.\n\n### Resumen adicional\n\nEl PQP de la OMS es un programa clave para garantizar que los medicamentos esenciales sean de alta calidad y est\u00e9n disponibles para quienes los necesitan, especialmente en \u00e1reas de alta prioridad como enfermedades infecciosas. La colaboraci\u00f3n con diversas organizaciones y la aplicaci\u00f3n de est\u00e1ndares internacionales son fundamentales para el \u00e9xito del programa.", "prev_section_summary": "### Temas Clave:\n\n1. **Revisi\u00f3n de Documentos**: El Comit\u00e9 de Expertos de la OMS revis\u00f3 un documento que incorporaba comentarios de diversas partes interesadas, incluyendo IMPACT y la Uni\u00f3n Europea. Se organiz\u00f3 una reuni\u00f3n en Ginebra para discutir y preparar un nuevo documento basado en estos comentarios.\n\n2. **Gesti\u00f3n de la Cadena de Fr\u00edo Farmac\u00e9utica**: Se present\u00f3 un borrador sobre la regulaci\u00f3n de la gesti\u00f3n de la cadena de fr\u00edo para productos farmac\u00e9uticos sensibles a la temperatura. Este documento, desarrollado por un grupo de expertos, se considera maduro y se planea presentar en una reuni\u00f3n futura para obtener retroalimentaci\u00f3n y posible adopci\u00f3n.\n\n3. **Actualizaci\u00f3n y Circulaci\u00f3n de Documentos**: Se realiz\u00f3 una actualizaci\u00f3n oral sobre el proyecto de gesti\u00f3n de la cadena de fr\u00edo, y se sugiri\u00f3 la circulaci\u00f3n del documento entre el Panel Asesor de la OMS y el grupo de trabajo de IMPACT que revis\u00f3 las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP).\n\n### Entidades:\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la salud p\u00fablica internacional que lidera la revisi\u00f3n y adopci\u00f3n de documentos t\u00e9cnicos.\n- **IMPACT**: Asociaci\u00f3n de socios que contribuyen a la revisi\u00f3n de documentos y pr\u00e1cticas en el \u00e1mbito farmac\u00e9utico.\n- **Uni\u00f3n Europea (UE)**: Entidad que participa en la discusi\u00f3n y revisi\u00f3n de documentos relacionados con la regulaci\u00f3n farmac\u00e9utica.\n- **ECBS (Comit\u00e9 de Expertos para la Normalizaci\u00f3n Biol\u00f3gica)**: Comit\u00e9 que organiza actualizaciones y revisiones sobre temas de estandarizaci\u00f3n biol\u00f3gica y farmac\u00e9utica.\n- **Panel Asesor de la OMS sobre la Farmacopea Internacional y Preparaciones Farmac\u00e9uticas**: Grupo que proporciona asesoramiento sobre est\u00e1ndares y pr\u00e1cticas en farmacolog\u00eda.", "excerpt_keywords": "Keywords: prequalification, essential medicines, WHO, quality assurance, regulatory capacity"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5d160806-2b4c-4bd5-b196-4cd126ed5a2d", "node_type": "4", "metadata": {"page_label": "66", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9. Prequalification of priority essential medicines\n\n## 9.1 Prequalification Programme managed by WHO\n\nThe WHO Prequalification Programme (PQP) ensured that medicines procured with international funds were assessed and that the manufacturers of these medicines were inspected, in order to provide a high level of assurance of their quality, efficacy and safety. This was supported by building national regulatory capacity, providing technical assistance to selected manufacturers and postmarket monitoring through quality control (QC) testing by prequalified quality control laboratories. Ultimately the aim was to make low-cost quality priority medicines available for the benefit of those in need.\n\nPQP continued to expand in order to meet the needs of procurers and currently covered priority essential medicines in the following areas:\n\n- HIV/AIDS\n- tuberculosis\n- malaria\n- reproductive health\n- selected individual products for other diseases such as oseltamivir and zinc sulfate.\n\nManufacturers were invited to apply for prequalification of medicines included in invitations for Expressions of Interest (EOI) published on the PQP web site.\n\nThe Programme was reliant upon and appreciated the assistance and support of many partners, including national medicines regulatory authorities (NMRAs), QC laboratories, WHO disease departments and programmes, regional and country offices, United Nations and other drug procurement agencies (including UNICEF, the Global Fund and M\u00e9decins Sans Fronti\u00e8res) and donors such as the Bill and Melinda Gates Foundation and UNITAID, as well as the colleagues of the Medicines Quality Assurance and Regulatory Support Programmes of WHO. The Programme relied heavily on the standards and guidelines adopted by this Expert Committee.\n\n### Assessment of product dossiers (see Table 1)\n\nAssessment of product dossiers was conducted both in-house and by external international experts. WHO standards as defined in WHO guidelines and *The International Pharmacopoeia* were applied. If these did not exist, ICH guidelines were used and, in case of need, guidelines of stringent regulatory authorities were considered.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "392d5e8f37cb25f9770ac87f82b24eda6a5ed5750641002db74787e6b012c9fd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9. Prequalification of priority essential medicines\n\n## 9.1 Prequalification Programme managed by WHO\n\nThe WHO Prequalification Programme (PQP) ensured that medicines procured with international funds were assessed and that the manufacturers of these medicines were inspected, in order to provide a high level of assurance of their quality, efficacy and safety. This was supported by building national regulatory capacity, providing technical assistance to selected manufacturers and postmarket monitoring through quality control (QC) testing by prequalified quality control laboratories. Ultimately the aim was to make low-cost quality priority medicines available for the benefit of those in need.\n\nPQP continued to expand in order to meet the needs of procurers and currently covered priority essential medicines in the following areas:\n\n- HIV/AIDS\n- tuberculosis\n- malaria\n- reproductive health\n- selected individual products for other diseases such as oseltamivir and zinc sulfate.\n\nManufacturers were invited to apply for prequalification of medicines included in invitations for Expressions of Interest (EOI) published on the PQP web site.\n\nThe Programme was reliant upon and appreciated the assistance and support of many partners, including national medicines regulatory authorities (NMRAs), QC laboratories, WHO disease departments and programmes, regional and country offices, United Nations and other drug procurement agencies (including UNICEF, the Global Fund and M\u00e9decins Sans Fronti\u00e8res) and donors such as the Bill and Melinda Gates Foundation and UNITAID, as well as the colleagues of the Medicines Quality Assurance and Regulatory Support Programmes of WHO. The Programme relied heavily on the standards and guidelines adopted by this Expert Committee.\n\n### Assessment of product dossiers (see Table 1)\n\nAssessment of product dossiers was conducted both in-house and by external international experts. WHO standards as defined in WHO guidelines and *The International Pharmacopoeia* were applied. If these did not exist, ICH guidelines were used and, in case of need, guidelines of stringent regulatory authorities were considered.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2152, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ac90a656-c2aa-43be-852b-f01e5ed5ca2c": {"__data__": {"id_": "ac90a656-c2aa-43be-852b-f01e5ed5ca2c", "embedding": null, "metadata": {"page_label": "67", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "regulatory authorities were applied. Much of the assessment work was done in Copenhagen during bimonthly meetings of 15\u201320 assessors. Variations to prequalified products were processed in-house and during the meetings in Copenhagen.\n\n### Table 1\n**Assessment of product dossiers: statistics**\n\n| | 2007 | 2008 | 2009(As at 16/09/2009) |\n| - | - | - | - |\n| Products prequalified | 21 | 40 | 24 |\n| Dossiers submitted | 90 | 92 | 55 |\n\n\nMedicines assessed and prequalified by WHO were included in a List of WHO Prequalified Medicinal Products on the PQP web site. Also listed were medicines assessed by SRAs, following an abbreviated procedure.\n\nCurrently prequalified products (16 September 2009):\n\n- 247 for treatment of HIV/AIDS and related diseases\n- one for treatment of influenza (prequalified in 2009)\n- 23 for treatment of tuberculosis\n- 16 for treatment of malaria\n- 2 for reproductive health (prequalified in 2009)\n- Total: 289\n\n### Inspections of manufacturers (see Table 2)\n\nManufacturers of finished products, selected APIs and also selected contract research organizations (CROs) (which carried out clinical/bioequivalence studies) were inspected as part of the prequalification process.\n\nInspections were conducted by a team of inspectors consisting of:\n\n- a WHO lead GMP inspector\n- an inspector from a well-established inspectorate\n- national inspectors from the country of the manufacturer, who were invited to be part of the team as observers but had no decision-making power (because of different GMP standards and potential conflict of interest)\n- inspectors from developing target countries who might also be invited as observers, for capacity-building purposes.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento presenta informaci\u00f3n sobre el proceso de evaluaci\u00f3n y precalificaci\u00f3n de productos medicinales por parte de la Organizaci\u00f3n Mundial de la Salud (OMS). Se detalla el trabajo realizado en Copenhague, donde se llevaron a cabo reuniones bimestrales con un grupo de evaluadores. Se incluyen estad\u00edsticas sobre la cantidad de productos precalificados y los expedientes presentados entre 2007 y 2009. Adem\u00e1s, se menciona la inspecci\u00f3n de fabricantes y organizaciones de investigaci\u00f3n contratadas como parte del proceso de precalificaci\u00f3n, destacando la composici\u00f3n del equipo de inspectores.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1ntos productos fueron precalificados para el tratamiento de malaria hasta el 16 de septiembre de 2009?**\n   - Respuesta: Hasta el 16 de septiembre de 2009, se precalificaron 16 productos para el tratamiento de malaria.\n\n2. **\u00bfQu\u00e9 tipo de inspectores forman parte del equipo de inspecci\u00f3n durante el proceso de precalificaci\u00f3n de productos medicinales?**\n   - Respuesta: El equipo de inspecci\u00f3n est\u00e1 compuesto por un inspector l\u00edder de GMP de la OMS, un inspector de una autoridad de inspecci\u00f3n bien establecida, inspectores nacionales del pa\u00eds del fabricante (como observadores) y inspectores de pa\u00edses en desarrollo (tambi\u00e9n como observadores).\n\n3. **\u00bfCu\u00e1l fue la tendencia en la cantidad de expedientes presentados para precalificaci\u00f3n entre 2007 y 2009?**\n   - Respuesta: La cantidad de expedientes presentados para precalificaci\u00f3n mostr\u00f3 una ligera disminuci\u00f3n, pasando de 90 en 2007 a 55 en 2009 (hasta el 16 de septiembre de 2009).", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**Programa de Precalificaci\u00f3n de Medicamentos Esenciales Prioritarios (PQP) de la OMS:**\n- **Objetivo:** Asegurar que los medicamentos adquiridos con fondos internacionales sean evaluados y que los fabricantes sean inspeccionados, garantizando su calidad, eficacia y seguridad.\n- **Apoyo:** Construcci\u00f3n de capacidades regulatorias nacionales, asistencia t\u00e9cnica a fabricantes seleccionados y monitoreo postcomercializaci\u00f3n a trav\u00e9s de laboratorios de control de calidad precalificados.\n\n**\u00c1reas prioritarias cubiertas por el PQP:**\n- VIH/SIDA\n- Tuberculosis\n- Malaria\n- Salud reproductiva\n- Productos individuales seleccionados para otras enfermedades (ej. oseltamivir y sulfato de zinc).\n\n**Colaboraciones y socios:**\n- Autoridades regulatorias nacionales de medicamentos (NMRAs)\n- Laboratorios de control de calidad (QC)\n- Departamentos y programas de enfermedades de la OMS\n- Oficinas regionales y de pa\u00eds de la OMS\n- Agencias de adquisici\u00f3n de medicamentos de la ONU (ej. UNICEF, Global Fund, M\u00e9dicos Sin Fronteras)\n- Donantes como la Fundaci\u00f3n Bill y Melinda Gates y UNITAID.\n\n**Evaluaci\u00f3n de expedientes de productos:**\n- Realizada tanto internamente como por expertos internacionales externos.\n- Aplicaci\u00f3n de est\u00e1ndares definidos en las directrices de la OMS y *The International Pharmacopoeia*.\n- Uso de directrices del ICH y de autoridades regulatorias estrictas cuando sea necesario.\n\nEste programa es fundamental para garantizar la disponibilidad de medicamentos esenciales de alta calidad, especialmente en \u00e1reas cr\u00edticas de salud p\u00fablica.", "excerpt_keywords": "Keywords: WHO, prequalification, medicinal products, inspections, regulatory authorities"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "39112a93-e6ca-4c13-9cd8-92064b394126", "node_type": "4", "metadata": {"page_label": "67", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "regulatory authorities were applied. Much of the assessment work was done in Copenhagen during bimonthly meetings of 15\u201320 assessors. Variations to prequalified products were processed in-house and during the meetings in Copenhagen.\n\n### Table 1\n**Assessment of product dossiers: statistics**\n\n| | 2007 | 2008 | 2009(As at 16/09/2009) |\n| - | - | - | - |\n| Products prequalified | 21 | 40 | 24 |\n| Dossiers submitted | 90 | 92 | 55 |\n\n\nMedicines assessed and prequalified by WHO were included in a List of WHO Prequalified Medicinal Products on the PQP web site. Also listed were medicines assessed by SRAs, following an abbreviated procedure.\n\nCurrently prequalified products (16 September 2009):\n\n- 247 for treatment of HIV/AIDS and related diseases\n- one for treatment of influenza (prequalified in 2009)\n- 23 for treatment of tuberculosis\n- 16 for treatment of malaria\n- 2 for reproductive health (prequalified in 2009)\n- Total: 289\n\n### Inspections of manufacturers (see Table 2)\n\nManufacturers of finished products, selected APIs and also selected contract research organizations (CROs) (which carried out clinical/bioequivalence studies) were inspected as part of the prequalification process.\n\nInspections were conducted by a team of inspectors consisting of:\n\n- a WHO lead GMP inspector\n- an inspector from a well-established inspectorate\n- national inspectors from the country of the manufacturer, who were invited to be part of the team as observers but had no decision-making power (because of different GMP standards and potential conflict of interest)\n- inspectors from developing target countries who might also be invited as observers, for capacity-building purposes.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "666662e5b019903f8097979f312159ca3bce2386ddb13c0b3826aafe6eb6608d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "regulatory authorities were applied. Much of the assessment work was done in Copenhagen during bimonthly meetings of 15\u201320 assessors. Variations to prequalified products were processed in-house and during the meetings in Copenhagen.\n\n### Table 1\n**Assessment of product dossiers: statistics**\n\n| | 2007 | 2008 | 2009(As at 16/09/2009) |\n| - | - | - | - |\n| Products prequalified | 21 | 40 | 24 |\n| Dossiers submitted | 90 | 92 | 55 |\n\n\nMedicines assessed and prequalified by WHO were included in a List of WHO Prequalified Medicinal Products on the PQP web site. Also listed were medicines assessed by SRAs, following an abbreviated procedure.\n\nCurrently prequalified products (16 September 2009):\n\n- 247 for treatment of HIV/AIDS and related diseases\n- one for treatment of influenza (prequalified in 2009)\n- 23 for treatment of tuberculosis\n- 16 for treatment of malaria\n- 2 for reproductive health (prequalified in 2009)\n- Total: 289\n\n### Inspections of manufacturers (see Table 2)\n\nManufacturers of finished products, selected APIs and also selected contract research organizations (CROs) (which carried out clinical/bioequivalence studies) were inspected as part of the prequalification process.\n\nInspections were conducted by a team of inspectors consisting of:\n\n- a WHO lead GMP inspector\n- an inspector from a well-established inspectorate\n- national inspectors from the country of the manufacturer, who were invited to be part of the team as observers but had no decision-making power (because of different GMP standards and potential conflict of interest)\n- inspectors from developing target countries who might also be invited as observers, for capacity-building purposes.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1683, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "435a5633-b92b-499a-9ceb-0a26a98e0abd": {"__data__": {"id_": "435a5633-b92b-499a-9ceb-0a26a98e0abd", "embedding": null, "metadata": {"page_label": "68", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Inspections carried out since 2005\n\n| Manufacturer: | 2005 | 2006 | 2007 | 2008 | 2009 (to September) |\n| - | - | - | - | - | - |\n| Finished product | 20 | 17 | 26 | 27 | 22 |\n| Active pharmaceutical ingredient | 10 | 10 | 6 | 11 | 5 |\n| Contract research organization | 14 | 15 | 13 | 14 | 6 |\n| Quality control laboratory | 3 | 1 | 1 | 6 | 3 |\n\n\n## Prequalification of medicines \u2014 transparency\n\nThe World Health Assembly through Resolution WHA57.14 of 22 May 2004, requested WHO:\n\n\"3. (4) to ensure that the prequalification review process and the results of inspection and assessment reports of the listed products, aside from proprietary and confidential information, are made publicly available.\"\n\nA WHO Public Assessment Report (WHOPAR) provided a summary of the dossier assessment (where found to be compliant).\n\nA WHO Public Inspection Report (WHOPIR) provided a summary of the inspection (where found to be GMP-compliant).\n\nA Notice of Concern (NOC) was a letter reflecting areas of concern where the non-compliances required urgent attention and corrective action by the manufacturer or research organization.\n\nA Notice of Suspension was a letter reflecting areas of concern when deficiencies identified during an inspection indicate significant non-compliance with GMP, good clinical practices (GCP) or good laboratory practices (GLP), as relevant, resulting in inadequate assurance of product quality.\n\n## Prequalification of QC laboratories\n\nThe PQP was established in 2004 for QC laboratories in Africa only; however, the programme had since broadened its scope for participation and was now voluntary and without regional limitation. Any laboratory (private or governmental) could participate and the programme was free of charge. The third invitation for EOI was published in September 2007 at the following address: http://www.who.int/prequal/info_applicants/eoi/EOI-QCLabsV3.pdf.\n\nPriority regarding assessment was given to national QC laboratories, laboratories providing testing services to the government, and QC laboratories in areas where United Nations agencies had identified the need for quality testing.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla las inspecciones realizadas desde 2005 en diferentes tipos de fabricantes y laboratorios, as\u00ed como la transparencia en el proceso de precalificaci\u00f3n de medicamentos. Se menciona la importancia de los informes p\u00fablicos de evaluaci\u00f3n e inspecci\u00f3n, as\u00ed como las acciones correctivas que se pueden tomar en caso de incumplimientos. Adem\u00e1s, se describe el Programa de Precalificaci\u00f3n de Laboratorios de Control de Calidad (PQP), que se estableci\u00f3 inicialmente para \u00c1frica y se ha expandido a nivel global.\n\n### Preguntas:\n1. **\u00bfCu\u00e1ntas inspecciones de laboratorios de control de calidad se llevaron a cabo en 2008 y qu\u00e9 tendencia se observa en los a\u00f1os anteriores?**\n   - Respuesta: En 2008 se realizaron 6 inspecciones de laboratorios de control de calidad. La tendencia muestra un aumento en 2008 en comparaci\u00f3n con solo 1 inspecci\u00f3n en 2006 y 2007, pero una disminuci\u00f3n respecto a las 3 inspecciones en 2009 hasta septiembre.\n\n2. **\u00bfQu\u00e9 tipo de informes proporciona la OMS para asegurar la transparencia en el proceso de precalificaci\u00f3n de medicamentos y qu\u00e9 informaci\u00f3n contienen?**\n   - Respuesta: La OMS proporciona dos tipos de informes: el Informe P\u00fablico de Evaluaci\u00f3n de la OMS (WHOPAR), que resume la evaluaci\u00f3n del expediente, y el Informe P\u00fablico de Inspecci\u00f3n de la OMS (WHOPIR), que resume la inspecci\u00f3n y la conformidad con las Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n3. **\u00bfCu\u00e1l es la prioridad en la evaluaci\u00f3n de laboratorios de control de calidad seg\u00fan el Programa de Precalificaci\u00f3n (PQP) y qu\u00e9 tipo de laboratorios pueden participar?**\n   - Respuesta: La prioridad en la evaluaci\u00f3n se otorga a los laboratorios nacionales de control de calidad, aquellos que brindan servicios de pruebas al gobierno y los laboratorios en \u00e1reas donde las agencias de las Naciones Unidas han identificado la necesidad de pruebas de calidad. Cualquier laboratorio, ya sea privado o gubernamental, puede participar en el programa, que es gratuito.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Proceso de Evaluaci\u00f3n y Precalificaci\u00f3n**:\n   - La Organizaci\u00f3n Mundial de la Salud (OMS) lleva a cabo la evaluaci\u00f3n y precalificaci\u00f3n de productos medicinales.\n   - Las reuniones de evaluaci\u00f3n se realizan bimestralmente en Copenhague con un grupo de 15 a 20 evaluadores.\n\n2. **Estad\u00edsticas de Precalificaci\u00f3n**:\n   - Se presentan datos sobre la cantidad de productos precalificados y expedientes presentados entre 2007 y 2009:\n     - Productos precalificados: 21 (2007), 40 (2008), 24 (2009).\n     - Dossiers presentados: 90 (2007), 92 (2008), 55 (2009).\n\n3. **Medicamentos Precalificados (hasta el 16 de septiembre de 2009)**:\n   - Total de productos precalificados: 289.\n   - Desglose:\n     - 247 para tratamiento de VIH/SIDA y enfermedades relacionadas.\n     - 1 para tratamiento de influenza.\n     - 23 para tratamiento de tuberculosis.\n     - 16 para tratamiento de malaria.\n     - 2 para salud reproductiva.\n\n4. **Inspecciones de Fabricantes**:\n   - Se inspeccionan fabricantes de productos terminados, APIs seleccionados y organizaciones de investigaci\u00f3n contratadas (CROs).\n   - El equipo de inspecci\u00f3n incluye:\n     - Un inspector l\u00edder de GMP de la OMS.\n     - Un inspector de una autoridad de inspecci\u00f3n bien establecida.\n     - Inspectores nacionales del pa\u00eds del fabricante (como observadores).\n     - Inspectores de pa\u00edses en desarrollo (tambi\u00e9n como observadores).\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Responsable de la evaluaci\u00f3n y precalificaci\u00f3n de productos medicinales.\n- **Productos Medicinales**: Incluyen tratamientos para VIH/SIDA, tuberculosis, malaria, influenza y salud reproductiva.\n- **Inspectores**: Compuestos por representantes de la OMS y autoridades de inspecci\u00f3n nacionales e internacionales.", "excerpt_keywords": "Keywords: inspections, prequalification, WHO, quality control laboratories, transparency"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "30f9445e-d74e-4e99-af24-cf4950deacfa", "node_type": "4", "metadata": {"page_label": "68", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Inspections carried out since 2005\n\n| Manufacturer: | 2005 | 2006 | 2007 | 2008 | 2009 (to September) |\n| - | - | - | - | - | - |\n| Finished product | 20 | 17 | 26 | 27 | 22 |\n| Active pharmaceutical ingredient | 10 | 10 | 6 | 11 | 5 |\n| Contract research organization | 14 | 15 | 13 | 14 | 6 |\n| Quality control laboratory | 3 | 1 | 1 | 6 | 3 |\n\n\n## Prequalification of medicines \u2014 transparency\n\nThe World Health Assembly through Resolution WHA57.14 of 22 May 2004, requested WHO:\n\n\"3. (4) to ensure that the prequalification review process and the results of inspection and assessment reports of the listed products, aside from proprietary and confidential information, are made publicly available.\"\n\nA WHO Public Assessment Report (WHOPAR) provided a summary of the dossier assessment (where found to be compliant).\n\nA WHO Public Inspection Report (WHOPIR) provided a summary of the inspection (where found to be GMP-compliant).\n\nA Notice of Concern (NOC) was a letter reflecting areas of concern where the non-compliances required urgent attention and corrective action by the manufacturer or research organization.\n\nA Notice of Suspension was a letter reflecting areas of concern when deficiencies identified during an inspection indicate significant non-compliance with GMP, good clinical practices (GCP) or good laboratory practices (GLP), as relevant, resulting in inadequate assurance of product quality.\n\n## Prequalification of QC laboratories\n\nThe PQP was established in 2004 for QC laboratories in Africa only; however, the programme had since broadened its scope for participation and was now voluntary and without regional limitation. Any laboratory (private or governmental) could participate and the programme was free of charge. The third invitation for EOI was published in September 2007 at the following address: http://www.who.int/prequal/info_applicants/eoi/EOI-QCLabsV3.pdf.\n\nPriority regarding assessment was given to national QC laboratories, laboratories providing testing services to the government, and QC laboratories in areas where United Nations agencies had identified the need for quality testing.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "6384a8761139b595fd475db3c615d2262bcd5f2904316730bdf7a8f26d22ac63", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Inspections carried out since 2005\n\n| Manufacturer: | 2005 | 2006 | 2007 | 2008 | 2009 (to September) |\n| - | - | - | - | - | - |\n| Finished product | 20 | 17 | 26 | 27 | 22 |\n| Active pharmaceutical ingredient | 10 | 10 | 6 | 11 | 5 |\n| Contract research organization | 14 | 15 | 13 | 14 | 6 |\n| Quality control laboratory | 3 | 1 | 1 | 6 | 3 |\n\n\n## Prequalification of medicines \u2014 transparency\n\nThe World Health Assembly through Resolution WHA57.14 of 22 May 2004, requested WHO:\n\n\"3. (4) to ensure that the prequalification review process and the results of inspection and assessment reports of the listed products, aside from proprietary and confidential information, are made publicly available.\"\n\nA WHO Public Assessment Report (WHOPAR) provided a summary of the dossier assessment (where found to be compliant).\n\nA WHO Public Inspection Report (WHOPIR) provided a summary of the inspection (where found to be GMP-compliant).\n\nA Notice of Concern (NOC) was a letter reflecting areas of concern where the non-compliances required urgent attention and corrective action by the manufacturer or research organization.\n\nA Notice of Suspension was a letter reflecting areas of concern when deficiencies identified during an inspection indicate significant non-compliance with GMP, good clinical practices (GCP) or good laboratory practices (GLP), as relevant, resulting in inadequate assurance of product quality.\n\n## Prequalification of QC laboratories\n\nThe PQP was established in 2004 for QC laboratories in Africa only; however, the programme had since broadened its scope for participation and was now voluntary and without regional limitation. Any laboratory (private or governmental) could participate and the programme was free of charge. The third invitation for EOI was published in September 2007 at the following address: http://www.who.int/prequal/info_applicants/eoi/EOI-QCLabsV3.pdf.\n\nPriority regarding assessment was given to national QC laboratories, laboratories providing testing services to the government, and QC laboratories in areas where United Nations agencies had identified the need for quality testing.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2132, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "fd485735-e957-4688-8de9-5e9e90505868": {"__data__": {"id_": "fd485735-e957-4688-8de9-5e9e90505868", "embedding": null, "metadata": {"page_label": "69", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Monitoring after prequalification involved:\n\n- **Re-inspections at regular intervals**\n  - Normally three years\n  - Two re-inspections performed\n\n- **A brief report to be submitted annually**\n  - Summary of services provided to United Nations agencies, number of samples analysed, methods used, complaints received\n  - Brief details of proficiency testing\n  - Changes to key personnel, facility, equipment or other change with significant impact on the laboratory\n  - Update of the laboratory information file (LIF), in case of changes with significant impact on LIF content\n\n- **Evaluation of results from participation in proficiency testing**\n  - WHO EQAAS, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (AFSSAPS) network of francophone African countries\n\n- **WHO might suspend or withdraw a laboratory from the list when there was evidence of noncompliance.**\n\nAt present the PQP had surpassed expectations and a significant number of laboratories around the world were applying for prequalification.\n\nThe object was to increase access to QC laboratories that met recommended standards and that were committed to providing a service to United Nations agencies for testing of medicines, including but not limited to HIV/AIDS, tuberculosis and malaria products.\n\nAs of September 2009, there were 11 prequalified laboratories in: Algeria; France; India; Kenya (2); Morocco; Singapore (2); South Africa (2); and Viet Nam.\n\nThe PQP was also involved in capacity building: technical assistance provided to eight national medicines QC laboratories; training in quality assurance, quality control and Ph.Int. (2007); a seminar on rational sampling and testing in quality control of medicines (2009); and participation in EDQM in quality assurance training for official medicines control laboratories (2007). The Programme also monitored the quality of medicines through its policy, sampling and testing projects and prequalified laboratories or laboratories for which the evidence of reliability was available. The major quality monitoring projects were the following:\n\n## Quality monitoring of medicines funded by UNITAID (2008/9)\n\nThe pilot phase focused on paediatric and second-line antiretrovirals and co-trimoxazole-containing medicines. In cooperation with NMRAs in Kenya, Uganda, the United Republic of Tanzania and Zambia, 378 samples produced by 24 manufacturers were collected, mostly from treatment centres and tested in the laboratory. Only three samples did not", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento detalla el proceso de monitoreo posterior a la precalificaci\u00f3n de laboratorios por parte de la Organizaci\u00f3n Mundial de la Salud (OMS). Este proceso incluye re-inspecciones regulares, la presentaci\u00f3n de informes anuales, la evaluaci\u00f3n de resultados de pruebas de competencia y la posibilidad de suspensi\u00f3n de laboratorios en caso de incumplimiento. A partir de septiembre de 2009, hab\u00eda 11 laboratorios precalificados en varios pa\u00edses, y el Programa de Precalificaci\u00f3n (PQP) tambi\u00e9n se enfocaba en la capacitaci\u00f3n y el fortalecimiento de capacidades en laboratorios nacionales. Adem\u00e1s, se menciona un proyecto de monitoreo de calidad de medicamentos financiado por UNITAID, que se centr\u00f3 en medicamentos pedi\u00e1tricos y antirretrovirales de segunda l\u00ednea.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que pueden llevar a la OMS a suspender o retirar un laboratorio de la lista de laboratorios precalificados?**\n   - Esta pregunta busca detalles sobre las evidencias de incumplimiento que la OMS considera para tomar tal decisi\u00f3n, lo cual no se menciona expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 tipo de asistencia t\u00e9cnica se proporcion\u00f3 a los laboratorios nacionales de control de calidad de medicamentos y cu\u00e1les fueron los resultados de dicha asistencia?**\n   - Aunque se menciona que se brind\u00f3 asistencia t\u00e9cnica y capacitaci\u00f3n, no se detallan los resultados espec\u00edficos o el impacto de estas actividades en los laboratorios.\n\n3. **\u00bfQu\u00e9 m\u00e9todos espec\u00edficos se utilizaron para la recolecci\u00f3n y an\u00e1lisis de las 378 muestras en el proyecto de monitoreo de medicamentos financiado por UNITAID?**\n   - La pregunta busca informaci\u00f3n sobre los procedimientos y t\u00e9cnicas de laboratorio utilizados en el an\u00e1lisis de las muestras, que no se especifican en el contexto proporcionado.", "prev_section_summary": "### Temas Clave:\n\n1. **Inspecciones de Fabricantes y Laboratorios**: Se presentan datos sobre las inspecciones realizadas desde 2005 en diferentes categor\u00edas, incluyendo productos terminados, ingredientes farmac\u00e9uticos activos, organizaciones de investigaci\u00f3n por contrato y laboratorios de control de calidad. Se observa una variabilidad en el n\u00famero de inspecciones a lo largo de los a\u00f1os.\n\n2. **Transparencia en la Precalificaci\u00f3n de Medicamentos**: La OMS, a trav\u00e9s de la Resoluci\u00f3n WHA57.14, se compromete a hacer p\u00fablicos los procesos de revisi\u00f3n de precalificaci\u00f3n y los resultados de las inspecciones, excluyendo informaci\u00f3n confidencial. Se describen los tipos de informes que se generan, como el WHOPAR y el WHOPIR, as\u00ed como las Notificaciones de Preocupaci\u00f3n y Suspensi\u00f3n.\n\n3. **Programa de Precalificaci\u00f3n de Laboratorios de Control de Calidad (PQP)**: Este programa, inicialmente establecido para laboratorios en \u00c1frica, se ha expandido a nivel global y permite la participaci\u00f3n de cualquier laboratorio, ya sea privado o gubernamental. Se prioriza la evaluaci\u00f3n de laboratorios nacionales y aquellos que brindan servicios a gobiernos o en \u00e1reas identificadas por agencias de la ONU.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la precalificaci\u00f3n y regulaci\u00f3n de medicamentos y laboratorios.\n- **World Health Assembly**: Cuerpo que emite resoluciones como la WHA57.14, que establece directrices para la transparencia en la precalificaci\u00f3n de medicamentos.\n- **Laboratorios de Control de Calidad**: Entidades que participan en el PQP y son evaluadas para asegurar la calidad de los productos farmac\u00e9uticos.\n- **Fabricantes de Productos Farmac\u00e9uticos**: Incluyen aquellos que producen productos terminados y ingredientes activos, as\u00ed como organizaciones de investigaci\u00f3n por contrato.\n\nEste resumen destaca la importancia de la regulaci\u00f3n y la transparencia en la industria farmac\u00e9utica, as\u00ed como el compromiso de la OMS para asegurar la calidad de los medicamentos a trav\u00e9s de inspecciones y programas de precalificaci\u00f3n.", "excerpt_keywords": "Keywords: prequalification, quality control, WHO, laboratory monitoring, medicines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "65ae2c06-0ecd-4517-8092-1a9e5f0dc897", "node_type": "4", "metadata": {"page_label": "69", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Monitoring after prequalification involved:\n\n- **Re-inspections at regular intervals**\n  - Normally three years\n  - Two re-inspections performed\n\n- **A brief report to be submitted annually**\n  - Summary of services provided to United Nations agencies, number of samples analysed, methods used, complaints received\n  - Brief details of proficiency testing\n  - Changes to key personnel, facility, equipment or other change with significant impact on the laboratory\n  - Update of the laboratory information file (LIF), in case of changes with significant impact on LIF content\n\n- **Evaluation of results from participation in proficiency testing**\n  - WHO EQAAS, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (AFSSAPS) network of francophone African countries\n\n- **WHO might suspend or withdraw a laboratory from the list when there was evidence of noncompliance.**\n\nAt present the PQP had surpassed expectations and a significant number of laboratories around the world were applying for prequalification.\n\nThe object was to increase access to QC laboratories that met recommended standards and that were committed to providing a service to United Nations agencies for testing of medicines, including but not limited to HIV/AIDS, tuberculosis and malaria products.\n\nAs of September 2009, there were 11 prequalified laboratories in: Algeria; France; India; Kenya (2); Morocco; Singapore (2); South Africa (2); and Viet Nam.\n\nThe PQP was also involved in capacity building: technical assistance provided to eight national medicines QC laboratories; training in quality assurance, quality control and Ph.Int. (2007); a seminar on rational sampling and testing in quality control of medicines (2009); and participation in EDQM in quality assurance training for official medicines control laboratories (2007). The Programme also monitored the quality of medicines through its policy, sampling and testing projects and prequalified laboratories or laboratories for which the evidence of reliability was available. The major quality monitoring projects were the following:\n\n## Quality monitoring of medicines funded by UNITAID (2008/9)\n\nThe pilot phase focused on paediatric and second-line antiretrovirals and co-trimoxazole-containing medicines. In cooperation with NMRAs in Kenya, Uganda, the United Republic of Tanzania and Zambia, 378 samples produced by 24 manufacturers were collected, mostly from treatment centres and tested in the laboratory. Only three samples did not", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "33ed8d7f13b1e65239005902138dcf7ed878bcd412c746543bf3d12ea15ee016", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Monitoring after prequalification involved:\n\n- **Re-inspections at regular intervals**\n  - Normally three years\n  - Two re-inspections performed\n\n- **A brief report to be submitted annually**\n  - Summary of services provided to United Nations agencies, number of samples analysed, methods used, complaints received\n  - Brief details of proficiency testing\n  - Changes to key personnel, facility, equipment or other change with significant impact on the laboratory\n  - Update of the laboratory information file (LIF), in case of changes with significant impact on LIF content\n\n- **Evaluation of results from participation in proficiency testing**\n  - WHO EQAAS, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (AFSSAPS) network of francophone African countries\n\n- **WHO might suspend or withdraw a laboratory from the list when there was evidence of noncompliance.**\n\nAt present the PQP had surpassed expectations and a significant number of laboratories around the world were applying for prequalification.\n\nThe object was to increase access to QC laboratories that met recommended standards and that were committed to providing a service to United Nations agencies for testing of medicines, including but not limited to HIV/AIDS, tuberculosis and malaria products.\n\nAs of September 2009, there were 11 prequalified laboratories in: Algeria; France; India; Kenya (2); Morocco; Singapore (2); South Africa (2); and Viet Nam.\n\nThe PQP was also involved in capacity building: technical assistance provided to eight national medicines QC laboratories; training in quality assurance, quality control and Ph.Int. (2007); a seminar on rational sampling and testing in quality control of medicines (2009); and participation in EDQM in quality assurance training for official medicines control laboratories (2007). The Programme also monitored the quality of medicines through its policy, sampling and testing projects and prequalified laboratories or laboratories for which the evidence of reliability was available. The major quality monitoring projects were the following:\n\n## Quality monitoring of medicines funded by UNITAID (2008/9)\n\nThe pilot phase focused on paediatric and second-line antiretrovirals and co-trimoxazole-containing medicines. In cooperation with NMRAs in Kenya, Uganda, the United Republic of Tanzania and Zambia, 378 samples produced by 24 manufacturers were collected, mostly from treatment centres and tested in the laboratory. Only three samples did not", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2488, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3994220b-67b9-4347-bcdb-e055ae8f9bf5": {"__data__": {"id_": "3994220b-67b9-4347-bcdb-e055ae8f9bf5", "embedding": null, "metadata": {"page_label": "70", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Quality Survey of Antimalarial Medicines in Africa (2008-2009)\n\nA quality survey of antimalarial medicines focused on artemisinin-based combination therapies (ACTs) and sulfadoxine-pyrimethamine oral dosage forms was performed in six African countries; 936 medicine samples were collected at all levels of the distribution chain and the informal market and were screened by Minilab in cooperation with NMRAs. Three hundred and six samples were then tested fully in the laboratory, of which 74 were found to be non-compliant with a range of quality problems, from very minor non-compliance to absence of the API in two samples.\n\n# Quality Survey of Antituberculosis Medicines in Eastern Europe (2009)\n\nA quality survey of antituberculosis medicines focused on products containing rifampicin, isoniazid, kanamycin and ofloxacin was initiated in Armenia, Azerbaijan, Belarus, Kazakhstan, Ukraine and Uzbekistan; 291 samples were collected and testing is ongoing.\n\nSeveral other quality monitoring projects had been conducted since 2005.\n\n# Training and Capacity Building\n\nTraining and capacity building were important components of the PQP with the aim of increasing the regulatory capacity of NMRAs in developing countries and to assist manufacturers, CROs and QC laboratories in these countries to improve standards and meet prequalification requirements.\n\nTraining was generally provided through seminars and workshops, and might include visits to manufacturers. It was based on prequalification and WHO requirements, but might also be problem-oriented, e.g. relating to a specific product type. NMRA staff and manufacturers frequently participated together in the same training programme and, where possible, the focus was on \u201ctrain the trainer\u201d for maximum effect.\n\nThirteen training sessions were organized or supported by WHO in 2007, 15 in 2008 and seven up to September 2009.\n\nIn addition to training activities, capacity building of regulatory authorities was supported by the programme hosting rotational posts for assessors in Geneva. These were available for periods of three months during which the participant worked alongside WHO experts and also attended the sessions in Copenhagen to learn from external international experts.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Encuesta de Calidad de Medicamentos Antimal\u00e1ricos en \u00c1frica (2008-2009)**: Se realiz\u00f3 una encuesta de calidad de medicamentos antimal\u00e1ricos en seis pa\u00edses africanos, donde se recolectaron 936 muestras de medicamentos. De estas, 306 fueron analizadas en laboratorio, encontrando que 74 no cumpl\u00edan con los est\u00e1ndares de calidad, incluyendo casos de ausencia del principio activo.\n\n2. **Encuesta de Calidad de Medicamentos Antituberculosos en Europa del Este (2009)**: Se inici\u00f3 una encuesta de calidad de medicamentos antituberculosos en varios pa\u00edses de Europa del Este, recolectando 291 muestras. Las pruebas est\u00e1n en curso, y se han realizado otros proyectos de monitoreo de calidad desde 2005.\n\n3. **Capacitaci\u00f3n y Fortalecimiento de Capacidades**: La capacitaci\u00f3n y el fortalecimiento de capacidades son componentes clave del Programa de Precalificaci\u00f3n (PQP) de la OMS, destinados a aumentar la capacidad regulatoria de las Autoridades Nacionales de Regulaci\u00f3n de Medicamentos (NMRAs) en pa\u00edses en desarrollo. Se llevaron a cabo m\u00faltiples sesiones de capacitaci\u00f3n y se ofrecieron puestos rotativos en Ginebra para evaluadores.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1ntas muestras de medicamentos antimal\u00e1ricos fueron recolectadas y cu\u00e1ntas de ellas resultaron no cumplir con los est\u00e1ndares de calidad?**\n   - Respuesta: Se recolectaron 936 muestras de medicamentos antimal\u00e1ricos, de las cuales 74 resultaron no cumplir con los est\u00e1ndares de calidad.\n\n2. **\u00bfQu\u00e9 tipo de medicamentos antituberculosos fueron objeto de la encuesta en Europa del Este y en cu\u00e1ntos pa\u00edses se realiz\u00f3?**\n   - Respuesta: La encuesta se centr\u00f3 en medicamentos que contienen rifampicina, isoniazida, kanamicina y ofloxacino, y se realiz\u00f3 en seis pa\u00edses: Armenia, Azerbaiy\u00e1n, Bielorrusia, Kazajist\u00e1n, Ucrania y Uzbekist\u00e1n.\n\n3. **\u00bfCu\u00e1ntas sesiones de capacitaci\u00f3n fueron organizadas o apoyadas por la OMS entre 2007 y septiembre de 2009?**\n   - Respuesta: Se organizaron o apoyaron 13 sesiones de capacitaci\u00f3n en 2007, 15 en 2008 y 7 hasta septiembre de 2009.", "prev_section_summary": "### Temas Clave\n\n1. **Monitoreo Posterior a la Precalificaci\u00f3n**:\n   - Re-inspecciones regulares cada tres a\u00f1os.\n   - Informes anuales sobre servicios, muestras analizadas, m\u00e9todos utilizados y cambios significativos en el laboratorio.\n   - Evaluaci\u00f3n de resultados de pruebas de competencia.\n\n2. **Suspensi\u00f3n de Laboratorios**:\n   - La OMS puede suspender o retirar un laboratorio de la lista si hay evidencia de incumplimiento.\n\n3. **Programa de Precalificaci\u00f3n (PQP)**:\n   - Aumento del acceso a laboratorios de control de calidad (QC) que cumplen con est\u00e1ndares recomendados.\n   - Capacitaci\u00f3n y asistencia t\u00e9cnica a laboratorios nacionales.\n\n4. **Laboratorios Precalificados**:\n   - A partir de septiembre de 2009, hab\u00eda 11 laboratorios precalificados en varios pa\u00edses, incluyendo Argelia, Francia, India, y Sud\u00e1frica.\n\n5. **Proyectos de Monitoreo de Calidad**:\n   - Proyecto financiado por UNITAID centrado en medicamentos pedi\u00e1tricos y antirretrovirales de segunda l\u00ednea, con recolecci\u00f3n y an\u00e1lisis de 378 muestras.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Responsable de la precalificaci\u00f3n y monitoreo de laboratorios.\n- **PQP (Programa de Precalificaci\u00f3n)**: Iniciativa de la OMS para asegurar la calidad de los laboratorios.\n- **NMRAs (Agencias Nacionales de Regulaci\u00f3n de Medicamentos)**: Colaboraci\u00f3n en la recolecci\u00f3n de muestras en varios pa\u00edses africanos.\n- **UNITAID**: Financiador del proyecto de monitoreo de calidad de medicamentos. \n\nEste resumen destaca los aspectos fundamentales del proceso de monitoreo de laboratorios precalificados y los esfuerzos de la OMS para garantizar la calidad de los medicamentos a nivel global.", "excerpt_keywords": "Keywords: antimalarial medicines, quality survey, capacity building, WHO, regulatory authorities"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bd202fb7-3a80-46bf-a4f4-92f3e0907bb9", "node_type": "4", "metadata": {"page_label": "70", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Quality Survey of Antimalarial Medicines in Africa (2008-2009)\n\nA quality survey of antimalarial medicines focused on artemisinin-based combination therapies (ACTs) and sulfadoxine-pyrimethamine oral dosage forms was performed in six African countries; 936 medicine samples were collected at all levels of the distribution chain and the informal market and were screened by Minilab in cooperation with NMRAs. Three hundred and six samples were then tested fully in the laboratory, of which 74 were found to be non-compliant with a range of quality problems, from very minor non-compliance to absence of the API in two samples.\n\n# Quality Survey of Antituberculosis Medicines in Eastern Europe (2009)\n\nA quality survey of antituberculosis medicines focused on products containing rifampicin, isoniazid, kanamycin and ofloxacin was initiated in Armenia, Azerbaijan, Belarus, Kazakhstan, Ukraine and Uzbekistan; 291 samples were collected and testing is ongoing.\n\nSeveral other quality monitoring projects had been conducted since 2005.\n\n# Training and Capacity Building\n\nTraining and capacity building were important components of the PQP with the aim of increasing the regulatory capacity of NMRAs in developing countries and to assist manufacturers, CROs and QC laboratories in these countries to improve standards and meet prequalification requirements.\n\nTraining was generally provided through seminars and workshops, and might include visits to manufacturers. It was based on prequalification and WHO requirements, but might also be problem-oriented, e.g. relating to a specific product type. NMRA staff and manufacturers frequently participated together in the same training programme and, where possible, the focus was on \u201ctrain the trainer\u201d for maximum effect.\n\nThirteen training sessions were organized or supported by WHO in 2007, 15 in 2008 and seven up to September 2009.\n\nIn addition to training activities, capacity building of regulatory authorities was supported by the programme hosting rotational posts for assessors in Geneva. These were available for periods of three months during which the participant worked alongside WHO experts and also attended the sessions in Copenhagen to learn from external international experts.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "083193e5a0a2ce7cc4ad77726615f207de36cfec7a9052fd1297969ee6ba9adb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Quality Survey of Antimalarial Medicines in Africa (2008-2009)\n\nA quality survey of antimalarial medicines focused on artemisinin-based combination therapies (ACTs) and sulfadoxine-pyrimethamine oral dosage forms was performed in six African countries; 936 medicine samples were collected at all levels of the distribution chain and the informal market and were screened by Minilab in cooperation with NMRAs. Three hundred and six samples were then tested fully in the laboratory, of which 74 were found to be non-compliant with a range of quality problems, from very minor non-compliance to absence of the API in two samples.\n\n# Quality Survey of Antituberculosis Medicines in Eastern Europe (2009)\n\nA quality survey of antituberculosis medicines focused on products containing rifampicin, isoniazid, kanamycin and ofloxacin was initiated in Armenia, Azerbaijan, Belarus, Kazakhstan, Ukraine and Uzbekistan; 291 samples were collected and testing is ongoing.\n\nSeveral other quality monitoring projects had been conducted since 2005.\n\n# Training and Capacity Building\n\nTraining and capacity building were important components of the PQP with the aim of increasing the regulatory capacity of NMRAs in developing countries and to assist manufacturers, CROs and QC laboratories in these countries to improve standards and meet prequalification requirements.\n\nTraining was generally provided through seminars and workshops, and might include visits to manufacturers. It was based on prequalification and WHO requirements, but might also be problem-oriented, e.g. relating to a specific product type. NMRA staff and manufacturers frequently participated together in the same training programme and, where possible, the focus was on \u201ctrain the trainer\u201d for maximum effect.\n\nThirteen training sessions were organized or supported by WHO in 2007, 15 in 2008 and seven up to September 2009.\n\nIn addition to training activities, capacity building of regulatory authorities was supported by the programme hosting rotational posts for assessors in Geneva. These were available for periods of three months during which the participant worked alongside WHO experts and also attended the sessions in Copenhagen to learn from external international experts.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2243, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7e7a3c03-77f5-4226-afd7-57a78b341a6c": {"__data__": {"id_": "7e7a3c03-77f5-4226-afd7-57a78b341a6c", "embedding": null, "metadata": {"page_label": "71", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Technical assistance\n\nTechnical assistance might be provided to a specific manufacturer, which was committed to participation in the PQP, found to be capable and willing to improve, and was located in a developing country. The products manufactured were to be included in an EOI list, must be of high value for public health purposes and must be poorly represented on the list of prequalified medicines.\n\nExpert consultants were provided by WHO to assist a manufacturer with compliance with GMP, GCP or GLP, as well as with data development and compilation of dossiers or regulatory guidance.\n\nTo avoid conflict of interest, technical assistance was independent from dossier assessments and inspections.\n\nDuring 2008 technical assistance was provided to eight manufacturers.\n\n# Future challenges\n\nSome of the key challenges facing the PQP were:\n\n- motivating manufacturers to apply for prequalification and maintain prequalification, to ensure the continued supply of essential priority medicines;\n- submission of incomplete or poor quality dossiers;\n- non-compliance with GMP by all types of manufacturers;\n- difficulty in filling technical positions within PQP;\n- lack of availability of national experts (assessors and inspectors);\n- reducing the total time taken to prequalify;\n- an increasing demand for capacity building (shift from general to more specific technical training); and\n- trust-building and information exchange to avoid duplication of effort.\n\nThe Committee was provided with an update on the PQP activities in 2009 and took note of the progress made.\n\n## 9.2 Guidelines on requalification of prequalified dossiers\n\nSection 12 (Maintenance of prequalification status) of WHO\u2019s *Procedure for prequalification of pharmaceutical products* (WHO Technical Report Series, No. 953, Annex 3, 2009) stated under \u201cMaintenance of prequalification status\u201d that:\n\n\u201cWHO will furthermore arrange for the products and manufacturing sites included in the list to be re-evaluated at regular intervals. If, as a result of this re-evaluation, it is found that a product and/or specified manufacturing site no longer complies with the WHO-recommended standards, such products and manufacturing sites will be removed from the list.\u201d", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento aborda la asistencia t\u00e9cnica proporcionada por la OMS a fabricantes de medicamentos en pa\u00edses en desarrollo que participan en el Programa de Precalificaci\u00f3n (PQP). Se destaca la importancia de la asistencia para cumplir con las Buenas Pr\u00e1cticas de Manufactura (GMP), Buenas Pr\u00e1cticas Cl\u00ednicas (GCP) y Buenas Pr\u00e1cticas de Laboratorio (GLP). Tambi\u00e9n se mencionan los desaf\u00edos futuros que enfrenta el PQP, como la motivaci\u00f3n de los fabricantes para mantener la precalificaci\u00f3n, la calidad de los expedientes presentados y la disponibilidad de expertos nacionales. Adem\u00e1s, se establece que la OMS re-evaluar\u00e1 peri\u00f3dicamente los productos y sitios de fabricaci\u00f3n para asegurar el cumplimiento de los est\u00e1ndares recomendados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios debe cumplir un fabricante para recibir asistencia t\u00e9cnica de la OMS en el contexto del PQP?**\n   - Los fabricantes deben estar comprometidos con la participaci\u00f3n en el PQP, ser capaces y estar dispuestos a mejorar, y estar ubicados en un pa\u00eds en desarrollo. Adem\u00e1s, los productos fabricados deben ser de alto valor para la salud p\u00fablica y estar poco representados en la lista de medicamentos precalificados.\n\n2. **\u00bfCu\u00e1les son algunos de los desaf\u00edos espec\u00edficos que enfrenta el PQP en relaci\u00f3n con la calidad de los expedientes presentados por los fabricantes?**\n   - Uno de los desaf\u00edos es la presentaci\u00f3n de expedientes incompletos o de mala calidad, lo que dificulta el proceso de precalificaci\u00f3n. Esto se suma a la no conformidad con las GMP por parte de todos los tipos de fabricantes.\n\n3. **\u00bfQu\u00e9 medidas toma la OMS para garantizar que los productos y sitios de fabricaci\u00f3n mantengan su estatus de precalificaci\u00f3n?**\n   - La OMS organiza re-evaluaciones peri\u00f3dicas de los productos y sitios de fabricaci\u00f3n incluidos en la lista de precalificaci\u00f3n. Si se determina que un producto o sitio ya no cumple con los est\u00e1ndares recomendados, ser\u00e1 eliminado de la lista.", "prev_section_summary": "### Temas Clave y Entidades\n\n1. **Encuesta de Calidad de Medicamentos Antimal\u00e1ricos en \u00c1frica (2008-2009)**:\n   - **Objetivo**: Evaluar la calidad de medicamentos antimal\u00e1ricos, espec\u00edficamente terapias combinadas basadas en artemisinina (ACTs) y sulfadoxina-pirimetamina.\n   - **Pa\u00edses involucrados**: Seis pa\u00edses africanos.\n   - **Muestras recolectadas**: 936 muestras.\n   - **Resultados**: 306 muestras analizadas, 74 no cumpl\u00edan con los est\u00e1ndares de calidad.\n\n2. **Encuesta de Calidad de Medicamentos Antituberculosos en Europa del Este (2009)**:\n   - **Objetivo**: Evaluar la calidad de medicamentos antituberculosos que contienen rifampicina, isoniazida, kanamicina y ofloxacino.\n   - **Pa\u00edses involucrados**: Armenia, Azerbaiy\u00e1n, Bielorrusia, Kazajist\u00e1n, Ucrania y Uzbekist\u00e1n.\n   - **Muestras recolectadas**: 291 muestras, con pruebas en curso.\n\n3. **Capacitaci\u00f3n y Fortalecimiento de Capacidades**:\n   - **Programa**: Programa de Precalificaci\u00f3n (PQP) de la OMS.\n   - **Objetivo**: Aumentar la capacidad regulatoria de las Autoridades Nacionales de Regulaci\u00f3n de Medicamentos (NMRAs) en pa\u00edses en desarrollo.\n   - **Actividades**: Seminarios, talleres y visitas a fabricantes.\n   - **Sesiones de capacitaci\u00f3n**: 13 en 2007, 15 en 2008, 7 hasta septiembre de 2009.\n   - **Oportunidades adicionales**: Puestos rotativos en Ginebra para evaluadores, con duraci\u00f3n de tres meses.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Responsable de la supervisi\u00f3n y apoyo en las encuestas de calidad y capacitaci\u00f3n.\n- **Autoridades Nacionales de Regulaci\u00f3n de Medicamentos (NMRAs)**: Entidades reguladoras en los pa\u00edses participantes.\n- **Medicamentos evaluados**: Antimal\u00e1ricos (ACTs, sulfadoxina-pirimetamina) y antituberculosos (rifampicina, isoniazida, kanamicina, ofloxacino).", "excerpt_keywords": "Keywords: technical assistance, prequalification, public health, GMP compliance, capacity building"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9ebe0502-a55c-4cf6-8e18-d50fe607c3ac", "node_type": "4", "metadata": {"page_label": "71", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Technical assistance\n\nTechnical assistance might be provided to a specific manufacturer, which was committed to participation in the PQP, found to be capable and willing to improve, and was located in a developing country. The products manufactured were to be included in an EOI list, must be of high value for public health purposes and must be poorly represented on the list of prequalified medicines.\n\nExpert consultants were provided by WHO to assist a manufacturer with compliance with GMP, GCP or GLP, as well as with data development and compilation of dossiers or regulatory guidance.\n\nTo avoid conflict of interest, technical assistance was independent from dossier assessments and inspections.\n\nDuring 2008 technical assistance was provided to eight manufacturers.\n\n# Future challenges\n\nSome of the key challenges facing the PQP were:\n\n- motivating manufacturers to apply for prequalification and maintain prequalification, to ensure the continued supply of essential priority medicines;\n- submission of incomplete or poor quality dossiers;\n- non-compliance with GMP by all types of manufacturers;\n- difficulty in filling technical positions within PQP;\n- lack of availability of national experts (assessors and inspectors);\n- reducing the total time taken to prequalify;\n- an increasing demand for capacity building (shift from general to more specific technical training); and\n- trust-building and information exchange to avoid duplication of effort.\n\nThe Committee was provided with an update on the PQP activities in 2009 and took note of the progress made.\n\n## 9.2 Guidelines on requalification of prequalified dossiers\n\nSection 12 (Maintenance of prequalification status) of WHO\u2019s *Procedure for prequalification of pharmaceutical products* (WHO Technical Report Series, No. 953, Annex 3, 2009) stated under \u201cMaintenance of prequalification status\u201d that:\n\n\u201cWHO will furthermore arrange for the products and manufacturing sites included in the list to be re-evaluated at regular intervals. If, as a result of this re-evaluation, it is found that a product and/or specified manufacturing site no longer complies with the WHO-recommended standards, such products and manufacturing sites will be removed from the list.\u201d", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "48b3bdea6b9eb054405652d3f47bbf176b41be6d6af691b0544f3013b6cf1794", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Technical assistance\n\nTechnical assistance might be provided to a specific manufacturer, which was committed to participation in the PQP, found to be capable and willing to improve, and was located in a developing country. The products manufactured were to be included in an EOI list, must be of high value for public health purposes and must be poorly represented on the list of prequalified medicines.\n\nExpert consultants were provided by WHO to assist a manufacturer with compliance with GMP, GCP or GLP, as well as with data development and compilation of dossiers or regulatory guidance.\n\nTo avoid conflict of interest, technical assistance was independent from dossier assessments and inspections.\n\nDuring 2008 technical assistance was provided to eight manufacturers.\n\n# Future challenges\n\nSome of the key challenges facing the PQP were:\n\n- motivating manufacturers to apply for prequalification and maintain prequalification, to ensure the continued supply of essential priority medicines;\n- submission of incomplete or poor quality dossiers;\n- non-compliance with GMP by all types of manufacturers;\n- difficulty in filling technical positions within PQP;\n- lack of availability of national experts (assessors and inspectors);\n- reducing the total time taken to prequalify;\n- an increasing demand for capacity building (shift from general to more specific technical training); and\n- trust-building and information exchange to avoid duplication of effort.\n\nThe Committee was provided with an update on the PQP activities in 2009 and took note of the progress made.\n\n## 9.2 Guidelines on requalification of prequalified dossiers\n\nSection 12 (Maintenance of prequalification status) of WHO\u2019s *Procedure for prequalification of pharmaceutical products* (WHO Technical Report Series, No. 953, Annex 3, 2009) stated under \u201cMaintenance of prequalification status\u201d that:\n\n\u201cWHO will furthermore arrange for the products and manufacturing sites included in the list to be re-evaluated at regular intervals. If, as a result of this re-evaluation, it is found that a product and/or specified manufacturing site no longer complies with the WHO-recommended standards, such products and manufacturing sites will be removed from the list.\u201d", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2233, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "dbbf2f1a-5432-4049-bf57-7d0665fd211f": {"__data__": {"id_": "dbbf2f1a-5432-4049-bf57-7d0665fd211f", "embedding": null, "metadata": {"page_label": "72", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the list. Failure of a manufacturer or applicant to participate in the re-evaluation procedure will also lead to removal from the list.\n\nRe-evaluation, including re-inspections of manufacturing sites and CROs, would be done at regular intervals, based on risk assessment, but at least once every five years.\n\nRe-evaluation, including re-inspections, should also be performed:\n- if any fraud or omissions by the applicant, manufacturer(s) of an FPP or API, or CROs in the initial assessment procedure or during the follow-up activities, became evident; and\n- if WHO or any United Nations agency considered that a batch or batches of supplied prequalified pharmaceutical products were not in compliance with the specifications which were found to be applicable upon prequalification.\n\nIn order to define the documentation and information required from the applicants or manufacturers whereby the quality part of the prequalified product could be re-evaluated by WHO, a draft of the *Guidelines on the requalification of prequalified dossiers* had been developed by the quality assessors of the PQP.\n\nThese draft guidelines were circulated for comment and discussed at a meeting of the PQP assessment and inspector teams. The resulting revised draft was tabled and discussed at the consultation on WHO guidelines for medicines quality assurance, quality control laboratories and technology transfer in July 2009. At this meeting it was recommended that the document be tabled at the Expert Committee meeting for possible adoption. Following review during the consultation, the revised guidelines were once again circulated for comments.\n\nThe comments received were provided to the Committee in the form of a table.\n\nFollowing discussion, the Expert Committee adopted these new guidelines (Annex 6).\n\n## 9.3 Guidelines for the preparation of a contract research organization master file\n\nWHO, PIC/S and several NMRAs recommended that manufacturers submit a site master file (SMF) for review when applying for registration of a medicine. An SMF is a document prepared by the manufacturer containing specific and factual GMP information about the production and/or control of pharmaceutical manufacturing operations carried out at the named site and any closely integrated operations carried out in adjacent and nearby buildings. If only part of a pharmaceutical operation was carried out on", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento aborda el proceso de re-evaluaci\u00f3n de productos farmac\u00e9uticos precalificados por la OMS, incluyendo la frecuencia de las re-evaluaciones, las circunstancias que pueden desencadenar una re-evaluaci\u00f3n adicional, y la importancia de la presentaci\u00f3n de un archivo maestro de organizaci\u00f3n de investigaci\u00f3n por parte de los fabricantes. Se menciona que la re-evaluaci\u00f3n se realiza al menos cada cinco a\u00f1os y se detalla el proceso de desarrollo y adopci\u00f3n de nuevas directrices para la re-evaluaci\u00f3n de expedientes precalificados.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las circunstancias que pueden llevar a una re-evaluaci\u00f3n adicional de un producto farmac\u00e9utico precalificado por la OMS?**\n   - Respuesta: Una re-evaluaci\u00f3n adicional puede ser necesaria si se evidencia fraude u omisiones por parte del solicitante o fabricante, o si la OMS o alguna agencia de la ONU determina que un lote de productos farmac\u00e9uticos suministrados no cumple con las especificaciones aplicables.\n\n2. **\u00bfCon qu\u00e9 frecuencia se realizan las re-evaluaciones de los productos farmac\u00e9uticos precalificados y qu\u00e9 criterios se utilizan para determinar la frecuencia de estas re-evaluaciones?**\n   - Respuesta: Las re-evaluaciones se realizan al menos cada cinco a\u00f1os, y la frecuencia puede ajustarse en funci\u00f3n de una evaluaci\u00f3n de riesgos.\n\n3. **\u00bfQu\u00e9 es un archivo maestro de organizaci\u00f3n de investigaci\u00f3n (SMF) y qu\u00e9 informaci\u00f3n debe contener seg\u00fan las recomendaciones de la OMS?**\n   - Respuesta: Un SMF es un documento que contiene informaci\u00f3n espec\u00edfica y factual sobre las Buenas Pr\u00e1cticas de Manufactura (GMP) relacionadas con las operaciones de producci\u00f3n y control de medicamentos en un sitio espec\u00edfico. Debe incluir informaci\u00f3n sobre las operaciones realizadas en el sitio y en edificios adyacentes o cercanos que est\u00e9n estrechamente integrados.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Asistencia T\u00e9cnica de la OMS**:\n   - La OMS proporciona asistencia t\u00e9cnica a fabricantes de medicamentos en pa\u00edses en desarrollo que participan en el Programa de Precalificaci\u00f3n (PQP).\n   - Los fabricantes deben estar comprometidos con el PQP, ser capaces y dispuestos a mejorar, y sus productos deben ser de alto valor para la salud p\u00fablica y poco representados en la lista de medicamentos precalificados.\n   - Consultores expertos ayudan a los fabricantes a cumplir con las Buenas Pr\u00e1cticas de Manufactura (GMP), Buenas Pr\u00e1cticas Cl\u00ednicas (GCP) y Buenas Pr\u00e1cticas de Laboratorio (GLP).\n\n2. **Desaf\u00edos Futuros del PQP**:\n   - Motivaci\u00f3n de los fabricantes para aplicar y mantener la precalificaci\u00f3n.\n   - Presentaci\u00f3n de expedientes incompletos o de mala calidad.\n   - No conformidad con las GMP por parte de diversos fabricantes.\n   - Dificultades para llenar posiciones t\u00e9cnicas dentro del PQP.\n   - Escasez de expertos nacionales (evaluadores e inspectores).\n   - Necesidad de reducir el tiempo total para la precalificaci\u00f3n.\n   - Aumento de la demanda de capacitaci\u00f3n espec\u00edfica.\n   - Construcci\u00f3n de confianza e intercambio de informaci\u00f3n para evitar duplicaciones de esfuerzo.\n\n3. **Mantenimiento del Estatus de Precalificaci\u00f3n**:\n   - La OMS realiza re-evaluaciones peri\u00f3dicas de productos y sitios de fabricaci\u00f3n para asegurar el cumplimiento de los est\u00e1ndares recomendados.\n   - Productos y sitios que no cumplan con los est\u00e1ndares ser\u00e1n eliminados de la lista de precalificaci\u00f3n.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Proporciona asistencia t\u00e9cnica y supervisa el PQP.\n- **PQP (Programa de Precalificaci\u00f3n)**: Iniciativa para asegurar la calidad de medicamentos esenciales.\n- **Fabricantes de Medicamentos**: Entidades que buscan precalificaci\u00f3n y asistencia t\u00e9cnica.\n- **Consultores Expertos**: Profesionales que ayudan a los fabricantes a cumplir con los est\u00e1ndares requeridos.", "excerpt_keywords": "Keywords: re-evaluation, prequalification, pharmaceutical manufacturing, site master file, WHO guidelines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1cd8e854-cff6-41bb-9105-bef0e72d5cec", "node_type": "4", "metadata": {"page_label": "72", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the list. Failure of a manufacturer or applicant to participate in the re-evaluation procedure will also lead to removal from the list.\n\nRe-evaluation, including re-inspections of manufacturing sites and CROs, would be done at regular intervals, based on risk assessment, but at least once every five years.\n\nRe-evaluation, including re-inspections, should also be performed:\n- if any fraud or omissions by the applicant, manufacturer(s) of an FPP or API, or CROs in the initial assessment procedure or during the follow-up activities, became evident; and\n- if WHO or any United Nations agency considered that a batch or batches of supplied prequalified pharmaceutical products were not in compliance with the specifications which were found to be applicable upon prequalification.\n\nIn order to define the documentation and information required from the applicants or manufacturers whereby the quality part of the prequalified product could be re-evaluated by WHO, a draft of the *Guidelines on the requalification of prequalified dossiers* had been developed by the quality assessors of the PQP.\n\nThese draft guidelines were circulated for comment and discussed at a meeting of the PQP assessment and inspector teams. The resulting revised draft was tabled and discussed at the consultation on WHO guidelines for medicines quality assurance, quality control laboratories and technology transfer in July 2009. At this meeting it was recommended that the document be tabled at the Expert Committee meeting for possible adoption. Following review during the consultation, the revised guidelines were once again circulated for comments.\n\nThe comments received were provided to the Committee in the form of a table.\n\nFollowing discussion, the Expert Committee adopted these new guidelines (Annex 6).\n\n## 9.3 Guidelines for the preparation of a contract research organization master file\n\nWHO, PIC/S and several NMRAs recommended that manufacturers submit a site master file (SMF) for review when applying for registration of a medicine. An SMF is a document prepared by the manufacturer containing specific and factual GMP information about the production and/or control of pharmaceutical manufacturing operations carried out at the named site and any closely integrated operations carried out in adjacent and nearby buildings. If only part of a pharmaceutical operation was carried out on", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "15c83037f0d7a8526cd8f5a9635ba39e352832b4179352b5f84d7c40828a09cb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "the list. Failure of a manufacturer or applicant to participate in the re-evaluation procedure will also lead to removal from the list.\n\nRe-evaluation, including re-inspections of manufacturing sites and CROs, would be done at regular intervals, based on risk assessment, but at least once every five years.\n\nRe-evaluation, including re-inspections, should also be performed:\n- if any fraud or omissions by the applicant, manufacturer(s) of an FPP or API, or CROs in the initial assessment procedure or during the follow-up activities, became evident; and\n- if WHO or any United Nations agency considered that a batch or batches of supplied prequalified pharmaceutical products were not in compliance with the specifications which were found to be applicable upon prequalification.\n\nIn order to define the documentation and information required from the applicants or manufacturers whereby the quality part of the prequalified product could be re-evaluated by WHO, a draft of the *Guidelines on the requalification of prequalified dossiers* had been developed by the quality assessors of the PQP.\n\nThese draft guidelines were circulated for comment and discussed at a meeting of the PQP assessment and inspector teams. The resulting revised draft was tabled and discussed at the consultation on WHO guidelines for medicines quality assurance, quality control laboratories and technology transfer in July 2009. At this meeting it was recommended that the document be tabled at the Expert Committee meeting for possible adoption. Following review during the consultation, the revised guidelines were once again circulated for comments.\n\nThe comments received were provided to the Committee in the form of a table.\n\nFollowing discussion, the Expert Committee adopted these new guidelines (Annex 6).\n\n## 9.3 Guidelines for the preparation of a contract research organization master file\n\nWHO, PIC/S and several NMRAs recommended that manufacturers submit a site master file (SMF) for review when applying for registration of a medicine. An SMF is a document prepared by the manufacturer containing specific and factual GMP information about the production and/or control of pharmaceutical manufacturing operations carried out at the named site and any closely integrated operations carried out in adjacent and nearby buildings. If only part of a pharmaceutical operation was carried out on", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2385, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "71cb5a26-eea4-41fb-9353-8534a5c3b9a6": {"__data__": {"id_": "71cb5a26-eea4-41fb-9353-8534a5c3b9a6", "embedding": null, "metadata": {"page_label": "73", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the site, the SMF needed to describe only those operations, e.g. analysis or packaging.\n\nSome NMRAs were also inspecting clinical trials. Clinical trials were often conducted at CROs. During inspections at CROs by WHO prequalification inspectors it was observed that not all information regarding such CROs was available to inspectors when preparing for their inspections. In addition, in several cases, significant changes had been implemented by the CROs from the time of the conduct of a trial or bioequivalence study opposed to what was reflected in the study report. These included changes in key personnel, activities, and even location of the site. This often made inspections problematic as some of the core information regarding the site could no longer be verified.\n\nAfter consultation with inspectors from NMRAs, sponsors and CROs, it was suggested that a document similar to the SMF would provide useful information in the preparation for an inspection, and for those responsible to review or perform a risk analysis when planning GCP or GLP inspections. The proposal of the establishment of a contract research organization master file (CROMF) was welcomed by all parties contacted. It could be seen as an extension of the existing recommendation for the SMF of a manufacturing facility.\n\nAn initial draft CROMF was prepared and circulated to specialists for initial comments. The comments were reviewed by the Secretariat and incorporated where appropriate. The draft was then widely circulated for comments, which were discussed and incorporated, after which the document was again widely circulated in line with the usual procedure.\n\nThe comments received were provided to the Expert Committee.\n\nThe Expert Committee took note of the update, reviewed the major comments received, and agreed and adopted the general principles. It furthermore agreed to the formation of a subgroup of specialists to review all comments in more detail and to prepare a new version of this working document for circulation to the Expert Committee members for ratification. This document was, therefore, adopted provided no major comments were received (Annex 7).\n\n## 10. Nomenclature, terminology and databases\n\n### 10.1 Quality assurance terminology\n\nThe update of the database, available on the WHO quality assurance web site (http://www.who.int/medicines/areas/quality_safety/quality_assurance/en/) was presented to the Committee, as well as a document.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto se centra en la necesidad de mejorar la informaci\u00f3n disponible para los inspectores de la OMS durante las inspecciones de ensayos cl\u00ednicos realizados por organizaciones de investigaci\u00f3n por contrato (CROs). Se destaca que, a menudo, la informaci\u00f3n sobre los CROs no est\u00e1 completamente disponible, lo que dificulta las inspecciones. Se propone la creaci\u00f3n de un archivo maestro para CROs (CROMF) como una extensi\u00f3n del archivo maestro de instalaciones de fabricaci\u00f3n (SMF), con el fin de facilitar la preparaci\u00f3n para las inspecciones y la realizaci\u00f3n de an\u00e1lisis de riesgo. Un borrador inicial del CROMF fue preparado, revisado y comentado por especialistas, y se acord\u00f3 la formaci\u00f3n de un subgrupo para revisar los comentarios y preparar una nueva versi\u00f3n del documento.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n se sugiere que contenga el archivo maestro para organizaciones de investigaci\u00f3n por contrato (CROMF) y c\u00f3mo se relaciona con el archivo maestro de instalaciones de fabricaci\u00f3n (SMF)?**\n   - El CROMF deber\u00eda contener informaci\u00f3n relevante sobre las operaciones de los CROs, como cambios en el personal clave, actividades y ubicaciones, similar a lo que se requiere en el SMF para las instalaciones de fabricaci\u00f3n.\n\n2. **\u00bfCu\u00e1les son los principales problemas que enfrentan los inspectores de la OMS durante las inspecciones de CROs y c\u00f3mo se propone solucionarlos?**\n   - Los inspectores enfrentan problemas debido a la falta de informaci\u00f3n actualizada sobre los CROs, lo que dificulta la verificaci\u00f3n de datos cr\u00edticos. La soluci\u00f3n propuesta es la creaci\u00f3n del CROMF, que proporcionar\u00eda informaci\u00f3n esencial para la preparaci\u00f3n de las inspecciones.\n\n3. **\u00bfQu\u00e9 proceso se sigui\u00f3 para desarrollar el borrador del CROMF y qui\u00e9nes participaron en la revisi\u00f3n del documento?**\n   - Se prepar\u00f3 un borrador inicial del CROMF que fue circulado a especialistas para comentarios. Estos comentarios fueron revisados e incorporados por la Secretar\u00eda, y el documento fue ampliamente discutido y revisado antes de ser presentado al Comit\u00e9 de Expertos para su ratificaci\u00f3n.\n\n### Resumen de Nivel Superior\n\nEl contexto aborda la necesidad de mejorar la informaci\u00f3n disponible para las inspecciones de ensayos cl\u00ednicos realizados por CROs, destacando la falta de datos actualizados y la dificultad que esto representa para los inspectores de la OMS. Se propone la creaci\u00f3n de un CROMF para facilitar la preparaci\u00f3n de las inspecciones y se describe el proceso de desarrollo y revisi\u00f3n de este documento por parte de especialistas y el Comit\u00e9 de Expertos.", "prev_section_summary": "### Temas Clave\n\n1. **Re-evaluaci\u00f3n de Productos Farmac\u00e9uticos**: El documento detalla el proceso de re-evaluaci\u00f3n de productos farmac\u00e9uticos precalificados por la OMS, que incluye re-inspecciones de sitios de fabricaci\u00f3n y organizaciones de investigaci\u00f3n por contrato (CROs). La re-evaluaci\u00f3n se realiza al menos cada cinco a\u00f1os y puede ser m\u00e1s frecuente seg\u00fan una evaluaci\u00f3n de riesgos.\n\n2. **Circunstancias para Re-evaluaci\u00f3n Adicional**: Se especifican situaciones que pueden desencadenar una re-evaluaci\u00f3n adicional, como la evidencia de fraude u omisiones en el procedimiento de evaluaci\u00f3n inicial, o si se determina que un lote de productos no cumple con las especificaciones aplicables.\n\n3. **Directrices para la Recalificaci\u00f3n**: Se menciona el desarrollo de un borrador de directrices sobre la recalificaci\u00f3n de expedientes precalificados, que fue discutido y adoptado por el Comit\u00e9 de Expertos de la OMS.\n\n4. **Archivo Maestro de Organizaci\u00f3n de Investigaci\u00f3n (SMF)**: Se recomienda que los fabricantes presenten un archivo maestro de organizaci\u00f3n de investigaci\u00f3n al solicitar el registro de un medicamento. Este documento debe contener informaci\u00f3n espec\u00edfica sobre las Buenas Pr\u00e1cticas de Manufactura (GMP) y las operaciones de producci\u00f3n y control en el sitio designado.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la regulaci\u00f3n y evaluaci\u00f3n de productos farmac\u00e9uticos.\n- **PQP (Prequalification Programme)**: Programa de la OMS que eval\u00faa la calidad de los productos farmac\u00e9uticos.\n- **PIC/S (Pharmaceutical Inspection Co-operation Scheme)**: Organizaci\u00f3n que promueve la cooperaci\u00f3n entre autoridades de inspecci\u00f3n farmac\u00e9utica.\n- **NMRAs (National Medicines Regulatory Authorities)**: Autoridades nacionales responsables de la regulaci\u00f3n de medicamentos en sus respectivos pa\u00edses.\n- **CROs (Contract Research Organizations)**: Organizaciones que realizan investigaciones por contrato para la industria farmac\u00e9utica.\n\n### Resumen\n\nEl documento aborda el proceso de re-evaluaci\u00f3n de productos farmac\u00e9uticos precalificados por la OMS, estableciendo la frecuencia de estas re-evaluaciones y las circunstancias que pueden requerir una revisi\u00f3n adicional. Tambi\u00e9n se discute el desarrollo y adopci\u00f3n de directrices para la recalificaci\u00f3n de expedientes, as\u00ed como la importancia de presentar un archivo maestro de organizaci\u00f3n de investigaci\u00f3n por parte de los fabricantes al solicitar el registro de medicamentos.", "excerpt_keywords": "CROMF, CROs, inspections, NMRAs, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a67e7c04-5dfe-40e7-b9ee-09fe48e601c9", "node_type": "4", "metadata": {"page_label": "73", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the site, the SMF needed to describe only those operations, e.g. analysis or packaging.\n\nSome NMRAs were also inspecting clinical trials. Clinical trials were often conducted at CROs. During inspections at CROs by WHO prequalification inspectors it was observed that not all information regarding such CROs was available to inspectors when preparing for their inspections. In addition, in several cases, significant changes had been implemented by the CROs from the time of the conduct of a trial or bioequivalence study opposed to what was reflected in the study report. These included changes in key personnel, activities, and even location of the site. This often made inspections problematic as some of the core information regarding the site could no longer be verified.\n\nAfter consultation with inspectors from NMRAs, sponsors and CROs, it was suggested that a document similar to the SMF would provide useful information in the preparation for an inspection, and for those responsible to review or perform a risk analysis when planning GCP or GLP inspections. The proposal of the establishment of a contract research organization master file (CROMF) was welcomed by all parties contacted. It could be seen as an extension of the existing recommendation for the SMF of a manufacturing facility.\n\nAn initial draft CROMF was prepared and circulated to specialists for initial comments. The comments were reviewed by the Secretariat and incorporated where appropriate. The draft was then widely circulated for comments, which were discussed and incorporated, after which the document was again widely circulated in line with the usual procedure.\n\nThe comments received were provided to the Expert Committee.\n\nThe Expert Committee took note of the update, reviewed the major comments received, and agreed and adopted the general principles. It furthermore agreed to the formation of a subgroup of specialists to review all comments in more detail and to prepare a new version of this working document for circulation to the Expert Committee members for ratification. This document was, therefore, adopted provided no major comments were received (Annex 7).\n\n## 10. Nomenclature, terminology and databases\n\n### 10.1 Quality assurance terminology\n\nThe update of the database, available on the WHO quality assurance web site (http://www.who.int/medicines/areas/quality_safety/quality_assurance/en/) was presented to the Committee, as well as a document.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "f47cd788a8c60b132a6babe4856eda1863695d32935b4eafc1ea8a333e9041a7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "the site, the SMF needed to describe only those operations, e.g. analysis or packaging.\n\nSome NMRAs were also inspecting clinical trials. Clinical trials were often conducted at CROs. During inspections at CROs by WHO prequalification inspectors it was observed that not all information regarding such CROs was available to inspectors when preparing for their inspections. In addition, in several cases, significant changes had been implemented by the CROs from the time of the conduct of a trial or bioequivalence study opposed to what was reflected in the study report. These included changes in key personnel, activities, and even location of the site. This often made inspections problematic as some of the core information regarding the site could no longer be verified.\n\nAfter consultation with inspectors from NMRAs, sponsors and CROs, it was suggested that a document similar to the SMF would provide useful information in the preparation for an inspection, and for those responsible to review or perform a risk analysis when planning GCP or GLP inspections. The proposal of the establishment of a contract research organization master file (CROMF) was welcomed by all parties contacted. It could be seen as an extension of the existing recommendation for the SMF of a manufacturing facility.\n\nAn initial draft CROMF was prepared and circulated to specialists for initial comments. The comments were reviewed by the Secretariat and incorporated where appropriate. The draft was then widely circulated for comments, which were discussed and incorporated, after which the document was again widely circulated in line with the usual procedure.\n\nThe comments received were provided to the Expert Committee.\n\nThe Expert Committee took note of the update, reviewed the major comments received, and agreed and adopted the general principles. It furthermore agreed to the formation of a subgroup of specialists to review all comments in more detail and to prepare a new version of this working document for circulation to the Expert Committee members for ratification. This document was, therefore, adopted provided no major comments were received (Annex 7).\n\n## 10. Nomenclature, terminology and databases\n\n### 10.1 Quality assurance terminology\n\nThe update of the database, available on the WHO quality assurance web site (http://www.who.int/medicines/areas/quality_safety/quality_assurance/en/) was presented to the Committee, as well as a document.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2452, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "798620ff-5712-49e6-9a4f-19b8fd8b3f53": {"__data__": {"id_": "798620ff-5712-49e6-9a4f-19b8fd8b3f53", "embedding": null, "metadata": {"page_label": "74", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "In connection with the discussions during the WHO Governing Bodies' meetings, the issue of terminology for \"counterfeit\" and \"substandard\" medicines was raised.\n\n## Counterfeit medicines\n\nWithin the context of the work of the Expert Committee, definitions for \"counterfeit medicines\" were included in the glossaries of the following WHO guidelines (WHO Database on Quality Assurance: for updates see documents included in the meeting file and also on the Medicines web site: http://www.who.int/medicines/services/expertcommittees/pharmprep/TermListcategory.pdf).\n\nIn: WHO good distribution practices for pharmaceutical products (*fortieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations*, WHO Technical Report Series, No. 937, 2006).\n\nIn: WHO Guidelines for inspection of drug distribution channels (*thirty-fifth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations*, WHO Technical Report Series, No. 885, 1999).\n\nIn: WHO Guidelines on import procedures for pharmaceutical products (*thirty-fourth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations*, WHO Technical Report Series, No. 863, 1996).\n\nWithin the context of the work of the IMPACT Annual Meeting held in December 2008 in Hammamet, Tunisia and based on the work done by the IMPACT Working group on Legislative and Regulatory Infrastructure, a new definition had been developed and was available at: http://www.who.int/impact/resources/IMPACTthirdgeneralmeeting_%20report.pdf.\n\nThese definitions are included in the *Draft principles and elements for national legislation against counterfeit medical products* which has been circulated for comments.\n\nThe Expert Committee:\n- took note of the above and suggested closely following the feedback received regarding the suggested IMPACT definition with a view to further discussion of the outcome during the next meeting of the Expert Committee; and\n- recommended the preparation of an overview on the definitions used in the various international, regional and national contexts.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS discute la terminolog\u00eda relacionada con los medicamentos \"falsificados\" y \"subest\u00e1ndar\", destacando la importancia de definir estos t\u00e9rminos en el contexto de las pr\u00e1cticas de distribuci\u00f3n y regulaci\u00f3n de productos farmac\u00e9uticos. Se mencionan definiciones incluidas en varias gu\u00edas de la OMS y se hace referencia a un nuevo enfoque desarrollado durante la reuni\u00f3n anual de IMPACT en 2008. El Comit\u00e9 de Expertos de la OMS sugiere seguir de cerca los comentarios sobre la definici\u00f3n propuesta y recomienda la elaboraci\u00f3n de un resumen sobre las definiciones utilizadas en diferentes contextos internacionales, regionales y nacionales.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son las fuentes espec\u00edficas donde se pueden encontrar las definiciones de \"medicamentos falsificados\" seg\u00fan la OMS?**\n   - Las definiciones se encuentran en las gu\u00edas de la OMS, incluyendo el *fortieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations* (WHO Technical Report Series, No. 937, 2006), el *thirty-fifth report* (No. 885, 1999), y el *thirty-fourth report* (No. 863, 1996).\n\n2. **\u00bfQu\u00e9 recomendaciones hizo el Comit\u00e9 de Expertos de la OMS respecto a la definici\u00f3n de \"medicamentos falsificados\" durante su reuni\u00f3n?**\n   - El Comit\u00e9 de Expertos sugiri\u00f3 seguir de cerca los comentarios sobre la definici\u00f3n propuesta por IMPACT y discutir los resultados en la pr\u00f3xima reuni\u00f3n del Comit\u00e9. Tambi\u00e9n recomendaron preparar un resumen sobre las definiciones utilizadas en diferentes contextos internacionales, regionales y nacionales.\n\n3. **\u00bfQu\u00e9 evento y grupo de trabajo contribuyeron al desarrollo de una nueva definici\u00f3n de \"medicamentos falsificados\" en 2008?**\n   - La nueva definici\u00f3n fue desarrollada durante la reuni\u00f3n anual de IMPACT celebrada en diciembre de 2008 en Hammamet, T\u00fanez, y fue basada en el trabajo del grupo de trabajo de IMPACT sobre Infraestructura Legislativa y Regulatoria.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Necesidad de Informaci\u00f3n para Inspecciones**:\n   - Se destaca la falta de informaci\u00f3n disponible para los inspectores de la OMS durante las inspecciones de ensayos cl\u00ednicos realizados por organizaciones de investigaci\u00f3n por contrato (CROs).\n   - Los inspectores enfrentan dificultades debido a cambios significativos en los CROs que no se reflejan en los informes de estudio, como cambios en personal clave, actividades y ubicaciones.\n\n2. **Propuesta del CROMF**:\n   - Se sugiere la creaci\u00f3n de un archivo maestro para organizaciones de investigaci\u00f3n por contrato (CROMF) como una extensi\u00f3n del archivo maestro de instalaciones de fabricaci\u00f3n (SMF).\n   - El CROMF deber\u00eda contener informaci\u00f3n relevante para facilitar la preparaci\u00f3n de las inspecciones y realizar an\u00e1lisis de riesgo.\n\n3. **Proceso de Desarrollo del CROMF**:\n   - Se prepar\u00f3 un borrador inicial del CROMF que fue revisado y comentado por especialistas.\n   - Los comentarios fueron incorporados por la Secretar\u00eda y el documento fue ampliamente discutido antes de ser presentado al Comit\u00e9 de Expertos para su ratificaci\u00f3n.\n\n4. **Comit\u00e9 de Expertos**:\n   - El Comit\u00e9 de Expertos revis\u00f3 los comentarios recibidos y adopt\u00f3 los principios generales del CROMF.\n   - Se acord\u00f3 la formaci\u00f3n de un subgrupo de especialistas para revisar los comentarios en detalle y preparar una nueva versi\u00f3n del documento.\n\n### Entidades Clave\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la supervisi\u00f3n y regulaci\u00f3n de la calidad en ensayos cl\u00ednicos.\n- **NMRAs (Agencias Nacionales de Regulaci\u00f3n de Medicamentos)**: Organismos que participan en la inspecci\u00f3n de ensayos cl\u00ednicos.\n- **CROs (Organizaciones de Investigaci\u00f3n por Contrato)**: Entidades que realizan ensayos cl\u00ednicos en nombre de patrocinadores.\n- **CROMF (Archivo Maestro para Organizaciones de Investigaci\u00f3n por Contrato)**: Propuesta para un nuevo documento que contenga informaci\u00f3n relevante sobre CROs.\n- **SMF (Archivo Maestro de Instalaciones de Fabricaci\u00f3n)**: Documento existente que se propone como modelo para el CROMF.\n\nEste resumen encapsula los temas centrales y las entidades involucradas en la discusi\u00f3n sobre la mejora de la informaci\u00f3n para las inspecciones de ensayos cl\u00ednicos.", "excerpt_keywords": "Keywords: counterfeit medicines, WHO guidelines, IMPACT meeting, pharmaceutical regulations, definitions"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "97171f7f-0e94-4268-8254-b7e98b5881c0", "node_type": "4", "metadata": {"page_label": "74", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "In connection with the discussions during the WHO Governing Bodies' meetings, the issue of terminology for \"counterfeit\" and \"substandard\" medicines was raised.\n\n## Counterfeit medicines\n\nWithin the context of the work of the Expert Committee, definitions for \"counterfeit medicines\" were included in the glossaries of the following WHO guidelines (WHO Database on Quality Assurance: for updates see documents included in the meeting file and also on the Medicines web site: http://www.who.int/medicines/services/expertcommittees/pharmprep/TermListcategory.pdf).\n\nIn: WHO good distribution practices for pharmaceutical products (*fortieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations*, WHO Technical Report Series, No. 937, 2006).\n\nIn: WHO Guidelines for inspection of drug distribution channels (*thirty-fifth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations*, WHO Technical Report Series, No. 885, 1999).\n\nIn: WHO Guidelines on import procedures for pharmaceutical products (*thirty-fourth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations*, WHO Technical Report Series, No. 863, 1996).\n\nWithin the context of the work of the IMPACT Annual Meeting held in December 2008 in Hammamet, Tunisia and based on the work done by the IMPACT Working group on Legislative and Regulatory Infrastructure, a new definition had been developed and was available at: http://www.who.int/impact/resources/IMPACTthirdgeneralmeeting_%20report.pdf.\n\nThese definitions are included in the *Draft principles and elements for national legislation against counterfeit medical products* which has been circulated for comments.\n\nThe Expert Committee:\n- took note of the above and suggested closely following the feedback received regarding the suggested IMPACT definition with a view to further discussion of the outcome during the next meeting of the Expert Committee; and\n- recommended the preparation of an overview on the definitions used in the various international, regional and national contexts.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "418da50d51b47710d63cbe9f5a20b66398fcaad6ad0675aebd875c20788d34b8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In connection with the discussions during the WHO Governing Bodies' meetings, the issue of terminology for \"counterfeit\" and \"substandard\" medicines was raised.\n\n## Counterfeit medicines\n\nWithin the context of the work of the Expert Committee, definitions for \"counterfeit medicines\" were included in the glossaries of the following WHO guidelines (WHO Database on Quality Assurance: for updates see documents included in the meeting file and also on the Medicines web site: http://www.who.int/medicines/services/expertcommittees/pharmprep/TermListcategory.pdf).\n\nIn: WHO good distribution practices for pharmaceutical products (*fortieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations*, WHO Technical Report Series, No. 937, 2006).\n\nIn: WHO Guidelines for inspection of drug distribution channels (*thirty-fifth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations*, WHO Technical Report Series, No. 885, 1999).\n\nIn: WHO Guidelines on import procedures for pharmaceutical products (*thirty-fourth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations*, WHO Technical Report Series, No. 863, 1996).\n\nWithin the context of the work of the IMPACT Annual Meeting held in December 2008 in Hammamet, Tunisia and based on the work done by the IMPACT Working group on Legislative and Regulatory Infrastructure, a new definition had been developed and was available at: http://www.who.int/impact/resources/IMPACTthirdgeneralmeeting_%20report.pdf.\n\nThese definitions are included in the *Draft principles and elements for national legislation against counterfeit medical products* which has been circulated for comments.\n\nThe Expert Committee:\n- took note of the above and suggested closely following the feedback received regarding the suggested IMPACT definition with a view to further discussion of the outcome during the next meeting of the Expert Committee; and\n- recommended the preparation of an overview on the definitions used in the various international, regional and national contexts.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2089, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "79104ddf-3fd0-4b65-81a1-b8487602d9c3": {"__data__": {"id_": "79104ddf-3fd0-4b65-81a1-b8487602d9c3", "embedding": null, "metadata": {"page_label": "75", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The importance of including NMRAs in this discussion was stressed as their expertise was needed to differentiate between the different issues. It was proposed that this discussion take place during the upcoming ICDRA in 2010.\n\n**\u201cSubstandard medicines\u201d**\n\nWithin the context of the work of this Expert Committee, no officially adopted definition currently existed for \u201csubstandard medicines\u201d. As this question was raised frequently a \u201cquestion and answer\u201d had been introduced on the WHO web site as follows:\n\n**\u201cWhat are substandard medicines?**\n\nSubstandard medicines (also called out-of-specification (OOS) products) are genuine medicines produced by manufacturers authorized by the NMRA which do not meet quality specifications set for them by national standards.\n\nNormally, each medicine that a manufacturer produces has to comply with quality standards and specifications. These standards and specifications are reviewed and assessed by the NMRA before the product is authorized for marketing.\u201d\n\nThe Expert Committee discussed the issue and agreed that there was a need for a definition. It suggested circulation of the proposal as amended during the meeting for comments within the usual consultative procedure.\n\n### 10.2 International Nonproprietary Names\n\nThe Expert Committee was briefed on the activities of the International Nonproprietary Names (INN) Programme. In the past 11 years 1445 INN had been named. The Programme had developed an integrated data management system which would permit access from the Internet, allow worldwide multiusers, multiplatform application, with all the user tasks \u201cintegrated\u201d within the process, standard and open-source technologies, secure and protected environment: confidentiality of data and process steps, electronic documentation at each step and track of each process step. The future steps for INN included the online INN Application, Report and Statistic Generator, offline use and integration with other databases.\n\n### 10.3 Pharmacopoeial references\n\nAn update was given to the Expert Committee on the ongoing revision of the pharmacopoeial references and pharmacopoeia commission secretariats would be contacted. The updated references would be posted on the Medicines web site. The Committee welcomed this information being made available in its updated form.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con sus respuestas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfCu\u00e1l es la definici\u00f3n de \"medicamentos subest\u00e1ndar\" seg\u00fan el contexto del Comit\u00e9 de Expertos de la OMS?**\n   - **Respuesta:** Los medicamentos subest\u00e1ndar, tambi\u00e9n conocidos como productos fuera de especificaci\u00f3n (OOS), son medicamentos genuinos producidos por fabricantes autorizados por la Autoridad Nacional Reguladora de Medicamentos (NMRA) que no cumplen con las especificaciones de calidad establecidas por las normas nacionales.\n\n2. **\u00bfQu\u00e9 se propuso en relaci\u00f3n con la discusi\u00f3n sobre los medicamentos subest\u00e1ndar durante la reuni\u00f3n del Comit\u00e9 de Expertos?**\n   - **Respuesta:** Se propuso que la discusi\u00f3n sobre los medicamentos subest\u00e1ndar se llevara a cabo durante el pr\u00f3ximo ICDRA en 2010, y se acord\u00f3 que era necesario establecer una definici\u00f3n oficial para estos medicamentos.\n\n3. **\u00bfQu\u00e9 avances se mencionaron en relaci\u00f3n con el Programa de Nombres No Propietarios Internacionales (INN)?**\n   - **Respuesta:** Se inform\u00f3 que en los \u00faltimos 11 a\u00f1os se hab\u00edan nombrado 1445 INN y que el Programa hab\u00eda desarrollado un sistema de gesti\u00f3n de datos integrado que permitir\u00eda el acceso en l\u00ednea, con capacidades para m\u00faltiples usuarios y plataformas, as\u00ed como la generaci\u00f3n de informes y estad\u00edsticas.\n\n### Resumen de Nivel Superior\n\nEl contexto se centra en una reuni\u00f3n del Comit\u00e9 de Expertos de la OMS, donde se discutieron temas relacionados con la calidad de los medicamentos, espec\u00edficamente la falta de una definici\u00f3n oficial para \"medicamentos subest\u00e1ndar\". Se destac\u00f3 la importancia de incluir a las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) en estas discusiones. Adem\u00e1s, se present\u00f3 un informe sobre el Programa de Nombres No Propietarios Internacionales (INN) y se mencionaron avances en la gesti\u00f3n de datos y la revisi\u00f3n de referencias farmacop\u00e9uticas.\n\n### Preguntas Adicionales Basadas en el Resumen\n\n1. **\u00bfPor qu\u00e9 es importante incluir a las NMRAs en la discusi\u00f3n sobre medicamentos subest\u00e1ndar?**\n   - **Respuesta:** Es importante incluir a las NMRAs porque su experiencia es necesaria para diferenciar entre los diversos problemas relacionados con la calidad de los medicamentos.\n\n2. **\u00bfQu\u00e9 medidas se est\u00e1n tomando para mejorar el acceso a la informaci\u00f3n sobre los Nombres No Propietarios Internacionales (INN)?**\n   - **Respuesta:** Se est\u00e1n desarrollando sistemas de gesti\u00f3n de datos integrados que permitir\u00e1n el acceso en l\u00ednea y la generaci\u00f3n de informes, facilitando as\u00ed el acceso a la informaci\u00f3n sobre los INN.\n\n3. **\u00bfQu\u00e9 se espera lograr con la revisi\u00f3n de las referencias farmacop\u00e9uticas mencionada en el contexto?**\n   - **Respuesta:** Se espera que la revisi\u00f3n de las referencias farmacop\u00e9uticas proporcione informaci\u00f3n actualizada que est\u00e9 disponible en el sitio web de Medicamentos, mejorando as\u00ed la accesibilidad y la calidad de la informaci\u00f3n sobre medicamentos.", "prev_section_summary": "### Temas Clave\n1. **Terminolog\u00eda de Medicamentos**: Se aborda la terminolog\u00eda relacionada con los medicamentos \"falsificados\" y \"subest\u00e1ndar\", destacando la necesidad de definiciones claras en el contexto de la regulaci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos.\n\n2. **Definiciones de Medicamentos Falsificados**: Se mencionan varias gu\u00edas de la OMS que incluyen definiciones de \"medicamentos falsificados\", como los informes de la Comisi\u00f3n de Expertos de la OMS sobre pr\u00e1cticas de distribuci\u00f3n y procedimientos de importaci\u00f3n.\n\n3. **IMPACT y Nueva Definici\u00f3n**: Durante la reuni\u00f3n anual de IMPACT en 2008, se desarroll\u00f3 una nueva definici\u00f3n de \"medicamentos falsificados\", basada en el trabajo de un grupo de trabajo sobre infraestructura legislativa y regulatoria.\n\n4. **Recomendaciones del Comit\u00e9 de Expertos**: El Comit\u00e9 sugiere seguir de cerca los comentarios sobre la definici\u00f3n propuesta y elaborar un resumen sobre las definiciones utilizadas en diferentes contextos internacionales, regionales y nacionales.\n\n### Entidades\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo que establece gu\u00edas y recomendaciones sobre la calidad y regulaci\u00f3n de medicamentos.\n- **IMPACT (Medicamentos Falsificados y Subest\u00e1ndares)**: Grupo de trabajo que se centra en la legislaci\u00f3n y regulaci\u00f3n de medicamentos falsificados.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que revisa y discute definiciones y pr\u00e1cticas relacionadas con medicamentos en el \u00e1mbito internacional. \n\nEste resumen destaca la importancia de la claridad terminol\u00f3gica y la colaboraci\u00f3n internacional en la lucha contra los medicamentos falsificados y subest\u00e1ndares.", "excerpt_keywords": "Keywords: substandard medicines, NMRA, International Nonproprietary Names, pharmacopoeial references, quality specifications"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9a4fe314-f847-49a6-9111-9daffcf3a2a6", "node_type": "4", "metadata": {"page_label": "75", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The importance of including NMRAs in this discussion was stressed as their expertise was needed to differentiate between the different issues. It was proposed that this discussion take place during the upcoming ICDRA in 2010.\n\n**\u201cSubstandard medicines\u201d**\n\nWithin the context of the work of this Expert Committee, no officially adopted definition currently existed for \u201csubstandard medicines\u201d. As this question was raised frequently a \u201cquestion and answer\u201d had been introduced on the WHO web site as follows:\n\n**\u201cWhat are substandard medicines?**\n\nSubstandard medicines (also called out-of-specification (OOS) products) are genuine medicines produced by manufacturers authorized by the NMRA which do not meet quality specifications set for them by national standards.\n\nNormally, each medicine that a manufacturer produces has to comply with quality standards and specifications. These standards and specifications are reviewed and assessed by the NMRA before the product is authorized for marketing.\u201d\n\nThe Expert Committee discussed the issue and agreed that there was a need for a definition. It suggested circulation of the proposal as amended during the meeting for comments within the usual consultative procedure.\n\n### 10.2 International Nonproprietary Names\n\nThe Expert Committee was briefed on the activities of the International Nonproprietary Names (INN) Programme. In the past 11 years 1445 INN had been named. The Programme had developed an integrated data management system which would permit access from the Internet, allow worldwide multiusers, multiplatform application, with all the user tasks \u201cintegrated\u201d within the process, standard and open-source technologies, secure and protected environment: confidentiality of data and process steps, electronic documentation at each step and track of each process step. The future steps for INN included the online INN Application, Report and Statistic Generator, offline use and integration with other databases.\n\n### 10.3 Pharmacopoeial references\n\nAn update was given to the Expert Committee on the ongoing revision of the pharmacopoeial references and pharmacopoeia commission secretariats would be contacted. The updated references would be posted on the Medicines web site. The Committee welcomed this information being made available in its updated form.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "6bf028da06decbc416cc36463ce537185433083e4aeda0eca4f5dbf42c2c00da", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The importance of including NMRAs in this discussion was stressed as their expertise was needed to differentiate between the different issues. It was proposed that this discussion take place during the upcoming ICDRA in 2010.\n\n**\u201cSubstandard medicines\u201d**\n\nWithin the context of the work of this Expert Committee, no officially adopted definition currently existed for \u201csubstandard medicines\u201d. As this question was raised frequently a \u201cquestion and answer\u201d had been introduced on the WHO web site as follows:\n\n**\u201cWhat are substandard medicines?**\n\nSubstandard medicines (also called out-of-specification (OOS) products) are genuine medicines produced by manufacturers authorized by the NMRA which do not meet quality specifications set for them by national standards.\n\nNormally, each medicine that a manufacturer produces has to comply with quality standards and specifications. These standards and specifications are reviewed and assessed by the NMRA before the product is authorized for marketing.\u201d\n\nThe Expert Committee discussed the issue and agreed that there was a need for a definition. It suggested circulation of the proposal as amended during the meeting for comments within the usual consultative procedure.\n\n### 10.2 International Nonproprietary Names\n\nThe Expert Committee was briefed on the activities of the International Nonproprietary Names (INN) Programme. In the past 11 years 1445 INN had been named. The Programme had developed an integrated data management system which would permit access from the Internet, allow worldwide multiusers, multiplatform application, with all the user tasks \u201cintegrated\u201d within the process, standard and open-source technologies, secure and protected environment: confidentiality of data and process steps, electronic documentation at each step and track of each process step. The future steps for INN included the online INN Application, Report and Statistic Generator, offline use and integration with other databases.\n\n### 10.3 Pharmacopoeial references\n\nAn update was given to the Expert Committee on the ongoing revision of the pharmacopoeial references and pharmacopoeia commission secretariats would be contacted. The updated references would be posted on the Medicines web site. The Committee welcomed this information being made available in its updated form.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2319, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a787ad78-583e-47af-b6cc-660f1521aa67": {"__data__": {"id_": "a787ad78-583e-47af-b6cc-660f1521aa67", "embedding": null, "metadata": {"page_label": "76", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11. Miscellaneous\n\n## 11.1 WHO Model List of Essential Medicines\n\nA paper presented by QSM (working document QAS/09.293/Rev.1) was discussed by the Expert Committee for the Selection and Use of Essential Medicines at its meeting in March 2009. The Expert Committee broadly endorsed the QSM proposals concerning:\n\n- dosage form terminology; and\n- expression of medicine strength.\n\nThe expanded Explanatory notes in the sixteenth edition of the WHO Model List of Essential Medicines (and in the second edition of the WHO Model List of Essential Medicines for Children) included a link to the Quality assurance area of the WHO Medicines web site and to the online text of the current edition of *The International Pharmacopoeia*. In addition, an Annex on dosage form terminology had been included. The Explanatory notes and Annex 1 (as published on the Medicines web site: http://www.who.int/selection_medicines/committees/expert/17/en/index.html) were presented to the Expert Committee on Specifications for Pharmaceutical Preparations for information.\n\nWith respect to the expression of medicines strengths, the Expert Committee for the Selection and Use of Essential Medicines agreed the principles that would be applied in future lists and requested its Secretariat to review the current entries and revise them accordingly. The principles were set out in the report of the Expert Committee; an extract from the unedited report, as made available on the WHO Medicines web site, was presented for information.\n\nWhen revised in accordance with these principles, entries in cases where the API was not the active moiety would more clearly distinguish between:\n\n- those for which the strength was expressed in terms of active moiety (the salt would be indicated in parentheses, e.g. \u201c50 mg (as sodium salt)\u201d)\n- those for which the strength was expressed in terms of API (the salt would be given in full, e.g. \u201c50 mg codeine phosphate\u201d).\n\nWhere necessary, in instances of potential confusion (e.g. amodiaquine, quinine salts) a warning note would be included.\n\nThe Committee congratulated the Secretariat on its efforts to provide more clarity with regard to strengths and dosage form references within the Model List.\n\n## 11.2 Update on stability\n\nThe revised working document on *Stability testing of active pharmaceutical ingredients and finished pharmaceutical products* was adopted by the Expert.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Revisi\u00f3n de la Lista Modelo de Medicamentos Esenciales de la OMS**: En marzo de 2009, el Comit\u00e9 de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales discuti\u00f3 propuestas sobre la terminolog\u00eda de formas de dosificaci\u00f3n y la expresi\u00f3n de la fuerza de los medicamentos. Se incluyeron notas explicativas y un anexo sobre la terminolog\u00eda de formas de dosificaci\u00f3n en la edici\u00f3n m\u00e1s reciente de la lista.\n\n2. **Principios para la Expresi\u00f3n de Fuerzas de Medicamentos**: El Comit\u00e9 acord\u00f3 principios para la expresi\u00f3n de las fuerzas de los medicamentos que se aplicar\u00edan en futuras listas, buscando mayor claridad en la distinci\u00f3n entre el principio activo y la sal utilizada en la formulaci\u00f3n.\n\n3. **Actualizaci\u00f3n sobre Estabilidad**: Se adopt\u00f3 un documento de trabajo revisado sobre las pruebas de estabilidad de ingredientes farmac\u00e9uticos activos y productos farmac\u00e9uticos terminados, lo que indica un enfoque continuo en la calidad y seguridad de los medicamentos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 cambios se propusieron en la terminolog\u00eda de las formas de dosificaci\u00f3n en la Lista Modelo de Medicamentos Esenciales de la OMS?**\n   - Se propuso una revisi\u00f3n de la terminolog\u00eda de las formas de dosificaci\u00f3n, que se incluy\u00f3 en un anexo en la edici\u00f3n m\u00e1s reciente de la lista, con el objetivo de proporcionar una mayor claridad en la presentaci\u00f3n de los medicamentos.\n\n2. **\u00bfC\u00f3mo se diferenciar\u00e1n las entradas en la lista de medicamentos en funci\u00f3n de la expresi\u00f3n de la fuerza del principio activo y la sal?**\n   - Las entradas se diferenciar\u00e1n claramente entre aquellas donde la fuerza se expresa en t\u00e9rminos de la moiety activa (indicando la sal entre par\u00e9ntesis) y aquellas donde se expresa en t\u00e9rminos del principio activo (dando el nombre completo de la sal).\n\n3. **\u00bfQu\u00e9 aspectos se abordaron en el documento revisado sobre pruebas de estabilidad adoptado por el Comit\u00e9?**\n   - El documento revisado sobre pruebas de estabilidad se centr\u00f3 en la estabilidad de los ingredientes farmac\u00e9uticos activos y los productos farmac\u00e9uticos terminados, lo que refleja un compromiso continuo con la calidad y la seguridad de los medicamentos en el mercado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Importancia de las NMRAs**: Se destac\u00f3 la necesidad de incluir a las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) en las discusiones sobre medicamentos subest\u00e1ndar, debido a su experiencia en la diferenciaci\u00f3n de problemas relacionados con la calidad de los medicamentos.\n\n2. **Definici\u00f3n de Medicamentos Subest\u00e1ndar**: No exist\u00eda una definici\u00f3n oficialmente adoptada para \"medicamentos subest\u00e1ndar\". Se definieron como medicamentos genuinos producidos por fabricantes autorizados por la NMRA que no cumplen con las especificaciones de calidad establecidas por las normas nacionales.\n\n3. **Propuesta de Discusi\u00f3n**: Se propuso que la discusi\u00f3n sobre medicamentos subest\u00e1ndar se llevara a cabo durante el pr\u00f3ximo ICDRA en 2010, y se acord\u00f3 la necesidad de establecer una definici\u00f3n oficial.\n\n4. **Programa de Nombres No Propietarios Internacionales (INN)**: Se inform\u00f3 sobre el nombramiento de 1445 INN en los \u00faltimos 11 a\u00f1os y el desarrollo de un sistema de gesti\u00f3n de datos integrado que permitir\u00e1 el acceso en l\u00ednea y la generaci\u00f3n de informes y estad\u00edsticas.\n\n5. **Referencias Farmac\u00e9uticas**: Se proporcion\u00f3 una actualizaci\u00f3n sobre la revisi\u00f3n en curso de las referencias farmac\u00e9uticas, con la intenci\u00f3n de que la informaci\u00f3n actualizada est\u00e9 disponible en el sitio web de Medicamentos.\n\n### Entidades Clave\n\n- **NMRAs (Autoridades Nacionales Reguladoras de Medicamentos)**: Entidades responsables de la regulaci\u00f3n y autorizaci\u00f3n de medicamentos en sus respectivos pa\u00edses.\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organizaci\u00f3n que coordina la discusi\u00f3n y regulaci\u00f3n de temas de salud a nivel internacional.\n- **INN (Nombres No Propietarios Internacionales)**: Programa que asigna nombres a medicamentos para su identificaci\u00f3n global.\n- **ICDRA (Conferencia Internacional de Reguladores de Medicamentos)**: Evento propuesto para discutir temas relacionados con la regulaci\u00f3n de medicamentos.", "excerpt_keywords": "Keywords: Essential Medicines, dosage form terminology, medicine strength, stability testing, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "04782179-e8f9-42cd-8047-77608c2d6c2f", "node_type": "4", "metadata": {"page_label": "76", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11. Miscellaneous\n\n## 11.1 WHO Model List of Essential Medicines\n\nA paper presented by QSM (working document QAS/09.293/Rev.1) was discussed by the Expert Committee for the Selection and Use of Essential Medicines at its meeting in March 2009. The Expert Committee broadly endorsed the QSM proposals concerning:\n\n- dosage form terminology; and\n- expression of medicine strength.\n\nThe expanded Explanatory notes in the sixteenth edition of the WHO Model List of Essential Medicines (and in the second edition of the WHO Model List of Essential Medicines for Children) included a link to the Quality assurance area of the WHO Medicines web site and to the online text of the current edition of *The International Pharmacopoeia*. In addition, an Annex on dosage form terminology had been included. The Explanatory notes and Annex 1 (as published on the Medicines web site: http://www.who.int/selection_medicines/committees/expert/17/en/index.html) were presented to the Expert Committee on Specifications for Pharmaceutical Preparations for information.\n\nWith respect to the expression of medicines strengths, the Expert Committee for the Selection and Use of Essential Medicines agreed the principles that would be applied in future lists and requested its Secretariat to review the current entries and revise them accordingly. The principles were set out in the report of the Expert Committee; an extract from the unedited report, as made available on the WHO Medicines web site, was presented for information.\n\nWhen revised in accordance with these principles, entries in cases where the API was not the active moiety would more clearly distinguish between:\n\n- those for which the strength was expressed in terms of active moiety (the salt would be indicated in parentheses, e.g. \u201c50 mg (as sodium salt)\u201d)\n- those for which the strength was expressed in terms of API (the salt would be given in full, e.g. \u201c50 mg codeine phosphate\u201d).\n\nWhere necessary, in instances of potential confusion (e.g. amodiaquine, quinine salts) a warning note would be included.\n\nThe Committee congratulated the Secretariat on its efforts to provide more clarity with regard to strengths and dosage form references within the Model List.\n\n## 11.2 Update on stability\n\nThe revised working document on *Stability testing of active pharmaceutical ingredients and finished pharmaceutical products* was adopted by the Expert.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "70b438015139173b5251110d05cab8437ab381c75d7652932fd8cb7d01cb10ff", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 11. Miscellaneous\n\n## 11.1 WHO Model List of Essential Medicines\n\nA paper presented by QSM (working document QAS/09.293/Rev.1) was discussed by the Expert Committee for the Selection and Use of Essential Medicines at its meeting in March 2009. The Expert Committee broadly endorsed the QSM proposals concerning:\n\n- dosage form terminology; and\n- expression of medicine strength.\n\nThe expanded Explanatory notes in the sixteenth edition of the WHO Model List of Essential Medicines (and in the second edition of the WHO Model List of Essential Medicines for Children) included a link to the Quality assurance area of the WHO Medicines web site and to the online text of the current edition of *The International Pharmacopoeia*. In addition, an Annex on dosage form terminology had been included. The Explanatory notes and Annex 1 (as published on the Medicines web site: http://www.who.int/selection_medicines/committees/expert/17/en/index.html) were presented to the Expert Committee on Specifications for Pharmaceutical Preparations for information.\n\nWith respect to the expression of medicines strengths, the Expert Committee for the Selection and Use of Essential Medicines agreed the principles that would be applied in future lists and requested its Secretariat to review the current entries and revise them accordingly. The principles were set out in the report of the Expert Committee; an extract from the unedited report, as made available on the WHO Medicines web site, was presented for information.\n\nWhen revised in accordance with these principles, entries in cases where the API was not the active moiety would more clearly distinguish between:\n\n- those for which the strength was expressed in terms of active moiety (the salt would be indicated in parentheses, e.g. \u201c50 mg (as sodium salt)\u201d)\n- those for which the strength was expressed in terms of API (the salt would be given in full, e.g. \u201c50 mg codeine phosphate\u201d).\n\nWhere necessary, in instances of potential confusion (e.g. amodiaquine, quinine salts) a warning note would be included.\n\nThe Committee congratulated the Secretariat on its efforts to provide more clarity with regard to strengths and dosage form references within the Model List.\n\n## 11.2 Update on stability\n\nThe revised working document on *Stability testing of active pharmaceutical ingredients and finished pharmaceutical products* was adopted by the Expert.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2399, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f9670648-251b-4cd1-9837-222a5cf6a273": {"__data__": {"id_": "f9670648-251b-4cd1-9837-222a5cf6a273", "embedding": null, "metadata": {"page_label": "77", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Committee at its forty-third meeting after a long and intensive consultation process (see *Stability testing of active pharmaceutical ingredients and finished pharmaceutical products*, Annex 2, WHO Technical Report Series, No. 953, 2009).\n\nAppendix 1 included a *List of WHO Member States\u2019 required long-term stability conditions* as per information received from countries. Preference was given \u2014 based on the comments received from NMRAs \u2014 to providing \u201creal\u201d conditions required by national authorities. Completing the table for all WHO Member States proved to be a major challenge. However, thanks to IFPMA and special efforts made during and subsequent to the ICDRA meeting, the list could be completed. As a consequence the list comprised three different types of entries as follows.\n\n<div style=\"border: 1px solid black; padding: 10px;\">\n\n**Entries in bold type:**\n\nInformation obtained through respective regional harmonization groups (e.g. Association of Southeast Asian Nations (ASEAN, ICH) and Gulf Cooperation Council (GCC)) and from official communications from NMRAs to WHO.\n\n**Entries in normal type:**\n\nInformation collated during the 13th ICDRA in September 2008, from representatives of NMRAs.\n\n**Entries in italic type:**\n\nInformation provided by IFPMA based on the references given in the guidelines.\n\n</div>\n\nMoreover, during and following the preparation of the Expert Committee report, the Secretariat actively contacted again, with the help of colleagues from the Medicines Regulatory Support Programme, those national authorities for which the entries were \u201cinformal\u201d and/or in accordance with published studies.\n\nThe aim was to update the list on the Medicines web site upon receipt of confirmed new information from NMRAs. Any changes would be based on information received through official correspondence with accompanying reference to national guidance.\n\nDetailed feedback was received from IFPMA regarding possible updates of the stability testing conditions for Afghanistan, Canada, Chile, India and Israel, as well as the labelling statements listed in Appendix 3 of the guidelines.\n\nIn accordance with the process described and suggested above for the update of the table in Appendix 1 of the stability guidelines, the Secretariat would, with the agreement of the Expert Committee:", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla el proceso de consulta y recopilaci\u00f3n de informaci\u00f3n sobre las condiciones de estabilidad a largo plazo requeridas por los Estados Miembros de la OMS para ingredientes farmac\u00e9uticos activos y productos farmac\u00e9uticos terminados. Se menciona la colaboraci\u00f3n con grupos de armonizaci\u00f3n regional y la importancia de la informaci\u00f3n oficial de las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs). Adem\u00e1s, se destaca el esfuerzo por actualizar la lista de condiciones de estabilidad en el sitio web de Medicamentos, bas\u00e1ndose en la retroalimentaci\u00f3n recibida de la IFPMA (Federaci\u00f3n Internacional de Asociaciones de Fabricantes y Asociaciones).\n\n### Preguntas Espec\u00edficas:\n1. **\u00bfQu\u00e9 tipos de entradas se incluyen en la lista de condiciones de estabilidad a largo plazo y c\u00f3mo se clasifican?**\n   - La lista incluye tres tipos de entradas: en negrita (informaci\u00f3n de grupos de armonizaci\u00f3n regional y comunicaciones oficiales de NMRAs), en tipo normal (informaci\u00f3n recopilada durante la 13\u00aa ICDRA) y en cursiva (informaci\u00f3n proporcionada por IFPMA).\n\n2. **\u00bfCu\u00e1l fue el papel de la IFPMA en la recopilaci\u00f3n de informaci\u00f3n sobre las condiciones de estabilidad?**\n   - La IFPMA proporcion\u00f3 informaci\u00f3n detallada sobre las condiciones de estabilidad para varios pa\u00edses y ayud\u00f3 a completar la lista de condiciones de estabilidad a largo plazo, as\u00ed como a ofrecer retroalimentaci\u00f3n sobre las declaraciones de etiquetado.\n\n3. **\u00bfQu\u00e9 proceso se seguir\u00e1 para actualizar la lista de condiciones de estabilidad en el sitio web de Medicamentos de la OMS?**\n   - La actualizaci\u00f3n de la lista se realizar\u00e1 tras recibir informaci\u00f3n confirmada de las NMRAs, y cualquier cambio se basar\u00e1 en correspondencia oficial que incluya referencias a la gu\u00eda nacional correspondiente. La Secretar\u00eda, con el acuerdo del Comit\u00e9 de Expertos, llevar\u00e1 a cabo este proceso.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Lista Modelo de Medicamentos Esenciales de la OMS**:\n   - Se discutieron propuestas sobre la terminolog\u00eda de formas de dosificaci\u00f3n y la expresi\u00f3n de la fuerza de los medicamentos en una reuni\u00f3n del Comit\u00e9 de Expertos en marzo de 2009.\n   - Se incluyeron notas explicativas y un anexo sobre terminolog\u00eda de formas de dosificaci\u00f3n en la edici\u00f3n m\u00e1s reciente de la lista.\n\n2. **Principios para la Expresi\u00f3n de Fuerzas de Medicamentos**:\n   - Se acordaron principios para la expresi\u00f3n de las fuerzas de los medicamentos que se aplicar\u00e1n en futuras listas.\n   - Se busca una mayor claridad en la distinci\u00f3n entre el principio activo (API) y la sal utilizada en la formulaci\u00f3n.\n\n3. **Actualizaci\u00f3n sobre Estabilidad**:\n   - Se adopt\u00f3 un documento revisado sobre pruebas de estabilidad de ingredientes farmac\u00e9uticos activos y productos farmac\u00e9uticos terminados, reflejando un compromiso con la calidad y seguridad de los medicamentos.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la elaboraci\u00f3n de la Lista Modelo de Medicamentos Esenciales.\n- **Comit\u00e9 de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales**: Grupo que revisa y aprueba propuestas relacionadas con medicamentos esenciales.\n- **QSM (Quality Assurance Medicines)**: Entidad que present\u00f3 el documento de trabajo discutido.\n- **API (Active Pharmaceutical Ingredient)**: Ingrediente farmac\u00e9utico activo cuya fuerza se expresa en la lista de medicamentos.\n- ***The International Pharmacopoeia***: Texto de referencia mencionado en relaci\u00f3n con la calidad de los medicamentos.", "excerpt_keywords": "Keywords: stability testing, WHO Member States, NMRAs, IFPMA, pharmaceutical products"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b2504a85-6fe2-4baa-a3f7-9608e9350a04", "node_type": "4", "metadata": {"page_label": "77", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Committee at its forty-third meeting after a long and intensive consultation process (see *Stability testing of active pharmaceutical ingredients and finished pharmaceutical products*, Annex 2, WHO Technical Report Series, No. 953, 2009).\n\nAppendix 1 included a *List of WHO Member States\u2019 required long-term stability conditions* as per information received from countries. Preference was given \u2014 based on the comments received from NMRAs \u2014 to providing \u201creal\u201d conditions required by national authorities. Completing the table for all WHO Member States proved to be a major challenge. However, thanks to IFPMA and special efforts made during and subsequent to the ICDRA meeting, the list could be completed. As a consequence the list comprised three different types of entries as follows.\n\n<div style=\"border: 1px solid black; padding: 10px;\">\n\n**Entries in bold type:**\n\nInformation obtained through respective regional harmonization groups (e.g. Association of Southeast Asian Nations (ASEAN, ICH) and Gulf Cooperation Council (GCC)) and from official communications from NMRAs to WHO.\n\n**Entries in normal type:**\n\nInformation collated during the 13th ICDRA in September 2008, from representatives of NMRAs.\n\n**Entries in italic type:**\n\nInformation provided by IFPMA based on the references given in the guidelines.\n\n</div>\n\nMoreover, during and following the preparation of the Expert Committee report, the Secretariat actively contacted again, with the help of colleagues from the Medicines Regulatory Support Programme, those national authorities for which the entries were \u201cinformal\u201d and/or in accordance with published studies.\n\nThe aim was to update the list on the Medicines web site upon receipt of confirmed new information from NMRAs. Any changes would be based on information received through official correspondence with accompanying reference to national guidance.\n\nDetailed feedback was received from IFPMA regarding possible updates of the stability testing conditions for Afghanistan, Canada, Chile, India and Israel, as well as the labelling statements listed in Appendix 3 of the guidelines.\n\nIn accordance with the process described and suggested above for the update of the table in Appendix 1 of the stability guidelines, the Secretariat would, with the agreement of the Expert Committee:", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "3343f032f9c31fea4c9393558d158d9c7f2c258401b1f25f188be3d8ead6aa36", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Committee at its forty-third meeting after a long and intensive consultation process (see *Stability testing of active pharmaceutical ingredients and finished pharmaceutical products*, Annex 2, WHO Technical Report Series, No. 953, 2009).\n\nAppendix 1 included a *List of WHO Member States\u2019 required long-term stability conditions* as per information received from countries. Preference was given \u2014 based on the comments received from NMRAs \u2014 to providing \u201creal\u201d conditions required by national authorities. Completing the table for all WHO Member States proved to be a major challenge. However, thanks to IFPMA and special efforts made during and subsequent to the ICDRA meeting, the list could be completed. As a consequence the list comprised three different types of entries as follows.\n\n<div style=\"border: 1px solid black; padding: 10px;\">\n\n**Entries in bold type:**\n\nInformation obtained through respective regional harmonization groups (e.g. Association of Southeast Asian Nations (ASEAN, ICH) and Gulf Cooperation Council (GCC)) and from official communications from NMRAs to WHO.\n\n**Entries in normal type:**\n\nInformation collated during the 13th ICDRA in September 2008, from representatives of NMRAs.\n\n**Entries in italic type:**\n\nInformation provided by IFPMA based on the references given in the guidelines.\n\n</div>\n\nMoreover, during and following the preparation of the Expert Committee report, the Secretariat actively contacted again, with the help of colleagues from the Medicines Regulatory Support Programme, those national authorities for which the entries were \u201cinformal\u201d and/or in accordance with published studies.\n\nThe aim was to update the list on the Medicines web site upon receipt of confirmed new information from NMRAs. Any changes would be based on information received through official correspondence with accompanying reference to national guidance.\n\nDetailed feedback was received from IFPMA regarding possible updates of the stability testing conditions for Afghanistan, Canada, Chile, India and Israel, as well as the labelling statements listed in Appendix 3 of the guidelines.\n\nIn accordance with the process described and suggested above for the update of the table in Appendix 1 of the stability guidelines, the Secretariat would, with the agreement of the Expert Committee:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2314, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "bd848c18-01ea-4223-9089-2326e0fd3b9c": {"__data__": {"id_": "bd848c18-01ea-4223-9089-2326e0fd3b9c", "embedding": null, "metadata": {"page_label": "78", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- update the entry for Canada, as the official information had been received; and\n- continue to contact the NMRAs of the other countries listed above with respect to the correctness of their entries.\n\nAs regards the proposal for the labelling information, intensive discussions were held on this topic during the consultation process. The final decision was to add the labelling statements in an Appendix as a recommendation. IFPMA might submit a concrete proposal which could be circulated for comments and discussed at the next Expert Committee meeting.\n\n**Implementation**\n\nFollowing the intense cooperation with the Quality Expert Working Groups within the ICH, the ICH web site included a new reference to the WHO stability guidelines as follows:\n\n\u201cQ1F: Stability Data Package for Registration Applications in Climatic Zones III and IV\n\n\u27a1\ufe0f The ICH Steering Committee endorsed the withdrawal of the Q1F guideline at its meeting in Yokohama, June 2006 and decided to leave definition of storage conditions in Climatic Zones III and IV to the respective regions and WHO. Click here to open the Explanatory Note and have access to the WHO Stability Guideline in the electronic version of this report.\u201d\n\nThe Expert Committee endorsed:\n- that updates of long-term conditions required for marketing authorization in WHO Member States would be made as received from authorities; and\n- the suggestion to include the details of this major harmonization effort and resolution of any possible further concerns during the ICDRA meeting to be held in Singapore in 2010.\n\n## 11.3 Diethylene glycol\n\nOver the years accidental or deliberate counterfeiting of medicines with diethylene glycol (DEG) had occurred many times and in many countries. The first recorded incident occurred in the USA in 1937. The episode killed a large number of Americans, mostly children. The latest incident happened in Nigeria where an equally large number of people were reported to have died. Beyond Nigeria the toxic chemical had caused mass poisoning in Argentina, Bangladesh, China, Ha\u00efti, India, Nigeria, Panama and South Africa. Numerous articles and references have referred to detected cases.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a formularlas:\n\n### Resumen de nivel superior:\nEl documento de la OMS discute la actualizaci\u00f3n de informaci\u00f3n sobre la autorizaci\u00f3n de medicamentos en diferentes pa\u00edses, la propuesta de etiquetado de medicamentos y la cooperaci\u00f3n con grupos de expertos en calidad. Tambi\u00e9n se aborda el problema de la falsificaci\u00f3n de medicamentos que contienen diethylene glycol (DEG), un compuesto t\u00f3xico que ha causado numerosas muertes en varios pa\u00edses a lo largo de los a\u00f1os.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 medidas se est\u00e1n tomando para asegurar la correcci\u00f3n de la informaci\u00f3n de los medicamentos en los pa\u00edses mencionados?**\n   - Respuesta: Se est\u00e1 actualizando la entrada para Canad\u00e1 tras recibir informaci\u00f3n oficial y se contin\u00faa contactando a las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) de otros pa\u00edses para verificar la correcci\u00f3n de sus entradas.\n\n2. **\u00bfCu\u00e1l fue la decisi\u00f3n final respecto a la propuesta de informaci\u00f3n de etiquetado discutida durante el proceso de consulta?**\n   - Respuesta: La decisi\u00f3n final fue a\u00f1adir las declaraciones de etiquetado en un Ap\u00e9ndice como recomendaci\u00f3n, y se mencion\u00f3 que la IFPMA podr\u00eda presentar una propuesta concreta para ser discutida en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos.\n\n3. **\u00bfQu\u00e9 incidentes hist\u00f3ricos se mencionan en relaci\u00f3n con el diethylene glycol (DEG) y cu\u00e1les han sido sus consecuencias?**\n   - Respuesta: Se menciona que el primer incidente registrado ocurri\u00f3 en EE. UU. en 1937, causando la muerte de muchos, principalmente ni\u00f1os. El \u00faltimo incidente reportado fue en Nigeria, donde tambi\u00e9n se registraron numerosas muertes. Adem\u00e1s, se han documentado casos de envenenamiento masivo en varios otros pa\u00edses, incluyendo Argentina, Bangladesh, y Sud\u00e1frica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Consulta y Recopilaci\u00f3n de Informaci\u00f3n:** Se detalla el proceso de consulta llevado a cabo por el Comit\u00e9 de Expertos de la OMS para establecer las condiciones de estabilidad a largo plazo requeridas por los Estados Miembros.\n2. **Clasificaci\u00f3n de Entradas:** La lista de condiciones de estabilidad se clasifica en tres tipos de entradas: \n   - **Negrita:** Informaci\u00f3n de grupos de armonizaci\u00f3n regional y comunicaciones oficiales de NMRAs.\n   - **Tipo Normal:** Informaci\u00f3n recopilada durante la 13\u00aa ICDRA.\n   - **Cursiva:** Informaci\u00f3n proporcionada por la IFPMA.\n3. **Colaboraci\u00f3n con NMRAs e IFPMA:** Se destaca la colaboraci\u00f3n con las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) y la Federaci\u00f3n Internacional de Asociaciones de Fabricantes y Asociaciones (IFPMA) para completar y actualizar la lista de condiciones de estabilidad.\n4. **Proceso de Actualizaci\u00f3n:** Se describe el proceso para actualizar la lista en el sitio web de Medicamentos de la OMS, basado en informaci\u00f3n confirmada de las NMRAs y correspondencia oficial.\n\n**Entidades:**\n- **OMS (Organizaci\u00f3n Mundial de la Salud):** Organismo responsable de la elaboraci\u00f3n del informe y la recopilaci\u00f3n de datos sobre estabilidad.\n- **NMRAs (Autoridades Nacionales Reguladoras de Medicamentos):** Entidades que proporcionan informaci\u00f3n sobre las condiciones de estabilidad requeridas en sus respectivos pa\u00edses.\n- **IFPMA (Federaci\u00f3n Internacional de Asociaciones de Fabricantes y Asociaciones):** Organizaci\u00f3n que contribuye con informaci\u00f3n y retroalimentaci\u00f3n sobre las condiciones de estabilidad y etiquetado.\n- **ICDRA (Reuni\u00f3n Internacional de Autoridades Reguladoras de Medicamentos):** Evento donde se recopila informaci\u00f3n relevante de representantes de NMRAs.\n\nEste resumen abarca los aspectos fundamentales del proceso de consulta y recopilaci\u00f3n de informaci\u00f3n sobre las condiciones de estabilidad a largo plazo, as\u00ed como las entidades involucradas en este esfuerzo.", "excerpt_keywords": "Keywords: WHO, diethylene glycol, labelling information, stability guidelines, NMRAs"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "64bf87ec-b06e-4f22-bf4a-4a183c4dded0", "node_type": "4", "metadata": {"page_label": "78", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- update the entry for Canada, as the official information had been received; and\n- continue to contact the NMRAs of the other countries listed above with respect to the correctness of their entries.\n\nAs regards the proposal for the labelling information, intensive discussions were held on this topic during the consultation process. The final decision was to add the labelling statements in an Appendix as a recommendation. IFPMA might submit a concrete proposal which could be circulated for comments and discussed at the next Expert Committee meeting.\n\n**Implementation**\n\nFollowing the intense cooperation with the Quality Expert Working Groups within the ICH, the ICH web site included a new reference to the WHO stability guidelines as follows:\n\n\u201cQ1F: Stability Data Package for Registration Applications in Climatic Zones III and IV\n\n\u27a1\ufe0f The ICH Steering Committee endorsed the withdrawal of the Q1F guideline at its meeting in Yokohama, June 2006 and decided to leave definition of storage conditions in Climatic Zones III and IV to the respective regions and WHO. Click here to open the Explanatory Note and have access to the WHO Stability Guideline in the electronic version of this report.\u201d\n\nThe Expert Committee endorsed:\n- that updates of long-term conditions required for marketing authorization in WHO Member States would be made as received from authorities; and\n- the suggestion to include the details of this major harmonization effort and resolution of any possible further concerns during the ICDRA meeting to be held in Singapore in 2010.\n\n## 11.3 Diethylene glycol\n\nOver the years accidental or deliberate counterfeiting of medicines with diethylene glycol (DEG) had occurred many times and in many countries. The first recorded incident occurred in the USA in 1937. The episode killed a large number of Americans, mostly children. The latest incident happened in Nigeria where an equally large number of people were reported to have died. Beyond Nigeria the toxic chemical had caused mass poisoning in Argentina, Bangladesh, China, Ha\u00efti, India, Nigeria, Panama and South Africa. Numerous articles and references have referred to detected cases.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "ca6bdc662986968bf90318f49011926f4f921845d0d075c8df8e3f1327e055ed", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- update the entry for Canada, as the official information had been received; and\n- continue to contact the NMRAs of the other countries listed above with respect to the correctness of their entries.\n\nAs regards the proposal for the labelling information, intensive discussions were held on this topic during the consultation process. The final decision was to add the labelling statements in an Appendix as a recommendation. IFPMA might submit a concrete proposal which could be circulated for comments and discussed at the next Expert Committee meeting.\n\n**Implementation**\n\nFollowing the intense cooperation with the Quality Expert Working Groups within the ICH, the ICH web site included a new reference to the WHO stability guidelines as follows:\n\n\u201cQ1F: Stability Data Package for Registration Applications in Climatic Zones III and IV\n\n\u27a1\ufe0f The ICH Steering Committee endorsed the withdrawal of the Q1F guideline at its meeting in Yokohama, June 2006 and decided to leave definition of storage conditions in Climatic Zones III and IV to the respective regions and WHO. Click here to open the Explanatory Note and have access to the WHO Stability Guideline in the electronic version of this report.\u201d\n\nThe Expert Committee endorsed:\n- that updates of long-term conditions required for marketing authorization in WHO Member States would be made as received from authorities; and\n- the suggestion to include the details of this major harmonization effort and resolution of any possible further concerns during the ICDRA meeting to be held in Singapore in 2010.\n\n## 11.3 Diethylene glycol\n\nOver the years accidental or deliberate counterfeiting of medicines with diethylene glycol (DEG) had occurred many times and in many countries. The first recorded incident occurred in the USA in 1937. The episode killed a large number of Americans, mostly children. The latest incident happened in Nigeria where an equally large number of people were reported to have died. Beyond Nigeria the toxic chemical had caused mass poisoning in Argentina, Bangladesh, China, Ha\u00efti, India, Nigeria, Panama and South Africa. Numerous articles and references have referred to detected cases.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2169, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6b919226-63c5-4b5a-8426-7bf38f3dff40": {"__data__": {"id_": "6b919226-63c5-4b5a-8426-7bf38f3dff40", "embedding": null, "metadata": {"page_label": "79", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "of deaths due to DEG poisoning during the past decades. However, it was not known how many unreported deaths had actually occurred since some victims might have perished without visiting a health-care facility or seeing medical doctors.\n\nInvestigation of some of the above-mentioned incidents had revealed the main contributing factors for the incidents to be:\n\n- absence of control by NMRAs of the manufacture, export and import of glycerol and propylene glycol;\n- purchase of glycerol and propylene glycol by pharmaceutical manufacturers from unreliable sources or through brokers and traders; and\n- lack of testing of the quality of glycerol and propylene glycol prior to using them in the manufacture of pharmaceutical products.\n\nThe above situation clearly showed that unless strict controls and safeguard measures were put in place by NMRAs, more people would fall victim to DEG poisoning.\n\nFollowing up on the recurring incidents of DEG poisoning the Expert Committee discussed a proposal to send out a general alert to the NMRAs which should include recommendations to prevent such events in the future. Extensive discussion took place and the proposed text was amended to include further details. It was decided to form a small group to work out the final text. The Committee endorsed the proposal in general and agreed that the working group should submit the final text to the Committee members for final adoption.\n\n## 12. Summary and recommendations\n\nThe Expert Committee on Specifications for Pharmaceutical Preparations provides recommendations and tools to assure the quality of medicines from their development phase to their final distribution to the patients. It advises the Director-General in the area of quality assurance of medicines.\n\nThis Expert Committee is looking back on a history of more than 60 years! The first meeting of the Expert Committee, named \u201cUnification on Pharmacopoeias\u201d at that time, was held in 1947. Since the inception of this WHO Expert Committee, its members have worked towards making available clear, independent and practical recommendations, written and physical standards, as well as international guidelines for quality medicines. Standards in the area of quality assurance for medicines are developed by the Committee through a wide international consensus building process. Detailed recommendations can be found under each relevant section in the report.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS discute los incidentes de envenenamiento por dietilenglicol (DEG) en las \u00faltimas d\u00e9cadas, destacando la falta de control por parte de las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) sobre la fabricaci\u00f3n y calidad de productos como el glicerol y el propilenglicol. Se identifican factores que contribuyen a estos incidentes y se propone enviar una alerta general a las NMRAs con recomendaciones para prevenir futuros casos. Adem\u00e1s, se menciona la historia de m\u00e1s de 60 a\u00f1os del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas, que trabaja en la creaci\u00f3n de est\u00e1ndares y directrices para asegurar la calidad de los medicamentos.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son los principales factores que contribuyen a los incidentes de envenenamiento por DEG seg\u00fan las investigaciones mencionadas en el documento?**\n   - Respuesta: Los principales factores son la ausencia de control por parte de las NMRAs sobre la fabricaci\u00f3n, exportaci\u00f3n e importaci\u00f3n de glicerol y propilenglicol, la compra de estos productos de fuentes poco fiables y la falta de pruebas de calidad antes de su uso en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 acciones se propusieron para abordar el problema del envenenamiento por DEG y qui\u00e9nes est\u00e1n involucrados en la implementaci\u00f3n de estas acciones?**\n   - Respuesta: Se propuso enviar una alerta general a las NMRAs con recomendaciones para prevenir futuros incidentes. Un grupo peque\u00f1o fue formado para trabajar en el texto final de la propuesta, que ser\u00e1 sometido a los miembros del Comit\u00e9 para su adopci\u00f3n final.\n\n3. **\u00bfCu\u00e1l ha sido el enfoque del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas en los \u00faltimos 60 a\u00f1os en relaci\u00f3n con la calidad de los medicamentos?**\n   - Respuesta: El Comit\u00e9 ha trabajado en la creaci\u00f3n de recomendaciones claras, est\u00e1ndares escritos y f\u00edsicos, as\u00ed como directrices internacionales para asegurar la calidad de los medicamentos, desarrollando est\u00e1ndares a trav\u00e9s de un proceso de consenso internacional.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Actualizaci\u00f3n de Informaci\u00f3n sobre Medicamentos**:\n   - Se est\u00e1 actualizando la entrada para Canad\u00e1 tras recibir informaci\u00f3n oficial.\n   - Se contin\u00faa en contacto con las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) de otros pa\u00edses para verificar la correcci\u00f3n de sus entradas.\n\n2. **Propuesta de Etiquetado de Medicamentos**:\n   - Se llevaron a cabo discusiones intensivas sobre la informaci\u00f3n de etiquetado durante el proceso de consulta.\n   - La decisi\u00f3n final fue incluir las declaraciones de etiquetado en un Ap\u00e9ndice como recomendaci\u00f3n.\n   - La IFPMA (Federaci\u00f3n Internacional de Fabricantes y Asociaciones Farmac\u00e9uticas) podr\u00eda presentar una propuesta concreta para discusi\u00f3n en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos.\n\n3. **Cooperaci\u00f3n con Grupos de Expertos**:\n   - Se menciona la cooperaci\u00f3n con los Grupos de Trabajo de Expertos en Calidad dentro del ICH (Conferencia Internacional sobre Armonizaci\u00f3n).\n   - Se incluy\u00f3 una nueva referencia a las directrices de estabilidad de la OMS en el sitio web del ICH.\n\n4. **Diethylene Glycol (DEG)**:\n   - Se ha documentado la falsificaci\u00f3n accidental o deliberada de medicamentos que contienen DEG en varios pa\u00edses a lo largo de los a\u00f1os.\n   - El primer incidente registrado ocurri\u00f3 en EE. UU. en 1937, causando la muerte de muchos, principalmente ni\u00f1os.\n   - El \u00faltimo incidente reportado fue en Nigeria, con un n\u00famero significativo de muertes.\n   - Se han registrado casos de envenenamiento masivo en otros pa\u00edses, incluyendo Argentina, Bangladesh, China, Hait\u00ed, India, Panam\u00e1 y Sud\u00e1frica.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo que supervisa la salud p\u00fablica y regula la informaci\u00f3n sobre medicamentos.\n- **IFPMA (Federaci\u00f3n Internacional de Fabricantes y Asociaciones Farmac\u00e9uticas)**: Organizaci\u00f3n que representa a la industria farmac\u00e9utica.\n- **ICH (Conferencia Internacional sobre Armonizaci\u00f3n)**: Colaboraci\u00f3n entre reguladores y la industria farmac\u00e9utica para armonizar las regulaciones de medicamentos.\n- **NMRAs (Autoridades Nacionales Reguladoras de Medicamentos)**: Entidades responsables de la regulaci\u00f3n de medicamentos en sus respectivos pa\u00edses. \n\nEste resumen destaca los esfuerzos en la regulaci\u00f3n y seguridad de medicamentos, as\u00ed como los problemas hist\u00f3ricos relacionados con la falsificaci\u00f3n de medicamentos peligrosos.", "excerpt_keywords": "Keywords: DEG poisoning, NMRAs, quality assurance, pharmaceutical standards, WHO Expert Committee"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8d55cfc2-7464-459e-bfe5-db7926daa6bb", "node_type": "4", "metadata": {"page_label": "79", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "of deaths due to DEG poisoning during the past decades. However, it was not known how many unreported deaths had actually occurred since some victims might have perished without visiting a health-care facility or seeing medical doctors.\n\nInvestigation of some of the above-mentioned incidents had revealed the main contributing factors for the incidents to be:\n\n- absence of control by NMRAs of the manufacture, export and import of glycerol and propylene glycol;\n- purchase of glycerol and propylene glycol by pharmaceutical manufacturers from unreliable sources or through brokers and traders; and\n- lack of testing of the quality of glycerol and propylene glycol prior to using them in the manufacture of pharmaceutical products.\n\nThe above situation clearly showed that unless strict controls and safeguard measures were put in place by NMRAs, more people would fall victim to DEG poisoning.\n\nFollowing up on the recurring incidents of DEG poisoning the Expert Committee discussed a proposal to send out a general alert to the NMRAs which should include recommendations to prevent such events in the future. Extensive discussion took place and the proposed text was amended to include further details. It was decided to form a small group to work out the final text. The Committee endorsed the proposal in general and agreed that the working group should submit the final text to the Committee members for final adoption.\n\n## 12. Summary and recommendations\n\nThe Expert Committee on Specifications for Pharmaceutical Preparations provides recommendations and tools to assure the quality of medicines from their development phase to their final distribution to the patients. It advises the Director-General in the area of quality assurance of medicines.\n\nThis Expert Committee is looking back on a history of more than 60 years! The first meeting of the Expert Committee, named \u201cUnification on Pharmacopoeias\u201d at that time, was held in 1947. Since the inception of this WHO Expert Committee, its members have worked towards making available clear, independent and practical recommendations, written and physical standards, as well as international guidelines for quality medicines. Standards in the area of quality assurance for medicines are developed by the Committee through a wide international consensus building process. Detailed recommendations can be found under each relevant section in the report.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "0296d4dddc5d4247504f778c1642113f3af9f260310e5563b8d557f7237a18d5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "of deaths due to DEG poisoning during the past decades. However, it was not known how many unreported deaths had actually occurred since some victims might have perished without visiting a health-care facility or seeing medical doctors.\n\nInvestigation of some of the above-mentioned incidents had revealed the main contributing factors for the incidents to be:\n\n- absence of control by NMRAs of the manufacture, export and import of glycerol and propylene glycol;\n- purchase of glycerol and propylene glycol by pharmaceutical manufacturers from unreliable sources or through brokers and traders; and\n- lack of testing of the quality of glycerol and propylene glycol prior to using them in the manufacture of pharmaceutical products.\n\nThe above situation clearly showed that unless strict controls and safeguard measures were put in place by NMRAs, more people would fall victim to DEG poisoning.\n\nFollowing up on the recurring incidents of DEG poisoning the Expert Committee discussed a proposal to send out a general alert to the NMRAs which should include recommendations to prevent such events in the future. Extensive discussion took place and the proposed text was amended to include further details. It was decided to form a small group to work out the final text. The Committee endorsed the proposal in general and agreed that the working group should submit the final text to the Committee members for final adoption.\n\n## 12. Summary and recommendations\n\nThe Expert Committee on Specifications for Pharmaceutical Preparations provides recommendations and tools to assure the quality of medicines from their development phase to their final distribution to the patients. It advises the Director-General in the area of quality assurance of medicines.\n\nThis Expert Committee is looking back on a history of more than 60 years! The first meeting of the Expert Committee, named \u201cUnification on Pharmacopoeias\u201d at that time, was held in 1947. Since the inception of this WHO Expert Committee, its members have worked towards making available clear, independent and practical recommendations, written and physical standards, as well as international guidelines for quality medicines. Standards in the area of quality assurance for medicines are developed by the Committee through a wide international consensus building process. Detailed recommendations can be found under each relevant section in the report.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2410, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "afe758a0-ac22-4a9e-a78c-ae74de9645a6": {"__data__": {"id_": "afe758a0-ac22-4a9e-a78c-ae74de9645a6", "embedding": null, "metadata": {"page_label": "80", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The activities discussed during this Expert Committee meeting have broad inter- and intracluster relationships and links. There are joint activities, specifically with the WHO Expert Committee on Biological Standardization, and on the Selection and Use of Essential Medicines and its Subcommittee on Medicines for Children. In addition, the Committee serves to develop specific additional guidance and specifications as needed for the various medicines recommended by WHO Programmes.\n\nThis Committee also serves the United Nations Programme on Prequalification of Medicines managed and operated by WHO, as the Programme could not function without the guidelines, standards and specifications adopted by this Committee after passage through its rigorous, international and wide consultative process. The advantage for the Committee is that, as a result of implementing these guidelines and specifications, practical suggestions for potential revision or on the need for additional guidance are communicated in return to the Expert Committee.\n\nRegarding implementation from a wider perspective, the international guidelines, specifications and nomenclature developed under the aegis of this Committee serve all Member States, international organizations, United Nations agencies, regional and interregional harmonization efforts, and underpin important initiatives, including the prequalification of medicines, the Roll Back Malaria Programme, Stop TB, essential medicines and medicines for children. The advice and recommendations provided by this Expert Committee are intended to help national and regional authorities and procurement agencies, as well as major international bodies and institutions, such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, and international organizations such as UNICEF \u2014 to combat circulation of substandard medicines and to work towards access to quality medicines.\n\nIn conclusion, the Expert Committee on Specifications for Pharmaceutical Preparations gives recommendations and provides independent international standards and guidelines in the area of quality assurance for implementation by WHO Member States, international organizations, United Nations agencies, regional and interregional harmonization efforts, as well as WHO\u2019s medicines' related programmes and initiatives. Making resources available for these activities is, therefore, very cost-effective.\n\n**The following new guidelines were adopted and recommended for use:**\n\n- WHO good practices for pharmaceutical quality control laboratories (Annex 1)\n- WHO good manufacturing practices for active pharmaceutical ingredients (Annex 2)\n- WHO good manufacturing practices for pharmaceutical products containing hazardous substances (Annex 3)", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS se encarga de desarrollar directrices y est\u00e1ndares internacionales para asegurar la calidad de los medicamentos. Colabora con otros comit\u00e9s de la OMS y programas de la ONU, como el Programa de Precalificaci\u00f3n de Medicamentos, para combatir la circulaci\u00f3n de medicamentos de calidad inferior y mejorar el acceso a medicamentos de calidad. Recientemente, se adoptaron nuevas directrices sobre buenas pr\u00e1cticas en laboratorios de control de calidad y fabricaci\u00f3n de ingredientes y productos farmac\u00e9uticos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1l es el papel del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas en relaci\u00f3n con el Programa de Precalificaci\u00f3n de Medicamentos de la OMS?**\n   - Respuesta: El Comit\u00e9 proporciona las directrices, est\u00e1ndares y especificaciones necesarias para que el Programa de Precalificaci\u00f3n de Medicamentos funcione adecuadamente, ya que este programa depende de las recomendaciones adoptadas por el Comit\u00e9 tras un proceso consultivo riguroso.\n\n2. **\u00bfQu\u00e9 iniciativas importantes se apoyan mediante las directrices y especificaciones desarrolladas por el Comit\u00e9?**\n   - Respuesta: Las directrices y especificaciones respaldan iniciativas como la precalificaci\u00f3n de medicamentos, el Programa Roll Back Malaria, Stop TB, y los esfuerzos relacionados con medicamentos esenciales y medicamentos para ni\u00f1os.\n\n3. **\u00bfCu\u00e1les son las nuevas directrices adoptadas por el Comit\u00e9 y qu\u00e9 \u00e1reas espec\u00edficas abordan?**\n   - Respuesta: Las nuevas directrices adoptadas incluyen: \n     - Buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica (Anexo 1).\n     - Buenas pr\u00e1cticas de fabricaci\u00f3n para ingredientes farmac\u00e9uticos activos (Anexo 2).\n     - Buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos que contienen sustancias peligrosas (Anexo 3).", "prev_section_summary": "### Temas Clave\n\n1. **Envenenamiento por Dietilenglicol (DEG)**: El documento aborda los incidentes de envenenamiento por DEG en las \u00faltimas d\u00e9cadas, destacando la falta de control y regulaci\u00f3n en la fabricaci\u00f3n y calidad de productos como el glicerol y el propilenglicol.\n\n2. **Factores Contribuyentes**: Se identifican tres factores principales que contribuyen a los incidentes de envenenamiento:\n   - Ausencia de control por parte de las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs).\n   - Compra de glicerol y propilenglicol de fuentes poco fiables.\n   - Falta de pruebas de calidad antes de su uso en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n\n3. **Propuestas de Acci\u00f3n**: Se propone enviar una alerta general a las NMRAs con recomendaciones para prevenir futuros incidentes de envenenamiento por DEG. Se form\u00f3 un grupo de trabajo para elaborar el texto final de la propuesta.\n\n4. **Historia del Comit\u00e9 de Expertos**: El Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas tiene m\u00e1s de 60 a\u00f1os de historia, trabajando en la creaci\u00f3n de est\u00e1ndares y directrices para asegurar la calidad de los medicamentos.\n\n5. **Recomendaciones y Herramientas**: El Comit\u00e9 proporciona recomendaciones y herramientas para asegurar la calidad de los medicamentos desde su desarrollo hasta su distribuci\u00f3n final.\n\n### Entidades\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: La entidad que publica el informe y supervisa la calidad de los medicamentos a nivel internacional.\n- **NMRAs (Autoridades Nacionales Reguladoras de Medicamentos)**: Organismos responsables de la regulaci\u00f3n y control de medicamentos en cada pa\u00eds.\n- **Expert Committee on Specifications for Pharmaceutical Preparations**: El grupo de expertos que se encarga de desarrollar est\u00e1ndares y recomendaciones para la calidad de los medicamentos.\n- **Glicerol y Propilenglicol**: Sustancias qu\u00edmicas involucradas en la fabricaci\u00f3n de productos farmac\u00e9uticos que han sido objeto de control y regulaci\u00f3n en el contexto del envenenamiento por DEG.", "excerpt_keywords": "Keywords: WHO, pharmaceutical quality, guidelines, medicines, standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7f38336a-e505-43f6-8e12-fb87398c1294", "node_type": "4", "metadata": {"page_label": "80", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The activities discussed during this Expert Committee meeting have broad inter- and intracluster relationships and links. There are joint activities, specifically with the WHO Expert Committee on Biological Standardization, and on the Selection and Use of Essential Medicines and its Subcommittee on Medicines for Children. In addition, the Committee serves to develop specific additional guidance and specifications as needed for the various medicines recommended by WHO Programmes.\n\nThis Committee also serves the United Nations Programme on Prequalification of Medicines managed and operated by WHO, as the Programme could not function without the guidelines, standards and specifications adopted by this Committee after passage through its rigorous, international and wide consultative process. The advantage for the Committee is that, as a result of implementing these guidelines and specifications, practical suggestions for potential revision or on the need for additional guidance are communicated in return to the Expert Committee.\n\nRegarding implementation from a wider perspective, the international guidelines, specifications and nomenclature developed under the aegis of this Committee serve all Member States, international organizations, United Nations agencies, regional and interregional harmonization efforts, and underpin important initiatives, including the prequalification of medicines, the Roll Back Malaria Programme, Stop TB, essential medicines and medicines for children. The advice and recommendations provided by this Expert Committee are intended to help national and regional authorities and procurement agencies, as well as major international bodies and institutions, such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, and international organizations such as UNICEF \u2014 to combat circulation of substandard medicines and to work towards access to quality medicines.\n\nIn conclusion, the Expert Committee on Specifications for Pharmaceutical Preparations gives recommendations and provides independent international standards and guidelines in the area of quality assurance for implementation by WHO Member States, international organizations, United Nations agencies, regional and interregional harmonization efforts, as well as WHO\u2019s medicines' related programmes and initiatives. Making resources available for these activities is, therefore, very cost-effective.\n\n**The following new guidelines were adopted and recommended for use:**\n\n- WHO good practices for pharmaceutical quality control laboratories (Annex 1)\n- WHO good manufacturing practices for active pharmaceutical ingredients (Annex 2)\n- WHO good manufacturing practices for pharmaceutical products containing hazardous substances (Annex 3)", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "6b3368bb143df447567e2e6789fe89c775b90e7b727e1c29c8810ae51196ac30", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The activities discussed during this Expert Committee meeting have broad inter- and intracluster relationships and links. There are joint activities, specifically with the WHO Expert Committee on Biological Standardization, and on the Selection and Use of Essential Medicines and its Subcommittee on Medicines for Children. In addition, the Committee serves to develop specific additional guidance and specifications as needed for the various medicines recommended by WHO Programmes.\n\nThis Committee also serves the United Nations Programme on Prequalification of Medicines managed and operated by WHO, as the Programme could not function without the guidelines, standards and specifications adopted by this Committee after passage through its rigorous, international and wide consultative process. The advantage for the Committee is that, as a result of implementing these guidelines and specifications, practical suggestions for potential revision or on the need for additional guidance are communicated in return to the Expert Committee.\n\nRegarding implementation from a wider perspective, the international guidelines, specifications and nomenclature developed under the aegis of this Committee serve all Member States, international organizations, United Nations agencies, regional and interregional harmonization efforts, and underpin important initiatives, including the prequalification of medicines, the Roll Back Malaria Programme, Stop TB, essential medicines and medicines for children. The advice and recommendations provided by this Expert Committee are intended to help national and regional authorities and procurement agencies, as well as major international bodies and institutions, such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, and international organizations such as UNICEF \u2014 to combat circulation of substandard medicines and to work towards access to quality medicines.\n\nIn conclusion, the Expert Committee on Specifications for Pharmaceutical Preparations gives recommendations and provides independent international standards and guidelines in the area of quality assurance for implementation by WHO Member States, international organizations, United Nations agencies, regional and interregional harmonization efforts, as well as WHO\u2019s medicines' related programmes and initiatives. Making resources available for these activities is, therefore, very cost-effective.\n\n**The following new guidelines were adopted and recommended for use:**\n\n- WHO good practices for pharmaceutical quality control laboratories (Annex 1)\n- WHO good manufacturing practices for active pharmaceutical ingredients (Annex 2)\n- WHO good manufacturing practices for pharmaceutical products containing hazardous substances (Annex 3)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2749, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3dc6963a-b5ea-4bdb-a307-1d3bdd15f556": {"__data__": {"id_": "3dc6963a-b5ea-4bdb-a307-1d3bdd15f556", "embedding": null, "metadata": {"page_label": "81", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- WHO good manufacturing practices for sterile pharmaceutical products (Annex 4)\n- WHO good distribution practices for pharmaceutical products (Annex 5)\n- Guidelines on the requalification of prequalified dossiers (Annex 6)\n- Guidelines for the preparation of a contract research organization master file (Annex 7)\n\n**For inclusion in The International Pharmacopoeia**\n\nThe following monographs were adopted:\n\n- **For antiretroviral medicines**\n  - Lopinavir\n  - Tenofovir disoproxil fumarate\n  - Indinavir capsules\n  - Saquinavir tablets\n  - Tenofovir tablets\n  - Lopinavir and ritonavir tablets\n  - Efavirenz\n\n- **For antimalarial medicines**\n  - Amodiaquine tablets\n  - Artesunate\n  - Artesunate tablets\n  - Quinine bisulfate tablets\n  - Quinine sulfate tablets\n\n- **For antituberculosis medicines**\n  - Amikacin\n  - Amikacin sulfate\n  - Amikacin injection\n  - Kanamycin monosulfate\n  - Kanamycin acid sulfate\n  - Kanamycin injection\n\n- **For radiopharmaceuticals**\n  - Iobenguane (\u00b9\u00b3\u00b9I) injection\n  - Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm) injection\n  - Sodium iodide (\u00b9\u00b3\u00b9I) capsules\n  - Sodium iothalamate (\u00b9\u00b2\u2075I) injection\n  - Sodium phosphate (\u00b3\u00b2P) injection\n  - Strontium chloride (\u2078\u2079Sr) injection\n  - Technetium (\u2079\u2079mTc) bicisate complex injection\n  - Technetium (\u2079\u2079mTc) exametazime complex injection\n  - Technetium (\u2079\u2079mTc) mebrofenin complex injection", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 957\" incluye directrices sobre buenas pr\u00e1cticas de fabricaci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos, as\u00ed como pautas para la revalidaci\u00f3n de expedientes precalificados y la preparaci\u00f3n de archivos maestros de organizaciones de investigaci\u00f3n por contrato. Adem\u00e1s, se presentan monograf\u00edas adoptadas para la inclusi\u00f3n en la Farmacopea Internacional, que abarcan medicamentos antirretrovirales, antimal\u00e1ricos, antituberculosos y radiotrazadores.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las pautas espec\u00edficas mencionadas en el documento para la preparaci\u00f3n de un archivo maestro de una organizaci\u00f3n de investigaci\u00f3n por contrato?**\n   - Esta pregunta se centra en las \"Guidelines for the preparation of a contract research organization master file (Annex 7)\", que no se detallan en el texto, pero que son relevantes para la investigaci\u00f3n farmac\u00e9utica.\n\n2. **\u00bfQu\u00e9 medicamentos antirretrovirales fueron adoptados para su inclusi\u00f3n en la Farmacopea Internacional seg\u00fan el informe?**\n   - Aunque se mencionan los nombres de los medicamentos, esta pregunta busca una lista espec\u00edfica y detallada de los antirretrovirales adoptados, que puede ser \u00fatil para profesionales de la salud y farmac\u00e9uticos.\n\n3. **\u00bfQu\u00e9 tipo de inyecciones de radiotrazadores se han incluido en las monograf\u00edas adoptadas y cu\u00e1les son sus aplicaciones potenciales?**\n   - Esta pregunta se enfoca en los \"radiopharmaceuticals\" mencionados, buscando informaci\u00f3n sobre sus aplicaciones cl\u00ednicas y su importancia en la medicina nuclear, que no se detalla en el contexto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Colaboraci\u00f3n Interinstitucional:** El Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS trabaja en conjunto con otros comit\u00e9s de la OMS y programas de la ONU, como el Programa de Precalificaci\u00f3n de Medicamentos.\n2. **Desarrollo de Directrices y Est\u00e1ndares:** El Comit\u00e9 es responsable de desarrollar directrices, est\u00e1ndares y especificaciones internacionales para asegurar la calidad de los medicamentos.\n3. **Implementaci\u00f3n de Directrices:** Las directrices y est\u00e1ndares adoptados son fundamentales para la implementaci\u00f3n de iniciativas globales, como la precalificaci\u00f3n de medicamentos y programas de salud p\u00fablica.\n4. **Acceso a Medicamentos de Calidad:** El Comit\u00e9 busca combatir la circulaci\u00f3n de medicamentos de calidad inferior y mejorar el acceso a medicamentos seguros y eficaces.\n5. **Nuevas Directrices Adoptadas:** Se han adoptado nuevas directrices sobre buenas pr\u00e1cticas en laboratorios de control de calidad y fabricaci\u00f3n de productos farmac\u00e9uticos.\n\n**Entidades:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Principal entidad responsable de la salud p\u00fablica a nivel internacional.\n- **Programa de Precalificaci\u00f3n de Medicamentos:** Iniciativa de la OMS que asegura que los medicamentos cumplen con est\u00e1ndares de calidad.\n- **UNICEF:** Organizaci\u00f3n de la ONU que trabaja en la mejora de la salud y el bienestar de los ni\u00f1os.\n- **Global Fund to Fight AIDS, Tuberculosis and Malaria:** Fondo internacional que financia programas para combatir estas enfermedades.\n- **Expert Committee on Biological Standardization:** Otro comit\u00e9 de la OMS que colabora con el Comit\u00e9 de Especificaciones.\n\nEste resumen destaca la importancia del trabajo del Comit\u00e9 en la regulaci\u00f3n y mejora de la calidad de los medicamentos a nivel global, as\u00ed como su colaboraci\u00f3n con diversas entidades para lograr estos objetivos.", "excerpt_keywords": "Keywords: WHO, good manufacturing practices, antiretroviral medicines, radiopharmaceuticals, International Pharmacopoeia"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a988d4f5-6f7a-41a6-9ed9-51953e1207f0", "node_type": "4", "metadata": {"page_label": "81", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- WHO good manufacturing practices for sterile pharmaceutical products (Annex 4)\n- WHO good distribution practices for pharmaceutical products (Annex 5)\n- Guidelines on the requalification of prequalified dossiers (Annex 6)\n- Guidelines for the preparation of a contract research organization master file (Annex 7)\n\n**For inclusion in The International Pharmacopoeia**\n\nThe following monographs were adopted:\n\n- **For antiretroviral medicines**\n  - Lopinavir\n  - Tenofovir disoproxil fumarate\n  - Indinavir capsules\n  - Saquinavir tablets\n  - Tenofovir tablets\n  - Lopinavir and ritonavir tablets\n  - Efavirenz\n\n- **For antimalarial medicines**\n  - Amodiaquine tablets\n  - Artesunate\n  - Artesunate tablets\n  - Quinine bisulfate tablets\n  - Quinine sulfate tablets\n\n- **For antituberculosis medicines**\n  - Amikacin\n  - Amikacin sulfate\n  - Amikacin injection\n  - Kanamycin monosulfate\n  - Kanamycin acid sulfate\n  - Kanamycin injection\n\n- **For radiopharmaceuticals**\n  - Iobenguane (\u00b9\u00b3\u00b9I) injection\n  - Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm) injection\n  - Sodium iodide (\u00b9\u00b3\u00b9I) capsules\n  - Sodium iothalamate (\u00b9\u00b2\u2075I) injection\n  - Sodium phosphate (\u00b3\u00b2P) injection\n  - Strontium chloride (\u2078\u2079Sr) injection\n  - Technetium (\u2079\u2079mTc) bicisate complex injection\n  - Technetium (\u2079\u2079mTc) exametazime complex injection\n  - Technetium (\u2079\u2079mTc) mebrofenin complex injection", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "881cacce0e1c3676a68965a6dae7591c36ed7816dba66780b524d34c069d98af", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- WHO good manufacturing practices for sterile pharmaceutical products (Annex 4)\n- WHO good distribution practices for pharmaceutical products (Annex 5)\n- Guidelines on the requalification of prequalified dossiers (Annex 6)\n- Guidelines for the preparation of a contract research organization master file (Annex 7)\n\n**For inclusion in The International Pharmacopoeia**\n\nThe following monographs were adopted:\n\n- **For antiretroviral medicines**\n  - Lopinavir\n  - Tenofovir disoproxil fumarate\n  - Indinavir capsules\n  - Saquinavir tablets\n  - Tenofovir tablets\n  - Lopinavir and ritonavir tablets\n  - Efavirenz\n\n- **For antimalarial medicines**\n  - Amodiaquine tablets\n  - Artesunate\n  - Artesunate tablets\n  - Quinine bisulfate tablets\n  - Quinine sulfate tablets\n\n- **For antituberculosis medicines**\n  - Amikacin\n  - Amikacin sulfate\n  - Amikacin injection\n  - Kanamycin monosulfate\n  - Kanamycin acid sulfate\n  - Kanamycin injection\n\n- **For radiopharmaceuticals**\n  - Iobenguane (\u00b9\u00b3\u00b9I) injection\n  - Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm) injection\n  - Sodium iodide (\u00b9\u00b3\u00b9I) capsules\n  - Sodium iothalamate (\u00b9\u00b2\u2075I) injection\n  - Sodium phosphate (\u00b3\u00b2P) injection\n  - Strontium chloride (\u2078\u2079Sr) injection\n  - Technetium (\u2079\u2079mTc) bicisate complex injection\n  - Technetium (\u2079\u2079mTc) exametazime complex injection\n  - Technetium (\u2079\u2079mTc) mebrofenin complex injection", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1389, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0ce65769-8474-4c59-838c-4a6353e36014": {"__data__": {"id_": "0ce65769-8474-4c59-838c-4a6353e36014", "embedding": null, "metadata": {"page_label": "82", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Technetium (\u2079\u2079\u1d50Tc) mertiatide injection\n- Technetium (\u2079\u2079\u1d50Tc) succimer complex injection\n- Technetium (\u2079\u2079\u1d50Tc) sulfur colloid injection\n- Technetium (\u2079\u2079\u1d50Tc) tetrofosmin complex injection\n- Technetium (\u2079\u2079\u1d50Tc) tin colloidal injection\n- Technetium (\u2079\u2079\u1d50Tc) pyrophosphate tin complex injection\n- Technetium (\u2079\u2079\u1d50Tc) methylene diphosphonate (MDP) complex injection\n- Technetium (\u2079\u2079\u1d50Tc) sestamibi complex injection\n- Yttrium silicate (\u2079\u2070Y) colloid injection\n\n- **Other medicines**\n  - Mebendazole\n  - Oseltamivir phosphate\n  - Oxytocin\n  - Oxytocin injection\n\n- **General monographs for**\n  - Tablets\n  - Capsules\n\n- **General policy topics and general revision issues for**\n  - Monographs title and strengths\n  - Strengths available statement\n  - Identity tests\n  - Polymorphism\n\n### Adoption of new International Chemical Reference Substances\n\n- Carbidopa\n- Colchicine\n- Lumefantrine\n- DL-Methionine\n- Naloxone hydrochloride\n- Oseltamivir phosphate for system suitability\n- Oseltamivir phosphate\n\n**And the following replacements**\n- Artemisinin\n- Prednisone\n\n**The following recommendations were made in the various quality assurance-related areas. Progress on the suggested actions should be reported to the Expert Committee at its next meeting.**\n\nThe underlying principle is that the development of specifications and guidelines will be carried out using the established international consultative process.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento \"WHO - Technical Report Series 957\" presenta una serie de inyecciones de tecn\u00e9cio y otros medicamentos, as\u00ed como monograf\u00edas generales para tabletas y c\u00e1psulas. Tambi\u00e9n se discuten temas de pol\u00edtica general y cuestiones de revisi\u00f3n relacionadas con las monograf\u00edas, como t\u00edtulos, fortalezas, pruebas de identidad y polimorfismo. Adem\u00e1s, se mencionan nuevas sustancias qu\u00edmicas de referencia internacional adoptadas, junto con recomendaciones en \u00e1reas de aseguramiento de calidad que deben ser reportadas en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que se deben considerar al desarrollar especificaciones y directrices para las nuevas sustancias qu\u00edmicas de referencia internacional mencionadas en el informe?**\n   - Esta pregunta busca detalles sobre el proceso de desarrollo de especificaciones que no se encuentran expl\u00edcitamente en el documento.\n\n2. **\u00bfQu\u00e9 criterios se utilizan para determinar la inclusi\u00f3n de medicamentos como el oseltamivir fosfato y el mebendazol en el contexto de la calidad y la seguridad de los medicamentos?**\n   - Esta pregunta se centra en los criterios de selecci\u00f3n y evaluaci\u00f3n de medicamentos, que no se abordan directamente en el texto.\n\n3. **\u00bfQu\u00e9 acciones espec\u00edficas se han sugerido en relaci\u00f3n con los temas de calidad y c\u00f3mo se espera que se informe sobre el progreso en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos?**\n   - Esta pregunta busca informaci\u00f3n sobre las acciones recomendadas y el mecanismo de seguimiento, que no se detalla en el contexto proporcionado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 957\" aborda varios aspectos importantes relacionados con las buenas pr\u00e1cticas en la industria farmac\u00e9utica y la inclusi\u00f3n de medicamentos en la Farmacopea Internacional. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n y Distribuci\u00f3n**:\n   - Directrices sobre buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles.\n   - Directrices sobre buenas pr\u00e1cticas de distribuci\u00f3n para productos farmac\u00e9uticos.\n\n2. **Revalidaci\u00f3n de Dossiers**:\n   - Pautas para la revalidaci\u00f3n de expedientes precalificados.\n\n3. **Archivos Maestros de Organizaciones de Investigaci\u00f3n**:\n   - Directrices para la preparaci\u00f3n de archivos maestros de organizaciones de investigaci\u00f3n por contrato.\n\n4. **Monograf\u00edas para la Farmacopea Internacional**:\n   - Inclusi\u00f3n de monograf\u00edas de medicamentos antirretrovirales, antimal\u00e1ricos, antituberculosos y radiotrazadores.\n\n#### Entidades Mencionadas:\n- **Medicamentos Antirretrovirales**:\n  - Lopinavir\n  - Tenofovir disoproxil fumarate\n  - Indinavir (c\u00e1psulas)\n  - Saquinavir (tabletas)\n  - Tenofovir (tabletas)\n  - Lopinavir y ritonavir (tabletas)\n  - Efavirenz\n\n- **Medicamentos Antimal\u00e1ricos**:\n  - Amodiaquine (tabletas)\n  - Artesunate\n  - Artesunate (tabletas)\n  - Quinine bisulfate (tabletas)\n  - Quinine sulfate (tabletas)\n\n- **Medicamentos Antituberculosos**:\n  - Amikacin\n  - Amikacin sulfate\n  - Amikacin (inyecci\u00f3n)\n  - Kanamycin monosulfate\n  - Kanamycin acid sulfate\n  - Kanamycin (inyecci\u00f3n)\n\n- **Radiotrazadores**:\n  - Iobenguane (\u00b9\u00b3\u00b9I) (inyecci\u00f3n)\n  - Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm) (inyecci\u00f3n)\n  - Sodium iodide (\u00b9\u00b3\u00b9I) (c\u00e1psulas)\n  - Sodium iothalamate (\u00b9\u00b2\u2075I) (inyecci\u00f3n)\n  - Sodium phosphate (\u00b3\u00b2P) (inyecci\u00f3n)\n  - Strontium chloride (\u2078\u2079Sr) (inyecci\u00f3n)\n  - Technetium (\u2079\u2079mTc) bicisate complex (inyecci\u00f3n)\n  - Technetium (\u2079\u2079mTc) exametazime complex (inyecci\u00f3n)\n  - Technetium (\u2079\u2079mTc) mebrofenin complex (inyecci\u00f3n)\n\nEste resumen destaca la importancia de las buenas pr\u00e1cticas en la fabricaci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos, as\u00ed como la inclusi\u00f3n de medicamentos esenciales en la Farmacopea Internacional, lo que es crucial para la salud p\u00fablica y el acceso a tratamientos efectivos.", "excerpt_keywords": "Keywords: Technetium, International Chemical Reference Substances, quality assurance, pharmaceuticals, monographs"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1f9ee5a4-96f4-47b9-8f42-93b896a4be2c", "node_type": "4", "metadata": {"page_label": "82", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Technetium (\u2079\u2079\u1d50Tc) mertiatide injection\n- Technetium (\u2079\u2079\u1d50Tc) succimer complex injection\n- Technetium (\u2079\u2079\u1d50Tc) sulfur colloid injection\n- Technetium (\u2079\u2079\u1d50Tc) tetrofosmin complex injection\n- Technetium (\u2079\u2079\u1d50Tc) tin colloidal injection\n- Technetium (\u2079\u2079\u1d50Tc) pyrophosphate tin complex injection\n- Technetium (\u2079\u2079\u1d50Tc) methylene diphosphonate (MDP) complex injection\n- Technetium (\u2079\u2079\u1d50Tc) sestamibi complex injection\n- Yttrium silicate (\u2079\u2070Y) colloid injection\n\n- **Other medicines**\n  - Mebendazole\n  - Oseltamivir phosphate\n  - Oxytocin\n  - Oxytocin injection\n\n- **General monographs for**\n  - Tablets\n  - Capsules\n\n- **General policy topics and general revision issues for**\n  - Monographs title and strengths\n  - Strengths available statement\n  - Identity tests\n  - Polymorphism\n\n### Adoption of new International Chemical Reference Substances\n\n- Carbidopa\n- Colchicine\n- Lumefantrine\n- DL-Methionine\n- Naloxone hydrochloride\n- Oseltamivir phosphate for system suitability\n- Oseltamivir phosphate\n\n**And the following replacements**\n- Artemisinin\n- Prednisone\n\n**The following recommendations were made in the various quality assurance-related areas. Progress on the suggested actions should be reported to the Expert Committee at its next meeting.**\n\nThe underlying principle is that the development of specifications and guidelines will be carried out using the established international consultative process.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "319e6e807c62d20e6ecb96912abf94f4d7d03283c5cbe374e16fba1f9c771367", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- Technetium (\u2079\u2079\u1d50Tc) mertiatide injection\n- Technetium (\u2079\u2079\u1d50Tc) succimer complex injection\n- Technetium (\u2079\u2079\u1d50Tc) sulfur colloid injection\n- Technetium (\u2079\u2079\u1d50Tc) tetrofosmin complex injection\n- Technetium (\u2079\u2079\u1d50Tc) tin colloidal injection\n- Technetium (\u2079\u2079\u1d50Tc) pyrophosphate tin complex injection\n- Technetium (\u2079\u2079\u1d50Tc) methylene diphosphonate (MDP) complex injection\n- Technetium (\u2079\u2079\u1d50Tc) sestamibi complex injection\n- Yttrium silicate (\u2079\u2070Y) colloid injection\n\n- **Other medicines**\n  - Mebendazole\n  - Oseltamivir phosphate\n  - Oxytocin\n  - Oxytocin injection\n\n- **General monographs for**\n  - Tablets\n  - Capsules\n\n- **General policy topics and general revision issues for**\n  - Monographs title and strengths\n  - Strengths available statement\n  - Identity tests\n  - Polymorphism\n\n### Adoption of new International Chemical Reference Substances\n\n- Carbidopa\n- Colchicine\n- Lumefantrine\n- DL-Methionine\n- Naloxone hydrochloride\n- Oseltamivir phosphate for system suitability\n- Oseltamivir phosphate\n\n**And the following replacements**\n- Artemisinin\n- Prednisone\n\n**The following recommendations were made in the various quality assurance-related areas. Progress on the suggested actions should be reported to the Expert Committee at its next meeting.**\n\nThe underlying principle is that the development of specifications and guidelines will be carried out using the established international consultative process.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1404, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "acbbec95-3a73-45b0-975c-4fff3247b133": {"__data__": {"id_": "acbbec95-3a73-45b0-975c-4fff3247b133", "embedding": null, "metadata": {"page_label": "83", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# The International Pharmacopoeia\n\n- Continue development of specifications for medicines in accordance with the work plan revised and adopted at this meeting.\n- Continue the efforts of international collaboration in relation to the revision and inclusion of general methods and new monographs for excipients.\n- Continue the preparatory work on the supplements to *The International Pharmacopoeia*, 4th edition and towards the 5th edition, especially in electronic form (CD-ROM and online).\n\n# International Chemical Reference Substances (ICRS)\n\n- Continue promoting the use of ICRS through various activities, including a promotional offer to national authorities and improvements of the ICRS web site.\n\n# External Quality Assurance Assessment Scheme\n\n- Continue the External Quality Assurance Assessment Scheme (EQAAS) for pharmaceutical quality control laboratories with a new phase 5.\n\n# Good practices for pharmaceutical microbiology laboratories\n\n- Continue the consultation process through preparation of a new text on good practices for pharmaceutical microbiology laboratories.\n\n# Good manufacturing practices (GMP) and manufacture\n\n- Follow up on the revision process for GMP for biologicals currently being undertaken under the aegis of the Expert Committee on Biological Standardization.\n- Follow up on development of the WHO guidelines on GMP for blood establishments currently being undertaken under the aegis of the Expert Committee on Biological Standardization and ensure that these new guidelines also be sent for comment to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations.\n- Initiate the consultation process for a revision of the main principles of GMP, considering inclusion of the quality unit concept, quality risk management and product quality review.\n- Initiate a revision process as identified for some paragraphs of the GMP for heating, ventilation and air-conditioning (HVAC).\n- Review and initiate an update of the WHO guidelines on Hazard Analysis and Critical Control Points (HACCP) to cover new trends in quality risk management.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que aborda varios temas relacionados con la farmacopoeia internacional, la promoci\u00f3n de sustancias qu\u00edmicas de referencia, la evaluaci\u00f3n de la calidad externa en laboratorios de control de calidad farmac\u00e9utica, buenas pr\u00e1cticas en microbiolog\u00eda farmac\u00e9utica y buenas pr\u00e1cticas de manufactura (GMP). Se mencionan esfuerzos continuos para desarrollar especificaciones para medicamentos, colaborar internacionalmente en la revisi\u00f3n de m\u00e9todos y monograf\u00edas, y actualizar directrices sobre GMP y HACCP.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos se est\u00e1n tomando para la inclusi\u00f3n de nuevos excipientes en la farmacopoeia internacional?**\n   - La OMS est\u00e1 trabajando en la colaboraci\u00f3n internacional para la revisi\u00f3n e inclusi\u00f3n de m\u00e9todos generales y nuevas monograf\u00edas para excipientes, lo que implica un proceso continuo de desarrollo y revisi\u00f3n.\n\n2. **\u00bfCu\u00e1les son las novedades en la evaluaci\u00f3n de la calidad externa para laboratorios farmac\u00e9uticos?**\n   - Se est\u00e1 implementando una nueva fase (fase 5) del Esquema de Evaluaci\u00f3n de Calidad Externa (EQAAS) para laboratorios de control de calidad farmac\u00e9utica, lo que sugiere un enfoque renovado en la evaluaci\u00f3n de la calidad.\n\n3. **\u00bfQu\u00e9 cambios se est\u00e1n considerando en las directrices de Buenas Pr\u00e1cticas de Manufactura (GMP) para incluir conceptos modernos?**\n   - Se est\u00e1 iniciando un proceso de consulta para revisar los principios principales de GMP, considerando la inclusi\u00f3n del concepto de unidad de calidad, gesti\u00f3n de riesgos de calidad y revisi\u00f3n de la calidad del producto, as\u00ed como la actualizaci\u00f3n de las directrices sobre HACCP para reflejar nuevas tendencias en la gesti\u00f3n de riesgos de calidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Inyecciones de Tecn\u00e9cio**: Se enumeran varias inyecciones que utilizan tecn\u00e9cio (\u2079\u2079\u1d50Tc), incluyendo:\n   - Mertiatide\n   - Succimer complex\n   - Sulfur colloid\n   - Tetrofosmin complex\n   - Tin colloidal\n   - Pyrophosphate tin complex\n   - Methylene diphosphonate (MDP) complex\n   - Sestamibi complex\n   - Yttrium silicate (\u2079\u2070Y) colloid\n\n2. **Otros Medicamentos**: Se mencionan medicamentos adicionales como:\n   - Mebendazole\n   - Oseltamivir phosphate\n   - Oxytocin y su forma inyectable\n\n3. **Monograf\u00edas Generales**: Se abordan las monograf\u00edas generales para:\n   - Tabletas\n   - C\u00e1psulas\n\n4. **Temas de Pol\u00edtica General y Revisi\u00f3n**: Se discuten cuestiones relacionadas con:\n   - T\u00edtulos y fortalezas de las monograf\u00edas\n   - Declaraciones sobre fortalezas disponibles\n   - Pruebas de identidad\n   - Polimorfismo\n\n5. **Adopci\u00f3n de Nuevas Sustancias Qu\u00edmicas de Referencia Internacional**: Se listan nuevas sustancias adoptadas, incluyendo:\n   - Carbidopa\n   - Colchicina\n   - Lumefantrina\n   - DL-Metionina\n   - Naloxona hidrocloruro\n   - Oseltamivir fosfato (para idoneidad del sistema)\n\n6. **Reemplazos**: Se mencionan los reemplazos de:\n   - Artemisinina\n   - Prednisona\n\n7. **Recomendaciones en Aseguramiento de Calidad**: Se indican recomendaciones en \u00e1reas de calidad, con un llamado a reportar el progreso en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos. Se enfatiza que el desarrollo de especificaciones y directrices se llevar\u00e1 a cabo mediante un proceso consultivo internacional establecido. \n\nEste resumen abarca los temas clave y las entidades mencionadas en la secci\u00f3n del documento \"WHO - Technical Report Series 957\".", "excerpt_keywords": "Keywords: pharmacopoeia, quality assurance, good manufacturing practices, international collaboration, chemical reference substances"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c7610a0f-4a22-4376-b9d6-09d2dc19ee94", "node_type": "4", "metadata": {"page_label": "83", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# The International Pharmacopoeia\n\n- Continue development of specifications for medicines in accordance with the work plan revised and adopted at this meeting.\n- Continue the efforts of international collaboration in relation to the revision and inclusion of general methods and new monographs for excipients.\n- Continue the preparatory work on the supplements to *The International Pharmacopoeia*, 4th edition and towards the 5th edition, especially in electronic form (CD-ROM and online).\n\n# International Chemical Reference Substances (ICRS)\n\n- Continue promoting the use of ICRS through various activities, including a promotional offer to national authorities and improvements of the ICRS web site.\n\n# External Quality Assurance Assessment Scheme\n\n- Continue the External Quality Assurance Assessment Scheme (EQAAS) for pharmaceutical quality control laboratories with a new phase 5.\n\n# Good practices for pharmaceutical microbiology laboratories\n\n- Continue the consultation process through preparation of a new text on good practices for pharmaceutical microbiology laboratories.\n\n# Good manufacturing practices (GMP) and manufacture\n\n- Follow up on the revision process for GMP for biologicals currently being undertaken under the aegis of the Expert Committee on Biological Standardization.\n- Follow up on development of the WHO guidelines on GMP for blood establishments currently being undertaken under the aegis of the Expert Committee on Biological Standardization and ensure that these new guidelines also be sent for comment to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations.\n- Initiate the consultation process for a revision of the main principles of GMP, considering inclusion of the quality unit concept, quality risk management and product quality review.\n- Initiate a revision process as identified for some paragraphs of the GMP for heating, ventilation and air-conditioning (HVAC).\n- Review and initiate an update of the WHO guidelines on Hazard Analysis and Critical Control Points (HACCP) to cover new trends in quality risk management.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "54e8cb2a2084e7715fd8611e25d79a6f46313aadc42942d32e5426846f1f808f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# The International Pharmacopoeia\n\n- Continue development of specifications for medicines in accordance with the work plan revised and adopted at this meeting.\n- Continue the efforts of international collaboration in relation to the revision and inclusion of general methods and new monographs for excipients.\n- Continue the preparatory work on the supplements to *The International Pharmacopoeia*, 4th edition and towards the 5th edition, especially in electronic form (CD-ROM and online).\n\n# International Chemical Reference Substances (ICRS)\n\n- Continue promoting the use of ICRS through various activities, including a promotional offer to national authorities and improvements of the ICRS web site.\n\n# External Quality Assurance Assessment Scheme\n\n- Continue the External Quality Assurance Assessment Scheme (EQAAS) for pharmaceutical quality control laboratories with a new phase 5.\n\n# Good practices for pharmaceutical microbiology laboratories\n\n- Continue the consultation process through preparation of a new text on good practices for pharmaceutical microbiology laboratories.\n\n# Good manufacturing practices (GMP) and manufacture\n\n- Follow up on the revision process for GMP for biologicals currently being undertaken under the aegis of the Expert Committee on Biological Standardization.\n- Follow up on development of the WHO guidelines on GMP for blood establishments currently being undertaken under the aegis of the Expert Committee on Biological Standardization and ensure that these new guidelines also be sent for comment to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations.\n- Initiate the consultation process for a revision of the main principles of GMP, considering inclusion of the quality unit concept, quality risk management and product quality review.\n- Initiate a revision process as identified for some paragraphs of the GMP for heating, ventilation and air-conditioning (HVAC).\n- Review and initiate an update of the WHO guidelines on Hazard Analysis and Critical Control Points (HACCP) to cover new trends in quality risk management.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2111, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "44b236d2-fc11-49c1-bc2d-93283623436f": {"__data__": {"id_": "44b236d2-fc11-49c1-bc2d-93283623436f", "embedding": null, "metadata": {"page_label": "84", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Transfer of technology\n\n- Continue the development of the **WHO guidelines on transfer of technology**, giving special consideration to keeping the balance between GMP and business criteria, including the concept of quality by design and the possibility of optional requirements depending on the type of transfer.\n\n# WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce\n\n- Continue the steps to be taken regarding the **WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce** in consultation with WHO Member States and the WHO Legal Counsel.\n- Post the revised \u201cQuestions and Answers\u201d on the functioning of the Scheme on the revised document on the WHO website and include it in **WHO Drug Information**, with the possibility of receiving comments and reviewing any question(s) that might raise major concerns.\n\n# Good distribution practices (GDP) for pharmaceutical products\n\nFollow up on development of the WHO guidelines on regulatory oversight on pharmaceutical cold chain management. Harmonized guidance for the storage and transport of temperature-sensitive pharmaceutical products is currently being developed under the aegis of the Expert Committee on Biological Standardization. Ensure that these new guidelines are also sent for comment to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and to the IMPACT working group that developed the revision of the GDP.\n\n# Regulatory guidance\n\n- Continue the consultation process and advancement of the **Development of paediatric medicines: pharmaceutical development. Points to consider**.\n- Continue the development of the **Pharmaceutical development for multisource (generic) pharmaceutical products**.\n- Continue updating the long-term stability testing requirements for marketing authorization in WHO Member States as received from authorities.\n- Follow up on the recurring incidents of DEG poisoning, prepare a proposal for a general alert to the NMRAs, including recommendations to prevent such events in the future.\n\n# Quality assurance terminology\n\n- Make the updated database on quality assurance terminology widely available.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda varios aspectos clave relacionados con la regulaci\u00f3n y la calidad de los productos farmac\u00e9uticos. Se enfoca en el desarrollo de directrices sobre la transferencia de tecnolog\u00eda, la certificaci\u00f3n de productos farmac\u00e9uticos en el comercio internacional, las buenas pr\u00e1cticas de distribuci\u00f3n, la regulaci\u00f3n de medicamentos pedi\u00e1tricos y gen\u00e9ricos, y la terminolog\u00eda de aseguramiento de calidad. Adem\u00e1s, se menciona la importancia de la gesti\u00f3n de la cadena de fr\u00edo para productos farmac\u00e9uticos sensibles a la temperatura y la necesidad de alertar sobre incidentes de intoxicaci\u00f3n por DEG.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que se est\u00e1n considerando para equilibrar las Buenas Pr\u00e1cticas de Manufactura (GMP) y los criterios comerciales en las directrices de transferencia de tecnolog\u00eda de la OMS?**\n   - Esta pregunta busca detalles sobre c\u00f3mo la OMS planea abordar la interacci\u00f3n entre la calidad y los aspectos comerciales en la transferencia de tecnolog\u00eda, lo cual no se detalla expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 medidas se est\u00e1n proponiendo para prevenir futuros incidentes de intoxicaci\u00f3n por DEG, y c\u00f3mo se planea comunicar estas recomendaciones a las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs)?**\n   - Esta pregunta se centra en las acciones espec\u00edficas que se tomar\u00e1n para abordar un problema recurrente de salud p\u00fablica, lo que podr\u00eda no estar disponible en otras fuentes.\n\n3. **\u00bfC\u00f3mo se planea integrar los comentarios de los grupos de expertos en las nuevas directrices sobre la gesti\u00f3n de la cadena de fr\u00edo para productos farmac\u00e9uticos?**\n   - Esta pregunta busca informaci\u00f3n sobre el proceso de consulta y revisi\u00f3n que se llevar\u00e1 a cabo para asegurar que las nuevas directrices sean efectivas y est\u00e9n alineadas con las mejores pr\u00e1cticas, un aspecto que puede no estar claramente delineado en el documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Farmacopea Internacional**:\n   - Desarrollo continuo de especificaciones para medicamentos.\n   - Colaboraci\u00f3n internacional para la revisi\u00f3n e inclusi\u00f3n de m\u00e9todos generales y nuevas monograf\u00edas para excipientes.\n   - Preparaci\u00f3n de suplementos para la 4\u00aa y 5\u00aa edici\u00f3n de *The International Pharmacopoeia*, con \u00e9nfasis en formatos electr\u00f3nicos.\n\n2. **Sustancias Qu\u00edmicas de Referencia Internacional (ICRS)**:\n   - Promoci\u00f3n del uso de ICRS mediante actividades diversas y mejoras en el sitio web de ICRS.\n\n3. **Esquema de Evaluaci\u00f3n de Calidad Externa (EQAAS)**:\n   - Implementaci\u00f3n de la fase 5 del EQAAS para laboratorios de control de calidad farmac\u00e9utica.\n\n4. **Buenas Pr\u00e1cticas en Microbiolog\u00eda Farmac\u00e9utica**:\n   - Proceso de consulta para la elaboraci\u00f3n de un nuevo texto sobre buenas pr\u00e1cticas en microbiolog\u00eda farmac\u00e9utica.\n\n5. **Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Revisi\u00f3n de GMP para biol\u00f3gicos y desarrollo de directrices para establecimientos de sangre.\n   - Consulta para revisar principios de GMP, incluyendo conceptos modernos como unidad de calidad y gesti\u00f3n de riesgos de calidad.\n   - Revisi\u00f3n de directrices sobre An\u00e1lisis de Peligros y Puntos Cr\u00edticos de Control (HACCP) para reflejar nuevas tendencias en gesti\u00f3n de riesgos de calidad.\n\n### Entidades Involucradas\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Principal entidad responsable de la elaboraci\u00f3n y revisi\u00f3n de directrices y est\u00e1ndares.\n- **Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica**: Encargado de la revisi\u00f3n de GMP para biol\u00f3gicos y directrices para establecimientos de sangre.\n- **Panel Asesor de Expertos de la OMS sobre la Farmacopea Internacional y Preparaciones Farmac\u00e9uticas**: Involucrado en la revisi\u00f3n de nuevas directrices de GMP.", "excerpt_keywords": "Keywords: transfer of technology, WHO certification, good distribution practices, regulatory guidance, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "607041ac-a745-4098-84af-b08c32ab0886", "node_type": "4", "metadata": {"page_label": "84", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Transfer of technology\n\n- Continue the development of the **WHO guidelines on transfer of technology**, giving special consideration to keeping the balance between GMP and business criteria, including the concept of quality by design and the possibility of optional requirements depending on the type of transfer.\n\n# WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce\n\n- Continue the steps to be taken regarding the **WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce** in consultation with WHO Member States and the WHO Legal Counsel.\n- Post the revised \u201cQuestions and Answers\u201d on the functioning of the Scheme on the revised document on the WHO website and include it in **WHO Drug Information**, with the possibility of receiving comments and reviewing any question(s) that might raise major concerns.\n\n# Good distribution practices (GDP) for pharmaceutical products\n\nFollow up on development of the WHO guidelines on regulatory oversight on pharmaceutical cold chain management. Harmonized guidance for the storage and transport of temperature-sensitive pharmaceutical products is currently being developed under the aegis of the Expert Committee on Biological Standardization. Ensure that these new guidelines are also sent for comment to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and to the IMPACT working group that developed the revision of the GDP.\n\n# Regulatory guidance\n\n- Continue the consultation process and advancement of the **Development of paediatric medicines: pharmaceutical development. Points to consider**.\n- Continue the development of the **Pharmaceutical development for multisource (generic) pharmaceutical products**.\n- Continue updating the long-term stability testing requirements for marketing authorization in WHO Member States as received from authorities.\n- Follow up on the recurring incidents of DEG poisoning, prepare a proposal for a general alert to the NMRAs, including recommendations to prevent such events in the future.\n\n# Quality assurance terminology\n\n- Make the updated database on quality assurance terminology widely available.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "c5aa6a69b047be058d78f8a1e7b0becb17d03a1ed8edf68bb348a4042ab3d186", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Transfer of technology\n\n- Continue the development of the **WHO guidelines on transfer of technology**, giving special consideration to keeping the balance between GMP and business criteria, including the concept of quality by design and the possibility of optional requirements depending on the type of transfer.\n\n# WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce\n\n- Continue the steps to be taken regarding the **WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce** in consultation with WHO Member States and the WHO Legal Counsel.\n- Post the revised \u201cQuestions and Answers\u201d on the functioning of the Scheme on the revised document on the WHO website and include it in **WHO Drug Information**, with the possibility of receiving comments and reviewing any question(s) that might raise major concerns.\n\n# Good distribution practices (GDP) for pharmaceutical products\n\nFollow up on development of the WHO guidelines on regulatory oversight on pharmaceutical cold chain management. Harmonized guidance for the storage and transport of temperature-sensitive pharmaceutical products is currently being developed under the aegis of the Expert Committee on Biological Standardization. Ensure that these new guidelines are also sent for comment to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and to the IMPACT working group that developed the revision of the GDP.\n\n# Regulatory guidance\n\n- Continue the consultation process and advancement of the **Development of paediatric medicines: pharmaceutical development. Points to consider**.\n- Continue the development of the **Pharmaceutical development for multisource (generic) pharmaceutical products**.\n- Continue updating the long-term stability testing requirements for marketing authorization in WHO Member States as received from authorities.\n- Follow up on the recurring incidents of DEG poisoning, prepare a proposal for a general alert to the NMRAs, including recommendations to prevent such events in the future.\n\n# Quality assurance terminology\n\n- Make the updated database on quality assurance terminology widely available.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2232, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "191a016c-49ee-494a-a0dc-4c7c29cd2615": {"__data__": {"id_": "191a016c-49ee-494a-a0dc-4c7c29cd2615", "embedding": null, "metadata": {"page_label": "85", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Provide feedback from the Circular Letter mailed to all Member States regarding the terminology used within the national legislation for \u201ccounterfeit medicines\u201d or equivalent terms used, with a view to further discussion of the outcome during the next meeting of the Expert Committee and possibly during the ICDRA.\n- Circulate a proposal for a new definition for \u201csubstandard medicines\u201d as discussed during the meeting.\n\n### Pharmacopoeia references\n\n- Post an update of the references and contact details for national, regional and international pharmacopoeias on the Medicines Quality Assurance web site.\n\n### WHO databases\n\n- Maintain the consolidated database on nomenclature used in WHO quality assurance.\n- Maintain the INN database and continue to make it available on the web site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento se centra en la calidad de los medicamentos y las definiciones relacionadas con t\u00e9rminos como \"medicamentos falsificados\" y \"medicamentos subest\u00e1ndar\". Se menciona la necesidad de recopilar comentarios de los Estados Miembros sobre la terminolog\u00eda utilizada en su legislaci\u00f3n nacional y la propuesta de una nueva definici\u00f3n para \"medicamentos subest\u00e1ndar\". Adem\u00e1s, se destaca la importancia de mantener actualizadas las referencias de las farmacopeas y las bases de datos de la OMS relacionadas con la calidad de los medicamentos.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 pasos se est\u00e1n tomando para abordar la terminolog\u00eda relacionada con los \"medicamentos falsificados\" en la legislaci\u00f3n nacional de los Estados Miembros?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el proceso de recopilaci\u00f3n de comentarios y la discusi\u00f3n futura en la reuni\u00f3n del Comit\u00e9 de Expertos.\n\n2. **\u00bfCu\u00e1l es la propuesta para la nueva definici\u00f3n de \"medicamentos subest\u00e1ndar\" y c\u00f3mo se espera que impacte en la regulaci\u00f3n de medicamentos?**\n   - Aqu\u00ed se busca una respuesta que detalle la propuesta discutida y su posible efecto en la calidad y regulaci\u00f3n de los medicamentos.\n\n3. **\u00bfQu\u00e9 tipo de informaci\u00f3n se actualizar\u00e1 en el sitio web de Aseguramiento de la Calidad de Medicamentos de la OMS en relaci\u00f3n con las farmacopeas?**\n   - Esta pregunta se centra en los detalles espec\u00edficos sobre las actualizaciones que se realizar\u00e1n en las referencias y contactos de las farmacopeas nacionales, regionales e internacionales.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Transferencia de Tecnolog\u00eda**:\n   - Desarrollo de directrices de la OMS sobre la transferencia de tecnolog\u00eda, considerando el equilibrio entre las Buenas Pr\u00e1cticas de Manufactura (GMP) y criterios comerciales, as\u00ed como la calidad por dise\u00f1o.\n\n2. **Esquema de Certificaci\u00f3n de la OMS**:\n   - Continuaci\u00f3n de los pasos para el Esquema de Certificaci\u00f3n de la OMS sobre la calidad de productos farmac\u00e9uticos en el comercio internacional, en consulta con los Estados Miembros y el Asesor Legal de la OMS. Publicaci\u00f3n de preguntas y respuestas revisadas en el sitio web de la OMS.\n\n3. **Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP)**:\n   - Desarrollo de directrices sobre la gesti\u00f3n de la cadena de fr\u00edo para productos farmac\u00e9uticos sensibles a la temperatura, con la participaci\u00f3n de grupos de expertos para asegurar la armonizaci\u00f3n.\n\n4. **Orientaci\u00f3n Regulatoria**:\n   - Avance en el desarrollo de medicamentos pedi\u00e1tricos y productos farmac\u00e9uticos multisource (gen\u00e9ricos). Actualizaci\u00f3n de requisitos de pruebas de estabilidad a largo plazo y seguimiento de incidentes de intoxicaci\u00f3n por DEG, con propuestas para alertar a las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs).\n\n5. **Terminolog\u00eda de Aseguramiento de Calidad**:\n   - Disponibilidad amplia de una base de datos actualizada sobre terminolog\u00eda de aseguramiento de calidad.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Principal entidad responsable del desarrollo de directrices y esquemas de certificaci\u00f3n.\n- **Estados Miembros de la OMS**: Participantes en la consulta sobre el esquema de certificaci\u00f3n y otras directrices.\n- **Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica**: Encargado del desarrollo de directrices sobre la gesti\u00f3n de la cadena de fr\u00edo.\n- **Panel Asesor de la OMS sobre la Farmacopea Internacional y Preparaciones Farmac\u00e9uticas**: Grupo consultivo para las nuevas directrices.\n- **NMRAs (Autoridades Nacionales Reguladoras de Medicamentos)**: Entidades que recibir\u00e1n alertas y recomendaciones sobre incidentes de salud p\u00fablica.", "excerpt_keywords": "Keywords: counterfeit medicines, substandard medicines, pharmacopoeia references, WHO quality assurance, INN database"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4904060c-eefe-4778-9e80-ef53f8db46fe", "node_type": "4", "metadata": {"page_label": "85", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Provide feedback from the Circular Letter mailed to all Member States regarding the terminology used within the national legislation for \u201ccounterfeit medicines\u201d or equivalent terms used, with a view to further discussion of the outcome during the next meeting of the Expert Committee and possibly during the ICDRA.\n- Circulate a proposal for a new definition for \u201csubstandard medicines\u201d as discussed during the meeting.\n\n### Pharmacopoeia references\n\n- Post an update of the references and contact details for national, regional and international pharmacopoeias on the Medicines Quality Assurance web site.\n\n### WHO databases\n\n- Maintain the consolidated database on nomenclature used in WHO quality assurance.\n- Maintain the INN database and continue to make it available on the web site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "dc0e3980408c864b85563d940b880e0edcc6458dac8f6c3d72dfda58e34bb4a3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- Provide feedback from the Circular Letter mailed to all Member States regarding the terminology used within the national legislation for \u201ccounterfeit medicines\u201d or equivalent terms used, with a view to further discussion of the outcome during the next meeting of the Expert Committee and possibly during the ICDRA.\n- Circulate a proposal for a new definition for \u201csubstandard medicines\u201d as discussed during the meeting.\n\n### Pharmacopoeia references\n\n- Post an update of the references and contact details for national, regional and international pharmacopoeias on the Medicines Quality Assurance web site.\n\n### WHO databases\n\n- Maintain the consolidated database on nomenclature used in WHO quality assurance.\n- Maintain the INN database and continue to make it available on the web site.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 791, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "95698f63-1c3b-45ac-83a8-3787d15ec5c4": {"__data__": {"id_": "95698f63-1c3b-45ac-83a8-3787d15ec5c4", "embedding": null, "metadata": {"page_label": "86", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Acknowledgements\n\nSpecial acknowledgement was made by the Committee to Mrs W. Bonny, Ms M. Gaspard, Dr S. Kopp, Ms C. Mendy and to Dr L. R\u00e4go, Quality Assurance and Safety: Medicines, Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland, who were instrumental in the preparation and proceedings of the meeting.\n\nTechnical guidance included in this report has been produced with the financial assistance of the European Community, the Bill & Melinda Gates Foundation and UNITAID.\n\nThe Committee also acknowledged with thanks the valuable contributions made to its work by the following agencies, institutions, organizations, WHO Collaborating Centres, WHO programmes and persons:\n\nActive Pharmaceutical Ingredients Committee, European Chemical Industry Council, Brussels, Belgium; Danish Medicines Agency, Copenhagen, Denmark; European Association of Pharmaceutical Full-line Wholesalers, Groupement International de la R\u00e9partition Pharmaceutique, Brussels, Belgium; European Commission, Brussels, Belgium; European Directorate for the Quality of Medicines and HealthCare, Council of Europe, Strasbourg, France; European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; European Medicines Agency, London, England; Global Fund to Fight AIDS, Tuberculosis and Malaria, Vernier, Switzerland; Healthcare Distribution Management Association, Arlington, VA, USA; International Atomic Energy Agency, Vienna, Austria; Indian Drug Manufacturers' Association, Worli, Mumbai, India; International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland; International Generic Pharmaceutical Alliance, Brussels, Belgium; International Pharmaceutical Excipients Council, Strasbourg, France; International Pharmaceutical Federation, The Hague, Netherlands; International Society for Pharmaceutical Engineering, Tampa, FL, USA; Pharmaceutical Research and Manufacturers of America, Washington, DC, USA; Swissmedic, Swiss Agency for Therapeutic Products, Berne, Switzerland; Therapeutic Goods Administration, Woden, ACT, Australia; United Nations Children's Fund, New York, NY, USA; Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland; United Nations Development Programme, New York, NY, USA; World Bank, Washington, DC, USA; World Intellectual Property Organization, Geneva, Switzerland; World Self-Medication Industry, Ferney-Voltaire, France.\n\nLaboratoire National de Contr\u00f4le des Produits Pharmaceutiques, Ch\u00e9raga, Algeria; Instituto Nacional de Medicamentos, Buenos Aires, Argentina; Expert Analytic Laboratory, Centre of Drug and Medical Technology Expertise, Yerevan, Armenia; Institute for Quality Control of Medicines, Sarajevo, Bosnia and Herzegovina; Instituto Nacional de Controle de Qualidade em Sa\u00fade, Rio de Janeiro, Brazil; Laboratoire National de Sant\u00e9 Publique, Ouagadougou, Burkina Faso; National Laboratory for Drug Quality Control, Ministry of Health, Phnom Penh, Cambodia; Departamento de Control Nacional, Unidad de control de calidad de productos farmac\u00e9uticos del mercado nacional (Control de Estanter\u00eda), Instituto de Salud P\u00fablica, Santiago de Chile, Chile; Laboratorio de An\u00e1lisis y Asesor\u00eda Farmac\u00e9utica,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que incluye un apartado de agradecimientos. En este apartado, se reconoce la contribuci\u00f3n de diversas personas y organizaciones que participaron en la preparaci\u00f3n y desarrollo de la reuni\u00f3n. Se menciona el apoyo financiero de la Comunidad Europea, la Fundaci\u00f3n Bill & Melinda Gates y UNITAID. Adem\u00e1s, se enumeran numerosas agencias, instituciones y organizaciones que colaboraron en el trabajo del Comit\u00e9, destacando su importancia en el \u00e1mbito de la calidad y seguridad de los medicamentos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQui\u00e9nes son las personas clave mencionadas en el informe que contribuyeron a la preparaci\u00f3n de la reuni\u00f3n?**\n   - Respuesta: Las personas clave mencionadas son Mrs W. Bonny, Ms M. Gaspard, Dr S. Kopp, Ms C. Mendy y Dr L. R\u00e4go.\n\n2. **\u00bfQu\u00e9 organizaciones proporcionaron asistencia financiera para la elaboraci\u00f3n de la gu\u00eda t\u00e9cnica incluida en el informe?**\n   - Respuesta: La asistencia financiera fue proporcionada por la Comunidad Europea, la Fundaci\u00f3n Bill & Melinda Gates y UNITAID.\n\n3. **\u00bfCu\u00e1les son algunas de las instituciones y agencias que el Comit\u00e9 agradeci\u00f3 por sus contribuciones?**\n   - Respuesta: Algunas de las instituciones y agencias mencionadas son la Agencia Europea de Medicamentos, el Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria, y la Organizaci\u00f3n Mundial de la Propiedad Intelectual, entre otras.\n\n### Resumen de Nivel Superior\n\nEl informe t\u00e9cnico de la OMS destaca la importancia de la colaboraci\u00f3n internacional en la calidad y seguridad de los medicamentos. Reconoce a individuos y organizaciones que han contribuido significativamente a estos esfuerzos, as\u00ed como el apoyo financiero recibido de entidades prominentes. Este reconocimiento subraya la interconexi\u00f3n entre diferentes actores en el \u00e1mbito de la salud p\u00fablica y la farmac\u00e9utica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Terminolog\u00eda de Medicamentos Falsificados**:\n   - Se solicita retroalimentaci\u00f3n de los Estados Miembros sobre la terminolog\u00eda utilizada en su legislaci\u00f3n nacional respecto a \"medicamentos falsificados\" y t\u00e9rminos equivalentes.\n   - Se planea discutir los resultados en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos y posiblemente en el ICDRA (International Conference of Drug Regulatory Authorities).\n\n2. **Definici\u00f3n de Medicamentos Subest\u00e1ndar**:\n   - Se propone una nueva definici\u00f3n para \"medicamentos subest\u00e1ndar\", que ser\u00e1 circulada para su consideraci\u00f3n.\n\n3. **Actualizaci\u00f3n de Referencias de Farmacopeas**:\n   - Se actualizar\u00e1n las referencias y los detalles de contacto de las farmacopeas nacionales, regionales e internacionales en el sitio web de Aseguramiento de la Calidad de Medicamentos de la OMS.\n\n4. **Bases de Datos de la OMS**:\n   - Se mantendr\u00e1 la base de datos consolidada sobre la nomenclatura utilizada en el aseguramiento de la calidad de la OMS.\n   - Se continuar\u00e1 manteniendo la base de datos de Nombres Comunes Internacionales (INN) y se asegurar\u00e1 su disponibilidad en el sitio web.\n\n### Entidades Involucradas\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Responsable de la recopilaci\u00f3n de comentarios, la propuesta de definiciones y la actualizaci\u00f3n de bases de datos.\n- **Estados Miembros**: Participantes en la retroalimentaci\u00f3n sobre la terminolog\u00eda y la regulaci\u00f3n de medicamentos.\n- **Comit\u00e9 de Expertos**: Grupo que discutir\u00e1 los resultados de la retroalimentaci\u00f3n y la nueva definici\u00f3n propuesta.\n- **ICDRA**: Conferencia donde se podr\u00eda discutir la terminolog\u00eda y regulaciones relacionadas con medicamentos.", "excerpt_keywords": "Keywords: acknowledgements, WHO, pharmaceutical policies, quality assurance, international collaboration"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6ea8327a-851f-4736-9285-1009cb9944b8", "node_type": "4", "metadata": {"page_label": "86", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Acknowledgements\n\nSpecial acknowledgement was made by the Committee to Mrs W. Bonny, Ms M. Gaspard, Dr S. Kopp, Ms C. Mendy and to Dr L. R\u00e4go, Quality Assurance and Safety: Medicines, Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland, who were instrumental in the preparation and proceedings of the meeting.\n\nTechnical guidance included in this report has been produced with the financial assistance of the European Community, the Bill & Melinda Gates Foundation and UNITAID.\n\nThe Committee also acknowledged with thanks the valuable contributions made to its work by the following agencies, institutions, organizations, WHO Collaborating Centres, WHO programmes and persons:\n\nActive Pharmaceutical Ingredients Committee, European Chemical Industry Council, Brussels, Belgium; Danish Medicines Agency, Copenhagen, Denmark; European Association of Pharmaceutical Full-line Wholesalers, Groupement International de la R\u00e9partition Pharmaceutique, Brussels, Belgium; European Commission, Brussels, Belgium; European Directorate for the Quality of Medicines and HealthCare, Council of Europe, Strasbourg, France; European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; European Medicines Agency, London, England; Global Fund to Fight AIDS, Tuberculosis and Malaria, Vernier, Switzerland; Healthcare Distribution Management Association, Arlington, VA, USA; International Atomic Energy Agency, Vienna, Austria; Indian Drug Manufacturers' Association, Worli, Mumbai, India; International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland; International Generic Pharmaceutical Alliance, Brussels, Belgium; International Pharmaceutical Excipients Council, Strasbourg, France; International Pharmaceutical Federation, The Hague, Netherlands; International Society for Pharmaceutical Engineering, Tampa, FL, USA; Pharmaceutical Research and Manufacturers of America, Washington, DC, USA; Swissmedic, Swiss Agency for Therapeutic Products, Berne, Switzerland; Therapeutic Goods Administration, Woden, ACT, Australia; United Nations Children's Fund, New York, NY, USA; Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland; United Nations Development Programme, New York, NY, USA; World Bank, Washington, DC, USA; World Intellectual Property Organization, Geneva, Switzerland; World Self-Medication Industry, Ferney-Voltaire, France.\n\nLaboratoire National de Contr\u00f4le des Produits Pharmaceutiques, Ch\u00e9raga, Algeria; Instituto Nacional de Medicamentos, Buenos Aires, Argentina; Expert Analytic Laboratory, Centre of Drug and Medical Technology Expertise, Yerevan, Armenia; Institute for Quality Control of Medicines, Sarajevo, Bosnia and Herzegovina; Instituto Nacional de Controle de Qualidade em Sa\u00fade, Rio de Janeiro, Brazil; Laboratoire National de Sant\u00e9 Publique, Ouagadougou, Burkina Faso; National Laboratory for Drug Quality Control, Ministry of Health, Phnom Penh, Cambodia; Departamento de Control Nacional, Unidad de control de calidad de productos farmac\u00e9uticos del mercado nacional (Control de Estanter\u00eda), Instituto de Salud P\u00fablica, Santiago de Chile, Chile; Laboratorio de An\u00e1lisis y Asesor\u00eda Farmac\u00e9utica,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "4b8a8416a806356fb9c54df65535d8b37492f49cc928ee2ed7538127f973ec58", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Acknowledgements\n\nSpecial acknowledgement was made by the Committee to Mrs W. Bonny, Ms M. Gaspard, Dr S. Kopp, Ms C. Mendy and to Dr L. R\u00e4go, Quality Assurance and Safety: Medicines, Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland, who were instrumental in the preparation and proceedings of the meeting.\n\nTechnical guidance included in this report has been produced with the financial assistance of the European Community, the Bill & Melinda Gates Foundation and UNITAID.\n\nThe Committee also acknowledged with thanks the valuable contributions made to its work by the following agencies, institutions, organizations, WHO Collaborating Centres, WHO programmes and persons:\n\nActive Pharmaceutical Ingredients Committee, European Chemical Industry Council, Brussels, Belgium; Danish Medicines Agency, Copenhagen, Denmark; European Association of Pharmaceutical Full-line Wholesalers, Groupement International de la R\u00e9partition Pharmaceutique, Brussels, Belgium; European Commission, Brussels, Belgium; European Directorate for the Quality of Medicines and HealthCare, Council of Europe, Strasbourg, France; European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; European Medicines Agency, London, England; Global Fund to Fight AIDS, Tuberculosis and Malaria, Vernier, Switzerland; Healthcare Distribution Management Association, Arlington, VA, USA; International Atomic Energy Agency, Vienna, Austria; Indian Drug Manufacturers' Association, Worli, Mumbai, India; International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland; International Generic Pharmaceutical Alliance, Brussels, Belgium; International Pharmaceutical Excipients Council, Strasbourg, France; International Pharmaceutical Federation, The Hague, Netherlands; International Society for Pharmaceutical Engineering, Tampa, FL, USA; Pharmaceutical Research and Manufacturers of America, Washington, DC, USA; Swissmedic, Swiss Agency for Therapeutic Products, Berne, Switzerland; Therapeutic Goods Administration, Woden, ACT, Australia; United Nations Children's Fund, New York, NY, USA; Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland; United Nations Development Programme, New York, NY, USA; World Bank, Washington, DC, USA; World Intellectual Property Organization, Geneva, Switzerland; World Self-Medication Industry, Ferney-Voltaire, France.\n\nLaboratoire National de Contr\u00f4le des Produits Pharmaceutiques, Ch\u00e9raga, Algeria; Instituto Nacional de Medicamentos, Buenos Aires, Argentina; Expert Analytic Laboratory, Centre of Drug and Medical Technology Expertise, Yerevan, Armenia; Institute for Quality Control of Medicines, Sarajevo, Bosnia and Herzegovina; Instituto Nacional de Controle de Qualidade em Sa\u00fade, Rio de Janeiro, Brazil; Laboratoire National de Sant\u00e9 Publique, Ouagadougou, Burkina Faso; National Laboratory for Drug Quality Control, Ministry of Health, Phnom Penh, Cambodia; Departamento de Control Nacional, Unidad de control de calidad de productos farmac\u00e9uticos del mercado nacional (Control de Estanter\u00eda), Instituto de Salud P\u00fablica, Santiago de Chile, Chile; Laboratorio de An\u00e1lisis y Asesor\u00eda Farmac\u00e9utica,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3207, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ef4eb977-7c62-453d-bcd5-ab484506eccd": {"__data__": {"id_": "ef4eb977-7c62-453d-bcd5-ab484506eccd", "embedding": null, "metadata": {"page_label": "87", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Facultad de Farmacia, Universidad de Costa Rica, San Jos\u00e9, Costa Rica; Laboratorio de Normas y Calidad de Medicamentos, Caja Costarricense de Seguro Social, Antiguo Hospital de Alajuela, Alajuela, Costa Rica; Medicamentos y Productos Biol\u00f3gicos del INVIMA, Bogot\u00e1, Colombia; Oficina Sanitaria Panamericana, OPS/OMS, La Habana, Cuba; Food and Drugs Board, Quality Control Laboratory, Accra, Ghana; Department for Quality Evaluation and Control, National Institute of Pharmacy, Budapest, Hungary; Central Drugs Laboratory, Calcutta, India; Provincial Quality Control Laboratory of Drug and Food, Yogyakarta, Indonesia; Caribbean Regional Drug Testing Laboratory, Kingston, Jamaica; Mission for Essential Drugs and Supplies, Nairobi, Kenya; National Quality Control Laboratory for Drugs and Medical Devices, Nairobi, Kenya; Laboratoire de Contr\u00f4le de Qualit\u00e9 des M\u00e9dicaments, Agence du M\u00e9dicament de Madagascar, Antananarivo, Madagascar; Centre for Quality Control, National Pharmaceutical Control Bureau, Petaling Jaya, Sengalor, Malaysia; Laboratoire National de la Sant\u00e9 du Mali, Bamako, Mali; Laboratoire National de Contr\u00f4le des M\u00e9dicaments, Rabat, Morocco; Quality Surveillance Laboratory, Windhoek, Namibia; National Medicines Laboratory, Department of Drug Administration, Kathmandu, Nepal;\n\nLaboratoire National de Sant\u00e9 Publique et d'Expertise, Niamey, Niger; Central Quality Control Laboratory, Muscat, Oman; Drug Control and Traditional Medicine Division, National Institute of Health, Islamabad, Pakistan; Instituto Especializado de An\u00e1lisis, Universidad de Panam\u00e1, Panama; Food and Drug Quality Control Center, Ministry of Health, Vientiane, People's Democratic Republic of Lao; National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People's Republic of China; Centro Nacional de Control de Calidad, Instituto Nacional de Salud, Lima, Peru; Bureau of Food and Drugs, Department of Health, Alabang, Muntinlupa City, Philippines; Laboratory for Quality Control of Medicines, Medicines Agency, Ministry of Health, Chisinau, Republic of Moldova; Laboratoire National de Contr\u00f4le des M\u00e9dicaments, Dakar Etoile, Senegal; Centre for Quality Assurance of Medicines, Faculty of Pharmacy, North-West University, Potchefstroom, South Africa; Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa; National Drug Quality Assurance Laboratory, Colombo, Sri Lanka; Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand; Laboratoire National de Contr\u00f4le des M\u00e9dicaments, Tunis, Tunisia; National Drug Quality Control Laboratory, National Drug Authority, Kampala, Uganda; Central Laboratory for Quality Control of Medicines of the Ministry of Health of Ukraine, Kiev, Ukraine; School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, United Republic of Tanzania; Tanzania Food and Drugs Authority, Dar-es-Salaam, United Republic of Tanzania; Laboratorio Control de Productos MSP, Comisi\u00f3n Para El Control de Calidad de Medicamentos, Montevideo, Uruguay; Instituto Nacional de Higiene \u201cRafael Rangel\u201d, Caracas, Venezuela; National Institute of Drug Quality Control, Hanoi, Viet Nam; Medicines Control Authority, Control Laboratory of Zimbabwe, Harare, Zimbabwe.\n\nWHO Collaborating Centre for Drug Quality Assurance, Therapeutic Goods Administration Laboratories, Woden, Australian Capital Territory, Australia; WHO Collaborating Centre for Research on Bioequivalence Testing of Medicines, Frankfurt am Main, Germany; WHO Collaborating Centre for Drug Information and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que incluye una lista de instituciones y laboratorios de control de calidad de medicamentos de diferentes pa\u00edses. Estas instituciones est\u00e1n involucradas en la evaluaci\u00f3n y control de la calidad de productos farmac\u00e9uticos y biol\u00f3gicos, y representan una red global de colaboraci\u00f3n en el \u00e1mbito de la salud p\u00fablica y la regulaci\u00f3n de medicamentos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 papel desempe\u00f1a la Oficina Sanitaria Panamericana en la red de laboratorios de control de calidad de medicamentos mencionados en el informe?**\n   - Esta pregunta busca informaci\u00f3n sobre la funci\u00f3n espec\u00edfica de la Oficina Sanitaria Panamericana (OPS) en el contexto de la calidad de medicamentos, que podr\u00eda no estar detallada en otros documentos.\n\n2. **\u00bfCu\u00e1les son las principales responsabilidades del Laboratorio Nacional de Salud P\u00fablica y de Experticia en Niamey, N\u00edger, seg\u00fan el contexto del informe?**\n   - Esta pregunta se centra en las funciones espec\u00edficas de un laboratorio mencionado, lo que puede proporcionar detalles sobre su papel en la regulaci\u00f3n de medicamentos en su pa\u00eds.\n\n3. **\u00bfC\u00f3mo se relacionan los centros de control de calidad de medicamentos en Am\u00e9rica Latina con los de otras regiones, como \u00c1frica o Asia, seg\u00fan el informe?**\n   - Esta pregunta busca explorar las conexiones y colaboraciones entre diferentes regiones en el \u00e1mbito del control de calidad de medicamentos, lo que puede no estar claramente delineado en otros textos.\n\n### Resumen de Nivel Superior\nEl informe t\u00e9cnico de la OMS destaca la importancia de la colaboraci\u00f3n internacional en el control de calidad de medicamentos. Incluye una extensa lista de laboratorios y centros de control de calidad de diversas naciones, subrayando la necesidad de est\u00e1ndares globales y la cooperaci\u00f3n entre pa\u00edses para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.", "prev_section_summary": "La secci\u00f3n de agradecimientos del informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) destaca la colaboraci\u00f3n y contribuciones de diversas personas y organizaciones en la preparaci\u00f3n y desarrollo de la reuni\u00f3n. Los temas clave incluyen:\n\n1. **Reconocimiento a Individuos Clave**: Se menciona a varias personas que jugaron un papel fundamental en la organizaci\u00f3n del evento, incluyendo a Mrs W. Bonny, Ms M. Gaspard, Dr S. Kopp, Ms C. Mendy y Dr L. R\u00e4go.\n\n2. **Asistencia Financiera**: El informe se\u00f1ala que la gu\u00eda t\u00e9cnica fue elaborada con el apoyo financiero de la Comunidad Europea, la Fundaci\u00f3n Bill & Melinda Gates y UNITAID.\n\n3. **Contribuciones de Organizaciones**: Se agradece a una amplia variedad de agencias, instituciones y organizaciones que colaboraron, entre las que se incluyen:\n   - Agencia Europea de Medicamentos\n   - Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria\n   - Organizaci\u00f3n Mundial de la Propiedad Intelectual\n   - Diversas agencias nacionales y laboratorios de control de calidad de medicamentos de varios pa\u00edses.\n\n4. **Importancia de la Colaboraci\u00f3n Internacional**: El reconocimiento de estas entidades subraya la interconexi\u00f3n y la colaboraci\u00f3n necesaria en el \u00e1mbito de la calidad y seguridad de los medicamentos a nivel global.\n\nEn resumen, la secci\u00f3n enfatiza la importancia de la cooperaci\u00f3n internacional y el apoyo financiero en los esfuerzos por mejorar la calidad y seguridad de los medicamentos.", "excerpt_keywords": "Keywords: medicamentos, control de calidad, colaboraci\u00f3n internacional, OMS, laboratorios"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9935211a-edda-4251-9fd5-68bc5225f630", "node_type": "4", "metadata": {"page_label": "87", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Facultad de Farmacia, Universidad de Costa Rica, San Jos\u00e9, Costa Rica; Laboratorio de Normas y Calidad de Medicamentos, Caja Costarricense de Seguro Social, Antiguo Hospital de Alajuela, Alajuela, Costa Rica; Medicamentos y Productos Biol\u00f3gicos del INVIMA, Bogot\u00e1, Colombia; Oficina Sanitaria Panamericana, OPS/OMS, La Habana, Cuba; Food and Drugs Board, Quality Control Laboratory, Accra, Ghana; Department for Quality Evaluation and Control, National Institute of Pharmacy, Budapest, Hungary; Central Drugs Laboratory, Calcutta, India; Provincial Quality Control Laboratory of Drug and Food, Yogyakarta, Indonesia; Caribbean Regional Drug Testing Laboratory, Kingston, Jamaica; Mission for Essential Drugs and Supplies, Nairobi, Kenya; National Quality Control Laboratory for Drugs and Medical Devices, Nairobi, Kenya; Laboratoire de Contr\u00f4le de Qualit\u00e9 des M\u00e9dicaments, Agence du M\u00e9dicament de Madagascar, Antananarivo, Madagascar; Centre for Quality Control, National Pharmaceutical Control Bureau, Petaling Jaya, Sengalor, Malaysia; Laboratoire National de la Sant\u00e9 du Mali, Bamako, Mali; Laboratoire National de Contr\u00f4le des M\u00e9dicaments, Rabat, Morocco; Quality Surveillance Laboratory, Windhoek, Namibia; National Medicines Laboratory, Department of Drug Administration, Kathmandu, Nepal;\n\nLaboratoire National de Sant\u00e9 Publique et d'Expertise, Niamey, Niger; Central Quality Control Laboratory, Muscat, Oman; Drug Control and Traditional Medicine Division, National Institute of Health, Islamabad, Pakistan; Instituto Especializado de An\u00e1lisis, Universidad de Panam\u00e1, Panama; Food and Drug Quality Control Center, Ministry of Health, Vientiane, People's Democratic Republic of Lao; National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People's Republic of China; Centro Nacional de Control de Calidad, Instituto Nacional de Salud, Lima, Peru; Bureau of Food and Drugs, Department of Health, Alabang, Muntinlupa City, Philippines; Laboratory for Quality Control of Medicines, Medicines Agency, Ministry of Health, Chisinau, Republic of Moldova; Laboratoire National de Contr\u00f4le des M\u00e9dicaments, Dakar Etoile, Senegal; Centre for Quality Assurance of Medicines, Faculty of Pharmacy, North-West University, Potchefstroom, South Africa; Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa; National Drug Quality Assurance Laboratory, Colombo, Sri Lanka; Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand; Laboratoire National de Contr\u00f4le des M\u00e9dicaments, Tunis, Tunisia; National Drug Quality Control Laboratory, National Drug Authority, Kampala, Uganda; Central Laboratory for Quality Control of Medicines of the Ministry of Health of Ukraine, Kiev, Ukraine; School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, United Republic of Tanzania; Tanzania Food and Drugs Authority, Dar-es-Salaam, United Republic of Tanzania; Laboratorio Control de Productos MSP, Comisi\u00f3n Para El Control de Calidad de Medicamentos, Montevideo, Uruguay; Instituto Nacional de Higiene \u201cRafael Rangel\u201d, Caracas, Venezuela; National Institute of Drug Quality Control, Hanoi, Viet Nam; Medicines Control Authority, Control Laboratory of Zimbabwe, Harare, Zimbabwe.\n\nWHO Collaborating Centre for Drug Quality Assurance, Therapeutic Goods Administration Laboratories, Woden, Australian Capital Territory, Australia; WHO Collaborating Centre for Research on Bioequivalence Testing of Medicines, Frankfurt am Main, Germany; WHO Collaborating Centre for Drug Information and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "fc1db91a632b6316c26d951b102cd856dbb30b5cbce15a24b94fe59f277421d1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Facultad de Farmacia, Universidad de Costa Rica, San Jos\u00e9, Costa Rica; Laboratorio de Normas y Calidad de Medicamentos, Caja Costarricense de Seguro Social, Antiguo Hospital de Alajuela, Alajuela, Costa Rica; Medicamentos y Productos Biol\u00f3gicos del INVIMA, Bogot\u00e1, Colombia; Oficina Sanitaria Panamericana, OPS/OMS, La Habana, Cuba; Food and Drugs Board, Quality Control Laboratory, Accra, Ghana; Department for Quality Evaluation and Control, National Institute of Pharmacy, Budapest, Hungary; Central Drugs Laboratory, Calcutta, India; Provincial Quality Control Laboratory of Drug and Food, Yogyakarta, Indonesia; Caribbean Regional Drug Testing Laboratory, Kingston, Jamaica; Mission for Essential Drugs and Supplies, Nairobi, Kenya; National Quality Control Laboratory for Drugs and Medical Devices, Nairobi, Kenya; Laboratoire de Contr\u00f4le de Qualit\u00e9 des M\u00e9dicaments, Agence du M\u00e9dicament de Madagascar, Antananarivo, Madagascar; Centre for Quality Control, National Pharmaceutical Control Bureau, Petaling Jaya, Sengalor, Malaysia; Laboratoire National de la Sant\u00e9 du Mali, Bamako, Mali; Laboratoire National de Contr\u00f4le des M\u00e9dicaments, Rabat, Morocco; Quality Surveillance Laboratory, Windhoek, Namibia; National Medicines Laboratory, Department of Drug Administration, Kathmandu, Nepal;\n\nLaboratoire National de Sant\u00e9 Publique et d'Expertise, Niamey, Niger; Central Quality Control Laboratory, Muscat, Oman; Drug Control and Traditional Medicine Division, National Institute of Health, Islamabad, Pakistan; Instituto Especializado de An\u00e1lisis, Universidad de Panam\u00e1, Panama; Food and Drug Quality Control Center, Ministry of Health, Vientiane, People's Democratic Republic of Lao; National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People's Republic of China; Centro Nacional de Control de Calidad, Instituto Nacional de Salud, Lima, Peru; Bureau of Food and Drugs, Department of Health, Alabang, Muntinlupa City, Philippines; Laboratory for Quality Control of Medicines, Medicines Agency, Ministry of Health, Chisinau, Republic of Moldova; Laboratoire National de Contr\u00f4le des M\u00e9dicaments, Dakar Etoile, Senegal; Centre for Quality Assurance of Medicines, Faculty of Pharmacy, North-West University, Potchefstroom, South Africa; Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa; National Drug Quality Assurance Laboratory, Colombo, Sri Lanka; Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand; Laboratoire National de Contr\u00f4le des M\u00e9dicaments, Tunis, Tunisia; National Drug Quality Control Laboratory, National Drug Authority, Kampala, Uganda; Central Laboratory for Quality Control of Medicines of the Ministry of Health of Ukraine, Kiev, Ukraine; School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, United Republic of Tanzania; Tanzania Food and Drugs Authority, Dar-es-Salaam, United Republic of Tanzania; Laboratorio Control de Productos MSP, Comisi\u00f3n Para El Control de Calidad de Medicamentos, Montevideo, Uruguay; Instituto Nacional de Higiene \u201cRafael Rangel\u201d, Caracas, Venezuela; National Institute of Drug Quality Control, Hanoi, Viet Nam; Medicines Control Authority, Control Laboratory of Zimbabwe, Harare, Zimbabwe.\n\nWHO Collaborating Centre for Drug Quality Assurance, Therapeutic Goods Administration Laboratories, Woden, Australian Capital Territory, Australia; WHO Collaborating Centre for Research on Bioequivalence Testing of Medicines, Frankfurt am Main, Germany; WHO Collaborating Centre for Drug Information and", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3619, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ffa9441b-a450-45fe-aed6-6830bf5c086b": {"__data__": {"id_": "ffa9441b-a450-45fe-aed6-6830bf5c086b", "embedding": null, "metadata": {"page_label": "88", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Quality Assurance, National Institute of Pharmacy, Budapest, Hungary; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Central Drugs Laboratory, Calcutta, India; WHO Collaborating Centre for Regulatory Control of Pharmaceuticals, National Pharmaceutical Control Bureau, Jalan University, Ministry of Health, Petaling Jaya, Malaysia; WHO Collaborating Centre for Drug Quality Assurance, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People\u2019s Republic of China; WHO Collaborating Centre for Drug Quality Assurance, Pharmaceutical Laboratory, Centre for Analytical Science, Health Sciences Authority, Singapore; WHO Collaborating Centre for Quality Assurance of Drugs, North-West University, Potchefstroom, South Africa; WHO Collaborating Centre for International Infrared Reference Spectra, Institute for Pharmaceutical Sciences, Zurich, Switzerland; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.\n\nAnti-Counterfeiting Medicines Programme, WHO, Geneva, Switzerland; Blood Products and Related Biologicals Programme, WHO, Geneva, Switzerland; Global Malaria Programme, WHO, Geneva, Switzerland; HIV/AIDS Programme, WHO, Geneva, Switzerland; International Medical Products Anti-Counterfeiting Taskforce (IMPACT), WHO, Geneva, Switzerland; Medicine Access and Rational Use Team, WHO, Geneva, Switzerland; Medicines Regulatory Support Programme, WHO, Geneva, Switzerland; Prequalification Programme, WHO, Geneva, Switzerland; Quality and Safety: Medicines Team, WHO, Geneva, Switzerland; Quality, Safety and Standards Team, WHO, Geneva, Switzerland; Traditional Medicine Team, WHO, Geneva, Switzerland; WHO/FIP Training Workshop on Pharmaceutical Development with Focus on Paediatric Formulations, Mumbai, India; WHO Regional Office for Africa, Brazzaville, Congo; WHO Regional Office for the Americas/Pan American Health Organization, Washington, DC, USA; WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt; WHO Regional Office for Europe, Copenhagen, Denmark; WHO Regional Office for South-East Asia, New Delhi, India; WHO Regional Office for the Western Pacific, Manila, Philippines.\n\nMrs T. Abdul Sattar, Acting Director General, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman; Dr F. Abiodun, Benin City, Nigeria; Dr E. Adams, Labo Voor Farmaceutische Chemie en Analyse van Geneesmiddelen, Leuven, Belgium; Mr M. Adarkwah-Yiadom, Standard Officer, Ghana Standards Board, Drugs, Cosmetics and Forensic Laboratory, Testing Division, Accra, Ghana; Professor I. Addae-Mensah, University of Ghana, Legon, Ghana; Ms R. Ahmad, Centre for Product Registration, National Pharmaceutical Control Bureau, Ministry of Health, Petaling Jaya, Malaysia; Mrs S. Ahmed Jaffar, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman; Professor J.-M. Aiache, Clermont-Ferrand, France; Dr A. Akkermans, the Netherlands; Dr R. Andrews, Medicines and Healthcare Products Regulatory Agency, London, England; Dr C. Anquez Traxler, European Self-Medication Industry, Brussels, Belgium; Dr H. Arentsen, Regulatory Intelligence and Policy Specialist, Regulatory Development Strategy, H. Lundbeck A/S, Copenhagen-Valby, Denmark; Dr C. Athlan, Quality Reviewer, Swissmedic, Berne, Switzerland; Dr A. Ba, Directeur, Qualit\u00e9 et D\u00e9veloppement, Centrale Humanitaire", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que se centra en la calidad y regulaci\u00f3n de los medicamentos. Se mencionan varios centros de colaboraci\u00f3n de la OMS en diferentes pa\u00edses que se dedican a la garant\u00eda de calidad de los medicamentos esenciales y a la regulaci\u00f3n de productos farmac\u00e9uticos. Adem\u00e1s, se enumeran programas espec\u00edficos de la OMS relacionados con la lucha contra la falsificaci\u00f3n de medicamentos, el acceso a medicamentos y el uso racional de los mismos. Tambi\u00e9n se incluyen nombres y cargos de profesionales de la salud y la regulaci\u00f3n de varios pa\u00edses, lo que sugiere una colaboraci\u00f3n internacional en estos temas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los principales programas de la OMS mencionados en el informe que se centran en la calidad y seguridad de los medicamentos?**\n   - Respuesta: Los programas incluyen el Programa de Medicamentos Antifalsificaci\u00f3n, el Programa de Productos Biol\u00f3gicos y Relacionados con la Sangre, el Programa Global de Malaria, el Programa de VIH/SIDA, y el Programa de Apoyo Regulatorio de Medicamentos, entre otros.\n\n2. **\u00bfQu\u00e9 instituciones y centros de colaboraci\u00f3n de la OMS est\u00e1n involucrados en la garant\u00eda de calidad de los medicamentos en Asia?**\n   - Respuesta: En Asia, se mencionan el Centro de Control de Productos Farmac\u00e9uticos de Malasia, el Laboratorio Central de Medicamentos en Calcuta, India, y el Instituto Nacional para el Control de Productos Farmac\u00e9uticos y Biol\u00f3gicos en Beijing, China.\n\n3. **\u00bfQui\u00e9nes son algunos de los profesionales destacados en el informe y qu\u00e9 roles desempe\u00f1an en sus respectivos pa\u00edses?**\n   - Respuesta: Algunos profesionales destacados incluyen a Mrs. T. Abdul Sattar, Directora General Actuante en Om\u00e1n; Dr. E. Adams de B\u00e9lgica; y Dr. R. Andrews de la Agencia Reguladora de Medicamentos y Productos de Salud en Inglaterra, entre otros, quienes desempe\u00f1an roles en la regulaci\u00f3n y control de medicamentos en sus pa\u00edses.", "prev_section_summary": "La secci\u00f3n del documento t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) presenta una lista extensa de instituciones y laboratorios dedicados al control de calidad de medicamentos en diversos pa\u00edses. Estos laboratorios son fundamentales para la evaluaci\u00f3n y regulaci\u00f3n de productos farmac\u00e9uticos y biol\u00f3gicos, destacando la importancia de la colaboraci\u00f3n internacional en el \u00e1mbito de la salud p\u00fablica.\n\n### Temas Clave:\n1. **Control de Calidad de Medicamentos**: La secci\u00f3n enfatiza la necesidad de est\u00e1ndares globales y la cooperaci\u00f3n entre pa\u00edses para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.\n2. **Colaboraci\u00f3n Internacional**: Se resalta la red global de laboratorios y centros de control de calidad, que trabajan juntos para mejorar la regulaci\u00f3n de medicamentos.\n3. **Diversidad Geogr\u00e1fica**: La lista incluye instituciones de Am\u00e9rica Latina, \u00c1frica, Asia, Europa y Ocean\u00eda, mostrando la amplitud de la colaboraci\u00f3n en el control de calidad.\n\n### Entidades Mencionadas:\n- **Instituciones Acad\u00e9micas**: Ejemplo: Facultad de Farmacia, Universidad de Costa Rica.\n- **Laboratorios Nacionales**: Ejemplo: Laboratorio Nacional de Salud P\u00fablica y de Experticia, Niamey, N\u00edger.\n- **Agencias de Salud**: Ejemplo: Oficina Sanitaria Panamericana (OPS/OMS), La Habana, Cuba.\n- **Centros de Control de Calidad**: Ejemplo: National Institute for the Control of Pharmaceutical and Biological Products, Beijing, China.\n- **Colaboraci\u00f3n con la OMS**: Ejemplo: WHO Collaborating Centre for Drug Quality Assurance, Australia.\n\nEste resumen destaca la relevancia de la red de laboratorios en la regulaci\u00f3n de medicamentos y la importancia de la cooperaci\u00f3n internacional en este \u00e1mbito.", "excerpt_keywords": "Keywords: Quality Assurance, WHO Collaborating Centres, Pharmaceuticals, Anti-Counterfeiting, International Collaboration"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d992393f-64d6-43a0-8d59-62e850b9256a", "node_type": "4", "metadata": {"page_label": "88", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Quality Assurance, National Institute of Pharmacy, Budapest, Hungary; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Central Drugs Laboratory, Calcutta, India; WHO Collaborating Centre for Regulatory Control of Pharmaceuticals, National Pharmaceutical Control Bureau, Jalan University, Ministry of Health, Petaling Jaya, Malaysia; WHO Collaborating Centre for Drug Quality Assurance, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People\u2019s Republic of China; WHO Collaborating Centre for Drug Quality Assurance, Pharmaceutical Laboratory, Centre for Analytical Science, Health Sciences Authority, Singapore; WHO Collaborating Centre for Quality Assurance of Drugs, North-West University, Potchefstroom, South Africa; WHO Collaborating Centre for International Infrared Reference Spectra, Institute for Pharmaceutical Sciences, Zurich, Switzerland; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.\n\nAnti-Counterfeiting Medicines Programme, WHO, Geneva, Switzerland; Blood Products and Related Biologicals Programme, WHO, Geneva, Switzerland; Global Malaria Programme, WHO, Geneva, Switzerland; HIV/AIDS Programme, WHO, Geneva, Switzerland; International Medical Products Anti-Counterfeiting Taskforce (IMPACT), WHO, Geneva, Switzerland; Medicine Access and Rational Use Team, WHO, Geneva, Switzerland; Medicines Regulatory Support Programme, WHO, Geneva, Switzerland; Prequalification Programme, WHO, Geneva, Switzerland; Quality and Safety: Medicines Team, WHO, Geneva, Switzerland; Quality, Safety and Standards Team, WHO, Geneva, Switzerland; Traditional Medicine Team, WHO, Geneva, Switzerland; WHO/FIP Training Workshop on Pharmaceutical Development with Focus on Paediatric Formulations, Mumbai, India; WHO Regional Office for Africa, Brazzaville, Congo; WHO Regional Office for the Americas/Pan American Health Organization, Washington, DC, USA; WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt; WHO Regional Office for Europe, Copenhagen, Denmark; WHO Regional Office for South-East Asia, New Delhi, India; WHO Regional Office for the Western Pacific, Manila, Philippines.\n\nMrs T. Abdul Sattar, Acting Director General, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman; Dr F. Abiodun, Benin City, Nigeria; Dr E. Adams, Labo Voor Farmaceutische Chemie en Analyse van Geneesmiddelen, Leuven, Belgium; Mr M. Adarkwah-Yiadom, Standard Officer, Ghana Standards Board, Drugs, Cosmetics and Forensic Laboratory, Testing Division, Accra, Ghana; Professor I. Addae-Mensah, University of Ghana, Legon, Ghana; Ms R. Ahmad, Centre for Product Registration, National Pharmaceutical Control Bureau, Ministry of Health, Petaling Jaya, Malaysia; Mrs S. Ahmed Jaffar, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman; Professor J.-M. Aiache, Clermont-Ferrand, France; Dr A. Akkermans, the Netherlands; Dr R. Andrews, Medicines and Healthcare Products Regulatory Agency, London, England; Dr C. Anquez Traxler, European Self-Medication Industry, Brussels, Belgium; Dr H. Arentsen, Regulatory Intelligence and Policy Specialist, Regulatory Development Strategy, H. Lundbeck A/S, Copenhagen-Valby, Denmark; Dr C. Athlan, Quality Reviewer, Swissmedic, Berne, Switzerland; Dr A. Ba, Directeur, Qualit\u00e9 et D\u00e9veloppement, Centrale Humanitaire", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "8ac531635c48619f38d72dfb87ba79f19e81863451ab0225b489a1c27d20d3cd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Quality Assurance, National Institute of Pharmacy, Budapest, Hungary; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Central Drugs Laboratory, Calcutta, India; WHO Collaborating Centre for Regulatory Control of Pharmaceuticals, National Pharmaceutical Control Bureau, Jalan University, Ministry of Health, Petaling Jaya, Malaysia; WHO Collaborating Centre for Drug Quality Assurance, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People\u2019s Republic of China; WHO Collaborating Centre for Drug Quality Assurance, Pharmaceutical Laboratory, Centre for Analytical Science, Health Sciences Authority, Singapore; WHO Collaborating Centre for Quality Assurance of Drugs, North-West University, Potchefstroom, South Africa; WHO Collaborating Centre for International Infrared Reference Spectra, Institute for Pharmaceutical Sciences, Zurich, Switzerland; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.\n\nAnti-Counterfeiting Medicines Programme, WHO, Geneva, Switzerland; Blood Products and Related Biologicals Programme, WHO, Geneva, Switzerland; Global Malaria Programme, WHO, Geneva, Switzerland; HIV/AIDS Programme, WHO, Geneva, Switzerland; International Medical Products Anti-Counterfeiting Taskforce (IMPACT), WHO, Geneva, Switzerland; Medicine Access and Rational Use Team, WHO, Geneva, Switzerland; Medicines Regulatory Support Programme, WHO, Geneva, Switzerland; Prequalification Programme, WHO, Geneva, Switzerland; Quality and Safety: Medicines Team, WHO, Geneva, Switzerland; Quality, Safety and Standards Team, WHO, Geneva, Switzerland; Traditional Medicine Team, WHO, Geneva, Switzerland; WHO/FIP Training Workshop on Pharmaceutical Development with Focus on Paediatric Formulations, Mumbai, India; WHO Regional Office for Africa, Brazzaville, Congo; WHO Regional Office for the Americas/Pan American Health Organization, Washington, DC, USA; WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt; WHO Regional Office for Europe, Copenhagen, Denmark; WHO Regional Office for South-East Asia, New Delhi, India; WHO Regional Office for the Western Pacific, Manila, Philippines.\n\nMrs T. Abdul Sattar, Acting Director General, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman; Dr F. Abiodun, Benin City, Nigeria; Dr E. Adams, Labo Voor Farmaceutische Chemie en Analyse van Geneesmiddelen, Leuven, Belgium; Mr M. Adarkwah-Yiadom, Standard Officer, Ghana Standards Board, Drugs, Cosmetics and Forensic Laboratory, Testing Division, Accra, Ghana; Professor I. Addae-Mensah, University of Ghana, Legon, Ghana; Ms R. Ahmad, Centre for Product Registration, National Pharmaceutical Control Bureau, Ministry of Health, Petaling Jaya, Malaysia; Mrs S. Ahmed Jaffar, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman; Professor J.-M. Aiache, Clermont-Ferrand, France; Dr A. Akkermans, the Netherlands; Dr R. Andrews, Medicines and Healthcare Products Regulatory Agency, London, England; Dr C. Anquez Traxler, European Self-Medication Industry, Brussels, Belgium; Dr H. Arentsen, Regulatory Intelligence and Policy Specialist, Regulatory Development Strategy, H. Lundbeck A/S, Copenhagen-Valby, Denmark; Dr C. Athlan, Quality Reviewer, Swissmedic, Berne, Switzerland; Dr A. Ba, Directeur, Qualit\u00e9 et D\u00e9veloppement, Centrale Humanitaire", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3524, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5cd169f9-9189-4e45-854c-b15b7c356506": {"__data__": {"id_": "5cd169f9-9189-4e45-854c-b15b7c356506", "embedding": null, "metadata": {"page_label": "89", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Medico-Pharmaceutique, Clermont-Ferrand, France; Dr H. Batista, US Food and Drug Administration, Silver Spring, MD, USA; Mr B. Baudrand, OTECI, Paris, France; Dr O.P. Baula, Deputy Director, State Pharmacological Center, Ministry of Health, Kiev, Ukraine; Professor S.A. Bawazir, Vice-President, Saudi Food and Drug Authority, Head of Drug Sector, Riyadh, Saudi Arabia; Dr M.G. Beatrice, Vice President, Corporate Regulatory and Quality Science, Abbott, Abbott Park, USA; Dr T.L. Bedane, Drug Administration and Control, Addis Ababa, Ethiopia; Ms T.J. Bell, WHO Focal Point, US Food and Drug Administration, Silver Spring, MD, USA; Dr I.B.G. Bernstein, Director, Pharmacy Affairs, Office of the Commissioner/Office of Policy, US Food and Drug Administration, Silver Spring, MD, USA; Dr R.P. Best, President and CEO, International Society for Pharmaceutical Engineering, Tampa, FL, USA; Dr L. Bigger, Regulatory and Scientific Affairs, International Federation of Pharmaceutical Manufacturers Associations, Geneva, Switzerland; Dr L. Bonthuys, Pretoria, South Africa; Professor R. Boudet-Dalbin, Facult\u00e9 de Pharmacie, Laboratoire de Chimie Th\u00e9rapeutique, Paris, France; Dr S.K. Branch, Acting Group Manager, Special Populations Group, Medicines and Healthcare products Regulatory Agency, London, England; Dr E. Brendel, Bayer HealthCare AG, Elberfeld, Germany; Mr C. Brown, Inspections Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency, London, England; Dr W. Bukachi, Project Coordinator, International Affairs, US Pharmacopeia, Rockville, MD, USA; Dr F. Burnett, Managing Director, Pharmaceutical Procurement Service, Organization of Eastern Caribbean States, Castries, St Lucia; Dr D. Calam, Wiltshire, England; Dr N. Cappuccio, Lambertville, NJ, USA; Dr A. Castro, Regulatory Affairs Director and Senior Pharmacist, Roche Servicios SA, Heredia, Costa Rica; Dr D. Catsoulacos, Scientific Administrator, Manufacturing and Quality Compliance, Compliance and Inspection, European Medicines Agency, London, England; Mr Xuanhao Chan, Project Manager, International Pharmaceutical Federation, The Hague, Netherlands; Dr B. Chapart, Pharma Review Manager, Global Analytical Development, Sanofi-Aventis Pharma, Anthony, France; Ms Cheah Nuan Ping, Director, Cosmetics & Cigarette Testing Laboratory, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore; Dr Xu Chen, Director, Division of Drug Distribution Supervision, State Food and Drug Administration, Beijing, People's Republic of China; Professor Y. Cherrah, Facult\u00e9 de M\u00e9decine et Pharmacie, Rabat, Morocco; Ms I. Clamou, Assistant Manager, Scientific, Technical and Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; Dr M. Cooke, Senior Manager, Global Quality, Operations, AstraZeneca, Macclesfield, Cheshire, England; Dr C. Craft, Member, United States Pharmacopeia International Health Expert Committee, Rockville, MD, USA; Dr R.L. Dana, Senior Vice President, Regulatory Affairs and Parenteral Drug Association Training and Research Institute, Parenteral Drug Association, Bethesda, MD, USA; Dr V. Davoust, Quality & Regulatory Policy, Global CMC, WW Pharmaceutical Sciences, Pfizer Global Research & Development Paris, France; Professor T. Dekker, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa; Dr M. Dereque-Pois, Director General, European Association of Pharmaceutical Full-line Wholesalers, Brussels, Belgium; Professor J.B. Dressman, Institut f\u00fcr Pharmazeutische Technologie, Biozentrum, Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt/Main, Germany; Dr A.T. Ducca, Senior Director, Regulatory", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (Organizaci\u00f3n Mundial de la Salud) y presenta una lista de profesionales y expertos en el campo de la farmac\u00e9utica y la regulaci\u00f3n de medicamentos. Incluye nombres, t\u00edtulos y afiliaciones de personas de diversas organizaciones y pa\u00edses, destacando la colaboraci\u00f3n internacional en temas de regulaci\u00f3n y calidad en la industria farmac\u00e9utica.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 roles desempe\u00f1an los diferentes expertos mencionados en el documento en sus respectivas organizaciones?**\n   - Esta pregunta busca detalles sobre las funciones espec\u00edficas de cada individuo en sus organizaciones, lo cual no se detalla en el texto.\n\n2. **\u00bfC\u00f3mo se relacionan las instituciones representadas por los expertos en el contexto de la regulaci\u00f3n farmac\u00e9utica global?**\n   - Esta pregunta indaga sobre la interconexi\u00f3n y colaboraci\u00f3n entre las diversas instituciones mencionadas, lo que podr\u00eda no estar expl\u00edcitamente abordado en el documento.\n\n3. **\u00bfQu\u00e9 temas espec\u00edficos de regulaci\u00f3n y calidad en la industria farmac\u00e9utica podr\u00edan estar siendo discutidos por los expertos listados en el documento?**\n   - Esta pregunta busca explorar los posibles temas de discusi\u00f3n o \u00e1reas de enfoque que podr\u00edan ser relevantes para los expertos, bas\u00e1ndose en sus roles y organizaciones, pero que no se mencionan directamente en el texto. \n\n### Resumen de Nivel Superior\nEl contexto presenta una lista de expertos en regulaci\u00f3n farmac\u00e9utica de diversas organizaciones internacionales, lo que sugiere un esfuerzo colaborativo para abordar cuestiones de calidad y regulaci\u00f3n en la industria farmac\u00e9utica. La diversidad geogr\u00e1fica y profesional de los participantes indica un enfoque global hacia la mejora de las pr\u00e1cticas en este campo.", "prev_section_summary": "La secci\u00f3n del documento se centra en la calidad y regulaci\u00f3n de los medicamentos, destacando la colaboraci\u00f3n internacional a trav\u00e9s de diversos centros de la Organizaci\u00f3n Mundial de la Salud (OMS) y programas espec\u00edficos. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n### Temas Clave:\n1. **Calidad y Regulaci\u00f3n de Medicamentos**: Se enfatiza la importancia de la garant\u00eda de calidad de los medicamentos esenciales y la regulaci\u00f3n de productos farmac\u00e9uticos.\n2. **Programas de la OMS**: Se enumeran varios programas de la OMS que abordan la falsificaci\u00f3n de medicamentos, el acceso a medicamentos, y el uso racional de estos.\n3. **Colaboraci\u00f3n Internacional**: Se menciona la participaci\u00f3n de m\u00faltiples pa\u00edses y profesionales en la regulaci\u00f3n y control de medicamentos, lo que sugiere un esfuerzo global coordinado.\n\n### Entidades y Centros de Colaboraci\u00f3n de la OMS:\n- **Centros de Calidad**:\n  - Instituto Nacional de Farmacia, Budapest, Hungr\u00eda.\n  - Laboratorio Central de Medicamentos, Calcuta, India.\n  - Bureau de Control Farmac\u00e9utico, Malasia.\n  - Instituto Nacional para el Control de Productos Farmac\u00e9uticos y Biol\u00f3gicos, Beijing, China.\n  - Autoridad de Salud de Singapur.\n  - Universidad del Noroeste, Potchefstroom, Sud\u00e1frica.\n  - Instituto de Ciencias Farmac\u00e9uticas, Zurich, Suiza.\n  - Departamento de Ciencias M\u00e9dicas, Ministerio de Salud, Tailandia.\n\n- **Programas de la OMS**:\n  - Programa de Medicamentos Antifalsificaci\u00f3n.\n  - Programa de Productos Biol\u00f3gicos y Relacionados con la Sangre.\n  - Programa Global de Malaria.\n  - Programa de VIH/SIDA.\n  - Programa de Apoyo Regulatorio de Medicamentos.\n  - Programa de Precalificaci\u00f3n.\n\n### Profesionales Destacados:\n- **Mrs. T. Abdul Sattar**: Directora General Actuante, Om\u00e1n.\n- **Dr. E. Adams**: B\u00e9lgica.\n- **Dr. R. Andrews**: Agencia Reguladora de Medicamentos y Productos de Salud, Inglaterra.\n- **Dr. H. Arentsen**: Especialista en Inteligencia Regulatoria, Dinamarca.\n- **Dr. C. Athlan**: Revisor de Calidad, Suiza.\n\nEste resumen refleja la colaboraci\u00f3n y los esfuerzos globales en la regulaci\u00f3n y garant\u00eda de calidad de los medicamentos, as\u00ed como la participaci\u00f3n de diversas instituciones y profesionales en este \u00e1mbito.", "excerpt_keywords": "Keywords: regulaci\u00f3n farmac\u00e9utica, calidad de medicamentos, colaboraci\u00f3n internacional, expertos en salud, Organizaci\u00f3n Mundial de la Salud"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "651197fc-34c5-4d86-873c-3f994abd31d4", "node_type": "4", "metadata": {"page_label": "89", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Medico-Pharmaceutique, Clermont-Ferrand, France; Dr H. Batista, US Food and Drug Administration, Silver Spring, MD, USA; Mr B. Baudrand, OTECI, Paris, France; Dr O.P. Baula, Deputy Director, State Pharmacological Center, Ministry of Health, Kiev, Ukraine; Professor S.A. Bawazir, Vice-President, Saudi Food and Drug Authority, Head of Drug Sector, Riyadh, Saudi Arabia; Dr M.G. Beatrice, Vice President, Corporate Regulatory and Quality Science, Abbott, Abbott Park, USA; Dr T.L. Bedane, Drug Administration and Control, Addis Ababa, Ethiopia; Ms T.J. Bell, WHO Focal Point, US Food and Drug Administration, Silver Spring, MD, USA; Dr I.B.G. Bernstein, Director, Pharmacy Affairs, Office of the Commissioner/Office of Policy, US Food and Drug Administration, Silver Spring, MD, USA; Dr R.P. Best, President and CEO, International Society for Pharmaceutical Engineering, Tampa, FL, USA; Dr L. Bigger, Regulatory and Scientific Affairs, International Federation of Pharmaceutical Manufacturers Associations, Geneva, Switzerland; Dr L. Bonthuys, Pretoria, South Africa; Professor R. Boudet-Dalbin, Facult\u00e9 de Pharmacie, Laboratoire de Chimie Th\u00e9rapeutique, Paris, France; Dr S.K. Branch, Acting Group Manager, Special Populations Group, Medicines and Healthcare products Regulatory Agency, London, England; Dr E. Brendel, Bayer HealthCare AG, Elberfeld, Germany; Mr C. Brown, Inspections Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency, London, England; Dr W. Bukachi, Project Coordinator, International Affairs, US Pharmacopeia, Rockville, MD, USA; Dr F. Burnett, Managing Director, Pharmaceutical Procurement Service, Organization of Eastern Caribbean States, Castries, St Lucia; Dr D. Calam, Wiltshire, England; Dr N. Cappuccio, Lambertville, NJ, USA; Dr A. Castro, Regulatory Affairs Director and Senior Pharmacist, Roche Servicios SA, Heredia, Costa Rica; Dr D. Catsoulacos, Scientific Administrator, Manufacturing and Quality Compliance, Compliance and Inspection, European Medicines Agency, London, England; Mr Xuanhao Chan, Project Manager, International Pharmaceutical Federation, The Hague, Netherlands; Dr B. Chapart, Pharma Review Manager, Global Analytical Development, Sanofi-Aventis Pharma, Anthony, France; Ms Cheah Nuan Ping, Director, Cosmetics & Cigarette Testing Laboratory, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore; Dr Xu Chen, Director, Division of Drug Distribution Supervision, State Food and Drug Administration, Beijing, People's Republic of China; Professor Y. Cherrah, Facult\u00e9 de M\u00e9decine et Pharmacie, Rabat, Morocco; Ms I. Clamou, Assistant Manager, Scientific, Technical and Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; Dr M. Cooke, Senior Manager, Global Quality, Operations, AstraZeneca, Macclesfield, Cheshire, England; Dr C. Craft, Member, United States Pharmacopeia International Health Expert Committee, Rockville, MD, USA; Dr R.L. Dana, Senior Vice President, Regulatory Affairs and Parenteral Drug Association Training and Research Institute, Parenteral Drug Association, Bethesda, MD, USA; Dr V. Davoust, Quality & Regulatory Policy, Global CMC, WW Pharmaceutical Sciences, Pfizer Global Research & Development Paris, France; Professor T. Dekker, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa; Dr M. Dereque-Pois, Director General, European Association of Pharmaceutical Full-line Wholesalers, Brussels, Belgium; Professor J.B. Dressman, Institut f\u00fcr Pharmazeutische Technologie, Biozentrum, Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt/Main, Germany; Dr A.T. Ducca, Senior Director, Regulatory", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b4f110b4ee95070c5c4b904c3a83c496a8053f5580b8b45304b5582bf4d1eefe", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Medico-Pharmaceutique, Clermont-Ferrand, France; Dr H. Batista, US Food and Drug Administration, Silver Spring, MD, USA; Mr B. Baudrand, OTECI, Paris, France; Dr O.P. Baula, Deputy Director, State Pharmacological Center, Ministry of Health, Kiev, Ukraine; Professor S.A. Bawazir, Vice-President, Saudi Food and Drug Authority, Head of Drug Sector, Riyadh, Saudi Arabia; Dr M.G. Beatrice, Vice President, Corporate Regulatory and Quality Science, Abbott, Abbott Park, USA; Dr T.L. Bedane, Drug Administration and Control, Addis Ababa, Ethiopia; Ms T.J. Bell, WHO Focal Point, US Food and Drug Administration, Silver Spring, MD, USA; Dr I.B.G. Bernstein, Director, Pharmacy Affairs, Office of the Commissioner/Office of Policy, US Food and Drug Administration, Silver Spring, MD, USA; Dr R.P. Best, President and CEO, International Society for Pharmaceutical Engineering, Tampa, FL, USA; Dr L. Bigger, Regulatory and Scientific Affairs, International Federation of Pharmaceutical Manufacturers Associations, Geneva, Switzerland; Dr L. Bonthuys, Pretoria, South Africa; Professor R. Boudet-Dalbin, Facult\u00e9 de Pharmacie, Laboratoire de Chimie Th\u00e9rapeutique, Paris, France; Dr S.K. Branch, Acting Group Manager, Special Populations Group, Medicines and Healthcare products Regulatory Agency, London, England; Dr E. Brendel, Bayer HealthCare AG, Elberfeld, Germany; Mr C. Brown, Inspections Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency, London, England; Dr W. Bukachi, Project Coordinator, International Affairs, US Pharmacopeia, Rockville, MD, USA; Dr F. Burnett, Managing Director, Pharmaceutical Procurement Service, Organization of Eastern Caribbean States, Castries, St Lucia; Dr D. Calam, Wiltshire, England; Dr N. Cappuccio, Lambertville, NJ, USA; Dr A. Castro, Regulatory Affairs Director and Senior Pharmacist, Roche Servicios SA, Heredia, Costa Rica; Dr D. Catsoulacos, Scientific Administrator, Manufacturing and Quality Compliance, Compliance and Inspection, European Medicines Agency, London, England; Mr Xuanhao Chan, Project Manager, International Pharmaceutical Federation, The Hague, Netherlands; Dr B. Chapart, Pharma Review Manager, Global Analytical Development, Sanofi-Aventis Pharma, Anthony, France; Ms Cheah Nuan Ping, Director, Cosmetics & Cigarette Testing Laboratory, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore; Dr Xu Chen, Director, Division of Drug Distribution Supervision, State Food and Drug Administration, Beijing, People's Republic of China; Professor Y. Cherrah, Facult\u00e9 de M\u00e9decine et Pharmacie, Rabat, Morocco; Ms I. Clamou, Assistant Manager, Scientific, Technical and Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; Dr M. Cooke, Senior Manager, Global Quality, Operations, AstraZeneca, Macclesfield, Cheshire, England; Dr C. Craft, Member, United States Pharmacopeia International Health Expert Committee, Rockville, MD, USA; Dr R.L. Dana, Senior Vice President, Regulatory Affairs and Parenteral Drug Association Training and Research Institute, Parenteral Drug Association, Bethesda, MD, USA; Dr V. Davoust, Quality & Regulatory Policy, Global CMC, WW Pharmaceutical Sciences, Pfizer Global Research & Development Paris, France; Professor T. Dekker, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa; Dr M. Dereque-Pois, Director General, European Association of Pharmaceutical Full-line Wholesalers, Brussels, Belgium; Professor J.B. Dressman, Institut f\u00fcr Pharmazeutische Technologie, Biozentrum, Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt/Main, Germany; Dr A.T. Ducca, Senior Director, Regulatory", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3727, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f1136d7b-2bf1-4aff-adf5-234cfc95d1af": {"__data__": {"id_": "f1136d7b-2bf1-4aff-adf5-234cfc95d1af", "embedding": null, "metadata": {"page_label": "90", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento mencionado es el \"WHO - Technical Report Series 957\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica y recomendaciones para la pr\u00e1ctica cl\u00ednica y la pol\u00edtica de salud. Sin embargo, el contenido espec\u00edfico del informe en la p\u00e1gina 90 no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las principales recomendaciones de salud p\u00fablica presentadas en la p\u00e1gina 90 del informe WHO - Technical Report Series 957?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las recomendaciones que podr\u00edan estar incluidas en esa secci\u00f3n del informe.\n\n2. **\u00bfQu\u00e9 metodolog\u00eda se utiliz\u00f3 para recopilar los datos presentados en la p\u00e1gina 90 del informe?**\n   - Esta pregunta se centra en la metodolog\u00eda de investigaci\u00f3n, que es un aspecto crucial en los informes t\u00e9cnicos de la OMS.\n\n3. **\u00bfQu\u00e9 temas espec\u00edficos se abordan en la secci\u00f3n de la p\u00e1gina 90 del informe y c\u00f3mo se relacionan con las tendencias actuales en salud p\u00fablica?**\n   - Esta pregunta busca conectar el contenido espec\u00edfico de la p\u00e1gina con las tendencias m\u00e1s amplias en el campo de la salud p\u00fablica, lo que podr\u00eda no estar disponible en otras fuentes. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n que probablemente sea \u00fanica y relevante dentro del contexto del informe t\u00e9cnico de la OMS.", "prev_section_summary": "La secci\u00f3n presenta una lista de expertos en regulaci\u00f3n farmac\u00e9utica y calidad de medicamentos, pertenecientes a diversas organizaciones internacionales y de diferentes pa\u00edses. Los temas clave incluyen:\n\n1. **Colaboraci\u00f3n Internacional**: La diversidad de los participantes sugiere un esfuerzo conjunto para abordar cuestiones de regulaci\u00f3n y calidad en la industria farmac\u00e9utica a nivel global.\n\n2. **Expertos y sus Afiliaciones**: Se mencionan nombres, t\u00edtulos y organizaciones de profesionales destacados en el campo, como la OMS, la FDA de EE. UU., la Agencia Europea de Medicamentos, y varias instituciones acad\u00e9micas y de investigaci\u00f3n.\n\n3. **Roles y Funciones**: Aunque no se detallan las funciones espec\u00edficas de cada experto, se infiere que est\u00e1n involucrados en la regulaci\u00f3n, calidad, investigaci\u00f3n y desarrollo de medicamentos.\n\n4. **Temas de Regulaci\u00f3n y Calidad**: Aunque no se especifican, se puede suponer que los expertos discuten temas relevantes para la regulaci\u00f3n farmac\u00e9utica, como est\u00e1ndares de calidad, cumplimiento normativo y pr\u00e1cticas de fabricaci\u00f3n.\n\nEn resumen, la secci\u00f3n destaca la importancia de la colaboraci\u00f3n internacional en la regulaci\u00f3n farmac\u00e9utica, reflejando un enfoque global hacia la mejora de las pr\u00e1cticas en este campo.", "excerpt_keywords": "Keywords: OMS, regulaci\u00f3n farmac\u00e9utica, calidad de medicamentos, colaboraci\u00f3n internacional, salud p\u00fablica"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "02d8eabb-37a0-4fd5-a3fb-3004c1edbd1b", "node_type": "4", "metadata": {"page_label": "90", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "21820e22-6d99-4152-b443-2f081ea740ce": {"__data__": {"id_": "21820e22-6d99-4152-b443-2f081ea740ce", "embedding": null, "metadata": {"page_label": "91", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Dr M. James, GlaxoSmithKline, Brentford, Middlesex, England; Professor Jin Shaohong, Executive Director-General, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People\u2019s Republic of China; Dr P. Jones, Director, Analytical Control, Pharmaceutical Sciences, Pfizer Global R&D, Sandwich, England; Dr Y. Juillet, France; Ms A. Juntonen, Senior Pharmaceutical Inspector, National Agency for Medicines, Helsinki, Finland; Mr D. J\u00fcnemann, Teaching Assistant; Institut f\u00fcr Pharmazeutische Technologie, Biozentrum, Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt/Main, Germany; Dr M. Kaplan, Director, Institute for Standardization and Control of Pharmaceuticals, Jerusalem, Israel; Dr A.M. Kaukonen, National Agency for Medicines, Helsinki, Finland; Dr T. Kawanishi, Division of Drugs, National Institute of Health Sciences, Tokyo, Japan; Dr S. Keitel, Director, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France; Dr M. Keller, Division of Certificates & Licences, Licensing Sector, Berne, Switzerland; Dr H. K\u00f6szegi-Szalai, Head, Department for Quality Assessment and Control, National Institute of Pharmacy, Budapest, Hungary; Dr A. Kovacs, Secretariat, Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland; Dr A. Krauss, Principal Scientist, Chemist Laboratory, Therapeutic Goods Administration Laboratories, Woden, Australian Capital Territory, Australia; Professor H.G. Kristensen, Vedbaek, Denmark; Mr A. Kupfermann, Industry Pharmacist, Strasbourg, France; Professor S. L\u00e4r, Institut f\u00fcr Klinische Pharmazie und Pharmakotherapie, Heinrich-Heine-Universit\u00e4t, D\u00fcsseldorf, Germany; Dr J.-M. Legrand, GlaxoSmithKline Biologicals, Wavre, Belgium; Dr A. Lodi, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France; Mr M. Lok, Head of Office, Office of Manufacturing Quality, Therapeutic Goods Administration, Woden, Australian Capital Territory, Australia; Ms Low Min Yong, Director, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore; Dr J.C. Lyda, Senior Director, Regulatory Affairs, Parenteral Drug Association Europe, Glienicke/Berlin, Germany; Mr D. Mader, Compliance Auditor, GlaxoSmithKline, Cape Town, South Africa; Mr J-D. Mallet, OTECI, Paris, France; Reverend J.Y. Martey, Head, Laboratory Services, Quality Control Laboratory, Food and Drugs Board, Accra, Ghana; Dr T. Massa, Vice President, Global Regulatory Sciences \u2014 Chemistry, Manufacturing and Control, Bristol-Myers Squibb, USA; Dr B. Matthews, Alcon, Hemel Hempstead, Herts, England; Dr Y. Matthews, Regulatory Operations Executive, GE Healthcare, Amersham, Bucks, England; Dr J.-L. Mazert, Rueil, France; Dr G. McGurk, Executive Inspector, Irish Medicines Board, Dublin, Ireland; Dr A. Mechkovski, Moscow, Russian Federation; Dr M. Mehmandoust, DEMEB/DEQPH, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9, Saint-Denis, France; Dr D. Mehta, Vigilance and Risk Management of Medicines, Medicines and Healthcare Products Regulatory Agency, London, England; Dr J.H.McB. Miller, Strasbourg, France; Dr O. Milling, Medicines Inspector, Medicines Control Division, Danish Medicines Agency, Copenhagen, Denmark; Dr R.H. Mocchettino, Head of INAME Inspectorate, ANMAT, Caba, Argentina; Ms N.H. Mohd Potri, Senior Assistant, Director, GMP and Licensing Division, Centre for Compliance and Licensing, National Pharmaceutical Control Bureau, Ministry of Health Malaysia, Petaling Jaya, Malaysia; Dr J.A. Molzon, Associate Director for International Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA; Dr I. Moore, Product and Quality Assurance Manager, Croda", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl texto presenta una lista de profesionales y sus respectivas afiliaciones en el \u00e1mbito de la regulaci\u00f3n y control de productos farmac\u00e9uticos y biol\u00f3gicos. Incluye nombres, t\u00edtulos y organizaciones de diversas partes del mundo, destacando la colaboraci\u00f3n internacional en la regulaci\u00f3n de medicamentos y la calidad de productos farmac\u00e9uticos. Este contexto sugiere un enfoque en la cooperaci\u00f3n global para asegurar la calidad y seguridad de los productos de salud.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 papel desempe\u00f1a el Dr. M. James en GlaxoSmithKline y c\u00f3mo podr\u00eda su experiencia contribuir a la regulaci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta busca explorar la funci\u00f3n espec\u00edfica del Dr. M. James y su impacto en la industria farmac\u00e9utica, lo que puede no estar documentado en otras fuentes.\n\n2. **\u00bfCu\u00e1les son las responsabilidades del Dr. T. Kawanishi en el National Institute of Health Sciences de Jap\u00f3n y c\u00f3mo se relacionan con la calidad de los medicamentos?**\n   - Esta pregunta se centra en el rol del Dr. Kawanishi, proporcionando informaci\u00f3n sobre su trabajo en un contexto espec\u00edfico que podr\u00eda no estar disponible en otros lugares.\n\n3. **\u00bfQu\u00e9 iniciativas ha tomado la European Directorate for the Quality of Medicines and Healthcare, bajo la direcci\u00f3n del Dr. S. Keitel, para mejorar la regulaci\u00f3n de medicamentos en Europa?**\n   - Esta pregunta busca detalles sobre las acciones espec\u00edficas y pol\u00edticas implementadas por esta organizaci\u00f3n, que pueden no estar ampliamente documentadas.\n\n### Resumen de Nivel Superior\nEl documento destaca la importancia de la colaboraci\u00f3n internacional en el \u00e1mbito de la regulaci\u00f3n farmac\u00e9utica, presentando a expertos de diversas organizaciones y pa\u00edses. Este enfoque global es crucial para garantizar la calidad y seguridad de los productos farmac\u00e9uticos, lo que implica un intercambio de conocimientos y mejores pr\u00e1cticas entre diferentes entidades reguladoras.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl contenido proporcionado se refiere al \"WHO - Technical Report Series 957\", un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque no se dispone de informaci\u00f3n espec\u00edfica sobre la p\u00e1gina 90 del documento, se pueden inferir algunos temas clave y entidades relevantes:\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n del informe, que se centra en la salud p\u00fablica y la investigaci\u00f3n m\u00e9dica.\n\n2. **Informe T\u00e9cnico**: Parte de una serie que aborda diversas cuestiones relacionadas con la salud, incluyendo recomendaciones y pol\u00edticas de salud.\n\n3. **Salud P\u00fablica**: Tema central del informe, que probablemente incluye recomendaciones y metodolog\u00edas relacionadas con la mejora de la salud a nivel poblacional.\n\n4. **Investigaci\u00f3n M\u00e9dica**: Es probable que el informe incluya datos y an\u00e1lisis sobre pr\u00e1cticas m\u00e9dicas y su impacto en la salud p\u00fablica.\n\n5. **Metodolog\u00eda de Investigaci\u00f3n**: Un aspecto importante en los informes t\u00e9cnicos, que detalla c\u00f3mo se recopilaron y analizaron los datos presentados.\n\n6. **Tendencias en Salud P\u00fablica**: El informe podr\u00eda relacionar sus hallazgos con tendencias actuales en el campo de la salud, aunque esto no se detalla en el contenido proporcionado.\n\n### Conclusi\u00f3n:\nEl documento es parte de una serie t\u00e9cnica de la OMS que aborda temas relevantes en salud p\u00fablica, aunque el contenido espec\u00edfico de la p\u00e1gina 90 no est\u00e1 disponible. Las preguntas formuladas buscan profundizar en las recomendaciones, metodolog\u00edas y temas tratados en esa secci\u00f3n del informe.", "excerpt_keywords": "Keywords: regulaci\u00f3n farmac\u00e9utica, colaboraci\u00f3n internacional, calidad de medicamentos, organismos reguladores, productos biol\u00f3gicos"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cd6eed2f-1428-4923-81ca-25e04d8dffa5", "node_type": "4", "metadata": {"page_label": "91", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Dr M. James, GlaxoSmithKline, Brentford, Middlesex, England; Professor Jin Shaohong, Executive Director-General, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People\u2019s Republic of China; Dr P. Jones, Director, Analytical Control, Pharmaceutical Sciences, Pfizer Global R&D, Sandwich, England; Dr Y. Juillet, France; Ms A. Juntonen, Senior Pharmaceutical Inspector, National Agency for Medicines, Helsinki, Finland; Mr D. J\u00fcnemann, Teaching Assistant; Institut f\u00fcr Pharmazeutische Technologie, Biozentrum, Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt/Main, Germany; Dr M. Kaplan, Director, Institute for Standardization and Control of Pharmaceuticals, Jerusalem, Israel; Dr A.M. Kaukonen, National Agency for Medicines, Helsinki, Finland; Dr T. Kawanishi, Division of Drugs, National Institute of Health Sciences, Tokyo, Japan; Dr S. Keitel, Director, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France; Dr M. Keller, Division of Certificates & Licences, Licensing Sector, Berne, Switzerland; Dr H. K\u00f6szegi-Szalai, Head, Department for Quality Assessment and Control, National Institute of Pharmacy, Budapest, Hungary; Dr A. Kovacs, Secretariat, Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland; Dr A. Krauss, Principal Scientist, Chemist Laboratory, Therapeutic Goods Administration Laboratories, Woden, Australian Capital Territory, Australia; Professor H.G. Kristensen, Vedbaek, Denmark; Mr A. Kupfermann, Industry Pharmacist, Strasbourg, France; Professor S. L\u00e4r, Institut f\u00fcr Klinische Pharmazie und Pharmakotherapie, Heinrich-Heine-Universit\u00e4t, D\u00fcsseldorf, Germany; Dr J.-M. Legrand, GlaxoSmithKline Biologicals, Wavre, Belgium; Dr A. Lodi, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France; Mr M. Lok, Head of Office, Office of Manufacturing Quality, Therapeutic Goods Administration, Woden, Australian Capital Territory, Australia; Ms Low Min Yong, Director, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore; Dr J.C. Lyda, Senior Director, Regulatory Affairs, Parenteral Drug Association Europe, Glienicke/Berlin, Germany; Mr D. Mader, Compliance Auditor, GlaxoSmithKline, Cape Town, South Africa; Mr J-D. Mallet, OTECI, Paris, France; Reverend J.Y. Martey, Head, Laboratory Services, Quality Control Laboratory, Food and Drugs Board, Accra, Ghana; Dr T. Massa, Vice President, Global Regulatory Sciences \u2014 Chemistry, Manufacturing and Control, Bristol-Myers Squibb, USA; Dr B. Matthews, Alcon, Hemel Hempstead, Herts, England; Dr Y. Matthews, Regulatory Operations Executive, GE Healthcare, Amersham, Bucks, England; Dr J.-L. Mazert, Rueil, France; Dr G. McGurk, Executive Inspector, Irish Medicines Board, Dublin, Ireland; Dr A. Mechkovski, Moscow, Russian Federation; Dr M. Mehmandoust, DEMEB/DEQPH, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9, Saint-Denis, France; Dr D. Mehta, Vigilance and Risk Management of Medicines, Medicines and Healthcare Products Regulatory Agency, London, England; Dr J.H.McB. Miller, Strasbourg, France; Dr O. Milling, Medicines Inspector, Medicines Control Division, Danish Medicines Agency, Copenhagen, Denmark; Dr R.H. Mocchettino, Head of INAME Inspectorate, ANMAT, Caba, Argentina; Ms N.H. Mohd Potri, Senior Assistant, Director, GMP and Licensing Division, Centre for Compliance and Licensing, National Pharmaceutical Control Bureau, Ministry of Health Malaysia, Petaling Jaya, Malaysia; Dr J.A. Molzon, Associate Director for International Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA; Dr I. Moore, Product and Quality Assurance Manager, Croda", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "f51e5c10bdb6a1a2582b5ca9c136074644616d71b3a96550ca64f2423f976006", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Dr M. James, GlaxoSmithKline, Brentford, Middlesex, England; Professor Jin Shaohong, Executive Director-General, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People\u2019s Republic of China; Dr P. Jones, Director, Analytical Control, Pharmaceutical Sciences, Pfizer Global R&D, Sandwich, England; Dr Y. Juillet, France; Ms A. Juntonen, Senior Pharmaceutical Inspector, National Agency for Medicines, Helsinki, Finland; Mr D. J\u00fcnemann, Teaching Assistant; Institut f\u00fcr Pharmazeutische Technologie, Biozentrum, Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt/Main, Germany; Dr M. Kaplan, Director, Institute for Standardization and Control of Pharmaceuticals, Jerusalem, Israel; Dr A.M. Kaukonen, National Agency for Medicines, Helsinki, Finland; Dr T. Kawanishi, Division of Drugs, National Institute of Health Sciences, Tokyo, Japan; Dr S. Keitel, Director, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France; Dr M. Keller, Division of Certificates & Licences, Licensing Sector, Berne, Switzerland; Dr H. K\u00f6szegi-Szalai, Head, Department for Quality Assessment and Control, National Institute of Pharmacy, Budapest, Hungary; Dr A. Kovacs, Secretariat, Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland; Dr A. Krauss, Principal Scientist, Chemist Laboratory, Therapeutic Goods Administration Laboratories, Woden, Australian Capital Territory, Australia; Professor H.G. Kristensen, Vedbaek, Denmark; Mr A. Kupfermann, Industry Pharmacist, Strasbourg, France; Professor S. L\u00e4r, Institut f\u00fcr Klinische Pharmazie und Pharmakotherapie, Heinrich-Heine-Universit\u00e4t, D\u00fcsseldorf, Germany; Dr J.-M. Legrand, GlaxoSmithKline Biologicals, Wavre, Belgium; Dr A. Lodi, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France; Mr M. Lok, Head of Office, Office of Manufacturing Quality, Therapeutic Goods Administration, Woden, Australian Capital Territory, Australia; Ms Low Min Yong, Director, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore; Dr J.C. Lyda, Senior Director, Regulatory Affairs, Parenteral Drug Association Europe, Glienicke/Berlin, Germany; Mr D. Mader, Compliance Auditor, GlaxoSmithKline, Cape Town, South Africa; Mr J-D. Mallet, OTECI, Paris, France; Reverend J.Y. Martey, Head, Laboratory Services, Quality Control Laboratory, Food and Drugs Board, Accra, Ghana; Dr T. Massa, Vice President, Global Regulatory Sciences \u2014 Chemistry, Manufacturing and Control, Bristol-Myers Squibb, USA; Dr B. Matthews, Alcon, Hemel Hempstead, Herts, England; Dr Y. Matthews, Regulatory Operations Executive, GE Healthcare, Amersham, Bucks, England; Dr J.-L. Mazert, Rueil, France; Dr G. McGurk, Executive Inspector, Irish Medicines Board, Dublin, Ireland; Dr A. Mechkovski, Moscow, Russian Federation; Dr M. Mehmandoust, DEMEB/DEQPH, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9, Saint-Denis, France; Dr D. Mehta, Vigilance and Risk Management of Medicines, Medicines and Healthcare Products Regulatory Agency, London, England; Dr J.H.McB. Miller, Strasbourg, France; Dr O. Milling, Medicines Inspector, Medicines Control Division, Danish Medicines Agency, Copenhagen, Denmark; Dr R.H. Mocchettino, Head of INAME Inspectorate, ANMAT, Caba, Argentina; Ms N.H. Mohd Potri, Senior Assistant, Director, GMP and Licensing Division, Centre for Compliance and Licensing, National Pharmaceutical Control Bureau, Ministry of Health Malaysia, Petaling Jaya, Malaysia; Dr J.A. Molzon, Associate Director for International Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA; Dr I. Moore, Product and Quality Assurance Manager, Croda", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3734, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "142b149a-fd55-4b1a-82d1-1675242f065a": {"__data__": {"id_": "142b149a-fd55-4b1a-82d1-1675242f065a", "embedding": null, "metadata": {"page_label": "92", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido que podr\u00eda estar relacionado:\n\n### Resumen del Contexto\nEl documento mencionado es el \"WHO - Technical Report Series 957\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica, y recomendaciones para pr\u00e1cticas de salud a nivel global. Sin embargo, el contenido espec\u00edfico del documento no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el informe t\u00e9cnico de la OMS en la serie 957?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el contenido del informe, que podr\u00eda incluir datos sobre enfermedades, tratamientos, o pol\u00edticas de salud.\n\n2. **\u00bfQu\u00e9 temas de salud p\u00fablica se abordan en el documento \"WHO - Technical Report Series 957\"?**\n   - Esta pregunta se centra en identificar los temas clave tratados en el informe, lo que podr\u00eda incluir enfermedades infecciosas, salud materno-infantil, o estrategias de prevenci\u00f3n.\n\n3. **\u00bfC\u00f3mo se compara el contenido del informe 957 con otros informes anteriores de la serie de la OMS?**\n   - Esta pregunta busca establecer una comparaci\u00f3n entre el informe actual y los anteriores, lo que podr\u00eda revelar tendencias en la investigaci\u00f3n y cambios en las recomendaciones de salud p\u00fablica.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que probablemente no se encuentre f\u00e1cilmente en otros documentos o fuentes, dado que se centran en el contenido particular del informe t\u00e9cnico de la OMS.", "prev_section_summary": "La secci\u00f3n presenta una lista de profesionales destacados en el \u00e1mbito de la regulaci\u00f3n y control de productos farmac\u00e9uticos y biol\u00f3gicos, provenientes de diversas organizaciones y pa\u00edses. Los temas clave incluyen:\n\n1. **Colaboraci\u00f3n Internacional**: Se enfatiza la importancia de la cooperaci\u00f3n global en la regulaci\u00f3n de medicamentos y la garant\u00eda de la calidad y seguridad de los productos de salud.\n\n2. **Diversidad de Expertos**: La lista incluye a expertos de diferentes disciplinas y pa\u00edses, lo que refleja un enfoque multidisciplinario y multicultural en la regulaci\u00f3n farmac\u00e9utica.\n\n3. **Entidades Reguladoras**: Se mencionan varias organizaciones clave, como:\n   - GlaxoSmithKline\n   - Pfizer Global R&D\n   - National Institute for the Control of Pharmaceutical and Biological Products (China)\n   - European Directorate for the Quality of Medicines and Healthcare (Francia)\n   - Medicines and Healthcare Products Regulatory Agency (Reino Unido)\n   - Therapeutic Goods Administration (Australia)\n   - US Food and Drug Administration (EE. UU.)\n\n4. **Roles y Responsabilidades**: Se destacan los t\u00edtulos y roles de los profesionales, lo que sugiere una amplia gama de responsabilidades en la regulaci\u00f3n, control de calidad, y desarrollo de pol\u00edticas en el sector farmac\u00e9utico.\n\nEn resumen, la secci\u00f3n subraya la relevancia de la colaboraci\u00f3n internacional y la diversidad de expertos en la regulaci\u00f3n de productos farmac\u00e9uticos, lo que es esencial para asegurar la calidad y seguridad de los medicamentos a nivel global.", "excerpt_keywords": "Keywords: OMS, regulaci\u00f3n farmac\u00e9utica, cooperaci\u00f3n internacional, calidad de medicamentos, salud p\u00fablica"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8a3f516b-90bf-48f0-afc3-99f3d245ae2e", "node_type": "4", "metadata": {"page_label": "92", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c68c5d53-eb45-40eb-9d78-ed0e0e01e60c": {"__data__": {"id_": "c68c5d53-eb45-40eb-9d78-ed0e0e01e60c", "embedding": null, "metadata": {"page_label": "93", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt/Main, Germany; Dr U. Shah, Formulation Research Fellow, Cheshire, Merseyside & North Wales LRN, Medicines for Children Research Network, Royal Liverpool Children's NHS Trust, Liverpool, England; Dr P.D. Sheth, Vice-President, International Pharmaceutical Federation, New Delhi, India; Dr P.G. Shrotriya, Ambli, Ahmedabad, India; Dr M. Sigonda, Director-General, Tanzania Food and Drugs Authority, Dar-es-Salaam, United Republic of Tanzania; Dr G.N. Singh, Secretary-cum-Scientific Director, Government of India, Ministry of Health and Family Welfare, Central Indian Pharmacopoeia Laboratory, Ghaziabad, India; Dr S. Singh, Professor and Head, Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Nagar, Punjab, India; Ms K. Siniivuo, Senior Researcher and Secretary, National Agency for Medicines, Helsinki, Finland; Dr L. Slamet, Director, Drug Control, General Directorate of Drug and Food Control, Jakarta, Indonesia; Mr D. Smith, Principal Scientist, SSI, Gauteng, South Africa; Dr C. Sokhan, Deputy Director, Department of Drug and Food, Phnom Penh, Cambodia; Dr A. Spreitzhofer, AGES PharmMed GmbH, Vienna, Austria; Dr Y. Stewart, Scientific, Technical and Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; Dr L. Stoppa, Agenzia Italiana del Farmaco, Rome, Italy; Dr S. Sur, Kiev, Ukraine; Dr E. Swanepoel, Head, Operations, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa; Professor M. Sznitowska, Department of Pharmaceutical Technology, Medical University of Gdansk, Gdansk, Poland; Dr D. Teitz, Manager, Bristol-Myers Squibb Company, New Brunswick, NJ, USA; Dr B.B. Thapa, Chief Drug Administrator, Department of Drug Administration, Ministry of Health and Population, Kathmandu, Nepal; Dr R. Torano, Pharmacopoeial Intelligence and Advocacy Specialist, GlaxoSmithKline, Brentford, Middlesex, England; Ms M. Treebamroong, Senior Pharmacist, Drug Quality and Safety, Department of Medical Sciences, Bureau of Drug and Narcotic, Ministry of Public Health, Nonthaburi, Thailand; Mr R. Tribe, Holder, Australian Capital Territory, Australia; Associate Professor Trinh Van Lau, Director, National Institute of Drug Quality Control, Hanoi Viet Nam; Professor Tu Guoshi, National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing, People's Republic of China; Dr C. Tuleu, Senior Lecturer and Deputy Director, Department of Pharmaceutics and Centre for Paediatric Pharmacy Research, School of Pharmacy, University of London, London, England; Ms E. Uramis, La Havana, Cuba; Dr A.R.T. Utami, National Agency for Drugs and Food Control, Jakarta Pusat, Indonesia; Mrs M. Vallender, Editor-in-Chief, British Pharmacopoeia Commission Secretariat, London, England; Mr P. van der Hoeven, APIC Secretary General and Cefic Manager, Active Pharmaceutical Ingredients Committee, Managing Director, Fine Chemicals, European Chemical Industry Council, Brussels, Belgium; Mr L. Viornery, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9, Saint Denis, France; Dr L. Virgili, USA; Professor Wang Ping, Deputy Director, China Pharmacopoeia Committee, Beijing, People's Republic of China; Dr G. Wang'ang'a, Head, Microbiological and Medical Devices Units, National Quality Control Laboratory, Nairobi, Kenya; Dr A. Ward, Regulatory Affairs, Avecia Vaccines, Billingham, England; Dr W. Watson, Associate Manager, CMC Regulatory Affairs, Gilead Sciences International, Cambridge, England; Dr D.E. Webber, Director-General, World Self-Medication Industry, Ferney-Voltaire, France; Professor W. Wieniawski,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl contexto presenta una lista de profesionales y acad\u00e9micos de diversas instituciones y pa\u00edses que est\u00e1n involucrados en el \u00e1mbito de la farmacolog\u00eda, la regulaci\u00f3n de medicamentos y la investigaci\u00f3n en salud. Se mencionan sus cargos y las organizaciones a las que pertenecen, lo que sugiere una colaboraci\u00f3n internacional en temas relacionados con la calidad y seguridad de los medicamentos.\n\n### Preguntas Generadas\n\n1. **\u00bfQu\u00e9 papel desempe\u00f1a Dr. U. Shah en la investigaci\u00f3n sobre medicamentos para ni\u00f1os y c\u00f3mo se relaciona su trabajo con la red de investigaci\u00f3n mencionada?**\n   - Esta pregunta busca profundizar en la contribuci\u00f3n espec\u00edfica de Dr. U. Shah en el contexto de la investigaci\u00f3n pedi\u00e1trica y su conexi\u00f3n con la Medicines for Children Research Network.\n\n2. **\u00bfCu\u00e1les son las principales responsabilidades de Dr. G.N. Singh como Secretario-cum-Scientific Director en el Gobierno de India, y c\u00f3mo impacta su trabajo en la farmacopoeia india?**\n   - Esta pregunta se centra en el papel de Dr. G.N. Singh y su influencia en la regulaci\u00f3n y est\u00e1ndares de medicamentos en India, lo que puede no estar ampliamente documentado en otras fuentes.\n\n3. **\u00bfQu\u00e9 iniciativas ha tomado la Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9, representada por Mr. L. Viornery, para mejorar la seguridad de los productos farmac\u00e9uticos en Francia?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las acciones y pol\u00edticas implementadas por la agencia francesa en el \u00e1mbito de la seguridad de medicamentos, que puede no estar disponible en otras publicaciones.\n\n### Resumen de Nivel Superior\nEl documento parece ser un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que incluye contribuciones de expertos internacionales en el campo de la farmacolog\u00eda y la regulaci\u00f3n de medicamentos. Los participantes provienen de diversas instituciones y pa\u00edses, lo que indica un esfuerzo colaborativo para abordar cuestiones relacionadas con la calidad y la seguridad de los medicamentos a nivel global.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 957\" es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS) que se enfoca en temas de salud p\u00fablica y recomendaciones para pr\u00e1cticas de salud a nivel global. Aunque el contenido espec\u00edfico no est\u00e1 disponible, se pueden inferir algunos temas clave y entidades relevantes:\n\n#### Temas Clave\n1. **Salud P\u00fablica**: El informe probablemente aborda cuestiones relacionadas con la salud p\u00fablica, incluyendo enfermedades, prevenci\u00f3n y control de epidemias.\n2. **Investigaci\u00f3n M\u00e9dica**: Es posible que se presenten hallazgos de investigaciones recientes en el campo de la medicina y la salud.\n3. **Recomendaciones de Salud**: El documento puede incluir directrices y recomendaciones para mejorar la salud a nivel global, basadas en evidencia cient\u00edfica.\n\n#### Entidades\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la publicaci\u00f3n del informe, que se dedica a coordinar esfuerzos internacionales en salud p\u00fablica.\n- **Informe T\u00e9cnico**: El tipo de documento que se presenta, que generalmente incluye an\u00e1lisis, datos y recomendaciones sobre temas de salud.\n\nEste resumen proporciona una visi\u00f3n general de lo que podr\u00eda incluir el informe, a pesar de la falta de contenido espec\u00edfico en el extracto proporcionado.", "excerpt_keywords": "Keywords: farmacolog\u00eda, regulaci\u00f3n de medicamentos, investigaci\u00f3n en salud, colaboraci\u00f3n internacional, calidad y seguridad de medicamentos"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c4251d76-0956-45d9-8347-deec778e5792", "node_type": "4", "metadata": {"page_label": "93", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt/Main, Germany; Dr U. Shah, Formulation Research Fellow, Cheshire, Merseyside & North Wales LRN, Medicines for Children Research Network, Royal Liverpool Children's NHS Trust, Liverpool, England; Dr P.D. Sheth, Vice-President, International Pharmaceutical Federation, New Delhi, India; Dr P.G. Shrotriya, Ambli, Ahmedabad, India; Dr M. Sigonda, Director-General, Tanzania Food and Drugs Authority, Dar-es-Salaam, United Republic of Tanzania; Dr G.N. Singh, Secretary-cum-Scientific Director, Government of India, Ministry of Health and Family Welfare, Central Indian Pharmacopoeia Laboratory, Ghaziabad, India; Dr S. Singh, Professor and Head, Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Nagar, Punjab, India; Ms K. Siniivuo, Senior Researcher and Secretary, National Agency for Medicines, Helsinki, Finland; Dr L. Slamet, Director, Drug Control, General Directorate of Drug and Food Control, Jakarta, Indonesia; Mr D. Smith, Principal Scientist, SSI, Gauteng, South Africa; Dr C. Sokhan, Deputy Director, Department of Drug and Food, Phnom Penh, Cambodia; Dr A. Spreitzhofer, AGES PharmMed GmbH, Vienna, Austria; Dr Y. Stewart, Scientific, Technical and Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; Dr L. Stoppa, Agenzia Italiana del Farmaco, Rome, Italy; Dr S. Sur, Kiev, Ukraine; Dr E. Swanepoel, Head, Operations, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa; Professor M. Sznitowska, Department of Pharmaceutical Technology, Medical University of Gdansk, Gdansk, Poland; Dr D. Teitz, Manager, Bristol-Myers Squibb Company, New Brunswick, NJ, USA; Dr B.B. Thapa, Chief Drug Administrator, Department of Drug Administration, Ministry of Health and Population, Kathmandu, Nepal; Dr R. Torano, Pharmacopoeial Intelligence and Advocacy Specialist, GlaxoSmithKline, Brentford, Middlesex, England; Ms M. Treebamroong, Senior Pharmacist, Drug Quality and Safety, Department of Medical Sciences, Bureau of Drug and Narcotic, Ministry of Public Health, Nonthaburi, Thailand; Mr R. Tribe, Holder, Australian Capital Territory, Australia; Associate Professor Trinh Van Lau, Director, National Institute of Drug Quality Control, Hanoi Viet Nam; Professor Tu Guoshi, National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing, People's Republic of China; Dr C. Tuleu, Senior Lecturer and Deputy Director, Department of Pharmaceutics and Centre for Paediatric Pharmacy Research, School of Pharmacy, University of London, London, England; Ms E. Uramis, La Havana, Cuba; Dr A.R.T. Utami, National Agency for Drugs and Food Control, Jakarta Pusat, Indonesia; Mrs M. Vallender, Editor-in-Chief, British Pharmacopoeia Commission Secretariat, London, England; Mr P. van der Hoeven, APIC Secretary General and Cefic Manager, Active Pharmaceutical Ingredients Committee, Managing Director, Fine Chemicals, European Chemical Industry Council, Brussels, Belgium; Mr L. Viornery, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9, Saint Denis, France; Dr L. Virgili, USA; Professor Wang Ping, Deputy Director, China Pharmacopoeia Committee, Beijing, People's Republic of China; Dr G. Wang'ang'a, Head, Microbiological and Medical Devices Units, National Quality Control Laboratory, Nairobi, Kenya; Dr A. Ward, Regulatory Affairs, Avecia Vaccines, Billingham, England; Dr W. Watson, Associate Manager, CMC Regulatory Affairs, Gilead Sciences International, Cambridge, England; Dr D.E. Webber, Director-General, World Self-Medication Industry, Ferney-Voltaire, France; Professor W. Wieniawski,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "416eef2428360ce374684238c6fe62094204a123804ce9434d6a8816df083405", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt/Main, Germany; Dr U. Shah, Formulation Research Fellow, Cheshire, Merseyside & North Wales LRN, Medicines for Children Research Network, Royal Liverpool Children's NHS Trust, Liverpool, England; Dr P.D. Sheth, Vice-President, International Pharmaceutical Federation, New Delhi, India; Dr P.G. Shrotriya, Ambli, Ahmedabad, India; Dr M. Sigonda, Director-General, Tanzania Food and Drugs Authority, Dar-es-Salaam, United Republic of Tanzania; Dr G.N. Singh, Secretary-cum-Scientific Director, Government of India, Ministry of Health and Family Welfare, Central Indian Pharmacopoeia Laboratory, Ghaziabad, India; Dr S. Singh, Professor and Head, Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Nagar, Punjab, India; Ms K. Siniivuo, Senior Researcher and Secretary, National Agency for Medicines, Helsinki, Finland; Dr L. Slamet, Director, Drug Control, General Directorate of Drug and Food Control, Jakarta, Indonesia; Mr D. Smith, Principal Scientist, SSI, Gauteng, South Africa; Dr C. Sokhan, Deputy Director, Department of Drug and Food, Phnom Penh, Cambodia; Dr A. Spreitzhofer, AGES PharmMed GmbH, Vienna, Austria; Dr Y. Stewart, Scientific, Technical and Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; Dr L. Stoppa, Agenzia Italiana del Farmaco, Rome, Italy; Dr S. Sur, Kiev, Ukraine; Dr E. Swanepoel, Head, Operations, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa; Professor M. Sznitowska, Department of Pharmaceutical Technology, Medical University of Gdansk, Gdansk, Poland; Dr D. Teitz, Manager, Bristol-Myers Squibb Company, New Brunswick, NJ, USA; Dr B.B. Thapa, Chief Drug Administrator, Department of Drug Administration, Ministry of Health and Population, Kathmandu, Nepal; Dr R. Torano, Pharmacopoeial Intelligence and Advocacy Specialist, GlaxoSmithKline, Brentford, Middlesex, England; Ms M. Treebamroong, Senior Pharmacist, Drug Quality and Safety, Department of Medical Sciences, Bureau of Drug and Narcotic, Ministry of Public Health, Nonthaburi, Thailand; Mr R. Tribe, Holder, Australian Capital Territory, Australia; Associate Professor Trinh Van Lau, Director, National Institute of Drug Quality Control, Hanoi Viet Nam; Professor Tu Guoshi, National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing, People's Republic of China; Dr C. Tuleu, Senior Lecturer and Deputy Director, Department of Pharmaceutics and Centre for Paediatric Pharmacy Research, School of Pharmacy, University of London, London, England; Ms E. Uramis, La Havana, Cuba; Dr A.R.T. Utami, National Agency for Drugs and Food Control, Jakarta Pusat, Indonesia; Mrs M. Vallender, Editor-in-Chief, British Pharmacopoeia Commission Secretariat, London, England; Mr P. van der Hoeven, APIC Secretary General and Cefic Manager, Active Pharmaceutical Ingredients Committee, Managing Director, Fine Chemicals, European Chemical Industry Council, Brussels, Belgium; Mr L. Viornery, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9, Saint Denis, France; Dr L. Virgili, USA; Professor Wang Ping, Deputy Director, China Pharmacopoeia Committee, Beijing, People's Republic of China; Dr G. Wang'ang'a, Head, Microbiological and Medical Devices Units, National Quality Control Laboratory, Nairobi, Kenya; Dr A. Ward, Regulatory Affairs, Avecia Vaccines, Billingham, England; Dr W. Watson, Associate Manager, CMC Regulatory Affairs, Gilead Sciences International, Cambridge, England; Dr D.E. Webber, Director-General, World Self-Medication Industry, Ferney-Voltaire, France; Professor W. Wieniawski,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3747, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1cb001e3-d1ed-4a6e-944a-3ccd3d6826d4": {"__data__": {"id_": "1cb001e3-d1ed-4a6e-944a-3ccd3d6826d4", "embedding": null, "metadata": {"page_label": "94", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Polish Pharmaceutical Society, Warsaw, Poland; Dr S. Wolfgang, US Food and Drug Administration, Silver Spring, MD, USA; Mr E. Wondemagegnehu Biwota, Addis Ababa, Ethiopia; Dr B. Wright, Group Manager, GMP/GDP, North East Region, Medicines Inspectorate, Medicines and Healthcare products Regulatory Agency, York, England; Professor Yang Zhong-Yuan, Director, Guangzhou Municipal Institute for Drug Control, Guangzhou, People\u2019s Republic of China; Dr Yi Dang, Scientist, US Pharmacopeia, Rockville, MD, USA; Dr H. Yusufu, National Agency for Food and Drug Administration and Control, Abuja, Nigeria; Dr M. Zahn, Keltern Germany; Dr Hua Zhang, GMP Department Head, Center for Certification & Evaluation, Shanghai Food and Drug Administration, Shanghai, People\u2019s Republic of China; Professor Zhong-Yuan Yang, Member, United States Pharmacopeia International Health Expert Committee, Rockville, MD, USA; Dr T. Zimmer, CD Safety, Quality & Environmental Protection, Boehringer Ingelheim GmbH, Ingelheim, Germany; Dr N. Zvolinska, Deputy Director, Pharmaceutical Department, State Pharmacological Centre, Ministry of Health, Kiev, Ukraine.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 957\" incluye una lista de profesionales y expertos de diversas organizaciones y pa\u00edses que est\u00e1n involucrados en la regulaci\u00f3n y control de medicamentos. Estos individuos provienen de instituciones como la Administraci\u00f3n de Alimentos y Medicamentos de EE. UU., la Agencia de Medicamentos y Productos de Salud del Reino Unido, y varias agencias y universidades de otros pa\u00edses, lo que refleja una colaboraci\u00f3n internacional en el \u00e1mbito de la farmacolog\u00eda y la regulaci\u00f3n de medicamentos.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 instituciones est\u00e1n representadas por los expertos mencionados en el documento?**\n   - Respuesta: Las instituciones incluyen la Polish Pharmaceutical Society, la US Food and Drug Administration, la Medicines and Healthcare products Regulatory Agency del Reino Unido, el Guangzhou Municipal Institute for Drug Control en China, y la National Agency for Food and Drug Administration and Control en Nigeria, entre otras.\n\n2. **\u00bfCu\u00e1les son las \u00e1reas de especializaci\u00f3n de algunos de los expertos listados en el documento?**\n   - Respuesta: Las \u00e1reas de especializaci\u00f3n incluyen la gesti\u00f3n de buenas pr\u00e1cticas de manufactura (GMP/GDP), la ciencia farmac\u00e9utica, la seguridad y calidad de los medicamentos, y la regulaci\u00f3n farmacol\u00f3gica.\n\n3. **\u00bfQu\u00e9 pa\u00edses est\u00e1n representados por los expertos mencionados en el contexto?**\n   - Respuesta: Los pa\u00edses representados incluyen Polonia, Estados Unidos, Etiop\u00eda, Inglaterra, China, Nigeria, Alemania y Ucrania.", "prev_section_summary": "La secci\u00f3n presenta una lista de profesionales destacados en el \u00e1mbito de la farmacolog\u00eda, regulaci\u00f3n de medicamentos e investigaci\u00f3n en salud, provenientes de diversas instituciones y pa\u00edses. A continuaci\u00f3n se resumen los temas clave y entidades mencionadas:\n\n### Temas Clave:\n1. **Colaboraci\u00f3n Internacional**: La lista incluye expertos de diferentes pa\u00edses, lo que sugiere un esfuerzo global para abordar cuestiones relacionadas con la calidad y seguridad de los medicamentos.\n2. **Regulaci\u00f3n de Medicamentos**: Se mencionan varios directores y funcionarios de agencias reguladoras, indicando un enfoque en la normativa y control de productos farmac\u00e9uticos.\n3. **Investigaci\u00f3n en Salud**: Varios participantes est\u00e1n involucrados en la investigaci\u00f3n y desarrollo de medicamentos, especialmente en el contexto pedi\u00e1trico.\n4. **Calidad y Seguridad**: La seguridad de los productos farmac\u00e9uticos es un tema recurrente, con representantes de agencias dedicadas a la vigilancia y control de medicamentos.\n\n### Entidades Mencionadas:\n- **Organizaciones y Agencias**:\n  - Medicines for Children Research Network (Reino Unido)\n  - Tanzania Food and Drugs Authority (Tanzania)\n  - National Agency for Medicines (Finlandia)\n  - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Francia)\n  - National Institute for Drug Quality Control (Vietnam)\n  - China Pharmacopoeia Committee (China)\n  \n- **Instituciones Acad\u00e9micas**:\n  - Johann Wolfgang Goethe-Universit\u00e4t (Alemania)\n  - National Institute of Pharmaceutical Education and Research (India)\n  - Medical University of Gdansk (Polonia)\n  - University of London (Reino Unido)\n\n- **Empresas Farmac\u00e9uticas**:\n  - Bristol-Myers Squibb Company (EE. UU.)\n  - GlaxoSmithKline (Reino Unido)\n  - Gilead Sciences International (Reino Unido)\n\n### Profesionales Destacados:\n- Dr. U. Shah (Reino Unido)\n- Dr. G.N. Singh (India)\n- Dr. M. Sigonda (Tanzania)\n- Dr. L. Virgili (EE. UU.)\n- Dr. A.R.T. Utami (Indonesia)\n\nEste resumen refleja la diversidad y el enfoque colaborativo de los expertos en el \u00e1mbito de la farmacolog\u00eda y la regulaci\u00f3n de medicamentos a nivel global.", "excerpt_keywords": "Keywords: pharmaceutical regulation, international collaboration, drug safety, GMP/GDP, health experts"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1b153ebe-776a-4e6b-8ba7-00bee8acd554", "node_type": "4", "metadata": {"page_label": "94", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Polish Pharmaceutical Society, Warsaw, Poland; Dr S. Wolfgang, US Food and Drug Administration, Silver Spring, MD, USA; Mr E. Wondemagegnehu Biwota, Addis Ababa, Ethiopia; Dr B. Wright, Group Manager, GMP/GDP, North East Region, Medicines Inspectorate, Medicines and Healthcare products Regulatory Agency, York, England; Professor Yang Zhong-Yuan, Director, Guangzhou Municipal Institute for Drug Control, Guangzhou, People\u2019s Republic of China; Dr Yi Dang, Scientist, US Pharmacopeia, Rockville, MD, USA; Dr H. Yusufu, National Agency for Food and Drug Administration and Control, Abuja, Nigeria; Dr M. Zahn, Keltern Germany; Dr Hua Zhang, GMP Department Head, Center for Certification & Evaluation, Shanghai Food and Drug Administration, Shanghai, People\u2019s Republic of China; Professor Zhong-Yuan Yang, Member, United States Pharmacopeia International Health Expert Committee, Rockville, MD, USA; Dr T. Zimmer, CD Safety, Quality & Environmental Protection, Boehringer Ingelheim GmbH, Ingelheim, Germany; Dr N. Zvolinska, Deputy Director, Pharmaceutical Department, State Pharmacological Centre, Ministry of Health, Kiev, Ukraine.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "4521786e8866baaf4658c091f38ebf244bb42327052c77930e0283196f770499", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Polish Pharmaceutical Society, Warsaw, Poland; Dr S. Wolfgang, US Food and Drug Administration, Silver Spring, MD, USA; Mr E. Wondemagegnehu Biwota, Addis Ababa, Ethiopia; Dr B. Wright, Group Manager, GMP/GDP, North East Region, Medicines Inspectorate, Medicines and Healthcare products Regulatory Agency, York, England; Professor Yang Zhong-Yuan, Director, Guangzhou Municipal Institute for Drug Control, Guangzhou, People\u2019s Republic of China; Dr Yi Dang, Scientist, US Pharmacopeia, Rockville, MD, USA; Dr H. Yusufu, National Agency for Food and Drug Administration and Control, Abuja, Nigeria; Dr M. Zahn, Keltern Germany; Dr Hua Zhang, GMP Department Head, Center for Certification & Evaluation, Shanghai Food and Drug Administration, Shanghai, People\u2019s Republic of China; Professor Zhong-Yuan Yang, Member, United States Pharmacopeia International Health Expert Committee, Rockville, MD, USA; Dr T. Zimmer, CD Safety, Quality & Environmental Protection, Boehringer Ingelheim GmbH, Ingelheim, Germany; Dr N. Zvolinska, Deputy Director, Pharmaceutical Department, State Pharmacological Centre, Ministry of Health, Kiev, Ukraine.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1131, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0ea7fc1e-16b6-4a33-9a5f-77d9159707cd": {"__data__": {"id_": "0ea7fc1e-16b6-4a33-9a5f-77d9159707cd", "embedding": null, "metadata": {"page_label": "95", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 1\n\n## WHO good practices for pharmaceutical quality control laboratories\n\n### General considerations\n\n- Glossary\n\n### Part one. Management and infrastructure\n\n1. Organization and management\n2. Quality management system\n3. Control of documentation\n4. Records\n5. Data-processing equipment\n6. Personnel\n7. Premises\n8. Equipment, instruments and other devices\n9. Contracts\n\n### Part two. Materials, equipment, instruments and other devices\n\n10. Reagents\n11. Reference substances and reference materials\n12. Calibration, verification of performance and qualification of equipment, instruments and other devices\n13. Traceability\n\n### Part three. Working procedures\n\n14. Incoming samples\n15. Analytical worksheet\n16. Validation of analytical procedures\n17. Testing\n18. Evaluation of test results\n19. Certificate of analysis\n20. Retained samples\n\n### Part four. Safety\n\n21. General rules\n\n### References\n\n### Appendix\n\nEquipment for a first-stage and medium-sized pharmaceutical quality control laboratory", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 957\" incluye un anexo que detalla las buenas pr\u00e1cticas de la OMS para laboratorios de control de calidad farmac\u00e9utica. Se organiza en varias partes que abordan consideraciones generales, gesti\u00f3n e infraestructura, materiales y equipos, procedimientos de trabajo y seguridad. Cada secci\u00f3n incluye aspectos clave como la gesti\u00f3n de la calidad, el control de documentaci\u00f3n, la validaci\u00f3n de procedimientos anal\u00edticos y las normas de seguridad.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los componentes clave de un sistema de gesti\u00f3n de calidad en un laboratorio de control de calidad farmac\u00e9utica seg\u00fan la OMS?**\n   - Esta pregunta se centra en la secci\u00f3n sobre \"Sistema de gesti\u00f3n de calidad\" y puede proporcionar detalles espec\u00edficos sobre los elementos que deben implementarse para asegurar la calidad en el laboratorio.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir para la validaci\u00f3n de procedimientos anal\u00edticos en un laboratorio de control de calidad farmac\u00e9utica?**\n   - Esta pregunta se refiere a la parte que trata sobre la \"Validaci\u00f3n de procedimientos anal\u00edticos\" y puede ofrecer informaci\u00f3n sobre los pasos y criterios necesarios para validar m\u00e9todos de an\u00e1lisis.\n\n3. **\u00bfQu\u00e9 equipos son recomendados para un laboratorio de control de calidad farmac\u00e9utica de primera etapa y de tama\u00f1o mediano?**\n   - Esta pregunta se dirige a la secci\u00f3n del ap\u00e9ndice que menciona el equipo necesario, lo que puede proporcionar una lista espec\u00edfica de instrumentos y dispositivos que se consideran esenciales para este tipo de laboratorio.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento \"WHO - Technical Report Series 957\" presenta una lista de expertos y profesionales de diversas organizaciones y pa\u00edses que participan en la regulaci\u00f3n y control de medicamentos. Los temas clave incluyen:\n\n1. **Colaboraci\u00f3n Internacional**: Se destaca la cooperaci\u00f3n entre diferentes pa\u00edses y organizaciones en el \u00e1mbito de la farmacolog\u00eda y la regulaci\u00f3n de medicamentos.\n\n2. **Instituciones Representadas**: Las entidades mencionadas incluyen:\n   - Polish Pharmaceutical Society (Polonia)\n   - US Food and Drug Administration (EE. UU.)\n   - Medicines and Healthcare products Regulatory Agency (Reino Unido)\n   - Guangzhou Municipal Institute for Drug Control (China)\n   - National Agency for Food and Drug Administration and Control (Nigeria)\n   - US Pharmacopeia (EE. UU.)\n   - Boehringer Ingelheim GmbH (Alemania)\n   - State Pharmacological Centre, Ministry of Health (Ucrania)\n\n3. **\u00c1reas de Especializaci\u00f3n**: Los expertos tienen diversas especializaciones, como:\n   - Buenas pr\u00e1cticas de manufactura (GMP/GDP)\n   - Ciencia farmac\u00e9utica\n   - Seguridad y calidad de los medicamentos\n   - Regulaci\u00f3n farmacol\u00f3gica\n\n4. **Diversidad Geogr\u00e1fica**: Los pa\u00edses representados en la lista de expertos incluyen Polonia, Estados Unidos, Etiop\u00eda, Inglaterra, China, Nigeria, Alemania y Ucrania, lo que refleja una amplia representaci\u00f3n global en el campo de la regulaci\u00f3n de medicamentos. \n\nEste resumen resalta la importancia de la colaboraci\u00f3n internacional y la diversidad de expertos en la regulaci\u00f3n y control de medicamentos a nivel global.", "excerpt_keywords": "Keywords: pharmaceutical quality control, WHO guidelines, laboratory management, analytical procedures, safety standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "91bc6956-1bb9-486c-b34e-2ee6413a66a8", "node_type": "4", "metadata": {"page_label": "95", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 1\n\n## WHO good practices for pharmaceutical quality control laboratories\n\n### General considerations\n\n- Glossary\n\n### Part one. Management and infrastructure\n\n1. Organization and management\n2. Quality management system\n3. Control of documentation\n4. Records\n5. Data-processing equipment\n6. Personnel\n7. Premises\n8. Equipment, instruments and other devices\n9. Contracts\n\n### Part two. Materials, equipment, instruments and other devices\n\n10. Reagents\n11. Reference substances and reference materials\n12. Calibration, verification of performance and qualification of equipment, instruments and other devices\n13. Traceability\n\n### Part three. Working procedures\n\n14. Incoming samples\n15. Analytical worksheet\n16. Validation of analytical procedures\n17. Testing\n18. Evaluation of test results\n19. Certificate of analysis\n20. Retained samples\n\n### Part four. Safety\n\n21. General rules\n\n### References\n\n### Appendix\n\nEquipment for a first-stage and medium-sized pharmaceutical quality control laboratory", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "f531594d44957d63dbb5946a2466e8fc6eb62e993a06250833af8d1f36b2e328", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 1\n\n## WHO good practices for pharmaceutical quality control laboratories\n\n### General considerations\n\n- Glossary\n\n### Part one. Management and infrastructure\n\n1. Organization and management\n2. Quality management system\n3. Control of documentation\n4. Records\n5. Data-processing equipment\n6. Personnel\n7. Premises\n8. Equipment, instruments and other devices\n9. Contracts\n\n### Part two. Materials, equipment, instruments and other devices\n\n10. Reagents\n11. Reference substances and reference materials\n12. Calibration, verification of performance and qualification of equipment, instruments and other devices\n13. Traceability\n\n### Part three. Working procedures\n\n14. Incoming samples\n15. Analytical worksheet\n16. Validation of analytical procedures\n17. Testing\n18. Evaluation of test results\n19. Certificate of analysis\n20. Retained samples\n\n### Part four. Safety\n\n21. General rules\n\n### References\n\n### Appendix\n\nEquipment for a first-stage and medium-sized pharmaceutical quality control laboratory", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1005, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "87bfb874-4cfb-4d2e-b5ae-d1ddeec06d22": {"__data__": {"id_": "87bfb874-4cfb-4d2e-b5ae-d1ddeec06d22", "embedding": null, "metadata": {"page_label": "96", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# General Considerations\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Products adopted in 1999 the guidelines entitled *WHO Good practices for national pharmaceutical control laboratories*, which were published as Annex 3 of the WHO Technical Report Series, No. 902, 2002. As the other guidelines related to laboratory quality assurance have been updated and subsequent inspections for the compliance with the guidelines on good practices for national pharmaceutical control laboratories indicated that some sections were in need of improvement and clarification, it was considered necessary to prepare a revised text.\n\nThese guidelines provide advice on the quality management system within which the analysis of active pharmaceutical ingredients (APIs), excipients and pharmaceutical products should be performed to demonstrate that reliable results are obtained.\n\nCompliance with the recommendations provided in these guidelines will help promote international harmonization of laboratory practices and will facilitate cooperation among laboratories and mutual recognition of results.\n\nSpecial attention should be given to ensure the correct and efficient functioning of the laboratory. Planning and future budgets should ensure that the necessary resources are available inter alia for the maintenance of the laboratory, as well as for an appropriate infrastructure and energy supply. Means and procedures should be in place (in case of possible supply problems) to ensure that the laboratory can continue its activities.\n\nThese guidelines are applicable to any pharmaceutical quality control laboratory, be it national, commercial or nongovernmental. However, they do not include guidance for those laboratories involved in the testing of biological products, e.g. vaccines and blood products. Separate guidance for such laboratories is available.\n\nThese guidelines are consistent with the requirements of the *WHO guidelines for good manufacturing practices* (1) and with the requirements of the International Standard ISO/IEC 17025:2005 (2), and provide detailed guidance for laboratories performing quality control of medicines. The guidance specific to microbiology laboratories can be found in the draft working document *WHO guideline on good practices for pharmaceutical microbiology laboratories* (reference QAS/09.297).\n\nThe good practice outlined below is to be considered as a general guide and it may be adapted to meet individual needs provided that an equivalent level of quality assurance is achieved. The notes given provide clarification of the text or examples; they do not contain requirements which should be fulfilled to comply with these guidelines.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en las directrices adoptadas por el Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Productos Farmac\u00e9uticos, que se publicaron en 1999 y se revisaron posteriormente. Estas directrices abordan el sistema de gesti\u00f3n de calidad en laboratorios de control farmac\u00e9utico, enfatizando la importancia de obtener resultados confiables en el an\u00e1lisis de ingredientes farmac\u00e9uticos activos (APIs), excipientes y productos farmac\u00e9uticos. Se destaca la necesidad de recursos adecuados, infraestructura y procedimientos para asegurar el funcionamiento continuo del laboratorio. Las directrices son aplicables a laboratorios de control de calidad farmac\u00e9utica, pero no incluyen laboratorios que prueban productos biol\u00f3gicos. Tambi\u00e9n se alinean con las buenas pr\u00e1cticas de fabricaci\u00f3n de la OMS y la norma ISO/IEC 17025:2005.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 aspectos espec\u00edficos se deben considerar para garantizar el funcionamiento eficiente de un laboratorio de control de calidad farmac\u00e9utica seg\u00fan las directrices de la OMS?**\n   - Esta pregunta busca detalles sobre la planificaci\u00f3n, el presupuesto y los recursos necesarios para el mantenimiento y la infraestructura del laboratorio.\n\n2. **\u00bfC\u00f3mo se relacionan las directrices de la OMS para laboratorios de control de calidad farmac\u00e9utica con las normas internacionales como ISO/IEC 17025:2005?**\n   - Esta pregunta se centra en la alineaci\u00f3n y la consistencia entre las directrices de la OMS y las normas internacionales, lo que puede no estar claramente definido en otros documentos.\n\n3. **\u00bfQu\u00e9 tipo de laboratorios no est\u00e1n cubiertos por estas directrices y d\u00f3nde se puede encontrar orientaci\u00f3n espec\u00edfica para ellos?**\n   - Esta pregunta busca informaci\u00f3n sobre las limitaciones de las directrices y la disponibilidad de orientaci\u00f3n para laboratorios que trabajan con productos biol\u00f3gicos, como vacunas y productos sangu\u00edneos.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\nEl anexo del documento \"WHO - Technical Report Series 957\" se centra en las buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave organizados por partes:\n\n1. **Consideraciones Generales**:\n   - Incluye un glosario que define t\u00e9rminos relevantes.\n\n2. **Parte Uno: Gesti\u00f3n e Infraestructura**:\n   - **Organizaci\u00f3n y gesti\u00f3n**: Estructura y roles dentro del laboratorio.\n   - **Sistema de gesti\u00f3n de calidad**: Estrategias para asegurar la calidad en los procesos.\n   - **Control de documentaci\u00f3n**: Procedimientos para manejar documentos y registros.\n   - **Registros**: Importancia de mantener registros precisos.\n   - **Equipos de procesamiento de datos**: Herramientas tecnol\u00f3gicas utilizadas.\n   - **Personal**: Capacitaci\u00f3n y competencias requeridas.\n   - **Instalaciones**: Requisitos f\u00edsicos del laboratorio.\n   - **Equipos, instrumentos y otros dispositivos**: Herramientas necesarias para el an\u00e1lisis.\n   - **Contratos**: Gesti\u00f3n de acuerdos con terceros.\n\n3. **Parte Dos: Materiales, Equipos, Instrumentos y Otros Dispositivos**:\n   - **Reactivos**: Sustancias qu\u00edmicas utilizadas en pruebas.\n   - **Sustancias de referencia y materiales de referencia**: Est\u00e1ndares para asegurar la precisi\u00f3n.\n   - **Calibraci\u00f3n, verificaci\u00f3n de rendimiento y calificaci\u00f3n**: Procesos para asegurar que los equipos funcionen correctamente.\n   - **Trazabilidad**: Mecanismos para rastrear la procedencia de los materiales.\n\n4. **Parte Tres: Procedimientos de Trabajo**:\n   - **Muestras entrantes**: Manejo de muestras recibidas.\n   - **Hoja de trabajo anal\u00edtica**: Documentaci\u00f3n de los procedimientos de an\u00e1lisis.\n   - **Validaci\u00f3n de procedimientos anal\u00edticos**: Aseguramiento de que los m\u00e9todos son adecuados.\n   - **Pruebas**: Ejecuci\u00f3n de an\u00e1lisis.\n   - **Evaluaci\u00f3n de resultados de pruebas**: Interpretaci\u00f3n de datos obtenidos.\n   - **Certificado de an\u00e1lisis**: Documentaci\u00f3n de resultados.\n   - **Muestras retenidas**: Almacenamiento de muestras para referencia futura.\n\n5. **Parte Cuatro: Seguridad**:\n   - **Reglas generales**: Normas de seguridad a seguir en el laboratorio.\n\n6. **Referencias**: Fuentes y documentos citados.\n\n7. **Ap\u00e9ndice**:\n   - Equipos recomendados para un laboratorio de control de calidad farmac\u00e9utica de primera etapa y de tama\u00f1o mediano.\n\nEste resumen destaca la estructura y los componentes esenciales que deben considerarse para establecer y mantener un laboratorio de control de calidad farmac\u00e9utica conforme a las directrices de la OMS.", "excerpt_keywords": "Keywords: pharmaceutical quality control, WHO guidelines, laboratory practices, active pharmaceutical ingredients, quality management system"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17ffdc95-f13c-46cd-9a10-5b80f5f6f74e", "node_type": "4", "metadata": {"page_label": "96", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# General Considerations\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Products adopted in 1999 the guidelines entitled *WHO Good practices for national pharmaceutical control laboratories*, which were published as Annex 3 of the WHO Technical Report Series, No. 902, 2002. As the other guidelines related to laboratory quality assurance have been updated and subsequent inspections for the compliance with the guidelines on good practices for national pharmaceutical control laboratories indicated that some sections were in need of improvement and clarification, it was considered necessary to prepare a revised text.\n\nThese guidelines provide advice on the quality management system within which the analysis of active pharmaceutical ingredients (APIs), excipients and pharmaceutical products should be performed to demonstrate that reliable results are obtained.\n\nCompliance with the recommendations provided in these guidelines will help promote international harmonization of laboratory practices and will facilitate cooperation among laboratories and mutual recognition of results.\n\nSpecial attention should be given to ensure the correct and efficient functioning of the laboratory. Planning and future budgets should ensure that the necessary resources are available inter alia for the maintenance of the laboratory, as well as for an appropriate infrastructure and energy supply. Means and procedures should be in place (in case of possible supply problems) to ensure that the laboratory can continue its activities.\n\nThese guidelines are applicable to any pharmaceutical quality control laboratory, be it national, commercial or nongovernmental. However, they do not include guidance for those laboratories involved in the testing of biological products, e.g. vaccines and blood products. Separate guidance for such laboratories is available.\n\nThese guidelines are consistent with the requirements of the *WHO guidelines for good manufacturing practices* (1) and with the requirements of the International Standard ISO/IEC 17025:2005 (2), and provide detailed guidance for laboratories performing quality control of medicines. The guidance specific to microbiology laboratories can be found in the draft working document *WHO guideline on good practices for pharmaceutical microbiology laboratories* (reference QAS/09.297).\n\nThe good practice outlined below is to be considered as a general guide and it may be adapted to meet individual needs provided that an equivalent level of quality assurance is achieved. The notes given provide clarification of the text or examples; they do not contain requirements which should be fulfilled to comply with these guidelines.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "4756f9c536acfe0993553a4e04504193734ca4eee5d93710a227a22229bef621", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# General Considerations\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Products adopted in 1999 the guidelines entitled *WHO Good practices for national pharmaceutical control laboratories*, which were published as Annex 3 of the WHO Technical Report Series, No. 902, 2002. As the other guidelines related to laboratory quality assurance have been updated and subsequent inspections for the compliance with the guidelines on good practices for national pharmaceutical control laboratories indicated that some sections were in need of improvement and clarification, it was considered necessary to prepare a revised text.\n\nThese guidelines provide advice on the quality management system within which the analysis of active pharmaceutical ingredients (APIs), excipients and pharmaceutical products should be performed to demonstrate that reliable results are obtained.\n\nCompliance with the recommendations provided in these guidelines will help promote international harmonization of laboratory practices and will facilitate cooperation among laboratories and mutual recognition of results.\n\nSpecial attention should be given to ensure the correct and efficient functioning of the laboratory. Planning and future budgets should ensure that the necessary resources are available inter alia for the maintenance of the laboratory, as well as for an appropriate infrastructure and energy supply. Means and procedures should be in place (in case of possible supply problems) to ensure that the laboratory can continue its activities.\n\nThese guidelines are applicable to any pharmaceutical quality control laboratory, be it national, commercial or nongovernmental. However, they do not include guidance for those laboratories involved in the testing of biological products, e.g. vaccines and blood products. Separate guidance for such laboratories is available.\n\nThese guidelines are consistent with the requirements of the *WHO guidelines for good manufacturing practices* (1) and with the requirements of the International Standard ISO/IEC 17025:2005 (2), and provide detailed guidance for laboratories performing quality control of medicines. The guidance specific to microbiology laboratories can be found in the draft working document *WHO guideline on good practices for pharmaceutical microbiology laboratories* (reference QAS/09.297).\n\nThe good practice outlined below is to be considered as a general guide and it may be adapted to meet individual needs provided that an equivalent level of quality assurance is achieved. The notes given provide clarification of the text or examples; they do not contain requirements which should be fulfilled to comply with these guidelines.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2694, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "668b17bc-eda3-481f-a990-fb108ade4b52": {"__data__": {"id_": "668b17bc-eda3-481f-a990-fb108ade4b52", "embedding": null, "metadata": {"page_label": "97", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Pharmaceutical quality control testing is usually a matter of repetitive testing of samples of APIs or of a limited number of pharmaceutical products, whereas national quality control laboratories have to be able to deal with a much wider range of pharmaceutical substances and products and, therefore, have to apply a wider variety of test methods. Specific recommendations for national pharmaceutical quality control laboratories are addressed in the following text. Particular consideration is given to countries with limited resources wishing to establish a governmental pharmaceutical quality control laboratory, having recently done so, or which are planning to modernize an existing laboratory.\n\nQuality control laboratories may perform some or all quality control activities, e.g. sampling, testing of APIs, excipients, packaging materials and/or pharmaceutical products, stability testing, testing against specifications and investigative testing.\n\nFor the quality of a medicine sample to be correctly assessed:\n\n- The submission of a sample of an API, excipient or pharmaceutical product or a suspected counterfeit material to the laboratory, selected in accordance with national requirements, should be accompanied by a statement of the reason why the analysis has been requested.\n- The analysis should be correctly planned and meticulously executed.\n- The results should be competently evaluated to determine whether the sample complies with the specifications or other relevant criteria.\n\n*National pharmaceutical quality control laboratories*\n\nThe government, normally through the national medicines regulatory authority (NMRA), may establish and maintain a pharmaceutical quality control laboratory to carry out the required tests and assays to verify that APIs, excipients and pharmaceutical products meet the prescribed specifications. Large countries may require several pharmaceutical quality control laboratories which conform to national legislation, and appropriate arrangements should, therefore, be in place to monitor their compliance with a quality management system. Throughout the process of marketing authorization and postmarketing surveillance, the laboratory or laboratories work closely with the NMRA.\n\nA national pharmaceutical quality control laboratory provides effective support for an NMRA acting together with its inspection services. The analytical results obtained should accurately describe the properties of the samples assessed, permitting correct conclusions to be drawn about the quality of the samples of medicines analysed, and also serving as an adequate basis for any subsequent administrative regulations and legal action.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda la importancia de los laboratorios nacionales de control de calidad farmac\u00e9utica, especialmente en pa\u00edses con recursos limitados. Se discuten las actividades que estos laboratorios pueden realizar, como el muestreo y las pruebas de ingredientes farmac\u00e9uticos activos (APIs), excipientes y productos farmac\u00e9uticos. Se enfatiza la necesidad de un proceso riguroso para la evaluaci\u00f3n de la calidad de las muestras y la colaboraci\u00f3n entre los laboratorios y las autoridades reguladoras de medicamentos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las actividades espec\u00edficas que pueden realizar los laboratorios nacionales de control de calidad farmac\u00e9utica?**\n   - Respuesta: Los laboratorios pueden realizar actividades como muestreo, pruebas de APIs, excipientes, materiales de embalaje y productos farmac\u00e9uticos, pruebas de estabilidad, pruebas contra especificaciones y pruebas investigativas.\n\n2. **\u00bfQu\u00e9 requisitos deben cumplirse al enviar una muestra a un laboratorio de control de calidad?**\n   - Respuesta: La muestra debe ir acompa\u00f1ada de una declaraci\u00f3n que explique el motivo de la solicitud de an\u00e1lisis, la planificaci\u00f3n del an\u00e1lisis debe ser correcta y ejecutada meticulosamente, y los resultados deben ser evaluados competentemente para determinar si la muestra cumple con las especificaciones o criterios relevantes.\n\n3. **\u00bfC\u00f3mo deben los laboratorios nacionales de control de calidad colaborar con las autoridades reguladoras de medicamentos?**\n   - Respuesta: Los laboratorios deben trabajar en estrecha colaboraci\u00f3n con la autoridad reguladora nacional de medicamentos (NMRA) durante el proceso de autorizaci\u00f3n de comercializaci\u00f3n y la vigilancia posterior a la comercializaci\u00f3n, asegurando que los resultados anal\u00edticos describan con precisi\u00f3n las propiedades de las muestras evaluadas y sirvan como base para regulaciones administrativas y acciones legales.", "prev_section_summary": "### Temas Clave\n\n1. **Directrices de la OMS**: Se adoptaron en 1999 y revisadas posteriormente, enfoc\u00e1ndose en las buenas pr\u00e1cticas para laboratorios de control farmac\u00e9utico nacional.\n  \n2. **Sistema de Gesti\u00f3n de Calidad**: Las directrices proporcionan un marco para asegurar que el an\u00e1lisis de ingredientes farmac\u00e9uticos activos (APIs), excipientes y productos farmac\u00e9uticos produzca resultados confiables.\n\n3. **Harmonizaci\u00f3n Internacional**: El cumplimiento de estas directrices promueve la armonizaci\u00f3n de pr\u00e1cticas de laboratorio y facilita la cooperaci\u00f3n y el reconocimiento mutuo de resultados entre laboratorios.\n\n4. **Recursos y Mantenimiento**: Se enfatiza la importancia de la planificaci\u00f3n, el presupuesto y la disponibilidad de recursos para el mantenimiento y la infraestructura del laboratorio.\n\n5. **Aplicabilidad**: Las directrices son aplicables a laboratorios de control de calidad farmac\u00e9utica, pero excluyen laboratorios que prueban productos biol\u00f3gicos, para los cuales hay orientaci\u00f3n separada.\n\n6. **Consistencia con Normas Internacionales**: Las directrices son coherentes con las buenas pr\u00e1cticas de fabricaci\u00f3n de la OMS y con la norma ISO/IEC 17025:2005.\n\n7. **Adaptabilidad**: Las buenas pr\u00e1cticas pueden adaptarse a las necesidades individuales siempre que se mantenga un nivel equivalente de aseguramiento de calidad.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la adopci\u00f3n de las directrices.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que adopt\u00f3 las directrices.\n- **Laboratorios de Control de Calidad**: Incluye laboratorios nacionales, comerciales y no gubernamentales.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Sustancias que se analizan seg\u00fan las directrices.\n- **Norma ISO/IEC 17025:2005**: Est\u00e1ndar internacional con el que las directrices son consistentes.\n- **Productos Biol\u00f3gicos**: Tipo de productos que no est\u00e1n cubiertos por estas directrices, como vacunas y productos sangu\u00edneos.", "excerpt_keywords": "Keywords: pharmaceutical quality control, national laboratories, APIs, regulatory authority, quality management system"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "316a1ca7-1501-435a-96c6-e98ce3964dbb", "node_type": "4", "metadata": {"page_label": "97", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Pharmaceutical quality control testing is usually a matter of repetitive testing of samples of APIs or of a limited number of pharmaceutical products, whereas national quality control laboratories have to be able to deal with a much wider range of pharmaceutical substances and products and, therefore, have to apply a wider variety of test methods. Specific recommendations for national pharmaceutical quality control laboratories are addressed in the following text. Particular consideration is given to countries with limited resources wishing to establish a governmental pharmaceutical quality control laboratory, having recently done so, or which are planning to modernize an existing laboratory.\n\nQuality control laboratories may perform some or all quality control activities, e.g. sampling, testing of APIs, excipients, packaging materials and/or pharmaceutical products, stability testing, testing against specifications and investigative testing.\n\nFor the quality of a medicine sample to be correctly assessed:\n\n- The submission of a sample of an API, excipient or pharmaceutical product or a suspected counterfeit material to the laboratory, selected in accordance with national requirements, should be accompanied by a statement of the reason why the analysis has been requested.\n- The analysis should be correctly planned and meticulously executed.\n- The results should be competently evaluated to determine whether the sample complies with the specifications or other relevant criteria.\n\n*National pharmaceutical quality control laboratories*\n\nThe government, normally through the national medicines regulatory authority (NMRA), may establish and maintain a pharmaceutical quality control laboratory to carry out the required tests and assays to verify that APIs, excipients and pharmaceutical products meet the prescribed specifications. Large countries may require several pharmaceutical quality control laboratories which conform to national legislation, and appropriate arrangements should, therefore, be in place to monitor their compliance with a quality management system. Throughout the process of marketing authorization and postmarketing surveillance, the laboratory or laboratories work closely with the NMRA.\n\nA national pharmaceutical quality control laboratory provides effective support for an NMRA acting together with its inspection services. The analytical results obtained should accurately describe the properties of the samples assessed, permitting correct conclusions to be drawn about the quality of the samples of medicines analysed, and also serving as an adequate basis for any subsequent administrative regulations and legal action.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b443f3c0678f1d826e0d03230b59984d8ba330dd9e17c4e976cc2428484cacc0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Pharmaceutical quality control testing is usually a matter of repetitive testing of samples of APIs or of a limited number of pharmaceutical products, whereas national quality control laboratories have to be able to deal with a much wider range of pharmaceutical substances and products and, therefore, have to apply a wider variety of test methods. Specific recommendations for national pharmaceutical quality control laboratories are addressed in the following text. Particular consideration is given to countries with limited resources wishing to establish a governmental pharmaceutical quality control laboratory, having recently done so, or which are planning to modernize an existing laboratory.\n\nQuality control laboratories may perform some or all quality control activities, e.g. sampling, testing of APIs, excipients, packaging materials and/or pharmaceutical products, stability testing, testing against specifications and investigative testing.\n\nFor the quality of a medicine sample to be correctly assessed:\n\n- The submission of a sample of an API, excipient or pharmaceutical product or a suspected counterfeit material to the laboratory, selected in accordance with national requirements, should be accompanied by a statement of the reason why the analysis has been requested.\n- The analysis should be correctly planned and meticulously executed.\n- The results should be competently evaluated to determine whether the sample complies with the specifications or other relevant criteria.\n\n*National pharmaceutical quality control laboratories*\n\nThe government, normally through the national medicines regulatory authority (NMRA), may establish and maintain a pharmaceutical quality control laboratory to carry out the required tests and assays to verify that APIs, excipients and pharmaceutical products meet the prescribed specifications. Large countries may require several pharmaceutical quality control laboratories which conform to national legislation, and appropriate arrangements should, therefore, be in place to monitor their compliance with a quality management system. Throughout the process of marketing authorization and postmarketing surveillance, the laboratory or laboratories work closely with the NMRA.\n\nA national pharmaceutical quality control laboratory provides effective support for an NMRA acting together with its inspection services. The analytical results obtained should accurately describe the properties of the samples assessed, permitting correct conclusions to be drawn about the quality of the samples of medicines analysed, and also serving as an adequate basis for any subsequent administrative regulations and legal action.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2673, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "abe5c177-472d-41f3-a69f-d21ff3af76dc": {"__data__": {"id_": "abe5c177-472d-41f3-a69f-d21ff3af76dc", "embedding": null, "metadata": {"page_label": "98", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "National pharmaceutical quality control laboratories usually encompass essentially two types of activity:\n\n- compliance testing of APIs, pharmaceutical excipients and pharmaceutical products employing \u201cofficial\u201d methods including pharmacopoeial methods, validated analytical procedures provided by the manufacturer and approved by the relevant government authority for marketing authorization or validated analytical procedures developed by the laboratory; and\n- investigative testing of suspicious, illegal, counterfeit substances or products, submitted for examination by medicine inspectors, customs or police.\n\nTo ensure patient safety, the role of the national pharmaceutical quality control laboratory should be defined in the general pharmaceutical legislation of the country in such a way that the results provided by it can, if necessary, lead to enforcement of the law and legal action.\n\n# Glossary\n\nThe definitions given below apply to the terms as used in these guidelines. They may have different meanings in other contexts.\n\n**acceptance criterion for an analytical result**  \nPredefined and documented indicators by which a result is considered to be within the limit(s) or to exceed the limit(s) indicated in the specification.\n\n**accuracy**  \nThe degree of agreement of test results with the true value or the closeness of the results obtained by the procedure to the true value (1).\n\n*Note:* It is normally established on samples of the material to be examined that have been prepared to quantitative accuracy. Accuracy should be established across the specified range of the analytical procedure. It is generally acceptable to use a \u201cspiked\u201d placebo which contains a known quantity or concentration of a reference substance.\n\n**active pharmaceutical ingredient (API)**  \nAny substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body (1).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) describe las funciones de los laboratorios nacionales de control de calidad farmac\u00e9utica, que se dividen en dos actividades principales: pruebas de cumplimiento de ingredientes farmac\u00e9uticos activos (API) y productos farmac\u00e9uticos, y pruebas investigativas de sustancias o productos sospechosos. Se enfatiza la importancia de definir el papel de estos laboratorios en la legislaci\u00f3n farmac\u00e9utica nacional para garantizar la seguridad del paciente. Adem\u00e1s, se incluye un glosario con definiciones clave relacionadas con los resultados anal\u00edticos y los ingredientes farmac\u00e9uticos activos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipos de pruebas realizan los laboratorios nacionales de control de calidad farmac\u00e9utica y cu\u00e1l es su prop\u00f3sito principal?**\n   - Respuesta: Los laboratorios realizan pruebas de cumplimiento de ingredientes farmac\u00e9uticos activos (API), excipientes y productos farmac\u00e9uticos utilizando m\u00e9todos oficiales, as\u00ed como pruebas investigativas de sustancias o productos sospechosos. Su prop\u00f3sito principal es garantizar la seguridad del paciente y la calidad de los productos farmac\u00e9uticos.\n\n2. **\u00bfC\u00f3mo debe estar definido el papel de los laboratorios de control de calidad en la legislaci\u00f3n farmac\u00e9utica de un pa\u00eds?**\n   - Respuesta: El papel de los laboratorios de control de calidad debe estar definido de tal manera que los resultados que proporcionen puedan, si es necesario, llevar a la aplicaci\u00f3n de la ley y a acciones legales, asegurando as\u00ed la protecci\u00f3n del paciente.\n\n3. **\u00bfQu\u00e9 se entiende por \"criterio de aceptaci\u00f3n para un resultado anal\u00edtico\" seg\u00fan el documento?**\n   - Respuesta: El \"criterio de aceptaci\u00f3n para un resultado anal\u00edtico\" se refiere a los indicadores predefinidos y documentados que determinan si un resultado se considera dentro de los l\u00edmites especificados o si los excede, asegurando as\u00ed la validez de los resultados anal\u00edticos.", "prev_section_summary": "### Temas Clave:\n1. **Control de Calidad Farmac\u00e9utica**: Se enfatiza la importancia de los laboratorios nacionales de control de calidad farmac\u00e9utica, que deben manejar una amplia gama de sustancias y productos farmac\u00e9uticos.\n2. **Actividades de los Laboratorios**: Los laboratorios pueden realizar diversas actividades de control de calidad, incluyendo muestreo, pruebas de ingredientes farmac\u00e9uticos activos (APIs), excipientes, materiales de embalaje y productos farmac\u00e9uticos, as\u00ed como pruebas de estabilidad y pruebas investigativas.\n3. **Requisitos para el An\u00e1lisis**: Se establecen criterios para la correcta evaluaci\u00f3n de la calidad de las muestras, que incluyen la presentaci\u00f3n de una declaraci\u00f3n de motivos, una planificaci\u00f3n y ejecuci\u00f3n meticulosa del an\u00e1lisis, y una evaluaci\u00f3n competente de los resultados.\n4. **Colaboraci\u00f3n con Autoridades Reguladoras**: Los laboratorios deben trabajar en estrecha colaboraci\u00f3n con la autoridad reguladora nacional de medicamentos (NMRA) durante el proceso de autorizaci\u00f3n de comercializaci\u00f3n y vigilancia post-comercializaci\u00f3n.\n5. **Soporte a la NMRA**: Los laboratorios nacionales de control de calidad proporcionan apoyo efectivo a la NMRA, asegurando que los resultados anal\u00edticos sean precisos y \u00fatiles para regulaciones administrativas y acciones legales.\n\n### Entidades:\n- **Laboratorios Nacionales de Control de Calidad Farmac\u00e9utica**: Instituciones encargadas de realizar pruebas y an\u00e1lisis de calidad de productos farmac\u00e9uticos.\n- **Autoridad Reguladora Nacional de Medicamentos (NMRA)**: Entidad gubernamental responsable de la regulaci\u00f3n y supervisi\u00f3n de medicamentos en el pa\u00eds.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Sustancias que se utilizan en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Excipientes**: Sustancias inactivas que se utilizan en la formulaci\u00f3n de medicamentos junto con los APIs.\n- **Productos Farmac\u00e9uticos**: Medicamentos que se ofrecen al p\u00fablico para su uso terap\u00e9utico. \n\nEste resumen destaca la importancia de los laboratorios de control de calidad en la garant\u00eda de la seguridad y eficacia de los medicamentos, as\u00ed como la necesidad de un enfoque riguroso y colaborativo en su funcionamiento.", "excerpt_keywords": "Keywords: pharmaceutical quality control, compliance testing, active pharmaceutical ingredient, investigative testing, patient safety"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "260d17a6-8f9f-4307-a273-820c3693b9f1", "node_type": "4", "metadata": {"page_label": "98", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "National pharmaceutical quality control laboratories usually encompass essentially two types of activity:\n\n- compliance testing of APIs, pharmaceutical excipients and pharmaceutical products employing \u201cofficial\u201d methods including pharmacopoeial methods, validated analytical procedures provided by the manufacturer and approved by the relevant government authority for marketing authorization or validated analytical procedures developed by the laboratory; and\n- investigative testing of suspicious, illegal, counterfeit substances or products, submitted for examination by medicine inspectors, customs or police.\n\nTo ensure patient safety, the role of the national pharmaceutical quality control laboratory should be defined in the general pharmaceutical legislation of the country in such a way that the results provided by it can, if necessary, lead to enforcement of the law and legal action.\n\n# Glossary\n\nThe definitions given below apply to the terms as used in these guidelines. They may have different meanings in other contexts.\n\n**acceptance criterion for an analytical result**  \nPredefined and documented indicators by which a result is considered to be within the limit(s) or to exceed the limit(s) indicated in the specification.\n\n**accuracy**  \nThe degree of agreement of test results with the true value or the closeness of the results obtained by the procedure to the true value (1).\n\n*Note:* It is normally established on samples of the material to be examined that have been prepared to quantitative accuracy. Accuracy should be established across the specified range of the analytical procedure. It is generally acceptable to use a \u201cspiked\u201d placebo which contains a known quantity or concentration of a reference substance.\n\n**active pharmaceutical ingredient (API)**  \nAny substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body (1).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "3f27cf52b4b35ab8b3141285bc2f9754d8d0bd00d2eea0352ef9ba51de69626f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "National pharmaceutical quality control laboratories usually encompass essentially two types of activity:\n\n- compliance testing of APIs, pharmaceutical excipients and pharmaceutical products employing \u201cofficial\u201d methods including pharmacopoeial methods, validated analytical procedures provided by the manufacturer and approved by the relevant government authority for marketing authorization or validated analytical procedures developed by the laboratory; and\n- investigative testing of suspicious, illegal, counterfeit substances or products, submitted for examination by medicine inspectors, customs or police.\n\nTo ensure patient safety, the role of the national pharmaceutical quality control laboratory should be defined in the general pharmaceutical legislation of the country in such a way that the results provided by it can, if necessary, lead to enforcement of the law and legal action.\n\n# Glossary\n\nThe definitions given below apply to the terms as used in these guidelines. They may have different meanings in other contexts.\n\n**acceptance criterion for an analytical result**  \nPredefined and documented indicators by which a result is considered to be within the limit(s) or to exceed the limit(s) indicated in the specification.\n\n**accuracy**  \nThe degree of agreement of test results with the true value or the closeness of the results obtained by the procedure to the true value (1).\n\n*Note:* It is normally established on samples of the material to be examined that have been prepared to quantitative accuracy. Accuracy should be established across the specified range of the analytical procedure. It is generally acceptable to use a \u201cspiked\u201d placebo which contains a known quantity or concentration of a reference substance.\n\n**active pharmaceutical ingredient (API)**  \nAny substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body (1).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2205, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ce3e9555-cbef-472c-a722-a7d90f252571": {"__data__": {"id_": "ce3e9555-cbef-472c-a722-a7d90f252571", "embedding": null, "metadata": {"page_label": "99", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# analytical test report\n\nAn analytical test report usually includes a description of the test procedure(s) employed, results of the analysis, discussion and conclusions and/or recommendations for one or more samples submitted for testing (see Part three, sections 18.7\u201318.11).\n\n# analytical worksheet\n\nA printed form, an analytical workbook or electronic means (e-records) for recording information about the sample, as well as reagents and solvents used, test procedure applied, calculations made, results and any other relevant information or comments (see Part three, section 15).\n\n# batch (or lot)\n\nA defined quantity of starting material, packaging material or product processed in a single process or series of processes so that it is expected to be homogeneous. It may sometimes be necessary to divide a batch into a number of sub-batches which are later brought together to form a final homogeneous batch. In the case of terminal sterilization the batch size is determined by the capacity of the autoclave. In continuous manufacture the batch should correspond to a defined fraction of the production, characterized by its intended homogeneity. The batch size can be defined either as a fixed quantity or as the amount produced in a fixed time interval (I).\n\n# batch number (or lot number)\n\nA distinctive combination of numbers and/or letters which uniquely identifies a batch on the labels, its batch records and corresponding certificates of analysis (I).\n\n# calibration\n\nThe set of operations that establish, under specified conditions, the relationship between values indicated by an instrument or system for measuring (especially weighing), recording and controlling, or the values represented by a material measure, and the corresponding known values of a reference standard. Limits for acceptance of the results of measuring should be established (I).\n\n# certificate of analysis\n\nThe list of test procedures applied to a particular sample with the results obtained and the acceptance criteria applied. It indicates whether or not the sample complies with the specification (3).\n\n# certified reference material\n\nReference material, characterized by a metrologically valid procedure for one or more specified properties, accompanied by a certificate that provides", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) titulado \"Technical Report Series 957\" aborda varios aspectos relacionados con la realizaci\u00f3n de pruebas anal\u00edticas en muestras. Incluye definiciones y descripciones de informes anal\u00edticos, hojas de trabajo anal\u00edticas, lotes de productos, n\u00fameros de lote, calibraci\u00f3n de instrumentos, certificados de an\u00e1lisis y materiales de referencia certificados. Cada secci\u00f3n proporciona informaci\u00f3n sobre los procedimientos, requisitos y est\u00e1ndares necesarios para asegurar la calidad y la homogeneidad de los productos analizados.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 informaci\u00f3n se incluye t\u00edpicamente en un informe anal\u00edtico y por qu\u00e9 es importante para la evaluaci\u00f3n de muestras?**\n   - Respuesta: Un informe anal\u00edtico incluye una descripci\u00f3n de los procedimientos de prueba, los resultados del an\u00e1lisis, discusiones, conclusiones y recomendaciones para las muestras sometidas a prueba. Esta informaci\u00f3n es crucial para determinar si las muestras cumplen con las especificaciones requeridas.\n\n2. **\u00bfC\u00f3mo se define un \"lote\" en el contexto de la producci\u00f3n y qu\u00e9 factores pueden influir en su tama\u00f1o?**\n   - Respuesta: Un lote se define como una cantidad espec\u00edfica de material de partida, material de embalaje o producto procesado en un solo proceso o serie de procesos, con la expectativa de homogeneidad. El tama\u00f1o del lote puede verse influenciado por la capacidad del autoclave en la esterilizaci\u00f3n terminal o por la fracci\u00f3n de producci\u00f3n en la fabricaci\u00f3n continua.\n\n3. **\u00bfCu\u00e1l es la funci\u00f3n de un certificado de an\u00e1lisis y qu\u00e9 informaci\u00f3n debe contener?**\n   - Respuesta: Un certificado de an\u00e1lisis lista los procedimientos de prueba aplicados a una muestra particular, junto con los resultados obtenidos y los criterios de aceptaci\u00f3n aplicados. Indica si la muestra cumple o no con las especificaciones establecidas, lo que es fundamental para garantizar la calidad del producto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Funciones de los Laboratorios Nacionales de Control de Calidad Farmac\u00e9utica**:\n   - **Pruebas de Cumplimiento**: Evaluaci\u00f3n de ingredientes farmac\u00e9uticos activos (API), excipientes y productos farmac\u00e9uticos utilizando m\u00e9todos oficiales, como m\u00e9todos farmacopoeicos y procedimientos anal\u00edticos validados.\n   - **Pruebas Investigativas**: An\u00e1lisis de sustancias o productos sospechosos, ilegales o falsificados, que son enviados por inspectores de medicamentos, aduanas o polic\u00eda.\n\n2. **Importancia de la Legislaci\u00f3n**:\n   - El papel de los laboratorios debe estar claramente definido en la legislaci\u00f3n farmac\u00e9utica nacional para garantizar que sus resultados puedan llevar a la aplicaci\u00f3n de la ley y acciones legales, asegurando as\u00ed la seguridad del paciente.\n\n3. **Glosario de T\u00e9rminos Clave**:\n   - **Criterio de Aceptaci\u00f3n para un Resultado Anal\u00edtico**: Indicadores predefinidos que determinan si un resultado est\u00e1 dentro de los l\u00edmites especificados.\n   - **Precisi\u00f3n**: Grado de concordancia de los resultados de las pruebas con el valor verdadero.\n   - **Ingrediente Farmac\u00e9utico Activo (API)**: Sustancia utilizada en la fabricaci\u00f3n de formas farmac\u00e9uticas que proporciona actividad farmacol\u00f3gica o efecto directo en el tratamiento de enfermedades.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite directrices sobre el control de calidad farmac\u00e9utica.\n- **Laboratorios Nacionales de Control de Calidad**: Instituciones responsables de garantizar la calidad y seguridad de los productos farmac\u00e9uticos.\n- **Ingredientes Farmac\u00e9uticos Activos (API)**: Componentes esenciales en la formulaci\u00f3n de medicamentos.\n- **Legislaci\u00f3n Farmac\u00e9utica**: Marco legal que regula las actividades de los laboratorios y la calidad de los productos farmac\u00e9uticos. \n\nEste resumen destaca la funci\u00f3n cr\u00edtica de los laboratorios de control de calidad en la protecci\u00f3n de la salud p\u00fablica y la importancia de un marco legal s\u00f3lido para su operaci\u00f3n.", "excerpt_keywords": "Keywords: analytical test report, batch number, calibration, certificate of analysis, certified reference material"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f6be0507-2d6b-4930-9c54-ce3318504297", "node_type": "4", "metadata": {"page_label": "99", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# analytical test report\n\nAn analytical test report usually includes a description of the test procedure(s) employed, results of the analysis, discussion and conclusions and/or recommendations for one or more samples submitted for testing (see Part three, sections 18.7\u201318.11).\n\n# analytical worksheet\n\nA printed form, an analytical workbook or electronic means (e-records) for recording information about the sample, as well as reagents and solvents used, test procedure applied, calculations made, results and any other relevant information or comments (see Part three, section 15).\n\n# batch (or lot)\n\nA defined quantity of starting material, packaging material or product processed in a single process or series of processes so that it is expected to be homogeneous. It may sometimes be necessary to divide a batch into a number of sub-batches which are later brought together to form a final homogeneous batch. In the case of terminal sterilization the batch size is determined by the capacity of the autoclave. In continuous manufacture the batch should correspond to a defined fraction of the production, characterized by its intended homogeneity. The batch size can be defined either as a fixed quantity or as the amount produced in a fixed time interval (I).\n\n# batch number (or lot number)\n\nA distinctive combination of numbers and/or letters which uniquely identifies a batch on the labels, its batch records and corresponding certificates of analysis (I).\n\n# calibration\n\nThe set of operations that establish, under specified conditions, the relationship between values indicated by an instrument or system for measuring (especially weighing), recording and controlling, or the values represented by a material measure, and the corresponding known values of a reference standard. Limits for acceptance of the results of measuring should be established (I).\n\n# certificate of analysis\n\nThe list of test procedures applied to a particular sample with the results obtained and the acceptance criteria applied. It indicates whether or not the sample complies with the specification (3).\n\n# certified reference material\n\nReference material, characterized by a metrologically valid procedure for one or more specified properties, accompanied by a certificate that provides", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "34fa0109071b6f889c7fa6739b4d3e277aa8758361178938ec235fb337c8bfdd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# analytical test report\n\nAn analytical test report usually includes a description of the test procedure(s) employed, results of the analysis, discussion and conclusions and/or recommendations for one or more samples submitted for testing (see Part three, sections 18.7\u201318.11).\n\n# analytical worksheet\n\nA printed form, an analytical workbook or electronic means (e-records) for recording information about the sample, as well as reagents and solvents used, test procedure applied, calculations made, results and any other relevant information or comments (see Part three, section 15).\n\n# batch (or lot)\n\nA defined quantity of starting material, packaging material or product processed in a single process or series of processes so that it is expected to be homogeneous. It may sometimes be necessary to divide a batch into a number of sub-batches which are later brought together to form a final homogeneous batch. In the case of terminal sterilization the batch size is determined by the capacity of the autoclave. In continuous manufacture the batch should correspond to a defined fraction of the production, characterized by its intended homogeneity. The batch size can be defined either as a fixed quantity or as the amount produced in a fixed time interval (I).\n\n# batch number (or lot number)\n\nA distinctive combination of numbers and/or letters which uniquely identifies a batch on the labels, its batch records and corresponding certificates of analysis (I).\n\n# calibration\n\nThe set of operations that establish, under specified conditions, the relationship between values indicated by an instrument or system for measuring (especially weighing), recording and controlling, or the values represented by a material measure, and the corresponding known values of a reference standard. Limits for acceptance of the results of measuring should be established (I).\n\n# certificate of analysis\n\nThe list of test procedures applied to a particular sample with the results obtained and the acceptance criteria applied. It indicates whether or not the sample complies with the specification (3).\n\n# certified reference material\n\nReference material, characterized by a metrologically valid procedure for one or more specified properties, accompanied by a certificate that provides", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2277, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e8c47258-92b8-47d5-8fb7-2899719a6d35": {"__data__": {"id_": "e8c47258-92b8-47d5-8fb7-2899719a6d35", "embedding": null, "metadata": {"page_label": "100", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the value of the specified property, its associated uncertainty and a statement of metrological traceability (4).\n\n**compliance testing**  \nAnalysis of active pharmaceutical ingredients (APIs), pharmaceutical excipients, packaging material or pharmaceutical products according to the requirements of a pharmacopoeial monograph or a specification in an approved marketing authorization.\n\n**control sample**  \nA sample used for testing the continued accuracy and precision of the procedure. It should have a matrix similar to that of the samples to be analysed. It has an assigned value with its associated uncertainty.\n\n**design qualification (DQ)**  \nDocumented collection of activities that define the functional and operational specifications of the instrument and criteria for selection of the vendor, based on the intended purpose of the instrument.\n\n*Note:* Selection and purchase of a new instrument should follow a conscious decision process, based on the needs of the technical management. When designing a new laboratory facility, the design specification and the requirements for services should be agreed between the management team and the agreed suppliers and documented.\n\n**good manufacturing practice(s) (GMP)**  \nThat part of quality assurance which ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization (1).\n\n**installation qualification (IQ)**  \nThe performance of tests to ensure that the analytical equipment used in a laboratory is correctly installed and operates in accordance with established specifications.\n\n**management review**  \nA formal, documented review of the key performance indicators of a quality management system performed by top management.\n\n**manufacturer**  \nA company that carries out operations such as production, packaging, testing, repackaging, labelling and/or relabelling of pharmaceuticals (1).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la Serie de Informes T\u00e9cnicos 957 aborda aspectos clave de la calidad y el control en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se definen t\u00e9rminos importantes como \"pruebas de cumplimiento\", \"muestra de control\", \"calificaci\u00f3n de dise\u00f1o\", \"buenas pr\u00e1cticas de manufactura (GMP)\", \"calificaci\u00f3n de instalaci\u00f3n\", \"revisi\u00f3n de gesti\u00f3n\" y \"fabricante\". Estos conceptos son fundamentales para asegurar que los productos farmac\u00e9uticos se produzcan y controlen de acuerdo con est\u00e1ndares de calidad apropiados.\n\n### Preguntas Espec\u00edficas:\n1. **\u00bfQu\u00e9 criterios se deben considerar al seleccionar un proveedor para un nuevo instrumento en un laboratorio?**\n   - La selecci\u00f3n debe basarse en una colecci\u00f3n documentada de actividades que definen las especificaciones funcionales y operativas del instrumento, as\u00ed como en el prop\u00f3sito previsto del mismo.\n\n2. **\u00bfCu\u00e1l es la importancia de las \"buenas pr\u00e1cticas de manufactura (GMP)\" en la producci\u00f3n farmac\u00e9utica?**\n   - Las GMP son esenciales para garantizar que los productos farmac\u00e9uticos se produzcan y controlen de manera consistente, cumpliendo con los est\u00e1ndares de calidad apropiados para su uso previsto y seg\u00fan lo requerido por la autorizaci\u00f3n de comercializaci\u00f3n.\n\n3. **\u00bfQu\u00e9 es una \"muestra de control\" y por qu\u00e9 es relevante en el an\u00e1lisis de productos farmac\u00e9uticos?**\n   - Una muestra de control es utilizada para probar la precisi\u00f3n y exactitud continuas del procedimiento anal\u00edtico. Debe tener una matriz similar a la de las muestras que se van a analizar y cuenta con un valor asignado y su incertidumbre asociada, lo que la hace crucial para validar los resultados de las pruebas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Informe Anal\u00edtico**:\n   - Contenido: Descripci\u00f3n de procedimientos de prueba, resultados, discusiones, conclusiones y recomendaciones.\n   - Importancia: Fundamental para evaluar la conformidad de las muestras con las especificaciones.\n\n2. **Hoja de Trabajo Anal\u00edtica**:\n   - Descripci\u00f3n: Formulario impreso o medio electr\u00f3nico para registrar informaci\u00f3n sobre la muestra, reactivos, procedimientos de prueba, c\u00e1lculos y resultados.\n\n3. **Lote (Batch)**:\n   - Definici\u00f3n: Cantidad definida de material procesado en un solo proceso, esperado ser homog\u00e9neo.\n   - Factores que influyen: Capacidad del autoclave en esterilizaci\u00f3n y fracci\u00f3n de producci\u00f3n en fabricaci\u00f3n continua.\n\n4. **N\u00famero de Lote**:\n   - Descripci\u00f3n: Combinaci\u00f3n \u00fanica de n\u00fameros y/o letras que identifica un lote en etiquetas y certificados de an\u00e1lisis.\n\n5. **Calibraci\u00f3n**:\n   - Definici\u00f3n: Operaciones que establecen la relaci\u00f3n entre los valores indicados por un instrumento y los valores conocidos de un est\u00e1ndar de referencia.\n\n6. **Certificado de An\u00e1lisis**:\n   - Contenido: Lista de procedimientos de prueba aplicados a una muestra, resultados obtenidos y criterios de aceptaci\u00f3n.\n   - Funci\u00f3n: Indica si la muestra cumple con las especificaciones.\n\n7. **Material de Referencia Certificado**:\n   - Descripci\u00f3n: Material caracterizado por un procedimiento metrol\u00f3gicamente v\u00e1lido, acompa\u00f1ado de un certificado que proporciona informaci\u00f3n sobre propiedades espec\u00edficas.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el documento.\n- **Muestras**: Elementos sometidos a pruebas anal\u00edticas.\n- **Procedimientos de Prueba**: M\u00e9todos utilizados para analizar las muestras.\n- **Est\u00e1ndares de Calidad**: Criterios que las muestras deben cumplir para ser aceptadas. \n\nEste resumen abarca los conceptos y definiciones esenciales presentados en la secci\u00f3n del documento, proporcionando una visi\u00f3n clara de los procedimientos y requisitos en el contexto de pruebas anal\u00edticas.", "excerpt_keywords": "Keywords: compliance testing, good manufacturing practices, control sample, design qualification, installation qualification"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3828b4ea-ce4f-4cb1-b819-094100aec4d8", "node_type": "4", "metadata": {"page_label": "100", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the value of the specified property, its associated uncertainty and a statement of metrological traceability (4).\n\n**compliance testing**  \nAnalysis of active pharmaceutical ingredients (APIs), pharmaceutical excipients, packaging material or pharmaceutical products according to the requirements of a pharmacopoeial monograph or a specification in an approved marketing authorization.\n\n**control sample**  \nA sample used for testing the continued accuracy and precision of the procedure. It should have a matrix similar to that of the samples to be analysed. It has an assigned value with its associated uncertainty.\n\n**design qualification (DQ)**  \nDocumented collection of activities that define the functional and operational specifications of the instrument and criteria for selection of the vendor, based on the intended purpose of the instrument.\n\n*Note:* Selection and purchase of a new instrument should follow a conscious decision process, based on the needs of the technical management. When designing a new laboratory facility, the design specification and the requirements for services should be agreed between the management team and the agreed suppliers and documented.\n\n**good manufacturing practice(s) (GMP)**  \nThat part of quality assurance which ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization (1).\n\n**installation qualification (IQ)**  \nThe performance of tests to ensure that the analytical equipment used in a laboratory is correctly installed and operates in accordance with established specifications.\n\n**management review**  \nA formal, documented review of the key performance indicators of a quality management system performed by top management.\n\n**manufacturer**  \nA company that carries out operations such as production, packaging, testing, repackaging, labelling and/or relabelling of pharmaceuticals (1).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "c32a468cd9e68e781f6ac60e0668eeaca48d36740962f8d0b93066cd32e0ba8b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "the value of the specified property, its associated uncertainty and a statement of metrological traceability (4).\n\n**compliance testing**  \nAnalysis of active pharmaceutical ingredients (APIs), pharmaceutical excipients, packaging material or pharmaceutical products according to the requirements of a pharmacopoeial monograph or a specification in an approved marketing authorization.\n\n**control sample**  \nA sample used for testing the continued accuracy and precision of the procedure. It should have a matrix similar to that of the samples to be analysed. It has an assigned value with its associated uncertainty.\n\n**design qualification (DQ)**  \nDocumented collection of activities that define the functional and operational specifications of the instrument and criteria for selection of the vendor, based on the intended purpose of the instrument.\n\n*Note:* Selection and purchase of a new instrument should follow a conscious decision process, based on the needs of the technical management. When designing a new laboratory facility, the design specification and the requirements for services should be agreed between the management team and the agreed suppliers and documented.\n\n**good manufacturing practice(s) (GMP)**  \nThat part of quality assurance which ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization (1).\n\n**installation qualification (IQ)**  \nThe performance of tests to ensure that the analytical equipment used in a laboratory is correctly installed and operates in accordance with established specifications.\n\n**management review**  \nA formal, documented review of the key performance indicators of a quality management system performed by top management.\n\n**manufacturer**  \nA company that carries out operations such as production, packaging, testing, repackaging, labelling and/or relabelling of pharmaceuticals (1).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1973, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b23a968d-dcb7-436e-80f7-e5732d43eeaf": {"__data__": {"id_": "b23a968d-dcb7-436e-80f7-e5732d43eeaf", "embedding": null, "metadata": {"page_label": "101", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# marketing authorization (product licence, registration certificate)\n\nA legal document issued by the competent medicines regulatory authority that authorizes the marketing or free distribution of a pharmaceutical product in the respective country after evaluation for safety, efficacy and quality. In terms of quality it establishes inter alia the detailed composition and formulation of the pharmaceutical product and the quality requirements for the product and its ingredients. It also includes details of packaging, labelling, storage conditions, shelf-life and approved conditions of use.\n\n# measurement uncertainty\n\nNon-negative parameter characterizing the dispersion of quantity values being attributed to a measurand (analyte), based on the information used (4).\n\n# metrological traceability\n\nProperty of a measurement result whereby the result can be related to a reference through a documented, unbroken chain of calibrations, each contributing to the measurement uncertainty (4).\n\n# operational qualification (OQ)\n\nDocumented verification that the analytical equipment performs as intended over all anticipated operating ranges.\n\n# out-of-specification (OOS) result\n\nAll test results that fall outside the specifications or acceptance criteria established in product dossiers, drug master files, pharmacopoeias or by the manufacturer (5).\n\n# performance qualification (PQ)\n\nDocumented verification that the analytical equipment operates consistently and gives reproducibility within the defined specifications and parameters for prolonged periods.\n\n# pharmaceutical excipient\n\nA substance, other than the active pharmaceutical ingredient (API), which has been appropriately evaluated for safety and is included in a medicines delivery system to:\n\n- aid in the processing of the medicines delivery system during its manufacture;\n- protect, support or enhance stability, bioavailability or patient acceptability;\n- assist in pharmaceutical product identification; or\n- enhance any other attribute of the overall safety and effectiveness of the medicine during its storage or use (6, 7).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfQu\u00e9 informaci\u00f3n espec\u00edfica se incluye en un documento de autorizaci\u00f3n de comercializaci\u00f3n (marketing authorization) para un producto farmac\u00e9utico?**\n   - Respuesta: El documento de autorizaci\u00f3n de comercializaci\u00f3n incluye la composici\u00f3n y formulaci\u00f3n detallada del producto farmac\u00e9utico, los requisitos de calidad para el producto y sus ingredientes, as\u00ed como detalles sobre el embalaje, etiquetado, condiciones de almacenamiento, vida \u00fatil y condiciones de uso aprobadas.\n\n2. **\u00bfCu\u00e1l es la diferencia entre la calificaci\u00f3n operativa (Operational Qualification, OQ) y la calificaci\u00f3n de rendimiento (Performance Qualification, PQ) en el contexto de equipos anal\u00edticos?**\n   - Respuesta: La calificaci\u00f3n operativa (OQ) se refiere a la verificaci\u00f3n documentada de que el equipo anal\u00edtico funciona como se espera en todos los rangos operativos anticipados, mientras que la calificaci\u00f3n de rendimiento (PQ) se refiere a la verificaci\u00f3n documentada de que el equipo opera de manera consistente y reproduce resultados dentro de las especificaciones definidas durante per\u00edodos prolongados.\n\n3. **\u00bfQu\u00e9 se entiende por un resultado fuera de especificaci\u00f3n (Out-of-Specification, OOS) y c\u00f3mo se determina?**\n   - Respuesta: Un resultado fuera de especificaci\u00f3n (OOS) se refiere a todos los resultados de pruebas que caen fuera de las especificaciones o criterios de aceptaci\u00f3n establecidos en los expedientes del producto, archivos maestros de medicamentos, farmacopeas o por el fabricante. Se determina comparando los resultados de las pruebas con los criterios establecidos.\n\n### Resumen de nivel superior del contexto:\nEl contexto se centra en varios t\u00e9rminos y conceptos clave relacionados con la regulaci\u00f3n y evaluaci\u00f3n de productos farmac\u00e9uticos, incluyendo la autorizaci\u00f3n de comercializaci\u00f3n, la incertidumbre de medici\u00f3n, la trazabilidad metrol\u00f3gica, y las calificaciones operativas y de rendimiento de equipos anal\u00edticos. Tambi\u00e9n se aborda el concepto de excipientes farmac\u00e9uticos y los resultados fuera de especificaci\u00f3n, proporcionando un marco para entender c\u00f3mo se eval\u00faan y regulan los productos farmac\u00e9uticos en t\u00e9rminos de seguridad, eficacia y calidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n extra\u00edda del documento de la OMS en la Serie de Informes T\u00e9cnicos 957 se centra en conceptos fundamentales relacionados con la calidad y el control en la fabricaci\u00f3n de productos farmac\u00e9uticos. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n1. **Pruebas de Cumplimiento (Compliance Testing)**:\n   - An\u00e1lisis de ingredientes farmac\u00e9uticos activos (APIs), excipientes, materiales de embalaje o productos farmac\u00e9uticos seg\u00fan los requisitos de una monograf\u00eda farmacop\u00e9ica o especificaciones de autorizaci\u00f3n de comercializaci\u00f3n.\n\n2. **Muestra de Control (Control Sample)**:\n   - Utilizada para verificar la precisi\u00f3n y exactitud del procedimiento anal\u00edtico. Debe tener una matriz similar a las muestras a analizar y cuenta con un valor asignado y su incertidumbre asociada.\n\n3. **Calificaci\u00f3n de Dise\u00f1o (Design Qualification - DQ)**:\n   - Conjunto documentado de actividades que definen las especificaciones funcionales y operativas del instrumento, as\u00ed como los criterios para la selecci\u00f3n del proveedor.\n\n4. **Buenas Pr\u00e1cticas de Manufactura (Good Manufacturing Practice - GMP)**:\n   - Parte de la garant\u00eda de calidad que asegura que los productos farmac\u00e9uticos se produzcan y controlen de manera consistente, cumpliendo con los est\u00e1ndares de calidad requeridos.\n\n5. **Calificaci\u00f3n de Instalaci\u00f3n (Installation Qualification - IQ)**:\n   - Pruebas realizadas para asegurar que el equipo anal\u00edtico est\u00e1 correctamente instalado y opera de acuerdo con las especificaciones establecidas.\n\n6. **Revisi\u00f3n de Gesti\u00f3n (Management Review)**:\n   - Revisi\u00f3n formal y documentada de los indicadores clave de rendimiento de un sistema de gesti\u00f3n de calidad realizada por la alta direcci\u00f3n.\n\n7. **Fabricante (Manufacturer)**:\n   - Empresa que realiza operaciones como producci\u00f3n, embalaje, pruebas, reembalaje, etiquetado y/o reetiquetado de productos farmac\u00e9uticos.\n\n### Conclusi\u00f3n\nEstos conceptos son esenciales para garantizar que los productos farmac\u00e9uticos se desarrollen y controlen de acuerdo con los est\u00e1ndares de calidad necesarios, asegurando as\u00ed la seguridad y eficacia de los medicamentos en el mercado.", "excerpt_keywords": "Keywords: marketing authorization, measurement uncertainty, operational qualification, out-of-specification, pharmaceutical excipient"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ca472f55-5d60-459a-8500-1f84384c12ac", "node_type": "4", "metadata": {"page_label": "101", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# marketing authorization (product licence, registration certificate)\n\nA legal document issued by the competent medicines regulatory authority that authorizes the marketing or free distribution of a pharmaceutical product in the respective country after evaluation for safety, efficacy and quality. In terms of quality it establishes inter alia the detailed composition and formulation of the pharmaceutical product and the quality requirements for the product and its ingredients. It also includes details of packaging, labelling, storage conditions, shelf-life and approved conditions of use.\n\n# measurement uncertainty\n\nNon-negative parameter characterizing the dispersion of quantity values being attributed to a measurand (analyte), based on the information used (4).\n\n# metrological traceability\n\nProperty of a measurement result whereby the result can be related to a reference through a documented, unbroken chain of calibrations, each contributing to the measurement uncertainty (4).\n\n# operational qualification (OQ)\n\nDocumented verification that the analytical equipment performs as intended over all anticipated operating ranges.\n\n# out-of-specification (OOS) result\n\nAll test results that fall outside the specifications or acceptance criteria established in product dossiers, drug master files, pharmacopoeias or by the manufacturer (5).\n\n# performance qualification (PQ)\n\nDocumented verification that the analytical equipment operates consistently and gives reproducibility within the defined specifications and parameters for prolonged periods.\n\n# pharmaceutical excipient\n\nA substance, other than the active pharmaceutical ingredient (API), which has been appropriately evaluated for safety and is included in a medicines delivery system to:\n\n- aid in the processing of the medicines delivery system during its manufacture;\n- protect, support or enhance stability, bioavailability or patient acceptability;\n- assist in pharmaceutical product identification; or\n- enhance any other attribute of the overall safety and effectiveness of the medicine during its storage or use (6, 7).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "ac81927a62fa6d00400ccd38388d6c4a2a3d53a9693888c53cd6c31c677abb0b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# marketing authorization (product licence, registration certificate)\n\nA legal document issued by the competent medicines regulatory authority that authorizes the marketing or free distribution of a pharmaceutical product in the respective country after evaluation for safety, efficacy and quality. In terms of quality it establishes inter alia the detailed composition and formulation of the pharmaceutical product and the quality requirements for the product and its ingredients. It also includes details of packaging, labelling, storage conditions, shelf-life and approved conditions of use.\n\n# measurement uncertainty\n\nNon-negative parameter characterizing the dispersion of quantity values being attributed to a measurand (analyte), based on the information used (4).\n\n# metrological traceability\n\nProperty of a measurement result whereby the result can be related to a reference through a documented, unbroken chain of calibrations, each contributing to the measurement uncertainty (4).\n\n# operational qualification (OQ)\n\nDocumented verification that the analytical equipment performs as intended over all anticipated operating ranges.\n\n# out-of-specification (OOS) result\n\nAll test results that fall outside the specifications or acceptance criteria established in product dossiers, drug master files, pharmacopoeias or by the manufacturer (5).\n\n# performance qualification (PQ)\n\nDocumented verification that the analytical equipment operates consistently and gives reproducibility within the defined specifications and parameters for prolonged periods.\n\n# pharmaceutical excipient\n\nA substance, other than the active pharmaceutical ingredient (API), which has been appropriately evaluated for safety and is included in a medicines delivery system to:\n\n- aid in the processing of the medicines delivery system during its manufacture;\n- protect, support or enhance stability, bioavailability or patient acceptability;\n- assist in pharmaceutical product identification; or\n- enhance any other attribute of the overall safety and effectiveness of the medicine during its storage or use (6, 7).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2097, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0b6f27df-0121-4c3e-954f-f6d07c99ffda": {"__data__": {"id_": "0b6f27df-0121-4c3e-954f-f6d07c99ffda", "embedding": null, "metadata": {"page_label": "102", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "pharmaceutical product  \nAny material or product intended for human or veterinary use, presented in its finished dosage form or as a starting material for use in such a dosage form, which is subject to control by pharmaceutical legislation in the exporting state and/or the importing state (1).\n\nprecision  \nThe degree of agreement among individual results when the procedure is applied repeatedly to multiple samplings of a homogeneous sample. Precision, usually expressed as relative standard deviation, may be considered at three levels: repeatability (precision under the same operating conditions over a short period of time), intermediate precision (within laboratory variations \u2014 different days, different analysts or different equipment) and reproducibility (precision between laboratories).\n\nprimary reference substance (or standard)  \nA substance that is widely acknowledged to possess the appropriate qualities within a specified context, and whose assigned content is accepted without requiring comparison with another chemical substance (8).\n\n*Note:* Pharmacopoeial chemical reference substances are considered to be primary reference substances. In the absence of a pharmacopoeial reference substance, a manufacturer should establish a primary reference substance.\n\nqualification of equipment  \nAction of proving and documenting that any analytical equipment complies with the required specifications and performs suitably for its intended purpose (see Part two, section 12).\n\nquality control  \nAll measures taken, including the setting of specifications, sampling, testing and analytical clearance, to ensure that raw materials, intermediates, packaging materials and finished pharmaceutical products conform with established specifications for identity, strength, purity and other characteristics.\n\nquality management system  \nAn appropriate infrastructure, encompassing the organizational structure, procedures, processes and resources, and systematic actions necessary to ensure adequate confidence that a product or service will satisfy given requirements for quality (see Part one, section 2).\n\nquality manager  \nA member of staff who has a defined responsibility and authority for ensuring that the management system related to quality is implemented and followed at all times (see Part one, section 1.3(j)).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 se entiende por \"producto farmac\u00e9utico\" seg\u00fan el documento de la OMS?**\n   - **Respuesta:** Un \"producto farmac\u00e9utico\" se define como cualquier material o producto destinado para uso humano o veterinario, presentado en su forma de dosificaci\u00f3n final o como material inicial para su uso en tal forma de dosificaci\u00f3n, que est\u00e1 sujeto a control por la legislaci\u00f3n farmac\u00e9utica en el estado exportador y/o en el estado importador.\n\n2. **\u00bfCu\u00e1les son los tres niveles de precisi\u00f3n mencionados en el documento y c\u00f3mo se diferencian entre s\u00ed?**\n   - **Respuesta:** Los tres niveles de precisi\u00f3n son: \n     - **Repetibilidad:** Precisi\u00f3n bajo las mismas condiciones operativas durante un corto per\u00edodo de tiempo.\n     - **Precisi\u00f3n intermedia:** Variaciones dentro del laboratorio, que pueden incluir diferentes d\u00edas, analistas o equipos.\n     - **Reproducibilidad:** Precisi\u00f3n entre diferentes laboratorios.\n\n3. **\u00bfCu\u00e1l es el papel de un \"gerente de calidad\" seg\u00fan el documento?**\n   - **Respuesta:** Un \"gerente de calidad\" es un miembro del personal que tiene una responsabilidad y autoridad definidas para asegurar que el sistema de gesti\u00f3n relacionado con la calidad se implemente y siga en todo momento.\n\n### Resumen de nivel superior del contexto:\nEl documento de la OMS proporciona definiciones clave y conceptos relacionados con la calidad y el control de productos farmac\u00e9uticos. Incluye definiciones de t\u00e9rminos como \"producto farmac\u00e9utico\", \"precisi\u00f3n\", \"sustancia de referencia primaria\", \"calificaci\u00f3n de equipos\", \"control de calidad\", \"sistema de gesti\u00f3n de calidad\" y \"gerente de calidad\". Estos conceptos son fundamentales para garantizar que los productos farmac\u00e9uticos cumplan con las especificaciones establecidas en t\u00e9rminos de identidad, fuerza, pureza y otras caracter\u00edsticas relevantes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Autorizaci\u00f3n de Comercializaci\u00f3n (Marketing Authorization)**:\n   - Documento legal emitido por la autoridad reguladora de medicamentos que permite la comercializaci\u00f3n de un producto farmac\u00e9utico tras su evaluaci\u00f3n en t\u00e9rminos de seguridad, eficacia y calidad.\n   - Incluye informaci\u00f3n sobre la composici\u00f3n, formulaci\u00f3n, requisitos de calidad, embalaje, etiquetado, condiciones de almacenamiento, vida \u00fatil y condiciones de uso aprobadas.\n\n2. **Incertidumbre de Medici\u00f3n (Measurement Uncertainty)**:\n   - Par\u00e1metro no negativo que caracteriza la dispersi\u00f3n de los valores de cantidad atribuidos a un analito, basado en la informaci\u00f3n utilizada.\n\n3. **Trazabilidad Metrol\u00f3gica (Metrological Traceability)**:\n   - Propiedad de un resultado de medici\u00f3n que permite relacionarlo con un referente a trav\u00e9s de una cadena documentada de calibraciones.\n\n4. **Calificaci\u00f3n Operativa (Operational Qualification, OQ)**:\n   - Verificaci\u00f3n documentada de que el equipo anal\u00edtico funciona como se espera en todos los rangos operativos anticipados.\n\n5. **Resultado Fuera de Especificaci\u00f3n (Out-of-Specification, OOS)**:\n   - Resultados de pruebas que no cumplen con las especificaciones o criterios de aceptaci\u00f3n establecidos en documentos de producto, archivos maestros de medicamentos o farmacopeas.\n\n6. **Calificaci\u00f3n de Rendimiento (Performance Qualification, PQ)**:\n   - Verificaci\u00f3n documentada de que el equipo anal\u00edtico opera de manera consistente y reproduce resultados dentro de las especificaciones definidas durante per\u00edodos prolongados.\n\n7. **Excipiente Farmac\u00e9utico (Pharmaceutical Excipient)**:\n   - Sustancia distinta del ingrediente farmac\u00e9utico activo (API) que ha sido evaluada por su seguridad y se incluye en un sistema de entrega de medicamentos para mejorar su procesamiento, estabilidad, biodisponibilidad, aceptabilidad del paciente, identificaci\u00f3n del producto y otros atributos de seguridad y eficacia.\n\n### Entidades Clave:\n- **Autoridad Reguladora de Medicamentos**: Entidad responsable de emitir autorizaciones de comercializaci\u00f3n.\n- **Analito**: Sustancia cuya cantidad se mide.\n- **Equipos Anal\u00edticos**: Herramientas utilizadas para realizar pruebas y mediciones en productos farmac\u00e9uticos.\n- **Documentos de Producto**: Expedientes que contienen especificaciones y criterios de aceptaci\u00f3n para productos farmac\u00e9uticos.\n\nEste resumen proporciona una visi\u00f3n general de los conceptos y t\u00e9rminos clave relacionados con la regulaci\u00f3n y evaluaci\u00f3n de productos farmac\u00e9uticos, enfatizando la importancia de la calidad, seguridad y eficacia en el desarrollo y comercializaci\u00f3n de medicamentos.", "excerpt_keywords": "Keywords: pharmaceutical product, precision, quality control, primary reference substance, quality management system"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "09d519ef-02ff-4b66-95ff-cc720c3286c9", "node_type": "4", "metadata": {"page_label": "102", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "pharmaceutical product  \nAny material or product intended for human or veterinary use, presented in its finished dosage form or as a starting material for use in such a dosage form, which is subject to control by pharmaceutical legislation in the exporting state and/or the importing state (1).\n\nprecision  \nThe degree of agreement among individual results when the procedure is applied repeatedly to multiple samplings of a homogeneous sample. Precision, usually expressed as relative standard deviation, may be considered at three levels: repeatability (precision under the same operating conditions over a short period of time), intermediate precision (within laboratory variations \u2014 different days, different analysts or different equipment) and reproducibility (precision between laboratories).\n\nprimary reference substance (or standard)  \nA substance that is widely acknowledged to possess the appropriate qualities within a specified context, and whose assigned content is accepted without requiring comparison with another chemical substance (8).\n\n*Note:* Pharmacopoeial chemical reference substances are considered to be primary reference substances. In the absence of a pharmacopoeial reference substance, a manufacturer should establish a primary reference substance.\n\nqualification of equipment  \nAction of proving and documenting that any analytical equipment complies with the required specifications and performs suitably for its intended purpose (see Part two, section 12).\n\nquality control  \nAll measures taken, including the setting of specifications, sampling, testing and analytical clearance, to ensure that raw materials, intermediates, packaging materials and finished pharmaceutical products conform with established specifications for identity, strength, purity and other characteristics.\n\nquality management system  \nAn appropriate infrastructure, encompassing the organizational structure, procedures, processes and resources, and systematic actions necessary to ensure adequate confidence that a product or service will satisfy given requirements for quality (see Part one, section 2).\n\nquality manager  \nA member of staff who has a defined responsibility and authority for ensuring that the management system related to quality is implemented and followed at all times (see Part one, section 1.3(j)).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "92cebcd636fa2cfe45732aae502fb344fe8526ce6aa87c143e839b2756d56b60", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "pharmaceutical product  \nAny material or product intended for human or veterinary use, presented in its finished dosage form or as a starting material for use in such a dosage form, which is subject to control by pharmaceutical legislation in the exporting state and/or the importing state (1).\n\nprecision  \nThe degree of agreement among individual results when the procedure is applied repeatedly to multiple samplings of a homogeneous sample. Precision, usually expressed as relative standard deviation, may be considered at three levels: repeatability (precision under the same operating conditions over a short period of time), intermediate precision (within laboratory variations \u2014 different days, different analysts or different equipment) and reproducibility (precision between laboratories).\n\nprimary reference substance (or standard)  \nA substance that is widely acknowledged to possess the appropriate qualities within a specified context, and whose assigned content is accepted without requiring comparison with another chemical substance (8).\n\n*Note:* Pharmacopoeial chemical reference substances are considered to be primary reference substances. In the absence of a pharmacopoeial reference substance, a manufacturer should establish a primary reference substance.\n\nqualification of equipment  \nAction of proving and documenting that any analytical equipment complies with the required specifications and performs suitably for its intended purpose (see Part two, section 12).\n\nquality control  \nAll measures taken, including the setting of specifications, sampling, testing and analytical clearance, to ensure that raw materials, intermediates, packaging materials and finished pharmaceutical products conform with established specifications for identity, strength, purity and other characteristics.\n\nquality management system  \nAn appropriate infrastructure, encompassing the organizational structure, procedures, processes and resources, and systematic actions necessary to ensure adequate confidence that a product or service will satisfy given requirements for quality (see Part one, section 2).\n\nquality manager  \nA member of staff who has a defined responsibility and authority for ensuring that the management system related to quality is implemented and followed at all times (see Part one, section 1.3(j)).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2329, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3ee95f29-c29f-466a-90b1-ff7fa666eb9f": {"__data__": {"id_": "3ee95f29-c29f-466a-90b1-ff7fa666eb9f", "embedding": null, "metadata": {"page_label": "103", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "quality manual  \nA handbook that describes the various elements of the quality management system for assuring the quality of the test results generated by a laboratory (see Part one, sections 2.1\u20132.2).\n\nquality unit(s)  \nAn organizational unit, independent of production, which fulfils both quality assurance and quality control responsibilities. This can be in the form of separate quality assurance and quality control or a single individual or group, depending on the size and structure of the organization.\n\nreference material  \nMaterial sufficiently homogeneous and stable with respect to one or more specified properties, which has been established to be fit for its intended use in a measurement process (4).\n\nreference substance (or standard)  \nAn authenticated, uniform material that is intended for use in specified chemical and physical tests, in which its properties are compared with those of the product under examination, and which possesses a degree of purity adequate for its intended use (8).\n\nsecondary reference substance (or standard)  \nA substance whose characteristics are assigned and/or calibrated by comparison with a primary reference substance. The extent of characterization and testing of a secondary reference substance may be less than for a primary reference substance (8).\n\n*Note:* Often referred to as an \u201cin-house\u201d working standard.\n\nsignature (signed)  \nRecord of the individual who performed a particular action or review. The record can be initials, full handwritten signature, personal seal or authenticated and secure electronic signature.\n\nspecification  \nA list of detailed requirements (acceptance criteria for the prescribed test procedures) with which the substance or pharmaceutical product has to conform to ensure suitable quality.\n\nstandard operating procedure (SOP)  \nAn authorized written procedure giving instructions for performing operations both general and specific.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento \"WHO - Technical Report Series 957\" aborda aspectos clave del sistema de gesti\u00f3n de calidad en laboratorios, incluyendo definiciones y funciones de unidades de calidad, materiales de referencia, procedimientos operativos est\u00e1ndar y la importancia de la firma en registros. Se enfatiza la necesidad de especificaciones detalladas para asegurar la calidad de los productos farmac\u00e9uticos y los m\u00e9todos de prueba.\n\n### Preguntas:\n1. **\u00bfCu\u00e1l es la funci\u00f3n principal de una unidad de calidad en un laboratorio seg\u00fan el documento?**\n   - Respuesta: La unidad de calidad es un organismo independiente de la producci\u00f3n que cumple con responsabilidades tanto de aseguramiento de la calidad como de control de calidad, pudiendo estar estructurada como unidades separadas o como un solo grupo, dependiendo del tama\u00f1o de la organizaci\u00f3n.\n\n2. **\u00bfQu\u00e9 se entiende por 'material de referencia' y por qu\u00e9 es importante en un proceso de medici\u00f3n?**\n   - Respuesta: El material de referencia es un material que es suficientemente homog\u00e9neo y estable en relaci\u00f3n con propiedades espec\u00edficas, y se ha establecido que es adecuado para su uso en un proceso de medici\u00f3n. Su importancia radica en que asegura la precisi\u00f3n y la fiabilidad de los resultados de las pruebas.\n\n3. **\u00bfQu\u00e9 se considera una 'procedimiento operativo est\u00e1ndar' (SOP) y cu\u00e1l es su prop\u00f3sito?**\n   - Respuesta: Un procedimiento operativo est\u00e1ndar (SOP) es un documento escrito autorizado que proporciona instrucciones para realizar operaciones, tanto generales como espec\u00edficas. Su prop\u00f3sito es garantizar que las actividades se realicen de manera consistente y conforme a los requisitos establecidos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Producto Farmac\u00e9utico**: Se refiere a cualquier material o producto destinado al uso humano o veterinario, que puede presentarse en forma de dosificaci\u00f3n final o como material inicial, y que est\u00e1 regulado por la legislaci\u00f3n farmac\u00e9utica del pa\u00eds exportador e importador.\n\n2. **Precisi\u00f3n**: Se define como el grado de acuerdo entre resultados individuales en m\u00faltiples muestreos de una muestra homog\u00e9nea. Se clasifica en tres niveles:\n   - **Repetibilidad**: Precisi\u00f3n bajo las mismas condiciones operativas en un corto per\u00edodo.\n   - **Precisi\u00f3n Intermedia**: Variaciones dentro del laboratorio (diferentes d\u00edas, analistas o equipos).\n   - **Reproducibilidad**: Precisi\u00f3n entre diferentes laboratorios.\n\n3. **Sustancia de Referencia Primaria**: Sustancia reconocida por poseer cualidades adecuadas en un contexto espec\u00edfico, cuya composici\u00f3n se acepta sin necesidad de comparaci\u00f3n con otra sustancia qu\u00edmica.\n\n4. **Calificaci\u00f3n de Equipos**: Proceso de demostrar y documentar que el equipo anal\u00edtico cumple con las especificaciones requeridas y es adecuado para su prop\u00f3sito.\n\n5. **Control de Calidad**: Conjunto de medidas que incluyen la fijaci\u00f3n de especificaciones, muestreo, pruebas y aprobaci\u00f3n anal\u00edtica, para asegurar que los productos farmac\u00e9uticos cumplan con las especificaciones establecidas.\n\n6. **Sistema de Gesti\u00f3n de Calidad**: Infraestructura que incluye la estructura organizativa, procedimientos, procesos y recursos necesarios para garantizar que un producto o servicio cumpla con los requisitos de calidad.\n\n7. **Gerente de Calidad**: Personal responsable de asegurar que el sistema de gesti\u00f3n de calidad se implemente y mantenga en todo momento.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Fuente del documento.\n- **Legislaci\u00f3n Farmac\u00e9utica**: Marco regulatorio que rige los productos farmac\u00e9uticos.\n- **Sustancias de Referencia**: Incluyen sustancias qu\u00edmicas de referencia farmacop\u00e9ica.\n- **Equipos Anal\u00edticos**: Herramientas utilizadas en el control de calidad y an\u00e1lisis de productos farmac\u00e9uticos.\n\nEste resumen abarca los conceptos fundamentales y las entidades relevantes en el contexto de la calidad y el control de productos farmac\u00e9uticos seg\u00fan el documento de la OMS.", "excerpt_keywords": "Keywords: quality management, reference material, standard operating procedure, quality assurance, pharmaceutical products"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "afaaad83-fbdd-4905-b5a4-1bb579be28c6", "node_type": "4", "metadata": {"page_label": "103", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "quality manual  \nA handbook that describes the various elements of the quality management system for assuring the quality of the test results generated by a laboratory (see Part one, sections 2.1\u20132.2).\n\nquality unit(s)  \nAn organizational unit, independent of production, which fulfils both quality assurance and quality control responsibilities. This can be in the form of separate quality assurance and quality control or a single individual or group, depending on the size and structure of the organization.\n\nreference material  \nMaterial sufficiently homogeneous and stable with respect to one or more specified properties, which has been established to be fit for its intended use in a measurement process (4).\n\nreference substance (or standard)  \nAn authenticated, uniform material that is intended for use in specified chemical and physical tests, in which its properties are compared with those of the product under examination, and which possesses a degree of purity adequate for its intended use (8).\n\nsecondary reference substance (or standard)  \nA substance whose characteristics are assigned and/or calibrated by comparison with a primary reference substance. The extent of characterization and testing of a secondary reference substance may be less than for a primary reference substance (8).\n\n*Note:* Often referred to as an \u201cin-house\u201d working standard.\n\nsignature (signed)  \nRecord of the individual who performed a particular action or review. The record can be initials, full handwritten signature, personal seal or authenticated and secure electronic signature.\n\nspecification  \nA list of detailed requirements (acceptance criteria for the prescribed test procedures) with which the substance or pharmaceutical product has to conform to ensure suitable quality.\n\nstandard operating procedure (SOP)  \nAn authorized written procedure giving instructions for performing operations both general and specific.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "46d22ba02ac26e8d6585f64d7526223276f17d172c6e0a8f100eeafba667c7cf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "quality manual  \nA handbook that describes the various elements of the quality management system for assuring the quality of the test results generated by a laboratory (see Part one, sections 2.1\u20132.2).\n\nquality unit(s)  \nAn organizational unit, independent of production, which fulfils both quality assurance and quality control responsibilities. This can be in the form of separate quality assurance and quality control or a single individual or group, depending on the size and structure of the organization.\n\nreference material  \nMaterial sufficiently homogeneous and stable with respect to one or more specified properties, which has been established to be fit for its intended use in a measurement process (4).\n\nreference substance (or standard)  \nAn authenticated, uniform material that is intended for use in specified chemical and physical tests, in which its properties are compared with those of the product under examination, and which possesses a degree of purity adequate for its intended use (8).\n\nsecondary reference substance (or standard)  \nA substance whose characteristics are assigned and/or calibrated by comparison with a primary reference substance. The extent of characterization and testing of a secondary reference substance may be less than for a primary reference substance (8).\n\n*Note:* Often referred to as an \u201cin-house\u201d working standard.\n\nsignature (signed)  \nRecord of the individual who performed a particular action or review. The record can be initials, full handwritten signature, personal seal or authenticated and secure electronic signature.\n\nspecification  \nA list of detailed requirements (acceptance criteria for the prescribed test procedures) with which the substance or pharmaceutical product has to conform to ensure suitable quality.\n\nstandard operating procedure (SOP)  \nAn authorized written procedure giving instructions for performing operations both general and specific.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1923, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "49f48fee-fdd9-4eae-8c25-d5fb5ab60037": {"__data__": {"id_": "49f48fee-fdd9-4eae-8c25-d5fb5ab60037", "embedding": null, "metadata": {"page_label": "104", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# standard uncertainty\n\nUncertainty of the result of a measurement expressed as a standard deviation (4, 9, 10).\n\n# system suitability test\n\nA test which is performed to ensure that the analytical procedure fulfils the acceptance criteria which had been established during the validation of the procedure. This test is performed before starting the analytical procedure and is to be repeated regularly, as appropriate, throughout the analytical run to ensure that the system\u2019s performance is acceptable at the time of the test.\n\n# validation of an analytical procedure\n\nThe documented process by which an analytical procedure (or method) is demonstrated to be suitable for its intended use.\n\n# verification of an analytical procedure\n\nProcess by which a pharmacopoeial method or validated analytical procedure is demonstrated to be suitable for the analysis to be performed.\n\n# verification of performance\n\nTest procedure regularly applied to a system (e.g. liquid chromatographic system) to demonstrate consistency of response.\n\n# Part One. Management and infrastructure\n\n## 1. Organization and management\n\n1.1 The laboratory, or the organization of which it is part, should be an entity that is legally authorized to function and can be held legally responsible.\n\n1.2 The laboratory should be organized and operate so as to meet the requirements laid down in these guidelines.\n\n1.3 The laboratory should:\n\n- (a) have managerial and technical personnel with the authority and resources needed to carry out their duties and to identify the occurrence of departures from the quality management system or the procedures for performing tests and/or calibrations, validation and verification, and to initiate actions to prevent or minimize such departures;\n- (b) have arrangements to ensure that its management and personnel are not subject to commercial, political, financial and other influences.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en su Informe T\u00e9cnico 957 aborda aspectos fundamentales de la gesti\u00f3n y la infraestructura de laboratorios, centr\u00e1ndose en la organizaci\u00f3n y el manejo de procedimientos anal\u00edticos. Se definen conceptos clave como la incertidumbre est\u00e1ndar, las pruebas de idoneidad del sistema, la validaci\u00f3n y verificaci\u00f3n de procedimientos anal\u00edticos, y se establecen requisitos para la organizaci\u00f3n y el personal del laboratorio para asegurar la calidad y la responsabilidad legal.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben cumplirse para que un laboratorio sea considerado legalmente autorizado seg\u00fan las directrices de la OMS?**\n   - El laboratorio debe ser una entidad legalmente autorizada para funcionar y debe poder ser responsabilizada legalmente por sus actividades.\n\n2. **\u00bfCu\u00e1l es la importancia de realizar pruebas de idoneidad del sistema antes y durante un procedimiento anal\u00edtico?**\n   - Estas pruebas son cruciales para asegurar que el procedimiento anal\u00edtico cumple con los criterios de aceptaci\u00f3n establecidos durante su validaci\u00f3n, garantizando as\u00ed que el rendimiento del sistema sea aceptable en el momento de la prueba.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse para evitar influencias externas en la gesti\u00f3n y el personal del laboratorio?**\n   - El laboratorio debe tener arreglos que aseguren que su gesti\u00f3n y personal no est\u00e9n sujetos a influencias comerciales, pol\u00edticas, financieras u otras que puedan comprometer la integridad de sus operaciones.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 957\" se centra en la gesti\u00f3n de calidad en laboratorios, abordando varios conceptos esenciales:\n\n1. **Manual de Calidad**: Describe los elementos del sistema de gesti\u00f3n de calidad que aseguran la calidad de los resultados de las pruebas en un laboratorio.\n\n2. **Unidad de Calidad**: Se define como una unidad organizativa independiente de la producci\u00f3n que se encarga de las responsabilidades de aseguramiento y control de calidad. Puede estar estructurada como unidades separadas o como un solo grupo, dependiendo del tama\u00f1o de la organizaci\u00f3n.\n\n3. **Material de Referencia**: Se refiere a un material que es homog\u00e9neo y estable en relaci\u00f3n con propiedades espec\u00edficas, utilizado en procesos de medici\u00f3n para garantizar la precisi\u00f3n de los resultados.\n\n4. **Sustancia de Referencia (o Est\u00e1ndar)**: Material autenticado y uniforme utilizado en pruebas qu\u00edmicas y f\u00edsicas, cuyas propiedades se comparan con las del producto en examen.\n\n5. **Sustancia de Referencia Secundaria (o Est\u00e1ndar)**: Sustancia cuya caracterizaci\u00f3n se realiza en comparaci\u00f3n con una sustancia de referencia primaria, con un nivel de caracterizaci\u00f3n que puede ser menor.\n\n6. **Firma (Firmado)**: Registro del individuo que realiz\u00f3 una acci\u00f3n o revisi\u00f3n, que puede ser en forma de iniciales, firma manuscrita, sello personal o firma electr\u00f3nica segura.\n\n7. **Especificaci\u00f3n**: Lista de requisitos detallados que un producto farmac\u00e9utico debe cumplir para asegurar su calidad.\n\n8. **Procedimiento Operativo Est\u00e1ndar (SOP)**: Documento escrito que proporciona instrucciones autorizadas para realizar operaciones, tanto generales como espec\u00edficas, asegurando la consistencia en la ejecuci\u00f3n de actividades.\n\n### Entidades Clave\n- **Organizaci\u00f3n**: Laboratorio\n- **Funciones**: Aseguramiento de calidad, control de calidad\n- **Materiales**: Material de referencia, sustancia de referencia, sustancia de referencia secundaria\n- **Documentaci\u00f3n**: Manual de calidad, especificaciones, SOP\n\nEste resumen destaca la importancia de un sistema de gesti\u00f3n de calidad robusto en laboratorios para asegurar la fiabilidad y precisi\u00f3n de los resultados de las pruebas.", "excerpt_keywords": "Keywords: uncertainty, validation, verification, laboratory management, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "096baf02-7d37-4ec6-9032-0a32e8919d93", "node_type": "4", "metadata": {"page_label": "104", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# standard uncertainty\n\nUncertainty of the result of a measurement expressed as a standard deviation (4, 9, 10).\n\n# system suitability test\n\nA test which is performed to ensure that the analytical procedure fulfils the acceptance criteria which had been established during the validation of the procedure. This test is performed before starting the analytical procedure and is to be repeated regularly, as appropriate, throughout the analytical run to ensure that the system\u2019s performance is acceptable at the time of the test.\n\n# validation of an analytical procedure\n\nThe documented process by which an analytical procedure (or method) is demonstrated to be suitable for its intended use.\n\n# verification of an analytical procedure\n\nProcess by which a pharmacopoeial method or validated analytical procedure is demonstrated to be suitable for the analysis to be performed.\n\n# verification of performance\n\nTest procedure regularly applied to a system (e.g. liquid chromatographic system) to demonstrate consistency of response.\n\n# Part One. Management and infrastructure\n\n## 1. Organization and management\n\n1.1 The laboratory, or the organization of which it is part, should be an entity that is legally authorized to function and can be held legally responsible.\n\n1.2 The laboratory should be organized and operate so as to meet the requirements laid down in these guidelines.\n\n1.3 The laboratory should:\n\n- (a) have managerial and technical personnel with the authority and resources needed to carry out their duties and to identify the occurrence of departures from the quality management system or the procedures for performing tests and/or calibrations, validation and verification, and to initiate actions to prevent or minimize such departures;\n- (b) have arrangements to ensure that its management and personnel are not subject to commercial, political, financial and other influences.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "82f8824aa8d73ab013c851d2475f026c708982740730626f5e8cea4702b5a5a3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# standard uncertainty\n\nUncertainty of the result of a measurement expressed as a standard deviation (4, 9, 10).\n\n# system suitability test\n\nA test which is performed to ensure that the analytical procedure fulfils the acceptance criteria which had been established during the validation of the procedure. This test is performed before starting the analytical procedure and is to be repeated regularly, as appropriate, throughout the analytical run to ensure that the system\u2019s performance is acceptable at the time of the test.\n\n# validation of an analytical procedure\n\nThe documented process by which an analytical procedure (or method) is demonstrated to be suitable for its intended use.\n\n# verification of an analytical procedure\n\nProcess by which a pharmacopoeial method or validated analytical procedure is demonstrated to be suitable for the analysis to be performed.\n\n# verification of performance\n\nTest procedure regularly applied to a system (e.g. liquid chromatographic system) to demonstrate consistency of response.\n\n# Part One. Management and infrastructure\n\n## 1. Organization and management\n\n1.1 The laboratory, or the organization of which it is part, should be an entity that is legally authorized to function and can be held legally responsible.\n\n1.2 The laboratory should be organized and operate so as to meet the requirements laid down in these guidelines.\n\n1.3 The laboratory should:\n\n- (a) have managerial and technical personnel with the authority and resources needed to carry out their duties and to identify the occurrence of departures from the quality management system or the procedures for performing tests and/or calibrations, validation and verification, and to initiate actions to prevent or minimize such departures;\n- (b) have arrangements to ensure that its management and personnel are not subject to commercial, political, financial and other influences.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1894, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "dfe442b5-79ab-47c5-a794-e164cb5dcee4": {"__data__": {"id_": "dfe442b5-79ab-47c5-a794-e164cb5dcee4", "embedding": null, "metadata": {"page_label": "105", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\npressures or conflicts of interest that may adversely affect the \nquality of their work; \n(c) have a policy and procedure in place to ensure confidentiality of \n   \u2014 information contained in marketing authorizations, \n   \u2014 transfer of results or reports, \n   \u2014 and to protect data in archives (paper and electronic); \n\n(d) define, with the aid of organizational charts, the organization and \n    management structure of the laboratory, its place in any parent \n    organization (such as the ministry or the NMRA in the case \n    of a national pharmaceutical quality control laboratory), and \n    the relationships between management, technical operations, \n    support services and the quality management system; \n\n(e) specify the responsibility, authority and interrelationships of all \n    personnel who manage, perform or verify work which affects \n    the quality of the tests and/or calibrations, validations and \n    verifications; \n\n(f) ensure the precise allocation of responsibilities, particularly in \n    the designation of specific units for particular types of medicines; \n\n(g) nominate trained substitutes/deputies for key management and \n    specialized scientific personnel; \n\n(h) provide adequate supervision of staff, including trainees, by \n    persons familiar with the test and/or calibration, validation and \n    verification methods and procedures, as well as their purpose \n    and the assessment of the results; \n\n(i) have management which has overall responsibility for the \n    technical operations and the provision of resources needed to \n    ensure the required quality of laboratory operations; \n\n(j) designate a member of staff as quality manager who, \n    irrespective of other duties he/she may have, will ensure \n    compliance with the quality management system. The \n    nominated quality manager should have direct access to the \n    highest level of management at which decisions are taken on \n    laboratory policies or resources; \n\n(k) ensure adequate information flow between staff at all levels. \n    Staff are to be made aware of the relevance and importance of \n    their activities; \n\n(l) ensure the traceability of the sample from receipt, throughout \n    the stages of testing, to the completion of the analytical test \n    report; \n\n(m) maintain an up-to-date collection of all specifications and related \n    documents (paper or electronic) used in the laboratory; and \n\n(n) have appropriate safety procedures (see Part four).\n```\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 957) establece directrices para la gesti\u00f3n y operaci\u00f3n de laboratorios, especialmente en el contexto de control de calidad farmac\u00e9utica. Se enfatiza la importancia de la confidencialidad, la organizaci\u00f3n estructural, la asignaci\u00f3n de responsabilidades, la supervisi\u00f3n del personal, y la implementaci\u00f3n de un sistema de gesti\u00f3n de calidad. Adem\u00e1s, se menciona la necesidad de asegurar la trazabilidad de las muestras y mantener actualizada la documentaci\u00f3n relacionada con las especificaciones del laboratorio.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas del gerente de calidad en un laboratorio seg\u00fan el documento?**\n   - Esta pregunta busca una respuesta detallada sobre el rol del gerente de calidad, que incluye su acceso a la alta direcci\u00f3n y su responsabilidad en el cumplimiento del sistema de gesti\u00f3n de calidad.\n\n2. **\u00bfQu\u00e9 procedimientos se deben implementar para garantizar la confidencialidad de la informaci\u00f3n en un laboratorio?**\n   - Esta pregunta se centra en las pol\u00edticas y procedimientos necesarios para proteger la informaci\u00f3n sensible, como los datos de autorizaciones de comercializaci\u00f3n y resultados de pruebas.\n\n3. **\u00bfC\u00f3mo se debe estructurar la organizaci\u00f3n y gesti\u00f3n de un laboratorio para asegurar la calidad de las pruebas y calibraciones?**\n   - Esta pregunta busca una descripci\u00f3n de la estructura organizativa y las interrelaciones entre el personal, as\u00ed como la asignaci\u00f3n de responsabilidades para mantener la calidad en las operaciones del laboratorio. \n\nEstas preguntas est\u00e1n dise\u00f1adas para obtener informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otros documentos, centr\u00e1ndose en aspectos clave de la gesti\u00f3n de calidad en laboratorios farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n del documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en el Informe T\u00e9cnico 957 aborda varios conceptos y directrices esenciales para la gesti\u00f3n y operaci\u00f3n de laboratorios anal\u00edticos. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave\n\n1. **Incertidumbre Est\u00e1ndar**: Se refiere a la incertidumbre en los resultados de mediciones, expresada como una desviaci\u00f3n est\u00e1ndar.\n\n2. **Prueba de Idoneidad del Sistema**: Es una evaluaci\u00f3n que se realiza para asegurar que un procedimiento anal\u00edtico cumple con los criterios de aceptaci\u00f3n establecidos durante su validaci\u00f3n. Debe realizarse antes de iniciar el procedimiento y repetirse regularmente.\n\n3. **Validaci\u00f3n de un Procedimiento Anal\u00edtico**: Proceso documentado que demuestra que un procedimiento anal\u00edtico es adecuado para su uso previsto.\n\n4. **Verificaci\u00f3n de un Procedimiento Anal\u00edtico**: Proceso que asegura que un m\u00e9todo farmacop\u00e9ico o un procedimiento anal\u00edtico validado es adecuado para el an\u00e1lisis que se va a realizar.\n\n5. **Verificaci\u00f3n del Rendimiento**: Procedimiento de prueba aplicado regularmente a un sistema (como un sistema de cromatograf\u00eda l\u00edquida) para demostrar la consistencia de la respuesta.\n\n6. **Organizaci\u00f3n y Gesti\u00f3n del Laboratorio**: Directrices sobre c\u00f3mo debe estar estructurado y operar un laboratorio para cumplir con los requisitos establecidos, incluyendo la responsabilidad legal y la independencia de influencias externas.\n\n#### Entidades\n\n- **Laboratorio**: Entidad que debe estar legalmente autorizada para operar y ser responsable de sus actividades.\n- **Personal Gerencial y T\u00e9cnico**: Debe tener la autoridad y los recursos necesarios para llevar a cabo sus funciones y gestionar la calidad del sistema.\n- **Sistema Anal\u00edtico**: Incluye procedimientos y m\u00e9todos que deben ser validados y verificados para asegurar su eficacia.\n\nEste resumen destaca la importancia de la calidad y la responsabilidad en la operaci\u00f3n de laboratorios anal\u00edticos, as\u00ed como la necesidad de procedimientos rigurosos para garantizar resultados confiables y v\u00e1lidos.", "excerpt_keywords": "Keywords: calidad, laboratorio, gesti\u00f3n, confidencialidad, trazabilidad"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "70bd48ec-272b-473d-882c-5fc1266e6f22", "node_type": "4", "metadata": {"page_label": "105", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\npressures or conflicts of interest that may adversely affect the \nquality of their work; \n(c) have a policy and procedure in place to ensure confidentiality of \n   \u2014 information contained in marketing authorizations, \n   \u2014 transfer of results or reports, \n   \u2014 and to protect data in archives (paper and electronic); \n\n(d) define, with the aid of organizational charts, the organization and \n    management structure of the laboratory, its place in any parent \n    organization (such as the ministry or the NMRA in the case \n    of a national pharmaceutical quality control laboratory), and \n    the relationships between management, technical operations, \n    support services and the quality management system; \n\n(e) specify the responsibility, authority and interrelationships of all \n    personnel who manage, perform or verify work which affects \n    the quality of the tests and/or calibrations, validations and \n    verifications; \n\n(f) ensure the precise allocation of responsibilities, particularly in \n    the designation of specific units for particular types of medicines; \n\n(g) nominate trained substitutes/deputies for key management and \n    specialized scientific personnel; \n\n(h) provide adequate supervision of staff, including trainees, by \n    persons familiar with the test and/or calibration, validation and \n    verification methods and procedures, as well as their purpose \n    and the assessment of the results; \n\n(i) have management which has overall responsibility for the \n    technical operations and the provision of resources needed to \n    ensure the required quality of laboratory operations; \n\n(j) designate a member of staff as quality manager who, \n    irrespective of other duties he/she may have, will ensure \n    compliance with the quality management system. The \n    nominated quality manager should have direct access to the \n    highest level of management at which decisions are taken on \n    laboratory policies or resources; \n\n(k) ensure adequate information flow between staff at all levels. \n    Staff are to be made aware of the relevance and importance of \n    their activities; \n\n(l) ensure the traceability of the sample from receipt, throughout \n    the stages of testing, to the completion of the analytical test \n    report; \n\n(m) maintain an up-to-date collection of all specifications and related \n    documents (paper or electronic) used in the laboratory; and \n\n(n) have appropriate safety procedures (see Part four).\n```\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "28441d3df6d1c1ae84f40a6264bc1ccdec97b5f31103b08aa6f698a39b930011", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "```\npressures or conflicts of interest that may adversely affect the \nquality of their work; \n(c) have a policy and procedure in place to ensure confidentiality of \n   \u2014 information contained in marketing authorizations, \n   \u2014 transfer of results or reports, \n   \u2014 and to protect data in archives (paper and electronic); \n\n(d) define, with the aid of organizational charts, the organization and \n    management structure of the laboratory, its place in any parent \n    organization (such as the ministry or the NMRA in the case \n    of a national pharmaceutical quality control laboratory), and \n    the relationships between management, technical operations, \n    support services and the quality management system; \n\n(e) specify the responsibility, authority and interrelationships of all \n    personnel who manage, perform or verify work which affects \n    the quality of the tests and/or calibrations, validations and \n    verifications; \n\n(f) ensure the precise allocation of responsibilities, particularly in \n    the designation of specific units for particular types of medicines; \n\n(g) nominate trained substitutes/deputies for key management and \n    specialized scientific personnel; \n\n(h) provide adequate supervision of staff, including trainees, by \n    persons familiar with the test and/or calibration, validation and \n    verification methods and procedures, as well as their purpose \n    and the assessment of the results; \n\n(i) have management which has overall responsibility for the \n    technical operations and the provision of resources needed to \n    ensure the required quality of laboratory operations; \n\n(j) designate a member of staff as quality manager who, \n    irrespective of other duties he/she may have, will ensure \n    compliance with the quality management system. The \n    nominated quality manager should have direct access to the \n    highest level of management at which decisions are taken on \n    laboratory policies or resources; \n\n(k) ensure adequate information flow between staff at all levels. \n    Staff are to be made aware of the relevance and importance of \n    their activities; \n\n(l) ensure the traceability of the sample from receipt, throughout \n    the stages of testing, to the completion of the analytical test \n    report; \n\n(m) maintain an up-to-date collection of all specifications and related \n    documents (paper or electronic) used in the laboratory; and \n\n(n) have appropriate safety procedures (see Part four).\n```", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2484, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e9fbcb89-5827-4db8-b96e-00e266275213": {"__data__": {"id_": "e9fbcb89-5827-4db8-b96e-00e266275213", "embedding": null, "metadata": {"page_label": "106", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 1.4 \nThe laboratory should maintain a registry with the following functions:\n\n(a) receiving, distributing and supervising the consignment of the samples to the specific units; and  \n(b) keeping records on all incoming samples and accompanying documents.\n\n1.5 In a large laboratory, it is necessary to guarantee communication and coordination between the staff involved in the testing of the same sample in different units.\n\n# 2. Quality management system\n\n2.1 The laboratory or organization management should establish, implement and maintain a quality management system appropriate to the scope of its activities, including the type, range and volume of testing and/or calibration, validation and verification activities it undertakes. The laboratory management should ensure that its policies, systems, programmes, procedures and instructions are described to the extent necessary to enable the laboratory to assure the quality of the test results that it generates. The documentation used in this quality management system should be communicated, available to, and understood and implemented by, the appropriate personnel. The elements of this system should be documented, e.g. in a quality manual, for the organization as a whole and/or for a laboratory within the organization.\n\n*Note:* Quality control laboratories of a manufacturer may have this information in other documents than a quality manual.\n\n2.2 The quality manual should contain as a minimum:\n\n(a) a quality policy statement, including at least the following:\n   (i) a statement of the laboratory management\u2019s intentions with respect to the standard of service it will provide,\n   (ii) a commitment to establishing, implementing and maintaining an effective quality management system,\n   (iii) the laboratory management\u2019s commitment to good professional practice and quality of testing, calibration, validation and verification,\n   (iv) the laboratory management\u2019s commitment to compliance with the content of these guidelines,\n   (v) a requirement that all personnel concerned with testing and calibration activities within the laboratory familiarize themselves with the documentation concerning quality and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices para la gesti\u00f3n de laboratorios, enfatizando la importancia de mantener un registro de muestras, garantizar la comunicaci\u00f3n entre el personal y establecer un sistema de gesti\u00f3n de calidad. Este sistema debe ser adecuado para las actividades del laboratorio y debe incluir un manual de calidad que contenga pol\u00edticas y compromisos claros de la direcci\u00f3n del laboratorio respecto a la calidad del servicio y la pr\u00e1ctica profesional.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las funciones espec\u00edficas que debe cumplir el registro de un laboratorio seg\u00fan las directrices de la OMS?**\n   - El registro debe cumplir con las funciones de recibir, distribuir y supervisar la consignaci\u00f3n de muestras a las unidades espec\u00edficas, as\u00ed como mantener registros de todas las muestras entrantes y los documentos que las acompa\u00f1an.\n\n2. **\u00bfQu\u00e9 elementos m\u00ednimos debe contener el manual de calidad de un laboratorio seg\u00fan las recomendaciones de la OMS?**\n   - El manual de calidad debe incluir, como m\u00ednimo, una declaraci\u00f3n de pol\u00edtica de calidad que abarque la intenci\u00f3n de la direcci\u00f3n respecto al est\u00e1ndar de servicio, el compromiso con un sistema de gesti\u00f3n de calidad efectivo, la pr\u00e1ctica profesional adecuada, el cumplimiento de las directrices y la familiarizaci\u00f3n del personal con la documentaci\u00f3n de calidad.\n\n3. **\u00bfPor qu\u00e9 es importante la comunicaci\u00f3n y coordinaci\u00f3n entre el personal en un laboratorio grande seg\u00fan el documento?**\n   - Es crucial garantizar la comunicaci\u00f3n y coordinaci\u00f3n entre el personal involucrado en la prueba de la misma muestra en diferentes unidades para asegurar la coherencia y la calidad de los resultados de las pruebas, lo que contribuye a la eficacia del sistema de gesti\u00f3n de calidad del laboratorio.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n del documento de la OMS (Serie de Informes T\u00e9cnicos 957) aborda directrices esenciales para la gesti\u00f3n y operaci\u00f3n de laboratorios, especialmente en el \u00e1mbito del control de calidad farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n#### Temas Clave:\n1. **Confidencialidad**: Importancia de tener pol\u00edticas y procedimientos para proteger la informaci\u00f3n sensible relacionada con autorizaciones de comercializaci\u00f3n y resultados de pruebas.\n   \n2. **Estructura Organizativa**: Necesidad de definir la organizaci\u00f3n y la estructura de gesti\u00f3n del laboratorio, incluyendo su relaci\u00f3n con organizaciones parentales (como ministerios o agencias reguladoras).\n\n3. **Responsabilidades y Autoridad**: Especificaci\u00f3n de las responsabilidades y la autoridad de todo el personal involucrado en la gesti\u00f3n, ejecuci\u00f3n y verificaci\u00f3n de trabajos que afectan la calidad de las pruebas.\n\n4. **Supervisi\u00f3n del Personal**: Provisi\u00f3n de supervisi\u00f3n adecuada para el personal, incluidos los aprendices, por parte de personas familiarizadas con los m\u00e9todos y procedimientos de prueba.\n\n5. **Gesti\u00f3n de Calidad**: Designaci\u00f3n de un gerente de calidad que garantice el cumplimiento del sistema de gesti\u00f3n de calidad y tenga acceso a la alta direcci\u00f3n.\n\n6. **Flujo de Informaci\u00f3n**: Asegurar una comunicaci\u00f3n adecuada entre el personal en todos los niveles y la concienciaci\u00f3n sobre la importancia de sus actividades.\n\n7. **Trazabilidad de Muestras**: Garantizar la trazabilidad de las muestras desde su recepci\u00f3n hasta la finalizaci\u00f3n del informe de prueba anal\u00edtica.\n\n8. **Documentaci\u00f3n Actualizada**: Mantenimiento de una colecci\u00f3n actualizada de especificaciones y documentos relacionados utilizados en el laboratorio.\n\n9. **Procedimientos de Seguridad**: Implementaci\u00f3n de procedimientos de seguridad adecuados en el laboratorio.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Laboratorios**: Entidades que deben cumplir con las directrices de calidad.\n- **Ministerios y Agencias Reguladoras**: Organizaciones parentales que pueden estar relacionadas con laboratorios nacionales de control de calidad farmac\u00e9utica.\n- **Personal del Laboratorio**: Incluye gerentes, t\u00e9cnicos, personal de apoyo y aprendices.\n\nEste resumen destaca la importancia de una gesti\u00f3n estructurada y de calidad en los laboratorios, as\u00ed como la necesidad de mantener la confidencialidad y la trazabilidad en los procesos de prueba.", "excerpt_keywords": "Keywords: laboratory management, quality management system, sample registry, testing coordination, quality manual"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "40c4f355-74a7-4fec-a53a-0bbaee986e7d", "node_type": "4", "metadata": {"page_label": "106", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 1.4 \nThe laboratory should maintain a registry with the following functions:\n\n(a) receiving, distributing and supervising the consignment of the samples to the specific units; and  \n(b) keeping records on all incoming samples and accompanying documents.\n\n1.5 In a large laboratory, it is necessary to guarantee communication and coordination between the staff involved in the testing of the same sample in different units.\n\n# 2. Quality management system\n\n2.1 The laboratory or organization management should establish, implement and maintain a quality management system appropriate to the scope of its activities, including the type, range and volume of testing and/or calibration, validation and verification activities it undertakes. The laboratory management should ensure that its policies, systems, programmes, procedures and instructions are described to the extent necessary to enable the laboratory to assure the quality of the test results that it generates. The documentation used in this quality management system should be communicated, available to, and understood and implemented by, the appropriate personnel. The elements of this system should be documented, e.g. in a quality manual, for the organization as a whole and/or for a laboratory within the organization.\n\n*Note:* Quality control laboratories of a manufacturer may have this information in other documents than a quality manual.\n\n2.2 The quality manual should contain as a minimum:\n\n(a) a quality policy statement, including at least the following:\n   (i) a statement of the laboratory management\u2019s intentions with respect to the standard of service it will provide,\n   (ii) a commitment to establishing, implementing and maintaining an effective quality management system,\n   (iii) the laboratory management\u2019s commitment to good professional practice and quality of testing, calibration, validation and verification,\n   (iv) the laboratory management\u2019s commitment to compliance with the content of these guidelines,\n   (v) a requirement that all personnel concerned with testing and calibration activities within the laboratory familiarize themselves with the documentation concerning quality and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "ba8747c9bfc8f46a377da97e5cdde85a54c29b4d858ca5bc4469270e2deb41ad", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 1.4 \nThe laboratory should maintain a registry with the following functions:\n\n(a) receiving, distributing and supervising the consignment of the samples to the specific units; and  \n(b) keeping records on all incoming samples and accompanying documents.\n\n1.5 In a large laboratory, it is necessary to guarantee communication and coordination between the staff involved in the testing of the same sample in different units.\n\n# 2. Quality management system\n\n2.1 The laboratory or organization management should establish, implement and maintain a quality management system appropriate to the scope of its activities, including the type, range and volume of testing and/or calibration, validation and verification activities it undertakes. The laboratory management should ensure that its policies, systems, programmes, procedures and instructions are described to the extent necessary to enable the laboratory to assure the quality of the test results that it generates. The documentation used in this quality management system should be communicated, available to, and understood and implemented by, the appropriate personnel. The elements of this system should be documented, e.g. in a quality manual, for the organization as a whole and/or for a laboratory within the organization.\n\n*Note:* Quality control laboratories of a manufacturer may have this information in other documents than a quality manual.\n\n2.2 The quality manual should contain as a minimum:\n\n(a) a quality policy statement, including at least the following:\n   (i) a statement of the laboratory management\u2019s intentions with respect to the standard of service it will provide,\n   (ii) a commitment to establishing, implementing and maintaining an effective quality management system,\n   (iii) the laboratory management\u2019s commitment to good professional practice and quality of testing, calibration, validation and verification,\n   (iv) the laboratory management\u2019s commitment to compliance with the content of these guidelines,\n   (v) a requirement that all personnel concerned with testing and calibration activities within the laboratory familiarize themselves with the documentation concerning quality and", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2177, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d76fd27e-9193-4edf-b976-eb92f3264d0c": {"__data__": {"id_": "d76fd27e-9193-4edf-b976-eb92f3264d0c", "embedding": null, "metadata": {"page_label": "107", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the implementation of the policies and procedures in their work;  \n(b) the structure of the laboratory (organizational chart);  \n(c) the operational and functional activities pertaining to quality, so that the extent and the limits of the responsibilities are clearly defined;  \n(d) outline of the structure of documentation used in the laboratory quality management system;  \n(e) the general internal quality management procedures;  \n(f) references to specific procedures for each test;  \n(g) information on the appropriate qualifications, experience and competencies that personnel are required to possess;  \n(h) information on initial and in-service training of staff;  \n(i) a policy for internal and external audit;  \n(j) a policy for implementing and verifying corrective and preventive actions;  \n(k) a policy for dealing with complaints;  \n(l) a policy for performing management reviews of the quality management system;  \n(m) a policy for selecting, establishing and approving analytical procedures;  \n(n) a policy for handling of OOS results;  \n(o) a policy for the employment of appropriate reference substances and reference materials;  \n(p) a policy for participation in appropriate proficiency testing schemes and collaborative trials and the evaluation of the performance (applicable to national pharmaceutical quality control laboratories, but may be applied by other laboratories); and  \n(q) a policy to select service providers and suppliers.  \n\n2.3 The laboratory should establish, implement and maintain authorized written SOPs including, but not limited to, administrative and technical operations, such as:  \n\n(a) personnel matters, including qualifications, training, clothing and hygiene;  \n(b) the change control;  \n(c) internal audit;  \n(d) dealing with complaints;  \n(e) implementation and verification of corrective and preventive actions;  \n(f) the purchase and receipt of consignments of materials (e.g. samples, reagents);  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 957) establece directrices para la implementaci\u00f3n y mantenimiento de un sistema de gesti\u00f3n de calidad en laboratorios. Se detallan pol\u00edticas y procedimientos que deben ser establecidos, incluyendo la estructura organizativa, la capacitaci\u00f3n del personal, auditor\u00edas internas y externas, manejo de quejas, y procedimientos operativos est\u00e1ndar (SOPs) para diversas actividades administrativas y t\u00e9cnicas. Estas directrices son aplicables a laboratorios de control de calidad farmac\u00e9utica y pueden ser adaptadas por otros laboratorios.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las competencias y calificaciones espec\u00edficas que se requieren para el personal en un laboratorio seg\u00fan las directrices de la OMS?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre las expectativas de formaci\u00f3n y experiencia del personal, que no se puede encontrar f\u00e1cilmente en otros documentos.\n\n2. **\u00bfQu\u00e9 pol\u00edticas deben implementarse para manejar resultados fuera de especificaci\u00f3n (OOS) en un laboratorio?**\n   - Esta pregunta se centra en un aspecto cr\u00edtico de la gesti\u00f3n de calidad que puede no estar ampliamente documentado en otras fuentes.\n\n3. **\u00bfQu\u00e9 procedimientos operativos est\u00e1ndar (SOPs) se consideran esenciales para las operaciones administrativas y t\u00e9cnicas en un laboratorio, seg\u00fan el informe?**\n   - Esta pregunta busca una lista espec\u00edfica de SOPs que son fundamentales para el funcionamiento eficaz de un laboratorio, lo cual puede no estar claramente delineado en otros documentos.", "prev_section_summary": "### Temas Clave\n\n1. **Registro de Muestras**: \n   - Funciones del registro en el laboratorio: recibir, distribuir y supervisar la consignaci\u00f3n de muestras, as\u00ed como mantener registros de todas las muestras entrantes y documentos asociados.\n\n2. **Comunicaci\u00f3n en Laboratorios Grandes**: \n   - Importancia de la comunicaci\u00f3n y coordinaci\u00f3n entre el personal que trabaja con la misma muestra en diferentes unidades para asegurar la calidad y coherencia de los resultados.\n\n3. **Sistema de Gesti\u00f3n de Calidad**: \n   - Necesidad de establecer, implementar y mantener un sistema de gesti\u00f3n de calidad que sea adecuado para las actividades del laboratorio, incluyendo pruebas, calibraciones, validaciones y verificaciones.\n\n4. **Manual de Calidad**: \n   - Contenido m\u00ednimo que debe incluir el manual de calidad, como la declaraci\u00f3n de pol\u00edtica de calidad, compromisos de la direcci\u00f3n respecto a la calidad del servicio y la pr\u00e1ctica profesional, y la familiarizaci\u00f3n del personal con la documentaci\u00f3n de calidad.\n\n### Entidades\n\n- **Laboratorio**: Entidad responsable de realizar pruebas y mantener la calidad de los resultados.\n- **Muestras**: Elementos que se reciben y distribuyen en el laboratorio para su an\u00e1lisis.\n- **Personal del Laboratorio**: Empleados que realizan las pruebas y deben estar coordinados y comunicados.\n- **Sistema de Gesti\u00f3n de Calidad**: Conjunto de pol\u00edticas y procedimientos que aseguran la calidad de los resultados del laboratorio.\n- **Manual de Calidad**: Documento que describe las pol\u00edticas y compromisos del laboratorio en relaci\u00f3n con la calidad.\n\n### Resumen\nEl documento de la OMS establece directrices para la gesti\u00f3n de laboratorios, enfatizando la importancia de mantener un registro de muestras, garantizar la comunicaci\u00f3n entre el personal y establecer un sistema de gesti\u00f3n de calidad. Este sistema debe ser adecuado para las actividades del laboratorio y debe incluir un manual de calidad que contenga pol\u00edticas y compromisos claros de la direcci\u00f3n del laboratorio respecto a la calidad del servicio y la pr\u00e1ctica profesional.", "excerpt_keywords": "Keywords: calidad, laboratorio, procedimientos, gesti\u00f3n, auditor\u00eda"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "22730bbd-f3ca-4cdb-ba6c-1b073bdd4625", "node_type": "4", "metadata": {"page_label": "107", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the implementation of the policies and procedures in their work;  \n(b) the structure of the laboratory (organizational chart);  \n(c) the operational and functional activities pertaining to quality, so that the extent and the limits of the responsibilities are clearly defined;  \n(d) outline of the structure of documentation used in the laboratory quality management system;  \n(e) the general internal quality management procedures;  \n(f) references to specific procedures for each test;  \n(g) information on the appropriate qualifications, experience and competencies that personnel are required to possess;  \n(h) information on initial and in-service training of staff;  \n(i) a policy for internal and external audit;  \n(j) a policy for implementing and verifying corrective and preventive actions;  \n(k) a policy for dealing with complaints;  \n(l) a policy for performing management reviews of the quality management system;  \n(m) a policy for selecting, establishing and approving analytical procedures;  \n(n) a policy for handling of OOS results;  \n(o) a policy for the employment of appropriate reference substances and reference materials;  \n(p) a policy for participation in appropriate proficiency testing schemes and collaborative trials and the evaluation of the performance (applicable to national pharmaceutical quality control laboratories, but may be applied by other laboratories); and  \n(q) a policy to select service providers and suppliers.  \n\n2.3 The laboratory should establish, implement and maintain authorized written SOPs including, but not limited to, administrative and technical operations, such as:  \n\n(a) personnel matters, including qualifications, training, clothing and hygiene;  \n(b) the change control;  \n(c) internal audit;  \n(d) dealing with complaints;  \n(e) implementation and verification of corrective and preventive actions;  \n(f) the purchase and receipt of consignments of materials (e.g. samples, reagents);  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "06a7aa6ae9ed7ebe39d7508342ad8a4852685850ca8ba35f87ecd3cfca47c3ea", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "the implementation of the policies and procedures in their work;  \n(b) the structure of the laboratory (organizational chart);  \n(c) the operational and functional activities pertaining to quality, so that the extent and the limits of the responsibilities are clearly defined;  \n(d) outline of the structure of documentation used in the laboratory quality management system;  \n(e) the general internal quality management procedures;  \n(f) references to specific procedures for each test;  \n(g) information on the appropriate qualifications, experience and competencies that personnel are required to possess;  \n(h) information on initial and in-service training of staff;  \n(i) a policy for internal and external audit;  \n(j) a policy for implementing and verifying corrective and preventive actions;  \n(k) a policy for dealing with complaints;  \n(l) a policy for performing management reviews of the quality management system;  \n(m) a policy for selecting, establishing and approving analytical procedures;  \n(n) a policy for handling of OOS results;  \n(o) a policy for the employment of appropriate reference substances and reference materials;  \n(p) a policy for participation in appropriate proficiency testing schemes and collaborative trials and the evaluation of the performance (applicable to national pharmaceutical quality control laboratories, but may be applied by other laboratories); and  \n(q) a policy to select service providers and suppliers.  \n\n2.3 The laboratory should establish, implement and maintain authorized written SOPs including, but not limited to, administrative and technical operations, such as:  \n\n(a) personnel matters, including qualifications, training, clothing and hygiene;  \n(b) the change control;  \n(c) internal audit;  \n(d) dealing with complaints;  \n(e) implementation and verification of corrective and preventive actions;  \n(f) the purchase and receipt of consignments of materials (e.g. samples, reagents);", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1952, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a25ff74d-d82a-4706-8fdd-0f58302cf908": {"__data__": {"id_": "a25ff74d-d82a-4706-8fdd-0f58302cf908", "embedding": null, "metadata": {"page_label": "108", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "(g) the procurement, preparation and control of reference substances and reference materials (8);\n\n(h) the internal labelling, quarantine and storage of materials;\n\n(i) the qualification of equipment (11);\n\n(j) the calibration of equipment;\n\n(k) preventive maintenance and verification of instruments and equipment;\n\n(l) sampling, if performed by the laboratory, and visual inspection;\n\n(m) the testing of samples with descriptions of the methods and equipment used;\n\n(n) atypical and OOS results;\n\n(o) validation of analytical procedures;\n\n(p) cleaning of laboratory facilities, including bench tops, equipment, work stations, clean rooms (aseptic suites) and glassware;\n\n(q) monitoring of environmental conditions, e.g. temperature and humidity;\n\n(r) monitoring storage conditions;\n\n(s) disposal of reagents and solvent samples; and\n\n(t) safety measures.\n\n2.4 The activities of the laboratory should be systematically and periodically audited (internally and, where appropriate, by external audits or inspections) to verify compliance with the requirements of the quality management system and to apply corrective and preventive actions, if necessary. The audits should be carried out by trained and qualified personnel, who are independent of the activity to be audited. The quality manager is responsible for planning and organizing internal audits addressing all elements of the quality management system. Such audits should be recorded, together with details of any corrective and preventive action taken.\n\n2.5 Management review of quality issues should be regularly undertaken (at least annually), including:\n\n(a) reports on internal and external audits or inspections and any follow-up required to correct any deficiencies;\n\n(b) the outcome of investigations carried out as a result of complaints received, doubtful (atypical) or aberrant results reported in collaborative trials and/or proficiency tests; and\n\n(c) corrective actions applied and preventive actions introduced as a result of these investigations.\n\n# 3. Control of documentation\n\n3.1 Documentation is an essential part of the quality management system. The laboratory should establish and maintain procedures", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda aspectos clave de un sistema de gesti\u00f3n de calidad en laboratorios. Se enumeran diversas actividades que deben llevarse a cabo, como la adquisici\u00f3n y control de sustancias de referencia, la calibraci\u00f3n y mantenimiento de equipos, la limpieza de instalaciones, y la gesti\u00f3n de condiciones ambientales. Adem\u00e1s, se enfatiza la importancia de realizar auditor\u00edas internas y externas para garantizar el cumplimiento de los requisitos del sistema de gesti\u00f3n de calidad, as\u00ed como la revisi\u00f3n regular de los problemas de calidad por parte de la direcci\u00f3n. La documentaci\u00f3n es considerada un componente esencial del sistema de gesti\u00f3n de calidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben cumplirse para que un auditor sea considerado calificado para llevar a cabo auditor\u00edas internas en el laboratorio?**\n   - Esta pregunta busca informaci\u00f3n sobre las calificaciones y criterios espec\u00edficos que deben tener los auditores, que no se detalla expl\u00edcitamente en el texto.\n\n2. **\u00bfCu\u00e1les son los procedimientos espec\u00edficos que el laboratorio debe establecer para el control de la documentaci\u00f3n dentro del sistema de gesti\u00f3n de calidad?**\n   - Aunque se menciona que la documentaci\u00f3n es esencial, no se proporcionan detalles sobre los procedimientos espec\u00edficos que deben implementarse.\n\n3. **\u00bfQu\u00e9 acciones correctivas y preventivas se deben tomar en caso de que se identifiquen deficiencias durante las auditor\u00edas internas o externas?**\n   - Esta pregunta busca ejemplos concretos de acciones que se deben implementar, m\u00e1s all\u00e1 de la menci\u00f3n general de que deben aplicarse acciones correctivas y preventivas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades:\n\n1. **Sistema de Gesti\u00f3n de Calidad en Laboratorios**:\n   - Directrices para la implementaci\u00f3n y mantenimiento de un sistema de gesti\u00f3n de calidad en laboratorios, especialmente en el contexto de control de calidad farmac\u00e9utica.\n\n2. **Pol\u00edticas y Procedimientos**:\n   - Se requiere establecer pol\u00edticas claras que aborden diversas \u00e1reas, incluyendo:\n     - Estructura organizativa del laboratorio.\n     - Actividades operativas y funcionales relacionadas con la calidad.\n     - Procedimientos para auditor\u00edas internas y externas.\n     - Manejo de quejas y resultados fuera de especificaci\u00f3n (OOS).\n     - Capacitaci\u00f3n y competencias del personal.\n\n3. **Documentaci\u00f3n y Procedimientos Operativos Est\u00e1ndar (SOPs)**:\n   - Importancia de tener SOPs escritos y autorizados que cubran tanto operaciones administrativas como t\u00e9cnicas, tales como:\n     - Asuntos de personal (calificaciones, formaci\u00f3n, higiene).\n     - Control de cambios y auditor\u00edas internas.\n     - Proceso de compra y recepci\u00f3n de materiales.\n\n4. **Calificaciones y Capacitaci\u00f3n del Personal**:\n   - Informaci\u00f3n sobre las calificaciones, experiencia y competencias necesarias para el personal del laboratorio, as\u00ed como la formaci\u00f3n inicial y continua.\n\n5. **Pol\u00edticas Espec\u00edficas**:\n   - Pol\u00edticas para la selecci\u00f3n y aprobaci\u00f3n de procedimientos anal\u00edticos, manejo de materiales de referencia, participaci\u00f3n en pruebas de competencia y evaluaci\u00f3n del rendimiento.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Laboratorios**: Entidades que deben implementar las pol\u00edticas y procedimientos.\n- **Personal del Laboratorio**: Sujetos que deben cumplir con las calificaciones y capacitaci\u00f3n requeridas.\n- **SOPs**: Documentos que establecen procedimientos operativos est\u00e1ndar necesarios para el funcionamiento del laboratorio. \n\nEste resumen destaca la importancia de un enfoque sistem\u00e1tico y documentado para asegurar la calidad en los laboratorios, as\u00ed como la necesidad de personal competente y bien entrenado.", "excerpt_keywords": "Keywords: calidad, auditor\u00edas, documentaci\u00f3n, laboratorio, procedimientos"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d7f23d32-aae6-448d-ad40-df21233debb9", "node_type": "4", "metadata": {"page_label": "108", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "(g) the procurement, preparation and control of reference substances and reference materials (8);\n\n(h) the internal labelling, quarantine and storage of materials;\n\n(i) the qualification of equipment (11);\n\n(j) the calibration of equipment;\n\n(k) preventive maintenance and verification of instruments and equipment;\n\n(l) sampling, if performed by the laboratory, and visual inspection;\n\n(m) the testing of samples with descriptions of the methods and equipment used;\n\n(n) atypical and OOS results;\n\n(o) validation of analytical procedures;\n\n(p) cleaning of laboratory facilities, including bench tops, equipment, work stations, clean rooms (aseptic suites) and glassware;\n\n(q) monitoring of environmental conditions, e.g. temperature and humidity;\n\n(r) monitoring storage conditions;\n\n(s) disposal of reagents and solvent samples; and\n\n(t) safety measures.\n\n2.4 The activities of the laboratory should be systematically and periodically audited (internally and, where appropriate, by external audits or inspections) to verify compliance with the requirements of the quality management system and to apply corrective and preventive actions, if necessary. The audits should be carried out by trained and qualified personnel, who are independent of the activity to be audited. The quality manager is responsible for planning and organizing internal audits addressing all elements of the quality management system. Such audits should be recorded, together with details of any corrective and preventive action taken.\n\n2.5 Management review of quality issues should be regularly undertaken (at least annually), including:\n\n(a) reports on internal and external audits or inspections and any follow-up required to correct any deficiencies;\n\n(b) the outcome of investigations carried out as a result of complaints received, doubtful (atypical) or aberrant results reported in collaborative trials and/or proficiency tests; and\n\n(c) corrective actions applied and preventive actions introduced as a result of these investigations.\n\n# 3. Control of documentation\n\n3.1 Documentation is an essential part of the quality management system. The laboratory should establish and maintain procedures", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "726f56654b7a61a21fabee903ba80b1659573b8d4a2a710c53d5a018a252f1a8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(g) the procurement, preparation and control of reference substances and reference materials (8);\n\n(h) the internal labelling, quarantine and storage of materials;\n\n(i) the qualification of equipment (11);\n\n(j) the calibration of equipment;\n\n(k) preventive maintenance and verification of instruments and equipment;\n\n(l) sampling, if performed by the laboratory, and visual inspection;\n\n(m) the testing of samples with descriptions of the methods and equipment used;\n\n(n) atypical and OOS results;\n\n(o) validation of analytical procedures;\n\n(p) cleaning of laboratory facilities, including bench tops, equipment, work stations, clean rooms (aseptic suites) and glassware;\n\n(q) monitoring of environmental conditions, e.g. temperature and humidity;\n\n(r) monitoring storage conditions;\n\n(s) disposal of reagents and solvent samples; and\n\n(t) safety measures.\n\n2.4 The activities of the laboratory should be systematically and periodically audited (internally and, where appropriate, by external audits or inspections) to verify compliance with the requirements of the quality management system and to apply corrective and preventive actions, if necessary. The audits should be carried out by trained and qualified personnel, who are independent of the activity to be audited. The quality manager is responsible for planning and organizing internal audits addressing all elements of the quality management system. Such audits should be recorded, together with details of any corrective and preventive action taken.\n\n2.5 Management review of quality issues should be regularly undertaken (at least annually), including:\n\n(a) reports on internal and external audits or inspections and any follow-up required to correct any deficiencies;\n\n(b) the outcome of investigations carried out as a result of complaints received, doubtful (atypical) or aberrant results reported in collaborative trials and/or proficiency tests; and\n\n(c) corrective actions applied and preventive actions introduced as a result of these investigations.\n\n# 3. Control of documentation\n\n3.1 Documentation is an essential part of the quality management system. The laboratory should establish and maintain procedures", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2181, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1373ad86-e30b-4c76-b3df-0cd14c31b2a3": {"__data__": {"id_": "1373ad86-e30b-4c76-b3df-0cd14c31b2a3", "embedding": null, "metadata": {"page_label": "109", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 3.2 The procedures should ensure that:\n\n(a) each document, whether a technical or a quality document, has a unique identifier, version number and date of implementation;\n\n(b) appropriate, authorized SOPs are available at the relevant locations, e.g. near instruments;\n\n(c) documents are kept up to date and reviewed as required;\n\n(d) any invalid document is removed and replaced with the authorized, revised document with immediate effect;\n\n(e) a revised document includes references to the previous document;\n\n(f) old, invalid documents are retained in the archives to ensure traceability of the evolution of the procedures; any copies are destroyed;\n\n(g) all relevant staff are trained for the new and revised SOPs; and\n\n(h) quality documentation, including records, is retained for a minimum of five years.\n\n## 3.3 A system of change control should be in place to inform staff of new and revised procedures. The system should ensure that:\n\n(a) revised documents are prepared by the initiator, or a person who performs the same function, reviewed and approved at the same level as the original document and subsequently released by the quality manager (quality unit); and\n\n(b) staff acknowledge by a signature that they are aware of applicable changes and their date of implementation.\n\n# 4. Records\n\n## 4.1 \n\nThe laboratory should establish and maintain procedures for the identification, collection, indexing, retrieval, storage, maintenance and disposal of and access to all quality and technical/scientific records.\n\n## 4.2 \n\nAll original observations, including calculations and derived data, calibration, validation and verification records and final results, should be retained on record for an appropriate period of time in accordance with national regulations and, if applicable, contractual arrangements, whichever is longer. The records should include the data recorded in the analytical worksheet by the technician or analyst.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece procedimientos y requisitos para la gesti\u00f3n de documentos y registros en laboratorios. Se enfatiza la importancia de tener identificadores \u00fanicos para cada documento, mantener los documentos actualizados, y asegurar que el personal est\u00e9 capacitado en los procedimientos operativos est\u00e1ndar (SOPs). Tambi\u00e9n se menciona la necesidad de un sistema de control de cambios para informar al personal sobre nuevas y revisadas SOPs, as\u00ed como la retenci\u00f3n de registros originales por un per\u00edodo adecuado, de acuerdo con las regulaciones nacionales.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 elementos deben incluirse en cada documento t\u00e9cnico o de calidad seg\u00fan las directrices de la OMS?**\n   - Respuesta: Cada documento debe tener un identificador \u00fanico, un n\u00famero de versi\u00f3n y una fecha de implementaci\u00f3n.\n\n2. **\u00bfCu\u00e1l es el per\u00edodo m\u00ednimo de retenci\u00f3n para la documentaci\u00f3n de calidad y registros seg\u00fan las recomendaciones de la OMS?**\n   - Respuesta: La documentaci\u00f3n de calidad, incluidos los registros, debe ser retenida por un m\u00ednimo de cinco a\u00f1os.\n\n3. **\u00bfQu\u00e9 pasos deben seguirse para asegurar que el personal est\u00e9 informado sobre los cambios en los procedimientos?**\n   - Respuesta: Se debe implementar un sistema de control de cambios que garantice que los documentos revisados sean preparados, revisados y aprobados adecuadamente, y que el personal firme para reconocer que est\u00e1 al tanto de los cambios y su fecha de implementaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Actividades del Laboratorio**: Se enumeran diversas actividades esenciales para el funcionamiento de un laboratorio, que incluyen:\n   - Adquisici\u00f3n y control de sustancias de referencia.\n   - Etiquetado interno, cuarentena y almacenamiento de materiales.\n   - Calibraci\u00f3n y mantenimiento de equipos.\n   - Muestreo y pruebas de muestras.\n   - Limpieza de instalaciones y monitoreo de condiciones ambientales.\n   - Gesti\u00f3n de resultados at\u00edpicos y validaci\u00f3n de procedimientos anal\u00edticos.\n   - Medidas de seguridad y disposici\u00f3n de reactivos.\n\n2. **Auditor\u00edas**: Se enfatiza la importancia de realizar auditor\u00edas internas y externas de manera sistem\u00e1tica y peri\u00f3dica para asegurar el cumplimiento del sistema de gesti\u00f3n de calidad. Estas auditor\u00edas deben ser realizadas por personal capacitado e independiente.\n\n3. **Revisi\u00f3n de la Gesti\u00f3n**: La direcci\u00f3n del laboratorio debe llevar a cabo revisiones regulares de los problemas de calidad, incluyendo informes de auditor\u00edas, resultados de investigaciones de quejas y acciones correctivas y preventivas.\n\n4. **Control de Documentaci\u00f3n**: La documentaci\u00f3n es considerada un componente esencial del sistema de gesti\u00f3n de calidad, y se requiere que el laboratorio establezca y mantenga procedimientos para su control.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Sistema de Gesti\u00f3n de Calidad**: Marco que gu\u00eda las operaciones del laboratorio.\n- **Auditores**: Personal encargado de realizar auditor\u00edas, que debe ser capacitado y calificado.\n- **Gerente de Calidad**: Responsable de planificar y organizar auditor\u00edas internas.\n- **Laboratorio**: Entidad que debe cumplir con los est\u00e1ndares y procedimientos establecidos.\n\nEste resumen destaca los aspectos fundamentales del sistema de gesti\u00f3n de calidad en laboratorios, as\u00ed como las responsabilidades y procedimientos necesarios para su implementaci\u00f3n efectiva.", "excerpt_keywords": "Keywords: document control, quality management, standard operating procedures, record retention, change control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "73699b63-6e49-4076-8708-c4ea8660cbb3", "node_type": "4", "metadata": {"page_label": "109", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 3.2 The procedures should ensure that:\n\n(a) each document, whether a technical or a quality document, has a unique identifier, version number and date of implementation;\n\n(b) appropriate, authorized SOPs are available at the relevant locations, e.g. near instruments;\n\n(c) documents are kept up to date and reviewed as required;\n\n(d) any invalid document is removed and replaced with the authorized, revised document with immediate effect;\n\n(e) a revised document includes references to the previous document;\n\n(f) old, invalid documents are retained in the archives to ensure traceability of the evolution of the procedures; any copies are destroyed;\n\n(g) all relevant staff are trained for the new and revised SOPs; and\n\n(h) quality documentation, including records, is retained for a minimum of five years.\n\n## 3.3 A system of change control should be in place to inform staff of new and revised procedures. The system should ensure that:\n\n(a) revised documents are prepared by the initiator, or a person who performs the same function, reviewed and approved at the same level as the original document and subsequently released by the quality manager (quality unit); and\n\n(b) staff acknowledge by a signature that they are aware of applicable changes and their date of implementation.\n\n# 4. Records\n\n## 4.1 \n\nThe laboratory should establish and maintain procedures for the identification, collection, indexing, retrieval, storage, maintenance and disposal of and access to all quality and technical/scientific records.\n\n## 4.2 \n\nAll original observations, including calculations and derived data, calibration, validation and verification records and final results, should be retained on record for an appropriate period of time in accordance with national regulations and, if applicable, contractual arrangements, whichever is longer. The records should include the data recorded in the analytical worksheet by the technician or analyst.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "7a0c2a54b163ed9cb32952835bb64142321f60e295b5a1ebf05a218a10a7ebbb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 3.2 The procedures should ensure that:\n\n(a) each document, whether a technical or a quality document, has a unique identifier, version number and date of implementation;\n\n(b) appropriate, authorized SOPs are available at the relevant locations, e.g. near instruments;\n\n(c) documents are kept up to date and reviewed as required;\n\n(d) any invalid document is removed and replaced with the authorized, revised document with immediate effect;\n\n(e) a revised document includes references to the previous document;\n\n(f) old, invalid documents are retained in the archives to ensure traceability of the evolution of the procedures; any copies are destroyed;\n\n(g) all relevant staff are trained for the new and revised SOPs; and\n\n(h) quality documentation, including records, is retained for a minimum of five years.\n\n## 3.3 A system of change control should be in place to inform staff of new and revised procedures. The system should ensure that:\n\n(a) revised documents are prepared by the initiator, or a person who performs the same function, reviewed and approved at the same level as the original document and subsequently released by the quality manager (quality unit); and\n\n(b) staff acknowledge by a signature that they are aware of applicable changes and their date of implementation.\n\n# 4. Records\n\n## 4.1 \n\nThe laboratory should establish and maintain procedures for the identification, collection, indexing, retrieval, storage, maintenance and disposal of and access to all quality and technical/scientific records.\n\n## 4.2 \n\nAll original observations, including calculations and derived data, calibration, validation and verification records and final results, should be retained on record for an appropriate period of time in accordance with national regulations and, if applicable, contractual arrangements, whichever is longer. The records should include the data recorded in the analytical worksheet by the technician or analyst.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1942, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "596daecd-4cfa-4847-b797-395a404b5805": {"__data__": {"id_": "596daecd-4cfa-4847-b797-395a404b5805", "embedding": null, "metadata": {"page_label": "110", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.3\n\nAll quality and technical/scientific records (including analytical test reports, certificates of analysis and analytical worksheets) should be legible, readily retrievable, stored and retained within facilities that provide a suitable environment that will prevent modification, damage or deterioration and/or loss. The conditions under which all original records are stored should be such as to ensure their security and confidentiality and access to them should be restricted to authorized personnel. Electronic storage and signatures may also be employed but with restricted access and in conformance with requirements for electronic records (12\u201316).\n\n# 4.4\n\nQuality management records should include reports from internal (and external if performed) audits and management reviews, as well as records of all complaints and their investigations, including records of possible corrective and preventive actions.\n\n# 5. Data-processing equipment\n\n## 5.1\n\nDetailed recommendations are provided in Appendix 5 to Annex 4 of the *Fortieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations*: Supplementary guidelines in good manufacturing practice: validation. Validation of computerized systems (12).\n\n## 5.2\n\nFor computers, automated tests or calibration equipment, and the collection, processing, recording, reporting, storage or retrieval of test and/or calibration data, the laboratory should ensure that:\n\n(a) computer software developed by the user is documented in sufficient detail and appropriately validated or verified as being suitable for use;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Almacenamiento y Seguridad de Registros**: Se enfatiza la importancia de que todos los registros de calidad y t\u00e9cnicos sean legibles, f\u00e1cilmente recuperables y almacenados en un entorno que prevenga su modificaci\u00f3n, da\u00f1o o p\u00e9rdida. Adem\u00e1s, se establece que el acceso a estos registros debe ser restringido a personal autorizado para garantizar su seguridad y confidencialidad.\n\n2. **Gesti\u00f3n de Calidad**: Los registros de gesti\u00f3n de calidad deben incluir auditor\u00edas internas y externas, revisiones de gesti\u00f3n, as\u00ed como registros de quejas y sus investigaciones, incluyendo acciones correctivas y preventivas.\n\n3. **Validaci\u00f3n de Sistemas Inform\u00e1ticos**: Se menciona la necesidad de validar o verificar el software desarrollado por el usuario para asegurar que sea adecuado para su uso en la recolecci\u00f3n y procesamiento de datos de pruebas y calibraciones.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 medidas se deben tomar para garantizar la seguridad y confidencialidad de los registros originales en un laboratorio?**\n   - Respuesta: Los registros originales deben ser almacenados en condiciones que aseguren su seguridad y confidencialidad, con acceso restringido a personal autorizado. Adem\u00e1s, se pueden emplear sistemas de almacenamiento electr\u00f3nico con acceso restringido y en conformidad con los requisitos para registros electr\u00f3nicos.\n\n2. **\u00bfQu\u00e9 tipo de registros deben incluirse en la gesti\u00f3n de calidad seg\u00fan el documento?**\n   - Respuesta: Los registros de gesti\u00f3n de calidad deben incluir informes de auditor\u00edas internas y externas, revisiones de gesti\u00f3n, as\u00ed como registros de todas las quejas y sus investigaciones, incluyendo posibles acciones correctivas y preventivas.\n\n3. **\u00bfCu\u00e1les son las recomendaciones para la validaci\u00f3n de software en el contexto de equipos de procesamiento de datos?**\n   - Respuesta: El laboratorio debe asegurarse de que el software desarrollado por el usuario est\u00e9 documentado en suficiente detalle y validado o verificado como adecuado para su uso en la recolecci\u00f3n, procesamiento, registro, reporte, almacenamiento o recuperaci\u00f3n de datos de pruebas y/o calibraciones.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Gesti\u00f3n de Documentos**:\n   - Cada documento debe tener un **identificador \u00fanico**, **n\u00famero de versi\u00f3n** y **fecha de implementaci\u00f3n**.\n   - Los **SOPs (Procedimientos Operativos Est\u00e1ndar)** autorizados deben estar disponibles en lugares relevantes, como cerca de los instrumentos.\n\n2. **Actualizaci\u00f3n y Revisi\u00f3n**:\n   - Los documentos deben mantenerse **actualizados** y revisarse seg\u00fan sea necesario.\n   - Los documentos inv\u00e1lidos deben ser **eliminados** y reemplazados de inmediato por versiones autorizadas y revisadas.\n\n3. **Control de Cambios**:\n   - Se debe establecer un **sistema de control de cambios** para informar al personal sobre nuevos y revisados procedimientos.\n   - Los documentos revisados deben ser preparados, revisados y aprobados adecuadamente, y el personal debe **firmar** para reconocer los cambios.\n\n4. **Retenci\u00f3n de Registros**:\n   - La documentaci\u00f3n de calidad y los registros deben ser **retenidos por un m\u00ednimo de cinco a\u00f1os**.\n   - Se deben establecer procedimientos para la **identificaci\u00f3n, colecci\u00f3n, almacenamiento y disposici\u00f3n** de registros t\u00e9cnicos y de calidad.\n\n5. **Registros Originales**:\n   - Todas las observaciones originales, incluidos c\u00e1lculos y datos derivados, deben ser **retenidos** por un per\u00edodo adecuado, conforme a las regulaciones nacionales y acuerdos contractuales.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices.\n- **SOPs**: Procedimientos Operativos Est\u00e1ndar que deben ser autorizados y disponibles.\n- **Documentos**: Incluyen documentos t\u00e9cnicos y de calidad que deben cumplir con requisitos espec\u00edficos.\n- **Registros**: Incluyen observaciones originales, datos de calibraci\u00f3n, validaci\u00f3n y verificaci\u00f3n que deben ser mantenidos adecuadamente. \n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de documentos y registros en laboratorios, asegurando la calidad y la trazabilidad de los procedimientos.", "excerpt_keywords": "Keywords: quality management, record retention, data processing, electronic storage, validation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "64e8507f-6c5e-44e3-b471-1787c20fa03e", "node_type": "4", "metadata": {"page_label": "110", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.3\n\nAll quality and technical/scientific records (including analytical test reports, certificates of analysis and analytical worksheets) should be legible, readily retrievable, stored and retained within facilities that provide a suitable environment that will prevent modification, damage or deterioration and/or loss. The conditions under which all original records are stored should be such as to ensure their security and confidentiality and access to them should be restricted to authorized personnel. Electronic storage and signatures may also be employed but with restricted access and in conformance with requirements for electronic records (12\u201316).\n\n# 4.4\n\nQuality management records should include reports from internal (and external if performed) audits and management reviews, as well as records of all complaints and their investigations, including records of possible corrective and preventive actions.\n\n# 5. Data-processing equipment\n\n## 5.1\n\nDetailed recommendations are provided in Appendix 5 to Annex 4 of the *Fortieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations*: Supplementary guidelines in good manufacturing practice: validation. Validation of computerized systems (12).\n\n## 5.2\n\nFor computers, automated tests or calibration equipment, and the collection, processing, recording, reporting, storage or retrieval of test and/or calibration data, the laboratory should ensure that:\n\n(a) computer software developed by the user is documented in sufficient detail and appropriately validated or verified as being suitable for use;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "97b35527a969aa565034752ec5b37944b5f9f51961b6c3d9dcaad96c2039caa9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.3\n\nAll quality and technical/scientific records (including analytical test reports, certificates of analysis and analytical worksheets) should be legible, readily retrievable, stored and retained within facilities that provide a suitable environment that will prevent modification, damage or deterioration and/or loss. The conditions under which all original records are stored should be such as to ensure their security and confidentiality and access to them should be restricted to authorized personnel. Electronic storage and signatures may also be employed but with restricted access and in conformance with requirements for electronic records (12\u201316).\n\n# 4.4\n\nQuality management records should include reports from internal (and external if performed) audits and management reviews, as well as records of all complaints and their investigations, including records of possible corrective and preventive actions.\n\n# 5. Data-processing equipment\n\n## 5.1\n\nDetailed recommendations are provided in Appendix 5 to Annex 4 of the *Fortieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations*: Supplementary guidelines in good manufacturing practice: validation. Validation of computerized systems (12).\n\n## 5.2\n\nFor computers, automated tests or calibration equipment, and the collection, processing, recording, reporting, storage or retrieval of test and/or calibration data, the laboratory should ensure that:\n\n(a) computer software developed by the user is documented in sufficient detail and appropriately validated or verified as being suitable for use;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1593, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "bb8d9d44-d37e-499d-8309-8fbe64202b3d": {"__data__": {"id_": "bb8d9d44-d37e-499d-8309-8fbe64202b3d", "embedding": null, "metadata": {"page_label": "111", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\n(b) procedures are established and implemented for protecting the \n    integrity of data. Such procedures should include, but are not \n    limited to, measures to ensure the integrity and confidentiality \n    of data entry or collection and the storage, transmission and \n    processing of data. In particular, electronic data should be \n    protected from unauthorized access and an audit trail of any \n    amendments should be maintained;\n(c) computers and automated equipment are maintained so as to \n    function properly and are provided with the environmental and \n    operating conditions necessary to ensure the integrity of test and \n    calibration data;\n(d) procedures are established and implemented for making, \n    documenting and controlling changes to information stored in \n    computerized systems; and\n(e) electronic data should be backed up at appropriate regular intervals \n    according to a documented procedure. Backed-up data should be \n    retrievable and stored in such a manner as to prevent data loss.\n\nNote: For further guidance on validation of data-processing equipment, \nrefer to documents published by the International Society for \nPharmaceutical Engineering (13, 14), US Food and Drug Administration \n(15), European Commission (16) and the Official Medicines Control \nLaboratories Network of the Council of Europe (17).\n\n6. **Personnel**\n\n6.1 The laboratory should have sufficient personnel with the necessary \n    education, training, technical knowledge and experience for their \n    assigned functions.\n\n6.2 The technical management should ensure the competence of all \n    personnel operating specific equipment, instruments or other \n    devices, who are performing tests and/or calibrations, validations or \n    verifications. Their duties also involve the evaluation of results as \n    well as signing analytical test reports and certificates of analysis (see \n    Part three, sections 18.7\u201318.11 and 19).\n\n6.3 Staff undergoing training should be appropriately supervised \n    and should be assessed on completion of the training. Personnel \n    performing specific tasks should be appropriately qualified in terms \n    of their education, training and experience, as required.\n\n6.4 The laboratory personnel should be permanently employed or under \n    contract. The laboratory should ensure that additional technical and \n    key support personnel who are under contract are supervised and\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfQu\u00e9 medidas se deben implementar para proteger la integridad de los datos en un laboratorio?**\n   - Se deben establecer y aplicar procedimientos que incluyan medidas para garantizar la integridad y confidencialidad de la entrada o recolecci\u00f3n de datos, as\u00ed como su almacenamiento, transmisi\u00f3n y procesamiento. Esto incluye proteger los datos electr\u00f3nicos contra accesos no autorizados y mantener un registro de auditor\u00eda de cualquier enmienda.\n\n2. **\u00bfCu\u00e1l es la responsabilidad del personal t\u00e9cnico en relaci\u00f3n con el equipo y los dispositivos utilizados en el laboratorio?**\n   - La gesti\u00f3n t\u00e9cnica debe asegurar la competencia de todo el personal que opera equipos espec\u00edficos, instrumentos u otros dispositivos, as\u00ed como aquellos que realizan pruebas, calibraciones, validaciones o verificaciones. Esto incluye la evaluaci\u00f3n de resultados y la firma de informes anal\u00edticos y certificados de an\u00e1lisis.\n\n3. **\u00bfQu\u00e9 requisitos se establecen para el personal en formaci\u00f3n dentro del laboratorio?**\n   - El personal en formaci\u00f3n debe estar adecuadamente supervisado y ser evaluado al finalizar su capacitaci\u00f3n. Adem\u00e1s, el personal que realice tareas espec\u00edficas debe estar debidamente calificado en t\u00e9rminos de educaci\u00f3n, formaci\u00f3n y experiencia, seg\u00fan lo requerido.\n\n### Resumen de Nivel Superior\n\nEl contexto se centra en las directrices para la protecci\u00f3n de la integridad de los datos en laboratorios, destacando la importancia de establecer procedimientos adecuados para la gesti\u00f3n de datos electr\u00f3nicos y la competencia del personal. Se enfatiza la necesidad de mantener un entorno adecuado para el funcionamiento de equipos y la capacitaci\u00f3n del personal, asegurando que todos los empleados tengan la formaci\u00f3n y experiencia necesarias para realizar sus funciones de manera efectiva.\n\n### Preguntas Adicionales Basadas en el Resumen\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se sugiere para el respaldo de datos electr\u00f3nicos en un laboratorio?**\n   - Se sugiere que los datos electr\u00f3nicos sean respaldados a intervalos regulares de acuerdo con un procedimiento documentado, asegurando que los datos respaldados sean recuperables y almacenados de manera que se prevenga la p\u00e9rdida de datos.\n\n2. **\u00bfQu\u00e9 organismos se mencionan como fuentes de orientaci\u00f3n adicional sobre la validaci\u00f3n de equipos de procesamiento de datos?**\n   - Se mencionan documentos publicados por la International Society for Pharmaceutical Engineering, la US Food and Drug Administration, la Comisi\u00f3n Europea y la Red de Laboratorios de Control de Medicamentos Oficiales del Consejo de Europa como fuentes de orientaci\u00f3n adicional.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse para el personal adicional que trabaja en el laboratorio bajo contrato?**\n   - El laboratorio debe asegurarse de que el personal t\u00e9cnico adicional y el personal clave que trabaja bajo contrato est\u00e9n supervisados adecuadamente.", "prev_section_summary": "### Temas Clave:\n\n1. **Almacenamiento y Seguridad de Registros**:\n   - Importancia de que los registros de calidad y t\u00e9cnicos sean legibles y f\u00e1cilmente recuperables.\n   - Necesidad de un entorno adecuado para prevenir modificaci\u00f3n, da\u00f1o o p\u00e9rdida de registros.\n   - Acceso restringido a personal autorizado para garantizar la seguridad y confidencialidad de los registros.\n   - Posibilidad de utilizar almacenamiento electr\u00f3nico con acceso controlado.\n\n2. **Gesti\u00f3n de Calidad**:\n   - Inclusi\u00f3n de informes de auditor\u00edas internas y externas, revisiones de gesti\u00f3n.\n   - Registro de quejas y sus investigaciones, as\u00ed como acciones correctivas y preventivas.\n\n3. **Validaci\u00f3n de Sistemas Inform\u00e1ticos**:\n   - Recomendaciones para la validaci\u00f3n de software utilizado en la recolecci\u00f3n y procesamiento de datos.\n   - Documentaci\u00f3n y verificaci\u00f3n del software desarrollado por el usuario para asegurar su idoneidad.\n\n### Entidades:\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Registros de Calidad**: Documentos que incluyen informes de auditor\u00eda, quejas y acciones correctivas.\n- **Sistemas Inform\u00e1ticos**: Equipos y software utilizados para el procesamiento de datos en laboratorios.\n- **Personal Autorizado**: Individuos con acceso restringido a los registros para garantizar la seguridad y confidencialidad.\n\nEste resumen abarca los aspectos fundamentales de la secci\u00f3n, destacando la importancia de la gesti\u00f3n adecuada de registros y la validaci\u00f3n de sistemas en el contexto de la calidad y la seguridad en laboratorios.", "excerpt_keywords": "Keywords: data integrity, laboratory personnel, electronic data security, validation procedures, quality management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cfb0a0d1-e0a5-4bc7-a363-9f29d2099f08", "node_type": "4", "metadata": {"page_label": "111", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\n(b) procedures are established and implemented for protecting the \n    integrity of data. Such procedures should include, but are not \n    limited to, measures to ensure the integrity and confidentiality \n    of data entry or collection and the storage, transmission and \n    processing of data. In particular, electronic data should be \n    protected from unauthorized access and an audit trail of any \n    amendments should be maintained;\n(c) computers and automated equipment are maintained so as to \n    function properly and are provided with the environmental and \n    operating conditions necessary to ensure the integrity of test and \n    calibration data;\n(d) procedures are established and implemented for making, \n    documenting and controlling changes to information stored in \n    computerized systems; and\n(e) electronic data should be backed up at appropriate regular intervals \n    according to a documented procedure. Backed-up data should be \n    retrievable and stored in such a manner as to prevent data loss.\n\nNote: For further guidance on validation of data-processing equipment, \nrefer to documents published by the International Society for \nPharmaceutical Engineering (13, 14), US Food and Drug Administration \n(15), European Commission (16) and the Official Medicines Control \nLaboratories Network of the Council of Europe (17).\n\n6. **Personnel**\n\n6.1 The laboratory should have sufficient personnel with the necessary \n    education, training, technical knowledge and experience for their \n    assigned functions.\n\n6.2 The technical management should ensure the competence of all \n    personnel operating specific equipment, instruments or other \n    devices, who are performing tests and/or calibrations, validations or \n    verifications. Their duties also involve the evaluation of results as \n    well as signing analytical test reports and certificates of analysis (see \n    Part three, sections 18.7\u201318.11 and 19).\n\n6.3 Staff undergoing training should be appropriately supervised \n    and should be assessed on completion of the training. Personnel \n    performing specific tasks should be appropriately qualified in terms \n    of their education, training and experience, as required.\n\n6.4 The laboratory personnel should be permanently employed or under \n    contract. The laboratory should ensure that additional technical and \n    key support personnel who are under contract are supervised and\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "60d49ce1cfcf369fd620cabe708cfff5b0bc5b814f1f1c51e388868c17bdb224", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "```\n(b) procedures are established and implemented for protecting the \n    integrity of data. Such procedures should include, but are not \n    limited to, measures to ensure the integrity and confidentiality \n    of data entry or collection and the storage, transmission and \n    processing of data. In particular, electronic data should be \n    protected from unauthorized access and an audit trail of any \n    amendments should be maintained;\n(c) computers and automated equipment are maintained so as to \n    function properly and are provided with the environmental and \n    operating conditions necessary to ensure the integrity of test and \n    calibration data;\n(d) procedures are established and implemented for making, \n    documenting and controlling changes to information stored in \n    computerized systems; and\n(e) electronic data should be backed up at appropriate regular intervals \n    according to a documented procedure. Backed-up data should be \n    retrievable and stored in such a manner as to prevent data loss.\n\nNote: For further guidance on validation of data-processing equipment, \nrefer to documents published by the International Society for \nPharmaceutical Engineering (13, 14), US Food and Drug Administration \n(15), European Commission (16) and the Official Medicines Control \nLaboratories Network of the Council of Europe (17).\n\n6. **Personnel**\n\n6.1 The laboratory should have sufficient personnel with the necessary \n    education, training, technical knowledge and experience for their \n    assigned functions.\n\n6.2 The technical management should ensure the competence of all \n    personnel operating specific equipment, instruments or other \n    devices, who are performing tests and/or calibrations, validations or \n    verifications. Their duties also involve the evaluation of results as \n    well as signing analytical test reports and certificates of analysis (see \n    Part three, sections 18.7\u201318.11 and 19).\n\n6.3 Staff undergoing training should be appropriately supervised \n    and should be assessed on completion of the training. Personnel \n    performing specific tasks should be appropriately qualified in terms \n    of their education, training and experience, as required.\n\n6.4 The laboratory personnel should be permanently employed or under \n    contract. The laboratory should ensure that additional technical and \n    key support personnel who are under contract are supervised and\n```", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2441, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3d88ec92-cc22-4a57-bece-75e1a23bee9d": {"__data__": {"id_": "3d88ec92-cc22-4a57-bece-75e1a23bee9d", "embedding": null, "metadata": {"page_label": "112", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "sufficiently competent and that their work is in accordance with the quality management system.\n\n6.5 The laboratory should maintain current job descriptions for all personnel involved in tests and/or calibrations, validations and verifications. The laboratory should also maintain records of all technical personnel, describing their qualifications, training and experience.\n\n6.6 The laboratory should have the following managerial and technical personnel:\n\n(a) a head of laboratory (supervisor), who should have qualifications appropriate to the position, with extensive experience in medicines analysis and laboratory management in a pharmaceutical quality control laboratory in the regulatory sector or in industry. The head of laboratory is responsible for the content of certificates of analysis and analytical testing reports. This person is also responsible for ensuring that:\n   (i) all key members of the laboratory staff have the requisite competence for the required functions and their grades reflect their responsibilities,\n   (ii) the adequacy of existing staffing, management and training procedures is reviewed periodically,\n   (iii) the technical management is adequately supervised;\n\n(b) the technical management who ensure that:\n   (i) procedures for performing calibration, verification and (re-) qualification of instruments, monitoring of environmental and storage conditions are in place and are conducted as required,\n   (ii) regular in-service training programmes to update and extend the skills of both professionals and technicians are arranged,\n   (iii) the safekeeping of any materials subject to poison regulation or to the controls applied to narcotic and psychotropic substances (see Part one, section 7.12) kept in the workplace is under the supervision of an authorized person,\n   (iv) national pharmaceutical quality control laboratories regularly participate in suitable proficiency testing schemes and collaborative trials to assess analytical procedures or reference substances;\n\n(c) analysts, who should normally be graduates in pharmacy, analytical chemistry, microbiology or other relevant subjects,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl texto proviene del informe t\u00e9cnico de la OMS (Organizaci\u00f3n Mundial de la Salud) y se centra en los requisitos de personal y gesti\u00f3n en laboratorios de control de calidad farmac\u00e9utica. Se enfatiza la importancia de mantener descripciones de trabajo actualizadas, registros de personal t\u00e9cnico, y la necesidad de contar con un equipo de gesti\u00f3n y t\u00e9cnicos competentes. Se especifican las responsabilidades del jefe de laboratorio, la gesti\u00f3n t\u00e9cnica y los analistas, as\u00ed como la importancia de la capacitaci\u00f3n continua y la supervisi\u00f3n de materiales regulados.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas del jefe de laboratorio en un laboratorio de control de calidad farmac\u00e9utica seg\u00fan el informe?**\n   - Respuesta: El jefe de laboratorio es responsable del contenido de los certificados de an\u00e1lisis y los informes de pruebas anal\u00edticas, asegurando que todos los miembros clave del personal tengan la competencia necesaria, revisando peri\u00f3dicamente la adecuaci\u00f3n de los procedimientos de gesti\u00f3n y formaci\u00f3n, y supervisando adecuadamente la gesti\u00f3n t\u00e9cnica.\n\n2. **\u00bfQu\u00e9 tipo de formaci\u00f3n y experiencia se espera de los analistas que trabajan en un laboratorio de control de calidad farmac\u00e9utica?**\n   - Respuesta: Se espera que los analistas sean normalmente graduados en farmacia, qu\u00edmica anal\u00edtica, microbiolog\u00eda u otras disciplinas relevantes.\n\n3. **\u00bfQu\u00e9 procedimientos deben estar en su lugar para garantizar la seguridad de los materiales regulados en el laboratorio?**\n   - Respuesta: Deben existir procedimientos para la calibraci\u00f3n, verificaci\u00f3n y (re)calificaci\u00f3n de instrumentos, as\u00ed como para el monitoreo de condiciones ambientales y de almacenamiento. Adem\u00e1s, la supervisi\u00f3n de materiales sujetos a regulaciones de venenos o controles de sustancias narc\u00f3ticas y psicotr\u00f3picas debe estar a cargo de una persona autorizada.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Protecci\u00f3n de la Integridad de los Datos**:\n   - Se deben establecer procedimientos para garantizar la integridad y confidencialidad de la entrada, almacenamiento, transmisi\u00f3n y procesamiento de datos.\n   - Es esencial proteger los datos electr\u00f3nicos contra accesos no autorizados y mantener un registro de auditor\u00eda de enmiendas.\n   - Los datos electr\u00f3nicos deben ser respaldados regularmente y almacenados de manera que se evite la p\u00e9rdida de informaci\u00f3n.\n\n2. **Mantenimiento de Equipos**:\n   - Los ordenadores y equipos automatizados deben ser mantenidos adecuadamente para asegurar su correcto funcionamiento y las condiciones ambientales necesarias para la integridad de los datos de pruebas y calibraciones.\n\n3. **Gesti\u00f3n de Cambios en Sistemas Inform\u00e1ticos**:\n   - Se deben establecer procedimientos para documentar y controlar cambios en la informaci\u00f3n almacenada en sistemas computarizados.\n\n4. **Personal del Laboratorio**:\n   - El laboratorio debe contar con personal suficiente que posea la educaci\u00f3n, formaci\u00f3n, conocimientos t\u00e9cnicos y experiencia necesarios para sus funciones asignadas.\n   - La gesti\u00f3n t\u00e9cnica es responsable de asegurar la competencia del personal que opera equipos espec\u00edficos y realiza pruebas, calibraciones, validaciones o verificaciones.\n   - El personal en formaci\u00f3n debe ser supervisado y evaluado al finalizar su capacitaci\u00f3n, y debe estar debidamente calificado.\n\n5. **Contrataci\u00f3n y Supervisi\u00f3n de Personal**:\n   - El personal del laboratorio debe ser empleado permanente o estar bajo contrato, y se debe garantizar la supervisi\u00f3n adecuada del personal t\u00e9cnico adicional y del personal clave que trabaja bajo contrato.\n\n### Entidades Mencionadas:\n- **Organismos de Referencia**:\n  - International Society for Pharmaceutical Engineering\n  - US Food and Drug Administration\n  - Comisi\u00f3n Europea\n  - Red de Laboratorios de Control de Medicamentos Oficiales del Consejo de Europa\n\nEste resumen destaca la importancia de la gesti\u00f3n de datos y la competencia del personal en el contexto de laboratorios, enfatizando la necesidad de procedimientos claros y mantenimiento adecuado de equipos.", "excerpt_keywords": "Keywords: laboratory management, pharmaceutical quality control, personnel qualifications, analytical testing, training programs"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "97a1e7a7-4ae5-4730-9071-3511c8b5f09c", "node_type": "4", "metadata": {"page_label": "112", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "sufficiently competent and that their work is in accordance with the quality management system.\n\n6.5 The laboratory should maintain current job descriptions for all personnel involved in tests and/or calibrations, validations and verifications. The laboratory should also maintain records of all technical personnel, describing their qualifications, training and experience.\n\n6.6 The laboratory should have the following managerial and technical personnel:\n\n(a) a head of laboratory (supervisor), who should have qualifications appropriate to the position, with extensive experience in medicines analysis and laboratory management in a pharmaceutical quality control laboratory in the regulatory sector or in industry. The head of laboratory is responsible for the content of certificates of analysis and analytical testing reports. This person is also responsible for ensuring that:\n   (i) all key members of the laboratory staff have the requisite competence for the required functions and their grades reflect their responsibilities,\n   (ii) the adequacy of existing staffing, management and training procedures is reviewed periodically,\n   (iii) the technical management is adequately supervised;\n\n(b) the technical management who ensure that:\n   (i) procedures for performing calibration, verification and (re-) qualification of instruments, monitoring of environmental and storage conditions are in place and are conducted as required,\n   (ii) regular in-service training programmes to update and extend the skills of both professionals and technicians are arranged,\n   (iii) the safekeeping of any materials subject to poison regulation or to the controls applied to narcotic and psychotropic substances (see Part one, section 7.12) kept in the workplace is under the supervision of an authorized person,\n   (iv) national pharmaceutical quality control laboratories regularly participate in suitable proficiency testing schemes and collaborative trials to assess analytical procedures or reference substances;\n\n(c) analysts, who should normally be graduates in pharmacy, analytical chemistry, microbiology or other relevant subjects,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "fe9a0cbeff5c17a322ae504ea26327a1c557373234e3370c70444d4d19ebc18a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "sufficiently competent and that their work is in accordance with the quality management system.\n\n6.5 The laboratory should maintain current job descriptions for all personnel involved in tests and/or calibrations, validations and verifications. The laboratory should also maintain records of all technical personnel, describing their qualifications, training and experience.\n\n6.6 The laboratory should have the following managerial and technical personnel:\n\n(a) a head of laboratory (supervisor), who should have qualifications appropriate to the position, with extensive experience in medicines analysis and laboratory management in a pharmaceutical quality control laboratory in the regulatory sector or in industry. The head of laboratory is responsible for the content of certificates of analysis and analytical testing reports. This person is also responsible for ensuring that:\n   (i) all key members of the laboratory staff have the requisite competence for the required functions and their grades reflect their responsibilities,\n   (ii) the adequacy of existing staffing, management and training procedures is reviewed periodically,\n   (iii) the technical management is adequately supervised;\n\n(b) the technical management who ensure that:\n   (i) procedures for performing calibration, verification and (re-) qualification of instruments, monitoring of environmental and storage conditions are in place and are conducted as required,\n   (ii) regular in-service training programmes to update and extend the skills of both professionals and technicians are arranged,\n   (iii) the safekeeping of any materials subject to poison regulation or to the controls applied to narcotic and psychotropic substances (see Part one, section 7.12) kept in the workplace is under the supervision of an authorized person,\n   (iv) national pharmaceutical quality control laboratories regularly participate in suitable proficiency testing schemes and collaborative trials to assess analytical procedures or reference substances;\n\n(c) analysts, who should normally be graduates in pharmacy, analytical chemistry, microbiology or other relevant subjects,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2140, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c8c82f0f-6e91-4f6b-aaa6-f49d4a3a0340": {"__data__": {"id_": "c8c82f0f-6e91-4f6b-aaa6-f49d4a3a0340", "embedding": null, "metadata": {"page_label": "113", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Premises\n\n7.1 The laboratory facilities are to be of a suitable size, construction and location. These facilities are to be designed to suit the functions and operations to be conducted in them. Rest and refreshment rooms should be separate from laboratory areas. Changing areas and toilets should be easily accessible and appropriate for the number of users.\n\n7.2 The laboratory facilities should have adequate safety equipment located appropriately and measures should be in place to ensure good housekeeping. Each laboratory should be equipped with adequate instruments and equipment, including work benches, work stations and fume hoods.\n\n7.3 The environmental conditions, including lighting, energy sources, temperature, humidity and air pressure, are to be appropriate to the functions and operations to be performed. The laboratory should ensure that the environmental conditions are monitored, controlled and documented and do not invalidate the results or adversely affect the quality of the measurements.\n\n7.4 Special precautions should be taken and, if necessary, there should be a separate and dedicated unit or equipment (e.g. isolator, laminar flow work bench) to handle, weigh and manipulate highly toxic substances, including genotoxic substances. Procedures should be in place to avoid exposure and contamination.\n\n7.5 Archive facilities should be provided to ensure the secure storage and retrieval of all documents. The design and condition of the archives should be such as to protect the contents from deterioration. Access to the archives should be restricted to designated personnel.\n\n7.6 Procedures should be in place for the safe removal of types of waste including toxic waste (chemical and biological), reagents, samples, solvents and air filters.\n\n7.7 Microbiological testing, if performed, should be contained in an appropriately designed and constructed laboratory unit. For further guidance see the draft working document *WHO guideline on good*", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices para las instalaciones de laboratorio, enfatizando la importancia de un dise\u00f1o adecuado, condiciones ambientales controladas, equipos de seguridad, manejo de sustancias t\u00f3xicas, y procedimientos para la gesti\u00f3n de residuos. Tambi\u00e9n se menciona la necesidad de instalaciones de archivo seguras y la contenci\u00f3n adecuada para pruebas microbiol\u00f3gicas.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 caracter\u00edsticas deben tener las instalaciones de archivo en un laboratorio seg\u00fan las directrices de la OMS?**\n   - Respuesta: Las instalaciones de archivo deben garantizar el almacenamiento y recuperaci\u00f3n seguros de todos los documentos, proteger el contenido de la deterioraci\u00f3n y restringir el acceso a personal designado.\n\n2. **\u00bfCu\u00e1les son las condiciones ambientales que deben ser monitoreadas y controladas en un laboratorio para asegurar la calidad de las mediciones?**\n   - Respuesta: Las condiciones ambientales incluyen iluminaci\u00f3n, fuentes de energ\u00eda, temperatura, humedad y presi\u00f3n del aire, y deben ser documentadas para no invalidar los resultados ni afectar negativamente la calidad de las mediciones.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse para el manejo de sustancias altamente t\u00f3xicas en un laboratorio?**\n   - Respuesta: Se deben tomar precauciones especiales, y si es necesario, contar con una unidad o equipo dedicado (como un aislador o banco de flujo laminar) para manejar, pesar y manipular estas sustancias, adem\u00e1s de establecer procedimientos para evitar la exposici\u00f3n y la contaminaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Requisitos de Personal en Laboratorios de Control de Calidad Farmac\u00e9utica**:\n   - Importancia de mantener descripciones de trabajo actualizadas para todo el personal involucrado en pruebas, calibraciones, validaciones y verificaciones.\n   - Necesidad de mantener registros de personal t\u00e9cnico que incluyan sus calificaciones, formaci\u00f3n y experiencia.\n\n2. **Estructura del Personal**:\n   - **Jefe de Laboratorio**:\n     - Debe tener calificaciones adecuadas y experiencia extensa en an\u00e1lisis de medicamentos y gesti\u00f3n de laboratorios.\n     - Responsable del contenido de certificados de an\u00e1lisis e informes de pruebas.\n     - Asegura la competencia del personal, revisa procedimientos de gesti\u00f3n y formaci\u00f3n, y supervisa la gesti\u00f3n t\u00e9cnica.\n   \n   - **Gesti\u00f3n T\u00e9cnica**:\n     - Encargada de asegurar que existan procedimientos para calibraci\u00f3n, verificaci\u00f3n y (re)calificaci\u00f3n de instrumentos.\n     - Organiza programas de formaci\u00f3n continua para actualizar habilidades del personal.\n     - Supervisa la seguridad de materiales regulados bajo la normativa de venenos y sustancias controladas.\n\n   - **Analistas**:\n     - Se espera que sean graduados en farmacia, qu\u00edmica anal\u00edtica, microbiolog\u00eda u otras disciplinas relevantes.\n\n3. **Capacitaci\u00f3n y Supervisi\u00f3n**:\n   - Importancia de la capacitaci\u00f3n continua y la participaci\u00f3n en esquemas de pruebas de competencia y ensayos colaborativos para evaluar procedimientos anal\u00edticos.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Emisora del informe.\n- **Laboratorio de Control de Calidad Farmac\u00e9utica**: Contexto del contenido.\n- **Personal T\u00e9cnico**: Incluye jefe de laboratorio, gesti\u00f3n t\u00e9cnica y analistas.\n- **Materiales Regulados**: Incluye sustancias controladas y venenos. \n\nEste resumen destaca la importancia de la competencia del personal y la gesti\u00f3n adecuada en laboratorios de control de calidad farmac\u00e9utica, as\u00ed como los procedimientos necesarios para garantizar la calidad y seguridad en el an\u00e1lisis de medicamentos.", "excerpt_keywords": "Keywords: laboratory facilities, safety equipment, environmental conditions, toxic substances, waste management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3654c3ae-5954-40ec-b92f-fb40ab368bc8", "node_type": "4", "metadata": {"page_label": "113", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Premises\n\n7.1 The laboratory facilities are to be of a suitable size, construction and location. These facilities are to be designed to suit the functions and operations to be conducted in them. Rest and refreshment rooms should be separate from laboratory areas. Changing areas and toilets should be easily accessible and appropriate for the number of users.\n\n7.2 The laboratory facilities should have adequate safety equipment located appropriately and measures should be in place to ensure good housekeeping. Each laboratory should be equipped with adequate instruments and equipment, including work benches, work stations and fume hoods.\n\n7.3 The environmental conditions, including lighting, energy sources, temperature, humidity and air pressure, are to be appropriate to the functions and operations to be performed. The laboratory should ensure that the environmental conditions are monitored, controlled and documented and do not invalidate the results or adversely affect the quality of the measurements.\n\n7.4 Special precautions should be taken and, if necessary, there should be a separate and dedicated unit or equipment (e.g. isolator, laminar flow work bench) to handle, weigh and manipulate highly toxic substances, including genotoxic substances. Procedures should be in place to avoid exposure and contamination.\n\n7.5 Archive facilities should be provided to ensure the secure storage and retrieval of all documents. The design and condition of the archives should be such as to protect the contents from deterioration. Access to the archives should be restricted to designated personnel.\n\n7.6 Procedures should be in place for the safe removal of types of waste including toxic waste (chemical and biological), reagents, samples, solvents and air filters.\n\n7.7 Microbiological testing, if performed, should be contained in an appropriately designed and constructed laboratory unit. For further guidance see the draft working document *WHO guideline on good*", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "1dd9857046f73fd985337473d162647af0f0e86a568ad18135cb84b304cd7156", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Premises\n\n7.1 The laboratory facilities are to be of a suitable size, construction and location. These facilities are to be designed to suit the functions and operations to be conducted in them. Rest and refreshment rooms should be separate from laboratory areas. Changing areas and toilets should be easily accessible and appropriate for the number of users.\n\n7.2 The laboratory facilities should have adequate safety equipment located appropriately and measures should be in place to ensure good housekeeping. Each laboratory should be equipped with adequate instruments and equipment, including work benches, work stations and fume hoods.\n\n7.3 The environmental conditions, including lighting, energy sources, temperature, humidity and air pressure, are to be appropriate to the functions and operations to be performed. The laboratory should ensure that the environmental conditions are monitored, controlled and documented and do not invalidate the results or adversely affect the quality of the measurements.\n\n7.4 Special precautions should be taken and, if necessary, there should be a separate and dedicated unit or equipment (e.g. isolator, laminar flow work bench) to handle, weigh and manipulate highly toxic substances, including genotoxic substances. Procedures should be in place to avoid exposure and contamination.\n\n7.5 Archive facilities should be provided to ensure the secure storage and retrieval of all documents. The design and condition of the archives should be such as to protect the contents from deterioration. Access to the archives should be restricted to designated personnel.\n\n7.6 Procedures should be in place for the safe removal of types of waste including toxic waste (chemical and biological), reagents, samples, solvents and air filters.\n\n7.7 Microbiological testing, if performed, should be contained in an appropriately designed and constructed laboratory unit. For further guidance see the draft working document *WHO guideline on good*", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1978, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e49b0c5d-84e5-4509-af75-b4532eb9f34c": {"__data__": {"id_": "e49b0c5d-84e5-4509-af75-b4532eb9f34c", "embedding": null, "metadata": {"page_label": "114", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "practices for pharmaceutical microbiology laboratories (reference QAS/09.297).\n\n7.8 If in vivo biological testing (e.g. rabbit pyrogen test) is included in the scope of the laboratory activities then the animal houses should be isolated from the other laboratory areas with a separate entrance and air-conditioning system. The relevant guidance and regulations are to be applied (18).\n\n## Laboratory storage facilities\n\n7.9 The storage facilities should be well organized for the correct storage of samples, reagents and equipment.\n\n7.10 Separate storage facilities should be maintained for the secure storage of samples, retained samples (see Part three, section 20), reagents and laboratory accessories (see Part two, sections 10.13\u201310.14), reference substances and reference materials (see Part two, section 11). Storage facilities should be equipped to store material, if necessary, under refrigeration (2\u20138\u00b0C) and frozen (-20\u00b0C) and securely locked. All specified storage conditions should be controlled, monitored and records maintained. Access should be restricted to designated personnel.\n\n7.11 Appropriate safety procedures should be drawn up and rigorously implemented wherever toxic or flammable reagents are stored or used. The laboratory should provide separate rooms or areas for storing flammable substances, fuming and concentrated acids and bases, volatile amines and other reagents, such as hydrochloric acid, nitric acid, ammonia and bromine. Self-igniting materials, such as metallic sodium and potassium, should also be stored separately. Small stocks of acids, bases and solvents may be kept in the laboratory store but the main stocks of these items should preferably be retained in a store separate from the laboratory building.\n\n7.12 Reagents subject to poison regulations or to the controls applied to narcotic and psychotropic substances should be clearly marked as required by national legislation. They should be kept separately from other reagents in locked cabinets. A designated responsible member of staff should maintain a register of these substances. The head of each unit should accept personal responsibility for the safekeeping of any of these reagents kept in the workplace.\n\n7.13 Gases also should be stored in a dedicated store, if possible isolated from the main building. Wherever possible gas bottles in the laboratory are to be avoided and distribution from an external gas", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 957) establece directrices para laboratorios de microbiolog\u00eda farmac\u00e9utica, enfoc\u00e1ndose en la organizaci\u00f3n y almacenamiento de materiales, as\u00ed como en la seguridad en el manejo de sustancias qu\u00edmicas. Se menciona la necesidad de mantener instalaciones de almacenamiento separadas y bien organizadas para muestras, reactivos y equipos, as\u00ed como la implementaci\u00f3n de procedimientos de seguridad rigurosos para el manejo de sustancias t\u00f3xicas y inflamables. Tambi\u00e9n se abordan las regulaciones sobre el almacenamiento de sustancias controladas y la gesti\u00f3n de gases.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones de almacenamiento recomendadas para los reactivos que requieren refrigeraci\u00f3n y congelaci\u00f3n?**\n   - El documento especifica que los materiales deben almacenarse bajo refrigeraci\u00f3n (2\u20138\u00b0C) y congelaci\u00f3n (-20\u00b0C), y que las instalaciones de almacenamiento deben estar aseguradas y controladas.\n\n2. **\u00bfQu\u00e9 medidas de seguridad deben implementarse al almacenar sustancias t\u00f3xicas o inflamables en el laboratorio?**\n   - Se deben establecer procedimientos de seguridad apropiados y rigurosos, y proporcionar \u00e1reas separadas para el almacenamiento de sustancias inflamables, \u00e1cidos concentrados, bases, y otros reactivos peligrosos.\n\n3. **\u00bfC\u00f3mo se debe gestionar el almacenamiento de reactivos sujetos a regulaciones de venenos o sustancias controladas?**\n   - Estos reactivos deben estar claramente marcados seg\u00fan la legislaci\u00f3n nacional, almacenados en gabinetes cerrados y mantenidos bajo un registro por un miembro del personal designado, con el jefe de unidad asumiendo la responsabilidad de su seguridad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Instalaciones de Laboratorio**: \n   - Deben ser de tama\u00f1o, construcci\u00f3n y ubicaci\u00f3n adecuados.\n   - Deben incluir \u00e1reas separadas para descanso y refresco, as\u00ed como cambiadores y ba\u00f1os accesibles.\n\n2. **Equipamiento de Seguridad**: \n   - Se requiere equipo de seguridad adecuado y medidas de limpieza para mantener un entorno seguro.\n\n3. **Condiciones Ambientales**: \n   - Las condiciones como iluminaci\u00f3n, temperatura, humedad y presi\u00f3n del aire deben ser controladas y documentadas para asegurar la calidad de las mediciones.\n\n4. **Manejo de Sustancias T\u00f3xicas**: \n   - Se deben tomar precauciones especiales y, si es necesario, utilizar unidades o equipos dedicados para manejar sustancias altamente t\u00f3xicas y genot\u00f3xicas.\n\n5. **Instalaciones de Archivo**: \n   - Deben garantizar el almacenamiento seguro de documentos, protegerlos de la deterioraci\u00f3n y restringir el acceso a personal autorizado.\n\n6. **Gesti\u00f3n de Residuos**: \n   - Deben existir procedimientos para la eliminaci\u00f3n segura de residuos t\u00f3xicos, reactivos, muestras, disolventes y filtros de aire.\n\n7. **Pruebas Microbiol\u00f3gicas**: \n   - Si se realizan, deben llevarse a cabo en unidades de laboratorio dise\u00f1adas y construidas adecuadamente.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Laboratorio**: Entidad donde se realizan las pruebas y experimentos.\n- **Sustancias T\u00f3xicas**: Materiales que requieren manejo especial.\n- **Residuos**: Incluyen desechos qu\u00edmicos y biol\u00f3gicos que deben ser gestionados adecuadamente.\n- **Archivos**: Documentos que deben ser almacenados de manera segura. \n\nEste resumen destaca la importancia de un dise\u00f1o adecuado y la gesti\u00f3n segura en las instalaciones de laboratorio, as\u00ed como la protecci\u00f3n de la salud y la seguridad de los trabajadores.", "excerpt_keywords": "Keywords: pharmaceutical microbiology, laboratory storage, safety procedures, toxic substances, regulatory compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "73a0fc13-f3c4-4c20-ab3e-30beb18cd2ef", "node_type": "4", "metadata": {"page_label": "114", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "practices for pharmaceutical microbiology laboratories (reference QAS/09.297).\n\n7.8 If in vivo biological testing (e.g. rabbit pyrogen test) is included in the scope of the laboratory activities then the animal houses should be isolated from the other laboratory areas with a separate entrance and air-conditioning system. The relevant guidance and regulations are to be applied (18).\n\n## Laboratory storage facilities\n\n7.9 The storage facilities should be well organized for the correct storage of samples, reagents and equipment.\n\n7.10 Separate storage facilities should be maintained for the secure storage of samples, retained samples (see Part three, section 20), reagents and laboratory accessories (see Part two, sections 10.13\u201310.14), reference substances and reference materials (see Part two, section 11). Storage facilities should be equipped to store material, if necessary, under refrigeration (2\u20138\u00b0C) and frozen (-20\u00b0C) and securely locked. All specified storage conditions should be controlled, monitored and records maintained. Access should be restricted to designated personnel.\n\n7.11 Appropriate safety procedures should be drawn up and rigorously implemented wherever toxic or flammable reagents are stored or used. The laboratory should provide separate rooms or areas for storing flammable substances, fuming and concentrated acids and bases, volatile amines and other reagents, such as hydrochloric acid, nitric acid, ammonia and bromine. Self-igniting materials, such as metallic sodium and potassium, should also be stored separately. Small stocks of acids, bases and solvents may be kept in the laboratory store but the main stocks of these items should preferably be retained in a store separate from the laboratory building.\n\n7.12 Reagents subject to poison regulations or to the controls applied to narcotic and psychotropic substances should be clearly marked as required by national legislation. They should be kept separately from other reagents in locked cabinets. A designated responsible member of staff should maintain a register of these substances. The head of each unit should accept personal responsibility for the safekeeping of any of these reagents kept in the workplace.\n\n7.13 Gases also should be stored in a dedicated store, if possible isolated from the main building. Wherever possible gas bottles in the laboratory are to be avoided and distribution from an external gas", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "66b532152db9b9b42601c595f7ace12d8977aab65b89650d62f07a11e6bfe3ed", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "practices for pharmaceutical microbiology laboratories (reference QAS/09.297).\n\n7.8 If in vivo biological testing (e.g. rabbit pyrogen test) is included in the scope of the laboratory activities then the animal houses should be isolated from the other laboratory areas with a separate entrance and air-conditioning system. The relevant guidance and regulations are to be applied (18).\n\n## Laboratory storage facilities\n\n7.9 The storage facilities should be well organized for the correct storage of samples, reagents and equipment.\n\n7.10 Separate storage facilities should be maintained for the secure storage of samples, retained samples (see Part three, section 20), reagents and laboratory accessories (see Part two, sections 10.13\u201310.14), reference substances and reference materials (see Part two, section 11). Storage facilities should be equipped to store material, if necessary, under refrigeration (2\u20138\u00b0C) and frozen (-20\u00b0C) and securely locked. All specified storage conditions should be controlled, monitored and records maintained. Access should be restricted to designated personnel.\n\n7.11 Appropriate safety procedures should be drawn up and rigorously implemented wherever toxic or flammable reagents are stored or used. The laboratory should provide separate rooms or areas for storing flammable substances, fuming and concentrated acids and bases, volatile amines and other reagents, such as hydrochloric acid, nitric acid, ammonia and bromine. Self-igniting materials, such as metallic sodium and potassium, should also be stored separately. Small stocks of acids, bases and solvents may be kept in the laboratory store but the main stocks of these items should preferably be retained in a store separate from the laboratory building.\n\n7.12 Reagents subject to poison regulations or to the controls applied to narcotic and psychotropic substances should be clearly marked as required by national legislation. They should be kept separately from other reagents in locked cabinets. A designated responsible member of staff should maintain a register of these substances. The head of each unit should accept personal responsibility for the safekeeping of any of these reagents kept in the workplace.\n\n7.13 Gases also should be stored in a dedicated store, if possible isolated from the main building. Wherever possible gas bottles in the laboratory are to be avoided and distribution from an external gas", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2419, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "db3bb1ad-985e-4967-bc40-cd0883248267": {"__data__": {"id_": "db3bb1ad-985e-4967-bc40-cd0883248267", "embedding": null, "metadata": {"page_label": "115", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Equipment, instruments and other devices\n\n8.1 Equipment, instruments and other devices should be designed, constructed, adapted, located, calibrated, qualified, verified and maintained as required by the operations to be carried out in the local environment. The user should purchase the equipment from an agent capable of providing full technical support and maintenance when necessary.\n\n8.2 The laboratory should have the required test equipment, instruments and other devices for the correct performance of the tests and/or calibrations, validations and verifications (including the preparation of samples and the processing and analysis of test and/or calibration data).\n\n8.3 Equipment, instruments and other devices, including those used for sampling, should meet the laboratory\u2019s requirements and comply with the relevant standard specifications, as well as being verified, qualified and/or calibrated regularly (see Part two, section 12).\n\n# Contracts\n\n## Purchasing services and supplies\n\n9.1 The laboratory should have a procedure for the selection and purchasing of services and supplies it uses that affect the quality of testing.\n\n9.2 The laboratory should evaluate suppliers of critical consumables, supplies and services which affect quality of testing, maintain records of these evaluations and list approved suppliers, which have been demonstrated to be of a suitable quality with respect to the requirements of the laboratory.\n\n## Subcontracting of testing\n\n9.3 When a laboratory subcontracts work, which may include specific testing, it is to be done with organizations approved for the type of activity required. The laboratory is responsible for periodically assessing the competence of a contracted organization.\n\n9.4 When a laboratory performs testing for a customer and subcontracts part of the testing, it should advise the customer of the arrangement in writing and, if appropriate, gain his or her approval.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia del dise\u00f1o, construcci\u00f3n, calibraci\u00f3n y mantenimiento de equipos e instrumentos en laboratorios, asegurando que cumplan con las especificaciones est\u00e1ndar y las necesidades del entorno local. Tambi\u00e9n se discuten procedimientos para la selecci\u00f3n y compra de servicios y suministros que afectan la calidad de las pruebas, as\u00ed como la evaluaci\u00f3n de proveedores y la subcontrataci\u00f3n de pruebas. Se enfatiza la responsabilidad del laboratorio en la evaluaci\u00f3n continua de la competencia de las organizaciones contratadas y la comunicaci\u00f3n con los clientes sobre cualquier subcontrataci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que un laboratorio debe considerar al seleccionar un proveedor de equipos e instrumentos?**\n   - Esta pregunta busca detalles sobre los criterios de evaluaci\u00f3n que no se mencionan expl\u00edcitamente en el texto, como la experiencia del proveedor, la calidad del servicio postventa, o la disponibilidad de piezas de repuesto.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse para la verificaci\u00f3n y calibraci\u00f3n de equipos en un laboratorio, y con qu\u00e9 frecuencia deben realizarse estas actividades?**\n   - Aunque se menciona que los equipos deben ser verificados y calibrados regularmente, la pregunta busca informaci\u00f3n m\u00e1s detallada sobre los procedimientos espec\u00edficos y las recomendaciones de frecuencia.\n\n3. **\u00bfQu\u00e9 pasos debe seguir un laboratorio para documentar y comunicar la subcontrataci\u00f3n de pruebas a sus clientes, y qu\u00e9 informaci\u00f3n espec\u00edfica debe incluirse en esta comunicaci\u00f3n?**\n   - Esta pregunta se centra en los detalles pr\u00e1cticos de la comunicaci\u00f3n con los clientes sobre la subcontrataci\u00f3n, que no se abordan en profundidad en el texto, como el formato de la comunicaci\u00f3n y los plazos para informar a los clientes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Pr\u00e1cticas de Laboratorio**: El documento establece directrices para laboratorios de microbiolog\u00eda farmac\u00e9utica, enfatizando la organizaci\u00f3n y el almacenamiento seguro de materiales.\n\n2. **Almacenamiento de Materiales**:\n   - **Condiciones de Almacenamiento**: Se requiere que las instalaciones de almacenamiento est\u00e9n bien organizadas y equipadas para mantener muestras, reactivos y equipos bajo condiciones espec\u00edficas (refrigeraci\u00f3n de 2\u20138\u00b0C y congelaci\u00f3n de -20\u00b0C).\n   - **Acceso Restringido**: El acceso a las instalaciones de almacenamiento debe ser limitado a personal designado.\n\n3. **Seguridad en el Manejo de Sustancias**:\n   - **Sustancias T\u00f3xicas e Inflamables**: Se deben implementar procedimientos de seguridad rigurosos y proporcionar \u00e1reas separadas para el almacenamiento de sustancias peligrosas, como \u00e1cidos concentrados y bases.\n   - **Almacenamiento de Reactivos Controlados**: Los reactivos sujetos a regulaciones de venenos deben estar claramente marcados, almacenados en gabinetes cerrados y registrados por un miembro del personal designado.\n\n4. **Almacenamiento de Gases**: Se recomienda que los gases se almacenen en un \u00e1rea dedicada, preferiblemente aislada del edificio principal, y se sugiere evitar el uso de botellas de gas en el laboratorio.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Laboratorios de Microbiolog\u00eda Farmac\u00e9utica**: Contexto espec\u00edfico de las pr\u00e1cticas descritas.\n- **Reactivos Qu\u00edmicos**: Incluyen sustancias t\u00f3xicas, inflamables y controladas.\n- **Condiciones de Almacenamiento**: Refrigeraci\u00f3n y congelaci\u00f3n espec\u00edficas para materiales.\n- **Personal Designado**: Responsables del manejo y almacenamiento seguro de sustancias.", "excerpt_keywords": "Keywords: equipment, laboratory, subcontracting, quality assurance, supplier evaluation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "56269283-83de-4272-a4f8-86a886a5085e", "node_type": "4", "metadata": {"page_label": "115", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Equipment, instruments and other devices\n\n8.1 Equipment, instruments and other devices should be designed, constructed, adapted, located, calibrated, qualified, verified and maintained as required by the operations to be carried out in the local environment. The user should purchase the equipment from an agent capable of providing full technical support and maintenance when necessary.\n\n8.2 The laboratory should have the required test equipment, instruments and other devices for the correct performance of the tests and/or calibrations, validations and verifications (including the preparation of samples and the processing and analysis of test and/or calibration data).\n\n8.3 Equipment, instruments and other devices, including those used for sampling, should meet the laboratory\u2019s requirements and comply with the relevant standard specifications, as well as being verified, qualified and/or calibrated regularly (see Part two, section 12).\n\n# Contracts\n\n## Purchasing services and supplies\n\n9.1 The laboratory should have a procedure for the selection and purchasing of services and supplies it uses that affect the quality of testing.\n\n9.2 The laboratory should evaluate suppliers of critical consumables, supplies and services which affect quality of testing, maintain records of these evaluations and list approved suppliers, which have been demonstrated to be of a suitable quality with respect to the requirements of the laboratory.\n\n## Subcontracting of testing\n\n9.3 When a laboratory subcontracts work, which may include specific testing, it is to be done with organizations approved for the type of activity required. The laboratory is responsible for periodically assessing the competence of a contracted organization.\n\n9.4 When a laboratory performs testing for a customer and subcontracts part of the testing, it should advise the customer of the arrangement in writing and, if appropriate, gain his or her approval.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "ba7d7e4b91868904d8e088796089cee3c1d30faaba816b4089bce3bfae31e603", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Equipment, instruments and other devices\n\n8.1 Equipment, instruments and other devices should be designed, constructed, adapted, located, calibrated, qualified, verified and maintained as required by the operations to be carried out in the local environment. The user should purchase the equipment from an agent capable of providing full technical support and maintenance when necessary.\n\n8.2 The laboratory should have the required test equipment, instruments and other devices for the correct performance of the tests and/or calibrations, validations and verifications (including the preparation of samples and the processing and analysis of test and/or calibration data).\n\n8.3 Equipment, instruments and other devices, including those used for sampling, should meet the laboratory\u2019s requirements and comply with the relevant standard specifications, as well as being verified, qualified and/or calibrated regularly (see Part two, section 12).\n\n# Contracts\n\n## Purchasing services and supplies\n\n9.1 The laboratory should have a procedure for the selection and purchasing of services and supplies it uses that affect the quality of testing.\n\n9.2 The laboratory should evaluate suppliers of critical consumables, supplies and services which affect quality of testing, maintain records of these evaluations and list approved suppliers, which have been demonstrated to be of a suitable quality with respect to the requirements of the laboratory.\n\n## Subcontracting of testing\n\n9.3 When a laboratory subcontracts work, which may include specific testing, it is to be done with organizations approved for the type of activity required. The laboratory is responsible for periodically assessing the competence of a contracted organization.\n\n9.4 When a laboratory performs testing for a customer and subcontracts part of the testing, it should advise the customer of the arrangement in writing and, if appropriate, gain his or her approval.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1935, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c2276905-97f3-4ee5-9cde-6965843e5016": {"__data__": {"id_": "c2276905-97f3-4ee5-9cde-6965843e5016", "embedding": null, "metadata": {"page_label": "116", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9.5\nThere should be a written contract which clearly establishes the duties and responsibilities of each party, defines the contracted work and any technical arrangements made in connection with it. The contract should permit the laboratory to audit the facilities and competencies of the contracted organization and ensure the access of the laboratory to records and retained samples.\n\n# 9.6\nThe contracted organization should not pass to a third party any work entrusted to it under contract without the laboratory\u2019s prior evaluation and approval of the arrangements.\n\n# 9.7\nThe laboratory should maintain a register of all subcontractors that it uses and a record of the assessment of the competence of subcontractors.\n\n# 9.8\nThe laboratory takes the responsibility for all results reported, including those furnished by the subcontracting organization.\n\n# Part two. Materials, equipment, instruments and other devices\n\n## 10. Reagents\n\n### 10.1\nAll reagents and chemicals, including solvents and materials used in tests and assays, should be of appropriate quality.\n\n### 10.2\nReagents should be purchased from reputable, approved suppliers and should be accompanied by the certificate of analysis, and the material safety data sheet, if required.\n\n### 10.3\nIn the preparation of reagent solutions in the laboratory:\n\n- (a) responsibility for this task should be clearly specified in the job description of the person assigned to carry it out; and\n- (b) prescribed procedures should be used which are in accordance with published pharmacopoeial or other standards where available. Records should be kept of the preparation and standardization of volumetric solutions.\n\n### 10.4\nThe labels of all reagents should clearly specify:\n\n- (a) content;\n- (b) manufacturer;\n- (c) date received and date of opening of the container;\n- (d) concentration, if applicable;\n- (e) storage conditions; and\n- (f) expiry date or retest date, as justified.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Informe T\u00e9cnico 957) establece directrices sobre la gesti\u00f3n de contratos en laboratorios, enfatizando la importancia de tener contratos escritos que definan claramente las responsabilidades de las partes involucradas. Tambi\u00e9n se aborda la gesti\u00f3n de reactivos, destacando la necesidad de que sean de calidad adecuada, adquiridos de proveedores aprobados y etiquetados correctamente. Se subraya la responsabilidad del laboratorio en la supervisi\u00f3n de subcontratistas y en la validez de los resultados reportados.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 elementos deben incluirse en un contrato entre un laboratorio y una organizaci\u00f3n contratada seg\u00fan el documento?**\n   - El contrato debe establecer claramente las responsabilidades de cada parte, definir el trabajo contratado y cualquier arreglo t\u00e9cnico relacionado, permitir auditor\u00edas de las instalaciones y competencias de la organizaci\u00f3n contratada, y asegurar el acceso a registros y muestras retenidas.\n\n2. **\u00bfCu\u00e1les son los requisitos para la adquisici\u00f3n de reactivos en un laboratorio seg\u00fan las directrices?**\n   - Los reactivos deben ser de calidad apropiada, comprados a proveedores aprobados y deben estar acompa\u00f1ados de un certificado de an\u00e1lisis y, si es necesario, una hoja de datos de seguridad del material.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n debe contener la etiqueta de un reactivo en el laboratorio?**\n   - La etiqueta debe especificar el contenido, el fabricante, la fecha de recepci\u00f3n y de apertura del envase, la concentraci\u00f3n (si aplica), las condiciones de almacenamiento y la fecha de caducidad o de rean\u00e1lisis, seg\u00fan lo justificado.", "prev_section_summary": "### Temas Clave\n\n1. **Dise\u00f1o y Mantenimiento de Equipos**: Se enfatiza la importancia de que los equipos, instrumentos y dispositivos en laboratorios sean dise\u00f1ados, construidos, calibrados y mantenidos de acuerdo con las operaciones espec\u00edficas y el entorno local.\n\n2. **Selecci\u00f3n y Compra de Servicios y Suministros**: Los laboratorios deben tener procedimientos establecidos para la selecci\u00f3n y compra de servicios y suministros que impacten la calidad de las pruebas.\n\n3. **Evaluaci\u00f3n de Proveedores**: Es fundamental que los laboratorios eval\u00faen a los proveedores de consumibles y servicios cr\u00edticos, manteniendo registros de estas evaluaciones y listando a los proveedores aprobados.\n\n4. **Subcontrataci\u00f3n de Pruebas**: Cuando un laboratorio subcontrata pruebas, debe hacerlo con organizaciones aprobadas y es responsable de evaluar peri\u00f3dicamente la competencia de estas organizaciones. Adem\u00e1s, debe comunicar a los clientes sobre cualquier subcontrataci\u00f3n realizada.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Laboratorio**: Entidad responsable de realizar pruebas y mantener la calidad.\n- **Equipos e Instrumentos**: Herramientas necesarias para la realizaci\u00f3n de pruebas y an\u00e1lisis.\n- **Proveedores**: Entidades que suministran equipos, consumibles y servicios al laboratorio.\n- **Clientes**: Personas o entidades que solicitan pruebas y servicios del laboratorio. \n\nEste resumen destaca la importancia de la calidad y la responsabilidad en la gesti\u00f3n de equipos y servicios en el contexto de laboratorios, as\u00ed como la necesidad de una comunicaci\u00f3n clara con los clientes sobre la subcontrataci\u00f3n.", "excerpt_keywords": "Keywords: contract management, laboratory standards, reagents quality, subcontractor responsibility, supplier evaluation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bddc182a-822b-4049-b6fc-423a9b19d707", "node_type": "4", "metadata": {"page_label": "116", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9.5\nThere should be a written contract which clearly establishes the duties and responsibilities of each party, defines the contracted work and any technical arrangements made in connection with it. The contract should permit the laboratory to audit the facilities and competencies of the contracted organization and ensure the access of the laboratory to records and retained samples.\n\n# 9.6\nThe contracted organization should not pass to a third party any work entrusted to it under contract without the laboratory\u2019s prior evaluation and approval of the arrangements.\n\n# 9.7\nThe laboratory should maintain a register of all subcontractors that it uses and a record of the assessment of the competence of subcontractors.\n\n# 9.8\nThe laboratory takes the responsibility for all results reported, including those furnished by the subcontracting organization.\n\n# Part two. Materials, equipment, instruments and other devices\n\n## 10. Reagents\n\n### 10.1\nAll reagents and chemicals, including solvents and materials used in tests and assays, should be of appropriate quality.\n\n### 10.2\nReagents should be purchased from reputable, approved suppliers and should be accompanied by the certificate of analysis, and the material safety data sheet, if required.\n\n### 10.3\nIn the preparation of reagent solutions in the laboratory:\n\n- (a) responsibility for this task should be clearly specified in the job description of the person assigned to carry it out; and\n- (b) prescribed procedures should be used which are in accordance with published pharmacopoeial or other standards where available. Records should be kept of the preparation and standardization of volumetric solutions.\n\n### 10.4\nThe labels of all reagents should clearly specify:\n\n- (a) content;\n- (b) manufacturer;\n- (c) date received and date of opening of the container;\n- (d) concentration, if applicable;\n- (e) storage conditions; and\n- (f) expiry date or retest date, as justified.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "8c12e74d3dbea825191e3a663136163fa7563a92b31db2c07a0edd0d592e4f18", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9.5\nThere should be a written contract which clearly establishes the duties and responsibilities of each party, defines the contracted work and any technical arrangements made in connection with it. The contract should permit the laboratory to audit the facilities and competencies of the contracted organization and ensure the access of the laboratory to records and retained samples.\n\n# 9.6\nThe contracted organization should not pass to a third party any work entrusted to it under contract without the laboratory\u2019s prior evaluation and approval of the arrangements.\n\n# 9.7\nThe laboratory should maintain a register of all subcontractors that it uses and a record of the assessment of the competence of subcontractors.\n\n# 9.8\nThe laboratory takes the responsibility for all results reported, including those furnished by the subcontracting organization.\n\n# Part two. Materials, equipment, instruments and other devices\n\n## 10. Reagents\n\n### 10.1\nAll reagents and chemicals, including solvents and materials used in tests and assays, should be of appropriate quality.\n\n### 10.2\nReagents should be purchased from reputable, approved suppliers and should be accompanied by the certificate of analysis, and the material safety data sheet, if required.\n\n### 10.3\nIn the preparation of reagent solutions in the laboratory:\n\n- (a) responsibility for this task should be clearly specified in the job description of the person assigned to carry it out; and\n- (b) prescribed procedures should be used which are in accordance with published pharmacopoeial or other standards where available. Records should be kept of the preparation and standardization of volumetric solutions.\n\n### 10.4\nThe labels of all reagents should clearly specify:\n\n- (a) content;\n- (b) manufacturer;\n- (c) date received and date of opening of the container;\n- (d) concentration, if applicable;\n- (e) storage conditions; and\n- (f) expiry date or retest date, as justified.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1941, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e939ea27-ef4f-4436-8fc4-59f96e333155": {"__data__": {"id_": "e939ea27-ef4f-4436-8fc4-59f96e333155", "embedding": null, "metadata": {"page_label": "117", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 10.5 \nThe labels of reagent solutions prepared in the laboratory should clearly specify:\n\n- (a) name;\n- (b) date of preparation and initials of technician or analyst;\n- (c) expiry date or retest date, as justified; and\n- (d) concentration, if applicable.\n\n## 10.6 \nThe labels for volumetric solutions prepared in the laboratory should clearly specify:\n\n- (a) name;\n- (b) molarity (or concentration);\n- (c) date of preparation and initials of technician/analyst;\n- (d) date of standardization and initials of technician/analyst; and\n- (e) standardization factor.\n\n*Note:* The laboratory should ensure that the volumetric solution is suitable for use at the time of use.\n\n## 10.7 \nIn the transportation and subdivision of reagents:\n\n- (a) whenever possible they should be transported in the original containers; and\n- (b) when subdivision is necessary, clean containers should be used and appropriately labelled.\n\n### Visual inspection\n\n## 10.8 \nAll reagent containers should be visually inspected to ensure that the seals are intact, both when they are delivered to the store and when they are distributed to the units.\n\n## 10.9 \nReagents that appear to have been tampered with should be rejected; however, this requirement may exceptionally be waived if the identity and purity of the reagent concerned can be confirmed by testing.\n\n### Water\n\n## 10.10 \nWater should be considered as a reagent. The appropriate grade for a specific test should be used as described in the pharmacopoeias or in an approved test when available.\n\n## 10.11 \nPrecautions should be taken to avoid contamination during its supply, storage and distribution.\n\n## 10.12 \nThe quality of the water should be verified regularly to ensure that the various grades of water meet the appropriate specifications.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl contexto se centra en las directrices para el etiquetado, transporte, inspecci\u00f3n y calidad de los reactivos y soluciones volum\u00e9tricas en un laboratorio, seg\u00fan el informe de la OMS. Se especifican los elementos que deben incluirse en las etiquetas de las soluciones, la importancia de la inspecci\u00f3n visual de los envases, y se considera el agua como un reactivo que debe cumplir con ciertas especificaciones de calidad. Tambi\u00e9n se enfatiza la necesidad de evitar la contaminaci\u00f3n y de verificar regularmente la calidad del agua utilizada en los procedimientos de laboratorio.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n espec\u00edfica debe incluirse en la etiqueta de una soluci\u00f3n volum\u00e9trica preparada en el laboratorio, y por qu\u00e9 es importante cada uno de estos elementos?**\n   - Esta pregunta busca respuestas detalladas sobre la importancia de cada elemento en la etiqueta, lo que no se puede encontrar f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfCu\u00e1les son las medidas que deben tomarse si se sospecha que un reactivo ha sido manipulado, y en qu\u00e9 circunstancias se puede hacer una excepci\u00f3n a esta regla?**\n   - Esta pregunta se centra en las acciones espec\u00edficas a seguir en caso de manipulaci\u00f3n de reactivos, lo que puede no estar claramente documentado en otras gu\u00edas.\n\n3. **\u00bfQu\u00e9 criterios se deben considerar para determinar la calidad del agua utilizada en un laboratorio, y c\u00f3mo se verifica que cumpla con las especificaciones adecuadas?**\n   - Esta pregunta busca informaci\u00f3n sobre los criterios espec\u00edficos y los m\u00e9todos de verificaci\u00f3n de la calidad del agua, que pueden no estar ampliamente disponibles en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Contratos en Laboratorios**:\n   - Importancia de tener un contrato escrito que defina claramente las responsabilidades de cada parte.\n   - El contrato debe incluir la posibilidad de auditor\u00edas por parte del laboratorio y acceso a registros y muestras.\n   - Prohibici\u00f3n de subcontratar trabajos sin la evaluaci\u00f3n y aprobaci\u00f3n previa del laboratorio.\n   - Registro de subcontratistas y evaluaci\u00f3n de su competencia son responsabilidades del laboratorio.\n   - El laboratorio es responsable de todos los resultados reportados, incluidos los de subcontratistas.\n\n2. **Gesti\u00f3n de Reactivos**:\n   - Los reactivos y qu\u00edmicos deben ser de calidad adecuada.\n   - Deben ser adquiridos de proveedores aprobados y acompa\u00f1ados de un certificado de an\u00e1lisis y, si es necesario, una hoja de datos de seguridad.\n   - Preparaci\u00f3n de soluciones de reactivos debe seguir procedimientos prescritos y estar documentada.\n   - Etiquetas de reactivos deben incluir informaci\u00f3n esencial como contenido, fabricante, fechas relevantes, concentraci\u00f3n, condiciones de almacenamiento y fechas de caducidad o rean\u00e1lisis.\n\n### Entidades Clave\n- **Laboratorio**: Entidad responsable de la supervisi\u00f3n y gesti\u00f3n de contratos y reactivos.\n- **Organizaci\u00f3n Contratada**: Entidad que realiza trabajos bajo contrato con el laboratorio.\n- **Subcontratistas**: Terceros que pueden ser utilizados por la organizaci\u00f3n contratada, cuya competencia debe ser evaluada por el laboratorio.\n- **Proveedores**: Entidades que suministran reactivos y qu\u00edmicos al laboratorio, deben ser aprobados y reputables. \n\nEste resumen destaca la importancia de la claridad contractual y la gesti\u00f3n adecuada de reactivos en el contexto de laboratorios, asegurando la calidad y responsabilidad en los resultados obtenidos.", "excerpt_keywords": "Keywords: reagent labeling, volumetric solutions, quality control, contamination prevention, water specifications"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "56d740e3-04a8-4521-baaa-890ee7104d6e", "node_type": "4", "metadata": {"page_label": "117", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 10.5 \nThe labels of reagent solutions prepared in the laboratory should clearly specify:\n\n- (a) name;\n- (b) date of preparation and initials of technician or analyst;\n- (c) expiry date or retest date, as justified; and\n- (d) concentration, if applicable.\n\n## 10.6 \nThe labels for volumetric solutions prepared in the laboratory should clearly specify:\n\n- (a) name;\n- (b) molarity (or concentration);\n- (c) date of preparation and initials of technician/analyst;\n- (d) date of standardization and initials of technician/analyst; and\n- (e) standardization factor.\n\n*Note:* The laboratory should ensure that the volumetric solution is suitable for use at the time of use.\n\n## 10.7 \nIn the transportation and subdivision of reagents:\n\n- (a) whenever possible they should be transported in the original containers; and\n- (b) when subdivision is necessary, clean containers should be used and appropriately labelled.\n\n### Visual inspection\n\n## 10.8 \nAll reagent containers should be visually inspected to ensure that the seals are intact, both when they are delivered to the store and when they are distributed to the units.\n\n## 10.9 \nReagents that appear to have been tampered with should be rejected; however, this requirement may exceptionally be waived if the identity and purity of the reagent concerned can be confirmed by testing.\n\n### Water\n\n## 10.10 \nWater should be considered as a reagent. The appropriate grade for a specific test should be used as described in the pharmacopoeias or in an approved test when available.\n\n## 10.11 \nPrecautions should be taken to avoid contamination during its supply, storage and distribution.\n\n## 10.12 \nThe quality of the water should be verified regularly to ensure that the various grades of water meet the appropriate specifications.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "bc047df8a91acba1173dc0389f6d47c5d6b7cbefb511c730eaff1585735916d2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 10.5 \nThe labels of reagent solutions prepared in the laboratory should clearly specify:\n\n- (a) name;\n- (b) date of preparation and initials of technician or analyst;\n- (c) expiry date or retest date, as justified; and\n- (d) concentration, if applicable.\n\n## 10.6 \nThe labels for volumetric solutions prepared in the laboratory should clearly specify:\n\n- (a) name;\n- (b) molarity (or concentration);\n- (c) date of preparation and initials of technician/analyst;\n- (d) date of standardization and initials of technician/analyst; and\n- (e) standardization factor.\n\n*Note:* The laboratory should ensure that the volumetric solution is suitable for use at the time of use.\n\n## 10.7 \nIn the transportation and subdivision of reagents:\n\n- (a) whenever possible they should be transported in the original containers; and\n- (b) when subdivision is necessary, clean containers should be used and appropriately labelled.\n\n### Visual inspection\n\n## 10.8 \nAll reagent containers should be visually inspected to ensure that the seals are intact, both when they are delivered to the store and when they are distributed to the units.\n\n## 10.9 \nReagents that appear to have been tampered with should be rejected; however, this requirement may exceptionally be waived if the identity and purity of the reagent concerned can be confirmed by testing.\n\n### Water\n\n## 10.10 \nWater should be considered as a reagent. The appropriate grade for a specific test should be used as described in the pharmacopoeias or in an approved test when available.\n\n## 10.11 \nPrecautions should be taken to avoid contamination during its supply, storage and distribution.\n\n## 10.12 \nThe quality of the water should be verified regularly to ensure that the various grades of water meet the appropriate specifications.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1780, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e75c4250-7160-4aba-9c04-ba54368de8df": {"__data__": {"id_": "e75c4250-7160-4aba-9c04-ba54368de8df", "embedding": null, "metadata": {"page_label": "118", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Storage\n\n10.13 Stocks of reagents should be maintained in a store under the appropriate storage conditions (ambient temperature, under refrigeration or frozen). The store should contain a supply of clean bottles, vials, spoons, funnels and labels, as required, for dispensing reagents from larger to smaller containers. Special equipment may be needed for the transfer of larger volumes of corrosive liquids.\n\n10.14 The person in charge of the store is responsible for looking after the storage facilities and their inventory and for noting the expiry date of chemicals and reagents. Training may be needed in handling chemicals safely and with the necessary care.\n\n# 11. Reference substances and reference materials\n\n11.1 Reference substances (primary reference substances or secondary reference substances (8)) are used for the testing of a sample.\n\n*Note:* Pharmacopoeial reference substances should be employed when available and appropriate for the analysis. When a pharmacopoeia reference substance has not been established then the manufacturer should use its own reference substance.\n\n11.2 Reference materials may be necessary for the calibration and/or qualification of equipment, instruments or other devices.\n\n## Registration and labelling\n\n11.3 An identification number should be assigned to all reference substances, except for pharmacopoeial reference substances.\n\n11.4 A new identification number should be assigned to each new batch.\n\n11.5 This number should be marked on each vial of the reference substance.\n\n11.6 The identification number should be quoted on the analytical worksheet every time the reference substance is used (see Part three, section 15.5). In the case of pharmacopoeial reference substances the batch number and/or the batch validity statement should be attached to the worksheet.\n\n11.7 The register for all reference substances and reference materials should be maintained and contain the following information:\n\n- (a) the identification number of the substance or material;\n- (b) a precise description of the substance or material;\n- (c) the source;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia del almacenamiento adecuado de reactivos y la gesti\u00f3n de sustancias de referencia en laboratorios. Se enfatiza la necesidad de mantener los reactivos en condiciones de almacenamiento apropiadas y de contar con un inventario bien gestionado. Adem\u00e1s, se detalla la asignaci\u00f3n de n\u00fameros de identificaci\u00f3n a las sustancias de referencia, la necesidad de un registro que contenga informaci\u00f3n espec\u00edfica sobre estas sustancias y la importancia de utilizar sustancias de referencia farmacop\u00e9icas cuando est\u00e9n disponibles.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas de la persona encargada del almac\u00e9n de reactivos seg\u00fan el documento?**\n   - Esta pregunta busca obtener detalles sobre las funciones y obligaciones del responsable del almac\u00e9n, que pueden no estar claramente definidas en otros documentos.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en el registro de sustancias de referencia y materiales, y por qu\u00e9 es importante mantener este registro?**\n   - Esta pregunta se centra en la importancia de la documentaci\u00f3n y el seguimiento de las sustancias de referencia, lo cual es crucial para la calidad y la trazabilidad en los an\u00e1lisis.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse si no hay una sustancia de referencia farmacop\u00e9ica disponible para un an\u00e1lisis?**\n   - Esta pregunta busca aclarar el protocolo a seguir en situaciones espec\u00edficas donde no se dispone de sustancias de referencia est\u00e1ndar, lo que puede ser un aspecto cr\u00edtico en la pr\u00e1ctica de laboratorio.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Etiquetado de Reactivos y Soluciones Volum\u00e9tricas**:\n   - **Elementos Esenciales en Etiquetas**:\n     - Nombre del reactivo.\n     - Fecha de preparaci\u00f3n e iniciales del t\u00e9cnico o analista.\n     - Fecha de caducidad o fecha de rean\u00e1lisis, si es justificada.\n     - Concentraci\u00f3n (si aplica).\n     - Para soluciones volum\u00e9tricas: molaridad, fecha de estandarizaci\u00f3n, iniciales del t\u00e9cnico y factor de estandarizaci\u00f3n.\n\n2. **Transporte y Subdivisi\u00f3n de Reactivos**:\n   - Preferencia por el transporte en envases originales.\n   - Uso de envases limpios y etiquetados adecuadamente en caso de subdivisi\u00f3n.\n\n3. **Inspecci\u00f3n Visual**:\n   - Inspecci\u00f3n de contenedores de reactivos para asegurar que los sellos est\u00e9n intactos al recibir y distribuir.\n\n4. **Manejo de Reactivos Manipulados**:\n   - Rechazo de reactivos que parecen haber sido manipulados, con una excepci\u00f3n si se puede confirmar su identidad y pureza mediante pruebas.\n\n5. **Agua como Reactivo**:\n   - Consideraci\u00f3n del agua como un reactivo que debe cumplir con especificaciones de calidad.\n   - Verificaci\u00f3n regular de la calidad del agua utilizada en el laboratorio.\n\n6. **Prevenci\u00f3n de Contaminaci\u00f3n**:\n   - Precauciones necesarias para evitar la contaminaci\u00f3n durante el suministro, almacenamiento y distribuci\u00f3n de reactivos y agua.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Fuente del documento.\n- **Reactivos**: Sustancias qu\u00edmicas utilizadas en el laboratorio.\n- **Soluciones Volum\u00e9tricas**: Soluciones con una concentraci\u00f3n espec\u00edfica.\n- **T\u00e9cnico/Analista**: Personal responsable de la preparaci\u00f3n y manejo de reactivos.\n- **Contenedores**: Envases utilizados para el transporte y almacenamiento de reactivos.\n- **Agua**: Considerada un reactivo, con requisitos espec\u00edficos de calidad. \n\nEste resumen abarca los aspectos fundamentales de la secci\u00f3n, destacando la importancia del etiquetado, la inspecci\u00f3n, el manejo adecuado de reactivos y la calidad del agua en el contexto de un laboratorio.", "excerpt_keywords": "Keywords: storage, reagents, reference substances, identification number, laboratory management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "58b2620e-921c-46e6-ae2f-44e0b211b34e", "node_type": "4", "metadata": {"page_label": "118", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Storage\n\n10.13 Stocks of reagents should be maintained in a store under the appropriate storage conditions (ambient temperature, under refrigeration or frozen). The store should contain a supply of clean bottles, vials, spoons, funnels and labels, as required, for dispensing reagents from larger to smaller containers. Special equipment may be needed for the transfer of larger volumes of corrosive liquids.\n\n10.14 The person in charge of the store is responsible for looking after the storage facilities and their inventory and for noting the expiry date of chemicals and reagents. Training may be needed in handling chemicals safely and with the necessary care.\n\n# 11. Reference substances and reference materials\n\n11.1 Reference substances (primary reference substances or secondary reference substances (8)) are used for the testing of a sample.\n\n*Note:* Pharmacopoeial reference substances should be employed when available and appropriate for the analysis. When a pharmacopoeia reference substance has not been established then the manufacturer should use its own reference substance.\n\n11.2 Reference materials may be necessary for the calibration and/or qualification of equipment, instruments or other devices.\n\n## Registration and labelling\n\n11.3 An identification number should be assigned to all reference substances, except for pharmacopoeial reference substances.\n\n11.4 A new identification number should be assigned to each new batch.\n\n11.5 This number should be marked on each vial of the reference substance.\n\n11.6 The identification number should be quoted on the analytical worksheet every time the reference substance is used (see Part three, section 15.5). In the case of pharmacopoeial reference substances the batch number and/or the batch validity statement should be attached to the worksheet.\n\n11.7 The register for all reference substances and reference materials should be maintained and contain the following information:\n\n- (a) the identification number of the substance or material;\n- (b) a precise description of the substance or material;\n- (c) the source;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "5b3589850278b8e8f961b0d3d1156efd452287a1cecbc306183e0f0a48086596", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Storage\n\n10.13 Stocks of reagents should be maintained in a store under the appropriate storage conditions (ambient temperature, under refrigeration or frozen). The store should contain a supply of clean bottles, vials, spoons, funnels and labels, as required, for dispensing reagents from larger to smaller containers. Special equipment may be needed for the transfer of larger volumes of corrosive liquids.\n\n10.14 The person in charge of the store is responsible for looking after the storage facilities and their inventory and for noting the expiry date of chemicals and reagents. Training may be needed in handling chemicals safely and with the necessary care.\n\n# 11. Reference substances and reference materials\n\n11.1 Reference substances (primary reference substances or secondary reference substances (8)) are used for the testing of a sample.\n\n*Note:* Pharmacopoeial reference substances should be employed when available and appropriate for the analysis. When a pharmacopoeia reference substance has not been established then the manufacturer should use its own reference substance.\n\n11.2 Reference materials may be necessary for the calibration and/or qualification of equipment, instruments or other devices.\n\n## Registration and labelling\n\n11.3 An identification number should be assigned to all reference substances, except for pharmacopoeial reference substances.\n\n11.4 A new identification number should be assigned to each new batch.\n\n11.5 This number should be marked on each vial of the reference substance.\n\n11.6 The identification number should be quoted on the analytical worksheet every time the reference substance is used (see Part three, section 15.5). In the case of pharmacopoeial reference substances the batch number and/or the batch validity statement should be attached to the worksheet.\n\n11.7 The register for all reference substances and reference materials should be maintained and contain the following information:\n\n- (a) the identification number of the substance or material;\n- (b) a precise description of the substance or material;\n- (c) the source;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2091, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "379f0b5c-ab93-47bb-a0a5-d1b94cd7baa2": {"__data__": {"id_": "379f0b5c-ab93-47bb-a0a5-d1b94cd7baa2", "embedding": null, "metadata": {"page_label": "119", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\n(d) the date of receipt;\n(e) the batch designation or other identification code;\n(f) the intended use of the substance or material (e.g. as an infrared \n    reference substance or as an impurity reference substance for \n    thin-layer chromatography);\n(g) the location of storage in the laboratory, and any special storage \n    conditions;\n(h) any further necessary information (e.g. the results of visual \n    inspections);\n(i) expiry date or retest date;\n(j) certificate (batch validity statement) of a pharmacopoeial \n    reference substance and a certified reference material which \n    indicates its use, the assigned content, if applicable, and its \n    status (validity); and\n(k) in the case of secondary reference substances prepared and \n    supplied by the manufacturer, the certificate of analysis.\n\n11.8 A person should be nominated to be responsible for reference \n    substances and reference materials.\n\n11.9 If a national pharmaceutical quality control laboratory is required to \n    establish reference substances for use by other institutions, a separate \n    reference substances unit should be established.\n\n11.10 In addition a file should be kept in which all information on the \n     properties of each reference substance is entered including the safety \n     data sheets.\n\n11.11 For reference substances prepared in the laboratory, the file should \n     include the results of all tests and verifications used to establish the \n     reference substances and expiry date or retest date; these should be \n     signed by the responsible analyst.\n\nRetesting (monitoring)\n\n11.12 All reference substances prepared in the laboratory or supplied \n     externally should be retested at regular intervals to ensure that \n     deterioration has not occurred. The interval for retesting depends \n     on a number of factors, including stability of the substance, storage \n     conditions employed, type of container and extent of use (how often \n     the container is opened and closed). More detailed information on \n     the handling, storage and retesting of reference substances is given \n     in the WHO General guidelines for the establishment, maintenance \n     and distribution of chemical reference substances (8).\n\n11.13 The results of these tests should be recorded and signed by the \n     responsible analyst.\n```\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla las pautas para el manejo de sustancias de referencia y materiales de referencia en laboratorios farmac\u00e9uticos. Se especifican los requisitos para la documentaci\u00f3n, almacenamiento, y retesting de estas sustancias, as\u00ed como la designaci\u00f3n de un responsable para su gesti\u00f3n. Tambi\u00e9n se menciona la importancia de mantener un archivo con informaci\u00f3n sobre las propiedades de cada sustancia y la necesidad de realizar pruebas regulares para asegurar su calidad.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en el archivo de cada sustancia de referencia preparada en el laboratorio?**\n   - Respuesta: El archivo debe incluir los resultados de todas las pruebas y verificaciones utilizadas para establecer las sustancias de referencia, as\u00ed como la fecha de caducidad o la fecha de rean\u00e1lisis, y debe estar firmado por el analista responsable.\n\n2. **\u00bfCu\u00e1les son los factores que determinan el intervalo de rean\u00e1lisis para las sustancias de referencia?**\n   - Respuesta: El intervalo para el rean\u00e1lisis depende de varios factores, incluyendo la estabilidad de la sustancia, las condiciones de almacenamiento empleadas, el tipo de contenedor y la frecuencia con la que se abre y cierra el contenedor.\n\n3. **\u00bfQu\u00e9 se debe hacer si un laboratorio nacional de control de calidad farmac\u00e9utica necesita establecer sustancias de referencia para otras instituciones?**\n   - Respuesta: Se debe establecer una unidad separada de sustancias de referencia para gestionar esta tarea.", "prev_section_summary": "### Temas Clave\n\n1. **Almacenamiento de Reactivos**:\n   - Importancia de mantener los reactivos en condiciones adecuadas (temperatura ambiente, refrigeraci\u00f3n o congelaci\u00f3n).\n   - Necesidad de contar con suministros como botellas, viales, cucharas, embudos y etiquetas para el manejo de reactivos.\n   - Responsabilidad del encargado del almac\u00e9n en la gesti\u00f3n de las instalaciones y el inventario, as\u00ed como en el seguimiento de las fechas de caducidad de los reactivos.\n\n2. **Sustancias de Referencia y Materiales de Referencia**:\n   - Definici\u00f3n de sustancias de referencia (primarias y secundarias) y su uso en pruebas de muestras.\n   - Uso de sustancias de referencia farmacop\u00e9icas cuando est\u00e9n disponibles; en su ausencia, el fabricante debe utilizar su propia sustancia de referencia.\n   - Necesidad de materiales de referencia para la calibraci\u00f3n y/o cualificaci\u00f3n de equipos e instrumentos.\n\n3. **Registro y Etiquetado**:\n   - Asignaci\u00f3n de un n\u00famero de identificaci\u00f3n a todas las sustancias de referencia, excepto a las farmacop\u00e9icas.\n   - Protocolo para asignar un nuevo n\u00famero de identificaci\u00f3n a cada nuevo lote.\n   - Importancia de marcar el n\u00famero de identificaci\u00f3n en cada vial y de incluirlo en las hojas de trabajo anal\u00edticas.\n   - Mantenimiento de un registro que contenga informaci\u00f3n espec\u00edfica sobre las sustancias de referencia, incluyendo el n\u00famero de identificaci\u00f3n, descripci\u00f3n precisa y fuente.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Reactivos**: Sustancias qu\u00edmicas que requieren almacenamiento adecuado.\n- **Sustancias de Referencia**: Incluyen sustancias primarias y secundarias utilizadas en an\u00e1lisis.\n- **Materiales de Referencia**: Utilizados para calibraci\u00f3n y cualificaci\u00f3n de equipos.\n- **N\u00famero de Identificaci\u00f3n**: Sistema de etiquetado para sustancias de referencia.\n- **Registro**: Documento que mantiene informaci\u00f3n sobre sustancias de referencia y materiales.", "excerpt_keywords": "Keywords: referencia, sustancias, laboratorio, rean\u00e1lisis, almacenamiento"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3d7a2910-ee96-4a6d-b473-14026b054de6", "node_type": "4", "metadata": {"page_label": "119", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\n(d) the date of receipt;\n(e) the batch designation or other identification code;\n(f) the intended use of the substance or material (e.g. as an infrared \n    reference substance or as an impurity reference substance for \n    thin-layer chromatography);\n(g) the location of storage in the laboratory, and any special storage \n    conditions;\n(h) any further necessary information (e.g. the results of visual \n    inspections);\n(i) expiry date or retest date;\n(j) certificate (batch validity statement) of a pharmacopoeial \n    reference substance and a certified reference material which \n    indicates its use, the assigned content, if applicable, and its \n    status (validity); and\n(k) in the case of secondary reference substances prepared and \n    supplied by the manufacturer, the certificate of analysis.\n\n11.8 A person should be nominated to be responsible for reference \n    substances and reference materials.\n\n11.9 If a national pharmaceutical quality control laboratory is required to \n    establish reference substances for use by other institutions, a separate \n    reference substances unit should be established.\n\n11.10 In addition a file should be kept in which all information on the \n     properties of each reference substance is entered including the safety \n     data sheets.\n\n11.11 For reference substances prepared in the laboratory, the file should \n     include the results of all tests and verifications used to establish the \n     reference substances and expiry date or retest date; these should be \n     signed by the responsible analyst.\n\nRetesting (monitoring)\n\n11.12 All reference substances prepared in the laboratory or supplied \n     externally should be retested at regular intervals to ensure that \n     deterioration has not occurred. The interval for retesting depends \n     on a number of factors, including stability of the substance, storage \n     conditions employed, type of container and extent of use (how often \n     the container is opened and closed). More detailed information on \n     the handling, storage and retesting of reference substances is given \n     in the WHO General guidelines for the establishment, maintenance \n     and distribution of chemical reference substances (8).\n\n11.13 The results of these tests should be recorded and signed by the \n     responsible analyst.\n```\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "650ab6dba904cb48d73cfca4189f8e0c38db0a5fb1f1242b9d54b54a0bc3dc03", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "```\n(d) the date of receipt;\n(e) the batch designation or other identification code;\n(f) the intended use of the substance or material (e.g. as an infrared \n    reference substance or as an impurity reference substance for \n    thin-layer chromatography);\n(g) the location of storage in the laboratory, and any special storage \n    conditions;\n(h) any further necessary information (e.g. the results of visual \n    inspections);\n(i) expiry date or retest date;\n(j) certificate (batch validity statement) of a pharmacopoeial \n    reference substance and a certified reference material which \n    indicates its use, the assigned content, if applicable, and its \n    status (validity); and\n(k) in the case of secondary reference substances prepared and \n    supplied by the manufacturer, the certificate of analysis.\n\n11.8 A person should be nominated to be responsible for reference \n    substances and reference materials.\n\n11.9 If a national pharmaceutical quality control laboratory is required to \n    establish reference substances for use by other institutions, a separate \n    reference substances unit should be established.\n\n11.10 In addition a file should be kept in which all information on the \n     properties of each reference substance is entered including the safety \n     data sheets.\n\n11.11 For reference substances prepared in the laboratory, the file should \n     include the results of all tests and verifications used to establish the \n     reference substances and expiry date or retest date; these should be \n     signed by the responsible analyst.\n\nRetesting (monitoring)\n\n11.12 All reference substances prepared in the laboratory or supplied \n     externally should be retested at regular intervals to ensure that \n     deterioration has not occurred. The interval for retesting depends \n     on a number of factors, including stability of the substance, storage \n     conditions employed, type of container and extent of use (how often \n     the container is opened and closed). More detailed information on \n     the handling, storage and retesting of reference substances is given \n     in the WHO General guidelines for the establishment, maintenance \n     and distribution of chemical reference substances (8).\n\n11.13 The results of these tests should be recorded and signed by the \n     responsible analyst.\n```", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2341, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "05714d7b-fdaa-4022-8540-8df07c765421": {"__data__": {"id_": "05714d7b-fdaa-4022-8540-8df07c765421", "embedding": null, "metadata": {"page_label": "120", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 11.14 \nIn the case that the result of retesting of a reference substance is non-compliant, a retrospective check of tests performed using this reference substance since its previous examination should be carried out. For evaluation of outcomes of retrospective checks and consideration of possible corrective actions, risk analysis should be applied.\n\n## 11.15 \nPharmacopoeial reference substances are regularly retested and the validity (current status) of these reference substances is available from the issuing pharmacopoeia by various means, e.g. web sites or catalogues. Retesting by the laboratory is not necessary, provided the reference substances are stored in accordance with the storage conditions indicated.\n\n## 12. Calibration, verification of performance and qualification of equipment, instruments and other devices\n\n### 12.1 \nEach item of equipment, instrument or other device used for testing, verification and/or calibration should, when practicable, be uniquely identified.\n\n### 12.2 \nAll equipment, instruments and other devices (e.g. volumetric glassware and automatic dispensers) requiring calibration should be labelled, coded or otherwise identified to indicate the status of calibration and the date when recalibration is due.\n\n### 12.3 \nLaboratory equipment should undergo design qualification, installation qualification, operation qualification and performance qualification (for definitions of these terms see the Glossary) (11). Depending on the function and operation of the instrument, the design qualification of a commercially available standard instrument may be omitted as the installation qualification, operational qualification and performance qualification may be considered to be a sufficient indicator of its suitable design.\n\n### 12.4 \nAs applicable, the performance of equipment should be verified at appropriate intervals according to a plan established by the laboratory.\n\n### 12.5 \nMeasuring equipment should be regularly calibrated according to a plan established by the laboratory (11).\n\n### 12.6 \nSpecific procedures should be established for each type of measuring equipment, taking into account the type of equipment, the extent of use and supplier\u2019s recommendations. For example:\n\n- pH meters are verified with standard certified buffer solutions before use;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen de Nivel Superior del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia de la gesti\u00f3n de sustancias de referencia y el mantenimiento de equipos en laboratorios. Se enfatiza la necesidad de realizar verificaciones y calibraciones regulares de los equipos utilizados en pruebas y an\u00e1lisis, as\u00ed como la identificaci\u00f3n \u00fanica de cada dispositivo. Tambi\u00e9n se menciona que las sustancias de referencia farmacop\u00e9icas son retestadas regularmente y que su validez puede ser consultada a trav\u00e9s de diversas fuentes. Adem\u00e1s, se establece que, en caso de resultados no conformes en las pruebas de sustancias de referencia, se debe realizar un an\u00e1lisis retrospectivo y aplicar un an\u00e1lisis de riesgo para determinar acciones correctivas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse si se obtiene un resultado no conforme al retestar una sustancia de referencia?**\n   - En caso de un resultado no conforme, se debe llevar a cabo una verificaci\u00f3n retrospectiva de las pruebas realizadas con esa sustancia desde su \u00faltima evaluaci\u00f3n. Adem\u00e1s, se debe aplicar un an\u00e1lisis de riesgo para evaluar los resultados de estas verificaciones y considerar posibles acciones correctivas.\n\n2. **\u00bfCu\u00e1les son los requisitos para la identificaci\u00f3n y el etiquetado de equipos de laboratorio que requieren calibraci\u00f3n?**\n   - Todos los equipos, instrumentos y dispositivos que requieran calibraci\u00f3n deben estar etiquetados, codificados o identificados de alguna manera que indique su estado de calibraci\u00f3n y la fecha en que se debe realizar la recalibraci\u00f3n.\n\n3. **\u00bfQu\u00e9 calificaciones deben obtener los equipos de laboratorio y en qu\u00e9 circunstancias se puede omitir la calificaci\u00f3n de dise\u00f1o?**\n   - Los equipos de laboratorio deben pasar por calificaciones de dise\u00f1o, instalaci\u00f3n, operaci\u00f3n y rendimiento. Sin embargo, la calificaci\u00f3n de dise\u00f1o puede omitirse para instrumentos est\u00e1ndar comercialmente disponibles si las calificaciones de instalaci\u00f3n, operaci\u00f3n y rendimiento son consideradas suficientes para indicar que el dise\u00f1o es adecuado.", "prev_section_summary": "### Temas Clave\n\n1. **Documentaci\u00f3n de Sustancias de Referencia**: Se requiere un archivo que contenga informaci\u00f3n detallada sobre cada sustancia de referencia, incluyendo la fecha de recepci\u00f3n, el c\u00f3digo de identificaci\u00f3n, el uso previsto, las condiciones de almacenamiento, la fecha de caducidad o rean\u00e1lisis, y certificados de validez.\n\n2. **Responsabilidad**: Se debe designar a una persona responsable de la gesti\u00f3n de las sustancias y materiales de referencia en el laboratorio.\n\n3. **Unidad de Sustancias de Referencia**: Si un laboratorio nacional de control de calidad farmac\u00e9utica necesita establecer sustancias de referencia para otras instituciones, debe crear una unidad separada para esta tarea.\n\n4. **Retesting (Rean\u00e1lisis)**: Las sustancias de referencia deben ser reanalizadas a intervalos regulares para asegurar que no haya deterioro. El intervalo de rean\u00e1lisis depende de factores como la estabilidad de la sustancia y las condiciones de almacenamiento.\n\n5. **Registro de Resultados**: Los resultados de las pruebas de rean\u00e1lisis deben ser registrados y firmados por el analista responsable.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las pautas.\n- **Sustancias de Referencia**: Materiales utilizados para asegurar la calidad en laboratorios.\n- **Laboratorio Nacional de Control de Calidad Farmac\u00e9utica**: Instituci\u00f3n que puede establecer sustancias de referencia.\n- **Analista Responsable**: Persona encargada de firmar los resultados de las pruebas y gestionar las sustancias de referencia.\n\n### Resumen\nEl documento de la OMS establece directrices para la gesti\u00f3n de sustancias de referencia en laboratorios farmac\u00e9uticos, enfatizando la importancia de la documentaci\u00f3n, la designaci\u00f3n de responsabilidades, la creaci\u00f3n de unidades espec\u00edficas para el manejo de estas sustancias, y la necesidad de realizar rean\u00e1lisis regulares para garantizar su calidad.", "excerpt_keywords": "Keywords: reference substances, calibration, laboratory equipment, risk analysis, pharmacopoeial standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4aee77c7-852f-40e0-9422-085df9a919c1", "node_type": "4", "metadata": {"page_label": "120", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 11.14 \nIn the case that the result of retesting of a reference substance is non-compliant, a retrospective check of tests performed using this reference substance since its previous examination should be carried out. For evaluation of outcomes of retrospective checks and consideration of possible corrective actions, risk analysis should be applied.\n\n## 11.15 \nPharmacopoeial reference substances are regularly retested and the validity (current status) of these reference substances is available from the issuing pharmacopoeia by various means, e.g. web sites or catalogues. Retesting by the laboratory is not necessary, provided the reference substances are stored in accordance with the storage conditions indicated.\n\n## 12. Calibration, verification of performance and qualification of equipment, instruments and other devices\n\n### 12.1 \nEach item of equipment, instrument or other device used for testing, verification and/or calibration should, when practicable, be uniquely identified.\n\n### 12.2 \nAll equipment, instruments and other devices (e.g. volumetric glassware and automatic dispensers) requiring calibration should be labelled, coded or otherwise identified to indicate the status of calibration and the date when recalibration is due.\n\n### 12.3 \nLaboratory equipment should undergo design qualification, installation qualification, operation qualification and performance qualification (for definitions of these terms see the Glossary) (11). Depending on the function and operation of the instrument, the design qualification of a commercially available standard instrument may be omitted as the installation qualification, operational qualification and performance qualification may be considered to be a sufficient indicator of its suitable design.\n\n### 12.4 \nAs applicable, the performance of equipment should be verified at appropriate intervals according to a plan established by the laboratory.\n\n### 12.5 \nMeasuring equipment should be regularly calibrated according to a plan established by the laboratory (11).\n\n### 12.6 \nSpecific procedures should be established for each type of measuring equipment, taking into account the type of equipment, the extent of use and supplier\u2019s recommendations. For example:\n\n- pH meters are verified with standard certified buffer solutions before use;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "29fcb82bc24ab13349e4f659931a85788d0d14cf2701d65f361e6c519c5db17c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 11.14 \nIn the case that the result of retesting of a reference substance is non-compliant, a retrospective check of tests performed using this reference substance since its previous examination should be carried out. For evaluation of outcomes of retrospective checks and consideration of possible corrective actions, risk analysis should be applied.\n\n## 11.15 \nPharmacopoeial reference substances are regularly retested and the validity (current status) of these reference substances is available from the issuing pharmacopoeia by various means, e.g. web sites or catalogues. Retesting by the laboratory is not necessary, provided the reference substances are stored in accordance with the storage conditions indicated.\n\n## 12. Calibration, verification of performance and qualification of equipment, instruments and other devices\n\n### 12.1 \nEach item of equipment, instrument or other device used for testing, verification and/or calibration should, when practicable, be uniquely identified.\n\n### 12.2 \nAll equipment, instruments and other devices (e.g. volumetric glassware and automatic dispensers) requiring calibration should be labelled, coded or otherwise identified to indicate the status of calibration and the date when recalibration is due.\n\n### 12.3 \nLaboratory equipment should undergo design qualification, installation qualification, operation qualification and performance qualification (for definitions of these terms see the Glossary) (11). Depending on the function and operation of the instrument, the design qualification of a commercially available standard instrument may be omitted as the installation qualification, operational qualification and performance qualification may be considered to be a sufficient indicator of its suitable design.\n\n### 12.4 \nAs applicable, the performance of equipment should be verified at appropriate intervals according to a plan established by the laboratory.\n\n### 12.5 \nMeasuring equipment should be regularly calibrated according to a plan established by the laboratory (11).\n\n### 12.6 \nSpecific procedures should be established for each type of measuring equipment, taking into account the type of equipment, the extent of use and supplier\u2019s recommendations. For example:\n\n- pH meters are verified with standard certified buffer solutions before use;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2315, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "39f0c614-6096-474c-aecc-717577a8ddee": {"__data__": {"id_": "39f0c614-6096-474c-aecc-717577a8ddee", "embedding": null, "metadata": {"page_label": "121", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 balances are to be checked daily using internal calibration and regularly using suitable test weights, and requalification should be performed annually using certified reference weights.\n\n12.7 Only authorized personnel should operate equipment, instruments and devices. Up-to-date SOPs on the use, maintenance, verification, qualification and calibration of equipment, instruments and devices (including any relevant manuals provided by the manufacturer) should be readily available for use by the appropriate laboratory personnel together with a schedule of the dates on which verification and/or calibration is due.\n\n12.8 Records should be kept of each item of equipment, instrument or other device used to perform testing, verification and/or calibration. The records should include at least the following:\n\n(a) the identity of the equipment, instrument or other device;\n(b) the manufacturer\u2019s name and the equipment model, serial number or other unique identification;\n(c) the qualification, verification and/or calibration required;\n(d) the current location, where appropriate;\n(e) the equipment manufacturer\u2019s instructions, if available, or an indication of their location;\n(f) the dates, results and copies of reports, verifications and certificates of all calibrations, adjustments, acceptance criteria and the due date of the next qualification, verification and/or calibration;\n(g) the maintenance carried out to date and the maintenance plan; and\n(h) a history of any damage, malfunction, modification or repair.\n\nIt is also recommended that records should be kept and additional observations made of the time for which the equipment, instruments or devices were used.\n\n12.9 Procedures should include instructions for the safe handling, transport and storage of measuring equipment. On reinstallation, requalification of the equipment is required to ensure that it functions properly.\n\n12.10 Maintenance procedures should be established, e.g. regular servicing should be performed by a team of maintenance specialists, whether internal or external, followed by verification of performance.\n\n12.11 Equipment, instruments and other devices, either subjected to overloading or mishandling, giving suspect results, shown to be defective or outside specified limits, should be taken out of service and clearly labelled or marked. Wherever possible they should not be used until they have been repaired and requalified.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 957) establece directrices sobre el manejo, calibraci\u00f3n y mantenimiento de equipos e instrumentos en laboratorios. Se enfatiza la importancia de que solo el personal autorizado opere estos dispositivos, la necesidad de mantener registros detallados de cada equipo, y la implementaci\u00f3n de procedimientos para el manejo seguro y la requalificaci\u00f3n de los equipos. Adem\u00e1s, se menciona que los equipos defectuosos deben ser retirados de servicio y etiquetados adecuadamente.\n\n### Preguntas Espec\u00edficas:\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en los registros de cada equipo, instrumento o dispositivo utilizado en el laboratorio?**\n   - La respuesta se puede encontrar en el apartado 12.8, que detalla los elementos que deben ser documentados, como la identidad del equipo, el nombre del fabricante, el modelo, el historial de mantenimiento, y m\u00e1s.\n\n2. **\u00bfCu\u00e1les son las recomendaciones para el manejo y almacenamiento seguro de los equipos de medici\u00f3n?**\n   - El apartado 12.9 menciona que deben incluirse instrucciones espec\u00edficas para el manejo, transporte y almacenamiento seguro de los equipos, as\u00ed como la necesidad de requalificaci\u00f3n tras la reinstalaci\u00f3n.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse si un equipo se sospecha que est\u00e1 defectuoso o ha sido sobrecargado?**\n   - Seg\u00fan el apartado 12.11, los equipos que presenten resultados sospechosos, que est\u00e9n defectuosos o que hayan sido sobrecargados deben ser retirados de servicio, etiquetados claramente y no deben ser utilizados hasta que sean reparados y requalificados.", "prev_section_summary": "### Temas Clave\n\n1. **Gesti\u00f3n de Sustancias de Referencia**:\n   - Importancia de realizar verificaciones retrospectivas en caso de resultados no conformes al retestar sustancias de referencia.\n   - Aplicaci\u00f3n de an\u00e1lisis de riesgo para evaluar resultados y considerar acciones correctivas.\n   - Las sustancias de referencia farmacop\u00e9icas son retestadas regularmente y su validez puede ser consultada a trav\u00e9s de diversas fuentes.\n\n2. **Calibraci\u00f3n y Verificaci\u00f3n de Equipos**:\n   - Necesidad de identificar de manera \u00fanica cada equipo, instrumento o dispositivo utilizado en pruebas y calibraciones.\n   - Etiquetado y codificaci\u00f3n de equipos que requieren calibraci\u00f3n para indicar su estado y fechas de recalibraci\u00f3n.\n   - Proceso de calificaci\u00f3n de equipos que incluye calificaciones de dise\u00f1o, instalaci\u00f3n, operaci\u00f3n y rendimiento, con la posibilidad de omitir la calificaci\u00f3n de dise\u00f1o para instrumentos est\u00e1ndar.\n\n3. **Procedimientos de Verificaci\u00f3n y Calibraci\u00f3n**:\n   - Verificaci\u00f3n del rendimiento de equipos a intervalos apropiados seg\u00fan un plan establecido por el laboratorio.\n   - Calibraci\u00f3n regular de equipos de medici\u00f3n seg\u00fan un plan espec\u00edfico.\n   - Establecimiento de procedimientos espec\u00edficos para cada tipo de equipo de medici\u00f3n, considerando recomendaciones del proveedor.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Emisora del documento.\n- **Sustancias de Referencia Farmacop\u00e9icas**: Sustancias que requieren retesting y validaci\u00f3n.\n- **Equipos de Laboratorio**: Incluyen instrumentos, dispositivos y vidrio volum\u00e9trico que requieren calibraci\u00f3n.\n- **An\u00e1lisis de Riesgo**: M\u00e9todo para evaluar resultados de pruebas no conformes.\n- **Calificaci\u00f3n de Equipos**: Proceso que incluye dise\u00f1o, instalaci\u00f3n, operaci\u00f3n y rendimiento. \n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de sustancias de referencia y el mantenimiento riguroso de los equipos en laboratorios para asegurar la calidad y precisi\u00f3n en los resultados de pruebas.", "excerpt_keywords": "Keywords: calibration, maintenance, laboratory equipment, verification, authorized personnel"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "59a0564e-9341-477d-ae85-669ccfbec3ed", "node_type": "4", "metadata": {"page_label": "121", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 balances are to be checked daily using internal calibration and regularly using suitable test weights, and requalification should be performed annually using certified reference weights.\n\n12.7 Only authorized personnel should operate equipment, instruments and devices. Up-to-date SOPs on the use, maintenance, verification, qualification and calibration of equipment, instruments and devices (including any relevant manuals provided by the manufacturer) should be readily available for use by the appropriate laboratory personnel together with a schedule of the dates on which verification and/or calibration is due.\n\n12.8 Records should be kept of each item of equipment, instrument or other device used to perform testing, verification and/or calibration. The records should include at least the following:\n\n(a) the identity of the equipment, instrument or other device;\n(b) the manufacturer\u2019s name and the equipment model, serial number or other unique identification;\n(c) the qualification, verification and/or calibration required;\n(d) the current location, where appropriate;\n(e) the equipment manufacturer\u2019s instructions, if available, or an indication of their location;\n(f) the dates, results and copies of reports, verifications and certificates of all calibrations, adjustments, acceptance criteria and the due date of the next qualification, verification and/or calibration;\n(g) the maintenance carried out to date and the maintenance plan; and\n(h) a history of any damage, malfunction, modification or repair.\n\nIt is also recommended that records should be kept and additional observations made of the time for which the equipment, instruments or devices were used.\n\n12.9 Procedures should include instructions for the safe handling, transport and storage of measuring equipment. On reinstallation, requalification of the equipment is required to ensure that it functions properly.\n\n12.10 Maintenance procedures should be established, e.g. regular servicing should be performed by a team of maintenance specialists, whether internal or external, followed by verification of performance.\n\n12.11 Equipment, instruments and other devices, either subjected to overloading or mishandling, giving suspect results, shown to be defective or outside specified limits, should be taken out of service and clearly labelled or marked. Wherever possible they should not be used until they have been repaired and requalified.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "9718c37199b65972d4fa13a63d155dc0d158a026fbc94e58f3f7249ed49973a6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2014 balances are to be checked daily using internal calibration and regularly using suitable test weights, and requalification should be performed annually using certified reference weights.\n\n12.7 Only authorized personnel should operate equipment, instruments and devices. Up-to-date SOPs on the use, maintenance, verification, qualification and calibration of equipment, instruments and devices (including any relevant manuals provided by the manufacturer) should be readily available for use by the appropriate laboratory personnel together with a schedule of the dates on which verification and/or calibration is due.\n\n12.8 Records should be kept of each item of equipment, instrument or other device used to perform testing, verification and/or calibration. The records should include at least the following:\n\n(a) the identity of the equipment, instrument or other device;\n(b) the manufacturer\u2019s name and the equipment model, serial number or other unique identification;\n(c) the qualification, verification and/or calibration required;\n(d) the current location, where appropriate;\n(e) the equipment manufacturer\u2019s instructions, if available, or an indication of their location;\n(f) the dates, results and copies of reports, verifications and certificates of all calibrations, adjustments, acceptance criteria and the due date of the next qualification, verification and/or calibration;\n(g) the maintenance carried out to date and the maintenance plan; and\n(h) a history of any damage, malfunction, modification or repair.\n\nIt is also recommended that records should be kept and additional observations made of the time for which the equipment, instruments or devices were used.\n\n12.9 Procedures should include instructions for the safe handling, transport and storage of measuring equipment. On reinstallation, requalification of the equipment is required to ensure that it functions properly.\n\n12.10 Maintenance procedures should be established, e.g. regular servicing should be performed by a team of maintenance specialists, whether internal or external, followed by verification of performance.\n\n12.11 Equipment, instruments and other devices, either subjected to overloading or mishandling, giving suspect results, shown to be defective or outside specified limits, should be taken out of service and clearly labelled or marked. Wherever possible they should not be used until they have been repaired and requalified.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2426, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b1b357e4-2337-45dc-bc56-eca4ff9b42be": {"__data__": {"id_": "b1b357e4-2337-45dc-bc56-eca4ff9b42be", "embedding": null, "metadata": {"page_label": "122", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 12.12\n\nWhen the equipment, instruments and other devices are outside the direct control of the laboratory for a certain period or have undergone major repair, the laboratory should requalify the equipment to ensure its suitability for use.\n\n*Note:* For further guidance on calibration, verification of performance and qualification of equipment refer to:\n\n- *Procedures for verifying and calibrating refractometers, thermometers used in determinations of melting temperatures and potentiometers for pH determinations and methods for verifying the reliability of scales for ultraviolet and infrared spectrophotometers and spectrofluorometers in The International Pharmacopoeia (19);*\n\n- *Specific guidelines for qualification of equipment elaborated by the European Network of Official Medicines Control Laboratories (OMCL) (20);* and\n\n- *General chapter of the US Pharmacopeia on Analytical instrument qualification (21).*\n\n# 13. Traceability\n\n## 13.1\n\nThe result of an analysis should be traceable, when appropriate, ultimately to a primary reference substance.\n\n## 13.2\n\nAll calibrations or qualification of instruments should be traceable to certified reference materials and to SI units (metrological traceability).\n\n# Part Three. Working procedures\n\n## 14. Incoming samples\n\nSections 14.1\u201314.3 are applicable to national pharmaceutical quality control laboratories.\n\n### 14.1\n\nSamples received by a laboratory may be for compliance testing or for investigative testing. Samples for compliance testing include routine samples for control, samples suspected of not complying with the specifications or samples submitted in connection with a marketing authorization process. Close collaboration with the providers of the samples is important. In particular it is important that the sample is large enough to enable, if required, a number of replicate tests to be carried out (see Part three, section 14.3) and for part of the sample to be retained (see Part three, section 20).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 957) aborda la importancia de la recalificaci\u00f3n de equipos en laboratorios, especialmente despu\u00e9s de que estos han estado fuera de control directo o han sido sometidos a reparaciones importantes. Tambi\u00e9n se enfatiza la necesidad de trazabilidad en los resultados de an\u00e1lisis, asegurando que las calibraciones y calificaciones de instrumentos est\u00e9n vinculadas a materiales de referencia certificados y a unidades del Sistema Internacional (SI). Adem\u00e1s, se discuten los procedimientos para el manejo de muestras entrantes en laboratorios de control de calidad farmac\u00e9utica.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para la recalificaci\u00f3n de equipos en un laboratorio despu\u00e9s de reparaciones importantes?**\n   - El laboratorio debe requalificar el equipo para asegurar su idoneidad para el uso, siguiendo las gu\u00edas espec\u00edficas mencionadas en el documento, como las de la Farmacopea Internacional y las elaboradas por la Red Europea de Laboratorios de Control de Medicamentos Oficiales (OMCL).\n\n2. **\u00bfCu\u00e1l es la importancia de la trazabilidad en los resultados de an\u00e1lisis en un laboratorio?**\n   - La trazabilidad es crucial porque asegura que los resultados de un an\u00e1lisis puedan ser rastreados hasta una sustancia de referencia primaria, lo que garantiza la fiabilidad y la precisi\u00f3n de los resultados obtenidos.\n\n3. **\u00bfQu\u00e9 tipo de muestras pueden recibir los laboratorios de control de calidad farmac\u00e9utica y cu\u00e1l es la importancia de la colaboraci\u00f3n con los proveedores de muestras?**\n   - Los laboratorios pueden recibir muestras para pruebas de cumplimiento o pruebas investigativas. Es importante que las muestras sean lo suficientemente grandes para permitir m\u00faltiples pruebas replicadas y para que parte de la muestra pueda ser retenida, lo que requiere una estrecha colaboraci\u00f3n con los proveedores de las muestras.", "prev_section_summary": "### Temas Clave:\n\n1. **Calibraci\u00f3n y Verificaci\u00f3n de Equipos**: Se establece la necesidad de realizar calibraciones diarias y anuales de los balances y otros equipos, utilizando pesos de referencia certificados.\n\n2. **Operaci\u00f3n por Personal Autorizado**: Solo el personal autorizado debe operar los equipos, y se deben tener disponibles procedimientos operativos est\u00e1ndar (SOP) actualizados sobre su uso y mantenimiento.\n\n3. **Registro de Equipos**: Es fundamental mantener registros detallados de cada equipo, que incluyan informaci\u00f3n como la identidad del equipo, el fabricante, el modelo, el historial de mantenimiento y los resultados de calibraciones.\n\n4. **Manejo Seguro de Equipos**: Se deben seguir procedimientos espec\u00edficos para el manejo, transporte y almacenamiento seguro de los equipos de medici\u00f3n, as\u00ed como la requalificaci\u00f3n tras su reinstalaci\u00f3n.\n\n5. **Mantenimiento Regular**: Se deben establecer procedimientos de mantenimiento, que incluyan servicios regulares realizados por especialistas, seguidos de verificaciones de rendimiento.\n\n6. **Retiro de Equipos Defectuosos**: Los equipos que presenten resultados sospechosos o que hayan sido sobrecargados deben ser retirados de servicio y etiquetados, y no deben ser utilizados hasta que sean reparados y requalificados.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Equipos e Instrumentos**: Dispositivos utilizados en laboratorios para pruebas y mediciones.\n- **Personal Autorizado**: Individuos capacitados para operar los equipos.\n- **SOP (Procedimientos Operativos Est\u00e1ndar)**: Documentos que gu\u00edan el uso y mantenimiento de los equipos.\n- **Pesos de Referencia Certificados**: Herramientas utilizadas para la calibraci\u00f3n de equipos.\n- **Registros de Mantenimiento**: Documentaci\u00f3n que detalla el historial y el estado de los equipos.\n\nEste resumen destaca la importancia de la calibraci\u00f3n, el mantenimiento y el manejo seguro de los equipos en entornos de laboratorio, as\u00ed como la necesidad de documentaci\u00f3n adecuada para garantizar la calidad y la seguridad en las operaciones.", "excerpt_keywords": "Keywords: recalibration, traceability, pharmaceutical quality control, reference materials, compliance testing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e93918ca-7308-49dd-88ca-34844446536a", "node_type": "4", "metadata": {"page_label": "122", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 12.12\n\nWhen the equipment, instruments and other devices are outside the direct control of the laboratory for a certain period or have undergone major repair, the laboratory should requalify the equipment to ensure its suitability for use.\n\n*Note:* For further guidance on calibration, verification of performance and qualification of equipment refer to:\n\n- *Procedures for verifying and calibrating refractometers, thermometers used in determinations of melting temperatures and potentiometers for pH determinations and methods for verifying the reliability of scales for ultraviolet and infrared spectrophotometers and spectrofluorometers in The International Pharmacopoeia (19);*\n\n- *Specific guidelines for qualification of equipment elaborated by the European Network of Official Medicines Control Laboratories (OMCL) (20);* and\n\n- *General chapter of the US Pharmacopeia on Analytical instrument qualification (21).*\n\n# 13. Traceability\n\n## 13.1\n\nThe result of an analysis should be traceable, when appropriate, ultimately to a primary reference substance.\n\n## 13.2\n\nAll calibrations or qualification of instruments should be traceable to certified reference materials and to SI units (metrological traceability).\n\n# Part Three. Working procedures\n\n## 14. Incoming samples\n\nSections 14.1\u201314.3 are applicable to national pharmaceutical quality control laboratories.\n\n### 14.1\n\nSamples received by a laboratory may be for compliance testing or for investigative testing. Samples for compliance testing include routine samples for control, samples suspected of not complying with the specifications or samples submitted in connection with a marketing authorization process. Close collaboration with the providers of the samples is important. In particular it is important that the sample is large enough to enable, if required, a number of replicate tests to be carried out (see Part three, section 14.3) and for part of the sample to be retained (see Part three, section 20).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "aa7025b8363dbf088b7d34785394ebeb17723727e9ed6eef3eb070ab06021d2e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 12.12\n\nWhen the equipment, instruments and other devices are outside the direct control of the laboratory for a certain period or have undergone major repair, the laboratory should requalify the equipment to ensure its suitability for use.\n\n*Note:* For further guidance on calibration, verification of performance and qualification of equipment refer to:\n\n- *Procedures for verifying and calibrating refractometers, thermometers used in determinations of melting temperatures and potentiometers for pH determinations and methods for verifying the reliability of scales for ultraviolet and infrared spectrophotometers and spectrofluorometers in The International Pharmacopoeia (19);*\n\n- *Specific guidelines for qualification of equipment elaborated by the European Network of Official Medicines Control Laboratories (OMCL) (20);* and\n\n- *General chapter of the US Pharmacopeia on Analytical instrument qualification (21).*\n\n# 13. Traceability\n\n## 13.1\n\nThe result of an analysis should be traceable, when appropriate, ultimately to a primary reference substance.\n\n## 13.2\n\nAll calibrations or qualification of instruments should be traceable to certified reference materials and to SI units (metrological traceability).\n\n# Part Three. Working procedures\n\n## 14. Incoming samples\n\nSections 14.1\u201314.3 are applicable to national pharmaceutical quality control laboratories.\n\n### 14.1\n\nSamples received by a laboratory may be for compliance testing or for investigative testing. Samples for compliance testing include routine samples for control, samples suspected of not complying with the specifications or samples submitted in connection with a marketing authorization process. Close collaboration with the providers of the samples is important. In particular it is important that the sample is large enough to enable, if required, a number of replicate tests to be carried out (see Part three, section 14.3) and for part of the sample to be retained (see Part three, section 20).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1981, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9bda69c7-fe02-49ed-86f6-6188581aee6b": {"__data__": {"id_": "9bda69c7-fe02-49ed-86f6-6188581aee6b", "embedding": null, "metadata": {"page_label": "123", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 14.2\n\nSamples for investigative testing may be submitted by various sources including customs, police and medicines inspectors. These samples comprise suspicious, illegal or counterfeit substances or products. Usually, the primary objective of investigative testing is to identify the substance or the ingredient in the product and, if sufficient substance or product is available, to estimate the purity or content. Well-documented screening procedures should be in place as well as confirmatory analytical procedures to positively identify the substance or the ingredient(s). If an estimation of the content of an identified ingredient is required then an appropriate quantitative analytical procedure should be applied. The value obtained should be reported with an indication of the uncertainty of measurement if required (see Part three, section 18.10).\n\n# 14.3\n\nIt is common for a sample to be taken and divided into three approximately equal portions for submission to the laboratory:\n\n- one for immediate testing;\n- the second for confirmation of testing if required; and\n- the third for retention in case of dispute.\n\n# 14.4\n\nIf the laboratory is responsible for sampling of substances, materials or products for subsequent testing then it should have a sampling plan and an internal procedure for sampling available to all analysts and technicians working in the laboratory. Samples should be representative of the batches of material from which they are taken and sampling should be carried out so as to avoid contamination and other adverse effects on quality, or mix-up of or by the material being sampled. All the relevant data related to sampling should be recorded.\n\n*Note:* Guidelines for sampling of pharmaceutical products and related materials were adopted by the WHO Expert Committee on Specifications for Pharmaceutical Preparations at its thirty-ninth meeting (22).\n\n## Test request\n\n# 14.5\n\nA standard test request form should be filled out and should accompany each sample submitted to the laboratory. In the case of a pharmaceutical manufacturer\u2019s laboratory the requirements may be given in the master production instructions.\n\n# 14.6\n\nThe test request form should provide or leave space for the following information:\n\n(a) the name of the institution or inspector that supplied the sample;\n(b) the source of the material;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1l es el objetivo principal de las pruebas de investigaci\u00f3n de muestras sospechosas?**\n   - El objetivo principal de las pruebas de investigaci\u00f3n es identificar la sustancia o el ingrediente en el producto y, si hay suficiente sustancia o producto disponible, estimar la pureza o contenido.\n\n2. **\u00bfQu\u00e9 procedimientos deben estar documentados en un laboratorio que realiza pruebas de investigaci\u00f3n?**\n   - Deben estar documentados procedimientos de cribado bien establecidos, as\u00ed como procedimientos anal\u00edticos confirmatorios para identificar positivamente la sustancia o los ingredientes. Adem\u00e1s, si se requiere una estimaci\u00f3n del contenido de un ingrediente identificado, se debe aplicar un procedimiento anal\u00edtico cuantitativo apropiado.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en el formulario de solicitud de prueba que acompa\u00f1a a cada muestra?**\n   - El formulario de solicitud de prueba debe incluir o dejar espacio para la siguiente informaci\u00f3n: (a) el nombre de la instituci\u00f3n o inspector que suministr\u00f3 la muestra; (b) la fuente del material.\n\n### Resumen de nivel superior del contexto:\n\nEl documento proporciona directrices sobre el manejo de muestras para pruebas de investigaci\u00f3n de sustancias sospechosas, ilegales o falsificadas. Se enfatiza la importancia de identificar correctamente las sustancias y estimar su pureza, as\u00ed como la necesidad de procedimientos de muestreo adecuados para evitar la contaminaci\u00f3n. Tambi\u00e9n se menciona la importancia de un formulario de solicitud de prueba que acompa\u00f1e a cada muestra, el cual debe contener informaci\u00f3n relevante sobre la fuente y el proveedor de la muestra.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Recalificaci\u00f3n de Equipos**:\n   - Es esencial que los laboratorios requalifiquen sus equipos, instrumentos y dispositivos despu\u00e9s de que hayan estado fuera de control directo o tras reparaciones importantes. Esto asegura que el equipo sea adecuado para su uso.\n\n2. **Trazabilidad**:\n   - Los resultados de los an\u00e1lisis deben ser trazables a una sustancia de referencia primaria. Adem\u00e1s, todas las calibraciones y calificaciones de instrumentos deben estar vinculadas a materiales de referencia certificados y a unidades del Sistema Internacional (SI), garantizando la trazabilidad metrol\u00f3gica.\n\n3. **Manejo de Muestras Entrantes**:\n   - Los laboratorios de control de calidad farmac\u00e9utica reciben muestras para pruebas de cumplimiento o investigativas. Es crucial que las muestras sean lo suficientemente grandes para permitir m\u00faltiples pruebas y que parte de la muestra pueda ser retenida. La colaboraci\u00f3n estrecha con los proveedores de muestras es fundamental para asegurar la calidad y cantidad adecuadas.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Farmacopea Internacional**: Proporciona gu\u00edas sobre la verificaci\u00f3n y calibraci\u00f3n de equipos.\n- **Red Europea de Laboratorios de Control de Medicamentos Oficiales (OMCL)**: Elabora directrices espec\u00edficas para la calificaci\u00f3n de equipos.\n- **Farmacopea de EE. UU.**: Incluye un cap\u00edtulo general sobre la calificaci\u00f3n de instrumentos anal\u00edticos.\n- **Muestras**: Pueden ser para pruebas de cumplimiento o investigativas, y su manejo adecuado es crucial para los resultados del laboratorio.", "excerpt_keywords": "Keywords: investigative testing, sample handling, analytical procedures, pharmaceutical guidelines, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "daf252ae-8dcb-4f1e-8f70-0bc0f711fcea", "node_type": "4", "metadata": {"page_label": "123", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 14.2\n\nSamples for investigative testing may be submitted by various sources including customs, police and medicines inspectors. These samples comprise suspicious, illegal or counterfeit substances or products. Usually, the primary objective of investigative testing is to identify the substance or the ingredient in the product and, if sufficient substance or product is available, to estimate the purity or content. Well-documented screening procedures should be in place as well as confirmatory analytical procedures to positively identify the substance or the ingredient(s). If an estimation of the content of an identified ingredient is required then an appropriate quantitative analytical procedure should be applied. The value obtained should be reported with an indication of the uncertainty of measurement if required (see Part three, section 18.10).\n\n# 14.3\n\nIt is common for a sample to be taken and divided into three approximately equal portions for submission to the laboratory:\n\n- one for immediate testing;\n- the second for confirmation of testing if required; and\n- the third for retention in case of dispute.\n\n# 14.4\n\nIf the laboratory is responsible for sampling of substances, materials or products for subsequent testing then it should have a sampling plan and an internal procedure for sampling available to all analysts and technicians working in the laboratory. Samples should be representative of the batches of material from which they are taken and sampling should be carried out so as to avoid contamination and other adverse effects on quality, or mix-up of or by the material being sampled. All the relevant data related to sampling should be recorded.\n\n*Note:* Guidelines for sampling of pharmaceutical products and related materials were adopted by the WHO Expert Committee on Specifications for Pharmaceutical Preparations at its thirty-ninth meeting (22).\n\n## Test request\n\n# 14.5\n\nA standard test request form should be filled out and should accompany each sample submitted to the laboratory. In the case of a pharmaceutical manufacturer\u2019s laboratory the requirements may be given in the master production instructions.\n\n# 14.6\n\nThe test request form should provide or leave space for the following information:\n\n(a) the name of the institution or inspector that supplied the sample;\n(b) the source of the material;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "062161db57d919e2d0a0d31b25fd8e7a9b6e2f22b0c9c99fc4e0544749ba36c0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 14.2\n\nSamples for investigative testing may be submitted by various sources including customs, police and medicines inspectors. These samples comprise suspicious, illegal or counterfeit substances or products. Usually, the primary objective of investigative testing is to identify the substance or the ingredient in the product and, if sufficient substance or product is available, to estimate the purity or content. Well-documented screening procedures should be in place as well as confirmatory analytical procedures to positively identify the substance or the ingredient(s). If an estimation of the content of an identified ingredient is required then an appropriate quantitative analytical procedure should be applied. The value obtained should be reported with an indication of the uncertainty of measurement if required (see Part three, section 18.10).\n\n# 14.3\n\nIt is common for a sample to be taken and divided into three approximately equal portions for submission to the laboratory:\n\n- one for immediate testing;\n- the second for confirmation of testing if required; and\n- the third for retention in case of dispute.\n\n# 14.4\n\nIf the laboratory is responsible for sampling of substances, materials or products for subsequent testing then it should have a sampling plan and an internal procedure for sampling available to all analysts and technicians working in the laboratory. Samples should be representative of the batches of material from which they are taken and sampling should be carried out so as to avoid contamination and other adverse effects on quality, or mix-up of or by the material being sampled. All the relevant data related to sampling should be recorded.\n\n*Note:* Guidelines for sampling of pharmaceutical products and related materials were adopted by the WHO Expert Committee on Specifications for Pharmaceutical Preparations at its thirty-ninth meeting (22).\n\n## Test request\n\n# 14.5\n\nA standard test request form should be filled out and should accompany each sample submitted to the laboratory. In the case of a pharmaceutical manufacturer\u2019s laboratory the requirements may be given in the master production instructions.\n\n# 14.6\n\nThe test request form should provide or leave space for the following information:\n\n(a) the name of the institution or inspector that supplied the sample;\n(b) the source of the material;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2351, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8bb8ed41-36a2-41eb-a1d8-a21264385bc7": {"__data__": {"id_": "8bb8ed41-36a2-41eb-a1d8-a21264385bc7", "embedding": null, "metadata": {"page_label": "124", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\n(c) a full description of the medicine, including its composition, \n    international nonproprietary name (INN) (if available) and \n    brand name(s);\n(d) dosage form and concentration or strength, the manufacturer, \n    the batch number (if available) and the marketing authorization \n    number;\n(e) the size of the sample;\n(f) the reason for requesting the analysis;\n(g) the date on which the sample was collected;\n(h) the size of the consignment from which it was taken, when \n    appropriate;\n(i) the expiry date (for pharmaceutical products) or retest date (for \n    APIs and pharmaceutical excipients);\n(j) the specification to be used for testing;\n(k) a record of any further comments (e.g. discrepancies found or \n    associated hazard); and\n(l) the required storage conditions.\n\n14.7 The laboratory should review the test request to ensure that:\n\n(a) the requirements are adequately defined and the laboratory has \n    the capability and resources to meet them; and\n(b) the appropriate tests and/or methods are selected and are capable \n    of meeting customers\u2019 requirements.\n\n    Any issue should be resolved with the originator of the request for \n    analysis before testing starts and a record of the review should be \n    kept.\n\n**Registration and labelling**\n\n14.8 All newly delivered samples and accompanying documents (e.g. \n    the test request) should be assigned a registration number. Separate \n    registration numbers should be assigned to requests referring to two \n    or more medicines, different dosage forms, or different batches of the \n    same medicine or different sources of the same batch. If applicable, a \n    unique registration number should also be assigned to any incoming \n    retained sample (see Part three, section 20).\n\n14.9 A label bearing the registration number should be affixed to each \n    container of the sample. Care should be taken to avoid obscuring any \n    other markings or inscriptions.\n\n14.10 A register should be kept, which may be a record book, a card file \n     or data-processing equipment, in which the following information is \n     recorded:\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los procedimientos y requisitos para la recolecci\u00f3n, an\u00e1lisis y registro de muestras de medicamentos. Se especifican los elementos que deben incluirse en la solicitud de an\u00e1lisis, como la descripci\u00f3n del medicamento, la forma de dosificaci\u00f3n, el tama\u00f1o de la muestra, y otros datos relevantes. Adem\u00e1s, se establece la importancia de asignar n\u00fameros de registro a las muestras y mantener un registro adecuado de la informaci\u00f3n relacionada.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la solicitud de an\u00e1lisis de una muestra de medicamento?**\n   - La solicitud debe incluir una descripci\u00f3n completa del medicamento, su nombre no propietario internacional (INN), forma de dosificaci\u00f3n, concentraci\u00f3n, fabricante, n\u00famero de lote, n\u00famero de autorizaci\u00f3n de comercializaci\u00f3n, tama\u00f1o de la muestra, raz\u00f3n de la solicitud, fecha de recolecci\u00f3n, tama\u00f1o del env\u00edo, fecha de caducidad o fecha de rean\u00e1lisis, especificaciones para las pruebas, comentarios adicionales y condiciones de almacenamiento requeridas.\n\n2. **\u00bfCu\u00e1l es el procedimiento que debe seguir un laboratorio al recibir una solicitud de an\u00e1lisis?**\n   - El laboratorio debe revisar la solicitud para asegurarse de que los requisitos est\u00e9n claramente definidos y que tenga la capacidad y recursos para cumplirlos. Tambi\u00e9n debe seleccionar las pruebas y/o m\u00e9todos apropiados que satisfagan las necesidades del cliente. Cualquier problema debe resolverse con el originador de la solicitud antes de comenzar las pruebas, y se debe mantener un registro de esta revisi\u00f3n.\n\n3. **\u00bfC\u00f3mo se debe manejar el registro y etiquetado de las muestras en el laboratorio?**\n   - Todas las muestras reci\u00e9n entregadas deben recibir un n\u00famero de registro \u00fanico, y se deben asignar n\u00fameros separados para solicitudes que se refieran a diferentes medicamentos, formas de dosificaci\u00f3n o lotes. Cada contenedor de muestra debe llevar una etiqueta con el n\u00famero de registro, asegur\u00e1ndose de no ocultar otras marcas. Adem\u00e1s, se debe mantener un registro que contenga informaci\u00f3n relevante sobre las muestras y solicitudes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Objetivo de las Pruebas de Investigaci\u00f3n**:\n   - Identificaci\u00f3n de sustancias o ingredientes en muestras sospechosas, ilegales o falsificadas.\n   - Estimaci\u00f3n de la pureza o contenido si hay suficiente material disponible.\n\n2. **Procedimientos de Muestreo**:\n   - Las muestras deben ser representativas y divididas en tres partes: una para pruebas inmediatas, otra para confirmaci\u00f3n y una tercera para retenci\u00f3n en caso de disputa.\n   - Se deben seguir procedimientos de muestreo para evitar contaminaci\u00f3n y asegurar la calidad.\n\n3. **Documentaci\u00f3n y Procedimientos**:\n   - Es necesario contar con procedimientos de cribado y anal\u00edticos bien documentados.\n   - Se debe tener un plan de muestreo y procedimientos internos accesibles para todos los analistas y t\u00e9cnicos del laboratorio.\n\n4. **Formulario de Solicitud de Prueba**:\n   - Cada muestra debe ir acompa\u00f1ada de un formulario de solicitud est\u00e1ndar que incluya informaci\u00f3n sobre la instituci\u00f3n o inspector que suministr\u00f3 la muestra y la fuente del material.\n\n5. **Entidades Involucradas**:\n   - Fuentes de muestras: aduanas, polic\u00eda, inspectores de medicamentos.\n   - Laboratorios responsables de la prueba y muestreo de sustancias.\n\n### Conclusi\u00f3n\nEl documento establece directrices claras para el manejo y an\u00e1lisis de muestras sospechosas, enfatizando la importancia de la identificaci\u00f3n precisa, la documentaci\u00f3n adecuada y los procedimientos de muestreo para garantizar la calidad y la integridad de los resultados de las pruebas.", "excerpt_keywords": "Keywords: medicine analysis, sample registration, laboratory procedures, test request, pharmaceutical documentation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ab68a24b-16a3-46cc-9ca2-a5ee5da8488d", "node_type": "4", "metadata": {"page_label": "124", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\n(c) a full description of the medicine, including its composition, \n    international nonproprietary name (INN) (if available) and \n    brand name(s);\n(d) dosage form and concentration or strength, the manufacturer, \n    the batch number (if available) and the marketing authorization \n    number;\n(e) the size of the sample;\n(f) the reason for requesting the analysis;\n(g) the date on which the sample was collected;\n(h) the size of the consignment from which it was taken, when \n    appropriate;\n(i) the expiry date (for pharmaceutical products) or retest date (for \n    APIs and pharmaceutical excipients);\n(j) the specification to be used for testing;\n(k) a record of any further comments (e.g. discrepancies found or \n    associated hazard); and\n(l) the required storage conditions.\n\n14.7 The laboratory should review the test request to ensure that:\n\n(a) the requirements are adequately defined and the laboratory has \n    the capability and resources to meet them; and\n(b) the appropriate tests and/or methods are selected and are capable \n    of meeting customers\u2019 requirements.\n\n    Any issue should be resolved with the originator of the request for \n    analysis before testing starts and a record of the review should be \n    kept.\n\n**Registration and labelling**\n\n14.8 All newly delivered samples and accompanying documents (e.g. \n    the test request) should be assigned a registration number. Separate \n    registration numbers should be assigned to requests referring to two \n    or more medicines, different dosage forms, or different batches of the \n    same medicine or different sources of the same batch. If applicable, a \n    unique registration number should also be assigned to any incoming \n    retained sample (see Part three, section 20).\n\n14.9 A label bearing the registration number should be affixed to each \n    container of the sample. Care should be taken to avoid obscuring any \n    other markings or inscriptions.\n\n14.10 A register should be kept, which may be a record book, a card file \n     or data-processing equipment, in which the following information is \n     recorded:\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "54feefa96e3524b8fb08c0810caacd377d401a5011e5b9155d4fd9dc4b5e1c66", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "```\n(c) a full description of the medicine, including its composition, \n    international nonproprietary name (INN) (if available) and \n    brand name(s);\n(d) dosage form and concentration or strength, the manufacturer, \n    the batch number (if available) and the marketing authorization \n    number;\n(e) the size of the sample;\n(f) the reason for requesting the analysis;\n(g) the date on which the sample was collected;\n(h) the size of the consignment from which it was taken, when \n    appropriate;\n(i) the expiry date (for pharmaceutical products) or retest date (for \n    APIs and pharmaceutical excipients);\n(j) the specification to be used for testing;\n(k) a record of any further comments (e.g. discrepancies found or \n    associated hazard); and\n(l) the required storage conditions.\n\n14.7 The laboratory should review the test request to ensure that:\n\n(a) the requirements are adequately defined and the laboratory has \n    the capability and resources to meet them; and\n(b) the appropriate tests and/or methods are selected and are capable \n    of meeting customers\u2019 requirements.\n\n    Any issue should be resolved with the originator of the request for \n    analysis before testing starts and a record of the review should be \n    kept.\n\n**Registration and labelling**\n\n14.8 All newly delivered samples and accompanying documents (e.g. \n    the test request) should be assigned a registration number. Separate \n    registration numbers should be assigned to requests referring to two \n    or more medicines, different dosage forms, or different batches of the \n    same medicine or different sources of the same batch. If applicable, a \n    unique registration number should also be assigned to any incoming \n    retained sample (see Part three, section 20).\n\n14.9 A label bearing the registration number should be affixed to each \n    container of the sample. Care should be taken to avoid obscuring any \n    other markings or inscriptions.\n\n14.10 A register should be kept, which may be a record book, a card file \n     or data-processing equipment, in which the following information is \n     recorded:\n```", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2120, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "06e07bc0-f605-46e6-9194-798d83a4edc2": {"__data__": {"id_": "06e07bc0-f605-46e6-9194-798d83a4edc2", "embedding": null, "metadata": {"page_label": "125", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "(a) the registration number of the sample;  \n(b) the date of receipt; and  \n(c) the specific unit to which the sample was forwarded.  \n\n### Visual inspection of the submitted sample\n\n14.11 The sample received should be visually inspected by laboratory staff to ensure that the labelling conforms with the information contained in the test request. The findings should be recorded, dated and signed. If discrepancies are found, or if the sample is obviously damaged, this fact should be recorded without delay on the test request form. Any queries should be immediately referred back to the provider of the sample.\n\n### Storage\n\n14.12 The sample prior to testing, the retained sample (see Part three, section 20) and any portions of the sample remaining after performance of all the required tests should be stored safely, taking into account the storage conditions (22, 23) specified for the sample.\n\n### Forwarding to testing\n\n14.13 The specific unit to which the sample is sent for testing is determined by the person responsible.\n\n14.14 The examination of a sample should not be started before the relevant test request has been received.\n\n14.15 The sample should be properly stored until all relevant documentation has been received.\n\n14.16 A request for analysis may be accepted verbally only in emergencies. All details should immediately be placed on record pending the receipt of written confirmation.\n\n14.17 Unless a computerized system is used, copies or duplicates of all documentation should accompany each numbered sample when sent to the specific unit.\n\n14.18 Testing should be performed as described under Part three, section 17.\n\n## 15. Analytical worksheet\n\n15.1 The analytical worksheet is an internal document to be used by the analyst for recording information about the sample, the test procedure, calculations and the results of testing. It is to be complemented by the raw data obtained in the analysis.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento proporciona directrices sobre el manejo de muestras en un laboratorio, incluyendo la inspecci\u00f3n visual de las muestras recibidas, el almacenamiento adecuado, el env\u00edo a la unidad de pruebas y la documentaci\u00f3n necesaria. Se enfatiza la importancia de registrar cualquier discrepancia y de mantener la muestra en condiciones adecuadas hasta que se complete el an\u00e1lisis. Tambi\u00e9n se menciona la necesidad de un documento interno, conocido como \"hoja de trabajo anal\u00edtica\", para registrar informaci\u00f3n sobre el procedimiento de prueba y los resultados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse si se encuentra una discrepancia en la etiqueta de la muestra durante la inspecci\u00f3n visual?**\n   - La discrepancia debe ser registrada sin demora en el formulario de solicitud de prueba y cualquier consulta debe ser referida inmediatamente al proveedor de la muestra.\n\n2. **\u00bfQu\u00e9 condiciones de almacenamiento deben considerarse para las muestras antes de las pruebas?**\n   - Las muestras deben ser almacenadas de manera segura, teniendo en cuenta las condiciones de almacenamiento especificadas para cada tipo de muestra, as\u00ed como el almacenamiento de muestras retenidas y porciones restantes despu\u00e9s de las pruebas.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la hoja de trabajo anal\u00edtica utilizada por el analista?**\n   - La hoja de trabajo anal\u00edtica debe registrar informaci\u00f3n sobre la muestra, el procedimiento de prueba, los c\u00e1lculos realizados y los resultados obtenidos, complement\u00e1ndose con los datos en bruto obtenidos durante el an\u00e1lisis.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Descripci\u00f3n del Medicamento**: Se requiere una descripci\u00f3n completa que incluya la composici\u00f3n, el nombre no propietario internacional (INN), y los nombres de marca.\n\n2. **Informaci\u00f3n de la Muestra**:\n   - Forma de dosificaci\u00f3n y concentraci\u00f3n o fuerza.\n   - Fabricante y n\u00famero de lote (si est\u00e1 disponible).\n   - N\u00famero de autorizaci\u00f3n de comercializaci\u00f3n.\n   - Tama\u00f1o de la muestra y del env\u00edo.\n   - Fecha de recolecci\u00f3n y fechas de caducidad o rean\u00e1lisis.\n   - Especificaciones para las pruebas y condiciones de almacenamiento requeridas.\n\n3. **Revisi\u00f3n de Solicitudes de An\u00e1lisis**: \n   - El laboratorio debe asegurarse de que los requisitos est\u00e9n claramente definidos y que tenga la capacidad para cumplirlos.\n   - Selecci\u00f3n de pruebas y m\u00e9todos adecuados para satisfacer las necesidades del cliente.\n   - Resoluci\u00f3n de problemas con el originador de la solicitud antes de iniciar las pruebas.\n\n4. **Registro y Etiquetado**:\n   - Asignaci\u00f3n de un n\u00famero de registro \u00fanico a cada muestra y solicitud.\n   - Etiquetado de cada contenedor de muestra con el n\u00famero de registro, evitando ocultar otras marcas.\n   - Mantenimiento de un registro que contenga informaci\u00f3n relevante sobre las muestras y solicitudes.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Medicamento**: Producto farmac\u00e9utico que se analiza.\n- **Laboratorio**: Entidad responsable de realizar las pruebas y an\u00e1lisis.\n- **Registro**: Sistema para documentar y rastrear muestras y solicitudes. \n\nEste resumen abarca los procedimientos y requisitos esenciales para la recolecci\u00f3n, an\u00e1lisis y registro de muestras de medicamentos, asegurando la calidad y la trazabilidad en el proceso.", "excerpt_keywords": "Keywords: sample handling, visual inspection, storage conditions, analytical worksheet, test request"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6359a181-f012-407b-91bc-1e2b718caa89", "node_type": "4", "metadata": {"page_label": "125", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "(a) the registration number of the sample;  \n(b) the date of receipt; and  \n(c) the specific unit to which the sample was forwarded.  \n\n### Visual inspection of the submitted sample\n\n14.11 The sample received should be visually inspected by laboratory staff to ensure that the labelling conforms with the information contained in the test request. The findings should be recorded, dated and signed. If discrepancies are found, or if the sample is obviously damaged, this fact should be recorded without delay on the test request form. Any queries should be immediately referred back to the provider of the sample.\n\n### Storage\n\n14.12 The sample prior to testing, the retained sample (see Part three, section 20) and any portions of the sample remaining after performance of all the required tests should be stored safely, taking into account the storage conditions (22, 23) specified for the sample.\n\n### Forwarding to testing\n\n14.13 The specific unit to which the sample is sent for testing is determined by the person responsible.\n\n14.14 The examination of a sample should not be started before the relevant test request has been received.\n\n14.15 The sample should be properly stored until all relevant documentation has been received.\n\n14.16 A request for analysis may be accepted verbally only in emergencies. All details should immediately be placed on record pending the receipt of written confirmation.\n\n14.17 Unless a computerized system is used, copies or duplicates of all documentation should accompany each numbered sample when sent to the specific unit.\n\n14.18 Testing should be performed as described under Part three, section 17.\n\n## 15. Analytical worksheet\n\n15.1 The analytical worksheet is an internal document to be used by the analyst for recording information about the sample, the test procedure, calculations and the results of testing. It is to be complemented by the raw data obtained in the analysis.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "ba40ee66f6d19fc28002ea8de8b6cb3c826f0fe31ec49b11d3a2604f530f33e8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(a) the registration number of the sample;  \n(b) the date of receipt; and  \n(c) the specific unit to which the sample was forwarded.  \n\n### Visual inspection of the submitted sample\n\n14.11 The sample received should be visually inspected by laboratory staff to ensure that the labelling conforms with the information contained in the test request. The findings should be recorded, dated and signed. If discrepancies are found, or if the sample is obviously damaged, this fact should be recorded without delay on the test request form. Any queries should be immediately referred back to the provider of the sample.\n\n### Storage\n\n14.12 The sample prior to testing, the retained sample (see Part three, section 20) and any portions of the sample remaining after performance of all the required tests should be stored safely, taking into account the storage conditions (22, 23) specified for the sample.\n\n### Forwarding to testing\n\n14.13 The specific unit to which the sample is sent for testing is determined by the person responsible.\n\n14.14 The examination of a sample should not be started before the relevant test request has been received.\n\n14.15 The sample should be properly stored until all relevant documentation has been received.\n\n14.16 A request for analysis may be accepted verbally only in emergencies. All details should immediately be placed on record pending the receipt of written confirmation.\n\n14.17 Unless a computerized system is used, copies or duplicates of all documentation should accompany each numbered sample when sent to the specific unit.\n\n14.18 Testing should be performed as described under Part three, section 17.\n\n## 15. Analytical worksheet\n\n15.1 The analytical worksheet is an internal document to be used by the analyst for recording information about the sample, the test procedure, calculations and the results of testing. It is to be complemented by the raw data obtained in the analysis.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1926, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "23e03133-78b3-4e48-8ef5-b33b9cbc2737": {"__data__": {"id_": "23e03133-78b3-4e48-8ef5-b33b9cbc2737", "embedding": null, "metadata": {"page_label": "126", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Purpose\n\n15.2 The analytical worksheet contains documentary evidence either:\n\n- to confirm that the sample being examined is in accordance with the requirements; or\n- to support an OOS result (see Part three, sections 18.1\u201318.3).\n\n# Use\n\n15.3 A separate analytical worksheet should usually be used for each numbered sample or group of samples.\n\n15.4 Analytical worksheets from different units relating to the same sample should be assembled together.\n\n# Content\n\n15.5 The analytical worksheet should provide the following information:\n\n(a) the registration number of the sample (see Part three, section 14.9);\n\n(b) page numbering, including the total number of pages (and including annexes);\n\n(c) the date of the test request;\n\n(d) the date on which the analysis was started and completed;\n\n(e) the name and signature of the analyst;\n\n(f) a description of the sample received;\n\n(g) references to the specifications and a full description of test methods by which the sample was tested, including the limits;\n\n(h) the identification of the test equipment used (see Part two, section 12.1);\n\n(i) the identification number of any reference substance used (see Part two, section 11.5);\n\n(j) if applicable, the results of the system suitability test;\n\n(k) the identification of reagents and solvents employed;\n\n(l) the results obtained;\n\n(m) the interpretation of the results and the final conclusions (whether or not the sample was found to comply with the specifications), approved and signed by the supervisor; and\n\n(n) any further comments, for example, for internal information (see Part three, section 17.1), or detailed notes on the specifications selected and the methods of assessment used (see Part three, section 15.9), or any deviation from the prescribed procedure, which should be approved and reported, or whether and when portions of the sample were forwarded to other units for special tests and the date on which the results were received.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para la elaboraci\u00f3n de hojas de trabajo anal\u00edticas en el contexto de pruebas de muestras. Se especifica que estas hojas deben contener informaci\u00f3n clave sobre la muestra, el an\u00e1lisis realizado y los resultados obtenidos. Adem\u00e1s, se enfatiza la importancia de documentar adecuadamente cada paso del proceso anal\u00edtico para asegurar la trazabilidad y la conformidad con las especificaciones.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n espec\u00edfica debe incluirse en la hoja de trabajo anal\u00edtica para garantizar la trazabilidad del an\u00e1lisis de la muestra?**\n   - Respuesta: La hoja de trabajo anal\u00edtica debe incluir el n\u00famero de registro de la muestra, la numeraci\u00f3n de p\u00e1ginas, la fecha de solicitud de prueba, las fechas de inicio y finalizaci\u00f3n del an\u00e1lisis, el nombre y firma del analista, una descripci\u00f3n de la muestra, referencias a las especificaciones y m\u00e9todos de prueba, identificaci\u00f3n del equipo de prueba, resultados obtenidos, interpretaci\u00f3n de resultados y conclusiones firmadas por el supervisor, entre otros detalles.\n\n2. **\u00bfCu\u00e1l es el prop\u00f3sito de utilizar una hoja de trabajo anal\u00edtica en el contexto de pruebas de muestras?**\n   - Respuesta: El prop\u00f3sito de la hoja de trabajo anal\u00edtica es proporcionar evidencia documental que confirme que la muestra analizada cumple con los requisitos establecidos o, en su defecto, apoyar un resultado fuera de especificaci\u00f3n (OOS).\n\n3. **\u00bfQu\u00e9 se debe hacer con las hojas de trabajo anal\u00edticas de diferentes unidades que se relacionan con la misma muestra?**\n   - Respuesta: Las hojas de trabajo anal\u00edticas de diferentes unidades que se relacionan con la misma muestra deben ser ensambladas juntas para asegurar que toda la informaci\u00f3n relevante est\u00e9 disponible y organizada en un solo lugar.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manejo de Muestras en el Laboratorio**:\n   - Proceso de inspecci\u00f3n visual de las muestras recibidas.\n   - Importancia de la conformidad entre la etiqueta de la muestra y la informaci\u00f3n de la solicitud de prueba.\n\n2. **Registro de Discrepancias**:\n   - Procedimiento para registrar discrepancias o da\u00f1os en la muestra.\n   - Necesidad de referir consultas al proveedor de la muestra.\n\n3. **Almacenamiento de Muestras**:\n   - Requisitos para el almacenamiento seguro de muestras antes de las pruebas.\n   - Consideraciones para muestras retenidas y porciones restantes despu\u00e9s de las pruebas.\n\n4. **Env\u00edo a la Unidad de Pruebas**:\n   - Determinaci\u00f3n de la unidad espec\u00edfica a la que se env\u00eda la muestra.\n   - Prohibici\u00f3n de iniciar el examen de la muestra antes de recibir la solicitud de prueba correspondiente.\n   - Almacenamiento adecuado hasta recibir toda la documentaci\u00f3n relevante.\n\n5. **Documentaci\u00f3n y Registro**:\n   - Aceptaci\u00f3n de solicitudes de an\u00e1lisis verbal solo en emergencias, con registro inmediato de los detalles.\n   - Requerimiento de copias de documentaci\u00f3n que acompa\u00f1en a cada muestra numerada.\n\n6. **Hoja de Trabajo Anal\u00edtica**:\n   - Uso de un documento interno para registrar informaci\u00f3n sobre la muestra, el procedimiento de prueba, c\u00e1lculos y resultados.\n   - Complementaci\u00f3n con datos en bruto obtenidos durante el an\u00e1lisis.\n\n### Entidades Clave:\n- **Muestra**: Elemento a ser analizado en el laboratorio.\n- **Solicitud de Prueba**: Documento que acompa\u00f1a a la muestra y contiene informaci\u00f3n relevante.\n- **Unidad de Pruebas**: Lugar al que se env\u00eda la muestra para su an\u00e1lisis.\n- **Hoja de Trabajo Anal\u00edtica**: Documento interno utilizado por el analista para registrar informaci\u00f3n del an\u00e1lisis.", "excerpt_keywords": "Keywords: analytical worksheet, sample testing, documentary evidence, compliance, laboratory procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "dc1de551-60e5-401e-80f3-a97c1c5a79f7", "node_type": "4", "metadata": {"page_label": "126", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Purpose\n\n15.2 The analytical worksheet contains documentary evidence either:\n\n- to confirm that the sample being examined is in accordance with the requirements; or\n- to support an OOS result (see Part three, sections 18.1\u201318.3).\n\n# Use\n\n15.3 A separate analytical worksheet should usually be used for each numbered sample or group of samples.\n\n15.4 Analytical worksheets from different units relating to the same sample should be assembled together.\n\n# Content\n\n15.5 The analytical worksheet should provide the following information:\n\n(a) the registration number of the sample (see Part three, section 14.9);\n\n(b) page numbering, including the total number of pages (and including annexes);\n\n(c) the date of the test request;\n\n(d) the date on which the analysis was started and completed;\n\n(e) the name and signature of the analyst;\n\n(f) a description of the sample received;\n\n(g) references to the specifications and a full description of test methods by which the sample was tested, including the limits;\n\n(h) the identification of the test equipment used (see Part two, section 12.1);\n\n(i) the identification number of any reference substance used (see Part two, section 11.5);\n\n(j) if applicable, the results of the system suitability test;\n\n(k) the identification of reagents and solvents employed;\n\n(l) the results obtained;\n\n(m) the interpretation of the results and the final conclusions (whether or not the sample was found to comply with the specifications), approved and signed by the supervisor; and\n\n(n) any further comments, for example, for internal information (see Part three, section 17.1), or detailed notes on the specifications selected and the methods of assessment used (see Part three, section 15.9), or any deviation from the prescribed procedure, which should be approved and reported, or whether and when portions of the sample were forwarded to other units for special tests and the date on which the results were received.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "d965b36ace604c276c1a3200f649a6ec0a8921a1e12763df48ca487045eba111", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Purpose\n\n15.2 The analytical worksheet contains documentary evidence either:\n\n- to confirm that the sample being examined is in accordance with the requirements; or\n- to support an OOS result (see Part three, sections 18.1\u201318.3).\n\n# Use\n\n15.3 A separate analytical worksheet should usually be used for each numbered sample or group of samples.\n\n15.4 Analytical worksheets from different units relating to the same sample should be assembled together.\n\n# Content\n\n15.5 The analytical worksheet should provide the following information:\n\n(a) the registration number of the sample (see Part three, section 14.9);\n\n(b) page numbering, including the total number of pages (and including annexes);\n\n(c) the date of the test request;\n\n(d) the date on which the analysis was started and completed;\n\n(e) the name and signature of the analyst;\n\n(f) a description of the sample received;\n\n(g) references to the specifications and a full description of test methods by which the sample was tested, including the limits;\n\n(h) the identification of the test equipment used (see Part two, section 12.1);\n\n(i) the identification number of any reference substance used (see Part two, section 11.5);\n\n(j) if applicable, the results of the system suitability test;\n\n(k) the identification of reagents and solvents employed;\n\n(l) the results obtained;\n\n(m) the interpretation of the results and the final conclusions (whether or not the sample was found to comply with the specifications), approved and signed by the supervisor; and\n\n(n) any further comments, for example, for internal information (see Part three, section 17.1), or detailed notes on the specifications selected and the methods of assessment used (see Part three, section 15.9), or any deviation from the prescribed procedure, which should be approved and reported, or whether and when portions of the sample were forwarded to other units for special tests and the date on which the results were received.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1954, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9b641b67-8a47-4665-a294-e5365972eed3": {"__data__": {"id_": "9b641b67-8a47-4665-a294-e5365972eed3", "embedding": null, "metadata": {"page_label": "127", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 15.6 \nAll values obtained from each test, including blank results, should immediately be entered on the analytical worksheet and all graphical data, whether obtained from recording instruments or plotted by hand, should be attached or be traceable to an electronic record file or document where the data are available.\n\n15.7 \nThe completed analytical worksheet should be signed by the responsible analyst(s), verified and approved and signed by the supervisor.\n\n15.8 \nWhen a mistake is made in an analytical worksheet or when data or text need to be amended, the old information should be deleted by putting a single line through it (it should not be erased or made illegible) and the new information added alongside. All such alterations should be signed by the person making the correction and the date of the change inserted. The reason for the change should also be given on the worksheet (suitable procedures should be in place for amending electronic worksheets).\n\n## Selection of the specifications to be used\n\n15.9 \nThe specification necessary to assess the sample may be that given in the test request or master production instructions. If no precise instruction is given, the specification in the officially recognized national pharmacopoeia may be used or, failing this, the manufacturer\u2019s officially approved or other nationally recognized specification. If no suitable method is available:\n\n- (a) the specification contained in the marketing authorization or product licence may be requested from the marketing authorization holder or manufacturer and verified by the laboratory; or\n- (b) the requirements may be set by the laboratory itself on the basis of published information and any procedure employed is to be validated by the testing laboratory (see Part three, section 16).\n\n15.10 \nFor official specifications the current version of the relevant pharmacopoeia should be available.\n\n## Filing\n\n15.11 \nThe analytical worksheet should be kept safely together with any attachments, including calculations and recordings of instrumental analyses.\n\n# 16. Validation of analytical procedures\n\n16.1 \nAll analytical procedures employed for testing should be suitable for the intended use. This is demonstrated by validation (24). Validation", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre la gesti\u00f3n de datos en hojas de trabajo anal\u00edticas, incluyendo la entrada de resultados, la firma y verificaci\u00f3n de documentos, la correcci\u00f3n de errores, la selecci\u00f3n de especificaciones para pruebas y la validaci\u00f3n de procedimientos anal\u00edticos. Se enfatiza la importancia de mantener registros precisos y accesibles, as\u00ed como de seguir procedimientos establecidos para la modificaci\u00f3n de datos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimiento se debe seguir si se comete un error en una hoja de trabajo anal\u00edtica?**\n   - Cuando se comete un error en una hoja de trabajo anal\u00edtica, el procedimiento correcto es tachar la informaci\u00f3n incorrecta con una l\u00ednea simple (sin borrarla o hacerla ilegible) y a\u00f1adir la nueva informaci\u00f3n al lado. Adem\u00e1s, la persona que realiza la correcci\u00f3n debe firmar y fechar el cambio, y proporcionar una raz\u00f3n para la modificaci\u00f3n.\n\n2. **\u00bfQu\u00e9 especificaciones se deben utilizar si no hay instrucciones precisas en la solicitud de prueba?**\n   - Si no hay instrucciones precisas en la solicitud de prueba, se puede utilizar la especificaci\u00f3n de la farmacopea nacional oficialmente reconocida. Si no est\u00e1 disponible, se puede solicitar la especificaci\u00f3n del titular de la autorizaci\u00f3n de comercializaci\u00f3n o establecer requisitos basados en informaci\u00f3n publicada, siempre que el procedimiento sea validado por el laboratorio de pruebas.\n\n3. **\u00bfQu\u00e9 se debe hacer con la hoja de trabajo anal\u00edtica y sus anexos una vez completados?**\n   - La hoja de trabajo anal\u00edtica debe ser guardada de manera segura junto con cualquier anexo, que incluya c\u00e1lculos y registros de an\u00e1lisis instrumentales, para asegurar que toda la informaci\u00f3n relevante est\u00e9 disponible y protegida.", "prev_section_summary": "### Temas Clave\n\n1. **Prop\u00f3sito de la Hoja de Trabajo Anal\u00edtica**: La hoja de trabajo anal\u00edtica sirve como evidencia documental para confirmar que una muestra cumple con los requisitos establecidos o para respaldar un resultado fuera de especificaci\u00f3n (OOS).\n\n2. **Uso de la Hoja de Trabajo**: Se recomienda utilizar una hoja de trabajo separada para cada muestra numerada o grupo de muestras. Adem\u00e1s, las hojas de trabajo de diferentes unidades relacionadas con la misma muestra deben ser organizadas juntas.\n\n3. **Contenido Requerido**: La hoja de trabajo anal\u00edtica debe incluir informaci\u00f3n detallada, como:\n   - N\u00famero de registro de la muestra.\n   - Numeraci\u00f3n de p\u00e1ginas y total de p\u00e1ginas.\n   - Fechas de solicitud y an\u00e1lisis.\n   - Nombre y firma del analista.\n   - Descripci\u00f3n de la muestra.\n   - Referencias a especificaciones y m\u00e9todos de prueba.\n   - Identificaci\u00f3n del equipo de prueba y sustancias de referencia.\n   - Resultados de pruebas y su interpretaci\u00f3n.\n   - Conclusiones firmadas por un supervisor.\n   - Comentarios adicionales relevantes.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable del documento.\n- **Muestra**: Elemento analizado cuyo cumplimiento con los requisitos se eval\u00faa.\n- **Analista**: Persona que realiza el an\u00e1lisis y firma la hoja de trabajo.\n- **Supervisor**: Persona que aprueba y firma las conclusiones de la hoja de trabajo.\n- **Especificaciones**: Normas y criterios que la muestra debe cumplir.\n- **Resultados**: Datos obtenidos del an\u00e1lisis que se interpretan para determinar la conformidad de la muestra.\n\nEste resumen destaca la importancia de la documentaci\u00f3n adecuada en el proceso anal\u00edtico y los elementos esenciales que deben ser registrados para asegurar la trazabilidad y la conformidad con los est\u00e1ndares establecidos.", "excerpt_keywords": "Keywords: analytical worksheet, validation, specifications, data management, corrections"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cc0e5b3a-ab53-4a5a-969e-ce685dd6ce35", "node_type": "4", "metadata": {"page_label": "127", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 15.6 \nAll values obtained from each test, including blank results, should immediately be entered on the analytical worksheet and all graphical data, whether obtained from recording instruments or plotted by hand, should be attached or be traceable to an electronic record file or document where the data are available.\n\n15.7 \nThe completed analytical worksheet should be signed by the responsible analyst(s), verified and approved and signed by the supervisor.\n\n15.8 \nWhen a mistake is made in an analytical worksheet or when data or text need to be amended, the old information should be deleted by putting a single line through it (it should not be erased or made illegible) and the new information added alongside. All such alterations should be signed by the person making the correction and the date of the change inserted. The reason for the change should also be given on the worksheet (suitable procedures should be in place for amending electronic worksheets).\n\n## Selection of the specifications to be used\n\n15.9 \nThe specification necessary to assess the sample may be that given in the test request or master production instructions. If no precise instruction is given, the specification in the officially recognized national pharmacopoeia may be used or, failing this, the manufacturer\u2019s officially approved or other nationally recognized specification. If no suitable method is available:\n\n- (a) the specification contained in the marketing authorization or product licence may be requested from the marketing authorization holder or manufacturer and verified by the laboratory; or\n- (b) the requirements may be set by the laboratory itself on the basis of published information and any procedure employed is to be validated by the testing laboratory (see Part three, section 16).\n\n15.10 \nFor official specifications the current version of the relevant pharmacopoeia should be available.\n\n## Filing\n\n15.11 \nThe analytical worksheet should be kept safely together with any attachments, including calculations and recordings of instrumental analyses.\n\n# 16. Validation of analytical procedures\n\n16.1 \nAll analytical procedures employed for testing should be suitable for the intended use. This is demonstrated by validation (24). Validation", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "1a9c2fcd46e6255ffaf57c5368e46497b3b454a271338ca242b2e1954085eb0a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 15.6 \nAll values obtained from each test, including blank results, should immediately be entered on the analytical worksheet and all graphical data, whether obtained from recording instruments or plotted by hand, should be attached or be traceable to an electronic record file or document where the data are available.\n\n15.7 \nThe completed analytical worksheet should be signed by the responsible analyst(s), verified and approved and signed by the supervisor.\n\n15.8 \nWhen a mistake is made in an analytical worksheet or when data or text need to be amended, the old information should be deleted by putting a single line through it (it should not be erased or made illegible) and the new information added alongside. All such alterations should be signed by the person making the correction and the date of the change inserted. The reason for the change should also be given on the worksheet (suitable procedures should be in place for amending electronic worksheets).\n\n## Selection of the specifications to be used\n\n15.9 \nThe specification necessary to assess the sample may be that given in the test request or master production instructions. If no precise instruction is given, the specification in the officially recognized national pharmacopoeia may be used or, failing this, the manufacturer\u2019s officially approved or other nationally recognized specification. If no suitable method is available:\n\n- (a) the specification contained in the marketing authorization or product licence may be requested from the marketing authorization holder or manufacturer and verified by the laboratory; or\n- (b) the requirements may be set by the laboratory itself on the basis of published information and any procedure employed is to be validated by the testing laboratory (see Part three, section 16).\n\n15.10 \nFor official specifications the current version of the relevant pharmacopoeia should be available.\n\n## Filing\n\n15.11 \nThe analytical worksheet should be kept safely together with any attachments, including calculations and recordings of instrumental analyses.\n\n# 16. Validation of analytical procedures\n\n16.1 \nAll analytical procedures employed for testing should be suitable for the intended use. This is demonstrated by validation (24). Validation", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2254, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "841333a0-eeea-4304-91a8-6f50cdf48e30": {"__data__": {"id_": "841333a0-eeea-4304-91a8-6f50cdf48e30", "embedding": null, "metadata": {"page_label": "128", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "16.2 Validation should be performed according to a validation protocol, which includes analytical performance characteristics to be verified for various types of analytical procedures. Typical characteristics which should be considered are listed in Table 1 (in the development phase of an analytical procedure, robustness, i.e. the ability of the procedure to provide results of acceptable accuracy and precision under a variety of conditions should also be considered). The results are to be documented in the validation report.\n\n**Table 1**  \nCharacteristics to consider during validation of analytical procedures\n\n| Type of analytical Procedure\\<br/>Quantitative tests | Identification\\<br/>Limit tests | Testing for impurities | Testing for impurities\\<br/>Assay | |\n| - | - | - | - | - |\n| Characteristics | | | | dissolution (measurement only) content/potency |\n| Accuracy | \u2013 | + | \u2013 | + |\n| Precision | | | | |\n| Repeatability | \u2013 | + | \u2013 | + |\n| Intermediate precisiona | \u2013 | + | \u2013 | + |\n| Specificity | + | + | + | + |\n| Detection limit | \u2013 | \u2013b | + | \u2013 |\n| Quantitation limit | \u2013 | + | \u2013 | \u2013 |\n| Linearity | \u2013 | + | \u2013 | + |\n| Range | \u2013 | + | \u2013 | + |\n\n\n\u2013 Characteristic is normally not evaluated; + characteristic should normally be evaluated.  \n<sup>a</sup> In cases where a reproducibility study has been performed, intermediate precision is not needed.  \n<sup>b</sup> May be needed in some cases.\n\n16.3 Pharmacopoeial methods are considered to be validated for the intended use as prescribed in the monograph(s). However, the laboratory should also confirm that, for example, for a particular finished pharmaceutical product (FPP) examined for the first time, no interference arises from the excipients present, or that for an API, impurities coming from a new route of synthesis are adequately differentiated. If the pharmacopoeial method is adapted for another use then it should be validated for such a use to demonstrate that it is fit-for-purpose.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la validaci\u00f3n de procedimientos anal\u00edticos en el contexto de la farmacolog\u00eda. Se enfatiza la importancia de seguir un protocolo de validaci\u00f3n que incluya caracter\u00edsticas de rendimiento anal\u00edtico, como precisi\u00f3n, exactitud y especificidad. Se presenta una tabla que detalla las caracter\u00edsticas a considerar durante la validaci\u00f3n de diferentes tipos de procedimientos anal\u00edticos. Adem\u00e1s, se menciona que los m\u00e9todos farmacop\u00e9icos son considerados validados para su uso previsto, pero es necesario confirmar su aplicabilidad en situaciones espec\u00edficas, como la evaluaci\u00f3n de productos farmac\u00e9uticos terminados o la adaptaci\u00f3n de m\u00e9todos para nuevos usos.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas anal\u00edticas que deben ser evaluadas durante la validaci\u00f3n de procedimientos anal\u00edticos seg\u00fan la tabla presentada en el documento?**\n   - Respuesta: La tabla enumera caracter\u00edsticas como precisi\u00f3n, exactitud, especificidad, l\u00edmite de detecci\u00f3n, l\u00edmite de cuantificaci\u00f3n, linealidad y rango, indicando cu\u00e1les deben ser evaluadas para diferentes tipos de procedimientos anal\u00edticos.\n\n2. **\u00bfQu\u00e9 se debe hacer si un m\u00e9todo farmacop\u00e9ico se adapta para un uso diferente al que fue originalmente validado?**\n   - Respuesta: Si un m\u00e9todo farmacop\u00e9ico se adapta para otro uso, debe ser validado para ese nuevo uso para demostrar que es adecuado para el prop\u00f3sito previsto.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al validar un m\u00e9todo para un producto farmac\u00e9utico terminado (FPP) por primera vez?**\n   - Respuesta: El laboratorio debe confirmar que no hay interferencias de los excipientes presentes en el FPP examinado por primera vez, y que las impurezas provenientes de una nueva ruta de s\u00edntesis para un principio activo (API) est\u00e1n adecuadamente diferenciadas.", "prev_section_summary": "### Temas Clave\n\n1. **Registro de Datos**: Se enfatiza la importancia de ingresar inmediatamente todos los resultados de las pruebas en la hoja de trabajo anal\u00edtica, incluyendo datos gr\u00e1ficos que deben ser adjuntados o ser rastreables a un archivo electr\u00f3nico.\n\n2. **Firma y Verificaci\u00f3n**: La hoja de trabajo anal\u00edtica completada debe ser firmada por el analista responsable y verificada y aprobada por un supervisor.\n\n3. **Correcci\u00f3n de Errores**: Se establece un procedimiento espec\u00edfico para corregir errores en la hoja de trabajo, que incluye tachar la informaci\u00f3n incorrecta y a\u00f1adir la nueva informaci\u00f3n, junto con la firma y fecha del responsable de la correcci\u00f3n.\n\n4. **Selecci\u00f3n de Especificaciones**: Se detalla c\u00f3mo seleccionar las especificaciones necesarias para evaluar una muestra, incluyendo el uso de farmacopeas nacionales reconocidas o especificaciones aprobadas por el fabricante.\n\n5. **Archivo de Documentos**: Se requiere que la hoja de trabajo anal\u00edtica y sus anexos se mantengan de manera segura para asegurar la disponibilidad y protecci\u00f3n de la informaci\u00f3n.\n\n6. **Validaci\u00f3n de Procedimientos Anal\u00edticos**: Se menciona que todos los procedimientos anal\u00edticos deben ser adecuados para su uso previsto y deben ser validados.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Analista(s)**: Persona(s) responsable(s) de realizar las pruebas y completar la hoja de trabajo.\n- **Supervisor**: Persona que verifica y aprueba la hoja de trabajo anal\u00edtica.\n- **Farmacopea Nacional**: Documento oficial que contiene especificaciones para pruebas.\n- **Titular de la Autorizaci\u00f3n de Comercializaci\u00f3n**: Entidad que puede proporcionar especificaciones cuando no hay instrucciones precisas.\n- **Laboratorio de Pruebas**: Entidad responsable de validar los procedimientos anal\u00edticos.\n\n### Resumen\nEl documento de la OMS proporciona directrices sobre la gesti\u00f3n de datos en hojas de trabajo anal\u00edticas, incluyendo la entrada de resultados, la firma y verificaci\u00f3n de documentos, la correcci\u00f3n de errores, la selecci\u00f3n de especificaciones para pruebas y la validaci\u00f3n de procedimientos anal\u00edticos. Se destaca la necesidad de mantener registros precisos y accesibles, as\u00ed como seguir procedimientos establecidos para la modificaci\u00f3n de datos.", "excerpt_keywords": "Keywords: validation, analytical procedures, pharmacopoeial methods, performance characteristics, pharmaceutical products"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d05834e0-82cd-4958-b0e8-bc40fe8d119d", "node_type": "4", "metadata": {"page_label": "128", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "16.2 Validation should be performed according to a validation protocol, which includes analytical performance characteristics to be verified for various types of analytical procedures. Typical characteristics which should be considered are listed in Table 1 (in the development phase of an analytical procedure, robustness, i.e. the ability of the procedure to provide results of acceptable accuracy and precision under a variety of conditions should also be considered). The results are to be documented in the validation report.\n\n**Table 1**  \nCharacteristics to consider during validation of analytical procedures\n\n| Type of analytical Procedure\\<br/>Quantitative tests | Identification\\<br/>Limit tests | Testing for impurities | Testing for impurities\\<br/>Assay | |\n| - | - | - | - | - |\n| Characteristics | | | | dissolution (measurement only) content/potency |\n| Accuracy | \u2013 | + | \u2013 | + |\n| Precision | | | | |\n| Repeatability | \u2013 | + | \u2013 | + |\n| Intermediate precisiona | \u2013 | + | \u2013 | + |\n| Specificity | + | + | + | + |\n| Detection limit | \u2013 | \u2013b | + | \u2013 |\n| Quantitation limit | \u2013 | + | \u2013 | \u2013 |\n| Linearity | \u2013 | + | \u2013 | + |\n| Range | \u2013 | + | \u2013 | + |\n\n\n\u2013 Characteristic is normally not evaluated; + characteristic should normally be evaluated.  \n<sup>a</sup> In cases where a reproducibility study has been performed, intermediate precision is not needed.  \n<sup>b</sup> May be needed in some cases.\n\n16.3 Pharmacopoeial methods are considered to be validated for the intended use as prescribed in the monograph(s). However, the laboratory should also confirm that, for example, for a particular finished pharmaceutical product (FPP) examined for the first time, no interference arises from the excipients present, or that for an API, impurities coming from a new route of synthesis are adequately differentiated. If the pharmacopoeial method is adapted for another use then it should be validated for such a use to demonstrate that it is fit-for-purpose.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "9af6b7b0d4a49cf976e80ecef096b6d3c589039fab259b43f76960d342dffa27", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "16.2 Validation should be performed according to a validation protocol, which includes analytical performance characteristics to be verified for various types of analytical procedures. Typical characteristics which should be considered are listed in Table 1 (in the development phase of an analytical procedure, robustness, i.e. the ability of the procedure to provide results of acceptable accuracy and precision under a variety of conditions should also be considered). The results are to be documented in the validation report.\n\n**Table 1**  \nCharacteristics to consider during validation of analytical procedures\n\n| Type of analytical Procedure\\<br/>Quantitative tests | Identification\\<br/>Limit tests | Testing for impurities | Testing for impurities\\<br/>Assay | |\n| - | - | - | - | - |\n| Characteristics | | | | dissolution (measurement only) content/potency |\n| Accuracy | \u2013 | + | \u2013 | + |\n| Precision | | | | |\n| Repeatability | \u2013 | + | \u2013 | + |\n| Intermediate precisiona | \u2013 | + | \u2013 | + |\n| Specificity | + | + | + | + |\n| Detection limit | \u2013 | \u2013b | + | \u2013 |\n| Quantitation limit | \u2013 | + | \u2013 | \u2013 |\n| Linearity | \u2013 | + | \u2013 | + |\n| Range | \u2013 | + | \u2013 | + |\n\n\n\u2013 Characteristic is normally not evaluated; + characteristic should normally be evaluated.  \n<sup>a</sup> In cases where a reproducibility study has been performed, intermediate precision is not needed.  \n<sup>b</sup> May be needed in some cases.\n\n16.3 Pharmacopoeial methods are considered to be validated for the intended use as prescribed in the monograph(s). However, the laboratory should also confirm that, for example, for a particular finished pharmaceutical product (FPP) examined for the first time, no interference arises from the excipients present, or that for an API, impurities coming from a new route of synthesis are adequately differentiated. If the pharmacopoeial method is adapted for another use then it should be validated for such a use to demonstrate that it is fit-for-purpose.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1966, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c67d8fe6-8c9d-47fb-91a6-11015fb7b6a0": {"__data__": {"id_": "c67d8fe6-8c9d-47fb-91a6-11015fb7b6a0", "embedding": null, "metadata": {"page_label": "129", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 16.4\n\nSystem suitability testing is an integral part of many analytical procedures. The tests are based on the fact that the equipment, electronics, analytical operations and samples to be analysed contribute to the system. Which system suitability tests are to be applied depends on the type of procedure to be used. System suitability tests are employed for the verification of pharmacopoeial methods or validated analytical procedures and should be performed prior to the analysis. Provided the system suitability criteria are fulfilled the method or procedure is considered to be suitable for the intended purpose.\n\n*Note:* If a large number of samples is being analysed in sequence, then appropriate system suitability tests are to be performed throughout the sequence to demonstrate that the performance of the procedure is satisfactory.\n\nVerification is not required for basic pharmacopoeial methods such as (but not limited to) pH, loss on drying and wet chemical methods.\n\n## 16.5\n\nA major change to the analytical procedure, or in the composition of the product tested, or in the synthesis of the API, will require revalidation of the analytical procedure.\n\n*Note:* Further guidance on validation of analytical procedures is available in the following:\n\n- *Guideline elaborated by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (25);*\n- *Guideline elaborated by the European Network of Official Medicines Control Laboratories (OMCL) (26);*\n- *General chapters of the US Pharmacopeia on Validation of compendial procedures and on Verification of compendial procedures (27).*\n\n# 17. Testing\n\n## 17.1\n\nThe sample should be tested in accordance with the work plan of the laboratory after completion of the preliminary procedures. If this is not feasible the reasons should be noted, e.g. in the analytical worksheet (see Part three, section 15), and the sample should be stored in a special place which is kept locked (see Part three, section 14.12).\n\n## 17.2\n\nSpecific tests required may need to be carried out by another unit or by a specialized external laboratory (see Part one, section 9). The responsible person should prepare the request and arrange for the", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto aborda la importancia de las pruebas de idoneidad del sistema en procedimientos anal\u00edticos, destacando que estas pruebas son esenciales para verificar m\u00e9todos farmacopoeiales y procedimientos anal\u00edticos validados. Se menciona que las pruebas deben realizarse antes del an\u00e1lisis y que, si se analizan muchos muestras en secuencia, se deben realizar pruebas de idoneidad a lo largo de la secuencia. Adem\u00e1s, se indica que cualquier cambio significativo en el procedimiento anal\u00edtico o en la composici\u00f3n del producto requiere una revalidaci\u00f3n. Tambi\u00e9n se menciona que las muestras deben ser probadas de acuerdo con el plan de trabajo del laboratorio y que algunas pruebas espec\u00edficas pueden requerir la intervenci\u00f3n de laboratorios externos.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 criterios deben cumplirse para considerar que un m\u00e9todo anal\u00edtico es adecuado para su prop\u00f3sito?**\n   - La respuesta se puede encontrar en la secci\u00f3n sobre pruebas de idoneidad del sistema, donde se menciona que si se cumplen los criterios de idoneidad del sistema, el m\u00e9todo o procedimiento se considera adecuado para el prop\u00f3sito previsto.\n\n2. **\u00bfCu\u00e1les son las implicaciones de un cambio mayor en el procedimiento anal\u00edtico o en la composici\u00f3n del producto en t\u00e9rminos de validaci\u00f3n?**\n   - El texto indica que un cambio significativo en el procedimiento anal\u00edtico, la composici\u00f3n del producto o la s\u00edntesis del API requiere una revalidaci\u00f3n del procedimiento anal\u00edtico.\n\n3. **\u00bfQu\u00e9 pasos deben seguirse si no es factible probar una muestra de acuerdo con el plan de trabajo del laboratorio?**\n   - Si no es factible probar la muestra, se deben anotar las razones en la hoja de trabajo anal\u00edtica y la muestra debe ser almacenada en un lugar especial que est\u00e9 cerrado con llave.", "prev_section_summary": "### Temas Clave\n1. **Validaci\u00f3n de Procedimientos Anal\u00edticos**: Se establece la necesidad de seguir un protocolo de validaci\u00f3n que incluya caracter\u00edsticas de rendimiento anal\u00edtico para diferentes tipos de procedimientos anal\u00edticos.\n  \n2. **Caracter\u00edsticas Anal\u00edticas**: Se enumeran caracter\u00edsticas importantes a considerar durante la validaci\u00f3n, como precisi\u00f3n, exactitud, especificidad, l\u00edmite de detecci\u00f3n, l\u00edmite de cuantificaci\u00f3n, linealidad y rango.\n\n3. **M\u00e9todos Farmacop\u00e9icos**: Se considera que estos m\u00e9todos est\u00e1n validados para su uso previsto, pero se requiere confirmaci\u00f3n adicional para situaciones espec\u00edficas, como la evaluaci\u00f3n de productos farmac\u00e9uticos terminados o la adaptaci\u00f3n de m\u00e9todos para nuevos usos.\n\n4. **Interferencia de Excipientes**: Es crucial verificar que no haya interferencias de excipientes en productos farmac\u00e9uticos examinados por primera vez.\n\n5. **Diferenciaci\u00f3n de Impurezas**: Se debe asegurar que las impurezas de nuevas rutas de s\u00edntesis sean adecuadamente diferenciadas.\n\n### Entidades\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Procedimientos Anal\u00edticos**: M\u00e9todos utilizados para analizar productos farmac\u00e9uticos.\n- **Caracter\u00edsticas Anal\u00edticas**: Par\u00e1metros como precisi\u00f3n, exactitud, especificidad, etc.\n- **M\u00e9todos Farmacop\u00e9icos**: M\u00e9todos estandarizados para el an\u00e1lisis de productos farmac\u00e9uticos.\n- **Producto Farmac\u00e9utico Terminado (FPP)**: Producto final que se eval\u00faa por primera vez.\n- **Principio Activo (API)**: Sustancia activa en un producto farmac\u00e9utico que puede tener impurezas. \n\nEste resumen destaca la importancia de la validaci\u00f3n en el contexto anal\u00edtico y las consideraciones espec\u00edficas que deben tenerse en cuenta para asegurar la calidad y la eficacia de los m\u00e9todos utilizados en la industria farmac\u00e9utica.", "excerpt_keywords": "System suitability, analytical procedures, validation, pharmacopoeial methods, testing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a68bef5b-0b3d-4d4b-a151-250189beec81", "node_type": "4", "metadata": {"page_label": "129", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 16.4\n\nSystem suitability testing is an integral part of many analytical procedures. The tests are based on the fact that the equipment, electronics, analytical operations and samples to be analysed contribute to the system. Which system suitability tests are to be applied depends on the type of procedure to be used. System suitability tests are employed for the verification of pharmacopoeial methods or validated analytical procedures and should be performed prior to the analysis. Provided the system suitability criteria are fulfilled the method or procedure is considered to be suitable for the intended purpose.\n\n*Note:* If a large number of samples is being analysed in sequence, then appropriate system suitability tests are to be performed throughout the sequence to demonstrate that the performance of the procedure is satisfactory.\n\nVerification is not required for basic pharmacopoeial methods such as (but not limited to) pH, loss on drying and wet chemical methods.\n\n## 16.5\n\nA major change to the analytical procedure, or in the composition of the product tested, or in the synthesis of the API, will require revalidation of the analytical procedure.\n\n*Note:* Further guidance on validation of analytical procedures is available in the following:\n\n- *Guideline elaborated by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (25);*\n- *Guideline elaborated by the European Network of Official Medicines Control Laboratories (OMCL) (26);*\n- *General chapters of the US Pharmacopeia on Validation of compendial procedures and on Verification of compendial procedures (27).*\n\n# 17. Testing\n\n## 17.1\n\nThe sample should be tested in accordance with the work plan of the laboratory after completion of the preliminary procedures. If this is not feasible the reasons should be noted, e.g. in the analytical worksheet (see Part three, section 15), and the sample should be stored in a special place which is kept locked (see Part three, section 14.12).\n\n## 17.2\n\nSpecific tests required may need to be carried out by another unit or by a specialized external laboratory (see Part one, section 9). The responsible person should prepare the request and arrange for the", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "bc4242d9a76daf12d381eb743db84258c92d81893abd1eebc6e6c3093fe67b5c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 16.4\n\nSystem suitability testing is an integral part of many analytical procedures. The tests are based on the fact that the equipment, electronics, analytical operations and samples to be analysed contribute to the system. Which system suitability tests are to be applied depends on the type of procedure to be used. System suitability tests are employed for the verification of pharmacopoeial methods or validated analytical procedures and should be performed prior to the analysis. Provided the system suitability criteria are fulfilled the method or procedure is considered to be suitable for the intended purpose.\n\n*Note:* If a large number of samples is being analysed in sequence, then appropriate system suitability tests are to be performed throughout the sequence to demonstrate that the performance of the procedure is satisfactory.\n\nVerification is not required for basic pharmacopoeial methods such as (but not limited to) pH, loss on drying and wet chemical methods.\n\n## 16.5\n\nA major change to the analytical procedure, or in the composition of the product tested, or in the synthesis of the API, will require revalidation of the analytical procedure.\n\n*Note:* Further guidance on validation of analytical procedures is available in the following:\n\n- *Guideline elaborated by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (25);*\n- *Guideline elaborated by the European Network of Official Medicines Control Laboratories (OMCL) (26);*\n- *General chapters of the US Pharmacopeia on Validation of compendial procedures and on Verification of compendial procedures (27).*\n\n# 17. Testing\n\n## 17.1\n\nThe sample should be tested in accordance with the work plan of the laboratory after completion of the preliminary procedures. If this is not feasible the reasons should be noted, e.g. in the analytical worksheet (see Part three, section 15), and the sample should be stored in a special place which is kept locked (see Part three, section 14.12).\n\n## 17.2\n\nSpecific tests required may need to be carried out by another unit or by a specialized external laboratory (see Part one, section 9). The responsible person should prepare the request and arrange for the", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2253, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6cadbf65-61f4-47f3-8876-cc2fcfda3040": {"__data__": {"id_": "6cadbf65-61f4-47f3-8876-cc2fcfda3040", "embedding": null, "metadata": {"page_label": "130", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Evaluation of Test Results\n\n18.1 Test results should be reviewed and, where appropriate, evaluated statistically after completion of all the tests to determine whether they are mutually consistent and if they meet the specifications used. The evaluation should take into consideration the results of all the tests (all test data). Whenever doubtful (atypical) results are obtained they should be investigated. The complete testing procedure needs to be checked according to the internal quality management system (see also Part one, section 2).\n\n18.2 When a doubtful result (suspected OOS result) has been identified, a review of the different procedures applied during the testing process is to be undertaken by the supervisor with the analyst or technician before retesting is permitted. The following steps should be followed:\n\n- (a) confirm with the analyst or technician that the appropriate procedure(s) was (were) applied and followed correctly;\n- (b) examine the raw data to identify possible discrepancies;\n- (c) check all calculations;\n- (d) check that the equipment used was qualified and calibrated, and that system suitability tests were performed and were acceptable;\n- (e) ensure that the appropriate reagents, solvents and reference substances were used;\n- (f) confirm that the correct glassware was used; and\n- (g) ensure that original sample preparations are not discarded until the investigation is complete.\n\n18.3 The identification of an error which caused an aberrant result will invalidate the result and a retest of the sample will be necessary.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto se centra en la evaluaci\u00f3n de resultados de pruebas en un contexto de control de calidad. Se enfatiza la importancia de revisar y evaluar estad\u00edsticamente los resultados de las pruebas para asegurar su consistencia y conformidad con las especificaciones. En caso de obtener resultados dudosos o at\u00edpicos, se deben seguir procedimientos espec\u00edficos para investigar y validar los resultados antes de proceder con un nuevo an\u00e1lisis. Se detallan pasos espec\u00edficos que deben ser seguidos por el supervisor y el analista para asegurar la integridad del proceso de prueba.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos que deben seguirse para investigar un resultado dudoso antes de realizar un nuevo an\u00e1lisis?**\n   - Esta pregunta se centra en los procedimientos detallados que deben ser seguidos, que incluyen la confirmaci\u00f3n de procedimientos, la revisi\u00f3n de datos y c\u00e1lculos, y la verificaci\u00f3n del equipo utilizado.\n\n2. **\u00bfQu\u00e9 criterios se deben considerar al evaluar si los resultados de las pruebas son mutuamente consistentes?**\n   - Esta pregunta busca profundizar en los criterios estad\u00edsticos y de calidad que se deben aplicar al revisar los resultados de las pruebas, lo cual no se detalla expl\u00edcitamente en el texto.\n\n3. **\u00bfQu\u00e9 implicaciones tiene la identificaci\u00f3n de un error que causa un resultado aberrante en el proceso de pruebas?**\n   - Esta pregunta se enfoca en las consecuencias de encontrar un error en el proceso de prueba, espec\u00edficamente en c\u00f3mo afecta la validez del resultado y la necesidad de realizar un nuevo an\u00e1lisis.", "prev_section_summary": "### Temas Clave\n\n1. **Pruebas de Idoneidad del Sistema**: Son esenciales en procedimientos anal\u00edticos para verificar m\u00e9todos farmacopoeiales y procedimientos anal\u00edticos validados. Deben realizarse antes del an\u00e1lisis y, si se analizan muchas muestras en secuencia, a lo largo de esta.\n\n2. **Criterios de Idoneidad**: Un m\u00e9todo se considera adecuado para su prop\u00f3sito si se cumplen los criterios de idoneidad del sistema.\n\n3. **Revalidaci\u00f3n**: Cualquier cambio significativo en el procedimiento anal\u00edtico, la composici\u00f3n del producto o la s\u00edntesis del API requiere revalidaci\u00f3n del procedimiento anal\u00edtico.\n\n4. **Procedimientos de Prueba**: Las muestras deben ser probadas seg\u00fan el plan de trabajo del laboratorio. Si no es factible, se deben documentar las razones y almacenar la muestra en un lugar seguro.\n\n5. **Intervenci\u00f3n de Laboratorios Externos**: Algunas pruebas espec\u00edficas pueden requerir la realizaci\u00f3n por parte de otra unidad o un laboratorio externo especializado.\n\n### Entidades\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el documento.\n- **ICH (International Conference on Harmonisation)**: Proporciona directrices sobre validaci\u00f3n de procedimientos anal\u00edticos.\n- **OMCL (European Network of Official Medicines Control Laboratories)**: Ofrece directrices relacionadas con el control de medicamentos.\n- **US Pharmacopeia**: Proporciona cap\u00edtulos generales sobre validaci\u00f3n y verificaci\u00f3n de procedimientos farmacopoeiales. \n\nEste resumen destaca la importancia de las pruebas de idoneidad y la necesidad de seguir procedimientos adecuados en el an\u00e1lisis de muestras, as\u00ed como las implicaciones de los cambios en los procedimientos anal\u00edticos.", "excerpt_keywords": "Keywords: evaluation, test results, quality management, statistical analysis, retesting"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "44b0a1fa-e059-497e-8ac6-a7d52ece28f1", "node_type": "4", "metadata": {"page_label": "130", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Evaluation of Test Results\n\n18.1 Test results should be reviewed and, where appropriate, evaluated statistically after completion of all the tests to determine whether they are mutually consistent and if they meet the specifications used. The evaluation should take into consideration the results of all the tests (all test data). Whenever doubtful (atypical) results are obtained they should be investigated. The complete testing procedure needs to be checked according to the internal quality management system (see also Part one, section 2).\n\n18.2 When a doubtful result (suspected OOS result) has been identified, a review of the different procedures applied during the testing process is to be undertaken by the supervisor with the analyst or technician before retesting is permitted. The following steps should be followed:\n\n- (a) confirm with the analyst or technician that the appropriate procedure(s) was (were) applied and followed correctly;\n- (b) examine the raw data to identify possible discrepancies;\n- (c) check all calculations;\n- (d) check that the equipment used was qualified and calibrated, and that system suitability tests were performed and were acceptable;\n- (e) ensure that the appropriate reagents, solvents and reference substances were used;\n- (f) confirm that the correct glassware was used; and\n- (g) ensure that original sample preparations are not discarded until the investigation is complete.\n\n18.3 The identification of an error which caused an aberrant result will invalidate the result and a retest of the sample will be necessary.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a725734eecee12c06c8742ed234a23961712d88b0389318ae65df9f0eaaf11ca", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Evaluation of Test Results\n\n18.1 Test results should be reviewed and, where appropriate, evaluated statistically after completion of all the tests to determine whether they are mutually consistent and if they meet the specifications used. The evaluation should take into consideration the results of all the tests (all test data). Whenever doubtful (atypical) results are obtained they should be investigated. The complete testing procedure needs to be checked according to the internal quality management system (see also Part one, section 2).\n\n18.2 When a doubtful result (suspected OOS result) has been identified, a review of the different procedures applied during the testing process is to be undertaken by the supervisor with the analyst or technician before retesting is permitted. The following steps should be followed:\n\n- (a) confirm with the analyst or technician that the appropriate procedure(s) was (were) applied and followed correctly;\n- (b) examine the raw data to identify possible discrepancies;\n- (c) check all calculations;\n- (d) check that the equipment used was qualified and calibrated, and that system suitability tests were performed and were acceptable;\n- (e) ensure that the appropriate reagents, solvents and reference substances were used;\n- (f) confirm that the correct glassware was used; and\n- (g) ensure that original sample preparations are not discarded until the investigation is complete.\n\n18.3 The identification of an error which caused an aberrant result will invalidate the result and a retest of the sample will be necessary.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1571, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a82a84d5-38ea-498a-8d25-e76ab1bff7ed": {"__data__": {"id_": "a82a84d5-38ea-498a-8d25-e76ab1bff7ed", "embedding": null, "metadata": {"page_label": "131", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Doubtful results can be rejected only if they are clearly due to an identified error. Sometimes the outcome of the investigation is inconclusive \u2014 no obvious cause can be identified \u2014 in which case a confirmatory determination is to be performed by another analyst who should be at least as experienced and competent in the analytical procedure as the original analyst. A similar value would indicate an OOS result. However, further confirmation using another validated method, if available, may be advised.\n\n18.4 An SOP should be in place for the conduct of an investigation of an OOS test result. The SOP should give clear guidance on the number of retests allowed (based on sound statistical principles). All investigations and their conclusions should be recorded. In the event of an error, any corrective action taken and any preventive measure introduced should be recorded and implemented.\n\n18.5 All individual results (all test data) with acceptance criteria should be reported.\n\n18.6 All conclusions should be entered on the analytical worksheet (see Part three, section 15) by the analyst and signed by the supervisor.\n\n*Note:* Further guidance on evaluation and reporting of test results is available in the following:\n\n- *Guideline elaborated by the US Food and Drug Administration (5);*\n- *Guideline elaborated by the European Network of Official Medicines Control Laboratories (OMCL) (28).*\n\n## Analytical test report\n\n18.7 The analytical test report is a compilation of the results and states the conclusions of the examination of a sample. It should be:\n\n(a) issued by the laboratory; and  \n(b) based on the analytical worksheet (see Part three, section 15).\n\n18.8 Any amendments to the original analytical test report will require the issue of a new corrected document.\n\n18.9 Pharmacopoeial content limits are set taking into account the uncertainty of measurement, and the production capability and acceptance criteria for an analytical result should be predefined. Under presently applicable rules neither the pharmacopoeias nor the NMRAs require the value found to be expressed with its associated expanded uncertainty for compliance testing. However, when reporting the results of investigative testing, although the primary objective is to identify a substance in the sample, a determination of", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS detalla los procedimientos y directrices para la investigaci\u00f3n de resultados fuera de especificaci\u00f3n (OOS) en pruebas anal\u00edticas. Se enfatiza la importancia de tener un Procedimiento Operativo Est\u00e1ndar (SOP) para guiar las investigaciones, la necesidad de registrar todas las conclusiones y acciones correctivas, y la forma en que deben ser reportados los resultados anal\u00edticos. Tambi\u00e9n se menciona que los l\u00edmites de contenido farmacop\u00e9ico deben considerar la incertidumbre de medici\u00f3n y que las enmiendas a los informes de prueba deben ser documentadas adecuadamente.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse si un resultado anal\u00edtico es considerado dudoso y no se puede identificar una causa obvia?**\n   - La investigaci\u00f3n debe ser realizada por otro analista que tenga al menos la misma experiencia y competencia en el procedimiento anal\u00edtico. Adem\u00e1s, se puede aconsejar una confirmaci\u00f3n adicional utilizando otro m\u00e9todo validado, si est\u00e1 disponible.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en un informe de prueba anal\u00edtica seg\u00fan el documento?**\n   - El informe debe compilar los resultados y las conclusiones de la evaluaci\u00f3n de una muestra, debe ser emitido por el laboratorio y basarse en la hoja de trabajo anal\u00edtica. Cualquier enmienda al informe original requerir\u00e1 la emisi\u00f3n de un nuevo documento corregido.\n\n3. **\u00bfC\u00f3mo se deben manejar los resultados individuales de las pruebas en relaci\u00f3n con los criterios de aceptaci\u00f3n?**\n   - Todos los resultados individuales (todos los datos de prueba) deben ser reportados junto con sus criterios de aceptaci\u00f3n, y todas las conclusiones deben ser registradas en la hoja de trabajo anal\u00edtica y firmadas por el supervisor.", "prev_section_summary": "### Temas Clave\n\n1. **Evaluaci\u00f3n de Resultados de Pruebas**: Se enfatiza la importancia de revisar y evaluar estad\u00edsticamente los resultados de las pruebas para asegurar su consistencia y conformidad con las especificaciones establecidas.\n\n2. **Resultados Dudosos**: Se establece un procedimiento claro para investigar resultados at\u00edpicos o dudosos, asegurando que se sigan pasos espec\u00edficos antes de proceder con un nuevo an\u00e1lisis.\n\n3. **Control de Calidad**: La necesidad de verificar que todos los procedimientos de prueba se realicen de acuerdo con el sistema de gesti\u00f3n de calidad interno.\n\n4. **Revisi\u00f3n de Procedimientos**: Se requiere una revisi\u00f3n exhaustiva de los procedimientos aplicados durante el proceso de prueba en caso de resultados dudosos, involucrando al supervisor y al analista o t\u00e9cnico.\n\n5. **Consecuencias de Errores**: La identificaci\u00f3n de un error que causa un resultado aberrante invalida dicho resultado, lo que implica la necesidad de realizar un nuevo an\u00e1lisis.\n\n### Entidades\n\n- **Resultados de Pruebas**: Datos obtenidos de las pruebas que deben ser evaluados.\n- **Procedimientos de Prueba**: M\u00e9todos y protocolos que deben seguirse durante el an\u00e1lisis.\n- **Analista/T\u00e9cnico**: Personal responsable de realizar las pruebas y an\u00e1lisis.\n- **Supervisor**: Persona encargada de revisar y validar los procedimientos y resultados.\n- **Sistema de Gesti\u00f3n de Calidad**: Estructura que asegura que los procesos de prueba se realicen de manera adecuada y conforme a las normas.\n- **Equipos y Materiales**: Herramientas y sustancias utilizadas en las pruebas, que deben ser verificadas para asegurar su calidad y adecuaci\u00f3n. \n\nEste resumen destaca la importancia de la evaluaci\u00f3n rigurosa de los resultados de pruebas y los procedimientos necesarios para garantizar la validez de los mismos en un contexto de control de calidad.", "excerpt_keywords": "Keywords: OOS results, analytical test report, SOP, quality control, measurement uncertainty"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7edf1f0b-3701-4e4c-bb65-aa4fefdb784a", "node_type": "4", "metadata": {"page_label": "131", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Doubtful results can be rejected only if they are clearly due to an identified error. Sometimes the outcome of the investigation is inconclusive \u2014 no obvious cause can be identified \u2014 in which case a confirmatory determination is to be performed by another analyst who should be at least as experienced and competent in the analytical procedure as the original analyst. A similar value would indicate an OOS result. However, further confirmation using another validated method, if available, may be advised.\n\n18.4 An SOP should be in place for the conduct of an investigation of an OOS test result. The SOP should give clear guidance on the number of retests allowed (based on sound statistical principles). All investigations and their conclusions should be recorded. In the event of an error, any corrective action taken and any preventive measure introduced should be recorded and implemented.\n\n18.5 All individual results (all test data) with acceptance criteria should be reported.\n\n18.6 All conclusions should be entered on the analytical worksheet (see Part three, section 15) by the analyst and signed by the supervisor.\n\n*Note:* Further guidance on evaluation and reporting of test results is available in the following:\n\n- *Guideline elaborated by the US Food and Drug Administration (5);*\n- *Guideline elaborated by the European Network of Official Medicines Control Laboratories (OMCL) (28).*\n\n## Analytical test report\n\n18.7 The analytical test report is a compilation of the results and states the conclusions of the examination of a sample. It should be:\n\n(a) issued by the laboratory; and  \n(b) based on the analytical worksheet (see Part three, section 15).\n\n18.8 Any amendments to the original analytical test report will require the issue of a new corrected document.\n\n18.9 Pharmacopoeial content limits are set taking into account the uncertainty of measurement, and the production capability and acceptance criteria for an analytical result should be predefined. Under presently applicable rules neither the pharmacopoeias nor the NMRAs require the value found to be expressed with its associated expanded uncertainty for compliance testing. However, when reporting the results of investigative testing, although the primary objective is to identify a substance in the sample, a determination of", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "628211ea4b956f57992a993952b9d59e648a2f37fd3b5c9fde11c29157e887b2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Doubtful results can be rejected only if they are clearly due to an identified error. Sometimes the outcome of the investigation is inconclusive \u2014 no obvious cause can be identified \u2014 in which case a confirmatory determination is to be performed by another analyst who should be at least as experienced and competent in the analytical procedure as the original analyst. A similar value would indicate an OOS result. However, further confirmation using another validated method, if available, may be advised.\n\n18.4 An SOP should be in place for the conduct of an investigation of an OOS test result. The SOP should give clear guidance on the number of retests allowed (based on sound statistical principles). All investigations and their conclusions should be recorded. In the event of an error, any corrective action taken and any preventive measure introduced should be recorded and implemented.\n\n18.5 All individual results (all test data) with acceptance criteria should be reported.\n\n18.6 All conclusions should be entered on the analytical worksheet (see Part three, section 15) by the analyst and signed by the supervisor.\n\n*Note:* Further guidance on evaluation and reporting of test results is available in the following:\n\n- *Guideline elaborated by the US Food and Drug Administration (5);*\n- *Guideline elaborated by the European Network of Official Medicines Control Laboratories (OMCL) (28).*\n\n## Analytical test report\n\n18.7 The analytical test report is a compilation of the results and states the conclusions of the examination of a sample. It should be:\n\n(a) issued by the laboratory; and  \n(b) based on the analytical worksheet (see Part three, section 15).\n\n18.8 Any amendments to the original analytical test report will require the issue of a new corrected document.\n\n18.9 Pharmacopoeial content limits are set taking into account the uncertainty of measurement, and the production capability and acceptance criteria for an analytical result should be predefined. Under presently applicable rules neither the pharmacopoeias nor the NMRAs require the value found to be expressed with its associated expanded uncertainty for compliance testing. However, when reporting the results of investigative testing, although the primary objective is to identify a substance in the sample, a determination of", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2316, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3f334bbc-26f8-48f7-9eab-84269cdbe4da": {"__data__": {"id_": "3f334bbc-26f8-48f7-9eab-84269cdbe4da", "embedding": null, "metadata": {"page_label": "132", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "its concentration may be also requested, in which case the estimated uncertainty should also be given.\n\n18.10 Measurement uncertainty can be estimated in a number of ways, e.g.:\n\n(a) by preparing an uncertainty budget for each uncertainty component identified in an analytical procedure (bottom-up approach);\n\n(b) from validation data and control charts (29); and\n\n(c) from the data obtained from proficiency tests or collaborative trials (top-down approach).\n\n*Note:* Further guidance can be found in various guidelines (9, 10, 30, 31, 32).\n\n### Content of the analytical test report\n\n18.11 The analytical test report should provide the following information:\n\n(a) the laboratory registration number of the sample;\n\n(b) the laboratory test report number;\n\n(c) the name and address of the laboratory testing the sample;\n\n(d) the name and address of the originator of the request for analysis;\n\n(e) the name, description and batch number of the sample, where appropriate;\n\n(f) an introduction giving the background to and the purpose of the investigation;\n\n(g) a reference to the specifications used for testing the sample or a detailed description of the procedures employed (sample for investigative testing), including the limits;\n\n(h) the results of all the tests performed or the numerical results with the standard deviation of all the tests performed (if applicable);\n\n(i) a discussion of the results obtained;\n\n(j) a conclusion as to whether or not the sample(s) was (were) found to be within the limits of the specifications used, or for a sample for investigative testing, the substance(s) or ingredient(s) identified;\n\n(k) the date on which the test(s) was (were) completed;\n\n(l) the signature of the head of the laboratory or authorized person;\n\n(m) the name and address of the original manufacturer and, if applicable, those of the repacker and/or trader;\n\n(n) whether or not the sample(s) complies (comply) with the requirements;\n\n(o) the date on which the sample was received;\n\n(p) the expiry date or retest date, if applicable; and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla la importancia de la incertidumbre de medici\u00f3n en los procedimientos anal\u00edticos y proporciona directrices sobre el contenido que debe incluir un informe de prueba anal\u00edtica. Se mencionan m\u00e9todos para estimar la incertidumbre y se enumeran los elementos esenciales que deben estar presentes en un informe de laboratorio, como la identificaci\u00f3n del laboratorio, los resultados de las pruebas y la conformidad con las especificaciones.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los m\u00e9todos recomendados para estimar la incertidumbre de medici\u00f3n en un procedimiento anal\u00edtico?**\n   - Respuesta: La incertidumbre de medici\u00f3n puede estimarse mediante: (a) la preparaci\u00f3n de un presupuesto de incertidumbre para cada componente identificado en el procedimiento anal\u00edtico (enfoque de abajo hacia arriba); (b) datos de validaci\u00f3n y gr\u00e1ficos de control; y (c) datos obtenidos de pruebas de competencia o ensayos colaborativos (enfoque de arriba hacia abajo).\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en un informe de prueba anal\u00edtica seg\u00fan las directrices de la OMS?**\n   - Respuesta: Un informe de prueba anal\u00edtica debe incluir, entre otros, el n\u00famero de registro del laboratorio, el n\u00famero del informe de prueba, la direcci\u00f3n del laboratorio, la descripci\u00f3n y n\u00famero de lote de la muestra, los resultados de las pruebas realizadas, una discusi\u00f3n de los resultados, la conclusi\u00f3n sobre la conformidad de la muestra con las especificaciones, y la firma del responsable del laboratorio.\n\n3. **\u00bfQu\u00e9 se debe considerar al discutir los resultados obtenidos en un informe de prueba anal\u00edtica?**\n   - Respuesta: Al discutir los resultados, se debe considerar si la(s) muestra(s) se encontraron dentro de los l\u00edmites de las especificaciones utilizadas, o si se identificaron las sustancias o ingredientes en el caso de una muestra para pruebas investigativas. Adem\u00e1s, se debe incluir una interpretaci\u00f3n de los resultados en el contexto del prop\u00f3sito de la investigaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Resultados Dudosos y OOS**: Se establece que los resultados dudosos solo pueden ser rechazados si se debe a un error identificado. Si no se puede identificar una causa obvia, se debe realizar una determinaci\u00f3n confirmatoria por otro analista competente.\n\n2. **Procedimiento Operativo Est\u00e1ndar (SOP)**: Es esencial tener un SOP para guiar la investigaci\u00f3n de resultados fuera de especificaci\u00f3n (OOS), que incluya directrices sobre el n\u00famero de retests permitidos y la documentaci\u00f3n de todas las investigaciones y conclusiones.\n\n3. **Reportes de Resultados**: Todos los resultados individuales de las pruebas deben ser reportados junto con sus criterios de aceptaci\u00f3n. Las conclusiones deben ser registradas en la hoja de trabajo anal\u00edtica y firmadas por un supervisor.\n\n4. **Informe de Prueba Anal\u00edtica**: El informe debe compilar los resultados y conclusiones de la evaluaci\u00f3n de una muestra, ser emitido por el laboratorio y basarse en la hoja de trabajo anal\u00edtica. Cualquier enmienda al informe original requiere la emisi\u00f3n de un nuevo documento corregido.\n\n5. **L\u00edmites de Contenido Farmac\u00e9utico**: Los l\u00edmites deben considerar la incertidumbre de medici\u00f3n, y no se requiere que los valores se expresen con su incertidumbre expandida para pruebas de cumplimiento.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **FDA (Administraci\u00f3n de Alimentos y Medicamentos de EE. UU.)**: Referencia para directrices adicionales sobre evaluaci\u00f3n y reporte de resultados.\n- **OMCL (Red Europea de Laboratorios Oficiales de Control de Medicamentos)**: Otra referencia para directrices sobre pruebas anal\u00edticas.\n- **Analista**: Profesional responsable de realizar las pruebas y documentar los resultados.\n- **Supervisor**: Persona que revisa y firma las conclusiones en la hoja de trabajo anal\u00edtica.\n\nEste resumen abarca los aspectos fundamentales de la secci\u00f3n, destacando la importancia de la documentaci\u00f3n, la competencia anal\u00edtica y la claridad en la comunicaci\u00f3n de resultados.", "excerpt_keywords": "Keywords: measurement uncertainty, analytical test report, laboratory procedures, specifications, compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "58fedafa-30e8-4722-898d-e384971db23d", "node_type": "4", "metadata": {"page_label": "132", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "its concentration may be also requested, in which case the estimated uncertainty should also be given.\n\n18.10 Measurement uncertainty can be estimated in a number of ways, e.g.:\n\n(a) by preparing an uncertainty budget for each uncertainty component identified in an analytical procedure (bottom-up approach);\n\n(b) from validation data and control charts (29); and\n\n(c) from the data obtained from proficiency tests or collaborative trials (top-down approach).\n\n*Note:* Further guidance can be found in various guidelines (9, 10, 30, 31, 32).\n\n### Content of the analytical test report\n\n18.11 The analytical test report should provide the following information:\n\n(a) the laboratory registration number of the sample;\n\n(b) the laboratory test report number;\n\n(c) the name and address of the laboratory testing the sample;\n\n(d) the name and address of the originator of the request for analysis;\n\n(e) the name, description and batch number of the sample, where appropriate;\n\n(f) an introduction giving the background to and the purpose of the investigation;\n\n(g) a reference to the specifications used for testing the sample or a detailed description of the procedures employed (sample for investigative testing), including the limits;\n\n(h) the results of all the tests performed or the numerical results with the standard deviation of all the tests performed (if applicable);\n\n(i) a discussion of the results obtained;\n\n(j) a conclusion as to whether or not the sample(s) was (were) found to be within the limits of the specifications used, or for a sample for investigative testing, the substance(s) or ingredient(s) identified;\n\n(k) the date on which the test(s) was (were) completed;\n\n(l) the signature of the head of the laboratory or authorized person;\n\n(m) the name and address of the original manufacturer and, if applicable, those of the repacker and/or trader;\n\n(n) whether or not the sample(s) complies (comply) with the requirements;\n\n(o) the date on which the sample was received;\n\n(p) the expiry date or retest date, if applicable; and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "9bc2116a1b8d78695acf593cb28823bb06a2cc9ae3e04288c6ec2325bab7b5ee", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "its concentration may be also requested, in which case the estimated uncertainty should also be given.\n\n18.10 Measurement uncertainty can be estimated in a number of ways, e.g.:\n\n(a) by preparing an uncertainty budget for each uncertainty component identified in an analytical procedure (bottom-up approach);\n\n(b) from validation data and control charts (29); and\n\n(c) from the data obtained from proficiency tests or collaborative trials (top-down approach).\n\n*Note:* Further guidance can be found in various guidelines (9, 10, 30, 31, 32).\n\n### Content of the analytical test report\n\n18.11 The analytical test report should provide the following information:\n\n(a) the laboratory registration number of the sample;\n\n(b) the laboratory test report number;\n\n(c) the name and address of the laboratory testing the sample;\n\n(d) the name and address of the originator of the request for analysis;\n\n(e) the name, description and batch number of the sample, where appropriate;\n\n(f) an introduction giving the background to and the purpose of the investigation;\n\n(g) a reference to the specifications used for testing the sample or a detailed description of the procedures employed (sample for investigative testing), including the limits;\n\n(h) the results of all the tests performed or the numerical results with the standard deviation of all the tests performed (if applicable);\n\n(i) a discussion of the results obtained;\n\n(j) a conclusion as to whether or not the sample(s) was (were) found to be within the limits of the specifications used, or for a sample for investigative testing, the substance(s) or ingredient(s) identified;\n\n(k) the date on which the test(s) was (were) completed;\n\n(l) the signature of the head of the laboratory or authorized person;\n\n(m) the name and address of the original manufacturer and, if applicable, those of the repacker and/or trader;\n\n(n) whether or not the sample(s) complies (comply) with the requirements;\n\n(o) the date on which the sample was received;\n\n(p) the expiry date or retest date, if applicable; and", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2046, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3a77984c-6e51-47f9-9862-3571e07468aa": {"__data__": {"id_": "3a77984c-6e51-47f9-9862-3571e07468aa", "embedding": null, "metadata": {"page_label": "133", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Certificate of analysis\n\n19.1 A certificate of analysis is prepared for each batch of a substance or product and usually contains the following information:\n\n(a) the registration number of the sample;  \n(b) date of receipt;  \n(c) the name and address of the laboratory testing the sample;  \n(d) the name and address of the originator of the request for analysis;  \n(e) the name, description and batch number of the sample where appropriate;  \n(f) the name and address of the original manufacturer and, if applicable, those of the repacker and/or trader;  \n(g) the reference to the specification used for testing the sample;  \n(h) the results of all tests performed (mean and standard deviation, if applicable) with the prescribed limits;  \n(i) a conclusion as to whether or not the sample was found to be within the limits of the specification;  \n(j) expiry date or retest date if applicable;  \n(k) date on which the test(s) was (were) completed; and  \n(l) the signature of the head of laboratory or other authorized person.  \n\n*Note: The Guideline on model certificate of analysis was adopted by the WHO Expert Committee on Specifications for Pharmaceutical Preparations at its thirty-sixth meeting (3).*\n\n# Retained samples\n\n20.1 Samples should be retained as required by the legislation or by the originator of the request for analysis. There should be a sufficient amount of retained sample to allow at least two re-analyses. The retained sample should be kept in its final pack.\n\n# Part four. Safety\n\n## General rules\n\n21.1 General and specific safety instructions reflecting identified risk, should be made available to each staff member and supplemented regularly as appropriate (e.g. with written material, poster displays, audiovisual material and occasional seminars).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para un certificado de an\u00e1lisis que debe prepararse para cada lote de una sustancia o producto. Este certificado incluye informaci\u00f3n clave como el n\u00famero de registro, los resultados de las pruebas realizadas, y la firma del responsable del laboratorio. Adem\u00e1s, se menciona la importancia de retener muestras para an\u00e1lisis futuros y se establecen directrices sobre la seguridad en el laboratorio, enfatizando la necesidad de proporcionar instrucciones de seguridad a todo el personal.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en un certificado de an\u00e1lisis seg\u00fan el documento de la OMS?**\n   - El certificado de an\u00e1lisis debe incluir el n\u00famero de registro de la muestra, la fecha de recepci\u00f3n, el nombre y direcci\u00f3n del laboratorio, el nombre y direcci\u00f3n del originador de la solicitud, la descripci\u00f3n y n\u00famero de lote de la muestra, informaci\u00f3n sobre el fabricante, los resultados de las pruebas, una conclusi\u00f3n sobre la conformidad con las especificaciones, la fecha de caducidad o rean\u00e1lisis, la fecha de finalizaci\u00f3n de las pruebas y la firma del responsable del laboratorio.\n\n2. **\u00bfCu\u00e1nto tiempo deben conservarse las muestras seg\u00fan las directrices de la OMS?**\n   - Las muestras deben conservarse seg\u00fan lo requerido por la legislaci\u00f3n o por el originador de la solicitud de an\u00e1lisis, y debe haber suficiente cantidad de muestra retenida para permitir al menos dos rean\u00e1lisis.\n\n3. **\u00bfQu\u00e9 tipo de instrucciones de seguridad se deben proporcionar al personal del laboratorio?**\n   - Se deben proporcionar instrucciones de seguridad generales y espec\u00edficas que reflejen los riesgos identificados, y estas deben ser accesibles a cada miembro del personal, complementadas regularmente con material escrito, exhibiciones en carteles, material audiovisual y seminarios ocasionales.", "prev_section_summary": "### Temas Clave:\n\n1. **Incertidumbre de Medici\u00f3n**: Se discuten m\u00e9todos para estimar la incertidumbre en procedimientos anal\u00edticos, incluyendo enfoques de abajo hacia arriba (presupuesto de incertidumbre) y de arriba hacia abajo (datos de validaci\u00f3n y pruebas de competencia).\n\n2. **Contenido del Informe de Prueba Anal\u00edtica**: Se especifica la informaci\u00f3n que debe incluirse en un informe de prueba anal\u00edtica, como:\n   - Identificaci\u00f3n del laboratorio y del solicitante.\n   - Descripci\u00f3n de la muestra y resultados de las pruebas.\n   - Discusi\u00f3n y conclusi\u00f3n sobre la conformidad de la muestra con las especificaciones.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que proporciona las directrices.\n- **Laboratorio**: Entidad que realiza las pruebas y emite el informe.\n- **Muestra**: Sustancia o material analizado.\n- **Especificaciones**: Normas o criterios utilizados para evaluar la muestra.\n- **Resultados de Pruebas**: Datos obtenidos de los an\u00e1lisis realizados.\n\n### Resumen:\n\nEl documento de la OMS aborda la importancia de la incertidumbre de medici\u00f3n en los procedimientos anal\u00edticos y establece directrices sobre el contenido que debe incluir un informe de prueba anal\u00edtica. Se detallan m\u00e9todos para estimar la incertidumbre y se enumeran los elementos esenciales que deben estar presentes en el informe, como la identificaci\u00f3n del laboratorio, los resultados de las pruebas y la conformidad con las especificaciones.", "excerpt_keywords": "Keywords: certificate of analysis, retained samples, safety instructions, laboratory testing, WHO guidelines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "86c609a5-b3f6-48f0-9d8f-474638b6b30f", "node_type": "4", "metadata": {"page_label": "133", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Certificate of analysis\n\n19.1 A certificate of analysis is prepared for each batch of a substance or product and usually contains the following information:\n\n(a) the registration number of the sample;  \n(b) date of receipt;  \n(c) the name and address of the laboratory testing the sample;  \n(d) the name and address of the originator of the request for analysis;  \n(e) the name, description and batch number of the sample where appropriate;  \n(f) the name and address of the original manufacturer and, if applicable, those of the repacker and/or trader;  \n(g) the reference to the specification used for testing the sample;  \n(h) the results of all tests performed (mean and standard deviation, if applicable) with the prescribed limits;  \n(i) a conclusion as to whether or not the sample was found to be within the limits of the specification;  \n(j) expiry date or retest date if applicable;  \n(k) date on which the test(s) was (were) completed; and  \n(l) the signature of the head of laboratory or other authorized person.  \n\n*Note: The Guideline on model certificate of analysis was adopted by the WHO Expert Committee on Specifications for Pharmaceutical Preparations at its thirty-sixth meeting (3).*\n\n# Retained samples\n\n20.1 Samples should be retained as required by the legislation or by the originator of the request for analysis. There should be a sufficient amount of retained sample to allow at least two re-analyses. The retained sample should be kept in its final pack.\n\n# Part four. Safety\n\n## General rules\n\n21.1 General and specific safety instructions reflecting identified risk, should be made available to each staff member and supplemented regularly as appropriate (e.g. with written material, poster displays, audiovisual material and occasional seminars).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "8d13cc7efdf35132d50ac96a50f2aaec369397111f2f17e47eb4807cbe7226c5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Certificate of analysis\n\n19.1 A certificate of analysis is prepared for each batch of a substance or product and usually contains the following information:\n\n(a) the registration number of the sample;  \n(b) date of receipt;  \n(c) the name and address of the laboratory testing the sample;  \n(d) the name and address of the originator of the request for analysis;  \n(e) the name, description and batch number of the sample where appropriate;  \n(f) the name and address of the original manufacturer and, if applicable, those of the repacker and/or trader;  \n(g) the reference to the specification used for testing the sample;  \n(h) the results of all tests performed (mean and standard deviation, if applicable) with the prescribed limits;  \n(i) a conclusion as to whether or not the sample was found to be within the limits of the specification;  \n(j) expiry date or retest date if applicable;  \n(k) date on which the test(s) was (were) completed; and  \n(l) the signature of the head of laboratory or other authorized person.  \n\n*Note: The Guideline on model certificate of analysis was adopted by the WHO Expert Committee on Specifications for Pharmaceutical Preparations at its thirty-sixth meeting (3).*\n\n# Retained samples\n\n20.1 Samples should be retained as required by the legislation or by the originator of the request for analysis. There should be a sufficient amount of retained sample to allow at least two re-analyses. The retained sample should be kept in its final pack.\n\n# Part four. Safety\n\n## General rules\n\n21.1 General and specific safety instructions reflecting identified risk, should be made available to each staff member and supplemented regularly as appropriate (e.g. with written material, poster displays, audiovisual material and occasional seminars).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1780, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "dfabce79-9699-4719-8cc5-1a4a399e8701": {"__data__": {"id_": "dfabce79-9699-4719-8cc5-1a4a399e8701", "embedding": null, "metadata": {"page_label": "134", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 21.2 General rules for safe working in accordance with national regulations and SOPs normally include the following requirements:\n\n(a) Safety data sheets should be available to staff before testing is carried out;\n\n(b) Smoking, eating and drinking in the laboratory should be prohibited;\n\n(c) Staff should be familiar with the use of fire-fighting equipment, including fire extinguishers, fire blankets and gas masks;\n\n(d) Staff should wear laboratory coats or other protective clothing, including eye protection;\n\n(e) Special care should be taken, as appropriate, in handling, for example, highly potent, infectious or volatile substances;\n\n(f) Highly toxic and/or genotoxic samples should be handled in a specially designed facility to avoid the risk of contamination;\n\n(g) All containers of chemicals should be fully labelled and include prominent warnings (e.g. \u201cpoison\u201d, \u201cflammable\u201d, \u201cradioactive\u201d) whenever appropriate;\n\n(h) Adequate insulation and spark-proofing should be provided for electrical wiring and equipment, including refrigerators;\n\n(i) Rules on safe handling of cylinders of compressed gases should be observed and staff should be familiar with the relevant colour identification codes;\n\n(j) Staff should be aware of the need to avoid working alone in the laboratory; and\n\n(k) First-aid materials should be provided and staff instructed in first-aid techniques, emergency care and the use of antidotes.\n\n## 21.3 Protective clothing should be available, including eye protection, masks and gloves. \n\nSafety showers should be installed. Rubber suction bulbs should be used on manual pipettes and siphons. Staff should be instructed in the safe handling of glassware, corrosive reagents and solvents and particularly in the use of safety containers or baskets to avoid spillage from containers. Warnings, precautions and instructions should be given for work with violent, uncontrollable or dangerous reactions when handling specific reagents (e.g. mixing water and acids, or acetone\u2013chloroform and ammonia), flammable products, oxidizing or radioactive agents and especially biologicals such as infectious agents. Peroxide-free solvents should be used. Staff should be aware of methods for the safe disposal of unwanted corrosive or dangerous products by neutralization or deactivation and of the need for safe and complete disposal of mercury and its salts.\n\n## 21.4 Poisonous or hazardous products should be singled out and labelled appropriately, but it should not be taken for granted that all other", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Reglas generales para el trabajo seguro en laboratorios**: El documento establece una serie de requisitos que deben seguirse en los laboratorios para garantizar la seguridad del personal, incluyendo la disponibilidad de hojas de datos de seguridad, la prohibici\u00f3n de fumar y comer, y la necesidad de usar ropa de protecci\u00f3n adecuada.\n\n2. **Equipamiento y procedimientos de seguridad**: Se enfatiza la importancia de que el personal est\u00e9 familiarizado con el uso de equipos de lucha contra incendios, as\u00ed como la correcta manipulaci\u00f3n de sustancias peligrosas y la disposici\u00f3n segura de productos qu\u00edmicos.\n\n3. **Manejo de productos peligrosos**: Se menciona la necesidad de etiquetar adecuadamente los productos t\u00f3xicos y peligrosos, y se dan directrices sobre el uso de ropa de protecci\u00f3n, duchas de seguridad y t\u00e9cnicas de primeros auxilios.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe contener una hoja de datos de seguridad y por qu\u00e9 es importante que est\u00e9 disponible antes de realizar pruebas en el laboratorio?**\n   - Respuesta: Las hojas de datos de seguridad deben contener informaci\u00f3n sobre las propiedades qu\u00edmicas, riesgos, medidas de seguridad y procedimientos de emergencia relacionados con las sustancias que se van a utilizar. Su disponibilidad es crucial para que el personal pueda tomar decisiones informadas y seguras antes de manipular productos qu\u00edmicos.\n\n2. **\u00bfCu\u00e1les son las medidas espec\u00edficas que se deben tomar al manejar sustancias altamente t\u00f3xicas o genot\u00f3xicas en el laboratorio?**\n   - Respuesta: Las sustancias altamente t\u00f3xicas o genot\u00f3xicas deben ser manipuladas en instalaciones especialmente dise\u00f1adas para evitar la contaminaci\u00f3n. Adem\u00e1s, se deben seguir estrictas normas de seguridad, como el uso de ropa de protecci\u00f3n adecuada y la implementaci\u00f3n de procedimientos de manejo seguro.\n\n3. **\u00bfQu\u00e9 precauciones deben tomarse al trabajar con productos qu\u00edmicos que pueden reaccionar violentamente, y qu\u00e9 ejemplos se mencionan en el documento?**\n   - Respuesta: Se deben proporcionar advertencias, precauciones e instrucciones espec\u00edficas para el trabajo con productos qu\u00edmicos que pueden reaccionar de manera violenta o incontrolable. Ejemplos mencionados incluyen la mezcla de agua con \u00e1cidos y la combinaci\u00f3n de acetona\u2013cloroformo con amon\u00edaco, que pueden generar reacciones peligrosas.", "prev_section_summary": "### Temas clave:\n\n1. **Certificado de an\u00e1lisis**: Se detalla la informaci\u00f3n que debe incluir un certificado de an\u00e1lisis para cada lote de una sustancia o producto, como el n\u00famero de registro, resultados de pruebas, y la firma del responsable del laboratorio.\n\n2. **Muestras retenidas**: Se establece la necesidad de conservar muestras de acuerdo con la legislaci\u00f3n o la solicitud del an\u00e1lisis, asegurando que haya suficiente cantidad para al menos dos rean\u00e1lisis.\n\n3. **Instrucciones de seguridad**: Se enfatiza la importancia de proporcionar instrucciones de seguridad generales y espec\u00edficas al personal del laboratorio, complementadas con materiales educativos y seminarios.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad que establece las directrices.\n- **Laboratorio**: Entidad responsable de realizar las pruebas y emitir el certificado de an\u00e1lisis.\n- **Muestras**: Sustancias o productos que son objeto de an\u00e1lisis.\n- **Personal del laboratorio**: Individuos que deben recibir formaci\u00f3n en seguridad.\n- **Especificaciones**: Normas a las que deben ajustarse los resultados de las pruebas.\n\n### Resumen:\nEl documento de la OMS establece los requisitos para un certificado de an\u00e1lisis, que debe incluir informaci\u00f3n esencial sobre el lote de una sustancia o producto. Tambi\u00e9n se menciona la importancia de conservar muestras para futuros an\u00e1lisis y se subraya la necesidad de proporcionar instrucciones de seguridad adecuadas al personal del laboratorio.", "excerpt_keywords": "Keywords: safety regulations, laboratory practices, hazardous materials, protective equipment, emergency procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5a015644-6d09-4257-a83a-2a7d8d233417", "node_type": "4", "metadata": {"page_label": "134", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 21.2 General rules for safe working in accordance with national regulations and SOPs normally include the following requirements:\n\n(a) Safety data sheets should be available to staff before testing is carried out;\n\n(b) Smoking, eating and drinking in the laboratory should be prohibited;\n\n(c) Staff should be familiar with the use of fire-fighting equipment, including fire extinguishers, fire blankets and gas masks;\n\n(d) Staff should wear laboratory coats or other protective clothing, including eye protection;\n\n(e) Special care should be taken, as appropriate, in handling, for example, highly potent, infectious or volatile substances;\n\n(f) Highly toxic and/or genotoxic samples should be handled in a specially designed facility to avoid the risk of contamination;\n\n(g) All containers of chemicals should be fully labelled and include prominent warnings (e.g. \u201cpoison\u201d, \u201cflammable\u201d, \u201cradioactive\u201d) whenever appropriate;\n\n(h) Adequate insulation and spark-proofing should be provided for electrical wiring and equipment, including refrigerators;\n\n(i) Rules on safe handling of cylinders of compressed gases should be observed and staff should be familiar with the relevant colour identification codes;\n\n(j) Staff should be aware of the need to avoid working alone in the laboratory; and\n\n(k) First-aid materials should be provided and staff instructed in first-aid techniques, emergency care and the use of antidotes.\n\n## 21.3 Protective clothing should be available, including eye protection, masks and gloves. \n\nSafety showers should be installed. Rubber suction bulbs should be used on manual pipettes and siphons. Staff should be instructed in the safe handling of glassware, corrosive reagents and solvents and particularly in the use of safety containers or baskets to avoid spillage from containers. Warnings, precautions and instructions should be given for work with violent, uncontrollable or dangerous reactions when handling specific reagents (e.g. mixing water and acids, or acetone\u2013chloroform and ammonia), flammable products, oxidizing or radioactive agents and especially biologicals such as infectious agents. Peroxide-free solvents should be used. Staff should be aware of methods for the safe disposal of unwanted corrosive or dangerous products by neutralization or deactivation and of the need for safe and complete disposal of mercury and its salts.\n\n## 21.4 Poisonous or hazardous products should be singled out and labelled appropriately, but it should not be taken for granted that all other", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "51342d46d0ba56d23434d962a9c7cf4667798097302442b65a281774c7cddce9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 21.2 General rules for safe working in accordance with national regulations and SOPs normally include the following requirements:\n\n(a) Safety data sheets should be available to staff before testing is carried out;\n\n(b) Smoking, eating and drinking in the laboratory should be prohibited;\n\n(c) Staff should be familiar with the use of fire-fighting equipment, including fire extinguishers, fire blankets and gas masks;\n\n(d) Staff should wear laboratory coats or other protective clothing, including eye protection;\n\n(e) Special care should be taken, as appropriate, in handling, for example, highly potent, infectious or volatile substances;\n\n(f) Highly toxic and/or genotoxic samples should be handled in a specially designed facility to avoid the risk of contamination;\n\n(g) All containers of chemicals should be fully labelled and include prominent warnings (e.g. \u201cpoison\u201d, \u201cflammable\u201d, \u201cradioactive\u201d) whenever appropriate;\n\n(h) Adequate insulation and spark-proofing should be provided for electrical wiring and equipment, including refrigerators;\n\n(i) Rules on safe handling of cylinders of compressed gases should be observed and staff should be familiar with the relevant colour identification codes;\n\n(j) Staff should be aware of the need to avoid working alone in the laboratory; and\n\n(k) First-aid materials should be provided and staff instructed in first-aid techniques, emergency care and the use of antidotes.\n\n## 21.3 Protective clothing should be available, including eye protection, masks and gloves. \n\nSafety showers should be installed. Rubber suction bulbs should be used on manual pipettes and siphons. Staff should be instructed in the safe handling of glassware, corrosive reagents and solvents and particularly in the use of safety containers or baskets to avoid spillage from containers. Warnings, precautions and instructions should be given for work with violent, uncontrollable or dangerous reactions when handling specific reagents (e.g. mixing water and acids, or acetone\u2013chloroform and ammonia), flammable products, oxidizing or radioactive agents and especially biologicals such as infectious agents. Peroxide-free solvents should be used. Staff should be aware of methods for the safe disposal of unwanted corrosive or dangerous products by neutralization or deactivation and of the need for safe and complete disposal of mercury and its salts.\n\n## 21.4 Poisonous or hazardous products should be singled out and labelled appropriately, but it should not be taken for granted that all other", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2524, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "fedf5bdc-5963-4c0f-8189-309707c1fd41": {"__data__": {"id_": "fedf5bdc-5963-4c0f-8189-309707c1fd41", "embedding": null, "metadata": {"page_label": "135", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. **Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, 2nd updated edition. Good manufacturing practices and inspection.** Geneva, World Health Organization, 2007.\n\n2. **International Organization for Standardization.** General requirements for the competence of testing and calibration laboratories. ISO/IEC 17025:2005.\n\n3. **Model certificate of analysis.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report. Geneva, World Health Organization, 2002, Annex 10 (WHO Technical Report Series, No. 902).\n\n4. **International vocabulary of metrology \u2014 Basic and general concepts and associated terms. VIM 3rd ed.**, Joint Committee for Guides in Metrology (JCGM) 200:2008 (http://www.bipm.org/utils/common/documents/jcgm/JCGM_200_2008.pdf).\n\n5. **Guidance for industry \u2014 Investigating out-of-specification test results for pharmaceutical production.** US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), October 2006 (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070287.pdf).\n\n6. **Guidelines for inspection of drug distribution channels.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report. Geneva, World Health Organization, 1999, Annex 6 (WHO Technical Report Series, No. 885).\n\n7. **Good manufacturing practices: supplementary guidelines for the manufacture of pharmaceutical excipients.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report. Geneva, World Health Organization, 1999, Annex 5 (WHO Technical Report Series, No. 885).\n\n8. **General guidelines for the establishment, maintenance and distribution of chemical reference substances.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report. Geneva, World Health Organization, 2007, Annex 3 (WHO Technical Report Series, No. 943).\n\n9. **International Organization for Standardization.** Guidance for the use of repeatability, reproducibility and trueness estimates in measurement uncertainty estimation. 2004 (ISO Guide 21748).\n\n10. **International Organization for Standardization/International Electrotechnical Commission.** Uncertainty of measurement \u2014 Part 3: Guide to the expression of uncertainty in measurement (GUM:1995) 2008 (ISO/IEC Guide 98-3).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfCu\u00e1les son las ediciones y a\u00f1os de publicaci\u00f3n de las gu\u00edas de buenas pr\u00e1cticas de fabricaci\u00f3n mencionadas en el documento?**\n   - **Respuesta:** La gu\u00eda \"Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, 2nd updated edition. Good manufacturing practices and inspection\" fue publicada por la OMS en 2007. Adem\u00e1s, las \"Good manufacturing practices: supplementary guidelines for the manufacture of pharmaceutical excipients\" tambi\u00e9n se mencionan en el contexto de la 35\u00aa reuni\u00f3n del Comit\u00e9 de Expertos de la OMS, publicada en 1999.\n\n2. **\u00bfQu\u00e9 documento proporciona directrices sobre la investigaci\u00f3n de resultados de pruebas fuera de especificaci\u00f3n en la producci\u00f3n farmac\u00e9utica?**\n   - **Respuesta:** El documento titulado \"Guidance for industry \u2014 Investigating out-of-specification test results for pharmaceutical production\" publicado por la US Food and Drug Administration, Center for Drug Evaluation and Research (CDER) en octubre de 2006, proporciona directrices sobre este tema.\n\n3. **\u00bfQu\u00e9 organizaci\u00f3n internacional establece los requisitos generales para la competencia de laboratorios de ensayo y calibraci\u00f3n?**\n   - **Respuesta:** La organizaci\u00f3n que establece estos requisitos es la **International Organization for Standardization (ISO)**, espec\u00edficamente en el documento ISO/IEC 17025:2005.\n\n### Resumen de Nivel Superior\n\nEl contexto se centra en una serie de referencias relacionadas con la calidad y las buenas pr\u00e1cticas en la fabricaci\u00f3n de productos farmac\u00e9uticos, as\u00ed como en la metrolog\u00eda y la calibraci\u00f3n de laboratorios. Se mencionan documentos clave de la Organizaci\u00f3n Mundial de la Salud (OMS) y de la Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO), que abordan desde la garant\u00eda de calidad hasta la incertidumbre en las mediciones. Estas referencias son esenciales para asegurar que los productos farmac\u00e9uticos cumplan con los est\u00e1ndares internacionales de calidad y seguridad.\n\n### Preguntas Mejoradas\n\n1. **\u00bfQu\u00e9 papel juega la OMS en la regulaci\u00f3n de las buenas pr\u00e1cticas de fabricaci\u00f3n de productos farmac\u00e9uticos seg\u00fan las referencias citadas?**\n2. **\u00bfC\u00f3mo se relacionan las gu\u00edas de la ISO con la calidad en los laboratorios de ensayo y calibraci\u00f3n en el contexto farmac\u00e9utico?**\n3. **\u00bfQu\u00e9 importancia tienen los certificados de an\u00e1lisis en el contexto de las especificaciones farmac\u00e9uticas seg\u00fan el documento mencionado?**", "prev_section_summary": "### Temas Clave:\n\n1. **Reglas Generales de Seguridad en Laboratorios**: Se establecen requisitos fundamentales para garantizar un entorno de trabajo seguro, incluyendo la disponibilidad de hojas de datos de seguridad y la prohibici\u00f3n de fumar, comer y beber en el laboratorio.\n\n2. **Equipamiento de Seguridad**: Se enfatiza la importancia de que el personal est\u00e9 familiarizado con el uso de equipos de lucha contra incendios y que utilice ropa de protecci\u00f3n adecuada, como batas de laboratorio y protecci\u00f3n ocular.\n\n3. **Manejo de Sustancias Peligrosas**: Se requiere un manejo cuidadoso de sustancias altamente t\u00f3xicas, genot\u00f3xicas e infecciosas, que deben ser manipuladas en instalaciones dise\u00f1adas espec\u00edficamente para evitar la contaminaci\u00f3n.\n\n4. **Etiquetado y Almacenamiento de Productos Qu\u00edmicos**: Todos los contenedores de productos qu\u00edmicos deben estar debidamente etiquetados con advertencias claras sobre su peligrosidad.\n\n5. **Precauciones en el Manejo de Productos Qu\u00edmicos Reactivos**: Se deben seguir instrucciones espec\u00edficas al trabajar con productos qu\u00edmicos que pueden reaccionar violentamente, como la mezcla de agua con \u00e1cidos.\n\n6. **Disposici\u00f3n Segura de Residuos**: Se debe tener conocimiento sobre la disposici\u00f3n segura de productos qu\u00edmicos peligrosos y la eliminaci\u00f3n adecuada de mercurio y sus sales.\n\n### Entidades:\n\n- **Hojas de Datos de Seguridad**: Documentos que contienen informaci\u00f3n sobre riesgos y medidas de seguridad de sustancias qu\u00edmicas.\n- **Equipos de Lucha Contra Incendios**: Incluyen extintores, mantas ign\u00edfugas y m\u00e1scaras de gas.\n- **Ropa de Protecci\u00f3n**: Batas de laboratorio, gafas de seguridad, guantes y m\u00e1scaras.\n- **Sustancias Peligrosas**: Incluyen productos qu\u00edmicos altamente t\u00f3xicos, genot\u00f3xicos, inflamables y biol\u00f3gicos.\n- **Contenedores de Productos Qu\u00edmicos**: Deben estar etiquetados con advertencias como \"veneno\", \"inflamable\" y \"radiactivo\".\n- **Duchas de Seguridad y Materiales de Primeros Auxilios**: Equipos necesarios para responder a emergencias en el laboratorio.\n\nEste resumen destaca la importancia de seguir protocolos de seguridad rigurosos en el laboratorio para proteger al personal y manejar adecuadamente los productos qu\u00edmicos peligrosos.", "excerpt_keywords": "Keywords: pharmaceuticals, quality assurance, good manufacturing practices, ISO standards, metrology"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "97215990-e6ec-45ac-b944-3d6c8e41f9b6", "node_type": "4", "metadata": {"page_label": "135", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. **Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, 2nd updated edition. Good manufacturing practices and inspection.** Geneva, World Health Organization, 2007.\n\n2. **International Organization for Standardization.** General requirements for the competence of testing and calibration laboratories. ISO/IEC 17025:2005.\n\n3. **Model certificate of analysis.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report. Geneva, World Health Organization, 2002, Annex 10 (WHO Technical Report Series, No. 902).\n\n4. **International vocabulary of metrology \u2014 Basic and general concepts and associated terms. VIM 3rd ed.**, Joint Committee for Guides in Metrology (JCGM) 200:2008 (http://www.bipm.org/utils/common/documents/jcgm/JCGM_200_2008.pdf).\n\n5. **Guidance for industry \u2014 Investigating out-of-specification test results for pharmaceutical production.** US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), October 2006 (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070287.pdf).\n\n6. **Guidelines for inspection of drug distribution channels.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report. Geneva, World Health Organization, 1999, Annex 6 (WHO Technical Report Series, No. 885).\n\n7. **Good manufacturing practices: supplementary guidelines for the manufacture of pharmaceutical excipients.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report. Geneva, World Health Organization, 1999, Annex 5 (WHO Technical Report Series, No. 885).\n\n8. **General guidelines for the establishment, maintenance and distribution of chemical reference substances.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report. Geneva, World Health Organization, 2007, Annex 3 (WHO Technical Report Series, No. 943).\n\n9. **International Organization for Standardization.** Guidance for the use of repeatability, reproducibility and trueness estimates in measurement uncertainty estimation. 2004 (ISO Guide 21748).\n\n10. **International Organization for Standardization/International Electrotechnical Commission.** Uncertainty of measurement \u2014 Part 3: Guide to the expression of uncertainty in measurement (GUM:1995) 2008 (ISO/IEC Guide 98-3).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "4d4841d96eace5bca786bcbf6976a2610d71066bdac3af9b760cb95e711537bd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# References\n\n1. **Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, 2nd updated edition. Good manufacturing practices and inspection.** Geneva, World Health Organization, 2007.\n\n2. **International Organization for Standardization.** General requirements for the competence of testing and calibration laboratories. ISO/IEC 17025:2005.\n\n3. **Model certificate of analysis.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report. Geneva, World Health Organization, 2002, Annex 10 (WHO Technical Report Series, No. 902).\n\n4. **International vocabulary of metrology \u2014 Basic and general concepts and associated terms. VIM 3rd ed.**, Joint Committee for Guides in Metrology (JCGM) 200:2008 (http://www.bipm.org/utils/common/documents/jcgm/JCGM_200_2008.pdf).\n\n5. **Guidance for industry \u2014 Investigating out-of-specification test results for pharmaceutical production.** US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), October 2006 (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070287.pdf).\n\n6. **Guidelines for inspection of drug distribution channels.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report. Geneva, World Health Organization, 1999, Annex 6 (WHO Technical Report Series, No. 885).\n\n7. **Good manufacturing practices: supplementary guidelines for the manufacture of pharmaceutical excipients.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report. Geneva, World Health Organization, 1999, Annex 5 (WHO Technical Report Series, No. 885).\n\n8. **General guidelines for the establishment, maintenance and distribution of chemical reference substances.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report. Geneva, World Health Organization, 2007, Annex 3 (WHO Technical Report Series, No. 943).\n\n9. **International Organization for Standardization.** Guidance for the use of repeatability, reproducibility and trueness estimates in measurement uncertainty estimation. 2004 (ISO Guide 21748).\n\n10. **International Organization for Standardization/International Electrotechnical Commission.** Uncertainty of measurement \u2014 Part 3: Guide to the expression of uncertainty in measurement (GUM:1995) 2008 (ISO/IEC Guide 98-3).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2421, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "08d9bdfb-346c-4bcf-ac71-0a99a4a415eb": {"__data__": {"id_": "08d9bdfb-346c-4bcf-ac71-0a99a4a415eb", "embedding": null, "metadata": {"page_label": "136", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n11. Supplementary guidelines in good manufacturing practice: validation. Qualification of systems and equipment. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 4, Appendix 6 (WHO Technical Report Series, No. 937).\n\n12. Supplementary guidelines in good manufacturing practice: validation. Validation of computerized systems. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 4, Appendix 6 (WHO Technical Report Series, No. 937).\n\n13. *Good automated manufacturing practice (GAMP) Good Practice Guides: Validation of laboratory computerized systems*. International Society for Pharmaceutical Engineering (ISPE), 2005.\n\n14. *Good automated manufacturing practice (GAMP) Good Practice Guides: Electronic data archiving*. International Society for Pharmaceutical Engineering (ISPE), 2007.\n\n15. *Title 21 Code of Federal Regulations (21 CFR Part 11): Electronic records; electronic signatures*. US Food and Drug Administration. The current status of 21 CFR Part 11 Guidance is located under Regulations and Guidance at: http://www.fda.gov/cder/gmp/index.htm \u2014 see background: http://www.fda.gov/OHRMS/DOCKETS/98fr/03-4312.pdf\n\n16. Computerised systems. In: *The rules governing medicinal products in the European Union. Vol. 4. Good manufacturing practice (GMP) guidelines*. Annex 11 (http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-4/pdfs-en/annex11en.pdf).\n\n17. Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents: PA/PH/OMCL (08) 69 3R \u2014 *Validation of computerised systems \u2014 core document* (http://www.edqm.eu/site/Validation_of_Computerised_Systems_Core_Documentpdf-en-8390-2.html) and its annexes:\n\n    - PA/PH/OMCL (08) 87 2R \u2014 Annex 1: Validation of computerised calculation systems: example of validation of in-house software (http://www.edqm.eu/site/NEW_Annex_1_Validation_of_computerised_calculationpdf-en-8391-2.html).\n\n    - PA/PH/OMCL (08) 88 R \u2014 Annex 2: Validation of Databases (DB), Laboratory Information Management Systems (LIMS) and Electronic Laboratory Notebooks (ELN) (http://www.edqm.eu/site/NEW_Annex_2_Validation_of_Databases_DB_Laboratory_pdf-en-8392-2.html).\n\n    - PA/PH/OMCL (08) 89 R \u2014 Annex 3: Validation of computers as part of test equipment (http://www.edqm.eu/site/NEW_Annex_3_Validation_of_computers_as_part_of_tespcdf-en-8393-2.html).\n\n18. *Guidelines for good laboratory practice and guidelines for the testing of chemicals*. Organisation for Economic Co-operation and Development (OECD), Environment Directorate, Chemical Safety. (http://www.oecd.org/document/63/0,3343,en_2649_34381_2346175_1_1_1_1,00.html).\n\n19. *The International Pharmacopoeia*, Fourth Edition (including First Supplement). Vol. 2. Methods of analysis. Geneva, World Health Organization, 2008 (http://www.who.int/phint).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl contexto proporciona una lista de referencias relacionadas con las buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) y la validaci\u00f3n de sistemas computarizados en el \u00e1mbito farmac\u00e9utico. Incluye directrices de la Organizaci\u00f3n Mundial de la Salud (OMS), la Administraci\u00f3n de Alimentos y Medicamentos de EE. UU. (FDA), y la Organizaci\u00f3n para la Cooperaci\u00f3n y el Desarrollo Econ\u00f3mico (OCDE), as\u00ed como documentos de la Sociedad Internacional de Ingenier\u00eda Farmac\u00e9utica (ISPE). Las referencias abarcan temas como la validaci\u00f3n de sistemas y equipos, la gesti\u00f3n de datos electr\u00f3nicos y las buenas pr\u00e1cticas de laboratorio.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las diferencias clave entre las directrices de validaci\u00f3n de sistemas computarizados de la OMS y las de la FDA seg\u00fan las referencias proporcionadas?**\n   - Esta pregunta busca una comparaci\u00f3n directa entre las directrices de dos organizaciones importantes en el \u00e1mbito de la regulaci\u00f3n farmac\u00e9utica, lo que puede no estar disponible en otros documentos.\n\n2. **\u00bfQu\u00e9 documentos espec\u00edficos de la red de Laboratorios de Control de Medicamentos Oficiales del Consejo de Europa se mencionan y qu\u00e9 aspectos de la validaci\u00f3n abordan?**\n   - Esta pregunta se centra en los documentos espec\u00edficos y sus enfoques, lo que puede no ser ampliamente conocido fuera de este contexto.\n\n3. **\u00bfC\u00f3mo se relacionan las gu\u00edas de buenas pr\u00e1cticas de fabricaci\u00f3n automatizadas (GAMP) con las regulaciones de la UE sobre sistemas computarizados?**\n   - Esta pregunta busca explorar la interconexi\u00f3n entre las gu\u00edas de GAMP y las regulaciones europeas, proporcionando una perspectiva que puede no estar claramente delineada en otros textos. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n detallada y espec\u00edfica que se encuentra en el contexto proporcionado, lo que puede no ser f\u00e1cilmente accesible en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nLa secci\u00f3n se centra en referencias relacionadas con la **calidad y las buenas pr\u00e1cticas en la fabricaci\u00f3n de productos farmac\u00e9uticos**, as\u00ed como en la **metrolog\u00eda** y la **calibraci\u00f3n de laboratorios**. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF)**: Se discuten gu\u00edas y est\u00e1ndares para asegurar la calidad en la producci\u00f3n farmac\u00e9utica.\n2. **Calidad y Aseguramiento**: Importancia de la calidad en los productos farmac\u00e9uticos y la necesidad de cumplir con est\u00e1ndares internacionales.\n3. **Metrolog\u00eda**: Conceptos b\u00e1sicos y t\u00e9rminos asociados a la metrolog\u00eda, as\u00ed como la incertidumbre en las mediciones.\n4. **Regulaci\u00f3n y Directrices**: Documentos que proporcionan directrices sobre la investigaci\u00f3n de resultados de pruebas fuera de especificaci\u00f3n y la inspecci\u00f3n de canales de distribuci\u00f3n de medicamentos.\n5. **Certificados de An\u00e1lisis**: Importancia de los certificados en el contexto de las especificaciones farmac\u00e9uticas.\n\n#### Entidades Mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Publica gu\u00edas y reportes sobre buenas pr\u00e1cticas y est\u00e1ndares en la industria farmac\u00e9utica.\n- **International Organization for Standardization (ISO)**: Establece requisitos y gu\u00edas para la competencia de laboratorios de ensayo y calibraci\u00f3n.\n- **US Food and Drug Administration (FDA)**: Proporciona directrices sobre la investigaci\u00f3n de resultados de pruebas en la producci\u00f3n farmac\u00e9utica.\n\nEste resumen destaca la relevancia de las referencias citadas para asegurar que los productos farmac\u00e9uticos cumplan con los est\u00e1ndares de calidad y seguridad a nivel internacional.", "excerpt_keywords": "Keywords: buenas pr\u00e1cticas de fabricaci\u00f3n, validaci\u00f3n de sistemas, OMS, FDA, GAMP"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "94f2026b-0279-4b96-8f55-b8415fda5434", "node_type": "4", "metadata": {"page_label": "136", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n11. Supplementary guidelines in good manufacturing practice: validation. Qualification of systems and equipment. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 4, Appendix 6 (WHO Technical Report Series, No. 937).\n\n12. Supplementary guidelines in good manufacturing practice: validation. Validation of computerized systems. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 4, Appendix 6 (WHO Technical Report Series, No. 937).\n\n13. *Good automated manufacturing practice (GAMP) Good Practice Guides: Validation of laboratory computerized systems*. International Society for Pharmaceutical Engineering (ISPE), 2005.\n\n14. *Good automated manufacturing practice (GAMP) Good Practice Guides: Electronic data archiving*. International Society for Pharmaceutical Engineering (ISPE), 2007.\n\n15. *Title 21 Code of Federal Regulations (21 CFR Part 11): Electronic records; electronic signatures*. US Food and Drug Administration. The current status of 21 CFR Part 11 Guidance is located under Regulations and Guidance at: http://www.fda.gov/cder/gmp/index.htm \u2014 see background: http://www.fda.gov/OHRMS/DOCKETS/98fr/03-4312.pdf\n\n16. Computerised systems. In: *The rules governing medicinal products in the European Union. Vol. 4. Good manufacturing practice (GMP) guidelines*. Annex 11 (http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-4/pdfs-en/annex11en.pdf).\n\n17. Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents: PA/PH/OMCL (08) 69 3R \u2014 *Validation of computerised systems \u2014 core document* (http://www.edqm.eu/site/Validation_of_Computerised_Systems_Core_Documentpdf-en-8390-2.html) and its annexes:\n\n    - PA/PH/OMCL (08) 87 2R \u2014 Annex 1: Validation of computerised calculation systems: example of validation of in-house software (http://www.edqm.eu/site/NEW_Annex_1_Validation_of_computerised_calculationpdf-en-8391-2.html).\n\n    - PA/PH/OMCL (08) 88 R \u2014 Annex 2: Validation of Databases (DB), Laboratory Information Management Systems (LIMS) and Electronic Laboratory Notebooks (ELN) (http://www.edqm.eu/site/NEW_Annex_2_Validation_of_Databases_DB_Laboratory_pdf-en-8392-2.html).\n\n    - PA/PH/OMCL (08) 89 R \u2014 Annex 3: Validation of computers as part of test equipment (http://www.edqm.eu/site/NEW_Annex_3_Validation_of_computers_as_part_of_tespcdf-en-8393-2.html).\n\n18. *Guidelines for good laboratory practice and guidelines for the testing of chemicals*. Organisation for Economic Co-operation and Development (OECD), Environment Directorate, Chemical Safety. (http://www.oecd.org/document/63/0,3343,en_2649_34381_2346175_1_1_1_1,00.html).\n\n19. *The International Pharmacopoeia*, Fourth Edition (including First Supplement). Vol. 2. Methods of analysis. Geneva, World Health Organization, 2008 (http://www.who.int/phint).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "e56780000005fa467183223d35d113fd34337c530edf9684172ccda033bb69ad", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# References\n\n11. Supplementary guidelines in good manufacturing practice: validation. Qualification of systems and equipment. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 4, Appendix 6 (WHO Technical Report Series, No. 937).\n\n12. Supplementary guidelines in good manufacturing practice: validation. Validation of computerized systems. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 4, Appendix 6 (WHO Technical Report Series, No. 937).\n\n13. *Good automated manufacturing practice (GAMP) Good Practice Guides: Validation of laboratory computerized systems*. International Society for Pharmaceutical Engineering (ISPE), 2005.\n\n14. *Good automated manufacturing practice (GAMP) Good Practice Guides: Electronic data archiving*. International Society for Pharmaceutical Engineering (ISPE), 2007.\n\n15. *Title 21 Code of Federal Regulations (21 CFR Part 11): Electronic records; electronic signatures*. US Food and Drug Administration. The current status of 21 CFR Part 11 Guidance is located under Regulations and Guidance at: http://www.fda.gov/cder/gmp/index.htm \u2014 see background: http://www.fda.gov/OHRMS/DOCKETS/98fr/03-4312.pdf\n\n16. Computerised systems. In: *The rules governing medicinal products in the European Union. Vol. 4. Good manufacturing practice (GMP) guidelines*. Annex 11 (http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-4/pdfs-en/annex11en.pdf).\n\n17. Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents: PA/PH/OMCL (08) 69 3R \u2014 *Validation of computerised systems \u2014 core document* (http://www.edqm.eu/site/Validation_of_Computerised_Systems_Core_Documentpdf-en-8390-2.html) and its annexes:\n\n    - PA/PH/OMCL (08) 87 2R \u2014 Annex 1: Validation of computerised calculation systems: example of validation of in-house software (http://www.edqm.eu/site/NEW_Annex_1_Validation_of_computerised_calculationpdf-en-8391-2.html).\n\n    - PA/PH/OMCL (08) 88 R \u2014 Annex 2: Validation of Databases (DB), Laboratory Information Management Systems (LIMS) and Electronic Laboratory Notebooks (ELN) (http://www.edqm.eu/site/NEW_Annex_2_Validation_of_Databases_DB_Laboratory_pdf-en-8392-2.html).\n\n    - PA/PH/OMCL (08) 89 R \u2014 Annex 3: Validation of computers as part of test equipment (http://www.edqm.eu/site/NEW_Annex_3_Validation_of_computers_as_part_of_tespcdf-en-8393-2.html).\n\n18. *Guidelines for good laboratory practice and guidelines for the testing of chemicals*. Organisation for Economic Co-operation and Development (OECD), Environment Directorate, Chemical Safety. (http://www.oecd.org/document/63/0,3343,en_2649_34381_2346175_1_1_1_1,00.html).\n\n19. *The International Pharmacopoeia*, Fourth Edition (including First Supplement). Vol. 2. Methods of analysis. Geneva, World Health Organization, 2008 (http://www.who.int/phint).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2988, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "783b5a2c-f01e-43eb-a108-ea3fa02809a6": {"__data__": {"id_": "783b5a2c-f01e-43eb-a108-ea3fa02809a6", "embedding": null, "metadata": {"page_label": "137", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 20. Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents:\n\n- PA/PH/OMCL (08) 73 \u2014 Qualification of equipment (http://www.edqm.eu/medias/fichiers/NEW_Qualification_of_equipment_core_document.pdf).\n- PA/PH/OMCL (07) 17 DEF \u2013Annex 1: Qualification of HPLC equipment (http://www.edqm.eu/medias/fichiers/Annex_1_Qualification_of_HPLC_Equipment.pdf).\n- PA/PH/OMCL (06) 86 DEF \u2014 Annex 2: Qualification of GC Equipment (http://www.edqm.eu/medias/fichiers/Annex_2_Qualification_of_GC_equipment.pdf).\n- PA/PH/OMCL (07) 11 DEF CORR \u2014 Annex 3: Qualification of UV-visible spectrophotometers (http://www.edqm.eu/medias/fichiers/Annex_3_Qualification_of_UV_Visible_spectrophotometers.pdf).\n- PA/PH/OMCL (07) 12 DEF CORR - Annex 4: Qualification of IR spectrophotometers (http://www.edqm.eu/medias/fichiers/Annex_4_Qualification_of_IR_spectrophotometers.pdf).\n- PA/PH/OMCL (07) 108 3R \u2014 Annex 5: Qualification of automatic titrators (http://www.edqm.eu/medias/fichiers/NEW_Annex_5_Qualification_of_Automatic_Titrators.pdf).\n\n# 21. *US Pharmacopeia*, 32nd ed. General chapters: <1058> Analytical instrument qualification. Rockville, MD, 2009.\n\n# 22. WHO guidelines for sampling of pharmaceutical products and related materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 4 (WHO Technical Report Series, No. 929).\n\n# 23. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 2 (WHO Technical Report Series, No. 953).\n\n# 24. Supplementary guidelines in good manufacturing practice: validation. Analytical method validation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 4, Appendix 4 (WHO Technical Report Series, No. 937).\n\n# 25. Guideline of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH Q2(R1): Validation of analytical procedures: text and methodology (http://www.ich.org/LOB/media/MEDIA417.pdf).\n\n# 26. Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents: PA/PH/OMCL (05) 47 DEF \u2014 Validation of analytical procedures (http://www.edqm.eu/medias/fichiers/Validation_of_Analytical_Procedures.pdf).\n\n# 27. *The US Pharmacopeia*, 32nd ed. General chapters: <1225> Validation of compendial procedures and <1226> Verification of compendial procedures. Rockville, MD, 2009.\n\n# 28. Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents: PA/PH/OMCL (07) 28 DEF CORR \u2014", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series) y se centra en la calidad y validaci\u00f3n de procedimientos anal\u00edticos en laboratorios de control de medicamentos. Incluye referencias a documentos de calidad de la Red de Laboratorios de Control de Medicamentos de Europa, as\u00ed como gu\u00edas de la OMS y la Farmacopea de EE. UU. sobre la calificaci\u00f3n de equipos, validaci\u00f3n de procedimientos anal\u00edticos y muestreo de productos farmac\u00e9uticos. Se mencionan varios documentos espec\u00edficos que abordan la calificaci\u00f3n de diferentes tipos de equipos anal\u00edticos, as\u00ed como directrices sobre la validaci\u00f3n de m\u00e9todos anal\u00edticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los documentos clave de la Red de Laboratorios de Control de Medicamentos de Europa que abordan la calificaci\u00f3n de equipos anal\u00edticos y qu\u00e9 tipos de equipos cubren?**\n   - Respuesta: Los documentos clave incluyen PA/PH/OMCL (08) 73 sobre la calificaci\u00f3n de equipos en general, PA/PH/OMCL (07) 17 DEF sobre la calificaci\u00f3n de equipos HPLC, PA/PH/OMCL (06) 86 DEF sobre la calificaci\u00f3n de equipos GC, y otros que cubren espectrofot\u00f3metros UV-visible, espectrofot\u00f3metros IR y tituladores autom\u00e1ticos.\n\n2. **\u00bfQu\u00e9 directrices proporciona la OMS sobre la validaci\u00f3n de m\u00e9todos anal\u00edticos y en qu\u00e9 informes se encuentran?**\n   - Respuesta: La OMS proporciona directrices sobre la validaci\u00f3n de m\u00e9todos anal\u00edticos en el informe de la *Expert Committee on Specifications for Pharmaceutical Preparations* (Fortieth report, 2006), que incluye un anexo sobre validaci\u00f3n de m\u00e9todos anal\u00edticos. Tambi\u00e9n se menciona el documento PA/PH/OMCL (05) 47 DEF sobre la validaci\u00f3n de procedimientos anal\u00edticos.\n\n3. **\u00bfQu\u00e9 importancia tiene la calificaci\u00f3n de instrumentos anal\u00edticos seg\u00fan la Farmacopea de EE. UU. y qu\u00e9 cap\u00edtulos espec\u00edficos se mencionan en el contexto?**\n   - Respuesta: La calificaci\u00f3n de instrumentos anal\u00edticos es crucial para asegurar la precisi\u00f3n y confiabilidad de los resultados en el an\u00e1lisis de productos farmac\u00e9uticos. En la 32\u00aa edici\u00f3n de la Farmacopea de EE. UU., se mencionan los cap\u00edtulos <1058> sobre la calificaci\u00f3n de instrumentos anal\u00edticos y <1225> y <1226> sobre la validaci\u00f3n y verificaci\u00f3n de procedimientos compendiales.", "prev_section_summary": "La secci\u00f3n proporcionada contiene una lista de referencias relacionadas con las buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) y la validaci\u00f3n de sistemas computarizados en el \u00e1mbito farmac\u00e9utico. A continuaci\u00f3n se resumen los temas clave y las entidades mencionadas:\n\n### Temas Clave:\n1. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (GMP)**: Directrices y recomendaciones para asegurar la calidad en la producci\u00f3n farmac\u00e9utica.\n2. **Validaci\u00f3n de Sistemas Computarizados**: Proceso de asegurar que los sistemas inform\u00e1ticos utilizados en la fabricaci\u00f3n y control de productos farmac\u00e9uticos funcionan correctamente y cumplen con los requisitos establecidos.\n3. **Regulaciones y Normativas**: Incluye regulaciones de la OMS, FDA y la UE sobre la gesti\u00f3n de datos electr\u00f3nicos y la validaci\u00f3n de sistemas.\n4. **Gu\u00edas de Buenas Pr\u00e1cticas Automatizadas (GAMP)**: Documentos que proporcionan directrices sobre la validaci\u00f3n de sistemas automatizados en laboratorios y la gesti\u00f3n de datos electr\u00f3nicos.\n5. **Pr\u00e1cticas de Laboratorio**: Normativas sobre buenas pr\u00e1cticas de laboratorio y pruebas de productos qu\u00edmicos.\n\n### Entidades Mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Proporciona directrices y recomendaciones sobre GMP y validaci\u00f3n.\n- **Administraci\u00f3n de Alimentos y Medicamentos de EE. UU. (FDA)**: Regula el uso de registros electr\u00f3nicos y firmas electr\u00f3nicas en la industria farmac\u00e9utica.\n- **Organizaci\u00f3n para la Cooperaci\u00f3n y el Desarrollo Econ\u00f3mico (OCDE)**: Ofrece directrices sobre buenas pr\u00e1cticas de laboratorio.\n- **Sociedad Internacional de Ingenier\u00eda Farmac\u00e9utica (ISPE)**: Publica gu\u00edas sobre buenas pr\u00e1cticas automatizadas.\n- **Consejo de Europa**: A trav\u00e9s de su red de Laboratorios de Control de Medicamentos Oficiales, proporciona documentos sobre la validaci\u00f3n de sistemas computarizados.\n\n### Documentos Espec\u00edficos:\n- Directrices de la OMS sobre la validaci\u00f3n de sistemas y equipos.\n- Regulaciones del 21 CFR Part 11 de la FDA sobre registros y firmas electr\u00f3nicas.\n- Anexos de la red de Laboratorios de Control de Medicamentos Oficiales del Consejo de Europa que abordan la validaci\u00f3n de sistemas computarizados, bases de datos y equipos de prueba.\n\nEste resumen destaca la importancia de la regulaci\u00f3n y las buenas pr\u00e1cticas en la industria farmac\u00e9utica, as\u00ed como la interconexi\u00f3n entre diferentes entidades y sus directrices.", "excerpt_keywords": "Keywords: validation, analytical procedures, quality assurance, pharmaceutical, equipment qualification"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bd26c895-3f3a-4511-9110-df3ffee9494c", "node_type": "4", "metadata": {"page_label": "137", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 20. Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents:\n\n- PA/PH/OMCL (08) 73 \u2014 Qualification of equipment (http://www.edqm.eu/medias/fichiers/NEW_Qualification_of_equipment_core_document.pdf).\n- PA/PH/OMCL (07) 17 DEF \u2013Annex 1: Qualification of HPLC equipment (http://www.edqm.eu/medias/fichiers/Annex_1_Qualification_of_HPLC_Equipment.pdf).\n- PA/PH/OMCL (06) 86 DEF \u2014 Annex 2: Qualification of GC Equipment (http://www.edqm.eu/medias/fichiers/Annex_2_Qualification_of_GC_equipment.pdf).\n- PA/PH/OMCL (07) 11 DEF CORR \u2014 Annex 3: Qualification of UV-visible spectrophotometers (http://www.edqm.eu/medias/fichiers/Annex_3_Qualification_of_UV_Visible_spectrophotometers.pdf).\n- PA/PH/OMCL (07) 12 DEF CORR - Annex 4: Qualification of IR spectrophotometers (http://www.edqm.eu/medias/fichiers/Annex_4_Qualification_of_IR_spectrophotometers.pdf).\n- PA/PH/OMCL (07) 108 3R \u2014 Annex 5: Qualification of automatic titrators (http://www.edqm.eu/medias/fichiers/NEW_Annex_5_Qualification_of_Automatic_Titrators.pdf).\n\n# 21. *US Pharmacopeia*, 32nd ed. General chapters: <1058> Analytical instrument qualification. Rockville, MD, 2009.\n\n# 22. WHO guidelines for sampling of pharmaceutical products and related materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 4 (WHO Technical Report Series, No. 929).\n\n# 23. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 2 (WHO Technical Report Series, No. 953).\n\n# 24. Supplementary guidelines in good manufacturing practice: validation. Analytical method validation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 4, Appendix 4 (WHO Technical Report Series, No. 937).\n\n# 25. Guideline of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH Q2(R1): Validation of analytical procedures: text and methodology (http://www.ich.org/LOB/media/MEDIA417.pdf).\n\n# 26. Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents: PA/PH/OMCL (05) 47 DEF \u2014 Validation of analytical procedures (http://www.edqm.eu/medias/fichiers/Validation_of_Analytical_Procedures.pdf).\n\n# 27. *The US Pharmacopeia*, 32nd ed. General chapters: <1225> Validation of compendial procedures and <1226> Verification of compendial procedures. Rockville, MD, 2009.\n\n# 28. Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents: PA/PH/OMCL (07) 28 DEF CORR \u2014", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "46bdcfa93badb42baf85c04fcc3b7435995764c2e4523ddb6bcb2ecbb74d980a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 20. Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents:\n\n- PA/PH/OMCL (08) 73 \u2014 Qualification of equipment (http://www.edqm.eu/medias/fichiers/NEW_Qualification_of_equipment_core_document.pdf).\n- PA/PH/OMCL (07) 17 DEF \u2013Annex 1: Qualification of HPLC equipment (http://www.edqm.eu/medias/fichiers/Annex_1_Qualification_of_HPLC_Equipment.pdf).\n- PA/PH/OMCL (06) 86 DEF \u2014 Annex 2: Qualification of GC Equipment (http://www.edqm.eu/medias/fichiers/Annex_2_Qualification_of_GC_equipment.pdf).\n- PA/PH/OMCL (07) 11 DEF CORR \u2014 Annex 3: Qualification of UV-visible spectrophotometers (http://www.edqm.eu/medias/fichiers/Annex_3_Qualification_of_UV_Visible_spectrophotometers.pdf).\n- PA/PH/OMCL (07) 12 DEF CORR - Annex 4: Qualification of IR spectrophotometers (http://www.edqm.eu/medias/fichiers/Annex_4_Qualification_of_IR_spectrophotometers.pdf).\n- PA/PH/OMCL (07) 108 3R \u2014 Annex 5: Qualification of automatic titrators (http://www.edqm.eu/medias/fichiers/NEW_Annex_5_Qualification_of_Automatic_Titrators.pdf).\n\n# 21. *US Pharmacopeia*, 32nd ed. General chapters: <1058> Analytical instrument qualification. Rockville, MD, 2009.\n\n# 22. WHO guidelines for sampling of pharmaceutical products and related materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 4 (WHO Technical Report Series, No. 929).\n\n# 23. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 2 (WHO Technical Report Series, No. 953).\n\n# 24. Supplementary guidelines in good manufacturing practice: validation. Analytical method validation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 4, Appendix 4 (WHO Technical Report Series, No. 937).\n\n# 25. Guideline of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH Q2(R1): Validation of analytical procedures: text and methodology (http://www.ich.org/LOB/media/MEDIA417.pdf).\n\n# 26. Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents: PA/PH/OMCL (05) 47 DEF \u2014 Validation of analytical procedures (http://www.edqm.eu/medias/fichiers/Validation_of_Analytical_Procedures.pdf).\n\n# 27. *The US Pharmacopeia*, 32nd ed. General chapters: <1225> Validation of compendial procedures and <1226> Verification of compendial procedures. Rockville, MD, 2009.\n\n# 28. Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents: PA/PH/OMCL (07) 28 DEF CORR \u2014", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2857, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "570d9214-026b-4faf-b558-2f3702c757e8": {"__data__": {"id_": "570d9214-026b-4faf-b558-2f3702c757e8", "embedding": null, "metadata": {"page_label": "138", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\nEvaluation and reporting of results (http://www.edqm.eu/medias/fichiers/ Evaluation_Reporting_of_Results.pdf).\n\n29. **Shewhart control charts.** International Organization for Standardization, 1991 (ISO 8258).\n\n30. **Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents:**\n\n   \u2014 PA/PH/OMCL (05) 49 DEF CORR \u2014 Uncertainty of measurement \u2014 Part 1: General OMCL policy for implementation of measurement uncertainty in compliance testing (http://www.edqm.eu/medias/fichiers/Uncertainty_ of_Measurements_Part_I_Compliance_testing.pdf).\n\n   \u2014 PA/PH/OMCL (07) 106 DEF \u2014 Uncertainty of measurement \u2014 Part 2: OMCL policy on the estimation and application of uncertainty in analytical measurement (http://www.edqm.eu/medias/fichiers/ Uncertainty_of_Measurements_Part_II_Other_than_compliance_testing. pdf).\n\n31. **EURACHEM/Cooperation on International Traceability in Analytical Chemistry (CITAC) Guides.** *Quantifying uncertainty in analytical measurement,* 2nd ed, EURACHEM/CITAC, 2000.\n\n32. **EURACHEM/Cooperation on International Traceability in Analytical Chemistry (CITAC) Guides.** *Use of uncertainty information in compliance assessment,* EURACHEM/CITAC, 2007 (http://www.measurementuncertainty.org/).\n```\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 957\" incluye informaci\u00f3n sobre la evaluaci\u00f3n y el reporte de resultados en el contexto de laboratorios de control de medicamentos. Se mencionan gu\u00edas y documentos relacionados con la incertidumbre de medici\u00f3n, as\u00ed como est\u00e1ndares internacionales, como los gr\u00e1ficos de control de Shewhart y las pol\u00edticas de la Red de Laboratorios de Control de Medicamentos de Europa. Tambi\u00e9n se abordan gu\u00edas de EURACHEM sobre la cuantificaci\u00f3n de la incertidumbre en mediciones anal\u00edticas y su uso en la evaluaci\u00f3n de cumplimiento.\n\n### Preguntas\n1. **\u00bfQu\u00e9 documentos espec\u00edficos se mencionan en relaci\u00f3n con la incertidumbre de medici\u00f3n en el contexto de los laboratorios de control de medicamentos?**\n   - Respuesta: Se mencionan dos documentos de la Red de Laboratorios de Control de Medicamentos de Europa: PA/PH/OMCL (05) 49 DEF CORR, que trata sobre la pol\u00edtica general para la implementaci\u00f3n de la incertidumbre de medici\u00f3n en pruebas de cumplimiento, y PA/PH/OMCL (07) 106 DEF, que aborda la estimaci\u00f3n y aplicaci\u00f3n de la incertidumbre en mediciones anal\u00edticas.\n\n2. **\u00bfCu\u00e1l es el prop\u00f3sito de los gr\u00e1ficos de control de Shewhart seg\u00fan el contexto del documento?**\n   - Respuesta: Los gr\u00e1ficos de control de Shewhart, mencionados en el documento, son herramientas utilizadas para el control de calidad en procesos, permitiendo la visualizaci\u00f3n de la variabilidad en los resultados de mediciones y ayudando a identificar tendencias o desviaciones en el proceso.\n\n3. **\u00bfQu\u00e9 gu\u00edas de EURACHEM se citan en el documento y cu\u00e1l es su enfoque principal?**\n   - Respuesta: Se citan dos gu\u00edas de EURACHEM: \"Quantifying uncertainty in analytical measurement,\" que se centra en la cuantificaci\u00f3n de la incertidumbre en mediciones anal\u00edticas, y \"Use of uncertainty information in compliance assessment,\" que aborda c\u00f3mo utilizar la informaci\u00f3n sobre incertidumbre en la evaluaci\u00f3n de cumplimiento.", "prev_section_summary": "La secci\u00f3n proporciona informaci\u00f3n sobre la calidad y validaci\u00f3n de procedimientos anal\u00edticos en laboratorios de control de medicamentos, destacando documentos y directrices relevantes de diversas entidades. A continuaci\u00f3n se resumen los temas clave y entidades mencionadas:\n\n### Temas Clave:\n1. **Calificaci\u00f3n de Equipos Anal\u00edticos**: Se mencionan documentos espec\u00edficos que abordan la calificaci\u00f3n de diferentes tipos de equipos anal\u00edticos, como HPLC, GC, espectrofot\u00f3metros UV-visible e IR, y tituladores autom\u00e1ticos.\n2. **Validaci\u00f3n de M\u00e9todos Anal\u00edticos**: Se discuten directrices sobre la validaci\u00f3n de procedimientos anal\u00edticos, incluyendo la validaci\u00f3n de m\u00e9todos y procedimientos compendiales.\n3. **Muestreo de Productos Farmac\u00e9uticos**: Se incluyen pautas de la OMS sobre el muestreo de productos farmac\u00e9uticos y materiales relacionados.\n4. **Estabilidad de Ingredientes Activos**: Se abordan las pruebas de estabilidad de ingredientes farmac\u00e9uticos activos y productos farmac\u00e9uticos terminados.\n5. **Buenas Pr\u00e1cticas de Manufactura**: Se mencionan directrices suplementarias sobre la validaci\u00f3n en el contexto de las buenas pr\u00e1cticas de manufactura.\n\n### Entidades Mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Proporciona directrices y recomendaciones sobre la calidad y validaci\u00f3n de procedimientos anal\u00edticos.\n- **Farmacopea de EE. UU.**: Incluye cap\u00edtulos relevantes sobre la calificaci\u00f3n y validaci\u00f3n de instrumentos anal\u00edticos.\n- **Red de Laboratorios de Control de Medicamentos de Europa**: Publica documentos de calidad que abordan la calificaci\u00f3n y validaci\u00f3n de equipos y procedimientos anal\u00edticos.\n\n### Documentos Clave Citados:\n- PA/PH/OMCL documentos sobre calificaci\u00f3n y validaci\u00f3n de equipos.\n- Informes de la OMS sobre especificaciones para preparaciones farmac\u00e9uticas.\n- Directrices de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) sobre validaci\u00f3n de procedimientos anal\u00edticos.\n\nEste resumen destaca la importancia de la calificaci\u00f3n y validaci\u00f3n en el contexto de la calidad de los productos farmac\u00e9uticos y el cumplimiento de normativas internacionales.", "excerpt_keywords": "Keywords: incertidumbre de medici\u00f3n, gr\u00e1ficos de control, validaci\u00f3n anal\u00edtica, laboratorios de control de medicamentos, EURACHEM"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ae06a615-5c92-4d52-b938-f6b5dff9c1bc", "node_type": "4", "metadata": {"page_label": "138", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\nEvaluation and reporting of results (http://www.edqm.eu/medias/fichiers/ Evaluation_Reporting_of_Results.pdf).\n\n29. **Shewhart control charts.** International Organization for Standardization, 1991 (ISO 8258).\n\n30. **Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents:**\n\n   \u2014 PA/PH/OMCL (05) 49 DEF CORR \u2014 Uncertainty of measurement \u2014 Part 1: General OMCL policy for implementation of measurement uncertainty in compliance testing (http://www.edqm.eu/medias/fichiers/Uncertainty_ of_Measurements_Part_I_Compliance_testing.pdf).\n\n   \u2014 PA/PH/OMCL (07) 106 DEF \u2014 Uncertainty of measurement \u2014 Part 2: OMCL policy on the estimation and application of uncertainty in analytical measurement (http://www.edqm.eu/medias/fichiers/ Uncertainty_of_Measurements_Part_II_Other_than_compliance_testing. pdf).\n\n31. **EURACHEM/Cooperation on International Traceability in Analytical Chemistry (CITAC) Guides.** *Quantifying uncertainty in analytical measurement,* 2nd ed, EURACHEM/CITAC, 2000.\n\n32. **EURACHEM/Cooperation on International Traceability in Analytical Chemistry (CITAC) Guides.** *Use of uncertainty information in compliance assessment,* EURACHEM/CITAC, 2007 (http://www.measurementuncertainty.org/).\n```\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "287277aab5eee91542de974a48695ce60be7bbec5c7f753aebe7621f293f1276", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "```\nEvaluation and reporting of results (http://www.edqm.eu/medias/fichiers/ Evaluation_Reporting_of_Results.pdf).\n\n29. **Shewhart control charts.** International Organization for Standardization, 1991 (ISO 8258).\n\n30. **Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents:**\n\n   \u2014 PA/PH/OMCL (05) 49 DEF CORR \u2014 Uncertainty of measurement \u2014 Part 1: General OMCL policy for implementation of measurement uncertainty in compliance testing (http://www.edqm.eu/medias/fichiers/Uncertainty_ of_Measurements_Part_I_Compliance_testing.pdf).\n\n   \u2014 PA/PH/OMCL (07) 106 DEF \u2014 Uncertainty of measurement \u2014 Part 2: OMCL policy on the estimation and application of uncertainty in analytical measurement (http://www.edqm.eu/medias/fichiers/ Uncertainty_of_Measurements_Part_II_Other_than_compliance_testing. pdf).\n\n31. **EURACHEM/Cooperation on International Traceability in Analytical Chemistry (CITAC) Guides.** *Quantifying uncertainty in analytical measurement,* 2nd ed, EURACHEM/CITAC, 2000.\n\n32. **EURACHEM/Cooperation on International Traceability in Analytical Chemistry (CITAC) Guides.** *Use of uncertainty information in compliance assessment,* EURACHEM/CITAC, 2007 (http://www.measurementuncertainty.org/).\n```", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1258, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "2c5b8818-24c9-4588-9d05-d619c26c784c": {"__data__": {"id_": "2c5b8818-24c9-4588-9d05-d619c26c784c", "embedding": null, "metadata": {"page_label": "139", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Appendix\n\n## Equipment for a first-stage and medium-sized pharmaceutical quality control laboratory\n\nA list of equipment considered by the Committee to be adequate either for a first-stage or medium-sized pharmaceutical quality control laboratory is given in the table. In the case of a medium-sized laboratory, specific sectors are devoted to a microbiology unit and pharmacognosy/phytochemistry unit. For a first-stage laboratory testing herbal medicines, the additional equipment recommended is specified in the table.\n\nThis list does not represent any requirements which should be fulfilled to comply with these guidelines. NMRAs or laboratories wishing to perform pharmaceutical analyses may consider the following list in the establishment or upgrading of their testing facilities. For budgetary reasons it is necessary, besides the cost of equipment, to take into consideration the cost of reference materials, reagents, solvents, glassware, other laboratory commodities and personnel. Experience has shown that for sustainability, a laboratory should allow a margin of 10\u201315% per year of the purchasing expenditure on equipment to cover the cost of maintenance.\n\n### Table\n\n**Equipment for a first-stage and medium-sized pharmaceutical quality control laboratory**\n\n| First-stage laboratory | Quantity |\n| - | - |\n| **Equipment and major instruments** | |\n| Top-loading balance | 1 |\n| Analytical balance (5 digits) | 1 or 2 |\n| Melting-point apparatus | 1 |\n| pH meter (with assorted electrodes) | 1 |\n| Microscope | 1 |\n| Polarimeter | 1 |\n| High-performance liquid chromatograph with ultraviolet detector | 2 |\n| Ultraviolet/visible spectrophotometer | 1 |\n| Infrared spectrophotometer with pellet press | 1 |\n| Karl Fischer titrator (semi-micro determination of water) | 1 |\n| Agate mortar with pestle | 1 |\n| Equipment for thin-layer chromatography | 1 |\n| Thin-layer chromatography spotter | 1 |\n| Developing chambers | 6 + 1a |\n| Atomizers | 6 |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona una lista de equipos recomendados para laboratorios de control de calidad farmac\u00e9utica de primera etapa y de tama\u00f1o mediano. Se menciona que los laboratorios de tama\u00f1o mediano deben tener unidades espec\u00edficas para microbiolog\u00eda y farmacognosia/fitoqu\u00edmica. Adem\u00e1s, se destaca que la lista no es un requisito obligatorio, sino una gu\u00eda para que las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) y laboratorios consideren al establecer o mejorar sus instalaciones de an\u00e1lisis farmac\u00e9utico. Tambi\u00e9n se enfatiza la importancia de considerar los costos de mantenimiento y otros insumos al planificar el presupuesto del laboratorio.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 tipo de equipo adicional se recomienda espec\u00edficamente para un laboratorio de primera etapa que se dedica a la prueba de medicamentos herbales?**\n   - Esta pregunta busca informaci\u00f3n sobre los equipos que son necesarios para un laboratorio que se especializa en medicamentos herbales, que no se menciona expl\u00edcitamente en la tabla.\n\n2. **\u00bfCu\u00e1l es la proporci\u00f3n recomendada del gasto en equipos que un laboratorio debe reservar anualmente para cubrir los costos de mantenimiento?**\n   - Esta pregunta se centra en la sostenibilidad financiera del laboratorio, un aspecto que puede no ser evidente en otros documentos relacionados.\n\n3. **\u00bfQu\u00e9 consideraciones presupuestarias deben tener en cuenta las NMRAs al establecer un laboratorio de control de calidad farmac\u00e9utica?**\n   - Esta pregunta busca detalles sobre los factores financieros que deben ser considerados m\u00e1s all\u00e1 del costo del equipo, como materiales de referencia, reactivos y personal, que son cruciales para la operaci\u00f3n efectiva del laboratorio.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Evaluaci\u00f3n y Reporte de Resultados**: Se aborda la importancia de la evaluaci\u00f3n y el reporte de resultados en el contexto de los laboratorios de control de medicamentos.\n\n2. **Gr\u00e1ficos de Control de Shewhart**: Se menciona el uso de gr\u00e1ficos de control de Shewhart como herramientas para el control de calidad, que permiten visualizar la variabilidad en los resultados de mediciones.\n\n3. **Incertidumbre de Medici\u00f3n**: Se citan documentos espec\u00edficos de la Red de Laboratorios de Control de Medicamentos de Europa que tratan sobre la pol\u00edtica de implementaci\u00f3n y estimaci\u00f3n de la incertidumbre de medici\u00f3n en pruebas de cumplimiento y en mediciones anal\u00edticas.\n\n4. **Gu\u00edas de EURACHEM**: Se mencionan dos gu\u00edas de EURACHEM:\n   - *Quantifying uncertainty in analytical measurement* (2\u00aa ed., 2000): Enfocada en la cuantificaci\u00f3n de la incertidumbre en mediciones anal\u00edticas.\n   - *Use of uncertainty information in compliance assessment* (2007): Aborda el uso de la informaci\u00f3n sobre incertidumbre en la evaluaci\u00f3n de cumplimiento.\n\n### Entidades Clave\n- **Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO)**: Referenciada en relaci\u00f3n con los gr\u00e1ficos de control de Shewhart.\n- **Red de Laboratorios de Control de Medicamentos de Europa (OMCL)**: Proporciona documentos sobre la incertidumbre de medici\u00f3n.\n- **EURACHEM**: Organizaci\u00f3n que ofrece gu\u00edas sobre la incertidumbre en mediciones anal\u00edticas y su aplicaci\u00f3n en la evaluaci\u00f3n de cumplimiento. \n\nEste resumen destaca los aspectos fundamentales del contenido, centr\u00e1ndose en la evaluaci\u00f3n de resultados, la incertidumbre de medici\u00f3n y las gu\u00edas relevantes para los laboratorios de control de medicamentos.", "excerpt_keywords": "Keywords: pharmaceutical quality control, laboratory equipment, herbal medicines, budget considerations, sustainability"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "21c0a27a-4243-4558-b285-896062db867d", "node_type": "4", "metadata": {"page_label": "139", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Appendix\n\n## Equipment for a first-stage and medium-sized pharmaceutical quality control laboratory\n\nA list of equipment considered by the Committee to be adequate either for a first-stage or medium-sized pharmaceutical quality control laboratory is given in the table. In the case of a medium-sized laboratory, specific sectors are devoted to a microbiology unit and pharmacognosy/phytochemistry unit. For a first-stage laboratory testing herbal medicines, the additional equipment recommended is specified in the table.\n\nThis list does not represent any requirements which should be fulfilled to comply with these guidelines. NMRAs or laboratories wishing to perform pharmaceutical analyses may consider the following list in the establishment or upgrading of their testing facilities. For budgetary reasons it is necessary, besides the cost of equipment, to take into consideration the cost of reference materials, reagents, solvents, glassware, other laboratory commodities and personnel. Experience has shown that for sustainability, a laboratory should allow a margin of 10\u201315% per year of the purchasing expenditure on equipment to cover the cost of maintenance.\n\n### Table\n\n**Equipment for a first-stage and medium-sized pharmaceutical quality control laboratory**\n\n| First-stage laboratory | Quantity |\n| - | - |\n| **Equipment and major instruments** | |\n| Top-loading balance | 1 |\n| Analytical balance (5 digits) | 1 or 2 |\n| Melting-point apparatus | 1 |\n| pH meter (with assorted electrodes) | 1 |\n| Microscope | 1 |\n| Polarimeter | 1 |\n| High-performance liquid chromatograph with ultraviolet detector | 2 |\n| Ultraviolet/visible spectrophotometer | 1 |\n| Infrared spectrophotometer with pellet press | 1 |\n| Karl Fischer titrator (semi-micro determination of water) | 1 |\n| Agate mortar with pestle | 1 |\n| Equipment for thin-layer chromatography | 1 |\n| Thin-layer chromatography spotter | 1 |\n| Developing chambers | 6 + 1a |\n| Atomizers | 6 |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "c35a1b6e7e445da8bb87f93f729f2a5413b99c5624a0b0d42eea45b5bdbea8f7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Appendix\n\n## Equipment for a first-stage and medium-sized pharmaceutical quality control laboratory\n\nA list of equipment considered by the Committee to be adequate either for a first-stage or medium-sized pharmaceutical quality control laboratory is given in the table. In the case of a medium-sized laboratory, specific sectors are devoted to a microbiology unit and pharmacognosy/phytochemistry unit. For a first-stage laboratory testing herbal medicines, the additional equipment recommended is specified in the table.\n\nThis list does not represent any requirements which should be fulfilled to comply with these guidelines. NMRAs or laboratories wishing to perform pharmaceutical analyses may consider the following list in the establishment or upgrading of their testing facilities. For budgetary reasons it is necessary, besides the cost of equipment, to take into consideration the cost of reference materials, reagents, solvents, glassware, other laboratory commodities and personnel. Experience has shown that for sustainability, a laboratory should allow a margin of 10\u201315% per year of the purchasing expenditure on equipment to cover the cost of maintenance.\n\n### Table\n\n**Equipment for a first-stage and medium-sized pharmaceutical quality control laboratory**\n\n| First-stage laboratory | Quantity |\n| - | - |\n| **Equipment and major instruments** | |\n| Top-loading balance | 1 |\n| Analytical balance (5 digits) | 1 or 2 |\n| Melting-point apparatus | 1 |\n| pH meter (with assorted electrodes) | 1 |\n| Microscope | 1 |\n| Polarimeter | 1 |\n| High-performance liquid chromatograph with ultraviolet detector | 2 |\n| Ultraviolet/visible spectrophotometer | 1 |\n| Infrared spectrophotometer with pellet press | 1 |\n| Karl Fischer titrator (semi-micro determination of water) | 1 |\n| Agate mortar with pestle | 1 |\n| Equipment for thin-layer chromatography | 1 |\n| Thin-layer chromatography spotter | 1 |\n| Developing chambers | 6 + 1a |\n| Atomizers | 6 |", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1962, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c150a8d2-e191-4c89-b1ef-af078d380260": {"__data__": {"id_": "c150a8d2-e191-4c89-b1ef-af078d380260", "embedding": null, "metadata": {"page_label": "140", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\n| First-stage laboratory (cont.) | First-stage laboratory (cont.) |\n| - | - |\n| Ultraviolet viewing lamp | 1 |\n| Disintegration test equipment (1 basket for 6 tablets) | 1 |\n| Dissolution apparatus | 1 |\n| Soxhlet extraction apparatus (60 ml) | 3 + 1a |\n| Micrometer callipers | 1 |\n| Pycnometers | 2 |\n| Burettes/pipettes (10 ml and 25 ml/1, 2, 5, 10, 20, 25, 50 ml) | 3 of each |\n| Desiccator | 1 + 1a |\n| Centrifuge (table-top model, 4-place swing rotor) | 1 |\n| Water-bath (20 litres) | 1 |\n| Hot plates with magnetic stirrers | 3 |\n| Vacuum pump (rotary, oil) | 1 |\n| Drying oven (60 litres) | 1 |\n| Vacuum oven (17 litres) | 1 |\n| Muffle furnace | 1 |\n| Refrigerator (explosion-proof) | 1 |\n| Water distilling apparatus (8 litres/hour) | 1 |\n| Water deionizer (10 litres/hour) | 1 |\n| Dehumidifier (where needed) | 1 |\n| Fume hood | 1 |\n\n\n| Optional items | Optional items |\n| - | - |\n| Analytical microbalance | 1 |\n| Flame photometer (including air compressor) | 1 |\n| Refractometer | 1 |\n| Viscometer | 1 |\n| Vortex mixer | 1 |\n| Shaker (wrist-action) | 1 |\n| Pipette rinser | 1 |\n| Constant temperature water-bath | 1 |\n| Ultrasonic cleaner (5 litres) | 1 |\n\n\n| Medium-sized laboratory\\<br/>Equipment and major instruments | Medium-sized laboratory\\<br/>Quantity |\n| - | - |\n| Top-loading balance | 1 or 2 |\n| Analytical balance (5 digits) | 2 |\n| Analytical microbalance | 1 |\n\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1ntos Soxhlet extraction apparatus se requieren en un primer laboratorio de etapa?**\n   - Se requieren tres Soxhlet extraction apparatus de 60 ml, m\u00e1s uno adicional (3 + 1a).\n\n2. **\u00bfQu\u00e9 tipo de refrigerador se especifica para el primer laboratorio de etapa?**\n   - Se especifica un refrigerador que sea a prueba de explosiones.\n\n3. **\u00bfCu\u00e1ntos tipos diferentes de buretas y pipetas se necesitan y en qu\u00e9 vol\u00famenes?**\n   - Se necesitan tres buretas/pipetas de cada uno de los siguientes vol\u00famenes: 10 ml y 25 ml, as\u00ed como de 1, 2, 5, 10, 20, 25 y 50 ml.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona una lista detallada de equipos y aparatos necesarios para establecer un laboratorio de primer nivel y de tama\u00f1o mediano, seg\u00fan las recomendaciones de la OMS. Incluye tanto elementos obligatorios como opcionales, especificando cantidades y caracter\u00edsticas de cada uno. Los equipos abarcan desde instrumentos b\u00e1sicos como l\u00e1mparas UV y balanzas anal\u00edticas hasta aparatos m\u00e1s especializados como hornos de mufla y extractores Soxhlet.\n\n### Preguntas adicionales basadas en el resumen:\n4. **\u00bfQu\u00e9 tipo de balance se recomienda para un laboratorio de tama\u00f1o mediano y cu\u00e1ntos se deben tener?**\n   - Se recomienda tener uno o dos balances de carga superior y dos balances anal\u00edticos de 5 d\u00edgitos, adem\u00e1s de un microbalanza anal\u00edtica.\n\n5. **\u00bfQu\u00e9 tipo de equipo opcional se sugiere para mejorar las capacidades del laboratorio?**\n   - Se sugiere equipo opcional como un fot\u00f3metro de llama, un refract\u00f3metro, un viscometro, un mezclador de v\u00f3rtice, y un limpiador ultras\u00f3nico de 5 litros, entre otros.\n\n6. **\u00bfCu\u00e1l es la funci\u00f3n de un deshidratador en el laboratorio y cu\u00e1ndo es necesario?**\n   - Un deshidratador se utiliza para eliminar la humedad del aire en el laboratorio y se requiere donde sea necesario, dependiendo de las condiciones ambientales y los experimentos que se realicen.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Equipos Recomendados**: Se presenta una lista de equipos considerados adecuados para laboratorios de control de calidad farmac\u00e9utica de primera etapa y de tama\u00f1o mediano. Esta lista incluye instrumentos como balanzas, espectrofot\u00f3metros, y equipos para cromatograf\u00eda.\n\n2. **Laboratorios de Tama\u00f1o Mediano**: Se menciona que estos laboratorios deben contar con unidades espec\u00edficas para microbiolog\u00eda y farmacognosia/fitoqu\u00edmica.\n\n3. **Gu\u00eda y No Requisitos**: La lista de equipos no es un requisito obligatorio, sino una gu\u00eda para las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) y laboratorios que deseen establecer o mejorar sus instalaciones.\n\n4. **Consideraciones Presupuestarias**: Se enfatiza la importancia de considerar no solo el costo del equipo, sino tambi\u00e9n los costos de materiales de referencia, reactivos, solventes, vidrio de laboratorio y personal al planificar el presupuesto.\n\n5. **Sostenibilidad Financiera**: Se recomienda que un laboratorio reserve entre el 10% y el 15% del gasto en equipos anualmente para cubrir los costos de mantenimiento.\n\n### Entidades Clave\n\n- **NMRAs**: Autoridades Nacionales Reguladoras de Medicamentos que pueden utilizar esta gu\u00eda para establecer laboratorios.\n- **Equipos de Laboratorio**: Incluyen balanzas, espectrofot\u00f3metros, cromat\u00f3grafos, entre otros.\n- **Unidades Espec\u00edficas**: Microbiolog\u00eda y farmacognosia/fitoqu\u00edmica en laboratorios de tama\u00f1o mediano. \n\nEste resumen destaca la importancia de la planificaci\u00f3n adecuada y la sostenibilidad en la operaci\u00f3n de laboratorios de control de calidad farmac\u00e9utica.", "excerpt_keywords": "Keywords: laboratory equipment, WHO guidelines, pharmaceutical quality control, analytical instruments, laboratory setup"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "12605885-5ed8-40e6-a888-5c34871c7242", "node_type": "4", "metadata": {"page_label": "140", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\n| First-stage laboratory (cont.) | First-stage laboratory (cont.) |\n| - | - |\n| Ultraviolet viewing lamp | 1 |\n| Disintegration test equipment (1 basket for 6 tablets) | 1 |\n| Dissolution apparatus | 1 |\n| Soxhlet extraction apparatus (60 ml) | 3 + 1a |\n| Micrometer callipers | 1 |\n| Pycnometers | 2 |\n| Burettes/pipettes (10 ml and 25 ml/1, 2, 5, 10, 20, 25, 50 ml) | 3 of each |\n| Desiccator | 1 + 1a |\n| Centrifuge (table-top model, 4-place swing rotor) | 1 |\n| Water-bath (20 litres) | 1 |\n| Hot plates with magnetic stirrers | 3 |\n| Vacuum pump (rotary, oil) | 1 |\n| Drying oven (60 litres) | 1 |\n| Vacuum oven (17 litres) | 1 |\n| Muffle furnace | 1 |\n| Refrigerator (explosion-proof) | 1 |\n| Water distilling apparatus (8 litres/hour) | 1 |\n| Water deionizer (10 litres/hour) | 1 |\n| Dehumidifier (where needed) | 1 |\n| Fume hood | 1 |\n\n\n| Optional items | Optional items |\n| - | - |\n| Analytical microbalance | 1 |\n| Flame photometer (including air compressor) | 1 |\n| Refractometer | 1 |\n| Viscometer | 1 |\n| Vortex mixer | 1 |\n| Shaker (wrist-action) | 1 |\n| Pipette rinser | 1 |\n| Constant temperature water-bath | 1 |\n| Ultrasonic cleaner (5 litres) | 1 |\n\n\n| Medium-sized laboratory\\<br/>Equipment and major instruments | Medium-sized laboratory\\<br/>Quantity |\n| - | - |\n| Top-loading balance | 1 or 2 |\n| Analytical balance (5 digits) | 2 |\n| Analytical microbalance | 1 |\n\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "3738b36e7c8b86ef98f594664a8aff06cf677eeaef1e9624216986887b8f1757", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| First-stage laboratory (cont.) | First-stage laboratory (cont.) |\n| - | - |\n| Ultraviolet viewing lamp | 1 |\n| Disintegration test equipment (1 basket for 6 tablets) | 1 |\n| Dissolution apparatus | 1 |\n| Soxhlet extraction apparatus (60 ml) | 3 + 1a |\n| Micrometer callipers | 1 |\n| Pycnometers | 2 |\n| Burettes/pipettes (10 ml and 25 ml/1, 2, 5, 10, 20, 25, 50 ml) | 3 of each |\n| Desiccator | 1 + 1a |\n| Centrifuge (table-top model, 4-place swing rotor) | 1 |\n| Water-bath (20 litres) | 1 |\n| Hot plates with magnetic stirrers | 3 |\n| Vacuum pump (rotary, oil) | 1 |\n| Drying oven (60 litres) | 1 |\n| Vacuum oven (17 litres) | 1 |\n| Muffle furnace | 1 |\n| Refrigerator (explosion-proof) | 1 |\n| Water distilling apparatus (8 litres/hour) | 1 |\n| Water deionizer (10 litres/hour) | 1 |\n| Dehumidifier (where needed) | 1 |\n| Fume hood | 1 |\n\n\n| Optional items | Optional items |\n| - | - |\n| Analytical microbalance | 1 |\n| Flame photometer (including air compressor) | 1 |\n| Refractometer | 1 |\n| Viscometer | 1 |\n| Vortex mixer | 1 |\n| Shaker (wrist-action) | 1 |\n| Pipette rinser | 1 |\n| Constant temperature water-bath | 1 |\n| Ultrasonic cleaner (5 litres) | 1 |\n\n\n| Medium-sized laboratory\\<br/>Equipment and major instruments | Medium-sized laboratory\\<br/>Quantity |\n| - | - |\n| Top-loading balance | 1 or 2 |\n| Analytical balance (5 digits) | 2 |\n| Analytical microbalance | 1 |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1388, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "163589c7-2d38-4505-8cc1-d5de8ae8f72c": {"__data__": {"id_": "163589c7-2d38-4505-8cc1-d5de8ae8f72c", "embedding": null, "metadata": {"page_label": "141", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\n| Medium-sized laboratory (cont.) | |\n| - | - |\n| Microscope | 1 or 2 |\n| Equipment for thin-layer chromatography | 1 |\n| Thin-layer chromatography multispotter | 1 |\n| Developing chambers | 6 |\n| Atomizers | 6 |\n| Ultraviolet viewing lamp | 1 |\n| Potentiometric titrimeter | 1 |\n| Micro-Kjeldahl equipment (including fume flasks) | 1 |\n| Soxhlet extraction apparatus (60 ml) | 3 |\n| Pycnometers | 2 |\n| Burettes/pipettes (10 ml and 25 ml/1, 2, 5, 10, 20, 25, 50 ml) | 6 of each |\n| Micrometer callipers | 1 |\n| Heating mantles for flasks (assorted sizes: 50, 200 and 2000 ml) | 6 |\n| Sieves (assorted sizes) | 1 set |\n| Centrifuge (floor model) | 1 |\n| Shaker (wrist-action) | 1 |\n| Vortex mixers | 2 |\n| Water-bath (electrical, 20 litres) | 2 or 3 |\n| Hot plates with magnetic stirrers | 3 or 4 |\n| Vacuum pump (rotary, oil) | 2 |\n| Vacuum rotary evaporator | 1 |\n| Drying oven (60 litres) | 2 or 3 |\n| Muffle furnace (23 litres) | 1 |\n| Vacuum oven (17 litres) | 1 |\n| Desiccators | 2 |\n| Refrigerator (explosion-proof) | 2 |\n| Freezer | 1 |\n| Ultrasonic cleaners (5 litres) | 2 |\n| Laboratory glassware washing machine | 1 |\n| Water distilling apparatus (8 litres/hour) | 1 |\n| Water deionizing equipment (10 litres/hour) | 1 |\n| Fume hoods | 2 |\n| Melting-point apparatus | 1 |\n| Polarimeter | 1 |\n| pH meters (with assorted electrodes) | 2 |\n| High-performance liquid chromatograph with variable wavelength | |\n| Ultraviolet/visible detector | 3 or 4 |\n\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 957\" detalla el equipamiento necesario para un laboratorio de tama\u00f1o mediano, incluyendo una lista exhaustiva de instrumentos y equipos esenciales para realizar diversas pruebas y an\u00e1lisis. La lista incluye microscopios, equipos de cromatograf\u00eda, centr\u00edfugas, y otros dispositivos de laboratorio, junto con cantidades recomendadas para cada uno.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1ntos tipos de equipos de cromatograf\u00eda se mencionan en el contexto y cu\u00e1les son?**\n   - Respuesta: Se mencionan dos tipos de equipos de cromatograf\u00eda: \"Equipo para cromatograf\u00eda en capa fina\" (1 unidad) y \"Cromat\u00f3grafo l\u00edquido de alta eficacia con longitud de onda variable\" (sin cantidad especificada).\n\n2. **\u00bfQu\u00e9 tipo de equipo se recomienda para la determinaci\u00f3n del pH y cu\u00e1ntas unidades se sugieren?**\n   - Respuesta: Se recomienda el uso de \"pH metros (con electrodos variados)\" y se sugieren 2 unidades.\n\n3. **\u00bfQu\u00e9 equipos de refrigeraci\u00f3n est\u00e1n incluidos en la lista y cu\u00e1ntas unidades de cada uno se requieren?**\n   - Respuesta: La lista incluye \"Refrigerador (a prueba de explosiones)\" con 2 unidades y \"Congelador\" con 1 unidad.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Equipos de laboratorio**: La secci\u00f3n detalla una lista de equipos y aparatos necesarios para establecer un laboratorio de primer nivel y de tama\u00f1o mediano, seg\u00fan las recomendaciones de la OMS.\n\n2. **Categor\u00edas de equipos**:\n   - **Equipos obligatorios**: Incluyen l\u00e1mparas UV, equipos de prueba de desintegraci\u00f3n, aparatos de disoluci\u00f3n, extractores Soxhlet, balanzas, centr\u00edfugas, hornos, refrigeradores a prueba de explosiones, entre otros.\n   - **Equipos opcionales**: Se mencionan elementos como fot\u00f3metros de llama, refract\u00f3metros, viscometros, mezcladores de v\u00f3rtice y limpiadores ultras\u00f3nicos.\n\n3. **Cantidades espec\u00edficas**: Se especifican las cantidades requeridas para cada tipo de equipo, como por ejemplo:\n   - 1 l\u00e1mpara UV\n   - 3 extractores Soxhlet\n   - 1 refrigerador a prueba de explosiones\n   - 1 o 2 balances de carga superior en laboratorios de tama\u00f1o mediano.\n\n4. **Instrumentos de medici\u00f3n**: Se incluyen instrumentos de medici\u00f3n precisos como balances anal\u00edticos y microbalanzas, esenciales para la investigaci\u00f3n y an\u00e1lisis en el laboratorio.\n\n5. **Condiciones ambientales**: Se menciona la necesidad de un deshidratador en funci\u00f3n de las condiciones ambientales del laboratorio.\n\n6. **Funcionalidad de los equipos**: Cada equipo tiene una funci\u00f3n espec\u00edfica que contribuye a la realizaci\u00f3n de experimentos y an\u00e1lisis en el laboratorio, desde la medici\u00f3n precisa hasta la manipulaci\u00f3n de sustancias qu\u00edmicas.\n\n### Entidades clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Fuente de las recomendaciones.\n- **Tipos de equipos**: L\u00e1mparas UV, extractores Soxhlet, balances, refrigeradores, etc.\n- **Categor\u00edas**: Equipos obligatorios y opcionales.\n- **Cantidades**: Especificaciones num\u00e9ricas para cada tipo de equipo. \n\nEste resumen proporciona una visi\u00f3n general de los elementos esenciales y opcionales necesarios para establecer un laboratorio eficaz, as\u00ed como la importancia de cada uno en el contexto de la investigaci\u00f3n cient\u00edfica.", "excerpt_keywords": "Keywords: laboratory equipment, WHO recommendations, medium-sized laboratory, analytical instruments, chromatography"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17f68f55-cab6-4fd2-9bcd-b75e92e72b33", "node_type": "4", "metadata": {"page_label": "141", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\n| Medium-sized laboratory (cont.) | |\n| - | - |\n| Microscope | 1 or 2 |\n| Equipment for thin-layer chromatography | 1 |\n| Thin-layer chromatography multispotter | 1 |\n| Developing chambers | 6 |\n| Atomizers | 6 |\n| Ultraviolet viewing lamp | 1 |\n| Potentiometric titrimeter | 1 |\n| Micro-Kjeldahl equipment (including fume flasks) | 1 |\n| Soxhlet extraction apparatus (60 ml) | 3 |\n| Pycnometers | 2 |\n| Burettes/pipettes (10 ml and 25 ml/1, 2, 5, 10, 20, 25, 50 ml) | 6 of each |\n| Micrometer callipers | 1 |\n| Heating mantles for flasks (assorted sizes: 50, 200 and 2000 ml) | 6 |\n| Sieves (assorted sizes) | 1 set |\n| Centrifuge (floor model) | 1 |\n| Shaker (wrist-action) | 1 |\n| Vortex mixers | 2 |\n| Water-bath (electrical, 20 litres) | 2 or 3 |\n| Hot plates with magnetic stirrers | 3 or 4 |\n| Vacuum pump (rotary, oil) | 2 |\n| Vacuum rotary evaporator | 1 |\n| Drying oven (60 litres) | 2 or 3 |\n| Muffle furnace (23 litres) | 1 |\n| Vacuum oven (17 litres) | 1 |\n| Desiccators | 2 |\n| Refrigerator (explosion-proof) | 2 |\n| Freezer | 1 |\n| Ultrasonic cleaners (5 litres) | 2 |\n| Laboratory glassware washing machine | 1 |\n| Water distilling apparatus (8 litres/hour) | 1 |\n| Water deionizing equipment (10 litres/hour) | 1 |\n| Fume hoods | 2 |\n| Melting-point apparatus | 1 |\n| Polarimeter | 1 |\n| pH meters (with assorted electrodes) | 2 |\n| High-performance liquid chromatograph with variable wavelength | |\n| Ultraviolet/visible detector | 3 or 4 |\n\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "ccaffc878583f5bc074d224c1153f336274df95933c125f4ae605f691f5292b5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| Medium-sized laboratory (cont.) | |\n| - | - |\n| Microscope | 1 or 2 |\n| Equipment for thin-layer chromatography | 1 |\n| Thin-layer chromatography multispotter | 1 |\n| Developing chambers | 6 |\n| Atomizers | 6 |\n| Ultraviolet viewing lamp | 1 |\n| Potentiometric titrimeter | 1 |\n| Micro-Kjeldahl equipment (including fume flasks) | 1 |\n| Soxhlet extraction apparatus (60 ml) | 3 |\n| Pycnometers | 2 |\n| Burettes/pipettes (10 ml and 25 ml/1, 2, 5, 10, 20, 25, 50 ml) | 6 of each |\n| Micrometer callipers | 1 |\n| Heating mantles for flasks (assorted sizes: 50, 200 and 2000 ml) | 6 |\n| Sieves (assorted sizes) | 1 set |\n| Centrifuge (floor model) | 1 |\n| Shaker (wrist-action) | 1 |\n| Vortex mixers | 2 |\n| Water-bath (electrical, 20 litres) | 2 or 3 |\n| Hot plates with magnetic stirrers | 3 or 4 |\n| Vacuum pump (rotary, oil) | 2 |\n| Vacuum rotary evaporator | 1 |\n| Drying oven (60 litres) | 2 or 3 |\n| Muffle furnace (23 litres) | 1 |\n| Vacuum oven (17 litres) | 1 |\n| Desiccators | 2 |\n| Refrigerator (explosion-proof) | 2 |\n| Freezer | 1 |\n| Ultrasonic cleaners (5 litres) | 2 |\n| Laboratory glassware washing machine | 1 |\n| Water distilling apparatus (8 litres/hour) | 1 |\n| Water deionizing equipment (10 litres/hour) | 1 |\n| Fume hoods | 2 |\n| Melting-point apparatus | 1 |\n| Polarimeter | 1 |\n| pH meters (with assorted electrodes) | 2 |\n| High-performance liquid chromatograph with variable wavelength | |\n| Ultraviolet/visible detector | 3 or 4 |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1459, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e74dd961-38af-4dd5-a21f-e2e2f27c8510": {"__data__": {"id_": "e74dd961-38af-4dd5-a21f-e2e2f27c8510", "embedding": null, "metadata": {"page_label": "142", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "| Medium-sized laboratory (cont.) | |\n| - | - |\n| Ultraviolet/visible spectrophotometer, double-beam | 1 |\n| Infrared spectrophotometer with pellet press | 1 |\n| Agate mortar with pestle | 1 |\n| Gas chromatograph (flame ionization, direct and static head space injection) | 1 |\n| Refractometer | 1 |\n| Karl Fischer titrators (1 semi-micro and 1 coulometric for micro-determination of water) | 2 |\n| Oxygen flask combustion apparatus | 1 |\n| Disintegration test equipment (1 basket for 6 tablets) | 1 |\n| Dissolution test equipment (for 6 tablets/capsules) | 1 |\n| **Optional items** | |\n| Atomic absorption spectrophotometer | 1 |\n| Spectrofluorometer | 1 |\n| High-performance liquid chromatograph detectors: | |\n| \u2014 fluorescence | 1 |\n| \u2014 diode-array | 1 |\n| \u2014 refractive index | 1 |\n| \u2014 evaporative light scattering (ELSD) | 1 |\n| \u2014 charged aerosol (CAD) | 1 |\n| \u2014 mass spectrometric (MS) | 1 |\n| Gas chromatograph detectors: | |\n| \u2014 conductivity | 1 |\n| \u2014 nitrogen/phosphorous (NPD) | 1 |\n| \u2014 mass spectrometric (MS) | 1 |\n| Capillary electrophoresis equipment | 1 |\n| Thin-layer chromatography scanner | 1 |\n| Crushing strength tester | 1 |\n| Friability tester | 1 |\n| Viscometer | 1 |\n| Ice machine | 1 |\n| Solvent-recovery apparatus | 1 |\n| **Equipment for microbiology unit** | |\n| pH meter | 1 |\n| Ultraviolet/visible spectrophotometer, single-beam | 1 |\n| Microscopes (for bacteriology) | 2 |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior que puede ayudar a formular preguntas m\u00e1s relevantes:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 957\" detalla el equipamiento necesario para un laboratorio de tama\u00f1o mediano, incluyendo instrumentos de an\u00e1lisis f\u00edsico-qu\u00edmico y microbiol\u00f3gico. Se enumeran equipos esenciales y opcionales, as\u00ed como herramientas espec\u00edficas para la determinaci\u00f3n de propiedades de sustancias y an\u00e1lisis microbiol\u00f3gicos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1ntos tipos de espectrofot\u00f3metros se mencionan en el contexto y cu\u00e1les son sus caracter\u00edsticas?**\n   - Respuesta: Se mencionan dos tipos de espectrofot\u00f3metros: un espectrofot\u00f3metro ultravioleta/visible de doble haz y un espectrofot\u00f3metro ultravioleta/visible de haz simple.\n\n2. **\u00bfQu\u00e9 equipos son necesarios para realizar pruebas de disoluci\u00f3n y desintegraci\u00f3n en tabletas?**\n   - Respuesta: Se requiere un equipo de prueba de disoluci\u00f3n (para 6 tabletas/c\u00e1psulas) y un equipo de prueba de desintegraci\u00f3n (con una canasta para 6 tabletas).\n\n3. **\u00bfQu\u00e9 tipo de equipos microbiol\u00f3gicos se incluyen en la lista y cu\u00e1ntos de cada uno se necesitan?**\n   - Respuesta: Se incluyen un medidor de pH (1 unidad), un espectrofot\u00f3metro ultravioleta/visible de haz simple (1 unidad) y microscopios para bacteriolog\u00eda (2 unidades).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido proporcionado detalla el equipamiento necesario para un laboratorio de tama\u00f1o mediano, seg\u00fan el documento \"WHO - Technical Report Series 957\". A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Equipamiento de Laboratorio**: Se enumeran diversos instrumentos y equipos esenciales para realizar pruebas y an\u00e1lisis en un laboratorio.\n2. **Cromatograf\u00eda**: Se mencionan equipos espec\u00edficos para cromatograf\u00eda en capa fina y cromatograf\u00eda l\u00edquida de alta eficacia.\n3. **Equipos de Refrigeraci\u00f3n**: Incluye refrigeradores y congeladores, esenciales para la conservaci\u00f3n de muestras.\n4. **Instrumentos de Medici\u00f3n**: Se destacan equipos como pH metros y potenci\u00f3metros, utilizados para mediciones precisas en an\u00e1lisis qu\u00edmicos.\n5. **Equipos de Calentamiento y Secado**: Se incluyen mantas de calentamiento, hornos de secado y muflas, necesarios para procesos de calentamiento y secado de muestras.\n6. **Centrifugaci\u00f3n y Mezcla**: Se mencionan centrifugadoras y mezcladores, que son cruciales para la separaci\u00f3n y mezcla de componentes en soluciones.\n\n#### Entidades Mencionadas:\n- **Microscopio**: 1 o 2 unidades.\n- **Equipo para cromatograf\u00eda en capa fina**: 1 unidad.\n- **Cromat\u00f3grafo l\u00edquido de alta eficacia**: Sin cantidad especificada.\n- **pH metros**: 2 unidades.\n- **Refrigerador (a prueba de explosiones)**: 2 unidades.\n- **Congelador**: 1 unidad.\n- **Centr\u00edfuga (modelo de suelo)**: 1 unidad.\n- **Horno de secado (60 litros)**: 2 o 3 unidades.\n- **Mufla (23 litros)**: 1 unidad.\n- **Deshidratadores**: 2 unidades.\n- **Ultrasonic cleaners (5 litros)**: 2 unidades.\n\nEste resumen proporciona una visi\u00f3n general de los equipos y su importancia en el contexto de un laboratorio de tama\u00f1o mediano, as\u00ed como las cantidades recomendadas para cada tipo de equipo.", "excerpt_keywords": "Keywords: laboratory equipment, spectrophotometer, chromatography, microbiology, analytical instruments"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fbbcb968-159c-4d68-a64c-75f96224aec9", "node_type": "4", "metadata": {"page_label": "142", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "| Medium-sized laboratory (cont.) | |\n| - | - |\n| Ultraviolet/visible spectrophotometer, double-beam | 1 |\n| Infrared spectrophotometer with pellet press | 1 |\n| Agate mortar with pestle | 1 |\n| Gas chromatograph (flame ionization, direct and static head space injection) | 1 |\n| Refractometer | 1 |\n| Karl Fischer titrators (1 semi-micro and 1 coulometric for micro-determination of water) | 2 |\n| Oxygen flask combustion apparatus | 1 |\n| Disintegration test equipment (1 basket for 6 tablets) | 1 |\n| Dissolution test equipment (for 6 tablets/capsules) | 1 |\n| **Optional items** | |\n| Atomic absorption spectrophotometer | 1 |\n| Spectrofluorometer | 1 |\n| High-performance liquid chromatograph detectors: | |\n| \u2014 fluorescence | 1 |\n| \u2014 diode-array | 1 |\n| \u2014 refractive index | 1 |\n| \u2014 evaporative light scattering (ELSD) | 1 |\n| \u2014 charged aerosol (CAD) | 1 |\n| \u2014 mass spectrometric (MS) | 1 |\n| Gas chromatograph detectors: | |\n| \u2014 conductivity | 1 |\n| \u2014 nitrogen/phosphorous (NPD) | 1 |\n| \u2014 mass spectrometric (MS) | 1 |\n| Capillary electrophoresis equipment | 1 |\n| Thin-layer chromatography scanner | 1 |\n| Crushing strength tester | 1 |\n| Friability tester | 1 |\n| Viscometer | 1 |\n| Ice machine | 1 |\n| Solvent-recovery apparatus | 1 |\n| **Equipment for microbiology unit** | |\n| pH meter | 1 |\n| Ultraviolet/visible spectrophotometer, single-beam | 1 |\n| Microscopes (for bacteriology) | 2 |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "f77f535942718a3fa4b5d95eeb85e9afe481bc8c495e64d11535a82ba8f2a9d4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| Medium-sized laboratory (cont.) | |\n| - | - |\n| Ultraviolet/visible spectrophotometer, double-beam | 1 |\n| Infrared spectrophotometer with pellet press | 1 |\n| Agate mortar with pestle | 1 |\n| Gas chromatograph (flame ionization, direct and static head space injection) | 1 |\n| Refractometer | 1 |\n| Karl Fischer titrators (1 semi-micro and 1 coulometric for micro-determination of water) | 2 |\n| Oxygen flask combustion apparatus | 1 |\n| Disintegration test equipment (1 basket for 6 tablets) | 1 |\n| Dissolution test equipment (for 6 tablets/capsules) | 1 |\n| **Optional items** | |\n| Atomic absorption spectrophotometer | 1 |\n| Spectrofluorometer | 1 |\n| High-performance liquid chromatograph detectors: | |\n| \u2014 fluorescence | 1 |\n| \u2014 diode-array | 1 |\n| \u2014 refractive index | 1 |\n| \u2014 evaporative light scattering (ELSD) | 1 |\n| \u2014 charged aerosol (CAD) | 1 |\n| \u2014 mass spectrometric (MS) | 1 |\n| Gas chromatograph detectors: | |\n| \u2014 conductivity | 1 |\n| \u2014 nitrogen/phosphorous (NPD) | 1 |\n| \u2014 mass spectrometric (MS) | 1 |\n| Capillary electrophoresis equipment | 1 |\n| Thin-layer chromatography scanner | 1 |\n| Crushing strength tester | 1 |\n| Friability tester | 1 |\n| Viscometer | 1 |\n| Ice machine | 1 |\n| Solvent-recovery apparatus | 1 |\n| **Equipment for microbiology unit** | |\n| pH meter | 1 |\n| Ultraviolet/visible spectrophotometer, single-beam | 1 |\n| Microscopes (for bacteriology) | 2 |", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1401, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1aa0bef6-38dc-4af6-a128-43003142963c": {"__data__": {"id_": "1aa0bef6-38dc-4af6-a128-43003142963c", "embedding": null, "metadata": {"page_label": "143", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "| Medium-sized laboratory (cont.) | Medium-sized laboratory (cont.) |\n| - | - |\n| Membrane filter assembly for sterility tests | 1 |\n| Colony counter with magnifier | 1 |\n| Laminar air flow unit | 1 |\n| Hot-air sterilizer | 1 |\n| Incubators, 60 litres | 2 or 3 |\n| Anaerobic jar | 1 |\n| Zone reader | 1 |\n| Centrifuge | 1 |\n| Water-bath (thermostatically controlled) | 2 |\n| Autoclaves (100 litres, top-loading) | 2 |\n| Refrigerators (340 litres) | 2 |\n| Deep freeze | 1 |\n| Laboratory glassware washing machine | 1 |\n\n\n| Equipment for pharmacognosy/phytochemistry unit | Equipment for pharmacognosy/phytochemistry unit |\n| - | - |\n| Grinder/mill (for preparation of sample of herbal materials) | 1 |\n| Top loading balance | 1 |\n| Sieves | 1 set |\n| Microscopeb | 1 |\n| Soxhlet extraction apparatus | 2 or 3 |\n| Water-bath | 1 |\n| Heating mantles for flasks | 1 or 2 |\n| Hot plates with magnetic stirrers | 2 |\n| Equipment for thin-layer chromatography | 1 or 2 |\n| Developing chambers | 3 or 4 |\n| Desiccators | 2 |\n| Rotary vacuum apparatus | 1 |\n| Distillation equipment | 1 |\n| Conical percolators | 2 or 3 |\n| Apparatus for determination of water content by azeotropic methodb | 1 |\n| Apparatus for determination of volatile oilsb | 1 |\n| Apparatus for determination of arsenic limit testc | 1 |\n\n\n<sup>a</sup> Needed in the case that herbal medicines are also tested.  \n<sup>b</sup> *Quality control methods for medicinal plant materials*. Geneva, World Health Organization, 1998.  \n<sup>c</sup> *WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues*. Geneva, World Health Organization, 2006.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que detalla el equipo necesario para un laboratorio de tama\u00f1o mediano y una unidad de farmacognosia/fitoqu\u00edmica. Se enumeran diversos equipos, incluyendo filtros de membrana, incubadoras, autoclaves, y aparatos para extracci\u00f3n y an\u00e1lisis de compuestos de origen vegetal. Tambi\u00e9n se mencionan referencias a m\u00e9todos de control de calidad para materiales de plantas medicinales y directrices sobre la evaluaci\u00f3n de la calidad de los medicamentos herbales.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de equipo se recomienda para realizar pruebas de esterilidad en un laboratorio de tama\u00f1o mediano?**\n   - Respuesta: Se recomienda un ensamblaje de filtro de membrana para pruebas de esterilidad, junto con un contador de colonias con lupa, una unidad de flujo de aire laminar, y un esterilizador de aire caliente.\n\n2. **\u00bfCu\u00e1ntos Soxhlet extraction apparatus se sugieren para la unidad de farmacognosia/fitoqu\u00edmica?**\n   - Respuesta: Se sugieren de 2 a 3 aparatos de extracci\u00f3n Soxhlet para la unidad de farmacognosia/fitoqu\u00edmica.\n\n3. **\u00bfQu\u00e9 equipos son necesarios para la determinaci\u00f3n de contenido de agua y aceites vol\u00e1tiles en materiales herbales?**\n   - Respuesta: Se necesita un aparato para la determinaci\u00f3n del contenido de agua por el m\u00e9todo azeotr\u00f3pico y un aparato para la determinaci\u00f3n de aceites vol\u00e1tiles, ambos en la unidad de farmacognosia/fitoqu\u00edmica.\n\n### Resumen de Nivel Superior\nEl informe de la OMS proporciona una gu\u00eda detallada sobre el equipo necesario para laboratorios que trabajan con materiales herbales y medicamentos, enfatizando la importancia de la calidad y la seguridad en el an\u00e1lisis de productos de origen vegetal. Se incluyen equipos espec\u00edficos para pruebas de esterilidad y an\u00e1lisis fitoqu\u00edmico, as\u00ed como referencias a est\u00e1ndares de calidad y m\u00e9todos de evaluaci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento \"WHO - Technical Report Series 957\" proporciona una lista detallada del equipamiento necesario para un laboratorio de tama\u00f1o mediano, dividiendo los equipos en esenciales y opcionales, as\u00ed como en categor\u00edas espec\u00edficas para an\u00e1lisis f\u00edsico-qu\u00edmico y microbiol\u00f3gico.\n\n#### Equipos esenciales:\n1. **Espectrofot\u00f3metros:**\n   - Ultraviolet/visible, doble haz (1 unidad)\n   - Ultraviolet/visible, haz simple (1 unidad en microbiolog\u00eda)\n\n2. **Espectrofot\u00f3metros de infrarrojos:**\n   - Con prensa de pellet (1 unidad)\n\n3. **Equipos de cromatograf\u00eda:**\n   - Cromat\u00f3grafo de gases (1 unidad)\n   - Detectores de cromatograf\u00eda l\u00edquida de alto rendimiento (HPLC) y cromatograf\u00eda de gases (1 unidad cada uno para varios tipos)\n\n4. **Equipos de titulaci\u00f3n:**\n   - Tituladores de Karl Fischer (2 unidades)\n\n5. **Equipos de pruebas de disoluci\u00f3n y desintegraci\u00f3n:**\n   - Equipos para pruebas de disoluci\u00f3n (1 unidad)\n   - Equipos para pruebas de desintegraci\u00f3n (1 unidad)\n\n6. **Otros equipos:**\n   - Mortero de \u00e1gata con pistilo (1 unidad)\n   - Refract\u00f3metro (1 unidad)\n   - Aparato de combusti\u00f3n en frasco de ox\u00edgeno (1 unidad)\n   - Equipos para pruebas de resistencia a la trituraci\u00f3n y friabilidad (1 unidad cada uno)\n   - Viscometro (1 unidad)\n   - M\u00e1quina de hielo (1 unidad)\n   - Aparato de recuperaci\u00f3n de solventes (1 unidad)\n\n#### Equipos opcionales:\n- Espectrofot\u00f3metro de absorci\u00f3n at\u00f3mica (1 unidad)\n- Espectrofluor\u00f3metro (1 unidad)\n- Equipos de detecci\u00f3n para HPLC y cromatograf\u00eda de gases (1 unidad cada uno para varios tipos)\n\n#### Equipos para la unidad de microbiolog\u00eda:\n- Medidor de pH (1 unidad)\n- Microscopios para bacteriolog\u00eda (2 unidades)\n\n### Entidades clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Laboratorio de tama\u00f1o mediano**\n- **Equipos de an\u00e1lisis f\u00edsico-qu\u00edmico**\n- **Equipos de microbiolog\u00eda**\n\nEste resumen destaca la importancia de contar con un equipamiento adecuado para realizar an\u00e1lisis precisos y efectivos en un laboratorio, as\u00ed como la variedad de instrumentos necesarios para diferentes tipos de pruebas.", "excerpt_keywords": "Keywords: laboratory equipment, pharmacognosy, phytochemistry, sterility tests, herbal medicines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6dff4e86-ecdb-4954-a327-da5e9aa3bbd1", "node_type": "4", "metadata": {"page_label": "143", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "| Medium-sized laboratory (cont.) | Medium-sized laboratory (cont.) |\n| - | - |\n| Membrane filter assembly for sterility tests | 1 |\n| Colony counter with magnifier | 1 |\n| Laminar air flow unit | 1 |\n| Hot-air sterilizer | 1 |\n| Incubators, 60 litres | 2 or 3 |\n| Anaerobic jar | 1 |\n| Zone reader | 1 |\n| Centrifuge | 1 |\n| Water-bath (thermostatically controlled) | 2 |\n| Autoclaves (100 litres, top-loading) | 2 |\n| Refrigerators (340 litres) | 2 |\n| Deep freeze | 1 |\n| Laboratory glassware washing machine | 1 |\n\n\n| Equipment for pharmacognosy/phytochemistry unit | Equipment for pharmacognosy/phytochemistry unit |\n| - | - |\n| Grinder/mill (for preparation of sample of herbal materials) | 1 |\n| Top loading balance | 1 |\n| Sieves | 1 set |\n| Microscopeb | 1 |\n| Soxhlet extraction apparatus | 2 or 3 |\n| Water-bath | 1 |\n| Heating mantles for flasks | 1 or 2 |\n| Hot plates with magnetic stirrers | 2 |\n| Equipment for thin-layer chromatography | 1 or 2 |\n| Developing chambers | 3 or 4 |\n| Desiccators | 2 |\n| Rotary vacuum apparatus | 1 |\n| Distillation equipment | 1 |\n| Conical percolators | 2 or 3 |\n| Apparatus for determination of water content by azeotropic methodb | 1 |\n| Apparatus for determination of volatile oilsb | 1 |\n| Apparatus for determination of arsenic limit testc | 1 |\n\n\n<sup>a</sup> Needed in the case that herbal medicines are also tested.  \n<sup>b</sup> *Quality control methods for medicinal plant materials*. Geneva, World Health Organization, 1998.  \n<sup>c</sup> *WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues*. Geneva, World Health Organization, 2006.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "5c78ea48ef66ec9e90a0271454e15d4a0a17f5bd9e7b3330b4329f688f9c4df1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| Medium-sized laboratory (cont.) | Medium-sized laboratory (cont.) |\n| - | - |\n| Membrane filter assembly for sterility tests | 1 |\n| Colony counter with magnifier | 1 |\n| Laminar air flow unit | 1 |\n| Hot-air sterilizer | 1 |\n| Incubators, 60 litres | 2 or 3 |\n| Anaerobic jar | 1 |\n| Zone reader | 1 |\n| Centrifuge | 1 |\n| Water-bath (thermostatically controlled) | 2 |\n| Autoclaves (100 litres, top-loading) | 2 |\n| Refrigerators (340 litres) | 2 |\n| Deep freeze | 1 |\n| Laboratory glassware washing machine | 1 |\n\n\n| Equipment for pharmacognosy/phytochemistry unit | Equipment for pharmacognosy/phytochemistry unit |\n| - | - |\n| Grinder/mill (for preparation of sample of herbal materials) | 1 |\n| Top loading balance | 1 |\n| Sieves | 1 set |\n| Microscopeb | 1 |\n| Soxhlet extraction apparatus | 2 or 3 |\n| Water-bath | 1 |\n| Heating mantles for flasks | 1 or 2 |\n| Hot plates with magnetic stirrers | 2 |\n| Equipment for thin-layer chromatography | 1 or 2 |\n| Developing chambers | 3 or 4 |\n| Desiccators | 2 |\n| Rotary vacuum apparatus | 1 |\n| Distillation equipment | 1 |\n| Conical percolators | 2 or 3 |\n| Apparatus for determination of water content by azeotropic methodb | 1 |\n| Apparatus for determination of volatile oilsb | 1 |\n| Apparatus for determination of arsenic limit testc | 1 |\n\n\n<sup>a</sup> Needed in the case that herbal medicines are also tested.  \n<sup>b</sup> *Quality control methods for medicinal plant materials*. Geneva, World Health Organization, 1998.  \n<sup>c</sup> *WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues*. Geneva, World Health Organization, 2006.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1646, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a76c61cd-c15d-4c0f-b841-e053148000a7": {"__data__": {"id_": "a76c61cd-c15d-4c0f-b841-e053148000a7", "embedding": null, "metadata": {"page_label": "144", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 2\n\n## WHO good manufacturing practices for active pharmaceutical ingredients\n\n1. **Introduction**\n   1.1 Objective  \n   1.2 Regulatory applicability  \n   1.3 Scope  \n\n2. **Quality management**\n   2.1 Principles  \n   2.2 Responsibilities of the quality unit(s)  \n   2.3 Responsibility for production activities  \n   2.4 Internal audits (self-inspection)  \n   2.5 Product quality review  \n\n3. **Personnel**\n   3.1 Personnel qualifications  \n   3.2 Personnel hygiene  \n   3.3 Consultants  \n\n4. **Buildings and facilities**\n   4.1 Design and construction  \n   4.2 Utilities  \n   4.3 Water  \n   4.4 Containment  \n   4.5 Lighting  \n   4.6 Sewage and refuse  \n   4.7 Sanitation and maintenance  \n\n5. **Process equipment**\n   5.1 Design and construction  \n   5.2 Equipment maintenance and cleaning  \n   5.3 Calibration  \n   5.4 Computerized systems  \n\n6. **Documentation and records**\n   6.1 Documentation system and specifications  \n   6.2 Equipment cleaning and use record  \n   6.3 Records of raw materials, intermediates, API labelling and packaging materials  \n   6.4 Master production instructions (master production and control records)  \n   6.5 Batch production records (batch production and control records)  \n   6.6 Laboratory control records  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior\nEl documento \"WHO - Technical Report Series 957\" incluye un anexo que detalla las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para los ingredientes farmac\u00e9uticos activos (API). Este anexo abarca varios aspectos esenciales, como la gesti\u00f3n de calidad, la calificaci\u00f3n y la higiene del personal, el dise\u00f1o y la construcci\u00f3n de instalaciones, el mantenimiento de equipos, y la documentaci\u00f3n y registros necesarios para asegurar la calidad y la seguridad en la producci\u00f3n de API.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas del personal de calidad seg\u00fan las buenas pr\u00e1cticas de fabricaci\u00f3n para los ingredientes farmac\u00e9uticos activos?**\n   - Esta pregunta se centra en el apartado 2.2 del documento, que detalla las responsabilidades de las unidades de calidad.\n\n2. **\u00bfQu\u00e9 aspectos se consideran en el dise\u00f1o y construcci\u00f3n de edificios y instalaciones para la producci\u00f3n de ingredientes farmac\u00e9uticos activos?**\n   - Esta pregunta se relaciona con el apartado 4.1 y otros subapartados que abordan el dise\u00f1o y la construcci\u00f3n de las instalaciones.\n\n3. **\u00bfQu\u00e9 tipo de registros se deben mantener para asegurar la calidad del proceso de producci\u00f3n de ingredientes farmac\u00e9uticos activos?**\n   - Esta pregunta se refiere a la secci\u00f3n 6, que detalla los diferentes tipos de documentaci\u00f3n y registros necesarios, como los registros de limpieza de equipos y los registros de producci\u00f3n por lotes. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otros documentos o fuentes, ya que se basan en detalles concretos del contexto proporcionado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Tipo de Laboratorio**: Se describe el equipo necesario para un laboratorio de tama\u00f1o mediano y una unidad de farmacognosia/fitoqu\u00edmica.\n\n2. **Equipos para Pruebas de Esterilidad**:\n   - Filtro de membrana para pruebas de esterilidad.\n   - Contador de colonias con lupa.\n   - Unidad de flujo de aire laminar.\n   - Esterilizador de aire caliente.\n   - Incubadoras (2 o 3 unidades de 60 litros).\n   - Otros equipos como autoclaves, refrigeradores y centrifugas.\n\n3. **Equipos para la Unidad de Farmacognosia/Fitoqu\u00edmica**:\n   - Molino/grinder para preparaci\u00f3n de muestras de materiales herbales.\n   - Balanza de carga superior.\n   - Microscopio.\n   - Aparatos de extracci\u00f3n Soxhlet (2 o 3 unidades).\n   - Equipos para cromatograf\u00eda en capa fina y distilaci\u00f3n.\n\n4. **Determinaci\u00f3n de Contenido**:\n   - Aparatos para determinar el contenido de agua por el m\u00e9todo azeotr\u00f3pico.\n   - Aparatos para determinar aceites vol\u00e1tiles y pruebas de l\u00edmite de ars\u00e9nico.\n\n5. **Referencias**:\n   - M\u00e9todos de control de calidad para materiales de plantas medicinales (1998).\n   - Directrices de la OMS para evaluar la calidad de medicamentos herbales (2006).\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que proporciona directrices y est\u00e1ndares.\n- **Equipos de laboratorio**: Incluyen filtros de membrana, incubadoras, autoclaves, y equipos de extracci\u00f3n y an\u00e1lisis.\n- **Farmacognosia/Fitoqu\u00edmica**: Disciplina que estudia los productos de origen vegetal y su calidad.\n\n### Conclusi\u00f3n\nEl informe de la OMS es una gu\u00eda exhaustiva sobre el equipo necesario para laboratorios que trabajan con materiales herbales, subrayando la importancia de la calidad y la seguridad en el an\u00e1lisis de productos de origen vegetal.", "excerpt_keywords": "Keywords: good manufacturing practices, active pharmaceutical ingredients, quality management, documentation, personnel qualifications"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ea1d0b40-2d09-4cbd-9acb-112f7f16babd", "node_type": "4", "metadata": {"page_label": "144", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 2\n\n## WHO good manufacturing practices for active pharmaceutical ingredients\n\n1. **Introduction**\n   1.1 Objective  \n   1.2 Regulatory applicability  \n   1.3 Scope  \n\n2. **Quality management**\n   2.1 Principles  \n   2.2 Responsibilities of the quality unit(s)  \n   2.3 Responsibility for production activities  \n   2.4 Internal audits (self-inspection)  \n   2.5 Product quality review  \n\n3. **Personnel**\n   3.1 Personnel qualifications  \n   3.2 Personnel hygiene  \n   3.3 Consultants  \n\n4. **Buildings and facilities**\n   4.1 Design and construction  \n   4.2 Utilities  \n   4.3 Water  \n   4.4 Containment  \n   4.5 Lighting  \n   4.6 Sewage and refuse  \n   4.7 Sanitation and maintenance  \n\n5. **Process equipment**\n   5.1 Design and construction  \n   5.2 Equipment maintenance and cleaning  \n   5.3 Calibration  \n   5.4 Computerized systems  \n\n6. **Documentation and records**\n   6.1 Documentation system and specifications  \n   6.2 Equipment cleaning and use record  \n   6.3 Records of raw materials, intermediates, API labelling and packaging materials  \n   6.4 Master production instructions (master production and control records)  \n   6.5 Batch production records (batch production and control records)  \n   6.6 Laboratory control records  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "0e3428d69dd0952dee98dcdae5a982206e4bad35e854428baadcd9928717dc2a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 2\n\n## WHO good manufacturing practices for active pharmaceutical ingredients\n\n1. **Introduction**\n   1.1 Objective  \n   1.2 Regulatory applicability  \n   1.3 Scope  \n\n2. **Quality management**\n   2.1 Principles  \n   2.2 Responsibilities of the quality unit(s)  \n   2.3 Responsibility for production activities  \n   2.4 Internal audits (self-inspection)  \n   2.5 Product quality review  \n\n3. **Personnel**\n   3.1 Personnel qualifications  \n   3.2 Personnel hygiene  \n   3.3 Consultants  \n\n4. **Buildings and facilities**\n   4.1 Design and construction  \n   4.2 Utilities  \n   4.3 Water  \n   4.4 Containment  \n   4.5 Lighting  \n   4.6 Sewage and refuse  \n   4.7 Sanitation and maintenance  \n\n5. **Process equipment**\n   5.1 Design and construction  \n   5.2 Equipment maintenance and cleaning  \n   5.3 Calibration  \n   5.4 Computerized systems  \n\n6. **Documentation and records**\n   6.1 Documentation system and specifications  \n   6.2 Equipment cleaning and use record  \n   6.3 Records of raw materials, intermediates, API labelling and packaging materials  \n   6.4 Master production instructions (master production and control records)  \n   6.5 Batch production records (batch production and control records)  \n   6.6 Laboratory control records", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1251, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "bf9109cd-3780-48ee-aa97-e6e8423bf76f": {"__data__": {"id_": "bf9109cd-3780-48ee-aa97-e6e8423bf76f", "embedding": null, "metadata": {"page_label": "145", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 6.7 Batch production record review\n\n# 7. Materials management\n- 7.1 General controls\n- 7.2 Receipt and quarantine\n- 7.3 Sampling and testing of incoming production materials\n- 7.4 Storage\n- 7.5 Re-evaluation\n\n# 8. Production and in-process controls\n- 8.1 Production operations\n- 8.2 Time limits\n- 8.3 In-process sampling and controls\n- 8.4 Blending batches of intermediates or APIs\n- 8.5 Contamination control\n\n# 9. Packaging and identification labelling of APIs and intermediates\n- 9.1 General\n- 9.2 Packaging materials\n- 9.3 Label issuance and control\n- 9.4 Packaging and labelling operations\n\n# 10. Storage and distribution\n- 10.1 Warehousing procedures\n- 10.2 Distribution procedures\n\n# 11. Laboratory controls\n- 11.1 General controls\n- 11.2 Testing of intermediates and APIs\n- 11.3 Validation of analytical procedures\n- 11.4 Certificates of analysis\n- 11.5 Stability monitoring of APIs\n- 11.6 Expiry and retest dating\n- 11.7 Reserve/retention samples\n\n# 12. Validation\n- 12.1 Validation policy\n- 12.2 Validation documentation\n- 12.3 Qualification\n- 12.4 Approaches to process validation\n- 12.5 Process validation programme\n- 12.6 Periodic review of validated systems\n- 12.7 Cleaning validation\n- 12.8 Validation of analytical methods\n\n# 13. Change control\n\n# 14. Rejection and reuse of materials\n- 14.1 Rejection\n- 14.2 Reprocessing\n- 14.3 Reworking\n- 14.4 Recovery of materials and solvents", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 957\" aborda diversas \u00e1reas cr\u00edticas en la producci\u00f3n y control de materiales farmac\u00e9uticos. Se enfoca en la gesti\u00f3n de materiales, controles de producci\u00f3n, etiquetado y empaquetado de ingredientes activos (APIs), almacenamiento y distribuci\u00f3n, as\u00ed como en los controles de laboratorio y validaci\u00f3n de procesos. Tambi\u00e9n se discuten procedimientos para el rechazo y reutilizaci\u00f3n de materiales, asegurando que se mantengan est\u00e1ndares de calidad y seguridad en la producci\u00f3n farmac\u00e9utica.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los procedimientos espec\u00edficos para la re-evaluaci\u00f3n de materiales en la gesti\u00f3n de materiales seg\u00fan el documento?**\n   - Esta pregunta busca detalles sobre el proceso de re-evaluaci\u00f3n que no se puede encontrar f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 enfoques se sugieren para la validaci\u00f3n de m\u00e9todos anal\u00edticos en el contexto de los controles de laboratorio?**\n   - Esta pregunta se centra en los enfoques espec\u00edficos mencionados en el documento para validar m\u00e9todos anal\u00edticos, que pueden no estar ampliamente cubiertos en otras gu\u00edas.\n\n3. **\u00bfQu\u00e9 medidas se describen para el control de contaminaci\u00f3n durante las operaciones de producci\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n sobre las pr\u00e1cticas espec\u00edficas de control de contaminaci\u00f3n que son cr\u00edticas para la producci\u00f3n segura de APIs y que pueden no estar detalladas en otras normativas. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y detallada que se encuentra en el contexto del documento, lo que puede no estar disponible en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl anexo 2 del documento \"WHO - Technical Report Series 957\" se centra en las **buenas pr\u00e1cticas de fabricaci\u00f3n (BPF)** para los **ingredientes farmac\u00e9uticos activos (API)**. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas en la secci\u00f3n:\n\n1. **Introducci\u00f3n**\n   - **Objetivo**: Establecer directrices para asegurar la calidad en la producci\u00f3n de API.\n   - **Aplicabilidad regulatoria**: Normativas que rigen la fabricaci\u00f3n de API.\n   - **Alcance**: \u00c1reas cubiertas por las BPF.\n\n2. **Gesti\u00f3n de calidad**\n   - **Principios**: Fundamentos de la gesti\u00f3n de calidad en la producci\u00f3n.\n   - **Responsabilidades de las unidades de calidad**: Funciones espec\u00edficas del personal encargado de la calidad.\n   - **Responsabilidad en actividades de producci\u00f3n**: Roles en la supervisi\u00f3n de la producci\u00f3n.\n   - **Auditor\u00edas internas**: Procedimientos de autoinspecci\u00f3n.\n   - **Revisi\u00f3n de calidad del producto**: Evaluaci\u00f3n de la calidad de los productos fabricados.\n\n3. **Personal**\n   - **Calificaciones del personal**: Requisitos de formaci\u00f3n y experiencia.\n   - **Higiene del personal**: Normas de higiene que deben seguir los empleados.\n   - **Consultores**: Uso de expertos externos en el proceso de producci\u00f3n.\n\n4. **Edificios e instalaciones**\n   - **Dise\u00f1o y construcci\u00f3n**: Consideraciones para la infraestructura de producci\u00f3n.\n   - **Utilidades**: Sistemas de soporte necesarios (agua, electricidad, etc.).\n   - **Contenci\u00f3n**: Medidas para evitar la contaminaci\u00f3n.\n   - **Iluminaci\u00f3n**: Requisitos de luz en las instalaciones.\n   - **Saneamiento y mantenimiento**: Pr\u00e1cticas para mantener la limpieza y el funcionamiento adecuado.\n\n5. **Equipos de proceso**\n   - **Dise\u00f1o y construcci\u00f3n**: Especificaciones para el equipo utilizado en la producci\u00f3n.\n   - **Mantenimiento y limpieza de equipos**: Procedimientos para asegurar el buen estado del equipo.\n   - **Calibraci\u00f3n**: Verificaci\u00f3n de la precisi\u00f3n de los instrumentos.\n   - **Sistemas computarizados**: Uso de tecnolog\u00eda en la gesti\u00f3n de procesos.\n\n6. **Documentaci\u00f3n y registros**\n   - **Sistema de documentaci\u00f3n y especificaciones**: Estructura para la gesti\u00f3n de documentos.\n   - **Registros de limpieza y uso de equipos**: Documentaci\u00f3n de las actividades de mantenimiento.\n   - **Registros de materias primas y materiales de envasado**: Seguimiento de los insumos utilizados.\n   - **Instrucciones de producci\u00f3n maestra**: Directrices para la fabricaci\u00f3n.\n   - **Registros de producci\u00f3n por lotes**: Documentaci\u00f3n de cada lote producido.\n   - **Registros de control de laboratorio**: Datos de pruebas y an\u00e1lisis realizados.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **API (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias utilizadas en la fabricaci\u00f3n de medicamentos.\n- **Unidades de calidad**: Personal responsable de asegurar la calidad en la producci\u00f3n.\n- **Personal**: Empleados involucrados en la fabricaci\u00f3n y control de calidad.\n- **Instalaciones y equipos**: Infraestructura y maquinaria utilizadas en el proceso de producci\u00f3n.\n\nEste resumen proporciona una visi\u00f3n general de los elementos esenciales que se abordan en las buenas pr\u00e1cticas de fabricaci\u00f3n para los ingredientes farmac\u00e9uticos activos, destacando la importancia de la calidad, la higiene, el dise\u00f1o de instalaciones y la documentaci\u00f3n adecuada.", "excerpt_keywords": "Keywords: Batch production, Materials management, Quality control, Validation, Contamination control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c0645f08-762b-4cd7-a250-a60a43141a0e", "node_type": "4", "metadata": {"page_label": "145", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 6.7 Batch production record review\n\n# 7. Materials management\n- 7.1 General controls\n- 7.2 Receipt and quarantine\n- 7.3 Sampling and testing of incoming production materials\n- 7.4 Storage\n- 7.5 Re-evaluation\n\n# 8. Production and in-process controls\n- 8.1 Production operations\n- 8.2 Time limits\n- 8.3 In-process sampling and controls\n- 8.4 Blending batches of intermediates or APIs\n- 8.5 Contamination control\n\n# 9. Packaging and identification labelling of APIs and intermediates\n- 9.1 General\n- 9.2 Packaging materials\n- 9.3 Label issuance and control\n- 9.4 Packaging and labelling operations\n\n# 10. Storage and distribution\n- 10.1 Warehousing procedures\n- 10.2 Distribution procedures\n\n# 11. Laboratory controls\n- 11.1 General controls\n- 11.2 Testing of intermediates and APIs\n- 11.3 Validation of analytical procedures\n- 11.4 Certificates of analysis\n- 11.5 Stability monitoring of APIs\n- 11.6 Expiry and retest dating\n- 11.7 Reserve/retention samples\n\n# 12. Validation\n- 12.1 Validation policy\n- 12.2 Validation documentation\n- 12.3 Qualification\n- 12.4 Approaches to process validation\n- 12.5 Process validation programme\n- 12.6 Periodic review of validated systems\n- 12.7 Cleaning validation\n- 12.8 Validation of analytical methods\n\n# 13. Change control\n\n# 14. Rejection and reuse of materials\n- 14.1 Rejection\n- 14.2 Reprocessing\n- 14.3 Reworking\n- 14.4 Recovery of materials and solvents", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "da81afda30efb8dbd32d5333d35e1362dd87e2d5aae8371583e8ffddbeefbb6b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6.7 Batch production record review\n\n# 7. Materials management\n- 7.1 General controls\n- 7.2 Receipt and quarantine\n- 7.3 Sampling and testing of incoming production materials\n- 7.4 Storage\n- 7.5 Re-evaluation\n\n# 8. Production and in-process controls\n- 8.1 Production operations\n- 8.2 Time limits\n- 8.3 In-process sampling and controls\n- 8.4 Blending batches of intermediates or APIs\n- 8.5 Contamination control\n\n# 9. Packaging and identification labelling of APIs and intermediates\n- 9.1 General\n- 9.2 Packaging materials\n- 9.3 Label issuance and control\n- 9.4 Packaging and labelling operations\n\n# 10. Storage and distribution\n- 10.1 Warehousing procedures\n- 10.2 Distribution procedures\n\n# 11. Laboratory controls\n- 11.1 General controls\n- 11.2 Testing of intermediates and APIs\n- 11.3 Validation of analytical procedures\n- 11.4 Certificates of analysis\n- 11.5 Stability monitoring of APIs\n- 11.6 Expiry and retest dating\n- 11.7 Reserve/retention samples\n\n# 12. Validation\n- 12.1 Validation policy\n- 12.2 Validation documentation\n- 12.3 Qualification\n- 12.4 Approaches to process validation\n- 12.5 Process validation programme\n- 12.6 Periodic review of validated systems\n- 12.7 Cleaning validation\n- 12.8 Validation of analytical methods\n\n# 13. Change control\n\n# 14. Rejection and reuse of materials\n- 14.1 Rejection\n- 14.2 Reprocessing\n- 14.3 Reworking\n- 14.4 Recovery of materials and solvents", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1398, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5f12bcaf-3256-495a-ae1f-e64932816b01": {"__data__": {"id_": "5f12bcaf-3256-495a-ae1f-e64932816b01", "embedding": null, "metadata": {"page_label": "146", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 14.5 Returns\n\n15. Complaints and recalls\n\n16. Contract manufacturers (including laboratories)\n\n17. Agents, brokers, traders, distributors, repackers and relabellers\n   - 17.1 Applicability\n   - 17.2 Traceability of distributed APIs and intermediates\n   - 17.3 Quality management\n   - 17.4 Repackaging, relabelling and holding of APIs and intermediates\n   - 17.5 Stability\n   - 17.6 Transfer of information\n   - 17.7 Handling of complaints and recalls\n   - 17.8 Handling of returns\n\n18. Specific guidance for APIs manufactured by cell culture/fermentation\n   - 18.1 General\n   - 18.2 Cell bank maintenance and record keeping\n   - 18.3 Cell culture/fermentation\n   - 18.4 Harvesting, isolation and purification\n   - 18.5 Viral removal/inactivation steps\n\n19. APIs for use in clinical trials\n   - 19.1 General\n   - 19.2 Quality\n   - 19.3 Equipment and facilities\n   - 19.4 Control of raw materials\n   - 19.5 Production\n   - 19.6 Validation\n   - 19.7 Changes\n   - 19.8 Laboratory controls\n   - 19.9 Documentation\n\n20. Glossary\n\nReferences\n\nAppendix 1  \nList of references for related WHO guidelines\n\nAppendix 2  \nGeneral notes: additional clarifications and explanations\n\n----\n\nThis text is based on the International Conference on Harmonisation (ICH) Q7: *Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients*. November 2000.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los aspectos clave que deben considerarse en la gesti\u00f3n de quejas y retiradas de productos seg\u00fan el documento?**\n   - El documento menciona varios aspectos clave en la gesti\u00f3n de quejas y retiradas, incluyendo la trazabilidad de los APIs y productos intermedios distribuidos, la gesti\u00f3n de calidad, y los procedimientos espec\u00edficos para el manejo de quejas y retiradas. Tambi\u00e9n se abordan las pr\u00e1cticas de reempaquetado y relabeling, as\u00ed como la estabilidad de los productos.\n\n2. **\u00bfQu\u00e9 consideraciones se deben tener en cuenta para los APIs fabricados mediante cultivos celulares o fermentaci\u00f3n?**\n   - Para los APIs fabricados mediante cultivos celulares o fermentaci\u00f3n, el documento proporciona orientaci\u00f3n espec\u00edfica que incluye el mantenimiento de bancos celulares y el registro de datos, as\u00ed como los procesos de cultivo, cosecha, aislamiento y purificaci\u00f3n. Tambi\u00e9n se enfatiza la importancia de los pasos de eliminaci\u00f3n/inactivaci\u00f3n viral.\n\n3. **\u00bfQu\u00e9 requisitos se establecen para los APIs destinados a ensayos cl\u00ednicos en t\u00e9rminos de calidad y documentaci\u00f3n?**\n   - El documento establece que los APIs destinados a ensayos cl\u00ednicos deben cumplir con requisitos espec\u00edficos de calidad, que incluyen el control de materias primas, la validaci\u00f3n de procesos, y la documentaci\u00f3n adecuada de todos los procedimientos. Tambi\u00e9n se menciona la necesidad de realizar cambios controlados y mantener laboratorios que cumplan con los est\u00e1ndares requeridos.\n\n### Resumen de nivel superior del contexto:\nEl documento \"WHO - Technical Report Series 957\" se basa en las directrices de Buenas Pr\u00e1cticas de Manufactura (GMP) para Ingredientes Farmac\u00e9uticos Activos (APIs) seg\u00fan la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) Q7. Aborda temas cr\u00edticos como la gesti\u00f3n de quejas y retiradas, la responsabilidad de los fabricantes contratados, y la trazabilidad de los productos. Tambi\u00e9n proporciona directrices espec\u00edficas para APIs producidos mediante cultivos celulares y para aquellos destinados a ensayos cl\u00ednicos, enfatizando la importancia de la calidad, la documentaci\u00f3n y el cumplimiento de normativas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 957\" aborda varios aspectos fundamentales en la producci\u00f3n y control de materiales farmac\u00e9uticos. A continuaci\u00f3n se presentan los temas clave y entidades de la secci\u00f3n:\n\n1. **Gesti\u00f3n de Materiales**:\n   - **Controles Generales**: Establecimiento de normas y procedimientos para la gesti\u00f3n de materiales.\n   - **Recepci\u00f3n y Cuarentena**: Proceso de recepci\u00f3n de materiales y su aislamiento para asegurar calidad.\n   - **Muestreo y Pruebas**: Evaluaci\u00f3n de materiales entrantes para verificar su conformidad.\n   - **Almacenamiento**: M\u00e9todos para almacenar materiales de manera segura.\n   - **Re-evaluaci\u00f3n**: Proceso de revisi\u00f3n peri\u00f3dica de materiales para asegurar su idoneidad.\n\n2. **Controles de Producci\u00f3n y en Proceso**:\n   - **Operaciones de Producci\u00f3n**: Procedimientos para llevar a cabo la producci\u00f3n de manera efectiva.\n   - **L\u00edmites de Tiempo**: Establecimiento de plazos para las operaciones de producci\u00f3n.\n   - **Muestreo y Controles en Proceso**: Monitoreo continuo durante la producci\u00f3n.\n   - **Control de Contaminaci\u00f3n**: Estrategias para prevenir la contaminaci\u00f3n durante la producci\u00f3n.\n\n3. **Empaque y Etiquetado**:\n   - **Materiales de Empaque**: Selecci\u00f3n y control de materiales utilizados para el empaque.\n   - **Control de Etiquetas**: Procedimientos para la emisi\u00f3n y control de etiquetas.\n\n4. **Almacenamiento y Distribuci\u00f3n**:\n   - **Procedimientos de Almacenamiento**: Normas para el almacenamiento seguro de productos.\n   - **Procedimientos de Distribuci\u00f3n**: M\u00e9todos para la distribuci\u00f3n eficiente y segura de productos.\n\n5. **Controles de Laboratorio**:\n   - **Pruebas de Intermediarios y APIs**: Evaluaci\u00f3n de la calidad de productos intermedios y APIs.\n   - **Validaci\u00f3n de Procedimientos Anal\u00edticos**: Aseguramiento de que los m\u00e9todos anal\u00edticos son precisos y confiables.\n   - **Monitoreo de Estabilidad**: Evaluaci\u00f3n de la estabilidad de los APIs a lo largo del tiempo.\n\n6. **Validaci\u00f3n**:\n   - **Pol\u00edtica de Validaci\u00f3n**: Directrices para la validaci\u00f3n de procesos y sistemas.\n   - **Documentaci\u00f3n de Validaci\u00f3n**: Registro de los procedimientos de validaci\u00f3n.\n   - **Validaci\u00f3n de M\u00e9todos Anal\u00edticos**: Aseguramiento de la eficacia de los m\u00e9todos utilizados en el laboratorio.\n\n7. **Control de Cambios**: Procedimientos para gestionar cambios en los procesos y materiales.\n\n8. **Rechazo y Reutilizaci\u00f3n de Materiales**:\n   - **Rechazo**: Proceso para descartar materiales no conformes.\n   - **Reprocesamiento y Re-trabajo**: M\u00e9todos para manejar materiales rechazados.\n   - **Recuperaci\u00f3n de Materiales y Solventes**: Estrategias para recuperar y reutilizar materiales.\n\n### Entidades Clave\n- **APIs (Ingredientes Activos Farmac\u00e9uticos)**: Sustancias que tienen un efecto farmacol\u00f3gico.\n- **Intermediarios**: Productos que se utilizan en la producci\u00f3n de APIs.\n- **Controles de Calidad**: Procedimientos para asegurar que los productos cumplen con los est\u00e1ndares requeridos.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades clave abordados en la secci\u00f3n del documento, destacando la importancia de la calidad y la seguridad en la producci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: Active Pharmaceutical Ingredients, Good Manufacturing Practice, Quality Management, Clinical Trials, Cell Culture"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "427ea000-9031-47fa-9267-f66b1d22e029", "node_type": "4", "metadata": {"page_label": "146", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 14.5 Returns\n\n15. Complaints and recalls\n\n16. Contract manufacturers (including laboratories)\n\n17. Agents, brokers, traders, distributors, repackers and relabellers\n   - 17.1 Applicability\n   - 17.2 Traceability of distributed APIs and intermediates\n   - 17.3 Quality management\n   - 17.4 Repackaging, relabelling and holding of APIs and intermediates\n   - 17.5 Stability\n   - 17.6 Transfer of information\n   - 17.7 Handling of complaints and recalls\n   - 17.8 Handling of returns\n\n18. Specific guidance for APIs manufactured by cell culture/fermentation\n   - 18.1 General\n   - 18.2 Cell bank maintenance and record keeping\n   - 18.3 Cell culture/fermentation\n   - 18.4 Harvesting, isolation and purification\n   - 18.5 Viral removal/inactivation steps\n\n19. APIs for use in clinical trials\n   - 19.1 General\n   - 19.2 Quality\n   - 19.3 Equipment and facilities\n   - 19.4 Control of raw materials\n   - 19.5 Production\n   - 19.6 Validation\n   - 19.7 Changes\n   - 19.8 Laboratory controls\n   - 19.9 Documentation\n\n20. Glossary\n\nReferences\n\nAppendix 1  \nList of references for related WHO guidelines\n\nAppendix 2  \nGeneral notes: additional clarifications and explanations\n\n----\n\nThis text is based on the International Conference on Harmonisation (ICH) Q7: *Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients*. November 2000.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a6403a0839a00b4737b300d96ac10bce72fc4c500bc91366b835f0c5c1043f40", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 14.5 Returns\n\n15. Complaints and recalls\n\n16. Contract manufacturers (including laboratories)\n\n17. Agents, brokers, traders, distributors, repackers and relabellers\n   - 17.1 Applicability\n   - 17.2 Traceability of distributed APIs and intermediates\n   - 17.3 Quality management\n   - 17.4 Repackaging, relabelling and holding of APIs and intermediates\n   - 17.5 Stability\n   - 17.6 Transfer of information\n   - 17.7 Handling of complaints and recalls\n   - 17.8 Handling of returns\n\n18. Specific guidance for APIs manufactured by cell culture/fermentation\n   - 18.1 General\n   - 18.2 Cell bank maintenance and record keeping\n   - 18.3 Cell culture/fermentation\n   - 18.4 Harvesting, isolation and purification\n   - 18.5 Viral removal/inactivation steps\n\n19. APIs for use in clinical trials\n   - 19.1 General\n   - 19.2 Quality\n   - 19.3 Equipment and facilities\n   - 19.4 Control of raw materials\n   - 19.5 Production\n   - 19.6 Validation\n   - 19.7 Changes\n   - 19.8 Laboratory controls\n   - 19.9 Documentation\n\n20. Glossary\n\nReferences\n\nAppendix 1  \nList of references for related WHO guidelines\n\nAppendix 2  \nGeneral notes: additional clarifications and explanations\n\n----\n\nThis text is based on the International Conference on Harmonisation (ICH) Q7: *Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients*. November 2000.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1343, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "20a7ac5f-44a0-4f84-86d8-92e548acadb1": {"__data__": {"id_": "20a7ac5f-44a0-4f84-86d8-92e548acadb1", "embedding": null, "metadata": {"page_label": "147", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\n## 1.1 Objective\n\nThis document (guide) is intended to provide guidance regarding good manufacturing practices (GMP) for the manufacturing of active pharmaceutical ingredients (APIs) under an appropriate system for managing quality. It is also intended to help ensure that APIs meet the requirements for quality and purity that they purport or are represented to possess.\n\nIn this guide \u201cmanufacturing\u201d is defined to include all operations of receipt of materials, production, packaging, repackaging, labelling, relabelling, quality control, release, storage and distribution of APIs and the related controls. In this guide the term \u201cshould\u201d indicates recommendations that are expected to apply unless shown to be inapplicable or replaced by an alternative demonstrated to provide at least an equivalent level of quality assurance. For the purposes of this guide, the terms \u201ccurrent good manufacturing practices\u201d and \u201cgood manufacturing practices\u201d are equivalent.\n\nThe guide as a whole does not cover safety aspects for the personnel engaged in the manufacture, nor aspects of protection of the environment. These controls are inherent responsibilities of the manufacturer and are governed by national laws.\n\nThis guide is not intended to define registration and filing requirements or modify pharmacopoeial requirements. This guide does not affect the ability of the responsible regulatory agency to establish specific registration or filing requirements regarding APIs within the context of marketing or manufacturing authorizations or pharmaceutical applications. All commitments in registration and filing documents must be met.\n\n## 1.2 Regulatory applicability\n\nWithin the world community, materials may vary as to the legal classification as an API. When a material is classified as an API in the region or country in which it is manufactured or used in a pharmaceutical product, it should be manufactured according to this guide.\n\n## 1.3 Scope\n\nThis guide applies to the manufacture of APIs for use in finished pharmaceutical products (FPPs). It applies to the manufacture of sterile APIs only up to the point immediately prior to the APIs being rendered sterile. The sterilization and aseptic processing of sterile APIs are not covered by this guidance, but should be performed in accordance with GMP guidelines for FPPs as defined by local authorities.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento es una gu\u00eda de la OMS sobre buenas pr\u00e1cticas de manufactura (GMP) para la producci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs). Su objetivo es asegurar que los APIs cumplan con los est\u00e1ndares de calidad y pureza. La gu\u00eda abarca todos los aspectos de la manufactura, desde la recepci\u00f3n de materiales hasta la distribuci\u00f3n, pero no incluye la esterilizaci\u00f3n de APIs. Adem\u00e1s, aclara que las regulaciones pueden variar seg\u00fan la regi\u00f3n y que la gu\u00eda no modifica los requisitos de registro o farmacopoeia.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 operaciones se consideran parte del proceso de \"manufactura\" seg\u00fan la gu\u00eda de la OMS?**\n   - La gu\u00eda define \"manufactura\" como todas las operaciones que incluyen la recepci\u00f3n de materiales, producci\u00f3n, empaque, reempaque, etiquetado, control de calidad, liberaci\u00f3n, almacenamiento y distribuci\u00f3n de APIs, as\u00ed como los controles relacionados.\n\n2. **\u00bfQu\u00e9 aspectos no cubre la gu\u00eda en relaci\u00f3n con la seguridad y el medio ambiente?**\n   - La gu\u00eda no aborda los aspectos de seguridad para el personal involucrado en la manufactura ni la protecci\u00f3n del medio ambiente, ya que estas son responsabilidades inherentes del fabricante y est\u00e1n reguladas por las leyes nacionales.\n\n3. **\u00bfC\u00f3mo se aplica la gu\u00eda a los APIs que se consideran est\u00e9riles?**\n   - La gu\u00eda se aplica a la manufactura de APIs est\u00e9riles solo hasta el punto inmediatamente anterior a que los APIs sean esterilizados. La esterilizaci\u00f3n y el procesamiento as\u00e9ptico de los APIs est\u00e9riles deben realizarse de acuerdo con las directrices de GMP para productos farmac\u00e9uticos terminados, seg\u00fan lo definido por las autoridades locales.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n\n\n1. **Devoluciones (Returns)**: Secci\u00f3n que aborda el manejo de devoluciones de productos.\n\n2. **Quejas y Retiradas (Complaints and Recalls)**: Incluye directrices sobre c\u00f3mo gestionar quejas de productos y retiradas del mercado, enfatizando la importancia de la trazabilidad y la gesti\u00f3n de calidad.\n\n3. **Fabricantes Contratados (Contract Manufacturers)**: Se refiere a las responsabilidades y regulaciones que deben seguir los fabricantes contratados, incluidos laboratorios.\n\n4. **Agentes y Distribuidores (Agents, Brokers, Traders, Distributors, Repackers and Relabellers)**: \n   - **Aplicabilidad (Applicability)**: Definici\u00f3n de a qui\u00e9nes se aplican las regulaciones.\n   - **Trazabilidad (Traceability)**: Importancia de rastrear los APIs y productos intermedios distribuidos.\n   - **Gesti\u00f3n de Calidad (Quality Management)**: Normas y pr\u00e1cticas para asegurar la calidad de los productos.\n   - **Reempaquetado y Relabeling (Repackaging and Relabelling)**: Procedimientos para el manejo de productos.\n   - **Estabilidad (Stability)**: Consideraciones sobre la estabilidad de los productos.\n   - **Transferencia de Informaci\u00f3n (Transfer of Information)**: Protocolo para compartir informaci\u00f3n relevante.\n   - **Manejo de Quejas y Retiradas (Handling of Complaints and Recalls)**: Estrategias para abordar quejas y retiradas.\n   - **Manejo de Devoluciones (Handling of Returns)**: Proceso para gestionar devoluciones de productos.\n\n5. **Orientaci\u00f3n Espec\u00edfica para APIs Fabricados por Cultivos Celulares/Fermentaci\u00f3n (Specific Guidance for APIs Manufactured by Cell Culture/Fermentation)**:\n   - **Mantenimiento de Bancos Celulares (Cell Bank Maintenance)**: Importancia del mantenimiento y registro de bancos celulares.\n   - **Cultivo y Fermentaci\u00f3n (Cell Culture/Fermentation)**: Procesos involucrados en la producci\u00f3n.\n   - **Cosecha, Aislamiento y Purificaci\u00f3n (Harvesting, Isolation and Purification)**: Pasos cr\u00edticos en la producci\u00f3n.\n   - **Eliminaci\u00f3n/Inactivaci\u00f3n Viral (Viral Removal/Inactivation Steps)**: Medidas para asegurar la seguridad del producto.\n\n6. **APIs para Ensayos Cl\u00ednicos (APIs for Use in Clinical Trials)**:\n   - **Calidad (Quality)**: Requisitos de calidad espec\u00edficos para APIs en ensayos cl\u00ednicos.\n   - **Equipos e Instalaciones (Equipment and Facilities)**: Normas para el equipamiento y las instalaciones.\n   - **Control de Materias Primas (Control of Raw Materials)**: Procedimientos para asegurar la calidad de las materias primas.\n   - **Producci\u00f3n (Production)**: Directrices para el proceso de producci\u00f3n.\n   - **Validaci\u00f3n (Validation)**: Importancia de la validaci\u00f3n de procesos.\n   - **Cambios (Changes)**: Manejo de cambios en los procesos.\n   - **Controles de Laboratorio (Laboratory Controls)**: Normas para el control de calidad en laboratorios.\n   - **Documentaci\u00f3n (Documentation)**: Requisitos de documentaci\u00f3n para todos los procedimientos.\n\n7. **Glosario (Glossary)**: Definiciones de t\u00e9rminos clave utilizados en el documento.\n\n8. **Referencias y Ap\u00e9ndices**: Incluye una lista de referencias para gu\u00edas relacionadas de la OMS y notas generales para aclaraciones adicionales.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**\n- **ICH (Conferencia Internacional sobre Armonizaci\u00f3n)**\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**\n- **Cultivos Celulares/Fermentaci\u00f3n**\n- **Ensayos Cl\u00ednicos** \n\nEste resumen destaca los temas y entidades m\u00e1s relevantes de la secci\u00f3n, proporcionando una visi\u00f3n general de las directrices y regulaciones en la producci\u00f3n y manejo de APIs.", "excerpt_keywords": "Keywords: good manufacturing practices, active pharmaceutical ingredients, quality assurance, regulatory applicability, sterile APIs"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7f9465d2-781a-4d51-8f39-aa653ffd53eb", "node_type": "4", "metadata": {"page_label": "147", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\n## 1.1 Objective\n\nThis document (guide) is intended to provide guidance regarding good manufacturing practices (GMP) for the manufacturing of active pharmaceutical ingredients (APIs) under an appropriate system for managing quality. It is also intended to help ensure that APIs meet the requirements for quality and purity that they purport or are represented to possess.\n\nIn this guide \u201cmanufacturing\u201d is defined to include all operations of receipt of materials, production, packaging, repackaging, labelling, relabelling, quality control, release, storage and distribution of APIs and the related controls. In this guide the term \u201cshould\u201d indicates recommendations that are expected to apply unless shown to be inapplicable or replaced by an alternative demonstrated to provide at least an equivalent level of quality assurance. For the purposes of this guide, the terms \u201ccurrent good manufacturing practices\u201d and \u201cgood manufacturing practices\u201d are equivalent.\n\nThe guide as a whole does not cover safety aspects for the personnel engaged in the manufacture, nor aspects of protection of the environment. These controls are inherent responsibilities of the manufacturer and are governed by national laws.\n\nThis guide is not intended to define registration and filing requirements or modify pharmacopoeial requirements. This guide does not affect the ability of the responsible regulatory agency to establish specific registration or filing requirements regarding APIs within the context of marketing or manufacturing authorizations or pharmaceutical applications. All commitments in registration and filing documents must be met.\n\n## 1.2 Regulatory applicability\n\nWithin the world community, materials may vary as to the legal classification as an API. When a material is classified as an API in the region or country in which it is manufactured or used in a pharmaceutical product, it should be manufactured according to this guide.\n\n## 1.3 Scope\n\nThis guide applies to the manufacture of APIs for use in finished pharmaceutical products (FPPs). It applies to the manufacture of sterile APIs only up to the point immediately prior to the APIs being rendered sterile. The sterilization and aseptic processing of sterile APIs are not covered by this guidance, but should be performed in accordance with GMP guidelines for FPPs as defined by local authorities.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "ba3da78a46235d792b3468909115c17328762058149e60b16dfecc9f96f4b4ad", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Introduction\n\n## 1.1 Objective\n\nThis document (guide) is intended to provide guidance regarding good manufacturing practices (GMP) for the manufacturing of active pharmaceutical ingredients (APIs) under an appropriate system for managing quality. It is also intended to help ensure that APIs meet the requirements for quality and purity that they purport or are represented to possess.\n\nIn this guide \u201cmanufacturing\u201d is defined to include all operations of receipt of materials, production, packaging, repackaging, labelling, relabelling, quality control, release, storage and distribution of APIs and the related controls. In this guide the term \u201cshould\u201d indicates recommendations that are expected to apply unless shown to be inapplicable or replaced by an alternative demonstrated to provide at least an equivalent level of quality assurance. For the purposes of this guide, the terms \u201ccurrent good manufacturing practices\u201d and \u201cgood manufacturing practices\u201d are equivalent.\n\nThe guide as a whole does not cover safety aspects for the personnel engaged in the manufacture, nor aspects of protection of the environment. These controls are inherent responsibilities of the manufacturer and are governed by national laws.\n\nThis guide is not intended to define registration and filing requirements or modify pharmacopoeial requirements. This guide does not affect the ability of the responsible regulatory agency to establish specific registration or filing requirements regarding APIs within the context of marketing or manufacturing authorizations or pharmaceutical applications. All commitments in registration and filing documents must be met.\n\n## 1.2 Regulatory applicability\n\nWithin the world community, materials may vary as to the legal classification as an API. When a material is classified as an API in the region or country in which it is manufactured or used in a pharmaceutical product, it should be manufactured according to this guide.\n\n## 1.3 Scope\n\nThis guide applies to the manufacture of APIs for use in finished pharmaceutical products (FPPs). It applies to the manufacture of sterile APIs only up to the point immediately prior to the APIs being rendered sterile. The sterilization and aseptic processing of sterile APIs are not covered by this guidance, but should be performed in accordance with GMP guidelines for FPPs as defined by local authorities.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2377, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7c594074-7e0e-4906-93f1-45864eec3713": {"__data__": {"id_": "7c594074-7e0e-4906-93f1-45864eec3713", "embedding": null, "metadata": {"page_label": "148", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "This guide covers APIs that are manufactured by chemical synthesis, extraction, cell culture or fermentation, by recovery from natural sources, or by any combination of these processes.\n\nSpecific guidance for APIs manufactured by cell culture or fermentation is described in section 18.\n\nThis guide excludes all vaccines, whole cells, whole blood and plasma, blood and plasma derivatives (plasma fractionation), and gene therapy APIs. However, it does include APIs that are produced using blood or plasma as raw materials. Note that cell substrates (mammalian, plant, insect or microbial cells, tissue or animal sources including transgenic animals) and early process steps may be subject to GMP but are not covered by this guide. In addition, the guide does not apply to medical gases, bulk-packaged FPPs, and manufacturing and control aspects specific to radiopharmaceuticals.\n\nSection 19 contains guidance that only applies to the manufacture of APIs used in the production of FPPs specifically for clinical trials (investigational medicinal products).\n\nAn \u201cAPI starting material\u201d is a raw material, intermediate, or an API that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. An API starting material can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement, or produced in house.\n\nAPI starting materials normally have defined chemical properties and structure. The company should designate and document the rationale for the point at which production of the API begins. For synthetic processes, this is known as the point at which \u201cAPI starting materials\u201d are entered into the process. For other processes (e.g. fermentation, extraction or purification), this rationale should be established on a case-by-case basis.\n\nTable 1 gives guidance on the point at which the API starting material is normally introduced into the process. From this point on, appropriate GMP as defined in this guide should be applied to these intermediate and/or API manufacturing steps. This would include the validation of critical process steps determined to impact the quality of the API. However, it should be noted that the fact that a company chooses to validate a process step does not necessarily define that step as critical.\n\nThe guidance in this document would normally be applied to the steps shown in grey in Table 1. It does not imply that all steps shown should be completed. The stringency of GMP in API manufacturing should increase as the process proceeds from early API steps to final steps, purification and packaging. Physical processing of APIs, such as granulation, coating", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen de Nivel Superior\n\nEl documento de la OMS proporciona directrices sobre la fabricaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (API) a trav\u00e9s de diversos procesos, incluyendo s\u00edntesis qu\u00edmica, extracci\u00f3n, cultivo celular y fermentaci\u00f3n. Se excluyen ciertos productos como vacunas, c\u00e9lulas completas, derivados de sangre y terapia g\u00e9nica, aunque se incluyen APIs producidos a partir de sangre o plasma. Se define el concepto de \"material de partida de API\" y se establece la importancia de documentar el inicio del proceso de producci\u00f3n. Adem\u00e1s, se enfatiza la necesidad de aplicar Buenas Pr\u00e1cticas de Manufactura (GMP) a medida que se avanza en el proceso de fabricaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar para establecer el punto de inicio de la producci\u00f3n de un API en procesos de fermentaci\u00f3n o extracci\u00f3n?**\n   - La gu\u00eda sugiere que este criterio debe ser establecido caso por caso, y la empresa debe documentar la justificaci\u00f3n para el punto en el que comienza la producci\u00f3n del API.\n\n2. **\u00bfC\u00f3mo se determina si un paso del proceso de fabricaci\u00f3n de un API es cr\u00edtico para la calidad del producto?**\n   - La validaci\u00f3n de pasos cr\u00edticos debe ser realizada, pero la decisi\u00f3n de validar un paso no necesariamente lo define como cr\u00edtico. La gu\u00eda enfatiza que la validaci\u00f3n debe centrarse en los pasos que impactan la calidad del API.\n\n3. **\u00bfQu\u00e9 tipo de materiales se consideran como \"materiales de partida de API\" y c\u00f3mo se clasifican?**\n   - Los materiales de partida de API pueden ser materias primas, intermedios o APIs que se incorporan como fragmentos estructurales significativos en la producci\u00f3n del API. Pueden ser art\u00edculos de comercio, materiales adquiridos bajo contrato o producidos internamente, y normalmente tienen propiedades y estructuras qu\u00edmicas definidas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Objetivo de la Gu\u00eda:**\n   - Proporcionar orientaci\u00f3n sobre buenas pr\u00e1cticas de manufactura (GMP) para la producci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs).\n   - Asegurar que los APIs cumplan con los est\u00e1ndares de calidad y pureza.\n\n2. **Definici\u00f3n de Manufactura:**\n   - Incluye operaciones como recepci\u00f3n de materiales, producci\u00f3n, empaque, etiquetado, control de calidad, almacenamiento y distribuci\u00f3n de APIs.\n\n3. **Recomendaciones y Regulaciones:**\n   - El t\u00e9rmino \"deber\u00eda\" indica recomendaciones que se espera que se apliquen, salvo que se demuestre lo contrario.\n   - La gu\u00eda no modifica requisitos de registro o farmacopoeia y no cubre aspectos de seguridad laboral ni protecci\u00f3n ambiental.\n\n4. **Aplicabilidad Regulatoria:**\n   - La clasificaci\u00f3n legal de un material como API puede variar seg\u00fan la regi\u00f3n; debe fabricarse conforme a esta gu\u00eda si se clasifica como tal.\n\n5. **Alcance de la Gu\u00eda:**\n   - Se aplica a la manufactura de APIs para productos farmac\u00e9uticos terminados (FPPs) y a APIs est\u00e9riles solo hasta antes de su esterilizaci\u00f3n.\n\n**Entidades:**\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud):** Autoridad que emite la gu\u00eda.\n- **APIs (Ingredientes Farmac\u00e9uticos Activos):** Sustancias que se producen bajo las directrices de la gu\u00eda.\n- **FPPs (Productos Farmac\u00e9uticos Terminados):** Productos que utilizan los APIs fabricados seg\u00fan la gu\u00eda.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura):** Conjunto de directrices que rigen la producci\u00f3n de APIs.\n- **Autoridades Locales:** Entidades que definen las directrices de GMP para productos farmac\u00e9uticos terminados y regulaciones espec\u00edficas de registro. \n\nEste resumen destaca los aspectos fundamentales de la gu\u00eda y las entidades involucradas en el contexto de las buenas pr\u00e1cticas de manufactura para APIs.", "excerpt_keywords": "Keywords: APIs, GMP, manufacturing, fermentation, starting materials"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ee23fe6d-27f3-432a-a38f-e1635a69a46f", "node_type": "4", "metadata": {"page_label": "148", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "This guide covers APIs that are manufactured by chemical synthesis, extraction, cell culture or fermentation, by recovery from natural sources, or by any combination of these processes.\n\nSpecific guidance for APIs manufactured by cell culture or fermentation is described in section 18.\n\nThis guide excludes all vaccines, whole cells, whole blood and plasma, blood and plasma derivatives (plasma fractionation), and gene therapy APIs. However, it does include APIs that are produced using blood or plasma as raw materials. Note that cell substrates (mammalian, plant, insect or microbial cells, tissue or animal sources including transgenic animals) and early process steps may be subject to GMP but are not covered by this guide. In addition, the guide does not apply to medical gases, bulk-packaged FPPs, and manufacturing and control aspects specific to radiopharmaceuticals.\n\nSection 19 contains guidance that only applies to the manufacture of APIs used in the production of FPPs specifically for clinical trials (investigational medicinal products).\n\nAn \u201cAPI starting material\u201d is a raw material, intermediate, or an API that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. An API starting material can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement, or produced in house.\n\nAPI starting materials normally have defined chemical properties and structure. The company should designate and document the rationale for the point at which production of the API begins. For synthetic processes, this is known as the point at which \u201cAPI starting materials\u201d are entered into the process. For other processes (e.g. fermentation, extraction or purification), this rationale should be established on a case-by-case basis.\n\nTable 1 gives guidance on the point at which the API starting material is normally introduced into the process. From this point on, appropriate GMP as defined in this guide should be applied to these intermediate and/or API manufacturing steps. This would include the validation of critical process steps determined to impact the quality of the API. However, it should be noted that the fact that a company chooses to validate a process step does not necessarily define that step as critical.\n\nThe guidance in this document would normally be applied to the steps shown in grey in Table 1. It does not imply that all steps shown should be completed. The stringency of GMP in API manufacturing should increase as the process proceeds from early API steps to final steps, purification and packaging. Physical processing of APIs, such as granulation, coating", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "d6b15cae48b1cdf09446bba644ce0fbfd2278b26b6a0585496db64d91132073b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "This guide covers APIs that are manufactured by chemical synthesis, extraction, cell culture or fermentation, by recovery from natural sources, or by any combination of these processes.\n\nSpecific guidance for APIs manufactured by cell culture or fermentation is described in section 18.\n\nThis guide excludes all vaccines, whole cells, whole blood and plasma, blood and plasma derivatives (plasma fractionation), and gene therapy APIs. However, it does include APIs that are produced using blood or plasma as raw materials. Note that cell substrates (mammalian, plant, insect or microbial cells, tissue or animal sources including transgenic animals) and early process steps may be subject to GMP but are not covered by this guide. In addition, the guide does not apply to medical gases, bulk-packaged FPPs, and manufacturing and control aspects specific to radiopharmaceuticals.\n\nSection 19 contains guidance that only applies to the manufacture of APIs used in the production of FPPs specifically for clinical trials (investigational medicinal products).\n\nAn \u201cAPI starting material\u201d is a raw material, intermediate, or an API that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. An API starting material can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement, or produced in house.\n\nAPI starting materials normally have defined chemical properties and structure. The company should designate and document the rationale for the point at which production of the API begins. For synthetic processes, this is known as the point at which \u201cAPI starting materials\u201d are entered into the process. For other processes (e.g. fermentation, extraction or purification), this rationale should be established on a case-by-case basis.\n\nTable 1 gives guidance on the point at which the API starting material is normally introduced into the process. From this point on, appropriate GMP as defined in this guide should be applied to these intermediate and/or API manufacturing steps. This would include the validation of critical process steps determined to impact the quality of the API. However, it should be noted that the fact that a company chooses to validate a process step does not necessarily define that step as critical.\n\nThe guidance in this document would normally be applied to the steps shown in grey in Table 1. It does not imply that all steps shown should be completed. The stringency of GMP in API manufacturing should increase as the process proceeds from early API steps to final steps, purification and packaging. Physical processing of APIs, such as granulation, coating", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2719, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d42cf2f2-974f-4882-93c2-be71245d8c05": {"__data__": {"id_": "d42cf2f2-974f-4882-93c2-be71245d8c05", "embedding": null, "metadata": {"page_label": "149", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Application of this Guide to API Manufacturing\n\n| Type of manufacturing | Application of this guide to steps (shown in grey) used in this type of manufacturing |\n| - | - |\n| Chemical manufacturing | * Production of the API starting material\n* Introduction of the API starting material into process\n* Production of intermediate(s)\n* Isolation and purification\n* Physical processing, and packaging |\n| API derived from animal sources | - Collection of organ, fluid, or tissue\n- Cutting, mixing, and/or initial processing\n- Introduction of the API starting material into process\n- Isolation and purification\n- Physical processing, and packaging |\n| API extracted from plant sources | * Collection of plants\n* Cutting and initial extraction(s)\n* Introduction of the API starting material into process\n* Isolation and purification\n* Physical processing, and packaging |\n| Herbal extracts used as API | - Collection of plants\n- Cutting and initial extraction\n- Further extraction\n- Physical processing, and packaging |\n| API consisting of comminuted or powdered herbs | * Collection of plants and/or cultivation and harvesting\n* Cutting/communiting\n* Physical processing, and packaging |\n| Biotechnology: fermentation/cell culture | - Establishment of master cell bank and working cell bank\n- Maintenance of working cell bank\n- Cell culture and/or fermentation\n- Isolation and purification\n- Physical processing, and packaging |\n| \"Classical\" fermentation to produce an API | * Establishment of cell bank\n* Maintenance of the cell bank\n* Introduction of the cells into fermentation\n* Isolation and purification\n* Physical processing, and packaging |\n\n\n<a>This table has been taken from the ICH Harmonised Tripartite Guideline: Active Pharmaceutical Ingredients Q7. Current Step 4 version, dated 10 November 2000.</a>\n\n**Increasing GMP requirements**", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS, titulado \"Technical Report Series 957\", aborda la aplicaci\u00f3n de directrices para la fabricaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (API). Se presenta una tabla que detalla los diferentes tipos de fabricaci\u00f3n de API, incluyendo qu\u00edmica, fuentes animales, fuentes vegetales, extractos herbales, hierbas en polvo, biotecnolog\u00eda y fermentaci\u00f3n cl\u00e1sica. Cada tipo de fabricaci\u00f3n incluye pasos espec\u00edficos que deben seguirse, como la recolecci\u00f3n, el procesamiento, la purificaci\u00f3n y el empaquetado. Adem\u00e1s, se menciona un aumento en los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos involucrados en la producci\u00f3n de un API derivado de fuentes animales seg\u00fan la gu\u00eda de la OMS?**\n   - Respuesta: Los pasos incluyen la colecci\u00f3n de \u00f3rganos, fluidos o tejidos, el corte, mezcla y/o procesamiento inicial, la introducci\u00f3n del material inicial del API en el proceso, la aislamiento y purificaci\u00f3n, y el procesamiento f\u00edsico y empaquetado.\n\n2. **\u00bfQu\u00e9 diferencias existen entre la producci\u00f3n de un API a partir de fuentes vegetales y la producci\u00f3n de extractos herbales utilizados como API?**\n   - Respuesta: En la producci\u00f3n de un API a partir de fuentes vegetales, los pasos incluyen la recolecci\u00f3n de plantas, el corte y las extracciones iniciales, mientras que en el caso de los extractos herbales, se incluyen la recolecci\u00f3n de plantas, el corte y la extracci\u00f3n inicial, seguido de una extracci\u00f3n adicional.\n\n3. **\u00bfQu\u00e9 pasos son comunes en la producci\u00f3n de APIs mediante biotecnolog\u00eda y fermentaci\u00f3n cl\u00e1sica, seg\u00fan el documento?**\n   - Respuesta: Ambos procesos incluyen el establecimiento y mantenimiento de un banco celular, la introducci\u00f3n de c\u00e9lulas en el proceso de fermentaci\u00f3n, la aislamiento y purificaci\u00f3n, y el procesamiento f\u00edsico y empaquetado.", "prev_section_summary": "### Temas Clave\n\n1. **Manufactura de Ingredientes Farmac\u00e9uticos Activos (API)**:\n   - La gu\u00eda abarca la producci\u00f3n de APIs mediante s\u00edntesis qu\u00edmica, extracci\u00f3n, cultivo celular, fermentaci\u00f3n y recuperaci\u00f3n de fuentes naturales.\n\n2. **Exclusiones**:\n   - Se excluyen vacunas, c\u00e9lulas completas, derivados de sangre, terapia g\u00e9nica y gases m\u00e9dicos. Sin embargo, se incluyen APIs producidos a partir de sangre o plasma.\n\n3. **Materiales de Partida de API**:\n   - Se define el concepto de \"material de partida de API\", que puede ser una materia prima, intermedio o API que se incorpora en la estructura del API final.\n\n4. **Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Se enfatiza la aplicaci\u00f3n de GMP a partir del punto en que se introducen los materiales de partida en el proceso de producci\u00f3n, con un enfoque en la validaci\u00f3n de pasos cr\u00edticos que impactan la calidad del API.\n\n5. **Documentaci\u00f3n y Justificaci\u00f3n**:\n   - La empresa debe documentar el punto de inicio de la producci\u00f3n del API y establecer criterios espec\u00edficos para procesos como fermentaci\u00f3n y extracci\u00f3n.\n\n6. **Incremento de la Estricta de GMP**:\n   - La rigurosidad de las GMP debe aumentar a medida que se avanza en el proceso de fabricaci\u00f3n, desde los pasos iniciales hasta la purificaci\u00f3n y el empaquetado final.\n\n### Entidades\n\n- **API (Ingrediente Farmac\u00e9utico Activo)**: Sustancia utilizada en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normas que aseguran la calidad y seguridad en la producci\u00f3n de medicamentos.\n- **Material de Partida de API**: Materia prima o intermedio utilizado en la producci\u00f3n de un API.\n- **Secci\u00f3n 18 y 19**: Secciones espec\u00edficas de la gu\u00eda que abordan la fabricaci\u00f3n de APIs por cultivo celular y fermentaci\u00f3n, y la producci\u00f3n de APIs para ensayos cl\u00ednicos, respectivamente.\n\nEste resumen destaca los aspectos fundamentales de la gu\u00eda de la OMS sobre la fabricaci\u00f3n de APIs y las consideraciones clave para asegurar la calidad y la conformidad en el proceso de producci\u00f3n.", "excerpt_keywords": "Keywords: API manufacturing, GMP requirements, fermentation, purification, extraction"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6d57ca74-9f44-4125-ad60-b214a04a2547", "node_type": "4", "metadata": {"page_label": "149", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Application of this Guide to API Manufacturing\n\n| Type of manufacturing | Application of this guide to steps (shown in grey) used in this type of manufacturing |\n| - | - |\n| Chemical manufacturing | * Production of the API starting material\n* Introduction of the API starting material into process\n* Production of intermediate(s)\n* Isolation and purification\n* Physical processing, and packaging |\n| API derived from animal sources | - Collection of organ, fluid, or tissue\n- Cutting, mixing, and/or initial processing\n- Introduction of the API starting material into process\n- Isolation and purification\n- Physical processing, and packaging |\n| API extracted from plant sources | * Collection of plants\n* Cutting and initial extraction(s)\n* Introduction of the API starting material into process\n* Isolation and purification\n* Physical processing, and packaging |\n| Herbal extracts used as API | - Collection of plants\n- Cutting and initial extraction\n- Further extraction\n- Physical processing, and packaging |\n| API consisting of comminuted or powdered herbs | * Collection of plants and/or cultivation and harvesting\n* Cutting/communiting\n* Physical processing, and packaging |\n| Biotechnology: fermentation/cell culture | - Establishment of master cell bank and working cell bank\n- Maintenance of working cell bank\n- Cell culture and/or fermentation\n- Isolation and purification\n- Physical processing, and packaging |\n| \"Classical\" fermentation to produce an API | * Establishment of cell bank\n* Maintenance of the cell bank\n* Introduction of the cells into fermentation\n* Isolation and purification\n* Physical processing, and packaging |\n\n\n<a>This table has been taken from the ICH Harmonised Tripartite Guideline: Active Pharmaceutical Ingredients Q7. Current Step 4 version, dated 10 November 2000.</a>\n\n**Increasing GMP requirements**", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "86b2426b6ad5e1f351ce17421563465cff1efe0d5dec9f853482c9a71db17181", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Application of this Guide to API Manufacturing\n\n| Type of manufacturing | Application of this guide to steps (shown in grey) used in this type of manufacturing |\n| - | - |\n| Chemical manufacturing | * Production of the API starting material\n* Introduction of the API starting material into process\n* Production of intermediate(s)\n* Isolation and purification\n* Physical processing, and packaging |\n| API derived from animal sources | - Collection of organ, fluid, or tissue\n- Cutting, mixing, and/or initial processing\n- Introduction of the API starting material into process\n- Isolation and purification\n- Physical processing, and packaging |\n| API extracted from plant sources | * Collection of plants\n* Cutting and initial extraction(s)\n* Introduction of the API starting material into process\n* Isolation and purification\n* Physical processing, and packaging |\n| Herbal extracts used as API | - Collection of plants\n- Cutting and initial extraction\n- Further extraction\n- Physical processing, and packaging |\n| API consisting of comminuted or powdered herbs | * Collection of plants and/or cultivation and harvesting\n* Cutting/communiting\n* Physical processing, and packaging |\n| Biotechnology: fermentation/cell culture | - Establishment of master cell bank and working cell bank\n- Maintenance of working cell bank\n- Cell culture and/or fermentation\n- Isolation and purification\n- Physical processing, and packaging |\n| \"Classical\" fermentation to produce an API | * Establishment of cell bank\n* Maintenance of the cell bank\n* Introduction of the cells into fermentation\n* Isolation and purification\n* Physical processing, and packaging |\n\n\n<a>This table has been taken from the ICH Harmonised Tripartite Guideline: Active Pharmaceutical Ingredients Q7. Current Step 4 version, dated 10 November 2000.</a>\n\n**Increasing GMP requirements**", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1845, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ba25ab16-1534-4c86-8fdf-f6eb7cc5313a": {"__data__": {"id_": "ba25ab16-1534-4c86-8fdf-f6eb7cc5313a", "embedding": null, "metadata": {"page_label": "150", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 2. Quality management\n\n## 2.1 Principles\n\n2.10 Quality should be the responsibility of all persons involved in manufacturing.\n\n2.11 Each manufacturer should establish, document and implement an effective system for managing quality that involves the active participation of management and appropriate manufacturing personnel.\n\n2.12 The system for managing quality should encompass the organizational structure, procedures, processes and resources, as well as activities necessary to ensure confidence that the API will meet its intended specifications for quality and purity. All quality-related activities should be defined and documented.\n\n2.13 There should be a quality unit(s) that is independent of production and that fulfils both quality assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization.\n\n2.14 The persons authorized to release intermediates and APIs should be specified.\n\n2.15 All quality-related activities should be recorded at the time they are performed.\n\n2.16 Any deviation from established procedures should be documented and explained. Critical deviations should be investigated, and the investigation and its conclusions should be documented.\n\n2.17 No materials should be released or used before the satisfactory completion of evaluation by the quality unit(s) unless there are appropriate systems in place to allow for such use (e.g. release under quarantine as described in section 10.20 or the use of raw materials or intermediates pending completion of evaluation).\n\n2.18 Procedures should exist for notifying responsible management in a timely manner of regulatory inspections, serious GMP deficiencies, product defects and related actions (e.g. quality related complaints, recalls and regulatory actions).\n\n## 2.2 Responsibilities of the quality unit(s)\n\n2.20 The quality unit(s) should be involved in all quality-related matters.\n\n----\n\n1 This system of numbering sections is different to the usual WHO style. It is used here to harmonize with the guide used in inspection reports internationally.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la Serie de Informes T\u00e9cnicos 957 aborda la gesti\u00f3n de calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza que la calidad es responsabilidad de todos los involucrados en el proceso de fabricaci\u00f3n y que debe existir un sistema documentado y efectivo para gestionar la calidad. Este sistema debe incluir una unidad de calidad independiente que se encargue de asegurar tanto la calidad como el control de calidad. Adem\u00e1s, se establecen procedimientos para la documentaci\u00f3n de actividades relacionadas con la calidad, la gesti\u00f3n de desviaciones y la notificaci\u00f3n de problemas a la direcci\u00f3n responsable.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 papel desempe\u00f1a la unidad de calidad en la gesti\u00f3n de calidad seg\u00fan el documento?**\n   - La unidad de calidad debe ser independiente de la producci\u00f3n y cumplir con las responsabilidades de aseguramiento de calidad (QA) y control de calidad (QC). Su participaci\u00f3n es esencial en todos los asuntos relacionados con la calidad.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse en caso de desviaciones cr\u00edticas de los procedimientos establecidos?**\n   - Cualquier desviaci\u00f3n de los procedimientos establecidos debe ser documentada y explicada. Las desviaciones cr\u00edticas deben ser investigadas, y tanto la investigaci\u00f3n como sus conclusiones deben ser documentadas.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse antes de que se puedan liberar o utilizar materiales en el proceso de fabricaci\u00f3n?**\n   - No se deben liberar ni utilizar materiales antes de que se complete satisfactoriamente la evaluaci\u00f3n por parte de la unidad de calidad, a menos que existan sistemas apropiados que permitan su uso, como la liberaci\u00f3n bajo cuarentena o el uso de materias primas o intermedios mientras se completa la evaluaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **T\u00edtulo del Documento**: WHO - Technical Report Series 957\n   - Este documento de la OMS se centra en la fabricaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (API).\n\n2. **Tipos de Fabricaci\u00f3n de API**:\n   - **Qu\u00edmica**: Incluye la producci\u00f3n del material inicial, introducci\u00f3n en el proceso, producci\u00f3n de intermedios, aislamiento, purificaci\u00f3n, procesamiento f\u00edsico y empaquetado.\n   - **Fuentes Animales**: Implica la recolecci\u00f3n de \u00f3rganos, fluidos o tejidos, procesamiento inicial, introducci\u00f3n del material inicial, aislamiento, purificaci\u00f3n, y empaquetado.\n   - **Fuentes Vegetales**: Comprende la recolecci\u00f3n de plantas, corte, extracciones iniciales, introducci\u00f3n del material inicial, aislamiento, purificaci\u00f3n, y empaquetado.\n   - **Extractos Herbales**: Incluye recolecci\u00f3n, corte, extracci\u00f3n inicial, extracci\u00f3n adicional, y empaquetado.\n   - **Hierbas en Polvo**: Involucra recolecci\u00f3n, corte, procesamiento f\u00edsico y empaquetado.\n   - **Biotecnolog\u00eda**: Abarca el establecimiento y mantenimiento de bancos celulares, cultivo celular o fermentaci\u00f3n, aislamiento, purificaci\u00f3n, y empaquetado.\n   - **Fermentaci\u00f3n Cl\u00e1sica**: Similar a la biotecnolog\u00eda, incluye el establecimiento y mantenimiento de bancos celulares, introducci\u00f3n de c\u00e9lulas en fermentaci\u00f3n, aislamiento, purificaci\u00f3n, y empaquetado.\n\n3. **Requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Se menciona un aumento en los requisitos de GMP, lo que indica una creciente regulaci\u00f3n y est\u00e1ndares en la fabricaci\u00f3n de APIs.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que publica el documento.\n- **API (Ingrediente Farmac\u00e9utico Activo)**: Sustancia utilizada en la fabricaci\u00f3n de medicamentos.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normativas que aseguran la calidad y seguridad en la producci\u00f3n de productos farmac\u00e9uticos.\n\nEste resumen destaca los aspectos fundamentales de la secci\u00f3n, incluyendo los tipos de fabricaci\u00f3n de APIs y la importancia de cumplir con los est\u00e1ndares de GMP.", "excerpt_keywords": "Keywords: quality management, pharmaceutical manufacturing, quality assurance, good manufacturing practices, regulatory compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "712b0e77-011f-4ab4-b102-e5a8cfc1a0cc", "node_type": "4", "metadata": {"page_label": "150", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 2. Quality management\n\n## 2.1 Principles\n\n2.10 Quality should be the responsibility of all persons involved in manufacturing.\n\n2.11 Each manufacturer should establish, document and implement an effective system for managing quality that involves the active participation of management and appropriate manufacturing personnel.\n\n2.12 The system for managing quality should encompass the organizational structure, procedures, processes and resources, as well as activities necessary to ensure confidence that the API will meet its intended specifications for quality and purity. All quality-related activities should be defined and documented.\n\n2.13 There should be a quality unit(s) that is independent of production and that fulfils both quality assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization.\n\n2.14 The persons authorized to release intermediates and APIs should be specified.\n\n2.15 All quality-related activities should be recorded at the time they are performed.\n\n2.16 Any deviation from established procedures should be documented and explained. Critical deviations should be investigated, and the investigation and its conclusions should be documented.\n\n2.17 No materials should be released or used before the satisfactory completion of evaluation by the quality unit(s) unless there are appropriate systems in place to allow for such use (e.g. release under quarantine as described in section 10.20 or the use of raw materials or intermediates pending completion of evaluation).\n\n2.18 Procedures should exist for notifying responsible management in a timely manner of regulatory inspections, serious GMP deficiencies, product defects and related actions (e.g. quality related complaints, recalls and regulatory actions).\n\n## 2.2 Responsibilities of the quality unit(s)\n\n2.20 The quality unit(s) should be involved in all quality-related matters.\n\n----\n\n1 This system of numbering sections is different to the usual WHO style. It is used here to harmonize with the guide used in inspection reports internationally.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "167aec5f65735c3730a5caa79711f056c9184adf3d8216c962ce36ee3f112177", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 2. Quality management\n\n## 2.1 Principles\n\n2.10 Quality should be the responsibility of all persons involved in manufacturing.\n\n2.11 Each manufacturer should establish, document and implement an effective system for managing quality that involves the active participation of management and appropriate manufacturing personnel.\n\n2.12 The system for managing quality should encompass the organizational structure, procedures, processes and resources, as well as activities necessary to ensure confidence that the API will meet its intended specifications for quality and purity. All quality-related activities should be defined and documented.\n\n2.13 There should be a quality unit(s) that is independent of production and that fulfils both quality assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization.\n\n2.14 The persons authorized to release intermediates and APIs should be specified.\n\n2.15 All quality-related activities should be recorded at the time they are performed.\n\n2.16 Any deviation from established procedures should be documented and explained. Critical deviations should be investigated, and the investigation and its conclusions should be documented.\n\n2.17 No materials should be released or used before the satisfactory completion of evaluation by the quality unit(s) unless there are appropriate systems in place to allow for such use (e.g. release under quarantine as described in section 10.20 or the use of raw materials or intermediates pending completion of evaluation).\n\n2.18 Procedures should exist for notifying responsible management in a timely manner of regulatory inspections, serious GMP deficiencies, product defects and related actions (e.g. quality related complaints, recalls and regulatory actions).\n\n## 2.2 Responsibilities of the quality unit(s)\n\n2.20 The quality unit(s) should be involved in all quality-related matters.\n\n----\n\n1 This system of numbering sections is different to the usual WHO style. It is used here to harmonize with the guide used in inspection reports internationally.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2174, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4375986e-034a-4b30-9065-73450675e123": {"__data__": {"id_": "4375986e-034a-4b30-9065-73450675e123", "embedding": null, "metadata": {"page_label": "151", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 2.21\n\nThe quality unit(s) should review and approve all appropriate quality-related documents.\n\n## 2.22\n\nThe main responsibilities of the independent quality unit(s) should not be delegated.\n\nThese responsibilities should be described in writing and should include but not necessarily be limited to:\n\n1. Releasing or rejecting all APIs. Releasing or rejecting intermediates for use outside the control of the manufacturing company.\n2. Establishing a system to release or reject raw materials, intermediates, packaging and labelling materials.\n3. Reviewing completed batch production and laboratory control records of critical process steps before release of the API for distribution.\n4. Making sure that critical deviations are investigated and resolved.\n5. Approving all specifications and master production instructions.\n6. Approving all procedures impacting the quality of intermediates or APIs.\n7. Making sure that internal audits (self-inspections) are performed.\n8. Approving intermediate and API contract manufacturers.\n9. Approving changes that potentially impact quality of intermediates or APIs.\n10. Reviewing and approving validation protocols and reports.\n11. Making sure that quality-related complaints are investigated and resolved.\n12. Making sure that effective systems are used for maintaining and calibrating critical equipment.\n13. Making sure that materials are appropriately tested and the results are reported.\n14. Making sure that there are stability data to support retest or expiry dates and storage conditions on APIs and/or intermediates where appropriate.\n15. Performing product quality reviews (as defined in section 2.5).\n\n## 2.3 Responsibility for production activities\n\nThe responsibility for production activities should be described in writing, and should include but not necessarily be limited to:\n\n1. Preparing, reviewing, approving and distributing the instructions for the production of intermediates or APIs according to written procedures.\n2. Producing APIs and, when appropriate, intermediates according to pre-approved instructions.\n3. Reviewing all production batch records and ensuring that these are completed and signed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla las responsabilidades de las unidades de calidad independientes en la producci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs) y otros materiales relacionados. Se enfatiza que estas responsabilidades no deben ser delegadas y deben estar claramente documentadas. Adem\u00e1s, se establece que la responsabilidad de las actividades de producci\u00f3n tambi\u00e9n debe ser descrita por escrito, asegurando que se sigan procedimientos aprobados y que se mantenga la calidad en todas las etapas del proceso.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales responsabilidades que no deben ser delegadas a otras unidades en el contexto de la calidad de los APIs?**\n   - Respuesta: Las principales responsabilidades incluyen la liberaci\u00f3n o rechazo de todos los APIs, la revisi\u00f3n de registros de producci\u00f3n y control de laboratorio, la aprobaci\u00f3n de especificaciones y procedimientos, la investigaci\u00f3n de desviaciones cr\u00edticas, y la realizaci\u00f3n de auditor\u00edas internas, entre otras.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse para asegurar que los materiales utilizados en la producci\u00f3n de APIs sean de calidad adecuada?**\n   - Respuesta: Se debe establecer un sistema para liberar o rechazar materias primas, intermedios, y materiales de envasado y etiquetado. Adem\u00e1s, se deben realizar pruebas adecuadas de los materiales y asegurar que los resultados sean reportados.\n\n3. **\u00bfQu\u00e9 pasos se deben tomar para abordar las quejas relacionadas con la calidad de los productos?**\n   - Respuesta: Es fundamental investigar y resolver todas las quejas relacionadas con la calidad, asegurando que se implementen sistemas efectivos para manejar estas situaciones y que se mantenga la calidad del producto final.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n#### Temas clave:\n1. **Responsabilidad de la calidad**: La calidad es una responsabilidad compartida por todas las personas involucradas en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n2. **Sistema de gesti\u00f3n de calidad**: Cada fabricante debe establecer un sistema documentado y efectivo para gestionar la calidad, que incluya la participaci\u00f3n activa de la direcci\u00f3n y el personal de fabricaci\u00f3n.\n3. **Unidad de calidad independiente**: Debe existir una unidad de calidad que sea independiente de la producci\u00f3n, encargada de las funciones de aseguramiento de calidad (QA) y control de calidad (QC).\n4. **Documentaci\u00f3n de actividades**: Todas las actividades relacionadas con la calidad deben ser registradas y documentadas en el momento en que se realizan.\n5. **Manejo de desviaciones**: Las desviaciones de los procedimientos establecidos deben ser documentadas y explicadas, y las desviaciones cr\u00edticas deben ser investigadas.\n6. **Liberaci\u00f3n de materiales**: No se deben liberar ni utilizar materiales hasta que se complete satisfactoriamente la evaluaci\u00f3n por parte de la unidad de calidad, salvo que existan sistemas que lo permitan.\n7. **Notificaci\u00f3n de problemas**: Deben existir procedimientos para notificar a la direcci\u00f3n sobre inspecciones regulatorias, deficiencias graves en GMP, defectos de productos y acciones relacionadas.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices sobre gesti\u00f3n de calidad.\n- **Unidad de calidad**: Entidad responsable de asegurar y controlar la calidad en el proceso de fabricaci\u00f3n.\n- **Fabricantes**: Entidades que deben implementar el sistema de gesti\u00f3n de calidad.\n- **Personal de fabricaci\u00f3n**: Personas involucradas en el proceso de producci\u00f3n que comparten la responsabilidad de la calidad.\n- **Gesti\u00f3n responsable**: Direcci\u00f3n que debe ser notificada sobre problemas relacionados con la calidad y cumplimiento normativo. \n\nEste resumen destaca la importancia de un enfoque sistem\u00e1tico y documentado para la gesti\u00f3n de calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos, as\u00ed como la necesidad de una unidad de calidad independiente para garantizar el cumplimiento de los est\u00e1ndares establecidos.", "excerpt_keywords": "Keywords: calidad, unidades independientes, producci\u00f3n, APIs, documentaci\u00f3n"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "db741599-719b-4aa3-ae4e-8be2798b7b84", "node_type": "4", "metadata": {"page_label": "151", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 2.21\n\nThe quality unit(s) should review and approve all appropriate quality-related documents.\n\n## 2.22\n\nThe main responsibilities of the independent quality unit(s) should not be delegated.\n\nThese responsibilities should be described in writing and should include but not necessarily be limited to:\n\n1. Releasing or rejecting all APIs. Releasing or rejecting intermediates for use outside the control of the manufacturing company.\n2. Establishing a system to release or reject raw materials, intermediates, packaging and labelling materials.\n3. Reviewing completed batch production and laboratory control records of critical process steps before release of the API for distribution.\n4. Making sure that critical deviations are investigated and resolved.\n5. Approving all specifications and master production instructions.\n6. Approving all procedures impacting the quality of intermediates or APIs.\n7. Making sure that internal audits (self-inspections) are performed.\n8. Approving intermediate and API contract manufacturers.\n9. Approving changes that potentially impact quality of intermediates or APIs.\n10. Reviewing and approving validation protocols and reports.\n11. Making sure that quality-related complaints are investigated and resolved.\n12. Making sure that effective systems are used for maintaining and calibrating critical equipment.\n13. Making sure that materials are appropriately tested and the results are reported.\n14. Making sure that there are stability data to support retest or expiry dates and storage conditions on APIs and/or intermediates where appropriate.\n15. Performing product quality reviews (as defined in section 2.5).\n\n## 2.3 Responsibility for production activities\n\nThe responsibility for production activities should be described in writing, and should include but not necessarily be limited to:\n\n1. Preparing, reviewing, approving and distributing the instructions for the production of intermediates or APIs according to written procedures.\n2. Producing APIs and, when appropriate, intermediates according to pre-approved instructions.\n3. Reviewing all production batch records and ensuring that these are completed and signed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "1ed55d53881f1703e147e1ec20707b5190628a464205ebdd5a0514286b8d3842", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 2.21\n\nThe quality unit(s) should review and approve all appropriate quality-related documents.\n\n## 2.22\n\nThe main responsibilities of the independent quality unit(s) should not be delegated.\n\nThese responsibilities should be described in writing and should include but not necessarily be limited to:\n\n1. Releasing or rejecting all APIs. Releasing or rejecting intermediates for use outside the control of the manufacturing company.\n2. Establishing a system to release or reject raw materials, intermediates, packaging and labelling materials.\n3. Reviewing completed batch production and laboratory control records of critical process steps before release of the API for distribution.\n4. Making sure that critical deviations are investigated and resolved.\n5. Approving all specifications and master production instructions.\n6. Approving all procedures impacting the quality of intermediates or APIs.\n7. Making sure that internal audits (self-inspections) are performed.\n8. Approving intermediate and API contract manufacturers.\n9. Approving changes that potentially impact quality of intermediates or APIs.\n10. Reviewing and approving validation protocols and reports.\n11. Making sure that quality-related complaints are investigated and resolved.\n12. Making sure that effective systems are used for maintaining and calibrating critical equipment.\n13. Making sure that materials are appropriately tested and the results are reported.\n14. Making sure that there are stability data to support retest or expiry dates and storage conditions on APIs and/or intermediates where appropriate.\n15. Performing product quality reviews (as defined in section 2.5).\n\n## 2.3 Responsibility for production activities\n\nThe responsibility for production activities should be described in writing, and should include but not necessarily be limited to:\n\n1. Preparing, reviewing, approving and distributing the instructions for the production of intermediates or APIs according to written procedures.\n2. Producing APIs and, when appropriate, intermediates according to pre-approved instructions.\n3. Reviewing all production batch records and ensuring that these are completed and signed.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2169, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "561bf65d-4766-42cb-9c9b-154f401a9ea5": {"__data__": {"id_": "561bf65d-4766-42cb-9c9b-154f401a9ea5", "embedding": null, "metadata": {"page_label": "152", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "4. Making sure that all production deviations are reported and evaluated and that critical deviations are investigated and the conclusions are recorded.  \n5. Making sure that production facilities are clean and when appropriate disinfected.  \n6. Making sure that the necessary calibrations are performed and records kept.  \n7. Making sure that the premises and equipment are maintained and records kept.  \n8. Making sure that validation protocols and reports are reviewed and approved.  \n9. Evaluating proposed changes in product, process or equipment.  \n10. Making sure that new and, when appropriate, modified facilities and equipment are qualified.\n\n## 2.4 Internal audits (self-inspection)\n\n2.40 In order to verify compliance with the principles of GMP for APIs, regular internal audits should be performed in accordance with an approved schedule.\n\n2.41 Audit findings and corrective actions should be documented and brought to the attention of the responsible management of the firm. Agreed corrective actions should be completed in a timely and effective manner.\n\n## 2.5 Product quality review\n\n2.50 Regular quality reviews of APIs should be conducted with the objective of verifying the consistency of the process. Such reviews should normally be conducted and documented annually and should include at least a review of:\n\n- critical in-process control and critical API test results;\n- all batches that failed to meet established specification(s);\n- all critical deviations or non-conformances and related investigations;\n- any changes carried out to the processes or analytical methods;\n- results of the stability monitoring programme;\n- quality-related returns, complaints and recalls; and\n- adequacy of corrective actions.\n\n2.51 The results of this review should be evaluated and an assessment made of whether corrective action or any revalidation should be undertaken. Reasons for such corrective action should be documented. Agreed corrective actions should be completed in a timely and effective manner.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la serie de informes t\u00e9cnicos 957 aborda las Buenas Pr\u00e1cticas de Manufactura (GMP) para los Ingredientes Farmac\u00e9uticos Activos (APIs). Se enfatiza la importancia de asegurar que todas las desviaciones en la producci\u00f3n sean reportadas y evaluadas, que las instalaciones de producci\u00f3n est\u00e9n limpias y desinfectadas cuando sea necesario, y que se realicen calibraciones y mantenimientos adecuados de los equipos. Adem\u00e1s, se menciona la necesidad de realizar auditor\u00edas internas regulares y revisiones de calidad de los APIs para verificar la consistencia del proceso y documentar hallazgos y acciones correctivas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para documentar las desviaciones cr\u00edticas en la producci\u00f3n de APIs?**\n   - El contexto menciona que todas las desviaciones de producci\u00f3n deben ser reportadas y evaluadas, y que las desviaciones cr\u00edticas deben ser investigadas y sus conclusiones registradas. Sin embargo, no se especifican los procedimientos exactos para esta documentaci\u00f3n.\n\n2. **\u00bfCu\u00e1l es la frecuencia recomendada para realizar auditor\u00edas internas y qu\u00e9 aspectos deben ser evaluados durante estas auditor\u00edas?**\n   - Se indica que las auditor\u00edas internas deben realizarse de acuerdo con un cronograma aprobado, pero no se detallan los aspectos espec\u00edficos que deben ser evaluados durante estas auditor\u00edas.\n\n3. **\u00bfQu\u00e9 elementos deben incluirse en la revisi\u00f3n de calidad anual de los APIs para asegurar la consistencia del proceso?**\n   - El contexto menciona varios elementos que deben ser revisados, como los resultados de control cr\u00edtico y las quejas relacionadas con la calidad, pero no se proporciona un desglose detallado de c\u00f3mo se deben evaluar estos elementos o qu\u00e9 criterios se deben utilizar.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar disponible en otras partes del documento o en fuentes externas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### Temas Clave:\n1. **Responsabilidades de la Unidad de Calidad**: Se enfatiza que las responsabilidades de las unidades de calidad independientes no deben ser delegadas y deben estar documentadas. Estas responsabilidades incluyen la liberaci\u00f3n y rechazo de APIs, la revisi\u00f3n de registros de producci\u00f3n, la aprobaci\u00f3n de especificaciones y procedimientos, y la investigaci\u00f3n de desviaciones cr\u00edticas.\n\n2. **Control de Calidad**: Se establece la necesidad de un sistema para liberar o rechazar materias primas, intermedios y materiales de envasado. Tambi\u00e9n se requiere que los materiales sean probados adecuadamente y que los resultados sean reportados.\n\n3. **Manejo de Quejas**: Es crucial investigar y resolver las quejas relacionadas con la calidad de los productos, asegurando que se implementen sistemas efectivos para mantener la calidad.\n\n4. **Responsabilidad en Actividades de Producci\u00f3n**: Las responsabilidades de producci\u00f3n deben estar claramente descritas y seguir procedimientos aprobados, asegurando que se mantenga la calidad en todas las etapas del proceso de producci\u00f3n de APIs e intermedios.\n\n#### Entidades:\n- **Unidad de Calidad**: Entidad responsable de asegurar la calidad de los productos farmac\u00e9uticos.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Sustancias que se utilizan en la producci\u00f3n de medicamentos.\n- **Intermedios**: Productos que se utilizan en la fabricaci\u00f3n de APIs.\n- **Materiales de Envasado y Etiquetado**: Elementos que se utilizan para el envasado y etiquetado de productos farmac\u00e9uticos.\n- **Registros de Producci\u00f3n y Control de Laboratorio**: Documentaci\u00f3n que debe ser revisada y aprobada antes de la liberaci\u00f3n de los productos.\n- **Auditor\u00edas Internas**: Evaluaciones que deben realizarse para asegurar el cumplimiento de los est\u00e1ndares de calidad.\n\nEste resumen destaca la importancia de la calidad y la responsabilidad en la producci\u00f3n de productos farmac\u00e9uticos, as\u00ed como la necesidad de procedimientos claros y documentados para garantizar la seguridad y eficacia de los mismos.", "excerpt_keywords": "Keywords: Good Manufacturing Practices, Active Pharmaceutical Ingredients, internal audits, product quality review, production deviations"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d8b93e95-ddf5-4679-8f02-0f1ab1e933c3", "node_type": "4", "metadata": {"page_label": "152", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "4. Making sure that all production deviations are reported and evaluated and that critical deviations are investigated and the conclusions are recorded.  \n5. Making sure that production facilities are clean and when appropriate disinfected.  \n6. Making sure that the necessary calibrations are performed and records kept.  \n7. Making sure that the premises and equipment are maintained and records kept.  \n8. Making sure that validation protocols and reports are reviewed and approved.  \n9. Evaluating proposed changes in product, process or equipment.  \n10. Making sure that new and, when appropriate, modified facilities and equipment are qualified.\n\n## 2.4 Internal audits (self-inspection)\n\n2.40 In order to verify compliance with the principles of GMP for APIs, regular internal audits should be performed in accordance with an approved schedule.\n\n2.41 Audit findings and corrective actions should be documented and brought to the attention of the responsible management of the firm. Agreed corrective actions should be completed in a timely and effective manner.\n\n## 2.5 Product quality review\n\n2.50 Regular quality reviews of APIs should be conducted with the objective of verifying the consistency of the process. Such reviews should normally be conducted and documented annually and should include at least a review of:\n\n- critical in-process control and critical API test results;\n- all batches that failed to meet established specification(s);\n- all critical deviations or non-conformances and related investigations;\n- any changes carried out to the processes or analytical methods;\n- results of the stability monitoring programme;\n- quality-related returns, complaints and recalls; and\n- adequacy of corrective actions.\n\n2.51 The results of this review should be evaluated and an assessment made of whether corrective action or any revalidation should be undertaken. Reasons for such corrective action should be documented. Agreed corrective actions should be completed in a timely and effective manner.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "33a7c741020113840275e4f0e11b2946816423f872d176b7ca1f0f7e449501e3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "4. Making sure that all production deviations are reported and evaluated and that critical deviations are investigated and the conclusions are recorded.  \n5. Making sure that production facilities are clean and when appropriate disinfected.  \n6. Making sure that the necessary calibrations are performed and records kept.  \n7. Making sure that the premises and equipment are maintained and records kept.  \n8. Making sure that validation protocols and reports are reviewed and approved.  \n9. Evaluating proposed changes in product, process or equipment.  \n10. Making sure that new and, when appropriate, modified facilities and equipment are qualified.\n\n## 2.4 Internal audits (self-inspection)\n\n2.40 In order to verify compliance with the principles of GMP for APIs, regular internal audits should be performed in accordance with an approved schedule.\n\n2.41 Audit findings and corrective actions should be documented and brought to the attention of the responsible management of the firm. Agreed corrective actions should be completed in a timely and effective manner.\n\n## 2.5 Product quality review\n\n2.50 Regular quality reviews of APIs should be conducted with the objective of verifying the consistency of the process. Such reviews should normally be conducted and documented annually and should include at least a review of:\n\n- critical in-process control and critical API test results;\n- all batches that failed to meet established specification(s);\n- all critical deviations or non-conformances and related investigations;\n- any changes carried out to the processes or analytical methods;\n- results of the stability monitoring programme;\n- quality-related returns, complaints and recalls; and\n- adequacy of corrective actions.\n\n2.51 The results of this review should be evaluated and an assessment made of whether corrective action or any revalidation should be undertaken. Reasons for such corrective action should be documented. Agreed corrective actions should be completed in a timely and effective manner.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2016, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4dc68a3a-e907-40e5-8b03-f54a9d7138d7": {"__data__": {"id_": "4dc68a3a-e907-40e5-8b03-f54a9d7138d7", "embedding": null, "metadata": {"page_label": "153", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 3. Personnel\n\n## 3.1 Personnel qualifications\n\n3.10 There should be an adequate number of personnel qualified by appropriate education, training and/or experience to perform and supervise the manufacture of intermediates and APIs.\n\n3.11 The responsibilities of all personnel engaged in the manufacture of intermediates and APIs should be specified in writing.\n\n3.12 Training should be regularly conducted by qualified individuals and should cover, at a minimum, the particular operations that the employee performs, and GMP as it relates to the employee\u2019s functions. Records of training should be maintained. Training should be periodically assessed.\n\n## 3.2 Personnel hygiene\n\n3.20 Personnel should practice good sanitation and health habits.\n\n3.21 Personnel should wear clean clothing suitable for the manufacturing activity with which they are involved and this clothing should be changed when appropriate. Additional protective apparel, such as head, face, hand and arm coverings, should be worn when necessary, to protect intermediates and APIs from contamination.\n\n3.22 Personnel should avoid direct contact with intermediates or APIs.\n\n3.23 Smoking, eating, drinking, chewing and the storage of food should be restricted to certain designated areas separate from the manufacturing areas.\n\n3.24 Personnel with an infectious disease or who have open lesions on the exposed surface of the body should not engage in activities that could result in compromising the quality of APIs. Any person shown at any time (either by medical examination or supervisory observation) to have an apparent illness or open lesions should be excluded from activities where their health condition could adversely affect the quality of the APIs, until the condition is corrected or qualified medical personnel determine that the person\u2019s inclusion would not jeopardize the safety or quality of the APIs.\n\n## 3.3 Consultants\n\n3.30 Consultants advising on the manufacture and control of intermediates or APIs should have sufficient education, training, and experience, or any combination thereof, to advise on the subject for which they are retained.\n\n3.31 Records should be maintained stating the name, address, qualifications and type of service provided by these consultants.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las calificaciones, la higiene y la gesti\u00f3n de personal involucrado en la fabricaci\u00f3n de intermediarios y principios activos (APIs). Se enfatiza la necesidad de contar con personal calificado, la importancia de la formaci\u00f3n continua, y las pr\u00e1cticas de higiene que deben seguirse para evitar la contaminaci\u00f3n de los productos. Adem\u00e1s, se menciona la necesidad de mantener registros de consultores que asesoren en la fabricaci\u00f3n y control de estos productos.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas que deben ser documentadas para el personal involucrado en la fabricaci\u00f3n de intermediarios y APIs?**\n   - Esta pregunta busca detalles sobre la documentaci\u00f3n de responsabilidades que no se especifican en el texto, pero que son cruciales para la gesti\u00f3n del personal.\n\n2. **\u00bfQu\u00e9 tipo de formaci\u00f3n se considera adecuada para el personal que trabaja en la fabricaci\u00f3n de intermediarios y APIs, y c\u00f3mo se eval\u00faa su efectividad?**\n   - Esta pregunta se centra en los m\u00e9todos de formaci\u00f3n y evaluaci\u00f3n que podr\u00edan no estar claramente definidos en el contexto, pero son esenciales para asegurar la competencia del personal.\n\n3. **\u00bfQu\u00e9 criterios se utilizan para determinar si un consultor es adecuado para asesorar en la fabricaci\u00f3n y control de intermediarios o APIs?**\n   - Esta pregunta busca profundizar en los criterios de selecci\u00f3n de consultores, que no se detallan en el texto, pero son importantes para garantizar la calidad del asesoramiento recibido.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Buenas Pr\u00e1cticas de Manufactura (GMP)**: El documento se centra en la implementaci\u00f3n de GMP para los Ingredientes Farmac\u00e9uticos Activos (APIs), destacando la importancia de la calidad y la consistencia en la producci\u00f3n.\n\n2. **Desviaciones en la Producci\u00f3n**: Se enfatiza la necesidad de reportar y evaluar todas las desviaciones en la producci\u00f3n, con un enfoque especial en las desviaciones cr\u00edticas que deben ser investigadas y documentadas.\n\n3. **Limpieza y Mantenimiento**: Se requiere que las instalaciones de producci\u00f3n est\u00e9n limpias y desinfectadas cuando sea necesario, y que se mantengan adecuadamente los equipos y las instalaciones.\n\n4. **Calibraciones y Validaciones**: Es esencial realizar calibraciones necesarias y mantener registros, as\u00ed como revisar y aprobar protocolos y reportes de validaci\u00f3n.\n\n5. **Auditor\u00edas Internas**: Se deben llevar a cabo auditor\u00edas internas regulares seg\u00fan un cronograma aprobado para verificar el cumplimiento de los principios de GMP. Los hallazgos y acciones correctivas deben ser documentados y comunicados a la gerencia responsable.\n\n6. **Revisi\u00f3n de Calidad del Producto**: Se deben realizar revisiones de calidad de los APIs de manera regular, normalmente de forma anual, para verificar la consistencia del proceso. Esto incluye la revisi\u00f3n de controles cr\u00edticos, lotes que no cumplieron con las especificaciones, desviaciones cr\u00edticas, cambios en procesos o m\u00e9todos anal\u00edticos, y quejas relacionadas con la calidad.\n\n7. **Acciones Correctivas**: Los resultados de las revisiones de calidad deben ser evaluados para determinar si se requieren acciones correctivas o revalidaciones, y estas deben ser documentadas y completadas de manera oportuna y efectiva.\n\n### Entidades Clave\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el documento.\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Producto central del documento.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Principios que gu\u00edan la producci\u00f3n de APIs.\n- **Auditor\u00edas Internas**: Proceso de verificaci\u00f3n del cumplimiento de GMP.\n- **Revisi\u00f3n de Calidad**: Evaluaci\u00f3n regular de la consistencia del proceso de producci\u00f3n de APIs. \n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades clave abordados en la secci\u00f3n del documento.", "excerpt_keywords": "Keywords: personnel qualifications, good manufacturing practices, hygiene, training records, consultants"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e4807678-22c9-4e55-af8c-72be1e069211", "node_type": "4", "metadata": {"page_label": "153", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 3. Personnel\n\n## 3.1 Personnel qualifications\n\n3.10 There should be an adequate number of personnel qualified by appropriate education, training and/or experience to perform and supervise the manufacture of intermediates and APIs.\n\n3.11 The responsibilities of all personnel engaged in the manufacture of intermediates and APIs should be specified in writing.\n\n3.12 Training should be regularly conducted by qualified individuals and should cover, at a minimum, the particular operations that the employee performs, and GMP as it relates to the employee\u2019s functions. Records of training should be maintained. Training should be periodically assessed.\n\n## 3.2 Personnel hygiene\n\n3.20 Personnel should practice good sanitation and health habits.\n\n3.21 Personnel should wear clean clothing suitable for the manufacturing activity with which they are involved and this clothing should be changed when appropriate. Additional protective apparel, such as head, face, hand and arm coverings, should be worn when necessary, to protect intermediates and APIs from contamination.\n\n3.22 Personnel should avoid direct contact with intermediates or APIs.\n\n3.23 Smoking, eating, drinking, chewing and the storage of food should be restricted to certain designated areas separate from the manufacturing areas.\n\n3.24 Personnel with an infectious disease or who have open lesions on the exposed surface of the body should not engage in activities that could result in compromising the quality of APIs. Any person shown at any time (either by medical examination or supervisory observation) to have an apparent illness or open lesions should be excluded from activities where their health condition could adversely affect the quality of the APIs, until the condition is corrected or qualified medical personnel determine that the person\u2019s inclusion would not jeopardize the safety or quality of the APIs.\n\n## 3.3 Consultants\n\n3.30 Consultants advising on the manufacture and control of intermediates or APIs should have sufficient education, training, and experience, or any combination thereof, to advise on the subject for which they are retained.\n\n3.31 Records should be maintained stating the name, address, qualifications and type of service provided by these consultants.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "ec73d4194d09258302054706eb674216fed49e089a91f9a4b18d4b89bac3730e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 3. Personnel\n\n## 3.1 Personnel qualifications\n\n3.10 There should be an adequate number of personnel qualified by appropriate education, training and/or experience to perform and supervise the manufacture of intermediates and APIs.\n\n3.11 The responsibilities of all personnel engaged in the manufacture of intermediates and APIs should be specified in writing.\n\n3.12 Training should be regularly conducted by qualified individuals and should cover, at a minimum, the particular operations that the employee performs, and GMP as it relates to the employee\u2019s functions. Records of training should be maintained. Training should be periodically assessed.\n\n## 3.2 Personnel hygiene\n\n3.20 Personnel should practice good sanitation and health habits.\n\n3.21 Personnel should wear clean clothing suitable for the manufacturing activity with which they are involved and this clothing should be changed when appropriate. Additional protective apparel, such as head, face, hand and arm coverings, should be worn when necessary, to protect intermediates and APIs from contamination.\n\n3.22 Personnel should avoid direct contact with intermediates or APIs.\n\n3.23 Smoking, eating, drinking, chewing and the storage of food should be restricted to certain designated areas separate from the manufacturing areas.\n\n3.24 Personnel with an infectious disease or who have open lesions on the exposed surface of the body should not engage in activities that could result in compromising the quality of APIs. Any person shown at any time (either by medical examination or supervisory observation) to have an apparent illness or open lesions should be excluded from activities where their health condition could adversely affect the quality of the APIs, until the condition is corrected or qualified medical personnel determine that the person\u2019s inclusion would not jeopardize the safety or quality of the APIs.\n\n## 3.3 Consultants\n\n3.30 Consultants advising on the manufacture and control of intermediates or APIs should have sufficient education, training, and experience, or any combination thereof, to advise on the subject for which they are retained.\n\n3.31 Records should be maintained stating the name, address, qualifications and type of service provided by these consultants.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2261, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "566e0b53-09e7-4502-822b-7273f5e93d9d": {"__data__": {"id_": "566e0b53-09e7-4502-822b-7273f5e93d9d", "embedding": null, "metadata": {"page_label": "154", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4. Buildings and facilities\n\n## 4.1 Design and construction\n\n4.10 Buildings and facilities used in the manufacture of intermediates and APIs should be located, designed, and constructed to facilitate cleaning, maintenance and operations as appropriate to the type and stage of manufacture. Facilities should also be designed to minimize potential contamination. Where microbiological specifications have been established for the intermediate or API, facilities should also be designed to limit exposure to objectionable microbiological contaminants as appropriate.\n\n4.11 Buildings and facilities should have adequate space for the orderly placement of equipment and materials to prevent mix-ups and contamination.\n\n4.12 Where the equipment itself (e.g. closed or contained systems) provides adequate protection of the material, such equipment can be located outdoors.\n\n4.13 The flow of materials and personnel through the building or facilities should be designed to prevent mix-ups or contamination.\n\n4.14 There should be defined areas or other control systems for the following activities:\n\n- receipt, identification, sampling, and quarantine of incoming materials, pending release or rejection;\n- quarantine before release or rejection of intermediates and APIs;\n- sampling of intermediates and APIs;\n- holding rejected materials before further disposition (e.g. return, reprocessing or destruction);\n- storage of released materials;\n- production operations;\n- packaging and labelling operations; and\n- laboratory operations.\n\n4.15 Adequate, clean washing and toilet facilities should be provided for personnel. These washing facilities should be equipped with hot and cold water as appropriate, soap or detergent, air driers or single-use towels. The washing and toilet facilities should be separate from, but easily accessible to, manufacturing areas. Adequate facilities for showering and/or changing clothes should be provided, when appropriate.\n\n4.16 Laboratory areas and operations should normally be separated from production areas. Some laboratory areas, in particular those used for in-process controls, can be located in production areas, provided the operations of the production process do not adversely affect the accuracy of the laboratory measurements, and the laboratory and its operations do not adversely affect the production process or intermediate or API.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Dise\u00f1o y construcci\u00f3n de instalaciones**: Las instalaciones utilizadas en la fabricaci\u00f3n de intermediarios y principios activos (APIs) deben ser dise\u00f1adas y construidas para facilitar la limpieza y el mantenimiento, minimizando la contaminaci\u00f3n y limitando la exposici\u00f3n a contaminantes microbiol\u00f3gicos.\n\n2. **Flujo de materiales y personal**: Es crucial que el flujo de materiales y personal dentro de las instalaciones est\u00e9 dise\u00f1ado para prevenir confusiones y contaminaci\u00f3n, con \u00e1reas definidas para diversas actividades relacionadas con la recepci\u00f3n, almacenamiento, producci\u00f3n y laboratorio.\n\n3. **Instalaciones para el personal**: Se deben proporcionar instalaciones adecuadas y limpias para el lavado y el uso de ba\u00f1os, separadas de las \u00e1reas de fabricaci\u00f3n, y se deben incluir facilidades para duchas y cambios de ropa cuando sea necesario.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 caracter\u00edsticas espec\u00edficas deben tener las instalaciones para minimizar la contaminaci\u00f3n microbiol\u00f3gica en la fabricaci\u00f3n de intermediarios y APIs?**\n   - Esta pregunta busca detalles sobre el dise\u00f1o y las caracter\u00edsticas de las instalaciones que no se mencionan expl\u00edcitamente en otras normativas o documentos.\n\n2. **\u00bfCu\u00e1les son las consideraciones clave para el dise\u00f1o del flujo de materiales y personal en las instalaciones de fabricaci\u00f3n de intermediarios y APIs?**\n   - Esta pregunta se centra en los aspectos pr\u00e1cticos del dise\u00f1o de instalaciones que previenen la contaminaci\u00f3n y las confusiones, lo cual puede no estar claramente definido en otras fuentes.\n\n3. **\u00bfQu\u00e9 requisitos espec\u00edficos se deben cumplir para las instalaciones de lavado y ba\u00f1o en las \u00e1reas de fabricaci\u00f3n de intermediarios y APIs?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre las especificaciones de las instalaciones de higiene para el personal, que pueden no estar cubiertas en otras regulaciones o gu\u00edas.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Calificaciones del Personal**:\n   - Se requiere un n\u00famero adecuado de personal calificado en educaci\u00f3n, formaci\u00f3n y/o experiencia para la fabricaci\u00f3n y supervisi\u00f3n de intermediarios y principios activos (APIs).\n   - Las responsabilidades del personal deben estar documentadas por escrito.\n   - La formaci\u00f3n debe ser regular, realizada por individuos calificados, y debe incluir operaciones espec\u00edficas y Buenas Pr\u00e1cticas de Manufactura (GMP). Se deben mantener registros de formaci\u00f3n y realizar evaluaciones peri\u00f3dicas.\n\n2. **Higiene del Personal**:\n   - Se enfatiza la importancia de buenas pr\u00e1cticas de sanidad y salud.\n   - El personal debe usar ropa limpia y adecuada, cambi\u00e1ndola cuando sea necesario, y utilizar ropa protectora adicional para evitar la contaminaci\u00f3n de intermediarios y APIs.\n   - Se proh\u00edbe el contacto directo con intermediarios o APIs, as\u00ed como actividades como fumar, comer o almacenar alimentos en \u00e1reas de fabricaci\u00f3n.\n   - El personal con enfermedades infecciosas o lesiones abiertas debe ser excluido de actividades que puedan comprometer la calidad de los APIs.\n\n3. **Consultores**:\n   - Los consultores deben tener la educaci\u00f3n, formaci\u00f3n y experiencia adecuadas para asesorar sobre la fabricaci\u00f3n y control de intermediarios y APIs.\n   - Se deben mantener registros que incluyan el nombre, direcci\u00f3n, calificaciones y tipo de servicio proporcionado por los consultores.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Intermediarios y APIs**: Productos farmac\u00e9uticos cuya fabricaci\u00f3n y control son el foco de las directrices.\n- **Personal**: Incluye a todos los empleados involucrados en la fabricaci\u00f3n y supervisi\u00f3n de intermediarios y APIs.\n- **Consultores**: Profesionales externos que asesoran sobre la fabricaci\u00f3n y control de intermediarios y APIs. \n\nEste resumen destaca la importancia de la calificaci\u00f3n, la higiene y la gesti\u00f3n adecuada del personal en la industria farmac\u00e9utica, as\u00ed como la necesidad de contar con consultores competentes.", "excerpt_keywords": "Keywords: buildings, facilities, design, contamination, hygiene"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cd7e7d79-7882-437d-9045-db7165899874", "node_type": "4", "metadata": {"page_label": "154", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4. Buildings and facilities\n\n## 4.1 Design and construction\n\n4.10 Buildings and facilities used in the manufacture of intermediates and APIs should be located, designed, and constructed to facilitate cleaning, maintenance and operations as appropriate to the type and stage of manufacture. Facilities should also be designed to minimize potential contamination. Where microbiological specifications have been established for the intermediate or API, facilities should also be designed to limit exposure to objectionable microbiological contaminants as appropriate.\n\n4.11 Buildings and facilities should have adequate space for the orderly placement of equipment and materials to prevent mix-ups and contamination.\n\n4.12 Where the equipment itself (e.g. closed or contained systems) provides adequate protection of the material, such equipment can be located outdoors.\n\n4.13 The flow of materials and personnel through the building or facilities should be designed to prevent mix-ups or contamination.\n\n4.14 There should be defined areas or other control systems for the following activities:\n\n- receipt, identification, sampling, and quarantine of incoming materials, pending release or rejection;\n- quarantine before release or rejection of intermediates and APIs;\n- sampling of intermediates and APIs;\n- holding rejected materials before further disposition (e.g. return, reprocessing or destruction);\n- storage of released materials;\n- production operations;\n- packaging and labelling operations; and\n- laboratory operations.\n\n4.15 Adequate, clean washing and toilet facilities should be provided for personnel. These washing facilities should be equipped with hot and cold water as appropriate, soap or detergent, air driers or single-use towels. The washing and toilet facilities should be separate from, but easily accessible to, manufacturing areas. Adequate facilities for showering and/or changing clothes should be provided, when appropriate.\n\n4.16 Laboratory areas and operations should normally be separated from production areas. Some laboratory areas, in particular those used for in-process controls, can be located in production areas, provided the operations of the production process do not adversely affect the accuracy of the laboratory measurements, and the laboratory and its operations do not adversely affect the production process or intermediate or API.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b105d0d504f7328a0efdfea8f005a6bb4a4c5c06c2dc5d1d2231f2d675fb2a57", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4. Buildings and facilities\n\n## 4.1 Design and construction\n\n4.10 Buildings and facilities used in the manufacture of intermediates and APIs should be located, designed, and constructed to facilitate cleaning, maintenance and operations as appropriate to the type and stage of manufacture. Facilities should also be designed to minimize potential contamination. Where microbiological specifications have been established for the intermediate or API, facilities should also be designed to limit exposure to objectionable microbiological contaminants as appropriate.\n\n4.11 Buildings and facilities should have adequate space for the orderly placement of equipment and materials to prevent mix-ups and contamination.\n\n4.12 Where the equipment itself (e.g. closed or contained systems) provides adequate protection of the material, such equipment can be located outdoors.\n\n4.13 The flow of materials and personnel through the building or facilities should be designed to prevent mix-ups or contamination.\n\n4.14 There should be defined areas or other control systems for the following activities:\n\n- receipt, identification, sampling, and quarantine of incoming materials, pending release or rejection;\n- quarantine before release or rejection of intermediates and APIs;\n- sampling of intermediates and APIs;\n- holding rejected materials before further disposition (e.g. return, reprocessing or destruction);\n- storage of released materials;\n- production operations;\n- packaging and labelling operations; and\n- laboratory operations.\n\n4.15 Adequate, clean washing and toilet facilities should be provided for personnel. These washing facilities should be equipped with hot and cold water as appropriate, soap or detergent, air driers or single-use towels. The washing and toilet facilities should be separate from, but easily accessible to, manufacturing areas. Adequate facilities for showering and/or changing clothes should be provided, when appropriate.\n\n4.16 Laboratory areas and operations should normally be separated from production areas. Some laboratory areas, in particular those used for in-process controls, can be located in production areas, provided the operations of the production process do not adversely affect the accuracy of the laboratory measurements, and the laboratory and its operations do not adversely affect the production process or intermediate or API.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2381, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8e66e1f0-67a5-41f8-9de5-f0d5b0ca7a7c": {"__data__": {"id_": "8e66e1f0-67a5-41f8-9de5-f0d5b0ca7a7c", "embedding": null, "metadata": {"page_label": "155", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.2 Utilities\n\n4.20 All utilities that could impact on product quality (e.g. steam, gases, compressed air, and heating, ventilation and air conditioning) should be qualified and appropriately monitored and action should be taken when limits are exceeded. Drawings for these utility systems should be available.\n\n4.21 Adequate ventilation, air filtration and exhaust systems should be provided, where appropriate. These systems should be designed and constructed to minimize risks of contamination and cross-contamination and should include equipment for control of air pressure, microorganisms (if appropriate), dust, humidity, and temperature, as appropriate to the stage of manufacture. Particular attention should be given to areas where APIs are exposed to the environment.\n\n4.22 If air is recirculated to production areas, appropriate measures should be taken to control risks of contamination and cross-contamination.\n\n4.23 Permanently installed pipework should be appropriately identified. This can be accomplished by identifying individual lines, documentation, computer control systems, or alternative means. Pipework should be located to avoid risks of contamination of the intermediate or API.\n\n4.24 Drains should be of adequate size and should be provided with an air break or a suitable device to prevent back-siphonage, when appropriate.\n\n# 4.3 Water\n\n4.30 Water used in the manufacture of APIs should be demonstrated to be suitable for its intended use.\n\n4.31 Unless otherwise justified, process water should, at a minimum, meet WHO guidelines for drinking (potable) water quality.\n\n4.32 If drinking (potable) water is insufficient to assure API quality, and tighter chemical and/or microbiological water quality specifications are called for, appropriate specifications for physical and chemical attributes, total microbial counts, objectionable organisms and/or endotoxins should be established.\n\n4.33 Where water used in the process is treated by the manufacturer to achieve a defined quality, the treatment process should be validated and monitored with appropriate action limits.\n\n4.34 Where the manufacturer of a non-sterile API either intends or claims that it is suitable for use in further processing to produce a sterile FPP, water used in the final isolation and purification steps should be monitored and controlled for total microbial counts, objectionable organisms and endotoxins.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las directrices sobre la calidad de las utilidades y el agua en la fabricaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (API). Se enfatiza la importancia de calificar y monitorear utilidades como vapor, gases y sistemas de ventilaci\u00f3n para minimizar riesgos de contaminaci\u00f3n. Adem\u00e1s, se establecen requisitos espec\u00edficos para la calidad del agua utilizada en la producci\u00f3n de API, incluyendo la necesidad de cumplir con las pautas de calidad del agua potable y de establecer especificaciones m\u00e1s estrictas si es necesario.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben tomarse si se exceden los l\u00edmites de monitoreo de las utilidades que impactan la calidad del producto?**\n   - El documento indica que se deben tomar acciones apropiadas cuando se exceden los l\u00edmites de monitoreo de las utilidades, aunque no especifica qu\u00e9 acciones exactas deben implementarse.\n\n2. **\u00bfCu\u00e1les son las especificaciones m\u00ednimas que debe cumplir el agua de proceso utilizada en la fabricaci\u00f3n de APIs?**\n   - A menos que se justifique lo contrario, el agua de proceso debe cumplir, como m\u00ednimo, con las pautas de la OMS para la calidad del agua potable.\n\n3. **\u00bfQu\u00e9 tipo de control se debe ejercer sobre el agua utilizada en los pasos finales de aislamiento y purificaci\u00f3n de un API no est\u00e9ril que se pretende utilizar para producir un producto farmac\u00e9utico est\u00e9ril?**\n   - El agua utilizada en estos pasos debe ser monitoreada y controlada para total de recuentos microbianos, organismos objetables y endotoxinas, asegurando as\u00ed la calidad del producto final.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n 4: Edificios e Instalaciones\n\n#### Temas Clave:\n\n1. **Dise\u00f1o y Construcci\u00f3n de Instalaciones**:\n   - Las instalaciones para la fabricaci\u00f3n de intermediarios y principios activos (APIs) deben facilitar la limpieza y el mantenimiento.\n   - Deben minimizar la contaminaci\u00f3n y limitar la exposici\u00f3n a contaminantes microbiol\u00f3gicos.\n\n2. **Espacio y Organizaci\u00f3n**:\n   - Es esencial contar con espacio adecuado para la colocaci\u00f3n ordenada de equipos y materiales, evitando confusiones y contaminaci\u00f3n.\n\n3. **Flujo de Materiales y Personal**:\n   - El dise\u00f1o debe prevenir la mezcla de materiales y la contaminaci\u00f3n, estableciendo un flujo claro para el movimiento de personas y materiales.\n\n4. **\u00c1reas Definidas para Actividades**:\n   - Se deben establecer \u00e1reas espec\u00edficas para actividades como recepci\u00f3n, muestreo, cuarentena, almacenamiento, producci\u00f3n, envasado y operaciones de laboratorio.\n\n5. **Instalaciones de Higiene para el Personal**:\n   - Deben existir instalaciones limpias para el lavado y uso de ba\u00f1os, separadas de las \u00e1reas de fabricaci\u00f3n, con acceso a agua caliente y fr\u00eda, jab\u00f3n, y opciones para secado.\n\n6. **Separaci\u00f3n de \u00c1reas de Laboratorio y Producci\u00f3n**:\n   - Las \u00e1reas de laboratorio deben estar separadas de las de producci\u00f3n, salvo en casos espec\u00edficos donde no afecten la precisi\u00f3n de los controles de proceso.\n\n#### Entidades:\n\n- **Intermediarios**: Sustancias qu\u00edmicas utilizadas en la fabricaci\u00f3n de APIs.\n- **APIs (Principios Activos)**: Sustancias que tienen un efecto farmacol\u00f3gico.\n- **Contaminantes Microbiol\u00f3gicos**: Organismos que pueden causar contaminaci\u00f3n en el proceso de fabricaci\u00f3n.\n- **Instalaciones de Lavado y Ba\u00f1o**: Espacios destinados a la higiene del personal.\n- **\u00c1reas de Producci\u00f3n**: Espacios donde se llevan a cabo las operaciones de fabricaci\u00f3n.\n- **\u00c1reas de Laboratorio**: Espacios dedicados a pruebas y controles de calidad.\n\nEste resumen destaca la importancia del dise\u00f1o y la organizaci\u00f3n de las instalaciones en la fabricaci\u00f3n de productos farmac\u00e9uticos, enfatizando la necesidad de mantener est\u00e1ndares de higiene y prevenir la contaminaci\u00f3n.", "excerpt_keywords": "Keywords: utilities, water quality, contamination control, API manufacturing, WHO guidelines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "39e44bb9-df93-4f57-9e56-2f6d07133863", "node_type": "4", "metadata": {"page_label": "155", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.2 Utilities\n\n4.20 All utilities that could impact on product quality (e.g. steam, gases, compressed air, and heating, ventilation and air conditioning) should be qualified and appropriately monitored and action should be taken when limits are exceeded. Drawings for these utility systems should be available.\n\n4.21 Adequate ventilation, air filtration and exhaust systems should be provided, where appropriate. These systems should be designed and constructed to minimize risks of contamination and cross-contamination and should include equipment for control of air pressure, microorganisms (if appropriate), dust, humidity, and temperature, as appropriate to the stage of manufacture. Particular attention should be given to areas where APIs are exposed to the environment.\n\n4.22 If air is recirculated to production areas, appropriate measures should be taken to control risks of contamination and cross-contamination.\n\n4.23 Permanently installed pipework should be appropriately identified. This can be accomplished by identifying individual lines, documentation, computer control systems, or alternative means. Pipework should be located to avoid risks of contamination of the intermediate or API.\n\n4.24 Drains should be of adequate size and should be provided with an air break or a suitable device to prevent back-siphonage, when appropriate.\n\n# 4.3 Water\n\n4.30 Water used in the manufacture of APIs should be demonstrated to be suitable for its intended use.\n\n4.31 Unless otherwise justified, process water should, at a minimum, meet WHO guidelines for drinking (potable) water quality.\n\n4.32 If drinking (potable) water is insufficient to assure API quality, and tighter chemical and/or microbiological water quality specifications are called for, appropriate specifications for physical and chemical attributes, total microbial counts, objectionable organisms and/or endotoxins should be established.\n\n4.33 Where water used in the process is treated by the manufacturer to achieve a defined quality, the treatment process should be validated and monitored with appropriate action limits.\n\n4.34 Where the manufacturer of a non-sterile API either intends or claims that it is suitable for use in further processing to produce a sterile FPP, water used in the final isolation and purification steps should be monitored and controlled for total microbial counts, objectionable organisms and endotoxins.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a04a6137c037114ea06f14b71a959c785686fc9dc821aee311e78df06e909148", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.2 Utilities\n\n4.20 All utilities that could impact on product quality (e.g. steam, gases, compressed air, and heating, ventilation and air conditioning) should be qualified and appropriately monitored and action should be taken when limits are exceeded. Drawings for these utility systems should be available.\n\n4.21 Adequate ventilation, air filtration and exhaust systems should be provided, where appropriate. These systems should be designed and constructed to minimize risks of contamination and cross-contamination and should include equipment for control of air pressure, microorganisms (if appropriate), dust, humidity, and temperature, as appropriate to the stage of manufacture. Particular attention should be given to areas where APIs are exposed to the environment.\n\n4.22 If air is recirculated to production areas, appropriate measures should be taken to control risks of contamination and cross-contamination.\n\n4.23 Permanently installed pipework should be appropriately identified. This can be accomplished by identifying individual lines, documentation, computer control systems, or alternative means. Pipework should be located to avoid risks of contamination of the intermediate or API.\n\n4.24 Drains should be of adequate size and should be provided with an air break or a suitable device to prevent back-siphonage, when appropriate.\n\n# 4.3 Water\n\n4.30 Water used in the manufacture of APIs should be demonstrated to be suitable for its intended use.\n\n4.31 Unless otherwise justified, process water should, at a minimum, meet WHO guidelines for drinking (potable) water quality.\n\n4.32 If drinking (potable) water is insufficient to assure API quality, and tighter chemical and/or microbiological water quality specifications are called for, appropriate specifications for physical and chemical attributes, total microbial counts, objectionable organisms and/or endotoxins should be established.\n\n4.33 Where water used in the process is treated by the manufacturer to achieve a defined quality, the treatment process should be validated and monitored with appropriate action limits.\n\n4.34 Where the manufacturer of a non-sterile API either intends or claims that it is suitable for use in further processing to produce a sterile FPP, water used in the final isolation and purification steps should be monitored and controlled for total microbial counts, objectionable organisms and endotoxins.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2412, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c377e99c-2cd6-4449-8c3a-e94b1af11013": {"__data__": {"id_": "c377e99c-2cd6-4449-8c3a-e94b1af11013", "embedding": null, "metadata": {"page_label": "156", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.4 Containment\n\n4.40 Dedicated production areas, which can include facilities, air handling equipment and/or process equipment, should be employed in the production of highly sensitizing materials, such as penicillins or cephalosporins.\n\n4.41 Dedicated production areas should also be considered when material of an infectious nature or high pharmacological activity or toxicity is involved (e.g. certain steroids or cytotoxic anti-cancer agents) unless validated inactivation and/or cleaning procedures are established and maintained.\n\n4.42 Appropriate measures should be established and implemented to prevent cross-contamination, e.g. from personnel or materials, moving from one dedicated area to another.\n\n4.43 Any production activities (including weighing, milling or packaging) of highly toxic non-pharmaceutical materials such as herbicides and pesticides should not be conducted using the buildings and/or equipment being used for the production of APIs. Handling and storage of these highly toxic non-pharmaceutical materials should be separate from APIs.\n\n# 4.5 Lighting\n\n4.50 Adequate lighting should be provided in all areas to facilitate cleaning, maintenance and proper operations.\n\n# 4.6 Sewage and refuse\n\n4.60 Sewage, refuse and other waste (e.g. solids, liquids, or gaseous by-products from manufacturing) in and from buildings and the immediate surrounding area should be disposed of in a safe, timely and sanitary manner. Containers and/or pipes for waste material should be clearly identified.\n\n# 4.7 Sanitation and maintenance\n\n4.70 Buildings used in the manufacture of intermediates and APIs should be properly maintained and repaired and kept in a clean condition.\n\n4.71 Written procedures should be established assigning responsibility for sanitation and describing the cleaning schedules, methods, equipment and materials to be used in cleaning buildings and facilities.\n\n4.72 When necessary, written procedures should also be established for the use of suitable rodenticides, insecticides, fungicides, fumigating agents and cleaning and sanitizing agents to prevent the contamination of equipment, raw materials, packaging or labelling materials, intermediates and APIs.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para la producci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs) y otros materiales relacionados. Se enfatiza la importancia de \u00e1reas de producci\u00f3n dedicadas para evitar la contaminaci\u00f3n cruzada, especialmente al manejar materiales altamente sensibilizantes o t\u00f3xicos. Tambi\u00e9n se discuten aspectos como la iluminaci\u00f3n adecuada, la gesti\u00f3n de residuos y la sanidad y mantenimiento de las instalaciones.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 medidas se deben implementar para prevenir la contaminaci\u00f3n cruzada en \u00e1reas de producci\u00f3n dedicadas?**\n   - El documento menciona que se deben establecer y aplicar medidas apropiadas para prevenir la contaminaci\u00f3n cruzada, como el control del movimiento de personal y materiales entre diferentes \u00e1reas dedicadas.\n\n2. **\u00bfCu\u00e1les son las consideraciones espec\u00edficas para la producci\u00f3n de materiales altamente t\u00f3xicos no farmac\u00e9uticos en relaci\u00f3n con los edificios y equipos utilizados para la producci\u00f3n de APIs?**\n   - Se establece que cualquier actividad de producci\u00f3n de materiales altamente t\u00f3xicos no farmac\u00e9uticos, como herbicidas y pesticidas, no debe realizarse en los mismos edificios o equipos que se utilizan para la producci\u00f3n de APIs, y su manejo y almacenamiento deben ser separados.\n\n3. **\u00bfQu\u00e9 procedimientos escritos se deben establecer para garantizar la sanidad y limpieza de las instalaciones de fabricaci\u00f3n?**\n   - Se deben establecer procedimientos escritos que asignen responsabilidades para la sanidad, describan los horarios de limpieza, los m\u00e9todos, el equipo y los materiales a utilizar. Adem\u00e1s, se deben establecer procedimientos para el uso de agentes de limpieza y desinfecci\u00f3n, as\u00ed como para el control de plagas, para prevenir la contaminaci\u00f3n de los productos.", "prev_section_summary": "### Temas Clave\n\n1. **Calidad de Utilidades**: Se enfatiza la importancia de calificar y monitorear utilidades como vapor, gases, aire comprimido y sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) para asegurar que no impacten negativamente la calidad del producto. Se deben tomar acciones cuando se exceden los l\u00edmites establecidos.\n\n2. **Sistemas de Ventilaci\u00f3n y Filtraci\u00f3n**: Se requiere la instalaci\u00f3n de sistemas adecuados de ventilaci\u00f3n, filtraci\u00f3n de aire y extracci\u00f3n, dise\u00f1ados para minimizar riesgos de contaminaci\u00f3n y cruzamiento. Estos sistemas deben incluir controles para presi\u00f3n del aire, microorganismos, polvo, humedad y temperatura.\n\n3. **Identificaci\u00f3n de Tuber\u00edas**: Las tuber\u00edas instaladas permanentemente deben ser identificadas adecuadamente para evitar riesgos de contaminaci\u00f3n de los ingredientes intermedios o activos.\n\n4. **Control de Drenajes**: Los drenajes deben ser de tama\u00f1o adecuado y contar con dispositivos que prevengan el retroceso de agua, cuando sea necesario.\n\n5. **Calidad del Agua**: El agua utilizada en la fabricaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (API) debe ser adecuada para su uso previsto y, al menos, cumplir con las pautas de calidad del agua potable de la OMS. Si el agua potable no es suficiente, se deben establecer especificaciones m\u00e1s estrictas.\n\n6. **Monitoreo del Agua**: El agua utilizada en los pasos finales de aislamiento y purificaci\u00f3n de un API no est\u00e9ril que se destina a la producci\u00f3n de un producto farmac\u00e9utico est\u00e9ril debe ser monitoreada para asegurar que cumpla con los est\u00e1ndares de recuentos microbianos, organismos objetables y endotoxinas.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las pautas de calidad del agua y utilidades en la fabricaci\u00f3n de APIs.\n- **API (Ingrediente Farmac\u00e9utico Activo)**: Sustancia utilizada en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **FPP (Forma Farmac\u00e9utica Final)**: Producto farmac\u00e9utico que se obtiene tras el procesamiento de un API.\n- **Sistemas de Ventilaci\u00f3n y Filtraci\u00f3n**: Infraestructura necesaria para mantener la calidad del aire en las \u00e1reas de producci\u00f3n.\n- **Tuber\u00edas y Drenajes**: Componentes de infraestructura que deben ser gestionados para evitar la contaminaci\u00f3n. \n\nEste resumen destaca la importancia de la calidad de las utilidades y el agua en la producci\u00f3n de APIs, as\u00ed como las medidas necesarias para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: containment, cross-contamination, sanitation, APIs, waste disposal"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4f22b7ff-a94a-491a-b8b4-cd1f8e76e9ff", "node_type": "4", "metadata": {"page_label": "156", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.4 Containment\n\n4.40 Dedicated production areas, which can include facilities, air handling equipment and/or process equipment, should be employed in the production of highly sensitizing materials, such as penicillins or cephalosporins.\n\n4.41 Dedicated production areas should also be considered when material of an infectious nature or high pharmacological activity or toxicity is involved (e.g. certain steroids or cytotoxic anti-cancer agents) unless validated inactivation and/or cleaning procedures are established and maintained.\n\n4.42 Appropriate measures should be established and implemented to prevent cross-contamination, e.g. from personnel or materials, moving from one dedicated area to another.\n\n4.43 Any production activities (including weighing, milling or packaging) of highly toxic non-pharmaceutical materials such as herbicides and pesticides should not be conducted using the buildings and/or equipment being used for the production of APIs. Handling and storage of these highly toxic non-pharmaceutical materials should be separate from APIs.\n\n# 4.5 Lighting\n\n4.50 Adequate lighting should be provided in all areas to facilitate cleaning, maintenance and proper operations.\n\n# 4.6 Sewage and refuse\n\n4.60 Sewage, refuse and other waste (e.g. solids, liquids, or gaseous by-products from manufacturing) in and from buildings and the immediate surrounding area should be disposed of in a safe, timely and sanitary manner. Containers and/or pipes for waste material should be clearly identified.\n\n# 4.7 Sanitation and maintenance\n\n4.70 Buildings used in the manufacture of intermediates and APIs should be properly maintained and repaired and kept in a clean condition.\n\n4.71 Written procedures should be established assigning responsibility for sanitation and describing the cleaning schedules, methods, equipment and materials to be used in cleaning buildings and facilities.\n\n4.72 When necessary, written procedures should also be established for the use of suitable rodenticides, insecticides, fungicides, fumigating agents and cleaning and sanitizing agents to prevent the contamination of equipment, raw materials, packaging or labelling materials, intermediates and APIs.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "c2cecccc52433150d4b062111b4378f9d7e5fc903f02a3c47dcb1e422b982fa4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.4 Containment\n\n4.40 Dedicated production areas, which can include facilities, air handling equipment and/or process equipment, should be employed in the production of highly sensitizing materials, such as penicillins or cephalosporins.\n\n4.41 Dedicated production areas should also be considered when material of an infectious nature or high pharmacological activity or toxicity is involved (e.g. certain steroids or cytotoxic anti-cancer agents) unless validated inactivation and/or cleaning procedures are established and maintained.\n\n4.42 Appropriate measures should be established and implemented to prevent cross-contamination, e.g. from personnel or materials, moving from one dedicated area to another.\n\n4.43 Any production activities (including weighing, milling or packaging) of highly toxic non-pharmaceutical materials such as herbicides and pesticides should not be conducted using the buildings and/or equipment being used for the production of APIs. Handling and storage of these highly toxic non-pharmaceutical materials should be separate from APIs.\n\n# 4.5 Lighting\n\n4.50 Adequate lighting should be provided in all areas to facilitate cleaning, maintenance and proper operations.\n\n# 4.6 Sewage and refuse\n\n4.60 Sewage, refuse and other waste (e.g. solids, liquids, or gaseous by-products from manufacturing) in and from buildings and the immediate surrounding area should be disposed of in a safe, timely and sanitary manner. Containers and/or pipes for waste material should be clearly identified.\n\n# 4.7 Sanitation and maintenance\n\n4.70 Buildings used in the manufacture of intermediates and APIs should be properly maintained and repaired and kept in a clean condition.\n\n4.71 Written procedures should be established assigning responsibility for sanitation and describing the cleaning schedules, methods, equipment and materials to be used in cleaning buildings and facilities.\n\n4.72 When necessary, written procedures should also be established for the use of suitable rodenticides, insecticides, fungicides, fumigating agents and cleaning and sanitizing agents to prevent the contamination of equipment, raw materials, packaging or labelling materials, intermediates and APIs.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2201, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ccd3cacc-90ee-4ce3-8116-6e4010f84cea": {"__data__": {"id_": "ccd3cacc-90ee-4ce3-8116-6e4010f84cea", "embedding": null, "metadata": {"page_label": "157", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 5. Process equipment\n\n## 5.1 Design and construction\n\n5.10 Equipment used in the manufacture of intermediates and APIs should be of appropriate design and adequate size, and suitably located for its intended use, cleaning, sanitization (where appropriate) and maintenance.\n\n5.11 Equipment should be constructed so that surfaces that contact raw materials, intermediates or APIs do not alter the quality of the intermediates and APIs beyond the official or other established specifications.\n\n5.12 Production equipment should only be used within its qualified operating range.\n\n5.13 Major equipment (e.g. reactors, storage containers) and permanently installed processing lines used during the production of an intermediate or API should be appropriately identified.\n\n5.14 Any substances associated with the operation of equipment, such as lubricants, heating fluids or coolants, should not contact intermediates or APIs so as to alter their quality beyond the official or other established specifications. Any deviations from this should be evaluated to ensure that there are no detrimental effects upon the fitness for purpose of the material. Wherever possible, food-grade lubricants and oils should be used.\n\n5.15 Closed or contained equipment should be used whenever appropriate. Where open equipment is used, or equipment is opened, appropriate precautions should be taken to minimize the risk of contamination.\n\n5.16 A set of current drawings should be maintained for equipment and critical installations (e.g. instrumentation and utility systems).\n\n## 5.2 Equipment maintenance and cleaning\n\n5.20 Schedules and procedures (including assignment of responsibility) should be established for the preventive maintenance of equipment.\n\n5.21 Written procedures should be established for cleaning of equipment and its subsequent release for use in the manufacture of intermediates and APIs. Cleaning procedures should contain sufficient details to enable operators to clean each type of equipment in a reproducible and effective manner. These procedures should include:\n\n- assignment of responsibility for cleaning of equipment;\n- cleaning schedules, including, where appropriate, sanitizing schedules;\n- a complete description of the methods and materials, including dilution of cleaning agents used to clean equipment;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las directrices sobre el dise\u00f1o, construcci\u00f3n, mantenimiento y limpieza del equipo utilizado en la fabricaci\u00f3n de intermediarios y principios activos (APIs). Se enfatiza la importancia de que el equipo est\u00e9 dise\u00f1ado adecuadamente, construido con materiales que no alteren la calidad de los productos, y que se mantenga dentro de un rango operativo calificado. Tambi\u00e9n se destacan las pr\u00e1cticas de limpieza y mantenimiento preventivo, as\u00ed como la necesidad de documentaci\u00f3n y procedimientos claros para garantizar la calidad y seguridad en la producci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de lubricantes se recomienda utilizar en el equipo de producci\u00f3n para minimizar el riesgo de contaminaci\u00f3n de los intermediarios y APIs?**\n   - Respuesta: Se recomienda utilizar lubricantes y aceites de grado alimenticio siempre que sea posible, para minimizar el riesgo de alterar la calidad de los intermediarios y APIs.\n\n2. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en los procedimientos escritos para la limpieza del equipo?**\n   - Respuesta: Los procedimientos escritos para la limpieza del equipo deben incluir la asignaci\u00f3n de responsabilidad para la limpieza, los horarios de limpieza (incluyendo horarios de sanitizaci\u00f3n donde sea apropiado) y una descripci\u00f3n completa de los m\u00e9todos y materiales, incluyendo la diluci\u00f3n de los agentes de limpieza utilizados.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse cuando se utiliza equipo abierto o se abre el equipo durante el proceso de producci\u00f3n?**\n   - Respuesta: Cuando se utiliza equipo abierto o se abre el equipo, se deben tomar precauciones apropiadas para minimizar el riesgo de contaminaci\u00f3n, asegurando as\u00ed la integridad de los intermediarios y APIs producidos.", "prev_section_summary": "### Temas Clave:\n\n1. **\u00c1reas de Producci\u00f3n Dedicadas**: Se enfatiza la necesidad de contar con \u00e1reas de producci\u00f3n espec\u00edficas para manejar materiales altamente sensibilizantes y t\u00f3xicos, como penicilinas, esteroides y agentes citot\u00f3xicos, para evitar la contaminaci\u00f3n cruzada.\n\n2. **Prevenci\u00f3n de Contaminaci\u00f3n Cruzada**: Se deben implementar medidas adecuadas para prevenir la contaminaci\u00f3n cruzada entre diferentes \u00e1reas de producci\u00f3n, controlando el movimiento de personal y materiales.\n\n3. **Separaci\u00f3n de Materiales T\u00f3xicos**: Las actividades de producci\u00f3n de materiales altamente t\u00f3xicos no farmac\u00e9uticos, como herbicidas y pesticidas, deben realizarse en instalaciones y equipos separados de aquellos utilizados para la producci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs).\n\n4. **Iluminaci\u00f3n Adecuada**: Es esencial proporcionar una iluminaci\u00f3n adecuada en todas las \u00e1reas para facilitar la limpieza, el mantenimiento y las operaciones.\n\n5. **Gesti\u00f3n de Residuos**: Los desechos generados en el proceso de fabricaci\u00f3n deben ser eliminados de manera segura y sanitaria, con contenedores y tuber\u00edas claramente identificados.\n\n6. **Sanidad y Mantenimiento**: Las instalaciones deben mantenerse en condiciones limpias y reparadas, con procedimientos escritos que asignen responsabilidades y describan los m\u00e9todos de limpieza y desinfecci\u00f3n.\n\n7. **Control de Plagas**: Se deben establecer procedimientos para el uso de agentes de limpieza y control de plagas para prevenir la contaminaci\u00f3n de productos y materiales.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Productos cuya producci\u00f3n est\u00e1 regulada por las buenas pr\u00e1cticas de fabricaci\u00f3n.\n- **Materiales Altamente Sensibilizantes**: Incluyen penicilinas y cephalosporinas.\n- **Materiales T\u00f3xicos No Farmac\u00e9uticos**: Incluyen herbicidas y pesticidas.\n- **Esteroides y Agentes Citot\u00f3xicos**: Ejemplos de materiales de alta actividad farmacol\u00f3gica o toxicidad.\n- **Procedimientos Escritos**: Documentaci\u00f3n necesaria para garantizar la sanidad y limpieza de las instalaciones. \n\nEste resumen destaca la importancia de las buenas pr\u00e1cticas de fabricaci\u00f3n en la producci\u00f3n de productos farmac\u00e9uticos y la necesidad de mantener est\u00e1ndares rigurosos para garantizar la seguridad y la calidad.", "excerpt_keywords": "Keywords: equipment design, API manufacturing, cleaning procedures, contamination prevention, maintenance schedules"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d3bd3be9-92d9-4d19-baa6-a171f253d7f9", "node_type": "4", "metadata": {"page_label": "157", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 5. Process equipment\n\n## 5.1 Design and construction\n\n5.10 Equipment used in the manufacture of intermediates and APIs should be of appropriate design and adequate size, and suitably located for its intended use, cleaning, sanitization (where appropriate) and maintenance.\n\n5.11 Equipment should be constructed so that surfaces that contact raw materials, intermediates or APIs do not alter the quality of the intermediates and APIs beyond the official or other established specifications.\n\n5.12 Production equipment should only be used within its qualified operating range.\n\n5.13 Major equipment (e.g. reactors, storage containers) and permanently installed processing lines used during the production of an intermediate or API should be appropriately identified.\n\n5.14 Any substances associated with the operation of equipment, such as lubricants, heating fluids or coolants, should not contact intermediates or APIs so as to alter their quality beyond the official or other established specifications. Any deviations from this should be evaluated to ensure that there are no detrimental effects upon the fitness for purpose of the material. Wherever possible, food-grade lubricants and oils should be used.\n\n5.15 Closed or contained equipment should be used whenever appropriate. Where open equipment is used, or equipment is opened, appropriate precautions should be taken to minimize the risk of contamination.\n\n5.16 A set of current drawings should be maintained for equipment and critical installations (e.g. instrumentation and utility systems).\n\n## 5.2 Equipment maintenance and cleaning\n\n5.20 Schedules and procedures (including assignment of responsibility) should be established for the preventive maintenance of equipment.\n\n5.21 Written procedures should be established for cleaning of equipment and its subsequent release for use in the manufacture of intermediates and APIs. Cleaning procedures should contain sufficient details to enable operators to clean each type of equipment in a reproducible and effective manner. These procedures should include:\n\n- assignment of responsibility for cleaning of equipment;\n- cleaning schedules, including, where appropriate, sanitizing schedules;\n- a complete description of the methods and materials, including dilution of cleaning agents used to clean equipment;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "2fbb6ba29e54f617fd7a74e3f922f274c4bde61c4151e94efa530d01a5afe22f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 5. Process equipment\n\n## 5.1 Design and construction\n\n5.10 Equipment used in the manufacture of intermediates and APIs should be of appropriate design and adequate size, and suitably located for its intended use, cleaning, sanitization (where appropriate) and maintenance.\n\n5.11 Equipment should be constructed so that surfaces that contact raw materials, intermediates or APIs do not alter the quality of the intermediates and APIs beyond the official or other established specifications.\n\n5.12 Production equipment should only be used within its qualified operating range.\n\n5.13 Major equipment (e.g. reactors, storage containers) and permanently installed processing lines used during the production of an intermediate or API should be appropriately identified.\n\n5.14 Any substances associated with the operation of equipment, such as lubricants, heating fluids or coolants, should not contact intermediates or APIs so as to alter their quality beyond the official or other established specifications. Any deviations from this should be evaluated to ensure that there are no detrimental effects upon the fitness for purpose of the material. Wherever possible, food-grade lubricants and oils should be used.\n\n5.15 Closed or contained equipment should be used whenever appropriate. Where open equipment is used, or equipment is opened, appropriate precautions should be taken to minimize the risk of contamination.\n\n5.16 A set of current drawings should be maintained for equipment and critical installations (e.g. instrumentation and utility systems).\n\n## 5.2 Equipment maintenance and cleaning\n\n5.20 Schedules and procedures (including assignment of responsibility) should be established for the preventive maintenance of equipment.\n\n5.21 Written procedures should be established for cleaning of equipment and its subsequent release for use in the manufacture of intermediates and APIs. Cleaning procedures should contain sufficient details to enable operators to clean each type of equipment in a reproducible and effective manner. These procedures should include:\n\n- assignment of responsibility for cleaning of equipment;\n- cleaning schedules, including, where appropriate, sanitizing schedules;\n- a complete description of the methods and materials, including dilution of cleaning agents used to clean equipment;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2321, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d6fd1243-981c-41b5-bb0c-b47471416650": {"__data__": {"id_": "d6fd1243-981c-41b5-bb0c-b47471416650", "embedding": null, "metadata": {"page_label": "158", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 when appropriate, instructions for disassembling and reassembling each article of equipment to ensure proper cleaning;  \n\u2014 instructions for the removal or obliteration of previous batch identification;  \n\u2014 instructions for the protection of clean equipment from contamination prior to use;  \n\u2014 inspection of equipment for cleanliness immediately before use, if practical; and  \n\u2014 establishing the maximum time that may elapse between the completion of processing and equipment cleaning, when appropriate.  \n\n5.22 Equipment and utensils should be cleaned, stored and, where appropriate, sanitized or sterilized to prevent contamination or carry-over of a material that would alter the quality of the intermediate or API beyond the official or other established specifications.  \n\n5.23 Where equipment is assigned to continuous production or campaign production of successive batches of the same intermediate or API, this equipment should be cleaned at appropriate intervals to prevent build-up and carry-over of contaminants (e.g. degradants or objectionable levels of microorganisms).  \n\n5.24 Non-dedicated equipment should be cleaned between production of different materials to prevent cross-contamination.  \n\n5.25 Acceptance criteria for residues and the choice of cleaning procedures and cleaning agents should be defined and justified.  \n\n5.26 Equipment should be identified as to its contents and its cleanliness status by appropriate means.  \n\n### 5.3 Calibration\n\n5.30 Control, weighing, measuring, monitoring and test equipment that is critical for assuring the quality of intermediates or APIs should be calibrated according to written procedures and an established schedule.  \n\n5.31 Equipment calibrations should be performed using standards traceable to certified standards, if these exist.  \n\n5.32 Records of these calibrations should be maintained.  \n\n5.33 The current calibration status of critical equipment should be known and verifiable.  \n\n5.34 Instruments that do not meet calibration criteria should not be used.  \n\n5.35 Deviations from approved standards of calibration on critical instruments should be investigated to determine if these could have had an impact.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Limpieza y Mantenimiento de Equipos**: El documento establece directrices sobre la limpieza, almacenamiento y desinfecci\u00f3n de equipos y utensilios utilizados en la producci\u00f3n de intermediarios y principios activos (API). Se enfatiza la importancia de evitar la contaminaci\u00f3n y la alteraci\u00f3n de la calidad del producto final.\n\n2. **Calibraci\u00f3n de Equipos**: Se detallan los procedimientos para la calibraci\u00f3n de equipos cr\u00edticos que aseguran la calidad de los intermediarios y APIs. Esto incluye la necesidad de utilizar est\u00e1ndares trazables, mantener registros de calibraci\u00f3n y verificar el estado de calibraci\u00f3n de los instrumentos.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las instrucciones espec\u00edficas para la limpieza de equipos no dedicados entre la producci\u00f3n de diferentes materiales?**\n   - Este contexto proporciona detalles sobre la limpieza necesaria para evitar la contaminaci\u00f3n cruzada, lo que no se encuentra f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 criterios de aceptaci\u00f3n se deben definir para los residuos en los equipos utilizados en la producci\u00f3n de intermediarios y APIs?**\n   - La respuesta a esta pregunta se basa en la necesidad de establecer y justificar criterios espec\u00edficos para los residuos, un aspecto que puede no estar ampliamente documentado en otras normativas.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse si un instrumento cr\u00edtico no cumple con los criterios de calibraci\u00f3n establecidos?**\n   - El contexto menciona la importancia de investigar las desviaciones en la calibraci\u00f3n, lo que proporciona una gu\u00eda sobre c\u00f3mo manejar situaciones de incumplimiento que puede no estar claramente delineada en otras fuentes.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n\n\n**1. Dise\u00f1o y construcci\u00f3n del equipo:**\n   - El equipo utilizado en la fabricaci\u00f3n de intermediarios y principios activos (APIs) debe ser de dise\u00f1o adecuado, tama\u00f1o suficiente y ubicado correctamente para su uso, limpieza y mantenimiento.\n   - Las superficies que entran en contacto con materias primas, intermediarios o APIs no deben alterar su calidad m\u00e1s all\u00e1 de las especificaciones establecidas.\n   - El equipo debe operar dentro de un rango calificado y debe ser identificado adecuadamente.\n\n**2. Lubricantes y sustancias operativas:**\n   - Los lubricantes, fluidos de calefacci\u00f3n y refrigerantes no deben entrar en contacto con los intermediarios o APIs de manera que alteren su calidad. Se recomienda el uso de lubricantes y aceites de grado alimenticio siempre que sea posible.\n\n**3. Equipos cerrados y abiertos:**\n   - Se debe utilizar equipo cerrado o contenido siempre que sea apropiado. En el caso de usar equipo abierto, se deben tomar precauciones para minimizar el riesgo de contaminaci\u00f3n.\n\n**4. Mantenimiento y limpieza del equipo:**\n   - Se deben establecer horarios y procedimientos para el mantenimiento preventivo del equipo, incluyendo la asignaci\u00f3n de responsabilidades.\n   - Los procedimientos de limpieza deben ser documentados y contener detalles suficientes para asegurar una limpieza efectiva y reproducible. Esto incluye la asignaci\u00f3n de responsabilidades, horarios de limpieza y una descripci\u00f3n completa de los m\u00e9todos y materiales utilizados.\n\n**5. Documentaci\u00f3n:**\n   - Es necesario mantener un conjunto de dibujos actualizados para el equipo y las instalaciones cr\u00edticas, como sistemas de instrumentaci\u00f3n y utilidades.\n\n### Entidades clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Intermediarios**\n- **Principios Activos (APIs)**\n- **Equipos de producci\u00f3n**\n- **Lubricantes de grado alimenticio**\n- **Procedimientos de limpieza y mantenimiento**", "excerpt_keywords": "Keywords: limpieza de equipos, calibraci\u00f3n, principios activos, contaminaci\u00f3n cruzada, procedimientos de mantenimiento"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1da2ff8e-e36f-42a9-8397-d65179296b0f", "node_type": "4", "metadata": {"page_label": "158", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 when appropriate, instructions for disassembling and reassembling each article of equipment to ensure proper cleaning;  \n\u2014 instructions for the removal or obliteration of previous batch identification;  \n\u2014 instructions for the protection of clean equipment from contamination prior to use;  \n\u2014 inspection of equipment for cleanliness immediately before use, if practical; and  \n\u2014 establishing the maximum time that may elapse between the completion of processing and equipment cleaning, when appropriate.  \n\n5.22 Equipment and utensils should be cleaned, stored and, where appropriate, sanitized or sterilized to prevent contamination or carry-over of a material that would alter the quality of the intermediate or API beyond the official or other established specifications.  \n\n5.23 Where equipment is assigned to continuous production or campaign production of successive batches of the same intermediate or API, this equipment should be cleaned at appropriate intervals to prevent build-up and carry-over of contaminants (e.g. degradants or objectionable levels of microorganisms).  \n\n5.24 Non-dedicated equipment should be cleaned between production of different materials to prevent cross-contamination.  \n\n5.25 Acceptance criteria for residues and the choice of cleaning procedures and cleaning agents should be defined and justified.  \n\n5.26 Equipment should be identified as to its contents and its cleanliness status by appropriate means.  \n\n### 5.3 Calibration\n\n5.30 Control, weighing, measuring, monitoring and test equipment that is critical for assuring the quality of intermediates or APIs should be calibrated according to written procedures and an established schedule.  \n\n5.31 Equipment calibrations should be performed using standards traceable to certified standards, if these exist.  \n\n5.32 Records of these calibrations should be maintained.  \n\n5.33 The current calibration status of critical equipment should be known and verifiable.  \n\n5.34 Instruments that do not meet calibration criteria should not be used.  \n\n5.35 Deviations from approved standards of calibration on critical instruments should be investigated to determine if these could have had an impact.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "8ad668c55d463e03652cffff6b2047005f8bb8808779368081a90ad63a50dbdf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2014 when appropriate, instructions for disassembling and reassembling each article of equipment to ensure proper cleaning;  \n\u2014 instructions for the removal or obliteration of previous batch identification;  \n\u2014 instructions for the protection of clean equipment from contamination prior to use;  \n\u2014 inspection of equipment for cleanliness immediately before use, if practical; and  \n\u2014 establishing the maximum time that may elapse between the completion of processing and equipment cleaning, when appropriate.  \n\n5.22 Equipment and utensils should be cleaned, stored and, where appropriate, sanitized or sterilized to prevent contamination or carry-over of a material that would alter the quality of the intermediate or API beyond the official or other established specifications.  \n\n5.23 Where equipment is assigned to continuous production or campaign production of successive batches of the same intermediate or API, this equipment should be cleaned at appropriate intervals to prevent build-up and carry-over of contaminants (e.g. degradants or objectionable levels of microorganisms).  \n\n5.24 Non-dedicated equipment should be cleaned between production of different materials to prevent cross-contamination.  \n\n5.25 Acceptance criteria for residues and the choice of cleaning procedures and cleaning agents should be defined and justified.  \n\n5.26 Equipment should be identified as to its contents and its cleanliness status by appropriate means.  \n\n### 5.3 Calibration\n\n5.30 Control, weighing, measuring, monitoring and test equipment that is critical for assuring the quality of intermediates or APIs should be calibrated according to written procedures and an established schedule.  \n\n5.31 Equipment calibrations should be performed using standards traceable to certified standards, if these exist.  \n\n5.32 Records of these calibrations should be maintained.  \n\n5.33 The current calibration status of critical equipment should be known and verifiable.  \n\n5.34 Instruments that do not meet calibration criteria should not be used.  \n\n5.35 Deviations from approved standards of calibration on critical instruments should be investigated to determine if these could have had an impact.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2188, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "62fb316e-d6aa-4fef-8580-1b701bc54eb9": {"__data__": {"id_": "62fb316e-d6aa-4fef-8580-1b701bc54eb9", "embedding": null, "metadata": {"page_label": "159", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 5.4 Computerized systems\n\n5.40 GMP-related computerized systems should be validated. The depth and scope of validation depends on the diversity, complexity and criticality of the computerized application.\n\n5.41 Appropriate installation qualification and operational qualification should demonstrate the suitability of computer hardware and software to perform assigned tasks.\n\n5.42 Commercially available software that has been qualified does not require the same level of testing. If an existing system was not validated at the time of installation, a retrospective validation could be conducted if appropriate documentation is available.\n\n5.43 Computerized systems should have sufficient controls to prevent unauthorized access or changes to data. There should be controls to prevent omissions in data (e.g., the system being turned off and data not captured). There should be a record of any data change made, the previous entry, the person who made the change and when the change was made.\n\n5.44 Written procedures should be available for the operation and maintenance of computerized systems.\n\n5.45 Where critical data are being entered manually, there should be an additional check on the accuracy of the data entered. This can be done by a second operator or by the system itself.\n\n5.46 Incidents related to computerized systems that could affect the quality of intermediates or APIs or the reliability of records or test results should be recorded and investigated.\n\n5.47 Changes to the computerized system should be made according to a change procedure and should be formally authorized, documented and tested. Records should be kept of all changes, including modifications and enhancements made to the hardware, software and any other critical component of the system. These records should demonstrate that the system is maintained in a validated state.\n\n5.48 If system breakdowns or failures will result in the permanent loss of records, a back-up system should be provided. A means of ensuring data protection should be established for all computerized systems.\n\n5.49 Data can be recorded by a second means in addition to the computer system.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la validaci\u00f3n y el control de sistemas computarizados relacionados con las Buenas Pr\u00e1cticas de Manufactura (GMP). Se enfatiza la importancia de validar estos sistemas en funci\u00f3n de su diversidad y complejidad, as\u00ed como la necesidad de establecer procedimientos escritos para su operaci\u00f3n y mantenimiento. Tambi\u00e9n se menciona la importancia de prevenir accesos no autorizados, registrar cambios en los datos y tener un sistema de respaldo para proteger la informaci\u00f3n cr\u00edtica.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar para determinar la profundidad y el alcance de la validaci\u00f3n de un sistema computarizado relacionado con GMP?**\n   - Respuesta: La profundidad y el alcance de la validaci\u00f3n dependen de la diversidad, complejidad y criticidad de la aplicaci\u00f3n computarizada.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse en caso de que un sistema computarizado no haya sido validado en el momento de su instalaci\u00f3n?**\n   - Respuesta: Si un sistema existente no fue validado al momento de la instalaci\u00f3n, se puede realizar una validaci\u00f3n retrospectiva siempre que se disponga de la documentaci\u00f3n apropiada.\n\n3. **\u00bfQu\u00e9 medidas deben implementarse para garantizar la protecci\u00f3n de datos en sistemas computarizados, especialmente en caso de fallos del sistema?**\n   - Respuesta: Se debe proporcionar un sistema de respaldo para evitar la p\u00e9rdida permanente de registros y establecer medios para garantizar la protecci\u00f3n de datos en todos los sistemas computarizados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### 1. Limpieza y Mantenimiento de Equipos\n- **Instrucciones de Limpieza**: Directrices para desensamblar y ensamblar equipos para asegurar una limpieza adecuada, eliminaci\u00f3n de identificaciones de lotes anteriores, y protecci\u00f3n de equipos limpios de contaminaci\u00f3n.\n- **Inspecci\u00f3n de Equipos**: Se recomienda inspeccionar la limpieza de los equipos justo antes de su uso.\n- **Tiempo M\u00e1ximo entre Procesamiento y Limpieza**: Establecimiento de un tiempo m\u00e1ximo que puede transcurrir entre la finalizaci\u00f3n del procesamiento y la limpieza del equipo.\n- **Almacenamiento y Sanitizaci\u00f3n**: Equipos y utensilios deben ser limpiados, almacenados y, cuando sea apropiado, desinfectados o esterilizados para prevenir contaminaci\u00f3n y alteraci\u00f3n de la calidad del producto.\n- **Producci\u00f3n Continua y Campa\u00f1as**: Equipos utilizados para producci\u00f3n continua deben limpiarse a intervalos apropiados para evitar acumulaci\u00f3n de contaminantes.\n- **Equipos No Dedicados**: Deben limpiarse entre la producci\u00f3n de diferentes materiales para prevenir la contaminaci\u00f3n cruzada.\n- **Criterios de Aceptaci\u00f3n**: Se deben definir y justificar criterios de aceptaci\u00f3n para residuos y elecci\u00f3n de procedimientos y agentes de limpieza.\n- **Identificaci\u00f3n de Equipos**: Equipos deben ser identificados seg\u00fan su contenido y estado de limpieza.\n\n#### 2. Calibraci\u00f3n de Equipos\n- **Calibraci\u00f3n de Equipos Cr\u00edticos**: Equipos de control, pesaje, medici\u00f3n y prueba deben ser calibrados seg\u00fan procedimientos escritos y un cronograma establecido.\n- **Est\u00e1ndares Trazables**: Las calibraciones deben realizarse utilizando est\u00e1ndares que sean trazables a est\u00e1ndares certificados, si existen.\n- **Mantenimiento de Registros**: Se deben mantener registros de las calibraciones realizadas.\n- **Estado de Calibraci\u00f3n**: El estado actual de calibraci\u00f3n de los equipos cr\u00edticos debe ser conocido y verificable.\n- **Uso de Instrumentos**: Instrumentos que no cumplan con los criterios de calibraci\u00f3n no deben ser utilizados.\n- **Investigaci\u00f3n de Desviaciones**: Desviaciones de los est\u00e1ndares aprobados de calibraci\u00f3n deben ser investigadas para determinar su posible impacto.\n\n### Entidades Clave\n- **Equipos y Utensilios**: Elementos utilizados en la producci\u00f3n de intermediarios y principios activos (APIs).\n- **Contaminantes**: Sustancias que pueden alterar la calidad del producto.\n- **Est\u00e1ndares de Calibraci\u00f3n**: Normas que gu\u00edan la calibraci\u00f3n de equipos cr\u00edticos.\n- **Registros de Calibraci\u00f3n**: Documentaci\u00f3n que respalda las actividades de calibraci\u00f3n realizadas. \n\nEste resumen destaca la importancia de la limpieza y calibraci\u00f3n de equipos en la producci\u00f3n farmac\u00e9utica para asegurar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: validation, computerized systems, data protection, GMP, record keeping"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "466ac9ff-eb56-4529-ba6e-33845903b2de", "node_type": "4", "metadata": {"page_label": "159", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 5.4 Computerized systems\n\n5.40 GMP-related computerized systems should be validated. The depth and scope of validation depends on the diversity, complexity and criticality of the computerized application.\n\n5.41 Appropriate installation qualification and operational qualification should demonstrate the suitability of computer hardware and software to perform assigned tasks.\n\n5.42 Commercially available software that has been qualified does not require the same level of testing. If an existing system was not validated at the time of installation, a retrospective validation could be conducted if appropriate documentation is available.\n\n5.43 Computerized systems should have sufficient controls to prevent unauthorized access or changes to data. There should be controls to prevent omissions in data (e.g., the system being turned off and data not captured). There should be a record of any data change made, the previous entry, the person who made the change and when the change was made.\n\n5.44 Written procedures should be available for the operation and maintenance of computerized systems.\n\n5.45 Where critical data are being entered manually, there should be an additional check on the accuracy of the data entered. This can be done by a second operator or by the system itself.\n\n5.46 Incidents related to computerized systems that could affect the quality of intermediates or APIs or the reliability of records or test results should be recorded and investigated.\n\n5.47 Changes to the computerized system should be made according to a change procedure and should be formally authorized, documented and tested. Records should be kept of all changes, including modifications and enhancements made to the hardware, software and any other critical component of the system. These records should demonstrate that the system is maintained in a validated state.\n\n5.48 If system breakdowns or failures will result in the permanent loss of records, a back-up system should be provided. A means of ensuring data protection should be established for all computerized systems.\n\n5.49 Data can be recorded by a second means in addition to the computer system.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "fb53c7ddb075076ddbb2641c09730891cd1e89c1c2ac99fb3daeb19c5fa157b5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 5.4 Computerized systems\n\n5.40 GMP-related computerized systems should be validated. The depth and scope of validation depends on the diversity, complexity and criticality of the computerized application.\n\n5.41 Appropriate installation qualification and operational qualification should demonstrate the suitability of computer hardware and software to perform assigned tasks.\n\n5.42 Commercially available software that has been qualified does not require the same level of testing. If an existing system was not validated at the time of installation, a retrospective validation could be conducted if appropriate documentation is available.\n\n5.43 Computerized systems should have sufficient controls to prevent unauthorized access or changes to data. There should be controls to prevent omissions in data (e.g., the system being turned off and data not captured). There should be a record of any data change made, the previous entry, the person who made the change and when the change was made.\n\n5.44 Written procedures should be available for the operation and maintenance of computerized systems.\n\n5.45 Where critical data are being entered manually, there should be an additional check on the accuracy of the data entered. This can be done by a second operator or by the system itself.\n\n5.46 Incidents related to computerized systems that could affect the quality of intermediates or APIs or the reliability of records or test results should be recorded and investigated.\n\n5.47 Changes to the computerized system should be made according to a change procedure and should be formally authorized, documented and tested. Records should be kept of all changes, including modifications and enhancements made to the hardware, software and any other critical component of the system. These records should demonstrate that the system is maintained in a validated state.\n\n5.48 If system breakdowns or failures will result in the permanent loss of records, a back-up system should be provided. A means of ensuring data protection should be established for all computerized systems.\n\n5.49 Data can be recorded by a second means in addition to the computer system.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2156, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f5bad0c3-a3d3-414e-96aa-861f406cf9aa": {"__data__": {"id_": "f5bad0c3-a3d3-414e-96aa-861f406cf9aa", "embedding": null, "metadata": {"page_label": "160", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 6. Documentation and records\n\n## 6.1 Documentation system and specifications\n\n6.10 All documents related to the manufacture of intermediates or APIs should be prepared, reviewed, approved and distributed according to written procedures. Such documents can be in paper or electronic form.\n\n6.11 The issuance, revision, superseding and withdrawal of all documents should be controlled with maintenance of revision histories.\n\n6.12 A procedure should be established for retaining all appropriate documents (e.g. development history reports, scale-up reports, technical transfer reports, process validation reports, training records, production records, control records and distribution records). The retention periods for these documents should be specified.\n\n6.13 All production, control and distribution records should be retained for at least one year after the expiry date of the batch. For APIs with retest dates, records should be retained for at least three years after the batch is completely distributed.\n\n6.14 Entries in records should be made indelibly in spaces provided for such entries, directly after performing the activities, and should identify the person making the entry. Corrections to entries should be dated and signed ensuring that the original entry remains readable.\n\n6.15 During the retention period, originals or copies of records should be readily available at the establishment where the activities described in these records occurred. Records that can be promptly retrieved from another location by electronic or other means are acceptable.\n\n6.16 Specifications, instructions, procedures and records can be retained either as originals or as true copies such as photocopies, microfilm, microfiche, or other accurate reproductions of the original records. Where reduction techniques such as microfilming or electronic records are used, suitable retrieval equipment and a means to produce a hard copy should be readily available.\n\n6.17 Specifications should be established and documented for raw materials, intermediates where necessary, APIs and labelling and packaging materials. In addition, specifications may be appropriate for certain other materials, such as process aids, gaskets or other materials used during the production of intermediates or APIs that could critically impact on quality. Acceptance criteria should be established and documented for in-process controls.\n\n6.18 If electronic signatures are used on documents they should be authenticated and secure.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece directrices sobre la documentaci\u00f3n y los registros relacionados con la fabricaci\u00f3n de intermediarios y principios activos (APIs). Se enfatiza la importancia de tener procedimientos escritos para la preparaci\u00f3n, revisi\u00f3n, aprobaci\u00f3n y distribuci\u00f3n de documentos. Adem\u00e1s, se especifican los requisitos para la retenci\u00f3n de registros, la autenticaci\u00f3n de firmas electr\u00f3nicas y la necesidad de mantener la integridad y disponibilidad de los documentos durante su per\u00edodo de retenci\u00f3n.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los tipos de documentos que deben ser retenidos seg\u00fan las directrices de la OMS y cu\u00e1les son los per\u00edodos de retenci\u00f3n espec\u00edficos para ellos?**\n   - Respuesta: Se deben retener documentos como informes de historia de desarrollo, informes de escalado, informes de transferencia t\u00e9cnica, informes de validaci\u00f3n de procesos, registros de capacitaci\u00f3n, registros de producci\u00f3n, registros de control y registros de distribuci\u00f3n. Los registros de producci\u00f3n, control y distribuci\u00f3n deben ser retenidos por al menos un a\u00f1o despu\u00e9s de la fecha de caducidad del lote, y para APIs con fechas de rean\u00e1lisis, los registros deben ser retenidos por al menos tres a\u00f1os despu\u00e9s de que el lote haya sido completamente distribuido.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse para realizar correcciones en los registros, seg\u00fan las directrices?**\n   - Respuesta: Las correcciones a las entradas en los registros deben ser fechadas y firmadas, asegurando que la entrada original permanezca legible. Adem\u00e1s, las entradas deben hacerse de manera indeleble en los espacios proporcionados, inmediatamente despu\u00e9s de realizar las actividades, e identificar a la persona que realiza la entrada.\n\n3. **\u00bfQu\u00e9 requisitos se establecen para las firmas electr\u00f3nicas en los documentos?**\n   - Respuesta: Si se utilizan firmas electr\u00f3nicas en los documentos, estas deben ser autenticadas y seguras, garantizando la integridad y la validez de los registros.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Validaci\u00f3n de Sistemas Computarizados**: \n   - Los sistemas computarizados relacionados con las Buenas Pr\u00e1cticas de Manufactura (GMP) deben ser validados. La profundidad y el alcance de esta validaci\u00f3n dependen de la diversidad, complejidad y criticidad de la aplicaci\u00f3n.\n\n2. **Calificaci\u00f3n de Instalaci\u00f3n y Operativa**: \n   - Se requiere demostrar la idoneidad del hardware y software mediante calificaciones adecuadas.\n\n3. **Software Comercial**: \n   - El software comercial calificado no necesita el mismo nivel de pruebas. Si un sistema no fue validado al momento de la instalaci\u00f3n, se puede realizar una validaci\u00f3n retrospectiva si hay documentaci\u00f3n adecuada.\n\n4. **Controles de Seguridad**: \n   - Los sistemas deben tener controles para prevenir accesos no autorizados y cambios en los datos. Se deben registrar todos los cambios, incluyendo la entrada anterior, el responsable y la fecha.\n\n5. **Procedimientos Escritos**: \n   - Deben existir procedimientos documentados para la operaci\u00f3n y mantenimiento de los sistemas computarizados.\n\n6. **Verificaci\u00f3n de Datos Cr\u00edticos**: \n   - Para la entrada manual de datos cr\u00edticos, se debe realizar una verificaci\u00f3n adicional de la precisi\u00f3n, ya sea por un segundo operador o por el sistema.\n\n7. **Registro de Incidentes**: \n   - Los incidentes que puedan afectar la calidad de los productos intermedios o APIs, as\u00ed como la fiabilidad de los registros o resultados de pruebas, deben ser registrados e investigados.\n\n8. **Procedimientos de Cambio**: \n   - Los cambios en el sistema deben seguir un procedimiento formal de autorizaci\u00f3n, documentaci\u00f3n y pruebas, manteniendo registros de todas las modificaciones.\n\n9. **Sistema de Respaldo**: \n   - Se debe proporcionar un sistema de respaldo para evitar la p\u00e9rdida permanente de registros en caso de fallos del sistema.\n\n10. **M\u00e9todos Adicionales de Registro**: \n    - Los datos pueden ser registrados por un segundo medio adem\u00e1s del sistema computarizado.\n\n### Entidades Clave\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normativa que regula la producci\u00f3n y control de calidad en la industria farmac\u00e9utica.\n- **Sistemas Computarizados**: Herramientas tecnol\u00f3gicas utilizadas en la gesti\u00f3n de datos y procesos en la manufactura.\n- **Software Comercial**: Programas disponibles en el mercado que pueden ser utilizados en entornos GMP.\n- **Datos Cr\u00edticos**: Informaci\u00f3n esencial que requiere un manejo cuidadoso para garantizar la calidad y la integridad de los productos. \n\nEste resumen destaca la importancia de la validaci\u00f3n, el control de acceso, la documentaci\u00f3n y la protecci\u00f3n de datos en los sistemas computarizados dentro del contexto de las GMP.", "excerpt_keywords": "Keywords: documentation, records, APIs, retention, electronic signatures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ce8129f0-3a0a-45b7-94c0-113b33d90687", "node_type": "4", "metadata": {"page_label": "160", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 6. Documentation and records\n\n## 6.1 Documentation system and specifications\n\n6.10 All documents related to the manufacture of intermediates or APIs should be prepared, reviewed, approved and distributed according to written procedures. Such documents can be in paper or electronic form.\n\n6.11 The issuance, revision, superseding and withdrawal of all documents should be controlled with maintenance of revision histories.\n\n6.12 A procedure should be established for retaining all appropriate documents (e.g. development history reports, scale-up reports, technical transfer reports, process validation reports, training records, production records, control records and distribution records). The retention periods for these documents should be specified.\n\n6.13 All production, control and distribution records should be retained for at least one year after the expiry date of the batch. For APIs with retest dates, records should be retained for at least three years after the batch is completely distributed.\n\n6.14 Entries in records should be made indelibly in spaces provided for such entries, directly after performing the activities, and should identify the person making the entry. Corrections to entries should be dated and signed ensuring that the original entry remains readable.\n\n6.15 During the retention period, originals or copies of records should be readily available at the establishment where the activities described in these records occurred. Records that can be promptly retrieved from another location by electronic or other means are acceptable.\n\n6.16 Specifications, instructions, procedures and records can be retained either as originals or as true copies such as photocopies, microfilm, microfiche, or other accurate reproductions of the original records. Where reduction techniques such as microfilming or electronic records are used, suitable retrieval equipment and a means to produce a hard copy should be readily available.\n\n6.17 Specifications should be established and documented for raw materials, intermediates where necessary, APIs and labelling and packaging materials. In addition, specifications may be appropriate for certain other materials, such as process aids, gaskets or other materials used during the production of intermediates or APIs that could critically impact on quality. Acceptance criteria should be established and documented for in-process controls.\n\n6.18 If electronic signatures are used on documents they should be authenticated and secure.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "5418fb883c0be88c3d398046d1d7991cac9a54b01bfd10be38557f3568e16139", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6. Documentation and records\n\n## 6.1 Documentation system and specifications\n\n6.10 All documents related to the manufacture of intermediates or APIs should be prepared, reviewed, approved and distributed according to written procedures. Such documents can be in paper or electronic form.\n\n6.11 The issuance, revision, superseding and withdrawal of all documents should be controlled with maintenance of revision histories.\n\n6.12 A procedure should be established for retaining all appropriate documents (e.g. development history reports, scale-up reports, technical transfer reports, process validation reports, training records, production records, control records and distribution records). The retention periods for these documents should be specified.\n\n6.13 All production, control and distribution records should be retained for at least one year after the expiry date of the batch. For APIs with retest dates, records should be retained for at least three years after the batch is completely distributed.\n\n6.14 Entries in records should be made indelibly in spaces provided for such entries, directly after performing the activities, and should identify the person making the entry. Corrections to entries should be dated and signed ensuring that the original entry remains readable.\n\n6.15 During the retention period, originals or copies of records should be readily available at the establishment where the activities described in these records occurred. Records that can be promptly retrieved from another location by electronic or other means are acceptable.\n\n6.16 Specifications, instructions, procedures and records can be retained either as originals or as true copies such as photocopies, microfilm, microfiche, or other accurate reproductions of the original records. Where reduction techniques such as microfilming or electronic records are used, suitable retrieval equipment and a means to produce a hard copy should be readily available.\n\n6.17 Specifications should be established and documented for raw materials, intermediates where necessary, APIs and labelling and packaging materials. In addition, specifications may be appropriate for certain other materials, such as process aids, gaskets or other materials used during the production of intermediates or APIs that could critically impact on quality. Acceptance criteria should be established and documented for in-process controls.\n\n6.18 If electronic signatures are used on documents they should be authenticated and secure.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2503, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7cc76db2-d4ef-4cac-9dff-0a8ae3c43a58": {"__data__": {"id_": "7cc76db2-d4ef-4cac-9dff-0a8ae3c43a58", "embedding": null, "metadata": {"page_label": "161", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 6.2 Equipment cleaning and use record\n\n6.20 Records of major equipment use, cleaning, sanitization and/or sterilization and maintenance should show the date, time (if appropriate), product and batch number of each batch processed in the equipment, and the person who performed the cleaning and maintenance.\n\n6.21 If equipment is dedicated to manufacturing one intermediate or API, then individual equipment records are not necessary if batches of the intermediate or API follow in traceable sequence. In cases where dedicated equipment is employed, the records of cleaning, maintenance and use can be part of the batch record or maintained separately.\n\n# 6.3 Records of raw materials, intermediates, API labelling and packaging materials\n\n6.30 Records of raw materials, intermediates, API labelling and packaging materials should be maintained including:\n\n- the name of the manufacturer, identity and quantity of each shipment of each batch of raw materials, intermediates or labelling and packaging materials for APIs; the name of the supplier; the supplier\u2019s control number(s), if known, or other identification number; the number allocated on receipt; and the date of receipt;\n- the results of any test or examination performed and the conclusions derived from this;\n- records tracing the use of materials;\n- documentation of the examination and review of API labelling and packaging material for conformity with established specifications; and\n- the final decision regarding rejected raw materials, intermediates or API labelling and packaging materials.\n\n6.31 Master (approved) labels should be maintained for comparison to issued labels.\n\n# 6.4 Master production instructions (master production and control records)\n\n6.40 To ensure uniformity from batch to batch, master production instructions for each intermediate and API should be prepared, dated and signed by one person and independently checked, dated and signed by a person in the quality unit(s).\n\n6.41 Master production instructions should include:\n\n- the name of the intermediate or API being manufactured and an identifying document reference code, if applicable;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para el mantenimiento de registros relacionados con el uso, limpieza, sanitizaci\u00f3n, esterilizaci\u00f3n y mantenimiento de equipos en la producci\u00f3n de productos farmac\u00e9uticos, as\u00ed como la documentaci\u00f3n necesaria para materias primas, intermedios y materiales de etiquetado y empaque. Se enfatiza la importancia de mantener registros precisos y trazables para garantizar la calidad y la conformidad de los productos fabricados.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en los registros de limpieza y mantenimiento de equipos dedicados a la fabricaci\u00f3n de un intermedio o API?**\n   - Respuesta: Los registros deben incluir la fecha, hora (si es apropiado), producto y n\u00famero de lote de cada lote procesado en el equipo, as\u00ed como la persona que realiz\u00f3 la limpieza y el mantenimiento.\n\n2. **\u00bfCu\u00e1les son los elementos clave que deben documentarse en los registros de materias primas y materiales de etiquetado y empaque para APIs?**\n   - Respuesta: Los registros deben incluir el nombre del fabricante, la identidad y cantidad de cada env\u00edo, el nombre del proveedor, los n\u00fameros de control del proveedor (si se conocen), el n\u00famero asignado al recibir, la fecha de recepci\u00f3n, los resultados de pruebas realizadas, la trazabilidad de los materiales, la documentaci\u00f3n de la revisi\u00f3n de conformidad de los materiales de etiquetado y empaque, y la decisi\u00f3n final sobre materiales rechazados.\n\n3. **\u00bfQu\u00e9 pasos deben seguirse para la preparaci\u00f3n y verificaci\u00f3n de las instrucciones de producci\u00f3n maestra para intermedios y APIs?**\n   - Respuesta: Las instrucciones de producci\u00f3n maestra deben ser preparadas, fechadas y firmadas por una persona, y luego ser verificadas de manera independiente, fechadas y firmadas por una persona del(s) departamento(s) de calidad.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Documentaci\u00f3n y Registros**: La secci\u00f3n aborda la importancia de un sistema de documentaci\u00f3n adecuado para la fabricaci\u00f3n de intermediarios y principios activos (APIs).\n\n2. **Procedimientos Escritos**: Se requiere que todos los documentos sean preparados, revisados, aprobados y distribuidos de acuerdo con procedimientos escritos, ya sea en formato papel o electr\u00f3nico.\n\n3. **Control de Documentos**: Se debe mantener un control sobre la emisi\u00f3n, revisi\u00f3n, sustituci\u00f3n y retirada de documentos, incluyendo el mantenimiento de historiales de revisi\u00f3n.\n\n4. **Retenci\u00f3n de Documentos**: Se establece la necesidad de un procedimiento para la retenci\u00f3n de documentos relevantes, especificando per\u00edodos de retenci\u00f3n:\n   - Registros de producci\u00f3n, control y distribuci\u00f3n: al menos un a\u00f1o despu\u00e9s de la fecha de caducidad del lote.\n   - Registros de APIs con fechas de rean\u00e1lisis: al menos tres a\u00f1os despu\u00e9s de la distribuci\u00f3n completa del lote.\n\n5. **Integridad de Registros**: Las entradas en los registros deben ser indelibles y realizadas inmediatamente despu\u00e9s de las actividades, identificando a la persona responsable. Las correcciones deben ser fechadas y firmadas.\n\n6. **Disponibilidad de Registros**: Durante el per\u00edodo de retenci\u00f3n, los registros deben estar disponibles en el establecimiento donde se realizaron las actividades, y se aceptan registros que puedan ser recuperados electr\u00f3nicamente.\n\n7. **Especificaciones y Criterios de Aceptaci\u00f3n**: Se deben establecer y documentar especificaciones para materias primas, intermediarios, APIs y materiales de etiquetado y empaque, as\u00ed como criterios de aceptaci\u00f3n para controles en proceso.\n\n8. **Firmas Electr\u00f3nicas**: Si se utilizan firmas electr\u00f3nicas, estas deben ser autenticadas y seguras para garantizar la validez de los documentos.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Intermediarios y APIs**: Productos cuya fabricaci\u00f3n est\u00e1 regulada por las directrices.\n- **Documentos**: Incluyen informes de desarrollo, informes de escalado, informes de validaci\u00f3n, registros de producci\u00f3n, entre otros.\n- **Firmas Electr\u00f3nicas**: Elemento de seguridad en la documentaci\u00f3n electr\u00f3nica. \n\nEste resumen destaca la importancia de la documentaci\u00f3n adecuada y el cumplimiento de procedimientos para garantizar la calidad y la trazabilidad en la fabricaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: equipment cleaning, record keeping, raw materials, master production instructions, API compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "181110fb-8a95-401b-916e-a2fd07fbb8da", "node_type": "4", "metadata": {"page_label": "161", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 6.2 Equipment cleaning and use record\n\n6.20 Records of major equipment use, cleaning, sanitization and/or sterilization and maintenance should show the date, time (if appropriate), product and batch number of each batch processed in the equipment, and the person who performed the cleaning and maintenance.\n\n6.21 If equipment is dedicated to manufacturing one intermediate or API, then individual equipment records are not necessary if batches of the intermediate or API follow in traceable sequence. In cases where dedicated equipment is employed, the records of cleaning, maintenance and use can be part of the batch record or maintained separately.\n\n# 6.3 Records of raw materials, intermediates, API labelling and packaging materials\n\n6.30 Records of raw materials, intermediates, API labelling and packaging materials should be maintained including:\n\n- the name of the manufacturer, identity and quantity of each shipment of each batch of raw materials, intermediates or labelling and packaging materials for APIs; the name of the supplier; the supplier\u2019s control number(s), if known, or other identification number; the number allocated on receipt; and the date of receipt;\n- the results of any test or examination performed and the conclusions derived from this;\n- records tracing the use of materials;\n- documentation of the examination and review of API labelling and packaging material for conformity with established specifications; and\n- the final decision regarding rejected raw materials, intermediates or API labelling and packaging materials.\n\n6.31 Master (approved) labels should be maintained for comparison to issued labels.\n\n# 6.4 Master production instructions (master production and control records)\n\n6.40 To ensure uniformity from batch to batch, master production instructions for each intermediate and API should be prepared, dated and signed by one person and independently checked, dated and signed by a person in the quality unit(s).\n\n6.41 Master production instructions should include:\n\n- the name of the intermediate or API being manufactured and an identifying document reference code, if applicable;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "791702991f64153abf25f91b2e432cadfa6fe0ca149a9e6e79a85517f3535ca9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6.2 Equipment cleaning and use record\n\n6.20 Records of major equipment use, cleaning, sanitization and/or sterilization and maintenance should show the date, time (if appropriate), product and batch number of each batch processed in the equipment, and the person who performed the cleaning and maintenance.\n\n6.21 If equipment is dedicated to manufacturing one intermediate or API, then individual equipment records are not necessary if batches of the intermediate or API follow in traceable sequence. In cases where dedicated equipment is employed, the records of cleaning, maintenance and use can be part of the batch record or maintained separately.\n\n# 6.3 Records of raw materials, intermediates, API labelling and packaging materials\n\n6.30 Records of raw materials, intermediates, API labelling and packaging materials should be maintained including:\n\n- the name of the manufacturer, identity and quantity of each shipment of each batch of raw materials, intermediates or labelling and packaging materials for APIs; the name of the supplier; the supplier\u2019s control number(s), if known, or other identification number; the number allocated on receipt; and the date of receipt;\n- the results of any test or examination performed and the conclusions derived from this;\n- records tracing the use of materials;\n- documentation of the examination and review of API labelling and packaging material for conformity with established specifications; and\n- the final decision regarding rejected raw materials, intermediates or API labelling and packaging materials.\n\n6.31 Master (approved) labels should be maintained for comparison to issued labels.\n\n# 6.4 Master production instructions (master production and control records)\n\n6.40 To ensure uniformity from batch to batch, master production instructions for each intermediate and API should be prepared, dated and signed by one person and independently checked, dated and signed by a person in the quality unit(s).\n\n6.41 Master production instructions should include:\n\n- the name of the intermediate or API being manufactured and an identifying document reference code, if applicable;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2133, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4f8eee38-bcd1-46e3-9103-70bd4890c057": {"__data__": {"id_": "4f8eee38-bcd1-46e3-9103-70bd4890c057", "embedding": null, "metadata": {"page_label": "162", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- a complete list of raw materials and intermediates designated by names or codes sufficiently specific to identify any special quality characteristics;\n- an accurate statement of the quantity or ratio of each raw material or intermediate to be used, including the unit of measure. Where the quantity is not fixed, the calculation for each batch size or rate of production should be included. Variations to quantities should be included where they are justified;\n- the production location and major production equipment to be used;\n- detailed production instructions, including the:\n  - sequences to be followed,\n  - ranges of process parameters to be used,\n  - sampling instructions and in-process controls with their acceptance criteria, where appropriate,\n  - time limits for completion of individual processing steps and/or the total process, where appropriate, and\n  - expected yield ranges at appropriate phases of processing or time;\n- where appropriate, special notations and precautions to be followed, or cross-references to these; and\n- the instructions for storage of the intermediate or API to assure its suitability for use, including the labelling and packaging materials and special storage conditions with time limits, where appropriate.\n\n## 6.5 Batch production records (batch production and control records)\n\n6.50 Batch production records should be prepared for each intermediate and API and should include complete information relating to the production and control of each batch. The batch production record should be checked before issuance to assure that it is the correct version and is a legible accurate reproduction of the appropriate master production instruction. If the batch production record is produced from a separate part of the master document, that document should include a reference to the current master production instruction being used.\n\n6.51 These records should be numbered with a unique batch or identification number, dated and signed when issued. In continuous production, the product code, together with the date and time, can serve as the unique identifier until the final number is allocated.\n\n6.52 Documentation of completion of each significant step in the batch production records (batch production and control records) should include:\n\n- dates and, when appropriate, times;\n- identity of major equipment (e.g., reactors, driers and mills) used;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para la producci\u00f3n y control de materias primas e intermediarios en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de mantener registros de producci\u00f3n de lotes que incluyan informaci\u00f3n detallada sobre los materiales utilizados, las instrucciones de producci\u00f3n, el equipo, y la documentaci\u00f3n de cada paso significativo en el proceso. Adem\u00e1s, se menciona la necesidad de asegurar que los registros sean precisos y est\u00e9n actualizados, as\u00ed como la importancia de las condiciones de almacenamiento para garantizar la idoneidad de los productos intermedios o API (ingredientes farmac\u00e9uticos activos).\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en los registros de producci\u00f3n de lotes para asegurar la trazabilidad y el control de calidad?**\n   - Los registros de producci\u00f3n de lotes deben incluir una lista completa de materias primas e intermediarios, cantidades o proporciones, ubicaci\u00f3n de producci\u00f3n, instrucciones detalladas de producci\u00f3n, y documentaci\u00f3n de cada paso significativo, incluyendo fechas, tiempos y equipos utilizados.\n\n2. **\u00bfCu\u00e1les son las precauciones y notaciones especiales que deben considerarse durante el proceso de producci\u00f3n?**\n   - El documento menciona que deben incluirse notaciones y precauciones especiales donde sea apropiado, as\u00ed como referencias cruzadas a estas, aunque no se especifican ejemplos concretos en el texto.\n\n3. **\u00bfC\u00f3mo se debe manejar la documentaci\u00f3n de los registros de producci\u00f3n en caso de que se utilice una versi\u00f3n separada del documento maestro?**\n   - Si los registros de producci\u00f3n se generan a partir de una parte separada del documento maestro, este debe incluir una referencia a la instrucci\u00f3n de producci\u00f3n maestra actual que se est\u00e1 utilizando, asegurando as\u00ed que la informaci\u00f3n sea coherente y actualizada.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Registros de Limpieza y Mantenimiento de Equipos (Secci\u00f3n 6.2)**:\n   - **Requisitos de Registro**: Deben incluir la fecha, hora (si es relevante), producto y n\u00famero de lote de cada lote procesado, as\u00ed como la identificaci\u00f3n de la persona que realiz\u00f3 la limpieza y el mantenimiento.\n   - **Equipos Dedicados**: Si el equipo est\u00e1 dedicado a un solo intermedio o API, no se requieren registros individuales si los lotes son trazables. Los registros pueden formar parte del registro del lote o mantenerse por separado.\n\n2. **Registros de Materias Primas y Materiales de Etiquetado y Empaque (Secci\u00f3n 6.3)**:\n   - **Elementos Clave**: Deben incluir el nombre del fabricante, identidad y cantidad de cada env\u00edo, nombre del proveedor, n\u00fameros de control del proveedor, n\u00famero asignado al recibir, fecha de recepci\u00f3n, resultados de pruebas, trazabilidad de materiales, documentaci\u00f3n de revisi\u00f3n de conformidad y decisiones sobre materiales rechazados.\n   - **Etiquetas Maestras**: Se deben mantener etiquetas maestras aprobadas para comparaci\u00f3n con las etiquetas emitidas.\n\n3. **Instrucciones de Producci\u00f3n Maestra (Secci\u00f3n 6.4)**:\n   - **Preparaci\u00f3n y Verificaci\u00f3n**: Las instrucciones deben ser preparadas, fechadas y firmadas por una persona, y luego verificadas de manera independiente por una persona del departamento de calidad.\n   - **Contenido de las Instrucciones**: Deben incluir el nombre del intermedio o API y un c\u00f3digo de referencia del documento, si es aplicable.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Intermedios y APIs**: Productos farmac\u00e9uticos cuya producci\u00f3n est\u00e1 regulada.\n- **Equipos de Producci\u00f3n**: Herramientas utilizadas en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Materias Primas**: Materiales utilizados en la producci\u00f3n de intermedios y APIs.\n- **Proveedores**: Entidades que suministran materias primas y materiales de etiquetado y empaque.\n- **Departamento de Calidad**: Unidad responsable de la verificaci\u00f3n y control de calidad en la producci\u00f3n. \n\nEste resumen destaca la importancia de mantener registros precisos y trazables en la producci\u00f3n farmac\u00e9utica para garantizar la calidad y la conformidad de los productos.", "excerpt_keywords": "Keywords: batch production records, raw materials, production instructions, quality control, pharmaceutical manufacturing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "dfcfbed1-cd49-4082-8b1d-f4198e087a6b", "node_type": "4", "metadata": {"page_label": "162", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- a complete list of raw materials and intermediates designated by names or codes sufficiently specific to identify any special quality characteristics;\n- an accurate statement of the quantity or ratio of each raw material or intermediate to be used, including the unit of measure. Where the quantity is not fixed, the calculation for each batch size or rate of production should be included. Variations to quantities should be included where they are justified;\n- the production location and major production equipment to be used;\n- detailed production instructions, including the:\n  - sequences to be followed,\n  - ranges of process parameters to be used,\n  - sampling instructions and in-process controls with their acceptance criteria, where appropriate,\n  - time limits for completion of individual processing steps and/or the total process, where appropriate, and\n  - expected yield ranges at appropriate phases of processing or time;\n- where appropriate, special notations and precautions to be followed, or cross-references to these; and\n- the instructions for storage of the intermediate or API to assure its suitability for use, including the labelling and packaging materials and special storage conditions with time limits, where appropriate.\n\n## 6.5 Batch production records (batch production and control records)\n\n6.50 Batch production records should be prepared for each intermediate and API and should include complete information relating to the production and control of each batch. The batch production record should be checked before issuance to assure that it is the correct version and is a legible accurate reproduction of the appropriate master production instruction. If the batch production record is produced from a separate part of the master document, that document should include a reference to the current master production instruction being used.\n\n6.51 These records should be numbered with a unique batch or identification number, dated and signed when issued. In continuous production, the product code, together with the date and time, can serve as the unique identifier until the final number is allocated.\n\n6.52 Documentation of completion of each significant step in the batch production records (batch production and control records) should include:\n\n- dates and, when appropriate, times;\n- identity of major equipment (e.g., reactors, driers and mills) used;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "3eb8be0519583811ef1a430a50129949bbebf45114fc600f7a14bd522c90c30e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- a complete list of raw materials and intermediates designated by names or codes sufficiently specific to identify any special quality characteristics;\n- an accurate statement of the quantity or ratio of each raw material or intermediate to be used, including the unit of measure. Where the quantity is not fixed, the calculation for each batch size or rate of production should be included. Variations to quantities should be included where they are justified;\n- the production location and major production equipment to be used;\n- detailed production instructions, including the:\n  - sequences to be followed,\n  - ranges of process parameters to be used,\n  - sampling instructions and in-process controls with their acceptance criteria, where appropriate,\n  - time limits for completion of individual processing steps and/or the total process, where appropriate, and\n  - expected yield ranges at appropriate phases of processing or time;\n- where appropriate, special notations and precautions to be followed, or cross-references to these; and\n- the instructions for storage of the intermediate or API to assure its suitability for use, including the labelling and packaging materials and special storage conditions with time limits, where appropriate.\n\n## 6.5 Batch production records (batch production and control records)\n\n6.50 Batch production records should be prepared for each intermediate and API and should include complete information relating to the production and control of each batch. The batch production record should be checked before issuance to assure that it is the correct version and is a legible accurate reproduction of the appropriate master production instruction. If the batch production record is produced from a separate part of the master document, that document should include a reference to the current master production instruction being used.\n\n6.51 These records should be numbered with a unique batch or identification number, dated and signed when issued. In continuous production, the product code, together with the date and time, can serve as the unique identifier until the final number is allocated.\n\n6.52 Documentation of completion of each significant step in the batch production records (batch production and control records) should include:\n\n- dates and, when appropriate, times;\n- identity of major equipment (e.g., reactors, driers and mills) used;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2398, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3a7743bb-aa01-44bf-8281-5fe37fc2246b": {"__data__": {"id_": "3a7743bb-aa01-44bf-8281-5fe37fc2246b", "embedding": null, "metadata": {"page_label": "163", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 specific identification of each batch, including weights, measures, and batch numbers of raw materials, intermediates, or any reprocessed materials used during manufacturing;  \n\u2014 actual results recorded for critical process parameters;  \n\u2014 any sampling performed;  \n\u2014 signatures of the persons performing and directly supervising or checking each critical step in the operation;  \n\u2014 in-process and laboratory test results;  \n\u2014 actual yield at appropriate phases or times;  \n\u2014 description of packaging and label for intermediate or API;  \n\u2014 representative label of API or intermediate if made commercially available;  \n\u2014 any deviation noted, its evaluation, investigation conducted (if appropriate) or reference to that investigation if stored separately; and  \n\u2014 results of release testing.  \n\n6.53 Written procedures should be established and followed for investigating critical deviations or the failure of a batch of intermediate or API to meet specifications. The investigation should extend to other batches that may have been associated with the specific failure or deviation.\n\n## 6.6 Laboratory control records\n\n6.60 Laboratory control records should include complete data derived from all tests conducted to ensure compliance with established specifications and standards, including examinations and assays, as follows:\n\n\u2014 a description of samples received for testing, including the name of the material or its source, batch number or other distinctive code, the date the sample was taken and, where appropriate, the quantity and date the sample was received for testing;  \n\u2014 a statement of or reference to each test method used;  \n\u2014 a statement of the weight or measure of sample used for each test as described by the method;  \n\u2014 data on or cross-reference to the preparation and testing of reference standards, reagents and standard solutions;  \n\u2014 a complete record of all raw data generated during each test, in addition to graphs, charts and spectra from laboratory instrumentation, properly identified to show the specific material and batch tested;  \n\u2014 a record of all calculations performed in connection with the test, including, for example, units of measure, conversion factors and equivalency factors;  \n\u2014 a statement of the test results and how they compare with established acceptance criteria;  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para el control de calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos, espec\u00edficamente en lo que respecta a la documentaci\u00f3n y registros de laboratorio. Se enfatiza la importancia de mantener registros precisos y completos de cada lote de materiales, los resultados de pruebas, las desviaciones y las investigaciones relacionadas. Tambi\u00e9n se menciona la necesidad de procedimientos escritos para investigar cualquier desviaci\u00f3n cr\u00edtica o fallo en los lotes de productos intermedios o principios activos (API). Los registros de control de laboratorio deben incluir datos exhaustivos de todas las pruebas realizadas para asegurar el cumplimiento de las especificaciones establecidas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe incluirse en los registros de control de laboratorio para asegurar la trazabilidad de los materiales probados?**\n   - Respuesta: Los registros deben incluir una descripci\u00f3n de las muestras recibidas, el nombre del material o su fuente, el n\u00famero de lote o c\u00f3digo distintivo, la fecha en que se tom\u00f3 la muestra, y la cantidad y fecha en que se recibi\u00f3 para pruebas.\n\n2. **\u00bfCu\u00e1les son los pasos recomendados para investigar una desviaci\u00f3n cr\u00edtica en la producci\u00f3n de un lote de API?**\n   - Respuesta: Se deben establecer y seguir procedimientos escritos para investigar las desviaciones cr\u00edticas, extendiendo la investigaci\u00f3n a otros lotes que puedan estar asociados con la falla o desviaci\u00f3n espec\u00edfica.\n\n3. **\u00bfQu\u00e9 tipo de datos deben ser registrados durante las pruebas de laboratorio para garantizar la conformidad con las especificaciones establecidas?**\n   - Respuesta: Los datos deben incluir un registro completo de todos los datos brutos generados durante cada prueba, gr\u00e1ficos, tablas y espectros de la instrumentaci\u00f3n de laboratorio, as\u00ed como un registro de todos los c\u00e1lculos realizados en relaci\u00f3n con la prueba y una declaraci\u00f3n de los resultados de la prueba en comparaci\u00f3n con los criterios de aceptaci\u00f3n establecidos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Producci\u00f3n y Control de Materias Primas e Intermediarios**:\n   - Se requiere una lista completa de materias primas e intermediarios, con nombres o c\u00f3digos que identifiquen caracter\u00edsticas de calidad espec\u00edficas.\n\n2. **Documentaci\u00f3n de Cantidades**:\n   - Es necesario incluir una declaraci\u00f3n precisa de la cantidad o proporci\u00f3n de cada materia prima o intermedio, junto con la unidad de medida. Se deben documentar c\u00e1lculos para tama\u00f1os de lote o tasas de producci\u00f3n, as\u00ed como variaciones justificadas.\n\n3. **Ubicaci\u00f3n y Equipos de Producci\u00f3n**:\n   - Se debe especificar la ubicaci\u00f3n de producci\u00f3n y el equipo principal que se utilizar\u00e1 en el proceso.\n\n4. **Instrucciones de Producci\u00f3n Detalladas**:\n   - Instrucciones que incluyan secuencias de producci\u00f3n, rangos de par\u00e1metros de proceso, instrucciones de muestreo, controles en proceso, l\u00edmites de tiempo para pasos de procesamiento y rangos de rendimiento esperados.\n\n5. **Precauciones y Notaciones Especiales**:\n   - Se deben incluir notaciones y precauciones especiales, as\u00ed como referencias cruzadas a estas cuando sea apropiado.\n\n6. **Instrucciones de Almacenamiento**:\n   - Instrucciones para el almacenamiento de intermedios o API, incluyendo etiquetado, materiales de embalaje y condiciones especiales de almacenamiento.\n\n7. **Registros de Producci\u00f3n de Lotes**:\n   - Los registros deben ser preparados para cada intermedio y API, incluyendo informaci\u00f3n completa sobre la producci\u00f3n y control de cada lote. Deben ser verificados antes de su emisi\u00f3n para asegurar su precisi\u00f3n.\n\n8. **Identificaci\u00f3n y Documentaci\u00f3n**:\n   - Los registros deben tener un n\u00famero de lote \u00fanico, estar fechados y firmados al ser emitidos. En producci\u00f3n continua, el c\u00f3digo del producto junto con la fecha y hora puede servir como identificador \u00fanico.\n\n9. **Documentaci\u00f3n de Pasos Significativos**:\n   - La documentaci\u00f3n debe incluir fechas, tiempos y la identidad del equipo principal utilizado en cada paso significativo del proceso de producci\u00f3n.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece los lineamientos.\n- **API (Ingredientes Farmac\u00e9uticos Activos)**: Productos intermedios en la producci\u00f3n farmac\u00e9utica.\n- **Materias Primas e Intermediarios**: Componentes utilizados en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Registros de Producci\u00f3n**: Documentaci\u00f3n esencial para el control de calidad y trazabilidad en la producci\u00f3n.", "excerpt_keywords": "Keywords: control records, quality assurance, pharmaceutical manufacturing, laboratory testing, deviation investigation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9f0c14af-be3d-4f8c-88c1-0b7c0a45ac14", "node_type": "4", "metadata": {"page_label": "163", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 specific identification of each batch, including weights, measures, and batch numbers of raw materials, intermediates, or any reprocessed materials used during manufacturing;  \n\u2014 actual results recorded for critical process parameters;  \n\u2014 any sampling performed;  \n\u2014 signatures of the persons performing and directly supervising or checking each critical step in the operation;  \n\u2014 in-process and laboratory test results;  \n\u2014 actual yield at appropriate phases or times;  \n\u2014 description of packaging and label for intermediate or API;  \n\u2014 representative label of API or intermediate if made commercially available;  \n\u2014 any deviation noted, its evaluation, investigation conducted (if appropriate) or reference to that investigation if stored separately; and  \n\u2014 results of release testing.  \n\n6.53 Written procedures should be established and followed for investigating critical deviations or the failure of a batch of intermediate or API to meet specifications. The investigation should extend to other batches that may have been associated with the specific failure or deviation.\n\n## 6.6 Laboratory control records\n\n6.60 Laboratory control records should include complete data derived from all tests conducted to ensure compliance with established specifications and standards, including examinations and assays, as follows:\n\n\u2014 a description of samples received for testing, including the name of the material or its source, batch number or other distinctive code, the date the sample was taken and, where appropriate, the quantity and date the sample was received for testing;  \n\u2014 a statement of or reference to each test method used;  \n\u2014 a statement of the weight or measure of sample used for each test as described by the method;  \n\u2014 data on or cross-reference to the preparation and testing of reference standards, reagents and standard solutions;  \n\u2014 a complete record of all raw data generated during each test, in addition to graphs, charts and spectra from laboratory instrumentation, properly identified to show the specific material and batch tested;  \n\u2014 a record of all calculations performed in connection with the test, including, for example, units of measure, conversion factors and equivalency factors;  \n\u2014 a statement of the test results and how they compare with established acceptance criteria;  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "5f65abb8f2b5f033a0fa81ab56d2b86650dff958e390d6eeb53b4a973b8a9cba", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2014 specific identification of each batch, including weights, measures, and batch numbers of raw materials, intermediates, or any reprocessed materials used during manufacturing;  \n\u2014 actual results recorded for critical process parameters;  \n\u2014 any sampling performed;  \n\u2014 signatures of the persons performing and directly supervising or checking each critical step in the operation;  \n\u2014 in-process and laboratory test results;  \n\u2014 actual yield at appropriate phases or times;  \n\u2014 description of packaging and label for intermediate or API;  \n\u2014 representative label of API or intermediate if made commercially available;  \n\u2014 any deviation noted, its evaluation, investigation conducted (if appropriate) or reference to that investigation if stored separately; and  \n\u2014 results of release testing.  \n\n6.53 Written procedures should be established and followed for investigating critical deviations or the failure of a batch of intermediate or API to meet specifications. The investigation should extend to other batches that may have been associated with the specific failure or deviation.\n\n## 6.6 Laboratory control records\n\n6.60 Laboratory control records should include complete data derived from all tests conducted to ensure compliance with established specifications and standards, including examinations and assays, as follows:\n\n\u2014 a description of samples received for testing, including the name of the material or its source, batch number or other distinctive code, the date the sample was taken and, where appropriate, the quantity and date the sample was received for testing;  \n\u2014 a statement of or reference to each test method used;  \n\u2014 a statement of the weight or measure of sample used for each test as described by the method;  \n\u2014 data on or cross-reference to the preparation and testing of reference standards, reagents and standard solutions;  \n\u2014 a complete record of all raw data generated during each test, in addition to graphs, charts and spectra from laboratory instrumentation, properly identified to show the specific material and batch tested;  \n\u2014 a record of all calculations performed in connection with the test, including, for example, units of measure, conversion factors and equivalency factors;  \n\u2014 a statement of the test results and how they compare with established acceptance criteria;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2319, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "29cf852d-eee3-4e42-9eb9-d398e0e6c0b4": {"__data__": {"id_": "29cf852d-eee3-4e42-9eb9-d398e0e6c0b4", "embedding": null, "metadata": {"page_label": "164", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 6.61 Complete records should also be maintained for:\n\n- any modifications to an established analytical method;\n- periodic calibration of laboratory instruments, apparatus, gauges and recording devices;\n- all stability testing performed on APIs; and\n- out-of-specification (OOS) investigations.\n\n## 6.7 Batch production record review\n\n6.70 Written procedures should be established and followed for the review and approval of batch production and laboratory control records, including packaging and labelling, to determine compliance of the intermediate or API with established specifications before a batch is released or distributed.\n\n6.71 Batch production and laboratory control records of critical process steps should be reviewed and approved by the quality unit(s) before an API batch is released or distributed. Production and laboratory control records of non-critical process steps can be reviewed by qualified production personnel or other units following procedures approved by the quality unit(s).\n\n6.72 All deviation, investigation and OOS reports should be reviewed as part of the batch record review before the batch is released.\n\n6.73 The quality unit(s) can delegate to the production unit the responsibility and authority for release of intermediates, except for those shipped outside the control of the manufacturing company.\n\n# 7. Materials management\n\n## 7.1 General controls\n\n7.10 There should be written procedures describing the receipt, identification, quarantine, storage, handling, sampling, testing and approval or rejection of materials.\n\n7.11 Manufacturers of intermediates and/or APIs should have a system for evaluating the suppliers of critical materials.\n\n7.12 Materials should be purchased against an agreed specification, from a supplier or suppliers approved by the quality unit(s).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Mantenimiento de Registros**: Es fundamental mantener registros completos de modificaciones en m\u00e9todos anal\u00edticos, calibraciones de instrumentos, pruebas de estabilidad de APIs y las investigaciones de resultados fuera de especificaci\u00f3n (OOS).\n\n2. **Revisi\u00f3n de Registros de Producci\u00f3n por Lotes**: Se deben establecer procedimientos escritos para la revisi\u00f3n y aprobaci\u00f3n de los registros de producci\u00f3n y control de laboratorio antes de liberar o distribuir un lote de intermediarios o APIs. Los registros de pasos cr\u00edticos deben ser revisados por la unidad de calidad, mientras que los no cr\u00edticos pueden ser revisados por personal calificado.\n\n3. **Gesti\u00f3n de Materiales**: Se requieren procedimientos escritos para la gesti\u00f3n de materiales, que incluyan su recepci\u00f3n, identificaci\u00f3n, almacenamiento y aprobaci\u00f3n. Adem\u00e1s, es esencial evaluar a los proveedores de materiales cr\u00edticos y asegurarse de que los materiales se compren de acuerdo con especificaciones acordadas.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de modificaciones deben registrarse en los m\u00e9todos anal\u00edticos seg\u00fan el documento?**\n   - El documento especifica que se deben mantener registros de cualquier modificaci\u00f3n a un m\u00e9todo anal\u00edtico establecido.\n\n2. **\u00bfQui\u00e9n es responsable de revisar los registros de producci\u00f3n de pasos cr\u00edticos y no cr\u00edticos antes de la liberaci\u00f3n de un lote de API?**\n   - Los registros de producci\u00f3n y control de laboratorio de pasos cr\u00edticos deben ser revisados y aprobados por la unidad de calidad, mientras que los de pasos no cr\u00edticos pueden ser revisados por personal de producci\u00f3n calificado o por otras unidades, siguiendo procedimientos aprobados por la unidad de calidad.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse para la gesti\u00f3n de materiales en la producci\u00f3n de intermediarios y APIs?**\n   - Deben existir procedimientos escritos que describan la recepci\u00f3n, identificaci\u00f3n, cuarentena, almacenamiento, manejo, muestreo, pruebas y aprobaci\u00f3n o rechazo de materiales, as\u00ed como un sistema para evaluar a los proveedores de materiales cr\u00edticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Documentaci\u00f3n y Registros de Calidad:**\n   - Importancia de mantener registros precisos y completos de cada lote de materiales utilizados en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n   - Inclusi\u00f3n de informaci\u00f3n sobre pesos, medidas, n\u00fameros de lote, resultados de pruebas y desviaciones.\n\n2. **Investigaci\u00f3n de Desviaciones Cr\u00edticas:**\n   - Necesidad de establecer procedimientos escritos para investigar desviaciones cr\u00edticas o fallos en lotes de productos intermedios o principios activos (API).\n   - Extensi\u00f3n de la investigaci\u00f3n a otros lotes asociados con la desviaci\u00f3n.\n\n3. **Registros de Control de Laboratorio:**\n   - Inclusi\u00f3n de datos completos de todas las pruebas realizadas para asegurar el cumplimiento de especificaciones y est\u00e1ndares.\n   - Registro de muestras, m\u00e9todos de prueba, datos brutos, c\u00e1lculos y resultados en comparaci\u00f3n con criterios de aceptaci\u00f3n.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Entidad responsable de establecer los lineamientos y est\u00e1ndares para el control de calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Productos Intermedios y API:** Tipos de productos farmac\u00e9uticos cuya calidad y conformidad deben ser monitoreadas.\n- **Lotes de Materiales:** Referencia a las cantidades espec\u00edficas de materiales utilizados en la producci\u00f3n que deben ser documentadas.\n- **Registros de Laboratorio:** Documentaci\u00f3n que incluye datos de pruebas, m\u00e9todos utilizados y resultados obtenidos.\n\nEste resumen destaca la importancia de la documentaci\u00f3n y el control de calidad en la industria farmac\u00e9utica, as\u00ed como los procedimientos necesarios para garantizar la conformidad y la trazabilidad de los productos.", "excerpt_keywords": "Keywords: quality control, batch production, analytical methods, materials management, out-of-specification"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "745bff58-1987-4bfb-954b-738679cc371a", "node_type": "4", "metadata": {"page_label": "164", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 6.61 Complete records should also be maintained for:\n\n- any modifications to an established analytical method;\n- periodic calibration of laboratory instruments, apparatus, gauges and recording devices;\n- all stability testing performed on APIs; and\n- out-of-specification (OOS) investigations.\n\n## 6.7 Batch production record review\n\n6.70 Written procedures should be established and followed for the review and approval of batch production and laboratory control records, including packaging and labelling, to determine compliance of the intermediate or API with established specifications before a batch is released or distributed.\n\n6.71 Batch production and laboratory control records of critical process steps should be reviewed and approved by the quality unit(s) before an API batch is released or distributed. Production and laboratory control records of non-critical process steps can be reviewed by qualified production personnel or other units following procedures approved by the quality unit(s).\n\n6.72 All deviation, investigation and OOS reports should be reviewed as part of the batch record review before the batch is released.\n\n6.73 The quality unit(s) can delegate to the production unit the responsibility and authority for release of intermediates, except for those shipped outside the control of the manufacturing company.\n\n# 7. Materials management\n\n## 7.1 General controls\n\n7.10 There should be written procedures describing the receipt, identification, quarantine, storage, handling, sampling, testing and approval or rejection of materials.\n\n7.11 Manufacturers of intermediates and/or APIs should have a system for evaluating the suppliers of critical materials.\n\n7.12 Materials should be purchased against an agreed specification, from a supplier or suppliers approved by the quality unit(s).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "6f11d948e2950c0be99fa59289f7d63b01f39db06bf89a1c4ab8b15a91a46d7f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6.61 Complete records should also be maintained for:\n\n- any modifications to an established analytical method;\n- periodic calibration of laboratory instruments, apparatus, gauges and recording devices;\n- all stability testing performed on APIs; and\n- out-of-specification (OOS) investigations.\n\n## 6.7 Batch production record review\n\n6.70 Written procedures should be established and followed for the review and approval of batch production and laboratory control records, including packaging and labelling, to determine compliance of the intermediate or API with established specifications before a batch is released or distributed.\n\n6.71 Batch production and laboratory control records of critical process steps should be reviewed and approved by the quality unit(s) before an API batch is released or distributed. Production and laboratory control records of non-critical process steps can be reviewed by qualified production personnel or other units following procedures approved by the quality unit(s).\n\n6.72 All deviation, investigation and OOS reports should be reviewed as part of the batch record review before the batch is released.\n\n6.73 The quality unit(s) can delegate to the production unit the responsibility and authority for release of intermediates, except for those shipped outside the control of the manufacturing company.\n\n# 7. Materials management\n\n## 7.1 General controls\n\n7.10 There should be written procedures describing the receipt, identification, quarantine, storage, handling, sampling, testing and approval or rejection of materials.\n\n7.11 Manufacturers of intermediates and/or APIs should have a system for evaluating the suppliers of critical materials.\n\n7.12 Materials should be purchased against an agreed specification, from a supplier or suppliers approved by the quality unit(s).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1819, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "867a6875-9ffe-4820-b84f-722732d5ea4f": {"__data__": {"id_": "867a6875-9ffe-4820-b84f-722732d5ea4f", "embedding": null, "metadata": {"page_label": "165", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 7.2 Receipt and Quarantine\n\n7.13 If the supplier of a critical material is not the manufacturer of that material, the name and address of that manufacturer should be known to the intermediate and/or API manufacturer.\n\n7.14 Changing the source of supply of critical raw materials should be done according to section 13, Change control.\n\n## Receipt and Quarantine\n\n7.20 Upon receipt and before acceptance, each container or grouping of containers of materials should be examined visually for correct labelling (including correlation between the name used by the supplier and the in-house name, if these are different), damage to containers, broken seals and evidence of tampering or contamination. Materials should be held under quarantine until they have been sampled, examined or tested as appropriate, and then released for use.\n\n7.21 Before incoming materials are mixed with existing stocks (e.g. solvents or stocks in silos), they should be identified as correct, tested, if appropriate, and released. Procedures should be available to prevent discharging incoming materials wrongly into the existing stock.\n\n7.22 If bulk deliveries are made in non-dedicated tankers, there should be assurance of no cross-contamination from the tanker. Means of providing this assurance could include one or more of the following:\n\n- certificate of cleaning;\n- testing for trace impurities;\n- audit of the supplier.\n\n7.23 Large storage containers, and their attendant manifolds, filling and discharge lines should be appropriately identified.\n\n7.24 Each container or grouping of containers (batches) of materials should be assigned and identified with a distinctive code, batch or receipt number. This number should be used in recording the disposition of each batch. A system should be in place to identify the status of each batch.\n\n# 7.3 Sampling and Testing of Incoming Production Materials\n\n7.30 At least one test to verify the identity of each batch of material should be conducted, with the exception of the materials described below in section 7.3.2. A supplier\u2019s certificate of analysis can be used in place of performing other tests, provided that the manufacturer has a system in place to evaluate suppliers.\n\n7.31 Supplier approval should include an evaluation that provides adequate evidence (e.g. past quality history) that the manufacturer can consistently", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS, en su secci\u00f3n sobre \"Recepci\u00f3n y Cuarentena\", establece directrices para la recepci\u00f3n de materiales cr\u00edticos en la producci\u00f3n. Se enfatiza la importancia de examinar visualmente los contenedores al recibirlos, asegurando que est\u00e9n correctamente etiquetados y libres de da\u00f1os o contaminaci\u00f3n. Los materiales deben ser mantenidos en cuarentena hasta que se realicen las pruebas necesarias. Adem\u00e1s, se abordan las medidas para evitar la contaminaci\u00f3n cruzada en entregas a granel y la necesidad de un sistema de identificaci\u00f3n para cada lote de materiales.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse al recibir materiales cr\u00edticos para garantizar su calidad y seguridad?**\n   - Al recibir materiales cr\u00edticos, cada contenedor debe ser examinado visualmente para verificar el etiquetado correcto, da\u00f1os, sellos rotos y evidencia de contaminaci\u00f3n. Los materiales deben mantenerse en cuarentena hasta que se realicen las pruebas adecuadas.\n\n2. **\u00bfQu\u00e9 medidas se pueden tomar para asegurar que no haya contaminaci\u00f3n cruzada en entregas a granel?**\n   - Para asegurar que no haya contaminaci\u00f3n cruzada en entregas a granel, se pueden utilizar certificados de limpieza, realizar pruebas para detectar impurezas residuales o llevar a cabo auditor\u00edas del proveedor.\n\n3. **\u00bfC\u00f3mo se debe identificar y registrar el estado de cada lote de materiales recibidos?**\n   - Cada contenedor o agrupaci\u00f3n de contenedores debe ser asignado e identificado con un c\u00f3digo distintivo, n\u00famero de lote o n\u00famero de recibo. Este n\u00famero debe ser utilizado para registrar la disposici\u00f3n de cada lote, y debe existir un sistema para identificar el estado de cada lote.", "prev_section_summary": "### Temas Clave:\n\n1. **Mantenimiento de Registros**:\n   - Importancia de mantener registros completos de modificaciones en m\u00e9todos anal\u00edticos, calibraciones de instrumentos, pruebas de estabilidad de APIs y resultados fuera de especificaci\u00f3n (OOS).\n\n2. **Revisi\u00f3n de Registros de Producci\u00f3n por Lotes**:\n   - Necesidad de establecer procedimientos escritos para la revisi\u00f3n y aprobaci\u00f3n de registros de producci\u00f3n y control de laboratorio antes de la liberaci\u00f3n de lotes.\n   - Diferenciaci\u00f3n entre registros de pasos cr\u00edticos (revisados por la unidad de calidad) y no cr\u00edticos (revisados por personal calificado).\n\n3. **Gesti\u00f3n de Materiales**:\n   - Procedimientos escritos requeridos para la gesti\u00f3n de materiales, incluyendo recepci\u00f3n, identificaci\u00f3n, almacenamiento y aprobaci\u00f3n.\n   - Evaluaci\u00f3n de proveedores de materiales cr\u00edticos y compra de materiales seg\u00fan especificaciones acordadas.\n\n### Entidades:\n\n- **Registros**: Modificaciones de m\u00e9todos anal\u00edticos, calibraciones, pruebas de estabilidad, investigaciones OOS.\n- **Unidades**: Unidad de calidad, personal de producci\u00f3n calificado.\n- **Materiales**: Intermediarios, APIs, materiales cr\u00edticos.\n- **Procedimientos**: Revisi\u00f3n y aprobaci\u00f3n de registros, gesti\u00f3n de materiales.", "excerpt_keywords": "Keywords: receipt, quarantine, contamination, supplier evaluation, batch identification"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "93d456ae-ce20-4c13-9bac-a33a18e1bad9", "node_type": "4", "metadata": {"page_label": "165", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 7.2 Receipt and Quarantine\n\n7.13 If the supplier of a critical material is not the manufacturer of that material, the name and address of that manufacturer should be known to the intermediate and/or API manufacturer.\n\n7.14 Changing the source of supply of critical raw materials should be done according to section 13, Change control.\n\n## Receipt and Quarantine\n\n7.20 Upon receipt and before acceptance, each container or grouping of containers of materials should be examined visually for correct labelling (including correlation between the name used by the supplier and the in-house name, if these are different), damage to containers, broken seals and evidence of tampering or contamination. Materials should be held under quarantine until they have been sampled, examined or tested as appropriate, and then released for use.\n\n7.21 Before incoming materials are mixed with existing stocks (e.g. solvents or stocks in silos), they should be identified as correct, tested, if appropriate, and released. Procedures should be available to prevent discharging incoming materials wrongly into the existing stock.\n\n7.22 If bulk deliveries are made in non-dedicated tankers, there should be assurance of no cross-contamination from the tanker. Means of providing this assurance could include one or more of the following:\n\n- certificate of cleaning;\n- testing for trace impurities;\n- audit of the supplier.\n\n7.23 Large storage containers, and their attendant manifolds, filling and discharge lines should be appropriately identified.\n\n7.24 Each container or grouping of containers (batches) of materials should be assigned and identified with a distinctive code, batch or receipt number. This number should be used in recording the disposition of each batch. A system should be in place to identify the status of each batch.\n\n# 7.3 Sampling and Testing of Incoming Production Materials\n\n7.30 At least one test to verify the identity of each batch of material should be conducted, with the exception of the materials described below in section 7.3.2. A supplier\u2019s certificate of analysis can be used in place of performing other tests, provided that the manufacturer has a system in place to evaluate suppliers.\n\n7.31 Supplier approval should include an evaluation that provides adequate evidence (e.g. past quality history) that the manufacturer can consistently", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "d4f76e73a59bb614e1fc5d90d305838d8b829d866ba751589168b827c0d0b005", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 7.2 Receipt and Quarantine\n\n7.13 If the supplier of a critical material is not the manufacturer of that material, the name and address of that manufacturer should be known to the intermediate and/or API manufacturer.\n\n7.14 Changing the source of supply of critical raw materials should be done according to section 13, Change control.\n\n## Receipt and Quarantine\n\n7.20 Upon receipt and before acceptance, each container or grouping of containers of materials should be examined visually for correct labelling (including correlation between the name used by the supplier and the in-house name, if these are different), damage to containers, broken seals and evidence of tampering or contamination. Materials should be held under quarantine until they have been sampled, examined or tested as appropriate, and then released for use.\n\n7.21 Before incoming materials are mixed with existing stocks (e.g. solvents or stocks in silos), they should be identified as correct, tested, if appropriate, and released. Procedures should be available to prevent discharging incoming materials wrongly into the existing stock.\n\n7.22 If bulk deliveries are made in non-dedicated tankers, there should be assurance of no cross-contamination from the tanker. Means of providing this assurance could include one or more of the following:\n\n- certificate of cleaning;\n- testing for trace impurities;\n- audit of the supplier.\n\n7.23 Large storage containers, and their attendant manifolds, filling and discharge lines should be appropriately identified.\n\n7.24 Each container or grouping of containers (batches) of materials should be assigned and identified with a distinctive code, batch or receipt number. This number should be used in recording the disposition of each batch. A system should be in place to identify the status of each batch.\n\n# 7.3 Sampling and Testing of Incoming Production Materials\n\n7.30 At least one test to verify the identity of each batch of material should be conducted, with the exception of the materials described below in section 7.3.2. A supplier\u2019s certificate of analysis can be used in place of performing other tests, provided that the manufacturer has a system in place to evaluate suppliers.\n\n7.31 Supplier approval should include an evaluation that provides adequate evidence (e.g. past quality history) that the manufacturer can consistently", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2360, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c9bc4427-5853-483d-9913-708c0a8c25c7": {"__data__": {"id_": "c9bc4427-5853-483d-9913-708c0a8c25c7", "embedding": null, "metadata": {"page_label": "166", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 7.32\n\nProcessing aids, hazardous or highly toxic raw materials, other special materials or materials transferred to another unit within the company\u2019s control do not need to be tested if the manufacturer\u2019s certificate of analysis is obtained, showing that these raw materials conform to established specifications. Visual examination of containers, labels and recording of batch numbers should help in establishing the identity of these materials. The lack of on-site testing for these materials should be justified and documented.\n\n# 7.33\n\nSamples should be representative of the batch of material from which they are taken. Sampling methods should specify the number of containers to be sampled, which part of the container to sample, and the amount of material to be taken from each container. The decision on the number of containers to sample and the sample size should be based upon a sampling plan that takes into consideration the criticality of the material, variability of the material, past quality history of the supplier and the quantity needed for analysis.\n\n# 7.34\n\nSampling should be conducted at defined locations and by procedures designed to prevent contamination of the material sampled and contamination of other materials.\n\n# 7.35\n\nContainers from which samples are withdrawn should be opened carefully and subsequently reclosed. They should be marked to indicate that a sample has been taken.\n\n## 7.4 Storage\n\n7.40 Materials should be handled and stored in such a manner as to prevent degradation, contamination and cross-contamination.\n\n7.41 Materials stored in fibre drums, bags or boxes should be stored off the floor and, when appropriate, suitably spaced to permit cleaning and inspection.\n\n7.42 Materials should be stored under conditions and for a period that will have no adverse affect on their quality and should normally be controlled so that the oldest stock is used first.\n\n7.43 Certain materials in suitable containers can be stored outdoors, provided identifying labels remain legible and containers are appropriately cleaned before opening and use.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Requisitos de prueba y an\u00e1lisis de materiales**: Los materiales de procesamiento, as\u00ed como los materiales peligrosos o altamente t\u00f3xicos, no necesitan ser probados si se cuenta con un certificado de an\u00e1lisis del fabricante que confirme que cumplen con las especificaciones establecidas. La identificaci\u00f3n de estos materiales se puede establecer mediante la inspecci\u00f3n visual de los envases y el registro de n\u00fameros de lote.\n\n2. **M\u00e9todos de muestreo**: El muestreo de materiales debe ser representativo del lote del cual se extraen. Los m\u00e9todos de muestreo deben detallar cu\u00e1ntos envases se muestrear\u00e1n, qu\u00e9 parte del envase se muestrear\u00e1 y la cantidad de material a tomar de cada envase. La planificaci\u00f3n del muestreo debe considerar la criticidad del material y la historia de calidad del proveedor.\n\n3. **Almacenamiento de materiales**: Los materiales deben ser manejados y almacenados de manera que se evite su degradaci\u00f3n y contaminaci\u00f3n. Deben ser almacenados en condiciones que no afecten su calidad y, en general, se debe seguir un sistema de \"primeras entradas, primeras salidas\" para su uso.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 justificaci\u00f3n se requiere si no se realiza una prueba in situ de los materiales peligrosos?**\n   - La falta de pruebas in situ debe ser justificada y documentada, y se debe contar con un certificado de an\u00e1lisis del fabricante que confirme que los materiales cumplen con las especificaciones establecidas.\n\n2. **\u00bfCu\u00e1les son los factores que deben considerarse al decidir el n\u00famero de envases a muestrear y el tama\u00f1o de la muestra?**\n   - La decisi\u00f3n debe basarse en un plan de muestreo que considere la criticidad del material, la variabilidad del material, la historia de calidad del proveedor y la cantidad necesaria para el an\u00e1lisis.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse para el almacenamiento de materiales en contenedores al aire libre?**\n   - Los materiales pueden ser almacenados al aire libre siempre que las etiquetas identificativas permanezcan legibles y los contenedores sean limpiados adecuadamente antes de abrirse y usarse.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Recepci\u00f3n de Materiales Cr\u00edticos:**\n   - Importancia de la inspecci\u00f3n visual de contenedores al recibir materiales.\n   - Verificaci\u00f3n del etiquetado correcto y la ausencia de da\u00f1os o contaminaci\u00f3n.\n   - Mantenimiento de los materiales en cuarentena hasta que se realicen las pruebas necesarias.\n\n2. **Prevenci\u00f3n de Contaminaci\u00f3n Cruzada:**\n   - Medidas a seguir para asegurar que no haya contaminaci\u00f3n cruzada en entregas a granel, como certificados de limpieza, pruebas de impurezas y auditor\u00edas de proveedores.\n\n3. **Identificaci\u00f3n y Registro de Lotes:**\n   - Asignaci\u00f3n de un c\u00f3digo distintivo, n\u00famero de lote o n\u00famero de recibo a cada contenedor o agrupaci\u00f3n de contenedores.\n   - Necesidad de un sistema para registrar y monitorear el estado de cada lote de materiales.\n\n4. **Control de Cambios:**\n   - Procedimientos para cambiar la fuente de suministro de materias primas cr\u00edticas, conforme a las directrices de control de cambios.\n\n5. **Muestreo y Pruebas:**\n   - Realizaci\u00f3n de al menos una prueba para verificar la identidad de cada lote de material.\n   - Uso de certificados de an\u00e1lisis del proveedor como alternativa a pruebas adicionales, siempre que exista un sistema de evaluaci\u00f3n de proveedores.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite las directrices.\n- **Materiales Cr\u00edticos:** Materias primas esenciales para la producci\u00f3n.\n- **Proveedores:** Entidades que suministran materiales, que pueden no ser los fabricantes.\n- **Contenedores:** Recipientes que almacenan los materiales recibidos.\n- **Lotes:** Agrupaciones de contenedores que deben ser identificadas y registradas.\n\nEste resumen destaca la importancia de los procedimientos de recepci\u00f3n y control de calidad en la gesti\u00f3n de materiales cr\u00edticos en la producci\u00f3n, as\u00ed como las medidas necesarias para garantizar la seguridad y la integridad de los productos.", "excerpt_keywords": "Keywords: sampling, storage, contamination, materials, analysis"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "80ebe34f-e926-40c2-8655-b12e58cee011", "node_type": "4", "metadata": {"page_label": "166", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 7.32\n\nProcessing aids, hazardous or highly toxic raw materials, other special materials or materials transferred to another unit within the company\u2019s control do not need to be tested if the manufacturer\u2019s certificate of analysis is obtained, showing that these raw materials conform to established specifications. Visual examination of containers, labels and recording of batch numbers should help in establishing the identity of these materials. The lack of on-site testing for these materials should be justified and documented.\n\n# 7.33\n\nSamples should be representative of the batch of material from which they are taken. Sampling methods should specify the number of containers to be sampled, which part of the container to sample, and the amount of material to be taken from each container. The decision on the number of containers to sample and the sample size should be based upon a sampling plan that takes into consideration the criticality of the material, variability of the material, past quality history of the supplier and the quantity needed for analysis.\n\n# 7.34\n\nSampling should be conducted at defined locations and by procedures designed to prevent contamination of the material sampled and contamination of other materials.\n\n# 7.35\n\nContainers from which samples are withdrawn should be opened carefully and subsequently reclosed. They should be marked to indicate that a sample has been taken.\n\n## 7.4 Storage\n\n7.40 Materials should be handled and stored in such a manner as to prevent degradation, contamination and cross-contamination.\n\n7.41 Materials stored in fibre drums, bags or boxes should be stored off the floor and, when appropriate, suitably spaced to permit cleaning and inspection.\n\n7.42 Materials should be stored under conditions and for a period that will have no adverse affect on their quality and should normally be controlled so that the oldest stock is used first.\n\n7.43 Certain materials in suitable containers can be stored outdoors, provided identifying labels remain legible and containers are appropriately cleaned before opening and use.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "61dc0f7e2341e88535de09fb69f7f398e5f7327c0b2ef3140e2ffcb68acee128", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 7.32\n\nProcessing aids, hazardous or highly toxic raw materials, other special materials or materials transferred to another unit within the company\u2019s control do not need to be tested if the manufacturer\u2019s certificate of analysis is obtained, showing that these raw materials conform to established specifications. Visual examination of containers, labels and recording of batch numbers should help in establishing the identity of these materials. The lack of on-site testing for these materials should be justified and documented.\n\n# 7.33\n\nSamples should be representative of the batch of material from which they are taken. Sampling methods should specify the number of containers to be sampled, which part of the container to sample, and the amount of material to be taken from each container. The decision on the number of containers to sample and the sample size should be based upon a sampling plan that takes into consideration the criticality of the material, variability of the material, past quality history of the supplier and the quantity needed for analysis.\n\n# 7.34\n\nSampling should be conducted at defined locations and by procedures designed to prevent contamination of the material sampled and contamination of other materials.\n\n# 7.35\n\nContainers from which samples are withdrawn should be opened carefully and subsequently reclosed. They should be marked to indicate that a sample has been taken.\n\n## 7.4 Storage\n\n7.40 Materials should be handled and stored in such a manner as to prevent degradation, contamination and cross-contamination.\n\n7.41 Materials stored in fibre drums, bags or boxes should be stored off the floor and, when appropriate, suitably spaced to permit cleaning and inspection.\n\n7.42 Materials should be stored under conditions and for a period that will have no adverse affect on their quality and should normally be controlled so that the oldest stock is used first.\n\n7.43 Certain materials in suitable containers can be stored outdoors, provided identifying labels remain legible and containers are appropriately cleaned before opening and use.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2088, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3896d26c-f419-4787-aa16-c4a8de8ba24d": {"__data__": {"id_": "3896d26c-f419-4787-aa16-c4a8de8ba24d", "embedding": null, "metadata": {"page_label": "167", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 7.5 Re-evaluation\n\n7.50 Materials should be re-evaluated as appropriate to determine their suitability for use (e.g. after prolonged storage or exposure to heat or humidity).\n\n# 8. Production and in-process controls\n\n## 8.1 Production operations\n\n8.10 Raw materials for manufacturing of intermediates and APIs should be weighed or measured under appropriate conditions that do not affect their suitability for use. Weighing and measuring devices should be of suitable accuracy for the intended use.\n\n8.11 If a material is subdivided for later use in production operations, the container receiving the material should be suitable and should be so identified that the following information is available:\n\n- material name and/or item code;\n- receiving or control number;\n- weight or measure of material in the new container; and\n- re-evaluation or retest date if appropriate.\n\n8.12 Critical weighing, measuring or subdividing operations should be witnessed or subjected to an equivalent control. Prior to use, production personnel should verify that the materials are those specified in the batch record for the intended intermediate or API.\n\n8.13 Other critical activities should be witnessed or subjected to an equivalent control.\n\n8.14 Actual yields should be compared with expected yields at designated steps in the production process. Expected yields with appropriate ranges should be established based on previous laboratory, pilot scale or manufacturing data. Deviations in yield associated with critical process steps should be investigated to determine their impact or potential impact on the resulting quality of affected batches.\n\n8.15 Any deviation should be documented and explained. Any critical deviation should be investigated.\n\n8.16 The processing status of major units of equipment should be indicated either on the individual units of equipment or by appropriate documentation, computer control systems or alternative means.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la re-evaluaci\u00f3n de materiales y los controles de producci\u00f3n en la fabricaci\u00f3n de intermediarios y principios activos (APIs). Se enfatiza la importancia de pesar y medir los materiales bajo condiciones adecuadas, la documentaci\u00f3n de la informaci\u00f3n relevante sobre los materiales, la verificaci\u00f3n de su idoneidad, y el control de las operaciones cr\u00edticas. Tambi\u00e9n se menciona la necesidad de comparar los rendimientos reales con los esperados y documentar cualquier desviaci\u00f3n en el proceso de producci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe estar disponible en el contenedor que recibe un material subdividido para su uso posterior en operaciones de producci\u00f3n?**\n   - La informaci\u00f3n que debe estar disponible incluye el nombre y/o c\u00f3digo del material, el n\u00famero de recepci\u00f3n o control, el peso o medida del material en el nuevo contenedor, y la fecha de re-evaluaci\u00f3n o rean\u00e1lisis si es apropiado.\n\n2. **\u00bfC\u00f3mo deben ser controladas las operaciones cr\u00edticas de pesaje, medici\u00f3n o subdivisi\u00f3n en el proceso de producci\u00f3n?**\n   - Estas operaciones deben ser presenciadas o sometidas a un control equivalente. Adem\u00e1s, el personal de producci\u00f3n debe verificar que los materiales sean los especificados en el registro de lote para el intermedio o API previsto.\n\n3. **\u00bfQu\u00e9 se debe hacer si se observa una desviaci\u00f3n en los rendimientos durante el proceso de producci\u00f3n?**\n   - Cualquier desviaci\u00f3n debe ser documentada y explicada. Las desviaciones cr\u00edticas deben ser investigadas para determinar su impacto o potencial impacto en la calidad de los lotes afectados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Requisitos de Prueba y An\u00e1lisis de Materiales**:\n   - Los materiales de procesamiento y los materiales peligrosos o altamente t\u00f3xicos no requieren pruebas si se cuenta con un certificado de an\u00e1lisis del fabricante.\n   - La identificaci\u00f3n de estos materiales se establece mediante la inspecci\u00f3n visual de envases y el registro de n\u00fameros de lote.\n   - La falta de pruebas in situ debe ser justificada y documentada.\n\n2. **M\u00e9todos de Muestreo**:\n   - Las muestras deben ser representativas del lote de material.\n   - Los m\u00e9todos de muestreo deben especificar:\n     - N\u00famero de envases a muestrear.\n     - Parte del envase a muestrear.\n     - Cantidad de material a tomar de cada envase.\n   - La planificaci\u00f3n del muestreo debe considerar:\n     - Criticidad del material.\n     - Variabilidad del material.\n     - Historia de calidad del proveedor.\n     - Cantidad necesaria para an\u00e1lisis.\n\n3. **Almacenamiento de Materiales**:\n   - Los materiales deben ser manejados y almacenados para prevenir degradaci\u00f3n y contaminaci\u00f3n.\n   - Deben ser almacenados en condiciones que no afecten su calidad, siguiendo un sistema de \"primeras entradas, primeras salidas\".\n   - Materiales en contenedores adecuados pueden ser almacenados al aire libre, siempre que las etiquetas sean legibles y los contenedores est\u00e9n limpios antes de su uso.\n\n### Entidades Clave:\n- **Materiales**: Procesamiento, peligrosos, altamente t\u00f3xicos, especiales.\n- **Documentaci\u00f3n**: Certificado de an\u00e1lisis, registro de n\u00fameros de lote.\n- **Muestreo**: M\u00e9todos, representatividad, planificaci\u00f3n.\n- **Almacenamiento**: Condiciones, limpieza, etiquetado.", "excerpt_keywords": "Keywords: re-evaluation, production controls, raw materials, critical operations, yield comparison"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "60d8a618-1859-45ff-a741-589a8144b3e4", "node_type": "4", "metadata": {"page_label": "167", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 7.5 Re-evaluation\n\n7.50 Materials should be re-evaluated as appropriate to determine their suitability for use (e.g. after prolonged storage or exposure to heat or humidity).\n\n# 8. Production and in-process controls\n\n## 8.1 Production operations\n\n8.10 Raw materials for manufacturing of intermediates and APIs should be weighed or measured under appropriate conditions that do not affect their suitability for use. Weighing and measuring devices should be of suitable accuracy for the intended use.\n\n8.11 If a material is subdivided for later use in production operations, the container receiving the material should be suitable and should be so identified that the following information is available:\n\n- material name and/or item code;\n- receiving or control number;\n- weight or measure of material in the new container; and\n- re-evaluation or retest date if appropriate.\n\n8.12 Critical weighing, measuring or subdividing operations should be witnessed or subjected to an equivalent control. Prior to use, production personnel should verify that the materials are those specified in the batch record for the intended intermediate or API.\n\n8.13 Other critical activities should be witnessed or subjected to an equivalent control.\n\n8.14 Actual yields should be compared with expected yields at designated steps in the production process. Expected yields with appropriate ranges should be established based on previous laboratory, pilot scale or manufacturing data. Deviations in yield associated with critical process steps should be investigated to determine their impact or potential impact on the resulting quality of affected batches.\n\n8.15 Any deviation should be documented and explained. Any critical deviation should be investigated.\n\n8.16 The processing status of major units of equipment should be indicated either on the individual units of equipment or by appropriate documentation, computer control systems or alternative means.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b6993070c0268b6e9c04bef91fcd17d026f051b75564d6d8e43d0c90444b36b0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 7.5 Re-evaluation\n\n7.50 Materials should be re-evaluated as appropriate to determine their suitability for use (e.g. after prolonged storage or exposure to heat or humidity).\n\n# 8. Production and in-process controls\n\n## 8.1 Production operations\n\n8.10 Raw materials for manufacturing of intermediates and APIs should be weighed or measured under appropriate conditions that do not affect their suitability for use. Weighing and measuring devices should be of suitable accuracy for the intended use.\n\n8.11 If a material is subdivided for later use in production operations, the container receiving the material should be suitable and should be so identified that the following information is available:\n\n- material name and/or item code;\n- receiving or control number;\n- weight or measure of material in the new container; and\n- re-evaluation or retest date if appropriate.\n\n8.12 Critical weighing, measuring or subdividing operations should be witnessed or subjected to an equivalent control. Prior to use, production personnel should verify that the materials are those specified in the batch record for the intended intermediate or API.\n\n8.13 Other critical activities should be witnessed or subjected to an equivalent control.\n\n8.14 Actual yields should be compared with expected yields at designated steps in the production process. Expected yields with appropriate ranges should be established based on previous laboratory, pilot scale or manufacturing data. Deviations in yield associated with critical process steps should be investigated to determine their impact or potential impact on the resulting quality of affected batches.\n\n8.15 Any deviation should be documented and explained. Any critical deviation should be investigated.\n\n8.16 The processing status of major units of equipment should be indicated either on the individual units of equipment or by appropriate documentation, computer control systems or alternative means.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1942, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e0103ddc-0001-49fb-b787-c90dad74226f": {"__data__": {"id_": "e0103ddc-0001-49fb-b787-c90dad74226f", "embedding": null, "metadata": {"page_label": "168", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 8.2 Time limits\n\n8.20 If time limits are specified in the master production instruction (see section 6.41), these time limits should be met to ensure the quality of intermediates and APIs. Deviations should be documented and evaluated. Time limits may be inappropriate when processing to a target value (e.g. pH adjustment, hydrogenation or drying to a predetermined specification) because completion of reactions or processing steps are determined by in-process sampling and testing.\n\n8.21 Intermediates held for further processing should be stored under appropriate conditions to ensure their suitability for use.\n\n# 8.3 In-process sampling and controls\n\n8.30 Written procedures should be established to monitor the progress and control the performance of processing steps that cause variability in the quality characteristics of intermediates and APIs. In-process controls and their acceptance criteria should be defined based on the information gained during the development stage or historical data.\n\n8.31 The acceptance criteria and type and extent of testing can depend on the nature of the intermediate or API being manufactured, the reaction or process step being conducted and the degree to which the process introduces variability in the product\u2019s quality. Less stringent in-process controls may be appropriate in early processing steps, whereas tighter controls may be appropriate for later processing steps (e.g. isolation and purification steps).\n\n8.32 Critical in-process controls (and critical process monitoring), including the control points and methods, should be stated in writing and approved by the quality unit(s).\n\n8.33 In-process controls can be performed by qualified production department personnel and the process adjusted without prior quality unit(s)\u2019 approval if the adjustments are made within pre-established limits approved by the quality unit(s). All tests and results should be fully documented as part of the batch record.\n\n8.34 Written procedures should describe the sampling methods for in-process materials, intermediates and APIs. Sampling plans and procedures should be based on scientifically sound sampling practices.\n\n8.35 In-process sampling should be conducted using procedures designed to prevent contamination of the sampled material and other intermediates or", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto circundante\n\n1. **Control de Calidad en la Producci\u00f3n de Intermediarios y APIs**: El documento establece directrices sobre la importancia de cumplir con los l\u00edmites de tiempo especificados en las instrucciones de producci\u00f3n para asegurar la calidad de los intermediarios y los principios activos (APIs). Tambi\u00e9n se discute la necesidad de almacenar adecuadamente los intermediarios y de realizar controles en proceso para monitorear y ajustar la calidad del producto.\n\n2. **Procedimientos de Muestreo y Control en Proceso**: Se enfatiza la necesidad de establecer procedimientos escritos para el muestreo y control de calidad durante la producci\u00f3n. Estos procedimientos deben basarse en datos hist\u00f3ricos y deben ser aprobados por unidades de calidad. Adem\u00e1s, se menciona que los controles en proceso pueden ser realizados por personal calificado, siempre que se mantengan dentro de l\u00edmites preestablecidos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar al establecer los l\u00edmites de tiempo en las instrucciones de producci\u00f3n para intermediarios y APIs?**\n   - La respuesta a esta pregunta se puede encontrar en la secci\u00f3n 8.20, donde se menciona que los l\u00edmites de tiempo deben ser cumplidos para asegurar la calidad, y que las desviaciones deben ser documentadas y evaluadas.\n\n2. **\u00bfC\u00f3mo se determina la naturaleza y el alcance de los controles en proceso para un API espec\u00edfico?**\n   - La secci\u00f3n 8.31 proporciona informaci\u00f3n sobre c\u00f3mo los criterios de aceptaci\u00f3n y el tipo de pruebas dependen de la naturaleza del API, el paso del proceso y el grado de variabilidad introducido por el proceso.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse para el muestreo de materiales en proceso y c\u00f3mo se asegura que no haya contaminaci\u00f3n?**\n   - La secci\u00f3n 8.34 y 8.35 abordan la necesidad de tener procedimientos escritos que describan los m\u00e9todos de muestreo y c\u00f3mo estos deben ser dise\u00f1ados para prevenir la contaminaci\u00f3n del material muestreado y otros intermediarios.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### Temas Clave:\n1. **Re-evaluaci\u00f3n de Materiales**:\n   - Importancia de re-evaluar materiales para determinar su idoneidad para el uso, especialmente despu\u00e9s de almacenamiento prolongado o exposici\u00f3n a condiciones adversas (calor, humedad).\n\n2. **Controles de Producci\u00f3n**:\n   - **Pesaje y Medici\u00f3n**: Los materiales crudos deben ser pesados o medidos bajo condiciones adecuadas, utilizando dispositivos de precisi\u00f3n apropiados.\n   - **Documentaci\u00f3n de Materiales**: Los contenedores que reciben materiales subdivididos deben estar debidamente identificados y contener informaci\u00f3n relevante como nombre del material, n\u00famero de control, peso y fecha de re-evaluaci\u00f3n.\n   - **Control de Operaciones Cr\u00edticas**: Las operaciones cr\u00edticas deben ser presenciadas o controladas de manera equivalente, y el personal debe verificar la conformidad de los materiales con los registros de lote.\n   - **Comparaci\u00f3n de Rendimientos**: Se deben comparar los rendimientos reales con los esperados en etapas designadas del proceso de producci\u00f3n, investigando desviaciones cr\u00edticas.\n   - **Documentaci\u00f3n de Desviaciones**: Cualquier desviaci\u00f3n en el proceso debe ser documentada y explicada, con investigaciones para desviaciones cr\u00edticas.\n\n3. **Estado de Procesamiento de Equipos**:\n   - El estado de procesamiento de los equipos principales debe ser indicado en los propios equipos o mediante documentaci\u00f3n adecuada.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Materiales Crudos**: Sustancias utilizadas en la fabricaci\u00f3n de intermediarios y principios activos (APIs).\n- **Intermediarios y APIs**: Productos farmac\u00e9uticos en proceso de fabricaci\u00f3n.\n- **Personal de Producci\u00f3n**: Empleados responsables de verificar y controlar los materiales y procesos.\n- **Contenedores**: Recipientes utilizados para almacenar materiales subdivididos.\n- **Dispositivos de Pesaje y Medici\u00f3n**: Herramientas utilizadas para asegurar la precisi\u00f3n en la medici\u00f3n de materiales.\n\nEste resumen destaca la importancia de la re-evaluaci\u00f3n y el control riguroso en la producci\u00f3n farmac\u00e9utica para garantizar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: time limits, in-process controls, quality assurance, sampling procedures, intermediates"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fc4fe7d1-e586-4723-bf5b-263abf796d0a", "node_type": "4", "metadata": {"page_label": "168", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 8.2 Time limits\n\n8.20 If time limits are specified in the master production instruction (see section 6.41), these time limits should be met to ensure the quality of intermediates and APIs. Deviations should be documented and evaluated. Time limits may be inappropriate when processing to a target value (e.g. pH adjustment, hydrogenation or drying to a predetermined specification) because completion of reactions or processing steps are determined by in-process sampling and testing.\n\n8.21 Intermediates held for further processing should be stored under appropriate conditions to ensure their suitability for use.\n\n# 8.3 In-process sampling and controls\n\n8.30 Written procedures should be established to monitor the progress and control the performance of processing steps that cause variability in the quality characteristics of intermediates and APIs. In-process controls and their acceptance criteria should be defined based on the information gained during the development stage or historical data.\n\n8.31 The acceptance criteria and type and extent of testing can depend on the nature of the intermediate or API being manufactured, the reaction or process step being conducted and the degree to which the process introduces variability in the product\u2019s quality. Less stringent in-process controls may be appropriate in early processing steps, whereas tighter controls may be appropriate for later processing steps (e.g. isolation and purification steps).\n\n8.32 Critical in-process controls (and critical process monitoring), including the control points and methods, should be stated in writing and approved by the quality unit(s).\n\n8.33 In-process controls can be performed by qualified production department personnel and the process adjusted without prior quality unit(s)\u2019 approval if the adjustments are made within pre-established limits approved by the quality unit(s). All tests and results should be fully documented as part of the batch record.\n\n8.34 Written procedures should describe the sampling methods for in-process materials, intermediates and APIs. Sampling plans and procedures should be based on scientifically sound sampling practices.\n\n8.35 In-process sampling should be conducted using procedures designed to prevent contamination of the sampled material and other intermediates or", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "809a72e1be118a05a4eb07c3b86d2d0e7d7aa5e125d5c8f60aec64263ebd8c2e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 8.2 Time limits\n\n8.20 If time limits are specified in the master production instruction (see section 6.41), these time limits should be met to ensure the quality of intermediates and APIs. Deviations should be documented and evaluated. Time limits may be inappropriate when processing to a target value (e.g. pH adjustment, hydrogenation or drying to a predetermined specification) because completion of reactions or processing steps are determined by in-process sampling and testing.\n\n8.21 Intermediates held for further processing should be stored under appropriate conditions to ensure their suitability for use.\n\n# 8.3 In-process sampling and controls\n\n8.30 Written procedures should be established to monitor the progress and control the performance of processing steps that cause variability in the quality characteristics of intermediates and APIs. In-process controls and their acceptance criteria should be defined based on the information gained during the development stage or historical data.\n\n8.31 The acceptance criteria and type and extent of testing can depend on the nature of the intermediate or API being manufactured, the reaction or process step being conducted and the degree to which the process introduces variability in the product\u2019s quality. Less stringent in-process controls may be appropriate in early processing steps, whereas tighter controls may be appropriate for later processing steps (e.g. isolation and purification steps).\n\n8.32 Critical in-process controls (and critical process monitoring), including the control points and methods, should be stated in writing and approved by the quality unit(s).\n\n8.33 In-process controls can be performed by qualified production department personnel and the process adjusted without prior quality unit(s)\u2019 approval if the adjustments are made within pre-established limits approved by the quality unit(s). All tests and results should be fully documented as part of the batch record.\n\n8.34 Written procedures should describe the sampling methods for in-process materials, intermediates and APIs. Sampling plans and procedures should be based on scientifically sound sampling practices.\n\n8.35 In-process sampling should be conducted using procedures designed to prevent contamination of the sampled material and other intermediates or", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2311, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7e372e0b-bb0f-4c0f-ab44-4d243f81fdc5": {"__data__": {"id_": "7e372e0b-bb0f-4c0f-ab44-4d243f81fdc5", "embedding": null, "metadata": {"page_label": "169", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Blending Batches of Intermediates or APIs\n\n8.40 For the purpose of this document, blending is defined as the process of combining materials within the same specification to produce a homogeneous intermediate or API. In-process mixing of fractions from single batches (e.g., collecting several centrifuge loads from a single crystallization batch) or combining fractions from several batches for further processing is considered to be part of the production process and is not considered to be blending.\n\n8.41 OOS batches should not be blended with other batches for the purpose of meeting specifications. Each batch incorporated into the blend should have been manufactured using an established process and should have been individually tested and found to meet appropriate specifications prior to blending.\n\n8.42 Acceptable blending operations include but are not limited to:\n\n- Blending of small batches to increase batch size;\n- Blending of tailings (i.e., relatively small quantities of isolated material) from batches of the same intermediate or API to form a single batch.\n\n8.43 Blending processes should be adequately controlled and documented and the blended batch should be tested for conformance to established specifications where appropriate.\n\n8.44 The batch record of the blending process should allow traceability back to the individual batches that make up the blend.\n\n8.45 Where physical attributes of the API are critical (e.g., APIs intended for use in solid oral dosage forms or suspensions), blending operations should be validated to show homogeneity of the combined batch. Validation should include testing of critical attributes (e.g., particle size distribution, bulk density and tap density) that may be affected by the blending process.\n\n8.46 If the blending could adversely affect stability, stability testing of the final blended batches should be performed.\n\n8.47 The expiry or retest date of the blended batch should be based on the manufacturing date of the oldest tailings or batch in the blend.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Definici\u00f3n de Blending**: El blending se refiere al proceso de combinar materiales que cumplen con las mismas especificaciones para producir un intermedio o API homog\u00e9neo. No incluye la mezcla de fracciones de un solo lote o la combinaci\u00f3n de fracciones de varios lotes para procesamiento adicional.\n\n2. **Requisitos para Lotes OOS**: Los lotes fuera de especificaci\u00f3n (OOS) no deben ser mezclados con otros lotes para cumplir con las especificaciones. Cada lote que se incorpora a la mezcla debe haber sido fabricado bajo un proceso establecido y haber sido probado individualmente.\n\n3. **Control y Documentaci\u00f3n**: Las operaciones de blending deben ser controladas y documentadas adecuadamente, y el lote mezclado debe ser probado para asegurar que cumple con las especificaciones establecidas. Adem\u00e1s, se debe permitir la trazabilidad de los lotes individuales que componen la mezcla.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben cumplirse para que un lote OOS no sea mezclado con otros lotes?**\n   - Los lotes OOS no deben ser mezclados con otros lotes para cumplir con las especificaciones. Cada lote incorporado a la mezcla debe haber sido fabricado utilizando un proceso establecido y debe haber sido probado individualmente para cumplir con las especificaciones apropiadas antes de la mezcla.\n\n2. **\u00bfQu\u00e9 tipo de pruebas se deben realizar para validar las operaciones de blending de APIs cr\u00edticos?**\n   - Las operaciones de blending deben ser validadas para demostrar la homogeneidad del lote combinado. Esto incluye pruebas de atributos cr\u00edticos como la distribuci\u00f3n del tama\u00f1o de part\u00edculas, la densidad a granel y la densidad de tapado, que pueden verse afectadas por el proceso de blending.\n\n3. **\u00bfC\u00f3mo se determina la fecha de caducidad o rean\u00e1lisis de un lote mezclado?**\n   - La fecha de caducidad o rean\u00e1lisis del lote mezclado debe basarse en la fecha de fabricaci\u00f3n del material m\u00e1s antiguo (tailings o lote) que forma parte de la mezcla.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n\n\n#### Temas Clave:\n\n1. **L\u00edmites de Tiempo en la Producci\u00f3n**:\n   - Importancia de cumplir con los l\u00edmites de tiempo especificados en las instrucciones de producci\u00f3n para garantizar la calidad de los intermediarios y APIs.\n   - Necesidad de documentar y evaluar cualquier desviaci\u00f3n de estos l\u00edmites.\n   - Consideraciones sobre la inadecuaci\u00f3n de los l\u00edmites de tiempo en procesos que requieren ajustes a valores espec\u00edficos (pH, hidrogenaci\u00f3n, secado).\n\n2. **Almacenamiento de Intermediarios**:\n   - Los intermediarios deben ser almacenados bajo condiciones adecuadas para asegurar su idoneidad para el uso posterior.\n\n3. **Muestreo y Control en Proceso**:\n   - Establecimiento de procedimientos escritos para monitorear y controlar los pasos de procesamiento que afectan la calidad de intermediarios y APIs.\n   - Definici\u00f3n de criterios de aceptaci\u00f3n y tipo de pruebas basadas en datos hist\u00f3ricos y la naturaleza del producto.\n   - Diferenciaci\u00f3n en la rigurosidad de los controles en proceso seg\u00fan la etapa del procesamiento.\n\n4. **Controles Cr\u00edticos en Proceso**:\n   - Necesidad de documentar y aprobar por parte de la unidad de calidad los controles cr\u00edticos y m\u00e9todos de monitoreo.\n\n5. **Procedimientos de Muestreo**:\n   - Descripci\u00f3n de m\u00e9todos de muestreo para materiales en proceso, intermediarios y APIs, basados en pr\u00e1cticas cient\u00edficas s\u00f3lidas.\n   - Importancia de prevenir la contaminaci\u00f3n durante el muestreo.\n\n#### Entidades:\n\n- **Intermediarios**: Sustancias qu\u00edmicas producidas durante la fabricaci\u00f3n de APIs.\n- **APIs (Principios Activos)**: Sustancias que tienen un efecto farmacol\u00f3gico y son el componente activo de un medicamento.\n- **Unidad de Calidad**: Departamento responsable de asegurar que los procesos y productos cumplan con los est\u00e1ndares de calidad.\n- **Personal Calificado**: Empleados capacitados para realizar controles en proceso y ajustes necesarios dentro de l\u00edmites preestablecidos.\n- **Documentaci\u00f3n**: Registros que deben ser mantenidos para todas las pruebas y resultados como parte del proceso de producci\u00f3n.\n\nEste resumen destaca la importancia de los l\u00edmites de tiempo, el almacenamiento adecuado, los controles en proceso y los procedimientos de muestreo para asegurar la calidad en la producci\u00f3n de intermediarios y APIs.", "excerpt_keywords": "Keywords: blending, intermediates, APIs, specifications, quality control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "263bba47-3203-470f-a5a4-a5caa6beba24", "node_type": "4", "metadata": {"page_label": "169", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Blending Batches of Intermediates or APIs\n\n8.40 For the purpose of this document, blending is defined as the process of combining materials within the same specification to produce a homogeneous intermediate or API. In-process mixing of fractions from single batches (e.g., collecting several centrifuge loads from a single crystallization batch) or combining fractions from several batches for further processing is considered to be part of the production process and is not considered to be blending.\n\n8.41 OOS batches should not be blended with other batches for the purpose of meeting specifications. Each batch incorporated into the blend should have been manufactured using an established process and should have been individually tested and found to meet appropriate specifications prior to blending.\n\n8.42 Acceptable blending operations include but are not limited to:\n\n- Blending of small batches to increase batch size;\n- Blending of tailings (i.e., relatively small quantities of isolated material) from batches of the same intermediate or API to form a single batch.\n\n8.43 Blending processes should be adequately controlled and documented and the blended batch should be tested for conformance to established specifications where appropriate.\n\n8.44 The batch record of the blending process should allow traceability back to the individual batches that make up the blend.\n\n8.45 Where physical attributes of the API are critical (e.g., APIs intended for use in solid oral dosage forms or suspensions), blending operations should be validated to show homogeneity of the combined batch. Validation should include testing of critical attributes (e.g., particle size distribution, bulk density and tap density) that may be affected by the blending process.\n\n8.46 If the blending could adversely affect stability, stability testing of the final blended batches should be performed.\n\n8.47 The expiry or retest date of the blended batch should be based on the manufacturing date of the oldest tailings or batch in the blend.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "3b05e49a9c6146a784a72c6ad526def5cf3a67952b97e0025274943ffb4cd108", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Blending Batches of Intermediates or APIs\n\n8.40 For the purpose of this document, blending is defined as the process of combining materials within the same specification to produce a homogeneous intermediate or API. In-process mixing of fractions from single batches (e.g., collecting several centrifuge loads from a single crystallization batch) or combining fractions from several batches for further processing is considered to be part of the production process and is not considered to be blending.\n\n8.41 OOS batches should not be blended with other batches for the purpose of meeting specifications. Each batch incorporated into the blend should have been manufactured using an established process and should have been individually tested and found to meet appropriate specifications prior to blending.\n\n8.42 Acceptable blending operations include but are not limited to:\n\n- Blending of small batches to increase batch size;\n- Blending of tailings (i.e., relatively small quantities of isolated material) from batches of the same intermediate or API to form a single batch.\n\n8.43 Blending processes should be adequately controlled and documented and the blended batch should be tested for conformance to established specifications where appropriate.\n\n8.44 The batch record of the blending process should allow traceability back to the individual batches that make up the blend.\n\n8.45 Where physical attributes of the API are critical (e.g., APIs intended for use in solid oral dosage forms or suspensions), blending operations should be validated to show homogeneity of the combined batch. Validation should include testing of critical attributes (e.g., particle size distribution, bulk density and tap density) that may be affected by the blending process.\n\n8.46 If the blending could adversely affect stability, stability testing of the final blended batches should be performed.\n\n8.47 The expiry or retest date of the blended batch should be based on the manufacturing date of the oldest tailings or batch in the blend.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2029, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "fa42c770-159b-402f-9b88-94824a8901d6": {"__data__": {"id_": "fa42c770-159b-402f-9b88-94824a8901d6", "embedding": null, "metadata": {"page_label": "170", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 8.5 Contamination control\n\n8.50 Residual materials can be carried over into successive batches of the same intermediate or API if there is adequate control. Examples include residue adhering to the wall of a micronizer, residual layer of damp crystals remaining in a centrifuge bowl after discharge and incomplete discharge of fluids or crystals from a processing vessel upon transfer of the material to the next step in the process. Such carry-over should not result in the carry-over of degradants or microbial contamination that may adversely alter the established impurity profile of the API.\n\n8.51 Production operations should be conducted in a manner that will prevent contamination of intermediates or APIs by other materials.\n\n8.52 Precautions to avoid contamination should be taken when APIs are handled after purification.\n\n# 9. Packaging and identification labelling of APIs and intermediates\n\n## 9.1 General\n\n9.10 There should be written procedures describing the receipt, identification, quarantine, sampling, examination and/or testing and release and handling of packaging and labelling materials.\n\n9.11 Packaging and labelling materials should conform to established specifications. Those that do not comply with such specifications should be rejected to prevent their use in operations for which they are unsuitable.\n\n9.12 Records should be maintained for each shipment of labels and packaging materials showing receipt, examination, or testing and whether they are accepted or rejected.\n\n## 9.2 Packaging materials\n\n9.20 Containers should provide adequate protection against deterioration or contamination of the intermediate or API that may occur during transportation and recommended storage.\n\n9.21 Containers should be clean and, where indicated by the nature of the intermediate or API, sanitized to ensure that they are suitable for their intended use. These containers should not be reactive, additive or absorptive to ensure that they do not alter the quality of the intermediate or API beyond the specified limits.\n\n9.22 If containers are reused, they should be cleaned in accordance with documented procedures and all previous labels should be removed or defaced.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en su Informe T\u00e9cnico 957 aborda el control de la contaminaci\u00f3n en la producci\u00f3n de intermediarios y principios activos (API). Se enfatiza la importancia de evitar la contaminaci\u00f3n cruzada entre lotes y de manejar adecuadamente los materiales de embalaje y etiquetado. Se establecen procedimientos escritos para la recepci\u00f3n, identificaci\u00f3n y manejo de estos materiales, as\u00ed como requisitos para la limpieza y sanitizaci\u00f3n de los contenedores utilizados para el almacenamiento y transporte de los API.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 medidas espec\u00edficas se deben tomar para evitar la contaminaci\u00f3n de los intermediarios o API durante la producci\u00f3n?**\n   - Respuesta: Las operaciones de producci\u00f3n deben llevarse a cabo de manera que se prevenga la contaminaci\u00f3n de los intermediarios o API por otros materiales. Adem\u00e1s, se deben tomar precauciones al manejar los API despu\u00e9s de la purificaci\u00f3n.\n\n2. **\u00bfCu\u00e1les son los requisitos para los materiales de embalaje y etiquetado de los API seg\u00fan el documento?**\n   - Respuesta: Los materiales de embalaje y etiquetado deben cumplir con especificaciones establecidas y aquellos que no lo hagan deben ser rechazados. Tambi\u00e9n se deben mantener registros de cada env\u00edo de materiales, mostrando su recepci\u00f3n, examen, pruebas y aceptaci\u00f3n o rechazo.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse si se reutilizan los contenedores para el almacenamiento de intermediarios o API?**\n   - Respuesta: Si los contenedores son reutilizados, deben limpiarse de acuerdo con procedimientos documentados y todas las etiquetas anteriores deben ser eliminadas o desfiguradas para evitar confusiones y asegurar la integridad del contenido.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Definici\u00f3n de Blending**:\n   - El blending se refiere a la combinaci\u00f3n de materiales que cumplen con las mismas especificaciones para crear un intermedio o API homog\u00e9neo. No incluye la mezcla de fracciones de un solo lote ni la combinaci\u00f3n de fracciones de varios lotes para procesamiento adicional.\n\n2. **Lotes Fuera de Especificaci\u00f3n (OOS)**:\n   - Los lotes OOS no deben ser mezclados con otros lotes para cumplir con las especificaciones. Cada lote en la mezcla debe haber sido fabricado bajo un proceso establecido y probado individualmente.\n\n3. **Operaciones de Blending Aceptables**:\n   - Mezcla de peque\u00f1os lotes para aumentar el tama\u00f1o del lote.\n   - Mezcla de tailings de lotes del mismo intermedio o API para formar un solo lote.\n\n4. **Control y Documentaci\u00f3n**:\n   - Las operaciones de blending deben ser controladas y documentadas adecuadamente. El lote mezclado debe ser probado para asegurar su conformidad con las especificaciones establecidas.\n\n5. **Trazabilidad**:\n   - Se debe permitir la trazabilidad de los lotes individuales que componen la mezcla.\n\n6. **Validaci\u00f3n de Blending**:\n   - Para APIs cr\u00edticos, las operaciones de blending deben ser validadas para demostrar la homogeneidad del lote combinado. Esto incluye pruebas de atributos cr\u00edticos como la distribuci\u00f3n del tama\u00f1o de part\u00edculas y densidades.\n\n7. **Pruebas de Estabilidad**:\n   - Si el blending puede afectar la estabilidad, se deben realizar pruebas de estabilidad en los lotes mezclados finales.\n\n8. **Fecha de Caducidad o Rean\u00e1lisis**:\n   - La fecha de caducidad o rean\u00e1lisis del lote mezclado debe basarse en la fecha de fabricaci\u00f3n del material m\u00e1s antiguo en la mezcla.\n\n### Entidades Clave:\n- **Blending**: Proceso de combinaci\u00f3n de materiales.\n- **Intermedios y APIs**: Productos farmac\u00e9uticos intermedios y principios activos.\n- **Lotes OOS**: Lotes fuera de especificaci\u00f3n.\n- **Tailings**: Cantidades peque\u00f1as de material aislado de lotes.\n- **Atributos Cr\u00edticos**: Caracter\u00edsticas f\u00edsicas que deben ser probadas para asegurar la calidad del producto.", "excerpt_keywords": "Keywords: contamination control, APIs, packaging materials, production operations, labeling procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "585aedb8-65d6-45a1-9130-ad267b5d14fb", "node_type": "4", "metadata": {"page_label": "170", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 8.5 Contamination control\n\n8.50 Residual materials can be carried over into successive batches of the same intermediate or API if there is adequate control. Examples include residue adhering to the wall of a micronizer, residual layer of damp crystals remaining in a centrifuge bowl after discharge and incomplete discharge of fluids or crystals from a processing vessel upon transfer of the material to the next step in the process. Such carry-over should not result in the carry-over of degradants or microbial contamination that may adversely alter the established impurity profile of the API.\n\n8.51 Production operations should be conducted in a manner that will prevent contamination of intermediates or APIs by other materials.\n\n8.52 Precautions to avoid contamination should be taken when APIs are handled after purification.\n\n# 9. Packaging and identification labelling of APIs and intermediates\n\n## 9.1 General\n\n9.10 There should be written procedures describing the receipt, identification, quarantine, sampling, examination and/or testing and release and handling of packaging and labelling materials.\n\n9.11 Packaging and labelling materials should conform to established specifications. Those that do not comply with such specifications should be rejected to prevent their use in operations for which they are unsuitable.\n\n9.12 Records should be maintained for each shipment of labels and packaging materials showing receipt, examination, or testing and whether they are accepted or rejected.\n\n## 9.2 Packaging materials\n\n9.20 Containers should provide adequate protection against deterioration or contamination of the intermediate or API that may occur during transportation and recommended storage.\n\n9.21 Containers should be clean and, where indicated by the nature of the intermediate or API, sanitized to ensure that they are suitable for their intended use. These containers should not be reactive, additive or absorptive to ensure that they do not alter the quality of the intermediate or API beyond the specified limits.\n\n9.22 If containers are reused, they should be cleaned in accordance with documented procedures and all previous labels should be removed or defaced.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "9cee7cc6e17db50c92db9c28121dfef0787f4bb5ac0ea55a3dc97fe2c18d5094", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 8.5 Contamination control\n\n8.50 Residual materials can be carried over into successive batches of the same intermediate or API if there is adequate control. Examples include residue adhering to the wall of a micronizer, residual layer of damp crystals remaining in a centrifuge bowl after discharge and incomplete discharge of fluids or crystals from a processing vessel upon transfer of the material to the next step in the process. Such carry-over should not result in the carry-over of degradants or microbial contamination that may adversely alter the established impurity profile of the API.\n\n8.51 Production operations should be conducted in a manner that will prevent contamination of intermediates or APIs by other materials.\n\n8.52 Precautions to avoid contamination should be taken when APIs are handled after purification.\n\n# 9. Packaging and identification labelling of APIs and intermediates\n\n## 9.1 General\n\n9.10 There should be written procedures describing the receipt, identification, quarantine, sampling, examination and/or testing and release and handling of packaging and labelling materials.\n\n9.11 Packaging and labelling materials should conform to established specifications. Those that do not comply with such specifications should be rejected to prevent their use in operations for which they are unsuitable.\n\n9.12 Records should be maintained for each shipment of labels and packaging materials showing receipt, examination, or testing and whether they are accepted or rejected.\n\n## 9.2 Packaging materials\n\n9.20 Containers should provide adequate protection against deterioration or contamination of the intermediate or API that may occur during transportation and recommended storage.\n\n9.21 Containers should be clean and, where indicated by the nature of the intermediate or API, sanitized to ensure that they are suitable for their intended use. These containers should not be reactive, additive or absorptive to ensure that they do not alter the quality of the intermediate or API beyond the specified limits.\n\n9.22 If containers are reused, they should be cleaned in accordance with documented procedures and all previous labels should be removed or defaced.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2192, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f1099729-2439-432b-a2c4-b80aa18f3785": {"__data__": {"id_": "f1099729-2439-432b-a2c4-b80aa18f3785", "embedding": null, "metadata": {"page_label": "171", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9.3 Label issuance and control\n\n9.30 Access to the label storage areas should be limited to authorized personnel.\n\n9.31 Procedures should be used to reconcile the quantities of labels issued, used and returned and to evaluate discrepancies found between the number of containers labelled and the number of labels issued. Such discrepancies should be investigated and the investigation should be approved by the quality unit(s).\n\n9.32 All excess labels bearing batch numbers or other batch-related printing should be destroyed. Returned labels should be retained and stored in a manner that prevents mix-ups and provides proper identification.\n\n9.33 Obsolete and outdated labels should be destroyed.\n\n9.34 Printing devices used to print labels for packaging operations should be controlled to ensure that all imprinting conforms to the print specified in the batch production record.\n\n9.35 Printed labels issued for a batch should be carefully examined for proper identity and conformity to specifications in the master production record. The results of this examination should be documented.\n\n9.36 A printed label representative of those used should be included in the batch production record.\n\n# 9.4 Packaging and labelling operations\n\n9.40 There should be documented procedures designed to ensure that the correct packaging materials and labels are used.\n\n9.41 Labelling operations should be designed to prevent mix-ups. They should be physically or spatially separated from operations involving other intermediates or APIs.\n\n9.42 Labels used on containers of intermediates or APIs should indicate the name or identifying code, the batch number of the product and the storage conditions, when such information is critical to assure the quality of the intermediate or API.\n\n9.43 If the intermediate or API is intended to be transferred outside the control of the manufacturer\u2019s material management system, the name and address of the manufacturer, quantity of contents and special transport conditions and any special legal requirements should also be included on the label. For intermediates or APIs with an expiry date, this date should be indicated on the label and certificate of analysis. For intermediates or APIs with a retest date, the retest date should be indicated on the label and/or certificate of analysis.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl contexto se centra en las directrices de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre la emisi\u00f3n y control de etiquetas, as\u00ed como sobre las operaciones de empaquetado y etiquetado en la producci\u00f3n de intermediarios y principios activos (APIs). Se enfatiza la importancia de limitar el acceso a las \u00e1reas de almacenamiento de etiquetas, la necesidad de procedimientos documentados para reconciliar las etiquetas emitidas y utilizadas, y la destrucci\u00f3n de etiquetas obsoletas o en exceso. Tambi\u00e9n se destacan las especificaciones que deben incluirse en las etiquetas para asegurar la calidad y el cumplimiento normativo.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben implementarse para manejar las discrepancias entre las etiquetas emitidas y los contenedores etiquetados?**\n   - El contexto menciona que se deben utilizar procedimientos para reconciliar las cantidades de etiquetas emitidas, usadas y devueltas, y que cualquier discrepancia debe ser investigada y aprobada por las unidades de calidad.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n cr\u00edtica debe incluirse en las etiquetas de los intermediarios o APIs para asegurar su calidad?**\n   - Las etiquetas deben indicar el nombre o c\u00f3digo identificador, el n\u00famero de lote del producto y las condiciones de almacenamiento, cuando esta informaci\u00f3n sea cr\u00edtica para asegurar la calidad del intermediario o API.\n\n3. **\u00bfCu\u00e1les son las medidas que deben tomarse con respecto a las etiquetas que son obsoletas o que tienen informaci\u00f3n de lote?**\n   - Todas las etiquetas en exceso que contengan n\u00fameros de lote o impresi\u00f3n relacionada con el lote deben ser destruidas, y las etiquetas devueltas deben ser retenidas y almacenadas de manera que se eviten confusiones y se garantice una identificaci\u00f3n adecuada.", "prev_section_summary": "### Temas Clave:\n\n1. **Control de Contaminaci\u00f3n**:\n   - Importancia de evitar la contaminaci\u00f3n cruzada entre lotes de intermediarios y principios activos (API).\n   - Ejemplos de materiales residuales que pueden transferirse entre lotes y su impacto en el perfil de impurezas del API.\n   - Necesidad de realizar operaciones de producci\u00f3n que prevengan la contaminaci\u00f3n por otros materiales.\n   - Precauciones necesarias al manejar APIs despu\u00e9s de la purificaci\u00f3n.\n\n2. **Embalaje y Etiquetado**:\n   - Procedimientos escritos requeridos para la recepci\u00f3n, identificaci\u00f3n, cuarentena, muestreo, examen, pruebas y manejo de materiales de embalaje y etiquetado.\n   - Cumplimiento de especificaciones establecidas para materiales de embalaje y etiquetado, y rechazo de aquellos que no cumplan.\n   - Mantenimiento de registros para cada env\u00edo de materiales de embalaje y etiquetado.\n\n3. **Materiales de Embalaje**:\n   - Protecci\u00f3n adecuada de los contenedores contra la deterioraci\u00f3n o contaminaci\u00f3n durante el transporte y almacenamiento.\n   - Limpieza y sanitizaci\u00f3n de contenedores, asegurando que no alteren la calidad del API.\n   - Procedimientos documentados para la limpieza de contenedores reutilizados y eliminaci\u00f3n de etiquetas anteriores.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Intermediarios**: Sustancias qu\u00edmicas utilizadas en la producci\u00f3n de APIs.\n- **Principios Activos (API)**: Compuestos farmac\u00e9uticos que tienen un efecto terap\u00e9utico.\n- **Contaminaci\u00f3n**: Presencia no deseada de materiales que pueden afectar la calidad del producto.\n- **Contenedores**: Recipientes utilizados para el almacenamiento y transporte de intermediarios y APIs.\n- **Materiales de Embalaje y Etiquetado**: Elementos utilizados para proteger y identificar los productos farmac\u00e9uticos.\n\nEste resumen destaca la importancia del control de la contaminaci\u00f3n y el manejo adecuado de los materiales de embalaje y etiquetado en la producci\u00f3n de intermediarios y APIs, asegurando la calidad y seguridad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: etiquetas, control de calidad, intermediarios, principios activos, procedimientos documentados"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "81ba575b-2ccc-4f51-bca3-af80cc7d0881", "node_type": "4", "metadata": {"page_label": "171", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9.3 Label issuance and control\n\n9.30 Access to the label storage areas should be limited to authorized personnel.\n\n9.31 Procedures should be used to reconcile the quantities of labels issued, used and returned and to evaluate discrepancies found between the number of containers labelled and the number of labels issued. Such discrepancies should be investigated and the investigation should be approved by the quality unit(s).\n\n9.32 All excess labels bearing batch numbers or other batch-related printing should be destroyed. Returned labels should be retained and stored in a manner that prevents mix-ups and provides proper identification.\n\n9.33 Obsolete and outdated labels should be destroyed.\n\n9.34 Printing devices used to print labels for packaging operations should be controlled to ensure that all imprinting conforms to the print specified in the batch production record.\n\n9.35 Printed labels issued for a batch should be carefully examined for proper identity and conformity to specifications in the master production record. The results of this examination should be documented.\n\n9.36 A printed label representative of those used should be included in the batch production record.\n\n# 9.4 Packaging and labelling operations\n\n9.40 There should be documented procedures designed to ensure that the correct packaging materials and labels are used.\n\n9.41 Labelling operations should be designed to prevent mix-ups. They should be physically or spatially separated from operations involving other intermediates or APIs.\n\n9.42 Labels used on containers of intermediates or APIs should indicate the name or identifying code, the batch number of the product and the storage conditions, when such information is critical to assure the quality of the intermediate or API.\n\n9.43 If the intermediate or API is intended to be transferred outside the control of the manufacturer\u2019s material management system, the name and address of the manufacturer, quantity of contents and special transport conditions and any special legal requirements should also be included on the label. For intermediates or APIs with an expiry date, this date should be indicated on the label and certificate of analysis. For intermediates or APIs with a retest date, the retest date should be indicated on the label and/or certificate of analysis.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a157b13e422fbe2b85767ef8ee542f5d51b0b407cf402bbbe9f15a2e68d7f453", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9.3 Label issuance and control\n\n9.30 Access to the label storage areas should be limited to authorized personnel.\n\n9.31 Procedures should be used to reconcile the quantities of labels issued, used and returned and to evaluate discrepancies found between the number of containers labelled and the number of labels issued. Such discrepancies should be investigated and the investigation should be approved by the quality unit(s).\n\n9.32 All excess labels bearing batch numbers or other batch-related printing should be destroyed. Returned labels should be retained and stored in a manner that prevents mix-ups and provides proper identification.\n\n9.33 Obsolete and outdated labels should be destroyed.\n\n9.34 Printing devices used to print labels for packaging operations should be controlled to ensure that all imprinting conforms to the print specified in the batch production record.\n\n9.35 Printed labels issued for a batch should be carefully examined for proper identity and conformity to specifications in the master production record. The results of this examination should be documented.\n\n9.36 A printed label representative of those used should be included in the batch production record.\n\n# 9.4 Packaging and labelling operations\n\n9.40 There should be documented procedures designed to ensure that the correct packaging materials and labels are used.\n\n9.41 Labelling operations should be designed to prevent mix-ups. They should be physically or spatially separated from operations involving other intermediates or APIs.\n\n9.42 Labels used on containers of intermediates or APIs should indicate the name or identifying code, the batch number of the product and the storage conditions, when such information is critical to assure the quality of the intermediate or API.\n\n9.43 If the intermediate or API is intended to be transferred outside the control of the manufacturer\u2019s material management system, the name and address of the manufacturer, quantity of contents and special transport conditions and any special legal requirements should also be included on the label. For intermediates or APIs with an expiry date, this date should be indicated on the label and certificate of analysis. For intermediates or APIs with a retest date, the retest date should be indicated on the label and/or certificate of analysis.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2323, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "320ce1b3-18e8-4e0b-8e9c-579c0c2bca96": {"__data__": {"id_": "320ce1b3-18e8-4e0b-8e9c-579c0c2bca96", "embedding": null, "metadata": {"page_label": "172", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9.44 \nPackaging and labelling facilities should be inspected immediately before use to ensure that all materials not needed for the next packaging operation have been removed. This examination should be documented in the batch production records, the facility log or other documentation system.\n\n# 9.45 \nPackaged and labelled intermediates or APIs should be examined to ensure that containers and packages in the batch have the correct label. This examination should be part of the packaging operation. Results of these examinations should be recorded in the batch production or control records.\n\n# 9.46 \nIntermediate or API containers that are transported outside the manufacturer\u2019s control should be sealed in a manner such that, if the seal is breached or missing, the recipient will be alerted to the possibility that the contents may have been altered.\n\n# 10. Storage and distribution\n\n## 10.1 Warehousing procedures\n\n10.10 Facilities should be available for the storage of all materials under appropriate conditions (e.g. controlled temperature and humidity when necessary). Records should be maintained of these conditions if they are critical for the maintenance of material characteristics.\n\n10.11 Unless there is an alternative system to prevent the unintentional or unauthorized use of quarantined, rejected, returned or recalled materials, separate storage areas should be assigned for their temporary storage until the decision as to their future use has been taken.\n\n## 10.2 Distribution procedures\n\n10.20 APIs and intermediates should only be released for distribution to third parties after they have been released by the quality unit(s). APIs and intermediates can be transferred under quarantine to another unit under the company\u2019s control when authorized by the quality unit(s) and if appropriate controls and documentation are in place.\n\n10.21 APIs and intermediates should be transported in a manner that does not adversely affect their quality.\n\n10.22 Special transport or storage conditions for an API or intermediate should be stated on the label.\n\n10.23 The manufacturer should ensure that the contract acceptor (contractor) for transportation of the API or intermediate knows and follows the appropriate transport and storage conditions.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 957) aborda las directrices sobre el empaquetado, etiquetado, almacenamiento y distribuci\u00f3n de intermediarios y principios activos (APIs) en la industria farmac\u00e9utica. Se enfatiza la importancia de inspeccionar las instalaciones de empaquetado antes de su uso, asegurarse de que los productos est\u00e9n correctamente etiquetados, y mantener condiciones adecuadas de almacenamiento. Tambi\u00e9n se establecen procedimientos para la distribuci\u00f3n, asegurando que los productos solo sean liberados tras la aprobaci\u00f3n de la unidad de calidad y que se sigan las condiciones de transporte y almacenamiento adecuadas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 documentaci\u00f3n se requiere para registrar la inspecci\u00f3n de las instalaciones de empaquetado antes de su uso?**\n   - La inspecci\u00f3n debe ser documentada en los registros de producci\u00f3n por lotes, el registro de la instalaci\u00f3n o en otro sistema de documentaci\u00f3n.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse si se transportan contenedores de intermediarios o APIs fuera del control del fabricante?**\n   - Los contenedores deben estar sellados de tal manera que, si el sello est\u00e1 roto o falta, el destinatario sea alertado sobre la posibilidad de que el contenido haya sido alterado.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse para que un API o intermediario sea liberado para distribuci\u00f3n a terceros?**\n   - Los APIs e intermediarios solo deben ser liberados para distribuci\u00f3n despu\u00e9s de haber sido aprobados por la(s) unidad(es) de calidad. Adem\u00e1s, pueden ser transferidos bajo cuarentena a otra unidad bajo el control de la empresa, siempre que haya controles y documentaci\u00f3n apropiados en su lugar.\n\n### Resumen de nivel superior\n\nEl documento establece directrices claras para asegurar la calidad y la integridad de los intermediarios y APIs en la industria farmac\u00e9utica, desde el empaquetado y etiquetado hasta el almacenamiento y distribuci\u00f3n. Se subraya la importancia de la documentaci\u00f3n y el cumplimiento de las condiciones de almacenamiento y transporte para prevenir la alteraci\u00f3n de los productos.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n\n\n#### Temas clave:\n1. **Control de acceso a etiquetas**: Se debe limitar el acceso a las \u00e1reas de almacenamiento de etiquetas a personal autorizado.\n2. **Reconciliaci\u00f3n de etiquetas**: Es necesario implementar procedimientos para reconciliar las cantidades de etiquetas emitidas, utilizadas y devueltas, as\u00ed como investigar discrepancias entre el n\u00famero de contenedores etiquetados y las etiquetas emitidas.\n3. **Destrucci\u00f3n de etiquetas**: Las etiquetas en exceso, obsoletas o desactualizadas deben ser destruidas. Las etiquetas devueltas deben ser almacenadas adecuadamente para evitar confusiones.\n4. **Control de dispositivos de impresi\u00f3n**: Los dispositivos utilizados para imprimir etiquetas deben ser controlados para asegurar que la impresi\u00f3n cumpla con las especificaciones del registro de producci\u00f3n.\n5. **Examen de etiquetas impresas**: Las etiquetas impresas deben ser examinadas cuidadosamente para verificar su identidad y conformidad con las especificaciones, y los resultados de esta revisi\u00f3n deben ser documentados.\n6. **Procedimientos de empaquetado y etiquetado**: Deben existir procedimientos documentados para asegurar el uso correcto de materiales de empaquetado y etiquetas, as\u00ed como medidas para prevenir confusiones durante las operaciones de etiquetado.\n7. **Informaci\u00f3n cr\u00edtica en etiquetas**: Las etiquetas de intermediarios o APIs deben incluir informaci\u00f3n esencial como el nombre o c\u00f3digo identificador, n\u00famero de lote y condiciones de almacenamiento. Si se transfieren fuera del control del fabricante, deben incluir informaci\u00f3n adicional como nombre y direcci\u00f3n del fabricante, cantidad, condiciones de transporte y requisitos legales especiales.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad que proporciona las directrices.\n- **Personal autorizado**: Individuos con permiso para acceder a las \u00e1reas de almacenamiento de etiquetas.\n- **Unidades de calidad**: Entidades responsables de aprobar las investigaciones sobre discrepancias en etiquetas.\n- **Intermediarios y principios activos (APIs)**: Productos cuya etiquetado y empaquetado deben cumplir con las regulaciones establecidas.\n- **Registro de producci\u00f3n**: Documentaci\u00f3n que especifica los detalles de la producci\u00f3n y etiquetado de los productos. \n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de etiquetas y empaquetado en la producci\u00f3n farmac\u00e9utica para asegurar la calidad y el cumplimiento normativo.", "excerpt_keywords": "Keywords: packaging, labeling, storage, distribution, quality control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e2dc0e0a-ded8-4f0a-a3d0-cc4a8b543b55", "node_type": "4", "metadata": {"page_label": "172", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9.44 \nPackaging and labelling facilities should be inspected immediately before use to ensure that all materials not needed for the next packaging operation have been removed. This examination should be documented in the batch production records, the facility log or other documentation system.\n\n# 9.45 \nPackaged and labelled intermediates or APIs should be examined to ensure that containers and packages in the batch have the correct label. This examination should be part of the packaging operation. Results of these examinations should be recorded in the batch production or control records.\n\n# 9.46 \nIntermediate or API containers that are transported outside the manufacturer\u2019s control should be sealed in a manner such that, if the seal is breached or missing, the recipient will be alerted to the possibility that the contents may have been altered.\n\n# 10. Storage and distribution\n\n## 10.1 Warehousing procedures\n\n10.10 Facilities should be available for the storage of all materials under appropriate conditions (e.g. controlled temperature and humidity when necessary). Records should be maintained of these conditions if they are critical for the maintenance of material characteristics.\n\n10.11 Unless there is an alternative system to prevent the unintentional or unauthorized use of quarantined, rejected, returned or recalled materials, separate storage areas should be assigned for their temporary storage until the decision as to their future use has been taken.\n\n## 10.2 Distribution procedures\n\n10.20 APIs and intermediates should only be released for distribution to third parties after they have been released by the quality unit(s). APIs and intermediates can be transferred under quarantine to another unit under the company\u2019s control when authorized by the quality unit(s) and if appropriate controls and documentation are in place.\n\n10.21 APIs and intermediates should be transported in a manner that does not adversely affect their quality.\n\n10.22 Special transport or storage conditions for an API or intermediate should be stated on the label.\n\n10.23 The manufacturer should ensure that the contract acceptor (contractor) for transportation of the API or intermediate knows and follows the appropriate transport and storage conditions.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "041532da5292569dbff20407d260d88ad774a4f841a44fc9f8780867ecbd5f6f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9.44 \nPackaging and labelling facilities should be inspected immediately before use to ensure that all materials not needed for the next packaging operation have been removed. This examination should be documented in the batch production records, the facility log or other documentation system.\n\n# 9.45 \nPackaged and labelled intermediates or APIs should be examined to ensure that containers and packages in the batch have the correct label. This examination should be part of the packaging operation. Results of these examinations should be recorded in the batch production or control records.\n\n# 9.46 \nIntermediate or API containers that are transported outside the manufacturer\u2019s control should be sealed in a manner such that, if the seal is breached or missing, the recipient will be alerted to the possibility that the contents may have been altered.\n\n# 10. Storage and distribution\n\n## 10.1 Warehousing procedures\n\n10.10 Facilities should be available for the storage of all materials under appropriate conditions (e.g. controlled temperature and humidity when necessary). Records should be maintained of these conditions if they are critical for the maintenance of material characteristics.\n\n10.11 Unless there is an alternative system to prevent the unintentional or unauthorized use of quarantined, rejected, returned or recalled materials, separate storage areas should be assigned for their temporary storage until the decision as to their future use has been taken.\n\n## 10.2 Distribution procedures\n\n10.20 APIs and intermediates should only be released for distribution to third parties after they have been released by the quality unit(s). APIs and intermediates can be transferred under quarantine to another unit under the company\u2019s control when authorized by the quality unit(s) and if appropriate controls and documentation are in place.\n\n10.21 APIs and intermediates should be transported in a manner that does not adversely affect their quality.\n\n10.22 Special transport or storage conditions for an API or intermediate should be stated on the label.\n\n10.23 The manufacturer should ensure that the contract acceptor (contractor) for transportation of the API or intermediate knows and follows the appropriate transport and storage conditions.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2265, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a13d483f-4664-4569-b18b-a1eadf59d8d8": {"__data__": {"id_": "a13d483f-4664-4569-b18b-a1eadf59d8d8", "embedding": null, "metadata": {"page_label": "173", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Laboratory controls\n\n## General controls\n\n11.10 The independent quality unit(s) should have at its disposal adequate laboratory facilities.\n\n11.11 There should be documented procedures describing sampling, testing, approval or rejection of materials and recording and storage of laboratory data. Laboratory records should be maintained in accordance with section 6.6.\n\n11.12 All specifications, sampling plans and test procedures should be scientifically sound and appropriate to ensure that raw materials, intermediates, APIs, labels and packaging materials conform to established standards of quality and/or purity. Specifications and test procedures should be consistent with those included in the registration/filing. There can be specifications in addition to those in the registration/filing. Specifications, sampling plans and test procedures, including changes to them, should be drafted by the appropriate organizational unit and reviewed and approved by the quality unit(s).\n\n11.13 Appropriate specifications should be established for APIs in accordance with accepted standards and be consistent with the manufacturing process. The specifications should include a control of the impurities (e.g. organic impurities, inorganic impurities and residual solvents). If the API has a specification for microbiological purity, appropriate action limits for total microbial counts and objectionable organisms should be established and met. If the API has a specification for endotoxins, appropriate action limits should be established and met.\n\n11.14 Laboratory controls should be followed and documented at the time of performance. Any departures from the above-described procedures should be documented and explained.\n\n11.15 Any OOS result obtained should be investigated and documented according to a procedure. This procedure should require analysis of the data, assessment of whether a significant problem exists, allocation of the tasks for corrective actions and conclusions. Any resampling and/or retesting after OOS results should be performed according to a documented procedure.\n\n11.16 Reagents and standard solutions should be prepared and labelled following written procedures. \u201cUse by\u201d dates should be applied as appropriate for analytical reagents or standard solutions.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre los controles de laboratorio en el contexto de la calidad de los productos farmac\u00e9uticos, seg\u00fan el informe t\u00e9cnico de la OMS. Se enfatiza la importancia de tener instalaciones adecuadas, procedimientos documentados para el muestreo y pruebas, y la necesidad de especificaciones cient\u00edficas para asegurar la calidad y pureza de los materiales. Tambi\u00e9n se abordan los procedimientos para manejar resultados fuera de especificaci\u00f3n (OOS) y la preparaci\u00f3n y etiquetado de reactivos y soluciones est\u00e1ndar.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse si se obtiene un resultado fuera de especificaci\u00f3n (OOS) en el laboratorio?**\n   - El texto detalla que cualquier resultado OOS debe ser investigado y documentado seg\u00fan un procedimiento que incluya el an\u00e1lisis de datos, la evaluaci\u00f3n de la existencia de un problema significativo, la asignaci\u00f3n de tareas para acciones correctivas y la conclusi\u00f3n del an\u00e1lisis. Adem\u00e1s, cualquier re-muestreo o re-prueba debe realizarse de acuerdo con un procedimiento documentado.\n\n2. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en las especificaciones para los ingredientes farmac\u00e9uticos activos (APIs)?**\n   - Las especificaciones para los APIs deben incluir el control de impurezas (como impurezas org\u00e1nicas, inorg\u00e1nicas y solventes residuales) y, si corresponde, l\u00edmites de acci\u00f3n para la pureza microbiol\u00f3gica y endotoxinas. Estas especificaciones deben ser consistentes con el proceso de fabricaci\u00f3n y con los est\u00e1ndares aceptados.\n\n3. **\u00bfQu\u00e9 requisitos existen para la documentaci\u00f3n y el almacenamiento de los datos de laboratorio?**\n   - Se requiere que existan procedimientos documentados que describan el muestreo, las pruebas, la aprobaci\u00f3n o rechazo de materiales, as\u00ed como el registro y almacenamiento de datos de laboratorio. Los registros de laboratorio deben mantenerse de acuerdo con la secci\u00f3n 6.6 del documento.", "prev_section_summary": "### Temas Clave\n\n1. **Inspecci\u00f3n de Instalaciones de Empaquetado**:\n   - Las instalaciones deben ser inspeccionadas antes de su uso para asegurar que no haya materiales innecesarios.\n   - La inspecci\u00f3n debe ser documentada en registros de producci\u00f3n por lotes o en otros sistemas de documentaci\u00f3n.\n\n2. **Etiquetado de Intermediarios y APIs**:\n   - Los productos empaquetados deben ser examinados para verificar que tienen la etiqueta correcta.\n   - Los resultados de estas inspecciones deben ser registrados.\n\n3. **Transporte de Contenedores**:\n   - Los contenedores que se transportan fuera del control del fabricante deben estar sellados para alertar sobre posibles alteraciones si el sello est\u00e1 roto o falta.\n\n4. **Almacenamiento**:\n   - Se deben mantener condiciones adecuadas de almacenamiento (temperatura y humedad controladas).\n   - Se deben llevar registros de estas condiciones si son cr\u00edticas para la calidad del material.\n\n5. **Procedimientos de Distribuci\u00f3n**:\n   - Los APIs e intermediarios solo deben ser liberados para distribuci\u00f3n tras la aprobaci\u00f3n de la unidad de calidad.\n   - Pueden ser transferidos bajo cuarentena a otra unidad bajo control de la empresa, siempre que haya controles y documentaci\u00f3n adecuados.\n   - El transporte debe realizarse de manera que no afecte la calidad del producto.\n\n6. **Condiciones Especiales de Transporte y Almacenamiento**:\n   - Las condiciones especiales deben ser indicadas en la etiqueta del producto.\n   - El contratista de transporte debe estar informado y seguir las condiciones adecuadas.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Intermediarios**: Productos intermedios en la cadena de producci\u00f3n farmac\u00e9utica.\n- **Principios Activos (APIs)**: Sustancias que proporcionan la acci\u00f3n farmacol\u00f3gica en los medicamentos.\n- **Unidad de Calidad**: Entidad responsable de la aprobaci\u00f3n de productos para distribuci\u00f3n.\n- **Contratista de Transporte**: Entidad encargada del transporte de los productos, que debe cumplir con las condiciones establecidas. \n\nEste resumen destaca la importancia de la inspecci\u00f3n, el etiquetado correcto, el almacenamiento adecuado y el cumplimiento de las normativas en la industria farmac\u00e9utica para garantizar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: laboratory controls, quality unit, specifications, active pharmaceutical ingredients, OOS results"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2d1bf720-8100-4516-8f84-70e1ea41bb77", "node_type": "4", "metadata": {"page_label": "173", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Laboratory controls\n\n## General controls\n\n11.10 The independent quality unit(s) should have at its disposal adequate laboratory facilities.\n\n11.11 There should be documented procedures describing sampling, testing, approval or rejection of materials and recording and storage of laboratory data. Laboratory records should be maintained in accordance with section 6.6.\n\n11.12 All specifications, sampling plans and test procedures should be scientifically sound and appropriate to ensure that raw materials, intermediates, APIs, labels and packaging materials conform to established standards of quality and/or purity. Specifications and test procedures should be consistent with those included in the registration/filing. There can be specifications in addition to those in the registration/filing. Specifications, sampling plans and test procedures, including changes to them, should be drafted by the appropriate organizational unit and reviewed and approved by the quality unit(s).\n\n11.13 Appropriate specifications should be established for APIs in accordance with accepted standards and be consistent with the manufacturing process. The specifications should include a control of the impurities (e.g. organic impurities, inorganic impurities and residual solvents). If the API has a specification for microbiological purity, appropriate action limits for total microbial counts and objectionable organisms should be established and met. If the API has a specification for endotoxins, appropriate action limits should be established and met.\n\n11.14 Laboratory controls should be followed and documented at the time of performance. Any departures from the above-described procedures should be documented and explained.\n\n11.15 Any OOS result obtained should be investigated and documented according to a procedure. This procedure should require analysis of the data, assessment of whether a significant problem exists, allocation of the tasks for corrective actions and conclusions. Any resampling and/or retesting after OOS results should be performed according to a documented procedure.\n\n11.16 Reagents and standard solutions should be prepared and labelled following written procedures. \u201cUse by\u201d dates should be applied as appropriate for analytical reagents or standard solutions.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "8ad29d4903207deb1dbd4c9fddc72e79970d5b0dd3d39c1d19ffa2fb0978121e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Laboratory controls\n\n## General controls\n\n11.10 The independent quality unit(s) should have at its disposal adequate laboratory facilities.\n\n11.11 There should be documented procedures describing sampling, testing, approval or rejection of materials and recording and storage of laboratory data. Laboratory records should be maintained in accordance with section 6.6.\n\n11.12 All specifications, sampling plans and test procedures should be scientifically sound and appropriate to ensure that raw materials, intermediates, APIs, labels and packaging materials conform to established standards of quality and/or purity. Specifications and test procedures should be consistent with those included in the registration/filing. There can be specifications in addition to those in the registration/filing. Specifications, sampling plans and test procedures, including changes to them, should be drafted by the appropriate organizational unit and reviewed and approved by the quality unit(s).\n\n11.13 Appropriate specifications should be established for APIs in accordance with accepted standards and be consistent with the manufacturing process. The specifications should include a control of the impurities (e.g. organic impurities, inorganic impurities and residual solvents). If the API has a specification for microbiological purity, appropriate action limits for total microbial counts and objectionable organisms should be established and met. If the API has a specification for endotoxins, appropriate action limits should be established and met.\n\n11.14 Laboratory controls should be followed and documented at the time of performance. Any departures from the above-described procedures should be documented and explained.\n\n11.15 Any OOS result obtained should be investigated and documented according to a procedure. This procedure should require analysis of the data, assessment of whether a significant problem exists, allocation of the tasks for corrective actions and conclusions. Any resampling and/or retesting after OOS results should be performed according to a documented procedure.\n\n11.16 Reagents and standard solutions should be prepared and labelled following written procedures. \u201cUse by\u201d dates should be applied as appropriate for analytical reagents or standard solutions.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2289, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c41a8dc1-6f41-42b1-adb5-b804b5fe365a": {"__data__": {"id_": "c41a8dc1-6f41-42b1-adb5-b804b5fe365a", "embedding": null, "metadata": {"page_label": "174", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11.17\n\nPrimary reference standards should be obtained as appropriate for the manufacture of APIs. The source of each primary reference standard should be documented. Records should be maintained of each primary reference standard\u2019s storage and use in accordance with the supplier\u2019s recommendations. Primary reference standards obtained from an officially recognized source are normally used without testing if stored under conditions consistent with the supplier\u2019s recommendations.\n\n11.18 Where a primary reference standard is not available from an officially recognized source, an \u201cin-house primary standard\u201d should be established. Appropriate testing should be performed to establish fully the identity and purity of the primary reference standard. Appropriate documentation of this testing should be maintained.\n\n11.19 Secondary reference standards should be appropriately prepared, identified, tested, approved and stored. The suitability of each batch of secondary reference standard should be determined prior to first use by comparing against a primary reference standard. Each batch of secondary reference standard should be periodically requalified in accordance with a written protocol.\n\n## 11.2 Testing of intermediates and APIs\n\n11.20 For each batch of intermediate and API, appropriate laboratory tests should be conducted to determine conformance to specifications.\n\n11.21 An impurity profile describing the identified and unidentified impurities present in a typical batch produced by a specific controlled production process should normally be established for each API. The impurity profile should include the identity or some qualitative analytical designation (e.g. retention time), the range of each impurity observed and classification of each identified impurity (e.g. inorganic, organic or solvent). The impurity profile is normally dependent upon the production process and origin of the API. Impurity profiles are normally not necessary for APIs of herbal or animal tissue origin. Biotechnology considerations are covered in ICH Guideline Q6B (1).\n\n11.22 The impurity profile should be compared at appropriate intervals with the impurity profile in the regulatory submission or compared with historical data in order to detect changes to the API resulting from modifications to raw materials, equipment operating parameters or the production process.\n\n11.23 Appropriate microbiological tests should be conducted on each batch of intermediate and API where microbial quality is specified.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en las normas y procedimientos relacionados con los est\u00e1ndares de referencia primarios y secundarios en la fabricaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (APIs). Se enfatiza la importancia de documentar la fuente de los est\u00e1ndares de referencia, mantener registros de su almacenamiento y uso, y realizar pruebas adecuadas para establecer la identidad y pureza de los est\u00e1ndares. Tambi\u00e9n se discute la necesidad de establecer perfiles de impurezas para cada API y realizar pruebas microbiol\u00f3gicas cuando se especifica la calidad microbiana.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 documentaci\u00f3n es necesaria para el almacenamiento y uso de los est\u00e1ndares de referencia primarios?**\n   - La documentaci\u00f3n necesaria incluye registros que mantengan informaci\u00f3n sobre la fuente de cada est\u00e1ndar de referencia primario, as\u00ed como detalles sobre su almacenamiento y uso, de acuerdo con las recomendaciones del proveedor.\n\n2. **\u00bfQu\u00e9 pasos se deben seguir si no se puede obtener un est\u00e1ndar de referencia primario de una fuente oficialmente reconocida?**\n   - En este caso, se debe establecer un \"est\u00e1ndar primario interno\", lo que implica realizar pruebas adecuadas para establecer completamente la identidad y pureza del est\u00e1ndar, y mantener la documentaci\u00f3n correspondiente de estas pruebas.\n\n3. **\u00bfC\u00f3mo se determina la idoneidad de cada lote de est\u00e1ndar de referencia secundario antes de su primer uso?**\n   - La idoneidad de cada lote de est\u00e1ndar de referencia secundario se determina compar\u00e1ndolo con un est\u00e1ndar de referencia primario. Adem\u00e1s, cada lote debe ser requalificado peri\u00f3dicamente de acuerdo con un protocolo escrito.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Controles de Laboratorio**: Se establecen directrices para asegurar la calidad y pureza de los productos farmac\u00e9uticos a trav\u00e9s de controles de laboratorio adecuados.\n\n2. **Instalaciones de Laboratorio**: Se requiere que las unidades de calidad independientes dispongan de instalaciones de laboratorio adecuadas.\n\n3. **Procedimientos Documentados**: Es esencial contar con procedimientos documentados que aborden el muestreo, pruebas, aprobaci\u00f3n o rechazo de materiales, as\u00ed como el registro y almacenamiento de datos de laboratorio.\n\n4. **Especificaciones Cient\u00edficas**: Las especificaciones, planes de muestreo y procedimientos de prueba deben ser cient\u00edficamente s\u00f3lidos y alineados con los est\u00e1ndares de calidad y pureza establecidos. Deben ser consistentes con la documentaci\u00f3n de registro.\n\n5. **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Se deben establecer especificaciones apropiadas para los APIs, incluyendo el control de impurezas y l\u00edmites de acci\u00f3n para pureza microbiol\u00f3gica y endotoxinas.\n\n6. **Resultados Fuera de Especificaci\u00f3n (OOS)**: Cualquier resultado OOS debe ser investigado y documentado, incluyendo el an\u00e1lisis de datos y la evaluaci\u00f3n de problemas significativos. Se deben seguir procedimientos documentados para re-muestreo y re-pruebas.\n\n7. **Preparaci\u00f3n de Reactivos**: Los reactivos y soluciones est\u00e1ndar deben ser preparados y etiquetados siguiendo procedimientos escritos, con fechas de \"uso hasta\" aplicadas seg\u00fan sea necesario.\n\n### Entidades Clave\n\n- **Unidades de Calidad Independientes**: Responsables de asegurar la calidad en el laboratorio.\n- **Procedimientos Documentados**: Gu\u00edas que regulan las operaciones de laboratorio.\n- **Especificaciones**: Criterios que deben cumplir los materiales y productos.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Sustancias que se utilizan en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Resultados OOS**: Resultados que no cumplen con las especificaciones establecidas.\n- **Reactivos y Soluciones Est\u00e1ndar**: Sustancias utilizadas en an\u00e1lisis y pruebas de laboratorio. \n\nEste resumen destaca la importancia de los controles de laboratorio y la documentaci\u00f3n adecuada para garantizar la calidad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: reference standards, APIs, impurity profile, microbiological tests, quality control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e2eaca3a-b863-45c2-8c05-faf887e0d4be", "node_type": "4", "metadata": {"page_label": "174", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11.17\n\nPrimary reference standards should be obtained as appropriate for the manufacture of APIs. The source of each primary reference standard should be documented. Records should be maintained of each primary reference standard\u2019s storage and use in accordance with the supplier\u2019s recommendations. Primary reference standards obtained from an officially recognized source are normally used without testing if stored under conditions consistent with the supplier\u2019s recommendations.\n\n11.18 Where a primary reference standard is not available from an officially recognized source, an \u201cin-house primary standard\u201d should be established. Appropriate testing should be performed to establish fully the identity and purity of the primary reference standard. Appropriate documentation of this testing should be maintained.\n\n11.19 Secondary reference standards should be appropriately prepared, identified, tested, approved and stored. The suitability of each batch of secondary reference standard should be determined prior to first use by comparing against a primary reference standard. Each batch of secondary reference standard should be periodically requalified in accordance with a written protocol.\n\n## 11.2 Testing of intermediates and APIs\n\n11.20 For each batch of intermediate and API, appropriate laboratory tests should be conducted to determine conformance to specifications.\n\n11.21 An impurity profile describing the identified and unidentified impurities present in a typical batch produced by a specific controlled production process should normally be established for each API. The impurity profile should include the identity or some qualitative analytical designation (e.g. retention time), the range of each impurity observed and classification of each identified impurity (e.g. inorganic, organic or solvent). The impurity profile is normally dependent upon the production process and origin of the API. Impurity profiles are normally not necessary for APIs of herbal or animal tissue origin. Biotechnology considerations are covered in ICH Guideline Q6B (1).\n\n11.22 The impurity profile should be compared at appropriate intervals with the impurity profile in the regulatory submission or compared with historical data in order to detect changes to the API resulting from modifications to raw materials, equipment operating parameters or the production process.\n\n11.23 Appropriate microbiological tests should be conducted on each batch of intermediate and API where microbial quality is specified.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "655b0dc11e971131a4f51b902186eb683927b80b7ac7f250d70d8a6f34673c5e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 11.17\n\nPrimary reference standards should be obtained as appropriate for the manufacture of APIs. The source of each primary reference standard should be documented. Records should be maintained of each primary reference standard\u2019s storage and use in accordance with the supplier\u2019s recommendations. Primary reference standards obtained from an officially recognized source are normally used without testing if stored under conditions consistent with the supplier\u2019s recommendations.\n\n11.18 Where a primary reference standard is not available from an officially recognized source, an \u201cin-house primary standard\u201d should be established. Appropriate testing should be performed to establish fully the identity and purity of the primary reference standard. Appropriate documentation of this testing should be maintained.\n\n11.19 Secondary reference standards should be appropriately prepared, identified, tested, approved and stored. The suitability of each batch of secondary reference standard should be determined prior to first use by comparing against a primary reference standard. Each batch of secondary reference standard should be periodically requalified in accordance with a written protocol.\n\n## 11.2 Testing of intermediates and APIs\n\n11.20 For each batch of intermediate and API, appropriate laboratory tests should be conducted to determine conformance to specifications.\n\n11.21 An impurity profile describing the identified and unidentified impurities present in a typical batch produced by a specific controlled production process should normally be established for each API. The impurity profile should include the identity or some qualitative analytical designation (e.g. retention time), the range of each impurity observed and classification of each identified impurity (e.g. inorganic, organic or solvent). The impurity profile is normally dependent upon the production process and origin of the API. Impurity profiles are normally not necessary for APIs of herbal or animal tissue origin. Biotechnology considerations are covered in ICH Guideline Q6B (1).\n\n11.22 The impurity profile should be compared at appropriate intervals with the impurity profile in the regulatory submission or compared with historical data in order to detect changes to the API resulting from modifications to raw materials, equipment operating parameters or the production process.\n\n11.23 Appropriate microbiological tests should be conducted on each batch of intermediate and API where microbial quality is specified.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2513, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "87535ebe-f642-4f10-8b28-596ebd73005a": {"__data__": {"id_": "87535ebe-f642-4f10-8b28-596ebd73005a", "embedding": null, "metadata": {"page_label": "175", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11.3 Validation of analytical procedures\n\nSee section 12.\n\n# 11.4 Certificates of analysis\n\n11.40 Authentic certificates of analysis should be issued for each batch of intermediate or API on request.\n\n11.41 Information on the name of the intermediate or API, including where appropriate its grade, the batch number and the date of release, should be provided on the certificate of analysis. For intermediates or APIs with an expiry date, the expiry date should be provided on the label and certificate of analysis. For intermediates or APIs with a retest date, the retest date should be indicated on the label and/or certificate of analysis.\n\n11.42 The certificate should list each test performed in accordance with compendial or customer requirements, including the acceptance limits and the numerical results obtained (if test results are numerical).\n\n11.43 Certificates should be dated and signed by authorized personnel from the quality unit(s) and should show the name, address and telephone number of the original manufacturer. Where the analysis has been carried out by a repacker or reprocessor, the certificate of analysis should show the name, address and telephone number of the repacker or reprocessor and a reference to the name of the original manufacturer.\n\n11.44 If new certificates are issued by or on behalf of repackers or reprocessors, agents or brokers, these certificates should show the name, address and telephone number of the laboratory that performed the analysis. They should also contain a reference to the name and address of the original manufacturer and to the original batch certificate, a copy of which should be attached.\n\n# 11.5 Stability monitoring of APIs\n\n11.50 A documented, ongoing testing programme should be designed to monitor the stability characteristics of APIs and the results should be used to confirm appropriate storage conditions and retest or expiry dates.\n\n11.51 The test procedures used in stability testing should be validated and be stability-indicating.\n\n11.52 Stability samples should be stored in containers that simulate the market container. For example, if the API is marketed in bags within fibre drums, stability samples can be packaged in bags of the same material and in smaller drums of similar or identical material composition to the drums in which the API is marketed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la validaci\u00f3n de procedimientos anal\u00edticos y la emisi\u00f3n de certificados de an\u00e1lisis para intermediarios y principios activos (API). Se enfatiza la importancia de proporcionar informaci\u00f3n detallada en los certificados, como el nombre del producto, el n\u00famero de lote, las fechas de caducidad y rean\u00e1lisis, as\u00ed como la firma de personal autorizado. Adem\u00e1s, se menciona la necesidad de un programa de monitoreo de estabilidad para los API, que debe incluir pruebas validadas y el almacenamiento de muestras en condiciones que simulen el envase comercial.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en un certificado de an\u00e1lisis para un API o intermediario?**\n   - El certificado de an\u00e1lisis debe incluir el nombre del intermediario o API, su grado (si corresponde), el n\u00famero de lote, la fecha de liberaci\u00f3n, la fecha de caducidad o rean\u00e1lisis (si aplica), y los resultados de las pruebas realizadas, incluyendo l\u00edmites de aceptaci\u00f3n y resultados num\u00e9ricos.\n\n2. **\u00bfQu\u00e9 requisitos deben cumplir los procedimientos de prueba utilizados en el monitoreo de estabilidad de los API?**\n   - Los procedimientos de prueba utilizados en el monitoreo de estabilidad deben estar validados y ser indicativos de estabilidad, asegurando que los resultados reflejen adecuadamente las caracter\u00edsticas de estabilidad del API.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n adicional debe incluirse en los certificados de an\u00e1lisis emitidos por repackers o reprocessors?**\n   - Los certificados emitidos por repackers o reprocessors deben incluir el nombre, direcci\u00f3n y n\u00famero de tel\u00e9fono del laboratorio que realiz\u00f3 el an\u00e1lisis, as\u00ed como una referencia al nombre y direcci\u00f3n del fabricante original y al certificado de lote original, que debe ser adjuntado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Est\u00e1ndares de Referencia Primarios**:\n   - Obtenci\u00f3n y documentaci\u00f3n de la fuente.\n   - Mantenimiento de registros de almacenamiento y uso seg\u00fan recomendaciones del proveedor.\n   - Uso sin pruebas si provienen de fuentes oficialmente reconocidas y se almacenan adecuadamente.\n\n2. **Est\u00e1ndares Primarios Internos**:\n   - Establecimiento de un est\u00e1ndar primario interno si no se dispone de uno reconocido.\n   - Realizaci\u00f3n de pruebas para determinar identidad y pureza.\n   - Mantenimiento de documentaci\u00f3n de las pruebas realizadas.\n\n3. **Est\u00e1ndares de Referencia Secundarios**:\n   - Preparaci\u00f3n, identificaci\u00f3n, prueba, aprobaci\u00f3n y almacenamiento adecuados.\n   - Determinaci\u00f3n de idoneidad mediante comparaci\u00f3n con un est\u00e1ndar primario antes del primer uso.\n   - Recalificaci\u00f3n peri\u00f3dica de cada lote seg\u00fan un protocolo escrito.\n\n4. **Pruebas de Intermedios y APIs**:\n   - Realizaci\u00f3n de pruebas de laboratorio para cada lote de intermedio y API para verificar conformidad con especificaciones.\n\n5. **Perfiles de Impurezas**:\n   - Establecimiento de un perfil de impurezas que incluya impurezas identificadas y no identificadas, su rango y clasificaci\u00f3n.\n   - Comparaci\u00f3n peri\u00f3dica del perfil de impurezas con datos hist\u00f3ricos o perfiles presentados en regulaciones para detectar cambios.\n\n6. **Pruebas Microbiol\u00f3gicas**:\n   - Realizaci\u00f3n de pruebas microbiol\u00f3gicas en cada lote de intermedio y API cuando se especifique calidad microbiana.\n\n### Entidades Clave\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias utilizadas en la fabricaci\u00f3n de medicamentos.\n- **Est\u00e1ndares de Referencia**: Normas utilizadas para asegurar la calidad y pureza de los productos farmac\u00e9uticos.\n- **Proveedores**: Entidades que suministran los est\u00e1ndares de referencia.\n- **Protocolos Escritos**: Documentos que establecen procedimientos para la requalificaci\u00f3n de est\u00e1ndares secundarios.\n- **Perfiles de Impurezas**: Documentaci\u00f3n que detalla las impurezas presentes en los lotes de APIs.", "excerpt_keywords": "Keywords: certificates of analysis, stability monitoring, analytical procedures, active pharmaceutical ingredients, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "42f885a0-49c8-4b04-b776-18c78a204770", "node_type": "4", "metadata": {"page_label": "175", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11.3 Validation of analytical procedures\n\nSee section 12.\n\n# 11.4 Certificates of analysis\n\n11.40 Authentic certificates of analysis should be issued for each batch of intermediate or API on request.\n\n11.41 Information on the name of the intermediate or API, including where appropriate its grade, the batch number and the date of release, should be provided on the certificate of analysis. For intermediates or APIs with an expiry date, the expiry date should be provided on the label and certificate of analysis. For intermediates or APIs with a retest date, the retest date should be indicated on the label and/or certificate of analysis.\n\n11.42 The certificate should list each test performed in accordance with compendial or customer requirements, including the acceptance limits and the numerical results obtained (if test results are numerical).\n\n11.43 Certificates should be dated and signed by authorized personnel from the quality unit(s) and should show the name, address and telephone number of the original manufacturer. Where the analysis has been carried out by a repacker or reprocessor, the certificate of analysis should show the name, address and telephone number of the repacker or reprocessor and a reference to the name of the original manufacturer.\n\n11.44 If new certificates are issued by or on behalf of repackers or reprocessors, agents or brokers, these certificates should show the name, address and telephone number of the laboratory that performed the analysis. They should also contain a reference to the name and address of the original manufacturer and to the original batch certificate, a copy of which should be attached.\n\n# 11.5 Stability monitoring of APIs\n\n11.50 A documented, ongoing testing programme should be designed to monitor the stability characteristics of APIs and the results should be used to confirm appropriate storage conditions and retest or expiry dates.\n\n11.51 The test procedures used in stability testing should be validated and be stability-indicating.\n\n11.52 Stability samples should be stored in containers that simulate the market container. For example, if the API is marketed in bags within fibre drums, stability samples can be packaged in bags of the same material and in smaller drums of similar or identical material composition to the drums in which the API is marketed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "c9c623d1160f7bb59cca7fe3ffd6d15d3e3648dfd1259c86fb6aec7bbccc1af7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 11.3 Validation of analytical procedures\n\nSee section 12.\n\n# 11.4 Certificates of analysis\n\n11.40 Authentic certificates of analysis should be issued for each batch of intermediate or API on request.\n\n11.41 Information on the name of the intermediate or API, including where appropriate its grade, the batch number and the date of release, should be provided on the certificate of analysis. For intermediates or APIs with an expiry date, the expiry date should be provided on the label and certificate of analysis. For intermediates or APIs with a retest date, the retest date should be indicated on the label and/or certificate of analysis.\n\n11.42 The certificate should list each test performed in accordance with compendial or customer requirements, including the acceptance limits and the numerical results obtained (if test results are numerical).\n\n11.43 Certificates should be dated and signed by authorized personnel from the quality unit(s) and should show the name, address and telephone number of the original manufacturer. Where the analysis has been carried out by a repacker or reprocessor, the certificate of analysis should show the name, address and telephone number of the repacker or reprocessor and a reference to the name of the original manufacturer.\n\n11.44 If new certificates are issued by or on behalf of repackers or reprocessors, agents or brokers, these certificates should show the name, address and telephone number of the laboratory that performed the analysis. They should also contain a reference to the name and address of the original manufacturer and to the original batch certificate, a copy of which should be attached.\n\n# 11.5 Stability monitoring of APIs\n\n11.50 A documented, ongoing testing programme should be designed to monitor the stability characteristics of APIs and the results should be used to confirm appropriate storage conditions and retest or expiry dates.\n\n11.51 The test procedures used in stability testing should be validated and be stability-indicating.\n\n11.52 Stability samples should be stored in containers that simulate the market container. For example, if the API is marketed in bags within fibre drums, stability samples can be packaged in bags of the same material and in smaller drums of similar or identical material composition to the drums in which the API is marketed.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2341, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d00b4394-5c19-4bf6-a0c3-d8cd77cb2879": {"__data__": {"id_": "d00b4394-5c19-4bf6-a0c3-d8cd77cb2879", "embedding": null, "metadata": {"page_label": "176", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 11.53\n\nNormally the first three commercial production batches should be placed on the stability monitoring programme to confirm the retest or expiry date. However, where data from previous studies show that the API is expected to remain stable for at least two years, fewer than three batches can be used.\n\n## 11.54\n\nThereafter at least one batch per year of API manufactured (unless none is produced that year) should be added to the stability monitoring programme and tested at least annually to confirm the stability.\n\n## 11.55\n\nFor APIs with short shelf-lives, testing should be done more frequently. For example, for those biotechnological/biological and other APIs with shelf-lives of one year or less, stability samples should be obtained and should be tested monthly for the first three months, and at three-monthly intervals after that. When data exist that confirm that the stability of the API is not compromised, elimination of specific test intervals (e.g. nine-month testing) can be considered.\n\n## 11.56\n\nWhere appropriate, the stability storage conditions should be consistent with the WHO guidelines on stability.\n\n### 11.6 Expiry and retest dating\n\n## 11.60\n\nWhen an intermediate is intended to be transferred outside the control of the manufacturer\u2019s material management system and an expiry or retest date is assigned, supporting stability information should be available (e.g. published data and test results).\n\n## 11.61\n\nAn API expiry or retest date should be based on an evaluation of data derived from stability studies. Common practice is to use a retest date, not an expiration date.\n\n## 11.62\n\nPreliminary API expiry or retest dates can be based on pilot-scale batches if:\n\n- the pilot batches employ a method of manufacture and a procedure that simulates the final process to be used on a commercial manufacturing scale; and\n- the quality of the API represents the material to be made on a commercial scale.\n\n## 11.63\n\nA representative sample should be taken for the purpose of performing a retest.\n\n### 11.7 Reserve/retention samples\n\n## 11.70\n\nThe packaging and holding of reserve samples is for the purpose of potential future evaluation of the quality of batches of API and not for future stability testing.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece directrices sobre el monitoreo de la estabilidad de los ingredientes farmac\u00e9uticos activos (API). Se recomienda que los primeros tres lotes de producci\u00f3n comercial se incluyan en un programa de monitoreo de estabilidad para confirmar las fechas de rean\u00e1lisis o caducidad. Para APIs con vida \u00fatil corta, se sugiere realizar pruebas m\u00e1s frecuentes. Adem\u00e1s, se discuten las condiciones de almacenamiento y la importancia de la informaci\u00f3n de estabilidad al asignar fechas de caducidad o rean\u00e1lisis. Tambi\u00e9n se menciona la necesidad de muestras de reserva para la evaluaci\u00f3n futura de la calidad.\n\n### Preguntas:\n1. **\u00bfCu\u00e1ntos lotes de producci\u00f3n comercial deben incluirse inicialmente en el programa de monitoreo de estabilidad y bajo qu\u00e9 condiciones se puede reducir este n\u00famero?**\n   - Respuesta: Normalmente, se deben incluir los primeros tres lotes de producci\u00f3n comercial en el programa de monitoreo de estabilidad. Sin embargo, si los datos de estudios previos indican que el API se espera que permanezca estable durante al menos dos a\u00f1os, se puede utilizar menos de tres lotes.\n\n2. **\u00bfCon qu\u00e9 frecuencia deben realizarse las pruebas de estabilidad para APIs con vida \u00fatil corta y qu\u00e9 intervalos se sugieren despu\u00e9s de los primeros meses?**\n   - Respuesta: Para APIs con vida \u00fatil corta (un a\u00f1o o menos), se deben obtener y probar muestras de estabilidad mensualmente durante los primeros tres meses, y luego a intervalos de tres meses despu\u00e9s de eso.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse para que las fechas preliminares de caducidad o rean\u00e1lisis de un API se basen en lotes de escala piloto?**\n   - Respuesta: Las fechas preliminares de caducidad o rean\u00e1lisis pueden basarse en lotes de escala piloto si estos emplean un m\u00e9todo de fabricaci\u00f3n y un procedimiento que simulan el proceso final que se utilizar\u00e1 a escala comercial, y si la calidad del API representa el material que se fabricar\u00e1 a escala comercial.", "prev_section_summary": "### Temas clave:\n\n1. **Validaci\u00f3n de procedimientos anal\u00edticos**: Se menciona que los procedimientos anal\u00edticos deben ser validados, aunque se remite a la secci\u00f3n 12 para m\u00e1s detalles.\n\n2. **Certificados de an\u00e1lisis**: \n   - Se requiere la emisi\u00f3n de certificados aut\u00e9nticos para cada lote de intermediarios o principios activos (API) a solicitud.\n   - Los certificados deben incluir informaci\u00f3n detallada como el nombre del producto, grado, n\u00famero de lote, fecha de liberaci\u00f3n, fechas de caducidad y rean\u00e1lisis, as\u00ed como los resultados de las pruebas realizadas.\n   - Deben ser firmados y fechados por personal autorizado y contener informaci\u00f3n del fabricante original y, si aplica, del repacker o reprocessor.\n\n3. **Monitoreo de estabilidad de los API**: \n   - Se debe establecer un programa de pruebas documentado y continuo para monitorear las caracter\u00edsticas de estabilidad de los API.\n   - Los procedimientos de prueba deben ser validados y reflejar la estabilidad del producto.\n   - Las muestras de estabilidad deben almacenarse en contenedores que simulen el envase comercial.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Intermediarios y principios activos (API)**: Productos cuya calidad y estabilidad se est\u00e1n evaluando.\n- **Personal autorizado**: Individuos responsables de firmar los certificados de an\u00e1lisis.\n- **Repackers y reprocessors**: Entidades que pueden realizar an\u00e1lisis y emitir certificados en nombre del fabricante original.\n- **Laboratorios**: Entidades que realizan las pruebas de an\u00e1lisis y estabilidad.\n\nEste resumen destaca la importancia de la documentaci\u00f3n y el cumplimiento de est\u00e1ndares en la producci\u00f3n y an\u00e1lisis de intermediarios y API, as\u00ed como la necesidad de un monitoreo continuo de su estabilidad.", "excerpt_keywords": "Keywords: stability monitoring, active pharmaceutical ingredients, expiry dating, retest dates, reserve samples"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2c3017e2-626e-4a3a-94c9-e7febf650b1a", "node_type": "4", "metadata": {"page_label": "176", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 11.53\n\nNormally the first three commercial production batches should be placed on the stability monitoring programme to confirm the retest or expiry date. However, where data from previous studies show that the API is expected to remain stable for at least two years, fewer than three batches can be used.\n\n## 11.54\n\nThereafter at least one batch per year of API manufactured (unless none is produced that year) should be added to the stability monitoring programme and tested at least annually to confirm the stability.\n\n## 11.55\n\nFor APIs with short shelf-lives, testing should be done more frequently. For example, for those biotechnological/biological and other APIs with shelf-lives of one year or less, stability samples should be obtained and should be tested monthly for the first three months, and at three-monthly intervals after that. When data exist that confirm that the stability of the API is not compromised, elimination of specific test intervals (e.g. nine-month testing) can be considered.\n\n## 11.56\n\nWhere appropriate, the stability storage conditions should be consistent with the WHO guidelines on stability.\n\n### 11.6 Expiry and retest dating\n\n## 11.60\n\nWhen an intermediate is intended to be transferred outside the control of the manufacturer\u2019s material management system and an expiry or retest date is assigned, supporting stability information should be available (e.g. published data and test results).\n\n## 11.61\n\nAn API expiry or retest date should be based on an evaluation of data derived from stability studies. Common practice is to use a retest date, not an expiration date.\n\n## 11.62\n\nPreliminary API expiry or retest dates can be based on pilot-scale batches if:\n\n- the pilot batches employ a method of manufacture and a procedure that simulates the final process to be used on a commercial manufacturing scale; and\n- the quality of the API represents the material to be made on a commercial scale.\n\n## 11.63\n\nA representative sample should be taken for the purpose of performing a retest.\n\n### 11.7 Reserve/retention samples\n\n## 11.70\n\nThe packaging and holding of reserve samples is for the purpose of potential future evaluation of the quality of batches of API and not for future stability testing.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "ec848d755ee1e852bf7e830c8db432027d129b48bc1d015deb4082b0527fec2b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 11.53\n\nNormally the first three commercial production batches should be placed on the stability monitoring programme to confirm the retest or expiry date. However, where data from previous studies show that the API is expected to remain stable for at least two years, fewer than three batches can be used.\n\n## 11.54\n\nThereafter at least one batch per year of API manufactured (unless none is produced that year) should be added to the stability monitoring programme and tested at least annually to confirm the stability.\n\n## 11.55\n\nFor APIs with short shelf-lives, testing should be done more frequently. For example, for those biotechnological/biological and other APIs with shelf-lives of one year or less, stability samples should be obtained and should be tested monthly for the first three months, and at three-monthly intervals after that. When data exist that confirm that the stability of the API is not compromised, elimination of specific test intervals (e.g. nine-month testing) can be considered.\n\n## 11.56\n\nWhere appropriate, the stability storage conditions should be consistent with the WHO guidelines on stability.\n\n### 11.6 Expiry and retest dating\n\n## 11.60\n\nWhen an intermediate is intended to be transferred outside the control of the manufacturer\u2019s material management system and an expiry or retest date is assigned, supporting stability information should be available (e.g. published data and test results).\n\n## 11.61\n\nAn API expiry or retest date should be based on an evaluation of data derived from stability studies. Common practice is to use a retest date, not an expiration date.\n\n## 11.62\n\nPreliminary API expiry or retest dates can be based on pilot-scale batches if:\n\n- the pilot batches employ a method of manufacture and a procedure that simulates the final process to be used on a commercial manufacturing scale; and\n- the quality of the API represents the material to be made on a commercial scale.\n\n## 11.63\n\nA representative sample should be taken for the purpose of performing a retest.\n\n### 11.7 Reserve/retention samples\n\n## 11.70\n\nThe packaging and holding of reserve samples is for the purpose of potential future evaluation of the quality of batches of API and not for future stability testing.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2242, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7a381825-1f8a-4f82-835c-f71aee746826": {"__data__": {"id_": "7a381825-1f8a-4f82-835c-f71aee746826", "embedding": null, "metadata": {"page_label": "177", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11.71\nAppropriately identified reserve samples of each batch of API should be retained for one year after the expiry date assigned by the manufacturer to the batch, or for three years after distribution of the batch, whichever is the longer. For APIs with retest dates, similar reserve samples should be retained for three years after the batch has been completely distributed by the manufacturer.\n\n11.72 The reserve sample should be stored in the same packaging system in which the API is stored or in one that is equivalent to or more protective than the marketed packaging system. Sufficient quantities should be retained to conduct at least two full compendial analyses or, when there is no pharmacopoeial monograph, two full specification analyses.\n\n# 12. Validation\n\n## 12.1 Validation policy\n\n12.10 The company\u2019s overall policy, intentions and approach to validation, including the validation of production processes, cleaning procedures, analytical methods, in-process control test procedures, computerized systems and personnel responsible for design, review, approval and documentation of each validation phase, should be documented.\n\n12.11 The critical parameters and attributes should normally be identified during the development stage or from historical data and the ranges necessary for the reproducible operation should be defined. This should include:\n\n- defining the API in terms of its critical product attributes;\n- identifying process parameters that could affect the critical quality attributes of the API;\n- determining the range for each critical process parameter expected to be used during routine manufacturing and process control.\n\n12.12 Validation should extend to those operations determined to be critical to the quality and purity of the API.\n\n## 12.2 Validation documentation\n\n12.20 A written validation protocol should be established that specifies how validation of a particular process will be conducted. The protocol should be reviewed and approved by the quality unit(s) and other designated units.\n\n12.21 The validation protocol should specify critical process steps and acceptance criteria as well as the type of validation to be conducted (e.g. retrospective, prospective or concurrent) and the number of process runs.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la gesti\u00f3n de muestras de reserva de ingredientes farmac\u00e9uticos activos (API) y la importancia de la validaci\u00f3n en los procesos de producci\u00f3n. Se establece que las muestras de reserva deben conservarse durante un per\u00edodo espec\u00edfico, dependiendo de la fecha de caducidad o la distribuci\u00f3n. Adem\u00e1s, se detalla la pol\u00edtica de validaci\u00f3n que debe seguir una empresa, incluyendo la documentaci\u00f3n necesaria y la identificaci\u00f3n de par\u00e1metros cr\u00edticos que afectan la calidad del API.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1nto tiempo deben conservarse las muestras de reserva de un lote de API y bajo qu\u00e9 condiciones?**\n   - Las muestras de reserva de cada lote de API deben conservarse durante un a\u00f1o despu\u00e9s de la fecha de caducidad asignada por el fabricante o durante tres a\u00f1os despu\u00e9s de la distribuci\u00f3n del lote, lo que sea m\u00e1s largo. Para los API con fechas de rean\u00e1lisis, las muestras deben conservarse durante tres a\u00f1os despu\u00e9s de que el lote haya sido completamente distribuido.\n\n2. **\u00bfQu\u00e9 debe incluir un protocolo de validaci\u00f3n seg\u00fan el documento de la OMS?**\n   - Un protocolo de validaci\u00f3n debe especificar c\u00f3mo se llevar\u00e1 a cabo la validaci\u00f3n de un proceso particular, incluyendo los pasos cr\u00edticos del proceso, los criterios de aceptaci\u00f3n, el tipo de validaci\u00f3n (retrospectiva, prospectiva o concurrente) y el n\u00famero de ejecuciones del proceso. Adem\u00e1s, debe ser revisado y aprobado por las unidades de calidad y otras unidades designadas.\n\n3. **\u00bfCu\u00e1les son los par\u00e1metros cr\u00edticos que deben identificarse durante la etapa de desarrollo de un API?**\n   - Durante la etapa de desarrollo, se deben identificar los par\u00e1metros cr\u00edticos y atributos del API, que incluyen la definici\u00f3n del API en t\u00e9rminos de sus atributos cr\u00edticos del producto, la identificaci\u00f3n de par\u00e1metros de proceso que podr\u00edan afectar la calidad cr\u00edtica del API y la determinaci\u00f3n del rango para cada par\u00e1metro cr\u00edtico de proceso que se espera utilizar durante la fabricaci\u00f3n y el control del proceso.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Monitoreo de estabilidad de APIs**:\n   - Se recomienda que los primeros tres lotes de producci\u00f3n comercial se incluyan en un programa de monitoreo de estabilidad para confirmar las fechas de rean\u00e1lisis o caducidad.\n   - Si hay datos previos que indican que el API se mantendr\u00e1 estable por al menos dos a\u00f1os, se puede reducir el n\u00famero de lotes a menos de tres.\n\n2. **Frecuencia de pruebas**:\n   - Al menos un lote por a\u00f1o debe ser a\u00f1adido al programa de monitoreo de estabilidad y probado anualmente.\n   - Para APIs con vida \u00fatil corta (un a\u00f1o o menos), se deben realizar pruebas mensuales durante los primeros tres meses y luego a intervalos de tres meses.\n\n3. **Condiciones de almacenamiento**:\n   - Las condiciones de almacenamiento de estabilidad deben alinearse con las directrices de la OMS sobre estabilidad.\n\n4. **Fechas de caducidad y rean\u00e1lisis**:\n   - Las fechas de caducidad o rean\u00e1lisis deben basarse en datos de estudios de estabilidad.\n   - Se prefiere utilizar una fecha de rean\u00e1lisis en lugar de una fecha de caducidad.\n\n5. **Lotes de escala piloto**:\n   - Las fechas preliminares de caducidad o rean\u00e1lisis pueden basarse en lotes de escala piloto si simulan el proceso final de fabricaci\u00f3n y la calidad del API es representativa del material comercial.\n\n6. **Muestras de reserva**:\n   - Las muestras de reserva se utilizan para la evaluaci\u00f3n futura de la calidad de los lotes de API, no para pruebas de estabilidad.\n\n### Entidades:\n- **API (Ingrediente Farmac\u00e9utico Activo)**: Sustancia que se utiliza en la fabricaci\u00f3n de medicamentos.\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organizaci\u00f3n que proporciona directrices sobre la estabilidad de los productos farmac\u00e9uticos.\n- **Estudios de estabilidad**: Investigaciones que eval\u00faan la estabilidad de un API a lo largo del tiempo bajo condiciones espec\u00edficas.\n- **Lotes de producci\u00f3n**: Cantidades de productos fabricados en un solo ciclo de producci\u00f3n.", "excerpt_keywords": "Keywords: API, validation, reserve samples, quality control, pharmaceutical standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2a07ad8a-43bb-4cf9-955f-92e0062ab51f", "node_type": "4", "metadata": {"page_label": "177", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11.71\nAppropriately identified reserve samples of each batch of API should be retained for one year after the expiry date assigned by the manufacturer to the batch, or for three years after distribution of the batch, whichever is the longer. For APIs with retest dates, similar reserve samples should be retained for three years after the batch has been completely distributed by the manufacturer.\n\n11.72 The reserve sample should be stored in the same packaging system in which the API is stored or in one that is equivalent to or more protective than the marketed packaging system. Sufficient quantities should be retained to conduct at least two full compendial analyses or, when there is no pharmacopoeial monograph, two full specification analyses.\n\n# 12. Validation\n\n## 12.1 Validation policy\n\n12.10 The company\u2019s overall policy, intentions and approach to validation, including the validation of production processes, cleaning procedures, analytical methods, in-process control test procedures, computerized systems and personnel responsible for design, review, approval and documentation of each validation phase, should be documented.\n\n12.11 The critical parameters and attributes should normally be identified during the development stage or from historical data and the ranges necessary for the reproducible operation should be defined. This should include:\n\n- defining the API in terms of its critical product attributes;\n- identifying process parameters that could affect the critical quality attributes of the API;\n- determining the range for each critical process parameter expected to be used during routine manufacturing and process control.\n\n12.12 Validation should extend to those operations determined to be critical to the quality and purity of the API.\n\n## 12.2 Validation documentation\n\n12.20 A written validation protocol should be established that specifies how validation of a particular process will be conducted. The protocol should be reviewed and approved by the quality unit(s) and other designated units.\n\n12.21 The validation protocol should specify critical process steps and acceptance criteria as well as the type of validation to be conducted (e.g. retrospective, prospective or concurrent) and the number of process runs.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "242082fb3ba7b336719d5e82db5c8a4373391d0217248b81aa264bf5d6b6ad64", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 11.71\nAppropriately identified reserve samples of each batch of API should be retained for one year after the expiry date assigned by the manufacturer to the batch, or for three years after distribution of the batch, whichever is the longer. For APIs with retest dates, similar reserve samples should be retained for three years after the batch has been completely distributed by the manufacturer.\n\n11.72 The reserve sample should be stored in the same packaging system in which the API is stored or in one that is equivalent to or more protective than the marketed packaging system. Sufficient quantities should be retained to conduct at least two full compendial analyses or, when there is no pharmacopoeial monograph, two full specification analyses.\n\n# 12. Validation\n\n## 12.1 Validation policy\n\n12.10 The company\u2019s overall policy, intentions and approach to validation, including the validation of production processes, cleaning procedures, analytical methods, in-process control test procedures, computerized systems and personnel responsible for design, review, approval and documentation of each validation phase, should be documented.\n\n12.11 The critical parameters and attributes should normally be identified during the development stage or from historical data and the ranges necessary for the reproducible operation should be defined. This should include:\n\n- defining the API in terms of its critical product attributes;\n- identifying process parameters that could affect the critical quality attributes of the API;\n- determining the range for each critical process parameter expected to be used during routine manufacturing and process control.\n\n12.12 Validation should extend to those operations determined to be critical to the quality and purity of the API.\n\n## 12.2 Validation documentation\n\n12.20 A written validation protocol should be established that specifies how validation of a particular process will be conducted. The protocol should be reviewed and approved by the quality unit(s) and other designated units.\n\n12.21 The validation protocol should specify critical process steps and acceptance criteria as well as the type of validation to be conducted (e.g. retrospective, prospective or concurrent) and the number of process runs.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2261, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a209e0c2-130b-4385-a9d2-8f5489fd947b": {"__data__": {"id_": "a209e0c2-130b-4385-a9d2-8f5489fd947b", "embedding": null, "metadata": {"page_label": "178", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Qualification\n\n12.22 A validation report that cross-references the validation protocol should be prepared, summarizing the results obtained, commenting on any deviations observed and drawing the appropriate conclusions, including recommending changes to correct deficiencies.\n\n12.23 Any variations from the validation protocol should be documented with appropriate justification.\n\n## 12.3 Qualification\n\n12.30 Before starting process validation activities, appropriate qualification of critical equipment and ancillary systems should be completed. Qualification is usually carried out by conducting the following activities, individually or combined:\n\n- **Design qualification (DQ):** Documented verification that the proposed design of the facilities, equipment, or systems is suitable for the intended purpose;\n- **Installation qualification (IQ):** Documented verification that the equipment or systems, as installed or modified, comply with the approved design, the manufacturer\u2019s recommendations and/or user requirements;\n- **Operational qualification (OQ):** Documented verification that the equipment or systems, as installed or modified, perform as intended throughout the anticipated operating ranges;\n- **Performance qualification (PQ):** Documented verification that the equipment and ancillary systems, as connected together, can perform effectively and reproducibly based on the approved process method and specifications.\n\n## 12.4 Approaches to process validation\n\n12.40 Process validation (PV) is the documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce an intermediate or API meeting its predetermined specifications and quality attributes.\n\n12.41 There are three approaches to validation. Prospective validation is the preferred approach, but there are exceptions where the other approaches can be used. These three approaches and their applicability are outlined below.\n\n12.42 Prospective validation should normally be performed for all API processes as defined in section 12.1.3. Prospective validation performed on an API process should be completed before the commercial distribution of the FPP manufactured from that API.\n\n12.43 Concurrent validation can be conducted when data from replicate production runs are unavailable because only a limited number of API.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla los procedimientos de calificaci\u00f3n y validaci\u00f3n de procesos en la producci\u00f3n de ingredientes farmac\u00e9uticos activos (API). Se enfatiza la importancia de realizar una calificaci\u00f3n adecuada de equipos cr\u00edticos y sistemas auxiliares antes de iniciar actividades de validaci\u00f3n de procesos. Se describen cuatro tipos de calificaci\u00f3n: DQ, IQ, OQ y PQ, cada una con su prop\u00f3sito espec\u00edfico. Adem\u00e1s, se presentan tres enfoques para la validaci\u00f3n de procesos, siendo la validaci\u00f3n prospectiva la m\u00e1s recomendada, aunque se permiten excepciones.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los cuatro tipos de calificaci\u00f3n que deben realizarse antes de iniciar la validaci\u00f3n de procesos, y qu\u00e9 verifica cada uno?**\n   - Respuesta: Los cuatro tipos de calificaci\u00f3n son: \n     - **Design Qualification (DQ):** Verifica que el dise\u00f1o propuesto sea adecuado para su prop\u00f3sito.\n     - **Installation Qualification (IQ):** Verifica que el equipo o sistemas instalados cumplan con el dise\u00f1o aprobado y las recomendaciones del fabricante.\n     - **Operational Qualification (OQ):** Verifica que el equipo o sistemas funcionen como se espera dentro de los rangos operativos anticipados.\n     - **Performance Qualification (PQ):** Verifica que los equipos y sistemas conectados funcionen de manera efectiva y reproducible seg\u00fan el m\u00e9todo y especificaciones aprobadas.\n\n2. **\u00bfQu\u00e9 se debe hacer si hay variaciones del protocolo de validaci\u00f3n durante el proceso?**\n   - Respuesta: Cualquier variaci\u00f3n del protocolo de validaci\u00f3n debe ser documentada con la justificaci\u00f3n apropiada.\n\n3. **\u00bfEn qu\u00e9 situaciones se puede utilizar la validaci\u00f3n concurrente en lugar de la validaci\u00f3n prospectiva?**\n   - Respuesta: La validaci\u00f3n concurrente puede llevarse a cabo cuando no hay datos disponibles de corridas de producci\u00f3n replicadas debido a que solo se dispone de un n\u00famero limitado de API.", "prev_section_summary": "### Temas Clave:\n\n1. **Muestras de Reserva de API**:\n   - Las muestras de reserva de cada lote de Ingredientes Farmac\u00e9uticos Activos (API) deben conservarse durante un a\u00f1o despu\u00e9s de la fecha de caducidad o tres a\u00f1os despu\u00e9s de la distribuci\u00f3n, lo que sea m\u00e1s largo.\n   - Para APIs con fechas de rean\u00e1lisis, las muestras deben conservarse tres a\u00f1os despu\u00e9s de la distribuci\u00f3n completa del lote.\n   - Las muestras deben almacenarse en el mismo sistema de empaquetado que el API o en uno que ofrezca igual o mayor protecci\u00f3n.\n\n2. **Validaci\u00f3n**:\n   - La pol\u00edtica de validaci\u00f3n de la empresa debe documentar el enfoque hacia la validaci\u00f3n de procesos de producci\u00f3n, m\u00e9todos anal\u00edticos, procedimientos de limpieza, y sistemas computarizados.\n   - Se deben identificar par\u00e1metros cr\u00edticos y atributos durante la etapa de desarrollo, as\u00ed como definir los rangos necesarios para la operaci\u00f3n reproducible.\n   - La validaci\u00f3n debe abarcar operaciones cr\u00edticas para la calidad y pureza del API.\n\n3. **Documentaci\u00f3n de Validaci\u00f3n**:\n   - Se debe establecer un protocolo de validaci\u00f3n escrito que especifique c\u00f3mo se llevar\u00e1 a cabo la validaci\u00f3n de un proceso particular.\n   - El protocolo debe ser revisado y aprobado por las unidades de calidad y otras unidades designadas, e incluir pasos cr\u00edticos del proceso, criterios de aceptaci\u00f3n y el tipo de validaci\u00f3n a realizar.\n\n### Entidades:\n\n- **API (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias utilizadas en la fabricaci\u00f3n de medicamentos.\n- **Muestras de Reserva**: Muestras conservadas para an\u00e1lisis futuros.\n- **Protocolo de Validaci\u00f3n**: Documento que detalla el proceso de validaci\u00f3n.\n- **Par\u00e1metros Cr\u00edticos**: Factores que afectan la calidad del API.\n- **Unidades de Calidad**: Departamentos responsables de asegurar la calidad en la producci\u00f3n.\n\nEste resumen destaca la importancia de la gesti\u00f3n de muestras de reserva y la validaci\u00f3n en la producci\u00f3n de APIs, asegurando que se mantenga la calidad y la pureza de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: Qualification, Validation, Process Validation, Design Qualification, Performance Qualification"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "34554caa-8089-4238-ac7a-f6ffd2037731", "node_type": "4", "metadata": {"page_label": "178", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Qualification\n\n12.22 A validation report that cross-references the validation protocol should be prepared, summarizing the results obtained, commenting on any deviations observed and drawing the appropriate conclusions, including recommending changes to correct deficiencies.\n\n12.23 Any variations from the validation protocol should be documented with appropriate justification.\n\n## 12.3 Qualification\n\n12.30 Before starting process validation activities, appropriate qualification of critical equipment and ancillary systems should be completed. Qualification is usually carried out by conducting the following activities, individually or combined:\n\n- **Design qualification (DQ):** Documented verification that the proposed design of the facilities, equipment, or systems is suitable for the intended purpose;\n- **Installation qualification (IQ):** Documented verification that the equipment or systems, as installed or modified, comply with the approved design, the manufacturer\u2019s recommendations and/or user requirements;\n- **Operational qualification (OQ):** Documented verification that the equipment or systems, as installed or modified, perform as intended throughout the anticipated operating ranges;\n- **Performance qualification (PQ):** Documented verification that the equipment and ancillary systems, as connected together, can perform effectively and reproducibly based on the approved process method and specifications.\n\n## 12.4 Approaches to process validation\n\n12.40 Process validation (PV) is the documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce an intermediate or API meeting its predetermined specifications and quality attributes.\n\n12.41 There are three approaches to validation. Prospective validation is the preferred approach, but there are exceptions where the other approaches can be used. These three approaches and their applicability are outlined below.\n\n12.42 Prospective validation should normally be performed for all API processes as defined in section 12.1.3. Prospective validation performed on an API process should be completed before the commercial distribution of the FPP manufactured from that API.\n\n12.43 Concurrent validation can be conducted when data from replicate production runs are unavailable because only a limited number of API.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "95aa6a4bb1cb909db09a3f61126973bfd6c9598d3f7848675d6495ed169a3951", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Qualification\n\n12.22 A validation report that cross-references the validation protocol should be prepared, summarizing the results obtained, commenting on any deviations observed and drawing the appropriate conclusions, including recommending changes to correct deficiencies.\n\n12.23 Any variations from the validation protocol should be documented with appropriate justification.\n\n## 12.3 Qualification\n\n12.30 Before starting process validation activities, appropriate qualification of critical equipment and ancillary systems should be completed. Qualification is usually carried out by conducting the following activities, individually or combined:\n\n- **Design qualification (DQ):** Documented verification that the proposed design of the facilities, equipment, or systems is suitable for the intended purpose;\n- **Installation qualification (IQ):** Documented verification that the equipment or systems, as installed or modified, comply with the approved design, the manufacturer\u2019s recommendations and/or user requirements;\n- **Operational qualification (OQ):** Documented verification that the equipment or systems, as installed or modified, perform as intended throughout the anticipated operating ranges;\n- **Performance qualification (PQ):** Documented verification that the equipment and ancillary systems, as connected together, can perform effectively and reproducibly based on the approved process method and specifications.\n\n## 12.4 Approaches to process validation\n\n12.40 Process validation (PV) is the documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce an intermediate or API meeting its predetermined specifications and quality attributes.\n\n12.41 There are three approaches to validation. Prospective validation is the preferred approach, but there are exceptions where the other approaches can be used. These three approaches and their applicability are outlined below.\n\n12.42 Prospective validation should normally be performed for all API processes as defined in section 12.1.3. Prospective validation performed on an API process should be completed before the commercial distribution of the FPP manufactured from that API.\n\n12.43 Concurrent validation can be conducted when data from replicate production runs are unavailable because only a limited number of API.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2363, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "cfe7a901-5c05-4c35-b6ba-acf9bd54a3eb": {"__data__": {"id_": "cfe7a901-5c05-4c35-b6ba-acf9bd54a3eb", "embedding": null, "metadata": {"page_label": "179", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "batches have been produced, API batches are produced infrequently, or API batches are produced by a validated process that has been modified. Prior to the completion of concurrent validation, batches can be released and used in FPPs for commercial distribution based on thorough monitoring and testing of the API batches.\n\n12.44 An exception can be made for retrospective validation for well-established processes that have been used without significant changes to API quality due to changes in raw materials, equipment, systems, facilities or the production process. This validation approach may be used where:\n\n1. Critical quality attributes and critical process parameters have been identified.\n2. Appropriate in-process acceptance criteria and controls have been established.\n3. There have not been significant process or product failures attributable to causes other than operator error or equipment failures unrelated to equipment suitability.\n4. Impurity profiles have been established for the existing API.\n\n12.45 Batches selected for retrospective validation should be representative of all batches made during the review period, including any batches that failed to meet specifications, and should be sufficient in number to demonstrate process consistency. Retained samples can be tested to obtain data to retrospectively validate the process.\n\n## 12.5 Process validation programme\n\n12.50 The number of process runs for validation should depend on the complexity of the process or the magnitude of the process change being considered. For prospective and concurrent validation, three consecutive successful production batches should be used as a guide, but there may be situations where additional process runs are warranted to prove consistency of the process (e.g. complex API processes or API processes with prolonged completion times). Generally, for retrospective validation, data from 10 to 30 consecutive batches should be examined to assess process consistency, but fewer batches can be examined if justified.\n\n12.51 Critical process parameters should be controlled and monitored during process validation studies. Process parameters unrelated to quality, such as variables controlled to minimize energy consumption or equipment use, need not be included in the process validation.\n\n12.52 Process validation should confirm that the impurity profile for each API is within the limits specified. The impurity profile should be comparable to or better than historical data and, where applicable, the profile determined.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en la validaci\u00f3n de procesos en la producci\u00f3n de ingredientes farmac\u00e9uticos activos (API). Se discuten diferentes enfoques de validaci\u00f3n: prospectiva, concurrente y retrospectiva. La validaci\u00f3n retrospectiva se permite para procesos bien establecidos que no han sufrido cambios significativos en la calidad del API. Se establecen criterios para seleccionar lotes para la validaci\u00f3n retrospectiva, as\u00ed como la cantidad de lotes que deben ser examinados para asegurar la consistencia del proceso. Tambi\u00e9n se enfatiza la importancia de controlar y monitorear par\u00e1metros cr\u00edticos del proceso y de confirmar que el perfil de impurezas del API est\u00e9 dentro de los l\u00edmites especificados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios que deben cumplirse para considerar la validaci\u00f3n retrospectiva de un proceso de producci\u00f3n de API?**\n   - La validaci\u00f3n retrospectiva puede considerarse si se han identificado atributos cr\u00edticos de calidad y par\u00e1metros cr\u00edticos del proceso, se han establecido criterios de aceptaci\u00f3n y controles en proceso, no ha habido fallos significativos en el proceso o producto, y se han establecido perfiles de impurezas para el API existente.\n\n2. **\u00bfQu\u00e9 cantidad de lotes se recomienda examinar para la validaci\u00f3n retrospectiva y bajo qu\u00e9 condiciones se puede justificar un n\u00famero menor?**\n   - Se recomienda examinar entre 10 y 30 lotes consecutivos para la validaci\u00f3n retrospectiva, pero se puede justificar un n\u00famero menor si hay razones adecuadas que lo respalden.\n\n3. **\u00bfQu\u00e9 par\u00e1metros del proceso deben ser controlados y monitoreados durante los estudios de validaci\u00f3n del proceso?**\n   - Durante la validaci\u00f3n del proceso, deben ser controlados y monitoreados los par\u00e1metros cr\u00edticos del proceso. Los par\u00e1metros no relacionados con la calidad, como aquellos que minimizan el consumo de energ\u00eda o el uso de equipos, no necesitan ser incluidos en la validaci\u00f3n del proceso.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Calificaci\u00f3n (Qualification)**:\n   - Se refiere a la verificaci\u00f3n documentada de que los equipos cr\u00edticos y sistemas auxiliares cumplen con los requisitos necesarios antes de iniciar la validaci\u00f3n de procesos.\n   - Incluye cuatro tipos de calificaci\u00f3n:\n     - **Design Qualification (DQ)**: Verifica la adecuaci\u00f3n del dise\u00f1o propuesto.\n     - **Installation Qualification (IQ)**: Verifica que la instalaci\u00f3n cumpla con el dise\u00f1o aprobado y recomendaciones del fabricante.\n     - **Operational Qualification (OQ)**: Verifica que el equipo funcione como se espera dentro de los rangos operativos.\n     - **Performance Qualification (PQ)**: Verifica que los sistemas conectados funcionen de manera efectiva y reproducible.\n\n2. **Validaci\u00f3n de Procesos (Process Validation)**:\n   - Es la evidencia documentada de que un proceso puede operar dentro de par\u00e1metros establecidos para producir un producto intermedio o API que cumpla con especificaciones y atributos de calidad predeterminados.\n   - Se identifican tres enfoques para la validaci\u00f3n:\n     - **Validaci\u00f3n Prospectiva**: Preferida y debe completarse antes de la distribuci\u00f3n comercial del producto final.\n     - **Validaci\u00f3n Concurrente**: Se utiliza cuando no hay datos de corridas de producci\u00f3n replicadas disponibles.\n\n3. **Documentaci\u00f3n y Justificaci\u00f3n**:\n   - Se requiere un informe de validaci\u00f3n que resuma los resultados y comente sobre cualquier desviaci\u00f3n observada.\n   - Cualquier variaci\u00f3n del protocolo de validaci\u00f3n debe ser documentada con justificaci\u00f3n adecuada.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Ingredientes Farmac\u00e9uticos Activos (API)**: Sustancias que se utilizan en la producci\u00f3n de medicamentos.\n- **Proceso de Validaci\u00f3n**: Conjunto de actividades para asegurar que un proceso cumple con los est\u00e1ndares requeridos.\n\nEste resumen destaca la importancia de la calificaci\u00f3n y validaci\u00f3n en la producci\u00f3n farmac\u00e9utica, as\u00ed como los procedimientos y enfoques necesarios para garantizar la calidad y eficacia de los productos.", "excerpt_keywords": "Keywords: validaci\u00f3n de procesos, ingredientes farmac\u00e9uticos activos, calidad, par\u00e1metros cr\u00edticos, perfil de impurezas"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "499749d7-8761-45c1-9276-b7fbcced6607", "node_type": "4", "metadata": {"page_label": "179", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "batches have been produced, API batches are produced infrequently, or API batches are produced by a validated process that has been modified. Prior to the completion of concurrent validation, batches can be released and used in FPPs for commercial distribution based on thorough monitoring and testing of the API batches.\n\n12.44 An exception can be made for retrospective validation for well-established processes that have been used without significant changes to API quality due to changes in raw materials, equipment, systems, facilities or the production process. This validation approach may be used where:\n\n1. Critical quality attributes and critical process parameters have been identified.\n2. Appropriate in-process acceptance criteria and controls have been established.\n3. There have not been significant process or product failures attributable to causes other than operator error or equipment failures unrelated to equipment suitability.\n4. Impurity profiles have been established for the existing API.\n\n12.45 Batches selected for retrospective validation should be representative of all batches made during the review period, including any batches that failed to meet specifications, and should be sufficient in number to demonstrate process consistency. Retained samples can be tested to obtain data to retrospectively validate the process.\n\n## 12.5 Process validation programme\n\n12.50 The number of process runs for validation should depend on the complexity of the process or the magnitude of the process change being considered. For prospective and concurrent validation, three consecutive successful production batches should be used as a guide, but there may be situations where additional process runs are warranted to prove consistency of the process (e.g. complex API processes or API processes with prolonged completion times). Generally, for retrospective validation, data from 10 to 30 consecutive batches should be examined to assess process consistency, but fewer batches can be examined if justified.\n\n12.51 Critical process parameters should be controlled and monitored during process validation studies. Process parameters unrelated to quality, such as variables controlled to minimize energy consumption or equipment use, need not be included in the process validation.\n\n12.52 Process validation should confirm that the impurity profile for each API is within the limits specified. The impurity profile should be comparable to or better than historical data and, where applicable, the profile determined.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "760a2e37d62176047f2afc7ab4fd9a02483ce7907e78f10aa60fa9b21f1ac76b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "batches have been produced, API batches are produced infrequently, or API batches are produced by a validated process that has been modified. Prior to the completion of concurrent validation, batches can be released and used in FPPs for commercial distribution based on thorough monitoring and testing of the API batches.\n\n12.44 An exception can be made for retrospective validation for well-established processes that have been used without significant changes to API quality due to changes in raw materials, equipment, systems, facilities or the production process. This validation approach may be used where:\n\n1. Critical quality attributes and critical process parameters have been identified.\n2. Appropriate in-process acceptance criteria and controls have been established.\n3. There have not been significant process or product failures attributable to causes other than operator error or equipment failures unrelated to equipment suitability.\n4. Impurity profiles have been established for the existing API.\n\n12.45 Batches selected for retrospective validation should be representative of all batches made during the review period, including any batches that failed to meet specifications, and should be sufficient in number to demonstrate process consistency. Retained samples can be tested to obtain data to retrospectively validate the process.\n\n## 12.5 Process validation programme\n\n12.50 The number of process runs for validation should depend on the complexity of the process or the magnitude of the process change being considered. For prospective and concurrent validation, three consecutive successful production batches should be used as a guide, but there may be situations where additional process runs are warranted to prove consistency of the process (e.g. complex API processes or API processes with prolonged completion times). Generally, for retrospective validation, data from 10 to 30 consecutive batches should be examined to assess process consistency, but fewer batches can be examined if justified.\n\n12.51 Critical process parameters should be controlled and monitored during process validation studies. Process parameters unrelated to quality, such as variables controlled to minimize energy consumption or equipment use, need not be included in the process validation.\n\n12.52 Process validation should confirm that the impurity profile for each API is within the limits specified. The impurity profile should be comparable to or better than historical data and, where applicable, the profile determined.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2535, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "613e0c61-f90c-41bc-9148-ee89351cceb9": {"__data__": {"id_": "613e0c61-f90c-41bc-9148-ee89351cceb9", "embedding": null, "metadata": {"page_label": "180", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 12.6 Periodic review of validated systems\n\n12.60 Systems and processes should be periodically evaluated to verify that they are still operating in a valid manner. Where no significant changes have been made to the system or process, and a quality review confirms that the system or process is consistently producing material meeting its specifications, there is normally no need for revalidation.\n\n# 12.7 Cleaning validation\n\n12.70 Cleaning procedures should normally be validated. In general, cleaning validation should be directed to those situations or process steps where contamination or carry-over of materials poses the greatest risk to API quality. For example, in early production it may be unnecessary to validate equipment cleaning procedures where residues are removed by subsequent purification steps.\n\n12.71 Validation of cleaning procedures should reflect actual equipment usage patterns. If various APIs or intermediates are manufactured in the same equipment and the equipment is cleaned by the same process, a representative intermediate or API can be selected for cleaning validation. This selection should be based on the solubility and difficulty of cleaning and the calculation of residue limits based on potency, toxicity and stability.\n\n12.72 The cleaning validation protocol should describe the equipment to be cleaned, procedures, materials, acceptable cleaning levels, parameters to be monitored and controlled and analytical methods. The protocol should also indicate the type of samples to be obtained and how they are collected and labelled.\n\n12.73 Sampling should include swabbing, rinsing or alternative methods (e.g. direct extraction), as appropriate, to detect both insoluble and soluble residues. The sampling methods used should be capable of quantitatively measuring levels of residues remaining on the equipment surfaces after cleaning. Swab sampling may be impractical when product contact surfaces are not easily accessible due to equipment design and/or process limitations (e.g. inner surfaces of hoses, transfer pipes, reactor tanks with small ports for handling toxic materials and small intricate equipment such as micronizers and microfluidizers).\n\n12.74 Validated analytical methods with the sensitivity to detect residues or contaminants should be used. The detection limit for each analytical method should be sufficiently sensitive to detect the established acceptable limits.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS aborda la revisi\u00f3n peri\u00f3dica de sistemas validados y la validaci\u00f3n de procedimientos de limpieza en la producci\u00f3n de ingredientes farmac\u00e9uticos activos (API). Se enfatiza la importancia de evaluar regularmente los sistemas para asegurar su validez y la necesidad de validar los procedimientos de limpieza, especialmente en situaciones donde hay un alto riesgo de contaminaci\u00f3n. Se detallan los aspectos que deben incluirse en un protocolo de validaci\u00f3n de limpieza, como la descripci\u00f3n del equipo, los procedimientos, los niveles de limpieza aceptables y los m\u00e9todos anal\u00edticos. Tambi\u00e9n se menciona la importancia de utilizar m\u00e9todos anal\u00edticos validados que sean sensibles para detectar residuos o contaminantes.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar al seleccionar un API o intermedio representativo para la validaci\u00f3n de limpieza?**\n   - La selecci\u00f3n debe basarse en la solubilidad y la dificultad de limpieza, as\u00ed como en el c\u00e1lculo de l\u00edmites de residuos considerando la potencia, toxicidad y estabilidad del material.\n\n2. **\u00bfCu\u00e1les son los m\u00e9todos de muestreo recomendados para la validaci\u00f3n de limpieza y qu\u00e9 desaf\u00edos pueden presentarse?**\n   - Los m\u00e9todos de muestreo incluyen swabbing, enjuague o m\u00e9todos alternativos como la extracci\u00f3n directa. Sin embargo, el muestreo por swabbing puede ser impr\u00e1ctico en superficies de contacto con el producto que no son f\u00e1cilmente accesibles debido al dise\u00f1o del equipo o limitaciones del proceso.\n\n3. **\u00bfQu\u00e9 elementos debe incluir un protocolo de validaci\u00f3n de limpieza?**\n   - El protocolo debe describir el equipo a limpiar, los procedimientos, los materiales, los niveles de limpieza aceptables, los par\u00e1metros a monitorear y controlar, los m\u00e9todos anal\u00edticos, as\u00ed como el tipo de muestras a obtener y c\u00f3mo se recolectan y etiquetan.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Validaci\u00f3n de Procesos:**\n   - Se discuten tres enfoques de validaci\u00f3n: prospectiva, concurrente y retrospectiva.\n   - La validaci\u00f3n retrospectiva se permite para procesos bien establecidos sin cambios significativos en la calidad del API.\n\n2. **Criterios para Validaci\u00f3n Retrospectiva:**\n   - Identificaci\u00f3n de atributos cr\u00edticos de calidad y par\u00e1metros cr\u00edticos del proceso.\n   - Establecimiento de criterios de aceptaci\u00f3n y controles en proceso.\n   - Ausencia de fallos significativos en el proceso o producto, excepto por errores de operador o fallos de equipo no relacionados con la idoneidad del equipo.\n   - Establecimiento de perfiles de impurezas para el API existente.\n\n3. **Selecci\u00f3n de Lotes para Validaci\u00f3n:**\n   - Los lotes seleccionados deben ser representativos de todos los lotes producidos durante el per\u00edodo de revisi\u00f3n.\n   - Se recomienda examinar entre 10 y 30 lotes consecutivos, aunque se puede justificar un n\u00famero menor.\n\n4. **Control y Monitoreo de Par\u00e1metros Cr\u00edticos:**\n   - Los par\u00e1metros cr\u00edticos del proceso deben ser controlados y monitoreados durante los estudios de validaci\u00f3n.\n   - Par\u00e1metros no relacionados con la calidad no necesitan ser incluidos en la validaci\u00f3n.\n\n5. **Confirmaci\u00f3n del Perfil de Impurezas:**\n   - La validaci\u00f3n del proceso debe confirmar que el perfil de impurezas del API est\u00e9 dentro de los l\u00edmites especificados y sea comparable o mejor que los datos hist\u00f3ricos.\n\n**Entidades:**\n\n- **API (Ingrediente Farmac\u00e9utico Activo):** Sustancia utilizada en la producci\u00f3n de medicamentos.\n- **FPP (Forma Farmac\u00e9utica del Producto):** Producto final que contiene el API.\n- **Par\u00e1metros Cr\u00edticos de Proceso:** Variables que afectan la calidad del producto.\n- **Perfiles de Impurezas:** Composici\u00f3n de impurezas en el API que debe ser controlada y validada.\n\nEste resumen destaca los aspectos esenciales de la validaci\u00f3n de procesos en la producci\u00f3n de API, enfatizando la importancia de criterios espec\u00edficos y el control de calidad.", "excerpt_keywords": "Keywords: validation, cleaning procedures, API quality, sampling methods, analytical methods"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1be8ffcc-306e-4c50-bf4a-d5d13bccd097", "node_type": "4", "metadata": {"page_label": "180", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 12.6 Periodic review of validated systems\n\n12.60 Systems and processes should be periodically evaluated to verify that they are still operating in a valid manner. Where no significant changes have been made to the system or process, and a quality review confirms that the system or process is consistently producing material meeting its specifications, there is normally no need for revalidation.\n\n# 12.7 Cleaning validation\n\n12.70 Cleaning procedures should normally be validated. In general, cleaning validation should be directed to those situations or process steps where contamination or carry-over of materials poses the greatest risk to API quality. For example, in early production it may be unnecessary to validate equipment cleaning procedures where residues are removed by subsequent purification steps.\n\n12.71 Validation of cleaning procedures should reflect actual equipment usage patterns. If various APIs or intermediates are manufactured in the same equipment and the equipment is cleaned by the same process, a representative intermediate or API can be selected for cleaning validation. This selection should be based on the solubility and difficulty of cleaning and the calculation of residue limits based on potency, toxicity and stability.\n\n12.72 The cleaning validation protocol should describe the equipment to be cleaned, procedures, materials, acceptable cleaning levels, parameters to be monitored and controlled and analytical methods. The protocol should also indicate the type of samples to be obtained and how they are collected and labelled.\n\n12.73 Sampling should include swabbing, rinsing or alternative methods (e.g. direct extraction), as appropriate, to detect both insoluble and soluble residues. The sampling methods used should be capable of quantitatively measuring levels of residues remaining on the equipment surfaces after cleaning. Swab sampling may be impractical when product contact surfaces are not easily accessible due to equipment design and/or process limitations (e.g. inner surfaces of hoses, transfer pipes, reactor tanks with small ports for handling toxic materials and small intricate equipment such as micronizers and microfluidizers).\n\n12.74 Validated analytical methods with the sensitivity to detect residues or contaminants should be used. The detection limit for each analytical method should be sufficiently sensitive to detect the established acceptable limits.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "13e411bc2eedefdff35bb1fb8dcbe3213c94f3be26c09475d2cfc892e7147b34", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 12.6 Periodic review of validated systems\n\n12.60 Systems and processes should be periodically evaluated to verify that they are still operating in a valid manner. Where no significant changes have been made to the system or process, and a quality review confirms that the system or process is consistently producing material meeting its specifications, there is normally no need for revalidation.\n\n# 12.7 Cleaning validation\n\n12.70 Cleaning procedures should normally be validated. In general, cleaning validation should be directed to those situations or process steps where contamination or carry-over of materials poses the greatest risk to API quality. For example, in early production it may be unnecessary to validate equipment cleaning procedures where residues are removed by subsequent purification steps.\n\n12.71 Validation of cleaning procedures should reflect actual equipment usage patterns. If various APIs or intermediates are manufactured in the same equipment and the equipment is cleaned by the same process, a representative intermediate or API can be selected for cleaning validation. This selection should be based on the solubility and difficulty of cleaning and the calculation of residue limits based on potency, toxicity and stability.\n\n12.72 The cleaning validation protocol should describe the equipment to be cleaned, procedures, materials, acceptable cleaning levels, parameters to be monitored and controlled and analytical methods. The protocol should also indicate the type of samples to be obtained and how they are collected and labelled.\n\n12.73 Sampling should include swabbing, rinsing or alternative methods (e.g. direct extraction), as appropriate, to detect both insoluble and soluble residues. The sampling methods used should be capable of quantitatively measuring levels of residues remaining on the equipment surfaces after cleaning. Swab sampling may be impractical when product contact surfaces are not easily accessible due to equipment design and/or process limitations (e.g. inner surfaces of hoses, transfer pipes, reactor tanks with small ports for handling toxic materials and small intricate equipment such as micronizers and microfluidizers).\n\n12.74 Validated analytical methods with the sensitivity to detect residues or contaminants should be used. The detection limit for each analytical method should be sufficiently sensitive to detect the established acceptable limits.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2429, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "42aa6792-8a98-436f-8974-1cbd8f109a99": {"__data__": {"id_": "42aa6792-8a98-436f-8974-1cbd8f109a99", "embedding": null, "metadata": {"page_label": "181", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Validation of Analytical Methods\n\n12.8 **Validation of analytical methods**\n\n12.80 Analytical methods should be validated unless the method employed is included in the relevant pharmacopoeia or other recognized standard reference. The suitability of all testing methods used should nonetheless be verified under actual conditions of use and documented.\n\n12.81 Methods should be validated to include consideration of characteristics included within the ICH guidelines on validation of analytical methods. The degree of analytical validation performed should reflect the purpose of the analysis and the stage of the API production process.\n\n12.82 Appropriate qualification of analytical equipment should be considered before starting validation of analytical methods.\n\n12.83 Complete records should be maintained of any modification of a validated analytical method. Such records should include the reason for the modification and appropriate data to verify that the modification produces results that are as accurate and reliable as the established method.\n\n# Change Control\n\n13. **Change control**\n\n13.10 A formal change control system should be established to evaluate all changes that may affect the production and control of the intermediate or API.\n\n13.11 Written procedures should cover the identification, documentation, appropriate review, and approval of changes in raw materials, specifications,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a formularlas:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda la validaci\u00f3n de m\u00e9todos anal\u00edticos y el control de cambios en la producci\u00f3n de ingredientes farmac\u00e9uticos activos (API). Se enfatiza la necesidad de validar m\u00e9todos anal\u00edticos, a menos que est\u00e9n incluidos en una farmacopea reconocida, y se requiere documentaci\u00f3n rigurosa de cualquier modificaci\u00f3n a estos m\u00e9todos. Adem\u00e1s, se establece la importancia de un sistema formal de control de cambios para gestionar cualquier alteraci\u00f3n que pueda afectar la producci\u00f3n y el control de los API.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 caracter\u00edsticas deben considerarse al validar m\u00e9todos anal\u00edticos seg\u00fan las pautas de la ICH?**\n   - Esta pregunta se centra en los criterios espec\u00edficos que deben tenerse en cuenta durante la validaci\u00f3n, que no se detallan en otros documentos.\n\n2. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para las modificaciones de un m\u00e9todo anal\u00edtico validado?**\n   - Esta pregunta busca informaci\u00f3n sobre los requisitos espec\u00edficos de documentaci\u00f3n que deben cumplirse al modificar un m\u00e9todo, lo cual es crucial para mantener la integridad del proceso anal\u00edtico.\n\n3. **\u00bfCu\u00e1les son los pasos clave que deben seguirse en un sistema de control de cambios formal seg\u00fan el documento?**\n   - Esta pregunta se enfoca en los procedimientos espec\u00edficos que deben implementarse para gestionar cambios en la producci\u00f3n y control de API, lo que puede no estar claramente definido en otras fuentes. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n detallada y espec\u00edfica que se encuentra en el contexto proporcionado y que puede no estar disponible en otros documentos.", "prev_section_summary": "### Temas Clave\n\n1. **Revisi\u00f3n Peri\u00f3dica de Sistemas Validados**:\n   - Importancia de evaluar regularmente los sistemas y procesos para asegurar que operan de manera v\u00e1lida.\n   - No es necesaria la revalidaci\u00f3n si no hay cambios significativos y se confirma que el sistema produce material que cumple con las especificaciones.\n\n2. **Validaci\u00f3n de Procedimientos de Limpieza**:\n   - Necesidad de validar los procedimientos de limpieza, especialmente en situaciones de alto riesgo de contaminaci\u00f3n.\n   - La validaci\u00f3n debe reflejar los patrones de uso real del equipo.\n\n3. **Selecci\u00f3n de APIs o Intermedios para Validaci\u00f3n**:\n   - La selecci\u00f3n debe basarse en la solubilidad, dificultad de limpieza y l\u00edmites de residuos considerando potencia, toxicidad y estabilidad.\n\n4. **Protocolo de Validaci\u00f3n de Limpieza**:\n   - Debe incluir descripci\u00f3n del equipo, procedimientos, materiales, niveles de limpieza aceptables, par\u00e1metros a monitorear y m\u00e9todos anal\u00edticos.\n   - Especificaci\u00f3n de tipos de muestras y su recolecci\u00f3n y etiquetado.\n\n5. **M\u00e9todos de Muestreo**:\n   - M\u00e9todos recomendados: swabbing, enjuague y extracci\u00f3n directa.\n   - Desaf\u00edos en el muestreo, especialmente en superficies de contacto de dif\u00edcil acceso.\n\n6. **M\u00e9todos Anal\u00edticos**:\n   - Uso de m\u00e9todos anal\u00edticos validados con sensibilidad adecuada para detectar residuos o contaminantes.\n   - Importancia de establecer l\u00edmites de detecci\u00f3n que sean suficientemente sensibles.\n\n### Entidades\n\n- **Sistemas y Procesos**: Referidos a los sistemas validados en la producci\u00f3n de ingredientes farmac\u00e9uticos activos (API).\n- **API (Ingredientes Farmac\u00e9uticos Activos)**: Materiales cuya calidad debe ser protegida mediante validaci\u00f3n de limpieza.\n- **Protocolo de Validaci\u00f3n**: Documento que detalla los procedimientos y criterios para la validaci\u00f3n de limpieza.\n- **M\u00e9todos de Muestreo**: T\u00e9cnicas utilizadas para recolectar muestras y evaluar la limpieza del equipo.\n- **M\u00e9todos Anal\u00edticos**: T\u00e9cnicas utilizadas para detectar residuos o contaminantes en el equipo.", "excerpt_keywords": "Keywords: validation, analytical methods, change control, API production, documentation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f56f935d-d01e-4553-bfaa-a44e5ce45602", "node_type": "4", "metadata": {"page_label": "181", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Validation of Analytical Methods\n\n12.8 **Validation of analytical methods**\n\n12.80 Analytical methods should be validated unless the method employed is included in the relevant pharmacopoeia or other recognized standard reference. The suitability of all testing methods used should nonetheless be verified under actual conditions of use and documented.\n\n12.81 Methods should be validated to include consideration of characteristics included within the ICH guidelines on validation of analytical methods. The degree of analytical validation performed should reflect the purpose of the analysis and the stage of the API production process.\n\n12.82 Appropriate qualification of analytical equipment should be considered before starting validation of analytical methods.\n\n12.83 Complete records should be maintained of any modification of a validated analytical method. Such records should include the reason for the modification and appropriate data to verify that the modification produces results that are as accurate and reliable as the established method.\n\n# Change Control\n\n13. **Change control**\n\n13.10 A formal change control system should be established to evaluate all changes that may affect the production and control of the intermediate or API.\n\n13.11 Written procedures should cover the identification, documentation, appropriate review, and approval of changes in raw materials, specifications,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "5f15900387886f7f69b81dae63cba59182bd84914c50f35e7ee21ab086538187", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Validation of Analytical Methods\n\n12.8 **Validation of analytical methods**\n\n12.80 Analytical methods should be validated unless the method employed is included in the relevant pharmacopoeia or other recognized standard reference. The suitability of all testing methods used should nonetheless be verified under actual conditions of use and documented.\n\n12.81 Methods should be validated to include consideration of characteristics included within the ICH guidelines on validation of analytical methods. The degree of analytical validation performed should reflect the purpose of the analysis and the stage of the API production process.\n\n12.82 Appropriate qualification of analytical equipment should be considered before starting validation of analytical methods.\n\n12.83 Complete records should be maintained of any modification of a validated analytical method. Such records should include the reason for the modification and appropriate data to verify that the modification produces results that are as accurate and reliable as the established method.\n\n# Change Control\n\n13. **Change control**\n\n13.10 A formal change control system should be established to evaluate all changes that may affect the production and control of the intermediate or API.\n\n13.11 Written procedures should cover the identification, documentation, appropriate review, and approval of changes in raw materials, specifications,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1406, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c3c618da-1605-47e6-80fa-e6ce94204ef4": {"__data__": {"id_": "c3c618da-1605-47e6-80fa-e6ce94204ef4", "embedding": null, "metadata": {"page_label": "182", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 13.12 \nAny proposals for relevant changes to GMP should be drafted, reviewed and approved by the appropriate organizational units and reviewed and approved by the quality unit(s).\n\n13.13 \nThe potential impact of the proposed change on the quality of the intermediate or API should be evaluated. A classification procedure may help in determining the level of testing, validation and documentation needed to justify changes to a validated process. Changes can be classified (e.g. as minor or major) depending on their nature and extent and the effects these changes may have on the process. Scientific judgement should be used to determine what additional testing and validation studies are appropriate to justify a change in a validated process.\n\n13.14 \nWhen implementing approved changes, measures should be taken to ensure that all documents affected by the changes are revised.\n\n13.15 \nAfter the change has been implemented there should be an evaluation of the first batches produced or tested under the change.\n\n13.16 \nThe potential for critical changes to affect established retest or expiry dates should be evaluated. If necessary, samples of the intermediate or API produced by the modified process can be placed on an accelerated stability programme and/or can be added to the stability monitoring programme.\n\n13.17 \nManufacturers of the current dosage form should be notified of changes from established production and process control procedures that can impact the quality of the API.\n\n# 14. Rejection and reuse of materials\n\n## 14.1 Rejection\n\n14.10 \nIntermediates and APIs failing to meet established specifications should be identified as such and quarantined. These intermediates or APIs can be reprocessed or reworked as described below. The final disposition of rejected materials should be recorded.\n\n## 14.2 Reprocessing\n\n14.20 \nIntroducing an intermediate or API, including one that does not conform to standards or specifications, back into the process and reprocessing by repeating a crystallization step or other appropriate chemical or physical manipulation steps (e.g. distillation, filtration,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en las Buenas Pr\u00e1cticas de Manufactura (GMP) relacionadas con la gesti\u00f3n de cambios en la producci\u00f3n de intermediarios y principios activos (API). Se discuten los procedimientos para evaluar el impacto de los cambios propuestos en la calidad del producto, la clasificaci\u00f3n de los cambios como menores o mayores, la necesidad de revisar documentos afectados, y la evaluaci\u00f3n de lotes producidos bajo los cambios. Tambi\u00e9n se aborda el rechazo y la reutilizaci\u00f3n de materiales que no cumplen con las especificaciones, as\u00ed como el proceso de reprocesamiento de estos materiales.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se utilizan para clasificar un cambio en el proceso de producci\u00f3n como menor o mayor, y c\u00f3mo afecta esto a los requisitos de validaci\u00f3n y documentaci\u00f3n?**\n   - Esta pregunta busca detalles sobre el proceso de clasificaci\u00f3n de cambios y su impacto en la gesti\u00f3n de calidad, que no se detalla expl\u00edcitamente en otros documentos.\n\n2. **\u00bfCu\u00e1les son los pasos espec\u00edficos que deben seguirse para garantizar que todos los documentos afectados por un cambio aprobado sean revisados y actualizados?**\n   - Esta pregunta se centra en el procedimiento pr\u00e1ctico de revisi\u00f3n de documentos, que puede no estar claramente definido en otras fuentes.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar si un cambio cr\u00edtico afecta las fechas de rean\u00e1lisis o caducidad de un API, y c\u00f3mo se implementa un programa de estabilidad acelerada?**\n   - Esta pregunta busca informaci\u00f3n sobre las acciones espec\u00edficas que deben tomarse en respuesta a cambios cr\u00edticos, as\u00ed como detalles sobre la implementaci\u00f3n de programas de estabilidad, que pueden no estar disponibles en otros contextos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### Temas Clave:\n\n1. **Validaci\u00f3n de M\u00e9todos Anal\u00edticos**:\n   - La validaci\u00f3n de m\u00e9todos anal\u00edticos es esencial, salvo que el m\u00e9todo est\u00e9 en una farmacopea reconocida.\n   - Se debe verificar la idoneidad de los m\u00e9todos de prueba en condiciones reales de uso.\n   - La validaci\u00f3n debe considerar las caracter\u00edsticas de las pautas de la ICH y debe adaptarse al prop\u00f3sito del an\u00e1lisis y la etapa del proceso de producci\u00f3n del API.\n   - Es necesario calificar adecuadamente el equipo anal\u00edtico antes de iniciar la validaci\u00f3n.\n   - Se deben mantener registros completos de cualquier modificaci\u00f3n a un m\u00e9todo anal\u00edtico validado, incluyendo la raz\u00f3n de la modificaci\u00f3n y datos que respalden la precisi\u00f3n y fiabilidad de los resultados.\n\n2. **Control de Cambios**:\n   - Se debe establecer un sistema formal de control de cambios para evaluar cualquier alteraci\u00f3n que pueda afectar la producci\u00f3n y control de intermediarios o APIs.\n   - Las procedimientos escritos deben abarcar la identificaci\u00f3n, documentaci\u00f3n, revisi\u00f3n y aprobaci\u00f3n de cambios en materias primas y especificaciones.\n\n#### Entidades:\n\n- **M\u00e9todos Anal\u00edticos**: T\u00e9cnicas utilizadas para analizar la calidad y composici\u00f3n de los ingredientes farmac\u00e9uticos activos.\n- **Farmacopea**: Compendio de est\u00e1ndares de calidad para medicamentos.\n- **ICH (International Council for Harmonisation)**: Organizaci\u00f3n que establece pautas para la validaci\u00f3n de m\u00e9todos anal\u00edticos.\n- **API (Active Pharmaceutical Ingredient)**: Ingrediente farmac\u00e9utico activo utilizado en la producci\u00f3n de medicamentos.\n- **Sistema de Control de Cambios**: Proceso formal para gestionar y documentar cambios en la producci\u00f3n y control de APIs.\n\nEste resumen destaca la importancia de la validaci\u00f3n y el control de cambios en la producci\u00f3n de ingredientes farmac\u00e9uticos, asegurando la calidad y fiabilidad de los m\u00e9todos anal\u00edticos utilizados.", "excerpt_keywords": "Keywords: GMP, API, quality control, reprocessing, validation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "803e6c34-755f-4637-88da-ccf8273bdaaf", "node_type": "4", "metadata": {"page_label": "182", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 13.12 \nAny proposals for relevant changes to GMP should be drafted, reviewed and approved by the appropriate organizational units and reviewed and approved by the quality unit(s).\n\n13.13 \nThe potential impact of the proposed change on the quality of the intermediate or API should be evaluated. A classification procedure may help in determining the level of testing, validation and documentation needed to justify changes to a validated process. Changes can be classified (e.g. as minor or major) depending on their nature and extent and the effects these changes may have on the process. Scientific judgement should be used to determine what additional testing and validation studies are appropriate to justify a change in a validated process.\n\n13.14 \nWhen implementing approved changes, measures should be taken to ensure that all documents affected by the changes are revised.\n\n13.15 \nAfter the change has been implemented there should be an evaluation of the first batches produced or tested under the change.\n\n13.16 \nThe potential for critical changes to affect established retest or expiry dates should be evaluated. If necessary, samples of the intermediate or API produced by the modified process can be placed on an accelerated stability programme and/or can be added to the stability monitoring programme.\n\n13.17 \nManufacturers of the current dosage form should be notified of changes from established production and process control procedures that can impact the quality of the API.\n\n# 14. Rejection and reuse of materials\n\n## 14.1 Rejection\n\n14.10 \nIntermediates and APIs failing to meet established specifications should be identified as such and quarantined. These intermediates or APIs can be reprocessed or reworked as described below. The final disposition of rejected materials should be recorded.\n\n## 14.2 Reprocessing\n\n14.20 \nIntroducing an intermediate or API, including one that does not conform to standards or specifications, back into the process and reprocessing by repeating a crystallization step or other appropriate chemical or physical manipulation steps (e.g. distillation, filtration,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "6e9238fcde0e79450873ad99dbeddb676c60382a0ce33d2e5224a2989016851f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 13.12 \nAny proposals for relevant changes to GMP should be drafted, reviewed and approved by the appropriate organizational units and reviewed and approved by the quality unit(s).\n\n13.13 \nThe potential impact of the proposed change on the quality of the intermediate or API should be evaluated. A classification procedure may help in determining the level of testing, validation and documentation needed to justify changes to a validated process. Changes can be classified (e.g. as minor or major) depending on their nature and extent and the effects these changes may have on the process. Scientific judgement should be used to determine what additional testing and validation studies are appropriate to justify a change in a validated process.\n\n13.14 \nWhen implementing approved changes, measures should be taken to ensure that all documents affected by the changes are revised.\n\n13.15 \nAfter the change has been implemented there should be an evaluation of the first batches produced or tested under the change.\n\n13.16 \nThe potential for critical changes to affect established retest or expiry dates should be evaluated. If necessary, samples of the intermediate or API produced by the modified process can be placed on an accelerated stability programme and/or can be added to the stability monitoring programme.\n\n13.17 \nManufacturers of the current dosage form should be notified of changes from established production and process control procedures that can impact the quality of the API.\n\n# 14. Rejection and reuse of materials\n\n## 14.1 Rejection\n\n14.10 \nIntermediates and APIs failing to meet established specifications should be identified as such and quarantined. These intermediates or APIs can be reprocessed or reworked as described below. The final disposition of rejected materials should be recorded.\n\n## 14.2 Reprocessing\n\n14.20 \nIntroducing an intermediate or API, including one that does not conform to standards or specifications, back into the process and reprocessing by repeating a crystallization step or other appropriate chemical or physical manipulation steps (e.g. distillation, filtration,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2120, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c2d1e1e3-e988-40c3-ad61-ede9641000f3": {"__data__": {"id_": "c2d1e1e3-e988-40c3-ad61-ede9641000f3", "embedding": null, "metadata": {"page_label": "183", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "chromatography, milling) that are part of the established manufacturing process is generally considered acceptable. However, if such reprocessing is used for a majority of batches it should be included as part of the standard manufacturing process.\n\n14.21 Continuation of a process step after an in-process control test has shown that the step is incomplete is considered to be part of the normal process. This is not considered to be reprocessing.\n\n14.22 Introducing unreacted material back into a process and repeating a chemical reaction is considered to be reprocessing unless it is part of the established process. Such reprocessing should be preceded by careful evaluation to ensure that the quality of the intermediate or API is not adversely affected due to the potential formation of by-products and overreacted materials.\n\n## 14.3 Reworking\n\n14.30 Before a decision is taken to rework batches that do not conform to established standards or specifications, an investigation into the reason for non-conformance should be performed.\n\n14.31 Batches that have been reworked should be subjected to appropriate evaluation, testing, stability testing if warranted and documentation to show that the reworked product is of equivalent quality to that produced by the original process. Concurrent validation is often the appropriate validation approach for rework procedures. This allows a protocol to define the rework procedure, how it will be carried out and the expected results. If there is only one batch to be reworked, then a report can be written and the batch released once it is found to be acceptable.\n\n14.32 Procedures should provide for comparing the impurity profile of each reworked batch with batches manufactured by the established process. Where routine analytical methods are inadequate to characterize the reworked batch, additional methods should be used.\n\n## 14.4 Recovery of materials and solvents\n\n14.40 Recovery (e.g. from mother liquor or filtrates) of reactants, intermediates or the API is considered acceptable, provided that approved procedures exist for the recovery and the recovered materials meet specifications suitable for their intended use.\n\n14.41 Solvents can be recovered and reused in the same processes or in different processes, provided that the recovery procedures are controlled and monitored to ensure that solvents meet appropriate standards before reuse or comingling with other approved materials.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda aspectos relacionados con la fabricaci\u00f3n de productos farmac\u00e9uticos, espec\u00edficamente en lo que respecta a la reprocesamiento, reworking y recuperaci\u00f3n de materiales y solventes. Se establece que ciertas pr\u00e1cticas, como la continuaci\u00f3n de un proceso despu\u00e9s de un control de calidad o la recuperaci\u00f3n de reactantes, son aceptables bajo condiciones espec\u00edficas. Adem\u00e1s, se enfatiza la importancia de la evaluaci\u00f3n y documentaci\u00f3n adecuada para asegurar que los productos reworkeados mantengan la calidad requerida.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 condiciones deben cumplirse para que la recuperaci\u00f3n de reactantes, intermedios o APIs sea considerada aceptable?**\n   - La recuperaci\u00f3n es aceptable siempre que existan procedimientos aprobados para el proceso de recuperaci\u00f3n y que los materiales recuperados cumplan con las especificaciones adecuadas para su uso previsto.\n\n2. **\u00bfCu\u00e1l es el enfoque recomendado para validar procedimientos de reworking?**\n   - Se sugiere el uso de la validaci\u00f3n concurrente, que permite definir un protocolo para el procedimiento de reworking, incluyendo c\u00f3mo se llevar\u00e1 a cabo y los resultados esperados. Esto incluye la evaluaci\u00f3n y documentaci\u00f3n de que el producto reworkeado es de calidad equivalente al producido por el proceso original.\n\n3. **\u00bfQu\u00e9 pasos deben seguirse antes de decidir reworkear un lote que no cumple con los est\u00e1ndares establecidos?**\n   - Antes de tomar la decisi\u00f3n de reworkear, se debe realizar una investigaci\u00f3n para determinar la raz\u00f3n de la no conformidad. Adem\u00e1s, los lotes reworkeados deben ser evaluados y sometidos a pruebas adecuadas para asegurar que cumplen con los est\u00e1ndares de calidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Gesti\u00f3n de Cambios en GMP**:\n   - Propuestas de cambios en las Buenas Pr\u00e1cticas de Manufactura (GMP) deben ser redactadas, revisadas y aprobadas por unidades organizativas y unidades de calidad.\n   - Evaluaci\u00f3n del impacto de los cambios propuestos en la calidad de intermediarios y principios activos (API).\n   - Clasificaci\u00f3n de cambios como menores o mayores, basada en su naturaleza y efectos en el proceso, lo que determina los requisitos de pruebas, validaci\u00f3n y documentaci\u00f3n.\n\n2. **Documentaci\u00f3n y Revisi\u00f3n**:\n   - Asegurar que todos los documentos afectados por cambios aprobados sean revisados y actualizados.\n   - Evaluaci\u00f3n de los primeros lotes producidos o probados bajo los cambios implementados.\n\n3. **Estabilidad y Fechas de Caducidad**:\n   - Evaluaci\u00f3n del impacto de cambios cr\u00edticos en las fechas de rean\u00e1lisis o caducidad de los API.\n   - Posibilidad de colocar muestras de intermediarios o API en un programa de estabilidad acelerada o en un programa de monitoreo de estabilidad.\n\n4. **Rechazo y Reprocesamiento de Materiales**:\n   - Identificaci\u00f3n y cuarentena de intermediarios y API que no cumplen con las especificaciones.\n   - Registro de la disposici\u00f3n final de materiales rechazados.\n   - Proceso de reprocesamiento de materiales que no cumplen con los est\u00e1ndares, incluyendo pasos como cristalizaci\u00f3n, destilaci\u00f3n y filtraci\u00f3n.\n\n### Entidades Clave\n- **Organizaciones**: Unidades organizativas y unidades de calidad.\n- **Materiales**: Intermediarios y principios activos (API).\n- **Procesos**: Cambios en producci\u00f3n y control de procesos, rean\u00e1lisis, caducidad, estabilidad.\n- **Documentaci\u00f3n**: Documentos afectados por cambios, registros de disposici\u00f3n de materiales rechazados. \n\nEste resumen abarca los aspectos fundamentales de la gesti\u00f3n de cambios en GMP, el manejo de documentos, la estabilidad de productos y el tratamiento de materiales rechazados.", "excerpt_keywords": "Keywords: reprocessing, reworking, recovery, quality control, pharmaceutical manufacturing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5fbe75ba-4128-4c92-8068-9ec28dac270e", "node_type": "4", "metadata": {"page_label": "183", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "chromatography, milling) that are part of the established manufacturing process is generally considered acceptable. However, if such reprocessing is used for a majority of batches it should be included as part of the standard manufacturing process.\n\n14.21 Continuation of a process step after an in-process control test has shown that the step is incomplete is considered to be part of the normal process. This is not considered to be reprocessing.\n\n14.22 Introducing unreacted material back into a process and repeating a chemical reaction is considered to be reprocessing unless it is part of the established process. Such reprocessing should be preceded by careful evaluation to ensure that the quality of the intermediate or API is not adversely affected due to the potential formation of by-products and overreacted materials.\n\n## 14.3 Reworking\n\n14.30 Before a decision is taken to rework batches that do not conform to established standards or specifications, an investigation into the reason for non-conformance should be performed.\n\n14.31 Batches that have been reworked should be subjected to appropriate evaluation, testing, stability testing if warranted and documentation to show that the reworked product is of equivalent quality to that produced by the original process. Concurrent validation is often the appropriate validation approach for rework procedures. This allows a protocol to define the rework procedure, how it will be carried out and the expected results. If there is only one batch to be reworked, then a report can be written and the batch released once it is found to be acceptable.\n\n14.32 Procedures should provide for comparing the impurity profile of each reworked batch with batches manufactured by the established process. Where routine analytical methods are inadequate to characterize the reworked batch, additional methods should be used.\n\n## 14.4 Recovery of materials and solvents\n\n14.40 Recovery (e.g. from mother liquor or filtrates) of reactants, intermediates or the API is considered acceptable, provided that approved procedures exist for the recovery and the recovered materials meet specifications suitable for their intended use.\n\n14.41 Solvents can be recovered and reused in the same processes or in different processes, provided that the recovery procedures are controlled and monitored to ensure that solvents meet appropriate standards before reuse or comingling with other approved materials.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "5a5b5612babff6279fcce5f721bea07164b59b3986b0a02e9f9bfacdbc6bcddd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "chromatography, milling) that are part of the established manufacturing process is generally considered acceptable. However, if such reprocessing is used for a majority of batches it should be included as part of the standard manufacturing process.\n\n14.21 Continuation of a process step after an in-process control test has shown that the step is incomplete is considered to be part of the normal process. This is not considered to be reprocessing.\n\n14.22 Introducing unreacted material back into a process and repeating a chemical reaction is considered to be reprocessing unless it is part of the established process. Such reprocessing should be preceded by careful evaluation to ensure that the quality of the intermediate or API is not adversely affected due to the potential formation of by-products and overreacted materials.\n\n## 14.3 Reworking\n\n14.30 Before a decision is taken to rework batches that do not conform to established standards or specifications, an investigation into the reason for non-conformance should be performed.\n\n14.31 Batches that have been reworked should be subjected to appropriate evaluation, testing, stability testing if warranted and documentation to show that the reworked product is of equivalent quality to that produced by the original process. Concurrent validation is often the appropriate validation approach for rework procedures. This allows a protocol to define the rework procedure, how it will be carried out and the expected results. If there is only one batch to be reworked, then a report can be written and the batch released once it is found to be acceptable.\n\n14.32 Procedures should provide for comparing the impurity profile of each reworked batch with batches manufactured by the established process. Where routine analytical methods are inadequate to characterize the reworked batch, additional methods should be used.\n\n## 14.4 Recovery of materials and solvents\n\n14.40 Recovery (e.g. from mother liquor or filtrates) of reactants, intermediates or the API is considered acceptable, provided that approved procedures exist for the recovery and the recovered materials meet specifications suitable for their intended use.\n\n14.41 Solvents can be recovered and reused in the same processes or in different processes, provided that the recovery procedures are controlled and monitored to ensure that solvents meet appropriate standards before reuse or comingling with other approved materials.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2448, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4f05f4fc-0adc-4b6e-b1c8-92187d3e83be": {"__data__": {"id_": "4f05f4fc-0adc-4b6e-b1c8-92187d3e83be", "embedding": null, "metadata": {"page_label": "184", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 14.5 Returns\n\n14.50 Returned intermediates or APIs should be identified as such and quarantined.\n\n14.51 If the conditions under which returned intermediates or APIs have been stored or shipped before or during their return, or the condition of their containers casts doubt on their quality, the returned intermediates or APIs should be reprocessed, reworked or destroyed, as appropriate.\n\n14.52 Records of returned intermediates or APIs should be maintained. For each return, documentation should include:\n\n- name and address of the consignee;\n- intermediate or API, batch number and quantity returned;\n- reason for return; and\n- use or disposal of the returned intermediate or API.\n\n# 15. Complaints and recalls\n\n15.10 All quality-related complaints, whether received orally or in writing, should be recorded and investigated according to a written procedure.\n\n15.11 Complaint records should include:\n\n- name and address of complainant;\n- name (and, where appropriate, title) and telephone number of person submitting the complaint;\n- nature of the complaint (including name and batch number of the API);\n- date the complaint was received;\n- action initially taken (including dates and identity of person taking the action);\n- any follow-up action taken;\n- response provided to the originator of complaint (including date on which the response was sent); and\n- final decision on intermediate or API batch or lot.\n\n15.12 Records of complaints should be retained in order to evaluate trends, product-related frequencies and severity with a view to taking additional, and if appropriate, immediate corrective action.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las directrices sobre el manejo de intermediarios y principios activos (APIs) devueltos, as\u00ed como la gesti\u00f3n de quejas y retiradas de productos. Se enfatiza la importancia de identificar y poner en cuarentena los productos devueltos, as\u00ed como la necesidad de mantener registros detallados de las devoluciones y quejas para garantizar la calidad y la seguridad de los productos farmac\u00e9uticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 acciones deben tomarse si las condiciones de almacenamiento o env\u00edo de los intermediarios o APIs devueltos generan dudas sobre su calidad?**\n   - Respuesta: Si las condiciones de almacenamiento o env\u00edo de los intermediarios o APIs devueltos generan dudas sobre su calidad, estos deben ser reprocesados, retrabajados o destruidos, seg\u00fan corresponda.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la documentaci\u00f3n de cada devoluci\u00f3n de intermediarios o APIs?**\n   - Respuesta: La documentaci\u00f3n de cada devoluci\u00f3n debe incluir el nombre y direcci\u00f3n del consignatario, el nombre del intermediario o API, el n\u00famero de lote y la cantidad devuelta, la raz\u00f3n de la devoluci\u00f3n y el uso o disposici\u00f3n del intermediario o API devuelto.\n\n3. **\u00bfQu\u00e9 elementos deben registrarse en los registros de quejas relacionadas con la calidad de los productos?**\n   - Respuesta: Los registros de quejas deben incluir el nombre y direcci\u00f3n del reclamante, el nombre y n\u00famero de tel\u00e9fono de la persona que presenta la queja, la naturaleza de la queja (incluyendo el nombre y n\u00famero de lote del API), la fecha en que se recibi\u00f3 la queja, las acciones iniciales tomadas, cualquier acci\u00f3n de seguimiento, la respuesta proporcionada al reclamante y la decisi\u00f3n final sobre el lote o lote del intermediario o API.", "prev_section_summary": "### Temas Clave\n\n1. **Reprocesamiento**: Se considera aceptable la continuaci\u00f3n de ciertos pasos del proceso de fabricaci\u00f3n, como la cromatograf\u00eda y el fresado, siempre que no se utilicen de manera excesiva y se integren en el proceso est\u00e1ndar. La introducci\u00f3n de material no reaccionado y la repetici\u00f3n de reacciones qu\u00edmicas se consideran reprocesamiento, que debe ser evaluado cuidadosamente.\n\n2. **Reworking (Reprocesamiento de lotes)**: Antes de reworkear lotes que no cumplen con los est\u00e1ndares, es necesario investigar la causa de la no conformidad. Los lotes reworkeados deben ser evaluados y documentados para asegurar que su calidad sea equivalente a la del proceso original. Se recomienda la validaci\u00f3n concurrente para definir los procedimientos de reworking.\n\n3. **Recuperaci\u00f3n de materiales y solventes**: La recuperaci\u00f3n de reactantes, intermedios o APIs es aceptable si existen procedimientos aprobados y los materiales recuperados cumplen con las especificaciones necesarias. Los solventes tambi\u00e9n pueden ser recuperados y reutilizados, siempre que se controlen y monitoreen adecuadamente los procedimientos de recuperaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices sobre la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Reactantes, Intermedios, API**: Sustancias involucradas en el proceso de fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Procedimientos aprobados**: Normativas que deben seguirse para asegurar la calidad y la seguridad en el proceso de recuperaci\u00f3n y reworking.\n- **Validaci\u00f3n concurrente**: M\u00e9todo recomendado para validar procedimientos de reworking, asegurando que se cumplan los est\u00e1ndares de calidad.\n\n### Resumen\n\nEl documento de la OMS establece directrices sobre el reprocesamiento, reworking y recuperaci\u00f3n de materiales en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de seguir procedimientos aprobados y realizar evaluaciones rigurosas para garantizar que los productos reworkeados y los materiales recuperados mantengan la calidad adecuada.", "excerpt_keywords": "Keywords: returns, intermediates, APIs, complaints, quality management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7c651d92-d9ad-4187-915d-eac8f6283d6f", "node_type": "4", "metadata": {"page_label": "184", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 14.5 Returns\n\n14.50 Returned intermediates or APIs should be identified as such and quarantined.\n\n14.51 If the conditions under which returned intermediates or APIs have been stored or shipped before or during their return, or the condition of their containers casts doubt on their quality, the returned intermediates or APIs should be reprocessed, reworked or destroyed, as appropriate.\n\n14.52 Records of returned intermediates or APIs should be maintained. For each return, documentation should include:\n\n- name and address of the consignee;\n- intermediate or API, batch number and quantity returned;\n- reason for return; and\n- use or disposal of the returned intermediate or API.\n\n# 15. Complaints and recalls\n\n15.10 All quality-related complaints, whether received orally or in writing, should be recorded and investigated according to a written procedure.\n\n15.11 Complaint records should include:\n\n- name and address of complainant;\n- name (and, where appropriate, title) and telephone number of person submitting the complaint;\n- nature of the complaint (including name and batch number of the API);\n- date the complaint was received;\n- action initially taken (including dates and identity of person taking the action);\n- any follow-up action taken;\n- response provided to the originator of complaint (including date on which the response was sent); and\n- final decision on intermediate or API batch or lot.\n\n15.12 Records of complaints should be retained in order to evaluate trends, product-related frequencies and severity with a view to taking additional, and if appropriate, immediate corrective action.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a41dd6fba62c346b37de8d2de56f4605884d8379d4e7cf2515cc34f95dd1227e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 14.5 Returns\n\n14.50 Returned intermediates or APIs should be identified as such and quarantined.\n\n14.51 If the conditions under which returned intermediates or APIs have been stored or shipped before or during their return, or the condition of their containers casts doubt on their quality, the returned intermediates or APIs should be reprocessed, reworked or destroyed, as appropriate.\n\n14.52 Records of returned intermediates or APIs should be maintained. For each return, documentation should include:\n\n- name and address of the consignee;\n- intermediate or API, batch number and quantity returned;\n- reason for return; and\n- use or disposal of the returned intermediate or API.\n\n# 15. Complaints and recalls\n\n15.10 All quality-related complaints, whether received orally or in writing, should be recorded and investigated according to a written procedure.\n\n15.11 Complaint records should include:\n\n- name and address of complainant;\n- name (and, where appropriate, title) and telephone number of person submitting the complaint;\n- nature of the complaint (including name and batch number of the API);\n- date the complaint was received;\n- action initially taken (including dates and identity of person taking the action);\n- any follow-up action taken;\n- response provided to the originator of complaint (including date on which the response was sent); and\n- final decision on intermediate or API batch or lot.\n\n15.12 Records of complaints should be retained in order to evaluate trends, product-related frequencies and severity with a view to taking additional, and if appropriate, immediate corrective action.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1616, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "07f992cf-8567-46b0-b17f-f97f47bdbd05": {"__data__": {"id_": "07f992cf-8567-46b0-b17f-f97f47bdbd05", "embedding": null, "metadata": {"page_label": "185", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "15.13 There should be a written procedure that defines the circumstances under which a recall of an intermediate or API should be considered.\n\n15.14 The recall procedure should designate who should be involved in evaluating the information, how a recall should be initiated, who should be informed about the recall and how the recalled material should be treated.\n\n15.15 In the event of a serious or potentially life-threatening situation, local, national and/or international authorities should be informed and their advice sought.\n\n## 16. Contract manufacturers (including laboratories)\n\n16.10 All contract manufacturers (including laboratories) should comply with GMP defined in this guide. Special consideration should be given to the prevention of cross-contamination and to maintaining traceability.\n\n16.11 Contract manufacturers (including laboratories) should be evaluated by the contract giver to ensure GMP compliance of the specific operations taking place at the contract sites.\n\n16.12 There should be a written and approved contract or formal agreement between the contract giver and the contract acceptor that defines in detail the GMP responsibilities, including the quality measures, of each party.\n\n16.13 The contract should permit the contract giver to audit the contract acceptor\u2019s facilities for compliance with GMP.\n\n16.14 Where subcontracting is allowed the contract acceptor should not pass to a third party any of the work entrusted to him or her under the contract without the contract giver\u2019s prior evaluation and approval of the arrangements.\n\n16.15 Manufacturing and laboratory records should be kept at the site where the activity takes place and be readily available.\n\n16.16 Changes in the process, equipment, test methods, specifications or other contractual requirements should not be made unless the contract giver is informed and approves the changes.\n\n## 17. Agents, brokers, traders, distributors, repackers and relabellers\n\n### 17.1 Applicability\n\n17.10 This section applies to any party other than the original manufacturer who may trade and/or take possession of, repack, relabel, manipulate, distribute or store an API or intermediate.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda procedimientos y regulaciones relacionados con la gesti\u00f3n de productos farmac\u00e9uticos, espec\u00edficamente en lo que respecta a la retirada de productos intermedios o de ingredientes farmac\u00e9uticos activos (API), as\u00ed como las responsabilidades de los fabricantes contratados y otros actores en la cadena de suministro. Se enfatiza la importancia de tener procedimientos escritos para las retiradas, la evaluaci\u00f3n de la conformidad con las Buenas Pr\u00e1cticas de Manufactura (GMP), y la necesidad de contratos claros que definan las responsabilidades de cada parte involucrada.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse en el procedimiento de retirada de un API o intermedio, seg\u00fan el documento?**\n   - El documento establece que debe haber un procedimiento escrito que defina las circunstancias para considerar una retirada, qui\u00e9n evaluar\u00e1 la informaci\u00f3n, c\u00f3mo se iniciar\u00e1 la retirada, qui\u00e9n ser\u00e1 informado y c\u00f3mo se tratar\u00e1 el material retirado.\n\n2. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas que deben incluirse en el contrato entre el contratante y el contratista en relaci\u00f3n con las GMP?**\n   - El contrato debe detallar las responsabilidades de GMP de cada parte, incluyendo las medidas de calidad, y debe permitir que el contratante audite las instalaciones del contratista para verificar el cumplimiento de las GMP.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse para que un contratista pueda subcontratar parte de su trabajo seg\u00fan el documento?**\n   - El contratista no puede pasar el trabajo a un tercero sin la evaluaci\u00f3n y aprobaci\u00f3n previa del contratante sobre los arreglos de subcontrataci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Devoluciones de Intermediarios y APIs**:\n   - Identificaci\u00f3n y cuarentena de productos devueltos.\n   - Evaluaci\u00f3n de las condiciones de almacenamiento y env\u00edo para determinar la calidad.\n   - Procedimientos para reprocesar, retrabajar o destruir productos devueltos si hay dudas sobre su calidad.\n   - Mantenimiento de registros detallados de las devoluciones, incluyendo informaci\u00f3n del consignatario, detalles del producto y razones de la devoluci\u00f3n.\n\n2. **Quejas y Retiradas de Productos**:\n   - Registro y an\u00e1lisis de quejas relacionadas con la calidad de los productos.\n   - Procedimientos escritos para investigar quejas, ya sean orales o escritas.\n   - Documentaci\u00f3n necesaria para los registros de quejas, que incluye informaci\u00f3n del reclamante, naturaleza de la queja, acciones tomadas y decisiones finales.\n   - Importancia de conservar registros de quejas para evaluar tendencias y tomar acciones correctivas.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Intermediarios**: Productos farmac\u00e9uticos que pueden ser devueltos.\n- **Principios Activos (APIs)**: Sustancias que pueden ser devueltas y que requieren un manejo espec\u00edfico.\n- **Consignatario**: Persona o entidad a la que se env\u00edan los productos.\n- **Reclamante**: Persona que presenta una queja sobre un producto.\n- **Registros de Quejas**: Documentaci\u00f3n que se mantiene para evaluar la calidad y seguridad de los productos. \n\nEste resumen destaca la importancia de los procedimientos adecuados para el manejo de devoluciones y quejas en el contexto de la calidad farmac\u00e9utica.", "excerpt_keywords": "Keywords: recall procedure, contract manufacturers, GMP compliance, pharmaceutical quality, intermediates"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "77cb5145-cc16-4059-9b3e-b63880715840", "node_type": "4", "metadata": {"page_label": "185", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "15.13 There should be a written procedure that defines the circumstances under which a recall of an intermediate or API should be considered.\n\n15.14 The recall procedure should designate who should be involved in evaluating the information, how a recall should be initiated, who should be informed about the recall and how the recalled material should be treated.\n\n15.15 In the event of a serious or potentially life-threatening situation, local, national and/or international authorities should be informed and their advice sought.\n\n## 16. Contract manufacturers (including laboratories)\n\n16.10 All contract manufacturers (including laboratories) should comply with GMP defined in this guide. Special consideration should be given to the prevention of cross-contamination and to maintaining traceability.\n\n16.11 Contract manufacturers (including laboratories) should be evaluated by the contract giver to ensure GMP compliance of the specific operations taking place at the contract sites.\n\n16.12 There should be a written and approved contract or formal agreement between the contract giver and the contract acceptor that defines in detail the GMP responsibilities, including the quality measures, of each party.\n\n16.13 The contract should permit the contract giver to audit the contract acceptor\u2019s facilities for compliance with GMP.\n\n16.14 Where subcontracting is allowed the contract acceptor should not pass to a third party any of the work entrusted to him or her under the contract without the contract giver\u2019s prior evaluation and approval of the arrangements.\n\n16.15 Manufacturing and laboratory records should be kept at the site where the activity takes place and be readily available.\n\n16.16 Changes in the process, equipment, test methods, specifications or other contractual requirements should not be made unless the contract giver is informed and approves the changes.\n\n## 17. Agents, brokers, traders, distributors, repackers and relabellers\n\n### 17.1 Applicability\n\n17.10 This section applies to any party other than the original manufacturer who may trade and/or take possession of, repack, relabel, manipulate, distribute or store an API or intermediate.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "5decdc40170155024243550bec2511278218561648a4a0e55acd9086cd616a05", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "15.13 There should be a written procedure that defines the circumstances under which a recall of an intermediate or API should be considered.\n\n15.14 The recall procedure should designate who should be involved in evaluating the information, how a recall should be initiated, who should be informed about the recall and how the recalled material should be treated.\n\n15.15 In the event of a serious or potentially life-threatening situation, local, national and/or international authorities should be informed and their advice sought.\n\n## 16. Contract manufacturers (including laboratories)\n\n16.10 All contract manufacturers (including laboratories) should comply with GMP defined in this guide. Special consideration should be given to the prevention of cross-contamination and to maintaining traceability.\n\n16.11 Contract manufacturers (including laboratories) should be evaluated by the contract giver to ensure GMP compliance of the specific operations taking place at the contract sites.\n\n16.12 There should be a written and approved contract or formal agreement between the contract giver and the contract acceptor that defines in detail the GMP responsibilities, including the quality measures, of each party.\n\n16.13 The contract should permit the contract giver to audit the contract acceptor\u2019s facilities for compliance with GMP.\n\n16.14 Where subcontracting is allowed the contract acceptor should not pass to a third party any of the work entrusted to him or her under the contract without the contract giver\u2019s prior evaluation and approval of the arrangements.\n\n16.15 Manufacturing and laboratory records should be kept at the site where the activity takes place and be readily available.\n\n16.16 Changes in the process, equipment, test methods, specifications or other contractual requirements should not be made unless the contract giver is informed and approves the changes.\n\n## 17. Agents, brokers, traders, distributors, repackers and relabellers\n\n### 17.1 Applicability\n\n17.10 This section applies to any party other than the original manufacturer who may trade and/or take possession of, repack, relabel, manipulate, distribute or store an API or intermediate.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2175, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "899f9f44-09a8-4e22-95d0-d250ad1ff4c2": {"__data__": {"id_": "899f9f44-09a8-4e22-95d0-d250ad1ff4c2", "embedding": null, "metadata": {"page_label": "186", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 17.2 Traceability of distributed APIs and intermediates\n\n17.20 Agents, brokers, traders, distributors, repackers or relabellers should maintain complete traceability of the APIs and intermediates that they distribute. Documents that should be retained and available should include:\n\n- identity of original manufacturer;\n- address of original manufacturer;\n- purchase orders;\n- bills of lading (transportation documentation);\n- receipt documents;\n- name or designation of API or intermediate;\n- manufacturer\u2019s batch number;\n- transportation and distribution records;\n- all authentic certificates of analysis, including those of the original manufacturer; and\n- retest or expiry date.\n\n# 17.3 Quality management\n\n17.30 Agents, brokers, traders, distributors, repackers or relabellers should establish, document and implement an effective system of managing quality, as specified in section 2.\n\n# 17.4 Repackaging, relabelling and holding of APIs and intermediates\n\n17.40 Repackaging, relabelling and holding of APIs and intermediates should be performed under appropriate GMP controls as stipulated in this guide, to avoid mix-ups and loss of API or intermediate identity or purity.\n\n17.41 Repackaging should be conducted under appropriate environmental conditions to avoid contamination and cross-contamination.\n\n# 17.5 Stability\n\n17.50 Stability studies to justify assigned expiration or retest dates should be conducted if the API or intermediate is repackaged in a different type of container than that used by the manufacturer of the API or intermediate.\n\n# 17.6 Transfer of information\n\n17.60 Agents, brokers, distributors, repackers or relabellers should transfer all quality or regulatory information received from the manufacturer.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la trazabilidad, gesti\u00f3n de calidad, y el manejo de APIs (ingredientes farmac\u00e9uticos activos) e intermedios en la cadena de distribuci\u00f3n. Se enfatiza la importancia de mantener registros completos y precisos, realizar repacking y relabeling bajo buenas pr\u00e1cticas de manufactura (GMP), y llevar a cabo estudios de estabilidad para garantizar la calidad y seguridad de los productos farmac\u00e9uticos.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 documentos espec\u00edficos deben mantener los agentes y distribuidores para asegurar la trazabilidad de los APIs e intermedios?**\n   - Respuesta: Los agentes, brokers, traders, distribuidores, repackers o relabellers deben mantener documentos como la identidad y direcci\u00f3n del fabricante original, \u00f3rdenes de compra, documentos de transporte (bills of lading), recibos, nombre o designaci\u00f3n del API o intermedio, n\u00famero de lote del fabricante, registros de transporte y distribuci\u00f3n, certificados de an\u00e1lisis aut\u00e9nticos, y fechas de retest o expiraci\u00f3n.\n\n2. **\u00bfCu\u00e1les son las condiciones que deben cumplirse durante el repacking de APIs e intermedios para evitar problemas de calidad?**\n   - Respuesta: El repacking debe realizarse bajo controles de buenas pr\u00e1cticas de manufactura (GMP) para evitar confusiones y p\u00e9rdida de identidad o pureza del API o intermedio. Adem\u00e1s, debe llevarse a cabo en condiciones ambientales adecuadas para prevenir la contaminaci\u00f3n y la contaminaci\u00f3n cruzada.\n\n3. **\u00bfQu\u00e9 tipo de estudios se requieren si un API o intermedio se repackaged en un contenedor diferente al utilizado por el fabricante?**\n   - Respuesta: Se deben realizar estudios de estabilidad para justificar las fechas de expiraci\u00f3n o retest asignadas si el API o intermedio se repackaged en un tipo de contenedor diferente al que utiliz\u00f3 el fabricante original.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Procedimiento de Retirada de Productos**:\n   - Importancia de tener un procedimiento escrito que defina las circunstancias para considerar la retirada de un intermedio o ingrediente farmac\u00e9utico activo (API).\n   - Designaci\u00f3n de responsables para evaluar la informaci\u00f3n, iniciar la retirada, informar a las partes pertinentes y tratar el material retirado.\n   - En situaciones graves o potencialmente mortales, se debe informar a las autoridades locales, nacionales e internacionales y buscar su consejo.\n\n2. **Fabricantes Contratados**:\n   - Todos los fabricantes contratados, incluidos laboratorios, deben cumplir con las Buenas Pr\u00e1cticas de Manufactura (GMP).\n   - Evaluaci\u00f3n de los fabricantes contratados por parte del contratante para asegurar el cumplimiento de las GMP en las operaciones espec\u00edficas.\n   - Necesidad de un contrato escrito y aprobado que detalle las responsabilidades de GMP y las medidas de calidad de cada parte.\n   - Permiso para que el contratante audite las instalaciones del contratista para verificar el cumplimiento de las GMP.\n   - Restricciones sobre la subcontrataci\u00f3n, donde el contratista no puede transferir trabajo a un tercero sin la evaluaci\u00f3n y aprobaci\u00f3n del contratante.\n\n3. **Registros y Cambios**:\n   - Los registros de fabricaci\u00f3n y laboratorio deben mantenerse en el sitio de la actividad y estar f\u00e1cilmente disponibles.\n   - Cambios en procesos, equipos, m\u00e9todos de prueba, especificaciones u otros requisitos contractuales deben ser aprobados por el contratante antes de su implementaci\u00f3n.\n\n4. **Actores en la Cadena de Suministro**:\n   - Secci\u00f3n aplicable a agentes, corredores, comerciantes, distribuidores, reempaquetadores y etiquetadores que manipulan, distribuyen o almacenan un API o intermedio.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices.\n- **Contratante**: Parte que contrata a un fabricante o laboratorio.\n- **Contratista**: Parte que realiza el trabajo bajo contrato.\n- **Autoridades Locales/Nacionales/Internacionales**: Entidades a las que se debe informar en caso de situaciones graves.\n- **API (Ingrediente Farmac\u00e9utico Activo)**: Sustancia que se utiliza en la fabricaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: traceability, APIs, quality management, repackaging, stability studies"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9331b45e-367f-4386-a7fe-37e5d68d27c4", "node_type": "4", "metadata": {"page_label": "186", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 17.2 Traceability of distributed APIs and intermediates\n\n17.20 Agents, brokers, traders, distributors, repackers or relabellers should maintain complete traceability of the APIs and intermediates that they distribute. Documents that should be retained and available should include:\n\n- identity of original manufacturer;\n- address of original manufacturer;\n- purchase orders;\n- bills of lading (transportation documentation);\n- receipt documents;\n- name or designation of API or intermediate;\n- manufacturer\u2019s batch number;\n- transportation and distribution records;\n- all authentic certificates of analysis, including those of the original manufacturer; and\n- retest or expiry date.\n\n# 17.3 Quality management\n\n17.30 Agents, brokers, traders, distributors, repackers or relabellers should establish, document and implement an effective system of managing quality, as specified in section 2.\n\n# 17.4 Repackaging, relabelling and holding of APIs and intermediates\n\n17.40 Repackaging, relabelling and holding of APIs and intermediates should be performed under appropriate GMP controls as stipulated in this guide, to avoid mix-ups and loss of API or intermediate identity or purity.\n\n17.41 Repackaging should be conducted under appropriate environmental conditions to avoid contamination and cross-contamination.\n\n# 17.5 Stability\n\n17.50 Stability studies to justify assigned expiration or retest dates should be conducted if the API or intermediate is repackaged in a different type of container than that used by the manufacturer of the API or intermediate.\n\n# 17.6 Transfer of information\n\n17.60 Agents, brokers, distributors, repackers or relabellers should transfer all quality or regulatory information received from the manufacturer.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "2a8e761a3ce75dabf5352edea7e6ee0bb633aed4312875c6b479ff8180d80402", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 17.2 Traceability of distributed APIs and intermediates\n\n17.20 Agents, brokers, traders, distributors, repackers or relabellers should maintain complete traceability of the APIs and intermediates that they distribute. Documents that should be retained and available should include:\n\n- identity of original manufacturer;\n- address of original manufacturer;\n- purchase orders;\n- bills of lading (transportation documentation);\n- receipt documents;\n- name or designation of API or intermediate;\n- manufacturer\u2019s batch number;\n- transportation and distribution records;\n- all authentic certificates of analysis, including those of the original manufacturer; and\n- retest or expiry date.\n\n# 17.3 Quality management\n\n17.30 Agents, brokers, traders, distributors, repackers or relabellers should establish, document and implement an effective system of managing quality, as specified in section 2.\n\n# 17.4 Repackaging, relabelling and holding of APIs and intermediates\n\n17.40 Repackaging, relabelling and holding of APIs and intermediates should be performed under appropriate GMP controls as stipulated in this guide, to avoid mix-ups and loss of API or intermediate identity or purity.\n\n17.41 Repackaging should be conducted under appropriate environmental conditions to avoid contamination and cross-contamination.\n\n# 17.5 Stability\n\n17.50 Stability studies to justify assigned expiration or retest dates should be conducted if the API or intermediate is repackaged in a different type of container than that used by the manufacturer of the API or intermediate.\n\n# 17.6 Transfer of information\n\n17.60 Agents, brokers, distributors, repackers or relabellers should transfer all quality or regulatory information received from the manufacturer.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1740, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3b40347a-139f-452d-85b8-ecbafb47a6c6": {"__data__": {"id_": "3b40347a-139f-452d-85b8-ecbafb47a6c6", "embedding": null, "metadata": {"page_label": "187", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 17.6\n\nThe agent, broker, trader, distributor, repacker, or relabeller who supplies the API or intermediate to the customer should provide the name of the original manufacturer of the API or intermediate and the batch number(s) supplied.\n\nThe agent should also provide the identity of the manufacturer of the original API or intermediate to regulatory authorities upon request. The original manufacturer can respond to the regulatory authority directly or through its authorized agents, depending on the legal relationship between the authorized agents and the original manufacturer of the API or intermediate. (In this context \u201cauthorized\u201d refers to authorized by the manufacturer.)\n\nThe specific guidance for certificates of analysis included in section 11.4 should be met.\n\n## 17.7 Handling of complaints and recalls\n\nAgents, brokers, traders, distributors, repackers, or relabellers should maintain records of complaints and recalls as specified in section 15 for all complaints and recalls that come to their attention.\n\nIf the situation warrants, the agents, brokers, traders, distributors, repackers, or relabellers should review the complaint with the manufacturer of the original API or intermediate to determine whether any further action, either with other customers who may have received this API or intermediate or with the regulatory authority, or both, should be initiated. The investigation into the cause for the complaint or recall should be conducted and documented by the appropriate party.\n\nWhere a complaint is referred to the original manufacturer of the API or intermediate, the record maintained by the agents, brokers, traders, distributors, repackers, or relabellers should include any response received from the original manufacturer of the API or intermediate (including date and information provided).\n\n## 17.8 Handling of returns\n\nReturns should be handled as specified in section 14.5.3. The agents, brokers, traders, distributors, repackers, or relabellers should maintain documentation of returned APIs and intermediates.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre la responsabilidad de agentes, corredores, comerciantes, distribuidores, reacondicionadores y reetiquetadores en relaci\u00f3n con la gesti\u00f3n de ingredientes farmac\u00e9uticos activos (API) o intermedios. Se enfatiza la importancia de proporcionar informaci\u00f3n sobre el fabricante original y los n\u00fameros de lote, as\u00ed como la necesidad de mantener registros de quejas y retiradas de productos. Tambi\u00e9n se menciona la obligaci\u00f3n de manejar devoluciones de acuerdo con procedimientos espec\u00edficos y de documentar adecuadamente todas las interacciones relacionadas con quejas y devoluciones.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe proporcionar un agente o distribuidor al cliente sobre el API o intermedio suministrado?**\n   - Respuesta: El agente, corredor, comerciante, distribuidor, reacondicionador o reetiquetador debe proporcionar el nombre del fabricante original del API o intermedio y los n\u00fameros de lote suministrados.\n\n2. **\u00bfC\u00f3mo deben manejarse las quejas y retiradas de productos seg\u00fan las directrices?**\n   - Respuesta: Los agentes, corredores, comerciantes, distribuidores, reacondicionadores o reetiquetadores deben mantener registros de todas las quejas y retiradas, revisar las quejas con el fabricante original si es necesario, y documentar la investigaci\u00f3n sobre la causa de la queja o retirada.\n\n3. **\u00bfQu\u00e9 documentaci\u00f3n se requiere para las devoluciones de APIs e intermedios?**\n   - Respuesta: Se debe mantener documentaci\u00f3n de las APIs e intermedios devueltos, siguiendo las especificaciones establecidas en la secci\u00f3n 14.5.3 del documento.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Trazabilidad de APIs e Intermedios**:\n   - Importancia de mantener registros completos para asegurar la trazabilidad en la distribuci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs) e intermedios.\n   - Documentos esenciales incluyen:\n     - Identidad y direcci\u00f3n del fabricante original.\n     - \u00d3rdenes de compra y documentos de transporte.\n     - Registros de distribuci\u00f3n y certificados de an\u00e1lisis.\n\n2. **Gesti\u00f3n de Calidad**:\n   - Necesidad de establecer un sistema efectivo de gesti\u00f3n de calidad por parte de agentes, distribuidores y repackers.\n   - Documentaci\u00f3n y cumplimiento de est\u00e1ndares de calidad son fundamentales.\n\n3. **Reempaquetado y Reetiquetado**:\n   - El reempaquetado y reetiquetado deben realizarse bajo buenas pr\u00e1cticas de manufactura (GMP) para evitar confusiones y mantener la pureza del producto.\n   - Condiciones ambientales adecuadas son necesarias para prevenir contaminaci\u00f3n.\n\n4. **Estudios de Estabilidad**:\n   - Se requieren estudios de estabilidad si el API o intermedio se reempaqueta en un contenedor diferente al original, para justificar las fechas de expiraci\u00f3n o retest.\n\n5. **Transferencia de Informaci\u00f3n**:\n   - Es esencial que los agentes y distribuidores transfieran toda la informaci\u00f3n de calidad y regulatoria recibida del fabricante.\n\n### Entidades Clave:\n- **Agentes, Brokers, Traders, Distribuidores, Repackers, Relabellers**: Entidades responsables de la distribuci\u00f3n y manejo de APIs e intermedios.\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias utilizadas en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Documentos de Trazabilidad**: Incluyen \u00f3rdenes de compra, certificados de an\u00e1lisis, registros de transporte, etc.\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Normativas que aseguran la calidad y seguridad en la producci\u00f3n y manejo de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: APIs, complaints, recalls, documentation, manufacturers"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fca78862-4dc1-41eb-afe9-d452b4a2507c", "node_type": "4", "metadata": {"page_label": "187", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 17.6\n\nThe agent, broker, trader, distributor, repacker, or relabeller who supplies the API or intermediate to the customer should provide the name of the original manufacturer of the API or intermediate and the batch number(s) supplied.\n\nThe agent should also provide the identity of the manufacturer of the original API or intermediate to regulatory authorities upon request. The original manufacturer can respond to the regulatory authority directly or through its authorized agents, depending on the legal relationship between the authorized agents and the original manufacturer of the API or intermediate. (In this context \u201cauthorized\u201d refers to authorized by the manufacturer.)\n\nThe specific guidance for certificates of analysis included in section 11.4 should be met.\n\n## 17.7 Handling of complaints and recalls\n\nAgents, brokers, traders, distributors, repackers, or relabellers should maintain records of complaints and recalls as specified in section 15 for all complaints and recalls that come to their attention.\n\nIf the situation warrants, the agents, brokers, traders, distributors, repackers, or relabellers should review the complaint with the manufacturer of the original API or intermediate to determine whether any further action, either with other customers who may have received this API or intermediate or with the regulatory authority, or both, should be initiated. The investigation into the cause for the complaint or recall should be conducted and documented by the appropriate party.\n\nWhere a complaint is referred to the original manufacturer of the API or intermediate, the record maintained by the agents, brokers, traders, distributors, repackers, or relabellers should include any response received from the original manufacturer of the API or intermediate (including date and information provided).\n\n## 17.8 Handling of returns\n\nReturns should be handled as specified in section 14.5.3. The agents, brokers, traders, distributors, repackers, or relabellers should maintain documentation of returned APIs and intermediates.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a78648d998d9811c0bf20ac3badcf74e74a38dee2e465992b3e32f768f8df15c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 17.6\n\nThe agent, broker, trader, distributor, repacker, or relabeller who supplies the API or intermediate to the customer should provide the name of the original manufacturer of the API or intermediate and the batch number(s) supplied.\n\nThe agent should also provide the identity of the manufacturer of the original API or intermediate to regulatory authorities upon request. The original manufacturer can respond to the regulatory authority directly or through its authorized agents, depending on the legal relationship between the authorized agents and the original manufacturer of the API or intermediate. (In this context \u201cauthorized\u201d refers to authorized by the manufacturer.)\n\nThe specific guidance for certificates of analysis included in section 11.4 should be met.\n\n## 17.7 Handling of complaints and recalls\n\nAgents, brokers, traders, distributors, repackers, or relabellers should maintain records of complaints and recalls as specified in section 15 for all complaints and recalls that come to their attention.\n\nIf the situation warrants, the agents, brokers, traders, distributors, repackers, or relabellers should review the complaint with the manufacturer of the original API or intermediate to determine whether any further action, either with other customers who may have received this API or intermediate or with the regulatory authority, or both, should be initiated. The investigation into the cause for the complaint or recall should be conducted and documented by the appropriate party.\n\nWhere a complaint is referred to the original manufacturer of the API or intermediate, the record maintained by the agents, brokers, traders, distributors, repackers, or relabellers should include any response received from the original manufacturer of the API or intermediate (including date and information provided).\n\n## 17.8 Handling of returns\n\nReturns should be handled as specified in section 14.5.3. The agents, brokers, traders, distributors, repackers, or relabellers should maintain documentation of returned APIs and intermediates.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2056, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "fed5070f-897c-4fab-83e3-f30cc9d33501": {"__data__": {"id_": "fed5070f-897c-4fab-83e3-f30cc9d33501", "embedding": null, "metadata": {"page_label": "188", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Specific guidance for APIs manufactured by cell culture/fermentation\n\n## 18.1 General\n\n18.10 Section 18 is intended to address specific controls for APIs or intermediates manufactured by cell culture or fermentation using natural or recombinant organisms and that have not been covered adequately in the previous sections. It is not intended to be a stand-alone section. In general, the GMP principles in the other sections of this document apply. Note that the principles of fermentation for \u201cclassical\u201d processes for production of small molecules and for processes using recombinant and non-recombinant organisms for production of proteins and/or polypeptides are the same, although the degree of control will differ. Where practical, this section will address these differences. In general, the degree of control for biotechnological processes used to produce proteins and polypeptides is greater than that for classical fermentation processes.\n\n18.11 The term \u201cbiotechnological process\u201d (biotech) refers to the use of cells or organisms that have been generated or modified by recombinant DNA, hybridoma or other technology to produce APIs. The APIs produced by biotechnological processes normally consist of high molecular weight substances, such as proteins and polypeptides, for which specific guidance is given in this Section. Certain APIs of low molecular weight, such as antibiotics, amino acids, vitamins, and carbohydrates, can also be produced by recombinant DNA technology. The level of control for these types of APIs is similar to that employed for classical fermentation.\n\n18.12 The term \u201cclassical fermentation\u201d refers to processes that use microorganisms existing in nature and/or modified by conventional methods (e.g. irradiation or chemical mutagenesis) to produce APIs. APIs produced by \u201cclassical fermentation\u201d are normally low molecular weight products such as antibiotics, amino acids, vitamins, and carbohydrates.\n\n18.13 Production of APIs or intermediates from cell culture or fermentation involves biological processes such as cultivation of cells or extraction and purification of material from living organisms. Note that there may be additional process steps, such as physicochemical modification, that are part of the manufacturing process. The raw materials used (media, buffer components) may provide the potential for growth of microbiological contaminants. Depending on the source, method of preparation, and the intended use of the API or intermediate, control of bioburden, viral\n\n----\n\n2 This section has been referred to the Expert Committee on Biological Standardization for discussion and consideration. Reproduced here but currently not adopted by the aforementioned Expert Committee.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nLa secci\u00f3n 18 del documento de la OMS se centra en las directrices espec\u00edficas para la fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs) mediante cultivos celulares o fermentaci\u00f3n. Se distingue entre procesos biotecnol\u00f3gicos, que utilizan organismos modificados gen\u00e9ticamente para producir sustancias de alto peso molecular como prote\u00ednas y polip\u00e9ptidos, y la fermentaci\u00f3n cl\u00e1sica, que utiliza microorganismos naturales o modificados convencionalmente para producir productos de bajo peso molecular como antibi\u00f3ticos y amino\u00e1cidos. La secci\u00f3n tambi\u00e9n aborda la importancia del control de contaminantes microbiol\u00f3gicos y virales en estos procesos.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las diferencias clave en el control de calidad entre los procesos biotecnol\u00f3gicos y la fermentaci\u00f3n cl\u00e1sica en la producci\u00f3n de APIs?**\n   - Esta pregunta busca detalles espec\u00edficos sobre c\u00f3mo var\u00edan los niveles de control en cada tipo de proceso, lo cual no se detalla en otras secciones del documento.\n\n2. **\u00bfQu\u00e9 tipos de contaminantes microbiol\u00f3gicos y virales deben ser controlados en la producci\u00f3n de APIs a partir de cultivos celulares o fermentaci\u00f3n, y c\u00f3mo se gestionan estos riesgos?**\n   - Esta pregunta se centra en los riesgos espec\u00edficos asociados con la producci\u00f3n de APIs en estos contextos y las estrategias de mitigaci\u00f3n, que pueden no estar ampliamente cubiertas en otras partes del documento.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al seleccionar los materiales crudos (medios, componentes de tampones) para la producci\u00f3n de APIs mediante fermentaci\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n sobre la selecci\u00f3n de materiales y su impacto en el proceso de producci\u00f3n, un aspecto que puede no ser evidente en otras secciones del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Responsabilidad de los Proveedores**:\n   - Los agentes, corredores, comerciantes, distribuidores, reacondicionadores y reetiquetadores deben proporcionar informaci\u00f3n sobre el fabricante original del ingrediente farmac\u00e9utico activo (API) o intermedio, as\u00ed como los n\u00fameros de lote correspondientes.\n\n2. **Interacci\u00f3n con Autoridades Regulatorias**:\n   - Los agentes deben estar preparados para identificar al fabricante original ante las autoridades regulatorias si se solicita. La comunicaci\u00f3n puede ser directa o a trav\u00e9s de agentes autorizados.\n\n3. **Manejo de Quejas y Retiradas**:\n   - Se requiere que los proveedores mantengan registros de quejas y retiradas de productos, revisen las quejas con el fabricante original cuando sea necesario, y documenten las investigaciones sobre las causas de quejas o retiradas.\n\n4. **Documentaci\u00f3n de Respuestas**:\n   - Cualquier respuesta del fabricante original a las quejas debe ser registrada, incluyendo la fecha y la informaci\u00f3n proporcionada.\n\n5. **Manejo de Devoluciones**:\n   - Las devoluciones de APIs e intermedios deben ser gestionadas de acuerdo con procedimientos espec\u00edficos, y se debe mantener documentaci\u00f3n adecuada de los productos devueltos.\n\n### Entidades Clave\n- **Agentes, Corredores, Comerciantes, Distribuidores, Reacondicionadores, Reetiquetadores**: Entidades responsables de la gesti\u00f3n y suministro de APIs e intermedios.\n- **Fabricante Original**: Entidad que produce el API o intermedio y que debe ser identificada en la documentaci\u00f3n.\n- **Autoridades Regulatorias**: Entidades que supervisan el cumplimiento de las normativas relacionadas con la producci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos. \n\nEste resumen destaca la importancia de la transparencia y la documentaci\u00f3n en la cadena de suministro de ingredientes farmac\u00e9uticos, as\u00ed como la necesidad de una comunicaci\u00f3n efectiva entre todas las partes involucradas.", "excerpt_keywords": "Keywords: APIs, cell culture, fermentation, biotechnological processes, quality control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "62140cf6-9b36-4b04-ab11-59a5ed3c989e", "node_type": "4", "metadata": {"page_label": "188", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Specific guidance for APIs manufactured by cell culture/fermentation\n\n## 18.1 General\n\n18.10 Section 18 is intended to address specific controls for APIs or intermediates manufactured by cell culture or fermentation using natural or recombinant organisms and that have not been covered adequately in the previous sections. It is not intended to be a stand-alone section. In general, the GMP principles in the other sections of this document apply. Note that the principles of fermentation for \u201cclassical\u201d processes for production of small molecules and for processes using recombinant and non-recombinant organisms for production of proteins and/or polypeptides are the same, although the degree of control will differ. Where practical, this section will address these differences. In general, the degree of control for biotechnological processes used to produce proteins and polypeptides is greater than that for classical fermentation processes.\n\n18.11 The term \u201cbiotechnological process\u201d (biotech) refers to the use of cells or organisms that have been generated or modified by recombinant DNA, hybridoma or other technology to produce APIs. The APIs produced by biotechnological processes normally consist of high molecular weight substances, such as proteins and polypeptides, for which specific guidance is given in this Section. Certain APIs of low molecular weight, such as antibiotics, amino acids, vitamins, and carbohydrates, can also be produced by recombinant DNA technology. The level of control for these types of APIs is similar to that employed for classical fermentation.\n\n18.12 The term \u201cclassical fermentation\u201d refers to processes that use microorganisms existing in nature and/or modified by conventional methods (e.g. irradiation or chemical mutagenesis) to produce APIs. APIs produced by \u201cclassical fermentation\u201d are normally low molecular weight products such as antibiotics, amino acids, vitamins, and carbohydrates.\n\n18.13 Production of APIs or intermediates from cell culture or fermentation involves biological processes such as cultivation of cells or extraction and purification of material from living organisms. Note that there may be additional process steps, such as physicochemical modification, that are part of the manufacturing process. The raw materials used (media, buffer components) may provide the potential for growth of microbiological contaminants. Depending on the source, method of preparation, and the intended use of the API or intermediate, control of bioburden, viral\n\n----\n\n2 This section has been referred to the Expert Committee on Biological Standardization for discussion and consideration. Reproduced here but currently not adopted by the aforementioned Expert Committee.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "4ea6f482afdd7965b007fcfe96dd16f6bf492b55ffe70f399c6a9347ba2aed94", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Specific guidance for APIs manufactured by cell culture/fermentation\n\n## 18.1 General\n\n18.10 Section 18 is intended to address specific controls for APIs or intermediates manufactured by cell culture or fermentation using natural or recombinant organisms and that have not been covered adequately in the previous sections. It is not intended to be a stand-alone section. In general, the GMP principles in the other sections of this document apply. Note that the principles of fermentation for \u201cclassical\u201d processes for production of small molecules and for processes using recombinant and non-recombinant organisms for production of proteins and/or polypeptides are the same, although the degree of control will differ. Where practical, this section will address these differences. In general, the degree of control for biotechnological processes used to produce proteins and polypeptides is greater than that for classical fermentation processes.\n\n18.11 The term \u201cbiotechnological process\u201d (biotech) refers to the use of cells or organisms that have been generated or modified by recombinant DNA, hybridoma or other technology to produce APIs. The APIs produced by biotechnological processes normally consist of high molecular weight substances, such as proteins and polypeptides, for which specific guidance is given in this Section. Certain APIs of low molecular weight, such as antibiotics, amino acids, vitamins, and carbohydrates, can also be produced by recombinant DNA technology. The level of control for these types of APIs is similar to that employed for classical fermentation.\n\n18.12 The term \u201cclassical fermentation\u201d refers to processes that use microorganisms existing in nature and/or modified by conventional methods (e.g. irradiation or chemical mutagenesis) to produce APIs. APIs produced by \u201cclassical fermentation\u201d are normally low molecular weight products such as antibiotics, amino acids, vitamins, and carbohydrates.\n\n18.13 Production of APIs or intermediates from cell culture or fermentation involves biological processes such as cultivation of cells or extraction and purification of material from living organisms. Note that there may be additional process steps, such as physicochemical modification, that are part of the manufacturing process. The raw materials used (media, buffer components) may provide the potential for growth of microbiological contaminants. Depending on the source, method of preparation, and the intended use of the API or intermediate, control of bioburden, viral\n\n----\n\n2 This section has been referred to the Expert Committee on Biological Standardization for discussion and consideration. Reproduced here but currently not adopted by the aforementioned Expert Committee.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2731, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5fe23a0f-b011-4ed9-9106-3c87dfdd316a": {"__data__": {"id_": "5fe23a0f-b011-4ed9-9106-3c87dfdd316a", "embedding": null, "metadata": {"page_label": "189", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "contamination, and/or endotoxins during manufacturing and monitoring of the process at appropriate stages may be necessary.\n\n18.14 Appropriate controls should be established at all stages of manufacturing to assure intermediate and/or API quality. While this guide starts at the cell culture/fermentation step, prior steps (e.g. cell banking) should be performed under appropriate process controls. This guide covers cell culture/fermentation from the point at which a vial of the cell bank is retrieved for use in manufacturing.\n\n18.15 Appropriate equipment and environmental controls should be used to minimize the risk of contamination. The acceptance criteria for quality of the environment and the frequency of monitoring should depend on the step in production and the production conditions (open, closed or contained systems).\n\n18.16 In general, process controls should take into account:\n\n\u2014 maintenance of the working cell bank (where appropriate);\n\u2014 proper inoculation and expansion of the culture;\n\u2014 control of the critical operating parameters during fermentation/cell culture;\n\u2014 monitoring of the process for cell growth, viability (for most cell culture processes) and productivity where appropriate;\n\u2014 harvest and purification procedures that remove cells, cellular debris and media components while protecting the intermediate or API from contamination (particularly of a microbiological nature) and from loss of quality;\n\u2014 monitoring of bioburden and, where needed, endotoxin levels at appropriate stages of production; and\n\u2014 viral safety concerns as described in ICH Guideline Q5A (2).\n\n18.17 Where appropriate, the removal of media components, host cell proteins, other process-related impurities, product-related impurities and contaminants should be demonstrated.\n\n### 18.2 Cell bank maintenance and record keeping\n\n18.20 Access to cell banks should be limited to authorized personnel.\n\n18.21 Cell banks should be maintained under storage conditions designed to maintain viability and prevent contamination.\n\n18.22 Records of the use of the vials from the cell banks and storage conditions should be maintained.\n\n18.23 Where appropriate, cell banks should be periodically monitored to determine suitability for use.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Controles en la fabricaci\u00f3n de productos biol\u00f3gicos**: El documento enfatiza la importancia de establecer controles apropiados en todas las etapas de la fabricaci\u00f3n de productos biol\u00f3gicos, comenzando desde el cultivo celular y la fermentaci\u00f3n, hasta la recolecci\u00f3n y purificaci\u00f3n del producto. Se menciona la necesidad de monitorear par\u00e1metros cr\u00edticos y asegurar la calidad del ambiente de producci\u00f3n.\n\n2. **Mantenimiento y registro de bancos celulares**: Se destaca la importancia de mantener los bancos celulares en condiciones adecuadas para preservar su viabilidad y prevenir la contaminaci\u00f3n. Adem\u00e1s, se requiere un registro detallado del uso de viales y las condiciones de almacenamiento, as\u00ed como monitoreos peri\u00f3dicos para asegurar la idoneidad de los bancos celulares.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios de aceptaci\u00f3n para la calidad del ambiente en la producci\u00f3n de cultivos celulares?**\n   - El documento indica que los criterios de aceptaci\u00f3n dependen del paso en la producci\u00f3n y de las condiciones de producci\u00f3n, ya sea en sistemas abiertos, cerrados o contenidos.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir para asegurar la calidad del producto intermedio o del API durante la cosecha y purificaci\u00f3n?**\n   - Se deben implementar procedimientos que eliminen c\u00e9lulas, debris celulares y componentes del medio, protegiendo al mismo tiempo el producto intermedio o API de la contaminaci\u00f3n, especialmente de naturaleza microbiol\u00f3gica, y de la p\u00e9rdida de calidad.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar para garantizar la seguridad viral en la producci\u00f3n de productos biol\u00f3gicos?**\n   - Se deben considerar las preocupaciones de seguridad viral seg\u00fan lo descrito en la Gu\u00eda ICH Q5A, lo que implica la implementaci\u00f3n de controles y monitoreos espec\u00edficos durante el proceso de fabricaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Control de Calidad en la Producci\u00f3n de APIs**: La secci\u00f3n aborda las directrices espec\u00edficas para el control de calidad de los ingredientes farmac\u00e9uticos activos (APIs) producidos mediante cultivos celulares o fermentaci\u00f3n, destacando que no es una secci\u00f3n independiente y que se basa en principios de Buenas Pr\u00e1cticas de Manufactura (GMP) de otras secciones.\n\n2. **Diferenciaci\u00f3n entre Procesos**: Se distingue entre procesos biotecnol\u00f3gicos, que utilizan organismos modificados gen\u00e9ticamente para producir sustancias de alto peso molecular (como prote\u00ednas y polip\u00e9ptidos), y la fermentaci\u00f3n cl\u00e1sica, que utiliza microorganismos naturales o modificados convencionalmente para producir productos de bajo peso molecular (como antibi\u00f3ticos y amino\u00e1cidos).\n\n3. **Control de Contaminantes**: Se enfatiza la importancia del control de contaminantes microbiol\u00f3gicos y virales en la producci\u00f3n de APIs, dado que los materiales crudos utilizados pueden ser fuentes de contaminaci\u00f3n.\n\n4. **Materiales Crudos**: Se menciona que la selecci\u00f3n de materiales crudos (medios y componentes de tampones) es crucial, ya que pueden influir en el crecimiento de contaminantes microbiol\u00f3gicos.\n\n### Entidades\n\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias producidas mediante cultivos celulares o fermentaci\u00f3n.\n- **Procesos Biotecnol\u00f3gicos**: M\u00e9todos que utilizan organismos modificados gen\u00e9ticamente para la producci\u00f3n de APIs de alto peso molecular.\n- **Fermentaci\u00f3n Cl\u00e1sica**: Procesos que utilizan microorganismos naturales o modificados convencionalmente para la producci\u00f3n de APIs de bajo peso molecular.\n- **Contaminantes Microbiol\u00f3gicos y Virales**: Riesgos asociados con la producci\u00f3n de APIs que deben ser controlados.\n- **Materiales Crudos**: Medios y componentes utilizados en la producci\u00f3n de APIs que pueden afectar la calidad del producto final.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos m\u00e1s relevantes de la secci\u00f3n, destacando la importancia de los controles espec\u00edficos en la producci\u00f3n de APIs mediante cultivos celulares y fermentaci\u00f3n.", "excerpt_keywords": "Keywords: contamination, cell culture, process controls, bioburden, viral safety"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "191e621a-f529-470c-8830-bff208608998", "node_type": "4", "metadata": {"page_label": "189", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "contamination, and/or endotoxins during manufacturing and monitoring of the process at appropriate stages may be necessary.\n\n18.14 Appropriate controls should be established at all stages of manufacturing to assure intermediate and/or API quality. While this guide starts at the cell culture/fermentation step, prior steps (e.g. cell banking) should be performed under appropriate process controls. This guide covers cell culture/fermentation from the point at which a vial of the cell bank is retrieved for use in manufacturing.\n\n18.15 Appropriate equipment and environmental controls should be used to minimize the risk of contamination. The acceptance criteria for quality of the environment and the frequency of monitoring should depend on the step in production and the production conditions (open, closed or contained systems).\n\n18.16 In general, process controls should take into account:\n\n\u2014 maintenance of the working cell bank (where appropriate);\n\u2014 proper inoculation and expansion of the culture;\n\u2014 control of the critical operating parameters during fermentation/cell culture;\n\u2014 monitoring of the process for cell growth, viability (for most cell culture processes) and productivity where appropriate;\n\u2014 harvest and purification procedures that remove cells, cellular debris and media components while protecting the intermediate or API from contamination (particularly of a microbiological nature) and from loss of quality;\n\u2014 monitoring of bioburden and, where needed, endotoxin levels at appropriate stages of production; and\n\u2014 viral safety concerns as described in ICH Guideline Q5A (2).\n\n18.17 Where appropriate, the removal of media components, host cell proteins, other process-related impurities, product-related impurities and contaminants should be demonstrated.\n\n### 18.2 Cell bank maintenance and record keeping\n\n18.20 Access to cell banks should be limited to authorized personnel.\n\n18.21 Cell banks should be maintained under storage conditions designed to maintain viability and prevent contamination.\n\n18.22 Records of the use of the vials from the cell banks and storage conditions should be maintained.\n\n18.23 Where appropriate, cell banks should be periodically monitored to determine suitability for use.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "df5ff5298b435f91a02b2a85b939783cdb4d3fc05addf660910497f75804194d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "contamination, and/or endotoxins during manufacturing and monitoring of the process at appropriate stages may be necessary.\n\n18.14 Appropriate controls should be established at all stages of manufacturing to assure intermediate and/or API quality. While this guide starts at the cell culture/fermentation step, prior steps (e.g. cell banking) should be performed under appropriate process controls. This guide covers cell culture/fermentation from the point at which a vial of the cell bank is retrieved for use in manufacturing.\n\n18.15 Appropriate equipment and environmental controls should be used to minimize the risk of contamination. The acceptance criteria for quality of the environment and the frequency of monitoring should depend on the step in production and the production conditions (open, closed or contained systems).\n\n18.16 In general, process controls should take into account:\n\n\u2014 maintenance of the working cell bank (where appropriate);\n\u2014 proper inoculation and expansion of the culture;\n\u2014 control of the critical operating parameters during fermentation/cell culture;\n\u2014 monitoring of the process for cell growth, viability (for most cell culture processes) and productivity where appropriate;\n\u2014 harvest and purification procedures that remove cells, cellular debris and media components while protecting the intermediate or API from contamination (particularly of a microbiological nature) and from loss of quality;\n\u2014 monitoring of bioburden and, where needed, endotoxin levels at appropriate stages of production; and\n\u2014 viral safety concerns as described in ICH Guideline Q5A (2).\n\n18.17 Where appropriate, the removal of media components, host cell proteins, other process-related impurities, product-related impurities and contaminants should be demonstrated.\n\n### 18.2 Cell bank maintenance and record keeping\n\n18.20 Access to cell banks should be limited to authorized personnel.\n\n18.21 Cell banks should be maintained under storage conditions designed to maintain viability and prevent contamination.\n\n18.22 Records of the use of the vials from the cell banks and storage conditions should be maintained.\n\n18.23 Where appropriate, cell banks should be periodically monitored to determine suitability for use.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2235, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5e016980-41a7-4fee-a1dd-c773067f433f": {"__data__": {"id_": "5e016980-41a7-4fee-a1dd-c773067f433f", "embedding": null, "metadata": {"page_label": "190", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 18.3 Cell culture/fermentation\n\n18.30 Where aseptic addition of cell substrates, media, buffers, and gases is needed, closed or contained systems should be used where possible. If the inoculation of the initial vessel or subsequent transfers or additions (media, buffers) are performed in open vessels, there should be controls and procedures in place to minimize the risk of contamination.\n\n18.31 Where the quality of the API can be affected by microbial contamination, manipulations using open vessels should be performed in a biosafety cabinet or similarly controlled environment.\n\n18.32 Personnel should be appropriately gowned and take special precautions handling the cultures.\n\n18.33 Critical operating parameters (for example temperature, pH, agitation rates, addition of gases, pressure) should be monitored to ensure consistency with the established process. Cell growth, viability (for most cell culture processes), and, where appropriate, productivity should also be monitored. Critical parameters will vary from one process to another, and for classical fermentation, certain parameters (cell viability, for example) may not need to be monitored.\n\n18.34 Cell culture equipment should be cleaned and sterilized after use. As appropriate, fermentation equipment should be cleaned, and sanitized or sterilized.\n\n18.35 Culture media should be sterilized before use when appropriate to protect the quality of the API.\n\n18.36 There should be appropriate procedures in place to detect contamination and determine the course of action to be taken. This should include procedures to determine the impact of the contamination on the product and those to decontaminate the equipment and return it to a condition to be used in subsequent batches. Foreign organisms observed during fermentation processes should be identified as appropriate and the effect of their presence on product quality should be assessed, if necessary. The results of such assessments should be taken into consideration in the disposition of the material produced.\n\n18.37 Records of contamination events should be maintained.\n\n18.38 Shared (multiproduct) equipment may warrant additional testing after cleaning between product campaigns, as appropriate, to minimize the risk of cross-contamination.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre las pr\u00e1cticas de cultivo celular y fermentaci\u00f3n, enfatizando la importancia de mantener condiciones as\u00e9pticas para evitar la contaminaci\u00f3n microbiana en la producci\u00f3n de ingredientes farmac\u00e9uticos activos (API). Se destacan procedimientos para el manejo de cultivos, la monitorizaci\u00f3n de par\u00e1metros cr\u00edticos, la limpieza y esterilizaci\u00f3n de equipos, y la gesti\u00f3n de eventos de contaminaci\u00f3n. Tambi\u00e9n se menciona la necesidad de mantener registros de contaminaci\u00f3n y realizar pruebas adicionales en equipos compartidos para minimizar el riesgo de contaminaci\u00f3n cruzada.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben implementarse para minimizar el riesgo de contaminaci\u00f3n al utilizar recipientes abiertos durante la inoculaci\u00f3n o transferencias en el cultivo celular?**\n   - Respuesta: Se deben establecer controles y procedimientos espec\u00edficos para minimizar el riesgo de contaminaci\u00f3n al realizar inoculaciones o transferencias en recipientes abiertos.\n\n2. **\u00bfCu\u00e1les son los par\u00e1metros cr\u00edticos que deben ser monitoreados durante el proceso de cultivo celular y c\u00f3mo pueden variar entre diferentes procesos?**\n   - Respuesta: Los par\u00e1metros cr\u00edticos incluyen temperatura, pH, tasas de agitaci\u00f3n, adici\u00f3n de gases y presi\u00f3n. Estos par\u00e1metros pueden variar de un proceso a otro, y en algunos casos, como en la fermentaci\u00f3n cl\u00e1sica, ciertos par\u00e1metros como la viabilidad celular pueden no ser necesarios de monitorear.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse si se detecta contaminaci\u00f3n en el proceso de fermentaci\u00f3n y c\u00f3mo se eval\u00faa su impacto en la calidad del producto?**\n   - Respuesta: Deben existir procedimientos para detectar la contaminaci\u00f3n y determinar el curso de acci\u00f3n, que incluye evaluar el impacto de la contaminaci\u00f3n en el producto y desinfectar el equipo para su uso en lotes posteriores. Los organismos extra\u00f1os observados deben ser identificados y su efecto en la calidad del producto evaluado, considerando los resultados en la disposici\u00f3n del material producido.", "prev_section_summary": "### Temas Clave\n\n1. **Controles en la Fabricaci\u00f3n**: Se enfatiza la necesidad de establecer controles apropiados en todas las etapas de la fabricaci\u00f3n de productos biol\u00f3gicos, desde el cultivo celular y la fermentaci\u00f3n hasta la cosecha y purificaci\u00f3n del producto. Esto incluye la monitorizaci\u00f3n de par\u00e1metros cr\u00edticos y la calidad del ambiente de producci\u00f3n.\n\n2. **Mantenimiento de Bancos Celulares**: Se destaca la importancia de mantener los bancos celulares en condiciones adecuadas para preservar su viabilidad y prevenir la contaminaci\u00f3n. Esto implica un acceso restringido a personal autorizado y un registro detallado del uso de los viales y las condiciones de almacenamiento.\n\n3. **Monitoreo y Control de Calidad**: Se requiere un monitoreo continuo de la calidad del ambiente y de los procesos, as\u00ed como la implementaci\u00f3n de procedimientos para eliminar contaminantes y asegurar la calidad del producto intermedio o del API.\n\n4. **Seguridad Viral**: Se deben considerar las preocupaciones de seguridad viral durante la producci\u00f3n, siguiendo las directrices establecidas en la Gu\u00eda ICH Q5A.\n\n### Entidades\n\n- **Bancos Celulares**: Almacenes de c\u00e9lulas que deben ser mantenidos y monitoreados adecuadamente.\n- **API (Ingrediente Farmac\u00e9utico Activo)**: Producto intermedio cuya calidad debe ser asegurada durante la fabricaci\u00f3n.\n- **Contaminantes**: Incluyen c\u00e9lulas, debris celulares, endotoxinas y otros impurezas que deben ser eliminados durante el proceso de producci\u00f3n.\n- **Gu\u00eda ICH Q5A**: Directrices que abordan la seguridad viral en la producci\u00f3n de productos biol\u00f3gicos.\n- **Condiciones de Producci\u00f3n**: Pueden ser sistemas abiertos, cerrados o contenidos, que afectan los criterios de aceptaci\u00f3n para la calidad del ambiente.\n\nEste resumen abarca los aspectos fundamentales y las entidades relevantes mencionadas en la secci\u00f3n del documento.", "excerpt_keywords": "Keywords: cell culture, fermentation, contamination control, aseptic techniques, API quality"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ddd4a719-0602-4533-bf33-6ee632116b76", "node_type": "4", "metadata": {"page_label": "190", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 18.3 Cell culture/fermentation\n\n18.30 Where aseptic addition of cell substrates, media, buffers, and gases is needed, closed or contained systems should be used where possible. If the inoculation of the initial vessel or subsequent transfers or additions (media, buffers) are performed in open vessels, there should be controls and procedures in place to minimize the risk of contamination.\n\n18.31 Where the quality of the API can be affected by microbial contamination, manipulations using open vessels should be performed in a biosafety cabinet or similarly controlled environment.\n\n18.32 Personnel should be appropriately gowned and take special precautions handling the cultures.\n\n18.33 Critical operating parameters (for example temperature, pH, agitation rates, addition of gases, pressure) should be monitored to ensure consistency with the established process. Cell growth, viability (for most cell culture processes), and, where appropriate, productivity should also be monitored. Critical parameters will vary from one process to another, and for classical fermentation, certain parameters (cell viability, for example) may not need to be monitored.\n\n18.34 Cell culture equipment should be cleaned and sterilized after use. As appropriate, fermentation equipment should be cleaned, and sanitized or sterilized.\n\n18.35 Culture media should be sterilized before use when appropriate to protect the quality of the API.\n\n18.36 There should be appropriate procedures in place to detect contamination and determine the course of action to be taken. This should include procedures to determine the impact of the contamination on the product and those to decontaminate the equipment and return it to a condition to be used in subsequent batches. Foreign organisms observed during fermentation processes should be identified as appropriate and the effect of their presence on product quality should be assessed, if necessary. The results of such assessments should be taken into consideration in the disposition of the material produced.\n\n18.37 Records of contamination events should be maintained.\n\n18.38 Shared (multiproduct) equipment may warrant additional testing after cleaning between product campaigns, as appropriate, to minimize the risk of cross-contamination.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "056ed90c5054eb2d2263eb3eeb53fc180f33c9440c88cbe1ac1fdff3d75e899d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 18.3 Cell culture/fermentation\n\n18.30 Where aseptic addition of cell substrates, media, buffers, and gases is needed, closed or contained systems should be used where possible. If the inoculation of the initial vessel or subsequent transfers or additions (media, buffers) are performed in open vessels, there should be controls and procedures in place to minimize the risk of contamination.\n\n18.31 Where the quality of the API can be affected by microbial contamination, manipulations using open vessels should be performed in a biosafety cabinet or similarly controlled environment.\n\n18.32 Personnel should be appropriately gowned and take special precautions handling the cultures.\n\n18.33 Critical operating parameters (for example temperature, pH, agitation rates, addition of gases, pressure) should be monitored to ensure consistency with the established process. Cell growth, viability (for most cell culture processes), and, where appropriate, productivity should also be monitored. Critical parameters will vary from one process to another, and for classical fermentation, certain parameters (cell viability, for example) may not need to be monitored.\n\n18.34 Cell culture equipment should be cleaned and sterilized after use. As appropriate, fermentation equipment should be cleaned, and sanitized or sterilized.\n\n18.35 Culture media should be sterilized before use when appropriate to protect the quality of the API.\n\n18.36 There should be appropriate procedures in place to detect contamination and determine the course of action to be taken. This should include procedures to determine the impact of the contamination on the product and those to decontaminate the equipment and return it to a condition to be used in subsequent batches. Foreign organisms observed during fermentation processes should be identified as appropriate and the effect of their presence on product quality should be assessed, if necessary. The results of such assessments should be taken into consideration in the disposition of the material produced.\n\n18.37 Records of contamination events should be maintained.\n\n18.38 Shared (multiproduct) equipment may warrant additional testing after cleaning between product campaigns, as appropriate, to minimize the risk of cross-contamination.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2274, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "811d1803-1a7e-49f2-a486-85492a09df7f": {"__data__": {"id_": "811d1803-1a7e-49f2-a486-85492a09df7f", "embedding": null, "metadata": {"page_label": "191", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 18.4 Harvesting, isolation and purification\n\n18.40 Harvesting steps, either to remove cells or cellular components or to collect cellular components after disruption, should be performed in equipment and areas designed to minimize the risk of contamination.\n\n18.41 Harvest and purification procedures that remove or inactivate the producing organism, cellular debris and media components (while minimizing degradation, contamination, and loss of quality) should be adequate to ensure that the intermediate or API is recovered with consistent quality.\n\n18.42 All equipment should be properly cleaned and, as appropriate, sanitized after use. Multiple successive batching without cleaning can be used if intermediate or API quality is not compromised.\n\n18.43 If open systems are used, purification should be performed under environmental conditions appropriate for the preservation of product quality.\n\n18.44 Additional controls, such as the use of dedicated chromatography resins or additional testing, may be appropriate if equipment is to be used for multiple products.\n\n# 18.5 Viral removal/inactivation steps\n\n18.50 See the ICH Guideline Q5A (2) for more specific information.\n\n18.51 Viral removal and viral inactivation steps are critical processing steps for some processes and should be performed within their validated parameters.\n\n18.52 Appropriate precautions should be taken to prevent potential viral contamination from pre-viral to post-viral removal/inactivation steps. Therefore, open processing should be performed in areas that are separate from other processing activities and have separate air handling units.\n\n18.53 The same equipment is not normally used for different purification steps. However, if the same equipment is to be used, the equipment should be appropriately cleaned and sanitized before reuse. Appropriate precautions should be taken to prevent potential virus carry-over (e.g. through equipment or environment) from previous steps.\n\n# 19. APIs for use in clinical trials\n\n## 19.1 General\n\n19.10 Not all the controls in the previous sections of this guide are appropriate for the manufacture of a new API for investigational use during", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda los procedimientos de cosecha, aislamiento y purificaci\u00f3n de productos farmac\u00e9uticos, enfatizando la importancia de minimizar la contaminaci\u00f3n y asegurar la calidad del producto intermedio o del principio activo (API). Se detallan las medidas necesarias para la eliminaci\u00f3n o inactivaci\u00f3n de virus, subrayando la necesidad de realizar estos pasos dentro de par\u00e1metros validados y en \u00e1reas separadas para evitar la contaminaci\u00f3n cruzada. Tambi\u00e9n se menciona que no todos los controles aplicables a la fabricaci\u00f3n de APIs son pertinentes para su uso en ensayos cl\u00ednicos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las condiciones ambientales recomendadas para realizar la purificaci\u00f3n en sistemas abiertos y por qu\u00e9 son importantes?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las condiciones ambientales necesarias para preservar la calidad del producto durante la purificaci\u00f3n en sistemas abiertos, que no se detalla en otras secciones del documento.\n\n2. **\u00bfQu\u00e9 medidas adicionales se pueden implementar si se utiliza el mismo equipo para m\u00faltiples productos durante el proceso de purificaci\u00f3n?**\n   - Esta pregunta se centra en las medidas espec\u00edficas que se pueden tomar para evitar la contaminaci\u00f3n cruzada cuando se reutiliza el equipo, lo cual es un aspecto cr\u00edtico en la producci\u00f3n farmac\u00e9utica.\n\n3. **\u00bfQu\u00e9 precauciones espec\u00edficas se deben tomar para prevenir la contaminaci\u00f3n viral durante las etapas de eliminaci\u00f3n/inactivaci\u00f3n de virus?**\n   - Esta pregunta busca detalles sobre las precauciones que deben implementarse para evitar la contaminaci\u00f3n viral, lo que es crucial para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.", "prev_section_summary": "### Temas Clave\n\n1. **Condiciones Asepticas**: Importancia de utilizar sistemas cerrados o contenidos para la adici\u00f3n as\u00e9ptica de sustratos celulares, medios, tampones y gases, minimizando el riesgo de contaminaci\u00f3n.\n\n2. **Manipulaciones en Vasos Abiertos**: Cuando se utilizan recipientes abiertos, se deben realizar en entornos controlados como cabinas de bioseguridad para proteger la calidad de los ingredientes farmac\u00e9uticos activos (API).\n\n3. **Precauciones del Personal**: El personal debe estar debidamente vestido y tomar precauciones especiales al manejar cultivos celulares.\n\n4. **Monitoreo de Par\u00e1metros Cr\u00edticos**: Se deben monitorear par\u00e1metros operativos cr\u00edticos (temperatura, pH, tasas de agitaci\u00f3n, adici\u00f3n de gases, presi\u00f3n) y, cuando sea apropiado, el crecimiento celular y la viabilidad.\n\n5. **Limpieza y Esterilizaci\u00f3n de Equipos**: Equipos de cultivo celular y fermentaci\u00f3n deben ser limpiados y esterilizados despu\u00e9s de su uso.\n\n6. **Esterilizaci\u00f3n de Medios de Cultivo**: Los medios de cultivo deben ser esterilizados antes de su uso para proteger la calidad del API.\n\n7. **Detecci\u00f3n y Manejo de Contaminaci\u00f3n**: Deben existir procedimientos para detectar contaminaci\u00f3n, evaluar su impacto en el producto y desinfectar el equipo.\n\n8. **Registros de Contaminaci\u00f3n**: Es necesario mantener registros de eventos de contaminaci\u00f3n.\n\n9. **Pruebas Adicionales en Equipos Compartidos**: Equipos utilizados para m\u00faltiples productos pueden requerir pruebas adicionales despu\u00e9s de la limpieza para minimizar el riesgo de contaminaci\u00f3n cruzada.\n\n### Entidades\n\n- **API (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias cuya calidad puede verse afectada por la contaminaci\u00f3n microbiana.\n- **Cabinas de Bioseguridad**: Entornos controlados recomendados para manipulaciones en recipientes abiertos.\n- **Par\u00e1metros Cr\u00edticos**: Incluyen temperatura, pH, tasas de agitaci\u00f3n, adici\u00f3n de gases y presi\u00f3n.\n- **Equipos de Cultivo Celular y Fermentaci\u00f3n**: Equipos que deben ser limpiados y esterilizados despu\u00e9s de su uso.\n- **Contaminaci\u00f3n Microbiana**: Riesgo que se busca minimizar a trav\u00e9s de procedimientos adecuados y monitoreo.", "excerpt_keywords": "Keywords: harvesting, purification, viral inactivation, contamination control, APIs"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "240e099a-de09-487c-a152-fd7136922bba", "node_type": "4", "metadata": {"page_label": "191", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 18.4 Harvesting, isolation and purification\n\n18.40 Harvesting steps, either to remove cells or cellular components or to collect cellular components after disruption, should be performed in equipment and areas designed to minimize the risk of contamination.\n\n18.41 Harvest and purification procedures that remove or inactivate the producing organism, cellular debris and media components (while minimizing degradation, contamination, and loss of quality) should be adequate to ensure that the intermediate or API is recovered with consistent quality.\n\n18.42 All equipment should be properly cleaned and, as appropriate, sanitized after use. Multiple successive batching without cleaning can be used if intermediate or API quality is not compromised.\n\n18.43 If open systems are used, purification should be performed under environmental conditions appropriate for the preservation of product quality.\n\n18.44 Additional controls, such as the use of dedicated chromatography resins or additional testing, may be appropriate if equipment is to be used for multiple products.\n\n# 18.5 Viral removal/inactivation steps\n\n18.50 See the ICH Guideline Q5A (2) for more specific information.\n\n18.51 Viral removal and viral inactivation steps are critical processing steps for some processes and should be performed within their validated parameters.\n\n18.52 Appropriate precautions should be taken to prevent potential viral contamination from pre-viral to post-viral removal/inactivation steps. Therefore, open processing should be performed in areas that are separate from other processing activities and have separate air handling units.\n\n18.53 The same equipment is not normally used for different purification steps. However, if the same equipment is to be used, the equipment should be appropriately cleaned and sanitized before reuse. Appropriate precautions should be taken to prevent potential virus carry-over (e.g. through equipment or environment) from previous steps.\n\n# 19. APIs for use in clinical trials\n\n## 19.1 General\n\n19.10 Not all the controls in the previous sections of this guide are appropriate for the manufacture of a new API for investigational use during", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "e645802c3b28f15e39e219d155867e6d43d26262119ab08b0ba262e52a9064da", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 18.4 Harvesting, isolation and purification\n\n18.40 Harvesting steps, either to remove cells or cellular components or to collect cellular components after disruption, should be performed in equipment and areas designed to minimize the risk of contamination.\n\n18.41 Harvest and purification procedures that remove or inactivate the producing organism, cellular debris and media components (while minimizing degradation, contamination, and loss of quality) should be adequate to ensure that the intermediate or API is recovered with consistent quality.\n\n18.42 All equipment should be properly cleaned and, as appropriate, sanitized after use. Multiple successive batching without cleaning can be used if intermediate or API quality is not compromised.\n\n18.43 If open systems are used, purification should be performed under environmental conditions appropriate for the preservation of product quality.\n\n18.44 Additional controls, such as the use of dedicated chromatography resins or additional testing, may be appropriate if equipment is to be used for multiple products.\n\n# 18.5 Viral removal/inactivation steps\n\n18.50 See the ICH Guideline Q5A (2) for more specific information.\n\n18.51 Viral removal and viral inactivation steps are critical processing steps for some processes and should be performed within their validated parameters.\n\n18.52 Appropriate precautions should be taken to prevent potential viral contamination from pre-viral to post-viral removal/inactivation steps. Therefore, open processing should be performed in areas that are separate from other processing activities and have separate air handling units.\n\n18.53 The same equipment is not normally used for different purification steps. However, if the same equipment is to be used, the equipment should be appropriately cleaned and sanitized before reuse. Appropriate precautions should be taken to prevent potential virus carry-over (e.g. through equipment or environment) from previous steps.\n\n# 19. APIs for use in clinical trials\n\n## 19.1 General\n\n19.10 Not all the controls in the previous sections of this guide are appropriate for the manufacture of a new API for investigational use during", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2172, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8252b4ef-610e-4def-9377-ef6743aab7dd": {"__data__": {"id_": "8252b4ef-610e-4def-9377-ef6743aab7dd", "embedding": null, "metadata": {"page_label": "192", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "its development. Section 19 provides specific guidance unique to these circumstances.\n\n19.11 The controls used in the manufacture of APIs for use in clinical trials should be consistent with the stage of development of the pharmaceutical product incorporating the API. Process and test procedures should be flexible to allow for changes to be made as knowledge of the process increases and clinical testing of a pharmaceutical product progresses from the preclinical stages through the clinical stages. Once pharmaceutical development reaches the stage where the API is produced for use in pharmaceutical products intended for clinical trials, manufacturers should ensure that APIs are manufactured in suitable facilities using appropriate production and control procedures to ensure the quality of the API.\n\n## 19.2 Quality\n\n19.20 Appropriate GMP concepts should be applied in the production of APIs for use in clinical trials with a suitable mechanism for the approval of each batch.\n\n19.21 A quality unit(s) independent from production should be established for the approval or rejection of each batch of API for use in clinical trials.\n\n19.22 Some of the testing functions commonly performed by the quality unit(s) can be performed within other organizational units.\n\n19.23 Quality measures should include a system for testing of raw materials, packaging materials, intermediates and APIs.\n\n19.24 Process and quality problems should be evaluated.\n\n19.25 Labelling for APIs intended for use in clinical trials should be appropriately controlled and should identify the material as being for investigational use.\n\n## 19.3 Equipment and facilities\n\n19.30 During all phases of clinical development, including the use of small-scale facilities or laboratories to manufacture batches of APIs for use in clinical trials, procedures should be in place to ensure that equipment is calibrated, clean and suitable for its intended use.\n\n19.31 Procedures for the use of facilities should ensure that materials are handled in a manner that minimizes the risk of contamination and cross-contamination.\n\n## 19.4 Control of raw materials\n\n19.40 Raw materials used in production of APIs for use in clinical trials should be evaluated by testing or be received with a supplier\u2019s analysis and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Desarrollo y Control de APIs en Ensayos Cl\u00ednicos**: El documento proporciona directrices sobre el control y la fabricaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (APIs) destinados a ensayos cl\u00ednicos, enfatizando la necesidad de que los procedimientos de producci\u00f3n y prueba sean flexibles y se adapten a las etapas de desarrollo del producto farmac\u00e9utico.\n\n2. **Calidad y Aprobaci\u00f3n de Lotes**: Se establece la importancia de aplicar conceptos de Buenas Pr\u00e1cticas de Manufactura (GMP) en la producci\u00f3n de APIs, incluyendo la creaci\u00f3n de unidades de calidad independientes para la aprobaci\u00f3n de lotes y la implementaci\u00f3n de sistemas de prueba para asegurar la calidad de los materiales utilizados.\n\n3. **Equipos y Instalaciones**: Se subraya la necesidad de que los equipos y las instalaciones utilizadas en la producci\u00f3n de APIs est\u00e9n debidamente calibrados y limpios, y que se sigan procedimientos para minimizar el riesgo de contaminaci\u00f3n durante todas las fases del desarrollo cl\u00ednico.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 flexibilidad se requiere en los procedimientos de producci\u00f3n y prueba de APIs durante las diferentes etapas de desarrollo de un producto farmac\u00e9utico?**\n   - Esta pregunta busca detalles sobre c\u00f3mo los procedimientos deben adaptarse a medida que avanza el conocimiento del proceso y se realizan pruebas cl\u00ednicas.\n\n2. **\u00bfCu\u00e1les son los requisitos espec\u00edficos para la creaci\u00f3n de una unidad de calidad independiente en la producci\u00f3n de APIs para ensayos cl\u00ednicos?**\n   - Esta pregunta se centra en la estructura y las funciones de la unidad de calidad, as\u00ed como en su papel en la aprobaci\u00f3n o rechazo de lotes de APIs.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que los materiales utilizados en la producci\u00f3n de APIs est\u00e9n libres de contaminaci\u00f3n y cumplan con los est\u00e1ndares de calidad?**\n   - Esta pregunta indaga sobre los procedimientos espec\u00edficos que deben implementarse para manejar materiales y minimizar riesgos de contaminaci\u00f3n en las instalaciones de producci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Cosecha, Aislamiento y Purificaci\u00f3n (Secci\u00f3n 18.4)**:\n   - **Objetivo**: Minimizar la contaminaci\u00f3n y asegurar la calidad del producto intermedio o del principio activo (API).\n   - **Condiciones de Equipos**: Se deben utilizar equipos y \u00e1reas dise\u00f1adas para reducir el riesgo de contaminaci\u00f3n durante la cosecha y purificaci\u00f3n.\n   - **Procedimientos**: Los procedimientos deben eliminar o inactivar organismos productores, residuos celulares y componentes del medio, manteniendo la calidad del API.\n   - **Limpieza de Equipos**: Es esencial limpiar y, cuando sea necesario, desinfectar el equipo despu\u00e9s de su uso. Se permite el uso de m\u00faltiples lotes sucesivos sin limpieza si no se compromete la calidad del API.\n   - **Sistemas Abiertos**: La purificaci\u00f3n en sistemas abiertos debe realizarse bajo condiciones ambientales que preserven la calidad del producto.\n   - **Controles Adicionales**: Se pueden implementar controles adicionales, como resinas de cromatograf\u00eda dedicadas, si se utiliza el mismo equipo para m\u00faltiples productos.\n\n2. **Eliminaci\u00f3n/Inactivaci\u00f3n Viral (Secci\u00f3n 18.5)**:\n   - **Importancia**: Los pasos de eliminaci\u00f3n e inactivaci\u00f3n viral son cr\u00edticos y deben realizarse dentro de par\u00e1metros validados.\n   - **Precauciones**: Se deben tomar precauciones para prevenir la contaminaci\u00f3n viral, realizando el procesamiento abierto en \u00e1reas separadas con unidades de manejo de aire independientes.\n   - **Uso de Equipos**: Normalmente, no se utiliza el mismo equipo para diferentes pasos de purificaci\u00f3n. Si se reutiliza, el equipo debe ser limpiado y desinfectado adecuadamente para evitar la contaminaci\u00f3n cruzada.\n\n3. **APIs para Ensayos Cl\u00ednicos (Secci\u00f3n 19.1)**:\n   - **Consideraciones**: No todos los controles mencionados anteriormente son aplicables a la fabricaci\u00f3n de nuevos APIs para uso investigacional.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Principio Activo (API)**: Sustancia activa en productos farmac\u00e9uticos.\n- **Contaminaci\u00f3n Viral**: Riesgo que se debe gestionar durante la producci\u00f3n.\n- **Equipos de Purificaci\u00f3n**: Herramientas utilizadas en los procesos de cosecha y purificaci\u00f3n.\n- **Par\u00e1metros Validados**: Normas que deben cumplirse durante los procesos cr\u00edticos. \n\nEste resumen destaca la importancia de las pr\u00e1cticas de manufactura adecuadas para garantizar la calidad y seguridad de los productos farmac\u00e9uticos, as\u00ed como las consideraciones espec\u00edficas para la producci\u00f3n de APIs destinados a ensayos cl\u00ednicos.", "excerpt_keywords": "Keywords: APIs, clinical trials, GMP, quality control, contamination"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a0be8509-024a-4e2e-8ed1-f22354761c5e", "node_type": "4", "metadata": {"page_label": "192", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "its development. Section 19 provides specific guidance unique to these circumstances.\n\n19.11 The controls used in the manufacture of APIs for use in clinical trials should be consistent with the stage of development of the pharmaceutical product incorporating the API. Process and test procedures should be flexible to allow for changes to be made as knowledge of the process increases and clinical testing of a pharmaceutical product progresses from the preclinical stages through the clinical stages. Once pharmaceutical development reaches the stage where the API is produced for use in pharmaceutical products intended for clinical trials, manufacturers should ensure that APIs are manufactured in suitable facilities using appropriate production and control procedures to ensure the quality of the API.\n\n## 19.2 Quality\n\n19.20 Appropriate GMP concepts should be applied in the production of APIs for use in clinical trials with a suitable mechanism for the approval of each batch.\n\n19.21 A quality unit(s) independent from production should be established for the approval or rejection of each batch of API for use in clinical trials.\n\n19.22 Some of the testing functions commonly performed by the quality unit(s) can be performed within other organizational units.\n\n19.23 Quality measures should include a system for testing of raw materials, packaging materials, intermediates and APIs.\n\n19.24 Process and quality problems should be evaluated.\n\n19.25 Labelling for APIs intended for use in clinical trials should be appropriately controlled and should identify the material as being for investigational use.\n\n## 19.3 Equipment and facilities\n\n19.30 During all phases of clinical development, including the use of small-scale facilities or laboratories to manufacture batches of APIs for use in clinical trials, procedures should be in place to ensure that equipment is calibrated, clean and suitable for its intended use.\n\n19.31 Procedures for the use of facilities should ensure that materials are handled in a manner that minimizes the risk of contamination and cross-contamination.\n\n## 19.4 Control of raw materials\n\n19.40 Raw materials used in production of APIs for use in clinical trials should be evaluated by testing or be received with a supplier\u2019s analysis and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "5783dad89c954d199188c0b1962afe63be858e9763b6e30b420b68e249ac1dba", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "its development. Section 19 provides specific guidance unique to these circumstances.\n\n19.11 The controls used in the manufacture of APIs for use in clinical trials should be consistent with the stage of development of the pharmaceutical product incorporating the API. Process and test procedures should be flexible to allow for changes to be made as knowledge of the process increases and clinical testing of a pharmaceutical product progresses from the preclinical stages through the clinical stages. Once pharmaceutical development reaches the stage where the API is produced for use in pharmaceutical products intended for clinical trials, manufacturers should ensure that APIs are manufactured in suitable facilities using appropriate production and control procedures to ensure the quality of the API.\n\n## 19.2 Quality\n\n19.20 Appropriate GMP concepts should be applied in the production of APIs for use in clinical trials with a suitable mechanism for the approval of each batch.\n\n19.21 A quality unit(s) independent from production should be established for the approval or rejection of each batch of API for use in clinical trials.\n\n19.22 Some of the testing functions commonly performed by the quality unit(s) can be performed within other organizational units.\n\n19.23 Quality measures should include a system for testing of raw materials, packaging materials, intermediates and APIs.\n\n19.24 Process and quality problems should be evaluated.\n\n19.25 Labelling for APIs intended for use in clinical trials should be appropriately controlled and should identify the material as being for investigational use.\n\n## 19.3 Equipment and facilities\n\n19.30 During all phases of clinical development, including the use of small-scale facilities or laboratories to manufacture batches of APIs for use in clinical trials, procedures should be in place to ensure that equipment is calibrated, clean and suitable for its intended use.\n\n19.31 Procedures for the use of facilities should ensure that materials are handled in a manner that minimizes the risk of contamination and cross-contamination.\n\n## 19.4 Control of raw materials\n\n19.40 Raw materials used in production of APIs for use in clinical trials should be evaluated by testing or be received with a supplier\u2019s analysis and", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2277, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4123d9cb-9b5a-4067-b84a-f6695e650218": {"__data__": {"id_": "4123d9cb-9b5a-4067-b84a-f6695e650218", "embedding": null, "metadata": {"page_label": "193", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 19.5 Production\n\n19.50 The production of APIs for use in clinical trials should be documented in laboratory notebooks, batch records or by other appropriate means. These documents should include information on the use of production materials, equipment, processing and scientific observations.\n\n19.51 Expected yields can be more variable and less defined than the expected yields used in commercial processes. Investigations into yield variations are not expected.\n\n# 19.6 Validation\n\n19.60 Process validation for the production of APIs for use in clinical trials is normally inappropriate where a single API batch is produced or where process changes during development of an API make batch replication difficult or inexact. The combination of controls, calibration and, where appropriate, equipment qualification assures quality of the API during this development phase.\n\n19.61 Process validation should be conducted in accordance with section 12 when batches are produced for commercial use, even when such batches are produced on a pilot scale or small scale.\n\n# 19.7 Changes\n\n19.70 Changes are expected during development as knowledge is gained and the production is scaled up. Every change in the production, specifications or test procedures should be adequately recorded.\n\n# 19.8 Laboratory controls\n\n19.80 While analytical methods performed to evaluate a batch of API for clinical trials may not yet be validated they should be scientifically sound.\n\n19.81 A system for retaining reserve samples of all batches should be in place. This system should ensure that a sufficient quantity of each reserve sample is retained for an appropriate length of time after approval, termination or discontinuation of an application.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la producci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (APIs) para ensayos cl\u00ednicos, destacando la importancia de la documentaci\u00f3n, la validaci\u00f3n de procesos, la gesti\u00f3n de cambios y el control de laboratorio. Se enfatiza que la producci\u00f3n debe ser registrada adecuadamente, que las variaciones en los rendimientos son esperadas y que la validaci\u00f3n de procesos es crucial para la producci\u00f3n comercial. Adem\u00e1s, se menciona la necesidad de un sistema para conservar muestras de reserva de todos los lotes producidos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para la producci\u00f3n de APIs en ensayos cl\u00ednicos y qu\u00e9 informaci\u00f3n debe incluir?**\n   - La producci\u00f3n de APIs debe ser documentada en cuadernos de laboratorio, registros de lotes u otros medios apropiados, incluyendo informaci\u00f3n sobre materiales de producci\u00f3n, equipos, procesamiento y observaciones cient\u00edficas.\n\n2. **\u00bfPor qu\u00e9 no se espera realizar investigaciones sobre las variaciones en los rendimientos de los APIs durante los ensayos cl\u00ednicos?**\n   - Se considera que los rendimientos esperados pueden ser m\u00e1s variables y menos definidos en comparaci\u00f3n con los procesos comerciales, lo que hace que las investigaciones sobre estas variaciones no sean necesarias.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse en relaci\u00f3n con los cambios en la producci\u00f3n de APIs durante el desarrollo?**\n   - Todos los cambios en la producci\u00f3n, especificaciones o procedimientos de prueba deben ser registrados adecuadamente, ya que se espera que ocurran cambios a medida que se adquiere conocimiento y se escala la producci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manufactura de APIs en Ensayos Cl\u00ednicos**:\n   - Se enfatiza la necesidad de que los controles en la fabricaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (APIs) sean coherentes con la etapa de desarrollo del producto farmac\u00e9utico. Los procedimientos de producci\u00f3n y prueba deben ser flexibles para adaptarse a los avances en el conocimiento del proceso y en las pruebas cl\u00ednicas.\n\n2. **Calidad y Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Se requiere la aplicaci\u00f3n de conceptos de GMP en la producci\u00f3n de APIs, incluyendo la creaci\u00f3n de unidades de calidad independientes que se encarguen de la aprobaci\u00f3n o rechazo de cada lote. Tambi\u00e9n se menciona la importancia de un sistema de pruebas para asegurar la calidad de los materiales utilizados.\n\n3. **Equipos e Instalaciones**:\n   - Es crucial que los equipos y las instalaciones est\u00e9n calibrados, limpios y adecuados para su uso previsto. Se deben seguir procedimientos para minimizar el riesgo de contaminaci\u00f3n y cross-contaminaci\u00f3n durante todas las fases del desarrollo cl\u00ednico.\n\n4. **Control de Materias Primas**:\n   - Las materias primas utilizadas en la producci\u00f3n de APIs deben ser evaluadas mediante pruebas o recibidas con un an\u00e1lisis del proveedor, asegurando as\u00ed su calidad y adecuaci\u00f3n para el uso en ensayos cl\u00ednicos.\n\n### Entidades Clave\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias utilizadas en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Conjunto de directrices que aseguran la calidad y seguridad en la producci\u00f3n de medicamentos.\n- **Unidades de Calidad**: Departamentos independientes responsables de la evaluaci\u00f3n de la calidad de los lotes de APIs.\n- **Contaminaci\u00f3n y Cross-Contaminaci\u00f3n**: Riesgos asociados a la manipulaci\u00f3n de materiales en la producci\u00f3n que deben ser controlados.\n\nEste resumen destaca la importancia de la calidad, el control y la flexibilidad en la producci\u00f3n de APIs para ensayos cl\u00ednicos, asegurando que se cumplan los est\u00e1ndares necesarios para la investigaci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: APIs, clinical trials, production documentation, process validation, laboratory controls"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1ea24a96-2051-41b3-90c5-870d64c353fe", "node_type": "4", "metadata": {"page_label": "193", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 19.5 Production\n\n19.50 The production of APIs for use in clinical trials should be documented in laboratory notebooks, batch records or by other appropriate means. These documents should include information on the use of production materials, equipment, processing and scientific observations.\n\n19.51 Expected yields can be more variable and less defined than the expected yields used in commercial processes. Investigations into yield variations are not expected.\n\n# 19.6 Validation\n\n19.60 Process validation for the production of APIs for use in clinical trials is normally inappropriate where a single API batch is produced or where process changes during development of an API make batch replication difficult or inexact. The combination of controls, calibration and, where appropriate, equipment qualification assures quality of the API during this development phase.\n\n19.61 Process validation should be conducted in accordance with section 12 when batches are produced for commercial use, even when such batches are produced on a pilot scale or small scale.\n\n# 19.7 Changes\n\n19.70 Changes are expected during development as knowledge is gained and the production is scaled up. Every change in the production, specifications or test procedures should be adequately recorded.\n\n# 19.8 Laboratory controls\n\n19.80 While analytical methods performed to evaluate a batch of API for clinical trials may not yet be validated they should be scientifically sound.\n\n19.81 A system for retaining reserve samples of all batches should be in place. This system should ensure that a sufficient quantity of each reserve sample is retained for an appropriate length of time after approval, termination or discontinuation of an application.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "df8ae8a8bca42caf08618b1d37e3080e279edb27e5b376bcb8bbbae53b0a451b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 19.5 Production\n\n19.50 The production of APIs for use in clinical trials should be documented in laboratory notebooks, batch records or by other appropriate means. These documents should include information on the use of production materials, equipment, processing and scientific observations.\n\n19.51 Expected yields can be more variable and less defined than the expected yields used in commercial processes. Investigations into yield variations are not expected.\n\n# 19.6 Validation\n\n19.60 Process validation for the production of APIs for use in clinical trials is normally inappropriate where a single API batch is produced or where process changes during development of an API make batch replication difficult or inexact. The combination of controls, calibration and, where appropriate, equipment qualification assures quality of the API during this development phase.\n\n19.61 Process validation should be conducted in accordance with section 12 when batches are produced for commercial use, even when such batches are produced on a pilot scale or small scale.\n\n# 19.7 Changes\n\n19.70 Changes are expected during development as knowledge is gained and the production is scaled up. Every change in the production, specifications or test procedures should be adequately recorded.\n\n# 19.8 Laboratory controls\n\n19.80 While analytical methods performed to evaluate a batch of API for clinical trials may not yet be validated they should be scientifically sound.\n\n19.81 A system for retaining reserve samples of all batches should be in place. This system should ensure that a sufficient quantity of each reserve sample is retained for an appropriate length of time after approval, termination or discontinuation of an application.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1729, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1f6fd653-524f-433e-a002-498183d8331b": {"__data__": {"id_": "1f6fd653-524f-433e-a002-498183d8331b", "embedding": null, "metadata": {"page_label": "194", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 19.9 Documentation\n\n19.82 Expiry and retest dating as defined in section 11.6 applies to existing APIs used in clinical trials. For new APIs section 11.6 does not normally apply in early stages of clinical trials.\n\n19.90 A system should be in place to ensure that information gained during the development and the manufacture of APIs for use in clinical trials is documented and available.\n\n19.91 The development and implementation of the analytical methods used to support the release of a batch of API for use in clinical trials should be appropriately documented.\n\n19.92 A system for retaining production and control records and documents should be used. This system should ensure that records and documents are retained for an appropriate length of time after the approval, termination or discontinuation of an application.\n\n# 20. Glossary\n\n**acceptance criteria**  \nNumerical limits, ranges or other suitable measures for acceptance of test results.\n\n**active pharmaceutical ingredient (API) (or pharmaceutical substance)**  \nAny substance or mixture of substances intended to be used in the manufacture of a finished pharmaceutical product (FPP) and that, when used in the production of a pharmaceutical product, becomes an active ingredient of the pharmaceutical product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the body.\n\n**API starting material**  \nA raw material, intermediate or an API that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. An API starting material can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement or produced in-house. API starting materials normally have defined chemical properties and structure.\n\n**batch (or lot)**  \nA specific quantity of material produced in a process or series of processes so that it is expected to be homogeneous within specified limits. In the case", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la documentaci\u00f3n relacionada con los ingredientes farmac\u00e9uticos activos (API) utilizados en ensayos cl\u00ednicos. Se enfatiza la importancia de mantener registros adecuados durante el desarrollo y la fabricaci\u00f3n de APIs, as\u00ed como la necesidad de documentar los m\u00e9todos anal\u00edticos utilizados para liberar lotes de API. Tambi\u00e9n se menciona la retenci\u00f3n de registros de producci\u00f3n y control por un per\u00edodo adecuado tras la aprobaci\u00f3n o finalizaci\u00f3n de una aplicaci\u00f3n. Adem\u00e1s, se proporciona un glosario que define t\u00e9rminos clave como \"criterios de aceptaci\u00f3n\", \"ingrediente farmac\u00e9utico activo\" y \"material de partida de API\".\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 se debe documentar espec\u00edficamente durante el desarrollo y la fabricaci\u00f3n de APIs para ensayos cl\u00ednicos?**\n   - El contexto menciona que debe haber un sistema para asegurar que la informaci\u00f3n obtenida durante el desarrollo y la fabricaci\u00f3n de APIs est\u00e9 documentada y disponible. Sin embargo, no se especifican los tipos exactos de informaci\u00f3n que deben ser documentados.\n\n2. **\u00bfCu\u00e1l es la duraci\u00f3n adecuada para la retenci\u00f3n de registros y documentos relacionados con la producci\u00f3n y control de APIs?**\n   - Aunque se menciona que los registros deben ser retenidos por un \"per\u00edodo adecuado\" despu\u00e9s de la aprobaci\u00f3n o finalizaci\u00f3n de una aplicaci\u00f3n, el contexto no proporciona detalles sobre qu\u00e9 se considera un per\u00edodo adecuado.\n\n3. **\u00bfQu\u00e9 criterios se utilizan para determinar si un lote de API es homog\u00e9neo dentro de los l\u00edmites especificados?**\n   - El t\u00e9rmino \"lote\" se define en el contexto, pero no se explican los m\u00e9todos o criterios espec\u00edficos que se utilizan para evaluar la homogeneidad de un lote de material producido.\n\nEstas preguntas est\u00e1n dise\u00f1adas para profundizar en aspectos espec\u00edficos del proceso de documentaci\u00f3n y control de calidad de los APIs en ensayos cl\u00ednicos, que no se abordan de manera exhaustiva en el texto proporcionado.", "prev_section_summary": "### Temas Clave\n\n1. **Documentaci\u00f3n de Producci\u00f3n**: La producci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (APIs) para ensayos cl\u00ednicos debe ser documentada adecuadamente en cuadernos de laboratorio y registros de lotes, incluyendo detalles sobre materiales, equipos, procesos y observaciones cient\u00edficas.\n\n2. **Variabilidad en Rendimientos**: Se reconoce que los rendimientos esperados de los APIs pueden ser m\u00e1s variables en ensayos cl\u00ednicos que en procesos comerciales, y no se espera realizar investigaciones sobre estas variaciones.\n\n3. **Validaci\u00f3n de Procesos**: La validaci\u00f3n de procesos es generalmente inapropiada para lotes \u00fanicos de APIs en desarrollo, pero es esencial para la producci\u00f3n comercial. Se deben seguir las directrices establecidas en el documento para la validaci\u00f3n de lotes comerciales.\n\n4. **Gesti\u00f3n de Cambios**: Se anticipan cambios durante el desarrollo de APIs, y todos los cambios en producci\u00f3n, especificaciones o procedimientos de prueba deben ser registrados adecuadamente.\n\n5. **Controles de Laboratorio**: Aunque los m\u00e9todos anal\u00edticos para evaluar los lotes de APIs pueden no estar validados, deben ser cient\u00edficamente s\u00f3lidos. Adem\u00e1s, se debe establecer un sistema para conservar muestras de reserva de todos los lotes producidos.\n\n### Entidades\n\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias utilizadas en la producci\u00f3n de medicamentos.\n- **Ensayos Cl\u00ednicos**: Estudios realizados para evaluar la eficacia y seguridad de un medicamento.\n- **Documentaci\u00f3n**: Cuadernos de laboratorio, registros de lotes.\n- **Validaci\u00f3n de Procesos**: Proceso de asegurar que los m\u00e9todos de producci\u00f3n cumplen con los est\u00e1ndares de calidad.\n- **Muestras de Reserva**: Muestras conservadas de cada lote producido para referencia futura.", "excerpt_keywords": "Keywords: documentaci\u00f3n, ingredientes farmac\u00e9uticos activos, ensayos cl\u00ednicos, registros de producci\u00f3n, criterios de aceptaci\u00f3n"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4e4e6edb-3903-4af7-91f6-9658abd6d7c0", "node_type": "4", "metadata": {"page_label": "194", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 19.9 Documentation\n\n19.82 Expiry and retest dating as defined in section 11.6 applies to existing APIs used in clinical trials. For new APIs section 11.6 does not normally apply in early stages of clinical trials.\n\n19.90 A system should be in place to ensure that information gained during the development and the manufacture of APIs for use in clinical trials is documented and available.\n\n19.91 The development and implementation of the analytical methods used to support the release of a batch of API for use in clinical trials should be appropriately documented.\n\n19.92 A system for retaining production and control records and documents should be used. This system should ensure that records and documents are retained for an appropriate length of time after the approval, termination or discontinuation of an application.\n\n# 20. Glossary\n\n**acceptance criteria**  \nNumerical limits, ranges or other suitable measures for acceptance of test results.\n\n**active pharmaceutical ingredient (API) (or pharmaceutical substance)**  \nAny substance or mixture of substances intended to be used in the manufacture of a finished pharmaceutical product (FPP) and that, when used in the production of a pharmaceutical product, becomes an active ingredient of the pharmaceutical product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the body.\n\n**API starting material**  \nA raw material, intermediate or an API that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. An API starting material can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement or produced in-house. API starting materials normally have defined chemical properties and structure.\n\n**batch (or lot)**  \nA specific quantity of material produced in a process or series of processes so that it is expected to be homogeneous within specified limits. In the case", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "61c613f4b344713a17562bc9a57892ccc6cbf01673b60311ae18e11359b3143c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 19.9 Documentation\n\n19.82 Expiry and retest dating as defined in section 11.6 applies to existing APIs used in clinical trials. For new APIs section 11.6 does not normally apply in early stages of clinical trials.\n\n19.90 A system should be in place to ensure that information gained during the development and the manufacture of APIs for use in clinical trials is documented and available.\n\n19.91 The development and implementation of the analytical methods used to support the release of a batch of API for use in clinical trials should be appropriately documented.\n\n19.92 A system for retaining production and control records and documents should be used. This system should ensure that records and documents are retained for an appropriate length of time after the approval, termination or discontinuation of an application.\n\n# 20. Glossary\n\n**acceptance criteria**  \nNumerical limits, ranges or other suitable measures for acceptance of test results.\n\n**active pharmaceutical ingredient (API) (or pharmaceutical substance)**  \nAny substance or mixture of substances intended to be used in the manufacture of a finished pharmaceutical product (FPP) and that, when used in the production of a pharmaceutical product, becomes an active ingredient of the pharmaceutical product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the body.\n\n**API starting material**  \nA raw material, intermediate or an API that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. An API starting material can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement or produced in-house. API starting materials normally have defined chemical properties and structure.\n\n**batch (or lot)**  \nA specific quantity of material produced in a process or series of processes so that it is expected to be homogeneous within specified limits. In the case", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2116, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "62aa30e0-1d77-47ba-b2ed-eea7dae1e75e": {"__data__": {"id_": "62aa30e0-1d77-47ba-b2ed-eea7dae1e75e", "embedding": null, "metadata": {"page_label": "195", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "of continuous production, a batch may correspond to a defined fraction of the production. The batch size can be defined either by a fixed quantity or by the amount produced in a fixed time interval.\n\n**batch number (or lot number)**  \nA unique combination of numbers, letters and/or symbols that identifies a batch (or lot) and from which the production and distribution history can be determined.\n\n**bioburden**  \nThe level and type (e.g. objectionable or not) of microorganisms that can be present in raw materials, API starting materials, intermediates or APIs. Bioburden should not be considered contamination unless the levels have been exceeded or defined objectionable organisms have been detected.\n\n**calibration**  \nThe demonstration that a particular instrument or device produces results within specified limits by comparison with those produced by a reference or traceable standard over an appropriate range of measurements.\n\n**computer system**  \nA group of hardware components and associated software, designed and assembled to perform a specific function or group of functions.\n\n**computerized system**  \nA process or operation integrated with a computer system.\n\n**contamination**  \nThe undesired introduction of impurities of a chemical or microbiological nature or of foreign matter into or on to a raw material, intermediate or API during production, sampling, packaging or repackaging, storage or transport.\n\n**contract manufacturer**  \nA manufacturer performing some aspect of manufacturing on behalf of the original manufacturer.\n\n**critical**  \nDescribes a process step, process condition, test requirement or other relevant parameter or item that must be controlled within predetermined criteria to ensure that the API meets its specification.\n\n**cross-contamination**  \nContamination of a material or product with another material or product.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en su Serie de Informes T\u00e9cnicos 957 aborda conceptos clave relacionados con la producci\u00f3n de productos farmac\u00e9uticos, incluyendo definiciones de t\u00e9rminos como \"n\u00famero de lote\", \"bioburden\", \"calibraci\u00f3n\", \"sistemas computarizados\", \"contaminaci\u00f3n\", \"fabricante por contrato\", \"cr\u00edtico\" y \"contaminaci\u00f3n cruzada\". Estos t\u00e9rminos son esenciales para entender los procesos de fabricaci\u00f3n y control de calidad en la producci\u00f3n de ingredientes farmac\u00e9uticos activos (API).\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar para definir el tama\u00f1o de un lote en la producci\u00f3n continua?**\n   - Respuesta: El tama\u00f1o de un lote puede definirse ya sea por una cantidad fija o por la cantidad producida en un intervalo de tiempo fijo.\n\n2. **\u00bfC\u00f3mo se determina si el bioburden en un material es considerado contaminaci\u00f3n?**\n   - Respuesta: El bioburden no debe considerarse contaminaci\u00f3n a menos que los niveles hayan sido superados o se hayan detectado organismos objetables definidos.\n\n3. **\u00bfQu\u00e9 implica la calibraci\u00f3n de un instrumento en el contexto de la producci\u00f3n farmac\u00e9utica?**\n   - Respuesta: La calibraci\u00f3n implica demostrar que un instrumento o dispositivo produce resultados dentro de l\u00edmites especificados mediante comparaci\u00f3n con resultados producidos por un est\u00e1ndar de referencia o trazable a lo largo de un rango apropiado de mediciones.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Documentaci\u00f3n de APIs en Ensayos Cl\u00ednicos**:\n   - Se establece la necesidad de un sistema que garantice la documentaci\u00f3n y disponibilidad de la informaci\u00f3n obtenida durante el desarrollo y fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs) utilizados en ensayos cl\u00ednicos.\n\n2. **M\u00e9todos Anal\u00edticos**:\n   - Es fundamental documentar el desarrollo e implementaci\u00f3n de los m\u00e9todos anal\u00edticos que respaldan la liberaci\u00f3n de lotes de API para su uso en ensayos cl\u00ednicos.\n\n3. **Retenci\u00f3n de Registros**:\n   - Se requiere un sistema para la retenci\u00f3n de registros y documentos de producci\u00f3n y control, asegurando que se mantengan por un per\u00edodo adecuado tras la aprobaci\u00f3n, terminaci\u00f3n o discontinuaci\u00f3n de una aplicaci\u00f3n.\n\n4. **Glosario de T\u00e9rminos Clave**:\n   - **Criterios de Aceptaci\u00f3n**: L\u00edmites num\u00e9ricos o rangos para la aceptaci\u00f3n de resultados de pruebas.\n   - **Ingrediente Farmac\u00e9utico Activo (API)**: Sustancia utilizada en la fabricaci\u00f3n de un producto farmac\u00e9utico terminado que proporciona actividad farmacol\u00f3gica.\n   - **Material de Partida de API**: Materia prima o intermedio utilizado en la producci\u00f3n de un API, que se incorpora significativamente en su estructura.\n   - **Lote**: Cantidad espec\u00edfica de material producida en un proceso, esper\u00e1ndose que sea homog\u00e9nea dentro de l\u00edmites especificados.\n\nEstos temas resaltan la importancia de la documentaci\u00f3n y el control de calidad en el desarrollo y uso de APIs en ensayos cl\u00ednicos, as\u00ed como la definici\u00f3n de t\u00e9rminos clave que son esenciales para entender el proceso.", "excerpt_keywords": "Keywords: batch production, bioburden, calibration, contamination, contract manufacturer"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1f3f6769-307e-4ca1-9a5a-de7c5c763a9b", "node_type": "4", "metadata": {"page_label": "195", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "of continuous production, a batch may correspond to a defined fraction of the production. The batch size can be defined either by a fixed quantity or by the amount produced in a fixed time interval.\n\n**batch number (or lot number)**  \nA unique combination of numbers, letters and/or symbols that identifies a batch (or lot) and from which the production and distribution history can be determined.\n\n**bioburden**  \nThe level and type (e.g. objectionable or not) of microorganisms that can be present in raw materials, API starting materials, intermediates or APIs. Bioburden should not be considered contamination unless the levels have been exceeded or defined objectionable organisms have been detected.\n\n**calibration**  \nThe demonstration that a particular instrument or device produces results within specified limits by comparison with those produced by a reference or traceable standard over an appropriate range of measurements.\n\n**computer system**  \nA group of hardware components and associated software, designed and assembled to perform a specific function or group of functions.\n\n**computerized system**  \nA process or operation integrated with a computer system.\n\n**contamination**  \nThe undesired introduction of impurities of a chemical or microbiological nature or of foreign matter into or on to a raw material, intermediate or API during production, sampling, packaging or repackaging, storage or transport.\n\n**contract manufacturer**  \nA manufacturer performing some aspect of manufacturing on behalf of the original manufacturer.\n\n**critical**  \nDescribes a process step, process condition, test requirement or other relevant parameter or item that must be controlled within predetermined criteria to ensure that the API meets its specification.\n\n**cross-contamination**  \nContamination of a material or product with another material or product.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "3efaed3679dd4c49d72f93b77bedde71097d59174891be078d56c5be77bf7a8e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "of continuous production, a batch may correspond to a defined fraction of the production. The batch size can be defined either by a fixed quantity or by the amount produced in a fixed time interval.\n\n**batch number (or lot number)**  \nA unique combination of numbers, letters and/or symbols that identifies a batch (or lot) and from which the production and distribution history can be determined.\n\n**bioburden**  \nThe level and type (e.g. objectionable or not) of microorganisms that can be present in raw materials, API starting materials, intermediates or APIs. Bioburden should not be considered contamination unless the levels have been exceeded or defined objectionable organisms have been detected.\n\n**calibration**  \nThe demonstration that a particular instrument or device produces results within specified limits by comparison with those produced by a reference or traceable standard over an appropriate range of measurements.\n\n**computer system**  \nA group of hardware components and associated software, designed and assembled to perform a specific function or group of functions.\n\n**computerized system**  \nA process or operation integrated with a computer system.\n\n**contamination**  \nThe undesired introduction of impurities of a chemical or microbiological nature or of foreign matter into or on to a raw material, intermediate or API during production, sampling, packaging or repackaging, storage or transport.\n\n**contract manufacturer**  \nA manufacturer performing some aspect of manufacturing on behalf of the original manufacturer.\n\n**critical**  \nDescribes a process step, process condition, test requirement or other relevant parameter or item that must be controlled within predetermined criteria to ensure that the API meets its specification.\n\n**cross-contamination**  \nContamination of a material or product with another material or product.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1867, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d1317093-a15a-4293-841b-14532684c2e6": {"__data__": {"id_": "d1317093-a15a-4293-841b-14532684c2e6", "embedding": null, "metadata": {"page_label": "196", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Deviation\n\nDeparture from an approved instruction or established standard.\n\n# Expiry Date (or Expiration Date)\n\nThe date placed on the container or labels of an API designating the time during which the API is expected to remain within established shelf-life specifications if stored under defined conditions and after which it should not be used.\n\n# Finished Pharmaceutical Product (FPP)\n\n- **ICH**: The dosage form in the final immediate packaging intended for marketing (reference Q1A (4)).\n- **WHO**: A product that has undergone all stages of production, including packaging in its final container and labelling. An FPP may contain one or more APIs.\n\n# Impurity\n\nAny component present in the intermediate or API that is not the desired entity.\n\n# Impurity Profile\n\nA description of the identified and unidentified impurities present in an API.\n\n# In-Process Control (or Process Control)\n\nChecks performed during production in order to monitor and, if appropriate, to adjust the process and/or to ensure that the intermediate or API conforms to its specifications.\n\n# Intermediate\n\nA material produced during steps of the processing of an API that undergoes further molecular change or purification before it becomes an API. Intermediates may or may not be isolated.\n\n(Note: this guide only addresses those intermediates produced after the point that the company has defined as the point at which the production of the API begins.)\n\n# Lot\n\nSee Batch.\n\n# Lot Number\n\nSee Batch number.\n\n# Manufacture\n\nAll operations of receipt of materials, production, packaging, repackaging, labelling, relabelling, quality control, release, storage and distribution of APIs and related controls.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1l es la diferencia entre un Producto Farmac\u00e9utico Terminado (FPP) seg\u00fan la ICH y la OMS?**\n   - **Respuesta:** Seg\u00fan la ICH, un Producto Farmac\u00e9utico Terminado (FPP) es la forma de dosificaci\u00f3n en el envase inmediato final destinada a la comercializaci\u00f3n. Por otro lado, la OMS define un FPP como un producto que ha pasado por todas las etapas de producci\u00f3n, incluyendo el envasado en su contenedor final y etiquetado. Adem\u00e1s, un FPP puede contener uno o m\u00e1s Ingredientes Activos (APIs).\n\n2. **\u00bfQu\u00e9 se entiende por \"Control en Proceso\" y cu\u00e1l es su prop\u00f3sito durante la producci\u00f3n de un API?**\n   - **Respuesta:** El \"Control en Proceso\" se refiere a las verificaciones realizadas durante la producci\u00f3n para monitorear y, si es apropiado, ajustar el proceso. Su prop\u00f3sito es asegurar que el intermedio o el API cumplan con sus especificaciones establecidas, garantizando as\u00ed la calidad del producto final.\n\n3. **\u00bfQu\u00e9 implica el t\u00e9rmino \"Manufactura\" en el contexto de los Ingredientes Activos (APIs)?**\n   - **Respuesta:** El t\u00e9rmino \"Manufactura\" abarca todas las operaciones relacionadas con la recepci\u00f3n de materiales, producci\u00f3n, envasado, reenvase, etiquetado, control de calidad, liberaci\u00f3n, almacenamiento y distribuci\u00f3n de APIs, as\u00ed como los controles relacionados con estos procesos.\n\n### Resumen de nivel superior:\nEl documento proporciona definiciones clave relacionadas con la producci\u00f3n y control de Ingredientes Activos (APIs) y Productos Farmac\u00e9uticos Terminados (FPP). Se abordan conceptos como desviaciones, fechas de caducidad, perfiles de impurezas, controles en proceso, intermedios y el proceso de manufactura. Estas definiciones son esenciales para entender los est\u00e1ndares y procedimientos en la industria farmac\u00e9utica, asegurando la calidad y seguridad de los productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n extra\u00edda del documento de la OMS en su Serie de Informes T\u00e9cnicos 957 se centra en definiciones y conceptos fundamentales relacionados con la producci\u00f3n de ingredientes farmac\u00e9uticos activos (API). A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n1. **Producci\u00f3n Continua**:\n   - Se define un lote como una fracci\u00f3n espec\u00edfica de la producci\u00f3n, que puede ser determinada por una cantidad fija o por el tiempo de producci\u00f3n.\n\n2. **N\u00famero de Lote**:\n   - Identificaci\u00f3n \u00fanica de un lote mediante una combinaci\u00f3n de n\u00fameros, letras y/o s\u00edmbolos, que permite rastrear la historia de producci\u00f3n y distribuci\u00f3n.\n\n3. **Bioburden**:\n   - Se refiere al nivel y tipo de microorganismos presentes en materiales crudos y APIs. No se considera contaminaci\u00f3n a menos que se superen los niveles permitidos o se detecten organismos objetables.\n\n4. **Calibraci\u00f3n**:\n   - Proceso de demostrar que un instrumento produce resultados dentro de l\u00edmites especificados, compar\u00e1ndolo con un est\u00e1ndar de referencia.\n\n5. **Sistemas Computarizados**:\n   - Incluyen tanto hardware como software dise\u00f1ados para realizar funciones espec\u00edficas, y pueden integrarse en procesos u operaciones.\n\n6. **Contaminaci\u00f3n**:\n   - Introducci\u00f3n no deseada de impurezas qu\u00edmicas o microbiol\u00f3gicas en materiales durante diversas etapas de producci\u00f3n y manejo.\n\n7. **Fabricante por Contrato**:\n   - Un fabricante que realiza parte del proceso de producci\u00f3n en nombre de otro fabricante.\n\n8. **Par\u00e1metros Cr\u00edticos**:\n   - Elementos que deben ser controlados dentro de criterios predeterminados para asegurar que el API cumpla con sus especificaciones.\n\n9. **Contaminaci\u00f3n Cruzada**:\n   - Contaminaci\u00f3n de un material o producto con otro material o producto.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que publica el documento.\n- **Ingredientes Farmac\u00e9uticos Activos (API)**: Productos cuya producci\u00f3n y control de calidad son el foco del documento.\n\nEste resumen proporciona una visi\u00f3n general de los conceptos esenciales que son fundamentales para entender los procesos de fabricaci\u00f3n y control de calidad en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: Deviation, Expiry Date, Finished Pharmaceutical Product, Impurity Profile, In-Process Control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5552ccb1-83b5-42fe-813c-b725ee407807", "node_type": "4", "metadata": {"page_label": "196", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Deviation\n\nDeparture from an approved instruction or established standard.\n\n# Expiry Date (or Expiration Date)\n\nThe date placed on the container or labels of an API designating the time during which the API is expected to remain within established shelf-life specifications if stored under defined conditions and after which it should not be used.\n\n# Finished Pharmaceutical Product (FPP)\n\n- **ICH**: The dosage form in the final immediate packaging intended for marketing (reference Q1A (4)).\n- **WHO**: A product that has undergone all stages of production, including packaging in its final container and labelling. An FPP may contain one or more APIs.\n\n# Impurity\n\nAny component present in the intermediate or API that is not the desired entity.\n\n# Impurity Profile\n\nA description of the identified and unidentified impurities present in an API.\n\n# In-Process Control (or Process Control)\n\nChecks performed during production in order to monitor and, if appropriate, to adjust the process and/or to ensure that the intermediate or API conforms to its specifications.\n\n# Intermediate\n\nA material produced during steps of the processing of an API that undergoes further molecular change or purification before it becomes an API. Intermediates may or may not be isolated.\n\n(Note: this guide only addresses those intermediates produced after the point that the company has defined as the point at which the production of the API begins.)\n\n# Lot\n\nSee Batch.\n\n# Lot Number\n\nSee Batch number.\n\n# Manufacture\n\nAll operations of receipt of materials, production, packaging, repackaging, labelling, relabelling, quality control, release, storage and distribution of APIs and related controls.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "cc7b2286c518c89a9530ea3b1c3d79714549533f29d46d0adc89eaae681984f6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Deviation\n\nDeparture from an approved instruction or established standard.\n\n# Expiry Date (or Expiration Date)\n\nThe date placed on the container or labels of an API designating the time during which the API is expected to remain within established shelf-life specifications if stored under defined conditions and after which it should not be used.\n\n# Finished Pharmaceutical Product (FPP)\n\n- **ICH**: The dosage form in the final immediate packaging intended for marketing (reference Q1A (4)).\n- **WHO**: A product that has undergone all stages of production, including packaging in its final container and labelling. An FPP may contain one or more APIs.\n\n# Impurity\n\nAny component present in the intermediate or API that is not the desired entity.\n\n# Impurity Profile\n\nA description of the identified and unidentified impurities present in an API.\n\n# In-Process Control (or Process Control)\n\nChecks performed during production in order to monitor and, if appropriate, to adjust the process and/or to ensure that the intermediate or API conforms to its specifications.\n\n# Intermediate\n\nA material produced during steps of the processing of an API that undergoes further molecular change or purification before it becomes an API. Intermediates may or may not be isolated.\n\n(Note: this guide only addresses those intermediates produced after the point that the company has defined as the point at which the production of the API begins.)\n\n# Lot\n\nSee Batch.\n\n# Lot Number\n\nSee Batch number.\n\n# Manufacture\n\nAll operations of receipt of materials, production, packaging, repackaging, labelling, relabelling, quality control, release, storage and distribution of APIs and related controls.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1686, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5ac5f603-2b4b-4fea-ae98-10f5261707b6": {"__data__": {"id_": "5ac5f603-2b4b-4fea-ae98-10f5261707b6", "embedding": null, "metadata": {"page_label": "197", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Material\n\nA general term used to denote raw materials (starting materials, reagents, solvents), process aids, intermediates, APIs and packaging and labelling materials.\n\n# Mother Liquor\n\nThe residual liquid which remains after the crystallization or isolation processes. A mother liquor may contain unreacted materials, intermediates, levels of the API and/or impurities. It may be used for further processing.\n\n# Packaging Material\n\nAny material intended to protect an intermediate or API during storage and transport.\n\n# Pharmaceutical Substance\n\nSee Active pharmaceutical ingredient.\n\n# Procedure\n\nA documented description of the operations to be performed, the precautions to be taken and measures to be applied, directly or indirectly related to the manufacture of an intermediate or API.\n\n# Process Aids\n\nMaterials, excluding solvents, used as an aid in the manufacture of an intermediate or API that do not themselves participate in a chemical or biological reaction (e.g. filter aid or activated carbon).\n\n# Process Control\n\nSee In-process control.\n\n# Production\n\nAll operations involved in the preparation of an API from receipt of materials through processing and packaging of the API.\n\n# Qualification\n\nAction of proving and documenting that equipment or ancillary systems are properly installed, work correctly and actually lead to the expected results. Qualification is part of validation, but the individual qualification steps alone do not constitute process validation.\n\n# Quality Assurance (QA)\n\nThe sum total of the organized arrangements made with the object of ensuring that all APIs are of the quality required for their intended use and that quality systems are maintained.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la serie de informes t\u00e9cnicos 957 aborda definiciones y conceptos clave relacionados con la fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (API). Se describen t\u00e9rminos como \"materia prima\", \"licor madre\", \"material de embalaje\", \"procedimiento\", \"ayudas de proceso\", \"control de proceso\", \"producci\u00f3n\", \"calificaci\u00f3n\" y \"aseguramiento de calidad\". Cada t\u00e9rmino se define en el contexto de la producci\u00f3n y el manejo de sustancias farmac\u00e9uticas, destacando la importancia de la calidad y la documentaci\u00f3n en los procesos de fabricaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 se entiende por \"licor madre\" y c\u00f3mo se puede utilizar en el proceso de fabricaci\u00f3n de un API?**\n   - Respuesta: El \"licor madre\" es el l\u00edquido residual que queda despu\u00e9s de los procesos de cristalizaci\u00f3n o aislamiento. Puede contener materiales no reaccionados, intermedios, niveles del API y/o impurezas, y puede ser utilizado para un procesamiento adicional.\n\n2. **\u00bfCu\u00e1l es la diferencia entre \"calificaci\u00f3n\" y \"validaci\u00f3n\" en el contexto de la producci\u00f3n de APIs?**\n   - Respuesta: La \"calificaci\u00f3n\" se refiere a la acci\u00f3n de probar y documentar que el equipo o sistemas auxiliares est\u00e1n correctamente instalados, funcionan adecuadamente y producen los resultados esperados. Es parte del proceso de \"validaci\u00f3n\", pero los pasos individuales de calificaci\u00f3n no constituyen por s\u00ed solos la validaci\u00f3n del proceso.\n\n3. **\u00bfQu\u00e9 papel juega el \"aseguramiento de calidad\" (QA) en la producci\u00f3n de APIs seg\u00fan el documento?**\n   - Respuesta: El \"aseguramiento de calidad\" (QA) implica un conjunto organizado de arreglos destinados a garantizar que todos los APIs cumplan con la calidad requerida para su uso previsto y que se mantengan los sistemas de calidad. Esto es crucial para asegurar la eficacia y seguridad de los productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Desviaci\u00f3n (Deviation)**: Se refiere a cualquier salida de instrucciones aprobadas o est\u00e1ndares establecidos en el proceso de producci\u00f3n.\n\n2. **Fecha de Caducidad (Expiry Date)**: Es la fecha indicada en el envase o etiquetas de un Ingrediente Activo (API), que se\u00f1ala el per\u00edodo durante el cual se espera que el API mantenga sus especificaciones de vida \u00fatil bajo condiciones definidas.\n\n3. **Producto Farmac\u00e9utico Terminado (FPP)**:\n   - **Definici\u00f3n ICH**: Forma de dosificaci\u00f3n en el envase inmediato final destinada a la comercializaci\u00f3n.\n   - **Definici\u00f3n OMS**: Producto que ha completado todas las etapas de producci\u00f3n, incluyendo el envasado y etiquetado final. Puede contener uno o m\u00e1s APIs.\n\n4. **Impureza (Impurity)**: Cualquier componente presente en un intermedio o API que no es el deseado.\n\n5. **Perfil de Impurezas (Impurity Profile)**: Descripci\u00f3n de las impurezas identificadas y no identificadas presentes en un API.\n\n6. **Control en Proceso (In-Process Control)**: Verificaciones realizadas durante la producci\u00f3n para monitorear y ajustar el proceso, asegurando que el intermedio o API cumpla con sus especificaciones.\n\n7. **Intermedio (Intermediate)**: Material producido durante el procesamiento de un API que requiere cambios moleculares o purificaci\u00f3n adicional antes de convertirse en un API. Puede o no ser aislado.\n\n8. **Lote (Lot)**: T\u00e9rmino relacionado con \"Batch\", que se refiere a una cantidad espec\u00edfica de producto fabricado en un solo ciclo de producci\u00f3n.\n\n9. **N\u00famero de Lote (Lot Number)**: Identificaci\u00f3n espec\u00edfica de un lote de producci\u00f3n.\n\n10. **Manufactura (Manufacture)**: Conjunto de operaciones que incluyen la recepci\u00f3n de materiales, producci\u00f3n, envasado, etiquetado, control de calidad, liberaci\u00f3n, almacenamiento y distribuci\u00f3n de APIs, as\u00ed como los controles asociados.\n\n### Conclusi\u00f3n\nEl contenido aborda definiciones y conceptos fundamentales relacionados con la producci\u00f3n y control de APIs y FPPs, esenciales para garantizar la calidad y seguridad en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: Material, Mother Liquor, Qualification, Quality Assurance, Production"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d6f67fe0-20ec-4d01-814c-aaf494ea09ca", "node_type": "4", "metadata": {"page_label": "197", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Material\n\nA general term used to denote raw materials (starting materials, reagents, solvents), process aids, intermediates, APIs and packaging and labelling materials.\n\n# Mother Liquor\n\nThe residual liquid which remains after the crystallization or isolation processes. A mother liquor may contain unreacted materials, intermediates, levels of the API and/or impurities. It may be used for further processing.\n\n# Packaging Material\n\nAny material intended to protect an intermediate or API during storage and transport.\n\n# Pharmaceutical Substance\n\nSee Active pharmaceutical ingredient.\n\n# Procedure\n\nA documented description of the operations to be performed, the precautions to be taken and measures to be applied, directly or indirectly related to the manufacture of an intermediate or API.\n\n# Process Aids\n\nMaterials, excluding solvents, used as an aid in the manufacture of an intermediate or API that do not themselves participate in a chemical or biological reaction (e.g. filter aid or activated carbon).\n\n# Process Control\n\nSee In-process control.\n\n# Production\n\nAll operations involved in the preparation of an API from receipt of materials through processing and packaging of the API.\n\n# Qualification\n\nAction of proving and documenting that equipment or ancillary systems are properly installed, work correctly and actually lead to the expected results. Qualification is part of validation, but the individual qualification steps alone do not constitute process validation.\n\n# Quality Assurance (QA)\n\nThe sum total of the organized arrangements made with the object of ensuring that all APIs are of the quality required for their intended use and that quality systems are maintained.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "976988ed4ce4ff2ffd79b6147b783c3b3fd57c21b2cdc8924542498d880952ad", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Material\n\nA general term used to denote raw materials (starting materials, reagents, solvents), process aids, intermediates, APIs and packaging and labelling materials.\n\n# Mother Liquor\n\nThe residual liquid which remains after the crystallization or isolation processes. A mother liquor may contain unreacted materials, intermediates, levels of the API and/or impurities. It may be used for further processing.\n\n# Packaging Material\n\nAny material intended to protect an intermediate or API during storage and transport.\n\n# Pharmaceutical Substance\n\nSee Active pharmaceutical ingredient.\n\n# Procedure\n\nA documented description of the operations to be performed, the precautions to be taken and measures to be applied, directly or indirectly related to the manufacture of an intermediate or API.\n\n# Process Aids\n\nMaterials, excluding solvents, used as an aid in the manufacture of an intermediate or API that do not themselves participate in a chemical or biological reaction (e.g. filter aid or activated carbon).\n\n# Process Control\n\nSee In-process control.\n\n# Production\n\nAll operations involved in the preparation of an API from receipt of materials through processing and packaging of the API.\n\n# Qualification\n\nAction of proving and documenting that equipment or ancillary systems are properly installed, work correctly and actually lead to the expected results. Qualification is part of validation, but the individual qualification steps alone do not constitute process validation.\n\n# Quality Assurance (QA)\n\nThe sum total of the organized arrangements made with the object of ensuring that all APIs are of the quality required for their intended use and that quality systems are maintained.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1697, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9813143d-fb46-41f6-837a-8806bbc895c0": {"__data__": {"id_": "9813143d-fb46-41f6-837a-8806bbc895c0", "embedding": null, "metadata": {"page_label": "198", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# quality control (QC)\nChecking or testing that specifications are met.\n\n# quality unit(s)\nAn organizational unit independent of production which fulfills both quality assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization.\n\n# quarantine\nThe status of materials isolated physically or by other effective means pending a decision on their subsequent approval or rejection.\n\n# raw material\nA general term used to denote starting materials, reagents and solvents intended for use in the production of intermediates or APIs.\n\n# reference standard, primary\nA substance that has been shown by an extensive set of analytical tests to be authentic material that should be of high purity. This standard can be:\n\n- obtained from an officially recognized source;\n- prepared by independent synthesis;\n- obtained from existing production material of high purity; or\n- prepared by further purification of existing production material.\n\n# reference standard, secondary\nA substance of established quality and purity, as shown by comparison to a primary reference standard, used as a reference standard for routine laboratory analysis.\n\n# reprocessing\nIntroducing an intermediate or API, including one that does not conform to standards or specifications, back into the process and repeating a crystallization step or other appropriate chemical or physical manipulation steps (e.g. distillation, filtration, chromatography or milling) that are part of the established manufacturing process. Continuation of a process step after an in-process control test has shown that the step is incomplete is considered to be part of the normal process and not to be reprocessing.\n\n# retest date\nThe date when a material should be re-examined to ensure that it is still suitable for use.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda conceptos clave relacionados con el control de calidad (QC) y la garant\u00eda de calidad (QA) en la producci\u00f3n de materiales farmac\u00e9uticos. Se definen t\u00e9rminos como \"unidad de calidad\", \"cuarentena\", \"materia prima\", \"est\u00e1ndar de referencia primario y secundario\", \"reprocesamiento\" y \"fecha de rean\u00e1lisis\". Estos t\u00e9rminos son fundamentales para asegurar que los productos farmac\u00e9uticos cumplan con las especificaciones necesarias para su uso seguro y efectivo.\n\n### Preguntas espec\u00edficas\n1. **\u00bfCu\u00e1les son las diferencias clave entre un est\u00e1ndar de referencia primario y uno secundario, y c\u00f3mo se utilizan en el an\u00e1lisis de laboratorio?**\n   - Esta pregunta busca una comparaci\u00f3n detallada que no se encuentra f\u00e1cilmente en otras fuentes, enfoc\u00e1ndose en la aplicaci\u00f3n pr\u00e1ctica de estos est\u00e1ndares en el contexto de control de calidad.\n\n2. **\u00bfQu\u00e9 procedimientos se consideran parte del \"reprocesamiento\" en la fabricaci\u00f3n de intermediarios o APIs, y c\u00f3mo se diferencia de la continuaci\u00f3n de un paso de proceso normal?**\n   - Esta pregunta se centra en la distinci\u00f3n entre reprocessing y los pasos de proceso est\u00e1ndar, lo que puede no estar claramente definido en otras fuentes.\n\n3. **\u00bfQu\u00e9 criterios se utilizan para determinar la fecha de rean\u00e1lisis de un material, y qu\u00e9 implicaciones tiene esto para su uso en la producci\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre los criterios y procesos que gu\u00edan la decisi\u00f3n de cu\u00e1ndo un material debe ser reexaminado, lo cual es crucial para la gesti\u00f3n de calidad en la producci\u00f3n farmac\u00e9utica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Material**: T\u00e9rmino general que abarca materias primas, reactivos, disolventes, ayudas de proceso, intermedios, ingredientes farmac\u00e9uticos activos (API) y materiales de embalaje y etiquetado.\n\n2. **Licor Madre**: L\u00edquido residual que queda tras los procesos de cristalizaci\u00f3n o aislamiento, que puede contener materiales no reaccionados, intermedios, niveles del API y/o impurezas. Puede ser utilizado para procesamiento adicional.\n\n3. **Material de Embalaje**: Cualquier material destinado a proteger un intermedio o API durante su almacenamiento y transporte.\n\n4. **Sustancia Farmac\u00e9utica**: Se refiere al ingrediente farmac\u00e9utico activo (API).\n\n5. **Procedimiento**: Descripci\u00f3n documentada de las operaciones a realizar, precauciones a tomar y medidas a aplicar en la fabricaci\u00f3n de un intermedio o API.\n\n6. **Ayudas de Proceso**: Materiales utilizados en la fabricaci\u00f3n de un intermedio o API que no participan en reacciones qu\u00edmicas o biol\u00f3gicas, como filtros o carb\u00f3n activado.\n\n7. **Control de Proceso**: Se refiere al control en proceso, que asegura que las operaciones se realicen de manera adecuada.\n\n8. **Producci\u00f3n**: Conjunto de operaciones involucradas en la preparaci\u00f3n de un API, desde la recepci\u00f3n de materiales hasta el procesamiento y embalaje del API.\n\n9. **Calificaci\u00f3n**: Proceso de demostrar y documentar que el equipo o sistemas auxiliares est\u00e1n correctamente instalados y funcionan adecuadamente. Es parte de la validaci\u00f3n, pero no constituye validaci\u00f3n por s\u00ed solo.\n\n10. **Aseguramiento de Calidad (QA)**: Conjunto de arreglos organizados para garantizar que todos los APIs cumplan con la calidad requerida para su uso previsto y que se mantengan los sistemas de calidad.\n\n### Entidades Clave\n- **API (Ingrediente Farmac\u00e9utico Activo)**\n- **Licor Madre**\n- **Material de Embalaje**\n- **Procedimiento**\n- **Ayudas de Proceso**\n- **Calificaci\u00f3n**\n- **Aseguramiento de Calidad (QA)**\n\nEste resumen destaca los conceptos fundamentales y las definiciones relevantes en el contexto de la fabricaci\u00f3n y manejo de ingredientes farmac\u00e9uticos activos, enfatizando la importancia de la calidad y la documentaci\u00f3n en estos procesos.", "excerpt_keywords": "Keywords: quality control, reference standard, reprocessing, raw material, quarantine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e2b2011b-e3f5-4aa7-8b98-8ea9accc5022", "node_type": "4", "metadata": {"page_label": "198", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# quality control (QC)\nChecking or testing that specifications are met.\n\n# quality unit(s)\nAn organizational unit independent of production which fulfills both quality assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization.\n\n# quarantine\nThe status of materials isolated physically or by other effective means pending a decision on their subsequent approval or rejection.\n\n# raw material\nA general term used to denote starting materials, reagents and solvents intended for use in the production of intermediates or APIs.\n\n# reference standard, primary\nA substance that has been shown by an extensive set of analytical tests to be authentic material that should be of high purity. This standard can be:\n\n- obtained from an officially recognized source;\n- prepared by independent synthesis;\n- obtained from existing production material of high purity; or\n- prepared by further purification of existing production material.\n\n# reference standard, secondary\nA substance of established quality and purity, as shown by comparison to a primary reference standard, used as a reference standard for routine laboratory analysis.\n\n# reprocessing\nIntroducing an intermediate or API, including one that does not conform to standards or specifications, back into the process and repeating a crystallization step or other appropriate chemical or physical manipulation steps (e.g. distillation, filtration, chromatography or milling) that are part of the established manufacturing process. Continuation of a process step after an in-process control test has shown that the step is incomplete is considered to be part of the normal process and not to be reprocessing.\n\n# retest date\nThe date when a material should be re-examined to ensure that it is still suitable for use.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "410ac7ffc0456cbed4fc2828b23566b88e71ea3cd9cb5109c30bbc0702be26b7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# quality control (QC)\nChecking or testing that specifications are met.\n\n# quality unit(s)\nAn organizational unit independent of production which fulfills both quality assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization.\n\n# quarantine\nThe status of materials isolated physically or by other effective means pending a decision on their subsequent approval or rejection.\n\n# raw material\nA general term used to denote starting materials, reagents and solvents intended for use in the production of intermediates or APIs.\n\n# reference standard, primary\nA substance that has been shown by an extensive set of analytical tests to be authentic material that should be of high purity. This standard can be:\n\n- obtained from an officially recognized source;\n- prepared by independent synthesis;\n- obtained from existing production material of high purity; or\n- prepared by further purification of existing production material.\n\n# reference standard, secondary\nA substance of established quality and purity, as shown by comparison to a primary reference standard, used as a reference standard for routine laboratory analysis.\n\n# reprocessing\nIntroducing an intermediate or API, including one that does not conform to standards or specifications, back into the process and repeating a crystallization step or other appropriate chemical or physical manipulation steps (e.g. distillation, filtration, chromatography or milling) that are part of the established manufacturing process. Continuation of a process step after an in-process control test has shown that the step is incomplete is considered to be part of the normal process and not to be reprocessing.\n\n# retest date\nThe date when a material should be re-examined to ensure that it is still suitable for use.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1903, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "eb1b852f-fd7c-47de-bbf0-cbc09ae3d6df": {"__data__": {"id_": "eb1b852f-fd7c-47de-bbf0-cbc09ae3d6df", "embedding": null, "metadata": {"page_label": "199", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# reworking\n\nSubjecting an intermediate or API that does not conform to standards or specifications to one or more processing steps that are different from the established manufacturing process to obtain acceptable quality intermediate or API (e.g. recrystallizing with a different solvent).\n\n# signature (signed)\n\nSee Signed.\n\n# signed (signature)\n\nThe record of the individual who performed a particular action or review. This record can be in the form of initials, full handwritten signature, personal seal or an authenticated and secure electronic signature.\n\n# solvent\n\nAn inorganic or organic liquid used as a vehicle for the preparation of solutions or suspensions in the manufacture of an intermediate or API.\n\n# specification\n\nA list of tests, references to analytical procedures and appropriate acceptance criteria that are numerical limits, ranges or other criteria for the test described. It establishes the set of criteria to which a material should conform to be considered acceptable for its intended use. \u201cConformance to specification\u201d means that the material, when tested according to the listed analytical procedures, will meet the listed acceptance criteria.\n\n# validation\n\nA documented programme that provides a high degree of assurance that a specific process, method or system will consistently produce a result meeting predetermined acceptance criteria.\n\n# validation protocol\n\nA written plan stating how validation will be conducted and defining acceptance criteria. For example, the protocol for a manufacturing process identifies processing equipment, critical process parameters and operating ranges, product characteristics, sampling, test data to be collected, number of validation runs and acceptable test results.\n\n# yield, expected\n\nThe quantity of material or the percentage of theoretical yield anticipated at any appropriate phase of production based on previous laboratory, pilot-scale or manufacturing data.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) titulado \"Technical Report Series 957\" aborda varios conceptos clave relacionados con la fabricaci\u00f3n de intermediarios y principios activos (API). Se definen t\u00e9rminos como \"reworking\", \"signature\", \"solvent\", \"specification\", \"validation\", \"validation protocol\" y \"yield, expected\". Cada uno de estos t\u00e9rminos se relaciona con los procesos de producci\u00f3n y control de calidad en la industria farmac\u00e9utica, estableciendo criterios y procedimientos para asegurar que los productos cumplan con los est\u00e1ndares requeridos.\n\n### Preguntas\n1. **\u00bfQu\u00e9 pasos se deben seguir para realizar un \"reworking\" de un intermediario o API que no cumple con las especificaciones?**\n   - Esta pregunta se centra en el proceso espec\u00edfico de reworking y los pasos que se deben seguir, que no se detallan en el contexto.\n\n2. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en un \"validation protocol\" para asegurar la calidad de un proceso de fabricaci\u00f3n?**\n   - Aunque se menciona que un validation protocol debe incluir ciertos elementos, esta pregunta busca una lista m\u00e1s detallada y espec\u00edfica de esos elementos.\n\n3. **\u00bfC\u00f3mo se determina el \"expected yield\" en un proceso de producci\u00f3n y qu\u00e9 factores pueden influir en su c\u00e1lculo?**\n   - Esta pregunta busca profundizar en el concepto de rendimiento esperado y los factores que pueden afectar su estimaci\u00f3n, lo cual no se aborda expl\u00edcitamente en el contexto.", "prev_section_summary": "La secci\u00f3n aborda conceptos fundamentales relacionados con el control de calidad (QC) y la garant\u00eda de calidad (QA) en la producci\u00f3n farmac\u00e9utica. A continuaci\u00f3n se resumen los temas clave y entidades mencionadas:\n\n1. **Control de Calidad (QC)**: Se refiere a la verificaci\u00f3n o prueba de que se cumplen las especificaciones establecidas para los productos.\n\n2. **Unidad de Calidad**: Es una unidad organizativa independiente de la producci\u00f3n que se encarga de las responsabilidades tanto de QA como de QC. Puede estar compuesta por unidades separadas o por un solo individuo o grupo, dependiendo de la estructura de la organizaci\u00f3n.\n\n3. **Cuarentena**: Estado de los materiales que han sido aislados, ya sea f\u00edsicamente o por otros medios, mientras se espera una decisi\u00f3n sobre su aprobaci\u00f3n o rechazo.\n\n4. **Materia Prima**: T\u00e9rmino general que se refiere a los materiales iniciales, reactivos y disolventes destinados a la producci\u00f3n de intermediarios o principios activos (APIs).\n\n5. **Est\u00e1ndar de Referencia Primario**: Sustancia de alta pureza que ha sido validada mediante un conjunto extenso de pruebas anal\u00edticas. Puede obtenerse de fuentes reconocidas, ser preparada por s\u00edntesis independiente, provenir de material de producci\u00f3n existente de alta pureza o ser purificada a partir de material de producci\u00f3n existente.\n\n6. **Est\u00e1ndar de Referencia Secundario**: Sustancia de calidad y pureza establecidas, comparada con un est\u00e1ndar primario, utilizada para an\u00e1lisis de laboratorio rutinarios.\n\n7. **Reprocesamiento**: Proceso de reintegrar un intermedio o API que no cumple con las especificaciones de vuelta al proceso, repitiendo pasos de manipulaci\u00f3n qu\u00edmica o f\u00edsica. La continuaci\u00f3n de un paso de proceso tras un control en proceso que indica que el paso est\u00e1 incompleto se considera parte del proceso normal, no reprocessing.\n\n8. **Fecha de Rean\u00e1lisis**: Fecha en la que un material debe ser reexaminado para asegurar que sigue siendo adecuado para su uso.\n\nEstos conceptos son esenciales para garantizar que los productos farmac\u00e9uticos sean seguros y efectivos, cumpliendo con las normativas y est\u00e1ndares de calidad establecidos.", "excerpt_keywords": "Keywords: reworking, validation, specification, solvent, yield"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "028abf06-7ac9-48e9-956f-33c159ca0673", "node_type": "4", "metadata": {"page_label": "199", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# reworking\n\nSubjecting an intermediate or API that does not conform to standards or specifications to one or more processing steps that are different from the established manufacturing process to obtain acceptable quality intermediate or API (e.g. recrystallizing with a different solvent).\n\n# signature (signed)\n\nSee Signed.\n\n# signed (signature)\n\nThe record of the individual who performed a particular action or review. This record can be in the form of initials, full handwritten signature, personal seal or an authenticated and secure electronic signature.\n\n# solvent\n\nAn inorganic or organic liquid used as a vehicle for the preparation of solutions or suspensions in the manufacture of an intermediate or API.\n\n# specification\n\nA list of tests, references to analytical procedures and appropriate acceptance criteria that are numerical limits, ranges or other criteria for the test described. It establishes the set of criteria to which a material should conform to be considered acceptable for its intended use. \u201cConformance to specification\u201d means that the material, when tested according to the listed analytical procedures, will meet the listed acceptance criteria.\n\n# validation\n\nA documented programme that provides a high degree of assurance that a specific process, method or system will consistently produce a result meeting predetermined acceptance criteria.\n\n# validation protocol\n\nA written plan stating how validation will be conducted and defining acceptance criteria. For example, the protocol for a manufacturing process identifies processing equipment, critical process parameters and operating ranges, product characteristics, sampling, test data to be collected, number of validation runs and acceptable test results.\n\n# yield, expected\n\nThe quantity of material or the percentage of theoretical yield anticipated at any appropriate phase of production based on previous laboratory, pilot-scale or manufacturing data.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "40ef0f7a10881e1cbc91409f5e540d7659fda18510da003043645c13ccd31799", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# reworking\n\nSubjecting an intermediate or API that does not conform to standards or specifications to one or more processing steps that are different from the established manufacturing process to obtain acceptable quality intermediate or API (e.g. recrystallizing with a different solvent).\n\n# signature (signed)\n\nSee Signed.\n\n# signed (signature)\n\nThe record of the individual who performed a particular action or review. This record can be in the form of initials, full handwritten signature, personal seal or an authenticated and secure electronic signature.\n\n# solvent\n\nAn inorganic or organic liquid used as a vehicle for the preparation of solutions or suspensions in the manufacture of an intermediate or API.\n\n# specification\n\nA list of tests, references to analytical procedures and appropriate acceptance criteria that are numerical limits, ranges or other criteria for the test described. It establishes the set of criteria to which a material should conform to be considered acceptable for its intended use. \u201cConformance to specification\u201d means that the material, when tested according to the listed analytical procedures, will meet the listed acceptance criteria.\n\n# validation\n\nA documented programme that provides a high degree of assurance that a specific process, method or system will consistently produce a result meeting predetermined acceptance criteria.\n\n# validation protocol\n\nA written plan stating how validation will be conducted and defining acceptance criteria. For example, the protocol for a manufacturing process identifies processing equipment, critical process parameters and operating ranges, product characteristics, sampling, test data to be collected, number of validation runs and acceptable test results.\n\n# yield, expected\n\nThe quantity of material or the percentage of theoretical yield anticipated at any appropriate phase of production based on previous laboratory, pilot-scale or manufacturing data.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1944, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "91f75c63-8292-47d9-9714-7d61848ca532": {"__data__": {"id_": "91f75c63-8292-47d9-9714-7d61848ca532", "embedding": null, "metadata": {"page_label": "200", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# yield, theoretical\n\nThe quantity that would be produced at any appropriate phase of production, based upon the quantity of material to be used, in the absence of any loss or error in actual production.\n\n# References\n\n1. *ICH Harmonised Tripartite Guideline: Specifications: test procedures and acceptance criteria for biotechnological/biological products Q6B.* International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1999.\n\n2. *ICH Harmonised Tripartite Guideline: Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin Q5A.* International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1999.\n\n3. *ICH Harmonised Tripartite Guideline: Derivation and characterisation of cell substrates used for production of biotechnological/biological products Q5D.* International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1997.\n\n4. *ICH Harmonised Tripartite Guideline: Stability testing of new drug substances and products Q1A.* International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2003.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 957\" aborda el concepto de \"rendimiento te\u00f3rico\" en la producci\u00f3n de productos biotecnol\u00f3gicos y biol\u00f3gicos. Define el rendimiento te\u00f3rico como la cantidad que se podr\u00eda producir en cualquier fase de producci\u00f3n, asumiendo que no hay p\u00e9rdidas ni errores. Adem\u00e1s, se citan varias directrices de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) que establecen criterios y procedimientos para la evaluaci\u00f3n de productos biotecnol\u00f3gicos, incluyendo especificaciones, seguridad viral, caracterizaci\u00f3n de sustratos celulares y pruebas de estabilidad.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 se entiende por \"rendimiento te\u00f3rico\" en el contexto de la producci\u00f3n biotecnol\u00f3gica?**\n   - Respuesta: El rendimiento te\u00f3rico se refiere a la cantidad que se podr\u00eda producir en cualquier fase de producci\u00f3n, basado en la cantidad de material utilizado, sin considerar p\u00e9rdidas o errores en la producci\u00f3n real.\n\n2. **\u00bfCu\u00e1les son algunas de las directrices de la ICH mencionadas en el documento y qu\u00e9 aspectos regulan?**\n   - Respuesta: Se mencionan varias directrices de la ICH, incluyendo: \n     - Q6B: Especificaciones, procedimientos de prueba y criterios de aceptaci\u00f3n para productos biotecnol\u00f3gicos/biol\u00f3gicos.\n     - Q5A: Evaluaci\u00f3n de la seguridad viral de productos biotecnol\u00f3gicos derivados de l\u00edneas celulares de origen humano o animal.\n     - Q5D: Derivaci\u00f3n y caracterizaci\u00f3n de sustratos celulares utilizados para la producci\u00f3n de productos biotecnol\u00f3gicos/biol\u00f3gicos.\n     - Q1A: Pruebas de estabilidad de nuevas sustancias y productos farmac\u00e9uticos.\n\n3. **\u00bfQu\u00e9 implicaciones tiene el concepto de rendimiento te\u00f3rico para la industria farmac\u00e9utica y biotecnol\u00f3gica?**\n   - Respuesta: El concepto de rendimiento te\u00f3rico es crucial para la industria farmac\u00e9utica y biotecnol\u00f3gica, ya que permite establecer expectativas de producci\u00f3n y evaluar la eficiencia de los procesos. Adem\u00e1s, ayuda a identificar \u00e1reas donde se pueden producir p\u00e9rdidas o errores, lo que es fundamental para mejorar la calidad y la seguridad de los productos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n extra\u00edda del documento \"Technical Report Series 957\" de la OMS aborda varios conceptos fundamentales relacionados con la fabricaci\u00f3n de intermediarios y principios activos (API) en la industria farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n1. **Reworking**: Se refiere al proceso de someter un intermediario o API que no cumple con las especificaciones a pasos de procesamiento diferentes a los establecidos, con el fin de obtener un producto de calidad aceptable.\n\n2. **Signature (Firmado)**: Se define como el registro de la persona que realiz\u00f3 una acci\u00f3n o revisi\u00f3n espec\u00edfica, que puede presentarse en diversas formas, incluyendo iniciales, firma manuscrita, sello personal o firma electr\u00f3nica segura.\n\n3. **Solvent**: Se describe como un l\u00edquido, ya sea inorg\u00e1nico u org\u00e1nico, utilizado como veh\u00edculo para la preparaci\u00f3n de soluciones o suspensiones en la fabricaci\u00f3n de intermediarios o API.\n\n4. **Specification**: Se establece como una lista de pruebas y criterios de aceptaci\u00f3n que determinan si un material es aceptable para su uso previsto. Incluye l\u00edmites num\u00e9ricos y procedimientos anal\u00edticos.\n\n5. **Validation**: Se refiere a un programa documentado que asegura que un proceso, m\u00e9todo o sistema producir\u00e1 consistentemente resultados que cumplan con criterios de aceptaci\u00f3n predeterminados.\n\n6. **Validation Protocol**: Es un plan escrito que detalla c\u00f3mo se llevar\u00e1 a cabo la validaci\u00f3n y define los criterios de aceptaci\u00f3n, incluyendo equipos de procesamiento, par\u00e1metros cr\u00edticos, caracter\u00edsticas del producto y datos de prueba a recolectar.\n\n7. **Yield, Expected**: Se refiere a la cantidad de material o porcentaje de rendimiento te\u00f3rico anticipado en cualquier fase de producci\u00f3n, basado en datos de laboratorio, escalas piloto o fabricaci\u00f3n previa.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el documento.\n- **Intermediarios y API**: Productos farmac\u00e9uticos cuya calidad y conformidad son objeto de los procesos descritos.\n- **Criterios de aceptaci\u00f3n**: Est\u00e1ndares que los materiales deben cumplir para ser considerados aceptables.\n\nEste resumen proporciona una visi\u00f3n general de los conceptos y t\u00e9rminos clave que son esenciales para entender los procesos de producci\u00f3n y control de calidad en la industria farmac\u00e9utica seg\u00fan el documento de la OMS.", "excerpt_keywords": "Keywords: yield, theoretical, biotechnological products, ICH guidelines, production efficiency"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "90b7e1ae-259a-4a9e-b777-c04b4df558a6", "node_type": "4", "metadata": {"page_label": "200", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# yield, theoretical\n\nThe quantity that would be produced at any appropriate phase of production, based upon the quantity of material to be used, in the absence of any loss or error in actual production.\n\n# References\n\n1. *ICH Harmonised Tripartite Guideline: Specifications: test procedures and acceptance criteria for biotechnological/biological products Q6B.* International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1999.\n\n2. *ICH Harmonised Tripartite Guideline: Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin Q5A.* International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1999.\n\n3. *ICH Harmonised Tripartite Guideline: Derivation and characterisation of cell substrates used for production of biotechnological/biological products Q5D.* International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1997.\n\n4. *ICH Harmonised Tripartite Guideline: Stability testing of new drug substances and products Q1A.* International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2003.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "3f5fbef0e2f175287bac379f85b35e70b9ab29dbc35022d4fd7d2ab6cc581092", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# yield, theoretical\n\nThe quantity that would be produced at any appropriate phase of production, based upon the quantity of material to be used, in the absence of any loss or error in actual production.\n\n# References\n\n1. *ICH Harmonised Tripartite Guideline: Specifications: test procedures and acceptance criteria for biotechnological/biological products Q6B.* International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1999.\n\n2. *ICH Harmonised Tripartite Guideline: Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin Q5A.* International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1999.\n\n3. *ICH Harmonised Tripartite Guideline: Derivation and characterisation of cell substrates used for production of biotechnological/biological products Q5D.* International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1997.\n\n4. *ICH Harmonised Tripartite Guideline: Stability testing of new drug substances and products Q1A.* International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2003.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1271, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c87f6cf9-bdf7-4e77-89a6-b4431cd92b4d": {"__data__": {"id_": "c87f6cf9-bdf7-4e77-89a6-b4431cd92b4d", "embedding": null, "metadata": {"page_label": "201", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 1\n\n## List of references for related WHO guidelines\n\n### Distribution\n\nhttp://www.who.int/medicines/areas/quality_safety/quality_assurance/distribution/en/\n\nGood trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2003, Annex 2 (WHO Technical Report Series, No. 917).\n\nWHO pharmaceutical starting materials certification scheme (SMACS): guidelines on implementation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2003, Annex 3 (WHO Technical Report Series, No. 917).\n\nGuide to good storage practices for pharmaceuticals In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 9 (WHO Technical Report Series, No. 908).\n\n### Production\n\nhttp://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/index.html\n\nGood Manufacturing Practices for Pharmaceutical Products: Main Principles. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 4 (WHO Technical Report Series, No. 908).\n\nGood manufacturing practices: requirement for the sampling of starting materials (amendment). In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 2 (WHO Technical Report Series, No. 929).\n\nSterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 6 (WHO Technical Report Series, No. 902).\n\nInvestigational pharmaceutical products for clinical trials in humans. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations*.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es un ap\u00e9ndice del *WHO Technical Report Series 957*, que incluye una lista de referencias relacionadas con las directrices de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre la distribuci\u00f3n y producci\u00f3n de productos farmac\u00e9uticos. Se mencionan pr\u00e1cticas recomendadas para la distribuci\u00f3n y almacenamiento de materiales farmac\u00e9uticos, as\u00ed como buenas pr\u00e1cticas de manufactura. Tambi\u00e9n se incluyen enlaces a recursos en l\u00ednea y detalles sobre informes espec\u00edficos de comit\u00e9s de expertos de la OMS.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son las principales directrices de la OMS para las buenas pr\u00e1cticas de distribuci\u00f3n de materiales farmac\u00e9uticos?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las recomendaciones de la OMS en cuanto a la distribuci\u00f3n de productos farmac\u00e9uticos, que se detalla en el contexto.\n\n2. **\u00bfQu\u00e9 documentos de la OMS abordan las buenas pr\u00e1cticas de manufactura y cu\u00e1les son sus principales enfoques?**\n   - Esta pregunta se centra en identificar los informes espec\u00edficos mencionados en el contexto que tratan sobre las buenas pr\u00e1cticas de manufactura y sus enfoques clave.\n\n3. **\u00bfQu\u00e9 se entiende por el esquema de certificaci\u00f3n de materiales farmac\u00e9uticos de la OMS (SMACS) y cu\u00e1les son sus directrices de implementaci\u00f3n?**\n   - Esta pregunta busca profundizar en el esquema SMACS mencionado en el contexto, solicitando detalles sobre su prop\u00f3sito y las directrices que lo acompa\u00f1an.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Tema Clave: Rendimiento Te\u00f3rico**\n- Definici\u00f3n: El rendimiento te\u00f3rico se refiere a la cantidad de producto que se podr\u00eda generar en cualquier fase de producci\u00f3n, basado en la cantidad de material utilizado, sin considerar p\u00e9rdidas o errores en la producci\u00f3n real.\n\n**Entidades Clave:**\n1. **Organizaci\u00f3n:**\n   - **WHO (Organizaci\u00f3n Mundial de la Salud)**: Publica el documento \"Technical Report Series 957\".\n\n2. **Directrices de la ICH (Conferencia Internacional sobre Armonizaci\u00f3n):**\n   - **Q6B**: Especificaciones, procedimientos de prueba y criterios de aceptaci\u00f3n para productos biotecnol\u00f3gicos/biol\u00f3gicos.\n   - **Q5A**: Evaluaci\u00f3n de la seguridad viral de productos biotecnol\u00f3gicos derivados de l\u00edneas celulares de origen humano o animal.\n   - **Q5D**: Derivaci\u00f3n y caracterizaci\u00f3n de sustratos celulares utilizados para la producci\u00f3n de productos biotecnol\u00f3gicos/biol\u00f3gicos.\n   - **Q1A**: Pruebas de estabilidad de nuevas sustancias y productos farmac\u00e9uticos.\n\n**Implicaciones:**\n- El concepto de rendimiento te\u00f3rico es fundamental para la industria farmac\u00e9utica y biotecnol\u00f3gica, ya que permite establecer expectativas de producci\u00f3n, evaluar la eficiencia de los procesos y mejorar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: WHO, pharmaceutical guidelines, good manufacturing practices, distribution, certification scheme"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "42d97730-6d15-459c-868b-566a07ebe4cb", "node_type": "4", "metadata": {"page_label": "201", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 1\n\n## List of references for related WHO guidelines\n\n### Distribution\n\nhttp://www.who.int/medicines/areas/quality_safety/quality_assurance/distribution/en/\n\nGood trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2003, Annex 2 (WHO Technical Report Series, No. 917).\n\nWHO pharmaceutical starting materials certification scheme (SMACS): guidelines on implementation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2003, Annex 3 (WHO Technical Report Series, No. 917).\n\nGuide to good storage practices for pharmaceuticals In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 9 (WHO Technical Report Series, No. 908).\n\n### Production\n\nhttp://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/index.html\n\nGood Manufacturing Practices for Pharmaceutical Products: Main Principles. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 4 (WHO Technical Report Series, No. 908).\n\nGood manufacturing practices: requirement for the sampling of starting materials (amendment). In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 2 (WHO Technical Report Series, No. 929).\n\nSterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 6 (WHO Technical Report Series, No. 902).\n\nInvestigational pharmaceutical products for clinical trials in humans. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations*.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a01840c88dcce9f685c0f41c91fefcf88ffc16ead7a18db0a39d125e8c14bae6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Appendix 1\n\n## List of references for related WHO guidelines\n\n### Distribution\n\nhttp://www.who.int/medicines/areas/quality_safety/quality_assurance/distribution/en/\n\nGood trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2003, Annex 2 (WHO Technical Report Series, No. 917).\n\nWHO pharmaceutical starting materials certification scheme (SMACS): guidelines on implementation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2003, Annex 3 (WHO Technical Report Series, No. 917).\n\nGuide to good storage practices for pharmaceuticals In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 9 (WHO Technical Report Series, No. 908).\n\n### Production\n\nhttp://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/index.html\n\nGood Manufacturing Practices for Pharmaceutical Products: Main Principles. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 4 (WHO Technical Report Series, No. 908).\n\nGood manufacturing practices: requirement for the sampling of starting materials (amendment). In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 2 (WHO Technical Report Series, No. 929).\n\nSterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 6 (WHO Technical Report Series, No. 902).\n\nInvestigational pharmaceutical products for clinical trials in humans. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations*.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1995, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "96461032-f9e1-40f0-8590-0a42741ad196": {"__data__": {"id_": "96461032-f9e1-40f0-8590-0a42741ad196", "embedding": null, "metadata": {"page_label": "202", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Thirty-fourth report\n\nGeneva, World Health Organization, 1996, Annex 7 (WHO Technical Report Series, No. 863).\n\nHerbal medicinal products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 3 (WHO Technical Report Series, No. 937).\n\nWater for pharmaceutical use. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 3 (WHO Technical Report Series, No. 929).\n\nHeating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 2 (WHO Technical Report Series, No. 937).\n\nValidation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 4 (WHO Technical Report Series, No. 937).\n\n## Quality control\n\nhttp://www.who.int/medicines/areas/quality_safety/quality_assurance/control/en/index.html\n\n*The International Pharmacopoeia (Ph. Int.)* \u2014 Fourth Edition + First Supplement. Geneva, World Health Organization, 2006.\n\nGeneral guidelines for the establishment, maintenance and distribution of chemical reference substances. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report*. Geneva, World Health Organization, 2007, Annex 3 (WHO Technical Report Series, No. 943).\n\nConsiderations for requesting analyses of drug samples. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 4 (WHO Technical Report Series, No. 902).\n\nModel certificate of analysis. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 10 (WHO Technical Report Series, No. 902).\n\n## Related regulatory standards\n\nhttp://www.who.int/medicines/areas/quality_safety/quality_assurance/regulatory_standards/en/", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que se centra en las especificaciones para preparaciones farmac\u00e9uticas. Incluye referencias a productos medicinales herbales, agua para uso farmac\u00e9utico, sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado para formas de dosificaci\u00f3n farmac\u00e9utica no est\u00e9riles, y la validaci\u00f3n de procesos. Tambi\u00e9n aborda el control de calidad y proporciona enlaces a recursos relacionados con est\u00e1ndares regulatorios y gu\u00edas sobre sustancias qu\u00edmicas de referencia.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las recomendaciones espec\u00edficas de la OMS sobre el uso de productos medicinales herbales seg\u00fan el informe mencionado?**\n   - Esta pregunta busca detalles sobre las directrices espec\u00edficas que la OMS proporciona en relaci\u00f3n con los productos herbales, que pueden no estar disponibles en otras fuentes.\n\n2. **\u00bfQu\u00e9 aspectos se consideran en la validaci\u00f3n de procesos seg\u00fan el informe de la OMS?**\n   - Esta pregunta se centra en los criterios y procedimientos que la OMS establece para la validaci\u00f3n, que son cruciales para garantizar la calidad y seguridad de los productos farmac\u00e9uticos.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n se incluye en el modelo de certificado de an\u00e1lisis mencionado en el informe?**\n   - Esta pregunta busca detalles sobre el contenido y la estructura del certificado de an\u00e1lisis, que es un documento importante en el control de calidad de los productos farmac\u00e9uticos.\n\n### Resumen de nivel superior\n\nEl informe de la OMS proporciona directrices y est\u00e1ndares para la calidad y seguridad de las preparaciones farmac\u00e9uticas, abarcando desde productos herbales hasta sistemas de control de calidad. Incluye referencias a informes anteriores y recursos en l\u00ednea que ofrecen informaci\u00f3n adicional sobre regulaciones y pr\u00e1cticas recomendadas en la industria farmac\u00e9utica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Distribuci\u00f3n de Productos Farmac\u00e9uticos:**\n   - Buenas pr\u00e1cticas de comercio y distribuci\u00f3n de materiales farmac\u00e9uticos.\n   - Esquema de certificaci\u00f3n de materiales farmac\u00e9uticos de la OMS (SMACS).\n   - Pr\u00e1cticas de almacenamiento adecuadas para productos farmac\u00e9uticos.\n\n2. **Producci\u00f3n de Productos Farmac\u00e9uticos:**\n   - Buenas pr\u00e1cticas de manufactura (BPM) para productos farmac\u00e9uticos.\n   - Requisitos para el muestreo de materiales de partida.\n   - Normativas para productos farmac\u00e9uticos est\u00e9riles.\n   - Productos farmac\u00e9uticos investigacionales para ensayos cl\u00ednicos en humanos.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Entidad responsable de la elaboraci\u00f3n de las directrices y recomendaciones.\n- **Comit\u00e9s de Expertos de la OMS:** Grupos que elaboran informes y recomendaciones sobre especificaciones para preparaciones farmac\u00e9uticas.\n- **Documentos Citados:**\n  - *WHO Technical Report Series, No. 917*\n  - *WHO Technical Report Series, No. 908*\n  - *WHO Technical Report Series, No. 929*\n  \n**Enlaces Relevantes:**\n- Recursos en l\u00ednea sobre buenas pr\u00e1cticas de distribuci\u00f3n y producci\u00f3n de productos farmac\u00e9uticos proporcionados por la OMS. \n\nEste resumen destaca la importancia de las directrices de la OMS en la regulaci\u00f3n de la distribuci\u00f3n y producci\u00f3n de productos farmac\u00e9uticos, as\u00ed como los documentos clave que respaldan estas pr\u00e1cticas.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, quality control, herbal medicinal products, validation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "173a2358-dcc0-463e-8b97-773a98ed625a", "node_type": "4", "metadata": {"page_label": "202", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Thirty-fourth report\n\nGeneva, World Health Organization, 1996, Annex 7 (WHO Technical Report Series, No. 863).\n\nHerbal medicinal products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 3 (WHO Technical Report Series, No. 937).\n\nWater for pharmaceutical use. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 3 (WHO Technical Report Series, No. 929).\n\nHeating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 2 (WHO Technical Report Series, No. 937).\n\nValidation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 4 (WHO Technical Report Series, No. 937).\n\n## Quality control\n\nhttp://www.who.int/medicines/areas/quality_safety/quality_assurance/control/en/index.html\n\n*The International Pharmacopoeia (Ph. Int.)* \u2014 Fourth Edition + First Supplement. Geneva, World Health Organization, 2006.\n\nGeneral guidelines for the establishment, maintenance and distribution of chemical reference substances. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report*. Geneva, World Health Organization, 2007, Annex 3 (WHO Technical Report Series, No. 943).\n\nConsiderations for requesting analyses of drug samples. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 4 (WHO Technical Report Series, No. 902).\n\nModel certificate of analysis. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 10 (WHO Technical Report Series, No. 902).\n\n## Related regulatory standards\n\nhttp://www.who.int/medicines/areas/quality_safety/quality_assurance/regulatory_standards/en/", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b4a5b34ce46439d5cf9d373cc42b841e195df50a88720570586d692a5ebc7906", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Thirty-fourth report\n\nGeneva, World Health Organization, 1996, Annex 7 (WHO Technical Report Series, No. 863).\n\nHerbal medicinal products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 3 (WHO Technical Report Series, No. 937).\n\nWater for pharmaceutical use. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 3 (WHO Technical Report Series, No. 929).\n\nHeating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 2 (WHO Technical Report Series, No. 937).\n\nValidation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 4 (WHO Technical Report Series, No. 937).\n\n## Quality control\n\nhttp://www.who.int/medicines/areas/quality_safety/quality_assurance/control/en/index.html\n\n*The International Pharmacopoeia (Ph. Int.)* \u2014 Fourth Edition + First Supplement. Geneva, World Health Organization, 2006.\n\nGeneral guidelines for the establishment, maintenance and distribution of chemical reference substances. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report*. Geneva, World Health Organization, 2007, Annex 3 (WHO Technical Report Series, No. 943).\n\nConsiderations for requesting analyses of drug samples. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 4 (WHO Technical Report Series, No. 902).\n\nModel certificate of analysis. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 10 (WHO Technical Report Series, No. 902).\n\n## Related regulatory standards\n\nhttp://www.who.int/medicines/areas/quality_safety/quality_assurance/regulatory_standards/en/", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2141, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "518cb51f-73de-466c-8e3f-ffcf7917363d": {"__data__": {"id_": "518cb51f-73de-466c-8e3f-ffcf7917363d", "embedding": null, "metadata": {"page_label": "203", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 2 (WHO Technical Report Series, No. 953).\n\nProcedure for assessing the acceptability, in principle, of active pharmaceutical ingredients for use in pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 4 (WHO Technical Report Series, No. 953).\n\nGuidelines on active pharmaceutical ingredient master file procedure. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-second report*. Geneva, World Health Organization, 2008, Annex 4 (WHO Technical Report Series, No. 948).\n\nGuidance on variations to a prequalified product dossier. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report*. Geneva, World Health Organization, 2007, Annex 6 (WHO Technical Report Series, No. 943).\n\nWHO guidelines for sampling of pharmaceutical products and related materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 4 (WHO Technical Report Series, No. 929).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (Organizaci\u00f3n Mundial de la Salud) y se centra en las especificaciones y directrices relacionadas con los ingredientes farmac\u00e9uticos activos y los productos farmac\u00e9uticos terminados. Incluye informes de varias reuniones del Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas, donde se abordan temas como la estabilidad de los ingredientes, la aceptaci\u00f3n de ingredientes para productos farmac\u00e9uticos, procedimientos para archivos maestros de ingredientes activos y gu\u00edas sobre variaciones en los expedientes de productos prequalificados.\n\n### Preguntas espec\u00edficas\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que se utilizan para evaluar la aceptabilidad de los ingredientes farmac\u00e9uticos activos seg\u00fan el informe de 2009?**\n   - Esta pregunta busca detalles sobre los criterios de evaluaci\u00f3n que pueden no estar disponibles en otras fuentes.\n\n2. **\u00bfQu\u00e9 procedimientos se describen en el documento para la elaboraci\u00f3n y mantenimiento de un archivo maestro de ingredientes activos?**\n   - Esta pregunta se centra en los procedimientos espec\u00edficos que se deben seguir, que pueden no estar ampliamente documentados en otros lugares.\n\n3. **\u00bfQu\u00e9 recomendaciones se ofrecen en el informe de 2005 sobre el muestreo de productos farmac\u00e9uticos y materiales relacionados?**\n   - Esta pregunta busca informaci\u00f3n sobre las pr\u00e1cticas de muestreo que son cruciales para la calidad y seguridad de los productos farmac\u00e9uticos, y que pueden no ser f\u00e1cilmente accesibles en otras fuentes.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Informe T\u00e9cnico de la OMS**: El documento es parte de la Serie de Informes T\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS), espec\u00edficamente el No. 957, que aborda especificaciones para preparaciones farmac\u00e9uticas.\n\n2. **Productos Medicinales Herbales**: Se mencionan directrices sobre el uso y la regulaci\u00f3n de productos herbales en el contexto farmac\u00e9utico, referenciando el informe de la OMS de 2006.\n\n3. **Agua para Uso Farmac\u00e9utico**: Se incluyen especificaciones sobre la calidad del agua utilizada en la fabricaci\u00f3n de productos farmac\u00e9uticos, citando un informe de 2005.\n\n4. **Sistemas de HVAC**: Se abordan las recomendaciones para sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado en la producci\u00f3n de formas de dosificaci\u00f3n farmac\u00e9utica no est\u00e9riles.\n\n5. **Validaci\u00f3n de Procesos**: Se discuten los criterios y procedimientos necesarios para validar procesos en la producci\u00f3n farmac\u00e9utica, asegurando la calidad y seguridad de los productos.\n\n6. **Control de Calidad**: Se proporciona un enlace a recursos sobre control de calidad y se menciona la *Farmacopea Internacional* como referencia clave.\n\n7. **Sustancias Qu\u00edmicas de Referencia**: Se ofrecen pautas generales para el establecimiento y mantenimiento de sustancias qu\u00edmicas de referencia, as\u00ed como consideraciones para el an\u00e1lisis de muestras de medicamentos.\n\n8. **Certificado de An\u00e1lisis**: Se menciona un modelo de certificado de an\u00e1lisis que es fundamental para el control de calidad en la industria farmac\u00e9utica.\n\n9. **Est\u00e1ndares Regulatorios**: Se incluyen enlaces a recursos relacionados con est\u00e1ndares regulatorios y gu\u00edas sobre la calidad y seguridad de los productos farmac\u00e9uticos.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **WHO Technical Report Series**\n- **Productos Medicinales Herbales**\n- **Agua para Uso Farmac\u00e9utico**\n- **Sistemas de Calefacci\u00f3n, Ventilaci\u00f3n y Aire Acondicionado (HVAC)**\n- **Control de Calidad**\n- **Farmacopea Internacional (Ph. Int.)**\n- **Sustancias Qu\u00edmicas de Referencia** \n\nEste resumen destaca los temas centrales y las entidades relevantes en el contexto del informe t\u00e9cnico de la OMS sobre especificaciones para preparaciones farmac\u00e9uticas.", "excerpt_keywords": "Keywords: estabilidad, ingredientes farmac\u00e9uticos activos, muestreo, archivo maestro, directrices"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f2d002eb-6d82-4e34-a131-c624b4a1cf18", "node_type": "4", "metadata": {"page_label": "203", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 2 (WHO Technical Report Series, No. 953).\n\nProcedure for assessing the acceptability, in principle, of active pharmaceutical ingredients for use in pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 4 (WHO Technical Report Series, No. 953).\n\nGuidelines on active pharmaceutical ingredient master file procedure. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-second report*. Geneva, World Health Organization, 2008, Annex 4 (WHO Technical Report Series, No. 948).\n\nGuidance on variations to a prequalified product dossier. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report*. Geneva, World Health Organization, 2007, Annex 6 (WHO Technical Report Series, No. 943).\n\nWHO guidelines for sampling of pharmaceutical products and related materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 4 (WHO Technical Report Series, No. 929).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "c02c669433f81d28b876bad4380e1da2208c8724b44ce0e882590f895ab3f8a8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 2 (WHO Technical Report Series, No. 953).\n\nProcedure for assessing the acceptability, in principle, of active pharmaceutical ingredients for use in pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 4 (WHO Technical Report Series, No. 953).\n\nGuidelines on active pharmaceutical ingredient master file procedure. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-second report*. Geneva, World Health Organization, 2008, Annex 4 (WHO Technical Report Series, No. 948).\n\nGuidance on variations to a prequalified product dossier. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report*. Geneva, World Health Organization, 2007, Annex 6 (WHO Technical Report Series, No. 943).\n\nWHO guidelines for sampling of pharmaceutical products and related materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 4 (WHO Technical Report Series, No. 929).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1369, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ef79f78a-8a1c-4bc4-8516-ade6a9cd1c6f": {"__data__": {"id_": "ef79f78a-8a1c-4bc4-8516-ade6a9cd1c6f", "embedding": null, "metadata": {"page_label": "204", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 2\n\n## General notes: additional clarifications and explanations\n\n2.1.1 The intent of this clause is that senior management of the API manufacturer has the responsibility to ensure that there is an effective quality management system in place and that all employees are made aware of their roles and responsibilities in assuring the quality of the API(s) produced.\n\n2.3 The intent of this clause is to specify the roles and responsibilities that should apply to production activities and, in particular, that these responsibilities should not be delegated to non-production personnel within the company or to any persons outside the company.\n\n5.2.1 This clause requires a written standard operating procedure (SOP) covering the maintenance of equipment. Important information to specify in this SOP should include:\n\n- who is responsible for coordinating equipment maintenance activities (usually production management or engineering management);\n- a provision that a schedule of planned preventive maintenance of equipment should be available (a useful reference is *ISPE Good Practice Guide: Maintenance. May 2009* (1));\n- a statement of the necessity to follow proper change control procedures where non-routine repairs, or modifications, replacements or other activities, are required.\n\n7.1.2 There is an expectation that suppliers of critical materials should be subject to on-site audits as part of the company\u2019s supplier qualification programme.\n\n7.2.1 There is an expectation that upon receipt and before acceptance of materials, each container or grouping of containers of materials should be examined visually for correct labelling, including correlation between the name used by the supplier and the in-house name. If these names are different, both names should be recorded and verified against a previously approved list of synonyms and checked by a scientifically qualified person.\n\n7.3.1 This clause requires that at least one test be performed to verify the identity of each batch of material received. For clarification, one test for identity may not be sufficient in the majority of cases as this is dependent on various aspects, including supplier qualification.\n\n11.7.3 For clarification, the reserve sample should be stored in a packaging system designed to give maximum protection of the API against change over time, e.g. a glass bottle with tightly fitted cap.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es un ap\u00e9ndice del Informe T\u00e9cnico de la OMS sobre la calidad de los principios activos farmac\u00e9uticos (API). Se centra en la responsabilidad de la alta direcci\u00f3n en la implementaci\u00f3n de un sistema de gesti\u00f3n de calidad efectivo, la importancia de las responsabilidades en las actividades de producci\u00f3n, y los procedimientos operativos est\u00e1ndar (SOP) necesarios para el mantenimiento de equipos y la gesti\u00f3n de materiales cr\u00edticos. Tambi\u00e9n se menciona la necesidad de auditor\u00edas a proveedores y la verificaci\u00f3n de la identidad de los materiales recibidos.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1l es la responsabilidad espec\u00edfica de la alta direcci\u00f3n en relaci\u00f3n con el sistema de gesti\u00f3n de calidad de los API?**\n   - La alta direcci\u00f3n del fabricante de API es responsable de asegurar que exista un sistema de gesti\u00f3n de calidad efectivo y que todos los empleados conozcan sus roles y responsabilidades en la garant\u00eda de calidad de los API producidos.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse al recibir materiales cr\u00edticos para asegurar su correcta identificaci\u00f3n?**\n   - Al recibir materiales, cada contenedor debe ser examinado visualmente para verificar el etiquetado correcto, asegurando que el nombre del proveedor coincida con el nombre interno. Si hay discrepancias, ambos nombres deben ser registrados y verificados contra una lista aprobada de sin\u00f3nimos por una persona calificada cient\u00edficamente.\n\n3. **\u00bfQu\u00e9 se debe incluir en un procedimiento operativo est\u00e1ndar (SOP) para el mantenimiento de equipos?**\n   - El SOP debe incluir qui\u00e9n es responsable de coordinar las actividades de mantenimiento, un cronograma de mantenimiento preventivo planificado, y la necesidad de seguir procedimientos de control de cambios adecuados para reparaciones no rutinarias o modificaciones.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Estabilidad de Ingredientes Farmac\u00e9uticos Activos y Productos Farmac\u00e9uticos Terminados**:\n   - Se aborda la importancia de realizar pruebas de estabilidad para garantizar la calidad y seguridad de los productos farmac\u00e9uticos.\n\n2. **Aceptabilidad de Ingredientes Farmac\u00e9uticos Activos**:\n   - Se describen los procedimientos para evaluar la aceptabilidad de los ingredientes activos en productos farmac\u00e9uticos, lo que es crucial para su uso seguro.\n\n3. **Archivo Maestro de Ingredientes Activos**:\n   - Se proporcionan directrices sobre c\u00f3mo elaborar y mantener un archivo maestro para ingredientes activos, que es esencial para la regulaci\u00f3n y control de calidad.\n\n4. **Variaciones en Expedientes de Productos Precalificados**:\n   - Se ofrecen orientaciones sobre c\u00f3mo manejar las variaciones en los expedientes de productos que han sido precalificados, asegurando que se mantenga la calidad.\n\n5. **Muestreo de Productos Farmac\u00e9uticos**:\n   - Se presentan directrices sobre las pr\u00e1cticas de muestreo de productos farmac\u00e9uticos y materiales relacionados, que son fundamentales para la evaluaci\u00f3n de la calidad.\n\n### Entidades Clave\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad responsable de la elaboraci\u00f3n de las directrices y especificaciones.\n- **Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas**: Grupo que elabora los informes y recomendaciones.\n- **Informes T\u00e9cnicos de la OMS**: Serie de documentos que contienen las especificaciones y directrices mencionadas.\n\n### Documentos Citados\n\n- **WHO Technical Report Series, No. 953**: Informe de 2009 que incluye temas sobre estabilidad y aceptabilidad de ingredientes.\n- **WHO Technical Report Series, No. 948**: Informe de 2008 que trata sobre el archivo maestro de ingredientes activos.\n- **WHO Technical Report Series, No. 943**: Informe de 2007 que aborda las variaciones en expedientes de productos.\n- **WHO Technical Report Series, No. 929**: Informe de 2005 que proporciona directrices sobre el muestreo de productos farmac\u00e9uticos. \n\nEste resumen destaca los aspectos fundamentales y las entidades relevantes en la secci\u00f3n del documento, proporcionando una visi\u00f3n clara de su contenido y prop\u00f3sito.", "excerpt_keywords": "Keywords: quality management, active pharmaceutical ingredients, standard operating procedures, supplier qualification, equipment maintenance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e73cdffd-4dca-450d-a8eb-0c4ded11757e", "node_type": "4", "metadata": {"page_label": "204", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 2\n\n## General notes: additional clarifications and explanations\n\n2.1.1 The intent of this clause is that senior management of the API manufacturer has the responsibility to ensure that there is an effective quality management system in place and that all employees are made aware of their roles and responsibilities in assuring the quality of the API(s) produced.\n\n2.3 The intent of this clause is to specify the roles and responsibilities that should apply to production activities and, in particular, that these responsibilities should not be delegated to non-production personnel within the company or to any persons outside the company.\n\n5.2.1 This clause requires a written standard operating procedure (SOP) covering the maintenance of equipment. Important information to specify in this SOP should include:\n\n- who is responsible for coordinating equipment maintenance activities (usually production management or engineering management);\n- a provision that a schedule of planned preventive maintenance of equipment should be available (a useful reference is *ISPE Good Practice Guide: Maintenance. May 2009* (1));\n- a statement of the necessity to follow proper change control procedures where non-routine repairs, or modifications, replacements or other activities, are required.\n\n7.1.2 There is an expectation that suppliers of critical materials should be subject to on-site audits as part of the company\u2019s supplier qualification programme.\n\n7.2.1 There is an expectation that upon receipt and before acceptance of materials, each container or grouping of containers of materials should be examined visually for correct labelling, including correlation between the name used by the supplier and the in-house name. If these names are different, both names should be recorded and verified against a previously approved list of synonyms and checked by a scientifically qualified person.\n\n7.3.1 This clause requires that at least one test be performed to verify the identity of each batch of material received. For clarification, one test for identity may not be sufficient in the majority of cases as this is dependent on various aspects, including supplier qualification.\n\n11.7.3 For clarification, the reserve sample should be stored in a packaging system designed to give maximum protection of the API against change over time, e.g. a glass bottle with tightly fitted cap.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "e9bc76ac95ba22bc7a80b26557b298d51a3a528167d0812cbab780b058430f5e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Appendix 2\n\n## General notes: additional clarifications and explanations\n\n2.1.1 The intent of this clause is that senior management of the API manufacturer has the responsibility to ensure that there is an effective quality management system in place and that all employees are made aware of their roles and responsibilities in assuring the quality of the API(s) produced.\n\n2.3 The intent of this clause is to specify the roles and responsibilities that should apply to production activities and, in particular, that these responsibilities should not be delegated to non-production personnel within the company or to any persons outside the company.\n\n5.2.1 This clause requires a written standard operating procedure (SOP) covering the maintenance of equipment. Important information to specify in this SOP should include:\n\n- who is responsible for coordinating equipment maintenance activities (usually production management or engineering management);\n- a provision that a schedule of planned preventive maintenance of equipment should be available (a useful reference is *ISPE Good Practice Guide: Maintenance. May 2009* (1));\n- a statement of the necessity to follow proper change control procedures where non-routine repairs, or modifications, replacements or other activities, are required.\n\n7.1.2 There is an expectation that suppliers of critical materials should be subject to on-site audits as part of the company\u2019s supplier qualification programme.\n\n7.2.1 There is an expectation that upon receipt and before acceptance of materials, each container or grouping of containers of materials should be examined visually for correct labelling, including correlation between the name used by the supplier and the in-house name. If these names are different, both names should be recorded and verified against a previously approved list of synonyms and checked by a scientifically qualified person.\n\n7.3.1 This clause requires that at least one test be performed to verify the identity of each batch of material received. For clarification, one test for identity may not be sufficient in the majority of cases as this is dependent on various aspects, including supplier qualification.\n\n11.7.3 For clarification, the reserve sample should be stored in a packaging system designed to give maximum protection of the API against change over time, e.g. a glass bottle with tightly fitted cap.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2393, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b11b5e92-85a9-4c69-b5a8-d746bb2475e5": {"__data__": {"id_": "b11b5e92-85a9-4c69-b5a8-d746bb2475e5", "embedding": null, "metadata": {"page_label": "205", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "17. Refer to WHO GTDP (2) and WHO GMP for excipients (3).\n\n18. See footnote on p. 174.\n\n## API starting material\n\nAs discussed in this document the introduction of the API starting material into the manufacturing process is where the requirements of GMP commence.\n\nThe API starting material itself needs to be proposed and justified by the manufacturer and accepted as such by assessors. This justification should be documented and be available for review by WHO GMP inspectors.\n\nThe API starting material should be fully characterized according to identity and purity. In addition, the steps prior to the step where the API starting material appears, which may involve \u201cstarting materials for synthesis\u201d, should be available in the form of a flow chart.\n\nIn general, the starting materials for synthesis should:\n\n- be a synthetic precursor one or more synthetic steps prior to the final API intermediate;\n- be a well characterized, isolated and purified substance with a fully elucidated structure;\n- have well defined specifications which include one or more specific identity tests, and tests and limits for potency, specified and unspecified impurities and total impurities.\n\n## References\n\n1. International Society for Pharmaceutical Engineering. *ISPE good practice guide: maintenance*. 2009 (http://www.ispe.org/cs/ispe_good_practice_guides_section/ispe_good_practice_guides).\n\n2. Good trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2003, Annex 2 (WHO Technical Report Series, No. 917) (http://www.who.int/medicines/areas/quality_safety/quality_assurance/distribution/en/index.html).\n\n3. WHO GMP for excipients In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report*. Geneva, World Health Organization, 1999, Annex 5 (WHO Technical Report Series, No. 885) (http://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/index.html); and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, 2nd updated ed., Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las pr\u00e1cticas de buenas manufacturas (GMP) relacionadas con los materiales de partida de los ingredientes farmac\u00e9uticos activos (API). Se enfatiza que la introducci\u00f3n del material de partida en el proceso de fabricaci\u00f3n es el punto donde comienzan los requisitos de GMP. El material de partida debe ser propuesto y justificado por el fabricante, y esta justificaci\u00f3n debe estar documentada y disponible para revisi\u00f3n. Adem\u00e1s, se requiere que el material de partida est\u00e9 completamente caracterizado en t\u00e9rminos de identidad y pureza, y que se presenten los pasos previos en un diagrama de flujo. Se establecen especificaciones claras para los materiales de partida, que incluyen pruebas de identidad y l\u00edmites para impurezas.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son los requisitos espec\u00edficos que debe cumplir un material de partida para ser aceptado como ingrediente farmac\u00e9utico activo (API) seg\u00fan las directrices de la OMS?**\n   - Esta pregunta busca detalles sobre las especificaciones y caracter\u00edsticas que un material de partida debe tener para cumplir con las normativas de la OMS.\n\n2. **\u00bfQu\u00e9 documentaci\u00f3n se requiere para justificar la aceptaci\u00f3n de un material de partida por parte de los evaluadores de la OMS?**\n   - Esta pregunta se centra en el tipo de documentaci\u00f3n que los fabricantes deben proporcionar para respaldar su propuesta de material de partida.\n\n3. **\u00bfC\u00f3mo deben presentarse los pasos previos a la introducci\u00f3n del material de partida en el proceso de fabricaci\u00f3n?**\n   - Esta pregunta indaga sobre la forma en que se deben documentar y presentar los pasos anteriores al material de partida, espec\u00edficamente en relaci\u00f3n con el uso de diagramas de flujo. \n\nEstas preguntas est\u00e1n dise\u00f1adas para obtener informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otras fuentes, ya que se centran en los requisitos y procedimientos establecidos por la OMS en el contexto de la fabricaci\u00f3n de productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Responsabilidad de la Alta Direcci\u00f3n**:\n   - La alta direcci\u00f3n de los fabricantes de principios activos farmac\u00e9uticos (API) debe garantizar un sistema de gesti\u00f3n de calidad efectivo y asegurar que todos los empleados comprendan sus roles en la calidad del producto.\n\n2. **Roles y Responsabilidades en Producci\u00f3n**:\n   - Se especifica que las responsabilidades en las actividades de producci\u00f3n no deben ser delegadas a personal no relacionado con la producci\u00f3n ni a personas externas a la empresa.\n\n3. **Procedimientos Operativos Est\u00e1ndar (SOP)**:\n   - Se requiere un SOP escrito para el mantenimiento de equipos, que debe incluir:\n     - Coordinaci\u00f3n de actividades de mantenimiento.\n     - Un cronograma de mantenimiento preventivo.\n     - Procedimientos de control de cambios para reparaciones no rutinarias.\n\n4. **Auditor\u00edas a Proveedores**:\n   - Se espera que los proveedores de materiales cr\u00edticos sean sometidos a auditor\u00edas en el sitio como parte del programa de calificaci\u00f3n de proveedores de la empresa.\n\n5. **Verificaci\u00f3n de Materiales Recibidos**:\n   - Al recibir materiales, cada contenedor debe ser examinado visualmente para verificar el etiquetado correcto. Si hay discrepancias en los nombres, deben ser registradas y verificadas.\n\n6. **Pruebas de Identidad de Materiales**:\n   - Se requiere realizar al menos una prueba para verificar la identidad de cada lote de material recibido, aunque una sola prueba puede no ser suficiente dependiendo de la calificaci\u00f3n del proveedor.\n\n7. **Almacenamiento de Muestras de Reserva**:\n   - Las muestras de reserva deben almacenarse en un sistema de embalaje que ofrezca m\u00e1xima protecci\u00f3n contra cambios a lo largo del tiempo.\n\n### Entidades Clave:\n- **API (Principios Activos Farmac\u00e9uticos)**: Sustancias utilizadas en la fabricaci\u00f3n de medicamentos.\n- **SOP (Procedimientos Operativos Est\u00e1ndar)**: Documentos que describen c\u00f3mo realizar tareas espec\u00edficas.\n- **ISPE (International Society for Pharmaceutical Engineering)**: Referencia mencionada para buenas pr\u00e1cticas en mantenimiento.\n- **Proveedores de Materiales Cr\u00edticos**: Entidades que suministran materiales esenciales para la producci\u00f3n de API.\n- **Muestras de Reserva**: Muestras de productos almacenadas para referencia futura.", "excerpt_keywords": "Keywords: API starting material, GMP, pharmaceutical manufacturing, specifications, WHO guidelines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "feddbbc9-1870-4c76-b611-fe4909d44af0", "node_type": "4", "metadata": {"page_label": "205", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "17. Refer to WHO GTDP (2) and WHO GMP for excipients (3).\n\n18. See footnote on p. 174.\n\n## API starting material\n\nAs discussed in this document the introduction of the API starting material into the manufacturing process is where the requirements of GMP commence.\n\nThe API starting material itself needs to be proposed and justified by the manufacturer and accepted as such by assessors. This justification should be documented and be available for review by WHO GMP inspectors.\n\nThe API starting material should be fully characterized according to identity and purity. In addition, the steps prior to the step where the API starting material appears, which may involve \u201cstarting materials for synthesis\u201d, should be available in the form of a flow chart.\n\nIn general, the starting materials for synthesis should:\n\n- be a synthetic precursor one or more synthetic steps prior to the final API intermediate;\n- be a well characterized, isolated and purified substance with a fully elucidated structure;\n- have well defined specifications which include one or more specific identity tests, and tests and limits for potency, specified and unspecified impurities and total impurities.\n\n## References\n\n1. International Society for Pharmaceutical Engineering. *ISPE good practice guide: maintenance*. 2009 (http://www.ispe.org/cs/ispe_good_practice_guides_section/ispe_good_practice_guides).\n\n2. Good trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2003, Annex 2 (WHO Technical Report Series, No. 917) (http://www.who.int/medicines/areas/quality_safety/quality_assurance/distribution/en/index.html).\n\n3. WHO GMP for excipients In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report*. Geneva, World Health Organization, 1999, Annex 5 (WHO Technical Report Series, No. 885) (http://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/index.html); and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, 2nd updated ed., Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "d59a7511894d6cc15614a536b3c6a65fa3d25eaf2b449c7de15d860e8d0dffd8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "17. Refer to WHO GTDP (2) and WHO GMP for excipients (3).\n\n18. See footnote on p. 174.\n\n## API starting material\n\nAs discussed in this document the introduction of the API starting material into the manufacturing process is where the requirements of GMP commence.\n\nThe API starting material itself needs to be proposed and justified by the manufacturer and accepted as such by assessors. This justification should be documented and be available for review by WHO GMP inspectors.\n\nThe API starting material should be fully characterized according to identity and purity. In addition, the steps prior to the step where the API starting material appears, which may involve \u201cstarting materials for synthesis\u201d, should be available in the form of a flow chart.\n\nIn general, the starting materials for synthesis should:\n\n- be a synthetic precursor one or more synthetic steps prior to the final API intermediate;\n- be a well characterized, isolated and purified substance with a fully elucidated structure;\n- have well defined specifications which include one or more specific identity tests, and tests and limits for potency, specified and unspecified impurities and total impurities.\n\n## References\n\n1. International Society for Pharmaceutical Engineering. *ISPE good practice guide: maintenance*. 2009 (http://www.ispe.org/cs/ispe_good_practice_guides_section/ispe_good_practice_guides).\n\n2. Good trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2003, Annex 2 (WHO Technical Report Series, No. 917) (http://www.who.int/medicines/areas/quality_safety/quality_assurance/distribution/en/index.html).\n\n3. WHO GMP for excipients In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report*. Geneva, World Health Organization, 1999, Annex 5 (WHO Technical Report Series, No. 885) (http://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/index.html); and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, 2nd updated ed., Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2269, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c91287e3-67ac-46be-9fe3-47623d155594": {"__data__": {"id_": "c91287e3-67ac-46be-9fe3-47623d155594", "embedding": null, "metadata": {"page_label": "206", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 3\n\n## WHO good manufacturing practices for pharmaceutical products containing hazardous substances\n\n1. Introduction\n2. General\n3. Glossary\n4. Risk assessment\n5. Product protection\n6. Personal protection equipment and breathing air systems\n7. Environmental protection\n8. Facility layout\n9. Air-handling systems\n10. Air-handling units\n11. Safe change filter housings\n12. Personnel decontamination systems\n13. Effluent treatment\n14. Maintenance\n15. Qualification and validation\n\nReferences", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 957\" incluye un anexo que detalla las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para productos farmac\u00e9uticos que contienen sustancias peligrosas. Este anexo abarca una variedad de temas esenciales para garantizar la seguridad y la calidad en la producci\u00f3n de estos productos, incluyendo la evaluaci\u00f3n de riesgos, la protecci\u00f3n del producto, el equipo de protecci\u00f3n personal, la disposici\u00f3n de las instalaciones y la validaci\u00f3n de procesos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los componentes clave que se deben considerar en la evaluaci\u00f3n de riesgos para productos farmac\u00e9uticos que contienen sustancias peligrosas?**\n   - Esta pregunta se centra en el apartado de \"Evaluaci\u00f3n de riesgos\" y busca detalles sobre los factores espec\u00edficos que deben ser analizados para garantizar la seguridad en la fabricaci\u00f3n.\n\n2. **\u00bfQu\u00e9 medidas de protecci\u00f3n personal se recomiendan para el manejo de sustancias peligrosas en la fabricaci\u00f3n farmac\u00e9utica?**\n   - Esta pregunta se relaciona con el tema de \"Equipo de protecci\u00f3n personal y sistemas de aire respirable\", buscando informaci\u00f3n sobre las mejores pr\u00e1cticas y equipos necesarios para proteger a los trabajadores.\n\n3. **\u00bfQu\u00e9 aspectos se deben considerar en el dise\u00f1o de la disposici\u00f3n de las instalaciones para minimizar la exposici\u00f3n a sustancias peligrosas?**\n   - Esta pregunta se refiere al apartado de \"Disposici\u00f3n de las instalaciones\" y busca entender c\u00f3mo el dise\u00f1o f\u00edsico de las instalaciones puede influir en la seguridad y la eficacia de la producci\u00f3n. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que probablemente no se encuentre f\u00e1cilmente en otros documentos o fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Material de Partida de API**: \n   - La introducci\u00f3n del material de partida de ingredientes farmac\u00e9uticos activos (API) en el proceso de fabricaci\u00f3n marca el inicio de los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP).\n   - El material de partida debe ser propuesto y justificado por el fabricante, y esta justificaci\u00f3n debe estar documentada y disponible para revisi\u00f3n por inspectores de la OMS.\n\n2. **Caracterizaci\u00f3n**:\n   - El material de partida debe estar completamente caracterizado en t\u00e9rminos de identidad y pureza.\n   - Se requiere un diagrama de flujo que muestre los pasos previos a la introducci\u00f3n del material de partida, que pueden incluir \"materiales de partida para la s\u00edntesis\".\n\n3. **Especificaciones de Materiales de Partida**:\n   - Deben ser precursores sint\u00e9ticos en uno o m\u00e1s pasos sint\u00e9ticos antes del intermediario final del API.\n   - Deben ser sustancias bien caracterizadas, aisladas y purificadas, con una estructura completamente elucidada.\n   - Deben tener especificaciones bien definidas que incluyan pruebas de identidad y l\u00edmites para potencia, impurezas especificadas y no especificadas, y total de impurezas.\n\n4. **Referencias**:\n   - Se citan documentos y gu\u00edas relevantes de la OMS y otras organizaciones que establecen est\u00e1ndares y pr\u00e1cticas para la manufactura y distribuci\u00f3n de materiales farmac\u00e9uticos.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices de GMP.\n- **API (Ingrediente Farmac\u00e9utico Activo)**: Sustancia que se utiliza en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Conjunto de regulaciones que aseguran que los productos farmac\u00e9uticos se fabriquen de manera consistente y controlada.\n- **ISPE (International Society for Pharmaceutical Engineering)**: Organizaci\u00f3n que proporciona gu\u00edas y buenas pr\u00e1cticas en la ingenier\u00eda farmac\u00e9utica. \n\nEste resumen destaca los aspectos fundamentales relacionados con los materiales de partida en la fabricaci\u00f3n de productos farmac\u00e9uticos, as\u00ed como las normativas y requisitos establecidos por la OMS.", "excerpt_keywords": "Keywords: manufacturing practices, hazardous substances, risk assessment, personal protection, environmental protection"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ff13a061-005d-48a2-b0d8-bd029ee8a109", "node_type": "4", "metadata": {"page_label": "206", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 3\n\n## WHO good manufacturing practices for pharmaceutical products containing hazardous substances\n\n1. Introduction\n2. General\n3. Glossary\n4. Risk assessment\n5. Product protection\n6. Personal protection equipment and breathing air systems\n7. Environmental protection\n8. Facility layout\n9. Air-handling systems\n10. Air-handling units\n11. Safe change filter housings\n12. Personnel decontamination systems\n13. Effluent treatment\n14. Maintenance\n15. Qualification and validation\n\nReferences", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a504d3386430b0bd0ff1535c7444a41a8765560e39a64274f3d8cce955031ba5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 3\n\n## WHO good manufacturing practices for pharmaceutical products containing hazardous substances\n\n1. Introduction\n2. General\n3. Glossary\n4. Risk assessment\n5. Product protection\n6. Personal protection equipment and breathing air systems\n7. Environmental protection\n8. Facility layout\n9. Air-handling systems\n10. Air-handling units\n11. Safe change filter housings\n12. Personnel decontamination systems\n13. Effluent treatment\n14. Maintenance\n15. Qualification and validation\n\nReferences", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 494, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ba096cb1-0346-4383-b1a8-d3617b29d07d": {"__data__": {"id_": "ba096cb1-0346-4383-b1a8-d3617b29d07d", "embedding": null, "metadata": {"page_label": "207", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 1. Introduction\n\n1.1 These guidelines set out good practices applicable to facilities handling pharmaceutical products (including active pharmaceutical ingredients (APIs)) that contain hazardous substances such as certain hormones, steroids or cytotoxins. They do not replace national legislation for protection of the environment and personnel. Other WHO guides to good manufacturing practices (GMP) and regulations need to be observed in addition to the workers\u2019 safety criteria (1\u20134).\n\n1.2 These guidelines are to be read in conjunction with other WHO GMP guidelines with respect to building finishes and general services installations, among others. See the reference list for relevant publications which serve as additional background material. The primary focus of these guidelines is on the air-conditioning and ventilation systems of the facility; however, the document also provides some guidance on personnel protection.\n\n1.3 The areas to which this document applies include all zones where the handling of products could lead to cross-contamination, exposure of personnel, or discharge to the environment. This includes research and development facilities, and the sites of API manufacturing and storage and of finished product manufacturing.\n\n1.4 Where possible products should be manufactured in closed systems.\n\n# 2. General\n\n2.1 Facilities should be designed and operated in accordance with the main GMP principles, as follows:\n\n- to ensure quality of product;\n- to protect the operators from possible harmful effects of products containing hazardous substances; and\n- to protect the environment from contamination and thereby protect the public from possible harmful effects of products containing hazardous substances.\n\n2.2 The production of certain products containing hazardous substances should generally be conducted in separate, dedicated, self-contained facilities.\n\nThese **self-contained facilities** may be in the same building as another facility but should be separated by a physical barrier and have, e.g. separate entrances, staff facilities and air-handling systems. The extent of the separation from adjacent facilities and sharing of common services should be determined by risk assessment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Objetivo de las directrices**: Las directrices establecen buenas pr\u00e1cticas para las instalaciones que manejan productos farmac\u00e9uticos que contienen sustancias peligrosas, enfatizando la importancia de la seguridad del personal y la protecci\u00f3n del medio ambiente, sin reemplazar la legislaci\u00f3n nacional.\n\n2. **\u00c1reas de aplicaci\u00f3n**: Las directrices se aplican a todas las zonas donde el manejo de productos puede causar contaminaci\u00f3n cruzada, exposici\u00f3n del personal o descarga al medio ambiente, incluyendo instalaciones de investigaci\u00f3n y desarrollo, as\u00ed como sitios de fabricaci\u00f3n y almacenamiento de ingredientes farmac\u00e9uticos activos (APIs) y productos terminados.\n\n3. **Dise\u00f1o y operaci\u00f3n de instalaciones**: Se enfatiza que las instalaciones deben ser dise\u00f1adas y operadas de acuerdo con los principios de buenas pr\u00e1cticas de manufactura (GMP), asegurando la calidad del producto y protegiendo tanto a los operadores como al medio ambiente de los efectos nocivos de las sustancias peligrosas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de instalaciones deben ser consideradas como \"autocontenidas\" seg\u00fan las directrices y qu\u00e9 caracter\u00edsticas deben tener para cumplir con esta definici\u00f3n?**\n   - Respuesta: Las instalaciones autocontenidas deben estar separadas por una barrera f\u00edsica de otras instalaciones, tener entradas y salidas separadas, as\u00ed como instalaciones para el personal y sistemas de manejo de aire independientes. La extensi\u00f3n de esta separaci\u00f3n debe ser determinada por una evaluaci\u00f3n de riesgos.\n\n2. **\u00bfCu\u00e1les son los principios clave de las buenas pr\u00e1cticas de manufactura (GMP) que deben seguir las instalaciones que manejan productos farmac\u00e9uticos peligrosos?**\n   - Respuesta: Los principios clave incluyen asegurar la calidad del producto, proteger a los operadores de los efectos nocivos de las sustancias peligrosas y proteger el medio ambiente de la contaminaci\u00f3n, lo que a su vez protege al p\u00fablico de posibles efectos perjudiciales.\n\n3. **\u00bfQu\u00e9 se recomienda en cuanto a la fabricaci\u00f3n de productos que contienen sustancias peligrosas en relaci\u00f3n con los sistemas de producci\u00f3n?**\n   - Respuesta: Se recomienda que, siempre que sea posible, los productos se fabriquen en sistemas cerrados para minimizar la exposici\u00f3n y el riesgo de contaminaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl anexo 3 del documento \"WHO - Technical Report Series 957\" se centra en las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para productos farmac\u00e9uticos que contienen sustancias peligrosas. A continuaci\u00f3n se presentan los temas clave abordados en esta secci\u00f3n:\n\n1. **Introducci\u00f3n**: Presenta el contexto y la importancia de las BPF en la fabricaci\u00f3n de productos farmac\u00e9uticos peligrosos.\n2. **General**: Proporciona principios generales que gu\u00edan las pr\u00e1cticas de fabricaci\u00f3n.\n3. **Glosario**: Define t\u00e9rminos relevantes utilizados en el documento.\n4. **Evaluaci\u00f3n de riesgos**: Detalla el proceso de identificaci\u00f3n y an\u00e1lisis de riesgos asociados con sustancias peligrosas.\n5. **Protecci\u00f3n del producto**: Describe medidas para asegurar la integridad y calidad del producto durante su fabricaci\u00f3n.\n6. **Equipo de protecci\u00f3n personal y sistemas de aire respirable**: Especifica el equipo necesario para proteger a los trabajadores que manejan sustancias peligrosas.\n7. **Protecci\u00f3n ambiental**: Aborda las pr\u00e1cticas para minimizar el impacto ambiental de la fabricaci\u00f3n.\n8. **Disposici\u00f3n de las instalaciones**: Discute el dise\u00f1o f\u00edsico de las instalaciones para mejorar la seguridad.\n9. **Sistemas de manejo de aire**: Explica la importancia de los sistemas de ventilaci\u00f3n y filtraci\u00f3n en el entorno de trabajo.\n10. **Unidades de manejo de aire**: Detalla las caracter\u00edsticas y funciones de estas unidades en la fabricaci\u00f3n.\n11. **C\u00e1maras de cambio seguro de filtros**: Describe las pr\u00e1cticas para el manejo seguro de filtros en el proceso de fabricaci\u00f3n.\n12. **Sistemas de descontaminaci\u00f3n del personal**: Proporciona directrices para la descontaminaci\u00f3n de trabajadores expuestos a sustancias peligrosas.\n13. **Tratamiento de efluentes**: Aborda la gesti\u00f3n y tratamiento de desechos generados durante la producci\u00f3n.\n14. **Mantenimiento**: Resalta la importancia del mantenimiento regular de equipos e instalaciones.\n15. **Calificaci\u00f3n y validaci\u00f3n**: Describe los procesos necesarios para asegurar que los sistemas y procesos cumplen con los est\u00e1ndares requeridos.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Productos farmac\u00e9uticos**: Categor\u00eda de productos en discusi\u00f3n.\n- **Sustancias peligrosas**: Tipo de materiales que requieren pr\u00e1cticas especiales de manejo.\n- **Buenas pr\u00e1cticas de fabricaci\u00f3n (BPF)**: Conjunto de directrices para asegurar la calidad y seguridad en la producci\u00f3n.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades clave que se abordan en el anexo, destacando la importancia de las BPF en la fabricaci\u00f3n de productos farmac\u00e9uticos que contienen sustancias peligrosas.", "excerpt_keywords": "Keywords: pharmaceutical products, hazardous substances, good manufacturing practices, air-conditioning systems, risk assessment"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6cb923c9-7aec-4c3b-a13e-ef3608eef36a", "node_type": "4", "metadata": {"page_label": "207", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 1. Introduction\n\n1.1 These guidelines set out good practices applicable to facilities handling pharmaceutical products (including active pharmaceutical ingredients (APIs)) that contain hazardous substances such as certain hormones, steroids or cytotoxins. They do not replace national legislation for protection of the environment and personnel. Other WHO guides to good manufacturing practices (GMP) and regulations need to be observed in addition to the workers\u2019 safety criteria (1\u20134).\n\n1.2 These guidelines are to be read in conjunction with other WHO GMP guidelines with respect to building finishes and general services installations, among others. See the reference list for relevant publications which serve as additional background material. The primary focus of these guidelines is on the air-conditioning and ventilation systems of the facility; however, the document also provides some guidance on personnel protection.\n\n1.3 The areas to which this document applies include all zones where the handling of products could lead to cross-contamination, exposure of personnel, or discharge to the environment. This includes research and development facilities, and the sites of API manufacturing and storage and of finished product manufacturing.\n\n1.4 Where possible products should be manufactured in closed systems.\n\n# 2. General\n\n2.1 Facilities should be designed and operated in accordance with the main GMP principles, as follows:\n\n- to ensure quality of product;\n- to protect the operators from possible harmful effects of products containing hazardous substances; and\n- to protect the environment from contamination and thereby protect the public from possible harmful effects of products containing hazardous substances.\n\n2.2 The production of certain products containing hazardous substances should generally be conducted in separate, dedicated, self-contained facilities.\n\nThese **self-contained facilities** may be in the same building as another facility but should be separated by a physical barrier and have, e.g. separate entrances, staff facilities and air-handling systems. The extent of the separation from adjacent facilities and sharing of common services should be determined by risk assessment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a0f3ce3907bf6c849525ff7b7418b0c741c8fc44a5c97895780ed0821e74a73c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 1. Introduction\n\n1.1 These guidelines set out good practices applicable to facilities handling pharmaceutical products (including active pharmaceutical ingredients (APIs)) that contain hazardous substances such as certain hormones, steroids or cytotoxins. They do not replace national legislation for protection of the environment and personnel. Other WHO guides to good manufacturing practices (GMP) and regulations need to be observed in addition to the workers\u2019 safety criteria (1\u20134).\n\n1.2 These guidelines are to be read in conjunction with other WHO GMP guidelines with respect to building finishes and general services installations, among others. See the reference list for relevant publications which serve as additional background material. The primary focus of these guidelines is on the air-conditioning and ventilation systems of the facility; however, the document also provides some guidance on personnel protection.\n\n1.3 The areas to which this document applies include all zones where the handling of products could lead to cross-contamination, exposure of personnel, or discharge to the environment. This includes research and development facilities, and the sites of API manufacturing and storage and of finished product manufacturing.\n\n1.4 Where possible products should be manufactured in closed systems.\n\n# 2. General\n\n2.1 Facilities should be designed and operated in accordance with the main GMP principles, as follows:\n\n- to ensure quality of product;\n- to protect the operators from possible harmful effects of products containing hazardous substances; and\n- to protect the environment from contamination and thereby protect the public from possible harmful effects of products containing hazardous substances.\n\n2.2 The production of certain products containing hazardous substances should generally be conducted in separate, dedicated, self-contained facilities.\n\nThese **self-contained facilities** may be in the same building as another facility but should be separated by a physical barrier and have, e.g. separate entrances, staff facilities and air-handling systems. The extent of the separation from adjacent facilities and sharing of common services should be determined by risk assessment.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2225, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f11563f4-38c8-44d7-9360-538bb39e6500": {"__data__": {"id_": "f11563f4-38c8-44d7-9360-538bb39e6500", "embedding": null, "metadata": {"page_label": "208", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 2.3\n\nIn general these manufacturing facilities should be regarded as containment facilities.\n\n## 2.4\n\nThe effective operation of a facility may require the combination of some or all of the following aspects:\n- Appropriate facility design and layout, with the emphasis on safely containing the materials being handled. Manufacturing processes using closed systems or barrier technology enhance operator and product protection;\n- Manufacturing process controls including adherence to standard operating procedures (SOPs);\n- Appropriately designed environmental control systems (ECS) or heating, ventilation and air-conditioning (HVAC);\n- Extraction systems;\n- Personal protective equipment (PPE);\n- Appropriate degowning and decontamination procedures;\n- Industrial hygiene (monitoring staff exposure levels);\n- Medical surveillance (monitoring staff exposure levels); and\n- Administrative controls.\n\n## 3. Glossary\n\nThe definitions given below apply to terms used in these guidelines. They may have a different meaning in other contexts.\n\n### action limit\n\nThe action limit is reached when the acceptance criteria of a critical parameter have been exceeded. Results outside these limits will require specified action and investigation.\n\n### active pharmaceutical ingredient (API)\n\nAny substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the body.\n\n### air-handling unit (AHU)\n\nThe air-handling unit serves to condition the air and provide the required air movement within a facility.\n\n### airlock\n\nAn enclosed space with two or more doors, which is interposed between two or more rooms, e.g. of differing classes of cleanliness, for the purpose of", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en su Informe T\u00e9cnico 957 aborda las instalaciones de fabricaci\u00f3n de productos farmac\u00e9uticos, enfatizando la importancia de considerarlas como instalaciones de contenci\u00f3n. Se describen varios aspectos clave para el funcionamiento efectivo de estas instalaciones, incluyendo el dise\u00f1o adecuado, controles de procesos, sistemas de control ambiental, y el uso de equipos de protecci\u00f3n personal. Adem\u00e1s, se proporciona un glosario de t\u00e9rminos relevantes, como \"l\u00edmite de acci\u00f3n\", \"ingrediente farmac\u00e9utico activo\" y \"unidad de tratamiento de aire\".\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los aspectos clave que deben considerarse para el dise\u00f1o y operaci\u00f3n efectiva de una instalaci\u00f3n de fabricaci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Los aspectos clave incluyen un dise\u00f1o y disposici\u00f3n adecuados de la instalaci\u00f3n, controles de procesos de fabricaci\u00f3n, sistemas de control ambiental, sistemas de extracci\u00f3n, uso de equipos de protecci\u00f3n personal, procedimientos de desvestido y descontaminaci\u00f3n, higiene industrial, vigilancia m\u00e9dica y controles administrativos.\n\n2. **\u00bfQu\u00e9 se entiende por \"l\u00edmite de acci\u00f3n\" en el contexto de las instalaciones de fabricaci\u00f3n farmac\u00e9utica?**\n   - Respuesta: El \"l\u00edmite de acci\u00f3n\" se alcanza cuando se superan los criterios de aceptaci\u00f3n de un par\u00e1metro cr\u00edtico. Los resultados que se encuentren fuera de estos l\u00edmites requerir\u00e1n acciones e investigaciones espec\u00edficas.\n\n3. **\u00bfQu\u00e9 es un \"air-handling unit\" (AHU) y cu\u00e1l es su funci\u00f3n en una instalaci\u00f3n de fabricaci\u00f3n?**\n   - Respuesta: Una \"unidad de tratamiento de aire\" (AHU) es un sistema que se encarga de acondicionar el aire y proporcionar el movimiento de aire requerido dentro de una instalaci\u00f3n, lo que es crucial para mantener las condiciones ambientales adecuadas en el proceso de fabricaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Objetivo de las Directrices**: Establecer buenas pr\u00e1cticas para instalaciones que manejan productos farmac\u00e9uticos con sustancias peligrosas, enfatizando la seguridad del personal y la protecci\u00f3n del medio ambiente, sin sustituir la legislaci\u00f3n nacional.\n\n2. **\u00c1reas de Aplicaci\u00f3n**: Las directrices son aplicables a todas las zonas donde el manejo de productos puede causar contaminaci\u00f3n cruzada, exposici\u00f3n del personal o descarga al medio ambiente, incluyendo instalaciones de investigaci\u00f3n y desarrollo, as\u00ed como sitios de fabricaci\u00f3n y almacenamiento de ingredientes farmac\u00e9uticos activos (APIs) y productos terminados.\n\n3. **Dise\u00f1o y Operaci\u00f3n de Instalaciones**: Las instalaciones deben ser dise\u00f1adas y operadas de acuerdo con los principios de buenas pr\u00e1cticas de manufactura (GMP), asegurando la calidad del producto y protegiendo a los operadores y al medio ambiente de los efectos nocivos de las sustancias peligrosas.\n\n4. **Instalaciones Autocontenidas**: Se recomienda que la producci\u00f3n de ciertos productos peligrosos se realice en instalaciones autocontenidas, que deben estar separadas por barreras f\u00edsicas y contar con entradas, instalaciones para el personal y sistemas de manejo de aire independientes.\n\n5. **Sistemas Cerrados**: Se sugiere que, siempre que sea posible, los productos se fabriquen en sistemas cerrados para minimizar la exposici\u00f3n y el riesgo de contaminaci\u00f3n.\n\n### Entidades\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Principios que deben seguir las instalaciones.\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Productos farmac\u00e9uticos que contienen sustancias peligrosas.\n- **Sustancias Peligrosas**: Hormonas, esteroides, citotoxinas y otros productos que pueden ser nocivos para la salud y el medio ambiente.\n- **Instalaciones Autocontenidas**: Espacios dise\u00f1ados para manejar productos peligrosos de manera segura y aislada.", "excerpt_keywords": "Keywords: containment facilities, active pharmaceutical ingredient, air-handling unit, manufacturing process controls, personal protective equipment"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d9bf7809-87f5-4749-9830-37bf38e77a7a", "node_type": "4", "metadata": {"page_label": "208", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 2.3\n\nIn general these manufacturing facilities should be regarded as containment facilities.\n\n## 2.4\n\nThe effective operation of a facility may require the combination of some or all of the following aspects:\n- Appropriate facility design and layout, with the emphasis on safely containing the materials being handled. Manufacturing processes using closed systems or barrier technology enhance operator and product protection;\n- Manufacturing process controls including adherence to standard operating procedures (SOPs);\n- Appropriately designed environmental control systems (ECS) or heating, ventilation and air-conditioning (HVAC);\n- Extraction systems;\n- Personal protective equipment (PPE);\n- Appropriate degowning and decontamination procedures;\n- Industrial hygiene (monitoring staff exposure levels);\n- Medical surveillance (monitoring staff exposure levels); and\n- Administrative controls.\n\n## 3. Glossary\n\nThe definitions given below apply to terms used in these guidelines. They may have a different meaning in other contexts.\n\n### action limit\n\nThe action limit is reached when the acceptance criteria of a critical parameter have been exceeded. Results outside these limits will require specified action and investigation.\n\n### active pharmaceutical ingredient (API)\n\nAny substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the body.\n\n### air-handling unit (AHU)\n\nThe air-handling unit serves to condition the air and provide the required air movement within a facility.\n\n### airlock\n\nAn enclosed space with two or more doors, which is interposed between two or more rooms, e.g. of differing classes of cleanliness, for the purpose of", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "f280e7b63f46521fd3c36e56500cb4bc0afd113da867a51b68ef7ee5453b5221", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 2.3\n\nIn general these manufacturing facilities should be regarded as containment facilities.\n\n## 2.4\n\nThe effective operation of a facility may require the combination of some or all of the following aspects:\n- Appropriate facility design and layout, with the emphasis on safely containing the materials being handled. Manufacturing processes using closed systems or barrier technology enhance operator and product protection;\n- Manufacturing process controls including adherence to standard operating procedures (SOPs);\n- Appropriately designed environmental control systems (ECS) or heating, ventilation and air-conditioning (HVAC);\n- Extraction systems;\n- Personal protective equipment (PPE);\n- Appropriate degowning and decontamination procedures;\n- Industrial hygiene (monitoring staff exposure levels);\n- Medical surveillance (monitoring staff exposure levels); and\n- Administrative controls.\n\n## 3. Glossary\n\nThe definitions given below apply to terms used in these guidelines. They may have a different meaning in other contexts.\n\n### action limit\n\nThe action limit is reached when the acceptance criteria of a critical parameter have been exceeded. Results outside these limits will require specified action and investigation.\n\n### active pharmaceutical ingredient (API)\n\nAny substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the body.\n\n### air-handling unit (AHU)\n\nThe air-handling unit serves to condition the air and provide the required air movement within a facility.\n\n### airlock\n\nAn enclosed space with two or more doors, which is interposed between two or more rooms, e.g. of differing classes of cleanliness, for the purpose of", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1995, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c0726ef1-ba31-4b83-99fd-cc6e156da529": {"__data__": {"id_": "c0726ef1-ba31-4b83-99fd-cc6e156da529", "embedding": null, "metadata": {"page_label": "209", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "controlling the airflow between those rooms when they need to be entered. An airlock is designed for and used by either people or goods (this can be a personnel airlock (PAL) or a material airlock (MAL)).\n\n**alert limit**  \nThe alert limit is reached when the normal operating range of a critical parameter has been exceeded, indicating that corrective measures may need to be taken to prevent the action limit being reached.\n\n**barrier technology**  \nA system designed to segregate people from the product, contain contaminants or segregate two areas, which could be a barrier isolator (BI) or a restricted access barrier system (RABS):\n\n- A BI is a unit supplied with high-efficiency particulate air (HEPA) filtered air that provides uncompromised continuous isolation of its interior from the external environment, including surrounding clean room air and personnel.\n- A RABS is a type of barrier system that reduces or eliminates interventions into the critical zone. In practice, its level of contamination control is less than that of a barrier isolator.\n\n**clean room**  \nA room or area with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation and retention of contaminants within the area.\n\n**commissioning**  \nCommissioning is the documented process of verifying that the equipment and systems are installed according to specifications, placing the equipment into active service and verifying its proper action. Commissioning takes place at the conclusion of project construction but prior to validation.\n\n**containment**  \nA process or device to contain product, dust or contaminants in one zone, preventing it from escaping to another zone.\n\n**contamination**  \nThe undesired introduction of impurities of a chemical or microbial nature, or of foreign matter, into or on to a starting material or intermediate, during production, sampling, packaging or repackaging, storage or transport.\n\n**cross-contamination**  \nContamination of a starting material, intermediate product or finished product with another starting material or material during production.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1l es la diferencia principal entre un Barrier Isolator (BI) y un Restricted Access Barrier System (RABS)?**\n   - **Respuesta:** La principal diferencia radica en el nivel de control de contaminaci\u00f3n. Un Barrier Isolator (BI) proporciona una aislamiento continuo e ininterrumpido del ambiente externo, utilizando aire filtrado de alta eficiencia (HEPA), mientras que un Restricted Access Barrier System (RABS) reduce o elimina las intervenciones en la zona cr\u00edtica, pero su nivel de control de contaminaci\u00f3n es inferior al de un BI.\n\n2. **\u00bfQu\u00e9 implica el proceso de \"commissioning\" en el contexto de la instalaci\u00f3n de equipos y sistemas?**\n   - **Respuesta:** El \"commissioning\" es el proceso documentado que verifica que los equipos y sistemas est\u00e1n instalados de acuerdo con las especificaciones, se ponen en servicio activo y se verifica su correcto funcionamiento. Este proceso se lleva a cabo al final de la construcci\u00f3n del proyecto, pero antes de la validaci\u00f3n.\n\n3. **\u00bfQu\u00e9 se entiende por \"cross-contamination\" y en qu\u00e9 etapa del proceso de producci\u00f3n puede ocurrir?**\n   - **Respuesta:** La \"cross-contamination\" se refiere a la contaminaci\u00f3n de un material inicial, producto intermedio o producto terminado con otro material durante el proceso de producci\u00f3n. Esto puede ocurrir en cualquier etapa del proceso, incluyendo la producci\u00f3n, muestreo, empaquetado o transporte.\n\n### Resumen de nivel superior del contexto circundante:\nEl contexto se centra en la gesti\u00f3n de la contaminaci\u00f3n en entornos controlados, como salas limpias, y describe tecnolog\u00edas y procesos dise\u00f1ados para prevenir la introducci\u00f3n de contaminantes. Se definen t\u00e9rminos clave como \"alert limit\", \"barrier technology\", \"clean room\", \"commissioning\", \"containment\", \"contamination\" y \"cross-contamination\", proporcionando una comprensi\u00f3n clara de las pr\u00e1cticas y sistemas necesarios para mantener la integridad de los productos en la producci\u00f3n y manipulaci\u00f3n de materiales sensibles.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS en su Informe T\u00e9cnico 957 aborda la importancia de las instalaciones de fabricaci\u00f3n farmac\u00e9utica, enfatizando que deben ser consideradas como instalaciones de contenci\u00f3n. A continuaci\u00f3n se presentan los temas clave y entidades relevantes:\n\n#### Temas Clave:\n1. **Contenci\u00f3n en Instalaciones de Fabricaci\u00f3n**: Se establece que estas instalaciones deben ser vistas como espacios de contenci\u00f3n para manejar materiales de manera segura.\n  \n2. **Aspectos para la Operaci\u00f3n Efectiva**:\n   - **Dise\u00f1o y Disposici\u00f3n de la Instalaci\u00f3n**: Enfoque en la contenci\u00f3n segura de los materiales.\n   - **Controles de Procesos de Fabricaci\u00f3n**: Cumplimiento de procedimientos operativos est\u00e1ndar (SOPs).\n   - **Sistemas de Control Ambiental**: Sistemas de control ambiental (ECS) y calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) adecuadamente dise\u00f1ados.\n   - **Sistemas de Extracci\u00f3n**: Importancia de sistemas para la extracci\u00f3n de contaminantes.\n   - **Equipos de Protecci\u00f3n Personal (PPE)**: Uso de PPE para la seguridad del personal.\n   - **Procedimientos de Desvestido y Descontaminaci\u00f3n**: Protocolos adecuados para la seguridad.\n   - **Higiene Industrial y Vigilancia M\u00e9dica**: Monitoreo de la exposici\u00f3n del personal.\n   - **Controles Administrativos**: Implementaci\u00f3n de controles administrativos para la gesti\u00f3n de riesgos.\n\n3. **Glosario de T\u00e9rminos**:\n   - **L\u00edmite de Acci\u00f3n**: Criterios que, al ser superados, requieren acciones espec\u00edficas.\n   - **Ingrediente Farmac\u00e9utico Activo (API)**: Sustancias utilizadas en la fabricaci\u00f3n de formas farmac\u00e9uticas que tienen efectos farmacol\u00f3gicos.\n   - **Unidad de Tratamiento de Aire (AHU)**: Sistema que acondiciona y mueve el aire dentro de la instalaci\u00f3n.\n   - **Airlock**: Espacio cerrado con dos o m\u00e1s puertas que separa \u00e1reas de diferentes niveles de limpieza.\n\n#### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Instalaciones de Fabricaci\u00f3n Farmac\u00e9utica**: Espacios donde se producen medicamentos.\n- **Personal de Salud**: Trabajadores que deben seguir los protocolos de seguridad y salud.\n- **Sistemas de Control Ambiental (ECS)**: Infraestructura para mantener condiciones ambientales adecuadas.\n- **Equipos de Protecci\u00f3n Personal (PPE)**: Herramientas y vestimenta para proteger al personal.\n\nEste resumen destaca la importancia de la seguridad y el control en las instalaciones de fabricaci\u00f3n farmac\u00e9utica, as\u00ed como la necesidad de seguir directrices espec\u00edficas para garantizar la protecci\u00f3n tanto de los productos como de los trabajadores.", "excerpt_keywords": "Keywords: airlock, barrier technology, clean room, commissioning, cross-contamination"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bcc4fd7f-a6b8-46c3-ab85-fd19aa2718f8", "node_type": "4", "metadata": {"page_label": "209", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "controlling the airflow between those rooms when they need to be entered. An airlock is designed for and used by either people or goods (this can be a personnel airlock (PAL) or a material airlock (MAL)).\n\n**alert limit**  \nThe alert limit is reached when the normal operating range of a critical parameter has been exceeded, indicating that corrective measures may need to be taken to prevent the action limit being reached.\n\n**barrier technology**  \nA system designed to segregate people from the product, contain contaminants or segregate two areas, which could be a barrier isolator (BI) or a restricted access barrier system (RABS):\n\n- A BI is a unit supplied with high-efficiency particulate air (HEPA) filtered air that provides uncompromised continuous isolation of its interior from the external environment, including surrounding clean room air and personnel.\n- A RABS is a type of barrier system that reduces or eliminates interventions into the critical zone. In practice, its level of contamination control is less than that of a barrier isolator.\n\n**clean room**  \nA room or area with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation and retention of contaminants within the area.\n\n**commissioning**  \nCommissioning is the documented process of verifying that the equipment and systems are installed according to specifications, placing the equipment into active service and verifying its proper action. Commissioning takes place at the conclusion of project construction but prior to validation.\n\n**containment**  \nA process or device to contain product, dust or contaminants in one zone, preventing it from escaping to another zone.\n\n**contamination**  \nThe undesired introduction of impurities of a chemical or microbial nature, or of foreign matter, into or on to a starting material or intermediate, during production, sampling, packaging or repackaging, storage or transport.\n\n**cross-contamination**  \nContamination of a starting material, intermediate product or finished product with another starting material or material during production.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "07d2016b5638aa1e24bb48f893063eb9b07711180e10ef56cfac2e4ca9bae2c0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "controlling the airflow between those rooms when they need to be entered. An airlock is designed for and used by either people or goods (this can be a personnel airlock (PAL) or a material airlock (MAL)).\n\n**alert limit**  \nThe alert limit is reached when the normal operating range of a critical parameter has been exceeded, indicating that corrective measures may need to be taken to prevent the action limit being reached.\n\n**barrier technology**  \nA system designed to segregate people from the product, contain contaminants or segregate two areas, which could be a barrier isolator (BI) or a restricted access barrier system (RABS):\n\n- A BI is a unit supplied with high-efficiency particulate air (HEPA) filtered air that provides uncompromised continuous isolation of its interior from the external environment, including surrounding clean room air and personnel.\n- A RABS is a type of barrier system that reduces or eliminates interventions into the critical zone. In practice, its level of contamination control is less than that of a barrier isolator.\n\n**clean room**  \nA room or area with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation and retention of contaminants within the area.\n\n**commissioning**  \nCommissioning is the documented process of verifying that the equipment and systems are installed according to specifications, placing the equipment into active service and verifying its proper action. Commissioning takes place at the conclusion of project construction but prior to validation.\n\n**containment**  \nA process or device to contain product, dust or contaminants in one zone, preventing it from escaping to another zone.\n\n**contamination**  \nThe undesired introduction of impurities of a chemical or microbial nature, or of foreign matter, into or on to a starting material or intermediate, during production, sampling, packaging or repackaging, storage or transport.\n\n**cross-contamination**  \nContamination of a starting material, intermediate product or finished product with another starting material or material during production.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2165, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a13f61d4-1159-4ada-9416-d580bdcb5b1d": {"__data__": {"id_": "a13f61d4-1159-4ada-9416-d580bdcb5b1d", "embedding": null, "metadata": {"page_label": "210", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# design condition\n\nDesign condition relates to the specified range or accuracy of a controlled variable used by the designer as a basis for determining the performance requirements of an engineered system.\n\n# environmental control system (ECS)\n\nEnvironmental control system, also referred to as heating, ventilation and air-conditioning (HVAC).\n\n# facility\n\nThe built environment within which the clean area installation and associated controlled environments operate together with their supporting infrastructure.\n\n# hazardous substance or product\n\nA product or substance that may present a substantial risk of injury, to health or to the environment.\n\n# heating, ventilation and air-conditioning (HVAC)\n\nHeating, ventilation and air-conditioning, also referred to as environmental control system (ECS).\n\n# high efficiency particulate air (HEPA) filter\n\nHigh efficiency particulate air filter.\n\n# ISO 14644\n\nInternational standard relating to the design, classification and testing of clean environments (5).\n\n# laminar airflow (LAF)\n\nA rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (modern standards no longer refer to laminar flow, but have adopted the term unidirectional airflow).\n\n# normal operating range\n\nThe range that the manufacturer selects as the acceptable values for a parameter during normal operations. This range must be within the operating range.\n\n# occupational exposure level (OEL)\n\nAirborne concentration of substances that will not result in adverse effects to most healthy workers, exposed for 8 hours/day, 40 hours/week.\n\n# operating range\n\nThe range of validated critical parameters within which acceptable products can be manufactured.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1l es la diferencia entre el rango de operaci\u00f3n normal y el rango de operaci\u00f3n en el contexto de un sistema de control ambiental?**\n   - Respuesta: El rango de operaci\u00f3n normal es el rango que el fabricante selecciona como valores aceptables para un par\u00e1metro durante las operaciones normales, mientras que el rango de operaci\u00f3n se refiere a los par\u00e1metros cr\u00edticos validados dentro de los cuales se pueden fabricar productos aceptables.\n\n2. **\u00bfQu\u00e9 implica el t\u00e9rmino \"flujo de aire laminar\" y c\u00f3mo ha evolucionado su definici\u00f3n en los est\u00e1ndares modernos?**\n   - Respuesta: El flujo de aire laminar se refiere a un flujo de aire rectificado sobre toda el \u00e1rea transversal de una zona limpia con una velocidad constante y l\u00edneas de corriente aproximadamente paralelas. Sin embargo, los est\u00e1ndares modernos ya no utilizan el t\u00e9rmino \"flujo laminar\" y han adoptado el t\u00e9rmino \"flujo unidireccional\".\n\n3. **\u00bfQu\u00e9 es un filtro HEPA y cu\u00e1l es su importancia en un sistema de control ambiental?**\n   - Respuesta: Un filtro HEPA (High Efficiency Particulate Air) es un tipo de filtro que captura part\u00edculas muy peque\u00f1as y es crucial en sistemas de control ambiental para mantener la calidad del aire y proteger tanto la salud humana como el medio ambiente.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona definiciones y conceptos clave relacionados con el dise\u00f1o y operaci\u00f3n de sistemas de control ambiental, espec\u00edficamente en entornos limpios. Se abordan t\u00e9rminos como condiciones de dise\u00f1o, sistemas de control ambiental (HVAC), filtros HEPA, y est\u00e1ndares internacionales como ISO 14644. Tambi\u00e9n se discuten conceptos de seguridad laboral, como el nivel de exposici\u00f3n ocupacional (OEL), y se clarifican diferencias entre rangos de operaci\u00f3n y condiciones normales de operaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Airlock**: Dispositivo dise\u00f1ado para controlar el flujo de aire entre habitaciones, utilizado para personas (PAL) o bienes (MAL).\n\n2. **Alert Limit**: Umbral que indica que un par\u00e1metro cr\u00edtico ha superado su rango operativo normal, sugiriendo la necesidad de medidas correctivas.\n\n3. **Barrier Technology**: Sistemas que segregan personas del producto y contienen contaminantes. Incluye:\n   - **Barrier Isolator (BI)**: Proporciona aislamiento continuo con aire filtrado HEPA.\n   - **Restricted Access Barrier System (RABS)**: Reduce intervenciones en la zona cr\u00edtica, con menor control de contaminaci\u00f3n que un BI.\n\n4. **Clean Room**: \u00c1rea con control ambiental para minimizar la contaminaci\u00f3n particulada y microbiana.\n\n5. **Commissioning**: Proceso documentado que verifica la instalaci\u00f3n y funcionamiento correcto de equipos y sistemas, realizado al final de la construcci\u00f3n y antes de la validaci\u00f3n.\n\n6. **Containment**: M\u00e9todos o dispositivos que evitan que productos o contaminantes escapen de una zona espec\u00edfica.\n\n7. **Contamination**: Introducci\u00f3n no deseada de impurezas qu\u00edmicas, microbianas o materia extra\u00f1a en materiales durante diversas etapas de producci\u00f3n.\n\n8. **Cross-Contamination**: Contaminaci\u00f3n de un material inicial, intermedio o terminado con otro material durante el proceso de producci\u00f3n.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que proporciona directrices sobre pr\u00e1cticas de control de contaminaci\u00f3n.\n- **HEPA (High-Efficiency Particulate Air)**: Tipo de filtro utilizado en sistemas de aislamiento para mantener la pureza del aire.\n- **Materiales Sensibles**: Productos que requieren un entorno controlado para evitar contaminaci\u00f3n.\n\nEste resumen abarca los conceptos fundamentales relacionados con la gesti\u00f3n de la contaminaci\u00f3n en entornos controlados, destacando la importancia de las tecnolog\u00edas y procesos para mantener la integridad de los productos.", "excerpt_keywords": "Keywords: design condition, environmental control system, HEPA filter, ISO 14644, occupational exposure level"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e8a3be29-739f-4b9e-9a6c-838136d2f009", "node_type": "4", "metadata": {"page_label": "210", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# design condition\n\nDesign condition relates to the specified range or accuracy of a controlled variable used by the designer as a basis for determining the performance requirements of an engineered system.\n\n# environmental control system (ECS)\n\nEnvironmental control system, also referred to as heating, ventilation and air-conditioning (HVAC).\n\n# facility\n\nThe built environment within which the clean area installation and associated controlled environments operate together with their supporting infrastructure.\n\n# hazardous substance or product\n\nA product or substance that may present a substantial risk of injury, to health or to the environment.\n\n# heating, ventilation and air-conditioning (HVAC)\n\nHeating, ventilation and air-conditioning, also referred to as environmental control system (ECS).\n\n# high efficiency particulate air (HEPA) filter\n\nHigh efficiency particulate air filter.\n\n# ISO 14644\n\nInternational standard relating to the design, classification and testing of clean environments (5).\n\n# laminar airflow (LAF)\n\nA rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (modern standards no longer refer to laminar flow, but have adopted the term unidirectional airflow).\n\n# normal operating range\n\nThe range that the manufacturer selects as the acceptable values for a parameter during normal operations. This range must be within the operating range.\n\n# occupational exposure level (OEL)\n\nAirborne concentration of substances that will not result in adverse effects to most healthy workers, exposed for 8 hours/day, 40 hours/week.\n\n# operating range\n\nThe range of validated critical parameters within which acceptable products can be manufactured.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "4635c3823ebbecfde44bf918f0ee8a2bf2968183dcf3c63318b0f4f1cd1ca7bd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# design condition\n\nDesign condition relates to the specified range or accuracy of a controlled variable used by the designer as a basis for determining the performance requirements of an engineered system.\n\n# environmental control system (ECS)\n\nEnvironmental control system, also referred to as heating, ventilation and air-conditioning (HVAC).\n\n# facility\n\nThe built environment within which the clean area installation and associated controlled environments operate together with their supporting infrastructure.\n\n# hazardous substance or product\n\nA product or substance that may present a substantial risk of injury, to health or to the environment.\n\n# heating, ventilation and air-conditioning (HVAC)\n\nHeating, ventilation and air-conditioning, also referred to as environmental control system (ECS).\n\n# high efficiency particulate air (HEPA) filter\n\nHigh efficiency particulate air filter.\n\n# ISO 14644\n\nInternational standard relating to the design, classification and testing of clean environments (5).\n\n# laminar airflow (LAF)\n\nA rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (modern standards no longer refer to laminar flow, but have adopted the term unidirectional airflow).\n\n# normal operating range\n\nThe range that the manufacturer selects as the acceptable values for a parameter during normal operations. This range must be within the operating range.\n\n# occupational exposure level (OEL)\n\nAirborne concentration of substances that will not result in adverse effects to most healthy workers, exposed for 8 hours/day, 40 hours/week.\n\n# operating range\n\nThe range of validated critical parameters within which acceptable products can be manufactured.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1751, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9e38393f-db0f-4165-907e-8ac4c34579f7": {"__data__": {"id_": "9e38393f-db0f-4165-907e-8ac4c34579f7", "embedding": null, "metadata": {"page_label": "211", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "personal protective equipment (PPE)  \nThe necessary garments and equipment required to protect the operator in the workplace.\n\npressure cascade  \nA process whereby air flows from one area, which is maintained at a higher pressure, to another area at a lower pressure.\n\nqualification  \nThe planning, carrying out and recording of tests on equipment and a system, which forms part of the validated process, to demonstrate that it will perform as intended.\n\nstandard operating procedure (SOP)  \nAn authorized written procedure, giving instructions for performing operations, not necessarily specific to a given product or material, but of a more general nature (e.g. operation of equipment, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation.\n\nunidirectional airflow (UDAF)  \nA rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines.\n\nvalidation  \nThe documented act of proving that any procedure, process, equipment, material, activity or system actually leads to the expected results.\n\n# 4. Risk assessment\n\n4.1 Not all products containing hazardous substances are equally potent and risk assessments should be carried out to determine the potential hazards to operators and to the environment. The risk assessment should also determine which phases of the product production and control cycles, from manufacture of the API to distribution of the finished product, would fall under the requirements of these guidelines. Risk assessments applicable to the environment should include airborne contamination as well as liquid effluent contamination.\n\n4.2 Assuming that the risk assessment determines that the products or materials being handled pose a risk to the operators and/or the public and/or the environment, the guidelines to be followed for the design and operation of the facility should be as detailed in this document.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es un informe t\u00e9cnico de la OMS que aborda la seguridad en el manejo de productos que contienen sustancias peligrosas. Se definen t\u00e9rminos clave como equipo de protecci\u00f3n personal (PPE), flujo de aire unidireccional (UDAF), y procedimientos operativos est\u00e1ndar (SOP). Adem\u00e1s, se enfatiza la importancia de realizar evaluaciones de riesgo para identificar peligros potenciales para los operadores y el medio ambiente, as\u00ed como para determinar las fases de producci\u00f3n que deben cumplir con las directrices establecidas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los componentes esenciales que deben incluirse en una evaluaci\u00f3n de riesgo seg\u00fan el documento?**\n   - Esta pregunta busca detalles sobre los elementos espec\u00edficos que deben considerarse al realizar una evaluaci\u00f3n de riesgo, que no se encuentran expl\u00edcitamente en otras fuentes.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse si la evaluaci\u00f3n de riesgo indica que los productos manejados representan un riesgo para los operadores o el medio ambiente?**\n   - Esta pregunta se centra en las acciones concretas que deben tomarse en respuesta a los hallazgos de la evaluaci\u00f3n de riesgo, proporcionando informaci\u00f3n que puede no estar disponible en otros documentos.\n\n3. **\u00bfC\u00f3mo se define y qu\u00e9 importancia tiene la validaci\u00f3n en el contexto de la producci\u00f3n de productos farmac\u00e9uticos seg\u00fan el informe?**\n   - Esta pregunta busca una comprensi\u00f3n m\u00e1s profunda de la funci\u00f3n de la validaci\u00f3n en el proceso de producci\u00f3n, un aspecto cr\u00edtico que puede no estar claramente delineado en otras fuentes. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y detallada que se encuentra en el contexto del documento, lo que puede no estar disponible en otros lugares.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Condiciones de Dise\u00f1o**: Se refiere al rango o precisi\u00f3n especificada de una variable controlada que el dise\u00f1ador utiliza para determinar los requisitos de rendimiento de un sistema ingenierizado.\n\n2. **Sistema de Control Ambiental (ECS)**: Tambi\u00e9n conocido como calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC), es fundamental para mantener condiciones ambientales adecuadas en entornos controlados.\n\n3. **Instalaciones**: El entorno construido donde operan las instalaciones de \u00e1reas limpias y sus infraestructuras de soporte.\n\n4. **Sustancias o Productos Peligrosos**: Productos o sustancias que pueden representar un riesgo significativo para la salud o el medio ambiente.\n\n5. **Filtro HEPA**: Filtro de aire de alta eficiencia que captura part\u00edculas muy peque\u00f1as, esencial para mantener la calidad del aire en sistemas de control ambiental.\n\n6. **Norma ISO 14644**: Est\u00e1ndar internacional relacionado con el dise\u00f1o, clasificaci\u00f3n y prueba de entornos limpios.\n\n7. **Flujo de Aire Laminar (LAF)**: Flujo de aire rectificado en una zona limpia, que ha evolucionado en los est\u00e1ndares modernos a ser denominado \"flujo unidireccional\".\n\n8. **Rango de Operaci\u00f3n Normal**: Rango de valores aceptables seleccionados por el fabricante para un par\u00e1metro durante operaciones normales.\n\n9. **Nivel de Exposici\u00f3n Ocupacional (OEL)**: Concentraci\u00f3n de sustancias en el aire que no causar\u00e1 efectos adversos en la mayor\u00eda de los trabajadores sanos expuestos durante un tiempo determinado.\n\n10. **Rango de Operaci\u00f3n**: Rango de par\u00e1metros cr\u00edticos validados dentro del cual se pueden fabricar productos aceptables.\n\n### Entidades Clave\n- **ECS** (Sistema de Control Ambiental)\n- **HVAC** (Calefacci\u00f3n, Ventilaci\u00f3n y Aire Acondicionado)\n- **HEPA** (Filtro de Aire de Alta Eficiencia)\n- **ISO 14644** (Norma Internacional)\n- **OEL** (Nivel de Exposici\u00f3n Ocupacional)\n\nEste resumen abarca los conceptos y t\u00e9rminos esenciales relacionados con el dise\u00f1o y operaci\u00f3n de sistemas de control ambiental, as\u00ed como las normativas y est\u00e1ndares relevantes en el contexto de entornos limpios.", "excerpt_keywords": "Keywords: personal protective equipment, risk assessment, validation, standard operating procedure, unidirectional airflow"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "64879eaf-d04a-442e-9cb1-4be5af1cc984", "node_type": "4", "metadata": {"page_label": "211", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "personal protective equipment (PPE)  \nThe necessary garments and equipment required to protect the operator in the workplace.\n\npressure cascade  \nA process whereby air flows from one area, which is maintained at a higher pressure, to another area at a lower pressure.\n\nqualification  \nThe planning, carrying out and recording of tests on equipment and a system, which forms part of the validated process, to demonstrate that it will perform as intended.\n\nstandard operating procedure (SOP)  \nAn authorized written procedure, giving instructions for performing operations, not necessarily specific to a given product or material, but of a more general nature (e.g. operation of equipment, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation.\n\nunidirectional airflow (UDAF)  \nA rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines.\n\nvalidation  \nThe documented act of proving that any procedure, process, equipment, material, activity or system actually leads to the expected results.\n\n# 4. Risk assessment\n\n4.1 Not all products containing hazardous substances are equally potent and risk assessments should be carried out to determine the potential hazards to operators and to the environment. The risk assessment should also determine which phases of the product production and control cycles, from manufacture of the API to distribution of the finished product, would fall under the requirements of these guidelines. Risk assessments applicable to the environment should include airborne contamination as well as liquid effluent contamination.\n\n4.2 Assuming that the risk assessment determines that the products or materials being handled pose a risk to the operators and/or the public and/or the environment, the guidelines to be followed for the design and operation of the facility should be as detailed in this document.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "89207c884ab384b28c4ca06eb28c3c55b90c0ff07e4cf9acc9dd914b38a479bd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "personal protective equipment (PPE)  \nThe necessary garments and equipment required to protect the operator in the workplace.\n\npressure cascade  \nA process whereby air flows from one area, which is maintained at a higher pressure, to another area at a lower pressure.\n\nqualification  \nThe planning, carrying out and recording of tests on equipment and a system, which forms part of the validated process, to demonstrate that it will perform as intended.\n\nstandard operating procedure (SOP)  \nAn authorized written procedure, giving instructions for performing operations, not necessarily specific to a given product or material, but of a more general nature (e.g. operation of equipment, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation.\n\nunidirectional airflow (UDAF)  \nA rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines.\n\nvalidation  \nThe documented act of proving that any procedure, process, equipment, material, activity or system actually leads to the expected results.\n\n# 4. Risk assessment\n\n4.1 Not all products containing hazardous substances are equally potent and risk assessments should be carried out to determine the potential hazards to operators and to the environment. The risk assessment should also determine which phases of the product production and control cycles, from manufacture of the API to distribution of the finished product, would fall under the requirements of these guidelines. Risk assessments applicable to the environment should include airborne contamination as well as liquid effluent contamination.\n\n4.2 Assuming that the risk assessment determines that the products or materials being handled pose a risk to the operators and/or the public and/or the environment, the guidelines to be followed for the design and operation of the facility should be as detailed in this document.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2063, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d31f8a17-4964-4982-a99e-d92cf0b7cdec": {"__data__": {"id_": "d31f8a17-4964-4982-a99e-d92cf0b7cdec", "embedding": null, "metadata": {"page_label": "212", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.3 \nThe toxicological data available, such as permissible occupational exposure levels (OEL) for the product, should be taken into account when conducting the risk assessment.\n\n4.4 The risk assessment should take into account the national or international occupational health and safety requirements for OELs in the work environment.\n\n## 5. Product protection\n\n5.1 The requirement for producing quality products, with respect to protection from contamination and cross-contamination, clean room class of air, temperature and humidity should be as for other pharmaceutical products. These requirements are covered in other WHO GMP guidelines.\n\n## 6. Personal protection equipment and breathing air systems\n\n6.1 The fundamental design principle for a facility and its production equipment is to provide product containment and operator protection. Should the facility and equipment design not provide adequate product containment, operator protection should be provided. If facility and equipment design are adequate, a spillage or non-routine incident could cause a hazardous situation, in which case PPE should be available. Unless otherwise specified in the material safety data sheet, operators should be protected from exposure with an appropriate method, such as by wearing:\n\n- flash-spun, high-density polyethylene fibre material suits or impervious washable protective suits. Integral hoods may be required depending on the respirator type used;\n- flash-spun, high-density polyethylene fibre material shoes, lower leg covers or cleanable boots;\n- suitable single-use, disposable gloves. Double gloves should be worn where direct active contact with the product cannot be avoided. Gloves should be taped or sealed on to the protective suit sleeves; and\n- respirator eye and face protection with associated breathing air systems.\n\n6.2 Where breathing air systems are used, these should be provided to supply safe breathing air to the operators to prevent them from inhaling air from within the facility. Personnel should be appropriately trained and assessed in the use of these systems before they can enter the area. The breathing air systems should comprise a protective face mask, which should form an integral part of a protective suit. The breathing air systems could be any of the systems described below:", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Evaluaci\u00f3n de riesgos y OELs**: La evaluaci\u00f3n de riesgos en el entorno laboral debe considerar los niveles de exposici\u00f3n ocupacional permisibles (OEL) y cumplir con las normativas nacionales e internacionales de salud y seguridad ocupacional.\n\n2. **Protecci\u00f3n del producto**: La producci\u00f3n de productos farmac\u00e9uticos debe seguir estrictas normas de calidad para evitar la contaminaci\u00f3n y garantizar condiciones adecuadas de aire, temperatura y humedad, aline\u00e1ndose con las directrices de Buenas Pr\u00e1cticas de Manufactura (GMP) de la OMS.\n\n3. **Equipos de protecci\u00f3n personal (EPP)**: Se deben implementar medidas de protecci\u00f3n para los operadores, incluyendo el uso de equipos de protecci\u00f3n personal adecuados y sistemas de aire respirable, especialmente en situaciones de derrames o incidentes no rutinarios.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los requisitos espec\u00edficos para el dise\u00f1o de instalaciones y equipos en relaci\u00f3n con la contenci\u00f3n del producto y la protecci\u00f3n del operador?**\n   - Esta pregunta busca detalles sobre las normas de dise\u00f1o que deben seguirse para garantizar la seguridad en la producci\u00f3n, que no se encuentran expl\u00edcitamente en otras secciones del documento.\n\n2. **\u00bfQu\u00e9 tipo de formaci\u00f3n y evaluaci\u00f3n se requiere para el personal que utiliza sistemas de aire respirable en el entorno de trabajo?**\n   - Esta pregunta se centra en los requisitos de capacitaci\u00f3n y evaluaci\u00f3n del personal, un aspecto cr\u00edtico para la seguridad que puede no estar ampliamente cubierto en otras fuentes.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse si el dise\u00f1o de la instalaci\u00f3n y el equipo no proporciona una contenci\u00f3n adecuada del producto?**\n   - Esta pregunta aborda las acciones correctivas y las medidas de protecci\u00f3n adicionales que deben implementarse en caso de que el dise\u00f1o no cumpla con los est\u00e1ndares de seguridad, un tema que puede no ser tratado en otros documentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Equipo de Protecci\u00f3n Personal (PPE)**: Se refiere a las prendas y equipos necesarios para proteger a los operadores en el lugar de trabajo.\n\n2. **Flujo de Aire Unidireccional (UDAF)**: Describe un flujo de aire rectificado en una zona limpia, caracterizado por una velocidad constante y l\u00edneas de corriente aproximadamente paralelas.\n\n3. **Procedimientos Operativos Est\u00e1ndar (SOP)**: Son procedimientos escritos autorizados que proporcionan instrucciones para realizar operaciones de manera general, no necesariamente espec\u00edficas para un producto o material.\n\n4. **Validaci\u00f3n**: Es el acto documentado de demostrar que un procedimiento, proceso, equipo, material, actividad o sistema produce los resultados esperados.\n\n5. **Evaluaci\u00f3n de Riesgo**: Se enfatiza la importancia de realizar evaluaciones de riesgo para identificar peligros potenciales para los operadores y el medio ambiente. Esto incluye la evaluaci\u00f3n de la contaminaci\u00f3n a\u00e9rea y de efluentes l\u00edquidos.\n\n6. **Fases de Producci\u00f3n**: La evaluaci\u00f3n de riesgo debe determinar qu\u00e9 fases del ciclo de producci\u00f3n y control, desde la fabricaci\u00f3n del ingrediente activo (API) hasta la distribuci\u00f3n del producto terminado, deben cumplir con las directrices establecidas.\n\n### Entidades Clave\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe t\u00e9cnico.\n- **Sustancias Peligrosas**: Productos que requieren un manejo cuidadoso debido a su potencial riesgo.\n- **Operadores**: Personas que manejan productos que contienen sustancias peligrosas.\n- **Medio Ambiente**: Consideraci\u00f3n importante en las evaluaciones de riesgo.\n\nEste resumen destaca los conceptos fundamentales y las entidades relevantes en el contexto de la seguridad en el manejo de productos peligrosos, tal como se detalla en el documento de la OMS.", "excerpt_keywords": "Keywords: risk assessment, occupational exposure levels, personal protective equipment, product protection, breathing air systems"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "18efe620-ecfe-4da3-bed9-032a52084a73", "node_type": "4", "metadata": {"page_label": "212", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.3 \nThe toxicological data available, such as permissible occupational exposure levels (OEL) for the product, should be taken into account when conducting the risk assessment.\n\n4.4 The risk assessment should take into account the national or international occupational health and safety requirements for OELs in the work environment.\n\n## 5. Product protection\n\n5.1 The requirement for producing quality products, with respect to protection from contamination and cross-contamination, clean room class of air, temperature and humidity should be as for other pharmaceutical products. These requirements are covered in other WHO GMP guidelines.\n\n## 6. Personal protection equipment and breathing air systems\n\n6.1 The fundamental design principle for a facility and its production equipment is to provide product containment and operator protection. Should the facility and equipment design not provide adequate product containment, operator protection should be provided. If facility and equipment design are adequate, a spillage or non-routine incident could cause a hazardous situation, in which case PPE should be available. Unless otherwise specified in the material safety data sheet, operators should be protected from exposure with an appropriate method, such as by wearing:\n\n- flash-spun, high-density polyethylene fibre material suits or impervious washable protective suits. Integral hoods may be required depending on the respirator type used;\n- flash-spun, high-density polyethylene fibre material shoes, lower leg covers or cleanable boots;\n- suitable single-use, disposable gloves. Double gloves should be worn where direct active contact with the product cannot be avoided. Gloves should be taped or sealed on to the protective suit sleeves; and\n- respirator eye and face protection with associated breathing air systems.\n\n6.2 Where breathing air systems are used, these should be provided to supply safe breathing air to the operators to prevent them from inhaling air from within the facility. Personnel should be appropriately trained and assessed in the use of these systems before they can enter the area. The breathing air systems should comprise a protective face mask, which should form an integral part of a protective suit. The breathing air systems could be any of the systems described below:", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "2fd31ca67879e6ee30120262850c966e54444302ac0e7ae44ff93d5d27638c25", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.3 \nThe toxicological data available, such as permissible occupational exposure levels (OEL) for the product, should be taken into account when conducting the risk assessment.\n\n4.4 The risk assessment should take into account the national or international occupational health and safety requirements for OELs in the work environment.\n\n## 5. Product protection\n\n5.1 The requirement for producing quality products, with respect to protection from contamination and cross-contamination, clean room class of air, temperature and humidity should be as for other pharmaceutical products. These requirements are covered in other WHO GMP guidelines.\n\n## 6. Personal protection equipment and breathing air systems\n\n6.1 The fundamental design principle for a facility and its production equipment is to provide product containment and operator protection. Should the facility and equipment design not provide adequate product containment, operator protection should be provided. If facility and equipment design are adequate, a spillage or non-routine incident could cause a hazardous situation, in which case PPE should be available. Unless otherwise specified in the material safety data sheet, operators should be protected from exposure with an appropriate method, such as by wearing:\n\n- flash-spun, high-density polyethylene fibre material suits or impervious washable protective suits. Integral hoods may be required depending on the respirator type used;\n- flash-spun, high-density polyethylene fibre material shoes, lower leg covers or cleanable boots;\n- suitable single-use, disposable gloves. Double gloves should be worn where direct active contact with the product cannot be avoided. Gloves should be taped or sealed on to the protective suit sleeves; and\n- respirator eye and face protection with associated breathing air systems.\n\n6.2 Where breathing air systems are used, these should be provided to supply safe breathing air to the operators to prevent them from inhaling air from within the facility. Personnel should be appropriately trained and assessed in the use of these systems before they can enter the area. The breathing air systems should comprise a protective face mask, which should form an integral part of a protective suit. The breathing air systems could be any of the systems described below:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2319, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c6a9ed63-7cb6-443e-9ba2-1b281492946a": {"__data__": {"id_": "c6a9ed63-7cb6-443e-9ba2-1b281492946a", "embedding": null, "metadata": {"page_label": "213", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- a central air supply system which connects to the operator\u2019s face mask by means of flexible hoses and quick coupling sockets, also called an airline respirator (AR). The air connection should incorporate a one-way air system to prevent contaminated air entering the face mask during connection or disconnection. The air supply should be treated to ensure a temperature and level of humidity that are comfortable for the operator. The air source could be a high pressure fan or an air compressor. If an air compressor is used, it should be of the oil-free type or have suitable oil removal filters fitted;\n- a self-contained breathing apparatus (SCBA) or powered air purifying respirator (PAPR) that is securely attached to the operator\u2019s belt and connects to the operator\u2019s face mask. This system draws air from the room in which the operator is working and the air supply is delivered to the face mask by means of a battery-driven fan. The AR provides superior protection to the PAPR apparatus;\n- for zones with lower contamination levels, a half-mask high efficiency particulate air filter (HEPA) cartridge respirator of N95-type paper filter mask may be acceptable.\n\n6.3 The selection of the respirator type is based on the relationship between the accepted OEL and the respirator-certified protection factor (PF).\n\n6.4 The air supplies should be filtered through a final filter, which should be a HEPA filter rated as an H13 filter according to EN 1822 (European Norm). The supply of breathing air into the face mask and/or protective suit should result in the interior of the mask and suit being at a positive pressure relative to the facility environment.\n\n6.5 Central breathing air supply systems should have a 100% back-up system in the event of the main system failing. This could be in the form of a gas bottle system with at least 5 minutes supply. Changeover from the normal supply to the back-up supply should be automatic. The system should have a monitoring system and send alarm signals to a permanently manned location in the following situations:\n\n- failure of main air supply;\n- temperature out of specification (OOS);\n- humidity OOS;\n- carbon dioxide (CO2) OOS;\n- carbon monoxide (CO) OOS; and\n- sulfur dioxide (SO2) OOS.\n\n6.6 Breathing air should be filtered by means of pre-filters, coalescing filters and final filters to have the minimum air quality specifications of ISO 8573-1 3-9-1 and EN 12021:1999.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Sistemas de suministro de aire respirable**: El documento describe diferentes tipos de sistemas de suministro de aire respirable, incluyendo respiradores de aire central, aparatos de respiraci\u00f3n aut\u00f3nomos (SCBA) y respiradores de purificaci\u00f3n de aire impulsados (PAPR). Se enfatiza la importancia de la calidad del aire y la presi\u00f3n positiva en las m\u00e1scaras y trajes de protecci\u00f3n.\n\n2. **Selecci\u00f3n y filtraci\u00f3n de respiradores**: La selecci\u00f3n del tipo de respirador se basa en la relaci\u00f3n entre el l\u00edmite de exposici\u00f3n ocupacional (OEL) aceptado y el factor de protecci\u00f3n certificado del respirador. Adem\u00e1s, se requiere que el aire suministrado est\u00e9 filtrado adecuadamente para cumplir con normas espec\u00edficas de calidad del aire.\n\n3. **Sistemas de respaldo y monitoreo**: Se establece que los sistemas de suministro de aire central deben contar con un sistema de respaldo del 100% en caso de fallo del sistema principal, as\u00ed como un sistema de monitoreo que alerte sobre diversas condiciones fuera de especificaci\u00f3n, como temperatura, humedad y niveles de gases peligrosos.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de filtros se requieren para asegurar la calidad del aire en los sistemas de suministro de respiradores seg\u00fan el documento?**\n   - Respuesta: Se requieren pre-filtros, filtros coalescentes y filtros finales que cumplan con las especificaciones m\u00ednimas de calidad del aire de ISO 8573-1 3-9-1 y EN 12021:1999.\n\n2. **\u00bfCu\u00e1les son las condiciones que deben ser monitoreadas en un sistema de suministro de aire respirable y que pueden activar una alarma?**\n   - Respuesta: Las condiciones que deben ser monitoreadas incluyen la falla del suministro de aire principal, temperatura fuera de especificaci\u00f3n, humedad fuera de especificaci\u00f3n, y niveles de di\u00f3xido de carbono (CO2), mon\u00f3xido de carbono (CO) y di\u00f3xido de azufre (SO2) fuera de especificaci\u00f3n.\n\n3. **\u00bfQu\u00e9 caracter\u00edsticas debe tener un compresor de aire si se utiliza en un sistema de suministro de aire respirable?**\n   - Respuesta: Si se utiliza un compresor de aire, debe ser del tipo libre de aceite o tener filtros de eliminaci\u00f3n de aceite adecuados instalados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Evaluaci\u00f3n de Riesgos**:\n   - Importancia de considerar los niveles de exposici\u00f3n ocupacional permisibles (OEL) en la evaluaci\u00f3n de riesgos.\n   - Necesidad de cumplir con normativas nacionales e internacionales de salud y seguridad ocupacional.\n\n2. **Protecci\u00f3n del Producto**:\n   - Requisitos para la producci\u00f3n de productos farmac\u00e9uticos, incluyendo la protecci\u00f3n contra contaminaci\u00f3n y condiciones controladas de aire, temperatura y humedad.\n   - Referencia a las directrices de Buenas Pr\u00e1cticas de Manufactura (GMP) de la OMS.\n\n3. **Equipos de Protecci\u00f3n Personal (EPP)**:\n   - Dise\u00f1o de instalaciones y equipos debe garantizar la contenci\u00f3n del producto y la protecci\u00f3n del operador.\n   - Uso de EPP adecuado en caso de incidentes, incluyendo trajes, guantes y protecci\u00f3n respiratoria.\n   - Provisi\u00f3n de sistemas de aire respirable para proteger a los operadores de la inhalaci\u00f3n de aire contaminado.\n\n4. **Formaci\u00f3n y Evaluaci\u00f3n**:\n   - Requisitos de capacitaci\u00f3n y evaluaci\u00f3n para el personal que utiliza sistemas de aire respirable, asegurando su competencia antes de ingresar a \u00e1reas de riesgo.\n\n### Entidades Clave:\n- **OEL (Niveles de Exposici\u00f3n Ocupacional Permisibles)**: Indicadores cr\u00edticos en la evaluaci\u00f3n de riesgos.\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Entidad que establece directrices y est\u00e1ndares para la producci\u00f3n farmac\u00e9utica.\n- **EPP (Equipos de Protecci\u00f3n Personal)**: Elementos esenciales para la seguridad de los operadores en entornos de trabajo peligrosos.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normativas que regulan la calidad en la producci\u00f3n de productos farmac\u00e9uticos. \n\nEste resumen destaca la importancia de la seguridad en el entorno laboral, la calidad en la producci\u00f3n farmac\u00e9utica y la necesidad de formaci\u00f3n adecuada para el personal expuesto a riesgos.", "excerpt_keywords": "Keywords: respirators, air supply systems, HEPA filters, occupational exposure limits, personal protective equipment"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8a781219-906d-4674-b336-0767864eabc5", "node_type": "4", "metadata": {"page_label": "213", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- a central air supply system which connects to the operator\u2019s face mask by means of flexible hoses and quick coupling sockets, also called an airline respirator (AR). The air connection should incorporate a one-way air system to prevent contaminated air entering the face mask during connection or disconnection. The air supply should be treated to ensure a temperature and level of humidity that are comfortable for the operator. The air source could be a high pressure fan or an air compressor. If an air compressor is used, it should be of the oil-free type or have suitable oil removal filters fitted;\n- a self-contained breathing apparatus (SCBA) or powered air purifying respirator (PAPR) that is securely attached to the operator\u2019s belt and connects to the operator\u2019s face mask. This system draws air from the room in which the operator is working and the air supply is delivered to the face mask by means of a battery-driven fan. The AR provides superior protection to the PAPR apparatus;\n- for zones with lower contamination levels, a half-mask high efficiency particulate air filter (HEPA) cartridge respirator of N95-type paper filter mask may be acceptable.\n\n6.3 The selection of the respirator type is based on the relationship between the accepted OEL and the respirator-certified protection factor (PF).\n\n6.4 The air supplies should be filtered through a final filter, which should be a HEPA filter rated as an H13 filter according to EN 1822 (European Norm). The supply of breathing air into the face mask and/or protective suit should result in the interior of the mask and suit being at a positive pressure relative to the facility environment.\n\n6.5 Central breathing air supply systems should have a 100% back-up system in the event of the main system failing. This could be in the form of a gas bottle system with at least 5 minutes supply. Changeover from the normal supply to the back-up supply should be automatic. The system should have a monitoring system and send alarm signals to a permanently manned location in the following situations:\n\n- failure of main air supply;\n- temperature out of specification (OOS);\n- humidity OOS;\n- carbon dioxide (CO2) OOS;\n- carbon monoxide (CO) OOS; and\n- sulfur dioxide (SO2) OOS.\n\n6.6 Breathing air should be filtered by means of pre-filters, coalescing filters and final filters to have the minimum air quality specifications of ISO 8573-1 3-9-1 and EN 12021:1999.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "87264e54f86a2ecb91c195ebf11cdfa4a6f5716e9bdcabf03653cad500475175", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- a central air supply system which connects to the operator\u2019s face mask by means of flexible hoses and quick coupling sockets, also called an airline respirator (AR). The air connection should incorporate a one-way air system to prevent contaminated air entering the face mask during connection or disconnection. The air supply should be treated to ensure a temperature and level of humidity that are comfortable for the operator. The air source could be a high pressure fan or an air compressor. If an air compressor is used, it should be of the oil-free type or have suitable oil removal filters fitted;\n- a self-contained breathing apparatus (SCBA) or powered air purifying respirator (PAPR) that is securely attached to the operator\u2019s belt and connects to the operator\u2019s face mask. This system draws air from the room in which the operator is working and the air supply is delivered to the face mask by means of a battery-driven fan. The AR provides superior protection to the PAPR apparatus;\n- for zones with lower contamination levels, a half-mask high efficiency particulate air filter (HEPA) cartridge respirator of N95-type paper filter mask may be acceptable.\n\n6.3 The selection of the respirator type is based on the relationship between the accepted OEL and the respirator-certified protection factor (PF).\n\n6.4 The air supplies should be filtered through a final filter, which should be a HEPA filter rated as an H13 filter according to EN 1822 (European Norm). The supply of breathing air into the face mask and/or protective suit should result in the interior of the mask and suit being at a positive pressure relative to the facility environment.\n\n6.5 Central breathing air supply systems should have a 100% back-up system in the event of the main system failing. This could be in the form of a gas bottle system with at least 5 minutes supply. Changeover from the normal supply to the back-up supply should be automatic. The system should have a monitoring system and send alarm signals to a permanently manned location in the following situations:\n\n- failure of main air supply;\n- temperature out of specification (OOS);\n- humidity OOS;\n- carbon dioxide (CO2) OOS;\n- carbon monoxide (CO) OOS; and\n- sulfur dioxide (SO2) OOS.\n\n6.6 Breathing air should be filtered by means of pre-filters, coalescing filters and final filters to have the minimum air quality specifications of ISO 8573-1 3-9-1 and EN 12021:1999.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2429, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "85a98416-33b4-4b65-a4f9-728a1c5fcd7c": {"__data__": {"id_": "85a98416-33b4-4b65-a4f9-728a1c5fcd7c", "embedding": null, "metadata": {"page_label": "214", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "6.7 Where air is delivered through a central system the piping should not cause any contamination to be liberated into the air stream. Stainless steel piping is preferred. The final filters should be as close as possible to the operator connection points. The operator hose connection to the air supply should be a dedicated connection specific to the breathing air system (to avoid inadvertent connection to a different gas system).\n\n# 7. Environmental protection\n\n7.1 Due to the hazardous nature of the products being handled in the facility, neither the product nor its residues should be allowed to escape into the atmosphere or to be discharged directly to normal drainage systems.\n\n7.2 The external atmosphere and the public in the vicinity of the facility should be protected from possible harm from hazardous substances.\n\n7.3 If liquid effluent poses a safety or contamination risk, the effluent should be treated before being discharged to a municipal drain.\n\n7.4 Exhaust air filtration to ensure environmental protection is discussed in section 11.\n\n# 8. Facility layout\n\n8.1 The premises should be designed and constructed to prevent the ingress or egress of contaminants. In drawing up the facility design, attention should be paid to the level of containment provided by the equipment.\n\n8.2 The link between the interior and exterior of the premises should be through airlocks (PAL and/or MAL), changing rooms, pass boxes, pass-through hatches, decontamination devices, etc. These entry and exit doors for materials and personnel should have an interlock mechanism or other appropriate system to prevent the opening of more than one door at a time.\n\n8.3 The changing rooms should have an arrangement with a step-over-bench. The facilities on the exit side should incorporate showers for the operators.\n\n8.4 The premises should be laid out and designed so as to facilitate the required pressure cascades and containment.\n\n8.5 The premises (and equipment) should be appropriately designed and installed to facilitate cleaning and decontamination.\n\n8.6 The manufacturing site and buildings should be described in sufficient detail (by means of plans and written explanations) to ensure that the designation and conditions of use of all the rooms are correctly shown.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de material se prefiere para las tuber\u00edas en un sistema de aire central y por qu\u00e9?**\n   - Se prefiere el uso de tuber\u00edas de acero inoxidable en un sistema de aire central para evitar que se liberen contaminantes en la corriente de aire. Este material es menos propenso a la corrosi\u00f3n y facilita la limpieza, lo que contribuye a mantener la calidad del aire.\n\n2. **\u00bfCu\u00e1les son las medidas recomendadas para proteger el ambiente y la salud p\u00fablica en instalaciones que manejan productos peligrosos?**\n   - Las instalaciones deben asegurarse de que ni los productos ni sus residuos escapen a la atm\u00f3sfera o se descarguen en sistemas de drenaje normales. Adem\u00e1s, se deben implementar tratamientos para los efluentes l\u00edquidos que representen un riesgo de seguridad o contaminaci\u00f3n antes de ser descargados en desag\u00fces municipales. Tambi\u00e9n se debe proteger a la atm\u00f3sfera externa y al p\u00fablico circundante de sustancias peligrosas.\n\n3. **\u00bfQu\u00e9 caracter\u00edsticas deben tener las \u00e1reas de cambio y salida en las instalaciones para garantizar la seguridad y la contenci\u00f3n?**\n   - Las \u00e1reas de cambio deben contar con un banco de paso y las instalaciones de salida deben incluir duchas para los operadores. Adem\u00e1s, se deben utilizar mecanismos de interbloqueo en las puertas de entrada y salida para evitar que se abran m\u00e1s de una puerta a la vez, lo que ayuda a prevenir la entrada o salida de contaminantes.\n\n### Resumen de nivel superior del contexto:\nEl documento de la OMS proporciona directrices sobre la protecci\u00f3n ambiental y el dise\u00f1o de instalaciones que manejan productos peligrosos. Se enfatiza la importancia de evitar la contaminaci\u00f3n del aire y el agua, as\u00ed como la necesidad de un dise\u00f1o de instalaciones que prevenga la entrada y salida de contaminantes. Se destacan medidas espec\u00edficas como el uso de tuber\u00edas de acero inoxidable, la implementaci\u00f3n de duchas en \u00e1reas de cambio y la necesidad de un dise\u00f1o que facilite la limpieza y la decontaminaci\u00f3n.\n\nEstas preguntas y respuestas est\u00e1n dise\u00f1adas para abordar aspectos espec\u00edficos del contexto que pueden no ser f\u00e1cilmente accesibles en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistemas de Suministro de Aire Respirable**:\n   - **Tipos de Sistemas**:\n     - **Respirador de Aire Central (AR)**: Conexi\u00f3n a la m\u00e1scara del operador mediante mangueras flexibles y sistemas de acoplamiento r\u00e1pido. Debe tener un sistema de aire unidireccional y un suministro de aire tratado para comodidad del operador.\n     - **Aparato de Respiraci\u00f3n Aut\u00f3nomo (SCBA)**: Conectado al cintur\u00f3n del operador, utiliza aire del entorno y lo suministra a la m\u00e1scara mediante un ventilador a bater\u00eda.\n     - **Respirador de Purificaci\u00f3n de Aire Impulsado (PAPR)**: Similar al SCBA, pero proporciona una protecci\u00f3n inferior.\n     - **Mascarillas de Papel N95**: Aceptables en zonas con niveles de contaminaci\u00f3n m\u00e1s bajos.\n\n2. **Selecci\u00f3n de Respiradores**:\n   - Basada en la relaci\u00f3n entre el L\u00edmite de Exposici\u00f3n Ocupacional (OEL) y el Factor de Protecci\u00f3n (PF) certificado del respirador.\n\n3. **Filtraci\u00f3n de Aire**:\n   - El aire suministrado debe ser filtrado a trav\u00e9s de un filtro HEPA (H13) y cumplir con las especificaciones de calidad del aire de ISO 8573-1 3-9-1 y EN 12021:1999.\n\n4. **Sistemas de Respaldo y Monitoreo**:\n   - Los sistemas de aire central deben tener un sistema de respaldo del 100% en caso de fallo, como un sistema de botellas de gas con al menos 5 minutos de suministro.\n   - Monitoreo de condiciones cr\u00edticas que pueden activar alarmas: \n     - Falla del suministro de aire principal.\n     - Temperatura fuera de especificaci\u00f3n.\n     - Humedad fuera de especificaci\u00f3n.\n     - Niveles de CO2, CO y SO2 fuera de especificaci\u00f3n.\n\n5. **Requisitos para Compresores de Aire**:\n   - Si se utiliza un compresor, debe ser libre de aceite o tener filtros adecuados para la eliminaci\u00f3n de aceite.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad del documento.\n- **Normas de Calidad del Aire**: ISO 8573-1, EN 12021:1999, EN 1822.\n- **Tipos de Respiradores**: AR, SCBA, PAPR, N95.\n- **Condiciones de Monitoreo**: Temperatura, humedad, CO2, CO, SO2.", "excerpt_keywords": "Keywords: air supply system, environmental protection, facility layout, contamination prevention, hazardous substances"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f752a712-7916-41fe-92ff-bfda9981f116", "node_type": "4", "metadata": {"page_label": "214", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "6.7 Where air is delivered through a central system the piping should not cause any contamination to be liberated into the air stream. Stainless steel piping is preferred. The final filters should be as close as possible to the operator connection points. The operator hose connection to the air supply should be a dedicated connection specific to the breathing air system (to avoid inadvertent connection to a different gas system).\n\n# 7. Environmental protection\n\n7.1 Due to the hazardous nature of the products being handled in the facility, neither the product nor its residues should be allowed to escape into the atmosphere or to be discharged directly to normal drainage systems.\n\n7.2 The external atmosphere and the public in the vicinity of the facility should be protected from possible harm from hazardous substances.\n\n7.3 If liquid effluent poses a safety or contamination risk, the effluent should be treated before being discharged to a municipal drain.\n\n7.4 Exhaust air filtration to ensure environmental protection is discussed in section 11.\n\n# 8. Facility layout\n\n8.1 The premises should be designed and constructed to prevent the ingress or egress of contaminants. In drawing up the facility design, attention should be paid to the level of containment provided by the equipment.\n\n8.2 The link between the interior and exterior of the premises should be through airlocks (PAL and/or MAL), changing rooms, pass boxes, pass-through hatches, decontamination devices, etc. These entry and exit doors for materials and personnel should have an interlock mechanism or other appropriate system to prevent the opening of more than one door at a time.\n\n8.3 The changing rooms should have an arrangement with a step-over-bench. The facilities on the exit side should incorporate showers for the operators.\n\n8.4 The premises should be laid out and designed so as to facilitate the required pressure cascades and containment.\n\n8.5 The premises (and equipment) should be appropriately designed and installed to facilitate cleaning and decontamination.\n\n8.6 The manufacturing site and buildings should be described in sufficient detail (by means of plans and written explanations) to ensure that the designation and conditions of use of all the rooms are correctly shown.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "c074891c8d676f50fe8d5d7a3c547d5cb8ccf23267028ad07be837d0263f68dd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "6.7 Where air is delivered through a central system the piping should not cause any contamination to be liberated into the air stream. Stainless steel piping is preferred. The final filters should be as close as possible to the operator connection points. The operator hose connection to the air supply should be a dedicated connection specific to the breathing air system (to avoid inadvertent connection to a different gas system).\n\n# 7. Environmental protection\n\n7.1 Due to the hazardous nature of the products being handled in the facility, neither the product nor its residues should be allowed to escape into the atmosphere or to be discharged directly to normal drainage systems.\n\n7.2 The external atmosphere and the public in the vicinity of the facility should be protected from possible harm from hazardous substances.\n\n7.3 If liquid effluent poses a safety or contamination risk, the effluent should be treated before being discharged to a municipal drain.\n\n7.4 Exhaust air filtration to ensure environmental protection is discussed in section 11.\n\n# 8. Facility layout\n\n8.1 The premises should be designed and constructed to prevent the ingress or egress of contaminants. In drawing up the facility design, attention should be paid to the level of containment provided by the equipment.\n\n8.2 The link between the interior and exterior of the premises should be through airlocks (PAL and/or MAL), changing rooms, pass boxes, pass-through hatches, decontamination devices, etc. These entry and exit doors for materials and personnel should have an interlock mechanism or other appropriate system to prevent the opening of more than one door at a time.\n\n8.3 The changing rooms should have an arrangement with a step-over-bench. The facilities on the exit side should incorporate showers for the operators.\n\n8.4 The premises should be laid out and designed so as to facilitate the required pressure cascades and containment.\n\n8.5 The premises (and equipment) should be appropriately designed and installed to facilitate cleaning and decontamination.\n\n8.6 The manufacturing site and buildings should be described in sufficient detail (by means of plans and written explanations) to ensure that the designation and conditions of use of all the rooms are correctly shown.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2276, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7cae8f59-7dc6-484f-8680-33a4ae04de95": {"__data__": {"id_": "7cae8f59-7dc6-484f-8680-33a4ae04de95", "embedding": null, "metadata": {"page_label": "215", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "8.7 The flow of people and products should be clearly marked on the layouts and plans.\n\n8.8 The activities carried out in the vicinity of the site should be indicated.\n\n8.9 Plans should describe the ventilation systems, indicating inlets and outlets, in relation to other facility air inlet and outlet points.\n\n8.10 The facility should be a well-sealed structure with no air leakage through ceilings, cracks or service areas.\n\n8.11 Areas of the facility where exposed product presents a risk should be maintained at a negative air pressure relative to the environment.\n\n# 9. Air-handling systems\n\n9.1 The HVAC system should be appropriately designed, installed and maintained to ensure protection of product, personnel and the environment.\n\n9.2 The principles of airflow direction, air filtration standards, temperature, humidity and related parameters should comply with the minimum requirements as set out in Annex 2 of the fortieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, 2006 (2).\n\n9.3 Facilities and premises dealing with hazardous substances should have the following basic air-handling characteristics:\n\n- There should be no direct venting of air to the outside.\n- Air-conditioning or ventilation should result in a negative pressure relative to the outside. Air pressure differentials should be such that there is no uncontrolled flow of air between the work area and the external environment.\n- Appropriate air pressure alarm systems should be provided to warn of any pressure cascade reversal or loss of design pressure status. The appropriate design, alert and action limits should be in place. System redundancies should be in place to respond appropriately to pressure cascade failure.\n- The starting and stopping of the supply and exhaust air fan should be synchronized such that the premises remain at a negative pressure during start-up and shut-down.\n- The air pressure cascade within the facility, although negative relative to the environment, should comply with normal pharmaceutical pressure cascade requirements with regards to product protection, dust containment and personnel protection.\n- Visual indication of the status of room pressures should be provided in each room.\n- Air should be exhausted to the outside through HEPA filters and not be recirculated except to the same area, and provided that a further HEPA filtration stage is applied to the return air. Where HEPA filters are", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Informe T\u00e9cnico 957) establece directrices sobre el dise\u00f1o y mantenimiento de instalaciones que manejan productos farmac\u00e9uticos y sustancias peligrosas. Se enfatiza la importancia de un flujo de aire controlado y la presi\u00f3n negativa en \u00e1reas donde se manipulan productos expuestos a riesgos. Tambi\u00e9n se detallan los requisitos para los sistemas de manejo de aire, incluyendo la necesidad de alarmas de presi\u00f3n, sincronizaci\u00f3n de ventiladores y el uso de filtros HEPA para asegurar la calidad del aire y la protecci\u00f3n del producto, el personal y el medio ambiente.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas b\u00e1sicas que deben tener los sistemas de manejo de aire en instalaciones que tratan sustancias peligrosas seg\u00fan el informe?**\n   - Respuesta: Los sistemas deben evitar la ventilaci\u00f3n directa al exterior, mantener una presi\u00f3n negativa relativa al exterior, contar con alarmas de presi\u00f3n, sincronizar el funcionamiento de los ventiladores de suministro y extracci\u00f3n, y asegurar que el aire se expulse a trav\u00e9s de filtros HEPA sin recirculaci\u00f3n, salvo en condiciones espec\u00edficas.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para garantizar que las \u00e1reas donde hay productos expuestos mantengan una presi\u00f3n negativa?**\n   - Respuesta: Las \u00e1reas deben ser dise\u00f1adas para mantener una presi\u00f3n negativa en relaci\u00f3n con el entorno, lo que implica que no debe haber flujo de aire incontrolado entre el \u00e1rea de trabajo y el ambiente externo, y se deben implementar alarmas para detectar cualquier reversi\u00f3n de la presi\u00f3n.\n\n3. **\u00bfQu\u00e9 requisitos se establecen para la visualizaci\u00f3n del estado de la presi\u00f3n en las habitaciones de las instalaciones?**\n   - Respuesta: Se debe proporcionar una indicaci\u00f3n visual del estado de la presi\u00f3n en cada habitaci\u00f3n, lo que permite a los operadores monitorear y asegurar que las condiciones de presi\u00f3n se mantengan dentro de los l\u00edmites establecidos para la protecci\u00f3n del producto y del personal.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistemas de Aire Central**:\n   - **Material Preferido**: Tuber\u00edas de acero inoxidable para evitar la liberaci\u00f3n de contaminantes en la corriente de aire.\n   - **Filtros Finales**: Deben estar ubicados lo m\u00e1s cerca posible de los puntos de conexi\u00f3n del operador.\n\n2. **Protecci\u00f3n Ambiental**:\n   - **Manejo de Productos Peligrosos**: Prohibici\u00f3n de que productos o residuos escapen a la atm\u00f3sfera o se descarguen en sistemas de drenaje normales.\n   - **Tratamiento de Efluentes**: Los efluentes l\u00edquidos que representen un riesgo deben ser tratados antes de ser descargados en desag\u00fces municipales.\n   - **Filtraci\u00f3n de Aire de Escape**: Se menciona en la secci\u00f3n 11 para asegurar la protecci\u00f3n ambiental.\n\n3. **Dise\u00f1o de Instalaciones**:\n   - **Prevenci\u00f3n de Contaminaci\u00f3n**: Las instalaciones deben estar dise\u00f1adas para evitar la entrada y salida de contaminantes.\n   - **Accesos Controlados**: Uso de sistemas de interbloqueo en puertas de entrada y salida para evitar la apertura simult\u00e1nea de m\u00e1s de una puerta.\n   - **\u00c1reas de Cambio**: Deben incluir bancos de paso y duchas para los operadores.\n   - **Facilidad de Limpieza**: Las instalaciones y equipos deben estar dise\u00f1ados para facilitar la limpieza y decontaminaci\u00f3n.\n\n4. **Documentaci\u00f3n y Descripci\u00f3n**:\n   - **Planes y Explicaciones**: El sitio de fabricaci\u00f3n y los edificios deben ser descritos en detalle para asegurar la correcta designaci\u00f3n y condiciones de uso de todas las habitaciones.\n\n### Entidades Clave\n- **Organizaci\u00f3n**: OMS (Organizaci\u00f3n Mundial de la Salud)\n- **Documentos**: WHO - Technical Report Series 957\n- **Componentes de Instalaci\u00f3n**: Tuber\u00edas, filtros, duchas, bancos de paso, sistemas de interbloqueo.\n- **Sustancias**: Productos peligrosos, efluentes l\u00edquidos, contaminantes. \n\nEste resumen destaca los aspectos esenciales relacionados con la protecci\u00f3n ambiental y el dise\u00f1o de instalaciones que manejan productos peligrosos, enfatizando la importancia de la contenci\u00f3n y la prevenci\u00f3n de la contaminaci\u00f3n.", "excerpt_keywords": "Keywords: air-handling systems, negative pressure, hazardous substances, HEPA filters, pharmaceutical facilities"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "823a56e0-6ba7-4653-847f-58386a5ca1e7", "node_type": "4", "metadata": {"page_label": "215", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "8.7 The flow of people and products should be clearly marked on the layouts and plans.\n\n8.8 The activities carried out in the vicinity of the site should be indicated.\n\n8.9 Plans should describe the ventilation systems, indicating inlets and outlets, in relation to other facility air inlet and outlet points.\n\n8.10 The facility should be a well-sealed structure with no air leakage through ceilings, cracks or service areas.\n\n8.11 Areas of the facility where exposed product presents a risk should be maintained at a negative air pressure relative to the environment.\n\n# 9. Air-handling systems\n\n9.1 The HVAC system should be appropriately designed, installed and maintained to ensure protection of product, personnel and the environment.\n\n9.2 The principles of airflow direction, air filtration standards, temperature, humidity and related parameters should comply with the minimum requirements as set out in Annex 2 of the fortieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, 2006 (2).\n\n9.3 Facilities and premises dealing with hazardous substances should have the following basic air-handling characteristics:\n\n- There should be no direct venting of air to the outside.\n- Air-conditioning or ventilation should result in a negative pressure relative to the outside. Air pressure differentials should be such that there is no uncontrolled flow of air between the work area and the external environment.\n- Appropriate air pressure alarm systems should be provided to warn of any pressure cascade reversal or loss of design pressure status. The appropriate design, alert and action limits should be in place. System redundancies should be in place to respond appropriately to pressure cascade failure.\n- The starting and stopping of the supply and exhaust air fan should be synchronized such that the premises remain at a negative pressure during start-up and shut-down.\n- The air pressure cascade within the facility, although negative relative to the environment, should comply with normal pharmaceutical pressure cascade requirements with regards to product protection, dust containment and personnel protection.\n- Visual indication of the status of room pressures should be provided in each room.\n- Air should be exhausted to the outside through HEPA filters and not be recirculated except to the same area, and provided that a further HEPA filtration stage is applied to the return air. Where HEPA filters are", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "6e9d9eaed328c4a079c97af4a9b0e178383fd671fa822c412b367a5f546fe3d9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "8.7 The flow of people and products should be clearly marked on the layouts and plans.\n\n8.8 The activities carried out in the vicinity of the site should be indicated.\n\n8.9 Plans should describe the ventilation systems, indicating inlets and outlets, in relation to other facility air inlet and outlet points.\n\n8.10 The facility should be a well-sealed structure with no air leakage through ceilings, cracks or service areas.\n\n8.11 Areas of the facility where exposed product presents a risk should be maintained at a negative air pressure relative to the environment.\n\n# 9. Air-handling systems\n\n9.1 The HVAC system should be appropriately designed, installed and maintained to ensure protection of product, personnel and the environment.\n\n9.2 The principles of airflow direction, air filtration standards, temperature, humidity and related parameters should comply with the minimum requirements as set out in Annex 2 of the fortieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, 2006 (2).\n\n9.3 Facilities and premises dealing with hazardous substances should have the following basic air-handling characteristics:\n\n- There should be no direct venting of air to the outside.\n- Air-conditioning or ventilation should result in a negative pressure relative to the outside. Air pressure differentials should be such that there is no uncontrolled flow of air between the work area and the external environment.\n- Appropriate air pressure alarm systems should be provided to warn of any pressure cascade reversal or loss of design pressure status. The appropriate design, alert and action limits should be in place. System redundancies should be in place to respond appropriately to pressure cascade failure.\n- The starting and stopping of the supply and exhaust air fan should be synchronized such that the premises remain at a negative pressure during start-up and shut-down.\n- The air pressure cascade within the facility, although negative relative to the environment, should comply with normal pharmaceutical pressure cascade requirements with regards to product protection, dust containment and personnel protection.\n- Visual indication of the status of room pressures should be provided in each room.\n- Air should be exhausted to the outside through HEPA filters and not be recirculated except to the same area, and provided that a further HEPA filtration stage is applied to the return air. Where HEPA filters are", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2457, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5e63ac13-717d-423e-a1ac-1ef059d1f569": {"__data__": {"id_": "5e63ac13-717d-423e-a1ac-1ef059d1f569", "embedding": null, "metadata": {"page_label": "216", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Figure 1\n\n## Typical airflow pattern for contaminant\n\n!Airflow Diagram\n\n- **Primary Packing**  \n  (Negative Pressure --)\n\n- **Secondary Packing**  \n  (Negative Pressure -)\n\n- **Extraction**  \n  (Negative Pressure)\n\n- **Supply Air**  \n  (Arrows indicating airflow direction)\n\n- **Extract Air**  \n  (Arrows indicating airflow direction)\n\n----\n\n- Mentioned in these guidelines, this refers to HEPA filters with a minimum rating of H13 according to EN 1822.\n- Where possible, single-pass air-handling systems with no recirculation should be provided.\n- Exhaust air or return air should be filtered through a safe-change or bag-in-bag-out filter housing. The filter housing should contain pre-filters and HEPA filters, both of which should be removable with the safe bagging system.\n- Changing rooms should be supplied with air filtered to the same standard as that for the work area they serve.\n- Airlocks, pass-through hatches, etc., should have supply and extract air to provide the necessary air pressure cascade and containment. The final, or containment perimeter, airlock or pass-through hatch bordering on an external or non-GMP area should be at a positive pressure relative to the environment, to prevent the ingress of contaminants to the facility.\n- If the facility provides insufficient containment, and operators\u2019 garments are contaminated with dust, the operators leaving the containment area should pass through a decontamination system, e.g., air showers or a mist shower system, to assist with removing or controlling dust particles on their garments. Operators should follow this route before de-gowning to use the ablutions or canteen facilities. All garments leaving the facility for laundering should be safely bagged. Appropriate means for protecting laundry staff and prevention of contamination of other garments from non-hazardous facilities should be in place.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de filtros se mencionan en las pautas y cu\u00e1l es su clasificaci\u00f3n m\u00ednima?**\n   - Las pautas mencionan filtros HEPA con una clasificaci\u00f3n m\u00ednima de H13 seg\u00fan la norma EN 1822.\n\n2. **\u00bfCu\u00e1l es la recomendaci\u00f3n sobre el manejo del aire en las \u00e1reas de trabajo y c\u00f3mo se debe tratar el aire de escape o retorno?**\n   - Se recomienda proporcionar sistemas de manejo de aire de paso \u00fanico sin recirculaci\u00f3n siempre que sea posible. El aire de escape o retorno debe ser filtrado a trav\u00e9s de un sistema de filtro de cambio seguro o de bolsa dentro de bolsa, que contenga prefiltros y filtros HEPA, ambos removibles con el sistema de envasado seguro.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar si los operadores salen de un \u00e1rea de contenci\u00f3n y sus prendas est\u00e1n contaminadas con polvo?**\n   - Si los operadores tienen prendas contaminadas con polvo al salir de un \u00e1rea de contenci\u00f3n, deben pasar por un sistema de descontaminaci\u00f3n, como duchas de aire o sistemas de duchas de niebla, para ayudar a eliminar o controlar las part\u00edculas de polvo en sus prendas. Deben seguir esta ruta antes de desvestirse para usar las instalaciones de abluci\u00f3n o el comedor.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona directrices sobre el manejo del aire en instalaciones que requieren un control estricto de contaminantes, enfatizando la importancia de utilizar filtros HEPA de alta eficiencia, sistemas de aire de paso \u00fanico y medidas de descontaminaci\u00f3n para los operadores. Se destaca la necesidad de mantener presiones negativas en \u00e1reas cr\u00edticas y asegurar que las \u00e1reas de cambio y los accesos est\u00e9n adecuadamente presurizados para prevenir la entrada de contaminantes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Flujo de Personas y Productos**:\n   - Importancia de marcar claramente el flujo de personas y productos en los planos de las instalaciones.\n\n2. **Actividades en la Vecindad**:\n   - Necesidad de indicar las actividades realizadas en las cercan\u00edas del sitio.\n\n3. **Sistemas de Ventilaci\u00f3n**:\n   - Descripci\u00f3n de los sistemas de ventilaci\u00f3n, incluyendo entradas y salidas de aire en relaci\u00f3n con otros puntos de entrada y salida de la instalaci\u00f3n.\n\n4. **Estructura Sellada**:\n   - Requerimiento de que la instalaci\u00f3n sea una estructura bien sellada, sin fugas de aire a trav\u00e9s de techos, grietas o \u00e1reas de servicio.\n\n5. **Presi\u00f3n Negativa**:\n   - Mantenimiento de presi\u00f3n negativa en \u00e1reas donde hay productos expuestos a riesgos.\n\n6. **Sistemas de Manejo de Aire (HVAC)**:\n   - Dise\u00f1o, instalaci\u00f3n y mantenimiento adecuados del sistema HVAC para proteger productos, personal y medio ambiente.\n   - Cumplimiento de est\u00e1ndares de direcci\u00f3n del flujo de aire, filtraci\u00f3n, temperatura y humedad seg\u00fan directrices de la OMS.\n\n7. **Caracter\u00edsticas B\u00e1sicas para Sustancias Peligrosas**:\n   - Prohibici\u00f3n de ventilaci\u00f3n directa al exterior.\n   - Mantenimiento de presi\u00f3n negativa en relaci\u00f3n con el exterior.\n   - Sistemas de alarma para detectar reversi\u00f3n de presi\u00f3n.\n   - Sincronizaci\u00f3n en el funcionamiento de ventiladores de suministro y extracci\u00f3n.\n   - Cumplimiento de requisitos de presi\u00f3n para protecci\u00f3n de productos y personal.\n   - Indicaci\u00f3n visual del estado de presi\u00f3n en cada habitaci\u00f3n.\n   - Uso de filtros HEPA para la expulsi\u00f3n de aire, evitando la recirculaci\u00f3n, salvo en condiciones espec\u00edficas.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices.\n- **HVAC (Calefacci\u00f3n, Ventilaci\u00f3n y Aire Acondicionado)**: Sistema cr\u00edtico para el manejo del aire en instalaciones.\n- **HEPA (Filtros de Aire de Alta Eficiencia)**: Tecnolog\u00eda de filtraci\u00f3n utilizada para asegurar la calidad del aire. \n\nEste resumen destaca la importancia de un dise\u00f1o adecuado y el mantenimiento de las instalaciones que manejan productos farmac\u00e9uticos y sustancias peligrosas, enfatizando la seguridad y la protecci\u00f3n del medio ambiente y del personal.", "excerpt_keywords": "Keywords: airflow, HEPA filters, contamination control, air-handling systems, decontamination"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3878ce82-b8a3-4602-85b1-f142b6567da1", "node_type": "4", "metadata": {"page_label": "216", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Figure 1\n\n## Typical airflow pattern for contaminant\n\n!Airflow Diagram\n\n- **Primary Packing**  \n  (Negative Pressure --)\n\n- **Secondary Packing**  \n  (Negative Pressure -)\n\n- **Extraction**  \n  (Negative Pressure)\n\n- **Supply Air**  \n  (Arrows indicating airflow direction)\n\n- **Extract Air**  \n  (Arrows indicating airflow direction)\n\n----\n\n- Mentioned in these guidelines, this refers to HEPA filters with a minimum rating of H13 according to EN 1822.\n- Where possible, single-pass air-handling systems with no recirculation should be provided.\n- Exhaust air or return air should be filtered through a safe-change or bag-in-bag-out filter housing. The filter housing should contain pre-filters and HEPA filters, both of which should be removable with the safe bagging system.\n- Changing rooms should be supplied with air filtered to the same standard as that for the work area they serve.\n- Airlocks, pass-through hatches, etc., should have supply and extract air to provide the necessary air pressure cascade and containment. The final, or containment perimeter, airlock or pass-through hatch bordering on an external or non-GMP area should be at a positive pressure relative to the environment, to prevent the ingress of contaminants to the facility.\n- If the facility provides insufficient containment, and operators\u2019 garments are contaminated with dust, the operators leaving the containment area should pass through a decontamination system, e.g., air showers or a mist shower system, to assist with removing or controlling dust particles on their garments. Operators should follow this route before de-gowning to use the ablutions or canteen facilities. All garments leaving the facility for laundering should be safely bagged. Appropriate means for protecting laundry staff and prevention of contamination of other garments from non-hazardous facilities should be in place.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "61f67db654cb7ab1c0c755ba69a539144522643a36e024df8390668354264413", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Figure 1\n\n## Typical airflow pattern for contaminant\n\n!Airflow Diagram\n\n- **Primary Packing**  \n  (Negative Pressure --)\n\n- **Secondary Packing**  \n  (Negative Pressure -)\n\n- **Extraction**  \n  (Negative Pressure)\n\n- **Supply Air**  \n  (Arrows indicating airflow direction)\n\n- **Extract Air**  \n  (Arrows indicating airflow direction)\n\n----\n\n- Mentioned in these guidelines, this refers to HEPA filters with a minimum rating of H13 according to EN 1822.\n- Where possible, single-pass air-handling systems with no recirculation should be provided.\n- Exhaust air or return air should be filtered through a safe-change or bag-in-bag-out filter housing. The filter housing should contain pre-filters and HEPA filters, both of which should be removable with the safe bagging system.\n- Changing rooms should be supplied with air filtered to the same standard as that for the work area they serve.\n- Airlocks, pass-through hatches, etc., should have supply and extract air to provide the necessary air pressure cascade and containment. The final, or containment perimeter, airlock or pass-through hatch bordering on an external or non-GMP area should be at a positive pressure relative to the environment, to prevent the ingress of contaminants to the facility.\n- If the facility provides insufficient containment, and operators\u2019 garments are contaminated with dust, the operators leaving the containment area should pass through a decontamination system, e.g., air showers or a mist shower system, to assist with removing or controlling dust particles on their garments. Operators should follow this route before de-gowning to use the ablutions or canteen facilities. All garments leaving the facility for laundering should be safely bagged. Appropriate means for protecting laundry staff and prevention of contamination of other garments from non-hazardous facilities should be in place.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1884, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ac2bb7be-88be-4601-835f-81bc8f005b38": {"__data__": {"id_": "ac2bb7be-88be-4601-835f-81bc8f005b38", "embedding": null, "metadata": {"page_label": "217", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9.4\n\nIf required, appropriate measures should be taken to prevent airflow from the primary packing area (through the conveyor \u201cmouse hole\u201d) to the secondary packing area.\n\n*Note:* This could be overcome by having a pass-through chamber over the \u201cmouse hole\u201d, which is maintained at a negative pressure to both primary and secondary packing. This typical arrangement is illustrated in Figure 1. This principle can be applied to other situations where containment from two sides is required.\n\n9.5 Where possible, HEPA filters in the supply air system should be terminally mounted to provide protection against back-flow cross-contamination in the event of a failure in the supply airflow.\n\n9.6 In some cases consideration can be given to the use of biosafety cabinets, isolation systems or glove boxes as a means for containment and operator protection.\n\n9.7 There should be a system description including schematic drawings detailing the filters and their specifications, the number of air changes per hour, pressure gradients, clean room classes and related specifications. These should be available for inspection.\n\n9.8 There should be an indication of pressure gradients that are monitored by means of digital or analogue pressure indicators.\n\n9.9 Consideration should be given to providing an emergency power supply, e.g. diesel generators, to ensure that safe operation of the premises and systems can be maintained at all times.\n\n# 10. Air-handling units\n\n10.1 The air-handling units (AHUs) supplying air to the facility should conform to AHU requirements as detailed in *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials (1)* and *Supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms (2)* and the filtration should be consistent with the zone concepts and product protection required.\n\n10.2 The decision to use return air or recirculated air should be made on the basis of a risk assessment.\n\n10.3 Where a full fresh-air or single-pass system is used, an energy recovery wheel could be considered. In such cases, there should not be any potential for air leakage between the supply air and exhaust air as it passes through the wheel. The relative pressures between supply and exhaust air systems should be such that the exhaust-air system operates at a lower", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto aborda directrices sobre el manejo del aire en instalaciones farmac\u00e9uticas, enfoc\u00e1ndose en la prevenci\u00f3n de la contaminaci\u00f3n cruzada y la protecci\u00f3n del personal. Se mencionan medidas espec\u00edficas como el uso de c\u00e1maras de paso con presi\u00f3n negativa, filtros HEPA, y la importancia de un suministro de energ\u00eda de emergencia. Tambi\u00e9n se discuten los requisitos para las unidades de manejo de aire (AHUs) y la necesidad de realizar evaluaciones de riesgo al decidir entre aire de retorno o recirculado.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas se pueden implementar para evitar el flujo de aire entre las \u00e1reas de empaque primaria y secundaria, y c\u00f3mo se puede mantener la presi\u00f3n negativa en estas \u00e1reas?**\n   - Respuesta: Se pueden implementar c\u00e1maras de paso sobre el \"mouse hole\" que se mantengan a presi\u00f3n negativa respecto a ambas \u00e1reas de empaque, lo que ayuda a prevenir el flujo de aire no deseado.\n\n2. **\u00bfCu\u00e1les son las especificaciones que deben incluirse en la descripci\u00f3n del sistema de manejo de aire para su inspecci\u00f3n?**\n   - Respuesta: La descripci\u00f3n del sistema debe incluir dibujos esquem\u00e1ticos que detallen los filtros y sus especificaciones, el n\u00famero de cambios de aire por hora, los gradientes de presi\u00f3n, las clases de sala limpia y otras especificaciones relacionadas.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al decidir entre el uso de aire de retorno o aire recirculado en un sistema de manejo de aire?**\n   - Respuesta: La decisi\u00f3n debe basarse en una evaluaci\u00f3n de riesgo que considere los posibles impactos en la calidad del aire y la seguridad del producto.\n\n### Resumen de nivel superior\n\nEl documento proporciona directrices sobre el manejo del aire en instalaciones farmac\u00e9uticas, enfatizando la importancia de la prevenci\u00f3n de la contaminaci\u00f3n cruzada y la protecci\u00f3n del personal. Se sugieren medidas como el uso de filtros HEPA y sistemas de presi\u00f3n negativa, as\u00ed como la necesidad de un suministro de energ\u00eda de emergencia. Adem\u00e1s, se establecen requisitos para las unidades de manejo de aire, destacando la importancia de realizar evaluaciones de riesgo al seleccionar sistemas de aire.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Manejo del aire en instalaciones controladas**:\n   - Se enfatiza la importancia de mantener un flujo de aire adecuado para prevenir la contaminaci\u00f3n en \u00e1reas cr\u00edticas.\n\n2. **Filtros HEPA**:\n   - Se mencionan filtros HEPA con una clasificaci\u00f3n m\u00ednima de H13 seg\u00fan la norma EN 1822, que son esenciales para la filtraci\u00f3n del aire.\n\n3. **Sistemas de manejo de aire**:\n   - Se recomienda el uso de sistemas de manejo de aire de paso \u00fanico sin recirculaci\u00f3n, para asegurar la calidad del aire en las \u00e1reas de trabajo.\n\n4. **Filtraci\u00f3n del aire de escape o retorno**:\n   - El aire de escape o retorno debe ser filtrado a trav\u00e9s de sistemas de filtro de cambio seguro o de bolsa dentro de bolsa, que incluyen prefiltros y filtros HEPA.\n\n5. **\u00c1reas de cambio y presi\u00f3n del aire**:\n   - Las \u00e1reas de cambio deben recibir aire filtrado al mismo est\u00e1ndar que el \u00e1rea de trabajo. Se requiere que las esclusas de aire y los accesos tengan un flujo de aire adecuado para mantener la presi\u00f3n necesaria y evitar la entrada de contaminantes.\n\n6. **Descontaminaci\u00f3n de operadores**:\n   - Si los operadores salen de un \u00e1rea de contenci\u00f3n con prendas contaminadas, deben pasar por un sistema de descontaminaci\u00f3n (duchas de aire o de niebla) antes de desvestirse. Las prendas que salen de la instalaci\u00f3n deben ser empaquetadas de manera segura para su lavander\u00eda.\n\n7. **Protecci\u00f3n del personal de lavander\u00eda**:\n   - Se deben implementar medidas adecuadas para proteger al personal de lavander\u00eda y prevenir la contaminaci\u00f3n de otras prendas provenientes de instalaciones no peligrosas.\n\n### Entidades clave:\n- **HEPA**: Filtros de alta eficiencia.\n- **EN 1822**: Norma de clasificaci\u00f3n de filtros.\n- **Sistemas de manejo de aire**: Sistemas de filtraci\u00f3n y flujo de aire.\n- **\u00c1reas de cambio**: Espacios destinados a la vestimenta de los operadores.\n- **Sistemas de descontaminaci\u00f3n**: M\u00e9todos para eliminar contaminantes de las prendas de los operadores.", "excerpt_keywords": "Keywords: airflow management, HEPA filters, contamination prevention, air-handling units, emergency power supply"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fce7cba5-9add-4ba1-800f-7c3c5de32806", "node_type": "4", "metadata": {"page_label": "217", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9.4\n\nIf required, appropriate measures should be taken to prevent airflow from the primary packing area (through the conveyor \u201cmouse hole\u201d) to the secondary packing area.\n\n*Note:* This could be overcome by having a pass-through chamber over the \u201cmouse hole\u201d, which is maintained at a negative pressure to both primary and secondary packing. This typical arrangement is illustrated in Figure 1. This principle can be applied to other situations where containment from two sides is required.\n\n9.5 Where possible, HEPA filters in the supply air system should be terminally mounted to provide protection against back-flow cross-contamination in the event of a failure in the supply airflow.\n\n9.6 In some cases consideration can be given to the use of biosafety cabinets, isolation systems or glove boxes as a means for containment and operator protection.\n\n9.7 There should be a system description including schematic drawings detailing the filters and their specifications, the number of air changes per hour, pressure gradients, clean room classes and related specifications. These should be available for inspection.\n\n9.8 There should be an indication of pressure gradients that are monitored by means of digital or analogue pressure indicators.\n\n9.9 Consideration should be given to providing an emergency power supply, e.g. diesel generators, to ensure that safe operation of the premises and systems can be maintained at all times.\n\n# 10. Air-handling units\n\n10.1 The air-handling units (AHUs) supplying air to the facility should conform to AHU requirements as detailed in *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials (1)* and *Supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms (2)* and the filtration should be consistent with the zone concepts and product protection required.\n\n10.2 The decision to use return air or recirculated air should be made on the basis of a risk assessment.\n\n10.3 Where a full fresh-air or single-pass system is used, an energy recovery wheel could be considered. In such cases, there should not be any potential for air leakage between the supply air and exhaust air as it passes through the wheel. The relative pressures between supply and exhaust air systems should be such that the exhaust-air system operates at a lower", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "6c289417a6e2e8cf65678456306781100deca1f8d239f6390479ee7a90bb2751", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9.4\n\nIf required, appropriate measures should be taken to prevent airflow from the primary packing area (through the conveyor \u201cmouse hole\u201d) to the secondary packing area.\n\n*Note:* This could be overcome by having a pass-through chamber over the \u201cmouse hole\u201d, which is maintained at a negative pressure to both primary and secondary packing. This typical arrangement is illustrated in Figure 1. This principle can be applied to other situations where containment from two sides is required.\n\n9.5 Where possible, HEPA filters in the supply air system should be terminally mounted to provide protection against back-flow cross-contamination in the event of a failure in the supply airflow.\n\n9.6 In some cases consideration can be given to the use of biosafety cabinets, isolation systems or glove boxes as a means for containment and operator protection.\n\n9.7 There should be a system description including schematic drawings detailing the filters and their specifications, the number of air changes per hour, pressure gradients, clean room classes and related specifications. These should be available for inspection.\n\n9.8 There should be an indication of pressure gradients that are monitored by means of digital or analogue pressure indicators.\n\n9.9 Consideration should be given to providing an emergency power supply, e.g. diesel generators, to ensure that safe operation of the premises and systems can be maintained at all times.\n\n# 10. Air-handling units\n\n10.1 The air-handling units (AHUs) supplying air to the facility should conform to AHU requirements as detailed in *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials (1)* and *Supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms (2)* and the filtration should be consistent with the zone concepts and product protection required.\n\n10.2 The decision to use return air or recirculated air should be made on the basis of a risk assessment.\n\n10.3 Where a full fresh-air or single-pass system is used, an energy recovery wheel could be considered. In such cases, there should not be any potential for air leakage between the supply air and exhaust air as it passes through the wheel. The relative pressures between supply and exhaust air systems should be such that the exhaust-air system operates at a lower", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2405, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4d2b4ae3-d28a-452f-a7a1-fb1bc0c796d3": {"__data__": {"id_": "4d2b4ae3-d28a-452f-a7a1-fb1bc0c796d3", "embedding": null, "metadata": {"page_label": "218", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# \n\npressure than the supply system. (Alternatives to the energy recovery wheel, such as crossover plate heat exchangers, heat pipes and water coil heat exchangers, may be used.)\n\n10.4 Risk management principles should be applied to address the potential of cross-contamination where energy wheels are used.\n\n10.5 If return air is to be recirculated it should pass through a safe change filtration system before being introduced back into the supply AHU. The return air fan could form part of the AHU; however, the safe change filter should be a dedicated unit. With this arrangement the return air passes through two sets of HEPA filters in series, i.e. the return air filters in the safe change housing and the supply air HEPA filters. The supply air HEPA filters could either be located in the AHU or terminally located at the supply diffusers, depending on the clean room classification of the facility.\n\n10.6 The starting and stopping of the supply and exhaust air fans, and associated system ventilation fans, should be synchronized such that the premises retain their design pressure and flow relationships during start-up and shut-down. Processing should stop when the fans are not running. This fan interlock sequence should also apply if any fan should fail, to ensure that there is no airflow reversal in the system.\n\n## 11. Safe change filter housings\n\n11.1 Safe change or bag-in-bag-out filter housings should be suitably designed to provide operator protection and to prevent dust from the filters entering the atmosphere when filters are changed.\n\n**Figure 2**  \n**Safe change filter bypass arrangement**\n\n!Safe change filter bypass arrangement\n\n- **E**: Shut-off Dampers\n- **VFD**: Velocity Sensor\n- **VFD**: Variable Frequency Drive\n- **Filter Pressure Differential Gauge**\n\n- **HEPA Bag-In, Bag-Out Units**\n- **SECONDARY FILTER**\n- **HEPA FILTER**\n\n- **Filter integrity test & De-contamination by-pass duct**\n- **DOP Injection**", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en las recomendaciones para el manejo de sistemas de filtraci\u00f3n de aire en instalaciones que requieren un control estricto de la contaminaci\u00f3n, como las salas limpias. Se discuten principios de gesti\u00f3n de riesgos para evitar la contaminaci\u00f3n cruzada, la importancia de un sistema de filtraci\u00f3n seguro para el aire de retorno, y la sincronizaci\u00f3n de los ventiladores de suministro y extracci\u00f3n para mantener la presi\u00f3n y el flujo de aire adecuados. Tambi\u00e9n se menciona el dise\u00f1o de las carcasas de filtros de cambio seguro para proteger a los operadores durante el mantenimiento.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las consideraciones clave para el dise\u00f1o de un sistema de filtraci\u00f3n de aire que minimice el riesgo de contaminaci\u00f3n cruzada en instalaciones cr\u00edticas?**\n   - Respuesta: Se deben aplicar principios de gesti\u00f3n de riesgos, utilizar un sistema de filtraci\u00f3n seguro para el aire de retorno que incluya filtros HEPA en serie, y asegurar que los ventiladores de suministro y extracci\u00f3n est\u00e9n sincronizados para mantener la presi\u00f3n y el flujo de aire adecuados.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para garantizar la seguridad del operador al cambiar filtros en un sistema de filtraci\u00f3n de aire?**\n   - Respuesta: Las carcasas de los filtros deben estar dise\u00f1adas para proporcionar protecci\u00f3n al operador y evitar que el polvo de los filtros entre en la atm\u00f3sfera durante el cambio de filtros, utilizando sistemas de cambio seguro como el \"bag-in-bag-out\".\n\n3. **\u00bfC\u00f3mo se debe manejar la operaci\u00f3n de los ventiladores en un sistema de filtraci\u00f3n de aire para evitar problemas de flujo de aire?**\n   - Respuesta: Los ventiladores de suministro y extracci\u00f3n deben ser operados de manera sincronizada, y el procesamiento debe detenerse si los ventiladores no est\u00e1n funcionando. Adem\u00e1s, se debe implementar un sistema de interbloqueo para prevenir la reversi\u00f3n del flujo de aire en caso de falla de alg\u00fan ventilador.", "prev_section_summary": "### Temas Clave\n\n1. **Prevenci\u00f3n de Contaminaci\u00f3n Cruzada**: Se enfatiza la importancia de evitar el flujo de aire entre \u00e1reas de empaque primaria y secundaria mediante el uso de c\u00e1maras de paso con presi\u00f3n negativa.\n\n2. **Uso de Filtros HEPA**: Se recomienda la instalaci\u00f3n de filtros HEPA en el sistema de suministro de aire para proteger contra la contaminaci\u00f3n cruzada en caso de fallos en el flujo de aire.\n\n3. **Sistemas de Contenci\u00f3n**: Se sugiere considerar el uso de gabinetes de bioseguridad, sistemas de aislamiento o cajas de guantes para la protecci\u00f3n del operador y la contenci\u00f3n de productos.\n\n4. **Descripci\u00f3n del Sistema de Manejo de Aire**: Se requiere una descripci\u00f3n detallada del sistema que incluya dibujos esquem\u00e1ticos, especificaciones de filtros, cambios de aire por hora, gradientes de presi\u00f3n y clases de sala limpia.\n\n5. **Monitoreo de Presiones**: Es necesario contar con indicadores de presi\u00f3n digitales o anal\u00f3gicos para monitorear los gradientes de presi\u00f3n en el sistema.\n\n6. **Suministro de Energ\u00eda de Emergencia**: Se debe considerar la provisi\u00f3n de un suministro de energ\u00eda de emergencia, como generadores di\u00e9sel, para mantener la operaci\u00f3n segura de las instalaciones.\n\n7. **Unidades de Manejo de Aire (AHUs)**: Las AHUs deben cumplir con requisitos espec\u00edficos y las decisiones sobre el uso de aire de retorno o recirculado deben basarse en evaluaciones de riesgo.\n\n8. **Sistemas de Aire Fresco**: En sistemas de aire fresco o de paso \u00fanico, se debe evitar la fuga de aire entre los sistemas de suministro y escape.\n\n### Entidades\n\n- **C\u00e1maras de Paso**: Estructuras dise\u00f1adas para mantener la presi\u00f3n negativa y prevenir el flujo de aire no deseado.\n- **Filtros HEPA**: Filtros de alta eficiencia utilizados para asegurar la calidad del aire.\n- **Gabinetes de Bioseguridad**: Equipos que proporcionan un entorno seguro para el manejo de materiales peligrosos.\n- **Unidades de Manejo de Aire (AHUs)**: Equipos que regulan y distribuyen el aire en las instalaciones.\n- **Generadores Di\u00e9sel**: Fuentes de energ\u00eda de emergencia para mantener la operaci\u00f3n de los sistemas.\n\nEste resumen destaca la importancia de las medidas de control ambiental en instalaciones farmac\u00e9uticas para garantizar la seguridad y la calidad del producto.", "excerpt_keywords": "Keywords: filtration, cross-contamination, HEPA filters, air handling units, risk management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3705ed84-1765-4393-873e-6e92b272d1a3", "node_type": "4", "metadata": {"page_label": "218", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# \n\npressure than the supply system. (Alternatives to the energy recovery wheel, such as crossover plate heat exchangers, heat pipes and water coil heat exchangers, may be used.)\n\n10.4 Risk management principles should be applied to address the potential of cross-contamination where energy wheels are used.\n\n10.5 If return air is to be recirculated it should pass through a safe change filtration system before being introduced back into the supply AHU. The return air fan could form part of the AHU; however, the safe change filter should be a dedicated unit. With this arrangement the return air passes through two sets of HEPA filters in series, i.e. the return air filters in the safe change housing and the supply air HEPA filters. The supply air HEPA filters could either be located in the AHU or terminally located at the supply diffusers, depending on the clean room classification of the facility.\n\n10.6 The starting and stopping of the supply and exhaust air fans, and associated system ventilation fans, should be synchronized such that the premises retain their design pressure and flow relationships during start-up and shut-down. Processing should stop when the fans are not running. This fan interlock sequence should also apply if any fan should fail, to ensure that there is no airflow reversal in the system.\n\n## 11. Safe change filter housings\n\n11.1 Safe change or bag-in-bag-out filter housings should be suitably designed to provide operator protection and to prevent dust from the filters entering the atmosphere when filters are changed.\n\n**Figure 2**  \n**Safe change filter bypass arrangement**\n\n!Safe change filter bypass arrangement\n\n- **E**: Shut-off Dampers\n- **VFD**: Velocity Sensor\n- **VFD**: Variable Frequency Drive\n- **Filter Pressure Differential Gauge**\n\n- **HEPA Bag-In, Bag-Out Units**\n- **SECONDARY FILTER**\n- **HEPA FILTER**\n\n- **Filter integrity test & De-contamination by-pass duct**\n- **DOP Injection**", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "e5c265d650249edfcdbea512695fdb07e6ab43d1f4c79001d3c43306ba851952", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# \n\npressure than the supply system. (Alternatives to the energy recovery wheel, such as crossover plate heat exchangers, heat pipes and water coil heat exchangers, may be used.)\n\n10.4 Risk management principles should be applied to address the potential of cross-contamination where energy wheels are used.\n\n10.5 If return air is to be recirculated it should pass through a safe change filtration system before being introduced back into the supply AHU. The return air fan could form part of the AHU; however, the safe change filter should be a dedicated unit. With this arrangement the return air passes through two sets of HEPA filters in series, i.e. the return air filters in the safe change housing and the supply air HEPA filters. The supply air HEPA filters could either be located in the AHU or terminally located at the supply diffusers, depending on the clean room classification of the facility.\n\n10.6 The starting and stopping of the supply and exhaust air fans, and associated system ventilation fans, should be synchronized such that the premises retain their design pressure and flow relationships during start-up and shut-down. Processing should stop when the fans are not running. This fan interlock sequence should also apply if any fan should fail, to ensure that there is no airflow reversal in the system.\n\n## 11. Safe change filter housings\n\n11.1 Safe change or bag-in-bag-out filter housings should be suitably designed to provide operator protection and to prevent dust from the filters entering the atmosphere when filters are changed.\n\n**Figure 2**  \n**Safe change filter bypass arrangement**\n\n!Safe change filter bypass arrangement\n\n- **E**: Shut-off Dampers\n- **VFD**: Velocity Sensor\n- **VFD**: Variable Frequency Drive\n- **Filter Pressure Differential Gauge**\n\n- **HEPA Bag-In, Bag-Out Units**\n- **SECONDARY FILTER**\n- **HEPA FILTER**\n\n- **Filter integrity test & De-contamination by-pass duct**\n- **DOP Injection**", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1946, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5135f2f1-0f78-41ff-8f18-fdaa6c4a9544": {"__data__": {"id_": "5135f2f1-0f78-41ff-8f18-fdaa6c4a9544", "embedding": null, "metadata": {"page_label": "219", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11.2 \nThe final filters on the safe change unit should be HEPA filters with at least an H13 classification according to EN 1822 filter standards. For dusty return, air pre-filtration may also be required to prolong the life of the HEPA filters. The pre-filtration filters should also be removable through the bag-in-bag-out method.\n\n11.3 \nFor exhaust systems where the discharge contaminant is considered particularly hazardous, two banks of HEPA filters in series should be considered to provide additional protection should the first filter fail.\n\n11.4 \nAll filter banks should be provided with pressure differential indication gauges to indicate the filter dust loading and remaining lifespan of the filters. Connection to these gauges should be copper or stainless steel and not plastic tubing, which could perish causing a contamination hazard. The tube connections on the filter casing should be provided with stopcocks, for safe removal or calibration of gauges.\n\n11.5 \nMonitoring of filters should be done at regular intervals to prevent excessive filter loading that could force dust particles through the filter media, or could cause the filters to burst, resulting in ambient contamination.\n\n11.6 \nComputer-based data monitoring systems may be installed to monitor filter condition.\n\n11.7 \nFilter pressure gauges should be marked with the clean filter resistance and the change-out filter resistance.\n\n11.8 \nInstalled filter leakage tests should be performed in accordance with ISO 14644-3. Injection ports (upstream) and access ports (downstream) should, therefore, be provided for this purpose.\n\n11.9 \nThe exhaust air fan on a safe change filter system should be located after the filters so that the filter housing is maintained at a negative pressure. This poses a difficulty when carrying out filter integrity tests, and for this reason a bypass damper system should be provided, as illustrated in Figure 2, so that air can be circulated through the HEPA filters, while the scanning ports are open. Alternatively an independent booster fan system can be used, with appropriate shut-off dampers.\n\n11.10 \nThe bypass arrangement as shown in Figure 2 also permits decontamination of the filters by means of circulation of a sanitizing agent.\n\n11.11 \nAll exhaust systems from the facility, including dust extraction systems, vacuum system exhaust, fluid bed drier exhaust and coating pan exhaust, should be passed through safe change filter housings before being exhausted to the atmosphere.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Filtraci\u00f3n y Monitoreo de Sistemas de Aire**: El documento detalla las especificaciones y requisitos para los sistemas de filtraci\u00f3n de aire en entornos donde se manejan contaminantes peligrosos. Se enfatiza la importancia de utilizar filtros HEPA de clasificaci\u00f3n H13, la necesidad de un sistema de pre-filtraci\u00f3n, y la implementaci\u00f3n de monitoreo regular para asegurar la eficacia de los filtros.\n\n2. **Pruebas de Integridad y Seguridad**: Se menciona la necesidad de realizar pruebas de integridad de los filtros y de mantener la presi\u00f3n negativa en las unidades de filtraci\u00f3n. Tambi\u00e9n se discuten los m\u00e9todos para la desinfecci\u00f3n de los filtros y la importancia de un sistema de bypass para facilitar estas pruebas.\n\n3. **Conexiones y Materiales**: El documento especifica que las conexiones a los man\u00f3metros de presi\u00f3n deben ser de cobre o acero inoxidable, evitando el uso de tuber\u00edas de pl\u00e1stico que podr\u00edan representar un riesgo de contaminaci\u00f3n. Adem\u00e1s, se requiere que todos los sistemas de extracci\u00f3n de aire pasen por filtros seguros antes de ser liberados al ambiente.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de filtros se recomienda para las unidades de cambio seguro y cu\u00e1l es su clasificaci\u00f3n m\u00ednima seg\u00fan las normas EN 1822?**\n   - Se recomienda el uso de filtros HEPA con al menos una clasificaci\u00f3n H13 seg\u00fan las normas EN 1822.\n\n2. **\u00bfCu\u00e1l es la funci\u00f3n de los man\u00f3metros de presi\u00f3n diferencial en los bancos de filtros y qu\u00e9 materiales se deben utilizar para las conexiones?**\n   - Los man\u00f3metros de presi\u00f3n diferencial indican la carga de polvo en los filtros y su vida \u00fatil restante. Las conexiones deben ser de cobre o acero inoxidable, no de pl\u00e1stico, para evitar riesgos de contaminaci\u00f3n.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar para asegurar la integridad de los filtros en un sistema de extracci\u00f3n de aire que maneja contaminantes peligrosos?**\n   - Se deben realizar pruebas de integridad de los filtros de acuerdo con la norma ISO 14644-3, y se debe mantener la presi\u00f3n negativa en la vivienda del filtro. Adem\u00e1s, se debe considerar un sistema de bypass para facilitar la circulaci\u00f3n de aire durante las pruebas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistemas de Filtraci\u00f3n de Aire**:\n   - Importancia de un dise\u00f1o adecuado para minimizar el riesgo de contaminaci\u00f3n cruzada en instalaciones cr\u00edticas, como salas limpias.\n\n2. **Gesti\u00f3n de Riesgos**:\n   - Aplicaci\u00f3n de principios de gesti\u00f3n de riesgos para abordar la potencial contaminaci\u00f3n cruzada, especialmente en sistemas que utilizan ruedas de recuperaci\u00f3n de energ\u00eda.\n\n3. **Filtraci\u00f3n de Aire de Retorno**:\n   - El aire de retorno debe pasar por un sistema de filtraci\u00f3n seguro antes de ser reintroducido en la unidad de manejo de aire (AHU). Se recomienda el uso de filtros HEPA en serie.\n\n4. **Sincronizaci\u00f3n de Ventiladores**:\n   - Los ventiladores de suministro y extracci\u00f3n deben operar de manera sincronizada para mantener la presi\u00f3n y el flujo de aire adecuados. Se debe detener el procesamiento si los ventiladores no est\u00e1n funcionando.\n\n5. **Carcasas de Filtros de Cambio Seguro**:\n   - Dise\u00f1o de carcasas de filtros (bag-in-bag-out) que protejan a los operadores y eviten la liberaci\u00f3n de polvo al ambiente durante el cambio de filtros.\n\n6. **Componentes del Sistema**:\n   - Elementos como dampers de cierre, sensores de velocidad, unidades de frecuencia variable (VFD), y medidores de presi\u00f3n diferencial de filtros son cruciales para el funcionamiento del sistema.\n\n### Entidades Clave\n- **HEPA**: Filtros de alta eficiencia para la captura de part\u00edculas.\n- **AHU**: Unidad de Manejo de Aire.\n- **DOP**: Disolvente utilizado para pruebas de integridad de filtros.\n- **VFD**: Variador de Frecuencia, utilizado para controlar la velocidad de los ventiladores.\n- **Safe Change Filter**: Sistema de filtraci\u00f3n dise\u00f1ado para facilitar el cambio de filtros de manera segura. \n\nEste resumen abarca los aspectos fundamentales del manejo de sistemas de filtraci\u00f3n de aire en entornos controlados, enfatizando la seguridad y la eficacia en la prevenci\u00f3n de la contaminaci\u00f3n.", "excerpt_keywords": "Keywords: HEPA filters, air filtration, contamination control, pressure differential gauges, safe change systems"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ec32098b-ec61-411d-a088-e9c5ea02c16b", "node_type": "4", "metadata": {"page_label": "219", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11.2 \nThe final filters on the safe change unit should be HEPA filters with at least an H13 classification according to EN 1822 filter standards. For dusty return, air pre-filtration may also be required to prolong the life of the HEPA filters. The pre-filtration filters should also be removable through the bag-in-bag-out method.\n\n11.3 \nFor exhaust systems where the discharge contaminant is considered particularly hazardous, two banks of HEPA filters in series should be considered to provide additional protection should the first filter fail.\n\n11.4 \nAll filter banks should be provided with pressure differential indication gauges to indicate the filter dust loading and remaining lifespan of the filters. Connection to these gauges should be copper or stainless steel and not plastic tubing, which could perish causing a contamination hazard. The tube connections on the filter casing should be provided with stopcocks, for safe removal or calibration of gauges.\n\n11.5 \nMonitoring of filters should be done at regular intervals to prevent excessive filter loading that could force dust particles through the filter media, or could cause the filters to burst, resulting in ambient contamination.\n\n11.6 \nComputer-based data monitoring systems may be installed to monitor filter condition.\n\n11.7 \nFilter pressure gauges should be marked with the clean filter resistance and the change-out filter resistance.\n\n11.8 \nInstalled filter leakage tests should be performed in accordance with ISO 14644-3. Injection ports (upstream) and access ports (downstream) should, therefore, be provided for this purpose.\n\n11.9 \nThe exhaust air fan on a safe change filter system should be located after the filters so that the filter housing is maintained at a negative pressure. This poses a difficulty when carrying out filter integrity tests, and for this reason a bypass damper system should be provided, as illustrated in Figure 2, so that air can be circulated through the HEPA filters, while the scanning ports are open. Alternatively an independent booster fan system can be used, with appropriate shut-off dampers.\n\n11.10 \nThe bypass arrangement as shown in Figure 2 also permits decontamination of the filters by means of circulation of a sanitizing agent.\n\n11.11 \nAll exhaust systems from the facility, including dust extraction systems, vacuum system exhaust, fluid bed drier exhaust and coating pan exhaust, should be passed through safe change filter housings before being exhausted to the atmosphere.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "c9a6ac596469cf1870d1c34be11867b3a7130df971e7e11f89cf4d50767aa75b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 11.2 \nThe final filters on the safe change unit should be HEPA filters with at least an H13 classification according to EN 1822 filter standards. For dusty return, air pre-filtration may also be required to prolong the life of the HEPA filters. The pre-filtration filters should also be removable through the bag-in-bag-out method.\n\n11.3 \nFor exhaust systems where the discharge contaminant is considered particularly hazardous, two banks of HEPA filters in series should be considered to provide additional protection should the first filter fail.\n\n11.4 \nAll filter banks should be provided with pressure differential indication gauges to indicate the filter dust loading and remaining lifespan of the filters. Connection to these gauges should be copper or stainless steel and not plastic tubing, which could perish causing a contamination hazard. The tube connections on the filter casing should be provided with stopcocks, for safe removal or calibration of gauges.\n\n11.5 \nMonitoring of filters should be done at regular intervals to prevent excessive filter loading that could force dust particles through the filter media, or could cause the filters to burst, resulting in ambient contamination.\n\n11.6 \nComputer-based data monitoring systems may be installed to monitor filter condition.\n\n11.7 \nFilter pressure gauges should be marked with the clean filter resistance and the change-out filter resistance.\n\n11.8 \nInstalled filter leakage tests should be performed in accordance with ISO 14644-3. Injection ports (upstream) and access ports (downstream) should, therefore, be provided for this purpose.\n\n11.9 \nThe exhaust air fan on a safe change filter system should be located after the filters so that the filter housing is maintained at a negative pressure. This poses a difficulty when carrying out filter integrity tests, and for this reason a bypass damper system should be provided, as illustrated in Figure 2, so that air can be circulated through the HEPA filters, while the scanning ports are open. Alternatively an independent booster fan system can be used, with appropriate shut-off dampers.\n\n11.10 \nThe bypass arrangement as shown in Figure 2 also permits decontamination of the filters by means of circulation of a sanitizing agent.\n\n11.11 \nAll exhaust systems from the facility, including dust extraction systems, vacuum system exhaust, fluid bed drier exhaust and coating pan exhaust, should be passed through safe change filter housings before being exhausted to the atmosphere.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2504, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ee79e3aa-4369-4007-9c15-3d6b13a8e622": {"__data__": {"id_": "ee79e3aa-4369-4007-9c15-3d6b13a8e622", "embedding": null, "metadata": {"page_label": "220", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11.12\n\nAll exhaust points outside the building should be located as far as possible from air entry points, and exit points should be at a high level to minimize the possibility of re-entrainment of exhaust air. Dominant and seasonal wind directions should be taken into account when positioning exhaust and supply points.\n\n11.13 Where excessively dust-laden air is handled, a dust collector or bag house should be considered, with the dust collector being located in an enclosed room maintained at a negative pressure. Access control, maintenance staff, personal protection equipment (PPE) and breathing air systems should then be provided to protect the operators during removal of dust from the collector bins.\n\n11.14 Portable vacuum cleaners and portable dust collectors should be fitted with H13 HEPA filters. These types of units should be emptied and cleaned in a room which is under negative pressure relative to the environment. Personnel should be provided with suitable PPE.\n\n11.15 Records of the safe disposal of all contaminated filters and dust should be kept.\n\n# 12. Personnel decontamination systems\n\n12.1 If required, a means of preventing contaminants from leaving the facility on the garments of personnel should be provided. This could be in the form of an air shower; mist shower, water shower or appropriate device.\n\n12.2 An air shower comprises an airlock where high velocity air is supplied through air nozzles (e.g. from the sides of the airlock) in order to dislodge dust particles. Air extraction grilles (e.g. at low level) should draw the air away and return it to the filtration system. Some air showers may also incorporate a vertical unidirectional airflow section at the exit end, to flush contaminants away.\n\n*Note:* When air showers are used these should be correctly designed to effectively extract dust.\n\nAir filtration of the supply air and return or exhaust air should comply with the same filtration standards as used in the manufacturing facility. Normally the fan should be activated by opening the door as the operator enters the shower, with a timing device on the exit door interlock to allow sufficient time for the decontamination process to be effective.\n\n12.3 Flushing devices similar to air or mist showers for personnel could be used at material exits to assist with removing contaminants.\n\n12.4 Wet mist or fog decontamination systems for operators can be employed for deactivating contaminants on the operator\u2019s garments, or", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las mejores pr\u00e1cticas para la gesti\u00f3n de la calidad del aire en instalaciones que manejan aire cargado de polvo y la descontaminaci\u00f3n del personal. Se enfatiza la importancia de ubicar los puntos de escape de aire lejos de las entradas de aire, el uso de colectores de polvo en habitaciones con presi\u00f3n negativa, y la implementaci\u00f3n de sistemas de descontaminaci\u00f3n para el personal, como duchas de aire y sistemas de niebla h\u00fameda. Tambi\u00e9n se menciona la necesidad de mantener registros de la disposici\u00f3n segura de filtros y polvo contaminado.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las consideraciones clave para la ubicaci\u00f3n de los puntos de escape de aire en relaci\u00f3n con las entradas de aire en un edificio?**\n   - Esta pregunta se centra en las directrices espec\u00edficas sobre la ubicaci\u00f3n de los puntos de escape de aire y c\u00f3mo deben tener en cuenta las direcciones del viento.\n\n2. **\u00bfQu\u00e9 medidas de protecci\u00f3n deben implementarse para los operadores que manejan colectores de polvo en habitaciones de presi\u00f3n negativa?**\n   - Esta pregunta busca detalles sobre el equipo de protecci\u00f3n personal (PPE) y otros sistemas de seguridad que deben estar disponibles para los operadores durante la manipulaci\u00f3n de polvo.\n\n3. **\u00bfC\u00f3mo deben dise\u00f1arse y operar las duchas de aire para garantizar una descontaminaci\u00f3n efectiva del personal?**\n   - Esta pregunta se enfoca en los aspectos t\u00e9cnicos del dise\u00f1o y funcionamiento de las duchas de aire, incluyendo la activaci\u00f3n del ventilador y el tiempo de exposici\u00f3n necesario para una descontaminaci\u00f3n adecuada.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar disponible en otras fuentes, bas\u00e1ndose en el contenido detallado del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Filtros HEPA**:\n   - Se requiere el uso de filtros HEPA con una clasificaci\u00f3n m\u00ednima de H13 seg\u00fan las normas EN 1822.\n   - Para prolongar la vida \u00fatil de los filtros HEPA, se sugiere un sistema de pre-filtraci\u00f3n, especialmente en entornos con polvo.\n\n2. **Sistemas de Filtraci\u00f3n en Serie**:\n   - En sistemas de extracci\u00f3n donde los contaminantes son particularmente peligrosos, se recomienda utilizar dos bancos de filtros HEPA en serie para mayor protecci\u00f3n.\n\n3. **Monitoreo y Mantenimiento**:\n   - Es esencial contar con man\u00f3metros de presi\u00f3n diferencial para indicar la carga de polvo y la vida \u00fatil restante de los filtros.\n   - Se deben realizar monitoreos regulares para evitar la sobrecarga de los filtros, lo que podr\u00eda causar contaminaci\u00f3n ambiental.\n\n4. **Pruebas de Integridad**:\n   - Las pruebas de integridad de los filtros deben realizarse de acuerdo con la norma ISO 14644-3, y se deben proporcionar puertos de inyecci\u00f3n y acceso para facilitar estas pruebas.\n\n5. **Presi\u00f3n Negativa y Sistemas de Bypass**:\n   - El ventilador de extracci\u00f3n debe estar ubicado despu\u00e9s de los filtros para mantener la presi\u00f3n negativa en la vivienda del filtro.\n   - Se sugiere un sistema de compuerta de bypass para permitir la circulaci\u00f3n de aire durante las pruebas de integridad y para la desinfecci\u00f3n de los filtros.\n\n6. **Conexiones y Materiales**:\n   - Las conexiones a los man\u00f3metros deben ser de cobre o acero inoxidable, evitando el uso de tuber\u00edas de pl\u00e1stico que pueden representar un riesgo de contaminaci\u00f3n.\n\n7. **Exhaustos de Sistemas**:\n   - Todos los sistemas de extracci\u00f3n de aire, incluidos los de extracci\u00f3n de polvo y sistemas de vac\u00edo, deben pasar por alojamientos de filtros seguros antes de ser liberados al ambiente.\n\n### Entidades Clave:\n- **Filtros HEPA**: H13, pre-filtraci\u00f3n, pruebas de integridad.\n- **Normas**: EN 1822, ISO 14644-3.\n- **Materiales**: Cobre, acero inoxidable, tuber\u00edas de pl\u00e1stico (no recomendadas).\n- **Sistemas**: Sistemas de extracci\u00f3n, sistemas de bypass, ventiladores de extracci\u00f3n.", "excerpt_keywords": "Keywords: exhaust points, dust collector, HEPA filters, personnel decontamination, air filtration"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "756de20d-dd81-47ba-992a-23cf259da245", "node_type": "4", "metadata": {"page_label": "220", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11.12\n\nAll exhaust points outside the building should be located as far as possible from air entry points, and exit points should be at a high level to minimize the possibility of re-entrainment of exhaust air. Dominant and seasonal wind directions should be taken into account when positioning exhaust and supply points.\n\n11.13 Where excessively dust-laden air is handled, a dust collector or bag house should be considered, with the dust collector being located in an enclosed room maintained at a negative pressure. Access control, maintenance staff, personal protection equipment (PPE) and breathing air systems should then be provided to protect the operators during removal of dust from the collector bins.\n\n11.14 Portable vacuum cleaners and portable dust collectors should be fitted with H13 HEPA filters. These types of units should be emptied and cleaned in a room which is under negative pressure relative to the environment. Personnel should be provided with suitable PPE.\n\n11.15 Records of the safe disposal of all contaminated filters and dust should be kept.\n\n# 12. Personnel decontamination systems\n\n12.1 If required, a means of preventing contaminants from leaving the facility on the garments of personnel should be provided. This could be in the form of an air shower; mist shower, water shower or appropriate device.\n\n12.2 An air shower comprises an airlock where high velocity air is supplied through air nozzles (e.g. from the sides of the airlock) in order to dislodge dust particles. Air extraction grilles (e.g. at low level) should draw the air away and return it to the filtration system. Some air showers may also incorporate a vertical unidirectional airflow section at the exit end, to flush contaminants away.\n\n*Note:* When air showers are used these should be correctly designed to effectively extract dust.\n\nAir filtration of the supply air and return or exhaust air should comply with the same filtration standards as used in the manufacturing facility. Normally the fan should be activated by opening the door as the operator enters the shower, with a timing device on the exit door interlock to allow sufficient time for the decontamination process to be effective.\n\n12.3 Flushing devices similar to air or mist showers for personnel could be used at material exits to assist with removing contaminants.\n\n12.4 Wet mist or fog decontamination systems for operators can be employed for deactivating contaminants on the operator\u2019s garments, or", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "214a176274061c13760864939fd915aab45193e7b7dd8acee19faef57c7be3d9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 11.12\n\nAll exhaust points outside the building should be located as far as possible from air entry points, and exit points should be at a high level to minimize the possibility of re-entrainment of exhaust air. Dominant and seasonal wind directions should be taken into account when positioning exhaust and supply points.\n\n11.13 Where excessively dust-laden air is handled, a dust collector or bag house should be considered, with the dust collector being located in an enclosed room maintained at a negative pressure. Access control, maintenance staff, personal protection equipment (PPE) and breathing air systems should then be provided to protect the operators during removal of dust from the collector bins.\n\n11.14 Portable vacuum cleaners and portable dust collectors should be fitted with H13 HEPA filters. These types of units should be emptied and cleaned in a room which is under negative pressure relative to the environment. Personnel should be provided with suitable PPE.\n\n11.15 Records of the safe disposal of all contaminated filters and dust should be kept.\n\n# 12. Personnel decontamination systems\n\n12.1 If required, a means of preventing contaminants from leaving the facility on the garments of personnel should be provided. This could be in the form of an air shower; mist shower, water shower or appropriate device.\n\n12.2 An air shower comprises an airlock where high velocity air is supplied through air nozzles (e.g. from the sides of the airlock) in order to dislodge dust particles. Air extraction grilles (e.g. at low level) should draw the air away and return it to the filtration system. Some air showers may also incorporate a vertical unidirectional airflow section at the exit end, to flush contaminants away.\n\n*Note:* When air showers are used these should be correctly designed to effectively extract dust.\n\nAir filtration of the supply air and return or exhaust air should comply with the same filtration standards as used in the manufacturing facility. Normally the fan should be activated by opening the door as the operator enters the shower, with a timing device on the exit door interlock to allow sufficient time for the decontamination process to be effective.\n\n12.3 Flushing devices similar to air or mist showers for personnel could be used at material exits to assist with removing contaminants.\n\n12.4 Wet mist or fog decontamination systems for operators can be employed for deactivating contaminants on the operator\u2019s garments, or", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2478, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5332fcc5-3d42-40ad-bb6e-33a51f278875": {"__data__": {"id_": "5332fcc5-3d42-40ad-bb6e-33a51f278875", "embedding": null, "metadata": {"page_label": "221", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "causing contaminants to adhere to the garments so that they are not easily liberated.\n\n12.5 Personnel should change into clean garments after having taken a shower.\n\n## 13. Effluent treatment\n\n13.1 Liquid and solid waste effluent should be handled in such a manner as not to present a risk of contamination to the product, personnel or to the environment.\n\n13.2 All effluent should be disposed of in a safe manner, and the means of disposal should be documented. Where external contractors are used for effluent disposal they should have certification authorizing them to handle and treat hazardous products.\n\n## 14. Maintenance\n\n14.1 The efficient and safe operation of a facility handling hazardous materials is reliant on regular maintenance being carried out, to ensure that all parameters remain within specified tolerances. See *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials (1)* or WHO Technical Report Series, No. 937, Annex 2, section 8.3 (2) for further details on maintenance.\n\n## 15. Qualification and validation\n\n15.1 System qualification and validation should be carried out as described in other WHO guidelines.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior del contenido:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda directrices sobre el manejo seguro de materiales peligrosos en instalaciones, enfatizando la importancia de la higiene del personal, el tratamiento adecuado de efluentes, el mantenimiento regular de las instalaciones y la calificaci\u00f3n y validaci\u00f3n de sistemas. Se destacan pr\u00e1cticas espec\u00edficas para evitar la contaminaci\u00f3n y asegurar la seguridad tanto del producto como del personal y el medio ambiente.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las recomendaciones espec\u00edficas para el cambio de vestimenta del personal en instalaciones que manejan materiales peligrosos?**\n   - Respuesta: El personal debe cambiarse a prendas limpias despu\u00e9s de haberse duchado para evitar que los contaminantes se adhieran a la ropa y no se liberen f\u00e1cilmente.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse para el tratamiento y disposici\u00f3n de efluentes en instalaciones que manejan residuos peligrosos?**\n   - Respuesta: Los efluentes l\u00edquidos y s\u00f3lidos deben manejarse de manera que no presenten riesgos de contaminaci\u00f3n. Adem\u00e1s, todos los efluentes deben ser desechados de forma segura y documentada, y los contratistas externos que se encarguen de la disposici\u00f3n deben tener certificaci\u00f3n para manejar y tratar productos peligrosos.\n\n3. **\u00bfPor qu\u00e9 es crucial el mantenimiento regular en instalaciones que manejan materiales peligrosos, seg\u00fan el documento de la OMS?**\n   - Respuesta: El mantenimiento regular es esencial para garantizar el funcionamiento eficiente y seguro de la instalaci\u00f3n, asegurando que todos los par\u00e1metros se mantengan dentro de las tolerancias especificadas. Esto ayuda a prevenir incidentes que podr\u00edan comprometer la seguridad del producto, del personal y del medio ambiente.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Ubicaci\u00f3n de Puntos de Escape de Aire**:\n   - Los puntos de escape deben estar lo m\u00e1s alejados posible de las entradas de aire.\n   - Deben situarse a una altura elevada para minimizar la recirculaci\u00f3n del aire de escape.\n   - Se deben considerar las direcciones del viento dominantes y estacionales al posicionar los puntos de escape y suministro.\n\n2. **Manejo de Aire Cargado de Polvo**:\n   - Se recomienda el uso de colectores de polvo o casas de bolsa en \u00e1reas con aire excesivamente cargado de polvo.\n   - Los colectores deben estar en habitaciones con presi\u00f3n negativa.\n   - Se deben implementar controles de acceso, personal de mantenimiento, equipo de protecci\u00f3n personal (PPE) y sistemas de aire respirable para proteger a los operadores.\n\n3. **Filtros y Equipos de Limpieza**:\n   - Los aspiradores port\u00e1tiles y colectores de polvo deben estar equipados con filtros HEPA H13.\n   - Estos equipos deben vaciarse y limpiarse en habitaciones con presi\u00f3n negativa.\n   - Es necesario mantener registros de la disposici\u00f3n segura de filtros y polvo contaminado.\n\n4. **Sistemas de Descontaminaci\u00f3n del Personal**:\n   - Se deben proporcionar medios para evitar que los contaminantes salgan de la instalaci\u00f3n en la ropa del personal, como duchas de aire, duchas de niebla o agua.\n   - Las duchas de aire deben estar dise\u00f1adas para extraer eficazmente el polvo mediante aire de alta velocidad.\n   - La filtraci\u00f3n del aire de suministro y retorno debe cumplir con los mismos est\u00e1ndares de filtraci\u00f3n que la instalaci\u00f3n de fabricaci\u00f3n.\n\n5. **Dispositivos de Flushing**:\n   - Se pueden utilizar dispositivos de flushing similares a duchas de aire o niebla en las salidas de materiales para ayudar a eliminar contaminantes.\n   - Sistemas de niebla h\u00fameda pueden ser empleados para desactivar contaminantes en la vestimenta de los operadores.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Colectores de polvo**: Equipos recomendados para manejar aire cargado de polvo.\n- **Filtros HEPA H13**: Tipo de filtro recomendado para equipos de limpieza.\n- **Equipo de Protecci\u00f3n Personal (PPE)**: Elementos necesarios para la seguridad de los operadores.\n- **Duchas de aire**: Sistemas de descontaminaci\u00f3n para el personal.\n- **Sistemas de niebla h\u00fameda**: M\u00e9todos de descontaminaci\u00f3n adicionales para operadores. \n\nEste resumen destaca las mejores pr\u00e1cticas y consideraciones para la gesti\u00f3n de la calidad del aire y la descontaminaci\u00f3n del personal en instalaciones que manejan aire contaminado.", "excerpt_keywords": "Keywords: hazardous materials, effluent treatment, personnel hygiene, maintenance, qualification and validation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "881b1adf-34eb-4d4c-b671-8031a4fba642", "node_type": "4", "metadata": {"page_label": "221", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "causing contaminants to adhere to the garments so that they are not easily liberated.\n\n12.5 Personnel should change into clean garments after having taken a shower.\n\n## 13. Effluent treatment\n\n13.1 Liquid and solid waste effluent should be handled in such a manner as not to present a risk of contamination to the product, personnel or to the environment.\n\n13.2 All effluent should be disposed of in a safe manner, and the means of disposal should be documented. Where external contractors are used for effluent disposal they should have certification authorizing them to handle and treat hazardous products.\n\n## 14. Maintenance\n\n14.1 The efficient and safe operation of a facility handling hazardous materials is reliant on regular maintenance being carried out, to ensure that all parameters remain within specified tolerances. See *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials (1)* or WHO Technical Report Series, No. 937, Annex 2, section 8.3 (2) for further details on maintenance.\n\n## 15. Qualification and validation\n\n15.1 System qualification and validation should be carried out as described in other WHO guidelines.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "50acf443f2f348106baa5319475297853590c950083e453b150af4cc10f96226", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "causing contaminants to adhere to the garments so that they are not easily liberated.\n\n12.5 Personnel should change into clean garments after having taken a shower.\n\n## 13. Effluent treatment\n\n13.1 Liquid and solid waste effluent should be handled in such a manner as not to present a risk of contamination to the product, personnel or to the environment.\n\n13.2 All effluent should be disposed of in a safe manner, and the means of disposal should be documented. Where external contractors are used for effluent disposal they should have certification authorizing them to handle and treat hazardous products.\n\n## 14. Maintenance\n\n14.1 The efficient and safe operation of a facility handling hazardous materials is reliant on regular maintenance being carried out, to ensure that all parameters remain within specified tolerances. See *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials (1)* or WHO Technical Report Series, No. 937, Annex 2, section 8.3 (2) for further details on maintenance.\n\n## 15. Qualification and validation\n\n15.1 System qualification and validation should be carried out as described in other WHO guidelines.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1167, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1794134f-2395-40d1-af06-ee4cadb7f802": {"__data__": {"id_": "1794134f-2395-40d1-af06-ee4cadb7f802", "embedding": null, "metadata": {"page_label": "222", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, 2nd updated ed. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007.\n\n2. Supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report. Geneva, World Health Organization, 2006, Annex 2 (WHO Technical Report Series, No. 937).\n\n3. Health Canada: Laboratory biosafety guidelines, 3rd ed. Ottawa, Health Canada, 2004.\n\n4. WHO good manufacturing practices for sterile pharmaceutical products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report. Geneva, World Health Organization, 2010, Annex 4 (WHO Technical Report Series, No. 957).\n\n5. ISO: International Standard. Clean rooms and associated controlled environments. ISO 14644. Geneva, International Organization for Standardization.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento \"WHO - Technical Report Series 957\" incluye referencias a diversas gu\u00edas y est\u00e1ndares relacionados con las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) en la industria farmac\u00e9utica. Se mencionan directrices espec\u00edficas de la Organizaci\u00f3n Mundial de la Salud (OMS) y de Health Canada, as\u00ed como normas internacionales sobre salas limpias y entornos controlados. Estas referencias son cruciales para asegurar la calidad y la seguridad en la producci\u00f3n de productos farmac\u00e9uticos, tanto est\u00e9riles como no est\u00e9riles.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales diferencias entre las buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles y no est\u00e9riles seg\u00fan las gu\u00edas de la OMS?**\n   - Esta pregunta busca una comparaci\u00f3n directa entre las dos categor\u00edas de productos, que puede no estar claramente delineada en otros documentos.\n\n2. **\u00bfQu\u00e9 aspectos espec\u00edficos se abordan en las \"Supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems\" mencionadas en el documento?**\n   - Esta pregunta se centra en un tema t\u00e9cnico espec\u00edfico que puede no ser ampliamente discutido en otras fuentes.\n\n3. **\u00bfC\u00f3mo se relacionan las normas ISO 14644 sobre salas limpias con las buenas pr\u00e1cticas de fabricaci\u00f3n mencionadas en el informe de la OMS?**\n   - Esta pregunta busca una conexi\u00f3n entre est\u00e1ndares internacionales y las directrices de la OMS, lo que puede no ser evidente en otros contextos. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n detallada y espec\u00edfica que puede no estar disponible en otros documentos o fuentes.", "prev_section_summary": "### Temas Clave:\n\n1. **Higiene del Personal**: Se enfatiza la importancia de que el personal cambie a prendas limpias despu\u00e9s de ducharse para evitar la contaminaci\u00f3n.\n\n2. **Tratamiento de Efluentes**: Se establecen directrices para el manejo seguro de efluentes l\u00edquidos y s\u00f3lidos, asegurando que no representen un riesgo de contaminaci\u00f3n para productos, personal o medio ambiente. Tambi\u00e9n se requiere documentaci\u00f3n del proceso de disposici\u00f3n y certificaci\u00f3n de contratistas externos.\n\n3. **Mantenimiento de Instalaciones**: Se destaca la necesidad de realizar mantenimiento regular en instalaciones que manejan materiales peligrosos para garantizar su operaci\u00f3n eficiente y segura, manteniendo todos los par\u00e1metros dentro de tolerancias especificadas.\n\n4. **Calificaci\u00f3n y Validaci\u00f3n de Sistemas**: Se menciona que la calificaci\u00f3n y validaci\u00f3n de sistemas deben seguir las pautas establecidas por la OMS.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Materiales Peligrosos**: Tipo de sustancias que requieren manejo especial.\n- **Efluentes L\u00edquidos y S\u00f3lidos**: Residuos generados que deben ser tratados adecuadamente.\n- **Contratistas Externos**: Entidades que pueden ser contratadas para la disposici\u00f3n de efluentes, que deben estar certificadas.\n- **Instalaciones**: Lugares donde se manejan materiales peligrosos y que requieren mantenimiento regular.\n\n### Resumen:\nEl documento de la OMS proporciona directrices sobre la higiene del personal, el tratamiento seguro de efluentes, la importancia del mantenimiento regular en instalaciones que manejan materiales peligrosos y la necesidad de calificaci\u00f3n y validaci\u00f3n de sistemas. Estas pr\u00e1cticas son esenciales para prevenir la contaminaci\u00f3n y garantizar la seguridad del producto, del personal y del medio ambiente.", "excerpt_keywords": "Keywords: buenas pr\u00e1cticas de fabricaci\u00f3n, OMS, productos farmac\u00e9uticos, normas ISO, calidad y seguridad"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4ab8e6fc-6373-4832-b6ef-cfd14228b9f4", "node_type": "4", "metadata": {"page_label": "222", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, 2nd updated ed. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007.\n\n2. Supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report. Geneva, World Health Organization, 2006, Annex 2 (WHO Technical Report Series, No. 937).\n\n3. Health Canada: Laboratory biosafety guidelines, 3rd ed. Ottawa, Health Canada, 2004.\n\n4. WHO good manufacturing practices for sterile pharmaceutical products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report. Geneva, World Health Organization, 2010, Annex 4 (WHO Technical Report Series, No. 957).\n\n5. ISO: International Standard. Clean rooms and associated controlled environments. ISO 14644. Geneva, International Organization for Standardization.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "77ff651e8dec9c1a6ce49c78b1c293b3b218f0c7c56cd58c346794ff3b23797f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# References\n\n1. Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, 2nd updated ed. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007.\n\n2. Supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report. Geneva, World Health Organization, 2006, Annex 2 (WHO Technical Report Series, No. 937).\n\n3. Health Canada: Laboratory biosafety guidelines, 3rd ed. Ottawa, Health Canada, 2004.\n\n4. WHO good manufacturing practices for sterile pharmaceutical products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report. Geneva, World Health Organization, 2010, Annex 4 (WHO Technical Report Series, No. 957).\n\n5. ISO: International Standard. Clean rooms and associated controlled environments. ISO 14644. Geneva, International Organization for Standardization.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1057, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "78ee4e74-ea72-4554-9dcf-c5eb9464c215": {"__data__": {"id_": "78ee4e74-ea72-4554-9dcf-c5eb9464c215", "embedding": null, "metadata": {"page_label": "223", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 4\n\n## WHO good manufacturing practices for sterile pharmaceutical products\n\n### Introduction\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations in its thirty-sixth report in 1999 adopted *WHO good manufacturing practices for sterile pharmaceutical products* (WHO Technical Report Series, No. 902, 2002, Annex 6) (http://whqlibdoc.who.int/trs/WHO_TRS_902.pdf); and published in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection (2007) (1).*\n\nFollowing implementation of these WHO good manufacturing practices (GMP) within the context of the WHO Prequalification Programme, a proposal for revision is being submitted to take into consideration new developments. The proposal for revision of the above-mentioned guidance is being made to bring the WHO GMP into line with International Standardization Organization standard ISO 14644-1 (2) and recent practices of the United States (3), Japan (4), the European Union (5) and the Pharmaceutical Inspection Co-operation Scheme.\n\n- New chapters on Isolator technology and Blow/fill/seal technology have been added to the document.\n- The chapter on Finishing of sterile products has been amended and provisions have been given for capping of vials.\n- The chapter entitled Manufacture of sterile preparations has been amended and provisions have been given for clean room and clean-air device monitoring.\n\nImplementation of these new practices may need to be undertaken for certain parts using a step-wise approach, especially the part relating to the provision for capping in a clean or sterile environment, as this is currently not implemented in most industries.\n\nOn the basis of the above, the following text is proposed to replace the previously published guidance.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento se centra en las Buenas Pr\u00e1cticas de Manufactura (GMP) de la OMS para productos farmac\u00e9uticos est\u00e9riles, revisadas para alinearse con est\u00e1ndares internacionales y recientes pr\u00e1cticas de varios pa\u00edses. Se han a\u00f1adido nuevos cap\u00edtulos sobre tecnolog\u00edas espec\u00edficas y se han realizado enmiendas en secciones clave, como el acabado de productos est\u00e9riles y la fabricaci\u00f3n de preparaciones est\u00e9riles. La implementaci\u00f3n de estas pr\u00e1cticas puede requerir un enfoque gradual, especialmente en lo que respecta al encapsulado en entornos limpios o est\u00e9riles.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 nuevas tecnolog\u00edas se han incorporado en la revisi\u00f3n de las Buenas Pr\u00e1cticas de Manufactura para productos farmac\u00e9uticos est\u00e9riles?**\n   - Respuesta: Se han a\u00f1adido nuevos cap\u00edtulos sobre tecnolog\u00eda de aisladores y tecnolog\u00eda de llenado/sellado.\n\n2. **\u00bfCu\u00e1les son las enmiendas realizadas en el cap\u00edtulo sobre el acabado de productos est\u00e9riles?**\n   - Respuesta: Se han realizado enmiendas para incluir disposiciones sobre el encapsulado de viales.\n\n3. **\u00bfPor qu\u00e9 se sugiere un enfoque gradual para la implementaci\u00f3n de las nuevas pr\u00e1cticas, especialmente en relaci\u00f3n con el encapsulado en un entorno limpio o est\u00e9ril?**\n   - Respuesta: Se sugiere un enfoque gradual porque actualmente esta pr\u00e1ctica no se implementa en la mayor\u00eda de las industrias.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n se centra en las referencias relacionadas con las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) en la industria farmac\u00e9utica, destacando la importancia de seguir directrices y est\u00e1ndares para garantizar la calidad y seguridad de los productos farmac\u00e9uticos. \n\n#### Temas Clave:\n1. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF)**: Se enfatiza la necesidad de seguir gu\u00edas espec\u00edficas para asegurar la calidad en la producci\u00f3n de productos farmac\u00e9uticos, tanto est\u00e9riles como no est\u00e9riles.\n2. **Normas Internacionales**: Se menciona la norma ISO 14644, que se refiere a las salas limpias y entornos controlados, cruciales para la fabricaci\u00f3n de productos farmac\u00e9uticos.\n3. **Directrices de la OMS**: Se citan varias publicaciones de la Organizaci\u00f3n Mundial de la Salud que abordan las BPF y aspectos t\u00e9cnicos relacionados con la producci\u00f3n farmac\u00e9utica.\n4. **Biosafety**: Se hace referencia a las pautas de biosalubridad de Health Canada, que son relevantes para la seguridad en laboratorios.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Publica directrices y est\u00e1ndares sobre BPF.\n- **Health Canada**: Proporciona pautas sobre biosalubridad.\n- **International Organization for Standardization (ISO)**: Establece normas internacionales, como la ISO 14644.\n\nEste resumen destaca la interconexi\u00f3n entre las directrices de la OMS, las normas internacionales y las pautas de biosalubridad, subrayando su relevancia para la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: Good Manufacturing Practices, sterile pharmaceutical products, ISO 14644, Isolator technology, clean room monitoring"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e622c5a4-2eb3-46d4-af90-0de4edcbb3d2", "node_type": "4", "metadata": {"page_label": "223", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 4\n\n## WHO good manufacturing practices for sterile pharmaceutical products\n\n### Introduction\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations in its thirty-sixth report in 1999 adopted *WHO good manufacturing practices for sterile pharmaceutical products* (WHO Technical Report Series, No. 902, 2002, Annex 6) (http://whqlibdoc.who.int/trs/WHO_TRS_902.pdf); and published in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection (2007) (1).*\n\nFollowing implementation of these WHO good manufacturing practices (GMP) within the context of the WHO Prequalification Programme, a proposal for revision is being submitted to take into consideration new developments. The proposal for revision of the above-mentioned guidance is being made to bring the WHO GMP into line with International Standardization Organization standard ISO 14644-1 (2) and recent practices of the United States (3), Japan (4), the European Union (5) and the Pharmaceutical Inspection Co-operation Scheme.\n\n- New chapters on Isolator technology and Blow/fill/seal technology have been added to the document.\n- The chapter on Finishing of sterile products has been amended and provisions have been given for capping of vials.\n- The chapter entitled Manufacture of sterile preparations has been amended and provisions have been given for clean room and clean-air device monitoring.\n\nImplementation of these new practices may need to be undertaken for certain parts using a step-wise approach, especially the part relating to the provision for capping in a clean or sterile environment, as this is currently not implemented in most industries.\n\nOn the basis of the above, the following text is proposed to replace the previously published guidance.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "888ce790e29e135f4e08083892f47ce674ad3e600878e5d28e2f96c386239f95", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 4\n\n## WHO good manufacturing practices for sterile pharmaceutical products\n\n### Introduction\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations in its thirty-sixth report in 1999 adopted *WHO good manufacturing practices for sterile pharmaceutical products* (WHO Technical Report Series, No. 902, 2002, Annex 6) (http://whqlibdoc.who.int/trs/WHO_TRS_902.pdf); and published in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection (2007) (1).*\n\nFollowing implementation of these WHO good manufacturing practices (GMP) within the context of the WHO Prequalification Programme, a proposal for revision is being submitted to take into consideration new developments. The proposal for revision of the above-mentioned guidance is being made to bring the WHO GMP into line with International Standardization Organization standard ISO 14644-1 (2) and recent practices of the United States (3), Japan (4), the European Union (5) and the Pharmaceutical Inspection Co-operation Scheme.\n\n- New chapters on Isolator technology and Blow/fill/seal technology have been added to the document.\n- The chapter on Finishing of sterile products has been amended and provisions have been given for capping of vials.\n- The chapter entitled Manufacture of sterile preparations has been amended and provisions have been given for clean room and clean-air device monitoring.\n\nImplementation of these new practices may need to be undertaken for certain parts using a step-wise approach, especially the part relating to the provision for capping in a clean or sterile environment, as this is currently not implemented in most industries.\n\nOn the basis of the above, the following text is proposed to replace the previously published guidance.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1852, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "285174ca-ba4d-43e9-93fc-4b3bb33f1866": {"__data__": {"id_": "285174ca-ba4d-43e9-93fc-4b3bb33f1866", "embedding": null, "metadata": {"page_label": "224", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# WHO Good Manufacturing Practices for Sterile Pharmaceutical Products\n\n1. General considerations\n2. Quality control\n3. Sanitation\n4. Manufacture of sterile preparations\n5. Sterilization\n6. Terminal sterilization\n7. Aseptic processing and sterilization by filtration\n8. Isolator technology\n9. Blow/fill/seal technology\n10. Personnel\n11. Premises\n12. Equipment\n13. Finishing of sterile products\n\nReferences", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO Good Manufacturing Practices for Sterile Pharmaceutical Products\" de la OMS establece directrices y pr\u00e1cticas recomendadas para la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles. Se abordan aspectos clave como el control de calidad, la sanidad, los procesos de esterilizaci\u00f3n, el uso de tecnolog\u00eda aislante y de llenado/sellado, as\u00ed como la importancia del personal, las instalaciones y el equipo en la producci\u00f3n de estos productos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las consideraciones generales que se deben tener en cuenta al implementar buenas pr\u00e1cticas de manufactura para productos farmac\u00e9uticos est\u00e9riles?**\n   - Esta pregunta busca detalles sobre los principios fundamentales que gu\u00edan la producci\u00f3n est\u00e9ril, que pueden no estar ampliamente disponibles en otras fuentes.\n\n2. **\u00bfQu\u00e9 m\u00e9todos de esterilizaci\u00f3n se describen en el documento y cu\u00e1les son sus aplicaciones espec\u00edficas en la fabricaci\u00f3n de productos est\u00e9riles?**\n   - Esta pregunta se centra en los m\u00e9todos de esterilizaci\u00f3n mencionados, como la esterilizaci\u00f3n terminal y la filtraci\u00f3n as\u00e9ptica, y su relevancia en la industria farmac\u00e9utica.\n\n3. **\u00bfQu\u00e9 papel juega el personal en el cumplimiento de las buenas pr\u00e1cticas de manufactura para productos farmac\u00e9uticos est\u00e9riles seg\u00fan el documento de la OMS?**\n   - Esta pregunta indaga sobre la importancia del personal en el proceso de fabricaci\u00f3n, incluyendo su capacitaci\u00f3n y las pr\u00e1cticas que deben seguir para garantizar la calidad y seguridad de los productos est\u00e9riles.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Buenas Pr\u00e1cticas de Manufactura (GMP)**: El documento se centra en las GMP de la OMS para productos farmac\u00e9uticos est\u00e9riles, revisadas para alinearse con est\u00e1ndares internacionales y pr\u00e1cticas recientes.\n\n2. **Revisi\u00f3n y Actualizaci\u00f3n**: Se propone una revisi\u00f3n de las GMP para incorporar nuevos desarrollos y alinearse con la norma ISO 14644-1 y pr\u00e1cticas de pa\u00edses como Estados Unidos, Jap\u00f3n, la Uni\u00f3n Europea y el esquema de cooperaci\u00f3n de inspecci\u00f3n farmac\u00e9utica.\n\n3. **Nuevos Cap\u00edtulos**:\n   - **Tecnolog\u00eda de Aisladores**: Se ha a\u00f1adido un cap\u00edtulo sobre esta tecnolog\u00eda.\n   - **Tecnolog\u00eda de Llenado/Sellado**: Tambi\u00e9n se ha incluido un cap\u00edtulo sobre esta t\u00e9cnica.\n\n4. **Enmiendas en Cap\u00edtulos Existentes**:\n   - **Acabado de Productos Est\u00e9riles**: Se han realizado enmiendas para incluir disposiciones sobre el encapsulado de viales.\n   - **Fabricaci\u00f3n de Preparaciones Est\u00e9riles**: Se han actualizado las provisiones para el monitoreo de salas limpias y dispositivos de aire limpio.\n\n5. **Implementaci\u00f3n Gradual**: Se sugiere un enfoque gradual para la implementaci\u00f3n de las nuevas pr\u00e1cticas, especialmente en lo que respecta al encapsulado en entornos limpios o est\u00e9riles, dado que esta pr\u00e1ctica no se aplica actualmente en la mayor\u00eda de las industrias.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las GMP.\n- **ISO (Organizaci\u00f3n Internacional de Normalizaci\u00f3n)**: Est\u00e1ndar ISO 14644-1 mencionado.\n- **Pa\u00edses**: Estados Unidos, Jap\u00f3n, Uni\u00f3n Europea, que influyen en las pr\u00e1cticas de manufactura.\n- **Esquema de Cooperaci\u00f3n de Inspecci\u00f3n Farmac\u00e9utica**: Entidad que colabora en la estandarizaci\u00f3n de pr\u00e1cticas.", "excerpt_keywords": "Keywords: Good Manufacturing Practices, sterile pharmaceutical products, sterilization methods, quality control, aseptic processing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "56b3c7dd-5f15-40c3-9e16-68c3cb365349", "node_type": "4", "metadata": {"page_label": "224", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# WHO Good Manufacturing Practices for Sterile Pharmaceutical Products\n\n1. General considerations\n2. Quality control\n3. Sanitation\n4. Manufacture of sterile preparations\n5. Sterilization\n6. Terminal sterilization\n7. Aseptic processing and sterilization by filtration\n8. Isolator technology\n9. Blow/fill/seal technology\n10. Personnel\n11. Premises\n12. Equipment\n13. Finishing of sterile products\n\nReferences", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a7d5b0b2ebf8b42d768f34a7b637519ff6a838627dd63d757d6e63bd45004e72", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# WHO Good Manufacturing Practices for Sterile Pharmaceutical Products\n\n1. General considerations\n2. Quality control\n3. Sanitation\n4. Manufacture of sterile preparations\n5. Sterilization\n6. Terminal sterilization\n7. Aseptic processing and sterilization by filtration\n8. Isolator technology\n9. Blow/fill/seal technology\n10. Personnel\n11. Premises\n12. Equipment\n13. Finishing of sterile products\n\nReferences", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 405, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "78f5f09c-5840-4659-a947-bb9960fe0fed": {"__data__": {"id_": "78f5f09c-5840-4659-a947-bb9960fe0fed", "embedding": null, "metadata": {"page_label": "225", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 1. General considerations\n\n1.1 The production of sterile preparations should be carried out in clean areas, entry to which should be through airlocks for personnel and/or for equipment and materials. Clean areas should be maintained to an appropriate standard of cleanliness and supplied with air that has passed through filters of the required efficiency.\n\n1.2 The various operations of component preparation (such as those involving containers and closures), product preparation, filling and sterilization should be carried out in separate areas within the clean area. These areas are classified into four grades (see section 4).\n\nManufacturing operations are divided here into two categories:\n- first, those where the product is terminally sterilized; and\n- second, those which are conducted aseptically at some or all stages.\n\n# 2. Quality control\n\n2.1 The sterility test applied to the finished product should only be regarded as the last in a series of control measures by which sterility is assured. The test should be validated for the product(s) concerned.\n\n2.2 Samples taken for sterility testing should be representative of the whole of the batch but should, in particular, include samples taken from parts of the batch considered to be most at risk of contamination, for example:\n- for products that have been filled aseptically, samples should include containers filled at the beginning and end of the batch and after any significant interruption of work;\n- for products that have been heat sterilized in their final containers, consideration should be given to taking samples from that part of the load that is potentially the coolest.\n\n2.3 The sterility of the finished product is assured by validation of the sterilization cycle in the case of terminally sterilized products, and by \u201cmedia simulation\u201d or \u201cmedia fill\u201d runs for aseptically processed products. Batch-processing records and, in the case of aseptic processing, environmental quality records, should be examined in conjunction with the results of the sterility tests. The sterility test procedure should be validated for a given product. Pharmacopoeial methods should be used for the validation and performance of the sterility test. In those cases where parametric release has been authorized in place of sterility testing special attention should be paid to the validation and the monitoring of the entire manufacturing process.\n\n2.4 For injectable products the water for injection and the intermediate, if appropriate, and finished products should be monitored for endotoxins,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda consideraciones generales y controles de calidad en la producci\u00f3n de preparaciones est\u00e9riles. Se enfatiza la importancia de realizar estas operaciones en \u00e1reas limpias y clasificadas, as\u00ed como la necesidad de pruebas de esterilidad que validen el proceso de fabricaci\u00f3n. Se describen dos categor\u00edas de operaciones de fabricaci\u00f3n: aquellas que son esterilizadas terminalmente y aquellas que se realizan de manera as\u00e9ptica. Adem\u00e1s, se menciona la importancia de monitorear productos inyectables para endotoxinas y la validaci\u00f3n de los m\u00e9todos de prueba de esterilidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las cuatro categor\u00edas de \u00e1reas limpias mencionadas en el documento y c\u00f3mo se clasifican?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre la clasificaci\u00f3n de las \u00e1reas limpias, que no se detalla en el texto proporcionado.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir para validar el ciclo de esterilizaci\u00f3n de productos que son esterilizados terminalmente?**\n   - Esta pregunta se centra en los pasos espec\u00edficos requeridos para la validaci\u00f3n del ciclo de esterilizaci\u00f3n, que no se explican en detalle en el contexto.\n\n3. **\u00bfQu\u00e9 medidas adicionales se deben considerar en el caso de que se autorice la liberaci\u00f3n param\u00e9trica en lugar de las pruebas de esterilidad?**\n   - Esta pregunta busca informaci\u00f3n sobre las consideraciones especiales que deben tenerse en cuenta cuando se opta por la liberaci\u00f3n param\u00e9trica, un aspecto que no se aborda en profundidad en el texto.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento \"WHO Good Manufacturing Practices for Sterile Pharmaceutical Products\" de la OMS aborda una serie de temas fundamentales relacionados con la producci\u00f3n de productos farmac\u00e9uticos est\u00e9riles. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas en la secci\u00f3n:\n\n1. **Consideraciones Generales**: Principios y fundamentos que gu\u00edan la implementaci\u00f3n de buenas pr\u00e1cticas en la manufactura de productos est\u00e9riles.\n\n2. **Control de Calidad**: M\u00e9todos y procedimientos para asegurar que los productos cumplan con los est\u00e1ndares de calidad requeridos.\n\n3. **Sanidad**: Pr\u00e1cticas de limpieza y desinfecci\u00f3n necesarias para mantener un entorno de producci\u00f3n est\u00e9ril.\n\n4. **Fabricaci\u00f3n de Preparaciones Est\u00e9riles**: Proceso y t\u00e9cnicas involucradas en la producci\u00f3n de productos farmac\u00e9uticos est\u00e9riles.\n\n5. **Esterilizaci\u00f3n**: M\u00e9todos utilizados para eliminar microorganismos y asegurar la esterilidad del producto.\n\n6. **Esterilizaci\u00f3n Terminal**: Proceso de esterilizaci\u00f3n que se realiza en el producto final antes de su envasado.\n\n7. **Procesamiento Aseptico y Esterilizaci\u00f3n por Filtraci\u00f3n**: T\u00e9cnicas espec\u00edficas para mantener la esterilidad durante la producci\u00f3n.\n\n8. **Tecnolog\u00eda de Aisladores**: Uso de sistemas aislantes para proteger el proceso de fabricaci\u00f3n de contaminantes externos.\n\n9. **Tecnolog\u00eda de Llenado/Sellado**: M\u00e9todos de envasado que aseguran la esterilidad del producto final.\n\n10. **Personal**: Importancia del personal en la producci\u00f3n, incluyendo capacitaci\u00f3n y pr\u00e1cticas de trabajo.\n\n11. **Instalaciones**: Dise\u00f1o y mantenimiento de las instalaciones de producci\u00f3n para garantizar un entorno est\u00e9ril.\n\n12. **Equipo**: Herramientas y maquinaria utilizadas en la fabricaci\u00f3n de productos est\u00e9riles.\n\n13. **Finalizaci\u00f3n de Productos Est\u00e9riles**: Procesos finales que aseguran que los productos est\u00e9n listos para su distribuci\u00f3n y uso.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Productos Farmac\u00e9uticos Est\u00e9riles**: Tipo de productos que se est\u00e1n fabricando bajo estas buenas pr\u00e1cticas.\n- **M\u00e9todos de Esterilizaci\u00f3n**: Incluyen esterilizaci\u00f3n terminal y filtraci\u00f3n as\u00e9ptica.\n- **Tecnolog\u00edas**: Aisladores y sistemas de llenado/sellado.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades clave que se abordan en el documento, destacando la importancia de cada uno en el contexto de las buenas pr\u00e1cticas de manufactura para productos farmac\u00e9uticos est\u00e9riles.", "excerpt_keywords": "Keywords: sterile preparations, clean areas, quality control, sterility testing, endotoxins"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "70bed42c-b350-41d4-9315-1fb51a48a49b", "node_type": "4", "metadata": {"page_label": "225", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 1. General considerations\n\n1.1 The production of sterile preparations should be carried out in clean areas, entry to which should be through airlocks for personnel and/or for equipment and materials. Clean areas should be maintained to an appropriate standard of cleanliness and supplied with air that has passed through filters of the required efficiency.\n\n1.2 The various operations of component preparation (such as those involving containers and closures), product preparation, filling and sterilization should be carried out in separate areas within the clean area. These areas are classified into four grades (see section 4).\n\nManufacturing operations are divided here into two categories:\n- first, those where the product is terminally sterilized; and\n- second, those which are conducted aseptically at some or all stages.\n\n# 2. Quality control\n\n2.1 The sterility test applied to the finished product should only be regarded as the last in a series of control measures by which sterility is assured. The test should be validated for the product(s) concerned.\n\n2.2 Samples taken for sterility testing should be representative of the whole of the batch but should, in particular, include samples taken from parts of the batch considered to be most at risk of contamination, for example:\n- for products that have been filled aseptically, samples should include containers filled at the beginning and end of the batch and after any significant interruption of work;\n- for products that have been heat sterilized in their final containers, consideration should be given to taking samples from that part of the load that is potentially the coolest.\n\n2.3 The sterility of the finished product is assured by validation of the sterilization cycle in the case of terminally sterilized products, and by \u201cmedia simulation\u201d or \u201cmedia fill\u201d runs for aseptically processed products. Batch-processing records and, in the case of aseptic processing, environmental quality records, should be examined in conjunction with the results of the sterility tests. The sterility test procedure should be validated for a given product. Pharmacopoeial methods should be used for the validation and performance of the sterility test. In those cases where parametric release has been authorized in place of sterility testing special attention should be paid to the validation and the monitoring of the entire manufacturing process.\n\n2.4 For injectable products the water for injection and the intermediate, if appropriate, and finished products should be monitored for endotoxins,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "731afc8805c9b5e29ee639098f36dec0e15d52a66c14118ffb47fae446d95ccf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 1. General considerations\n\n1.1 The production of sterile preparations should be carried out in clean areas, entry to which should be through airlocks for personnel and/or for equipment and materials. Clean areas should be maintained to an appropriate standard of cleanliness and supplied with air that has passed through filters of the required efficiency.\n\n1.2 The various operations of component preparation (such as those involving containers and closures), product preparation, filling and sterilization should be carried out in separate areas within the clean area. These areas are classified into four grades (see section 4).\n\nManufacturing operations are divided here into two categories:\n- first, those where the product is terminally sterilized; and\n- second, those which are conducted aseptically at some or all stages.\n\n# 2. Quality control\n\n2.1 The sterility test applied to the finished product should only be regarded as the last in a series of control measures by which sterility is assured. The test should be validated for the product(s) concerned.\n\n2.2 Samples taken for sterility testing should be representative of the whole of the batch but should, in particular, include samples taken from parts of the batch considered to be most at risk of contamination, for example:\n- for products that have been filled aseptically, samples should include containers filled at the beginning and end of the batch and after any significant interruption of work;\n- for products that have been heat sterilized in their final containers, consideration should be given to taking samples from that part of the load that is potentially the coolest.\n\n2.3 The sterility of the finished product is assured by validation of the sterilization cycle in the case of terminally sterilized products, and by \u201cmedia simulation\u201d or \u201cmedia fill\u201d runs for aseptically processed products. Batch-processing records and, in the case of aseptic processing, environmental quality records, should be examined in conjunction with the results of the sterility tests. The sterility test procedure should be validated for a given product. Pharmacopoeial methods should be used for the validation and performance of the sterility test. In those cases where parametric release has been authorized in place of sterility testing special attention should be paid to the validation and the monitoring of the entire manufacturing process.\n\n2.4 For injectable products the water for injection and the intermediate, if appropriate, and finished products should be monitored for endotoxins,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2559, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e3746c66-e044-4188-b48f-ce177422ac83": {"__data__": {"id_": "e3746c66-e044-4188-b48f-ce177422ac83", "embedding": null, "metadata": {"page_label": "226", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Sanitation\n\n3.1 The sanitation of clean areas is particularly important. They should be cleaned frequently and thoroughly in accordance with an approved written programme. Where disinfectants are used, more than one type should be employed. Monitoring should be regularly undertaken to detect contamination or the presence of an organism against which the cleaning procedure is ineffective. Interactions between different cleaning materials should be validated. Appropriate cleaning validation should be carried out to ensure disinfectant residuals can be detected and are removed by the cleaning process.\n\n3.2 Disinfectants and detergents should be monitored for microbial contamination; dilutions should be kept in previously cleaned containers and should only be stored for defined periods unless sterilized. Disinfectants and detergents used in grade A and B areas should be sterile before use.\n\n3.3 A disinfectant programme should also include a sporicidal agent since many common disinfectants are ineffective against spores. The effectiveness of cleaning and disinfectant procedures should be demonstrated.\n\n3.4 Fumigation of clean areas may be useful for reducing microbial contamination in inaccessible places.\n\n# Manufacture of sterile preparations\n\n4.1 Clean areas for the manufacture of sterile products are classified according to the required characteristics of the environment. Each manufacturing operation requires an appropriate level of environmental cleanliness in the operational state to minimize the risks of particulate or microbial contamination of the product or materials being handled.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Informe T\u00e9cnico 957) aborda la importancia de la sanidad en \u00e1reas limpias, especialmente en la fabricaci\u00f3n de productos est\u00e9riles. Se enfatiza la necesidad de un programa de limpieza aprobado, el uso de m\u00faltiples tipos de desinfectantes, la monitorizaci\u00f3n de la contaminaci\u00f3n microbiana, y la validaci\u00f3n de interacciones entre materiales de limpieza. Tambi\u00e9n se menciona la importancia de utilizar agentes esporicidas y la posible fumigaci\u00f3n de \u00e1reas limpias para reducir la contaminaci\u00f3n microbiana. Adem\u00e1s, se clasifica la limpieza de \u00e1reas seg\u00fan las caracter\u00edsticas requeridas para minimizar riesgos de contaminaci\u00f3n en la producci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de programa de limpieza se recomienda para las \u00e1reas limpias y qu\u00e9 aspectos deben ser considerados en su implementaci\u00f3n?**\n   - Respuesta: Se recomienda un programa de limpieza aprobado que incluya limpieza frecuente y exhaustiva, el uso de m\u00e1s de un tipo de desinfectante, y la monitorizaci\u00f3n regular para detectar contaminaci\u00f3n. Tambi\u00e9n se debe validar las interacciones entre diferentes materiales de limpieza y realizar una validaci\u00f3n adecuada de la limpieza.\n\n2. **\u00bfPor qu\u00e9 es importante incluir un agente esporicida en el programa de desinfecci\u00f3n y qu\u00e9 limitaciones tienen los desinfectantes comunes?**\n   - Respuesta: Es importante incluir un agente esporicida porque muchos desinfectantes comunes son ineficaces contra esporas. Esto asegura que se aborden todos los tipos de microorganismos, incluyendo aquellos que pueden ser m\u00e1s resistentes.\n\n3. **\u00bfQu\u00e9 medidas se pueden tomar para reducir la contaminaci\u00f3n microbiana en lugares de dif\u00edcil acceso dentro de las \u00e1reas limpias?**\n   - Respuesta: La fumigaci\u00f3n de \u00e1reas limpias puede ser \u00fatil para reducir la contaminaci\u00f3n microbiana en lugares de dif\u00edcil acceso, complementando as\u00ed otros m\u00e9todos de limpieza y desinfecci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Producci\u00f3n de Preparaciones Est\u00e9riles**:\n   - Debe realizarse en \u00e1reas limpias con acceso a trav\u00e9s de airlocks.\n   - Las \u00e1reas limpias deben mantener un est\u00e1ndar adecuado de limpieza y contar con aire filtrado.\n\n2. **Clasificaci\u00f3n de \u00c1reas Limpias**:\n   - Las operaciones de preparaci\u00f3n de componentes, preparaci\u00f3n de productos, llenado y esterilizaci\u00f3n deben llevarse a cabo en \u00e1reas separadas dentro de la zona limpia.\n   - Estas \u00e1reas est\u00e1n clasificadas en cuatro grados (detalles no proporcionados en el texto).\n\n3. **Categor\u00edas de Operaciones de Fabricaci\u00f3n**:\n   - **Esterilizaci\u00f3n Terminal**: Productos que son esterilizados al final del proceso.\n   - **Procesamiento Aseptico**: Productos que se manejan de manera as\u00e9ptica en alguna o todas las etapas.\n\n4. **Control de Calidad**:\n   - La prueba de esterilidad es el \u00faltimo control para asegurar la esterilidad del producto.\n   - Las muestras para pruebas de esterilidad deben ser representativas y tomar en cuenta las partes m\u00e1s vulnerables a la contaminaci\u00f3n.\n\n5. **Validaci\u00f3n de Procesos**:\n   - La esterilidad se asegura mediante la validaci\u00f3n del ciclo de esterilizaci\u00f3n para productos terminalmente esterilizados y mediante simulaciones de medios para productos procesados as\u00e9pticamente.\n   - Se deben revisar los registros de procesamiento por lotes y los registros de calidad ambiental en el caso de procesamiento as\u00e9ptico.\n\n6. **Liberaci\u00f3n Param\u00e9trica**:\n   - En casos donde se autoriza la liberaci\u00f3n param\u00e9trica en lugar de pruebas de esterilidad, se debe prestar especial atenci\u00f3n a la validaci\u00f3n y monitoreo del proceso de fabricaci\u00f3n.\n\n7. **Monitoreo de Endotoxinas**:\n   - Para productos inyectables, se debe monitorear el agua para inyecci\u00f3n y los productos intermedios y finales para endotoxinas.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad del documento.\n- **Preparaciones Est\u00e9riles**: Tipo de producto discutido.\n- **\u00c1reas Limpias**: Espacios de producci\u00f3n clasificados en grados.\n- **Esterilizaci\u00f3n Terminal y Aseptica**: Tipos de procesos de fabricaci\u00f3n.\n- **Pruebas de Esterilidad**: M\u00e9todo de control de calidad.\n- **Liberaci\u00f3n Param\u00e9trica**: Proceso alternativo a las pruebas de esterilidad.\n- **Endotoxinas**: Contaminantes a monitorear en productos inyectables.", "excerpt_keywords": "Keywords: sanitation, disinfectants, sterile preparations, microbial contamination, cleaning validation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "30ff21c2-5e93-403e-ad74-1482cc31219f", "node_type": "4", "metadata": {"page_label": "226", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Sanitation\n\n3.1 The sanitation of clean areas is particularly important. They should be cleaned frequently and thoroughly in accordance with an approved written programme. Where disinfectants are used, more than one type should be employed. Monitoring should be regularly undertaken to detect contamination or the presence of an organism against which the cleaning procedure is ineffective. Interactions between different cleaning materials should be validated. Appropriate cleaning validation should be carried out to ensure disinfectant residuals can be detected and are removed by the cleaning process.\n\n3.2 Disinfectants and detergents should be monitored for microbial contamination; dilutions should be kept in previously cleaned containers and should only be stored for defined periods unless sterilized. Disinfectants and detergents used in grade A and B areas should be sterile before use.\n\n3.3 A disinfectant programme should also include a sporicidal agent since many common disinfectants are ineffective against spores. The effectiveness of cleaning and disinfectant procedures should be demonstrated.\n\n3.4 Fumigation of clean areas may be useful for reducing microbial contamination in inaccessible places.\n\n# Manufacture of sterile preparations\n\n4.1 Clean areas for the manufacture of sterile products are classified according to the required characteristics of the environment. Each manufacturing operation requires an appropriate level of environmental cleanliness in the operational state to minimize the risks of particulate or microbial contamination of the product or materials being handled.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a24824b2377fae84138bf3090ed213db0bce9f21ba2a5032e8c51a7a7060d7d9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Sanitation\n\n3.1 The sanitation of clean areas is particularly important. They should be cleaned frequently and thoroughly in accordance with an approved written programme. Where disinfectants are used, more than one type should be employed. Monitoring should be regularly undertaken to detect contamination or the presence of an organism against which the cleaning procedure is ineffective. Interactions between different cleaning materials should be validated. Appropriate cleaning validation should be carried out to ensure disinfectant residuals can be detected and are removed by the cleaning process.\n\n3.2 Disinfectants and detergents should be monitored for microbial contamination; dilutions should be kept in previously cleaned containers and should only be stored for defined periods unless sterilized. Disinfectants and detergents used in grade A and B areas should be sterile before use.\n\n3.3 A disinfectant programme should also include a sporicidal agent since many common disinfectants are ineffective against spores. The effectiveness of cleaning and disinfectant procedures should be demonstrated.\n\n3.4 Fumigation of clean areas may be useful for reducing microbial contamination in inaccessible places.\n\n# Manufacture of sterile preparations\n\n4.1 Clean areas for the manufacture of sterile products are classified according to the required characteristics of the environment. Each manufacturing operation requires an appropriate level of environmental cleanliness in the operational state to minimize the risks of particulate or microbial contamination of the product or materials being handled.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1614, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "214e2124-897d-4efd-b405-fb2a5f71cab2": {"__data__": {"id_": "214e2124-897d-4efd-b405-fb2a5f71cab2", "embedding": null, "metadata": {"page_label": "227", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.2 Detailed Information\n\nDetailed information on methods for determining the microbiological and particulate cleanliness of air, surfaces, etc., is not given in these guidelines.\n\nISO 14644-1 (2) should be used for classification of cleanliness according to concentration of airborne particles (determination of number of sample locations, calculation of sample size and evaluation of classification from the data obtained). Table 1 should also be used to define the levels to be used as the basis for monitoring clean areas for airborne particles.\n\n# 4.3 Grades of Clean Areas\n\nFor the manufacture of sterile pharmaceutical preparations, four grades of clean areas are distinguished as follows:\n\n- **Grade A**: The local zone for high-risk operations, e.g. filling and making aseptic connections. Normally such conditions are achieved by using a unidirectional airflow workstation. Unidirectional airflow systems should provide a homogeneous air speed of 0.36\u20130.54 m/s (guidance value) at a defined test position 15\u201330 cm below the terminal filter or air distributor system. The velocity at working level should not be less than 0.36 m/s. The uniformity and effectiveness of the unidirectional airflow should be demonstrated by undertaking airflow visualization tests;\n\n- **Grade B**: In aseptic preparation and filling, this is the background environment for the grade A zone;\n\n- **Grades C and D**: Clean areas for carrying out less critical stages in the manufacture of sterile products or carrying out activities during which the product is not directly exposed (i.e. aseptic connection with aseptic connectors and operations in a closed system).\n\nA unidirectional airflow and lower velocities may be used in closed isolators and glove boxes.\n\n# 4.4 Air Changes\n\nIn order to reach the B, C and D air grades the number of air changes should be appropriate for the size of the room and the equipment and personnel present in it.\n\n# 4.5 HEPA Filters\n\nHigh-efficiency particulate air (HEPA) filters should be subjected to an installed filter leakage test in accordance with ISO 14644-3 (6) at a recommended interval of every 6 months, but not exceeding 12 months. The purpose of performing regular leak tests is to ensure the filter media, filter frame and filter seal are free from leaks. The aerosol selected for HEPA leak testing should not support microbial growth and should be composed of a sufficient number or mass of particles. HEPA filter patching is allowed at the filter manufacturer and in situ operation provided that the patch sizes and procedures follow the recommendations of ISO 1822-4 (7).\n\n# 4.6 Clean Room and Clean-Air Device Classification", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona directrices sobre la clasificaci\u00f3n y los est\u00e1ndares de limpieza en \u00e1reas de fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles. Se describen cuatro grados de \u00e1reas limpias (A, B, C y D) y se especifican las condiciones necesarias para cada uno, incluyendo la velocidad del aire, el n\u00famero de cambios de aire y las pruebas de fugas para filtros HEPA. Tambi\u00e9n se menciona la importancia de utilizar normas ISO para la clasificaci\u00f3n de la limpieza del aire y la evaluaci\u00f3n de la efectividad de los sistemas de flujo de aire unidireccional.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones espec\u00edficas que deben cumplirse para que un \u00e1rea se clasifique como \"Grado A\" en la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles?**\n   - Respuesta: Un \u00e1rea se clasifica como \"Grado A\" si es la zona local para operaciones de alto riesgo, como el llenado y la realizaci\u00f3n de conexiones as\u00e9pticas. Debe utilizar un sistema de flujo de aire unidireccional que proporcione una velocidad de aire homog\u00e9nea de 0.36\u20130.54 m/s a una posici\u00f3n de prueba definida entre 15 y 30 cm por debajo del filtro terminal. La velocidad en el nivel de trabajo no debe ser inferior a 0.36 m/s, y se deben realizar pruebas de visualizaci\u00f3n del flujo de aire para demostrar la uniformidad y efectividad del sistema.\n\n2. **\u00bfQu\u00e9 intervalos se recomiendan para realizar pruebas de fugas en filtros HEPA y cu\u00e1l es el objetivo de estas pruebas?**\n   - Respuesta: Se recomienda realizar pruebas de fugas en filtros HEPA cada 6 meses, sin exceder los 12 meses. El objetivo de estas pruebas es asegurar que el medio del filtro, el marco del filtro y el sello del filtro est\u00e9n libres de fugas.\n\n3. **\u00bfC\u00f3mo se determina el n\u00famero adecuado de cambios de aire necesarios para alcanzar las clasificaciones de aire B, C y D?**\n   - Respuesta: El n\u00famero adecuado de cambios de aire se determina en funci\u00f3n del tama\u00f1o de la habitaci\u00f3n, as\u00ed como del equipo y el personal presentes en ella. Esto asegura que se mantengan las condiciones de limpieza necesarias para cada grado de aire.\n\n### Resumen de Nivel Superior\n\nEl documento establece directrices para la clasificaci\u00f3n de \u00e1reas limpias en la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles, definiendo cuatro grados de limpieza y los requisitos asociados a cada uno. Se enfatiza la importancia de mantener condiciones controladas de aire y la realizaci\u00f3n de pruebas regulares para asegurar la efectividad de los sistemas de filtraci\u00f3n y flujo de aire. Las normas ISO son fundamentales para la evaluaci\u00f3n y monitoreo de la limpieza del aire en estas \u00e1reas.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Sanidad en \u00c1reas Limpias**:\n   - Importancia de la limpieza frecuente y exhaustiva.\n   - Necesidad de un programa de limpieza aprobado.\n   - Uso de m\u00faltiples tipos de desinfectantes.\n   - Monitorizaci\u00f3n regular para detectar contaminaci\u00f3n microbiana.\n\n2. **Validaci\u00f3n de Materiales de Limpieza**:\n   - Validaci\u00f3n de interacciones entre diferentes materiales de limpieza.\n   - Validaci\u00f3n adecuada para asegurar que los residuos de desinfectantes sean detectables y eliminados.\n\n3. **Desinfectantes y Detergentes**:\n   - Monitoreo de la contaminaci\u00f3n microbiana en desinfectantes y detergentes.\n   - Almacenamiento en contenedores previamente limpios y por per\u00edodos definidos, a menos que sean esterilizados.\n   - Desinfectantes y detergentes en \u00e1reas de grado A y B deben ser est\u00e9riles antes de su uso.\n\n4. **Agentes Esporicidas**:\n   - Inclusi\u00f3n de un agente esporicida en el programa de desinfecci\u00f3n debido a la ineficacia de muchos desinfectantes comunes contra esporas.\n\n5. **Fumigaci\u00f3n**:\n   - Utilidad de la fumigaci\u00f3n en \u00e1reas limpias para reducir la contaminaci\u00f3n microbiana en lugares de dif\u00edcil acceso.\n\n6. **Fabricaci\u00f3n de Preparaciones Est\u00e9riles**:\n   - Clasificaci\u00f3n de \u00e1reas limpias seg\u00fan las caracter\u00edsticas requeridas para minimizar riesgos de contaminaci\u00f3n.\n   - Importancia de mantener un nivel adecuado de limpieza ambiental durante las operaciones de fabricaci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Desinfectantes**: Sustancias utilizadas para eliminar microorganismos.\n- **Detergentes**: Productos de limpieza que ayudan a eliminar suciedad y contaminantes.\n- **Agentes Esporicidas**: Sustancias espec\u00edficas para eliminar esporas de microorganismos.\n- **\u00c1reas Limpias**: Espacios controlados donde se fabrican productos est\u00e9riles.", "excerpt_keywords": "Keywords: clean areas, sterile pharmaceutical preparations, HEPA filters, unidirectional airflow, ISO standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cc264dbe-9481-47f9-bc2c-3e5061be4436", "node_type": "4", "metadata": {"page_label": "227", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.2 Detailed Information\n\nDetailed information on methods for determining the microbiological and particulate cleanliness of air, surfaces, etc., is not given in these guidelines.\n\nISO 14644-1 (2) should be used for classification of cleanliness according to concentration of airborne particles (determination of number of sample locations, calculation of sample size and evaluation of classification from the data obtained). Table 1 should also be used to define the levels to be used as the basis for monitoring clean areas for airborne particles.\n\n# 4.3 Grades of Clean Areas\n\nFor the manufacture of sterile pharmaceutical preparations, four grades of clean areas are distinguished as follows:\n\n- **Grade A**: The local zone for high-risk operations, e.g. filling and making aseptic connections. Normally such conditions are achieved by using a unidirectional airflow workstation. Unidirectional airflow systems should provide a homogeneous air speed of 0.36\u20130.54 m/s (guidance value) at a defined test position 15\u201330 cm below the terminal filter or air distributor system. The velocity at working level should not be less than 0.36 m/s. The uniformity and effectiveness of the unidirectional airflow should be demonstrated by undertaking airflow visualization tests;\n\n- **Grade B**: In aseptic preparation and filling, this is the background environment for the grade A zone;\n\n- **Grades C and D**: Clean areas for carrying out less critical stages in the manufacture of sterile products or carrying out activities during which the product is not directly exposed (i.e. aseptic connection with aseptic connectors and operations in a closed system).\n\nA unidirectional airflow and lower velocities may be used in closed isolators and glove boxes.\n\n# 4.4 Air Changes\n\nIn order to reach the B, C and D air grades the number of air changes should be appropriate for the size of the room and the equipment and personnel present in it.\n\n# 4.5 HEPA Filters\n\nHigh-efficiency particulate air (HEPA) filters should be subjected to an installed filter leakage test in accordance with ISO 14644-3 (6) at a recommended interval of every 6 months, but not exceeding 12 months. The purpose of performing regular leak tests is to ensure the filter media, filter frame and filter seal are free from leaks. The aerosol selected for HEPA leak testing should not support microbial growth and should be composed of a sufficient number or mass of particles. HEPA filter patching is allowed at the filter manufacturer and in situ operation provided that the patch sizes and procedures follow the recommendations of ISO 1822-4 (7).\n\n# 4.6 Clean Room and Clean-Air Device Classification", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "954e8bda4a4454a1eb613a811b3e225562689e279137077f12236d0ea9889190", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.2 Detailed Information\n\nDetailed information on methods for determining the microbiological and particulate cleanliness of air, surfaces, etc., is not given in these guidelines.\n\nISO 14644-1 (2) should be used for classification of cleanliness according to concentration of airborne particles (determination of number of sample locations, calculation of sample size and evaluation of classification from the data obtained). Table 1 should also be used to define the levels to be used as the basis for monitoring clean areas for airborne particles.\n\n# 4.3 Grades of Clean Areas\n\nFor the manufacture of sterile pharmaceutical preparations, four grades of clean areas are distinguished as follows:\n\n- **Grade A**: The local zone for high-risk operations, e.g. filling and making aseptic connections. Normally such conditions are achieved by using a unidirectional airflow workstation. Unidirectional airflow systems should provide a homogeneous air speed of 0.36\u20130.54 m/s (guidance value) at a defined test position 15\u201330 cm below the terminal filter or air distributor system. The velocity at working level should not be less than 0.36 m/s. The uniformity and effectiveness of the unidirectional airflow should be demonstrated by undertaking airflow visualization tests;\n\n- **Grade B**: In aseptic preparation and filling, this is the background environment for the grade A zone;\n\n- **Grades C and D**: Clean areas for carrying out less critical stages in the manufacture of sterile products or carrying out activities during which the product is not directly exposed (i.e. aseptic connection with aseptic connectors and operations in a closed system).\n\nA unidirectional airflow and lower velocities may be used in closed isolators and glove boxes.\n\n# 4.4 Air Changes\n\nIn order to reach the B, C and D air grades the number of air changes should be appropriate for the size of the room and the equipment and personnel present in it.\n\n# 4.5 HEPA Filters\n\nHigh-efficiency particulate air (HEPA) filters should be subjected to an installed filter leakage test in accordance with ISO 14644-3 (6) at a recommended interval of every 6 months, but not exceeding 12 months. The purpose of performing regular leak tests is to ensure the filter media, filter frame and filter seal are free from leaks. The aerosol selected for HEPA leak testing should not support microbial growth and should be composed of a sufficient number or mass of particles. HEPA filter patching is allowed at the filter manufacturer and in situ operation provided that the patch sizes and procedures follow the recommendations of ISO 1822-4 (7).\n\n# 4.6 Clean Room and Clean-Air Device Classification", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2666, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c30242b7-66f7-4650-bed7-83618eac952d": {"__data__": {"id_": "c30242b7-66f7-4650-bed7-83618eac952d", "embedding": null, "metadata": {"page_label": "228", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "4.6.1 Clean rooms and clean-air devices should be classified in accordance with ISO 14644 (2, 6\u20139).\n\n4.6.1.1 Classification should be clearly differentiated from operational process environmental monitoring. The maximum permitted airborne particle concentration for each grade is given in Table 1.\n\n**Table 1**  \nMaximum permitted airborne particle concentration\n\n| Grade\\<br/>0.5 \u00b5m | Maximum permitted number of particles per m\u00b3 greater than or equal to the tabulated size\\<br/>5.0\u00b5m | Maximum permitted number of particles per m\u00b3 greater than or equal to the tabulated size\\<br/>In operation\\<br/>0.5 \u00b5m | In operation\\<br/>5.0\u00b5m | |\n| - | - | - | - | - |\n| A | 3 520 | 20 | 3 520 | 20 |\n| B | 3 520 | 29 | 352 000 | 2 900 |\n| C | 352 000 | 2 900 | 3 520 000 | 29 000 |\n| D | 3 520 000 | 29 000 | Not defined | Not defined |\n\n\n<sup>a</sup> The \"at rest\" state is the condition where the installation is complete with equipment installed and operating in a manner agreed upon by the customer and supplier, but with no personnel present.  \n<sup>b</sup> The \"in operation\" state is the condition where the installation is functioning in the defined operating mode and the specified number of personnel is present. The areas and their associated environmental control systems should be designed to achieve both the \"at rest\" and \"in operation\" states.\n\n4.6.2 For classification purposes, ISO 14644-1 (2) methodology defines both the minimum number of sample locations and the sample size based on the class limit of the largest considered particle size and the method for evaluation of the data collected. For classification of grade A zones (at rest and operational) and grade B zones (at rest), the minimum sample volume is based on the ISO 5 limit for the number of particles \u2265 0.5 \u00b5m (3520). Similarly, for classification of grade B (operational), grade C (at rest and operational), and grade D (at rest), the minimum sample volume is based on the class limits for particles \u2265 0.5 \u00b5m shown in Table 1.\n\nFor classification purposes in grade A zones, a minimum sample volume of 1 m\u00b3 should be taken per sample location. Referring to Table 1, for grade A the airborne particle classification is ISO 4.8 dictated by the limit for particles \u2265 5.0 \u00b5m. For grade B (at rest) the airborne particle classification is ISO 5 for both particle sizes considered. For grade C (at rest and in operation) the airborne particle classification is ISO 7 and ISO 8, respectively. For grade D (at rest) the airborne particle classification is ISO 8. For classification purposes ISO 14644-1 (2) methodology defines both the minimum number of sample locations and the sample size based on the class limit of the largest particle size considered and the method of evaluation of the data collected. The sample volume should be determined according to ISO 14644-1 (2) clause B.4.2. However, for lower grades.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior que puede ayudar a formular preguntas m\u00e1s relevantes:\n\n### Resumen de Nivel Superior\nEl documento se centra en la clasificaci\u00f3n de salas limpias y dispositivos de aire limpio seg\u00fan la norma ISO 14644. Se detalla la concentraci\u00f3n m\u00e1xima permitida de part\u00edculas en el aire para diferentes grados de limpieza (A, B, C y D), tanto en condiciones \"en reposo\" como \"en operaci\u00f3n\". Adem\u00e1s, se especifican los m\u00e9todos de muestreo y los vol\u00famenes m\u00ednimos requeridos para la clasificaci\u00f3n de estas \u00e1reas, as\u00ed como las diferencias entre los estados de operaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1l es la diferencia en la concentraci\u00f3n m\u00e1xima permitida de part\u00edculas de 0.5 \u00b5m entre los estados \"en reposo\" y \"en operaci\u00f3n\" para las salas limpias de grado A?**\n   - Respuesta: Para las salas limpias de grado A, la concentraci\u00f3n m\u00e1xima permitida de part\u00edculas de 0.5 \u00b5m es de 3,520 part\u00edculas por m\u00b3 tanto en estado \"en reposo\" como \"en operaci\u00f3n\".\n\n2. **\u00bfQu\u00e9 volumen m\u00ednimo de muestra se requiere para la clasificaci\u00f3n de zonas de grado A y qu\u00e9 clasificaci\u00f3n de part\u00edculas se aplica en este caso?**\n   - Respuesta: Para la clasificaci\u00f3n de zonas de grado A, se requiere un volumen m\u00ednimo de muestra de 1 m\u00b3 por ubicaci\u00f3n de muestra, y la clasificaci\u00f3n de part\u00edculas es ISO 4.8, dictada por el l\u00edmite para part\u00edculas \u2265 5.0 \u00b5m.\n\n3. **\u00bfC\u00f3mo se define el estado \"en operaci\u00f3n\" y qu\u00e9 implicaciones tiene para el dise\u00f1o de las \u00e1reas de control ambiental?**\n   - Respuesta: El estado \"en operaci\u00f3n\" se define como la condici\u00f3n en la que la instalaci\u00f3n est\u00e1 funcionando en el modo operativo definido y con el n\u00famero especificado de personal presente. Esto implica que las \u00e1reas y sus sistemas de control ambiental deben estar dise\u00f1ados para lograr tanto el estado \"en reposo\" como el \"en operaci\u00f3n\".", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Clasificaci\u00f3n de \u00c1reas Limpias**:\n   - Se definen cuatro grados de \u00e1reas limpias para la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles: **Grado A**, **Grado B**, **Grado C** y **Grado D**.\n   - Cada grado tiene requisitos espec\u00edficos relacionados con el flujo de aire, la velocidad del aire y el entorno de trabajo.\n\n2. **Grado A**:\n   - Zona local para operaciones de alto riesgo (ej. llenado y conexiones as\u00e9pticas).\n   - Requiere un sistema de flujo de aire unidireccional con velocidad de aire homog\u00e9nea de 0.36\u20130.54 m/s.\n   - Se deben realizar pruebas de visualizaci\u00f3n del flujo de aire para asegurar su efectividad.\n\n3. **Grado B**:\n   - Entorno de fondo para el Grado A durante la preparaci\u00f3n y llenado as\u00e9ptico.\n\n4. **Grados C y D**:\n   - \u00c1reas limpias para etapas menos cr\u00edticas en la fabricaci\u00f3n de productos est\u00e9riles.\n   - Actividades donde el producto no est\u00e1 directamente expuesto.\n\n5. **Cambios de Aire**:\n   - El n\u00famero de cambios de aire debe ser adecuado seg\u00fan el tama\u00f1o de la habitaci\u00f3n, el equipo y el personal presente.\n\n6. **Filtros HEPA**:\n   - Los filtros HEPA deben someterse a pruebas de fugas cada 6 meses, sin exceder 12 meses.\n   - Las pruebas aseguran que no haya fugas en el medio del filtro, el marco y el sello.\n   - Se debe utilizar un aerosol que no soporte el crecimiento microbiano para las pruebas de fugas.\n\n7. **Normas ISO**:\n   - Se menciona la importancia de las normas ISO (ISO 14644-1 y ISO 14644-3) para la clasificaci\u00f3n de la limpieza del aire y la evaluaci\u00f3n de la efectividad de los sistemas de filtraci\u00f3n.\n\n### Entidades Clave\n- **ISO 14644-1**: Norma para la clasificaci\u00f3n de limpieza seg\u00fan la concentraci\u00f3n de part\u00edculas en el aire.\n- **ISO 14644-3**: Norma para pruebas de fugas en filtros HEPA.\n- **ISO 1822-4**: Norma relacionada con el parcheo de filtros HEPA.\n- **Grados de limpieza**: A, B, C, D.\n- **Filtros HEPA**: Filtros de aire de alta eficiencia para la eliminaci\u00f3n de part\u00edculas. \n\nEste resumen destaca los aspectos fundamentales de la secci\u00f3n, incluyendo la clasificaci\u00f3n de \u00e1reas limpias, los requisitos espec\u00edficos para cada grado, la importancia de los cambios de aire y las pruebas de filtros HEPA, as\u00ed como la referencia a normas ISO relevantes.", "excerpt_keywords": "Keywords: clean rooms, ISO 14644, airborne particle concentration, classification, environmental monitoring"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "385e8c9d-5a31-41e4-883c-8a79ce4beb42", "node_type": "4", "metadata": {"page_label": "228", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "4.6.1 Clean rooms and clean-air devices should be classified in accordance with ISO 14644 (2, 6\u20139).\n\n4.6.1.1 Classification should be clearly differentiated from operational process environmental monitoring. The maximum permitted airborne particle concentration for each grade is given in Table 1.\n\n**Table 1**  \nMaximum permitted airborne particle concentration\n\n| Grade\\<br/>0.5 \u00b5m | Maximum permitted number of particles per m\u00b3 greater than or equal to the tabulated size\\<br/>5.0\u00b5m | Maximum permitted number of particles per m\u00b3 greater than or equal to the tabulated size\\<br/>In operation\\<br/>0.5 \u00b5m | In operation\\<br/>5.0\u00b5m | |\n| - | - | - | - | - |\n| A | 3 520 | 20 | 3 520 | 20 |\n| B | 3 520 | 29 | 352 000 | 2 900 |\n| C | 352 000 | 2 900 | 3 520 000 | 29 000 |\n| D | 3 520 000 | 29 000 | Not defined | Not defined |\n\n\n<sup>a</sup> The \"at rest\" state is the condition where the installation is complete with equipment installed and operating in a manner agreed upon by the customer and supplier, but with no personnel present.  \n<sup>b</sup> The \"in operation\" state is the condition where the installation is functioning in the defined operating mode and the specified number of personnel is present. The areas and their associated environmental control systems should be designed to achieve both the \"at rest\" and \"in operation\" states.\n\n4.6.2 For classification purposes, ISO 14644-1 (2) methodology defines both the minimum number of sample locations and the sample size based on the class limit of the largest considered particle size and the method for evaluation of the data collected. For classification of grade A zones (at rest and operational) and grade B zones (at rest), the minimum sample volume is based on the ISO 5 limit for the number of particles \u2265 0.5 \u00b5m (3520). Similarly, for classification of grade B (operational), grade C (at rest and operational), and grade D (at rest), the minimum sample volume is based on the class limits for particles \u2265 0.5 \u00b5m shown in Table 1.\n\nFor classification purposes in grade A zones, a minimum sample volume of 1 m\u00b3 should be taken per sample location. Referring to Table 1, for grade A the airborne particle classification is ISO 4.8 dictated by the limit for particles \u2265 5.0 \u00b5m. For grade B (at rest) the airborne particle classification is ISO 5 for both particle sizes considered. For grade C (at rest and in operation) the airborne particle classification is ISO 7 and ISO 8, respectively. For grade D (at rest) the airborne particle classification is ISO 8. For classification purposes ISO 14644-1 (2) methodology defines both the minimum number of sample locations and the sample size based on the class limit of the largest particle size considered and the method of evaluation of the data collected. The sample volume should be determined according to ISO 14644-1 (2) clause B.4.2. However, for lower grades.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "99d640d30cb6a6462669b99ea3c7579640de1ed4895123aea23acea0ed688c9b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "4.6.1 Clean rooms and clean-air devices should be classified in accordance with ISO 14644 (2, 6\u20139).\n\n4.6.1.1 Classification should be clearly differentiated from operational process environmental monitoring. The maximum permitted airborne particle concentration for each grade is given in Table 1.\n\n**Table 1**  \nMaximum permitted airborne particle concentration\n\n| Grade\\<br/>0.5 \u00b5m | Maximum permitted number of particles per m\u00b3 greater than or equal to the tabulated size\\<br/>5.0\u00b5m | Maximum permitted number of particles per m\u00b3 greater than or equal to the tabulated size\\<br/>In operation\\<br/>0.5 \u00b5m | In operation\\<br/>5.0\u00b5m | |\n| - | - | - | - | - |\n| A | 3 520 | 20 | 3 520 | 20 |\n| B | 3 520 | 29 | 352 000 | 2 900 |\n| C | 352 000 | 2 900 | 3 520 000 | 29 000 |\n| D | 3 520 000 | 29 000 | Not defined | Not defined |\n\n\n<sup>a</sup> The \"at rest\" state is the condition where the installation is complete with equipment installed and operating in a manner agreed upon by the customer and supplier, but with no personnel present.  \n<sup>b</sup> The \"in operation\" state is the condition where the installation is functioning in the defined operating mode and the specified number of personnel is present. The areas and their associated environmental control systems should be designed to achieve both the \"at rest\" and \"in operation\" states.\n\n4.6.2 For classification purposes, ISO 14644-1 (2) methodology defines both the minimum number of sample locations and the sample size based on the class limit of the largest considered particle size and the method for evaluation of the data collected. For classification of grade A zones (at rest and operational) and grade B zones (at rest), the minimum sample volume is based on the ISO 5 limit for the number of particles \u2265 0.5 \u00b5m (3520). Similarly, for classification of grade B (operational), grade C (at rest and operational), and grade D (at rest), the minimum sample volume is based on the class limits for particles \u2265 0.5 \u00b5m shown in Table 1.\n\nFor classification purposes in grade A zones, a minimum sample volume of 1 m\u00b3 should be taken per sample location. Referring to Table 1, for grade A the airborne particle classification is ISO 4.8 dictated by the limit for particles \u2265 5.0 \u00b5m. For grade B (at rest) the airborne particle classification is ISO 5 for both particle sizes considered. For grade C (at rest and in operation) the airborne particle classification is ISO 7 and ISO 8, respectively. For grade D (at rest) the airborne particle classification is ISO 8. For classification purposes ISO 14644-1 (2) methodology defines both the minimum number of sample locations and the sample size based on the class limit of the largest particle size considered and the method of evaluation of the data collected. The sample volume should be determined according to ISO 14644-1 (2) clause B.4.2. However, for lower grades.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2885, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "2b4a7d02-975f-4c86-84a7-3773d71250d3": {"__data__": {"id_": "2b4a7d02-975f-4c86-84a7-3773d71250d3", "embedding": null, "metadata": {"page_label": "229", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.6.3\n\nPortable particle counters with a short length of sample tubing should be used for classification purposes to avoid the loss of particles \u2265 5.0 \u03bcm. Isokinetic sample heads should be used in unidirectional airflow systems.\n\n# 4.6.4\n\n\"In operation\" classification may be demonstrated during normal operations, simulated operations or during media fills as worst-case simulation is required for this. ISO 14644-2 (8) provides information on testing to demonstrate continued compliance with the assigned cleanliness classification.\n\n# 4.7 Clean room and clean-air device monitoring\n\n## 4.7.1\n\nClean rooms and clean-air devices should be routinely monitored while in operation and the monitoring locations based on a formal risk analysis study and the results obtained during the classification of rooms and/or clean-air devices.\n\n## 4.7.2\n\nFor grade A zones, particle monitoring should be undertaken for the full duration of critical processing, including equipment assembly, except where justified by contaminants in the process that would damage the particle counter or present a hazard, for example, live organisms and radiological hazards. In such cases monitoring during routine equipment set-up operations should be undertaken before exposure to the risk. Monitoring during simulated operations should also be performed. The grade A zone should be monitored at a frequency and sample size such that all interventions, transient events and any system deterioration would be captured and alarms triggered if alert limits are exceeded. It is accepted that it may not always be possible to demonstrate low levels of \u2265 5.0 \u03bcm particles at the point of fill when filling is in progress, due to the generation of particles or droplets from the product itself.\n\n## 4.7.3\n\nIt is recommended that a similar system be used for grade B zones, although the sample frequency may be decreased. The importance of the particle monitoring system should be determined by the effectiveness of the segregation between the adjacent grade A and B zones. The grade B zone should be monitored at a frequency and with a sample size such that changes in levels of contamination and any deterioration of the system would be captured and alarms triggered if alert limits are exceeded.\n\n## 4.7.4\n\nAirborne particle monitoring systems may consist of independent particle counters; a network of sequentially accessed sampling points.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 957) aborda la clasificaci\u00f3n y monitoreo de salas limpias y dispositivos de aire limpio. Se enfatiza la importancia de utilizar contadores de part\u00edculas port\u00e1tiles con tuber\u00edas de muestreo cortas para evitar la p\u00e9rdida de part\u00edculas de 5.0 \u03bcm o m\u00e1s. Se establece que la clasificaci\u00f3n \"en operaci\u00f3n\" puede demostrarse durante operaciones normales, simuladas o durante llenados de medios. Adem\u00e1s, se detallan los procedimientos de monitoreo para zonas de grado A y B, destacando la necesidad de monitoreo continuo y la respuesta a eventos transitorios y deterioro del sistema.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de contadores de part\u00edculas se recomienda utilizar para la clasificaci\u00f3n en salas limpias y por qu\u00e9?**\n   - Se recomienda el uso de contadores de part\u00edculas port\u00e1tiles con una longitud corta de tuber\u00eda de muestreo para evitar la p\u00e9rdida de part\u00edculas de 5.0 \u03bcm o m\u00e1s. Adem\u00e1s, se deben utilizar cabezales de muestreo isocin\u00e9ticos en sistemas de flujo de aire unidireccional.\n\n2. **\u00bfCu\u00e1les son las condiciones bajo las cuales se puede justificar la falta de monitoreo de part\u00edculas en zonas de grado A durante el procesamiento cr\u00edtico?**\n   - El monitoreo de part\u00edculas puede no llevarse a cabo durante el procesamiento cr\u00edtico en zonas de grado A si hay contaminantes en el proceso que podr\u00edan da\u00f1ar el contador de part\u00edculas o presentar un riesgo, como organismos vivos o peligros radiol\u00f3gicos. En tales casos, se debe realizar el monitoreo durante las operaciones de configuraci\u00f3n del equipo antes de la exposici\u00f3n al riesgo.\n\n3. **\u00bfC\u00f3mo se determina la frecuencia y el tama\u00f1o de la muestra para el monitoreo en zonas de grado B?**\n   - La frecuencia y el tama\u00f1o de la muestra para el monitoreo en zonas de grado B deben ser tales que se capturen los cambios en los niveles de contaminaci\u00f3n y cualquier deterioro del sistema. La importancia del sistema de monitoreo de part\u00edculas se determina por la efectividad de la segregaci\u00f3n entre las zonas adyacentes de grado A y B.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Clasificaci\u00f3n de Salas Limpias**: \n   - Las salas limpias y dispositivos de aire limpio deben clasificarse de acuerdo con la norma ISO 14644.\n   - Se diferencian dos estados de operaci\u00f3n: \"en reposo\" y \"en operaci\u00f3n\".\n\n2. **Concentraci\u00f3n M\u00e1xima Permitida de Part\u00edculas**:\n   - Se establece una tabla (Tabla 1) que detalla la concentraci\u00f3n m\u00e1xima permitida de part\u00edculas en el aire para diferentes grados de limpieza (A, B, C y D) en ambos estados.\n   - Grado A: 3,520 part\u00edculas/m\u00b3 (0.5 \u00b5m) en ambos estados.\n   - Grado B: 3,520 part\u00edculas/m\u00b3 (0.5 \u00b5m) en reposo y 352,000 en operaci\u00f3n.\n   - Grado C y D tienen l\u00edmites m\u00e1s altos y no definidos para ciertos tama\u00f1os de part\u00edculas.\n\n3. **Definiciones de Estados**:\n   - **\"En reposo\"**: Instalaci\u00f3n completa y operativa sin personal presente.\n   - **\"En operaci\u00f3n\"**: Instalaci\u00f3n funcionando con el n\u00famero especificado de personal presente.\n\n4. **M\u00e9todos de Muestreo**:\n   - La metodolog\u00eda ISO 14644-1 define el n\u00famero m\u00ednimo de ubicaciones de muestreo y el tama\u00f1o de la muestra basado en el l\u00edmite de clase del tama\u00f1o de part\u00edcula m\u00e1s grande considerado.\n   - Para zonas de grado A, se requiere un volumen m\u00ednimo de muestra de 1 m\u00b3 por ubicaci\u00f3n de muestra.\n\n5. **Clasificaci\u00f3n de Part\u00edculas**:\n   - Grado A: ISO 4.8 (part\u00edculas \u2265 5.0 \u00b5m).\n   - Grado B: ISO 5.\n   - Grado C: ISO 7 (en reposo) y ISO 8 (en operaci\u00f3n).\n   - Grado D: ISO 8 (en reposo).\n\n### Entidades Clave\n- **Norma ISO 14644**: Est\u00e1ndar para la clasificaci\u00f3n de salas limpias.\n- **Grados de Limpieza**: A, B, C, D.\n- **Tama\u00f1os de Part\u00edculas**: 0.5 \u00b5m y 5.0 \u00b5m.\n- **Estados de Operaci\u00f3n**: \"En reposo\" y \"En operaci\u00f3n\".\n- **Volumen de Muestra**: 1 m\u00b3 para grado A. \n\nEste resumen proporciona una visi\u00f3n general de los aspectos m\u00e1s importantes relacionados con la clasificaci\u00f3n y el monitoreo de la calidad del aire en salas limpias seg\u00fan la norma ISO 14644.", "excerpt_keywords": "Keywords: clean rooms, particle monitoring, ISO 14644, contamination control, air quality"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fa059e79-bd7a-42a8-8515-edf654539627", "node_type": "4", "metadata": {"page_label": "229", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.6.3\n\nPortable particle counters with a short length of sample tubing should be used for classification purposes to avoid the loss of particles \u2265 5.0 \u03bcm. Isokinetic sample heads should be used in unidirectional airflow systems.\n\n# 4.6.4\n\n\"In operation\" classification may be demonstrated during normal operations, simulated operations or during media fills as worst-case simulation is required for this. ISO 14644-2 (8) provides information on testing to demonstrate continued compliance with the assigned cleanliness classification.\n\n# 4.7 Clean room and clean-air device monitoring\n\n## 4.7.1\n\nClean rooms and clean-air devices should be routinely monitored while in operation and the monitoring locations based on a formal risk analysis study and the results obtained during the classification of rooms and/or clean-air devices.\n\n## 4.7.2\n\nFor grade A zones, particle monitoring should be undertaken for the full duration of critical processing, including equipment assembly, except where justified by contaminants in the process that would damage the particle counter or present a hazard, for example, live organisms and radiological hazards. In such cases monitoring during routine equipment set-up operations should be undertaken before exposure to the risk. Monitoring during simulated operations should also be performed. The grade A zone should be monitored at a frequency and sample size such that all interventions, transient events and any system deterioration would be captured and alarms triggered if alert limits are exceeded. It is accepted that it may not always be possible to demonstrate low levels of \u2265 5.0 \u03bcm particles at the point of fill when filling is in progress, due to the generation of particles or droplets from the product itself.\n\n## 4.7.3\n\nIt is recommended that a similar system be used for grade B zones, although the sample frequency may be decreased. The importance of the particle monitoring system should be determined by the effectiveness of the segregation between the adjacent grade A and B zones. The grade B zone should be monitored at a frequency and with a sample size such that changes in levels of contamination and any deterioration of the system would be captured and alarms triggered if alert limits are exceeded.\n\n## 4.7.4\n\nAirborne particle monitoring systems may consist of independent particle counters; a network of sequentially accessed sampling points.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "6d39b2329a6b9e827bb9627f499821a6a2ef8eebaf9204c775b99bdf64e9b049", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.6.3\n\nPortable particle counters with a short length of sample tubing should be used for classification purposes to avoid the loss of particles \u2265 5.0 \u03bcm. Isokinetic sample heads should be used in unidirectional airflow systems.\n\n# 4.6.4\n\n\"In operation\" classification may be demonstrated during normal operations, simulated operations or during media fills as worst-case simulation is required for this. ISO 14644-2 (8) provides information on testing to demonstrate continued compliance with the assigned cleanliness classification.\n\n# 4.7 Clean room and clean-air device monitoring\n\n## 4.7.1\n\nClean rooms and clean-air devices should be routinely monitored while in operation and the monitoring locations based on a formal risk analysis study and the results obtained during the classification of rooms and/or clean-air devices.\n\n## 4.7.2\n\nFor grade A zones, particle monitoring should be undertaken for the full duration of critical processing, including equipment assembly, except where justified by contaminants in the process that would damage the particle counter or present a hazard, for example, live organisms and radiological hazards. In such cases monitoring during routine equipment set-up operations should be undertaken before exposure to the risk. Monitoring during simulated operations should also be performed. The grade A zone should be monitored at a frequency and sample size such that all interventions, transient events and any system deterioration would be captured and alarms triggered if alert limits are exceeded. It is accepted that it may not always be possible to demonstrate low levels of \u2265 5.0 \u03bcm particles at the point of fill when filling is in progress, due to the generation of particles or droplets from the product itself.\n\n## 4.7.3\n\nIt is recommended that a similar system be used for grade B zones, although the sample frequency may be decreased. The importance of the particle monitoring system should be determined by the effectiveness of the segregation between the adjacent grade A and B zones. The grade B zone should be monitored at a frequency and with a sample size such that changes in levels of contamination and any deterioration of the system would be captured and alarms triggered if alert limits are exceeded.\n\n## 4.7.4\n\nAirborne particle monitoring systems may consist of independent particle counters; a network of sequentially accessed sampling points.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2412, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4c617fd8-c6e2-42d8-b9dd-5959e9ffcb22": {"__data__": {"id_": "4c617fd8-c6e2-42d8-b9dd-5959e9ffcb22", "embedding": null, "metadata": {"page_label": "230", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "connected by manifold to a single particle counter; or multiple small particle counters located near monitoring points and networked to a data acquisition system. Combinations of systems can also be used. The system selected should be appropriate for the particle size considered. Where remote sampling systems are used, the length of tubing and the radii of any bends in the tubing should be considered in the context of particle losses in the tubing. The selection of the monitoring system should take account of any risk presented by the materials used in the manufacturing operation, for example, those involving live organisms or radiopharmaceuticals.\n\n4.7.5 The sizes of samples taken for monitoring purposes using automated systems will usually be a function of the sampling rate of the system used. It is not necessary for the sample volume to be the same as that used for formal classification of clean rooms and clean-air devices.\n\n4.7.6 The airborne particle conditions given in Table 1 for the \u201cat rest\u201d state should be achieved in the absence of the operating personnel after a short \u201cclean-up\u201d or \u201crecovery\u201d period of about 15\u201320 minutes (guidance value), after completion of the operations. The particulate conditions given in Table 1 for grade A \u201cin operation\u201d should be maintained in the zone immediately surrounding the product whenever the product or open container is exposed to the environment. The \u201cclean-up\u201d or \u201crecovery\u201d test should demonstrate a change in particle concentration by a factor of 100 within the prescribed time (ISO 14644-3 clause B.12) (6).\n\n4.7.7 In order to demonstrate control of the cleanliness of the various clean areas during operation, they should be monitored for airborne particles and microbial contamination. In addition to \u201cat rest\u201d and \u201cin operation\u201d classification, airborne particles should be monitored periodically \u201cin operation\u201d at critical locations. The sampling plan need not be the same as that used for classification. Locations and sample sizes should be determined based on an assessment of the process and contamination risk.\n\n4.7.8 The monitoring of grade C and D areas in operation should be performed in accordance with the principles of quality risk management. The requirements and alert/action limits will depend on the nature of the operations carried out, but the recommended \u201cclean-up period\u201d should be attained.\n\n4.7.9 Other characteristics such as temperature and relative humidity depend on the product and nature of the operations carried out. These parameters should not interfere with the defined cleanliness standard.\n\n4.7.10 Examples of operations to be carried out in the various grades are given in Table 2 (see also sections 4.14\u20134.22).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen de Nivel Superior del Contexto\n\nEl texto se centra en la monitorizaci\u00f3n de part\u00edculas en entornos controlados, como salas limpias y \u00e1reas de producci\u00f3n que manejan materiales sensibles, incluidos organismos vivos y productos farmac\u00e9uticos. Se discuten los sistemas de muestreo, la importancia de la limpieza y el control de la contaminaci\u00f3n, as\u00ed como los par\u00e1metros que deben considerarse para mantener la calidad del aire y la limpieza en estas \u00e1reas. Se mencionan las condiciones de part\u00edculas en el estado \"en reposo\" y \"en operaci\u00f3n\", as\u00ed como la necesidad de un per\u00edodo de \"limpieza\" o \"recuperaci\u00f3n\" despu\u00e9s de las operaciones. Tambi\u00e9n se hace hincapi\u00e9 en la gesti\u00f3n de riesgos de calidad y en la importancia de monitorear \u00e1reas de diferentes grados (A, C y D) para asegurar la conformidad con los est\u00e1ndares de limpieza.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 factores deben considerarse al seleccionar un sistema de monitoreo para part\u00edculas en entornos controlados?**\n   - La selecci\u00f3n del sistema debe tener en cuenta el tama\u00f1o de las part\u00edculas, la longitud y el radio de las curvas en el tubo de muestreo, as\u00ed como los riesgos asociados con los materiales utilizados en la operaci\u00f3n de fabricaci\u00f3n.\n\n2. **\u00bfCu\u00e1l es el objetivo del per\u00edodo de \"limpieza\" o \"recuperaci\u00f3n\" despu\u00e9s de las operaciones en \u00e1reas de grado A?**\n   - El objetivo es lograr las condiciones de part\u00edculas especificadas para el estado \"en reposo\" en ausencia del personal operativo, lo que implica una reducci\u00f3n en la concentraci\u00f3n de part\u00edculas por un factor de 100 dentro de un per\u00edodo de 15 a 20 minutos.\n\n3. **\u00bfC\u00f3mo se determina el tama\u00f1o y la ubicaci\u00f3n de las muestras para el monitoreo de part\u00edculas en \u00e1reas limpias?**\n   - El tama\u00f1o y la ubicaci\u00f3n de las muestras deben ser determinados en funci\u00f3n de una evaluaci\u00f3n del proceso y del riesgo de contaminaci\u00f3n, y no necesariamente deben coincidir con el plan de muestreo utilizado para la clasificaci\u00f3n formal de las \u00e1reas limpias.", "prev_section_summary": "### Temas Clave:\n\n1. **Clasificaci\u00f3n de Salas Limpias**:\n   - Uso de contadores de part\u00edculas port\u00e1tiles con tuber\u00edas de muestreo cortas para evitar la p\u00e9rdida de part\u00edculas de 5.0 \u03bcm o m\u00e1s.\n   - Implementaci\u00f3n de cabezales de muestreo isocin\u00e9ticos en sistemas de flujo de aire unidireccional.\n\n2. **Monitoreo de Salas Limpias y Dispositivos de Aire Limpio**:\n   - Monitoreo rutinario de salas limpias y dispositivos de aire limpio durante su operaci\u00f3n, basado en un an\u00e1lisis de riesgo formal.\n   - Importancia del monitoreo continuo en zonas de grado A y B, con \u00e9nfasis en la detecci\u00f3n de eventos transitorios y deterioro del sistema.\n\n3. **Condiciones de Monitoreo en Zonas de Grado A**:\n   - Monitoreo de part\u00edculas durante el procesamiento cr\u00edtico, con excepciones justificadas por contaminantes que puedan da\u00f1ar el equipo de monitoreo.\n   - Necesidad de realizar monitoreo durante operaciones simuladas y en la configuraci\u00f3n del equipo antes de la exposici\u00f3n a riesgos.\n\n4. **Monitoreo en Zonas de Grado B**:\n   - Recomendaci\u00f3n de un sistema de monitoreo similar al de grado A, con una frecuencia de muestreo que capture cambios en los niveles de contaminaci\u00f3n.\n   - Determinaci\u00f3n de la importancia del sistema de monitoreo seg\u00fan la efectividad de la segregaci\u00f3n entre zonas de grado A y B.\n\n5. **Sistemas de Monitoreo de Part\u00edculas**:\n   - Posibilidad de utilizar contadores de part\u00edculas independientes o una red de puntos de muestreo accesibles secuencialmente.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que publica el documento.\n- **ISO 14644-2**: Norma que proporciona informaci\u00f3n sobre pruebas para demostrar el cumplimiento de la clasificaci\u00f3n de limpieza.\n- **Zonas de Grado A y B**: Clasificaciones de \u00e1reas dentro de un entorno controlado que requieren diferentes niveles de monitoreo y control de part\u00edculas.\n- **Contadores de Part\u00edculas**: Dispositivos utilizados para medir la cantidad de part\u00edculas en el aire, esenciales para el monitoreo de la calidad del aire en salas limpias. \n\nEste resumen destaca la importancia de la clasificaci\u00f3n y el monitoreo en entornos controlados, as\u00ed como las pr\u00e1cticas recomendadas para garantizar la calidad del aire y la seguridad en procesos cr\u00edticos.", "excerpt_keywords": "Keywords: particle monitoring, clean rooms, contamination control, quality risk management, airborne particles"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2948318f-f9ce-4779-b9ee-97f93d996255", "node_type": "4", "metadata": {"page_label": "230", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "connected by manifold to a single particle counter; or multiple small particle counters located near monitoring points and networked to a data acquisition system. Combinations of systems can also be used. The system selected should be appropriate for the particle size considered. Where remote sampling systems are used, the length of tubing and the radii of any bends in the tubing should be considered in the context of particle losses in the tubing. The selection of the monitoring system should take account of any risk presented by the materials used in the manufacturing operation, for example, those involving live organisms or radiopharmaceuticals.\n\n4.7.5 The sizes of samples taken for monitoring purposes using automated systems will usually be a function of the sampling rate of the system used. It is not necessary for the sample volume to be the same as that used for formal classification of clean rooms and clean-air devices.\n\n4.7.6 The airborne particle conditions given in Table 1 for the \u201cat rest\u201d state should be achieved in the absence of the operating personnel after a short \u201cclean-up\u201d or \u201crecovery\u201d period of about 15\u201320 minutes (guidance value), after completion of the operations. The particulate conditions given in Table 1 for grade A \u201cin operation\u201d should be maintained in the zone immediately surrounding the product whenever the product or open container is exposed to the environment. The \u201cclean-up\u201d or \u201crecovery\u201d test should demonstrate a change in particle concentration by a factor of 100 within the prescribed time (ISO 14644-3 clause B.12) (6).\n\n4.7.7 In order to demonstrate control of the cleanliness of the various clean areas during operation, they should be monitored for airborne particles and microbial contamination. In addition to \u201cat rest\u201d and \u201cin operation\u201d classification, airborne particles should be monitored periodically \u201cin operation\u201d at critical locations. The sampling plan need not be the same as that used for classification. Locations and sample sizes should be determined based on an assessment of the process and contamination risk.\n\n4.7.8 The monitoring of grade C and D areas in operation should be performed in accordance with the principles of quality risk management. The requirements and alert/action limits will depend on the nature of the operations carried out, but the recommended \u201cclean-up period\u201d should be attained.\n\n4.7.9 Other characteristics such as temperature and relative humidity depend on the product and nature of the operations carried out. These parameters should not interfere with the defined cleanliness standard.\n\n4.7.10 Examples of operations to be carried out in the various grades are given in Table 2 (see also sections 4.14\u20134.22).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "23b60894ad9dab3ad6b1dd4dd5e789ed323f82d91f175c6e99eeccd966aab7ab", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "connected by manifold to a single particle counter; or multiple small particle counters located near monitoring points and networked to a data acquisition system. Combinations of systems can also be used. The system selected should be appropriate for the particle size considered. Where remote sampling systems are used, the length of tubing and the radii of any bends in the tubing should be considered in the context of particle losses in the tubing. The selection of the monitoring system should take account of any risk presented by the materials used in the manufacturing operation, for example, those involving live organisms or radiopharmaceuticals.\n\n4.7.5 The sizes of samples taken for monitoring purposes using automated systems will usually be a function of the sampling rate of the system used. It is not necessary for the sample volume to be the same as that used for formal classification of clean rooms and clean-air devices.\n\n4.7.6 The airborne particle conditions given in Table 1 for the \u201cat rest\u201d state should be achieved in the absence of the operating personnel after a short \u201cclean-up\u201d or \u201crecovery\u201d period of about 15\u201320 minutes (guidance value), after completion of the operations. The particulate conditions given in Table 1 for grade A \u201cin operation\u201d should be maintained in the zone immediately surrounding the product whenever the product or open container is exposed to the environment. The \u201cclean-up\u201d or \u201crecovery\u201d test should demonstrate a change in particle concentration by a factor of 100 within the prescribed time (ISO 14644-3 clause B.12) (6).\n\n4.7.7 In order to demonstrate control of the cleanliness of the various clean areas during operation, they should be monitored for airborne particles and microbial contamination. In addition to \u201cat rest\u201d and \u201cin operation\u201d classification, airborne particles should be monitored periodically \u201cin operation\u201d at critical locations. The sampling plan need not be the same as that used for classification. Locations and sample sizes should be determined based on an assessment of the process and contamination risk.\n\n4.7.8 The monitoring of grade C and D areas in operation should be performed in accordance with the principles of quality risk management. The requirements and alert/action limits will depend on the nature of the operations carried out, but the recommended \u201cclean-up period\u201d should be attained.\n\n4.7.9 Other characteristics such as temperature and relative humidity depend on the product and nature of the operations carried out. These parameters should not interfere with the defined cleanliness standard.\n\n4.7.10 Examples of operations to be carried out in the various grades are given in Table 2 (see also sections 4.14\u20134.22).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2723, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d65d8f76-7d85-4088-a3d1-60dee5029c27": {"__data__": {"id_": "d65d8f76-7d85-4088-a3d1-60dee5029c27", "embedding": null, "metadata": {"page_label": "231", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Table 2\n**Examples of operations to be carried out in the various grades**\n\n| Grade | Examples of operations for terminally sterilized products(see sections 4.14\u20134.17) |\n| - | - |\n| A | Filling of products when unusually at risk |\n| C | Preparation of solutions when unusually at risk. Filling of products |\n| D | Preparation of solutions and components for subsequent filling |\n\n\n| Grade | Examples of operations for aseptic preparations(see sections 4.18\u20134.22) |\n| - | - |\n| A | Aseptic preparation and filling |\n| C | Preparation of solutions to be filtered |\n| D | Handling of components after washing |\n\n\n4.8 To control the microbiological cleanliness of the cleanliness grades A\u2013D in operation the clean areas should be monitored. Where aseptic operations are performed, monitoring should be frequent using methods such as settle plates, volumetric air and surface sampling (e.g. swabs and contact plates). Sampling methods used in operation should not interfere with zone protection. Results from monitoring should be considered when reviewing batch documentation for finished product release. Surfaces and personnel should be monitored after critical operations. Additional microbiological monitoring is also required outside production operations, e.g. after validation of systems, cleaning and sanitization.\n\n4.9 Levels of detection of microbial contamination should be established for the purpose of setting alert and action levels and for monitoring the trends in environmental cleanliness in the facility. Limits expressed in colony-forming units (CFU) for the microbiological monitoring of clean areas in operation are given in Table 3. The sampling methods and numerical values included in the table are not intended to represent specifications, but are for information only.\n\n# Table 3\n**Recommended limits for microbial contamination<sup>a</sup>**\n\n| Grade | Air sample(CFU/m) | Settle plates(diameter 90 mm)(CFU/4 hours) | Contact plates(diameter 55 mm)(CFU/plate) | Glove print(5 fingers)(CFU/glove) |\n| - | - | - | - | - |\n| A | < 1 | < 1 | < 1 | < 1 |\n| B | 10 | 5 | 5 | 5 |\n| C | 100 | 50 | 25 | \u2013 |\n| D | 200 | 100 | 50 | \u2013 |\n\n\nCFU, colony-forming units.  \n<sup>a</sup> These are average values.  \n<sup>b</sup> Individual settle plates may be exposed for less than 4 hours.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Informe T\u00e9cnico 957) aborda las operaciones en \u00e1reas limpias clasificadas en diferentes grados (A, B, C, D) para garantizar la esterilidad y la limpieza microbiol\u00f3gica en la producci\u00f3n de productos farmac\u00e9uticos. Se detallan ejemplos de operaciones para productos terminalmente esterilizados y preparaciones as\u00e9pticas, as\u00ed como los m\u00e9todos de monitoreo microbiol\u00f3gico y los l\u00edmites recomendados para la contaminaci\u00f3n microbiana en cada grado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las operaciones espec\u00edficas que se deben realizar en el grado A para productos terminalmente esterilizados y para preparaciones as\u00e9pticas?**\n   - Respuesta: En el grado A para productos terminalmente esterilizados, se debe realizar el llenado de productos cuando est\u00e1n inusualmente en riesgo. Para preparaciones as\u00e9pticas, se debe llevar a cabo la preparaci\u00f3n y el llenado as\u00e9ptico.\n\n2. **\u00bfQu\u00e9 m\u00e9todos de monitoreo microbiol\u00f3gico se recomiendan para las \u00e1reas limpias de los grados A\u2013D y con qu\u00e9 frecuencia deben realizarse?**\n   - Respuesta: Se recomienda el uso de placas de asentamiento, muestreo volum\u00e9trico de aire y muestreo de superficie (como hisopos y placas de contacto). El monitoreo debe ser frecuente, especialmente donde se realizan operaciones as\u00e9pticas.\n\n3. **\u00bfCu\u00e1les son los l\u00edmites recomendados para la contaminaci\u00f3n microbiana en el grado C seg\u00fan el muestreo de aire y las placas de asentamiento?**\n   - Respuesta: Para el grado C, los l\u00edmites recomendados son 100 CFU/m para muestras de aire y 50 CFU/4 horas para placas de asentamiento de 90 mm de di\u00e1metro.", "prev_section_summary": "### Temas Clave\n\n1. **Monitoreo de Part\u00edculas**: Se discute la importancia de seleccionar sistemas de monitoreo adecuados para part\u00edculas en entornos controlados, considerando el tama\u00f1o de las part\u00edculas y el riesgo asociado con los materiales utilizados.\n\n2. **Condiciones de Limpieza**: Se establecen condiciones espec\u00edficas para el estado \"en reposo\" y \"en operaci\u00f3n\" de las \u00e1reas limpias, as\u00ed como la necesidad de un per\u00edodo de \"limpieza\" o \"recuperaci\u00f3n\" despu\u00e9s de las operaciones.\n\n3. **Muestreo y Clasificaci\u00f3n**: Se menciona que el tama\u00f1o y la ubicaci\u00f3n de las muestras deben basarse en una evaluaci\u00f3n del proceso y el riesgo de contaminaci\u00f3n, y no necesariamente deben coincidir con los planes de muestreo para la clasificaci\u00f3n formal.\n\n4. **Gesti\u00f3n de Riesgos de Calidad**: Se enfatiza la importancia de aplicar principios de gesti\u00f3n de riesgos de calidad en el monitoreo de \u00e1reas de grado C y D.\n\n5. **Par\u00e1metros Ambientales**: Se se\u00f1ala que caracter\u00edsticas como la temperatura y la humedad relativa deben ser consideradas, pero no deben interferir con los est\u00e1ndares de limpieza definidos.\n\n### Entidades\n\n- **Sistemas de Monitoreo**: Contadores de part\u00edculas, sistemas de muestreo remoto.\n- **Condiciones de Part\u00edculas**: Estado \"en reposo\", estado \"en operaci\u00f3n\".\n- **Normas de Limpieza**: ISO 14644-3.\n- **\u00c1reas Limpias**: Grados A, C y D.\n- **Par\u00e1metros Ambientales**: Temperatura, humedad relativa.\n- **Materiales Sensibles**: Organismos vivos, productos farmac\u00e9uticos. \n\nEste resumen abarca los aspectos fundamentales del monitoreo de part\u00edculas en entornos controlados, destacando la importancia de la limpieza y el control de la contaminaci\u00f3n en la producci\u00f3n de materiales sensibles.", "excerpt_keywords": "Keywords: microbiological monitoring, aseptic preparations, terminally sterilized products, contamination limits, clean areas"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "55b73b54-3677-4cc3-b7cd-c56360ac9665", "node_type": "4", "metadata": {"page_label": "231", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Table 2\n**Examples of operations to be carried out in the various grades**\n\n| Grade | Examples of operations for terminally sterilized products(see sections 4.14\u20134.17) |\n| - | - |\n| A | Filling of products when unusually at risk |\n| C | Preparation of solutions when unusually at risk. Filling of products |\n| D | Preparation of solutions and components for subsequent filling |\n\n\n| Grade | Examples of operations for aseptic preparations(see sections 4.18\u20134.22) |\n| - | - |\n| A | Aseptic preparation and filling |\n| C | Preparation of solutions to be filtered |\n| D | Handling of components after washing |\n\n\n4.8 To control the microbiological cleanliness of the cleanliness grades A\u2013D in operation the clean areas should be monitored. Where aseptic operations are performed, monitoring should be frequent using methods such as settle plates, volumetric air and surface sampling (e.g. swabs and contact plates). Sampling methods used in operation should not interfere with zone protection. Results from monitoring should be considered when reviewing batch documentation for finished product release. Surfaces and personnel should be monitored after critical operations. Additional microbiological monitoring is also required outside production operations, e.g. after validation of systems, cleaning and sanitization.\n\n4.9 Levels of detection of microbial contamination should be established for the purpose of setting alert and action levels and for monitoring the trends in environmental cleanliness in the facility. Limits expressed in colony-forming units (CFU) for the microbiological monitoring of clean areas in operation are given in Table 3. The sampling methods and numerical values included in the table are not intended to represent specifications, but are for information only.\n\n# Table 3\n**Recommended limits for microbial contamination<sup>a</sup>**\n\n| Grade | Air sample(CFU/m) | Settle plates(diameter 90 mm)(CFU/4 hours) | Contact plates(diameter 55 mm)(CFU/plate) | Glove print(5 fingers)(CFU/glove) |\n| - | - | - | - | - |\n| A | < 1 | < 1 | < 1 | < 1 |\n| B | 10 | 5 | 5 | 5 |\n| C | 100 | 50 | 25 | \u2013 |\n| D | 200 | 100 | 50 | \u2013 |\n\n\nCFU, colony-forming units.  \n<sup>a</sup> These are average values.  \n<sup>b</sup> Individual settle plates may be exposed for less than 4 hours.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "11561fb5792eda5d8ba51d6fb7d23b8e62e890682036868d17ee2f972470e391", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Table 2\n**Examples of operations to be carried out in the various grades**\n\n| Grade | Examples of operations for terminally sterilized products(see sections 4.14\u20134.17) |\n| - | - |\n| A | Filling of products when unusually at risk |\n| C | Preparation of solutions when unusually at risk. Filling of products |\n| D | Preparation of solutions and components for subsequent filling |\n\n\n| Grade | Examples of operations for aseptic preparations(see sections 4.18\u20134.22) |\n| - | - |\n| A | Aseptic preparation and filling |\n| C | Preparation of solutions to be filtered |\n| D | Handling of components after washing |\n\n\n4.8 To control the microbiological cleanliness of the cleanliness grades A\u2013D in operation the clean areas should be monitored. Where aseptic operations are performed, monitoring should be frequent using methods such as settle plates, volumetric air and surface sampling (e.g. swabs and contact plates). Sampling methods used in operation should not interfere with zone protection. Results from monitoring should be considered when reviewing batch documentation for finished product release. Surfaces and personnel should be monitored after critical operations. Additional microbiological monitoring is also required outside production operations, e.g. after validation of systems, cleaning and sanitization.\n\n4.9 Levels of detection of microbial contamination should be established for the purpose of setting alert and action levels and for monitoring the trends in environmental cleanliness in the facility. Limits expressed in colony-forming units (CFU) for the microbiological monitoring of clean areas in operation are given in Table 3. The sampling methods and numerical values included in the table are not intended to represent specifications, but are for information only.\n\n# Table 3\n**Recommended limits for microbial contamination<sup>a</sup>**\n\n| Grade | Air sample(CFU/m) | Settle plates(diameter 90 mm)(CFU/4 hours) | Contact plates(diameter 55 mm)(CFU/plate) | Glove print(5 fingers)(CFU/glove) |\n| - | - | - | - | - |\n| A | < 1 | < 1 | < 1 | < 1 |\n| B | 10 | 5 | 5 | 5 |\n| C | 100 | 50 | 25 | \u2013 |\n| D | 200 | 100 | 50 | \u2013 |\n\n\nCFU, colony-forming units.  \n<sup>a</sup> These are average values.  \n<sup>b</sup> Individual settle plates may be exposed for less than 4 hours.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2298, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "764aec1d-ed90-4248-9d56-38663200ea64": {"__data__": {"id_": "764aec1d-ed90-4248-9d56-38663200ea64", "embedding": null, "metadata": {"page_label": "232", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.10\n\nAppropriate alert and action limits should be set for the results of particulate and microbiological monitoring. If the action limits are exceeded or a trend is identified in the alert levels, investigation should be initiated and the appropriate corrective actions should be taken, as prescribed in the operating procedures.\n\n# 4.11\n\nThe area grades as specified in sections 4.12 to 4.20 should be selected by the manufacturer on the basis of the nature of the process operations being performed and validation runs (e.g. aseptic media fills or others types of process simulations) are used to establish processing hold times and a maximum fill duration. The determination of an appropriate process area environment and a time limit should be based on the microbial contamination (bioburden) found.\n\n## Terminally sterilized products\n\n### 4.12\n\nComponents and most products should be prepared in at least a grade D environment to ensure low microbial bioburden and particulate counts prior to filtration and sterilization. Where the product is at unusual risk of microbial contamination (e.g. because it actively supports microbial growth, must be held for a long period before sterilization, or is necessarily processed mainly in open vessels), the preparation should generally be done in a grade C environment.\n\n### 4.13\n\nThe filling of products for terminal sterilization should generally be done in at least a grade C environment.\n\n### 4.14\n\nWhere the product is at unusual risk of contamination from the environment (e.g. because the filling operation is slow, the containers are wide-necked or are necessarily exposed for more than a few seconds before sealing), the filling should be done in a grade A zone with at least a grade C background.\n\n### 4.15\n\nThe preparation and filling of ointments, creams, suspensions and emulsions should generally be done in a grade C environment before terminal sterilization.\n\n## Aseptic preparation\n\n### 4.16\n\nComponents after washing should be handled in at least a grade D environment. The handling of sterile starting materials and components, unless subjected to sterilization or filtration through a microorganism-retaining filter later in the process, should be undertaken in a grade A environment with a grade B background.\n\n### 4.17\n\nThe preparation of solutions which are to be sterile-filtered during the process should be undertaken in a grade C environment (unless a closed system is used, in which case a Class D environment may be justifiable).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece directrices sobre los l\u00edmites de alerta y acci\u00f3n para el monitoreo de part\u00edculas y microorganismos en entornos de producci\u00f3n de productos farmac\u00e9uticos. Se especifican diferentes grados de ambientes (A, B, C, D) que deben ser seleccionados por los fabricantes seg\u00fan el tipo de operaci\u00f3n y el riesgo de contaminaci\u00f3n microbiana. Las secciones detallan las condiciones necesarias para la preparaci\u00f3n y llenado de productos que ser\u00e1n esterilizados terminalmente o preparados de manera as\u00e9ptica, enfatizando la importancia de minimizar la biocarga microbiana y las part\u00edculas en el proceso.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 criterios deben considerarse al seleccionar el grado de ambiente para la preparaci\u00f3n de productos que est\u00e1n en riesgo inusual de contaminaci\u00f3n microbiana?**\n   - Respuesta: El grado de ambiente debe seleccionarse en funci\u00f3n de factores como si el producto apoya activamente el crecimiento microbiano, si debe mantenerse durante un largo per\u00edodo antes de la esterilizaci\u00f3n, o si se procesa principalmente en recipientes abiertos. En tales casos, se recomienda generalmente un ambiente de grado C.\n\n2. **\u00bfCu\u00e1les son las implicaciones de exceder los l\u00edmites de acci\u00f3n establecidos durante el monitoreo de part\u00edculas y microorganismos?**\n   - Respuesta: Si se exceden los l\u00edmites de acci\u00f3n o se identifica una tendencia en los niveles de alerta, se debe iniciar una investigaci\u00f3n y tomar las acciones correctivas apropiadas, seg\u00fan lo prescrito en los procedimientos operativos.\n\n3. **\u00bfQu\u00e9 ambiente se recomienda para el manejo de materiales est\u00e9riles y componentes despu\u00e9s del lavado?**\n   - Respuesta: Los componentes despu\u00e9s del lavado deben ser manejados en un ambiente de al menos grado D. Sin embargo, el manejo de materiales est\u00e9riles y componentes, a menos que sean sometidos a esterilizaci\u00f3n o filtraci\u00f3n a trav\u00e9s de un filtro retentivo de microorganismos m\u00e1s adelante en el proceso, debe realizarse en un ambiente de grado A con un fondo de grado B.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Clasificaci\u00f3n de \u00e1reas limpias**: El documento clasifica las \u00e1reas limpias en grados A, B, C y D, cada uno con diferentes requisitos y operaciones espec\u00edficas para garantizar la esterilidad y la limpieza microbiol\u00f3gica.\n\n2. **Operaciones espec\u00edficas**:\n   - **Productos terminalmente esterilizados**:\n     - **Grado A**: Llenado de productos cuando est\u00e1n inusualmente en riesgo.\n     - **Grado C**: Preparaci\u00f3n de soluciones cuando est\u00e1n inusualmente en riesgo y llenado de productos.\n     - **Grado D**: Preparaci\u00f3n de soluciones y componentes para llenado posterior.\n   - **Preparaciones as\u00e9pticas**:\n     - **Grado A**: Preparaci\u00f3n y llenado as\u00e9ptico.\n     - **Grado C**: Preparaci\u00f3n de soluciones para ser filtradas.\n     - **Grado D**: Manejo de componentes despu\u00e9s del lavado.\n\n3. **Monitoreo microbiol\u00f3gico**: Se enfatiza la importancia de monitorear la limpieza microbiol\u00f3gica en las \u00e1reas limpias de los grados A\u2013D. Se deben utilizar m\u00e9todos como placas de asentamiento, muestreo volum\u00e9trico de aire y muestreo de superficie. El monitoreo debe ser frecuente, especialmente en operaciones as\u00e9pticas.\n\n4. **L\u00edmites de contaminaci\u00f3n microbiana**: Se establecen l\u00edmites recomendados para la contaminaci\u00f3n microbiana en funci\u00f3n del grado:\n   - **Grado A**: < 1 CFU/m (aire), < 1 CFU/4 horas (placas de asentamiento).\n   - **Grado B**: 10 CFU/m (aire), 5 CFU/4 horas (placas de asentamiento).\n   - **Grado C**: 100 CFU/m (aire), 50 CFU/4 horas (placas de asentamiento).\n   - **Grado D**: 200 CFU/m (aire), 100 CFU/4 horas (placas de asentamiento).\n\n5. **CFU (Unidades formadoras de colonias)**: Se utiliza como medida para establecer los l\u00edmites de contaminaci\u00f3n microbiana y se aclara que los valores son promedios y no especificaciones.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad del documento.\n- **Informe T\u00e9cnico 957**: T\u00edtulo del documento.\n- **Grados de limpieza (A, B, C, D)**: Clasificaci\u00f3n de \u00e1reas limpias.\n- **M\u00e9todos de monitoreo**: Placas de asentamiento, muestreo volum\u00e9trico de aire, muestreo de superficie.\n- **Contaminaci\u00f3n microbiana**: Medida en CFU.", "excerpt_keywords": "Keywords: microbiological monitoring, sterile environment, contamination risk, aseptic preparation, terminal sterilization"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "075adb14-e78d-47dc-8453-6c7f60d53630", "node_type": "4", "metadata": {"page_label": "232", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.10\n\nAppropriate alert and action limits should be set for the results of particulate and microbiological monitoring. If the action limits are exceeded or a trend is identified in the alert levels, investigation should be initiated and the appropriate corrective actions should be taken, as prescribed in the operating procedures.\n\n# 4.11\n\nThe area grades as specified in sections 4.12 to 4.20 should be selected by the manufacturer on the basis of the nature of the process operations being performed and validation runs (e.g. aseptic media fills or others types of process simulations) are used to establish processing hold times and a maximum fill duration. The determination of an appropriate process area environment and a time limit should be based on the microbial contamination (bioburden) found.\n\n## Terminally sterilized products\n\n### 4.12\n\nComponents and most products should be prepared in at least a grade D environment to ensure low microbial bioburden and particulate counts prior to filtration and sterilization. Where the product is at unusual risk of microbial contamination (e.g. because it actively supports microbial growth, must be held for a long period before sterilization, or is necessarily processed mainly in open vessels), the preparation should generally be done in a grade C environment.\n\n### 4.13\n\nThe filling of products for terminal sterilization should generally be done in at least a grade C environment.\n\n### 4.14\n\nWhere the product is at unusual risk of contamination from the environment (e.g. because the filling operation is slow, the containers are wide-necked or are necessarily exposed for more than a few seconds before sealing), the filling should be done in a grade A zone with at least a grade C background.\n\n### 4.15\n\nThe preparation and filling of ointments, creams, suspensions and emulsions should generally be done in a grade C environment before terminal sterilization.\n\n## Aseptic preparation\n\n### 4.16\n\nComponents after washing should be handled in at least a grade D environment. The handling of sterile starting materials and components, unless subjected to sterilization or filtration through a microorganism-retaining filter later in the process, should be undertaken in a grade A environment with a grade B background.\n\n### 4.17\n\nThe preparation of solutions which are to be sterile-filtered during the process should be undertaken in a grade C environment (unless a closed system is used, in which case a Class D environment may be justifiable).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "8b934cbce21268c72a014abf03908f72f4467095be7d20348040a8fceeacbb5d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.10\n\nAppropriate alert and action limits should be set for the results of particulate and microbiological monitoring. If the action limits are exceeded or a trend is identified in the alert levels, investigation should be initiated and the appropriate corrective actions should be taken, as prescribed in the operating procedures.\n\n# 4.11\n\nThe area grades as specified in sections 4.12 to 4.20 should be selected by the manufacturer on the basis of the nature of the process operations being performed and validation runs (e.g. aseptic media fills or others types of process simulations) are used to establish processing hold times and a maximum fill duration. The determination of an appropriate process area environment and a time limit should be based on the microbial contamination (bioburden) found.\n\n## Terminally sterilized products\n\n### 4.12\n\nComponents and most products should be prepared in at least a grade D environment to ensure low microbial bioburden and particulate counts prior to filtration and sterilization. Where the product is at unusual risk of microbial contamination (e.g. because it actively supports microbial growth, must be held for a long period before sterilization, or is necessarily processed mainly in open vessels), the preparation should generally be done in a grade C environment.\n\n### 4.13\n\nThe filling of products for terminal sterilization should generally be done in at least a grade C environment.\n\n### 4.14\n\nWhere the product is at unusual risk of contamination from the environment (e.g. because the filling operation is slow, the containers are wide-necked or are necessarily exposed for more than a few seconds before sealing), the filling should be done in a grade A zone with at least a grade C background.\n\n### 4.15\n\nThe preparation and filling of ointments, creams, suspensions and emulsions should generally be done in a grade C environment before terminal sterilization.\n\n## Aseptic preparation\n\n### 4.16\n\nComponents after washing should be handled in at least a grade D environment. The handling of sterile starting materials and components, unless subjected to sterilization or filtration through a microorganism-retaining filter later in the process, should be undertaken in a grade A environment with a grade B background.\n\n### 4.17\n\nThe preparation of solutions which are to be sterile-filtered during the process should be undertaken in a grade C environment (unless a closed system is used, in which case a Class D environment may be justifiable).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2510, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "525e2afe-ffb8-4f05-aced-c123be20fdf2": {"__data__": {"id_": "525e2afe-ffb8-4f05-aced-c123be20fdf2", "embedding": null, "metadata": {"page_label": "233", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "If not sterile-filtered (therefore an aseptic manipulation) the preparation of materials and products should be undertaken in a grade A environment with a grade B background.\n\n4.18 The handling and filling of aseptically prepared products, as well as the handling of exposed sterile equipment, should be undertaken in a grade A environment with a grade B background.\n\n4.19 The transfer of partially closed containers, as used in freeze-drying, before stoppering is completed, should be undertaken either in a grade A environment with a grade B background or in sealed transfer trays in a grade B environment.\n\n4.20 The preparation and filling of sterile ointments, creams, suspensions and emulsions should be undertaken in a grade A environment with a grade B background when the product is exposed and is not subsequently filtered.\n\n*Processing*\n\n4.21 Precautions to minimize contamination should be taken during all processing stages, including the stages before sterilization.\n\n4.22 In general, preparations containing live microorganisms should not be made, nor should containers be filled in areas used for the processing of other pharmaceutical products. However, if the manufacturer can demonstrate and validate effective containment and decontamination of the live microorganisms, the use of multiproduct facilities may be justifiable. Vaccines consisting of dead organisms or of bacterial extracts may be dispensed into containers in the same premises as other sterile pharmaceutical products, provided that the inactivation procedure has been properly validated.\n\nWhen multiproduct facilities are used to manufacture sterile preparations containing live microorganisms and other sterile pharmaceutical products, the manufacturer should demonstrate and validate the effective decontamination of the live microorganisms, in addition to precautions taken to minimize contamination.\n\n4.23 Validation of aseptic processing should include a process simulation test using a nutrient medium (media fill). Selection of the nutrient medium should be made based on dosage form of the product and selectivity, clarity, concentration and suitability for sterilization of the nutrient medium.\n\n4.24 The process simulation test should imitate as closely as possible the routine aseptic manufacturing steps except where the activity may lead to any potential microbial contamination.\n\n4.25 Process simulation tests should be performed as part of validation by running three consecutive satisfactory simulation tests. These tests should be repeated at defined intervals and after any significant modification to the process.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Entorno de Asepsia**: El documento establece que la preparaci\u00f3n y el manejo de productos y materiales que no han sido filtrados est\u00e9rilmente deben realizarse en un entorno de grado A con un fondo de grado B. Esto se aplica a la manipulaci\u00f3n de productos preparados asepticamente y equipos est\u00e9riles expuestos.\n\n2. **Contaminaci\u00f3n y Validaci\u00f3n**: Se enfatiza la importancia de minimizar la contaminaci\u00f3n durante todas las etapas de procesamiento, especialmente antes de la esterilizaci\u00f3n. Adem\u00e1s, se menciona que las instalaciones multiproducto pueden ser utilizadas bajo ciertas condiciones, siempre que se valide la contenci\u00f3n y desinfecci\u00f3n de microorganismos vivos.\n\n3. **Pruebas de Simulaci\u00f3n de Procesos**: La validaci\u00f3n del procesamiento as\u00e9ptico debe incluir pruebas de simulaci\u00f3n de procesos utilizando un medio nutritivo, y estas pruebas deben realizarse de manera regular y tras modificaciones significativas en el proceso.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 condiciones deben cumplirse para que un fabricante utilice instalaciones multiproducto para la fabricaci\u00f3n de preparaciones est\u00e9riles que contengan microorganismos vivos?**\n   - Respuesta: El fabricante debe demostrar y validar la efectiva contenci\u00f3n y desinfecci\u00f3n de los microorganismos vivos, adem\u00e1s de tomar precauciones para minimizar la contaminaci\u00f3n.\n\n2. **\u00bfCu\u00e1ntas pruebas de simulaci\u00f3n de procesos son necesarias para validar el procesamiento as\u00e9ptico y con qu\u00e9 frecuencia deben repetirse?**\n   - Respuesta: Se deben realizar tres pruebas de simulaci\u00f3n satisfactorias consecutivas como parte de la validaci\u00f3n, y estas deben repetirse a intervalos definidos y despu\u00e9s de cualquier modificaci\u00f3n significativa en el proceso.\n\n3. **\u00bfQu\u00e9 factores deben considerarse al seleccionar el medio nutritivo para las pruebas de simulaci\u00f3n de procesos?**\n   - Respuesta: La selecci\u00f3n del medio nutritivo debe basarse en la forma de dosificaci\u00f3n del producto, as\u00ed como en la selectividad, claridad, concentraci\u00f3n y adecuaci\u00f3n para la esterilizaci\u00f3n del medio nutritivo.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **L\u00edmites de alerta y acci\u00f3n**:\n   - Se deben establecer l\u00edmites apropiados para el monitoreo de part\u00edculas y microorganismos.\n   - Si se superan los l\u00edmites de acci\u00f3n o se identifican tendencias en los niveles de alerta, se debe iniciar una investigaci\u00f3n y tomar acciones correctivas.\n\n2. **Clasificaci\u00f3n de ambientes**:\n   - Los fabricantes deben seleccionar el grado de ambiente (A, B, C, D) seg\u00fan la naturaleza de las operaciones y la validaci\u00f3n de procesos.\n   - La selecci\u00f3n del ambiente debe basarse en la biocarga microbiana encontrada.\n\n3. **Productos esterilizados terminalmente**:\n   - Preparaci\u00f3n de componentes y productos en un ambiente de al menos grado D.\n   - Para productos con riesgo inusual de contaminaci\u00f3n, se recomienda un ambiente de grado C.\n   - El llenado de productos debe realizarse en un ambiente de al menos grado C, y en casos de alto riesgo, en una zona de grado A con fondo de grado C.\n\n4. **Preparaci\u00f3n as\u00e9ptica**:\n   - Manejo de componentes despu\u00e9s del lavado en un ambiente de al menos grado D.\n   - Manejo de materiales est\u00e9riles en un ambiente de grado A con fondo de grado B, a menos que se sometan a esterilizaci\u00f3n o filtraci\u00f3n.\n   - Preparaci\u00f3n de soluciones que ser\u00e1n filtradas as\u00e9pticamente en un ambiente de grado C, salvo en sistemas cerrados donde puede justificarse un ambiente de grado D.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Grados de ambiente**: A, B, C, D, que indican el nivel de control de contaminaci\u00f3n.\n- **Biocarga microbiana**: Cantidad de microorganismos presentes en un producto o ambiente.\n- **Productos farmac\u00e9uticos**: Incluyen componentes, soluciones, ung\u00fcentos, cremas, suspensiones y emulsiones que requieren esterilizaci\u00f3n o preparaci\u00f3n as\u00e9ptica.", "excerpt_keywords": "Keywords: aseptic processing, contamination control, sterile environment, validation, nutrient medium"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "14d388f8-0a90-4a2a-9725-e179101430c6", "node_type": "4", "metadata": {"page_label": "233", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "If not sterile-filtered (therefore an aseptic manipulation) the preparation of materials and products should be undertaken in a grade A environment with a grade B background.\n\n4.18 The handling and filling of aseptically prepared products, as well as the handling of exposed sterile equipment, should be undertaken in a grade A environment with a grade B background.\n\n4.19 The transfer of partially closed containers, as used in freeze-drying, before stoppering is completed, should be undertaken either in a grade A environment with a grade B background or in sealed transfer trays in a grade B environment.\n\n4.20 The preparation and filling of sterile ointments, creams, suspensions and emulsions should be undertaken in a grade A environment with a grade B background when the product is exposed and is not subsequently filtered.\n\n*Processing*\n\n4.21 Precautions to minimize contamination should be taken during all processing stages, including the stages before sterilization.\n\n4.22 In general, preparations containing live microorganisms should not be made, nor should containers be filled in areas used for the processing of other pharmaceutical products. However, if the manufacturer can demonstrate and validate effective containment and decontamination of the live microorganisms, the use of multiproduct facilities may be justifiable. Vaccines consisting of dead organisms or of bacterial extracts may be dispensed into containers in the same premises as other sterile pharmaceutical products, provided that the inactivation procedure has been properly validated.\n\nWhen multiproduct facilities are used to manufacture sterile preparations containing live microorganisms and other sterile pharmaceutical products, the manufacturer should demonstrate and validate the effective decontamination of the live microorganisms, in addition to precautions taken to minimize contamination.\n\n4.23 Validation of aseptic processing should include a process simulation test using a nutrient medium (media fill). Selection of the nutrient medium should be made based on dosage form of the product and selectivity, clarity, concentration and suitability for sterilization of the nutrient medium.\n\n4.24 The process simulation test should imitate as closely as possible the routine aseptic manufacturing steps except where the activity may lead to any potential microbial contamination.\n\n4.25 Process simulation tests should be performed as part of validation by running three consecutive satisfactory simulation tests. These tests should be repeated at defined intervals and after any significant modification to the process.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "3ba75880ea00d5828d619a11209a4e003ef2470db1f44931b55967f3f37f052a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "If not sterile-filtered (therefore an aseptic manipulation) the preparation of materials and products should be undertaken in a grade A environment with a grade B background.\n\n4.18 The handling and filling of aseptically prepared products, as well as the handling of exposed sterile equipment, should be undertaken in a grade A environment with a grade B background.\n\n4.19 The transfer of partially closed containers, as used in freeze-drying, before stoppering is completed, should be undertaken either in a grade A environment with a grade B background or in sealed transfer trays in a grade B environment.\n\n4.20 The preparation and filling of sterile ointments, creams, suspensions and emulsions should be undertaken in a grade A environment with a grade B background when the product is exposed and is not subsequently filtered.\n\n*Processing*\n\n4.21 Precautions to minimize contamination should be taken during all processing stages, including the stages before sterilization.\n\n4.22 In general, preparations containing live microorganisms should not be made, nor should containers be filled in areas used for the processing of other pharmaceutical products. However, if the manufacturer can demonstrate and validate effective containment and decontamination of the live microorganisms, the use of multiproduct facilities may be justifiable. Vaccines consisting of dead organisms or of bacterial extracts may be dispensed into containers in the same premises as other sterile pharmaceutical products, provided that the inactivation procedure has been properly validated.\n\nWhen multiproduct facilities are used to manufacture sterile preparations containing live microorganisms and other sterile pharmaceutical products, the manufacturer should demonstrate and validate the effective decontamination of the live microorganisms, in addition to precautions taken to minimize contamination.\n\n4.23 Validation of aseptic processing should include a process simulation test using a nutrient medium (media fill). Selection of the nutrient medium should be made based on dosage form of the product and selectivity, clarity, concentration and suitability for sterilization of the nutrient medium.\n\n4.24 The process simulation test should imitate as closely as possible the routine aseptic manufacturing steps except where the activity may lead to any potential microbial contamination.\n\n4.25 Process simulation tests should be performed as part of validation by running three consecutive satisfactory simulation tests. These tests should be repeated at defined intervals and after any significant modification to the process.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2617, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a3546723-9728-453f-8863-88322599e9ba": {"__data__": {"id_": "a3546723-9728-453f-8863-88322599e9ba", "embedding": null, "metadata": {"page_label": "234", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the heating, ventilation and air-conditioning (HVAC)-system, equipment or process. Process simulation tests should incorporate activities and interventions known to occur during normal production as well as the worst-case situation. The process simulation tests should be representative of each shift and shift changeover to address any time-related and operational features.\n\n4.26 The number of containers used for media fills should be sufficient to enable a valid evaluation. For small batches the number of containers for media fills should at least equal the size of the product batch. The target should be zero growth and the following should apply:\n\n- when filling fewer than 5000 units, no contaminated units should be detected;\n- when filling 5000\u201310 000 units:\n  - one contaminated unit should result in an investigation, including consideration of a repeat media fill,\n  - two contaminated units are considered cause for revalidation following investigation;\n- when filling more than 10 000 units:\n  - one contaminated unit should result in an investigation,\n  - two contaminated units are considered cause for revalidation following investigation.\n\n4.27 For any run size, intermittent incidents of microbial contamination may be indicative of low-level contamination that should be investigated. Investigation of gross failures should include the potential impact on the sterility assurance of batches manufactured since the last successful media fill.\n\n4.28 Care should be taken to ensure that any validation does not compromise the processes.\n\n4.29 Water sources, water-treatment equipment and treated water should be monitored regularly for chemicals, biological contamination and contamination with endotoxins to ensure that the water complies with the specifications appropriate to its use. Records should be maintained of the results of the monitoring and of any action taken (10).\n\n4.30 Activities in clean areas, especially when aseptic operations are in progress, should be kept to a minimum and the movement of personnel should be controlled and methodical, so as to avoid excessive shedding of particles and organisms due to over-vigorous activity. As far as possible, personnel should be excluded from grade A zones. The ambient temperature and humidity should not be uncomfortably high because of the nature of the garments worn and to reduce the risk of contamination liberated from the personnel.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen de nivel superior del contexto\n\nEl documento de la OMS (Informe T\u00e9cnico 957) aborda la validaci\u00f3n de procesos en la producci\u00f3n farmac\u00e9utica, centr\u00e1ndose en la importancia de las pruebas de simulaci\u00f3n de procesos, la evaluaci\u00f3n de la contaminaci\u00f3n microbiana durante los llenados de medios, y el monitoreo de fuentes de agua y equipos de tratamiento. Se establecen criterios espec\u00edficos para la aceptaci\u00f3n de unidades contaminadas en funci\u00f3n del tama\u00f1o del lote, as\u00ed como recomendaciones para minimizar la actividad en \u00e1reas limpias durante operaciones as\u00e9pticas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos para la investigaci\u00f3n de unidades contaminadas en lotes de diferentes tama\u00f1os durante los llenados de medios?**\n   - Respuesta: Para lotes de menos de 5000 unidades, no se deben detectar unidades contaminadas. Para lotes de 5000 a 10,000 unidades, una unidad contaminada requiere una investigaci\u00f3n y la consideraci\u00f3n de un llenado de medios repetido, mientras que dos unidades contaminadas son motivo para revalidaci\u00f3n. Para lotes de m\u00e1s de 10,000 unidades, una unidad contaminada tambi\u00e9n requiere investigaci\u00f3n, y dos unidades contaminadas son causa para revalidaci\u00f3n.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que la validaci\u00f3n de procesos no comprometa la producci\u00f3n?**\n   - Respuesta: Se debe tener cuidado para asegurar que cualquier validaci\u00f3n no comprometa los procesos, lo que implica realizar pruebas y simulaciones que reflejen tanto las condiciones normales de producci\u00f3n como las situaciones de peor caso, y mantener un control riguroso sobre las actividades en \u00e1reas limpias.\n\n3. **\u00bfQu\u00e9 tipo de monitoreo se recomienda para las fuentes de agua y el equipo de tratamiento de agua en el contexto de la producci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Se recomienda monitorear regularmente las fuentes de agua, el equipo de tratamiento de agua y el agua tratada para detectar contaminantes qu\u00edmicos, biol\u00f3gicos y endotoxinas, asegurando que el agua cumpla con las especificaciones adecuadas para su uso. Adem\u00e1s, se deben mantener registros de los resultados del monitoreo y de cualquier acci\u00f3n tomada.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Entorno de Asepsia**:\n   - **Grado A y Grado B**: La preparaci\u00f3n y manejo de productos no est\u00e9riles debe realizarse en un entorno de grado A con un fondo de grado B. Esto incluye la manipulaci\u00f3n de productos preparados asepticamente y equipos est\u00e9riles expuestos.\n\n2. **Manejo de Productos Asepticos**:\n   - La transferencia de contenedores parcialmente cerrados y la preparaci\u00f3n de productos est\u00e9riles (como ung\u00fcentos, cremas, suspensiones y emulsiones) tambi\u00e9n deben realizarse en un entorno de grado A con un fondo de grado B.\n\n3. **Minimizaci\u00f3n de Contaminaci\u00f3n**:\n   - Se deben tomar precauciones para minimizar la contaminaci\u00f3n en todas las etapas de procesamiento, especialmente antes de la esterilizaci\u00f3n.\n\n4. **Instalaciones Multiproducto**:\n   - Generalmente, no se deben hacer preparaciones que contengan microorganismos vivos en \u00e1reas utilizadas para otros productos farmac\u00e9uticos. Sin embargo, se permite su uso si se valida la contenci\u00f3n y desinfecci\u00f3n de los microorganismos vivos.\n\n5. **Validaci\u00f3n de Procesos Asepticos**:\n   - La validaci\u00f3n debe incluir pruebas de simulaci\u00f3n de procesos utilizando un medio nutritivo, el cual debe ser seleccionado seg\u00fan la forma de dosificaci\u00f3n del producto y su adecuaci\u00f3n para la esterilizaci\u00f3n.\n\n6. **Pruebas de Simulaci\u00f3n de Procesos**:\n   - Se requieren tres pruebas de simulaci\u00f3n satisfactorias consecutivas para validar el procesamiento as\u00e9ptico, y estas deben repetirse a intervalos definidos y tras modificaciones significativas en el proceso.\n\n### Entidades Clave:\n- **Grado A y Grado B**: Clasificaciones de ambientes para la manipulaci\u00f3n de productos est\u00e9riles.\n- **Microorganismos Vivos**: Organismos que deben ser manejados con precauciones especiales en la producci\u00f3n farmac\u00e9utica.\n- **Medio Nutritivo**: Sustancia utilizada en pruebas de simulaci\u00f3n para validar procesos as\u00e9pticos.\n- **Pruebas de Simulaci\u00f3n**: M\u00e9todos para validar la efectividad del procesamiento as\u00e9ptico. \n\nEste resumen destaca la importancia de mantener condiciones controladas y validar procesos en la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles para garantizar su seguridad y eficacia.", "excerpt_keywords": "Keywords: validation, contamination, aseptic, media fills, monitoring"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "da2e2215-2a96-4122-84cf-131a3f88baaf", "node_type": "4", "metadata": {"page_label": "234", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the heating, ventilation and air-conditioning (HVAC)-system, equipment or process. Process simulation tests should incorporate activities and interventions known to occur during normal production as well as the worst-case situation. The process simulation tests should be representative of each shift and shift changeover to address any time-related and operational features.\n\n4.26 The number of containers used for media fills should be sufficient to enable a valid evaluation. For small batches the number of containers for media fills should at least equal the size of the product batch. The target should be zero growth and the following should apply:\n\n- when filling fewer than 5000 units, no contaminated units should be detected;\n- when filling 5000\u201310 000 units:\n  - one contaminated unit should result in an investigation, including consideration of a repeat media fill,\n  - two contaminated units are considered cause for revalidation following investigation;\n- when filling more than 10 000 units:\n  - one contaminated unit should result in an investigation,\n  - two contaminated units are considered cause for revalidation following investigation.\n\n4.27 For any run size, intermittent incidents of microbial contamination may be indicative of low-level contamination that should be investigated. Investigation of gross failures should include the potential impact on the sterility assurance of batches manufactured since the last successful media fill.\n\n4.28 Care should be taken to ensure that any validation does not compromise the processes.\n\n4.29 Water sources, water-treatment equipment and treated water should be monitored regularly for chemicals, biological contamination and contamination with endotoxins to ensure that the water complies with the specifications appropriate to its use. Records should be maintained of the results of the monitoring and of any action taken (10).\n\n4.30 Activities in clean areas, especially when aseptic operations are in progress, should be kept to a minimum and the movement of personnel should be controlled and methodical, so as to avoid excessive shedding of particles and organisms due to over-vigorous activity. As far as possible, personnel should be excluded from grade A zones. The ambient temperature and humidity should not be uncomfortably high because of the nature of the garments worn and to reduce the risk of contamination liberated from the personnel.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "1e7573f96c1bbd85ee25fc5b4c05ef5876eca428a1ee761b2f107eeaf107196a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "the heating, ventilation and air-conditioning (HVAC)-system, equipment or process. Process simulation tests should incorporate activities and interventions known to occur during normal production as well as the worst-case situation. The process simulation tests should be representative of each shift and shift changeover to address any time-related and operational features.\n\n4.26 The number of containers used for media fills should be sufficient to enable a valid evaluation. For small batches the number of containers for media fills should at least equal the size of the product batch. The target should be zero growth and the following should apply:\n\n- when filling fewer than 5000 units, no contaminated units should be detected;\n- when filling 5000\u201310 000 units:\n  - one contaminated unit should result in an investigation, including consideration of a repeat media fill,\n  - two contaminated units are considered cause for revalidation following investigation;\n- when filling more than 10 000 units:\n  - one contaminated unit should result in an investigation,\n  - two contaminated units are considered cause for revalidation following investigation.\n\n4.27 For any run size, intermittent incidents of microbial contamination may be indicative of low-level contamination that should be investigated. Investigation of gross failures should include the potential impact on the sterility assurance of batches manufactured since the last successful media fill.\n\n4.28 Care should be taken to ensure that any validation does not compromise the processes.\n\n4.29 Water sources, water-treatment equipment and treated water should be monitored regularly for chemicals, biological contamination and contamination with endotoxins to ensure that the water complies with the specifications appropriate to its use. Records should be maintained of the results of the monitoring and of any action taken (10).\n\n4.30 Activities in clean areas, especially when aseptic operations are in progress, should be kept to a minimum and the movement of personnel should be controlled and methodical, so as to avoid excessive shedding of particles and organisms due to over-vigorous activity. As far as possible, personnel should be excluded from grade A zones. The ambient temperature and humidity should not be uncomfortably high because of the nature of the garments worn and to reduce the risk of contamination liberated from the personnel.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2423, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "98efa0eb-df2b-4fb7-b7ec-4b10d3ab866d": {"__data__": {"id_": "98efa0eb-df2b-4fb7-b7ec-4b10d3ab866d", "embedding": null, "metadata": {"page_label": "235", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.31\nThe presence of containers and materials liable to generate fibres should be minimized in clean areas and avoided completely when aseptic work is in progress.\n\n# 4.32\nComponents, bulk-product containers and equipment should be handled after the final cleaning process in such a way as to ensure that they are not recontaminated. The stage of processing of components as well as the bulk-product containers and equipment should be properly identified.\n\n# 4.33\nThe interval between the washing and drying and the sterilization of components, bulk-product containers and equipment, as well as between sterilization and use, should be as short as possible and subject to a time-limit appropriate to the validated storage conditions.\n\n# 4.34\nThe time between the start of the preparation of a solution and its sterilization or filtration through a bacteria-retaining filter should be as short as possible. A maximum permissible time should be set for each product that takes into account its composition and the prescribed method of storage.\n\n# 4.35\nAny gas that is used to purge a solution or blanket a product should be passed through a sterilizing filter.\n\n# 4.36\nThe bioburden should be monitored before sterilization. There should be working limits on contamination immediately before sterilization, which are related to the efficiency of the method to be used. Bioburden assay should be performed on each batch for both aseptically filled products and terminally sterilized products. Where overkill sterilization parameters are set for terminally sterilized products, bioburden might be monitored only at suitable scheduled intervals. For parametric release systems, bioburden assay should be performed on each batch and considered as an in-process test. Where appropriate, the level of endotoxins should be monitored. All solutions, in particular large-volume infusion fluids, should be passed through a microorganism-retaining filter, if possible sited immediately before filling.\n\n# 4.37\nComponents, bulk-product containers, equipment, and any other articles required in a clean area where aseptic work is in progress, should be sterilized and wherever possible passed into the area through double-ended sterilizers sealed into the wall. Other procedures that prevent the introduction of contamination may be acceptable in some circumstances.\n\n# 4.38\nThe efficacy of any new processing procedure should be validated and the validation should be repeated at regular intervals thereafter or when any significant change is made in the process or equipment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Informe T\u00e9cnico 957) aborda las pr\u00e1cticas y procedimientos necesarios para mantener la asepsia en \u00e1reas limpias durante la manipulaci\u00f3n de componentes y productos. Se enfatiza la importancia de minimizar la contaminaci\u00f3n, controlar la bioburden antes de la esterilizaci\u00f3n, y asegurar que todos los procesos de limpieza y esterilizaci\u00f3n se realicen en el menor tiempo posible. Tambi\u00e9n se menciona la necesidad de validar los procedimientos de procesamiento y monitorear los niveles de endotoxinas.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las medidas espec\u00edficas que se deben tomar para evitar la recontaminaci\u00f3n de componentes y equipos despu\u00e9s de su limpieza final?**\n   - Esta pregunta se centra en las pr\u00e1cticas recomendadas para manejar componentes y equipos en un entorno limpio, lo cual no se detalla en otras secciones del documento.\n\n2. **\u00bfQu\u00e9 criterios se deben considerar al establecer un tiempo m\u00e1ximo permisible entre la preparaci\u00f3n de una soluci\u00f3n y su esterilizaci\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n sobre c\u00f3mo se determina el tiempo m\u00e1ximo permisible para la preparaci\u00f3n y esterilizaci\u00f3n de soluciones, un aspecto cr\u00edtico que puede no estar ampliamente discutido en otras fuentes.\n\n3. **\u00bfQu\u00e9 procedimientos alternativos pueden ser aceptables para prevenir la introducci\u00f3n de contaminaci\u00f3n en \u00e1reas limpias, adem\u00e1s del uso de esterilizadores de doble extremo?**\n   - Esta pregunta explora las opciones disponibles para mantener la asepsia en \u00e1reas limpias, lo que puede no estar claramente especificado en otros documentos o gu\u00edas. \n\nEstas preguntas est\u00e1n dise\u00f1adas para profundizar en aspectos espec\u00edficos del manejo de asepsia y esterilizaci\u00f3n que son cruciales para la seguridad y eficacia en entornos de producci\u00f3n farmac\u00e9utica y m\u00e9dica.", "prev_section_summary": "### Temas Clave\n\n1. **Validaci\u00f3n de Procesos**: Se enfatiza la importancia de realizar pruebas de simulaci\u00f3n de procesos que reflejen tanto las condiciones normales de producci\u00f3n como las situaciones de peor caso. Estas pruebas deben ser representativas de cada turno y los cambios de turno.\n\n2. **Contaminaci\u00f3n Microbiana en Llenados de Medios**: Se establecen criterios espec\u00edficos para la aceptaci\u00f3n de unidades contaminadas durante los llenados de medios, dependiendo del tama\u00f1o del lote. Se busca un objetivo de cero crecimiento microbiano.\n\n3. **Monitoreo de Fuentes de Agua**: Se recomienda un monitoreo regular de las fuentes de agua, el equipo de tratamiento y el agua tratada para detectar contaminantes qu\u00edmicos, biol\u00f3gicos y endotoxinas, asegurando que cumplan con las especificaciones adecuadas.\n\n4. **Control de Actividades en \u00c1reas Limpias**: Se sugiere minimizar las actividades en \u00e1reas limpias durante operaciones as\u00e9pticas y controlar el movimiento del personal para reducir la contaminaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad del documento.\n- **HVAC**: Sistema de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado mencionado en el contexto de la producci\u00f3n.\n- **Contaminaci\u00f3n Microbiana**: Problema a investigar durante los procesos de llenado.\n- **Llenados de Medios**: Proceso cr\u00edtico en la producci\u00f3n farmac\u00e9utica.\n- **Agua y Equipos de Tratamiento**: Elementos que deben ser monitoreados para asegurar la calidad del agua utilizada en la producci\u00f3n.\n- **\u00c1reas Limpias**: Espacios donde se llevan a cabo operaciones as\u00e9pticas que requieren control riguroso de actividades.", "excerpt_keywords": "Keywords: aseptic processing, sterilization, bioburden monitoring, clean areas, validation procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "13d9db7e-1432-40d7-a7e6-d2bea8551398", "node_type": "4", "metadata": {"page_label": "235", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.31\nThe presence of containers and materials liable to generate fibres should be minimized in clean areas and avoided completely when aseptic work is in progress.\n\n# 4.32\nComponents, bulk-product containers and equipment should be handled after the final cleaning process in such a way as to ensure that they are not recontaminated. The stage of processing of components as well as the bulk-product containers and equipment should be properly identified.\n\n# 4.33\nThe interval between the washing and drying and the sterilization of components, bulk-product containers and equipment, as well as between sterilization and use, should be as short as possible and subject to a time-limit appropriate to the validated storage conditions.\n\n# 4.34\nThe time between the start of the preparation of a solution and its sterilization or filtration through a bacteria-retaining filter should be as short as possible. A maximum permissible time should be set for each product that takes into account its composition and the prescribed method of storage.\n\n# 4.35\nAny gas that is used to purge a solution or blanket a product should be passed through a sterilizing filter.\n\n# 4.36\nThe bioburden should be monitored before sterilization. There should be working limits on contamination immediately before sterilization, which are related to the efficiency of the method to be used. Bioburden assay should be performed on each batch for both aseptically filled products and terminally sterilized products. Where overkill sterilization parameters are set for terminally sterilized products, bioburden might be monitored only at suitable scheduled intervals. For parametric release systems, bioburden assay should be performed on each batch and considered as an in-process test. Where appropriate, the level of endotoxins should be monitored. All solutions, in particular large-volume infusion fluids, should be passed through a microorganism-retaining filter, if possible sited immediately before filling.\n\n# 4.37\nComponents, bulk-product containers, equipment, and any other articles required in a clean area where aseptic work is in progress, should be sterilized and wherever possible passed into the area through double-ended sterilizers sealed into the wall. Other procedures that prevent the introduction of contamination may be acceptable in some circumstances.\n\n# 4.38\nThe efficacy of any new processing procedure should be validated and the validation should be repeated at regular intervals thereafter or when any significant change is made in the process or equipment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "5e5ea4a307464dbb374879fef52acc45a1126a93f6d4e640e2435ae825c85981", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.31\nThe presence of containers and materials liable to generate fibres should be minimized in clean areas and avoided completely when aseptic work is in progress.\n\n# 4.32\nComponents, bulk-product containers and equipment should be handled after the final cleaning process in such a way as to ensure that they are not recontaminated. The stage of processing of components as well as the bulk-product containers and equipment should be properly identified.\n\n# 4.33\nThe interval between the washing and drying and the sterilization of components, bulk-product containers and equipment, as well as between sterilization and use, should be as short as possible and subject to a time-limit appropriate to the validated storage conditions.\n\n# 4.34\nThe time between the start of the preparation of a solution and its sterilization or filtration through a bacteria-retaining filter should be as short as possible. A maximum permissible time should be set for each product that takes into account its composition and the prescribed method of storage.\n\n# 4.35\nAny gas that is used to purge a solution or blanket a product should be passed through a sterilizing filter.\n\n# 4.36\nThe bioburden should be monitored before sterilization. There should be working limits on contamination immediately before sterilization, which are related to the efficiency of the method to be used. Bioburden assay should be performed on each batch for both aseptically filled products and terminally sterilized products. Where overkill sterilization parameters are set for terminally sterilized products, bioburden might be monitored only at suitable scheduled intervals. For parametric release systems, bioburden assay should be performed on each batch and considered as an in-process test. Where appropriate, the level of endotoxins should be monitored. All solutions, in particular large-volume infusion fluids, should be passed through a microorganism-retaining filter, if possible sited immediately before filling.\n\n# 4.37\nComponents, bulk-product containers, equipment, and any other articles required in a clean area where aseptic work is in progress, should be sterilized and wherever possible passed into the area through double-ended sterilizers sealed into the wall. Other procedures that prevent the introduction of contamination may be acceptable in some circumstances.\n\n# 4.38\nThe efficacy of any new processing procedure should be validated and the validation should be repeated at regular intervals thereafter or when any significant change is made in the process or equipment.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2564, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "aa609065-3541-4da2-9599-e41eb1c9ca21": {"__data__": {"id_": "aa609065-3541-4da2-9599-e41eb1c9ca21", "embedding": null, "metadata": {"page_label": "236", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Sterilization\n\n5.1 Whenever possible products intended to be sterile should be terminally sterilized by heat in their final container. Where it is not possible to carry out terminal sterilization by heating due to the instability of a formulation or incompatibility of a pack type (necessary to the administration of the product, e.g. plastic eye-dropper bottles), a decision should be taken to use an alternative method of terminal sterilization following filtration and/or aseptic processing.\n\n5.2 Sterilization can be achieved by the use of moist or dry heat, by irradiation with ionizing radiation (noting that ultraviolet irradiation is not normally an acceptable method of sterilization), by ethylene oxide (or other suitable gaseous sterilizing agents), or by filtration with subsequent aseptic filling of sterile final containers. Each method has its advantages and disadvantages. Where possible and practicable, heat sterilization is the method of choice. In any case the sterilization process must be in accordance with the marketing and manufacturing authorizations.\n\n5.3 The microbial contamination of starting materials should be minimal and their bioburden should be monitored before sterilization. Specifications should include requirements for microbiological quality when the need for this has been indicated by monitoring.\n\n5.4 All sterilization processes should be validated. Particular attention should be paid when the adopted sterilization method is not in accordance with pharmacopoeial standards or other national standards, or when it is used for a preparation that is not a simple aqueous or oily solution, for example, colloidal suspensions.\n\n5.5 Before any sterilization process is adopted, its suitability for the product and its efficacy in achieving the desired sterilizing conditions in all parts of each type of load to be processed should be demonstrated by physical measurements and by biological indicators, where appropriate. The validity of the process should be verified at scheduled intervals, at least annually, and whenever significant modifications have been made to the equipment. Records should be kept of the results.\n\n5.6 For effective sterilization the whole of the material should be subjected to the required treatment and the process should be designed to ensure that this is achieved.\n\n5.7 Biological indicators should be considered only as an additional method of monitoring the sterilization process. They should be stored and used according to the manufacturer\u2019s instructions, and their quality checked by positive controls. If they are used, strict precautions should be taken to avoid any transfer of microbial contamination from them.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las pr\u00e1cticas de esterilizaci\u00f3n de productos destinados a ser est\u00e9riles. Se enfatiza la importancia de la esterilizaci\u00f3n terminal por calor en el envase final, aunque se reconocen alternativas cuando esto no es posible. Se describen diferentes m\u00e9todos de esterilizaci\u00f3n, como el calor h\u00famedo o seco, la irradiaci\u00f3n, el \u00f3xido de etileno y la filtraci\u00f3n, cada uno con sus ventajas y desventajas. Adem\u00e1s, se subraya la necesidad de validar todos los procesos de esterilizaci\u00f3n y de monitorear la contaminaci\u00f3n microbiana de los materiales de partida.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones que justifican el uso de m\u00e9todos alternativos de esterilizaci\u00f3n en lugar de la esterilizaci\u00f3n terminal por calor?**\n   - Respuesta: Se deben considerar m\u00e9todos alternativos cuando la formulaci\u00f3n es inestable o cuando hay incompatibilidad con el tipo de envase necesario para la administraci\u00f3n del producto, como en el caso de botellas de pl\u00e1stico para gotas oculares.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse para validar un proceso de esterilizaci\u00f3n que no cumple con los est\u00e1ndares farmacopoeiales?**\n   - Respuesta: Se debe prestar especial atenci\u00f3n a la validaci\u00f3n del proceso, demostrando su idoneidad para el producto y su eficacia en alcanzar las condiciones de esterilizaci\u00f3n deseadas en todas las partes de cada tipo de carga procesada. Esto debe incluir mediciones f\u00edsicas y, cuando sea apropiado, indicadores biol\u00f3gicos.\n\n3. **\u00bfQu\u00e9 papel juegan los indicadores biol\u00f3gicos en el monitoreo del proceso de esterilizaci\u00f3n y cu\u00e1les son las precauciones necesarias al usarlos?**\n   - Respuesta: Los indicadores biol\u00f3gicos deben considerarse como un m\u00e9todo adicional de monitoreo del proceso de esterilizaci\u00f3n. Deben ser almacenados y utilizados de acuerdo con las instrucciones del fabricante, y su calidad debe ser verificada mediante controles positivos. Es crucial tomar estrictas precauciones para evitar la transferencia de contaminaci\u00f3n microbiana desde ellos.", "prev_section_summary": "### Temas Clave:\n1. **Minimizaci\u00f3n de Contaminaci\u00f3n**: Se enfatiza la importancia de reducir la presencia de materiales que puedan generar fibras en \u00e1reas limpias, especialmente durante trabajos as\u00e9pticos.\n  \n2. **Manejo de Componentes y Equipos**: Se deben seguir pr\u00e1cticas espec\u00edficas para manejar componentes y equipos despu\u00e9s de su limpieza final, asegurando que no se recontaminen.\n\n3. **Intervalos de Tiempo Cr\u00edticos**: Se establece que el tiempo entre la limpieza, secado, esterilizaci\u00f3n y uso de componentes debe ser lo m\u00e1s corto posible, y se deben definir l\u00edmites de tiempo apropiados seg\u00fan las condiciones de almacenamiento validadas.\n\n4. **Preparaci\u00f3n y Esterilizaci\u00f3n de Soluciones**: Se debe minimizar el tiempo entre la preparaci\u00f3n de soluciones y su esterilizaci\u00f3n o filtraci\u00f3n, estableciendo un tiempo m\u00e1ximo permisible basado en la composici\u00f3n del producto.\n\n5. **Monitoreo de Bioburden**: Es crucial monitorear la bioburden antes de la esterilizaci\u00f3n, con l\u00edmites de contaminaci\u00f3n establecidos y ensayos realizados en cada lote.\n\n6. **Esterilizaci\u00f3n de Art\u00edculos**: Todos los componentes y art\u00edculos necesarios en \u00e1reas limpias deben ser esterilizados y, de ser posible, introducidos a trav\u00e9s de esterilizadores de doble extremo.\n\n7. **Validaci\u00f3n de Procedimientos**: La eficacia de nuevos procedimientos de procesamiento debe ser validada y revisada peri\u00f3dicamente, especialmente tras cambios significativos en el proceso o equipo.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Bioburden**: Concepto relacionado con la carga microbiana que debe ser monitoreada.\n- **Esterilizadores de Doble Extremo**: Equipos recomendados para la introducci\u00f3n de art\u00edculos en \u00e1reas limpias.\n- **Filtros de Retenci\u00f3n de Microorganismos**: Dispositivos utilizados para asegurar la esterilidad de soluciones.\n- **Productos Asepticamente Llenados y Esterilizados Terminalmente**: Tipos de productos que requieren monitoreo de bioburden.\n\nEste resumen proporciona una visi\u00f3n general de las pr\u00e1cticas recomendadas para mantener la asepsia y la seguridad en entornos de producci\u00f3n farmac\u00e9utica y m\u00e9dica, destacando la importancia de la validaci\u00f3n y el monitoreo continuo.", "excerpt_keywords": "Sterilization, Aseptic processing, Microbial contamination, Validation, Biological indicators"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c14b61b0-2b21-4b7e-93c6-53d49185d8aa", "node_type": "4", "metadata": {"page_label": "236", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Sterilization\n\n5.1 Whenever possible products intended to be sterile should be terminally sterilized by heat in their final container. Where it is not possible to carry out terminal sterilization by heating due to the instability of a formulation or incompatibility of a pack type (necessary to the administration of the product, e.g. plastic eye-dropper bottles), a decision should be taken to use an alternative method of terminal sterilization following filtration and/or aseptic processing.\n\n5.2 Sterilization can be achieved by the use of moist or dry heat, by irradiation with ionizing radiation (noting that ultraviolet irradiation is not normally an acceptable method of sterilization), by ethylene oxide (or other suitable gaseous sterilizing agents), or by filtration with subsequent aseptic filling of sterile final containers. Each method has its advantages and disadvantages. Where possible and practicable, heat sterilization is the method of choice. In any case the sterilization process must be in accordance with the marketing and manufacturing authorizations.\n\n5.3 The microbial contamination of starting materials should be minimal and their bioburden should be monitored before sterilization. Specifications should include requirements for microbiological quality when the need for this has been indicated by monitoring.\n\n5.4 All sterilization processes should be validated. Particular attention should be paid when the adopted sterilization method is not in accordance with pharmacopoeial standards or other national standards, or when it is used for a preparation that is not a simple aqueous or oily solution, for example, colloidal suspensions.\n\n5.5 Before any sterilization process is adopted, its suitability for the product and its efficacy in achieving the desired sterilizing conditions in all parts of each type of load to be processed should be demonstrated by physical measurements and by biological indicators, where appropriate. The validity of the process should be verified at scheduled intervals, at least annually, and whenever significant modifications have been made to the equipment. Records should be kept of the results.\n\n5.6 For effective sterilization the whole of the material should be subjected to the required treatment and the process should be designed to ensure that this is achieved.\n\n5.7 Biological indicators should be considered only as an additional method of monitoring the sterilization process. They should be stored and used according to the manufacturer\u2019s instructions, and their quality checked by positive controls. If they are used, strict precautions should be taken to avoid any transfer of microbial contamination from them.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "78a0afa6d43e7beea76426260a06b74cc2dfa99d51d0c1dd3fbfa4d816284cb4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Sterilization\n\n5.1 Whenever possible products intended to be sterile should be terminally sterilized by heat in their final container. Where it is not possible to carry out terminal sterilization by heating due to the instability of a formulation or incompatibility of a pack type (necessary to the administration of the product, e.g. plastic eye-dropper bottles), a decision should be taken to use an alternative method of terminal sterilization following filtration and/or aseptic processing.\n\n5.2 Sterilization can be achieved by the use of moist or dry heat, by irradiation with ionizing radiation (noting that ultraviolet irradiation is not normally an acceptable method of sterilization), by ethylene oxide (or other suitable gaseous sterilizing agents), or by filtration with subsequent aseptic filling of sterile final containers. Each method has its advantages and disadvantages. Where possible and practicable, heat sterilization is the method of choice. In any case the sterilization process must be in accordance with the marketing and manufacturing authorizations.\n\n5.3 The microbial contamination of starting materials should be minimal and their bioburden should be monitored before sterilization. Specifications should include requirements for microbiological quality when the need for this has been indicated by monitoring.\n\n5.4 All sterilization processes should be validated. Particular attention should be paid when the adopted sterilization method is not in accordance with pharmacopoeial standards or other national standards, or when it is used for a preparation that is not a simple aqueous or oily solution, for example, colloidal suspensions.\n\n5.5 Before any sterilization process is adopted, its suitability for the product and its efficacy in achieving the desired sterilizing conditions in all parts of each type of load to be processed should be demonstrated by physical measurements and by biological indicators, where appropriate. The validity of the process should be verified at scheduled intervals, at least annually, and whenever significant modifications have been made to the equipment. Records should be kept of the results.\n\n5.6 For effective sterilization the whole of the material should be subjected to the required treatment and the process should be designed to ensure that this is achieved.\n\n5.7 Biological indicators should be considered only as an additional method of monitoring the sterilization process. They should be stored and used according to the manufacturer\u2019s instructions, and their quality checked by positive controls. If they are used, strict precautions should be taken to avoid any transfer of microbial contamination from them.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2694, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "68baa6bc-9c86-4d3f-afcb-c03416b6ffa1": {"__data__": {"id_": "68baa6bc-9c86-4d3f-afcb-c03416b6ffa1", "embedding": null, "metadata": {"page_label": "237", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 5.8  \nThere should be a clear means of differentiating products that have not been sterilized from those which have. Each basket, tray, or other carrier of products or components should be clearly labelled with the name of the material, its batch number and an indication of whether or not it has been sterilized. Indicators such as autoclave tape may be used where appropriate to indicate whether or not a batch (or sub-batch) has passed through a sterilization process, but they do not give a reliable indication that the batch is in fact sterile.\n\n5.9  \nValidated loading patterns should be established for all sterilization processes.\n\n5.10  \nSterilization records should be available for each sterilization run. They should be approved as part of the batch-release procedure.\n\n# 6. Terminal sterilization\n\n## Sterilization by heat\n\n6.1  \nEach heat-sterilization cycle should be recorded by means of appropriate equipment of suitable accuracy and precision, e.g. on a time/temperature chart with a suitably large scale. The temperature should be recorded by a probe situated at the coolest part of the load or loaded chamber, this point having been determined during the validation; the temperature should preferably be checked against a second independent temperature probe located at the same position. Sterilization records should be available for each sterilization run and should be approved as part of the batch release procedure. Chemical or biological indicators may also be used but should not take the place of physical controls.\n\n6.2  \nSufficient time should be allowed for the whole of the load to reach the required temperature before measurement of the sterilizing time is started. This time should be determined for each type of load to be processed.\n\n6.3  \nAfter the high-temperature phase of a heat sterilization cycle, precautions should be taken against contamination of a sterilized load during cooling. Any cooling fluid or gas in contact with the product should be sterilized.\n\n## Sterilization by moist heat\n\n6.4  \nBoth temperature and pressure should be used to monitor the process. Control instrumentation should normally be independent of monitoring instrumentation and recording charts. Where automated control and monitoring systems are used for these applications they should be validated to ensure that critical process requirements are met. System and cycle faults should be registered by the system and observed by the operator.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Diferenciaci\u00f3n de productos esterilizados y no esterilizados**: Es fundamental que los productos y componentes sean claramente etiquetados para distinguir entre aquellos que han sido esterilizados y los que no. Esto incluye informaci\u00f3n sobre el material, el n\u00famero de lote y el estado de esterilizaci\u00f3n.\n\n2. **Registros y validaci\u00f3n de procesos de esterilizaci\u00f3n**: Se requiere que existan patrones de carga validados y registros de esterilizaci\u00f3n para cada ciclo, los cuales deben ser aprobados como parte del procedimiento de liberaci\u00f3n de lotes. Esto asegura la trazabilidad y la conformidad con los est\u00e1ndares de esterilizaci\u00f3n.\n\n3. **Monitoreo de procesos de esterilizaci\u00f3n**: Tanto la esterilizaci\u00f3n por calor como por calor h\u00famedo requieren un monitoreo riguroso de temperatura y presi\u00f3n. Los sistemas de control deben ser validados y los fallos del sistema deben ser registrados y observados por el operador.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la etiqueta de los productos o componentes que han sido esterilizados?**\n   - La etiqueta debe incluir el nombre del material, el n\u00famero de lote y una indicaci\u00f3n de si ha sido esterilizado o no.\n\n2. **\u00bfCu\u00e1l es la importancia de registrar la temperatura en el ciclo de esterilizaci\u00f3n por calor?**\n   - La temperatura debe ser registrada en el punto m\u00e1s fr\u00edo de la carga para asegurar que todo el contenido haya alcanzado la temperatura requerida para la esterilizaci\u00f3n, lo que es crucial para garantizar la efectividad del proceso.\n\n3. **\u00bfQu\u00e9 precauciones deben tomarse despu\u00e9s de la fase de alta temperatura en un ciclo de esterilizaci\u00f3n por calor?**\n   - Se deben tomar precauciones para evitar la contaminaci\u00f3n de la carga esterilizada durante el enfriamiento, asegurando que cualquier fluido o gas de enfriamiento en contacto con el producto tambi\u00e9n est\u00e9 esterilizado.", "prev_section_summary": "### Temas Clave\n\n1. **Esterilizaci\u00f3n Terminal**: Se enfatiza que los productos destinados a ser est\u00e9riles deben ser esterilizados terminalmente por calor en su envase final siempre que sea posible.\n\n2. **M\u00e9todos de Esterilizaci\u00f3n**: Se describen varios m\u00e9todos de esterilizaci\u00f3n, incluyendo:\n   - Calor h\u00famedo o seco\n   - Irradiaci\u00f3n con radiaci\u00f3n ionizante\n   - \u00d3xido de etileno y otros agentes gaseosos\n   - Filtraci\u00f3n con llenado as\u00e9ptico de envases finales est\u00e9riles\n\n3. **Contaminaci\u00f3n Microbiana**: Se debe monitorear la contaminaci\u00f3n microbiana de los materiales de partida y asegurar que su bioburden sea m\u00ednimo antes de la esterilizaci\u00f3n.\n\n4. **Validaci\u00f3n de Procesos**: Todos los procesos de esterilizaci\u00f3n deben ser validados, especialmente si no cumplen con los est\u00e1ndares farmacopoeiales o se utilizan para preparaciones complejas.\n\n5. **Indicadores Biol\u00f3gicos**: Se consideran como un m\u00e9todo adicional para monitorear el proceso de esterilizaci\u00f3n, con la necesidad de seguir las instrucciones del fabricante y tomar precauciones para evitar contaminaci\u00f3n.\n\n6. **Documentaci\u00f3n y Registros**: Es importante mantener registros de los resultados de la validaci\u00f3n y monitoreo de los procesos de esterilizaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices sobre esterilizaci\u00f3n.\n- **M\u00e9todos de Esterilizaci\u00f3n**: Calor h\u00famedo, calor seco, irradiaci\u00f3n, \u00f3xido de etileno, filtraci\u00f3n.\n- **Contaminaci\u00f3n Microbiana**: Concepto relacionado con la calidad microbiol\u00f3gica de los materiales.\n- **Est\u00e1ndares Farmacopoeiales**: Normativas que regulan los m\u00e9todos de esterilizaci\u00f3n.\n- **Indicadores Biol\u00f3gicos**: Herramientas utilizadas para verificar la eficacia del proceso de esterilizaci\u00f3n.\n\nEste resumen abarca los aspectos fundamentales de la secci\u00f3n sobre esterilizaci\u00f3n, destacando la importancia de los m\u00e9todos, la validaci\u00f3n y el monitoreo en la producci\u00f3n de productos est\u00e9riles.", "excerpt_keywords": "Keywords: sterilization, heat, monitoring, validation, contamination"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "379d13a7-8c90-439d-a040-e8dcd610af0f", "node_type": "4", "metadata": {"page_label": "237", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 5.8  \nThere should be a clear means of differentiating products that have not been sterilized from those which have. Each basket, tray, or other carrier of products or components should be clearly labelled with the name of the material, its batch number and an indication of whether or not it has been sterilized. Indicators such as autoclave tape may be used where appropriate to indicate whether or not a batch (or sub-batch) has passed through a sterilization process, but they do not give a reliable indication that the batch is in fact sterile.\n\n5.9  \nValidated loading patterns should be established for all sterilization processes.\n\n5.10  \nSterilization records should be available for each sterilization run. They should be approved as part of the batch-release procedure.\n\n# 6. Terminal sterilization\n\n## Sterilization by heat\n\n6.1  \nEach heat-sterilization cycle should be recorded by means of appropriate equipment of suitable accuracy and precision, e.g. on a time/temperature chart with a suitably large scale. The temperature should be recorded by a probe situated at the coolest part of the load or loaded chamber, this point having been determined during the validation; the temperature should preferably be checked against a second independent temperature probe located at the same position. Sterilization records should be available for each sterilization run and should be approved as part of the batch release procedure. Chemical or biological indicators may also be used but should not take the place of physical controls.\n\n6.2  \nSufficient time should be allowed for the whole of the load to reach the required temperature before measurement of the sterilizing time is started. This time should be determined for each type of load to be processed.\n\n6.3  \nAfter the high-temperature phase of a heat sterilization cycle, precautions should be taken against contamination of a sterilized load during cooling. Any cooling fluid or gas in contact with the product should be sterilized.\n\n## Sterilization by moist heat\n\n6.4  \nBoth temperature and pressure should be used to monitor the process. Control instrumentation should normally be independent of monitoring instrumentation and recording charts. Where automated control and monitoring systems are used for these applications they should be validated to ensure that critical process requirements are met. System and cycle faults should be registered by the system and observed by the operator.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "165fdc86897d412f4a02363dec6f27341d2d51e12d535a117d933244f7fb9dfb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 5.8  \nThere should be a clear means of differentiating products that have not been sterilized from those which have. Each basket, tray, or other carrier of products or components should be clearly labelled with the name of the material, its batch number and an indication of whether or not it has been sterilized. Indicators such as autoclave tape may be used where appropriate to indicate whether or not a batch (or sub-batch) has passed through a sterilization process, but they do not give a reliable indication that the batch is in fact sterile.\n\n5.9  \nValidated loading patterns should be established for all sterilization processes.\n\n5.10  \nSterilization records should be available for each sterilization run. They should be approved as part of the batch-release procedure.\n\n# 6. Terminal sterilization\n\n## Sterilization by heat\n\n6.1  \nEach heat-sterilization cycle should be recorded by means of appropriate equipment of suitable accuracy and precision, e.g. on a time/temperature chart with a suitably large scale. The temperature should be recorded by a probe situated at the coolest part of the load or loaded chamber, this point having been determined during the validation; the temperature should preferably be checked against a second independent temperature probe located at the same position. Sterilization records should be available for each sterilization run and should be approved as part of the batch release procedure. Chemical or biological indicators may also be used but should not take the place of physical controls.\n\n6.2  \nSufficient time should be allowed for the whole of the load to reach the required temperature before measurement of the sterilizing time is started. This time should be determined for each type of load to be processed.\n\n6.3  \nAfter the high-temperature phase of a heat sterilization cycle, precautions should be taken against contamination of a sterilized load during cooling. Any cooling fluid or gas in contact with the product should be sterilized.\n\n## Sterilization by moist heat\n\n6.4  \nBoth temperature and pressure should be used to monitor the process. Control instrumentation should normally be independent of monitoring instrumentation and recording charts. Where automated control and monitoring systems are used for these applications they should be validated to ensure that critical process requirements are met. System and cycle faults should be registered by the system and observed by the operator.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2466, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "36a59a01-03c8-47e0-8a69-1947d800e32c": {"__data__": {"id_": "36a59a01-03c8-47e0-8a69-1947d800e32c", "embedding": null, "metadata": {"page_label": "238", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The reading of the independent temperature indicator should be routinely checked against the reading on the chart recorder during the sterilization period. For sterilizers fitted with a drain at the bottom of the chamber, it may also be necessary to record the temperature at this position throughout the sterilization period. There should be regular leak tests on the chamber when a vacuum phase is part of the cycle.\n\n6.5 The items to be sterilized, other than products in sealed containers, should be wrapped in a material that allows the removal of air and the penetration of steam but prevents recontamination after sterilization. Specially designed autoclavable stainless steel containers, that allow steam to enter and air to leave, can also be used. All parts of the load should be in contact with water or saturated steam at the required temperature for the required time.\n\n6.6 Care should be taken to ensure that the steam used for sterilization is of suitable quality (chemical, microbiological and endotoxin analysis of condensate and physical examination of steam (such as dryness, superheat, and non-condensable gases)) and does not contain additives at a level that could cause contamination of the product or equipment. Steam used for sterilization should be tested regularly.\n\n*Sterilization by dry heat*\n\n6.7 Sterilization by dry heat may be suitable for non-aqueous liquids or dry-powder products.\n\nThe process used should include air circulation within the chamber and the maintenance of a positive pressure to prevent the entry of non-sterile air. If air is supplied it should be passed through a microorganism-retaining filter (e.g. a HEPA filter). Where sterilization by dry heat is also intended to remove pyrogens, challenge tests using endotoxins are required as part of the validation.\n\n*Sterilization by radiation*\n\n6.8 Sterilization by radiation is used mainly for heat-sensitive materials and products. Many pharmaceutical products and some packaging materials are radiation-sensitive, so this method is permissible only when the absence of deleterious effects on the product has been confirmed experimentally. Ultraviolet irradiation is not an acceptable method for terminal sterilization.\n\n6.9 If sterilization by radiation is done by an outside contractor, the manufacturer is responsible for ensuring that the requirements of section 6.8 are met and that the sterilization process is validated.\n\n6.10 During the sterilization procedure the radiation dose should be measured. The dosimeters used for this purpose should be independent of", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona directrices sobre los procedimientos de esterilizaci\u00f3n en el \u00e1mbito farmac\u00e9utico, centr\u00e1ndose en la importancia de verificar las lecturas de temperatura durante el proceso de esterilizaci\u00f3n, la calidad del vapor utilizado, y las condiciones necesarias para la esterilizaci\u00f3n por calor seco y radiaci\u00f3n. Se enfatiza la necesidad de pruebas regulares y validaciones para garantizar la eficacia de los m\u00e9todos de esterilizaci\u00f3n, as\u00ed como la responsabilidad del fabricante en el caso de que se utilicen contratistas externos para la esterilizaci\u00f3n por radiaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de materiales se recomienda utilizar para envolver los art\u00edculos que se van a esterilizar, y por qu\u00e9 es importante esta elecci\u00f3n?**\n   - Respuesta: Se recomienda utilizar materiales que permitan la eliminaci\u00f3n de aire y la penetraci\u00f3n de vapor, pero que eviten la recontaminaci\u00f3n despu\u00e9s de la esterilizaci\u00f3n. Esto es crucial para asegurar que los art\u00edculos est\u00e9n completamente esterilizados y no se contaminen nuevamente antes de su uso.\n\n2. **\u00bfCu\u00e1les son los requisitos espec\u00edficos para el vapor utilizado en el proceso de esterilizaci\u00f3n, y qu\u00e9 an\u00e1lisis se deben realizar para garantizar su calidad?**\n   - Respuesta: El vapor utilizado debe ser de calidad adecuada, lo que implica realizar an\u00e1lisis qu\u00edmicos, microbiol\u00f3gicos y de endotoxinas del condensado, as\u00ed como una evaluaci\u00f3n f\u00edsica del vapor (seco, sobrecalentado y gases no condensables). Esto asegura que el vapor no contenga aditivos que puedan contaminar los productos o equipos.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse si se utiliza la esterilizaci\u00f3n por radiaci\u00f3n a trav\u00e9s de un contratista externo?**\n   - Respuesta: El fabricante es responsable de asegurarse de que se cumplan los requisitos establecidos en la secci\u00f3n 6.8 del documento y de que el proceso de esterilizaci\u00f3n est\u00e9 validado. Esto incluye confirmar experimentalmente que no hay efectos perjudiciales en los productos debido a la radiaci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Diferenciaci\u00f3n de productos esterilizados y no esterilizados**:\n   - Importancia de etiquetar claramente los productos y componentes.\n   - Informaci\u00f3n requerida en las etiquetas: nombre del material, n\u00famero de lote y estado de esterilizaci\u00f3n.\n\n2. **Registros de esterilizaci\u00f3n**:\n   - Necesidad de mantener registros de cada ciclo de esterilizaci\u00f3n.\n   - Aprobaci\u00f3n de los registros como parte del procedimiento de liberaci\u00f3n de lotes.\n\n3. **Patrones de carga validados**:\n   - Establecimiento de patrones de carga para todos los procesos de esterilizaci\u00f3n.\n\n4. **Monitoreo de procesos de esterilizaci\u00f3n por calor**:\n   - Registro de ciclos de esterilizaci\u00f3n por calor mediante equipos precisos.\n   - Uso de sondas para medir la temperatura en el punto m\u00e1s fr\u00edo de la carga.\n   - Importancia de permitir tiempo suficiente para que toda la carga alcance la temperatura requerida.\n\n5. **Precauciones post-esterilizaci\u00f3n**:\n   - Medidas para evitar la contaminaci\u00f3n de la carga esterilizada durante el enfriamiento.\n   - Necesidad de esterilizar cualquier fluido o gas en contacto con el producto.\n\n6. **Esterilizaci\u00f3n por calor h\u00famedo**:\n   - Monitoreo de temperatura y presi\u00f3n durante el proceso.\n   - Validaci\u00f3n de sistemas de control y monitoreo automatizados.\n\n### Entidades clave\n- **Productos y componentes**: Elementos que requieren esterilizaci\u00f3n.\n- **Etiquetas**: Informaci\u00f3n sobre el estado de esterilizaci\u00f3n.\n- **Registros de esterilizaci\u00f3n**: Documentaci\u00f3n de cada ciclo.\n- **Patrones de carga**: Configuraciones validadas para procesos de esterilizaci\u00f3n.\n- **Equipos de monitoreo**: Herramientas para registrar temperatura y presi\u00f3n.\n- **Sondas de temperatura**: Dispositivos utilizados para medir la temperatura en el proceso de esterilizaci\u00f3n.", "excerpt_keywords": "Keywords: sterilization, steam quality, dry heat, radiation, validation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a11b2af6-6079-4166-9d95-bb85810e7eda", "node_type": "4", "metadata": {"page_label": "238", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The reading of the independent temperature indicator should be routinely checked against the reading on the chart recorder during the sterilization period. For sterilizers fitted with a drain at the bottom of the chamber, it may also be necessary to record the temperature at this position throughout the sterilization period. There should be regular leak tests on the chamber when a vacuum phase is part of the cycle.\n\n6.5 The items to be sterilized, other than products in sealed containers, should be wrapped in a material that allows the removal of air and the penetration of steam but prevents recontamination after sterilization. Specially designed autoclavable stainless steel containers, that allow steam to enter and air to leave, can also be used. All parts of the load should be in contact with water or saturated steam at the required temperature for the required time.\n\n6.6 Care should be taken to ensure that the steam used for sterilization is of suitable quality (chemical, microbiological and endotoxin analysis of condensate and physical examination of steam (such as dryness, superheat, and non-condensable gases)) and does not contain additives at a level that could cause contamination of the product or equipment. Steam used for sterilization should be tested regularly.\n\n*Sterilization by dry heat*\n\n6.7 Sterilization by dry heat may be suitable for non-aqueous liquids or dry-powder products.\n\nThe process used should include air circulation within the chamber and the maintenance of a positive pressure to prevent the entry of non-sterile air. If air is supplied it should be passed through a microorganism-retaining filter (e.g. a HEPA filter). Where sterilization by dry heat is also intended to remove pyrogens, challenge tests using endotoxins are required as part of the validation.\n\n*Sterilization by radiation*\n\n6.8 Sterilization by radiation is used mainly for heat-sensitive materials and products. Many pharmaceutical products and some packaging materials are radiation-sensitive, so this method is permissible only when the absence of deleterious effects on the product has been confirmed experimentally. Ultraviolet irradiation is not an acceptable method for terminal sterilization.\n\n6.9 If sterilization by radiation is done by an outside contractor, the manufacturer is responsible for ensuring that the requirements of section 6.8 are met and that the sterilization process is validated.\n\n6.10 During the sterilization procedure the radiation dose should be measured. The dosimeters used for this purpose should be independent of", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "6bf952ff40d2603d6737ec9bff06f82780576d989b8b14b6b0d87240e466e8f1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The reading of the independent temperature indicator should be routinely checked against the reading on the chart recorder during the sterilization period. For sterilizers fitted with a drain at the bottom of the chamber, it may also be necessary to record the temperature at this position throughout the sterilization period. There should be regular leak tests on the chamber when a vacuum phase is part of the cycle.\n\n6.5 The items to be sterilized, other than products in sealed containers, should be wrapped in a material that allows the removal of air and the penetration of steam but prevents recontamination after sterilization. Specially designed autoclavable stainless steel containers, that allow steam to enter and air to leave, can also be used. All parts of the load should be in contact with water or saturated steam at the required temperature for the required time.\n\n6.6 Care should be taken to ensure that the steam used for sterilization is of suitable quality (chemical, microbiological and endotoxin analysis of condensate and physical examination of steam (such as dryness, superheat, and non-condensable gases)) and does not contain additives at a level that could cause contamination of the product or equipment. Steam used for sterilization should be tested regularly.\n\n*Sterilization by dry heat*\n\n6.7 Sterilization by dry heat may be suitable for non-aqueous liquids or dry-powder products.\n\nThe process used should include air circulation within the chamber and the maintenance of a positive pressure to prevent the entry of non-sterile air. If air is supplied it should be passed through a microorganism-retaining filter (e.g. a HEPA filter). Where sterilization by dry heat is also intended to remove pyrogens, challenge tests using endotoxins are required as part of the validation.\n\n*Sterilization by radiation*\n\n6.8 Sterilization by radiation is used mainly for heat-sensitive materials and products. Many pharmaceutical products and some packaging materials are radiation-sensitive, so this method is permissible only when the absence of deleterious effects on the product has been confirmed experimentally. Ultraviolet irradiation is not an acceptable method for terminal sterilization.\n\n6.9 If sterilization by radiation is done by an outside contractor, the manufacturer is responsible for ensuring that the requirements of section 6.8 are met and that the sterilization process is validated.\n\n6.10 During the sterilization procedure the radiation dose should be measured. The dosimeters used for this purpose should be independent of", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2570, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1775c8c0-042d-41d4-b0c9-96b4851574e5": {"__data__": {"id_": "1775c8c0-042d-41d4-b0c9-96b4851574e5", "embedding": null, "metadata": {"page_label": "239", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the dose rate and should provide a quantitative measurement of the dose received by the product itself. Dosimeters should be inserted in the load in sufficient number and close enough together to ensure that there is always a dosimeter in the chamber. Where plastic dosimeters are used they should be used within the time-limit of their calibration. Dosimeter absorbance should be read shortly after exposure to radiation. Radiation-sensitive colour discs may be used to differentiate between packages that have been subjected to irradiation and those that have not; they are not indicators of successful sterilization. The information obtained should constitute part of the batch record.\n\n6.11 Validation procedures should ensure that consideration is given to the effects of variations in the density of the packages.\n\n6.12 Material-handling procedures should prevent any mix-up of irradiated and non-irradiated materials. Each package should carry a radiation-sensitive indicator to show whether or not it has been subjected to radiation treatment.\n\n6.13 The total radiation dose should be administered within a predetermined period.\n\n### Sterilization by gases and fumigants\n\n6.14 Sterilization by gases and fumigants should only be used for finished products where there is no suitable alternative.\n\n6.15 Various gases and fumigants may be used for sterilization (e.g. ethylene oxide and hydrogen peroxide vapour). Ethylene oxide should be used only when no other method is practicable. During process validation it should be shown that the gas has no damaging effect on the product and that the conditions and time allowed for degassing are such as to reduce any residual gas and reaction products to defined acceptable limits for the type of product or material concerned. These limits should be incorporated in the specifications.\n\n6.16 Direct contact between gas and microorganisms is essential; precautions should therefore be taken to avoid the presence of organisms likely to be enclosed in materials such as crystals or dried protein. The nature and quantity of packaging materials can significantly affect the process.\n\n6.17 Before exposure to the gas, materials should be brought into equilibrium with the humidity and temperature required by the process. This requirement should be balanced against the need to minimize the waiting time before sterilization.\n\n6.18 Each sterilization cycle should be monitored with suitable biological indicators, using the appropriate number of test pieces distributed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Procedimientos de validaci\u00f3n y manejo de materiales**: Se enfatiza la importancia de los procedimientos de validaci\u00f3n para asegurar que las variaciones en la densidad de los paquetes se consideren adecuadamente. Adem\u00e1s, se establecen protocolos para evitar la mezcla de materiales irradiados y no irradiados, incluyendo el uso de indicadores sensibles a la radiaci\u00f3n en cada paquete.\n\n2. **M\u00e9todos de esterilizaci\u00f3n por gases y fumigantes**: Se discute el uso de gases y fumigantes, como el \u00f3xido de etileno y el vapor de per\u00f3xido de hidr\u00f3geno, para la esterilizaci\u00f3n de productos terminados. Se subraya la necesidad de validar que estos gases no da\u00f1en el producto y que se cumplan los l\u00edmites aceptables de residuos.\n\n3. **Monitoreo de ciclos de esterilizaci\u00f3n**: Se requiere que cada ciclo de esterilizaci\u00f3n sea monitoreado utilizando indicadores biol\u00f3gicos adecuados y que se distribuyan suficientes piezas de prueba para garantizar la efectividad del proceso.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que los dos\u00edmetros utilizados en la medici\u00f3n de la dosis de radiaci\u00f3n est\u00e9n correctamente posicionados y calibrados?**\n   - La respuesta se puede encontrar en la secci\u00f3n que menciona la cantidad y disposici\u00f3n de los dos\u00edmetros en la carga, as\u00ed como el tiempo l\u00edmite de calibraci\u00f3n para los dos\u00edmetros pl\u00e1sticos.\n\n2. **\u00bfCu\u00e1les son las consideraciones clave al utilizar \u00f3xido de etileno como m\u00e9todo de esterilizaci\u00f3n, y qu\u00e9 pasos se deben seguir para validar su uso?**\n   - La respuesta se puede extraer de la discusi\u00f3n sobre el uso de \u00f3xido de etileno, incluyendo la necesidad de demostrar que no causa da\u00f1o al producto y los l\u00edmites aceptables de residuos que deben ser especificados.\n\n3. **\u00bfQu\u00e9 precauciones deben tomarse para garantizar el contacto directo entre el gas de esterilizaci\u00f3n y los microorganismos?**\n   - La respuesta se puede encontrar en la secci\u00f3n que aborda la importancia del contacto directo y las precauciones necesarias para evitar la presencia de organismos encerrados en materiales que podr\u00edan interferir con el proceso de esterilizaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Verificaci\u00f3n de Temperatura**: Es fundamental comprobar regularmente la lectura del indicador de temperatura independiente contra el registrador gr\u00e1fico durante el proceso de esterilizaci\u00f3n. Esto incluye registrar la temperatura en el fondo de la c\u00e1mara si el esterilizador tiene un desag\u00fce.\n\n2. **Materiales para Envoltura**: Los art\u00edculos a esterilizar deben envolverse en materiales que permitan la eliminaci\u00f3n de aire y la penetraci\u00f3n de vapor, evitando la recontaminaci\u00f3n posterior. Se pueden utilizar contenedores de acero inoxidable autoclavables dise\u00f1ados para este prop\u00f3sito.\n\n3. **Calidad del Vapor**: El vapor utilizado para la esterilizaci\u00f3n debe ser de calidad adecuada, lo que implica realizar an\u00e1lisis qu\u00edmicos, microbiol\u00f3gicos y de endotoxinas, as\u00ed como una evaluaci\u00f3n f\u00edsica del vapor. Se debe evitar la presencia de aditivos que puedan contaminar los productos.\n\n4. **Esterilizaci\u00f3n por Calor Seco**: Este m\u00e9todo es adecuado para l\u00edquidos no acuosos o productos en polvo seco. Se requiere circulaci\u00f3n de aire y mantenimiento de presi\u00f3n positiva para prevenir la entrada de aire no est\u00e9ril. Si se busca eliminar pir\u00f3genos, se deben realizar pruebas de desaf\u00edo con endotoxinas.\n\n5. **Esterilizaci\u00f3n por Radiaci\u00f3n**: Este m\u00e9todo se utiliza principalmente para materiales y productos sensibles al calor. Es necesario confirmar experimentalmente que no hay efectos perjudiciales en los productos. La irradiaci\u00f3n ultravioleta no es aceptable para la esterilizaci\u00f3n terminal.\n\n6. **Responsabilidad del Fabricante**: Si la esterilizaci\u00f3n por radiaci\u00f3n es realizada por un contratista externo, el fabricante debe asegurarse de que se cumplan los requisitos y que el proceso est\u00e9 validado.\n\n7. **Medici\u00f3n de Dosis de Radiaci\u00f3n**: Durante el procedimiento de esterilizaci\u00f3n, se debe medir la dosis de radiaci\u00f3n utilizando dos\u00edmetros independientes.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Esterilizaci\u00f3n**: Proceso de eliminaci\u00f3n de microorganismos.\n- **Vapor**: Medio utilizado para la esterilizaci\u00f3n.\n- **Contenedores de Acero Inoxidable**: Material recomendado para envolver art\u00edculos a esterilizar.\n- **Calor Seco**: M\u00e9todo de esterilizaci\u00f3n adecuado para ciertos productos.\n- **Radiaci\u00f3n**: M\u00e9todo de esterilizaci\u00f3n utilizado para materiales sensibles al calor.\n- **Contratistas Externos**: Entidades responsables de realizar la esterilizaci\u00f3n por radiaci\u00f3n en nombre del fabricante.", "excerpt_keywords": "Keywords: sterilization, dosimeters, ethylene oxide, radiation, validation procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2b6fd6be-c378-446b-8131-dfa4fc25148d", "node_type": "4", "metadata": {"page_label": "239", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the dose rate and should provide a quantitative measurement of the dose received by the product itself. Dosimeters should be inserted in the load in sufficient number and close enough together to ensure that there is always a dosimeter in the chamber. Where plastic dosimeters are used they should be used within the time-limit of their calibration. Dosimeter absorbance should be read shortly after exposure to radiation. Radiation-sensitive colour discs may be used to differentiate between packages that have been subjected to irradiation and those that have not; they are not indicators of successful sterilization. The information obtained should constitute part of the batch record.\n\n6.11 Validation procedures should ensure that consideration is given to the effects of variations in the density of the packages.\n\n6.12 Material-handling procedures should prevent any mix-up of irradiated and non-irradiated materials. Each package should carry a radiation-sensitive indicator to show whether or not it has been subjected to radiation treatment.\n\n6.13 The total radiation dose should be administered within a predetermined period.\n\n### Sterilization by gases and fumigants\n\n6.14 Sterilization by gases and fumigants should only be used for finished products where there is no suitable alternative.\n\n6.15 Various gases and fumigants may be used for sterilization (e.g. ethylene oxide and hydrogen peroxide vapour). Ethylene oxide should be used only when no other method is practicable. During process validation it should be shown that the gas has no damaging effect on the product and that the conditions and time allowed for degassing are such as to reduce any residual gas and reaction products to defined acceptable limits for the type of product or material concerned. These limits should be incorporated in the specifications.\n\n6.16 Direct contact between gas and microorganisms is essential; precautions should therefore be taken to avoid the presence of organisms likely to be enclosed in materials such as crystals or dried protein. The nature and quantity of packaging materials can significantly affect the process.\n\n6.17 Before exposure to the gas, materials should be brought into equilibrium with the humidity and temperature required by the process. This requirement should be balanced against the need to minimize the waiting time before sterilization.\n\n6.18 Each sterilization cycle should be monitored with suitable biological indicators, using the appropriate number of test pieces distributed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b0248dcbd3a15fdb0c89bd9bdc6ab366dd008067ec0495e2a893fe4472244fce", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "the dose rate and should provide a quantitative measurement of the dose received by the product itself. Dosimeters should be inserted in the load in sufficient number and close enough together to ensure that there is always a dosimeter in the chamber. Where plastic dosimeters are used they should be used within the time-limit of their calibration. Dosimeter absorbance should be read shortly after exposure to radiation. Radiation-sensitive colour discs may be used to differentiate between packages that have been subjected to irradiation and those that have not; they are not indicators of successful sterilization. The information obtained should constitute part of the batch record.\n\n6.11 Validation procedures should ensure that consideration is given to the effects of variations in the density of the packages.\n\n6.12 Material-handling procedures should prevent any mix-up of irradiated and non-irradiated materials. Each package should carry a radiation-sensitive indicator to show whether or not it has been subjected to radiation treatment.\n\n6.13 The total radiation dose should be administered within a predetermined period.\n\n### Sterilization by gases and fumigants\n\n6.14 Sterilization by gases and fumigants should only be used for finished products where there is no suitable alternative.\n\n6.15 Various gases and fumigants may be used for sterilization (e.g. ethylene oxide and hydrogen peroxide vapour). Ethylene oxide should be used only when no other method is practicable. During process validation it should be shown that the gas has no damaging effect on the product and that the conditions and time allowed for degassing are such as to reduce any residual gas and reaction products to defined acceptable limits for the type of product or material concerned. These limits should be incorporated in the specifications.\n\n6.16 Direct contact between gas and microorganisms is essential; precautions should therefore be taken to avoid the presence of organisms likely to be enclosed in materials such as crystals or dried protein. The nature and quantity of packaging materials can significantly affect the process.\n\n6.17 Before exposure to the gas, materials should be brought into equilibrium with the humidity and temperature required by the process. This requirement should be balanced against the need to minimize the waiting time before sterilization.\n\n6.18 Each sterilization cycle should be monitored with suitable biological indicators, using the appropriate number of test pieces distributed.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2519, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "42347d41-2858-4640-b45d-6d74ea80abac": {"__data__": {"id_": "42347d41-2858-4640-b45d-6d74ea80abac", "embedding": null, "metadata": {"page_label": "240", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Aseptic Processing and Sterilization by Filtration\n\n7.1 The objective of aseptic processing is to maintain the sterility of a product that is assembled from components, each of which has been sterilized by one of the above methods (see sections 5 and 6).\n\n7.2 The operating conditions should be such as to prevent microbial contamination.\n\n7.3 In order to maintain the sterility of the components and the product during aseptic processing, careful attention needs to be given to:\n\n- the environment;\n- personnel;\n- critical surfaces;\n- container/closure sterilization and transfer procedures;\n- the maximum holding period of the product before filling into the final container; and\n- the sterilizing filter.\n\n7.4 Certain solutions and liquids that cannot be sterilized in the final container can be filtered through a sterile filter of nominal pore size 0.22 micron (or less), or with at least equivalent microorganism-retaining properties, into a previously sterilized container. Such filters can remove bacteria and moulds, but not all viruses or mycoplasmas. Consideration should be given to complementing the filtration process with some degree of heat treatment. Filtration alone is not considered sufficient when sterilization in the final container is possible. Of the methods currently available, steam sterilization is to be preferred.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Objetivo del Procesamiento Aseptico**: El procesamiento as\u00e9ptico tiene como objetivo mantener la esterilidad de un producto que se ensambla a partir de componentes previamente esterilizados. Esto implica un control riguroso de las condiciones operativas para prevenir la contaminaci\u00f3n microbiana.\n\n2. **Factores Cr\u00edticos en el Procesamiento Aseptico**: Para asegurar la esterilidad durante el procesamiento as\u00e9ptico, es crucial prestar atenci\u00f3n a varios factores, incluyendo el entorno, el personal, las superficies cr\u00edticas, los procedimientos de esterilizaci\u00f3n y transferencia de envases/cierres, el tiempo m\u00e1ximo de retenci\u00f3n del producto antes del llenado, y el filtro esterilizante.\n\n3. **Filtraci\u00f3n y Esterilizaci\u00f3n**: La filtraci\u00f3n a trav\u00e9s de un filtro est\u00e9ril de 0.22 micrones es una opci\u00f3n para soluciones que no pueden ser esterilizadas en su envase final. Sin embargo, esta t\u00e9cnica no es suficiente por s\u00ed sola y se recomienda complementarla con un tratamiento t\u00e9rmico. La esterilizaci\u00f3n por vapor es el m\u00e9todo preferido cuando es posible.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los componentes cr\u00edticos que deben ser controlados para mantener la esterilidad durante el procesamiento as\u00e9ptico?**\n   - Respuesta: Los componentes cr\u00edticos incluyen el entorno, el personal, las superficies cr\u00edticas, los procedimientos de esterilizaci\u00f3n y transferencia de envases/cierres, el tiempo m\u00e1ximo de retenci\u00f3n del producto antes del llenado, y el filtro esterilizante.\n\n2. **\u00bfQu\u00e9 limitaciones tienen los filtros est\u00e9riles de 0.22 micrones en t\u00e9rminos de microorganismos que pueden eliminar?**\n   - Respuesta: Los filtros est\u00e9riles de 0.22 micrones pueden eliminar bacterias y mohos, pero no son efectivos contra todos los virus o micoplasmas.\n\n3. **\u00bfPor qu\u00e9 se considera que la filtraci\u00f3n sola no es suficiente para la esterilizaci\u00f3n en el envase final?**\n   - Respuesta: La filtraci\u00f3n sola no es suficiente porque no elimina todos los tipos de microorganismos, especialmente algunos virus y micoplasmas. Se recomienda complementar la filtraci\u00f3n con alg\u00fan grado de tratamiento t\u00e9rmico, y cuando sea posible, la esterilizaci\u00f3n por vapor es preferida.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Dosimetr\u00eda y Medici\u00f3n de Radiaci\u00f3n**:\n   - Importancia de los dos\u00edmetros para medir la dosis de radiaci\u00f3n recibida por los productos.\n   - Recomendaciones sobre la cantidad y disposici\u00f3n de los dos\u00edmetros en la carga.\n   - Uso de dos\u00edmetros pl\u00e1sticos dentro de su tiempo de calibraci\u00f3n y lectura de absorbancia poco despu\u00e9s de la exposici\u00f3n.\n\n2. **Procedimientos de Validaci\u00f3n**:\n   - Necesidad de considerar las variaciones en la densidad de los paquetes durante la validaci\u00f3n.\n   - Protocolo para evitar la mezcla de materiales irradiados y no irradiados, incluyendo el uso de indicadores sensibles a la radiaci\u00f3n en cada paquete.\n\n3. **Esterilizaci\u00f3n por Gases y Fumigantes**:\n   - Uso restringido de gases y fumigantes (como \u00f3xido de etileno y vapor de per\u00f3xido de hidr\u00f3geno) solo para productos terminados sin alternativas adecuadas.\n   - Validaci\u00f3n del uso de \u00f3xido de etileno, asegurando que no cause da\u00f1o al producto y que los residuos se mantengan dentro de l\u00edmites aceptables.\n\n4. **Contacto Directo y Preparaci\u00f3n de Materiales**:\n   - Importancia del contacto directo entre el gas de esterilizaci\u00f3n y los microorganismos.\n   - Precauciones para evitar la presencia de organismos encerrados en materiales que puedan interferir con el proceso.\n   - Necesidad de equilibrar la humedad y temperatura de los materiales antes de la exposici\u00f3n al gas.\n\n5. **Monitoreo de Ciclos de Esterilizaci\u00f3n**:\n   - Cada ciclo de esterilizaci\u00f3n debe ser monitoreado con indicadores biol\u00f3gicos adecuados y un n\u00famero suficiente de piezas de prueba distribuidas.\n\n### Entidades Clave\n- **Dos\u00edmetros**: Dispositivos para medir la dosis de radiaci\u00f3n.\n- **\u00d3xido de Etileno**: Gas utilizado para la esterilizaci\u00f3n.\n- **Per\u00f3xido de Hidr\u00f3geno**: Otro gas utilizado para la esterilizaci\u00f3n.\n- **Indicadores Sensibles a la Radiaci\u00f3n**: Herramientas para identificar si un paquete ha sido irradiado.\n- **Microorganismos**: Organismos que deben ser eliminados durante el proceso de esterilizaci\u00f3n. \n\nEste resumen destaca los aspectos cr\u00edticos relacionados con la medici\u00f3n de la dosis de radiaci\u00f3n, los procedimientos de validaci\u00f3n, los m\u00e9todos de esterilizaci\u00f3n, y la importancia del monitoreo en los procesos de esterilizaci\u00f3n.", "excerpt_keywords": "Aseptic processing, Sterilization, Filtration, Microbial contamination, Steam sterilization"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "43180f24-e29b-42bf-be3a-539e29738591", "node_type": "4", "metadata": {"page_label": "240", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Aseptic Processing and Sterilization by Filtration\n\n7.1 The objective of aseptic processing is to maintain the sterility of a product that is assembled from components, each of which has been sterilized by one of the above methods (see sections 5 and 6).\n\n7.2 The operating conditions should be such as to prevent microbial contamination.\n\n7.3 In order to maintain the sterility of the components and the product during aseptic processing, careful attention needs to be given to:\n\n- the environment;\n- personnel;\n- critical surfaces;\n- container/closure sterilization and transfer procedures;\n- the maximum holding period of the product before filling into the final container; and\n- the sterilizing filter.\n\n7.4 Certain solutions and liquids that cannot be sterilized in the final container can be filtered through a sterile filter of nominal pore size 0.22 micron (or less), or with at least equivalent microorganism-retaining properties, into a previously sterilized container. Such filters can remove bacteria and moulds, but not all viruses or mycoplasmas. Consideration should be given to complementing the filtration process with some degree of heat treatment. Filtration alone is not considered sufficient when sterilization in the final container is possible. Of the methods currently available, steam sterilization is to be preferred.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b96e4fa904ee0078566444a7d947592d4d2c07c497c75f9ddda0916ae50fa7f1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Aseptic Processing and Sterilization by Filtration\n\n7.1 The objective of aseptic processing is to maintain the sterility of a product that is assembled from components, each of which has been sterilized by one of the above methods (see sections 5 and 6).\n\n7.2 The operating conditions should be such as to prevent microbial contamination.\n\n7.3 In order to maintain the sterility of the components and the product during aseptic processing, careful attention needs to be given to:\n\n- the environment;\n- personnel;\n- critical surfaces;\n- container/closure sterilization and transfer procedures;\n- the maximum holding period of the product before filling into the final container; and\n- the sterilizing filter.\n\n7.4 Certain solutions and liquids that cannot be sterilized in the final container can be filtered through a sterile filter of nominal pore size 0.22 micron (or less), or with at least equivalent microorganism-retaining properties, into a previously sterilized container. Such filters can remove bacteria and moulds, but not all viruses or mycoplasmas. Consideration should be given to complementing the filtration process with some degree of heat treatment. Filtration alone is not considered sufficient when sterilization in the final container is possible. Of the methods currently available, steam sterilization is to be preferred.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1346, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7f6a22de-1b95-4922-b71d-e0172cbd75df": {"__data__": {"id_": "7f6a22de-1b95-4922-b71d-e0172cbd75df", "embedding": null, "metadata": {"page_label": "241", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 7.5\n\nOwing to the potential additional risks of the filtration method as compared with other sterilization processes, a double-filter layer or second filtration through a further sterilized microorganism-retaining filter immediately prior to filling may be advisable. The final sterile filtration should be carried out as close as possible to the filling point.\n\n## 7.6\n\nThe fibre-shedding characteristics of filters should be minimal (virtually zero). Asbestos-containing filters should not be used under any circumstances.\n\n## 7.7\n\nThe integrity of the sterilized filter should be verified before use and should be confirmed immediately after use by an appropriate method such as a bubble point, diffusive flow or pressure hold test. The time taken to filter a known volume of bulk solution and the pressure difference to be used across the filter should be determined during validation and any significant differences from these during routine manufacturing should be noted and investigated. Results of these checks should be included in the batch record. The integrity of critical gas and air vent filters should be confirmed after use. The integrity of other filters should be confirmed at appropriate intervals. Consideration should be given to increased monitoring of filter integrity in processes that involve harsh conditions, e.g. the circulation of high-temperature air.\n\n## 7.8\n\nThe same filter should not be used for more than one working day unless such use has been validated.\n\n## 7.9\n\nThe filter should not affect the product either by removing ingredients from it or by releasing substances into it.\n\n# 8. Isolator technology\n\n## 8.1\n\nThe use of isolator technology to minimize human interventions in processing areas may result in a significant decrease in the risk of microbial contamination of aseptically manufactured products from the environment. There are many possible designs of isolators and transfer devices. The isolator and the background environment should be designed so that the required air quality for each zone can be realized. Isolators are constructed of various materials more or less prone to puncture and leakage. Transfer devices may vary from single-door to double-door designs to fully-sealed systems incorporating sterilization mechanisms.\n\n## 8.2\n\nThe transfer of materials into and out of the unit is one of the greatest potential sources of contamination. In general the area inside the isolator is the local zone for high-risk manipulations, although it is recognized that unidirectional airflow may not exist in the working zone of all isolators and transfer devices.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Filtraci\u00f3n y Esterilizaci\u00f3n**: Se discuten las mejores pr\u00e1cticas para la filtraci\u00f3n y esterilizaci\u00f3n de productos, enfatizando la importancia de la integridad de los filtros, la minimizaci\u00f3n de riesgos asociados con la filtraci\u00f3n y la necesidad de realizar pruebas de integridad antes y despu\u00e9s de su uso.\n\n2. **Tecnolog\u00eda de Aisladores**: Se aborda el uso de tecnolog\u00eda de aisladores para reducir la contaminaci\u00f3n microbiana en productos fabricados as\u00e9pticamente. Se mencionan diferentes dise\u00f1os de aisladores y dispositivos de transferencia, as\u00ed como la importancia de mantener la calidad del aire en estas \u00e1reas.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los m\u00e9todos recomendados para verificar la integridad de un filtro esterilizado antes y despu\u00e9s de su uso?**\n   - Respuesta: La integridad del filtro esterilizado debe ser verificada antes de su uso y confirmada inmediatamente despu\u00e9s mediante m\u00e9todos apropiados como la prueba de punto de burbuja, flujo difusivo o prueba de retenci\u00f3n de presi\u00f3n.\n\n2. **\u00bfQu\u00e9 caracter\u00edsticas deben tener los filtros en t\u00e9rminos de desprendimiento de fibras y qu\u00e9 materiales est\u00e1n prohibidos?**\n   - Respuesta: Las caracter\u00edsticas de desprendimiento de fibras de los filtros deben ser m\u00ednimas (pr\u00e1cticamente cero), y los filtros que contengan asbesto no deben ser utilizados bajo ninguna circunstancia.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al transferir materiales dentro y fuera de un aislador?**\n   - Respuesta: La transferencia de materiales es una de las mayores fuentes potenciales de contaminaci\u00f3n. Se reconoce que el \u00e1rea dentro del aislador es la zona local para manipulaciones de alto riesgo, y se debe tener en cuenta que el flujo de aire unidireccional puede no existir en todas las zonas de trabajo de los aisladores y dispositivos de transferencia.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Objetivo del Procesamiento Aseptico**:\n   - Mantener la esterilidad de un producto ensamblado a partir de componentes previamente esterilizados.\n\n2. **Condiciones Operativas**:\n   - Deben prevenir la contaminaci\u00f3n microbiana.\n\n3. **Factores Cr\u00edticos para Mantener la Esterilidad**:\n   - **Entorno**: Control del ambiente donde se realiza el procesamiento.\n   - **Personal**: Capacitaci\u00f3n y control de la higiene del personal involucrado.\n   - **Superficies Cr\u00edticas**: Mantenimiento de la limpieza y esterilidad de las superficies en contacto con el producto.\n   - **Procedimientos de Esterilizaci\u00f3n y Transferencia de Envases/Cierres**: M\u00e9todos adecuados para asegurar la esterilidad de los envases.\n   - **Tiempo M\u00e1ximo de Retenci\u00f3n**: Control del tiempo que el producto puede estar retenido antes de ser llenado en el envase final.\n   - **Filtro Esterilizante**: Uso de filtros adecuados para mantener la esterilidad.\n\n4. **Filtraci\u00f3n y Esterilizaci\u00f3n**:\n   - Uso de filtros est\u00e9riles de 0.22 micrones para soluciones que no pueden ser esterilizadas en el envase final.\n   - Limitaciones de los filtros: Efectivos contra bacterias y mohos, pero no contra todos los virus o micoplasmas.\n   - Recomendaci\u00f3n de complementar la filtraci\u00f3n con tratamiento t\u00e9rmico.\n   - Preferencia por la esterilizaci\u00f3n por vapor cuando es posible.\n\n### Entidades Clave\n- **Procesamiento Aseptico**\n- **Contaminaci\u00f3n Microbiana**\n- **Filtraci\u00f3n Esteril** \n- **Esterilizaci\u00f3n por Vapor**\n- **Microorganismos**: Bacterias, mohos, virus, micoplasmas. \n\nEste resumen destaca los aspectos fundamentales del procesamiento as\u00e9ptico y la esterilizaci\u00f3n por filtraci\u00f3n, as\u00ed como las consideraciones necesarias para mantener la esterilidad en productos farmac\u00e9uticos y biol\u00f3gicos.", "excerpt_keywords": "Keywords: filtration, sterilization, microbial contamination, isolator technology, air quality"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6ad93f16-51a1-43d2-803b-856ade15be1d", "node_type": "4", "metadata": {"page_label": "241", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 7.5\n\nOwing to the potential additional risks of the filtration method as compared with other sterilization processes, a double-filter layer or second filtration through a further sterilized microorganism-retaining filter immediately prior to filling may be advisable. The final sterile filtration should be carried out as close as possible to the filling point.\n\n## 7.6\n\nThe fibre-shedding characteristics of filters should be minimal (virtually zero). Asbestos-containing filters should not be used under any circumstances.\n\n## 7.7\n\nThe integrity of the sterilized filter should be verified before use and should be confirmed immediately after use by an appropriate method such as a bubble point, diffusive flow or pressure hold test. The time taken to filter a known volume of bulk solution and the pressure difference to be used across the filter should be determined during validation and any significant differences from these during routine manufacturing should be noted and investigated. Results of these checks should be included in the batch record. The integrity of critical gas and air vent filters should be confirmed after use. The integrity of other filters should be confirmed at appropriate intervals. Consideration should be given to increased monitoring of filter integrity in processes that involve harsh conditions, e.g. the circulation of high-temperature air.\n\n## 7.8\n\nThe same filter should not be used for more than one working day unless such use has been validated.\n\n## 7.9\n\nThe filter should not affect the product either by removing ingredients from it or by releasing substances into it.\n\n# 8. Isolator technology\n\n## 8.1\n\nThe use of isolator technology to minimize human interventions in processing areas may result in a significant decrease in the risk of microbial contamination of aseptically manufactured products from the environment. There are many possible designs of isolators and transfer devices. The isolator and the background environment should be designed so that the required air quality for each zone can be realized. Isolators are constructed of various materials more or less prone to puncture and leakage. Transfer devices may vary from single-door to double-door designs to fully-sealed systems incorporating sterilization mechanisms.\n\n## 8.2\n\nThe transfer of materials into and out of the unit is one of the greatest potential sources of contamination. In general the area inside the isolator is the local zone for high-risk manipulations, although it is recognized that unidirectional airflow may not exist in the working zone of all isolators and transfer devices.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "ccbac5494f41b0059f40cb9690a26c50a613bd9de237a81707f9c6e715749e6e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 7.5\n\nOwing to the potential additional risks of the filtration method as compared with other sterilization processes, a double-filter layer or second filtration through a further sterilized microorganism-retaining filter immediately prior to filling may be advisable. The final sterile filtration should be carried out as close as possible to the filling point.\n\n## 7.6\n\nThe fibre-shedding characteristics of filters should be minimal (virtually zero). Asbestos-containing filters should not be used under any circumstances.\n\n## 7.7\n\nThe integrity of the sterilized filter should be verified before use and should be confirmed immediately after use by an appropriate method such as a bubble point, diffusive flow or pressure hold test. The time taken to filter a known volume of bulk solution and the pressure difference to be used across the filter should be determined during validation and any significant differences from these during routine manufacturing should be noted and investigated. Results of these checks should be included in the batch record. The integrity of critical gas and air vent filters should be confirmed after use. The integrity of other filters should be confirmed at appropriate intervals. Consideration should be given to increased monitoring of filter integrity in processes that involve harsh conditions, e.g. the circulation of high-temperature air.\n\n## 7.8\n\nThe same filter should not be used for more than one working day unless such use has been validated.\n\n## 7.9\n\nThe filter should not affect the product either by removing ingredients from it or by releasing substances into it.\n\n# 8. Isolator technology\n\n## 8.1\n\nThe use of isolator technology to minimize human interventions in processing areas may result in a significant decrease in the risk of microbial contamination of aseptically manufactured products from the environment. There are many possible designs of isolators and transfer devices. The isolator and the background environment should be designed so that the required air quality for each zone can be realized. Isolators are constructed of various materials more or less prone to puncture and leakage. Transfer devices may vary from single-door to double-door designs to fully-sealed systems incorporating sterilization mechanisms.\n\n## 8.2\n\nThe transfer of materials into and out of the unit is one of the greatest potential sources of contamination. In general the area inside the isolator is the local zone for high-risk manipulations, although it is recognized that unidirectional airflow may not exist in the working zone of all isolators and transfer devices.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2620, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e79f41df-6ff3-4acf-b03c-719013318091": {"__data__": {"id_": "e79f41df-6ff3-4acf-b03c-719013318091", "embedding": null, "metadata": {"page_label": "242", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 8.3 \nThe air classification required for the background environment depends on the design of the isolator and its application. It should be controlled, and for aseptic processing it should be at least grade D.\n\n8.4 \nIsolators should be introduced only after appropriate validation. Validation should take into account all critical factors of isolator technology, for example, the quality of the air inside and outside (background) the isolator, sanitization of the isolator, the transfer process and isolator integrity.\n\n8.5 \nMonitoring should be done routinely and should include frequent leak testing of the isolator and the glove/sleeve system.\n\n# 9. Blow/fill/seal technology\n\n9.1 \nBlow/fill/seal units are purpose-built machines in which, in one continuous operation, containers are formed from a thermoplastic granulate, filled and then sealed, all by the one automatic machine. Blow/fill/seal equipment used for aseptic production which is fitted with an effective grade A air shower may be installed in at least a grade C environment, provided that grade A or B clothing is used. The environment should comply with the viable and non-viable limits at rest and the viable limit only when in operation. Blow/fill/seal equipment used for the production of products which are terminally sterilized should be installed in at least a grade D environment.\n\n9.2 \nBecause of this special technology, particular attention should be paid to at least the following:\n\n- equipment design and qualification;\n- validation and reproducibility of cleaning-in-place and sterilization-in-place;\n- background clean room environment in which the equipment is located;\n- operator training and clothing; and\n- interventions in the critical zone of the equipment including any aseptic assembly prior to the commencement of filling.\n\n# 10. Personnel\n\n10.1 \nOnly the minimum number of personnel required should be present in clean areas; this is particularly important during aseptic processes. As far as possible, inspections and controls should be conducted from outside such areas.\n\n10.2 \nAll personnel (including those concerned with cleaning and maintenance) employed in such areas should receive initial and regular training in disciplines relevant to the correct manufacture of sterile products, including hygiene and the basic elements of microbiology. When outside", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Clasificaci\u00f3n del aire y validaci\u00f3n de aisladores**: La clasificaci\u00f3n del aire en el entorno de fondo de un aislador es crucial y debe ser al menos de grado D para procesos as\u00e9pticos. La introducci\u00f3n de aisladores debe estar precedida por una validaci\u00f3n adecuada que considere factores cr\u00edticos como la calidad del aire, la sanitizaci\u00f3n y la integridad del aislador.\n\n2. **Tecnolog\u00eda Blow/fill/seal**: Las unidades de tecnolog\u00eda Blow/fill/seal son m\u00e1quinas autom\u00e1ticas que forman, llenan y sellan contenedores en un solo proceso. Para la producci\u00f3n as\u00e9ptica, estas m\u00e1quinas deben estar en un entorno de al menos grado C, con ropa adecuada, y cumplir con l\u00edmites viables y no viables. La atenci\u00f3n especial debe prestarse a la validaci\u00f3n de limpieza y esterilizaci\u00f3n, as\u00ed como a la capacitaci\u00f3n del operador.\n\n3. **Personal en \u00e1reas limpias**: Es fundamental limitar el n\u00famero de personas en \u00e1reas limpias durante procesos as\u00e9pticos y realizar inspecciones desde el exterior cuando sea posible. Todo el personal debe recibir capacitaci\u00f3n regular en pr\u00e1cticas de fabricaci\u00f3n de productos est\u00e9riles, higiene y microbiolog\u00eda.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los factores cr\u00edticos que deben considerarse durante la validaci\u00f3n de un aislador en un entorno de producci\u00f3n as\u00e9ptica?**\n   - Respuesta: Los factores cr\u00edticos incluyen la calidad del aire dentro y fuera del aislador, la sanitizaci\u00f3n del aislador, el proceso de transferencia y la integridad del aislador.\n\n2. **\u00bfQu\u00e9 requisitos ambientales deben cumplirse para el equipo Blow/fill/seal utilizado en la producci\u00f3n as\u00e9ptica?**\n   - Respuesta: El equipo Blow/fill/seal debe estar instalado en un entorno de al menos grado C, siempre que se utilice ropa de grado A o B, y debe cumplir con los l\u00edmites viables y no viables en reposo y solo con el l\u00edmite viable en operaci\u00f3n.\n\n3. **\u00bfQu\u00e9 tipo de capacitaci\u00f3n deben recibir los empleados que trabajan en \u00e1reas limpias y por qu\u00e9 es importante?**\n   - Respuesta: Todos los empleados deben recibir capacitaci\u00f3n inicial y regular en disciplinas relevantes para la fabricaci\u00f3n correcta de productos est\u00e9riles, incluyendo higiene y microbiolog\u00eda, para asegurar la calidad y seguridad de los productos fabricados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### 1. Filtraci\u00f3n y Esterilizaci\u00f3n\n- **M\u00e9todos de Filtraci\u00f3n**: Se recomienda el uso de una capa de doble filtro o una segunda filtraci\u00f3n a trav\u00e9s de un filtro esterilizado que retenga microorganismos antes del llenado.\n- **Pruebas de Integridad**: Es crucial verificar la integridad de los filtros esterilizados antes y despu\u00e9s de su uso mediante pruebas como el punto de burbuja, flujo difusivo o prueba de retenci\u00f3n de presi\u00f3n.\n- **Caracter\u00edsticas de los Filtros**: Los filtros deben tener caracter\u00edsticas de desprendimiento de fibras m\u00ednimas (pr\u00e1cticamente cero) y no deben contener asbesto.\n- **Uso de Filtros**: Un filtro no debe utilizarse por m\u00e1s de un d\u00eda laboral a menos que su uso haya sido validado.\n- **Impacto en el Producto**: Los filtros no deben afectar el producto, ya sea eliminando ingredientes o liberando sustancias en \u00e9l.\n\n#### 2. Tecnolog\u00eda de Aisladores\n- **Minimizaci\u00f3n de Contaminaci\u00f3n**: La tecnolog\u00eda de aisladores se utiliza para reducir la intervenci\u00f3n humana en \u00e1reas de procesamiento, lo que disminuye el riesgo de contaminaci\u00f3n microbiana en productos fabricados as\u00e9pticamente.\n- **Dise\u00f1os de Aisladores**: Existen diversos dise\u00f1os de aisladores y dispositivos de transferencia, que deben garantizar la calidad del aire en cada zona.\n- **Transferencia de Materiales**: La transferencia de materiales dentro y fuera del aislador es una fuente significativa de contaminaci\u00f3n, y se reconoce que el flujo de aire unidireccional puede no estar presente en todas las zonas de trabajo.\n\n### Entidades Clave\n- **Filtros Esterilizados**: Dispositivos utilizados para asegurar la pureza de productos mediante la eliminaci\u00f3n de microorganismos.\n- **Aisladores**: Sistemas dise\u00f1ados para crear un ambiente controlado y minimizar la contaminaci\u00f3n durante la fabricaci\u00f3n as\u00e9ptica.\n- **Pruebas de Integridad**: M\u00e9todos utilizados para asegurar que los filtros funcionan correctamente y no comprometen la calidad del producto.\n\nEste resumen destaca la importancia de la filtraci\u00f3n y la tecnolog\u00eda de aisladores en la fabricaci\u00f3n as\u00e9ptica, as\u00ed como las mejores pr\u00e1cticas para garantizar la integridad y eficacia de los filtros utilizados en estos procesos.", "excerpt_keywords": "Keywords: air classification, isolators, blow/fill/seal technology, aseptic processing, personnel training"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f646d3cc-07fa-488f-86fe-a33eca9253dc", "node_type": "4", "metadata": {"page_label": "242", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 8.3 \nThe air classification required for the background environment depends on the design of the isolator and its application. It should be controlled, and for aseptic processing it should be at least grade D.\n\n8.4 \nIsolators should be introduced only after appropriate validation. Validation should take into account all critical factors of isolator technology, for example, the quality of the air inside and outside (background) the isolator, sanitization of the isolator, the transfer process and isolator integrity.\n\n8.5 \nMonitoring should be done routinely and should include frequent leak testing of the isolator and the glove/sleeve system.\n\n# 9. Blow/fill/seal technology\n\n9.1 \nBlow/fill/seal units are purpose-built machines in which, in one continuous operation, containers are formed from a thermoplastic granulate, filled and then sealed, all by the one automatic machine. Blow/fill/seal equipment used for aseptic production which is fitted with an effective grade A air shower may be installed in at least a grade C environment, provided that grade A or B clothing is used. The environment should comply with the viable and non-viable limits at rest and the viable limit only when in operation. Blow/fill/seal equipment used for the production of products which are terminally sterilized should be installed in at least a grade D environment.\n\n9.2 \nBecause of this special technology, particular attention should be paid to at least the following:\n\n- equipment design and qualification;\n- validation and reproducibility of cleaning-in-place and sterilization-in-place;\n- background clean room environment in which the equipment is located;\n- operator training and clothing; and\n- interventions in the critical zone of the equipment including any aseptic assembly prior to the commencement of filling.\n\n# 10. Personnel\n\n10.1 \nOnly the minimum number of personnel required should be present in clean areas; this is particularly important during aseptic processes. As far as possible, inspections and controls should be conducted from outside such areas.\n\n10.2 \nAll personnel (including those concerned with cleaning and maintenance) employed in such areas should receive initial and regular training in disciplines relevant to the correct manufacture of sterile products, including hygiene and the basic elements of microbiology. When outside", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "908f9a9a678a5fb16855b47c11fccc17d7f6f4a7915e80cae6488187105826b7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 8.3 \nThe air classification required for the background environment depends on the design of the isolator and its application. It should be controlled, and for aseptic processing it should be at least grade D.\n\n8.4 \nIsolators should be introduced only after appropriate validation. Validation should take into account all critical factors of isolator technology, for example, the quality of the air inside and outside (background) the isolator, sanitization of the isolator, the transfer process and isolator integrity.\n\n8.5 \nMonitoring should be done routinely and should include frequent leak testing of the isolator and the glove/sleeve system.\n\n# 9. Blow/fill/seal technology\n\n9.1 \nBlow/fill/seal units are purpose-built machines in which, in one continuous operation, containers are formed from a thermoplastic granulate, filled and then sealed, all by the one automatic machine. Blow/fill/seal equipment used for aseptic production which is fitted with an effective grade A air shower may be installed in at least a grade C environment, provided that grade A or B clothing is used. The environment should comply with the viable and non-viable limits at rest and the viable limit only when in operation. Blow/fill/seal equipment used for the production of products which are terminally sterilized should be installed in at least a grade D environment.\n\n9.2 \nBecause of this special technology, particular attention should be paid to at least the following:\n\n- equipment design and qualification;\n- validation and reproducibility of cleaning-in-place and sterilization-in-place;\n- background clean room environment in which the equipment is located;\n- operator training and clothing; and\n- interventions in the critical zone of the equipment including any aseptic assembly prior to the commencement of filling.\n\n# 10. Personnel\n\n10.1 \nOnly the minimum number of personnel required should be present in clean areas; this is particularly important during aseptic processes. As far as possible, inspections and controls should be conducted from outside such areas.\n\n10.2 \nAll personnel (including those concerned with cleaning and maintenance) employed in such areas should receive initial and regular training in disciplines relevant to the correct manufacture of sterile products, including hygiene and the basic elements of microbiology. When outside", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2356, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c35651ec-7c98-4e2c-829f-9c60234c8268": {"__data__": {"id_": "c35651ec-7c98-4e2c-829f-9c60234c8268", "embedding": null, "metadata": {"page_label": "243", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "staff who have not received such training (e.g. building or maintenance contractors) need to be brought in, particular care should be taken over their instruction and supervision.\n\n10.3 Staff who have been engaged in the processing of animal-tissue materials or of cultures of microorganisms other than those used in the current manufacturing process should not enter sterile-product areas unless rigorous and clearly defined decontamination procedures have been followed.\n\n10.4 High standards of personal hygiene and cleanliness are essential and personnel involved in the manufacture of sterile preparations should be instructed to report any conditions that may cause the shedding of abnormal numbers or types of contaminants; periodic health checks for such conditions are desirable. The action to be taken in respect of personnel who might be introducing undue microbial hazards should be decided by a designated competent person.\n\n10.5 Changing and washing should follow a written procedure designed to minimize the contamination of clean-area clothing or the carry-through of contaminants to clean areas. The clothing and its quality should be appropriate for the process and the grade of the working area. It should be worn in such a way as to protect the product from contamination.\n\n10.6 Outdoor clothing should not be brought into changing rooms leading to grade B and C rooms. For every worker in a grade A/B area, clean sterile (sterilized or adequately sanitized) protective garments should be provided at each work session. Gloves should be regularly disinfected during operations. Masks and gloves should be changed at least every working session. Operators working in grade A and B areas should wear sanitized goggles.\n\n10.7 Wrist-watches, cosmetics and jewellery should not be worn in clean areas.\n\n10.8 The clothing required for each grade is as follows:\n\n- **Grade D.** The hair and, where relevant, beard and moustache should be covered. Protective clothing and appropriate shoes or overshoes should be worn. Appropriate measures should be taken to avoid any contamination from outside the clean area.\n\n- **Grade C.** The hair and, where relevant, beard and moustache should be covered. A one-piece jumpsuit, gathered at the wrists and with a high neck, and appropriate shoes or overshoes should be worn. The clothing should shed virtually no fibres or particulate matter.\n\n- **Grades A and B.** Entry of personnel into grade A areas should be minimized. Headgear should totally enclose the hair and, where relevant, beard and moustache. A one-piece jumpsuit, gathered at the wrists and ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl texto proporciona directrices sobre las normas de higiene y vestimenta para el personal que trabaja en \u00e1reas de productos est\u00e9riles, seg\u00fan diferentes grados de limpieza (D, C, A y B). Se enfatiza la importancia de la capacitaci\u00f3n del personal, la desinfecci\u00f3n de ropa y equipo, y la prohibici\u00f3n de ciertos objetos personales en \u00e1reas limpias. Tambi\u00e9n se menciona la necesidad de procedimientos de descontaminaci\u00f3n para el personal que ha trabajado con materiales de tejido animal o microorganismos.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 procedimientos de descontaminaci\u00f3n deben seguir los empleados que han trabajado con materiales de tejido animal antes de ingresar a \u00e1reas de productos est\u00e9riles?**\n   - La respuesta se encuentra en la secci\u00f3n 10.3, que menciona que el personal debe seguir procedimientos de descontaminaci\u00f3n rigurosos y claramente definidos.\n\n2. **\u00bfCu\u00e1les son las medidas espec\u00edficas que deben tomarse para la vestimenta del personal en \u00e1reas de grado A y B?**\n   - Seg\u00fan la secci\u00f3n 10.8, se requiere que el personal use un traje de una sola pieza que cubra completamente el cabello y, si es relevante, la barba y el bigote, y que se minimice la entrada de personal en estas \u00e1reas.\n\n3. **\u00bfQu\u00e9 tipo de controles de salud se recomiendan para el personal involucrado en la fabricaci\u00f3n de preparaciones est\u00e9riles?**\n   - La secci\u00f3n 10.4 sugiere que se deben realizar chequeos de salud peri\u00f3dicos para detectar condiciones que puedan causar la liberaci\u00f3n de contaminantes anormales.\n\n### Resumen de Nivel Superior\nEl documento establece normas estrictas para la higiene y vestimenta del personal en la fabricaci\u00f3n de productos est\u00e9riles, enfatizando la capacitaci\u00f3n adecuada, la desinfecci\u00f3n de ropa y la prohibici\u00f3n de objetos personales que puedan contaminar las \u00e1reas limpias. Se detallan los requisitos espec\u00edficos de vestimenta seg\u00fan el grado de limpieza y se subraya la importancia de la salud del personal para prevenir la introducci\u00f3n de contaminantes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Clasificaci\u00f3n del Aire y Aisladores**:\n   - **Clasificaci\u00f3n del aire**: Debe ser al menos de grado D para procesos as\u00e9pticos.\n   - **Validaci\u00f3n de aisladores**: Implica considerar la calidad del aire, la sanitizaci\u00f3n, el proceso de transferencia y la integridad del aislador.\n   - **Monitoreo**: Se debe realizar de manera rutinaria, incluyendo pruebas de fugas.\n\n2. **Tecnolog\u00eda Blow/fill/seal**:\n   - **Definici\u00f3n**: M\u00e1quinas autom\u00e1ticas que forman, llenan y sellan contenedores en un solo proceso.\n   - **Requisitos ambientales**: Deben estar en un entorno de al menos grado C con ropa de grado A o B, cumpliendo con l\u00edmites viables y no viables.\n   - **Atenci\u00f3n especial**: Dise\u00f1o y calificaci\u00f3n del equipo, validaci\u00f3n de limpieza y esterilizaci\u00f3n, entorno de sala limpia, capacitaci\u00f3n del operador e intervenciones en la zona cr\u00edtica.\n\n3. **Personal en \u00c1reas Limpias**:\n   - **Limitaci\u00f3n de personal**: Solo el n\u00famero m\u00ednimo necesario debe estar presente durante procesos as\u00e9pticos.\n   - **Capacitaci\u00f3n**: Todo el personal debe recibir formaci\u00f3n inicial y regular en fabricaci\u00f3n de productos est\u00e9riles, higiene y microbiolog\u00eda.\n\n### Entidades Clave:\n- **Aisladores**: Equipos utilizados en procesos as\u00e9pticos.\n- **Tecnolog\u00eda Blow/fill/seal**: M\u00e9todo de producci\u00f3n automatizado para envases.\n- **Grados de ambiente**: Clasificaciones que determinan la calidad del aire en \u00e1reas de producci\u00f3n (Grado A, B, C, D).\n- **Personal**: Empleados que trabajan en \u00e1reas limpias, incluyendo limpieza y mantenimiento. \n\nEste resumen destaca la importancia de la clasificaci\u00f3n del aire, la validaci\u00f3n de equipos, el entorno de producci\u00f3n y la capacitaci\u00f3n del personal en la fabricaci\u00f3n de productos est\u00e9riles.", "excerpt_keywords": "Keywords: sterile preparations, personal hygiene, decontamination procedures, clean areas, protective clothing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b1aad2e0-b19c-48e3-8761-93edc53777ef", "node_type": "4", "metadata": {"page_label": "243", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "staff who have not received such training (e.g. building or maintenance contractors) need to be brought in, particular care should be taken over their instruction and supervision.\n\n10.3 Staff who have been engaged in the processing of animal-tissue materials or of cultures of microorganisms other than those used in the current manufacturing process should not enter sterile-product areas unless rigorous and clearly defined decontamination procedures have been followed.\n\n10.4 High standards of personal hygiene and cleanliness are essential and personnel involved in the manufacture of sterile preparations should be instructed to report any conditions that may cause the shedding of abnormal numbers or types of contaminants; periodic health checks for such conditions are desirable. The action to be taken in respect of personnel who might be introducing undue microbial hazards should be decided by a designated competent person.\n\n10.5 Changing and washing should follow a written procedure designed to minimize the contamination of clean-area clothing or the carry-through of contaminants to clean areas. The clothing and its quality should be appropriate for the process and the grade of the working area. It should be worn in such a way as to protect the product from contamination.\n\n10.6 Outdoor clothing should not be brought into changing rooms leading to grade B and C rooms. For every worker in a grade A/B area, clean sterile (sterilized or adequately sanitized) protective garments should be provided at each work session. Gloves should be regularly disinfected during operations. Masks and gloves should be changed at least every working session. Operators working in grade A and B areas should wear sanitized goggles.\n\n10.7 Wrist-watches, cosmetics and jewellery should not be worn in clean areas.\n\n10.8 The clothing required for each grade is as follows:\n\n- **Grade D.** The hair and, where relevant, beard and moustache should be covered. Protective clothing and appropriate shoes or overshoes should be worn. Appropriate measures should be taken to avoid any contamination from outside the clean area.\n\n- **Grade C.** The hair and, where relevant, beard and moustache should be covered. A one-piece jumpsuit, gathered at the wrists and with a high neck, and appropriate shoes or overshoes should be worn. The clothing should shed virtually no fibres or particulate matter.\n\n- **Grades A and B.** Entry of personnel into grade A areas should be minimized. Headgear should totally enclose the hair and, where relevant, beard and moustache. A one-piece jumpsuit, gathered at the wrists and ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a6ebc1d1e3b5cdc82ad194f6173eb97e1de7bc0700970cfff7fb1a2bd8cd2e8d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "staff who have not received such training (e.g. building or maintenance contractors) need to be brought in, particular care should be taken over their instruction and supervision.\n\n10.3 Staff who have been engaged in the processing of animal-tissue materials or of cultures of microorganisms other than those used in the current manufacturing process should not enter sterile-product areas unless rigorous and clearly defined decontamination procedures have been followed.\n\n10.4 High standards of personal hygiene and cleanliness are essential and personnel involved in the manufacture of sterile preparations should be instructed to report any conditions that may cause the shedding of abnormal numbers or types of contaminants; periodic health checks for such conditions are desirable. The action to be taken in respect of personnel who might be introducing undue microbial hazards should be decided by a designated competent person.\n\n10.5 Changing and washing should follow a written procedure designed to minimize the contamination of clean-area clothing or the carry-through of contaminants to clean areas. The clothing and its quality should be appropriate for the process and the grade of the working area. It should be worn in such a way as to protect the product from contamination.\n\n10.6 Outdoor clothing should not be brought into changing rooms leading to grade B and C rooms. For every worker in a grade A/B area, clean sterile (sterilized or adequately sanitized) protective garments should be provided at each work session. Gloves should be regularly disinfected during operations. Masks and gloves should be changed at least every working session. Operators working in grade A and B areas should wear sanitized goggles.\n\n10.7 Wrist-watches, cosmetics and jewellery should not be worn in clean areas.\n\n10.8 The clothing required for each grade is as follows:\n\n- **Grade D.** The hair and, where relevant, beard and moustache should be covered. Protective clothing and appropriate shoes or overshoes should be worn. Appropriate measures should be taken to avoid any contamination from outside the clean area.\n\n- **Grade C.** The hair and, where relevant, beard and moustache should be covered. A one-piece jumpsuit, gathered at the wrists and with a high neck, and appropriate shoes or overshoes should be worn. The clothing should shed virtually no fibres or particulate matter.\n\n- **Grades A and B.** Entry of personnel into grade A areas should be minimized. Headgear should totally enclose the hair and, where relevant, beard and moustache. A one-piece jumpsuit, gathered at the wrists and", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2607, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ef57c94b-381e-44e9-8d86-ef74661e97be": {"__data__": {"id_": "ef57c94b-381e-44e9-8d86-ef74661e97be", "embedding": null, "metadata": {"page_label": "244", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Premises\n\n11.1 All premises should as far as possible be designed to avoid the unnecessary entry of supervisory or control personnel. Grade A and B areas should be designed so that all operations can be observed from outside.\n\n11.2 In clean areas all exposed surfaces should be smooth, impervious and unbroken to minimize the shedding or accumulation of particles or microorganisms and to permit the repeated application of cleaning agents and disinfectants, where used.\n\n11.3 To reduce the accumulation of dust and to facilitate cleaning, there should be no uncleanable recesses and a minimum of projecting ledges, shelves, cupboards and equipment. Doors should be carefully designed to avoid uncleanable recesses; sliding doors may be undesirable for this reason. Swing doors should open to the high-pressure side and be provided with self-closers. Exceptions are permitted based on egress and site environmental, health and safety containment requirements.\n\n11.4 False ceilings should be sealed to prevent contamination from the void space above them.\n\n11.5 Pipes and ducts and other utilities should be installed so that they do not create recesses, unsealed openings and surfaces that are difficult to clean. Sanitary pipes and fittings should be used and threaded pipe connections should be avoided.\n\n11.6 Sinks and drains should be avoided wherever possible and should be excluded from grade A and B areas where aseptic operations are carried out. Where installed they should be designed, located and maintained so as to minimize the risks of microbial contamination; they should be fitted with", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proviene del \"Informe T\u00e9cnico de la OMS 957\" y se centra en las directrices para el dise\u00f1o y mantenimiento de instalaciones limpias, espec\u00edficamente en \u00e1reas clasificadas como Grado A y B. Se enfatiza la importancia de minimizar la entrada de personal no esencial, el dise\u00f1o de superficies para facilitar la limpieza y la prevenci\u00f3n de la contaminaci\u00f3n microbiana. Se abordan aspectos como la construcci\u00f3n de techos falsos, la instalaci\u00f3n de tuber\u00edas y desag\u00fces, y la necesidad de evitar recovecos que dificulten la limpieza.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que deben tener las superficies expuestas en \u00e1reas limpias para minimizar la acumulaci\u00f3n de part\u00edculas y microorganismos?**\n   - Respuesta: Las superficies expuestas en \u00e1reas limpias deben ser lisas, impermeables y sin interrupciones para minimizar la acumulaci\u00f3n de part\u00edculas y microorganismos, y permitir la aplicaci\u00f3n repetida de agentes de limpieza y desinfectantes.\n\n2. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al dise\u00f1ar puertas en \u00e1reas limpias para evitar la acumulaci\u00f3n de polvo y facilitar la limpieza?**\n   - Respuesta: Las puertas deben ser dise\u00f1adas para evitar recovecos no limpiables, preferiblemente deben ser puertas de oscilaci\u00f3n que abran hacia el lado de alta presi\u00f3n y deben estar equipadas con mecanismos de cierre autom\u00e1tico. Las puertas deslizantes pueden ser indeseables por esta raz\u00f3n.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar en relaci\u00f3n con los desag\u00fces y fregaderos en \u00e1reas de Grado A y B donde se realizan operaciones as\u00e9pticas?**\n   - Respuesta: Los fregaderos y desag\u00fces deben evitarse siempre que sea posible en \u00e1reas de Grado A y B. Si se instalan, deben ser dise\u00f1ados, ubicados y mantenidos de tal manera que minimicen los riesgos de contaminaci\u00f3n microbiana.", "prev_section_summary": "### Temas Clave\n\n1. **Capacitaci\u00f3n del Personal**: Se enfatiza la necesidad de que el personal reciba capacitaci\u00f3n adecuada, especialmente aquellos que no han sido entrenados, como contratistas de mantenimiento.\n\n2. **Procedimientos de Descontaminaci\u00f3n**: El personal que ha trabajado con materiales de tejido animal o microorganismos debe seguir procedimientos de descontaminaci\u00f3n rigurosos antes de ingresar a \u00e1reas de productos est\u00e9riles.\n\n3. **Higiene Personal**: Se requiere que el personal mantenga altos est\u00e1ndares de higiene y limpieza, reportando cualquier condici\u00f3n que pueda causar la liberaci\u00f3n de contaminantes.\n\n4. **Controles de Salud**: Se sugieren chequeos de salud peri\u00f3dicos para detectar condiciones que puedan introducir contaminantes.\n\n5. **Procedimientos de Cambio y Lavado**: Deben seguirse procedimientos escritos para minimizar la contaminaci\u00f3n de la ropa en \u00e1reas limpias.\n\n6. **Vestimenta Espec\u00edfica por Grado**: Se detallan los requisitos de vestimenta seg\u00fan el grado de limpieza (D, C, A y B), incluyendo el uso de trajes de una sola pieza y la prohibici\u00f3n de ropa exterior en \u00e1reas cr\u00edticas.\n\n7. **Prohibiciones en \u00c1reas Limpias**: Se proh\u00edbe el uso de relojes, cosm\u00e9ticos y joyer\u00eda en \u00e1reas limpias para evitar la contaminaci\u00f3n.\n\n### Entidades\n\n- **Grados de Limpieza**: D, C, A y B.\n- **Personal**: Empleados involucrados en la fabricaci\u00f3n de preparaciones est\u00e9riles, contratistas de mantenimiento.\n- **Contaminantes**: Materiales de tejido animal, microorganismos, contaminantes anormales.\n- **Equipamiento**: Ropa protectora, guantes, mascarillas, gafas sanitizadas.\n- **Procedimientos**: Descontaminaci\u00f3n, higiene personal, cambio y lavado de ropa.\n\nEste resumen destaca la importancia de la capacitaci\u00f3n, la higiene y el cumplimiento de normas espec\u00edficas para garantizar la seguridad y la calidad en la fabricaci\u00f3n de productos est\u00e9riles.", "excerpt_keywords": "Keywords: clean areas, microbial contamination, aseptic operations, facility design, hygiene standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0fa4b35b-e261-4123-a960-feb4da553cab", "node_type": "4", "metadata": {"page_label": "244", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Premises\n\n11.1 All premises should as far as possible be designed to avoid the unnecessary entry of supervisory or control personnel. Grade A and B areas should be designed so that all operations can be observed from outside.\n\n11.2 In clean areas all exposed surfaces should be smooth, impervious and unbroken to minimize the shedding or accumulation of particles or microorganisms and to permit the repeated application of cleaning agents and disinfectants, where used.\n\n11.3 To reduce the accumulation of dust and to facilitate cleaning, there should be no uncleanable recesses and a minimum of projecting ledges, shelves, cupboards and equipment. Doors should be carefully designed to avoid uncleanable recesses; sliding doors may be undesirable for this reason. Swing doors should open to the high-pressure side and be provided with self-closers. Exceptions are permitted based on egress and site environmental, health and safety containment requirements.\n\n11.4 False ceilings should be sealed to prevent contamination from the void space above them.\n\n11.5 Pipes and ducts and other utilities should be installed so that they do not create recesses, unsealed openings and surfaces that are difficult to clean. Sanitary pipes and fittings should be used and threaded pipe connections should be avoided.\n\n11.6 Sinks and drains should be avoided wherever possible and should be excluded from grade A and B areas where aseptic operations are carried out. Where installed they should be designed, located and maintained so as to minimize the risks of microbial contamination; they should be fitted with", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "8951c8d742437403718e14010c3ed763fafe43079add890fbd925627f9429de5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Premises\n\n11.1 All premises should as far as possible be designed to avoid the unnecessary entry of supervisory or control personnel. Grade A and B areas should be designed so that all operations can be observed from outside.\n\n11.2 In clean areas all exposed surfaces should be smooth, impervious and unbroken to minimize the shedding or accumulation of particles or microorganisms and to permit the repeated application of cleaning agents and disinfectants, where used.\n\n11.3 To reduce the accumulation of dust and to facilitate cleaning, there should be no uncleanable recesses and a minimum of projecting ledges, shelves, cupboards and equipment. Doors should be carefully designed to avoid uncleanable recesses; sliding doors may be undesirable for this reason. Swing doors should open to the high-pressure side and be provided with self-closers. Exceptions are permitted based on egress and site environmental, health and safety containment requirements.\n\n11.4 False ceilings should be sealed to prevent contamination from the void space above them.\n\n11.5 Pipes and ducts and other utilities should be installed so that they do not create recesses, unsealed openings and surfaces that are difficult to clean. Sanitary pipes and fittings should be used and threaded pipe connections should be avoided.\n\n11.6 Sinks and drains should be avoided wherever possible and should be excluded from grade A and B areas where aseptic operations are carried out. Where installed they should be designed, located and maintained so as to minimize the risks of microbial contamination; they should be fitted with", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1603, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "06cb7ed4-7c2d-42d5-a9fe-9e77c0ca46ee": {"__data__": {"id_": "06cb7ed4-7c2d-42d5-a9fe-9e77c0ca46ee", "embedding": null, "metadata": {"page_label": "245", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "effective, easily cleanable traps and with air breaks to prevent backflow. Any floor channels should be open and easily cleanable and be connected to drains outside the area in a manner that prevents the ingress of microbial contaminants.\n\n11.7 Changing rooms should be designed as airlocks and used to provide physical separation of the different stages of changing and so minimize microbial and particulate contamination of protective clothing. They should be flushed effectively with filtered air. The final stage of the changing room should, in the at-rest state, be the same grade as the area into which it leads. The use of separate changing rooms for entering and leaving clean areas is sometimes desirable. In general hand-washing facilities should be provided only in the first stage of the changing rooms.\n\nThere should not be a change of more than one grade between airlocks or passages and changing rooms, i.e. a grade D passage can lead to a grade C airlock, which leads to a grade B changing room, which leads to a grade B clean room. Changing rooms should of a sufficient size to allow for ease of changing. Changing rooms should be equipped with mirrors so that personnel can confirm the correct fit of garments before leaving the changing room.\n\n11.8 Airlock doors should not be opened simultaneously. An interlocking system and a visual and/or audible warning system should be operated to prevent the opening of more than one door at a time.\n\n11.9 A filtered air supply should be used to maintain a positive pressure and an airflow relative to surrounding areas of a lower grade under all operational conditions; it should flush the area effectively. Adjacent rooms of different grades should have a pressure differential of approximately 10\u201315 Pascals (guidance value). Particular attention should be paid to the protection of the zone of greatest risk, i.e. the immediate environment to which the product and the cleaned components in contact with it are exposed. The recommendations regarding air supplies and pressure differentials may need to be modified where it becomes necessary to contain certain materials, e.g. pathogenic, highly toxic, radioactive or live viral or bacterial materials or products. The decontamination of the facilities and the treatment of air leaving a clean area may be necessary for some operations.\n\n11.10 It should be demonstrated that airflow patterns do not present a contamination risk; for example, care should be taken to ensure that particles from a particle-generating person, operation or machine are not conveyed to a zone of higher product risk.\n\n11.11 A warning system should be operated to indicate failure in the air supply. Indicators of pressure differentials should be fitted between areas.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proviene del Informe T\u00e9cnico de la OMS (WHO - Technical Report Series 957) y se centra en las recomendaciones para el dise\u00f1o y funcionamiento de \u00e1reas limpias, espec\u00edficamente en lo que respecta a los vestuarios y sistemas de aire. Se enfatiza la importancia de mantener la separaci\u00f3n f\u00edsica entre diferentes etapas de cambio de ropa para minimizar la contaminaci\u00f3n microbiana y particulada. Se describen las caracter\u00edsticas de los vestuarios, la necesidad de un suministro de aire filtrado, la presi\u00f3n diferencial entre \u00e1reas de diferentes grados, y la implementaci\u00f3n de sistemas de advertencia para fallos en el suministro de aire.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que deben tener los vestuarios para minimizar la contaminaci\u00f3n en \u00e1reas limpias?**\n   - Esta pregunta busca detalles sobre el dise\u00f1o y las especificaciones de los vestuarios que no se encuentran f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que las puertas de los vestuarios no se abran simult\u00e1neamente y por qu\u00e9 es importante esto?**\n   - Esta pregunta se centra en el sistema de interlocking y su importancia en la prevenci\u00f3n de la contaminaci\u00f3n, un aspecto que puede no ser ampliamente discutido en otros documentos.\n\n3. **\u00bfC\u00f3mo se debe manejar el suministro de aire en \u00e1reas limpias para mantener la presi\u00f3n positiva y qu\u00e9 consideraciones especiales se deben tener en cuenta para materiales peligrosos?**\n   - Esta pregunta busca informaci\u00f3n sobre el manejo del aire en \u00e1reas limpias, especialmente en relaci\u00f3n con materiales que requieren un manejo especial, lo cual puede no estar presente en otras gu\u00edas generales. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y t\u00e9cnica que se detalla en el contexto proporcionado, y que podr\u00eda no estar disponible en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Dise\u00f1o de Instalaciones Limpias**:\n   - Las instalaciones deben evitar la entrada innecesaria de personal no esencial.\n   - Las \u00e1reas de Grado A y B deben permitir la observaci\u00f3n de todas las operaciones desde el exterior.\n\n2. **Superficies Expuestas**:\n   - Deben ser lisas, impermeables y sin interrupciones para minimizar la acumulaci\u00f3n de part\u00edculas y microorganismos.\n   - Se debe permitir la aplicaci\u00f3n repetida de agentes de limpieza y desinfectantes.\n\n3. **Dise\u00f1o de Puertas**:\n   - Las puertas deben evitar recovecos no limpiables.\n   - Preferiblemente, deben ser puertas de oscilaci\u00f3n que abran hacia el lado de alta presi\u00f3n y contar con mecanismos de cierre autom\u00e1tico.\n   - Las puertas deslizantes son indeseables por su dise\u00f1o.\n\n4. **Techos Falsos**:\n   - Deben estar sellados para prevenir la contaminaci\u00f3n desde el espacio vac\u00edo superior.\n\n5. **Instalaci\u00f3n de Tuber\u00edas y Ductos**:\n   - Deben evitar la creaci\u00f3n de recovecos, aberturas no selladas y superficies dif\u00edciles de limpiar.\n   - Se deben utilizar tuber\u00edas y accesorios sanitarios, evitando conexiones de tuber\u00edas roscadas.\n\n6. **Desag\u00fces y Fregaderos**:\n   - Deben evitarse en \u00e1reas de Grado A y B donde se realizan operaciones as\u00e9pticas.\n   - Si se instalan, deben ser dise\u00f1ados y mantenidos para minimizar el riesgo de contaminaci\u00f3n microbiana.\n\n### Entidades Clave\n- **Grado A y B**: Clasificaci\u00f3n de \u00e1reas limpias.\n- **Personal Supervisorio**: Personal que no debe ingresar innecesariamente a las \u00e1reas limpias.\n- **Agentes de Limpieza y Desinfectantes**: Sustancias utilizadas para mantener la limpieza y la asepsia.\n- **Contaminaci\u00f3n Microbiana**: Riesgo que se busca minimizar en el dise\u00f1o de las instalaciones.", "excerpt_keywords": "Keywords: \u00e1reas limpias, vestuarios, presi\u00f3n positiva, contaminaci\u00f3n microbiana, sistemas de advertencia"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "07ec0554-fb64-4158-b2f6-786622d47c5c", "node_type": "4", "metadata": {"page_label": "245", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "effective, easily cleanable traps and with air breaks to prevent backflow. Any floor channels should be open and easily cleanable and be connected to drains outside the area in a manner that prevents the ingress of microbial contaminants.\n\n11.7 Changing rooms should be designed as airlocks and used to provide physical separation of the different stages of changing and so minimize microbial and particulate contamination of protective clothing. They should be flushed effectively with filtered air. The final stage of the changing room should, in the at-rest state, be the same grade as the area into which it leads. The use of separate changing rooms for entering and leaving clean areas is sometimes desirable. In general hand-washing facilities should be provided only in the first stage of the changing rooms.\n\nThere should not be a change of more than one grade between airlocks or passages and changing rooms, i.e. a grade D passage can lead to a grade C airlock, which leads to a grade B changing room, which leads to a grade B clean room. Changing rooms should of a sufficient size to allow for ease of changing. Changing rooms should be equipped with mirrors so that personnel can confirm the correct fit of garments before leaving the changing room.\n\n11.8 Airlock doors should not be opened simultaneously. An interlocking system and a visual and/or audible warning system should be operated to prevent the opening of more than one door at a time.\n\n11.9 A filtered air supply should be used to maintain a positive pressure and an airflow relative to surrounding areas of a lower grade under all operational conditions; it should flush the area effectively. Adjacent rooms of different grades should have a pressure differential of approximately 10\u201315 Pascals (guidance value). Particular attention should be paid to the protection of the zone of greatest risk, i.e. the immediate environment to which the product and the cleaned components in contact with it are exposed. The recommendations regarding air supplies and pressure differentials may need to be modified where it becomes necessary to contain certain materials, e.g. pathogenic, highly toxic, radioactive or live viral or bacterial materials or products. The decontamination of the facilities and the treatment of air leaving a clean area may be necessary for some operations.\n\n11.10 It should be demonstrated that airflow patterns do not present a contamination risk; for example, care should be taken to ensure that particles from a particle-generating person, operation or machine are not conveyed to a zone of higher product risk.\n\n11.11 A warning system should be operated to indicate failure in the air supply. Indicators of pressure differentials should be fitted between areas.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "8669d31b25e1a3dfdf0679a4e0e3e2ba56f36205ea35ad2c64cc86cde35b6fa3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "effective, easily cleanable traps and with air breaks to prevent backflow. Any floor channels should be open and easily cleanable and be connected to drains outside the area in a manner that prevents the ingress of microbial contaminants.\n\n11.7 Changing rooms should be designed as airlocks and used to provide physical separation of the different stages of changing and so minimize microbial and particulate contamination of protective clothing. They should be flushed effectively with filtered air. The final stage of the changing room should, in the at-rest state, be the same grade as the area into which it leads. The use of separate changing rooms for entering and leaving clean areas is sometimes desirable. In general hand-washing facilities should be provided only in the first stage of the changing rooms.\n\nThere should not be a change of more than one grade between airlocks or passages and changing rooms, i.e. a grade D passage can lead to a grade C airlock, which leads to a grade B changing room, which leads to a grade B clean room. Changing rooms should of a sufficient size to allow for ease of changing. Changing rooms should be equipped with mirrors so that personnel can confirm the correct fit of garments before leaving the changing room.\n\n11.8 Airlock doors should not be opened simultaneously. An interlocking system and a visual and/or audible warning system should be operated to prevent the opening of more than one door at a time.\n\n11.9 A filtered air supply should be used to maintain a positive pressure and an airflow relative to surrounding areas of a lower grade under all operational conditions; it should flush the area effectively. Adjacent rooms of different grades should have a pressure differential of approximately 10\u201315 Pascals (guidance value). Particular attention should be paid to the protection of the zone of greatest risk, i.e. the immediate environment to which the product and the cleaned components in contact with it are exposed. The recommendations regarding air supplies and pressure differentials may need to be modified where it becomes necessary to contain certain materials, e.g. pathogenic, highly toxic, radioactive or live viral or bacterial materials or products. The decontamination of the facilities and the treatment of air leaving a clean area may be necessary for some operations.\n\n11.10 It should be demonstrated that airflow patterns do not present a contamination risk; for example, care should be taken to ensure that particles from a particle-generating person, operation or machine are not conveyed to a zone of higher product risk.\n\n11.11 A warning system should be operated to indicate failure in the air supply. Indicators of pressure differentials should be fitted between areas.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2758, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "44709eda-106f-4441-9477-34dd8e8ffdda": {"__data__": {"id_": "44709eda-106f-4441-9477-34dd8e8ffdda", "embedding": null, "metadata": {"page_label": "246", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Equipment\n\n12.1 A conveyor belt should not pass through a partition between a grade A or B clean area and a processing area of lower air cleanliness, unless the belt itself is continuously sterilized (e.g. in a sterilizing tunnel).\n\n12.2 Whenever possible, equipment used for processing sterile products should be chosen so that it can be effectively sterilized by steam or dry heat or other methods.\n\n12.3 As far as possible, equipment fittings and services should be designed and installed so that operations, maintenance and repairs can be carried out outside the clean area. Equipment that has to be taken apart for maintenance should be re-sterilized after complete reassembly, wherever possible.\n\n12.4 When equipment maintenance is carried out within a clean area, clean instruments and tools should be used and the area should be cleaned and disinfected again, where appropriate, before processing recommences, if the required standards of cleanliness and/or asepsis have not been maintained during the maintenance work.\n\n12.5 All equipment such as sterilizers, air-handling and filtration systems, air vent and gas filters, water treatment, generation, storage and distribution systems should be subject to validation and planned maintenance; their return to use should be approved.\n\n12.6 Water-treatment plants and distribution systems should be designed, constructed and maintained so as to ensure a reliable source of water of an appropriate quality. They should not be operated beyond their designed capacity. Consideration should be given to including a testing programme in the maintenance of a water system. Water for injection should be produced, stored and distributed in a manner which prevents the growth of microorganisms, e.g. by constant circulation at a temperature above 70\u00b0C or not more than 4\u00b0C (10).\n\n# Finishing of sterile products\n\n13.1 Containers should be closed by appropriately validated methods. Containers closed by fusion, e.g. glass or plastic ampoules, should be subject to 100% integrity testing. Samples of other containers should be checked for integrity according to appropriate procedures.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen de nivel superior del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las directrices sobre el equipo utilizado en la producci\u00f3n de productos est\u00e9riles. Se enfatiza la importancia de mantener la limpieza y la esterilidad en las \u00e1reas de procesamiento, as\u00ed como la necesidad de validar y mantener el equipo utilizado. Tambi\u00e9n se menciona la gesti\u00f3n del agua para inyecci\u00f3n, asegurando que se produzca y distribuya de manera que se evite el crecimiento de microorganismos. Adem\u00e1s, se establecen procedimientos para el cierre de contenedores de productos est\u00e9riles, destacando la necesidad de pruebas de integridad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 m\u00e9todos se recomiendan para la esterilizaci\u00f3n continua de una cinta transportadora que atraviesa una partici\u00f3n entre \u00e1reas de limpieza de diferentes grados?**\n   - Respuesta: La cinta transportadora debe ser continuamente esterilizada, por ejemplo, en un t\u00fanel de esterilizaci\u00f3n.\n\n2. **\u00bfCu\u00e1les son las consideraciones clave para el dise\u00f1o y mantenimiento de plantas de tratamiento de agua utilizadas en la producci\u00f3n de productos est\u00e9riles?**\n   - Respuesta: Las plantas de tratamiento de agua deben ser dise\u00f1adas, construidas y mantenidas para asegurar una fuente confiable de agua de calidad apropiada, no deben operar m\u00e1s all\u00e1 de su capacidad dise\u00f1ada, y se debe considerar un programa de pruebas en el mantenimiento del sistema de agua.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse para garantizar la integridad de los contenedores cerrados por fusi\u00f3n, como ampollas de vidrio o pl\u00e1stico?**\n   - Respuesta: Los contenedores cerrados por fusi\u00f3n deben someterse a pruebas de integridad al 100%, y las muestras de otros contenedores deben ser verificadas seg\u00fan procedimientos apropiados.", "prev_section_summary": "### Temas Clave\n\n1. **Dise\u00f1o de Vestuarios**: Los vestuarios deben ser dise\u00f1ados como airlocks para proporcionar separaci\u00f3n f\u00edsica entre las etapas de cambio de ropa, minimizando as\u00ed la contaminaci\u00f3n microbiana y particulada. Deben estar equipados con aire filtrado y ser de un tama\u00f1o adecuado para facilitar el cambio.\n\n2. **Sistemas de Aire**: Es esencial mantener un suministro de aire filtrado para mantener una presi\u00f3n positiva y un flujo de aire adecuado. Se recomienda una diferencia de presi\u00f3n de aproximadamente 10\u201315 Pascals entre \u00e1reas de diferentes grados.\n\n3. **Control de Contaminaci\u00f3n**: Se deben implementar sistemas que eviten la apertura simult\u00e1nea de puertas en los airlocks, utilizando sistemas de interlocking y advertencias visuales o audibles para prevenir la contaminaci\u00f3n cruzada.\n\n4. **Manejo de Materiales Peligrosos**: Las recomendaciones sobre el suministro de aire y las diferencias de presi\u00f3n pueden necesitar ajustes cuando se manejan materiales peligrosos, como pat\u00f3genos o sustancias t\u00f3xicas.\n\n5. **Patrones de Flujo de Aire**: Es crucial demostrar que los patrones de flujo de aire no representan un riesgo de contaminaci\u00f3n, asegurando que las part\u00edculas generadas no se transporten a zonas de mayor riesgo.\n\n6. **Sistemas de Advertencia**: Se deben instalar sistemas de advertencia para indicar fallos en el suministro de aire y para monitorear las diferencias de presi\u00f3n entre \u00e1reas.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las recomendaciones.\n- **Aire Filtrado**: Elemento clave para mantener la calidad del aire en \u00e1reas limpias.\n- **Vestuario/Airlock**: Espacio dise\u00f1ado para minimizar la contaminaci\u00f3n durante el cambio de ropa.\n- **Diferencia de Presi\u00f3n**: Par\u00e1metro cr\u00edtico para el control de la contaminaci\u00f3n entre \u00e1reas de diferentes grados.\n- **Materiales Peligrosos**: Sustancias que requieren manejo especial debido a su toxicidad o riesgo biol\u00f3gico.\n- **Sistema de Interlocking**: Mecanismo para prevenir la apertura simult\u00e1nea de puertas en los vestuarios. \n\nEste resumen abarca los aspectos m\u00e1s relevantes del contenido, destacando tanto los temas centrales como las entidades involucradas en el contexto de las \u00e1reas limpias y su dise\u00f1o.", "excerpt_keywords": "Keywords: sterilization, clean area, equipment maintenance, water treatment, integrity testing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "91809c1e-c2bd-4b92-9116-1282c1e622a8", "node_type": "4", "metadata": {"page_label": "246", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Equipment\n\n12.1 A conveyor belt should not pass through a partition between a grade A or B clean area and a processing area of lower air cleanliness, unless the belt itself is continuously sterilized (e.g. in a sterilizing tunnel).\n\n12.2 Whenever possible, equipment used for processing sterile products should be chosen so that it can be effectively sterilized by steam or dry heat or other methods.\n\n12.3 As far as possible, equipment fittings and services should be designed and installed so that operations, maintenance and repairs can be carried out outside the clean area. Equipment that has to be taken apart for maintenance should be re-sterilized after complete reassembly, wherever possible.\n\n12.4 When equipment maintenance is carried out within a clean area, clean instruments and tools should be used and the area should be cleaned and disinfected again, where appropriate, before processing recommences, if the required standards of cleanliness and/or asepsis have not been maintained during the maintenance work.\n\n12.5 All equipment such as sterilizers, air-handling and filtration systems, air vent and gas filters, water treatment, generation, storage and distribution systems should be subject to validation and planned maintenance; their return to use should be approved.\n\n12.6 Water-treatment plants and distribution systems should be designed, constructed and maintained so as to ensure a reliable source of water of an appropriate quality. They should not be operated beyond their designed capacity. Consideration should be given to including a testing programme in the maintenance of a water system. Water for injection should be produced, stored and distributed in a manner which prevents the growth of microorganisms, e.g. by constant circulation at a temperature above 70\u00b0C or not more than 4\u00b0C (10).\n\n# Finishing of sterile products\n\n13.1 Containers should be closed by appropriately validated methods. Containers closed by fusion, e.g. glass or plastic ampoules, should be subject to 100% integrity testing. Samples of other containers should be checked for integrity according to appropriate procedures.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "dc82aaf8e7959f32dbcddc46d809cb70b9f6d666037f8d881eb51f200c823366", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Equipment\n\n12.1 A conveyor belt should not pass through a partition between a grade A or B clean area and a processing area of lower air cleanliness, unless the belt itself is continuously sterilized (e.g. in a sterilizing tunnel).\n\n12.2 Whenever possible, equipment used for processing sterile products should be chosen so that it can be effectively sterilized by steam or dry heat or other methods.\n\n12.3 As far as possible, equipment fittings and services should be designed and installed so that operations, maintenance and repairs can be carried out outside the clean area. Equipment that has to be taken apart for maintenance should be re-sterilized after complete reassembly, wherever possible.\n\n12.4 When equipment maintenance is carried out within a clean area, clean instruments and tools should be used and the area should be cleaned and disinfected again, where appropriate, before processing recommences, if the required standards of cleanliness and/or asepsis have not been maintained during the maintenance work.\n\n12.5 All equipment such as sterilizers, air-handling and filtration systems, air vent and gas filters, water treatment, generation, storage and distribution systems should be subject to validation and planned maintenance; their return to use should be approved.\n\n12.6 Water-treatment plants and distribution systems should be designed, constructed and maintained so as to ensure a reliable source of water of an appropriate quality. They should not be operated beyond their designed capacity. Consideration should be given to including a testing programme in the maintenance of a water system. Water for injection should be produced, stored and distributed in a manner which prevents the growth of microorganisms, e.g. by constant circulation at a temperature above 70\u00b0C or not more than 4\u00b0C (10).\n\n# Finishing of sterile products\n\n13.1 Containers should be closed by appropriately validated methods. Containers closed by fusion, e.g. glass or plastic ampoules, should be subject to 100% integrity testing. Samples of other containers should be checked for integrity according to appropriate procedures.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2134, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "12b433c8-61ac-42f8-8bf1-01a026c8b818": {"__data__": {"id_": "12b433c8-61ac-42f8-8bf1-01a026c8b818", "embedding": null, "metadata": {"page_label": "247", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 13.2 \nThe container closure system for aseptically filled vials is not fully integral until the aluminum cap has been crimped into place on the stoppered vial. Crimping of the cap should, therefore, be performed as soon as possible after stopper insertion.\n\n# 13.3 \nAs the equipment used to crimp vial caps can generate large quantities of non-viable particulates, the equipment should be located at a separate station equipped with adequate air extraction.\n\n# 13.4 \nVial capping can be undertaken as an aseptic process using sterilized caps or as a clean process outside the aseptic core. Where this latter approach is adopted, vials should be protected by grade A conditions up to the point of leaving the aseptic processing area, and thereafter stoppered vials should be protected with a grade A air supply until the cap has been crimped.\n\n# 13.5 \nVials with missing or displaced stoppers should be rejected prior to capping. Where human intervention is required at the capping station, appropriate technology should be used to prevent direct contact with the vials and to minimize microbial contamination.\n\n# 13.6 \nRestricted access barriers and isolators may be beneficial in assuring the required conditions and minimizing direct human interventions into the capping operation.\n\n# 13.7 \nContainers sealed under vacuum should be tested for maintenance of that vacuum after an appropriate, predetermined period.\n\n# 13.8 \nFilled containers of parenteral products should be inspected individually for extraneous contamination or other defects. When inspection is carried out visually this should be done under suitable and controlled conditions of illumination and background. Operators doing the inspection should pass regular eyesight checks, using personal corrective lenses (e.g. spectacles or contact lenses) as required, and be allowed frequent breaks from inspection. Where other methods of inspection are used, the process should be validated and the performance of the equipment checked at intervals. Results should be recorded.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Cierre de viales y proceso de capping**: El sistema de cierre de los viales llenos de forma as\u00e9ptica no se considera completo hasta que la tapa de aluminio ha sido crimpada. Este proceso debe realizarse lo m\u00e1s pronto posible despu\u00e9s de insertar el tap\u00f3n, y se deben seguir estrictas medidas de control para evitar la contaminaci\u00f3n.\n\n2. **Control de contaminaci\u00f3n y condiciones de trabajo**: La maquinaria utilizada para crimpado puede generar part\u00edculas no viables, por lo que debe estar ubicada en una estaci\u00f3n separada con adecuada extracci\u00f3n de aire. Adem\u00e1s, se deben implementar barreras de acceso restringido y aisladores para minimizar la intervenci\u00f3n humana.\n\n3. **Inspecci\u00f3n de viales**: Los viales deben ser inspeccionados individualmente para detectar contaminaci\u00f3n o defectos, y esta inspecci\u00f3n debe realizarse bajo condiciones controladas. Los operadores deben tener buena visi\u00f3n y se deben registrar los resultados de las inspecciones.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1l es el procedimiento recomendado para el manejo de viales con tapones faltantes o desplazados antes del proceso de capping?**\n   - Respuesta: Los viales con tapones faltantes o desplazados deben ser rechazados antes de proceder al capping.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que el proceso de capping minimice la contaminaci\u00f3n microbiana cuando se requiere intervenci\u00f3n humana?**\n   - Respuesta: Se debe utilizar tecnolog\u00eda apropiada para prevenir el contacto directo con los viales y minimizar la contaminaci\u00f3n microbiana en el capping.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse para la inspecci\u00f3n visual de los viales llenos de productos parenterales?**\n   - Respuesta: La inspecci\u00f3n visual debe realizarse bajo condiciones adecuadas de iluminaci\u00f3n y fondo, y los operadores deben pasar chequeos regulares de visi\u00f3n, utilizando lentes correctivos si es necesario, adem\u00e1s de permitirles descansos frecuentes.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**Temas clave:**\n\n1. **Esterilizaci\u00f3n de Equipos:**\n   - Importancia de la esterilizaci\u00f3n continua de cintas transportadoras que cruzan particiones entre \u00e1reas de limpieza de diferentes grados.\n   - Preferencia por equipos que puedan ser esterilizados efectivamente mediante m\u00e9todos como vapor o calor seco.\n\n2. **Dise\u00f1o y Mantenimiento de Equipos:**\n   - Equipos deben ser dise\u00f1ados para permitir operaciones y mantenimiento fuera de \u00e1reas limpias.\n   - Re-esterilizaci\u00f3n de equipos despu\u00e9s de mantenimiento, cuando sea posible.\n\n3. **Mantenimiento en \u00c1reas Limpias:**\n   - Uso de instrumentos y herramientas limpias durante el mantenimiento.\n   - Limpieza y desinfecci\u00f3n del \u00e1rea antes de reanudar el procesamiento si no se mantienen los est\u00e1ndares de limpieza.\n\n4. **Validaci\u00f3n y Mantenimiento Planificado:**\n   - Equipos como esterilizadores y sistemas de tratamiento de agua deben ser validados y sometidos a mantenimiento planificado.\n\n5. **Calidad del Agua:**\n   - Plantas de tratamiento de agua deben asegurar una fuente confiable de agua de calidad adecuada.\n   - Prevenci\u00f3n del crecimiento de microorganismos en agua para inyecci\u00f3n mediante circulaci\u00f3n constante a temperaturas espec\u00edficas.\n\n6. **Cierre de Contenedores:**\n   - M\u00e9todos de cierre de contenedores deben ser validados.\n   - Contenedores cerrados por fusi\u00f3n deben someterse a pruebas de integridad al 100%.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite las directrices.\n- **Equipos de Procesamiento:** Incluyen cintas transportadoras, esterilizadores, sistemas de tratamiento de agua, etc.\n- **Contenedores:** Ampollas de vidrio o pl\u00e1stico y otros tipos de envases para productos est\u00e9riles.\n- **M\u00e9todos de Esterilizaci\u00f3n:** Vapor, calor seco, t\u00faneles de esterilizaci\u00f3n.\n- **Agua para Inyecci\u00f3n:** Agua tratada y distribuida para uso en productos est\u00e9riles. \n\nEste resumen destaca la importancia de la esterilidad y el mantenimiento adecuado en la producci\u00f3n de productos est\u00e9riles, as\u00ed como las pr\u00e1cticas recomendadas para garantizar la calidad y seguridad de los procesos involucrados.", "excerpt_keywords": "Keywords: aseptic processing, vial capping, contamination control, inspection procedures, sterile products"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4249ea8c-f6cf-435a-a15f-cb53aaa1898e", "node_type": "4", "metadata": {"page_label": "247", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 13.2 \nThe container closure system for aseptically filled vials is not fully integral until the aluminum cap has been crimped into place on the stoppered vial. Crimping of the cap should, therefore, be performed as soon as possible after stopper insertion.\n\n# 13.3 \nAs the equipment used to crimp vial caps can generate large quantities of non-viable particulates, the equipment should be located at a separate station equipped with adequate air extraction.\n\n# 13.4 \nVial capping can be undertaken as an aseptic process using sterilized caps or as a clean process outside the aseptic core. Where this latter approach is adopted, vials should be protected by grade A conditions up to the point of leaving the aseptic processing area, and thereafter stoppered vials should be protected with a grade A air supply until the cap has been crimped.\n\n# 13.5 \nVials with missing or displaced stoppers should be rejected prior to capping. Where human intervention is required at the capping station, appropriate technology should be used to prevent direct contact with the vials and to minimize microbial contamination.\n\n# 13.6 \nRestricted access barriers and isolators may be beneficial in assuring the required conditions and minimizing direct human interventions into the capping operation.\n\n# 13.7 \nContainers sealed under vacuum should be tested for maintenance of that vacuum after an appropriate, predetermined period.\n\n# 13.8 \nFilled containers of parenteral products should be inspected individually for extraneous contamination or other defects. When inspection is carried out visually this should be done under suitable and controlled conditions of illumination and background. Operators doing the inspection should pass regular eyesight checks, using personal corrective lenses (e.g. spectacles or contact lenses) as required, and be allowed frequent breaks from inspection. Where other methods of inspection are used, the process should be validated and the performance of the equipment checked at intervals. Results should be recorded.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a16704f9d386002ef370605279f5eaaf275295545672f0e2867870c5cee0022b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 13.2 \nThe container closure system for aseptically filled vials is not fully integral until the aluminum cap has been crimped into place on the stoppered vial. Crimping of the cap should, therefore, be performed as soon as possible after stopper insertion.\n\n# 13.3 \nAs the equipment used to crimp vial caps can generate large quantities of non-viable particulates, the equipment should be located at a separate station equipped with adequate air extraction.\n\n# 13.4 \nVial capping can be undertaken as an aseptic process using sterilized caps or as a clean process outside the aseptic core. Where this latter approach is adopted, vials should be protected by grade A conditions up to the point of leaving the aseptic processing area, and thereafter stoppered vials should be protected with a grade A air supply until the cap has been crimped.\n\n# 13.5 \nVials with missing or displaced stoppers should be rejected prior to capping. Where human intervention is required at the capping station, appropriate technology should be used to prevent direct contact with the vials and to minimize microbial contamination.\n\n# 13.6 \nRestricted access barriers and isolators may be beneficial in assuring the required conditions and minimizing direct human interventions into the capping operation.\n\n# 13.7 \nContainers sealed under vacuum should be tested for maintenance of that vacuum after an appropriate, predetermined period.\n\n# 13.8 \nFilled containers of parenteral products should be inspected individually for extraneous contamination or other defects. When inspection is carried out visually this should be done under suitable and controlled conditions of illumination and background. Operators doing the inspection should pass regular eyesight checks, using personal corrective lenses (e.g. spectacles or contact lenses) as required, and be allowed frequent breaks from inspection. Where other methods of inspection are used, the process should be validated and the performance of the equipment checked at intervals. Results should be recorded.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2041, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b6bba9e1-db1c-4fc8-8060-9437b2cd8f6d": {"__data__": {"id_": "b6bba9e1-db1c-4fc8-8060-9437b2cd8f6d", "embedding": null, "metadata": {"page_label": "248", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. Good manufacturing practices for sterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 6 (WHO Technical Report Series, No. 902); and in *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.\n\n2. ISO 14644-1. *Clean rooms and associated controlled environments. Part 1: Classification of airborne particles*. Geneva, International Organization for Standardization.\n\n3. FDA Guidance for Industry. *Sterile drug products produced by aseptic processing \u2014 cGMP*. US Food and Drug Administration, 2004.\n\n4. Guidance for industry. *Sterile drug products produced by aseptic processing*. Japan, 2005.\n\n5. Manufacture of sterile medicinal products. In: *The rules governing medicinal products in the European Union Vol. 4. EU guidelines to good manufacturing practice medicinal products for human and veterinary use*. Annex 1, Brussels, 2008.\n\n6. ISO 14644-3. *Clean rooms and associated controlled environments. Part 3: Test methods*. Geneva, International Organization for Standardization.\n\n7. ISO 14644-4. *Clean rooms and associated controlled environments. Part 4: Design, construction and start-up*. Geneva, International Organization for Standardization.\n\n8. ISO 14644-2. *Clean rooms and associated controlled environments. Part 2: Monitoring for continued compliance with ISO 14644-1*. Geneva, International Organization for Standardization.\n\n9. ISO 14644-5. *Clean rooms and associated controlled environments. Part 5: Cleanroom operations*. Geneva, International Organization for Standardization.\n\n10. Good manufacturing practices for pharmaceutical products: water for pharmaceutical use. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 3 (WHO Technical Report Series, No. 929); and in *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que se centra en las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para productos farmac\u00e9uticos est\u00e9riles. Incluye referencias a normas internacionales, gu\u00edas de la FDA y regulaciones de la Uni\u00f3n Europea sobre la producci\u00f3n y control de productos farmac\u00e9uticos est\u00e9riles. Se mencionan varias normas ISO relacionadas con salas limpias y entornos controlados, as\u00ed como directrices espec\u00edficas para la producci\u00f3n de medicamentos est\u00e9riles.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales diferencias entre las normas ISO 14644-1 y ISO 14644-2 en el contexto de las salas limpias?**\n   - Esta pregunta busca una comparaci\u00f3n espec\u00edfica entre dos normas ISO que son fundamentales para la clasificaci\u00f3n y el monitoreo de la calidad del aire en salas limpias, lo que no se detalla en el contexto.\n\n2. **\u00bfQu\u00e9 aspectos espec\u00edficos se abordan en el Anexo 1 de las directrices de la Uni\u00f3n Europea sobre la fabricaci\u00f3n de productos medicinales est\u00e9riles?**\n   - Esta pregunta se centra en el contenido del Anexo 1 mencionado en el contexto, que podr\u00eda contener detalles t\u00e9cnicos y requisitos que no est\u00e1n expl\u00edcitamente descritos en el resumen.\n\n3. **\u00bfQu\u00e9 recomendaciones espec\u00edficas proporciona la FDA en su gu\u00eda sobre productos farmac\u00e9uticos est\u00e9riles producidos mediante procesamiento as\u00e9ptico?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre las recomendaciones de la FDA, que pueden incluir pr\u00e1cticas y procedimientos espec\u00edficos que no se encuentran en el contexto proporcionado.\n\n### Resumen de Nivel Superior\n\nEl informe de la OMS proporciona un marco normativo y directrices sobre las buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles, destacando la importancia de la calidad y la seguridad en la producci\u00f3n. Se hace referencia a varias normas ISO y gu\u00edas de diferentes organismos reguladores, lo que subraya la necesidad de cumplir con est\u00e1ndares internacionales para garantizar la eficacia y seguridad de los productos farmac\u00e9uticos.\n\n### Preguntas Adicionales Basadas en el Resumen\n\n1. **\u00bfC\u00f3mo se relacionan las buenas pr\u00e1cticas de fabricaci\u00f3n de la OMS con las normas ISO y las gu\u00edas de la FDA en t\u00e9rminos de cumplimiento y regulaci\u00f3n?**\n   - Esta pregunta busca explorar la interconexi\u00f3n entre las directrices de la OMS y otros est\u00e1ndares internacionales, lo que puede proporcionar una visi\u00f3n m\u00e1s amplia de la regulaci\u00f3n en la industria farmac\u00e9utica.\n\n2. **\u00bfQu\u00e9 impacto tienen las buenas pr\u00e1cticas de fabricaci\u00f3n en la calidad de los productos farmac\u00e9uticos est\u00e9riles seg\u00fan el informe de la OMS?**\n   - Esta pregunta se centra en la relaci\u00f3n entre las BPF y la calidad del producto, lo que puede ofrecer informaci\u00f3n sobre la importancia de seguir estas directrices.\n\n3. **\u00bfCu\u00e1les son los desaf\u00edos comunes que enfrentan las empresas al implementar las buenas pr\u00e1cticas de fabricaci\u00f3n para productos est\u00e9riles?**\n   - Esta pregunta busca identificar los obst\u00e1culos que las empresas pueden encontrar al intentar cumplir con las regulaciones y est\u00e1ndares mencionados en el informe.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistema de Cierre de Viales**:\n   - El sistema de cierre de los viales llenos de forma as\u00e9ptica no se considera completo hasta que la tapa de aluminio ha sido crimpada.\n   - Se recomienda realizar el crimpado lo m\u00e1s pronto posible despu\u00e9s de insertar el tap\u00f3n.\n\n2. **Control de Contaminaci\u00f3n**:\n   - La maquinaria para crimpado puede generar part\u00edculas no viables, por lo que debe estar en una estaci\u00f3n separada con adecuada extracci\u00f3n de aire.\n   - Se deben implementar barreras de acceso restringido y aisladores para minimizar la intervenci\u00f3n humana.\n\n3. **Proceso de Capping**:\n   - El capping puede ser un proceso as\u00e9ptico con tapas esterilizadas o un proceso limpio fuera del n\u00facleo as\u00e9ptico.\n   - Los viales deben estar protegidos por condiciones de grado A hasta que se complete el crimpado.\n\n4. **Manejo de Viales Defectuosos**:\n   - Los viales con tapones faltantes o desplazados deben ser rechazados antes del capping.\n   - Se debe utilizar tecnolog\u00eda adecuada para evitar el contacto directo y minimizar la contaminaci\u00f3n microbiana.\n\n5. **Inspecci\u00f3n de Viales**:\n   - Los viales llenos de productos parenterales deben ser inspeccionados individualmente para detectar contaminaci\u00f3n o defectos.\n   - La inspecci\u00f3n visual debe realizarse bajo condiciones controladas de iluminaci\u00f3n y fondo, y los operadores deben pasar chequeos regulares de visi\u00f3n.\n\n6. **Mantenimiento de Vac\u00edo**:\n   - Los contenedores sellados al vac\u00edo deben ser probados para asegurar el mantenimiento del vac\u00edo despu\u00e9s de un per\u00edodo predeterminado.\n\n### Entidades Clave:\n- **Viales**: Contenedores utilizados para productos parenterales.\n- **Tapas de Aluminio**: Elemento crucial en el cierre de los viales.\n- **Part\u00edculas No Viables**: Contaminantes generados por el equipo de crimpado.\n- **Condiciones de Grado A**: Est\u00e1ndares de calidad del aire requeridos para la protecci\u00f3n de los viales.\n- **Tecnolog\u00eda de Capping**: Herramientas y m\u00e9todos utilizados para el proceso de crimpado.\n- **Inspecci\u00f3n Visual**: Proceso de revisi\u00f3n de viales para detectar defectos o contaminaci\u00f3n.", "excerpt_keywords": "Keywords: buenas pr\u00e1cticas de fabricaci\u00f3n, productos farmac\u00e9uticos est\u00e9riles, normas ISO, control de calidad, regulaci\u00f3n sanitaria"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fc403379-c18d-494f-95c5-a2e56a41305f", "node_type": "4", "metadata": {"page_label": "248", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. Good manufacturing practices for sterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 6 (WHO Technical Report Series, No. 902); and in *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.\n\n2. ISO 14644-1. *Clean rooms and associated controlled environments. Part 1: Classification of airborne particles*. Geneva, International Organization for Standardization.\n\n3. FDA Guidance for Industry. *Sterile drug products produced by aseptic processing \u2014 cGMP*. US Food and Drug Administration, 2004.\n\n4. Guidance for industry. *Sterile drug products produced by aseptic processing*. Japan, 2005.\n\n5. Manufacture of sterile medicinal products. In: *The rules governing medicinal products in the European Union Vol. 4. EU guidelines to good manufacturing practice medicinal products for human and veterinary use*. Annex 1, Brussels, 2008.\n\n6. ISO 14644-3. *Clean rooms and associated controlled environments. Part 3: Test methods*. Geneva, International Organization for Standardization.\n\n7. ISO 14644-4. *Clean rooms and associated controlled environments. Part 4: Design, construction and start-up*. Geneva, International Organization for Standardization.\n\n8. ISO 14644-2. *Clean rooms and associated controlled environments. Part 2: Monitoring for continued compliance with ISO 14644-1*. Geneva, International Organization for Standardization.\n\n9. ISO 14644-5. *Clean rooms and associated controlled environments. Part 5: Cleanroom operations*. Geneva, International Organization for Standardization.\n\n10. Good manufacturing practices for pharmaceutical products: water for pharmaceutical use. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 3 (WHO Technical Report Series, No. 929); and in *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "fa258d66f5230662bedf66f17b3657e7c08f459519a508a6bce54691cb2400b1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# References\n\n1. Good manufacturing practices for sterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 6 (WHO Technical Report Series, No. 902); and in *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.\n\n2. ISO 14644-1. *Clean rooms and associated controlled environments. Part 1: Classification of airborne particles*. Geneva, International Organization for Standardization.\n\n3. FDA Guidance for Industry. *Sterile drug products produced by aseptic processing \u2014 cGMP*. US Food and Drug Administration, 2004.\n\n4. Guidance for industry. *Sterile drug products produced by aseptic processing*. Japan, 2005.\n\n5. Manufacture of sterile medicinal products. In: *The rules governing medicinal products in the European Union Vol. 4. EU guidelines to good manufacturing practice medicinal products for human and veterinary use*. Annex 1, Brussels, 2008.\n\n6. ISO 14644-3. *Clean rooms and associated controlled environments. Part 3: Test methods*. Geneva, International Organization for Standardization.\n\n7. ISO 14644-4. *Clean rooms and associated controlled environments. Part 4: Design, construction and start-up*. Geneva, International Organization for Standardization.\n\n8. ISO 14644-2. *Clean rooms and associated controlled environments. Part 2: Monitoring for continued compliance with ISO 14644-1*. Geneva, International Organization for Standardization.\n\n9. ISO 14644-5. *Clean rooms and associated controlled environments. Part 5: Cleanroom operations*. Geneva, International Organization for Standardization.\n\n10. Good manufacturing practices for pharmaceutical products: water for pharmaceutical use. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 3 (WHO Technical Report Series, No. 929); and in *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2273, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5d561296-fb57-4aba-839a-3a31861055eb": {"__data__": {"id_": "5d561296-fb57-4aba-839a-3a31861055eb", "embedding": null, "metadata": {"page_label": "249", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 5\n\n## WHO good distribution practices for pharmaceutical products\n\n1. Introduction\n2. Scope of the document\n3. Glossary\n4. General principles\n5. Regulation of the distribution of pharmaceutical products\n6. Organization and management\n7. Personnel\n8. Quality system\n9. Premises, warehousing and storage\n10. Vehicles and equipment\n11. Shipment containers and container labelling\n12. Dispatch and receipt\n13. Transportation and products in transit\n14. Documentation\n15. Repackaging and relabelling\n16. Complaints\n17. Recalls\n18. Returned products\n19. Counterfeit pharmaceutical products\n20. Importation\n21. Contract activities\n22. Self-inspection\n\nReferences", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 957\" incluye un anexo que detalla las buenas pr\u00e1cticas de distribuci\u00f3n de productos farmac\u00e9uticos seg\u00fan la Organizaci\u00f3n Mundial de la Salud (OMS). Este anexo abarca una variedad de temas relacionados con la regulaci\u00f3n, organizaci\u00f3n, gesti\u00f3n, calidad, almacenamiento, transporte y manejo de productos farmac\u00e9uticos, as\u00ed como la gesti\u00f3n de quejas, retiradas del mercado y productos falsificados.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los principios generales que rigen las buenas pr\u00e1cticas de distribuci\u00f3n de productos farmac\u00e9uticos seg\u00fan la OMS?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre los principios que gu\u00edan la distribuci\u00f3n segura y efectiva de productos farmac\u00e9uticos, que se detalla en el documento.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir en caso de quejas o retiradas de productos farmac\u00e9uticos seg\u00fan las directrices de la OMS?**\n   - Esta pregunta se centra en los protocolos establecidos para manejar situaciones de quejas y retiradas, que son cruciales para la seguridad del paciente y la integridad del sistema de distribuci\u00f3n.\n\n3. **\u00bfQu\u00e9 medidas se recomiendan para prevenir la distribuci\u00f3n de productos farmac\u00e9uticos falsificados?**\n   - Esta pregunta aborda un tema cr\u00edtico en la distribuci\u00f3n de productos farmac\u00e9uticos, buscando las estrategias y pr\u00e1cticas recomendadas por la OMS para combatir la falsificaci\u00f3n en la cadena de suministro. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar f\u00e1cilmente disponible en otras fuentes, enfoc\u00e1ndose en aspectos clave de las buenas pr\u00e1cticas de distribuci\u00f3n seg\u00fan la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF):** El documento se centra en las BPF para productos farmac\u00e9uticos est\u00e9riles, destacando la importancia de seguir est\u00e1ndares internacionales para garantizar la calidad y seguridad de estos productos.\n\n2. **Normas ISO:** Se mencionan varias normas ISO relacionadas con salas limpias y entornos controlados, que son esenciales para la clasificaci\u00f3n, monitoreo y operaci\u00f3n de estos espacios en la producci\u00f3n farmac\u00e9utica.\n\n3. **Regulaciones de la FDA y la Uni\u00f3n Europea:** Se incluyen gu\u00edas y regulaciones espec\u00edficas de la FDA y la Uni\u00f3n Europea que abordan la producci\u00f3n de medicamentos est\u00e9riles, enfatizando la necesidad de cumplir con estas directrices para asegurar la calidad del producto.\n\n4. **Control de Calidad:** El informe subraya la importancia del control de calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles, lo que implica la implementaci\u00f3n de procedimientos y est\u00e1ndares rigurosos.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite directrices y recomendaciones sobre BPF.\n- **International Organization for Standardization (ISO):** Organizaci\u00f3n que establece normas internacionales, como la serie ISO 14644 relacionada con salas limpias.\n- **US Food and Drug Administration (FDA):** Agencia reguladora que proporciona gu\u00edas sobre la producci\u00f3n de productos farmac\u00e9uticos est\u00e9riles.\n- **Uni\u00f3n Europea:** Entidad que regula la fabricaci\u00f3n de productos medicinales a trav\u00e9s de directrices espec\u00edficas.\n\nEste resumen destaca la interconexi\u00f3n entre las BPF, las normas ISO y las regulaciones de diferentes organismos, enfatizando la importancia de cumplir con estos est\u00e1ndares para garantizar la eficacia y seguridad de los productos farmac\u00e9uticos est\u00e9riles.", "excerpt_keywords": "Keywords: distribution, pharmaceutical, WHO, good practices, regulations"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3298d3c9-ac4c-4fa4-8c46-580d6a02dff1", "node_type": "4", "metadata": {"page_label": "249", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 5\n\n## WHO good distribution practices for pharmaceutical products\n\n1. Introduction\n2. Scope of the document\n3. Glossary\n4. General principles\n5. Regulation of the distribution of pharmaceutical products\n6. Organization and management\n7. Personnel\n8. Quality system\n9. Premises, warehousing and storage\n10. Vehicles and equipment\n11. Shipment containers and container labelling\n12. Dispatch and receipt\n13. Transportation and products in transit\n14. Documentation\n15. Repackaging and relabelling\n16. Complaints\n17. Recalls\n18. Returned products\n19. Counterfeit pharmaceutical products\n20. Importation\n21. Contract activities\n22. Self-inspection\n\nReferences", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a5e9f7ed9f39e34b3af554109db11bef4874a440bb8c4f24b495d2a9c3ee401a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 5\n\n## WHO good distribution practices for pharmaceutical products\n\n1. Introduction\n2. Scope of the document\n3. Glossary\n4. General principles\n5. Regulation of the distribution of pharmaceutical products\n6. Organization and management\n7. Personnel\n8. Quality system\n9. Premises, warehousing and storage\n10. Vehicles and equipment\n11. Shipment containers and container labelling\n12. Dispatch and receipt\n13. Transportation and products in transit\n14. Documentation\n15. Repackaging and relabelling\n16. Complaints\n17. Recalls\n18. Returned products\n19. Counterfeit pharmaceutical products\n20. Importation\n21. Contract activities\n22. Self-inspection\n\nReferences", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 663, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "bebe27fa-9d77-41d4-afcf-1f6f1e253e4c": {"__data__": {"id_": "bebe27fa-9d77-41d4-afcf-1f6f1e253e4c", "embedding": null, "metadata": {"page_label": "250", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nDistribution is an important activity in the integrated supply-chain management of pharmaceutical products. Various people and entities are generally responsible for the handling, storage and distribution of such products. In some cases, however, a person or entity is only involved in and responsible for certain elements of the distribution process. The objective of these guidelines is to assist in ensuring the quality and identity of pharmaceutical products during all aspects of the distribution process. These aspects include, but are not limited to, procurement, purchasing, storage, distribution, transportation, repackaging, relabelling, documentation and record-keeping practices.\n\nThe storage, sale and distribution of pharmaceutical products are often carried out by various companies, institutions and individuals. This document sets out appropriate steps to assist in fulfilling the responsibilities involved in the different aspects of the distribution process within the supply chain and to avoid the introduction of counterfeits into the marketplace via the distribution chain. The relevant sections should be considered by various participants as applicable to the particular role that they play in the distribution of pharmaceutical products.\n\nThe nature of the risks involved is likely to be similar to that for risks encountered in the manufacturing environment, e.g. mix-ups, adulteration, contamination and cross-contamination. When the distribution chain is interrupted by manufacturing steps such as repackaging and relabelling, the principles of good manufacturing practices (GMP) should be applied to these processes.\n\nCounterfeit pharmaceutical products are a real threat to public health and safety. Consequently, it is essential to protect the pharmaceutical supply chain against the penetration of such products. Weak points in the distribution processes of pharmaceutical products provide an avenue for counterfeit as well as illegally imported, stolen and substandard medicines to enter the supply chain. This is a concern in both developed and developing countries. The methods by which such products enter the supply chain have become increasingly complex and have resulted in the development of thriving secondary and grey markets throughout the world. The involvement of unauthorized entities in the distribution and sale of pharmaceutical products is a particular concern. Only a joint approach including all parties involved in the supply chain can be successful in the fight against counterfeit pharmaceutical products and, therefore, all parties active in the market should take an active part in collaborative activities.\n\nDifferent models for the distribution of pharmaceutical products are used in different countries and sometimes within the same country, for example,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS se centra en la importancia de la distribuci\u00f3n en la gesti\u00f3n de la cadena de suministro de productos farmac\u00e9uticos. Establece directrices para asegurar la calidad e identidad de estos productos durante todo el proceso de distribuci\u00f3n, que incluye la adquisici\u00f3n, almacenamiento, transporte, y pr\u00e1cticas de documentaci\u00f3n. Se enfatiza la amenaza de los productos farmac\u00e9uticos falsificados y la necesidad de proteger la cadena de suministro contra su penetraci\u00f3n. Adem\u00e1s, se menciona que los riesgos en la distribuci\u00f3n son similares a los encontrados en la fabricaci\u00f3n, y que la colaboraci\u00f3n entre todas las partes involucradas es crucial para combatir este problema.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos que se deben seguir para evitar la introducci\u00f3n de productos farmac\u00e9uticos falsificados en la cadena de suministro?**\n   - Esta pregunta busca respuestas sobre las medidas concretas que se deben implementar en cada etapa del proceso de distribuci\u00f3n para prevenir la entrada de productos falsificados.\n\n2. **\u00bfQu\u00e9 principios de buenas pr\u00e1cticas de manufactura (GMP) deben aplicarse durante los procesos de reempaquetado y reetiquetado en la cadena de distribuci\u00f3n?**\n   - Esta pregunta se enfoca en los est\u00e1ndares espec\u00edficos de GMP que son relevantes cuando se interrumpe la cadena de distribuci\u00f3n por actividades de manufactura.\n\n3. **\u00bfQu\u00e9 modelos de distribuci\u00f3n de productos farmac\u00e9uticos se utilizan en diferentes pa\u00edses y c\u00f3mo var\u00edan dentro de un mismo pa\u00eds?**\n   - Esta pregunta busca informaci\u00f3n sobre las diferentes estrategias y estructuras de distribuci\u00f3n que se emplean globalmente y las variaciones que pueden existir en un solo pa\u00eds, lo que podr\u00eda influir en la efectividad de la lucha contra los productos falsificados.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\nEl **Anexo 5** del documento \"WHO - Technical Report Series 957\" se centra en las **buenas pr\u00e1cticas de distribuci\u00f3n de productos farmac\u00e9uticos** seg\u00fan la **Organizaci\u00f3n Mundial de la Salud (OMS)**. A continuaci\u00f3n se presentan los temas clave abordados en esta secci\u00f3n:\n\n1. **Introducci\u00f3n**: Presenta el prop\u00f3sito y la importancia de las buenas pr\u00e1cticas en la distribuci\u00f3n de productos farmac\u00e9uticos.\n2. **Alcance del documento**: Define el \u00e1mbito de aplicaci\u00f3n de las directrices.\n3. **Glosario**: Proporciona definiciones de t\u00e9rminos relevantes utilizados en el documento.\n4. **Principios generales**: Establece los fundamentos que gu\u00edan las pr\u00e1cticas de distribuci\u00f3n.\n5. **Regulaci\u00f3n de la distribuci\u00f3n**: Describe las normativas que rigen la distribuci\u00f3n de productos farmac\u00e9uticos.\n6. **Organizaci\u00f3n y gesti\u00f3n**: Aborda la estructura organizativa necesaria para una distribuci\u00f3n efectiva.\n7. **Personal**: Detalla los requisitos y responsabilidades del personal involucrado en la distribuci\u00f3n.\n8. **Sistema de calidad**: Enfatiza la importancia de un sistema de calidad en la distribuci\u00f3n.\n9. **Instalaciones, almacenamiento y almacenamiento**: Discute las condiciones necesarias para el almacenamiento adecuado de productos farmac\u00e9uticos.\n10. **Veh\u00edculos y equipos**: Especifica los requisitos para los medios de transporte y equipos utilizados.\n11. **Contenedores de env\u00edo y etiquetado**: Proporciona directrices sobre el embalaje y etiquetado de productos.\n12. **Despacho y recepci\u00f3n**: Describe los procedimientos para el manejo de productos al ser enviados y recibidos.\n13. **Transporte y productos en tr\u00e1nsito**: Aborda las consideraciones durante el transporte de productos.\n14. **Documentaci\u00f3n**: Resalta la importancia de mantener registros adecuados.\n15. **Reempaquetado y reetiquetado**: Establece directrices para estas pr\u00e1cticas.\n16. **Quejas**: Define el proceso para manejar quejas sobre productos.\n17. **Retiradas**: Describe los procedimientos a seguir en caso de retiradas de productos del mercado.\n18. **Productos devueltos**: Aborda el manejo de productos que son devueltos.\n19. **Productos farmac\u00e9uticos falsificados**: Discute las medidas para prevenir la distribuci\u00f3n de productos falsificados.\n20. **Importaci\u00f3n**: Proporciona directrices sobre la importaci\u00f3n de productos farmac\u00e9uticos.\n21. **Actividades por contrato**: Aborda las pr\u00e1cticas relacionadas con actividades subcontratadas.\n22. **Autoinspecci\u00f3n**: Enfatiza la importancia de la autoevaluaci\u00f3n en la distribuci\u00f3n.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de establecer las directrices.\n- **Productos farmac\u00e9uticos**: El foco principal del documento.\n- **Sistema de calidad**: Elemento esencial para asegurar la integridad de la distribuci\u00f3n.\n- **Personal**: Los individuos que manejan y distribuyen productos farmac\u00e9uticos.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades clave que se abordan en el anexo sobre las buenas pr\u00e1cticas de distribuci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: distribution, pharmaceutical products, counterfeit, supply chain, good manufacturing practices"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "62cf158b-f6d5-42d0-8c85-0b52011455b3", "node_type": "4", "metadata": {"page_label": "250", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nDistribution is an important activity in the integrated supply-chain management of pharmaceutical products. Various people and entities are generally responsible for the handling, storage and distribution of such products. In some cases, however, a person or entity is only involved in and responsible for certain elements of the distribution process. The objective of these guidelines is to assist in ensuring the quality and identity of pharmaceutical products during all aspects of the distribution process. These aspects include, but are not limited to, procurement, purchasing, storage, distribution, transportation, repackaging, relabelling, documentation and record-keeping practices.\n\nThe storage, sale and distribution of pharmaceutical products are often carried out by various companies, institutions and individuals. This document sets out appropriate steps to assist in fulfilling the responsibilities involved in the different aspects of the distribution process within the supply chain and to avoid the introduction of counterfeits into the marketplace via the distribution chain. The relevant sections should be considered by various participants as applicable to the particular role that they play in the distribution of pharmaceutical products.\n\nThe nature of the risks involved is likely to be similar to that for risks encountered in the manufacturing environment, e.g. mix-ups, adulteration, contamination and cross-contamination. When the distribution chain is interrupted by manufacturing steps such as repackaging and relabelling, the principles of good manufacturing practices (GMP) should be applied to these processes.\n\nCounterfeit pharmaceutical products are a real threat to public health and safety. Consequently, it is essential to protect the pharmaceutical supply chain against the penetration of such products. Weak points in the distribution processes of pharmaceutical products provide an avenue for counterfeit as well as illegally imported, stolen and substandard medicines to enter the supply chain. This is a concern in both developed and developing countries. The methods by which such products enter the supply chain have become increasingly complex and have resulted in the development of thriving secondary and grey markets throughout the world. The involvement of unauthorized entities in the distribution and sale of pharmaceutical products is a particular concern. Only a joint approach including all parties involved in the supply chain can be successful in the fight against counterfeit pharmaceutical products and, therefore, all parties active in the market should take an active part in collaborative activities.\n\nDifferent models for the distribution of pharmaceutical products are used in different countries and sometimes within the same country, for example,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "987a9731a1abe654d20bf20312074dcef03b64088ae399cf32d549253e29ed85", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Introduction\n\nDistribution is an important activity in the integrated supply-chain management of pharmaceutical products. Various people and entities are generally responsible for the handling, storage and distribution of such products. In some cases, however, a person or entity is only involved in and responsible for certain elements of the distribution process. The objective of these guidelines is to assist in ensuring the quality and identity of pharmaceutical products during all aspects of the distribution process. These aspects include, but are not limited to, procurement, purchasing, storage, distribution, transportation, repackaging, relabelling, documentation and record-keeping practices.\n\nThe storage, sale and distribution of pharmaceutical products are often carried out by various companies, institutions and individuals. This document sets out appropriate steps to assist in fulfilling the responsibilities involved in the different aspects of the distribution process within the supply chain and to avoid the introduction of counterfeits into the marketplace via the distribution chain. The relevant sections should be considered by various participants as applicable to the particular role that they play in the distribution of pharmaceutical products.\n\nThe nature of the risks involved is likely to be similar to that for risks encountered in the manufacturing environment, e.g. mix-ups, adulteration, contamination and cross-contamination. When the distribution chain is interrupted by manufacturing steps such as repackaging and relabelling, the principles of good manufacturing practices (GMP) should be applied to these processes.\n\nCounterfeit pharmaceutical products are a real threat to public health and safety. Consequently, it is essential to protect the pharmaceutical supply chain against the penetration of such products. Weak points in the distribution processes of pharmaceutical products provide an avenue for counterfeit as well as illegally imported, stolen and substandard medicines to enter the supply chain. This is a concern in both developed and developing countries. The methods by which such products enter the supply chain have become increasingly complex and have resulted in the development of thriving secondary and grey markets throughout the world. The involvement of unauthorized entities in the distribution and sale of pharmaceutical products is a particular concern. Only a joint approach including all parties involved in the supply chain can be successful in the fight against counterfeit pharmaceutical products and, therefore, all parties active in the market should take an active part in collaborative activities.\n\nDifferent models for the distribution of pharmaceutical products are used in different countries and sometimes within the same country, for example,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2830, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ae05ef28-72ef-45ee-9471-89364e5d150a": {"__data__": {"id_": "ae05ef28-72ef-45ee-9471-89364e5d150a", "embedding": null, "metadata": {"page_label": "251", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "in the public and the private sector. These guidelines are intended to be applicable to all persons and outlets involved in any aspect of the distribution of pharmaceutical products from the premises of the manufacturer of the product to the person dispensing or providing pharmaceutical products directly to a patient or his or her agent. This includes all parties involved in trade and distribution of medicines, pharmaceutical manufacturers, including the manufacturers of finished products and pharmaceutical wholesalers as well as other parties such as brokers, suppliers, distributors, logistics providers, traders, transport companies and forwarding agents and their employees.\n\nThe relevant sections of these guidelines should also be considered for implementation by, among others, governments, regulatory bodies, international procurement organizations, donor agencies and certifying bodies, as well as all parties involved in any aspect of the trade and distribution of pharmaceutical products, including health care workers. The guidelines can also be used as a tool in the prevention of the distribution of counterfeit pharmaceutical products. It should, however, be noted that these are general guidelines which may be adapted to suit the prevailing situations and conditions in individual countries. National or regional guidelines may be developed to meet specific needs and situations in a particular region or country.\n\nTo maintain the original quality of pharmaceutical products, every party active in the distribution chain has to comply with the applicable legislation and regulations. Every activity in the distribution of pharmaceutical products should be carried out according to the principles of GMP, good storage practice (GSP) and good distribution practice (GDP) as applicable. These guidelines do not deal with all aspects of the standards for the storage of pharmaceuticals which are covered in the *WHO guide to good storage practices for pharmaceuticals* (1). The dispensing to patients is addressed in the WHO good pharmacy practice (GPP) guide (2). These guidelines should also be read in conjunction with other WHO guidelines (3\u20136).\n\n## 2. Scope of the document\n\nThis document lays down guidelines for the distribution of pharmaceutical products. Depending on the national and regional legislation on pharmaceuticals, these guidelines may apply equally to products for human and for veterinary use. The guidelines thus cover products for which a prescription is required by the patient, products which may be provided to a patient without a prescription, biologicals and vaccines. Although medical devices are not included in the definition of pharmaceutical products for the purposes of this document, the main principles established in this document may also be used where applicable for medical devices.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS establece directrices para la distribuci\u00f3n de productos farmac\u00e9uticos, aplicables a todos los actores involucrados en la cadena de distribuci\u00f3n, desde los fabricantes hasta los dispensadores. Estas directrices buscan asegurar la calidad de los productos farmac\u00e9uticos y prevenir la distribuci\u00f3n de productos falsificados. Se enfatiza la importancia de cumplir con la legislaci\u00f3n y regulaciones pertinentes, as\u00ed como con las buenas pr\u00e1cticas de manufactura (GMP), almacenamiento (GSP) y distribuci\u00f3n (GDP). Adem\u00e1s, se menciona que las directrices pueden adaptarse a las necesidades espec\u00edficas de diferentes pa\u00edses y regiones, y que tambi\u00e9n son relevantes para productos veterinarios y, en algunos casos, dispositivos m\u00e9dicos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 actores espec\u00edficos en la cadena de distribuci\u00f3n de productos farmac\u00e9uticos est\u00e1n incluidos en las directrices de la OMS?**\n   - Respuesta: Las directrices son aplicables a todos los actores involucrados en la distribuci\u00f3n de productos farmac\u00e9uticos, incluyendo fabricantes, mayoristas, corredores, proveedores, distribuidores, empresas de log\u00edstica, transportistas y agentes de aduanas, as\u00ed como sus empleados.\n\n2. **\u00bfC\u00f3mo pueden las directrices de la OMS ayudar en la prevenci\u00f3n de productos farmac\u00e9uticos falsificados?**\n   - Respuesta: Las directrices pueden ser utilizadas como una herramienta para prevenir la distribuci\u00f3n de productos farmac\u00e9uticos falsificados al establecer est\u00e1ndares y pr\u00e1cticas que todos los actores en la cadena de distribuci\u00f3n deben seguir, asegurando as\u00ed la calidad y autenticidad de los productos.\n\n3. **\u00bfQu\u00e9 principios deben seguir las actividades en la distribuci\u00f3n de productos farmac\u00e9uticos seg\u00fan las directrices de la OMS?**\n   - Respuesta: Todas las actividades en la distribuci\u00f3n de productos farmac\u00e9uticos deben llevarse a cabo de acuerdo con los principios de buenas pr\u00e1cticas de manufactura (GMP), buenas pr\u00e1cticas de almacenamiento (GSP) y buenas pr\u00e1cticas de distribuci\u00f3n (GDP), seg\u00fan sea aplicable.\n\n### Resumen de nivel superior\n\nEl documento de la OMS proporciona un marco de directrices para la distribuci\u00f3n de productos farmac\u00e9uticos, enfatizando la importancia de la calidad y la prevenci\u00f3n de la falsificaci\u00f3n. Las directrices son flexibles y pueden adaptarse a las condiciones locales, y son relevantes tanto para productos destinados a humanos como a animales. Se requiere que todos los actores en la cadena de distribuci\u00f3n cumplan con las regulaciones y buenas pr\u00e1cticas establecidas para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Importancia de la Distribuci\u00f3n**: La distribuci\u00f3n es fundamental en la gesti\u00f3n de la cadena de suministro de productos farmac\u00e9uticos, involucrando a diversas personas y entidades en el manejo, almacenamiento y distribuci\u00f3n.\n\n2. **Objetivo de las Directrices**: Las directrices tienen como objetivo asegurar la calidad e identidad de los productos farmac\u00e9uticos durante todo el proceso de distribuci\u00f3n, que incluye la adquisici\u00f3n, almacenamiento, transporte, reempaquetado, reetiquetado, y pr\u00e1cticas de documentaci\u00f3n.\n\n3. **Prevenci\u00f3n de Productos Falsificados**: Se enfatiza la necesidad de evitar la introducci\u00f3n de productos farmac\u00e9uticos falsificados en la cadena de suministro, destacando que los puntos d\u00e9biles en los procesos de distribuci\u00f3n pueden facilitar la entrada de medicamentos falsificados, importados ilegalmente, robados o de calidad inferior.\n\n4. **Riesgos en la Distribuci\u00f3n**: Los riesgos en la distribuci\u00f3n son similares a los encontrados en la fabricaci\u00f3n, incluyendo mezclas, adulteraci\u00f3n y contaminaci\u00f3n. Se recomienda aplicar principios de Buenas Pr\u00e1cticas de Manufactura (GMP) durante procesos de reempaquetado y reetiquetado.\n\n5. **Colaboraci\u00f3n en la Cadena de Suministro**: La lucha contra los productos farmac\u00e9uticos falsificados requiere un enfoque conjunto de todas las partes involucradas en la cadena de suministro, incluyendo empresas, instituciones y otros actores del mercado.\n\n6. **Modelos de Distribuci\u00f3n**: Existen diferentes modelos de distribuci\u00f3n de productos farmac\u00e9uticos que var\u00edan entre pa\u00edses y, a veces, dentro de un mismo pa\u00eds, lo que puede influir en la efectividad de las medidas contra los productos falsificados.\n\n### Entidades Involucradas\n- **Empresas farmac\u00e9uticas**: Responsables de la producci\u00f3n y distribuci\u00f3n de medicamentos.\n- **Instituciones de salud**: Involucradas en la regulaci\u00f3n y supervisi\u00f3n de la cadena de suministro.\n- **Distribuidores**: Actores clave en el manejo y transporte de productos farmac\u00e9uticos.\n- **Entidades no autorizadas**: Representan un riesgo al involucrarse en la distribuci\u00f3n y venta de productos farmac\u00e9uticos. \n\nEste resumen destaca la importancia de la distribuci\u00f3n en la cadena de suministro farmac\u00e9utica y la necesidad de medidas colaborativas para combatir la falsificaci\u00f3n de medicamentos.", "excerpt_keywords": "Keywords: pharmaceutical distribution, guidelines, counterfeit prevention, good distribution practice, regulatory compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "529016f1-4955-4c37-a5f4-9f2405e75141", "node_type": "4", "metadata": {"page_label": "251", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "in the public and the private sector. These guidelines are intended to be applicable to all persons and outlets involved in any aspect of the distribution of pharmaceutical products from the premises of the manufacturer of the product to the person dispensing or providing pharmaceutical products directly to a patient or his or her agent. This includes all parties involved in trade and distribution of medicines, pharmaceutical manufacturers, including the manufacturers of finished products and pharmaceutical wholesalers as well as other parties such as brokers, suppliers, distributors, logistics providers, traders, transport companies and forwarding agents and their employees.\n\nThe relevant sections of these guidelines should also be considered for implementation by, among others, governments, regulatory bodies, international procurement organizations, donor agencies and certifying bodies, as well as all parties involved in any aspect of the trade and distribution of pharmaceutical products, including health care workers. The guidelines can also be used as a tool in the prevention of the distribution of counterfeit pharmaceutical products. It should, however, be noted that these are general guidelines which may be adapted to suit the prevailing situations and conditions in individual countries. National or regional guidelines may be developed to meet specific needs and situations in a particular region or country.\n\nTo maintain the original quality of pharmaceutical products, every party active in the distribution chain has to comply with the applicable legislation and regulations. Every activity in the distribution of pharmaceutical products should be carried out according to the principles of GMP, good storage practice (GSP) and good distribution practice (GDP) as applicable. These guidelines do not deal with all aspects of the standards for the storage of pharmaceuticals which are covered in the *WHO guide to good storage practices for pharmaceuticals* (1). The dispensing to patients is addressed in the WHO good pharmacy practice (GPP) guide (2). These guidelines should also be read in conjunction with other WHO guidelines (3\u20136).\n\n## 2. Scope of the document\n\nThis document lays down guidelines for the distribution of pharmaceutical products. Depending on the national and regional legislation on pharmaceuticals, these guidelines may apply equally to products for human and for veterinary use. The guidelines thus cover products for which a prescription is required by the patient, products which may be provided to a patient without a prescription, biologicals and vaccines. Although medical devices are not included in the definition of pharmaceutical products for the purposes of this document, the main principles established in this document may also be used where applicable for medical devices.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "00fb1ccd82f00317b306bd650b9e554937d132cf31c1a039767c4d9327094a96", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "in the public and the private sector. These guidelines are intended to be applicable to all persons and outlets involved in any aspect of the distribution of pharmaceutical products from the premises of the manufacturer of the product to the person dispensing or providing pharmaceutical products directly to a patient or his or her agent. This includes all parties involved in trade and distribution of medicines, pharmaceutical manufacturers, including the manufacturers of finished products and pharmaceutical wholesalers as well as other parties such as brokers, suppliers, distributors, logistics providers, traders, transport companies and forwarding agents and their employees.\n\nThe relevant sections of these guidelines should also be considered for implementation by, among others, governments, regulatory bodies, international procurement organizations, donor agencies and certifying bodies, as well as all parties involved in any aspect of the trade and distribution of pharmaceutical products, including health care workers. The guidelines can also be used as a tool in the prevention of the distribution of counterfeit pharmaceutical products. It should, however, be noted that these are general guidelines which may be adapted to suit the prevailing situations and conditions in individual countries. National or regional guidelines may be developed to meet specific needs and situations in a particular region or country.\n\nTo maintain the original quality of pharmaceutical products, every party active in the distribution chain has to comply with the applicable legislation and regulations. Every activity in the distribution of pharmaceutical products should be carried out according to the principles of GMP, good storage practice (GSP) and good distribution practice (GDP) as applicable. These guidelines do not deal with all aspects of the standards for the storage of pharmaceuticals which are covered in the *WHO guide to good storage practices for pharmaceuticals* (1). The dispensing to patients is addressed in the WHO good pharmacy practice (GPP) guide (2). These guidelines should also be read in conjunction with other WHO guidelines (3\u20136).\n\n## 2. Scope of the document\n\nThis document lays down guidelines for the distribution of pharmaceutical products. Depending on the national and regional legislation on pharmaceuticals, these guidelines may apply equally to products for human and for veterinary use. The guidelines thus cover products for which a prescription is required by the patient, products which may be provided to a patient without a prescription, biologicals and vaccines. Although medical devices are not included in the definition of pharmaceutical products for the purposes of this document, the main principles established in this document may also be used where applicable for medical devices.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2842, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "de23a472-dfdb-4f6f-b95e-fba4114d1a1d": {"__data__": {"id_": "de23a472-dfdb-4f6f-b95e-fba4114d1a1d", "embedding": null, "metadata": {"page_label": "252", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The document does not specifically cover GMP aspects of finished products in bulk, distribution of labels or packaging, as these aspects are considered to be covered by other guidelines (3).\n\nThe principles for the distribution of starting materials (active pharmaceutical ingredients (APIs) and excipients) are also not covered here. These are laid down in the WHO guidance *Good trade and distribution practices for pharmaceutical starting materials* (7).\n\n## 3. Glossary\n\nThe definitions provided below apply to the words and phrases used in these guidelines. Although an effort has been made to use standard definitions as far as possible, they may have different meanings in other contexts and documents.\n\n**agreement**  \nArrangement undertaken by and legally binding on parties.\n\n**auditing**  \nAn independent and objective activity designed to add value and improve an organization\u2019s operations by helping the organization to accomplish its objectives by using a systematic, disciplined approach to evaluate and improve the effectiveness of risk management, control and governance processes.\n\n**batch**  \nA defined quantity of pharmaceutical products processed in a single process or series of processes so that it is expected to be homogeneous.\n\n**batch number**  \nA distinctive combination of numbers and/or letters which uniquely identifies a batch, for example, on the labels, its batch records and corresponding certificates of analysis.\n\n**consignment**  \nThe quantity of pharmaceutical products supplied at one time in response to a particular request or order. A consignment may comprise one or more packages or containers and may include pharmaceutical products belonging to more than one batch.\n\n**container**  \nThe material employed in the packaging of a pharmaceutical product. Containers include primary, secondary and transportation containers.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 aspectos de las Buenas Pr\u00e1cticas de Manufactura (GMP) no se abordan en el documento de la OMS?**\n   - El documento no cubre espec\u00edficamente los aspectos de GMP relacionados con los productos terminados en grandes cantidades, la distribuci\u00f3n de etiquetas o el embalaje, ya que se considera que estos aspectos est\u00e1n cubiertos por otras directrices.\n\n2. **\u00bfD\u00f3nde se encuentran los principios para la distribuci\u00f3n de materiales de partida, como los ingredientes farmac\u00e9uticos activos (APIs) y excipientes?**\n   - Los principios para la distribuci\u00f3n de materiales de partida no se abordan en este documento, sino que est\u00e1n establecidos en la gu\u00eda de la OMS titulada *Buenas pr\u00e1cticas comerciales y de distribuci\u00f3n para materiales farmac\u00e9uticos de partida*.\n\n3. **\u00bfQu\u00e9 se entiende por \"n\u00famero de lote\" seg\u00fan el documento?**\n   - El \"n\u00famero de lote\" se define como una combinaci\u00f3n distintiva de n\u00fameros y/o letras que identifica de manera \u00fanica un lote, y se utiliza en las etiquetas, los registros de lote y los certificados de an\u00e1lisis correspondientes.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento de la OMS, parte de la Serie de Informes T\u00e9cnicos 957, aborda directrices relacionadas con la distribuci\u00f3n de productos farmac\u00e9uticos, pero no se centra en los aspectos de GMP de productos terminados, etiquetas o embalaje. Tambi\u00e9n se menciona que los principios para la distribuci\u00f3n de materiales de partida est\u00e1n cubiertos en otras gu\u00edas de la OMS. Adem\u00e1s, se proporciona un glosario con definiciones clave que son relevantes para la comprensi\u00f3n de los t\u00e9rminos utilizados en las directrices.", "prev_section_summary": "### Temas Clave\n\n1. **Directrices para la Distribuci\u00f3n de Productos Farmac\u00e9uticos**: El documento establece normas aplicables a todos los actores en la cadena de distribuci\u00f3n, desde los fabricantes hasta los dispensadores, con el objetivo de asegurar la calidad de los productos farmac\u00e9uticos.\n\n2. **Prevenci\u00f3n de Productos Falsificados**: Las directrices sirven como herramienta para prevenir la distribuci\u00f3n de productos farmac\u00e9uticos falsificados, promoviendo est\u00e1ndares y pr\u00e1cticas que deben seguir todos los involucrados.\n\n3. **Cumplimiento de Normativas**: Se enfatiza la necesidad de que todos los actores en la cadena de distribuci\u00f3n cumplan con la legislaci\u00f3n y regulaciones pertinentes, as\u00ed como con las buenas pr\u00e1cticas de manufactura (GMP), almacenamiento (GSP) y distribuci\u00f3n (GDP).\n\n4. **Adaptabilidad de las Directrices**: Las directrices son generales y pueden adaptarse a las condiciones espec\u00edficas de cada pa\u00eds o regi\u00f3n, permitiendo el desarrollo de gu\u00edas nacionales o regionales.\n\n5. **Alcance de las Directrices**: Las directrices son aplicables a productos farmac\u00e9uticos para uso humano y veterinario, incluyendo medicamentos que requieren receta y aquellos que no, as\u00ed como biol\u00f3gicos y vacunas.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Actores en la Cadena de Distribuci\u00f3n**: Incluye fabricantes, mayoristas, corredores, proveedores, distribuidores, empresas de log\u00edstica, transportistas y agentes de aduanas.\n- **Reguladores y Gobiernos**: Entidades que deben considerar la implementaci\u00f3n de las directrices.\n- **Productos Farmac\u00e9uticos**: Incluye medicamentos, biol\u00f3gicos, vacunas y, en algunos casos, dispositivos m\u00e9dicos.\n- **Buenas Pr\u00e1cticas**: GMP, GSP y GDP son principios fundamentales que deben seguirse en la distribuci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: GMP, pharmaceutical distribution, WHO guidelines, active pharmaceutical ingredients, batch number"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "361e471b-00c6-45a7-ba94-00c834894e78", "node_type": "4", "metadata": {"page_label": "252", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The document does not specifically cover GMP aspects of finished products in bulk, distribution of labels or packaging, as these aspects are considered to be covered by other guidelines (3).\n\nThe principles for the distribution of starting materials (active pharmaceutical ingredients (APIs) and excipients) are also not covered here. These are laid down in the WHO guidance *Good trade and distribution practices for pharmaceutical starting materials* (7).\n\n## 3. Glossary\n\nThe definitions provided below apply to the words and phrases used in these guidelines. Although an effort has been made to use standard definitions as far as possible, they may have different meanings in other contexts and documents.\n\n**agreement**  \nArrangement undertaken by and legally binding on parties.\n\n**auditing**  \nAn independent and objective activity designed to add value and improve an organization\u2019s operations by helping the organization to accomplish its objectives by using a systematic, disciplined approach to evaluate and improve the effectiveness of risk management, control and governance processes.\n\n**batch**  \nA defined quantity of pharmaceutical products processed in a single process or series of processes so that it is expected to be homogeneous.\n\n**batch number**  \nA distinctive combination of numbers and/or letters which uniquely identifies a batch, for example, on the labels, its batch records and corresponding certificates of analysis.\n\n**consignment**  \nThe quantity of pharmaceutical products supplied at one time in response to a particular request or order. A consignment may comprise one or more packages or containers and may include pharmaceutical products belonging to more than one batch.\n\n**container**  \nThe material employed in the packaging of a pharmaceutical product. Containers include primary, secondary and transportation containers.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "97dfb1240d00a4c8f3f89fde7ff40220fb65de71adb7de097e5a9d5b24520cef", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The document does not specifically cover GMP aspects of finished products in bulk, distribution of labels or packaging, as these aspects are considered to be covered by other guidelines (3).\n\nThe principles for the distribution of starting materials (active pharmaceutical ingredients (APIs) and excipients) are also not covered here. These are laid down in the WHO guidance *Good trade and distribution practices for pharmaceutical starting materials* (7).\n\n## 3. Glossary\n\nThe definitions provided below apply to the words and phrases used in these guidelines. Although an effort has been made to use standard definitions as far as possible, they may have different meanings in other contexts and documents.\n\n**agreement**  \nArrangement undertaken by and legally binding on parties.\n\n**auditing**  \nAn independent and objective activity designed to add value and improve an organization\u2019s operations by helping the organization to accomplish its objectives by using a systematic, disciplined approach to evaluate and improve the effectiveness of risk management, control and governance processes.\n\n**batch**  \nA defined quantity of pharmaceutical products processed in a single process or series of processes so that it is expected to be homogeneous.\n\n**batch number**  \nA distinctive combination of numbers and/or letters which uniquely identifies a batch, for example, on the labels, its batch records and corresponding certificates of analysis.\n\n**consignment**  \nThe quantity of pharmaceutical products supplied at one time in response to a particular request or order. A consignment may comprise one or more packages or containers and may include pharmaceutical products belonging to more than one batch.\n\n**container**  \nThe material employed in the packaging of a pharmaceutical product. Containers include primary, secondary and transportation containers.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1865, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "bbf54aab-5db8-4a1a-be62-673c5ce338c4": {"__data__": {"id_": "bbf54aab-5db8-4a1a-be62-673c5ce338c4", "embedding": null, "metadata": {"page_label": "253", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Containers are referred to as primary if they are intended to be in direct contact with the product. Secondary containers are not intended to be in direct contact with the product.\n\n**contamination**  \nThe undesired introduction of impurities of a chemical or microbiological nature, or of foreign matter, into or on to a starting material, intermediate or pharmaceutical product during handling, production, sampling, packaging or repackaging, storage or transportation.\n\n**contract**  \nBusiness agreement for the supply of goods or performance of work at a specified price.\n\n**counterfeit pharmaceutical product**  \nA pharmaceutical product which is deliberately and fraudulently mislabelled with respect to identity and/or source. Counterfeiting can apply to both branded and generic products, and counterfeit pharmaceutical products may include products with the correct ingredients, with the wrong ingredients, without active ingredients, with an incorrect quantity of active ingredient or with fake packaging.\n\n**cross-contamination**  \nContamination of a starting material, intermediate product or finished pharmaceutical product with another starting material or product during production, storage and transportation.\n\n**distribution**  \nThe procuring, purchasing, holding, storing, selling, supplying, importing, exporting, or movement of pharmaceutical products, with the exception of the dispensing or providing pharmaceutical products directly to a patient or his or her agent.\n\n**expiry date**  \nThe date given on the individual container (usually on the label) of a pharmaceutical product up to and including the date on which the product is expected to remain within specifications, if stored correctly. It is established for each batch by adding the shelf-life to the date of manufacture.\n\n**first expiry/first out (FEFO)**  \nA distribution procedure that ensures that the stock with the earliest expiry date is distributed and/or used before an identical stock item with a later expiry date is distributed and/or used.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la serie de informes t\u00e9cnicos 957 aborda definiciones clave relacionadas con la manipulaci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos. Se explican conceptos como la contaminaci\u00f3n, los contratos, los productos farmac\u00e9uticos falsificados, la distribuci\u00f3n, la fecha de caducidad y el procedimiento de \"primeras fechas de caducidad primero\" (FEFO). Estas definiciones son esenciales para garantizar la calidad y seguridad de los productos farmac\u00e9uticos en todas las etapas de su ciclo de vida.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 medidas se pueden tomar para prevenir la contaminaci\u00f3n y la contaminaci\u00f3n cruzada en la producci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta busca informaci\u00f3n sobre pr\u00e1cticas espec\u00edficas que no se mencionan directamente en el texto, pero que son relevantes para el manejo seguro de productos farmac\u00e9uticos.\n\n2. **\u00bfCu\u00e1les son las implicaciones legales y de salud p\u00fablica de la distribuci\u00f3n de productos farmac\u00e9uticos falsificados?**\n   - Aunque el texto define qu\u00e9 es un producto farmac\u00e9utico falsificado, no aborda las consecuencias de su distribuci\u00f3n, lo que podr\u00eda ser crucial para entender su impacto en la salud p\u00fablica.\n\n3. **\u00bfC\u00f3mo se determina la fecha de caducidad de un producto farmac\u00e9utico y qu\u00e9 factores pueden influir en su establecimiento?**\n   - La definici\u00f3n de la fecha de caducidad se menciona, pero no se detallan los criterios o estudios que se utilizan para establecerla, lo que podr\u00eda ser un tema de inter\u00e9s para la industria farmac\u00e9utica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Aspectos de GMP No Cubiertos**:\n   - El documento no aborda los aspectos de Buenas Pr\u00e1cticas de Manufactura (GMP) relacionados con productos terminados en grandes cantidades, distribuci\u00f3n de etiquetas o embalaje, ya que se considera que est\u00e1n cubiertos por otras directrices.\n\n2. **Distribuci\u00f3n de Materiales de Partida**:\n   - Los principios para la distribuci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs) y excipientes no se tratan en este documento, sino que est\u00e1n establecidos en la gu\u00eda de la OMS sobre *Buenas pr\u00e1cticas comerciales y de distribuci\u00f3n para materiales farmac\u00e9uticos de partida*.\n\n3. **Glosario de T\u00e9rminos**:\n   - Se proporciona un glosario con definiciones clave que incluyen:\n     - **Acuerdo**: Un arreglo legalmente vinculante entre partes.\n     - **Auditor\u00eda**: Actividad independiente y objetiva para mejorar las operaciones de una organizaci\u00f3n.\n     - **Lote**: Cantidad definida de productos farmac\u00e9uticos procesados en un solo proceso.\n     - **N\u00famero de Lote**: Combinaci\u00f3n \u00fanica de n\u00fameros y/o letras que identifica un lote.\n     - **Consignaci\u00f3n**: Cantidad de productos farmac\u00e9uticos suministrados en respuesta a un pedido.\n     - **Contenedor**: Material utilizado en el embalaje de un producto farmac\u00e9utico.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite directrices sobre pr\u00e1cticas farmac\u00e9uticas.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Conjunto de directrices para asegurar la calidad en la producci\u00f3n farmac\u00e9utica.\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias que tienen un efecto farmacol\u00f3gico.\n- **Excipientes**: Sustancias inactivas que se utilizan en la formulaci\u00f3n de productos farmac\u00e9uticos. \n\nEste resumen destaca los puntos principales y las definiciones relevantes que se encuentran en la secci\u00f3n del documento de la OMS.", "excerpt_keywords": "Keywords: contamination, counterfeit pharmaceutical product, distribution, expiry date, first expiry/first out"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2ac17a3b-4b00-4404-8a5c-052b3cc57c02", "node_type": "4", "metadata": {"page_label": "253", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Containers are referred to as primary if they are intended to be in direct contact with the product. Secondary containers are not intended to be in direct contact with the product.\n\n**contamination**  \nThe undesired introduction of impurities of a chemical or microbiological nature, or of foreign matter, into or on to a starting material, intermediate or pharmaceutical product during handling, production, sampling, packaging or repackaging, storage or transportation.\n\n**contract**  \nBusiness agreement for the supply of goods or performance of work at a specified price.\n\n**counterfeit pharmaceutical product**  \nA pharmaceutical product which is deliberately and fraudulently mislabelled with respect to identity and/or source. Counterfeiting can apply to both branded and generic products, and counterfeit pharmaceutical products may include products with the correct ingredients, with the wrong ingredients, without active ingredients, with an incorrect quantity of active ingredient or with fake packaging.\n\n**cross-contamination**  \nContamination of a starting material, intermediate product or finished pharmaceutical product with another starting material or product during production, storage and transportation.\n\n**distribution**  \nThe procuring, purchasing, holding, storing, selling, supplying, importing, exporting, or movement of pharmaceutical products, with the exception of the dispensing or providing pharmaceutical products directly to a patient or his or her agent.\n\n**expiry date**  \nThe date given on the individual container (usually on the label) of a pharmaceutical product up to and including the date on which the product is expected to remain within specifications, if stored correctly. It is established for each batch by adding the shelf-life to the date of manufacture.\n\n**first expiry/first out (FEFO)**  \nA distribution procedure that ensures that the stock with the earliest expiry date is distributed and/or used before an identical stock item with a later expiry date is distributed and/or used.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "0046016f8b9525d95e18ec98a385f236a33be3fdf1470527388df01ed778a4f2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Containers are referred to as primary if they are intended to be in direct contact with the product. Secondary containers are not intended to be in direct contact with the product.\n\n**contamination**  \nThe undesired introduction of impurities of a chemical or microbiological nature, or of foreign matter, into or on to a starting material, intermediate or pharmaceutical product during handling, production, sampling, packaging or repackaging, storage or transportation.\n\n**contract**  \nBusiness agreement for the supply of goods or performance of work at a specified price.\n\n**counterfeit pharmaceutical product**  \nA pharmaceutical product which is deliberately and fraudulently mislabelled with respect to identity and/or source. Counterfeiting can apply to both branded and generic products, and counterfeit pharmaceutical products may include products with the correct ingredients, with the wrong ingredients, without active ingredients, with an incorrect quantity of active ingredient or with fake packaging.\n\n**cross-contamination**  \nContamination of a starting material, intermediate product or finished pharmaceutical product with another starting material or product during production, storage and transportation.\n\n**distribution**  \nThe procuring, purchasing, holding, storing, selling, supplying, importing, exporting, or movement of pharmaceutical products, with the exception of the dispensing or providing pharmaceutical products directly to a patient or his or her agent.\n\n**expiry date**  \nThe date given on the individual container (usually on the label) of a pharmaceutical product up to and including the date on which the product is expected to remain within specifications, if stored correctly. It is established for each batch by adding the shelf-life to the date of manufacture.\n\n**first expiry/first out (FEFO)**  \nA distribution procedure that ensures that the stock with the earliest expiry date is distributed and/or used before an identical stock item with a later expiry date is distributed and/or used.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2035, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "38b3d38f-5320-4bd1-b750-b46e27aede6e": {"__data__": {"id_": "38b3d38f-5320-4bd1-b750-b46e27aede6e", "embedding": null, "metadata": {"page_label": "254", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# forwarding agent\n\nA person or entity engaged in providing, either directly or indirectly, any service concerned with clearing and forwarding operations in any manner to any other person and includes a consignment agent.\n\n# good distribution practices (GDP)\n\nThat part of quality assurance that ensures that the quality of a pharmaceutical product is maintained by means of adequate control of the numerous activities which occur during the distribution process as well as providing a tool to secure the distribution system from counterfeits, unapproved, illegally imported, stolen, counterfeit, substandard, adulterated, and/or misbranded pharmaceutical products.\n\n# good manufacturing practices (GMP)\n\nThat part of quality assurance which ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization.\n\n# good pharmacy practice (GPP)\n\nThe practice of pharmacy aimed at providing and promoting the best use of medicines and other health care services and products, by patients and members of the public. It requires that the welfare of the patient is the pharmacist\u2019s prime concern at all times.\n\n# good storage practices (GSP)\n\nThat part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the storage thereof.\n\n# good trade and distribution practices (GTDP)\n\nThat part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the numerous activities which occur during the trade and the distribution process.\n\n# importation\n\nThe act of bringing or causing any goods to be brought into a customs territory (national territory, excluding any free zone).\n\n# intermediate product\n\nPartly processed product that must undergo further manufacturing steps before it becomes a bulk finished product.\n\n# labelling\n\nProcess of identifying a pharmaceutical product including the following information, as appropriate: name of the product; active ingredient(s),", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda diversas pr\u00e1cticas de calidad en la industria farmac\u00e9utica, incluyendo las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP), Buenas Pr\u00e1cticas de Manufactura (GMP), Buenas Pr\u00e1cticas de Farmacia (GPP), Buenas Pr\u00e1cticas de Almacenamiento (GSP) y Buenas Pr\u00e1cticas de Comercio y Distribuci\u00f3n (GTDP). Estas pr\u00e1cticas son esenciales para garantizar que los productos farmac\u00e9uticos mantengan su calidad a lo largo de todo el proceso de distribuci\u00f3n y almacenamiento, as\u00ed como para proteger a los pacientes de productos falsificados o de calidad inferior. Tambi\u00e9n se define el proceso de importaci\u00f3n y se menciona la importancia del etiquetado de productos farmac\u00e9uticos.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las principales diferencias entre las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) y las Buenas Pr\u00e1cticas de Almacenamiento (GSP) en el contexto de la calidad farmac\u00e9utica?**\n   - Esta pregunta busca aclarar las especificidades de cada pr\u00e1ctica y c\u00f3mo se complementan en el proceso de asegurar la calidad de los productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 medidas se pueden implementar para prevenir la entrada de productos farmac\u00e9uticos falsificados en el sistema de distribuci\u00f3n, seg\u00fan las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP)?**\n   - Esta pregunta se centra en las estrategias espec\u00edficas que se pueden adoptar para proteger el sistema de distribuci\u00f3n de productos no autorizados o de baja calidad.\n\n3. **\u00bfC\u00f3mo se define un \"producto intermedio\" en el contexto de la manufactura farmac\u00e9utica y qu\u00e9 pasos adicionales son necesarios para convertirlo en un producto terminado?**\n   - Esta pregunta busca profundizar en el proceso de manufactura y los requisitos que deben cumplirse para que un producto intermedio alcance su estado final como producto farmac\u00e9utico listo para el mercado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n extra\u00edda del documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la serie de informes t\u00e9cnicos 957 se centra en definiciones fundamentales relacionadas con la manipulaci\u00f3n, distribuci\u00f3n y calidad de los productos farmac\u00e9uticos. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n1. **Contenedores**:\n   - **Primarios**: Contenedores en contacto directo con el producto.\n   - **Secundarios**: Contenedores que no est\u00e1n en contacto directo con el producto.\n\n2. **Contaminaci\u00f3n**:\n   - Introducci\u00f3n no deseada de impurezas qu\u00edmicas, microbiol\u00f3gicas o materia extra\u00f1a en productos farmac\u00e9uticos durante diversas etapas como manejo, producci\u00f3n, almacenamiento y transporte.\n\n3. **Contratos**:\n   - Acuerdos comerciales para el suministro de bienes o la realizaci\u00f3n de trabajos a un precio espec\u00edfico.\n\n4. **Productos farmac\u00e9uticos falsificados**:\n   - Productos que est\u00e1n deliberadamente y fraudulentamente etiquetados incorrectamente en cuanto a identidad y/o fuente, que pueden incluir ingredientes correctos o incorrectos, o incluso carecer de ingredientes activos.\n\n5. **Contaminaci\u00f3n cruzada**:\n   - Contaminaci\u00f3n de un material inicial, producto intermedio o producto farmac\u00e9utico terminado con otro material o producto durante la producci\u00f3n, almacenamiento o transporte.\n\n6. **Distribuci\u00f3n**:\n   - Proceso de adquisici\u00f3n, almacenamiento, venta y movimiento de productos farmac\u00e9uticos, excluyendo la dispensaci\u00f3n directa a pacientes.\n\n7. **Fecha de caducidad**:\n   - Fecha en la que se espera que un producto farmac\u00e9utico mantenga sus especificaciones, determinada por la vida \u00fatil a\u00f1adida a la fecha de fabricaci\u00f3n.\n\n8. **Primeras fechas de caducidad primero (FEFO)**:\n   - Procedimiento de distribuci\u00f3n que asegura que los productos con la fecha de caducidad m\u00e1s temprana se utilicen antes que aquellos con fechas posteriores.\n\n### Conclusi\u00f3n\nEstas definiciones son esenciales para garantizar la calidad y seguridad de los productos farmac\u00e9uticos a lo largo de su ciclo de vida, desde la producci\u00f3n hasta la distribuci\u00f3n. La comprensi\u00f3n de estos t\u00e9rminos es crucial para los profesionales de la salud y la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: pharmaceutical quality assurance, good distribution practices, good manufacturing practices, importation, labeling"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3f901f5a-6000-48cb-865a-0fb24ffa5ec9", "node_type": "4", "metadata": {"page_label": "254", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# forwarding agent\n\nA person or entity engaged in providing, either directly or indirectly, any service concerned with clearing and forwarding operations in any manner to any other person and includes a consignment agent.\n\n# good distribution practices (GDP)\n\nThat part of quality assurance that ensures that the quality of a pharmaceutical product is maintained by means of adequate control of the numerous activities which occur during the distribution process as well as providing a tool to secure the distribution system from counterfeits, unapproved, illegally imported, stolen, counterfeit, substandard, adulterated, and/or misbranded pharmaceutical products.\n\n# good manufacturing practices (GMP)\n\nThat part of quality assurance which ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization.\n\n# good pharmacy practice (GPP)\n\nThe practice of pharmacy aimed at providing and promoting the best use of medicines and other health care services and products, by patients and members of the public. It requires that the welfare of the patient is the pharmacist\u2019s prime concern at all times.\n\n# good storage practices (GSP)\n\nThat part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the storage thereof.\n\n# good trade and distribution practices (GTDP)\n\nThat part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the numerous activities which occur during the trade and the distribution process.\n\n# importation\n\nThe act of bringing or causing any goods to be brought into a customs territory (national territory, excluding any free zone).\n\n# intermediate product\n\nPartly processed product that must undergo further manufacturing steps before it becomes a bulk finished product.\n\n# labelling\n\nProcess of identifying a pharmaceutical product including the following information, as appropriate: name of the product; active ingredient(s),", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "152361e95b893c202d55cee29d8dab4faf382a4fe59a32295cdc8471c54f78d2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# forwarding agent\n\nA person or entity engaged in providing, either directly or indirectly, any service concerned with clearing and forwarding operations in any manner to any other person and includes a consignment agent.\n\n# good distribution practices (GDP)\n\nThat part of quality assurance that ensures that the quality of a pharmaceutical product is maintained by means of adequate control of the numerous activities which occur during the distribution process as well as providing a tool to secure the distribution system from counterfeits, unapproved, illegally imported, stolen, counterfeit, substandard, adulterated, and/or misbranded pharmaceutical products.\n\n# good manufacturing practices (GMP)\n\nThat part of quality assurance which ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization.\n\n# good pharmacy practice (GPP)\n\nThe practice of pharmacy aimed at providing and promoting the best use of medicines and other health care services and products, by patients and members of the public. It requires that the welfare of the patient is the pharmacist\u2019s prime concern at all times.\n\n# good storage practices (GSP)\n\nThat part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the storage thereof.\n\n# good trade and distribution practices (GTDP)\n\nThat part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the numerous activities which occur during the trade and the distribution process.\n\n# importation\n\nThe act of bringing or causing any goods to be brought into a customs territory (national territory, excluding any free zone).\n\n# intermediate product\n\nPartly processed product that must undergo further manufacturing steps before it becomes a bulk finished product.\n\n# labelling\n\nProcess of identifying a pharmaceutical product including the following information, as appropriate: name of the product; active ingredient(s),", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2129, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "2955a0f9-d1f2-4c51-b3dc-ba0496b3cff3": {"__data__": {"id_": "2955a0f9-d1f2-4c51-b3dc-ba0496b3cff3", "embedding": null, "metadata": {"page_label": "255", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "type and amount; batch number; expiry date; special storage conditions or handling precautions; directions for use, warnings and precautions; names and addresses of the manufacturer and/or the supplier.\n\n**manufacture**  \nAll operations of purchase of materials and products, production, packaging, labelling, quality control, release, storage and distribution of pharmaceutical products, and the related controls.\n\n**marketing authorization**  \nA legal document issued by the competent medicines regulatory authority for the purpose of marketing or free distribution of a product after evaluation for safety, efficacy and quality. It must set out, inter alia, the name of the product, the pharmaceutical dosage form, the quantitative formula (including excipients) per unit dose (using INNs or national generic names where they exist), the shelf-life and storage conditions, and packaging characteristics. It specifies the information on which authorization is based (e.g. \u201cThe product(s) must conform to all the details provided in your application and as modified in subsequent correspondence\u201d). It also contains the product information approved for health professionals and the public, the sales category, the name and address of the holder of the authorization, and the period of validity of the authorization.\n\nOnce a product has been given marketing authorization, it is included on a list of authorized products \u2014 the register \u2014 and is often said to be \u201cregistered\u201d or to \u201chave registration\u201d. Market authorization may occasionally also be referred to as a \u201clicence\u201d or \u201cproduct licence\u201d.\n\n**pedigree**  \nA complete record that traces the ownership of and transactions relating to a pharmaceutical product as it is distributed through the supply chain.\n\n**pharmaceutical product**  \nAny product intended for human use, or veterinary product intended for administration to food-producing animals, presented in its finished dosage form, which is subject to control by pharmaceutical legislation in either the exporting or the importing state and includes products for which a prescription is required, products which may be sold to patients without a prescription, biologicals and vaccines. It does not, however, include medical devices.\n\n**product recall**  \nA process for withdrawing or removing a pharmaceutical product from the pharmaceutical distribution chain because of defects in the product, complaints of serious adverse reactions to the product and/or concerns.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la autorizaci\u00f3n de comercializaci\u00f3n de un producto farmac\u00e9utico?**\n   - La autorizaci\u00f3n de comercializaci\u00f3n debe incluir, entre otros aspectos, el nombre del producto, la forma farmac\u00e9utica, la f\u00f3rmula cuantitativa (incluyendo excipientes) por dosis, la vida \u00fatil y las condiciones de almacenamiento, as\u00ed como las caracter\u00edsticas del envase. Tambi\u00e9n debe especificar la informaci\u00f3n sobre la que se basa la autorizaci\u00f3n y contener la informaci\u00f3n del producto aprobada para profesionales de la salud y el p\u00fablico.\n\n2. **\u00bfCu\u00e1l es la diferencia entre un producto farmac\u00e9utico y un dispositivo m\u00e9dico seg\u00fan el contexto proporcionado?**\n   - Un producto farmac\u00e9utico se define como cualquier producto destinado para uso humano o veterinario, presentado en su forma de dosificaci\u00f3n final y sujeto a control por la legislaci\u00f3n farmac\u00e9utica. Esto incluye productos que requieren receta, productos de venta libre, biol\u00f3gicos y vacunas. En cambio, los dispositivos m\u00e9dicos no est\u00e1n incluidos en esta definici\u00f3n.\n\n3. **\u00bfQu\u00e9 implica el proceso de \"recall\" de un producto farmac\u00e9utico?**\n   - El proceso de \"recall\" implica la retirada o eliminaci\u00f3n de un producto farmac\u00e9utico de la cadena de distribuci\u00f3n debido a defectos en el producto, quejas de reacciones adversas graves o preocupaciones relacionadas con la seguridad del producto.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona definiciones y descripciones clave relacionadas con la fabricaci\u00f3n, autorizaci\u00f3n de comercializaci\u00f3n, trazabilidad y retirada de productos farmac\u00e9uticos. Se enfatiza la importancia de la regulaci\u00f3n y control en la producci\u00f3n y distribuci\u00f3n de productos destinados a la salud humana y animal, as\u00ed como los procedimientos necesarios para garantizar la seguridad y eficacia de estos productos en el mercado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) se centra en las pr\u00e1cticas de calidad en la industria farmac\u00e9utica, destacando varios conceptos fundamentales:\n\n1. **Agente de Forwarding**: Persona o entidad que proporciona servicios relacionados con las operaciones de despacho y env\u00edo de productos.\n\n2. **Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP)**: Aseguran que la calidad de los productos farmac\u00e9uticos se mantenga durante el proceso de distribuci\u00f3n, protegiendo el sistema de productos falsificados y de calidad inferior.\n\n3. **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Garantizan que los productos farmac\u00e9uticos se produzcan y controlen de acuerdo con est\u00e1ndares de calidad apropiados para su uso previsto.\n\n4. **Buenas Pr\u00e1cticas de Farmacia (GPP)**: Se enfocan en el uso \u00f3ptimo de medicamentos y servicios de salud, priorizando el bienestar del paciente.\n\n5. **Buenas Pr\u00e1cticas de Almacenamiento (GSP)**: Aseguran que la calidad de los productos farmac\u00e9uticos se mantenga durante su almacenamiento.\n\n6. **Buenas Pr\u00e1cticas de Comercio y Distribuci\u00f3n (GTDP)**: Aseguran la calidad de los productos durante las actividades de comercio y distribuci\u00f3n.\n\n7. **Importaci\u00f3n**: Acto de traer bienes a un territorio aduanero.\n\n8. **Producto Intermedio**: Producto parcialmente procesado que requiere pasos adicionales de manufactura para convertirse en un producto terminado.\n\n9. **Etiquetado**: Proceso de identificaci\u00f3n de un producto farmac\u00e9utico, que incluye informaci\u00f3n relevante como el nombre del producto y los ingredientes activos.\n\n### Conclusi\u00f3n\nEstos conceptos son esenciales para garantizar la calidad y seguridad de los productos farmac\u00e9uticos, protegiendo tanto a los consumidores como a la integridad del sistema de salud.", "excerpt_keywords": "Keywords: marketing authorization, pharmaceutical product, product recall, manufacture, pedigree"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "08f354ca-2695-416b-8137-6eb975303764", "node_type": "4", "metadata": {"page_label": "255", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "type and amount; batch number; expiry date; special storage conditions or handling precautions; directions for use, warnings and precautions; names and addresses of the manufacturer and/or the supplier.\n\n**manufacture**  \nAll operations of purchase of materials and products, production, packaging, labelling, quality control, release, storage and distribution of pharmaceutical products, and the related controls.\n\n**marketing authorization**  \nA legal document issued by the competent medicines regulatory authority for the purpose of marketing or free distribution of a product after evaluation for safety, efficacy and quality. It must set out, inter alia, the name of the product, the pharmaceutical dosage form, the quantitative formula (including excipients) per unit dose (using INNs or national generic names where they exist), the shelf-life and storage conditions, and packaging characteristics. It specifies the information on which authorization is based (e.g. \u201cThe product(s) must conform to all the details provided in your application and as modified in subsequent correspondence\u201d). It also contains the product information approved for health professionals and the public, the sales category, the name and address of the holder of the authorization, and the period of validity of the authorization.\n\nOnce a product has been given marketing authorization, it is included on a list of authorized products \u2014 the register \u2014 and is often said to be \u201cregistered\u201d or to \u201chave registration\u201d. Market authorization may occasionally also be referred to as a \u201clicence\u201d or \u201cproduct licence\u201d.\n\n**pedigree**  \nA complete record that traces the ownership of and transactions relating to a pharmaceutical product as it is distributed through the supply chain.\n\n**pharmaceutical product**  \nAny product intended for human use, or veterinary product intended for administration to food-producing animals, presented in its finished dosage form, which is subject to control by pharmaceutical legislation in either the exporting or the importing state and includes products for which a prescription is required, products which may be sold to patients without a prescription, biologicals and vaccines. It does not, however, include medical devices.\n\n**product recall**  \nA process for withdrawing or removing a pharmaceutical product from the pharmaceutical distribution chain because of defects in the product, complaints of serious adverse reactions to the product and/or concerns.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a4f4ce06c8efeb829d4dd3a6b18bf2b561ff8ca0870a1d5c680ff327c57fb6b4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "type and amount; batch number; expiry date; special storage conditions or handling precautions; directions for use, warnings and precautions; names and addresses of the manufacturer and/or the supplier.\n\n**manufacture**  \nAll operations of purchase of materials and products, production, packaging, labelling, quality control, release, storage and distribution of pharmaceutical products, and the related controls.\n\n**marketing authorization**  \nA legal document issued by the competent medicines regulatory authority for the purpose of marketing or free distribution of a product after evaluation for safety, efficacy and quality. It must set out, inter alia, the name of the product, the pharmaceutical dosage form, the quantitative formula (including excipients) per unit dose (using INNs or national generic names where they exist), the shelf-life and storage conditions, and packaging characteristics. It specifies the information on which authorization is based (e.g. \u201cThe product(s) must conform to all the details provided in your application and as modified in subsequent correspondence\u201d). It also contains the product information approved for health professionals and the public, the sales category, the name and address of the holder of the authorization, and the period of validity of the authorization.\n\nOnce a product has been given marketing authorization, it is included on a list of authorized products \u2014 the register \u2014 and is often said to be \u201cregistered\u201d or to \u201chave registration\u201d. Market authorization may occasionally also be referred to as a \u201clicence\u201d or \u201cproduct licence\u201d.\n\n**pedigree**  \nA complete record that traces the ownership of and transactions relating to a pharmaceutical product as it is distributed through the supply chain.\n\n**pharmaceutical product**  \nAny product intended for human use, or veterinary product intended for administration to food-producing animals, presented in its finished dosage form, which is subject to control by pharmaceutical legislation in either the exporting or the importing state and includes products for which a prescription is required, products which may be sold to patients without a prescription, biologicals and vaccines. It does not, however, include medical devices.\n\n**product recall**  \nA process for withdrawing or removing a pharmaceutical product from the pharmaceutical distribution chain because of defects in the product, complaints of serious adverse reactions to the product and/or concerns.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2477, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f542bb61-6fda-45b2-a0c9-385964ced52b": {"__data__": {"id_": "f542bb61-6fda-45b2-a0c9-385964ced52b", "embedding": null, "metadata": {"page_label": "256", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "that the product is or may be counterfeit. The recall might be initiated by the manufacturer, importer, wholesaler, distributor or a responsible agency.\n\n**quality assurance**  \nA wide-ranging concept covering all matters that individually or collectively influence the quality of a product. It is the totality of the arrangements made with the object of ensuring that pharmaceutical products are of the quality required for their intended use.\n\n**quality system**  \nAn appropriate infrastructure, encompassing the organizational structure, procedures, processes and resources, and systematic actions necessary to ensure adequate confidence that a product (or services) will satisfy given requirements for quality.\n\n**quarantine**  \nThe status of pharmaceutical products isolated physically or by other effective means while a decision is awaited on their release, rejection or reprocessing.\n\n**sampling**  \nOperations designed to obtain a representative portion of a pharmaceutical product, based on an appropriate statistical procedure, for a defined purpose, e.g. acceptance of consignments or batch release.\n\n**shelf-life**  \nThe period of time during which a pharmaceutical product, if stored correctly, is expected to comply with the specification as determined by stability studies on a number of batches of the product. The shelf-life is used to establish the expiry date of each batch.\n\n**standard operating procedure (SOP)**  \nAn authorized, written procedure giving instructions for performing operations not necessarily specific to a given product but of a more general nature (e.g. equipment operation, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection).\n\n**storage**  \nThe storing of pharmaceutical products up to the point of use.\n\n**supplier**  \nA person or entity engaged in the activity of providing products and/or services.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda conceptos clave relacionados con la calidad de los productos farmac\u00e9uticos. Define t\u00e9rminos como \"aseguramiento de la calidad\", \"sistema de calidad\", \"cuarentena\", \"muestreo\", \"vida \u00fatil\", \"procedimiento operativo est\u00e1ndar (SOP)\", \"almacenamiento\" y \"proveedor\". Estos t\u00e9rminos son fundamentales para garantizar que los productos farmac\u00e9uticos cumplan con los est\u00e1ndares requeridos para su uso previsto y para manejar situaciones como el retiro de productos potencialmente falsificados.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 procedimientos se deben seguir para garantizar que un producto farmac\u00e9utico cumpla con los est\u00e1ndares de calidad requeridos?**\n   - Esta pregunta se puede responder a partir de la definici\u00f3n de \"sistema de calidad\" y \"procedimiento operativo est\u00e1ndar (SOP)\" en el contexto.\n\n2. **\u00bfCu\u00e1l es el proceso que se sigue cuando un producto farmac\u00e9utico es aislado en cuarentena?**\n   - La respuesta se puede encontrar en la definici\u00f3n de \"cuarentena\", que describe el estado de los productos farmac\u00e9uticos mientras se espera una decisi\u00f3n sobre su liberaci\u00f3n o rechazo.\n\n3. **\u00bfC\u00f3mo se determina la vida \u00fatil de un producto farmac\u00e9utico y qu\u00e9 factores influyen en su establecimiento?**\n   - La respuesta se puede derivar de la explicaci\u00f3n sobre \"vida \u00fatil\", que menciona la importancia de los estudios de estabilidad y el almacenamiento correcto para determinar el periodo en que un producto cumple con sus especificaciones.", "prev_section_summary": "La secci\u00f3n proporciona definiciones y descripciones clave relacionadas con la regulaci\u00f3n y control de productos farmac\u00e9uticos. Los temas clave incluyen:\n\n1. **Autorizaci\u00f3n de Comercializaci\u00f3n**: Documento legal emitido por la autoridad reguladora que permite la comercializaci\u00f3n de un producto tras evaluar su seguridad, eficacia y calidad. Debe incluir informaci\u00f3n como el nombre del producto, forma farmac\u00e9utica, f\u00f3rmula cuantitativa, vida \u00fatil, condiciones de almacenamiento y detalles del titular de la autorizaci\u00f3n.\n\n2. **Manufactura**: Se refiere a todas las operaciones relacionadas con la compra de materiales, producci\u00f3n, envasado, etiquetado, control de calidad, almacenamiento y distribuci\u00f3n de productos farmac\u00e9uticos.\n\n3. **Pedigr\u00ed**: Registro completo que rastrea la propiedad y las transacciones de un producto farmac\u00e9utico a lo largo de la cadena de suministro.\n\n4. **Producto Farmac\u00e9utico**: Cualquier producto destinado al uso humano o veterinario, presentado en su forma de dosificaci\u00f3n final y sujeto a la legislaci\u00f3n farmac\u00e9utica, excluyendo dispositivos m\u00e9dicos.\n\n5. **Retirada de Producto (Recall)**: Proceso de retirar un producto farmac\u00e9utico de la cadena de distribuci\u00f3n debido a defectos, quejas de reacciones adversas graves o preocupaciones de seguridad.\n\n### Entidades Clave:\n- **Autoridad Reguladora**: Entidad competente que emite la autorizaci\u00f3n de comercializaci\u00f3n.\n- **Titular de la Autorizaci\u00f3n**: Nombre y direcci\u00f3n de la entidad que posee la autorizaci\u00f3n.\n- **Productos Farmac\u00e9uticos**: Incluyen medicamentos con receta, de venta libre, biol\u00f3gicos y vacunas.\n\nEste resumen destaca la importancia de la regulaci\u00f3n en la producci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos para garantizar su seguridad y eficacia en el mercado.", "excerpt_keywords": "Keywords: quality assurance, quarantine, shelf-life, standard operating procedure, pharmaceutical products"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "07ce91a8-97af-471f-9d7f-2cd7f299d58b", "node_type": "4", "metadata": {"page_label": "256", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "that the product is or may be counterfeit. The recall might be initiated by the manufacturer, importer, wholesaler, distributor or a responsible agency.\n\n**quality assurance**  \nA wide-ranging concept covering all matters that individually or collectively influence the quality of a product. It is the totality of the arrangements made with the object of ensuring that pharmaceutical products are of the quality required for their intended use.\n\n**quality system**  \nAn appropriate infrastructure, encompassing the organizational structure, procedures, processes and resources, and systematic actions necessary to ensure adequate confidence that a product (or services) will satisfy given requirements for quality.\n\n**quarantine**  \nThe status of pharmaceutical products isolated physically or by other effective means while a decision is awaited on their release, rejection or reprocessing.\n\n**sampling**  \nOperations designed to obtain a representative portion of a pharmaceutical product, based on an appropriate statistical procedure, for a defined purpose, e.g. acceptance of consignments or batch release.\n\n**shelf-life**  \nThe period of time during which a pharmaceutical product, if stored correctly, is expected to comply with the specification as determined by stability studies on a number of batches of the product. The shelf-life is used to establish the expiry date of each batch.\n\n**standard operating procedure (SOP)**  \nAn authorized, written procedure giving instructions for performing operations not necessarily specific to a given product but of a more general nature (e.g. equipment operation, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection).\n\n**storage**  \nThe storing of pharmaceutical products up to the point of use.\n\n**supplier**  \nA person or entity engaged in the activity of providing products and/or services.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "8cc96a872a06bb56d361e790aa7c04a26d0c8a580e04beb7bdd4f5e33c252a6e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "that the product is or may be counterfeit. The recall might be initiated by the manufacturer, importer, wholesaler, distributor or a responsible agency.\n\n**quality assurance**  \nA wide-ranging concept covering all matters that individually or collectively influence the quality of a product. It is the totality of the arrangements made with the object of ensuring that pharmaceutical products are of the quality required for their intended use.\n\n**quality system**  \nAn appropriate infrastructure, encompassing the organizational structure, procedures, processes and resources, and systematic actions necessary to ensure adequate confidence that a product (or services) will satisfy given requirements for quality.\n\n**quarantine**  \nThe status of pharmaceutical products isolated physically or by other effective means while a decision is awaited on their release, rejection or reprocessing.\n\n**sampling**  \nOperations designed to obtain a representative portion of a pharmaceutical product, based on an appropriate statistical procedure, for a defined purpose, e.g. acceptance of consignments or batch release.\n\n**shelf-life**  \nThe period of time during which a pharmaceutical product, if stored correctly, is expected to comply with the specification as determined by stability studies on a number of batches of the product. The shelf-life is used to establish the expiry date of each batch.\n\n**standard operating procedure (SOP)**  \nAn authorized, written procedure giving instructions for performing operations not necessarily specific to a given product but of a more general nature (e.g. equipment operation, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection).\n\n**storage**  \nThe storing of pharmaceutical products up to the point of use.\n\n**supplier**  \nA person or entity engaged in the activity of providing products and/or services.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1903, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "dff11a93-a5ca-4a58-b972-d7402574f00f": {"__data__": {"id_": "dff11a93-a5ca-4a58-b972-d7402574f00f", "embedding": null, "metadata": {"page_label": "257", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# General principles\n\n4.1 All parties involved in the distribution of pharmaceutical products have a responsibility to ensure that the quality of pharmaceutical products and the integrity of the distribution chain is maintained throughout the distribution process from the site of the manufacturer to the entity responsible for dispensing or providing the product to the patient or his or her agent.\n\n4.2 The principles of GDP should be included in national legislation and guidelines for the distribution of pharmaceutical products, in a country or region as applicable, as a means of establishing minimum standards.\n\n4.3 The principles of GDP are applicable both to pharmaceutical products moving forward in the distribution chain from the manufacturer to the entity responsible for dispensing or providing pharmaceutical products to the patient and to products which are moving backwards in the chain, for example, as a result of the return or recall thereof.\n\n4.4 The principles of GDP should also be adhered to in the case of pharmaceutical products which are donated.\n\n4.5 All entities involved in the distribution process should apply due diligence with adherence to the principles of GDP, for example, in procedures relating to traceability and in recognition of security risks.\n\n4.6 There should be collaboration between all parties including governments, customs agencies, law enforcement agencies, regulatory authorities, manufacturers, distributors and entities responsible for the supply of pharmaceutical products to patients to ensure the quality and safety of pharmaceutical products and prevent the exposure of patients to counterfeit pharmaceutical products.\n\n# Regulation of the distribution of pharmaceutical products\n\n5.1 National legislation should be in place to regulate the activities of persons or entities involved in the distribution of pharmaceutical products.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Responsabilidad en la distribuci\u00f3n de productos farmac\u00e9uticos**: Todas las partes involucradas en la distribuci\u00f3n de productos farmac\u00e9uticos deben garantizar la calidad de los productos y la integridad de la cadena de distribuci\u00f3n desde el fabricante hasta el paciente.\n\n2. **Principios de Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP)**: Los principios de GDP deben ser incorporados en la legislaci\u00f3n nacional y aplicarse a todos los productos farmac\u00e9uticos, independientemente de si se mueven hacia adelante o hacia atr\u00e1s en la cadena de distribuci\u00f3n.\n\n3. **Colaboraci\u00f3n y regulaci\u00f3n**: Es esencial la colaboraci\u00f3n entre diversas entidades, como gobiernos y agencias de regulaci\u00f3n, para asegurar la calidad y seguridad de los productos farmac\u00e9uticos y prevenir la exposici\u00f3n de los pacientes a productos falsificados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben tomar las entidades involucradas en la distribuci\u00f3n para asegurar la trazabilidad de los productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en las pr\u00e1cticas espec\u00edficas que deben seguir las entidades para cumplir con los principios de GDP, que no se detalla expl\u00edcitamente en el texto.\n\n2. **\u00bfC\u00f3mo se deben manejar los productos farmac\u00e9uticos que son devueltos o retirados del mercado seg\u00fan los principios de GDP?**\n   - Esta pregunta busca informaci\u00f3n sobre el manejo espec\u00edfico de productos que regresan a la cadena de distribuci\u00f3n, un aspecto que podr\u00eda no estar ampliamente cubierto en otras fuentes.\n\n3. **\u00bfQu\u00e9 papel juegan las agencias de aduanas y las fuerzas del orden en la colaboraci\u00f3n para prevenir la distribuci\u00f3n de productos farmac\u00e9uticos falsificados?**\n   - Esta pregunta se enfoca en el papel espec\u00edfico de estas entidades en la cadena de distribuci\u00f3n y c\u00f3mo contribuyen a la seguridad del suministro farmac\u00e9utico, un detalle que puede no ser evidente en otros documentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta definiciones y conceptos esenciales relacionados con la calidad de los productos farmac\u00e9uticos. A continuaci\u00f3n se resumen los temas clave y las entidades mencionadas:\n\n1. **Aseguramiento de la Calidad**: Concepto amplio que abarca todos los aspectos que influyen en la calidad de un producto farmac\u00e9utico, asegurando que cumpla con los est\u00e1ndares requeridos para su uso previsto.\n\n2. **Sistema de Calidad**: Infraestructura adecuada que incluye la estructura organizativa, procedimientos, procesos y recursos necesarios para garantizar que un producto o servicio satisfaga los requisitos de calidad.\n\n3. **Cuarentena**: Estado de los productos farmac\u00e9uticos que han sido aislados mientras se espera una decisi\u00f3n sobre su liberaci\u00f3n, rechazo o reprocesamiento.\n\n4. **Muestreo**: Operaciones dise\u00f1adas para obtener una porci\u00f3n representativa de un producto farmac\u00e9utico, utilizando procedimientos estad\u00edsticos adecuados para fines espec\u00edficos, como la aceptaci\u00f3n de consignaciones o la liberaci\u00f3n de lotes.\n\n5. **Vida \u00datil**: Per\u00edodo durante el cual un producto farmac\u00e9utico, si se almacena correctamente, se espera que cumpla con las especificaciones establecidas a partir de estudios de estabilidad.\n\n6. **Procedimiento Operativo Est\u00e1ndar (SOP)**: Procedimiento escrito autorizado que proporciona instrucciones para realizar operaciones generales, no necesariamente espec\u00edficas de un producto.\n\n7. **Almacenamiento**: Proceso de guardar productos farmac\u00e9uticos hasta el momento de su uso.\n\n8. **Proveedor**: Persona o entidad que se dedica a proporcionar productos y/o servicios.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece directrices y est\u00e1ndares para la calidad de los productos farmac\u00e9uticos.\n- **Fabricante, Importador, Mayorista, Distribuidor**: Entidades involucradas en la cadena de suministro de productos farmac\u00e9uticos, especialmente en el contexto de retiros de productos.\n\nEste resumen destaca la importancia de estos conceptos en la garant\u00eda de la calidad y seguridad de los productos farmac\u00e9uticos en el mercado.", "excerpt_keywords": "Keywords: pharmaceutical distribution, quality assurance, Good Distribution Practices, regulatory compliance, counterfeit prevention"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "48def0cc-4f00-4942-94c3-f22222aa35e4", "node_type": "4", "metadata": {"page_label": "257", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# General principles\n\n4.1 All parties involved in the distribution of pharmaceutical products have a responsibility to ensure that the quality of pharmaceutical products and the integrity of the distribution chain is maintained throughout the distribution process from the site of the manufacturer to the entity responsible for dispensing or providing the product to the patient or his or her agent.\n\n4.2 The principles of GDP should be included in national legislation and guidelines for the distribution of pharmaceutical products, in a country or region as applicable, as a means of establishing minimum standards.\n\n4.3 The principles of GDP are applicable both to pharmaceutical products moving forward in the distribution chain from the manufacturer to the entity responsible for dispensing or providing pharmaceutical products to the patient and to products which are moving backwards in the chain, for example, as a result of the return or recall thereof.\n\n4.4 The principles of GDP should also be adhered to in the case of pharmaceutical products which are donated.\n\n4.5 All entities involved in the distribution process should apply due diligence with adherence to the principles of GDP, for example, in procedures relating to traceability and in recognition of security risks.\n\n4.6 There should be collaboration between all parties including governments, customs agencies, law enforcement agencies, regulatory authorities, manufacturers, distributors and entities responsible for the supply of pharmaceutical products to patients to ensure the quality and safety of pharmaceutical products and prevent the exposure of patients to counterfeit pharmaceutical products.\n\n# Regulation of the distribution of pharmaceutical products\n\n5.1 National legislation should be in place to regulate the activities of persons or entities involved in the distribution of pharmaceutical products.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "6d5490bb994fb9d87dde0d0408a2336288388786599674a4d556c27f40630614", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# General principles\n\n4.1 All parties involved in the distribution of pharmaceutical products have a responsibility to ensure that the quality of pharmaceutical products and the integrity of the distribution chain is maintained throughout the distribution process from the site of the manufacturer to the entity responsible for dispensing or providing the product to the patient or his or her agent.\n\n4.2 The principles of GDP should be included in national legislation and guidelines for the distribution of pharmaceutical products, in a country or region as applicable, as a means of establishing minimum standards.\n\n4.3 The principles of GDP are applicable both to pharmaceutical products moving forward in the distribution chain from the manufacturer to the entity responsible for dispensing or providing pharmaceutical products to the patient and to products which are moving backwards in the chain, for example, as a result of the return or recall thereof.\n\n4.4 The principles of GDP should also be adhered to in the case of pharmaceutical products which are donated.\n\n4.5 All entities involved in the distribution process should apply due diligence with adherence to the principles of GDP, for example, in procedures relating to traceability and in recognition of security risks.\n\n4.6 There should be collaboration between all parties including governments, customs agencies, law enforcement agencies, regulatory authorities, manufacturers, distributors and entities responsible for the supply of pharmaceutical products to patients to ensure the quality and safety of pharmaceutical products and prevent the exposure of patients to counterfeit pharmaceutical products.\n\n# Regulation of the distribution of pharmaceutical products\n\n5.1 National legislation should be in place to regulate the activities of persons or entities involved in the distribution of pharmaceutical products.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1889, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a8491801-c310-498e-beec-9422bddae7d3": {"__data__": {"id_": "a8491801-c310-498e-beec-9422bddae7d3", "embedding": null, "metadata": {"page_label": "258", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 5.2\n\nThe distributor or the organization to which the distributor belongs should be an entity that is appropriately authorized in terms of applicable legislation to perform the function(s) that it intends to perform. The distributor or the organization to which it belongs should be held accountable for the activities that it performs which relate to the distribution of pharmaceutical products.\n\n# 5.3\n\nOnly persons or entities which are authorized to do so and/or which hold the appropriate licence should be entitled to import or export pharmaceutical products.\n\n# 5.4\n\nDistributors or their agents may only distribute a pharmaceutical product within or to a country or territory if a marketing authorization or similar authorization has been granted, which allows the use of that pharmaceutical product in that country or territory.\n\n# 5.5\n\nHolders of an authorization to distribute pharmaceutical products should obtain their supplies of pharmaceutical products only from persons or entities which are in possession of the applicable authorization to sell or supply such products to a distributor.\n\n# 5.6\n\nDistributors or their agents should supply pharmaceutical products only to persons or entities which are themselves authorized to acquire such products either in terms of an authorization to act as a distributor or to sell or supply products directly to a patient or to his or her agent.\n\n# 5.7\n\nSome duties and responsibilities may be delegated or contracted out to suitably designated persons or entities as authorized and as necessary. Duties and responsibilities may only be delegated to entities which are suitably authorized in line with the national legislation. Duties and responsibilities should be specified in a written agreement. There should be no gaps or unexplained overlaps with regard to the application of GDP. These delegated and contracted out activities should be documented in agreements or contracts. There should be a periodic audit of such activities with regard to application of GDP.\n\n# 5.8\n\nIf a distributor or his or her agent subcontracts an activity to another entity, the person or entity to whom the activity is subcontracted must be appropriately authorized to perform the subcontracted activity and should uphold the same standards as the distributor.\n\n# 5.9\n\nThe sale of pharmaceutical products via the Internet should be limited to registered and authorized mail-order pharmacies or other authorized entities.\n\n# 6. Organization and management\n\n6.1 There should be an adequate organizational structure for each entity defined with the aid of an organizational chart. The responsibility, authority and interrelationships of all personnel should be clearly indicated.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre la distribuci\u00f3n de productos farmac\u00e9uticos, enfatizando la necesidad de que los distribuidores y las entidades relacionadas est\u00e9n debidamente autorizados y cumplan con la legislaci\u00f3n aplicable. Se detallan las responsabilidades de los distribuidores, la importancia de la autorizaci\u00f3n para la importaci\u00f3n y exportaci\u00f3n, y las condiciones bajo las cuales se pueden subcontratar actividades. Tambi\u00e9n se menciona la regulaci\u00f3n de la venta de productos farmac\u00e9uticos a trav\u00e9s de Internet y la necesidad de una estructura organizativa adecuada.\n\n### Preguntas\n1. **\u00bfQu\u00e9 requisitos deben cumplir los distribuidores para obtener y mantener su autorizaci\u00f3n para distribuir productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en los criterios espec\u00edficos que los distribuidores deben cumplir seg\u00fan la legislaci\u00f3n aplicable, lo cual no se detalla en otras fuentes.\n\n2. **\u00bfCu\u00e1les son las implicaciones de subcontratar actividades en la distribuci\u00f3n de productos farmac\u00e9uticos seg\u00fan las directrices de la OMS?**\n   - Esta pregunta aborda las responsabilidades y condiciones que deben cumplirse al subcontratar, as\u00ed como la necesidad de documentaci\u00f3n y auditor\u00eda, aspectos que pueden no estar claramente especificados en otras normativas.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse para garantizar que la venta de productos farmac\u00e9uticos por Internet se realice de manera segura y legal?**\n   - Esta pregunta se enfoca en las restricciones y regulaciones espec\u00edficas que deben seguirse para la venta en l\u00ednea, un tema que puede no estar ampliamente cubierto en otras fuentes de informaci\u00f3n sobre comercio electr\u00f3nico y productos farmac\u00e9uticos.", "prev_section_summary": "### Temas Clave\n\n1. **Responsabilidad en la Distribuci\u00f3n**: Todas las partes involucradas en la distribuci\u00f3n de productos farmac\u00e9uticos deben asegurar la calidad de los productos y la integridad de la cadena de distribuci\u00f3n desde el fabricante hasta el paciente.\n\n2. **Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP)**: Los principios de GDP deben ser incorporados en la legislaci\u00f3n nacional y aplicarse a todos los productos farmac\u00e9uticos, tanto en su movimiento hacia adelante como en el retorno o la retirada del mercado.\n\n3. **Trazabilidad y Diligencia Debida**: Las entidades deben aplicar procedimientos de trazabilidad y reconocer los riesgos de seguridad, cumpliendo con los principios de GDP.\n\n4. **Colaboraci\u00f3n Interinstitucional**: Es fundamental la colaboraci\u00f3n entre gobiernos, agencias de aduanas, fuerzas del orden, autoridades regulatorias, fabricantes y distribuidores para garantizar la calidad y seguridad de los productos farmac\u00e9uticos y prevenir la distribuci\u00f3n de productos falsificados.\n\n5. **Regulaci\u00f3n Nacional**: Se debe establecer legislaci\u00f3n nacional para regular las actividades de las personas o entidades involucradas en la distribuci\u00f3n de productos farmac\u00e9uticos.\n\n### Entidades Involucradas\n\n- **Gobiernos**: Responsables de establecer y hacer cumplir la legislaci\u00f3n relacionada con la distribuci\u00f3n de productos farmac\u00e9uticos.\n- **Agencias de Aduanas**: Colaboran en la supervisi\u00f3n y control de la entrada y salida de productos farmac\u00e9uticos.\n- **Fuerzas del Orden**: Ayudan a prevenir la distribuci\u00f3n de productos falsificados y a mantener la seguridad en la cadena de suministro.\n- **Autoridades Regulatorias**: Se encargan de la regulaci\u00f3n y supervisi\u00f3n de la calidad de los productos farmac\u00e9uticos.\n- **Fabricantes**: Producen los productos farmac\u00e9uticos y deben asegurar su calidad desde el inicio.\n- **Distribuidores**: Encargados de la distribuci\u00f3n de productos farmac\u00e9uticos a los puntos de venta o a los pacientes.\n- **Entidades de Suministro**: Proporcionan los productos farmac\u00e9uticos a los pacientes o sus agentes.", "excerpt_keywords": "Keywords: distribution, pharmaceutical products, authorization, good distribution practices, regulatory compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "778fb013-d3dd-4975-99f0-bf5d95dcf7e6", "node_type": "4", "metadata": {"page_label": "258", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 5.2\n\nThe distributor or the organization to which the distributor belongs should be an entity that is appropriately authorized in terms of applicable legislation to perform the function(s) that it intends to perform. The distributor or the organization to which it belongs should be held accountable for the activities that it performs which relate to the distribution of pharmaceutical products.\n\n# 5.3\n\nOnly persons or entities which are authorized to do so and/or which hold the appropriate licence should be entitled to import or export pharmaceutical products.\n\n# 5.4\n\nDistributors or their agents may only distribute a pharmaceutical product within or to a country or territory if a marketing authorization or similar authorization has been granted, which allows the use of that pharmaceutical product in that country or territory.\n\n# 5.5\n\nHolders of an authorization to distribute pharmaceutical products should obtain their supplies of pharmaceutical products only from persons or entities which are in possession of the applicable authorization to sell or supply such products to a distributor.\n\n# 5.6\n\nDistributors or their agents should supply pharmaceutical products only to persons or entities which are themselves authorized to acquire such products either in terms of an authorization to act as a distributor or to sell or supply products directly to a patient or to his or her agent.\n\n# 5.7\n\nSome duties and responsibilities may be delegated or contracted out to suitably designated persons or entities as authorized and as necessary. Duties and responsibilities may only be delegated to entities which are suitably authorized in line with the national legislation. Duties and responsibilities should be specified in a written agreement. There should be no gaps or unexplained overlaps with regard to the application of GDP. These delegated and contracted out activities should be documented in agreements or contracts. There should be a periodic audit of such activities with regard to application of GDP.\n\n# 5.8\n\nIf a distributor or his or her agent subcontracts an activity to another entity, the person or entity to whom the activity is subcontracted must be appropriately authorized to perform the subcontracted activity and should uphold the same standards as the distributor.\n\n# 5.9\n\nThe sale of pharmaceutical products via the Internet should be limited to registered and authorized mail-order pharmacies or other authorized entities.\n\n# 6. Organization and management\n\n6.1 There should be an adequate organizational structure for each entity defined with the aid of an organizational chart. The responsibility, authority and interrelationships of all personnel should be clearly indicated.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "44e01d2e577fec0402ed47e33095318efd48d0e786916a04e3c08169d75c4a49", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 5.2\n\nThe distributor or the organization to which the distributor belongs should be an entity that is appropriately authorized in terms of applicable legislation to perform the function(s) that it intends to perform. The distributor or the organization to which it belongs should be held accountable for the activities that it performs which relate to the distribution of pharmaceutical products.\n\n# 5.3\n\nOnly persons or entities which are authorized to do so and/or which hold the appropriate licence should be entitled to import or export pharmaceutical products.\n\n# 5.4\n\nDistributors or their agents may only distribute a pharmaceutical product within or to a country or territory if a marketing authorization or similar authorization has been granted, which allows the use of that pharmaceutical product in that country or territory.\n\n# 5.5\n\nHolders of an authorization to distribute pharmaceutical products should obtain their supplies of pharmaceutical products only from persons or entities which are in possession of the applicable authorization to sell or supply such products to a distributor.\n\n# 5.6\n\nDistributors or their agents should supply pharmaceutical products only to persons or entities which are themselves authorized to acquire such products either in terms of an authorization to act as a distributor or to sell or supply products directly to a patient or to his or her agent.\n\n# 5.7\n\nSome duties and responsibilities may be delegated or contracted out to suitably designated persons or entities as authorized and as necessary. Duties and responsibilities may only be delegated to entities which are suitably authorized in line with the national legislation. Duties and responsibilities should be specified in a written agreement. There should be no gaps or unexplained overlaps with regard to the application of GDP. These delegated and contracted out activities should be documented in agreements or contracts. There should be a periodic audit of such activities with regard to application of GDP.\n\n# 5.8\n\nIf a distributor or his or her agent subcontracts an activity to another entity, the person or entity to whom the activity is subcontracted must be appropriately authorized to perform the subcontracted activity and should uphold the same standards as the distributor.\n\n# 5.9\n\nThe sale of pharmaceutical products via the Internet should be limited to registered and authorized mail-order pharmacies or other authorized entities.\n\n# 6. Organization and management\n\n6.1 There should be an adequate organizational structure for each entity defined with the aid of an organizational chart. The responsibility, authority and interrelationships of all personnel should be clearly indicated.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2716, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c34559a4-1cd1-47e0-a6f0-b3e833b7b1ee": {"__data__": {"id_": "c34559a4-1cd1-47e0-a6f0-b3e833b7b1ee", "embedding": null, "metadata": {"page_label": "259", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 6.2\n\nDuties and responsibilities should be clearly defined and understood by the individuals concerned and recorded as written job descriptions. Certain activities may require special attention, such as the supervision of performance of activities, in accordance with local legislation. At every level of the supply chain, employees should be fully informed and trained in their duties and responsibilities.\n\n## 6.3\n\nA designated person should be appointed within the organization, who has defined authority and responsibility for ensuring that a quality system is implemented and maintained.\n\n## 6.4\n\nManagerial and technical personnel must have the authority and resources needed to carry out their duties and to set up and maintain a quality system, as well as to identify and correct deviations from the established quality system (see section 8).\n\n## 6.5\n\nThe responsibilities placed on any one individual should not be so extensive as to present any risk to product quality.\n\n## 6.6\n\nThere should be arrangements in place to ensure that management and personnel are not subject to commercial, political, financial and other pressures or conflict of interest that may have an adverse effect on the quality of service provided or on the integrity of pharmaceutical products.\n\n## 6.7\n\nSafety procedures relating to all relevant aspects including the safety of personnel and property, environmental protection and product integrity, should be in place.\n\n# 7. Personnel\n\n## 7.1\n\nAll personnel involved in distribution activities should be trained and qualified in the requirements of GDP, as applicable. Training should be based on written standard operating procedures (SOPs). Personnel should receive initial and continuing training relevant to their tasks, and be assessed as applicable, in accordance with a written training programme. In addition, training of the personnel should include the topic of product security, as well as aspects of product identification, the detection of counterfeits and the avoidance of counterfeits entering the supply chain. A record of all training, which includes details of subjects covered and participants trained, should be kept.\n\n## 7.2\n\nKey personnel involved in the distribution of pharmaceutical products should have the ability and experience appropriate to their responsibility for ensuring that pharmaceutical products are distributed properly.\n\n## 7.3\n\nThere should be an adequate number of competent personnel involved in all stages of the distribution of pharmaceutical products in order to ensure that the quality of the product is maintained.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre la definici\u00f3n de deberes y responsabilidades en la cadena de suministro de productos farmac\u00e9uticos, enfatizando la importancia de la capacitaci\u00f3n del personal y la implementaci\u00f3n de un sistema de calidad. Se destaca la necesidad de designar a una persona responsable de mantener este sistema y de asegurar que el personal est\u00e9 adecuadamente entrenado y calificado para realizar sus tareas, evitando conflictos de inter\u00e9s y garantizando la seguridad en todos los aspectos relacionados con la distribuci\u00f3n de productos farmac\u00e9uticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben tomarse para garantizar que el personal involucrado en la distribuci\u00f3n de productos farmac\u00e9uticos est\u00e9 adecuadamente capacitado?**\n   - El personal debe recibir formaci\u00f3n inicial y continua basada en procedimientos operativos est\u00e1ndar (SOPs), que incluya temas de seguridad del producto, identificaci\u00f3n de productos y detecci\u00f3n de falsificaciones. Adem\u00e1s, se debe llevar un registro de toda la formaci\u00f3n recibida.\n\n2. **\u00bfCu\u00e1l es el papel de la persona designada dentro de la organizaci\u00f3n en relaci\u00f3n con el sistema de calidad?**\n   - La persona designada tiene la autoridad y responsabilidad definidas para asegurar que se implemente y mantenga un sistema de calidad dentro de la organizaci\u00f3n.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta para evitar que las responsabilidades de un individuo afecten la calidad del producto?**\n   - Las responsabilidades asignadas a un individuo no deben ser tan extensas que presenten un riesgo para la calidad del producto, y debe haber un n\u00famero adecuado de personal competente en todas las etapas de la distribuci\u00f3n para mantener la calidad del producto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS aborda varios aspectos fundamentales relacionados con la distribuci\u00f3n de productos farmac\u00e9uticos, destacando la importancia de la autorizaci\u00f3n y la responsabilidad de los distribuidores. A continuaci\u00f3n se presentan los temas clave y las entidades involucradas:\n\n#### Temas Clave:\n\n1. **Autorizaci\u00f3n de Distribuidores**:\n   - Los distribuidores deben ser entidades debidamente autorizadas seg\u00fan la legislaci\u00f3n aplicable para realizar funciones de distribuci\u00f3n de productos farmac\u00e9uticos.\n\n2. **Importaci\u00f3n y Exportaci\u00f3n**:\n   - Solo las personas o entidades autorizadas y con la licencia correspondiente pueden importar o exportar productos farmac\u00e9uticos.\n\n3. **Autorizaci\u00f3n de Comercializaci\u00f3n**:\n   - La distribuci\u00f3n de productos farmac\u00e9uticos en un pa\u00eds o territorio solo es permitida si se ha otorgado una autorizaci\u00f3n de comercializaci\u00f3n para esos productos.\n\n4. **Suministro de Productos**:\n   - Los distribuidores deben obtener sus productos \u00fanicamente de entidades que cuenten con la autorizaci\u00f3n necesaria para vender o suministrar a distribuidores.\n\n5. **Venta a Entidades Autorizadas**:\n   - Los distribuidores deben suministrar productos solo a personas o entidades que est\u00e9n autorizadas para adquirirlos.\n\n6. **Subcontrataci\u00f3n**:\n   - Las responsabilidades pueden ser delegadas o subcontratadas a entidades autorizadas, con la necesidad de documentaci\u00f3n y auditor\u00eda peri\u00f3dica para asegurar el cumplimiento de las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP).\n\n7. **Venta en L\u00ednea**:\n   - La venta de productos farmac\u00e9uticos a trav\u00e9s de Internet debe limitarse a farmacias de correo registradas y autorizadas u otras entidades autorizadas.\n\n8. **Estructura Organizativa**:\n   - Se requiere una estructura organizativa adecuada, con claridad en las responsabilidades y relaciones de autoridad entre el personal.\n\n#### Entidades Involucradas:\n\n- **Distribuidores**: Entidades responsables de la distribuci\u00f3n de productos farmac\u00e9uticos.\n- **Agentes de Distribuci\u00f3n**: Personas o entidades que act\u00faan en nombre de los distribuidores.\n- **Entidades Autorizadas**: Organizaciones que cumplen con los requisitos legales para importar, exportar, o vender productos farmac\u00e9uticos.\n- **Farmacias de Correo**: Entidades autorizadas para la venta de productos farmac\u00e9uticos a trav\u00e9s de Internet.\n\nEste resumen destaca la necesidad de cumplir con las regulaciones y mantener est\u00e1ndares de calidad en la distribuci\u00f3n de productos farmac\u00e9uticos, as\u00ed como la importancia de la documentaci\u00f3n y la auditor\u00eda en las actividades delegadas.", "excerpt_keywords": "Keywords: quality system, training, responsibilities, pharmaceutical distribution, personnel"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "87c4514b-258b-4bcc-a239-400ffe224c5c", "node_type": "4", "metadata": {"page_label": "259", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 6.2\n\nDuties and responsibilities should be clearly defined and understood by the individuals concerned and recorded as written job descriptions. Certain activities may require special attention, such as the supervision of performance of activities, in accordance with local legislation. At every level of the supply chain, employees should be fully informed and trained in their duties and responsibilities.\n\n## 6.3\n\nA designated person should be appointed within the organization, who has defined authority and responsibility for ensuring that a quality system is implemented and maintained.\n\n## 6.4\n\nManagerial and technical personnel must have the authority and resources needed to carry out their duties and to set up and maintain a quality system, as well as to identify and correct deviations from the established quality system (see section 8).\n\n## 6.5\n\nThe responsibilities placed on any one individual should not be so extensive as to present any risk to product quality.\n\n## 6.6\n\nThere should be arrangements in place to ensure that management and personnel are not subject to commercial, political, financial and other pressures or conflict of interest that may have an adverse effect on the quality of service provided or on the integrity of pharmaceutical products.\n\n## 6.7\n\nSafety procedures relating to all relevant aspects including the safety of personnel and property, environmental protection and product integrity, should be in place.\n\n# 7. Personnel\n\n## 7.1\n\nAll personnel involved in distribution activities should be trained and qualified in the requirements of GDP, as applicable. Training should be based on written standard operating procedures (SOPs). Personnel should receive initial and continuing training relevant to their tasks, and be assessed as applicable, in accordance with a written training programme. In addition, training of the personnel should include the topic of product security, as well as aspects of product identification, the detection of counterfeits and the avoidance of counterfeits entering the supply chain. A record of all training, which includes details of subjects covered and participants trained, should be kept.\n\n## 7.2\n\nKey personnel involved in the distribution of pharmaceutical products should have the ability and experience appropriate to their responsibility for ensuring that pharmaceutical products are distributed properly.\n\n## 7.3\n\nThere should be an adequate number of competent personnel involved in all stages of the distribution of pharmaceutical products in order to ensure that the quality of the product is maintained.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a289ecebdb29c6a943a0d15053fe21eff0e65fb0d1f6f811c55e27783aeb17d9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 6.2\n\nDuties and responsibilities should be clearly defined and understood by the individuals concerned and recorded as written job descriptions. Certain activities may require special attention, such as the supervision of performance of activities, in accordance with local legislation. At every level of the supply chain, employees should be fully informed and trained in their duties and responsibilities.\n\n## 6.3\n\nA designated person should be appointed within the organization, who has defined authority and responsibility for ensuring that a quality system is implemented and maintained.\n\n## 6.4\n\nManagerial and technical personnel must have the authority and resources needed to carry out their duties and to set up and maintain a quality system, as well as to identify and correct deviations from the established quality system (see section 8).\n\n## 6.5\n\nThe responsibilities placed on any one individual should not be so extensive as to present any risk to product quality.\n\n## 6.6\n\nThere should be arrangements in place to ensure that management and personnel are not subject to commercial, political, financial and other pressures or conflict of interest that may have an adverse effect on the quality of service provided or on the integrity of pharmaceutical products.\n\n## 6.7\n\nSafety procedures relating to all relevant aspects including the safety of personnel and property, environmental protection and product integrity, should be in place.\n\n# 7. Personnel\n\n## 7.1\n\nAll personnel involved in distribution activities should be trained and qualified in the requirements of GDP, as applicable. Training should be based on written standard operating procedures (SOPs). Personnel should receive initial and continuing training relevant to their tasks, and be assessed as applicable, in accordance with a written training programme. In addition, training of the personnel should include the topic of product security, as well as aspects of product identification, the detection of counterfeits and the avoidance of counterfeits entering the supply chain. A record of all training, which includes details of subjects covered and participants trained, should be kept.\n\n## 7.2\n\nKey personnel involved in the distribution of pharmaceutical products should have the ability and experience appropriate to their responsibility for ensuring that pharmaceutical products are distributed properly.\n\n## 7.3\n\nThere should be an adequate number of competent personnel involved in all stages of the distribution of pharmaceutical products in order to ensure that the quality of the product is maintained.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2601, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b5d6d445-f94a-4c35-a99c-0eab5630d86f": {"__data__": {"id_": "b5d6d445-f94a-4c35-a99c-0eab5630d86f", "embedding": null, "metadata": {"page_label": "260", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 7.4\n\nNational regulations relating to the qualifications and experience of personnel should be adhered to.\n\n7.5 Personnel dealing with hazardous pharmaceutical products (such as highly active materials, radioactive materials, narcotics, and other hazardous, environmentally sensitive and/or dangerous pharmaceutical products, as well as products presenting special risks of abuse, fire or explosion) should be given specific training.\n\n7.6 Personnel involved in the distribution of pharmaceutical products should wear garments suitable for the activities that they perform. Personnel dealing with hazardous pharmaceutical products, including products containing materials that are highly active, toxic, infectious or sensitizing, should be provided with protective garments as necessary.\n\n7.7 Appropriate procedures relating to personnel hygiene, relevant to the activities to be carried out, should be established and observed. Such procedures should cover health, hygiene and clothing of personnel.\n\n7.8 Procedures and conditions of employment for employees, including contract and temporary staff, and other personnel having access to pharmaceutical products must be designed and administered to assist in minimizing the possibility of such products coming into the possession of unauthorized persons or entities.\n\n7.9 Codes of practice and punitive procedures should be in place to prevent and address situations where persons involved in the distribution of pharmaceutical products are suspected of, or found to be implicated in, any activities relating to the misappropriation, tampering, diversion or counterfeiting of any product.\n\n# 8. Quality system\n\n8.1 Within an organization, quality assurance serves as a management tool. There should be a documented quality policy describing the overall intentions and requirements of the distributor regarding quality, as formally expressed and authorized by management.\n\n8.2 The quality system should include an appropriate organizational structure, procedure, processes and resources and systematic actions necessary to ensure adequate confidence that a product or service and its documentation will satisfy given requirements for quality. The totality of these actions is described as the quality system.\n\n8.3 The quality system should include provisions to ensure that the holder of the marketing authorization, entity identified on the label (if different from the manufacturer), the appropriate national and/or international", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl contexto se centra en las regulaciones y procedimientos relacionados con el personal que maneja productos farmac\u00e9uticos, especialmente aquellos que son peligrosos o presentan riesgos especiales. Se enfatiza la importancia de la capacitaci\u00f3n, el uso de vestimenta adecuada y la higiene del personal. Adem\u00e1s, se menciona la necesidad de establecer procedimientos para prevenir el acceso no autorizado a productos farmac\u00e9uticos y para abordar situaciones de mal uso o falsificaci\u00f3n. Tambi\u00e9n se introduce el concepto de un sistema de calidad dentro de una organizaci\u00f3n, que debe incluir una pol\u00edtica de calidad documentada y una estructura organizativa adecuada para garantizar que los productos y servicios cumplan con los requisitos de calidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de formaci\u00f3n espec\u00edfica se requiere para el personal que maneja productos farmac\u00e9uticos peligrosos, y cu\u00e1les son algunos ejemplos de estos productos?**\n   - Esta pregunta busca detalles sobre la formaci\u00f3n necesaria y ejemplos concretos de productos que requieren dicha formaci\u00f3n, lo cual no se detalla en otras partes del documento.\n\n2. **\u00bfCu\u00e1les son las medidas espec\u00edficas que deben implementarse para garantizar que los productos farmac\u00e9uticos no caigan en manos no autorizadas?**\n   - Esta pregunta se centra en las condiciones y procedimientos de empleo que deben establecerse para proteger los productos farmac\u00e9uticos, proporcionando informaci\u00f3n que puede no estar disponible en otras secciones.\n\n3. **\u00bfQu\u00e9 elementos debe incluir un sistema de calidad para asegurar que los productos y servicios cumplan con los requisitos establecidos?**\n   - Esta pregunta busca una descripci\u00f3n detallada de los componentes que conforman un sistema de calidad efectivo, lo que puede no estar claramente definido en otras partes del documento.\n\n### Resumen de nivel superior\n\nEl documento establece directrices sobre la gesti\u00f3n del personal en la distribuci\u00f3n de productos farmac\u00e9uticos, enfatizando la capacitaci\u00f3n, la higiene y la prevenci\u00f3n del acceso no autorizado. Tambi\u00e9n se aborda la importancia de un sistema de calidad que garantice que los productos cumplan con los est\u00e1ndares requeridos. Estas directrices son esenciales para asegurar la seguridad y la eficacia en la distribuci\u00f3n de productos farmac\u00e9uticos, as\u00ed como para prevenir actividades ilegales o peligrosas relacionadas con estos productos.", "prev_section_summary": "### Temas Clave\n\n1. **Definici\u00f3n de Deberes y Responsabilidades**: Es fundamental que los deberes y responsabilidades de los empleados en la cadena de suministro est\u00e9n claramente definidos y documentados en descripciones de trabajo escritas.\n\n2. **Sistema de Calidad**: Se debe designar a una persona responsable de implementar y mantener un sistema de calidad dentro de la organizaci\u00f3n, asegurando que el personal tenga la autoridad y los recursos necesarios para cumplir con sus funciones.\n\n3. **Capacitaci\u00f3n del Personal**: Todo el personal involucrado en la distribuci\u00f3n de productos farmac\u00e9uticos debe recibir formaci\u00f3n inicial y continua, basada en procedimientos operativos est\u00e1ndar (SOPs), que incluya temas de seguridad del producto y detecci\u00f3n de falsificaciones.\n\n4. **Prevenci\u00f3n de Conflictos de Inter\u00e9s**: Es necesario establecer medidas para evitar que la gesti\u00f3n y el personal est\u00e9n sujetos a presiones comerciales, pol\u00edticas o financieras que puedan afectar la calidad del servicio y la integridad de los productos farmac\u00e9uticos.\n\n5. **Seguridad y Protecci\u00f3n**: Deben implementarse procedimientos de seguridad que aborden la seguridad del personal, la protecci\u00f3n ambiental y la integridad del producto.\n\n6. **Competencia del Personal**: Se debe asegurar que haya un n\u00famero adecuado de personal competente en todas las etapas de la distribuci\u00f3n para mantener la calidad del producto.\n\n### Entidades\n\n- **Organizaci\u00f3n**: Se refiere a la entidad responsable de la distribuci\u00f3n de productos farmac\u00e9uticos.\n- **Personal**: Incluye a todos los empleados involucrados en actividades de distribuci\u00f3n.\n- **Sistema de Calidad**: El marco que asegura que los productos farmac\u00e9uticos se distribuyan de acuerdo con est\u00e1ndares establecidos.\n- **Procedimientos Operativos Est\u00e1ndar (SOPs)**: Documentos que gu\u00edan la capacitaci\u00f3n y las operaciones del personal.\n- **Conflictos de Inter\u00e9s**: Situaciones que pueden comprometer la calidad del servicio o la integridad del producto.\n- **Seguridad del Producto**: Aspectos relacionados con la protecci\u00f3n y autenticidad de los productos farmac\u00e9uticos. \n\nEste resumen destaca la importancia de la claridad en las responsabilidades, la capacitaci\u00f3n adecuada del personal y la implementaci\u00f3n de un sistema de calidad robusto para garantizar la integridad de la cadena de suministro de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: pharmaceutical regulations, hazardous products, quality assurance, personnel training, distribution security"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ed2a35bc-f311-4993-9006-47d5d82b7cdf", "node_type": "4", "metadata": {"page_label": "260", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 7.4\n\nNational regulations relating to the qualifications and experience of personnel should be adhered to.\n\n7.5 Personnel dealing with hazardous pharmaceutical products (such as highly active materials, radioactive materials, narcotics, and other hazardous, environmentally sensitive and/or dangerous pharmaceutical products, as well as products presenting special risks of abuse, fire or explosion) should be given specific training.\n\n7.6 Personnel involved in the distribution of pharmaceutical products should wear garments suitable for the activities that they perform. Personnel dealing with hazardous pharmaceutical products, including products containing materials that are highly active, toxic, infectious or sensitizing, should be provided with protective garments as necessary.\n\n7.7 Appropriate procedures relating to personnel hygiene, relevant to the activities to be carried out, should be established and observed. Such procedures should cover health, hygiene and clothing of personnel.\n\n7.8 Procedures and conditions of employment for employees, including contract and temporary staff, and other personnel having access to pharmaceutical products must be designed and administered to assist in minimizing the possibility of such products coming into the possession of unauthorized persons or entities.\n\n7.9 Codes of practice and punitive procedures should be in place to prevent and address situations where persons involved in the distribution of pharmaceutical products are suspected of, or found to be implicated in, any activities relating to the misappropriation, tampering, diversion or counterfeiting of any product.\n\n# 8. Quality system\n\n8.1 Within an organization, quality assurance serves as a management tool. There should be a documented quality policy describing the overall intentions and requirements of the distributor regarding quality, as formally expressed and authorized by management.\n\n8.2 The quality system should include an appropriate organizational structure, procedure, processes and resources and systematic actions necessary to ensure adequate confidence that a product or service and its documentation will satisfy given requirements for quality. The totality of these actions is described as the quality system.\n\n8.3 The quality system should include provisions to ensure that the holder of the marketing authorization, entity identified on the label (if different from the manufacturer), the appropriate national and/or international", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "6405b8d7e03d263ce6aee6f723e4fe709571cbb0c7412716e41134cbfdfc986f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 7.4\n\nNational regulations relating to the qualifications and experience of personnel should be adhered to.\n\n7.5 Personnel dealing with hazardous pharmaceutical products (such as highly active materials, radioactive materials, narcotics, and other hazardous, environmentally sensitive and/or dangerous pharmaceutical products, as well as products presenting special risks of abuse, fire or explosion) should be given specific training.\n\n7.6 Personnel involved in the distribution of pharmaceutical products should wear garments suitable for the activities that they perform. Personnel dealing with hazardous pharmaceutical products, including products containing materials that are highly active, toxic, infectious or sensitizing, should be provided with protective garments as necessary.\n\n7.7 Appropriate procedures relating to personnel hygiene, relevant to the activities to be carried out, should be established and observed. Such procedures should cover health, hygiene and clothing of personnel.\n\n7.8 Procedures and conditions of employment for employees, including contract and temporary staff, and other personnel having access to pharmaceutical products must be designed and administered to assist in minimizing the possibility of such products coming into the possession of unauthorized persons or entities.\n\n7.9 Codes of practice and punitive procedures should be in place to prevent and address situations where persons involved in the distribution of pharmaceutical products are suspected of, or found to be implicated in, any activities relating to the misappropriation, tampering, diversion or counterfeiting of any product.\n\n# 8. Quality system\n\n8.1 Within an organization, quality assurance serves as a management tool. There should be a documented quality policy describing the overall intentions and requirements of the distributor regarding quality, as formally expressed and authorized by management.\n\n8.2 The quality system should include an appropriate organizational structure, procedure, processes and resources and systematic actions necessary to ensure adequate confidence that a product or service and its documentation will satisfy given requirements for quality. The totality of these actions is described as the quality system.\n\n8.3 The quality system should include provisions to ensure that the holder of the marketing authorization, entity identified on the label (if different from the manufacturer), the appropriate national and/or international", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2482, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e6bfebe4-de76-479d-8b42-753030872fbe": {"__data__": {"id_": "e6bfebe4-de76-479d-8b42-753030872fbe", "embedding": null, "metadata": {"page_label": "261", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Regulatory Measures for Pharmaceutical Products\n\nRegulatory bodies, as well as other relevant competent authorities, should be informed immediately in a case of confirmed or suspected counterfeiting of a pharmaceutical product. Such products should be stored in a secure, segregated area and clearly identified to prevent further distribution or sale.\n\n## Electronic Commerce\n\n8.4 Where electronic commerce (e-commerce) is used, i.e., electronic means are used for any of the distribution steps, defined procedures and adequate systems should be in place to ensure traceability and confidence in the quality of the pharmaceutical products concerned. Electronic transactions (including those conducted via the Internet), relating to the distribution of pharmaceutical products, should be performed only by authorized persons or entities.\n\n## Procurement and Release Procedures\n\n8.5 Authorized procurement and release procedures for all administrative and technical operations performed should be in place to ensure that appropriate pharmaceutical products are sourced only from approved suppliers and distributed by approved entities. The approval should come from the competent authority of the individual country where the legal entity is registered.\n\n## Inspection and Certification\n\n8.6 Inspection, auditing, and certification of compliance with a quality system (such as the applicable International Standardization Organization (ISO) series, or national or international guidelines) by external bodies is recommended. Such certification should not, however, be seen as a substitute for compliance with these GDP guidelines and the applicable principles of GMP relating to pharmaceutical products.\n\n## Integrity of Products in Transit\n\n8.7 If measures to ensure the integrity of the pharmaceutical products in transit are in place, they should be managed properly. For example, if seal control programmes for transit shipment are used, numbers should be issued in a tracked and sequential manner, the integrity of seals should be monitored and numbers verified during transit and upon receipt. Written procedures should be in place for use in situations where pharmaceutical products are suspected of being or are found to be counterfeit.\n\n## Risk Assessment\n\n8.8 Distributors should from time to time conduct risk assessments to assess potential risks to the quality and integrity of pharmaceutical products. The quality system should be developed and implemented to address any potential risks identified. The quality system should be reviewed and revised periodically to address new risks identified during a risk assessment.\n\n## Traceability of Pharmaceutical Products\n\n8.9 Regulations should foster a safe, transparent, and secure distribution system which includes product traceability throughout the supply chain. This is a shared responsibility among the parties involved. There should be...", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS aborda las medidas regulatorias para los productos farmac\u00e9uticos, enfatizando la importancia de la notificaci\u00f3n inmediata en casos de falsificaci\u00f3n, la implementaci\u00f3n de procedimientos de comercio electr\u00f3nico seguros, la necesidad de procedimientos de adquisici\u00f3n y liberaci\u00f3n autorizados, y la importancia de la inspecci\u00f3n y certificaci\u00f3n de cumplimiento con sistemas de calidad. Tambi\u00e9n se discuten las medidas para garantizar la integridad de los productos en tr\u00e1nsito, la realizaci\u00f3n de evaluaciones de riesgo y la trazabilidad de los productos a lo largo de la cadena de suministro.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben implementarse para garantizar la trazabilidad de los productos farmac\u00e9uticos en el comercio electr\u00f3nico?**\n   - El contexto menciona que deben existir procedimientos definidos y sistemas adecuados para asegurar la trazabilidad y confianza en la calidad de los productos farmac\u00e9uticos distribuidos electr\u00f3nicamente.\n\n2. **\u00bfCu\u00e1l es el papel de las autoridades competentes en la aprobaci\u00f3n de proveedores de productos farmac\u00e9uticos?**\n   - Se establece que los productos farmac\u00e9uticos deben ser adquiridos solo de proveedores aprobados, y que la aprobaci\u00f3n debe provenir de la autoridad competente del pa\u00eds donde la entidad legal est\u00e1 registrada.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse si se sospecha que un producto farmac\u00e9utico es falsificado durante el tr\u00e1nsito?**\n   - El documento indica que deben existir procedimientos escritos para manejar situaciones en las que los productos farmac\u00e9uticos son sospechosos de ser falsificados, incluyendo el monitoreo de la integridad de los sellos durante el tr\u00e1nsito y la verificaci\u00f3n de n\u00fameros al recibir los productos.", "prev_section_summary": "### Temas Clave\n\n1. **Regulaciones Nacionales**: Se enfatiza la importancia de cumplir con las regulaciones nacionales relacionadas con las calificaciones y la experiencia del personal que maneja productos farmac\u00e9uticos.\n\n2. **Capacitaci\u00f3n del Personal**: El personal que maneja productos farmac\u00e9uticos peligrosos, como materiales altamente activos, radiactivos, narc\u00f3ticos y otros productos peligrosos, debe recibir formaci\u00f3n espec\u00edfica.\n\n3. **Vestimenta y Protecci\u00f3n**: Se requiere que el personal use prendas adecuadas para sus actividades, y aquellos que manejan productos peligrosos deben contar con ropa de protecci\u00f3n adecuada.\n\n4. **Higiene del Personal**: Se deben establecer y observar procedimientos apropiados de higiene que aborden la salud, la higiene y la vestimenta del personal.\n\n5. **Prevenci\u00f3n de Acceso No Autorizado**: Se deben dise\u00f1ar y administrar procedimientos y condiciones de empleo para minimizar el riesgo de que productos farmac\u00e9uticos caigan en manos no autorizadas.\n\n6. **C\u00f3digos de Pr\u00e1ctica y Procedimientos Punitivos**: Deben existir c\u00f3digos de pr\u00e1ctica y procedimientos para prevenir y abordar situaciones de mal uso, como la malversaci\u00f3n, el sabotaje, la desviaci\u00f3n o la falsificaci\u00f3n de productos.\n\n7. **Sistema de Calidad**: Se introduce el concepto de un sistema de calidad que debe incluir una pol\u00edtica de calidad documentada, una estructura organizativa adecuada y acciones sistem\u00e1ticas para garantizar que los productos y servicios cumplan con los requisitos de calidad.\n\n### Entidades\n\n- **Personal**: Incluye empleados, personal temporal y contratistas que manejan productos farmac\u00e9uticos.\n- **Productos Farmac\u00e9uticos**: Incluye productos peligrosos como materiales altamente activos, radiactivos, narc\u00f3ticos, y otros productos que presentan riesgos especiales.\n- **Organizaci\u00f3n**: Se refiere a la entidad que distribuye productos farmac\u00e9uticos y que debe implementar un sistema de calidad.\n- **Regulaciones Nacionales**: Normativas que rigen las calificaciones y la experiencia del personal en el manejo de productos farmac\u00e9uticos.\n- **Sistema de Calidad**: Conjunto de procedimientos y pol\u00edticas que aseguran la calidad de los productos y servicios ofrecidos por la organizaci\u00f3n. \n\nEste resumen destaca la importancia de la capacitaci\u00f3n, la higiene, la prevenci\u00f3n del acceso no autorizado y la implementaci\u00f3n de un sistema de calidad en la distribuci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: regulatory measures, pharmaceutical products, electronic commerce, traceability, risk assessment"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ab9e7fe5-4ca5-4666-9cd9-c37063242d91", "node_type": "4", "metadata": {"page_label": "261", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Regulatory Measures for Pharmaceutical Products\n\nRegulatory bodies, as well as other relevant competent authorities, should be informed immediately in a case of confirmed or suspected counterfeiting of a pharmaceutical product. Such products should be stored in a secure, segregated area and clearly identified to prevent further distribution or sale.\n\n## Electronic Commerce\n\n8.4 Where electronic commerce (e-commerce) is used, i.e., electronic means are used for any of the distribution steps, defined procedures and adequate systems should be in place to ensure traceability and confidence in the quality of the pharmaceutical products concerned. Electronic transactions (including those conducted via the Internet), relating to the distribution of pharmaceutical products, should be performed only by authorized persons or entities.\n\n## Procurement and Release Procedures\n\n8.5 Authorized procurement and release procedures for all administrative and technical operations performed should be in place to ensure that appropriate pharmaceutical products are sourced only from approved suppliers and distributed by approved entities. The approval should come from the competent authority of the individual country where the legal entity is registered.\n\n## Inspection and Certification\n\n8.6 Inspection, auditing, and certification of compliance with a quality system (such as the applicable International Standardization Organization (ISO) series, or national or international guidelines) by external bodies is recommended. Such certification should not, however, be seen as a substitute for compliance with these GDP guidelines and the applicable principles of GMP relating to pharmaceutical products.\n\n## Integrity of Products in Transit\n\n8.7 If measures to ensure the integrity of the pharmaceutical products in transit are in place, they should be managed properly. For example, if seal control programmes for transit shipment are used, numbers should be issued in a tracked and sequential manner, the integrity of seals should be monitored and numbers verified during transit and upon receipt. Written procedures should be in place for use in situations where pharmaceutical products are suspected of being or are found to be counterfeit.\n\n## Risk Assessment\n\n8.8 Distributors should from time to time conduct risk assessments to assess potential risks to the quality and integrity of pharmaceutical products. The quality system should be developed and implemented to address any potential risks identified. The quality system should be reviewed and revised periodically to address new risks identified during a risk assessment.\n\n## Traceability of Pharmaceutical Products\n\n8.9 Regulations should foster a safe, transparent, and secure distribution system which includes product traceability throughout the supply chain. This is a shared responsibility among the parties involved. There should be...", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b7825bd34aa0ad596221e308128f53b7fba45ec51bf4b3f308706d231639e198", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Regulatory Measures for Pharmaceutical Products\n\nRegulatory bodies, as well as other relevant competent authorities, should be informed immediately in a case of confirmed or suspected counterfeiting of a pharmaceutical product. Such products should be stored in a secure, segregated area and clearly identified to prevent further distribution or sale.\n\n## Electronic Commerce\n\n8.4 Where electronic commerce (e-commerce) is used, i.e., electronic means are used for any of the distribution steps, defined procedures and adequate systems should be in place to ensure traceability and confidence in the quality of the pharmaceutical products concerned. Electronic transactions (including those conducted via the Internet), relating to the distribution of pharmaceutical products, should be performed only by authorized persons or entities.\n\n## Procurement and Release Procedures\n\n8.5 Authorized procurement and release procedures for all administrative and technical operations performed should be in place to ensure that appropriate pharmaceutical products are sourced only from approved suppliers and distributed by approved entities. The approval should come from the competent authority of the individual country where the legal entity is registered.\n\n## Inspection and Certification\n\n8.6 Inspection, auditing, and certification of compliance with a quality system (such as the applicable International Standardization Organization (ISO) series, or national or international guidelines) by external bodies is recommended. Such certification should not, however, be seen as a substitute for compliance with these GDP guidelines and the applicable principles of GMP relating to pharmaceutical products.\n\n## Integrity of Products in Transit\n\n8.7 If measures to ensure the integrity of the pharmaceutical products in transit are in place, they should be managed properly. For example, if seal control programmes for transit shipment are used, numbers should be issued in a tracked and sequential manner, the integrity of seals should be monitored and numbers verified during transit and upon receipt. Written procedures should be in place for use in situations where pharmaceutical products are suspected of being or are found to be counterfeit.\n\n## Risk Assessment\n\n8.8 Distributors should from time to time conduct risk assessments to assess potential risks to the quality and integrity of pharmaceutical products. The quality system should be developed and implemented to address any potential risks identified. The quality system should be reviewed and revised periodically to address new risks identified during a risk assessment.\n\n## Traceability of Pharmaceutical Products\n\n8.9 Regulations should foster a safe, transparent, and secure distribution system which includes product traceability throughout the supply chain. This is a shared responsibility among the parties involved. There should be...", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2905, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "97c10ad1-fbc4-4071-93a5-0459aa5dcf95": {"__data__": {"id_": "97c10ad1-fbc4-4071-93a5-0459aa5dcf95", "embedding": null, "metadata": {"page_label": "262", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 8.10\n\nAll parties involved in the supply chain should be identifiable, depending on the type of product and on national policies and legislation.\n\n8.11 Measures should be in place to ensure that pharmaceutical products have documentation that can be used to permit traceability of the products throughout distribution channels from the manufacturer/importer to the entity responsible for selling or supplying the product to the patient or his or her agent (see also 14.2). Records including expiry dates and batch numbers may be part of a secure distribution documentation enabling traceability.\n\n8.12 Ideally there should be a procedure in place for the creation and maintenance of a pedigree for pharmaceutical products.\n\nProvision should be made for a visual and/or analytical identification of potential counterfeit products. The procedure to be followed when a suspected product is identified should include provisions for notification, as appropriate, of the holder of the marketing authorization, entity identified on the label (if different from the manufacturer), the appropriate national and/or international regulatory bodies, as well as other relevant competent authorities (see also section 19).\n\n8.13 A suitable and, to the extent possible, internationally compatible product coding, identification system should be in place and developed in collaboration with the various parties involved in the supply chain. While it is understood that a differentiated approach may be necessary for different products and regions, pedigree and/or track-and-trace technologies provide possible options to ensure traceability.\n\n# 9. Premises, warehousing and storage\n\n9.1 Good storage practices (GSP) are applicable in all circumstances where pharmaceutical products are stored and throughout the distribution process. For additional guidance relating to the general principles of storage of pharmaceutical products, refer to the *WHO guide to good storage practices for pharmaceuticals* (1).\n\n## Storage areas\n\n9.2 Precautions must be taken to prevent unauthorized persons from entering storage areas. Employees should comply with the company policies to maintain a safe, secure and efficient working environment.\n\n9.3 Storage areas should be of sufficient capacity to allow the orderly storage of the various categories of pharmaceutical products, namely commercial", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia de la trazabilidad y la identificaci\u00f3n en la cadena de suministro de productos farmac\u00e9uticos. Se enfatiza la necesidad de que todas las partes involucradas sean identificables y que existan medidas para asegurar la documentaci\u00f3n que permita rastrear los productos desde el fabricante hasta el paciente. Tambi\u00e9n se menciona la creaci\u00f3n de un \"pedigree\" para los productos farmac\u00e9uticos y la identificaci\u00f3n de productos potencialmente falsificados. Adem\u00e1s, se establecen buenas pr\u00e1cticas de almacenamiento y la importancia de mantener \u00e1reas de almacenamiento seguras y adecuadas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se sugiere para garantizar la trazabilidad de los productos farmac\u00e9uticos a lo largo de la cadena de suministro?**\n   - El contexto menciona que se deben tener registros que incluyan fechas de caducidad y n\u00fameros de lote como parte de la documentaci\u00f3n de distribuci\u00f3n segura que permita la trazabilidad.\n\n2. **\u00bfCu\u00e1les son las medidas recomendadas para la identificaci\u00f3n de productos farmac\u00e9uticos potencialmente falsificados?**\n   - Se sugiere que se debe establecer un procedimiento para la identificaci\u00f3n visual y/o anal\u00edtica de productos sospechosos, que incluya notificaciones a las autoridades competentes y al titular de la autorizaci\u00f3n de comercializaci\u00f3n.\n\n3. **\u00bfQu\u00e9 pr\u00e1cticas se deben seguir para asegurar un almacenamiento adecuado de productos farmac\u00e9uticos?**\n   - Se deben seguir las Buenas Pr\u00e1cticas de Almacenamiento (GSP), asegurando que las \u00e1reas de almacenamiento sean seguras, con acceso restringido a personas no autorizadas y con suficiente capacidad para almacenar adecuadamente las diferentes categor\u00edas de productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Notificaci\u00f3n de Falsificaci\u00f3n**: Se debe informar de inmediato a los organismos reguladores y autoridades competentes en caso de confirmaci\u00f3n o sospecha de falsificaci\u00f3n de productos farmac\u00e9uticos. Los productos sospechosos deben ser almacenados de manera segura y segregada.\n\n2. **Comercio Electr\u00f3nico**: Es esencial establecer procedimientos y sistemas adecuados para garantizar la trazabilidad y la confianza en la calidad de los productos farmac\u00e9uticos distribuidos electr\u00f3nicamente. Las transacciones electr\u00f3nicas deben ser realizadas solo por personas o entidades autorizadas.\n\n3. **Procedimientos de Adquisici\u00f3n y Liberaci\u00f3n**: Deben existir procedimientos autorizados para asegurar que los productos farmac\u00e9uticos sean adquiridos solo de proveedores aprobados, con la aprobaci\u00f3n proveniente de la autoridad competente del pa\u00eds de registro.\n\n4. **Inspecci\u00f3n y Certificaci\u00f3n**: Se recomienda la inspecci\u00f3n, auditor\u00eda y certificaci\u00f3n de cumplimiento con sistemas de calidad por parte de organismos externos. Sin embargo, esta certificaci\u00f3n no sustituye el cumplimiento de las directrices de Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) y Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n5. **Integridad de Productos en Tr\u00e1nsito**: Se deben implementar medidas para asegurar la integridad de los productos durante el tr\u00e1nsito, incluyendo programas de control de sellos y procedimientos escritos para manejar productos sospechosos de ser falsificados.\n\n6. **Evaluaci\u00f3n de Riesgos**: Los distribuidores deben realizar evaluaciones de riesgo peri\u00f3dicas para identificar y abordar riesgos potenciales a la calidad e integridad de los productos farmac\u00e9uticos. El sistema de calidad debe ser revisado y actualizado regularmente.\n\n7. **Trazabilidad de Productos Farmac\u00e9uticos**: Las regulaciones deben promover un sistema de distribuci\u00f3n seguro, transparente y seguro que incluya la trazabilidad de los productos a lo largo de la cadena de suministro, siendo una responsabilidad compartida entre todas las partes involucradas.\n\n### Entidades Clave\n- **Organismos Reguladores**: Autoridades responsables de la supervisi\u00f3n y regulaci\u00f3n de productos farmac\u00e9uticos.\n- **Proveedores Aprobados**: Entidades que han sido autorizadas para suministrar productos farmac\u00e9uticos.\n- **Entidades Autorizadas**: Personas o entidades que est\u00e1n autorizadas para realizar transacciones electr\u00f3nicas de productos farmac\u00e9uticos.\n- **Cuerpos Externos de Inspecci\u00f3n**: Organismos que realizan auditor\u00edas y certificaciones de cumplimiento con sistemas de calidad.", "excerpt_keywords": "Keywords: trazabilidad, productos farmac\u00e9uticos, almacenamiento, falsificaci\u00f3n, cadena de suministro"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "75e60126-c46a-45f3-af43-b5770ed72b0a", "node_type": "4", "metadata": {"page_label": "262", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 8.10\n\nAll parties involved in the supply chain should be identifiable, depending on the type of product and on national policies and legislation.\n\n8.11 Measures should be in place to ensure that pharmaceutical products have documentation that can be used to permit traceability of the products throughout distribution channels from the manufacturer/importer to the entity responsible for selling or supplying the product to the patient or his or her agent (see also 14.2). Records including expiry dates and batch numbers may be part of a secure distribution documentation enabling traceability.\n\n8.12 Ideally there should be a procedure in place for the creation and maintenance of a pedigree for pharmaceutical products.\n\nProvision should be made for a visual and/or analytical identification of potential counterfeit products. The procedure to be followed when a suspected product is identified should include provisions for notification, as appropriate, of the holder of the marketing authorization, entity identified on the label (if different from the manufacturer), the appropriate national and/or international regulatory bodies, as well as other relevant competent authorities (see also section 19).\n\n8.13 A suitable and, to the extent possible, internationally compatible product coding, identification system should be in place and developed in collaboration with the various parties involved in the supply chain. While it is understood that a differentiated approach may be necessary for different products and regions, pedigree and/or track-and-trace technologies provide possible options to ensure traceability.\n\n# 9. Premises, warehousing and storage\n\n9.1 Good storage practices (GSP) are applicable in all circumstances where pharmaceutical products are stored and throughout the distribution process. For additional guidance relating to the general principles of storage of pharmaceutical products, refer to the *WHO guide to good storage practices for pharmaceuticals* (1).\n\n## Storage areas\n\n9.2 Precautions must be taken to prevent unauthorized persons from entering storage areas. Employees should comply with the company policies to maintain a safe, secure and efficient working environment.\n\n9.3 Storage areas should be of sufficient capacity to allow the orderly storage of the various categories of pharmaceutical products, namely commercial", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b2e0852a220d0e9f500e74b3196eae0d9e0d8ac43614b7dada6877c1030b35b9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 8.10\n\nAll parties involved in the supply chain should be identifiable, depending on the type of product and on national policies and legislation.\n\n8.11 Measures should be in place to ensure that pharmaceutical products have documentation that can be used to permit traceability of the products throughout distribution channels from the manufacturer/importer to the entity responsible for selling or supplying the product to the patient or his or her agent (see also 14.2). Records including expiry dates and batch numbers may be part of a secure distribution documentation enabling traceability.\n\n8.12 Ideally there should be a procedure in place for the creation and maintenance of a pedigree for pharmaceutical products.\n\nProvision should be made for a visual and/or analytical identification of potential counterfeit products. The procedure to be followed when a suspected product is identified should include provisions for notification, as appropriate, of the holder of the marketing authorization, entity identified on the label (if different from the manufacturer), the appropriate national and/or international regulatory bodies, as well as other relevant competent authorities (see also section 19).\n\n8.13 A suitable and, to the extent possible, internationally compatible product coding, identification system should be in place and developed in collaboration with the various parties involved in the supply chain. While it is understood that a differentiated approach may be necessary for different products and regions, pedigree and/or track-and-trace technologies provide possible options to ensure traceability.\n\n# 9. Premises, warehousing and storage\n\n9.1 Good storage practices (GSP) are applicable in all circumstances where pharmaceutical products are stored and throughout the distribution process. For additional guidance relating to the general principles of storage of pharmaceutical products, refer to the *WHO guide to good storage practices for pharmaceuticals* (1).\n\n## Storage areas\n\n9.2 Precautions must be taken to prevent unauthorized persons from entering storage areas. Employees should comply with the company policies to maintain a safe, secure and efficient working environment.\n\n9.3 Storage areas should be of sufficient capacity to allow the orderly storage of the various categories of pharmaceutical products, namely commercial", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2368, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "792110f4-aafc-4e5d-b883-afaddf8350e1": {"__data__": {"id_": "792110f4-aafc-4e5d-b883-afaddf8350e1", "embedding": null, "metadata": {"page_label": "263", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Storage and Handling of Pharmaceutical Products\n\n9.4 Storage areas should be designed or adapted to ensure appropriate and good storage conditions. In particular, they should be clean and dry and maintained within acceptable temperature limits. Pharmaceutical products should be stored off the floor and suitably spaced to permit cleaning and inspection. Pallets should be kept in a good state of cleanliness and repair.\n\n9.5 Storage areas should be clean and free from accumulated waste and vermin. Organizations in charge of distribution must ensure that premises and storage areas are cleaned regularly. There should also be a written programme for pest control. The pest control agents used should be safe and there should be no risk of contamination of pharmaceutical products. There should be appropriate procedures for the clean-up of any spillage to ensure complete removal of any risk of contamination.\n\n9.6 If sampling is performed in the storage area, it should be conducted in such a way as to prevent contamination or cross-contamination. Adequate cleaning procedures should be in place for the sampling areas.\n\n9.7 Receiving and dispatch bays should protect pharmaceutical products from the weather. Receiving areas should be designed and equipped to allow incoming containers of pharmaceutical products to be cleaned, if necessary, before storage.\n\n9.8 Where quarantine status is ensured by storage in separate areas, these areas must be clearly marked and access restricted to authorized personnel. Any system replacing physical quarantine should provide equivalent security. For example, computerized systems can be used, provided that they are validated to demonstrate security of access.\n\n9.9 Physical or other equivalent validated (e.g. electronic) segregation should be provided for the storage of rejected, expired, recalled or returned products and suspected counterfeits. The products and the areas concerned should be appropriately identified.\n\n9.10 Unless there is an appropriate alternative system to prevent the unintentional or unauthorized use of quarantined, rejected, returned, recalled or suspected counterfeit pharmaceutical products, separate storage areas should be assigned for their temporary storage until a decision as to their future has been made.\n\n9.11 Radioactive materials, narcotics and other hazardous, sensitive and/or dangerous pharmaceutical products, as well as products presenting special risks of abuse, fire or explosion (e.g. combustible or flammable liquids and solids and pressurized gases) should be stored in a dedicated area(s) that is subject to appropriate additional safety and security measures.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS sobre el almacenamiento y manejo de productos farmac\u00e9uticos establece directrices claras para garantizar condiciones adecuadas de almacenamiento. Se enfatiza la importancia de mantener \u00e1reas de almacenamiento limpias, secas y organizadas, as\u00ed como la necesidad de programas de control de plagas y procedimientos para la limpieza de derrames. Tambi\u00e9n se abordan las medidas de seguridad para productos en estado de cuarentena, rechazados o peligrosos, y se especifican las condiciones para el almacenamiento de materiales sensibles como narc\u00f3ticos y productos radiactivos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben implementarse para garantizar la limpieza y el control de plagas en las \u00e1reas de almacenamiento de productos farmac\u00e9uticos?**\n   - El contexto menciona que las \u00e1reas de almacenamiento deben estar limpias y libres de desechos y plagas, y que debe existir un programa escrito de control de plagas que utilice agentes seguros para evitar la contaminaci\u00f3n de los productos farmac\u00e9uticos.\n\n2. **\u00bfC\u00f3mo se debe manejar el almacenamiento de productos farmac\u00e9uticos que han sido rechazados, expirados o sospechosos de ser falsificados?**\n   - Se debe proporcionar una segregaci\u00f3n f\u00edsica o equivalente para estos productos, y deben ser almacenados en \u00e1reas claramente identificadas y restringidas al acceso de personal autorizado hasta que se tome una decisi\u00f3n sobre su futuro.\n\n3. **\u00bfQu\u00e9 requisitos de seguridad adicionales se deben considerar para el almacenamiento de productos farmac\u00e9uticos peligrosos, como narc\u00f3ticos o materiales radiactivos?**\n   - Estos productos deben ser almacenados en \u00e1reas dedicadas que cuenten con medidas de seguridad y protecci\u00f3n adicionales adecuadas para prevenir riesgos de abuso, incendio o explosi\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Trazabilidad en la Cadena de Suministro**:\n   - Es esencial que todas las partes involucradas en la cadena de suministro de productos farmac\u00e9uticos sean identificables.\n   - Se deben implementar medidas para asegurar que los productos farmac\u00e9uticos cuenten con documentaci\u00f3n que permita su trazabilidad desde el fabricante hasta el paciente.\n\n2. **Documentaci\u00f3n y Registros**:\n   - La documentaci\u00f3n debe incluir registros de fechas de caducidad y n\u00fameros de lote, que son cruciales para la trazabilidad.\n\n3. **Creaci\u00f3n de un \"Pedigree\"**:\n   - Se sugiere establecer un procedimiento para la creaci\u00f3n y mantenimiento de un \"pedigree\" para los productos farmac\u00e9uticos, que ayude a rastrear su origen y distribuci\u00f3n.\n\n4. **Identificaci\u00f3n de Productos Falsificados**:\n   - Se deben implementar procedimientos para la identificaci\u00f3n visual y/o anal\u00edtica de productos sospechosos de ser falsificados, incluyendo notificaciones a las autoridades competentes y al titular de la autorizaci\u00f3n de comercializaci\u00f3n.\n\n5. **Sistema de Codificaci\u00f3n y Identificaci\u00f3n**:\n   - Es necesario desarrollar un sistema de codificaci\u00f3n e identificaci\u00f3n de productos que sea compatible internacionalmente, en colaboraci\u00f3n con las partes involucradas en la cadena de suministro.\n\n6. **Buenas Pr\u00e1cticas de Almacenamiento (GSP)**:\n   - Se deben seguir las Buenas Pr\u00e1cticas de Almacenamiento en todas las circunstancias donde se almacenen productos farmac\u00e9uticos.\n   - Las \u00e1reas de almacenamiento deben ser seguras, con acceso restringido a personas no autorizadas y con suficiente capacidad para almacenar adecuadamente los productos.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que proporciona directrices sobre la trazabilidad y almacenamiento de productos farmac\u00e9uticos.\n- **Titulares de Autorizaci\u00f3n de Comercializaci\u00f3n**: Entidades responsables de la comercializaci\u00f3n de productos farmac\u00e9uticos.\n- **Autoridades Reguladoras Nacionales e Internacionales**: Cuerpos que supervisan la seguridad y eficacia de los productos farmac\u00e9uticos.\n- **Partes Involucradas en la Cadena de Suministro**: Incluyen fabricantes, importadores, distribuidores y entidades que suministran productos a los pacientes.", "excerpt_keywords": "Keywords: storage, pharmaceutical, contamination, quarantine, safety"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7847ef49-18da-4125-949f-f135eafb0765", "node_type": "4", "metadata": {"page_label": "263", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Storage and Handling of Pharmaceutical Products\n\n9.4 Storage areas should be designed or adapted to ensure appropriate and good storage conditions. In particular, they should be clean and dry and maintained within acceptable temperature limits. Pharmaceutical products should be stored off the floor and suitably spaced to permit cleaning and inspection. Pallets should be kept in a good state of cleanliness and repair.\n\n9.5 Storage areas should be clean and free from accumulated waste and vermin. Organizations in charge of distribution must ensure that premises and storage areas are cleaned regularly. There should also be a written programme for pest control. The pest control agents used should be safe and there should be no risk of contamination of pharmaceutical products. There should be appropriate procedures for the clean-up of any spillage to ensure complete removal of any risk of contamination.\n\n9.6 If sampling is performed in the storage area, it should be conducted in such a way as to prevent contamination or cross-contamination. Adequate cleaning procedures should be in place for the sampling areas.\n\n9.7 Receiving and dispatch bays should protect pharmaceutical products from the weather. Receiving areas should be designed and equipped to allow incoming containers of pharmaceutical products to be cleaned, if necessary, before storage.\n\n9.8 Where quarantine status is ensured by storage in separate areas, these areas must be clearly marked and access restricted to authorized personnel. Any system replacing physical quarantine should provide equivalent security. For example, computerized systems can be used, provided that they are validated to demonstrate security of access.\n\n9.9 Physical or other equivalent validated (e.g. electronic) segregation should be provided for the storage of rejected, expired, recalled or returned products and suspected counterfeits. The products and the areas concerned should be appropriately identified.\n\n9.10 Unless there is an appropriate alternative system to prevent the unintentional or unauthorized use of quarantined, rejected, returned, recalled or suspected counterfeit pharmaceutical products, separate storage areas should be assigned for their temporary storage until a decision as to their future has been made.\n\n9.11 Radioactive materials, narcotics and other hazardous, sensitive and/or dangerous pharmaceutical products, as well as products presenting special risks of abuse, fire or explosion (e.g. combustible or flammable liquids and solids and pressurized gases) should be stored in a dedicated area(s) that is subject to appropriate additional safety and security measures.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "d281ad2d17650bd0e13e0104fb873873c3db39147a24cbb2225fb66227ca3579", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Storage and Handling of Pharmaceutical Products\n\n9.4 Storage areas should be designed or adapted to ensure appropriate and good storage conditions. In particular, they should be clean and dry and maintained within acceptable temperature limits. Pharmaceutical products should be stored off the floor and suitably spaced to permit cleaning and inspection. Pallets should be kept in a good state of cleanliness and repair.\n\n9.5 Storage areas should be clean and free from accumulated waste and vermin. Organizations in charge of distribution must ensure that premises and storage areas are cleaned regularly. There should also be a written programme for pest control. The pest control agents used should be safe and there should be no risk of contamination of pharmaceutical products. There should be appropriate procedures for the clean-up of any spillage to ensure complete removal of any risk of contamination.\n\n9.6 If sampling is performed in the storage area, it should be conducted in such a way as to prevent contamination or cross-contamination. Adequate cleaning procedures should be in place for the sampling areas.\n\n9.7 Receiving and dispatch bays should protect pharmaceutical products from the weather. Receiving areas should be designed and equipped to allow incoming containers of pharmaceutical products to be cleaned, if necessary, before storage.\n\n9.8 Where quarantine status is ensured by storage in separate areas, these areas must be clearly marked and access restricted to authorized personnel. Any system replacing physical quarantine should provide equivalent security. For example, computerized systems can be used, provided that they are validated to demonstrate security of access.\n\n9.9 Physical or other equivalent validated (e.g. electronic) segregation should be provided for the storage of rejected, expired, recalled or returned products and suspected counterfeits. The products and the areas concerned should be appropriately identified.\n\n9.10 Unless there is an appropriate alternative system to prevent the unintentional or unauthorized use of quarantined, rejected, returned, recalled or suspected counterfeit pharmaceutical products, separate storage areas should be assigned for their temporary storage until a decision as to their future has been made.\n\n9.11 Radioactive materials, narcotics and other hazardous, sensitive and/or dangerous pharmaceutical products, as well as products presenting special risks of abuse, fire or explosion (e.g. combustible or flammable liquids and solids and pressurized gases) should be stored in a dedicated area(s) that is subject to appropriate additional safety and security measures.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2661, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e7dacaa4-1fb5-473c-923a-8112abdfd803": {"__data__": {"id_": "e7dacaa4-1fb5-473c-923a-8112abdfd803", "embedding": null, "metadata": {"page_label": "264", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9.12 \nPharmaceutical products should be handled and stored in such a manner as to prevent contamination, mix-ups and cross-contamination.\n\n# 9.13 \nA system should be in place to ensure that the pharmaceutical products due to expire first are sold and/or distributed first (first expiry/first out (FEFO)). Exceptions may be permitted as appropriate, provided that adequate controls are in place to prevent the distribution of expired products.\n\n# 9.14 \nBroken or damaged items should be withdrawn from usable stock and stored separately.\n\n# 9.15 \nStorage areas should be provided with adequate lighting to enable all operations to be carried out accurately and safely.\n\n## Storage conditions and stock control\n\n# 9.16 \nStorage and handling conditions should comply with applicable national and local regulations (8).\n\n# 9.17 \nStorage conditions for pharmaceutical products should be in compliance with the recommendations of the manufacturer.\n\n# 9.18 \nFacilities should be available for the storage of all pharmaceutical products under appropriate conditions (e.g. environmentally controlled when necessary). Records should be maintained of these conditions if they are critical for the maintenance of the characteristics of the pharmaceutical product stored.\n\n# 9.19 \nRecords of temperature monitoring data should be available for review. There should be defined intervals for checking temperature. The equipment used for monitoring should be checked at suitable predetermined intervals and the results of such checks should be recorded and retained. All monitoring records should be kept for at least the shelf-life of the stored pharmaceutical product plus one year, or as required by national legislation. Temperature mapping should show uniformity of the temperature across the storage facility. It is recommended that temperature monitors be located in areas that are most likely to show fluctuations.\n\n# 9.20 \nEquipment used for monitoring of storage conditions should also be calibrated at defined intervals.\n\n# 9.21 \nPeriodic stock reconciliation should be performed by comparing the actual and recorded stocks. This should be done at defined intervals.\n\n# 9.22 \nStock discrepancies should be investigated in accordance with a specified procedure to check that there have been no inadvertent mix-ups, incorrect issues and receipts, thefts and/or misappropriations of pharmaceutical products.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl contexto se centra en las directrices de almacenamiento y manejo de productos farmac\u00e9uticos, tal como se detalla en el Informe T\u00e9cnico de la OMS. Se enfatiza la importancia de prevenir la contaminaci\u00f3n y los errores en el manejo de productos, as\u00ed como la necesidad de seguir un sistema de gesti\u00f3n de inventarios que priorice la venta de productos que est\u00e1n por expirar. Tambi\u00e9n se abordan las condiciones de almacenamiento, el monitoreo de temperatura, la calibraci\u00f3n de equipos y la reconciliaci\u00f3n peri\u00f3dica de inventarios para asegurar la integridad y seguridad de los productos farmac\u00e9uticos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para manejar productos farmac\u00e9uticos da\u00f1ados o rotos seg\u00fan el informe?**\n   - Respuesta: Los productos farmac\u00e9uticos da\u00f1ados o rotos deben ser retirados del stock utilizable y almacenados por separado.\n\n2. **\u00bfCu\u00e1les son los requisitos para el monitoreo de temperatura en las \u00e1reas de almacenamiento de productos farmac\u00e9uticos?**\n   - Respuesta: Se deben mantener registros de los datos de monitoreo de temperatura, realizar verificaciones a intervalos definidos, y conservar todos los registros de monitoreo durante al menos la vida \u00fatil del producto almacenado m\u00e1s un a\u00f1o, o seg\u00fan lo requiera la legislaci\u00f3n nacional.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse en caso de discrepancias en el inventario de productos farmac\u00e9uticos?**\n   - Respuesta: Las discrepancias en el inventario deben ser investigadas de acuerdo con un procedimiento espec\u00edfico para verificar que no haya habido errores involuntarios, problemas en la emisi\u00f3n y recepci\u00f3n, robos o apropiaciones indebidas de productos farmac\u00e9uticos.", "prev_section_summary": "### Temas Clave\n\n1. **Condiciones de Almacenamiento**: Las \u00e1reas de almacenamiento deben ser limpias, secas y mantener temperaturas adecuadas. Los productos farmac\u00e9uticos deben estar elevados del suelo y organizados para facilitar la limpieza y la inspecci\u00f3n.\n\n2. **Limpieza y Control de Plagas**: Es esencial que las \u00e1reas de almacenamiento est\u00e9n libres de desechos y plagas. Se requiere un programa escrito de control de plagas y procedimientos para la limpieza de derrames.\n\n3. **Manejo de Productos en Cuarentena**: Las \u00e1reas de cuarentena deben estar claramente marcadas y restringidas al acceso de personal autorizado. Se pueden utilizar sistemas inform\u00e1ticos validados para asegurar el acceso.\n\n4. **Almacenamiento de Productos Rechazados o Sospechosos**: Se debe proporcionar segregaci\u00f3n f\u00edsica o equivalente para productos rechazados, expirados, o sospechosos de ser falsificados, con \u00e1reas claramente identificadas.\n\n5. **Almacenamiento de Productos Peligrosos**: Los materiales radiactivos, narc\u00f3ticos y otros productos peligrosos deben almacenarse en \u00e1reas dedicadas con medidas de seguridad adicionales para prevenir riesgos.\n\n### Entidades\n\n- **Organizaciones de Distribuci\u00f3n**: Responsables de la limpieza y mantenimiento de las \u00e1reas de almacenamiento.\n- **Productos Farmac\u00e9uticos**: Incluyen medicamentos y otros productos relacionados que requieren condiciones espec\u00edficas de almacenamiento.\n- **Agentes de Control de Plagas**: Sustancias utilizadas para prevenir infestaciones que deben ser seguras y no contaminar productos.\n- **Personal Autorizado**: Individuos con permiso para acceder a \u00e1reas restringidas, especialmente en el contexto de productos en cuarentena o peligrosos.\n- **Sistemas Inform\u00e1ticos**: Herramientas que pueden ser utilizadas para asegurar el acceso a \u00e1reas de cuarentena, siempre que est\u00e9n validadas.\n\nEste resumen destaca la importancia de mantener est\u00e1ndares rigurosos en el almacenamiento y manejo de productos farmac\u00e9uticos para garantizar su integridad y seguridad.", "excerpt_keywords": "Keywords: pharmaceutical storage, contamination prevention, temperature monitoring, stock reconciliation, FEFO system"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7c30aa0a-7a23-40a8-9f6c-27b8d90fc0ef", "node_type": "4", "metadata": {"page_label": "264", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9.12 \nPharmaceutical products should be handled and stored in such a manner as to prevent contamination, mix-ups and cross-contamination.\n\n# 9.13 \nA system should be in place to ensure that the pharmaceutical products due to expire first are sold and/or distributed first (first expiry/first out (FEFO)). Exceptions may be permitted as appropriate, provided that adequate controls are in place to prevent the distribution of expired products.\n\n# 9.14 \nBroken or damaged items should be withdrawn from usable stock and stored separately.\n\n# 9.15 \nStorage areas should be provided with adequate lighting to enable all operations to be carried out accurately and safely.\n\n## Storage conditions and stock control\n\n# 9.16 \nStorage and handling conditions should comply with applicable national and local regulations (8).\n\n# 9.17 \nStorage conditions for pharmaceutical products should be in compliance with the recommendations of the manufacturer.\n\n# 9.18 \nFacilities should be available for the storage of all pharmaceutical products under appropriate conditions (e.g. environmentally controlled when necessary). Records should be maintained of these conditions if they are critical for the maintenance of the characteristics of the pharmaceutical product stored.\n\n# 9.19 \nRecords of temperature monitoring data should be available for review. There should be defined intervals for checking temperature. The equipment used for monitoring should be checked at suitable predetermined intervals and the results of such checks should be recorded and retained. All monitoring records should be kept for at least the shelf-life of the stored pharmaceutical product plus one year, or as required by national legislation. Temperature mapping should show uniformity of the temperature across the storage facility. It is recommended that temperature monitors be located in areas that are most likely to show fluctuations.\n\n# 9.20 \nEquipment used for monitoring of storage conditions should also be calibrated at defined intervals.\n\n# 9.21 \nPeriodic stock reconciliation should be performed by comparing the actual and recorded stocks. This should be done at defined intervals.\n\n# 9.22 \nStock discrepancies should be investigated in accordance with a specified procedure to check that there have been no inadvertent mix-ups, incorrect issues and receipts, thefts and/or misappropriations of pharmaceutical products.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "9db6bb3de0f030fdc2e23810ec9bfccf0a3e3bdb2af5fd6d3a5fe67dd84d893a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9.12 \nPharmaceutical products should be handled and stored in such a manner as to prevent contamination, mix-ups and cross-contamination.\n\n# 9.13 \nA system should be in place to ensure that the pharmaceutical products due to expire first are sold and/or distributed first (first expiry/first out (FEFO)). Exceptions may be permitted as appropriate, provided that adequate controls are in place to prevent the distribution of expired products.\n\n# 9.14 \nBroken or damaged items should be withdrawn from usable stock and stored separately.\n\n# 9.15 \nStorage areas should be provided with adequate lighting to enable all operations to be carried out accurately and safely.\n\n## Storage conditions and stock control\n\n# 9.16 \nStorage and handling conditions should comply with applicable national and local regulations (8).\n\n# 9.17 \nStorage conditions for pharmaceutical products should be in compliance with the recommendations of the manufacturer.\n\n# 9.18 \nFacilities should be available for the storage of all pharmaceutical products under appropriate conditions (e.g. environmentally controlled when necessary). Records should be maintained of these conditions if they are critical for the maintenance of the characteristics of the pharmaceutical product stored.\n\n# 9.19 \nRecords of temperature monitoring data should be available for review. There should be defined intervals for checking temperature. The equipment used for monitoring should be checked at suitable predetermined intervals and the results of such checks should be recorded and retained. All monitoring records should be kept for at least the shelf-life of the stored pharmaceutical product plus one year, or as required by national legislation. Temperature mapping should show uniformity of the temperature across the storage facility. It is recommended that temperature monitors be located in areas that are most likely to show fluctuations.\n\n# 9.20 \nEquipment used for monitoring of storage conditions should also be calibrated at defined intervals.\n\n# 9.21 \nPeriodic stock reconciliation should be performed by comparing the actual and recorded stocks. This should be done at defined intervals.\n\n# 9.22 \nStock discrepancies should be investigated in accordance with a specified procedure to check that there have been no inadvertent mix-ups, incorrect issues and receipts, thefts and/or misappropriations of pharmaceutical products.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2401, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c2f00f02-bfc5-4c42-a7cf-72cdf86775e2": {"__data__": {"id_": "c2f00f02-bfc5-4c42-a7cf-72cdf86775e2", "embedding": null, "metadata": {"page_label": "265", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Vehicles and equipment\n\n10.1 Vehicles and equipment used to distribute, store or handle pharmaceutical products should be suitable for their purpose and appropriately equipped to prevent exposure of the products to conditions that could affect their stability and packaging integrity, and to prevent contamination of any kind.\n\n10.2 The design and use of vehicles and equipment must aim to minimize the risk of errors and permit effective cleaning and/or maintenance to avoid contamination, build-up of dust or dirt and/or any adverse effect on the quality of the pharmaceutical products being distributed.\n\n10.3 Where feasible, consideration should be given to adding technology, such as global positioning system (GPS) electronic tracking devices and engine-kill buttons to vehicles, which would enhance the security of pharmaceutical products while in the vehicle.\n\n10.4 Dedicated vehicles and equipment should be used, where possible, when handling pharmaceutical products.\n\n10.5 Where non-dedicated vehicles and equipment are used, procedures should be in place to ensure that the quality of the pharmaceutical product will not be compromised. Appropriate cleaning should be performed, checked and recorded.\n\n10.6 Procedures should be in place to ensure that the integrity of the products is not compromised during transportation.\n\n10.7 Where third-party carriers are used, distributors should develop written agreements with carriers to ensure that appropriate measures are taken to safeguard pharmaceutical products, including maintaining appropriate documentation and records. Such agreements should be in line with national and regional regulatory requirements.\n\n10.8 Defective vehicles and equipment should not be used and should either be labelled as such or removed from service.\n\n10.9 There should be procedures in place for the operation and maintenance of all vehicles and equipment involved in the distribution process, including cleaning and safety precautions.\n\n10.10 Vehicles, containers and equipment should be kept clean and dry and free from accumulated waste. Organizations in charge of distribution must ensure that vehicles used are cleaned regularly.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las directrices sobre el uso de veh\u00edculos y equipos para la distribuci\u00f3n, almacenamiento y manejo de productos farmac\u00e9uticos. Se enfatiza la importancia de que estos veh\u00edculos y equipos sean adecuados para su prop\u00f3sito, minimizando riesgos de errores y contaminaci\u00f3n. Se sugiere el uso de tecnolog\u00eda para mejorar la seguridad, la necesidad de procedimientos de limpieza y mantenimiento, y la importancia de acuerdos escritos con transportistas de terceros. Tambi\u00e9n se menciona que los veh\u00edculos defectuosos no deben ser utilizados y que deben mantenerse limpios y secos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas espec\u00edficas deben implementarse para garantizar que los veh\u00edculos no dedicados no comprometan la calidad de los productos farmac\u00e9uticos?**\n   - Esta pregunta busca detalles sobre los procedimientos de limpieza y verificaci\u00f3n que deben seguirse cuando se utilizan veh\u00edculos que no est\u00e1n exclusivamente destinados al transporte de productos farmac\u00e9uticos.\n\n2. **\u00bfCu\u00e1les son las tecnolog\u00edas recomendadas para mejorar la seguridad de los productos farmac\u00e9uticos durante el transporte y c\u00f3mo se deben implementar?**\n   - Esta pregunta se centra en las tecnolog\u00edas mencionadas, como los dispositivos de seguimiento GPS y los botones de apagado del motor, y c\u00f3mo estas pueden ser integradas en la operaci\u00f3n de los veh\u00edculos.\n\n3. **\u00bfQu\u00e9 tipo de documentaci\u00f3n y registros deben mantenerse en los acuerdos con transportistas de terceros para asegurar la protecci\u00f3n de los productos farmac\u00e9uticos?**\n   - Esta pregunta busca informaci\u00f3n sobre los requisitos espec\u00edficos de documentaci\u00f3n y registros que deben incluirse en los acuerdos escritos con los transportistas, asegurando que se cumplan las normativas nacionales y regionales.", "prev_section_summary": "### Temas Clave\n\n1. **Manejo y Almacenamiento de Productos Farmac\u00e9uticos**: Se enfatiza la importancia de prevenir la contaminaci\u00f3n, los errores y la mezcla de productos durante su manejo y almacenamiento.\n\n2. **Sistema FEFO (First Expiry/First Out)**: Se debe implementar un sistema que garantice que los productos que est\u00e1n por expirar se vendan o distribuyan primero, con excepciones permitidas bajo controles adecuados.\n\n3. **Retiro de Productos Da\u00f1ados**: Los productos farmac\u00e9uticos da\u00f1ados o rotos deben ser retirados del stock utilizable y almacenados por separado.\n\n4. **Condiciones de Almacenamiento**: Las \u00e1reas de almacenamiento deben cumplir con regulaciones nacionales y locales, as\u00ed como con las recomendaciones del fabricante. Se deben mantener registros de las condiciones de almacenamiento.\n\n5. **Monitoreo de Temperatura**: Se requiere un registro de los datos de monitoreo de temperatura, con verificaciones a intervalos definidos y conservaci\u00f3n de registros por un per\u00edodo espec\u00edfico.\n\n6. **Calibraci\u00f3n de Equipos**: Los equipos utilizados para el monitoreo de condiciones de almacenamiento deben ser calibrados a intervalos definidos.\n\n7. **Reconciliaci\u00f3n de Inventarios**: Se debe realizar una reconciliaci\u00f3n peri\u00f3dica del inventario comparando los stocks reales con los registrados.\n\n8. **Investigaci\u00f3n de Discrepancias**: Las discrepancias en el inventario deben ser investigadas siguiendo un procedimiento espec\u00edfico para asegurar que no haya habido errores, robos o apropiaciones indebidas.\n\n### Entidades\n\n- **Productos Farmac\u00e9uticos**: Bienes que requieren manejo y almacenamiento cuidadoso.\n- **Sistema FEFO**: M\u00e9todo de gesti\u00f3n de inventarios basado en la fecha de caducidad.\n- **Regulaciones Nacionales y Locales**: Normativas que rigen el manejo y almacenamiento de productos farmac\u00e9uticos.\n- **Condiciones de Almacenamiento**: Factores ambientales que afectan la integridad de los productos.\n- **Equipos de Monitoreo**: Herramientas utilizadas para asegurar condiciones adecuadas de almacenamiento.\n- **Registros de Monitoreo**: Documentaci\u00f3n que respalda el cumplimiento de las condiciones de almacenamiento.\n- **Discrepancias de Inventario**: Diferencias entre el stock real y el registrado que requieren investigaci\u00f3n.", "excerpt_keywords": "Vehicles, pharmaceutical, distribution, contamination, equipment"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "62650d87-613c-4aa5-8319-e4dcbeb91750", "node_type": "4", "metadata": {"page_label": "265", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Vehicles and equipment\n\n10.1 Vehicles and equipment used to distribute, store or handle pharmaceutical products should be suitable for their purpose and appropriately equipped to prevent exposure of the products to conditions that could affect their stability and packaging integrity, and to prevent contamination of any kind.\n\n10.2 The design and use of vehicles and equipment must aim to minimize the risk of errors and permit effective cleaning and/or maintenance to avoid contamination, build-up of dust or dirt and/or any adverse effect on the quality of the pharmaceutical products being distributed.\n\n10.3 Where feasible, consideration should be given to adding technology, such as global positioning system (GPS) electronic tracking devices and engine-kill buttons to vehicles, which would enhance the security of pharmaceutical products while in the vehicle.\n\n10.4 Dedicated vehicles and equipment should be used, where possible, when handling pharmaceutical products.\n\n10.5 Where non-dedicated vehicles and equipment are used, procedures should be in place to ensure that the quality of the pharmaceutical product will not be compromised. Appropriate cleaning should be performed, checked and recorded.\n\n10.6 Procedures should be in place to ensure that the integrity of the products is not compromised during transportation.\n\n10.7 Where third-party carriers are used, distributors should develop written agreements with carriers to ensure that appropriate measures are taken to safeguard pharmaceutical products, including maintaining appropriate documentation and records. Such agreements should be in line with national and regional regulatory requirements.\n\n10.8 Defective vehicles and equipment should not be used and should either be labelled as such or removed from service.\n\n10.9 There should be procedures in place for the operation and maintenance of all vehicles and equipment involved in the distribution process, including cleaning and safety precautions.\n\n10.10 Vehicles, containers and equipment should be kept clean and dry and free from accumulated waste. Organizations in charge of distribution must ensure that vehicles used are cleaned regularly.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "955b9caa15660fc681b8325ba9cd3f64e3fb37e4e181bcb4f91a962d1f06c5a3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Vehicles and equipment\n\n10.1 Vehicles and equipment used to distribute, store or handle pharmaceutical products should be suitable for their purpose and appropriately equipped to prevent exposure of the products to conditions that could affect their stability and packaging integrity, and to prevent contamination of any kind.\n\n10.2 The design and use of vehicles and equipment must aim to minimize the risk of errors and permit effective cleaning and/or maintenance to avoid contamination, build-up of dust or dirt and/or any adverse effect on the quality of the pharmaceutical products being distributed.\n\n10.3 Where feasible, consideration should be given to adding technology, such as global positioning system (GPS) electronic tracking devices and engine-kill buttons to vehicles, which would enhance the security of pharmaceutical products while in the vehicle.\n\n10.4 Dedicated vehicles and equipment should be used, where possible, when handling pharmaceutical products.\n\n10.5 Where non-dedicated vehicles and equipment are used, procedures should be in place to ensure that the quality of the pharmaceutical product will not be compromised. Appropriate cleaning should be performed, checked and recorded.\n\n10.6 Procedures should be in place to ensure that the integrity of the products is not compromised during transportation.\n\n10.7 Where third-party carriers are used, distributors should develop written agreements with carriers to ensure that appropriate measures are taken to safeguard pharmaceutical products, including maintaining appropriate documentation and records. Such agreements should be in line with national and regional regulatory requirements.\n\n10.8 Defective vehicles and equipment should not be used and should either be labelled as such or removed from service.\n\n10.9 There should be procedures in place for the operation and maintenance of all vehicles and equipment involved in the distribution process, including cleaning and safety precautions.\n\n10.10 Vehicles, containers and equipment should be kept clean and dry and free from accumulated waste. Organizations in charge of distribution must ensure that vehicles used are cleaned regularly.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2178, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "48204bc4-21c4-46c3-a350-89018165b2b7": {"__data__": {"id_": "48204bc4-21c4-46c3-a350-89018165b2b7", "embedding": null, "metadata": {"page_label": "266", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 10.11\n\nVehicles, containers and equipment should be kept free from rodents, vermin, birds and other pests. There should be written programmes and records for such pest control. The cleaning and fumigation agents used should not have any adverse effect on product quality.\n\n# 10.12\n\nEquipment chosen and used for the cleaning of vehicles should not constitute a source of contamination. Agents used for the cleaning of vehicles should be approved by management.\n\n# 10.13\n\nSpecial attention should be paid to the design, use, cleaning and maintenance of all equipment used for the handling of pharmaceutical products which are not in a protective shipping carton or case.\n\n# 10.14\n\nWhere special storage conditions (e.g. temperature and/or relative humidity), different from, or limiting, the expected environmental conditions, are required during transportation, these should be provided, checked, monitored and recorded. All monitoring records should be kept for a minimum of the shelf-life of the product distributed plus one year, or as required by national legislation. Records of monitoring data should be made available for inspection by the regulatory or other oversight body.\n\n# 10.15\n\nEquipment used for monitoring conditions, e.g. temperature and humidity, within vehicles and containers should be calibrated at regular intervals.\n\n# 10.16\n\nVehicles and containers should be of sufficient capacity to allow orderly storage of the various categories of pharmaceutical products during transportation.\n\n# 10.17\n\nWhere possible, mechanisms should be available to allow for the segregation during transit of rejected, recalled and returned pharmaceutical products as well as those suspected of being counterfeits. Such goods should be securely packaged, clearly labelled, and be accompanied by appropriate supporting documentation.\n\n# 10.18\n\nMeasures should be in place to prevent unauthorized persons from entering and/or tampering with vehicles and/or equipment, as well as to prevent the theft or misappropriation thereof.\n\n# 11. Shipment containers and container labelling\n\n## 11.1\n\nPharmaceutical products should be stored and distributed in shipment containers that have no adverse effect on the quality of the products, and that offer adequate protection from external influences, including contamination.\n\n## 11.2\n\nShipping containers should bear labels providing sufficient information on handling and storage conditions and precautions to ensure", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Control de plagas y limpieza**: Se establece la importancia de mantener veh\u00edculos, contenedores y equipos libres de plagas y de utilizar agentes de limpieza que no afecten la calidad de los productos farmac\u00e9uticos. Se requiere documentaci\u00f3n y programas escritos para el control de plagas.\n\n2. **Condiciones de almacenamiento y transporte**: Se enfatiza la necesidad de cumplir con condiciones especiales de almacenamiento durante el transporte, incluyendo el monitoreo de temperatura y humedad. Los registros de monitoreo deben ser conservados por un per\u00edodo espec\u00edfico y estar disponibles para inspecci\u00f3n.\n\n3. **Seguridad y etiquetado de contenedores**: Se requiere que los contenedores de env\u00edo sean adecuados para proteger la calidad de los productos y que contengan etiquetas con informaci\u00f3n suficiente sobre las condiciones de manejo y almacenamiento.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para el control de plagas en veh\u00edculos y contenedores de productos farmac\u00e9uticos?**\n   - La normativa exige que haya programas escritos y registros espec\u00edficos para el control de plagas, asegurando que se mantengan libres de roedores, vermin, aves y otros pestes.\n\n2. **\u00bfCu\u00e1les son las obligaciones de los responsables sobre el monitoreo de condiciones especiales durante el transporte de productos farmac\u00e9uticos?**\n   - Se requiere que se proporcionen, verifiquen, monitoreen y registren las condiciones especiales de almacenamiento, como temperatura y humedad, y que los registros se mantengan por un m\u00ednimo de la vida \u00fatil del producto m\u00e1s un a\u00f1o.\n\n3. **\u00bfQu\u00e9 medidas de seguridad deben implementarse para prevenir el acceso no autorizado a veh\u00edculos y equipos de transporte de productos farmac\u00e9uticos?**\n   - Deben establecerse medidas para evitar que personas no autorizadas ingresen o manipulen veh\u00edculos y equipos, as\u00ed como para prevenir el robo o la apropiaci\u00f3n indebida de los mismos.", "prev_section_summary": "### Temas Clave\n\n1. **Adecuaci\u00f3n de Veh\u00edculos y Equipos**: Los veh\u00edculos y equipos utilizados para la distribuci\u00f3n, almacenamiento y manejo de productos farmac\u00e9uticos deben ser apropiados para su prop\u00f3sito y estar equipados para prevenir la exposici\u00f3n a condiciones que puedan afectar la estabilidad y la integridad del empaque de los productos.\n\n2. **Minimizaci\u00f3n de Errores y Contaminaci\u00f3n**: Se debe dise\u00f1ar y utilizar veh\u00edculos y equipos que minimicen el riesgo de errores y permitan una limpieza y mantenimiento efectivos para evitar la contaminaci\u00f3n y la acumulaci\u00f3n de suciedad.\n\n3. **Tecnolog\u00eda para Seguridad**: Se recomienda la incorporaci\u00f3n de tecnolog\u00edas como dispositivos de seguimiento GPS y botones de apagado del motor para mejorar la seguridad de los productos farmac\u00e9uticos durante el transporte.\n\n4. **Uso de Veh\u00edculos Dedicados**: Siempre que sea posible, se deben utilizar veh\u00edculos y equipos dedicados para el manejo de productos farmac\u00e9uticos.\n\n5. **Procedimientos para Veh\u00edculos No Dedicados**: Cuando se utilicen veh\u00edculos no dedicados, deben existir procedimientos para asegurar que la calidad de los productos farmac\u00e9uticos no se vea comprometida, incluyendo limpieza adecuada y verificaci\u00f3n.\n\n6. **Integridad Durante el Transporte**: Se deben establecer procedimientos para garantizar que la integridad de los productos no se comprometa durante el transporte.\n\n7. **Acuerdos con Transportistas de Terceros**: Es necesario desarrollar acuerdos escritos con transportistas de terceros que incluyan medidas para salvaguardar los productos farmac\u00e9uticos y mantener la documentaci\u00f3n adecuada, cumpliendo con las normativas nacionales y regionales.\n\n8. **Mantenimiento de Veh\u00edculos y Equipos**: Los veh\u00edculos y equipos defectuosos no deben ser utilizados y deben ser etiquetados o retirados del servicio. Adem\u00e1s, deben existir procedimientos para su operaci\u00f3n y mantenimiento, incluyendo limpieza y precauciones de seguridad.\n\n9. **Limpieza y Mantenimiento**: Los veh\u00edculos, contenedores y equipos deben mantenerse limpios, secos y libres de residuos acumulados, asegurando una limpieza regular.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Productos Farmac\u00e9uticos**: Bienes que se distribuyen, almacenan y manejan.\n- **Veh\u00edculos y Equipos**: Herramientas utilizadas en la distribuci\u00f3n y manejo de productos farmac\u00e9uticos.\n- **Transportistas de Terceros**: Entidades externas que pueden ser contratadas para el transporte de productos farmac\u00e9uticos.\n- **Tecnolog\u00eda**: Dispositivos como GPS y sistemas de seguridad que se pueden implementar para mejorar la seguridad durante el transporte.", "excerpt_keywords": "Keywords: pest control, pharmaceutical transportation, equipment maintenance, monitoring conditions, shipment containers"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c56fb46d-de57-4200-b42d-6e106d4bfe50", "node_type": "4", "metadata": {"page_label": "266", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 10.11\n\nVehicles, containers and equipment should be kept free from rodents, vermin, birds and other pests. There should be written programmes and records for such pest control. The cleaning and fumigation agents used should not have any adverse effect on product quality.\n\n# 10.12\n\nEquipment chosen and used for the cleaning of vehicles should not constitute a source of contamination. Agents used for the cleaning of vehicles should be approved by management.\n\n# 10.13\n\nSpecial attention should be paid to the design, use, cleaning and maintenance of all equipment used for the handling of pharmaceutical products which are not in a protective shipping carton or case.\n\n# 10.14\n\nWhere special storage conditions (e.g. temperature and/or relative humidity), different from, or limiting, the expected environmental conditions, are required during transportation, these should be provided, checked, monitored and recorded. All monitoring records should be kept for a minimum of the shelf-life of the product distributed plus one year, or as required by national legislation. Records of monitoring data should be made available for inspection by the regulatory or other oversight body.\n\n# 10.15\n\nEquipment used for monitoring conditions, e.g. temperature and humidity, within vehicles and containers should be calibrated at regular intervals.\n\n# 10.16\n\nVehicles and containers should be of sufficient capacity to allow orderly storage of the various categories of pharmaceutical products during transportation.\n\n# 10.17\n\nWhere possible, mechanisms should be available to allow for the segregation during transit of rejected, recalled and returned pharmaceutical products as well as those suspected of being counterfeits. Such goods should be securely packaged, clearly labelled, and be accompanied by appropriate supporting documentation.\n\n# 10.18\n\nMeasures should be in place to prevent unauthorized persons from entering and/or tampering with vehicles and/or equipment, as well as to prevent the theft or misappropriation thereof.\n\n# 11. Shipment containers and container labelling\n\n## 11.1\n\nPharmaceutical products should be stored and distributed in shipment containers that have no adverse effect on the quality of the products, and that offer adequate protection from external influences, including contamination.\n\n## 11.2\n\nShipping containers should bear labels providing sufficient information on handling and storage conditions and precautions to ensure", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "820e5451949a9b694941edad97e1ecf81a74b28b77c5fa9b96af4d2164761c7f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 10.11\n\nVehicles, containers and equipment should be kept free from rodents, vermin, birds and other pests. There should be written programmes and records for such pest control. The cleaning and fumigation agents used should not have any adverse effect on product quality.\n\n# 10.12\n\nEquipment chosen and used for the cleaning of vehicles should not constitute a source of contamination. Agents used for the cleaning of vehicles should be approved by management.\n\n# 10.13\n\nSpecial attention should be paid to the design, use, cleaning and maintenance of all equipment used for the handling of pharmaceutical products which are not in a protective shipping carton or case.\n\n# 10.14\n\nWhere special storage conditions (e.g. temperature and/or relative humidity), different from, or limiting, the expected environmental conditions, are required during transportation, these should be provided, checked, monitored and recorded. All monitoring records should be kept for a minimum of the shelf-life of the product distributed plus one year, or as required by national legislation. Records of monitoring data should be made available for inspection by the regulatory or other oversight body.\n\n# 10.15\n\nEquipment used for monitoring conditions, e.g. temperature and humidity, within vehicles and containers should be calibrated at regular intervals.\n\n# 10.16\n\nVehicles and containers should be of sufficient capacity to allow orderly storage of the various categories of pharmaceutical products during transportation.\n\n# 10.17\n\nWhere possible, mechanisms should be available to allow for the segregation during transit of rejected, recalled and returned pharmaceutical products as well as those suspected of being counterfeits. Such goods should be securely packaged, clearly labelled, and be accompanied by appropriate supporting documentation.\n\n# 10.18\n\nMeasures should be in place to prevent unauthorized persons from entering and/or tampering with vehicles and/or equipment, as well as to prevent the theft or misappropriation thereof.\n\n# 11. Shipment containers and container labelling\n\n## 11.1\n\nPharmaceutical products should be stored and distributed in shipment containers that have no adverse effect on the quality of the products, and that offer adequate protection from external influences, including contamination.\n\n## 11.2\n\nShipping containers should bear labels providing sufficient information on handling and storage conditions and precautions to ensure", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2461, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "62320a65-cec2-41c6-9dad-b747997468b2": {"__data__": {"id_": "62320a65-cec2-41c6-9dad-b747997468b2", "embedding": null, "metadata": {"page_label": "267", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "that the products are properly handled and secure at all times. The shipment container should enable identification of the container\u2019s contents and source.\n\n11.3 The need for any special transport and/or storage conditions should be stated on the shipment container label. If a pharmaceutical product is intended for transfer to areas outside the control of the manufacturer\u2019s products management system, the name and address of the manufacturer, special transport conditions and any special legal requirements, including safety symbols, should also be included on the container label.\n\n11.4 Normally, internationally and/or nationally accepted abbreviations, names or codes should be used in the labelling of shipment containers.\n\n11.5 Special care should be taken when using dry ice in shipment containers. In addition to safety issues it must be ensured that the pharmaceutical product does not come into contact with the dry ice, as it may have an adverse effect on the quality of the product.\n\n11.6 Written procedures should be available for the handling of damaged and/or broken shipment containers. Particular attention should be paid to those containing potentially toxic and hazardous products.\n\n# 12. Dispatch and receipt\n\n12.1 Pharmaceutical products should only be sold and/or distributed to persons or entities that are authorized to acquire such products in accordance with the applicable national, regional and international legislation. Written proof of such authority must be obtained prior to the distribution of products to such persons or entities.\n\n12.2 Prior to the dispatch of the pharmaceutical products, the supplier should ensure that the person or entity, e.g. the contract acceptor for transportation of the pharmaceutical products, is aware of the pharmaceutical products to be distributed and complies with the appropriate storage and transport conditions.\n\n12.3 The dispatch and transportation of pharmaceutical products should be undertaken only after the receipt of a valid delivery order or material replenishment plan, which should be documented.\n\n12.4 Written procedures for the dispatch of pharmaceutical products should be established. Such procedures should take into account the nature of the product as well as any special precautions to be observed. Pharmaceutical products under quarantine will require release for dispatch by the person responsible for quality (see 6.3).\n\n12.5 Records for the dispatch of pharmaceutical products should be prepared and should include at least the following information:", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre el manejo, transporte y despacho de productos farmac\u00e9uticos, enfatizando la importancia de la identificaci\u00f3n adecuada de los envases, el cumplimiento de las condiciones de transporte y almacenamiento, y la necesidad de procedimientos escritos para el manejo de productos da\u00f1ados. Tambi\u00e9n se menciona la importancia de asegurar que solo se distribuyan productos a entidades autorizadas y que se mantengan registros adecuados de los despachos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la etiqueta del contenedor de env\u00edo si un producto farmac\u00e9utico se transfiere a \u00e1reas fuera del control del sistema de gesti\u00f3n de productos del fabricante?**\n   - La etiqueta debe incluir el nombre y la direcci\u00f3n del fabricante, las condiciones especiales de transporte y cualquier requisito legal especial, incluidos los s\u00edmbolos de seguridad.\n\n2. **\u00bfCu\u00e1les son las precauciones espec\u00edficas que se deben tomar al utilizar hielo seco en los contenedores de env\u00edo de productos farmac\u00e9uticos?**\n   - Se debe tener especial cuidado para asegurar que el producto farmac\u00e9utico no entre en contacto con el hielo seco, ya que esto podr\u00eda afectar negativamente la calidad del producto.\n\n3. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere antes de despachar productos farmac\u00e9uticos?**\n   - Se requiere la recepci\u00f3n de una orden de entrega v\u00e1lida o un plan de reposici\u00f3n de materiales, que debe ser documentado antes de proceder con el despacho y transporte de los productos farmac\u00e9uticos.", "prev_section_summary": "### Temas Clave\n\n1. **Control de Plagas y Limpieza**: Es fundamental mantener veh\u00edculos, contenedores y equipos libres de plagas (roedores, vermin, aves, etc.). Se requiere la implementaci\u00f3n de programas escritos y registros para el control de plagas, as\u00ed como el uso de agentes de limpieza que no afecten la calidad de los productos farmac\u00e9uticos.\n\n2. **Condiciones de Almacenamiento y Transporte**: Se debe prestar especial atenci\u00f3n a las condiciones de almacenamiento durante el transporte, incluyendo temperatura y humedad. Estas condiciones deben ser verificadas, monitoreadas y registradas, y los registros deben conservarse por un m\u00ednimo de la vida \u00fatil del producto m\u00e1s un a\u00f1o.\n\n3. **Seguridad y Acceso**: Es necesario implementar medidas para prevenir el acceso no autorizado a veh\u00edculos y equipos, as\u00ed como para evitar el robo o la manipulaci\u00f3n indebida de los mismos.\n\n4. **Dise\u00f1o y Mantenimiento de Equipos**: Se debe asegurar que el dise\u00f1o, uso, limpieza y mantenimiento de los equipos utilizados para manejar productos farmac\u00e9uticos sean adecuados para evitar la contaminaci\u00f3n.\n\n5. **Etiquetado y Protecci\u00f3n de Contenedores**: Los contenedores de env\u00edo deben ser apropiados para proteger la calidad de los productos y deben llevar etiquetas que proporcionen informaci\u00f3n suficiente sobre las condiciones de manejo y almacenamiento.\n\n### Entidades\n\n- **Veh\u00edculos y Contenedores**: Elementos utilizados para el transporte de productos farmac\u00e9uticos.\n- **Agentes de Limpieza**: Sustancias utilizadas para mantener la limpieza de veh\u00edculos y equipos.\n- **Condiciones Especiales**: Requisitos espec\u00edficos de temperatura y humedad durante el transporte.\n- **Registros de Monitoreo**: Documentaci\u00f3n que debe ser mantenida para verificar el cumplimiento de las condiciones de almacenamiento.\n- **Productos Farmac\u00e9uticos**: Bienes que requieren condiciones espec\u00edficas para su manejo y transporte.\n- **Medidas de Seguridad**: Protocolos implementados para proteger los veh\u00edculos y equipos de acceso no autorizado.", "excerpt_keywords": "Keywords: pharmaceutical products, shipment containers, transport conditions, dispatch procedures, quality control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "73993a4d-3307-4d84-a223-e7b970b3891b", "node_type": "4", "metadata": {"page_label": "267", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "that the products are properly handled and secure at all times. The shipment container should enable identification of the container\u2019s contents and source.\n\n11.3 The need for any special transport and/or storage conditions should be stated on the shipment container label. If a pharmaceutical product is intended for transfer to areas outside the control of the manufacturer\u2019s products management system, the name and address of the manufacturer, special transport conditions and any special legal requirements, including safety symbols, should also be included on the container label.\n\n11.4 Normally, internationally and/or nationally accepted abbreviations, names or codes should be used in the labelling of shipment containers.\n\n11.5 Special care should be taken when using dry ice in shipment containers. In addition to safety issues it must be ensured that the pharmaceutical product does not come into contact with the dry ice, as it may have an adverse effect on the quality of the product.\n\n11.6 Written procedures should be available for the handling of damaged and/or broken shipment containers. Particular attention should be paid to those containing potentially toxic and hazardous products.\n\n# 12. Dispatch and receipt\n\n12.1 Pharmaceutical products should only be sold and/or distributed to persons or entities that are authorized to acquire such products in accordance with the applicable national, regional and international legislation. Written proof of such authority must be obtained prior to the distribution of products to such persons or entities.\n\n12.2 Prior to the dispatch of the pharmaceutical products, the supplier should ensure that the person or entity, e.g. the contract acceptor for transportation of the pharmaceutical products, is aware of the pharmaceutical products to be distributed and complies with the appropriate storage and transport conditions.\n\n12.3 The dispatch and transportation of pharmaceutical products should be undertaken only after the receipt of a valid delivery order or material replenishment plan, which should be documented.\n\n12.4 Written procedures for the dispatch of pharmaceutical products should be established. Such procedures should take into account the nature of the product as well as any special precautions to be observed. Pharmaceutical products under quarantine will require release for dispatch by the person responsible for quality (see 6.3).\n\n12.5 Records for the dispatch of pharmaceutical products should be prepared and should include at least the following information:", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "af7577765aea3ca2ecde7b1fe07c8637171e5e677e6796151a9116889e0b621f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "that the products are properly handled and secure at all times. The shipment container should enable identification of the container\u2019s contents and source.\n\n11.3 The need for any special transport and/or storage conditions should be stated on the shipment container label. If a pharmaceutical product is intended for transfer to areas outside the control of the manufacturer\u2019s products management system, the name and address of the manufacturer, special transport conditions and any special legal requirements, including safety symbols, should also be included on the container label.\n\n11.4 Normally, internationally and/or nationally accepted abbreviations, names or codes should be used in the labelling of shipment containers.\n\n11.5 Special care should be taken when using dry ice in shipment containers. In addition to safety issues it must be ensured that the pharmaceutical product does not come into contact with the dry ice, as it may have an adverse effect on the quality of the product.\n\n11.6 Written procedures should be available for the handling of damaged and/or broken shipment containers. Particular attention should be paid to those containing potentially toxic and hazardous products.\n\n# 12. Dispatch and receipt\n\n12.1 Pharmaceutical products should only be sold and/or distributed to persons or entities that are authorized to acquire such products in accordance with the applicable national, regional and international legislation. Written proof of such authority must be obtained prior to the distribution of products to such persons or entities.\n\n12.2 Prior to the dispatch of the pharmaceutical products, the supplier should ensure that the person or entity, e.g. the contract acceptor for transportation of the pharmaceutical products, is aware of the pharmaceutical products to be distributed and complies with the appropriate storage and transport conditions.\n\n12.3 The dispatch and transportation of pharmaceutical products should be undertaken only after the receipt of a valid delivery order or material replenishment plan, which should be documented.\n\n12.4 Written procedures for the dispatch of pharmaceutical products should be established. Such procedures should take into account the nature of the product as well as any special precautions to be observed. Pharmaceutical products under quarantine will require release for dispatch by the person responsible for quality (see 6.3).\n\n12.5 Records for the dispatch of pharmaceutical products should be prepared and should include at least the following information:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2547, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "18088118-b2e8-4ece-940b-105dc7b79d66": {"__data__": {"id_": "18088118-b2e8-4ece-940b-105dc7b79d66", "embedding": null, "metadata": {"page_label": "268", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 date of dispatch;  \n\u2014 complete business name and address (no acronyms), type of entity responsible for the transportation, telephone number and names of contact persons;  \n\u2014 complete business name, address (no acronyms), and status of the addressee (e.g. retail pharmacy, hospital or community clinic);  \n\u2014 a description of the products including, e.g. name, dosage form and strength (if applicable);  \n\u2014 quantity of the products, i.e. number of containers and quantity per container (if applicable);  \n\u2014 applicable transport and storage conditions;  \n\u2014 a unique number to allow identification of the delivery order; and  \n\u2014 assigned batch number and expiry date (where not possible at dispatch, this information should at least be kept at receipt to facilitate traceability).  \n\n12.6 Records of dispatch should contain enough information to enable traceability of the pharmaceutical product. Such records should facilitate the recall of a batch of a product, if necessary, as well as the investigation of counterfeit or potentially counterfeit pharmaceutical products.\n\n12.7 In addition, the assigned batch number and expiry date of pharmaceutical products should be recorded at the point of receipt to facilitate traceability.\n\n12.8 Methods of transportation, including vehicles to be used, should be selected with care, and local conditions should be considered, including the climate and any seasonal variations experienced. Delivery of products requiring controlled temperatures should be in accordance with the applicable storage and transport conditions.\n\n12.9 Delivery schedules should be established and routes planned, taking local needs and conditions into account. Such schedules and plans should be realistic and systematic. Security risks should also be taken into account when planning the schedules and routes of the delivery.\n\n12.10 Care should be taken to ensure that the volume of pharmaceutical products ordered does not exceed the capacity of storage facilities at the destination.\n\n12.11 Vehicles and containers should be loaded carefully and systematically, where applicable on a first-out/last-in basis, to save time when unloading, prevent physical damage and reduce security risks. Extra care should be taken during loading and unloading of cartons to avoid damage.\n\n12.12 Pharmaceutical products should not be supplied or received after their expiry date, or so close to the expiry date that this date is likely to be reached before the products are used by the consumer.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl texto proporciona directrices sobre el manejo y transporte de productos farmac\u00e9uticos, enfatizando la importancia de la trazabilidad, la documentaci\u00f3n adecuada y las condiciones de transporte. Se detallan los elementos que deben incluirse en los registros de despacho, como la informaci\u00f3n del remitente y destinatario, la descripci\u00f3n de los productos, las condiciones de transporte y almacenamiento, as\u00ed como la gesti\u00f3n de la carga y la planificaci\u00f3n de rutas. Tambi\u00e9n se menciona la necesidad de evitar el suministro de productos que est\u00e9n cerca de su fecha de caducidad.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en los registros de despacho para garantizar la trazabilidad de los productos farmac\u00e9uticos?**\n   - Respuesta: Los registros de despacho deben incluir la fecha de despacho, el nombre y direcci\u00f3n completos del remitente y destinatario, una descripci\u00f3n de los productos, la cantidad de productos, las condiciones de transporte y almacenamiento, un n\u00famero \u00fanico para identificar el pedido, y el n\u00famero de lote y fecha de caducidad.\n\n2. **\u00bfCu\u00e1les son las consideraciones que deben tenerse en cuenta al seleccionar los m\u00e9todos de transporte para productos farmac\u00e9uticos?**\n   - Respuesta: Al seleccionar los m\u00e9todos de transporte, se deben considerar las condiciones locales, el clima, las variaciones estacionales y las condiciones de almacenamiento y transporte aplicables, especialmente para productos que requieren temperaturas controladas.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse para asegurar que los productos farmac\u00e9uticos no se suministren o reciban despu\u00e9s de su fecha de caducidad?**\n   - Respuesta: Se debe tener cuidado para no suministrar o recibir productos que est\u00e9n cerca de su fecha de caducidad, asegurando que esta fecha no se alcance antes de que los productos sean utilizados por el consumidor. Adem\u00e1s, es importante registrar la fecha de caducidad en el punto de recepci\u00f3n para facilitar la trazabilidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manejo y Seguridad de Productos Farmac\u00e9uticos**:\n   - Importancia de asegurar que los productos farmac\u00e9uticos sean manejados y asegurados adecuadamente en todo momento.\n   - Los contenedores de env\u00edo deben permitir la identificaci\u00f3n de su contenido y origen.\n\n2. **Etiquetado de Contenedores de Env\u00edo**:\n   - La etiqueta del contenedor debe incluir condiciones especiales de transporte y almacenamiento.\n   - Para productos transferidos fuera del control del fabricante, se debe incluir el nombre y direcci\u00f3n del fabricante, condiciones especiales de transporte y requisitos legales, incluidos s\u00edmbolos de seguridad.\n   - Uso de abreviaturas, nombres o c\u00f3digos aceptados internacionalmente o nacionalmente en el etiquetado.\n\n3. **Uso de Hielo Seco**:\n   - Precauciones especiales al utilizar hielo seco en contenedores de env\u00edo, asegurando que el producto no entre en contacto con el hielo seco para evitar efectos adversos en la calidad.\n\n4. **Procedimientos para Productos Da\u00f1ados**:\n   - Disponibilidad de procedimientos escritos para el manejo de contenedores de env\u00edo da\u00f1ados, con atenci\u00f3n especial a productos potencialmente t\u00f3xicos y peligrosos.\n\n5. **Despacho y Recepci\u00f3n de Productos Farmac\u00e9uticos**:\n   - Solo se deben vender o distribuir productos a entidades autorizadas, con prueba escrita de dicha autoridad.\n   - Verificaci\u00f3n de que el transportista est\u00e9 informado sobre los productos y cumpla con las condiciones de almacenamiento y transporte.\n   - Requerimiento de una orden de entrega v\u00e1lida o plan de reposici\u00f3n de materiales antes del despacho.\n   - Establecimiento de procedimientos escritos para el despacho, considerando la naturaleza del producto y precauciones especiales.\n   - Preparaci\u00f3n de registros de despacho que incluyan informaci\u00f3n relevante.\n\n### Entidades Clave\n- **Productos Farmac\u00e9uticos**: Bienes que requieren manejo y transporte cuidadoso.\n- **Fabricante**: Entidad responsable de la producci\u00f3n y etiquetado de los productos.\n- **Entidades Autorizadas**: Personas o entidades que tienen permiso legal para adquirir productos farmac\u00e9uticos.\n- **Transportistas**: Entidades encargadas del transporte de productos farmac\u00e9uticos.\n- **Autoridades Legales**: Organismos que regulan la distribuci\u00f3n y venta de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: trazabilidad, productos farmac\u00e9uticos, transporte, condiciones de almacenamiento, fecha de caducidad"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "75f585ac-c459-4e7f-ad84-dcd1571dc294", "node_type": "4", "metadata": {"page_label": "268", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 date of dispatch;  \n\u2014 complete business name and address (no acronyms), type of entity responsible for the transportation, telephone number and names of contact persons;  \n\u2014 complete business name, address (no acronyms), and status of the addressee (e.g. retail pharmacy, hospital or community clinic);  \n\u2014 a description of the products including, e.g. name, dosage form and strength (if applicable);  \n\u2014 quantity of the products, i.e. number of containers and quantity per container (if applicable);  \n\u2014 applicable transport and storage conditions;  \n\u2014 a unique number to allow identification of the delivery order; and  \n\u2014 assigned batch number and expiry date (where not possible at dispatch, this information should at least be kept at receipt to facilitate traceability).  \n\n12.6 Records of dispatch should contain enough information to enable traceability of the pharmaceutical product. Such records should facilitate the recall of a batch of a product, if necessary, as well as the investigation of counterfeit or potentially counterfeit pharmaceutical products.\n\n12.7 In addition, the assigned batch number and expiry date of pharmaceutical products should be recorded at the point of receipt to facilitate traceability.\n\n12.8 Methods of transportation, including vehicles to be used, should be selected with care, and local conditions should be considered, including the climate and any seasonal variations experienced. Delivery of products requiring controlled temperatures should be in accordance with the applicable storage and transport conditions.\n\n12.9 Delivery schedules should be established and routes planned, taking local needs and conditions into account. Such schedules and plans should be realistic and systematic. Security risks should also be taken into account when planning the schedules and routes of the delivery.\n\n12.10 Care should be taken to ensure that the volume of pharmaceutical products ordered does not exceed the capacity of storage facilities at the destination.\n\n12.11 Vehicles and containers should be loaded carefully and systematically, where applicable on a first-out/last-in basis, to save time when unloading, prevent physical damage and reduce security risks. Extra care should be taken during loading and unloading of cartons to avoid damage.\n\n12.12 Pharmaceutical products should not be supplied or received after their expiry date, or so close to the expiry date that this date is likely to be reached before the products are used by the consumer.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "bae8b3f7f555a97cdccbae07c51d67be5f477d0ccfab58afbbdbc87876ec0cc3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2014 date of dispatch;  \n\u2014 complete business name and address (no acronyms), type of entity responsible for the transportation, telephone number and names of contact persons;  \n\u2014 complete business name, address (no acronyms), and status of the addressee (e.g. retail pharmacy, hospital or community clinic);  \n\u2014 a description of the products including, e.g. name, dosage form and strength (if applicable);  \n\u2014 quantity of the products, i.e. number of containers and quantity per container (if applicable);  \n\u2014 applicable transport and storage conditions;  \n\u2014 a unique number to allow identification of the delivery order; and  \n\u2014 assigned batch number and expiry date (where not possible at dispatch, this information should at least be kept at receipt to facilitate traceability).  \n\n12.6 Records of dispatch should contain enough information to enable traceability of the pharmaceutical product. Such records should facilitate the recall of a batch of a product, if necessary, as well as the investigation of counterfeit or potentially counterfeit pharmaceutical products.\n\n12.7 In addition, the assigned batch number and expiry date of pharmaceutical products should be recorded at the point of receipt to facilitate traceability.\n\n12.8 Methods of transportation, including vehicles to be used, should be selected with care, and local conditions should be considered, including the climate and any seasonal variations experienced. Delivery of products requiring controlled temperatures should be in accordance with the applicable storage and transport conditions.\n\n12.9 Delivery schedules should be established and routes planned, taking local needs and conditions into account. Such schedules and plans should be realistic and systematic. Security risks should also be taken into account when planning the schedules and routes of the delivery.\n\n12.10 Care should be taken to ensure that the volume of pharmaceutical products ordered does not exceed the capacity of storage facilities at the destination.\n\n12.11 Vehicles and containers should be loaded carefully and systematically, where applicable on a first-out/last-in basis, to save time when unloading, prevent physical damage and reduce security risks. Extra care should be taken during loading and unloading of cartons to avoid damage.\n\n12.12 Pharmaceutical products should not be supplied or received after their expiry date, or so close to the expiry date that this date is likely to be reached before the products are used by the consumer.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2500, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "bb69d4f6-37c7-49f2-aefe-686158865eae": {"__data__": {"id_": "bb69d4f6-37c7-49f2-aefe-686158865eae", "embedding": null, "metadata": {"page_label": "269", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Transportation and products in transit\n\n13.1 Products and shipment containers should be secured to prevent or provide evidence of unauthorized access. Vehicles and operators should be provided with additional security, as appropriate, to prevent theft and other misappropriation of products during transportation.\n\n13.2 Product shipments should be secured and include the appropriate documentation to facilitate identification and verification of compliance with regulatory requirements. Policies and procedures should be followed by all persons involved in the transportation, to secure pharmaceutical products.\n\n13.3 The people responsible for the transportation of pharmaceutical products should be informed about all relevant conditions for storage and transportation. These requirements should be adhered to throughout transportation and at any intermediate storage stages.\n\n13.4 Pharmaceutical products should be stored and transported in accordance with procedures such that:\n- The identity of the product is not lost.\n- The product does not contaminate and is not contaminated by other products.\n- Adequate precautions are taken against spillage, breakage, misappropriation and theft.\n- Appropriate environmental conditions are maintained, e.g. using cold chain for thermolabile products.\n\n13.5 The required storage conditions for pharmaceutical products should be maintained within acceptable limits during transportation. If a deviation has been noticed during transportation by the person or entity responsible for transportation, this should be reported to the distributor and recipient. In cases where the recipient notices the deviation, it should be reported to the distributor. Where necessary, the manufacturer of the pharmaceutical product should be contacted for information about appropriate steps to be taken.\n\n13.6 Where special conditions are required during transportation that are different from or limit the given environmental conditions (e.g. temperature and humidity) these should be provided by the manufacturer on the labels, monitored and recorded.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las mejores pr\u00e1cticas para el transporte y manejo de productos farmac\u00e9uticos. Se enfatiza la importancia de asegurar los productos y los contenedores de env\u00edo para prevenir el acceso no autorizado y el robo. Tambi\u00e9n se destacan las condiciones de almacenamiento y transporte que deben cumplirse para garantizar la integridad de los productos, as\u00ed como la necesidad de documentaci\u00f3n adecuada para verificar el cumplimiento de los requisitos regulatorios. Adem\u00e1s, se menciona la importancia de informar sobre cualquier desviaci\u00f3n en las condiciones de transporte y de seguir las instrucciones del fabricante en cuanto a condiciones especiales.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas de seguridad se deben implementar para prevenir el acceso no autorizado a los productos farmac\u00e9uticos durante el transporte?**\n   - Esta pregunta busca detalles sobre las pr\u00e1cticas espec\u00edficas de seguridad que deben seguirse, que no se encuentran f\u00e1cilmente en otros documentos.\n\n2. **\u00bfQu\u00e9 pasos deben seguir las personas responsables del transporte si se detecta una desviaci\u00f3n en las condiciones de almacenamiento durante el transporte?**\n   - Esta pregunta se centra en el protocolo a seguir en caso de problemas durante el transporte, lo cual puede no estar claramente definido en otras fuentes.\n\n3. **\u00bfC\u00f3mo deben documentarse y monitorearse las condiciones especiales de transporte que difieren de las condiciones ambientales est\u00e1ndar?**\n   - Esta pregunta busca informaci\u00f3n sobre la documentaci\u00f3n y el monitoreo de condiciones espec\u00edficas, un aspecto que puede no ser ampliamente cubierto en otros contextos relacionados con el transporte de productos farmac\u00e9uticos.", "prev_section_summary": "### Temas Clave\n\n1. **Trazabilidad de Productos Farmac\u00e9uticos**: Se enfatiza la importancia de mantener registros detallados que permitan la trazabilidad de los productos farmac\u00e9uticos, facilitando la recuperaci\u00f3n de lotes y la investigaci\u00f3n de productos falsificados.\n\n2. **Documentaci\u00f3n de Despacho**: Los registros de despacho deben incluir informaci\u00f3n esencial como la fecha de despacho, datos del remitente y destinatario, descripci\u00f3n de los productos, cantidad, condiciones de transporte y almacenamiento, y n\u00fameros de lote y fecha de caducidad.\n\n3. **Selecci\u00f3n de M\u00e9todos de Transporte**: Se deben considerar las condiciones locales, clim\u00e1ticas y estacionales al seleccionar los m\u00e9todos de transporte, especialmente para productos que requieren temperaturas controladas.\n\n4. **Planificaci\u00f3n de Rutas y Horarios de Entrega**: Es crucial establecer horarios de entrega y planificar rutas que sean realistas y sistem\u00e1ticas, teniendo en cuenta las necesidades locales y los riesgos de seguridad.\n\n5. **Manejo de Carga**: Se debe tener cuidado al cargar y descargar productos para evitar da\u00f1os y asegurar la eficiencia en el proceso.\n\n6. **Control de Fechas de Caducidad**: Se debe evitar el suministro de productos que est\u00e9n cerca de su fecha de caducidad, asegurando que no se alcancen antes de su uso por el consumidor.\n\n### Entidades\n\n- **Remitente**: Nombre y direcci\u00f3n completos, tipo de entidad responsable del transporte, n\u00famero de tel\u00e9fono y contactos.\n- **Destinatario**: Nombre y direcci\u00f3n completos, estado del destinatario (farmacia, hospital, cl\u00ednica comunitaria).\n- **Productos Farmac\u00e9uticos**: Nombre, forma de dosificaci\u00f3n, fuerza, cantidad y condiciones de transporte.\n- **Registros de Despacho**: Documentaci\u00f3n que incluye informaci\u00f3n para la trazabilidad y recuperaci\u00f3n de productos.\n- **M\u00e9todos de Transporte**: Veh\u00edculos y condiciones locales que afectan el transporte de productos.\n- **Fechas de Caducidad**: Informaci\u00f3n cr\u00edtica para asegurar la calidad y seguridad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: transportation, pharmaceutical products, security measures, storage conditions, regulatory compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9e0fa5ca-28a5-48fb-ad06-b2c1a504edd2", "node_type": "4", "metadata": {"page_label": "269", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Transportation and products in transit\n\n13.1 Products and shipment containers should be secured to prevent or provide evidence of unauthorized access. Vehicles and operators should be provided with additional security, as appropriate, to prevent theft and other misappropriation of products during transportation.\n\n13.2 Product shipments should be secured and include the appropriate documentation to facilitate identification and verification of compliance with regulatory requirements. Policies and procedures should be followed by all persons involved in the transportation, to secure pharmaceutical products.\n\n13.3 The people responsible for the transportation of pharmaceutical products should be informed about all relevant conditions for storage and transportation. These requirements should be adhered to throughout transportation and at any intermediate storage stages.\n\n13.4 Pharmaceutical products should be stored and transported in accordance with procedures such that:\n- The identity of the product is not lost.\n- The product does not contaminate and is not contaminated by other products.\n- Adequate precautions are taken against spillage, breakage, misappropriation and theft.\n- Appropriate environmental conditions are maintained, e.g. using cold chain for thermolabile products.\n\n13.5 The required storage conditions for pharmaceutical products should be maintained within acceptable limits during transportation. If a deviation has been noticed during transportation by the person or entity responsible for transportation, this should be reported to the distributor and recipient. In cases where the recipient notices the deviation, it should be reported to the distributor. Where necessary, the manufacturer of the pharmaceutical product should be contacted for information about appropriate steps to be taken.\n\n13.6 Where special conditions are required during transportation that are different from or limit the given environmental conditions (e.g. temperature and humidity) these should be provided by the manufacturer on the labels, monitored and recorded.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "5bb4955165fcb331a97532d390f281a1d4e1c06213311cf235e944d5cfaa70f2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Transportation and products in transit\n\n13.1 Products and shipment containers should be secured to prevent or provide evidence of unauthorized access. Vehicles and operators should be provided with additional security, as appropriate, to prevent theft and other misappropriation of products during transportation.\n\n13.2 Product shipments should be secured and include the appropriate documentation to facilitate identification and verification of compliance with regulatory requirements. Policies and procedures should be followed by all persons involved in the transportation, to secure pharmaceutical products.\n\n13.3 The people responsible for the transportation of pharmaceutical products should be informed about all relevant conditions for storage and transportation. These requirements should be adhered to throughout transportation and at any intermediate storage stages.\n\n13.4 Pharmaceutical products should be stored and transported in accordance with procedures such that:\n- The identity of the product is not lost.\n- The product does not contaminate and is not contaminated by other products.\n- Adequate precautions are taken against spillage, breakage, misappropriation and theft.\n- Appropriate environmental conditions are maintained, e.g. using cold chain for thermolabile products.\n\n13.5 The required storage conditions for pharmaceutical products should be maintained within acceptable limits during transportation. If a deviation has been noticed during transportation by the person or entity responsible for transportation, this should be reported to the distributor and recipient. In cases where the recipient notices the deviation, it should be reported to the distributor. Where necessary, the manufacturer of the pharmaceutical product should be contacted for information about appropriate steps to be taken.\n\n13.6 Where special conditions are required during transportation that are different from or limit the given environmental conditions (e.g. temperature and humidity) these should be provided by the manufacturer on the labels, monitored and recorded.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2082, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3e20c3ae-c300-41b0-bc04-896d953147f8": {"__data__": {"id_": "3e20c3ae-c300-41b0-bc04-896d953147f8", "embedding": null, "metadata": {"page_label": "270", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 13.7 \nWritten procedures should be in place for investigating and dealing with any failure to comply with storage requirements, e.g. temperature deviations.\n\n## 13.8 \nTransportation and storage of pharmaceutical products containing hazardous substances, such as toxic, radioactive material, and other dangerous pharmaceutical products presenting special risks of abuse, fire or explosion (e.g. combustible or flammable liquids, solids and pressurized gases) should be stored in safe, dedicated and secure areas, and transported in safe, suitably designed, secured containers and vehicles. In addition, the requirements of applicable international agreements and national legislation should be met.\n\n## 13.9 \nProducts containing narcotics and other dependence-producing substances should be transported in safe and secure containers and vehicles and be stored in safe and secure areas.\n\nIn addition, applicable international agreements and national legislation should be complied with.\n\n## 13.10 \nSpillages should be cleaned up as soon as possible to prevent possible contamination, cross-contamination and hazards. Written procedures should be in place for the handling of such occurrences.\n\n## 13.11 \nPhysical or other equivalent (e.g. electronic) segregation should be provided for the storage and distribution during transit of rejected, expired, recalled or returned pharmaceutical products and suspected counterfeits. The products should be appropriately identified, securely packaged, clearly labelled and be accompanied by appropriate supporting documentation.\n\n## 13.12 \nThe interiors of vehicles and containers should remain clean and dry while pharmaceutical products are in transit.\n\n## 13.13 \nPackaging materials and shipment containers should be of suitable design to prevent damage of pharmaceutical products during transport. Seal control programmes should be in place and managed properly.\n\n## 13.14 \nDrivers of vehicles should identify themselves and present appropriate documentation to demonstrate that they are authorized to transport the load.\n\n## 13.15 \nDamage to containers and any other event or problem that occurs during transit must be recorded and reported to the relevant department, entity or authority, and investigated.\n\n## 13.16 \nPharmaceutical products in transit must be accompanied by the appropriate documentation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl contexto se centra en las directrices de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre el almacenamiento y transporte de productos farmac\u00e9uticos, especialmente aquellos que contienen sustancias peligrosas, narc\u00f3ticos y otros productos que presentan riesgos especiales. Se enfatiza la importancia de tener procedimientos escritos para manejar desviaciones de temperatura, limpieza de derrames, segregaci\u00f3n de productos rechazados o sospechosos, y la necesidad de documentaci\u00f3n adecuada durante el transporte. Tambi\u00e9n se menciona la importancia de la seguridad en el transporte y almacenamiento de estos productos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben implementarse para manejar las desviaciones de temperatura en el almacenamiento de productos farmac\u00e9uticos?**\n   - Esta pregunta busca detalles sobre las acciones espec\u00edficas que deben tomarse cuando hay un incumplimiento de los requisitos de almacenamiento, que no se detalla en otras partes del documento.\n\n2. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que deben tener los contenedores y veh\u00edculos utilizados para el transporte de productos farmac\u00e9uticos peligrosos?**\n   - Esta pregunta se enfoca en las especificaciones de seguridad y dise\u00f1o que deben cumplir los contenedores y veh\u00edculos, que pueden no estar claramente definidas en otras secciones.\n\n3. **\u00bfQu\u00e9 tipo de documentaci\u00f3n es necesaria para acompa\u00f1ar los productos farmac\u00e9uticos durante su transporte?**\n   - Esta pregunta busca informaci\u00f3n sobre los documentos espec\u00edficos que deben estar presentes durante el transporte, lo cual es crucial para el cumplimiento normativo y la trazabilidad, y puede no estar ampliamente cubierto en otras partes del texto.", "prev_section_summary": "### Temas Clave\n\n1. **Seguridad en el Transporte**: Se enfatiza la necesidad de asegurar los productos y contenedores de env\u00edo para prevenir el acceso no autorizado y el robo. Se recomienda proporcionar seguridad adicional a veh\u00edculos y operadores.\n\n2. **Documentaci\u00f3n y Cumplimiento Regulatorio**: Los env\u00edos de productos deben incluir la documentaci\u00f3n adecuada para facilitar la identificaci\u00f3n y verificaci\u00f3n del cumplimiento de los requisitos regulatorios.\n\n3. **Condiciones de Almacenamiento y Transporte**: Es crucial que las personas responsables del transporte est\u00e9n informadas sobre las condiciones relevantes de almacenamiento y transporte, y que estas se mantengan durante todo el proceso.\n\n4. **Integridad del Producto**: Se deben seguir procedimientos para asegurar que la identidad del producto no se pierda, que no haya contaminaci\u00f3n entre productos, y que se tomen precauciones adecuadas contra derrames, roturas, y robos.\n\n5. **Mantenimiento de Condiciones de Almacenamiento**: Las condiciones de almacenamiento requeridas deben mantenerse dentro de l\u00edmites aceptables durante el transporte. Cualquier desviaci\u00f3n debe ser reportada a las partes correspondientes.\n\n6. **Condiciones Especiales de Transporte**: Si se requieren condiciones especiales durante el transporte, estas deben ser proporcionadas por el fabricante, y deben ser monitoreadas y registradas.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Productos Farmac\u00e9uticos**: Bienes que est\u00e1n siendo transportados y que requieren condiciones espec\u00edficas.\n- **Distribuidores y Recipientes**: Entidades involucradas en la cadena de suministro que deben ser informadas sobre cualquier desviaci\u00f3n en las condiciones de transporte.\n- **Fabricantes**: Responsables de proporcionar informaci\u00f3n sobre condiciones especiales de transporte y etiquetado. \n\nEste resumen destaca la importancia de la seguridad, la documentaci\u00f3n, y el cumplimiento de las condiciones de transporte para garantizar la integridad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: pharmaceutical storage, hazardous substances, transportation safety, compliance procedures, documentation requirements"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "59e0219d-b6c8-47ca-9185-a4a066a9267d", "node_type": "4", "metadata": {"page_label": "270", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 13.7 \nWritten procedures should be in place for investigating and dealing with any failure to comply with storage requirements, e.g. temperature deviations.\n\n## 13.8 \nTransportation and storage of pharmaceutical products containing hazardous substances, such as toxic, radioactive material, and other dangerous pharmaceutical products presenting special risks of abuse, fire or explosion (e.g. combustible or flammable liquids, solids and pressurized gases) should be stored in safe, dedicated and secure areas, and transported in safe, suitably designed, secured containers and vehicles. In addition, the requirements of applicable international agreements and national legislation should be met.\n\n## 13.9 \nProducts containing narcotics and other dependence-producing substances should be transported in safe and secure containers and vehicles and be stored in safe and secure areas.\n\nIn addition, applicable international agreements and national legislation should be complied with.\n\n## 13.10 \nSpillages should be cleaned up as soon as possible to prevent possible contamination, cross-contamination and hazards. Written procedures should be in place for the handling of such occurrences.\n\n## 13.11 \nPhysical or other equivalent (e.g. electronic) segregation should be provided for the storage and distribution during transit of rejected, expired, recalled or returned pharmaceutical products and suspected counterfeits. The products should be appropriately identified, securely packaged, clearly labelled and be accompanied by appropriate supporting documentation.\n\n## 13.12 \nThe interiors of vehicles and containers should remain clean and dry while pharmaceutical products are in transit.\n\n## 13.13 \nPackaging materials and shipment containers should be of suitable design to prevent damage of pharmaceutical products during transport. Seal control programmes should be in place and managed properly.\n\n## 13.14 \nDrivers of vehicles should identify themselves and present appropriate documentation to demonstrate that they are authorized to transport the load.\n\n## 13.15 \nDamage to containers and any other event or problem that occurs during transit must be recorded and reported to the relevant department, entity or authority, and investigated.\n\n## 13.16 \nPharmaceutical products in transit must be accompanied by the appropriate documentation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "bb7d9bec00aa04fb3f772deed1f239e0cc93d55a1ee8aa9cf40995d96fa9b129", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 13.7 \nWritten procedures should be in place for investigating and dealing with any failure to comply with storage requirements, e.g. temperature deviations.\n\n## 13.8 \nTransportation and storage of pharmaceutical products containing hazardous substances, such as toxic, radioactive material, and other dangerous pharmaceutical products presenting special risks of abuse, fire or explosion (e.g. combustible or flammable liquids, solids and pressurized gases) should be stored in safe, dedicated and secure areas, and transported in safe, suitably designed, secured containers and vehicles. In addition, the requirements of applicable international agreements and national legislation should be met.\n\n## 13.9 \nProducts containing narcotics and other dependence-producing substances should be transported in safe and secure containers and vehicles and be stored in safe and secure areas.\n\nIn addition, applicable international agreements and national legislation should be complied with.\n\n## 13.10 \nSpillages should be cleaned up as soon as possible to prevent possible contamination, cross-contamination and hazards. Written procedures should be in place for the handling of such occurrences.\n\n## 13.11 \nPhysical or other equivalent (e.g. electronic) segregation should be provided for the storage and distribution during transit of rejected, expired, recalled or returned pharmaceutical products and suspected counterfeits. The products should be appropriately identified, securely packaged, clearly labelled and be accompanied by appropriate supporting documentation.\n\n## 13.12 \nThe interiors of vehicles and containers should remain clean and dry while pharmaceutical products are in transit.\n\n## 13.13 \nPackaging materials and shipment containers should be of suitable design to prevent damage of pharmaceutical products during transport. Seal control programmes should be in place and managed properly.\n\n## 13.14 \nDrivers of vehicles should identify themselves and present appropriate documentation to demonstrate that they are authorized to transport the load.\n\n## 13.15 \nDamage to containers and any other event or problem that occurs during transit must be recorded and reported to the relevant department, entity or authority, and investigated.\n\n## 13.16 \nPharmaceutical products in transit must be accompanied by the appropriate documentation.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2354, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "eef29f94-f0ce-4455-99f0-504626af301f": {"__data__": {"id_": "eef29f94-f0ce-4455-99f0-504626af301f", "embedding": null, "metadata": {"page_label": "271", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Documentation\n\n14.1 Written instructions and records which document all activities relating to the distribution of pharmaceutical products, including all applicable receipts and issues (invoices) should be available. Records should be kept for seven years, unless otherwise specified in national or regional regulations.\n\n14.2 Distributors should keep records of all pharmaceutical products received. Records should contain at least the following information:\n- date;\n- name of the pharmaceutical product;\n- quantity received, or supplied; and\n- name and address of the supplier.\n\n14.3 Procedures should be established and maintained for the preparation, review, approval, use of and control of changes to all documents relating to the distribution process. Procedures must be in place for both internally generated documents and those from external sources.\n\n14.4 Documents, and in particular instructions and procedures relating to any activity that could have an impact on the quality of pharmaceutical products, should be designed, completed, reviewed and distributed with care.\n\n14.5 The title, nature and purpose of each document should be clearly stated. The contents of documents should be clear and unambiguous. Documents should be laid out in an orderly fashion and be easy to check.\n\n14.6 All documents should be completed, approved, signed (as required) and dated by an appropriate authorized person(s) and should not be changed without the necessary authorization.\n\n14.7 The nature, content and retention of documentation relating to the distribution of pharmaceutical products and any investigations conducted and action taken, should comply with national legislative requirements. Where such requirements are not in place, the documents should be retained for at least one year after the expiry date of the product concerned.\n\n14.8 The distributor must establish and maintain procedures for the identification, collection, indexing, retrieval, storage, maintenance, disposal of and access to all applicable documentation.\n\n14.9 All records must be readily retrievable, and be stored and retained using facilities that are safeguarded against unauthorized modification, damage, deterioration and/or loss of documentation.\n\n14.10 Documents should be reviewed regularly and kept up to date. When a document has been revised, a system should exist to prevent inadvertent use of the superseded version.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece directrices sobre la documentaci\u00f3n necesaria para la distribuci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de mantener registros detallados de las actividades de distribuci\u00f3n, as\u00ed como la necesidad de procedimientos claros para la gesti\u00f3n de documentos. Se especifica que los registros deben ser accesibles, seguros y actualizados, y se deben conservar durante un per\u00edodo determinado, cumpliendo con las regulaciones nacionales.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1nto tiempo deben conservarse los registros de distribuci\u00f3n de productos farmac\u00e9uticos seg\u00fan las directrices de la OMS?**\n   - Los registros deben conservarse durante siete a\u00f1os, a menos que las regulaciones nacionales o regionales indiquen un per\u00edodo diferente.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n m\u00ednima debe contener el registro de productos farmac\u00e9uticos recibidos por un distribuidor?**\n   - El registro debe incluir la fecha, el nombre del producto farmac\u00e9utico, la cantidad recibida o suministrada, y el nombre y direcci\u00f3n del proveedor.\n\n3. **\u00bfQu\u00e9 procedimientos deben establecerse para la gesti\u00f3n de documentos relacionados con la distribuci\u00f3n de productos farmac\u00e9uticos?**\n   - Se deben establecer procedimientos para la preparaci\u00f3n, revisi\u00f3n, aprobaci\u00f3n, uso y control de cambios en todos los documentos relacionados con el proceso de distribuci\u00f3n, tanto para documentos generados internamente como para aquellos de fuentes externas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Procedimientos Escritos**: Es fundamental contar con procedimientos documentados para investigar y manejar incumplimientos en los requisitos de almacenamiento, como desviaciones de temperatura.\n\n2. **Transporte y Almacenamiento de Sustancias Peligrosas**: Los productos farmac\u00e9uticos que contienen sustancias peligrosas (t\u00f3xicas, radiactivas, etc.) deben ser almacenados y transportados en \u00e1reas seguras y dedicadas, utilizando contenedores y veh\u00edculos dise\u00f1ados espec\u00edficamente para garantizar la seguridad.\n\n3. **Sustancias Narc\u00f3ticas**: Los productos que contienen narc\u00f3ticos y sustancias que generan dependencia deben ser transportados y almacenados en condiciones seguras, cumpliendo con acuerdos internacionales y legislaci\u00f3n nacional.\n\n4. **Manejo de Derrames**: Se deben establecer procedimientos para la limpieza de derrames de productos farmac\u00e9uticos para prevenir contaminaci\u00f3n y riesgos asociados.\n\n5. **Segregaci\u00f3n de Productos**: Es necesario proporcionar segregaci\u00f3n f\u00edsica o equivalente para productos rechazados, expirados, retirados o sospechosos de ser falsificados, asegurando su adecuada identificaci\u00f3n y documentaci\u00f3n.\n\n6. **Condiciones de Transporte**: Los veh\u00edculos y contenedores deben mantenerse limpios y secos durante el transporte de productos farmac\u00e9uticos.\n\n7. **Dise\u00f1o de Envases y Contenedores**: Los materiales de embalaje y los contenedores de env\u00edo deben ser adecuados para prevenir da\u00f1os a los productos durante el transporte, y se deben implementar programas de control de sellos.\n\n8. **Identificaci\u00f3n de Conductores**: Los conductores de veh\u00edculos deben identificarse y presentar la documentaci\u00f3n necesaria que demuestre su autorizaci\u00f3n para transportar la carga.\n\n9. **Registro de Incidentes**: Cualquier da\u00f1o a los contenedores o problemas ocurridos durante el transporte deben ser registrados, reportados e investigados.\n\n10. **Documentaci\u00f3n Durante el Transporte**: Los productos farmac\u00e9uticos en tr\u00e1nsito deben ir acompa\u00f1ados de la documentaci\u00f3n adecuada para asegurar el cumplimiento normativo y la trazabilidad.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de establecer las directrices.\n- **Productos Farmac\u00e9uticos**: Incluyen sustancias peligrosas, narc\u00f3ticos y otros productos con riesgos especiales.\n- **Legislaci\u00f3n Nacional e Internacional**: Normativas que deben cumplirse en el manejo y transporte de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: documentation, pharmaceutical distribution, record retention, quality control, regulatory compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4ee56aff-29a9-4368-9cfd-e9d9651c5969", "node_type": "4", "metadata": {"page_label": "271", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Documentation\n\n14.1 Written instructions and records which document all activities relating to the distribution of pharmaceutical products, including all applicable receipts and issues (invoices) should be available. Records should be kept for seven years, unless otherwise specified in national or regional regulations.\n\n14.2 Distributors should keep records of all pharmaceutical products received. Records should contain at least the following information:\n- date;\n- name of the pharmaceutical product;\n- quantity received, or supplied; and\n- name and address of the supplier.\n\n14.3 Procedures should be established and maintained for the preparation, review, approval, use of and control of changes to all documents relating to the distribution process. Procedures must be in place for both internally generated documents and those from external sources.\n\n14.4 Documents, and in particular instructions and procedures relating to any activity that could have an impact on the quality of pharmaceutical products, should be designed, completed, reviewed and distributed with care.\n\n14.5 The title, nature and purpose of each document should be clearly stated. The contents of documents should be clear and unambiguous. Documents should be laid out in an orderly fashion and be easy to check.\n\n14.6 All documents should be completed, approved, signed (as required) and dated by an appropriate authorized person(s) and should not be changed without the necessary authorization.\n\n14.7 The nature, content and retention of documentation relating to the distribution of pharmaceutical products and any investigations conducted and action taken, should comply with national legislative requirements. Where such requirements are not in place, the documents should be retained for at least one year after the expiry date of the product concerned.\n\n14.8 The distributor must establish and maintain procedures for the identification, collection, indexing, retrieval, storage, maintenance, disposal of and access to all applicable documentation.\n\n14.9 All records must be readily retrievable, and be stored and retained using facilities that are safeguarded against unauthorized modification, damage, deterioration and/or loss of documentation.\n\n14.10 Documents should be reviewed regularly and kept up to date. When a document has been revised, a system should exist to prevent inadvertent use of the superseded version.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "4a685821bd80030aa2a4c625f2539dcebc2a108e475bfe82890654484f5f0357", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Documentation\n\n14.1 Written instructions and records which document all activities relating to the distribution of pharmaceutical products, including all applicable receipts and issues (invoices) should be available. Records should be kept for seven years, unless otherwise specified in national or regional regulations.\n\n14.2 Distributors should keep records of all pharmaceutical products received. Records should contain at least the following information:\n- date;\n- name of the pharmaceutical product;\n- quantity received, or supplied; and\n- name and address of the supplier.\n\n14.3 Procedures should be established and maintained for the preparation, review, approval, use of and control of changes to all documents relating to the distribution process. Procedures must be in place for both internally generated documents and those from external sources.\n\n14.4 Documents, and in particular instructions and procedures relating to any activity that could have an impact on the quality of pharmaceutical products, should be designed, completed, reviewed and distributed with care.\n\n14.5 The title, nature and purpose of each document should be clearly stated. The contents of documents should be clear and unambiguous. Documents should be laid out in an orderly fashion and be easy to check.\n\n14.6 All documents should be completed, approved, signed (as required) and dated by an appropriate authorized person(s) and should not be changed without the necessary authorization.\n\n14.7 The nature, content and retention of documentation relating to the distribution of pharmaceutical products and any investigations conducted and action taken, should comply with national legislative requirements. Where such requirements are not in place, the documents should be retained for at least one year after the expiry date of the product concerned.\n\n14.8 The distributor must establish and maintain procedures for the identification, collection, indexing, retrieval, storage, maintenance, disposal of and access to all applicable documentation.\n\n14.9 All records must be readily retrievable, and be stored and retained using facilities that are safeguarded against unauthorized modification, damage, deterioration and/or loss of documentation.\n\n14.10 Documents should be reviewed regularly and kept up to date. When a document has been revised, a system should exist to prevent inadvertent use of the superseded version.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2414, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "67ae15c0-56ac-44d0-ae06-4176736732e3": {"__data__": {"id_": "67ae15c0-56ac-44d0-ae06-4176736732e3", "embedding": null, "metadata": {"page_label": "272", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 14.11\n\nMechanisms should exist to allow for transfer of information, including quality or regulatory information, between a manufacturer and a customer, as well as the transfer of information to the relevant regulatory authority as required.\n\n# 14.12\n\nRecords relating to storage of pharmaceutical products should be kept and be readily available upon request in accordance with the WHO guidelines on good storage practice for pharmaceuticals (1).\n\n# 14.13\n\nPermanent records, written or electronic, should exist for each stored product indicating recommended storage conditions, any precautions to be observed and retest dates. Pharmacopoeial requirements and current national regulations concerning labels and containers should be respected at all times.\n\n# 14.14\n\nProcedures should be in place for temperature mapping, security services to prevent theft or tampering with goods at the storage facilities, destruction of unsaleable or unusable stocks and on retention of the records.\n\n# 14.15\n\nWhere the records are generated and kept in electronic form, back ups should be maintained to prevent any accidental data loss.\n\n# 15. Repackaging and relabelling\n\n15.1 Repackaging and relabelling of pharmaceutical products should be limited, as these practices may represent a risk to the safety and security of the supply chain.\n\n15.2 Where they do occur, they should only be performed by entities appropriately authorized to do so and in compliance with the applicable national, regional and international guidelines, i.e. in accordance with GMP principles.\n\n15.3 In the event of repackaging by companies other than the original manufacturer, these operations should result in at least equivalent means of identification and authentication of the products.\n\n15.4 Procedures should be in place for the secure disposal of original packaging.\n\n# 16. Complaints\n\n16.1 There should be a written procedure in place for the handling of complaints. A distinction should be made between complaints about a product or its packaging and those relating to distribution. In the case of a complaint about the quality of a product or its packaging, the original manufacturer and/or marketing authorization holder should be informed as soon as possible.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Transferencia de Informaci\u00f3n**: Se establece la importancia de mecanismos que faciliten la transferencia de informaci\u00f3n entre fabricantes, clientes y autoridades regulatorias, asegurando que se mantenga la calidad y el cumplimiento normativo.\n\n2. **Mantenimiento de Registros**: Se enfatiza la necesidad de mantener registros permanentes sobre las condiciones de almacenamiento de productos farmac\u00e9uticos, as\u00ed como la importancia de cumplir con las regulaciones nacionales y farmacop\u00e9icas.\n\n3. **Reempaquetado y Reetiquetado**: Se discuten las limitaciones y regulaciones en torno al reempaquetado y reetiquetado de productos farmac\u00e9uticos, destacando la necesidad de autorizaci\u00f3n y cumplimiento de las buenas pr\u00e1cticas de manufactura (GMP).\n\n4. **Manejo de Quejas**: Se requiere un procedimiento escrito para el manejo de quejas, diferenciando entre quejas sobre productos y quejas sobre distribuci\u00f3n, y la necesidad de informar al fabricante en caso de problemas de calidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe ser transferida entre un fabricante y un cliente, y c\u00f3mo se asegura que esta informaci\u00f3n llegue a las autoridades regulatorias?**\n   - Esta pregunta se centra en los mecanismos espec\u00edficos de transferencia de informaci\u00f3n mencionados en el contexto, que no se detalla en otras fuentes.\n\n2. **\u00bfCu\u00e1les son las recomendaciones espec\u00edficas para el mantenimiento de registros de almacenamiento de productos farmac\u00e9uticos seg\u00fan las directrices de la OMS?**\n   - Esta pregunta busca detalles sobre las pr\u00e1cticas de registro y almacenamiento que son \u00fanicas a las directrices de la OMS y que pueden no estar disponibles en otras normativas.\n\n3. **\u00bfQu\u00e9 procedimientos deben implementarse para el manejo seguro de quejas relacionadas con la calidad de un producto farmac\u00e9utico?**\n   - Esta pregunta se enfoca en los procedimientos espec\u00edficos que deben seguirse para manejar quejas, lo cual es un aspecto cr\u00edtico que puede no estar claramente definido en otras regulaciones.", "prev_section_summary": "### Temas Clave\n\n1. **Documentaci\u00f3n de Distribuci\u00f3n**: Se requiere mantener instrucciones escritas y registros que documenten todas las actividades relacionadas con la distribuci\u00f3n de productos farmac\u00e9uticos, incluyendo recibos y facturas.\n\n2. **Conservaci\u00f3n de Registros**: Los registros deben conservarse durante siete a\u00f1os, salvo que las regulaciones nacionales o regionales indiquen un per\u00edodo diferente.\n\n3. **Informaci\u00f3n M\u00ednima en Registros**: Los registros de productos farmac\u00e9uticos recibidos deben incluir la fecha, nombre del producto, cantidad recibida o suministrada, y nombre y direcci\u00f3n del proveedor.\n\n4. **Procedimientos de Gesti\u00f3n Documental**: Se deben establecer procedimientos para la preparaci\u00f3n, revisi\u00f3n, aprobaci\u00f3n y control de cambios en documentos relacionados con la distribuci\u00f3n.\n\n5. **Calidad de Documentos**: Los documentos deben ser claros, ordenados y revisados regularmente para asegurar que est\u00e9n actualizados y sean precisos.\n\n6. **Acceso y Seguridad de Documentos**: Los registros deben ser f\u00e1cilmente recuperables y almacenados en instalaciones seguras para prevenir modificaciones no autorizadas o p\u00e9rdida de documentaci\u00f3n.\n\n7. **Cumplimiento Legal**: La documentaci\u00f3n debe cumplir con los requisitos legislativos nacionales, y en ausencia de estos, los documentos deben conservarse al menos un a\u00f1o despu\u00e9s de la fecha de caducidad del producto.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad que establece las directrices sobre la documentaci\u00f3n de distribuci\u00f3n de productos farmac\u00e9uticos.\n- **Distribuidores**: Entidades responsables de mantener registros y procedimientos relacionados con la distribuci\u00f3n de productos farmac\u00e9uticos.\n- **Productos Farmac\u00e9uticos**: Bienes cuya distribuci\u00f3n y documentaci\u00f3n est\u00e1n reguladas por las directrices de la OMS.\n- **Regulaciones Nacionales/Regionales**: Normativas que pueden influir en el per\u00edodo de conservaci\u00f3n de los registros y la gesti\u00f3n documental.", "excerpt_keywords": "Keywords: pharmaceutical storage, information transfer, repackaging regulations, complaint handling, record keeping"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1fa22bc9-de93-4b84-b276-e37071dfff69", "node_type": "4", "metadata": {"page_label": "272", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 14.11\n\nMechanisms should exist to allow for transfer of information, including quality or regulatory information, between a manufacturer and a customer, as well as the transfer of information to the relevant regulatory authority as required.\n\n# 14.12\n\nRecords relating to storage of pharmaceutical products should be kept and be readily available upon request in accordance with the WHO guidelines on good storage practice for pharmaceuticals (1).\n\n# 14.13\n\nPermanent records, written or electronic, should exist for each stored product indicating recommended storage conditions, any precautions to be observed and retest dates. Pharmacopoeial requirements and current national regulations concerning labels and containers should be respected at all times.\n\n# 14.14\n\nProcedures should be in place for temperature mapping, security services to prevent theft or tampering with goods at the storage facilities, destruction of unsaleable or unusable stocks and on retention of the records.\n\n# 14.15\n\nWhere the records are generated and kept in electronic form, back ups should be maintained to prevent any accidental data loss.\n\n# 15. Repackaging and relabelling\n\n15.1 Repackaging and relabelling of pharmaceutical products should be limited, as these practices may represent a risk to the safety and security of the supply chain.\n\n15.2 Where they do occur, they should only be performed by entities appropriately authorized to do so and in compliance with the applicable national, regional and international guidelines, i.e. in accordance with GMP principles.\n\n15.3 In the event of repackaging by companies other than the original manufacturer, these operations should result in at least equivalent means of identification and authentication of the products.\n\n15.4 Procedures should be in place for the secure disposal of original packaging.\n\n# 16. Complaints\n\n16.1 There should be a written procedure in place for the handling of complaints. A distinction should be made between complaints about a product or its packaging and those relating to distribution. In the case of a complaint about the quality of a product or its packaging, the original manufacturer and/or marketing authorization holder should be informed as soon as possible.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "a5fac5e8bc4a478c7b0b8c54b87d8c2d0461224ebeffc21c4159248463369c4f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 14.11\n\nMechanisms should exist to allow for transfer of information, including quality or regulatory information, between a manufacturer and a customer, as well as the transfer of information to the relevant regulatory authority as required.\n\n# 14.12\n\nRecords relating to storage of pharmaceutical products should be kept and be readily available upon request in accordance with the WHO guidelines on good storage practice for pharmaceuticals (1).\n\n# 14.13\n\nPermanent records, written or electronic, should exist for each stored product indicating recommended storage conditions, any precautions to be observed and retest dates. Pharmacopoeial requirements and current national regulations concerning labels and containers should be respected at all times.\n\n# 14.14\n\nProcedures should be in place for temperature mapping, security services to prevent theft or tampering with goods at the storage facilities, destruction of unsaleable or unusable stocks and on retention of the records.\n\n# 14.15\n\nWhere the records are generated and kept in electronic form, back ups should be maintained to prevent any accidental data loss.\n\n# 15. Repackaging and relabelling\n\n15.1 Repackaging and relabelling of pharmaceutical products should be limited, as these practices may represent a risk to the safety and security of the supply chain.\n\n15.2 Where they do occur, they should only be performed by entities appropriately authorized to do so and in compliance with the applicable national, regional and international guidelines, i.e. in accordance with GMP principles.\n\n15.3 In the event of repackaging by companies other than the original manufacturer, these operations should result in at least equivalent means of identification and authentication of the products.\n\n15.4 Procedures should be in place for the secure disposal of original packaging.\n\n# 16. Complaints\n\n16.1 There should be a written procedure in place for the handling of complaints. A distinction should be made between complaints about a product or its packaging and those relating to distribution. In the case of a complaint about the quality of a product or its packaging, the original manufacturer and/or marketing authorization holder should be informed as soon as possible.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2238, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f8a58b5b-edef-483a-8741-9e0914e65184": {"__data__": {"id_": "f8a58b5b-edef-483a-8741-9e0914e65184", "embedding": null, "metadata": {"page_label": "273", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 16.2 \nAll complaints and other information concerning potentially defective and potentially counterfeit pharmaceutical products should be reviewed carefully according to written procedures describing the action to be taken, including the need to consider a recall where appropriate.\n\n16.3 Any complaint concerning a material defect should be recorded and thoroughly investigated to identify the origin or reason for the complaint (e.g. repackaging procedure or original manufacturing process).\n\n16.4 If a defect relating to a pharmaceutical product is discovered or suspected, consideration should be given to whether other batches of the product should also be checked.\n\n16.5 Where necessary, appropriate follow-up action should be taken after investigation and evaluation of the complaint. There should be a system in place to ensure that the complaint, the response received from the original product manufacturer, or the results of the investigation of the complaint, are shared with all the relevant parties.\n\n16.6 Product quality problems or suspected cases of counterfeit products should be documented and the information shared with the appropriate national and/or regional regulatory authorities.\n\n# 17. Recalls\n\n17.1 There should be a system, which includes a written procedure, to effectively and promptly recall pharmaceutical products known or suspected to be defective or counterfeit, with a designated person(s) responsible for recalls. The system should comply with the guidance issued by the national or regional regulatory authority. This procedure should be checked regularly and updated as necessary.\n\n17.2 The original manufacturer and/or marketing authorization holder should be informed in the event of a recall. Where a recall is instituted by an entity other than the original manufacturer and/or marketing authorization holder, consultation with the original manufacturer and/or marketing authorization holder should, where possible, take place before the recall is instituted.\n\nInformation on a recall should be shared with the appropriate national or regional regulatory authority. If a recall of the original product is necessary because of a counterfeited product which is not easily distinguishable from the original product, the manufacturer of the original product and the relevant health authority should be informed.\n\n17.3 The effectiveness of the arrangements for recalls should be evaluated at regular intervals. All recalled pharmaceutical products should be stored in a secure, segregated area pending appropriate action.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Manejo de Quejas y Defectos**: El documento establece procedimientos claros para la revisi\u00f3n y manejo de quejas relacionadas con productos farmac\u00e9uticos potencialmente defectuosos o falsificados. Se enfatiza la importancia de investigar a fondo las quejas para identificar su origen y tomar las acciones adecuadas, incluyendo la posibilidad de un retiro del mercado.\n\n2. **Sistema de Retiro de Productos**: Se describe la necesidad de un sistema estructurado para llevar a cabo retiros de productos farmac\u00e9uticos que se sospeche sean defectuosos o falsificados. Este sistema debe incluir procedimientos escritos, designaci\u00f3n de responsables y cumplimiento con las regulaciones de las autoridades competentes.\n\n3. **Documentaci\u00f3n y Comunicaci\u00f3n**: El documento subraya la importancia de documentar problemas de calidad del producto y casos sospechosos de falsificaci\u00f3n, as\u00ed como la necesidad de compartir esta informaci\u00f3n con las autoridades regulatorias pertinentes para garantizar la seguridad p\u00fablica.\n\n### Preguntas espec\u00edficas que el contexto puede responder:\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse al recibir una queja sobre un producto farmac\u00e9utico defectuoso?**\n   - El contexto detalla que todas las quejas deben ser revisadas cuidadosamente seg\u00fan procedimientos escritos, que incluyen la necesidad de investigar a fondo la queja y considerar un retiro del producto si es apropiado.\n\n2. **\u00bfQu\u00e9 pasos deben tomarse si se descubre un defecto en un lote de productos farmac\u00e9uticos?**\n   - Se debe considerar la revisi\u00f3n de otros lotes del producto, y se deben tomar acciones de seguimiento apropiadas tras la investigaci\u00f3n de la queja, asegurando que la informaci\u00f3n se comparta con todas las partes relevantes.\n\n3. **\u00bfC\u00f3mo se debe manejar un retiro de un producto farmac\u00e9utico en caso de que se sospeche que es falsificado?**\n   - El documento establece que debe haber un sistema para realizar retiros de manera efectiva y r\u00e1pida, informando al fabricante original y a las autoridades regulatorias pertinentes, y evaluando la efectividad de los procedimientos de retiro de manera regular.", "prev_section_summary": "### Temas Clave\n\n1. **Transferencia de Informaci\u00f3n**: Se enfatiza la necesidad de establecer mecanismos para la transferencia de informaci\u00f3n entre fabricantes, clientes y autoridades regulatorias, asegurando la calidad y el cumplimiento normativo.\n\n2. **Mantenimiento de Registros**: Se requiere mantener registros permanentes sobre las condiciones de almacenamiento de productos farmac\u00e9uticos, cumpliendo con las directrices de la OMS y las regulaciones nacionales.\n\n3. **Reempaquetado y Reetiquetado**: Se discuten las limitaciones y regulaciones sobre el reempaquetado y reetiquetado de productos farmac\u00e9uticos, destacando la necesidad de autorizaci\u00f3n y cumplimiento de las buenas pr\u00e1cticas de manufactura (GMP).\n\n4. **Manejo de Quejas**: Se establece la necesidad de un procedimiento escrito para manejar quejas, diferenciando entre quejas sobre productos y distribuci\u00f3n, y la obligaci\u00f3n de informar al fabricante en caso de problemas de calidad.\n\n### Entidades\n\n- **Fabricantes**: Entidades responsables de la producci\u00f3n de productos farmac\u00e9uticos.\n- **Clientes**: Consumidores o entidades que adquieren productos farmac\u00e9uticos.\n- **Autoridades Regulatorias**: Organismos encargados de supervisar y regular la calidad y seguridad de los productos farmac\u00e9uticos.\n- **Productos Farmac\u00e9uticos**: Bienes que requieren condiciones espec\u00edficas de almacenamiento y manejo.\n- **Registros**: Documentaci\u00f3n escrita o electr\u00f3nica que detalla las condiciones de almacenamiento y otros aspectos relevantes de los productos.\n- **Entidades Autorizadas**: Organizaciones que tienen permiso para realizar actividades de reempaquetado y reetiquetado.\n- **Quejas**: Reclamos relacionados con la calidad de productos o su distribuci\u00f3n.", "excerpt_keywords": "Keywords: complaints, recalls, pharmaceutical products, counterfeit, regulatory authorities"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "16e57391-15ec-458a-857e-e54868b5be2e", "node_type": "4", "metadata": {"page_label": "273", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 16.2 \nAll complaints and other information concerning potentially defective and potentially counterfeit pharmaceutical products should be reviewed carefully according to written procedures describing the action to be taken, including the need to consider a recall where appropriate.\n\n16.3 Any complaint concerning a material defect should be recorded and thoroughly investigated to identify the origin or reason for the complaint (e.g. repackaging procedure or original manufacturing process).\n\n16.4 If a defect relating to a pharmaceutical product is discovered or suspected, consideration should be given to whether other batches of the product should also be checked.\n\n16.5 Where necessary, appropriate follow-up action should be taken after investigation and evaluation of the complaint. There should be a system in place to ensure that the complaint, the response received from the original product manufacturer, or the results of the investigation of the complaint, are shared with all the relevant parties.\n\n16.6 Product quality problems or suspected cases of counterfeit products should be documented and the information shared with the appropriate national and/or regional regulatory authorities.\n\n# 17. Recalls\n\n17.1 There should be a system, which includes a written procedure, to effectively and promptly recall pharmaceutical products known or suspected to be defective or counterfeit, with a designated person(s) responsible for recalls. The system should comply with the guidance issued by the national or regional regulatory authority. This procedure should be checked regularly and updated as necessary.\n\n17.2 The original manufacturer and/or marketing authorization holder should be informed in the event of a recall. Where a recall is instituted by an entity other than the original manufacturer and/or marketing authorization holder, consultation with the original manufacturer and/or marketing authorization holder should, where possible, take place before the recall is instituted.\n\nInformation on a recall should be shared with the appropriate national or regional regulatory authority. If a recall of the original product is necessary because of a counterfeited product which is not easily distinguishable from the original product, the manufacturer of the original product and the relevant health authority should be informed.\n\n17.3 The effectiveness of the arrangements for recalls should be evaluated at regular intervals. All recalled pharmaceutical products should be stored in a secure, segregated area pending appropriate action.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "033c95b6bc7095ca225594ec76af718652c537ce7e2176c2ca9be9b1a1d03e1f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 16.2 \nAll complaints and other information concerning potentially defective and potentially counterfeit pharmaceutical products should be reviewed carefully according to written procedures describing the action to be taken, including the need to consider a recall where appropriate.\n\n16.3 Any complaint concerning a material defect should be recorded and thoroughly investigated to identify the origin or reason for the complaint (e.g. repackaging procedure or original manufacturing process).\n\n16.4 If a defect relating to a pharmaceutical product is discovered or suspected, consideration should be given to whether other batches of the product should also be checked.\n\n16.5 Where necessary, appropriate follow-up action should be taken after investigation and evaluation of the complaint. There should be a system in place to ensure that the complaint, the response received from the original product manufacturer, or the results of the investigation of the complaint, are shared with all the relevant parties.\n\n16.6 Product quality problems or suspected cases of counterfeit products should be documented and the information shared with the appropriate national and/or regional regulatory authorities.\n\n# 17. Recalls\n\n17.1 There should be a system, which includes a written procedure, to effectively and promptly recall pharmaceutical products known or suspected to be defective or counterfeit, with a designated person(s) responsible for recalls. The system should comply with the guidance issued by the national or regional regulatory authority. This procedure should be checked regularly and updated as necessary.\n\n17.2 The original manufacturer and/or marketing authorization holder should be informed in the event of a recall. Where a recall is instituted by an entity other than the original manufacturer and/or marketing authorization holder, consultation with the original manufacturer and/or marketing authorization holder should, where possible, take place before the recall is instituted.\n\nInformation on a recall should be shared with the appropriate national or regional regulatory authority. If a recall of the original product is necessary because of a counterfeited product which is not easily distinguishable from the original product, the manufacturer of the original product and the relevant health authority should be informed.\n\n17.3 The effectiveness of the arrangements for recalls should be evaluated at regular intervals. All recalled pharmaceutical products should be stored in a secure, segregated area pending appropriate action.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2562, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "57609d4c-495a-4ec4-a83e-57b0c61a073d": {"__data__": {"id_": "57609d4c-495a-4ec4-a83e-57b0c61a073d", "embedding": null, "metadata": {"page_label": "274", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 17.4\n\nRecalled pharmaceutical products should be segregated during transit and clearly labelled as recalled products. Where segregation in transit is not possible, such goods must be securely packaged, clearly labelled, and be accompanied by appropriate documentation.\n\n# 17.5\n\nThe particular storage conditions applicable to a pharmaceutical product which is subject to recall should be maintained during storage and transit until such time as a decision has been made regarding the fate of the product in question.\n\n# 17.6\n\nAll customers and competent authorities of all countries to which a given pharmaceutical product may have been distributed should be informed promptly of any intention to recall the product because it is, or is suspected to be, defective or counterfeit.\n\n# 17.7\n\nAll records should be readily available to the designated person(s) responsible for recalls. These records should contain sufficient information on pharmaceutical products supplied to customers (including exported products).\n\n# 17.8\n\nThe progress of a recall process should be recorded and a final report issued, which includes a reconciliation between delivered and recovered quantities of products.\n\n# 17.9\n\nWhen necessary emergency recall procedures should be implemented.\n\n# 18. Returned products\n\n## 18.1\n\nA distributor should receive pharmaceutical product returns or exchanges pursuant to the terms and conditions of the agreement between the distributor and the recipient. Both distributors and recipients should be accountable for administering their returns process and ensuring that the aspects of this operation are secure and do not permit the entry of counterfeit products.\n\n## 18.2\n\nThe necessary assessment and decision regarding the disposition of such products must be made by a suitably authorized person. The nature of the product returned to the distributor, any special storage conditions required, its condition and history and the time elapsed since it was issued, should all be taken into account in this assessment. Where any doubt arises over the quality of a pharmaceutical product, it should not be considered suitable for reissue or reuse.\n\n## 18.3\n\nProvision should be made for the appropriate and safe transport of returned products in accordance with the relevant storage and other requirements.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfQu\u00e9 medidas deben tomarse durante el transporte de productos farmac\u00e9uticos que han sido retirados del mercado?**\n   - Los productos farmac\u00e9uticos retirados deben ser segregados durante el tr\u00e1nsito y etiquetados claramente como productos retirados. Si la segregaci\u00f3n no es posible, deben ser empaquetados de manera segura, etiquetados claramente y acompa\u00f1ados de la documentaci\u00f3n apropiada.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe contener la documentaci\u00f3n de los productos farmac\u00e9uticos retirados?**\n   - La documentaci\u00f3n debe incluir informaci\u00f3n suficiente sobre los productos farmac\u00e9uticos suministrados a los clientes, incluyendo productos exportados. Adem\u00e1s, todos los registros deben estar f\u00e1cilmente disponibles para las personas designadas responsables de los retiros.\n\n3. **\u00bfQu\u00e9 criterios deben considerarse al evaluar productos farmac\u00e9uticos devueltos?**\n   - La evaluaci\u00f3n de los productos devueltos debe ser realizada por una persona debidamente autorizada y debe tener en cuenta la naturaleza del producto, cualquier condici\u00f3n de almacenamiento especial requerida, su estado y historial, as\u00ed como el tiempo transcurrido desde que fue emitido. Si hay dudas sobre la calidad del producto, no debe considerarse apto para reemisi\u00f3n o reutilizaci\u00f3n.\n\n### Resumen de Nivel Superior\n\nEl contexto aborda las directrices para la gesti\u00f3n de productos farmac\u00e9uticos retirados del mercado y devueltos. Se enfatiza la importancia de la segregaci\u00f3n y etiquetado de productos retirados, la necesidad de mantener condiciones de almacenamiento adecuadas durante el transporte, y la obligaci\u00f3n de informar a las autoridades y clientes sobre los retiros. Tambi\u00e9n se menciona la responsabilidad de los distribuidores y receptores en el proceso de devoluciones, as\u00ed como la evaluaci\u00f3n cuidadosa de los productos devueltos para garantizar que no se introduzcan productos falsificados en el mercado.", "prev_section_summary": "### Temas Clave:\n\n1. **Manejo de Quejas**: Se establece la importancia de revisar y manejar quejas sobre productos farmac\u00e9uticos potencialmente defectuosos o falsificados, siguiendo procedimientos escritos que incluyan la posibilidad de un retiro del mercado.\n\n2. **Investigaci\u00f3n de Defectos**: Las quejas sobre defectos materiales deben ser registradas y analizadas a fondo para identificar su origen, considerando la revisi\u00f3n de otros lotes si se descubre o sospecha un defecto.\n\n3. **Acciones de Seguimiento**: Es necesario tomar acciones de seguimiento adecuadas tras la investigaci\u00f3n de quejas y asegurar que la informaci\u00f3n relevante se comparta con todas las partes involucradas.\n\n4. **Documentaci\u00f3n y Comunicaci\u00f3n**: Los problemas de calidad del producto y los casos sospechosos de falsificaci\u00f3n deben ser documentados y comunicados a las autoridades regulatorias pertinentes.\n\n5. **Sistema de Retiro de Productos**: Se requiere un sistema estructurado para realizar retiros de productos farmac\u00e9uticos defectuosos o falsificados, con procedimientos escritos y responsables designados.\n\n6. **Evaluaci\u00f3n de Efectividad**: La efectividad de los procedimientos de retiro debe ser evaluada regularmente, y los productos retirados deben ser almacenados de manera segura.\n\n### Entidades:\n\n- **Productos Farmac\u00e9uticos**: Incluyen aquellos que son potencialmente defectuosos o falsificados.\n- **Autoridades Regulatorias**: Nacionales y regionales que supervisan la seguridad y calidad de los productos farmac\u00e9uticos.\n- **Fabricantes Originales**: Entidades responsables de la producci\u00f3n de los productos farmac\u00e9uticos.\n- **Titulares de Autorizaci\u00f3n de Comercializaci\u00f3n**: Entidades que tienen la autorizaci\u00f3n para comercializar productos farmac\u00e9uticos.\n- **Sistema de Quejas y Retiro**: Procedimientos y protocolos establecidos para manejar quejas y realizar retiros de productos.", "excerpt_keywords": "Keywords: recall procedures, pharmaceutical products, product returns, counterfeit prevention, storage conditions"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c5983c6f-bfeb-4c57-b0d5-60c94b41cc7b", "node_type": "4", "metadata": {"page_label": "274", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 17.4\n\nRecalled pharmaceutical products should be segregated during transit and clearly labelled as recalled products. Where segregation in transit is not possible, such goods must be securely packaged, clearly labelled, and be accompanied by appropriate documentation.\n\n# 17.5\n\nThe particular storage conditions applicable to a pharmaceutical product which is subject to recall should be maintained during storage and transit until such time as a decision has been made regarding the fate of the product in question.\n\n# 17.6\n\nAll customers and competent authorities of all countries to which a given pharmaceutical product may have been distributed should be informed promptly of any intention to recall the product because it is, or is suspected to be, defective or counterfeit.\n\n# 17.7\n\nAll records should be readily available to the designated person(s) responsible for recalls. These records should contain sufficient information on pharmaceutical products supplied to customers (including exported products).\n\n# 17.8\n\nThe progress of a recall process should be recorded and a final report issued, which includes a reconciliation between delivered and recovered quantities of products.\n\n# 17.9\n\nWhen necessary emergency recall procedures should be implemented.\n\n# 18. Returned products\n\n## 18.1\n\nA distributor should receive pharmaceutical product returns or exchanges pursuant to the terms and conditions of the agreement between the distributor and the recipient. Both distributors and recipients should be accountable for administering their returns process and ensuring that the aspects of this operation are secure and do not permit the entry of counterfeit products.\n\n## 18.2\n\nThe necessary assessment and decision regarding the disposition of such products must be made by a suitably authorized person. The nature of the product returned to the distributor, any special storage conditions required, its condition and history and the time elapsed since it was issued, should all be taken into account in this assessment. Where any doubt arises over the quality of a pharmaceutical product, it should not be considered suitable for reissue or reuse.\n\n## 18.3\n\nProvision should be made for the appropriate and safe transport of returned products in accordance with the relevant storage and other requirements.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "feb20bce7d726d9ea537a87b3f2d21328044159e3538533a6449e4e4b17bcd3f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 17.4\n\nRecalled pharmaceutical products should be segregated during transit and clearly labelled as recalled products. Where segregation in transit is not possible, such goods must be securely packaged, clearly labelled, and be accompanied by appropriate documentation.\n\n# 17.5\n\nThe particular storage conditions applicable to a pharmaceutical product which is subject to recall should be maintained during storage and transit until such time as a decision has been made regarding the fate of the product in question.\n\n# 17.6\n\nAll customers and competent authorities of all countries to which a given pharmaceutical product may have been distributed should be informed promptly of any intention to recall the product because it is, or is suspected to be, defective or counterfeit.\n\n# 17.7\n\nAll records should be readily available to the designated person(s) responsible for recalls. These records should contain sufficient information on pharmaceutical products supplied to customers (including exported products).\n\n# 17.8\n\nThe progress of a recall process should be recorded and a final report issued, which includes a reconciliation between delivered and recovered quantities of products.\n\n# 17.9\n\nWhen necessary emergency recall procedures should be implemented.\n\n# 18. Returned products\n\n## 18.1\n\nA distributor should receive pharmaceutical product returns or exchanges pursuant to the terms and conditions of the agreement between the distributor and the recipient. Both distributors and recipients should be accountable for administering their returns process and ensuring that the aspects of this operation are secure and do not permit the entry of counterfeit products.\n\n## 18.2\n\nThe necessary assessment and decision regarding the disposition of such products must be made by a suitably authorized person. The nature of the product returned to the distributor, any special storage conditions required, its condition and history and the time elapsed since it was issued, should all be taken into account in this assessment. Where any doubt arises over the quality of a pharmaceutical product, it should not be considered suitable for reissue or reuse.\n\n## 18.3\n\nProvision should be made for the appropriate and safe transport of returned products in accordance with the relevant storage and other requirements.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2319, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "abc7144e-c3bd-46cb-a21f-9807ce99f1f6": {"__data__": {"id_": "abc7144e-c3bd-46cb-a21f-9807ce99f1f6", "embedding": null, "metadata": {"page_label": "275", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 18.4\n\nRejected pharmaceutical products and those returned to a distributor should be appropriately identified and handled in accordance with a procedure which involves at least:\n\n- the physical segregation of such pharmaceutical products in quarantine in a dedicated area; or\n- other equivalent (e.g. electronic) segregation.\n\nThis is to avoid confusion and prevent distribution until a decision has been taken with regard to their disposition. The particular storage conditions applicable to a pharmaceutical product which is rejected or returned should be maintained during storage and transit until such time as a decision has been made regarding the product in question.\n\n18.5 Provision should be made for the appropriate and safe transport of rejected pharmaceutical products prior to their disposal.\n\n18.6 Destruction of pharmaceutical products should be done in accordance with international, national and local requirements regarding disposal of such products, and with due consideration to protection of the environment.\n\n18.7 Records of all returned, rejected and/or destroyed pharmaceutical products should be kept for a predetermined period.\n\n# 19. Counterfeit pharmaceutical products\n\n19.1 Counterfeit pharmaceutical products found in the distribution chain should be kept apart from other pharmaceutical products to avoid any confusion. They should be clearly labelled as not for sale and national regulatory authorities and the holder of the marketing authorization for the original product should be informed immediately.\n\n19.2 The sale and distribution of a suspected counterfeit pharmaceutical product should be suspended and the national regulatory authority notified without delay.\n\n19.3 Upon confirmation of the product being counterfeit a formal decision should be taken on its disposal, ensuring that it does not re-enter the market, and the decision recorded.\n\n# 20. Importation\n\n20.1 Consideration should be given to the WHO guidelines on import procedures for pharmaceutical products (6). The following aspects should be given particular attention.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS aborda la gesti\u00f3n de productos farmac\u00e9uticos rechazados, devueltos y falsificados. Se establecen procedimientos para la identificaci\u00f3n, segregaci\u00f3n, transporte y destrucci\u00f3n de estos productos, asegurando que se manejen de acuerdo con las normativas internacionales, nacionales y locales. Tambi\u00e9n se enfatiza la importancia de mantener registros de estos productos durante un per\u00edodo determinado. En el caso de productos farmac\u00e9uticos falsificados, se deben tomar medidas inmediatas para evitar su distribuci\u00f3n y se debe notificar a las autoridades regulatorias pertinentes.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los requisitos espec\u00edficos para el almacenamiento de productos farmac\u00e9uticos rechazados o devueltos hasta que se tome una decisi\u00f3n sobre su disposici\u00f3n?**\n   - Respuesta: Los productos farmac\u00e9uticos rechazados o devueltos deben ser segregados f\u00edsicamente en un \u00e1rea dedicada en cuarentena o mediante un sistema de segregaci\u00f3n equivalente (como un sistema electr\u00f3nico). Adem\u00e1s, las condiciones de almacenamiento aplicables a estos productos deben mantenerse durante el almacenamiento y el transporte hasta que se tome una decisi\u00f3n sobre su disposici\u00f3n.\n\n2. **\u00bfQu\u00e9 pasos deben seguirse si se identifica un producto farmac\u00e9utico como falsificado en la cadena de distribuci\u00f3n?**\n   - Respuesta: Los productos farmac\u00e9uticos falsificados deben ser separados de otros productos para evitar confusiones y etiquetados claramente como no a la venta. Las autoridades regulatorias nacionales y el titular de la autorizaci\u00f3n de comercializaci\u00f3n del producto original deben ser informados de inmediato. La venta y distribuci\u00f3n del producto sospechoso deben suspenderse y la autoridad regulatoria nacional debe ser notificada sin demora.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta para el transporte seguro de productos farmac\u00e9uticos rechazados antes de su disposici\u00f3n?**\n   - Respuesta: Debe hacerse una provisi\u00f3n adecuada para el transporte seguro de los productos farmac\u00e9uticos rechazados, asegurando que se cumplan las condiciones de almacenamiento necesarias y que se sigan las normativas pertinentes para su manejo y disposici\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Retiro de Productos Farmac\u00e9uticos:**\n   - Importancia de la segregaci\u00f3n y etiquetado de productos retirados durante el transporte.\n   - Mantenimiento de condiciones de almacenamiento adecuadas hasta que se decida el destino del producto.\n\n2. **Comunicaci\u00f3n:**\n   - Notificaci\u00f3n a clientes y autoridades competentes sobre retiros de productos defectuosos o falsificados.\n\n3. **Documentaci\u00f3n y Registros:**\n   - Disponibilidad de registros para las personas responsables de los retiros, incluyendo informaci\u00f3n sobre productos suministrados.\n\n4. **Proceso de Retiro:**\n   - Registro del progreso del proceso de retiro y emisi\u00f3n de un informe final que incluya la reconciliaci\u00f3n de cantidades entregadas y recuperadas.\n\n5. **Devoluciones de Productos:**\n   - Proceso de recepci\u00f3n de devoluciones seg\u00fan acuerdos entre distribuidores y receptores.\n   - Evaluaci\u00f3n de productos devueltos por personal autorizado, considerando su estado, condiciones de almacenamiento y tiempo desde la emisi\u00f3n.\n\n6. **Transporte Seguro:**\n   - Necesidad de transporte seguro y apropiado de productos devueltos, cumpliendo con requisitos de almacenamiento.\n\n**Entidades:**\n\n- **Productos Farmac\u00e9uticos:** Incluyen aquellos que han sido retirados del mercado o devueltos.\n- **Distribuidores y Receptores:** Actores clave en el proceso de devoluci\u00f3n y gesti\u00f3n de productos.\n- **Autoridades Competentes:** Entidades que deben ser informadas sobre retiros de productos.\n- **Personal Autorizado:** Responsables de la evaluaci\u00f3n y decisi\u00f3n sobre la disposici\u00f3n de productos devueltos.\n\nEste resumen destaca la importancia de seguir procedimientos adecuados para la gesti\u00f3n de productos farmac\u00e9uticos retirados y devueltos, asegurando la seguridad y calidad en el suministro de medicamentos.", "excerpt_keywords": "Keywords: pharmaceutical products, rejection, counterfeit, disposal, regulatory authorities"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5fe8575f-324f-4b56-939e-403e837d4033", "node_type": "4", "metadata": {"page_label": "275", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 18.4\n\nRejected pharmaceutical products and those returned to a distributor should be appropriately identified and handled in accordance with a procedure which involves at least:\n\n- the physical segregation of such pharmaceutical products in quarantine in a dedicated area; or\n- other equivalent (e.g. electronic) segregation.\n\nThis is to avoid confusion and prevent distribution until a decision has been taken with regard to their disposition. The particular storage conditions applicable to a pharmaceutical product which is rejected or returned should be maintained during storage and transit until such time as a decision has been made regarding the product in question.\n\n18.5 Provision should be made for the appropriate and safe transport of rejected pharmaceutical products prior to their disposal.\n\n18.6 Destruction of pharmaceutical products should be done in accordance with international, national and local requirements regarding disposal of such products, and with due consideration to protection of the environment.\n\n18.7 Records of all returned, rejected and/or destroyed pharmaceutical products should be kept for a predetermined period.\n\n# 19. Counterfeit pharmaceutical products\n\n19.1 Counterfeit pharmaceutical products found in the distribution chain should be kept apart from other pharmaceutical products to avoid any confusion. They should be clearly labelled as not for sale and national regulatory authorities and the holder of the marketing authorization for the original product should be informed immediately.\n\n19.2 The sale and distribution of a suspected counterfeit pharmaceutical product should be suspended and the national regulatory authority notified without delay.\n\n19.3 Upon confirmation of the product being counterfeit a formal decision should be taken on its disposal, ensuring that it does not re-enter the market, and the decision recorded.\n\n# 20. Importation\n\n20.1 Consideration should be given to the WHO guidelines on import procedures for pharmaceutical products (6). The following aspects should be given particular attention.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "dbb97989201e85b14d2c12a0f15930e50c5d30b4e131a35af10bc70a5fa7ed23", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 18.4\n\nRejected pharmaceutical products and those returned to a distributor should be appropriately identified and handled in accordance with a procedure which involves at least:\n\n- the physical segregation of such pharmaceutical products in quarantine in a dedicated area; or\n- other equivalent (e.g. electronic) segregation.\n\nThis is to avoid confusion and prevent distribution until a decision has been taken with regard to their disposition. The particular storage conditions applicable to a pharmaceutical product which is rejected or returned should be maintained during storage and transit until such time as a decision has been made regarding the product in question.\n\n18.5 Provision should be made for the appropriate and safe transport of rejected pharmaceutical products prior to their disposal.\n\n18.6 Destruction of pharmaceutical products should be done in accordance with international, national and local requirements regarding disposal of such products, and with due consideration to protection of the environment.\n\n18.7 Records of all returned, rejected and/or destroyed pharmaceutical products should be kept for a predetermined period.\n\n# 19. Counterfeit pharmaceutical products\n\n19.1 Counterfeit pharmaceutical products found in the distribution chain should be kept apart from other pharmaceutical products to avoid any confusion. They should be clearly labelled as not for sale and national regulatory authorities and the holder of the marketing authorization for the original product should be informed immediately.\n\n19.2 The sale and distribution of a suspected counterfeit pharmaceutical product should be suspended and the national regulatory authority notified without delay.\n\n19.3 Upon confirmation of the product being counterfeit a formal decision should be taken on its disposal, ensuring that it does not re-enter the market, and the decision recorded.\n\n# 20. Importation\n\n20.1 Consideration should be given to the WHO guidelines on import procedures for pharmaceutical products (6). The following aspects should be given particular attention.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2076, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "32bc7209-77ab-4bce-8d63-d13bb100a19d": {"__data__": {"id_": "32bc7209-77ab-4bce-8d63-d13bb100a19d", "embedding": null, "metadata": {"page_label": "276", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 20.2 \nThe number of ports of entry in a country for the handling of imports of pharmaceutical products should be limited by appropriate legislation. Such ports could be designated by the state.\n\n## 20.3 \nThe chosen port(s) of entry should be those most appropriately located and best equipped to handle imports of pharmaceutical products.\n\n## 20.4 \nAt the port of entry, consignments of pharmaceutical products should be stored under suitable conditions for as short a time as possible.\n\n## 20.5 \nAll reasonable steps should be taken by importers to ensure that products are not mishandled or exposed to adverse storage conditions at wharves or airports.\n\n## 20.6 \nWhere necessary, persons with pharmaceutical training should be involved with the customs procedures or should be readily contactable.\n\n## 20.7 \nThe WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce should be used to provide data regarding quality assessment of imported pharmaceutical products.\n\n## 20.8 \nCustoms, enforcement agencies and regulatory agencies responsible for supervision of pharmaceutical products should establish means for cooperation and information exchange in order to prevent importation of counterfeit pharmaceutical products.\n\n# 21. Contract activities\n\n## 21.1 \nAny activity relating to the distribution of a pharmaceutical product which is delegated to another person or entity should be performed by parties appropriately authorized for that function and in accordance with the terms of a written contract.\n\n## 21.2 \nThe contract should define the responsibilities of each party including observance of the principles of GDP and relevant warranty clauses. It should also include responsibilities of the contractor for measures to avoid the entry of counterfeit medicines into the distribution chain, such as by suitable training programmes.\n\n## 21.3 \nAll contract accepters should comply with the requirements in these guidelines.\n\n## 21.4 \nSubcontracting may be permissible, under certain conditions and subject to the written approval of the contract giver; however, the subcontractors should be authorized for the function.\n\n## 21.5 \nContract accepters should be audited periodically.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Regulaci\u00f3n de Puertos de Entrada**: El documento establece directrices sobre la cantidad y ubicaci\u00f3n de los puertos de entrada para la importaci\u00f3n de productos farmac\u00e9uticos, enfatizando la necesidad de que estos puertos est\u00e9n adecuadamente equipados y designados por el estado. Tambi\u00e9n se menciona la importancia de almacenar los productos en condiciones adecuadas y minimizar el tiempo de almacenamiento.\n\n2. **Manejo de Productos Farmac\u00e9uticos**: Se subraya la responsabilidad de los importadores para evitar el manejo inadecuado y la exposici\u00f3n a condiciones adversas de almacenamiento. Adem\u00e1s, se destaca la necesidad de involucrar a personal con formaci\u00f3n farmac\u00e9utica en los procedimientos aduaneros.\n\n3. **Actividades Contractuales**: El documento detalla las obligaciones contractuales en la distribuci\u00f3n de productos farmac\u00e9uticos, incluyendo la necesidad de contratos escritos que definan responsabilidades y medidas para prevenir la entrada de medicamentos falsificados en la cadena de distribuci\u00f3n. Tambi\u00e9n se menciona la posibilidad de subcontrataci\u00f3n bajo ciertas condiciones y la necesidad de auditor\u00edas peri\u00f3dicas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben cumplirse para la designaci\u00f3n de puertos de entrada para la importaci\u00f3n de productos farmac\u00e9uticos?**\n   - El documento especifica que los puertos de entrada deben ser limitados por legislaci\u00f3n apropiada y deben estar ubicados y equipados de manera adecuada para manejar productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 medidas deben tomar los importadores para garantizar el manejo adecuado de los productos farmac\u00e9uticos en los puertos de entrada?**\n   - Los importadores deben tomar todas las medidas razonables para asegurar que los productos no sean mal manejados ni expuestos a condiciones de almacenamiento adversas en los muelles o aeropuertos.\n\n3. **\u00bfCu\u00e1les son las responsabilidades que deben incluirse en un contrato relacionado con la distribuci\u00f3n de productos farmac\u00e9uticos?**\n   - El contrato debe definir las responsabilidades de cada parte, incluyendo la observancia de los principios de Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) y cl\u00e1usulas de garant\u00eda relevantes, as\u00ed como las responsabilidades del contratista para evitar la entrada de medicamentos falsificados en la cadena de distribuci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manejo de Productos Farmac\u00e9uticos Rechazados y Devueltos**:\n   - **Identificaci\u00f3n y Segregaci\u00f3n**: Los productos rechazados o devueltos deben ser segregados f\u00edsicamente en un \u00e1rea de cuarentena o mediante un sistema de segregaci\u00f3n equivalente para evitar confusiones y prevenir su distribuci\u00f3n.\n   - **Condiciones de Almacenamiento**: Se deben mantener las condiciones de almacenamiento adecuadas durante el almacenamiento y el transporte hasta que se tome una decisi\u00f3n sobre su disposici\u00f3n.\n   - **Transporte Seguro**: Se debe garantizar un transporte adecuado y seguro de los productos rechazados antes de su disposici\u00f3n.\n\n2. **Destrucci\u00f3n de Productos Farmac\u00e9uticos**:\n   - La destrucci\u00f3n debe realizarse de acuerdo con las normativas internacionales, nacionales y locales, considerando la protecci\u00f3n del medio ambiente.\n\n3. **Registro de Productos**:\n   - Es necesario mantener registros de todos los productos devueltos, rechazados y/o destruidos durante un per\u00edodo determinado.\n\n4. **Productos Farmac\u00e9uticos Falsificados**:\n   - **Separaci\u00f3n y Etiquetado**: Los productos falsificados deben ser separados de otros productos y etiquetados claramente como no a la venta. Se debe informar de inmediato a las autoridades regulatorias nacionales y al titular de la autorizaci\u00f3n de comercializaci\u00f3n del producto original.\n   - **Suspensi\u00f3n de Venta y Distribuci\u00f3n**: La venta y distribuci\u00f3n de productos sospechosos de ser falsificados deben suspenderse y notificar a la autoridad regulatoria nacional sin demora.\n   - **Decisi\u00f3n sobre Disposici\u00f3n**: Una vez confirmado que un producto es falsificado, se debe tomar una decisi\u00f3n formal sobre su disposici\u00f3n para asegurar que no reingrese al mercado.\n\n5. **Importaci\u00f3n de Productos Farmac\u00e9uticos**:\n   - Se deben considerar las directrices de la OMS sobre los procedimientos de importaci\u00f3n de productos farmac\u00e9uticos.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Proporciona directrices y normativas sobre el manejo de productos farmac\u00e9uticos.\n- **Autoridades Regulatorias Nacionales**: Encargadas de supervisar y regular la venta y distribuci\u00f3n de productos farmac\u00e9uticos, as\u00ed como de ser notificadas en casos de productos falsificados.", "excerpt_keywords": "Keywords: pharmaceutical products, ports of entry, contract activities, counterfeit medicines, quality assessment"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f591e0df-79ae-482f-b861-d95e11f18bba", "node_type": "4", "metadata": {"page_label": "276", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 20.2 \nThe number of ports of entry in a country for the handling of imports of pharmaceutical products should be limited by appropriate legislation. Such ports could be designated by the state.\n\n## 20.3 \nThe chosen port(s) of entry should be those most appropriately located and best equipped to handle imports of pharmaceutical products.\n\n## 20.4 \nAt the port of entry, consignments of pharmaceutical products should be stored under suitable conditions for as short a time as possible.\n\n## 20.5 \nAll reasonable steps should be taken by importers to ensure that products are not mishandled or exposed to adverse storage conditions at wharves or airports.\n\n## 20.6 \nWhere necessary, persons with pharmaceutical training should be involved with the customs procedures or should be readily contactable.\n\n## 20.7 \nThe WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce should be used to provide data regarding quality assessment of imported pharmaceutical products.\n\n## 20.8 \nCustoms, enforcement agencies and regulatory agencies responsible for supervision of pharmaceutical products should establish means for cooperation and information exchange in order to prevent importation of counterfeit pharmaceutical products.\n\n# 21. Contract activities\n\n## 21.1 \nAny activity relating to the distribution of a pharmaceutical product which is delegated to another person or entity should be performed by parties appropriately authorized for that function and in accordance with the terms of a written contract.\n\n## 21.2 \nThe contract should define the responsibilities of each party including observance of the principles of GDP and relevant warranty clauses. It should also include responsibilities of the contractor for measures to avoid the entry of counterfeit medicines into the distribution chain, such as by suitable training programmes.\n\n## 21.3 \nAll contract accepters should comply with the requirements in these guidelines.\n\n## 21.4 \nSubcontracting may be permissible, under certain conditions and subject to the written approval of the contract giver; however, the subcontractors should be authorized for the function.\n\n## 21.5 \nContract accepters should be audited periodically.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "ff505a449e770633ac3b40c9ab66fc282fbe9583f89d2c0f5c3a0914486d8ccf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 20.2 \nThe number of ports of entry in a country for the handling of imports of pharmaceutical products should be limited by appropriate legislation. Such ports could be designated by the state.\n\n## 20.3 \nThe chosen port(s) of entry should be those most appropriately located and best equipped to handle imports of pharmaceutical products.\n\n## 20.4 \nAt the port of entry, consignments of pharmaceutical products should be stored under suitable conditions for as short a time as possible.\n\n## 20.5 \nAll reasonable steps should be taken by importers to ensure that products are not mishandled or exposed to adverse storage conditions at wharves or airports.\n\n## 20.6 \nWhere necessary, persons with pharmaceutical training should be involved with the customs procedures or should be readily contactable.\n\n## 20.7 \nThe WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce should be used to provide data regarding quality assessment of imported pharmaceutical products.\n\n## 20.8 \nCustoms, enforcement agencies and regulatory agencies responsible for supervision of pharmaceutical products should establish means for cooperation and information exchange in order to prevent importation of counterfeit pharmaceutical products.\n\n# 21. Contract activities\n\n## 21.1 \nAny activity relating to the distribution of a pharmaceutical product which is delegated to another person or entity should be performed by parties appropriately authorized for that function and in accordance with the terms of a written contract.\n\n## 21.2 \nThe contract should define the responsibilities of each party including observance of the principles of GDP and relevant warranty clauses. It should also include responsibilities of the contractor for measures to avoid the entry of counterfeit medicines into the distribution chain, such as by suitable training programmes.\n\n## 21.3 \nAll contract accepters should comply with the requirements in these guidelines.\n\n## 21.4 \nSubcontracting may be permissible, under certain conditions and subject to the written approval of the contract giver; however, the subcontractors should be authorized for the function.\n\n## 21.5 \nContract accepters should be audited periodically.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2233, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f4a7782e-145b-4d3c-b2ca-a81af494bb73": {"__data__": {"id_": "f4a7782e-145b-4d3c-b2ca-a81af494bb73", "embedding": null, "metadata": {"page_label": "277", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 22. Self-inspection\n\n22.1 The quality system should include self-inspections. These should be conducted to monitor implementation and compliance with the principles of GDP and, if necessary, to trigger corrective and preventive measures.\n\n22.2 Self-inspections should be conducted in an independent and detailed way by a designated, competent person.\n\n22.3 The results of all self-inspections should be recorded. Reports should contain all observations made during the inspection and, where applicable, proposals for corrective measures. There should be an effective follow-up programme. Management should evaluate the inspection report and the records of any corrective actions taken.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl documento de la OMS, parte de la Serie de Informes T\u00e9cnicos 957, aborda la importancia de las autoinspecciones dentro de un sistema de calidad. Se enfatiza que estas autoinspecciones deben realizarse de manera independiente y detallada por una persona competente designada. Adem\u00e1s, se requiere que los resultados de las autoinspecciones se registren adecuadamente, incluyendo observaciones y propuestas de medidas correctivas, y que haya un programa de seguimiento efectivo para evaluar las acciones correctivas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben cumplir las personas designadas para llevar a cabo las autoinspecciones seg\u00fan el documento?**\n   - Esta pregunta busca informaci\u00f3n sobre las calificaciones o competencias espec\u00edficas que se requieren para realizar autoinspecciones, que no se detalla expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 tipo de medidas correctivas se pueden proponer tras una autoinspecci\u00f3n y c\u00f3mo se determina su efectividad?**\n   - Esta pregunta se centra en ejemplos concretos de medidas correctivas y en el proceso de evaluaci\u00f3n de su efectividad, que no se aborda en el contexto proporcionado.\n\n3. **\u00bfCu\u00e1l es el proceso recomendado para el seguimiento de las acciones correctivas despu\u00e9s de una autoinspecci\u00f3n?**\n   - Esta pregunta busca detalles sobre el procedimiento espec\u00edfico que debe seguirse para asegurar que las acciones correctivas se implementen y se eval\u00faen adecuadamente, informaci\u00f3n que no se encuentra en el texto.", "prev_section_summary": "### Temas Clave\n\n1. **Regulaci\u00f3n de Puertos de Entrada**:\n   - Limitaci\u00f3n de puertos de entrada para la importaci\u00f3n de productos farmac\u00e9uticos mediante legislaci\u00f3n.\n   - Selecci\u00f3n de puertos adecuadamente ubicados y equipados.\n   - Almacenamiento de productos en condiciones adecuadas y por el menor tiempo posible.\n\n2. **Manejo de Productos Farmac\u00e9uticos**:\n   - Responsabilidad de los importadores para evitar el mal manejo y condiciones adversas de almacenamiento.\n   - Involucramiento de personal con formaci\u00f3n farmac\u00e9utica en procedimientos aduaneros.\n\n3. **Prevenci\u00f3n de Medicamentos Falsificados**:\n   - Uso del Esquema de Certificaci\u00f3n de la OMS para evaluar la calidad de productos farmac\u00e9uticos importados.\n   - Cooperaci\u00f3n entre agencias aduaneras, de enforcement y reguladoras para prevenir la importaci\u00f3n de productos falsificados.\n\n4. **Actividades Contractuales**:\n   - Necesidad de contratos escritos que definan responsabilidades en la distribuci\u00f3n de productos farmac\u00e9uticos.\n   - Inclusi\u00f3n de cl\u00e1usulas sobre Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) y medidas contra medicamentos falsificados.\n   - Permisibilidad de subcontrataci\u00f3n bajo condiciones espec\u00edficas y necesidad de auditor\u00edas peri\u00f3dicas.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Referenciada en el contexto de la certificaci\u00f3n y calidad de productos farmac\u00e9uticos.\n- **Agencias Aduaneras y Reguladoras**: Encargadas de la supervisi\u00f3n y control de la importaci\u00f3n de productos farmac\u00e9uticos.\n- **Importadores**: Responsables de asegurar el manejo adecuado de los productos en los puertos de entrada.\n- **Contratistas y Subcontratistas**: Entidades involucradas en la distribuci\u00f3n de productos farmac\u00e9uticos bajo contratos espec\u00edficos. \n\nEste resumen abarca los aspectos fundamentales de la regulaci\u00f3n y manejo de productos farmac\u00e9uticos en el contexto de importaciones y actividades contractuales, destacando la importancia de la calidad y la prevenci\u00f3n de falsificaciones.", "excerpt_keywords": "Keywords: self-inspection, quality system, GDP compliance, corrective measures, management evaluation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "da29050e-a714-4084-9010-689cfb215662", "node_type": "4", "metadata": {"page_label": "277", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 22. Self-inspection\n\n22.1 The quality system should include self-inspections. These should be conducted to monitor implementation and compliance with the principles of GDP and, if necessary, to trigger corrective and preventive measures.\n\n22.2 Self-inspections should be conducted in an independent and detailed way by a designated, competent person.\n\n22.3 The results of all self-inspections should be recorded. Reports should contain all observations made during the inspection and, where applicable, proposals for corrective measures. There should be an effective follow-up programme. Management should evaluate the inspection report and the records of any corrective actions taken.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "4f0e6875b9ef7f48d818660becdb78fe55a593119e6eece484344e1311ef91b7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 22. Self-inspection\n\n22.1 The quality system should include self-inspections. These should be conducted to monitor implementation and compliance with the principles of GDP and, if necessary, to trigger corrective and preventive measures.\n\n22.2 Self-inspections should be conducted in an independent and detailed way by a designated, competent person.\n\n22.3 The results of all self-inspections should be recorded. Reports should contain all observations made during the inspection and, where applicable, proposals for corrective measures. There should be an effective follow-up programme. Management should evaluate the inspection report and the records of any corrective actions taken.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 687, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a2170c76-e2bc-403a-8a69-fa2e43d84cda": {"__data__": {"id_": "a2170c76-e2bc-403a-8a69-fa2e43d84cda", "embedding": null, "metadata": {"page_label": "278", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. WHO guide to good storage practices for pharmaceuticals. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 9 (WHO Technical Report Series, No. 908).\n\n2. WHO good pharmacy practice in community and hospital pharmacy settings. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report*. Geneva, World Health Organization, 1999, Annex 7 (WHO Technical Report Series, No. 885).\n\n3. WHO good manufacturing practices. In: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Good manufacturing practices and inspection, Vol. 2, 2nd updated ed.* Geneva, World Health Organization, 2007.\n\n4. Guidelines for implementation of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth report*. Geneva, World Health Organization, 1996, Annex 10 (WHO Technical Report Series, No. 863).\n\n5. WHO pharmaceutical starting materials certification scheme (SMACS). In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2004, Annex 3 (Technical Report Series, No. 917).\n\n6. Guidelines on import procedures for pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth report*. Geneva, World Health Organization, 1996, Annex 12 (WHO Technical Report Series, No. 863).\n\n7. Good trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2004, Annex 2 (WHO Technical Report Series, No. 917).\n\n8. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 2 (WHO Technical Report Series, No. 953) (http://www.who.int/medicines/areas/quality_safety/quality_assurance/regulatory_standards/en/index.html).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfCu\u00e1l es el prop\u00f3sito del \"WHO pharmaceutical starting materials certification scheme (SMACS)\" mencionado en el documento?**\n   - **Respuesta:** El \"WHO pharmaceutical starting materials certification scheme (SMACS)\" tiene como objetivo establecer un sistema de certificaci\u00f3n para los materiales iniciales farmac\u00e9uticos, asegurando que estos cumplan con los est\u00e1ndares de calidad necesarios para la producci\u00f3n de medicamentos. Esto ayuda a garantizar la seguridad y eficacia de los productos farmac\u00e9uticos en el comercio internacional.\n\n2. **\u00bfQu\u00e9 documento de la OMS se refiere a las \"buenas pr\u00e1cticas de almacenamiento\" para productos farmac\u00e9uticos y en qu\u00e9 a\u00f1o fue publicado?**\n   - **Respuesta:** El documento que se refiere a las \"buenas pr\u00e1cticas de almacenamiento\" para productos farmac\u00e9uticos es la \"WHO guide to good storage practices for pharmaceuticals\", publicada en el 2003 como parte del \"Thirty-seventh report\" de la OMS.\n\n3. **\u00bfQu\u00e9 tipo de informaci\u00f3n se puede encontrar en el \"Technical Report Series, No. 953\" de la OMS?**\n   - **Respuesta:** El \"Technical Report Series, No. 953\" de la OMS incluye directrices sobre la \"Stability testing of active pharmaceutical ingredients and finished pharmaceutical products\", proporcionando criterios y m\u00e9todos para evaluar la estabilidad de los ingredientes farmac\u00e9uticos activos y los productos farmac\u00e9uticos terminados.\n\n### Resumen de Nivel Superior\n\nEl documento \"WHO - Technical Report Series 957\" incluye una serie de referencias que abordan las mejores pr\u00e1cticas y directrices de la Organizaci\u00f3n Mundial de la Salud (OMS) en relaci\u00f3n con la calidad y seguridad de los productos farmac\u00e9uticos. Estas referencias abarcan temas como el almacenamiento adecuado de medicamentos, buenas pr\u00e1cticas de farmacia, buenas pr\u00e1cticas de manufactura, y procedimientos de importaci\u00f3n y certificaci\u00f3n de materiales farmac\u00e9uticos. La informaci\u00f3n est\u00e1 destinada a asegurar que los productos farmac\u00e9uticos cumplan con los est\u00e1ndares internacionales de calidad y seguridad en el comercio global.", "prev_section_summary": "### Resumen de la Secci\u00f3n 22: Autoinspecci\u00f3n\n\nLa secci\u00f3n 22 del documento de la OMS, parte de la Serie de Informes T\u00e9cnicos 957, se centra en la importancia de las autoinspecciones dentro de un sistema de calidad. Los temas clave incluyen:\n\n1. **Incorporaci\u00f3n de Autoinspecciones**: Se establece que el sistema de calidad debe incluir autoinspecciones para monitorear la implementaci\u00f3n y el cumplimiento de los principios de Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP), as\u00ed como para activar medidas correctivas y preventivas cuando sea necesario.\n\n2. **Independencia y Competencia**: Las autoinspecciones deben ser realizadas de manera independiente y detallada por una persona designada que posea las competencias necesarias para llevar a cabo esta tarea.\n\n3. **Registro de Resultados**: Es fundamental que se registren los resultados de todas las autoinspecciones. Los informes deben incluir todas las observaciones realizadas durante la inspecci\u00f3n y, cuando sea pertinente, propuestas para medidas correctivas.\n\n4. **Programa de Seguimiento**: Debe existir un programa de seguimiento efectivo para evaluar las acciones correctivas. La gesti\u00f3n debe revisar el informe de la inspecci\u00f3n y los registros de las acciones correctivas implementadas.\n\n### Entidades Clave\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Sistema de Calidad**: Estructura que incluye las autoinspecciones como parte de su funcionamiento.\n- **Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP)**: Principios que deben cumplirse durante las autoinspecciones.\n- **Persona Designada**: Individuo competente responsable de realizar las autoinspecciones.\n- **Informes de Autoinspecci\u00f3n**: Documentos que registran las observaciones y propuestas de medidas correctivas.\n- **Programa de Seguimiento**: Proceso para evaluar la efectividad de las acciones correctivas.", "excerpt_keywords": "Keywords: WHO, pharmaceutical practices, quality assurance, good manufacturing practices, stability testing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "dd5a7351-3fb6-496d-8260-d171366f8bbc", "node_type": "4", "metadata": {"page_label": "278", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. WHO guide to good storage practices for pharmaceuticals. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 9 (WHO Technical Report Series, No. 908).\n\n2. WHO good pharmacy practice in community and hospital pharmacy settings. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report*. Geneva, World Health Organization, 1999, Annex 7 (WHO Technical Report Series, No. 885).\n\n3. WHO good manufacturing practices. In: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Good manufacturing practices and inspection, Vol. 2, 2nd updated ed.* Geneva, World Health Organization, 2007.\n\n4. Guidelines for implementation of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth report*. Geneva, World Health Organization, 1996, Annex 10 (WHO Technical Report Series, No. 863).\n\n5. WHO pharmaceutical starting materials certification scheme (SMACS). In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2004, Annex 3 (Technical Report Series, No. 917).\n\n6. Guidelines on import procedures for pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth report*. Geneva, World Health Organization, 1996, Annex 12 (WHO Technical Report Series, No. 863).\n\n7. Good trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2004, Annex 2 (WHO Technical Report Series, No. 917).\n\n8. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 2 (WHO Technical Report Series, No. 953) (http://www.who.int/medicines/areas/quality_safety/quality_assurance/regulatory_standards/en/index.html).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "f3dbada31af0eadce3d5e936b7939d99f46e7ae1b68a55ec06fe125c06982a42", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# References\n\n1. WHO guide to good storage practices for pharmaceuticals. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 9 (WHO Technical Report Series, No. 908).\n\n2. WHO good pharmacy practice in community and hospital pharmacy settings. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report*. Geneva, World Health Organization, 1999, Annex 7 (WHO Technical Report Series, No. 885).\n\n3. WHO good manufacturing practices. In: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Good manufacturing practices and inspection, Vol. 2, 2nd updated ed.* Geneva, World Health Organization, 2007.\n\n4. Guidelines for implementation of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth report*. Geneva, World Health Organization, 1996, Annex 10 (WHO Technical Report Series, No. 863).\n\n5. WHO pharmaceutical starting materials certification scheme (SMACS). In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2004, Annex 3 (Technical Report Series, No. 917).\n\n6. Guidelines on import procedures for pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth report*. Geneva, World Health Organization, 1996, Annex 12 (WHO Technical Report Series, No. 863).\n\n7. Good trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2004, Annex 2 (WHO Technical Report Series, No. 917).\n\n8. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 2 (WHO Technical Report Series, No. 953) (http://www.who.int/medicines/areas/quality_safety/quality_assurance/regulatory_standards/en/index.html).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2272, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8e920956-4282-4493-b922-31532f0a7db6": {"__data__": {"id_": "8e920956-4282-4493-b922-31532f0a7db6", "embedding": null, "metadata": {"page_label": "279", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 6\n\n## Guidelines on the requalification of prequalified dossiers\n\n1. Introduction\n2. Requalification of prequalified dossiers\n\nAppendix 1  \nSummary of key product information\n\nAppendix 2  \nVariations to the product\n\n### 1. Introduction\n\nIn accordance with the provisions set out in section 12 (Maintenance of prequalification status) of the *Procedure for prequalification of pharmaceutical products*[^1], holders of WHO-prequalified products should submit a quality review 5 years from the date of prequalification of the product, or when requested to do so by WHO Prequalification (whichever date is earlier).\n\nSection 12 of the above-mentioned guidelines states that:\n\n> WHO will furthermore arrange for the products and manufacturing sites included in the list to be re-evaluated at regular intervals. If, as a result of this re-evaluation, it is found that a product and/or specified manufacturing site no longer complies with the WHO-recommended standards, such products and manufacturing sites will be removed from the list. Failure of a manufacturer or applicant to participate in the re-evaluation procedure will also lead to removal from the list.\n>\n> Re-evaluation, including re-inspections of manufacturing sites and contract research organizations (CROs), will be done at regular intervals, based on risk assessment, but at least once every 5 years.\n>\n> Re-evaluation, including re-inspections, shall also be performed:\n\n[^1]: Procedure for prequalification of pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report.* Geneva, World Health Organization, 2009, Annex 4 (WHO Technical Report Series, No. 953) (http://www.who.int/medicines/publications/pharmprep/pdf_trs953.pdf#page=145).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento proporciona directrices sobre la revalidaci\u00f3n de expedientes prequalificados por la OMS, estableciendo que los titulares de productos prequalificados deben presentar una revisi\u00f3n de calidad cada cinco a\u00f1os o cuando la OMS lo solicite. Se menciona que la OMS llevar\u00e1 a cabo reevaluaciones peri\u00f3dicas de los productos y sitios de fabricaci\u00f3n, y que la falta de participaci\u00f3n en este proceso puede resultar en la eliminaci\u00f3n de la lista de productos prequalificados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 acciones se tomar\u00e1n si un producto o sitio de fabricaci\u00f3n no cumple con los est\u00e1ndares recomendados por la OMS durante la reevaluaci\u00f3n?**\n   - Respuesta: Si se determina que un producto o sitio de fabricaci\u00f3n no cumple con los est\u00e1ndares recomendados por la OMS durante la reevaluaci\u00f3n, dicho producto y/o sitio ser\u00e1 eliminado de la lista de productos prequalificados.\n\n2. **\u00bfCon qu\u00e9 frecuencia se realizar\u00e1n las reevaluaciones de los productos y sitios de fabricaci\u00f3n seg\u00fan las directrices de la OMS?**\n   - Respuesta: Las reevaluaciones, incluidas las reinspecciones de los sitios de fabricaci\u00f3n y organizaciones de investigaci\u00f3n por contrato (CROs), se realizar\u00e1n al menos una vez cada cinco a\u00f1os, bas\u00e1ndose en una evaluaci\u00f3n de riesgos.\n\n3. **\u00bfQu\u00e9 consecuencias puede enfrentar un fabricante o solicitante que no participe en el procedimiento de reevaluaci\u00f3n?**\n   - Respuesta: La falta de participaci\u00f3n en el procedimiento de reevaluaci\u00f3n resultar\u00e1 en la eliminaci\u00f3n del fabricante o solicitante de la lista de productos prequalificados por la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nLa secci\u00f3n de referencias del documento \"WHO - Technical Report Series 957\" aborda diversas directrices y pr\u00e1cticas recomendadas por la Organizaci\u00f3n Mundial de la Salud (OMS) en relaci\u00f3n con la calidad y seguridad de los productos farmac\u00e9uticos. Los temas clave incluyen:\n\n1. **Buenas Pr\u00e1cticas de Almacenamiento**: Se menciona la gu\u00eda de la OMS sobre buenas pr\u00e1cticas de almacenamiento para asegurar la integridad de los productos farmac\u00e9uticos.\n\n2. **Buenas Pr\u00e1cticas de Farmacia**: Se hace referencia a las pr\u00e1cticas recomendadas en entornos comunitarios y hospitalarios para garantizar la correcta dispensaci\u00f3n y manejo de medicamentos.\n\n3. **Buenas Pr\u00e1cticas de Manufactura**: Se discuten las normas que deben seguirse en la producci\u00f3n de productos farmac\u00e9uticos para asegurar su calidad.\n\n4. **Certificaci\u00f3n de Productos Farmac\u00e9uticos**: Se incluyen directrices sobre la implementaci\u00f3n de esquemas de certificaci\u00f3n para productos farmac\u00e9uticos en el comercio internacional.\n\n5. **Materiales Iniciales Farmac\u00e9uticos**: Se menciona el esquema de certificaci\u00f3n de materiales iniciales farmac\u00e9uticos (SMACS) para asegurar que estos cumplan con los est\u00e1ndares de calidad.\n\n6. **Procedimientos de Importaci\u00f3n**: Se proporcionan pautas sobre los procedimientos de importaci\u00f3n de productos farmac\u00e9uticos.\n\n7. **Pr\u00e1cticas de Comercio y Distribuci\u00f3n**: Se abordan las buenas pr\u00e1cticas en el comercio y distribuci\u00f3n de materiales farmac\u00e9uticos.\n\n8. **Pruebas de Estabilidad**: Se discuten las pruebas de estabilidad para ingredientes farmac\u00e9uticos activos y productos terminados, asegurando su eficacia y seguridad a lo largo del tiempo.\n\n### Entidades Clave\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la elaboraci\u00f3n de las directrices y pr\u00e1cticas mencionadas.\n- **WHO Technical Report Series**: Serie de informes t\u00e9cnicos que compilan las recomendaciones y est\u00e1ndares de la OMS.\n- **Expert Committee on Specifications for Pharmaceutical Preparations**: Comit\u00e9 de la OMS que elabora y revisa las especificaciones y directrices para productos farmac\u00e9uticos.\n\nEste resumen destaca la importancia de seguir est\u00e1ndares internacionales para garantizar la calidad y seguridad de los productos farmac\u00e9uticos en el comercio global.", "excerpt_keywords": "Keywords: requalification, prequalified dossiers, WHO guidelines, pharmaceutical products, quality review"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ccf28afd-0de8-4a9e-b626-188f787f67bd", "node_type": "4", "metadata": {"page_label": "279", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 6\n\n## Guidelines on the requalification of prequalified dossiers\n\n1. Introduction\n2. Requalification of prequalified dossiers\n\nAppendix 1  \nSummary of key product information\n\nAppendix 2  \nVariations to the product\n\n### 1. Introduction\n\nIn accordance with the provisions set out in section 12 (Maintenance of prequalification status) of the *Procedure for prequalification of pharmaceutical products*[^1], holders of WHO-prequalified products should submit a quality review 5 years from the date of prequalification of the product, or when requested to do so by WHO Prequalification (whichever date is earlier).\n\nSection 12 of the above-mentioned guidelines states that:\n\n> WHO will furthermore arrange for the products and manufacturing sites included in the list to be re-evaluated at regular intervals. If, as a result of this re-evaluation, it is found that a product and/or specified manufacturing site no longer complies with the WHO-recommended standards, such products and manufacturing sites will be removed from the list. Failure of a manufacturer or applicant to participate in the re-evaluation procedure will also lead to removal from the list.\n>\n> Re-evaluation, including re-inspections of manufacturing sites and contract research organizations (CROs), will be done at regular intervals, based on risk assessment, but at least once every 5 years.\n>\n> Re-evaluation, including re-inspections, shall also be performed:\n\n[^1]: Procedure for prequalification of pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report.* Geneva, World Health Organization, 2009, Annex 4 (WHO Technical Report Series, No. 953) (http://www.who.int/medicines/publications/pharmprep/pdf_trs953.pdf#page=145).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "bd1e42a3382e74b81b8bcf1e9d693e73e7bdb7f7b4cbfe90bdb00a63f82df6af", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 6\n\n## Guidelines on the requalification of prequalified dossiers\n\n1. Introduction\n2. Requalification of prequalified dossiers\n\nAppendix 1  \nSummary of key product information\n\nAppendix 2  \nVariations to the product\n\n### 1. Introduction\n\nIn accordance with the provisions set out in section 12 (Maintenance of prequalification status) of the *Procedure for prequalification of pharmaceutical products*[^1], holders of WHO-prequalified products should submit a quality review 5 years from the date of prequalification of the product, or when requested to do so by WHO Prequalification (whichever date is earlier).\n\nSection 12 of the above-mentioned guidelines states that:\n\n> WHO will furthermore arrange for the products and manufacturing sites included in the list to be re-evaluated at regular intervals. If, as a result of this re-evaluation, it is found that a product and/or specified manufacturing site no longer complies with the WHO-recommended standards, such products and manufacturing sites will be removed from the list. Failure of a manufacturer or applicant to participate in the re-evaluation procedure will also lead to removal from the list.\n>\n> Re-evaluation, including re-inspections of manufacturing sites and contract research organizations (CROs), will be done at regular intervals, based on risk assessment, but at least once every 5 years.\n>\n> Re-evaluation, including re-inspections, shall also be performed:\n\n[^1]: Procedure for prequalification of pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report.* Geneva, World Health Organization, 2009, Annex 4 (WHO Technical Report Series, No. 953) (http://www.who.int/medicines/publications/pharmprep/pdf_trs953.pdf#page=145).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1771, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "fb81ee37-34ee-4a0a-9458-e974f2f6995c": {"__data__": {"id_": "fb81ee37-34ee-4a0a-9458-e974f2f6995c", "embedding": null, "metadata": {"page_label": "280", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- if any fraud or omissions by the applicant, manufacturer(s) of a finished pharmaceutical product (FPP) or active pharmaceutical ingredient (API), or CROs in the initial assessment procedure or during the follow-up activities, becomes evident; and\n- if WHO or any United Nations agency considers that a batch or batches of supplied prequalified pharmaceutical products are not in compliance with the specifications which were found to be applicable upon prequalification.\n\nRequalification will be applicable to multisource FPPs (generics) where the full dossiers have been submitted, assessed and prequalified by WHO. Renewal of marketing authorization for products that have been listed by WHO based on approval by a stringent regulatory agency[^2^] (SRA) remains the responsibility of the relevant SRA.\n\n## 2. Requalification of prequalified dossiers\n\nThe objective of this quality review submission is to enable WHO to requalify the product based on an assessment of the data and information submitted by the holder of a prequalified product, which includes verification of the acceptability of the product and its conformity to current norms and standards, and assessment of consistency of the quality of the prequalified FPPs, and its manufacturing process(es) over the identified period.\n\nThe holder of a prequalified product should submit the following documents electronically (in pdf format and in also in WinWord where indicated):\n\n- A covering letter, which should contain a clear statement by the responsible person submitting the quality review, indicating that the information submitted is true and correct.\n- Summary of key product information (as per Appendix 1).\n- Variations to the product (as per Appendix 2).\n- A pharmaceutical quality information form (PQIF)[^3^], completed in WinWord format. It should reflect the requirements of current prequalification guidelines and should also take into account technical and\n\n[^2^]: Stringent regulatory authority (SRA): a regulatory authority which is:\n  - a member of the International Conference on Harmonisation (ICH) (as specified on www.ich.org); or\n  - an ICH observer, being the European Free Trade Association (EFTA), as represented by Swiss Medic, Health Canada and World Health Organization (WHO) (as may be updated from time to time); or\n  - a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (as may be updated from time to time).\n\n[^3^]: Presentation of pharmaceutical quality information. In: *Guidance for submission of documentation for prequalification of multi-source (generic) finished pharmaceutical products (FPPs) used in the treatment of HIV/AIDS, malaria and tuberculosis*. Annex 8 (http://apps.who.int/prequal/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX8.doc).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfQu\u00e9 documentos espec\u00edficos debe presentar el titular de un producto precalificado para la revalidaci\u00f3n ante la OMS?**\n   - Respuesta: El titular de un producto precalificado debe presentar los siguientes documentos electr\u00f3nicamente: una carta de presentaci\u00f3n que indique que la informaci\u00f3n es verdadera y correcta, un resumen de la informaci\u00f3n clave del producto (seg\u00fan el Ap\u00e9ndice 1), variaciones al producto (seg\u00fan el Ap\u00e9ndice 2) y un formulario de informaci\u00f3n de calidad farmac\u00e9utica (PQIF) completado en formato WinWord.\n\n2. **\u00bfCu\u00e1les son las condiciones bajo las cuales se puede llevar a cabo la revalidaci\u00f3n de un producto farmac\u00e9utico precalificado?**\n   - Respuesta: La revalidaci\u00f3n se puede llevar a cabo si se evidencia fraude u omisiones por parte del solicitante, fabricantes o CROs durante el procedimiento de evaluaci\u00f3n inicial o actividades de seguimiento, o si la OMS o alguna agencia de las Naciones Unidas considera que un lote de productos farmac\u00e9uticos precalificados no cumple con las especificaciones aplicables.\n\n3. **\u00bfQu\u00e9 responsabilidad tiene la autoridad reguladora estricta (SRA) en relaci\u00f3n con la renovaci\u00f3n de la autorizaci\u00f3n de comercializaci\u00f3n de productos listados por la OMS?**\n   - Respuesta: La renovaci\u00f3n de la autorizaci\u00f3n de comercializaci\u00f3n para productos que han sido listados por la OMS, bas\u00e1ndose en la aprobaci\u00f3n de una SRA, sigue siendo responsabilidad de la SRA relevante.\n\n### Resumen de nivel superior del contexto:\nEl documento de la OMS establece los procedimientos y requisitos para la revalidaci\u00f3n de productos farmac\u00e9uticos precalificados, especialmente aquellos que son gen\u00e9ricos. Se detalla la documentaci\u00f3n necesaria que debe presentar el titular del producto para que la OMS pueda evaluar la conformidad del producto con las normas y est\u00e1ndares actuales. Adem\u00e1s, se menciona la responsabilidad de las autoridades reguladoras estrictas en la renovaci\u00f3n de autorizaciones de comercializaci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**Temas clave:**\n\n1. **Revalidaci\u00f3n de expedientes prequalificados:** Se establecen directrices para la revalidaci\u00f3n de productos farmac\u00e9uticos que han sido prequalificados por la OMS.\n2. **Revisi\u00f3n de calidad:** Los titulares de productos prequalificados deben presentar una revisi\u00f3n de calidad cada cinco a\u00f1os o cuando la OMS lo solicite.\n3. **Reevaluaci\u00f3n peri\u00f3dica:** La OMS llevar\u00e1 a cabo reevaluaciones de productos y sitios de fabricaci\u00f3n a intervalos regulares, al menos cada cinco a\u00f1os, bas\u00e1ndose en una evaluaci\u00f3n de riesgos.\n4. **Consecuencias de no cumplir:** Si un producto o sitio de fabricaci\u00f3n no cumple con los est\u00e1ndares recomendados, ser\u00e1 eliminado de la lista de productos prequalificados. La falta de participaci\u00f3n en el proceso de reevaluaci\u00f3n tambi\u00e9n resultar\u00e1 en la eliminaci\u00f3n de la lista.\n\n**Entidades:**\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud):** Entidad responsable de la precalificaci\u00f3n y reevaluaci\u00f3n de productos farmac\u00e9uticos.\n- **Productos farmac\u00e9uticos prequalificados:** Productos que han sido evaluados y cumplen con los est\u00e1ndares de calidad establecidos por la OMS.\n- **Sitios de fabricaci\u00f3n:** Instalaciones donde se producen los productos farmac\u00e9uticos que est\u00e1n sujetos a reevaluaci\u00f3n.\n- **Organizaciones de investigaci\u00f3n por contrato (CROs):** Entidades que tambi\u00e9n pueden ser reevaluadas en el proceso de mantenimiento de la precalificaci\u00f3n.", "excerpt_keywords": "Keywords: requalification, prequalified products, pharmaceutical quality, WHO guidelines, marketing authorization"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "74445be5-ae9b-4d39-8afb-0f1e1eb9ff3b", "node_type": "4", "metadata": {"page_label": "280", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- if any fraud or omissions by the applicant, manufacturer(s) of a finished pharmaceutical product (FPP) or active pharmaceutical ingredient (API), or CROs in the initial assessment procedure or during the follow-up activities, becomes evident; and\n- if WHO or any United Nations agency considers that a batch or batches of supplied prequalified pharmaceutical products are not in compliance with the specifications which were found to be applicable upon prequalification.\n\nRequalification will be applicable to multisource FPPs (generics) where the full dossiers have been submitted, assessed and prequalified by WHO. Renewal of marketing authorization for products that have been listed by WHO based on approval by a stringent regulatory agency[^2^] (SRA) remains the responsibility of the relevant SRA.\n\n## 2. Requalification of prequalified dossiers\n\nThe objective of this quality review submission is to enable WHO to requalify the product based on an assessment of the data and information submitted by the holder of a prequalified product, which includes verification of the acceptability of the product and its conformity to current norms and standards, and assessment of consistency of the quality of the prequalified FPPs, and its manufacturing process(es) over the identified period.\n\nThe holder of a prequalified product should submit the following documents electronically (in pdf format and in also in WinWord where indicated):\n\n- A covering letter, which should contain a clear statement by the responsible person submitting the quality review, indicating that the information submitted is true and correct.\n- Summary of key product information (as per Appendix 1).\n- Variations to the product (as per Appendix 2).\n- A pharmaceutical quality information form (PQIF)[^3^], completed in WinWord format. It should reflect the requirements of current prequalification guidelines and should also take into account technical and\n\n[^2^]: Stringent regulatory authority (SRA): a regulatory authority which is:\n  - a member of the International Conference on Harmonisation (ICH) (as specified on www.ich.org); or\n  - an ICH observer, being the European Free Trade Association (EFTA), as represented by Swiss Medic, Health Canada and World Health Organization (WHO) (as may be updated from time to time); or\n  - a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (as may be updated from time to time).\n\n[^3^]: Presentation of pharmaceutical quality information. In: *Guidance for submission of documentation for prequalification of multi-source (generic) finished pharmaceutical products (FPPs) used in the treatment of HIV/AIDS, malaria and tuberculosis*. Annex 8 (http://apps.who.int/prequal/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX8.doc).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "7ae7e0d5109af0d43e6f3a6995ef4c655aac04e7f43e11b88aa48479c0a81b16", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- if any fraud or omissions by the applicant, manufacturer(s) of a finished pharmaceutical product (FPP) or active pharmaceutical ingredient (API), or CROs in the initial assessment procedure or during the follow-up activities, becomes evident; and\n- if WHO or any United Nations agency considers that a batch or batches of supplied prequalified pharmaceutical products are not in compliance with the specifications which were found to be applicable upon prequalification.\n\nRequalification will be applicable to multisource FPPs (generics) where the full dossiers have been submitted, assessed and prequalified by WHO. Renewal of marketing authorization for products that have been listed by WHO based on approval by a stringent regulatory agency[^2^] (SRA) remains the responsibility of the relevant SRA.\n\n## 2. Requalification of prequalified dossiers\n\nThe objective of this quality review submission is to enable WHO to requalify the product based on an assessment of the data and information submitted by the holder of a prequalified product, which includes verification of the acceptability of the product and its conformity to current norms and standards, and assessment of consistency of the quality of the prequalified FPPs, and its manufacturing process(es) over the identified period.\n\nThe holder of a prequalified product should submit the following documents electronically (in pdf format and in also in WinWord where indicated):\n\n- A covering letter, which should contain a clear statement by the responsible person submitting the quality review, indicating that the information submitted is true and correct.\n- Summary of key product information (as per Appendix 1).\n- Variations to the product (as per Appendix 2).\n- A pharmaceutical quality information form (PQIF)[^3^], completed in WinWord format. It should reflect the requirements of current prequalification guidelines and should also take into account technical and\n\n[^2^]: Stringent regulatory authority (SRA): a regulatory authority which is:\n  - a member of the International Conference on Harmonisation (ICH) (as specified on www.ich.org); or\n  - an ICH observer, being the European Free Trade Association (EFTA), as represented by Swiss Medic, Health Canada and World Health Organization (WHO) (as may be updated from time to time); or\n  - a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (as may be updated from time to time).\n\n[^3^]: Presentation of pharmaceutical quality information. In: *Guidance for submission of documentation for prequalification of multi-source (generic) finished pharmaceutical products (FPPs) used in the treatment of HIV/AIDS, malaria and tuberculosis*. Annex 8 (http://apps.who.int/prequal/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX8.doc).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2885, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f13fc810-bdce-46fe-b173-9aea0bd95359": {"__data__": {"id_": "f13fc810-bdce-46fe-b173-9aea0bd95359", "embedding": null, "metadata": {"page_label": "281", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido que podr\u00eda estar relacionado:\n\n### Resumen del Contexto\nEl documento mencionado es el \"WHO - Technical Report Series 957\", que es parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica, y recomendaciones sobre pr\u00e1cticas y pol\u00edticas de salud. Sin embargo, el contenido espec\u00edfico del informe no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el informe WHO - Technical Report Series 957?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el contenido del informe, que podr\u00eda incluir recomendaciones de salud p\u00fablica o resultados de investigaciones.\n\n2. **\u00bfQu\u00e9 temas de salud p\u00fablica se abordan en la serie de informes t\u00e9cnicos de la OMS, y c\u00f3mo se relaciona el informe 957 con esos temas?**\n   - Esta pregunta se enfoca en el contexto m\u00e1s amplio de la serie de informes y c\u00f3mo el informe espec\u00edfico se integra en la discusi\u00f3n general sobre salud p\u00fablica.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas se utilizan en el informe WHO - Technical Report Series 957 para evaluar los problemas de salud tratados?**\n   - Esta pregunta indaga sobre las t\u00e9cnicas y enfoques utilizados en el informe para abordar los temas de salud, lo que podr\u00eda incluir estudios de caso, an\u00e1lisis estad\u00edsticos, o revisiones sistem\u00e1ticas.\n\nEstas preguntas est\u00e1n dise\u00f1adas para obtener informaci\u00f3n que probablemente no se encuentre f\u00e1cilmente en otros lugares, dado que se centran en el contenido espec\u00edfico del informe y su contexto dentro de la serie de la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Revalidaci\u00f3n de Productos Farmac\u00e9uticos Precalificados**:\n   - La revalidaci\u00f3n se aplica a productos farmac\u00e9uticos gen\u00e9ricos (FPPs) que han sido evaluados y precalificados por la OMS.\n   - Se puede llevar a cabo si se detectan fraudes, omisiones o si un lote no cumple con las especificaciones.\n\n2. **Documentaci\u00f3n Requerida para la Revalidaci\u00f3n**:\n   - Carta de presentaci\u00f3n que certifique la veracidad de la informaci\u00f3n.\n   - Resumen de informaci\u00f3n clave del producto (seg\u00fan el Ap\u00e9ndice 1).\n   - Variaciones al producto (seg\u00fan el Ap\u00e9ndice 2).\n   - Formulario de informaci\u00f3n de calidad farmac\u00e9utica (PQIF) en formato WinWord.\n\n3. **Responsabilidad de las Autoridades Reguladoras**:\n   - La renovaci\u00f3n de la autorizaci\u00f3n de comercializaci\u00f3n de productos listados por la OMS, basados en la aprobaci\u00f3n de una autoridad reguladora estricta (SRA), es responsabilidad de la SRA correspondiente.\n\n4. **Entidades Mencionadas**:\n   - **OMS (Organizaci\u00f3n Mundial de la Salud)**: Responsable de la evaluaci\u00f3n y revalidaci\u00f3n de productos farmac\u00e9uticos.\n   - **SRA (Autoridad Reguladora Estricta)**: Autoridades que cumplen con est\u00e1ndares internacionales y son responsables de la aprobaci\u00f3n y renovaci\u00f3n de productos farmac\u00e9uticos.\n\n5. **Normas y Est\u00e1ndares**:\n   - La revalidaci\u00f3n implica la verificaci\u00f3n de la conformidad del producto con las normas y est\u00e1ndares actuales, as\u00ed como la consistencia en la calidad y procesos de fabricaci\u00f3n.\n\nEste resumen destaca los procedimientos y requisitos clave para la revalidaci\u00f3n de productos farmac\u00e9uticos precalificados, as\u00ed como las responsabilidades de las entidades involucradas.", "excerpt_keywords": "Keywords: revalidaci\u00f3n, productos farmac\u00e9uticos, OMS, autorizaci\u00f3n de comercializaci\u00f3n, est\u00e1ndares de calidad"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "643fa042-c48f-404f-91c8-7f70d282dccf", "node_type": "4", "metadata": {"page_label": "281", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "51f662b0-21fb-475b-85ae-6d463dcefdfb": {"__data__": {"id_": "51f662b0-21fb-475b-85ae-6d463dcefdfb", "embedding": null, "metadata": {"page_label": "282", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 1\n\n## Summary of key product information\n\nThis section compares key information on the FPP at the time of prequalification and at the time of the submission for requalification. Table A1.1 should be completed by the holder of the prequalified product. Include remarks as a footnote to Table A1.1, where deemed necessary, to clarify the information provided.\n\n**Table A1.1**\n\n### Summary of key product information\n\n| Item | Prequalified dossier | Current data |\n| - | - | - |\n| Product number (e.g. HA001) | | |\n| INN, strength and pharmaceutical form | | |\n| Applicant (name, physical address and contact numbers) | | |\n| Manufacturing site(s) of FPP, with physical address (including unit and block numbers) and contact numbers (list separately if different steps are performed by different sites, e.g. packaging, quality control) | | |\n| Batch size(s) of FPP | | |\n| Product description (visual appearance) | | |\n| Primary and secondary packaging material(s) and pack size(s) | | |\n| Storage conditions of FPP | | |\n| Shelf-life of FPP | | |\n| FPP specification(s) reference number and/or versionb | | |\n| Manufacturer(s) of API(s), with physical address (including unit and block numbers) and contact numbers (list each API separately) | | |\n| Number/version of each APIMF associated with the FPP | | |\n| Storage conditions of API | | |\n| Retest period of API(s) | | |\n| API specification(s) reference number and/or version (for each API)b | | |\n| All commitments and their outcomes | | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS y se centra en la informaci\u00f3n clave sobre productos farmac\u00e9uticos precalificados. En particular, se presenta una tabla (Tabla A1.1) que debe ser completada por el titular del producto precalificado, comparando la informaci\u00f3n del expediente precalificado con los datos actuales en el momento de la revalidaci\u00f3n. La tabla incluye detalles sobre el n\u00famero de producto, la forma farmac\u00e9utica, el solicitante, los sitios de fabricaci\u00f3n, las condiciones de almacenamiento, la vida \u00fatil, y otros aspectos relevantes del producto y sus ingredientes activos.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 informaci\u00f3n espec\u00edfica debe incluirse en la secci\u00f3n de \"Compromisos y sus resultados\" de la Tabla A1.1?**\n   - Esta pregunta busca detalles sobre los compromisos que el titular del producto debe reportar y c\u00f3mo se eval\u00faan sus resultados, lo cual no se detalla expl\u00edcitamente en el contexto.\n\n2. **\u00bfCu\u00e1les son las implicaciones de no proporcionar informaci\u00f3n actualizada en la secci\u00f3n de \"Tama\u00f1o de lote(s) de FPP\" en la Tabla A1.1?**\n   - Esta pregunta indaga sobre las consecuencias que podr\u00eda tener la falta de actualizaci\u00f3n en esta secci\u00f3n, lo que podr\u00eda afectar la evaluaci\u00f3n de la calidad y la disponibilidad del producto.\n\n3. **\u00bfQu\u00e9 criterios se utilizan para determinar las \"Condiciones de almacenamiento del FPP\" y c\u00f3mo pueden variar entre diferentes productos?**\n   - Esta pregunta busca entender los factores que influyen en las condiciones de almacenamiento y c\u00f3mo estas pueden diferir seg\u00fan el tipo de producto farmac\u00e9utico, lo que no se aborda directamente en el contexto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento mencionado, \"WHO - Technical Report Series 957\", es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque el contenido espec\u00edfico no est\u00e1 disponible, se pueden inferir algunos temas clave y entidades relevantes:\n\n#### Temas Clave:\n1. **Salud P\u00fablica**: El informe probablemente aborda cuestiones relacionadas con la salud p\u00fablica, incluyendo pol\u00edticas, pr\u00e1cticas y recomendaciones para mejorar la salud global.\n2. **Investigaci\u00f3n M\u00e9dica**: Es probable que el informe incluya hallazgos de investigaciones recientes en el campo de la medicina y la salud.\n3. **Recomendaciones de Salud**: Se espera que el documento contenga recomendaciones basadas en evidencia para abordar problemas de salud espec\u00edficos.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la publicaci\u00f3n del informe, que se dedica a coordinar esfuerzos internacionales en salud p\u00fablica.\n- **Informe T\u00e9cnico**: El tipo de documento que se presenta, que forma parte de una serie m\u00e1s amplia de informes t\u00e9cnicos.\n\nEste resumen destaca la importancia del informe en el contexto de la salud p\u00fablica y la investigaci\u00f3n m\u00e9dica, aunque no se proporcionan detalles espec\u00edficos sobre su contenido.", "excerpt_keywords": "Keywords: prequalification, pharmaceutical product, WHO, manufacturing, storage conditions"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bee3fbbb-ae52-4458-81e9-0d7d93034934", "node_type": "4", "metadata": {"page_label": "282", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 1\n\n## Summary of key product information\n\nThis section compares key information on the FPP at the time of prequalification and at the time of the submission for requalification. Table A1.1 should be completed by the holder of the prequalified product. Include remarks as a footnote to Table A1.1, where deemed necessary, to clarify the information provided.\n\n**Table A1.1**\n\n### Summary of key product information\n\n| Item | Prequalified dossier | Current data |\n| - | - | - |\n| Product number (e.g. HA001) | | |\n| INN, strength and pharmaceutical form | | |\n| Applicant (name, physical address and contact numbers) | | |\n| Manufacturing site(s) of FPP, with physical address (including unit and block numbers) and contact numbers (list separately if different steps are performed by different sites, e.g. packaging, quality control) | | |\n| Batch size(s) of FPP | | |\n| Product description (visual appearance) | | |\n| Primary and secondary packaging material(s) and pack size(s) | | |\n| Storage conditions of FPP | | |\n| Shelf-life of FPP | | |\n| FPP specification(s) reference number and/or versionb | | |\n| Manufacturer(s) of API(s), with physical address (including unit and block numbers) and contact numbers (list each API separately) | | |\n| Number/version of each APIMF associated with the FPP | | |\n| Storage conditions of API | | |\n| Retest period of API(s) | | |\n| API specification(s) reference number and/or version (for each API)b | | |\n| All commitments and their outcomes | | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "8f6c3e0f0ce5d2a31e23fba145ea02c742069f8e3758555045e3409ac8051fcb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Appendix 1\n\n## Summary of key product information\n\nThis section compares key information on the FPP at the time of prequalification and at the time of the submission for requalification. Table A1.1 should be completed by the holder of the prequalified product. Include remarks as a footnote to Table A1.1, where deemed necessary, to clarify the information provided.\n\n**Table A1.1**\n\n### Summary of key product information\n\n| Item | Prequalified dossier | Current data |\n| - | - | - |\n| Product number (e.g. HA001) | | |\n| INN, strength and pharmaceutical form | | |\n| Applicant (name, physical address and contact numbers) | | |\n| Manufacturing site(s) of FPP, with physical address (including unit and block numbers) and contact numbers (list separately if different steps are performed by different sites, e.g. packaging, quality control) | | |\n| Batch size(s) of FPP | | |\n| Product description (visual appearance) | | |\n| Primary and secondary packaging material(s) and pack size(s) | | |\n| Storage conditions of FPP | | |\n| Shelf-life of FPP | | |\n| FPP specification(s) reference number and/or versionb | | |\n| Manufacturer(s) of API(s), with physical address (including unit and block numbers) and contact numbers (list each API separately) | | |\n| Number/version of each APIMF associated with the FPP | | |\n| Storage conditions of API | | |\n| Retest period of API(s) | | |\n| API specification(s) reference number and/or version (for each API)b | | |\n| All commitments and their outcomes | | |", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1503, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "58a09cb7-ac05-476c-bef9-1200bd488e0e": {"__data__": {"id_": "58a09cb7-ac05-476c-bef9-1200bd488e0e", "embedding": null, "metadata": {"page_label": "283", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Dado el contexto proporcionado sobre el documento \"WHO - Technical Report Series 957\", aqu\u00ed tienes tres preguntas que podr\u00edan proporcionar respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el Informe T\u00e9cnico de la OMS, Serie 957?**\n   - Esta pregunta busca obtener informaci\u00f3n detallada sobre el contenido espec\u00edfico del informe, que podr\u00eda no estar disponible en otras fuentes.\n\n2. **\u00bfQu\u00e9 temas de salud p\u00fablica se abordan en el documento y c\u00f3mo se relacionan con las pol\u00edticas actuales de la OMS?**\n   - Esta pregunta se centra en la relevancia del informe en el contexto de las pol\u00edticas de salud p\u00fablica, lo que podr\u00eda ofrecer una perspectiva \u00fanica sobre su impacto.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas se utilizaron para recopilar y analizar los datos presentados en el Informe T\u00e9cnico de la OMS, Serie 957?**\n   - Esta pregunta busca profundizar en los m\u00e9todos de investigaci\u00f3n utilizados en el informe, lo que podr\u00eda no estar ampliamente discutido en otras publicaciones.\n\n### Resumen de nivel superior del contexto circundante:\nEl \"WHO - Technical Report Series 957\" es un documento t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud que probablemente aborda temas relevantes en el \u00e1mbito de la salud p\u00fablica, incluyendo recomendaciones, hallazgos de investigaciones y metodolog\u00edas utilizadas para la recopilaci\u00f3n de datos. Este tipo de informes son cruciales para informar pol\u00edticas y pr\u00e1cticas en salud a nivel global.", "prev_section_summary": "### Resumen de temas clave y entidades\n\nLa secci\u00f3n proporcionada es un extracto del documento \"WHO - Technical Report Series 957\" y se centra en la recopilaci\u00f3n y comparaci\u00f3n de informaci\u00f3n clave sobre productos farmac\u00e9uticos precalificados. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas clave:\n1. **Precalificaci\u00f3n y Revalidaci\u00f3n**: La secci\u00f3n aborda la importancia de comparar la informaci\u00f3n del expediente precalificado con los datos actuales en el momento de la revalidaci\u00f3n del producto.\n2. **Tabla A1.1**: Se presenta una tabla que debe ser completada por el titular del producto, que incluye diversos aspectos del producto farmac\u00e9utico y sus ingredientes activos.\n3. **Informaci\u00f3n del Producto**: La tabla incluye detalles como el n\u00famero de producto, forma farmac\u00e9utica, solicitante, sitios de fabricaci\u00f3n, condiciones de almacenamiento, vida \u00fatil, especificaciones, y compromisos asociados.\n4. **Compromisos y Resultados**: Se menciona la necesidad de incluir todos los compromisos y sus resultados, lo que implica un seguimiento de las obligaciones asumidas por el titular del producto.\n\n#### Entidades:\n- **FPP (Forma Farmac\u00e9utica del Producto)**: Se refiere al producto farmac\u00e9utico que est\u00e1 siendo evaluado.\n- **INN (Nombre Com\u00fan Internacional)**: Se refiere al nombre gen\u00e9rico del medicamento.\n- **API (Ingrediente Activo Farmac\u00e9utico)**: Sustancia activa que se utiliza en la fabricaci\u00f3n del FPP.\n- **Solicitante**: Entidad o persona que presenta el expediente para la precalificaci\u00f3n o revalidaci\u00f3n del producto.\n- **Sitios de fabricaci\u00f3n**: Lugares donde se produce el FPP, que deben ser detallados con direcciones f\u00edsicas y n\u00fameros de contacto.\n\nEste resumen destaca la estructura y el prop\u00f3sito de la secci\u00f3n, as\u00ed como los elementos esenciales que deben ser considerados en el proceso de precalificaci\u00f3n y revalidaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: precalificaci\u00f3n, revalidaci\u00f3n, productos farmac\u00e9uticos, metodolog\u00eda, salud p\u00fablica"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d865e322-2e33-4047-9bb9-0767496ee1f4", "node_type": "4", "metadata": {"page_label": "283", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f8b5b1cf-b3a3-4c9c-b5f8-0f3be0b40929": {"__data__": {"id_": "f8b5b1cf-b3a3-4c9c-b5f8-0f3be0b40929", "embedding": null, "metadata": {"page_label": "284", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 2\n\n## Variations to the product\n\nThe holder of the prequalified product should submit a review, in tabular format, of any minor and/or major changes (including those pending) to the initially prequalified product or to the terms of the initially prequalified dossier. Table A2.1 should be completed by the holder of the prequalified product.\n\n**Table A2.1**\n\nInformation on variations to the prequalified product\n\n| Reference no. | Date of submission | Date of approval/ rejection and reference number of the letter | Date of implementation |\n| - | - | - | - |\n| **Major changes** | | | |\n| Description of the change, e.g. change in the primary packaging site of a sterile product | | | |\n| **Minor changes** | | | |\n| Description of the change according to the PQ variation guide | | | |\n\n\nAdd as many rows as necessary.\n\nNote. Requests for variations should have been submitted in accordance with WHO's Guidance on variations to a prequalified product dossier<sup>4</sup>.\n\n----\n\n<sup>4</sup> WHO Guidance on variations to a prequalified product dossier. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report. Geneva, World Health Organization, 2007, Annex 6 (WHO Technical Report Series, No. 943) (http://apps.who.int/prequal/info_general/documents/TRS943/TRS943.pdf#page=121).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es un ap\u00e9ndice del Informe T\u00e9cnico de la OMS (WHO - Technical Report Series 957) que se centra en las variaciones de productos farmac\u00e9uticos precalificados. Se establece que el titular del producto debe presentar una revisi\u00f3n de cualquier cambio menor o mayor en un formato tabular. Se incluye una tabla (Tabla A2.1) donde se deben registrar los detalles de las variaciones, como el n\u00famero de referencia, fechas de presentaci\u00f3n y aprobaci\u00f3n, y la descripci\u00f3n de los cambios. Adem\u00e1s, se menciona que las solicitudes de variaciones deben seguir la gu\u00eda de la OMS sobre este tema.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de cambios deben ser reportados en la Tabla A2.1 y c\u00f3mo se diferencian entre s\u00ed?**\n   - La tabla debe incluir tanto cambios mayores, como un cambio en el sitio de empaquetado primario de un producto est\u00e9ril, como cambios menores, que deben describirse de acuerdo con la gu\u00eda de variaciones de la OMS.\n\n2. **\u00bfCu\u00e1l es el procedimiento que debe seguir el titular del producto para solicitar variaciones seg\u00fan la OMS?**\n   - Las solicitudes de variaciones deben ser presentadas de acuerdo con la \"Gu\u00eda de la OMS sobre variaciones a un expediente de producto precalificado\", lo que implica seguir un proceso espec\u00edfico que no se detalla en el contexto, pero que se menciona como un requisito.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n adicional se puede incluir en la Tabla A2.1 si es necesario?**\n   - Se indica que se pueden agregar tantas filas como sea necesario en la tabla para registrar m\u00faltiples variaciones, lo que sugiere que no hay un l\u00edmite en la cantidad de cambios que se pueden documentar, siempre que se sigan las pautas establecidas.", "prev_section_summary": "El documento \"WHO - Technical Report Series 957\" de la Organizaci\u00f3n Mundial de la Salud (OMS) aborda temas relevantes en el \u00e1mbito de la salud p\u00fablica. Aunque no se proporciona contenido espec\u00edfico en el extracto, se pueden inferir algunos temas clave y entidades relacionadas:\n\n1. **Hallazgos y Recomendaciones**: El informe presenta hallazgos significativos y recomendaciones que son cruciales para la salud p\u00fablica a nivel global.\n\n2. **Temas de Salud P\u00fablica**: Se abordan diversos temas de salud p\u00fablica que son relevantes para las pol\u00edticas actuales de la OMS, lo que sugiere un enfoque en la mejora de la salud a nivel mundial.\n\n3. **Metodolog\u00edas de Investigaci\u00f3n**: Se discuten las metodolog\u00edas utilizadas para la recopilaci\u00f3n y an\u00e1lisis de datos, lo que es fundamental para la validez y aplicabilidad de los hallazgos presentados.\n\nEn resumen, el informe es un recurso importante para informar pol\u00edticas y pr\u00e1cticas en salud, destacando la relevancia de la investigaci\u00f3n y las recomendaciones de la OMS en el contexto de la salud p\u00fablica global.", "excerpt_keywords": "Keywords: variations, prequalified product, WHO guidelines, pharmaceutical changes, product dossier"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "13b47a2f-455c-48f6-bc40-7effe19ec310", "node_type": "4", "metadata": {"page_label": "284", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 2\n\n## Variations to the product\n\nThe holder of the prequalified product should submit a review, in tabular format, of any minor and/or major changes (including those pending) to the initially prequalified product or to the terms of the initially prequalified dossier. Table A2.1 should be completed by the holder of the prequalified product.\n\n**Table A2.1**\n\nInformation on variations to the prequalified product\n\n| Reference no. | Date of submission | Date of approval/ rejection and reference number of the letter | Date of implementation |\n| - | - | - | - |\n| **Major changes** | | | |\n| Description of the change, e.g. change in the primary packaging site of a sterile product | | | |\n| **Minor changes** | | | |\n| Description of the change according to the PQ variation guide | | | |\n\n\nAdd as many rows as necessary.\n\nNote. Requests for variations should have been submitted in accordance with WHO's Guidance on variations to a prequalified product dossier<sup>4</sup>.\n\n----\n\n<sup>4</sup> WHO Guidance on variations to a prequalified product dossier. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report. Geneva, World Health Organization, 2007, Annex 6 (WHO Technical Report Series, No. 943) (http://apps.who.int/prequal/info_general/documents/TRS943/TRS943.pdf#page=121).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "655c7cff96774c90c62f1bbc910b71fc728fb8baa46e6ebe0f16e3c9bf535722", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Appendix 2\n\n## Variations to the product\n\nThe holder of the prequalified product should submit a review, in tabular format, of any minor and/or major changes (including those pending) to the initially prequalified product or to the terms of the initially prequalified dossier. Table A2.1 should be completed by the holder of the prequalified product.\n\n**Table A2.1**\n\nInformation on variations to the prequalified product\n\n| Reference no. | Date of submission | Date of approval/ rejection and reference number of the letter | Date of implementation |\n| - | - | - | - |\n| **Major changes** | | | |\n| Description of the change, e.g. change in the primary packaging site of a sterile product | | | |\n| **Minor changes** | | | |\n| Description of the change according to the PQ variation guide | | | |\n\n\nAdd as many rows as necessary.\n\nNote. Requests for variations should have been submitted in accordance with WHO's Guidance on variations to a prequalified product dossier<sup>4</sup>.\n\n----\n\n<sup>4</sup> WHO Guidance on variations to a prequalified product dossier. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report. Geneva, World Health Organization, 2007, Annex 6 (WHO Technical Report Series, No. 943) (http://apps.who.int/prequal/info_general/documents/TRS943/TRS943.pdf#page=121).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1332, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b54bb733-80a3-48d6-b143-381cd354c7ae": {"__data__": {"id_": "b54bb733-80a3-48d6-b143-381cd354c7ae", "embedding": null, "metadata": {"page_label": "285", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 7\n\n## Guidelines for the preparation of a contract research organization master file\n\n### Background\n\n1. General information\n2. Quality management system of the contract research organization\n3. Personnel\n4. Ethics committee\n5. Computer systems\n6. Equipment and instruments\n7. Documentation\n8. Safety monitoring\n9. Investigational medicinal products and comparator products\n10. Pathology\n11. Bioanalytical laboratory\n12. Biostatistics\n13. Study volunteers\n14. Other information", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que pueden ser respondidas por el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 957\" incluye una secci\u00f3n titulada \"Anexo 7\", que proporciona directrices para la preparaci\u00f3n de un archivo maestro de organizaciones de investigaci\u00f3n por contrato (CRO). Este anexo abarca diversos aspectos esenciales que deben considerarse al establecer un archivo maestro, incluyendo informaci\u00f3n general, sistemas de gesti\u00f3n de calidad, personal, comit\u00e9s de \u00e9tica, sistemas inform\u00e1ticos, equipos, documentaci\u00f3n, monitoreo de seguridad, productos medicinales en investigaci\u00f3n, patolog\u00eda, laboratorios bioanal\u00edticos, bioestad\u00edstica, voluntarios de estudio y otra informaci\u00f3n relevante.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 elementos espec\u00edficos se deben incluir en la secci\u00f3n de \"Documentaci\u00f3n\" del archivo maestro de una organizaci\u00f3n de investigaci\u00f3n por contrato seg\u00fan las directrices?**\n   - Esta pregunta busca detalles sobre los tipos de documentos y registros que son necesarios para cumplir con las normativas establecidas.\n\n2. **\u00bfCu\u00e1les son los requisitos para el \"Sistema de gesti\u00f3n de calidad\" que debe tener una organizaci\u00f3n de investigaci\u00f3n por contrato, seg\u00fan el anexo?**\n   - Esta pregunta se centra en los est\u00e1ndares y procedimientos que una CRO debe implementar para asegurar la calidad en sus operaciones.\n\n3. **\u00bfQu\u00e9 consideraciones \u00e9ticas se deben tener en cuenta al establecer un \"Comit\u00e9 de \u00e9tica\" en el contexto de un archivo maestro de CRO?**\n   - Esta pregunta indaga sobre los principios y pr\u00e1cticas que deben guiar la formaci\u00f3n y funcionamiento de un comit\u00e9 de \u00e9tica en la investigaci\u00f3n cl\u00ednica. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que probablemente no se encuentre f\u00e1cilmente en otros documentos o fuentes.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Variaciones de productos farmac\u00e9uticos**: La secci\u00f3n se centra en la necesidad de reportar cambios menores y mayores en productos farmac\u00e9uticos precalificados.\n\n2. **Responsabilidad del titular del producto**: El titular del producto precalificado es responsable de presentar una revisi\u00f3n de las variaciones en un formato tabular.\n\n3. **Tabla A2.1**: Se proporciona un formato espec\u00edfico (Tabla A2.1) para documentar las variaciones, que incluye columnas para el n\u00famero de referencia, fechas de presentaci\u00f3n, aprobaci\u00f3n/rechazo y descripci\u00f3n de los cambios.\n\n4. **Tipos de cambios**:\n   - **Cambios mayores**: Ejemplo dado es el cambio en el sitio de empaquetado primario de un producto est\u00e9ril.\n   - **Cambios menores**: Deben describirse de acuerdo con la gu\u00eda de variaciones de la OMS.\n\n5. **Gu\u00eda de la OMS**: Se menciona que las solicitudes de variaciones deben seguir la \"Gu\u00eda de la OMS sobre variaciones a un expediente de producto precalificado\".\n\n6. **Flexibilidad en la documentaci\u00f3n**: Se permite agregar tantas filas como sea necesario en la tabla para registrar m\u00faltiples variaciones.\n\n### Entidades\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la gu\u00eda y regulaci\u00f3n de productos farmac\u00e9uticos.\n- **Tabla A2.1**: Herramienta para la documentaci\u00f3n de variaciones.\n- **Productos farmac\u00e9uticos precalificados**: Productos que cumplen con los est\u00e1ndares de calidad establecidos por la OMS.", "excerpt_keywords": "Keywords: contract research organization, master file, quality management, ethics committee, investigational products"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7d150a0a-1e0f-4615-bb63-fcf1a1be0218", "node_type": "4", "metadata": {"page_label": "285", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 7\n\n## Guidelines for the preparation of a contract research organization master file\n\n### Background\n\n1. General information\n2. Quality management system of the contract research organization\n3. Personnel\n4. Ethics committee\n5. Computer systems\n6. Equipment and instruments\n7. Documentation\n8. Safety monitoring\n9. Investigational medicinal products and comparator products\n10. Pathology\n11. Bioanalytical laboratory\n12. Biostatistics\n13. Study volunteers\n14. Other information", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "3a2f191d7d4dd93c4454cfa8b91a92b6aef99f573b372b50b418376ff7ae34eb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 7\n\n## Guidelines for the preparation of a contract research organization master file\n\n### Background\n\n1. General information\n2. Quality management system of the contract research organization\n3. Personnel\n4. Ethics committee\n5. Computer systems\n6. Equipment and instruments\n7. Documentation\n8. Safety monitoring\n9. Investigational medicinal products and comparator products\n10. Pathology\n11. Bioanalytical laboratory\n12. Biostatistics\n13. Study volunteers\n14. Other information", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 485, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6da9d396-97e2-470c-ac2d-c6b53d97242b": {"__data__": {"id_": "6da9d396-97e2-470c-ac2d-c6b53d97242b", "embedding": null, "metadata": {"page_label": "286", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Background\n\nA contract research organization master file (CROMF) is a document prepared by the contract research organization (CRO) containing specific and factual information about the CRO and the conduct of clinical studies as well as the analyses of samples and related operations (including clinical trials, clinical data management, pharmacokinetics and statistical analysis and regulatory affairs) carried out at the named site. If only some of the operations referred to below are carried out at the site, the master file (MF) needs to be presented only for those operations.\n\nIn a case where a CRO is responsible for activities pertaining only to bioanalytical procedures, then only sections in the CROMF relating to these should be described. Other sections may be marked as \u201cnot applicable\u201d.\n\nWhere a CRO performs various activities, separate sections could be prepared for the different units, e.g. clinical pharmacology unit (CPU) and bioanalytical laboratory (BAL).\n\nA CROMF provides information on the policies, approach and general activities of a CRO. It is not trial-specific as trial-specific data are submitted in a product dossier. It serves as general information to regulators and can be used during preparation for inspections by regulatory inspectors in addition to the trial-specific data and information submitted for assessment. It also provides an overview of the organization\u2019s approach to good clinical practices (GCP), good laboratory practices (GLP) and other guidelines pertaining to its activities.\n\nA CROMF should be submitted to the national medicines regulatory authority (NMRA) where such a document is requested. It should be succinct and as far as possible not exceed 25 A4 pages (where appropriate, supportive documentation may be appended).\n\nAn updated CROMF should be submitted when requested by the NMRA, or if significant changes have been implemented by the CRO.\n\n## 1. General information\n\n1.1 Name and exact address of the CRO, including telephone, fax, 24-hour telephone numbers and e-mail address\n\n1.2 Short description of the CRO (including size, location, number of beds, layout and plan, areas for handling samples and waste)\n\n1.3 Activities as licensed/authorized by the national authority\n\n1.4 Inspections and approvals", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en un CROMF si un CRO solo realiza procedimientos bioanal\u00edticos?**\n   - Respuesta: En este caso, el CROMF debe describir \u00fanicamente las secciones relacionadas con los procedimientos bioanal\u00edticos, mientras que otras secciones pueden ser marcadas como \"no aplicable\".\n\n2. **\u00bfCu\u00e1l es la longitud m\u00e1xima recomendada para un CROMF y qu\u00e9 tipo de documentaci\u00f3n adicional puede incluirse?**\n   - Respuesta: Un CROMF debe ser sucinto y no exceder las 25 p\u00e1ginas A4. Se puede incluir documentaci\u00f3n de apoyo como ap\u00e9ndices si es apropiado.\n\n3. **\u00bfCu\u00e1ndo debe un CRO actualizar y presentar su CROMF a la autoridad reguladora nacional de medicamentos (NMRA)?**\n   - Respuesta: Un CRO debe presentar un CROMF actualizado cuando lo solicite la NMRA o si se han implementado cambios significativos en las operaciones del CRO.\n\n### Resumen de nivel superior del contexto:\nEl contexto describe el prop\u00f3sito y los requisitos de un archivo maestro de organizaci\u00f3n de investigaci\u00f3n por contrato (CROMF), que es un documento que proporciona informaci\u00f3n espec\u00edfica sobre las actividades de un CRO y su cumplimiento con las buenas pr\u00e1cticas cl\u00ednicas y de laboratorio. Se detalla la informaci\u00f3n que debe incluirse, la longitud m\u00e1xima del documento y las circunstancias bajo las cuales debe ser actualizado y presentado a las autoridades reguladoras.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\nLa secci\u00f3n \"Anexo 7\" del documento \"WHO - Technical Report Series 957\" se centra en las directrices para la preparaci\u00f3n de un archivo maestro de organizaciones de investigaci\u00f3n por contrato (CRO). Los temas clave abordados en esta secci\u00f3n incluyen:\n\n1. **Informaci\u00f3n General**: Proporciona un contexto b\u00e1sico sobre la organizaci\u00f3n y su funcionamiento.\n2. **Sistema de Gesti\u00f3n de Calidad**: Detalla los est\u00e1ndares y procedimientos necesarios para asegurar la calidad en las operaciones de la CRO.\n3. **Personal**: Describe la importancia del personal calificado y su rol en la investigaci\u00f3n.\n4. **Comit\u00e9 de \u00c9tica**: Establece las consideraciones \u00e9ticas que deben guiar la investigaci\u00f3n y la protecci\u00f3n de los participantes.\n5. **Sistemas Inform\u00e1ticos**: Aborda la infraestructura tecnol\u00f3gica necesaria para la gesti\u00f3n de datos y procesos.\n6. **Equipos e Instrumentos**: Especifica los equipos necesarios para llevar a cabo investigaciones de manera efectiva.\n7. **Documentaci\u00f3n**: Enumera los tipos de documentos y registros requeridos para cumplir con las normativas.\n8. **Monitoreo de Seguridad**: Enfatiza la importancia de la vigilancia de la seguridad de los participantes durante los estudios.\n9. **Productos Medicinales en Investigaci\u00f3n**: Incluye directrices sobre los productos utilizados en los ensayos cl\u00ednicos.\n10. **Patolog\u00eda**: Consideraciones relacionadas con el estudio de enfermedades y condiciones.\n11. **Laboratorio Bioanal\u00edtico**: Detalles sobre los laboratorios que realizan an\u00e1lisis de muestras biol\u00f3gicas.\n12. **Bioestad\u00edstica**: Importancia de la estad\u00edstica en el dise\u00f1o y an\u00e1lisis de estudios cl\u00ednicos.\n13. **Voluntarios de Estudio**: Aspectos relacionados con la selecci\u00f3n y manejo de los participantes en la investigaci\u00f3n.\n14. **Otra Informaci\u00f3n**: Cualquier otro aspecto relevante que no se haya cubierto en las secciones anteriores.\n\nEstos temas son fundamentales para establecer un archivo maestro que cumpla con los est\u00e1ndares internacionales y garantice la integridad y calidad de la investigaci\u00f3n cl\u00ednica.", "excerpt_keywords": "CROMF, CRO, clinical studies, regulatory authority, good clinical practices"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c3aeecc6-fcc5-4d9b-99d2-1a438123200e", "node_type": "4", "metadata": {"page_label": "286", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Background\n\nA contract research organization master file (CROMF) is a document prepared by the contract research organization (CRO) containing specific and factual information about the CRO and the conduct of clinical studies as well as the analyses of samples and related operations (including clinical trials, clinical data management, pharmacokinetics and statistical analysis and regulatory affairs) carried out at the named site. If only some of the operations referred to below are carried out at the site, the master file (MF) needs to be presented only for those operations.\n\nIn a case where a CRO is responsible for activities pertaining only to bioanalytical procedures, then only sections in the CROMF relating to these should be described. Other sections may be marked as \u201cnot applicable\u201d.\n\nWhere a CRO performs various activities, separate sections could be prepared for the different units, e.g. clinical pharmacology unit (CPU) and bioanalytical laboratory (BAL).\n\nA CROMF provides information on the policies, approach and general activities of a CRO. It is not trial-specific as trial-specific data are submitted in a product dossier. It serves as general information to regulators and can be used during preparation for inspections by regulatory inspectors in addition to the trial-specific data and information submitted for assessment. It also provides an overview of the organization\u2019s approach to good clinical practices (GCP), good laboratory practices (GLP) and other guidelines pertaining to its activities.\n\nA CROMF should be submitted to the national medicines regulatory authority (NMRA) where such a document is requested. It should be succinct and as far as possible not exceed 25 A4 pages (where appropriate, supportive documentation may be appended).\n\nAn updated CROMF should be submitted when requested by the NMRA, or if significant changes have been implemented by the CRO.\n\n## 1. General information\n\n1.1 Name and exact address of the CRO, including telephone, fax, 24-hour telephone numbers and e-mail address\n\n1.2 Short description of the CRO (including size, location, number of beds, layout and plan, areas for handling samples and waste)\n\n1.3 Activities as licensed/authorized by the national authority\n\n1.4 Inspections and approvals", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "141fdd0c3736c18c3aeb73aaca519ef7aabc94de6d7f13bf91d38bb719a6b350", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Background\n\nA contract research organization master file (CROMF) is a document prepared by the contract research organization (CRO) containing specific and factual information about the CRO and the conduct of clinical studies as well as the analyses of samples and related operations (including clinical trials, clinical data management, pharmacokinetics and statistical analysis and regulatory affairs) carried out at the named site. If only some of the operations referred to below are carried out at the site, the master file (MF) needs to be presented only for those operations.\n\nIn a case where a CRO is responsible for activities pertaining only to bioanalytical procedures, then only sections in the CROMF relating to these should be described. Other sections may be marked as \u201cnot applicable\u201d.\n\nWhere a CRO performs various activities, separate sections could be prepared for the different units, e.g. clinical pharmacology unit (CPU) and bioanalytical laboratory (BAL).\n\nA CROMF provides information on the policies, approach and general activities of a CRO. It is not trial-specific as trial-specific data are submitted in a product dossier. It serves as general information to regulators and can be used during preparation for inspections by regulatory inspectors in addition to the trial-specific data and information submitted for assessment. It also provides an overview of the organization\u2019s approach to good clinical practices (GCP), good laboratory practices (GLP) and other guidelines pertaining to its activities.\n\nA CROMF should be submitted to the national medicines regulatory authority (NMRA) where such a document is requested. It should be succinct and as far as possible not exceed 25 A4 pages (where appropriate, supportive documentation may be appended).\n\nAn updated CROMF should be submitted when requested by the NMRA, or if significant changes have been implemented by the CRO.\n\n## 1. General information\n\n1.1 Name and exact address of the CRO, including telephone, fax, 24-hour telephone numbers and e-mail address\n\n1.2 Short description of the CRO (including size, location, number of beds, layout and plan, areas for handling samples and waste)\n\n1.3 Activities as licensed/authorized by the national authority\n\n1.4 Inspections and approvals", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2276, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "250c678c-ff1d-4e6e-a99a-5e75c03e2b4a": {"__data__": {"id_": "250c678c-ff1d-4e6e-a99a-5e75c03e2b4a", "embedding": null, "metadata": {"page_label": "287", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 1.4.1 Inspections/approvals/accreditations by any regulatory agency\n\n1.4.2 Audits of subcontractors\n\n1.5 Type of studies (and indications, where appropriate) performed on site (a list of projects conducted at this site may be provided)\n\n1.6 Provisions for insurance\n\n1.6.1 Number of employees engaged in studies, quality, storage and distribution\n\n1.7 Contract services employed\n\n1.7.1 Use of outside scientific, analytical or other technical assistance in relation to studies and analysis (e.g. clinical laboratory, bioanalytical laboratory, X-ray facilities and caterers)\n\n1.7.2 Services outsourced, e.g. contracts with tertiary care hospital for handling of medical emergencies, ambulance facility, nutrition, biomedical waste, chemical waste, caterers, pest control and pathology laboratory\n\n# 2. Quality management system of the contract research organization\n\n(Short description including, e.g. responsibilities of the quality assurance unit. A list of quality system documents can be included)\n\n2.1 Organization chart including the arrangements for quality assurance\n\n2.2 Internal audits and self inspection\n\n2.3 Corrective and preventive action plans (CAPA)\n\n# 3. Personnel\n\n(A brief description can be presented in tabular format)\n\n3.1 Qualifications, experience and responsibilities of key personnel as applicable\n\n3.1.1 project manager\n\n3.1.2 principal investigator\n\n3.1.3 analytical investigator\n\n3.1.4 biostatistician\n\n3.1.5 clinical research associates\n\n3.1.6 data manager", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior del contenido:\n\n### Resumen de Nivel Superior\nEl documento de la OMS, \"Technical Report Series 957\", aborda aspectos clave relacionados con la gesti\u00f3n de organizaciones de investigaci\u00f3n por contrato (CRO). Se enfoca en las inspecciones y aprobaciones por agencias regulatorias, auditor\u00edas de subcontratistas, tipos de estudios realizados, provisiones de seguros, servicios contratados, y el sistema de gesti\u00f3n de calidad de la CRO. Tambi\u00e9n se detalla la organizaci\u00f3n del personal clave, incluyendo sus calificaciones y responsabilidades.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 tipo de estudios se realizan en el sitio y cu\u00e1les son las indicaciones espec\u00edficas para cada uno?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre los proyectos espec\u00edficos que se llevan a cabo en la CRO, lo cual no se detalla en el resumen general.\n\n2. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas del personal clave mencionado, como el gerente de proyecto y el investigador principal?**\n   - Aunque se mencionan los roles, esta pregunta busca una descripci\u00f3n m\u00e1s profunda de las funciones y responsabilidades de cada uno, que podr\u00eda no estar disponible en otras fuentes.\n\n3. **\u00bfQu\u00e9 medidas correctivas y preventivas se implementan en la organizaci\u00f3n para abordar las no conformidades identificadas durante las auditor\u00edas internas?**\n   - Esta pregunta se centra en los planes de acci\u00f3n correctiva y preventiva (CAPA) y busca ejemplos espec\u00edficos de c\u00f3mo la CRO maneja las deficiencias, lo que podr\u00eda no estar ampliamente documentado en otros lugares.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Definici\u00f3n de CROMF**: \n   - El archivo maestro de organizaci\u00f3n de investigaci\u00f3n por contrato (CROMF) es un documento que contiene informaci\u00f3n espec\u00edfica y factual sobre un CRO y sus actividades relacionadas con estudios cl\u00ednicos, an\u00e1lisis de muestras y operaciones relacionadas.\n\n2. **Contenido del CROMF**:\n   - Debe incluir informaci\u00f3n sobre pol\u00edticas, enfoques y actividades generales del CRO, pero no es espec\u00edfico para ensayos cl\u00ednicos.\n   - Secciones espec\u00edficas deben ser presentadas dependiendo de las actividades realizadas en el sitio, como procedimientos bioanal\u00edticos o unidades de farmacolog\u00eda cl\u00ednica.\n\n3. **Requisitos de Presentaci\u00f3n**:\n   - El CROMF debe ser presentado a la autoridad reguladora nacional de medicamentos (NMRA) cuando se solicite.\n   - Debe ser conciso, no excediendo las 25 p\u00e1ginas A4, y puede incluir documentaci\u00f3n de apoyo como ap\u00e9ndices.\n\n4. **Actualizaci\u00f3n del CROMF**:\n   - Debe actualizarse y presentarse nuevamente a la NMRA si se solicitan cambios o si se implementan cambios significativos en las operaciones del CRO.\n\n5. **Informaci\u00f3n General Requerida**:\n   - Nombre y direcci\u00f3n exacta del CRO, incluyendo datos de contacto.\n   - Descripci\u00f3n breve del CRO (tama\u00f1o, ubicaci\u00f3n, capacidad, etc.).\n   - Actividades autorizadas por la autoridad nacional.\n   - Inspecciones y aprobaciones recibidas.\n\n### Entidades Clave\n- **CRO (Organizaci\u00f3n de Investigaci\u00f3n por Contrato)**: Entidad responsable de realizar estudios cl\u00ednicos y an\u00e1lisis.\n- **CROMF (Archivo Maestro de Organizaci\u00f3n de Investigaci\u00f3n por Contrato)**: Documento que detalla las operaciones y pol\u00edticas del CRO.\n- **NMRA (Autoridad Reguladora Nacional de Medicamentos)**: Entidad que solicita y revisa el CROMF.\n- **GCP (Buenas Pr\u00e1cticas Cl\u00ednicas)** y **GLP (Buenas Pr\u00e1cticas de Laboratorio)**: Normativas que gu\u00edan las operaciones del CRO.", "excerpt_keywords": "Keywords: contract research organization, quality management system, audits, personnel qualifications, regulatory inspections"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "301265b8-7434-48b1-bd47-b3bf6af1bebb", "node_type": "4", "metadata": {"page_label": "287", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 1.4.1 Inspections/approvals/accreditations by any regulatory agency\n\n1.4.2 Audits of subcontractors\n\n1.5 Type of studies (and indications, where appropriate) performed on site (a list of projects conducted at this site may be provided)\n\n1.6 Provisions for insurance\n\n1.6.1 Number of employees engaged in studies, quality, storage and distribution\n\n1.7 Contract services employed\n\n1.7.1 Use of outside scientific, analytical or other technical assistance in relation to studies and analysis (e.g. clinical laboratory, bioanalytical laboratory, X-ray facilities and caterers)\n\n1.7.2 Services outsourced, e.g. contracts with tertiary care hospital for handling of medical emergencies, ambulance facility, nutrition, biomedical waste, chemical waste, caterers, pest control and pathology laboratory\n\n# 2. Quality management system of the contract research organization\n\n(Short description including, e.g. responsibilities of the quality assurance unit. A list of quality system documents can be included)\n\n2.1 Organization chart including the arrangements for quality assurance\n\n2.2 Internal audits and self inspection\n\n2.3 Corrective and preventive action plans (CAPA)\n\n# 3. Personnel\n\n(A brief description can be presented in tabular format)\n\n3.1 Qualifications, experience and responsibilities of key personnel as applicable\n\n3.1.1 project manager\n\n3.1.2 principal investigator\n\n3.1.3 analytical investigator\n\n3.1.4 biostatistician\n\n3.1.5 clinical research associates\n\n3.1.6 data manager", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "825aa9dadba25257f132aa5edde7855098f6efbbb72a21fba2dafecb23a6d6f8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 1.4.1 Inspections/approvals/accreditations by any regulatory agency\n\n1.4.2 Audits of subcontractors\n\n1.5 Type of studies (and indications, where appropriate) performed on site (a list of projects conducted at this site may be provided)\n\n1.6 Provisions for insurance\n\n1.6.1 Number of employees engaged in studies, quality, storage and distribution\n\n1.7 Contract services employed\n\n1.7.1 Use of outside scientific, analytical or other technical assistance in relation to studies and analysis (e.g. clinical laboratory, bioanalytical laboratory, X-ray facilities and caterers)\n\n1.7.2 Services outsourced, e.g. contracts with tertiary care hospital for handling of medical emergencies, ambulance facility, nutrition, biomedical waste, chemical waste, caterers, pest control and pathology laboratory\n\n# 2. Quality management system of the contract research organization\n\n(Short description including, e.g. responsibilities of the quality assurance unit. A list of quality system documents can be included)\n\n2.1 Organization chart including the arrangements for quality assurance\n\n2.2 Internal audits and self inspection\n\n2.3 Corrective and preventive action plans (CAPA)\n\n# 3. Personnel\n\n(A brief description can be presented in tabular format)\n\n3.1 Qualifications, experience and responsibilities of key personnel as applicable\n\n3.1.1 project manager\n\n3.1.2 principal investigator\n\n3.1.3 analytical investigator\n\n3.1.4 biostatistician\n\n3.1.5 clinical research associates\n\n3.1.6 data manager", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1488, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a0675d16-7c7e-4a64-9ded-59a6a2e0a84e": {"__data__": {"id_": "a0675d16-7c7e-4a64-9ded-59a6a2e0a84e", "embedding": null, "metadata": {"page_label": "288", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 3.1.7\n- monitor\n\n## 3.1.8\n- the study director(s)\n\n## 3.1.9\n- person responsible for quality assurance\n\n### 3.2 Training of personnel:\n- 3.2.1 training policy and procedure (brief description)\n- 3.2.2 training records\n\n## 4. Ethics committee\n\n### 4.1\n- Constitution and relation to CRO\n\n### 4.2\n- Procedures including review and approval of protocols\n\n## 5. Computer systems\n\n(Short description)\n\n### 5.1\n- Hardware\n\n### 5.2\n- Software (and version number) used (e.g. in the bioanalytical laboratory, in pharmacokinetic and statistical analysis) and change control procedure\n\n### 5.3\n- Data management systems (include a procedural flow chart and a brief description of query generation and resolution)\n\n### 5.4\n- Security procedures\n\n### 5.5\n- Electronic exchange of confidential information\n\n### 5.6\n- Brief description of validation programme\n\n### 5.7\n- Back-up and storage of electronic data\n\n## 6. Equipment and instruments\n\n### 6.1\n- Brief description of major equipment and instruments (a list of equipment is not required)\n\n### 6.2\n- Qualification, maintenance and calibration programme, including the temperature recording systems", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento \"WHO - Technical Report Series 957\" aborda aspectos clave relacionados con la gesti\u00f3n de estudios cl\u00ednicos, incluyendo la formaci\u00f3n del personal, la \u00e9tica en la investigaci\u00f3n, la gesti\u00f3n de sistemas inform\u00e1ticos y el uso de equipos e instrumentos. Se detallan las responsabilidades de los monitores, directores de estudio y personal de aseguramiento de calidad, as\u00ed como la importancia de los comit\u00e9s de \u00e9tica y la gesti\u00f3n de datos electr\u00f3nicos.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas del personal mencionado en la secci\u00f3n 3.1, como los monitores y los directores de estudio?**\n   - Esta pregunta busca obtener detalles sobre las funciones y responsabilidades espec\u00edficas de los monitores y directores de estudio en el contexto de la investigaci\u00f3n cl\u00ednica.\n\n2. **\u00bfQu\u00e9 procedimientos se describen para la formaci\u00f3n del personal en la secci\u00f3n 3.2, y c\u00f3mo se gestionan los registros de formaci\u00f3n?**\n   - Esta pregunta se centra en los procedimientos de formaci\u00f3n y la importancia de mantener registros adecuados, lo que es crucial para garantizar la competencia del personal involucrado en estudios cl\u00ednicos.\n\n3. **\u00bfQu\u00e9 aspectos se consideran en la secci\u00f3n 5.2 sobre el software utilizado en laboratorios bioanal\u00edticos y c\u00f3mo se gestiona el control de cambios?**\n   - Esta pregunta busca profundizar en los detalles sobre el software espec\u00edfico utilizado en el an\u00e1lisis de datos y c\u00f3mo se asegura que cualquier cambio en el software se maneje adecuadamente para mantener la integridad de los datos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Inspecciones y Aprobaciones**\n   - Inspecciones y acreditaciones por agencias regulatorias.\n   - Auditor\u00edas de subcontratistas.\n\n2. **Tipos de Estudios**\n   - Tipos de estudios realizados en el sitio, con posibles indicaciones espec\u00edficas.\n   - Provisi\u00f3n de seguros.\n\n3. **Personal y Recursos**\n   - N\u00famero de empleados involucrados en estudios, calidad, almacenamiento y distribuci\u00f3n.\n   - Servicios contratados y uso de asistencia t\u00e9cnica externa (laboratorios cl\u00ednicos, bioanal\u00edticos, etc.).\n   - Servicios subcontratados, incluyendo emergencias m\u00e9dicas y gesti\u00f3n de residuos.\n\n4. **Sistema de Gesti\u00f3n de Calidad**\n   - Descripci\u00f3n del sistema de gesti\u00f3n de calidad de la organizaci\u00f3n de investigaci\u00f3n por contrato (CRO).\n   - Organigrama y responsabilidades de la unidad de aseguramiento de calidad.\n   - Auditor\u00edas internas y autoinspecciones.\n   - Planes de acci\u00f3n correctiva y preventiva (CAPA).\n\n5. **Personal Clave**\n   - Calificaciones, experiencia y responsabilidades de personal clave, incluyendo:\n     - Gerente de proyecto.\n     - Investigador principal.\n     - Investigador anal\u00edtico.\n     - Bioestad\u00edstico.\n     - Asociados de investigaci\u00f3n cl\u00ednica.\n     - Gerente de datos.\n\nEste resumen destaca los aspectos fundamentales relacionados con la gesti\u00f3n y operaci\u00f3n de organizaciones de investigaci\u00f3n por contrato, as\u00ed como la estructura del personal y los sistemas de calidad implementados.", "excerpt_keywords": "Keywords: clinical research, quality assurance, training procedures, ethics committee, data management systems"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "24fc0c7e-d12e-4f23-94c4-75dbe325b531", "node_type": "4", "metadata": {"page_label": "288", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 3.1.7\n- monitor\n\n## 3.1.8\n- the study director(s)\n\n## 3.1.9\n- person responsible for quality assurance\n\n### 3.2 Training of personnel:\n- 3.2.1 training policy and procedure (brief description)\n- 3.2.2 training records\n\n## 4. Ethics committee\n\n### 4.1\n- Constitution and relation to CRO\n\n### 4.2\n- Procedures including review and approval of protocols\n\n## 5. Computer systems\n\n(Short description)\n\n### 5.1\n- Hardware\n\n### 5.2\n- Software (and version number) used (e.g. in the bioanalytical laboratory, in pharmacokinetic and statistical analysis) and change control procedure\n\n### 5.3\n- Data management systems (include a procedural flow chart and a brief description of query generation and resolution)\n\n### 5.4\n- Security procedures\n\n### 5.5\n- Electronic exchange of confidential information\n\n### 5.6\n- Brief description of validation programme\n\n### 5.7\n- Back-up and storage of electronic data\n\n## 6. Equipment and instruments\n\n### 6.1\n- Brief description of major equipment and instruments (a list of equipment is not required)\n\n### 6.2\n- Qualification, maintenance and calibration programme, including the temperature recording systems", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "446115274fc994edaf0b409cec2cf3ac442d97cafdd6343b428ae2574e592cb7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 3.1.7\n- monitor\n\n## 3.1.8\n- the study director(s)\n\n## 3.1.9\n- person responsible for quality assurance\n\n### 3.2 Training of personnel:\n- 3.2.1 training policy and procedure (brief description)\n- 3.2.2 training records\n\n## 4. Ethics committee\n\n### 4.1\n- Constitution and relation to CRO\n\n### 4.2\n- Procedures including review and approval of protocols\n\n## 5. Computer systems\n\n(Short description)\n\n### 5.1\n- Hardware\n\n### 5.2\n- Software (and version number) used (e.g. in the bioanalytical laboratory, in pharmacokinetic and statistical analysis) and change control procedure\n\n### 5.3\n- Data management systems (include a procedural flow chart and a brief description of query generation and resolution)\n\n### 5.4\n- Security procedures\n\n### 5.5\n- Electronic exchange of confidential information\n\n### 5.6\n- Brief description of validation programme\n\n### 5.7\n- Back-up and storage of electronic data\n\n## 6. Equipment and instruments\n\n### 6.1\n- Brief description of major equipment and instruments (a list of equipment is not required)\n\n### 6.2\n- Qualification, maintenance and calibration programme, including the temperature recording systems", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1142, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "de7f15a5-a44f-4896-81de-c0347f8e1a12": {"__data__": {"id_": "de7f15a5-a44f-4896-81de-c0347f8e1a12", "embedding": null, "metadata": {"page_label": "289", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Documentation\n\n7.1 Briefly describe document management systems\n\n7.2 Project work flow including quality assurance and control process\n\n7.3 Preparation of protocols\n\n7.4 Preparation of informed consent forms and subject information forms\n\n7.5 Preparation of report forms\n\n7.6 Preparation of final report\n\n# Safety monitoring\n\n(Brief description)\n\nAdverse drug reaction reporting procedure\n\nProvisions made for emergencies, including protocols and equipment available\n\n# Investigational medicinal products and comparator products\n\n(Brief description)\n\n9.1 Acquisition, storage, handling, sampling and disposal\n\n9.2 Pharmacy and dispensing\n\n# Pathology\n\n10.1 Biological sample collection and storage\n\n10.2 Handling and analysis of biological samples\n\n# Bioanalytical laboratory\n\n(Brief description)\n\n11.1 Method development and validation\n\n11.2 Reference standard materials used for preparation of calibration standards and quality control samples\n\n11.3 Biological matrix storage, and handling of matrix samples\n\n11.4 Analysis of unknown samples", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a generar mejores preguntas:\n\n### Resumen de nivel superior:\nEl documento se centra en la gesti\u00f3n de la documentaci\u00f3n y los procedimientos relacionados con la investigaci\u00f3n de productos medicinales, incluyendo la preparaci\u00f3n de protocolos, consentimientos informados, y la gesti\u00f3n de muestras biol\u00f3gicas. Tambi\u00e9n aborda la monitorizaci\u00f3n de la seguridad, la gesti\u00f3n de productos investigacionales, y los procesos en laboratorios bioanal\u00edticos.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en un sistema de gesti\u00f3n de documentos para garantizar la calidad y el control en un proyecto de investigaci\u00f3n?**\n   - Esta pregunta se centra en la secci\u00f3n 7.1 sobre sistemas de gesti\u00f3n de documentos y busca detalles espec\u00edficos que no se mencionan expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir para la recolecci\u00f3n y almacenamiento de muestras biol\u00f3gicas seg\u00fan las pautas del documento?**\n   - Esta pregunta se relaciona con las secciones 10.1 y 10.2, y busca informaci\u00f3n detallada sobre las mejores pr\u00e1cticas en la manipulaci\u00f3n de muestras biol\u00f3gicas.\n\n3. **\u00bfQu\u00e9 medidas de emergencia se deben tener en cuenta en el monitoreo de seguridad de los ensayos cl\u00ednicos, y qu\u00e9 protocolos deben estar disponibles?**\n   - Esta pregunta se refiere a la secci\u00f3n sobre monitoreo de seguridad y busca informaci\u00f3n espec\u00edfica sobre los protocolos y equipos necesarios en situaciones de emergencia.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar disponible en otras fuentes, bas\u00e1ndose en el contenido del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n:\n\n1. **Responsabilidades del Personal**:\n   - **Monitores**: Encargados de supervisar el desarrollo del estudio.\n   - **Directores de Estudio**: Responsables de la planificaci\u00f3n y ejecuci\u00f3n del estudio.\n   - **Personal de Aseguramiento de Calidad**: Asegura que se cumplan los est\u00e1ndares de calidad en el estudio.\n\n2. **Formaci\u00f3n del Personal**:\n   - **Pol\u00edtica y Procedimientos de Formaci\u00f3n**: Descripci\u00f3n breve de c\u00f3mo se lleva a cabo la formaci\u00f3n del personal.\n   - **Registros de Formaci\u00f3n**: Importancia de mantener registros adecuados para garantizar la competencia del personal.\n\n3. **Comit\u00e9 de \u00c9tica**:\n   - **Constituci\u00f3n y Relaci\u00f3n con CRO**: Estructura del comit\u00e9 y su relaci\u00f3n con la organizaci\u00f3n de investigaci\u00f3n por contrato (CRO).\n   - **Procedimientos de Revisi\u00f3n y Aprobaci\u00f3n de Protocolos**: Proceso para evaluar y aprobar los protocolos de investigaci\u00f3n.\n\n4. **Sistemas Inform\u00e1ticos**:\n   - **Hardware y Software**: Descripci\u00f3n de los sistemas utilizados, incluyendo el software en laboratorios bioanal\u00edticos y procedimientos de control de cambios.\n   - **Gesti\u00f3n de Datos**: Sistemas de gesti\u00f3n de datos, incluyendo generaci\u00f3n y resoluci\u00f3n de consultas.\n   - **Procedimientos de Seguridad**: Medidas para proteger la informaci\u00f3n confidencial y asegurar la integridad de los datos.\n   - **Programa de Validaci\u00f3n**: Breve descripci\u00f3n de c\u00f3mo se valida el software y los sistemas utilizados.\n   - **Respaldo y Almacenamiento de Datos Electr\u00f3nicos**: Estrategias para asegurar la disponibilidad y seguridad de los datos.\n\n5. **Equipos e Instrumentos**:\n   - **Descripci\u00f3n de Equipos Principales**: Resumen de los equipos utilizados sin necesidad de una lista exhaustiva.\n   - **Programa de Calificaci\u00f3n, Mantenimiento y Calibraci\u00f3n**: Procedimientos para asegurar que los equipos funcionen correctamente, incluyendo sistemas de registro de temperatura.\n\nEste resumen destaca los aspectos fundamentales relacionados con la gesti\u00f3n de estudios cl\u00ednicos, la formaci\u00f3n del personal, la \u00e9tica en la investigaci\u00f3n, la gesti\u00f3n de sistemas inform\u00e1ticos y el uso de equipos e instrumentos.", "excerpt_keywords": "Keywords: document management, safety monitoring, biological samples, investigational products, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5839449d-da40-43c8-88ef-d86b525784d2", "node_type": "4", "metadata": {"page_label": "289", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Documentation\n\n7.1 Briefly describe document management systems\n\n7.2 Project work flow including quality assurance and control process\n\n7.3 Preparation of protocols\n\n7.4 Preparation of informed consent forms and subject information forms\n\n7.5 Preparation of report forms\n\n7.6 Preparation of final report\n\n# Safety monitoring\n\n(Brief description)\n\nAdverse drug reaction reporting procedure\n\nProvisions made for emergencies, including protocols and equipment available\n\n# Investigational medicinal products and comparator products\n\n(Brief description)\n\n9.1 Acquisition, storage, handling, sampling and disposal\n\n9.2 Pharmacy and dispensing\n\n# Pathology\n\n10.1 Biological sample collection and storage\n\n10.2 Handling and analysis of biological samples\n\n# Bioanalytical laboratory\n\n(Brief description)\n\n11.1 Method development and validation\n\n11.2 Reference standard materials used for preparation of calibration standards and quality control samples\n\n11.3 Biological matrix storage, and handling of matrix samples\n\n11.4 Analysis of unknown samples", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "4a79bfa6f64159dec3aa0e22d484b7bb90072beb74f34e670aabdcaa21df54c4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Documentation\n\n7.1 Briefly describe document management systems\n\n7.2 Project work flow including quality assurance and control process\n\n7.3 Preparation of protocols\n\n7.4 Preparation of informed consent forms and subject information forms\n\n7.5 Preparation of report forms\n\n7.6 Preparation of final report\n\n# Safety monitoring\n\n(Brief description)\n\nAdverse drug reaction reporting procedure\n\nProvisions made for emergencies, including protocols and equipment available\n\n# Investigational medicinal products and comparator products\n\n(Brief description)\n\n9.1 Acquisition, storage, handling, sampling and disposal\n\n9.2 Pharmacy and dispensing\n\n# Pathology\n\n10.1 Biological sample collection and storage\n\n10.2 Handling and analysis of biological samples\n\n# Bioanalytical laboratory\n\n(Brief description)\n\n11.1 Method development and validation\n\n11.2 Reference standard materials used for preparation of calibration standards and quality control samples\n\n11.3 Biological matrix storage, and handling of matrix samples\n\n11.4 Analysis of unknown samples", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1045, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "dc289612-2057-40b5-b38a-9dc1d87506ca": {"__data__": {"id_": "dc289612-2057-40b5-b38a-9dc1d87506ca", "embedding": null, "metadata": {"page_label": "290", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 11.5 Preparation and labelling of reagents\n\n## 11.6 Storage of samples\n\n## 11.7 Stability procedures\n\n## 11.8 Waste management\n\n## 12. Biostatistics\n\n### 12.1 Data processing and analysis\n\n### 12.2 Data management\n\n## 13. Study volunteers\n\n### 13.1 Procedure for recruitment\n\n### 13.2 Collecting information on volunteers (e.g. databank), while confidentiality is maintained\n\n### 13.3 Procedure for obtaining informed consent\n\n## 14. Other information\n\n### 14.1 Power supply system \u2014 uninterrupted power supply and generator availability and capacity\n\n### 14.2 Brief description of any other activities performed on site by the CRO\n\n### 14.3 Any other information which the CRO may feel it appropriate to add", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfCu\u00e1les son los procedimientos espec\u00edficos para la preparaci\u00f3n y etiquetado de reactivos seg\u00fan el documento?**\n   - **Respuesta:** El documento menciona un apartado espec\u00edfico (11.5) que trata sobre la preparaci\u00f3n y etiquetado de reactivos, aunque no se proporciona un detalle espec\u00edfico en el texto extra\u00eddo. Para obtener informaci\u00f3n precisa, ser\u00eda necesario consultar el contenido completo de esa secci\u00f3n.\n\n2. **\u00bfQu\u00e9 medidas se describen para garantizar la confidencialidad de la informaci\u00f3n de los voluntarios en el estudio?**\n   - **Respuesta:** En la secci\u00f3n 13.2, se menciona que se debe recopilar informaci\u00f3n sobre los voluntarios (por ejemplo, en una base de datos) mientras se mantiene la confidencialidad. Sin embargo, el texto no detalla las medidas espec\u00edficas que se implementan para asegurar esta confidencialidad.\n\n3. **\u00bfQu\u00e9 tipo de informaci\u00f3n adicional puede incluir el CRO en su informe seg\u00fan el documento?**\n   - **Respuesta:** En la secci\u00f3n 14.3, se indica que el CRO puede agregar cualquier otra informaci\u00f3n que considere apropiada. Esto sugiere que hay flexibilidad para incluir detalles relevantes que no se hayan abordado en las secciones anteriores del informe.\n\n### Resumen de Nivel Superior\n\nEl documento \"WHO - Technical Report Series 957\" aborda varios aspectos relacionados con la preparaci\u00f3n y manejo de reactivos, almacenamiento de muestras, procedimientos de estabilidad y gesti\u00f3n de residuos. Tambi\u00e9n se enfoca en la biostat\u00edstica, incluyendo el procesamiento y gesti\u00f3n de datos, as\u00ed como en la participaci\u00f3n de voluntarios en estudios cl\u00ednicos, destacando la importancia de la confidencialidad y el consentimiento informado. Adem\u00e1s, se menciona la infraestructura necesaria para llevar a cabo estos estudios, como el suministro de energ\u00eda y otras actividades realizadas por la organizaci\u00f3n de investigaci\u00f3n cl\u00ednica (CRO). \n\nEste resumen proporciona un contexto m\u00e1s amplio que puede ayudar a formular preguntas m\u00e1s espec\u00edficas sobre los procedimientos y regulaciones en el \u00e1mbito de la investigaci\u00f3n cl\u00ednica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Gesti\u00f3n de Documentos**:\n   - Sistemas de gesti\u00f3n de documentos (secci\u00f3n 7.1).\n   - Flujo de trabajo del proyecto, incluyendo procesos de aseguramiento y control de calidad (secci\u00f3n 7.2).\n   - Preparaci\u00f3n de protocolos, formularios de consentimiento informado, y formularios de reporte (secciones 7.3, 7.4, 7.5).\n   - Elaboraci\u00f3n del informe final (secci\u00f3n 7.6).\n\n2. **Monitoreo de Seguridad**:\n   - Procedimientos para reportar reacciones adversas a medicamentos.\n   - Provisiones para emergencias, incluyendo protocolos y equipos disponibles.\n\n3. **Productos Medicinales Investigacionales**:\n   - Adquisici\u00f3n, almacenamiento, manejo, muestreo y eliminaci\u00f3n de productos (secci\u00f3n 9.1).\n   - Farmacia y dispensaci\u00f3n de productos (secci\u00f3n 9.2).\n\n4. **Patolog\u00eda**:\n   - Recolecci\u00f3n y almacenamiento de muestras biol\u00f3gicas (secci\u00f3n 10.1).\n   - Manejo y an\u00e1lisis de muestras biol\u00f3gicas (secci\u00f3n 10.2).\n\n5. **Laboratorio Bioanal\u00edtico**:\n   - Desarrollo y validaci\u00f3n de m\u00e9todos (secci\u00f3n 11.1).\n   - Materiales de referencia para la preparaci\u00f3n de est\u00e1ndares de calibraci\u00f3n y muestras de control de calidad (secci\u00f3n 11.2).\n   - Almacenamiento y manejo de muestras biol\u00f3gicas (secci\u00f3n 11.3).\n   - An\u00e1lisis de muestras desconocidas (secci\u00f3n 11.4).\n\n### Entidades Clave:\n- **Documentos**: Protocolos, formularios de consentimiento, informes.\n- **Procedimientos**: Monitoreo de seguridad, manejo de muestras biol\u00f3gicas.\n- **Productos**: Medicamentos investigacionales, productos comparadores.\n- **Laboratorios**: Bioanal\u00edticos, manejo de muestras biol\u00f3gicas.\n\nEste resumen destaca los aspectos fundamentales del documento, proporcionando una visi\u00f3n general de los procesos y procedimientos relacionados con la investigaci\u00f3n de productos medicinales y la gesti\u00f3n de la documentaci\u00f3n asociada.", "excerpt_keywords": "Keywords: reagents, biostatistics, study volunteers, informed consent, waste management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "033cce5e-e57f-4fe6-8b33-d5feedf63acd", "node_type": "4", "metadata": {"page_label": "290", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 11.5 Preparation and labelling of reagents\n\n## 11.6 Storage of samples\n\n## 11.7 Stability procedures\n\n## 11.8 Waste management\n\n## 12. Biostatistics\n\n### 12.1 Data processing and analysis\n\n### 12.2 Data management\n\n## 13. Study volunteers\n\n### 13.1 Procedure for recruitment\n\n### 13.2 Collecting information on volunteers (e.g. databank), while confidentiality is maintained\n\n### 13.3 Procedure for obtaining informed consent\n\n## 14. Other information\n\n### 14.1 Power supply system \u2014 uninterrupted power supply and generator availability and capacity\n\n### 14.2 Brief description of any other activities performed on site by the CRO\n\n### 14.3 Any other information which the CRO may feel it appropriate to add", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "65b54ec6d31a2ac42ddfcb717f30886b3124663dd18dae0bd00546844976c7ce", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 11.5 Preparation and labelling of reagents\n\n## 11.6 Storage of samples\n\n## 11.7 Stability procedures\n\n## 11.8 Waste management\n\n## 12. Biostatistics\n\n### 12.1 Data processing and analysis\n\n### 12.2 Data management\n\n## 13. Study volunteers\n\n### 13.1 Procedure for recruitment\n\n### 13.2 Collecting information on volunteers (e.g. databank), while confidentiality is maintained\n\n### 13.3 Procedure for obtaining informed consent\n\n## 14. Other information\n\n### 14.1 Power supply system \u2014 uninterrupted power supply and generator availability and capacity\n\n### 14.2 Brief description of any other activities performed on site by the CRO\n\n### 14.3 Any other information which the CRO may feel it appropriate to add", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 711, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e85ba49d-b17c-4409-88a9-f60f3c46b956": {"__data__": {"id_": "e85ba49d-b17c-4409-88a9-f60f3c46b956", "embedding": null, "metadata": {"page_label": "291", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# SELECTED WHO PUBLICATIONS OF RELATED INTEREST\n\n**The International Pharmacopoeia, fourth edition.**  \nVolume 1: general notices; monographs for pharmaceutical substances (A\u2013O)  \nVolume 2: monographs for pharmaceutical substances (P\u2013Z); monographs for dosage forms and radiopharmaceutical preparations; methods of analysis; reagents.  \n2006 (1500 pages), also available in CD-ROM format and online  \nFirst supplement: general notices; monographs for pharmaceutical substances; monographs for dosage forms; general and specific monographs; methods of analysis; International Chemical Reference Substances; International Infrared Reference Spectra; reagents, test solutions and volumetric solutions.  \n2008 (309 pages), also available in CD-ROM format and online  \n\n**Basic tests for drugs: pharmaceutical substances, medicinal plant materials and dosage forms**  \n1998 (94 pages)  \n\n**Basic tests for pharmaceutical dosage forms**  \n1991 (134 pages)  \n\n**Quality Assurance of Pharmaceuticals: a compendium of guidelines and related materials**  \nVolume 1: 1997 (244 pages)  \nVolume 2: good manufacturing practices and inspection.  \nSecond updated edition, 2007 (409 pages)  \nAlso available on: WHO training modules on GMP. A resource and study pack for trainers, 2007 (CD-ROM).  \n\n**WHO Expert Committee on Specifications for Pharmaceutical Preparations**  \nForty-third report.  \nWHO Technical Report Series, No. 953, 2009 (161 pages)  \n\n**International nonproprietary names (INN) for pharmaceutical substances**  \nCumulative list no. 13  \n2010 (available in CD-ROM format only)  \n\n**The selection and use of essential medicines**  \nReport of the WHO Expert Committee (including the 16th WHO Model List of Essential Medicines and the 2nd WHO Model List for Children).  \nWHO Technical Report Series, No. 958, 2010 (174 pages)  \n\n**WHO Expert Committee on Biological Standardization**  \nFifty-sixth report.  \nWHO Technical Report Series, No. 941, 2007 (340 pages)  \n\n----\n\nFurther information on these and other WHO publications can be obtained from  \nWHO Press, World Health Organization, 1211 Geneva 27, Switzerland  \n(tel. +41 22 791 3264; fax: +41 22 791 4857;  \ne-mail: bookorders@who.int; order online: http://www.who.int/bookorders)", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento presenta una lista de publicaciones seleccionadas de la Organizaci\u00f3n Mundial de la Salud (OMS) relacionadas con la farmacolog\u00eda y la calidad de los medicamentos. Incluye t\u00edtulos de la Farmacopea Internacional, pruebas b\u00e1sicas para sustancias farmac\u00e9uticas, gu\u00edas sobre aseguramiento de calidad, y reportes de comit\u00e9s expertos de la OMS. Tambi\u00e9n se proporciona informaci\u00f3n de contacto para obtener m\u00e1s detalles sobre estas publicaciones.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son los vol\u00famenes y el contenido espec\u00edfico de la cuarta edici\u00f3n de la Farmacopea Internacional?**\n   - Esta pregunta busca detalles sobre la estructura y el contenido de la Farmacopea Internacional, que se menciona en el contexto.\n\n2. **\u00bfQu\u00e9 temas se abordan en el segundo volumen de \"Quality Assurance of Pharmaceuticals\"?**\n   - Esta pregunta se centra en el contenido del segundo volumen de la publicaci\u00f3n sobre aseguramiento de calidad, que incluye buenas pr\u00e1cticas de manufactura e inspecci\u00f3n.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n se incluye en la \"Cumulative list no. 13\" de nombres no propietarios internacionales (INN) para sustancias farmac\u00e9uticas?**\n   - Esta pregunta busca aclarar el contenido espec\u00edfico de la lista acumulativa de nombres no propietarios, que es un recurso importante en la identificaci\u00f3n de sustancias farmac\u00e9uticas.\n\n### Resumen de Nivel Superior\nEl documento destaca la importancia de las publicaciones de la OMS en el \u00e1mbito farmac\u00e9utico, proporcionando gu\u00edas y est\u00e1ndares para la calidad y seguridad de los medicamentos. Incluye informaci\u00f3n sobre la Farmacopea Internacional, pruebas b\u00e1sicas para medicamentos, y reportes de comit\u00e9s expertos que ayudan a establecer normas y pr\u00e1cticas en la industria farmac\u00e9utica. Adem\u00e1s, se ofrece informaci\u00f3n de contacto para acceder a estas publicaciones, lo que facilita su consulta por parte de profesionales y organizaciones interesadas en la farmacolog\u00eda.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Preparaci\u00f3n y Etiquetado de Reactivos (Secci\u00f3n 11.5)**:\n   - Procedimientos relacionados con la preparaci\u00f3n y etiquetado de reactivos utilizados en estudios cl\u00ednicos.\n\n2. **Almacenamiento de Muestras (Secci\u00f3n 11.6)**:\n   - Directrices sobre c\u00f3mo almacenar adecuadamente las muestras para asegurar su integridad.\n\n3. **Procedimientos de Estabilidad (Secci\u00f3n 11.7)**:\n   - M\u00e9todos para evaluar y garantizar la estabilidad de los reactivos y muestras a lo largo del tiempo.\n\n4. **Gesti\u00f3n de Residuos (Secci\u00f3n 11.8)**:\n   - Estrategias para la correcta gesti\u00f3n y eliminaci\u00f3n de residuos generados durante los estudios.\n\n5. **Biostat\u00edstica (Secci\u00f3n 12)**:\n   - **Procesamiento y An\u00e1lisis de Datos (12.1)**: M\u00e9todos para analizar los datos recopilados en los estudios.\n   - **Gesti\u00f3n de Datos (12.2)**: Estrategias para manejar y almacenar datos de manera eficiente y segura.\n\n6. **Voluntarios del Estudio (Secci\u00f3n 13)**:\n   - **Procedimiento de Reclutamiento (13.1)**: M\u00e9todos para reclutar participantes para los estudios.\n   - **Recopilaci\u00f3n de Informaci\u00f3n (13.2)**: Proceso para recoger datos de los voluntarios manteniendo la confidencialidad.\n   - **Consentimiento Informado (13.3)**: Procedimientos para obtener el consentimiento de los voluntarios para participar en el estudio.\n\n7. **Otra Informaci\u00f3n (Secci\u00f3n 14)**:\n   - **Sistema de Suministro de Energ\u00eda (14.1)**: Disponibilidad y capacidad de sistemas de energ\u00eda ininterrumpida y generadores.\n   - **Actividades del CRO (14.2)**: Descripci\u00f3n breve de otras actividades realizadas por la organizaci\u00f3n de investigaci\u00f3n cl\u00ednica en el sitio.\n   - **Informaci\u00f3n Adicional (14.3)**: Oportunidad para que el CRO incluya informaci\u00f3n relevante que considere apropiada.\n\n### Entidades Clave\n- **CRO (Organizaci\u00f3n de Investigaci\u00f3n Cl\u00ednica)**: Entidad responsable de llevar a cabo estudios cl\u00ednicos.\n- **Voluntarios**: Participantes en los estudios cl\u00ednicos.\n- **Reactivos y Muestras**: Elementos utilizados en la investigaci\u00f3n que requieren manejo y almacenamiento adecuados.\n- **Datos**: Informaci\u00f3n recopilada durante los estudios que necesita ser procesada y gestionada. \n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades clave abordados en la secci\u00f3n del documento, destacando la importancia de los procedimientos y regulaciones en la investigaci\u00f3n cl\u00ednica.", "excerpt_keywords": "Keywords: WHO, pharmacopoeia, quality assurance, essential medicines, pharmaceutical standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1ca0d09a-c56a-4e41-bea4-fb6b3a8ce3ef", "node_type": "4", "metadata": {"page_label": "291", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# SELECTED WHO PUBLICATIONS OF RELATED INTEREST\n\n**The International Pharmacopoeia, fourth edition.**  \nVolume 1: general notices; monographs for pharmaceutical substances (A\u2013O)  \nVolume 2: monographs for pharmaceutical substances (P\u2013Z); monographs for dosage forms and radiopharmaceutical preparations; methods of analysis; reagents.  \n2006 (1500 pages), also available in CD-ROM format and online  \nFirst supplement: general notices; monographs for pharmaceutical substances; monographs for dosage forms; general and specific monographs; methods of analysis; International Chemical Reference Substances; International Infrared Reference Spectra; reagents, test solutions and volumetric solutions.  \n2008 (309 pages), also available in CD-ROM format and online  \n\n**Basic tests for drugs: pharmaceutical substances, medicinal plant materials and dosage forms**  \n1998 (94 pages)  \n\n**Basic tests for pharmaceutical dosage forms**  \n1991 (134 pages)  \n\n**Quality Assurance of Pharmaceuticals: a compendium of guidelines and related materials**  \nVolume 1: 1997 (244 pages)  \nVolume 2: good manufacturing practices and inspection.  \nSecond updated edition, 2007 (409 pages)  \nAlso available on: WHO training modules on GMP. A resource and study pack for trainers, 2007 (CD-ROM).  \n\n**WHO Expert Committee on Specifications for Pharmaceutical Preparations**  \nForty-third report.  \nWHO Technical Report Series, No. 953, 2009 (161 pages)  \n\n**International nonproprietary names (INN) for pharmaceutical substances**  \nCumulative list no. 13  \n2010 (available in CD-ROM format only)  \n\n**The selection and use of essential medicines**  \nReport of the WHO Expert Committee (including the 16th WHO Model List of Essential Medicines and the 2nd WHO Model List for Children).  \nWHO Technical Report Series, No. 958, 2010 (174 pages)  \n\n**WHO Expert Committee on Biological Standardization**  \nFifty-sixth report.  \nWHO Technical Report Series, No. 941, 2007 (340 pages)  \n\n----\n\nFurther information on these and other WHO publications can be obtained from  \nWHO Press, World Health Organization, 1211 Geneva 27, Switzerland  \n(tel. +41 22 791 3264; fax: +41 22 791 4857;  \ne-mail: bookorders@who.int; order online: http://www.who.int/bookorders)", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "deccd03255f59587eb4c97475b3831475eddb04bc519981a9a0892658992c797", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# SELECTED WHO PUBLICATIONS OF RELATED INTEREST\n\n**The International Pharmacopoeia, fourth edition.**  \nVolume 1: general notices; monographs for pharmaceutical substances (A\u2013O)  \nVolume 2: monographs for pharmaceutical substances (P\u2013Z); monographs for dosage forms and radiopharmaceutical preparations; methods of analysis; reagents.  \n2006 (1500 pages), also available in CD-ROM format and online  \nFirst supplement: general notices; monographs for pharmaceutical substances; monographs for dosage forms; general and specific monographs; methods of analysis; International Chemical Reference Substances; International Infrared Reference Spectra; reagents, test solutions and volumetric solutions.  \n2008 (309 pages), also available in CD-ROM format and online  \n\n**Basic tests for drugs: pharmaceutical substances, medicinal plant materials and dosage forms**  \n1998 (94 pages)  \n\n**Basic tests for pharmaceutical dosage forms**  \n1991 (134 pages)  \n\n**Quality Assurance of Pharmaceuticals: a compendium of guidelines and related materials**  \nVolume 1: 1997 (244 pages)  \nVolume 2: good manufacturing practices and inspection.  \nSecond updated edition, 2007 (409 pages)  \nAlso available on: WHO training modules on GMP. A resource and study pack for trainers, 2007 (CD-ROM).  \n\n**WHO Expert Committee on Specifications for Pharmaceutical Preparations**  \nForty-third report.  \nWHO Technical Report Series, No. 953, 2009 (161 pages)  \n\n**International nonproprietary names (INN) for pharmaceutical substances**  \nCumulative list no. 13  \n2010 (available in CD-ROM format only)  \n\n**The selection and use of essential medicines**  \nReport of the WHO Expert Committee (including the 16th WHO Model List of Essential Medicines and the 2nd WHO Model List for Children).  \nWHO Technical Report Series, No. 958, 2010 (174 pages)  \n\n**WHO Expert Committee on Biological Standardization**  \nFifty-sixth report.  \nWHO Technical Report Series, No. 941, 2007 (340 pages)  \n\n----\n\nFurther information on these and other WHO publications can be obtained from  \nWHO Press, World Health Organization, 1211 Geneva 27, Switzerland  \n(tel. +41 22 791 3264; fax: +41 22 791 4857;  \ne-mail: bookorders@who.int; order online: http://www.who.int/bookorders)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2237, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c4104df8-7b79-4f14-9e1f-292e3011b482": {"__data__": {"id_": "c4104df8-7b79-4f14-9e1f-292e3011b482", "embedding": null, "metadata": {"page_label": "292", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee on Specifications for Pharmaceutical Preparations works towards clear, independent and practical standards and guidelines for the quality assurance of medicines. Standards are developed by the Committee through worldwide consultation and an international consensus-building process. The following new guidelines were adopted and recommended for use: good practices for pharmaceutical quality control laboratories; supplementary guidelines for active pharmaceutical ingredients; good manufacturing practices for pharmaceutical products containing hazardous substances; good manufacturing practices for sterile pharmaceutical products; good distribution practices for pharmaceutical products; guidelines on the requalification of prequalified dossiers; and guidelines for the preparation of a contract research organization master file.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS se dedica a establecer est\u00e1ndares y directrices claras, independientes y pr\u00e1cticas para la garant\u00eda de calidad de los medicamentos. Estos est\u00e1ndares se desarrollan a trav\u00e9s de consultas a nivel mundial y un proceso de construcci\u00f3n de consenso internacional. Se han adoptado nuevas directrices que incluyen buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica, directrices suplementarias para ingredientes farmac\u00e9uticos activos, buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos que contienen sustancias peligrosas, buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles, buenas pr\u00e1cticas de distribuci\u00f3n, directrices sobre la revalidaci\u00f3n de expedientes precalificados y directrices para la preparaci\u00f3n de un archivo maestro de organizaciones de investigaci\u00f3n por contrato.\n\n### Preguntas espec\u00edficas\n1. **\u00bfCu\u00e1les son las nuevas directrices adoptadas por el Comit\u00e9 de Expertos para asegurar la calidad de los medicamentos?**\n   - Respuesta: Las nuevas directrices incluyen buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica, directrices suplementarias para ingredientes farmac\u00e9uticos activos, buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos que contienen sustancias peligrosas, buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles, buenas pr\u00e1cticas de distribuci\u00f3n, directrices sobre la revalidaci\u00f3n de expedientes precalificados y directrices para la preparaci\u00f3n de un archivo maestro de organizaciones de investigaci\u00f3n por contrato.\n\n2. **\u00bfC\u00f3mo se desarrollan los est\u00e1ndares y directrices del Comit\u00e9 de Expertos?**\n   - Respuesta: Los est\u00e1ndares se desarrollan a trav\u00e9s de consultas a nivel mundial y un proceso de construcci\u00f3n de consenso internacional.\n\n3. **\u00bfQu\u00e9 importancia tienen las buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles seg\u00fan el Comit\u00e9 de Expertos?**\n   - Respuesta: Las buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles son cruciales para garantizar la calidad y seguridad de los medicamentos que se administran a los pacientes, ya que estos productos deben cumplir con est\u00e1ndares rigurosos para prevenir la contaminaci\u00f3n y asegurar su eficacia.", "prev_section_summary": "La secci\u00f3n presenta una lista de publicaciones seleccionadas de la Organizaci\u00f3n Mundial de la Salud (OMS) que son relevantes para la farmacolog\u00eda y la calidad de los medicamentos. A continuaci\u00f3n se resumen los temas clave y entidades mencionadas:\n\n### Temas Clave:\n1. **Farmacopea Internacional**:\n   - Cuarta edici\u00f3n que incluye dos vol\u00famenes:\n     - **Volumen 1**: Avisos generales y monograf\u00edas para sustancias farmac\u00e9uticas (A\u2013O).\n     - **Volumen 2**: Monograf\u00edas para sustancias farmac\u00e9uticas (P\u2013Z), formas de dosificaci\u00f3n, preparaciones radiofarmac\u00e9uticas, m\u00e9todos de an\u00e1lisis y reactivos.\n   - Primer suplemento que abarca temas similares y se public\u00f3 en 2008.\n\n2. **Pruebas B\u00e1sicas para Medicamentos**:\n   - Publicaciones sobre pruebas para sustancias farmac\u00e9uticas, materiales de plantas medicinales y formas de dosificaci\u00f3n.\n\n3. **Aseguramiento de Calidad de los Productos Farmac\u00e9uticos**:\n   - Compendio de gu\u00edas y materiales relacionados, dividido en dos vol\u00famenes, con un enfoque en buenas pr\u00e1cticas de manufactura e inspecci\u00f3n.\n\n4. **Nombres No Propietarios Internacionales (INN)**:\n   - Lista acumulativa de nombres para sustancias farmac\u00e9uticas, disponible en formato CD-ROM.\n\n5. **Medicamentos Esenciales**:\n   - Informe sobre la selecci\u00f3n y uso de medicamentos esenciales, incluyendo listas modelo para adultos y ni\u00f1os.\n\n6. **Estandarizaci\u00f3n Biol\u00f3gica**:\n   - Reporte del Comit\u00e9 de Expertos de la OMS sobre estandarizaci\u00f3n biol\u00f3gica.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n de los documentos.\n- **WHO Press**: Proveedor de informaci\u00f3n adicional sobre las publicaciones de la OMS.\n- **Comit\u00e9s Expertos de la OMS**: Grupos que elaboran informes y gu\u00edas sobre est\u00e1ndares farmac\u00e9uticos.\n\n### Informaci\u00f3n de Contacto:\n- Se proporciona informaci\u00f3n de contacto para obtener m\u00e1s detalles sobre las publicaciones, incluyendo direcci\u00f3n, tel\u00e9fono, fax y correo electr\u00f3nico.\n\nEste resumen destaca la importancia de las publicaciones de la OMS en la regulaci\u00f3n y aseguramiento de la calidad de los medicamentos a nivel global.", "excerpt_keywords": "Keywords: pharmaceutical preparations, quality assurance, good manufacturing practices, active pharmaceutical ingredients, WHO guidelines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5687ef70-074d-416f-bcee-a5333d81db05", "node_type": "4", "metadata": {"page_label": "292", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee on Specifications for Pharmaceutical Preparations works towards clear, independent and practical standards and guidelines for the quality assurance of medicines. Standards are developed by the Committee through worldwide consultation and an international consensus-building process. The following new guidelines were adopted and recommended for use: good practices for pharmaceutical quality control laboratories; supplementary guidelines for active pharmaceutical ingredients; good manufacturing practices for pharmaceutical products containing hazardous substances; good manufacturing practices for sterile pharmaceutical products; good distribution practices for pharmaceutical products; guidelines on the requalification of prequalified dossiers; and guidelines for the preparation of a contract research organization master file.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957"}, "hash": "53eb46ac26954a94a0ce4f762cc737a4050bf8fa3953d60202151a9be75f5677", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The Expert Committee on Specifications for Pharmaceutical Preparations works towards clear, independent and practical standards and guidelines for the quality assurance of medicines. Standards are developed by the Committee through worldwide consultation and an international consensus-building process. The following new guidelines were adopted and recommended for use: good practices for pharmaceutical quality control laboratories; supplementary guidelines for active pharmaceutical ingredients; good manufacturing practices for pharmaceutical products containing hazardous substances; good manufacturing practices for sterile pharmaceutical products; good distribution practices for pharmaceutical products; guidelines on the requalification of prequalified dossiers; and guidelines for the preparation of a contract research organization master file.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 855, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"4131d99d-1dab-4e76-bcd5-465cf5e89648": {"doc_hash": "917f5c7971d05876b3241e2bac864c5e0ee78cbe07932e5e58fa4562f9f20a95", "ref_doc_id": "e6d5325e-bdd2-47ab-b611-6aa0165f3552"}, "441f993a-a697-4ca8-a84e-800acc7a1abf": {"doc_hash": "2c8a8265d1cee6d7293ffa6d7b705f6fc62d6f4f4754a83c2d918ae4ac47165f", "ref_doc_id": "6c5e5cef-722b-4ab8-aa76-f7735b954206"}, "49eeb952-0fe1-4ced-a73a-c8be3173b2b1": {"doc_hash": "726463990e93a53d665afe9b517fdead73fa8090b4204868ce63f43826d5e7fa", "ref_doc_id": "8d0b0a58-a1d8-4779-a673-b12be1a022ac"}, "19793f11-d73e-435d-9bd8-7a245690f691": {"doc_hash": "46482085bf32b839eee6d47f6d757460388a94fefa4bb7e20e13e366f8e7450b", "ref_doc_id": "12fadc77-0e2f-4907-8a90-9ae6f59152a3"}, "975f072c-b766-4ceb-8b61-0d754f1bf738": {"doc_hash": "97b1a5cc6c9c37199be32a59de8c08c106abb5973337eb438b1e590c4745e222", "ref_doc_id": "30fe9bc0-caf8-4f11-913f-90cc73eec111"}, "28b5a7f5-5d41-4cc9-b27b-137bb0fab6a5": {"doc_hash": "8349bf3107d87ef115dd0d078ba637c7a90236ffeaf31c7a1c315c19bef56a6a", "ref_doc_id": "88e4382f-b126-4d2b-9c9f-e955378d9fc7"}, "e44d2700-8361-410f-934c-6e2571538d92": {"doc_hash": "52fc6db4b13d36a33c5cca86808a95c44eb032ff00b9da95126d84bd018f25d7", "ref_doc_id": "47aac78d-be94-4b90-8b4b-2f99aa8b8076"}, "9bd902b8-e7ab-4a23-bdb3-3c57e121dcd3": {"doc_hash": "39c2fc1e6ff570773ecc231fe99bd907f839cb9130bf1db46e3d59c9615778ed", "ref_doc_id": "08349f13-d674-4036-a85a-d7a48961fa68"}, "e47e63b2-ff77-4698-a998-16a123df9a58": {"doc_hash": "b20c53c5b210239ccd0d09c1415d4cd5f8f33e3d21f676edc0ec1374269bdce0", "ref_doc_id": "25d3a2b3-a6be-42f4-ab0d-fe9ed2f6683a"}, "440ba407-8442-47a4-8cc3-0c76bc6b2cd4": {"doc_hash": "5e108c3fc6f0740c3b37693d094629d84689afbc927f380ef51a3dd685c2ffb4", "ref_doc_id": "fe7e1bf6-2d40-4f41-836d-03b113c308fc"}, "c2e2af33-88e0-4cd4-8262-d193083aa067": {"doc_hash": "a9a67a3996e6c891f6f3fa46e4e501afc3520cf31dd82141af47d137b09b500c", "ref_doc_id": "0d747e08-e8ff-456a-9670-56dc8ad644fa"}, "96c00675-7aa3-4533-8cc9-a15396472145": {"doc_hash": "aaadce40b2648dd4ac15928a9a78238b9c4c80f2c0d3a73f0b88efb24c7f9833", "ref_doc_id": "49a59c58-d1e8-4148-9fd7-49e71261673b"}, "b14c7316-cae3-4f0e-b3f0-af5dba802501": {"doc_hash": "25356311ecd9e58b113db3d3e3ec86f0dc7c6306ea1e2652091572cbc99610d2", "ref_doc_id": "94cc261e-bdb7-458c-9e5f-9365faddca92"}, "f4db7121-a2fb-4802-a501-deac4304a471": {"doc_hash": "24448590c4b04ed9d9819fd2fa2a29e787b0f8ae5e9a4801d715521b91c74131", "ref_doc_id": "522612e1-06f4-4ceb-8ec5-2a2ac80d2293"}, "aa9db07c-9b8d-4ea1-b84a-18001d1da416": {"doc_hash": "73cc5a84e26ee18a9696eb8c173ba42aea4c42eec09dea9a03c369052285648c", "ref_doc_id": "e5083336-2391-4dbc-b0ec-a3aafe747f0c"}, "afd770a7-1670-42e2-97bb-6248c77351f0": {"doc_hash": "a0a98084b3616812c3b1fd5c788a1ce8c7e33b59033f40a4810740fc56195c7f", "ref_doc_id": "4a35c891-6074-4bcd-97d4-e3b03e80f37b"}, "c4d72780-af99-4164-88d0-1467a0095b6c": {"doc_hash": "fdc9599b2f70a30ca4c320776320271a4da61d211da7acb6c3c752a9585adf3d", "ref_doc_id": "4c98a419-c2a9-4730-8ddf-b15994229c43"}, "cd8acc5b-e110-4a6d-a4dd-427c8baca7b0": {"doc_hash": "ec4931aae6da23bb2595070a401521e42c177294302bdf52e49d78af93efbce8", "ref_doc_id": "e21c9cc3-ef40-4e24-a8c5-df6b228b1dd4"}, "f77bfe70-c537-495c-bfba-59725a5427aa": {"doc_hash": "9e826a7275d41cb7dcadf9f95b31ddd6fbc60828cb674469e05c3a0a2762195f", "ref_doc_id": "385c048f-a2ad-4e30-969f-bd120e447119"}, "93c70357-9649-4d5b-a713-cf4485a84ba7": {"doc_hash": "ee0d1a7db3800bad097e468767288eb54d2a09a4f724a151c240243ffb8a9d87", "ref_doc_id": "5c3c32ab-7bed-4a65-a2ed-fbc7676cef35"}, "d5f83f2a-cd16-4ed9-9cab-da42a5eabd27": {"doc_hash": "f4dd6da38ce308c0b03ba9f8a69fbf63436b46708ce5d4d5dc566abd9e603b2a", "ref_doc_id": "0857578a-1422-4604-bd4b-16760b38af8f"}, "bd0c3afd-4869-434a-af6f-edd500fcbe7e": {"doc_hash": "2f2c8c8636df7a9ca432b8e069b35c737d17ab37918f060c6f49f81049326351", "ref_doc_id": "a0805be5-1c94-4b75-a11d-f354764788a5"}, "c919519a-7fe9-404e-b7f9-7e3a5c7e8b24": {"doc_hash": "fd82d08483dc052480b8c728ce089bd17aad6fdf83bc2a51b79d6ffe5ec3ff82", "ref_doc_id": "4beecf06-5053-4535-9689-01bc3a347514"}, "e6af2148-1187-4236-bd27-5f136f4e652c": {"doc_hash": "4439deed28507f0d8fd3e75afb2841986990e59155ec109e97761e6b72abfa2c", "ref_doc_id": "6acc044f-77da-4736-b2b3-2a3b8f8c7675"}, "17dc7703-0f23-46b1-96e3-9dedece5b26c": {"doc_hash": "ead97c10c2f4dfc2cfd5a14edb89c220fff1367ebe80306eec24735aad8aebef", "ref_doc_id": "db950072-3447-4d1d-a12a-77a12d5b4db6"}, "aad558f5-4e79-4c23-866b-850cd9586d04": {"doc_hash": "0a5527bbe63d36f059b1ee4e3d464a0b7ed4d5afa0d89d1fbb95b6f00594e6fa", "ref_doc_id": "91e8ca11-0c1c-45c9-a3f6-c68545ea48d7"}, "e36cdbd6-fa47-4b46-8697-796a3e9ecaf2": {"doc_hash": "b3b0079d190929ee947a056218b71360a7a04fbf8a64fd7bf7209cb0bd7aaa7b", "ref_doc_id": "67fd7f96-5902-4f79-923f-d0c43c5c661e"}, "4bd6ffdd-14a9-4a6b-b13a-454eb5ddf722": {"doc_hash": "7f3b088711e587f0006d4354fa39d69241a19571123fe02a55a568a9c01796f0", "ref_doc_id": "21cc1cb5-2632-45ee-a64f-455cbf4b70c2"}, "bde9f61e-5250-4d6b-af53-a36d083e27ac": {"doc_hash": "3c1f02780c0cb8e70d17aaf654e41dc4716b07a13b44b2fc51e3223ad1550253", "ref_doc_id": "85ed28c2-4805-4e71-a1f6-8a4aba258361"}, "3105dcea-764d-4ebb-9611-4e880c8ebb39": {"doc_hash": "352d409efffbadb0355b2e8ba6ef5d310b1e3131de81a426b926fface46e7d39", "ref_doc_id": "92712337-e490-4bb0-b54f-609cd1cbdb76"}, "70a3e194-5d04-4916-83dd-e2db2a5ad068": {"doc_hash": "7a47a282c20039968e8442a034dda884631a51a72fb47440eee7610bf8c2bd91", "ref_doc_id": "5037ce5a-65e2-406f-9a1e-a7796fb1ae2f"}, "273202dd-e553-4d9c-8f7b-fee4094bfe4b": {"doc_hash": "15adcbd21777cbd7efc38f22eae8befb093deb5e2e169b3fc0d5b20092e3177e", "ref_doc_id": "f5838db8-9e28-4336-a2ee-93f58d1eab6f"}, "733cf228-fea1-4998-bfd2-2f2e70efecbb": {"doc_hash": "58b5dd78d3ec1f07f0fb7fb1b02a3f4bce77d54248c1e1d24fa4f4bc2757a73b", "ref_doc_id": "5ebe0810-6743-4721-86dc-3caed80fbd32"}, "37de6464-5d57-427b-b388-b221010b9fea": {"doc_hash": "23157c7d6c07299127afb741249d67e5f8c442cce66f189c15e7e167169a4fb3", "ref_doc_id": "cb91d4c8-1dc7-484a-b3d1-4f2d7f3bc717"}, "34118b00-f2be-4762-bf8a-c41498c36382": {"doc_hash": "a58aa587f95bd5df6e6dc3a518f7e9baa49d6d8eceafb61a5b664f3db4c66098", "ref_doc_id": "6a0ff450-01e6-4471-9f83-d5fc5e2bafaa"}, "db10bc76-fb51-43bd-bf75-6203cb3fc3b8": {"doc_hash": "ef51154ce072d3e5af7280813b7efe1ca049c8306f16fa62b9d8bb6bab5521c6", "ref_doc_id": "064cb530-5a2f-45ca-8fdc-bed91214aa64"}, "dd261f9c-1c38-48e2-813c-59abf5a135f9": {"doc_hash": "f41d1d08f4e4da07b4dfd3efef4a07109eaadee0d63e8f84b968c9e1335768b5", "ref_doc_id": "6b39cbee-cb27-49aa-a372-08f4779cf3e3"}, "d7133a38-9520-4881-a1ae-9539f72dcda3": {"doc_hash": "f936c17653e659cbb46821bed87ac8f1b87cfe0850c2f273b668839829df16ec", "ref_doc_id": "5c807518-b2b6-4a4a-8bf1-511d04d136e2"}, "213e8ae8-3952-40a1-9a8f-ed3e3ab1390b": {"doc_hash": "46c6e0295dbb400e85dae9f08563e839336d2fd514ec330053e79aea6eb3be62", "ref_doc_id": "0da7133d-ec03-49b0-9e2f-48d601171103"}, "daa9c2b0-6804-4019-af11-4306244f9f19": {"doc_hash": "30a3c2641397dbb440de1f3684880d047f26a6eab86aecabcbc5ce10d2cfa596", "ref_doc_id": "14617eb9-e562-46fc-9561-ff93de8a9ce3"}, "b20ec46d-184a-453b-951d-c4820307a975": {"doc_hash": "4181136224de06b4f3be9510c52e4f4a70f0e9ce89061a4150631b0d338ec516", "ref_doc_id": "4067fc70-6271-4e43-bf82-7b29ea96d965"}, "6abc1c8a-8bae-4d38-b42c-337206c7bfb2": {"doc_hash": "4102faf5809680fb2ff9c248b876cf464671abe18562b64ad5bcc2c5b2fecefb", "ref_doc_id": "0083f1ba-c66b-4d6e-9b21-ac77fb86db8a"}, "4edce5c9-5e69-4366-81bc-89abd1bf1ace": {"doc_hash": "24d2567dfb88894edaacb53bbd0cfc0f8e3d94709dd6deb3fc121c866dc301d6", "ref_doc_id": "804459a6-c96c-4c8a-837e-c55638d56148"}, "9acd9313-4de3-4f9d-8bd7-e1e14949f095": {"doc_hash": "042fbc57709bb6322930babc984cf74c9fdf39b799f39c44d16416c092e7b405", "ref_doc_id": "584416c7-dcca-4b4a-a673-cd90298d7c83"}, "8e0fc01d-8be2-47ed-9481-91c724e6e35d": {"doc_hash": "6749b489129e14ae7fbe6408d49c313ba49d79d1a02024226b1e5d9ef37dc6b9", "ref_doc_id": "700c8bcd-c2f6-4aaf-ba88-e1038a238807"}, "d1a9e091-e658-41fd-92df-188519ad0fe5": {"doc_hash": "53f4ac6b635a9e8731e8a643285fc59945372af6f80307775cb8e36e222df026", "ref_doc_id": "33e87ffe-8582-444e-ac41-074aaf786654"}, "aeebc430-b39f-4112-aac5-9a9378f8df5d": {"doc_hash": "cb98aa23184826176c6dc841fba359a16c57f8db5fd2fffb3cf8681ce3b26f09", "ref_doc_id": "90534af2-e0d8-49e2-bf46-26838d6d81d2"}, "fb96bb01-a277-423a-997d-024afc16c7d8": {"doc_hash": "3fd6149257d2be7424f61a80b57eee8448e5e09ae1d7ea72cdcf1ba8b74a3659", "ref_doc_id": "0ea91eb0-bb6d-46c6-9aea-717ffa55a5ae"}, "01f4bd62-8d7a-438f-8f2f-e485775da3b2": {"doc_hash": "e1114805ee27fe412322457a930e85a3b7fcc2bc29c31f55b5be0b48760d2875", "ref_doc_id": "8e9b646b-c1bc-4491-98b1-eafae0cef6a7"}, "be7c3692-ab40-4f95-b49d-12712f43dd2b": {"doc_hash": "9dd32284b00c8e545a3578cf52db4cd20de0de82932b1030fb06971b51620b2a", "ref_doc_id": "85ca4664-fa8b-405b-b683-eb20d07cfeb2"}, "3ab063c6-b434-4453-ac75-69fb0dc6572c": {"doc_hash": "9e12b2635682c916264a2c1514ac11840c7deae97aedec0c53ad79998307e690", "ref_doc_id": "70145112-d36c-4552-ad20-88d70809a911"}, "865a68ec-9df1-4e96-b9cb-0ce979335124": {"doc_hash": "bb6478435a6ca90aeb2eb59c1e55b5d1d8356ede1d3d43626f640cfb7c4f425c", "ref_doc_id": "35f78f6b-b128-44fe-8260-c5fba43e85df"}, "e5aab092-e48e-4761-a0ee-a52fcba93fb0": {"doc_hash": "13fe49c4a7357ed6cce7198c2889f9f30f2514815313fed0f29b25217ddec986", "ref_doc_id": "7031af86-e6b0-4dd9-9cbe-73bf8d67f894"}, "958ab2bf-9805-4afd-8cd7-d810a558d728": {"doc_hash": "80b0d8f392c9367f4ea2d39a74b47bdbfd486b0244add2e20b2ac6e73ab06c2a", "ref_doc_id": "7df489d3-c38a-4284-a7fc-618ae60b895c"}, "9642d0ab-4c87-4915-920b-955d85644609": {"doc_hash": "5c04681a13c0526748edad60f673d36614a110a87473c2af40d4915ffb19c95b", "ref_doc_id": "10f493e8-3b03-46f6-bb21-2cf2d119ed7c"}, "93e79246-518c-47b8-9036-62a5ac91b9ea": {"doc_hash": "b1c1a0b7ac9d0e47b51979515d6d9cfee3beb78a2c210dbd334c6364ea9bb822", "ref_doc_id": "5cb5b786-894e-433c-bd00-a0e7f32ab781"}, "76ce5ef2-35b9-4382-a7fe-62004daaa775": {"doc_hash": "5bc80ce792d5c9965469645fd6c2bc70a01db39653914418415db7c62e13b80f", "ref_doc_id": "8bc3cb06-ba79-4085-be7e-8920e82fdd4b"}, "344beafa-a2de-4d81-9a76-0997241b6c54": {"doc_hash": "29f0d7494717e1b1c092a76c06c480f8f00186b6f687a1498f98b88671537d3c", "ref_doc_id": "001f8c08-4974-4e1b-8bdf-7188181b586c"}, "1d84446c-f3f5-4793-99d9-50a3a3e47e79": {"doc_hash": "dc3cf47b6490aa5d0e3f38d4ce15e91291381ce178c01619e08bcb43f5d5044d", "ref_doc_id": "d8b07ce2-3c41-4ef1-9409-0c23e40971ba"}, "b7a27ece-2646-42fe-96d4-dcffc2f0faa3": {"doc_hash": "496ca3c1c36b2f8ced6b3d71abd052a6b9c220e5bb71843c612e6428c92e24f2", "ref_doc_id": "ce9e40c2-89f6-43e7-ae4c-08c7b56c276b"}, "f0edf1f8-2f7d-4ccb-a8db-f3b185c53964": {"doc_hash": "877fa965b88b39a64bf4264267974073a05bb5b0f6a69b54b8e653a79e54a186", "ref_doc_id": "1075dcb9-bb2e-40e5-8246-45a75bd31ec7"}, "082039d9-c24e-4388-8cd8-a6cb874384e8": {"doc_hash": "5c2a3e09e74b732795b9a6d9a968d8b4b4298e74e31095913b7c3267722c8d41", "ref_doc_id": "d616ee1e-44db-49e2-808e-8c6352196292"}, "736da678-9f03-4bfc-b5b7-7ed64a3c1ad7": {"doc_hash": "1ce5728f50339f38b89cc49357c224b9cfd0f7de552d76aeebd6ff01e185e42e", "ref_doc_id": "19b34146-7515-4639-9709-18528c8d9cd5"}, "9a74fd4d-655b-4b18-940c-7c123eabd8c0": {"doc_hash": "8e8372df39a5d882889b3a581d0ccbb995f778c8b52a00a7c198c0e3f85ba663", "ref_doc_id": "411f29dc-66a1-4768-8480-d1c113945cf8"}, "a22236c8-3e3d-498c-ba80-e5ec862073d4": {"doc_hash": "0022bb0215f6c431728e31202c32513447ff653bb4a5d16f34b8286364d5c181", "ref_doc_id": "e764195e-527b-4cb1-bfcc-9b8d5b32cf19"}, "0e156791-be61-4b2d-99fa-c61eba413ec7": {"doc_hash": "0edec31d953f4ac7737edd4b108382514545b0122ce98444c631e54ae7e8166f", "ref_doc_id": "5d160806-2b4c-4bd5-b196-4cd126ed5a2d"}, "ac90a656-c2aa-43be-852b-f01e5ed5ca2c": {"doc_hash": "d4332e830a660477077ee872bc02e4955496d2467e89054d716bd328a47cfa82", "ref_doc_id": "39112a93-e6ca-4c13-9cd8-92064b394126"}, "435a5633-b92b-499a-9ceb-0a26a98e0abd": {"doc_hash": "14260f1d5a76029f4ff9d13e8d2a32e3bb15037c9422356e8bb8db33eadf0d09", "ref_doc_id": "30f9445e-d74e-4e99-af24-cf4950deacfa"}, "fd485735-e957-4688-8de9-5e9e90505868": {"doc_hash": "e85ed70aa0e2d1f49eab7ff9035c27db52a872221955a9abcbb525814459e3a6", "ref_doc_id": "65ae2c06-0ecd-4517-8092-1a9e5f0dc897"}, "3994220b-67b9-4347-bcdb-e055ae8f9bf5": {"doc_hash": "080ed3c1475474807c3e9814ee2cdc13dd576a2a03e797a844ad62f153205d93", "ref_doc_id": "bd202fb7-3a80-46bf-a4f4-92f3e0907bb9"}, "7e7a3c03-77f5-4226-afd7-57a78b341a6c": {"doc_hash": "a8f34be0c566ec561668f631cb225214b6843d87a407a0f0fc2398bf9c2f125e", "ref_doc_id": "9ebe0502-a55c-4cf6-8e18-d50fe607c3ac"}, "dbbf2f1a-5432-4049-bf57-7d0665fd211f": {"doc_hash": "0b173fb6b78d256cd39289dc9ea82c30aba4bf64309e6f1ad4899ac404923f8b", "ref_doc_id": "1cd8e854-cff6-41bb-9105-bef0e72d5cec"}, "71cb5a26-eea4-41fb-9353-8534a5c3b9a6": {"doc_hash": "7464c09a6d4e63eeb3daf2cb0514503dabf513d13116fbf730c310ba862cca64", "ref_doc_id": "a67e7c04-5dfe-40e7-b9ee-09fe48e601c9"}, "798620ff-5712-49e6-9a4f-19b8fd8b3f53": {"doc_hash": "16f7aad466b1ce004e70601d653df6ebcbca34a17a7212ec2b5b7e09ecd53041", "ref_doc_id": "97171f7f-0e94-4268-8254-b7e98b5881c0"}, "79104ddf-3fd0-4b65-81a1-b8487602d9c3": {"doc_hash": "ea90f66f13b3be7003e0b944d7563983061cd77f0e25d718c33386cd7cc77847", "ref_doc_id": "9a4fe314-f847-49a6-9111-9daffcf3a2a6"}, "a787ad78-583e-47af-b6cc-660f1521aa67": {"doc_hash": "a80ce1771296aeeeb20a5c3c63b33a7a382b01ed8a806aa6f006907f1c550b37", "ref_doc_id": "04782179-e8f9-42cd-8047-77608c2d6c2f"}, "f9670648-251b-4cd1-9837-222a5cf6a273": {"doc_hash": "ce5dad44dc30e17dfd369c77da41ad87bb9fbee77d164784d59b57dff04f32a1", "ref_doc_id": "b2504a85-6fe2-4baa-a3f7-9608e9350a04"}, "bd848c18-01ea-4223-9089-2326e0fd3b9c": {"doc_hash": "24ce15e9e676d3b95f0d775a6d8e55b4b061c26246caa0fda7206057528a2441", "ref_doc_id": "64bf87ec-b06e-4f22-bf4a-4a183c4dded0"}, "6b919226-63c5-4b5a-8426-7bf38f3dff40": {"doc_hash": "3c6fc5df2571071233ad529023dca94bc8c9c1bf3a70bf06c79e52d1d5be4ecd", "ref_doc_id": "8d55cfc2-7464-459e-bfe5-db7926daa6bb"}, "afe758a0-ac22-4a9e-a78c-ae74de9645a6": {"doc_hash": "b49b577309ab8fa53709cd4069fb79ed380b7cfab729409a5245abbece525708", "ref_doc_id": "7f38336a-e505-43f6-8e12-fb87398c1294"}, "3dc6963a-b5ea-4bdb-a307-1d3bdd15f556": {"doc_hash": "2473e7b719c2db2b1e91b798678a4cf6c2bc4d2b8ff332b6fafc973c856a7f95", "ref_doc_id": "a988d4f5-6f7a-41a6-9ed9-51953e1207f0"}, "0ce65769-8474-4c59-838c-4a6353e36014": {"doc_hash": "2719e61f3a6ef7f24a0d6fb280948cc167939a52fd2b3c4660ff3530aaec8d8c", "ref_doc_id": "1f9ee5a4-96f4-47b9-8f42-93b896a4be2c"}, "acbbec95-3a73-45b0-975c-4fff3247b133": {"doc_hash": "fb22da04f0a148a8e1e9804dcec1a23126a9db7f393a16b12ce68ddb1a9a55d5", "ref_doc_id": "c7610a0f-4a22-4376-b9d6-09d2dc19ee94"}, "44b236d2-fc11-49c1-bc2d-93283623436f": {"doc_hash": "73b683c3e20d871fe74968dff12ad10bb34ca99ca6ffe965d4af949d57317e35", "ref_doc_id": "607041ac-a745-4098-84af-b08c32ab0886"}, "191a016c-49ee-494a-a0dc-4c7c29cd2615": {"doc_hash": "6bcf78a239950cc4ae9f560efd38adb073d5b5086d02b957dcee8fdd8667ae34", "ref_doc_id": "4904060c-eefe-4778-9e80-ef53f8db46fe"}, "95698f63-1c3b-45ac-83a8-3787d15ec5c4": {"doc_hash": "cbdf2e3460595474b75c93decda0038560b4d8f8c0ad3b82d4a00b8247a9cfc2", "ref_doc_id": "6ea8327a-851f-4736-9285-1009cb9944b8"}, "ef4eb977-7c62-453d-bcd5-ab484506eccd": {"doc_hash": "21b6c2debb6fd0741d13bb394ab575db9ee98abe55efe62841542894f9ee232d", "ref_doc_id": "9935211a-edda-4251-9fd5-68bc5225f630"}, "ffa9441b-a450-45fe-aed6-6830bf5c086b": {"doc_hash": "2fb6af510caa2dc50e7994bf051b3c9d5021242d25f9034e635904d8653d9065", "ref_doc_id": "d992393f-64d6-43a0-8d59-62e850b9256a"}, "5cd169f9-9189-4e45-854c-b15b7c356506": {"doc_hash": "e5335bbc9062987601fa28ac9f5571bace5c9f96488d54ae58aa7b5150b2691e", "ref_doc_id": "651197fc-34c5-4d86-873c-3f994abd31d4"}, "f1136d7b-2bf1-4aff-adf5-234cfc95d1af": {"doc_hash": "44f4e9fbf83ab9ec998a60f0b1b5bb519d8aacbd98ed442d2cd3e41e61927c7d", "ref_doc_id": "02d8eabb-37a0-4fd5-a3fb-3004c1edbd1b"}, "21820e22-6d99-4152-b443-2f081ea740ce": {"doc_hash": "aadfb0ac0c12cd4ae9db3d06f902f3346d617d628420da19d3ea5cb07977f3f4", "ref_doc_id": "cd6eed2f-1428-4923-81ca-25e04d8dffa5"}, "142b149a-fd55-4b1a-82d1-1675242f065a": {"doc_hash": "8e4f603d78640b3a99e26fd0e30a0e7e0edda52041532e0c0ce7f0254576c9b8", "ref_doc_id": "8a3f516b-90bf-48f0-afc3-99f3d245ae2e"}, "c68c5d53-eb45-40eb-9d78-ed0e0e01e60c": {"doc_hash": "0b2a96f25dcb35962fc4a0c0dcf9a9c35de83b61f8d07b9517a40f21e0d2fd47", "ref_doc_id": "c4251d76-0956-45d9-8347-deec778e5792"}, "1cb001e3-d1ed-4a6e-944a-3ccd3d6826d4": {"doc_hash": "eda08a668db75e555b65963f13e5ddf07a263f88a6e21b2f47d8c0b98e3df2a3", "ref_doc_id": "1b153ebe-776a-4e6b-8ba7-00bee8acd554"}, "0ea7fc1e-16b6-4a33-9a5f-77d9159707cd": {"doc_hash": "da0e010a970766b748736a35ccc3455bde236b50915e21fadceb3b8a3500bfa2", "ref_doc_id": "91bc6956-1bb9-486c-b34e-2ee6413a66a8"}, "87bfb874-4cfb-4d2e-b5ae-d1ddeec06d22": {"doc_hash": "dab58d8bd2dcd1558035ef7cc018fb2644271032f6a5d04c9de9afa16a51d121", "ref_doc_id": "17ffdc95-f13c-46cd-9a10-5b80f5f6f74e"}, "668b17bc-eda3-481f-a990-fb108ade4b52": {"doc_hash": "4aa362ede820c6383a1eeefd597967ebc812d84bd72fcdbb1d50c37b6c593b4e", "ref_doc_id": "316a1ca7-1501-435a-96c6-e98ce3964dbb"}, "abe5c177-472d-41f3-a69f-d21ff3af76dc": {"doc_hash": "3f82f80c377f364a1bb7608a4be1fd5a0ee7f3780ad0b9676c86b0ca2152bed9", "ref_doc_id": "260d17a6-8f9f-4307-a273-820c3693b9f1"}, "ce3e9555-cbef-472c-a722-a7d90f252571": {"doc_hash": "a53a97e40ea58f2055dc69755ff493e082d4a6ffe41672cb413d997ff3b8cbe5", "ref_doc_id": "f6be0507-2d6b-4930-9c54-ce3318504297"}, "e8c47258-92b8-47d5-8fb7-2899719a6d35": {"doc_hash": "1a490c6ebd066ac11f581781999b677edc0750d7a22645cc9cb2228360276cc0", "ref_doc_id": "3828b4ea-ce4f-4cb1-b819-094100aec4d8"}, "b23a968d-dcb7-436e-80f7-e5732d43eeaf": {"doc_hash": "593e3d1a182dc3dd6a2fefb27317fd61197c5c7d4006dcae38fd030a21804c48", "ref_doc_id": "ca472f55-5d60-459a-8500-1f84384c12ac"}, "0b6f27df-0121-4c3e-954f-f6d07c99ffda": {"doc_hash": "3afed3313c7bada38ee091b32446bdf63b29552eeb588d75d5a2772dd720e0b4", "ref_doc_id": "09d519ef-02ff-4b66-95ff-cc720c3286c9"}, "3ee95f29-c29f-466a-90b1-ff7fa666eb9f": {"doc_hash": "5e742355c3c1fda1308d3efcd5628fde9e408a4dcd604021da0f4a20ce268511", "ref_doc_id": "afaaad83-fbdd-4905-b5a4-1bb579be28c6"}, "49f48fee-fdd9-4eae-8c25-d5fb5ab60037": {"doc_hash": "7e93adccf5ed74f9601fb24c6d7c816ca63cab007927f78848464da61999e808", "ref_doc_id": "096baf02-7d37-4ec6-9032-0a32e8919d93"}, "dfe442b5-79ab-47c5-a794-e164cb5dcee4": {"doc_hash": "b481103c80148f28f2ed74daaab0fb0955279ae565d61f2ec32cc39be40c7701", "ref_doc_id": "70bd48ec-272b-473d-882c-5fc1266e6f22"}, "e9fbcb89-5827-4db8-b96e-00e266275213": {"doc_hash": "73bb53a779a670ec6daf868cef41972339e602fdb391641a7a2e36dc065ce4a8", "ref_doc_id": "40c4f355-74a7-4fec-a53a-0bbaee986e7d"}, "d76fd27e-9193-4edf-b976-eb92f3264d0c": {"doc_hash": "5240df0a0c611f98ed5e8b9ae9925899f3e792c683be39724102f731aa31d33b", "ref_doc_id": "22730bbd-f3ca-4cdb-ba6c-1b073bdd4625"}, "a25ff74d-d82a-4706-8fdd-0f58302cf908": {"doc_hash": "e969719fcdd5ad29e9f666f661b805cda6132fdfb3bd94f4cd6dc9393d735e77", "ref_doc_id": "d7f23d32-aae6-448d-ad40-df21233debb9"}, "1373ad86-e30b-4c76-b3df-0cd14c31b2a3": {"doc_hash": "cd9bec1e2b50b4d24722b4852fdd6fd27378e341c7c373fb3d8036113cd3d51c", "ref_doc_id": "73699b63-6e49-4076-8708-c4ea8660cbb3"}, "596daecd-4cfa-4847-b797-395a404b5805": {"doc_hash": "6a0630fb2c5ec820e1bce5438e4ff9106642d4167fdeda62a7d6ea86f1ab5435", "ref_doc_id": "64e8507f-6c5e-44e3-b471-1787c20fa03e"}, "bb8d9d44-d37e-499d-8309-8fbe64202b3d": {"doc_hash": "7b2517f65648e49eaadf8156ff32bb8827ba4d0e36267e021ce6b8c0f35a906e", "ref_doc_id": "cfb0a0d1-e0a5-4bc7-a363-9f29d2099f08"}, "3d88ec92-cc22-4a57-bece-75e1a23bee9d": {"doc_hash": "5d4e0fe42d9658065359968d80be624950868024d79cf08f6b01f946d88b5751", "ref_doc_id": "97a1e7a7-4ae5-4730-9071-3511c8b5f09c"}, "c8c82f0f-6e91-4f6b-aaa6-f49d4a3a0340": {"doc_hash": "d18cf51d605c9d0dd4c5ec1bb605bd6a4a38abb8d0a63f784e21c3669fc6dd85", "ref_doc_id": "3654c3ae-5954-40ec-b92f-fb40ab368bc8"}, "e49b0c5d-84e5-4509-af75-b4532eb9f34c": {"doc_hash": "1b58b8a7ec16a681cc206d5ce8ea45035d9209cd0f6fb8e6671bde3834a9632e", "ref_doc_id": "73a0fc13-f3c4-4c20-ab3e-30beb18cd2ef"}, "db3bb1ad-985e-4967-bc40-cd0883248267": {"doc_hash": "6dea27b59eed66c82ded9c4cdf00054d995c706234874816fc50a33cbd84035b", "ref_doc_id": "56269283-83de-4272-a4f8-86a886a5085e"}, "c2276905-97f3-4ee5-9cde-6965843e5016": {"doc_hash": "c7abec2b17132efd6751d99706d00cac292d3bb1d4554f007e86a039742c3f2a", "ref_doc_id": "bddc182a-822b-4049-b6fc-423a9b19d707"}, "e939ea27-ef4f-4436-8fc4-59f96e333155": {"doc_hash": "31c7e4c017149155a4754e03f09a15e9144f1f14621e6dc470f733b59c65ec5e", "ref_doc_id": "56d740e3-04a8-4521-baaa-890ee7104d6e"}, "e75c4250-7160-4aba-9c04-ba54368de8df": {"doc_hash": "bbe565bf590fbefde79c67cebf1669ac6cbfa4af7e51a3f89a003c6c21a096c1", "ref_doc_id": "58b2620e-921c-46e6-ae2f-44e0b211b34e"}, "379f0b5c-ab93-47bb-a0a5-d1b94cd7baa2": {"doc_hash": "86e26eb8430cd35158c8db1822b43d6319c8256904f3ce3ff2ebca9bec416ddc", "ref_doc_id": "3d7a2910-ee96-4a6d-b473-14026b054de6"}, "05714d7b-fdaa-4022-8540-8df07c765421": {"doc_hash": "dd7bec0e0eec1c76a2bd70bd29dadbeea9450e3c2c6d523f0ed45098c2d3a366", "ref_doc_id": "4aee77c7-852f-40e0-9422-085df9a919c1"}, "39f0c614-6096-474c-aecc-717577a8ddee": {"doc_hash": "0b7414265c299f39c538faae0b4c36ac99afce68a4aab23d221bcc304215a33b", "ref_doc_id": "59a0564e-9341-477d-ae85-669ccfbec3ed"}, "b1b357e4-2337-45dc-bc56-eca4ff9b42be": {"doc_hash": "5e5640f81f7f98fb275cd3e6c60321165d4774bf1caecc881da598d7bb9dd1bd", "ref_doc_id": "e93918ca-7308-49dd-88ca-34844446536a"}, "9bda69c7-fe02-49ed-86f6-6188581aee6b": {"doc_hash": "a9ed9adc121663ad7a2bf8ef96dbe7cc2a582d4d368bded96c8cc36d6f8ad025", "ref_doc_id": "daf252ae-8dcb-4f1e-8f70-0bc0f711fcea"}, "8bb8ed41-36a2-41eb-a1d8-a21264385bc7": {"doc_hash": "8cfcc2e9af43281fbd22eef4d2aa8d6477114f8e2d9f82e92b62768c50080521", "ref_doc_id": "ab68a24b-16a3-46cc-9ca2-a5ee5da8488d"}, "06e07bc0-f605-46e6-9194-798d83a4edc2": {"doc_hash": "44a2e26d7fbac61bb740517199d543382be06f57f379b6fd42ef057b31ae104e", "ref_doc_id": "6359a181-f012-407b-91bc-1e2b718caa89"}, "23e03133-78b3-4e48-8ef5-b33b9cbc2737": {"doc_hash": "4b09185d93185eeb97d67a5c05b973967f8408d08b109bf23fe9dc0f0259e5f6", "ref_doc_id": "dc1de551-60e5-401e-80f3-a97c1c5a79f7"}, "9b641b67-8a47-4665-a294-e5365972eed3": {"doc_hash": "c692b1cc873f3a8f91c6a61a683a17a8730a1268b41c4b6d8bf32a73462c6b67", "ref_doc_id": "cc0e5b3a-ab53-4a5a-969e-ce685dd6ce35"}, "841333a0-eeea-4304-91a8-6f50cdf48e30": {"doc_hash": "90a2b1a121d1473bfffef37efbd6caa454caf5172509762cfb6e8fbaed196329", "ref_doc_id": "d05834e0-82cd-4958-b0e8-bc40fe8d119d"}, "c67d8fe6-8c9d-47fb-91a6-11015fb7b6a0": {"doc_hash": "1d60d1b470cb679be4c92821c28cb8a9c796f3baf8a78ae60dba3fbe6715567b", "ref_doc_id": "a68bef5b-0b3d-4d4b-a151-250189beec81"}, "6cadbf65-61f4-47f3-8876-cc2fcfda3040": {"doc_hash": "1dc56d72304fc35338b63888b79a94e04ea7b98adcfa07cba1e25988101b6b3e", "ref_doc_id": "44b0a1fa-e059-497e-8ac6-a7d52ece28f1"}, "a82a84d5-38ea-498a-8d25-e76ab1bff7ed": {"doc_hash": "1e0a0ec757162160e86be021466134d2c6763ef835afc984387d3b16989e3ac4", "ref_doc_id": "7edf1f0b-3701-4e4c-bb65-aa4fefdb784a"}, "3f334bbc-26f8-48f7-9eab-84269cdbe4da": {"doc_hash": "d95660e36e39fd3e122fa53e9510faf420713dc1b9cd37460cd9f4ca2f4ea99b", "ref_doc_id": "58fedafa-30e8-4722-898d-e384971db23d"}, "3a77984c-6e51-47f9-9862-3571e07468aa": {"doc_hash": "f2f2deb394cc250af990219b743467f219a5c7c7ec4422cbc09b1e5f40093dad", "ref_doc_id": "86c609a5-b3f6-48f0-9d8f-474638b6b30f"}, "dfabce79-9699-4719-8cc5-1a4a399e8701": {"doc_hash": "c61c2cad9d83d22544f7897bc987da7a7eb089355b9974256312bc12721171bd", "ref_doc_id": "5a015644-6d09-4257-a83a-2a7d8d233417"}, "fedf5bdc-5963-4c0f-8189-309707c1fd41": {"doc_hash": "869799eb79b575b6941c6a04e2f511cfc524237034dd2fa17a86edeb8fa9355c", "ref_doc_id": "97215990-e6ec-45ac-b944-3d6c8e41f9b6"}, "08d9bdfb-346c-4bcf-ac71-0a99a4a415eb": {"doc_hash": "829c75c50bb29db49f9c3fbe9c8b9c68b3457cb861fc26dc81834c5979feeb2e", "ref_doc_id": "94f2026b-0279-4b96-8f55-b8415fda5434"}, "783b5a2c-f01e-43eb-a108-ea3fa02809a6": {"doc_hash": "153a7403c728fe18afb398ad765ae10fb3cbf0110b590861688b74e9d06cd0da", "ref_doc_id": "bd26c895-3f3a-4511-9110-df3ffee9494c"}, "570d9214-026b-4faf-b558-2f3702c757e8": {"doc_hash": "2ecfe358f5c1962b98901bd016ff76f29ea368418568aa76f31155f1ddd76e6b", "ref_doc_id": "ae06a615-5c92-4d52-b938-f6b5dff9c1bc"}, "2c5b8818-24c9-4588-9d05-d619c26c784c": {"doc_hash": "cb6bdd7140e0e59a0273d2c69e8e3dcace0d483cba592f147a12df6fcbc79894", "ref_doc_id": "21c0a27a-4243-4558-b285-896062db867d"}, "c150a8d2-e191-4c89-b1ef-af078d380260": {"doc_hash": "5e8dd1a1d3498341ecf5f8e3e45df62a00e8f06334eaf4344272dfd5ca897578", "ref_doc_id": "12605885-5ed8-40e6-a888-5c34871c7242"}, "163589c7-2d38-4505-8cc1-d5de8ae8f72c": {"doc_hash": "9436f240f5517d3d88780dbb4f1d7d65f66cae4522adeb26db2a185d2d464fd7", "ref_doc_id": "17f68f55-cab6-4fd2-9bcd-b75e92e72b33"}, "e74dd961-38af-4dd5-a21f-e2e2f27c8510": {"doc_hash": "25de002758a42e0fc9fe8c56e6dd14419b6c37ca152e220d90081d5cae1ebcec", "ref_doc_id": "fbbcb968-159c-4d68-a64c-75f96224aec9"}, "1aa0bef6-38dc-4af6-a128-43003142963c": {"doc_hash": "2ed37bf490c4deec7d093fc98e97605cb430bda08709e4247a92fe2d2d25493d", "ref_doc_id": "6dff4e86-ecdb-4954-a327-da5e9aa3bbd1"}, "a76c61cd-c15d-4c0f-b841-e053148000a7": {"doc_hash": "8b4238f844c786ee10129ee053060ea6e9575f822e0c29559f3910e5bc24f4a7", "ref_doc_id": "ea1d0b40-2d09-4cbd-9acb-112f7f16babd"}, "bf9109cd-3780-48ee-aa97-e6e8423bf76f": {"doc_hash": "76c5542cfd37b3d1f2c2ba63862549b88ca0bb927f1ebc39298f2beb017c879d", "ref_doc_id": "c0645f08-762b-4cd7-a250-a60a43141a0e"}, "5f12bcaf-3256-495a-ae1f-e64932816b01": {"doc_hash": "aa919d5e687e26ead2083658c53bc396d5e69f7a4d37769e9d949bd9d5e1e069", "ref_doc_id": "427ea000-9031-47fa-9267-f66b1d22e029"}, "20a7ac5f-44a0-4f84-86d8-92e548acadb1": {"doc_hash": "7b1b247b2c1ef9567f692baddcfffac604b1b569219c30c3a01e5da5dfa33b61", "ref_doc_id": "7f9465d2-781a-4d51-8f39-aa653ffd53eb"}, "7c594074-7e0e-4906-93f1-45864eec3713": {"doc_hash": "f17b4deb5d8408907306cad78fb171b6bf1b76ae12b95882eadb79360fc713f9", "ref_doc_id": "ee23fe6d-27f3-432a-a38f-e1635a69a46f"}, "d42cf2f2-974f-4882-93c2-be71245d8c05": {"doc_hash": "fc56db519840f13e5d1adaf0b5992da94ce41974343f26211f8d3f37d49ec1a8", "ref_doc_id": "6d57ca74-9f44-4125-ad60-b214a04a2547"}, "ba25ab16-1534-4c86-8fdf-f6eb7cc5313a": {"doc_hash": "128189725c1d168cedad5c076d479e471459bb6eb44aa7bd753981b390c03fc9", "ref_doc_id": "712b0e77-011f-4ab4-b102-e5a8cfc1a0cc"}, "4375986e-034a-4b30-9065-73450675e123": {"doc_hash": "f6bbb74a3589869447243b5d64ed4071052112206f1d1ccdd180aa0ba5dda60c", "ref_doc_id": "db741599-719b-4aa3-ae4e-8be2798b7b84"}, "561bf65d-4766-42cb-9c9b-154f401a9ea5": {"doc_hash": "e6a6707f20c75581b5f6a6b59209b32873d8dd0395775bcc7e67214497eb0f78", "ref_doc_id": "d8b93e95-ddf5-4679-8f02-0f1ab1e933c3"}, "4dc68a3a-e907-40e5-8b03-f54a9d7138d7": {"doc_hash": "cdd4e1fe9e5e6e07a1149ad37757c420393ce6e036820ea6fd4e5291ea90c41c", "ref_doc_id": "e4807678-22c9-4e55-af8c-72be1e069211"}, "566e0b53-09e7-4502-822b-7273f5e93d9d": {"doc_hash": "154d647ba8451380cec80e7a654653d650df93e42d9a76282fbba115eaf1ffbd", "ref_doc_id": "cd7e7d79-7882-437d-9045-db7165899874"}, "8e66e1f0-67a5-41f8-9de5-f0d5b0ca7a7c": {"doc_hash": "c719476646c5da3598f82e3cadc4550996620a1af9b601823af991f60d9dde41", "ref_doc_id": "39e44bb9-df93-4f57-9e56-2f6d07133863"}, "c377e99c-2cd6-4449-8c3a-e94b1af11013": {"doc_hash": "c250a0a0ccc5518bfa66fb4c8d401fff2edec52a545585d9672a937943be4e05", "ref_doc_id": "4f22b7ff-a94a-491a-b8b4-cd1f8e76e9ff"}, "ccd3cacc-90ee-4ce3-8116-6e4010f84cea": {"doc_hash": "eae69754ce720dafacce02586173f8d3e3d49048e00566c0d2e09041ff778da2", "ref_doc_id": "d3bd3be9-92d9-4d19-baa6-a171f253d7f9"}, "d6fd1243-981c-41b5-bb0c-b47471416650": {"doc_hash": "84cf16daf786c21e82db1ef8cb6712c294f50be641a86d5c849af9b89c4abc38", "ref_doc_id": "1da2ff8e-e36f-42a9-8397-d65179296b0f"}, "62fb316e-d6aa-4fef-8580-1b701bc54eb9": {"doc_hash": "fb470ee4fda3d02e4362c530999b1570716e1f8bf257db0e246bac763fd38a71", "ref_doc_id": "466ac9ff-eb56-4529-ba6e-33845903b2de"}, "f5bad0c3-a3d3-414e-96aa-861f406cf9aa": {"doc_hash": "35b2f70bccf66f67845b7f41361e450d44530b0eb802a26fa0b4cfc8a30b1e73", "ref_doc_id": "ce8129f0-3a0a-45b7-94c0-113b33d90687"}, "7cc76db2-d4ef-4cac-9dff-0a8ae3c43a58": {"doc_hash": "843b57ac7e76ce6bda0ba778cec743111fec83c209778620ac6cc094c5b8503d", "ref_doc_id": "181110fb-8a95-401b-916e-a2fd07fbb8da"}, "4f8eee38-bcd1-46e3-9103-70bd4890c057": {"doc_hash": "c57e47581eb5554c06eea4f15eac2ebbde2855877ed7b84d9228ca4bbd6fb85e", "ref_doc_id": "dfcfbed1-cd49-4082-8b1d-f4198e087a6b"}, "3a7743bb-aa01-44bf-8281-5fe37fc2246b": {"doc_hash": "beb56650d16b215778e6a2e9a4d0de91f906a5dfd3ca136474935423707b7382", "ref_doc_id": "9f0c14af-be3d-4f8c-88c1-0b7c0a45ac14"}, "29cf852d-eee3-4e42-9eb9-d398e0e6c0b4": {"doc_hash": "f676d0fed04d3fc5b8c348d12f76941168a70b5825d98879242783d291dd255a", "ref_doc_id": "745bff58-1987-4bfb-954b-738679cc371a"}, "867a6875-9ffe-4820-b84f-722732d5ea4f": {"doc_hash": "afd98518d5d576d12a89197befef1527f233907fba83967c63ebbf32ecbb1534", "ref_doc_id": "93d456ae-ce20-4c13-9bac-a33a18e1bad9"}, "c9bc4427-5853-483d-9913-708c0a8c25c7": {"doc_hash": "e4b4c2b65d5dfa68aa824f662c69bdcff52c125d93ecc02648cd73b4359d794e", "ref_doc_id": "80ebe34f-e926-40c2-8655-b12e58cee011"}, "3896d26c-f419-4787-aa16-c4a8de8ba24d": {"doc_hash": "d2e03129c04462f5bf74c3de51c31696a74cb4620d7e5574e84e598cc9866fe0", "ref_doc_id": "60d8a618-1859-45ff-a741-589a8144b3e4"}, "e0103ddc-0001-49fb-b787-c90dad74226f": {"doc_hash": "c26c1fefb4e0757dc8f5c91453d2264c908710909b294d1201195318bb294223", "ref_doc_id": "fc4fe7d1-e586-4723-bf5b-263abf796d0a"}, "7e372e0b-bb0f-4c0f-ab44-4d243f81fdc5": {"doc_hash": "6a60937ae21aec9d6ee1a731f806250e2a1abd7c03a7a3278bb40fb2ec2db0f0", "ref_doc_id": "263bba47-3203-470f-a5a4-a5caa6beba24"}, "fa42c770-159b-402f-9b88-94824a8901d6": {"doc_hash": "2cc905f092775ade5b5acd8593f8ed810df25e4b7feb2692625ee7ea3aff5303", "ref_doc_id": "585aedb8-65d6-45a1-9130-ad267b5d14fb"}, "f1099729-2439-432b-a2c4-b80aa18f3785": {"doc_hash": "635f6de586bac24343f59f19b009732d08ed233f9ef67058621c5daf9823d192", "ref_doc_id": "81ba575b-2ccc-4f51-bca3-af80cc7d0881"}, "320ce1b3-18e8-4e0b-8e9c-579c0c2bca96": {"doc_hash": "0e0ea833754f16c54e85afd0141634b11b6c3ac8b9e8baa9aa0b19bac138701f", "ref_doc_id": "e2dc0e0a-ded8-4f0a-a3d0-cc4a8b543b55"}, "a13d483f-4664-4569-b18b-a1eadf59d8d8": {"doc_hash": "d501a84f1cda0bbc6e2d1ff8d18a1b8b0e50bba5c4d69c7be8d428b96e174613", "ref_doc_id": "2d1bf720-8100-4516-8f84-70e1ea41bb77"}, "c41a8dc1-6f41-42b1-adb5-b804b5fe365a": {"doc_hash": "7f1618041cdeaf17d6dd18fe2b64e9a4946da49c442aa19f312321522065707a", "ref_doc_id": "e2eaca3a-b863-45c2-8c05-faf887e0d4be"}, "87535ebe-f642-4f10-8b28-596ebd73005a": {"doc_hash": "6990cda056b5d59a66aa4f2ea08b8baa5f33526d96f9e38e733d967476a74344", "ref_doc_id": "42f885a0-49c8-4b04-b776-18c78a204770"}, "d00b4394-5c19-4bf6-a0c3-d8cd77cb2879": {"doc_hash": "23eb01a6b818b5ae83593fc18bc11174cf503d5a185d09bede968ea95427befe", "ref_doc_id": "2c3017e2-626e-4a3a-94c9-e7febf650b1a"}, "7a381825-1f8a-4f82-835c-f71aee746826": {"doc_hash": "7a3e598746e29a65cc59e79d54f9fc82620916bf195b7a7191fffb5ef4b586a5", "ref_doc_id": "2a07ad8a-43bb-4cf9-955f-92e0062ab51f"}, "a209e0c2-130b-4385-a9d2-8f5489fd947b": {"doc_hash": "5a40ed8034732363a2791749ac74ee1ffcb5b7391ff55df7de0a270410326f8e", "ref_doc_id": "34554caa-8089-4238-ac7a-f6ffd2037731"}, "cfe7a901-5c05-4c35-b6ba-acf9bd54a3eb": {"doc_hash": "2a17d9baf03a2f67bb437c1ed167ce23952108f19c2bf35a1ff32dd68f4ac3d8", "ref_doc_id": "499749d7-8761-45c1-9276-b7fbcced6607"}, "613e0c61-f90c-41bc-9148-ee89351cceb9": {"doc_hash": "5f67c6ea1c0eef9f67863ad0e071e05335b8a0045fd227ddb8a4bf6a3cd15fb5", "ref_doc_id": "1be8ffcc-306e-4c50-bf4a-d5d13bccd097"}, "42aa6792-8a98-436f-8974-1cbd8f109a99": {"doc_hash": "adad0d13f90ddae76da3d15cbca82105f28752881d4eff557386961b5c800ad6", "ref_doc_id": "f56f935d-d01e-4553-bfaa-a44e5ce45602"}, "c3c618da-1605-47e6-80fa-e6ce94204ef4": {"doc_hash": "553bd9ef0720c2dd76ce033f6d425aed4fd8cd99d6f559278099d2ad24cd575c", "ref_doc_id": "803e6c34-755f-4637-88da-ccf8273bdaaf"}, "c2d1e1e3-e988-40c3-ad61-ede9641000f3": {"doc_hash": "458cb6278381b490e9d32bc10de0ae986a9669ff523c1d657984ad81a73f0ba2", "ref_doc_id": "5fbe75ba-4128-4c92-8068-9ec28dac270e"}, "4f05f4fc-0adc-4b6e-b1c8-92187d3e83be": {"doc_hash": "4227ed98870405dcc61855678a23b2908235bb5beace912f4ac25f79072d052f", "ref_doc_id": "7c651d92-d9ad-4187-915d-eac8f6283d6f"}, "07f992cf-8567-46b0-b17f-f97f47bdbd05": {"doc_hash": "6de1b334e433cc6449487426e0eaedd366f176507f99bb106cb171e38cf591ce", "ref_doc_id": "77cb5145-cc16-4059-9b3e-b63880715840"}, "899f9f44-09a8-4e22-95d0-d250ad1ff4c2": {"doc_hash": "e1bc6118b0c68a1630937e4d01bea41e815d9107c061e80d96bb56797798433f", "ref_doc_id": "9331b45e-367f-4386-a7fe-37e5d68d27c4"}, "3b40347a-139f-452d-85b8-ecbafb47a6c6": {"doc_hash": "cb7dcf02e9e5c3c261014de83723d2b753f28789949a98bf697bb85562843eb9", "ref_doc_id": "fca78862-4dc1-41eb-afe9-d452b4a2507c"}, "fed5070f-897c-4fab-83e3-f30cc9d33501": {"doc_hash": "68bdb0d41d6f1da52c3e9fc40e901eac5f33d401a1d000fe5acd7425d2d6117a", "ref_doc_id": "62140cf6-9b36-4b04-ab11-59a5ed3c989e"}, "5fe23a0f-b011-4ed9-9106-3c87dfdd316a": {"doc_hash": "222483e05a7ffae7bfb460c502b450870a2402a70575a1316838a5a559bd787a", "ref_doc_id": "191e621a-f529-470c-8830-bff208608998"}, "5e016980-41a7-4fee-a1dd-c773067f433f": {"doc_hash": "e6a50e850a1c436126c94e76cd6f3ae7a9a99672a5333fa84f36cb25c6c55c77", "ref_doc_id": "ddd4a719-0602-4533-bf33-6ee632116b76"}, "811d1803-1a7e-49f2-a486-85492a09df7f": {"doc_hash": "10967c36f5624e3d1694f21a80e3100f08e320f87e5434a714fa154f4357e699", "ref_doc_id": "240e099a-de09-487c-a152-fd7136922bba"}, "8252b4ef-610e-4def-9377-ef6743aab7dd": {"doc_hash": "c7c57c6f2c8d356c8c4e2806872d6a9ce6e3914a6b8aa0a7c2f3fa2ce8b26001", "ref_doc_id": "a0be8509-024a-4e2e-8ed1-f22354761c5e"}, "4123d9cb-9b5a-4067-b84a-f6695e650218": {"doc_hash": "cd896bd440433914357276ec7411f41e2693e2c8329a0ac468c6e8668f5b8eae", "ref_doc_id": "1ea24a96-2051-41b3-90c5-870d64c353fe"}, "1f6fd653-524f-433e-a002-498183d8331b": {"doc_hash": "f91e7e983f7df445be5c64be40ec69a597c4ba89ebc9defdb3d20e4f62d62568", "ref_doc_id": "4e4e6edb-3903-4af7-91f6-9658abd6d7c0"}, "62aa30e0-1d77-47ba-b2ed-eea7dae1e75e": {"doc_hash": "ea8a2bc8eb9affc0e8ca2ea6ed4b0b991fd08439d93aac92f40c3498309f54da", "ref_doc_id": "1f3f6769-307e-4ca1-9a5a-de7c5c763a9b"}, "d1317093-a15a-4293-841b-14532684c2e6": {"doc_hash": "7703f8eda64f62a0c7b617168c769f2e0678b5cc42cb922d10771997be64f859", "ref_doc_id": "5552ccb1-83b5-42fe-813c-b725ee407807"}, "5ac5f603-2b4b-4fea-ae98-10f5261707b6": {"doc_hash": "927a2486c0f6022cec67ac26bdd197889c8a686a73bcb0b1e1b1da307428cd39", "ref_doc_id": "d6f67fe0-20ec-4d01-814c-aaf494ea09ca"}, "9813143d-fb46-41f6-837a-8806bbc895c0": {"doc_hash": "cc53e5758e75774a75a81368befa7602dcaa46455fa38476d5e4e0263df3854d", "ref_doc_id": "e2b2011b-e3f5-4aa7-8b98-8ea9accc5022"}, "eb1b852f-fd7c-47de-bbf0-cbc09ae3d6df": {"doc_hash": "a0172eb83416c1862b68a0093f267656c6756cbffc94e935793d8362ba2e9120", "ref_doc_id": "028abf06-7ac9-48e9-956f-33c159ca0673"}, "91f75c63-8292-47d9-9714-7d61848ca532": {"doc_hash": "fc520d8b001c8ec8e33995186a2ea45f69cab4ccfe20e6d28d52936301e90c1c", "ref_doc_id": "90b7e1ae-259a-4a9e-b777-c04b4df558a6"}, "c87f6cf9-bdf7-4e77-89a6-b4431cd92b4d": {"doc_hash": "b8516562bd8a17aed9a8b63e3bdde88c817d67836f0cbcd1d0e7d17d4540b772", "ref_doc_id": "42d97730-6d15-459c-868b-566a07ebe4cb"}, "96461032-f9e1-40f0-8590-0a42741ad196": {"doc_hash": "6203e1337ae503536a714bb5fc34b3d461843d58d30097e6e3b00e0def823592", "ref_doc_id": "173a2358-dcc0-463e-8b97-773a98ed625a"}, "518cb51f-73de-466c-8e3f-ffcf7917363d": {"doc_hash": "516f3fe128da2e197cfc5fd7b678e5ace3f2a26bffcbe7c20a74f167241e32db", "ref_doc_id": "f2d002eb-6d82-4e34-a131-c624b4a1cf18"}, "ef79f78a-8a1c-4bc4-8516-ade6a9cd1c6f": {"doc_hash": "69cde1781f2771bda655ed26618a6a25f4354a7b0ecd7f5d5c2a9dfcfef73956", "ref_doc_id": "e73cdffd-4dca-450d-a8eb-0c4ded11757e"}, "b11b5e92-85a9-4c69-b5a8-d746bb2475e5": {"doc_hash": "9687c8da92cf6cb0e6d88d03b8713ee72f41277602b44d31a2fd9568a2423b9c", "ref_doc_id": "feddbbc9-1870-4c76-b611-fe4909d44af0"}, "c91287e3-67ac-46be-9fe3-47623d155594": {"doc_hash": "7546280a0896b890a01d238d7d2d10762402786469da29d48f90b0785028b7b5", "ref_doc_id": "ff13a061-005d-48a2-b0d8-bd029ee8a109"}, "ba096cb1-0346-4383-b1a8-d3617b29d07d": {"doc_hash": "097d32d84eda9683bb19e39725ffabde56e1fef289659a7b2b869d173861feae", "ref_doc_id": "6cb923c9-7aec-4c3b-a13e-ef3608eef36a"}, "f11563f4-38c8-44d7-9360-538bb39e6500": {"doc_hash": "38d443bf9784e6830bb5ad05e15a6f6e54f00793223e1f008f581752de1d24ac", "ref_doc_id": "d9bf7809-87f5-4749-9830-37bf38e77a7a"}, "c0726ef1-ba31-4b83-99fd-cc6e156da529": {"doc_hash": "08080bfc7e3cbd0a091c79afd85a01139ed873477f8300b76cf24c29e4554bb9", "ref_doc_id": "bcc4fd7f-a6b8-46c3-ab85-fd19aa2718f8"}, "a13f61d4-1159-4ada-9416-d580bdcb5b1d": {"doc_hash": "ed3471d1c0fb686a4a88b652c441cf2043aef9d7e916fcf882e8c105c1612e5f", "ref_doc_id": "e8a3be29-739f-4b9e-9a6c-838136d2f009"}, "9e38393f-db0f-4165-907e-8ac4c34579f7": {"doc_hash": "8aa68699fbf931894b33e928c194bd1de981a168a6df040778d57bbc62f44521", "ref_doc_id": "64879eaf-d04a-442e-9cb1-4be5af1cc984"}, "d31f8a17-4964-4982-a99e-d92cf0b7cdec": {"doc_hash": "8b8dc5f4d574d83cb6a9f1a8c3cc35e96a8fdbc50c75b805e32b19d75e4f25ed", "ref_doc_id": "18efe620-ecfe-4da3-bed9-032a52084a73"}, "c6a9ed63-7cb6-443e-9ba2-1b281492946a": {"doc_hash": "46ca0a34a2cf16c4b3f780706f6d7cb35191bff53fd6a80857f0615101dafbb9", "ref_doc_id": "8a781219-906d-4674-b336-0767864eabc5"}, "85a98416-33b4-4b65-a4f9-728a1c5fcd7c": {"doc_hash": "befec99b3745f5467cef450eb11d8e2b7842ff66ca2daa8028fff5cf73434925", "ref_doc_id": "f752a712-7916-41fe-92ff-bfda9981f116"}, "7cae8f59-7dc6-484f-8680-33a4ae04de95": {"doc_hash": "60eaae6a61d1656c49303cfb93be8ba2be159dcf11a8a5f394531255524fab7b", "ref_doc_id": "823a56e0-6ba7-4653-847f-58386a5ca1e7"}, "5e63ac13-717d-423e-a1ac-1ef059d1f569": {"doc_hash": "39af3de61596758cea96264e331a2ebd49e1a2c8a234e8de3f4ceef49e225191", "ref_doc_id": "3878ce82-b8a3-4602-85b1-f142b6567da1"}, "ac2bb7be-88be-4601-835f-81bc8f005b38": {"doc_hash": "3c5ec005b25a83bb2980a493e05798beebfae2415d04e4c0bacec4bfb37e51d9", "ref_doc_id": "fce7cba5-9add-4ba1-800f-7c3c5de32806"}, "4d2b4ae3-d28a-452f-a7a1-fb1bc0c796d3": {"doc_hash": "7de1652cf49e820e2f69bacf59dc8d9bfe8430e0ab8e48d8f1f60311252c5766", "ref_doc_id": "3705ed84-1765-4393-873e-6e92b272d1a3"}, "5135f2f1-0f78-41ff-8f18-fdaa6c4a9544": {"doc_hash": "2d7fb5fdd7c7d606994de76bf2aeb3660341e6d75d294ac05bf4052f6a2912f0", "ref_doc_id": "ec32098b-ec61-411d-a088-e9c5ea02c16b"}, "ee79e3aa-4369-4007-9c15-3d6b13a8e622": {"doc_hash": "d5cd48378bee5ccabc4eec742d68492c73fed4fcfca6dde8a5e4343b99b0ae44", "ref_doc_id": "756de20d-dd81-47ba-992a-23cf259da245"}, "5332fcc5-3d42-40ad-bb6e-33a51f278875": {"doc_hash": "f2f8fed4625c457adc584d10d16646b573c7cefc6a0540c74aaa5eb8333af0a9", "ref_doc_id": "881b1adf-34eb-4d4c-b671-8031a4fba642"}, "1794134f-2395-40d1-af06-ee4cadb7f802": {"doc_hash": "dc5a3fc41966307882d433d7bebc3dff90c85f01ec2bf744dc8d84bbded89f71", "ref_doc_id": "4ab8e6fc-6373-4832-b6ef-cfd14228b9f4"}, "78ee4e74-ea72-4554-9dcf-c5eb9464c215": {"doc_hash": "8c9eec1a5676dbd526a21a064a95034bb05ca82fc0f3eff17cea7a2d73a07acc", "ref_doc_id": "e622c5a4-2eb3-46d4-af90-0de4edcbb3d2"}, "285174ca-ba4d-43e9-93fc-4b3bb33f1866": {"doc_hash": "d206e3b7a276c03fdb2cb3d2b33e8fefc9f0310d399ef4ed9c430cedcb89d003", "ref_doc_id": "56b3c7dd-5f15-40c3-9e16-68c3cb365349"}, "78f5f09c-5840-4659-a947-bb9960fe0fed": {"doc_hash": "76be63675c95c8b70959416c26810f122cf0aa490dd56592cd37b8fdb4dbd455", "ref_doc_id": "70bed42c-b350-41d4-9315-1fb51a48a49b"}, "e3746c66-e044-4188-b48f-ce177422ac83": {"doc_hash": "c49caf265ad866dffb0d36e5a9dee75c9e0a474ae503c1dc920945fda31ebeeb", "ref_doc_id": "30ff21c2-5e93-403e-ad74-1482cc31219f"}, "214e2124-897d-4efd-b405-fb2a5f71cab2": {"doc_hash": "78ae2594a402b9a306cc1928748f3b6701aeefb057b4411305d8b0cd3f484e73", "ref_doc_id": "cc264dbe-9481-47f9-bc2c-3e5061be4436"}, "c30242b7-66f7-4650-bed7-83618eac952d": {"doc_hash": "6f478c05e52dad54d164e087444b4b4fe5cc0fcb33fb9e83f6b2c22fd257d10d", "ref_doc_id": "385e8c9d-5a31-41e4-883c-8a79ce4beb42"}, "2b4a7d02-975f-4c86-84a7-3773d71250d3": {"doc_hash": "04945be543884aa0830532e1fc90c740b2ae0aaf4a753f876a147b5440656f8b", "ref_doc_id": "fa059e79-bd7a-42a8-8515-edf654539627"}, "4c617fd8-c6e2-42d8-b9dd-5959e9ffcb22": {"doc_hash": "5a35615bbaf36341054ed3c534aef3125f2e318897cad55dcb2762eb5bd0c534", "ref_doc_id": "2948318f-f9ce-4779-b9ee-97f93d996255"}, "d65d8f76-7d85-4088-a3d1-60dee5029c27": {"doc_hash": "50cb82992126693e9fe3397ba8c42b3907a2f31d96904ff481c5780ffe33115b", "ref_doc_id": "55b73b54-3677-4cc3-b7cd-c56360ac9665"}, "764aec1d-ed90-4248-9d56-38663200ea64": {"doc_hash": "ae6c308d5734e7acb7d9062cf1660744d5c0697ab6761fd40e42d0b5ba029937", "ref_doc_id": "075adb14-e78d-47dc-8453-6c7f60d53630"}, "525e2afe-ffb8-4f05-aced-c123be20fdf2": {"doc_hash": "29a6a919bca7147d21052596e937d1ea7a8f1596776a8d25a2404648c0b87c40", "ref_doc_id": "14d388f8-0a90-4a2a-9725-e179101430c6"}, "a3546723-9728-453f-8863-88322599e9ba": {"doc_hash": "78160860c3601d64308e86be0e97080cdb61c5471aeb276a95c08dcb21d64b86", "ref_doc_id": "da2e2215-2a96-4122-84cf-131a3f88baaf"}, "98efa0eb-df2b-4fb7-b7ec-4b10d3ab866d": {"doc_hash": "52fdf17f8e262da1f403fb8d4040d86e2c83fbb2b1bee0902c76946e121e23c2", "ref_doc_id": "13d9db7e-1432-40d7-a7e6-d2bea8551398"}, "aa609065-3541-4da2-9599-e41eb1c9ca21": {"doc_hash": "f8686c46fc91ab3269b1043143eddd5d79e9c6cc34b6f27aad5a88682f94a644", "ref_doc_id": "c14b61b0-2b21-4b7e-93c6-53d49185d8aa"}, "68baa6bc-9c86-4d3f-afcb-c03416b6ffa1": {"doc_hash": "c55074e635700ee06973879cd5abd23023fe3469172ea98f36a57a2beb0251b3", "ref_doc_id": "379d13a7-8c90-439d-a040-e8dcd610af0f"}, "36a59a01-03c8-47e0-8a69-1947d800e32c": {"doc_hash": "083b20d28b442ce476f8b5a568cf5bb2359b4137170182fe641d712100f947bb", "ref_doc_id": "a11b2af6-6079-4166-9d95-bb85810e7eda"}, "1775c8c0-042d-41d4-b0c9-96b4851574e5": {"doc_hash": "7c774d4ca0f66ea771943448f8b80976e07b5120f75bc3992caa18c38548ca38", "ref_doc_id": "2b6fd6be-c378-446b-8131-dfa4fc25148d"}, "42347d41-2858-4640-b45d-6d74ea80abac": {"doc_hash": "9d70cbbbb8a0171e7a2b95346f076b3fba66f6c584b0a1d4a2a6192cb12a0b9d", "ref_doc_id": "43180f24-e29b-42bf-be3a-539e29738591"}, "7f6a22de-1b95-4922-b71d-e0172cbd75df": {"doc_hash": "0fb00076fb74ac8e4a253ee092feeb7f282ad0286bc0f09f34dab4d1579a3419", "ref_doc_id": "6ad93f16-51a1-43d2-803b-856ade15be1d"}, "e79f41df-6ff3-4acf-b03c-719013318091": {"doc_hash": "627b2537105221b3437a1015651013a52192acb4af0c460917757818fb048b38", "ref_doc_id": "f646d3cc-07fa-488f-86fe-a33eca9253dc"}, "c35651ec-7c98-4e2c-829f-9c60234c8268": {"doc_hash": "e3331ad9e89183151384b5d2484a04b9825fcfa79b27105762f13df578b1f7ea", "ref_doc_id": "b1aad2e0-b19c-48e3-8761-93edc53777ef"}, "ef57c94b-381e-44e9-8d86-ef74661e97be": {"doc_hash": "71c66a6bed1d87bb58cd493b21ae68f3b0d10711ee4c11101c34bfd36ba4d734", "ref_doc_id": "0fa4b35b-e261-4123-a960-feb4da553cab"}, "06cb7ed4-7c2d-42d5-a9fe-9e77c0ca46ee": {"doc_hash": "d805ccb56738507b5c7cd4f97233426e827df34dde1d02140c4f8303b13a2273", "ref_doc_id": "07ec0554-fb64-4158-b2f6-786622d47c5c"}, "44709eda-106f-4441-9477-34dd8e8ffdda": {"doc_hash": "6841733bfa314f038a09c6f6be9e95926262a1ac25b94aa6fb4fa1d04e5934a1", "ref_doc_id": "91809c1e-c2bd-4b92-9116-1282c1e622a8"}, "12b433c8-61ac-42f8-8bf1-01a026c8b818": {"doc_hash": "7ce82620c53844703bff8104276f8f0ab153e778267d487f0285399e9dfd89c9", "ref_doc_id": "4249ea8c-f6cf-435a-a15f-cb53aaa1898e"}, "b6bba9e1-db1c-4fc8-8060-9437b2cd8f6d": {"doc_hash": "cc66f189b067ac02235f11ef556907fa52e9f5a3d76eabe597bcb2b1c9ac20b7", "ref_doc_id": "fc403379-c18d-494f-95c5-a2e56a41305f"}, "5d561296-fb57-4aba-839a-3a31861055eb": {"doc_hash": "3c5e1c0ecd55ea988dd6ea1dc8d844aac82fe535cbc182d63918ca217cb288a4", "ref_doc_id": "3298d3c9-ac4c-4fa4-8c46-580d6a02dff1"}, "bebe27fa-9d77-41d4-afcf-1f6f1e253e4c": {"doc_hash": "3878ccb2f00324772e213959ae9b10bd3560872d0f92c16cfecae7447ea2c9bc", "ref_doc_id": "62cf158b-f6d5-42d0-8c85-0b52011455b3"}, "ae05ef28-72ef-45ee-9471-89364e5d150a": {"doc_hash": "69fc714d7a85fe77930fb5574368707bcd8d31fd8713aa7b80aa265423bcfc49", "ref_doc_id": "529016f1-4955-4c37-a5f4-9f2405e75141"}, "de23a472-dfdb-4f6f-b95e-fba4114d1a1d": {"doc_hash": "4112cc9fefd5fc86e5c10f74fe5ae945b5ae9e5ff7e25be43fcc2411cb7c2d2a", "ref_doc_id": "361e471b-00c6-45a7-ba94-00c834894e78"}, "bbf54aab-5db8-4a1a-be62-673c5ce338c4": {"doc_hash": "b768c98ec4ce83e6a1b17d1629220181ee998323f865743c26e53ca71c7d2e6e", "ref_doc_id": "2ac17a3b-4b00-4404-8a5c-052b3cc57c02"}, "38b3d38f-5320-4bd1-b750-b46e27aede6e": {"doc_hash": "42a53344bdd03cef24697d551cb961834f3145f526e3f43e698cce6318c95159", "ref_doc_id": "3f901f5a-6000-48cb-865a-0fb24ffa5ec9"}, "2955a0f9-d1f2-4c51-b3dc-ba0496b3cff3": {"doc_hash": "beecdab3c0c2553f40c8265c935096dcb503edaca7812f213a8c3d609661ca07", "ref_doc_id": "08f354ca-2695-416b-8137-6eb975303764"}, "f542bb61-6fda-45b2-a0c9-385964ced52b": {"doc_hash": "394af56895f728a3c3dd6e61fcb00ad77122e97feb52320289f8760ea9774b3a", "ref_doc_id": "07ce91a8-97af-471f-9d7f-2cd7f299d58b"}, "dff11a93-a5ca-4a58-b972-d7402574f00f": {"doc_hash": "5e8855b3532ec2e77d98cc9f93fd89488c22b0cb74b1585a1e95643b69c78db4", "ref_doc_id": "48def0cc-4f00-4942-94c3-f22222aa35e4"}, "a8491801-c310-498e-beec-9422bddae7d3": {"doc_hash": "0a6260de681079d795b20033eb0d9873e7b8573eccc73a3977437d6b27b06ddf", "ref_doc_id": "778fb013-d3dd-4975-99f0-bf5d95dcf7e6"}, "c34559a4-1cd1-47e0-a6f0-b3e833b7b1ee": {"doc_hash": "dee451d23ac500b75e5d84669d0e0d9e745386c82c0d220048f5b7fbc0623682", "ref_doc_id": "87c4514b-258b-4bcc-a239-400ffe224c5c"}, "b5d6d445-f94a-4c35-a99c-0eab5630d86f": {"doc_hash": "b0a4a78acecde8e1dfa8817d5c112130254ba6eab17353060c2cd7c3b5173cae", "ref_doc_id": "ed2a35bc-f311-4993-9006-47d5d82b7cdf"}, "e6bfebe4-de76-479d-8b42-753030872fbe": {"doc_hash": "e0eda5a3327f01c213864bb21a1c79bc74977230ad04f6ab089053a3f4ed0f23", "ref_doc_id": "ab9e7fe5-4ca5-4666-9cd9-c37063242d91"}, "97c10ad1-fbc4-4071-93a5-0459aa5dcf95": {"doc_hash": "d7941cb1170f9f4279e7ca69cd39b0a75c00a5a39015ba524de3fbc63f3e4277", "ref_doc_id": "75e60126-c46a-45f3-af43-b5770ed72b0a"}, "792110f4-aafc-4e5d-b883-afaddf8350e1": {"doc_hash": "5ac79ece3a6ad711b15171e4246df361fc892aa1a08d7e5dfb4f50c1a70e8dee", "ref_doc_id": "7847ef49-18da-4125-949f-f135eafb0765"}, "e7dacaa4-1fb5-473c-923a-8112abdfd803": {"doc_hash": "a28d439f443c3ef7850efa5dde5601fc77c568552359a8970310113df7d27ee8", "ref_doc_id": "7c30aa0a-7a23-40a8-9f6c-27b8d90fc0ef"}, "c2f00f02-bfc5-4c42-a7cf-72cdf86775e2": {"doc_hash": "59eacc6b2868f30576ee0e0ae6bcb45f87825d53edc588c74953c5a983a789ff", "ref_doc_id": "62650d87-613c-4aa5-8319-e4dcbeb91750"}, "48204bc4-21c4-46c3-a350-89018165b2b7": {"doc_hash": "3d54c83b28a0e7a7fc6798ddf1ccc26b9645c604524b4e99e3c561b741f8c7ef", "ref_doc_id": "c56fb46d-de57-4200-b42d-6e106d4bfe50"}, "62320a65-cec2-41c6-9dad-b747997468b2": {"doc_hash": "f16806d7ae535a15318770e2a501ae5d047d3e51de707132b78401f3beeff574", "ref_doc_id": "73993a4d-3307-4d84-a223-e7b970b3891b"}, "18088118-b2e8-4ece-940b-105dc7b79d66": {"doc_hash": "42e7904f8b3a819f486893a3b4e9891f70610265e2570774fa5a9093298290a4", "ref_doc_id": "75f585ac-c459-4e7f-ad84-dcd1571dc294"}, "bb69d4f6-37c7-49f2-aefe-686158865eae": {"doc_hash": "8b0b0577218c94ae18d20b8ab74e10b78aa687dd64d6b6e580ffa50271123d5e", "ref_doc_id": "9e0fa5ca-28a5-48fb-ad06-b2c1a504edd2"}, "3e20c3ae-c300-41b0-bc04-896d953147f8": {"doc_hash": "389144736367be3238a365ead53a38845e270f89308793b672078e8f334b67cb", "ref_doc_id": "59e0219d-b6c8-47ca-9185-a4a066a9267d"}, "eef29f94-f0ce-4455-99f0-504626af301f": {"doc_hash": "861aef2b8f80108e18bb124b5b1d9349f595a353192776292af718a8b2edad3f", "ref_doc_id": "4ee56aff-29a9-4368-9cfd-e9d9651c5969"}, "67ae15c0-56ac-44d0-ae06-4176736732e3": {"doc_hash": "455b274f0e2bcfcb4da3a9e71262abe4bfa54b803c222e4f3e1e47973a68dc87", "ref_doc_id": "1fa22bc9-de93-4b84-b276-e37071dfff69"}, "f8a58b5b-edef-483a-8741-9e0914e65184": {"doc_hash": "c690331ea3557344f2046d1ce1e0d0dfd7daabc0cd8c86ce469e63baffb670a2", "ref_doc_id": "16e57391-15ec-458a-857e-e54868b5be2e"}, "57609d4c-495a-4ec4-a83e-57b0c61a073d": {"doc_hash": "9ed0f49efcb2ded9c56df5f54a08bb6b9d753ae5e9ed8cb401dfbc8c2073a366", "ref_doc_id": "c5983c6f-bfeb-4c57-b0d5-60c94b41cc7b"}, "abc7144e-c3bd-46cb-a21f-9807ce99f1f6": {"doc_hash": "c8a7db9bffc8d2daf9374369b0dad88e99306ba5d328363aa2b98a37c7356cf6", "ref_doc_id": "5fe8575f-324f-4b56-939e-403e837d4033"}, "32bc7209-77ab-4bce-8d63-d13bb100a19d": {"doc_hash": "222bb6cc91faa19a7daa1199149a000e6fa58b80d23f709e2512a9f7d92ba0ce", "ref_doc_id": "f591e0df-79ae-482f-b861-d95e11f18bba"}, "f4a7782e-145b-4d3c-b2ca-a81af494bb73": {"doc_hash": "6574d2866f99f7c7fb1804e9fb984a2e5d1eb28d26aa10b6bdd42c61912e3d90", "ref_doc_id": "da29050e-a714-4084-9010-689cfb215662"}, "a2170c76-e2bc-403a-8a69-fa2e43d84cda": {"doc_hash": "07b3125a3fe4eb9f3ab8e5004c35e10738cc59bf50d2cbe3763c3d5a2a2ea33c", "ref_doc_id": "dd5a7351-3fb6-496d-8260-d171366f8bbc"}, "8e920956-4282-4493-b922-31532f0a7db6": {"doc_hash": "1369d456d44525a157dc5b711c8b2693b390a48f1460a17ec041c0ae58381f63", "ref_doc_id": "ccf28afd-0de8-4a9e-b626-188f787f67bd"}, "fb81ee37-34ee-4a0a-9458-e974f2f6995c": {"doc_hash": "395a9cfe4df0ba3fce08d27559570dd2cdb4a54c5351f231f26a9de581a796c1", "ref_doc_id": "74445be5-ae9b-4d39-8afb-0f1e1eb9ff3b"}, "f13fc810-bdce-46fe-b173-9aea0bd95359": {"doc_hash": "5dcd2ad7a4ba0223ed48146e8c1af027256ec5cce298c5ecb875b822ac30fd53", "ref_doc_id": "643fa042-c48f-404f-91c8-7f70d282dccf"}, "51f662b0-21fb-475b-85ae-6d463dcefdfb": {"doc_hash": "69418de232c53f38d14c0c770924c71a851efdccde4c0ac309d48d7c8c2e4106", "ref_doc_id": "bee3fbbb-ae52-4458-81e9-0d7d93034934"}, "58a09cb7-ac05-476c-bef9-1200bd488e0e": {"doc_hash": "457edf55edfb859a402d5b6d75802accc4bc8b08febf6fc34697c8e57a98f426", "ref_doc_id": "d865e322-2e33-4047-9bb9-0767496ee1f4"}, "f8b5b1cf-b3a3-4c9c-b5f8-0f3be0b40929": {"doc_hash": "0e50b2b9244353c7475cd64c9b9935dd84fa0e94a12acb4ee0f7187dae2f128d", "ref_doc_id": "13b47a2f-455c-48f6-bc40-7effe19ec310"}, "b54bb733-80a3-48d6-b143-381cd354c7ae": {"doc_hash": "51a539209c038f4456527d533b1e734c85ca641627851c7648ca04b1f3b35860", "ref_doc_id": "7d150a0a-1e0f-4615-bb63-fcf1a1be0218"}, "6da9d396-97e2-470c-ac2d-c6b53d97242b": {"doc_hash": "075f51bd286b821163be19de0d9d420c74db03450ecd013008c20d0279c3d91e", "ref_doc_id": "c3aeecc6-fcc5-4d9b-99d2-1a438123200e"}, "250c678c-ff1d-4e6e-a99a-5e75c03e2b4a": {"doc_hash": "fca0f7782e4bad143d0a0c62c3bfead6addbbb3da480e3de1b6515807e43e05d", "ref_doc_id": "301265b8-7434-48b1-bd47-b3bf6af1bebb"}, "a0675d16-7c7e-4a64-9ded-59a6a2e0a84e": {"doc_hash": "6e509bc98ffb7c64332141fa325a28bc3ef473d19da5ed870b277c825380ac5d", "ref_doc_id": "24fc0c7e-d12e-4f23-94c4-75dbe325b531"}, "de7f15a5-a44f-4896-81de-c0347f8e1a12": {"doc_hash": "f7c021330fae77b3c4dd5131f2bea312bcb4c0c15f4700a457770dff3a6c1e29", "ref_doc_id": "5839449d-da40-43c8-88ef-d86b525784d2"}, "dc289612-2057-40b5-b38a-9dc1d87506ca": {"doc_hash": "087439fe1916db8a04acc93e9310b6edb0bdbdf0dd035b118470559f4b52db86", "ref_doc_id": "033cce5e-e57f-4fe6-8b33-d5feedf63acd"}, "e85ba49d-b17c-4409-88a9-f60f3c46b956": {"doc_hash": "59becdb163acb3b7cd860375b471b09805e77c38e50ada182602f170b2d6b59e", "ref_doc_id": "1ca0d09a-c56a-4e41-bea4-fb6b3a8ce3ef"}, "c4104df8-7b79-4f14-9e1f-292e3011b482": {"doc_hash": "86c368fac42f3dffdc85e856e9b9d053e2b034736c9b26741ec658e809057f33", "ref_doc_id": "5687ef70-074d-416f-bcee-a5333d81db05"}}, "docstore/ref_doc_info": {"e6d5325e-bdd2-47ab-b611-6aa0165f3552": {"node_ids": ["4131d99d-1dab-4e76-bcd5-465cf5e89648"], "metadata": {"page_label": "1", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido que podr\u00eda estar relacionado:\n\n### Resumen del Contexto\nEl documento mencionado es el \"WHO - Technical Report Series 957\", que forma parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica, y recomendaciones para pr\u00e1cticas de salud a nivel global. Sin embargo, en este caso espec\u00edfico, no se proporciona contenido detallado en el texto extra\u00eddo.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los principales temas o \u00e1reas de enfoque abordados en el informe t\u00e9cnico de la OMS en la serie 957?**\n   - Esta pregunta busca identificar los temas espec\u00edficos que se discuten en el informe, que podr\u00edan incluir enfermedades, pol\u00edticas de salud, o recomendaciones para la pr\u00e1ctica m\u00e9dica.\n\n2. **\u00bfQu\u00e9 recomendaciones espec\u00edficas se hacen en el informe WHO TRS 957 para mejorar la salud p\u00fablica a nivel global?**\n   - Esta pregunta se centra en las recomendaciones pr\u00e1cticas que la OMS podr\u00eda ofrecer en el informe, que son cruciales para la implementaci\u00f3n de pol\u00edticas de salud efectivas.\n\n3. **\u00bfC\u00f3mo se compara el contenido del informe WHO TRS 957 con otros informes anteriores de la serie t\u00e9cnica de la OMS?**\n   - Esta pregunta busca establecer un contexto comparativo que podr\u00eda revelar tendencias en la investigaci\u00f3n y las recomendaciones de la OMS a lo largo del tiempo.\n\nEstas preguntas est\u00e1n dise\u00f1adas para obtener informaci\u00f3n espec\u00edfica que probablemente no se encuentre f\u00e1cilmente en otros documentos o fuentes, dado que se centran en el contenido particular del informe t\u00e9cnico mencionado.", "excerpt_keywords": "Keywords: OMS, salud p\u00fablica, informe t\u00e9cnico, recomendaciones, investigaci\u00f3n m\u00e9dica"}}, "6c5e5cef-722b-4ab8-aa76-f7735b954206": {"node_ids": ["441f993a-a697-4ca8-a84e-800acc7a1abf"], "metadata": {"page_label": "2", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO\u2019s constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.\n\nThe Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization\u2019s priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO\u2019s Member countries and the collaboration of world leaders in public health and the biomedical sciences.\n\nTo ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO\u2019s books contribute to achieving the Organization\u2019s principal objective \u2014 the attainment by all people of the highest possible level of health.\n\n----\n\nThe *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about six such reports, costs CHF/US$ 188.00 (CHF/US$ 143.00 in developing countries). For further information, please contact WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int; order online at http://www.who.int/bookorders).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nLa Organizaci\u00f3n Mundial de la Salud (OMS) fue establecida en 1948 como una agencia especializada de las Naciones Unidas, con el objetivo de ser la autoridad coordinadora en asuntos de salud internacional y salud p\u00fablica. La OMS tiene la responsabilidad de proporcionar informaci\u00f3n objetiva y confiable en el campo de la salud humana, lo que realiza a trav\u00e9s de una amplia gama de publicaciones. Estas publicaciones buscan apoyar las estrategias de salud nacionales y abordar preocupaciones de salud p\u00fablica a nivel global, ofreciendo manuales, gu\u00edas, an\u00e1lisis de pol\u00edticas y recomendaciones t\u00e9cnicas. La serie de informes t\u00e9cnicos de la OMS presenta hallazgos de grupos de expertos que brindan asesoramiento cient\u00edfico y t\u00e9cnico sobre diversos temas de salud. La OMS tambi\u00e9n se esfuerza por asegurar la distribuci\u00f3n internacional de sus publicaciones y fomentar su traducci\u00f3n y adaptaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los tipos de publicaciones que la OMS ofrece para apoyar a los trabajadores de la salud y a los pa\u00edses en desarrollo?**\n   - La OMS publica manuales pr\u00e1cticos, gu\u00edas internacionales, an\u00e1lisis de pol\u00edticas y programas, y reportes de consenso que ofrecen recomendaciones t\u00e9cnicas.\n\n2. **\u00bfQu\u00e9 costo tiene una suscripci\u00f3n anual a la *Serie de Informes T\u00e9cnicos de la OMS* y c\u00f3mo var\u00eda seg\u00fan el nivel de desarrollo del pa\u00eds?**\n   - Una suscripci\u00f3n anual cuesta CHF/US$ 188.00, y CHF/US$ 143.00 en pa\u00edses en desarrollo.\n\n3. **\u00bfC\u00f3mo asegura la OMS la disponibilidad de informaci\u00f3n y gu\u00edas sobre salud a nivel internacional?**\n   - La OMS asegura la amplia distribuci\u00f3n internacional de sus publicaciones y fomenta su traducci\u00f3n y adaptaci\u00f3n para alcanzar una mayor disponibilidad de informaci\u00f3n autorizada sobre salud.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 957\" es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque el contenido espec\u00edfico no est\u00e1 disponible en el extracto proporcionado, se pueden inferir algunos temas clave y entidades relevantes:\n\n#### Temas Clave\n1. **Salud P\u00fablica**: El informe probablemente aborda cuestiones relacionadas con la salud p\u00fablica a nivel global, incluyendo enfermedades, prevenci\u00f3n y control de epidemias.\n2. **Investigaci\u00f3n M\u00e9dica**: Es posible que se discutan avances en la investigaci\u00f3n m\u00e9dica y su aplicaci\u00f3n en pol\u00edticas de salud.\n3. **Recomendaciones de Salud**: El informe podr\u00eda incluir recomendaciones para mejorar pr\u00e1cticas de salud y pol\u00edticas en diferentes contextos.\n\n#### Entidades\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la publicaci\u00f3n del informe, que se dedica a coordinar esfuerzos internacionales en salud p\u00fablica.\n- **Informe T\u00e9cnico**: El documento en s\u00ed, que forma parte de una serie m\u00e1s amplia de informes t\u00e9cnicos que la OMS publica regularmente.\n\nEste resumen proporciona una visi\u00f3n general de los posibles temas y entidades que podr\u00edan estar presentes en el informe, a pesar de la falta de contenido espec\u00edfico en el extracto.", "excerpt_keywords": "Keywords: World Health Organization, public health, technical reports, health publications, disease prevention"}}, "8d0b0a58-a1d8-4779-a673-b12be1a022ac": {"node_ids": ["49eeb952-0fe1-4ced-a73a-c8be3173b2b1"], "metadata": {"page_label": "3", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido:\n\n### Resumen del Contexto\nEl documento mencionado es el \"WHO - Technical Report Series 957\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica y recomendaciones para pr\u00e1cticas de salud a nivel global. Sin embargo, en este caso espec\u00edfico, no se proporciona contenido detallado en el texto extra\u00eddo.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los principales temas o \u00e1reas de enfoque abordados en el informe t\u00e9cnico de la OMS, \"Technical Report Series 957\"?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el contenido del informe, que podr\u00eda incluir temas de salud p\u00fablica, pol\u00edticas de salud, o investigaciones relevantes.\n\n2. **\u00bfQu\u00e9 recomendaciones o directrices espec\u00edficas se presentan en el \"Technical Report Series 957\" para mejorar la salud p\u00fablica a nivel global?**\n   - Aqu\u00ed se indaga sobre las posibles recomendaciones que la OMS podr\u00eda haber hecho en este informe, lo que podr\u00eda ser \u00fatil para profesionales de la salud y responsables de pol\u00edticas.\n\n3. **\u00bfC\u00f3mo se relaciona el \"Technical Report Series 957\" con otros informes de la OMS en t\u00e9rminos de continuidad de investigaci\u00f3n o evoluci\u00f3n de pol\u00edticas de salud?**\n   - Esta pregunta busca establecer conexiones entre este informe y otros documentos de la OMS, lo que podr\u00eda ayudar a entender la evoluci\u00f3n de las recomendaciones y pol\u00edticas de salud a lo largo del tiempo.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que podr\u00eda no estar disponible en otros documentos o fuentes, dado que el contenido del informe no se ha proporcionado en el contexto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**:\n   - Establecida en 1948 como agencia especializada de las Naciones Unidas.\n   - Funci\u00f3n principal: autoridad coordinadora en asuntos de salud internacional y salud p\u00fablica.\n\n2. **Publicaciones de la OMS**:\n   - Proporciona informaci\u00f3n objetiva y confiable en salud humana.\n   - Tipos de publicaciones:\n     - Manuales pr\u00e1cticos y material de capacitaci\u00f3n para trabajadores de la salud.\n     - Gu\u00edas y est\u00e1ndares internacionalmente aplicables.\n     - An\u00e1lisis de pol\u00edticas y programas de salud.\n     - Reportes de consenso con recomendaciones t\u00e9cnicas.\n\n3. **Objetivos de las Publicaciones**:\n   - Apoyar estrategias de salud nacionales.\n   - Abordar preocupaciones de salud p\u00fablica global.\n   - Promover la prevenci\u00f3n de enfermedades y el desarrollo de sistemas de salud equitativos.\n\n4. **Distribuci\u00f3n y Accesibilidad**:\n   - Asegura la distribuci\u00f3n internacional de sus publicaciones.\n   - Fomenta la traducci\u00f3n y adaptaci\u00f3n de materiales para mayor disponibilidad.\n\n5. **Serie de Informes T\u00e9cnicos de la OMS**:\n   - Presenta hallazgos de grupos de expertos en temas de salud.\n   - Suscripci\u00f3n anual: CHF/US$ 188.00 (CHF/US$ 143.00 en pa\u00edses en desarrollo).\n\n6. **Contacto**:\n   - Informaci\u00f3n de contacto para suscripciones y consultas: WHO Press, Ginebra, Suiza.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**\n- **Naciones Unidas**\n- **Expertos internacionales en salud p\u00fablica**\n- **Pa\u00edses en desarrollo** \n\nEste resumen destaca la misi\u00f3n de la OMS, la variedad de sus publicaciones y su compromiso con la salud global, as\u00ed como detalles sobre la suscripci\u00f3n a su serie de informes t\u00e9cnicos.", "excerpt_keywords": "Keywords: OMS, salud p\u00fablica, informes t\u00e9cnicos, recomendaciones, pol\u00edticas de salud"}}, "12fadc77-0e2f-4907-8a90-9ae6f59152a3": {"node_ids": ["19793f11-d73e-435d-9bd8-7a245690f691"], "metadata": {"page_label": "4", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# WHO Library Cataloguing-in-Publication Data\n\nForty-fourth report of the WHO Expert Committee on specifications for pharmaceutical preparations.\n\n(WHO technical report series; no. 957)\n\n1. Pharmaceutical preparations \u2014 standards. 2. Technology, Pharmaceuticals \u2014 standards. 3. Drug industry \u2014 legislation. 4. Quality control. I. World Health Organization. II. Series.\n\nISBN 978 92 4 120957 1  \nISSN 0512-3054  \n(NLM classification: QV 771)\n\n----\n\n\u00a9 World Health Organization 2010\n\nAll rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications\u2014whether for sale or for noncommercial distribution\u2014should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).\n\nThe designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.\n\nThe mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.\n\nAll reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.\n\nThis publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.\n\n*Typeset in Switzerland*  \n*Printed in Switzerland*", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es el \"Cuarenta y cuarto informe del Comit\u00e9 de Expertos de la OMS sobre especificaciones para preparaciones farmac\u00e9uticas\", publicado en la serie de informes t\u00e9cnicos de la OMS (n\u00famero 957). Este informe aborda est\u00e1ndares para preparaciones farmac\u00e9uticas, tecnolog\u00eda farmac\u00e9utica, legislaci\u00f3n en la industria farmac\u00e9utica y control de calidad. Se menciona que la publicaci\u00f3n contiene las opiniones colectivas de un grupo internacional de expertos y no necesariamente representa las decisiones o pol\u00edticas de la OMS. Adem\u00e1s, se incluyen detalles sobre derechos de autor, contacto para pedidos y permisos, y una declaraci\u00f3n de responsabilidad sobre la informaci\u00f3n presentada.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los temas principales abordados en el informe del Comit\u00e9 de Expertos de la OMS sobre especificaciones para preparaciones farmac\u00e9uticas?**\n   - Respuesta: Los temas principales incluyen est\u00e1ndares para preparaciones farmac\u00e9uticas, tecnolog\u00eda farmac\u00e9utica, legislaci\u00f3n en la industria farmac\u00e9utica y control de calidad.\n\n2. **\u00bfQu\u00e9 advertencias se hacen sobre la informaci\u00f3n contenida en la publicaci\u00f3n y la responsabilidad del lector?**\n   - Respuesta: Se advierte que la informaci\u00f3n se distribuye sin garant\u00eda de ning\u00fan tipo y que la responsabilidad de la interpretaci\u00f3n y uso del material recae en el lector. La OMS no ser\u00e1 responsable de da\u00f1os derivados del uso de la informaci\u00f3n.\n\n3. **\u00bfQu\u00e9 se indica sobre la menci\u00f3n de productos o empresas espec\u00edficas en el informe?**\n   - Respuesta: La menci\u00f3n de productos o empresas no implica que sean respaldados o recomendados por la OMS en preferencia a otros productos similares que no se mencionan. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no ser f\u00e1cilmente accesible en otros documentos o fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento mencionado, \"WHO - Technical Report Series 957\", es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque el contenido espec\u00edfico no est\u00e1 disponible en el texto extra\u00eddo, se pueden inferir algunos temas y entidades clave:\n\n#### Temas Clave\n1. **Salud P\u00fablica**: El informe probablemente aborda cuestiones relevantes para la salud p\u00fablica a nivel global, incluyendo pol\u00edticas, pr\u00e1cticas y recomendaciones.\n2. **Investigaci\u00f3n M\u00e9dica**: Es posible que el documento incluya hallazgos de investigaciones recientes en el campo de la salud.\n3. **Recomendaciones de la OMS**: Se espera que el informe contenga directrices o recomendaciones para mejorar la salud p\u00fablica y guiar a los profesionales de la salud.\n\n#### Entidades\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la publicaci\u00f3n del informe, que se dedica a coordinar esfuerzos internacionales en salud p\u00fablica.\n- **Technical Report Series**: La serie a la que pertenece este informe, que incluye m\u00faltiples documentos t\u00e9cnicos sobre diversos temas de salud.\n\nEste resumen proporciona una visi\u00f3n general de los posibles temas y entidades relevantes en el contexto del informe, a pesar de la falta de contenido espec\u00edfico en el texto extra\u00eddo.", "excerpt_keywords": "Pharmaceutical preparations, Quality control, WHO Expert Committee, Drug industry legislation, Technical report series"}}, "30fe9bc0-caf8-4f11-913f-90cc73eec111": {"node_ids": ["975f072c-b766-4ceb-8b61-0d754f1bf738"], "metadata": {"page_label": "5", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Contents\n\n1. **Introduction**  \n   1\n\n2. **General policy**  \n   3  \n   2.1 International collaboration  \n   3  \n   2.1.1 International organizations, agencies and nongovernmental organizations  \n   3  \n   - European Directorate for the Quality of Medicines and HealthCare  \n     3  \n   - European Medicines Agency  \n     4  \n   - The Global Fund to Fight AIDS, Tuberculosis and Malaria  \n     4  \n   - Groupement International de la R\u00e9partition Pharmaceutique \u2014 European Association of Pharmaceutical Full-line Wholesalers  \n     4  \n   - International Federation of Pharmaceutical Manufacturers and Associations  \n     5  \n   - International Generic Pharmaceutical Alliance  \n     5  \n   - International Pharmaceutical Federation  \n     6  \n   - United Nations Children\u2019s Fund  \n     6  \n   2.1.2 Pharmacopoeial Discussion Group  \n   7  \n   2.1.3 International Conference on Harmonisation  \n   8  \n   2.1.4 International Conference of Drug Regulatory Authorities  \n   8  \n   2.2 Cross-cutting issues in pharmaceuticals \u2014 quality assurance issues  \n   9  \n   2.2.1 Herbal medicines  \n   9  \n   2.2.2 Biologicals and vaccines  \n   10  \n   2.2.3 Blood products  \n   11  \n   2.2.4 Essential medicines  \n   11  \n   2.2.5 Regulatory support  \n   13  \n   2.2.6 HIV-related activities  \n   14  \n   2.3 Counterfeit medicines  \n   14  \n\n3. **Quality control \u2014 specifications and tests**  \n   16  \n   3.1 *The International Pharmacopoeia*  \n   16  \n   3.2 Current work plan and future work programme  \n   19  \n   3.3 Specifications for medicines, including children\u2019s medicines  \n   23  \n   3.3.1 Medicines for HIV and related conditions  \n   23  \n   3.3.2 Antimalarial medicines  \n   23  \n   3.3.3 Antituberculosis medicines  \n   24  \n   3.3.4 Other medicines  \n   25  \n   3.4 Revision of texts of *The International Pharmacopoeia*  \n   26  \n   3.4.1 Antimalarials: artemisinin derivatives  \n   26  \n   3.4.2 Antibiotics  \n   27  \n   3.4.3 Other medicines  \n   28  \n   3.4.4 Heparin  \n   28  \n   3.5 Review of published general monographs for dosage forms  \n   29  \n   3.6 General policy topics and general revision issues  \n   30  \n   3.7 Radiopharmaceuticals  \n   33  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a generar preguntas m\u00e1s espec\u00edficas:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 957\" aborda temas relacionados con la pol\u00edtica general en el \u00e1mbito farmac\u00e9utico, la colaboraci\u00f3n internacional, y la calidad y control de medicamentos. Se discuten diversas organizaciones internacionales y su papel en la regulaci\u00f3n y aseguramiento de la calidad de los medicamentos, as\u00ed como cuestiones espec\u00edficas como medicamentos esenciales, productos biol\u00f3gicos, y la lucha contra medicamentos falsificados. Tambi\u00e9n se detalla el trabajo en curso y los planes futuros para la elaboraci\u00f3n de especificaciones y pruebas de calidad, incluyendo la revisi\u00f3n de textos de la Farmacopea Internacional.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 papel desempe\u00f1an las organizaciones internacionales mencionadas en el documento en la regulaci\u00f3n de medicamentos y c\u00f3mo se coordinan entre s\u00ed?**\n   - Esta pregunta busca una respuesta detallada sobre la colaboraci\u00f3n y las funciones espec\u00edficas de las organizaciones como la EMA, el Global Fund, y otras, en el contexto de la regulaci\u00f3n farmac\u00e9utica.\n\n2. **\u00bfCu\u00e1les son los principales desaf\u00edos en la garant\u00eda de calidad de los medicamentos esenciales seg\u00fan el informe, y qu\u00e9 estrategias se proponen para abordarlos?**\n   - Esta pregunta se centra en los problemas espec\u00edficos que enfrenta la calidad de los medicamentos esenciales y las soluciones sugeridas en el documento.\n\n3. **\u00bfQu\u00e9 avances se han logrado en la revisi\u00f3n de textos de *La Farmacopea Internacional* y cu\u00e1les son las \u00e1reas prioritarias para futuras revisiones?**\n   - Esta pregunta busca informaci\u00f3n sobre el progreso en la actualizaci\u00f3n de la Farmacopea Internacional, as\u00ed como las \u00e1reas que requieren atenci\u00f3n inmediata, como los derivados de artemisinina y los antibi\u00f3ticos.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y detallada que probablemente no se encuentre f\u00e1cilmente en otras fuentes, bas\u00e1ndose en el contenido del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Est\u00e1ndares para Preparaciones Farmac\u00e9uticas:** El informe aborda las especificaciones y est\u00e1ndares necesarios para la calidad de las preparaciones farmac\u00e9uticas.\n2. **Tecnolog\u00eda Farmac\u00e9utica:** Se discuten las tecnolog\u00edas aplicadas en la industria farmac\u00e9utica y su estandarizaci\u00f3n.\n3. **Legislaci\u00f3n en la Industria Farmac\u00e9utica:** Se examinan las normativas y leyes que rigen la industria farmac\u00e9utica.\n4. **Control de Calidad:** Se enfatiza la importancia del control de calidad en la producci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos.\n\n**Entidades:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad responsable de la publicaci\u00f3n y del contenido del informe.\n- **Comit\u00e9 de Expertos de la OMS:** Grupo internacional de expertos que contribuye con sus opiniones y recomendaciones en el informe.\n- **WHO Press:** Entidad encargada de la distribuci\u00f3n de las publicaciones de la OMS.\n\n**Otros Detalles:**\n- **ISBN y ISSN:** Identificadores de la publicaci\u00f3n.\n- **Derechos de Autor:** Se menciona que todos los derechos est\u00e1n reservados y se proporcionan detalles de contacto para pedidos y permisos.\n- **Advertencias sobre la Informaci\u00f3n:** Se aclara que la informaci\u00f3n se distribuye sin garant\u00eda y que la responsabilidad de su uso recae en el lector. \n\nEste resumen proporciona una visi\u00f3n general de los temas tratados en el informe y las entidades involucradas en su creaci\u00f3n y distribuci\u00f3n.", "excerpt_keywords": "Keywords: pharmaceuticals, quality assurance, international collaboration, counterfeit medicines, pharmacopoeia"}}, "88e4382f-b126-4d2b-9c9f-e955378d9fc7": {"node_ids": ["28b5a7f5-5d41-4cc9-b27b-137bb0fab6a5"], "metadata": {"page_label": "6", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\n4. Quality control \u2014 international reference materials  \n   (International Chemical Reference Substances and  \n   International Infrared Reference Spectra)  \n   4.1 Annual report of the WHO Collaborating Centre 36  \n   4.2 Adoption of new International Chemical Reference Substances 36  \n   4.3 New institution for the establishment of international reference materials 36  \n\n5. Quality control \u2014 national laboratories  \n   5.1 External Quality Assurance Assessment Scheme 37  \n   5.2 WHO good practices for quality control laboratories 39  \n   5.3 WHO good practices for pharmaceutical microbiology laboratories 42  \n\n6. Quality assurance \u2014 good manufacturing practices  \n   6.1 WHO good manufacturing practices: main principles  \n       for pharmaceutical products 42  \n   6.2 WHO good manufacturing practices for active  \n       pharmaceutical ingredients 43  \n   6.3 WHO good manufacturing practices for pharmaceutical  \n       products containing hazardous substances 44  \n   6.4 WHO good manufacturing practices for sterile  \n       pharmaceutical products 44  \n   6.5 Updates of other WHO good manufacturing practices texts 45  \n   6.6 Good manufacturing practices for blood establishments 45  \n\n7. Quality assurance \u2014 new approaches  \n   7.1 Risk analysis 47  \n   7.2 WHO guidelines on technology transfer 48  \n\n8. Quality assurance \u2014 distribution and trade of pharmaceuticals  \n   8.1 WHO Certification Scheme on the quality of pharmaceutical  \n       products moving in international commerce 49  \n   8.2 WHO good distribution practices for pharmaceutical products 50  \n   8.3 Regulatory oversight on pharmaceutical cold chain management 51  \n\n9. Prequalification of priority essential medicines  \n   9.1 Prequalification Programme managed by WHO 52  \n   9.2 Guidelines on requalification of prequalified dossiers 57  \n   9.3 Guidelines for the preparation of a contract research  \n       organization master file 58  \n\n10. Nomenclature, terminology and databases  \n    10.1 Quality assurance terminology 59  \n    10.2 International nonproprietary names 61  \n    10.3 Pharmacopoeial references 61  \n\n11. Miscellaneous  \n    11.1 WHO Model List of Essential Medicines 62  \n    11.2 Update on stability 62  \n    11.3 Diethylene glycol 64  \n\n12. Summary and recommendations 65  \n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 957\" aborda diversos aspectos de la calidad y el control en la producci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos. Se centra en la calidad de los materiales de referencia internacionales, las buenas pr\u00e1cticas de fabricaci\u00f3n, la evaluaci\u00f3n de la calidad en laboratorios nacionales, y la precalificaci\u00f3n de medicamentos esenciales. Tambi\u00e9n se discuten nuevas aproximaciones en la garant\u00eda de calidad, incluyendo el an\u00e1lisis de riesgos y la transferencia de tecnolog\u00eda. Adem\u00e1s, se abordan temas de nomenclatura y bases de datos relevantes para la industria farmac\u00e9utica.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son los principales principios de las buenas pr\u00e1cticas de fabricaci\u00f3n seg\u00fan la OMS para productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en el apartado 6.1 del documento, que detalla los principios fundamentales que deben seguirse en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 incluye el esquema de evaluaci\u00f3n externa de aseguramiento de calidad para laboratorios nacionales mencionado en el documento?**\n   - Esta pregunta se relaciona con el apartado 5.1, que describe el esquema de evaluaci\u00f3n y c\u00f3mo se implementa en los laboratorios nacionales.\n\n3. **\u00bfCu\u00e1les son las pautas para la preparaci\u00f3n de un archivo maestro de organizaci\u00f3n de investigaci\u00f3n por contrato seg\u00fan el documento?**\n   - Esta pregunta se refiere al apartado 9.3, que proporciona directrices espec\u00edficas sobre c\u00f3mo preparar un archivo maestro para organizaciones de investigaci\u00f3n que trabajan en la precalificaci\u00f3n de medicamentos esenciales. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y detallada que no se puede encontrar f\u00e1cilmente en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 957\" aborda varios temas fundamentales relacionados con la pol\u00edtica farmac\u00e9utica y la calidad de los medicamentos. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas en la secci\u00f3n:\n\n#### Temas Clave\n\n1. **Introducci\u00f3n**: Presenta el contexto general del informe y su relevancia en el \u00e1mbito de la salud p\u00fablica y la regulaci\u00f3n farmac\u00e9utica.\n\n2. **Pol\u00edtica General**:\n   - **Colaboraci\u00f3n Internacional**: Se discute la importancia de la cooperaci\u00f3n entre diversas organizaciones para mejorar la regulaci\u00f3n y la calidad de los medicamentos.\n   - **Cuestiones Transversales en Farmac\u00e9uticos**: Incluye temas como la garant\u00eda de calidad, medicamentos esenciales, productos biol\u00f3gicos, y la lucha contra medicamentos falsificados.\n\n3. **Control de Calidad**:\n   - **Especificaciones y Pruebas**: Se detalla el trabajo en curso y los planes futuros para la elaboraci\u00f3n de especificaciones de calidad, incluyendo la revisi\u00f3n de textos de *La Farmacopea Internacional*.\n\n#### Entidades Mencionadas\n\n- **Organizaciones Internacionales**:\n  - **European Directorate for the Quality of Medicines and HealthCare**\n  - **European Medicines Agency (EMA)**\n  - **The Global Fund to Fight AIDS, Tuberculosis and Malaria**\n  - **International Federation of Pharmaceutical Manufacturers and Associations**\n  - **International Generic Pharmaceutical Alliance**\n  - **International Pharmaceutical Federation**\n  - **United Nations Children\u2019s Fund (UNICEF)**\n\n- **Grupos de Discusi\u00f3n y Conferencias**:\n  - **Pharmacopoeial Discussion Group**\n  - **International Conference on Harmonisation**\n  - **International Conference of Drug Regulatory Authorities**\n\n#### Conclusi\u00f3n\n\nEl documento enfatiza la necesidad de colaboraci\u00f3n internacional y el establecimiento de est\u00e1ndares de calidad para garantizar la seguridad y eficacia de los medicamentos. Se abordan desaf\u00edos espec\u00edficos en la regulaci\u00f3n de medicamentos esenciales y se delinean planes para la revisi\u00f3n y actualizaci\u00f3n de las especificaciones de calidad en la Farmacopea Internacional.", "excerpt_keywords": "Keywords: quality control, good manufacturing practices, pharmaceutical microbiology, prequalification, international reference materials"}}, "47aac78d-be94-4b90-8b4b-2f99aa8b8076": {"node_ids": ["e44d2700-8361-410f-934c-6e2571538d92"], "metadata": {"page_label": "7", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\nAnnex 1  \nWHO good practices for pharmaceutical quality control laboratories  81\n\nAnnex 2  \nWHO good manufacturing practices for active pharmaceutical ingredients  130\n\nAnnex 3  \nWHO good manufacturing practices for pharmaceutical products containing hazardous substances  192\n\nAnnex 4  \nWHO good manufacturing practices for sterile pharmaceutical products  209\n\nAnnex 5  \nWHO good distribution practices for pharmaceutical products  235\n\nAnnex 6  \nGuidelines on the requalification of prequalified dossiers  265\n\nAnnex 7  \nGuidelines for the preparation of a contract research organization master file  271\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 957\" incluye varios anexos que abordan buenas pr\u00e1cticas y directrices relacionadas con la calidad y fabricaci\u00f3n de productos farmac\u00e9uticos. Estos anexos cubren temas como el control de calidad, la fabricaci\u00f3n de ingredientes activos, la gesti\u00f3n de productos farmac\u00e9uticos peligrosos, la producci\u00f3n de productos est\u00e9riles, las pr\u00e1cticas de distribuci\u00f3n y la preparaci\u00f3n de archivos maestros para organizaciones de investigaci\u00f3n por contrato.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las buenas pr\u00e1cticas recomendadas por la OMS para los laboratorios de control de calidad farmac\u00e9utica seg\u00fan el Anexo 1?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las directrices que se encuentran en el primer anexo del documento, que no se puede encontrar f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 se aborda en el Anexo 3 sobre la fabricaci\u00f3n de productos farmac\u00e9uticos que contienen sustancias peligrosas?**\n   - Esta pregunta se centra en un tema cr\u00edtico que puede no estar ampliamente discutido en otros documentos, lo que permite obtener detalles sobre las buenas pr\u00e1cticas en este \u00e1mbito.\n\n3. **\u00bfQu\u00e9 directrices se ofrecen en el Anexo 7 para la preparaci\u00f3n de un archivo maestro de una organizaci\u00f3n de investigaci\u00f3n por contrato?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las recomendaciones para las organizaciones de investigaci\u00f3n, un tema que puede ser menos conocido y que tiene implicaciones importantes para la industria farmac\u00e9utica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 957\" aborda una variedad de temas relacionados con la calidad y el control en la producci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas en la secci\u00f3n:\n\n#### Temas Clave:\n1. **Control de Calidad**:\n   - Materiales de referencia internacionales (sustancias qu\u00edmicas y espectros infrarrojos).\n   - Evaluaci\u00f3n de calidad en laboratorios nacionales.\n   - Buenas pr\u00e1cticas de control de calidad en laboratorios y microbiolog\u00eda farmac\u00e9utica.\n\n2. **Aseguramiento de Calidad**:\n   - Buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para productos farmac\u00e9uticos, ingredientes activos y productos peligrosos.\n   - Nuevas aproximaciones en aseguramiento de calidad, incluyendo an\u00e1lisis de riesgos y transferencia de tecnolog\u00eda.\n\n3. **Distribuci\u00f3n y Comercio de Productos Farmac\u00e9uticos**:\n   - Esquema de certificaci\u00f3n de calidad para productos farmac\u00e9uticos en comercio internacional.\n   - Buenas pr\u00e1cticas de distribuci\u00f3n y gesti\u00f3n de la cadena de fr\u00edo.\n\n4. **Precalificaci\u00f3n de Medicamentos Esenciales**:\n   - Programa de precalificaci\u00f3n gestionado por la OMS.\n   - Directrices para la revalidaci\u00f3n de expedientes precalificados y preparaci\u00f3n de archivos maestros para organizaciones de investigaci\u00f3n.\n\n5. **Nomenclatura y Terminolog\u00eda**:\n   - Terminolog\u00eda de aseguramiento de calidad y nombres no propietarios internacionales.\n   - Referencias farmacop\u00e9icas.\n\n6. **Miscellaneous**:\n   - Lista Modelo de Medicamentos Esenciales de la OMS.\n   - Actualizaciones sobre estabilidad y sustancias espec\u00edficas como el glicol dietileno.\n\n#### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Principal entidad responsable de establecer y promover est\u00e1ndares de calidad en productos farmac\u00e9uticos.\n- **Laboratorios Nacionales**: Entidades que participan en la evaluaci\u00f3n y aseguramiento de la calidad de productos farmac\u00e9uticos a nivel nacional.\n- **Organizaciones de Investigaci\u00f3n por Contrato**: Entidades que colaboran en la precalificaci\u00f3n de medicamentos esenciales.\n\nEste resumen proporciona una visi\u00f3n general de los temas tratados en la secci\u00f3n, destacando la importancia de la calidad y el control en la industria farmac\u00e9utica, as\u00ed como las directrices y pr\u00e1cticas recomendadas por la OMS.", "excerpt_keywords": "Keywords: buenas pr\u00e1cticas, control de calidad, productos farmac\u00e9uticos, fabricaci\u00f3n, OMS"}}, "08349f13-d674-4036-a85a-d7a48961fa68": {"node_ids": ["9bd902b8-e7ab-4a23-bdb3-3c57e121dcd3"], "metadata": {"page_label": "8", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento mencionado es el \"WHO - Technical Report Series 957\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica y recomendaciones para la pr\u00e1ctica cl\u00ednica y la pol\u00edtica de salud. Sin embargo, el contenido espec\u00edfico del informe 957 no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el informe WHO - Technical Report Series 957?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el contenido del informe, que no se puede encontrar en otros lugares sin acceso al documento completo.\n\n2. **\u00bfQu\u00e9 temas de salud p\u00fablica se abordan en la serie de informes t\u00e9cnicos de la OMS, y c\u00f3mo se relaciona el informe 957 con esos temas?**\n   - Esta pregunta permite explorar el contexto m\u00e1s amplio de la serie de informes y c\u00f3mo el informe 957 se integra en la discusi\u00f3n general sobre salud p\u00fablica.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas se utilizan en el informe WHO - Technical Report Series 957 para abordar los problemas de salud discutidos?**\n   - Esta pregunta se centra en las t\u00e9cnicas y enfoques espec\u00edficos que el informe puede haber utilizado, lo que podr\u00eda no estar disponible en otros documentos o res\u00famenes. \n\nEstas preguntas est\u00e1n dise\u00f1adas para profundizar en el contenido espec\u00edfico del informe y su relevancia en el campo de la salud p\u00fablica.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento \"WHO - Technical Report Series 957\" presenta una serie de anexos que establecen directrices y buenas pr\u00e1cticas en el \u00e1mbito farmac\u00e9utico. A continuaci\u00f3n se detallan los temas clave de cada anexo:\n\n1. **Anexo 1: Buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica**\n   - Directrices sobre c\u00f3mo asegurar la calidad en los laboratorios que realizan pruebas y an\u00e1lisis de productos farmac\u00e9uticos.\n\n2. **Anexo 2: Buenas pr\u00e1cticas de fabricaci\u00f3n para ingredientes farmac\u00e9uticos activos**\n   - Normas para la producci\u00f3n de ingredientes que son fundamentales para la elaboraci\u00f3n de medicamentos.\n\n3. **Anexo 3: Buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos que contienen sustancias peligrosas**\n   - Recomendaciones espec\u00edficas para manejar y producir productos que contienen sustancias que pueden ser peligrosas para la salud.\n\n4. **Anexo 4: Buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles**\n   - Directrices para la producci\u00f3n de medicamentos que deben ser est\u00e9riles, asegurando la seguridad y eficacia del producto.\n\n5. **Anexo 5: Buenas pr\u00e1cticas de distribuci\u00f3n para productos farmac\u00e9uticos**\n   - Normas que regulan la distribuci\u00f3n de productos farmac\u00e9uticos para mantener su calidad y seguridad durante el transporte y almacenamiento.\n\n6. **Anexo 6: Directrices sobre la revalidaci\u00f3n de expedientes prequalificados**\n   - Procedimientos para asegurar que los expedientes de productos farmac\u00e9uticos mantengan su validez y calidad a lo largo del tiempo.\n\n7. **Anexo 7: Directrices para la preparaci\u00f3n de un archivo maestro de una organizaci\u00f3n de investigaci\u00f3n por contrato**\n   - Recomendaciones para la creaci\u00f3n y mantenimiento de archivos que documenten las actividades de investigaci\u00f3n realizadas por organizaciones externas.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices y buenas pr\u00e1cticas mencionadas en los anexos.\n- **Laboratorios de control de calidad**: Entidades que realizan pruebas y an\u00e1lisis de productos farmac\u00e9uticos.\n- **Ingredientes farmac\u00e9uticos activos**: Componentes esenciales en la fabricaci\u00f3n de medicamentos.\n- **Productos farmac\u00e9uticos peligrosos**: Medicamentos que contienen sustancias que pueden representar un riesgo para la salud.\n- **Productos farmac\u00e9uticos est\u00e9riles**: Medicamentos que deben estar libres de microorganismos.\n- **Organizaciones de investigaci\u00f3n por contrato**: Entidades que realizan investigaciones en nombre de otras organizaciones, siguiendo directrices espec\u00edficas. \n\nEste resumen proporciona una visi\u00f3n general de los temas tratados en el documento y las entidades involucradas en el contexto de las buenas pr\u00e1cticas farmac\u00e9uticas.", "excerpt_keywords": "Keywords: OMS, buenas pr\u00e1cticas, farmac\u00e9uticos, control de calidad, directrices"}}, "25d3a2b3-a6be-42f4-ab0d-fe9ed2f6683a": {"node_ids": ["e47e63b2-ff77-4698-a998-16a123df9a58"], "metadata": {"page_label": "9", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# WHO Expert Committee on Specifications for Pharmaceutical Preparations\n\nGeneva, 12\u201316 October 2009\n\n## Members\n\n- **Professor Saleh A. Bawazir**, Head of Drug Sector and Vice-President, Saudi Food and Drug Authority (SFDA), Riyadh, Saudi Arabia\n- **Mr Jean-Michel Caudron**,\u00b9 Braine-le-Ch\u00e2teau, Belgium\n- **Professor Theo G. Dekker**, Research Institute for Industrial Pharmacy, Potchefstroom, South Africa\n- **Ms Nilka M. Guerrero Rivas**, Aseguramiento de la Calidad, Instituto Especializado de An\u00e1lisis, Ciudad Universitaria Octavio M\u00e9ndez Pereira, Panam\u00e1, Republic of Panama *(Co-Rapporteur)*\n- **Professor Jos Hoogmartens**, Laboratorium voor Farmaceutische Analyse, Leuven, Belgium *(Chairperson)*\n- **Professor Jin Shaohong**, Executive Deputy Director, National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing, People\u2019s Republic of China\n- **Dr John H. McB. Miller**, Strasbourg, France\n- **Dr Justina A. Molzon**, Associate Director for International Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA *(Co-Chairperson)*\n- **Ms Metta Treebamrong**,\u00b9 Senior Pharmacist, Drug Quality and Safety, Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand\n- **Mr Eshetu Wondemagegnehu Biwota**, Addis Ababa, Ethiopia *(Co-Rapporteur)*\n\n## Temporary Advisers\n\n- **Professor Ivan Addae-Mensah**, Professor of Chemistry, University of Ghana, Legon, Ghana\n- **Professor Henning G. Kristensen**,\u00b9 Vedbaek, Denmark\n- **Ms Marie-Louise Rabouhans**, Chiswick, London, England\n- **Dr Jean-Louis Robert**,\u00b9 Service du Contr\u00f4le des M\u00e9dicaments, Laboratoire National de Sant\u00e9, Luxembourg\n- **Dr Saranjit Singh**, Professor and Head, Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Nagar, India\n- **Mr Robert Tribe**, Holder, ACT, Australia\n\n----\n\n\u00b9 Unable to attend.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es un informe de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre la reuni\u00f3n del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas, que tuvo lugar en Ginebra del 12 al 16 de octubre de 2009. El informe incluye una lista de miembros y asesores temporales que participaron en la reuni\u00f3n, destacando sus roles y afiliaciones. Algunos miembros son co-rapporteurs y se mencionan aquellos que no pudieron asistir.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQui\u00e9nes fueron los co-rapporteurs en la reuni\u00f3n del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS en 2009?**\n   - Respuesta: Los co-rapporteurs fueron Ms Nilka M. Guerrero Rivas y Mr Eshetu Wondemagegnehu Biwota.\n\n2. **\u00bfCu\u00e1l fue el rol de Professor Jos Hoogmartens en la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS?**\n   - Respuesta: Professor Jos Hoogmartens fue el presidente (Chairperson) de la reuni\u00f3n.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n se proporciona sobre los miembros que no pudieron asistir a la reuni\u00f3n?**\n   - Respuesta: Se indica que Mr Jean-Michel Caudron, Ms Metta Treebamrong, Professor Henning G. Kristensen y Dr Jean-Louis Robert no pudieron asistir a la reuni\u00f3n, como se se\u00f1ala con un asterisco en sus nombres.", "prev_section_summary": "### Resumen de Temas Clave y Entidades:\n\nEl documento \"WHO - Technical Report Series 957\" es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque el contenido espec\u00edfico del informe no est\u00e1 disponible en el contexto proporcionado, se pueden inferir algunos temas clave y entidades relevantes:\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n del informe, que se centra en la salud p\u00fablica y la investigaci\u00f3n m\u00e9dica.\n\n2. **Salud P\u00fablica**: Tema central de la serie de informes, que aborda diversas cuestiones relacionadas con la salud de la poblaci\u00f3n, pol\u00edticas de salud y pr\u00e1cticas cl\u00ednicas.\n\n3. **Investigaci\u00f3n M\u00e9dica**: Posible enfoque del informe, que podr\u00eda incluir hallazgos cient\u00edficos y recomendaciones basadas en evidencia.\n\n4. **Recomendaciones de Pr\u00e1ctica Cl\u00ednica**: El informe puede ofrecer directrices sobre c\u00f3mo abordar problemas de salud espec\u00edficos en la pr\u00e1ctica m\u00e9dica.\n\n5. **Metodolog\u00edas de Investigaci\u00f3n**: Aunque no se detalla en el contexto, es probable que el informe utilice diversas metodolog\u00edas para analizar y presentar sus hallazgos.\n\n### Conclusi\u00f3n:\nEl informe 957 de la OMS es un documento t\u00e9cnico que se inscribe en un contexto m\u00e1s amplio de salud p\u00fablica y puede contener informaci\u00f3n valiosa sobre hallazgos, recomendaciones y metodolog\u00edas en el \u00e1mbito de la salud. Sin embargo, para obtener detalles espec\u00edficos, ser\u00eda necesario acceder al documento completo.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, expert committee, health authority, drug quality"}}, "fe7e1bf6-2d40-4f41-836d-03b113c308fc": {"node_ids": ["440ba407-8442-47a4-8cc3-0c76bc6b2cd4"], "metadata": {"page_label": "10", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Special Advisers (Prequalification)\n\n- **Mr Gordon J Farquharson,\u00b2** Guildford, Surrey, England\n- **Dr Simon Mills,** Ware, Hertfordshire, England\n- **Ms Eija Pelkonen,\u00b2** Head of Inspectorate, National Agency for Medicines, Helsinki, Finland\n- **Dr Birgit Schmauser,** Federal Institute for Drugs and Medical Devices, Bonn, Germany\n- **Mr Deryck Smith,** Gauteng, South Africa\n- **Dr Angelika Spreitzhofer,\u00b2** AGES PharmMed, Institute for Inspections, Medical Devices and Haemovigilance, Vienna, Austria\n\n# Representation from United Nations Offices\u00b3\n\n**United Nations Children's Fund (UNICEF)**\n\n- **Dr Peter Svarrer Jakobsen,** Quality Assurance Officer, UNICEF Supply Division, Copenhagen, Denmark\n\n# Representation from Specialized Agencies and Related Organizations\u2074\n\n**Global Fund to Fight AIDS, Tuberculosis and Malaria**\n\n- **Ms Joelle Daviaud,** Senior QA Technical Officer, Pharmaceutical Management Unit, Geneva, Switzerland\n- **Mr Raghu Kumar Krishna Swamy**\n\n# Representation from Intergovernmental Organizations\u2075\n\n**Council of Europe**\n\n- **Dr Andrea Lodi,** Deputy Head, Laboratory Department, European Directorate for the Quality of Medicines & HealthCare (EDQM), Strasbourg, France\n\n**European Medicines Agency (EMA)**\n\n- **Dr Piotr Kozarewicz,** Scientific Administrator, Quality of Medicines Sector, Human Unit Pre-Authorization, London, England\n\n# Representation from Nongovernmental Organizations\u2076\n\n**International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)**\n\n- **Dr Michael G. Beatrice,** Vice President, Corporate Regulatory & Quality Science, Abbott, Abbott Park, IL, USA\n\n----\n\n\u00b2 Unable to attend.  \n\u00b3 Unable to attend: United Nations Development Programme (UNDP), New York, NY, USA.  \n\u2074 Unable to attend: International Atomic Energy Agency (IAEA), Vienna, Austria; United Nations Industrial Development Organization (UNIDO), Vienna, Austria; World Intellectual Property Organization (WIPO), Geneva, Switzerland; World Bank, Washington, DC, USA; World Customs Organization (WCO), Brussels, Belgium; World Trade Organization (WTO), Geneva, Switzerland.  \n\u2075 Unable to attend: European Commission (EC) Brussels, Belgium.  \n\u2076 Unable to attend: Commonwealth Pharmaceutical Association (CPA), London, England; European Chemical Industry Council (CEFIC)/APIC, Brussels, Belgium; International Society for Pharmaceutical Engineering (ISPE), Tampa, FL, USA.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (Organizaci\u00f3n Mundial de la Salud) y se centra en la representaci\u00f3n de asesores especiales, as\u00ed como de diversas organizaciones, en el \u00e1mbito de la precalificaci\u00f3n de medicamentos y dispositivos m\u00e9dicos. Se mencionan representantes de diferentes pa\u00edses y organizaciones, incluyendo agencias de la ONU, organizaciones intergubernamentales y no gubernamentales. Algunos representantes no pudieron asistir a la reuni\u00f3n, lo que se detalla al final del texto.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQui\u00e9nes son los asesores especiales que no pudieron asistir a la reuni\u00f3n y cu\u00e1les son sus afiliaciones?**\n   - Respuesta: Los asesores especiales que no pudieron asistir incluyen a Mr. Gordon J Farquharson y Ms. Eija Pelkonen, quienes est\u00e1n afiliados a Inglaterra y Finlandia, respectivamente.\n\n2. **\u00bfQu\u00e9 papel desempe\u00f1a Dr. Peter Svarrer Jakobsen en UNICEF y cu\u00e1l es su ubicaci\u00f3n?**\n   - Respuesta: Dr. Peter Svarrer Jakobsen es el Oficial de Aseguramiento de Calidad en la Divisi\u00f3n de Suministros de UNICEF, ubicado en Copenhague, Dinamarca.\n\n3. **\u00bfQu\u00e9 organizaciones intergubernamentales y no gubernamentales estaban representadas en la reuni\u00f3n y qui\u00e9nes eran sus representantes?**\n   - Respuesta: Las organizaciones intergubernamentales representadas incluyen el Consejo de Europa (Dr. Andrea Lodi) y la Agencia Europea de Medicamentos (Dr. Piotr Kozarewicz). En cuanto a las organizaciones no gubernamentales, la Federaci\u00f3n Internacional de Asociaciones y Fabricantes de Productos Farmac\u00e9uticos (IFPMA) estuvo representada por Dr. Michael G. Beatrice.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otros documentos o contextos, centr\u00e1ndose en detalles sobre la representaci\u00f3n y los roles de los participantes en la reuni\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento es un informe de la **Organizaci\u00f3n Mundial de la Salud (OMS)** sobre la reuni\u00f3n del **Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas**, que se llev\u00f3 a cabo en **Ginebra** del **12 al 16 de octubre de 2009**. A continuaci\u00f3n se presentan los temas y entidades clave:\n\n#### Temas Clave:\n- **Composici\u00f3n del Comit\u00e9**: Se detalla la lista de miembros y asesores temporales que participaron en la reuni\u00f3n, incluyendo sus roles y afiliaciones.\n- **Roles Espec\u00edficos**: Se identifican los roles de los miembros, como el presidente y los co-rapporteurs.\n- **Asistencia**: Se menciona que algunos miembros no pudieron asistir a la reuni\u00f3n, lo que se indica con un asterisco.\n\n#### Entidades:\n- **Miembros del Comit\u00e9**:\n  - **Professor Saleh A. Bawazir** (Saudi Food and Drug Authority, Arabia Saudita)\n  - **Mr Jean-Michel Caudron** (B\u00e9lgica)\n  - **Professor Theo G. Dekker** (Research Institute for Industrial Pharmacy, Sud\u00e1frica)\n  - **Ms Nilka M. Guerrero Rivas** (Panam\u00e1, Co-Rapporteur)\n  - **Professor Jos Hoogmartens** (Chairperson, B\u00e9lgica)\n  - **Professor Jin Shaohong** (China)\n  - **Dr John H. McB. Miller** (Francia)\n  - **Dr Justina A. Molzon** (USA, Co-Chairperson)\n  - **Ms Metta Treebamrong** (Tailandia)\n  - **Mr Eshetu Wondemagegnehu Biwota** (Etiop\u00eda, Co-Rapporteur)\n\n- **Asesores Temporales**:\n  - **Professor Ivan Addae-Mensah** (Ghana)\n  - **Professor Henning G. Kristensen** (Dinamarca)\n  - **Ms Marie-Louise Rabouhans** (Inglaterra)\n  - **Dr Jean-Louis Robert** (Luxemburgo)\n  - **Dr Saranjit Singh** (India)\n  - **Mr Robert Tribe** (Australia)\n\nEste resumen proporciona una visi\u00f3n general de la estructura y los participantes del Comit\u00e9, as\u00ed como de los roles desempe\u00f1ados durante la reuni\u00f3n.", "excerpt_keywords": "Keywords: WHO, prequalification, pharmaceutical, representation, quality assurance"}}, "0d747e08-e8ff-456a-9670-56dc8ad644fa": {"node_ids": ["c2e2af33-88e0-4cd4-8262-d193083aa067"], "metadata": {"page_label": "11", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# International Generic Pharmaceutical Alliance (IGPA)\n- Dr Nicholas Cappuccino, CEO, Pharmaceutical Intellectual Resource Services LLC, Lambertville, NJ, USA\n\n# International Pharmaceutical Excipients Council (IPEC)\n- Mrs Beam Suffolk, Vice Chair, IPEC Europe, Brussels, Belgium\n\n# International Pharmaceutical Federation (FIP)\n- Mr A.J.M. Hoek, General Secretary and CEO and Mr Xuan Hao Chan, Project Manager, The Hague, Netherlands\n\n# World Self-Medication Industry (WSMI)\n- Dr Christelle Anquez-Traxler, Regulatory & Scientific Affairs Manager, Association of the European Self-Medication Industry (AESGP), Brussels, Belgium\n\n## Observers\n### European Association of Pharmaceutical Full-line Wholesalers\n- Mr Martin FitzGerald, Legal Adviser, Groupement International de la Repartition Pharmaceutique (GIRP AISBL), Brussels, Belgium\n\n## Pharmacopoeias\n### British Pharmacopoeia Commission\n- Mrs Matilda Vallender, Editor-in-Chief, Secretariat, Medicines and Healthcare products Regulatory Agency (MHRA), London, England\n\n### European Pharmacopoeia\n- Council of Europe, Strasbourg, France\n\n### Pharmacopoeia of the Republic of Korea\n- Dr Hee-Sung Kim, Deputy Director, Pharmaceutical Standardization Division, Drug Evaluation Department and Dr Su-Jung Lee, Deputy Director, Scientific Drug Evaluation & Research Division, Pharmaceuticals & Medical Devices Research Department, National Institute of Food & Drug Safety Evaluation, Korea Food and Drug Administration, Seoul, Republic of Korea\n\n### United States Pharmacopeia\n- Dr Karen A. Russo, Vice President, Small Molecules, Documentary Standards Division, Rockville, MD, USA\n\n## Representation from WHO regional offices\n### WHO Secretariat\n- Dr C.F. Etienne, Assistant Director-General, Health Systems and Services, WHO, Geneva, Switzerland\n\n----\n\n7 Unable to attend: Pharmaceutical Inspection Co-operation Scheme (PIC/S), Geneva, Switzerland.  \n8 Unable to attend: Farmacopea Argentina, Buenos Aires, Argentina; Farmacopeia Brasileira, Santa Maria, RS, Brazil; Pharmacopoeia of the People's Republic of China, Beijing, People's Republic of China; Indian Pharmacopoeia, New Delhi, India; Japanese Pharmacopoeia, Tokyo, Japan; State Pharmacopoeia of the Russian Federation, Moscow, Russian Federation.  \n9 See Council of Europe.  \n10 Unable to attend: Regional Office for Africa; Regional Office for the Americas; Regional Office for the Eastern Mediterranean; Regional Office for Europe; Regional Office for South-East Asia; Regional Office for the Western Pacific.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que incluye una lista de representantes de diversas organizaciones y farmacopoeias que participaron en una reuni\u00f3n. Se mencionan representantes de la Alianza Internacional de Medicamentos Gen\u00e9ricos (IGPA), el Consejo Internacional de Excipientes Farmac\u00e9uticos (IPEC), la Federaci\u00f3n Internacional Farmac\u00e9utica (FIP), y la Industria Mundial de Autocuidado (WSMI), entre otros. Tambi\u00e9n se enumeran observadores y representantes de diferentes farmacopoeias, as\u00ed como la representaci\u00f3n de las oficinas regionales de la OMS. Adem\u00e1s, se indica qui\u00e9nes no pudieron asistir a la reuni\u00f3n.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQui\u00e9nes son los representantes de la Alianza Internacional de Medicamentos Gen\u00e9ricos (IGPA) y cu\u00e1l es su funci\u00f3n?**\n   - Respuesta: El representante de la IGPA es el Dr. Nicholas Cappuccino, CEO de Pharmaceutical Intellectual Resource Services LLC, ubicado en Lambertville, NJ, USA. Su funci\u00f3n es liderar la organizaci\u00f3n en temas relacionados con medicamentos gen\u00e9ricos.\n\n2. **\u00bfQu\u00e9 farmacopoeias est\u00e1n representadas en el informe y qui\u00e9nes son sus respectivos representantes?**\n   - Respuesta: Las farmacopoeias representadas son la British Pharmacopoeia Commission (Mrs. Matilda Vallender), la European Pharmacopoeia (Consejo de Europa), la Pharmacopoeia of the Republic of Korea (Dr. Hee-Sung Kim y Dr. Su-Jung Lee), y la United States Pharmacopeia (Dr. Karen A. Russo).\n\n3. **\u00bfQu\u00e9 organizaciones y farmacopoeias no pudieron asistir a la reuni\u00f3n y cu\u00e1les son sus ubicaciones?**\n   - Respuesta: No pudieron asistir: Pharmaceutical Inspection Co-operation Scheme (PIC/S) en Ginebra, Suiza; Farmacopea Argentina en Buenos Aires, Argentina; Farmacopeia Brasileira en Santa Maria, RS, Brasil; Pharmacopoeia of the People's Republic of China en Pek\u00edn, Rep\u00fablica Popular de China; Indian Pharmacopoeia en Nueva Delhi, India; Japanese Pharmacopoeia en Tokio, Jap\u00f3n; State Pharmacopoeia of the Russian Federation en Mosc\u00fa, Federaci\u00f3n Rusa; y las oficinas regionales de la OMS en varias regiones del mundo.\n\n### Resumen de Nivel Superior\nEl informe t\u00e9cnico de la OMS detalla la participaci\u00f3n de diversas organizaciones y farmacopoeias en una reuni\u00f3n, destacando a los representantes clave y sus roles. Tambi\u00e9n se menciona la ausencia de varias organizaciones importantes, lo que puede indicar la diversidad y el alcance global de la discusi\u00f3n sobre temas farmac\u00e9uticos. Este contexto es relevante para entender la colaboraci\u00f3n internacional en el \u00e1mbito de la salud y la regulaci\u00f3n farmac\u00e9utica.", "prev_section_summary": "La secci\u00f3n del documento se centra en la representaci\u00f3n de asesores especiales y diversas organizaciones en el contexto de la precalificaci\u00f3n de medicamentos y dispositivos m\u00e9dicos, seg\u00fan lo presentado en la Serie de Informes T\u00e9cnicos de la OMS. A continuaci\u00f3n se resumen los temas clave y las entidades mencionadas:\n\n### Temas Clave:\n1. **Asesores Especiales**: Se listan varios asesores que participan en el proceso de precalificaci\u00f3n, destacando sus afiliaciones y ubicaciones.\n2. **Representaci\u00f3n de Organizaciones**: Se menciona la participaci\u00f3n de diferentes organizaciones, incluyendo agencias de la ONU, organizaciones intergubernamentales y no gubernamentales.\n3. **Asistencia**: Se indica que algunos representantes no pudieron asistir a la reuni\u00f3n, lo que se detalla al final del texto.\n\n### Entidades Mencionadas:\n- **Asesores Especiales**:\n  - Mr. Gordon J Farquharson (Inglaterra)\n  - Dr. Simon Mills (Inglaterra)\n  - Ms. Eija Pelkonen (Finlandia)\n  - Dr. Birgit Schmauser (Alemania)\n  - Mr. Deryck Smith (Sud\u00e1frica)\n  - Dr. Angelika Spreitzhofer (Austria)\n\n- **Organizaciones de la ONU**:\n  - **UNICEF**: Dr. Peter Svarrer Jakobsen (Dinamarca)\n\n- **Agencias Especializadas**:\n  - **Global Fund to Fight AIDS, Tuberculosis and Malaria**: Ms. Joelle Daviaud (Suiza), Mr. Raghu Kumar Krishna Swamy\n\n- **Organizaciones Intergubernamentales**:\n  - **Consejo de Europa**: Dr. Andrea Lodi (Francia)\n  - **Agencia Europea de Medicamentos (EMA)**: Dr. Piotr Kozarewicz (Inglaterra)\n\n- **Organizaciones No Gubernamentales**:\n  - **IFPMA**: Dr. Michael G. Beatrice (EE. UU.)\n\nEste resumen proporciona una visi\u00f3n general de los participantes y su relevancia en el contexto de la precalificaci\u00f3n de medicamentos y dispositivos m\u00e9dicos.", "excerpt_keywords": "Keywords: pharmaceutical organizations, pharmacopoeias, WHO representation, international collaboration, generic medicines"}}, "49a59c58-d1e8-4148-9fd7-49e71261673b": {"node_ids": ["96c00675-7aa3-4533-8cc9-a15396472145"], "metadata": {"page_label": "12", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Dr H.V. Hogerzeil, Director, Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland\n\nDr L. R\u00e4go, Coordinator, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr S. Kopp, Manager, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland (Secretary)\n\nMs C. Mendy, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr R. Balocco, Manager, International Nonproprietary Names Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr A. Gould, Manager, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr R. Kuwana, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr M. Mehmandoust, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr D. Mubangizi, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nMs J. Sabartova, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr I. Streipa, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland, WHO, Geneva, Switzerland\n\nMr W.Z. Worku, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr Hua Yin, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr A. van Zyl, Head, Inspections, Prequalification Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr S. Azatyan, Manager, Medicines Regulatory Support Programme, WHO, Geneva, Switzerland\n\nMr J. Hetzke, Health Systems and Services, WHO, Geneva, Switzerland\n\nMs Y. Maruyama, Traditional Medicine, WHO, Geneva, Switzerland\n\nDr C. Ondari, Coordinator, Medicines Access and Rational Use, WHO, Geneva, Switzerland\n\nDr F. Renaud Th\u00e9ry, HIV Systems Strengthening, WHO, Geneva, Switzerland\n\nDr D.J. Wood, Coordinator, Quality, Safety and Standards Programme, WHO, Geneva, Switzerland", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) titulado \"WHO - Technical Report Series 957\". En \u00e9l, se enumeran varios profesionales de la OMS que ocupan roles clave en programas relacionados con la calidad y seguridad de los medicamentos, as\u00ed como en pol\u00edticas de medicamentos esenciales. Los participantes incluyen directores, coordinadores y gerentes de diferentes programas, todos ubicados en Ginebra, Suiza.\n\n### Preguntas:\n1. **\u00bfQui\u00e9nes son los principales responsables de los programas de calidad y seguridad de medicamentos en la OMS seg\u00fan el informe?**\n   - Esta pregunta busca identificar a los l\u00edderes y sus roles espec\u00edficos en la organizaci\u00f3n, lo cual no se encuentra f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 programas espec\u00edficos est\u00e1n siendo gestionados por los profesionales mencionados en el informe?**\n   - Esta pregunta se centra en los programas espec\u00edficos que cada uno de los profesionales est\u00e1 supervisando, proporcionando detalles que pueden no estar disponibles en otros documentos.\n\n3. **\u00bfCu\u00e1l es el enfoque de la OMS en relaci\u00f3n con los medicamentos esenciales y su regulaci\u00f3n, seg\u00fan los roles de los individuos listados en el informe?**\n   - Esta pregunta busca entender la perspectiva y el enfoque de la OMS sobre la regulaci\u00f3n y el acceso a medicamentos esenciales, lo cual puede no estar claramente articulado en otros contextos.", "prev_section_summary": "La secci\u00f3n del documento presenta una lista de representantes de diversas organizaciones y farmacopoeias que participaron en una reuni\u00f3n organizada por la Organizaci\u00f3n Mundial de la Salud (OMS). A continuaci\u00f3n se resumen los temas clave y las entidades mencionadas:\n\n### Temas Clave:\n1. **Participaci\u00f3n Internacional**: Se destaca la colaboraci\u00f3n de m\u00faltiples organizaciones y farmacopoeias en el \u00e1mbito farmac\u00e9utico a nivel global.\n2. **Representantes Clave**: Se enumeran los representantes de cada organizaci\u00f3n, indicando sus roles y ubicaciones.\n3. **Ausencias Notables**: Se menciona qui\u00e9nes no pudieron asistir a la reuni\u00f3n, lo que refleja la diversidad de actores involucrados en la discusi\u00f3n.\n\n### Entidades Mencionadas:\n- **Alianza Internacional de Medicamentos Gen\u00e9ricos (IGPA)**: Dr. Nicholas Cappuccino, CEO.\n- **Consejo Internacional de Excipientes Farmac\u00e9uticos (IPEC)**: Mrs. Beam Suffolk, Vice Chair.\n- **Federaci\u00f3n Internacional Farmac\u00e9utica (FIP)**: Mr. A.J.M. Hoek y Mr. Xuan Hao Chan.\n- **Industria Mundial de Autocuidado (WSMI)**: Dr. Christelle Anquez-Traxler.\n- **Observadores**: Mr. Martin FitzGerald de la Asociaci\u00f3n Europea de Mayoristas Farmac\u00e9uticos.\n- **Farmacopoeias**:\n  - British Pharmacopoeia Commission: Mrs. Matilda Vallender.\n  - European Pharmacopoeia: Consejo de Europa.\n  - Pharmacopoeia of the Republic of Korea: Dr. Hee-Sung Kim y Dr. Su-Jung Lee.\n  - United States Pharmacopeia: Dr. Karen A. Russo.\n- **Secretar\u00eda de la OMS**: Dr. C.F. Etienne.\n\n### Ausencias:\n- **Organizaciones que no asistieron**: Pharmaceutical Inspection Co-operation Scheme (PIC/S), Farmacopea Argentina, Farmacopeia Brasileira, Pharmacopoeia of the People's Republic of China, Indian Pharmacopoeia, Japanese Pharmacopoeia, State Pharmacopoeia of the Russian Federation, y varias oficinas regionales de la OMS.\n\nEste resumen resalta la importancia de la colaboraci\u00f3n internacional en la regulaci\u00f3n y desarrollo de productos farmac\u00e9uticos, as\u00ed como la diversidad de voces y perspectivas en la discusi\u00f3n.", "excerpt_keywords": "Keywords: WHO, Essential Medicines, Quality Assurance, Pharmaceutical Policies, Prequalification Programme"}}, "94cc261e-bdb7-458c-9e5f-9365faddca92": {"node_ids": ["b14c7316-cae3-4f0e-b3f0-af5dba802501"], "metadata": {"page_label": "13", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Declarations of interest\n\nMembers of the WHO Expert Committee on Specifications for Pharmaceutical Preparations reported the following:\n\nProfessor Saleh A. Bawazir, Professor Theo G. Dekker, Ms Nilka M. Guerrero Rivas, Professor Jos Hoogmartens, Professor Jin Shaohong, Dr John H. McB. Miller, Dr Justina A. Molzon and Mr Eshetu Wondemagegnehu Biwota reported no conflict of interest.\n\nTemporary and special advisers reported the following:\n\nProfessor Ivan Addae-Mensah, Dr Simon Mills, Ms Marie-Louise Rabouhans, Dr Birgit Schmauser, Dr Saranjit Singh and Mr Deryck Smith, reported no conflict of interest.\n\nMr Robert Tribe reported that he was a consultant with two commercial entities and was the owner of another one.\n\nMr Martin FitzGerald, attending as an observer, reported that he was Legal Adviser with the European Association of Pharmaceutical Full-Line Wholesalers; Dr Piotr Kozarewicz (representative of the European Medicines Agency) reported that he was employed by two different pharmaceutical companies in Poland from September 2003 until June 2006. Other participants reported no conflict of interest.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl documento es parte de un informe t\u00e9cnico de la OMS (Organizaci\u00f3n Mundial de la Salud) que incluye declaraciones de inter\u00e9s de los miembros del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas. Se menciona que la mayor\u00eda de los miembros y asesores no tienen conflictos de inter\u00e9s, mientras que algunos participantes han declarado v\u00ednculos con entidades comerciales o farmac\u00e9uticas.\n\n### Preguntas espec\u00edficas\n1. **\u00bfQui\u00e9nes son los miembros del Comit\u00e9 de Expertos que no reportaron conflictos de inter\u00e9s?**\n   - Respuesta: Los miembros que no reportaron conflictos de inter\u00e9s son el Profesor Saleh A. Bawazir, el Profesor Theo G. Dekker, la Sra. Nilka M. Guerrero Rivas, el Profesor Jos Hoogmartens, el Profesor Jin Shaohong, el Dr. John H. McB. Miller, la Dra. Justina A. Molzon y el Sr. Eshetu Wondemagegnehu Biwota.\n\n2. **\u00bfQu\u00e9 tipo de relaciones comerciales report\u00f3 el Sr. Robert Tribe?**\n   - Respuesta: El Sr. Robert Tribe report\u00f3 que era consultor de dos entidades comerciales y era propietario de otra.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n se proporcion\u00f3 sobre el Dr. Piotr Kozarewicz en relaci\u00f3n con su empleo previo?**\n   - Respuesta: El Dr. Piotr Kozarewicz, representante de la Agencia Europea de Medicamentos, report\u00f3 que estuvo empleado por dos diferentes compa\u00f1\u00edas farmac\u00e9uticas en Polonia desde septiembre de 2003 hasta junio de 2006.\n\n### Resumen de nivel superior\nEl informe de la OMS incluye declaraciones de inter\u00e9s de los miembros del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas, donde la mayor\u00eda no tiene conflictos de inter\u00e9s, pero algunos participantes han declarado v\u00ednculos con entidades comerciales. Esto es relevante para asegurar la transparencia y la integridad en las recomendaciones y decisiones del comit\u00e9.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 957\" de la Organizaci\u00f3n Mundial de la Salud (OMS) presenta una lista de profesionales que desempe\u00f1an roles cruciales en la gesti\u00f3n de programas relacionados con la calidad, seguridad y acceso a medicamentos. A continuaci\u00f3n se detallan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Calidad y Seguridad de Medicamentos**: Se enfatiza la importancia de asegurar la calidad y la seguridad de los medicamentos a trav\u00e9s de programas espec\u00edficos.\n2. **Medicamentos Esenciales**: Se aborda la pol\u00edtica de medicamentos esenciales y su regulaci\u00f3n, destacando la necesidad de acceso adecuado a estos productos.\n3. **Programas de Precalificaci\u00f3n**: Se menciona el programa de precalificaci\u00f3n, que busca garantizar que los medicamentos cumplan con est\u00e1ndares de calidad antes de ser utilizados en diferentes contextos.\n4. **Regulaci\u00f3n y Apoyo**: Se discuten los esfuerzos de la OMS en la regulaci\u00f3n de medicamentos y el apoyo a sistemas de salud para mejorar el acceso y uso racional de medicamentos.\n\n#### Entidades:\n- **Dr. H.V. Hogerzeil**: Director de Medicamentos Esenciales y Pol\u00edticas Farmac\u00e9uticas.\n- **Dr. L. R\u00e4go**: Coordinador de Calidad y Seguridad de Medicamentos.\n- **Dr. S. Kopp**: Gerente del Programa de Aseguramiento de Calidad de Medicamentos.\n- **Dr. R. Balocco**: Gerente del Programa de Nombres No Propietarios Internacionales.\n- **Dr. A. Gould**: Gerente del Programa de Precalificaci\u00f3n.\n- **Dr. S. Azatyan**: Gerente del Programa de Apoyo Regulatorio de Medicamentos.\n- **Dr. C. Ondari**: Coordinador de Acceso a Medicamentos y Uso Racional.\n- **Dr. D.J. Wood**: Coordinador del Programa de Calidad, Seguridad y Normas.\n\nEste resumen destaca la estructura organizativa y los enfoques de la OMS en relaci\u00f3n con la calidad y el acceso a medicamentos, as\u00ed como los profesionales clave involucrados en estos esfuerzos.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, conflict of interest, expert committee, declarations"}}, "522612e1-06f4-4ceb-8ec5-2a2ac80d2293": {"node_ids": ["f4db7121-a2fb-4802-a501-deac4304a471"], "metadata": {"page_label": "14", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento mencionado es el \"WHO - Technical Report Series 957\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica, y recomendaciones para pol\u00edticas de salud. Sin embargo, el contenido espec\u00edfico del documento no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el informe WHO - Technical Report Series 957?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el contenido del informe, que podr\u00eda incluir datos relevantes sobre salud p\u00fablica o recomendaciones de la OMS.\n\n2. **\u00bfQu\u00e9 temas espec\u00edficos se abordan en el documento y c\u00f3mo se relacionan con las pol\u00edticas de salud global?**\n   - Esta pregunta se enfoca en los temas tratados en el informe y su impacto en las pol\u00edticas de salud a nivel mundial, lo que podr\u00eda no estar disponible en otras fuentes.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas se utilizaron en la investigaci\u00f3n presentada en el WHO - Technical Report Series 957?**\n   - Esta pregunta indaga sobre las metodolog\u00edas espec\u00edficas empleadas en el informe, lo que podr\u00eda ofrecer una visi\u00f3n \u00fanica sobre c\u00f3mo se llev\u00f3 a cabo la investigaci\u00f3n y su validez.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n que probablemente no se encuentre f\u00e1cilmente en otros lugares, dado que el contenido espec\u00edfico del informe no est\u00e1 disponible en el contexto proporcionado.", "prev_section_summary": "La secci\u00f3n \"Declarations of interest\" del informe t\u00e9cnico de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta las declaraciones de inter\u00e9s de los miembros del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas. Los temas clave incluyen:\n\n1. **Miembros sin conflictos de inter\u00e9s**: La mayor\u00eda de los miembros del comit\u00e9, incluyendo a profesores y doctores, no reportaron conflictos de inter\u00e9s. Los nombres mencionados son:\n   - Profesor Saleh A. Bawazir\n   - Profesor Theo G. Dekker\n   - Sra. Nilka M. Guerrero Rivas\n   - Profesor Jos Hoogmartens\n   - Profesor Jin Shaohong\n   - Dr. John H. McB. Miller\n   - Dra. Justina A. Molzon\n   - Sr. Eshetu Wondemagegnehu Biwota\n\n2. **Asesores temporales y especiales**: Tambi\u00e9n se report\u00f3 que varios asesores no tienen conflictos de inter\u00e9s, incluyendo:\n   - Profesor Ivan Addae-Mensah\n   - Dr. Simon Mills\n   - Sra. Marie-Louise Rabouhans\n   - Dr. Birgit Schmauser\n   - Dr. Saranjit Singh\n   - Mr. Deryck Smith\n\n3. **Conflictos de inter\u00e9s reportados**:\n   - **Mr. Robert Tribe**: Consultor de dos entidades comerciales y propietario de otra.\n   - **Mr. Martin FitzGerald**: Asesor legal de la Asociaci\u00f3n Europea de Mayoristas Farmac\u00e9uticos.\n   - **Dr. Piotr Kozarewicz**: Empleado de dos compa\u00f1\u00edas farmac\u00e9uticas en Polonia entre septiembre de 2003 y junio de 2006.\n\n4. **Importancia de la transparencia**: La secci\u00f3n enfatiza la relevancia de estas declaraciones para asegurar la transparencia y la integridad en las recomendaciones y decisiones del comit\u00e9.\n\nEste resumen destaca la composici\u00f3n del comit\u00e9, las relaciones comerciales de algunos participantes y la importancia de la transparencia en el proceso.", "excerpt_keywords": "Keywords: OMS, informe t\u00e9cnico, salud p\u00fablica, conflictos de inter\u00e9s, transparencia"}}, "e5083336-2391-4dbc-b0ec-a3aafe747f0c": {"node_ids": ["aa9db07c-9b8d-4ea1-b84a-18001d1da416"], "metadata": {"page_label": "15", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations met in Geneva from 12 to 16 October 2009. Dr Carissa F. Etienne, Assistant Director-General, Health Systems and Services (HSS), opened the meeting and, on behalf of the Director-General of the World Health Organization, welcomed all the participants to the forty-fourth meeting. She expressed her appreciation of the Expert Committee for its knowledge of and expertise in the work of WHO in the area of quality assurance of medicines. Dr Etienne welcomed the members of the Committee, temporary advisers and special advisers for prequalification; representatives of the United Nations Children\u2019s Fund, the Global Fund to Fight AIDS, Tuberculosis and Malaria, Council of Europe/European Directorate for the Quality of Medicines and HealthCare, European Medicines Agency, International Federation of Pharmaceutical Manufacturers and Associations, International Generic Pharmaceutical Alliance, International Pharmaceutical Excipients Council, International Pharmaceutical Federation, World Self-Medication Industry and an observer from the European Association of Pharmaceutical Full-line Wholesalers; representatives of the Secretariats of the Pharmacopoeias of Republic of Korea and United States of America; as well as representatives from WHO Collaborating Centres in China and South Africa.\n\nShe said the WHO Member States and the world\u2019s political and international health leaders recognized the need to strengthen health systems, renew political interest in making sustainable improvements that benefited disease areas and health programmes, and to redouble global efforts to meet the challenge of achieving the Millennium Development Goals and renew primary health care systems. Dr Etienne said that health systems had to respond better and faster to the challenges of the changing world. She stressed the single framework for action with six building blocks (governance and leadership; financing; information; medical products, vaccines and technologies; health workforce; and service delivery); health systems and health outcome programmes; obtaining results; and a more effective role for WHO at country level.\n\nMedicines were an important component of the health system; however, unavailability, costliness and lack of quality, including counterfeit medicines, were issues of concern to countries. Developing countries with these problems were accepting policy and regulatory change as well as enforcing laws and regulations to improve availability.\n\nThe work of this Expert Committee was important to WHO Member States, United Nations and international organizations, and also in-house for all programmes dealing with medicines. One example was the Prequalification Programme (PQP) which was based entirely on the ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas se reuni\u00f3 en Ginebra del 12 al 16 de octubre de 2009. La reuni\u00f3n fue inaugurada por la Dra. Carissa F. Etienne, quien destac\u00f3 la importancia de fortalecer los sistemas de salud y mejorar la calidad de los medicamentos. Se abordaron temas como la disponibilidad, el costo y la calidad de los medicamentos, incluyendo el problema de los medicamentos falsificados. La Dra. Etienne enfatiz\u00f3 la necesidad de un marco de acci\u00f3n que incluya seis bloques fundamentales para mejorar los sistemas de salud y alcanzar los Objetivos de Desarrollo del Milenio.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los seis bloques fundamentales que se mencionan como parte del marco de acci\u00f3n para mejorar los sistemas de salud?**\n   - Respuesta: Los seis bloques fundamentales son: gobernanza y liderazgo, financiamiento, informaci\u00f3n, productos m\u00e9dicos, vacunas y tecnolog\u00edas, fuerza laboral de salud, y entrega de servicios.\n\n2. **\u00bfQu\u00e9 papel desempe\u00f1a el Programa de Precalificaci\u00f3n (PQP) en el contexto de la calidad de los medicamentos seg\u00fan la reuni\u00f3n del Comit\u00e9 de Expertos?**\n   - Respuesta: El Programa de Precalificaci\u00f3n (PQP) es un ejemplo del trabajo del Comit\u00e9, que se basa en asegurar la calidad de los medicamentos y es fundamental para los Estados Miembros de la OMS y otras organizaciones internacionales.\n\n3. **\u00bfQu\u00e9 desaf\u00edos enfrentan los pa\u00edses en desarrollo en relaci\u00f3n con la disponibilidad y calidad de los medicamentos, seg\u00fan la Dra. Etienne?**\n   - Respuesta: Los pa\u00edses en desarrollo enfrentan problemas de disponibilidad, altos costos y falta de calidad de los medicamentos, incluyendo la presencia de medicamentos falsificados, lo que ha llevado a estos pa\u00edses a aceptar cambios en pol\u00edticas y regulaciones para mejorar la situaci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento mencionado, \"WHO - Technical Report Series 957\", es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque el contenido espec\u00edfico no est\u00e1 disponible, se puede inferir que el informe aborda temas relevantes en el \u00e1mbito de la salud p\u00fablica, investigaci\u00f3n m\u00e9dica y pol\u00edticas de salud. \n\n#### Temas clave:\n- **Salud p\u00fablica**: Posiblemente incluye hallazgos y recomendaciones sobre la salud de las poblaciones.\n- **Investigaci\u00f3n m\u00e9dica**: Puede presentar estudios o datos relevantes en el campo de la medicina.\n- **Pol\u00edticas de salud**: Es probable que ofrezca recomendaciones que impacten las pol\u00edticas de salud a nivel global.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la publicaci\u00f3n del informe.\n- **Technical Report Series**: La serie a la que pertenece el documento, que se centra en temas t\u00e9cnicos relacionados con la salud.\n\nEste resumen proporciona una visi\u00f3n general de lo que se puede esperar del informe, a pesar de la falta de contenido espec\u00edfico en el contexto proporcionado.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, health systems, quality assurance, Prequalification Programme"}}, "4a35c891-6074-4bcd-97d4-e3b03e80f37b": {"node_ids": ["afd770a7-1670-42e2-97bb-6248c77351f0"], "metadata": {"page_label": "16", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The implementation of guidelines and standards recommended by the Expert Committee on Specifications for Pharmaceutical Preparations was closely linked to other organizations, such as the European Medicines Agency, European Directorate for the Quality of Medicines and HealthCare, the Global Fund to Fight AIDS, Tuberculosis and Malaria, International Atomic Energy Agency, United Nations Children\u2019s Fund, World Intellectual Property Organization, World Bank, International Pharmaceutical Federation, International Federation of Pharmaceutical Manufacturers and Associations, World Self-Medication Industry, national and regional pharmacopoeias, other clusters, institutions, bodies, authorities, and other WHO Expert Committees.\n\nExperts and the Secretariat were committed to enabling quality medicines to reach patients. Dr. Etienne raised the issue of counterfeit medicines, which should be addressed as a public health problem. Discussion during the Executive Board meeting in January 2009 regarding the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) and counterfeit medicines issues in general raised concerns regarding WHO\u2019s role in this area. (For a further update see section 2.3.)\n\nDr. Gilles Forte, speaking on behalf of the Director, Essential Medicines and Pharmaceutical Policies (EMP), expressed the importance of the Committee\u2019s work on standard-setting for the functionality of good manufacturing practices (GMP); he also emphasized that the improvement of quality assurance, updating of quality guidelines and laboratory testing were key functions of the Committee. Dr. Forte also acknowledged that the agenda was very impressive and thanked the Expert Committee for its support in helping define and address future challenges. He emphasized that WHO valued the work carried out by this Expert Committee.\n\nDr. Lembit R\u00e4go, Coordinator of the Quality Assurance and Safety: Medicines team, said that nowadays funding for the team mainly originated from external donors in order to sustain its activities, comprising those of this Expert Committee. The team, including the Medicines Quality Assurance Programme, must continue to attract donors and to date it had been relatively successful in obtaining donor funding.\n\nA current challenge was related to the fact that a WHO Collaborating Centre had closed due to restructuring in Sweden, but the Programme was very hopeful that it could obtain a replacement institute quickly.\n\nDr. R\u00e4go informed the Committee that the Medicines Strategy was in print following the usual consultative process. It would be put on the web site for the next biennium with a link to the Millennium Development Goals.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Colaboraci\u00f3n Internacional en Medicamentos**: El texto destaca la importancia de la colaboraci\u00f3n entre la OMS y diversas organizaciones internacionales en la implementaci\u00f3n de directrices y est\u00e1ndares para la preparaci\u00f3n farmac\u00e9utica. Se menciona la necesidad de asegurar que los medicamentos de calidad lleguen a los pacientes y se aborda el problema de los medicamentos falsificados como un desaf\u00edo de salud p\u00fablica.\n\n2. **Desaf\u00edos en la Garant\u00eda de Calidad**: Se discuten los esfuerzos del Comit\u00e9 de Expertos en establecer normas para las buenas pr\u00e1cticas de manufactura (GMP) y la importancia de la mejora de la garant\u00eda de calidad y la actualizaci\u00f3n de las directrices de calidad. Tambi\u00e9n se menciona la dependencia del financiamiento externo para mantener las actividades del equipo de Garant\u00eda de Calidad y Seguridad de Medicamentos.\n\n3. **Estrategia de Medicamentos y Desarrollo Sostenible**: Se informa que la Estrategia de Medicamentos est\u00e1 en proceso de publicaci\u00f3n y se vincular\u00e1 con los Objetivos de Desarrollo del Milenio, lo que subraya la conexi\u00f3n entre la calidad de los medicamentos y los objetivos globales de salud.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 papel desempe\u00f1a la OMS en la lucha contra los medicamentos falsificados y c\u00f3mo se relaciona esto con el trabajo del Comit\u00e9 de Expertos?**\n   - Respuesta: La OMS aborda el problema de los medicamentos falsificados como un desaf\u00edo de salud p\u00fablica, y el Comit\u00e9 de Expertos trabaja en la implementaci\u00f3n de directrices y est\u00e1ndares que ayudan a combatir este problema, como se discuti\u00f3 en la reuni\u00f3n del Consejo Ejecutivo en enero de 2009.\n\n2. **\u00bfCu\u00e1les son las principales funciones del Comit\u00e9 de Expertos en relaci\u00f3n con las buenas pr\u00e1cticas de manufactura (GMP) y la garant\u00eda de calidad?**\n   - Respuesta: Las principales funciones del Comit\u00e9 incluyen el establecimiento de normas para las GMP, la mejora de la garant\u00eda de calidad, la actualizaci\u00f3n de las directrices de calidad y la realizaci\u00f3n de pruebas de laboratorio, seg\u00fan lo expresado por Dr. Gilles Forte.\n\n3. **\u00bfC\u00f3mo afecta el cierre de un Centro Colaborador de la OMS en Suecia a las actividades del Programa de Garant\u00eda de Calidad de Medicamentos?**\n   - Respuesta: El cierre de un Centro Colaborador en Suecia representa un desaf\u00edo actual para el Programa de Garant\u00eda de Calidad de Medicamentos, aunque el Programa es optimista sobre la posibilidad de obtener un instituto de reemplazo r\u00e1pidamente para continuar sus actividades.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Fortalecimiento de Sistemas de Salud:** La Dra. Carissa F. Etienne destac\u00f3 la necesidad de mejorar los sistemas de salud a nivel global, enfatizando la importancia de realizar mejoras sostenibles en \u00e1reas de enfermedades y programas de salud.\n2. **Desaf\u00edos en la Disponibilidad y Calidad de Medicamentos:** Se abordaron problemas como la falta de disponibilidad, altos costos y la calidad de los medicamentos, incluyendo la amenaza de medicamentos falsificados.\n3. **Marco de Acci\u00f3n:** Se present\u00f3 un marco de acci\u00f3n que incluye seis bloques fundamentales para mejorar los sistemas de salud: gobernanza y liderazgo, financiamiento, informaci\u00f3n, productos m\u00e9dicos, vacunas y tecnolog\u00edas, fuerza laboral de salud, y entrega de servicios.\n4. **Programa de Precalificaci\u00f3n (PQP):** Se mencion\u00f3 el PQP como un ejemplo del trabajo del Comit\u00e9, enfocado en asegurar la calidad de los medicamentos y su relevancia para los Estados Miembros de la OMS y otras organizaciones internacionales.\n\n**Entidades Mencionadas:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Principal entidad organizadora de la reuni\u00f3n.\n- **Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas:** Grupo que se reuni\u00f3 para discutir temas de calidad de medicamentos.\n- **Representantes de diversas organizaciones:** Incluyendo UNICEF, el Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria, la Agencia Europea de Medicamentos, y varias federaciones y consejos internacionales relacionados con la industria farmac\u00e9utica.\n- **Centros Colaboradores de la OMS en China y Sud\u00e1frica:** Entidades que contribuyen a los esfuerzos de la OMS en el \u00e1mbito de la salud.\n\nEste resumen destaca la importancia de la reuni\u00f3n y los esfuerzos globales para mejorar la calidad y disponibilidad de los medicamentos, as\u00ed como el papel crucial de la OMS y otras organizaciones en este proceso.", "excerpt_keywords": "Keywords: WHO, counterfeit medicines, quality assurance, good manufacturing practices, international collaboration"}}, "4c98a419-c2a9-4730-8ddf-b15994229c43": {"node_ids": ["c4d72780-af99-4164-88d0-1467a0095b6c"], "metadata": {"page_label": "17", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Dr R\u00e4go thanked the members of the Expert Committee for their dedication and contribution to the work of WHO, and also for the help and time given.\n\nThe Secretary of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, Dr Sabine Kopp, explained the administrative process of appointment of experts and the working procedures related to the Expert Committee meeting.\n\nThe Secretary explained that the Expert Committee was an official advisory body to the Director-General of WHO and was governed through rules and procedures. The report of the WHO Expert Committee consisted of a summary of the discussions, recommendations to WHO and its Member States and included newly adopted guidelines. The report was presented to the WHO Governing Bodies for final comments, endorsement and implementation by Member States and constituted WHO technical guidance.\n\nThe Expert Committee consultation process involves several steps, i.e. preliminary consultation and drafting, circulation of the first draft for comments, revision of the draft, discussion of the draft by the WHO Expert Committee and finally, once adopted, publication in the Expert Committee report as an annex, submission to the WHO Governing Bodies and recommendation to Member States for implementation.\n\n## 2. General policy\n\n### 2.1 International collaboration\n\n#### 2.1.1 International organizations, agencies and nongovernmental organizations\n\nThe Expert Committee welcomed the collaboration of international organizations and agencies with the work of this Committee. The following presented their work in more detail.\n\n*European Directorate for the Quality of Medicines and HealthCare*\n\nThe European Directorate for the Quality of Medicines and HealthCare (EDQM) is responsible for a number of activities in collaboration with the European Union, related to surveillance of pharmaceutical products marketed and distributed in Europe. EDQM is at the centre of the European regulatory framework for medicines and one of its tasks since 2008 has been to protect patients in Europe from counterfeit medicines. Another activity transferred to EDQM in 2008 is the legal classification of medicines as regards their supply with or without medical prescription. Since 2009 EDQM activities have expanded to include newer areas, e.g. cosmetics and food contact materials, packaging and containers. EDQM collaborates in", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es un informe de la Organizaci\u00f3n Mundial de la Salud (OMS) que detalla el trabajo del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas. Se agradece a los miembros del Comit\u00e9 por su dedicaci\u00f3n y se explica el proceso administrativo de nombramiento de expertos y las normas que rigen el funcionamiento del Comit\u00e9. El informe incluye un resumen de las discusiones, recomendaciones y nuevas directrices adoptadas. Adem\u00e1s, se destaca la colaboraci\u00f3n con organizaciones internacionales, como la Direcci\u00f3n Europea de Calidad de Medicamentos y Atenci\u00f3n Sanitaria (EDQM), que se encarga de la vigilancia de productos farmac\u00e9uticos en Europa y de proteger a los pacientes de medicamentos falsificados.\n\n### Preguntas:\n1. **\u00bfCu\u00e1l es el proceso de consulta del Comit\u00e9 de Expertos de la OMS y qu\u00e9 pasos incluye?**\n   - El proceso de consulta del Comit\u00e9 de Expertos incluye varios pasos: consulta preliminar y redacci\u00f3n, circulaci\u00f3n del primer borrador para comentarios, revisi\u00f3n del borrador, discusi\u00f3n del borrador por el Comit\u00e9, y finalmente, una vez adoptado, su publicaci\u00f3n en el informe del Comit\u00e9 como un anexo, seguido de la presentaci\u00f3n a los \u00d3rganos de Gobierno de la OMS y recomendaci\u00f3n a los Estados Miembros para su implementaci\u00f3n.\n\n2. **\u00bfQu\u00e9 papel desempe\u00f1a la Direcci\u00f3n Europea de Calidad de Medicamentos y Atenci\u00f3n Sanitaria (EDQM) en la regulaci\u00f3n de medicamentos en Europa?**\n   - La EDQM es responsable de la vigilancia de productos farmac\u00e9uticos comercializados en Europa y ha estado protegiendo a los pacientes de medicamentos falsificados desde 2008. Tambi\u00e9n se encarga de la clasificaci\u00f3n legal de los medicamentos en cuanto a su suministro con o sin receta m\u00e9dica y ha ampliado sus actividades para incluir \u00e1reas como cosm\u00e9ticos y materiales en contacto con alimentos.\n\n3. **\u00bfQu\u00e9 tipo de recomendaciones se incluyen en el informe del Comit\u00e9 de Expertos de la OMS?**\n   - El informe del Comit\u00e9 de Expertos incluye un resumen de las discusiones mantenidas, recomendaciones dirigidas a la OMS y a sus Estados Miembros, as\u00ed como nuevas directrices adoptadas que constituyen la orientaci\u00f3n t\u00e9cnica de la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Colaboraci\u00f3n Internacional**: La implementaci\u00f3n de directrices y est\u00e1ndares para la preparaci\u00f3n farmac\u00e9utica est\u00e1 estrechamente vinculada a diversas organizaciones, incluyendo:\n   - Agencia Europea de Medicamentos\n   - Direcci\u00f3n Europea de Calidad de Medicamentos y Atenci\u00f3n Sanitaria\n   - Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria\n   - Agencia Internacional de Energ\u00eda At\u00f3mica\n   - Fondo de las Naciones Unidas para la Infancia (UNICEF)\n   - Organizaci\u00f3n Mundial de la Propiedad Intelectual\n   - Banco Mundial\n   - Federaci\u00f3n Internacional Farmac\u00e9utica\n   - Asociaci\u00f3n Internacional de Fabricantes y Asociaciones Farmac\u00e9uticas\n   - Industria Mundial de la Automedicaci\u00f3n\n   - Farmacopeas nacionales y regionales\n\n2. **Problemas de Salud P\u00fablica**: Se destaca la preocupaci\u00f3n por los medicamentos falsificados, considerados un problema de salud p\u00fablica, y la necesidad de que la OMS aborde este desaf\u00edo.\n\n3. **Funciones del Comit\u00e9 de Expertos**: El Comit\u00e9 se enfoca en:\n   - Establecimiento de normas para las Buenas Pr\u00e1cticas de Manufactura (GMP).\n   - Mejora de la garant\u00eda de calidad.\n   - Actualizaci\u00f3n de directrices de calidad y pruebas de laboratorio.\n\n4. **Financiamiento y Sostenibilidad**: La financiaci\u00f3n del equipo de Garant\u00eda de Calidad y Seguridad de Medicamentos proviene principalmente de donantes externos, lo que es crucial para mantener sus actividades.\n\n5. **Desaf\u00edos Actuales**: El cierre de un Centro Colaborador de la OMS en Suecia representa un desaf\u00edo, aunque se espera encontrar un instituto de reemplazo pronto.\n\n6. **Estrategia de Medicamentos**: La Estrategia de Medicamentos est\u00e1 en proceso de publicaci\u00f3n y se vincular\u00e1 con los Objetivos de Desarrollo del Milenio, subrayando la conexi\u00f3n entre la calidad de los medicamentos y los objetivos globales de salud.", "excerpt_keywords": "Keywords: WHO, Expert Committee, pharmaceutical preparations, international collaboration, counterfeit medicines"}}, "e21c9cc3-ef40-4e24-a8c5-df6b228b1dd4": {"node_ids": ["cd8acc5b-e110-4a6d-a4dd-427c8baca7b0"], "metadata": {"page_label": "18", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan proporcionar respuestas espec\u00edficas basadas en el contexto del documento \"WHO - Technical Report Series 957\":\n\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentadas en el Informe 44 de la Serie de Informes T\u00e9cnicos de la OMS?**\n   - Esta pregunta busca obtener informaci\u00f3n espec\u00edfica sobre el contenido del informe, que podr\u00eda no estar disponible en otras fuentes.\n\n2. **\u00bfQu\u00e9 metodolog\u00edas se utilizaron para la recopilaci\u00f3n de datos en el Informe 44 de la Serie de Informes T\u00e9cnicos de la OMS?**\n   - Esta pregunta se centra en los m\u00e9todos de investigaci\u00f3n y an\u00e1lisis que sustentan las conclusiones del informe, lo cual es crucial para entender la validez de los resultados.\n\n3. **\u00bfC\u00f3mo se relaciona el Informe 44 de la Serie de Informes T\u00e9cnicos de la OMS con otros informes previos en la misma serie?**\n   - Esta pregunta busca establecer conexiones y comparaciones entre diferentes informes, lo que podr\u00eda ofrecer una perspectiva m\u00e1s amplia sobre la evoluci\u00f3n de los temas tratados por la OMS.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento \"WHO - Technical Report Series 957\" es parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n cient\u00edfica y recomendaciones para pol\u00edticas de salud. El Informe 44, en particular, podr\u00eda contener an\u00e1lisis detallados sobre un tema espec\u00edfico de inter\u00e9s para la comunidad de salud global, as\u00ed como recomendaciones basadas en evidencia para mejorar la salud p\u00fablica.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Comit\u00e9 de Expertos de la OMS**:\n   - Agradecimiento a los miembros por su dedicaci\u00f3n y contribuciones.\n   - Funciona como un cuerpo asesor oficial del Director General de la OMS, regido por normas y procedimientos.\n\n2. **Proceso de Consulta**:\n   - Incluye pasos como consulta preliminar, redacci\u00f3n, circulaci\u00f3n del borrador para comentarios, revisi\u00f3n, discusi\u00f3n y publicaci\u00f3n en el informe del Comit\u00e9.\n   - El informe incluye un resumen de discusiones, recomendaciones y nuevas directrices, que son presentadas a los \u00d3rganos de Gobierno de la OMS para su implementaci\u00f3n.\n\n3. **Colaboraci\u00f3n Internacional**:\n   - Se destaca la colaboraci\u00f3n con organizaciones internacionales y agencias, en particular con la **Direcci\u00f3n Europea de Calidad de Medicamentos y Atenci\u00f3n Sanitaria (EDQM)**.\n\n4. **Direcci\u00f3n Europea de Calidad de Medicamentos y Atenci\u00f3n Sanitaria (EDQM)**:\n   - Responsable de la vigilancia de productos farmac\u00e9uticos en Europa.\n   - Protege a los pacientes de medicamentos falsificados desde 2008.\n   - Se encarga de la clasificaci\u00f3n legal de medicamentos y ha ampliado sus actividades a cosm\u00e9ticos y materiales en contacto con alimentos.\n\nEste resumen destaca la estructura y funcionamiento del Comit\u00e9 de Expertos de la OMS, su proceso de consulta y la colaboraci\u00f3n con la EDQM en la regulaci\u00f3n de medicamentos en Europa.", "excerpt_keywords": "Keywords: OMS, Informe 44, salud p\u00fablica, medicamentos, colaboraci\u00f3n internacional"}}, "385c048f-a2ad-4e30-969f-bd120e447119": {"node_ids": ["f77bfe70-c537-495c-bfba-59725a5427aa"], "metadata": {"page_label": "19", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# International Federation of Pharmaceutical Manufacturers and Associations\n\nThe International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) had official observer status with the United Nations in Geneva, including WHO. IFPMA represents the research-based pharmaceutical, biotechnological and vaccine industry, and global intergovernmental agencies. It advocates policies that encourage discovery of new life-saving and life-enhancing medicines.\n\nIFPMA supports high standards of manufacturing and quality assurance in two areas:\n\n- Vaccines and biotechnology products, working in collaboration with WHO/EMP and the WHO Expert Committee on Biological Standardization; and\n- Medicines, including medicines for children, in collaboration with this Expert Committee and the WHO Expert Committee on the Selection and Use of Essential Medicines.\n\n# International Generic Pharmaceutical Alliance\n\nThe International Generic Pharmaceutical Alliance (IGPA) has member generic trade associations from Canada, Europe, India, Japan and the USA. Observer status had been granted within the last year to generic associations from Brazil, the People\u2019s Republic of China, Jordan and South Africa; observer status for Malaysia and Mexico was currently under consideration.\n\nThe General Policy Initiatives of IGPA comprise cross-cutting quality assurance issues, collaboration with the WHO Expert Committee on Biological Standardization and International Collaboration (ICH Expert Working Groups on Quality and Safety). Other activities supported by IGPA are:\n\n- Nomenclature, terminology and databases \u2014 IGPA and the European Generic Medicines Association (EGA) have been involved in the discussion of international nonproprietary names (INN) for biologicals and biosimilars;\n- Prequalification of priority essential medicines \u2014 EGA works with WHO on an accelerated prequalification procedure for generics approved by SRAs;\n- Bioequivalence \u2014 although not on the WHO Expert Committee\u2019s agenda, IGPA was working on a proposal for international harmonization of bioequivalence requirements; and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento presenta informaci\u00f3n sobre dos organizaciones clave en la industria farmac\u00e9utica: la Federaci\u00f3n Internacional de Asociaciones de Fabricantes de Productos Farmac\u00e9uticos (IFPMA) y la Alianza Internacional de Productos Farmac\u00e9uticos Gen\u00e9ricos (IGPA). La IFPMA act\u00faa como observador ante las Naciones Unidas y representa a la industria farmac\u00e9utica basada en la investigaci\u00f3n, abogando por pol\u00edticas que fomenten el descubrimiento de nuevos medicamentos. La IGPA, por su parte, incluye asociaciones de gen\u00e9ricos de varios pa\u00edses y se enfoca en la calidad, la nomenclatura y la precalificaci\u00f3n de medicamentos esenciales. Ambas organizaciones colaboran con la OMS en diversas iniciativas relacionadas con la calidad y la regulaci\u00f3n de medicamentos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las \u00e1reas espec\u00edficas en las que la IFPMA colabora con la OMS y sus comit\u00e9s expertos?**\n   - La IFPMA colabora con la OMS en dos \u00e1reas principales: productos de vacunas y biotecnolog\u00eda, y medicamentos, incluyendo aquellos para ni\u00f1os, trabajando con el Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica y el Comit\u00e9 de Expertos en la Selecci\u00f3n y Uso de Medicamentos Esenciales.\n\n2. **\u00bfQu\u00e9 iniciativas de pol\u00edtica general se est\u00e1n llevando a cabo por la IGPA en relaci\u00f3n con la calidad de los medicamentos?**\n   - Las iniciativas de pol\u00edtica general de la IGPA incluyen cuestiones de aseguramiento de calidad, colaboraci\u00f3n con el Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica de la OMS, y el trabajo en nomenclatura y bases de datos para nombres no propietarios internacionales (INN) de biol\u00f3gicos y biosimilares.\n\n3. **\u00bfQu\u00e9 pa\u00edses han recibido recientemente el estatus de observador en la IGPA y cu\u00e1les est\u00e1n en consideraci\u00f3n?**\n   - Recientemente, se otorg\u00f3 el estatus de observador a asociaciones gen\u00e9ricas de Brasil, la Rep\u00fablica Popular de China, Jordania y Sud\u00e1frica. Actualmente, se est\u00e1 considerando el estatus de observador para Malasia y M\u00e9xico.", "prev_section_summary": "El contenido de la secci\u00f3n se refiere al \"WHO - Technical Report Series 957\", espec\u00edficamente al Informe 44 de esta serie. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n### Temas Clave:\n1. **Hallazgos y Recomendaciones**: Se busca informaci\u00f3n sobre los principales hallazgos y recomendaciones del Informe 44, que son cruciales para la salud p\u00fablica.\n2. **Metodolog\u00edas de Recopilaci\u00f3n de Datos**: Se enfatiza la importancia de las metodolog\u00edas utilizadas en la investigaci\u00f3n, lo que es fundamental para evaluar la validez de los resultados presentados en el informe.\n3. **Relaci\u00f3n con Informes Previos**: Se plantea la necesidad de comparar el Informe 44 con otros informes de la misma serie para entender la evoluci\u00f3n de los temas tratados por la OMS.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n de la serie de informes t\u00e9cnicos.\n- **Informe 44**: Documento espec\u00edfico dentro de la Serie de Informes T\u00e9cnicos de la OMS que aborda un tema relevante para la salud p\u00fablica.\n\n### Contexto General:\nEl documento es parte de una serie que aborda temas de salud p\u00fablica y proporciona recomendaciones basadas en evidencia para mejorar pol\u00edticas de salud a nivel global.", "excerpt_keywords": "Keywords: IFPMA, IGPA, pharmaceuticals, quality assurance, WHO"}}, "5c3c32ab-7bed-4a65-a2ed-fbc7676cef35": {"node_ids": ["93c70357-9649-4d5b-a713-cf4485a84ba7"], "metadata": {"page_label": "20", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# International Pharmaceutical Federation\n\nThe International Pharmaceutical Federation (FIP) reported that over the past year FIP and WHO had established work plans to support their involvement in key strategic collaborative areas of work. FIP\u2019s main priority was medicines and strengthening the pharmaceutical workforce. Other areas of importance included the roles and added value of pharmacists in patient safety, primary health care, noncommunicable diseases and maternal, newborn and child health. FIP continued to collaborate on these projects related to medicines in WHO.\n\nIn particular, the issue of good distribution practices (GDP) is an important element in securing the legitimate supply and distribution chain, and also in preventing the infiltration of counterfeit medical products (see section 8.2). FIP played an active role in the final revision and drafting of the WHO GDP guidelines in September 2009. FIP had produced a WHO/FIP Handbook on Developing Pharmacy Practice and is currently working towards a revision of the FIP/WHO guidelines on good pharmacy practice (GPP). FIP also assisted IMPACT in improving the information available to the public regarding counterfeit medicines and the work of IMPACT.\n\n# United Nations Children\u2019s Fund\n\nThe United Nations Children\u2019s Fund (UNICEF) promotes and protects children\u2019s rights, especially those of the most vulnerable in the poorest countries. UNICEF core commitments are health and nutrition, education, water and sanitation, child protection and HIV/AIDS.\n\nOne of the main activities of UNICEF is the supply of quality medicines to countries and communities in need; the supply headquarters is located in Copenhagen. The Supply Division oversees UNICEF\u2019s global supply procurement and logistics operations on behalf of UNICEF and its procurement services partners. It ensures that supplies of high quality and good value reach children and their families quickly.\n\nPrequalification of suppliers of pharmaceuticals in UNICEF involves the review of submitted documentation and/or GMP inspections to ensure compliance with WHO GMP guidelines using a technical questionnaire developed by WHO. The technical questionnaire covers manufacturing sites, dosage forms and products of interest, export experience and licence to manufacture pharmaceuticals. Local authorities are invited to participate in GMP inspections. There are also joint inspections with WHO and other partners.\n\nDecisions are based on the regulatory environment in the country of origin and prior experience of UNICEF, GMP inspection by UNICEF or by a", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento aborda la colaboraci\u00f3n entre la Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) y la Organizaci\u00f3n Mundial de la Salud (OMS) en \u00e1reas estrat\u00e9gicas relacionadas con medicamentos y el fortalecimiento de la fuerza laboral farmac\u00e9utica. Se destaca la importancia de las buenas pr\u00e1cticas de distribuci\u00f3n (GDP) para asegurar la cadena de suministro leg\u00edtima y prevenir productos m\u00e9dicos falsificados. Adem\u00e1s, se menciona el papel del Fondo de las Naciones Unidas para la Infancia (UNICEF) en la promoci\u00f3n y protecci\u00f3n de los derechos de los ni\u00f1os, as\u00ed como su compromiso con la provisi\u00f3n de medicamentos de calidad a comunidades necesitadas. UNICEF realiza la precalificaci\u00f3n de proveedores de productos farmac\u00e9uticos mediante revisiones y auditor\u00edas de buenas pr\u00e1cticas de manufactura (GMP).\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las \u00e1reas prioritarias en las que FIP y OMS han establecido planes de trabajo colaborativos?**\n   - Respuesta: Las \u00e1reas prioritarias incluyen medicamentos, el fortalecimiento de la fuerza laboral farmac\u00e9utica, la seguridad del paciente, la atenci\u00f3n primaria de salud, las enfermedades no transmisibles y la salud materna, neonatal y de los ni\u00f1os.\n\n2. **\u00bfQu\u00e9 papel desempe\u00f1a UNICEF en la provisi\u00f3n de medicamentos a comunidades vulnerables y c\u00f3mo se asegura la calidad de estos medicamentos?**\n   - Respuesta: UNICEF se encarga de suministrar medicamentos de calidad a comunidades necesitadas, y para asegurar la calidad, realiza la precalificaci\u00f3n de proveedores mediante revisiones de documentaci\u00f3n y auditor\u00edas de GMP, utilizando un cuestionario t\u00e9cnico desarrollado por la OMS.\n\n3. **\u00bfC\u00f3mo contribuy\u00f3 FIP a la elaboraci\u00f3n de las directrices de buenas pr\u00e1cticas de distribuci\u00f3n (GDP) de la OMS?**\n   - Respuesta: FIP jug\u00f3 un papel activo en la revisi\u00f3n final y redacci\u00f3n de las directrices de GDP de la OMS en septiembre de 2009, y ha trabajado en la producci\u00f3n de un manual sobre el desarrollo de la pr\u00e1ctica farmac\u00e9utica y en la revisi\u00f3n de las directrices de buenas pr\u00e1cticas farmac\u00e9uticas (GPP) de FIP/OMS.", "prev_section_summary": "La secci\u00f3n aborda dos organizaciones importantes en la industria farmac\u00e9utica: \n\n1. **Federaci\u00f3n Internacional de Asociaciones de Fabricantes de Productos Farmac\u00e9uticos (IFPMA)**:\n   - Tiene estatus de observador ante las Naciones Unidas y la OMS.\n   - Representa a la industria farmac\u00e9utica basada en la investigaci\u00f3n, biotecnolog\u00eda y vacunas.\n   - Aboga por pol\u00edticas que fomenten el descubrimiento de medicamentos nuevos y vitales.\n   - Colabora con la OMS en dos \u00e1reas principales: \n     - Productos de vacunas y biotecnolog\u00eda.\n     - Medicamentos, incluyendo aquellos para ni\u00f1os.\n\n2. **Alianza Internacional de Productos Farmac\u00e9uticos Gen\u00e9ricos (IGPA)**:\n   - Agrupa asociaciones de gen\u00e9ricos de varios pa\u00edses, incluyendo Canad\u00e1, Europa, India, Jap\u00f3n y EE. UU.\n   - Recientemente, se otorg\u00f3 estatus de observador a asociaciones de Brasil, China, Jordania y Sud\u00e1frica; Malasia y M\u00e9xico est\u00e1n en consideraci\u00f3n.\n   - Sus iniciativas de pol\u00edtica general se centran en:\n     - Aseguramiento de calidad.\n     - Colaboraci\u00f3n con la OMS en estandarizaci\u00f3n biol\u00f3gica.\n     - Nomenclatura y bases de datos para nombres no propietarios internacionales (INN) de biol\u00f3gicos y biosimilares.\n     - Precalificaci\u00f3n de medicamentos esenciales.\n     - Propuestas para la armonizaci\u00f3n internacional de requisitos de bioequivalencia.\n\nAmbas organizaciones trabajan en conjunto con la OMS para mejorar la calidad y regulaci\u00f3n de los medicamentos a nivel global.", "excerpt_keywords": "Keywords: International Pharmaceutical Federation, UNICEF, good distribution practices, pharmaceutical workforce, quality medicines"}}, "0857578a-1422-4604-bd4b-16760b38af8f": {"node_ids": ["d5f83f2a-cd16-4ed9-9cab-da42a5eabd27"], "metadata": {"page_label": "21", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "representative selected by UNICEF. Contract manufacture is only accepted if the subcontractor is also approved by UNICEF. Inspections are carried out primarily by UNICEF staff who check compliance with WHO GMP guidelines. During 2003\u20132009, 145 GMP inspections carried out in 47 companies failed (32%). In case of failure a detailed GMP inspection report is forwarded to the company with a request to respond within one month.\n\nIn case of prequalification of vaccines, HIV, malaria and tuberculosis products:\n- products have to be prequalified by WHO and listed on the WHO web site;\n- the supplier has to confirm to UNICEF that the products are identical to those assessed by WHO/UNICEF; and\n- UNICEF\u2019s purchase is traced in WHO/UNICEF GMP inspections.\n\n### 2.1.2 Pharmacopoeial Discussion Group\n\nThe Pharmacopoeial Discussion Group (PDG), which consists of the European Pharmacopoeia, Japanese Pharmacopoeia and United States Pharmacopeia, met in association with the Expert Working Groups of the International Conference on Harmonisation (ICH) from 8 to 12 June 2009 in Yokohama, Japan. The Secretary of this Expert Committee participated as an observer for WHO.\n\nThe experts recommended reviews of the following general methods against existing related *International Pharmacopoeia* (Ph.Int.) texts and adding those not yet included in the Ph.Int. for future adoption:\n- Test for extractable volume of parenteral preparations (General Chapter);\n- Test for particulate contamination: sub-visible particles (General Chapter);\n- Disintegration test;\n- Dissolution test (General Chapter) (pending availability of final text);\n- Sterility test (General Chapter);\n- Microbiological examination of non-sterile products; and\n- Acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use (General Chapter).\n\nThe Committee recommended that the following should be considered for adoption:\n- Microbiological examination of non-sterile products:\n  - Microbial enumeration tests (General Chapter);\n  - Tests for specified microorganisms (General Chapter); and\n- Tablet friability (General Chapter).\n\nThe Secretariat informed the experts that preliminary discussions had already been held with the PDG members, based on previous recommendations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento se centra en las directrices y procedimientos relacionados con la fabricaci\u00f3n y precalificaci\u00f3n de productos farmac\u00e9uticos, especialmente vacunas y tratamientos para el VIH, malaria y tuberculosis, bajo la supervisi\u00f3n de UNICEF y la OMS. Se menciona que las inspecciones de Buenas Pr\u00e1cticas de Manufactura (GMP) son realizadas principalmente por personal de UNICEF, y se reporta un porcentaje significativo de fallos en estas inspecciones. Adem\u00e1s, se discuten las recomendaciones del Grupo de Discusi\u00f3n Farmacopea (PDG) sobre m\u00e9todos generales que deben ser revisados y adoptados en relaci\u00f3n con la farmacopoeia internacional.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1l es el porcentaje de fallos en las inspecciones de GMP realizadas entre 2003 y 2009, y qu\u00e9 procedimiento se sigue en caso de un fallo?**\n   - Respuesta: Durante el per\u00edodo de 2003 a 2009, el 32% de las 145 inspecciones de GMP realizadas en 47 empresas fallaron. En caso de fallo, se env\u00eda un informe detallado de la inspecci\u00f3n a la empresa con una solicitud de respuesta dentro de un mes.\n\n2. **\u00bfQu\u00e9 requisitos deben cumplir los productos para ser precalificados por la OMS y adquiridos por UNICEF?**\n   - Respuesta: Los productos deben estar precalificados por la OMS y listados en su sitio web, el proveedor debe confirmar a UNICEF que los productos son id\u00e9nticos a los evaluados por la OMS/UNICEF, y la compra de UNICEF debe ser rastreada en las inspecciones de GMP de la OMS/UNICEF.\n\n3. **\u00bfCu\u00e1les son algunos de los m\u00e9todos generales recomendados para revisi\u00f3n y posible adopci\u00f3n por el Grupo de Discusi\u00f3n Farmacopea (PDG)?**\n   - Respuesta: Algunos de los m\u00e9todos recomendados incluyen la prueba de volumen extra\u00edble de preparaciones parenterales, la prueba de contaminaci\u00f3n particulada, la prueba de desintegraci\u00f3n, la prueba de disoluci\u00f3n, la prueba de esterilidad, la examen microbiol\u00f3gico de productos no est\u00e9riles, y criterios de aceptaci\u00f3n para preparaciones farmac\u00e9uticas y sustancias para uso farmac\u00e9utico.", "prev_section_summary": "La secci\u00f3n aborda la colaboraci\u00f3n entre la **Federaci\u00f3n Internacional Farmac\u00e9utica (FIP)** y la **Organizaci\u00f3n Mundial de la Salud (OMS)**, destacando sus planes de trabajo en \u00e1reas estrat\u00e9gicas como:\n\n- **Medicamentos** y fortalecimiento de la fuerza laboral farmac\u00e9utica.\n- **Seguridad del paciente**.\n- **Atenci\u00f3n primaria de salud**.\n- **Enfermedades no transmisibles**.\n- **Salud materna, neonatal y de los ni\u00f1os**.\n\nSe enfatiza la importancia de las **buenas pr\u00e1cticas de distribuci\u00f3n (GDP)** para asegurar la cadena de suministro leg\u00edtima y prevenir la infiltraci\u00f3n de productos m\u00e9dicos falsificados. FIP tuvo un papel activo en la elaboraci\u00f3n de las directrices de GDP de la OMS y en la producci\u00f3n de un manual sobre el desarrollo de la pr\u00e1ctica farmac\u00e9utica.\n\nAdem\u00e1s, se menciona el papel del **Fondo de las Naciones Unidas para la Infancia (UNICEF)** en la promoci\u00f3n y protecci\u00f3n de los derechos de los ni\u00f1os, especialmente en comunidades vulnerables. UNICEF se dedica a la provisi\u00f3n de medicamentos de calidad, asegurando su calidad a trav\u00e9s de la **precalificaci\u00f3n de proveedores** mediante revisiones de documentaci\u00f3n y auditor\u00edas de **buenas pr\u00e1cticas de manufactura (GMP)**, utilizando un cuestionario t\u00e9cnico desarrollado por la OMS.\n\nEn resumen, los temas clave incluyen la colaboraci\u00f3n en salud p\u00fablica, la seguridad en la distribuci\u00f3n de medicamentos y el compromiso de UNICEF con la salud infantil.", "excerpt_keywords": "Keywords: UNICEF, GMP inspections, prequalification, Pharmacopoeial Discussion Group, pharmaceutical standards"}}, "a0805be5-1c94-4b75-a11d-f354764788a5": {"node_ids": ["bd0c3afd-4869-434a-af6f-edd500fcbe7e"], "metadata": {"page_label": "22", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 2.1.3 International Conference on Harmonisation\n\nThe International Conference on Harmonisation (ICH) Expert Working Groups met from 8 to 12 June 2009 in Yokohama, Japan.\n\nThe Secretary of this Expert Committee also attended, as an observer for WHO, the ICH Q4B Working Group meetings (consisting of members from the six ICH partners and observers). An update of the current activities in the quality area was given by the co-chair of the meeting.\n\n# 2.1.4 International Conference of Drug Regulatory Authorities\n\nThe International Conference of Drug Regulatory Authorities (ICDRA) provide medicines regulatory authorities (MRAs) of WHO Member States with a forum to meet and discuss ways to strengthen collaboration. The conferences have been held since 1980 with the aim of promoting exchange of information and collaborative approaches to issues of common concern. As a platform established to develop international consensus, the ICDRA continues to be an important tool for WHO and MRAs in their efforts to harmonize regulation and improve the safety, efficacy and quality of medicines. The ICDRA programme is developed by a planning committee of representative medicines regulators. Discussions during the four days of the ICDRA usually include topics relating to quality issues, herbal medicines, homeopathy, regulatory reform, medicines safety, counterfeiting, access, regulation of clinical trials, harmonization, new technologies and e-commerce. Recommendations are proposed for action among agencies, WHO and related institutions.\n\nThe recommendations formulated by the 13th International Conference of Drug Regulatory Authorities held in Berne, Switzerland, from 16 to 19 September 2008 are available on the WHO web site (http://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra).\n\nThe 14th ICDRA would take place in Singapore from 30 November to 3 December 2010. A pre-ICDRA meeting on \u201cEffective Collaboration: The Future for Medicines Regulation\u201d would take place on 28\u201329 November.\n\nRegistration, details and programme are available on the ICDRA web site: http://www.icdra2010.sg/.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona informaci\u00f3n sobre dos importantes conferencias organizadas por la Organizaci\u00f3n Mundial de la Salud (OMS): la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) y la Conferencia Internacional de Autoridades Reguladoras de Medicamentos (ICDRA). La ICH se llev\u00f3 a cabo en junio de 2009 en Yokohama, Jap\u00f3n, y se centr\u00f3 en actividades relacionadas con la calidad de los medicamentos. Por otro lado, la ICDRA, que se ha celebrado desde 1980, ofrece un foro para que las autoridades reguladoras de medicamentos de los Estados Miembros de la OMS discutan la colaboraci\u00f3n y el intercambio de informaci\u00f3n sobre temas de inter\u00e9s com\u00fan. La 14\u00aa ICDRA est\u00e1 programada para realizarse en Singapur en diciembre de 2010.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los temas principales discutidos en la ICDRA y c\u00f3mo se relacionan con la regulaci\u00f3n de medicamentos?**\n   - Esta pregunta busca detalles sobre los temas espec\u00edficos que se abordan en la ICDRA, que incluyen calidad, seguridad de medicamentos, y nuevas tecnolog\u00edas, entre otros.\n\n2. **\u00bfQu\u00e9 recomendaciones se formularon en la 13\u00aa ICDRA y d\u00f3nde se pueden encontrar?**\n   - Esta pregunta se centra en las recomendaciones espec\u00edficas que surgieron de la 13\u00aa ICDRA en Berna, Suiza, y proporciona un enlace directo para acceder a esa informaci\u00f3n.\n\n3. **\u00bfCu\u00e1l es el prop\u00f3sito de la ICH y c\u00f3mo se involucra la OMS en sus actividades?**\n   - Esta pregunta busca aclarar el papel de la OMS en la ICH y c\u00f3mo contribuye a las actividades relacionadas con la calidad de los medicamentos a nivel internacional.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Supervisi\u00f3n de la Fabricaci\u00f3n de Productos Farmac\u00e9uticos**:\n   - La fabricaci\u00f3n de productos, especialmente vacunas y tratamientos para VIH, malaria y tuberculosis, est\u00e1 bajo la supervisi\u00f3n de UNICEF y la OMS.\n   - Las inspecciones de Buenas Pr\u00e1cticas de Manufactura (GMP) son realizadas principalmente por personal de UNICEF.\n\n2. **Resultados de Inspecciones de GMP**:\n   - Entre 2003 y 2009, el 32% de las 145 inspecciones de GMP realizadas en 47 empresas resultaron en fallos.\n   - En caso de fallo, se env\u00eda un informe detallado a la empresa con una solicitud de respuesta en un plazo de un mes.\n\n3. **Requisitos para la Precalificaci\u00f3n de Productos**:\n   - Los productos deben estar precalificados por la OMS y listados en su sitio web.\n   - El proveedor debe confirmar que los productos son id\u00e9nticos a los evaluados por la OMS/UNICEF.\n   - Las compras de UNICEF deben ser rastreadas en las inspecciones de GMP de la OMS/UNICEF.\n\n4. **Grupo de Discusi\u00f3n Farmacopea (PDG)**:\n   - Compuesto por la Farmacopea Europea, la Farmacopea Japonesa y la Farmacopea de los Estados Unidos.\n   - Se reuni\u00f3 del 8 al 12 de junio de 2009 en Yokohama, Jap\u00f3n, en asociaci\u00f3n con grupos de trabajo de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH).\n   - Se recomendaron revisiones de m\u00e9todos generales para su posible adopci\u00f3n en la Farmacopea Internacional.\n\n5. **M\u00e9todos Generales Recomendados para Revisi\u00f3n**:\n   - Prueba de volumen extra\u00edble de preparaciones parenterales.\n   - Prueba de contaminaci\u00f3n particulada.\n   - Pruebas de desintegraci\u00f3n y disoluci\u00f3n.\n   - Prueba de esterilidad.\n   - Examen microbiol\u00f3gico de productos no est\u00e9riles.\n   - Criterios de aceptaci\u00f3n para preparaciones farmac\u00e9uticas.\n\n6. **Consideraciones para la Adopci\u00f3n**:\n   - Ex\u00e1menes microbiol\u00f3gicos de productos no est\u00e9riles, incluyendo pruebas de enumeraci\u00f3n microbiana y pruebas para microorganismos espec\u00edficos.\n   - Prueba de friabilidad de tabletas.\n\n### Entidades Clave\n- **UNICEF**: Organizaci\u00f3n que supervisa la fabricaci\u00f3n y realiza inspecciones de GMP.\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad que establece directrices y requisitos para la precalificaci\u00f3n de productos.\n- **Grupo de Discusi\u00f3n Farmacopea (PDG)**: Grupo que incluye la Farmacopea Europea, Japonesa y de EE. UU., encargado de revisar y recomendar m\u00e9todos para la Farmacopea Internacional.", "excerpt_keywords": "Keywords: International Conference on Harmonisation, ICDRA, medicines regulation, WHO, quality assurance"}}, "4beecf06-5053-4535-9689-01bc3a347514": {"node_ids": ["c919519a-7fe9-404e-b7f9-7e3a5c7e8b24"], "metadata": {"page_label": "23", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 2.2 Cross-cutting issues in pharmaceuticals \u2014 quality assurance issues\n\n### 2.2.1 Herbal medicines\n\nThe Committee received a report on WHO\u2019s policy and activities in the field of traditional medicine.\n\nThe representative of the Traditional Medicine (TRM) team reported on the activities of International Regulatory Cooperation for Herbal Medicines (IRCH) \u2014 membership had increased to 22, consisting of 19 Member Countries and three Member Regional Bodies. The third annual meeting was held in Montreal, Canada in February 2009, at which a strategic plan of action for IRCH was discussed and agreed upon. Based on the review of current issues relating to herbal medicines, eight working groups addressing the priority issues identified had been established.\n\nTRM also reported on the publication of Volume 4, *WHO monographs on selected medicinal plants*, which contained 28 monographs. TRM thanked the Expert Committee and the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations for their technical contribution and support in the development of the monographs.\n\nA major outcome of the WHO Congress on Traditional Medicine was the adoption of the \u201cBeijing Declaration\u201d. The World Health Assembly in May 2009 adopted a new resolution on traditional medicine (resolution WHA 62.13), referring to the \u201cBeijing Declaration\u201d and requested the Director-General to update the WHO Traditional Medicine Strategy. It also requested WHO to support the efforts of Member States in integrating traditional medicine into national health systems.\n\nIn the context of primary health care, the report of the WHO interregional workshop on the use of traditional medicine in primary health care, held in Ulaanbaatar, Mongolia in August 2007, was printed in May 2009 and was widely disseminated.\n\nThe Committee was informed of WHO\u2019s new project on the development of international classification of traditional medicine, towards the integration of traditional medicine into general health information systems, and standardization of clinical terms used by providers of traditional medicine. This project also aimed at responding to the need expressed by national pharmacovigilance centres for an appropriate coding system accommodating the reporting of adverse events to herbal medicines.\n\nThe Committee was also informed about the progress of implementation of the Global Strategy and Plan of Action on public health, innovation and intellectual property (GSPOA) in the field of traditional medicine.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Actividades de la OMS en Medicina Tradicional**: La OMS ha estado trabajando en la regulaci\u00f3n y promoci\u00f3n de la medicina tradicional, especialmente en el \u00e1mbito de las medicinas herbales, a trav\u00e9s de la cooperaci\u00f3n internacional y la creaci\u00f3n de grupos de trabajo para abordar problemas prioritarios.\n\n2. **Publicaciones y Declaraciones Importantes**: Se ha publicado un volumen de monograf\u00edas sobre plantas medicinales y se adopt\u00f3 la \"Declaraci\u00f3n de Pek\u00edn\" en el Congreso de Medicina Tradicional, lo que llev\u00f3 a la adopci\u00f3n de una resoluci\u00f3n por parte de la Asamblea Mundial de la Salud para integrar la medicina tradicional en los sistemas de salud nacionales.\n\n3. **Proyectos de Clasificaci\u00f3n y Vigilancia**: La OMS est\u00e1 desarrollando un sistema de clasificaci\u00f3n internacional para la medicina tradicional y est\u00e1 trabajando en la estandarizaci\u00f3n de t\u00e9rminos cl\u00ednicos, as\u00ed como en la implementaci\u00f3n de estrategias para la innovaci\u00f3n y la propiedad intelectual en el campo de la medicina tradicional.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los objetivos espec\u00edficos de los ocho grupos de trabajo establecidos por la OMS en relaci\u00f3n con las medicinas herbales?**\n   - Esta pregunta busca detalles sobre las prioridades y enfoques espec\u00edficos que estos grupos est\u00e1n abordando, lo cual no se menciona expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 impacto tuvo la \"Declaraci\u00f3n de Pek\u00edn\" en las pol\u00edticas de salud de los Estados Miembros de la OMS?**\n   - Esta pregunta se centra en las repercusiones pr\u00e1cticas y pol\u00edticas de la declaraci\u00f3n, que no se detalla en el contexto proporcionado.\n\n3. **\u00bfC\u00f3mo se planea implementar el sistema de clasificaci\u00f3n internacional de medicina tradicional y qu\u00e9 desaf\u00edos se anticipan en este proceso?**\n   - Esta pregunta busca informaci\u00f3n sobre la implementaci\u00f3n pr\u00e1ctica del proyecto y los posibles obst\u00e1culos que podr\u00edan surgir, que no se abordan en el texto.", "prev_section_summary": "La secci\u00f3n aborda dos conferencias importantes organizadas por la Organizaci\u00f3n Mundial de la Salud (OMS):\n\n1. **Conferencia Internacional sobre Armonizaci\u00f3n (ICH)**:\n   - Se llev\u00f3 a cabo del 8 al 12 de junio de 2009 en Yokohama, Jap\u00f3n.\n   - Incluy\u00f3 la participaci\u00f3n de un secretario de la OMS como observador en las reuniones del Grupo de Trabajo ICH Q4B.\n   - Se centr\u00f3 en actividades relacionadas con la calidad de los medicamentos.\n\n2. **Conferencia Internacional de Autoridades Reguladoras de Medicamentos (ICDRA)**:\n   - Se ha celebrado desde 1980, proporcionando un foro para que las autoridades reguladoras de medicamentos de los Estados Miembros de la OMS discutan la colaboraci\u00f3n y el intercambio de informaci\u00f3n.\n   - La ICDRA busca desarrollar un consenso internacional y mejorar la regulaci\u00f3n, seguridad, eficacia y calidad de los medicamentos.\n   - Los temas discutidos incluyen calidad de medicamentos, seguridad, regulaci\u00f3n de ensayos cl\u00ednicos, nuevas tecnolog\u00edas, y m\u00e1s.\n   - La 13\u00aa ICDRA se realiz\u00f3 en Berna, Suiza, del 16 al 19 de septiembre de 2008, y sus recomendaciones est\u00e1n disponibles en el sitio web de la OMS.\n   - La 14\u00aa ICDRA est\u00e1 programada para llevarse a cabo en Singapur del 30 de noviembre al 3 de diciembre de 2010, con una reuni\u00f3n previa sobre colaboraci\u00f3n efectiva en la regulaci\u00f3n de medicamentos.\n\nEstos eventos son fundamentales para la armonizaci\u00f3n y mejora de la regulaci\u00f3n de medicamentos a nivel internacional.", "excerpt_keywords": "Keywords: herbal medicines, traditional medicine, WHO, Beijing Declaration, quality assurance"}}, "6acc044f-77da-4736-b2b3-2a3b8f8c7675": {"node_ids": ["e6af2148-1187-4236-bd27-5f136f4e652c"], "metadata": {"page_label": "24", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee encouraged countries to make use of the materials available from this Programme and took note of the role of traditional medicines within the concept of primary health care.\n\n## 2.2.2 Biologicals and vaccines\n\n### WHO Expert Committee on Biological Standardization\n\nThe role of the Expert Committee on Biological Standardization was to develop international recommendations for the production and control of biological medicines and the establishment of associated international biological reference materials. The Committee would next meet on 19\u201323 October 2009 and a key agenda item that might be of interest to the Expert Committee on Specifications for Pharmaceutical Preparations was the proposed guidelines on evaluation of similar biotherapeutic products. These guidelines, if established, would set international expectations for the regulatory evaluation of this increasingly important and relatively new class of biological medicines. It would, however, be only a first stage in providing equity of access to this type of product and WHO recognized that much would need to be done to assist Member States to develop the capacity to ensure effective use of such products.\n\nA second topic was the issue of transition of some drugs from biologicals to chemicals. The Expert Committee on Biological Standardization had initiated a process whereby all proposals for new or replacement reference materials were first submitted to the Committee for review. Proposals were being received for certain reference materials to be calibrated in SI units instead of the International Unit of biological activity. Where this was the case, consultation with the Expert Committee on Specifications for Pharmaceutical Preparations was also sought prior to the initiation of the study.\n\nTwo other topics for more detailed discussion by the Expert Committee on Specifications for Pharmaceutical Preparations were examples of cross-cutting initiatives between the two Committees. The first was the guidelines that were under development to establish GMP for blood establishments and the second, the guidelines for regulatory oversight of temperature-controlled distribution of pharmaceuticals.\n\nA joint concern of both Committees was to ensure effective implementation of guidelines and recommendations. Implementation workshops had been set up by the secretariat to promote the understanding and use of guidelines and recommendations established by the Expert Committee on Biological Standardization. New guidelines on regulatory expectations for stability evaluation of vaccines had been used as a case study and positive feedback had been obtained from all stakeholders on the value of such an approach.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl Comit\u00e9 de Expertos de la OMS en Estandarizaci\u00f3n Biol\u00f3gica se encarga de desarrollar recomendaciones internacionales para la producci\u00f3n y control de medicamentos biol\u00f3gicos y establecer materiales de referencia biol\u00f3gica. En su pr\u00f3xima reuni\u00f3n, se discutir\u00e1n pautas para la evaluaci\u00f3n de productos bioterap\u00e9uticos similares y la transici\u00f3n de algunos medicamentos de biol\u00f3gicos a qu\u00edmicos. Adem\u00e1s, se est\u00e1n desarrollando iniciativas conjuntas con el Comit\u00e9 de Especificaciones para Preparaciones Farmac\u00e9uticas, incluyendo directrices sobre buenas pr\u00e1cticas de manufactura (GMP) para establecimientos de sangre y la supervisi\u00f3n regulatoria de la distribuci\u00f3n de productos farmac\u00e9uticos controlados por temperatura. Se han establecido talleres de implementaci\u00f3n para promover la comprensi\u00f3n y uso de estas directrices.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son los temas clave que se discutir\u00e1n en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos sobre Estandarizaci\u00f3n Biol\u00f3gica programada para octubre de 2009?**\n   - Respuesta: Se discutir\u00e1n las pautas propuestas para la evaluaci\u00f3n de productos bioterap\u00e9uticos similares y la transici\u00f3n de algunos medicamentos de biol\u00f3gicos a qu\u00edmicos.\n\n2. **\u00bfQu\u00e9 proceso ha iniciado el Comit\u00e9 de Estandarizaci\u00f3n Biol\u00f3gica respecto a las propuestas de nuevos materiales de referencia?**\n   - Respuesta: El Comit\u00e9 ha iniciado un proceso en el que todas las propuestas para nuevos o materiales de referencia de reemplazo deben ser primero presentadas al Comit\u00e9 para su revisi\u00f3n.\n\n3. **\u00bfQu\u00e9 tipo de talleres ha establecido la secretar\u00eda para asegurar la implementaci\u00f3n efectiva de las directrices y recomendaciones del Comit\u00e9?**\n   - Respuesta: Se han establecido talleres de implementaci\u00f3n para promover la comprensi\u00f3n y uso de las directrices y recomendaciones establecidas por el Comit\u00e9 de Estandarizaci\u00f3n Biol\u00f3gica, utilizando nuevas directrices sobre la evaluaci\u00f3n de estabilidad de vacunas como estudio de caso.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Actividades de la OMS en Medicina Tradicional**:\n   - La OMS ha estado activa en la regulaci\u00f3n y promoci\u00f3n de la medicina tradicional, especialmente en el \u00e1mbito de las medicinas herbales.\n   - Se ha incrementado la membres\u00eda del grupo de cooperaci\u00f3n internacional IRCH a 22 miembros, incluyendo 19 pa\u00edses y 3 cuerpos regionales.\n\n2. **Grupos de Trabajo**:\n   - Se establecieron ocho grupos de trabajo para abordar problemas prioritarios relacionados con las medicinas herbales, aunque no se especifican los objetivos de cada grupo.\n\n3. **Publicaciones Importantes**:\n   - Se public\u00f3 el *Volumen 4 de las monograf\u00edas de la OMS sobre plantas medicinales*, que incluye 28 monograf\u00edas.\n   - La \"Declaraci\u00f3n de Pek\u00edn\" fue adoptada en el Congreso de Medicina Tradicional, lo que llev\u00f3 a la adopci\u00f3n de la resoluci\u00f3n WHA 62.13 por parte de la Asamblea Mundial de la Salud.\n\n4. **Integraci\u00f3n en Sistemas de Salud**:\n   - La OMS est\u00e1 apoyando a los Estados Miembros en la integraci\u00f3n de la medicina tradicional en los sistemas de salud nacionales.\n\n5. **Proyectos de Clasificaci\u00f3n y Vigilancia**:\n   - Se est\u00e1 desarrollando un sistema de clasificaci\u00f3n internacional para la medicina tradicional, con el objetivo de estandarizar t\u00e9rminos cl\u00ednicos y facilitar la vigilancia de eventos adversos relacionados con las medicinas herbales.\n\n6. **Estrategia Global**:\n   - Se informa sobre el progreso en la implementaci\u00f3n de la Estrategia Global y Plan de Acci\u00f3n sobre salud p\u00fablica, innovaci\u00f3n y propiedad intelectual en el campo de la medicina tradicional.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la regulaci\u00f3n y promoci\u00f3n de la medicina tradicional.\n- **IRCH (Cooperaci\u00f3n Internacional para Medicinas Herbales)**: Grupo que coordina esfuerzos entre pa\u00edses en el \u00e1mbito de las medicinas herbales.\n- **Asamblea Mundial de la Salud**: Cuerpo que adopt\u00f3 la resoluci\u00f3n sobre medicina tradicional y la \"Declaraci\u00f3n de Pek\u00edn\".\n- **Centros Nacionales de Farmacovigilancia**: Entidades que expresaron la necesidad de un sistema de codificaci\u00f3n para reportar eventos adversos a las medicinas herbales.", "excerpt_keywords": "Keywords: Biological Standardization, vaccines, regulatory guidelines, traditional medicines, pharmaceutical preparations"}}, "db950072-3447-4d1d-a12a-77a12d5b4db6": {"node_ids": ["17dc7703-0f23-46b1-96e3-9dedece5b26c"], "metadata": {"page_label": "25", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Finally, a review of the roles and responsibilities of the Expert Committee on Biological Standardization was proposed. It was approximately 10 years since the last such review and thus it was important to have such an external validation of the direction and output of the Committee. As part of the process comments from the Expert Committee on Specifications for Pharmaceutical Preparations would be invited.\n\n### 2.2.3 Blood products\n\nThe Committee was informed about WHO\u2019s work in the area of blood products and related biologicals. More details on the GMP for blood establishments can be found in section 6.6.\n\n### 2.2.4 Essential medicines\n\nFurther to the WHO-led initiative \u201cmake medicines child size\u201d launched in December 2007, WHO received a grant from the Bill & Melinda Gates Foundation in October 2008 to work in collaboration with UNICEF in order to conduct crucial research in the area of children\u2019s medicines. The aim of the project was to increase the number of child-size medicines designed and formulated specifically for children. The grant provided support for essential research to:\n\n- determine the optimum dosage forms for paediatric medicines (e.g. small tablets, dispersible tablets, powders);\n- develop dosing guides (e.g. a review of existing priority medicines and the identification of the appropriate doses for new medicines for children); and\n- develop guidelines for testing of medicines and treatment of use of medicines in children, including guidelines on conducting clinical trials in children.\n\nIn December 2008 a group of paediatricians, pharmacists, clinical pharmacologists and representatives of the European Medicines Agency (EMA), International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Medicines for Malaria Venture (MMV), National Institutes of Health (NIH), United Nations Children\u2019s Fund (UNICEF) and the Bill & Melinda Gates Foundation attended a meeting hosted by WHO to discuss the preferred dosage form of medicines for children. As a result of this consultation the dosage forms of medicines most suitable for children were identified, with particular attention paid to conditions prevailing in developing countries and future areas of research required in this area (http://www.who.int/childmedicines/progress/Dosage_form_reportDEC2008.pdf).\n\nThe report of the WHO Subcommittee for the Selection and Use of Medicines, including the second Essential Medicines List for Children (EMLc), was reviewed and endorsed by the Expert Committee on Selection.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Revisi\u00f3n del Comit\u00e9 de Expertos**: Se propone una revisi\u00f3n de las funciones y responsabilidades del Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica, destacando la importancia de una validaci\u00f3n externa despu\u00e9s de aproximadamente diez a\u00f1os desde la \u00faltima revisi\u00f3n.\n\n2. **Trabajo de la OMS en productos sangu\u00edneos**: La OMS est\u00e1 trabajando en el \u00e1rea de productos sangu\u00edneos y biol\u00f3gicos relacionados, con detalles adicionales sobre las Buenas Pr\u00e1cticas de Manufactura (GMP) para establecimientos de sangre.\n\n3. **Iniciativa de medicamentos para ni\u00f1os**: La OMS, en colaboraci\u00f3n con UNICEF y con el apoyo de la Fundaci\u00f3n Bill & Melinda Gates, est\u00e1 llevando a cabo una investigaci\u00f3n para aumentar la disponibilidad de medicamentos dise\u00f1ados espec\u00edficamente para ni\u00f1os, centr\u00e1ndose en formas de dosificaci\u00f3n \u00f3ptimas y gu\u00edas de dosificaci\u00f3n.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los objetivos espec\u00edficos del proyecto \"make medicines child size\" lanzado por la OMS?**\n   - Esta pregunta busca detalles sobre los objetivos del proyecto, que incluyen la determinaci\u00f3n de formas de dosificaci\u00f3n \u00f3ptimas y el desarrollo de gu\u00edas de dosificaci\u00f3n para medicamentos pedi\u00e1tricos.\n\n2. **\u00bfQu\u00e9 grupos participaron en la reuni\u00f3n de diciembre de 2008 sobre medicamentos para ni\u00f1os y cu\u00e1l fue el resultado de esa consulta?**\n   - Esta pregunta se centra en identificar a los participantes clave en la reuni\u00f3n y los resultados espec\u00edficos que surgieron de la discusi\u00f3n sobre las formas de dosificaci\u00f3n m\u00e1s adecuadas para los medicamentos infantiles.\n\n3. **\u00bfQu\u00e9 aspectos se consideraron en la revisi\u00f3n de la lista de Medicamentos Esenciales para Ni\u00f1os (EMLc) por parte del Comit\u00e9 de Expertos en Selecci\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n sobre los criterios y consideraciones que guiaron la revisi\u00f3n y aprobaci\u00f3n de la lista de medicamentos esenciales para ni\u00f1os, as\u00ed como su relevancia en el contexto de la salud infantil.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Comit\u00e9 de Expertos de la OMS en Estandarizaci\u00f3n Biol\u00f3gica**:\n   - Encargado de desarrollar recomendaciones internacionales para la producci\u00f3n y control de medicamentos biol\u00f3gicos.\n   - Establecimiento de materiales de referencia biol\u00f3gica.\n\n2. **Pr\u00f3xima reuni\u00f3n**:\n   - Programada del 19 al 23 de octubre de 2009.\n   - Temas clave a discutir:\n     - Pautas para la evaluaci\u00f3n de productos bioterap\u00e9uticos similares.\n     - Transici\u00f3n de algunos medicamentos de biol\u00f3gicos a qu\u00edmicos.\n\n3. **Propuestas de nuevos materiales de referencia**:\n   - Proceso de revisi\u00f3n de propuestas para nuevos o materiales de referencia de reemplazo por parte del Comit\u00e9.\n   - Consideraci\u00f3n de calibraci\u00f3n en unidades del SI en lugar de la Unidad Internacional de actividad biol\u00f3gica.\n\n4. **Iniciativas conjuntas**:\n   - Desarrollo de directrices sobre buenas pr\u00e1cticas de manufactura (GMP) para establecimientos de sangre.\n   - Supervisi\u00f3n regulatoria de la distribuci\u00f3n de productos farmac\u00e9uticos controlados por temperatura.\n\n5. **Talleres de implementaci\u00f3n**:\n   - Establecidos para promover la comprensi\u00f3n y uso de las directrices y recomendaciones del Comit\u00e9.\n   - Uso de nuevas directrices sobre la evaluaci\u00f3n de estabilidad de vacunas como estudio de caso.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la salud p\u00fablica internacional.\n- **Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica**: Grupo que desarrolla recomendaciones sobre medicamentos biol\u00f3gicos.\n- **Comit\u00e9 de Especificaciones para Preparaciones Farmac\u00e9uticas**: Colabora en iniciativas relacionadas con la regulaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: Expert Committee, Biological Standardization, Essential Medicines, Children's Medicines, WHO"}}, "91e8ca11-0c1c-45c9-a3f6-c68545ea48d7": {"node_ids": ["aad558f5-4e79-4c23-866b-850cd9586d04"], "metadata": {"page_label": "26", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "and Use of Essential Medicines at its seventeenth meeting in March 2009. New additions to the EMLc included sections on palliative care medicines; ear, nose and throat medicines and medicines for neonates, and also the inclusion of liposomal amphotericin B, a dispersible formulation of artemether + lumefantrine (20 mg + 120 mg) and enalapril tablets (2.5 mg and 5 mg). The Expert Committee agreed that the Subcommittee had fulfilled the terms of reference regarding the development and revision of the WHO EMLc and made the recommendation to the Executive Board and the Director-General that the Subcommittee should now be dissolved. However, it was recommended that future Expert Committees should include adequate expertise to consider medicines for children and maintain the EMLc.\n\nThe Expert Committee for the Selection and Use of Essential Medicines also reviewed simulation studies proposing potential new strengths for fixed-dose combinations (FDCs) of antituberculosis medicines for children: isoniazid 150 mg + pyrazinamide 400 mg + rifampicin 250 mg and ethambutol 250 mg + isoniazid 150 mg + pyrazinamide 400 mg + rifampicin 250 mg.\n\nHowever, it was noted that at this time there were no FDCs that delivered the ideal doses of first-line medicines for tuberculosis treatment in children with weights between 5 and 30 kg. It was also highlighted that there was a need for a two-drug FDC for use in the continuation phase of treatment and the Expert Committee for the Selection and Use of Essential Medicines recommended that the following combination (for continuation treatment only) would be reasonable based on the analyses presented: isoniazid 150 mg + rifampicin 250 mg.\n\nThe Expert Committee for the Selection and Use of Essential Medicines reviewed and agreed a proposal by the Medicines Quality Assurance Programme for a revision to the listing of pharmaceutical products in the Model Lists of Essential Medicines. As a result, the medicines listed in the left-hand column would in future be named as the active moieties, using INN and, where applicable, entries in the right-hand column would provide information on the dosage forms and strengths of products available in WHO Member States. The explanatory notes in the Model List of Essential Medicines and the EMLc had also been expanded to provide more information and guidance to users with regard to dosage form terminology and medicine strength (see section 11.1).\n\nFuture activities in relation to the Better Medicines for Children project would include a summit in Amsterdam in October 2009 to discuss scientific standards required for undertaking clinical research in children. As part of this meeting WHO would host a discussion day with a group of experts from developing countries to identify what might need to be done to", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Revisiones de la Lista de Medicamentos Esenciales para Ni\u00f1os (EMLc)**: En marzo de 2009, la Comisi\u00f3n de Expertos revis\u00f3 y actualiz\u00f3 la EMLc, incluyendo nuevos medicamentos para el cuidado paliativo, otorrinolaringolog\u00eda y neonatos, as\u00ed como formulaciones espec\u00edficas de medicamentos antituberculosos para ni\u00f1os.\n\n2. **Falta de combinaciones de dosis fijas (FDC) adecuadas**: Se identific\u00f3 que no exist\u00edan combinaciones de dosis fijas que proporcionaran las dosis ideales de medicamentos de primera l\u00ednea para el tratamiento de la tuberculosis en ni\u00f1os con pesos entre 5 y 30 kg, lo que resalta la necesidad de desarrollar nuevas formulaciones.\n\n3. **Actividades futuras para mejorar los medicamentos para ni\u00f1os**: Se plane\u00f3 un cumbre en \u00c1msterdam en octubre de 2009 para discutir est\u00e1ndares cient\u00edficos necesarios para la investigaci\u00f3n cl\u00ednica en ni\u00f1os, con la participaci\u00f3n de expertos de pa\u00edses en desarrollo.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 nuevos medicamentos se incluyeron en la EMLc durante la reuni\u00f3n de marzo de 2009 y cu\u00e1l fue su relevancia para el tratamiento de ni\u00f1os?**\n   - Respuesta: Se incluyeron medicamentos para el cuidado paliativo, otorrinolaringolog\u00eda y neonatos, as\u00ed como liposomal amphotericin B, una formulaci\u00f3n dispersible de artemether + lumefantrine (20 mg + 120 mg) y tabletas de enalapril (2.5 mg y 5 mg).\n\n2. **\u00bfCu\u00e1les son las combinaciones de dosis fijas (FDC) propuestas para el tratamiento de la tuberculosis en ni\u00f1os y qu\u00e9 limitaciones se identificaron en su uso?**\n   - Respuesta: Se propusieron las combinaciones de isoniazid 150 mg + pyrazinamide 400 mg + rifampicin 250 mg y ethambutol 250 mg + isoniazid 150 mg + pyrazinamide 400 mg + rifampicin 250 mg. Sin embargo, no hab\u00eda FDC que entregaran las dosis ideales para ni\u00f1os con pesos entre 5 y 30 kg.\n\n3. **\u00bfQu\u00e9 cambios se realizaron en la forma en que se listan los productos farmac\u00e9uticos en las Listas Modelo de Medicamentos Esenciales?**\n   - Respuesta: Se acord\u00f3 que los medicamentos se nombrar\u00edan como los moieties activos utilizando INN, y se proporcionar\u00eda informaci\u00f3n sobre las formas de dosificaci\u00f3n y las concentraciones de los productos disponibles en los Estados Miembros de la OMS. Adem\u00e1s, se expandieron las notas explicativas para ofrecer m\u00e1s informaci\u00f3n sobre la terminolog\u00eda de las formas de dosificaci\u00f3n y la fuerza de los medicamentos.", "prev_section_summary": "### Temas Clave:\n\n1. **Revisi\u00f3n del Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica**: Se propone una revisi\u00f3n de las funciones y responsabilidades del Comit\u00e9, destacando la necesidad de una validaci\u00f3n externa despu\u00e9s de aproximadamente diez a\u00f1os.\n\n2. **Trabajo de la OMS en Productos Sangu\u00edneos**: La OMS est\u00e1 involucrada en el desarrollo y regulaci\u00f3n de productos sangu\u00edneos y biol\u00f3gicos relacionados, con \u00e9nfasis en las Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n3. **Iniciativa \"make medicines child size\"**: La OMS, con el apoyo de la Fundaci\u00f3n Bill & Melinda Gates y en colaboraci\u00f3n con UNICEF, busca aumentar la disponibilidad de medicamentos dise\u00f1ados espec\u00edficamente para ni\u00f1os. Esto incluye la investigaci\u00f3n sobre formas de dosificaci\u00f3n \u00f3ptimas y gu\u00edas de dosificaci\u00f3n.\n\n### Entidades Clave:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Principal entidad responsable de la iniciativa y la investigaci\u00f3n en medicamentos para ni\u00f1os.\n- **Fundaci\u00f3n Bill & Melinda Gates**: Proporcion\u00f3 financiamiento para la investigaci\u00f3n sobre medicamentos pedi\u00e1tricos.\n- **UNICEF**: Colaborador en la iniciativa para mejorar la disponibilidad de medicamentos para ni\u00f1os.\n- **Agencia Europea de Medicamentos (EMA)**: Participante en la reuni\u00f3n sobre medicamentos para ni\u00f1os.\n- **Federaci\u00f3n Internacional de Fabricantes y Asociaciones Farmac\u00e9uticas (IFPMA)**: Tambi\u00e9n representada en la reuni\u00f3n.\n- **Medicines for Malaria Venture (MMV)**: Participante en la discusi\u00f3n sobre medicamentos pedi\u00e1tricos.\n- **Institutos Nacionales de Salud (NIH)**: Contribuyente a la investigaci\u00f3n sobre medicamentos para ni\u00f1os.\n\n### Resultados de la Consulta:\n\n- Identificaci\u00f3n de las formas de dosificaci\u00f3n m\u00e1s adecuadas para medicamentos infantiles, con un enfoque en las condiciones de los pa\u00edses en desarrollo y \u00e1reas futuras de investigaci\u00f3n. \n- Revisi\u00f3n y aprobaci\u00f3n de la segunda Lista de Medicamentos Esenciales para Ni\u00f1os (EMLc) por parte del Comit\u00e9 de Expertos en Selecci\u00f3n.", "excerpt_keywords": "Keywords: Essential Medicines, Pediatric Care, Fixed-Dose Combinations, WHO, Tuberculosis Treatment"}}, "67fd7f96-5902-4f79-923f-d0c43c5c661e": {"node_ids": ["e36cdbd6-fa47-4b46-8697-796a3e9ecaf2"], "metadata": {"page_label": "27", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 2.2.5 Regulatory support\n\nThe Expert Committee was updated on the area of medicines regulatory support. The mission of QSM in medicines regulatory support was to enhance the capacity of national and regional medicines regulatory systems to contribute to universal access to medicines of assured safety, quality and efficacy. Core functions included developing evidence on the situation and needs of medicines regulatory systems worldwide; providing direct support to countries and regions for strengthening medicines regulation; developing and continuously improving tools to assist regulatory activities (e.g. guidelines, manuals and other information materials); facilitating communication and promoting harmonization among MRAs; developing and continuously improving internal capacities; and developing and maintaining comprehensive databases on MRAs.\n\nThe scope of regulatory support activities involved assessing medicines regulatory systems to identify needs, assisting in the development of institutional plans and supporting capacity building. So far, 50 assessments had been performed on 46 regulatory systems with the involvement of the respective WHO regional offices.\n\nIn close collaboration with the capacity building teams of the WHO Prequalification Programme and the WHO Immunization, Vaccines and Biologicals Department, the Medicines Regulatory Support Programme had organized various training activities to strengthen capacity of national MRAs.\n\nRegional support involved provision of technical assistance to Regional Economic Communities in Africa, within the framework of the African Medicines Registration Harmonization Initiative.\n\nThe Medicines Regulatory Support Programme had been particularly active in promoting the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce; in facilitating harmonization of regulatory requirements with subregional economic blocs; and improving communication among MRAs through networking, sharing of information and regulatory decisions.\n\nThe Programme had also been active in providing feedback on the implementation of existing WHO guidelines, developing training materials, developing internal procedures, developing and maintaining technical competence of regulatory staff and enhancing technical cooperation with partners both within and outside the Organization.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Misi\u00f3n del Programa de Apoyo Regulatorio de Medicamentos**: El Programa tiene como objetivo mejorar la capacidad de los sistemas regulatorios de medicamentos a nivel nacional y regional para garantizar el acceso universal a medicamentos seguros, de calidad y eficaces. Esto incluye el desarrollo de herramientas, la evaluaci\u00f3n de sistemas regulatorios y la capacitaci\u00f3n de personal.\n\n2. **Actividades de Evaluaci\u00f3n y Capacitaci\u00f3n**: Hasta la fecha, se han realizado 50 evaluaciones en 46 sistemas regulatorios, y se han organizado diversas actividades de capacitaci\u00f3n en colaboraci\u00f3n con otros programas de la OMS para fortalecer las capacidades de las autoridades regulatorias nacionales.\n\n3. **Colaboraci\u00f3n Regional y Promoci\u00f3n de Normativas**: El Programa ha trabajado en estrecha colaboraci\u00f3n con comunidades econ\u00f3micas regionales en \u00c1frica para armonizar los requisitos regulatorios y mejorar la comunicaci\u00f3n entre las autoridades regulatorias a trav\u00e9s de redes y el intercambio de informaci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las funciones principales del Programa de Apoyo Regulatorio de Medicamentos de la OMS?**\n   - Respuesta: Las funciones principales incluyen desarrollar evidencia sobre las necesidades de los sistemas regulatorios, proporcionar apoyo directo a pa\u00edses, mejorar herramientas regulatorias, facilitar la comunicaci\u00f3n entre las autoridades regulatorias y mantener bases de datos sobre estas entidades.\n\n2. **\u00bfQu\u00e9 tipo de actividades de capacitaci\u00f3n se han organizado para fortalecer las capacidades de las autoridades regulatorias nacionales?**\n   - Respuesta: Se han organizado diversas actividades de capacitaci\u00f3n en colaboraci\u00f3n con los equipos de desarrollo de capacidades de la OMS, enfocadas en mejorar la competencia t\u00e9cnica del personal regulador y en la implementaci\u00f3n de directrices existentes.\n\n3. **\u00bfC\u00f3mo ha contribuido el Programa de Apoyo Regulatorio a la armonizaci\u00f3n de los requisitos regulatorios en \u00c1frica?**\n   - Respuesta: El Programa ha proporcionado asistencia t\u00e9cnica a las Comunidades Econ\u00f3micas Regionales en \u00c1frica, promoviendo la Iniciativa de Armonizaci\u00f3n de Registro de Medicamentos y facilitando la comunicaci\u00f3n y el intercambio de decisiones regulatorias entre las autoridades.", "prev_section_summary": "### Temas Clave:\n\n1. **Revisi\u00f3n de la EMLc**: En marzo de 2009, la Comisi\u00f3n de Expertos revis\u00f3 la Lista de Medicamentos Esenciales para Ni\u00f1os (EMLc), incorporando nuevos medicamentos para el cuidado paliativo, otorrinolaringolog\u00eda y neonatos, as\u00ed como formulaciones espec\u00edficas para el tratamiento de la tuberculosis en ni\u00f1os.\n\n2. **Combinaciones de Dosis Fijas (FDC)**: Se propusieron nuevas combinaciones de medicamentos antituberculosos para ni\u00f1os, pero se identific\u00f3 la falta de FDC que proporcionaran las dosis ideales para ni\u00f1os con pesos entre 5 y 30 kg.\n\n3. **Revisi\u00f3n de Listas de Medicamentos**: Se acord\u00f3 que los productos farmac\u00e9uticos en las Listas Modelo de Medicamentos Esenciales se nombrar\u00edan utilizando los moieties activos (INN) y se proporcionar\u00eda informaci\u00f3n sobre formas de dosificaci\u00f3n y concentraciones disponibles.\n\n4. **Actividades Futuras**: Se plane\u00f3 un cumbre en \u00c1msterdam en octubre de 2009 para discutir est\u00e1ndares cient\u00edficos necesarios para la investigaci\u00f3n cl\u00ednica en ni\u00f1os, con la participaci\u00f3n de expertos de pa\u00edses en desarrollo.\n\n### Entidades:\n\n- **Comisi\u00f3n de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales**: Grupo responsable de revisar y actualizar la EMLc.\n- **Medicamentos Incluidos**: Liposomal amphotericin B, artemether + lumefantrine (20 mg + 120 mg), enalapril (2.5 mg y 5 mg).\n- **Medicamentos Antituberculosos Propuestos**: Isoniazid, pyrazinamide, rifampicin, ethambutol.\n- **Proyecto Mejor Medicamentos para Ni\u00f1os**: Iniciativa de la OMS para mejorar la disponibilidad y calidad de medicamentos para ni\u00f1os.", "excerpt_keywords": "Regulatory support, medicines, WHO, capacity building, harmonization"}}, "21cc1cb5-2632-45ee-a64f-455cbf4b70c2": {"node_ids": ["4bd6ffdd-14a9-4a6b-b13a-454eb5ddf722"], "metadata": {"page_label": "28", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Future work would include improving feedback and identification of needs for guidance, establishing a pool of regulatory experts and conducting the assessment of medicines regulatory systems in a more systematic way and for training purposes. The programme intends to establish a network of centres of excellence in the regulatory affairs area to serve as training centres, design new intervention mechanisms for supporting activities and new concepts for conducting day-to-day work.\n\n### 2.2.6 HIV-related activities\n\nThe representative of the HIV Department, Strategic Information and Research Unit, gave a short update on how the work of this Expert Committee was useful to the HIV Department\u2019s activities. The Department published an annual report entitled \u201cTowards universal access\u201d on progress made in the health sector to address the HIV epidemic. In the section on access to treatment, it reported on the progress made on prequalification of antiretrovirals by QSM. A QSM quality assessment survey was also included in the 2008 report.\n\n### 2.3 Counterfeit medicines\n\nThe Committee was provided with an update by the Programme Manager of the newly created EMP/QSM Anti-Counterfeiting Programme (ACM), who was also Executive Secretary ad interim of the IMPACT Secretariat.\n\nDiscussion took place during the Executive Board meeting in January 2009 on IMPACT and counterfeit medicines in general. Concerns had been raised regarding WHO\u2019s role in this area. Two background papers had been prepared by the WHO Secretariat and submitted to the World Health Assembly (one on the activities of IMPACT and the second on WHO\u2019s activities in the area of counterfeit (http://apps.who.int/gb/e/e_wha62.html, WHA62: A62/13 Counterfeit medical products, and A62/14 Counterfeit medical products: International Medical Products Anti-Counterfeiting Taskforce). Additional information on IMPACT could be found on the web site (http://www.who.int/impact). The Assembly agenda item on counterfeits was subsequently postponed to 2010.\n\nThe Secretariat and Chair for IMPACT continued to be based in WHO.\n\nThe Director-General of WHO reconfirmed that counterfeit medicines were an important issue for the Organization and that WHO would continue to collaborate with partners in this field. The WHO Secretariat would work on the basis that there were no changes to this current situation at least until the World Health Assembly in May 2010, during which WHO\u2019s role should be clarified by its Member States.\n\nACM would complete the following activities in 2009:\n- Revise and update the WHO and IMPACT web sites.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS aborda varias iniciativas relacionadas con la regulaci\u00f3n de medicamentos, actividades relacionadas con el VIH y la lucha contra los medicamentos falsificados. Se menciona la intenci\u00f3n de mejorar la retroalimentaci\u00f3n y la identificaci\u00f3n de necesidades en la regulaci\u00f3n de medicamentos, as\u00ed como la creaci\u00f3n de una red de centros de excelencia en asuntos regulatorios. Tambi\u00e9n se destaca el trabajo del Departamento de VIH en la publicaci\u00f3n de informes sobre el acceso a tratamientos y el progreso en la precalificaci\u00f3n de antirretrovirales. Adem\u00e1s, se discute el programa anti-falsificaci\u00f3n de medicamentos de la OMS y la importancia de este tema para la organizaci\u00f3n, as\u00ed como la colaboraci\u00f3n continua con socios en este \u00e1mbito.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los objetivos espec\u00edficos del programa que busca establecer una red de centros de excelencia en el \u00e1rea de asuntos regulatorios?**\n   - Esta pregunta busca detalles sobre los objetivos y la estructura del programa que no se mencionan expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 tipo de actividades se planean para el Programa Anti-Counterfeiting (ACM) en 2009, adem\u00e1s de la revisi\u00f3n y actualizaci\u00f3n de los sitios web de la OMS e IMPACT?**\n   - Esta pregunta se centra en las actividades espec\u00edficas que se llevar\u00e1n a cabo en el marco del programa ACM, m\u00e1s all\u00e1 de lo que se menciona en el contexto.\n\n3. **\u00bfC\u00f3mo se ha evaluado el impacto de la precalificaci\u00f3n de antirretrovirales en el acceso a tratamientos para el VIH seg\u00fan el informe \u201cTowards universal access\u201d?**\n   - Esta pregunta busca informaci\u00f3n sobre la evaluaci\u00f3n del impacto de la precalificaci\u00f3n en el acceso a tratamientos, que podr\u00eda no estar detallada en el documento.\n\n### Resumen de nivel superior\n\nEl documento de la OMS destaca la importancia de mejorar la regulaci\u00f3n de medicamentos y la lucha contra los medicamentos falsificados, as\u00ed como el progreso en el tratamiento del VIH. Se mencionan iniciativas para establecer centros de excelencia en regulaci\u00f3n y la colaboraci\u00f3n continua con socios para abordar el problema de los medicamentos falsificados. Adem\u00e1s, se hace referencia a la publicaci\u00f3n de informes anuales sobre el acceso a tratamientos para el VIH y la precalificaci\u00f3n de antirretrovirales.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Misi\u00f3n del Programa de Apoyo Regulatorio de Medicamentos**:\n   - Mejorar la capacidad de los sistemas regulatorios de medicamentos a nivel nacional y regional.\n   - Contribuir al acceso universal a medicamentos seguros, de calidad y eficaces.\n\n2. **Funciones Principales**:\n   - Desarrollo de evidencia sobre las necesidades de los sistemas regulatorios.\n   - Apoyo directo a pa\u00edses y regiones para fortalecer la regulaci\u00f3n de medicamentos.\n   - Creaci\u00f3n y mejora continua de herramientas regulatorias (gu\u00edas, manuales, materiales informativos).\n   - Facilitaci\u00f3n de la comunicaci\u00f3n y promoci\u00f3n de la armonizaci\u00f3n entre las Autoridades Reguladoras de Medicamentos (MRAs).\n   - Desarrollo y mantenimiento de bases de datos sobre MRAs.\n\n3. **Actividades de Evaluaci\u00f3n y Capacitaci\u00f3n**:\n   - Realizaci\u00f3n de 50 evaluaciones en 46 sistemas regulatorios.\n   - Organizaci\u00f3n de actividades de capacitaci\u00f3n en colaboraci\u00f3n con otros programas de la OMS.\n\n4. **Colaboraci\u00f3n Regional**:\n   - Asistencia t\u00e9cnica a Comunidades Econ\u00f3micas Regionales en \u00c1frica.\n   - Promoci\u00f3n de la Iniciativa de Armonizaci\u00f3n de Registro de Medicamentos.\n\n5. **Promoci\u00f3n de Normativas y Comunicaci\u00f3n**:\n   - Actividades para promover el Esquema de Certificaci\u00f3n de la OMS sobre la Calidad de Productos Farmac\u00e9uticos.\n   - Mejora de la comunicaci\u00f3n entre MRAs a trav\u00e9s de redes y el intercambio de informaci\u00f3n.\n\n6. **Desarrollo de Capacidades**:\n   - Provisi\u00f3n de retroalimentaci\u00f3n sobre la implementaci\u00f3n de directrices de la OMS.\n   - Desarrollo de materiales de capacitaci\u00f3n y procedimientos internos.\n   - Mantenimiento de la competencia t\u00e9cnica del personal regulador.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Principal entidad responsable del Programa de Apoyo Regulatorio de Medicamentos.\n- **MRAs (Medicines Regulatory Authorities)**: Autoridades Reguladoras de Medicamentos involucradas en el proceso.\n- **Comunidades Econ\u00f3micas Regionales en \u00c1frica**: Entidades que reciben asistencia t\u00e9cnica para la armonizaci\u00f3n de requisitos regulatorios.", "excerpt_keywords": "Keywords: regulatory affairs, HIV treatment, counterfeit medicines, WHO initiatives, prequalification"}}, "85ed28c2-4805-4e71-a1f6-8a4aba258361": {"node_ids": ["bde9f61e-5250-4d6b-af53-a36d083e27ac"], "metadata": {"page_label": "29", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Proceed with the joint WHO Expert Committee on Specifications for Pharmaceutical Preparations/IMPACT review of the **WHO Good distribution practices (GDP) for pharmaceutical products**, which was proposed by IMPACT in 2007.\n- Start the review process of the draft document on Model Legislation developed by IMPACT in 2008, including a revision of the current definition of counterfeit medicines, possibly through the Expert Committee.\n- Plan and implement advocacy, training, country support and enforcement activities with interested governments in Africa, as far as specified donor funds were available (mostly from the European Union for African, Caribbean and Pacific countries).\n- Recruit one technical expert on regulatory matters and pursue the possibility of FIP arranging the secondment of a communication expert.\n- Prepare a fund-raising plan for future staff and activities to combat counterfeit medicines and approach interested donors.\n\nIn addition to WHO\u2019s work on counterfeit medicines described above, the Assistant Director-General, HSS would continue her two-year mandate as elected Chair of IMPACT and WHO would continue to fulfil the functions of the IMPACT Secretariat. As such WHO would continue to work with IMPACT, drawing on its technical input and the involvement of a large number of stakeholders, whilst clearly distinguishing between documents prepared by IMPACT and those issued by WHO.\n\nTechnical documents prepared by IMPACT working groups would be posted on the IMPACT web site, without the WHO logo. These could be reviewed, adapted and ultimately approved as appropriate, through the normal WHO consultative procedures.\n\nThe IMPACT web site would be revised and updated. It would include the proposal for the **Draft principles and elements for national legislation against counterfeit medical products**, inviting comments thereon. A Circular Letter would be prepared to draw Member States\u2019 attention to this draft document and the new proposal for the definition of counterfeit medical products contained therein.\n\nA direct link to the above-mentioned document was available in the news section of the IMPACT web site (http://www.who.int/impact/news/BonnMeetingDraftPrinciples.pdf).\n\nA proposed revision of the **WHO Good Distribution Practices (GDP) for pharmaceutical products** was discussed by this Expert Committee with a view to its adoption. The document could be found on the WHO web site at: http://www.who.int/medicines/services/expertcommittees/pharmprep/43rdpharmprep/en/index.html, and also with a direct link: http://www.who.int/medicines/", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en las actividades y planes de la Organizaci\u00f3n Mundial de la Salud (OMS) en relaci\u00f3n con la lucha contra los medicamentos falsificados y la mejora de las pr\u00e1cticas de distribuci\u00f3n de productos farmac\u00e9uticos. Se menciona la colaboraci\u00f3n con el Comit\u00e9 de Expertos de la OMS y el IMPACT (Medicamentos Falsificados y Productos M\u00e9dicos) para revisar y actualizar documentos clave, como las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) y la legislaci\u00f3n modelo contra los medicamentos falsificados. Tambi\u00e9n se destaca la importancia de la financiaci\u00f3n y el apoyo t\u00e9cnico en \u00c1frica, as\u00ed como la necesidad de distinguir entre los documentos de la OMS y los de IMPACT.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 papel desempe\u00f1ar\u00e1 la OMS en la revisi\u00f3n de las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) y c\u00f3mo se relaciona esto con el trabajo de IMPACT?**\n   - La OMS proceder\u00e1 con la revisi\u00f3n conjunta de las GDP para productos farmac\u00e9uticos, que fue propuesta por IMPACT en 2007. Esto implica que la OMS trabajar\u00e1 en colaboraci\u00f3n con el Comit\u00e9 de Expertos y utilizar\u00e1 la entrada t\u00e9cnica de IMPACT para actualizar y adoptar estas pr\u00e1cticas.\n\n2. **\u00bfCu\u00e1les son los planes espec\u00edficos de la OMS para abordar la problem\u00e1tica de los medicamentos falsificados en \u00c1frica?**\n   - La OMS planea implementar actividades de defensa, capacitaci\u00f3n, apoyo a pa\u00edses y actividades de aplicaci\u00f3n de la ley con gobiernos interesados en \u00c1frica, dependiendo de la disponibilidad de fondos de donantes, principalmente de la Uni\u00f3n Europea.\n\n3. **\u00bfC\u00f3mo se gestionar\u00e1 la distinci\u00f3n entre los documentos preparados por IMPACT y los emitidos por la OMS?**\n   - La OMS continuar\u00e1 trabajando con IMPACT, pero se asegurar\u00e1 de distinguir claramente entre los documentos de IMPACT y los de la OMS. Los documentos t\u00e9cnicos de IMPACT se publicar\u00e1n en su sitio web sin el logo de la OMS y seguir\u00e1n los procedimientos consultivos normales de la OMS para su revisi\u00f3n y aprobaci\u00f3n.", "prev_section_summary": "El contenido de la secci\u00f3n aborda varios temas clave relacionados con la regulaci\u00f3n de medicamentos, las actividades en el \u00e1mbito del VIH y la lucha contra los medicamentos falsificados. A continuaci\u00f3n se presenta un resumen de los temas y entidades principales:\n\n### Temas Clave:\n\n1. **Regulaci\u00f3n de Medicamentos**:\n   - Se planea mejorar la retroalimentaci\u00f3n y la identificaci\u00f3n de necesidades en la regulaci\u00f3n de medicamentos.\n   - Se busca establecer una red de centros de excelencia en asuntos regulatorios que funcionen como centros de capacitaci\u00f3n y dise\u00f1en nuevos mecanismos de intervenci\u00f3n.\n\n2. **Actividades Relacionadas con el VIH**:\n   - El Departamento de VIH de la OMS public\u00f3 un informe anual titulado \u201cTowards universal access\u201d, que detalla el progreso en el acceso a tratamientos para el VIH y la precalificaci\u00f3n de antirretrovirales.\n   - Se incluy\u00f3 una encuesta de evaluaci\u00f3n de calidad de QSM en el informe de 2008.\n\n3. **Medicamentos Falsificados**:\n   - Se present\u00f3 una actualizaci\u00f3n sobre el Programa Anti-Counterfeiting (ACM) de la OMS, que se centra en la lucha contra los medicamentos falsificados.\n   - Se discutieron preocupaciones sobre el papel de la OMS en este \u00e1mbito durante la reuni\u00f3n de la Junta Ejecutiva en enero de 2009.\n   - Se mencionaron dos documentos de antecedentes preparados por la Secretar\u00eda de la OMS para la Asamblea Mundial de la Salud sobre las actividades de IMPACT y la lucha contra los medicamentos falsificados.\n\n### Entidades Principales:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad principal que coordina las actividades relacionadas con la regulaci\u00f3n de medicamentos, el VIH y la lucha contra los medicamentos falsificados.\n- **Departamento de VIH**: Parte de la OMS que se encarga de las actividades relacionadas con el VIH y la publicaci\u00f3n de informes sobre el acceso a tratamientos.\n- **Programa Anti-Counterfeiting (ACM)**: Un programa creado por la OMS para abordar el problema de los medicamentos falsificados.\n- **IMPACT**: Grupo de trabajo de la OMS que se ocupa de la lucha contra los medicamentos falsificados.\n\nEste resumen destaca la importancia de la regulaci\u00f3n de medicamentos, el acceso a tratamientos para el VIH y la necesidad de combatir los medicamentos falsificados, as\u00ed como la colaboraci\u00f3n continua de la OMS con socios en estos temas.", "excerpt_keywords": "Keywords: WHO, counterfeit medicines, Good Distribution Practices, IMPACT, pharmaceutical regulation"}}, "92712337-e490-4bb0-b54f-609cd1cbdb76": {"node_ids": ["3105dcea-764d-4ebb-9611-4e880c8ebb39"], "metadata": {"page_label": "30", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "services/expertcommittees/pharmprep/170909Clean_GDP-counterfeits-QAS08252Rev1.pdf\n\nThe planned IMPACT meetings (subject to resources) were as follows:\n- regional meeting in South Africa (9\u201310 November 2009);\n- annual meeting of IMPACT Planning Group including all IMPACT Chairs and Co-Chairs (January 2010);\n- Open Forum for WHO Member States and interested parties, involving IMPACT partners (January 2010);\n- Working Group meetings (January 2010); and\n- annual IMPACT meeting (after the World Health Assembly in May 2010).\n\nThe Committee was pleased to note the continued cooperation with other WHO departments and programmes.\n\n## 3. Quality control \u2014 specifications and tests\n\n### 3.1 The International Pharmacopoeia\n\nFollowing the publication of the First Supplement to the Fourth Edition, the Expert Committee was informed that the final texts for the monographs adopted at the forty-second and forty-third meetings in October 2007 and 2008 had been made available to users of the WHO Medicines web site and that they were ready to be included in the forthcoming issue of *The International Pharmacopoeia* (Ph.Int.). While the format of this future publication was still to be defined (electronic, CD-ROM or book), a tentative table of contents of about 45 texts for inclusion in this publication was discussed and adopted.\n\n**Provisional list of contents for the forthcoming publication of The International Pharmacopoeia**  \nMonographs adopted at the forty-second meeting of the Expert Committee in October 2007\n\n**Pharmaceutical substances**\n- Lumefantrine\n- Zinc sulfate\n\n**Dosage forms**\n- Artemether and lumefantrine tablets\n- Magnesium sulfate injection\n- Rifampicin and isoniazid dispersible tablets\n- Rifampicin, isoniazid and ethambutol tablets", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento se refiere a las reuniones planificadas del grupo IMPACT de la OMS, que se centran en la cooperaci\u00f3n y el control de calidad de los medicamentos. Se menciona la publicaci\u00f3n de textos finales de monograf\u00edas en *The International Pharmacopoeia*, que incluye una lista provisional de sustancias farmac\u00e9uticas y formas de dosificaci\u00f3n adoptadas en reuniones anteriores. Se destaca la importancia de la colaboraci\u00f3n entre diferentes departamentos y programas de la OMS.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las fechas y tipos de reuniones planificadas para el grupo IMPACT de la OMS en 2009 y 2010?**\n   - Esta pregunta se centra en los detalles espec\u00edficos de las reuniones mencionadas, que incluyen fechas y tipos de encuentros.\n\n2. **\u00bfQu\u00e9 sustancias farmac\u00e9uticas y formas de dosificaci\u00f3n se incluir\u00e1n en la pr\u00f3xima publicaci\u00f3n de *The International Pharmacopoeia* seg\u00fan las reuniones del Comit\u00e9 de Expertos?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre los contenidos que se discutir\u00e1n y adoptar\u00e1n en la pr\u00f3xima edici\u00f3n de la farmacopoeia.\n\n3. **\u00bfQu\u00e9 importancia se le da a la cooperaci\u00f3n entre los diferentes departamentos de la OMS en el contexto de la calidad de los medicamentos?**\n   - Esta pregunta explora el papel de la colaboraci\u00f3n interdepartamental en el control de calidad y la regulaci\u00f3n de medicamentos, un aspecto que puede no ser ampliamente discutido en otros documentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**:\n   - La OMS est\u00e1 involucrada en la revisi\u00f3n de las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) para productos farmac\u00e9uticos, en colaboraci\u00f3n con el Comit\u00e9 de Expertos y el IMPACT.\n   - Continuar\u00e1 desempe\u00f1ando funciones como Secretar\u00eda de IMPACT y mantendr\u00e1 una distinci\u00f3n clara entre los documentos de la OMS y los de IMPACT.\n\n2. **IMPACT (Medicamentos Falsificados y Productos M\u00e9dicos)**:\n   - IMPACT propuso la revisi\u00f3n de las GDP en 2007 y desarroll\u00f3 un documento de legislaci\u00f3n modelo en 2008.\n   - Se espera que IMPACT proporcione insumos t\u00e9cnicos y facilite la participaci\u00f3n de m\u00faltiples interesados en la lucha contra los medicamentos falsificados.\n\n3. **Actividades en \u00c1frica**:\n   - La OMS planea implementar actividades de defensa, capacitaci\u00f3n y apoyo a pa\u00edses en \u00c1frica, dependiendo de la disponibilidad de fondos de donantes, principalmente de la Uni\u00f3n Europea.\n\n4. **Documentos T\u00e9cnicos**:\n   - Los documentos t\u00e9cnicos elaborados por los grupos de trabajo de IMPACT se publicar\u00e1n en su sitio web sin el logo de la OMS y seguir\u00e1n los procedimientos consultivos de la OMS para su revisi\u00f3n y aprobaci\u00f3n.\n\n5. **Revisi\u00f3n de Legislaci\u00f3n**:\n   - Se discutir\u00e1 una propuesta de revisi\u00f3n de las GDP y se invitar\u00e1 a comentarios sobre los principios y elementos para la legislaci\u00f3n nacional contra los productos m\u00e9dicos falsificados.\n\n6. **Financiaci\u00f3n y Recursos**:\n   - Se preparar\u00e1 un plan de recaudaci\u00f3n de fondos para futuras actividades y personal en la lucha contra los medicamentos falsificados.\n\n### Enlaces Relevantes:\n- Documentos y propuestas se pueden encontrar en el sitio web de la OMS y el sitio web de IMPACT, incluyendo enlaces directos a documentos espec\u00edficos.", "excerpt_keywords": "Keywords: WHO, IMPACT, International Pharmacopoeia, quality control, pharmaceutical substances"}}, "5037ce5a-65e2-406f-9a1e-a7796fb1ae2f": {"node_ids": ["70a3e194-5d04-4916-83dd-e2db2a5ad068"], "metadata": {"page_label": "31", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Rifampicin, isoniazid and pyrazinamide dispersible tablets\n- Zinc sulfate oral solution (paediatric)\n- Zinc sulfate tablets (paediatric)\n\n# Monographs adopted at the forty-third meeting of the Expert Committee in October 2008\n\n## Pharmaceutical substances\n- Emtricitabine\n- Mebendazole (revision of published monograph)\n- Nevirapine (revision of published monograph)\n- Oseltamivir phosphate\n\n## Dosage forms\n- Artemether and lumefantrine oral suspension\n- Mebendazole chewable tablets (revision of published monograph for mebendazole tablets)\n- Chloroquine sulfate oral solution\n- Cycloserine capsules\n- Efavirenz capsules\n- Efavirenz oral solution\n- Ethambutol hydrochloride tablets (revision of published monograph)\n- Nevirapine oral suspension\n- Nevirapine tablets\n- Quinine sulfate tablets\n- Zidovudine, lamivudine and nevirapine tablets\n\n## Radiopharmaceuticals\n\n### General monograph and related texts\n- General monograph\n- Methods of analysis\n- Supplementary information\n- Individual monographs\n- Fludeoxyglucose (\u00b9\u2078F) injection\n- Gallium citrate (\u2076\u2077Ga) injection\n- Iobenguane (\u00b9\u00b2\u00b3I) injection\n- Iobenguane (\u00b9\u00b3\u00b9I) injection\n- Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) capsules\n- Sodium iodide (\u00b9\u00b3\u00b9I) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) solution\n- Sodium iothalamate (\u00b9\u00b2\u2075I) injection", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con sus respuestas:\n\n1. **\u00bfCu\u00e1les son los medicamentos que se presentan en forma de tabletas dispersables seg\u00fan el informe?**\n   - **Respuesta:** Los medicamentos que se presentan en forma de tabletas dispersables son Rifampicin, isoniazid y pyrazinamide.\n\n2. **\u00bfQu\u00e9 revisiones se realizaron en las monograf\u00edas adoptadas en la reuni\u00f3n del Comit\u00e9 de Expertos en octubre de 2008?**\n   - **Respuesta:** Se realizaron revisiones de las monograf\u00edas de Mebendazole, Nevirapine y Ethambutol hydrochloride tablets.\n\n3. **\u00bfQu\u00e9 tipos de inyecciones de radiof\u00e1rmacos se mencionan en el informe?**\n   - **Respuesta:** Las inyecciones de radiof\u00e1rmacos mencionadas son Fludeoxyglucose (\u00b9\u2078F), Gallium citrate (\u2076\u2077Ga), Iobenguane (\u00b9\u00b2\u00b3I), Iobenguane (\u00b9\u00b3\u00b9I), Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm), Sodium iodide (\u00b9\u00b3\u00b9I) y Sodium iothalamate (\u00b9\u00b2\u2075I).\n\n### Resumen de nivel superior del contexto:\nEl documento \"WHO - Technical Report Series 957\" presenta una lista de medicamentos y formulaciones adoptadas en la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS en octubre de 2008. Incluye tanto sustancias farmac\u00e9uticas como formas de dosificaci\u00f3n, as\u00ed como una secci\u00f3n dedicada a radiopharmaceuticals, que detalla varios tipos de inyecciones y monograf\u00edas relacionadas. \n\nEste resumen puede ayudar a formular preguntas m\u00e1s amplias sobre el contenido del informe, como la importancia de las revisiones de monograf\u00edas o el impacto de los nuevos medicamentos en la salud p\u00fablica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Reuniones del Grupo IMPACT de la OMS**:\n   - Se planificaron varias reuniones para 2009 y 2010, incluyendo:\n     - Reuni\u00f3n regional en Sud\u00e1frica (9-10 de noviembre de 2009).\n     - Reuni\u00f3n anual del Grupo de Planificaci\u00f3n de IMPACT (enero de 2010).\n     - Foro Abierto para Estados Miembros de la OMS y partes interesadas (enero de 2010).\n     - Reuniones de Grupos de Trabajo (enero de 2010).\n     - Reuni\u00f3n anual de IMPACT (despu\u00e9s de la Asamblea Mundial de la Salud en mayo de 2010).\n\n2. **Cooperaci\u00f3n Interdepartamental**:\n   - Se destaca la importancia de la cooperaci\u00f3n continua entre diferentes departamentos y programas de la OMS en el contexto del control de calidad de los medicamentos.\n\n3. **Control de Calidad y Farmacopea Internacional**:\n   - Se informa sobre la publicaci\u00f3n de textos finales de monograf\u00edas que ser\u00e1n incluidos en la pr\u00f3xima edici\u00f3n de *The International Pharmacopoeia*.\n   - Se discute un contenido provisional que incluye:\n     - **Sustancias farmac\u00e9uticas**: Lumefantrine, Zinc sulfate.\n     - **Formas de dosificaci\u00f3n**: \n       - Tabletas de artemeter y lumefantrina.\n       - Inyecci\u00f3n de sulfato de magnesio.\n       - Tabletas dispersables de rifampicina e isoniazida.\n       - Tabletas de rifampicina, isoniazida y etambutol.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la salud p\u00fablica global.\n- **IMPACT**: Grupo de trabajo de la OMS enfocado en la calidad y regulaci\u00f3n de medicamentos.\n- **The International Pharmacopoeia**: Publicaci\u00f3n que establece est\u00e1ndares de calidad para medicamentos.\n- **Sustancias farmac\u00e9uticas mencionadas**: Lumefantrine, Zinc sulfate.\n- **Formas de dosificaci\u00f3n mencionadas**: Tabletas de artemeter y lumefantrina, inyecci\u00f3n de sulfato de magnesio, tabletas dispersables de rifampicina e isoniazida, tabletas de rifampicina, isoniazida y etambutol.", "excerpt_keywords": "Keywords: WHO, pharmaceuticals, radiopharmaceuticals, monographs, dosage forms"}}, "f5838db8-9e28-4336-a2ee-93f58d1eab6f": {"node_ids": ["273202dd-e553-4d9c-8f7b-fee4094bfe4b"], "metadata": {"page_label": "32", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Sodium pertechnetate (\u2079\u2079\u1d50Tc) injection (fission)\n- Sodium pertechnetate (\u2079\u2079\u1d50Tc) injection (non-fission)\n- Sodium phosphate (\u00b3\u00b2P) injection\n- Strontium chloride (\u2078\u2079Sr) injection\n- Technetium (\u2079\u2079\u1d50Tc) bicisate complex injection\n- Technetium (\u2079\u2079\u1d50Tc) exametazime complex injection\n- Technetium (\u2079\u2079\u1d50Tc) mebrofenin complex injection\n- Technetium (\u2079\u2079\u1d50Tc) mertiatide injection\n- Technetium (\u2079\u2079\u1d50Tc) pentetate complex injection\n- Technetium (\u2079\u2079\u1d50Tc) succimer complex injection\n- Technetium (\u2079\u2079\u1d50Tc) sulfur colloid injection\n- Technetium (\u2079\u2079\u1d50Tc) tetrofosmin complex injection\n- Technetium (\u2079\u2079\u1d50Tc) tin colloidal injection\n- Technetium(\u2079\u2079\u1d50Tc ) pyrophosphate tin complex injection\n- Technetium(\u2079\u2079\u1d50Tc) methylene diphosphonate (MDP) complex injection\n- Technetium(\u2079\u2079\u1d50Tc) sestamibi complex injection\n- Thallous chloride (\u00b2\u2070\u00b9Tl) injection\n- Yttrium silicate (\u2079\u2070Y) colloid injection\n\nThe Expert Committee recommended that the texts adopted at the forty-fourth meeting also be considered for inclusion.\n\n# WHO Medicines web site \u2014 International Pharmacopoeia pages\n\nThe Expert Committee was pleased to note that regular updates had been made in 2009 of the web pages devoted to the Ph.Int. on the WHO Medicines web site to inform users in a timely manner about recently adopted texts and, when relevant, about specific aspects of the work carried out to develop or revise monographs (e.g. the rapid revision posted for heparins or the note on artemisinin derivatives revision).\n\nIn view of the particularity of some of the substances for which monographs had been recently adopted and the large number of new substances included in the 2009 work plan belonging to the same category of medicines, the number of web pages had been increased to include:\n\n- radiopharmaceuticals; and\n- anti-infectives (including antibacterial, antiprotozoal, antifungal, antiviral and antimycobacterial agents \u2014 for diseases other than HIV/AIDS, tuberculosis and malaria \u2014 and anthelmintics).\n\nThe Expert Committee noted with appreciation that there had been a positive response to these updates and that requests had been received regarding subscription to a mailing list for receiving alerts on the latest Ph.Int. activities. Recognizing that this mailing system would help users keep track of the latest changes and that this would also improve the dissemination.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta una lista de inyecciones de radiotrazadores y otros medicamentos, as\u00ed como una actualizaci\u00f3n sobre las p\u00e1ginas web de la Farmacopea Internacional (Ph.Int.) en el sitio de medicamentos de la OMS. Se destaca que se han realizado actualizaciones regulares para informar a los usuarios sobre textos adoptados recientemente y aspectos espec\u00edficos del trabajo en monograf\u00edas. Adem\u00e1s, se ha incrementado el n\u00famero de p\u00e1ginas web para incluir radiopharmaceuticals y anti-infectivos, y se ha recibido una respuesta positiva de los usuarios, quienes han solicitado suscripciones a una lista de correo para recibir alertas sobre las actividades m\u00e1s recientes de la Ph.Int.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipos de inyecciones de radiotrazadores se mencionan en el documento y cu\u00e1les son sus aplicaciones espec\u00edficas?**\n   - Respuesta: El documento menciona varias inyecciones de radiotrazadores, como el sodio pertechnetate (\u2079\u2079\u1d50Tc) y el cloruro de talio (\u00b2\u2070\u00b9Tl), que se utilizan en diversas aplicaciones de diagn\u00f3stico m\u00e9dico, como la imagenolog\u00eda nuclear.\n\n2. **\u00bfQu\u00e9 cambios se realizaron en las p\u00e1ginas web de la Farmacopea Internacional en 2009 y por qu\u00e9 fueron necesarios?**\n   - Respuesta: En 2009, se realizaron actualizaciones para incluir m\u00e1s informaci\u00f3n sobre radiopharmaceuticals y anti-infectivos, debido a la particularidad de algunas sustancias y el aumento en el n\u00famero de nuevos medicamentos en el plan de trabajo de ese a\u00f1o.\n\n3. **\u00bfC\u00f3mo ha respondido la comunidad a las actualizaciones de la Farmacopea Internacional y qu\u00e9 medidas se est\u00e1n tomando para mejorar la comunicaci\u00f3n?**\n   - Respuesta: La comunidad ha respondido positivamente a las actualizaciones, solicitando suscripciones a una lista de correo para recibir alertas sobre las \u00faltimas actividades de la Ph.Int., lo que sugiere un inter\u00e9s en mantenerse informado sobre los cambios y mejoras en la farmacolog\u00eda internacional.", "prev_section_summary": "El documento \"WHO - Technical Report Series 957\" presenta una serie de medicamentos y formulaciones adoptadas en la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS en octubre de 2008. A continuaci\u00f3n se resumen los temas clave y entidades mencionadas en la secci\u00f3n:\n\n### Temas Clave:\n1. **Medicamentos en Formas de Dosificaci\u00f3n:**\n   - Se mencionan tabletas dispersables de Rifampicin, isoniazid y pyrazinamide, as\u00ed como soluciones y tabletas de sulfato de zinc para uso pedi\u00e1trico.\n\n2. **Sustancias Farmac\u00e9uticas:**\n   - Se adoptaron varias monograf\u00edas, incluyendo:\n     - Emtricitabine\n     - Mebendazole (con revisi\u00f3n de la monograf\u00eda publicada)\n     - Nevirapine (con revisi\u00f3n de la monograf\u00eda publicada)\n     - Oseltamivir phosphate\n\n3. **Formas de Dosificaci\u00f3n:**\n   - Se incluyen diversas formas de dosificaci\u00f3n como:\n     - Suspensi\u00f3n oral de Artemether y lumefantrine\n     - Tabletas masticables de Mebendazole (revisi\u00f3n)\n     - Soluciones orales de Chloroquine sulfate y otros medicamentos en c\u00e1psulas y tabletas.\n\n4. **Radiof\u00e1rmacos:**\n   - Se presenta una secci\u00f3n dedicada a los radiof\u00e1rmacos, que incluye:\n     - Monograf\u00edas generales y textos relacionados\n     - M\u00e9todos de an\u00e1lisis\n     - Inyecciones de varios radiof\u00e1rmacos como Fludeoxyglucose (\u00b9\u2078F), Gallium citrate (\u2076\u2077Ga), y diferentes formas de Iobenguane y Sodium iodide.\n\n### Entidades Mencionadas:\n- **Medicamentos:**\n  - Rifampicin, isoniazid, pyrazinamide, Zinc sulfate, Emtricitabine, Mebendazole, Nevirapine, Oseltamivir phosphate, Artemether, lumefantrine, Chloroquine, Cycloserine, Efavirenz, Ethambutol, Quinine, Zidovudine, lamivudine.\n\n- **Radiof\u00e1rmacos:**\n  - Fludeoxyglucose (\u00b9\u2078F), Gallium citrate (\u2076\u2077Ga), Iobenguane (\u00b9\u00b2\u00b3I), Iobenguane (\u00b9\u00b3\u00b9I), Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm), Sodium iodide (\u00b9\u00b3\u00b9I), Sodium iothalamate (\u00b9\u00b2\u2075I).\n\nEste resumen proporciona una visi\u00f3n general de los medicamentos y formulaciones discutidos en el informe, as\u00ed como de las revisiones y los tipos de radiof\u00e1rmacos incluidos.", "excerpt_keywords": "Keywords: radiopharmaceuticals, injections, WHO, International Pharmacopoeia, updates"}}, "5ebe0810-6743-4721-86dc-3caed80fbd32": {"node_ids": ["733cf228-fea1-4998-bfd2-2f2e70efecbb"], "metadata": {"page_label": "33", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# One-day briefing on The International Pharmacopoeia\n\nThe Secretariat informed the Expert Committee that a one-day overview of the Ph.Int. was given in April 2009 to industrial stakeholders. This included describing the process for developing monographs, together with explanations of the pharmacopoeial approach and policy on a variety of issues and of the role of the pharmacopoeia within WHO quality assurance activities. The meeting was interactive and informal to allow manufacturers (mostly those already collaborating with QSM) to raise issues and to have open discussions on the Ph.Int.\n\nIt was attended by representatives from generic and research-based pharmaceutical companies as well as pharmaceutical industry associations. The positive feedback received showed that the information provided was helpful and that the briefing session would assist in future collaborations in the development of monographs for the Ph.Int.\n\nIn response to requests from the participants to consider a future briefing with a larger audience, the Expert Committee recommended that the WHO Secretariat continue with organizing such information sessions.\n\n## 3.2 Current work plan and future work programme\n\nIn order to respond to the needs of WHO programmes and partner organizations, the Expert Committee agreed in 2008 to only consider for inclusion in the work programme those substances that had been assigned a high priority. A work plan, including a first group of six active pharmaceutical ingredients (APIs) and 36 dosage forms for monograph initiation, was thus adopted.\n\nSince good progress had been made in developing specifications from the 2009 work plan, a new work programme, including a second group for monograph initiation, was proposed to the Expert Committee, taking into account:\n\n- substances remaining from the 2009 work plan;\n- substances initially listed in the adopted work programme in 2008 that had now been prioritized, focusing on medicines for children, medicines important for the treatment of HIV/AIDS, tuberculosis and malaria and treatment of diseases with a high prevalence in developing countries);\n- additions from the sixteenth Model list of essential medicines and the second List of essential medicines for children;\n- additions from the expressions of interests (EOIs) within the WHO Prequalification Programme (PQP); and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento describe una sesi\u00f3n informativa de un d\u00eda sobre la Farmacopea Internacional (Ph.Int.) que se llev\u00f3 a cabo en abril de 2009, dirigida a partes interesadas de la industria farmac\u00e9utica. Durante la reuni\u00f3n, se discuti\u00f3 el proceso de desarrollo de monograf\u00edas y se abordaron diversas pol\u00edticas relacionadas con la calidad de los medicamentos. La sesi\u00f3n fue bien recibida, y se sugiri\u00f3 que se organizaran m\u00e1s sesiones informativas para un p\u00fablico m\u00e1s amplio. Adem\u00e1s, se presenta un plan de trabajo actual y un programa futuro que prioriza la inclusi\u00f3n de sustancias de alta prioridad en el trabajo de la Organizaci\u00f3n Mundial de la Salud (OMS), enfoc\u00e1ndose en medicamentos esenciales y en aquellos importantes para el tratamiento de enfermedades prevalentes en pa\u00edses en desarrollo.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les fueron los principales temas discutidos durante la sesi\u00f3n informativa sobre la Farmacopea Internacional en 2009?**\n   - La sesi\u00f3n abord\u00f3 el proceso de desarrollo de monograf\u00edas, la pol\u00edtica farmacop\u00e9ica y el papel de la farmacopea en las actividades de aseguramiento de calidad de la OMS.\n\n2. **\u00bfQu\u00e9 criterios se utilizaron para priorizar las sustancias en el nuevo programa de trabajo propuesto por el Comit\u00e9 de Expertos?**\n   - Se consideraron sustancias que quedaban del plan de trabajo de 2009, aquellas priorizadas en el programa de trabajo adoptado en 2008, y adiciones de listas de medicamentos esenciales y expresiones de inter\u00e9s dentro del Programa de Precalificaci\u00f3n de la OMS.\n\n3. **\u00bfQu\u00e9 tipo de retroalimentaci\u00f3n se recibi\u00f3 de los participantes de la sesi\u00f3n informativa y c\u00f3mo influy\u00f3 en las recomendaciones del Comit\u00e9 de Expertos?**\n   - La retroalimentaci\u00f3n fue positiva, indicando que la informaci\u00f3n proporcionada fue \u00fatil, lo que llev\u00f3 al Comit\u00e9 a recomendar la continuaci\u00f3n de estas sesiones informativas para un p\u00fablico m\u00e1s amplio.\n\n### Resumen de Nivel Superior\n\nEl documento destaca la importancia de la colaboraci\u00f3n entre la OMS y la industria farmac\u00e9utica en el desarrollo de est\u00e1ndares de calidad para medicamentos a trav\u00e9s de la Farmacopea Internacional. Se enfatiza la necesidad de priorizar sustancias cr\u00edticas para la salud p\u00fablica, especialmente en el contexto de enfermedades prevalentes en pa\u00edses en desarrollo. La interacci\u00f3n entre los fabricantes y la OMS se considera esencial para mejorar la calidad y disponibilidad de medicamentos a nivel global.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Inyecciones de Radiotrazadores**:\n   - Se enumeran diversas inyecciones de radiotrazadores, incluyendo:\n     - Sodio pertechnetate (\u2079\u2079\u1d50Tc) (fisi\u00f3n y no fisi\u00f3n)\n     - Sodio fosfato (\u00b3\u00b2P)\n     - Cloruro de estroncio (\u2078\u2079Sr)\n     - Varios complejos de tecn\u00e9cio (\u2079\u2079\u1d50Tc) como bicisato, exametazima, mebrofenin, mertiatide, pentetato, succimer, coloide de azufre, tetrofosmina, coloide de esta\u00f1o, pirofosfato de esta\u00f1o, metileno difosfonato (MDP) y sestamibi.\n     - Cloruro de talio (\u00b2\u2070\u00b9Tl)\n     - Silicato de yttrio (\u2079\u2070Y)\n\n2. **Actualizaciones de la Farmacopea Internacional (Ph.Int.)**:\n   - En 2009, se realizaron actualizaciones en las p\u00e1ginas web de la OMS dedicadas a la Ph.Int. para informar sobre textos adoptados recientemente y aspectos espec\u00edficos de las monograf\u00edas.\n   - Se increment\u00f3 el n\u00famero de p\u00e1ginas para incluir informaci\u00f3n sobre:\n     - Radiopharmaceuticals\n     - Anti-infectivos (antibacterianos, antiprotozoarios, antif\u00fangicos, antivirales, antimicobacterianos y anthelminticos).\n\n3. **Respuesta de la Comunidad**:\n   - Se recibi\u00f3 una respuesta positiva a las actualizaciones, con solicitudes para suscribirse a una lista de correo para recibir alertas sobre las actividades m\u00e1s recientes de la Ph.Int.\n   - Se reconoce que este sistema de correo ayudar\u00e1 a los usuarios a mantenerse informados sobre los cambios y mejorar\u00e1 la difusi\u00f3n de informaci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Farmacopea Internacional (Ph.Int.)**\n- **Inyecciones de Radiotrazadores** (ej. Sodio pertechnetate, Cloruro de talio)\n- **Medicamentos Anti-infectivos** (incluyendo antibacterianos, antivirales, etc.)", "excerpt_keywords": "Keywords: International Pharmacopoeia, WHO, pharmaceutical industry, monographs, quality assurance"}}, "cb91d4c8-1dc7-484a-b3d1-4f2d7f3bc717": {"node_ids": ["37de6464-5d57-427b-b388-b221010b9fea"], "metadata": {"page_label": "34", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 requests for priority medicines recommended in WHO specific disease programmes.\n\nAfter discussion, the Expert Committee adopted the following new work programme.\n\nAdditions to the 2009 work plan are indicated below in bold.\n\n# Updated new work programme\n\n## Medicines used in the treatment of HIV/AIDS and related conditions\n\n**API**\n- **Atazanavir**\n\n**Dosage forms**\n- **Atazanavir capsules**\n- Didanosine capsules\n- Efavirenz tablets\n- **Emtricitabine capsules**\n- **Emtricitabine oral solution**\n- Ritonavir capsules\n- Ritonavir oral solution\n- Stavudine powder for oral solution\n- Zidovudine tablets\n\n**Fixed-dose combinations**\n- Lopinavir and ritonavir capsules\n- Lopinavir and ritonavir oral solution\n\n**Dosage forms, including those for paediatric use, as available for:**\n- **Efavirenz + emtricitabine + tenofovir**\n- Lamivudine + stavudine\n- Lamivudine + stavudine + efavirenz\n- Lamivudine + stavudine + nevirapine\n- Lamivudine + zidovudine + efavirenz\n- Tenofovir + emtricitabine\n\n## Medicines used in malaria treatment\n\n**API**\n- **Piperaquine phosphate**\n\n**Dosage forms**\n- Mefloquine tablets (*used in co-blisters*)", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla un nuevo programa de trabajo que incluye medicamentos prioritarios recomendados para el tratamiento del VIH/SIDA y la malaria. Se enumeran los principios activos (API), las formas de dosificaci\u00f3n y las combinaciones de dosis fijas para el tratamiento de estas condiciones. Se destacan medicamentos como Atazanavir y Piperaquine phosphate, as\u00ed como varias combinaciones de medicamentos para el VIH.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las formas de dosificaci\u00f3n espec\u00edficas para Atazanavir y Emtricitabine mencionadas en el nuevo programa de trabajo de la OMS?**\n   - Respuesta: Las formas de dosificaci\u00f3n espec\u00edficas para Atazanavir son las c\u00e1psulas de Atazanavir, y para Emtricitabine son las c\u00e1psulas de Emtricitabine y la soluci\u00f3n oral de Emtricitabine.\n\n2. **\u00bfQu\u00e9 combinaciones de dosis fijas para el tratamiento del VIH se mencionan en el documento y cu\u00e1les son sus componentes?**\n   - Respuesta: Las combinaciones de dosis fijas mencionadas son: \n     - Efavirenz + Emtricitabine + Tenofovir\n     - Lamivudine + Stavudine\n     - Lamivudine + Stavudine + Efavirenz\n     - Lamivudine + Stavudine + Nevirapine\n     - Lamivudine + Zidovudine + Efavirenz\n     - Tenofovir + Emtricitabine.\n\n3. **\u00bfQu\u00e9 medicamento se menciona para el tratamiento de la malaria y cu\u00e1l es su forma de dosificaci\u00f3n?**\n   - Respuesta: El medicamento mencionado para el tratamiento de la malaria es el Fosfato de Piperaquina, y su forma de dosificaci\u00f3n es en tabletas de Mefloquina, que se utilizan en co-blisters.", "prev_section_summary": "### Temas Clave\n\n1. **Sesi\u00f3n Informativa sobre la Farmacopea Internacional (Ph.Int.)**:\n   - Se llev\u00f3 a cabo en abril de 2009 para partes interesadas de la industria farmac\u00e9utica.\n   - Se discuti\u00f3 el proceso de desarrollo de monograf\u00edas y la pol\u00edtica farmacop\u00e9ica.\n   - La reuni\u00f3n fue interactiva, permitiendo a los fabricantes plantear cuestiones y participar en discusiones abiertas.\n\n2. **Retroalimentaci\u00f3n Positiva**:\n   - Los participantes, que inclu\u00edan representantes de empresas farmac\u00e9uticas gen\u00e9ricas y de investigaci\u00f3n, encontraron \u00fatil la informaci\u00f3n proporcionada.\n   - Se recomend\u00f3 organizar m\u00e1s sesiones informativas para un p\u00fablico m\u00e1s amplio.\n\n3. **Plan de Trabajo Actual y Programa Futuro**:\n   - En 2008, el Comit\u00e9 de Expertos acord\u00f3 priorizar sustancias de alta prioridad para su inclusi\u00f3n en el programa de trabajo.\n   - Se adopt\u00f3 un plan de trabajo inicial que inclu\u00eda seis ingredientes farmac\u00e9uticos activos (APIs) y 36 formas de dosificaci\u00f3n para la iniciaci\u00f3n de monograf\u00edas.\n   - Se propuso un nuevo programa de trabajo que considera:\n     - Sustancias restantes del plan de trabajo de 2009.\n     - Sustancias priorizadas en el programa de trabajo adoptado en 2008, enfoc\u00e1ndose en medicamentos para ni\u00f1os y tratamientos para enfermedades prevalentes en pa\u00edses en desarrollo.\n     - Adiciones de listas de medicamentos esenciales y expresiones de inter\u00e9s dentro del Programa de Precalificaci\u00f3n de la OMS.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Instituci\u00f3n responsable de la calidad y regulaci\u00f3n de medicamentos a nivel global.\n- **Comit\u00e9 de Expertos**: Grupo que eval\u00faa y recomienda acciones sobre la Farmacopea Internacional y el programa de trabajo relacionado.\n- **Partes Interesadas de la Industria Farmac\u00e9utica**: Incluye representantes de empresas farmac\u00e9uticas gen\u00e9ricas y de investigaci\u00f3n, as\u00ed como asociaciones de la industria.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Sustancias que se consideran para el desarrollo de monograf\u00edas en el contexto de la calidad de los medicamentos.\n- **Programa de Precalificaci\u00f3n de la OMS (PQP)**: Iniciativa que busca asegurar la calidad de los medicamentos en mercados de pa\u00edses en desarrollo.", "excerpt_keywords": "medicines, HIV/AIDS, malaria, WHO, dosage forms"}}, "6a0ff450-01e6-4471-9f83-d5fc5e2bafaa": {"node_ids": ["34118b00-f2be-4762-bf8a-c41498c36382"], "metadata": {"page_label": "35", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Fixed-dose combinations\n\n- Artemether and lumefantrine capsules\n- Artemether and lumefantrine dispersible tablets\n- Artesunate and amodiaquine tablets\n- Artesunate, sulfadoxine and pyrimethamine tablets\n- Sulfadoxine and pyrimethamine tablets (*used in co-blisters*)\n\n**Dosage form, including that for paediatric use, as available for:**\n\n- Dihydroartemisinin + piperaquine phosphate\n\n**Revision**\n\n- Artemisinin derivatives (APIs and dosage forms) (see http://www.who.int/medicines/publications/pharmacopoeia/mon_mal/en/index.html)\n\n# Medicines used in tuberculosis treatment\n\n**APIs**\n\n- *p*-Aminosalicylic acid\n- Capreomycin\n- Levofloxacin\n- Ofloxacin\n- Terizidone\n\n**Dosage forms**\n\n- *p*-Aminosalicylic acid granules\n- Capreomycin powder for injection\n- Ethionamide tablets\n- Levofloxacin tablets\n- Ofloxacin tablets\n- Protionamide tablets\n- **Terizidone tablets**\n\n# Anti-infectives (antibacterials, antiprotozoal, antifungal, antiviral and antimycobacterial agents, anthelmintics)\n\n**APIs**\n\n- Ceftriaxone sodium\n- Fluconazole\n- Ivermectin\n\n**Dosage forms**\n\n- Albendazole chewable tablets\n- Amoxicillin oral suspension\n- Ceftriaxone injection\n- Doxycycline dispersible tablets", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta informaci\u00f3n sobre combinaciones de dosis fijas de medicamentos, tratamientos para la tuberculosis y agentes antiinfecciosos. Se enumeran los principios activos (APIs) y las formas de dosificaci\u00f3n disponibles para cada categor\u00eda de medicamentos. Se destacan combinaciones espec\u00edficas de medicamentos para el tratamiento de la malaria y la tuberculosis, as\u00ed como varios antibacterianos, antif\u00fangicos y antiparasitarios.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son las combinaciones de dosis fijas mencionadas para el tratamiento de la malaria y qu\u00e9 formas de dosificaci\u00f3n est\u00e1n disponibles para cada una?**\n   - Respuesta: Las combinaciones de dosis fijas mencionadas son: \n     - Artemether y lumefantrine (c\u00e1psulas y tabletas dispersables)\n     - Artesunate y amodiaquine (tabletas)\n     - Artesunate, sulfadoxina y pirimetamina (tabletas)\n     - Sulfadoxina y pirimetamina (tabletas, utilizadas en co-blisters)\n     - Dihidroartemisina + piperaquina fosfato (forma de dosificaci\u00f3n pedi\u00e1trica disponible).\n\n2. **\u00bfQu\u00e9 medicamentos se enumeran como tratamientos para la tuberculosis y cu\u00e1les son sus formas de dosificaci\u00f3n?**\n   - Respuesta: Los medicamentos para la tuberculosis incluyen:\n     - *p*-Aminosalicylic acid (granulados)\n     - Capreomycin (polvo para inyecci\u00f3n)\n     - Ethionamide (tabletas)\n     - Levofloxacin (tabletas)\n     - Ofloxacin (tabletas)\n     - Protionamide (tabletas)\n     - Terizidone (tabletas).\n\n3. **\u00bfQu\u00e9 agentes antiinfecciosos se mencionan en el documento y cu\u00e1les son sus formas de dosificaci\u00f3n?**\n   - Respuesta: Los agentes antiinfecciosos mencionados son:\n     - Ceftriaxone sodium (inyecci\u00f3n)\n     - Fluconazole (no se especifica forma de dosificaci\u00f3n)\n     - Ivermectin (no se especifica forma de dosificaci\u00f3n).\n     - Formas de dosificaci\u00f3n para otros medicamentos incluyen:\n       - Albendazole (tabletas masticables)\n       - Amoxicillin (suspensi\u00f3n oral)\n       - Doxycycline (tabletas dispersables).", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento de la OMS presenta un nuevo programa de trabajo que se centra en medicamentos prioritarios para el tratamiento del VIH/SIDA y la malaria. A continuaci\u00f3n se detallan los puntos m\u00e1s relevantes:\n\n#### Medicamentos para el tratamiento del VIH/SIDA:\n- **Principios Activos (API)**:\n  - Atazanavir\n  - Emtricitabine\n\n- **Formas de dosificaci\u00f3n**:\n  - **Atazanavir**: c\u00e1psulas\n  - **Emtricitabine**: c\u00e1psulas y soluci\u00f3n oral\n  - Otros medicamentos mencionados: Didanosine (c\u00e1psulas), Efavirenz (tabletas), Ritonavir (c\u00e1psulas y soluci\u00f3n oral), Stavudine (polvo para soluci\u00f3n oral), Zidovudine (tabletas).\n\n- **Combinaciones de dosis fijas**:\n  - Lopinavir y ritonavir (c\u00e1psulas y soluci\u00f3n oral)\n  - Efavirenz + Emtricitabine + Tenofovir\n  - Lamivudine + Stavudine\n  - Lamivudine + Stavudine + Efavirenz\n  - Lamivudine + Stavudine + Nevirapine\n  - Lamivudine + Zidovudine + Efavirenz\n  - Tenofovir + Emtricitabine\n\n#### Medicamentos para el tratamiento de la malaria:\n- **Principio Activo (API)**:\n  - Fosfato de Piperaquina\n\n- **Forma de dosificaci\u00f3n**:\n  - Tabletas de Mefloquina (utilizadas en co-blisters)\n\nEste resumen destaca los medicamentos y sus formas de dosificaci\u00f3n recomendados por la OMS para el tratamiento de VIH/SIDA y malaria, as\u00ed como las combinaciones de dosis fijas que se consideran prioritarias.", "excerpt_keywords": "Keywords: fixed-dose combinations, tuberculosis treatment, anti-infectives, artemisinin derivatives, WHO guidelines"}}, "064cb530-5a2f-45ca-8fdc-bed91214aa64": {"node_ids": ["db10bc76-fb51-43bd-bf75-6203cb3fc3b8"], "metadata": {"page_label": "36", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Fluconazole capsules\n- Fluconazole injection\n- Fluconazole oral solution/suspension\n- Ivermectin tablets\n- Levamisole tablets\n- Metronidazole oral suspension\n- Pyrantel chewable tablets\n- Pyrantel oral solution/suspension\n- Pyrimethamine tablets\n\n**Fixed-dose combinations**\n- Sulfamethoxazole and trimethoprim injection\n- Sulfamethoxazole and trimethoprim oral solution/suspension\n- Sulfamethoxazole and trimethoprim tablets\n\n## Oral rehydration therapy\n\n**APIs**\n- Zinc acetate\n- Zinc gluconate\n\n**Dosage forms**\n- Paediatric zinc acetate oral solution\n- Paediatric zinc acetate tablets\n- Paediatric zinc gluconate oral solution\n- Paediatric zinc gluconate tablets\n\n## Various other medicines (analgesics, antipyretics, palliative care, anti-epileptics, large volume parenterals, reproductive health)\n\n**Dosage forms**\n- Carbamazepine oral liquid\n- Chewable carbamazepine tablets\n- Chewable phenytoin tablets\n- Crushable valproic acid tablets\n- **Ethinylestradiol + levonorgestrel tablets**\n- Glucose intravenous infusion\n- **Levonorgestrel tablets**\n- **Medroxyprogesterone acetate (DMPA), depot injection**\n- Morphine oral solution\n- Oseltamivir capsules\n- Paediatric retinol capsules\n- Paediatric retinol oral solution\n- Paracetamol oral solution", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Informe T\u00e9cnico 957) enumera una variedad de medicamentos y formulaciones que son esenciales para el tratamiento de diversas condiciones de salud. Incluye medicamentos antif\u00fangicos, antiparasitarios, antibacterianos, y otros f\u00e1rmacos utilizados en terapia de rehidrataci\u00f3n oral, as\u00ed como en el manejo del dolor, la fiebre, y la salud reproductiva. Tambi\u00e9n se mencionan combinaciones de dosis fijas y formas de dosificaci\u00f3n pedi\u00e1trica.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las formas de dosificaci\u00f3n pedi\u00e1trica disponibles para el zinc en el contexto de la terapia de rehidrataci\u00f3n oral?**\n   - Respuesta: Las formas de dosificaci\u00f3n pedi\u00e1trica disponibles para el zinc son: soluci\u00f3n oral de acetato de zinc pedi\u00e1trico, tabletas de acetato de zinc pedi\u00e1trico, soluci\u00f3n oral de gluconato de zinc pedi\u00e1trico y tabletas de gluconato de zinc pedi\u00e1trico.\n\n2. **\u00bfQu\u00e9 medicamentos se incluyen en las combinaciones de dosis fijas mencionadas en el documento?**\n   - Respuesta: Las combinaciones de dosis fijas mencionadas son: inyecci\u00f3n de sulfametoxazol y trimetoprim, soluci\u00f3n/suspensi\u00f3n oral de sulfametoxazol y trimetoprim, y tabletas de sulfametoxazol y trimetoprim.\n\n3. **\u00bfQu\u00e9 medicamentos se enumeran espec\u00edficamente para el manejo del dolor y la fiebre en el contexto de cuidados paliativos?**\n   - Respuesta: Los medicamentos enumerados para el manejo del dolor y la fiebre son: soluci\u00f3n oral de morfina y soluci\u00f3n oral de paracetamol.", "prev_section_summary": "La secci\u00f3n del documento de la OMS se centra en tres categor\u00edas principales de medicamentos: combinaciones de dosis fijas para el tratamiento de la malaria, medicamentos utilizados en el tratamiento de la tuberculosis y agentes antiinfecciosos. \n\n### Temas Clave:\n\n1. **Combinaciones de Dosis Fijas para Malaria:**\n   - Se enumeran varias combinaciones de medicamentos, incluyendo:\n     - Artemether y lumefantrine (c\u00e1psulas y tabletas dispersables)\n     - Artesunate y amodiaquine (tabletas)\n     - Artesunate, sulfadoxina y pirimetamina (tabletas)\n     - Sulfadoxina y pirimetamina (tabletas, en co-blisters)\n     - Dihidroartemisina + piperaquina fosfato (disponible en forma pedi\u00e1trica).\n\n2. **Medicamentos para el Tratamiento de la Tuberculosis:**\n   - Se listan los principios activos (APIs) y sus formas de dosificaci\u00f3n:\n     - *p*-Aminosalicylic acid (granulados)\n     - Capreomycin (polvo para inyecci\u00f3n)\n     - Ethionamide (tabletas)\n     - Levofloxacin (tabletas)\n     - Ofloxacin (tabletas)\n     - Protionamide (tabletas)\n     - Terizidone (tabletas).\n\n3. **Agentes Antiinfecciosos:**\n   - Se mencionan varios agentes y sus formas de dosificaci\u00f3n:\n     - Ceftriaxone sodium (inyecci\u00f3n)\n     - Fluconazole (sin forma de dosificaci\u00f3n especificada)\n     - Ivermectin (sin forma de dosificaci\u00f3n especificada)\n     - Albendazole (tabletas masticables)\n     - Amoxicillin (suspensi\u00f3n oral)\n     - Doxycycline (tabletas dispersables).\n\n### Entidades Clave:\n- **Medicamentos para Malaria:** Artemether, lumefantrine, artesunate, amodiaquine, sulfadoxina, pirimetamina, dihidroartemisina, piperaquina.\n- **Medicamentos para Tuberculosis:** *p*-Aminosalicylic acid, capreomycin, ethionamide, levofloxacin, ofloxacin, protionamide, terizidone.\n- **Agentes Antiinfecciosos:** Ceftriaxone sodium, fluconazole, ivermectin, albendazole, amoxicillin, doxycycline.\n\nEste resumen proporciona una visi\u00f3n general de los medicamentos y sus formas de dosificaci\u00f3n, destacando su relevancia en el tratamiento de la malaria, la tuberculosis y las infecciones en general.", "excerpt_keywords": "Keywords: Fluconazole, Zinc, Fixed-dose combinations, Oral rehydration therapy, Palliative care"}}, "6b39cbee-cb27-49aa-a372-08f4779cf3e3": {"node_ids": ["dd261f9c-1c38-48e2-813c-59abf5a135f9"], "metadata": {"page_label": "37", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Paracetamol oral suspension\n- Phenobarbital oral liquid\n- Phenytoin oral liquid\n- Sodium chloride and glucose intravenous infusion\n- Sodium chloride intravenous infusion\n- Valproic acid oral liquid\n\nThis updated new work programme would be made available on the WHO Medicines web site.\n\n## 3.3 Specifications for medicines, including children\u2019s medicines\n\n### 3.3.1 Medicines for HIV and related conditions\n\nNew monographs for the following antiretroviral active substances and dosage forms were presented to the Expert Committee for discussion. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the consultative process and those made during discussion.\n\n**APIs**\n- Lopinavir\n- Tenofovir disoproxil fumarate\n\n**Dosage forms**\n- Indinavir capsules\n- Saquinavir tablets\n- Tenofovir tablets\n- Lopinavir and ritonavir tablets\n\nA revision of the published text of the following antiretroviral active substance was presented to the Expert Committee for discussion. The revised monograph was adopted, subject to confirmation of the proposed values for the specific absorbance by the collaborating laboratory:\n- Efavirenz\n\n### 3.3.2 Antimalarial medicines\n\nNew monographs for the following antimalarial dosage forms were presented to the Expert Committee for discussion. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during the discussion:\n- Amodiaquine tablets\n- Quinine bisulfate tablets", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta un programa de trabajo actualizado que incluye especificaciones para medicamentos, especialmente aquellos dirigidos a ni\u00f1os y condiciones espec\u00edficas como el VIH y la malaria. Se discuten nuevas monograf\u00edas para diversas sustancias activas y formas de dosificaci\u00f3n, que fueron adoptadas por el Comit\u00e9 de Expertos, con la condici\u00f3n de que se realicen cambios acordados y se confirmen ciertos valores. Se mencionan medicamentos antirretrovirales y antimal\u00e1ricos, as\u00ed como la importancia de la revisi\u00f3n y validaci\u00f3n de las monograf\u00edas.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son las condiciones que deben cumplirse para que las nuevas monograf\u00edas de medicamentos sean adoptadas por el Comit\u00e9 de Expertos de la OMS?**\n   - Respuesta: Las monograf\u00edas son adoptadas, sujeto a la inclusi\u00f3n de los cambios acordados basados en los comentarios recibidos durante el proceso consultivo y aquellos realizados durante la discusi\u00f3n.\n\n2. **\u00bfQu\u00e9 medicamentos antirretrovirales se mencionan en el documento y qu\u00e9 formas de dosificaci\u00f3n se han discutido?**\n   - Respuesta: Los medicamentos antirretrovirales mencionados son Lopinavir y Tenofovir disoproxil fumarate, con formas de dosificaci\u00f3n que incluyen c\u00e1psulas de Indinavir, tabletas de Saquinavir, tabletas de Tenofovir y tabletas de Lopinavir y ritonavir.\n\n3. **\u00bfQu\u00e9 revisi\u00f3n se realiz\u00f3 sobre el medicamento Efavirenz y qu\u00e9 condici\u00f3n se estableci\u00f3 para su adopci\u00f3n?**\n   - Respuesta: Se present\u00f3 una revisi\u00f3n del texto publicado del Efavirenz, y la monograf\u00eda revisada fue adoptada, sujeto a la confirmaci\u00f3n de los valores propuestos para la absorbancia espec\u00edfica por parte del laboratorio colaborador.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento de la OMS (Informe T\u00e9cnico 957) aborda una variedad de medicamentos esenciales para el tratamiento de diversas condiciones de salud. Los temas clave incluyen:\n\n1. **Medicamentos Antif\u00fangicos y Antiparasitarios**:\n   - **Fluconazol**: disponible en c\u00e1psulas, inyecci\u00f3n y soluci\u00f3n/suspensi\u00f3n oral.\n   - **Ivermectina**: en forma de tabletas.\n   - **Levamisole**: en tabletas.\n   - **Metronidazol**: en forma de suspensi\u00f3n oral.\n   - **Pyrantel**: en tabletas masticables y soluci\u00f3n/suspensi\u00f3n oral.\n   - **Pyrimethamina**: en tabletas.\n\n2. **Combinaciones de Dosis Fijas**:\n   - **Sulfametoxazol y Trimetoprim**: disponibles en inyecci\u00f3n, soluci\u00f3n/suspensi\u00f3n oral y tabletas.\n\n3. **Terapia de Rehidrataci\u00f3n Oral**:\n   - **Ingredientes Activos (APIs)**: Acetato de zinc y gluconato de zinc.\n   - **Formas de Dosificaci\u00f3n Pedi\u00e1trica**: soluci\u00f3n oral y tabletas de acetato y gluconato de zinc.\n\n4. **Medicamentos para el Manejo del Dolor y la Fiebre**:\n   - **Analgesicos y Antipir\u00e9ticos**: soluci\u00f3n oral de morfina y soluci\u00f3n oral de paracetamol.\n   - **Medicamentos para Cuidados Paliativos**: incluye otros analg\u00e9sicos y antiepil\u00e9pticos como carbamazepina y fenito\u00edna en diversas formas de dosificaci\u00f3n.\n\n5. **Salud Reproductiva**:\n   - **Combinaciones de Hormonas**: tabletas de etinilestradiol + levonorgestrel y tabletas de levonorgestrel.\n   - **Medroxyprogesterona**: inyecci\u00f3n de dep\u00f3sito (DMPA).\n\n### Entidades Clave:\n- **Medicamentos**: Fluconazol, Ivermectina, Levamisole, Metronidazol, Pyrantel, Pyrimethamina, Sulfametoxazol, Trimetoprim, Acetato de Zinc, Gluconato de Zinc, Carbamazepina, Fenito\u00edna, Valproato, Etinilestradiol, Levonorgestrel, Medroxyprogesterona, Morfina, Paracetamol, Oseltamivir, Retinol.\n- **Formas de Dosificaci\u00f3n**: C\u00e1psulas, tabletas, inyecci\u00f3n, soluci\u00f3n/suspensi\u00f3n oral, infusi\u00f3n intravenosa.\n- **\u00c1reas de Aplicaci\u00f3n**: Terapia de rehidrataci\u00f3n oral, cuidados paliativos, salud reproductiva, tratamiento de infecciones. \n\nEste resumen destaca la diversidad de medicamentos y su importancia en el tratamiento de condiciones de salud cr\u00edticas, as\u00ed como la atenci\u00f3n a las necesidades pedi\u00e1tricas y de salud reproductiva.", "excerpt_keywords": "Keywords: WHO, medicines, antiretroviral, specifications, monographs"}}, "5c807518-b2b6-4a4a-8bf1-511d04d136e2": {"node_ids": ["d7133a38-9520-4881-a1ae-9539f72dcda3"], "metadata": {"page_label": "38", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Consequent to the development of a new monograph for Quinine bisulfate tablets, a revision of the published text for the quinine sulfate dosage form adopted in October 2008 was required to add an additional identity test allowing the differentiation between the two sulfate forms of quinine possibly used in tablet formulations.\n\nA revision of the published text of the following antimalarial dosage form was thus presented to the Expert Committee for discussion. The revised monograph was adopted, subject to inclusion of the comments received during the public inquiry and those made during the discussion:\n\n- Quinine sulfate tablets\n\n### 3.3.3 Antituberculosis medicines\n\nRevisions of the published texts of the following antibiotics\u2019 active substances, for which an International Chemical Reference Substance (ICRS) was no longer available and thus a new method for assay was needed, were presented for discussion (see paragraph 3.4.2 for antibiotics), together with a new monograph for the corresponding dosage form. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during discussion:\n\n**APIs**\n- Amikacin\n- Amikacin sulfate\n\n**Dosage form**\n- Amikacin injection\n\nNew monographs for the following antibiotics active substances and dosage form for which an ICRS was still available, and thus included an assay by a microbiological method, were also presented for discussion. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during discussion:\n\n**APIs**\n- Kanamycin monosulfate\n- Kanamycin acid sulfate\n\n**Dosage form**\n- Kanamycin injection\n\nFor the Kanamycin injection monograph, the issue of the determination of the conversion factor from international units (IU) to micrograms was raised. The Expert Committee recommended that this monograph be circulated again for comment on this specific aspect.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Revisi\u00f3n de monograf\u00edas de medicamentos antimal\u00e1ricos y antituberculosos**: Se llev\u00f3 a cabo una revisi\u00f3n de las monograf\u00edas de los medicamentos antimal\u00e1ricos, espec\u00edficamente para los comprimidos de sulfato de quinina, para incluir una prueba de identidad adicional. Adem\u00e1s, se presentaron revisiones de las monograf\u00edas de antibi\u00f3ticos, como amikacina y kanamicina, debido a la falta de sustancias de referencia qu\u00edmica internacional (ICRS) y la necesidad de nuevos m\u00e9todos de ensayo.\n\n2. **Adopci\u00f3n de nuevas monograf\u00edas**: Las nuevas monograf\u00edas para los medicamentos revisados fueron adoptadas por el Comit\u00e9 de Expertos, con la condici\u00f3n de que se incluyeran los comentarios recibidos durante la consulta p\u00fablica y las discusiones. Esto incluye tanto las formas de dosificaci\u00f3n como las sustancias activas de los antibi\u00f3ticos.\n\n3. **Cuestiones sobre la conversi\u00f3n de unidades**: Se plante\u00f3 una cuesti\u00f3n espec\u00edfica sobre la conversi\u00f3n de unidades internacionales (IU) a microgramos en la monograf\u00eda de inyecci\u00f3n de kanamicina, lo que llev\u00f3 a la recomendaci\u00f3n de que se circulase nuevamente para comentarios.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la raz\u00f3n detr\u00e1s de la necesidad de una prueba de identidad adicional en la monograf\u00eda de los comprimidos de sulfato de quinina?**\n   - La prueba de identidad adicional se requiere para diferenciar entre las dos formas de sulfato de quinina que podr\u00edan utilizarse en las formulaciones de tabletas.\n\n2. **\u00bfQu\u00e9 cambios se realizaron en las monograf\u00edas de amikacina y kanamicina debido a la falta de ICRS?**\n   - Se presentaron revisiones de las monograf\u00edas de amikacina y amikacina sulfato, as\u00ed como de kanamicina monosulfato y kanamicina \u00e1cido sulfato, para establecer nuevos m\u00e9todos de ensayo debido a la falta de ICRS.\n\n3. **\u00bfQu\u00e9 aspecto espec\u00edfico de la monograf\u00eda de inyecci\u00f3n de kanamicina se recomend\u00f3 para discusi\u00f3n adicional?**\n   - Se recomend\u00f3 que se discutiera nuevamente el factor de conversi\u00f3n de unidades internacionales (IU) a microgramos en la monograf\u00eda de inyecci\u00f3n de kanamicina.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda un programa de trabajo actualizado que incluye especificaciones para medicamentos, con un enfoque particular en aquellos destinados a ni\u00f1os y en el tratamiento de condiciones espec\u00edficas como el VIH y la malaria. \n\n#### Temas clave:\n1. **Medicamentos para ni\u00f1os**: Se mencionan diversas formulaciones de medicamentos que son relevantes para el tratamiento pedi\u00e1trico.\n2. **Medicamentos antirretrovirales**: Se presentan nuevas monograf\u00edas para sustancias activas y formas de dosificaci\u00f3n relacionadas con el VIH.\n3. **Medicamentos antimal\u00e1ricos**: Se discuten nuevas monograf\u00edas para formas de dosificaci\u00f3n de medicamentos utilizados en el tratamiento de la malaria.\n4. **Proceso de adopci\u00f3n de monograf\u00edas**: Las monograf\u00edas son adoptadas por el Comit\u00e9 de Expertos bajo ciertas condiciones, como la inclusi\u00f3n de cambios acordados y la validaci\u00f3n de datos espec\u00edficos.\n\n#### Entidades mencionadas:\n- **Medicamentos**:\n  - Paracetamol (suspensi\u00f3n oral)\n  - Fenobarbital (l\u00edquido oral)\n  - Fenito\u00edna (l\u00edquido oral)\n  - Cloruro de sodio y glucosa (infusi\u00f3n intravenosa)\n  - Cloruro de sodio (infusi\u00f3n intravenosa)\n  - \u00c1cido valproico (l\u00edquido oral)\n  - Lopinavir (sustancia activa)\n  - Tenofovir disoproxil fumarato (sustancia activa)\n  - Indinavir (c\u00e1psulas)\n  - Saquinavir (tabletas)\n  - Tenofovir (tabletas)\n  - Lopinavir y ritonavir (tabletas)\n  - Efavirenz (sustancia activa)\n  - Amodiaquina (tabletas)\n  - Quinine bisulfate (tabletas)\n\nEste resumen destaca la importancia de la revisi\u00f3n y validaci\u00f3n de las monograf\u00edas para asegurar la calidad y eficacia de los medicamentos discutidos.", "excerpt_keywords": "Keywords: Quinine, Amikacin, Kanamycin, monograph, International Chemical Reference Substance"}}, "0da7133d-ec03-49b0-9e2f-48d601171103": {"node_ids": ["213e8ae8-3952-40a1-9a8f-ed3e3ab1390b"], "metadata": {"page_label": "39", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 3.3.4 Other medicines\n\n## Oxytocin\n\nA draft proposal for oxytocin was initially sent out for comment in 2007 and presented for discussion at the forty-second meeting of the Expert Committee in October 2008. A revised draft monograph, reflecting the comments received and the Expert Committee\u2019s recommendations, was recirculated for comment in January 2009. The new comments received were discussed during the consultation on specifications for medicines and quality control laboratory issues in June 2009, paying special attention to the following aspect of the monograph:\n\n- limits for assay\n\nA revised text was presented to the Expert Committee for discussion. The monograph was adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during the discussion.\n\n## Oxytocin injection\n\nA draft proposal for Oxytocin injection was initially sent out for comment in 2007 and presented for discussion at the forty-second meeting of the Expert Committee in 2008. A revised draft monograph, reflecting the comments received and the Expert Committee\u2019s recommendations, was recirculated for comment in January 2009. The new comments received were discussed during the consultation on specifications for medicines and quality control laboratory issues in June 2009, paying special attention to the aspects of the monograph presented below.\n\n### Storage/stability/pH\n\nThe storage of Oxytocin injection was a matter of concern since this injection was widely used in developing countries with hot climates and where refrigeration was not available. It was used by a range of health professionals and health providers (e.g. midwives) as well as in emergency situations. WHO was actively promoting its use by \u201cskilled attendants\u201d for the prevention and treatment of postpartum haemorrhage as part of \u201cMaking Pregnancy Safer\u201d (http://www.who.int/making_pregnancy_safer/en/) (Millennium Development Goals for maternal and child health).\n\nThe draft monograph circulated in 2007 recommended a storage temperature of between 2\u00b0C and 8\u00b0C (i.e. in a refrigerator) in line with the recommendations of the major manufacturers. This aspect of the monograph was reviewed by the Secretariat in light of current debate on stability of Oxytocin formulations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Proceso de desarrollo de la monograf\u00eda de Oxitocina**: La monograf\u00eda de Oxitocina ha pasado por un proceso de revisi\u00f3n y discusi\u00f3n desde 2007, con m\u00faltiples circulaciones de borradores y consultas para incorporar comentarios de expertos y del p\u00fablico. Este proceso culmin\u00f3 en la adopci\u00f3n de un texto revisado que incluye cambios acordados.\n\n2. **Preocupaciones sobre la estabilidad y almacenamiento de la inyecci\u00f3n de Oxitocina**: La inyecci\u00f3n de Oxitocina es crucial en pa\u00edses en desarrollo, especialmente en climas c\u00e1lidos donde la refrigeraci\u00f3n puede no estar disponible. La Organizaci\u00f3n Mundial de la Salud (OMS) promueve su uso para prevenir y tratar la hemorragia posparto, lo que plantea desaf\u00edos en cuanto a su almacenamiento y estabilidad.\n\n3. **Recomendaciones de almacenamiento para la inyecci\u00f3n de Oxitocina**: La monograf\u00eda de 2007 recomend\u00f3 que la inyecci\u00f3n de Oxitocina se almacenara entre 2\u00b0C y 8\u00b0C, aline\u00e1ndose con las recomendaciones de los principales fabricantes. Sin embargo, este aspecto fue revisado debido a debates sobre la estabilidad de las formulaciones de Oxitocina.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les fueron los principales cambios acordados en la monograf\u00eda de Oxitocina despu\u00e9s de la consulta p\u00fablica y las discusiones del Comit\u00e9 de Expertos?**\n   - Esta pregunta busca detalles sobre las modificaciones espec\u00edficas que se realizaron en la monograf\u00eda tras recibir comentarios, lo cual no se detalla en el texto.\n\n2. **\u00bfQu\u00e9 medidas se est\u00e1n considerando para abordar los problemas de almacenamiento de la inyecci\u00f3n de Oxitocina en climas c\u00e1lidos y sin refrigeraci\u00f3n?**\n   - Esta pregunta se centra en las soluciones potenciales o estrategias que la OMS y otros actores podr\u00edan estar explorando para garantizar la efectividad de la inyecci\u00f3n de Oxitocina en condiciones adversas.\n\n3. **\u00bfQu\u00e9 impacto ha tenido la promoci\u00f3n de la OMS sobre el uso de Oxitocina en la reducci\u00f3n de la hemorragia posparto en pa\u00edses en desarrollo?**\n   - Esta pregunta busca informaci\u00f3n sobre la efectividad de las iniciativas de la OMS en la pr\u00e1ctica cl\u00ednica y su impacto en la salud materna, un aspecto que no se aborda directamente en el texto.", "prev_section_summary": "### Temas Clave\n\n1. **Revisi\u00f3n de Monograf\u00edas**: Se llev\u00f3 a cabo una revisi\u00f3n de la monograf\u00eda de los comprimidos de sulfato de quinina para incluir una prueba de identidad adicional que permita diferenciar entre las dos formas de sulfato de quinina en las formulaciones de tabletas.\n\n2. **Medicamentos Antimal\u00e1ricos y Antituberculosos**: Se presentaron revisiones de las monograf\u00edas de antibi\u00f3ticos, como amikacina y kanamicina, debido a la falta de sustancias de referencia qu\u00edmica internacional (ICRS) y la necesidad de nuevos m\u00e9todos de ensayo.\n\n3. **Adopci\u00f3n de Nuevas Monograf\u00edas**: Las nuevas monograf\u00edas para los medicamentos revisados fueron adoptadas por el Comit\u00e9 de Expertos, con la condici\u00f3n de incluir los comentarios recibidos durante la consulta p\u00fablica y las discusiones.\n\n4. **Conversi\u00f3n de Unidades**: Se plante\u00f3 una cuesti\u00f3n sobre la conversi\u00f3n de unidades internacionales (IU) a microgramos en la monograf\u00eda de inyecci\u00f3n de kanamicina, recomendando su discusi\u00f3n adicional.\n\n### Entidades\n\n- **Medicamentos**:\n  - Quinine bisulfate tablets\n  - Quinine sulfate tablets\n  - Amikacin\n  - Amikacin sulfate\n  - Kanamycin monosulfate\n  - Kanamycin acid sulfate\n\n- **Formas de Dosificaci\u00f3n**:\n  - Amikacin injection\n  - Kanamycin injection\n\n- **Comit\u00e9**: Expert Committee\n\n- **Referencia**: International Chemical Reference Substance (ICRS)\n\nEste resumen destaca los cambios en las monograf\u00edas de medicamentos antimal\u00e1ricos y antituberculosos, as\u00ed como las discusiones sobre la conversi\u00f3n de unidades en la monograf\u00eda de kanamicina.", "excerpt_keywords": "Oxytocin, injection, stability, storage, WHO"}}, "14617eb9-e562-46fc-9561-ff93de8a9ce3": {"node_ids": ["daa9c2b0-6804-4019-af11-4306244f9f19"], "metadata": {"page_label": "40", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Bearing in mind the application of the Ph.Int., the revised draft circulated for comment in January 2009 retained 2\u20138\u00b0C as the default temperature recommended under Storage, but qualified it by including \u201cunless otherwise indicated on the label\u201d. This recommendation was supplemented by Additional information concerning short-term storage at higher temperatures in line with statements in summary of product information/patient information leaflets (SPCs/PILs) provided by major manufacturers. A Note from the Secretariat invited comment on this aspect of the revised draft together with any supporting data. Based on the above and the comments received, the storage temperature of 2\u20138\u00b0C for the injection was confirmed.\n\n**pH value**\n\nThe lower limit in the revised draft was changed taking account of the limits currently given in other pharmacopoeias.\n\n**Related substances**\n\nFurther to discussion in June 2009, a recently published article demonstrated that the high-performance liquid chromatography (HPLC) method used for the Related substances test currently described in the Ph.Int. monograph for Oxytocin was also suitable to detect the related substances for the injection. The Expert Committee thus recommended using this test in the Oxytocin injection monograph. The details of this method would be added to the revised draft.\n\nThe text was presented to the Expert Committee for discussion. The monograph was adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during discussion.\n\n### 3.4 Revision of texts of  \n*The International Pharmacopoeia*\n\n#### 3.4.1 Antimalarials: artemisinin derivatives\n\nThe revision of some aspects of the monographs for artemisinin derivatives (Artemether, Artemisinin, Artemotil, Artenimol and Artesunate and their associated dosage forms) was discussed by the Expert Committee in October 2008.\n\nIn view of the importance of this category of antimalarial medicines and the time that this extensive revision work would require, an explanatory note including preliminary variations to be carried out to improve the HPLC assay methods (sample preparation) had been posted on the WHO Medicines web site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Almacenamiento de inyecciones**: El documento discute la recomendaci\u00f3n de almacenamiento de inyecciones a una temperatura de 2\u20138\u00b0C, con la posibilidad de excepciones indicadas en las etiquetas de los productos. Tambi\u00e9n se menciona la inclusi\u00f3n de informaci\u00f3n adicional sobre el almacenamiento a temperaturas m\u00e1s altas y la confirmaci\u00f3n de esta recomendaci\u00f3n tras recibir comentarios.\n\n2. **M\u00e9todos de prueba para sustancias relacionadas**: Se destaca la recomendaci\u00f3n del Comit\u00e9 de Expertos de utilizar un m\u00e9todo de cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n (HPLC) para detectar sustancias relacionadas en la inyecci\u00f3n de oxitocina, basado en un art\u00edculo reciente que valida este m\u00e9todo.\n\n3. **Revisi\u00f3n de monograf\u00edas de antimal\u00e1ricos**: Se menciona la revisi\u00f3n de las monograf\u00edas de derivados de artemisinina, que incluye varios medicamentos antimal\u00e1ricos. Se indica que se est\u00e1n realizando variaciones preliminares en los m\u00e9todos de ensayo HPLC para mejorar la preparaci\u00f3n de muestras.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 condiciones de almacenamiento se recomiendan para las inyecciones seg\u00fan el documento, y qu\u00e9 excepciones se permiten?**\n   - El documento recomienda un almacenamiento a 2\u20138\u00b0C para las inyecciones, a menos que se indique lo contrario en la etiqueta del producto.\n\n2. **\u00bfCu\u00e1l es el m\u00e9todo de prueba recomendado para detectar sustancias relacionadas en la inyecci\u00f3n de oxitocina, y qu\u00e9 justificaci\u00f3n se proporciona para su uso?**\n   - Se recomienda el uso de un m\u00e9todo de cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n (HPLC) para detectar sustancias relacionadas en la inyecci\u00f3n de oxitocina, justificado por un art\u00edculo reciente que demuestra su idoneidad.\n\n3. **\u00bfQu\u00e9 aspectos se est\u00e1n revisando en las monograf\u00edas de los derivados de artemisinina y por qu\u00e9 es importante esta revisi\u00f3n?**\n   - Se est\u00e1n revisando algunos aspectos de las monograf\u00edas de derivados de artemisinina debido a la importancia de estos medicamentos antimal\u00e1ricos y el tiempo necesario para llevar a cabo esta extensa revisi\u00f3n. Se han publicado notas explicativas sobre variaciones preliminares en los m\u00e9todos de ensayo HPLC en el sitio web de la OMS.", "prev_section_summary": "### Temas Clave\n\n1. **Desarrollo de la Monograf\u00eda de Oxitocina**: La monograf\u00eda de Oxitocina ha sido objeto de un proceso de revisi\u00f3n desde 2007, con m\u00faltiples borradores y consultas para incorporar comentarios de expertos y del p\u00fablico. Finalmente, se adopt\u00f3 un texto revisado que incluye cambios acordados.\n\n2. **Inyecci\u00f3n de Oxitocina**: La inyecci\u00f3n de Oxitocina es esencial en pa\u00edses en desarrollo, especialmente en climas c\u00e1lidos donde la refrigeraci\u00f3n no siempre est\u00e1 disponible. Su uso es promovido por la OMS para prevenir y tratar la hemorragia posparto.\n\n3. **Almacenamiento y Estabilidad**: Se discutieron preocupaciones sobre el almacenamiento de la inyecci\u00f3n de Oxitocina, que debe mantenerse entre 2\u00b0C y 8\u00b0C, lo que puede ser un desaf\u00edo en entornos sin refrigeraci\u00f3n. Este aspecto fue revisado debido a debates sobre la estabilidad de las formulaciones de Oxitocina.\n\n### Entidades\n\n- **Oxitocina**: Hormona utilizada en medicina, especialmente en el contexto de la hemorragia posparto.\n- **Inyecci\u00f3n de Oxitocina**: Forma farmac\u00e9utica de la oxitocina utilizada en situaciones de emergencia y por profesionales de la salud.\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad que promueve el uso de la inyecci\u00f3n de Oxitocina como parte de sus iniciativas para mejorar la salud materna y neonatal.\n- **Comit\u00e9 de Expertos**: Grupo que revisa y discute las monograf\u00edas y recomendaciones sobre medicamentos.\n- **Millennium Development Goals**: Objetivos de desarrollo que incluyen la mejora de la salud materna y infantil.\n\n### Resumen\n\nLa secci\u00f3n aborda el proceso de desarrollo y revisi\u00f3n de la monograf\u00eda de Oxitocina y su inyecci\u00f3n, destacando la importancia de estos medicamentos en la atenci\u00f3n de la salud materna, especialmente en pa\u00edses en desarrollo. Se enfatiza la necesidad de un almacenamiento adecuado de la inyecci\u00f3n de Oxitocina, dado su uso en climas c\u00e1lidos y la falta de refrigeraci\u00f3n, as\u00ed como la promoci\u00f3n de su uso por parte de la OMS para prevenir la hemorragia posparto.", "excerpt_keywords": "Keywords: Oxytocin, storage temperature, HPLC method, artemisinin derivatives, pharmacopoeia"}}, "4067fc70-6271-4e43-bf82-7b29ea96d965": {"node_ids": ["b20ec46d-184a-453b-951d-c4820307a975"], "metadata": {"page_label": "41", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Following presentation of a detailed update the Committee was pleased to note that considerable progress had been made; specific revision proposals for two monographs had now been circulated for comment and laboratory work was in progress for other monographs.\n\nThe following revised antimalarial dosage forms monographs were presented to the Expert Committee for discussion with the comments received to date. The monographs were adopted, subject to inclusion of the agreed changes, based on the comments made during the discussion and provided no major comments were received during the public inquiry:\n\n- Artesunate\n- Artesunate tablets\n\n### 3.4.2 Antibiotics\n\nA number of revision issues related to antibiotics assay were identified and discussed by the Expert Committee at its meetings in October 2006 and 2008.\n\nThe Committee was pleased to note that a review had started of those monographs for antibiotics which specified a microbiological assay, with the aim of replacing this method by a chromatographic method where possible. Priority for revision had been awarded to those monographs in Volume 1 of the Fourth Edition of the Ph.Int. that still specified a microbiological assay while the relevant biological reference material (International Standards for Antibiotics (ISA9)) had been disestablished.\n\nThe following revision status for these texts (APIs and dosage forms) was presented:\n\n- Amikacin and Amikacin sulfate monographs: the microbiological assay was replaced by an HPLC method using ultraviolet (UV) detection and an alternative method by non-aqueous titration had been added whenever possible. These texts were adopted by the Expert Committee (see paragraph 3.3.3 for antituberculosis drugs);\n- Chlortetracycline hydrochloride, Oxytetracycline dehydrate, Oxytetracycline hydrochloride, Tetracycline, Tetracycline hydrochloride and Paromomycin monographs: the Committee agreed to revise these texts taking account of established pharmacopoeial HPLC methods which were also under active revision in other pharmacopoeias. It was, therefore, recommended to await the outcome of these efforts for further discussions of these monographs within the context of the Ph.Int.\n\nAs all these revisions were ongoing, the Expert Committee recommended that an information note on the revision status of these monographs be posted on the WHO Medicines web site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Progreso en la revisi\u00f3n de monograf\u00edas**: El Comit\u00e9 de Expertos ha realizado avances significativos en la revisi\u00f3n de monograf\u00edas, con propuestas espec\u00edficas para dos monograf\u00edas de antimal\u00e1ricos que han sido adoptadas, y se est\u00e1 llevando a cabo trabajo de laboratorio para otras monograf\u00edas.\n\n2. **Revisi\u00f3n de m\u00e9todos de ensayo de antibi\u00f3ticos**: Se ha iniciado una revisi\u00f3n de las monograf\u00edas de antibi\u00f3ticos que especifican un ensayo microbiol\u00f3gico, con el objetivo de reemplazar este m\u00e9todo por m\u00e9todos cromatogr\u00e1ficos. Se ha dado prioridad a las monograf\u00edas que a\u00fan utilizan ensayos microbiol\u00f3gicos y que est\u00e1n relacionadas con materiales de referencia biol\u00f3gica que han sido desestablecidos.\n\n3. **Estado de las revisiones de monograf\u00edas espec\u00edficas**: Se han presentado los estados de revisi\u00f3n de varias monograf\u00edas de antibi\u00f3ticos, destacando la adopci\u00f3n de m\u00e9todos HPLC para algunos antibi\u00f3ticos y la recomendaci\u00f3n de esperar los resultados de revisiones en otros farmacopoeias para discutir otras monograf\u00edas.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las monograf\u00edas de antimal\u00e1ricos que fueron adoptadas por el Comit\u00e9 de Expertos y qu\u00e9 condiciones se establecieron para su adopci\u00f3n?**\n   - Respuesta: Las monograf\u00edas de antimal\u00e1ricos adoptadas son Artesunate y Artesunate tablets, y su adopci\u00f3n est\u00e1 sujeta a la inclusi\u00f3n de cambios acordados basados en los comentarios realizados durante la discusi\u00f3n, siempre que no se reciban comentarios importantes durante la consulta p\u00fablica.\n\n2. **\u00bfQu\u00e9 cambios se realizaron en las monograf\u00edas de Amikacina y Amikacina sulfato en relaci\u00f3n con los m\u00e9todos de ensayo?**\n   - Respuesta: En las monograf\u00edas de Amikacina y Amikacina sulfato, el ensayo microbiol\u00f3gico fue reemplazado por un m\u00e9todo HPLC utilizando detecci\u00f3n ultravioleta (UV), y se a\u00f1adi\u00f3 un m\u00e9todo alternativo de titulaci\u00f3n no acuosa siempre que fue posible.\n\n3. **\u00bfQu\u00e9 recomendaciones hizo el Comit\u00e9 de Expertos respecto a las monograf\u00edas de antibi\u00f3ticos que a\u00fan utilizan ensayos microbiol\u00f3gicos?**\n   - Respuesta: El Comit\u00e9 de Expertos recomend\u00f3 esperar los resultados de las revisiones de m\u00e9todos HPLC establecidos en otras farmacopoeias antes de discutir m\u00e1s a fondo las monograf\u00edas de Chlortetracycline, Oxytetracycline, Tetracycline y Paromomycin. Adem\u00e1s, se sugiri\u00f3 que se publique una nota informativa sobre el estado de revisi\u00f3n de estas monograf\u00edas en el sitio web de Medicamentos de la OMS.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Almacenamiento de inyecciones**:\n   - **Temperatura recomendada**: 2\u20138\u00b0C como temperatura de almacenamiento est\u00e1ndar.\n   - **Excepciones**: Se permite el almacenamiento a temperaturas diferentes si se indica en la etiqueta del producto.\n   - **Informaci\u00f3n adicional**: Se proporciona informaci\u00f3n sobre el almacenamiento a temperaturas m\u00e1s altas, en l\u00ednea con las declaraciones de los fabricantes.\n\n2. **M\u00e9todo de prueba para sustancias relacionadas**:\n   - **M\u00e9todo recomendado**: Cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n (HPLC) para detectar sustancias relacionadas en la inyecci\u00f3n de oxitocina.\n   - **Justificaci\u00f3n**: Un art\u00edculo reciente valida la idoneidad del m\u00e9todo HPLC para este prop\u00f3sito.\n\n3. **Revisi\u00f3n de monograf\u00edas de antimal\u00e1ricos**:\n   - **Medicamentos revisados**: Derivados de artemisinina, incluyendo Artemether, Artemisinin, Artemotil, Artenimol y Artesunate.\n   - **Importancia de la revisi\u00f3n**: Se destaca la relevancia de estos medicamentos antimal\u00e1ricos y el tiempo necesario para realizar la revisi\u00f3n exhaustiva.\n   - **Notas explicativas**: Se han publicado variaciones preliminares en los m\u00e9todos de ensayo HPLC en el sitio web de la OMS para mejorar la preparaci\u00f3n de muestras.\n\n### Entidades clave:\n- **Ph.Int.**: Referencia a la Farmacopea Internacional.\n- **HPLC**: Cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n.\n- **Comit\u00e9 de Expertos**: Grupo que discute y adopta recomendaciones sobre monograf\u00edas y m\u00e9todos de prueba.\n- **OMS**: Organizaci\u00f3n Mundial de la Salud, responsable de la publicaci\u00f3n de las recomendaciones y monograf\u00edas.", "excerpt_keywords": "Keywords: antimalarials, antibiotics, microbiological assay, HPLC, WHO Medicines"}}, "0083f1ba-c66b-4d6e-9b21-ac77fb86db8a": {"node_ids": ["6abc1c8a-8bae-4d38-b42c-337206c7bfb2"], "metadata": {"page_label": "42", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 3.4.3 Other medicines\n\n### Mebendazole\n\nThe Expert Committee adopted a modification to the text for mebendazole to improve the interpretation of the revised monograph adopted in October 2008.\n\nFollowing adoption of the revised monographs for Mebendazole and Mebendazole chewable tablets by the Expert Committee in October 2008, the Secretariat had written to other pharmacopoeial authorities regarding the revision that had been carried out to explicitly restrict the substance to polymorph C in the Ph.Int. In view of the use of mebendazole in intestinal worm eradication programmes worldwide, harmonization of pharmacopoeial monographs had been suggested with respect to the control of polymorphism. The Committee appreciated the helpful replies received from several pharmacopoeias and noted that both the Chinese and European Pharmacopoeias also restricted mebendazole to polymorph C. The possibility of including an explicit statement to this effect within the European Pharmacopoeia (Ph. Eur) monograph was welcomed. It was noted that correspondence from the United States Pharmacopeia (USP) had indicated an interest in harmonizing the USP monograph (which currently did not control the polymorphic form). Members noted, however, that this would not currently be possible since the product currently licensed in the USA contained polymorph B.\n\nThe Secretariat undertook to provide feedback to the relevant pharmacopoeial authorities.\n\n### Oseltamivir phosphate\n\nThe monograph for Oseltamivir phosphate was adopted by the Expert Committee in October 2008 for addition to the Fourth Edition of *The International Pharmacopoeia*.\n\nA further revision for this text was proposed following receipt of comments from manufacturers on the tests for Sulfated ash and related substances. The changes proposed would harmonize the Ph.Int. text with the specifications for oseltamivir phosphate that were now available in other pharmacopoeias (Ph.Eur and USP).\n\nA revised text that included these proposed changes was presented to the Expert Committee for discussion. The monograph was adopted, subject to inclusion of the agreed changes, based on the comments received and those made during the discussion.\n\n## 3.4.4 Heparin\n\nRapid revisions of the monographs in *The International Pharmacopoeia* for Heparin calcium and Heparin sodium were adopted by the Expert.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Modificaciones a la monograf\u00eda de Mebendazole**: En octubre de 2008, se adopt\u00f3 una revisi\u00f3n de las monograf\u00edas de Mebendazole y Mebendazole en tabletas masticables, con un enfoque en restringir el uso a la forma polim\u00f3rfica C. Esto se hizo en respuesta a la necesidad de armonizar las monograf\u00edas farmacop\u00e9uticas a nivel mundial, especialmente en programas de erradicaci\u00f3n de lombrices intestinales.\n\n2. **Revisi\u00f3n de la monograf\u00eda de Oseltamivir fosfato**: La monograf\u00eda de Oseltamivir fosfato fue adoptada en octubre de 2008 y se propusieron revisiones adicionales para armonizar las especificaciones con otras farmacopoeias. Esto incluy\u00f3 cambios en las pruebas para cenizas sulfatadas y sustancias relacionadas, basados en comentarios de los fabricantes.\n\n3. **Revisiones r\u00e1pidas de Heparina**: Se adoptaron revisiones r\u00e1pidas de las monograf\u00edas de Heparina c\u00e1lcica y Heparina s\u00f3dica en *The International Pharmacopoeia*, aunque el contexto no proporciona detalles espec\u00edficos sobre estas revisiones.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1l fue la raz\u00f3n principal para restringir el uso de Mebendazole a la forma polim\u00f3rfica C en las monograf\u00edas farmacop\u00e9uticas?**\n   - La restricci\u00f3n se realiz\u00f3 para mejorar la interpretaci\u00f3n de la monograf\u00eda y asegurar la eficacia del Mebendazole en programas de erradicaci\u00f3n de lombrices intestinales a nivel mundial.\n\n2. **\u00bfQu\u00e9 cambios espec\u00edficos se propusieron para la monograf\u00eda de Oseltamivir fosfato y por qu\u00e9 fueron necesarios?**\n   - Se propusieron cambios en las pruebas para cenizas sulfatadas y sustancias relacionadas para armonizar el texto de la Ph.Int. con las especificaciones disponibles en otras farmacopoeias, como la Europea y la USP.\n\n3. **\u00bfQu\u00e9 desaf\u00edos enfrenta la armonizaci\u00f3n de la monograf\u00eda de Mebendazole en la USP en comparaci\u00f3n con otras farmacopoeias?**\n   - El desaf\u00edo principal es que el producto actualmente licenciado en los EE. UU. contiene la forma polim\u00f3rfica B, lo que impide la armonizaci\u00f3n con las restricciones de las formas polim\u00f3rficas C adoptadas por otras farmacopoeias.", "prev_section_summary": "### Temas Clave:\n\n1. **Progreso en la Revisi\u00f3n de Monograf\u00edas**: Se ha avanzado significativamente en la revisi\u00f3n de monograf\u00edas, con propuestas espec\u00edficas para dos monograf\u00edas de antimal\u00e1ricos que han sido adoptadas y trabajo de laboratorio en curso para otras.\n\n2. **Revisi\u00f3n de M\u00e9todos de Ensayo de Antibi\u00f3ticos**: Se ha iniciado una revisi\u00f3n de monograf\u00edas de antibi\u00f3ticos que utilizan ensayos microbiol\u00f3gicos, con el objetivo de reemplazarlos por m\u00e9todos cromatogr\u00e1ficos. Se ha priorizado la revisi\u00f3n de monograf\u00edas que a\u00fan dependen de ensayos microbiol\u00f3gicos.\n\n3. **Estado de Revisi\u00f3n de Monograf\u00edas Espec\u00edficas**: Se han presentado los estados de revisi\u00f3n de varias monograf\u00edas de antibi\u00f3ticos, destacando la adopci\u00f3n de m\u00e9todos HPLC para algunos y la recomendaci\u00f3n de esperar resultados de revisiones en otras farmacopoeias para discutir m\u00e1s monograf\u00edas.\n\n### Entidades:\n\n- **Comit\u00e9 de Expertos**: Grupo responsable de la revisi\u00f3n y adopci\u00f3n de monograf\u00edas.\n- **Monograf\u00edas de Antimal\u00e1ricos**: \n  - Artesunate\n  - Artesunate tablets\n- **Monograf\u00edas de Antibi\u00f3ticos**:\n  - Amikacina y Amikacina sulfato (m\u00e9todo HPLC adoptado)\n  - Chlortetraciclina, Oxitetraciclina, Tetraciclina y Paromomicina (en revisi\u00f3n)\n- **M\u00e9todos de Ensayo**: \n  - Ensayo microbiol\u00f3gico (reemplazado)\n  - M\u00e9todo HPLC (adoptado)\n  - Titulaci\u00f3n no acuosa (m\u00e9todo alternativo a\u00f1adido)\n- **Ph.Int.**: Farmacopea Internacional, donde se encuentran las monograf\u00edas en revisi\u00f3n.\n- **ISA9**: Material de referencia biol\u00f3gica para antibi\u00f3ticos que ha sido desestablecido. \n\n### Recomendaciones:\n- Publicar una nota informativa sobre el estado de revisi\u00f3n de las monograf\u00edas en el sitio web de Medicamentos de la OMS.", "excerpt_keywords": "Mebendazole, Oseltamivir, pharmacopoeia, polymorphism, Heparin"}}, "804459a6-c96c-4c8a-837e-c55638d56148": {"node_ids": ["4edce5c9-5e69-4366-81bc-89abd1bf1ace"], "metadata": {"page_label": "43", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Committee in October 2008 and had been published on the WHO Medicines web site, to bring them into line with the action of other pharmacopoeias concerning Heparin monographs. The statement on the web site indicated that the WHO Expert Committee on Specifications for Pharmaceutical Preparations, together with the WHO Expert Committee on Biological Standardization, would jointly review the scientific work being carried out by interested parties. The need for further revision of the monographs would be examined, and it was noted that discussion on heparin would be held during the next session of the Expert Committee on Biological Standardization.\n\nRevision of the Heparin monographs was also discussed during the informal consultation in June 2009, when it was recommended to investigate the possible inclusion of a cellulose acetate plate electrophoresis method for the analysis of heparin and its potential glycosaminoglycan impurities, e.g. dermatan sulfate, chondroitin sulfate and oversulfated chondroitin sulfate.\n\nThis method, routinely used in industry, had been shown to have a high selectivity for heparinoid impurities and could be performed with low-cost instrumentation. Therefore, this method could be beneficial for small quality control laboratories not equipped for the compendial HPLC methods.\n\nThe Expert Committee endorsed the recommendation that the Secretariat, in collaboration with a WHO collaborating laboratory, review the suitability of this proposed method for inclusion in the Ph.Int. and circulate revised draft proposals of the Heparin monographs for comment.\n\n### 3.5 Review of published general monographs for dosage forms\n\nAt its meeting in 2007, the Expert Committee agreed that the general monographs published in Volume 2 of *The International Pharmacopoeia* should be reviewed and revised as necessary, to follow a general monograph \u201ctemplate\u201d that had been prepared, based on the texts adopted for inclusion in the first supplement.\n\nFollowing the defined template, a draft revision of the general monograph for Tablets was discussed at the informal consultation in June 2009. It was then recommended that, based on the revision of the general monograph for Tablets, a similar revision should be done of the monograph for Capsules. Revised texts for the following monographs were presented to the Expert Committee for discussion. The revised monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during the discussion:\n\n- Tablets\n- Capsules", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto se centra en las discusiones y recomendaciones de la Comisi\u00f3n de Expertos de la OMS sobre las monograf\u00edas de Heparina y otros formularios farmac\u00e9uticos. En octubre de 2008, se decidi\u00f3 revisar las monograf\u00edas de Heparina para alinearlas con otras farmacopeas. Durante una consulta informal en junio de 2009, se sugiri\u00f3 investigar un m\u00e9todo de electroforesis en placa de acetato de celulosa para analizar la heparina y sus impurezas. Este m\u00e9todo podr\u00eda ser \u00fatil para laboratorios de control de calidad de bajo costo. Adem\u00e1s, se acord\u00f3 revisar las monograf\u00edas generales de formas de dosificaci\u00f3n, como tabletas y c\u00e1psulas, siguiendo un nuevo \"template\" para su revisi\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 m\u00e9todo se propuso para el an\u00e1lisis de heparina y cu\u00e1les son sus ventajas en comparaci\u00f3n con los m\u00e9todos tradicionales?**\n   - Se propuso un m\u00e9todo de electroforesis en placa de acetato de celulosa, que tiene alta selectividad para impurezas heparinoides y puede realizarse con instrumentaci\u00f3n de bajo costo, lo que lo hace accesible para peque\u00f1os laboratorios de control de calidad.\n\n2. **\u00bfQu\u00e9 cambios se acordaron para las monograf\u00edas de tabletas y c\u00e1psulas durante la reuni\u00f3n de la Comisi\u00f3n de Expertos?**\n   - Se acord\u00f3 que, tras la revisi\u00f3n de la monograf\u00eda de tabletas, se realizar\u00eda una revisi\u00f3n similar para la monograf\u00eda de c\u00e1psulas. Las monograf\u00edas revisadas fueron adoptadas, sujeta a la inclusi\u00f3n de cambios acordados basados en comentarios recibidos durante la consulta p\u00fablica.\n\n3. **\u00bfCu\u00e1l fue el prop\u00f3sito de la colaboraci\u00f3n entre la Secretar\u00eda de la OMS y un laboratorio colaborador en relaci\u00f3n con las monograf\u00edas de Heparina?**\n   - El prop\u00f3sito fue revisar la idoneidad del m\u00e9todo propuesto para su inclusi\u00f3n en la Farmacopea Internacional (Ph.Int.) y circular propuestas de borrador revisadas de las monograf\u00edas de Heparina para comentarios.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otros documentos, bas\u00e1ndose en los detalles proporcionados en el contexto.", "prev_section_summary": "### Temas Clave\n\n1. **Mebendazole**:\n   - Modificaci\u00f3n de la monograf\u00eda para mejorar la interpretaci\u00f3n de la revisi\u00f3n adoptada en octubre de 2008.\n   - Restricci\u00f3n del uso de Mebendazole a la forma polim\u00f3rfica C en respuesta a la necesidad de armonizaci\u00f3n en programas de erradicaci\u00f3n de lombrices intestinales.\n   - Inter\u00e9s de la USP en armonizar su monograf\u00eda, aunque actualmente no es posible debido a que el producto licenciado en EE. UU. contiene la forma polim\u00f3rfica B.\n\n2. **Oseltamivir fosfato**:\n   - Adopci\u00f3n de la monograf\u00eda en octubre de 2008 para su inclusi\u00f3n en la Cuarta Edici\u00f3n de *The International Pharmacopoeia*.\n   - Propuestas de revisi\u00f3n para armonizar las especificaciones con otras farmacopoeias, enfoc\u00e1ndose en pruebas para cenizas sulfatadas y sustancias relacionadas.\n\n3. **Heparina**:\n   - Revisi\u00f3n r\u00e1pida de las monograf\u00edas de Heparina c\u00e1lcica y Heparina s\u00f3dica en *The International Pharmacopoeia*.\n\n### Entidades\n\n- **Mebendazole**: Medicamento utilizado en programas de erradicaci\u00f3n de lombrices intestinales.\n- **Oseltamivir fosfato**: Medicamento adoptado en la Cuarta Edici\u00f3n de *The International Pharmacopoeia*.\n- **Heparina**: Medicamento con revisiones r\u00e1pidas en sus monograf\u00edas.\n- **Pharmacopoeias**: Incluye la Farmacopea Europea (Ph. Eur), la Farmacopea de los Estados Unidos (USP) y la Farmacopea China.\n- **Expert Committee**: Comit\u00e9 responsable de la adopci\u00f3n de las monograf\u00edas y revisiones.", "excerpt_keywords": "Heparin, pharmacopoeia, electrophoresis, quality control, monographs"}}, "584416c7-dcca-4b4a-a673-cd90298d7c83": {"node_ids": ["9acd9313-4de3-4f9d-8bd7-e1e14949f095"], "metadata": {"page_label": "44", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 3.6 General policy topics and general revision issues\n\nSeveral documents including guidance and explanation of the current pharmacopoeial approach as well as a review of application to published monographs for the following general revision issues were presented to the Expert Committee for consideration:\n\n- monographs title and strengths\n- strengths available statement\n- identity tests\n- polymorphism\n\nThe Committee discussed the background documents, endorsed the explanatory texts as summarized below and adopted the proposed revisions of the relevant monographs. It further agreed that, as a basis for a future policy, these guidance documents and explanatory texts would be helpful to assist those involved in the development of new and revised monographs. In this respect, the guidance documents might also be made available more widely to provide explanatory information to users of the Ph.Int. by inclusion in the Supplementary information section of the Pharmacopoeia and on the WHO Medicines web site.\n\n## Monographs title and strengths\n\n### Titles\n\nIt was noted that for older monographs the full name of the API was normally included for the dosage form (e.g. Atropine sulfate tablets). In more recent monographs (new texts or revisions) the name of the salt was, whenever possible, usually omitted. There were, however, inconsistencies, e.g. Nelfinavir mesilate tablets.\n\nFollowing the recommendation of the informal consultation in June 2009, the Expert Committee agreed that a standardized approach should be followed within *The International Pharmacopoeia*, which was to use the shortest title consistent with providing unambiguous information on the nature of the API. Such an approach was designed to facilitate the use of the monograph title for nonproprietary labelling and generic prescribing.\n\nThe titles of the following draft monographs presented to the Expert Committee illustrated this approach:\n\n- Indinavir capsules (API \u2014 indinavir sulfate)\n- Saquinavir tablets (API \u2014 saquinavir mesilate)\n- Tenofovir tablets (API \u2014 tenofovir disoproxil fumarate)\n- Amikacin injection (API \u2014 amikacin sulfate)\n\nThe Expert Committee endorsed the proposal that any change to the title agreed for published monographs could be made either when a monograph", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Revisi\u00f3n de monograf\u00edas en la Farmacopea Internacional**: El Comit\u00e9 de Expertos revis\u00f3 varios documentos relacionados con la pol\u00edtica farmacop\u00e9ica actual y discuti\u00f3 temas generales de revisi\u00f3n, incluyendo t\u00edtulos de monograf\u00edas, declaraciones de disponibilidad de fortalezas, pruebas de identidad y polimorfismo.\n\n2. **Estandarizaci\u00f3n de t\u00edtulos de monograf\u00edas**: Se acord\u00f3 que las monograf\u00edas m\u00e1s recientes deber\u00edan seguir un enfoque estandarizado en la titulaci\u00f3n, utilizando el nombre m\u00e1s corto posible del principio activo (API) para facilitar el etiquetado no propietario y la prescripci\u00f3n gen\u00e9rica.\n\n3. **Propuestas de cambios en monograf\u00edas**: El Comit\u00e9 aprob\u00f3 propuestas para cambios en los t\u00edtulos de las monograf\u00edas publicadas, enfatizando la importancia de la claridad y la consistencia en la nomenclatura de los productos farmac\u00e9uticos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1l es el enfoque estandarizado acordado por el Comit\u00e9 de Expertos para la titulaci\u00f3n de las monograf\u00edas en la Farmacopea Internacional?**\n   - El enfoque estandarizado consiste en utilizar el t\u00edtulo m\u00e1s corto posible que proporcione informaci\u00f3n clara y no ambigua sobre la naturaleza del principio activo (API), omitiendo el nombre de la sal siempre que sea posible.\n\n2. **\u00bfQu\u00e9 ejemplos de t\u00edtulos de monograf\u00edas se presentaron al Comit\u00e9 de Expertos para ilustrar el enfoque estandarizado?**\n   - Los ejemplos presentados incluyen: Indinavir c\u00e1psulas (API \u2014 indinavir sulfate), Saquinavir tabletas (API \u2014 saquinavir mesilate), Tenofovir tabletas (API \u2014 tenofovir disoproxil fumarate) y Amikacin inyecci\u00f3n (API \u2014 amikacin sulfate).\n\n3. **\u00bfQu\u00e9 se acord\u00f3 respecto a la disponibilidad de documentos de orientaci\u00f3n y textos explicativos para el desarrollo de nuevas monograf\u00edas?**\n   - Se acord\u00f3 que los documentos de orientaci\u00f3n y textos explicativos ser\u00edan \u00fatiles para aquellos involucrados en el desarrollo de nuevas y revisadas monograf\u00edas, y se propuso que estos documentos se hicieran m\u00e1s accesibles a trav\u00e9s de la secci\u00f3n de informaci\u00f3n suplementaria de la Farmacopea y en el sitio web de Medicamentos de la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Revisi\u00f3n de Monograf\u00edas de Heparina**:\n   - La Comisi\u00f3n de Expertos de la OMS decidi\u00f3 en octubre de 2008 revisar las monograf\u00edas de Heparina para alinearlas con otras farmacopeas.\n   - Se discuti\u00f3 la necesidad de revisar las monograf\u00edas en una consulta informal en junio de 2009.\n\n2. **M\u00e9todo Propuesto para An\u00e1lisis de Heparina**:\n   - Se recomend\u00f3 investigar un m\u00e9todo de electroforesis en placa de acetato de celulosa para el an\u00e1lisis de heparina y sus impurezas.\n   - Este m\u00e9todo es altamente selectivo para impurezas heparinoides y puede ser realizado con instrumentaci\u00f3n de bajo costo, lo que lo hace accesible para peque\u00f1os laboratorios de control de calidad.\n\n3. **Colaboraci\u00f3n de la OMS**:\n   - La Secretar\u00eda de la OMS colaborar\u00e1 con un laboratorio colaborador para revisar la idoneidad del m\u00e9todo propuesto y circular propuestas revisadas de las monograf\u00edas de Heparina para comentarios.\n\n4. **Revisi\u00f3n de Monograf\u00edas Generales de Formas de Dosificaci\u00f3n**:\n   - En 2007, se acord\u00f3 revisar las monograf\u00edas generales publicadas en el Volumen 2 de *The International Pharmacopoeia*.\n   - Se discuti\u00f3 una revisi\u00f3n de la monograf\u00eda de tabletas en junio de 2009, y se recomend\u00f3 realizar una revisi\u00f3n similar para la monograf\u00eda de c\u00e1psulas.\n   - Las monograf\u00edas revisadas fueron adoptadas, sujetas a cambios acordados basados en comentarios de la consulta p\u00fablica.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la revisi\u00f3n y establecimiento de est\u00e1ndares farmac\u00e9uticos.\n- **Heparina**: Anticoagulante cuyo an\u00e1lisis y monograf\u00edas est\u00e1n siendo revisados.\n- **Electroforesis en placa de acetato de celulosa**: M\u00e9todo propuesto para el an\u00e1lisis de heparina.\n- **Monograf\u00edas de Formas de Dosificaci\u00f3n**: Incluyen las de tabletas y c\u00e1psulas, que est\u00e1n siendo revisadas y actualizadas.", "excerpt_keywords": "Keywords: pharmacopoeia, monographs, standardization, active pharmaceutical ingredient, WHO"}}, "700c8bcd-c2f6-4aaf-ba88-e1038a238807": {"node_ids": ["8e0fc01d-8be2-47ed-9481-91c724e6e35d"], "metadata": {"page_label": "45", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "was revised for technical reasons or on publication of a new edition. At such a time, where necessary, the heading Definition would be added together with a statement clarifying the nature of the API used in preparing the dosage form and the Labelling statement would be checked for consistency.\n\n## Strengths\n\nHow the strength was stated in monographs, and hence the terms in which the content was calculated, was dictated by how products available on the market were labelled. The Committee agreed that having established how the content was declared on the label by the manufacturer and having included in monographs an appropriate labelling statement, where necessary, the content statement under Definition, the calculation under Assay and the amounts of the preparation taken for testing should all be expressed in the same way.\n\nIt was noted, however, that problems could arise when product labelling was not clear or where there were inconsistencies between products available on the market. Although it was recognized that neither pharmacopoeial authorities nor WHO had control over product labelling and that this would fall within the responsibility of MRAs, the Committee was informed that a document gathering proposals concerning dosage form terminology and expression of medicine strength was presented by QSM to the Expert Committee for the Selection and Use of Essential Medicines for discussion at its meeting in March 2009.\n\nThe Expert Committee welcomed this initiative and was pleased to note that the Expert Committee for the Selection and Use of Essential Medicines broadly endorsed the QSM proposals. As a consequence, the expanded explanatory notes included in the sixteenth WHO Model List of Essential Medicines and in the second WHO Model List of Essential Medicines for Children now included:\n\n- a link to the Quality assurance area of the WHO Medicines web site and to the online text of the current edition of the Ph.Int.; and\n- an annex on dosage form terminology.\n\nThe Expert Committee for the Selection and Use of Essential Medicines agreed the principles that would be applied to the expression of medicines strengths in future lists and had requested its Secretariat to review current entries and revise them accordingly. These principles were set out in the corresponding Report of the Expert Committee for the Selection and Use of Essential Medicines. WHO Technical Report Series, No. 958, 2010 (in print) as follows.\n\nWhen revised in accordance with these principles, entries where the active pharmaceutical substance is not the active moiety will more clearly distinguish between:", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Preguntas\n\n1. **\u00bfCu\u00e1les son los problemas que pueden surgir debido a la falta de claridad en el etiquetado de los productos farmac\u00e9uticos?**\n   - La falta de claridad en el etiquetado puede llevar a inconsistencias entre los productos disponibles en el mercado, lo que dificulta la correcta interpretaci\u00f3n de la fuerza y el contenido de los medicamentos. Esto puede resultar en confusiones para los profesionales de la salud y los pacientes, afectando la seguridad y eficacia del tratamiento.\n\n2. **\u00bfQu\u00e9 iniciativas se tomaron en respuesta a las propuestas de QSM sobre la terminolog\u00eda de formas de dosificaci\u00f3n y la expresi\u00f3n de la fuerza de los medicamentos?**\n   - La iniciativa presentada por QSM fue bien recibida por el Comit\u00e9 de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales, que la respald\u00f3. Como resultado, se incluyeron notas explicativas ampliadas en la lista de medicamentos esenciales de la OMS, as\u00ed como un anexo sobre la terminolog\u00eda de formas de dosificaci\u00f3n, y se establecieron principios para la expresi\u00f3n de la fuerza de los medicamentos en futuras listas.\n\n3. **\u00bfQu\u00e9 acciones se solicitaron al Secretariado del Comit\u00e9 de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales?**\n   - Se solicit\u00f3 al Secretariado que revisara las entradas actuales en las listas de medicamentos y las revisara de acuerdo con los principios acordados para la expresi\u00f3n de las fuerzas de los medicamentos, asegurando as\u00ed una mayor claridad y consistencia en la informaci\u00f3n presentada.\n\n### Resumen de nivel superior\n\nEl contexto aborda la importancia de la claridad en el etiquetado de los productos farmac\u00e9uticos y c\u00f3mo esto afecta la declaraci\u00f3n de la fuerza y el contenido de los medicamentos. Se menciona que, aunque las autoridades farmacop\u00e9uticas y la OMS no tienen control sobre el etiquetado de los productos, se han tomado iniciativas para mejorar la terminolog\u00eda y la expresi\u00f3n de la fuerza de los medicamentos. Estas iniciativas fueron bien recibidas por el Comit\u00e9 de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales, que acord\u00f3 principios para la revisi\u00f3n y actualizaci\u00f3n de las listas de medicamentos esenciales.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Revisi\u00f3n de Monograf\u00edas**: El Comit\u00e9 de Expertos revis\u00f3 documentos relacionados con la pol\u00edtica farmacop\u00e9ica actual, enfoc\u00e1ndose en temas como t\u00edtulos de monograf\u00edas, declaraciones de disponibilidad de fortalezas, pruebas de identidad y polimorfismo.\n\n2. **Estandarizaci\u00f3n de T\u00edtulos**: Se acord\u00f3 un enfoque estandarizado para la titulaci\u00f3n de monograf\u00edas en *La Farmacopea Internacional*, que consiste en utilizar el t\u00edtulo m\u00e1s corto posible que proporcione informaci\u00f3n clara sobre el principio activo (API), omitiendo el nombre de la sal cuando sea posible.\n\n3. **Ejemplos de T\u00edtulos**: Se presentaron ejemplos de t\u00edtulos de monograf\u00edas que ilustran este enfoque estandarizado:\n   - Indinavir c\u00e1psulas (API \u2014 indinavir sulfate)\n   - Saquinavir tabletas (API \u2014 saquinavir mesilate)\n   - Tenofovir tabletas (API \u2014 tenofovir disoproxil fumarate)\n   - Amikacin inyecci\u00f3n (API \u2014 amikacin sulfate)\n\n4. **Documentos de Orientaci\u00f3n**: Se acord\u00f3 que los documentos de orientaci\u00f3n y textos explicativos ser\u00edan \u00fatiles para el desarrollo de nuevas y revisadas monograf\u00edas, y se propuso su disponibilidad en la secci\u00f3n de informaci\u00f3n suplementaria de la Farmacopea y en el sitio web de Medicamentos de la OMS.\n\n### Entidades Clave\n- **Comit\u00e9 de Expertos**: Grupo responsable de revisar y aprobar cambios en las monograf\u00edas.\n- **Farmacopea Internacional**: Documento que contiene est\u00e1ndares para medicamentos.\n- **Principio Activo (API)**: Sustancia activa en un medicamento.\n- **Monograf\u00edas**: Documentos que describen las especificaciones y m\u00e9todos de prueba para medicamentos.", "excerpt_keywords": "Keywords: pharmaceutical labeling, dosage form terminology, medicine strength, WHO Essential Medicines, pharmacopoeial standards"}}, "33e87ffe-8582-444e-ac41-074aaf786654": {"node_ids": ["d1a9e091-e658-41fd-92df-188519ad0fe5"], "metadata": {"page_label": "46", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- those for which the strength is expressed in terms of active moiety (the salt will be indicated in parentheses, e.g. \u201c50 mg (as sodium salt)\u201d); and\n- those for which the strength is expressed in terms of API (the salt will be given in full, e.g. \u201c50 mg codeine phosphate\u201d).\n\nWhere necessary, in instances of potential confusion (e.g. amodiaquine, quinine salts) a warning note will be included.\n\n## Strengths available statement\n\nMonographs in the Ph.Int. for individual dosage forms have included information concerning the strengths of preparations available, referring to \u201cthe current WHO Model List of Essential Medicines\u201d. For example, the monograph for Lamivudine tablets published in the first supplement stated:\n\n**Additional information.** Strengths in the current WHO Model List of Essential Medicines: 150 mg, 300 mg. Strength in the current WHO Model list of essential medicines for children: 150 mg.\n\nThis statement was based on information from the fifteenth Model List of Essential Medicines published in 2007. It was, however, noted in 2009 that for lamivudine the then current Model List included only the 150 mg tablets. This example, therefore, illustrated the problem of keeping the strengths available as indicated in Ph.Int. monographs in step with the current Model List of Essential Medicines.\n\nTo keep track of changes affecting Ph.Int. monographs each time a new Model List was published would require the user to check for changes frequently, and the Secretariat to continuously revise monographs to correct this non-mandatory information.\n\nThe Expert Committee, therefore, endorsed the recommendation that, for the next edition of *The International Pharmacopoeia*, individual monographs would simply include the strengths without the words \u201cin the current WHO Model List of Essential Medicines\u201d. It was agreed instead that the General notices would state that, in general, the strengths indicated under Additional information in individual monographs for dosage forms were those given in the Model Lists. In addition a recommendation could be included to consult the current edition of the Model List and provide a reference to the appropriate page of the WHO Medicines web site (as a link in the electronic version). This would also strengthen the links between the Ph.Int. and the WHO Model List of Essential Medicines (http://www.who.int/medicines/publications/essentialmedicines/en/index.html).\n\nUsing terms such as \u201cin general\u201d or \u201cwherever appropriate\u201d in the General notices would accommodate the small number of exceptions where a", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Preguntas\n\n1. **\u00bfCu\u00e1l es la raz\u00f3n principal por la que se decidi\u00f3 eliminar la frase \"en la lista actual de medicamentos esenciales de la OMS\" de las monograf\u00edas individuales en la pr\u00f3xima edici\u00f3n de *The International Pharmacopoeia*?**\n   - La decisi\u00f3n se tom\u00f3 para evitar la confusi\u00f3n y la necesidad de revisiones constantes de las monograf\u00edas, ya que las listas de medicamentos esenciales pueden cambiar con frecuencia. Esto simplifica el proceso y asegura que la informaci\u00f3n sea m\u00e1s f\u00e1cil de seguir para los usuarios.\n\n2. **\u00bfQu\u00e9 medidas se proponen para mantener la conexi\u00f3n entre las monograf\u00edas de la Ph.Int. y la lista de medicamentos esenciales de la OMS?**\n   - Se recomienda que las monograf\u00edas incluyan una referencia a consultar la edici\u00f3n actual de la lista de medicamentos esenciales, proporcionando un enlace a la p\u00e1gina web de la OMS. Esto fortalecer\u00eda la relaci\u00f3n entre ambas fuentes de informaci\u00f3n.\n\n3. **\u00bfC\u00f3mo se abordar\u00e1 la confusi\u00f3n potencial en la nomenclatura de las sales de ciertos medicamentos, como la amodiaquina y la quinina?**\n   - Se incluir\u00e1n notas de advertencia donde sea necesario para aclarar cualquier posible confusi\u00f3n relacionada con las sales de estos medicamentos en las monograf\u00edas.\n\n### Resumen de nivel superior\n\nEl contexto aborda la necesidad de actualizar las monograf\u00edas en *The International Pharmacopoeia* para reflejar de manera m\u00e1s precisa las fortalezas de los medicamentos, aline\u00e1ndolas con la lista de medicamentos esenciales de la OMS. Se destaca el problema de mantener la informaci\u00f3n actualizada y se propone eliminar referencias directas a la lista de medicamentos en las monograf\u00edas, sugiriendo en su lugar que los usuarios consulten la lista actualizada en el sitio web de la OMS. Adem\u00e1s, se menciona la inclusi\u00f3n de notas de advertencia para evitar confusiones en la nomenclatura de ciertos medicamentos.", "prev_section_summary": "### Temas Clave\n\n1. **Claridad en el Etiquetado de Productos Farmac\u00e9uticos**: La secci\u00f3n destaca la importancia de un etiquetado claro para evitar inconsistencias en la declaraci\u00f3n de la fuerza y el contenido de los medicamentos, lo que puede afectar la seguridad y eficacia del tratamiento.\n\n2. **Iniciativas de Mejora**: Se menciona la presentaci\u00f3n de propuestas por parte de QSM sobre la terminolog\u00eda de formas de dosificaci\u00f3n y la expresi\u00f3n de la fuerza de los medicamentos, que fueron bien recibidas por el Comit\u00e9 de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales.\n\n3. **Principios para la Expresi\u00f3n de Fuerzas de Medicamentos**: Se acordaron principios que se aplicar\u00e1n a la expresi\u00f3n de las fuerzas de los medicamentos en futuras listas, con el objetivo de mejorar la claridad y consistencia en la informaci\u00f3n presentada.\n\n4. **Revisi\u00f3n de Entradas Actuales**: Se solicit\u00f3 al Secretariado del Comit\u00e9 de Expertos que revisara y actualizara las entradas actuales en las listas de medicamentos de acuerdo con los nuevos principios acordados.\n\n### Entidades\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: La entidad responsable de la regulaci\u00f3n y estandarizaci\u00f3n de medicamentos a nivel internacional.\n- **QSM (Quality Safety and Standards)**: Grupo que present\u00f3 propuestas sobre terminolog\u00eda y expresi\u00f3n de fuerza de medicamentos.\n- **Comit\u00e9 de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales**: Grupo que revisa y aprueba las propuestas relacionadas con medicamentos esenciales.\n- **MRAs (Medicines Regulatory Authorities)**: Autoridades responsables del etiquetado de productos farmac\u00e9uticos, que no est\u00e1n bajo el control de la OMS.\n\n### Resumen\n\nLa secci\u00f3n aborda la necesidad de claridad en el etiquetado de productos farmac\u00e9uticos para asegurar la correcta interpretaci\u00f3n de la fuerza y el contenido de los medicamentos. Se mencionan iniciativas para mejorar la terminolog\u00eda y la expresi\u00f3n de la fuerza de los medicamentos, respaldadas por el Comit\u00e9 de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales. Adem\u00e1s, se establecieron principios para la revisi\u00f3n de las listas de medicamentos esenciales, con el fin de garantizar una mayor consistencia y claridad en la informaci\u00f3n presentada.", "excerpt_keywords": "Pharmacopoeia, Essential Medicines, Strengths, Monographs, WHO"}}, "90534af2-e0d8-49e2-bf46-26838d6d81d2": {"node_ids": ["aeebc430-b39f-4112-aac5-9a9378f8df5d"], "metadata": {"page_label": "47", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "preparation that was the subject of a monograph was not included in the current Model Lists. Such exceptions included:\n\n- certain preparations recommended by WHO treatment programmes and/or included in WHO treatment guidelines that were not in the Model Lists (e.g. paediatric didanosine oral liquid);\n- strengths additional to those in the Model List that had been indicated for similar reasons (e.g. 20 mg Zn strength for zinc sulfate tablets); and\n- monographs for products which had been or which might be removed from the Model Lists (e.g. stavudine capsules).\n\nIt was also emphasized that, unless restricted by the Definition to a particular strength, a monograph was intended to cover any strength. In this context it was noted that in certain tests (for example, dissolution) explicit reference to particular strengths might sometimes be necessary.\n\n## Identity test\n\nEditorial guidance on selection, order and possibility for subsidiary choice of identity tests was discussed.\n\nThe current approach, which is to use a combination of different methods within the monograph rather than placing reliance on a single method, was reemphasized. This was particularly important since the Ph.Int. monographs might be applied to material from different manufacturers and by quality control laboratories equipped with different instruments.\n\n## Polymorphism\n\nFor an API known to exist in more than one morphic form, the way to frame the monograph would depend on whether or not it was restricted to a particular polymorph.\n\nIn most cases it was intended that the monograph place no restriction on morphic form. A statement had been included under Additional information to the effect that the substance \u201cmay exhibit polymorphism\u201d. In such cases, where an infrared identity test had been included, appropriate instructions were given on how to proceed (see, e.g. the monograph for Efavirenz). Without such instructions the monograph was, in effect, restricting the substance to the morphic form of the ICRS.\n\n## 3.7 Radiopharmaceuticals\n\nWork on the elaboration of specifications for radiopharmaceuticals was initiated in 2001, with the collaboration of WHO and the International Atomic Energy Agency (IAEA). Following consultations and discussion involving experts from both organizations, agreement was reached that this work would include inter alia the revision of the general monograph in *The International Pharmacopoeia*.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto se centra en la elaboraci\u00f3n de monograf\u00edas para preparaciones farmac\u00e9uticas, destacando excepciones a las listas de modelos de la OMS, la importancia de realizar pruebas de identidad utilizando m\u00faltiples m\u00e9todos, y el manejo de la polimorf\u00eda en sustancias activas. Tambi\u00e9n se menciona el trabajo en curso sobre especificaciones para radiopharmaceuticals, en colaboraci\u00f3n con la Agencia Internacional de Energ\u00eda At\u00f3mica (IAEA).\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de preparaciones farmac\u00e9uticas se excluyen de las listas de modelos de la OMS y por qu\u00e9?**\n   - Respuesta: Se excluyen ciertas preparaciones recomendadas por programas de tratamiento de la OMS, como el didanosina oral l\u00edquida pedi\u00e1trica, as\u00ed como fortalezas adicionales y monograf\u00edas de productos que han sido o podr\u00edan ser eliminados de las listas de modelos.\n\n2. **\u00bfCu\u00e1l es la importancia de utilizar m\u00faltiples m\u00e9todos en las pruebas de identidad seg\u00fan el texto?**\n   - Respuesta: La importancia radica en que las monograf\u00edas de la Farmacopea Internacional pueden aplicarse a materiales de diferentes fabricantes y ser utilizadas por laboratorios de control de calidad que disponen de diferentes instrumentos, lo que requiere un enfoque m\u00e1s robusto que depender de un solo m\u00e9todo.\n\n3. **\u00bfC\u00f3mo se aborda la polimorf\u00eda en las monograf\u00edas de sustancias activas?**\n   - Respuesta: En la mayor\u00eda de los casos, las monograf\u00edas no restringen la forma morfol\u00f3gica de la sustancia, y se incluye una declaraci\u00f3n que indica que la sustancia \"puede exhibir polimorfismo\". Se proporcionan instrucciones espec\u00edficas en casos donde se incluye una prueba de identidad por infrarrojos.\n\n### Resumen de Nivel Superior\n\nEl documento discute la elaboraci\u00f3n de monograf\u00edas para preparaciones farmac\u00e9uticas, subrayando excepciones a las listas de modelos de la OMS, la necesidad de pruebas de identidad diversificadas, y el tratamiento de la polimorf\u00eda en sustancias activas. Tambi\u00e9n se menciona la colaboraci\u00f3n entre la OMS y la IAEA para desarrollar especificaciones para radiopharmaceuticals.", "prev_section_summary": "### Temas Clave\n\n1. **Fortalezas de los Medicamentos**: Se discute c\u00f3mo se expresan las fortalezas de los medicamentos en las monograf\u00edas, diferenciando entre aquellas que se indican en t\u00e9rminos de la moiety activa y aquellas que se expresan en t\u00e9rminos del principio activo (API).\n\n2. **Actualizaci\u00f3n de Monograf\u00edas**: Se aborda la necesidad de mantener actualizadas las monograf\u00edas de *The International Pharmacopoeia* en relaci\u00f3n con la lista de medicamentos esenciales de la OMS, destacando los desaf\u00edos de sincronizar la informaci\u00f3n.\n\n3. **Eliminaci\u00f3n de Frases Confusas**: Se propone eliminar la frase \"en la lista actual de medicamentos esenciales de la OMS\" de las monograf\u00edas para simplificar la informaci\u00f3n y evitar confusiones.\n\n4. **Referencias a la Lista de Medicamentos Esenciales**: Se sugiere que las monograf\u00edas incluyan una recomendaci\u00f3n para consultar la lista actualizada de medicamentos esenciales en el sitio web de la OMS, fortaleciendo as\u00ed la conexi\u00f3n entre ambas fuentes.\n\n5. **Notas de Advertencia**: Se menciona la inclusi\u00f3n de notas de advertencia en casos de potencial confusi\u00f3n, como con las sales de amodiaquina y quinina.\n\n### Entidades\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la publicaci\u00f3n de la lista de medicamentos esenciales y de las monograf\u00edas en *The International Pharmacopoeia*.\n- **Ph.Int. (Farmacopea Internacional)**: Referencia a la Farmacopea Internacional que contiene monograf\u00edas de medicamentos.\n- **Lamivudina**: Ejemplo espec\u00edfico de un medicamento mencionado en el contexto de las fortalezas disponibles.\n- **Modelo de Lista de Medicamentos Esenciales**: Documento que enumera los medicamentos esenciales recomendados por la OMS.\n\n### Resumen\n\nLa secci\u00f3n aborda la necesidad de actualizar las monograf\u00edas en *The International Pharmacopoeia* para reflejar con precisi\u00f3n las fortalezas de los medicamentos, aline\u00e1ndolas con la lista de medicamentos esenciales de la OMS. Se propone eliminar referencias directas a la lista en las monograf\u00edas para simplificar la informaci\u00f3n y se sugiere que los usuarios consulten la lista actualizada en el sitio web de la OMS. Adem\u00e1s, se menciona la inclusi\u00f3n de notas de advertencia para evitar confusiones en la nomenclatura de ciertos medicamentos.", "excerpt_keywords": "Keywords: monographs, WHO, polymorphism, identity tests, radiopharmaceuticals"}}, "0ea91eb0-bb6d-46c6-9aea-717ffa55a5ae": {"node_ids": ["fb96bb01-a277-423a-997d-024afc16c7d8"], "metadata": {"page_label": "48", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "and the elaboration of 30 monographs for individual radiopharmaceuticals preparations, to which IAEA had awarded priority in 2005.\n\nBackground information on the development of these monographs was presented to the Expert Committee in October 2008 and was described in the forty-third report.\n\nAs a result of this joint work, the final versions of the following texts adopted in October 2008 were made available on *The International Pharmacopoeia\u2013Radiopharmaceuticals* page of the WHO Medicines web site.\n\n### General monograph and related texts\n- General monograph\n- Methods of analysis\n- Supplementary information\n\n### Individual monographs\n- Fludeoxyglucose (\u00b9\u2078F) injection\n- Gallium citrate (\u2076\u2077Ga) injection\n- Iobenguane (\u00b9\u00b2\u00b3I) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) solution\n- Sodium Pertechnetate (\u2079\u2079\u1d50Tc) injection (fission)\n- Sodium pertechnetate (\u2079\u2079\u1d50Tc) injection (non-fission)\n- Technetium (\u2079\u2079\u1d50Tc) pentetate complex injection\n- Thallous chloride (\u00b2\u2070\u00b9Tl) injection\n\nConsidering the extensive work already carried out and the need for specifications in *The International Pharmacopoeia* for these pharmaceutical preparations, the 20 remaining monographs (see the list below) were also adopted subject to final scrutiny of the reformatted texts by a small working group composed of experts from both the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and IAEA.\n\nTo undertake the editorial work needed to bring the remaining texts in line with those already published on the web site, the Secretariat had agreed with IAEA that the scrutiny would be carried out by the working group by correspondence, following a defined procedure.\n\nDraft monographs for the following substances were sent to the working group in two series of about 10 texts for review:\n- Iobenguane (\u00b9\u00b3\u00b9I) injection\n- Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm) injection\n- Sodium iodide (\u00b9\u00b3\u00b9I) capsules\n- Sodium iothalamate (\u00b9\u00b2\u2075I) injection", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen de nivel superior del contexto\n\nEl documento se centra en la elaboraci\u00f3n de monograf\u00edas para preparaciones de radiopharmaceuticals, un trabajo conjunto entre la Organizaci\u00f3n Mundial de la Salud (OMS) y la Agencia Internacional de Energ\u00eda At\u00f3mica (IAEA). En octubre de 2008, se adoptaron varias monograf\u00edas y textos relacionados, que se publicaron en la p\u00e1gina de *La Farmacopea Internacional\u2013Radiopharmaceuticals* del sitio web de la OMS. Se menciona la necesidad de especificaciones para estas preparaciones y se detalla un proceso de revisi\u00f3n para 20 monograf\u00edas restantes, que incluye la participaci\u00f3n de un grupo de trabajo de expertos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios que llevaron a la selecci\u00f3n de los 30 radiopharmaceuticals para la elaboraci\u00f3n de monograf\u00edas en 2005?**\n   - Esta pregunta busca informaci\u00f3n sobre los criterios espec\u00edficos utilizados por la IAEA para priorizar ciertos radiopharmaceuticals en el desarrollo de monograf\u00edas.\n\n2. **\u00bfQu\u00e9 procedimientos espec\u00edficos se establecieron para la revisi\u00f3n de las monograf\u00edas restantes por parte del grupo de trabajo?**\n   - Esta pregunta se centra en los detalles del proceso editorial acordado entre la OMS y la IAEA, que no se mencionan expl\u00edcitamente en el texto.\n\n3. **\u00bfQu\u00e9 impacto se espera que tenga la adopci\u00f3n de estas monograf\u00edas en la pr\u00e1ctica cl\u00ednica y la regulaci\u00f3n de los radiopharmaceuticals?**\n   - Esta pregunta busca explorar las implicaciones pr\u00e1cticas y regulatorias de la adopci\u00f3n de estas monograf\u00edas, un aspecto que no se aborda directamente en el contexto proporcionado.", "prev_section_summary": "### Temas Clave\n\n1. **Excepciones a las Listas de Modelos de la OMS**: Se discuten preparaciones farmac\u00e9uticas que no est\u00e1n incluidas en las listas de modelos, como ciertas formulaciones recomendadas por la OMS y monograf\u00edas de productos que han sido o podr\u00edan ser eliminados.\n\n2. **Pruebas de Identidad**: Se enfatiza la importancia de utilizar m\u00faltiples m\u00e9todos para las pruebas de identidad en lugar de depender de un solo m\u00e9todo, dado que las monograf\u00edas pueden aplicarse a materiales de diferentes fabricantes.\n\n3. **Polimorfismo**: Se aborda c\u00f3mo las monograf\u00edas tratan el polimorfismo de las sustancias activas, indicando que generalmente no se restringe la forma morfol\u00f3gica y se proporciona informaci\u00f3n sobre la posibilidad de polimorfismo.\n\n4. **Radiopharmaceuticals**: Se menciona el trabajo en curso para desarrollar especificaciones para radiopharmaceuticals, en colaboraci\u00f3n con la Agencia Internacional de Energ\u00eda At\u00f3mica (IAEA).\n\n### Entidades\n\n- **Organizaciones**: \n  - Organizaci\u00f3n Mundial de la Salud (OMS)\n  - Agencia Internacional de Energ\u00eda At\u00f3mica (IAEA)\n\n- **Sustancias y Preparaciones**:\n  - Didanosina oral l\u00edquida pedi\u00e1trica\n  - Sulfato de zinc (20 mg)\n  - C\u00e1psulas de estavudina\n  - Efavirenz\n\n- **Documentos**:\n  - *The International Pharmacopoeia*\n\nEste resumen destaca los aspectos m\u00e1s relevantes de la secci\u00f3n, incluyendo las excepciones a las listas de la OMS, la metodolog\u00eda de pruebas de identidad, el manejo del polimorfismo y la colaboraci\u00f3n en el desarrollo de especificaciones para radiopharmaceuticals.", "excerpt_keywords": "Keywords: radiopharmaceuticals, monographs, WHO, IAEA, International Pharmacopoeia"}}, "8e9b646b-c1bc-4491-98b1-eafae0cef6a7": {"node_ids": ["01f4bd62-8d7a-438f-8f2f-e485775da3b2"], "metadata": {"page_label": "49", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 Sodium phosphate (\u00b3\u00b2P) injection  \n\u2014 Strontium chloride (\u2078\u2079Sr) injection  \n\u2014 Technetium (\u2079\u2079mTc) bicisate complex injection  \n\u2014 Technetium (\u2079\u2079mTc) exametazime complex injection  \n\u2014 Technetium (\u2079\u2079mTc) mebrofenin complex injection  \n\u2014 Technetium (\u2079\u2079mTc) mertiatide injection  \n\u2014 Technetium (\u2079\u2079mTc) succimer complex injection  \n\u2014 Technetium (\u2079\u2079mTc) sulfur colloid injection  \n\u2014 Technetium (\u2079\u2079mTc) tetrofosmin complex injection  \n\u2014 Technetium (\u2079\u2079mTc) tin colloidal injection  \n\u2014 Technetium(\u2079\u2079mTc) pyrophosphate tin complex injection  \n\u2014 Technetium(\u2079\u2079mTc) methylene diphosphonate (MDP) complex injection  \n\u2014 Technetium(\u2079\u2079mTc) sestamibi complex injection  \n\u2014 Yttrium silicate (\u2079\u2070Y) colloid injection  \n\u2014 Technetium (\u2079\u2079mTc) labelled Macrosalb (\u2079\u2079mTc MAA) injection*  \n\u2014 Technetium (\u2079\u2079mTc) nanocolloid injection*  \n\n* Regarding the monographs for technetium (\u2079\u2079mTc) nanocolloid injection and technetium (\u2079\u2079mTc) labelled macrosalb (\u2079\u2079mTc MAA) injection, the Committee referred to its decision taken in October 2008 for technetium (\u2079\u2079mTc) labelled red blood cells injection, when it had been decided that the quality specifications for this type of blood product or derivative, not covered by the Ph.Int., would normally be the responsibility of the WHO Expert Committee on Biological Standardization or would be dealt with through the Blood Regulators Network for which WHO provided the Secretariat. Therefore, it was recommended that the quality specifications for these three biological products derived from albumin be dealt with by the above-mentioned committees.\n\nThe comments received thereon were discussed at the informal consultation on specifications for medicines and quality control laboratory issues in June 2009. Revised texts, reflecting the comments confirmed by IAEA, were presented to the Expert Committee for information.\n\nWhile formatting and reviewing these remaining texts, it was decided that, for the purposes of consistency, some changes needed to be made to all the individual monographs, including to the texts already published on the web site. Revised drafts for those texts were also presented to the Expert Committee for information.\n\nThe Expert Committee noted with appreciation the completion of this work and endorsed the reformatted monographs prepared following the recommendations made in 2008. It further agreed that those final texts be placed on The International Pharmacopoeia\u2013Radiopharmaceuticals page of the WHO Medicines web site, bringing the number of new individual monographs for radiopharmaceutical preparations for inclusion in the Fourth Edition of The International Pharmacopoeia to 27.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen de Nivel Superior\n\nEl documento de la OMS (WHO - Technical Report Series 957) presenta una lista de inyecciones de radiotrazadores, incluyendo varios compuestos de tecn\u00e9cio (\u2079\u2079mTc) y otros is\u00f3topos radiactivos. Se menciona que, para ciertos productos biol\u00f3gicos derivados de la alb\u00famina, las especificaciones de calidad son responsabilidad de comit\u00e9s espec\u00edficos de la OMS. Adem\u00e1s, se discuten las revisiones y la estandarizaci\u00f3n de los textos de las monograf\u00edas, que fueron aprobadas por el Comit\u00e9 de Expertos y se incluir\u00e1n en la Cuarta Edici\u00f3n de la Farmacopea Internacional.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 decisiones se tomaron en octubre de 2008 respecto a las especificaciones de calidad para inyecciones de productos sangu\u00edneos, y c\u00f3mo se relacionan con las inyecciones de tecn\u00e9cio (\u2079\u2079mTc) mencionadas en el documento?**\n   - Respuesta: En octubre de 2008, se decidi\u00f3 que las especificaciones de calidad para inyecciones de productos sangu\u00edneos o derivados, no cubiertos por la Farmacopea Internacional, ser\u00edan responsabilidad del Comit\u00e9 de Expertos de la OMS en Estandarizaci\u00f3n Biol\u00f3gica o se tratar\u00edan a trav\u00e9s de la Red de Reguladores de Sangre, con la OMS proporcionando la Secretar\u00eda. Esto se aplica tambi\u00e9n a las inyecciones de tecn\u00e9cio (\u2079\u2079mTc) nanocolloid y tecn\u00e9cio (\u2079\u2079mTc) etiquetado con Macrosalb.\n\n2. **\u00bfCu\u00e1ntas nuevas monograf\u00edas de preparaciones radiofarmac\u00e9uticas se incluir\u00e1n en la Cuarta Edici\u00f3n de la Farmacopea Internacional, seg\u00fan el documento?**\n   - Respuesta: Se acord\u00f3 que el n\u00famero de nuevas monograf\u00edas para preparaciones radiofarmac\u00e9uticas que se incluir\u00e1n en la Cuarta Edici\u00f3n de la Farmacopea Internacional ser\u00e1 de 27.\n\n3. **\u00bfQu\u00e9 cambios se realizaron en las monograf\u00edas individuales durante el proceso de revisi\u00f3n y por qu\u00e9 fueron necesarios?**\n   - Respuesta: Durante el proceso de revisi\u00f3n, se decidieron cambios en las monograf\u00edas individuales para asegurar la consistencia en los textos. Esto incluy\u00f3 la revisi\u00f3n de textos ya publicados en el sitio web, y se presentaron borradores revisados al Comit\u00e9 de Expertos para su informaci\u00f3n.\n\nEstas preguntas y respuestas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar f\u00e1cilmente disponible en otros documentos o fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Colaboraci\u00f3n entre Organizaciones**: El documento destaca la colaboraci\u00f3n entre la Organizaci\u00f3n Mundial de la Salud (OMS) y la Agencia Internacional de Energ\u00eda At\u00f3mica (IAEA) en la elaboraci\u00f3n de monograf\u00edas para preparaciones de radiopharmaceuticals.\n\n2. **Monograf\u00edas Adoptadas**: En octubre de 2008, se adoptaron varias monograf\u00edas y textos relacionados que fueron publicados en la p\u00e1gina de *La Farmacopea Internacional\u2013Radiopharmaceuticals* del sitio web de la OMS. Esto incluye una monograf\u00eda general, m\u00e9todos de an\u00e1lisis y textos suplementarios.\n\n3. **Lista de Monograf\u00edas Individuales**: Se mencionan varias monograf\u00edas individuales adoptadas, incluyendo:\n   - Fludeoxyglucose (\u00b9\u2078F) injection\n   - Gallium citrate (\u2076\u2077Ga) injection\n   - Iobenguane (\u00b9\u00b2\u00b3I) injection\n   - Sodium iodide (\u00b9\u00b3\u00b9I) injection\n   - Sodium Pertechnetate (\u2079\u2079\u1d50Tc) injection (fission y non-fission)\n   - Technetium (\u2079\u2079\u1d50Tc) pentetate complex injection\n   - Thallous chloride (\u00b2\u2070\u00b9Tl) injection\n\n4. **Monograf\u00edas Restantes**: Se identificaron 20 monograf\u00edas restantes que tambi\u00e9n fueron adoptadas, sujetas a revisi\u00f3n final por un grupo de trabajo de expertos de la OMS y la IAEA.\n\n5. **Proceso de Revisi\u00f3n**: Se acord\u00f3 que la revisi\u00f3n de las monograf\u00edas restantes se llevar\u00eda a cabo por correspondencia, siguiendo un procedimiento definido, con el env\u00edo de borradores en dos series para su revisi\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Agencia Internacional de Energ\u00eda At\u00f3mica (IAEA)**\n- **Radiopharmaceuticals**\n- **Expert Committee**\n- **Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations**\n\nEste resumen encapsula los aspectos fundamentales del contenido, incluyendo la colaboraci\u00f3n entre organizaciones, las monograf\u00edas adoptadas y el proceso de revisi\u00f3n para las monograf\u00edas restantes.", "excerpt_keywords": "Keywords: radiopharmaceuticals, technetium, quality specifications, WHO, International Pharmacopoeia"}}, "85ca4664-fa8b-405b-b683-eb20d07cfeb2": {"node_ids": ["be7c3692-ab40-4f95-b49d-12712f43dd2b"], "metadata": {"page_label": "50", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4. Quality control \u2014 international reference materials (International Chemical Reference Substances and International Infrared Reference Spectra)\n\n## 4.1 Annual report of the WHO Collaborating Centre\n\nThe Expert Committee noted with appreciation the work carried out by the WHO Collaborating Centre for Chemical Reference Substances as presented in its report for 2008. It was noted that the total number of International Chemical Reference Substances (ICRS) distributed from the Centre in 2008 was 2153 compared to the 2332 reported in 2007. The most frequently requested substances included artesunate, artemether, prednisolone, artemisinin and zidovudine impurity B.\n\nThe Expert Committee adopted the report for 2008.\n\n## 4.2 Adoption of new International Chemical Reference Substances\n\nNine ICRS were established in 2008, including the following seven new substances:\n\n- carbidopa\n- colchicine\n- lumefantrine\n- DL-methionine\n- naloxone hydrochloride\n- oseltamivir for system suitability\n- oseltamivir phosphate\n\nand the following replacements:\n\n- artemisinin\n- prednisone\n\nThe Expert Committee adopted the above-listed ICRS.\n\n## 4.3 New institution for the establishment of international reference materials\n\nWhile adopting its activities report for 2008, the Expert Committee was also informed that, since May 2009, Apoteket AB in Sweden had ceased its activities as host of the WHO Collaborating Centre for Chemical Reference Substances and that these activities were in the process of being transferred to a new institution.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento se centra en el control de calidad de los materiales de referencia internacionales, espec\u00edficamente los Sustancias Qu\u00edmicas de Referencia Internacional (ICRS) y los Espectros Infrarrojos de Referencia Internacional. En 2008, el Centro Colaborador de la OMS para Sustancias Qu\u00edmicas de Referencia distribuy\u00f3 2153 ICRS, con una disminuci\u00f3n en comparaci\u00f3n con el a\u00f1o anterior. Se adoptaron nuevos ICRS, incluyendo siete sustancias nuevas y dos reemplazos. Adem\u00e1s, se inform\u00f3 sobre la transferencia de actividades del centro a una nueva instituci\u00f3n tras el cese de operaciones de Apoteket AB en Suecia.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les fueron las sustancias qu\u00edmicas m\u00e1s solicitadas en 2008 y c\u00f3mo se comparan con las del a\u00f1o anterior?**\n   - Respuesta: Las sustancias m\u00e1s solicitadas en 2008 fueron artesunate, artemether, prednisolone, artemisinin y zidovudine impurity B. En 2007, se distribuyeron 2332 ICRS, lo que indica una disminuci\u00f3n en la demanda en 2008.\n\n2. **\u00bfQu\u00e9 nuevas sustancias qu\u00edmicas fueron adoptadas como ICRS en 2008 y cu\u00e1les fueron los reemplazos?**\n   - Respuesta: En 2008, se adoptaron siete nuevas sustancias: carbidopa, colchicine, lumefantrine, DL-methionine, naloxone hydrochloride, oseltamivir para sistema de idoneidad y oseltamivir phosphate. Los reemplazos fueron artemisinin y prednisone.\n\n3. **\u00bfQu\u00e9 cambios se produjeron en la gesti\u00f3n del Centro Colaborador de la OMS para Sustancias Qu\u00edmicas de Referencia en 2009?**\n   - Respuesta: Desde mayo de 2009, Apoteket AB en Suecia dej\u00f3 de ser el anfitri\u00f3n del Centro Colaborador de la OMS para Sustancias Qu\u00edmicas de Referencia, y las actividades del centro estaban en proceso de ser transferidas a una nueva instituci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Inyecciones de Radiotrazadores**: Se presenta una lista de inyecciones que incluyen varios compuestos de tecn\u00e9cio (\u2079\u2079mTc) y otros is\u00f3topos radiactivos, como el fosfato s\u00f3dico (\u00b3\u00b2P) y el cloruro de estroncio (\u2078\u2079Sr).\n\n2. **Especificaciones de Calidad**: Se discute la responsabilidad de las especificaciones de calidad para ciertos productos biol\u00f3gicos derivados de la alb\u00famina, que recaen en comit\u00e9s espec\u00edficos de la OMS, como el Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica y la Red de Reguladores de Sangre.\n\n3. **Revisi\u00f3n y Estandarizaci\u00f3n de Monograf\u00edas**: Se menciona el proceso de revisi\u00f3n y estandarizaci\u00f3n de los textos de las monograf\u00edas, que fueron aprobados por el Comit\u00e9 de Expertos y se incluir\u00e1n en la Cuarta Edici\u00f3n de la Farmacopea Internacional.\n\n4. **N\u00famero de Nuevas Monograf\u00edas**: Se establece que se incluir\u00e1n 27 nuevas monograf\u00edas para preparaciones radiofarmac\u00e9uticas en la Cuarta Edici\u00f3n de la Farmacopea Internacional.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la estandarizaci\u00f3n y regulaci\u00f3n de productos de salud.\n- **Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica**: Comit\u00e9 que se encarga de las especificaciones de calidad de productos biol\u00f3gicos.\n- **Red de Reguladores de Sangre**: Grupo que colabora en la regulaci\u00f3n de productos sangu\u00edneos.\n- **Agencia Internacional de Energ\u00eda At\u00f3mica (IAEA)**: Organizaci\u00f3n que proporciona comentarios y validaciones en el proceso de revisi\u00f3n de monograf\u00edas.\n- **Farmacopea Internacional**: Publicaci\u00f3n que compila est\u00e1ndares de calidad para medicamentos y productos farmac\u00e9uticos.\n\nEste resumen destaca los puntos m\u00e1s relevantes y las entidades involucradas en el contexto de las inyecciones de radiotrazadores y su regulaci\u00f3n.", "excerpt_keywords": "Keywords: quality control, international reference materials, chemical reference substances, WHO Collaborating Centre, adoption of substances"}}, "70145112-d36c-4552-ad20-88d70809a911": {"node_ids": ["3ab063c6-b434-4453-ac75-69fb0dc6572c"], "metadata": {"page_label": "51", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "It was emphasized with appreciation that Apoteket AB had started its collaboration with WHO and specifically *The International Pharmacopoeia* in 1956. In recognition of Apoteket AB\u2019s longstanding services to WHO, the Expert Committee expressed its gratitude to the WHO Collaborating Centre on Chemical Reference Substances and to the Government of Sweden which had supported these activities over the past 53 years.\n\nRecognizing the inconvenience caused by this transition from the former Collaborating Centre to the new institution, notably for the distribution of ICRS, the Expert Committee welcomed the announcements posted on the WHO Medicines web site to inform users during this transitional period. As this process was nearing finalization, another announcement indicating the new contact details for ordering ICRS was soon expected to be published.\n\nAs regards the new institution, the Committee made some proposals on the content of the future activity report and encouraged the possibility of reflecting in more detail certain activities such as the stability monitoring of ICRS. The Expert Committee also welcomed the future efforts of the Secretariat in assisting the new institution with regard to collaborative trials to identify any additional laboratories for the establishment of new ICRS. Pricing for the distribution of ICRS was also discussed and the Expert Committee was informed that owing to the change of currency with which the new institution would operate, the price of the ICRS would need to be adjusted. It, therefore, agreed that the price, which had not been changed over the past decade, be increased.\n\nThe Committee stated that it would look forward to receiving annual reports on work carried out on ICRS from the new institution.\n\n# 5. Quality control \u2014 national laboratories\n\n## 5.1 External Quality Assurance Assessment Scheme\n\nThe External Quality Assurance Assessment Scheme (EQAAS) aimed to give each laboratory the opportunity to measure its performance through a confidential system of testing of blind samples and to determine its ability to perform a given analytical procedure within a network of governmental control laboratories. The system was aimed at reinforcing mutual confidence within this network.\n\nWith a view to continuing the promotion of quality assurance in drug quality control laboratories in WHO Member States, five test series of Phase 4 of a proficiency testing scheme had taken place. Some 50 laboratories had participated in this phase of the Scheme, which was now finalized.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Colaboraci\u00f3n de Apoteket AB con la OMS**: Apoteket AB ha colaborado con la OMS desde 1956, contribuyendo significativamente a *La Farmacopea Internacional*. La OMS ha expresado su agradecimiento por los servicios de Apoteket AB y el apoyo del Gobierno de Suecia durante m\u00e1s de 53 a\u00f1os.\n\n2. **Transici\u00f3n a una nueva instituci\u00f3n**: La transici\u00f3n del antiguo Centro Colaborador a una nueva instituci\u00f3n ha causado inconvenientes, especialmente en la distribuci\u00f3n de Sustancias de Referencia de Control Internacional (ICRS). La OMS ha tomado medidas para informar a los usuarios sobre esta transici\u00f3n y se espera que se publiquen nuevos detalles de contacto para pedidos de ICRS.\n\n3. **Esquema de Evaluaci\u00f3n de Aseguramiento de Calidad Externa (EQAAS)**: Este esquema permite a los laboratorios medir su rendimiento mediante pruebas de muestras ciegas. Se han realizado cinco series de pruebas en la Fase 4 del esquema de competencia, con la participaci\u00f3n de aproximadamente 50 laboratorios, lo que refuerza la confianza mutua en la red de laboratorios de control gubernamentales.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas ha tomado la OMS para mitigar los inconvenientes causados por la transici\u00f3n del antiguo Centro Colaborador a la nueva instituci\u00f3n en relaci\u00f3n con la distribuci\u00f3n de ICRS?**\n   - La OMS ha publicado anuncios en su sitio web de Medicamentos para informar a los usuarios sobre la transici\u00f3n y est\u00e1 preparando un anuncio adicional con los nuevos detalles de contacto para realizar pedidos de ICRS.\n\n2. **\u00bfQu\u00e9 propuestas hizo el Comit\u00e9 sobre el contenido del futuro informe de actividades de la nueva instituci\u00f3n?**\n   - El Comit\u00e9 propuso que el informe incluya detalles sobre actividades espec\u00edficas, como el monitoreo de estabilidad de las ICRS, y tambi\u00e9n alent\u00f3 la identificaci\u00f3n de laboratorios adicionales para establecer nuevas ICRS.\n\n3. **\u00bfCu\u00e1ntos laboratorios participaron en la Fase 4 del esquema de competencia y cu\u00e1l es el objetivo de este esquema?**\n   - Aproximadamente 50 laboratorios participaron en la Fase 4 del Esquema de Evaluaci\u00f3n de Aseguramiento de Calidad Externa (EQAAS), cuyo objetivo es permitir que cada laboratorio mida su rendimiento y determine su capacidad para realizar procedimientos anal\u00edticos dentro de una red de laboratorios de control gubernamentales.", "prev_section_summary": "### Temas clave:\n1. **Control de calidad**: Se centra en los materiales de referencia internacionales, espec\u00edficamente en las Sustancias Qu\u00edmicas de Referencia Internacional (ICRS) y los Espectros Infrarrojos de Referencia Internacional.\n2. **Informe anual**: Se presenta el informe del Centro Colaborador de la OMS para Sustancias Qu\u00edmicas de Referencia correspondiente al a\u00f1o 2008, destacando la distribuci\u00f3n de ICRS.\n3. **Distribuci\u00f3n de ICRS**: En 2008 se distribuyeron 2153 ICRS, lo que representa una disminuci\u00f3n respecto a los 2332 distribuidos en 2007.\n4. **Sustancias m\u00e1s solicitadas**: Las sustancias m\u00e1s solicitadas en 2008 incluyeron artesunate, artemether, prednisolone, artemisinin y zidovudine impurity B.\n5. **Nuevas ICRS**: Se adoptaron nueve nuevas ICRS en 2008, de las cuales siete eran nuevas sustancias y dos eran reemplazos.\n6. **Cambio de gesti\u00f3n**: Se informa sobre la cesaci\u00f3n de actividades de Apoteket AB en Suecia como anfitri\u00f3n del Centro Colaborador y la transferencia de estas actividades a una nueva instituci\u00f3n.\n\n### Entidades:\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Organizaci\u00f3n responsable del informe y del establecimiento de ICRS.\n- **Apoteket AB**: Instituci\u00f3n sueca que dej\u00f3 de ser el anfitri\u00f3n del Centro Colaborador de la OMS.\n- **Sustancias qu\u00edmicas**: Incluyen carbidopa, colchicine, lumefantrine, DL-methionine, naloxone hydrochloride, oseltamivir y oseltamivir phosphate, as\u00ed como artemisinin y prednisone como reemplazos.\n\nEste resumen destaca los aspectos m\u00e1s relevantes del control de calidad de los materiales de referencia internacionales y los cambios en la gesti\u00f3n del centro colaborador.", "excerpt_keywords": "Keywords: Apoteket AB, ICRS, WHO, quality assurance, EQAAS"}}, "35f78f6b-b128-44fe-8260-c5fba43e85df": {"node_ids": ["865a68ec-9df1-4e96-b9cb-0ce979335124"], "metadata": {"page_label": "52", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The Committee noted the final reports on the five tests and the preliminary summary report for Phase 4 of this Scheme. The results reported were:\n\n- final report procedure 1: determination of water by the Karl Fischer method\n- final report procedure 2: dissolution testing\n- final report procedure 3: assay of tablets by HPLC\n- final report procedure 4: assay by titration\n- final report procedure 5: optical rotation by polarimetry\n- summary report, Phase 4\n\nDuring the informal consultation held in June 2009, the experts considered the Scheme to be most efficient, both for the participating laboratories and for the feedback on the methods from the Ph.Int. used in the Scheme. They strongly recommended continuation of the Scheme starting with a new phase. In addition they advised on how to revise the Ph.Int. methods used, e.g. in procedure 4.\n\nRegarding the samples, the experts from the consultation advised the retention of extra samples from each procedure for those laboratories which gave doubtful or unsatisfactory results and which would need to redo testing. Moreover, WHO should strongly encourage the participating laboratories to report back to WHO on the outcome of such investigations and follow-up actions, as necessary.\n\nThe Expert Committee acknowledged with thanks receipt of the samples from UNICEF and from the manufacturers involved.\n\nFurther to the previous agreements between WHO and EDQM (dated 21 March 2000, 26 January 2001, 8 July 2004 and 15 March 2007), it was decided to continue collaboration during the period 1 January 2010\u201331 December 2012 with a view to evaluating the technical performance of 60 drug quality control laboratories designated by WHO for participation in the EQAAS, in accordance with the programme of proficiency testing schemes developed by EDQM, in the following analytical procedures:\n\n- assay by titration (sample: metronidazole)\n- water content by Karl Fischer (sample: amodiaquine dihydrochloride dihydrate)\n- dissolution test (sample: artemether and lumefantrine tablets)\n- related substances by HPLC (sample: abacavir oral solution)\n- assay by HPLC (sample: amodiaquine tablets)\n- dissolution test (sample: rifampicin capsules)\n- related substances by thin-layer chromatography (TLC) (sample: artemether and lumefantrine oral suspension)", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento detalla las conclusiones de un Comit\u00e9 sobre un esquema de pruebas de control de calidad de medicamentos, destacando los resultados de cinco procedimientos anal\u00edticos y la recomendaci\u00f3n de continuar el esquema con una nueva fase. Se menciona la importancia de retener muestras adicionales para laboratorios con resultados dudosos y la colaboraci\u00f3n entre la OMS y EDQM para evaluar el rendimiento t\u00e9cnico de laboratorios de control de calidad de medicamentos en un periodo espec\u00edfico.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los procedimientos anal\u00edticos que se evaluaron en la fase 4 del esquema y qu\u00e9 m\u00e9todos se utilizaron para cada uno?**\n   - Respuesta: Los procedimientos anal\u00edticos evaluados en la fase 4 del esquema incluyen: \n     - Determinaci\u00f3n de agua por el m\u00e9todo de Karl Fischer.\n     - Pruebas de disoluci\u00f3n.\n     - Ensayo de tabletas por HPLC.\n     - Ensayo por titulaci\u00f3n.\n     - Rotaci\u00f3n \u00f3ptica por polarimetr\u00eda.\n\n2. **\u00bfQu\u00e9 recomendaciones se hicieron durante la consulta informal de junio de 2009 respecto a los laboratorios que obtuvieron resultados insatisfactorios?**\n   - Respuesta: Se recomend\u00f3 la retenci\u00f3n de muestras adicionales de cada procedimiento para aquellos laboratorios que obtuvieron resultados dudosos o insatisfactorios, y se sugiri\u00f3 que la OMS alentara a los laboratorios a informar sobre los resultados de sus investigaciones y acciones de seguimiento.\n\n3. **\u00bfCu\u00e1l es el objetivo de la colaboraci\u00f3n entre la OMS y EDQM durante el periodo de 2010 a 2012?**\n   - Respuesta: El objetivo de la colaboraci\u00f3n es evaluar el rendimiento t\u00e9cnico de 60 laboratorios de control de calidad de medicamentos designados por la OMS para participar en el EQAAS, utilizando un programa de esquemas de pruebas de competencia desarrollado por EDQM en varios procedimientos anal\u00edticos.\n\n### Resumen de Nivel Superior\nEl Comit\u00e9 evalu\u00f3 los resultados de un esquema de pruebas de control de calidad de medicamentos y recomend\u00f3 su continuaci\u00f3n. Se enfatiz\u00f3 la importancia de manejar adecuadamente los resultados insatisfactorios y se estableci\u00f3 una colaboraci\u00f3n entre la OMS y EDQM para evaluar laboratorios de control de calidad en un periodo espec\u00edfico, utilizando diversos m\u00e9todos anal\u00edticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Colaboraci\u00f3n de Apoteket AB con la OMS**:\n   - Apoteket AB ha colaborado con la OMS desde 1956, especialmente en *La Farmacopea Internacional*.\n   - La OMS ha expresado su agradecimiento por los servicios de Apoteket AB y el apoyo del Gobierno de Suecia durante m\u00e1s de 53 a\u00f1os.\n\n2. **Transici\u00f3n a una Nueva Instituci\u00f3n**:\n   - Se ha producido una transici\u00f3n del antiguo Centro Colaborador a una nueva instituci\u00f3n, lo que ha causado inconvenientes en la distribuci\u00f3n de Sustancias de Referencia de Control Internacional (ICRS).\n   - La OMS ha tomado medidas para informar a los usuarios sobre esta transici\u00f3n a trav\u00e9s de anuncios en su sitio web y se espera la publicaci\u00f3n de nuevos detalles de contacto para pedidos de ICRS.\n\n3. **Propuestas del Comit\u00e9**:\n   - El Comit\u00e9 propuso que el futuro informe de actividades de la nueva instituci\u00f3n incluya detalles sobre el monitoreo de estabilidad de las ICRS y la identificaci\u00f3n de laboratorios adicionales para establecer nuevas ICRS.\n   - Se discuti\u00f3 la necesidad de ajustar el precio de las ICRS debido a un cambio de moneda, acordando un aumento en el precio que no se hab\u00eda modificado en la \u00faltima d\u00e9cada.\n\n4. **Esquema de Evaluaci\u00f3n de Aseguramiento de Calidad Externa (EQAAS)**:\n   - Este esquema permite a los laboratorios medir su rendimiento mediante pruebas de muestras ciegas, reforzando la confianza mutua en la red de laboratorios de control gubernamentales.\n   - Se llevaron a cabo cinco series de pruebas en la Fase 4 del esquema, con la participaci\u00f3n de aproximadamente 50 laboratorios, que ahora ha finalizado.\n\n### Entidades Clave\n- **Apoteket AB**: Entidad colaboradora con la OMS.\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organizaci\u00f3n que supervisa la colaboraci\u00f3n y calidad en laboratorios.\n- **Gobierno de Suecia**: Entidad que ha apoyado las actividades de Apoteket AB y la OMS.\n- **ICRS (Sustancias de Referencia de Control Internacional)**: Sustancias cuyo manejo y distribuci\u00f3n est\u00e1n en transici\u00f3n.\n- **EQAAS (Esquema de Evaluaci\u00f3n de Aseguramiento de Calidad Externa)**: Programa para evaluar el rendimiento de laboratorios.", "excerpt_keywords": "Keywords: drug quality control, analytical procedures, WHO, EQAAS, proficiency testing"}}, "7031af86-e6b0-4dd9-9cbe-73bf8d67f894": {"node_ids": ["e5aab092-e48e-4761-a0ee-a52fcba93fb0"], "metadata": {"page_label": "53", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# WHO Good Practices for Quality Control Laboratories\n\n## Revision of WHO Good Practices for Pharmaceutical Quality Control Laboratories (GPCL)\n\nAt its forty-third meeting, the Expert Committee recommended that the WHO Secretariat initiate the process of revision of the *WHO good practices for national pharmaceutical control laboratories* (*Good practices for national pharmaceutical control laboratories*, Annex 3, WHO Technical Report Series, No. 902, 2002).\n\nThe following requirements were set for the revision, based on the recommendations of the Expert Committee at its forty-third meeting:\n\n- Include the most important parts of the WHO GMP guide, which were relevant to quality control laboratories, directly in the GPCL guideline and add references to other relevant parts of the WHO GMP guide;\n- Provide detailed guidance for the areas identified as being often deficient during inspections performed by the PQP;\n- Align the guidance with the requirements of ISO/IEC 17025:2005;\n- Apply to any pharmaceutical quality control laboratory, be it national, commercial or another nongovernmental laboratory; and\n- Harmonization of terms used in other WHO documents.\n\nThe first draft revision was prepared in March 2009 and was widely commented on. The comments received were discussed with laboratory experts at the informal consultation on specifications for medicines and quality control laboratory issues in June 2009 following which a second draft revision was prepared. The second draft revision was further discussed with inspectors in the informal consultation on WHO guidelines for medicines quality assurance, quality control laboratories and transfer of technology in July 2009, resulting in a third draft revision which was distributed for comments in September 2009.\n\nThis third draft revision was presented for discussion to the forty-fourth meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Proceso de Revisi\u00f3n de Buenas Pr\u00e1cticas**: La Organizaci\u00f3n Mundial de la Salud (OMS) inici\u00f3 un proceso de revisi\u00f3n de las Buenas Pr\u00e1cticas para Laboratorios de Control de Calidad Farmac\u00e9utica (GPCL) a partir de recomendaciones de su Comit\u00e9 de Expertos. Esta revisi\u00f3n busca integrar aspectos relevantes de la gu\u00eda de Buenas Pr\u00e1cticas de Manufactura (GMP) y alinearse con est\u00e1ndares internacionales como ISO/IEC 17025:2005.\n\n2. **Objetivos de la Revisi\u00f3n**: La revisi\u00f3n tiene como objetivo proporcionar orientaci\u00f3n detallada sobre \u00e1reas que suelen presentar deficiencias durante las inspecciones, aplicarse a cualquier laboratorio de control de calidad farmac\u00e9utica y armonizar la terminolog\u00eda utilizada en otros documentos de la OMS.\n\n3. **Desarrollo de Borradores**: Se han elaborado varios borradores de la revisi\u00f3n desde 2009, los cuales han sido discutidos y comentados por expertos y inspectores en diversas consultas informales, culminando en un tercer borrador que fue presentado para discusi\u00f3n en la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las \u00e1reas espec\u00edficas que se identificaron como deficientes durante las inspecciones realizadas por el PQP y que se abordar\u00e1n en la revisi\u00f3n de las GPCL?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre las deficiencias espec\u00edficas que se han observado en las inspecciones, que no se menciona expl\u00edcitamente en el contexto.\n\n2. **\u00bfQu\u00e9 partes de la gu\u00eda de Buenas Pr\u00e1cticas de Manufactura (GMP) se consideran m\u00e1s relevantes para los laboratorios de control de calidad y c\u00f3mo se integrar\u00e1n en la nueva gu\u00eda GPCL?**\n   - Esta pregunta se centra en identificar las secciones clave de la gu\u00eda GMP que se incluir\u00e1n en la revisi\u00f3n, lo cual no se detalla en el texto.\n\n3. **\u00bfQu\u00e9 cambios se han propuesto en la terminolog\u00eda utilizada en los documentos de la OMS como resultado de la revisi\u00f3n de las GPCL?**\n   - Esta pregunta busca informaci\u00f3n sobre las modificaciones espec\u00edficas en la terminolog\u00eda que se est\u00e1n considerando para lograr la armonizaci\u00f3n, un aspecto que no se aborda en el contexto proporcionado.", "prev_section_summary": "### Temas Clave\n\n1. **Evaluaci\u00f3n de Procedimientos Anal\u00edticos**: Se presentaron los resultados de cinco procedimientos anal\u00edticos en el contexto de un esquema de control de calidad de medicamentos, incluyendo m\u00e9todos como la determinaci\u00f3n de agua por el m\u00e9todo de Karl Fischer y ensayos por HPLC.\n\n2. **Recomendaciones del Comit\u00e9**: Durante una consulta informal en junio de 2009, se recomend\u00f3 la continuaci\u00f3n del esquema con una nueva fase y se sugiri\u00f3 la revisi\u00f3n de m\u00e9todos utilizados en el mismo.\n\n3. **Manejo de Resultados Insatisfactorios**: Se enfatiz\u00f3 la importancia de retener muestras adicionales para laboratorios con resultados dudosos y la necesidad de que estos laboratorios informen a la OMS sobre sus investigaciones y acciones de seguimiento.\n\n4. **Colaboraci\u00f3n entre OMS y EDQM**: Se estableci\u00f3 una colaboraci\u00f3n para evaluar el rendimiento t\u00e9cnico de 60 laboratorios de control de calidad de medicamentos entre 2010 y 2012, utilizando un programa de esquemas de pruebas de competencia.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la supervisi\u00f3n y evaluaci\u00f3n de los laboratorios de control de calidad.\n- **European Directorate for the Quality of Medicines & HealthCare (EDQM)**: Colaborador en la evaluaci\u00f3n de laboratorios y desarrollo de esquemas de pruebas de competencia.\n- **UNICEF**: Proveedor de muestras para el esquema de pruebas.\n- **Laboratorios Participantes**: 60 laboratorios de control de calidad designados por la OMS para participar en el EQAAS.\n\n### Resumen General\nEl documento detalla la evaluaci\u00f3n de un esquema de control de calidad de medicamentos, destacando la importancia de la colaboraci\u00f3n entre la OMS y EDQM, as\u00ed como la gesti\u00f3n de resultados insatisfactorios en laboratorios. Se recomienda la continuaci\u00f3n del esquema y se establecen procedimientos para evaluar el rendimiento t\u00e9cnico de los laboratorios participantes.", "excerpt_keywords": "Keywords: WHO, Good Practices, Pharmaceutical Quality Control, ISO/IEC 17025, GMP"}}, "7df489d3-c38a-4284-a7fc-618ae60b895c": {"node_ids": ["958ab2bf-9805-4afd-8cd7-d810a558d728"], "metadata": {"page_label": "54", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The following changes were made to the original guidelines published in 2002:\n\n\u2014 **Explanatory notes**  \nIn order to differentiate between requirements and advice, explanatory notes were introduced in the text.\n\n\u2014 **Glossary**  \nDefinitions were revised to bring them into line with current WHO documents and 15 definitions were added as a reflection of the extended text. Definitions from WHO guidelines were used where available, or else definitions were adopted from widely accepted documents such as *International Vocabulary of Metrology* published by the Joint Committee for Guides in Metrology.\n\n\u2014 **Part one \u2014 Management and infrastructure**  \nThe *Organization and management* and *Quality system* sections were amended and structured in such a way as to provide clearer guidance. Explicit requirements on internal audits, management review of quality issues, corrective and preventive measures were included. The *Control of documentation* section was substantially extended and the *Record* section was amended to provide electronic records. The section on *Personnel* was simplified to provide a laboratory with more flexibility in organization while assuring the essential functions. Requirements on *Premises* were focused more on chemical testing and for the requirements for microbiological testing and testing on animals, readers were referred to other guidelines. The section on *Contracts* was added, differentiating between contracts to purchase services and supplies and subcontracting tests.\n\n\u2014 **Part two \u2014 Materials, equipment, instruments and other devices**  \nRequirements on labelling of reagents, reagent solutions and volumetric solutions were specified in detail. Reference substances and reference materials were differentiated and clarification was provided on retesting of various types of reference substances. Requirements relating to the qualification of laboratory equipment were added, referring to the WHO guidelines. The section on *Traceability* was simplified.\n\n\u2014 **Part three \u2014 Working procedures**  \nThe requirement for review of a test request by the laboratory was included. In the case of a pharmaceutical manufacturer\u2019s laboratory, the test request form could be replaced by a master production instruction. A section was added dealing with validation of analytical procedures and system suitability test, including the requirement to demonstrate that a pharmacopoeial method or externally validated analytical method was suitable for the substance or product to be tested. Detailed guidance on", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 957\" presenta una serie de cambios y actualizaciones a las directrices originales publicadas en 2002. Se introducen notas explicativas para diferenciar entre requisitos y consejos, se revisa el glosario con nuevas definiciones, y se estructuran las secciones sobre gesti\u00f3n, infraestructura, materiales y procedimientos de trabajo para proporcionar una gu\u00eda m\u00e1s clara. Se enfatiza la importancia de la trazabilidad, la validaci\u00f3n de procedimientos anal\u00edticos y se establecen requisitos espec\u00edficos para la documentaci\u00f3n y el manejo de equipos de laboratorio.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 cambios se realizaron en la secci\u00f3n de \"Control de documentaci\u00f3n\" y c\u00f3mo se relacionan con los registros electr\u00f3nicos?**\n   - Respuesta: La secci\u00f3n de \"Control de documentaci\u00f3n\" fue sustancialmente ampliada y la secci\u00f3n de \"Registros\" fue modificada para incluir registros electr\u00f3nicos, proporcionando as\u00ed una mayor flexibilidad y modernizaci\u00f3n en la gesti\u00f3n de la documentaci\u00f3n en los laboratorios.\n\n2. **\u00bfCu\u00e1les son las diferencias clave entre las sustancias de referencia y los materiales de referencia seg\u00fan las nuevas directrices?**\n   - Respuesta: Las nuevas directrices especifican que las sustancias de referencia y los materiales de referencia son diferenciados, y se proporciona aclaraci\u00f3n sobre el retesting de varios tipos de sustancias de referencia, lo que ayuda a asegurar la calidad y la precisi\u00f3n en los an\u00e1lisis de laboratorio.\n\n3. **\u00bfQu\u00e9 requisitos se establecen para la validaci\u00f3n de procedimientos anal\u00edticos en laboratorios de fabricantes farmac\u00e9uticos?**\n   - Respuesta: Se a\u00f1adi\u00f3 una secci\u00f3n que trata sobre la validaci\u00f3n de procedimientos anal\u00edticos y pruebas de idoneidad del sistema, que incluye la obligaci\u00f3n de demostrar que un m\u00e9todo farmacopoeico o un m\u00e9todo anal\u00edtico validado externamente es adecuado para la sustancia o producto que se va a probar.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Revisi\u00f3n de Buenas Pr\u00e1cticas**: La OMS est\u00e1 revisando las Buenas Pr\u00e1cticas para Laboratorios de Control de Calidad Farmac\u00e9utica (GPCL) a partir de recomendaciones del Comit\u00e9 de Expertos en su cuadrag\u00e9sima tercera reuni\u00f3n.\n\n2. **Objetivos de la Revisi\u00f3n**:\n   - Integrar partes relevantes de la gu\u00eda de Buenas Pr\u00e1cticas de Manufactura (GMP) en la nueva gu\u00eda GPCL.\n   - Proporcionar orientaci\u00f3n detallada sobre \u00e1reas deficientes identificadas durante inspecciones.\n   - Alinear la gu\u00eda con los requisitos de ISO/IEC 17025:2005.\n   - Aplicar la gu\u00eda a todos los laboratorios de control de calidad farmac\u00e9utica, ya sean nacionales, comerciales o no gubernamentales.\n   - Armonizar la terminolog\u00eda utilizada en otros documentos de la OMS.\n\n3. **Desarrollo de Borradores**: Desde marzo de 2009, se han elaborado varios borradores de la revisi\u00f3n, los cuales han sido discutidos y comentados por expertos y inspectores en diversas consultas informales, culminando en un tercer borrador presentado en la cuadrag\u00e9sima cuarta reuni\u00f3n del Comit\u00e9 de Expertos de la OMS.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la revisi\u00f3n.\n- **Comit\u00e9 de Expertos**: Grupo que recomend\u00f3 la revisi\u00f3n de las GPCL.\n- **ISO/IEC 17025:2005**: Est\u00e1ndar internacional con el que se busca alinear la gu\u00eda.\n- **Laboratorios de Control de Calidad Farmac\u00e9utica**: Entidades a las que se aplica la nueva gu\u00eda.", "excerpt_keywords": "Keywords: WHO, guidelines, laboratory, validation, traceability"}}, "10f493e8-3b03-46f6-bb21-2cf2d119ed7c": {"node_ids": ["9642d0ab-4c87-4915-920b-955d85644609"], "metadata": {"page_label": "55", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the procedure for out-of-specification results, including references to the US Food and Drug Administration (FDA) and the European Official Medicines Control Laboratories (OMCL) network under the *Note* was provided. A brief explanation of uncertainty of measurement with further references was included. The contents of the analytical test report, which was used in investigative testing, and of the certificate of analysis were specified.\n\n\u2014 **Part four \u2014 Safety**  \nNo major changes were made to part four.\n\n\u2014 **References**  \nReferences to WHO documents were updated and a number of references to documents of other organizations, such as the International Organization for Standardization, Joint Committee for Guides in Metrology, US FDA, International Society for Pharmaceutical Engineering, European Union guidelines, the OMCL Network of the Council of Europe, US Pharmacopeia, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use and Eurachem/Cooperation on International Traceability in Analytical Chemistry (CITAC), were included under *Notes*.\n\n\u2014 **Appendices**  \nAppendix 1: *Model analytical test report for active pharmaceutical ingredients, excipients and pharmaceutical products* was deleted and was replaced by a reference to existing WHO guidelines.\n\nAppendix 2 (now Appendix 1): *Equipment for a first-stage and medium-size pharmaceutical quality control laboratory* did not represent any requirement; it would be helpful in establishing a new laboratory in a developing country. The list, which covered chemical and microbiological units, was updated according to currently used analytical methods and equipment and specific requirements for a pharmacognosy/phytochemistry unit were added.\n\n\u2014 **Applicability to any pharmaceutical quality control laboratory, be it national, commercial or another nongovernmental laboratory**  \nDue attention was paid to the applicability of the guidelines. The inappropriateness of some requirements in the first draft, specifically to laboratories belonging to a pharmaceutical manufacturer, was commented upon by several organizations. The text was subsequently thoroughly discussed with GMP inspectors during the aforementioned informal consultation and modified accordingly. Recommendations specific to national pharmaceutical quality control laboratories were stressed and some flexibility was introduced.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es un informe t\u00e9cnico de la OMS (Organizaci\u00f3n Mundial de la Salud) que aborda procedimientos y directrices para laboratorios de control de calidad farmac\u00e9utica. Se discuten cambios en la estructura del documento, incluyendo la eliminaci\u00f3n de un modelo de informe anal\u00edtico y la actualizaci\u00f3n de referencias a documentos de diversas organizaciones. Tambi\u00e9n se menciona la importancia de la aplicabilidad de las directrices a diferentes tipos de laboratorios, as\u00ed como la flexibilidad introducida en las recomendaciones para laboratorios nacionales de control de calidad farmac\u00e9utica.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 cambios se realizaron en la secci\u00f3n de referencias del documento y qu\u00e9 organizaciones se incluyeron?**\n   - El documento actualiz\u00f3 las referencias a documentos de la OMS y a\u00f1adi\u00f3 referencias a organizaciones como la ISO, la FDA de EE. UU., y la OMCL, entre otras.\n\n2. **\u00bfCu\u00e1l es la finalidad del nuevo Ap\u00e9ndice 1 sobre el equipo para laboratorios de control de calidad farmac\u00e9utica?**\n   - El nuevo Ap\u00e9ndice 1 proporciona una lista actualizada de equipos que son \u00fatiles para establecer un laboratorio de control de calidad farmac\u00e9utica en un pa\u00eds en desarrollo, abarcando unidades qu\u00edmicas y microbiol\u00f3gicas.\n\n3. **\u00bfC\u00f3mo se abordaron las preocupaciones sobre la aplicabilidad de las directrices a laboratorios de fabricantes farmac\u00e9uticos?**\n   - Se discutieron las preocupaciones con inspectores de Buenas Pr\u00e1cticas de Manufactura (GMP) y se modific\u00f3 el texto para introducir flexibilidad en las recomendaciones, enfatizando la aplicabilidad a laboratorios nacionales de control de calidad farmac\u00e9utica.\n\n### Resumen de Nivel Superior\n\nEl informe t\u00e9cnico de la OMS proporciona directrices actualizadas para laboratorios de control de calidad farmac\u00e9utica, abordando procedimientos para resultados fuera de especificaci\u00f3n, la seguridad, y la aplicabilidad de las directrices a diferentes tipos de laboratorios. Se realizaron cambios significativos en las referencias y se elimin\u00f3 un modelo de informe anal\u00edtico, mientras que se introdujeron recomendaciones espec\u00edficas para laboratorios nacionales.", "prev_section_summary": "### Temas Clave:\n\n1. **Actualizaci\u00f3n de Directrices**: Se realizaron cambios significativos a las directrices originales de 2002, con el objetivo de mejorar la claridad y la aplicabilidad de las normas.\n\n2. **Notas Explicativas**: Se introdujeron notas explicativas para diferenciar entre requisitos y consejos, facilitando la comprensi\u00f3n de las directrices.\n\n3. **Revisi\u00f3n del Glosario**: Se actualizaron y a\u00f1adieron definiciones para alinearse con documentos actuales de la OMS, incluyendo 15 nuevas definiciones.\n\n4. **Gesti\u00f3n e Infraestructura**: Se reestructuraron secciones clave como *Organizaci\u00f3n y gesti\u00f3n* y *Sistema de calidad*, con requisitos expl\u00edcitos sobre auditor\u00edas internas y revisi\u00f3n de calidad.\n\n5. **Control de Documentaci\u00f3n**: La secci\u00f3n fue ampliada para incluir registros electr\u00f3nicos, modernizando as\u00ed la gesti\u00f3n documental en laboratorios.\n\n6. **Materiales y Equipos**: Se especificaron requisitos detallados sobre el etiquetado de reactivos y se diferenciaron las sustancias de referencia de los materiales de referencia.\n\n7. **Procedimientos de Trabajo**: Se incluy\u00f3 la revisi\u00f3n de solicitudes de prueba y se a\u00f1adi\u00f3 una secci\u00f3n sobre la validaci\u00f3n de procedimientos anal\u00edticos, enfatizando la idoneidad de los m\u00e9todos utilizados.\n\n### Entidades:\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad responsable de las directrices.\n- **Directrices de 2002**: Documento original que fue actualizado.\n- **Sustancias de referencia y materiales de referencia**: Conceptos diferenciados en las nuevas directrices.\n- **Auditor\u00edas internas y revisi\u00f3n de calidad**: Requisitos establecidos para la gesti\u00f3n de calidad en laboratorios.\n- **Registros electr\u00f3nicos**: Innovaci\u00f3n en el control de documentaci\u00f3n.\n- **M\u00e9todos farmacopoeicos**: M\u00e9todos anal\u00edticos que deben ser validados seg\u00fan las nuevas directrices.\n\nEste resumen destaca los cambios clave y las entidades relevantes en la secci\u00f3n del documento, proporcionando una visi\u00f3n clara de las actualizaciones realizadas.", "excerpt_keywords": "Keywords: pharmaceutical quality control, WHO guidelines, analytical test report, out-of-specification results, GMP inspectors"}}, "5cb5b786-894e-433c-bd00-a0e7f32ab781": {"node_ids": ["93e79246-518c-47b8-9036-62a5ac91b9ea"], "metadata": {"page_label": "56", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The revised guidance text was presented to the Expert Committee for discussion of comments and this was adopted (Annex 1).\n\n## 5.3 WHO good practices for pharmaceutical microbiology laboratories\n\n### Introduction\n\nIn addition to the above-discussed update of the WHO good practices for pharmaceutical control laboratories, during the inspections carried out when prequalifying laboratories, the inspectors had noticed that these guidelines might benefit from complementation by a specific text for pharmaceutical microbiology laboratories.\n\nIn light of the above, the Expert Committee recommended that the WHO Secretariat initiate the process of revision of these good practices and in addition prepare a new text on good practices for pharmaceutical microbiology laboratories. The Committee took note that these guidelines were in production and would be sent out for comments.\n\n## 6. Quality assurance \u2014 good manufacturing practices\n\n### 6.1 WHO good manufacturing practices: main principles for pharmaceutical products\n\nAn informal consultation on WHO guidelines for medicines quality assurance, quality control laboratories and technology transfer was held in Geneva from 27 to 31 July 2009. *WHO GMP: main principles for pharmaceutical products* was discussed with the following outcomes:\n\nThe main changes recommended during that meeting and subject to presentation to the Expert Committee for review and possible approval were as follows:\n\n- Quality unit concept to be included in the main principles;\n- Inclusion of the quality risk management;\n- Addition of a reference and link to the product quality review; and\n- More detailed review of the responsibilities of key personnel.\n\nThe main changes recommended were:\n\n- Quality unit concept\n- Quality risk management\n- Product quality review\n- Responsibilities of key personnel.\n\nThe Expert Committee endorsed the suggested recommendations and recommended that the Secretariat distribute the revised text for comment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Actualizaci\u00f3n de las Buenas Pr\u00e1cticas de la OMS**: Se ha presentado un texto revisado sobre las buenas pr\u00e1cticas para laboratorios de microbiolog\u00eda farmac\u00e9utica a un Comit\u00e9 de Expertos, que ha sido adoptado. Se ha recomendado la creaci\u00f3n de un nuevo texto espec\u00edfico para estos laboratorios, en respuesta a observaciones realizadas durante las inspecciones de laboratorios en proceso de precalificaci\u00f3n.\n\n2. **Principios de Buenas Pr\u00e1cticas de Manufactura (GMP)**: Durante una consulta informal en Ginebra, se discutieron las directrices de la OMS sobre aseguramiento de calidad y control de calidad de medicamentos. Se propusieron cambios significativos en los principios de GMP, incluyendo la inclusi\u00f3n de un concepto de unidad de calidad, gesti\u00f3n de riesgos de calidad, revisi\u00f3n de calidad del producto y responsabilidades del personal clave.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 recomendaciones espec\u00edficas se hicieron para complementar las buenas pr\u00e1cticas de los laboratorios de microbiolog\u00eda farmac\u00e9utica?**\n   - Se recomend\u00f3 que la Secretar\u00eda de la OMS inicie el proceso de revisi\u00f3n de las buenas pr\u00e1cticas existentes y prepare un nuevo texto espec\u00edfico para laboratorios de microbiolog\u00eda farmac\u00e9utica, en respuesta a las observaciones realizadas durante las inspecciones.\n\n2. **\u00bfCu\u00e1les son los principales cambios propuestos en las Buenas Pr\u00e1cticas de Manufactura (GMP) seg\u00fan la consulta de 2009?**\n   - Los cambios propuestos incluyen la inclusi\u00f3n del concepto de unidad de calidad, la gesti\u00f3n de riesgos de calidad, la adici\u00f3n de un enlace a la revisi\u00f3n de calidad del producto y una revisi\u00f3n m\u00e1s detallada de las responsabilidades del personal clave.\n\n3. **\u00bfQu\u00e9 papel desempe\u00f1\u00f3 el Comit\u00e9 de Expertos en la revisi\u00f3n de las buenas pr\u00e1cticas para laboratorios farmac\u00e9uticos?**\n   - El Comit\u00e9 de Expertos revis\u00f3 y adopt\u00f3 el texto revisado de las buenas pr\u00e1cticas y respald\u00f3 las recomendaciones para la distribuci\u00f3n del texto revisado para comentarios, asegurando que se consideren las opiniones de los interesados en el proceso de revisi\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Procedimientos para Resultados Fuera de Especificaci\u00f3n**: Se proporcion\u00f3 un procedimiento que incluye referencias a la FDA de EE. UU. y a la red de Laboratorios Oficiales de Control de Medicamentos de Europa (OMCL).\n\n2. **Seguridad**: No se realizaron cambios significativos en la secci\u00f3n de seguridad del documento.\n\n3. **Referencias**: \n   - Se actualizaron las referencias a documentos de la OMS.\n   - Se incluyeron referencias a organizaciones como:\n     - Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO)\n     - Comit\u00e9 Conjunto de Gu\u00edas en Metrolog\u00eda\n     - Sociedad Internacional de Ingenier\u00eda Farmac\u00e9utica\n     - Directrices de la Uni\u00f3n Europea\n     - Farmacopea de EE. UU.\n     - Conferencia Internacional sobre Armonizaci\u00f3n de Requisitos T\u00e9cnicos para el Registro de Productos Farmac\u00e9uticos para Uso Humano\n     - Eurachem/CITAC (Cooperaci\u00f3n en Trazabilidad Internacional en Qu\u00edmica Anal\u00edtica).\n\n4. **Ap\u00e9ndices**:\n   - **Ap\u00e9ndice 1**: Se elimin\u00f3 el modelo de informe anal\u00edtico y se reemplaz\u00f3 por una referencia a las directrices existentes de la OMS.\n   - **Ap\u00e9ndice 2 (ahora Ap\u00e9ndice 1)**: Se actualiz\u00f3 la lista de equipos para laboratorios de control de calidad farmac\u00e9utica, enfoc\u00e1ndose en la utilidad para establecer laboratorios en pa\u00edses en desarrollo.\n\n5. **Aplicabilidad de las Directrices**: \n   - Se prest\u00f3 atenci\u00f3n a la aplicabilidad de las directrices a diferentes tipos de laboratorios, incluyendo laboratorios nacionales y comerciales.\n   - Se abordaron preocupaciones sobre la inadecuaci\u00f3n de algunos requisitos para laboratorios de fabricantes farmac\u00e9uticos, lo que llev\u00f3 a modificaciones en el texto y a la introducci\u00f3n de flexibilidad en las recomendaciones.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Administraci\u00f3n de Alimentos y Medicamentos de EE. UU. (FDA)**\n- **Laboratorios Oficiales de Control de Medicamentos (OMCL)**\n- **Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO)**\n- **Sociedad Internacional de Ingenier\u00eda Farmac\u00e9utica**\n- **Uni\u00f3n Europea**\n- **Farmacopea de EE. UU.**\n- **Eurachem/CITAC**", "excerpt_keywords": "Keywords: WHO, good practices, pharmaceutical microbiology, quality assurance, manufacturing practices"}}, "8bc3cb06-ba79-4085-be7e-8920e82fdd4b": {"node_ids": ["76ce5ef2-35b9-4382-a7fe-62004daaa775"], "metadata": {"page_label": "57", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 6.2 WHO good manufacturing practices for active pharmaceutical ingredients\n\nDuring several previous meetings of the Expert Committee, the revision of WHO GMP for active pharmaceutical ingredients (APIs) had been discussed. The Committee also closely followed development of the ICH GMP guidelines for APIs, including their initial preparation by the Pharmaceutical Inspection Co-operation Scheme (PIC/S).\n\nIn the past the Committee had recognized the difficulty that countries would have in implementing the ICH GMP guide in a short period of time. It, therefore, agreed that WHO should revise the current WHO GMP for APIs to reflect current GMP requirements and to take into account other published guidelines, including the ICH guide. The Committee endorsed the step-wise approach to the implementation of GMP for APIs.\n\nIn the meantime, the principles described in the ICH GMP for APIs had been recognized and implemented by numerous national inspectorates. In addition, they had been field-tested when inspecting in the context of the WHO PQP (for medicines).\n\nThe Secretariat had, therefore, prepared a WHO-style, edited version of this guide, fully in line with the internationally used text developed following the ICH process.\n\nThis draft working document was reviewed and discussed with inspectors, experts and interested parties during the informal consultation in July 2009. During this meeting it was recommended that the text be fully retained in line with the ICH principles in order to avoid any challenges regarding the further global implementation of this standard internationally.\n\nIn order to further assist with its implementation, the experts decided to add clarifying notes and explanations for some of the parts that had been questioned during inspections, i.e.\n\n- definition of API starting material;\n- (para. 2.1.1) role of senior management regarding the implementation of an effective quality management system;\n- (para. 2.3) delegation of the responsibility for production activities;\n- need for manufacturers of intermediates and/or APIs to have a system for evaluating the suppliers of critical materials in place;\n- examination of each container or grouping of containers of materials upon receipt and before acceptance;\n- identification of batch material;\n- reserve samples; and\n- inclusion of cross-references to Good trade and distribution practices (GTDP) and GMP for excipients in the section entitled: Agents, brokers, traders, distributors, repackers and relabellers.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento discute la revisi\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP) de la OMS para los ingredientes farmac\u00e9uticos activos (APIs). Se menciona la dificultad que enfrentan los pa\u00edses para implementar las gu\u00edas GMP del ICH en un corto per\u00edodo y la decisi\u00f3n de la OMS de actualizar sus propias gu\u00edas para alinearse con los est\u00e1ndares internacionales. Se destaca la importancia de un enfoque gradual para la implementaci\u00f3n de estas pr\u00e1cticas y se enumeran varios puntos clave que se aclarar\u00e1n en la revisi\u00f3n, como la definici\u00f3n de materiales de partida de API y la responsabilidad de la alta direcci\u00f3n en la gesti\u00f3n de calidad.\n\n### Preguntas Espec\u00edficas:\n1. **\u00bfQu\u00e9 enfoque se recomienda para la implementaci\u00f3n de las GMP para APIs seg\u00fan el Comit\u00e9 de Expertos de la OMS?**\n   - Respuesta: El Comit\u00e9 de Expertos de la OMS recomienda un enfoque gradual para la implementaci\u00f3n de las GMP para APIs, reconociendo las dificultades que los pa\u00edses pueden enfrentar al adoptar las gu\u00edas del ICH en un corto per\u00edodo de tiempo.\n\n2. **\u00bfCu\u00e1les son algunos de los puntos que se aclarar\u00e1n en la revisi\u00f3n de las GMP para APIs?**\n   - Respuesta: Algunos de los puntos que se aclarar\u00e1n incluyen la definici\u00f3n de material de partida de API, el papel de la alta direcci\u00f3n en la implementaci\u00f3n de un sistema de gesti\u00f3n de calidad efectivo, la delegaci\u00f3n de responsabilidades en las actividades de producci\u00f3n, y la necesidad de un sistema para evaluar a los proveedores de materiales cr\u00edticos.\n\n3. **\u00bfQu\u00e9 importancia tiene la consulta informal de julio de 2009 en el proceso de revisi\u00f3n de las GMP para APIs?**\n   - Respuesta: La consulta informal de julio de 2009 fue crucial porque permiti\u00f3 revisar y discutir el borrador del documento con inspectores, expertos y partes interesadas, lo que llev\u00f3 a la recomendaci\u00f3n de mantener el texto alineado con los principios del ICH para facilitar la implementaci\u00f3n global de este est\u00e1ndar.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Actualizaci\u00f3n de Buenas Pr\u00e1cticas de la OMS**:\n   - Se present\u00f3 un texto revisado sobre las buenas pr\u00e1cticas para laboratorios de microbiolog\u00eda farmac\u00e9utica al Comit\u00e9 de Expertos, que fue adoptado.\n   - Se recomend\u00f3 la creaci\u00f3n de un nuevo texto espec\u00edfico para estos laboratorios, basado en observaciones de inspecciones de laboratorios en proceso de precalificaci\u00f3n.\n\n2. **Principios de Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Se llev\u00f3 a cabo una consulta informal en Ginebra sobre las directrices de la OMS para el aseguramiento de calidad y control de calidad de medicamentos.\n   - Se propusieron cambios significativos en los principios de GMP, que incluyen:\n     - Inclusi\u00f3n del concepto de unidad de calidad.\n     - Gesti\u00f3n de riesgos de calidad.\n     - Revisi\u00f3n de calidad del producto.\n     - Responsabilidades del personal clave.\n\n3. **Comit\u00e9 de Expertos**:\n   - El Comit\u00e9 revis\u00f3 y adopt\u00f3 el texto revisado de las buenas pr\u00e1cticas.\n   - Respald\u00f3 las recomendaciones para la distribuci\u00f3n del texto revisado para comentarios, asegurando la consideraci\u00f3n de las opiniones de los interesados.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la elaboraci\u00f3n de las directrices y buenas pr\u00e1cticas.\n- **Comit\u00e9 de Expertos**: Grupo encargado de revisar y aprobar las recomendaciones sobre buenas pr\u00e1cticas.\n- **Laboratorios de Microbiolog\u00eda Farmac\u00e9utica**: Entidades que se beneficiar\u00e1n de las nuevas directrices espec\u00edficas.\n- **Ginebra**: Lugar donde se realiz\u00f3 la consulta informal sobre GMP.", "excerpt_keywords": "Keywords: WHO, GMP, active pharmaceutical ingredients, ICH guidelines, quality management system"}}, "001f8c08-4974-4e1b-8bdf-7188181b586c": {"node_ids": ["344beafa-a2de-4d81-9a76-0997241b6c54"], "metadata": {"page_label": "58", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee endorsed the above recommendations and considered the establishment of a small working group to finalize the wording of the explanatory notes. It agreed to the publication of the supplementary GMP text for APIs together with the explanatory notes to replace the GMP for APIs published in 1992 (Annex 2).\n\n### 6.3 WHO good manufacturing practices for pharmaceutical products containing hazardous substances\n\nA working document (\u201cWHO guidance to the inspection of hormone product manufacturing facilities\u201d) had been prepared previously and tabled at the Expert Committee meeting held in October 2008. These particular guidelines were intended to provide GMP principles for the production and control of products containing certain hormones or other hazardous substances.\n\nThere was international concern about the low quality of reproductive health products and the lack of compliance with GMP principles in manufacturing facilities. The PQP included reproductive health products, and to further facilitate improved quality of manufacture of these products, the Expert Committee acknowledged its previous recommendation to provide guidance in this area.\n\nA discussion with experts and interested parties took place during the consultation held from 27 to 31 July 2009. Considering all recommendations for amendment, the group recommended that the title of the document be changed to address not only products containing certain hormones, but also to ensure that the document and the title reflected the wider group of products containing hazardous substances. A revised version of the working document was, therefore, prepared for circulation and was mailed out for comments.\n\nThe new working document QAS/08.256/Rev.1 was submitted to the Expert Committee.\n\nThe text was presented to the Expert Committee for discussion of comments and the guidelines were adopted (Annex 3) after a review of all outstanding questions.\n\n### 6.4 WHO good manufacturing practices for sterile pharmaceutical products\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations adopted in its thirty-sixth report in 1999, WHO good manufacturing practices for sterile pharmaceutical products (WHO Technical Report Series, No. 902, 2002, Annex 6) (http://whqlibdoc.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en las recomendaciones del Comit\u00e9 de Expertos de la OMS sobre las Buenas Pr\u00e1cticas de Manufactura (GMP) para productos farmac\u00e9uticos, especialmente aquellos que contienen sustancias peligrosas. Se menciona la preocupaci\u00f3n internacional por la calidad de los productos de salud reproductiva y la falta de cumplimiento de las GMP en las instalaciones de manufactura. Se discute la necesidad de actualizar las gu\u00edas existentes para incluir no solo productos hormonales, sino tambi\u00e9n una gama m\u00e1s amplia de sustancias peligrosas. Adem\u00e1s, se hace referencia a la adopci\u00f3n de nuevas directrices y la publicaci\u00f3n de un texto suplementario para las GMP de ingredientes farmac\u00e9uticos activos (APIs).\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 cambios se propusieron en el t\u00edtulo del documento de directrices sobre productos que contienen sustancias peligrosas y por qu\u00e9?**\n   - Se recomend\u00f3 cambiar el t\u00edtulo del documento para reflejar no solo los productos que contienen ciertas hormonas, sino tambi\u00e9n una gama m\u00e1s amplia de productos que contienen sustancias peligrosas, en respuesta a la preocupaci\u00f3n internacional sobre la calidad de estos productos.\n\n2. **\u00bfCu\u00e1l fue la raz\u00f3n detr\u00e1s de la creaci\u00f3n de un grupo de trabajo para finalizar las notas explicativas sobre las GMP para APIs?**\n   - La creaci\u00f3n del grupo de trabajo se debi\u00f3 a la necesidad de establecer un texto claro y actualizado que reemplazara las GMP para APIs publicadas en 1992, asegurando que las recomendaciones fueran pertinentes y efectivas en el contexto actual.\n\n3. **\u00bfQu\u00e9 acciones se llevaron a cabo durante la consulta del 27 al 31 de julio de 2009 en relaci\u00f3n con las GMP para productos farmac\u00e9uticos que contienen sustancias peligrosas?**\n   - Durante la consulta, se discutieron recomendaciones para enmendar el documento existente, se revisaron los comentarios de expertos y partes interesadas, y se prepar\u00f3 una versi\u00f3n revisada del documento para su circulaci\u00f3n y comentarios, lo que llev\u00f3 a la adopci\u00f3n de nuevas directrices por parte del Comit\u00e9 de Expertos.", "prev_section_summary": "### Temas Clave:\n1. **Revisi\u00f3n de las GMP de la OMS**: Se discute la necesidad de actualizar las Buenas Pr\u00e1cticas de Manufactura (GMP) para los ingredientes farmac\u00e9uticos activos (APIs) para alinearse con las gu\u00edas internacionales, especialmente las del ICH.\n   \n2. **Dificultades en la Implementaci\u00f3n**: Se reconoce que muchos pa\u00edses enfrentar\u00e1n desaf\u00edos al intentar implementar las gu\u00edas GMP del ICH en un corto per\u00edodo de tiempo.\n\n3. **Enfoque Gradual**: Se recomienda un enfoque paso a paso para la implementaci\u00f3n de las GMP para facilitar la adopci\u00f3n de estas pr\u00e1cticas.\n\n4. **Consulta Informal**: La consulta informal de julio de 2009 fue un evento clave donde se revis\u00f3 el borrador del documento con expertos y partes interesadas, lo que llev\u00f3 a la recomendaci\u00f3n de mantener el texto alineado con los principios del ICH.\n\n5. **Notas Aclaratorias**: Se decidi\u00f3 incluir notas y explicaciones aclaratorias sobre varios aspectos de las GMP que hab\u00edan sido cuestionados durante las inspecciones.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la revisi\u00f3n y actualizaci\u00f3n de las GMP para APIs.\n- **ICH (International Council for Harmonisation)**: Organizaci\u00f3n que desarrolla gu\u00edas internacionales para la industria farmac\u00e9utica, cuyas pr\u00e1cticas se est\u00e1n adoptando en las GMP de la OMS.\n- **PIC/S (Pharmaceutical Inspection Co-operation Scheme)**: Iniciativa que contribuye a la preparaci\u00f3n de las gu\u00edas GMP.\n- **PQP (Prequalification Programme)**: Programa de la OMS que eval\u00faa la calidad de los medicamentos, donde se han probado los principios de las GMP del ICH.\n- **Expert Committee**: Comit\u00e9 de expertos que discute y revisa las GMP de la OMS.\n\n### Puntos Clave a Aclarar:\n- Definici\u00f3n de material de partida de API.\n- Rol de la alta direcci\u00f3n en la gesti\u00f3n de calidad.\n- Delegaci\u00f3n de responsabilidades en actividades de producci\u00f3n.\n- Evaluaci\u00f3n de proveedores de materiales cr\u00edticos.\n- Inspecci\u00f3n de contenedores de materiales al recibirlos.\n- Identificaci\u00f3n de material por lote.\n- Muestras de reserva.\n- Referencias cruzadas a buenas pr\u00e1cticas de comercio y distribuci\u00f3n (GTDP) y GMP para excipientes.", "excerpt_keywords": "Keywords: GMP, hazardous substances, reproductive health products, WHO guidelines, pharmaceutical manufacturing"}}, "d8b07ce2-3c41-4ef1-9409-0c23e40971ba": {"node_ids": ["1d84446c-f3f5-4793-99d9-50a3a3e47e79"], "metadata": {"page_label": "59", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "who.int/trs/WHO_TRS_902.pdf). This guidance was also published in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2. Second updated edition. Good manufacturing practices and inspection* (2007).\n\nFollowing implementation of these WHO GMP within the context of the PQP, a proposal for revision was being submitted to take into consideration new developments and to bring it into line with International Standardization Organization standard ISO 14644-1 and recent EU, Japanese, PIC/S and US practices.\n\nThe following major changes had been made to the text published in 1999:\n\n- New chapters on \u201cIsolator technology\u201d and \u201cBlow/fill/seal technology\u201d had been added.\n- The chapter on \u201cFinishing of sterile products\u201d had been amended and provisions had been given for capping of vials.\n- The chapter entitled \u201cManufacture of sterile preparations\u201d had been amended and provisions given for clean-room and clean-air-device monitoring.\n\nImplementation of certain parts of these new practices might need to be undertaken for using a step-wise approach, especially the part relating to the provision for capping in a clean or sterile environment, as this was currently not implemented in most industries.\n\nThe text was presented to the Expert Committee for discussion of comments and the guidelines were adopted (Annex 4), after review of the additional comments received by the deadline set for comments to be discussed at the meeting.\n\n### 6.5 Updates of other WHO good manufacturing practices texts\n\nIt was reported that during inspections when implementing the GMP for heating, ventilation and air-conditioning (HVAC) a need for slight revisions to certain chapters was noted. It was, therefore, suggested that these chapters be sent out for comments.\n\nThe Expert Committee endorsed this suggestion and recommended that the Secretariat distribute the revised text for comment.\n\n### 6.6 Good manufacturing practices for blood establishments\n\nAn update on the developments of the WHO GMP for blood establishments was presented to the Committee. There was an agreed need for quality and safety requirements, specifications and standards for blood and plasma collection, preparation, testing and distribution activities, the", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Revisi\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP)**: Se han realizado actualizaciones significativas a las directrices de GMP de la OMS desde su publicaci\u00f3n en 1999, incluyendo la adici\u00f3n de nuevos cap\u00edtulos sobre tecnolog\u00edas espec\u00edficas y la modificaci\u00f3n de cap\u00edtulos existentes para mejorar la calidad y seguridad en la fabricaci\u00f3n de productos est\u00e9riles.\n\n2. **Implementaci\u00f3n de nuevas pr\u00e1cticas**: La implementaci\u00f3n de ciertas pr\u00e1cticas nuevas, como el capping en un entorno limpio o est\u00e9ril, puede requerir un enfoque gradual, dado que no se est\u00e1n aplicando en la mayor\u00eda de las industrias actualmente.\n\n3. **Desarrollo de GMP para establecimientos de sangre**: Se ha reconocido la necesidad de establecer requisitos de calidad y seguridad para las actividades relacionadas con la recolecci\u00f3n, preparaci\u00f3n, prueba y distribuci\u00f3n de sangre y plasma, lo que implica la actualizaci\u00f3n de las GMP espec\u00edficas para estos establecimientos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las nuevas tecnolog\u00edas que se han incorporado en las directrices de GMP de la OMS desde 1999?**\n   - Respuesta: Se han a\u00f1adido nuevos cap\u00edtulos sobre \"Tecnolog\u00eda de aisladores\" y \"Tecnolog\u00eda de blow/fill/seal\".\n\n2. **\u00bfQu\u00e9 cambios se han realizado en el cap\u00edtulo sobre la \"Finalizaci\u00f3n de productos est\u00e9riles\"?**\n   - Respuesta: El cap\u00edtulo ha sido enmendado para incluir disposiciones sobre el capping de viales.\n\n3. **\u00bfQu\u00e9 se ha propuesto en relaci\u00f3n con las GMP para los establecimientos de sangre?**\n   - Respuesta: Se ha presentado la necesidad de establecer requisitos de calidad y seguridad, especificaciones y est\u00e1ndares para las actividades de recolecci\u00f3n, preparaci\u00f3n, prueba y distribuci\u00f3n de sangre y plasma.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Recomendaciones del Comit\u00e9 de Expertos de la OMS**: Se aprob\u00f3 la creaci\u00f3n de un grupo de trabajo para finalizar las notas explicativas sobre las Buenas Pr\u00e1cticas de Manufactura (GMP) para ingredientes farmac\u00e9uticos activos (APIs), con el objetivo de publicar un texto suplementario que reemplace las GMP para APIs de 1992.\n\n2. **GMP para Productos Farmac\u00e9uticos que Contienen Sustancias Peligrosas**: Se discutieron directrices para la producci\u00f3n y control de productos que contienen hormonas y otras sustancias peligrosas, en respuesta a preocupaciones internacionales sobre la calidad de los productos de salud reproductiva y el cumplimiento de las GMP en las instalaciones de manufactura.\n\n3. **Consulta de Expertos (27-31 de julio de 2009)**: Durante esta consulta, se revisaron recomendaciones para enmendar el documento existente, se propuso cambiar el t\u00edtulo del documento para incluir una gama m\u00e1s amplia de productos peligrosos, y se prepar\u00f3 una versi\u00f3n revisada del documento para su circulaci\u00f3n y comentarios.\n\n4. **Adopci\u00f3n de Nuevas Directrices**: El nuevo documento de trabajo (QAS/08.256/Rev.1) fue presentado al Comit\u00e9 de Expertos, que adopt\u00f3 las nuevas directrices despu\u00e9s de revisar los comentarios y preguntas pendientes.\n\n5. **GMP para Productos Farmac\u00e9uticos Est\u00e9riles**: Se hace referencia a la adopci\u00f3n de GMP para productos farmac\u00e9uticos est\u00e9riles en un informe anterior del Comit\u00e9 de Expertos de la OMS.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de las recomendaciones y directrices.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que revisa y aprueba las recomendaciones sobre GMP.\n- **PQP (Prequalification Programme)**: Programa que incluye productos de salud reproductiva y busca mejorar la calidad de fabricaci\u00f3n.\n- **Documentos de Trabajo**: Incluyen el documento QAS/08.256/Rev.1 y las gu\u00edas sobre la inspecci\u00f3n de instalaciones de fabricaci\u00f3n de productos hormonales.", "excerpt_keywords": "Keywords: Good Manufacturing Practices, WHO, sterile products, blood establishments, quality assurance"}}, "ce9e40c2-89f6-43e7-ae4c-08c7b56c276b": {"node_ids": ["b7a27ece-2646-42fe-96d4-dcffc2f0faa3"], "metadata": {"page_label": "60", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "implementation of internationally agreed quality and safety standards in the blood establishments, a harmonized and systematic approach to ensure compliance at all steps involved (from donor acceptance to release of products), and enforcement by competent MRAs.\n\nICDRA had recommended the following at its 13th meeting held in Berne in 2008:\n\n\u201cRecognizing the worldwide need for blood products regulation to ensure availability of safe blood and blood products in the face of known and emerging threats, including emerging infectious diseases, WHO should:\n\n- Take steps to further develop and strengthen national/regional blood regulatory authorities and to promote cooperation\n- Provide harmonized 'assessment criteria for blood regulatory systems' (BRN): convene a consultation of NMRAs to review Draft assessment tool\n- Prioritize development of WHO Guidelines on GMP for Blood Establishments\n- Promote introduction of WHO recommended plasma standards by NMRAs.\u201d\n\nWHO had issued requirements for the collection, processing and quality control of blood components and plasma derivatives (WHO Technical Report Series, No. 840, 1994, Annex 2) and recommendations for the production, control and regulation of plasma for fractionation (WHO Technical Report Series, No. 941, Annex 4). In addition, the GMP guide for blood establishments had been published by bodies such as the PIC/S.\n\nBased on the above, the project for WHO guidelines on GMP for blood establishments was intended to respond to the ICDRA recommendation, without inventing a new GMP standard, but taking into account the specifics of blood products, blood establishments and all existing complementary GMP standards.\n\nThe aim of the new document was to establish a wide international consensus on quality standards among blood establishments and among inspectors to ensure high-quality products and safety of recipients. It would then become a guidance document for blood establishments, for NMRAs to refer, implement and enforce GMP in blood establishments and to become widely applicable, independent of the activities of a single blood establishment.\n\nThe document addressed the general GMP topics, e.g. quality management, as well as the topics specific to manufacturing of blood products, from donor selection through distribution of final products and the newer GMP concepts, e.g. risk management and product quality review.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la implementaci\u00f3n de est\u00e1ndares internacionales de calidad y seguridad en los establecimientos de sangre. Se menciona la necesidad de regular los productos sangu\u00edneos para garantizar su disponibilidad y seguridad frente a amenazas conocidas y emergentes, como enfermedades infecciosas. En la reuni\u00f3n del ICDRA (Comit\u00e9 Internacional de Reguladores de Medicamentos) en 2008, se hicieron varias recomendaciones, incluyendo el fortalecimiento de las autoridades reguladoras de sangre y el desarrollo de gu\u00edas de Buenas Pr\u00e1cticas de Manufactura (GMP) espec\u00edficas para los establecimientos de sangre. El objetivo del proyecto de gu\u00edas de la OMS es establecer un consenso internacional sobre est\u00e1ndares de calidad y proporcionar un documento de orientaci\u00f3n para la implementaci\u00f3n y cumplimiento de GMP en estos establecimientos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las recomendaciones espec\u00edficas del ICDRA para fortalecer las autoridades reguladoras de sangre a nivel nacional y regional?**\n   - Respuesta: El ICDRA recomend\u00f3 desarrollar y fortalecer las autoridades reguladoras de sangre, promover la cooperaci\u00f3n entre ellas, proporcionar criterios de evaluaci\u00f3n armonizados para los sistemas regulatorios de sangre, priorizar el desarrollo de gu\u00edas de GMP para los establecimientos de sangre y promover la introducci\u00f3n de est\u00e1ndares de plasma recomendados por la OMS.\n\n2. **\u00bfQu\u00e9 aspectos espec\u00edficos de la manufactura de productos sangu\u00edneos se abordan en las nuevas gu\u00edas de GMP de la OMS?**\n   - Respuesta: Las nuevas gu\u00edas de GMP abordan temas generales como la gesti\u00f3n de calidad, as\u00ed como aspectos espec\u00edficos de la manufactura de productos sangu\u00edneos, que incluyen la selecci\u00f3n de donantes, el procesamiento de componentes sangu\u00edneos y la distribuci\u00f3n de productos finales, adem\u00e1s de conceptos m\u00e1s recientes como la gesti\u00f3n de riesgos y la revisi\u00f3n de la calidad del producto.\n\n3. **\u00bfCu\u00e1l es el prop\u00f3sito de establecer un consenso internacional sobre est\u00e1ndares de calidad entre los establecimientos de sangre?**\n   - Respuesta: El prop\u00f3sito es asegurar la producci\u00f3n de productos de alta calidad y la seguridad de los receptores, proporcionando un documento de orientaci\u00f3n que los establecimientos de sangre y las autoridades reguladoras nacionales puedan referenciar, implementar y hacer cumplir, de manera que sea aplicable independientemente de las actividades de un solo establecimiento de sangre.", "prev_section_summary": "### Temas Clave\n\n1. **Revisi\u00f3n de Buenas Pr\u00e1cticas de Manufactura (GMP)**: Se han actualizado las directrices de GMP de la OMS desde su publicaci\u00f3n en 1999, incorporando nuevos cap\u00edtulos y modificando cap\u00edtulos existentes para mejorar la calidad y seguridad en la fabricaci\u00f3n de productos est\u00e9riles.\n\n2. **Nuevas Tecnolog\u00edas**: Se han a\u00f1adido cap\u00edtulos sobre \"Tecnolog\u00eda de aisladores\" y \"Tecnolog\u00eda de blow/fill/seal\".\n\n3. **Capping de Viales**: Se han realizado enmiendas en el cap\u00edtulo sobre \"Finalizaci\u00f3n de productos est\u00e9riles\" para incluir disposiciones sobre el capping de viales.\n\n4. **Monitoreo de Ambientes Limpios**: Se han actualizado las provisiones en el cap\u00edtulo sobre \"Fabricaci\u00f3n de preparaciones est\u00e9riles\" para incluir el monitoreo de salas limpias y dispositivos de aire limpio.\n\n5. **Implementaci\u00f3n Gradual**: La implementaci\u00f3n de ciertas pr\u00e1cticas nuevas, como el capping en un entorno limpio o est\u00e9ril, puede requerir un enfoque gradual debido a su falta de aplicaci\u00f3n en la mayor\u00eda de las industrias.\n\n6. **GMP para Establecimientos de Sangre**: Se ha reconocido la necesidad de establecer requisitos de calidad y seguridad para la recolecci\u00f3n, preparaci\u00f3n, prueba y distribuci\u00f3n de sangre y plasma.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices de GMP.\n- **ISO (Organizaci\u00f3n Internacional de Normalizaci\u00f3n)**: Est\u00e1ndar ISO 14644-1 mencionado para alineaci\u00f3n de pr\u00e1cticas.\n- **Expert Committee**: Comit\u00e9 que revisa y adopta las directrices de GMP.\n- **PQP (Programa de Precalificaci\u00f3n)**: Contexto en el que se implementan las GMP de la OMS.\n- **Establecimientos de Sangre**: Entidades que requieren actualizaciones espec\u00edficas en GMP para asegurar la calidad y seguridad en sus operaciones.", "excerpt_keywords": "Keywords: blood safety, GMP guidelines, regulatory authorities, quality standards, plasma products"}}, "1075dcb9-bb2e-40e5-8246-45a75bd31ec7": {"node_ids": ["f0edf1f8-2f7d-4ccb-a8db-f3b185c53964"], "metadata": {"page_label": "61", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The detailed structure of the current working document was presented. This included the following chapters: Introduction, Glossary, Quality management, Manufacturing, Contract manufacturing, Analysis and services and a section on Authors, References and History.\n\nThe chapter on manufacturing included detailed process-specific guidance, covering donor registration, donor selection, collection, component preparation, laboratory testing, quality control, labelling, release, dispatch, shipping and returns. The product characteristics comprised whole blood, red cells, platelets, plasma for transfusion/fractionation and cryoprecipitate/CPP. The points to consider for validation of preparation steps would focus on centrifugation, separation, freezing, leukocyte reduction and irradiation.\n\nThe drafting process had started in January 2008. The text was reviewed during a WHO training workshop (in Teheran) in November 2008 and again in its revised format by a consultation of experts from July to September 2009. The text would also be presented for discussion to the ECBS in October 2009 and released for open consultation. It was expected that subsequent to the global consultation, review of comments and further revision of the document, it would be presented to the ECBS in 2010 with a view to adoption.\n\nThe comprehensive consultation process involved WHO Member States through WHO channels (e.g. ministries of health), WHO Regional Advisers, targeted regulatory authorities, blood transfusion services and professional institutions and associations and other interested parties through its publication on the WHO web site.\n\nThe Expert Committee took note of the progress made and recommended that this text be mailed out for comment to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and again be presented at the next meeting of the Committee with a view to its adoption within the full set of GMP texts.\n\n# 7. Quality assurance \u2014 new approaches\n\n## 7.1 Risk analysis\n\n### Introduction\n\nDuring the meeting of the Expert Committee in October 2007, an update on the new ICH Q10 was given to the Committee by the Secretariat. The Committee concluded that the ICH Q8, Q9 and Q10 documents were useful tools.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento t\u00e9cnico de la OMS (WHO - Technical Report Series 957) presenta una estructura detallada que incluye cap\u00edtulos sobre introducci\u00f3n, glosario, gesti\u00f3n de calidad, fabricaci\u00f3n, fabricaci\u00f3n por contrato, an\u00e1lisis y servicios, as\u00ed como secciones sobre autores, referencias e historia. Se destaca la importancia de la fabricaci\u00f3n de productos sangu\u00edneos, incluyendo directrices espec\u00edficas sobre el registro y selecci\u00f3n de donantes, pruebas de laboratorio y control de calidad. El proceso de redacci\u00f3n comenz\u00f3 en enero de 2008 y ha pasado por varias revisiones y consultas con expertos, con la intenci\u00f3n de adoptar el texto en 2010. Adem\u00e1s, se menciona un enfoque en el an\u00e1lisis de riesgos y la utilidad de los documentos ICH Q8, Q9 y Q10 en la gesti\u00f3n de calidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos de validaci\u00f3n que se deben considerar en la preparaci\u00f3n de componentes sangu\u00edneos seg\u00fan el documento?**\n   - Respuesta: Los pasos de validaci\u00f3n que se deben considerar incluyen centrifugaci\u00f3n, separaci\u00f3n, congelaci\u00f3n, reducci\u00f3n de leucocitos e irradiaci\u00f3n.\n\n2. **\u00bfQu\u00e9 organismos y partes interesadas participaron en el proceso de consulta para la elaboraci\u00f3n del documento?**\n   - Respuesta: El proceso de consulta involucr\u00f3 a Estados Miembros de la OMS a trav\u00e9s de canales de la OMS (como ministerios de salud), asesores regionales de la OMS, autoridades regulatorias espec\u00edficas, servicios de transfusi\u00f3n sangu\u00ednea, instituciones profesionales y asociaciones, as\u00ed como otras partes interesadas a trav\u00e9s de su publicaci\u00f3n en el sitio web de la OMS.\n\n3. **\u00bfQu\u00e9 se espera que ocurra despu\u00e9s de la consulta global sobre el documento?**\n   - Respuesta: Se espera que, tras la consulta global, se revisen los comentarios y se realicen m\u00e1s revisiones del documento, que luego se presentar\u00e1 al ECBS en 2010 con miras a su adopci\u00f3n.\n\n### Resumen de nivel superior\n\nEl documento de la OMS aborda la gesti\u00f3n de calidad y la fabricaci\u00f3n de productos sangu\u00edneos, destacando la importancia de un proceso de redacci\u00f3n colaborativo y la consulta con expertos. Se enfoca en la necesidad de establecer directrices claras para asegurar la calidad y seguridad en la transfusi\u00f3n de sangre, as\u00ed como en la implementaci\u00f3n de nuevos enfoques de gesti\u00f3n de calidad, como el an\u00e1lisis de riesgos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Est\u00e1ndares Internacionales de Calidad y Seguridad:** Se enfatiza la implementaci\u00f3n de est\u00e1ndares acordados internacionalmente en los establecimientos de sangre para garantizar la calidad y seguridad de los productos sangu\u00edneos.\n2. **Regulaci\u00f3n de Productos Sangu\u00edneos:** Se reconoce la necesidad de regular los productos sangu\u00edneos para asegurar su disponibilidad y seguridad frente a amenazas emergentes, como enfermedades infecciosas.\n3. **Recomendaciones del ICDRA:** En la reuni\u00f3n del ICDRA en 2008, se hicieron recomendaciones para fortalecer las autoridades reguladoras de sangre, desarrollar criterios de evaluaci\u00f3n armonizados y priorizar la creaci\u00f3n de gu\u00edas de Buenas Pr\u00e1cticas de Manufactura (GMP) espec\u00edficas para los establecimientos de sangre.\n4. **Gu\u00edas de GMP de la OMS:** El proyecto de gu\u00edas de la OMS busca establecer un consenso internacional sobre est\u00e1ndares de calidad y proporcionar un documento de orientaci\u00f3n para la implementaci\u00f3n y cumplimiento de GMP en los establecimientos de sangre.\n5. **Aspectos Espec\u00edficos de la Manufactura:** Las gu\u00edas abordan temas generales de gesti\u00f3n de calidad y aspectos espec\u00edficos de la manufactura de productos sangu\u00edneos, incluyendo la selecci\u00f3n de donantes, procesamiento y distribuci\u00f3n de productos finales, as\u00ed como conceptos recientes como gesti\u00f3n de riesgos y revisi\u00f3n de calidad del producto.\n\n**Entidades:**\n- **OMS (Organizaci\u00f3n Mundial de la Salud):** Responsable de emitir requisitos y gu\u00edas para la regulaci\u00f3n de productos sangu\u00edneos.\n- **ICDRA (Comit\u00e9 Internacional de Reguladores de Medicamentos):** Organismo que recomend\u00f3 acciones para mejorar la regulaci\u00f3n de productos sangu\u00edneos.\n- **NMRAs (Autoridades Nacionales Reguladoras de Medicamentos):** Entidades que deben implementar y hacer cumplir las gu\u00edas de GMP en los establecimientos de sangre.\n- **PIC/S (Pharmaceutical Inspection Co-operation Scheme):** Organismo que ha publicado gu\u00edas de GMP para establecimientos de sangre. \n\nEste resumen destaca la importancia de la regulaci\u00f3n y estandarizaci\u00f3n en la producci\u00f3n de productos sangu\u00edneos para garantizar la seguridad y calidad en el \u00e1mbito internacional.", "excerpt_keywords": "Keywords: quality management, blood manufacturing, WHO guidelines, risk analysis, GMP standards"}}, "d616ee1e-44db-49e2-808e-8c6352196292": {"node_ids": ["082039d9-c24e-4388-8cd8-a6cb874384e8"], "metadata": {"page_label": "62", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "On the topic of risk analysis, the Committee made recommendations for WHO to:\n\n- review and update the WHO guidelines on hazard analysis and critical control points (HACCP);\n- revise the main text of the WHO GMP to include the principles of application of risk management.\n\nConsidering the changes in the approach to quality risk management in the regulatory environment and the use of different tools to analyse risk, the Secretariat had started the process of reviewing the WHO guidelines on HACCP and expected to submit the proposed revised guidelines to the Expert Committee at its next meeting.\n\n## Recommendation\n\nThe Expert Committee:\n\n- supported the Secretariat in continuing the preparation of the revised draft guideline on HACCP; and\n- encouraged the Secretariat to include the principles of quality risk management and to provide examples of possible tools that may be used in quality risk management \u2014 not only focusing on HACCP.\n\n### 7.2 WHO guidelines on technology transfer\n\nThe need for new WHO guidance on transfer of technology was discussed at the forty-second meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2007. Colleagues from the WHO PQP shared their experience of recently submitted dossiers by, and inspections carried out in, plants that had undergone technology transfer. Technology transfer was happening worldwide both within and between companies, and within the same country as well as between countries. The Expert Committee, therefore, recommended that WHO guidelines on transfer of technology be developed. A draft document was subsequently prepared and sent out for comment. It was then discussed during the consultation on WHO guidelines for medicines quality assurance, quality control laboratories and transfer of technology on 27\u201331 July 2009 and a revision was prepared.\n\nThe Expert Committee discussed and reviewed the major points that were raised during the commentary period, keeping the balance between GMP and business criteria. Inclusion of the concept of quality by design and the possibility of optional requirements depended on the type of transfer. The Committee took note that the Secretariat would organize a consultation and prepare a new working document for wide circulation following the usual consultation procedure.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Recomendaciones sobre an\u00e1lisis de riesgos**: El Comit\u00e9 de Expertos de la OMS recomend\u00f3 la revisi\u00f3n y actualizaci\u00f3n de las directrices sobre an\u00e1lisis de peligros y puntos cr\u00edticos de control (HACCP) y la inclusi\u00f3n de principios de gesti\u00f3n de riesgos en el texto principal de las Buenas Pr\u00e1cticas de Manufactura (GMP) de la OMS. Se destac\u00f3 la importancia de adaptar estas directrices a los cambios en el entorno regulatorio y en las herramientas de an\u00e1lisis de riesgos.\n\n2. **Transferencia de tecnolog\u00eda**: Se discuti\u00f3 la necesidad de nuevas directrices de la OMS sobre la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica, bas\u00e1ndose en experiencias recientes de transferencias de tecnolog\u00eda a nivel mundial. Se recomend\u00f3 el desarrollo de estas directrices, que se revisaron y comentaron en varias consultas, buscando un equilibrio entre las Buenas Pr\u00e1cticas de Manufactura y los criterios empresariales.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 cambios se est\u00e1n considerando en las directrices de HACCP de la OMS y por qu\u00e9 son necesarios?**\n   - Se est\u00e1n considerando cambios en las directrices de HACCP para adaptarse a la evoluci\u00f3n del enfoque de gesti\u00f3n de riesgos de calidad en el entorno regulatorio y para incorporar herramientas modernas de an\u00e1lisis de riesgos.\n\n2. **\u00bfCu\u00e1l es la relaci\u00f3n entre las Buenas Pr\u00e1cticas de Manufactura (GMP) y la gesti\u00f3n de riesgos seg\u00fan las recomendaciones del Comit\u00e9?**\n   - El Comit\u00e9 recomend\u00f3 que el texto principal de las GMP de la OMS incluya principios de gesti\u00f3n de riesgos, lo que sugiere que la gesti\u00f3n de riesgos es fundamental para garantizar la calidad y la seguridad en la producci\u00f3n farmac\u00e9utica.\n\n3. **\u00bfQu\u00e9 aspectos se consideraron en la revisi\u00f3n de las directrices sobre transferencia de tecnolog\u00eda y c\u00f3mo se equilibraron?**\n   - En la revisi\u00f3n de las directrices sobre transferencia de tecnolog\u00eda, se consideraron puntos importantes que surgieron durante el per\u00edodo de comentarios, buscando un equilibrio entre las Buenas Pr\u00e1cticas de Manufactura y los criterios empresariales, as\u00ed como la inclusi\u00f3n del concepto de calidad por dise\u00f1o y requisitos opcionales seg\u00fan el tipo de transferencia.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Estructura del Documento**: El documento t\u00e9cnico de la OMS (WHO - Technical Report Series 957) est\u00e1 organizado en varios cap\u00edtulos, incluyendo:\n   - Introducci\u00f3n\n   - Glosario\n   - Gesti\u00f3n de calidad\n   - Fabricaci\u00f3n\n   - Fabricaci\u00f3n por contrato\n   - An\u00e1lisis y servicios\n   - Autores, referencias e historia\n\n2. **Cap\u00edtulo sobre Fabricaci\u00f3n**: Este cap\u00edtulo proporciona directrices espec\u00edficas sobre:\n   - Registro y selecci\u00f3n de donantes\n   - Recolecci\u00f3n de sangre\n   - Preparaci\u00f3n de componentes\n   - Pruebas de laboratorio\n   - Control de calidad\n   - Etiquetado\n   - Liberaci\u00f3n, despacho, env\u00edo y devoluciones\n\n3. **Caracter\u00edsticas del Producto**: Se abordan diferentes productos sangu\u00edneos, incluyendo:\n   - Sangre total\n   - Gl\u00f3bulos rojos\n   - Plaquetas\n   - Plasma para transfusi\u00f3n/fractionaci\u00f3n\n   - Crioprecipitado/CPP\n\n4. **Validaci\u00f3n de Pasos de Preparaci\u00f3n**: Los pasos de validaci\u00f3n a considerar son:\n   - Centrifugaci\u00f3n\n   - Separaci\u00f3n\n   - Congelaci\u00f3n\n   - Reducci\u00f3n de leucocitos\n   - Irradiaci\u00f3n\n\n5. **Proceso de Redacci\u00f3n**: \n   - Comenz\u00f3 en enero de 2008.\n   - Revisiones en talleres de capacitaci\u00f3n y consultas con expertos entre 2008 y 2009.\n   - Presentaci\u00f3n al ECBS (Comit\u00e9 de Expertos en Sangre) en octubre de 2009 y consulta abierta.\n\n6. **Consulta Global**: Involucra a:\n   - Estados Miembros de la OMS\n   - Asesores regionales de la OMS\n   - Autoridades regulatorias\n   - Servicios de transfusi\u00f3n sangu\u00ednea\n   - Instituciones profesionales y asociaciones\n   - Publicaci\u00f3n en el sitio web de la OMS\n\n7. **Recomendaciones del Comit\u00e9 de Expertos**: Se sugiere enviar el texto para comentarios al Panel Asesor de la OMS sobre la Farmacopea Internacional y Preparaciones Farmac\u00e9uticas, y presentarlo nuevamente en la pr\u00f3xima reuni\u00f3n del Comit\u00e9.\n\n8. **Gesti\u00f3n de Calidad y An\u00e1lisis de Riesgos**: Se menciona la utilidad de los documentos ICH Q8, Q9 y Q10 en la gesti\u00f3n de calidad, destacando un enfoque en el an\u00e1lisis de riesgos.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**\n- **ECBS (Comit\u00e9 de Expertos en Sangre)**\n- **ICH (Conferencia Internacional sobre Armonizaci\u00f3n)**\n- **Panel Asesor de la OMS sobre la Farmacopea Internacional y Preparaciones Farmac\u00e9uticas**", "excerpt_keywords": "Keywords: risk analysis, HACCP, technology transfer, quality risk management, WHO guidelines"}}, "19b34146-7515-4639-9709-18528c8d9cd5": {"node_ids": ["736da678-9f03-4bfc-b5b7-7ed64a3c1ad7"], "metadata": {"page_label": "63", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 8. Quality assurance \u2014 distribution and trade of pharmaceuticals\n\n## 8.1 WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce\n\nThe WHO Certification Scheme for finished pharmaceutical products was an international voluntary agreement intended to provide assurance to countries participating in the Scheme, about the quality of pharmaceutical products moving in international commerce (World Health Assembly resolution WHA22.50 (1969), World Health Assembly resolution WHA28.65 (1975), World Health Assembly resolution WHA41.18 (1988), World Health Assembly resolution WHA45.29 (1992), World Health Assembly resolution WHA50.3 (1997)). The primary document of the Scheme was the Certificate of Pharmaceutical Product (CPP).\n\nThe Expert Committee had recommended during discussion in 2008 that the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce should be reviewed in light of the changing environment, including the rapid globalization of the pharmaceutical manufacturing sector coupled with changes in the make-up of both the regulators and the groups involved in procurement. In addition, it acknowledged that legislation had been put in place in various countries and regions to assess products manufactured in them and produced for \u201cexport only\u201d, for which there was currently no adequate provision in the Scheme.\n\nAn oral presentation was given by the Secretariat of the work it had done following the recommendations made at the previous meeting of the Expert Committee.\n\n### Questions and answers\n\nBased on the Committee\u2019s recommendations a question and answer paper was prepared in the interim on the function of the Scheme.\n\nThe first working document was based on the feedback, draft questions and answers received from the International Federation of Pharmaceutical Manufacturers and Associations/European Federation of Pharmaceutical Industries and Associations (IFPMA/EFPIA). The working document was subsequently circulated for comments.\n\nReviewing all the comments received and the materials already available, a new set of questions and answers was prepared and made available.\n\nAn additional question and answer was provided for further discussion at the Expert Committee, raised by the specialist who had reviewed all.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de nivel superior:\nEl esquema de certificaci\u00f3n de la OMS para productos farmac\u00e9uticos terminados es un acuerdo internacional voluntario que busca asegurar la calidad de los productos farmac\u00e9uticos en el comercio internacional. Este esquema ha sido objeto de revisi\u00f3n debido a la globalizaci\u00f3n del sector farmac\u00e9utico y a los cambios en la regulaci\u00f3n y en los grupos de adquisici\u00f3n. Se han elaborado documentos de preguntas y respuestas para aclarar el funcionamiento del esquema, basados en comentarios de organizaciones relevantes.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las principales resoluciones de la Asamblea Mundial de la Salud que respaldan el Esquema de Certificaci\u00f3n de la OMS y qu\u00e9 cambios han motivado su revisi\u00f3n?**\n   - Esta pregunta busca respuestas sobre las resoluciones espec\u00edficas que han influido en el esquema y los factores que han llevado a la necesidad de su revisi\u00f3n.\n\n2. **\u00bfQu\u00e9 tipo de legislaci\u00f3n se ha implementado en diferentes pa\u00edses que afecta a los productos farmac\u00e9uticos destinados solo para exportaci\u00f3n, y c\u00f3mo se relaciona esto con el Esquema de Certificaci\u00f3n de la OMS?**\n   - Esta pregunta se centra en la legislaci\u00f3n espec\u00edfica que ha surgido en varios pa\u00edses y c\u00f3mo esto ha impactado la efectividad del esquema de certificaci\u00f3n.\n\n3. **\u00bfQu\u00e9 proceso se sigui\u00f3 para recopilar y revisar los comentarios sobre el documento de preguntas y respuestas del Esquema de Certificaci\u00f3n, y qui\u00e9nes fueron los principales contribuyentes a este proceso?**\n   - Esta pregunta busca detalles sobre el proceso de revisi\u00f3n y los actores involucrados, lo que puede proporcionar informaci\u00f3n sobre la colaboraci\u00f3n entre la OMS y las organizaciones farmac\u00e9uticas.", "prev_section_summary": "### Temas Clave\n\n1. **An\u00e1lisis de Riesgos**:\n   - Recomendaciones del Comit\u00e9 de Expertos de la OMS para revisar y actualizar las directrices sobre an\u00e1lisis de peligros y puntos cr\u00edticos de control (HACCP).\n   - Inclusi\u00f3n de principios de gesti\u00f3n de riesgos en el texto principal de las Buenas Pr\u00e1cticas de Manufactura (GMP) de la OMS.\n   - Adaptaci\u00f3n de las directrices a los cambios en el entorno regulatorio y en las herramientas de an\u00e1lisis de riesgos.\n\n2. **Transferencia de Tecnolog\u00eda**:\n   - Discusi\u00f3n sobre la necesidad de nuevas directrices de la OMS para la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica.\n   - Experiencias compartidas sobre transferencias de tecnolog\u00eda a nivel mundial y la importancia de equilibrar las Buenas Pr\u00e1cticas de Manufactura con criterios empresariales.\n   - Desarrollo y revisi\u00f3n de un documento de directrices sobre transferencia de tecnolog\u00eda, incluyendo conceptos como calidad por dise\u00f1o y requisitos opcionales.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la elaboraci\u00f3n de directrices y recomendaciones en el \u00e1mbito de la salud p\u00fablica y la industria farmac\u00e9utica.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que revisa y recomienda cambios en las directrices de la OMS, incluyendo HACCP y GMP.\n- **PQP (Programa de Garant\u00eda de Calidad)**: Parte de la OMS que comparte experiencias sobre la calidad y la transferencia de tecnolog\u00eda en la producci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: WHO Certification Scheme, pharmaceutical quality, international commerce, Expert Committee, regulatory changes"}}, "411f29dc-66a1-4768-8480-d1c113945cf8": {"node_ids": ["9a74fd4d-655b-4b18-940c-7c123eabd8c0"], "metadata": {"page_label": "64", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee:\n\n- noted the updated report from the Secretariat;\n- reviewed the document and considered the additional question; and\n- approved the questions and answers for posting on the WHO web site and publication in *WHO Drug Information*, with the possibility to receive comments and to review any question(s) and answers.\n\n## 8.2 WHO good distribution practices for pharmaceutical products\n\nFollowing the adoption of the WHO guidelines for good distribution practices (GDP) by the WHO Expert Committee on Specifications for Pharmaceutical Preparations at its fortieth meeting in October 2005 (http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf#page=191) (WHO Technical Report Series, No. 937, Annex 5, 2006) these guidelines had been revised by the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) partnership to strengthen the potential for prevention of counterfeit and other illegal medicines entering the supply chain. The following text outlines the process followed.\n\nAt an IMPACT meeting held in Bonn, Germany, in November 2006, the existing GDP was reviewed and amendments proposed relating to the specific issue of improving the security of the distribution chain vis-\u00e0-vis counterfeits. This was based on the consideration that even in highly regulated countries counterfeit medicines reached patients through the regulated distribution chain.\n\nA first draft was circulated in March 2007 to all the members of IMPACT\u2019s Regulatory Implementation Working Group (IRIWG). The IRIWG subsequently met in Washington, DC, USA from 23 to 25 April 2007 and discussed inter alia the draft and recommended amendments. A revised draft was circulated among the members of IRIWG and a final draft was then made available on the WHO web site for further comments. All IMPACT members (including the MRAs of 60 WHO Member States, plus other stakeholders) were actively encouraged to provide comments.\n\nThe draft was further revised and then finalized at the General Meeting of IMPACT held in Lisbon, Portugal, in December 2007. This text reflected the consensus reached at the Lisbon meeting and was submitted to the", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en las pr\u00e1cticas de buena distribuci\u00f3n (GDP) de productos farmac\u00e9uticos, revisadas por el Comit\u00e9 de Expertos de la OMS. Se menciona la adopci\u00f3n inicial de estas directrices en 2005 y su posterior revisi\u00f3n por el Grupo de Trabajo de Implementaci\u00f3n Regulatoria de la Alianza Internacional contra la Falsificaci\u00f3n de Productos M\u00e9dicos (IMPACT). Se destaca la importancia de mejorar la seguridad de la cadena de distribuci\u00f3n para prevenir la entrada de medicamentos falsificados, incluso en pa\u00edses altamente regulados. El proceso de revisi\u00f3n incluy\u00f3 reuniones y la participaci\u00f3n activa de miembros de IMPACT y otras partes interesadas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les fueron las principales preocupaciones que llevaron a la revisi\u00f3n de las directrices de GDP en la reuni\u00f3n de IMPACT en Bonn en 2006?**\n   - Respuesta: La revisi\u00f3n se centr\u00f3 en mejorar la seguridad de la cadena de distribuci\u00f3n frente a los medicamentos falsificados, considerando que incluso en pa\u00edses altamente regulados, estos productos pod\u00edan llegar a los pacientes a trav\u00e9s de la cadena de distribuci\u00f3n regulada.\n\n2. **\u00bfQu\u00e9 pasos se siguieron para la elaboraci\u00f3n y revisi\u00f3n del borrador de las nuevas directrices de GDP despu\u00e9s de la reuni\u00f3n de Bonn?**\n   - Respuesta: Se circul\u00f3 un primer borrador en marzo de 2007 a los miembros del Grupo de Trabajo de Implementaci\u00f3n Regulatoria (IRIWG), seguido de una reuni\u00f3n en Washington, DC, donde se discutieron y recomendaron enmiendas. Posteriormente, se realiz\u00f3 una revisi\u00f3n adicional y se public\u00f3 un borrador final en el sitio web de la OMS para recibir comentarios.\n\n3. **\u00bfQu\u00e9 resultados se obtuvieron en la reuni\u00f3n general de IMPACT en Lisboa en diciembre de 2007?**\n   - Respuesta: En esta reuni\u00f3n se finaliz\u00f3 el texto revisado de las directrices de GDP, que reflejaba el consenso alcanzado durante la reuni\u00f3n y se someti\u00f3 a consideraci\u00f3n para su publicaci\u00f3n.\n\n### Resumen de Nivel Superior\n\nEl documento detalla el proceso de revisi\u00f3n y actualizaci\u00f3n de las directrices de buenas pr\u00e1cticas de distribuci\u00f3n de la OMS, enfatizando la colaboraci\u00f3n internacional para combatir la falsificaci\u00f3n de medicamentos. Se describe c\u00f3mo las directrices originales fueron revisadas para abordar las preocupaciones sobre la seguridad de la cadena de suministro y se destaca la importancia de la participaci\u00f3n de m\u00faltiples partes interesadas en el proceso de revisi\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**1. Esquema de Certificaci\u00f3n de la OMS:**\n   - Es un acuerdo internacional voluntario que busca asegurar la calidad de los productos farmac\u00e9uticos en el comercio internacional.\n   - Se basa en varias resoluciones de la Asamblea Mundial de la Salud, que incluyen:\n     - WHA22.50 (1969)\n     - WHA28.65 (1975)\n     - WHA41.18 (1988)\n     - WHA45.29 (1992)\n     - WHA50.3 (1997)\n   - El documento principal del esquema es el Certificado de Producto Farmac\u00e9utico (CPP).\n\n**2. Revisi\u00f3n del Esquema:**\n   - En 2008, el Comit\u00e9 de Expertos recomend\u00f3 revisar el esquema debido a la globalizaci\u00f3n del sector farmac\u00e9utico y cambios en la regulaci\u00f3n y grupos de adquisici\u00f3n.\n   - Se identific\u00f3 la falta de provisiones adecuadas en el esquema para productos fabricados para \"exportaci\u00f3n solamente\".\n\n**3. Proceso de Preguntas y Respuestas:**\n   - Se elabor\u00f3 un documento de preguntas y respuestas basado en las recomendaciones del Comit\u00e9.\n   - El primer documento de trabajo se bas\u00f3 en comentarios de la Federaci\u00f3n Internacional de Fabricantes y Asociaciones Farmac\u00e9uticas (IFPMA) y la Federaci\u00f3n Europea de Industrias Farmac\u00e9uticas (EFPIA).\n   - Se revisaron los comentarios y se prepar\u00f3 un nuevo conjunto de preguntas y respuestas para su discusi\u00f3n en el Comit\u00e9 de Expertos.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Responsable del esquema de certificaci\u00f3n y de la revisi\u00f3n del mismo.\n- **Asamblea Mundial de la Salud:** Cuerpo que ha emitido las resoluciones que respaldan el esquema.\n- **Comit\u00e9 de Expertos:** Grupo que recomend\u00f3 la revisi\u00f3n del esquema y particip\u00f3 en la elaboraci\u00f3n del documento de preguntas y respuestas.\n- **IFPMA/EFPIA:** Organizaciones que proporcionaron comentarios y contribuyeron al desarrollo del documento de preguntas y respuestas.", "excerpt_keywords": "Keywords: WHO, good distribution practices, counterfeit medicines, IMPACT, pharmaceutical preparations"}}, "e764195e-527b-4cb1-bfcc-9b8d5b32cf19": {"node_ids": ["a22236c8-3e3d-498c-ba80-e5ec862073d4"], "metadata": {"page_label": "65", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "WHO Expert Committee in 2008 as a recommendation from the IMPACT partners.\n\nDuring its forty-third meeting the Committee recommended discussing the document further with IMPACT, the EU and with WHO in view of the comments received. A meeting was subsequently arranged in Geneva on 31 August\u20131 September 2009 with a view to preparing a new document containing all comments received from the various parties and members of the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations. The revised document resulting from this meeting was presented to the Expert Committee at its current meeting and the main comments received up until the date of the meeting were identified and discussed. A small subgroup was formed to review all comments received by the permissible deadline. The Committee adopted the text subject to input from this subgroup and provided no major additional comments were received. The Committee members would be duly informed of the outcome (Annex 5), in order to allow them to reconfirm their decision in light of the deliberations of this Expert Committee subgroup.\n\n### 8.3 Regulatory oversight on pharmaceutical cold chain management\n\nFollowing-up on the 2008 joint session of topics with common interest, the Secretary of the Expert Committee for Biological Standardization (ECBS) arranged for an update in relation to the draft *Regulatory oversight on pharmaceutical cold chain management. Harmonized guidance for the storage and transport of temperature-sensitive pharmaceutical products.* The table of contents of the current draft working document was presented to the Committee for information.\n\nThe document had been developed with a group of experts and took forward the agreement from the joint meeting between the two Committees in 2008, as one of the cross-cutting issues. The document was considered to be fairly mature and would be presented at the 2009 ECBS meeting to obtain feedback, with a view to possible adoption of the document in 2010.\n\nAn oral update by video was given by the technical officer responsible for this project.\n\nThe Expert Committee noted this update and suggested circulation of the document to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and to the IMPACT IRIWG that developed the revision of the GDP.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Revisi\u00f3n de Documentos y Colaboraci\u00f3n**: Durante su reuni\u00f3n, el Comit\u00e9 de Expertos de la OMS discuti\u00f3 un documento revisado que incorporaba comentarios de diversas partes interesadas, incluyendo IMPACT y la Uni\u00f3n Europea. Se form\u00f3 un subgrupo para revisar estos comentarios antes de adoptar el texto final.\n\n2. **Gesti\u00f3n de la Cadena de Fr\u00edo Farmac\u00e9utica**: Se present\u00f3 un borrador sobre la regulaci\u00f3n de la gesti\u00f3n de la cadena de fr\u00edo para productos farmac\u00e9uticos sensibles a la temperatura. Este documento, desarrollado por un grupo de expertos, se considera maduro y se planea presentar en una reuni\u00f3n futura para obtener retroalimentaci\u00f3n y posible adopci\u00f3n.\n\n3. **Actualizaci\u00f3n y Circulaci\u00f3n de Documentos**: Se realiz\u00f3 una actualizaci\u00f3n oral sobre el proyecto de gesti\u00f3n de la cadena de fr\u00edo, y se sugiri\u00f3 la circulaci\u00f3n del documento entre el Panel Asesor de la OMS y el grupo de trabajo de IMPACT que revis\u00f3 las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP).\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 proceso sigui\u00f3 el Comit\u00e9 de Expertos para incorporar los comentarios de las partes interesadas en el documento revisado?**\n   - El Comit\u00e9 recomend\u00f3 discutir el documento con IMPACT, la UE y la OMS, organizando una reuni\u00f3n en Ginebra donde se prepar\u00f3 un nuevo documento que inclu\u00eda todos los comentarios recibidos. Se form\u00f3 un subgrupo para revisar estos comentarios antes de la adopci\u00f3n final del texto.\n\n2. **\u00bfCu\u00e1l es el objetivo del documento sobre la regulaci\u00f3n de la gesti\u00f3n de la cadena de fr\u00edo y qu\u00e9 pasos se prev\u00e9n para su adopci\u00f3n?**\n   - El objetivo del documento es proporcionar orientaci\u00f3n armonizada para el almacenamiento y transporte de productos farmac\u00e9uticos sensibles a la temperatura. Se planea presentar el documento en la reuni\u00f3n del ECBS de 2009 para obtener retroalimentaci\u00f3n, con la posibilidad de adopci\u00f3n en 2010.\n\n3. **\u00bfQu\u00e9 recomendaciones se hicieron respecto a la circulaci\u00f3n del documento sobre la gesti\u00f3n de la cadena de fr\u00edo?**\n   - Se sugiri\u00f3 que el documento se circule entre el Panel Asesor de la OMS sobre la Farmacopea Internacional y Preparaciones Farmac\u00e9uticas, as\u00ed como al grupo de trabajo de IMPACT que desarroll\u00f3 la revisi\u00f3n de las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Comit\u00e9 de Expertos de la OMS**: \n   - Se reuni\u00f3 para revisar un informe actualizado y aprob\u00f3 preguntas y respuestas para su publicaci\u00f3n en el sitio web de la OMS y en *WHO Drug Information*.\n\n2. **Pr\u00e1cticas de Buena Distribuci\u00f3n (GDP)**:\n   - Las directrices de GDP fueron adoptadas inicialmente en octubre de 2005 y revisadas posteriormente por la Alianza Internacional contra la Falsificaci\u00f3n de Productos M\u00e9dicos (IMPACT) para prevenir la entrada de medicamentos falsificados en la cadena de suministro.\n\n3. **Revisi\u00f3n en Bonn (2006)**:\n   - En una reuni\u00f3n en Bonn, se propusieron enmiendas para mejorar la seguridad de la cadena de distribuci\u00f3n frente a medicamentos falsificados, reconociendo que estos pod\u00edan llegar a pacientes incluso en pa\u00edses con regulaciones estrictas.\n\n4. **Proceso de Elaboraci\u00f3n del Borrador**:\n   - Un primer borrador fue circulado en marzo de 2007 a los miembros del Grupo de Trabajo de Implementaci\u00f3n Regulatoria (IRIWG). Se discutieron enmiendas en una reuni\u00f3n en Washington, DC, y se solicit\u00f3 retroalimentaci\u00f3n adicional antes de finalizar el documento.\n\n5. **Reuni\u00f3n General en Lisboa (2007)**:\n   - El texto revisado de las directrices de GDP fue finalizado en la reuni\u00f3n general de IMPACT en Lisboa, reflejando el consenso alcanzado y preparado para su publicaci\u00f3n.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la adopci\u00f3n y revisi\u00f3n de las directrices de GDP.\n- **IMPACT (Alianza Internacional contra la Falsificaci\u00f3n de Productos M\u00e9dicos)**: Grupo que revis\u00f3 y propuso enmiendas a las directrices de GDP.\n- **IRIWG (Grupo de Trabajo de Implementaci\u00f3n Regulatoria)**: Grupo que particip\u00f3 en la revisi\u00f3n y discusi\u00f3n de las directrices de GDP.\n- **Estados Miembros de la OMS**: Incluyendo a las Autoridades Reguladoras de Medicamentos (MRAs) de 60 pa\u00edses que participaron en el proceso de revisi\u00f3n.", "excerpt_keywords": "Keywords: WHO, IMPACT, pharmaceutical cold chain management, regulatory oversight, Good Distribution Practices (GDP)"}}, "5d160806-2b4c-4bd5-b196-4cd126ed5a2d": {"node_ids": ["0e156791-be61-4b2d-99fa-c61eba413ec7"], "metadata": {"page_label": "66", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9. Prequalification of priority essential medicines\n\n## 9.1 Prequalification Programme managed by WHO\n\nThe WHO Prequalification Programme (PQP) ensured that medicines procured with international funds were assessed and that the manufacturers of these medicines were inspected, in order to provide a high level of assurance of their quality, efficacy and safety. This was supported by building national regulatory capacity, providing technical assistance to selected manufacturers and postmarket monitoring through quality control (QC) testing by prequalified quality control laboratories. Ultimately the aim was to make low-cost quality priority medicines available for the benefit of those in need.\n\nPQP continued to expand in order to meet the needs of procurers and currently covered priority essential medicines in the following areas:\n\n- HIV/AIDS\n- tuberculosis\n- malaria\n- reproductive health\n- selected individual products for other diseases such as oseltamivir and zinc sulfate.\n\nManufacturers were invited to apply for prequalification of medicines included in invitations for Expressions of Interest (EOI) published on the PQP web site.\n\nThe Programme was reliant upon and appreciated the assistance and support of many partners, including national medicines regulatory authorities (NMRAs), QC laboratories, WHO disease departments and programmes, regional and country offices, United Nations and other drug procurement agencies (including UNICEF, the Global Fund and M\u00e9decins Sans Fronti\u00e8res) and donors such as the Bill and Melinda Gates Foundation and UNITAID, as well as the colleagues of the Medicines Quality Assurance and Regulatory Support Programmes of WHO. The Programme relied heavily on the standards and guidelines adopted by this Expert Committee.\n\n### Assessment of product dossiers (see Table 1)\n\nAssessment of product dossiers was conducted both in-house and by external international experts. WHO standards as defined in WHO guidelines and *The International Pharmacopoeia* were applied. If these did not exist, ICH guidelines were used and, in case of need, guidelines of stringent regulatory authorities were considered.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl Programa de Precalificaci\u00f3n de Medicamentos Esenciales Prioritarios de la OMS (PQP) se encarga de asegurar que los medicamentos adquiridos con fondos internacionales sean evaluados y que los fabricantes sean inspeccionados, garantizando as\u00ed su calidad, eficacia y seguridad. Este programa se apoya en la construcci\u00f3n de capacidades regulatorias nacionales, asistencia t\u00e9cnica a fabricantes seleccionados y monitoreo postcomercializaci\u00f3n a trav\u00e9s de pruebas de control de calidad. Actualmente, el PQP abarca \u00e1reas prioritarias como VIH/SIDA, tuberculosis, malaria, salud reproductiva y otros productos individuales. La evaluaci\u00f3n de los expedientes de productos se realiza tanto internamente como por expertos internacionales externos, aplicando est\u00e1ndares y directrices de la OMS y otras autoridades regulatorias.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las \u00e1reas prioritarias que cubre actualmente el Programa de Precalificaci\u00f3n de Medicamentos de la OMS?**\n   - Respuesta: El PQP cubre \u00e1reas prioritarias como VIH/SIDA, tuberculosis, malaria, salud reproductiva y productos individuales seleccionados para otras enfermedades, como oseltamivir y sulfato de zinc.\n\n2. **\u00bfQu\u00e9 tipo de apoyo reciben los fabricantes para cumplir con los est\u00e1ndares del PQP?**\n   - Respuesta: Los fabricantes reciben asistencia t\u00e9cnica, apoyo en la construcci\u00f3n de capacidades regulatorias nacionales y monitoreo postcomercializaci\u00f3n a trav\u00e9s de laboratorios de control de calidad precalificados.\n\n3. **\u00bfQu\u00e9 est\u00e1ndares se aplican en la evaluaci\u00f3n de los expedientes de productos dentro del PQP?**\n   - Respuesta: Se aplican los est\u00e1ndares definidos en las directrices de la OMS y *The International Pharmacopoeia*. Si no existen, se utilizan las directrices del ICH y, si es necesario, las directrices de autoridades regulatorias estrictas.\n\n### Resumen adicional\n\nEl PQP de la OMS es un programa clave para garantizar que los medicamentos esenciales sean de alta calidad y est\u00e9n disponibles para quienes los necesitan, especialmente en \u00e1reas de alta prioridad como enfermedades infecciosas. La colaboraci\u00f3n con diversas organizaciones y la aplicaci\u00f3n de est\u00e1ndares internacionales son fundamentales para el \u00e9xito del programa.", "prev_section_summary": "### Temas Clave:\n\n1. **Revisi\u00f3n de Documentos**: El Comit\u00e9 de Expertos de la OMS revis\u00f3 un documento que incorporaba comentarios de diversas partes interesadas, incluyendo IMPACT y la Uni\u00f3n Europea. Se organiz\u00f3 una reuni\u00f3n en Ginebra para discutir y preparar un nuevo documento basado en estos comentarios.\n\n2. **Gesti\u00f3n de la Cadena de Fr\u00edo Farmac\u00e9utica**: Se present\u00f3 un borrador sobre la regulaci\u00f3n de la gesti\u00f3n de la cadena de fr\u00edo para productos farmac\u00e9uticos sensibles a la temperatura. Este documento, desarrollado por un grupo de expertos, se considera maduro y se planea presentar en una reuni\u00f3n futura para obtener retroalimentaci\u00f3n y posible adopci\u00f3n.\n\n3. **Actualizaci\u00f3n y Circulaci\u00f3n de Documentos**: Se realiz\u00f3 una actualizaci\u00f3n oral sobre el proyecto de gesti\u00f3n de la cadena de fr\u00edo, y se sugiri\u00f3 la circulaci\u00f3n del documento entre el Panel Asesor de la OMS y el grupo de trabajo de IMPACT que revis\u00f3 las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP).\n\n### Entidades:\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la salud p\u00fablica internacional que lidera la revisi\u00f3n y adopci\u00f3n de documentos t\u00e9cnicos.\n- **IMPACT**: Asociaci\u00f3n de socios que contribuyen a la revisi\u00f3n de documentos y pr\u00e1cticas en el \u00e1mbito farmac\u00e9utico.\n- **Uni\u00f3n Europea (UE)**: Entidad que participa en la discusi\u00f3n y revisi\u00f3n de documentos relacionados con la regulaci\u00f3n farmac\u00e9utica.\n- **ECBS (Comit\u00e9 de Expertos para la Normalizaci\u00f3n Biol\u00f3gica)**: Comit\u00e9 que organiza actualizaciones y revisiones sobre temas de estandarizaci\u00f3n biol\u00f3gica y farmac\u00e9utica.\n- **Panel Asesor de la OMS sobre la Farmacopea Internacional y Preparaciones Farmac\u00e9uticas**: Grupo que proporciona asesoramiento sobre est\u00e1ndares y pr\u00e1cticas en farmacolog\u00eda.", "excerpt_keywords": "Keywords: prequalification, essential medicines, WHO, quality assurance, regulatory capacity"}}, "39112a93-e6ca-4c13-9cd8-92064b394126": {"node_ids": ["ac90a656-c2aa-43be-852b-f01e5ed5ca2c"], "metadata": {"page_label": "67", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "regulatory authorities were applied. Much of the assessment work was done in Copenhagen during bimonthly meetings of 15\u201320 assessors. Variations to prequalified products were processed in-house and during the meetings in Copenhagen.\n\n### Table 1\n**Assessment of product dossiers: statistics**\n\n| | 2007 | 2008 | 2009(As at 16/09/2009) |\n| - | - | - | - |\n| Products prequalified | 21 | 40 | 24 |\n| Dossiers submitted | 90 | 92 | 55 |\n\n\nMedicines assessed and prequalified by WHO were included in a List of WHO Prequalified Medicinal Products on the PQP web site. Also listed were medicines assessed by SRAs, following an abbreviated procedure.\n\nCurrently prequalified products (16 September 2009):\n\n- 247 for treatment of HIV/AIDS and related diseases\n- one for treatment of influenza (prequalified in 2009)\n- 23 for treatment of tuberculosis\n- 16 for treatment of malaria\n- 2 for reproductive health (prequalified in 2009)\n- Total: 289\n\n### Inspections of manufacturers (see Table 2)\n\nManufacturers of finished products, selected APIs and also selected contract research organizations (CROs) (which carried out clinical/bioequivalence studies) were inspected as part of the prequalification process.\n\nInspections were conducted by a team of inspectors consisting of:\n\n- a WHO lead GMP inspector\n- an inspector from a well-established inspectorate\n- national inspectors from the country of the manufacturer, who were invited to be part of the team as observers but had no decision-making power (because of different GMP standards and potential conflict of interest)\n- inspectors from developing target countries who might also be invited as observers, for capacity-building purposes.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento presenta informaci\u00f3n sobre el proceso de evaluaci\u00f3n y precalificaci\u00f3n de productos medicinales por parte de la Organizaci\u00f3n Mundial de la Salud (OMS). Se detalla el trabajo realizado en Copenhague, donde se llevaron a cabo reuniones bimestrales con un grupo de evaluadores. Se incluyen estad\u00edsticas sobre la cantidad de productos precalificados y los expedientes presentados entre 2007 y 2009. Adem\u00e1s, se menciona la inspecci\u00f3n de fabricantes y organizaciones de investigaci\u00f3n contratadas como parte del proceso de precalificaci\u00f3n, destacando la composici\u00f3n del equipo de inspectores.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1ntos productos fueron precalificados para el tratamiento de malaria hasta el 16 de septiembre de 2009?**\n   - Respuesta: Hasta el 16 de septiembre de 2009, se precalificaron 16 productos para el tratamiento de malaria.\n\n2. **\u00bfQu\u00e9 tipo de inspectores forman parte del equipo de inspecci\u00f3n durante el proceso de precalificaci\u00f3n de productos medicinales?**\n   - Respuesta: El equipo de inspecci\u00f3n est\u00e1 compuesto por un inspector l\u00edder de GMP de la OMS, un inspector de una autoridad de inspecci\u00f3n bien establecida, inspectores nacionales del pa\u00eds del fabricante (como observadores) y inspectores de pa\u00edses en desarrollo (tambi\u00e9n como observadores).\n\n3. **\u00bfCu\u00e1l fue la tendencia en la cantidad de expedientes presentados para precalificaci\u00f3n entre 2007 y 2009?**\n   - Respuesta: La cantidad de expedientes presentados para precalificaci\u00f3n mostr\u00f3 una ligera disminuci\u00f3n, pasando de 90 en 2007 a 55 en 2009 (hasta el 16 de septiembre de 2009).", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**Programa de Precalificaci\u00f3n de Medicamentos Esenciales Prioritarios (PQP) de la OMS:**\n- **Objetivo:** Asegurar que los medicamentos adquiridos con fondos internacionales sean evaluados y que los fabricantes sean inspeccionados, garantizando su calidad, eficacia y seguridad.\n- **Apoyo:** Construcci\u00f3n de capacidades regulatorias nacionales, asistencia t\u00e9cnica a fabricantes seleccionados y monitoreo postcomercializaci\u00f3n a trav\u00e9s de laboratorios de control de calidad precalificados.\n\n**\u00c1reas prioritarias cubiertas por el PQP:**\n- VIH/SIDA\n- Tuberculosis\n- Malaria\n- Salud reproductiva\n- Productos individuales seleccionados para otras enfermedades (ej. oseltamivir y sulfato de zinc).\n\n**Colaboraciones y socios:**\n- Autoridades regulatorias nacionales de medicamentos (NMRAs)\n- Laboratorios de control de calidad (QC)\n- Departamentos y programas de enfermedades de la OMS\n- Oficinas regionales y de pa\u00eds de la OMS\n- Agencias de adquisici\u00f3n de medicamentos de la ONU (ej. UNICEF, Global Fund, M\u00e9dicos Sin Fronteras)\n- Donantes como la Fundaci\u00f3n Bill y Melinda Gates y UNITAID.\n\n**Evaluaci\u00f3n de expedientes de productos:**\n- Realizada tanto internamente como por expertos internacionales externos.\n- Aplicaci\u00f3n de est\u00e1ndares definidos en las directrices de la OMS y *The International Pharmacopoeia*.\n- Uso de directrices del ICH y de autoridades regulatorias estrictas cuando sea necesario.\n\nEste programa es fundamental para garantizar la disponibilidad de medicamentos esenciales de alta calidad, especialmente en \u00e1reas cr\u00edticas de salud p\u00fablica.", "excerpt_keywords": "Keywords: WHO, prequalification, medicinal products, inspections, regulatory authorities"}}, "30f9445e-d74e-4e99-af24-cf4950deacfa": {"node_ids": ["435a5633-b92b-499a-9ceb-0a26a98e0abd"], "metadata": {"page_label": "68", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Inspections carried out since 2005\n\n| Manufacturer: | 2005 | 2006 | 2007 | 2008 | 2009 (to September) |\n| - | - | - | - | - | - |\n| Finished product | 20 | 17 | 26 | 27 | 22 |\n| Active pharmaceutical ingredient | 10 | 10 | 6 | 11 | 5 |\n| Contract research organization | 14 | 15 | 13 | 14 | 6 |\n| Quality control laboratory | 3 | 1 | 1 | 6 | 3 |\n\n\n## Prequalification of medicines \u2014 transparency\n\nThe World Health Assembly through Resolution WHA57.14 of 22 May 2004, requested WHO:\n\n\"3. (4) to ensure that the prequalification review process and the results of inspection and assessment reports of the listed products, aside from proprietary and confidential information, are made publicly available.\"\n\nA WHO Public Assessment Report (WHOPAR) provided a summary of the dossier assessment (where found to be compliant).\n\nA WHO Public Inspection Report (WHOPIR) provided a summary of the inspection (where found to be GMP-compliant).\n\nA Notice of Concern (NOC) was a letter reflecting areas of concern where the non-compliances required urgent attention and corrective action by the manufacturer or research organization.\n\nA Notice of Suspension was a letter reflecting areas of concern when deficiencies identified during an inspection indicate significant non-compliance with GMP, good clinical practices (GCP) or good laboratory practices (GLP), as relevant, resulting in inadequate assurance of product quality.\n\n## Prequalification of QC laboratories\n\nThe PQP was established in 2004 for QC laboratories in Africa only; however, the programme had since broadened its scope for participation and was now voluntary and without regional limitation. Any laboratory (private or governmental) could participate and the programme was free of charge. The third invitation for EOI was published in September 2007 at the following address: http://www.who.int/prequal/info_applicants/eoi/EOI-QCLabsV3.pdf.\n\nPriority regarding assessment was given to national QC laboratories, laboratories providing testing services to the government, and QC laboratories in areas where United Nations agencies had identified the need for quality testing.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla las inspecciones realizadas desde 2005 en diferentes tipos de fabricantes y laboratorios, as\u00ed como la transparencia en el proceso de precalificaci\u00f3n de medicamentos. Se menciona la importancia de los informes p\u00fablicos de evaluaci\u00f3n e inspecci\u00f3n, as\u00ed como las acciones correctivas que se pueden tomar en caso de incumplimientos. Adem\u00e1s, se describe el Programa de Precalificaci\u00f3n de Laboratorios de Control de Calidad (PQP), que se estableci\u00f3 inicialmente para \u00c1frica y se ha expandido a nivel global.\n\n### Preguntas:\n1. **\u00bfCu\u00e1ntas inspecciones de laboratorios de control de calidad se llevaron a cabo en 2008 y qu\u00e9 tendencia se observa en los a\u00f1os anteriores?**\n   - Respuesta: En 2008 se realizaron 6 inspecciones de laboratorios de control de calidad. La tendencia muestra un aumento en 2008 en comparaci\u00f3n con solo 1 inspecci\u00f3n en 2006 y 2007, pero una disminuci\u00f3n respecto a las 3 inspecciones en 2009 hasta septiembre.\n\n2. **\u00bfQu\u00e9 tipo de informes proporciona la OMS para asegurar la transparencia en el proceso de precalificaci\u00f3n de medicamentos y qu\u00e9 informaci\u00f3n contienen?**\n   - Respuesta: La OMS proporciona dos tipos de informes: el Informe P\u00fablico de Evaluaci\u00f3n de la OMS (WHOPAR), que resume la evaluaci\u00f3n del expediente, y el Informe P\u00fablico de Inspecci\u00f3n de la OMS (WHOPIR), que resume la inspecci\u00f3n y la conformidad con las Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n3. **\u00bfCu\u00e1l es la prioridad en la evaluaci\u00f3n de laboratorios de control de calidad seg\u00fan el Programa de Precalificaci\u00f3n (PQP) y qu\u00e9 tipo de laboratorios pueden participar?**\n   - Respuesta: La prioridad en la evaluaci\u00f3n se otorga a los laboratorios nacionales de control de calidad, aquellos que brindan servicios de pruebas al gobierno y los laboratorios en \u00e1reas donde las agencias de las Naciones Unidas han identificado la necesidad de pruebas de calidad. Cualquier laboratorio, ya sea privado o gubernamental, puede participar en el programa, que es gratuito.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Proceso de Evaluaci\u00f3n y Precalificaci\u00f3n**:\n   - La Organizaci\u00f3n Mundial de la Salud (OMS) lleva a cabo la evaluaci\u00f3n y precalificaci\u00f3n de productos medicinales.\n   - Las reuniones de evaluaci\u00f3n se realizan bimestralmente en Copenhague con un grupo de 15 a 20 evaluadores.\n\n2. **Estad\u00edsticas de Precalificaci\u00f3n**:\n   - Se presentan datos sobre la cantidad de productos precalificados y expedientes presentados entre 2007 y 2009:\n     - Productos precalificados: 21 (2007), 40 (2008), 24 (2009).\n     - Dossiers presentados: 90 (2007), 92 (2008), 55 (2009).\n\n3. **Medicamentos Precalificados (hasta el 16 de septiembre de 2009)**:\n   - Total de productos precalificados: 289.\n   - Desglose:\n     - 247 para tratamiento de VIH/SIDA y enfermedades relacionadas.\n     - 1 para tratamiento de influenza.\n     - 23 para tratamiento de tuberculosis.\n     - 16 para tratamiento de malaria.\n     - 2 para salud reproductiva.\n\n4. **Inspecciones de Fabricantes**:\n   - Se inspeccionan fabricantes de productos terminados, APIs seleccionados y organizaciones de investigaci\u00f3n contratadas (CROs).\n   - El equipo de inspecci\u00f3n incluye:\n     - Un inspector l\u00edder de GMP de la OMS.\n     - Un inspector de una autoridad de inspecci\u00f3n bien establecida.\n     - Inspectores nacionales del pa\u00eds del fabricante (como observadores).\n     - Inspectores de pa\u00edses en desarrollo (tambi\u00e9n como observadores).\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Responsable de la evaluaci\u00f3n y precalificaci\u00f3n de productos medicinales.\n- **Productos Medicinales**: Incluyen tratamientos para VIH/SIDA, tuberculosis, malaria, influenza y salud reproductiva.\n- **Inspectores**: Compuestos por representantes de la OMS y autoridades de inspecci\u00f3n nacionales e internacionales.", "excerpt_keywords": "Keywords: inspections, prequalification, WHO, quality control laboratories, transparency"}}, "65ae2c06-0ecd-4517-8092-1a9e5f0dc897": {"node_ids": ["fd485735-e957-4688-8de9-5e9e90505868"], "metadata": {"page_label": "69", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Monitoring after prequalification involved:\n\n- **Re-inspections at regular intervals**\n  - Normally three years\n  - Two re-inspections performed\n\n- **A brief report to be submitted annually**\n  - Summary of services provided to United Nations agencies, number of samples analysed, methods used, complaints received\n  - Brief details of proficiency testing\n  - Changes to key personnel, facility, equipment or other change with significant impact on the laboratory\n  - Update of the laboratory information file (LIF), in case of changes with significant impact on LIF content\n\n- **Evaluation of results from participation in proficiency testing**\n  - WHO EQAAS, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (AFSSAPS) network of francophone African countries\n\n- **WHO might suspend or withdraw a laboratory from the list when there was evidence of noncompliance.**\n\nAt present the PQP had surpassed expectations and a significant number of laboratories around the world were applying for prequalification.\n\nThe object was to increase access to QC laboratories that met recommended standards and that were committed to providing a service to United Nations agencies for testing of medicines, including but not limited to HIV/AIDS, tuberculosis and malaria products.\n\nAs of September 2009, there were 11 prequalified laboratories in: Algeria; France; India; Kenya (2); Morocco; Singapore (2); South Africa (2); and Viet Nam.\n\nThe PQP was also involved in capacity building: technical assistance provided to eight national medicines QC laboratories; training in quality assurance, quality control and Ph.Int. (2007); a seminar on rational sampling and testing in quality control of medicines (2009); and participation in EDQM in quality assurance training for official medicines control laboratories (2007). The Programme also monitored the quality of medicines through its policy, sampling and testing projects and prequalified laboratories or laboratories for which the evidence of reliability was available. The major quality monitoring projects were the following:\n\n## Quality monitoring of medicines funded by UNITAID (2008/9)\n\nThe pilot phase focused on paediatric and second-line antiretrovirals and co-trimoxazole-containing medicines. In cooperation with NMRAs in Kenya, Uganda, the United Republic of Tanzania and Zambia, 378 samples produced by 24 manufacturers were collected, mostly from treatment centres and tested in the laboratory. Only three samples did not", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento detalla el proceso de monitoreo posterior a la precalificaci\u00f3n de laboratorios por parte de la Organizaci\u00f3n Mundial de la Salud (OMS). Este proceso incluye re-inspecciones regulares, la presentaci\u00f3n de informes anuales, la evaluaci\u00f3n de resultados de pruebas de competencia y la posibilidad de suspensi\u00f3n de laboratorios en caso de incumplimiento. A partir de septiembre de 2009, hab\u00eda 11 laboratorios precalificados en varios pa\u00edses, y el Programa de Precalificaci\u00f3n (PQP) tambi\u00e9n se enfocaba en la capacitaci\u00f3n y el fortalecimiento de capacidades en laboratorios nacionales. Adem\u00e1s, se menciona un proyecto de monitoreo de calidad de medicamentos financiado por UNITAID, que se centr\u00f3 en medicamentos pedi\u00e1tricos y antirretrovirales de segunda l\u00ednea.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que pueden llevar a la OMS a suspender o retirar un laboratorio de la lista de laboratorios precalificados?**\n   - Esta pregunta busca detalles sobre las evidencias de incumplimiento que la OMS considera para tomar tal decisi\u00f3n, lo cual no se menciona expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 tipo de asistencia t\u00e9cnica se proporcion\u00f3 a los laboratorios nacionales de control de calidad de medicamentos y cu\u00e1les fueron los resultados de dicha asistencia?**\n   - Aunque se menciona que se brind\u00f3 asistencia t\u00e9cnica y capacitaci\u00f3n, no se detallan los resultados espec\u00edficos o el impacto de estas actividades en los laboratorios.\n\n3. **\u00bfQu\u00e9 m\u00e9todos espec\u00edficos se utilizaron para la recolecci\u00f3n y an\u00e1lisis de las 378 muestras en el proyecto de monitoreo de medicamentos financiado por UNITAID?**\n   - La pregunta busca informaci\u00f3n sobre los procedimientos y t\u00e9cnicas de laboratorio utilizados en el an\u00e1lisis de las muestras, que no se especifican en el contexto proporcionado.", "prev_section_summary": "### Temas Clave:\n\n1. **Inspecciones de Fabricantes y Laboratorios**: Se presentan datos sobre las inspecciones realizadas desde 2005 en diferentes categor\u00edas, incluyendo productos terminados, ingredientes farmac\u00e9uticos activos, organizaciones de investigaci\u00f3n por contrato y laboratorios de control de calidad. Se observa una variabilidad en el n\u00famero de inspecciones a lo largo de los a\u00f1os.\n\n2. **Transparencia en la Precalificaci\u00f3n de Medicamentos**: La OMS, a trav\u00e9s de la Resoluci\u00f3n WHA57.14, se compromete a hacer p\u00fablicos los procesos de revisi\u00f3n de precalificaci\u00f3n y los resultados de las inspecciones, excluyendo informaci\u00f3n confidencial. Se describen los tipos de informes que se generan, como el WHOPAR y el WHOPIR, as\u00ed como las Notificaciones de Preocupaci\u00f3n y Suspensi\u00f3n.\n\n3. **Programa de Precalificaci\u00f3n de Laboratorios de Control de Calidad (PQP)**: Este programa, inicialmente establecido para laboratorios en \u00c1frica, se ha expandido a nivel global y permite la participaci\u00f3n de cualquier laboratorio, ya sea privado o gubernamental. Se prioriza la evaluaci\u00f3n de laboratorios nacionales y aquellos que brindan servicios a gobiernos o en \u00e1reas identificadas por agencias de la ONU.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la precalificaci\u00f3n y regulaci\u00f3n de medicamentos y laboratorios.\n- **World Health Assembly**: Cuerpo que emite resoluciones como la WHA57.14, que establece directrices para la transparencia en la precalificaci\u00f3n de medicamentos.\n- **Laboratorios de Control de Calidad**: Entidades que participan en el PQP y son evaluadas para asegurar la calidad de los productos farmac\u00e9uticos.\n- **Fabricantes de Productos Farmac\u00e9uticos**: Incluyen aquellos que producen productos terminados y ingredientes activos, as\u00ed como organizaciones de investigaci\u00f3n por contrato.\n\nEste resumen destaca la importancia de la regulaci\u00f3n y la transparencia en la industria farmac\u00e9utica, as\u00ed como el compromiso de la OMS para asegurar la calidad de los medicamentos a trav\u00e9s de inspecciones y programas de precalificaci\u00f3n.", "excerpt_keywords": "Keywords: prequalification, quality control, WHO, laboratory monitoring, medicines"}}, "bd202fb7-3a80-46bf-a4f4-92f3e0907bb9": {"node_ids": ["3994220b-67b9-4347-bcdb-e055ae8f9bf5"], "metadata": {"page_label": "70", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Quality Survey of Antimalarial Medicines in Africa (2008-2009)\n\nA quality survey of antimalarial medicines focused on artemisinin-based combination therapies (ACTs) and sulfadoxine-pyrimethamine oral dosage forms was performed in six African countries; 936 medicine samples were collected at all levels of the distribution chain and the informal market and were screened by Minilab in cooperation with NMRAs. Three hundred and six samples were then tested fully in the laboratory, of which 74 were found to be non-compliant with a range of quality problems, from very minor non-compliance to absence of the API in two samples.\n\n# Quality Survey of Antituberculosis Medicines in Eastern Europe (2009)\n\nA quality survey of antituberculosis medicines focused on products containing rifampicin, isoniazid, kanamycin and ofloxacin was initiated in Armenia, Azerbaijan, Belarus, Kazakhstan, Ukraine and Uzbekistan; 291 samples were collected and testing is ongoing.\n\nSeveral other quality monitoring projects had been conducted since 2005.\n\n# Training and Capacity Building\n\nTraining and capacity building were important components of the PQP with the aim of increasing the regulatory capacity of NMRAs in developing countries and to assist manufacturers, CROs and QC laboratories in these countries to improve standards and meet prequalification requirements.\n\nTraining was generally provided through seminars and workshops, and might include visits to manufacturers. It was based on prequalification and WHO requirements, but might also be problem-oriented, e.g. relating to a specific product type. NMRA staff and manufacturers frequently participated together in the same training programme and, where possible, the focus was on \u201ctrain the trainer\u201d for maximum effect.\n\nThirteen training sessions were organized or supported by WHO in 2007, 15 in 2008 and seven up to September 2009.\n\nIn addition to training activities, capacity building of regulatory authorities was supported by the programme hosting rotational posts for assessors in Geneva. These were available for periods of three months during which the participant worked alongside WHO experts and also attended the sessions in Copenhagen to learn from external international experts.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Encuesta de Calidad de Medicamentos Antimal\u00e1ricos en \u00c1frica (2008-2009)**: Se realiz\u00f3 una encuesta de calidad de medicamentos antimal\u00e1ricos en seis pa\u00edses africanos, donde se recolectaron 936 muestras de medicamentos. De estas, 306 fueron analizadas en laboratorio, encontrando que 74 no cumpl\u00edan con los est\u00e1ndares de calidad, incluyendo casos de ausencia del principio activo.\n\n2. **Encuesta de Calidad de Medicamentos Antituberculosos en Europa del Este (2009)**: Se inici\u00f3 una encuesta de calidad de medicamentos antituberculosos en varios pa\u00edses de Europa del Este, recolectando 291 muestras. Las pruebas est\u00e1n en curso, y se han realizado otros proyectos de monitoreo de calidad desde 2005.\n\n3. **Capacitaci\u00f3n y Fortalecimiento de Capacidades**: La capacitaci\u00f3n y el fortalecimiento de capacidades son componentes clave del Programa de Precalificaci\u00f3n (PQP) de la OMS, destinados a aumentar la capacidad regulatoria de las Autoridades Nacionales de Regulaci\u00f3n de Medicamentos (NMRAs) en pa\u00edses en desarrollo. Se llevaron a cabo m\u00faltiples sesiones de capacitaci\u00f3n y se ofrecieron puestos rotativos en Ginebra para evaluadores.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1ntas muestras de medicamentos antimal\u00e1ricos fueron recolectadas y cu\u00e1ntas de ellas resultaron no cumplir con los est\u00e1ndares de calidad?**\n   - Respuesta: Se recolectaron 936 muestras de medicamentos antimal\u00e1ricos, de las cuales 74 resultaron no cumplir con los est\u00e1ndares de calidad.\n\n2. **\u00bfQu\u00e9 tipo de medicamentos antituberculosos fueron objeto de la encuesta en Europa del Este y en cu\u00e1ntos pa\u00edses se realiz\u00f3?**\n   - Respuesta: La encuesta se centr\u00f3 en medicamentos que contienen rifampicina, isoniazida, kanamicina y ofloxacino, y se realiz\u00f3 en seis pa\u00edses: Armenia, Azerbaiy\u00e1n, Bielorrusia, Kazajist\u00e1n, Ucrania y Uzbekist\u00e1n.\n\n3. **\u00bfCu\u00e1ntas sesiones de capacitaci\u00f3n fueron organizadas o apoyadas por la OMS entre 2007 y septiembre de 2009?**\n   - Respuesta: Se organizaron o apoyaron 13 sesiones de capacitaci\u00f3n en 2007, 15 en 2008 y 7 hasta septiembre de 2009.", "prev_section_summary": "### Temas Clave\n\n1. **Monitoreo Posterior a la Precalificaci\u00f3n**:\n   - Re-inspecciones regulares cada tres a\u00f1os.\n   - Informes anuales sobre servicios, muestras analizadas, m\u00e9todos utilizados y cambios significativos en el laboratorio.\n   - Evaluaci\u00f3n de resultados de pruebas de competencia.\n\n2. **Suspensi\u00f3n de Laboratorios**:\n   - La OMS puede suspender o retirar un laboratorio de la lista si hay evidencia de incumplimiento.\n\n3. **Programa de Precalificaci\u00f3n (PQP)**:\n   - Aumento del acceso a laboratorios de control de calidad (QC) que cumplen con est\u00e1ndares recomendados.\n   - Capacitaci\u00f3n y asistencia t\u00e9cnica a laboratorios nacionales.\n\n4. **Laboratorios Precalificados**:\n   - A partir de septiembre de 2009, hab\u00eda 11 laboratorios precalificados en varios pa\u00edses, incluyendo Argelia, Francia, India, y Sud\u00e1frica.\n\n5. **Proyectos de Monitoreo de Calidad**:\n   - Proyecto financiado por UNITAID centrado en medicamentos pedi\u00e1tricos y antirretrovirales de segunda l\u00ednea, con recolecci\u00f3n y an\u00e1lisis de 378 muestras.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Responsable de la precalificaci\u00f3n y monitoreo de laboratorios.\n- **PQP (Programa de Precalificaci\u00f3n)**: Iniciativa de la OMS para asegurar la calidad de los laboratorios.\n- **NMRAs (Agencias Nacionales de Regulaci\u00f3n de Medicamentos)**: Colaboraci\u00f3n en la recolecci\u00f3n de muestras en varios pa\u00edses africanos.\n- **UNITAID**: Financiador del proyecto de monitoreo de calidad de medicamentos. \n\nEste resumen destaca los aspectos fundamentales del proceso de monitoreo de laboratorios precalificados y los esfuerzos de la OMS para garantizar la calidad de los medicamentos a nivel global.", "excerpt_keywords": "Keywords: antimalarial medicines, quality survey, capacity building, WHO, regulatory authorities"}}, "9ebe0502-a55c-4cf6-8e18-d50fe607c3ac": {"node_ids": ["7e7a3c03-77f5-4226-afd7-57a78b341a6c"], "metadata": {"page_label": "71", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Technical assistance\n\nTechnical assistance might be provided to a specific manufacturer, which was committed to participation in the PQP, found to be capable and willing to improve, and was located in a developing country. The products manufactured were to be included in an EOI list, must be of high value for public health purposes and must be poorly represented on the list of prequalified medicines.\n\nExpert consultants were provided by WHO to assist a manufacturer with compliance with GMP, GCP or GLP, as well as with data development and compilation of dossiers or regulatory guidance.\n\nTo avoid conflict of interest, technical assistance was independent from dossier assessments and inspections.\n\nDuring 2008 technical assistance was provided to eight manufacturers.\n\n# Future challenges\n\nSome of the key challenges facing the PQP were:\n\n- motivating manufacturers to apply for prequalification and maintain prequalification, to ensure the continued supply of essential priority medicines;\n- submission of incomplete or poor quality dossiers;\n- non-compliance with GMP by all types of manufacturers;\n- difficulty in filling technical positions within PQP;\n- lack of availability of national experts (assessors and inspectors);\n- reducing the total time taken to prequalify;\n- an increasing demand for capacity building (shift from general to more specific technical training); and\n- trust-building and information exchange to avoid duplication of effort.\n\nThe Committee was provided with an update on the PQP activities in 2009 and took note of the progress made.\n\n## 9.2 Guidelines on requalification of prequalified dossiers\n\nSection 12 (Maintenance of prequalification status) of WHO\u2019s *Procedure for prequalification of pharmaceutical products* (WHO Technical Report Series, No. 953, Annex 3, 2009) stated under \u201cMaintenance of prequalification status\u201d that:\n\n\u201cWHO will furthermore arrange for the products and manufacturing sites included in the list to be re-evaluated at regular intervals. If, as a result of this re-evaluation, it is found that a product and/or specified manufacturing site no longer complies with the WHO-recommended standards, such products and manufacturing sites will be removed from the list.\u201d", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento aborda la asistencia t\u00e9cnica proporcionada por la OMS a fabricantes de medicamentos en pa\u00edses en desarrollo que participan en el Programa de Precalificaci\u00f3n (PQP). Se destaca la importancia de la asistencia para cumplir con las Buenas Pr\u00e1cticas de Manufactura (GMP), Buenas Pr\u00e1cticas Cl\u00ednicas (GCP) y Buenas Pr\u00e1cticas de Laboratorio (GLP). Tambi\u00e9n se mencionan los desaf\u00edos futuros que enfrenta el PQP, como la motivaci\u00f3n de los fabricantes para mantener la precalificaci\u00f3n, la calidad de los expedientes presentados y la disponibilidad de expertos nacionales. Adem\u00e1s, se establece que la OMS re-evaluar\u00e1 peri\u00f3dicamente los productos y sitios de fabricaci\u00f3n para asegurar el cumplimiento de los est\u00e1ndares recomendados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios debe cumplir un fabricante para recibir asistencia t\u00e9cnica de la OMS en el contexto del PQP?**\n   - Los fabricantes deben estar comprometidos con la participaci\u00f3n en el PQP, ser capaces y estar dispuestos a mejorar, y estar ubicados en un pa\u00eds en desarrollo. Adem\u00e1s, los productos fabricados deben ser de alto valor para la salud p\u00fablica y estar poco representados en la lista de medicamentos precalificados.\n\n2. **\u00bfCu\u00e1les son algunos de los desaf\u00edos espec\u00edficos que enfrenta el PQP en relaci\u00f3n con la calidad de los expedientes presentados por los fabricantes?**\n   - Uno de los desaf\u00edos es la presentaci\u00f3n de expedientes incompletos o de mala calidad, lo que dificulta el proceso de precalificaci\u00f3n. Esto se suma a la no conformidad con las GMP por parte de todos los tipos de fabricantes.\n\n3. **\u00bfQu\u00e9 medidas toma la OMS para garantizar que los productos y sitios de fabricaci\u00f3n mantengan su estatus de precalificaci\u00f3n?**\n   - La OMS organiza re-evaluaciones peri\u00f3dicas de los productos y sitios de fabricaci\u00f3n incluidos en la lista de precalificaci\u00f3n. Si se determina que un producto o sitio ya no cumple con los est\u00e1ndares recomendados, ser\u00e1 eliminado de la lista.", "prev_section_summary": "### Temas Clave y Entidades\n\n1. **Encuesta de Calidad de Medicamentos Antimal\u00e1ricos en \u00c1frica (2008-2009)**:\n   - **Objetivo**: Evaluar la calidad de medicamentos antimal\u00e1ricos, espec\u00edficamente terapias combinadas basadas en artemisinina (ACTs) y sulfadoxina-pirimetamina.\n   - **Pa\u00edses involucrados**: Seis pa\u00edses africanos.\n   - **Muestras recolectadas**: 936 muestras.\n   - **Resultados**: 306 muestras analizadas, 74 no cumpl\u00edan con los est\u00e1ndares de calidad.\n\n2. **Encuesta de Calidad de Medicamentos Antituberculosos en Europa del Este (2009)**:\n   - **Objetivo**: Evaluar la calidad de medicamentos antituberculosos que contienen rifampicina, isoniazida, kanamicina y ofloxacino.\n   - **Pa\u00edses involucrados**: Armenia, Azerbaiy\u00e1n, Bielorrusia, Kazajist\u00e1n, Ucrania y Uzbekist\u00e1n.\n   - **Muestras recolectadas**: 291 muestras, con pruebas en curso.\n\n3. **Capacitaci\u00f3n y Fortalecimiento de Capacidades**:\n   - **Programa**: Programa de Precalificaci\u00f3n (PQP) de la OMS.\n   - **Objetivo**: Aumentar la capacidad regulatoria de las Autoridades Nacionales de Regulaci\u00f3n de Medicamentos (NMRAs) en pa\u00edses en desarrollo.\n   - **Actividades**: Seminarios, talleres y visitas a fabricantes.\n   - **Sesiones de capacitaci\u00f3n**: 13 en 2007, 15 en 2008, 7 hasta septiembre de 2009.\n   - **Oportunidades adicionales**: Puestos rotativos en Ginebra para evaluadores, con duraci\u00f3n de tres meses.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Responsable de la supervisi\u00f3n y apoyo en las encuestas de calidad y capacitaci\u00f3n.\n- **Autoridades Nacionales de Regulaci\u00f3n de Medicamentos (NMRAs)**: Entidades reguladoras en los pa\u00edses participantes.\n- **Medicamentos evaluados**: Antimal\u00e1ricos (ACTs, sulfadoxina-pirimetamina) y antituberculosos (rifampicina, isoniazida, kanamicina, ofloxacino).", "excerpt_keywords": "Keywords: technical assistance, prequalification, public health, GMP compliance, capacity building"}}, "1cd8e854-cff6-41bb-9105-bef0e72d5cec": {"node_ids": ["dbbf2f1a-5432-4049-bf57-7d0665fd211f"], "metadata": {"page_label": "72", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the list. Failure of a manufacturer or applicant to participate in the re-evaluation procedure will also lead to removal from the list.\n\nRe-evaluation, including re-inspections of manufacturing sites and CROs, would be done at regular intervals, based on risk assessment, but at least once every five years.\n\nRe-evaluation, including re-inspections, should also be performed:\n- if any fraud or omissions by the applicant, manufacturer(s) of an FPP or API, or CROs in the initial assessment procedure or during the follow-up activities, became evident; and\n- if WHO or any United Nations agency considered that a batch or batches of supplied prequalified pharmaceutical products were not in compliance with the specifications which were found to be applicable upon prequalification.\n\nIn order to define the documentation and information required from the applicants or manufacturers whereby the quality part of the prequalified product could be re-evaluated by WHO, a draft of the *Guidelines on the requalification of prequalified dossiers* had been developed by the quality assessors of the PQP.\n\nThese draft guidelines were circulated for comment and discussed at a meeting of the PQP assessment and inspector teams. The resulting revised draft was tabled and discussed at the consultation on WHO guidelines for medicines quality assurance, quality control laboratories and technology transfer in July 2009. At this meeting it was recommended that the document be tabled at the Expert Committee meeting for possible adoption. Following review during the consultation, the revised guidelines were once again circulated for comments.\n\nThe comments received were provided to the Committee in the form of a table.\n\nFollowing discussion, the Expert Committee adopted these new guidelines (Annex 6).\n\n## 9.3 Guidelines for the preparation of a contract research organization master file\n\nWHO, PIC/S and several NMRAs recommended that manufacturers submit a site master file (SMF) for review when applying for registration of a medicine. An SMF is a document prepared by the manufacturer containing specific and factual GMP information about the production and/or control of pharmaceutical manufacturing operations carried out at the named site and any closely integrated operations carried out in adjacent and nearby buildings. If only part of a pharmaceutical operation was carried out on", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento aborda el proceso de re-evaluaci\u00f3n de productos farmac\u00e9uticos precalificados por la OMS, incluyendo la frecuencia de las re-evaluaciones, las circunstancias que pueden desencadenar una re-evaluaci\u00f3n adicional, y la importancia de la presentaci\u00f3n de un archivo maestro de organizaci\u00f3n de investigaci\u00f3n por parte de los fabricantes. Se menciona que la re-evaluaci\u00f3n se realiza al menos cada cinco a\u00f1os y se detalla el proceso de desarrollo y adopci\u00f3n de nuevas directrices para la re-evaluaci\u00f3n de expedientes precalificados.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las circunstancias que pueden llevar a una re-evaluaci\u00f3n adicional de un producto farmac\u00e9utico precalificado por la OMS?**\n   - Respuesta: Una re-evaluaci\u00f3n adicional puede ser necesaria si se evidencia fraude u omisiones por parte del solicitante o fabricante, o si la OMS o alguna agencia de la ONU determina que un lote de productos farmac\u00e9uticos suministrados no cumple con las especificaciones aplicables.\n\n2. **\u00bfCon qu\u00e9 frecuencia se realizan las re-evaluaciones de los productos farmac\u00e9uticos precalificados y qu\u00e9 criterios se utilizan para determinar la frecuencia de estas re-evaluaciones?**\n   - Respuesta: Las re-evaluaciones se realizan al menos cada cinco a\u00f1os, y la frecuencia puede ajustarse en funci\u00f3n de una evaluaci\u00f3n de riesgos.\n\n3. **\u00bfQu\u00e9 es un archivo maestro de organizaci\u00f3n de investigaci\u00f3n (SMF) y qu\u00e9 informaci\u00f3n debe contener seg\u00fan las recomendaciones de la OMS?**\n   - Respuesta: Un SMF es un documento que contiene informaci\u00f3n espec\u00edfica y factual sobre las Buenas Pr\u00e1cticas de Manufactura (GMP) relacionadas con las operaciones de producci\u00f3n y control de medicamentos en un sitio espec\u00edfico. Debe incluir informaci\u00f3n sobre las operaciones realizadas en el sitio y en edificios adyacentes o cercanos que est\u00e9n estrechamente integrados.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Asistencia T\u00e9cnica de la OMS**:\n   - La OMS proporciona asistencia t\u00e9cnica a fabricantes de medicamentos en pa\u00edses en desarrollo que participan en el Programa de Precalificaci\u00f3n (PQP).\n   - Los fabricantes deben estar comprometidos con el PQP, ser capaces y dispuestos a mejorar, y sus productos deben ser de alto valor para la salud p\u00fablica y poco representados en la lista de medicamentos precalificados.\n   - Consultores expertos ayudan a los fabricantes a cumplir con las Buenas Pr\u00e1cticas de Manufactura (GMP), Buenas Pr\u00e1cticas Cl\u00ednicas (GCP) y Buenas Pr\u00e1cticas de Laboratorio (GLP).\n\n2. **Desaf\u00edos Futuros del PQP**:\n   - Motivaci\u00f3n de los fabricantes para aplicar y mantener la precalificaci\u00f3n.\n   - Presentaci\u00f3n de expedientes incompletos o de mala calidad.\n   - No conformidad con las GMP por parte de diversos fabricantes.\n   - Dificultades para llenar posiciones t\u00e9cnicas dentro del PQP.\n   - Escasez de expertos nacionales (evaluadores e inspectores).\n   - Necesidad de reducir el tiempo total para la precalificaci\u00f3n.\n   - Aumento de la demanda de capacitaci\u00f3n espec\u00edfica.\n   - Construcci\u00f3n de confianza e intercambio de informaci\u00f3n para evitar duplicaciones de esfuerzo.\n\n3. **Mantenimiento del Estatus de Precalificaci\u00f3n**:\n   - La OMS realiza re-evaluaciones peri\u00f3dicas de productos y sitios de fabricaci\u00f3n para asegurar el cumplimiento de los est\u00e1ndares recomendados.\n   - Productos y sitios que no cumplan con los est\u00e1ndares ser\u00e1n eliminados de la lista de precalificaci\u00f3n.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Proporciona asistencia t\u00e9cnica y supervisa el PQP.\n- **PQP (Programa de Precalificaci\u00f3n)**: Iniciativa para asegurar la calidad de medicamentos esenciales.\n- **Fabricantes de Medicamentos**: Entidades que buscan precalificaci\u00f3n y asistencia t\u00e9cnica.\n- **Consultores Expertos**: Profesionales que ayudan a los fabricantes a cumplir con los est\u00e1ndares requeridos.", "excerpt_keywords": "Keywords: re-evaluation, prequalification, pharmaceutical manufacturing, site master file, WHO guidelines"}}, "a67e7c04-5dfe-40e7-b9ee-09fe48e601c9": {"node_ids": ["71cb5a26-eea4-41fb-9353-8534a5c3b9a6"], "metadata": {"page_label": "73", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the site, the SMF needed to describe only those operations, e.g. analysis or packaging.\n\nSome NMRAs were also inspecting clinical trials. Clinical trials were often conducted at CROs. During inspections at CROs by WHO prequalification inspectors it was observed that not all information regarding such CROs was available to inspectors when preparing for their inspections. In addition, in several cases, significant changes had been implemented by the CROs from the time of the conduct of a trial or bioequivalence study opposed to what was reflected in the study report. These included changes in key personnel, activities, and even location of the site. This often made inspections problematic as some of the core information regarding the site could no longer be verified.\n\nAfter consultation with inspectors from NMRAs, sponsors and CROs, it was suggested that a document similar to the SMF would provide useful information in the preparation for an inspection, and for those responsible to review or perform a risk analysis when planning GCP or GLP inspections. The proposal of the establishment of a contract research organization master file (CROMF) was welcomed by all parties contacted. It could be seen as an extension of the existing recommendation for the SMF of a manufacturing facility.\n\nAn initial draft CROMF was prepared and circulated to specialists for initial comments. The comments were reviewed by the Secretariat and incorporated where appropriate. The draft was then widely circulated for comments, which were discussed and incorporated, after which the document was again widely circulated in line with the usual procedure.\n\nThe comments received were provided to the Expert Committee.\n\nThe Expert Committee took note of the update, reviewed the major comments received, and agreed and adopted the general principles. It furthermore agreed to the formation of a subgroup of specialists to review all comments in more detail and to prepare a new version of this working document for circulation to the Expert Committee members for ratification. This document was, therefore, adopted provided no major comments were received (Annex 7).\n\n## 10. Nomenclature, terminology and databases\n\n### 10.1 Quality assurance terminology\n\nThe update of the database, available on the WHO quality assurance web site (http://www.who.int/medicines/areas/quality_safety/quality_assurance/en/) was presented to the Committee, as well as a document.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto se centra en la necesidad de mejorar la informaci\u00f3n disponible para los inspectores de la OMS durante las inspecciones de ensayos cl\u00ednicos realizados por organizaciones de investigaci\u00f3n por contrato (CROs). Se destaca que, a menudo, la informaci\u00f3n sobre los CROs no est\u00e1 completamente disponible, lo que dificulta las inspecciones. Se propone la creaci\u00f3n de un archivo maestro para CROs (CROMF) como una extensi\u00f3n del archivo maestro de instalaciones de fabricaci\u00f3n (SMF), con el fin de facilitar la preparaci\u00f3n para las inspecciones y la realizaci\u00f3n de an\u00e1lisis de riesgo. Un borrador inicial del CROMF fue preparado, revisado y comentado por especialistas, y se acord\u00f3 la formaci\u00f3n de un subgrupo para revisar los comentarios y preparar una nueva versi\u00f3n del documento.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n se sugiere que contenga el archivo maestro para organizaciones de investigaci\u00f3n por contrato (CROMF) y c\u00f3mo se relaciona con el archivo maestro de instalaciones de fabricaci\u00f3n (SMF)?**\n   - El CROMF deber\u00eda contener informaci\u00f3n relevante sobre las operaciones de los CROs, como cambios en el personal clave, actividades y ubicaciones, similar a lo que se requiere en el SMF para las instalaciones de fabricaci\u00f3n.\n\n2. **\u00bfCu\u00e1les son los principales problemas que enfrentan los inspectores de la OMS durante las inspecciones de CROs y c\u00f3mo se propone solucionarlos?**\n   - Los inspectores enfrentan problemas debido a la falta de informaci\u00f3n actualizada sobre los CROs, lo que dificulta la verificaci\u00f3n de datos cr\u00edticos. La soluci\u00f3n propuesta es la creaci\u00f3n del CROMF, que proporcionar\u00eda informaci\u00f3n esencial para la preparaci\u00f3n de las inspecciones.\n\n3. **\u00bfQu\u00e9 proceso se sigui\u00f3 para desarrollar el borrador del CROMF y qui\u00e9nes participaron en la revisi\u00f3n del documento?**\n   - Se prepar\u00f3 un borrador inicial del CROMF que fue circulado a especialistas para comentarios. Estos comentarios fueron revisados e incorporados por la Secretar\u00eda, y el documento fue ampliamente discutido y revisado antes de ser presentado al Comit\u00e9 de Expertos para su ratificaci\u00f3n.\n\n### Resumen de Nivel Superior\n\nEl contexto aborda la necesidad de mejorar la informaci\u00f3n disponible para las inspecciones de ensayos cl\u00ednicos realizados por CROs, destacando la falta de datos actualizados y la dificultad que esto representa para los inspectores de la OMS. Se propone la creaci\u00f3n de un CROMF para facilitar la preparaci\u00f3n de las inspecciones y se describe el proceso de desarrollo y revisi\u00f3n de este documento por parte de especialistas y el Comit\u00e9 de Expertos.", "prev_section_summary": "### Temas Clave\n\n1. **Re-evaluaci\u00f3n de Productos Farmac\u00e9uticos**: El documento detalla el proceso de re-evaluaci\u00f3n de productos farmac\u00e9uticos precalificados por la OMS, que incluye re-inspecciones de sitios de fabricaci\u00f3n y organizaciones de investigaci\u00f3n por contrato (CROs). La re-evaluaci\u00f3n se realiza al menos cada cinco a\u00f1os y puede ser m\u00e1s frecuente seg\u00fan una evaluaci\u00f3n de riesgos.\n\n2. **Circunstancias para Re-evaluaci\u00f3n Adicional**: Se especifican situaciones que pueden desencadenar una re-evaluaci\u00f3n adicional, como la evidencia de fraude u omisiones en el procedimiento de evaluaci\u00f3n inicial, o si se determina que un lote de productos no cumple con las especificaciones aplicables.\n\n3. **Directrices para la Recalificaci\u00f3n**: Se menciona el desarrollo de un borrador de directrices sobre la recalificaci\u00f3n de expedientes precalificados, que fue discutido y adoptado por el Comit\u00e9 de Expertos de la OMS.\n\n4. **Archivo Maestro de Organizaci\u00f3n de Investigaci\u00f3n (SMF)**: Se recomienda que los fabricantes presenten un archivo maestro de organizaci\u00f3n de investigaci\u00f3n al solicitar el registro de un medicamento. Este documento debe contener informaci\u00f3n espec\u00edfica sobre las Buenas Pr\u00e1cticas de Manufactura (GMP) y las operaciones de producci\u00f3n y control en el sitio designado.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la regulaci\u00f3n y evaluaci\u00f3n de productos farmac\u00e9uticos.\n- **PQP (Prequalification Programme)**: Programa de la OMS que eval\u00faa la calidad de los productos farmac\u00e9uticos.\n- **PIC/S (Pharmaceutical Inspection Co-operation Scheme)**: Organizaci\u00f3n que promueve la cooperaci\u00f3n entre autoridades de inspecci\u00f3n farmac\u00e9utica.\n- **NMRAs (National Medicines Regulatory Authorities)**: Autoridades nacionales responsables de la regulaci\u00f3n de medicamentos en sus respectivos pa\u00edses.\n- **CROs (Contract Research Organizations)**: Organizaciones que realizan investigaciones por contrato para la industria farmac\u00e9utica.\n\n### Resumen\n\nEl documento aborda el proceso de re-evaluaci\u00f3n de productos farmac\u00e9uticos precalificados por la OMS, estableciendo la frecuencia de estas re-evaluaciones y las circunstancias que pueden requerir una revisi\u00f3n adicional. Tambi\u00e9n se discute el desarrollo y adopci\u00f3n de directrices para la recalificaci\u00f3n de expedientes, as\u00ed como la importancia de presentar un archivo maestro de organizaci\u00f3n de investigaci\u00f3n por parte de los fabricantes al solicitar el registro de medicamentos.", "excerpt_keywords": "CROMF, CROs, inspections, NMRAs, quality assurance"}}, "97171f7f-0e94-4268-8254-b7e98b5881c0": {"node_ids": ["798620ff-5712-49e6-9a4f-19b8fd8b3f53"], "metadata": {"page_label": "74", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "In connection with the discussions during the WHO Governing Bodies' meetings, the issue of terminology for \"counterfeit\" and \"substandard\" medicines was raised.\n\n## Counterfeit medicines\n\nWithin the context of the work of the Expert Committee, definitions for \"counterfeit medicines\" were included in the glossaries of the following WHO guidelines (WHO Database on Quality Assurance: for updates see documents included in the meeting file and also on the Medicines web site: http://www.who.int/medicines/services/expertcommittees/pharmprep/TermListcategory.pdf).\n\nIn: WHO good distribution practices for pharmaceutical products (*fortieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations*, WHO Technical Report Series, No. 937, 2006).\n\nIn: WHO Guidelines for inspection of drug distribution channels (*thirty-fifth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations*, WHO Technical Report Series, No. 885, 1999).\n\nIn: WHO Guidelines on import procedures for pharmaceutical products (*thirty-fourth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations*, WHO Technical Report Series, No. 863, 1996).\n\nWithin the context of the work of the IMPACT Annual Meeting held in December 2008 in Hammamet, Tunisia and based on the work done by the IMPACT Working group on Legislative and Regulatory Infrastructure, a new definition had been developed and was available at: http://www.who.int/impact/resources/IMPACTthirdgeneralmeeting_%20report.pdf.\n\nThese definitions are included in the *Draft principles and elements for national legislation against counterfeit medical products* which has been circulated for comments.\n\nThe Expert Committee:\n- took note of the above and suggested closely following the feedback received regarding the suggested IMPACT definition with a view to further discussion of the outcome during the next meeting of the Expert Committee; and\n- recommended the preparation of an overview on the definitions used in the various international, regional and national contexts.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS discute la terminolog\u00eda relacionada con los medicamentos \"falsificados\" y \"subest\u00e1ndar\", destacando la importancia de definir estos t\u00e9rminos en el contexto de las pr\u00e1cticas de distribuci\u00f3n y regulaci\u00f3n de productos farmac\u00e9uticos. Se mencionan definiciones incluidas en varias gu\u00edas de la OMS y se hace referencia a un nuevo enfoque desarrollado durante la reuni\u00f3n anual de IMPACT en 2008. El Comit\u00e9 de Expertos de la OMS sugiere seguir de cerca los comentarios sobre la definici\u00f3n propuesta y recomienda la elaboraci\u00f3n de un resumen sobre las definiciones utilizadas en diferentes contextos internacionales, regionales y nacionales.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son las fuentes espec\u00edficas donde se pueden encontrar las definiciones de \"medicamentos falsificados\" seg\u00fan la OMS?**\n   - Las definiciones se encuentran en las gu\u00edas de la OMS, incluyendo el *fortieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations* (WHO Technical Report Series, No. 937, 2006), el *thirty-fifth report* (No. 885, 1999), y el *thirty-fourth report* (No. 863, 1996).\n\n2. **\u00bfQu\u00e9 recomendaciones hizo el Comit\u00e9 de Expertos de la OMS respecto a la definici\u00f3n de \"medicamentos falsificados\" durante su reuni\u00f3n?**\n   - El Comit\u00e9 de Expertos sugiri\u00f3 seguir de cerca los comentarios sobre la definici\u00f3n propuesta por IMPACT y discutir los resultados en la pr\u00f3xima reuni\u00f3n del Comit\u00e9. Tambi\u00e9n recomendaron preparar un resumen sobre las definiciones utilizadas en diferentes contextos internacionales, regionales y nacionales.\n\n3. **\u00bfQu\u00e9 evento y grupo de trabajo contribuyeron al desarrollo de una nueva definici\u00f3n de \"medicamentos falsificados\" en 2008?**\n   - La nueva definici\u00f3n fue desarrollada durante la reuni\u00f3n anual de IMPACT celebrada en diciembre de 2008 en Hammamet, T\u00fanez, y fue basada en el trabajo del grupo de trabajo de IMPACT sobre Infraestructura Legislativa y Regulatoria.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Necesidad de Informaci\u00f3n para Inspecciones**:\n   - Se destaca la falta de informaci\u00f3n disponible para los inspectores de la OMS durante las inspecciones de ensayos cl\u00ednicos realizados por organizaciones de investigaci\u00f3n por contrato (CROs).\n   - Los inspectores enfrentan dificultades debido a cambios significativos en los CROs que no se reflejan en los informes de estudio, como cambios en personal clave, actividades y ubicaciones.\n\n2. **Propuesta del CROMF**:\n   - Se sugiere la creaci\u00f3n de un archivo maestro para organizaciones de investigaci\u00f3n por contrato (CROMF) como una extensi\u00f3n del archivo maestro de instalaciones de fabricaci\u00f3n (SMF).\n   - El CROMF deber\u00eda contener informaci\u00f3n relevante para facilitar la preparaci\u00f3n de las inspecciones y realizar an\u00e1lisis de riesgo.\n\n3. **Proceso de Desarrollo del CROMF**:\n   - Se prepar\u00f3 un borrador inicial del CROMF que fue revisado y comentado por especialistas.\n   - Los comentarios fueron incorporados por la Secretar\u00eda y el documento fue ampliamente discutido antes de ser presentado al Comit\u00e9 de Expertos para su ratificaci\u00f3n.\n\n4. **Comit\u00e9 de Expertos**:\n   - El Comit\u00e9 de Expertos revis\u00f3 los comentarios recibidos y adopt\u00f3 los principios generales del CROMF.\n   - Se acord\u00f3 la formaci\u00f3n de un subgrupo de especialistas para revisar los comentarios en detalle y preparar una nueva versi\u00f3n del documento.\n\n### Entidades Clave\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la supervisi\u00f3n y regulaci\u00f3n de la calidad en ensayos cl\u00ednicos.\n- **NMRAs (Agencias Nacionales de Regulaci\u00f3n de Medicamentos)**: Organismos que participan en la inspecci\u00f3n de ensayos cl\u00ednicos.\n- **CROs (Organizaciones de Investigaci\u00f3n por Contrato)**: Entidades que realizan ensayos cl\u00ednicos en nombre de patrocinadores.\n- **CROMF (Archivo Maestro para Organizaciones de Investigaci\u00f3n por Contrato)**: Propuesta para un nuevo documento que contenga informaci\u00f3n relevante sobre CROs.\n- **SMF (Archivo Maestro de Instalaciones de Fabricaci\u00f3n)**: Documento existente que se propone como modelo para el CROMF.\n\nEste resumen encapsula los temas centrales y las entidades involucradas en la discusi\u00f3n sobre la mejora de la informaci\u00f3n para las inspecciones de ensayos cl\u00ednicos.", "excerpt_keywords": "Keywords: counterfeit medicines, WHO guidelines, IMPACT meeting, pharmaceutical regulations, definitions"}}, "9a4fe314-f847-49a6-9111-9daffcf3a2a6": {"node_ids": ["79104ddf-3fd0-4b65-81a1-b8487602d9c3"], "metadata": {"page_label": "75", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The importance of including NMRAs in this discussion was stressed as their expertise was needed to differentiate between the different issues. It was proposed that this discussion take place during the upcoming ICDRA in 2010.\n\n**\u201cSubstandard medicines\u201d**\n\nWithin the context of the work of this Expert Committee, no officially adopted definition currently existed for \u201csubstandard medicines\u201d. As this question was raised frequently a \u201cquestion and answer\u201d had been introduced on the WHO web site as follows:\n\n**\u201cWhat are substandard medicines?**\n\nSubstandard medicines (also called out-of-specification (OOS) products) are genuine medicines produced by manufacturers authorized by the NMRA which do not meet quality specifications set for them by national standards.\n\nNormally, each medicine that a manufacturer produces has to comply with quality standards and specifications. These standards and specifications are reviewed and assessed by the NMRA before the product is authorized for marketing.\u201d\n\nThe Expert Committee discussed the issue and agreed that there was a need for a definition. It suggested circulation of the proposal as amended during the meeting for comments within the usual consultative procedure.\n\n### 10.2 International Nonproprietary Names\n\nThe Expert Committee was briefed on the activities of the International Nonproprietary Names (INN) Programme. In the past 11 years 1445 INN had been named. The Programme had developed an integrated data management system which would permit access from the Internet, allow worldwide multiusers, multiplatform application, with all the user tasks \u201cintegrated\u201d within the process, standard and open-source technologies, secure and protected environment: confidentiality of data and process steps, electronic documentation at each step and track of each process step. The future steps for INN included the online INN Application, Report and Statistic Generator, offline use and integration with other databases.\n\n### 10.3 Pharmacopoeial references\n\nAn update was given to the Expert Committee on the ongoing revision of the pharmacopoeial references and pharmacopoeia commission secretariats would be contacted. The updated references would be posted on the Medicines web site. The Committee welcomed this information being made available in its updated form.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con sus respuestas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfCu\u00e1l es la definici\u00f3n de \"medicamentos subest\u00e1ndar\" seg\u00fan el contexto del Comit\u00e9 de Expertos de la OMS?**\n   - **Respuesta:** Los medicamentos subest\u00e1ndar, tambi\u00e9n conocidos como productos fuera de especificaci\u00f3n (OOS), son medicamentos genuinos producidos por fabricantes autorizados por la Autoridad Nacional Reguladora de Medicamentos (NMRA) que no cumplen con las especificaciones de calidad establecidas por las normas nacionales.\n\n2. **\u00bfQu\u00e9 se propuso en relaci\u00f3n con la discusi\u00f3n sobre los medicamentos subest\u00e1ndar durante la reuni\u00f3n del Comit\u00e9 de Expertos?**\n   - **Respuesta:** Se propuso que la discusi\u00f3n sobre los medicamentos subest\u00e1ndar se llevara a cabo durante el pr\u00f3ximo ICDRA en 2010, y se acord\u00f3 que era necesario establecer una definici\u00f3n oficial para estos medicamentos.\n\n3. **\u00bfQu\u00e9 avances se mencionaron en relaci\u00f3n con el Programa de Nombres No Propietarios Internacionales (INN)?**\n   - **Respuesta:** Se inform\u00f3 que en los \u00faltimos 11 a\u00f1os se hab\u00edan nombrado 1445 INN y que el Programa hab\u00eda desarrollado un sistema de gesti\u00f3n de datos integrado que permitir\u00eda el acceso en l\u00ednea, con capacidades para m\u00faltiples usuarios y plataformas, as\u00ed como la generaci\u00f3n de informes y estad\u00edsticas.\n\n### Resumen de Nivel Superior\n\nEl contexto se centra en una reuni\u00f3n del Comit\u00e9 de Expertos de la OMS, donde se discutieron temas relacionados con la calidad de los medicamentos, espec\u00edficamente la falta de una definici\u00f3n oficial para \"medicamentos subest\u00e1ndar\". Se destac\u00f3 la importancia de incluir a las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) en estas discusiones. Adem\u00e1s, se present\u00f3 un informe sobre el Programa de Nombres No Propietarios Internacionales (INN) y se mencionaron avances en la gesti\u00f3n de datos y la revisi\u00f3n de referencias farmacop\u00e9uticas.\n\n### Preguntas Adicionales Basadas en el Resumen\n\n1. **\u00bfPor qu\u00e9 es importante incluir a las NMRAs en la discusi\u00f3n sobre medicamentos subest\u00e1ndar?**\n   - **Respuesta:** Es importante incluir a las NMRAs porque su experiencia es necesaria para diferenciar entre los diversos problemas relacionados con la calidad de los medicamentos.\n\n2. **\u00bfQu\u00e9 medidas se est\u00e1n tomando para mejorar el acceso a la informaci\u00f3n sobre los Nombres No Propietarios Internacionales (INN)?**\n   - **Respuesta:** Se est\u00e1n desarrollando sistemas de gesti\u00f3n de datos integrados que permitir\u00e1n el acceso en l\u00ednea y la generaci\u00f3n de informes, facilitando as\u00ed el acceso a la informaci\u00f3n sobre los INN.\n\n3. **\u00bfQu\u00e9 se espera lograr con la revisi\u00f3n de las referencias farmacop\u00e9uticas mencionada en el contexto?**\n   - **Respuesta:** Se espera que la revisi\u00f3n de las referencias farmacop\u00e9uticas proporcione informaci\u00f3n actualizada que est\u00e9 disponible en el sitio web de Medicamentos, mejorando as\u00ed la accesibilidad y la calidad de la informaci\u00f3n sobre medicamentos.", "prev_section_summary": "### Temas Clave\n1. **Terminolog\u00eda de Medicamentos**: Se aborda la terminolog\u00eda relacionada con los medicamentos \"falsificados\" y \"subest\u00e1ndar\", destacando la necesidad de definiciones claras en el contexto de la regulaci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos.\n\n2. **Definiciones de Medicamentos Falsificados**: Se mencionan varias gu\u00edas de la OMS que incluyen definiciones de \"medicamentos falsificados\", como los informes de la Comisi\u00f3n de Expertos de la OMS sobre pr\u00e1cticas de distribuci\u00f3n y procedimientos de importaci\u00f3n.\n\n3. **IMPACT y Nueva Definici\u00f3n**: Durante la reuni\u00f3n anual de IMPACT en 2008, se desarroll\u00f3 una nueva definici\u00f3n de \"medicamentos falsificados\", basada en el trabajo de un grupo de trabajo sobre infraestructura legislativa y regulatoria.\n\n4. **Recomendaciones del Comit\u00e9 de Expertos**: El Comit\u00e9 sugiere seguir de cerca los comentarios sobre la definici\u00f3n propuesta y elaborar un resumen sobre las definiciones utilizadas en diferentes contextos internacionales, regionales y nacionales.\n\n### Entidades\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo que establece gu\u00edas y recomendaciones sobre la calidad y regulaci\u00f3n de medicamentos.\n- **IMPACT (Medicamentos Falsificados y Subest\u00e1ndares)**: Grupo de trabajo que se centra en la legislaci\u00f3n y regulaci\u00f3n de medicamentos falsificados.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que revisa y discute definiciones y pr\u00e1cticas relacionadas con medicamentos en el \u00e1mbito internacional. \n\nEste resumen destaca la importancia de la claridad terminol\u00f3gica y la colaboraci\u00f3n internacional en la lucha contra los medicamentos falsificados y subest\u00e1ndares.", "excerpt_keywords": "Keywords: substandard medicines, NMRA, International Nonproprietary Names, pharmacopoeial references, quality specifications"}}, "04782179-e8f9-42cd-8047-77608c2d6c2f": {"node_ids": ["a787ad78-583e-47af-b6cc-660f1521aa67"], "metadata": {"page_label": "76", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11. Miscellaneous\n\n## 11.1 WHO Model List of Essential Medicines\n\nA paper presented by QSM (working document QAS/09.293/Rev.1) was discussed by the Expert Committee for the Selection and Use of Essential Medicines at its meeting in March 2009. The Expert Committee broadly endorsed the QSM proposals concerning:\n\n- dosage form terminology; and\n- expression of medicine strength.\n\nThe expanded Explanatory notes in the sixteenth edition of the WHO Model List of Essential Medicines (and in the second edition of the WHO Model List of Essential Medicines for Children) included a link to the Quality assurance area of the WHO Medicines web site and to the online text of the current edition of *The International Pharmacopoeia*. In addition, an Annex on dosage form terminology had been included. The Explanatory notes and Annex 1 (as published on the Medicines web site: http://www.who.int/selection_medicines/committees/expert/17/en/index.html) were presented to the Expert Committee on Specifications for Pharmaceutical Preparations for information.\n\nWith respect to the expression of medicines strengths, the Expert Committee for the Selection and Use of Essential Medicines agreed the principles that would be applied in future lists and requested its Secretariat to review the current entries and revise them accordingly. The principles were set out in the report of the Expert Committee; an extract from the unedited report, as made available on the WHO Medicines web site, was presented for information.\n\nWhen revised in accordance with these principles, entries in cases where the API was not the active moiety would more clearly distinguish between:\n\n- those for which the strength was expressed in terms of active moiety (the salt would be indicated in parentheses, e.g. \u201c50 mg (as sodium salt)\u201d)\n- those for which the strength was expressed in terms of API (the salt would be given in full, e.g. \u201c50 mg codeine phosphate\u201d).\n\nWhere necessary, in instances of potential confusion (e.g. amodiaquine, quinine salts) a warning note would be included.\n\nThe Committee congratulated the Secretariat on its efforts to provide more clarity with regard to strengths and dosage form references within the Model List.\n\n## 11.2 Update on stability\n\nThe revised working document on *Stability testing of active pharmaceutical ingredients and finished pharmaceutical products* was adopted by the Expert.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Revisi\u00f3n de la Lista Modelo de Medicamentos Esenciales de la OMS**: En marzo de 2009, el Comit\u00e9 de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales discuti\u00f3 propuestas sobre la terminolog\u00eda de formas de dosificaci\u00f3n y la expresi\u00f3n de la fuerza de los medicamentos. Se incluyeron notas explicativas y un anexo sobre la terminolog\u00eda de formas de dosificaci\u00f3n en la edici\u00f3n m\u00e1s reciente de la lista.\n\n2. **Principios para la Expresi\u00f3n de Fuerzas de Medicamentos**: El Comit\u00e9 acord\u00f3 principios para la expresi\u00f3n de las fuerzas de los medicamentos que se aplicar\u00edan en futuras listas, buscando mayor claridad en la distinci\u00f3n entre el principio activo y la sal utilizada en la formulaci\u00f3n.\n\n3. **Actualizaci\u00f3n sobre Estabilidad**: Se adopt\u00f3 un documento de trabajo revisado sobre las pruebas de estabilidad de ingredientes farmac\u00e9uticos activos y productos farmac\u00e9uticos terminados, lo que indica un enfoque continuo en la calidad y seguridad de los medicamentos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 cambios se propusieron en la terminolog\u00eda de las formas de dosificaci\u00f3n en la Lista Modelo de Medicamentos Esenciales de la OMS?**\n   - Se propuso una revisi\u00f3n de la terminolog\u00eda de las formas de dosificaci\u00f3n, que se incluy\u00f3 en un anexo en la edici\u00f3n m\u00e1s reciente de la lista, con el objetivo de proporcionar una mayor claridad en la presentaci\u00f3n de los medicamentos.\n\n2. **\u00bfC\u00f3mo se diferenciar\u00e1n las entradas en la lista de medicamentos en funci\u00f3n de la expresi\u00f3n de la fuerza del principio activo y la sal?**\n   - Las entradas se diferenciar\u00e1n claramente entre aquellas donde la fuerza se expresa en t\u00e9rminos de la moiety activa (indicando la sal entre par\u00e9ntesis) y aquellas donde se expresa en t\u00e9rminos del principio activo (dando el nombre completo de la sal).\n\n3. **\u00bfQu\u00e9 aspectos se abordaron en el documento revisado sobre pruebas de estabilidad adoptado por el Comit\u00e9?**\n   - El documento revisado sobre pruebas de estabilidad se centr\u00f3 en la estabilidad de los ingredientes farmac\u00e9uticos activos y los productos farmac\u00e9uticos terminados, lo que refleja un compromiso continuo con la calidad y la seguridad de los medicamentos en el mercado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Importancia de las NMRAs**: Se destac\u00f3 la necesidad de incluir a las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) en las discusiones sobre medicamentos subest\u00e1ndar, debido a su experiencia en la diferenciaci\u00f3n de problemas relacionados con la calidad de los medicamentos.\n\n2. **Definici\u00f3n de Medicamentos Subest\u00e1ndar**: No exist\u00eda una definici\u00f3n oficialmente adoptada para \"medicamentos subest\u00e1ndar\". Se definieron como medicamentos genuinos producidos por fabricantes autorizados por la NMRA que no cumplen con las especificaciones de calidad establecidas por las normas nacionales.\n\n3. **Propuesta de Discusi\u00f3n**: Se propuso que la discusi\u00f3n sobre medicamentos subest\u00e1ndar se llevara a cabo durante el pr\u00f3ximo ICDRA en 2010, y se acord\u00f3 la necesidad de establecer una definici\u00f3n oficial.\n\n4. **Programa de Nombres No Propietarios Internacionales (INN)**: Se inform\u00f3 sobre el nombramiento de 1445 INN en los \u00faltimos 11 a\u00f1os y el desarrollo de un sistema de gesti\u00f3n de datos integrado que permitir\u00e1 el acceso en l\u00ednea y la generaci\u00f3n de informes y estad\u00edsticas.\n\n5. **Referencias Farmac\u00e9uticas**: Se proporcion\u00f3 una actualizaci\u00f3n sobre la revisi\u00f3n en curso de las referencias farmac\u00e9uticas, con la intenci\u00f3n de que la informaci\u00f3n actualizada est\u00e9 disponible en el sitio web de Medicamentos.\n\n### Entidades Clave\n\n- **NMRAs (Autoridades Nacionales Reguladoras de Medicamentos)**: Entidades responsables de la regulaci\u00f3n y autorizaci\u00f3n de medicamentos en sus respectivos pa\u00edses.\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organizaci\u00f3n que coordina la discusi\u00f3n y regulaci\u00f3n de temas de salud a nivel internacional.\n- **INN (Nombres No Propietarios Internacionales)**: Programa que asigna nombres a medicamentos para su identificaci\u00f3n global.\n- **ICDRA (Conferencia Internacional de Reguladores de Medicamentos)**: Evento propuesto para discutir temas relacionados con la regulaci\u00f3n de medicamentos.", "excerpt_keywords": "Keywords: Essential Medicines, dosage form terminology, medicine strength, stability testing, WHO"}}, "b2504a85-6fe2-4baa-a3f7-9608e9350a04": {"node_ids": ["f9670648-251b-4cd1-9837-222a5cf6a273"], "metadata": {"page_label": "77", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Committee at its forty-third meeting after a long and intensive consultation process (see *Stability testing of active pharmaceutical ingredients and finished pharmaceutical products*, Annex 2, WHO Technical Report Series, No. 953, 2009).\n\nAppendix 1 included a *List of WHO Member States\u2019 required long-term stability conditions* as per information received from countries. Preference was given \u2014 based on the comments received from NMRAs \u2014 to providing \u201creal\u201d conditions required by national authorities. Completing the table for all WHO Member States proved to be a major challenge. However, thanks to IFPMA and special efforts made during and subsequent to the ICDRA meeting, the list could be completed. As a consequence the list comprised three different types of entries as follows.\n\n<div style=\"border: 1px solid black; padding: 10px;\">\n\n**Entries in bold type:**\n\nInformation obtained through respective regional harmonization groups (e.g. Association of Southeast Asian Nations (ASEAN, ICH) and Gulf Cooperation Council (GCC)) and from official communications from NMRAs to WHO.\n\n**Entries in normal type:**\n\nInformation collated during the 13th ICDRA in September 2008, from representatives of NMRAs.\n\n**Entries in italic type:**\n\nInformation provided by IFPMA based on the references given in the guidelines.\n\n</div>\n\nMoreover, during and following the preparation of the Expert Committee report, the Secretariat actively contacted again, with the help of colleagues from the Medicines Regulatory Support Programme, those national authorities for which the entries were \u201cinformal\u201d and/or in accordance with published studies.\n\nThe aim was to update the list on the Medicines web site upon receipt of confirmed new information from NMRAs. Any changes would be based on information received through official correspondence with accompanying reference to national guidance.\n\nDetailed feedback was received from IFPMA regarding possible updates of the stability testing conditions for Afghanistan, Canada, Chile, India and Israel, as well as the labelling statements listed in Appendix 3 of the guidelines.\n\nIn accordance with the process described and suggested above for the update of the table in Appendix 1 of the stability guidelines, the Secretariat would, with the agreement of the Expert Committee:", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla el proceso de consulta y recopilaci\u00f3n de informaci\u00f3n sobre las condiciones de estabilidad a largo plazo requeridas por los Estados Miembros de la OMS para ingredientes farmac\u00e9uticos activos y productos farmac\u00e9uticos terminados. Se menciona la colaboraci\u00f3n con grupos de armonizaci\u00f3n regional y la importancia de la informaci\u00f3n oficial de las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs). Adem\u00e1s, se destaca el esfuerzo por actualizar la lista de condiciones de estabilidad en el sitio web de Medicamentos, bas\u00e1ndose en la retroalimentaci\u00f3n recibida de la IFPMA (Federaci\u00f3n Internacional de Asociaciones de Fabricantes y Asociaciones).\n\n### Preguntas Espec\u00edficas:\n1. **\u00bfQu\u00e9 tipos de entradas se incluyen en la lista de condiciones de estabilidad a largo plazo y c\u00f3mo se clasifican?**\n   - La lista incluye tres tipos de entradas: en negrita (informaci\u00f3n de grupos de armonizaci\u00f3n regional y comunicaciones oficiales de NMRAs), en tipo normal (informaci\u00f3n recopilada durante la 13\u00aa ICDRA) y en cursiva (informaci\u00f3n proporcionada por IFPMA).\n\n2. **\u00bfCu\u00e1l fue el papel de la IFPMA en la recopilaci\u00f3n de informaci\u00f3n sobre las condiciones de estabilidad?**\n   - La IFPMA proporcion\u00f3 informaci\u00f3n detallada sobre las condiciones de estabilidad para varios pa\u00edses y ayud\u00f3 a completar la lista de condiciones de estabilidad a largo plazo, as\u00ed como a ofrecer retroalimentaci\u00f3n sobre las declaraciones de etiquetado.\n\n3. **\u00bfQu\u00e9 proceso se seguir\u00e1 para actualizar la lista de condiciones de estabilidad en el sitio web de Medicamentos de la OMS?**\n   - La actualizaci\u00f3n de la lista se realizar\u00e1 tras recibir informaci\u00f3n confirmada de las NMRAs, y cualquier cambio se basar\u00e1 en correspondencia oficial que incluya referencias a la gu\u00eda nacional correspondiente. La Secretar\u00eda, con el acuerdo del Comit\u00e9 de Expertos, llevar\u00e1 a cabo este proceso.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Lista Modelo de Medicamentos Esenciales de la OMS**:\n   - Se discutieron propuestas sobre la terminolog\u00eda de formas de dosificaci\u00f3n y la expresi\u00f3n de la fuerza de los medicamentos en una reuni\u00f3n del Comit\u00e9 de Expertos en marzo de 2009.\n   - Se incluyeron notas explicativas y un anexo sobre terminolog\u00eda de formas de dosificaci\u00f3n en la edici\u00f3n m\u00e1s reciente de la lista.\n\n2. **Principios para la Expresi\u00f3n de Fuerzas de Medicamentos**:\n   - Se acordaron principios para la expresi\u00f3n de las fuerzas de los medicamentos que se aplicar\u00e1n en futuras listas.\n   - Se busca una mayor claridad en la distinci\u00f3n entre el principio activo (API) y la sal utilizada en la formulaci\u00f3n.\n\n3. **Actualizaci\u00f3n sobre Estabilidad**:\n   - Se adopt\u00f3 un documento revisado sobre pruebas de estabilidad de ingredientes farmac\u00e9uticos activos y productos farmac\u00e9uticos terminados, reflejando un compromiso con la calidad y seguridad de los medicamentos.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la elaboraci\u00f3n de la Lista Modelo de Medicamentos Esenciales.\n- **Comit\u00e9 de Expertos para la Selecci\u00f3n y Uso de Medicamentos Esenciales**: Grupo que revisa y aprueba propuestas relacionadas con medicamentos esenciales.\n- **QSM (Quality Assurance Medicines)**: Entidad que present\u00f3 el documento de trabajo discutido.\n- **API (Active Pharmaceutical Ingredient)**: Ingrediente farmac\u00e9utico activo cuya fuerza se expresa en la lista de medicamentos.\n- ***The International Pharmacopoeia***: Texto de referencia mencionado en relaci\u00f3n con la calidad de los medicamentos.", "excerpt_keywords": "Keywords: stability testing, WHO Member States, NMRAs, IFPMA, pharmaceutical products"}}, "64bf87ec-b06e-4f22-bf4a-4a183c4dded0": {"node_ids": ["bd848c18-01ea-4223-9089-2326e0fd3b9c"], "metadata": {"page_label": "78", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- update the entry for Canada, as the official information had been received; and\n- continue to contact the NMRAs of the other countries listed above with respect to the correctness of their entries.\n\nAs regards the proposal for the labelling information, intensive discussions were held on this topic during the consultation process. The final decision was to add the labelling statements in an Appendix as a recommendation. IFPMA might submit a concrete proposal which could be circulated for comments and discussed at the next Expert Committee meeting.\n\n**Implementation**\n\nFollowing the intense cooperation with the Quality Expert Working Groups within the ICH, the ICH web site included a new reference to the WHO stability guidelines as follows:\n\n\u201cQ1F: Stability Data Package for Registration Applications in Climatic Zones III and IV\n\n\u27a1\ufe0f The ICH Steering Committee endorsed the withdrawal of the Q1F guideline at its meeting in Yokohama, June 2006 and decided to leave definition of storage conditions in Climatic Zones III and IV to the respective regions and WHO. Click here to open the Explanatory Note and have access to the WHO Stability Guideline in the electronic version of this report.\u201d\n\nThe Expert Committee endorsed:\n- that updates of long-term conditions required for marketing authorization in WHO Member States would be made as received from authorities; and\n- the suggestion to include the details of this major harmonization effort and resolution of any possible further concerns during the ICDRA meeting to be held in Singapore in 2010.\n\n## 11.3 Diethylene glycol\n\nOver the years accidental or deliberate counterfeiting of medicines with diethylene glycol (DEG) had occurred many times and in many countries. The first recorded incident occurred in the USA in 1937. The episode killed a large number of Americans, mostly children. The latest incident happened in Nigeria where an equally large number of people were reported to have died. Beyond Nigeria the toxic chemical had caused mass poisoning in Argentina, Bangladesh, China, Ha\u00efti, India, Nigeria, Panama and South Africa. Numerous articles and references have referred to detected cases.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a formularlas:\n\n### Resumen de nivel superior:\nEl documento de la OMS discute la actualizaci\u00f3n de informaci\u00f3n sobre la autorizaci\u00f3n de medicamentos en diferentes pa\u00edses, la propuesta de etiquetado de medicamentos y la cooperaci\u00f3n con grupos de expertos en calidad. Tambi\u00e9n se aborda el problema de la falsificaci\u00f3n de medicamentos que contienen diethylene glycol (DEG), un compuesto t\u00f3xico que ha causado numerosas muertes en varios pa\u00edses a lo largo de los a\u00f1os.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 medidas se est\u00e1n tomando para asegurar la correcci\u00f3n de la informaci\u00f3n de los medicamentos en los pa\u00edses mencionados?**\n   - Respuesta: Se est\u00e1 actualizando la entrada para Canad\u00e1 tras recibir informaci\u00f3n oficial y se contin\u00faa contactando a las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) de otros pa\u00edses para verificar la correcci\u00f3n de sus entradas.\n\n2. **\u00bfCu\u00e1l fue la decisi\u00f3n final respecto a la propuesta de informaci\u00f3n de etiquetado discutida durante el proceso de consulta?**\n   - Respuesta: La decisi\u00f3n final fue a\u00f1adir las declaraciones de etiquetado en un Ap\u00e9ndice como recomendaci\u00f3n, y se mencion\u00f3 que la IFPMA podr\u00eda presentar una propuesta concreta para ser discutida en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos.\n\n3. **\u00bfQu\u00e9 incidentes hist\u00f3ricos se mencionan en relaci\u00f3n con el diethylene glycol (DEG) y cu\u00e1les han sido sus consecuencias?**\n   - Respuesta: Se menciona que el primer incidente registrado ocurri\u00f3 en EE. UU. en 1937, causando la muerte de muchos, principalmente ni\u00f1os. El \u00faltimo incidente reportado fue en Nigeria, donde tambi\u00e9n se registraron numerosas muertes. Adem\u00e1s, se han documentado casos de envenenamiento masivo en varios otros pa\u00edses, incluyendo Argentina, Bangladesh, y Sud\u00e1frica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Consulta y Recopilaci\u00f3n de Informaci\u00f3n:** Se detalla el proceso de consulta llevado a cabo por el Comit\u00e9 de Expertos de la OMS para establecer las condiciones de estabilidad a largo plazo requeridas por los Estados Miembros.\n2. **Clasificaci\u00f3n de Entradas:** La lista de condiciones de estabilidad se clasifica en tres tipos de entradas: \n   - **Negrita:** Informaci\u00f3n de grupos de armonizaci\u00f3n regional y comunicaciones oficiales de NMRAs.\n   - **Tipo Normal:** Informaci\u00f3n recopilada durante la 13\u00aa ICDRA.\n   - **Cursiva:** Informaci\u00f3n proporcionada por la IFPMA.\n3. **Colaboraci\u00f3n con NMRAs e IFPMA:** Se destaca la colaboraci\u00f3n con las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) y la Federaci\u00f3n Internacional de Asociaciones de Fabricantes y Asociaciones (IFPMA) para completar y actualizar la lista de condiciones de estabilidad.\n4. **Proceso de Actualizaci\u00f3n:** Se describe el proceso para actualizar la lista en el sitio web de Medicamentos de la OMS, basado en informaci\u00f3n confirmada de las NMRAs y correspondencia oficial.\n\n**Entidades:**\n- **OMS (Organizaci\u00f3n Mundial de la Salud):** Organismo responsable de la elaboraci\u00f3n del informe y la recopilaci\u00f3n de datos sobre estabilidad.\n- **NMRAs (Autoridades Nacionales Reguladoras de Medicamentos):** Entidades que proporcionan informaci\u00f3n sobre las condiciones de estabilidad requeridas en sus respectivos pa\u00edses.\n- **IFPMA (Federaci\u00f3n Internacional de Asociaciones de Fabricantes y Asociaciones):** Organizaci\u00f3n que contribuye con informaci\u00f3n y retroalimentaci\u00f3n sobre las condiciones de estabilidad y etiquetado.\n- **ICDRA (Reuni\u00f3n Internacional de Autoridades Reguladoras de Medicamentos):** Evento donde se recopila informaci\u00f3n relevante de representantes de NMRAs.\n\nEste resumen abarca los aspectos fundamentales del proceso de consulta y recopilaci\u00f3n de informaci\u00f3n sobre las condiciones de estabilidad a largo plazo, as\u00ed como las entidades involucradas en este esfuerzo.", "excerpt_keywords": "Keywords: WHO, diethylene glycol, labelling information, stability guidelines, NMRAs"}}, "8d55cfc2-7464-459e-bfe5-db7926daa6bb": {"node_ids": ["6b919226-63c5-4b5a-8426-7bf38f3dff40"], "metadata": {"page_label": "79", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "of deaths due to DEG poisoning during the past decades. However, it was not known how many unreported deaths had actually occurred since some victims might have perished without visiting a health-care facility or seeing medical doctors.\n\nInvestigation of some of the above-mentioned incidents had revealed the main contributing factors for the incidents to be:\n\n- absence of control by NMRAs of the manufacture, export and import of glycerol and propylene glycol;\n- purchase of glycerol and propylene glycol by pharmaceutical manufacturers from unreliable sources or through brokers and traders; and\n- lack of testing of the quality of glycerol and propylene glycol prior to using them in the manufacture of pharmaceutical products.\n\nThe above situation clearly showed that unless strict controls and safeguard measures were put in place by NMRAs, more people would fall victim to DEG poisoning.\n\nFollowing up on the recurring incidents of DEG poisoning the Expert Committee discussed a proposal to send out a general alert to the NMRAs which should include recommendations to prevent such events in the future. Extensive discussion took place and the proposed text was amended to include further details. It was decided to form a small group to work out the final text. The Committee endorsed the proposal in general and agreed that the working group should submit the final text to the Committee members for final adoption.\n\n## 12. Summary and recommendations\n\nThe Expert Committee on Specifications for Pharmaceutical Preparations provides recommendations and tools to assure the quality of medicines from their development phase to their final distribution to the patients. It advises the Director-General in the area of quality assurance of medicines.\n\nThis Expert Committee is looking back on a history of more than 60 years! The first meeting of the Expert Committee, named \u201cUnification on Pharmacopoeias\u201d at that time, was held in 1947. Since the inception of this WHO Expert Committee, its members have worked towards making available clear, independent and practical recommendations, written and physical standards, as well as international guidelines for quality medicines. Standards in the area of quality assurance for medicines are developed by the Committee through a wide international consensus building process. Detailed recommendations can be found under each relevant section in the report.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS discute los incidentes de envenenamiento por dietilenglicol (DEG) en las \u00faltimas d\u00e9cadas, destacando la falta de control por parte de las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) sobre la fabricaci\u00f3n y calidad de productos como el glicerol y el propilenglicol. Se identifican factores que contribuyen a estos incidentes y se propone enviar una alerta general a las NMRAs con recomendaciones para prevenir futuros casos. Adem\u00e1s, se menciona la historia de m\u00e1s de 60 a\u00f1os del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas, que trabaja en la creaci\u00f3n de est\u00e1ndares y directrices para asegurar la calidad de los medicamentos.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son los principales factores que contribuyen a los incidentes de envenenamiento por DEG seg\u00fan las investigaciones mencionadas en el documento?**\n   - Respuesta: Los principales factores son la ausencia de control por parte de las NMRAs sobre la fabricaci\u00f3n, exportaci\u00f3n e importaci\u00f3n de glicerol y propilenglicol, la compra de estos productos de fuentes poco fiables y la falta de pruebas de calidad antes de su uso en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 acciones se propusieron para abordar el problema del envenenamiento por DEG y qui\u00e9nes est\u00e1n involucrados en la implementaci\u00f3n de estas acciones?**\n   - Respuesta: Se propuso enviar una alerta general a las NMRAs con recomendaciones para prevenir futuros incidentes. Un grupo peque\u00f1o fue formado para trabajar en el texto final de la propuesta, que ser\u00e1 sometido a los miembros del Comit\u00e9 para su adopci\u00f3n final.\n\n3. **\u00bfCu\u00e1l ha sido el enfoque del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas en los \u00faltimos 60 a\u00f1os en relaci\u00f3n con la calidad de los medicamentos?**\n   - Respuesta: El Comit\u00e9 ha trabajado en la creaci\u00f3n de recomendaciones claras, est\u00e1ndares escritos y f\u00edsicos, as\u00ed como directrices internacionales para asegurar la calidad de los medicamentos, desarrollando est\u00e1ndares a trav\u00e9s de un proceso de consenso internacional.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Actualizaci\u00f3n de Informaci\u00f3n sobre Medicamentos**:\n   - Se est\u00e1 actualizando la entrada para Canad\u00e1 tras recibir informaci\u00f3n oficial.\n   - Se contin\u00faa en contacto con las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) de otros pa\u00edses para verificar la correcci\u00f3n de sus entradas.\n\n2. **Propuesta de Etiquetado de Medicamentos**:\n   - Se llevaron a cabo discusiones intensivas sobre la informaci\u00f3n de etiquetado durante el proceso de consulta.\n   - La decisi\u00f3n final fue incluir las declaraciones de etiquetado en un Ap\u00e9ndice como recomendaci\u00f3n.\n   - La IFPMA (Federaci\u00f3n Internacional de Fabricantes y Asociaciones Farmac\u00e9uticas) podr\u00eda presentar una propuesta concreta para discusi\u00f3n en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos.\n\n3. **Cooperaci\u00f3n con Grupos de Expertos**:\n   - Se menciona la cooperaci\u00f3n con los Grupos de Trabajo de Expertos en Calidad dentro del ICH (Conferencia Internacional sobre Armonizaci\u00f3n).\n   - Se incluy\u00f3 una nueva referencia a las directrices de estabilidad de la OMS en el sitio web del ICH.\n\n4. **Diethylene Glycol (DEG)**:\n   - Se ha documentado la falsificaci\u00f3n accidental o deliberada de medicamentos que contienen DEG en varios pa\u00edses a lo largo de los a\u00f1os.\n   - El primer incidente registrado ocurri\u00f3 en EE. UU. en 1937, causando la muerte de muchos, principalmente ni\u00f1os.\n   - El \u00faltimo incidente reportado fue en Nigeria, con un n\u00famero significativo de muertes.\n   - Se han registrado casos de envenenamiento masivo en otros pa\u00edses, incluyendo Argentina, Bangladesh, China, Hait\u00ed, India, Panam\u00e1 y Sud\u00e1frica.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo que supervisa la salud p\u00fablica y regula la informaci\u00f3n sobre medicamentos.\n- **IFPMA (Federaci\u00f3n Internacional de Fabricantes y Asociaciones Farmac\u00e9uticas)**: Organizaci\u00f3n que representa a la industria farmac\u00e9utica.\n- **ICH (Conferencia Internacional sobre Armonizaci\u00f3n)**: Colaboraci\u00f3n entre reguladores y la industria farmac\u00e9utica para armonizar las regulaciones de medicamentos.\n- **NMRAs (Autoridades Nacionales Reguladoras de Medicamentos)**: Entidades responsables de la regulaci\u00f3n de medicamentos en sus respectivos pa\u00edses. \n\nEste resumen destaca los esfuerzos en la regulaci\u00f3n y seguridad de medicamentos, as\u00ed como los problemas hist\u00f3ricos relacionados con la falsificaci\u00f3n de medicamentos peligrosos.", "excerpt_keywords": "Keywords: DEG poisoning, NMRAs, quality assurance, pharmaceutical standards, WHO Expert Committee"}}, "7f38336a-e505-43f6-8e12-fb87398c1294": {"node_ids": ["afe758a0-ac22-4a9e-a78c-ae74de9645a6"], "metadata": {"page_label": "80", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The activities discussed during this Expert Committee meeting have broad inter- and intracluster relationships and links. There are joint activities, specifically with the WHO Expert Committee on Biological Standardization, and on the Selection and Use of Essential Medicines and its Subcommittee on Medicines for Children. In addition, the Committee serves to develop specific additional guidance and specifications as needed for the various medicines recommended by WHO Programmes.\n\nThis Committee also serves the United Nations Programme on Prequalification of Medicines managed and operated by WHO, as the Programme could not function without the guidelines, standards and specifications adopted by this Committee after passage through its rigorous, international and wide consultative process. The advantage for the Committee is that, as a result of implementing these guidelines and specifications, practical suggestions for potential revision or on the need for additional guidance are communicated in return to the Expert Committee.\n\nRegarding implementation from a wider perspective, the international guidelines, specifications and nomenclature developed under the aegis of this Committee serve all Member States, international organizations, United Nations agencies, regional and interregional harmonization efforts, and underpin important initiatives, including the prequalification of medicines, the Roll Back Malaria Programme, Stop TB, essential medicines and medicines for children. The advice and recommendations provided by this Expert Committee are intended to help national and regional authorities and procurement agencies, as well as major international bodies and institutions, such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, and international organizations such as UNICEF \u2014 to combat circulation of substandard medicines and to work towards access to quality medicines.\n\nIn conclusion, the Expert Committee on Specifications for Pharmaceutical Preparations gives recommendations and provides independent international standards and guidelines in the area of quality assurance for implementation by WHO Member States, international organizations, United Nations agencies, regional and interregional harmonization efforts, as well as WHO\u2019s medicines' related programmes and initiatives. Making resources available for these activities is, therefore, very cost-effective.\n\n**The following new guidelines were adopted and recommended for use:**\n\n- WHO good practices for pharmaceutical quality control laboratories (Annex 1)\n- WHO good manufacturing practices for active pharmaceutical ingredients (Annex 2)\n- WHO good manufacturing practices for pharmaceutical products containing hazardous substances (Annex 3)", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS se encarga de desarrollar directrices y est\u00e1ndares internacionales para asegurar la calidad de los medicamentos. Colabora con otros comit\u00e9s de la OMS y programas de la ONU, como el Programa de Precalificaci\u00f3n de Medicamentos, para combatir la circulaci\u00f3n de medicamentos de calidad inferior y mejorar el acceso a medicamentos de calidad. Recientemente, se adoptaron nuevas directrices sobre buenas pr\u00e1cticas en laboratorios de control de calidad y fabricaci\u00f3n de ingredientes y productos farmac\u00e9uticos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1l es el papel del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas en relaci\u00f3n con el Programa de Precalificaci\u00f3n de Medicamentos de la OMS?**\n   - Respuesta: El Comit\u00e9 proporciona las directrices, est\u00e1ndares y especificaciones necesarias para que el Programa de Precalificaci\u00f3n de Medicamentos funcione adecuadamente, ya que este programa depende de las recomendaciones adoptadas por el Comit\u00e9 tras un proceso consultivo riguroso.\n\n2. **\u00bfQu\u00e9 iniciativas importantes se apoyan mediante las directrices y especificaciones desarrolladas por el Comit\u00e9?**\n   - Respuesta: Las directrices y especificaciones respaldan iniciativas como la precalificaci\u00f3n de medicamentos, el Programa Roll Back Malaria, Stop TB, y los esfuerzos relacionados con medicamentos esenciales y medicamentos para ni\u00f1os.\n\n3. **\u00bfCu\u00e1les son las nuevas directrices adoptadas por el Comit\u00e9 y qu\u00e9 \u00e1reas espec\u00edficas abordan?**\n   - Respuesta: Las nuevas directrices adoptadas incluyen: \n     - Buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica (Anexo 1).\n     - Buenas pr\u00e1cticas de fabricaci\u00f3n para ingredientes farmac\u00e9uticos activos (Anexo 2).\n     - Buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos que contienen sustancias peligrosas (Anexo 3).", "prev_section_summary": "### Temas Clave\n\n1. **Envenenamiento por Dietilenglicol (DEG)**: El documento aborda los incidentes de envenenamiento por DEG en las \u00faltimas d\u00e9cadas, destacando la falta de control y regulaci\u00f3n en la fabricaci\u00f3n y calidad de productos como el glicerol y el propilenglicol.\n\n2. **Factores Contribuyentes**: Se identifican tres factores principales que contribuyen a los incidentes de envenenamiento:\n   - Ausencia de control por parte de las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs).\n   - Compra de glicerol y propilenglicol de fuentes poco fiables.\n   - Falta de pruebas de calidad antes de su uso en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n\n3. **Propuestas de Acci\u00f3n**: Se propone enviar una alerta general a las NMRAs con recomendaciones para prevenir futuros incidentes de envenenamiento por DEG. Se form\u00f3 un grupo de trabajo para elaborar el texto final de la propuesta.\n\n4. **Historia del Comit\u00e9 de Expertos**: El Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas tiene m\u00e1s de 60 a\u00f1os de historia, trabajando en la creaci\u00f3n de est\u00e1ndares y directrices para asegurar la calidad de los medicamentos.\n\n5. **Recomendaciones y Herramientas**: El Comit\u00e9 proporciona recomendaciones y herramientas para asegurar la calidad de los medicamentos desde su desarrollo hasta su distribuci\u00f3n final.\n\n### Entidades\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: La entidad que publica el informe y supervisa la calidad de los medicamentos a nivel internacional.\n- **NMRAs (Autoridades Nacionales Reguladoras de Medicamentos)**: Organismos responsables de la regulaci\u00f3n y control de medicamentos en cada pa\u00eds.\n- **Expert Committee on Specifications for Pharmaceutical Preparations**: El grupo de expertos que se encarga de desarrollar est\u00e1ndares y recomendaciones para la calidad de los medicamentos.\n- **Glicerol y Propilenglicol**: Sustancias qu\u00edmicas involucradas en la fabricaci\u00f3n de productos farmac\u00e9uticos que han sido objeto de control y regulaci\u00f3n en el contexto del envenenamiento por DEG.", "excerpt_keywords": "Keywords: WHO, pharmaceutical quality, guidelines, medicines, standards"}}, "a988d4f5-6f7a-41a6-9ed9-51953e1207f0": {"node_ids": ["3dc6963a-b5ea-4bdb-a307-1d3bdd15f556"], "metadata": {"page_label": "81", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- WHO good manufacturing practices for sterile pharmaceutical products (Annex 4)\n- WHO good distribution practices for pharmaceutical products (Annex 5)\n- Guidelines on the requalification of prequalified dossiers (Annex 6)\n- Guidelines for the preparation of a contract research organization master file (Annex 7)\n\n**For inclusion in The International Pharmacopoeia**\n\nThe following monographs were adopted:\n\n- **For antiretroviral medicines**\n  - Lopinavir\n  - Tenofovir disoproxil fumarate\n  - Indinavir capsules\n  - Saquinavir tablets\n  - Tenofovir tablets\n  - Lopinavir and ritonavir tablets\n  - Efavirenz\n\n- **For antimalarial medicines**\n  - Amodiaquine tablets\n  - Artesunate\n  - Artesunate tablets\n  - Quinine bisulfate tablets\n  - Quinine sulfate tablets\n\n- **For antituberculosis medicines**\n  - Amikacin\n  - Amikacin sulfate\n  - Amikacin injection\n  - Kanamycin monosulfate\n  - Kanamycin acid sulfate\n  - Kanamycin injection\n\n- **For radiopharmaceuticals**\n  - Iobenguane (\u00b9\u00b3\u00b9I) injection\n  - Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm) injection\n  - Sodium iodide (\u00b9\u00b3\u00b9I) capsules\n  - Sodium iothalamate (\u00b9\u00b2\u2075I) injection\n  - Sodium phosphate (\u00b3\u00b2P) injection\n  - Strontium chloride (\u2078\u2079Sr) injection\n  - Technetium (\u2079\u2079mTc) bicisate complex injection\n  - Technetium (\u2079\u2079mTc) exametazime complex injection\n  - Technetium (\u2079\u2079mTc) mebrofenin complex injection", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 957\" incluye directrices sobre buenas pr\u00e1cticas de fabricaci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos, as\u00ed como pautas para la revalidaci\u00f3n de expedientes precalificados y la preparaci\u00f3n de archivos maestros de organizaciones de investigaci\u00f3n por contrato. Adem\u00e1s, se presentan monograf\u00edas adoptadas para la inclusi\u00f3n en la Farmacopea Internacional, que abarcan medicamentos antirretrovirales, antimal\u00e1ricos, antituberculosos y radiotrazadores.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las pautas espec\u00edficas mencionadas en el documento para la preparaci\u00f3n de un archivo maestro de una organizaci\u00f3n de investigaci\u00f3n por contrato?**\n   - Esta pregunta se centra en las \"Guidelines for the preparation of a contract research organization master file (Annex 7)\", que no se detallan en el texto, pero que son relevantes para la investigaci\u00f3n farmac\u00e9utica.\n\n2. **\u00bfQu\u00e9 medicamentos antirretrovirales fueron adoptados para su inclusi\u00f3n en la Farmacopea Internacional seg\u00fan el informe?**\n   - Aunque se mencionan los nombres de los medicamentos, esta pregunta busca una lista espec\u00edfica y detallada de los antirretrovirales adoptados, que puede ser \u00fatil para profesionales de la salud y farmac\u00e9uticos.\n\n3. **\u00bfQu\u00e9 tipo de inyecciones de radiotrazadores se han incluido en las monograf\u00edas adoptadas y cu\u00e1les son sus aplicaciones potenciales?**\n   - Esta pregunta se enfoca en los \"radiopharmaceuticals\" mencionados, buscando informaci\u00f3n sobre sus aplicaciones cl\u00ednicas y su importancia en la medicina nuclear, que no se detalla en el contexto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Colaboraci\u00f3n Interinstitucional:** El Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS trabaja en conjunto con otros comit\u00e9s de la OMS y programas de la ONU, como el Programa de Precalificaci\u00f3n de Medicamentos.\n2. **Desarrollo de Directrices y Est\u00e1ndares:** El Comit\u00e9 es responsable de desarrollar directrices, est\u00e1ndares y especificaciones internacionales para asegurar la calidad de los medicamentos.\n3. **Implementaci\u00f3n de Directrices:** Las directrices y est\u00e1ndares adoptados son fundamentales para la implementaci\u00f3n de iniciativas globales, como la precalificaci\u00f3n de medicamentos y programas de salud p\u00fablica.\n4. **Acceso a Medicamentos de Calidad:** El Comit\u00e9 busca combatir la circulaci\u00f3n de medicamentos de calidad inferior y mejorar el acceso a medicamentos seguros y eficaces.\n5. **Nuevas Directrices Adoptadas:** Se han adoptado nuevas directrices sobre buenas pr\u00e1cticas en laboratorios de control de calidad y fabricaci\u00f3n de productos farmac\u00e9uticos.\n\n**Entidades:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Principal entidad responsable de la salud p\u00fablica a nivel internacional.\n- **Programa de Precalificaci\u00f3n de Medicamentos:** Iniciativa de la OMS que asegura que los medicamentos cumplen con est\u00e1ndares de calidad.\n- **UNICEF:** Organizaci\u00f3n de la ONU que trabaja en la mejora de la salud y el bienestar de los ni\u00f1os.\n- **Global Fund to Fight AIDS, Tuberculosis and Malaria:** Fondo internacional que financia programas para combatir estas enfermedades.\n- **Expert Committee on Biological Standardization:** Otro comit\u00e9 de la OMS que colabora con el Comit\u00e9 de Especificaciones.\n\nEste resumen destaca la importancia del trabajo del Comit\u00e9 en la regulaci\u00f3n y mejora de la calidad de los medicamentos a nivel global, as\u00ed como su colaboraci\u00f3n con diversas entidades para lograr estos objetivos.", "excerpt_keywords": "Keywords: WHO, good manufacturing practices, antiretroviral medicines, radiopharmaceuticals, International Pharmacopoeia"}}, "1f9ee5a4-96f4-47b9-8f42-93b896a4be2c": {"node_ids": ["0ce65769-8474-4c59-838c-4a6353e36014"], "metadata": {"page_label": "82", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Technetium (\u2079\u2079\u1d50Tc) mertiatide injection\n- Technetium (\u2079\u2079\u1d50Tc) succimer complex injection\n- Technetium (\u2079\u2079\u1d50Tc) sulfur colloid injection\n- Technetium (\u2079\u2079\u1d50Tc) tetrofosmin complex injection\n- Technetium (\u2079\u2079\u1d50Tc) tin colloidal injection\n- Technetium (\u2079\u2079\u1d50Tc) pyrophosphate tin complex injection\n- Technetium (\u2079\u2079\u1d50Tc) methylene diphosphonate (MDP) complex injection\n- Technetium (\u2079\u2079\u1d50Tc) sestamibi complex injection\n- Yttrium silicate (\u2079\u2070Y) colloid injection\n\n- **Other medicines**\n  - Mebendazole\n  - Oseltamivir phosphate\n  - Oxytocin\n  - Oxytocin injection\n\n- **General monographs for**\n  - Tablets\n  - Capsules\n\n- **General policy topics and general revision issues for**\n  - Monographs title and strengths\n  - Strengths available statement\n  - Identity tests\n  - Polymorphism\n\n### Adoption of new International Chemical Reference Substances\n\n- Carbidopa\n- Colchicine\n- Lumefantrine\n- DL-Methionine\n- Naloxone hydrochloride\n- Oseltamivir phosphate for system suitability\n- Oseltamivir phosphate\n\n**And the following replacements**\n- Artemisinin\n- Prednisone\n\n**The following recommendations were made in the various quality assurance-related areas. Progress on the suggested actions should be reported to the Expert Committee at its next meeting.**\n\nThe underlying principle is that the development of specifications and guidelines will be carried out using the established international consultative process.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento \"WHO - Technical Report Series 957\" presenta una serie de inyecciones de tecn\u00e9cio y otros medicamentos, as\u00ed como monograf\u00edas generales para tabletas y c\u00e1psulas. Tambi\u00e9n se discuten temas de pol\u00edtica general y cuestiones de revisi\u00f3n relacionadas con las monograf\u00edas, como t\u00edtulos, fortalezas, pruebas de identidad y polimorfismo. Adem\u00e1s, se mencionan nuevas sustancias qu\u00edmicas de referencia internacional adoptadas, junto con recomendaciones en \u00e1reas de aseguramiento de calidad que deben ser reportadas en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que se deben considerar al desarrollar especificaciones y directrices para las nuevas sustancias qu\u00edmicas de referencia internacional mencionadas en el informe?**\n   - Esta pregunta busca detalles sobre el proceso de desarrollo de especificaciones que no se encuentran expl\u00edcitamente en el documento.\n\n2. **\u00bfQu\u00e9 criterios se utilizan para determinar la inclusi\u00f3n de medicamentos como el oseltamivir fosfato y el mebendazol en el contexto de la calidad y la seguridad de los medicamentos?**\n   - Esta pregunta se centra en los criterios de selecci\u00f3n y evaluaci\u00f3n de medicamentos, que no se abordan directamente en el texto.\n\n3. **\u00bfQu\u00e9 acciones espec\u00edficas se han sugerido en relaci\u00f3n con los temas de calidad y c\u00f3mo se espera que se informe sobre el progreso en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos?**\n   - Esta pregunta busca informaci\u00f3n sobre las acciones recomendadas y el mecanismo de seguimiento, que no se detalla en el contexto proporcionado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 957\" aborda varios aspectos importantes relacionados con las buenas pr\u00e1cticas en la industria farmac\u00e9utica y la inclusi\u00f3n de medicamentos en la Farmacopea Internacional. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n y Distribuci\u00f3n**:\n   - Directrices sobre buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles.\n   - Directrices sobre buenas pr\u00e1cticas de distribuci\u00f3n para productos farmac\u00e9uticos.\n\n2. **Revalidaci\u00f3n de Dossiers**:\n   - Pautas para la revalidaci\u00f3n de expedientes precalificados.\n\n3. **Archivos Maestros de Organizaciones de Investigaci\u00f3n**:\n   - Directrices para la preparaci\u00f3n de archivos maestros de organizaciones de investigaci\u00f3n por contrato.\n\n4. **Monograf\u00edas para la Farmacopea Internacional**:\n   - Inclusi\u00f3n de monograf\u00edas de medicamentos antirretrovirales, antimal\u00e1ricos, antituberculosos y radiotrazadores.\n\n#### Entidades Mencionadas:\n- **Medicamentos Antirretrovirales**:\n  - Lopinavir\n  - Tenofovir disoproxil fumarate\n  - Indinavir (c\u00e1psulas)\n  - Saquinavir (tabletas)\n  - Tenofovir (tabletas)\n  - Lopinavir y ritonavir (tabletas)\n  - Efavirenz\n\n- **Medicamentos Antimal\u00e1ricos**:\n  - Amodiaquine (tabletas)\n  - Artesunate\n  - Artesunate (tabletas)\n  - Quinine bisulfate (tabletas)\n  - Quinine sulfate (tabletas)\n\n- **Medicamentos Antituberculosos**:\n  - Amikacin\n  - Amikacin sulfate\n  - Amikacin (inyecci\u00f3n)\n  - Kanamycin monosulfate\n  - Kanamycin acid sulfate\n  - Kanamycin (inyecci\u00f3n)\n\n- **Radiotrazadores**:\n  - Iobenguane (\u00b9\u00b3\u00b9I) (inyecci\u00f3n)\n  - Samarium ethylene diamine tetramethylene phosphonate complex (\u00b9\u2075\u00b3Sm) (inyecci\u00f3n)\n  - Sodium iodide (\u00b9\u00b3\u00b9I) (c\u00e1psulas)\n  - Sodium iothalamate (\u00b9\u00b2\u2075I) (inyecci\u00f3n)\n  - Sodium phosphate (\u00b3\u00b2P) (inyecci\u00f3n)\n  - Strontium chloride (\u2078\u2079Sr) (inyecci\u00f3n)\n  - Technetium (\u2079\u2079mTc) bicisate complex (inyecci\u00f3n)\n  - Technetium (\u2079\u2079mTc) exametazime complex (inyecci\u00f3n)\n  - Technetium (\u2079\u2079mTc) mebrofenin complex (inyecci\u00f3n)\n\nEste resumen destaca la importancia de las buenas pr\u00e1cticas en la fabricaci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos, as\u00ed como la inclusi\u00f3n de medicamentos esenciales en la Farmacopea Internacional, lo que es crucial para la salud p\u00fablica y el acceso a tratamientos efectivos.", "excerpt_keywords": "Keywords: Technetium, International Chemical Reference Substances, quality assurance, pharmaceuticals, monographs"}}, "c7610a0f-4a22-4376-b9d6-09d2dc19ee94": {"node_ids": ["acbbec95-3a73-45b0-975c-4fff3247b133"], "metadata": {"page_label": "83", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# The International Pharmacopoeia\n\n- Continue development of specifications for medicines in accordance with the work plan revised and adopted at this meeting.\n- Continue the efforts of international collaboration in relation to the revision and inclusion of general methods and new monographs for excipients.\n- Continue the preparatory work on the supplements to *The International Pharmacopoeia*, 4th edition and towards the 5th edition, especially in electronic form (CD-ROM and online).\n\n# International Chemical Reference Substances (ICRS)\n\n- Continue promoting the use of ICRS through various activities, including a promotional offer to national authorities and improvements of the ICRS web site.\n\n# External Quality Assurance Assessment Scheme\n\n- Continue the External Quality Assurance Assessment Scheme (EQAAS) for pharmaceutical quality control laboratories with a new phase 5.\n\n# Good practices for pharmaceutical microbiology laboratories\n\n- Continue the consultation process through preparation of a new text on good practices for pharmaceutical microbiology laboratories.\n\n# Good manufacturing practices (GMP) and manufacture\n\n- Follow up on the revision process for GMP for biologicals currently being undertaken under the aegis of the Expert Committee on Biological Standardization.\n- Follow up on development of the WHO guidelines on GMP for blood establishments currently being undertaken under the aegis of the Expert Committee on Biological Standardization and ensure that these new guidelines also be sent for comment to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations.\n- Initiate the consultation process for a revision of the main principles of GMP, considering inclusion of the quality unit concept, quality risk management and product quality review.\n- Initiate a revision process as identified for some paragraphs of the GMP for heating, ventilation and air-conditioning (HVAC).\n- Review and initiate an update of the WHO guidelines on Hazard Analysis and Critical Control Points (HACCP) to cover new trends in quality risk management.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que aborda varios temas relacionados con la farmacopoeia internacional, la promoci\u00f3n de sustancias qu\u00edmicas de referencia, la evaluaci\u00f3n de la calidad externa en laboratorios de control de calidad farmac\u00e9utica, buenas pr\u00e1cticas en microbiolog\u00eda farmac\u00e9utica y buenas pr\u00e1cticas de manufactura (GMP). Se mencionan esfuerzos continuos para desarrollar especificaciones para medicamentos, colaborar internacionalmente en la revisi\u00f3n de m\u00e9todos y monograf\u00edas, y actualizar directrices sobre GMP y HACCP.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos se est\u00e1n tomando para la inclusi\u00f3n de nuevos excipientes en la farmacopoeia internacional?**\n   - La OMS est\u00e1 trabajando en la colaboraci\u00f3n internacional para la revisi\u00f3n e inclusi\u00f3n de m\u00e9todos generales y nuevas monograf\u00edas para excipientes, lo que implica un proceso continuo de desarrollo y revisi\u00f3n.\n\n2. **\u00bfCu\u00e1les son las novedades en la evaluaci\u00f3n de la calidad externa para laboratorios farmac\u00e9uticos?**\n   - Se est\u00e1 implementando una nueva fase (fase 5) del Esquema de Evaluaci\u00f3n de Calidad Externa (EQAAS) para laboratorios de control de calidad farmac\u00e9utica, lo que sugiere un enfoque renovado en la evaluaci\u00f3n de la calidad.\n\n3. **\u00bfQu\u00e9 cambios se est\u00e1n considerando en las directrices de Buenas Pr\u00e1cticas de Manufactura (GMP) para incluir conceptos modernos?**\n   - Se est\u00e1 iniciando un proceso de consulta para revisar los principios principales de GMP, considerando la inclusi\u00f3n del concepto de unidad de calidad, gesti\u00f3n de riesgos de calidad y revisi\u00f3n de la calidad del producto, as\u00ed como la actualizaci\u00f3n de las directrices sobre HACCP para reflejar nuevas tendencias en la gesti\u00f3n de riesgos de calidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Inyecciones de Tecn\u00e9cio**: Se enumeran varias inyecciones que utilizan tecn\u00e9cio (\u2079\u2079\u1d50Tc), incluyendo:\n   - Mertiatide\n   - Succimer complex\n   - Sulfur colloid\n   - Tetrofosmin complex\n   - Tin colloidal\n   - Pyrophosphate tin complex\n   - Methylene diphosphonate (MDP) complex\n   - Sestamibi complex\n   - Yttrium silicate (\u2079\u2070Y) colloid\n\n2. **Otros Medicamentos**: Se mencionan medicamentos adicionales como:\n   - Mebendazole\n   - Oseltamivir phosphate\n   - Oxytocin y su forma inyectable\n\n3. **Monograf\u00edas Generales**: Se abordan las monograf\u00edas generales para:\n   - Tabletas\n   - C\u00e1psulas\n\n4. **Temas de Pol\u00edtica General y Revisi\u00f3n**: Se discuten cuestiones relacionadas con:\n   - T\u00edtulos y fortalezas de las monograf\u00edas\n   - Declaraciones sobre fortalezas disponibles\n   - Pruebas de identidad\n   - Polimorfismo\n\n5. **Adopci\u00f3n de Nuevas Sustancias Qu\u00edmicas de Referencia Internacional**: Se listan nuevas sustancias adoptadas, incluyendo:\n   - Carbidopa\n   - Colchicina\n   - Lumefantrina\n   - DL-Metionina\n   - Naloxona hidrocloruro\n   - Oseltamivir fosfato (para idoneidad del sistema)\n\n6. **Reemplazos**: Se mencionan los reemplazos de:\n   - Artemisinina\n   - Prednisona\n\n7. **Recomendaciones en Aseguramiento de Calidad**: Se indican recomendaciones en \u00e1reas de calidad, con un llamado a reportar el progreso en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos. Se enfatiza que el desarrollo de especificaciones y directrices se llevar\u00e1 a cabo mediante un proceso consultivo internacional establecido. \n\nEste resumen abarca los temas clave y las entidades mencionadas en la secci\u00f3n del documento \"WHO - Technical Report Series 957\".", "excerpt_keywords": "Keywords: pharmacopoeia, quality assurance, good manufacturing practices, international collaboration, chemical reference substances"}}, "607041ac-a745-4098-84af-b08c32ab0886": {"node_ids": ["44b236d2-fc11-49c1-bc2d-93283623436f"], "metadata": {"page_label": "84", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Transfer of technology\n\n- Continue the development of the **WHO guidelines on transfer of technology**, giving special consideration to keeping the balance between GMP and business criteria, including the concept of quality by design and the possibility of optional requirements depending on the type of transfer.\n\n# WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce\n\n- Continue the steps to be taken regarding the **WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce** in consultation with WHO Member States and the WHO Legal Counsel.\n- Post the revised \u201cQuestions and Answers\u201d on the functioning of the Scheme on the revised document on the WHO website and include it in **WHO Drug Information**, with the possibility of receiving comments and reviewing any question(s) that might raise major concerns.\n\n# Good distribution practices (GDP) for pharmaceutical products\n\nFollow up on development of the WHO guidelines on regulatory oversight on pharmaceutical cold chain management. Harmonized guidance for the storage and transport of temperature-sensitive pharmaceutical products is currently being developed under the aegis of the Expert Committee on Biological Standardization. Ensure that these new guidelines are also sent for comment to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and to the IMPACT working group that developed the revision of the GDP.\n\n# Regulatory guidance\n\n- Continue the consultation process and advancement of the **Development of paediatric medicines: pharmaceutical development. Points to consider**.\n- Continue the development of the **Pharmaceutical development for multisource (generic) pharmaceutical products**.\n- Continue updating the long-term stability testing requirements for marketing authorization in WHO Member States as received from authorities.\n- Follow up on the recurring incidents of DEG poisoning, prepare a proposal for a general alert to the NMRAs, including recommendations to prevent such events in the future.\n\n# Quality assurance terminology\n\n- Make the updated database on quality assurance terminology widely available.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda varios aspectos clave relacionados con la regulaci\u00f3n y la calidad de los productos farmac\u00e9uticos. Se enfoca en el desarrollo de directrices sobre la transferencia de tecnolog\u00eda, la certificaci\u00f3n de productos farmac\u00e9uticos en el comercio internacional, las buenas pr\u00e1cticas de distribuci\u00f3n, la regulaci\u00f3n de medicamentos pedi\u00e1tricos y gen\u00e9ricos, y la terminolog\u00eda de aseguramiento de calidad. Adem\u00e1s, se menciona la importancia de la gesti\u00f3n de la cadena de fr\u00edo para productos farmac\u00e9uticos sensibles a la temperatura y la necesidad de alertar sobre incidentes de intoxicaci\u00f3n por DEG.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que se est\u00e1n considerando para equilibrar las Buenas Pr\u00e1cticas de Manufactura (GMP) y los criterios comerciales en las directrices de transferencia de tecnolog\u00eda de la OMS?**\n   - Esta pregunta busca detalles sobre c\u00f3mo la OMS planea abordar la interacci\u00f3n entre la calidad y los aspectos comerciales en la transferencia de tecnolog\u00eda, lo cual no se detalla expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 medidas se est\u00e1n proponiendo para prevenir futuros incidentes de intoxicaci\u00f3n por DEG, y c\u00f3mo se planea comunicar estas recomendaciones a las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs)?**\n   - Esta pregunta se centra en las acciones espec\u00edficas que se tomar\u00e1n para abordar un problema recurrente de salud p\u00fablica, lo que podr\u00eda no estar disponible en otras fuentes.\n\n3. **\u00bfC\u00f3mo se planea integrar los comentarios de los grupos de expertos en las nuevas directrices sobre la gesti\u00f3n de la cadena de fr\u00edo para productos farmac\u00e9uticos?**\n   - Esta pregunta busca informaci\u00f3n sobre el proceso de consulta y revisi\u00f3n que se llevar\u00e1 a cabo para asegurar que las nuevas directrices sean efectivas y est\u00e9n alineadas con las mejores pr\u00e1cticas, un aspecto que puede no estar claramente delineado en el documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Farmacopea Internacional**:\n   - Desarrollo continuo de especificaciones para medicamentos.\n   - Colaboraci\u00f3n internacional para la revisi\u00f3n e inclusi\u00f3n de m\u00e9todos generales y nuevas monograf\u00edas para excipientes.\n   - Preparaci\u00f3n de suplementos para la 4\u00aa y 5\u00aa edici\u00f3n de *The International Pharmacopoeia*, con \u00e9nfasis en formatos electr\u00f3nicos.\n\n2. **Sustancias Qu\u00edmicas de Referencia Internacional (ICRS)**:\n   - Promoci\u00f3n del uso de ICRS mediante actividades diversas y mejoras en el sitio web de ICRS.\n\n3. **Esquema de Evaluaci\u00f3n de Calidad Externa (EQAAS)**:\n   - Implementaci\u00f3n de la fase 5 del EQAAS para laboratorios de control de calidad farmac\u00e9utica.\n\n4. **Buenas Pr\u00e1cticas en Microbiolog\u00eda Farmac\u00e9utica**:\n   - Proceso de consulta para la elaboraci\u00f3n de un nuevo texto sobre buenas pr\u00e1cticas en microbiolog\u00eda farmac\u00e9utica.\n\n5. **Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Revisi\u00f3n de GMP para biol\u00f3gicos y desarrollo de directrices para establecimientos de sangre.\n   - Consulta para revisar principios de GMP, incluyendo conceptos modernos como unidad de calidad y gesti\u00f3n de riesgos de calidad.\n   - Revisi\u00f3n de directrices sobre An\u00e1lisis de Peligros y Puntos Cr\u00edticos de Control (HACCP) para reflejar nuevas tendencias en gesti\u00f3n de riesgos de calidad.\n\n### Entidades Involucradas\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Principal entidad responsable de la elaboraci\u00f3n y revisi\u00f3n de directrices y est\u00e1ndares.\n- **Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica**: Encargado de la revisi\u00f3n de GMP para biol\u00f3gicos y directrices para establecimientos de sangre.\n- **Panel Asesor de Expertos de la OMS sobre la Farmacopea Internacional y Preparaciones Farmac\u00e9uticas**: Involucrado en la revisi\u00f3n de nuevas directrices de GMP.", "excerpt_keywords": "Keywords: transfer of technology, WHO certification, good distribution practices, regulatory guidance, quality assurance"}}, "4904060c-eefe-4778-9e80-ef53f8db46fe": {"node_ids": ["191a016c-49ee-494a-a0dc-4c7c29cd2615"], "metadata": {"page_label": "85", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- Provide feedback from the Circular Letter mailed to all Member States regarding the terminology used within the national legislation for \u201ccounterfeit medicines\u201d or equivalent terms used, with a view to further discussion of the outcome during the next meeting of the Expert Committee and possibly during the ICDRA.\n- Circulate a proposal for a new definition for \u201csubstandard medicines\u201d as discussed during the meeting.\n\n### Pharmacopoeia references\n\n- Post an update of the references and contact details for national, regional and international pharmacopoeias on the Medicines Quality Assurance web site.\n\n### WHO databases\n\n- Maintain the consolidated database on nomenclature used in WHO quality assurance.\n- Maintain the INN database and continue to make it available on the web site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento se centra en la calidad de los medicamentos y las definiciones relacionadas con t\u00e9rminos como \"medicamentos falsificados\" y \"medicamentos subest\u00e1ndar\". Se menciona la necesidad de recopilar comentarios de los Estados Miembros sobre la terminolog\u00eda utilizada en su legislaci\u00f3n nacional y la propuesta de una nueva definici\u00f3n para \"medicamentos subest\u00e1ndar\". Adem\u00e1s, se destaca la importancia de mantener actualizadas las referencias de las farmacopeas y las bases de datos de la OMS relacionadas con la calidad de los medicamentos.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 pasos se est\u00e1n tomando para abordar la terminolog\u00eda relacionada con los \"medicamentos falsificados\" en la legislaci\u00f3n nacional de los Estados Miembros?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el proceso de recopilaci\u00f3n de comentarios y la discusi\u00f3n futura en la reuni\u00f3n del Comit\u00e9 de Expertos.\n\n2. **\u00bfCu\u00e1l es la propuesta para la nueva definici\u00f3n de \"medicamentos subest\u00e1ndar\" y c\u00f3mo se espera que impacte en la regulaci\u00f3n de medicamentos?**\n   - Aqu\u00ed se busca una respuesta que detalle la propuesta discutida y su posible efecto en la calidad y regulaci\u00f3n de los medicamentos.\n\n3. **\u00bfQu\u00e9 tipo de informaci\u00f3n se actualizar\u00e1 en el sitio web de Aseguramiento de la Calidad de Medicamentos de la OMS en relaci\u00f3n con las farmacopeas?**\n   - Esta pregunta se centra en los detalles espec\u00edficos sobre las actualizaciones que se realizar\u00e1n en las referencias y contactos de las farmacopeas nacionales, regionales e internacionales.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Transferencia de Tecnolog\u00eda**:\n   - Desarrollo de directrices de la OMS sobre la transferencia de tecnolog\u00eda, considerando el equilibrio entre las Buenas Pr\u00e1cticas de Manufactura (GMP) y criterios comerciales, as\u00ed como la calidad por dise\u00f1o.\n\n2. **Esquema de Certificaci\u00f3n de la OMS**:\n   - Continuaci\u00f3n de los pasos para el Esquema de Certificaci\u00f3n de la OMS sobre la calidad de productos farmac\u00e9uticos en el comercio internacional, en consulta con los Estados Miembros y el Asesor Legal de la OMS. Publicaci\u00f3n de preguntas y respuestas revisadas en el sitio web de la OMS.\n\n3. **Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP)**:\n   - Desarrollo de directrices sobre la gesti\u00f3n de la cadena de fr\u00edo para productos farmac\u00e9uticos sensibles a la temperatura, con la participaci\u00f3n de grupos de expertos para asegurar la armonizaci\u00f3n.\n\n4. **Orientaci\u00f3n Regulatoria**:\n   - Avance en el desarrollo de medicamentos pedi\u00e1tricos y productos farmac\u00e9uticos multisource (gen\u00e9ricos). Actualizaci\u00f3n de requisitos de pruebas de estabilidad a largo plazo y seguimiento de incidentes de intoxicaci\u00f3n por DEG, con propuestas para alertar a las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs).\n\n5. **Terminolog\u00eda de Aseguramiento de Calidad**:\n   - Disponibilidad amplia de una base de datos actualizada sobre terminolog\u00eda de aseguramiento de calidad.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Principal entidad responsable del desarrollo de directrices y esquemas de certificaci\u00f3n.\n- **Estados Miembros de la OMS**: Participantes en la consulta sobre el esquema de certificaci\u00f3n y otras directrices.\n- **Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica**: Encargado del desarrollo de directrices sobre la gesti\u00f3n de la cadena de fr\u00edo.\n- **Panel Asesor de la OMS sobre la Farmacopea Internacional y Preparaciones Farmac\u00e9uticas**: Grupo consultivo para las nuevas directrices.\n- **NMRAs (Autoridades Nacionales Reguladoras de Medicamentos)**: Entidades que recibir\u00e1n alertas y recomendaciones sobre incidentes de salud p\u00fablica.", "excerpt_keywords": "Keywords: counterfeit medicines, substandard medicines, pharmacopoeia references, WHO quality assurance, INN database"}}, "6ea8327a-851f-4736-9285-1009cb9944b8": {"node_ids": ["95698f63-1c3b-45ac-83a8-3787d15ec5c4"], "metadata": {"page_label": "86", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Acknowledgements\n\nSpecial acknowledgement was made by the Committee to Mrs W. Bonny, Ms M. Gaspard, Dr S. Kopp, Ms C. Mendy and to Dr L. R\u00e4go, Quality Assurance and Safety: Medicines, Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland, who were instrumental in the preparation and proceedings of the meeting.\n\nTechnical guidance included in this report has been produced with the financial assistance of the European Community, the Bill & Melinda Gates Foundation and UNITAID.\n\nThe Committee also acknowledged with thanks the valuable contributions made to its work by the following agencies, institutions, organizations, WHO Collaborating Centres, WHO programmes and persons:\n\nActive Pharmaceutical Ingredients Committee, European Chemical Industry Council, Brussels, Belgium; Danish Medicines Agency, Copenhagen, Denmark; European Association of Pharmaceutical Full-line Wholesalers, Groupement International de la R\u00e9partition Pharmaceutique, Brussels, Belgium; European Commission, Brussels, Belgium; European Directorate for the Quality of Medicines and HealthCare, Council of Europe, Strasbourg, France; European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; European Medicines Agency, London, England; Global Fund to Fight AIDS, Tuberculosis and Malaria, Vernier, Switzerland; Healthcare Distribution Management Association, Arlington, VA, USA; International Atomic Energy Agency, Vienna, Austria; Indian Drug Manufacturers' Association, Worli, Mumbai, India; International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland; International Generic Pharmaceutical Alliance, Brussels, Belgium; International Pharmaceutical Excipients Council, Strasbourg, France; International Pharmaceutical Federation, The Hague, Netherlands; International Society for Pharmaceutical Engineering, Tampa, FL, USA; Pharmaceutical Research and Manufacturers of America, Washington, DC, USA; Swissmedic, Swiss Agency for Therapeutic Products, Berne, Switzerland; Therapeutic Goods Administration, Woden, ACT, Australia; United Nations Children's Fund, New York, NY, USA; Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland; United Nations Development Programme, New York, NY, USA; World Bank, Washington, DC, USA; World Intellectual Property Organization, Geneva, Switzerland; World Self-Medication Industry, Ferney-Voltaire, France.\n\nLaboratoire National de Contr\u00f4le des Produits Pharmaceutiques, Ch\u00e9raga, Algeria; Instituto Nacional de Medicamentos, Buenos Aires, Argentina; Expert Analytic Laboratory, Centre of Drug and Medical Technology Expertise, Yerevan, Armenia; Institute for Quality Control of Medicines, Sarajevo, Bosnia and Herzegovina; Instituto Nacional de Controle de Qualidade em Sa\u00fade, Rio de Janeiro, Brazil; Laboratoire National de Sant\u00e9 Publique, Ouagadougou, Burkina Faso; National Laboratory for Drug Quality Control, Ministry of Health, Phnom Penh, Cambodia; Departamento de Control Nacional, Unidad de control de calidad de productos farmac\u00e9uticos del mercado nacional (Control de Estanter\u00eda), Instituto de Salud P\u00fablica, Santiago de Chile, Chile; Laboratorio de An\u00e1lisis y Asesor\u00eda Farmac\u00e9utica,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que incluye un apartado de agradecimientos. En este apartado, se reconoce la contribuci\u00f3n de diversas personas y organizaciones que participaron en la preparaci\u00f3n y desarrollo de la reuni\u00f3n. Se menciona el apoyo financiero de la Comunidad Europea, la Fundaci\u00f3n Bill & Melinda Gates y UNITAID. Adem\u00e1s, se enumeran numerosas agencias, instituciones y organizaciones que colaboraron en el trabajo del Comit\u00e9, destacando su importancia en el \u00e1mbito de la calidad y seguridad de los medicamentos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQui\u00e9nes son las personas clave mencionadas en el informe que contribuyeron a la preparaci\u00f3n de la reuni\u00f3n?**\n   - Respuesta: Las personas clave mencionadas son Mrs W. Bonny, Ms M. Gaspard, Dr S. Kopp, Ms C. Mendy y Dr L. R\u00e4go.\n\n2. **\u00bfQu\u00e9 organizaciones proporcionaron asistencia financiera para la elaboraci\u00f3n de la gu\u00eda t\u00e9cnica incluida en el informe?**\n   - Respuesta: La asistencia financiera fue proporcionada por la Comunidad Europea, la Fundaci\u00f3n Bill & Melinda Gates y UNITAID.\n\n3. **\u00bfCu\u00e1les son algunas de las instituciones y agencias que el Comit\u00e9 agradeci\u00f3 por sus contribuciones?**\n   - Respuesta: Algunas de las instituciones y agencias mencionadas son la Agencia Europea de Medicamentos, el Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria, y la Organizaci\u00f3n Mundial de la Propiedad Intelectual, entre otras.\n\n### Resumen de Nivel Superior\n\nEl informe t\u00e9cnico de la OMS destaca la importancia de la colaboraci\u00f3n internacional en la calidad y seguridad de los medicamentos. Reconoce a individuos y organizaciones que han contribuido significativamente a estos esfuerzos, as\u00ed como el apoyo financiero recibido de entidades prominentes. Este reconocimiento subraya la interconexi\u00f3n entre diferentes actores en el \u00e1mbito de la salud p\u00fablica y la farmac\u00e9utica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Terminolog\u00eda de Medicamentos Falsificados**:\n   - Se solicita retroalimentaci\u00f3n de los Estados Miembros sobre la terminolog\u00eda utilizada en su legislaci\u00f3n nacional respecto a \"medicamentos falsificados\" y t\u00e9rminos equivalentes.\n   - Se planea discutir los resultados en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos y posiblemente en el ICDRA (International Conference of Drug Regulatory Authorities).\n\n2. **Definici\u00f3n de Medicamentos Subest\u00e1ndar**:\n   - Se propone una nueva definici\u00f3n para \"medicamentos subest\u00e1ndar\", que ser\u00e1 circulada para su consideraci\u00f3n.\n\n3. **Actualizaci\u00f3n de Referencias de Farmacopeas**:\n   - Se actualizar\u00e1n las referencias y los detalles de contacto de las farmacopeas nacionales, regionales e internacionales en el sitio web de Aseguramiento de la Calidad de Medicamentos de la OMS.\n\n4. **Bases de Datos de la OMS**:\n   - Se mantendr\u00e1 la base de datos consolidada sobre la nomenclatura utilizada en el aseguramiento de la calidad de la OMS.\n   - Se continuar\u00e1 manteniendo la base de datos de Nombres Comunes Internacionales (INN) y se asegurar\u00e1 su disponibilidad en el sitio web.\n\n### Entidades Involucradas\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Responsable de la recopilaci\u00f3n de comentarios, la propuesta de definiciones y la actualizaci\u00f3n de bases de datos.\n- **Estados Miembros**: Participantes en la retroalimentaci\u00f3n sobre la terminolog\u00eda y la regulaci\u00f3n de medicamentos.\n- **Comit\u00e9 de Expertos**: Grupo que discutir\u00e1 los resultados de la retroalimentaci\u00f3n y la nueva definici\u00f3n propuesta.\n- **ICDRA**: Conferencia donde se podr\u00eda discutir la terminolog\u00eda y regulaciones relacionadas con medicamentos.", "excerpt_keywords": "Keywords: acknowledgements, WHO, pharmaceutical policies, quality assurance, international collaboration"}}, "9935211a-edda-4251-9fd5-68bc5225f630": {"node_ids": ["ef4eb977-7c62-453d-bcd5-ab484506eccd"], "metadata": {"page_label": "87", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Facultad de Farmacia, Universidad de Costa Rica, San Jos\u00e9, Costa Rica; Laboratorio de Normas y Calidad de Medicamentos, Caja Costarricense de Seguro Social, Antiguo Hospital de Alajuela, Alajuela, Costa Rica; Medicamentos y Productos Biol\u00f3gicos del INVIMA, Bogot\u00e1, Colombia; Oficina Sanitaria Panamericana, OPS/OMS, La Habana, Cuba; Food and Drugs Board, Quality Control Laboratory, Accra, Ghana; Department for Quality Evaluation and Control, National Institute of Pharmacy, Budapest, Hungary; Central Drugs Laboratory, Calcutta, India; Provincial Quality Control Laboratory of Drug and Food, Yogyakarta, Indonesia; Caribbean Regional Drug Testing Laboratory, Kingston, Jamaica; Mission for Essential Drugs and Supplies, Nairobi, Kenya; National Quality Control Laboratory for Drugs and Medical Devices, Nairobi, Kenya; Laboratoire de Contr\u00f4le de Qualit\u00e9 des M\u00e9dicaments, Agence du M\u00e9dicament de Madagascar, Antananarivo, Madagascar; Centre for Quality Control, National Pharmaceutical Control Bureau, Petaling Jaya, Sengalor, Malaysia; Laboratoire National de la Sant\u00e9 du Mali, Bamako, Mali; Laboratoire National de Contr\u00f4le des M\u00e9dicaments, Rabat, Morocco; Quality Surveillance Laboratory, Windhoek, Namibia; National Medicines Laboratory, Department of Drug Administration, Kathmandu, Nepal;\n\nLaboratoire National de Sant\u00e9 Publique et d'Expertise, Niamey, Niger; Central Quality Control Laboratory, Muscat, Oman; Drug Control and Traditional Medicine Division, National Institute of Health, Islamabad, Pakistan; Instituto Especializado de An\u00e1lisis, Universidad de Panam\u00e1, Panama; Food and Drug Quality Control Center, Ministry of Health, Vientiane, People's Democratic Republic of Lao; National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People's Republic of China; Centro Nacional de Control de Calidad, Instituto Nacional de Salud, Lima, Peru; Bureau of Food and Drugs, Department of Health, Alabang, Muntinlupa City, Philippines; Laboratory for Quality Control of Medicines, Medicines Agency, Ministry of Health, Chisinau, Republic of Moldova; Laboratoire National de Contr\u00f4le des M\u00e9dicaments, Dakar Etoile, Senegal; Centre for Quality Assurance of Medicines, Faculty of Pharmacy, North-West University, Potchefstroom, South Africa; Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa; National Drug Quality Assurance Laboratory, Colombo, Sri Lanka; Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand; Laboratoire National de Contr\u00f4le des M\u00e9dicaments, Tunis, Tunisia; National Drug Quality Control Laboratory, National Drug Authority, Kampala, Uganda; Central Laboratory for Quality Control of Medicines of the Ministry of Health of Ukraine, Kiev, Ukraine; School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, United Republic of Tanzania; Tanzania Food and Drugs Authority, Dar-es-Salaam, United Republic of Tanzania; Laboratorio Control de Productos MSP, Comisi\u00f3n Para El Control de Calidad de Medicamentos, Montevideo, Uruguay; Instituto Nacional de Higiene \u201cRafael Rangel\u201d, Caracas, Venezuela; National Institute of Drug Quality Control, Hanoi, Viet Nam; Medicines Control Authority, Control Laboratory of Zimbabwe, Harare, Zimbabwe.\n\nWHO Collaborating Centre for Drug Quality Assurance, Therapeutic Goods Administration Laboratories, Woden, Australian Capital Territory, Australia; WHO Collaborating Centre for Research on Bioequivalence Testing of Medicines, Frankfurt am Main, Germany; WHO Collaborating Centre for Drug Information and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que incluye una lista de instituciones y laboratorios de control de calidad de medicamentos de diferentes pa\u00edses. Estas instituciones est\u00e1n involucradas en la evaluaci\u00f3n y control de la calidad de productos farmac\u00e9uticos y biol\u00f3gicos, y representan una red global de colaboraci\u00f3n en el \u00e1mbito de la salud p\u00fablica y la regulaci\u00f3n de medicamentos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 papel desempe\u00f1a la Oficina Sanitaria Panamericana en la red de laboratorios de control de calidad de medicamentos mencionados en el informe?**\n   - Esta pregunta busca informaci\u00f3n sobre la funci\u00f3n espec\u00edfica de la Oficina Sanitaria Panamericana (OPS) en el contexto de la calidad de medicamentos, que podr\u00eda no estar detallada en otros documentos.\n\n2. **\u00bfCu\u00e1les son las principales responsabilidades del Laboratorio Nacional de Salud P\u00fablica y de Experticia en Niamey, N\u00edger, seg\u00fan el contexto del informe?**\n   - Esta pregunta se centra en las funciones espec\u00edficas de un laboratorio mencionado, lo que puede proporcionar detalles sobre su papel en la regulaci\u00f3n de medicamentos en su pa\u00eds.\n\n3. **\u00bfC\u00f3mo se relacionan los centros de control de calidad de medicamentos en Am\u00e9rica Latina con los de otras regiones, como \u00c1frica o Asia, seg\u00fan el informe?**\n   - Esta pregunta busca explorar las conexiones y colaboraciones entre diferentes regiones en el \u00e1mbito del control de calidad de medicamentos, lo que puede no estar claramente delineado en otros textos.\n\n### Resumen de Nivel Superior\nEl informe t\u00e9cnico de la OMS destaca la importancia de la colaboraci\u00f3n internacional en el control de calidad de medicamentos. Incluye una extensa lista de laboratorios y centros de control de calidad de diversas naciones, subrayando la necesidad de est\u00e1ndares globales y la cooperaci\u00f3n entre pa\u00edses para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.", "prev_section_summary": "La secci\u00f3n de agradecimientos del informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) destaca la colaboraci\u00f3n y contribuciones de diversas personas y organizaciones en la preparaci\u00f3n y desarrollo de la reuni\u00f3n. Los temas clave incluyen:\n\n1. **Reconocimiento a Individuos Clave**: Se menciona a varias personas que jugaron un papel fundamental en la organizaci\u00f3n del evento, incluyendo a Mrs W. Bonny, Ms M. Gaspard, Dr S. Kopp, Ms C. Mendy y Dr L. R\u00e4go.\n\n2. **Asistencia Financiera**: El informe se\u00f1ala que la gu\u00eda t\u00e9cnica fue elaborada con el apoyo financiero de la Comunidad Europea, la Fundaci\u00f3n Bill & Melinda Gates y UNITAID.\n\n3. **Contribuciones de Organizaciones**: Se agradece a una amplia variedad de agencias, instituciones y organizaciones que colaboraron, entre las que se incluyen:\n   - Agencia Europea de Medicamentos\n   - Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria\n   - Organizaci\u00f3n Mundial de la Propiedad Intelectual\n   - Diversas agencias nacionales y laboratorios de control de calidad de medicamentos de varios pa\u00edses.\n\n4. **Importancia de la Colaboraci\u00f3n Internacional**: El reconocimiento de estas entidades subraya la interconexi\u00f3n y la colaboraci\u00f3n necesaria en el \u00e1mbito de la calidad y seguridad de los medicamentos a nivel global.\n\nEn resumen, la secci\u00f3n enfatiza la importancia de la cooperaci\u00f3n internacional y el apoyo financiero en los esfuerzos por mejorar la calidad y seguridad de los medicamentos.", "excerpt_keywords": "Keywords: medicamentos, control de calidad, colaboraci\u00f3n internacional, OMS, laboratorios"}}, "d992393f-64d6-43a0-8d59-62e850b9256a": {"node_ids": ["ffa9441b-a450-45fe-aed6-6830bf5c086b"], "metadata": {"page_label": "88", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Quality Assurance, National Institute of Pharmacy, Budapest, Hungary; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Central Drugs Laboratory, Calcutta, India; WHO Collaborating Centre for Regulatory Control of Pharmaceuticals, National Pharmaceutical Control Bureau, Jalan University, Ministry of Health, Petaling Jaya, Malaysia; WHO Collaborating Centre for Drug Quality Assurance, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People\u2019s Republic of China; WHO Collaborating Centre for Drug Quality Assurance, Pharmaceutical Laboratory, Centre for Analytical Science, Health Sciences Authority, Singapore; WHO Collaborating Centre for Quality Assurance of Drugs, North-West University, Potchefstroom, South Africa; WHO Collaborating Centre for International Infrared Reference Spectra, Institute for Pharmaceutical Sciences, Zurich, Switzerland; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.\n\nAnti-Counterfeiting Medicines Programme, WHO, Geneva, Switzerland; Blood Products and Related Biologicals Programme, WHO, Geneva, Switzerland; Global Malaria Programme, WHO, Geneva, Switzerland; HIV/AIDS Programme, WHO, Geneva, Switzerland; International Medical Products Anti-Counterfeiting Taskforce (IMPACT), WHO, Geneva, Switzerland; Medicine Access and Rational Use Team, WHO, Geneva, Switzerland; Medicines Regulatory Support Programme, WHO, Geneva, Switzerland; Prequalification Programme, WHO, Geneva, Switzerland; Quality and Safety: Medicines Team, WHO, Geneva, Switzerland; Quality, Safety and Standards Team, WHO, Geneva, Switzerland; Traditional Medicine Team, WHO, Geneva, Switzerland; WHO/FIP Training Workshop on Pharmaceutical Development with Focus on Paediatric Formulations, Mumbai, India; WHO Regional Office for Africa, Brazzaville, Congo; WHO Regional Office for the Americas/Pan American Health Organization, Washington, DC, USA; WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt; WHO Regional Office for Europe, Copenhagen, Denmark; WHO Regional Office for South-East Asia, New Delhi, India; WHO Regional Office for the Western Pacific, Manila, Philippines.\n\nMrs T. Abdul Sattar, Acting Director General, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman; Dr F. Abiodun, Benin City, Nigeria; Dr E. Adams, Labo Voor Farmaceutische Chemie en Analyse van Geneesmiddelen, Leuven, Belgium; Mr M. Adarkwah-Yiadom, Standard Officer, Ghana Standards Board, Drugs, Cosmetics and Forensic Laboratory, Testing Division, Accra, Ghana; Professor I. Addae-Mensah, University of Ghana, Legon, Ghana; Ms R. Ahmad, Centre for Product Registration, National Pharmaceutical Control Bureau, Ministry of Health, Petaling Jaya, Malaysia; Mrs S. Ahmed Jaffar, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman; Professor J.-M. Aiache, Clermont-Ferrand, France; Dr A. Akkermans, the Netherlands; Dr R. Andrews, Medicines and Healthcare Products Regulatory Agency, London, England; Dr C. Anquez Traxler, European Self-Medication Industry, Brussels, Belgium; Dr H. Arentsen, Regulatory Intelligence and Policy Specialist, Regulatory Development Strategy, H. Lundbeck A/S, Copenhagen-Valby, Denmark; Dr C. Athlan, Quality Reviewer, Swissmedic, Berne, Switzerland; Dr A. Ba, Directeur, Qualit\u00e9 et D\u00e9veloppement, Centrale Humanitaire", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que se centra en la calidad y regulaci\u00f3n de los medicamentos. Se mencionan varios centros de colaboraci\u00f3n de la OMS en diferentes pa\u00edses que se dedican a la garant\u00eda de calidad de los medicamentos esenciales y a la regulaci\u00f3n de productos farmac\u00e9uticos. Adem\u00e1s, se enumeran programas espec\u00edficos de la OMS relacionados con la lucha contra la falsificaci\u00f3n de medicamentos, el acceso a medicamentos y el uso racional de los mismos. Tambi\u00e9n se incluyen nombres y cargos de profesionales de la salud y la regulaci\u00f3n de varios pa\u00edses, lo que sugiere una colaboraci\u00f3n internacional en estos temas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los principales programas de la OMS mencionados en el informe que se centran en la calidad y seguridad de los medicamentos?**\n   - Respuesta: Los programas incluyen el Programa de Medicamentos Antifalsificaci\u00f3n, el Programa de Productos Biol\u00f3gicos y Relacionados con la Sangre, el Programa Global de Malaria, el Programa de VIH/SIDA, y el Programa de Apoyo Regulatorio de Medicamentos, entre otros.\n\n2. **\u00bfQu\u00e9 instituciones y centros de colaboraci\u00f3n de la OMS est\u00e1n involucrados en la garant\u00eda de calidad de los medicamentos en Asia?**\n   - Respuesta: En Asia, se mencionan el Centro de Control de Productos Farmac\u00e9uticos de Malasia, el Laboratorio Central de Medicamentos en Calcuta, India, y el Instituto Nacional para el Control de Productos Farmac\u00e9uticos y Biol\u00f3gicos en Beijing, China.\n\n3. **\u00bfQui\u00e9nes son algunos de los profesionales destacados en el informe y qu\u00e9 roles desempe\u00f1an en sus respectivos pa\u00edses?**\n   - Respuesta: Algunos profesionales destacados incluyen a Mrs. T. Abdul Sattar, Directora General Actuante en Om\u00e1n; Dr. E. Adams de B\u00e9lgica; y Dr. R. Andrews de la Agencia Reguladora de Medicamentos y Productos de Salud en Inglaterra, entre otros, quienes desempe\u00f1an roles en la regulaci\u00f3n y control de medicamentos en sus pa\u00edses.", "prev_section_summary": "La secci\u00f3n del documento t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) presenta una lista extensa de instituciones y laboratorios dedicados al control de calidad de medicamentos en diversos pa\u00edses. Estos laboratorios son fundamentales para la evaluaci\u00f3n y regulaci\u00f3n de productos farmac\u00e9uticos y biol\u00f3gicos, destacando la importancia de la colaboraci\u00f3n internacional en el \u00e1mbito de la salud p\u00fablica.\n\n### Temas Clave:\n1. **Control de Calidad de Medicamentos**: La secci\u00f3n enfatiza la necesidad de est\u00e1ndares globales y la cooperaci\u00f3n entre pa\u00edses para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.\n2. **Colaboraci\u00f3n Internacional**: Se resalta la red global de laboratorios y centros de control de calidad, que trabajan juntos para mejorar la regulaci\u00f3n de medicamentos.\n3. **Diversidad Geogr\u00e1fica**: La lista incluye instituciones de Am\u00e9rica Latina, \u00c1frica, Asia, Europa y Ocean\u00eda, mostrando la amplitud de la colaboraci\u00f3n en el control de calidad.\n\n### Entidades Mencionadas:\n- **Instituciones Acad\u00e9micas**: Ejemplo: Facultad de Farmacia, Universidad de Costa Rica.\n- **Laboratorios Nacionales**: Ejemplo: Laboratorio Nacional de Salud P\u00fablica y de Experticia, Niamey, N\u00edger.\n- **Agencias de Salud**: Ejemplo: Oficina Sanitaria Panamericana (OPS/OMS), La Habana, Cuba.\n- **Centros de Control de Calidad**: Ejemplo: National Institute for the Control of Pharmaceutical and Biological Products, Beijing, China.\n- **Colaboraci\u00f3n con la OMS**: Ejemplo: WHO Collaborating Centre for Drug Quality Assurance, Australia.\n\nEste resumen destaca la relevancia de la red de laboratorios en la regulaci\u00f3n de medicamentos y la importancia de la cooperaci\u00f3n internacional en este \u00e1mbito.", "excerpt_keywords": "Keywords: Quality Assurance, WHO Collaborating Centres, Pharmaceuticals, Anti-Counterfeiting, International Collaboration"}}, "651197fc-34c5-4d86-873c-3f994abd31d4": {"node_ids": ["5cd169f9-9189-4e45-854c-b15b7c356506"], "metadata": {"page_label": "89", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Medico-Pharmaceutique, Clermont-Ferrand, France; Dr H. Batista, US Food and Drug Administration, Silver Spring, MD, USA; Mr B. Baudrand, OTECI, Paris, France; Dr O.P. Baula, Deputy Director, State Pharmacological Center, Ministry of Health, Kiev, Ukraine; Professor S.A. Bawazir, Vice-President, Saudi Food and Drug Authority, Head of Drug Sector, Riyadh, Saudi Arabia; Dr M.G. Beatrice, Vice President, Corporate Regulatory and Quality Science, Abbott, Abbott Park, USA; Dr T.L. Bedane, Drug Administration and Control, Addis Ababa, Ethiopia; Ms T.J. Bell, WHO Focal Point, US Food and Drug Administration, Silver Spring, MD, USA; Dr I.B.G. Bernstein, Director, Pharmacy Affairs, Office of the Commissioner/Office of Policy, US Food and Drug Administration, Silver Spring, MD, USA; Dr R.P. Best, President and CEO, International Society for Pharmaceutical Engineering, Tampa, FL, USA; Dr L. Bigger, Regulatory and Scientific Affairs, International Federation of Pharmaceutical Manufacturers Associations, Geneva, Switzerland; Dr L. Bonthuys, Pretoria, South Africa; Professor R. Boudet-Dalbin, Facult\u00e9 de Pharmacie, Laboratoire de Chimie Th\u00e9rapeutique, Paris, France; Dr S.K. Branch, Acting Group Manager, Special Populations Group, Medicines and Healthcare products Regulatory Agency, London, England; Dr E. Brendel, Bayer HealthCare AG, Elberfeld, Germany; Mr C. Brown, Inspections Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency, London, England; Dr W. Bukachi, Project Coordinator, International Affairs, US Pharmacopeia, Rockville, MD, USA; Dr F. Burnett, Managing Director, Pharmaceutical Procurement Service, Organization of Eastern Caribbean States, Castries, St Lucia; Dr D. Calam, Wiltshire, England; Dr N. Cappuccio, Lambertville, NJ, USA; Dr A. Castro, Regulatory Affairs Director and Senior Pharmacist, Roche Servicios SA, Heredia, Costa Rica; Dr D. Catsoulacos, Scientific Administrator, Manufacturing and Quality Compliance, Compliance and Inspection, European Medicines Agency, London, England; Mr Xuanhao Chan, Project Manager, International Pharmaceutical Federation, The Hague, Netherlands; Dr B. Chapart, Pharma Review Manager, Global Analytical Development, Sanofi-Aventis Pharma, Anthony, France; Ms Cheah Nuan Ping, Director, Cosmetics & Cigarette Testing Laboratory, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore; Dr Xu Chen, Director, Division of Drug Distribution Supervision, State Food and Drug Administration, Beijing, People's Republic of China; Professor Y. Cherrah, Facult\u00e9 de M\u00e9decine et Pharmacie, Rabat, Morocco; Ms I. Clamou, Assistant Manager, Scientific, Technical and Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; Dr M. Cooke, Senior Manager, Global Quality, Operations, AstraZeneca, Macclesfield, Cheshire, England; Dr C. Craft, Member, United States Pharmacopeia International Health Expert Committee, Rockville, MD, USA; Dr R.L. Dana, Senior Vice President, Regulatory Affairs and Parenteral Drug Association Training and Research Institute, Parenteral Drug Association, Bethesda, MD, USA; Dr V. Davoust, Quality & Regulatory Policy, Global CMC, WW Pharmaceutical Sciences, Pfizer Global Research & Development Paris, France; Professor T. Dekker, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa; Dr M. Dereque-Pois, Director General, European Association of Pharmaceutical Full-line Wholesalers, Brussels, Belgium; Professor J.B. Dressman, Institut f\u00fcr Pharmazeutische Technologie, Biozentrum, Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt/Main, Germany; Dr A.T. Ducca, Senior Director, Regulatory", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (Organizaci\u00f3n Mundial de la Salud) y presenta una lista de profesionales y expertos en el campo de la farmac\u00e9utica y la regulaci\u00f3n de medicamentos. Incluye nombres, t\u00edtulos y afiliaciones de personas de diversas organizaciones y pa\u00edses, destacando la colaboraci\u00f3n internacional en temas de regulaci\u00f3n y calidad en la industria farmac\u00e9utica.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 roles desempe\u00f1an los diferentes expertos mencionados en el documento en sus respectivas organizaciones?**\n   - Esta pregunta busca detalles sobre las funciones espec\u00edficas de cada individuo en sus organizaciones, lo cual no se detalla en el texto.\n\n2. **\u00bfC\u00f3mo se relacionan las instituciones representadas por los expertos en el contexto de la regulaci\u00f3n farmac\u00e9utica global?**\n   - Esta pregunta indaga sobre la interconexi\u00f3n y colaboraci\u00f3n entre las diversas instituciones mencionadas, lo que podr\u00eda no estar expl\u00edcitamente abordado en el documento.\n\n3. **\u00bfQu\u00e9 temas espec\u00edficos de regulaci\u00f3n y calidad en la industria farmac\u00e9utica podr\u00edan estar siendo discutidos por los expertos listados en el documento?**\n   - Esta pregunta busca explorar los posibles temas de discusi\u00f3n o \u00e1reas de enfoque que podr\u00edan ser relevantes para los expertos, bas\u00e1ndose en sus roles y organizaciones, pero que no se mencionan directamente en el texto. \n\n### Resumen de Nivel Superior\nEl contexto presenta una lista de expertos en regulaci\u00f3n farmac\u00e9utica de diversas organizaciones internacionales, lo que sugiere un esfuerzo colaborativo para abordar cuestiones de calidad y regulaci\u00f3n en la industria farmac\u00e9utica. La diversidad geogr\u00e1fica y profesional de los participantes indica un enfoque global hacia la mejora de las pr\u00e1cticas en este campo.", "prev_section_summary": "La secci\u00f3n del documento se centra en la calidad y regulaci\u00f3n de los medicamentos, destacando la colaboraci\u00f3n internacional a trav\u00e9s de diversos centros de la Organizaci\u00f3n Mundial de la Salud (OMS) y programas espec\u00edficos. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n### Temas Clave:\n1. **Calidad y Regulaci\u00f3n de Medicamentos**: Se enfatiza la importancia de la garant\u00eda de calidad de los medicamentos esenciales y la regulaci\u00f3n de productos farmac\u00e9uticos.\n2. **Programas de la OMS**: Se enumeran varios programas de la OMS que abordan la falsificaci\u00f3n de medicamentos, el acceso a medicamentos, y el uso racional de estos.\n3. **Colaboraci\u00f3n Internacional**: Se menciona la participaci\u00f3n de m\u00faltiples pa\u00edses y profesionales en la regulaci\u00f3n y control de medicamentos, lo que sugiere un esfuerzo global coordinado.\n\n### Entidades y Centros de Colaboraci\u00f3n de la OMS:\n- **Centros de Calidad**:\n  - Instituto Nacional de Farmacia, Budapest, Hungr\u00eda.\n  - Laboratorio Central de Medicamentos, Calcuta, India.\n  - Bureau de Control Farmac\u00e9utico, Malasia.\n  - Instituto Nacional para el Control de Productos Farmac\u00e9uticos y Biol\u00f3gicos, Beijing, China.\n  - Autoridad de Salud de Singapur.\n  - Universidad del Noroeste, Potchefstroom, Sud\u00e1frica.\n  - Instituto de Ciencias Farmac\u00e9uticas, Zurich, Suiza.\n  - Departamento de Ciencias M\u00e9dicas, Ministerio de Salud, Tailandia.\n\n- **Programas de la OMS**:\n  - Programa de Medicamentos Antifalsificaci\u00f3n.\n  - Programa de Productos Biol\u00f3gicos y Relacionados con la Sangre.\n  - Programa Global de Malaria.\n  - Programa de VIH/SIDA.\n  - Programa de Apoyo Regulatorio de Medicamentos.\n  - Programa de Precalificaci\u00f3n.\n\n### Profesionales Destacados:\n- **Mrs. T. Abdul Sattar**: Directora General Actuante, Om\u00e1n.\n- **Dr. E. Adams**: B\u00e9lgica.\n- **Dr. R. Andrews**: Agencia Reguladora de Medicamentos y Productos de Salud, Inglaterra.\n- **Dr. H. Arentsen**: Especialista en Inteligencia Regulatoria, Dinamarca.\n- **Dr. C. Athlan**: Revisor de Calidad, Suiza.\n\nEste resumen refleja la colaboraci\u00f3n y los esfuerzos globales en la regulaci\u00f3n y garant\u00eda de calidad de los medicamentos, as\u00ed como la participaci\u00f3n de diversas instituciones y profesionales en este \u00e1mbito.", "excerpt_keywords": "Keywords: regulaci\u00f3n farmac\u00e9utica, calidad de medicamentos, colaboraci\u00f3n internacional, expertos en salud, Organizaci\u00f3n Mundial de la Salud"}}, "02d8eabb-37a0-4fd5-a3fb-3004c1edbd1b": {"node_ids": ["f1136d7b-2bf1-4aff-adf5-234cfc95d1af"], "metadata": {"page_label": "90", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento mencionado es el \"WHO - Technical Report Series 957\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica y recomendaciones para la pr\u00e1ctica cl\u00ednica y la pol\u00edtica de salud. Sin embargo, el contenido espec\u00edfico del informe en la p\u00e1gina 90 no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las principales recomendaciones de salud p\u00fablica presentadas en la p\u00e1gina 90 del informe WHO - Technical Report Series 957?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las recomendaciones que podr\u00edan estar incluidas en esa secci\u00f3n del informe.\n\n2. **\u00bfQu\u00e9 metodolog\u00eda se utiliz\u00f3 para recopilar los datos presentados en la p\u00e1gina 90 del informe?**\n   - Esta pregunta se centra en la metodolog\u00eda de investigaci\u00f3n, que es un aspecto crucial en los informes t\u00e9cnicos de la OMS.\n\n3. **\u00bfQu\u00e9 temas espec\u00edficos se abordan en la secci\u00f3n de la p\u00e1gina 90 del informe y c\u00f3mo se relacionan con las tendencias actuales en salud p\u00fablica?**\n   - Esta pregunta busca conectar el contenido espec\u00edfico de la p\u00e1gina con las tendencias m\u00e1s amplias en el campo de la salud p\u00fablica, lo que podr\u00eda no estar disponible en otras fuentes. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n que probablemente sea \u00fanica y relevante dentro del contexto del informe t\u00e9cnico de la OMS.", "prev_section_summary": "La secci\u00f3n presenta una lista de expertos en regulaci\u00f3n farmac\u00e9utica y calidad de medicamentos, pertenecientes a diversas organizaciones internacionales y de diferentes pa\u00edses. Los temas clave incluyen:\n\n1. **Colaboraci\u00f3n Internacional**: La diversidad de los participantes sugiere un esfuerzo conjunto para abordar cuestiones de regulaci\u00f3n y calidad en la industria farmac\u00e9utica a nivel global.\n\n2. **Expertos y sus Afiliaciones**: Se mencionan nombres, t\u00edtulos y organizaciones de profesionales destacados en el campo, como la OMS, la FDA de EE. UU., la Agencia Europea de Medicamentos, y varias instituciones acad\u00e9micas y de investigaci\u00f3n.\n\n3. **Roles y Funciones**: Aunque no se detallan las funciones espec\u00edficas de cada experto, se infiere que est\u00e1n involucrados en la regulaci\u00f3n, calidad, investigaci\u00f3n y desarrollo de medicamentos.\n\n4. **Temas de Regulaci\u00f3n y Calidad**: Aunque no se especifican, se puede suponer que los expertos discuten temas relevantes para la regulaci\u00f3n farmac\u00e9utica, como est\u00e1ndares de calidad, cumplimiento normativo y pr\u00e1cticas de fabricaci\u00f3n.\n\nEn resumen, la secci\u00f3n destaca la importancia de la colaboraci\u00f3n internacional en la regulaci\u00f3n farmac\u00e9utica, reflejando un enfoque global hacia la mejora de las pr\u00e1cticas en este campo.", "excerpt_keywords": "Keywords: OMS, regulaci\u00f3n farmac\u00e9utica, calidad de medicamentos, colaboraci\u00f3n internacional, salud p\u00fablica"}}, "cd6eed2f-1428-4923-81ca-25e04d8dffa5": {"node_ids": ["21820e22-6d99-4152-b443-2f081ea740ce"], "metadata": {"page_label": "91", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Dr M. James, GlaxoSmithKline, Brentford, Middlesex, England; Professor Jin Shaohong, Executive Director-General, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People\u2019s Republic of China; Dr P. Jones, Director, Analytical Control, Pharmaceutical Sciences, Pfizer Global R&D, Sandwich, England; Dr Y. Juillet, France; Ms A. Juntonen, Senior Pharmaceutical Inspector, National Agency for Medicines, Helsinki, Finland; Mr D. J\u00fcnemann, Teaching Assistant; Institut f\u00fcr Pharmazeutische Technologie, Biozentrum, Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt/Main, Germany; Dr M. Kaplan, Director, Institute for Standardization and Control of Pharmaceuticals, Jerusalem, Israel; Dr A.M. Kaukonen, National Agency for Medicines, Helsinki, Finland; Dr T. Kawanishi, Division of Drugs, National Institute of Health Sciences, Tokyo, Japan; Dr S. Keitel, Director, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France; Dr M. Keller, Division of Certificates & Licences, Licensing Sector, Berne, Switzerland; Dr H. K\u00f6szegi-Szalai, Head, Department for Quality Assessment and Control, National Institute of Pharmacy, Budapest, Hungary; Dr A. Kovacs, Secretariat, Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland; Dr A. Krauss, Principal Scientist, Chemist Laboratory, Therapeutic Goods Administration Laboratories, Woden, Australian Capital Territory, Australia; Professor H.G. Kristensen, Vedbaek, Denmark; Mr A. Kupfermann, Industry Pharmacist, Strasbourg, France; Professor S. L\u00e4r, Institut f\u00fcr Klinische Pharmazie und Pharmakotherapie, Heinrich-Heine-Universit\u00e4t, D\u00fcsseldorf, Germany; Dr J.-M. Legrand, GlaxoSmithKline Biologicals, Wavre, Belgium; Dr A. Lodi, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France; Mr M. Lok, Head of Office, Office of Manufacturing Quality, Therapeutic Goods Administration, Woden, Australian Capital Territory, Australia; Ms Low Min Yong, Director, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore; Dr J.C. Lyda, Senior Director, Regulatory Affairs, Parenteral Drug Association Europe, Glienicke/Berlin, Germany; Mr D. Mader, Compliance Auditor, GlaxoSmithKline, Cape Town, South Africa; Mr J-D. Mallet, OTECI, Paris, France; Reverend J.Y. Martey, Head, Laboratory Services, Quality Control Laboratory, Food and Drugs Board, Accra, Ghana; Dr T. Massa, Vice President, Global Regulatory Sciences \u2014 Chemistry, Manufacturing and Control, Bristol-Myers Squibb, USA; Dr B. Matthews, Alcon, Hemel Hempstead, Herts, England; Dr Y. Matthews, Regulatory Operations Executive, GE Healthcare, Amersham, Bucks, England; Dr J.-L. Mazert, Rueil, France; Dr G. McGurk, Executive Inspector, Irish Medicines Board, Dublin, Ireland; Dr A. Mechkovski, Moscow, Russian Federation; Dr M. Mehmandoust, DEMEB/DEQPH, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9, Saint-Denis, France; Dr D. Mehta, Vigilance and Risk Management of Medicines, Medicines and Healthcare Products Regulatory Agency, London, England; Dr J.H.McB. Miller, Strasbourg, France; Dr O. Milling, Medicines Inspector, Medicines Control Division, Danish Medicines Agency, Copenhagen, Denmark; Dr R.H. Mocchettino, Head of INAME Inspectorate, ANMAT, Caba, Argentina; Ms N.H. Mohd Potri, Senior Assistant, Director, GMP and Licensing Division, Centre for Compliance and Licensing, National Pharmaceutical Control Bureau, Ministry of Health Malaysia, Petaling Jaya, Malaysia; Dr J.A. Molzon, Associate Director for International Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA; Dr I. Moore, Product and Quality Assurance Manager, Croda", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl texto presenta una lista de profesionales y sus respectivas afiliaciones en el \u00e1mbito de la regulaci\u00f3n y control de productos farmac\u00e9uticos y biol\u00f3gicos. Incluye nombres, t\u00edtulos y organizaciones de diversas partes del mundo, destacando la colaboraci\u00f3n internacional en la regulaci\u00f3n de medicamentos y la calidad de productos farmac\u00e9uticos. Este contexto sugiere un enfoque en la cooperaci\u00f3n global para asegurar la calidad y seguridad de los productos de salud.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 papel desempe\u00f1a el Dr. M. James en GlaxoSmithKline y c\u00f3mo podr\u00eda su experiencia contribuir a la regulaci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta busca explorar la funci\u00f3n espec\u00edfica del Dr. M. James y su impacto en la industria farmac\u00e9utica, lo que puede no estar documentado en otras fuentes.\n\n2. **\u00bfCu\u00e1les son las responsabilidades del Dr. T. Kawanishi en el National Institute of Health Sciences de Jap\u00f3n y c\u00f3mo se relacionan con la calidad de los medicamentos?**\n   - Esta pregunta se centra en el rol del Dr. Kawanishi, proporcionando informaci\u00f3n sobre su trabajo en un contexto espec\u00edfico que podr\u00eda no estar disponible en otros lugares.\n\n3. **\u00bfQu\u00e9 iniciativas ha tomado la European Directorate for the Quality of Medicines and Healthcare, bajo la direcci\u00f3n del Dr. S. Keitel, para mejorar la regulaci\u00f3n de medicamentos en Europa?**\n   - Esta pregunta busca detalles sobre las acciones espec\u00edficas y pol\u00edticas implementadas por esta organizaci\u00f3n, que pueden no estar ampliamente documentadas.\n\n### Resumen de Nivel Superior\nEl documento destaca la importancia de la colaboraci\u00f3n internacional en el \u00e1mbito de la regulaci\u00f3n farmac\u00e9utica, presentando a expertos de diversas organizaciones y pa\u00edses. Este enfoque global es crucial para garantizar la calidad y seguridad de los productos farmac\u00e9uticos, lo que implica un intercambio de conocimientos y mejores pr\u00e1cticas entre diferentes entidades reguladoras.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl contenido proporcionado se refiere al \"WHO - Technical Report Series 957\", un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque no se dispone de informaci\u00f3n espec\u00edfica sobre la p\u00e1gina 90 del documento, se pueden inferir algunos temas clave y entidades relevantes:\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n del informe, que se centra en la salud p\u00fablica y la investigaci\u00f3n m\u00e9dica.\n\n2. **Informe T\u00e9cnico**: Parte de una serie que aborda diversas cuestiones relacionadas con la salud, incluyendo recomendaciones y pol\u00edticas de salud.\n\n3. **Salud P\u00fablica**: Tema central del informe, que probablemente incluye recomendaciones y metodolog\u00edas relacionadas con la mejora de la salud a nivel poblacional.\n\n4. **Investigaci\u00f3n M\u00e9dica**: Es probable que el informe incluya datos y an\u00e1lisis sobre pr\u00e1cticas m\u00e9dicas y su impacto en la salud p\u00fablica.\n\n5. **Metodolog\u00eda de Investigaci\u00f3n**: Un aspecto importante en los informes t\u00e9cnicos, que detalla c\u00f3mo se recopilaron y analizaron los datos presentados.\n\n6. **Tendencias en Salud P\u00fablica**: El informe podr\u00eda relacionar sus hallazgos con tendencias actuales en el campo de la salud, aunque esto no se detalla en el contenido proporcionado.\n\n### Conclusi\u00f3n:\nEl documento es parte de una serie t\u00e9cnica de la OMS que aborda temas relevantes en salud p\u00fablica, aunque el contenido espec\u00edfico de la p\u00e1gina 90 no est\u00e1 disponible. Las preguntas formuladas buscan profundizar en las recomendaciones, metodolog\u00edas y temas tratados en esa secci\u00f3n del informe.", "excerpt_keywords": "Keywords: regulaci\u00f3n farmac\u00e9utica, colaboraci\u00f3n internacional, calidad de medicamentos, organismos reguladores, productos biol\u00f3gicos"}}, "8a3f516b-90bf-48f0-afc3-99f3d245ae2e": {"node_ids": ["142b149a-fd55-4b1a-82d1-1675242f065a"], "metadata": {"page_label": "92", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido que podr\u00eda estar relacionado:\n\n### Resumen del Contexto\nEl documento mencionado es el \"WHO - Technical Report Series 957\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica, y recomendaciones para pr\u00e1cticas de salud a nivel global. Sin embargo, el contenido espec\u00edfico del documento no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el informe t\u00e9cnico de la OMS en la serie 957?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el contenido del informe, que podr\u00eda incluir datos sobre enfermedades, tratamientos, o pol\u00edticas de salud.\n\n2. **\u00bfQu\u00e9 temas de salud p\u00fablica se abordan en el documento \"WHO - Technical Report Series 957\"?**\n   - Esta pregunta se centra en identificar los temas clave tratados en el informe, lo que podr\u00eda incluir enfermedades infecciosas, salud materno-infantil, o estrategias de prevenci\u00f3n.\n\n3. **\u00bfC\u00f3mo se compara el contenido del informe 957 con otros informes anteriores de la serie de la OMS?**\n   - Esta pregunta busca establecer una comparaci\u00f3n entre el informe actual y los anteriores, lo que podr\u00eda revelar tendencias en la investigaci\u00f3n y cambios en las recomendaciones de salud p\u00fablica.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que probablemente no se encuentre f\u00e1cilmente en otros documentos o fuentes, dado que se centran en el contenido particular del informe t\u00e9cnico de la OMS.", "prev_section_summary": "La secci\u00f3n presenta una lista de profesionales destacados en el \u00e1mbito de la regulaci\u00f3n y control de productos farmac\u00e9uticos y biol\u00f3gicos, provenientes de diversas organizaciones y pa\u00edses. Los temas clave incluyen:\n\n1. **Colaboraci\u00f3n Internacional**: Se enfatiza la importancia de la cooperaci\u00f3n global en la regulaci\u00f3n de medicamentos y la garant\u00eda de la calidad y seguridad de los productos de salud.\n\n2. **Diversidad de Expertos**: La lista incluye a expertos de diferentes disciplinas y pa\u00edses, lo que refleja un enfoque multidisciplinario y multicultural en la regulaci\u00f3n farmac\u00e9utica.\n\n3. **Entidades Reguladoras**: Se mencionan varias organizaciones clave, como:\n   - GlaxoSmithKline\n   - Pfizer Global R&D\n   - National Institute for the Control of Pharmaceutical and Biological Products (China)\n   - European Directorate for the Quality of Medicines and Healthcare (Francia)\n   - Medicines and Healthcare Products Regulatory Agency (Reino Unido)\n   - Therapeutic Goods Administration (Australia)\n   - US Food and Drug Administration (EE. UU.)\n\n4. **Roles y Responsabilidades**: Se destacan los t\u00edtulos y roles de los profesionales, lo que sugiere una amplia gama de responsabilidades en la regulaci\u00f3n, control de calidad, y desarrollo de pol\u00edticas en el sector farmac\u00e9utico.\n\nEn resumen, la secci\u00f3n subraya la relevancia de la colaboraci\u00f3n internacional y la diversidad de expertos en la regulaci\u00f3n de productos farmac\u00e9uticos, lo que es esencial para asegurar la calidad y seguridad de los medicamentos a nivel global.", "excerpt_keywords": "Keywords: OMS, regulaci\u00f3n farmac\u00e9utica, cooperaci\u00f3n internacional, calidad de medicamentos, salud p\u00fablica"}}, "c4251d76-0956-45d9-8347-deec778e5792": {"node_ids": ["c68c5d53-eb45-40eb-9d78-ed0e0e01e60c"], "metadata": {"page_label": "93", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt/Main, Germany; Dr U. Shah, Formulation Research Fellow, Cheshire, Merseyside & North Wales LRN, Medicines for Children Research Network, Royal Liverpool Children's NHS Trust, Liverpool, England; Dr P.D. Sheth, Vice-President, International Pharmaceutical Federation, New Delhi, India; Dr P.G. Shrotriya, Ambli, Ahmedabad, India; Dr M. Sigonda, Director-General, Tanzania Food and Drugs Authority, Dar-es-Salaam, United Republic of Tanzania; Dr G.N. Singh, Secretary-cum-Scientific Director, Government of India, Ministry of Health and Family Welfare, Central Indian Pharmacopoeia Laboratory, Ghaziabad, India; Dr S. Singh, Professor and Head, Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Nagar, Punjab, India; Ms K. Siniivuo, Senior Researcher and Secretary, National Agency for Medicines, Helsinki, Finland; Dr L. Slamet, Director, Drug Control, General Directorate of Drug and Food Control, Jakarta, Indonesia; Mr D. Smith, Principal Scientist, SSI, Gauteng, South Africa; Dr C. Sokhan, Deputy Director, Department of Drug and Food, Phnom Penh, Cambodia; Dr A. Spreitzhofer, AGES PharmMed GmbH, Vienna, Austria; Dr Y. Stewart, Scientific, Technical and Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; Dr L. Stoppa, Agenzia Italiana del Farmaco, Rome, Italy; Dr S. Sur, Kiev, Ukraine; Dr E. Swanepoel, Head, Operations, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa; Professor M. Sznitowska, Department of Pharmaceutical Technology, Medical University of Gdansk, Gdansk, Poland; Dr D. Teitz, Manager, Bristol-Myers Squibb Company, New Brunswick, NJ, USA; Dr B.B. Thapa, Chief Drug Administrator, Department of Drug Administration, Ministry of Health and Population, Kathmandu, Nepal; Dr R. Torano, Pharmacopoeial Intelligence and Advocacy Specialist, GlaxoSmithKline, Brentford, Middlesex, England; Ms M. Treebamroong, Senior Pharmacist, Drug Quality and Safety, Department of Medical Sciences, Bureau of Drug and Narcotic, Ministry of Public Health, Nonthaburi, Thailand; Mr R. Tribe, Holder, Australian Capital Territory, Australia; Associate Professor Trinh Van Lau, Director, National Institute of Drug Quality Control, Hanoi Viet Nam; Professor Tu Guoshi, National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing, People's Republic of China; Dr C. Tuleu, Senior Lecturer and Deputy Director, Department of Pharmaceutics and Centre for Paediatric Pharmacy Research, School of Pharmacy, University of London, London, England; Ms E. Uramis, La Havana, Cuba; Dr A.R.T. Utami, National Agency for Drugs and Food Control, Jakarta Pusat, Indonesia; Mrs M. Vallender, Editor-in-Chief, British Pharmacopoeia Commission Secretariat, London, England; Mr P. van der Hoeven, APIC Secretary General and Cefic Manager, Active Pharmaceutical Ingredients Committee, Managing Director, Fine Chemicals, European Chemical Industry Council, Brussels, Belgium; Mr L. Viornery, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9, Saint Denis, France; Dr L. Virgili, USA; Professor Wang Ping, Deputy Director, China Pharmacopoeia Committee, Beijing, People's Republic of China; Dr G. Wang'ang'a, Head, Microbiological and Medical Devices Units, National Quality Control Laboratory, Nairobi, Kenya; Dr A. Ward, Regulatory Affairs, Avecia Vaccines, Billingham, England; Dr W. Watson, Associate Manager, CMC Regulatory Affairs, Gilead Sciences International, Cambridge, England; Dr D.E. Webber, Director-General, World Self-Medication Industry, Ferney-Voltaire, France; Professor W. Wieniawski,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl contexto presenta una lista de profesionales y acad\u00e9micos de diversas instituciones y pa\u00edses que est\u00e1n involucrados en el \u00e1mbito de la farmacolog\u00eda, la regulaci\u00f3n de medicamentos y la investigaci\u00f3n en salud. Se mencionan sus cargos y las organizaciones a las que pertenecen, lo que sugiere una colaboraci\u00f3n internacional en temas relacionados con la calidad y seguridad de los medicamentos.\n\n### Preguntas Generadas\n\n1. **\u00bfQu\u00e9 papel desempe\u00f1a Dr. U. Shah en la investigaci\u00f3n sobre medicamentos para ni\u00f1os y c\u00f3mo se relaciona su trabajo con la red de investigaci\u00f3n mencionada?**\n   - Esta pregunta busca profundizar en la contribuci\u00f3n espec\u00edfica de Dr. U. Shah en el contexto de la investigaci\u00f3n pedi\u00e1trica y su conexi\u00f3n con la Medicines for Children Research Network.\n\n2. **\u00bfCu\u00e1les son las principales responsabilidades de Dr. G.N. Singh como Secretario-cum-Scientific Director en el Gobierno de India, y c\u00f3mo impacta su trabajo en la farmacopoeia india?**\n   - Esta pregunta se centra en el papel de Dr. G.N. Singh y su influencia en la regulaci\u00f3n y est\u00e1ndares de medicamentos en India, lo que puede no estar ampliamente documentado en otras fuentes.\n\n3. **\u00bfQu\u00e9 iniciativas ha tomado la Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9, representada por Mr. L. Viornery, para mejorar la seguridad de los productos farmac\u00e9uticos en Francia?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las acciones y pol\u00edticas implementadas por la agencia francesa en el \u00e1mbito de la seguridad de medicamentos, que puede no estar disponible en otras publicaciones.\n\n### Resumen de Nivel Superior\nEl documento parece ser un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que incluye contribuciones de expertos internacionales en el campo de la farmacolog\u00eda y la regulaci\u00f3n de medicamentos. Los participantes provienen de diversas instituciones y pa\u00edses, lo que indica un esfuerzo colaborativo para abordar cuestiones relacionadas con la calidad y la seguridad de los medicamentos a nivel global.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 957\" es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS) que se enfoca en temas de salud p\u00fablica y recomendaciones para pr\u00e1cticas de salud a nivel global. Aunque el contenido espec\u00edfico no est\u00e1 disponible, se pueden inferir algunos temas clave y entidades relevantes:\n\n#### Temas Clave\n1. **Salud P\u00fablica**: El informe probablemente aborda cuestiones relacionadas con la salud p\u00fablica, incluyendo enfermedades, prevenci\u00f3n y control de epidemias.\n2. **Investigaci\u00f3n M\u00e9dica**: Es posible que se presenten hallazgos de investigaciones recientes en el campo de la medicina y la salud.\n3. **Recomendaciones de Salud**: El documento puede incluir directrices y recomendaciones para mejorar la salud a nivel global, basadas en evidencia cient\u00edfica.\n\n#### Entidades\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la publicaci\u00f3n del informe, que se dedica a coordinar esfuerzos internacionales en salud p\u00fablica.\n- **Informe T\u00e9cnico**: El tipo de documento que se presenta, que generalmente incluye an\u00e1lisis, datos y recomendaciones sobre temas de salud.\n\nEste resumen proporciona una visi\u00f3n general de lo que podr\u00eda incluir el informe, a pesar de la falta de contenido espec\u00edfico en el extracto proporcionado.", "excerpt_keywords": "Keywords: farmacolog\u00eda, regulaci\u00f3n de medicamentos, investigaci\u00f3n en salud, colaboraci\u00f3n internacional, calidad y seguridad de medicamentos"}}, "1b153ebe-776a-4e6b-8ba7-00bee8acd554": {"node_ids": ["1cb001e3-d1ed-4a6e-944a-3ccd3d6826d4"], "metadata": {"page_label": "94", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Polish Pharmaceutical Society, Warsaw, Poland; Dr S. Wolfgang, US Food and Drug Administration, Silver Spring, MD, USA; Mr E. Wondemagegnehu Biwota, Addis Ababa, Ethiopia; Dr B. Wright, Group Manager, GMP/GDP, North East Region, Medicines Inspectorate, Medicines and Healthcare products Regulatory Agency, York, England; Professor Yang Zhong-Yuan, Director, Guangzhou Municipal Institute for Drug Control, Guangzhou, People\u2019s Republic of China; Dr Yi Dang, Scientist, US Pharmacopeia, Rockville, MD, USA; Dr H. Yusufu, National Agency for Food and Drug Administration and Control, Abuja, Nigeria; Dr M. Zahn, Keltern Germany; Dr Hua Zhang, GMP Department Head, Center for Certification & Evaluation, Shanghai Food and Drug Administration, Shanghai, People\u2019s Republic of China; Professor Zhong-Yuan Yang, Member, United States Pharmacopeia International Health Expert Committee, Rockville, MD, USA; Dr T. Zimmer, CD Safety, Quality & Environmental Protection, Boehringer Ingelheim GmbH, Ingelheim, Germany; Dr N. Zvolinska, Deputy Director, Pharmaceutical Department, State Pharmacological Centre, Ministry of Health, Kiev, Ukraine.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 957\" incluye una lista de profesionales y expertos de diversas organizaciones y pa\u00edses que est\u00e1n involucrados en la regulaci\u00f3n y control de medicamentos. Estos individuos provienen de instituciones como la Administraci\u00f3n de Alimentos y Medicamentos de EE. UU., la Agencia de Medicamentos y Productos de Salud del Reino Unido, y varias agencias y universidades de otros pa\u00edses, lo que refleja una colaboraci\u00f3n internacional en el \u00e1mbito de la farmacolog\u00eda y la regulaci\u00f3n de medicamentos.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 instituciones est\u00e1n representadas por los expertos mencionados en el documento?**\n   - Respuesta: Las instituciones incluyen la Polish Pharmaceutical Society, la US Food and Drug Administration, la Medicines and Healthcare products Regulatory Agency del Reino Unido, el Guangzhou Municipal Institute for Drug Control en China, y la National Agency for Food and Drug Administration and Control en Nigeria, entre otras.\n\n2. **\u00bfCu\u00e1les son las \u00e1reas de especializaci\u00f3n de algunos de los expertos listados en el documento?**\n   - Respuesta: Las \u00e1reas de especializaci\u00f3n incluyen la gesti\u00f3n de buenas pr\u00e1cticas de manufactura (GMP/GDP), la ciencia farmac\u00e9utica, la seguridad y calidad de los medicamentos, y la regulaci\u00f3n farmacol\u00f3gica.\n\n3. **\u00bfQu\u00e9 pa\u00edses est\u00e1n representados por los expertos mencionados en el contexto?**\n   - Respuesta: Los pa\u00edses representados incluyen Polonia, Estados Unidos, Etiop\u00eda, Inglaterra, China, Nigeria, Alemania y Ucrania.", "prev_section_summary": "La secci\u00f3n presenta una lista de profesionales destacados en el \u00e1mbito de la farmacolog\u00eda, regulaci\u00f3n de medicamentos e investigaci\u00f3n en salud, provenientes de diversas instituciones y pa\u00edses. A continuaci\u00f3n se resumen los temas clave y entidades mencionadas:\n\n### Temas Clave:\n1. **Colaboraci\u00f3n Internacional**: La lista incluye expertos de diferentes pa\u00edses, lo que sugiere un esfuerzo global para abordar cuestiones relacionadas con la calidad y seguridad de los medicamentos.\n2. **Regulaci\u00f3n de Medicamentos**: Se mencionan varios directores y funcionarios de agencias reguladoras, indicando un enfoque en la normativa y control de productos farmac\u00e9uticos.\n3. **Investigaci\u00f3n en Salud**: Varios participantes est\u00e1n involucrados en la investigaci\u00f3n y desarrollo de medicamentos, especialmente en el contexto pedi\u00e1trico.\n4. **Calidad y Seguridad**: La seguridad de los productos farmac\u00e9uticos es un tema recurrente, con representantes de agencias dedicadas a la vigilancia y control de medicamentos.\n\n### Entidades Mencionadas:\n- **Organizaciones y Agencias**:\n  - Medicines for Children Research Network (Reino Unido)\n  - Tanzania Food and Drugs Authority (Tanzania)\n  - National Agency for Medicines (Finlandia)\n  - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Francia)\n  - National Institute for Drug Quality Control (Vietnam)\n  - China Pharmacopoeia Committee (China)\n  \n- **Instituciones Acad\u00e9micas**:\n  - Johann Wolfgang Goethe-Universit\u00e4t (Alemania)\n  - National Institute of Pharmaceutical Education and Research (India)\n  - Medical University of Gdansk (Polonia)\n  - University of London (Reino Unido)\n\n- **Empresas Farmac\u00e9uticas**:\n  - Bristol-Myers Squibb Company (EE. UU.)\n  - GlaxoSmithKline (Reino Unido)\n  - Gilead Sciences International (Reino Unido)\n\n### Profesionales Destacados:\n- Dr. U. Shah (Reino Unido)\n- Dr. G.N. Singh (India)\n- Dr. M. Sigonda (Tanzania)\n- Dr. L. Virgili (EE. UU.)\n- Dr. A.R.T. Utami (Indonesia)\n\nEste resumen refleja la diversidad y el enfoque colaborativo de los expertos en el \u00e1mbito de la farmacolog\u00eda y la regulaci\u00f3n de medicamentos a nivel global.", "excerpt_keywords": "Keywords: pharmaceutical regulation, international collaboration, drug safety, GMP/GDP, health experts"}}, "91bc6956-1bb9-486c-b34e-2ee6413a66a8": {"node_ids": ["0ea7fc1e-16b6-4a33-9a5f-77d9159707cd"], "metadata": {"page_label": "95", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 1\n\n## WHO good practices for pharmaceutical quality control laboratories\n\n### General considerations\n\n- Glossary\n\n### Part one. Management and infrastructure\n\n1. Organization and management\n2. Quality management system\n3. Control of documentation\n4. Records\n5. Data-processing equipment\n6. Personnel\n7. Premises\n8. Equipment, instruments and other devices\n9. Contracts\n\n### Part two. Materials, equipment, instruments and other devices\n\n10. Reagents\n11. Reference substances and reference materials\n12. Calibration, verification of performance and qualification of equipment, instruments and other devices\n13. Traceability\n\n### Part three. Working procedures\n\n14. Incoming samples\n15. Analytical worksheet\n16. Validation of analytical procedures\n17. Testing\n18. Evaluation of test results\n19. Certificate of analysis\n20. Retained samples\n\n### Part four. Safety\n\n21. General rules\n\n### References\n\n### Appendix\n\nEquipment for a first-stage and medium-sized pharmaceutical quality control laboratory", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 957\" incluye un anexo que detalla las buenas pr\u00e1cticas de la OMS para laboratorios de control de calidad farmac\u00e9utica. Se organiza en varias partes que abordan consideraciones generales, gesti\u00f3n e infraestructura, materiales y equipos, procedimientos de trabajo y seguridad. Cada secci\u00f3n incluye aspectos clave como la gesti\u00f3n de la calidad, el control de documentaci\u00f3n, la validaci\u00f3n de procedimientos anal\u00edticos y las normas de seguridad.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los componentes clave de un sistema de gesti\u00f3n de calidad en un laboratorio de control de calidad farmac\u00e9utica seg\u00fan la OMS?**\n   - Esta pregunta se centra en la secci\u00f3n sobre \"Sistema de gesti\u00f3n de calidad\" y puede proporcionar detalles espec\u00edficos sobre los elementos que deben implementarse para asegurar la calidad en el laboratorio.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir para la validaci\u00f3n de procedimientos anal\u00edticos en un laboratorio de control de calidad farmac\u00e9utica?**\n   - Esta pregunta se refiere a la parte que trata sobre la \"Validaci\u00f3n de procedimientos anal\u00edticos\" y puede ofrecer informaci\u00f3n sobre los pasos y criterios necesarios para validar m\u00e9todos de an\u00e1lisis.\n\n3. **\u00bfQu\u00e9 equipos son recomendados para un laboratorio de control de calidad farmac\u00e9utica de primera etapa y de tama\u00f1o mediano?**\n   - Esta pregunta se dirige a la secci\u00f3n del ap\u00e9ndice que menciona el equipo necesario, lo que puede proporcionar una lista espec\u00edfica de instrumentos y dispositivos que se consideran esenciales para este tipo de laboratorio.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento \"WHO - Technical Report Series 957\" presenta una lista de expertos y profesionales de diversas organizaciones y pa\u00edses que participan en la regulaci\u00f3n y control de medicamentos. Los temas clave incluyen:\n\n1. **Colaboraci\u00f3n Internacional**: Se destaca la cooperaci\u00f3n entre diferentes pa\u00edses y organizaciones en el \u00e1mbito de la farmacolog\u00eda y la regulaci\u00f3n de medicamentos.\n\n2. **Instituciones Representadas**: Las entidades mencionadas incluyen:\n   - Polish Pharmaceutical Society (Polonia)\n   - US Food and Drug Administration (EE. UU.)\n   - Medicines and Healthcare products Regulatory Agency (Reino Unido)\n   - Guangzhou Municipal Institute for Drug Control (China)\n   - National Agency for Food and Drug Administration and Control (Nigeria)\n   - US Pharmacopeia (EE. UU.)\n   - Boehringer Ingelheim GmbH (Alemania)\n   - State Pharmacological Centre, Ministry of Health (Ucrania)\n\n3. **\u00c1reas de Especializaci\u00f3n**: Los expertos tienen diversas especializaciones, como:\n   - Buenas pr\u00e1cticas de manufactura (GMP/GDP)\n   - Ciencia farmac\u00e9utica\n   - Seguridad y calidad de los medicamentos\n   - Regulaci\u00f3n farmacol\u00f3gica\n\n4. **Diversidad Geogr\u00e1fica**: Los pa\u00edses representados en la lista de expertos incluyen Polonia, Estados Unidos, Etiop\u00eda, Inglaterra, China, Nigeria, Alemania y Ucrania, lo que refleja una amplia representaci\u00f3n global en el campo de la regulaci\u00f3n de medicamentos. \n\nEste resumen resalta la importancia de la colaboraci\u00f3n internacional y la diversidad de expertos en la regulaci\u00f3n y control de medicamentos a nivel global.", "excerpt_keywords": "Keywords: pharmaceutical quality control, WHO guidelines, laboratory management, analytical procedures, safety standards"}}, "17ffdc95-f13c-46cd-9a10-5b80f5f6f74e": {"node_ids": ["87bfb874-4cfb-4d2e-b5ae-d1ddeec06d22"], "metadata": {"page_label": "96", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# General Considerations\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Products adopted in 1999 the guidelines entitled *WHO Good practices for national pharmaceutical control laboratories*, which were published as Annex 3 of the WHO Technical Report Series, No. 902, 2002. As the other guidelines related to laboratory quality assurance have been updated and subsequent inspections for the compliance with the guidelines on good practices for national pharmaceutical control laboratories indicated that some sections were in need of improvement and clarification, it was considered necessary to prepare a revised text.\n\nThese guidelines provide advice on the quality management system within which the analysis of active pharmaceutical ingredients (APIs), excipients and pharmaceutical products should be performed to demonstrate that reliable results are obtained.\n\nCompliance with the recommendations provided in these guidelines will help promote international harmonization of laboratory practices and will facilitate cooperation among laboratories and mutual recognition of results.\n\nSpecial attention should be given to ensure the correct and efficient functioning of the laboratory. Planning and future budgets should ensure that the necessary resources are available inter alia for the maintenance of the laboratory, as well as for an appropriate infrastructure and energy supply. Means and procedures should be in place (in case of possible supply problems) to ensure that the laboratory can continue its activities.\n\nThese guidelines are applicable to any pharmaceutical quality control laboratory, be it national, commercial or nongovernmental. However, they do not include guidance for those laboratories involved in the testing of biological products, e.g. vaccines and blood products. Separate guidance for such laboratories is available.\n\nThese guidelines are consistent with the requirements of the *WHO guidelines for good manufacturing practices* (1) and with the requirements of the International Standard ISO/IEC 17025:2005 (2), and provide detailed guidance for laboratories performing quality control of medicines. The guidance specific to microbiology laboratories can be found in the draft working document *WHO guideline on good practices for pharmaceutical microbiology laboratories* (reference QAS/09.297).\n\nThe good practice outlined below is to be considered as a general guide and it may be adapted to meet individual needs provided that an equivalent level of quality assurance is achieved. The notes given provide clarification of the text or examples; they do not contain requirements which should be fulfilled to comply with these guidelines.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en las directrices adoptadas por el Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Productos Farmac\u00e9uticos, que se publicaron en 1999 y se revisaron posteriormente. Estas directrices abordan el sistema de gesti\u00f3n de calidad en laboratorios de control farmac\u00e9utico, enfatizando la importancia de obtener resultados confiables en el an\u00e1lisis de ingredientes farmac\u00e9uticos activos (APIs), excipientes y productos farmac\u00e9uticos. Se destaca la necesidad de recursos adecuados, infraestructura y procedimientos para asegurar el funcionamiento continuo del laboratorio. Las directrices son aplicables a laboratorios de control de calidad farmac\u00e9utica, pero no incluyen laboratorios que prueban productos biol\u00f3gicos. Tambi\u00e9n se alinean con las buenas pr\u00e1cticas de fabricaci\u00f3n de la OMS y la norma ISO/IEC 17025:2005.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 aspectos espec\u00edficos se deben considerar para garantizar el funcionamiento eficiente de un laboratorio de control de calidad farmac\u00e9utica seg\u00fan las directrices de la OMS?**\n   - Esta pregunta busca detalles sobre la planificaci\u00f3n, el presupuesto y los recursos necesarios para el mantenimiento y la infraestructura del laboratorio.\n\n2. **\u00bfC\u00f3mo se relacionan las directrices de la OMS para laboratorios de control de calidad farmac\u00e9utica con las normas internacionales como ISO/IEC 17025:2005?**\n   - Esta pregunta se centra en la alineaci\u00f3n y la consistencia entre las directrices de la OMS y las normas internacionales, lo que puede no estar claramente definido en otros documentos.\n\n3. **\u00bfQu\u00e9 tipo de laboratorios no est\u00e1n cubiertos por estas directrices y d\u00f3nde se puede encontrar orientaci\u00f3n espec\u00edfica para ellos?**\n   - Esta pregunta busca informaci\u00f3n sobre las limitaciones de las directrices y la disponibilidad de orientaci\u00f3n para laboratorios que trabajan con productos biol\u00f3gicos, como vacunas y productos sangu\u00edneos.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\nEl anexo del documento \"WHO - Technical Report Series 957\" se centra en las buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave organizados por partes:\n\n1. **Consideraciones Generales**:\n   - Incluye un glosario que define t\u00e9rminos relevantes.\n\n2. **Parte Uno: Gesti\u00f3n e Infraestructura**:\n   - **Organizaci\u00f3n y gesti\u00f3n**: Estructura y roles dentro del laboratorio.\n   - **Sistema de gesti\u00f3n de calidad**: Estrategias para asegurar la calidad en los procesos.\n   - **Control de documentaci\u00f3n**: Procedimientos para manejar documentos y registros.\n   - **Registros**: Importancia de mantener registros precisos.\n   - **Equipos de procesamiento de datos**: Herramientas tecnol\u00f3gicas utilizadas.\n   - **Personal**: Capacitaci\u00f3n y competencias requeridas.\n   - **Instalaciones**: Requisitos f\u00edsicos del laboratorio.\n   - **Equipos, instrumentos y otros dispositivos**: Herramientas necesarias para el an\u00e1lisis.\n   - **Contratos**: Gesti\u00f3n de acuerdos con terceros.\n\n3. **Parte Dos: Materiales, Equipos, Instrumentos y Otros Dispositivos**:\n   - **Reactivos**: Sustancias qu\u00edmicas utilizadas en pruebas.\n   - **Sustancias de referencia y materiales de referencia**: Est\u00e1ndares para asegurar la precisi\u00f3n.\n   - **Calibraci\u00f3n, verificaci\u00f3n de rendimiento y calificaci\u00f3n**: Procesos para asegurar que los equipos funcionen correctamente.\n   - **Trazabilidad**: Mecanismos para rastrear la procedencia de los materiales.\n\n4. **Parte Tres: Procedimientos de Trabajo**:\n   - **Muestras entrantes**: Manejo de muestras recibidas.\n   - **Hoja de trabajo anal\u00edtica**: Documentaci\u00f3n de los procedimientos de an\u00e1lisis.\n   - **Validaci\u00f3n de procedimientos anal\u00edticos**: Aseguramiento de que los m\u00e9todos son adecuados.\n   - **Pruebas**: Ejecuci\u00f3n de an\u00e1lisis.\n   - **Evaluaci\u00f3n de resultados de pruebas**: Interpretaci\u00f3n de datos obtenidos.\n   - **Certificado de an\u00e1lisis**: Documentaci\u00f3n de resultados.\n   - **Muestras retenidas**: Almacenamiento de muestras para referencia futura.\n\n5. **Parte Cuatro: Seguridad**:\n   - **Reglas generales**: Normas de seguridad a seguir en el laboratorio.\n\n6. **Referencias**: Fuentes y documentos citados.\n\n7. **Ap\u00e9ndice**:\n   - Equipos recomendados para un laboratorio de control de calidad farmac\u00e9utica de primera etapa y de tama\u00f1o mediano.\n\nEste resumen destaca la estructura y los componentes esenciales que deben considerarse para establecer y mantener un laboratorio de control de calidad farmac\u00e9utica conforme a las directrices de la OMS.", "excerpt_keywords": "Keywords: pharmaceutical quality control, WHO guidelines, laboratory practices, active pharmaceutical ingredients, quality management system"}}, "316a1ca7-1501-435a-96c6-e98ce3964dbb": {"node_ids": ["668b17bc-eda3-481f-a990-fb108ade4b52"], "metadata": {"page_label": "97", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Pharmaceutical quality control testing is usually a matter of repetitive testing of samples of APIs or of a limited number of pharmaceutical products, whereas national quality control laboratories have to be able to deal with a much wider range of pharmaceutical substances and products and, therefore, have to apply a wider variety of test methods. Specific recommendations for national pharmaceutical quality control laboratories are addressed in the following text. Particular consideration is given to countries with limited resources wishing to establish a governmental pharmaceutical quality control laboratory, having recently done so, or which are planning to modernize an existing laboratory.\n\nQuality control laboratories may perform some or all quality control activities, e.g. sampling, testing of APIs, excipients, packaging materials and/or pharmaceutical products, stability testing, testing against specifications and investigative testing.\n\nFor the quality of a medicine sample to be correctly assessed:\n\n- The submission of a sample of an API, excipient or pharmaceutical product or a suspected counterfeit material to the laboratory, selected in accordance with national requirements, should be accompanied by a statement of the reason why the analysis has been requested.\n- The analysis should be correctly planned and meticulously executed.\n- The results should be competently evaluated to determine whether the sample complies with the specifications or other relevant criteria.\n\n*National pharmaceutical quality control laboratories*\n\nThe government, normally through the national medicines regulatory authority (NMRA), may establish and maintain a pharmaceutical quality control laboratory to carry out the required tests and assays to verify that APIs, excipients and pharmaceutical products meet the prescribed specifications. Large countries may require several pharmaceutical quality control laboratories which conform to national legislation, and appropriate arrangements should, therefore, be in place to monitor their compliance with a quality management system. Throughout the process of marketing authorization and postmarketing surveillance, the laboratory or laboratories work closely with the NMRA.\n\nA national pharmaceutical quality control laboratory provides effective support for an NMRA acting together with its inspection services. The analytical results obtained should accurately describe the properties of the samples assessed, permitting correct conclusions to be drawn about the quality of the samples of medicines analysed, and also serving as an adequate basis for any subsequent administrative regulations and legal action.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda la importancia de los laboratorios nacionales de control de calidad farmac\u00e9utica, especialmente en pa\u00edses con recursos limitados. Se discuten las actividades que estos laboratorios pueden realizar, como el muestreo y las pruebas de ingredientes farmac\u00e9uticos activos (APIs), excipientes y productos farmac\u00e9uticos. Se enfatiza la necesidad de un proceso riguroso para la evaluaci\u00f3n de la calidad de las muestras y la colaboraci\u00f3n entre los laboratorios y las autoridades reguladoras de medicamentos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las actividades espec\u00edficas que pueden realizar los laboratorios nacionales de control de calidad farmac\u00e9utica?**\n   - Respuesta: Los laboratorios pueden realizar actividades como muestreo, pruebas de APIs, excipientes, materiales de embalaje y productos farmac\u00e9uticos, pruebas de estabilidad, pruebas contra especificaciones y pruebas investigativas.\n\n2. **\u00bfQu\u00e9 requisitos deben cumplirse al enviar una muestra a un laboratorio de control de calidad?**\n   - Respuesta: La muestra debe ir acompa\u00f1ada de una declaraci\u00f3n que explique el motivo de la solicitud de an\u00e1lisis, la planificaci\u00f3n del an\u00e1lisis debe ser correcta y ejecutada meticulosamente, y los resultados deben ser evaluados competentemente para determinar si la muestra cumple con las especificaciones o criterios relevantes.\n\n3. **\u00bfC\u00f3mo deben los laboratorios nacionales de control de calidad colaborar con las autoridades reguladoras de medicamentos?**\n   - Respuesta: Los laboratorios deben trabajar en estrecha colaboraci\u00f3n con la autoridad reguladora nacional de medicamentos (NMRA) durante el proceso de autorizaci\u00f3n de comercializaci\u00f3n y la vigilancia posterior a la comercializaci\u00f3n, asegurando que los resultados anal\u00edticos describan con precisi\u00f3n las propiedades de las muestras evaluadas y sirvan como base para regulaciones administrativas y acciones legales.", "prev_section_summary": "### Temas Clave\n\n1. **Directrices de la OMS**: Se adoptaron en 1999 y revisadas posteriormente, enfoc\u00e1ndose en las buenas pr\u00e1cticas para laboratorios de control farmac\u00e9utico nacional.\n  \n2. **Sistema de Gesti\u00f3n de Calidad**: Las directrices proporcionan un marco para asegurar que el an\u00e1lisis de ingredientes farmac\u00e9uticos activos (APIs), excipientes y productos farmac\u00e9uticos produzca resultados confiables.\n\n3. **Harmonizaci\u00f3n Internacional**: El cumplimiento de estas directrices promueve la armonizaci\u00f3n de pr\u00e1cticas de laboratorio y facilita la cooperaci\u00f3n y el reconocimiento mutuo de resultados entre laboratorios.\n\n4. **Recursos y Mantenimiento**: Se enfatiza la importancia de la planificaci\u00f3n, el presupuesto y la disponibilidad de recursos para el mantenimiento y la infraestructura del laboratorio.\n\n5. **Aplicabilidad**: Las directrices son aplicables a laboratorios de control de calidad farmac\u00e9utica, pero excluyen laboratorios que prueban productos biol\u00f3gicos, para los cuales hay orientaci\u00f3n separada.\n\n6. **Consistencia con Normas Internacionales**: Las directrices son coherentes con las buenas pr\u00e1cticas de fabricaci\u00f3n de la OMS y con la norma ISO/IEC 17025:2005.\n\n7. **Adaptabilidad**: Las buenas pr\u00e1cticas pueden adaptarse a las necesidades individuales siempre que se mantenga un nivel equivalente de aseguramiento de calidad.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la adopci\u00f3n de las directrices.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que adopt\u00f3 las directrices.\n- **Laboratorios de Control de Calidad**: Incluye laboratorios nacionales, comerciales y no gubernamentales.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Sustancias que se analizan seg\u00fan las directrices.\n- **Norma ISO/IEC 17025:2005**: Est\u00e1ndar internacional con el que las directrices son consistentes.\n- **Productos Biol\u00f3gicos**: Tipo de productos que no est\u00e1n cubiertos por estas directrices, como vacunas y productos sangu\u00edneos.", "excerpt_keywords": "Keywords: pharmaceutical quality control, national laboratories, APIs, regulatory authority, quality management system"}}, "260d17a6-8f9f-4307-a273-820c3693b9f1": {"node_ids": ["abe5c177-472d-41f3-a69f-d21ff3af76dc"], "metadata": {"page_label": "98", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "National pharmaceutical quality control laboratories usually encompass essentially two types of activity:\n\n- compliance testing of APIs, pharmaceutical excipients and pharmaceutical products employing \u201cofficial\u201d methods including pharmacopoeial methods, validated analytical procedures provided by the manufacturer and approved by the relevant government authority for marketing authorization or validated analytical procedures developed by the laboratory; and\n- investigative testing of suspicious, illegal, counterfeit substances or products, submitted for examination by medicine inspectors, customs or police.\n\nTo ensure patient safety, the role of the national pharmaceutical quality control laboratory should be defined in the general pharmaceutical legislation of the country in such a way that the results provided by it can, if necessary, lead to enforcement of the law and legal action.\n\n# Glossary\n\nThe definitions given below apply to the terms as used in these guidelines. They may have different meanings in other contexts.\n\n**acceptance criterion for an analytical result**  \nPredefined and documented indicators by which a result is considered to be within the limit(s) or to exceed the limit(s) indicated in the specification.\n\n**accuracy**  \nThe degree of agreement of test results with the true value or the closeness of the results obtained by the procedure to the true value (1).\n\n*Note:* It is normally established on samples of the material to be examined that have been prepared to quantitative accuracy. Accuracy should be established across the specified range of the analytical procedure. It is generally acceptable to use a \u201cspiked\u201d placebo which contains a known quantity or concentration of a reference substance.\n\n**active pharmaceutical ingredient (API)**  \nAny substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body (1).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) describe las funciones de los laboratorios nacionales de control de calidad farmac\u00e9utica, que se dividen en dos actividades principales: pruebas de cumplimiento de ingredientes farmac\u00e9uticos activos (API) y productos farmac\u00e9uticos, y pruebas investigativas de sustancias o productos sospechosos. Se enfatiza la importancia de definir el papel de estos laboratorios en la legislaci\u00f3n farmac\u00e9utica nacional para garantizar la seguridad del paciente. Adem\u00e1s, se incluye un glosario con definiciones clave relacionadas con los resultados anal\u00edticos y los ingredientes farmac\u00e9uticos activos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipos de pruebas realizan los laboratorios nacionales de control de calidad farmac\u00e9utica y cu\u00e1l es su prop\u00f3sito principal?**\n   - Respuesta: Los laboratorios realizan pruebas de cumplimiento de ingredientes farmac\u00e9uticos activos (API), excipientes y productos farmac\u00e9uticos utilizando m\u00e9todos oficiales, as\u00ed como pruebas investigativas de sustancias o productos sospechosos. Su prop\u00f3sito principal es garantizar la seguridad del paciente y la calidad de los productos farmac\u00e9uticos.\n\n2. **\u00bfC\u00f3mo debe estar definido el papel de los laboratorios de control de calidad en la legislaci\u00f3n farmac\u00e9utica de un pa\u00eds?**\n   - Respuesta: El papel de los laboratorios de control de calidad debe estar definido de tal manera que los resultados que proporcionen puedan, si es necesario, llevar a la aplicaci\u00f3n de la ley y a acciones legales, asegurando as\u00ed la protecci\u00f3n del paciente.\n\n3. **\u00bfQu\u00e9 se entiende por \"criterio de aceptaci\u00f3n para un resultado anal\u00edtico\" seg\u00fan el documento?**\n   - Respuesta: El \"criterio de aceptaci\u00f3n para un resultado anal\u00edtico\" se refiere a los indicadores predefinidos y documentados que determinan si un resultado se considera dentro de los l\u00edmites especificados o si los excede, asegurando as\u00ed la validez de los resultados anal\u00edticos.", "prev_section_summary": "### Temas Clave:\n1. **Control de Calidad Farmac\u00e9utica**: Se enfatiza la importancia de los laboratorios nacionales de control de calidad farmac\u00e9utica, que deben manejar una amplia gama de sustancias y productos farmac\u00e9uticos.\n2. **Actividades de los Laboratorios**: Los laboratorios pueden realizar diversas actividades de control de calidad, incluyendo muestreo, pruebas de ingredientes farmac\u00e9uticos activos (APIs), excipientes, materiales de embalaje y productos farmac\u00e9uticos, as\u00ed como pruebas de estabilidad y pruebas investigativas.\n3. **Requisitos para el An\u00e1lisis**: Se establecen criterios para la correcta evaluaci\u00f3n de la calidad de las muestras, que incluyen la presentaci\u00f3n de una declaraci\u00f3n de motivos, una planificaci\u00f3n y ejecuci\u00f3n meticulosa del an\u00e1lisis, y una evaluaci\u00f3n competente de los resultados.\n4. **Colaboraci\u00f3n con Autoridades Reguladoras**: Los laboratorios deben trabajar en estrecha colaboraci\u00f3n con la autoridad reguladora nacional de medicamentos (NMRA) durante el proceso de autorizaci\u00f3n de comercializaci\u00f3n y vigilancia post-comercializaci\u00f3n.\n5. **Soporte a la NMRA**: Los laboratorios nacionales de control de calidad proporcionan apoyo efectivo a la NMRA, asegurando que los resultados anal\u00edticos sean precisos y \u00fatiles para regulaciones administrativas y acciones legales.\n\n### Entidades:\n- **Laboratorios Nacionales de Control de Calidad Farmac\u00e9utica**: Instituciones encargadas de realizar pruebas y an\u00e1lisis de calidad de productos farmac\u00e9uticos.\n- **Autoridad Reguladora Nacional de Medicamentos (NMRA)**: Entidad gubernamental responsable de la regulaci\u00f3n y supervisi\u00f3n de medicamentos en el pa\u00eds.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Sustancias que se utilizan en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Excipientes**: Sustancias inactivas que se utilizan en la formulaci\u00f3n de medicamentos junto con los APIs.\n- **Productos Farmac\u00e9uticos**: Medicamentos que se ofrecen al p\u00fablico para su uso terap\u00e9utico. \n\nEste resumen destaca la importancia de los laboratorios de control de calidad en la garant\u00eda de la seguridad y eficacia de los medicamentos, as\u00ed como la necesidad de un enfoque riguroso y colaborativo en su funcionamiento.", "excerpt_keywords": "Keywords: pharmaceutical quality control, compliance testing, active pharmaceutical ingredient, investigative testing, patient safety"}}, "f6be0507-2d6b-4930-9c54-ce3318504297": {"node_ids": ["ce3e9555-cbef-472c-a722-a7d90f252571"], "metadata": {"page_label": "99", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# analytical test report\n\nAn analytical test report usually includes a description of the test procedure(s) employed, results of the analysis, discussion and conclusions and/or recommendations for one or more samples submitted for testing (see Part three, sections 18.7\u201318.11).\n\n# analytical worksheet\n\nA printed form, an analytical workbook or electronic means (e-records) for recording information about the sample, as well as reagents and solvents used, test procedure applied, calculations made, results and any other relevant information or comments (see Part three, section 15).\n\n# batch (or lot)\n\nA defined quantity of starting material, packaging material or product processed in a single process or series of processes so that it is expected to be homogeneous. It may sometimes be necessary to divide a batch into a number of sub-batches which are later brought together to form a final homogeneous batch. In the case of terminal sterilization the batch size is determined by the capacity of the autoclave. In continuous manufacture the batch should correspond to a defined fraction of the production, characterized by its intended homogeneity. The batch size can be defined either as a fixed quantity or as the amount produced in a fixed time interval (I).\n\n# batch number (or lot number)\n\nA distinctive combination of numbers and/or letters which uniquely identifies a batch on the labels, its batch records and corresponding certificates of analysis (I).\n\n# calibration\n\nThe set of operations that establish, under specified conditions, the relationship between values indicated by an instrument or system for measuring (especially weighing), recording and controlling, or the values represented by a material measure, and the corresponding known values of a reference standard. Limits for acceptance of the results of measuring should be established (I).\n\n# certificate of analysis\n\nThe list of test procedures applied to a particular sample with the results obtained and the acceptance criteria applied. It indicates whether or not the sample complies with the specification (3).\n\n# certified reference material\n\nReference material, characterized by a metrologically valid procedure for one or more specified properties, accompanied by a certificate that provides", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) titulado \"Technical Report Series 957\" aborda varios aspectos relacionados con la realizaci\u00f3n de pruebas anal\u00edticas en muestras. Incluye definiciones y descripciones de informes anal\u00edticos, hojas de trabajo anal\u00edticas, lotes de productos, n\u00fameros de lote, calibraci\u00f3n de instrumentos, certificados de an\u00e1lisis y materiales de referencia certificados. Cada secci\u00f3n proporciona informaci\u00f3n sobre los procedimientos, requisitos y est\u00e1ndares necesarios para asegurar la calidad y la homogeneidad de los productos analizados.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 informaci\u00f3n se incluye t\u00edpicamente en un informe anal\u00edtico y por qu\u00e9 es importante para la evaluaci\u00f3n de muestras?**\n   - Respuesta: Un informe anal\u00edtico incluye una descripci\u00f3n de los procedimientos de prueba, los resultados del an\u00e1lisis, discusiones, conclusiones y recomendaciones para las muestras sometidas a prueba. Esta informaci\u00f3n es crucial para determinar si las muestras cumplen con las especificaciones requeridas.\n\n2. **\u00bfC\u00f3mo se define un \"lote\" en el contexto de la producci\u00f3n y qu\u00e9 factores pueden influir en su tama\u00f1o?**\n   - Respuesta: Un lote se define como una cantidad espec\u00edfica de material de partida, material de embalaje o producto procesado en un solo proceso o serie de procesos, con la expectativa de homogeneidad. El tama\u00f1o del lote puede verse influenciado por la capacidad del autoclave en la esterilizaci\u00f3n terminal o por la fracci\u00f3n de producci\u00f3n en la fabricaci\u00f3n continua.\n\n3. **\u00bfCu\u00e1l es la funci\u00f3n de un certificado de an\u00e1lisis y qu\u00e9 informaci\u00f3n debe contener?**\n   - Respuesta: Un certificado de an\u00e1lisis lista los procedimientos de prueba aplicados a una muestra particular, junto con los resultados obtenidos y los criterios de aceptaci\u00f3n aplicados. Indica si la muestra cumple o no con las especificaciones establecidas, lo que es fundamental para garantizar la calidad del producto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Funciones de los Laboratorios Nacionales de Control de Calidad Farmac\u00e9utica**:\n   - **Pruebas de Cumplimiento**: Evaluaci\u00f3n de ingredientes farmac\u00e9uticos activos (API), excipientes y productos farmac\u00e9uticos utilizando m\u00e9todos oficiales, como m\u00e9todos farmacopoeicos y procedimientos anal\u00edticos validados.\n   - **Pruebas Investigativas**: An\u00e1lisis de sustancias o productos sospechosos, ilegales o falsificados, que son enviados por inspectores de medicamentos, aduanas o polic\u00eda.\n\n2. **Importancia de la Legislaci\u00f3n**:\n   - El papel de los laboratorios debe estar claramente definido en la legislaci\u00f3n farmac\u00e9utica nacional para garantizar que sus resultados puedan llevar a la aplicaci\u00f3n de la ley y acciones legales, asegurando as\u00ed la seguridad del paciente.\n\n3. **Glosario de T\u00e9rminos Clave**:\n   - **Criterio de Aceptaci\u00f3n para un Resultado Anal\u00edtico**: Indicadores predefinidos que determinan si un resultado est\u00e1 dentro de los l\u00edmites especificados.\n   - **Precisi\u00f3n**: Grado de concordancia de los resultados de las pruebas con el valor verdadero.\n   - **Ingrediente Farmac\u00e9utico Activo (API)**: Sustancia utilizada en la fabricaci\u00f3n de formas farmac\u00e9uticas que proporciona actividad farmacol\u00f3gica o efecto directo en el tratamiento de enfermedades.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite directrices sobre el control de calidad farmac\u00e9utica.\n- **Laboratorios Nacionales de Control de Calidad**: Instituciones responsables de garantizar la calidad y seguridad de los productos farmac\u00e9uticos.\n- **Ingredientes Farmac\u00e9uticos Activos (API)**: Componentes esenciales en la formulaci\u00f3n de medicamentos.\n- **Legislaci\u00f3n Farmac\u00e9utica**: Marco legal que regula las actividades de los laboratorios y la calidad de los productos farmac\u00e9uticos. \n\nEste resumen destaca la funci\u00f3n cr\u00edtica de los laboratorios de control de calidad en la protecci\u00f3n de la salud p\u00fablica y la importancia de un marco legal s\u00f3lido para su operaci\u00f3n.", "excerpt_keywords": "Keywords: analytical test report, batch number, calibration, certificate of analysis, certified reference material"}}, "3828b4ea-ce4f-4cb1-b819-094100aec4d8": {"node_ids": ["e8c47258-92b8-47d5-8fb7-2899719a6d35"], "metadata": {"page_label": "100", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the value of the specified property, its associated uncertainty and a statement of metrological traceability (4).\n\n**compliance testing**  \nAnalysis of active pharmaceutical ingredients (APIs), pharmaceutical excipients, packaging material or pharmaceutical products according to the requirements of a pharmacopoeial monograph or a specification in an approved marketing authorization.\n\n**control sample**  \nA sample used for testing the continued accuracy and precision of the procedure. It should have a matrix similar to that of the samples to be analysed. It has an assigned value with its associated uncertainty.\n\n**design qualification (DQ)**  \nDocumented collection of activities that define the functional and operational specifications of the instrument and criteria for selection of the vendor, based on the intended purpose of the instrument.\n\n*Note:* Selection and purchase of a new instrument should follow a conscious decision process, based on the needs of the technical management. When designing a new laboratory facility, the design specification and the requirements for services should be agreed between the management team and the agreed suppliers and documented.\n\n**good manufacturing practice(s) (GMP)**  \nThat part of quality assurance which ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization (1).\n\n**installation qualification (IQ)**  \nThe performance of tests to ensure that the analytical equipment used in a laboratory is correctly installed and operates in accordance with established specifications.\n\n**management review**  \nA formal, documented review of the key performance indicators of a quality management system performed by top management.\n\n**manufacturer**  \nA company that carries out operations such as production, packaging, testing, repackaging, labelling and/or relabelling of pharmaceuticals (1).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la Serie de Informes T\u00e9cnicos 957 aborda aspectos clave de la calidad y el control en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se definen t\u00e9rminos importantes como \"pruebas de cumplimiento\", \"muestra de control\", \"calificaci\u00f3n de dise\u00f1o\", \"buenas pr\u00e1cticas de manufactura (GMP)\", \"calificaci\u00f3n de instalaci\u00f3n\", \"revisi\u00f3n de gesti\u00f3n\" y \"fabricante\". Estos conceptos son fundamentales para asegurar que los productos farmac\u00e9uticos se produzcan y controlen de acuerdo con est\u00e1ndares de calidad apropiados.\n\n### Preguntas Espec\u00edficas:\n1. **\u00bfQu\u00e9 criterios se deben considerar al seleccionar un proveedor para un nuevo instrumento en un laboratorio?**\n   - La selecci\u00f3n debe basarse en una colecci\u00f3n documentada de actividades que definen las especificaciones funcionales y operativas del instrumento, as\u00ed como en el prop\u00f3sito previsto del mismo.\n\n2. **\u00bfCu\u00e1l es la importancia de las \"buenas pr\u00e1cticas de manufactura (GMP)\" en la producci\u00f3n farmac\u00e9utica?**\n   - Las GMP son esenciales para garantizar que los productos farmac\u00e9uticos se produzcan y controlen de manera consistente, cumpliendo con los est\u00e1ndares de calidad apropiados para su uso previsto y seg\u00fan lo requerido por la autorizaci\u00f3n de comercializaci\u00f3n.\n\n3. **\u00bfQu\u00e9 es una \"muestra de control\" y por qu\u00e9 es relevante en el an\u00e1lisis de productos farmac\u00e9uticos?**\n   - Una muestra de control es utilizada para probar la precisi\u00f3n y exactitud continuas del procedimiento anal\u00edtico. Debe tener una matriz similar a la de las muestras que se van a analizar y cuenta con un valor asignado y su incertidumbre asociada, lo que la hace crucial para validar los resultados de las pruebas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Informe Anal\u00edtico**:\n   - Contenido: Descripci\u00f3n de procedimientos de prueba, resultados, discusiones, conclusiones y recomendaciones.\n   - Importancia: Fundamental para evaluar la conformidad de las muestras con las especificaciones.\n\n2. **Hoja de Trabajo Anal\u00edtica**:\n   - Descripci\u00f3n: Formulario impreso o medio electr\u00f3nico para registrar informaci\u00f3n sobre la muestra, reactivos, procedimientos de prueba, c\u00e1lculos y resultados.\n\n3. **Lote (Batch)**:\n   - Definici\u00f3n: Cantidad definida de material procesado en un solo proceso, esperado ser homog\u00e9neo.\n   - Factores que influyen: Capacidad del autoclave en esterilizaci\u00f3n y fracci\u00f3n de producci\u00f3n en fabricaci\u00f3n continua.\n\n4. **N\u00famero de Lote**:\n   - Descripci\u00f3n: Combinaci\u00f3n \u00fanica de n\u00fameros y/o letras que identifica un lote en etiquetas y certificados de an\u00e1lisis.\n\n5. **Calibraci\u00f3n**:\n   - Definici\u00f3n: Operaciones que establecen la relaci\u00f3n entre los valores indicados por un instrumento y los valores conocidos de un est\u00e1ndar de referencia.\n\n6. **Certificado de An\u00e1lisis**:\n   - Contenido: Lista de procedimientos de prueba aplicados a una muestra, resultados obtenidos y criterios de aceptaci\u00f3n.\n   - Funci\u00f3n: Indica si la muestra cumple con las especificaciones.\n\n7. **Material de Referencia Certificado**:\n   - Descripci\u00f3n: Material caracterizado por un procedimiento metrol\u00f3gicamente v\u00e1lido, acompa\u00f1ado de un certificado que proporciona informaci\u00f3n sobre propiedades espec\u00edficas.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el documento.\n- **Muestras**: Elementos sometidos a pruebas anal\u00edticas.\n- **Procedimientos de Prueba**: M\u00e9todos utilizados para analizar las muestras.\n- **Est\u00e1ndares de Calidad**: Criterios que las muestras deben cumplir para ser aceptadas. \n\nEste resumen abarca los conceptos y definiciones esenciales presentados en la secci\u00f3n del documento, proporcionando una visi\u00f3n clara de los procedimientos y requisitos en el contexto de pruebas anal\u00edticas.", "excerpt_keywords": "Keywords: compliance testing, good manufacturing practices, control sample, design qualification, installation qualification"}}, "ca472f55-5d60-459a-8500-1f84384c12ac": {"node_ids": ["b23a968d-dcb7-436e-80f7-e5732d43eeaf"], "metadata": {"page_label": "101", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# marketing authorization (product licence, registration certificate)\n\nA legal document issued by the competent medicines regulatory authority that authorizes the marketing or free distribution of a pharmaceutical product in the respective country after evaluation for safety, efficacy and quality. In terms of quality it establishes inter alia the detailed composition and formulation of the pharmaceutical product and the quality requirements for the product and its ingredients. It also includes details of packaging, labelling, storage conditions, shelf-life and approved conditions of use.\n\n# measurement uncertainty\n\nNon-negative parameter characterizing the dispersion of quantity values being attributed to a measurand (analyte), based on the information used (4).\n\n# metrological traceability\n\nProperty of a measurement result whereby the result can be related to a reference through a documented, unbroken chain of calibrations, each contributing to the measurement uncertainty (4).\n\n# operational qualification (OQ)\n\nDocumented verification that the analytical equipment performs as intended over all anticipated operating ranges.\n\n# out-of-specification (OOS) result\n\nAll test results that fall outside the specifications or acceptance criteria established in product dossiers, drug master files, pharmacopoeias or by the manufacturer (5).\n\n# performance qualification (PQ)\n\nDocumented verification that the analytical equipment operates consistently and gives reproducibility within the defined specifications and parameters for prolonged periods.\n\n# pharmaceutical excipient\n\nA substance, other than the active pharmaceutical ingredient (API), which has been appropriately evaluated for safety and is included in a medicines delivery system to:\n\n- aid in the processing of the medicines delivery system during its manufacture;\n- protect, support or enhance stability, bioavailability or patient acceptability;\n- assist in pharmaceutical product identification; or\n- enhance any other attribute of the overall safety and effectiveness of the medicine during its storage or use (6, 7).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfQu\u00e9 informaci\u00f3n espec\u00edfica se incluye en un documento de autorizaci\u00f3n de comercializaci\u00f3n (marketing authorization) para un producto farmac\u00e9utico?**\n   - Respuesta: El documento de autorizaci\u00f3n de comercializaci\u00f3n incluye la composici\u00f3n y formulaci\u00f3n detallada del producto farmac\u00e9utico, los requisitos de calidad para el producto y sus ingredientes, as\u00ed como detalles sobre el embalaje, etiquetado, condiciones de almacenamiento, vida \u00fatil y condiciones de uso aprobadas.\n\n2. **\u00bfCu\u00e1l es la diferencia entre la calificaci\u00f3n operativa (Operational Qualification, OQ) y la calificaci\u00f3n de rendimiento (Performance Qualification, PQ) en el contexto de equipos anal\u00edticos?**\n   - Respuesta: La calificaci\u00f3n operativa (OQ) se refiere a la verificaci\u00f3n documentada de que el equipo anal\u00edtico funciona como se espera en todos los rangos operativos anticipados, mientras que la calificaci\u00f3n de rendimiento (PQ) se refiere a la verificaci\u00f3n documentada de que el equipo opera de manera consistente y reproduce resultados dentro de las especificaciones definidas durante per\u00edodos prolongados.\n\n3. **\u00bfQu\u00e9 se entiende por un resultado fuera de especificaci\u00f3n (Out-of-Specification, OOS) y c\u00f3mo se determina?**\n   - Respuesta: Un resultado fuera de especificaci\u00f3n (OOS) se refiere a todos los resultados de pruebas que caen fuera de las especificaciones o criterios de aceptaci\u00f3n establecidos en los expedientes del producto, archivos maestros de medicamentos, farmacopeas o por el fabricante. Se determina comparando los resultados de las pruebas con los criterios establecidos.\n\n### Resumen de nivel superior del contexto:\nEl contexto se centra en varios t\u00e9rminos y conceptos clave relacionados con la regulaci\u00f3n y evaluaci\u00f3n de productos farmac\u00e9uticos, incluyendo la autorizaci\u00f3n de comercializaci\u00f3n, la incertidumbre de medici\u00f3n, la trazabilidad metrol\u00f3gica, y las calificaciones operativas y de rendimiento de equipos anal\u00edticos. Tambi\u00e9n se aborda el concepto de excipientes farmac\u00e9uticos y los resultados fuera de especificaci\u00f3n, proporcionando un marco para entender c\u00f3mo se eval\u00faan y regulan los productos farmac\u00e9uticos en t\u00e9rminos de seguridad, eficacia y calidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n extra\u00edda del documento de la OMS en la Serie de Informes T\u00e9cnicos 957 se centra en conceptos fundamentales relacionados con la calidad y el control en la fabricaci\u00f3n de productos farmac\u00e9uticos. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n1. **Pruebas de Cumplimiento (Compliance Testing)**:\n   - An\u00e1lisis de ingredientes farmac\u00e9uticos activos (APIs), excipientes, materiales de embalaje o productos farmac\u00e9uticos seg\u00fan los requisitos de una monograf\u00eda farmacop\u00e9ica o especificaciones de autorizaci\u00f3n de comercializaci\u00f3n.\n\n2. **Muestra de Control (Control Sample)**:\n   - Utilizada para verificar la precisi\u00f3n y exactitud del procedimiento anal\u00edtico. Debe tener una matriz similar a las muestras a analizar y cuenta con un valor asignado y su incertidumbre asociada.\n\n3. **Calificaci\u00f3n de Dise\u00f1o (Design Qualification - DQ)**:\n   - Conjunto documentado de actividades que definen las especificaciones funcionales y operativas del instrumento, as\u00ed como los criterios para la selecci\u00f3n del proveedor.\n\n4. **Buenas Pr\u00e1cticas de Manufactura (Good Manufacturing Practice - GMP)**:\n   - Parte de la garant\u00eda de calidad que asegura que los productos farmac\u00e9uticos se produzcan y controlen de manera consistente, cumpliendo con los est\u00e1ndares de calidad requeridos.\n\n5. **Calificaci\u00f3n de Instalaci\u00f3n (Installation Qualification - IQ)**:\n   - Pruebas realizadas para asegurar que el equipo anal\u00edtico est\u00e1 correctamente instalado y opera de acuerdo con las especificaciones establecidas.\n\n6. **Revisi\u00f3n de Gesti\u00f3n (Management Review)**:\n   - Revisi\u00f3n formal y documentada de los indicadores clave de rendimiento de un sistema de gesti\u00f3n de calidad realizada por la alta direcci\u00f3n.\n\n7. **Fabricante (Manufacturer)**:\n   - Empresa que realiza operaciones como producci\u00f3n, embalaje, pruebas, reembalaje, etiquetado y/o reetiquetado de productos farmac\u00e9uticos.\n\n### Conclusi\u00f3n\nEstos conceptos son esenciales para garantizar que los productos farmac\u00e9uticos se desarrollen y controlen de acuerdo con los est\u00e1ndares de calidad necesarios, asegurando as\u00ed la seguridad y eficacia de los medicamentos en el mercado.", "excerpt_keywords": "Keywords: marketing authorization, measurement uncertainty, operational qualification, out-of-specification, pharmaceutical excipient"}}, "09d519ef-02ff-4b66-95ff-cc720c3286c9": {"node_ids": ["0b6f27df-0121-4c3e-954f-f6d07c99ffda"], "metadata": {"page_label": "102", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "pharmaceutical product  \nAny material or product intended for human or veterinary use, presented in its finished dosage form or as a starting material for use in such a dosage form, which is subject to control by pharmaceutical legislation in the exporting state and/or the importing state (1).\n\nprecision  \nThe degree of agreement among individual results when the procedure is applied repeatedly to multiple samplings of a homogeneous sample. Precision, usually expressed as relative standard deviation, may be considered at three levels: repeatability (precision under the same operating conditions over a short period of time), intermediate precision (within laboratory variations \u2014 different days, different analysts or different equipment) and reproducibility (precision between laboratories).\n\nprimary reference substance (or standard)  \nA substance that is widely acknowledged to possess the appropriate qualities within a specified context, and whose assigned content is accepted without requiring comparison with another chemical substance (8).\n\n*Note:* Pharmacopoeial chemical reference substances are considered to be primary reference substances. In the absence of a pharmacopoeial reference substance, a manufacturer should establish a primary reference substance.\n\nqualification of equipment  \nAction of proving and documenting that any analytical equipment complies with the required specifications and performs suitably for its intended purpose (see Part two, section 12).\n\nquality control  \nAll measures taken, including the setting of specifications, sampling, testing and analytical clearance, to ensure that raw materials, intermediates, packaging materials and finished pharmaceutical products conform with established specifications for identity, strength, purity and other characteristics.\n\nquality management system  \nAn appropriate infrastructure, encompassing the organizational structure, procedures, processes and resources, and systematic actions necessary to ensure adequate confidence that a product or service will satisfy given requirements for quality (see Part one, section 2).\n\nquality manager  \nA member of staff who has a defined responsibility and authority for ensuring that the management system related to quality is implemented and followed at all times (see Part one, section 1.3(j)).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 se entiende por \"producto farmac\u00e9utico\" seg\u00fan el documento de la OMS?**\n   - **Respuesta:** Un \"producto farmac\u00e9utico\" se define como cualquier material o producto destinado para uso humano o veterinario, presentado en su forma de dosificaci\u00f3n final o como material inicial para su uso en tal forma de dosificaci\u00f3n, que est\u00e1 sujeto a control por la legislaci\u00f3n farmac\u00e9utica en el estado exportador y/o en el estado importador.\n\n2. **\u00bfCu\u00e1les son los tres niveles de precisi\u00f3n mencionados en el documento y c\u00f3mo se diferencian entre s\u00ed?**\n   - **Respuesta:** Los tres niveles de precisi\u00f3n son: \n     - **Repetibilidad:** Precisi\u00f3n bajo las mismas condiciones operativas durante un corto per\u00edodo de tiempo.\n     - **Precisi\u00f3n intermedia:** Variaciones dentro del laboratorio, que pueden incluir diferentes d\u00edas, analistas o equipos.\n     - **Reproducibilidad:** Precisi\u00f3n entre diferentes laboratorios.\n\n3. **\u00bfCu\u00e1l es el papel de un \"gerente de calidad\" seg\u00fan el documento?**\n   - **Respuesta:** Un \"gerente de calidad\" es un miembro del personal que tiene una responsabilidad y autoridad definidas para asegurar que el sistema de gesti\u00f3n relacionado con la calidad se implemente y siga en todo momento.\n\n### Resumen de nivel superior del contexto:\nEl documento de la OMS proporciona definiciones clave y conceptos relacionados con la calidad y el control de productos farmac\u00e9uticos. Incluye definiciones de t\u00e9rminos como \"producto farmac\u00e9utico\", \"precisi\u00f3n\", \"sustancia de referencia primaria\", \"calificaci\u00f3n de equipos\", \"control de calidad\", \"sistema de gesti\u00f3n de calidad\" y \"gerente de calidad\". Estos conceptos son fundamentales para garantizar que los productos farmac\u00e9uticos cumplan con las especificaciones establecidas en t\u00e9rminos de identidad, fuerza, pureza y otras caracter\u00edsticas relevantes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Autorizaci\u00f3n de Comercializaci\u00f3n (Marketing Authorization)**:\n   - Documento legal emitido por la autoridad reguladora de medicamentos que permite la comercializaci\u00f3n de un producto farmac\u00e9utico tras su evaluaci\u00f3n en t\u00e9rminos de seguridad, eficacia y calidad.\n   - Incluye informaci\u00f3n sobre la composici\u00f3n, formulaci\u00f3n, requisitos de calidad, embalaje, etiquetado, condiciones de almacenamiento, vida \u00fatil y condiciones de uso aprobadas.\n\n2. **Incertidumbre de Medici\u00f3n (Measurement Uncertainty)**:\n   - Par\u00e1metro no negativo que caracteriza la dispersi\u00f3n de los valores de cantidad atribuidos a un analito, basado en la informaci\u00f3n utilizada.\n\n3. **Trazabilidad Metrol\u00f3gica (Metrological Traceability)**:\n   - Propiedad de un resultado de medici\u00f3n que permite relacionarlo con un referente a trav\u00e9s de una cadena documentada de calibraciones.\n\n4. **Calificaci\u00f3n Operativa (Operational Qualification, OQ)**:\n   - Verificaci\u00f3n documentada de que el equipo anal\u00edtico funciona como se espera en todos los rangos operativos anticipados.\n\n5. **Resultado Fuera de Especificaci\u00f3n (Out-of-Specification, OOS)**:\n   - Resultados de pruebas que no cumplen con las especificaciones o criterios de aceptaci\u00f3n establecidos en documentos de producto, archivos maestros de medicamentos o farmacopeas.\n\n6. **Calificaci\u00f3n de Rendimiento (Performance Qualification, PQ)**:\n   - Verificaci\u00f3n documentada de que el equipo anal\u00edtico opera de manera consistente y reproduce resultados dentro de las especificaciones definidas durante per\u00edodos prolongados.\n\n7. **Excipiente Farmac\u00e9utico (Pharmaceutical Excipient)**:\n   - Sustancia distinta del ingrediente farmac\u00e9utico activo (API) que ha sido evaluada por su seguridad y se incluye en un sistema de entrega de medicamentos para mejorar su procesamiento, estabilidad, biodisponibilidad, aceptabilidad del paciente, identificaci\u00f3n del producto y otros atributos de seguridad y eficacia.\n\n### Entidades Clave:\n- **Autoridad Reguladora de Medicamentos**: Entidad responsable de emitir autorizaciones de comercializaci\u00f3n.\n- **Analito**: Sustancia cuya cantidad se mide.\n- **Equipos Anal\u00edticos**: Herramientas utilizadas para realizar pruebas y mediciones en productos farmac\u00e9uticos.\n- **Documentos de Producto**: Expedientes que contienen especificaciones y criterios de aceptaci\u00f3n para productos farmac\u00e9uticos.\n\nEste resumen proporciona una visi\u00f3n general de los conceptos y t\u00e9rminos clave relacionados con la regulaci\u00f3n y evaluaci\u00f3n de productos farmac\u00e9uticos, enfatizando la importancia de la calidad, seguridad y eficacia en el desarrollo y comercializaci\u00f3n de medicamentos.", "excerpt_keywords": "Keywords: pharmaceutical product, precision, quality control, primary reference substance, quality management system"}}, "afaaad83-fbdd-4905-b5a4-1bb579be28c6": {"node_ids": ["3ee95f29-c29f-466a-90b1-ff7fa666eb9f"], "metadata": {"page_label": "103", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "quality manual  \nA handbook that describes the various elements of the quality management system for assuring the quality of the test results generated by a laboratory (see Part one, sections 2.1\u20132.2).\n\nquality unit(s)  \nAn organizational unit, independent of production, which fulfils both quality assurance and quality control responsibilities. This can be in the form of separate quality assurance and quality control or a single individual or group, depending on the size and structure of the organization.\n\nreference material  \nMaterial sufficiently homogeneous and stable with respect to one or more specified properties, which has been established to be fit for its intended use in a measurement process (4).\n\nreference substance (or standard)  \nAn authenticated, uniform material that is intended for use in specified chemical and physical tests, in which its properties are compared with those of the product under examination, and which possesses a degree of purity adequate for its intended use (8).\n\nsecondary reference substance (or standard)  \nA substance whose characteristics are assigned and/or calibrated by comparison with a primary reference substance. The extent of characterization and testing of a secondary reference substance may be less than for a primary reference substance (8).\n\n*Note:* Often referred to as an \u201cin-house\u201d working standard.\n\nsignature (signed)  \nRecord of the individual who performed a particular action or review. The record can be initials, full handwritten signature, personal seal or authenticated and secure electronic signature.\n\nspecification  \nA list of detailed requirements (acceptance criteria for the prescribed test procedures) with which the substance or pharmaceutical product has to conform to ensure suitable quality.\n\nstandard operating procedure (SOP)  \nAn authorized written procedure giving instructions for performing operations both general and specific.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento \"WHO - Technical Report Series 957\" aborda aspectos clave del sistema de gesti\u00f3n de calidad en laboratorios, incluyendo definiciones y funciones de unidades de calidad, materiales de referencia, procedimientos operativos est\u00e1ndar y la importancia de la firma en registros. Se enfatiza la necesidad de especificaciones detalladas para asegurar la calidad de los productos farmac\u00e9uticos y los m\u00e9todos de prueba.\n\n### Preguntas:\n1. **\u00bfCu\u00e1l es la funci\u00f3n principal de una unidad de calidad en un laboratorio seg\u00fan el documento?**\n   - Respuesta: La unidad de calidad es un organismo independiente de la producci\u00f3n que cumple con responsabilidades tanto de aseguramiento de la calidad como de control de calidad, pudiendo estar estructurada como unidades separadas o como un solo grupo, dependiendo del tama\u00f1o de la organizaci\u00f3n.\n\n2. **\u00bfQu\u00e9 se entiende por 'material de referencia' y por qu\u00e9 es importante en un proceso de medici\u00f3n?**\n   - Respuesta: El material de referencia es un material que es suficientemente homog\u00e9neo y estable en relaci\u00f3n con propiedades espec\u00edficas, y se ha establecido que es adecuado para su uso en un proceso de medici\u00f3n. Su importancia radica en que asegura la precisi\u00f3n y la fiabilidad de los resultados de las pruebas.\n\n3. **\u00bfQu\u00e9 se considera una 'procedimiento operativo est\u00e1ndar' (SOP) y cu\u00e1l es su prop\u00f3sito?**\n   - Respuesta: Un procedimiento operativo est\u00e1ndar (SOP) es un documento escrito autorizado que proporciona instrucciones para realizar operaciones, tanto generales como espec\u00edficas. Su prop\u00f3sito es garantizar que las actividades se realicen de manera consistente y conforme a los requisitos establecidos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Producto Farmac\u00e9utico**: Se refiere a cualquier material o producto destinado al uso humano o veterinario, que puede presentarse en forma de dosificaci\u00f3n final o como material inicial, y que est\u00e1 regulado por la legislaci\u00f3n farmac\u00e9utica del pa\u00eds exportador e importador.\n\n2. **Precisi\u00f3n**: Se define como el grado de acuerdo entre resultados individuales en m\u00faltiples muestreos de una muestra homog\u00e9nea. Se clasifica en tres niveles:\n   - **Repetibilidad**: Precisi\u00f3n bajo las mismas condiciones operativas en un corto per\u00edodo.\n   - **Precisi\u00f3n Intermedia**: Variaciones dentro del laboratorio (diferentes d\u00edas, analistas o equipos).\n   - **Reproducibilidad**: Precisi\u00f3n entre diferentes laboratorios.\n\n3. **Sustancia de Referencia Primaria**: Sustancia reconocida por poseer cualidades adecuadas en un contexto espec\u00edfico, cuya composici\u00f3n se acepta sin necesidad de comparaci\u00f3n con otra sustancia qu\u00edmica.\n\n4. **Calificaci\u00f3n de Equipos**: Proceso de demostrar y documentar que el equipo anal\u00edtico cumple con las especificaciones requeridas y es adecuado para su prop\u00f3sito.\n\n5. **Control de Calidad**: Conjunto de medidas que incluyen la fijaci\u00f3n de especificaciones, muestreo, pruebas y aprobaci\u00f3n anal\u00edtica, para asegurar que los productos farmac\u00e9uticos cumplan con las especificaciones establecidas.\n\n6. **Sistema de Gesti\u00f3n de Calidad**: Infraestructura que incluye la estructura organizativa, procedimientos, procesos y recursos necesarios para garantizar que un producto o servicio cumpla con los requisitos de calidad.\n\n7. **Gerente de Calidad**: Personal responsable de asegurar que el sistema de gesti\u00f3n de calidad se implemente y mantenga en todo momento.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Fuente del documento.\n- **Legislaci\u00f3n Farmac\u00e9utica**: Marco regulatorio que rige los productos farmac\u00e9uticos.\n- **Sustancias de Referencia**: Incluyen sustancias qu\u00edmicas de referencia farmacop\u00e9ica.\n- **Equipos Anal\u00edticos**: Herramientas utilizadas en el control de calidad y an\u00e1lisis de productos farmac\u00e9uticos.\n\nEste resumen abarca los conceptos fundamentales y las entidades relevantes en el contexto de la calidad y el control de productos farmac\u00e9uticos seg\u00fan el documento de la OMS.", "excerpt_keywords": "Keywords: quality management, reference material, standard operating procedure, quality assurance, pharmaceutical products"}}, "096baf02-7d37-4ec6-9032-0a32e8919d93": {"node_ids": ["49f48fee-fdd9-4eae-8c25-d5fb5ab60037"], "metadata": {"page_label": "104", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# standard uncertainty\n\nUncertainty of the result of a measurement expressed as a standard deviation (4, 9, 10).\n\n# system suitability test\n\nA test which is performed to ensure that the analytical procedure fulfils the acceptance criteria which had been established during the validation of the procedure. This test is performed before starting the analytical procedure and is to be repeated regularly, as appropriate, throughout the analytical run to ensure that the system\u2019s performance is acceptable at the time of the test.\n\n# validation of an analytical procedure\n\nThe documented process by which an analytical procedure (or method) is demonstrated to be suitable for its intended use.\n\n# verification of an analytical procedure\n\nProcess by which a pharmacopoeial method or validated analytical procedure is demonstrated to be suitable for the analysis to be performed.\n\n# verification of performance\n\nTest procedure regularly applied to a system (e.g. liquid chromatographic system) to demonstrate consistency of response.\n\n# Part One. Management and infrastructure\n\n## 1. Organization and management\n\n1.1 The laboratory, or the organization of which it is part, should be an entity that is legally authorized to function and can be held legally responsible.\n\n1.2 The laboratory should be organized and operate so as to meet the requirements laid down in these guidelines.\n\n1.3 The laboratory should:\n\n- (a) have managerial and technical personnel with the authority and resources needed to carry out their duties and to identify the occurrence of departures from the quality management system or the procedures for performing tests and/or calibrations, validation and verification, and to initiate actions to prevent or minimize such departures;\n- (b) have arrangements to ensure that its management and personnel are not subject to commercial, political, financial and other influences.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en su Informe T\u00e9cnico 957 aborda aspectos fundamentales de la gesti\u00f3n y la infraestructura de laboratorios, centr\u00e1ndose en la organizaci\u00f3n y el manejo de procedimientos anal\u00edticos. Se definen conceptos clave como la incertidumbre est\u00e1ndar, las pruebas de idoneidad del sistema, la validaci\u00f3n y verificaci\u00f3n de procedimientos anal\u00edticos, y se establecen requisitos para la organizaci\u00f3n y el personal del laboratorio para asegurar la calidad y la responsabilidad legal.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben cumplirse para que un laboratorio sea considerado legalmente autorizado seg\u00fan las directrices de la OMS?**\n   - El laboratorio debe ser una entidad legalmente autorizada para funcionar y debe poder ser responsabilizada legalmente por sus actividades.\n\n2. **\u00bfCu\u00e1l es la importancia de realizar pruebas de idoneidad del sistema antes y durante un procedimiento anal\u00edtico?**\n   - Estas pruebas son cruciales para asegurar que el procedimiento anal\u00edtico cumple con los criterios de aceptaci\u00f3n establecidos durante su validaci\u00f3n, garantizando as\u00ed que el rendimiento del sistema sea aceptable en el momento de la prueba.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse para evitar influencias externas en la gesti\u00f3n y el personal del laboratorio?**\n   - El laboratorio debe tener arreglos que aseguren que su gesti\u00f3n y personal no est\u00e9n sujetos a influencias comerciales, pol\u00edticas, financieras u otras que puedan comprometer la integridad de sus operaciones.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 957\" se centra en la gesti\u00f3n de calidad en laboratorios, abordando varios conceptos esenciales:\n\n1. **Manual de Calidad**: Describe los elementos del sistema de gesti\u00f3n de calidad que aseguran la calidad de los resultados de las pruebas en un laboratorio.\n\n2. **Unidad de Calidad**: Se define como una unidad organizativa independiente de la producci\u00f3n que se encarga de las responsabilidades de aseguramiento y control de calidad. Puede estar estructurada como unidades separadas o como un solo grupo, dependiendo del tama\u00f1o de la organizaci\u00f3n.\n\n3. **Material de Referencia**: Se refiere a un material que es homog\u00e9neo y estable en relaci\u00f3n con propiedades espec\u00edficas, utilizado en procesos de medici\u00f3n para garantizar la precisi\u00f3n de los resultados.\n\n4. **Sustancia de Referencia (o Est\u00e1ndar)**: Material autenticado y uniforme utilizado en pruebas qu\u00edmicas y f\u00edsicas, cuyas propiedades se comparan con las del producto en examen.\n\n5. **Sustancia de Referencia Secundaria (o Est\u00e1ndar)**: Sustancia cuya caracterizaci\u00f3n se realiza en comparaci\u00f3n con una sustancia de referencia primaria, con un nivel de caracterizaci\u00f3n que puede ser menor.\n\n6. **Firma (Firmado)**: Registro del individuo que realiz\u00f3 una acci\u00f3n o revisi\u00f3n, que puede ser en forma de iniciales, firma manuscrita, sello personal o firma electr\u00f3nica segura.\n\n7. **Especificaci\u00f3n**: Lista de requisitos detallados que un producto farmac\u00e9utico debe cumplir para asegurar su calidad.\n\n8. **Procedimiento Operativo Est\u00e1ndar (SOP)**: Documento escrito que proporciona instrucciones autorizadas para realizar operaciones, tanto generales como espec\u00edficas, asegurando la consistencia en la ejecuci\u00f3n de actividades.\n\n### Entidades Clave\n- **Organizaci\u00f3n**: Laboratorio\n- **Funciones**: Aseguramiento de calidad, control de calidad\n- **Materiales**: Material de referencia, sustancia de referencia, sustancia de referencia secundaria\n- **Documentaci\u00f3n**: Manual de calidad, especificaciones, SOP\n\nEste resumen destaca la importancia de un sistema de gesti\u00f3n de calidad robusto en laboratorios para asegurar la fiabilidad y precisi\u00f3n de los resultados de las pruebas.", "excerpt_keywords": "Keywords: uncertainty, validation, verification, laboratory management, quality assurance"}}, "70bd48ec-272b-473d-882c-5fc1266e6f22": {"node_ids": ["dfe442b5-79ab-47c5-a794-e164cb5dcee4"], "metadata": {"page_label": "105", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\npressures or conflicts of interest that may adversely affect the \nquality of their work; \n(c) have a policy and procedure in place to ensure confidentiality of \n   \u2014 information contained in marketing authorizations, \n   \u2014 transfer of results or reports, \n   \u2014 and to protect data in archives (paper and electronic); \n\n(d) define, with the aid of organizational charts, the organization and \n    management structure of the laboratory, its place in any parent \n    organization (such as the ministry or the NMRA in the case \n    of a national pharmaceutical quality control laboratory), and \n    the relationships between management, technical operations, \n    support services and the quality management system; \n\n(e) specify the responsibility, authority and interrelationships of all \n    personnel who manage, perform or verify work which affects \n    the quality of the tests and/or calibrations, validations and \n    verifications; \n\n(f) ensure the precise allocation of responsibilities, particularly in \n    the designation of specific units for particular types of medicines; \n\n(g) nominate trained substitutes/deputies for key management and \n    specialized scientific personnel; \n\n(h) provide adequate supervision of staff, including trainees, by \n    persons familiar with the test and/or calibration, validation and \n    verification methods and procedures, as well as their purpose \n    and the assessment of the results; \n\n(i) have management which has overall responsibility for the \n    technical operations and the provision of resources needed to \n    ensure the required quality of laboratory operations; \n\n(j) designate a member of staff as quality manager who, \n    irrespective of other duties he/she may have, will ensure \n    compliance with the quality management system. The \n    nominated quality manager should have direct access to the \n    highest level of management at which decisions are taken on \n    laboratory policies or resources; \n\n(k) ensure adequate information flow between staff at all levels. \n    Staff are to be made aware of the relevance and importance of \n    their activities; \n\n(l) ensure the traceability of the sample from receipt, throughout \n    the stages of testing, to the completion of the analytical test \n    report; \n\n(m) maintain an up-to-date collection of all specifications and related \n    documents (paper or electronic) used in the laboratory; and \n\n(n) have appropriate safety procedures (see Part four).\n```\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 957) establece directrices para la gesti\u00f3n y operaci\u00f3n de laboratorios, especialmente en el contexto de control de calidad farmac\u00e9utica. Se enfatiza la importancia de la confidencialidad, la organizaci\u00f3n estructural, la asignaci\u00f3n de responsabilidades, la supervisi\u00f3n del personal, y la implementaci\u00f3n de un sistema de gesti\u00f3n de calidad. Adem\u00e1s, se menciona la necesidad de asegurar la trazabilidad de las muestras y mantener actualizada la documentaci\u00f3n relacionada con las especificaciones del laboratorio.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas del gerente de calidad en un laboratorio seg\u00fan el documento?**\n   - Esta pregunta busca una respuesta detallada sobre el rol del gerente de calidad, que incluye su acceso a la alta direcci\u00f3n y su responsabilidad en el cumplimiento del sistema de gesti\u00f3n de calidad.\n\n2. **\u00bfQu\u00e9 procedimientos se deben implementar para garantizar la confidencialidad de la informaci\u00f3n en un laboratorio?**\n   - Esta pregunta se centra en las pol\u00edticas y procedimientos necesarios para proteger la informaci\u00f3n sensible, como los datos de autorizaciones de comercializaci\u00f3n y resultados de pruebas.\n\n3. **\u00bfC\u00f3mo se debe estructurar la organizaci\u00f3n y gesti\u00f3n de un laboratorio para asegurar la calidad de las pruebas y calibraciones?**\n   - Esta pregunta busca una descripci\u00f3n de la estructura organizativa y las interrelaciones entre el personal, as\u00ed como la asignaci\u00f3n de responsabilidades para mantener la calidad en las operaciones del laboratorio. \n\nEstas preguntas est\u00e1n dise\u00f1adas para obtener informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otros documentos, centr\u00e1ndose en aspectos clave de la gesti\u00f3n de calidad en laboratorios farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n del documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en el Informe T\u00e9cnico 957 aborda varios conceptos y directrices esenciales para la gesti\u00f3n y operaci\u00f3n de laboratorios anal\u00edticos. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave\n\n1. **Incertidumbre Est\u00e1ndar**: Se refiere a la incertidumbre en los resultados de mediciones, expresada como una desviaci\u00f3n est\u00e1ndar.\n\n2. **Prueba de Idoneidad del Sistema**: Es una evaluaci\u00f3n que se realiza para asegurar que un procedimiento anal\u00edtico cumple con los criterios de aceptaci\u00f3n establecidos durante su validaci\u00f3n. Debe realizarse antes de iniciar el procedimiento y repetirse regularmente.\n\n3. **Validaci\u00f3n de un Procedimiento Anal\u00edtico**: Proceso documentado que demuestra que un procedimiento anal\u00edtico es adecuado para su uso previsto.\n\n4. **Verificaci\u00f3n de un Procedimiento Anal\u00edtico**: Proceso que asegura que un m\u00e9todo farmacop\u00e9ico o un procedimiento anal\u00edtico validado es adecuado para el an\u00e1lisis que se va a realizar.\n\n5. **Verificaci\u00f3n del Rendimiento**: Procedimiento de prueba aplicado regularmente a un sistema (como un sistema de cromatograf\u00eda l\u00edquida) para demostrar la consistencia de la respuesta.\n\n6. **Organizaci\u00f3n y Gesti\u00f3n del Laboratorio**: Directrices sobre c\u00f3mo debe estar estructurado y operar un laboratorio para cumplir con los requisitos establecidos, incluyendo la responsabilidad legal y la independencia de influencias externas.\n\n#### Entidades\n\n- **Laboratorio**: Entidad que debe estar legalmente autorizada para operar y ser responsable de sus actividades.\n- **Personal Gerencial y T\u00e9cnico**: Debe tener la autoridad y los recursos necesarios para llevar a cabo sus funciones y gestionar la calidad del sistema.\n- **Sistema Anal\u00edtico**: Incluye procedimientos y m\u00e9todos que deben ser validados y verificados para asegurar su eficacia.\n\nEste resumen destaca la importancia de la calidad y la responsabilidad en la operaci\u00f3n de laboratorios anal\u00edticos, as\u00ed como la necesidad de procedimientos rigurosos para garantizar resultados confiables y v\u00e1lidos.", "excerpt_keywords": "Keywords: calidad, laboratorio, gesti\u00f3n, confidencialidad, trazabilidad"}}, "40c4f355-74a7-4fec-a53a-0bbaee986e7d": {"node_ids": ["e9fbcb89-5827-4db8-b96e-00e266275213"], "metadata": {"page_label": "106", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 1.4 \nThe laboratory should maintain a registry with the following functions:\n\n(a) receiving, distributing and supervising the consignment of the samples to the specific units; and  \n(b) keeping records on all incoming samples and accompanying documents.\n\n1.5 In a large laboratory, it is necessary to guarantee communication and coordination between the staff involved in the testing of the same sample in different units.\n\n# 2. Quality management system\n\n2.1 The laboratory or organization management should establish, implement and maintain a quality management system appropriate to the scope of its activities, including the type, range and volume of testing and/or calibration, validation and verification activities it undertakes. The laboratory management should ensure that its policies, systems, programmes, procedures and instructions are described to the extent necessary to enable the laboratory to assure the quality of the test results that it generates. The documentation used in this quality management system should be communicated, available to, and understood and implemented by, the appropriate personnel. The elements of this system should be documented, e.g. in a quality manual, for the organization as a whole and/or for a laboratory within the organization.\n\n*Note:* Quality control laboratories of a manufacturer may have this information in other documents than a quality manual.\n\n2.2 The quality manual should contain as a minimum:\n\n(a) a quality policy statement, including at least the following:\n   (i) a statement of the laboratory management\u2019s intentions with respect to the standard of service it will provide,\n   (ii) a commitment to establishing, implementing and maintaining an effective quality management system,\n   (iii) the laboratory management\u2019s commitment to good professional practice and quality of testing, calibration, validation and verification,\n   (iv) the laboratory management\u2019s commitment to compliance with the content of these guidelines,\n   (v) a requirement that all personnel concerned with testing and calibration activities within the laboratory familiarize themselves with the documentation concerning quality and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices para la gesti\u00f3n de laboratorios, enfatizando la importancia de mantener un registro de muestras, garantizar la comunicaci\u00f3n entre el personal y establecer un sistema de gesti\u00f3n de calidad. Este sistema debe ser adecuado para las actividades del laboratorio y debe incluir un manual de calidad que contenga pol\u00edticas y compromisos claros de la direcci\u00f3n del laboratorio respecto a la calidad del servicio y la pr\u00e1ctica profesional.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las funciones espec\u00edficas que debe cumplir el registro de un laboratorio seg\u00fan las directrices de la OMS?**\n   - El registro debe cumplir con las funciones de recibir, distribuir y supervisar la consignaci\u00f3n de muestras a las unidades espec\u00edficas, as\u00ed como mantener registros de todas las muestras entrantes y los documentos que las acompa\u00f1an.\n\n2. **\u00bfQu\u00e9 elementos m\u00ednimos debe contener el manual de calidad de un laboratorio seg\u00fan las recomendaciones de la OMS?**\n   - El manual de calidad debe incluir, como m\u00ednimo, una declaraci\u00f3n de pol\u00edtica de calidad que abarque la intenci\u00f3n de la direcci\u00f3n respecto al est\u00e1ndar de servicio, el compromiso con un sistema de gesti\u00f3n de calidad efectivo, la pr\u00e1ctica profesional adecuada, el cumplimiento de las directrices y la familiarizaci\u00f3n del personal con la documentaci\u00f3n de calidad.\n\n3. **\u00bfPor qu\u00e9 es importante la comunicaci\u00f3n y coordinaci\u00f3n entre el personal en un laboratorio grande seg\u00fan el documento?**\n   - Es crucial garantizar la comunicaci\u00f3n y coordinaci\u00f3n entre el personal involucrado en la prueba de la misma muestra en diferentes unidades para asegurar la coherencia y la calidad de los resultados de las pruebas, lo que contribuye a la eficacia del sistema de gesti\u00f3n de calidad del laboratorio.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n del documento de la OMS (Serie de Informes T\u00e9cnicos 957) aborda directrices esenciales para la gesti\u00f3n y operaci\u00f3n de laboratorios, especialmente en el \u00e1mbito del control de calidad farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n#### Temas Clave:\n1. **Confidencialidad**: Importancia de tener pol\u00edticas y procedimientos para proteger la informaci\u00f3n sensible relacionada con autorizaciones de comercializaci\u00f3n y resultados de pruebas.\n   \n2. **Estructura Organizativa**: Necesidad de definir la organizaci\u00f3n y la estructura de gesti\u00f3n del laboratorio, incluyendo su relaci\u00f3n con organizaciones parentales (como ministerios o agencias reguladoras).\n\n3. **Responsabilidades y Autoridad**: Especificaci\u00f3n de las responsabilidades y la autoridad de todo el personal involucrado en la gesti\u00f3n, ejecuci\u00f3n y verificaci\u00f3n de trabajos que afectan la calidad de las pruebas.\n\n4. **Supervisi\u00f3n del Personal**: Provisi\u00f3n de supervisi\u00f3n adecuada para el personal, incluidos los aprendices, por parte de personas familiarizadas con los m\u00e9todos y procedimientos de prueba.\n\n5. **Gesti\u00f3n de Calidad**: Designaci\u00f3n de un gerente de calidad que garantice el cumplimiento del sistema de gesti\u00f3n de calidad y tenga acceso a la alta direcci\u00f3n.\n\n6. **Flujo de Informaci\u00f3n**: Asegurar una comunicaci\u00f3n adecuada entre el personal en todos los niveles y la concienciaci\u00f3n sobre la importancia de sus actividades.\n\n7. **Trazabilidad de Muestras**: Garantizar la trazabilidad de las muestras desde su recepci\u00f3n hasta la finalizaci\u00f3n del informe de prueba anal\u00edtica.\n\n8. **Documentaci\u00f3n Actualizada**: Mantenimiento de una colecci\u00f3n actualizada de especificaciones y documentos relacionados utilizados en el laboratorio.\n\n9. **Procedimientos de Seguridad**: Implementaci\u00f3n de procedimientos de seguridad adecuados en el laboratorio.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Laboratorios**: Entidades que deben cumplir con las directrices de calidad.\n- **Ministerios y Agencias Reguladoras**: Organizaciones parentales que pueden estar relacionadas con laboratorios nacionales de control de calidad farmac\u00e9utica.\n- **Personal del Laboratorio**: Incluye gerentes, t\u00e9cnicos, personal de apoyo y aprendices.\n\nEste resumen destaca la importancia de una gesti\u00f3n estructurada y de calidad en los laboratorios, as\u00ed como la necesidad de mantener la confidencialidad y la trazabilidad en los procesos de prueba.", "excerpt_keywords": "Keywords: laboratory management, quality management system, sample registry, testing coordination, quality manual"}}, "22730bbd-f3ca-4cdb-ba6c-1b073bdd4625": {"node_ids": ["d76fd27e-9193-4edf-b976-eb92f3264d0c"], "metadata": {"page_label": "107", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the implementation of the policies and procedures in their work;  \n(b) the structure of the laboratory (organizational chart);  \n(c) the operational and functional activities pertaining to quality, so that the extent and the limits of the responsibilities are clearly defined;  \n(d) outline of the structure of documentation used in the laboratory quality management system;  \n(e) the general internal quality management procedures;  \n(f) references to specific procedures for each test;  \n(g) information on the appropriate qualifications, experience and competencies that personnel are required to possess;  \n(h) information on initial and in-service training of staff;  \n(i) a policy for internal and external audit;  \n(j) a policy for implementing and verifying corrective and preventive actions;  \n(k) a policy for dealing with complaints;  \n(l) a policy for performing management reviews of the quality management system;  \n(m) a policy for selecting, establishing and approving analytical procedures;  \n(n) a policy for handling of OOS results;  \n(o) a policy for the employment of appropriate reference substances and reference materials;  \n(p) a policy for participation in appropriate proficiency testing schemes and collaborative trials and the evaluation of the performance (applicable to national pharmaceutical quality control laboratories, but may be applied by other laboratories); and  \n(q) a policy to select service providers and suppliers.  \n\n2.3 The laboratory should establish, implement and maintain authorized written SOPs including, but not limited to, administrative and technical operations, such as:  \n\n(a) personnel matters, including qualifications, training, clothing and hygiene;  \n(b) the change control;  \n(c) internal audit;  \n(d) dealing with complaints;  \n(e) implementation and verification of corrective and preventive actions;  \n(f) the purchase and receipt of consignments of materials (e.g. samples, reagents);  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 957) establece directrices para la implementaci\u00f3n y mantenimiento de un sistema de gesti\u00f3n de calidad en laboratorios. Se detallan pol\u00edticas y procedimientos que deben ser establecidos, incluyendo la estructura organizativa, la capacitaci\u00f3n del personal, auditor\u00edas internas y externas, manejo de quejas, y procedimientos operativos est\u00e1ndar (SOPs) para diversas actividades administrativas y t\u00e9cnicas. Estas directrices son aplicables a laboratorios de control de calidad farmac\u00e9utica y pueden ser adaptadas por otros laboratorios.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las competencias y calificaciones espec\u00edficas que se requieren para el personal en un laboratorio seg\u00fan las directrices de la OMS?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre las expectativas de formaci\u00f3n y experiencia del personal, que no se puede encontrar f\u00e1cilmente en otros documentos.\n\n2. **\u00bfQu\u00e9 pol\u00edticas deben implementarse para manejar resultados fuera de especificaci\u00f3n (OOS) en un laboratorio?**\n   - Esta pregunta se centra en un aspecto cr\u00edtico de la gesti\u00f3n de calidad que puede no estar ampliamente documentado en otras fuentes.\n\n3. **\u00bfQu\u00e9 procedimientos operativos est\u00e1ndar (SOPs) se consideran esenciales para las operaciones administrativas y t\u00e9cnicas en un laboratorio, seg\u00fan el informe?**\n   - Esta pregunta busca una lista espec\u00edfica de SOPs que son fundamentales para el funcionamiento eficaz de un laboratorio, lo cual puede no estar claramente delineado en otros documentos.", "prev_section_summary": "### Temas Clave\n\n1. **Registro de Muestras**: \n   - Funciones del registro en el laboratorio: recibir, distribuir y supervisar la consignaci\u00f3n de muestras, as\u00ed como mantener registros de todas las muestras entrantes y documentos asociados.\n\n2. **Comunicaci\u00f3n en Laboratorios Grandes**: \n   - Importancia de la comunicaci\u00f3n y coordinaci\u00f3n entre el personal que trabaja con la misma muestra en diferentes unidades para asegurar la calidad y coherencia de los resultados.\n\n3. **Sistema de Gesti\u00f3n de Calidad**: \n   - Necesidad de establecer, implementar y mantener un sistema de gesti\u00f3n de calidad que sea adecuado para las actividades del laboratorio, incluyendo pruebas, calibraciones, validaciones y verificaciones.\n\n4. **Manual de Calidad**: \n   - Contenido m\u00ednimo que debe incluir el manual de calidad, como la declaraci\u00f3n de pol\u00edtica de calidad, compromisos de la direcci\u00f3n respecto a la calidad del servicio y la pr\u00e1ctica profesional, y la familiarizaci\u00f3n del personal con la documentaci\u00f3n de calidad.\n\n### Entidades\n\n- **Laboratorio**: Entidad responsable de realizar pruebas y mantener la calidad de los resultados.\n- **Muestras**: Elementos que se reciben y distribuyen en el laboratorio para su an\u00e1lisis.\n- **Personal del Laboratorio**: Empleados que realizan las pruebas y deben estar coordinados y comunicados.\n- **Sistema de Gesti\u00f3n de Calidad**: Conjunto de pol\u00edticas y procedimientos que aseguran la calidad de los resultados del laboratorio.\n- **Manual de Calidad**: Documento que describe las pol\u00edticas y compromisos del laboratorio en relaci\u00f3n con la calidad.\n\n### Resumen\nEl documento de la OMS establece directrices para la gesti\u00f3n de laboratorios, enfatizando la importancia de mantener un registro de muestras, garantizar la comunicaci\u00f3n entre el personal y establecer un sistema de gesti\u00f3n de calidad. Este sistema debe ser adecuado para las actividades del laboratorio y debe incluir un manual de calidad que contenga pol\u00edticas y compromisos claros de la direcci\u00f3n del laboratorio respecto a la calidad del servicio y la pr\u00e1ctica profesional.", "excerpt_keywords": "Keywords: calidad, laboratorio, procedimientos, gesti\u00f3n, auditor\u00eda"}}, "d7f23d32-aae6-448d-ad40-df21233debb9": {"node_ids": ["a25ff74d-d82a-4706-8fdd-0f58302cf908"], "metadata": {"page_label": "108", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "(g) the procurement, preparation and control of reference substances and reference materials (8);\n\n(h) the internal labelling, quarantine and storage of materials;\n\n(i) the qualification of equipment (11);\n\n(j) the calibration of equipment;\n\n(k) preventive maintenance and verification of instruments and equipment;\n\n(l) sampling, if performed by the laboratory, and visual inspection;\n\n(m) the testing of samples with descriptions of the methods and equipment used;\n\n(n) atypical and OOS results;\n\n(o) validation of analytical procedures;\n\n(p) cleaning of laboratory facilities, including bench tops, equipment, work stations, clean rooms (aseptic suites) and glassware;\n\n(q) monitoring of environmental conditions, e.g. temperature and humidity;\n\n(r) monitoring storage conditions;\n\n(s) disposal of reagents and solvent samples; and\n\n(t) safety measures.\n\n2.4 The activities of the laboratory should be systematically and periodically audited (internally and, where appropriate, by external audits or inspections) to verify compliance with the requirements of the quality management system and to apply corrective and preventive actions, if necessary. The audits should be carried out by trained and qualified personnel, who are independent of the activity to be audited. The quality manager is responsible for planning and organizing internal audits addressing all elements of the quality management system. Such audits should be recorded, together with details of any corrective and preventive action taken.\n\n2.5 Management review of quality issues should be regularly undertaken (at least annually), including:\n\n(a) reports on internal and external audits or inspections and any follow-up required to correct any deficiencies;\n\n(b) the outcome of investigations carried out as a result of complaints received, doubtful (atypical) or aberrant results reported in collaborative trials and/or proficiency tests; and\n\n(c) corrective actions applied and preventive actions introduced as a result of these investigations.\n\n# 3. Control of documentation\n\n3.1 Documentation is an essential part of the quality management system. The laboratory should establish and maintain procedures", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda aspectos clave de un sistema de gesti\u00f3n de calidad en laboratorios. Se enumeran diversas actividades que deben llevarse a cabo, como la adquisici\u00f3n y control de sustancias de referencia, la calibraci\u00f3n y mantenimiento de equipos, la limpieza de instalaciones, y la gesti\u00f3n de condiciones ambientales. Adem\u00e1s, se enfatiza la importancia de realizar auditor\u00edas internas y externas para garantizar el cumplimiento de los requisitos del sistema de gesti\u00f3n de calidad, as\u00ed como la revisi\u00f3n regular de los problemas de calidad por parte de la direcci\u00f3n. La documentaci\u00f3n es considerada un componente esencial del sistema de gesti\u00f3n de calidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben cumplirse para que un auditor sea considerado calificado para llevar a cabo auditor\u00edas internas en el laboratorio?**\n   - Esta pregunta busca informaci\u00f3n sobre las calificaciones y criterios espec\u00edficos que deben tener los auditores, que no se detalla expl\u00edcitamente en el texto.\n\n2. **\u00bfCu\u00e1les son los procedimientos espec\u00edficos que el laboratorio debe establecer para el control de la documentaci\u00f3n dentro del sistema de gesti\u00f3n de calidad?**\n   - Aunque se menciona que la documentaci\u00f3n es esencial, no se proporcionan detalles sobre los procedimientos espec\u00edficos que deben implementarse.\n\n3. **\u00bfQu\u00e9 acciones correctivas y preventivas se deben tomar en caso de que se identifiquen deficiencias durante las auditor\u00edas internas o externas?**\n   - Esta pregunta busca ejemplos concretos de acciones que se deben implementar, m\u00e1s all\u00e1 de la menci\u00f3n general de que deben aplicarse acciones correctivas y preventivas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades:\n\n1. **Sistema de Gesti\u00f3n de Calidad en Laboratorios**:\n   - Directrices para la implementaci\u00f3n y mantenimiento de un sistema de gesti\u00f3n de calidad en laboratorios, especialmente en el contexto de control de calidad farmac\u00e9utica.\n\n2. **Pol\u00edticas y Procedimientos**:\n   - Se requiere establecer pol\u00edticas claras que aborden diversas \u00e1reas, incluyendo:\n     - Estructura organizativa del laboratorio.\n     - Actividades operativas y funcionales relacionadas con la calidad.\n     - Procedimientos para auditor\u00edas internas y externas.\n     - Manejo de quejas y resultados fuera de especificaci\u00f3n (OOS).\n     - Capacitaci\u00f3n y competencias del personal.\n\n3. **Documentaci\u00f3n y Procedimientos Operativos Est\u00e1ndar (SOPs)**:\n   - Importancia de tener SOPs escritos y autorizados que cubran tanto operaciones administrativas como t\u00e9cnicas, tales como:\n     - Asuntos de personal (calificaciones, formaci\u00f3n, higiene).\n     - Control de cambios y auditor\u00edas internas.\n     - Proceso de compra y recepci\u00f3n de materiales.\n\n4. **Calificaciones y Capacitaci\u00f3n del Personal**:\n   - Informaci\u00f3n sobre las calificaciones, experiencia y competencias necesarias para el personal del laboratorio, as\u00ed como la formaci\u00f3n inicial y continua.\n\n5. **Pol\u00edticas Espec\u00edficas**:\n   - Pol\u00edticas para la selecci\u00f3n y aprobaci\u00f3n de procedimientos anal\u00edticos, manejo de materiales de referencia, participaci\u00f3n en pruebas de competencia y evaluaci\u00f3n del rendimiento.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Laboratorios**: Entidades que deben implementar las pol\u00edticas y procedimientos.\n- **Personal del Laboratorio**: Sujetos que deben cumplir con las calificaciones y capacitaci\u00f3n requeridas.\n- **SOPs**: Documentos que establecen procedimientos operativos est\u00e1ndar necesarios para el funcionamiento del laboratorio. \n\nEste resumen destaca la importancia de un enfoque sistem\u00e1tico y documentado para asegurar la calidad en los laboratorios, as\u00ed como la necesidad de personal competente y bien entrenado.", "excerpt_keywords": "Keywords: calidad, auditor\u00edas, documentaci\u00f3n, laboratorio, procedimientos"}}, "73699b63-6e49-4076-8708-c4ea8660cbb3": {"node_ids": ["1373ad86-e30b-4c76-b3df-0cd14c31b2a3"], "metadata": {"page_label": "109", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 3.2 The procedures should ensure that:\n\n(a) each document, whether a technical or a quality document, has a unique identifier, version number and date of implementation;\n\n(b) appropriate, authorized SOPs are available at the relevant locations, e.g. near instruments;\n\n(c) documents are kept up to date and reviewed as required;\n\n(d) any invalid document is removed and replaced with the authorized, revised document with immediate effect;\n\n(e) a revised document includes references to the previous document;\n\n(f) old, invalid documents are retained in the archives to ensure traceability of the evolution of the procedures; any copies are destroyed;\n\n(g) all relevant staff are trained for the new and revised SOPs; and\n\n(h) quality documentation, including records, is retained for a minimum of five years.\n\n## 3.3 A system of change control should be in place to inform staff of new and revised procedures. The system should ensure that:\n\n(a) revised documents are prepared by the initiator, or a person who performs the same function, reviewed and approved at the same level as the original document and subsequently released by the quality manager (quality unit); and\n\n(b) staff acknowledge by a signature that they are aware of applicable changes and their date of implementation.\n\n# 4. Records\n\n## 4.1 \n\nThe laboratory should establish and maintain procedures for the identification, collection, indexing, retrieval, storage, maintenance and disposal of and access to all quality and technical/scientific records.\n\n## 4.2 \n\nAll original observations, including calculations and derived data, calibration, validation and verification records and final results, should be retained on record for an appropriate period of time in accordance with national regulations and, if applicable, contractual arrangements, whichever is longer. The records should include the data recorded in the analytical worksheet by the technician or analyst.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece procedimientos y requisitos para la gesti\u00f3n de documentos y registros en laboratorios. Se enfatiza la importancia de tener identificadores \u00fanicos para cada documento, mantener los documentos actualizados, y asegurar que el personal est\u00e9 capacitado en los procedimientos operativos est\u00e1ndar (SOPs). Tambi\u00e9n se menciona la necesidad de un sistema de control de cambios para informar al personal sobre nuevas y revisadas SOPs, as\u00ed como la retenci\u00f3n de registros originales por un per\u00edodo adecuado, de acuerdo con las regulaciones nacionales.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 elementos deben incluirse en cada documento t\u00e9cnico o de calidad seg\u00fan las directrices de la OMS?**\n   - Respuesta: Cada documento debe tener un identificador \u00fanico, un n\u00famero de versi\u00f3n y una fecha de implementaci\u00f3n.\n\n2. **\u00bfCu\u00e1l es el per\u00edodo m\u00ednimo de retenci\u00f3n para la documentaci\u00f3n de calidad y registros seg\u00fan las recomendaciones de la OMS?**\n   - Respuesta: La documentaci\u00f3n de calidad, incluidos los registros, debe ser retenida por un m\u00ednimo de cinco a\u00f1os.\n\n3. **\u00bfQu\u00e9 pasos deben seguirse para asegurar que el personal est\u00e9 informado sobre los cambios en los procedimientos?**\n   - Respuesta: Se debe implementar un sistema de control de cambios que garantice que los documentos revisados sean preparados, revisados y aprobados adecuadamente, y que el personal firme para reconocer que est\u00e1 al tanto de los cambios y su fecha de implementaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Actividades del Laboratorio**: Se enumeran diversas actividades esenciales para el funcionamiento de un laboratorio, que incluyen:\n   - Adquisici\u00f3n y control de sustancias de referencia.\n   - Etiquetado interno, cuarentena y almacenamiento de materiales.\n   - Calibraci\u00f3n y mantenimiento de equipos.\n   - Muestreo y pruebas de muestras.\n   - Limpieza de instalaciones y monitoreo de condiciones ambientales.\n   - Gesti\u00f3n de resultados at\u00edpicos y validaci\u00f3n de procedimientos anal\u00edticos.\n   - Medidas de seguridad y disposici\u00f3n de reactivos.\n\n2. **Auditor\u00edas**: Se enfatiza la importancia de realizar auditor\u00edas internas y externas de manera sistem\u00e1tica y peri\u00f3dica para asegurar el cumplimiento del sistema de gesti\u00f3n de calidad. Estas auditor\u00edas deben ser realizadas por personal capacitado e independiente.\n\n3. **Revisi\u00f3n de la Gesti\u00f3n**: La direcci\u00f3n del laboratorio debe llevar a cabo revisiones regulares de los problemas de calidad, incluyendo informes de auditor\u00edas, resultados de investigaciones de quejas y acciones correctivas y preventivas.\n\n4. **Control de Documentaci\u00f3n**: La documentaci\u00f3n es considerada un componente esencial del sistema de gesti\u00f3n de calidad, y se requiere que el laboratorio establezca y mantenga procedimientos para su control.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Sistema de Gesti\u00f3n de Calidad**: Marco que gu\u00eda las operaciones del laboratorio.\n- **Auditores**: Personal encargado de realizar auditor\u00edas, que debe ser capacitado y calificado.\n- **Gerente de Calidad**: Responsable de planificar y organizar auditor\u00edas internas.\n- **Laboratorio**: Entidad que debe cumplir con los est\u00e1ndares y procedimientos establecidos.\n\nEste resumen destaca los aspectos fundamentales del sistema de gesti\u00f3n de calidad en laboratorios, as\u00ed como las responsabilidades y procedimientos necesarios para su implementaci\u00f3n efectiva.", "excerpt_keywords": "Keywords: document control, quality management, standard operating procedures, record retention, change control"}}, "64e8507f-6c5e-44e3-b471-1787c20fa03e": {"node_ids": ["596daecd-4cfa-4847-b797-395a404b5805"], "metadata": {"page_label": "110", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.3\n\nAll quality and technical/scientific records (including analytical test reports, certificates of analysis and analytical worksheets) should be legible, readily retrievable, stored and retained within facilities that provide a suitable environment that will prevent modification, damage or deterioration and/or loss. The conditions under which all original records are stored should be such as to ensure their security and confidentiality and access to them should be restricted to authorized personnel. Electronic storage and signatures may also be employed but with restricted access and in conformance with requirements for electronic records (12\u201316).\n\n# 4.4\n\nQuality management records should include reports from internal (and external if performed) audits and management reviews, as well as records of all complaints and their investigations, including records of possible corrective and preventive actions.\n\n# 5. Data-processing equipment\n\n## 5.1\n\nDetailed recommendations are provided in Appendix 5 to Annex 4 of the *Fortieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations*: Supplementary guidelines in good manufacturing practice: validation. Validation of computerized systems (12).\n\n## 5.2\n\nFor computers, automated tests or calibration equipment, and the collection, processing, recording, reporting, storage or retrieval of test and/or calibration data, the laboratory should ensure that:\n\n(a) computer software developed by the user is documented in sufficient detail and appropriately validated or verified as being suitable for use;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Almacenamiento y Seguridad de Registros**: Se enfatiza la importancia de que todos los registros de calidad y t\u00e9cnicos sean legibles, f\u00e1cilmente recuperables y almacenados en un entorno que prevenga su modificaci\u00f3n, da\u00f1o o p\u00e9rdida. Adem\u00e1s, se establece que el acceso a estos registros debe ser restringido a personal autorizado para garantizar su seguridad y confidencialidad.\n\n2. **Gesti\u00f3n de Calidad**: Los registros de gesti\u00f3n de calidad deben incluir auditor\u00edas internas y externas, revisiones de gesti\u00f3n, as\u00ed como registros de quejas y sus investigaciones, incluyendo acciones correctivas y preventivas.\n\n3. **Validaci\u00f3n de Sistemas Inform\u00e1ticos**: Se menciona la necesidad de validar o verificar el software desarrollado por el usuario para asegurar que sea adecuado para su uso en la recolecci\u00f3n y procesamiento de datos de pruebas y calibraciones.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 medidas se deben tomar para garantizar la seguridad y confidencialidad de los registros originales en un laboratorio?**\n   - Respuesta: Los registros originales deben ser almacenados en condiciones que aseguren su seguridad y confidencialidad, con acceso restringido a personal autorizado. Adem\u00e1s, se pueden emplear sistemas de almacenamiento electr\u00f3nico con acceso restringido y en conformidad con los requisitos para registros electr\u00f3nicos.\n\n2. **\u00bfQu\u00e9 tipo de registros deben incluirse en la gesti\u00f3n de calidad seg\u00fan el documento?**\n   - Respuesta: Los registros de gesti\u00f3n de calidad deben incluir informes de auditor\u00edas internas y externas, revisiones de gesti\u00f3n, as\u00ed como registros de todas las quejas y sus investigaciones, incluyendo posibles acciones correctivas y preventivas.\n\n3. **\u00bfCu\u00e1les son las recomendaciones para la validaci\u00f3n de software en el contexto de equipos de procesamiento de datos?**\n   - Respuesta: El laboratorio debe asegurarse de que el software desarrollado por el usuario est\u00e9 documentado en suficiente detalle y validado o verificado como adecuado para su uso en la recolecci\u00f3n, procesamiento, registro, reporte, almacenamiento o recuperaci\u00f3n de datos de pruebas y/o calibraciones.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Gesti\u00f3n de Documentos**:\n   - Cada documento debe tener un **identificador \u00fanico**, **n\u00famero de versi\u00f3n** y **fecha de implementaci\u00f3n**.\n   - Los **SOPs (Procedimientos Operativos Est\u00e1ndar)** autorizados deben estar disponibles en lugares relevantes, como cerca de los instrumentos.\n\n2. **Actualizaci\u00f3n y Revisi\u00f3n**:\n   - Los documentos deben mantenerse **actualizados** y revisarse seg\u00fan sea necesario.\n   - Los documentos inv\u00e1lidos deben ser **eliminados** y reemplazados de inmediato por versiones autorizadas y revisadas.\n\n3. **Control de Cambios**:\n   - Se debe establecer un **sistema de control de cambios** para informar al personal sobre nuevos y revisados procedimientos.\n   - Los documentos revisados deben ser preparados, revisados y aprobados adecuadamente, y el personal debe **firmar** para reconocer los cambios.\n\n4. **Retenci\u00f3n de Registros**:\n   - La documentaci\u00f3n de calidad y los registros deben ser **retenidos por un m\u00ednimo de cinco a\u00f1os**.\n   - Se deben establecer procedimientos para la **identificaci\u00f3n, colecci\u00f3n, almacenamiento y disposici\u00f3n** de registros t\u00e9cnicos y de calidad.\n\n5. **Registros Originales**:\n   - Todas las observaciones originales, incluidos c\u00e1lculos y datos derivados, deben ser **retenidos** por un per\u00edodo adecuado, conforme a las regulaciones nacionales y acuerdos contractuales.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices.\n- **SOPs**: Procedimientos Operativos Est\u00e1ndar que deben ser autorizados y disponibles.\n- **Documentos**: Incluyen documentos t\u00e9cnicos y de calidad que deben cumplir con requisitos espec\u00edficos.\n- **Registros**: Incluyen observaciones originales, datos de calibraci\u00f3n, validaci\u00f3n y verificaci\u00f3n que deben ser mantenidos adecuadamente. \n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de documentos y registros en laboratorios, asegurando la calidad y la trazabilidad de los procedimientos.", "excerpt_keywords": "Keywords: quality management, record retention, data processing, electronic storage, validation"}}, "cfb0a0d1-e0a5-4bc7-a363-9f29d2099f08": {"node_ids": ["bb8d9d44-d37e-499d-8309-8fbe64202b3d"], "metadata": {"page_label": "111", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\n(b) procedures are established and implemented for protecting the \n    integrity of data. Such procedures should include, but are not \n    limited to, measures to ensure the integrity and confidentiality \n    of data entry or collection and the storage, transmission and \n    processing of data. In particular, electronic data should be \n    protected from unauthorized access and an audit trail of any \n    amendments should be maintained;\n(c) computers and automated equipment are maintained so as to \n    function properly and are provided with the environmental and \n    operating conditions necessary to ensure the integrity of test and \n    calibration data;\n(d) procedures are established and implemented for making, \n    documenting and controlling changes to information stored in \n    computerized systems; and\n(e) electronic data should be backed up at appropriate regular intervals \n    according to a documented procedure. Backed-up data should be \n    retrievable and stored in such a manner as to prevent data loss.\n\nNote: For further guidance on validation of data-processing equipment, \nrefer to documents published by the International Society for \nPharmaceutical Engineering (13, 14), US Food and Drug Administration \n(15), European Commission (16) and the Official Medicines Control \nLaboratories Network of the Council of Europe (17).\n\n6. **Personnel**\n\n6.1 The laboratory should have sufficient personnel with the necessary \n    education, training, technical knowledge and experience for their \n    assigned functions.\n\n6.2 The technical management should ensure the competence of all \n    personnel operating specific equipment, instruments or other \n    devices, who are performing tests and/or calibrations, validations or \n    verifications. Their duties also involve the evaluation of results as \n    well as signing analytical test reports and certificates of analysis (see \n    Part three, sections 18.7\u201318.11 and 19).\n\n6.3 Staff undergoing training should be appropriately supervised \n    and should be assessed on completion of the training. Personnel \n    performing specific tasks should be appropriately qualified in terms \n    of their education, training and experience, as required.\n\n6.4 The laboratory personnel should be permanently employed or under \n    contract. The laboratory should ensure that additional technical and \n    key support personnel who are under contract are supervised and\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfQu\u00e9 medidas se deben implementar para proteger la integridad de los datos en un laboratorio?**\n   - Se deben establecer y aplicar procedimientos que incluyan medidas para garantizar la integridad y confidencialidad de la entrada o recolecci\u00f3n de datos, as\u00ed como su almacenamiento, transmisi\u00f3n y procesamiento. Esto incluye proteger los datos electr\u00f3nicos contra accesos no autorizados y mantener un registro de auditor\u00eda de cualquier enmienda.\n\n2. **\u00bfCu\u00e1l es la responsabilidad del personal t\u00e9cnico en relaci\u00f3n con el equipo y los dispositivos utilizados en el laboratorio?**\n   - La gesti\u00f3n t\u00e9cnica debe asegurar la competencia de todo el personal que opera equipos espec\u00edficos, instrumentos u otros dispositivos, as\u00ed como aquellos que realizan pruebas, calibraciones, validaciones o verificaciones. Esto incluye la evaluaci\u00f3n de resultados y la firma de informes anal\u00edticos y certificados de an\u00e1lisis.\n\n3. **\u00bfQu\u00e9 requisitos se establecen para el personal en formaci\u00f3n dentro del laboratorio?**\n   - El personal en formaci\u00f3n debe estar adecuadamente supervisado y ser evaluado al finalizar su capacitaci\u00f3n. Adem\u00e1s, el personal que realice tareas espec\u00edficas debe estar debidamente calificado en t\u00e9rminos de educaci\u00f3n, formaci\u00f3n y experiencia, seg\u00fan lo requerido.\n\n### Resumen de Nivel Superior\n\nEl contexto se centra en las directrices para la protecci\u00f3n de la integridad de los datos en laboratorios, destacando la importancia de establecer procedimientos adecuados para la gesti\u00f3n de datos electr\u00f3nicos y la competencia del personal. Se enfatiza la necesidad de mantener un entorno adecuado para el funcionamiento de equipos y la capacitaci\u00f3n del personal, asegurando que todos los empleados tengan la formaci\u00f3n y experiencia necesarias para realizar sus funciones de manera efectiva.\n\n### Preguntas Adicionales Basadas en el Resumen\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se sugiere para el respaldo de datos electr\u00f3nicos en un laboratorio?**\n   - Se sugiere que los datos electr\u00f3nicos sean respaldados a intervalos regulares de acuerdo con un procedimiento documentado, asegurando que los datos respaldados sean recuperables y almacenados de manera que se prevenga la p\u00e9rdida de datos.\n\n2. **\u00bfQu\u00e9 organismos se mencionan como fuentes de orientaci\u00f3n adicional sobre la validaci\u00f3n de equipos de procesamiento de datos?**\n   - Se mencionan documentos publicados por la International Society for Pharmaceutical Engineering, la US Food and Drug Administration, la Comisi\u00f3n Europea y la Red de Laboratorios de Control de Medicamentos Oficiales del Consejo de Europa como fuentes de orientaci\u00f3n adicional.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse para el personal adicional que trabaja en el laboratorio bajo contrato?**\n   - El laboratorio debe asegurarse de que el personal t\u00e9cnico adicional y el personal clave que trabaja bajo contrato est\u00e9n supervisados adecuadamente.", "prev_section_summary": "### Temas Clave:\n\n1. **Almacenamiento y Seguridad de Registros**:\n   - Importancia de que los registros de calidad y t\u00e9cnicos sean legibles y f\u00e1cilmente recuperables.\n   - Necesidad de un entorno adecuado para prevenir modificaci\u00f3n, da\u00f1o o p\u00e9rdida de registros.\n   - Acceso restringido a personal autorizado para garantizar la seguridad y confidencialidad de los registros.\n   - Posibilidad de utilizar almacenamiento electr\u00f3nico con acceso controlado.\n\n2. **Gesti\u00f3n de Calidad**:\n   - Inclusi\u00f3n de informes de auditor\u00edas internas y externas, revisiones de gesti\u00f3n.\n   - Registro de quejas y sus investigaciones, as\u00ed como acciones correctivas y preventivas.\n\n3. **Validaci\u00f3n de Sistemas Inform\u00e1ticos**:\n   - Recomendaciones para la validaci\u00f3n de software utilizado en la recolecci\u00f3n y procesamiento de datos.\n   - Documentaci\u00f3n y verificaci\u00f3n del software desarrollado por el usuario para asegurar su idoneidad.\n\n### Entidades:\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Registros de Calidad**: Documentos que incluyen informes de auditor\u00eda, quejas y acciones correctivas.\n- **Sistemas Inform\u00e1ticos**: Equipos y software utilizados para el procesamiento de datos en laboratorios.\n- **Personal Autorizado**: Individuos con acceso restringido a los registros para garantizar la seguridad y confidencialidad.\n\nEste resumen abarca los aspectos fundamentales de la secci\u00f3n, destacando la importancia de la gesti\u00f3n adecuada de registros y la validaci\u00f3n de sistemas en el contexto de la calidad y la seguridad en laboratorios.", "excerpt_keywords": "Keywords: data integrity, laboratory personnel, electronic data security, validation procedures, quality management"}}, "97a1e7a7-4ae5-4730-9071-3511c8b5f09c": {"node_ids": ["3d88ec92-cc22-4a57-bece-75e1a23bee9d"], "metadata": {"page_label": "112", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "sufficiently competent and that their work is in accordance with the quality management system.\n\n6.5 The laboratory should maintain current job descriptions for all personnel involved in tests and/or calibrations, validations and verifications. The laboratory should also maintain records of all technical personnel, describing their qualifications, training and experience.\n\n6.6 The laboratory should have the following managerial and technical personnel:\n\n(a) a head of laboratory (supervisor), who should have qualifications appropriate to the position, with extensive experience in medicines analysis and laboratory management in a pharmaceutical quality control laboratory in the regulatory sector or in industry. The head of laboratory is responsible for the content of certificates of analysis and analytical testing reports. This person is also responsible for ensuring that:\n   (i) all key members of the laboratory staff have the requisite competence for the required functions and their grades reflect their responsibilities,\n   (ii) the adequacy of existing staffing, management and training procedures is reviewed periodically,\n   (iii) the technical management is adequately supervised;\n\n(b) the technical management who ensure that:\n   (i) procedures for performing calibration, verification and (re-) qualification of instruments, monitoring of environmental and storage conditions are in place and are conducted as required,\n   (ii) regular in-service training programmes to update and extend the skills of both professionals and technicians are arranged,\n   (iii) the safekeeping of any materials subject to poison regulation or to the controls applied to narcotic and psychotropic substances (see Part one, section 7.12) kept in the workplace is under the supervision of an authorized person,\n   (iv) national pharmaceutical quality control laboratories regularly participate in suitable proficiency testing schemes and collaborative trials to assess analytical procedures or reference substances;\n\n(c) analysts, who should normally be graduates in pharmacy, analytical chemistry, microbiology or other relevant subjects,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl texto proviene del informe t\u00e9cnico de la OMS (Organizaci\u00f3n Mundial de la Salud) y se centra en los requisitos de personal y gesti\u00f3n en laboratorios de control de calidad farmac\u00e9utica. Se enfatiza la importancia de mantener descripciones de trabajo actualizadas, registros de personal t\u00e9cnico, y la necesidad de contar con un equipo de gesti\u00f3n y t\u00e9cnicos competentes. Se especifican las responsabilidades del jefe de laboratorio, la gesti\u00f3n t\u00e9cnica y los analistas, as\u00ed como la importancia de la capacitaci\u00f3n continua y la supervisi\u00f3n de materiales regulados.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas del jefe de laboratorio en un laboratorio de control de calidad farmac\u00e9utica seg\u00fan el informe?**\n   - Respuesta: El jefe de laboratorio es responsable del contenido de los certificados de an\u00e1lisis y los informes de pruebas anal\u00edticas, asegurando que todos los miembros clave del personal tengan la competencia necesaria, revisando peri\u00f3dicamente la adecuaci\u00f3n de los procedimientos de gesti\u00f3n y formaci\u00f3n, y supervisando adecuadamente la gesti\u00f3n t\u00e9cnica.\n\n2. **\u00bfQu\u00e9 tipo de formaci\u00f3n y experiencia se espera de los analistas que trabajan en un laboratorio de control de calidad farmac\u00e9utica?**\n   - Respuesta: Se espera que los analistas sean normalmente graduados en farmacia, qu\u00edmica anal\u00edtica, microbiolog\u00eda u otras disciplinas relevantes.\n\n3. **\u00bfQu\u00e9 procedimientos deben estar en su lugar para garantizar la seguridad de los materiales regulados en el laboratorio?**\n   - Respuesta: Deben existir procedimientos para la calibraci\u00f3n, verificaci\u00f3n y (re)calificaci\u00f3n de instrumentos, as\u00ed como para el monitoreo de condiciones ambientales y de almacenamiento. Adem\u00e1s, la supervisi\u00f3n de materiales sujetos a regulaciones de venenos o controles de sustancias narc\u00f3ticas y psicotr\u00f3picas debe estar a cargo de una persona autorizada.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Protecci\u00f3n de la Integridad de los Datos**:\n   - Se deben establecer procedimientos para garantizar la integridad y confidencialidad de la entrada, almacenamiento, transmisi\u00f3n y procesamiento de datos.\n   - Es esencial proteger los datos electr\u00f3nicos contra accesos no autorizados y mantener un registro de auditor\u00eda de enmiendas.\n   - Los datos electr\u00f3nicos deben ser respaldados regularmente y almacenados de manera que se evite la p\u00e9rdida de informaci\u00f3n.\n\n2. **Mantenimiento de Equipos**:\n   - Los ordenadores y equipos automatizados deben ser mantenidos adecuadamente para asegurar su correcto funcionamiento y las condiciones ambientales necesarias para la integridad de los datos de pruebas y calibraciones.\n\n3. **Gesti\u00f3n de Cambios en Sistemas Inform\u00e1ticos**:\n   - Se deben establecer procedimientos para documentar y controlar cambios en la informaci\u00f3n almacenada en sistemas computarizados.\n\n4. **Personal del Laboratorio**:\n   - El laboratorio debe contar con personal suficiente que posea la educaci\u00f3n, formaci\u00f3n, conocimientos t\u00e9cnicos y experiencia necesarios para sus funciones asignadas.\n   - La gesti\u00f3n t\u00e9cnica es responsable de asegurar la competencia del personal que opera equipos espec\u00edficos y realiza pruebas, calibraciones, validaciones o verificaciones.\n   - El personal en formaci\u00f3n debe ser supervisado y evaluado al finalizar su capacitaci\u00f3n, y debe estar debidamente calificado.\n\n5. **Contrataci\u00f3n y Supervisi\u00f3n de Personal**:\n   - El personal del laboratorio debe ser empleado permanente o estar bajo contrato, y se debe garantizar la supervisi\u00f3n adecuada del personal t\u00e9cnico adicional y del personal clave que trabaja bajo contrato.\n\n### Entidades Mencionadas:\n- **Organismos de Referencia**:\n  - International Society for Pharmaceutical Engineering\n  - US Food and Drug Administration\n  - Comisi\u00f3n Europea\n  - Red de Laboratorios de Control de Medicamentos Oficiales del Consejo de Europa\n\nEste resumen destaca la importancia de la gesti\u00f3n de datos y la competencia del personal en el contexto de laboratorios, enfatizando la necesidad de procedimientos claros y mantenimiento adecuado de equipos.", "excerpt_keywords": "Keywords: laboratory management, pharmaceutical quality control, personnel qualifications, analytical testing, training programs"}}, "3654c3ae-5954-40ec-b92f-fb40ab368bc8": {"node_ids": ["c8c82f0f-6e91-4f6b-aaa6-f49d4a3a0340"], "metadata": {"page_label": "113", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Premises\n\n7.1 The laboratory facilities are to be of a suitable size, construction and location. These facilities are to be designed to suit the functions and operations to be conducted in them. Rest and refreshment rooms should be separate from laboratory areas. Changing areas and toilets should be easily accessible and appropriate for the number of users.\n\n7.2 The laboratory facilities should have adequate safety equipment located appropriately and measures should be in place to ensure good housekeeping. Each laboratory should be equipped with adequate instruments and equipment, including work benches, work stations and fume hoods.\n\n7.3 The environmental conditions, including lighting, energy sources, temperature, humidity and air pressure, are to be appropriate to the functions and operations to be performed. The laboratory should ensure that the environmental conditions are monitored, controlled and documented and do not invalidate the results or adversely affect the quality of the measurements.\n\n7.4 Special precautions should be taken and, if necessary, there should be a separate and dedicated unit or equipment (e.g. isolator, laminar flow work bench) to handle, weigh and manipulate highly toxic substances, including genotoxic substances. Procedures should be in place to avoid exposure and contamination.\n\n7.5 Archive facilities should be provided to ensure the secure storage and retrieval of all documents. The design and condition of the archives should be such as to protect the contents from deterioration. Access to the archives should be restricted to designated personnel.\n\n7.6 Procedures should be in place for the safe removal of types of waste including toxic waste (chemical and biological), reagents, samples, solvents and air filters.\n\n7.7 Microbiological testing, if performed, should be contained in an appropriately designed and constructed laboratory unit. For further guidance see the draft working document *WHO guideline on good*", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices para las instalaciones de laboratorio, enfatizando la importancia de un dise\u00f1o adecuado, condiciones ambientales controladas, equipos de seguridad, manejo de sustancias t\u00f3xicas, y procedimientos para la gesti\u00f3n de residuos. Tambi\u00e9n se menciona la necesidad de instalaciones de archivo seguras y la contenci\u00f3n adecuada para pruebas microbiol\u00f3gicas.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 caracter\u00edsticas deben tener las instalaciones de archivo en un laboratorio seg\u00fan las directrices de la OMS?**\n   - Respuesta: Las instalaciones de archivo deben garantizar el almacenamiento y recuperaci\u00f3n seguros de todos los documentos, proteger el contenido de la deterioraci\u00f3n y restringir el acceso a personal designado.\n\n2. **\u00bfCu\u00e1les son las condiciones ambientales que deben ser monitoreadas y controladas en un laboratorio para asegurar la calidad de las mediciones?**\n   - Respuesta: Las condiciones ambientales incluyen iluminaci\u00f3n, fuentes de energ\u00eda, temperatura, humedad y presi\u00f3n del aire, y deben ser documentadas para no invalidar los resultados ni afectar negativamente la calidad de las mediciones.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse para el manejo de sustancias altamente t\u00f3xicas en un laboratorio?**\n   - Respuesta: Se deben tomar precauciones especiales, y si es necesario, contar con una unidad o equipo dedicado (como un aislador o banco de flujo laminar) para manejar, pesar y manipular estas sustancias, adem\u00e1s de establecer procedimientos para evitar la exposici\u00f3n y la contaminaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Requisitos de Personal en Laboratorios de Control de Calidad Farmac\u00e9utica**:\n   - Importancia de mantener descripciones de trabajo actualizadas para todo el personal involucrado en pruebas, calibraciones, validaciones y verificaciones.\n   - Necesidad de mantener registros de personal t\u00e9cnico que incluyan sus calificaciones, formaci\u00f3n y experiencia.\n\n2. **Estructura del Personal**:\n   - **Jefe de Laboratorio**:\n     - Debe tener calificaciones adecuadas y experiencia extensa en an\u00e1lisis de medicamentos y gesti\u00f3n de laboratorios.\n     - Responsable del contenido de certificados de an\u00e1lisis e informes de pruebas.\n     - Asegura la competencia del personal, revisa procedimientos de gesti\u00f3n y formaci\u00f3n, y supervisa la gesti\u00f3n t\u00e9cnica.\n   \n   - **Gesti\u00f3n T\u00e9cnica**:\n     - Encargada de asegurar que existan procedimientos para calibraci\u00f3n, verificaci\u00f3n y (re)calificaci\u00f3n de instrumentos.\n     - Organiza programas de formaci\u00f3n continua para actualizar habilidades del personal.\n     - Supervisa la seguridad de materiales regulados bajo la normativa de venenos y sustancias controladas.\n\n   - **Analistas**:\n     - Se espera que sean graduados en farmacia, qu\u00edmica anal\u00edtica, microbiolog\u00eda u otras disciplinas relevantes.\n\n3. **Capacitaci\u00f3n y Supervisi\u00f3n**:\n   - Importancia de la capacitaci\u00f3n continua y la participaci\u00f3n en esquemas de pruebas de competencia y ensayos colaborativos para evaluar procedimientos anal\u00edticos.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Emisora del informe.\n- **Laboratorio de Control de Calidad Farmac\u00e9utica**: Contexto del contenido.\n- **Personal T\u00e9cnico**: Incluye jefe de laboratorio, gesti\u00f3n t\u00e9cnica y analistas.\n- **Materiales Regulados**: Incluye sustancias controladas y venenos. \n\nEste resumen destaca la importancia de la competencia del personal y la gesti\u00f3n adecuada en laboratorios de control de calidad farmac\u00e9utica, as\u00ed como los procedimientos necesarios para garantizar la calidad y seguridad en el an\u00e1lisis de medicamentos.", "excerpt_keywords": "Keywords: laboratory facilities, safety equipment, environmental conditions, toxic substances, waste management"}}, "73a0fc13-f3c4-4c20-ab3e-30beb18cd2ef": {"node_ids": ["e49b0c5d-84e5-4509-af75-b4532eb9f34c"], "metadata": {"page_label": "114", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "practices for pharmaceutical microbiology laboratories (reference QAS/09.297).\n\n7.8 If in vivo biological testing (e.g. rabbit pyrogen test) is included in the scope of the laboratory activities then the animal houses should be isolated from the other laboratory areas with a separate entrance and air-conditioning system. The relevant guidance and regulations are to be applied (18).\n\n## Laboratory storage facilities\n\n7.9 The storage facilities should be well organized for the correct storage of samples, reagents and equipment.\n\n7.10 Separate storage facilities should be maintained for the secure storage of samples, retained samples (see Part three, section 20), reagents and laboratory accessories (see Part two, sections 10.13\u201310.14), reference substances and reference materials (see Part two, section 11). Storage facilities should be equipped to store material, if necessary, under refrigeration (2\u20138\u00b0C) and frozen (-20\u00b0C) and securely locked. All specified storage conditions should be controlled, monitored and records maintained. Access should be restricted to designated personnel.\n\n7.11 Appropriate safety procedures should be drawn up and rigorously implemented wherever toxic or flammable reagents are stored or used. The laboratory should provide separate rooms or areas for storing flammable substances, fuming and concentrated acids and bases, volatile amines and other reagents, such as hydrochloric acid, nitric acid, ammonia and bromine. Self-igniting materials, such as metallic sodium and potassium, should also be stored separately. Small stocks of acids, bases and solvents may be kept in the laboratory store but the main stocks of these items should preferably be retained in a store separate from the laboratory building.\n\n7.12 Reagents subject to poison regulations or to the controls applied to narcotic and psychotropic substances should be clearly marked as required by national legislation. They should be kept separately from other reagents in locked cabinets. A designated responsible member of staff should maintain a register of these substances. The head of each unit should accept personal responsibility for the safekeeping of any of these reagents kept in the workplace.\n\n7.13 Gases also should be stored in a dedicated store, if possible isolated from the main building. Wherever possible gas bottles in the laboratory are to be avoided and distribution from an external gas", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 957) establece directrices para laboratorios de microbiolog\u00eda farmac\u00e9utica, enfoc\u00e1ndose en la organizaci\u00f3n y almacenamiento de materiales, as\u00ed como en la seguridad en el manejo de sustancias qu\u00edmicas. Se menciona la necesidad de mantener instalaciones de almacenamiento separadas y bien organizadas para muestras, reactivos y equipos, as\u00ed como la implementaci\u00f3n de procedimientos de seguridad rigurosos para el manejo de sustancias t\u00f3xicas y inflamables. Tambi\u00e9n se abordan las regulaciones sobre el almacenamiento de sustancias controladas y la gesti\u00f3n de gases.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones de almacenamiento recomendadas para los reactivos que requieren refrigeraci\u00f3n y congelaci\u00f3n?**\n   - El documento especifica que los materiales deben almacenarse bajo refrigeraci\u00f3n (2\u20138\u00b0C) y congelaci\u00f3n (-20\u00b0C), y que las instalaciones de almacenamiento deben estar aseguradas y controladas.\n\n2. **\u00bfQu\u00e9 medidas de seguridad deben implementarse al almacenar sustancias t\u00f3xicas o inflamables en el laboratorio?**\n   - Se deben establecer procedimientos de seguridad apropiados y rigurosos, y proporcionar \u00e1reas separadas para el almacenamiento de sustancias inflamables, \u00e1cidos concentrados, bases, y otros reactivos peligrosos.\n\n3. **\u00bfC\u00f3mo se debe gestionar el almacenamiento de reactivos sujetos a regulaciones de venenos o sustancias controladas?**\n   - Estos reactivos deben estar claramente marcados seg\u00fan la legislaci\u00f3n nacional, almacenados en gabinetes cerrados y mantenidos bajo un registro por un miembro del personal designado, con el jefe de unidad asumiendo la responsabilidad de su seguridad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Instalaciones de Laboratorio**: \n   - Deben ser de tama\u00f1o, construcci\u00f3n y ubicaci\u00f3n adecuados.\n   - Deben incluir \u00e1reas separadas para descanso y refresco, as\u00ed como cambiadores y ba\u00f1os accesibles.\n\n2. **Equipamiento de Seguridad**: \n   - Se requiere equipo de seguridad adecuado y medidas de limpieza para mantener un entorno seguro.\n\n3. **Condiciones Ambientales**: \n   - Las condiciones como iluminaci\u00f3n, temperatura, humedad y presi\u00f3n del aire deben ser controladas y documentadas para asegurar la calidad de las mediciones.\n\n4. **Manejo de Sustancias T\u00f3xicas**: \n   - Se deben tomar precauciones especiales y, si es necesario, utilizar unidades o equipos dedicados para manejar sustancias altamente t\u00f3xicas y genot\u00f3xicas.\n\n5. **Instalaciones de Archivo**: \n   - Deben garantizar el almacenamiento seguro de documentos, protegerlos de la deterioraci\u00f3n y restringir el acceso a personal autorizado.\n\n6. **Gesti\u00f3n de Residuos**: \n   - Deben existir procedimientos para la eliminaci\u00f3n segura de residuos t\u00f3xicos, reactivos, muestras, disolventes y filtros de aire.\n\n7. **Pruebas Microbiol\u00f3gicas**: \n   - Si se realizan, deben llevarse a cabo en unidades de laboratorio dise\u00f1adas y construidas adecuadamente.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Laboratorio**: Entidad donde se realizan las pruebas y experimentos.\n- **Sustancias T\u00f3xicas**: Materiales que requieren manejo especial.\n- **Residuos**: Incluyen desechos qu\u00edmicos y biol\u00f3gicos que deben ser gestionados adecuadamente.\n- **Archivos**: Documentos que deben ser almacenados de manera segura. \n\nEste resumen destaca la importancia de un dise\u00f1o adecuado y la gesti\u00f3n segura en las instalaciones de laboratorio, as\u00ed como la protecci\u00f3n de la salud y la seguridad de los trabajadores.", "excerpt_keywords": "Keywords: pharmaceutical microbiology, laboratory storage, safety procedures, toxic substances, regulatory compliance"}}, "56269283-83de-4272-a4f8-86a886a5085e": {"node_ids": ["db3bb1ad-985e-4967-bc40-cd0883248267"], "metadata": {"page_label": "115", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Equipment, instruments and other devices\n\n8.1 Equipment, instruments and other devices should be designed, constructed, adapted, located, calibrated, qualified, verified and maintained as required by the operations to be carried out in the local environment. The user should purchase the equipment from an agent capable of providing full technical support and maintenance when necessary.\n\n8.2 The laboratory should have the required test equipment, instruments and other devices for the correct performance of the tests and/or calibrations, validations and verifications (including the preparation of samples and the processing and analysis of test and/or calibration data).\n\n8.3 Equipment, instruments and other devices, including those used for sampling, should meet the laboratory\u2019s requirements and comply with the relevant standard specifications, as well as being verified, qualified and/or calibrated regularly (see Part two, section 12).\n\n# Contracts\n\n## Purchasing services and supplies\n\n9.1 The laboratory should have a procedure for the selection and purchasing of services and supplies it uses that affect the quality of testing.\n\n9.2 The laboratory should evaluate suppliers of critical consumables, supplies and services which affect quality of testing, maintain records of these evaluations and list approved suppliers, which have been demonstrated to be of a suitable quality with respect to the requirements of the laboratory.\n\n## Subcontracting of testing\n\n9.3 When a laboratory subcontracts work, which may include specific testing, it is to be done with organizations approved for the type of activity required. The laboratory is responsible for periodically assessing the competence of a contracted organization.\n\n9.4 When a laboratory performs testing for a customer and subcontracts part of the testing, it should advise the customer of the arrangement in writing and, if appropriate, gain his or her approval.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia del dise\u00f1o, construcci\u00f3n, calibraci\u00f3n y mantenimiento de equipos e instrumentos en laboratorios, asegurando que cumplan con las especificaciones est\u00e1ndar y las necesidades del entorno local. Tambi\u00e9n se discuten procedimientos para la selecci\u00f3n y compra de servicios y suministros que afectan la calidad de las pruebas, as\u00ed como la evaluaci\u00f3n de proveedores y la subcontrataci\u00f3n de pruebas. Se enfatiza la responsabilidad del laboratorio en la evaluaci\u00f3n continua de la competencia de las organizaciones contratadas y la comunicaci\u00f3n con los clientes sobre cualquier subcontrataci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que un laboratorio debe considerar al seleccionar un proveedor de equipos e instrumentos?**\n   - Esta pregunta busca detalles sobre los criterios de evaluaci\u00f3n que no se mencionan expl\u00edcitamente en el texto, como la experiencia del proveedor, la calidad del servicio postventa, o la disponibilidad de piezas de repuesto.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse para la verificaci\u00f3n y calibraci\u00f3n de equipos en un laboratorio, y con qu\u00e9 frecuencia deben realizarse estas actividades?**\n   - Aunque se menciona que los equipos deben ser verificados y calibrados regularmente, la pregunta busca informaci\u00f3n m\u00e1s detallada sobre los procedimientos espec\u00edficos y las recomendaciones de frecuencia.\n\n3. **\u00bfQu\u00e9 pasos debe seguir un laboratorio para documentar y comunicar la subcontrataci\u00f3n de pruebas a sus clientes, y qu\u00e9 informaci\u00f3n espec\u00edfica debe incluirse en esta comunicaci\u00f3n?**\n   - Esta pregunta se centra en los detalles pr\u00e1cticos de la comunicaci\u00f3n con los clientes sobre la subcontrataci\u00f3n, que no se abordan en profundidad en el texto, como el formato de la comunicaci\u00f3n y los plazos para informar a los clientes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Pr\u00e1cticas de Laboratorio**: El documento establece directrices para laboratorios de microbiolog\u00eda farmac\u00e9utica, enfatizando la organizaci\u00f3n y el almacenamiento seguro de materiales.\n\n2. **Almacenamiento de Materiales**:\n   - **Condiciones de Almacenamiento**: Se requiere que las instalaciones de almacenamiento est\u00e9n bien organizadas y equipadas para mantener muestras, reactivos y equipos bajo condiciones espec\u00edficas (refrigeraci\u00f3n de 2\u20138\u00b0C y congelaci\u00f3n de -20\u00b0C).\n   - **Acceso Restringido**: El acceso a las instalaciones de almacenamiento debe ser limitado a personal designado.\n\n3. **Seguridad en el Manejo de Sustancias**:\n   - **Sustancias T\u00f3xicas e Inflamables**: Se deben implementar procedimientos de seguridad rigurosos y proporcionar \u00e1reas separadas para el almacenamiento de sustancias peligrosas, como \u00e1cidos concentrados y bases.\n   - **Almacenamiento de Reactivos Controlados**: Los reactivos sujetos a regulaciones de venenos deben estar claramente marcados, almacenados en gabinetes cerrados y registrados por un miembro del personal designado.\n\n4. **Almacenamiento de Gases**: Se recomienda que los gases se almacenen en un \u00e1rea dedicada, preferiblemente aislada del edificio principal, y se sugiere evitar el uso de botellas de gas en el laboratorio.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Laboratorios de Microbiolog\u00eda Farmac\u00e9utica**: Contexto espec\u00edfico de las pr\u00e1cticas descritas.\n- **Reactivos Qu\u00edmicos**: Incluyen sustancias t\u00f3xicas, inflamables y controladas.\n- **Condiciones de Almacenamiento**: Refrigeraci\u00f3n y congelaci\u00f3n espec\u00edficas para materiales.\n- **Personal Designado**: Responsables del manejo y almacenamiento seguro de sustancias.", "excerpt_keywords": "Keywords: equipment, laboratory, subcontracting, quality assurance, supplier evaluation"}}, "bddc182a-822b-4049-b6fc-423a9b19d707": {"node_ids": ["c2276905-97f3-4ee5-9cde-6965843e5016"], "metadata": {"page_label": "116", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9.5\nThere should be a written contract which clearly establishes the duties and responsibilities of each party, defines the contracted work and any technical arrangements made in connection with it. The contract should permit the laboratory to audit the facilities and competencies of the contracted organization and ensure the access of the laboratory to records and retained samples.\n\n# 9.6\nThe contracted organization should not pass to a third party any work entrusted to it under contract without the laboratory\u2019s prior evaluation and approval of the arrangements.\n\n# 9.7\nThe laboratory should maintain a register of all subcontractors that it uses and a record of the assessment of the competence of subcontractors.\n\n# 9.8\nThe laboratory takes the responsibility for all results reported, including those furnished by the subcontracting organization.\n\n# Part two. Materials, equipment, instruments and other devices\n\n## 10. Reagents\n\n### 10.1\nAll reagents and chemicals, including solvents and materials used in tests and assays, should be of appropriate quality.\n\n### 10.2\nReagents should be purchased from reputable, approved suppliers and should be accompanied by the certificate of analysis, and the material safety data sheet, if required.\n\n### 10.3\nIn the preparation of reagent solutions in the laboratory:\n\n- (a) responsibility for this task should be clearly specified in the job description of the person assigned to carry it out; and\n- (b) prescribed procedures should be used which are in accordance with published pharmacopoeial or other standards where available. Records should be kept of the preparation and standardization of volumetric solutions.\n\n### 10.4\nThe labels of all reagents should clearly specify:\n\n- (a) content;\n- (b) manufacturer;\n- (c) date received and date of opening of the container;\n- (d) concentration, if applicable;\n- (e) storage conditions; and\n- (f) expiry date or retest date, as justified.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Informe T\u00e9cnico 957) establece directrices sobre la gesti\u00f3n de contratos en laboratorios, enfatizando la importancia de tener contratos escritos que definan claramente las responsabilidades de las partes involucradas. Tambi\u00e9n se aborda la gesti\u00f3n de reactivos, destacando la necesidad de que sean de calidad adecuada, adquiridos de proveedores aprobados y etiquetados correctamente. Se subraya la responsabilidad del laboratorio en la supervisi\u00f3n de subcontratistas y en la validez de los resultados reportados.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 elementos deben incluirse en un contrato entre un laboratorio y una organizaci\u00f3n contratada seg\u00fan el documento?**\n   - El contrato debe establecer claramente las responsabilidades de cada parte, definir el trabajo contratado y cualquier arreglo t\u00e9cnico relacionado, permitir auditor\u00edas de las instalaciones y competencias de la organizaci\u00f3n contratada, y asegurar el acceso a registros y muestras retenidas.\n\n2. **\u00bfCu\u00e1les son los requisitos para la adquisici\u00f3n de reactivos en un laboratorio seg\u00fan las directrices?**\n   - Los reactivos deben ser de calidad apropiada, comprados a proveedores aprobados y deben estar acompa\u00f1ados de un certificado de an\u00e1lisis y, si es necesario, una hoja de datos de seguridad del material.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n debe contener la etiqueta de un reactivo en el laboratorio?**\n   - La etiqueta debe especificar el contenido, el fabricante, la fecha de recepci\u00f3n y de apertura del envase, la concentraci\u00f3n (si aplica), las condiciones de almacenamiento y la fecha de caducidad o de rean\u00e1lisis, seg\u00fan lo justificado.", "prev_section_summary": "### Temas Clave\n\n1. **Dise\u00f1o y Mantenimiento de Equipos**: Se enfatiza la importancia de que los equipos, instrumentos y dispositivos en laboratorios sean dise\u00f1ados, construidos, calibrados y mantenidos de acuerdo con las operaciones espec\u00edficas y el entorno local.\n\n2. **Selecci\u00f3n y Compra de Servicios y Suministros**: Los laboratorios deben tener procedimientos establecidos para la selecci\u00f3n y compra de servicios y suministros que impacten la calidad de las pruebas.\n\n3. **Evaluaci\u00f3n de Proveedores**: Es fundamental que los laboratorios eval\u00faen a los proveedores de consumibles y servicios cr\u00edticos, manteniendo registros de estas evaluaciones y listando a los proveedores aprobados.\n\n4. **Subcontrataci\u00f3n de Pruebas**: Cuando un laboratorio subcontrata pruebas, debe hacerlo con organizaciones aprobadas y es responsable de evaluar peri\u00f3dicamente la competencia de estas organizaciones. Adem\u00e1s, debe comunicar a los clientes sobre cualquier subcontrataci\u00f3n realizada.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Laboratorio**: Entidad responsable de realizar pruebas y mantener la calidad.\n- **Equipos e Instrumentos**: Herramientas necesarias para la realizaci\u00f3n de pruebas y an\u00e1lisis.\n- **Proveedores**: Entidades que suministran equipos, consumibles y servicios al laboratorio.\n- **Clientes**: Personas o entidades que solicitan pruebas y servicios del laboratorio. \n\nEste resumen destaca la importancia de la calidad y la responsabilidad en la gesti\u00f3n de equipos y servicios en el contexto de laboratorios, as\u00ed como la necesidad de una comunicaci\u00f3n clara con los clientes sobre la subcontrataci\u00f3n.", "excerpt_keywords": "Keywords: contract management, laboratory standards, reagents quality, subcontractor responsibility, supplier evaluation"}}, "56d740e3-04a8-4521-baaa-890ee7104d6e": {"node_ids": ["e939ea27-ef4f-4436-8fc4-59f96e333155"], "metadata": {"page_label": "117", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 10.5 \nThe labels of reagent solutions prepared in the laboratory should clearly specify:\n\n- (a) name;\n- (b) date of preparation and initials of technician or analyst;\n- (c) expiry date or retest date, as justified; and\n- (d) concentration, if applicable.\n\n## 10.6 \nThe labels for volumetric solutions prepared in the laboratory should clearly specify:\n\n- (a) name;\n- (b) molarity (or concentration);\n- (c) date of preparation and initials of technician/analyst;\n- (d) date of standardization and initials of technician/analyst; and\n- (e) standardization factor.\n\n*Note:* The laboratory should ensure that the volumetric solution is suitable for use at the time of use.\n\n## 10.7 \nIn the transportation and subdivision of reagents:\n\n- (a) whenever possible they should be transported in the original containers; and\n- (b) when subdivision is necessary, clean containers should be used and appropriately labelled.\n\n### Visual inspection\n\n## 10.8 \nAll reagent containers should be visually inspected to ensure that the seals are intact, both when they are delivered to the store and when they are distributed to the units.\n\n## 10.9 \nReagents that appear to have been tampered with should be rejected; however, this requirement may exceptionally be waived if the identity and purity of the reagent concerned can be confirmed by testing.\n\n### Water\n\n## 10.10 \nWater should be considered as a reagent. The appropriate grade for a specific test should be used as described in the pharmacopoeias or in an approved test when available.\n\n## 10.11 \nPrecautions should be taken to avoid contamination during its supply, storage and distribution.\n\n## 10.12 \nThe quality of the water should be verified regularly to ensure that the various grades of water meet the appropriate specifications.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl contexto se centra en las directrices para el etiquetado, transporte, inspecci\u00f3n y calidad de los reactivos y soluciones volum\u00e9tricas en un laboratorio, seg\u00fan el informe de la OMS. Se especifican los elementos que deben incluirse en las etiquetas de las soluciones, la importancia de la inspecci\u00f3n visual de los envases, y se considera el agua como un reactivo que debe cumplir con ciertas especificaciones de calidad. Tambi\u00e9n se enfatiza la necesidad de evitar la contaminaci\u00f3n y de verificar regularmente la calidad del agua utilizada en los procedimientos de laboratorio.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n espec\u00edfica debe incluirse en la etiqueta de una soluci\u00f3n volum\u00e9trica preparada en el laboratorio, y por qu\u00e9 es importante cada uno de estos elementos?**\n   - Esta pregunta busca respuestas detalladas sobre la importancia de cada elemento en la etiqueta, lo que no se puede encontrar f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfCu\u00e1les son las medidas que deben tomarse si se sospecha que un reactivo ha sido manipulado, y en qu\u00e9 circunstancias se puede hacer una excepci\u00f3n a esta regla?**\n   - Esta pregunta se centra en las acciones espec\u00edficas a seguir en caso de manipulaci\u00f3n de reactivos, lo que puede no estar claramente documentado en otras gu\u00edas.\n\n3. **\u00bfQu\u00e9 criterios se deben considerar para determinar la calidad del agua utilizada en un laboratorio, y c\u00f3mo se verifica que cumpla con las especificaciones adecuadas?**\n   - Esta pregunta busca informaci\u00f3n sobre los criterios espec\u00edficos y los m\u00e9todos de verificaci\u00f3n de la calidad del agua, que pueden no estar ampliamente disponibles en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Contratos en Laboratorios**:\n   - Importancia de tener un contrato escrito que defina claramente las responsabilidades de cada parte.\n   - El contrato debe incluir la posibilidad de auditor\u00edas por parte del laboratorio y acceso a registros y muestras.\n   - Prohibici\u00f3n de subcontratar trabajos sin la evaluaci\u00f3n y aprobaci\u00f3n previa del laboratorio.\n   - Registro de subcontratistas y evaluaci\u00f3n de su competencia son responsabilidades del laboratorio.\n   - El laboratorio es responsable de todos los resultados reportados, incluidos los de subcontratistas.\n\n2. **Gesti\u00f3n de Reactivos**:\n   - Los reactivos y qu\u00edmicos deben ser de calidad adecuada.\n   - Deben ser adquiridos de proveedores aprobados y acompa\u00f1ados de un certificado de an\u00e1lisis y, si es necesario, una hoja de datos de seguridad.\n   - Preparaci\u00f3n de soluciones de reactivos debe seguir procedimientos prescritos y estar documentada.\n   - Etiquetas de reactivos deben incluir informaci\u00f3n esencial como contenido, fabricante, fechas relevantes, concentraci\u00f3n, condiciones de almacenamiento y fechas de caducidad o rean\u00e1lisis.\n\n### Entidades Clave\n- **Laboratorio**: Entidad responsable de la supervisi\u00f3n y gesti\u00f3n de contratos y reactivos.\n- **Organizaci\u00f3n Contratada**: Entidad que realiza trabajos bajo contrato con el laboratorio.\n- **Subcontratistas**: Terceros que pueden ser utilizados por la organizaci\u00f3n contratada, cuya competencia debe ser evaluada por el laboratorio.\n- **Proveedores**: Entidades que suministran reactivos y qu\u00edmicos al laboratorio, deben ser aprobados y reputables. \n\nEste resumen destaca la importancia de la claridad contractual y la gesti\u00f3n adecuada de reactivos en el contexto de laboratorios, asegurando la calidad y responsabilidad en los resultados obtenidos.", "excerpt_keywords": "Keywords: reagent labeling, volumetric solutions, quality control, contamination prevention, water specifications"}}, "58b2620e-921c-46e6-ae2f-44e0b211b34e": {"node_ids": ["e75c4250-7160-4aba-9c04-ba54368de8df"], "metadata": {"page_label": "118", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Storage\n\n10.13 Stocks of reagents should be maintained in a store under the appropriate storage conditions (ambient temperature, under refrigeration or frozen). The store should contain a supply of clean bottles, vials, spoons, funnels and labels, as required, for dispensing reagents from larger to smaller containers. Special equipment may be needed for the transfer of larger volumes of corrosive liquids.\n\n10.14 The person in charge of the store is responsible for looking after the storage facilities and their inventory and for noting the expiry date of chemicals and reagents. Training may be needed in handling chemicals safely and with the necessary care.\n\n# 11. Reference substances and reference materials\n\n11.1 Reference substances (primary reference substances or secondary reference substances (8)) are used for the testing of a sample.\n\n*Note:* Pharmacopoeial reference substances should be employed when available and appropriate for the analysis. When a pharmacopoeia reference substance has not been established then the manufacturer should use its own reference substance.\n\n11.2 Reference materials may be necessary for the calibration and/or qualification of equipment, instruments or other devices.\n\n## Registration and labelling\n\n11.3 An identification number should be assigned to all reference substances, except for pharmacopoeial reference substances.\n\n11.4 A new identification number should be assigned to each new batch.\n\n11.5 This number should be marked on each vial of the reference substance.\n\n11.6 The identification number should be quoted on the analytical worksheet every time the reference substance is used (see Part three, section 15.5). In the case of pharmacopoeial reference substances the batch number and/or the batch validity statement should be attached to the worksheet.\n\n11.7 The register for all reference substances and reference materials should be maintained and contain the following information:\n\n- (a) the identification number of the substance or material;\n- (b) a precise description of the substance or material;\n- (c) the source;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia del almacenamiento adecuado de reactivos y la gesti\u00f3n de sustancias de referencia en laboratorios. Se enfatiza la necesidad de mantener los reactivos en condiciones de almacenamiento apropiadas y de contar con un inventario bien gestionado. Adem\u00e1s, se detalla la asignaci\u00f3n de n\u00fameros de identificaci\u00f3n a las sustancias de referencia, la necesidad de un registro que contenga informaci\u00f3n espec\u00edfica sobre estas sustancias y la importancia de utilizar sustancias de referencia farmacop\u00e9icas cuando est\u00e9n disponibles.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas de la persona encargada del almac\u00e9n de reactivos seg\u00fan el documento?**\n   - Esta pregunta busca obtener detalles sobre las funciones y obligaciones del responsable del almac\u00e9n, que pueden no estar claramente definidas en otros documentos.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en el registro de sustancias de referencia y materiales, y por qu\u00e9 es importante mantener este registro?**\n   - Esta pregunta se centra en la importancia de la documentaci\u00f3n y el seguimiento de las sustancias de referencia, lo cual es crucial para la calidad y la trazabilidad en los an\u00e1lisis.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse si no hay una sustancia de referencia farmacop\u00e9ica disponible para un an\u00e1lisis?**\n   - Esta pregunta busca aclarar el protocolo a seguir en situaciones espec\u00edficas donde no se dispone de sustancias de referencia est\u00e1ndar, lo que puede ser un aspecto cr\u00edtico en la pr\u00e1ctica de laboratorio.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Etiquetado de Reactivos y Soluciones Volum\u00e9tricas**:\n   - **Elementos Esenciales en Etiquetas**:\n     - Nombre del reactivo.\n     - Fecha de preparaci\u00f3n e iniciales del t\u00e9cnico o analista.\n     - Fecha de caducidad o fecha de rean\u00e1lisis, si es justificada.\n     - Concentraci\u00f3n (si aplica).\n     - Para soluciones volum\u00e9tricas: molaridad, fecha de estandarizaci\u00f3n, iniciales del t\u00e9cnico y factor de estandarizaci\u00f3n.\n\n2. **Transporte y Subdivisi\u00f3n de Reactivos**:\n   - Preferencia por el transporte en envases originales.\n   - Uso de envases limpios y etiquetados adecuadamente en caso de subdivisi\u00f3n.\n\n3. **Inspecci\u00f3n Visual**:\n   - Inspecci\u00f3n de contenedores de reactivos para asegurar que los sellos est\u00e9n intactos al recibir y distribuir.\n\n4. **Manejo de Reactivos Manipulados**:\n   - Rechazo de reactivos que parecen haber sido manipulados, con una excepci\u00f3n si se puede confirmar su identidad y pureza mediante pruebas.\n\n5. **Agua como Reactivo**:\n   - Consideraci\u00f3n del agua como un reactivo que debe cumplir con especificaciones de calidad.\n   - Verificaci\u00f3n regular de la calidad del agua utilizada en el laboratorio.\n\n6. **Prevenci\u00f3n de Contaminaci\u00f3n**:\n   - Precauciones necesarias para evitar la contaminaci\u00f3n durante el suministro, almacenamiento y distribuci\u00f3n de reactivos y agua.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Fuente del documento.\n- **Reactivos**: Sustancias qu\u00edmicas utilizadas en el laboratorio.\n- **Soluciones Volum\u00e9tricas**: Soluciones con una concentraci\u00f3n espec\u00edfica.\n- **T\u00e9cnico/Analista**: Personal responsable de la preparaci\u00f3n y manejo de reactivos.\n- **Contenedores**: Envases utilizados para el transporte y almacenamiento de reactivos.\n- **Agua**: Considerada un reactivo, con requisitos espec\u00edficos de calidad. \n\nEste resumen abarca los aspectos fundamentales de la secci\u00f3n, destacando la importancia del etiquetado, la inspecci\u00f3n, el manejo adecuado de reactivos y la calidad del agua en el contexto de un laboratorio.", "excerpt_keywords": "Keywords: storage, reagents, reference substances, identification number, laboratory management"}}, "3d7a2910-ee96-4a6d-b473-14026b054de6": {"node_ids": ["379f0b5c-ab93-47bb-a0a5-d1b94cd7baa2"], "metadata": {"page_label": "119", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\n(d) the date of receipt;\n(e) the batch designation or other identification code;\n(f) the intended use of the substance or material (e.g. as an infrared \n    reference substance or as an impurity reference substance for \n    thin-layer chromatography);\n(g) the location of storage in the laboratory, and any special storage \n    conditions;\n(h) any further necessary information (e.g. the results of visual \n    inspections);\n(i) expiry date or retest date;\n(j) certificate (batch validity statement) of a pharmacopoeial \n    reference substance and a certified reference material which \n    indicates its use, the assigned content, if applicable, and its \n    status (validity); and\n(k) in the case of secondary reference substances prepared and \n    supplied by the manufacturer, the certificate of analysis.\n\n11.8 A person should be nominated to be responsible for reference \n    substances and reference materials.\n\n11.9 If a national pharmaceutical quality control laboratory is required to \n    establish reference substances for use by other institutions, a separate \n    reference substances unit should be established.\n\n11.10 In addition a file should be kept in which all information on the \n     properties of each reference substance is entered including the safety \n     data sheets.\n\n11.11 For reference substances prepared in the laboratory, the file should \n     include the results of all tests and verifications used to establish the \n     reference substances and expiry date or retest date; these should be \n     signed by the responsible analyst.\n\nRetesting (monitoring)\n\n11.12 All reference substances prepared in the laboratory or supplied \n     externally should be retested at regular intervals to ensure that \n     deterioration has not occurred. The interval for retesting depends \n     on a number of factors, including stability of the substance, storage \n     conditions employed, type of container and extent of use (how often \n     the container is opened and closed). More detailed information on \n     the handling, storage and retesting of reference substances is given \n     in the WHO General guidelines for the establishment, maintenance \n     and distribution of chemical reference substances (8).\n\n11.13 The results of these tests should be recorded and signed by the \n     responsible analyst.\n```\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla las pautas para el manejo de sustancias de referencia y materiales de referencia en laboratorios farmac\u00e9uticos. Se especifican los requisitos para la documentaci\u00f3n, almacenamiento, y retesting de estas sustancias, as\u00ed como la designaci\u00f3n de un responsable para su gesti\u00f3n. Tambi\u00e9n se menciona la importancia de mantener un archivo con informaci\u00f3n sobre las propiedades de cada sustancia y la necesidad de realizar pruebas regulares para asegurar su calidad.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en el archivo de cada sustancia de referencia preparada en el laboratorio?**\n   - Respuesta: El archivo debe incluir los resultados de todas las pruebas y verificaciones utilizadas para establecer las sustancias de referencia, as\u00ed como la fecha de caducidad o la fecha de rean\u00e1lisis, y debe estar firmado por el analista responsable.\n\n2. **\u00bfCu\u00e1les son los factores que determinan el intervalo de rean\u00e1lisis para las sustancias de referencia?**\n   - Respuesta: El intervalo para el rean\u00e1lisis depende de varios factores, incluyendo la estabilidad de la sustancia, las condiciones de almacenamiento empleadas, el tipo de contenedor y la frecuencia con la que se abre y cierra el contenedor.\n\n3. **\u00bfQu\u00e9 se debe hacer si un laboratorio nacional de control de calidad farmac\u00e9utica necesita establecer sustancias de referencia para otras instituciones?**\n   - Respuesta: Se debe establecer una unidad separada de sustancias de referencia para gestionar esta tarea.", "prev_section_summary": "### Temas Clave\n\n1. **Almacenamiento de Reactivos**:\n   - Importancia de mantener los reactivos en condiciones adecuadas (temperatura ambiente, refrigeraci\u00f3n o congelaci\u00f3n).\n   - Necesidad de contar con suministros como botellas, viales, cucharas, embudos y etiquetas para el manejo de reactivos.\n   - Responsabilidad del encargado del almac\u00e9n en la gesti\u00f3n de las instalaciones y el inventario, as\u00ed como en el seguimiento de las fechas de caducidad de los reactivos.\n\n2. **Sustancias de Referencia y Materiales de Referencia**:\n   - Definici\u00f3n de sustancias de referencia (primarias y secundarias) y su uso en pruebas de muestras.\n   - Uso de sustancias de referencia farmacop\u00e9icas cuando est\u00e9n disponibles; en su ausencia, el fabricante debe utilizar su propia sustancia de referencia.\n   - Necesidad de materiales de referencia para la calibraci\u00f3n y/o cualificaci\u00f3n de equipos e instrumentos.\n\n3. **Registro y Etiquetado**:\n   - Asignaci\u00f3n de un n\u00famero de identificaci\u00f3n a todas las sustancias de referencia, excepto a las farmacop\u00e9icas.\n   - Protocolo para asignar un nuevo n\u00famero de identificaci\u00f3n a cada nuevo lote.\n   - Importancia de marcar el n\u00famero de identificaci\u00f3n en cada vial y de incluirlo en las hojas de trabajo anal\u00edticas.\n   - Mantenimiento de un registro que contenga informaci\u00f3n espec\u00edfica sobre las sustancias de referencia, incluyendo el n\u00famero de identificaci\u00f3n, descripci\u00f3n precisa y fuente.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Reactivos**: Sustancias qu\u00edmicas que requieren almacenamiento adecuado.\n- **Sustancias de Referencia**: Incluyen sustancias primarias y secundarias utilizadas en an\u00e1lisis.\n- **Materiales de Referencia**: Utilizados para calibraci\u00f3n y cualificaci\u00f3n de equipos.\n- **N\u00famero de Identificaci\u00f3n**: Sistema de etiquetado para sustancias de referencia.\n- **Registro**: Documento que mantiene informaci\u00f3n sobre sustancias de referencia y materiales.", "excerpt_keywords": "Keywords: referencia, sustancias, laboratorio, rean\u00e1lisis, almacenamiento"}}, "4aee77c7-852f-40e0-9422-085df9a919c1": {"node_ids": ["05714d7b-fdaa-4022-8540-8df07c765421"], "metadata": {"page_label": "120", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 11.14 \nIn the case that the result of retesting of a reference substance is non-compliant, a retrospective check of tests performed using this reference substance since its previous examination should be carried out. For evaluation of outcomes of retrospective checks and consideration of possible corrective actions, risk analysis should be applied.\n\n## 11.15 \nPharmacopoeial reference substances are regularly retested and the validity (current status) of these reference substances is available from the issuing pharmacopoeia by various means, e.g. web sites or catalogues. Retesting by the laboratory is not necessary, provided the reference substances are stored in accordance with the storage conditions indicated.\n\n## 12. Calibration, verification of performance and qualification of equipment, instruments and other devices\n\n### 12.1 \nEach item of equipment, instrument or other device used for testing, verification and/or calibration should, when practicable, be uniquely identified.\n\n### 12.2 \nAll equipment, instruments and other devices (e.g. volumetric glassware and automatic dispensers) requiring calibration should be labelled, coded or otherwise identified to indicate the status of calibration and the date when recalibration is due.\n\n### 12.3 \nLaboratory equipment should undergo design qualification, installation qualification, operation qualification and performance qualification (for definitions of these terms see the Glossary) (11). Depending on the function and operation of the instrument, the design qualification of a commercially available standard instrument may be omitted as the installation qualification, operational qualification and performance qualification may be considered to be a sufficient indicator of its suitable design.\n\n### 12.4 \nAs applicable, the performance of equipment should be verified at appropriate intervals according to a plan established by the laboratory.\n\n### 12.5 \nMeasuring equipment should be regularly calibrated according to a plan established by the laboratory (11).\n\n### 12.6 \nSpecific procedures should be established for each type of measuring equipment, taking into account the type of equipment, the extent of use and supplier\u2019s recommendations. For example:\n\n- pH meters are verified with standard certified buffer solutions before use;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen de Nivel Superior del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia de la gesti\u00f3n de sustancias de referencia y el mantenimiento de equipos en laboratorios. Se enfatiza la necesidad de realizar verificaciones y calibraciones regulares de los equipos utilizados en pruebas y an\u00e1lisis, as\u00ed como la identificaci\u00f3n \u00fanica de cada dispositivo. Tambi\u00e9n se menciona que las sustancias de referencia farmacop\u00e9icas son retestadas regularmente y que su validez puede ser consultada a trav\u00e9s de diversas fuentes. Adem\u00e1s, se establece que, en caso de resultados no conformes en las pruebas de sustancias de referencia, se debe realizar un an\u00e1lisis retrospectivo y aplicar un an\u00e1lisis de riesgo para determinar acciones correctivas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse si se obtiene un resultado no conforme al retestar una sustancia de referencia?**\n   - En caso de un resultado no conforme, se debe llevar a cabo una verificaci\u00f3n retrospectiva de las pruebas realizadas con esa sustancia desde su \u00faltima evaluaci\u00f3n. Adem\u00e1s, se debe aplicar un an\u00e1lisis de riesgo para evaluar los resultados de estas verificaciones y considerar posibles acciones correctivas.\n\n2. **\u00bfCu\u00e1les son los requisitos para la identificaci\u00f3n y el etiquetado de equipos de laboratorio que requieren calibraci\u00f3n?**\n   - Todos los equipos, instrumentos y dispositivos que requieran calibraci\u00f3n deben estar etiquetados, codificados o identificados de alguna manera que indique su estado de calibraci\u00f3n y la fecha en que se debe realizar la recalibraci\u00f3n.\n\n3. **\u00bfQu\u00e9 calificaciones deben obtener los equipos de laboratorio y en qu\u00e9 circunstancias se puede omitir la calificaci\u00f3n de dise\u00f1o?**\n   - Los equipos de laboratorio deben pasar por calificaciones de dise\u00f1o, instalaci\u00f3n, operaci\u00f3n y rendimiento. Sin embargo, la calificaci\u00f3n de dise\u00f1o puede omitirse para instrumentos est\u00e1ndar comercialmente disponibles si las calificaciones de instalaci\u00f3n, operaci\u00f3n y rendimiento son consideradas suficientes para indicar que el dise\u00f1o es adecuado.", "prev_section_summary": "### Temas Clave\n\n1. **Documentaci\u00f3n de Sustancias de Referencia**: Se requiere un archivo que contenga informaci\u00f3n detallada sobre cada sustancia de referencia, incluyendo la fecha de recepci\u00f3n, el c\u00f3digo de identificaci\u00f3n, el uso previsto, las condiciones de almacenamiento, la fecha de caducidad o rean\u00e1lisis, y certificados de validez.\n\n2. **Responsabilidad**: Se debe designar a una persona responsable de la gesti\u00f3n de las sustancias y materiales de referencia en el laboratorio.\n\n3. **Unidad de Sustancias de Referencia**: Si un laboratorio nacional de control de calidad farmac\u00e9utica necesita establecer sustancias de referencia para otras instituciones, debe crear una unidad separada para esta tarea.\n\n4. **Retesting (Rean\u00e1lisis)**: Las sustancias de referencia deben ser reanalizadas a intervalos regulares para asegurar que no haya deterioro. El intervalo de rean\u00e1lisis depende de factores como la estabilidad de la sustancia y las condiciones de almacenamiento.\n\n5. **Registro de Resultados**: Los resultados de las pruebas de rean\u00e1lisis deben ser registrados y firmados por el analista responsable.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las pautas.\n- **Sustancias de Referencia**: Materiales utilizados para asegurar la calidad en laboratorios.\n- **Laboratorio Nacional de Control de Calidad Farmac\u00e9utica**: Instituci\u00f3n que puede establecer sustancias de referencia.\n- **Analista Responsable**: Persona encargada de firmar los resultados de las pruebas y gestionar las sustancias de referencia.\n\n### Resumen\nEl documento de la OMS establece directrices para la gesti\u00f3n de sustancias de referencia en laboratorios farmac\u00e9uticos, enfatizando la importancia de la documentaci\u00f3n, la designaci\u00f3n de responsabilidades, la creaci\u00f3n de unidades espec\u00edficas para el manejo de estas sustancias, y la necesidad de realizar rean\u00e1lisis regulares para garantizar su calidad.", "excerpt_keywords": "Keywords: reference substances, calibration, laboratory equipment, risk analysis, pharmacopoeial standards"}}, "59a0564e-9341-477d-ae85-669ccfbec3ed": {"node_ids": ["39f0c614-6096-474c-aecc-717577a8ddee"], "metadata": {"page_label": "121", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 balances are to be checked daily using internal calibration and regularly using suitable test weights, and requalification should be performed annually using certified reference weights.\n\n12.7 Only authorized personnel should operate equipment, instruments and devices. Up-to-date SOPs on the use, maintenance, verification, qualification and calibration of equipment, instruments and devices (including any relevant manuals provided by the manufacturer) should be readily available for use by the appropriate laboratory personnel together with a schedule of the dates on which verification and/or calibration is due.\n\n12.8 Records should be kept of each item of equipment, instrument or other device used to perform testing, verification and/or calibration. The records should include at least the following:\n\n(a) the identity of the equipment, instrument or other device;\n(b) the manufacturer\u2019s name and the equipment model, serial number or other unique identification;\n(c) the qualification, verification and/or calibration required;\n(d) the current location, where appropriate;\n(e) the equipment manufacturer\u2019s instructions, if available, or an indication of their location;\n(f) the dates, results and copies of reports, verifications and certificates of all calibrations, adjustments, acceptance criteria and the due date of the next qualification, verification and/or calibration;\n(g) the maintenance carried out to date and the maintenance plan; and\n(h) a history of any damage, malfunction, modification or repair.\n\nIt is also recommended that records should be kept and additional observations made of the time for which the equipment, instruments or devices were used.\n\n12.9 Procedures should include instructions for the safe handling, transport and storage of measuring equipment. On reinstallation, requalification of the equipment is required to ensure that it functions properly.\n\n12.10 Maintenance procedures should be established, e.g. regular servicing should be performed by a team of maintenance specialists, whether internal or external, followed by verification of performance.\n\n12.11 Equipment, instruments and other devices, either subjected to overloading or mishandling, giving suspect results, shown to be defective or outside specified limits, should be taken out of service and clearly labelled or marked. Wherever possible they should not be used until they have been repaired and requalified.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 957) establece directrices sobre el manejo, calibraci\u00f3n y mantenimiento de equipos e instrumentos en laboratorios. Se enfatiza la importancia de que solo el personal autorizado opere estos dispositivos, la necesidad de mantener registros detallados de cada equipo, y la implementaci\u00f3n de procedimientos para el manejo seguro y la requalificaci\u00f3n de los equipos. Adem\u00e1s, se menciona que los equipos defectuosos deben ser retirados de servicio y etiquetados adecuadamente.\n\n### Preguntas Espec\u00edficas:\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en los registros de cada equipo, instrumento o dispositivo utilizado en el laboratorio?**\n   - La respuesta se puede encontrar en el apartado 12.8, que detalla los elementos que deben ser documentados, como la identidad del equipo, el nombre del fabricante, el modelo, el historial de mantenimiento, y m\u00e1s.\n\n2. **\u00bfCu\u00e1les son las recomendaciones para el manejo y almacenamiento seguro de los equipos de medici\u00f3n?**\n   - El apartado 12.9 menciona que deben incluirse instrucciones espec\u00edficas para el manejo, transporte y almacenamiento seguro de los equipos, as\u00ed como la necesidad de requalificaci\u00f3n tras la reinstalaci\u00f3n.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse si un equipo se sospecha que est\u00e1 defectuoso o ha sido sobrecargado?**\n   - Seg\u00fan el apartado 12.11, los equipos que presenten resultados sospechosos, que est\u00e9n defectuosos o que hayan sido sobrecargados deben ser retirados de servicio, etiquetados claramente y no deben ser utilizados hasta que sean reparados y requalificados.", "prev_section_summary": "### Temas Clave\n\n1. **Gesti\u00f3n de Sustancias de Referencia**:\n   - Importancia de realizar verificaciones retrospectivas en caso de resultados no conformes al retestar sustancias de referencia.\n   - Aplicaci\u00f3n de an\u00e1lisis de riesgo para evaluar resultados y considerar acciones correctivas.\n   - Las sustancias de referencia farmacop\u00e9icas son retestadas regularmente y su validez puede ser consultada a trav\u00e9s de diversas fuentes.\n\n2. **Calibraci\u00f3n y Verificaci\u00f3n de Equipos**:\n   - Necesidad de identificar de manera \u00fanica cada equipo, instrumento o dispositivo utilizado en pruebas y calibraciones.\n   - Etiquetado y codificaci\u00f3n de equipos que requieren calibraci\u00f3n para indicar su estado y fechas de recalibraci\u00f3n.\n   - Proceso de calificaci\u00f3n de equipos que incluye calificaciones de dise\u00f1o, instalaci\u00f3n, operaci\u00f3n y rendimiento, con la posibilidad de omitir la calificaci\u00f3n de dise\u00f1o para instrumentos est\u00e1ndar.\n\n3. **Procedimientos de Verificaci\u00f3n y Calibraci\u00f3n**:\n   - Verificaci\u00f3n del rendimiento de equipos a intervalos apropiados seg\u00fan un plan establecido por el laboratorio.\n   - Calibraci\u00f3n regular de equipos de medici\u00f3n seg\u00fan un plan espec\u00edfico.\n   - Establecimiento de procedimientos espec\u00edficos para cada tipo de equipo de medici\u00f3n, considerando recomendaciones del proveedor.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Emisora del documento.\n- **Sustancias de Referencia Farmacop\u00e9icas**: Sustancias que requieren retesting y validaci\u00f3n.\n- **Equipos de Laboratorio**: Incluyen instrumentos, dispositivos y vidrio volum\u00e9trico que requieren calibraci\u00f3n.\n- **An\u00e1lisis de Riesgo**: M\u00e9todo para evaluar resultados de pruebas no conformes.\n- **Calificaci\u00f3n de Equipos**: Proceso que incluye dise\u00f1o, instalaci\u00f3n, operaci\u00f3n y rendimiento. \n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de sustancias de referencia y el mantenimiento riguroso de los equipos en laboratorios para asegurar la calidad y precisi\u00f3n en los resultados de pruebas.", "excerpt_keywords": "Keywords: calibration, maintenance, laboratory equipment, verification, authorized personnel"}}, "e93918ca-7308-49dd-88ca-34844446536a": {"node_ids": ["b1b357e4-2337-45dc-bc56-eca4ff9b42be"], "metadata": {"page_label": "122", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 12.12\n\nWhen the equipment, instruments and other devices are outside the direct control of the laboratory for a certain period or have undergone major repair, the laboratory should requalify the equipment to ensure its suitability for use.\n\n*Note:* For further guidance on calibration, verification of performance and qualification of equipment refer to:\n\n- *Procedures for verifying and calibrating refractometers, thermometers used in determinations of melting temperatures and potentiometers for pH determinations and methods for verifying the reliability of scales for ultraviolet and infrared spectrophotometers and spectrofluorometers in The International Pharmacopoeia (19);*\n\n- *Specific guidelines for qualification of equipment elaborated by the European Network of Official Medicines Control Laboratories (OMCL) (20);* and\n\n- *General chapter of the US Pharmacopeia on Analytical instrument qualification (21).*\n\n# 13. Traceability\n\n## 13.1\n\nThe result of an analysis should be traceable, when appropriate, ultimately to a primary reference substance.\n\n## 13.2\n\nAll calibrations or qualification of instruments should be traceable to certified reference materials and to SI units (metrological traceability).\n\n# Part Three. Working procedures\n\n## 14. Incoming samples\n\nSections 14.1\u201314.3 are applicable to national pharmaceutical quality control laboratories.\n\n### 14.1\n\nSamples received by a laboratory may be for compliance testing or for investigative testing. Samples for compliance testing include routine samples for control, samples suspected of not complying with the specifications or samples submitted in connection with a marketing authorization process. Close collaboration with the providers of the samples is important. In particular it is important that the sample is large enough to enable, if required, a number of replicate tests to be carried out (see Part three, section 14.3) and for part of the sample to be retained (see Part three, section 20).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 957) aborda la importancia de la recalificaci\u00f3n de equipos en laboratorios, especialmente despu\u00e9s de que estos han estado fuera de control directo o han sido sometidos a reparaciones importantes. Tambi\u00e9n se enfatiza la necesidad de trazabilidad en los resultados de an\u00e1lisis, asegurando que las calibraciones y calificaciones de instrumentos est\u00e9n vinculadas a materiales de referencia certificados y a unidades del Sistema Internacional (SI). Adem\u00e1s, se discuten los procedimientos para el manejo de muestras entrantes en laboratorios de control de calidad farmac\u00e9utica.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para la recalificaci\u00f3n de equipos en un laboratorio despu\u00e9s de reparaciones importantes?**\n   - El laboratorio debe requalificar el equipo para asegurar su idoneidad para el uso, siguiendo las gu\u00edas espec\u00edficas mencionadas en el documento, como las de la Farmacopea Internacional y las elaboradas por la Red Europea de Laboratorios de Control de Medicamentos Oficiales (OMCL).\n\n2. **\u00bfCu\u00e1l es la importancia de la trazabilidad en los resultados de an\u00e1lisis en un laboratorio?**\n   - La trazabilidad es crucial porque asegura que los resultados de un an\u00e1lisis puedan ser rastreados hasta una sustancia de referencia primaria, lo que garantiza la fiabilidad y la precisi\u00f3n de los resultados obtenidos.\n\n3. **\u00bfQu\u00e9 tipo de muestras pueden recibir los laboratorios de control de calidad farmac\u00e9utica y cu\u00e1l es la importancia de la colaboraci\u00f3n con los proveedores de muestras?**\n   - Los laboratorios pueden recibir muestras para pruebas de cumplimiento o pruebas investigativas. Es importante que las muestras sean lo suficientemente grandes para permitir m\u00faltiples pruebas replicadas y para que parte de la muestra pueda ser retenida, lo que requiere una estrecha colaboraci\u00f3n con los proveedores de las muestras.", "prev_section_summary": "### Temas Clave:\n\n1. **Calibraci\u00f3n y Verificaci\u00f3n de Equipos**: Se establece la necesidad de realizar calibraciones diarias y anuales de los balances y otros equipos, utilizando pesos de referencia certificados.\n\n2. **Operaci\u00f3n por Personal Autorizado**: Solo el personal autorizado debe operar los equipos, y se deben tener disponibles procedimientos operativos est\u00e1ndar (SOP) actualizados sobre su uso y mantenimiento.\n\n3. **Registro de Equipos**: Es fundamental mantener registros detallados de cada equipo, que incluyan informaci\u00f3n como la identidad del equipo, el fabricante, el modelo, el historial de mantenimiento y los resultados de calibraciones.\n\n4. **Manejo Seguro de Equipos**: Se deben seguir procedimientos espec\u00edficos para el manejo, transporte y almacenamiento seguro de los equipos de medici\u00f3n, as\u00ed como la requalificaci\u00f3n tras su reinstalaci\u00f3n.\n\n5. **Mantenimiento Regular**: Se deben establecer procedimientos de mantenimiento, que incluyan servicios regulares realizados por especialistas, seguidos de verificaciones de rendimiento.\n\n6. **Retiro de Equipos Defectuosos**: Los equipos que presenten resultados sospechosos o que hayan sido sobrecargados deben ser retirados de servicio y etiquetados, y no deben ser utilizados hasta que sean reparados y requalificados.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Equipos e Instrumentos**: Dispositivos utilizados en laboratorios para pruebas y mediciones.\n- **Personal Autorizado**: Individuos capacitados para operar los equipos.\n- **SOP (Procedimientos Operativos Est\u00e1ndar)**: Documentos que gu\u00edan el uso y mantenimiento de los equipos.\n- **Pesos de Referencia Certificados**: Herramientas utilizadas para la calibraci\u00f3n de equipos.\n- **Registros de Mantenimiento**: Documentaci\u00f3n que detalla el historial y el estado de los equipos.\n\nEste resumen destaca la importancia de la calibraci\u00f3n, el mantenimiento y el manejo seguro de los equipos en entornos de laboratorio, as\u00ed como la necesidad de documentaci\u00f3n adecuada para garantizar la calidad y la seguridad en las operaciones.", "excerpt_keywords": "Keywords: recalibration, traceability, pharmaceutical quality control, reference materials, compliance testing"}}, "daf252ae-8dcb-4f1e-8f70-0bc0f711fcea": {"node_ids": ["9bda69c7-fe02-49ed-86f6-6188581aee6b"], "metadata": {"page_label": "123", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 14.2\n\nSamples for investigative testing may be submitted by various sources including customs, police and medicines inspectors. These samples comprise suspicious, illegal or counterfeit substances or products. Usually, the primary objective of investigative testing is to identify the substance or the ingredient in the product and, if sufficient substance or product is available, to estimate the purity or content. Well-documented screening procedures should be in place as well as confirmatory analytical procedures to positively identify the substance or the ingredient(s). If an estimation of the content of an identified ingredient is required then an appropriate quantitative analytical procedure should be applied. The value obtained should be reported with an indication of the uncertainty of measurement if required (see Part three, section 18.10).\n\n# 14.3\n\nIt is common for a sample to be taken and divided into three approximately equal portions for submission to the laboratory:\n\n- one for immediate testing;\n- the second for confirmation of testing if required; and\n- the third for retention in case of dispute.\n\n# 14.4\n\nIf the laboratory is responsible for sampling of substances, materials or products for subsequent testing then it should have a sampling plan and an internal procedure for sampling available to all analysts and technicians working in the laboratory. Samples should be representative of the batches of material from which they are taken and sampling should be carried out so as to avoid contamination and other adverse effects on quality, or mix-up of or by the material being sampled. All the relevant data related to sampling should be recorded.\n\n*Note:* Guidelines for sampling of pharmaceutical products and related materials were adopted by the WHO Expert Committee on Specifications for Pharmaceutical Preparations at its thirty-ninth meeting (22).\n\n## Test request\n\n# 14.5\n\nA standard test request form should be filled out and should accompany each sample submitted to the laboratory. In the case of a pharmaceutical manufacturer\u2019s laboratory the requirements may be given in the master production instructions.\n\n# 14.6\n\nThe test request form should provide or leave space for the following information:\n\n(a) the name of the institution or inspector that supplied the sample;\n(b) the source of the material;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1l es el objetivo principal de las pruebas de investigaci\u00f3n de muestras sospechosas?**\n   - El objetivo principal de las pruebas de investigaci\u00f3n es identificar la sustancia o el ingrediente en el producto y, si hay suficiente sustancia o producto disponible, estimar la pureza o contenido.\n\n2. **\u00bfQu\u00e9 procedimientos deben estar documentados en un laboratorio que realiza pruebas de investigaci\u00f3n?**\n   - Deben estar documentados procedimientos de cribado bien establecidos, as\u00ed como procedimientos anal\u00edticos confirmatorios para identificar positivamente la sustancia o los ingredientes. Adem\u00e1s, si se requiere una estimaci\u00f3n del contenido de un ingrediente identificado, se debe aplicar un procedimiento anal\u00edtico cuantitativo apropiado.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en el formulario de solicitud de prueba que acompa\u00f1a a cada muestra?**\n   - El formulario de solicitud de prueba debe incluir o dejar espacio para la siguiente informaci\u00f3n: (a) el nombre de la instituci\u00f3n o inspector que suministr\u00f3 la muestra; (b) la fuente del material.\n\n### Resumen de nivel superior del contexto:\n\nEl documento proporciona directrices sobre el manejo de muestras para pruebas de investigaci\u00f3n de sustancias sospechosas, ilegales o falsificadas. Se enfatiza la importancia de identificar correctamente las sustancias y estimar su pureza, as\u00ed como la necesidad de procedimientos de muestreo adecuados para evitar la contaminaci\u00f3n. Tambi\u00e9n se menciona la importancia de un formulario de solicitud de prueba que acompa\u00f1e a cada muestra, el cual debe contener informaci\u00f3n relevante sobre la fuente y el proveedor de la muestra.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Recalificaci\u00f3n de Equipos**:\n   - Es esencial que los laboratorios requalifiquen sus equipos, instrumentos y dispositivos despu\u00e9s de que hayan estado fuera de control directo o tras reparaciones importantes. Esto asegura que el equipo sea adecuado para su uso.\n\n2. **Trazabilidad**:\n   - Los resultados de los an\u00e1lisis deben ser trazables a una sustancia de referencia primaria. Adem\u00e1s, todas las calibraciones y calificaciones de instrumentos deben estar vinculadas a materiales de referencia certificados y a unidades del Sistema Internacional (SI), garantizando la trazabilidad metrol\u00f3gica.\n\n3. **Manejo de Muestras Entrantes**:\n   - Los laboratorios de control de calidad farmac\u00e9utica reciben muestras para pruebas de cumplimiento o investigativas. Es crucial que las muestras sean lo suficientemente grandes para permitir m\u00faltiples pruebas y que parte de la muestra pueda ser retenida. La colaboraci\u00f3n estrecha con los proveedores de muestras es fundamental para asegurar la calidad y cantidad adecuadas.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Farmacopea Internacional**: Proporciona gu\u00edas sobre la verificaci\u00f3n y calibraci\u00f3n de equipos.\n- **Red Europea de Laboratorios de Control de Medicamentos Oficiales (OMCL)**: Elabora directrices espec\u00edficas para la calificaci\u00f3n de equipos.\n- **Farmacopea de EE. UU.**: Incluye un cap\u00edtulo general sobre la calificaci\u00f3n de instrumentos anal\u00edticos.\n- **Muestras**: Pueden ser para pruebas de cumplimiento o investigativas, y su manejo adecuado es crucial para los resultados del laboratorio.", "excerpt_keywords": "Keywords: investigative testing, sample handling, analytical procedures, pharmaceutical guidelines, quality assurance"}}, "ab68a24b-16a3-46cc-9ca2-a5ee5da8488d": {"node_ids": ["8bb8ed41-36a2-41eb-a1d8-a21264385bc7"], "metadata": {"page_label": "124", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\n(c) a full description of the medicine, including its composition, \n    international nonproprietary name (INN) (if available) and \n    brand name(s);\n(d) dosage form and concentration or strength, the manufacturer, \n    the batch number (if available) and the marketing authorization \n    number;\n(e) the size of the sample;\n(f) the reason for requesting the analysis;\n(g) the date on which the sample was collected;\n(h) the size of the consignment from which it was taken, when \n    appropriate;\n(i) the expiry date (for pharmaceutical products) or retest date (for \n    APIs and pharmaceutical excipients);\n(j) the specification to be used for testing;\n(k) a record of any further comments (e.g. discrepancies found or \n    associated hazard); and\n(l) the required storage conditions.\n\n14.7 The laboratory should review the test request to ensure that:\n\n(a) the requirements are adequately defined and the laboratory has \n    the capability and resources to meet them; and\n(b) the appropriate tests and/or methods are selected and are capable \n    of meeting customers\u2019 requirements.\n\n    Any issue should be resolved with the originator of the request for \n    analysis before testing starts and a record of the review should be \n    kept.\n\n**Registration and labelling**\n\n14.8 All newly delivered samples and accompanying documents (e.g. \n    the test request) should be assigned a registration number. Separate \n    registration numbers should be assigned to requests referring to two \n    or more medicines, different dosage forms, or different batches of the \n    same medicine or different sources of the same batch. If applicable, a \n    unique registration number should also be assigned to any incoming \n    retained sample (see Part three, section 20).\n\n14.9 A label bearing the registration number should be affixed to each \n    container of the sample. Care should be taken to avoid obscuring any \n    other markings or inscriptions.\n\n14.10 A register should be kept, which may be a record book, a card file \n     or data-processing equipment, in which the following information is \n     recorded:\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los procedimientos y requisitos para la recolecci\u00f3n, an\u00e1lisis y registro de muestras de medicamentos. Se especifican los elementos que deben incluirse en la solicitud de an\u00e1lisis, como la descripci\u00f3n del medicamento, la forma de dosificaci\u00f3n, el tama\u00f1o de la muestra, y otros datos relevantes. Adem\u00e1s, se establece la importancia de asignar n\u00fameros de registro a las muestras y mantener un registro adecuado de la informaci\u00f3n relacionada.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la solicitud de an\u00e1lisis de una muestra de medicamento?**\n   - La solicitud debe incluir una descripci\u00f3n completa del medicamento, su nombre no propietario internacional (INN), forma de dosificaci\u00f3n, concentraci\u00f3n, fabricante, n\u00famero de lote, n\u00famero de autorizaci\u00f3n de comercializaci\u00f3n, tama\u00f1o de la muestra, raz\u00f3n de la solicitud, fecha de recolecci\u00f3n, tama\u00f1o del env\u00edo, fecha de caducidad o fecha de rean\u00e1lisis, especificaciones para las pruebas, comentarios adicionales y condiciones de almacenamiento requeridas.\n\n2. **\u00bfCu\u00e1l es el procedimiento que debe seguir un laboratorio al recibir una solicitud de an\u00e1lisis?**\n   - El laboratorio debe revisar la solicitud para asegurarse de que los requisitos est\u00e9n claramente definidos y que tenga la capacidad y recursos para cumplirlos. Tambi\u00e9n debe seleccionar las pruebas y/o m\u00e9todos apropiados que satisfagan las necesidades del cliente. Cualquier problema debe resolverse con el originador de la solicitud antes de comenzar las pruebas, y se debe mantener un registro de esta revisi\u00f3n.\n\n3. **\u00bfC\u00f3mo se debe manejar el registro y etiquetado de las muestras en el laboratorio?**\n   - Todas las muestras reci\u00e9n entregadas deben recibir un n\u00famero de registro \u00fanico, y se deben asignar n\u00fameros separados para solicitudes que se refieran a diferentes medicamentos, formas de dosificaci\u00f3n o lotes. Cada contenedor de muestra debe llevar una etiqueta con el n\u00famero de registro, asegur\u00e1ndose de no ocultar otras marcas. Adem\u00e1s, se debe mantener un registro que contenga informaci\u00f3n relevante sobre las muestras y solicitudes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Objetivo de las Pruebas de Investigaci\u00f3n**:\n   - Identificaci\u00f3n de sustancias o ingredientes en muestras sospechosas, ilegales o falsificadas.\n   - Estimaci\u00f3n de la pureza o contenido si hay suficiente material disponible.\n\n2. **Procedimientos de Muestreo**:\n   - Las muestras deben ser representativas y divididas en tres partes: una para pruebas inmediatas, otra para confirmaci\u00f3n y una tercera para retenci\u00f3n en caso de disputa.\n   - Se deben seguir procedimientos de muestreo para evitar contaminaci\u00f3n y asegurar la calidad.\n\n3. **Documentaci\u00f3n y Procedimientos**:\n   - Es necesario contar con procedimientos de cribado y anal\u00edticos bien documentados.\n   - Se debe tener un plan de muestreo y procedimientos internos accesibles para todos los analistas y t\u00e9cnicos del laboratorio.\n\n4. **Formulario de Solicitud de Prueba**:\n   - Cada muestra debe ir acompa\u00f1ada de un formulario de solicitud est\u00e1ndar que incluya informaci\u00f3n sobre la instituci\u00f3n o inspector que suministr\u00f3 la muestra y la fuente del material.\n\n5. **Entidades Involucradas**:\n   - Fuentes de muestras: aduanas, polic\u00eda, inspectores de medicamentos.\n   - Laboratorios responsables de la prueba y muestreo de sustancias.\n\n### Conclusi\u00f3n\nEl documento establece directrices claras para el manejo y an\u00e1lisis de muestras sospechosas, enfatizando la importancia de la identificaci\u00f3n precisa, la documentaci\u00f3n adecuada y los procedimientos de muestreo para garantizar la calidad y la integridad de los resultados de las pruebas.", "excerpt_keywords": "Keywords: medicine analysis, sample registration, laboratory procedures, test request, pharmaceutical documentation"}}, "6359a181-f012-407b-91bc-1e2b718caa89": {"node_ids": ["06e07bc0-f605-46e6-9194-798d83a4edc2"], "metadata": {"page_label": "125", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "(a) the registration number of the sample;  \n(b) the date of receipt; and  \n(c) the specific unit to which the sample was forwarded.  \n\n### Visual inspection of the submitted sample\n\n14.11 The sample received should be visually inspected by laboratory staff to ensure that the labelling conforms with the information contained in the test request. The findings should be recorded, dated and signed. If discrepancies are found, or if the sample is obviously damaged, this fact should be recorded without delay on the test request form. Any queries should be immediately referred back to the provider of the sample.\n\n### Storage\n\n14.12 The sample prior to testing, the retained sample (see Part three, section 20) and any portions of the sample remaining after performance of all the required tests should be stored safely, taking into account the storage conditions (22, 23) specified for the sample.\n\n### Forwarding to testing\n\n14.13 The specific unit to which the sample is sent for testing is determined by the person responsible.\n\n14.14 The examination of a sample should not be started before the relevant test request has been received.\n\n14.15 The sample should be properly stored until all relevant documentation has been received.\n\n14.16 A request for analysis may be accepted verbally only in emergencies. All details should immediately be placed on record pending the receipt of written confirmation.\n\n14.17 Unless a computerized system is used, copies or duplicates of all documentation should accompany each numbered sample when sent to the specific unit.\n\n14.18 Testing should be performed as described under Part three, section 17.\n\n## 15. Analytical worksheet\n\n15.1 The analytical worksheet is an internal document to be used by the analyst for recording information about the sample, the test procedure, calculations and the results of testing. It is to be complemented by the raw data obtained in the analysis.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento proporciona directrices sobre el manejo de muestras en un laboratorio, incluyendo la inspecci\u00f3n visual de las muestras recibidas, el almacenamiento adecuado, el env\u00edo a la unidad de pruebas y la documentaci\u00f3n necesaria. Se enfatiza la importancia de registrar cualquier discrepancia y de mantener la muestra en condiciones adecuadas hasta que se complete el an\u00e1lisis. Tambi\u00e9n se menciona la necesidad de un documento interno, conocido como \"hoja de trabajo anal\u00edtica\", para registrar informaci\u00f3n sobre el procedimiento de prueba y los resultados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse si se encuentra una discrepancia en la etiqueta de la muestra durante la inspecci\u00f3n visual?**\n   - La discrepancia debe ser registrada sin demora en el formulario de solicitud de prueba y cualquier consulta debe ser referida inmediatamente al proveedor de la muestra.\n\n2. **\u00bfQu\u00e9 condiciones de almacenamiento deben considerarse para las muestras antes de las pruebas?**\n   - Las muestras deben ser almacenadas de manera segura, teniendo en cuenta las condiciones de almacenamiento especificadas para cada tipo de muestra, as\u00ed como el almacenamiento de muestras retenidas y porciones restantes despu\u00e9s de las pruebas.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la hoja de trabajo anal\u00edtica utilizada por el analista?**\n   - La hoja de trabajo anal\u00edtica debe registrar informaci\u00f3n sobre la muestra, el procedimiento de prueba, los c\u00e1lculos realizados y los resultados obtenidos, complement\u00e1ndose con los datos en bruto obtenidos durante el an\u00e1lisis.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Descripci\u00f3n del Medicamento**: Se requiere una descripci\u00f3n completa que incluya la composici\u00f3n, el nombre no propietario internacional (INN), y los nombres de marca.\n\n2. **Informaci\u00f3n de la Muestra**:\n   - Forma de dosificaci\u00f3n y concentraci\u00f3n o fuerza.\n   - Fabricante y n\u00famero de lote (si est\u00e1 disponible).\n   - N\u00famero de autorizaci\u00f3n de comercializaci\u00f3n.\n   - Tama\u00f1o de la muestra y del env\u00edo.\n   - Fecha de recolecci\u00f3n y fechas de caducidad o rean\u00e1lisis.\n   - Especificaciones para las pruebas y condiciones de almacenamiento requeridas.\n\n3. **Revisi\u00f3n de Solicitudes de An\u00e1lisis**: \n   - El laboratorio debe asegurarse de que los requisitos est\u00e9n claramente definidos y que tenga la capacidad para cumplirlos.\n   - Selecci\u00f3n de pruebas y m\u00e9todos adecuados para satisfacer las necesidades del cliente.\n   - Resoluci\u00f3n de problemas con el originador de la solicitud antes de iniciar las pruebas.\n\n4. **Registro y Etiquetado**:\n   - Asignaci\u00f3n de un n\u00famero de registro \u00fanico a cada muestra y solicitud.\n   - Etiquetado de cada contenedor de muestra con el n\u00famero de registro, evitando ocultar otras marcas.\n   - Mantenimiento de un registro que contenga informaci\u00f3n relevante sobre las muestras y solicitudes.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Medicamento**: Producto farmac\u00e9utico que se analiza.\n- **Laboratorio**: Entidad responsable de realizar las pruebas y an\u00e1lisis.\n- **Registro**: Sistema para documentar y rastrear muestras y solicitudes. \n\nEste resumen abarca los procedimientos y requisitos esenciales para la recolecci\u00f3n, an\u00e1lisis y registro de muestras de medicamentos, asegurando la calidad y la trazabilidad en el proceso.", "excerpt_keywords": "Keywords: sample handling, visual inspection, storage conditions, analytical worksheet, test request"}}, "dc1de551-60e5-401e-80f3-a97c1c5a79f7": {"node_ids": ["23e03133-78b3-4e48-8ef5-b33b9cbc2737"], "metadata": {"page_label": "126", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Purpose\n\n15.2 The analytical worksheet contains documentary evidence either:\n\n- to confirm that the sample being examined is in accordance with the requirements; or\n- to support an OOS result (see Part three, sections 18.1\u201318.3).\n\n# Use\n\n15.3 A separate analytical worksheet should usually be used for each numbered sample or group of samples.\n\n15.4 Analytical worksheets from different units relating to the same sample should be assembled together.\n\n# Content\n\n15.5 The analytical worksheet should provide the following information:\n\n(a) the registration number of the sample (see Part three, section 14.9);\n\n(b) page numbering, including the total number of pages (and including annexes);\n\n(c) the date of the test request;\n\n(d) the date on which the analysis was started and completed;\n\n(e) the name and signature of the analyst;\n\n(f) a description of the sample received;\n\n(g) references to the specifications and a full description of test methods by which the sample was tested, including the limits;\n\n(h) the identification of the test equipment used (see Part two, section 12.1);\n\n(i) the identification number of any reference substance used (see Part two, section 11.5);\n\n(j) if applicable, the results of the system suitability test;\n\n(k) the identification of reagents and solvents employed;\n\n(l) the results obtained;\n\n(m) the interpretation of the results and the final conclusions (whether or not the sample was found to comply with the specifications), approved and signed by the supervisor; and\n\n(n) any further comments, for example, for internal information (see Part three, section 17.1), or detailed notes on the specifications selected and the methods of assessment used (see Part three, section 15.9), or any deviation from the prescribed procedure, which should be approved and reported, or whether and when portions of the sample were forwarded to other units for special tests and the date on which the results were received.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para la elaboraci\u00f3n de hojas de trabajo anal\u00edticas en el contexto de pruebas de muestras. Se especifica que estas hojas deben contener informaci\u00f3n clave sobre la muestra, el an\u00e1lisis realizado y los resultados obtenidos. Adem\u00e1s, se enfatiza la importancia de documentar adecuadamente cada paso del proceso anal\u00edtico para asegurar la trazabilidad y la conformidad con las especificaciones.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n espec\u00edfica debe incluirse en la hoja de trabajo anal\u00edtica para garantizar la trazabilidad del an\u00e1lisis de la muestra?**\n   - Respuesta: La hoja de trabajo anal\u00edtica debe incluir el n\u00famero de registro de la muestra, la numeraci\u00f3n de p\u00e1ginas, la fecha de solicitud de prueba, las fechas de inicio y finalizaci\u00f3n del an\u00e1lisis, el nombre y firma del analista, una descripci\u00f3n de la muestra, referencias a las especificaciones y m\u00e9todos de prueba, identificaci\u00f3n del equipo de prueba, resultados obtenidos, interpretaci\u00f3n de resultados y conclusiones firmadas por el supervisor, entre otros detalles.\n\n2. **\u00bfCu\u00e1l es el prop\u00f3sito de utilizar una hoja de trabajo anal\u00edtica en el contexto de pruebas de muestras?**\n   - Respuesta: El prop\u00f3sito de la hoja de trabajo anal\u00edtica es proporcionar evidencia documental que confirme que la muestra analizada cumple con los requisitos establecidos o, en su defecto, apoyar un resultado fuera de especificaci\u00f3n (OOS).\n\n3. **\u00bfQu\u00e9 se debe hacer con las hojas de trabajo anal\u00edticas de diferentes unidades que se relacionan con la misma muestra?**\n   - Respuesta: Las hojas de trabajo anal\u00edticas de diferentes unidades que se relacionan con la misma muestra deben ser ensambladas juntas para asegurar que toda la informaci\u00f3n relevante est\u00e9 disponible y organizada en un solo lugar.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manejo de Muestras en el Laboratorio**:\n   - Proceso de inspecci\u00f3n visual de las muestras recibidas.\n   - Importancia de la conformidad entre la etiqueta de la muestra y la informaci\u00f3n de la solicitud de prueba.\n\n2. **Registro de Discrepancias**:\n   - Procedimiento para registrar discrepancias o da\u00f1os en la muestra.\n   - Necesidad de referir consultas al proveedor de la muestra.\n\n3. **Almacenamiento de Muestras**:\n   - Requisitos para el almacenamiento seguro de muestras antes de las pruebas.\n   - Consideraciones para muestras retenidas y porciones restantes despu\u00e9s de las pruebas.\n\n4. **Env\u00edo a la Unidad de Pruebas**:\n   - Determinaci\u00f3n de la unidad espec\u00edfica a la que se env\u00eda la muestra.\n   - Prohibici\u00f3n de iniciar el examen de la muestra antes de recibir la solicitud de prueba correspondiente.\n   - Almacenamiento adecuado hasta recibir toda la documentaci\u00f3n relevante.\n\n5. **Documentaci\u00f3n y Registro**:\n   - Aceptaci\u00f3n de solicitudes de an\u00e1lisis verbal solo en emergencias, con registro inmediato de los detalles.\n   - Requerimiento de copias de documentaci\u00f3n que acompa\u00f1en a cada muestra numerada.\n\n6. **Hoja de Trabajo Anal\u00edtica**:\n   - Uso de un documento interno para registrar informaci\u00f3n sobre la muestra, el procedimiento de prueba, c\u00e1lculos y resultados.\n   - Complementaci\u00f3n con datos en bruto obtenidos durante el an\u00e1lisis.\n\n### Entidades Clave:\n- **Muestra**: Elemento a ser analizado en el laboratorio.\n- **Solicitud de Prueba**: Documento que acompa\u00f1a a la muestra y contiene informaci\u00f3n relevante.\n- **Unidad de Pruebas**: Lugar al que se env\u00eda la muestra para su an\u00e1lisis.\n- **Hoja de Trabajo Anal\u00edtica**: Documento interno utilizado por el analista para registrar informaci\u00f3n del an\u00e1lisis.", "excerpt_keywords": "Keywords: analytical worksheet, sample testing, documentary evidence, compliance, laboratory procedures"}}, "cc0e5b3a-ab53-4a5a-969e-ce685dd6ce35": {"node_ids": ["9b641b67-8a47-4665-a294-e5365972eed3"], "metadata": {"page_label": "127", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 15.6 \nAll values obtained from each test, including blank results, should immediately be entered on the analytical worksheet and all graphical data, whether obtained from recording instruments or plotted by hand, should be attached or be traceable to an electronic record file or document where the data are available.\n\n15.7 \nThe completed analytical worksheet should be signed by the responsible analyst(s), verified and approved and signed by the supervisor.\n\n15.8 \nWhen a mistake is made in an analytical worksheet or when data or text need to be amended, the old information should be deleted by putting a single line through it (it should not be erased or made illegible) and the new information added alongside. All such alterations should be signed by the person making the correction and the date of the change inserted. The reason for the change should also be given on the worksheet (suitable procedures should be in place for amending electronic worksheets).\n\n## Selection of the specifications to be used\n\n15.9 \nThe specification necessary to assess the sample may be that given in the test request or master production instructions. If no precise instruction is given, the specification in the officially recognized national pharmacopoeia may be used or, failing this, the manufacturer\u2019s officially approved or other nationally recognized specification. If no suitable method is available:\n\n- (a) the specification contained in the marketing authorization or product licence may be requested from the marketing authorization holder or manufacturer and verified by the laboratory; or\n- (b) the requirements may be set by the laboratory itself on the basis of published information and any procedure employed is to be validated by the testing laboratory (see Part three, section 16).\n\n15.10 \nFor official specifications the current version of the relevant pharmacopoeia should be available.\n\n## Filing\n\n15.11 \nThe analytical worksheet should be kept safely together with any attachments, including calculations and recordings of instrumental analyses.\n\n# 16. Validation of analytical procedures\n\n16.1 \nAll analytical procedures employed for testing should be suitable for the intended use. This is demonstrated by validation (24). Validation", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre la gesti\u00f3n de datos en hojas de trabajo anal\u00edticas, incluyendo la entrada de resultados, la firma y verificaci\u00f3n de documentos, la correcci\u00f3n de errores, la selecci\u00f3n de especificaciones para pruebas y la validaci\u00f3n de procedimientos anal\u00edticos. Se enfatiza la importancia de mantener registros precisos y accesibles, as\u00ed como de seguir procedimientos establecidos para la modificaci\u00f3n de datos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimiento se debe seguir si se comete un error en una hoja de trabajo anal\u00edtica?**\n   - Cuando se comete un error en una hoja de trabajo anal\u00edtica, el procedimiento correcto es tachar la informaci\u00f3n incorrecta con una l\u00ednea simple (sin borrarla o hacerla ilegible) y a\u00f1adir la nueva informaci\u00f3n al lado. Adem\u00e1s, la persona que realiza la correcci\u00f3n debe firmar y fechar el cambio, y proporcionar una raz\u00f3n para la modificaci\u00f3n.\n\n2. **\u00bfQu\u00e9 especificaciones se deben utilizar si no hay instrucciones precisas en la solicitud de prueba?**\n   - Si no hay instrucciones precisas en la solicitud de prueba, se puede utilizar la especificaci\u00f3n de la farmacopea nacional oficialmente reconocida. Si no est\u00e1 disponible, se puede solicitar la especificaci\u00f3n del titular de la autorizaci\u00f3n de comercializaci\u00f3n o establecer requisitos basados en informaci\u00f3n publicada, siempre que el procedimiento sea validado por el laboratorio de pruebas.\n\n3. **\u00bfQu\u00e9 se debe hacer con la hoja de trabajo anal\u00edtica y sus anexos una vez completados?**\n   - La hoja de trabajo anal\u00edtica debe ser guardada de manera segura junto con cualquier anexo, que incluya c\u00e1lculos y registros de an\u00e1lisis instrumentales, para asegurar que toda la informaci\u00f3n relevante est\u00e9 disponible y protegida.", "prev_section_summary": "### Temas Clave\n\n1. **Prop\u00f3sito de la Hoja de Trabajo Anal\u00edtica**: La hoja de trabajo anal\u00edtica sirve como evidencia documental para confirmar que una muestra cumple con los requisitos establecidos o para respaldar un resultado fuera de especificaci\u00f3n (OOS).\n\n2. **Uso de la Hoja de Trabajo**: Se recomienda utilizar una hoja de trabajo separada para cada muestra numerada o grupo de muestras. Adem\u00e1s, las hojas de trabajo de diferentes unidades relacionadas con la misma muestra deben ser organizadas juntas.\n\n3. **Contenido Requerido**: La hoja de trabajo anal\u00edtica debe incluir informaci\u00f3n detallada, como:\n   - N\u00famero de registro de la muestra.\n   - Numeraci\u00f3n de p\u00e1ginas y total de p\u00e1ginas.\n   - Fechas de solicitud y an\u00e1lisis.\n   - Nombre y firma del analista.\n   - Descripci\u00f3n de la muestra.\n   - Referencias a especificaciones y m\u00e9todos de prueba.\n   - Identificaci\u00f3n del equipo de prueba y sustancias de referencia.\n   - Resultados de pruebas y su interpretaci\u00f3n.\n   - Conclusiones firmadas por un supervisor.\n   - Comentarios adicionales relevantes.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable del documento.\n- **Muestra**: Elemento analizado cuyo cumplimiento con los requisitos se eval\u00faa.\n- **Analista**: Persona que realiza el an\u00e1lisis y firma la hoja de trabajo.\n- **Supervisor**: Persona que aprueba y firma las conclusiones de la hoja de trabajo.\n- **Especificaciones**: Normas y criterios que la muestra debe cumplir.\n- **Resultados**: Datos obtenidos del an\u00e1lisis que se interpretan para determinar la conformidad de la muestra.\n\nEste resumen destaca la importancia de la documentaci\u00f3n adecuada en el proceso anal\u00edtico y los elementos esenciales que deben ser registrados para asegurar la trazabilidad y la conformidad con los est\u00e1ndares establecidos.", "excerpt_keywords": "Keywords: analytical worksheet, validation, specifications, data management, corrections"}}, "d05834e0-82cd-4958-b0e8-bc40fe8d119d": {"node_ids": ["841333a0-eeea-4304-91a8-6f50cdf48e30"], "metadata": {"page_label": "128", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "16.2 Validation should be performed according to a validation protocol, which includes analytical performance characteristics to be verified for various types of analytical procedures. Typical characteristics which should be considered are listed in Table 1 (in the development phase of an analytical procedure, robustness, i.e. the ability of the procedure to provide results of acceptable accuracy and precision under a variety of conditions should also be considered). The results are to be documented in the validation report.\n\n**Table 1**  \nCharacteristics to consider during validation of analytical procedures\n\n| Type of analytical Procedure\\<br/>Quantitative tests | Identification\\<br/>Limit tests | Testing for impurities | Testing for impurities\\<br/>Assay | |\n| - | - | - | - | - |\n| Characteristics | | | | dissolution (measurement only) content/potency |\n| Accuracy | \u2013 | + | \u2013 | + |\n| Precision | | | | |\n| Repeatability | \u2013 | + | \u2013 | + |\n| Intermediate precisiona | \u2013 | + | \u2013 | + |\n| Specificity | + | + | + | + |\n| Detection limit | \u2013 | \u2013b | + | \u2013 |\n| Quantitation limit | \u2013 | + | \u2013 | \u2013 |\n| Linearity | \u2013 | + | \u2013 | + |\n| Range | \u2013 | + | \u2013 | + |\n\n\n\u2013 Characteristic is normally not evaluated; + characteristic should normally be evaluated.  \n<sup>a</sup> In cases where a reproducibility study has been performed, intermediate precision is not needed.  \n<sup>b</sup> May be needed in some cases.\n\n16.3 Pharmacopoeial methods are considered to be validated for the intended use as prescribed in the monograph(s). However, the laboratory should also confirm that, for example, for a particular finished pharmaceutical product (FPP) examined for the first time, no interference arises from the excipients present, or that for an API, impurities coming from a new route of synthesis are adequately differentiated. If the pharmacopoeial method is adapted for another use then it should be validated for such a use to demonstrate that it is fit-for-purpose.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la validaci\u00f3n de procedimientos anal\u00edticos en el contexto de la farmacolog\u00eda. Se enfatiza la importancia de seguir un protocolo de validaci\u00f3n que incluya caracter\u00edsticas de rendimiento anal\u00edtico, como precisi\u00f3n, exactitud y especificidad. Se presenta una tabla que detalla las caracter\u00edsticas a considerar durante la validaci\u00f3n de diferentes tipos de procedimientos anal\u00edticos. Adem\u00e1s, se menciona que los m\u00e9todos farmacop\u00e9icos son considerados validados para su uso previsto, pero es necesario confirmar su aplicabilidad en situaciones espec\u00edficas, como la evaluaci\u00f3n de productos farmac\u00e9uticos terminados o la adaptaci\u00f3n de m\u00e9todos para nuevos usos.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas anal\u00edticas que deben ser evaluadas durante la validaci\u00f3n de procedimientos anal\u00edticos seg\u00fan la tabla presentada en el documento?**\n   - Respuesta: La tabla enumera caracter\u00edsticas como precisi\u00f3n, exactitud, especificidad, l\u00edmite de detecci\u00f3n, l\u00edmite de cuantificaci\u00f3n, linealidad y rango, indicando cu\u00e1les deben ser evaluadas para diferentes tipos de procedimientos anal\u00edticos.\n\n2. **\u00bfQu\u00e9 se debe hacer si un m\u00e9todo farmacop\u00e9ico se adapta para un uso diferente al que fue originalmente validado?**\n   - Respuesta: Si un m\u00e9todo farmacop\u00e9ico se adapta para otro uso, debe ser validado para ese nuevo uso para demostrar que es adecuado para el prop\u00f3sito previsto.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al validar un m\u00e9todo para un producto farmac\u00e9utico terminado (FPP) por primera vez?**\n   - Respuesta: El laboratorio debe confirmar que no hay interferencias de los excipientes presentes en el FPP examinado por primera vez, y que las impurezas provenientes de una nueva ruta de s\u00edntesis para un principio activo (API) est\u00e1n adecuadamente diferenciadas.", "prev_section_summary": "### Temas Clave\n\n1. **Registro de Datos**: Se enfatiza la importancia de ingresar inmediatamente todos los resultados de las pruebas en la hoja de trabajo anal\u00edtica, incluyendo datos gr\u00e1ficos que deben ser adjuntados o ser rastreables a un archivo electr\u00f3nico.\n\n2. **Firma y Verificaci\u00f3n**: La hoja de trabajo anal\u00edtica completada debe ser firmada por el analista responsable y verificada y aprobada por un supervisor.\n\n3. **Correcci\u00f3n de Errores**: Se establece un procedimiento espec\u00edfico para corregir errores en la hoja de trabajo, que incluye tachar la informaci\u00f3n incorrecta y a\u00f1adir la nueva informaci\u00f3n, junto con la firma y fecha del responsable de la correcci\u00f3n.\n\n4. **Selecci\u00f3n de Especificaciones**: Se detalla c\u00f3mo seleccionar las especificaciones necesarias para evaluar una muestra, incluyendo el uso de farmacopeas nacionales reconocidas o especificaciones aprobadas por el fabricante.\n\n5. **Archivo de Documentos**: Se requiere que la hoja de trabajo anal\u00edtica y sus anexos se mantengan de manera segura para asegurar la disponibilidad y protecci\u00f3n de la informaci\u00f3n.\n\n6. **Validaci\u00f3n de Procedimientos Anal\u00edticos**: Se menciona que todos los procedimientos anal\u00edticos deben ser adecuados para su uso previsto y deben ser validados.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Analista(s)**: Persona(s) responsable(s) de realizar las pruebas y completar la hoja de trabajo.\n- **Supervisor**: Persona que verifica y aprueba la hoja de trabajo anal\u00edtica.\n- **Farmacopea Nacional**: Documento oficial que contiene especificaciones para pruebas.\n- **Titular de la Autorizaci\u00f3n de Comercializaci\u00f3n**: Entidad que puede proporcionar especificaciones cuando no hay instrucciones precisas.\n- **Laboratorio de Pruebas**: Entidad responsable de validar los procedimientos anal\u00edticos.\n\n### Resumen\nEl documento de la OMS proporciona directrices sobre la gesti\u00f3n de datos en hojas de trabajo anal\u00edticas, incluyendo la entrada de resultados, la firma y verificaci\u00f3n de documentos, la correcci\u00f3n de errores, la selecci\u00f3n de especificaciones para pruebas y la validaci\u00f3n de procedimientos anal\u00edticos. Se destaca la necesidad de mantener registros precisos y accesibles, as\u00ed como seguir procedimientos establecidos para la modificaci\u00f3n de datos.", "excerpt_keywords": "Keywords: validation, analytical procedures, pharmacopoeial methods, performance characteristics, pharmaceutical products"}}, "a68bef5b-0b3d-4d4b-a151-250189beec81": {"node_ids": ["c67d8fe6-8c9d-47fb-91a6-11015fb7b6a0"], "metadata": {"page_label": "129", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 16.4\n\nSystem suitability testing is an integral part of many analytical procedures. The tests are based on the fact that the equipment, electronics, analytical operations and samples to be analysed contribute to the system. Which system suitability tests are to be applied depends on the type of procedure to be used. System suitability tests are employed for the verification of pharmacopoeial methods or validated analytical procedures and should be performed prior to the analysis. Provided the system suitability criteria are fulfilled the method or procedure is considered to be suitable for the intended purpose.\n\n*Note:* If a large number of samples is being analysed in sequence, then appropriate system suitability tests are to be performed throughout the sequence to demonstrate that the performance of the procedure is satisfactory.\n\nVerification is not required for basic pharmacopoeial methods such as (but not limited to) pH, loss on drying and wet chemical methods.\n\n## 16.5\n\nA major change to the analytical procedure, or in the composition of the product tested, or in the synthesis of the API, will require revalidation of the analytical procedure.\n\n*Note:* Further guidance on validation of analytical procedures is available in the following:\n\n- *Guideline elaborated by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (25);*\n- *Guideline elaborated by the European Network of Official Medicines Control Laboratories (OMCL) (26);*\n- *General chapters of the US Pharmacopeia on Validation of compendial procedures and on Verification of compendial procedures (27).*\n\n# 17. Testing\n\n## 17.1\n\nThe sample should be tested in accordance with the work plan of the laboratory after completion of the preliminary procedures. If this is not feasible the reasons should be noted, e.g. in the analytical worksheet (see Part three, section 15), and the sample should be stored in a special place which is kept locked (see Part three, section 14.12).\n\n## 17.2\n\nSpecific tests required may need to be carried out by another unit or by a specialized external laboratory (see Part one, section 9). The responsible person should prepare the request and arrange for the", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto aborda la importancia de las pruebas de idoneidad del sistema en procedimientos anal\u00edticos, destacando que estas pruebas son esenciales para verificar m\u00e9todos farmacopoeiales y procedimientos anal\u00edticos validados. Se menciona que las pruebas deben realizarse antes del an\u00e1lisis y que, si se analizan muchos muestras en secuencia, se deben realizar pruebas de idoneidad a lo largo de la secuencia. Adem\u00e1s, se indica que cualquier cambio significativo en el procedimiento anal\u00edtico o en la composici\u00f3n del producto requiere una revalidaci\u00f3n. Tambi\u00e9n se menciona que las muestras deben ser probadas de acuerdo con el plan de trabajo del laboratorio y que algunas pruebas espec\u00edficas pueden requerir la intervenci\u00f3n de laboratorios externos.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 criterios deben cumplirse para considerar que un m\u00e9todo anal\u00edtico es adecuado para su prop\u00f3sito?**\n   - La respuesta se puede encontrar en la secci\u00f3n sobre pruebas de idoneidad del sistema, donde se menciona que si se cumplen los criterios de idoneidad del sistema, el m\u00e9todo o procedimiento se considera adecuado para el prop\u00f3sito previsto.\n\n2. **\u00bfCu\u00e1les son las implicaciones de un cambio mayor en el procedimiento anal\u00edtico o en la composici\u00f3n del producto en t\u00e9rminos de validaci\u00f3n?**\n   - El texto indica que un cambio significativo en el procedimiento anal\u00edtico, la composici\u00f3n del producto o la s\u00edntesis del API requiere una revalidaci\u00f3n del procedimiento anal\u00edtico.\n\n3. **\u00bfQu\u00e9 pasos deben seguirse si no es factible probar una muestra de acuerdo con el plan de trabajo del laboratorio?**\n   - Si no es factible probar la muestra, se deben anotar las razones en la hoja de trabajo anal\u00edtica y la muestra debe ser almacenada en un lugar especial que est\u00e9 cerrado con llave.", "prev_section_summary": "### Temas Clave\n1. **Validaci\u00f3n de Procedimientos Anal\u00edticos**: Se establece la necesidad de seguir un protocolo de validaci\u00f3n que incluya caracter\u00edsticas de rendimiento anal\u00edtico para diferentes tipos de procedimientos anal\u00edticos.\n  \n2. **Caracter\u00edsticas Anal\u00edticas**: Se enumeran caracter\u00edsticas importantes a considerar durante la validaci\u00f3n, como precisi\u00f3n, exactitud, especificidad, l\u00edmite de detecci\u00f3n, l\u00edmite de cuantificaci\u00f3n, linealidad y rango.\n\n3. **M\u00e9todos Farmacop\u00e9icos**: Se considera que estos m\u00e9todos est\u00e1n validados para su uso previsto, pero se requiere confirmaci\u00f3n adicional para situaciones espec\u00edficas, como la evaluaci\u00f3n de productos farmac\u00e9uticos terminados o la adaptaci\u00f3n de m\u00e9todos para nuevos usos.\n\n4. **Interferencia de Excipientes**: Es crucial verificar que no haya interferencias de excipientes en productos farmac\u00e9uticos examinados por primera vez.\n\n5. **Diferenciaci\u00f3n de Impurezas**: Se debe asegurar que las impurezas de nuevas rutas de s\u00edntesis sean adecuadamente diferenciadas.\n\n### Entidades\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Procedimientos Anal\u00edticos**: M\u00e9todos utilizados para analizar productos farmac\u00e9uticos.\n- **Caracter\u00edsticas Anal\u00edticas**: Par\u00e1metros como precisi\u00f3n, exactitud, especificidad, etc.\n- **M\u00e9todos Farmacop\u00e9icos**: M\u00e9todos estandarizados para el an\u00e1lisis de productos farmac\u00e9uticos.\n- **Producto Farmac\u00e9utico Terminado (FPP)**: Producto final que se eval\u00faa por primera vez.\n- **Principio Activo (API)**: Sustancia activa en un producto farmac\u00e9utico que puede tener impurezas. \n\nEste resumen destaca la importancia de la validaci\u00f3n en el contexto anal\u00edtico y las consideraciones espec\u00edficas que deben tenerse en cuenta para asegurar la calidad y la eficacia de los m\u00e9todos utilizados en la industria farmac\u00e9utica.", "excerpt_keywords": "System suitability, analytical procedures, validation, pharmacopoeial methods, testing"}}, "44b0a1fa-e059-497e-8ac6-a7d52ece28f1": {"node_ids": ["6cadbf65-61f4-47f3-8876-cc2fcfda3040"], "metadata": {"page_label": "130", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Evaluation of Test Results\n\n18.1 Test results should be reviewed and, where appropriate, evaluated statistically after completion of all the tests to determine whether they are mutually consistent and if they meet the specifications used. The evaluation should take into consideration the results of all the tests (all test data). Whenever doubtful (atypical) results are obtained they should be investigated. The complete testing procedure needs to be checked according to the internal quality management system (see also Part one, section 2).\n\n18.2 When a doubtful result (suspected OOS result) has been identified, a review of the different procedures applied during the testing process is to be undertaken by the supervisor with the analyst or technician before retesting is permitted. The following steps should be followed:\n\n- (a) confirm with the analyst or technician that the appropriate procedure(s) was (were) applied and followed correctly;\n- (b) examine the raw data to identify possible discrepancies;\n- (c) check all calculations;\n- (d) check that the equipment used was qualified and calibrated, and that system suitability tests were performed and were acceptable;\n- (e) ensure that the appropriate reagents, solvents and reference substances were used;\n- (f) confirm that the correct glassware was used; and\n- (g) ensure that original sample preparations are not discarded until the investigation is complete.\n\n18.3 The identification of an error which caused an aberrant result will invalidate the result and a retest of the sample will be necessary.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto se centra en la evaluaci\u00f3n de resultados de pruebas en un contexto de control de calidad. Se enfatiza la importancia de revisar y evaluar estad\u00edsticamente los resultados de las pruebas para asegurar su consistencia y conformidad con las especificaciones. En caso de obtener resultados dudosos o at\u00edpicos, se deben seguir procedimientos espec\u00edficos para investigar y validar los resultados antes de proceder con un nuevo an\u00e1lisis. Se detallan pasos espec\u00edficos que deben ser seguidos por el supervisor y el analista para asegurar la integridad del proceso de prueba.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos que deben seguirse para investigar un resultado dudoso antes de realizar un nuevo an\u00e1lisis?**\n   - Esta pregunta se centra en los procedimientos detallados que deben ser seguidos, que incluyen la confirmaci\u00f3n de procedimientos, la revisi\u00f3n de datos y c\u00e1lculos, y la verificaci\u00f3n del equipo utilizado.\n\n2. **\u00bfQu\u00e9 criterios se deben considerar al evaluar si los resultados de las pruebas son mutuamente consistentes?**\n   - Esta pregunta busca profundizar en los criterios estad\u00edsticos y de calidad que se deben aplicar al revisar los resultados de las pruebas, lo cual no se detalla expl\u00edcitamente en el texto.\n\n3. **\u00bfQu\u00e9 implicaciones tiene la identificaci\u00f3n de un error que causa un resultado aberrante en el proceso de pruebas?**\n   - Esta pregunta se enfoca en las consecuencias de encontrar un error en el proceso de prueba, espec\u00edficamente en c\u00f3mo afecta la validez del resultado y la necesidad de realizar un nuevo an\u00e1lisis.", "prev_section_summary": "### Temas Clave\n\n1. **Pruebas de Idoneidad del Sistema**: Son esenciales en procedimientos anal\u00edticos para verificar m\u00e9todos farmacopoeiales y procedimientos anal\u00edticos validados. Deben realizarse antes del an\u00e1lisis y, si se analizan muchas muestras en secuencia, a lo largo de esta.\n\n2. **Criterios de Idoneidad**: Un m\u00e9todo se considera adecuado para su prop\u00f3sito si se cumplen los criterios de idoneidad del sistema.\n\n3. **Revalidaci\u00f3n**: Cualquier cambio significativo en el procedimiento anal\u00edtico, la composici\u00f3n del producto o la s\u00edntesis del API requiere revalidaci\u00f3n del procedimiento anal\u00edtico.\n\n4. **Procedimientos de Prueba**: Las muestras deben ser probadas seg\u00fan el plan de trabajo del laboratorio. Si no es factible, se deben documentar las razones y almacenar la muestra en un lugar seguro.\n\n5. **Intervenci\u00f3n de Laboratorios Externos**: Algunas pruebas espec\u00edficas pueden requerir la realizaci\u00f3n por parte de otra unidad o un laboratorio externo especializado.\n\n### Entidades\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el documento.\n- **ICH (International Conference on Harmonisation)**: Proporciona directrices sobre validaci\u00f3n de procedimientos anal\u00edticos.\n- **OMCL (European Network of Official Medicines Control Laboratories)**: Ofrece directrices relacionadas con el control de medicamentos.\n- **US Pharmacopeia**: Proporciona cap\u00edtulos generales sobre validaci\u00f3n y verificaci\u00f3n de procedimientos farmacopoeiales. \n\nEste resumen destaca la importancia de las pruebas de idoneidad y la necesidad de seguir procedimientos adecuados en el an\u00e1lisis de muestras, as\u00ed como las implicaciones de los cambios en los procedimientos anal\u00edticos.", "excerpt_keywords": "Keywords: evaluation, test results, quality management, statistical analysis, retesting"}}, "7edf1f0b-3701-4e4c-bb65-aa4fefdb784a": {"node_ids": ["a82a84d5-38ea-498a-8d25-e76ab1bff7ed"], "metadata": {"page_label": "131", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Doubtful results can be rejected only if they are clearly due to an identified error. Sometimes the outcome of the investigation is inconclusive \u2014 no obvious cause can be identified \u2014 in which case a confirmatory determination is to be performed by another analyst who should be at least as experienced and competent in the analytical procedure as the original analyst. A similar value would indicate an OOS result. However, further confirmation using another validated method, if available, may be advised.\n\n18.4 An SOP should be in place for the conduct of an investigation of an OOS test result. The SOP should give clear guidance on the number of retests allowed (based on sound statistical principles). All investigations and their conclusions should be recorded. In the event of an error, any corrective action taken and any preventive measure introduced should be recorded and implemented.\n\n18.5 All individual results (all test data) with acceptance criteria should be reported.\n\n18.6 All conclusions should be entered on the analytical worksheet (see Part three, section 15) by the analyst and signed by the supervisor.\n\n*Note:* Further guidance on evaluation and reporting of test results is available in the following:\n\n- *Guideline elaborated by the US Food and Drug Administration (5);*\n- *Guideline elaborated by the European Network of Official Medicines Control Laboratories (OMCL) (28).*\n\n## Analytical test report\n\n18.7 The analytical test report is a compilation of the results and states the conclusions of the examination of a sample. It should be:\n\n(a) issued by the laboratory; and  \n(b) based on the analytical worksheet (see Part three, section 15).\n\n18.8 Any amendments to the original analytical test report will require the issue of a new corrected document.\n\n18.9 Pharmacopoeial content limits are set taking into account the uncertainty of measurement, and the production capability and acceptance criteria for an analytical result should be predefined. Under presently applicable rules neither the pharmacopoeias nor the NMRAs require the value found to be expressed with its associated expanded uncertainty for compliance testing. However, when reporting the results of investigative testing, although the primary objective is to identify a substance in the sample, a determination of", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS detalla los procedimientos y directrices para la investigaci\u00f3n de resultados fuera de especificaci\u00f3n (OOS) en pruebas anal\u00edticas. Se enfatiza la importancia de tener un Procedimiento Operativo Est\u00e1ndar (SOP) para guiar las investigaciones, la necesidad de registrar todas las conclusiones y acciones correctivas, y la forma en que deben ser reportados los resultados anal\u00edticos. Tambi\u00e9n se menciona que los l\u00edmites de contenido farmacop\u00e9ico deben considerar la incertidumbre de medici\u00f3n y que las enmiendas a los informes de prueba deben ser documentadas adecuadamente.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse si un resultado anal\u00edtico es considerado dudoso y no se puede identificar una causa obvia?**\n   - La investigaci\u00f3n debe ser realizada por otro analista que tenga al menos la misma experiencia y competencia en el procedimiento anal\u00edtico. Adem\u00e1s, se puede aconsejar una confirmaci\u00f3n adicional utilizando otro m\u00e9todo validado, si est\u00e1 disponible.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en un informe de prueba anal\u00edtica seg\u00fan el documento?**\n   - El informe debe compilar los resultados y las conclusiones de la evaluaci\u00f3n de una muestra, debe ser emitido por el laboratorio y basarse en la hoja de trabajo anal\u00edtica. Cualquier enmienda al informe original requerir\u00e1 la emisi\u00f3n de un nuevo documento corregido.\n\n3. **\u00bfC\u00f3mo se deben manejar los resultados individuales de las pruebas en relaci\u00f3n con los criterios de aceptaci\u00f3n?**\n   - Todos los resultados individuales (todos los datos de prueba) deben ser reportados junto con sus criterios de aceptaci\u00f3n, y todas las conclusiones deben ser registradas en la hoja de trabajo anal\u00edtica y firmadas por el supervisor.", "prev_section_summary": "### Temas Clave\n\n1. **Evaluaci\u00f3n de Resultados de Pruebas**: Se enfatiza la importancia de revisar y evaluar estad\u00edsticamente los resultados de las pruebas para asegurar su consistencia y conformidad con las especificaciones establecidas.\n\n2. **Resultados Dudosos**: Se establece un procedimiento claro para investigar resultados at\u00edpicos o dudosos, asegurando que se sigan pasos espec\u00edficos antes de proceder con un nuevo an\u00e1lisis.\n\n3. **Control de Calidad**: La necesidad de verificar que todos los procedimientos de prueba se realicen de acuerdo con el sistema de gesti\u00f3n de calidad interno.\n\n4. **Revisi\u00f3n de Procedimientos**: Se requiere una revisi\u00f3n exhaustiva de los procedimientos aplicados durante el proceso de prueba en caso de resultados dudosos, involucrando al supervisor y al analista o t\u00e9cnico.\n\n5. **Consecuencias de Errores**: La identificaci\u00f3n de un error que causa un resultado aberrante invalida dicho resultado, lo que implica la necesidad de realizar un nuevo an\u00e1lisis.\n\n### Entidades\n\n- **Resultados de Pruebas**: Datos obtenidos de las pruebas que deben ser evaluados.\n- **Procedimientos de Prueba**: M\u00e9todos y protocolos que deben seguirse durante el an\u00e1lisis.\n- **Analista/T\u00e9cnico**: Personal responsable de realizar las pruebas y an\u00e1lisis.\n- **Supervisor**: Persona encargada de revisar y validar los procedimientos y resultados.\n- **Sistema de Gesti\u00f3n de Calidad**: Estructura que asegura que los procesos de prueba se realicen de manera adecuada y conforme a las normas.\n- **Equipos y Materiales**: Herramientas y sustancias utilizadas en las pruebas, que deben ser verificadas para asegurar su calidad y adecuaci\u00f3n. \n\nEste resumen destaca la importancia de la evaluaci\u00f3n rigurosa de los resultados de pruebas y los procedimientos necesarios para garantizar la validez de los mismos en un contexto de control de calidad.", "excerpt_keywords": "Keywords: OOS results, analytical test report, SOP, quality control, measurement uncertainty"}}, "58fedafa-30e8-4722-898d-e384971db23d": {"node_ids": ["3f334bbc-26f8-48f7-9eab-84269cdbe4da"], "metadata": {"page_label": "132", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "its concentration may be also requested, in which case the estimated uncertainty should also be given.\n\n18.10 Measurement uncertainty can be estimated in a number of ways, e.g.:\n\n(a) by preparing an uncertainty budget for each uncertainty component identified in an analytical procedure (bottom-up approach);\n\n(b) from validation data and control charts (29); and\n\n(c) from the data obtained from proficiency tests or collaborative trials (top-down approach).\n\n*Note:* Further guidance can be found in various guidelines (9, 10, 30, 31, 32).\n\n### Content of the analytical test report\n\n18.11 The analytical test report should provide the following information:\n\n(a) the laboratory registration number of the sample;\n\n(b) the laboratory test report number;\n\n(c) the name and address of the laboratory testing the sample;\n\n(d) the name and address of the originator of the request for analysis;\n\n(e) the name, description and batch number of the sample, where appropriate;\n\n(f) an introduction giving the background to and the purpose of the investigation;\n\n(g) a reference to the specifications used for testing the sample or a detailed description of the procedures employed (sample for investigative testing), including the limits;\n\n(h) the results of all the tests performed or the numerical results with the standard deviation of all the tests performed (if applicable);\n\n(i) a discussion of the results obtained;\n\n(j) a conclusion as to whether or not the sample(s) was (were) found to be within the limits of the specifications used, or for a sample for investigative testing, the substance(s) or ingredient(s) identified;\n\n(k) the date on which the test(s) was (were) completed;\n\n(l) the signature of the head of the laboratory or authorized person;\n\n(m) the name and address of the original manufacturer and, if applicable, those of the repacker and/or trader;\n\n(n) whether or not the sample(s) complies (comply) with the requirements;\n\n(o) the date on which the sample was received;\n\n(p) the expiry date or retest date, if applicable; and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla la importancia de la incertidumbre de medici\u00f3n en los procedimientos anal\u00edticos y proporciona directrices sobre el contenido que debe incluir un informe de prueba anal\u00edtica. Se mencionan m\u00e9todos para estimar la incertidumbre y se enumeran los elementos esenciales que deben estar presentes en un informe de laboratorio, como la identificaci\u00f3n del laboratorio, los resultados de las pruebas y la conformidad con las especificaciones.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los m\u00e9todos recomendados para estimar la incertidumbre de medici\u00f3n en un procedimiento anal\u00edtico?**\n   - Respuesta: La incertidumbre de medici\u00f3n puede estimarse mediante: (a) la preparaci\u00f3n de un presupuesto de incertidumbre para cada componente identificado en el procedimiento anal\u00edtico (enfoque de abajo hacia arriba); (b) datos de validaci\u00f3n y gr\u00e1ficos de control; y (c) datos obtenidos de pruebas de competencia o ensayos colaborativos (enfoque de arriba hacia abajo).\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en un informe de prueba anal\u00edtica seg\u00fan las directrices de la OMS?**\n   - Respuesta: Un informe de prueba anal\u00edtica debe incluir, entre otros, el n\u00famero de registro del laboratorio, el n\u00famero del informe de prueba, la direcci\u00f3n del laboratorio, la descripci\u00f3n y n\u00famero de lote de la muestra, los resultados de las pruebas realizadas, una discusi\u00f3n de los resultados, la conclusi\u00f3n sobre la conformidad de la muestra con las especificaciones, y la firma del responsable del laboratorio.\n\n3. **\u00bfQu\u00e9 se debe considerar al discutir los resultados obtenidos en un informe de prueba anal\u00edtica?**\n   - Respuesta: Al discutir los resultados, se debe considerar si la(s) muestra(s) se encontraron dentro de los l\u00edmites de las especificaciones utilizadas, o si se identificaron las sustancias o ingredientes en el caso de una muestra para pruebas investigativas. Adem\u00e1s, se debe incluir una interpretaci\u00f3n de los resultados en el contexto del prop\u00f3sito de la investigaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Resultados Dudosos y OOS**: Se establece que los resultados dudosos solo pueden ser rechazados si se debe a un error identificado. Si no se puede identificar una causa obvia, se debe realizar una determinaci\u00f3n confirmatoria por otro analista competente.\n\n2. **Procedimiento Operativo Est\u00e1ndar (SOP)**: Es esencial tener un SOP para guiar la investigaci\u00f3n de resultados fuera de especificaci\u00f3n (OOS), que incluya directrices sobre el n\u00famero de retests permitidos y la documentaci\u00f3n de todas las investigaciones y conclusiones.\n\n3. **Reportes de Resultados**: Todos los resultados individuales de las pruebas deben ser reportados junto con sus criterios de aceptaci\u00f3n. Las conclusiones deben ser registradas en la hoja de trabajo anal\u00edtica y firmadas por un supervisor.\n\n4. **Informe de Prueba Anal\u00edtica**: El informe debe compilar los resultados y conclusiones de la evaluaci\u00f3n de una muestra, ser emitido por el laboratorio y basarse en la hoja de trabajo anal\u00edtica. Cualquier enmienda al informe original requiere la emisi\u00f3n de un nuevo documento corregido.\n\n5. **L\u00edmites de Contenido Farmac\u00e9utico**: Los l\u00edmites deben considerar la incertidumbre de medici\u00f3n, y no se requiere que los valores se expresen con su incertidumbre expandida para pruebas de cumplimiento.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **FDA (Administraci\u00f3n de Alimentos y Medicamentos de EE. UU.)**: Referencia para directrices adicionales sobre evaluaci\u00f3n y reporte de resultados.\n- **OMCL (Red Europea de Laboratorios Oficiales de Control de Medicamentos)**: Otra referencia para directrices sobre pruebas anal\u00edticas.\n- **Analista**: Profesional responsable de realizar las pruebas y documentar los resultados.\n- **Supervisor**: Persona que revisa y firma las conclusiones en la hoja de trabajo anal\u00edtica.\n\nEste resumen abarca los aspectos fundamentales de la secci\u00f3n, destacando la importancia de la documentaci\u00f3n, la competencia anal\u00edtica y la claridad en la comunicaci\u00f3n de resultados.", "excerpt_keywords": "Keywords: measurement uncertainty, analytical test report, laboratory procedures, specifications, compliance"}}, "86c609a5-b3f6-48f0-9d8f-474638b6b30f": {"node_ids": ["3a77984c-6e51-47f9-9862-3571e07468aa"], "metadata": {"page_label": "133", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Certificate of analysis\n\n19.1 A certificate of analysis is prepared for each batch of a substance or product and usually contains the following information:\n\n(a) the registration number of the sample;  \n(b) date of receipt;  \n(c) the name and address of the laboratory testing the sample;  \n(d) the name and address of the originator of the request for analysis;  \n(e) the name, description and batch number of the sample where appropriate;  \n(f) the name and address of the original manufacturer and, if applicable, those of the repacker and/or trader;  \n(g) the reference to the specification used for testing the sample;  \n(h) the results of all tests performed (mean and standard deviation, if applicable) with the prescribed limits;  \n(i) a conclusion as to whether or not the sample was found to be within the limits of the specification;  \n(j) expiry date or retest date if applicable;  \n(k) date on which the test(s) was (were) completed; and  \n(l) the signature of the head of laboratory or other authorized person.  \n\n*Note: The Guideline on model certificate of analysis was adopted by the WHO Expert Committee on Specifications for Pharmaceutical Preparations at its thirty-sixth meeting (3).*\n\n# Retained samples\n\n20.1 Samples should be retained as required by the legislation or by the originator of the request for analysis. There should be a sufficient amount of retained sample to allow at least two re-analyses. The retained sample should be kept in its final pack.\n\n# Part four. Safety\n\n## General rules\n\n21.1 General and specific safety instructions reflecting identified risk, should be made available to each staff member and supplemented regularly as appropriate (e.g. with written material, poster displays, audiovisual material and occasional seminars).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para un certificado de an\u00e1lisis que debe prepararse para cada lote de una sustancia o producto. Este certificado incluye informaci\u00f3n clave como el n\u00famero de registro, los resultados de las pruebas realizadas, y la firma del responsable del laboratorio. Adem\u00e1s, se menciona la importancia de retener muestras para an\u00e1lisis futuros y se establecen directrices sobre la seguridad en el laboratorio, enfatizando la necesidad de proporcionar instrucciones de seguridad a todo el personal.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en un certificado de an\u00e1lisis seg\u00fan el documento de la OMS?**\n   - El certificado de an\u00e1lisis debe incluir el n\u00famero de registro de la muestra, la fecha de recepci\u00f3n, el nombre y direcci\u00f3n del laboratorio, el nombre y direcci\u00f3n del originador de la solicitud, la descripci\u00f3n y n\u00famero de lote de la muestra, informaci\u00f3n sobre el fabricante, los resultados de las pruebas, una conclusi\u00f3n sobre la conformidad con las especificaciones, la fecha de caducidad o rean\u00e1lisis, la fecha de finalizaci\u00f3n de las pruebas y la firma del responsable del laboratorio.\n\n2. **\u00bfCu\u00e1nto tiempo deben conservarse las muestras seg\u00fan las directrices de la OMS?**\n   - Las muestras deben conservarse seg\u00fan lo requerido por la legislaci\u00f3n o por el originador de la solicitud de an\u00e1lisis, y debe haber suficiente cantidad de muestra retenida para permitir al menos dos rean\u00e1lisis.\n\n3. **\u00bfQu\u00e9 tipo de instrucciones de seguridad se deben proporcionar al personal del laboratorio?**\n   - Se deben proporcionar instrucciones de seguridad generales y espec\u00edficas que reflejen los riesgos identificados, y estas deben ser accesibles a cada miembro del personal, complementadas regularmente con material escrito, exhibiciones en carteles, material audiovisual y seminarios ocasionales.", "prev_section_summary": "### Temas Clave:\n\n1. **Incertidumbre de Medici\u00f3n**: Se discuten m\u00e9todos para estimar la incertidumbre en procedimientos anal\u00edticos, incluyendo enfoques de abajo hacia arriba (presupuesto de incertidumbre) y de arriba hacia abajo (datos de validaci\u00f3n y pruebas de competencia).\n\n2. **Contenido del Informe de Prueba Anal\u00edtica**: Se especifica la informaci\u00f3n que debe incluirse en un informe de prueba anal\u00edtica, como:\n   - Identificaci\u00f3n del laboratorio y del solicitante.\n   - Descripci\u00f3n de la muestra y resultados de las pruebas.\n   - Discusi\u00f3n y conclusi\u00f3n sobre la conformidad de la muestra con las especificaciones.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que proporciona las directrices.\n- **Laboratorio**: Entidad que realiza las pruebas y emite el informe.\n- **Muestra**: Sustancia o material analizado.\n- **Especificaciones**: Normas o criterios utilizados para evaluar la muestra.\n- **Resultados de Pruebas**: Datos obtenidos de los an\u00e1lisis realizados.\n\n### Resumen:\n\nEl documento de la OMS aborda la importancia de la incertidumbre de medici\u00f3n en los procedimientos anal\u00edticos y establece directrices sobre el contenido que debe incluir un informe de prueba anal\u00edtica. Se detallan m\u00e9todos para estimar la incertidumbre y se enumeran los elementos esenciales que deben estar presentes en el informe, como la identificaci\u00f3n del laboratorio, los resultados de las pruebas y la conformidad con las especificaciones.", "excerpt_keywords": "Keywords: certificate of analysis, retained samples, safety instructions, laboratory testing, WHO guidelines"}}, "5a015644-6d09-4257-a83a-2a7d8d233417": {"node_ids": ["dfabce79-9699-4719-8cc5-1a4a399e8701"], "metadata": {"page_label": "134", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 21.2 General rules for safe working in accordance with national regulations and SOPs normally include the following requirements:\n\n(a) Safety data sheets should be available to staff before testing is carried out;\n\n(b) Smoking, eating and drinking in the laboratory should be prohibited;\n\n(c) Staff should be familiar with the use of fire-fighting equipment, including fire extinguishers, fire blankets and gas masks;\n\n(d) Staff should wear laboratory coats or other protective clothing, including eye protection;\n\n(e) Special care should be taken, as appropriate, in handling, for example, highly potent, infectious or volatile substances;\n\n(f) Highly toxic and/or genotoxic samples should be handled in a specially designed facility to avoid the risk of contamination;\n\n(g) All containers of chemicals should be fully labelled and include prominent warnings (e.g. \u201cpoison\u201d, \u201cflammable\u201d, \u201cradioactive\u201d) whenever appropriate;\n\n(h) Adequate insulation and spark-proofing should be provided for electrical wiring and equipment, including refrigerators;\n\n(i) Rules on safe handling of cylinders of compressed gases should be observed and staff should be familiar with the relevant colour identification codes;\n\n(j) Staff should be aware of the need to avoid working alone in the laboratory; and\n\n(k) First-aid materials should be provided and staff instructed in first-aid techniques, emergency care and the use of antidotes.\n\n## 21.3 Protective clothing should be available, including eye protection, masks and gloves. \n\nSafety showers should be installed. Rubber suction bulbs should be used on manual pipettes and siphons. Staff should be instructed in the safe handling of glassware, corrosive reagents and solvents and particularly in the use of safety containers or baskets to avoid spillage from containers. Warnings, precautions and instructions should be given for work with violent, uncontrollable or dangerous reactions when handling specific reagents (e.g. mixing water and acids, or acetone\u2013chloroform and ammonia), flammable products, oxidizing or radioactive agents and especially biologicals such as infectious agents. Peroxide-free solvents should be used. Staff should be aware of methods for the safe disposal of unwanted corrosive or dangerous products by neutralization or deactivation and of the need for safe and complete disposal of mercury and its salts.\n\n## 21.4 Poisonous or hazardous products should be singled out and labelled appropriately, but it should not be taken for granted that all other", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Reglas generales para el trabajo seguro en laboratorios**: El documento establece una serie de requisitos que deben seguirse en los laboratorios para garantizar la seguridad del personal, incluyendo la disponibilidad de hojas de datos de seguridad, la prohibici\u00f3n de fumar y comer, y la necesidad de usar ropa de protecci\u00f3n adecuada.\n\n2. **Equipamiento y procedimientos de seguridad**: Se enfatiza la importancia de que el personal est\u00e9 familiarizado con el uso de equipos de lucha contra incendios, as\u00ed como la correcta manipulaci\u00f3n de sustancias peligrosas y la disposici\u00f3n segura de productos qu\u00edmicos.\n\n3. **Manejo de productos peligrosos**: Se menciona la necesidad de etiquetar adecuadamente los productos t\u00f3xicos y peligrosos, y se dan directrices sobre el uso de ropa de protecci\u00f3n, duchas de seguridad y t\u00e9cnicas de primeros auxilios.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe contener una hoja de datos de seguridad y por qu\u00e9 es importante que est\u00e9 disponible antes de realizar pruebas en el laboratorio?**\n   - Respuesta: Las hojas de datos de seguridad deben contener informaci\u00f3n sobre las propiedades qu\u00edmicas, riesgos, medidas de seguridad y procedimientos de emergencia relacionados con las sustancias que se van a utilizar. Su disponibilidad es crucial para que el personal pueda tomar decisiones informadas y seguras antes de manipular productos qu\u00edmicos.\n\n2. **\u00bfCu\u00e1les son las medidas espec\u00edficas que se deben tomar al manejar sustancias altamente t\u00f3xicas o genot\u00f3xicas en el laboratorio?**\n   - Respuesta: Las sustancias altamente t\u00f3xicas o genot\u00f3xicas deben ser manipuladas en instalaciones especialmente dise\u00f1adas para evitar la contaminaci\u00f3n. Adem\u00e1s, se deben seguir estrictas normas de seguridad, como el uso de ropa de protecci\u00f3n adecuada y la implementaci\u00f3n de procedimientos de manejo seguro.\n\n3. **\u00bfQu\u00e9 precauciones deben tomarse al trabajar con productos qu\u00edmicos que pueden reaccionar violentamente, y qu\u00e9 ejemplos se mencionan en el documento?**\n   - Respuesta: Se deben proporcionar advertencias, precauciones e instrucciones espec\u00edficas para el trabajo con productos qu\u00edmicos que pueden reaccionar de manera violenta o incontrolable. Ejemplos mencionados incluyen la mezcla de agua con \u00e1cidos y la combinaci\u00f3n de acetona\u2013cloroformo con amon\u00edaco, que pueden generar reacciones peligrosas.", "prev_section_summary": "### Temas clave:\n\n1. **Certificado de an\u00e1lisis**: Se detalla la informaci\u00f3n que debe incluir un certificado de an\u00e1lisis para cada lote de una sustancia o producto, como el n\u00famero de registro, resultados de pruebas, y la firma del responsable del laboratorio.\n\n2. **Muestras retenidas**: Se establece la necesidad de conservar muestras de acuerdo con la legislaci\u00f3n o la solicitud del an\u00e1lisis, asegurando que haya suficiente cantidad para al menos dos rean\u00e1lisis.\n\n3. **Instrucciones de seguridad**: Se enfatiza la importancia de proporcionar instrucciones de seguridad generales y espec\u00edficas al personal del laboratorio, complementadas con materiales educativos y seminarios.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad que establece las directrices.\n- **Laboratorio**: Entidad responsable de realizar las pruebas y emitir el certificado de an\u00e1lisis.\n- **Muestras**: Sustancias o productos que son objeto de an\u00e1lisis.\n- **Personal del laboratorio**: Individuos que deben recibir formaci\u00f3n en seguridad.\n- **Especificaciones**: Normas a las que deben ajustarse los resultados de las pruebas.\n\n### Resumen:\nEl documento de la OMS establece los requisitos para un certificado de an\u00e1lisis, que debe incluir informaci\u00f3n esencial sobre el lote de una sustancia o producto. Tambi\u00e9n se menciona la importancia de conservar muestras para futuros an\u00e1lisis y se subraya la necesidad de proporcionar instrucciones de seguridad adecuadas al personal del laboratorio.", "excerpt_keywords": "Keywords: safety regulations, laboratory practices, hazardous materials, protective equipment, emergency procedures"}}, "97215990-e6ec-45ac-b944-3d6c8e41f9b6": {"node_ids": ["fedf5bdc-5963-4c0f-8189-309707c1fd41"], "metadata": {"page_label": "135", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. **Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, 2nd updated edition. Good manufacturing practices and inspection.** Geneva, World Health Organization, 2007.\n\n2. **International Organization for Standardization.** General requirements for the competence of testing and calibration laboratories. ISO/IEC 17025:2005.\n\n3. **Model certificate of analysis.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report. Geneva, World Health Organization, 2002, Annex 10 (WHO Technical Report Series, No. 902).\n\n4. **International vocabulary of metrology \u2014 Basic and general concepts and associated terms. VIM 3rd ed.**, Joint Committee for Guides in Metrology (JCGM) 200:2008 (http://www.bipm.org/utils/common/documents/jcgm/JCGM_200_2008.pdf).\n\n5. **Guidance for industry \u2014 Investigating out-of-specification test results for pharmaceutical production.** US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), October 2006 (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070287.pdf).\n\n6. **Guidelines for inspection of drug distribution channels.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report. Geneva, World Health Organization, 1999, Annex 6 (WHO Technical Report Series, No. 885).\n\n7. **Good manufacturing practices: supplementary guidelines for the manufacture of pharmaceutical excipients.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report. Geneva, World Health Organization, 1999, Annex 5 (WHO Technical Report Series, No. 885).\n\n8. **General guidelines for the establishment, maintenance and distribution of chemical reference substances.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report. Geneva, World Health Organization, 2007, Annex 3 (WHO Technical Report Series, No. 943).\n\n9. **International Organization for Standardization.** Guidance for the use of repeatability, reproducibility and trueness estimates in measurement uncertainty estimation. 2004 (ISO Guide 21748).\n\n10. **International Organization for Standardization/International Electrotechnical Commission.** Uncertainty of measurement \u2014 Part 3: Guide to the expression of uncertainty in measurement (GUM:1995) 2008 (ISO/IEC Guide 98-3).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfCu\u00e1les son las ediciones y a\u00f1os de publicaci\u00f3n de las gu\u00edas de buenas pr\u00e1cticas de fabricaci\u00f3n mencionadas en el documento?**\n   - **Respuesta:** La gu\u00eda \"Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, 2nd updated edition. Good manufacturing practices and inspection\" fue publicada por la OMS en 2007. Adem\u00e1s, las \"Good manufacturing practices: supplementary guidelines for the manufacture of pharmaceutical excipients\" tambi\u00e9n se mencionan en el contexto de la 35\u00aa reuni\u00f3n del Comit\u00e9 de Expertos de la OMS, publicada en 1999.\n\n2. **\u00bfQu\u00e9 documento proporciona directrices sobre la investigaci\u00f3n de resultados de pruebas fuera de especificaci\u00f3n en la producci\u00f3n farmac\u00e9utica?**\n   - **Respuesta:** El documento titulado \"Guidance for industry \u2014 Investigating out-of-specification test results for pharmaceutical production\" publicado por la US Food and Drug Administration, Center for Drug Evaluation and Research (CDER) en octubre de 2006, proporciona directrices sobre este tema.\n\n3. **\u00bfQu\u00e9 organizaci\u00f3n internacional establece los requisitos generales para la competencia de laboratorios de ensayo y calibraci\u00f3n?**\n   - **Respuesta:** La organizaci\u00f3n que establece estos requisitos es la **International Organization for Standardization (ISO)**, espec\u00edficamente en el documento ISO/IEC 17025:2005.\n\n### Resumen de Nivel Superior\n\nEl contexto se centra en una serie de referencias relacionadas con la calidad y las buenas pr\u00e1cticas en la fabricaci\u00f3n de productos farmac\u00e9uticos, as\u00ed como en la metrolog\u00eda y la calibraci\u00f3n de laboratorios. Se mencionan documentos clave de la Organizaci\u00f3n Mundial de la Salud (OMS) y de la Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO), que abordan desde la garant\u00eda de calidad hasta la incertidumbre en las mediciones. Estas referencias son esenciales para asegurar que los productos farmac\u00e9uticos cumplan con los est\u00e1ndares internacionales de calidad y seguridad.\n\n### Preguntas Mejoradas\n\n1. **\u00bfQu\u00e9 papel juega la OMS en la regulaci\u00f3n de las buenas pr\u00e1cticas de fabricaci\u00f3n de productos farmac\u00e9uticos seg\u00fan las referencias citadas?**\n2. **\u00bfC\u00f3mo se relacionan las gu\u00edas de la ISO con la calidad en los laboratorios de ensayo y calibraci\u00f3n en el contexto farmac\u00e9utico?**\n3. **\u00bfQu\u00e9 importancia tienen los certificados de an\u00e1lisis en el contexto de las especificaciones farmac\u00e9uticas seg\u00fan el documento mencionado?**", "prev_section_summary": "### Temas Clave:\n\n1. **Reglas Generales de Seguridad en Laboratorios**: Se establecen requisitos fundamentales para garantizar un entorno de trabajo seguro, incluyendo la disponibilidad de hojas de datos de seguridad y la prohibici\u00f3n de fumar, comer y beber en el laboratorio.\n\n2. **Equipamiento de Seguridad**: Se enfatiza la importancia de que el personal est\u00e9 familiarizado con el uso de equipos de lucha contra incendios y que utilice ropa de protecci\u00f3n adecuada, como batas de laboratorio y protecci\u00f3n ocular.\n\n3. **Manejo de Sustancias Peligrosas**: Se requiere un manejo cuidadoso de sustancias altamente t\u00f3xicas, genot\u00f3xicas e infecciosas, que deben ser manipuladas en instalaciones dise\u00f1adas espec\u00edficamente para evitar la contaminaci\u00f3n.\n\n4. **Etiquetado y Almacenamiento de Productos Qu\u00edmicos**: Todos los contenedores de productos qu\u00edmicos deben estar debidamente etiquetados con advertencias claras sobre su peligrosidad.\n\n5. **Precauciones en el Manejo de Productos Qu\u00edmicos Reactivos**: Se deben seguir instrucciones espec\u00edficas al trabajar con productos qu\u00edmicos que pueden reaccionar violentamente, como la mezcla de agua con \u00e1cidos.\n\n6. **Disposici\u00f3n Segura de Residuos**: Se debe tener conocimiento sobre la disposici\u00f3n segura de productos qu\u00edmicos peligrosos y la eliminaci\u00f3n adecuada de mercurio y sus sales.\n\n### Entidades:\n\n- **Hojas de Datos de Seguridad**: Documentos que contienen informaci\u00f3n sobre riesgos y medidas de seguridad de sustancias qu\u00edmicas.\n- **Equipos de Lucha Contra Incendios**: Incluyen extintores, mantas ign\u00edfugas y m\u00e1scaras de gas.\n- **Ropa de Protecci\u00f3n**: Batas de laboratorio, gafas de seguridad, guantes y m\u00e1scaras.\n- **Sustancias Peligrosas**: Incluyen productos qu\u00edmicos altamente t\u00f3xicos, genot\u00f3xicos, inflamables y biol\u00f3gicos.\n- **Contenedores de Productos Qu\u00edmicos**: Deben estar etiquetados con advertencias como \"veneno\", \"inflamable\" y \"radiactivo\".\n- **Duchas de Seguridad y Materiales de Primeros Auxilios**: Equipos necesarios para responder a emergencias en el laboratorio.\n\nEste resumen destaca la importancia de seguir protocolos de seguridad rigurosos en el laboratorio para proteger al personal y manejar adecuadamente los productos qu\u00edmicos peligrosos.", "excerpt_keywords": "Keywords: pharmaceuticals, quality assurance, good manufacturing practices, ISO standards, metrology"}}, "94f2026b-0279-4b96-8f55-b8415fda5434": {"node_ids": ["08d9bdfb-346c-4bcf-ac71-0a99a4a415eb"], "metadata": {"page_label": "136", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n11. Supplementary guidelines in good manufacturing practice: validation. Qualification of systems and equipment. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 4, Appendix 6 (WHO Technical Report Series, No. 937).\n\n12. Supplementary guidelines in good manufacturing practice: validation. Validation of computerized systems. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 4, Appendix 6 (WHO Technical Report Series, No. 937).\n\n13. *Good automated manufacturing practice (GAMP) Good Practice Guides: Validation of laboratory computerized systems*. International Society for Pharmaceutical Engineering (ISPE), 2005.\n\n14. *Good automated manufacturing practice (GAMP) Good Practice Guides: Electronic data archiving*. International Society for Pharmaceutical Engineering (ISPE), 2007.\n\n15. *Title 21 Code of Federal Regulations (21 CFR Part 11): Electronic records; electronic signatures*. US Food and Drug Administration. The current status of 21 CFR Part 11 Guidance is located under Regulations and Guidance at: http://www.fda.gov/cder/gmp/index.htm \u2014 see background: http://www.fda.gov/OHRMS/DOCKETS/98fr/03-4312.pdf\n\n16. Computerised systems. In: *The rules governing medicinal products in the European Union. Vol. 4. Good manufacturing practice (GMP) guidelines*. Annex 11 (http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-4/pdfs-en/annex11en.pdf).\n\n17. Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents: PA/PH/OMCL (08) 69 3R \u2014 *Validation of computerised systems \u2014 core document* (http://www.edqm.eu/site/Validation_of_Computerised_Systems_Core_Documentpdf-en-8390-2.html) and its annexes:\n\n    - PA/PH/OMCL (08) 87 2R \u2014 Annex 1: Validation of computerised calculation systems: example of validation of in-house software (http://www.edqm.eu/site/NEW_Annex_1_Validation_of_computerised_calculationpdf-en-8391-2.html).\n\n    - PA/PH/OMCL (08) 88 R \u2014 Annex 2: Validation of Databases (DB), Laboratory Information Management Systems (LIMS) and Electronic Laboratory Notebooks (ELN) (http://www.edqm.eu/site/NEW_Annex_2_Validation_of_Databases_DB_Laboratory_pdf-en-8392-2.html).\n\n    - PA/PH/OMCL (08) 89 R \u2014 Annex 3: Validation of computers as part of test equipment (http://www.edqm.eu/site/NEW_Annex_3_Validation_of_computers_as_part_of_tespcdf-en-8393-2.html).\n\n18. *Guidelines for good laboratory practice and guidelines for the testing of chemicals*. Organisation for Economic Co-operation and Development (OECD), Environment Directorate, Chemical Safety. (http://www.oecd.org/document/63/0,3343,en_2649_34381_2346175_1_1_1_1,00.html).\n\n19. *The International Pharmacopoeia*, Fourth Edition (including First Supplement). Vol. 2. Methods of analysis. Geneva, World Health Organization, 2008 (http://www.who.int/phint).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl contexto proporciona una lista de referencias relacionadas con las buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) y la validaci\u00f3n de sistemas computarizados en el \u00e1mbito farmac\u00e9utico. Incluye directrices de la Organizaci\u00f3n Mundial de la Salud (OMS), la Administraci\u00f3n de Alimentos y Medicamentos de EE. UU. (FDA), y la Organizaci\u00f3n para la Cooperaci\u00f3n y el Desarrollo Econ\u00f3mico (OCDE), as\u00ed como documentos de la Sociedad Internacional de Ingenier\u00eda Farmac\u00e9utica (ISPE). Las referencias abarcan temas como la validaci\u00f3n de sistemas y equipos, la gesti\u00f3n de datos electr\u00f3nicos y las buenas pr\u00e1cticas de laboratorio.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las diferencias clave entre las directrices de validaci\u00f3n de sistemas computarizados de la OMS y las de la FDA seg\u00fan las referencias proporcionadas?**\n   - Esta pregunta busca una comparaci\u00f3n directa entre las directrices de dos organizaciones importantes en el \u00e1mbito de la regulaci\u00f3n farmac\u00e9utica, lo que puede no estar disponible en otros documentos.\n\n2. **\u00bfQu\u00e9 documentos espec\u00edficos de la red de Laboratorios de Control de Medicamentos Oficiales del Consejo de Europa se mencionan y qu\u00e9 aspectos de la validaci\u00f3n abordan?**\n   - Esta pregunta se centra en los documentos espec\u00edficos y sus enfoques, lo que puede no ser ampliamente conocido fuera de este contexto.\n\n3. **\u00bfC\u00f3mo se relacionan las gu\u00edas de buenas pr\u00e1cticas de fabricaci\u00f3n automatizadas (GAMP) con las regulaciones de la UE sobre sistemas computarizados?**\n   - Esta pregunta busca explorar la interconexi\u00f3n entre las gu\u00edas de GAMP y las regulaciones europeas, proporcionando una perspectiva que puede no estar claramente delineada en otros textos. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n detallada y espec\u00edfica que se encuentra en el contexto proporcionado, lo que puede no ser f\u00e1cilmente accesible en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nLa secci\u00f3n se centra en referencias relacionadas con la **calidad y las buenas pr\u00e1cticas en la fabricaci\u00f3n de productos farmac\u00e9uticos**, as\u00ed como en la **metrolog\u00eda** y la **calibraci\u00f3n de laboratorios**. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF)**: Se discuten gu\u00edas y est\u00e1ndares para asegurar la calidad en la producci\u00f3n farmac\u00e9utica.\n2. **Calidad y Aseguramiento**: Importancia de la calidad en los productos farmac\u00e9uticos y la necesidad de cumplir con est\u00e1ndares internacionales.\n3. **Metrolog\u00eda**: Conceptos b\u00e1sicos y t\u00e9rminos asociados a la metrolog\u00eda, as\u00ed como la incertidumbre en las mediciones.\n4. **Regulaci\u00f3n y Directrices**: Documentos que proporcionan directrices sobre la investigaci\u00f3n de resultados de pruebas fuera de especificaci\u00f3n y la inspecci\u00f3n de canales de distribuci\u00f3n de medicamentos.\n5. **Certificados de An\u00e1lisis**: Importancia de los certificados en el contexto de las especificaciones farmac\u00e9uticas.\n\n#### Entidades Mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Publica gu\u00edas y reportes sobre buenas pr\u00e1cticas y est\u00e1ndares en la industria farmac\u00e9utica.\n- **International Organization for Standardization (ISO)**: Establece requisitos y gu\u00edas para la competencia de laboratorios de ensayo y calibraci\u00f3n.\n- **US Food and Drug Administration (FDA)**: Proporciona directrices sobre la investigaci\u00f3n de resultados de pruebas en la producci\u00f3n farmac\u00e9utica.\n\nEste resumen destaca la relevancia de las referencias citadas para asegurar que los productos farmac\u00e9uticos cumplan con los est\u00e1ndares de calidad y seguridad a nivel internacional.", "excerpt_keywords": "Keywords: buenas pr\u00e1cticas de fabricaci\u00f3n, validaci\u00f3n de sistemas, OMS, FDA, GAMP"}}, "bd26c895-3f3a-4511-9110-df3ffee9494c": {"node_ids": ["783b5a2c-f01e-43eb-a108-ea3fa02809a6"], "metadata": {"page_label": "137", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 20. Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents:\n\n- PA/PH/OMCL (08) 73 \u2014 Qualification of equipment (http://www.edqm.eu/medias/fichiers/NEW_Qualification_of_equipment_core_document.pdf).\n- PA/PH/OMCL (07) 17 DEF \u2013Annex 1: Qualification of HPLC equipment (http://www.edqm.eu/medias/fichiers/Annex_1_Qualification_of_HPLC_Equipment.pdf).\n- PA/PH/OMCL (06) 86 DEF \u2014 Annex 2: Qualification of GC Equipment (http://www.edqm.eu/medias/fichiers/Annex_2_Qualification_of_GC_equipment.pdf).\n- PA/PH/OMCL (07) 11 DEF CORR \u2014 Annex 3: Qualification of UV-visible spectrophotometers (http://www.edqm.eu/medias/fichiers/Annex_3_Qualification_of_UV_Visible_spectrophotometers.pdf).\n- PA/PH/OMCL (07) 12 DEF CORR - Annex 4: Qualification of IR spectrophotometers (http://www.edqm.eu/medias/fichiers/Annex_4_Qualification_of_IR_spectrophotometers.pdf).\n- PA/PH/OMCL (07) 108 3R \u2014 Annex 5: Qualification of automatic titrators (http://www.edqm.eu/medias/fichiers/NEW_Annex_5_Qualification_of_Automatic_Titrators.pdf).\n\n# 21. *US Pharmacopeia*, 32nd ed. General chapters: <1058> Analytical instrument qualification. Rockville, MD, 2009.\n\n# 22. WHO guidelines for sampling of pharmaceutical products and related materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 4 (WHO Technical Report Series, No. 929).\n\n# 23. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 2 (WHO Technical Report Series, No. 953).\n\n# 24. Supplementary guidelines in good manufacturing practice: validation. Analytical method validation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 4, Appendix 4 (WHO Technical Report Series, No. 937).\n\n# 25. Guideline of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH Q2(R1): Validation of analytical procedures: text and methodology (http://www.ich.org/LOB/media/MEDIA417.pdf).\n\n# 26. Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents: PA/PH/OMCL (05) 47 DEF \u2014 Validation of analytical procedures (http://www.edqm.eu/medias/fichiers/Validation_of_Analytical_Procedures.pdf).\n\n# 27. *The US Pharmacopeia*, 32nd ed. General chapters: <1225> Validation of compendial procedures and <1226> Verification of compendial procedures. Rockville, MD, 2009.\n\n# 28. Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents: PA/PH/OMCL (07) 28 DEF CORR \u2014", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series) y se centra en la calidad y validaci\u00f3n de procedimientos anal\u00edticos en laboratorios de control de medicamentos. Incluye referencias a documentos de calidad de la Red de Laboratorios de Control de Medicamentos de Europa, as\u00ed como gu\u00edas de la OMS y la Farmacopea de EE. UU. sobre la calificaci\u00f3n de equipos, validaci\u00f3n de procedimientos anal\u00edticos y muestreo de productos farmac\u00e9uticos. Se mencionan varios documentos espec\u00edficos que abordan la calificaci\u00f3n de diferentes tipos de equipos anal\u00edticos, as\u00ed como directrices sobre la validaci\u00f3n de m\u00e9todos anal\u00edticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los documentos clave de la Red de Laboratorios de Control de Medicamentos de Europa que abordan la calificaci\u00f3n de equipos anal\u00edticos y qu\u00e9 tipos de equipos cubren?**\n   - Respuesta: Los documentos clave incluyen PA/PH/OMCL (08) 73 sobre la calificaci\u00f3n de equipos en general, PA/PH/OMCL (07) 17 DEF sobre la calificaci\u00f3n de equipos HPLC, PA/PH/OMCL (06) 86 DEF sobre la calificaci\u00f3n de equipos GC, y otros que cubren espectrofot\u00f3metros UV-visible, espectrofot\u00f3metros IR y tituladores autom\u00e1ticos.\n\n2. **\u00bfQu\u00e9 directrices proporciona la OMS sobre la validaci\u00f3n de m\u00e9todos anal\u00edticos y en qu\u00e9 informes se encuentran?**\n   - Respuesta: La OMS proporciona directrices sobre la validaci\u00f3n de m\u00e9todos anal\u00edticos en el informe de la *Expert Committee on Specifications for Pharmaceutical Preparations* (Fortieth report, 2006), que incluye un anexo sobre validaci\u00f3n de m\u00e9todos anal\u00edticos. Tambi\u00e9n se menciona el documento PA/PH/OMCL (05) 47 DEF sobre la validaci\u00f3n de procedimientos anal\u00edticos.\n\n3. **\u00bfQu\u00e9 importancia tiene la calificaci\u00f3n de instrumentos anal\u00edticos seg\u00fan la Farmacopea de EE. UU. y qu\u00e9 cap\u00edtulos espec\u00edficos se mencionan en el contexto?**\n   - Respuesta: La calificaci\u00f3n de instrumentos anal\u00edticos es crucial para asegurar la precisi\u00f3n y confiabilidad de los resultados en el an\u00e1lisis de productos farmac\u00e9uticos. En la 32\u00aa edici\u00f3n de la Farmacopea de EE. UU., se mencionan los cap\u00edtulos <1058> sobre la calificaci\u00f3n de instrumentos anal\u00edticos y <1225> y <1226> sobre la validaci\u00f3n y verificaci\u00f3n de procedimientos compendiales.", "prev_section_summary": "La secci\u00f3n proporcionada contiene una lista de referencias relacionadas con las buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) y la validaci\u00f3n de sistemas computarizados en el \u00e1mbito farmac\u00e9utico. A continuaci\u00f3n se resumen los temas clave y las entidades mencionadas:\n\n### Temas Clave:\n1. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (GMP)**: Directrices y recomendaciones para asegurar la calidad en la producci\u00f3n farmac\u00e9utica.\n2. **Validaci\u00f3n de Sistemas Computarizados**: Proceso de asegurar que los sistemas inform\u00e1ticos utilizados en la fabricaci\u00f3n y control de productos farmac\u00e9uticos funcionan correctamente y cumplen con los requisitos establecidos.\n3. **Regulaciones y Normativas**: Incluye regulaciones de la OMS, FDA y la UE sobre la gesti\u00f3n de datos electr\u00f3nicos y la validaci\u00f3n de sistemas.\n4. **Gu\u00edas de Buenas Pr\u00e1cticas Automatizadas (GAMP)**: Documentos que proporcionan directrices sobre la validaci\u00f3n de sistemas automatizados en laboratorios y la gesti\u00f3n de datos electr\u00f3nicos.\n5. **Pr\u00e1cticas de Laboratorio**: Normativas sobre buenas pr\u00e1cticas de laboratorio y pruebas de productos qu\u00edmicos.\n\n### Entidades Mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Proporciona directrices y recomendaciones sobre GMP y validaci\u00f3n.\n- **Administraci\u00f3n de Alimentos y Medicamentos de EE. UU. (FDA)**: Regula el uso de registros electr\u00f3nicos y firmas electr\u00f3nicas en la industria farmac\u00e9utica.\n- **Organizaci\u00f3n para la Cooperaci\u00f3n y el Desarrollo Econ\u00f3mico (OCDE)**: Ofrece directrices sobre buenas pr\u00e1cticas de laboratorio.\n- **Sociedad Internacional de Ingenier\u00eda Farmac\u00e9utica (ISPE)**: Publica gu\u00edas sobre buenas pr\u00e1cticas automatizadas.\n- **Consejo de Europa**: A trav\u00e9s de su red de Laboratorios de Control de Medicamentos Oficiales, proporciona documentos sobre la validaci\u00f3n de sistemas computarizados.\n\n### Documentos Espec\u00edficos:\n- Directrices de la OMS sobre la validaci\u00f3n de sistemas y equipos.\n- Regulaciones del 21 CFR Part 11 de la FDA sobre registros y firmas electr\u00f3nicas.\n- Anexos de la red de Laboratorios de Control de Medicamentos Oficiales del Consejo de Europa que abordan la validaci\u00f3n de sistemas computarizados, bases de datos y equipos de prueba.\n\nEste resumen destaca la importancia de la regulaci\u00f3n y las buenas pr\u00e1cticas en la industria farmac\u00e9utica, as\u00ed como la interconexi\u00f3n entre diferentes entidades y sus directrices.", "excerpt_keywords": "Keywords: validation, analytical procedures, quality assurance, pharmaceutical, equipment qualification"}}, "ae06a615-5c92-4d52-b938-f6b5dff9c1bc": {"node_ids": ["570d9214-026b-4faf-b558-2f3702c757e8"], "metadata": {"page_label": "138", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "```\nEvaluation and reporting of results (http://www.edqm.eu/medias/fichiers/ Evaluation_Reporting_of_Results.pdf).\n\n29. **Shewhart control charts.** International Organization for Standardization, 1991 (ISO 8258).\n\n30. **Official Medicines Control Laboratories Network of the Council of Europe, Quality Assurance Documents:**\n\n   \u2014 PA/PH/OMCL (05) 49 DEF CORR \u2014 Uncertainty of measurement \u2014 Part 1: General OMCL policy for implementation of measurement uncertainty in compliance testing (http://www.edqm.eu/medias/fichiers/Uncertainty_ of_Measurements_Part_I_Compliance_testing.pdf).\n\n   \u2014 PA/PH/OMCL (07) 106 DEF \u2014 Uncertainty of measurement \u2014 Part 2: OMCL policy on the estimation and application of uncertainty in analytical measurement (http://www.edqm.eu/medias/fichiers/ Uncertainty_of_Measurements_Part_II_Other_than_compliance_testing. pdf).\n\n31. **EURACHEM/Cooperation on International Traceability in Analytical Chemistry (CITAC) Guides.** *Quantifying uncertainty in analytical measurement,* 2nd ed, EURACHEM/CITAC, 2000.\n\n32. **EURACHEM/Cooperation on International Traceability in Analytical Chemistry (CITAC) Guides.** *Use of uncertainty information in compliance assessment,* EURACHEM/CITAC, 2007 (http://www.measurementuncertainty.org/).\n```\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 957\" incluye informaci\u00f3n sobre la evaluaci\u00f3n y el reporte de resultados en el contexto de laboratorios de control de medicamentos. Se mencionan gu\u00edas y documentos relacionados con la incertidumbre de medici\u00f3n, as\u00ed como est\u00e1ndares internacionales, como los gr\u00e1ficos de control de Shewhart y las pol\u00edticas de la Red de Laboratorios de Control de Medicamentos de Europa. Tambi\u00e9n se abordan gu\u00edas de EURACHEM sobre la cuantificaci\u00f3n de la incertidumbre en mediciones anal\u00edticas y su uso en la evaluaci\u00f3n de cumplimiento.\n\n### Preguntas\n1. **\u00bfQu\u00e9 documentos espec\u00edficos se mencionan en relaci\u00f3n con la incertidumbre de medici\u00f3n en el contexto de los laboratorios de control de medicamentos?**\n   - Respuesta: Se mencionan dos documentos de la Red de Laboratorios de Control de Medicamentos de Europa: PA/PH/OMCL (05) 49 DEF CORR, que trata sobre la pol\u00edtica general para la implementaci\u00f3n de la incertidumbre de medici\u00f3n en pruebas de cumplimiento, y PA/PH/OMCL (07) 106 DEF, que aborda la estimaci\u00f3n y aplicaci\u00f3n de la incertidumbre en mediciones anal\u00edticas.\n\n2. **\u00bfCu\u00e1l es el prop\u00f3sito de los gr\u00e1ficos de control de Shewhart seg\u00fan el contexto del documento?**\n   - Respuesta: Los gr\u00e1ficos de control de Shewhart, mencionados en el documento, son herramientas utilizadas para el control de calidad en procesos, permitiendo la visualizaci\u00f3n de la variabilidad en los resultados de mediciones y ayudando a identificar tendencias o desviaciones en el proceso.\n\n3. **\u00bfQu\u00e9 gu\u00edas de EURACHEM se citan en el documento y cu\u00e1l es su enfoque principal?**\n   - Respuesta: Se citan dos gu\u00edas de EURACHEM: \"Quantifying uncertainty in analytical measurement,\" que se centra en la cuantificaci\u00f3n de la incertidumbre en mediciones anal\u00edticas, y \"Use of uncertainty information in compliance assessment,\" que aborda c\u00f3mo utilizar la informaci\u00f3n sobre incertidumbre en la evaluaci\u00f3n de cumplimiento.", "prev_section_summary": "La secci\u00f3n proporciona informaci\u00f3n sobre la calidad y validaci\u00f3n de procedimientos anal\u00edticos en laboratorios de control de medicamentos, destacando documentos y directrices relevantes de diversas entidades. A continuaci\u00f3n se resumen los temas clave y entidades mencionadas:\n\n### Temas Clave:\n1. **Calificaci\u00f3n de Equipos Anal\u00edticos**: Se mencionan documentos espec\u00edficos que abordan la calificaci\u00f3n de diferentes tipos de equipos anal\u00edticos, como HPLC, GC, espectrofot\u00f3metros UV-visible e IR, y tituladores autom\u00e1ticos.\n2. **Validaci\u00f3n de M\u00e9todos Anal\u00edticos**: Se discuten directrices sobre la validaci\u00f3n de procedimientos anal\u00edticos, incluyendo la validaci\u00f3n de m\u00e9todos y procedimientos compendiales.\n3. **Muestreo de Productos Farmac\u00e9uticos**: Se incluyen pautas de la OMS sobre el muestreo de productos farmac\u00e9uticos y materiales relacionados.\n4. **Estabilidad de Ingredientes Activos**: Se abordan las pruebas de estabilidad de ingredientes farmac\u00e9uticos activos y productos farmac\u00e9uticos terminados.\n5. **Buenas Pr\u00e1cticas de Manufactura**: Se mencionan directrices suplementarias sobre la validaci\u00f3n en el contexto de las buenas pr\u00e1cticas de manufactura.\n\n### Entidades Mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Proporciona directrices y recomendaciones sobre la calidad y validaci\u00f3n de procedimientos anal\u00edticos.\n- **Farmacopea de EE. UU.**: Incluye cap\u00edtulos relevantes sobre la calificaci\u00f3n y validaci\u00f3n de instrumentos anal\u00edticos.\n- **Red de Laboratorios de Control de Medicamentos de Europa**: Publica documentos de calidad que abordan la calificaci\u00f3n y validaci\u00f3n de equipos y procedimientos anal\u00edticos.\n\n### Documentos Clave Citados:\n- PA/PH/OMCL documentos sobre calificaci\u00f3n y validaci\u00f3n de equipos.\n- Informes de la OMS sobre especificaciones para preparaciones farmac\u00e9uticas.\n- Directrices de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) sobre validaci\u00f3n de procedimientos anal\u00edticos.\n\nEste resumen destaca la importancia de la calificaci\u00f3n y validaci\u00f3n en el contexto de la calidad de los productos farmac\u00e9uticos y el cumplimiento de normativas internacionales.", "excerpt_keywords": "Keywords: incertidumbre de medici\u00f3n, gr\u00e1ficos de control, validaci\u00f3n anal\u00edtica, laboratorios de control de medicamentos, EURACHEM"}}, "21c0a27a-4243-4558-b285-896062db867d": {"node_ids": ["2c5b8818-24c9-4588-9d05-d619c26c784c"], "metadata": {"page_label": "139", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Appendix\n\n## Equipment for a first-stage and medium-sized pharmaceutical quality control laboratory\n\nA list of equipment considered by the Committee to be adequate either for a first-stage or medium-sized pharmaceutical quality control laboratory is given in the table. In the case of a medium-sized laboratory, specific sectors are devoted to a microbiology unit and pharmacognosy/phytochemistry unit. For a first-stage laboratory testing herbal medicines, the additional equipment recommended is specified in the table.\n\nThis list does not represent any requirements which should be fulfilled to comply with these guidelines. NMRAs or laboratories wishing to perform pharmaceutical analyses may consider the following list in the establishment or upgrading of their testing facilities. For budgetary reasons it is necessary, besides the cost of equipment, to take into consideration the cost of reference materials, reagents, solvents, glassware, other laboratory commodities and personnel. Experience has shown that for sustainability, a laboratory should allow a margin of 10\u201315% per year of the purchasing expenditure on equipment to cover the cost of maintenance.\n\n### Table\n\n**Equipment for a first-stage and medium-sized pharmaceutical quality control laboratory**\n\n| First-stage laboratory | Quantity |\n| - | - |\n| **Equipment and major instruments** | |\n| Top-loading balance | 1 |\n| Analytical balance (5 digits) | 1 or 2 |\n| Melting-point apparatus | 1 |\n| pH meter (with assorted electrodes) | 1 |\n| Microscope | 1 |\n| Polarimeter | 1 |\n| High-performance liquid chromatograph with ultraviolet detector | 2 |\n| Ultraviolet/visible spectrophotometer | 1 |\n| Infrared spectrophotometer with pellet press | 1 |\n| Karl Fischer titrator (semi-micro determination of water) | 1 |\n| Agate mortar with pestle | 1 |\n| Equipment for thin-layer chromatography | 1 |\n| Thin-layer chromatography spotter | 1 |\n| Developing chambers | 6 + 1a |\n| Atomizers | 6 |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona una lista de equipos recomendados para laboratorios de control de calidad farmac\u00e9utica de primera etapa y de tama\u00f1o mediano. Se menciona que los laboratorios de tama\u00f1o mediano deben tener unidades espec\u00edficas para microbiolog\u00eda y farmacognosia/fitoqu\u00edmica. Adem\u00e1s, se destaca que la lista no es un requisito obligatorio, sino una gu\u00eda para que las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) y laboratorios consideren al establecer o mejorar sus instalaciones de an\u00e1lisis farmac\u00e9utico. Tambi\u00e9n se enfatiza la importancia de considerar los costos de mantenimiento y otros insumos al planificar el presupuesto del laboratorio.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 tipo de equipo adicional se recomienda espec\u00edficamente para un laboratorio de primera etapa que se dedica a la prueba de medicamentos herbales?**\n   - Esta pregunta busca informaci\u00f3n sobre los equipos que son necesarios para un laboratorio que se especializa en medicamentos herbales, que no se menciona expl\u00edcitamente en la tabla.\n\n2. **\u00bfCu\u00e1l es la proporci\u00f3n recomendada del gasto en equipos que un laboratorio debe reservar anualmente para cubrir los costos de mantenimiento?**\n   - Esta pregunta se centra en la sostenibilidad financiera del laboratorio, un aspecto que puede no ser evidente en otros documentos relacionados.\n\n3. **\u00bfQu\u00e9 consideraciones presupuestarias deben tener en cuenta las NMRAs al establecer un laboratorio de control de calidad farmac\u00e9utica?**\n   - Esta pregunta busca detalles sobre los factores financieros que deben ser considerados m\u00e1s all\u00e1 del costo del equipo, como materiales de referencia, reactivos y personal, que son cruciales para la operaci\u00f3n efectiva del laboratorio.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Evaluaci\u00f3n y Reporte de Resultados**: Se aborda la importancia de la evaluaci\u00f3n y el reporte de resultados en el contexto de los laboratorios de control de medicamentos.\n\n2. **Gr\u00e1ficos de Control de Shewhart**: Se menciona el uso de gr\u00e1ficos de control de Shewhart como herramientas para el control de calidad, que permiten visualizar la variabilidad en los resultados de mediciones.\n\n3. **Incertidumbre de Medici\u00f3n**: Se citan documentos espec\u00edficos de la Red de Laboratorios de Control de Medicamentos de Europa que tratan sobre la pol\u00edtica de implementaci\u00f3n y estimaci\u00f3n de la incertidumbre de medici\u00f3n en pruebas de cumplimiento y en mediciones anal\u00edticas.\n\n4. **Gu\u00edas de EURACHEM**: Se mencionan dos gu\u00edas de EURACHEM:\n   - *Quantifying uncertainty in analytical measurement* (2\u00aa ed., 2000): Enfocada en la cuantificaci\u00f3n de la incertidumbre en mediciones anal\u00edticas.\n   - *Use of uncertainty information in compliance assessment* (2007): Aborda el uso de la informaci\u00f3n sobre incertidumbre en la evaluaci\u00f3n de cumplimiento.\n\n### Entidades Clave\n- **Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO)**: Referenciada en relaci\u00f3n con los gr\u00e1ficos de control de Shewhart.\n- **Red de Laboratorios de Control de Medicamentos de Europa (OMCL)**: Proporciona documentos sobre la incertidumbre de medici\u00f3n.\n- **EURACHEM**: Organizaci\u00f3n que ofrece gu\u00edas sobre la incertidumbre en mediciones anal\u00edticas y su aplicaci\u00f3n en la evaluaci\u00f3n de cumplimiento. \n\nEste resumen destaca los aspectos fundamentales del contenido, centr\u00e1ndose en la evaluaci\u00f3n de resultados, la incertidumbre de medici\u00f3n y las gu\u00edas relevantes para los laboratorios de control de medicamentos.", "excerpt_keywords": "Keywords: pharmaceutical quality control, laboratory equipment, herbal medicines, budget considerations, sustainability"}}, "12605885-5ed8-40e6-a888-5c34871c7242": {"node_ids": ["c150a8d2-e191-4c89-b1ef-af078d380260"], "metadata": {"page_label": "140", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\n| First-stage laboratory (cont.) | First-stage laboratory (cont.) |\n| - | - |\n| Ultraviolet viewing lamp | 1 |\n| Disintegration test equipment (1 basket for 6 tablets) | 1 |\n| Dissolution apparatus | 1 |\n| Soxhlet extraction apparatus (60 ml) | 3 + 1a |\n| Micrometer callipers | 1 |\n| Pycnometers | 2 |\n| Burettes/pipettes (10 ml and 25 ml/1, 2, 5, 10, 20, 25, 50 ml) | 3 of each |\n| Desiccator | 1 + 1a |\n| Centrifuge (table-top model, 4-place swing rotor) | 1 |\n| Water-bath (20 litres) | 1 |\n| Hot plates with magnetic stirrers | 3 |\n| Vacuum pump (rotary, oil) | 1 |\n| Drying oven (60 litres) | 1 |\n| Vacuum oven (17 litres) | 1 |\n| Muffle furnace | 1 |\n| Refrigerator (explosion-proof) | 1 |\n| Water distilling apparatus (8 litres/hour) | 1 |\n| Water deionizer (10 litres/hour) | 1 |\n| Dehumidifier (where needed) | 1 |\n| Fume hood | 1 |\n\n\n| Optional items | Optional items |\n| - | - |\n| Analytical microbalance | 1 |\n| Flame photometer (including air compressor) | 1 |\n| Refractometer | 1 |\n| Viscometer | 1 |\n| Vortex mixer | 1 |\n| Shaker (wrist-action) | 1 |\n| Pipette rinser | 1 |\n| Constant temperature water-bath | 1 |\n| Ultrasonic cleaner (5 litres) | 1 |\n\n\n| Medium-sized laboratory\\<br/>Equipment and major instruments | Medium-sized laboratory\\<br/>Quantity |\n| - | - |\n| Top-loading balance | 1 or 2 |\n| Analytical balance (5 digits) | 2 |\n| Analytical microbalance | 1 |\n\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1ntos Soxhlet extraction apparatus se requieren en un primer laboratorio de etapa?**\n   - Se requieren tres Soxhlet extraction apparatus de 60 ml, m\u00e1s uno adicional (3 + 1a).\n\n2. **\u00bfQu\u00e9 tipo de refrigerador se especifica para el primer laboratorio de etapa?**\n   - Se especifica un refrigerador que sea a prueba de explosiones.\n\n3. **\u00bfCu\u00e1ntos tipos diferentes de buretas y pipetas se necesitan y en qu\u00e9 vol\u00famenes?**\n   - Se necesitan tres buretas/pipetas de cada uno de los siguientes vol\u00famenes: 10 ml y 25 ml, as\u00ed como de 1, 2, 5, 10, 20, 25 y 50 ml.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona una lista detallada de equipos y aparatos necesarios para establecer un laboratorio de primer nivel y de tama\u00f1o mediano, seg\u00fan las recomendaciones de la OMS. Incluye tanto elementos obligatorios como opcionales, especificando cantidades y caracter\u00edsticas de cada uno. Los equipos abarcan desde instrumentos b\u00e1sicos como l\u00e1mparas UV y balanzas anal\u00edticas hasta aparatos m\u00e1s especializados como hornos de mufla y extractores Soxhlet.\n\n### Preguntas adicionales basadas en el resumen:\n4. **\u00bfQu\u00e9 tipo de balance se recomienda para un laboratorio de tama\u00f1o mediano y cu\u00e1ntos se deben tener?**\n   - Se recomienda tener uno o dos balances de carga superior y dos balances anal\u00edticos de 5 d\u00edgitos, adem\u00e1s de un microbalanza anal\u00edtica.\n\n5. **\u00bfQu\u00e9 tipo de equipo opcional se sugiere para mejorar las capacidades del laboratorio?**\n   - Se sugiere equipo opcional como un fot\u00f3metro de llama, un refract\u00f3metro, un viscometro, un mezclador de v\u00f3rtice, y un limpiador ultras\u00f3nico de 5 litros, entre otros.\n\n6. **\u00bfCu\u00e1l es la funci\u00f3n de un deshidratador en el laboratorio y cu\u00e1ndo es necesario?**\n   - Un deshidratador se utiliza para eliminar la humedad del aire en el laboratorio y se requiere donde sea necesario, dependiendo de las condiciones ambientales y los experimentos que se realicen.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Equipos Recomendados**: Se presenta una lista de equipos considerados adecuados para laboratorios de control de calidad farmac\u00e9utica de primera etapa y de tama\u00f1o mediano. Esta lista incluye instrumentos como balanzas, espectrofot\u00f3metros, y equipos para cromatograf\u00eda.\n\n2. **Laboratorios de Tama\u00f1o Mediano**: Se menciona que estos laboratorios deben contar con unidades espec\u00edficas para microbiolog\u00eda y farmacognosia/fitoqu\u00edmica.\n\n3. **Gu\u00eda y No Requisitos**: La lista de equipos no es un requisito obligatorio, sino una gu\u00eda para las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) y laboratorios que deseen establecer o mejorar sus instalaciones.\n\n4. **Consideraciones Presupuestarias**: Se enfatiza la importancia de considerar no solo el costo del equipo, sino tambi\u00e9n los costos de materiales de referencia, reactivos, solventes, vidrio de laboratorio y personal al planificar el presupuesto.\n\n5. **Sostenibilidad Financiera**: Se recomienda que un laboratorio reserve entre el 10% y el 15% del gasto en equipos anualmente para cubrir los costos de mantenimiento.\n\n### Entidades Clave\n\n- **NMRAs**: Autoridades Nacionales Reguladoras de Medicamentos que pueden utilizar esta gu\u00eda para establecer laboratorios.\n- **Equipos de Laboratorio**: Incluyen balanzas, espectrofot\u00f3metros, cromat\u00f3grafos, entre otros.\n- **Unidades Espec\u00edficas**: Microbiolog\u00eda y farmacognosia/fitoqu\u00edmica en laboratorios de tama\u00f1o mediano. \n\nEste resumen destaca la importancia de la planificaci\u00f3n adecuada y la sostenibilidad en la operaci\u00f3n de laboratorios de control de calidad farmac\u00e9utica.", "excerpt_keywords": "Keywords: laboratory equipment, WHO guidelines, pharmaceutical quality control, analytical instruments, laboratory setup"}}, "17f68f55-cab6-4fd2-9bcd-b75e92e72b33": {"node_ids": ["163589c7-2d38-4505-8cc1-d5de8ae8f72c"], "metadata": {"page_label": "141", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\n| Medium-sized laboratory (cont.) | |\n| - | - |\n| Microscope | 1 or 2 |\n| Equipment for thin-layer chromatography | 1 |\n| Thin-layer chromatography multispotter | 1 |\n| Developing chambers | 6 |\n| Atomizers | 6 |\n| Ultraviolet viewing lamp | 1 |\n| Potentiometric titrimeter | 1 |\n| Micro-Kjeldahl equipment (including fume flasks) | 1 |\n| Soxhlet extraction apparatus (60 ml) | 3 |\n| Pycnometers | 2 |\n| Burettes/pipettes (10 ml and 25 ml/1, 2, 5, 10, 20, 25, 50 ml) | 6 of each |\n| Micrometer callipers | 1 |\n| Heating mantles for flasks (assorted sizes: 50, 200 and 2000 ml) | 6 |\n| Sieves (assorted sizes) | 1 set |\n| Centrifuge (floor model) | 1 |\n| Shaker (wrist-action) | 1 |\n| Vortex mixers | 2 |\n| Water-bath (electrical, 20 litres) | 2 or 3 |\n| Hot plates with magnetic stirrers | 3 or 4 |\n| Vacuum pump (rotary, oil) | 2 |\n| Vacuum rotary evaporator | 1 |\n| Drying oven (60 litres) | 2 or 3 |\n| Muffle furnace (23 litres) | 1 |\n| Vacuum oven (17 litres) | 1 |\n| Desiccators | 2 |\n| Refrigerator (explosion-proof) | 2 |\n| Freezer | 1 |\n| Ultrasonic cleaners (5 litres) | 2 |\n| Laboratory glassware washing machine | 1 |\n| Water distilling apparatus (8 litres/hour) | 1 |\n| Water deionizing equipment (10 litres/hour) | 1 |\n| Fume hoods | 2 |\n| Melting-point apparatus | 1 |\n| Polarimeter | 1 |\n| pH meters (with assorted electrodes) | 2 |\n| High-performance liquid chromatograph with variable wavelength | |\n| Ultraviolet/visible detector | 3 or 4 |\n\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 957\" detalla el equipamiento necesario para un laboratorio de tama\u00f1o mediano, incluyendo una lista exhaustiva de instrumentos y equipos esenciales para realizar diversas pruebas y an\u00e1lisis. La lista incluye microscopios, equipos de cromatograf\u00eda, centr\u00edfugas, y otros dispositivos de laboratorio, junto con cantidades recomendadas para cada uno.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1ntos tipos de equipos de cromatograf\u00eda se mencionan en el contexto y cu\u00e1les son?**\n   - Respuesta: Se mencionan dos tipos de equipos de cromatograf\u00eda: \"Equipo para cromatograf\u00eda en capa fina\" (1 unidad) y \"Cromat\u00f3grafo l\u00edquido de alta eficacia con longitud de onda variable\" (sin cantidad especificada).\n\n2. **\u00bfQu\u00e9 tipo de equipo se recomienda para la determinaci\u00f3n del pH y cu\u00e1ntas unidades se sugieren?**\n   - Respuesta: Se recomienda el uso de \"pH metros (con electrodos variados)\" y se sugieren 2 unidades.\n\n3. **\u00bfQu\u00e9 equipos de refrigeraci\u00f3n est\u00e1n incluidos en la lista y cu\u00e1ntas unidades de cada uno se requieren?**\n   - Respuesta: La lista incluye \"Refrigerador (a prueba de explosiones)\" con 2 unidades y \"Congelador\" con 1 unidad.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Equipos de laboratorio**: La secci\u00f3n detalla una lista de equipos y aparatos necesarios para establecer un laboratorio de primer nivel y de tama\u00f1o mediano, seg\u00fan las recomendaciones de la OMS.\n\n2. **Categor\u00edas de equipos**:\n   - **Equipos obligatorios**: Incluyen l\u00e1mparas UV, equipos de prueba de desintegraci\u00f3n, aparatos de disoluci\u00f3n, extractores Soxhlet, balanzas, centr\u00edfugas, hornos, refrigeradores a prueba de explosiones, entre otros.\n   - **Equipos opcionales**: Se mencionan elementos como fot\u00f3metros de llama, refract\u00f3metros, viscometros, mezcladores de v\u00f3rtice y limpiadores ultras\u00f3nicos.\n\n3. **Cantidades espec\u00edficas**: Se especifican las cantidades requeridas para cada tipo de equipo, como por ejemplo:\n   - 1 l\u00e1mpara UV\n   - 3 extractores Soxhlet\n   - 1 refrigerador a prueba de explosiones\n   - 1 o 2 balances de carga superior en laboratorios de tama\u00f1o mediano.\n\n4. **Instrumentos de medici\u00f3n**: Se incluyen instrumentos de medici\u00f3n precisos como balances anal\u00edticos y microbalanzas, esenciales para la investigaci\u00f3n y an\u00e1lisis en el laboratorio.\n\n5. **Condiciones ambientales**: Se menciona la necesidad de un deshidratador en funci\u00f3n de las condiciones ambientales del laboratorio.\n\n6. **Funcionalidad de los equipos**: Cada equipo tiene una funci\u00f3n espec\u00edfica que contribuye a la realizaci\u00f3n de experimentos y an\u00e1lisis en el laboratorio, desde la medici\u00f3n precisa hasta la manipulaci\u00f3n de sustancias qu\u00edmicas.\n\n### Entidades clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Fuente de las recomendaciones.\n- **Tipos de equipos**: L\u00e1mparas UV, extractores Soxhlet, balances, refrigeradores, etc.\n- **Categor\u00edas**: Equipos obligatorios y opcionales.\n- **Cantidades**: Especificaciones num\u00e9ricas para cada tipo de equipo. \n\nEste resumen proporciona una visi\u00f3n general de los elementos esenciales y opcionales necesarios para establecer un laboratorio eficaz, as\u00ed como la importancia de cada uno en el contexto de la investigaci\u00f3n cient\u00edfica.", "excerpt_keywords": "Keywords: laboratory equipment, WHO recommendations, medium-sized laboratory, analytical instruments, chromatography"}}, "fbbcb968-159c-4d68-a64c-75f96224aec9": {"node_ids": ["e74dd961-38af-4dd5-a21f-e2e2f27c8510"], "metadata": {"page_label": "142", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "| Medium-sized laboratory (cont.) | |\n| - | - |\n| Ultraviolet/visible spectrophotometer, double-beam | 1 |\n| Infrared spectrophotometer with pellet press | 1 |\n| Agate mortar with pestle | 1 |\n| Gas chromatograph (flame ionization, direct and static head space injection) | 1 |\n| Refractometer | 1 |\n| Karl Fischer titrators (1 semi-micro and 1 coulometric for micro-determination of water) | 2 |\n| Oxygen flask combustion apparatus | 1 |\n| Disintegration test equipment (1 basket for 6 tablets) | 1 |\n| Dissolution test equipment (for 6 tablets/capsules) | 1 |\n| **Optional items** | |\n| Atomic absorption spectrophotometer | 1 |\n| Spectrofluorometer | 1 |\n| High-performance liquid chromatograph detectors: | |\n| \u2014 fluorescence | 1 |\n| \u2014 diode-array | 1 |\n| \u2014 refractive index | 1 |\n| \u2014 evaporative light scattering (ELSD) | 1 |\n| \u2014 charged aerosol (CAD) | 1 |\n| \u2014 mass spectrometric (MS) | 1 |\n| Gas chromatograph detectors: | |\n| \u2014 conductivity | 1 |\n| \u2014 nitrogen/phosphorous (NPD) | 1 |\n| \u2014 mass spectrometric (MS) | 1 |\n| Capillary electrophoresis equipment | 1 |\n| Thin-layer chromatography scanner | 1 |\n| Crushing strength tester | 1 |\n| Friability tester | 1 |\n| Viscometer | 1 |\n| Ice machine | 1 |\n| Solvent-recovery apparatus | 1 |\n| **Equipment for microbiology unit** | |\n| pH meter | 1 |\n| Ultraviolet/visible spectrophotometer, single-beam | 1 |\n| Microscopes (for bacteriology) | 2 |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior que puede ayudar a formular preguntas m\u00e1s relevantes:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 957\" detalla el equipamiento necesario para un laboratorio de tama\u00f1o mediano, incluyendo instrumentos de an\u00e1lisis f\u00edsico-qu\u00edmico y microbiol\u00f3gico. Se enumeran equipos esenciales y opcionales, as\u00ed como herramientas espec\u00edficas para la determinaci\u00f3n de propiedades de sustancias y an\u00e1lisis microbiol\u00f3gicos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1ntos tipos de espectrofot\u00f3metros se mencionan en el contexto y cu\u00e1les son sus caracter\u00edsticas?**\n   - Respuesta: Se mencionan dos tipos de espectrofot\u00f3metros: un espectrofot\u00f3metro ultravioleta/visible de doble haz y un espectrofot\u00f3metro ultravioleta/visible de haz simple.\n\n2. **\u00bfQu\u00e9 equipos son necesarios para realizar pruebas de disoluci\u00f3n y desintegraci\u00f3n en tabletas?**\n   - Respuesta: Se requiere un equipo de prueba de disoluci\u00f3n (para 6 tabletas/c\u00e1psulas) y un equipo de prueba de desintegraci\u00f3n (con una canasta para 6 tabletas).\n\n3. **\u00bfQu\u00e9 tipo de equipos microbiol\u00f3gicos se incluyen en la lista y cu\u00e1ntos de cada uno se necesitan?**\n   - Respuesta: Se incluyen un medidor de pH (1 unidad), un espectrofot\u00f3metro ultravioleta/visible de haz simple (1 unidad) y microscopios para bacteriolog\u00eda (2 unidades).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido proporcionado detalla el equipamiento necesario para un laboratorio de tama\u00f1o mediano, seg\u00fan el documento \"WHO - Technical Report Series 957\". A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Equipamiento de Laboratorio**: Se enumeran diversos instrumentos y equipos esenciales para realizar pruebas y an\u00e1lisis en un laboratorio.\n2. **Cromatograf\u00eda**: Se mencionan equipos espec\u00edficos para cromatograf\u00eda en capa fina y cromatograf\u00eda l\u00edquida de alta eficacia.\n3. **Equipos de Refrigeraci\u00f3n**: Incluye refrigeradores y congeladores, esenciales para la conservaci\u00f3n de muestras.\n4. **Instrumentos de Medici\u00f3n**: Se destacan equipos como pH metros y potenci\u00f3metros, utilizados para mediciones precisas en an\u00e1lisis qu\u00edmicos.\n5. **Equipos de Calentamiento y Secado**: Se incluyen mantas de calentamiento, hornos de secado y muflas, necesarios para procesos de calentamiento y secado de muestras.\n6. **Centrifugaci\u00f3n y Mezcla**: Se mencionan centrifugadoras y mezcladores, que son cruciales para la separaci\u00f3n y mezcla de componentes en soluciones.\n\n#### Entidades Mencionadas:\n- **Microscopio**: 1 o 2 unidades.\n- **Equipo para cromatograf\u00eda en capa fina**: 1 unidad.\n- **Cromat\u00f3grafo l\u00edquido de alta eficacia**: Sin cantidad especificada.\n- **pH metros**: 2 unidades.\n- **Refrigerador (a prueba de explosiones)**: 2 unidades.\n- **Congelador**: 1 unidad.\n- **Centr\u00edfuga (modelo de suelo)**: 1 unidad.\n- **Horno de secado (60 litros)**: 2 o 3 unidades.\n- **Mufla (23 litros)**: 1 unidad.\n- **Deshidratadores**: 2 unidades.\n- **Ultrasonic cleaners (5 litros)**: 2 unidades.\n\nEste resumen proporciona una visi\u00f3n general de los equipos y su importancia en el contexto de un laboratorio de tama\u00f1o mediano, as\u00ed como las cantidades recomendadas para cada tipo de equipo.", "excerpt_keywords": "Keywords: laboratory equipment, spectrophotometer, chromatography, microbiology, analytical instruments"}}, "6dff4e86-ecdb-4954-a327-da5e9aa3bbd1": {"node_ids": ["1aa0bef6-38dc-4af6-a128-43003142963c"], "metadata": {"page_label": "143", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "| Medium-sized laboratory (cont.) | Medium-sized laboratory (cont.) |\n| - | - |\n| Membrane filter assembly for sterility tests | 1 |\n| Colony counter with magnifier | 1 |\n| Laminar air flow unit | 1 |\n| Hot-air sterilizer | 1 |\n| Incubators, 60 litres | 2 or 3 |\n| Anaerobic jar | 1 |\n| Zone reader | 1 |\n| Centrifuge | 1 |\n| Water-bath (thermostatically controlled) | 2 |\n| Autoclaves (100 litres, top-loading) | 2 |\n| Refrigerators (340 litres) | 2 |\n| Deep freeze | 1 |\n| Laboratory glassware washing machine | 1 |\n\n\n| Equipment for pharmacognosy/phytochemistry unit | Equipment for pharmacognosy/phytochemistry unit |\n| - | - |\n| Grinder/mill (for preparation of sample of herbal materials) | 1 |\n| Top loading balance | 1 |\n| Sieves | 1 set |\n| Microscopeb | 1 |\n| Soxhlet extraction apparatus | 2 or 3 |\n| Water-bath | 1 |\n| Heating mantles for flasks | 1 or 2 |\n| Hot plates with magnetic stirrers | 2 |\n| Equipment for thin-layer chromatography | 1 or 2 |\n| Developing chambers | 3 or 4 |\n| Desiccators | 2 |\n| Rotary vacuum apparatus | 1 |\n| Distillation equipment | 1 |\n| Conical percolators | 2 or 3 |\n| Apparatus for determination of water content by azeotropic methodb | 1 |\n| Apparatus for determination of volatile oilsb | 1 |\n| Apparatus for determination of arsenic limit testc | 1 |\n\n\n<sup>a</sup> Needed in the case that herbal medicines are also tested.  \n<sup>b</sup> *Quality control methods for medicinal plant materials*. Geneva, World Health Organization, 1998.  \n<sup>c</sup> *WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues*. Geneva, World Health Organization, 2006.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que detalla el equipo necesario para un laboratorio de tama\u00f1o mediano y una unidad de farmacognosia/fitoqu\u00edmica. Se enumeran diversos equipos, incluyendo filtros de membrana, incubadoras, autoclaves, y aparatos para extracci\u00f3n y an\u00e1lisis de compuestos de origen vegetal. Tambi\u00e9n se mencionan referencias a m\u00e9todos de control de calidad para materiales de plantas medicinales y directrices sobre la evaluaci\u00f3n de la calidad de los medicamentos herbales.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de equipo se recomienda para realizar pruebas de esterilidad en un laboratorio de tama\u00f1o mediano?**\n   - Respuesta: Se recomienda un ensamblaje de filtro de membrana para pruebas de esterilidad, junto con un contador de colonias con lupa, una unidad de flujo de aire laminar, y un esterilizador de aire caliente.\n\n2. **\u00bfCu\u00e1ntos Soxhlet extraction apparatus se sugieren para la unidad de farmacognosia/fitoqu\u00edmica?**\n   - Respuesta: Se sugieren de 2 a 3 aparatos de extracci\u00f3n Soxhlet para la unidad de farmacognosia/fitoqu\u00edmica.\n\n3. **\u00bfQu\u00e9 equipos son necesarios para la determinaci\u00f3n de contenido de agua y aceites vol\u00e1tiles en materiales herbales?**\n   - Respuesta: Se necesita un aparato para la determinaci\u00f3n del contenido de agua por el m\u00e9todo azeotr\u00f3pico y un aparato para la determinaci\u00f3n de aceites vol\u00e1tiles, ambos en la unidad de farmacognosia/fitoqu\u00edmica.\n\n### Resumen de Nivel Superior\nEl informe de la OMS proporciona una gu\u00eda detallada sobre el equipo necesario para laboratorios que trabajan con materiales herbales y medicamentos, enfatizando la importancia de la calidad y la seguridad en el an\u00e1lisis de productos de origen vegetal. Se incluyen equipos espec\u00edficos para pruebas de esterilidad y an\u00e1lisis fitoqu\u00edmico, as\u00ed como referencias a est\u00e1ndares de calidad y m\u00e9todos de evaluaci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento \"WHO - Technical Report Series 957\" proporciona una lista detallada del equipamiento necesario para un laboratorio de tama\u00f1o mediano, dividiendo los equipos en esenciales y opcionales, as\u00ed como en categor\u00edas espec\u00edficas para an\u00e1lisis f\u00edsico-qu\u00edmico y microbiol\u00f3gico.\n\n#### Equipos esenciales:\n1. **Espectrofot\u00f3metros:**\n   - Ultraviolet/visible, doble haz (1 unidad)\n   - Ultraviolet/visible, haz simple (1 unidad en microbiolog\u00eda)\n\n2. **Espectrofot\u00f3metros de infrarrojos:**\n   - Con prensa de pellet (1 unidad)\n\n3. **Equipos de cromatograf\u00eda:**\n   - Cromat\u00f3grafo de gases (1 unidad)\n   - Detectores de cromatograf\u00eda l\u00edquida de alto rendimiento (HPLC) y cromatograf\u00eda de gases (1 unidad cada uno para varios tipos)\n\n4. **Equipos de titulaci\u00f3n:**\n   - Tituladores de Karl Fischer (2 unidades)\n\n5. **Equipos de pruebas de disoluci\u00f3n y desintegraci\u00f3n:**\n   - Equipos para pruebas de disoluci\u00f3n (1 unidad)\n   - Equipos para pruebas de desintegraci\u00f3n (1 unidad)\n\n6. **Otros equipos:**\n   - Mortero de \u00e1gata con pistilo (1 unidad)\n   - Refract\u00f3metro (1 unidad)\n   - Aparato de combusti\u00f3n en frasco de ox\u00edgeno (1 unidad)\n   - Equipos para pruebas de resistencia a la trituraci\u00f3n y friabilidad (1 unidad cada uno)\n   - Viscometro (1 unidad)\n   - M\u00e1quina de hielo (1 unidad)\n   - Aparato de recuperaci\u00f3n de solventes (1 unidad)\n\n#### Equipos opcionales:\n- Espectrofot\u00f3metro de absorci\u00f3n at\u00f3mica (1 unidad)\n- Espectrofluor\u00f3metro (1 unidad)\n- Equipos de detecci\u00f3n para HPLC y cromatograf\u00eda de gases (1 unidad cada uno para varios tipos)\n\n#### Equipos para la unidad de microbiolog\u00eda:\n- Medidor de pH (1 unidad)\n- Microscopios para bacteriolog\u00eda (2 unidades)\n\n### Entidades clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Laboratorio de tama\u00f1o mediano**\n- **Equipos de an\u00e1lisis f\u00edsico-qu\u00edmico**\n- **Equipos de microbiolog\u00eda**\n\nEste resumen destaca la importancia de contar con un equipamiento adecuado para realizar an\u00e1lisis precisos y efectivos en un laboratorio, as\u00ed como la variedad de instrumentos necesarios para diferentes tipos de pruebas.", "excerpt_keywords": "Keywords: laboratory equipment, pharmacognosy, phytochemistry, sterility tests, herbal medicines"}}, "ea1d0b40-2d09-4cbd-9acb-112f7f16babd": {"node_ids": ["a76c61cd-c15d-4c0f-b841-e053148000a7"], "metadata": {"page_label": "144", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 2\n\n## WHO good manufacturing practices for active pharmaceutical ingredients\n\n1. **Introduction**\n   1.1 Objective  \n   1.2 Regulatory applicability  \n   1.3 Scope  \n\n2. **Quality management**\n   2.1 Principles  \n   2.2 Responsibilities of the quality unit(s)  \n   2.3 Responsibility for production activities  \n   2.4 Internal audits (self-inspection)  \n   2.5 Product quality review  \n\n3. **Personnel**\n   3.1 Personnel qualifications  \n   3.2 Personnel hygiene  \n   3.3 Consultants  \n\n4. **Buildings and facilities**\n   4.1 Design and construction  \n   4.2 Utilities  \n   4.3 Water  \n   4.4 Containment  \n   4.5 Lighting  \n   4.6 Sewage and refuse  \n   4.7 Sanitation and maintenance  \n\n5. **Process equipment**\n   5.1 Design and construction  \n   5.2 Equipment maintenance and cleaning  \n   5.3 Calibration  \n   5.4 Computerized systems  \n\n6. **Documentation and records**\n   6.1 Documentation system and specifications  \n   6.2 Equipment cleaning and use record  \n   6.3 Records of raw materials, intermediates, API labelling and packaging materials  \n   6.4 Master production instructions (master production and control records)  \n   6.5 Batch production records (batch production and control records)  \n   6.6 Laboratory control records  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior\nEl documento \"WHO - Technical Report Series 957\" incluye un anexo que detalla las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para los ingredientes farmac\u00e9uticos activos (API). Este anexo abarca varios aspectos esenciales, como la gesti\u00f3n de calidad, la calificaci\u00f3n y la higiene del personal, el dise\u00f1o y la construcci\u00f3n de instalaciones, el mantenimiento de equipos, y la documentaci\u00f3n y registros necesarios para asegurar la calidad y la seguridad en la producci\u00f3n de API.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas del personal de calidad seg\u00fan las buenas pr\u00e1cticas de fabricaci\u00f3n para los ingredientes farmac\u00e9uticos activos?**\n   - Esta pregunta se centra en el apartado 2.2 del documento, que detalla las responsabilidades de las unidades de calidad.\n\n2. **\u00bfQu\u00e9 aspectos se consideran en el dise\u00f1o y construcci\u00f3n de edificios y instalaciones para la producci\u00f3n de ingredientes farmac\u00e9uticos activos?**\n   - Esta pregunta se relaciona con el apartado 4.1 y otros subapartados que abordan el dise\u00f1o y la construcci\u00f3n de las instalaciones.\n\n3. **\u00bfQu\u00e9 tipo de registros se deben mantener para asegurar la calidad del proceso de producci\u00f3n de ingredientes farmac\u00e9uticos activos?**\n   - Esta pregunta se refiere a la secci\u00f3n 6, que detalla los diferentes tipos de documentaci\u00f3n y registros necesarios, como los registros de limpieza de equipos y los registros de producci\u00f3n por lotes. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otros documentos o fuentes, ya que se basan en detalles concretos del contexto proporcionado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Tipo de Laboratorio**: Se describe el equipo necesario para un laboratorio de tama\u00f1o mediano y una unidad de farmacognosia/fitoqu\u00edmica.\n\n2. **Equipos para Pruebas de Esterilidad**:\n   - Filtro de membrana para pruebas de esterilidad.\n   - Contador de colonias con lupa.\n   - Unidad de flujo de aire laminar.\n   - Esterilizador de aire caliente.\n   - Incubadoras (2 o 3 unidades de 60 litros).\n   - Otros equipos como autoclaves, refrigeradores y centrifugas.\n\n3. **Equipos para la Unidad de Farmacognosia/Fitoqu\u00edmica**:\n   - Molino/grinder para preparaci\u00f3n de muestras de materiales herbales.\n   - Balanza de carga superior.\n   - Microscopio.\n   - Aparatos de extracci\u00f3n Soxhlet (2 o 3 unidades).\n   - Equipos para cromatograf\u00eda en capa fina y distilaci\u00f3n.\n\n4. **Determinaci\u00f3n de Contenido**:\n   - Aparatos para determinar el contenido de agua por el m\u00e9todo azeotr\u00f3pico.\n   - Aparatos para determinar aceites vol\u00e1tiles y pruebas de l\u00edmite de ars\u00e9nico.\n\n5. **Referencias**:\n   - M\u00e9todos de control de calidad para materiales de plantas medicinales (1998).\n   - Directrices de la OMS para evaluar la calidad de medicamentos herbales (2006).\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que proporciona directrices y est\u00e1ndares.\n- **Equipos de laboratorio**: Incluyen filtros de membrana, incubadoras, autoclaves, y equipos de extracci\u00f3n y an\u00e1lisis.\n- **Farmacognosia/Fitoqu\u00edmica**: Disciplina que estudia los productos de origen vegetal y su calidad.\n\n### Conclusi\u00f3n\nEl informe de la OMS es una gu\u00eda exhaustiva sobre el equipo necesario para laboratorios que trabajan con materiales herbales, subrayando la importancia de la calidad y la seguridad en el an\u00e1lisis de productos de origen vegetal.", "excerpt_keywords": "Keywords: good manufacturing practices, active pharmaceutical ingredients, quality management, documentation, personnel qualifications"}}, "c0645f08-762b-4cd7-a250-a60a43141a0e": {"node_ids": ["bf9109cd-3780-48ee-aa97-e6e8423bf76f"], "metadata": {"page_label": "145", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 6.7 Batch production record review\n\n# 7. Materials management\n- 7.1 General controls\n- 7.2 Receipt and quarantine\n- 7.3 Sampling and testing of incoming production materials\n- 7.4 Storage\n- 7.5 Re-evaluation\n\n# 8. Production and in-process controls\n- 8.1 Production operations\n- 8.2 Time limits\n- 8.3 In-process sampling and controls\n- 8.4 Blending batches of intermediates or APIs\n- 8.5 Contamination control\n\n# 9. Packaging and identification labelling of APIs and intermediates\n- 9.1 General\n- 9.2 Packaging materials\n- 9.3 Label issuance and control\n- 9.4 Packaging and labelling operations\n\n# 10. Storage and distribution\n- 10.1 Warehousing procedures\n- 10.2 Distribution procedures\n\n# 11. Laboratory controls\n- 11.1 General controls\n- 11.2 Testing of intermediates and APIs\n- 11.3 Validation of analytical procedures\n- 11.4 Certificates of analysis\n- 11.5 Stability monitoring of APIs\n- 11.6 Expiry and retest dating\n- 11.7 Reserve/retention samples\n\n# 12. Validation\n- 12.1 Validation policy\n- 12.2 Validation documentation\n- 12.3 Qualification\n- 12.4 Approaches to process validation\n- 12.5 Process validation programme\n- 12.6 Periodic review of validated systems\n- 12.7 Cleaning validation\n- 12.8 Validation of analytical methods\n\n# 13. Change control\n\n# 14. Rejection and reuse of materials\n- 14.1 Rejection\n- 14.2 Reprocessing\n- 14.3 Reworking\n- 14.4 Recovery of materials and solvents", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 957\" aborda diversas \u00e1reas cr\u00edticas en la producci\u00f3n y control de materiales farmac\u00e9uticos. Se enfoca en la gesti\u00f3n de materiales, controles de producci\u00f3n, etiquetado y empaquetado de ingredientes activos (APIs), almacenamiento y distribuci\u00f3n, as\u00ed como en los controles de laboratorio y validaci\u00f3n de procesos. Tambi\u00e9n se discuten procedimientos para el rechazo y reutilizaci\u00f3n de materiales, asegurando que se mantengan est\u00e1ndares de calidad y seguridad en la producci\u00f3n farmac\u00e9utica.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los procedimientos espec\u00edficos para la re-evaluaci\u00f3n de materiales en la gesti\u00f3n de materiales seg\u00fan el documento?**\n   - Esta pregunta busca detalles sobre el proceso de re-evaluaci\u00f3n que no se puede encontrar f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 enfoques se sugieren para la validaci\u00f3n de m\u00e9todos anal\u00edticos en el contexto de los controles de laboratorio?**\n   - Esta pregunta se centra en los enfoques espec\u00edficos mencionados en el documento para validar m\u00e9todos anal\u00edticos, que pueden no estar ampliamente cubiertos en otras gu\u00edas.\n\n3. **\u00bfQu\u00e9 medidas se describen para el control de contaminaci\u00f3n durante las operaciones de producci\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n sobre las pr\u00e1cticas espec\u00edficas de control de contaminaci\u00f3n que son cr\u00edticas para la producci\u00f3n segura de APIs y que pueden no estar detalladas en otras normativas. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y detallada que se encuentra en el contexto del documento, lo que puede no estar disponible en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl anexo 2 del documento \"WHO - Technical Report Series 957\" se centra en las **buenas pr\u00e1cticas de fabricaci\u00f3n (BPF)** para los **ingredientes farmac\u00e9uticos activos (API)**. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas en la secci\u00f3n:\n\n1. **Introducci\u00f3n**\n   - **Objetivo**: Establecer directrices para asegurar la calidad en la producci\u00f3n de API.\n   - **Aplicabilidad regulatoria**: Normativas que rigen la fabricaci\u00f3n de API.\n   - **Alcance**: \u00c1reas cubiertas por las BPF.\n\n2. **Gesti\u00f3n de calidad**\n   - **Principios**: Fundamentos de la gesti\u00f3n de calidad en la producci\u00f3n.\n   - **Responsabilidades de las unidades de calidad**: Funciones espec\u00edficas del personal encargado de la calidad.\n   - **Responsabilidad en actividades de producci\u00f3n**: Roles en la supervisi\u00f3n de la producci\u00f3n.\n   - **Auditor\u00edas internas**: Procedimientos de autoinspecci\u00f3n.\n   - **Revisi\u00f3n de calidad del producto**: Evaluaci\u00f3n de la calidad de los productos fabricados.\n\n3. **Personal**\n   - **Calificaciones del personal**: Requisitos de formaci\u00f3n y experiencia.\n   - **Higiene del personal**: Normas de higiene que deben seguir los empleados.\n   - **Consultores**: Uso de expertos externos en el proceso de producci\u00f3n.\n\n4. **Edificios e instalaciones**\n   - **Dise\u00f1o y construcci\u00f3n**: Consideraciones para la infraestructura de producci\u00f3n.\n   - **Utilidades**: Sistemas de soporte necesarios (agua, electricidad, etc.).\n   - **Contenci\u00f3n**: Medidas para evitar la contaminaci\u00f3n.\n   - **Iluminaci\u00f3n**: Requisitos de luz en las instalaciones.\n   - **Saneamiento y mantenimiento**: Pr\u00e1cticas para mantener la limpieza y el funcionamiento adecuado.\n\n5. **Equipos de proceso**\n   - **Dise\u00f1o y construcci\u00f3n**: Especificaciones para el equipo utilizado en la producci\u00f3n.\n   - **Mantenimiento y limpieza de equipos**: Procedimientos para asegurar el buen estado del equipo.\n   - **Calibraci\u00f3n**: Verificaci\u00f3n de la precisi\u00f3n de los instrumentos.\n   - **Sistemas computarizados**: Uso de tecnolog\u00eda en la gesti\u00f3n de procesos.\n\n6. **Documentaci\u00f3n y registros**\n   - **Sistema de documentaci\u00f3n y especificaciones**: Estructura para la gesti\u00f3n de documentos.\n   - **Registros de limpieza y uso de equipos**: Documentaci\u00f3n de las actividades de mantenimiento.\n   - **Registros de materias primas y materiales de envasado**: Seguimiento de los insumos utilizados.\n   - **Instrucciones de producci\u00f3n maestra**: Directrices para la fabricaci\u00f3n.\n   - **Registros de producci\u00f3n por lotes**: Documentaci\u00f3n de cada lote producido.\n   - **Registros de control de laboratorio**: Datos de pruebas y an\u00e1lisis realizados.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **API (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias utilizadas en la fabricaci\u00f3n de medicamentos.\n- **Unidades de calidad**: Personal responsable de asegurar la calidad en la producci\u00f3n.\n- **Personal**: Empleados involucrados en la fabricaci\u00f3n y control de calidad.\n- **Instalaciones y equipos**: Infraestructura y maquinaria utilizadas en el proceso de producci\u00f3n.\n\nEste resumen proporciona una visi\u00f3n general de los elementos esenciales que se abordan en las buenas pr\u00e1cticas de fabricaci\u00f3n para los ingredientes farmac\u00e9uticos activos, destacando la importancia de la calidad, la higiene, el dise\u00f1o de instalaciones y la documentaci\u00f3n adecuada.", "excerpt_keywords": "Keywords: Batch production, Materials management, Quality control, Validation, Contamination control"}}, "427ea000-9031-47fa-9267-f66b1d22e029": {"node_ids": ["5f12bcaf-3256-495a-ae1f-e64932816b01"], "metadata": {"page_label": "146", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 14.5 Returns\n\n15. Complaints and recalls\n\n16. Contract manufacturers (including laboratories)\n\n17. Agents, brokers, traders, distributors, repackers and relabellers\n   - 17.1 Applicability\n   - 17.2 Traceability of distributed APIs and intermediates\n   - 17.3 Quality management\n   - 17.4 Repackaging, relabelling and holding of APIs and intermediates\n   - 17.5 Stability\n   - 17.6 Transfer of information\n   - 17.7 Handling of complaints and recalls\n   - 17.8 Handling of returns\n\n18. Specific guidance for APIs manufactured by cell culture/fermentation\n   - 18.1 General\n   - 18.2 Cell bank maintenance and record keeping\n   - 18.3 Cell culture/fermentation\n   - 18.4 Harvesting, isolation and purification\n   - 18.5 Viral removal/inactivation steps\n\n19. APIs for use in clinical trials\n   - 19.1 General\n   - 19.2 Quality\n   - 19.3 Equipment and facilities\n   - 19.4 Control of raw materials\n   - 19.5 Production\n   - 19.6 Validation\n   - 19.7 Changes\n   - 19.8 Laboratory controls\n   - 19.9 Documentation\n\n20. Glossary\n\nReferences\n\nAppendix 1  \nList of references for related WHO guidelines\n\nAppendix 2  \nGeneral notes: additional clarifications and explanations\n\n----\n\nThis text is based on the International Conference on Harmonisation (ICH) Q7: *Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients*. November 2000.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los aspectos clave que deben considerarse en la gesti\u00f3n de quejas y retiradas de productos seg\u00fan el documento?**\n   - El documento menciona varios aspectos clave en la gesti\u00f3n de quejas y retiradas, incluyendo la trazabilidad de los APIs y productos intermedios distribuidos, la gesti\u00f3n de calidad, y los procedimientos espec\u00edficos para el manejo de quejas y retiradas. Tambi\u00e9n se abordan las pr\u00e1cticas de reempaquetado y relabeling, as\u00ed como la estabilidad de los productos.\n\n2. **\u00bfQu\u00e9 consideraciones se deben tener en cuenta para los APIs fabricados mediante cultivos celulares o fermentaci\u00f3n?**\n   - Para los APIs fabricados mediante cultivos celulares o fermentaci\u00f3n, el documento proporciona orientaci\u00f3n espec\u00edfica que incluye el mantenimiento de bancos celulares y el registro de datos, as\u00ed como los procesos de cultivo, cosecha, aislamiento y purificaci\u00f3n. Tambi\u00e9n se enfatiza la importancia de los pasos de eliminaci\u00f3n/inactivaci\u00f3n viral.\n\n3. **\u00bfQu\u00e9 requisitos se establecen para los APIs destinados a ensayos cl\u00ednicos en t\u00e9rminos de calidad y documentaci\u00f3n?**\n   - El documento establece que los APIs destinados a ensayos cl\u00ednicos deben cumplir con requisitos espec\u00edficos de calidad, que incluyen el control de materias primas, la validaci\u00f3n de procesos, y la documentaci\u00f3n adecuada de todos los procedimientos. Tambi\u00e9n se menciona la necesidad de realizar cambios controlados y mantener laboratorios que cumplan con los est\u00e1ndares requeridos.\n\n### Resumen de nivel superior del contexto:\nEl documento \"WHO - Technical Report Series 957\" se basa en las directrices de Buenas Pr\u00e1cticas de Manufactura (GMP) para Ingredientes Farmac\u00e9uticos Activos (APIs) seg\u00fan la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) Q7. Aborda temas cr\u00edticos como la gesti\u00f3n de quejas y retiradas, la responsabilidad de los fabricantes contratados, y la trazabilidad de los productos. Tambi\u00e9n proporciona directrices espec\u00edficas para APIs producidos mediante cultivos celulares y para aquellos destinados a ensayos cl\u00ednicos, enfatizando la importancia de la calidad, la documentaci\u00f3n y el cumplimiento de normativas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 957\" aborda varios aspectos fundamentales en la producci\u00f3n y control de materiales farmac\u00e9uticos. A continuaci\u00f3n se presentan los temas clave y entidades de la secci\u00f3n:\n\n1. **Gesti\u00f3n de Materiales**:\n   - **Controles Generales**: Establecimiento de normas y procedimientos para la gesti\u00f3n de materiales.\n   - **Recepci\u00f3n y Cuarentena**: Proceso de recepci\u00f3n de materiales y su aislamiento para asegurar calidad.\n   - **Muestreo y Pruebas**: Evaluaci\u00f3n de materiales entrantes para verificar su conformidad.\n   - **Almacenamiento**: M\u00e9todos para almacenar materiales de manera segura.\n   - **Re-evaluaci\u00f3n**: Proceso de revisi\u00f3n peri\u00f3dica de materiales para asegurar su idoneidad.\n\n2. **Controles de Producci\u00f3n y en Proceso**:\n   - **Operaciones de Producci\u00f3n**: Procedimientos para llevar a cabo la producci\u00f3n de manera efectiva.\n   - **L\u00edmites de Tiempo**: Establecimiento de plazos para las operaciones de producci\u00f3n.\n   - **Muestreo y Controles en Proceso**: Monitoreo continuo durante la producci\u00f3n.\n   - **Control de Contaminaci\u00f3n**: Estrategias para prevenir la contaminaci\u00f3n durante la producci\u00f3n.\n\n3. **Empaque y Etiquetado**:\n   - **Materiales de Empaque**: Selecci\u00f3n y control de materiales utilizados para el empaque.\n   - **Control de Etiquetas**: Procedimientos para la emisi\u00f3n y control de etiquetas.\n\n4. **Almacenamiento y Distribuci\u00f3n**:\n   - **Procedimientos de Almacenamiento**: Normas para el almacenamiento seguro de productos.\n   - **Procedimientos de Distribuci\u00f3n**: M\u00e9todos para la distribuci\u00f3n eficiente y segura de productos.\n\n5. **Controles de Laboratorio**:\n   - **Pruebas de Intermediarios y APIs**: Evaluaci\u00f3n de la calidad de productos intermedios y APIs.\n   - **Validaci\u00f3n de Procedimientos Anal\u00edticos**: Aseguramiento de que los m\u00e9todos anal\u00edticos son precisos y confiables.\n   - **Monitoreo de Estabilidad**: Evaluaci\u00f3n de la estabilidad de los APIs a lo largo del tiempo.\n\n6. **Validaci\u00f3n**:\n   - **Pol\u00edtica de Validaci\u00f3n**: Directrices para la validaci\u00f3n de procesos y sistemas.\n   - **Documentaci\u00f3n de Validaci\u00f3n**: Registro de los procedimientos de validaci\u00f3n.\n   - **Validaci\u00f3n de M\u00e9todos Anal\u00edticos**: Aseguramiento de la eficacia de los m\u00e9todos utilizados en el laboratorio.\n\n7. **Control de Cambios**: Procedimientos para gestionar cambios en los procesos y materiales.\n\n8. **Rechazo y Reutilizaci\u00f3n de Materiales**:\n   - **Rechazo**: Proceso para descartar materiales no conformes.\n   - **Reprocesamiento y Re-trabajo**: M\u00e9todos para manejar materiales rechazados.\n   - **Recuperaci\u00f3n de Materiales y Solventes**: Estrategias para recuperar y reutilizar materiales.\n\n### Entidades Clave\n- **APIs (Ingredientes Activos Farmac\u00e9uticos)**: Sustancias que tienen un efecto farmacol\u00f3gico.\n- **Intermediarios**: Productos que se utilizan en la producci\u00f3n de APIs.\n- **Controles de Calidad**: Procedimientos para asegurar que los productos cumplen con los est\u00e1ndares requeridos.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades clave abordados en la secci\u00f3n del documento, destacando la importancia de la calidad y la seguridad en la producci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: Active Pharmaceutical Ingredients, Good Manufacturing Practice, Quality Management, Clinical Trials, Cell Culture"}}, "7f9465d2-781a-4d51-8f39-aa653ffd53eb": {"node_ids": ["20a7ac5f-44a0-4f84-86d8-92e548acadb1"], "metadata": {"page_label": "147", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\n## 1.1 Objective\n\nThis document (guide) is intended to provide guidance regarding good manufacturing practices (GMP) for the manufacturing of active pharmaceutical ingredients (APIs) under an appropriate system for managing quality. It is also intended to help ensure that APIs meet the requirements for quality and purity that they purport or are represented to possess.\n\nIn this guide \u201cmanufacturing\u201d is defined to include all operations of receipt of materials, production, packaging, repackaging, labelling, relabelling, quality control, release, storage and distribution of APIs and the related controls. In this guide the term \u201cshould\u201d indicates recommendations that are expected to apply unless shown to be inapplicable or replaced by an alternative demonstrated to provide at least an equivalent level of quality assurance. For the purposes of this guide, the terms \u201ccurrent good manufacturing practices\u201d and \u201cgood manufacturing practices\u201d are equivalent.\n\nThe guide as a whole does not cover safety aspects for the personnel engaged in the manufacture, nor aspects of protection of the environment. These controls are inherent responsibilities of the manufacturer and are governed by national laws.\n\nThis guide is not intended to define registration and filing requirements or modify pharmacopoeial requirements. This guide does not affect the ability of the responsible regulatory agency to establish specific registration or filing requirements regarding APIs within the context of marketing or manufacturing authorizations or pharmaceutical applications. All commitments in registration and filing documents must be met.\n\n## 1.2 Regulatory applicability\n\nWithin the world community, materials may vary as to the legal classification as an API. When a material is classified as an API in the region or country in which it is manufactured or used in a pharmaceutical product, it should be manufactured according to this guide.\n\n## 1.3 Scope\n\nThis guide applies to the manufacture of APIs for use in finished pharmaceutical products (FPPs). It applies to the manufacture of sterile APIs only up to the point immediately prior to the APIs being rendered sterile. The sterilization and aseptic processing of sterile APIs are not covered by this guidance, but should be performed in accordance with GMP guidelines for FPPs as defined by local authorities.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento es una gu\u00eda de la OMS sobre buenas pr\u00e1cticas de manufactura (GMP) para la producci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs). Su objetivo es asegurar que los APIs cumplan con los est\u00e1ndares de calidad y pureza. La gu\u00eda abarca todos los aspectos de la manufactura, desde la recepci\u00f3n de materiales hasta la distribuci\u00f3n, pero no incluye la esterilizaci\u00f3n de APIs. Adem\u00e1s, aclara que las regulaciones pueden variar seg\u00fan la regi\u00f3n y que la gu\u00eda no modifica los requisitos de registro o farmacopoeia.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 operaciones se consideran parte del proceso de \"manufactura\" seg\u00fan la gu\u00eda de la OMS?**\n   - La gu\u00eda define \"manufactura\" como todas las operaciones que incluyen la recepci\u00f3n de materiales, producci\u00f3n, empaque, reempaque, etiquetado, control de calidad, liberaci\u00f3n, almacenamiento y distribuci\u00f3n de APIs, as\u00ed como los controles relacionados.\n\n2. **\u00bfQu\u00e9 aspectos no cubre la gu\u00eda en relaci\u00f3n con la seguridad y el medio ambiente?**\n   - La gu\u00eda no aborda los aspectos de seguridad para el personal involucrado en la manufactura ni la protecci\u00f3n del medio ambiente, ya que estas son responsabilidades inherentes del fabricante y est\u00e1n reguladas por las leyes nacionales.\n\n3. **\u00bfC\u00f3mo se aplica la gu\u00eda a los APIs que se consideran est\u00e9riles?**\n   - La gu\u00eda se aplica a la manufactura de APIs est\u00e9riles solo hasta el punto inmediatamente anterior a que los APIs sean esterilizados. La esterilizaci\u00f3n y el procesamiento as\u00e9ptico de los APIs est\u00e9riles deben realizarse de acuerdo con las directrices de GMP para productos farmac\u00e9uticos terminados, seg\u00fan lo definido por las autoridades locales.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n\n\n1. **Devoluciones (Returns)**: Secci\u00f3n que aborda el manejo de devoluciones de productos.\n\n2. **Quejas y Retiradas (Complaints and Recalls)**: Incluye directrices sobre c\u00f3mo gestionar quejas de productos y retiradas del mercado, enfatizando la importancia de la trazabilidad y la gesti\u00f3n de calidad.\n\n3. **Fabricantes Contratados (Contract Manufacturers)**: Se refiere a las responsabilidades y regulaciones que deben seguir los fabricantes contratados, incluidos laboratorios.\n\n4. **Agentes y Distribuidores (Agents, Brokers, Traders, Distributors, Repackers and Relabellers)**: \n   - **Aplicabilidad (Applicability)**: Definici\u00f3n de a qui\u00e9nes se aplican las regulaciones.\n   - **Trazabilidad (Traceability)**: Importancia de rastrear los APIs y productos intermedios distribuidos.\n   - **Gesti\u00f3n de Calidad (Quality Management)**: Normas y pr\u00e1cticas para asegurar la calidad de los productos.\n   - **Reempaquetado y Relabeling (Repackaging and Relabelling)**: Procedimientos para el manejo de productos.\n   - **Estabilidad (Stability)**: Consideraciones sobre la estabilidad de los productos.\n   - **Transferencia de Informaci\u00f3n (Transfer of Information)**: Protocolo para compartir informaci\u00f3n relevante.\n   - **Manejo de Quejas y Retiradas (Handling of Complaints and Recalls)**: Estrategias para abordar quejas y retiradas.\n   - **Manejo de Devoluciones (Handling of Returns)**: Proceso para gestionar devoluciones de productos.\n\n5. **Orientaci\u00f3n Espec\u00edfica para APIs Fabricados por Cultivos Celulares/Fermentaci\u00f3n (Specific Guidance for APIs Manufactured by Cell Culture/Fermentation)**:\n   - **Mantenimiento de Bancos Celulares (Cell Bank Maintenance)**: Importancia del mantenimiento y registro de bancos celulares.\n   - **Cultivo y Fermentaci\u00f3n (Cell Culture/Fermentation)**: Procesos involucrados en la producci\u00f3n.\n   - **Cosecha, Aislamiento y Purificaci\u00f3n (Harvesting, Isolation and Purification)**: Pasos cr\u00edticos en la producci\u00f3n.\n   - **Eliminaci\u00f3n/Inactivaci\u00f3n Viral (Viral Removal/Inactivation Steps)**: Medidas para asegurar la seguridad del producto.\n\n6. **APIs para Ensayos Cl\u00ednicos (APIs for Use in Clinical Trials)**:\n   - **Calidad (Quality)**: Requisitos de calidad espec\u00edficos para APIs en ensayos cl\u00ednicos.\n   - **Equipos e Instalaciones (Equipment and Facilities)**: Normas para el equipamiento y las instalaciones.\n   - **Control de Materias Primas (Control of Raw Materials)**: Procedimientos para asegurar la calidad de las materias primas.\n   - **Producci\u00f3n (Production)**: Directrices para el proceso de producci\u00f3n.\n   - **Validaci\u00f3n (Validation)**: Importancia de la validaci\u00f3n de procesos.\n   - **Cambios (Changes)**: Manejo de cambios en los procesos.\n   - **Controles de Laboratorio (Laboratory Controls)**: Normas para el control de calidad en laboratorios.\n   - **Documentaci\u00f3n (Documentation)**: Requisitos de documentaci\u00f3n para todos los procedimientos.\n\n7. **Glosario (Glossary)**: Definiciones de t\u00e9rminos clave utilizados en el documento.\n\n8. **Referencias y Ap\u00e9ndices**: Incluye una lista de referencias para gu\u00edas relacionadas de la OMS y notas generales para aclaraciones adicionales.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**\n- **ICH (Conferencia Internacional sobre Armonizaci\u00f3n)**\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**\n- **Cultivos Celulares/Fermentaci\u00f3n**\n- **Ensayos Cl\u00ednicos** \n\nEste resumen destaca los temas y entidades m\u00e1s relevantes de la secci\u00f3n, proporcionando una visi\u00f3n general de las directrices y regulaciones en la producci\u00f3n y manejo de APIs.", "excerpt_keywords": "Keywords: good manufacturing practices, active pharmaceutical ingredients, quality assurance, regulatory applicability, sterile APIs"}}, "ee23fe6d-27f3-432a-a38f-e1635a69a46f": {"node_ids": ["7c594074-7e0e-4906-93f1-45864eec3713"], "metadata": {"page_label": "148", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "This guide covers APIs that are manufactured by chemical synthesis, extraction, cell culture or fermentation, by recovery from natural sources, or by any combination of these processes.\n\nSpecific guidance for APIs manufactured by cell culture or fermentation is described in section 18.\n\nThis guide excludes all vaccines, whole cells, whole blood and plasma, blood and plasma derivatives (plasma fractionation), and gene therapy APIs. However, it does include APIs that are produced using blood or plasma as raw materials. Note that cell substrates (mammalian, plant, insect or microbial cells, tissue or animal sources including transgenic animals) and early process steps may be subject to GMP but are not covered by this guide. In addition, the guide does not apply to medical gases, bulk-packaged FPPs, and manufacturing and control aspects specific to radiopharmaceuticals.\n\nSection 19 contains guidance that only applies to the manufacture of APIs used in the production of FPPs specifically for clinical trials (investigational medicinal products).\n\nAn \u201cAPI starting material\u201d is a raw material, intermediate, or an API that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. An API starting material can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement, or produced in house.\n\nAPI starting materials normally have defined chemical properties and structure. The company should designate and document the rationale for the point at which production of the API begins. For synthetic processes, this is known as the point at which \u201cAPI starting materials\u201d are entered into the process. For other processes (e.g. fermentation, extraction or purification), this rationale should be established on a case-by-case basis.\n\nTable 1 gives guidance on the point at which the API starting material is normally introduced into the process. From this point on, appropriate GMP as defined in this guide should be applied to these intermediate and/or API manufacturing steps. This would include the validation of critical process steps determined to impact the quality of the API. However, it should be noted that the fact that a company chooses to validate a process step does not necessarily define that step as critical.\n\nThe guidance in this document would normally be applied to the steps shown in grey in Table 1. It does not imply that all steps shown should be completed. The stringency of GMP in API manufacturing should increase as the process proceeds from early API steps to final steps, purification and packaging. Physical processing of APIs, such as granulation, coating", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen de Nivel Superior\n\nEl documento de la OMS proporciona directrices sobre la fabricaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (API) a trav\u00e9s de diversos procesos, incluyendo s\u00edntesis qu\u00edmica, extracci\u00f3n, cultivo celular y fermentaci\u00f3n. Se excluyen ciertos productos como vacunas, c\u00e9lulas completas, derivados de sangre y terapia g\u00e9nica, aunque se incluyen APIs producidos a partir de sangre o plasma. Se define el concepto de \"material de partida de API\" y se establece la importancia de documentar el inicio del proceso de producci\u00f3n. Adem\u00e1s, se enfatiza la necesidad de aplicar Buenas Pr\u00e1cticas de Manufactura (GMP) a medida que se avanza en el proceso de fabricaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar para establecer el punto de inicio de la producci\u00f3n de un API en procesos de fermentaci\u00f3n o extracci\u00f3n?**\n   - La gu\u00eda sugiere que este criterio debe ser establecido caso por caso, y la empresa debe documentar la justificaci\u00f3n para el punto en el que comienza la producci\u00f3n del API.\n\n2. **\u00bfC\u00f3mo se determina si un paso del proceso de fabricaci\u00f3n de un API es cr\u00edtico para la calidad del producto?**\n   - La validaci\u00f3n de pasos cr\u00edticos debe ser realizada, pero la decisi\u00f3n de validar un paso no necesariamente lo define como cr\u00edtico. La gu\u00eda enfatiza que la validaci\u00f3n debe centrarse en los pasos que impactan la calidad del API.\n\n3. **\u00bfQu\u00e9 tipo de materiales se consideran como \"materiales de partida de API\" y c\u00f3mo se clasifican?**\n   - Los materiales de partida de API pueden ser materias primas, intermedios o APIs que se incorporan como fragmentos estructurales significativos en la producci\u00f3n del API. Pueden ser art\u00edculos de comercio, materiales adquiridos bajo contrato o producidos internamente, y normalmente tienen propiedades y estructuras qu\u00edmicas definidas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Objetivo de la Gu\u00eda:**\n   - Proporcionar orientaci\u00f3n sobre buenas pr\u00e1cticas de manufactura (GMP) para la producci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs).\n   - Asegurar que los APIs cumplan con los est\u00e1ndares de calidad y pureza.\n\n2. **Definici\u00f3n de Manufactura:**\n   - Incluye operaciones como recepci\u00f3n de materiales, producci\u00f3n, empaque, etiquetado, control de calidad, almacenamiento y distribuci\u00f3n de APIs.\n\n3. **Recomendaciones y Regulaciones:**\n   - El t\u00e9rmino \"deber\u00eda\" indica recomendaciones que se espera que se apliquen, salvo que se demuestre lo contrario.\n   - La gu\u00eda no modifica requisitos de registro o farmacopoeia y no cubre aspectos de seguridad laboral ni protecci\u00f3n ambiental.\n\n4. **Aplicabilidad Regulatoria:**\n   - La clasificaci\u00f3n legal de un material como API puede variar seg\u00fan la regi\u00f3n; debe fabricarse conforme a esta gu\u00eda si se clasifica como tal.\n\n5. **Alcance de la Gu\u00eda:**\n   - Se aplica a la manufactura de APIs para productos farmac\u00e9uticos terminados (FPPs) y a APIs est\u00e9riles solo hasta antes de su esterilizaci\u00f3n.\n\n**Entidades:**\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud):** Autoridad que emite la gu\u00eda.\n- **APIs (Ingredientes Farmac\u00e9uticos Activos):** Sustancias que se producen bajo las directrices de la gu\u00eda.\n- **FPPs (Productos Farmac\u00e9uticos Terminados):** Productos que utilizan los APIs fabricados seg\u00fan la gu\u00eda.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura):** Conjunto de directrices que rigen la producci\u00f3n de APIs.\n- **Autoridades Locales:** Entidades que definen las directrices de GMP para productos farmac\u00e9uticos terminados y regulaciones espec\u00edficas de registro. \n\nEste resumen destaca los aspectos fundamentales de la gu\u00eda y las entidades involucradas en el contexto de las buenas pr\u00e1cticas de manufactura para APIs.", "excerpt_keywords": "Keywords: APIs, GMP, manufacturing, fermentation, starting materials"}}, "6d57ca74-9f44-4125-ad60-b214a04a2547": {"node_ids": ["d42cf2f2-974f-4882-93c2-be71245d8c05"], "metadata": {"page_label": "149", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Application of this Guide to API Manufacturing\n\n| Type of manufacturing | Application of this guide to steps (shown in grey) used in this type of manufacturing |\n| - | - |\n| Chemical manufacturing | * Production of the API starting material\n* Introduction of the API starting material into process\n* Production of intermediate(s)\n* Isolation and purification\n* Physical processing, and packaging |\n| API derived from animal sources | - Collection of organ, fluid, or tissue\n- Cutting, mixing, and/or initial processing\n- Introduction of the API starting material into process\n- Isolation and purification\n- Physical processing, and packaging |\n| API extracted from plant sources | * Collection of plants\n* Cutting and initial extraction(s)\n* Introduction of the API starting material into process\n* Isolation and purification\n* Physical processing, and packaging |\n| Herbal extracts used as API | - Collection of plants\n- Cutting and initial extraction\n- Further extraction\n- Physical processing, and packaging |\n| API consisting of comminuted or powdered herbs | * Collection of plants and/or cultivation and harvesting\n* Cutting/communiting\n* Physical processing, and packaging |\n| Biotechnology: fermentation/cell culture | - Establishment of master cell bank and working cell bank\n- Maintenance of working cell bank\n- Cell culture and/or fermentation\n- Isolation and purification\n- Physical processing, and packaging |\n| \"Classical\" fermentation to produce an API | * Establishment of cell bank\n* Maintenance of the cell bank\n* Introduction of the cells into fermentation\n* Isolation and purification\n* Physical processing, and packaging |\n\n\n<a>This table has been taken from the ICH Harmonised Tripartite Guideline: Active Pharmaceutical Ingredients Q7. Current Step 4 version, dated 10 November 2000.</a>\n\n**Increasing GMP requirements**", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS, titulado \"Technical Report Series 957\", aborda la aplicaci\u00f3n de directrices para la fabricaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (API). Se presenta una tabla que detalla los diferentes tipos de fabricaci\u00f3n de API, incluyendo qu\u00edmica, fuentes animales, fuentes vegetales, extractos herbales, hierbas en polvo, biotecnolog\u00eda y fermentaci\u00f3n cl\u00e1sica. Cada tipo de fabricaci\u00f3n incluye pasos espec\u00edficos que deben seguirse, como la recolecci\u00f3n, el procesamiento, la purificaci\u00f3n y el empaquetado. Adem\u00e1s, se menciona un aumento en los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos involucrados en la producci\u00f3n de un API derivado de fuentes animales seg\u00fan la gu\u00eda de la OMS?**\n   - Respuesta: Los pasos incluyen la colecci\u00f3n de \u00f3rganos, fluidos o tejidos, el corte, mezcla y/o procesamiento inicial, la introducci\u00f3n del material inicial del API en el proceso, la aislamiento y purificaci\u00f3n, y el procesamiento f\u00edsico y empaquetado.\n\n2. **\u00bfQu\u00e9 diferencias existen entre la producci\u00f3n de un API a partir de fuentes vegetales y la producci\u00f3n de extractos herbales utilizados como API?**\n   - Respuesta: En la producci\u00f3n de un API a partir de fuentes vegetales, los pasos incluyen la recolecci\u00f3n de plantas, el corte y las extracciones iniciales, mientras que en el caso de los extractos herbales, se incluyen la recolecci\u00f3n de plantas, el corte y la extracci\u00f3n inicial, seguido de una extracci\u00f3n adicional.\n\n3. **\u00bfQu\u00e9 pasos son comunes en la producci\u00f3n de APIs mediante biotecnolog\u00eda y fermentaci\u00f3n cl\u00e1sica, seg\u00fan el documento?**\n   - Respuesta: Ambos procesos incluyen el establecimiento y mantenimiento de un banco celular, la introducci\u00f3n de c\u00e9lulas en el proceso de fermentaci\u00f3n, la aislamiento y purificaci\u00f3n, y el procesamiento f\u00edsico y empaquetado.", "prev_section_summary": "### Temas Clave\n\n1. **Manufactura de Ingredientes Farmac\u00e9uticos Activos (API)**:\n   - La gu\u00eda abarca la producci\u00f3n de APIs mediante s\u00edntesis qu\u00edmica, extracci\u00f3n, cultivo celular, fermentaci\u00f3n y recuperaci\u00f3n de fuentes naturales.\n\n2. **Exclusiones**:\n   - Se excluyen vacunas, c\u00e9lulas completas, derivados de sangre, terapia g\u00e9nica y gases m\u00e9dicos. Sin embargo, se incluyen APIs producidos a partir de sangre o plasma.\n\n3. **Materiales de Partida de API**:\n   - Se define el concepto de \"material de partida de API\", que puede ser una materia prima, intermedio o API que se incorpora en la estructura del API final.\n\n4. **Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Se enfatiza la aplicaci\u00f3n de GMP a partir del punto en que se introducen los materiales de partida en el proceso de producci\u00f3n, con un enfoque en la validaci\u00f3n de pasos cr\u00edticos que impactan la calidad del API.\n\n5. **Documentaci\u00f3n y Justificaci\u00f3n**:\n   - La empresa debe documentar el punto de inicio de la producci\u00f3n del API y establecer criterios espec\u00edficos para procesos como fermentaci\u00f3n y extracci\u00f3n.\n\n6. **Incremento de la Estricta de GMP**:\n   - La rigurosidad de las GMP debe aumentar a medida que se avanza en el proceso de fabricaci\u00f3n, desde los pasos iniciales hasta la purificaci\u00f3n y el empaquetado final.\n\n### Entidades\n\n- **API (Ingrediente Farmac\u00e9utico Activo)**: Sustancia utilizada en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normas que aseguran la calidad y seguridad en la producci\u00f3n de medicamentos.\n- **Material de Partida de API**: Materia prima o intermedio utilizado en la producci\u00f3n de un API.\n- **Secci\u00f3n 18 y 19**: Secciones espec\u00edficas de la gu\u00eda que abordan la fabricaci\u00f3n de APIs por cultivo celular y fermentaci\u00f3n, y la producci\u00f3n de APIs para ensayos cl\u00ednicos, respectivamente.\n\nEste resumen destaca los aspectos fundamentales de la gu\u00eda de la OMS sobre la fabricaci\u00f3n de APIs y las consideraciones clave para asegurar la calidad y la conformidad en el proceso de producci\u00f3n.", "excerpt_keywords": "Keywords: API manufacturing, GMP requirements, fermentation, purification, extraction"}}, "712b0e77-011f-4ab4-b102-e5a8cfc1a0cc": {"node_ids": ["ba25ab16-1534-4c86-8fdf-f6eb7cc5313a"], "metadata": {"page_label": "150", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 2. Quality management\n\n## 2.1 Principles\n\n2.10 Quality should be the responsibility of all persons involved in manufacturing.\n\n2.11 Each manufacturer should establish, document and implement an effective system for managing quality that involves the active participation of management and appropriate manufacturing personnel.\n\n2.12 The system for managing quality should encompass the organizational structure, procedures, processes and resources, as well as activities necessary to ensure confidence that the API will meet its intended specifications for quality and purity. All quality-related activities should be defined and documented.\n\n2.13 There should be a quality unit(s) that is independent of production and that fulfils both quality assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization.\n\n2.14 The persons authorized to release intermediates and APIs should be specified.\n\n2.15 All quality-related activities should be recorded at the time they are performed.\n\n2.16 Any deviation from established procedures should be documented and explained. Critical deviations should be investigated, and the investigation and its conclusions should be documented.\n\n2.17 No materials should be released or used before the satisfactory completion of evaluation by the quality unit(s) unless there are appropriate systems in place to allow for such use (e.g. release under quarantine as described in section 10.20 or the use of raw materials or intermediates pending completion of evaluation).\n\n2.18 Procedures should exist for notifying responsible management in a timely manner of regulatory inspections, serious GMP deficiencies, product defects and related actions (e.g. quality related complaints, recalls and regulatory actions).\n\n## 2.2 Responsibilities of the quality unit(s)\n\n2.20 The quality unit(s) should be involved in all quality-related matters.\n\n----\n\n1 This system of numbering sections is different to the usual WHO style. It is used here to harmonize with the guide used in inspection reports internationally.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la Serie de Informes T\u00e9cnicos 957 aborda la gesti\u00f3n de calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza que la calidad es responsabilidad de todos los involucrados en el proceso de fabricaci\u00f3n y que debe existir un sistema documentado y efectivo para gestionar la calidad. Este sistema debe incluir una unidad de calidad independiente que se encargue de asegurar tanto la calidad como el control de calidad. Adem\u00e1s, se establecen procedimientos para la documentaci\u00f3n de actividades relacionadas con la calidad, la gesti\u00f3n de desviaciones y la notificaci\u00f3n de problemas a la direcci\u00f3n responsable.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 papel desempe\u00f1a la unidad de calidad en la gesti\u00f3n de calidad seg\u00fan el documento?**\n   - La unidad de calidad debe ser independiente de la producci\u00f3n y cumplir con las responsabilidades de aseguramiento de calidad (QA) y control de calidad (QC). Su participaci\u00f3n es esencial en todos los asuntos relacionados con la calidad.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse en caso de desviaciones cr\u00edticas de los procedimientos establecidos?**\n   - Cualquier desviaci\u00f3n de los procedimientos establecidos debe ser documentada y explicada. Las desviaciones cr\u00edticas deben ser investigadas, y tanto la investigaci\u00f3n como sus conclusiones deben ser documentadas.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse antes de que se puedan liberar o utilizar materiales en el proceso de fabricaci\u00f3n?**\n   - No se deben liberar ni utilizar materiales antes de que se complete satisfactoriamente la evaluaci\u00f3n por parte de la unidad de calidad, a menos que existan sistemas apropiados que permitan su uso, como la liberaci\u00f3n bajo cuarentena o el uso de materias primas o intermedios mientras se completa la evaluaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **T\u00edtulo del Documento**: WHO - Technical Report Series 957\n   - Este documento de la OMS se centra en la fabricaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (API).\n\n2. **Tipos de Fabricaci\u00f3n de API**:\n   - **Qu\u00edmica**: Incluye la producci\u00f3n del material inicial, introducci\u00f3n en el proceso, producci\u00f3n de intermedios, aislamiento, purificaci\u00f3n, procesamiento f\u00edsico y empaquetado.\n   - **Fuentes Animales**: Implica la recolecci\u00f3n de \u00f3rganos, fluidos o tejidos, procesamiento inicial, introducci\u00f3n del material inicial, aislamiento, purificaci\u00f3n, y empaquetado.\n   - **Fuentes Vegetales**: Comprende la recolecci\u00f3n de plantas, corte, extracciones iniciales, introducci\u00f3n del material inicial, aislamiento, purificaci\u00f3n, y empaquetado.\n   - **Extractos Herbales**: Incluye recolecci\u00f3n, corte, extracci\u00f3n inicial, extracci\u00f3n adicional, y empaquetado.\n   - **Hierbas en Polvo**: Involucra recolecci\u00f3n, corte, procesamiento f\u00edsico y empaquetado.\n   - **Biotecnolog\u00eda**: Abarca el establecimiento y mantenimiento de bancos celulares, cultivo celular o fermentaci\u00f3n, aislamiento, purificaci\u00f3n, y empaquetado.\n   - **Fermentaci\u00f3n Cl\u00e1sica**: Similar a la biotecnolog\u00eda, incluye el establecimiento y mantenimiento de bancos celulares, introducci\u00f3n de c\u00e9lulas en fermentaci\u00f3n, aislamiento, purificaci\u00f3n, y empaquetado.\n\n3. **Requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Se menciona un aumento en los requisitos de GMP, lo que indica una creciente regulaci\u00f3n y est\u00e1ndares en la fabricaci\u00f3n de APIs.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que publica el documento.\n- **API (Ingrediente Farmac\u00e9utico Activo)**: Sustancia utilizada en la fabricaci\u00f3n de medicamentos.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normativas que aseguran la calidad y seguridad en la producci\u00f3n de productos farmac\u00e9uticos.\n\nEste resumen destaca los aspectos fundamentales de la secci\u00f3n, incluyendo los tipos de fabricaci\u00f3n de APIs y la importancia de cumplir con los est\u00e1ndares de GMP.", "excerpt_keywords": "Keywords: quality management, pharmaceutical manufacturing, quality assurance, good manufacturing practices, regulatory compliance"}}, "db741599-719b-4aa3-ae4e-8be2798b7b84": {"node_ids": ["4375986e-034a-4b30-9065-73450675e123"], "metadata": {"page_label": "151", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 2.21\n\nThe quality unit(s) should review and approve all appropriate quality-related documents.\n\n## 2.22\n\nThe main responsibilities of the independent quality unit(s) should not be delegated.\n\nThese responsibilities should be described in writing and should include but not necessarily be limited to:\n\n1. Releasing or rejecting all APIs. Releasing or rejecting intermediates for use outside the control of the manufacturing company.\n2. Establishing a system to release or reject raw materials, intermediates, packaging and labelling materials.\n3. Reviewing completed batch production and laboratory control records of critical process steps before release of the API for distribution.\n4. Making sure that critical deviations are investigated and resolved.\n5. Approving all specifications and master production instructions.\n6. Approving all procedures impacting the quality of intermediates or APIs.\n7. Making sure that internal audits (self-inspections) are performed.\n8. Approving intermediate and API contract manufacturers.\n9. Approving changes that potentially impact quality of intermediates or APIs.\n10. Reviewing and approving validation protocols and reports.\n11. Making sure that quality-related complaints are investigated and resolved.\n12. Making sure that effective systems are used for maintaining and calibrating critical equipment.\n13. Making sure that materials are appropriately tested and the results are reported.\n14. Making sure that there are stability data to support retest or expiry dates and storage conditions on APIs and/or intermediates where appropriate.\n15. Performing product quality reviews (as defined in section 2.5).\n\n## 2.3 Responsibility for production activities\n\nThe responsibility for production activities should be described in writing, and should include but not necessarily be limited to:\n\n1. Preparing, reviewing, approving and distributing the instructions for the production of intermediates or APIs according to written procedures.\n2. Producing APIs and, when appropriate, intermediates according to pre-approved instructions.\n3. Reviewing all production batch records and ensuring that these are completed and signed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla las responsabilidades de las unidades de calidad independientes en la producci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs) y otros materiales relacionados. Se enfatiza que estas responsabilidades no deben ser delegadas y deben estar claramente documentadas. Adem\u00e1s, se establece que la responsabilidad de las actividades de producci\u00f3n tambi\u00e9n debe ser descrita por escrito, asegurando que se sigan procedimientos aprobados y que se mantenga la calidad en todas las etapas del proceso.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales responsabilidades que no deben ser delegadas a otras unidades en el contexto de la calidad de los APIs?**\n   - Respuesta: Las principales responsabilidades incluyen la liberaci\u00f3n o rechazo de todos los APIs, la revisi\u00f3n de registros de producci\u00f3n y control de laboratorio, la aprobaci\u00f3n de especificaciones y procedimientos, la investigaci\u00f3n de desviaciones cr\u00edticas, y la realizaci\u00f3n de auditor\u00edas internas, entre otras.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse para asegurar que los materiales utilizados en la producci\u00f3n de APIs sean de calidad adecuada?**\n   - Respuesta: Se debe establecer un sistema para liberar o rechazar materias primas, intermedios, y materiales de envasado y etiquetado. Adem\u00e1s, se deben realizar pruebas adecuadas de los materiales y asegurar que los resultados sean reportados.\n\n3. **\u00bfQu\u00e9 pasos se deben tomar para abordar las quejas relacionadas con la calidad de los productos?**\n   - Respuesta: Es fundamental investigar y resolver todas las quejas relacionadas con la calidad, asegurando que se implementen sistemas efectivos para manejar estas situaciones y que se mantenga la calidad del producto final.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n#### Temas clave:\n1. **Responsabilidad de la calidad**: La calidad es una responsabilidad compartida por todas las personas involucradas en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n2. **Sistema de gesti\u00f3n de calidad**: Cada fabricante debe establecer un sistema documentado y efectivo para gestionar la calidad, que incluya la participaci\u00f3n activa de la direcci\u00f3n y el personal de fabricaci\u00f3n.\n3. **Unidad de calidad independiente**: Debe existir una unidad de calidad que sea independiente de la producci\u00f3n, encargada de las funciones de aseguramiento de calidad (QA) y control de calidad (QC).\n4. **Documentaci\u00f3n de actividades**: Todas las actividades relacionadas con la calidad deben ser registradas y documentadas en el momento en que se realizan.\n5. **Manejo de desviaciones**: Las desviaciones de los procedimientos establecidos deben ser documentadas y explicadas, y las desviaciones cr\u00edticas deben ser investigadas.\n6. **Liberaci\u00f3n de materiales**: No se deben liberar ni utilizar materiales hasta que se complete satisfactoriamente la evaluaci\u00f3n por parte de la unidad de calidad, salvo que existan sistemas que lo permitan.\n7. **Notificaci\u00f3n de problemas**: Deben existir procedimientos para notificar a la direcci\u00f3n sobre inspecciones regulatorias, deficiencias graves en GMP, defectos de productos y acciones relacionadas.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices sobre gesti\u00f3n de calidad.\n- **Unidad de calidad**: Entidad responsable de asegurar y controlar la calidad en el proceso de fabricaci\u00f3n.\n- **Fabricantes**: Entidades que deben implementar el sistema de gesti\u00f3n de calidad.\n- **Personal de fabricaci\u00f3n**: Personas involucradas en el proceso de producci\u00f3n que comparten la responsabilidad de la calidad.\n- **Gesti\u00f3n responsable**: Direcci\u00f3n que debe ser notificada sobre problemas relacionados con la calidad y cumplimiento normativo. \n\nEste resumen destaca la importancia de un enfoque sistem\u00e1tico y documentado para la gesti\u00f3n de calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos, as\u00ed como la necesidad de una unidad de calidad independiente para garantizar el cumplimiento de los est\u00e1ndares establecidos.", "excerpt_keywords": "Keywords: calidad, unidades independientes, producci\u00f3n, APIs, documentaci\u00f3n"}}, "d8b93e95-ddf5-4679-8f02-0f1ab1e933c3": {"node_ids": ["561bf65d-4766-42cb-9c9b-154f401a9ea5"], "metadata": {"page_label": "152", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "4. Making sure that all production deviations are reported and evaluated and that critical deviations are investigated and the conclusions are recorded.  \n5. Making sure that production facilities are clean and when appropriate disinfected.  \n6. Making sure that the necessary calibrations are performed and records kept.  \n7. Making sure that the premises and equipment are maintained and records kept.  \n8. Making sure that validation protocols and reports are reviewed and approved.  \n9. Evaluating proposed changes in product, process or equipment.  \n10. Making sure that new and, when appropriate, modified facilities and equipment are qualified.\n\n## 2.4 Internal audits (self-inspection)\n\n2.40 In order to verify compliance with the principles of GMP for APIs, regular internal audits should be performed in accordance with an approved schedule.\n\n2.41 Audit findings and corrective actions should be documented and brought to the attention of the responsible management of the firm. Agreed corrective actions should be completed in a timely and effective manner.\n\n## 2.5 Product quality review\n\n2.50 Regular quality reviews of APIs should be conducted with the objective of verifying the consistency of the process. Such reviews should normally be conducted and documented annually and should include at least a review of:\n\n- critical in-process control and critical API test results;\n- all batches that failed to meet established specification(s);\n- all critical deviations or non-conformances and related investigations;\n- any changes carried out to the processes or analytical methods;\n- results of the stability monitoring programme;\n- quality-related returns, complaints and recalls; and\n- adequacy of corrective actions.\n\n2.51 The results of this review should be evaluated and an assessment made of whether corrective action or any revalidation should be undertaken. Reasons for such corrective action should be documented. Agreed corrective actions should be completed in a timely and effective manner.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la serie de informes t\u00e9cnicos 957 aborda las Buenas Pr\u00e1cticas de Manufactura (GMP) para los Ingredientes Farmac\u00e9uticos Activos (APIs). Se enfatiza la importancia de asegurar que todas las desviaciones en la producci\u00f3n sean reportadas y evaluadas, que las instalaciones de producci\u00f3n est\u00e9n limpias y desinfectadas cuando sea necesario, y que se realicen calibraciones y mantenimientos adecuados de los equipos. Adem\u00e1s, se menciona la necesidad de realizar auditor\u00edas internas regulares y revisiones de calidad de los APIs para verificar la consistencia del proceso y documentar hallazgos y acciones correctivas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para documentar las desviaciones cr\u00edticas en la producci\u00f3n de APIs?**\n   - El contexto menciona que todas las desviaciones de producci\u00f3n deben ser reportadas y evaluadas, y que las desviaciones cr\u00edticas deben ser investigadas y sus conclusiones registradas. Sin embargo, no se especifican los procedimientos exactos para esta documentaci\u00f3n.\n\n2. **\u00bfCu\u00e1l es la frecuencia recomendada para realizar auditor\u00edas internas y qu\u00e9 aspectos deben ser evaluados durante estas auditor\u00edas?**\n   - Se indica que las auditor\u00edas internas deben realizarse de acuerdo con un cronograma aprobado, pero no se detallan los aspectos espec\u00edficos que deben ser evaluados durante estas auditor\u00edas.\n\n3. **\u00bfQu\u00e9 elementos deben incluirse en la revisi\u00f3n de calidad anual de los APIs para asegurar la consistencia del proceso?**\n   - El contexto menciona varios elementos que deben ser revisados, como los resultados de control cr\u00edtico y las quejas relacionadas con la calidad, pero no se proporciona un desglose detallado de c\u00f3mo se deben evaluar estos elementos o qu\u00e9 criterios se deben utilizar.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar disponible en otras partes del documento o en fuentes externas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### Temas Clave:\n1. **Responsabilidades de la Unidad de Calidad**: Se enfatiza que las responsabilidades de las unidades de calidad independientes no deben ser delegadas y deben estar documentadas. Estas responsabilidades incluyen la liberaci\u00f3n y rechazo de APIs, la revisi\u00f3n de registros de producci\u00f3n, la aprobaci\u00f3n de especificaciones y procedimientos, y la investigaci\u00f3n de desviaciones cr\u00edticas.\n\n2. **Control de Calidad**: Se establece la necesidad de un sistema para liberar o rechazar materias primas, intermedios y materiales de envasado. Tambi\u00e9n se requiere que los materiales sean probados adecuadamente y que los resultados sean reportados.\n\n3. **Manejo de Quejas**: Es crucial investigar y resolver las quejas relacionadas con la calidad de los productos, asegurando que se implementen sistemas efectivos para mantener la calidad.\n\n4. **Responsabilidad en Actividades de Producci\u00f3n**: Las responsabilidades de producci\u00f3n deben estar claramente descritas y seguir procedimientos aprobados, asegurando que se mantenga la calidad en todas las etapas del proceso de producci\u00f3n de APIs e intermedios.\n\n#### Entidades:\n- **Unidad de Calidad**: Entidad responsable de asegurar la calidad de los productos farmac\u00e9uticos.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Sustancias que se utilizan en la producci\u00f3n de medicamentos.\n- **Intermedios**: Productos que se utilizan en la fabricaci\u00f3n de APIs.\n- **Materiales de Envasado y Etiquetado**: Elementos que se utilizan para el envasado y etiquetado de productos farmac\u00e9uticos.\n- **Registros de Producci\u00f3n y Control de Laboratorio**: Documentaci\u00f3n que debe ser revisada y aprobada antes de la liberaci\u00f3n de los productos.\n- **Auditor\u00edas Internas**: Evaluaciones que deben realizarse para asegurar el cumplimiento de los est\u00e1ndares de calidad.\n\nEste resumen destaca la importancia de la calidad y la responsabilidad en la producci\u00f3n de productos farmac\u00e9uticos, as\u00ed como la necesidad de procedimientos claros y documentados para garantizar la seguridad y eficacia de los mismos.", "excerpt_keywords": "Keywords: Good Manufacturing Practices, Active Pharmaceutical Ingredients, internal audits, product quality review, production deviations"}}, "e4807678-22c9-4e55-af8c-72be1e069211": {"node_ids": ["4dc68a3a-e907-40e5-8b03-f54a9d7138d7"], "metadata": {"page_label": "153", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 3. Personnel\n\n## 3.1 Personnel qualifications\n\n3.10 There should be an adequate number of personnel qualified by appropriate education, training and/or experience to perform and supervise the manufacture of intermediates and APIs.\n\n3.11 The responsibilities of all personnel engaged in the manufacture of intermediates and APIs should be specified in writing.\n\n3.12 Training should be regularly conducted by qualified individuals and should cover, at a minimum, the particular operations that the employee performs, and GMP as it relates to the employee\u2019s functions. Records of training should be maintained. Training should be periodically assessed.\n\n## 3.2 Personnel hygiene\n\n3.20 Personnel should practice good sanitation and health habits.\n\n3.21 Personnel should wear clean clothing suitable for the manufacturing activity with which they are involved and this clothing should be changed when appropriate. Additional protective apparel, such as head, face, hand and arm coverings, should be worn when necessary, to protect intermediates and APIs from contamination.\n\n3.22 Personnel should avoid direct contact with intermediates or APIs.\n\n3.23 Smoking, eating, drinking, chewing and the storage of food should be restricted to certain designated areas separate from the manufacturing areas.\n\n3.24 Personnel with an infectious disease or who have open lesions on the exposed surface of the body should not engage in activities that could result in compromising the quality of APIs. Any person shown at any time (either by medical examination or supervisory observation) to have an apparent illness or open lesions should be excluded from activities where their health condition could adversely affect the quality of the APIs, until the condition is corrected or qualified medical personnel determine that the person\u2019s inclusion would not jeopardize the safety or quality of the APIs.\n\n## 3.3 Consultants\n\n3.30 Consultants advising on the manufacture and control of intermediates or APIs should have sufficient education, training, and experience, or any combination thereof, to advise on the subject for which they are retained.\n\n3.31 Records should be maintained stating the name, address, qualifications and type of service provided by these consultants.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las calificaciones, la higiene y la gesti\u00f3n de personal involucrado en la fabricaci\u00f3n de intermediarios y principios activos (APIs). Se enfatiza la necesidad de contar con personal calificado, la importancia de la formaci\u00f3n continua, y las pr\u00e1cticas de higiene que deben seguirse para evitar la contaminaci\u00f3n de los productos. Adem\u00e1s, se menciona la necesidad de mantener registros de consultores que asesoren en la fabricaci\u00f3n y control de estos productos.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas que deben ser documentadas para el personal involucrado en la fabricaci\u00f3n de intermediarios y APIs?**\n   - Esta pregunta busca detalles sobre la documentaci\u00f3n de responsabilidades que no se especifican en el texto, pero que son cruciales para la gesti\u00f3n del personal.\n\n2. **\u00bfQu\u00e9 tipo de formaci\u00f3n se considera adecuada para el personal que trabaja en la fabricaci\u00f3n de intermediarios y APIs, y c\u00f3mo se eval\u00faa su efectividad?**\n   - Esta pregunta se centra en los m\u00e9todos de formaci\u00f3n y evaluaci\u00f3n que podr\u00edan no estar claramente definidos en el contexto, pero son esenciales para asegurar la competencia del personal.\n\n3. **\u00bfQu\u00e9 criterios se utilizan para determinar si un consultor es adecuado para asesorar en la fabricaci\u00f3n y control de intermediarios o APIs?**\n   - Esta pregunta busca profundizar en los criterios de selecci\u00f3n de consultores, que no se detallan en el texto, pero son importantes para garantizar la calidad del asesoramiento recibido.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Buenas Pr\u00e1cticas de Manufactura (GMP)**: El documento se centra en la implementaci\u00f3n de GMP para los Ingredientes Farmac\u00e9uticos Activos (APIs), destacando la importancia de la calidad y la consistencia en la producci\u00f3n.\n\n2. **Desviaciones en la Producci\u00f3n**: Se enfatiza la necesidad de reportar y evaluar todas las desviaciones en la producci\u00f3n, con un enfoque especial en las desviaciones cr\u00edticas que deben ser investigadas y documentadas.\n\n3. **Limpieza y Mantenimiento**: Se requiere que las instalaciones de producci\u00f3n est\u00e9n limpias y desinfectadas cuando sea necesario, y que se mantengan adecuadamente los equipos y las instalaciones.\n\n4. **Calibraciones y Validaciones**: Es esencial realizar calibraciones necesarias y mantener registros, as\u00ed como revisar y aprobar protocolos y reportes de validaci\u00f3n.\n\n5. **Auditor\u00edas Internas**: Se deben llevar a cabo auditor\u00edas internas regulares seg\u00fan un cronograma aprobado para verificar el cumplimiento de los principios de GMP. Los hallazgos y acciones correctivas deben ser documentados y comunicados a la gerencia responsable.\n\n6. **Revisi\u00f3n de Calidad del Producto**: Se deben realizar revisiones de calidad de los APIs de manera regular, normalmente de forma anual, para verificar la consistencia del proceso. Esto incluye la revisi\u00f3n de controles cr\u00edticos, lotes que no cumplieron con las especificaciones, desviaciones cr\u00edticas, cambios en procesos o m\u00e9todos anal\u00edticos, y quejas relacionadas con la calidad.\n\n7. **Acciones Correctivas**: Los resultados de las revisiones de calidad deben ser evaluados para determinar si se requieren acciones correctivas o revalidaciones, y estas deben ser documentadas y completadas de manera oportuna y efectiva.\n\n### Entidades Clave\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el documento.\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Producto central del documento.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Principios que gu\u00edan la producci\u00f3n de APIs.\n- **Auditor\u00edas Internas**: Proceso de verificaci\u00f3n del cumplimiento de GMP.\n- **Revisi\u00f3n de Calidad**: Evaluaci\u00f3n regular de la consistencia del proceso de producci\u00f3n de APIs. \n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades clave abordados en la secci\u00f3n del documento.", "excerpt_keywords": "Keywords: personnel qualifications, good manufacturing practices, hygiene, training records, consultants"}}, "cd7e7d79-7882-437d-9045-db7165899874": {"node_ids": ["566e0b53-09e7-4502-822b-7273f5e93d9d"], "metadata": {"page_label": "154", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4. Buildings and facilities\n\n## 4.1 Design and construction\n\n4.10 Buildings and facilities used in the manufacture of intermediates and APIs should be located, designed, and constructed to facilitate cleaning, maintenance and operations as appropriate to the type and stage of manufacture. Facilities should also be designed to minimize potential contamination. Where microbiological specifications have been established for the intermediate or API, facilities should also be designed to limit exposure to objectionable microbiological contaminants as appropriate.\n\n4.11 Buildings and facilities should have adequate space for the orderly placement of equipment and materials to prevent mix-ups and contamination.\n\n4.12 Where the equipment itself (e.g. closed or contained systems) provides adequate protection of the material, such equipment can be located outdoors.\n\n4.13 The flow of materials and personnel through the building or facilities should be designed to prevent mix-ups or contamination.\n\n4.14 There should be defined areas or other control systems for the following activities:\n\n- receipt, identification, sampling, and quarantine of incoming materials, pending release or rejection;\n- quarantine before release or rejection of intermediates and APIs;\n- sampling of intermediates and APIs;\n- holding rejected materials before further disposition (e.g. return, reprocessing or destruction);\n- storage of released materials;\n- production operations;\n- packaging and labelling operations; and\n- laboratory operations.\n\n4.15 Adequate, clean washing and toilet facilities should be provided for personnel. These washing facilities should be equipped with hot and cold water as appropriate, soap or detergent, air driers or single-use towels. The washing and toilet facilities should be separate from, but easily accessible to, manufacturing areas. Adequate facilities for showering and/or changing clothes should be provided, when appropriate.\n\n4.16 Laboratory areas and operations should normally be separated from production areas. Some laboratory areas, in particular those used for in-process controls, can be located in production areas, provided the operations of the production process do not adversely affect the accuracy of the laboratory measurements, and the laboratory and its operations do not adversely affect the production process or intermediate or API.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Dise\u00f1o y construcci\u00f3n de instalaciones**: Las instalaciones utilizadas en la fabricaci\u00f3n de intermediarios y principios activos (APIs) deben ser dise\u00f1adas y construidas para facilitar la limpieza y el mantenimiento, minimizando la contaminaci\u00f3n y limitando la exposici\u00f3n a contaminantes microbiol\u00f3gicos.\n\n2. **Flujo de materiales y personal**: Es crucial que el flujo de materiales y personal dentro de las instalaciones est\u00e9 dise\u00f1ado para prevenir confusiones y contaminaci\u00f3n, con \u00e1reas definidas para diversas actividades relacionadas con la recepci\u00f3n, almacenamiento, producci\u00f3n y laboratorio.\n\n3. **Instalaciones para el personal**: Se deben proporcionar instalaciones adecuadas y limpias para el lavado y el uso de ba\u00f1os, separadas de las \u00e1reas de fabricaci\u00f3n, y se deben incluir facilidades para duchas y cambios de ropa cuando sea necesario.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 caracter\u00edsticas espec\u00edficas deben tener las instalaciones para minimizar la contaminaci\u00f3n microbiol\u00f3gica en la fabricaci\u00f3n de intermediarios y APIs?**\n   - Esta pregunta busca detalles sobre el dise\u00f1o y las caracter\u00edsticas de las instalaciones que no se mencionan expl\u00edcitamente en otras normativas o documentos.\n\n2. **\u00bfCu\u00e1les son las consideraciones clave para el dise\u00f1o del flujo de materiales y personal en las instalaciones de fabricaci\u00f3n de intermediarios y APIs?**\n   - Esta pregunta se centra en los aspectos pr\u00e1cticos del dise\u00f1o de instalaciones que previenen la contaminaci\u00f3n y las confusiones, lo cual puede no estar claramente definido en otras fuentes.\n\n3. **\u00bfQu\u00e9 requisitos espec\u00edficos se deben cumplir para las instalaciones de lavado y ba\u00f1o en las \u00e1reas de fabricaci\u00f3n de intermediarios y APIs?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre las especificaciones de las instalaciones de higiene para el personal, que pueden no estar cubiertas en otras regulaciones o gu\u00edas.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Calificaciones del Personal**:\n   - Se requiere un n\u00famero adecuado de personal calificado en educaci\u00f3n, formaci\u00f3n y/o experiencia para la fabricaci\u00f3n y supervisi\u00f3n de intermediarios y principios activos (APIs).\n   - Las responsabilidades del personal deben estar documentadas por escrito.\n   - La formaci\u00f3n debe ser regular, realizada por individuos calificados, y debe incluir operaciones espec\u00edficas y Buenas Pr\u00e1cticas de Manufactura (GMP). Se deben mantener registros de formaci\u00f3n y realizar evaluaciones peri\u00f3dicas.\n\n2. **Higiene del Personal**:\n   - Se enfatiza la importancia de buenas pr\u00e1cticas de sanidad y salud.\n   - El personal debe usar ropa limpia y adecuada, cambi\u00e1ndola cuando sea necesario, y utilizar ropa protectora adicional para evitar la contaminaci\u00f3n de intermediarios y APIs.\n   - Se proh\u00edbe el contacto directo con intermediarios o APIs, as\u00ed como actividades como fumar, comer o almacenar alimentos en \u00e1reas de fabricaci\u00f3n.\n   - El personal con enfermedades infecciosas o lesiones abiertas debe ser excluido de actividades que puedan comprometer la calidad de los APIs.\n\n3. **Consultores**:\n   - Los consultores deben tener la educaci\u00f3n, formaci\u00f3n y experiencia adecuadas para asesorar sobre la fabricaci\u00f3n y control de intermediarios y APIs.\n   - Se deben mantener registros que incluyan el nombre, direcci\u00f3n, calificaciones y tipo de servicio proporcionado por los consultores.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Intermediarios y APIs**: Productos farmac\u00e9uticos cuya fabricaci\u00f3n y control son el foco de las directrices.\n- **Personal**: Incluye a todos los empleados involucrados en la fabricaci\u00f3n y supervisi\u00f3n de intermediarios y APIs.\n- **Consultores**: Profesionales externos que asesoran sobre la fabricaci\u00f3n y control de intermediarios y APIs. \n\nEste resumen destaca la importancia de la calificaci\u00f3n, la higiene y la gesti\u00f3n adecuada del personal en la industria farmac\u00e9utica, as\u00ed como la necesidad de contar con consultores competentes.", "excerpt_keywords": "Keywords: buildings, facilities, design, contamination, hygiene"}}, "39e44bb9-df93-4f57-9e56-2f6d07133863": {"node_ids": ["8e66e1f0-67a5-41f8-9de5-f0d5b0ca7a7c"], "metadata": {"page_label": "155", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.2 Utilities\n\n4.20 All utilities that could impact on product quality (e.g. steam, gases, compressed air, and heating, ventilation and air conditioning) should be qualified and appropriately monitored and action should be taken when limits are exceeded. Drawings for these utility systems should be available.\n\n4.21 Adequate ventilation, air filtration and exhaust systems should be provided, where appropriate. These systems should be designed and constructed to minimize risks of contamination and cross-contamination and should include equipment for control of air pressure, microorganisms (if appropriate), dust, humidity, and temperature, as appropriate to the stage of manufacture. Particular attention should be given to areas where APIs are exposed to the environment.\n\n4.22 If air is recirculated to production areas, appropriate measures should be taken to control risks of contamination and cross-contamination.\n\n4.23 Permanently installed pipework should be appropriately identified. This can be accomplished by identifying individual lines, documentation, computer control systems, or alternative means. Pipework should be located to avoid risks of contamination of the intermediate or API.\n\n4.24 Drains should be of adequate size and should be provided with an air break or a suitable device to prevent back-siphonage, when appropriate.\n\n# 4.3 Water\n\n4.30 Water used in the manufacture of APIs should be demonstrated to be suitable for its intended use.\n\n4.31 Unless otherwise justified, process water should, at a minimum, meet WHO guidelines for drinking (potable) water quality.\n\n4.32 If drinking (potable) water is insufficient to assure API quality, and tighter chemical and/or microbiological water quality specifications are called for, appropriate specifications for physical and chemical attributes, total microbial counts, objectionable organisms and/or endotoxins should be established.\n\n4.33 Where water used in the process is treated by the manufacturer to achieve a defined quality, the treatment process should be validated and monitored with appropriate action limits.\n\n4.34 Where the manufacturer of a non-sterile API either intends or claims that it is suitable for use in further processing to produce a sterile FPP, water used in the final isolation and purification steps should be monitored and controlled for total microbial counts, objectionable organisms and endotoxins.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las directrices sobre la calidad de las utilidades y el agua en la fabricaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (API). Se enfatiza la importancia de calificar y monitorear utilidades como vapor, gases y sistemas de ventilaci\u00f3n para minimizar riesgos de contaminaci\u00f3n. Adem\u00e1s, se establecen requisitos espec\u00edficos para la calidad del agua utilizada en la producci\u00f3n de API, incluyendo la necesidad de cumplir con las pautas de calidad del agua potable y de establecer especificaciones m\u00e1s estrictas si es necesario.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben tomarse si se exceden los l\u00edmites de monitoreo de las utilidades que impactan la calidad del producto?**\n   - El documento indica que se deben tomar acciones apropiadas cuando se exceden los l\u00edmites de monitoreo de las utilidades, aunque no especifica qu\u00e9 acciones exactas deben implementarse.\n\n2. **\u00bfCu\u00e1les son las especificaciones m\u00ednimas que debe cumplir el agua de proceso utilizada en la fabricaci\u00f3n de APIs?**\n   - A menos que se justifique lo contrario, el agua de proceso debe cumplir, como m\u00ednimo, con las pautas de la OMS para la calidad del agua potable.\n\n3. **\u00bfQu\u00e9 tipo de control se debe ejercer sobre el agua utilizada en los pasos finales de aislamiento y purificaci\u00f3n de un API no est\u00e9ril que se pretende utilizar para producir un producto farmac\u00e9utico est\u00e9ril?**\n   - El agua utilizada en estos pasos debe ser monitoreada y controlada para total de recuentos microbianos, organismos objetables y endotoxinas, asegurando as\u00ed la calidad del producto final.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n 4: Edificios e Instalaciones\n\n#### Temas Clave:\n\n1. **Dise\u00f1o y Construcci\u00f3n de Instalaciones**:\n   - Las instalaciones para la fabricaci\u00f3n de intermediarios y principios activos (APIs) deben facilitar la limpieza y el mantenimiento.\n   - Deben minimizar la contaminaci\u00f3n y limitar la exposici\u00f3n a contaminantes microbiol\u00f3gicos.\n\n2. **Espacio y Organizaci\u00f3n**:\n   - Es esencial contar con espacio adecuado para la colocaci\u00f3n ordenada de equipos y materiales, evitando confusiones y contaminaci\u00f3n.\n\n3. **Flujo de Materiales y Personal**:\n   - El dise\u00f1o debe prevenir la mezcla de materiales y la contaminaci\u00f3n, estableciendo un flujo claro para el movimiento de personas y materiales.\n\n4. **\u00c1reas Definidas para Actividades**:\n   - Se deben establecer \u00e1reas espec\u00edficas para actividades como recepci\u00f3n, muestreo, cuarentena, almacenamiento, producci\u00f3n, envasado y operaciones de laboratorio.\n\n5. **Instalaciones de Higiene para el Personal**:\n   - Deben existir instalaciones limpias para el lavado y uso de ba\u00f1os, separadas de las \u00e1reas de fabricaci\u00f3n, con acceso a agua caliente y fr\u00eda, jab\u00f3n, y opciones para secado.\n\n6. **Separaci\u00f3n de \u00c1reas de Laboratorio y Producci\u00f3n**:\n   - Las \u00e1reas de laboratorio deben estar separadas de las de producci\u00f3n, salvo en casos espec\u00edficos donde no afecten la precisi\u00f3n de los controles de proceso.\n\n#### Entidades:\n\n- **Intermediarios**: Sustancias qu\u00edmicas utilizadas en la fabricaci\u00f3n de APIs.\n- **APIs (Principios Activos)**: Sustancias que tienen un efecto farmacol\u00f3gico.\n- **Contaminantes Microbiol\u00f3gicos**: Organismos que pueden causar contaminaci\u00f3n en el proceso de fabricaci\u00f3n.\n- **Instalaciones de Lavado y Ba\u00f1o**: Espacios destinados a la higiene del personal.\n- **\u00c1reas de Producci\u00f3n**: Espacios donde se llevan a cabo las operaciones de fabricaci\u00f3n.\n- **\u00c1reas de Laboratorio**: Espacios dedicados a pruebas y controles de calidad.\n\nEste resumen destaca la importancia del dise\u00f1o y la organizaci\u00f3n de las instalaciones en la fabricaci\u00f3n de productos farmac\u00e9uticos, enfatizando la necesidad de mantener est\u00e1ndares de higiene y prevenir la contaminaci\u00f3n.", "excerpt_keywords": "Keywords: utilities, water quality, contamination control, API manufacturing, WHO guidelines"}}, "4f22b7ff-a94a-491a-b8b4-cd1f8e76e9ff": {"node_ids": ["c377e99c-2cd6-4449-8c3a-e94b1af11013"], "metadata": {"page_label": "156", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.4 Containment\n\n4.40 Dedicated production areas, which can include facilities, air handling equipment and/or process equipment, should be employed in the production of highly sensitizing materials, such as penicillins or cephalosporins.\n\n4.41 Dedicated production areas should also be considered when material of an infectious nature or high pharmacological activity or toxicity is involved (e.g. certain steroids or cytotoxic anti-cancer agents) unless validated inactivation and/or cleaning procedures are established and maintained.\n\n4.42 Appropriate measures should be established and implemented to prevent cross-contamination, e.g. from personnel or materials, moving from one dedicated area to another.\n\n4.43 Any production activities (including weighing, milling or packaging) of highly toxic non-pharmaceutical materials such as herbicides and pesticides should not be conducted using the buildings and/or equipment being used for the production of APIs. Handling and storage of these highly toxic non-pharmaceutical materials should be separate from APIs.\n\n# 4.5 Lighting\n\n4.50 Adequate lighting should be provided in all areas to facilitate cleaning, maintenance and proper operations.\n\n# 4.6 Sewage and refuse\n\n4.60 Sewage, refuse and other waste (e.g. solids, liquids, or gaseous by-products from manufacturing) in and from buildings and the immediate surrounding area should be disposed of in a safe, timely and sanitary manner. Containers and/or pipes for waste material should be clearly identified.\n\n# 4.7 Sanitation and maintenance\n\n4.70 Buildings used in the manufacture of intermediates and APIs should be properly maintained and repaired and kept in a clean condition.\n\n4.71 Written procedures should be established assigning responsibility for sanitation and describing the cleaning schedules, methods, equipment and materials to be used in cleaning buildings and facilities.\n\n4.72 When necessary, written procedures should also be established for the use of suitable rodenticides, insecticides, fungicides, fumigating agents and cleaning and sanitizing agents to prevent the contamination of equipment, raw materials, packaging or labelling materials, intermediates and APIs.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para la producci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs) y otros materiales relacionados. Se enfatiza la importancia de \u00e1reas de producci\u00f3n dedicadas para evitar la contaminaci\u00f3n cruzada, especialmente al manejar materiales altamente sensibilizantes o t\u00f3xicos. Tambi\u00e9n se discuten aspectos como la iluminaci\u00f3n adecuada, la gesti\u00f3n de residuos y la sanidad y mantenimiento de las instalaciones.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 medidas se deben implementar para prevenir la contaminaci\u00f3n cruzada en \u00e1reas de producci\u00f3n dedicadas?**\n   - El documento menciona que se deben establecer y aplicar medidas apropiadas para prevenir la contaminaci\u00f3n cruzada, como el control del movimiento de personal y materiales entre diferentes \u00e1reas dedicadas.\n\n2. **\u00bfCu\u00e1les son las consideraciones espec\u00edficas para la producci\u00f3n de materiales altamente t\u00f3xicos no farmac\u00e9uticos en relaci\u00f3n con los edificios y equipos utilizados para la producci\u00f3n de APIs?**\n   - Se establece que cualquier actividad de producci\u00f3n de materiales altamente t\u00f3xicos no farmac\u00e9uticos, como herbicidas y pesticidas, no debe realizarse en los mismos edificios o equipos que se utilizan para la producci\u00f3n de APIs, y su manejo y almacenamiento deben ser separados.\n\n3. **\u00bfQu\u00e9 procedimientos escritos se deben establecer para garantizar la sanidad y limpieza de las instalaciones de fabricaci\u00f3n?**\n   - Se deben establecer procedimientos escritos que asignen responsabilidades para la sanidad, describan los horarios de limpieza, los m\u00e9todos, el equipo y los materiales a utilizar. Adem\u00e1s, se deben establecer procedimientos para el uso de agentes de limpieza y desinfecci\u00f3n, as\u00ed como para el control de plagas, para prevenir la contaminaci\u00f3n de los productos.", "prev_section_summary": "### Temas Clave\n\n1. **Calidad de Utilidades**: Se enfatiza la importancia de calificar y monitorear utilidades como vapor, gases, aire comprimido y sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) para asegurar que no impacten negativamente la calidad del producto. Se deben tomar acciones cuando se exceden los l\u00edmites establecidos.\n\n2. **Sistemas de Ventilaci\u00f3n y Filtraci\u00f3n**: Se requiere la instalaci\u00f3n de sistemas adecuados de ventilaci\u00f3n, filtraci\u00f3n de aire y extracci\u00f3n, dise\u00f1ados para minimizar riesgos de contaminaci\u00f3n y cruzamiento. Estos sistemas deben incluir controles para presi\u00f3n del aire, microorganismos, polvo, humedad y temperatura.\n\n3. **Identificaci\u00f3n de Tuber\u00edas**: Las tuber\u00edas instaladas permanentemente deben ser identificadas adecuadamente para evitar riesgos de contaminaci\u00f3n de los ingredientes intermedios o activos.\n\n4. **Control de Drenajes**: Los drenajes deben ser de tama\u00f1o adecuado y contar con dispositivos que prevengan el retroceso de agua, cuando sea necesario.\n\n5. **Calidad del Agua**: El agua utilizada en la fabricaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (API) debe ser adecuada para su uso previsto y, al menos, cumplir con las pautas de calidad del agua potable de la OMS. Si el agua potable no es suficiente, se deben establecer especificaciones m\u00e1s estrictas.\n\n6. **Monitoreo del Agua**: El agua utilizada en los pasos finales de aislamiento y purificaci\u00f3n de un API no est\u00e9ril que se destina a la producci\u00f3n de un producto farmac\u00e9utico est\u00e9ril debe ser monitoreada para asegurar que cumpla con los est\u00e1ndares de recuentos microbianos, organismos objetables y endotoxinas.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las pautas de calidad del agua y utilidades en la fabricaci\u00f3n de APIs.\n- **API (Ingrediente Farmac\u00e9utico Activo)**: Sustancia utilizada en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **FPP (Forma Farmac\u00e9utica Final)**: Producto farmac\u00e9utico que se obtiene tras el procesamiento de un API.\n- **Sistemas de Ventilaci\u00f3n y Filtraci\u00f3n**: Infraestructura necesaria para mantener la calidad del aire en las \u00e1reas de producci\u00f3n.\n- **Tuber\u00edas y Drenajes**: Componentes de infraestructura que deben ser gestionados para evitar la contaminaci\u00f3n. \n\nEste resumen destaca la importancia de la calidad de las utilidades y el agua en la producci\u00f3n de APIs, as\u00ed como las medidas necesarias para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: containment, cross-contamination, sanitation, APIs, waste disposal"}}, "d3bd3be9-92d9-4d19-baa6-a171f253d7f9": {"node_ids": ["ccd3cacc-90ee-4ce3-8116-6e4010f84cea"], "metadata": {"page_label": "157", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 5. Process equipment\n\n## 5.1 Design and construction\n\n5.10 Equipment used in the manufacture of intermediates and APIs should be of appropriate design and adequate size, and suitably located for its intended use, cleaning, sanitization (where appropriate) and maintenance.\n\n5.11 Equipment should be constructed so that surfaces that contact raw materials, intermediates or APIs do not alter the quality of the intermediates and APIs beyond the official or other established specifications.\n\n5.12 Production equipment should only be used within its qualified operating range.\n\n5.13 Major equipment (e.g. reactors, storage containers) and permanently installed processing lines used during the production of an intermediate or API should be appropriately identified.\n\n5.14 Any substances associated with the operation of equipment, such as lubricants, heating fluids or coolants, should not contact intermediates or APIs so as to alter their quality beyond the official or other established specifications. Any deviations from this should be evaluated to ensure that there are no detrimental effects upon the fitness for purpose of the material. Wherever possible, food-grade lubricants and oils should be used.\n\n5.15 Closed or contained equipment should be used whenever appropriate. Where open equipment is used, or equipment is opened, appropriate precautions should be taken to minimize the risk of contamination.\n\n5.16 A set of current drawings should be maintained for equipment and critical installations (e.g. instrumentation and utility systems).\n\n## 5.2 Equipment maintenance and cleaning\n\n5.20 Schedules and procedures (including assignment of responsibility) should be established for the preventive maintenance of equipment.\n\n5.21 Written procedures should be established for cleaning of equipment and its subsequent release for use in the manufacture of intermediates and APIs. Cleaning procedures should contain sufficient details to enable operators to clean each type of equipment in a reproducible and effective manner. These procedures should include:\n\n- assignment of responsibility for cleaning of equipment;\n- cleaning schedules, including, where appropriate, sanitizing schedules;\n- a complete description of the methods and materials, including dilution of cleaning agents used to clean equipment;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las directrices sobre el dise\u00f1o, construcci\u00f3n, mantenimiento y limpieza del equipo utilizado en la fabricaci\u00f3n de intermediarios y principios activos (APIs). Se enfatiza la importancia de que el equipo est\u00e9 dise\u00f1ado adecuadamente, construido con materiales que no alteren la calidad de los productos, y que se mantenga dentro de un rango operativo calificado. Tambi\u00e9n se destacan las pr\u00e1cticas de limpieza y mantenimiento preventivo, as\u00ed como la necesidad de documentaci\u00f3n y procedimientos claros para garantizar la calidad y seguridad en la producci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de lubricantes se recomienda utilizar en el equipo de producci\u00f3n para minimizar el riesgo de contaminaci\u00f3n de los intermediarios y APIs?**\n   - Respuesta: Se recomienda utilizar lubricantes y aceites de grado alimenticio siempre que sea posible, para minimizar el riesgo de alterar la calidad de los intermediarios y APIs.\n\n2. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en los procedimientos escritos para la limpieza del equipo?**\n   - Respuesta: Los procedimientos escritos para la limpieza del equipo deben incluir la asignaci\u00f3n de responsabilidad para la limpieza, los horarios de limpieza (incluyendo horarios de sanitizaci\u00f3n donde sea apropiado) y una descripci\u00f3n completa de los m\u00e9todos y materiales, incluyendo la diluci\u00f3n de los agentes de limpieza utilizados.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse cuando se utiliza equipo abierto o se abre el equipo durante el proceso de producci\u00f3n?**\n   - Respuesta: Cuando se utiliza equipo abierto o se abre el equipo, se deben tomar precauciones apropiadas para minimizar el riesgo de contaminaci\u00f3n, asegurando as\u00ed la integridad de los intermediarios y APIs producidos.", "prev_section_summary": "### Temas Clave:\n\n1. **\u00c1reas de Producci\u00f3n Dedicadas**: Se enfatiza la necesidad de contar con \u00e1reas de producci\u00f3n espec\u00edficas para manejar materiales altamente sensibilizantes y t\u00f3xicos, como penicilinas, esteroides y agentes citot\u00f3xicos, para evitar la contaminaci\u00f3n cruzada.\n\n2. **Prevenci\u00f3n de Contaminaci\u00f3n Cruzada**: Se deben implementar medidas adecuadas para prevenir la contaminaci\u00f3n cruzada entre diferentes \u00e1reas de producci\u00f3n, controlando el movimiento de personal y materiales.\n\n3. **Separaci\u00f3n de Materiales T\u00f3xicos**: Las actividades de producci\u00f3n de materiales altamente t\u00f3xicos no farmac\u00e9uticos, como herbicidas y pesticidas, deben realizarse en instalaciones y equipos separados de aquellos utilizados para la producci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs).\n\n4. **Iluminaci\u00f3n Adecuada**: Es esencial proporcionar una iluminaci\u00f3n adecuada en todas las \u00e1reas para facilitar la limpieza, el mantenimiento y las operaciones.\n\n5. **Gesti\u00f3n de Residuos**: Los desechos generados en el proceso de fabricaci\u00f3n deben ser eliminados de manera segura y sanitaria, con contenedores y tuber\u00edas claramente identificados.\n\n6. **Sanidad y Mantenimiento**: Las instalaciones deben mantenerse en condiciones limpias y reparadas, con procedimientos escritos que asignen responsabilidades y describan los m\u00e9todos de limpieza y desinfecci\u00f3n.\n\n7. **Control de Plagas**: Se deben establecer procedimientos para el uso de agentes de limpieza y control de plagas para prevenir la contaminaci\u00f3n de productos y materiales.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Productos cuya producci\u00f3n est\u00e1 regulada por las buenas pr\u00e1cticas de fabricaci\u00f3n.\n- **Materiales Altamente Sensibilizantes**: Incluyen penicilinas y cephalosporinas.\n- **Materiales T\u00f3xicos No Farmac\u00e9uticos**: Incluyen herbicidas y pesticidas.\n- **Esteroides y Agentes Citot\u00f3xicos**: Ejemplos de materiales de alta actividad farmacol\u00f3gica o toxicidad.\n- **Procedimientos Escritos**: Documentaci\u00f3n necesaria para garantizar la sanidad y limpieza de las instalaciones. \n\nEste resumen destaca la importancia de las buenas pr\u00e1cticas de fabricaci\u00f3n en la producci\u00f3n de productos farmac\u00e9uticos y la necesidad de mantener est\u00e1ndares rigurosos para garantizar la seguridad y la calidad.", "excerpt_keywords": "Keywords: equipment design, API manufacturing, cleaning procedures, contamination prevention, maintenance schedules"}}, "1da2ff8e-e36f-42a9-8397-d65179296b0f": {"node_ids": ["d6fd1243-981c-41b5-bb0c-b47471416650"], "metadata": {"page_label": "158", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 when appropriate, instructions for disassembling and reassembling each article of equipment to ensure proper cleaning;  \n\u2014 instructions for the removal or obliteration of previous batch identification;  \n\u2014 instructions for the protection of clean equipment from contamination prior to use;  \n\u2014 inspection of equipment for cleanliness immediately before use, if practical; and  \n\u2014 establishing the maximum time that may elapse between the completion of processing and equipment cleaning, when appropriate.  \n\n5.22 Equipment and utensils should be cleaned, stored and, where appropriate, sanitized or sterilized to prevent contamination or carry-over of a material that would alter the quality of the intermediate or API beyond the official or other established specifications.  \n\n5.23 Where equipment is assigned to continuous production or campaign production of successive batches of the same intermediate or API, this equipment should be cleaned at appropriate intervals to prevent build-up and carry-over of contaminants (e.g. degradants or objectionable levels of microorganisms).  \n\n5.24 Non-dedicated equipment should be cleaned between production of different materials to prevent cross-contamination.  \n\n5.25 Acceptance criteria for residues and the choice of cleaning procedures and cleaning agents should be defined and justified.  \n\n5.26 Equipment should be identified as to its contents and its cleanliness status by appropriate means.  \n\n### 5.3 Calibration\n\n5.30 Control, weighing, measuring, monitoring and test equipment that is critical for assuring the quality of intermediates or APIs should be calibrated according to written procedures and an established schedule.  \n\n5.31 Equipment calibrations should be performed using standards traceable to certified standards, if these exist.  \n\n5.32 Records of these calibrations should be maintained.  \n\n5.33 The current calibration status of critical equipment should be known and verifiable.  \n\n5.34 Instruments that do not meet calibration criteria should not be used.  \n\n5.35 Deviations from approved standards of calibration on critical instruments should be investigated to determine if these could have had an impact.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Limpieza y Mantenimiento de Equipos**: El documento establece directrices sobre la limpieza, almacenamiento y desinfecci\u00f3n de equipos y utensilios utilizados en la producci\u00f3n de intermediarios y principios activos (API). Se enfatiza la importancia de evitar la contaminaci\u00f3n y la alteraci\u00f3n de la calidad del producto final.\n\n2. **Calibraci\u00f3n de Equipos**: Se detallan los procedimientos para la calibraci\u00f3n de equipos cr\u00edticos que aseguran la calidad de los intermediarios y APIs. Esto incluye la necesidad de utilizar est\u00e1ndares trazables, mantener registros de calibraci\u00f3n y verificar el estado de calibraci\u00f3n de los instrumentos.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las instrucciones espec\u00edficas para la limpieza de equipos no dedicados entre la producci\u00f3n de diferentes materiales?**\n   - Este contexto proporciona detalles sobre la limpieza necesaria para evitar la contaminaci\u00f3n cruzada, lo que no se encuentra f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 criterios de aceptaci\u00f3n se deben definir para los residuos en los equipos utilizados en la producci\u00f3n de intermediarios y APIs?**\n   - La respuesta a esta pregunta se basa en la necesidad de establecer y justificar criterios espec\u00edficos para los residuos, un aspecto que puede no estar ampliamente documentado en otras normativas.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse si un instrumento cr\u00edtico no cumple con los criterios de calibraci\u00f3n establecidos?**\n   - El contexto menciona la importancia de investigar las desviaciones en la calibraci\u00f3n, lo que proporciona una gu\u00eda sobre c\u00f3mo manejar situaciones de incumplimiento que puede no estar claramente delineada en otras fuentes.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n\n\n**1. Dise\u00f1o y construcci\u00f3n del equipo:**\n   - El equipo utilizado en la fabricaci\u00f3n de intermediarios y principios activos (APIs) debe ser de dise\u00f1o adecuado, tama\u00f1o suficiente y ubicado correctamente para su uso, limpieza y mantenimiento.\n   - Las superficies que entran en contacto con materias primas, intermediarios o APIs no deben alterar su calidad m\u00e1s all\u00e1 de las especificaciones establecidas.\n   - El equipo debe operar dentro de un rango calificado y debe ser identificado adecuadamente.\n\n**2. Lubricantes y sustancias operativas:**\n   - Los lubricantes, fluidos de calefacci\u00f3n y refrigerantes no deben entrar en contacto con los intermediarios o APIs de manera que alteren su calidad. Se recomienda el uso de lubricantes y aceites de grado alimenticio siempre que sea posible.\n\n**3. Equipos cerrados y abiertos:**\n   - Se debe utilizar equipo cerrado o contenido siempre que sea apropiado. En el caso de usar equipo abierto, se deben tomar precauciones para minimizar el riesgo de contaminaci\u00f3n.\n\n**4. Mantenimiento y limpieza del equipo:**\n   - Se deben establecer horarios y procedimientos para el mantenimiento preventivo del equipo, incluyendo la asignaci\u00f3n de responsabilidades.\n   - Los procedimientos de limpieza deben ser documentados y contener detalles suficientes para asegurar una limpieza efectiva y reproducible. Esto incluye la asignaci\u00f3n de responsabilidades, horarios de limpieza y una descripci\u00f3n completa de los m\u00e9todos y materiales utilizados.\n\n**5. Documentaci\u00f3n:**\n   - Es necesario mantener un conjunto de dibujos actualizados para el equipo y las instalaciones cr\u00edticas, como sistemas de instrumentaci\u00f3n y utilidades.\n\n### Entidades clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Intermediarios**\n- **Principios Activos (APIs)**\n- **Equipos de producci\u00f3n**\n- **Lubricantes de grado alimenticio**\n- **Procedimientos de limpieza y mantenimiento**", "excerpt_keywords": "Keywords: limpieza de equipos, calibraci\u00f3n, principios activos, contaminaci\u00f3n cruzada, procedimientos de mantenimiento"}}, "466ac9ff-eb56-4529-ba6e-33845903b2de": {"node_ids": ["62fb316e-d6aa-4fef-8580-1b701bc54eb9"], "metadata": {"page_label": "159", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 5.4 Computerized systems\n\n5.40 GMP-related computerized systems should be validated. The depth and scope of validation depends on the diversity, complexity and criticality of the computerized application.\n\n5.41 Appropriate installation qualification and operational qualification should demonstrate the suitability of computer hardware and software to perform assigned tasks.\n\n5.42 Commercially available software that has been qualified does not require the same level of testing. If an existing system was not validated at the time of installation, a retrospective validation could be conducted if appropriate documentation is available.\n\n5.43 Computerized systems should have sufficient controls to prevent unauthorized access or changes to data. There should be controls to prevent omissions in data (e.g., the system being turned off and data not captured). There should be a record of any data change made, the previous entry, the person who made the change and when the change was made.\n\n5.44 Written procedures should be available for the operation and maintenance of computerized systems.\n\n5.45 Where critical data are being entered manually, there should be an additional check on the accuracy of the data entered. This can be done by a second operator or by the system itself.\n\n5.46 Incidents related to computerized systems that could affect the quality of intermediates or APIs or the reliability of records or test results should be recorded and investigated.\n\n5.47 Changes to the computerized system should be made according to a change procedure and should be formally authorized, documented and tested. Records should be kept of all changes, including modifications and enhancements made to the hardware, software and any other critical component of the system. These records should demonstrate that the system is maintained in a validated state.\n\n5.48 If system breakdowns or failures will result in the permanent loss of records, a back-up system should be provided. A means of ensuring data protection should be established for all computerized systems.\n\n5.49 Data can be recorded by a second means in addition to the computer system.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la validaci\u00f3n y el control de sistemas computarizados relacionados con las Buenas Pr\u00e1cticas de Manufactura (GMP). Se enfatiza la importancia de validar estos sistemas en funci\u00f3n de su diversidad y complejidad, as\u00ed como la necesidad de establecer procedimientos escritos para su operaci\u00f3n y mantenimiento. Tambi\u00e9n se menciona la importancia de prevenir accesos no autorizados, registrar cambios en los datos y tener un sistema de respaldo para proteger la informaci\u00f3n cr\u00edtica.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar para determinar la profundidad y el alcance de la validaci\u00f3n de un sistema computarizado relacionado con GMP?**\n   - Respuesta: La profundidad y el alcance de la validaci\u00f3n dependen de la diversidad, complejidad y criticidad de la aplicaci\u00f3n computarizada.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse en caso de que un sistema computarizado no haya sido validado en el momento de su instalaci\u00f3n?**\n   - Respuesta: Si un sistema existente no fue validado al momento de la instalaci\u00f3n, se puede realizar una validaci\u00f3n retrospectiva siempre que se disponga de la documentaci\u00f3n apropiada.\n\n3. **\u00bfQu\u00e9 medidas deben implementarse para garantizar la protecci\u00f3n de datos en sistemas computarizados, especialmente en caso de fallos del sistema?**\n   - Respuesta: Se debe proporcionar un sistema de respaldo para evitar la p\u00e9rdida permanente de registros y establecer medios para garantizar la protecci\u00f3n de datos en todos los sistemas computarizados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### 1. Limpieza y Mantenimiento de Equipos\n- **Instrucciones de Limpieza**: Directrices para desensamblar y ensamblar equipos para asegurar una limpieza adecuada, eliminaci\u00f3n de identificaciones de lotes anteriores, y protecci\u00f3n de equipos limpios de contaminaci\u00f3n.\n- **Inspecci\u00f3n de Equipos**: Se recomienda inspeccionar la limpieza de los equipos justo antes de su uso.\n- **Tiempo M\u00e1ximo entre Procesamiento y Limpieza**: Establecimiento de un tiempo m\u00e1ximo que puede transcurrir entre la finalizaci\u00f3n del procesamiento y la limpieza del equipo.\n- **Almacenamiento y Sanitizaci\u00f3n**: Equipos y utensilios deben ser limpiados, almacenados y, cuando sea apropiado, desinfectados o esterilizados para prevenir contaminaci\u00f3n y alteraci\u00f3n de la calidad del producto.\n- **Producci\u00f3n Continua y Campa\u00f1as**: Equipos utilizados para producci\u00f3n continua deben limpiarse a intervalos apropiados para evitar acumulaci\u00f3n de contaminantes.\n- **Equipos No Dedicados**: Deben limpiarse entre la producci\u00f3n de diferentes materiales para prevenir la contaminaci\u00f3n cruzada.\n- **Criterios de Aceptaci\u00f3n**: Se deben definir y justificar criterios de aceptaci\u00f3n para residuos y elecci\u00f3n de procedimientos y agentes de limpieza.\n- **Identificaci\u00f3n de Equipos**: Equipos deben ser identificados seg\u00fan su contenido y estado de limpieza.\n\n#### 2. Calibraci\u00f3n de Equipos\n- **Calibraci\u00f3n de Equipos Cr\u00edticos**: Equipos de control, pesaje, medici\u00f3n y prueba deben ser calibrados seg\u00fan procedimientos escritos y un cronograma establecido.\n- **Est\u00e1ndares Trazables**: Las calibraciones deben realizarse utilizando est\u00e1ndares que sean trazables a est\u00e1ndares certificados, si existen.\n- **Mantenimiento de Registros**: Se deben mantener registros de las calibraciones realizadas.\n- **Estado de Calibraci\u00f3n**: El estado actual de calibraci\u00f3n de los equipos cr\u00edticos debe ser conocido y verificable.\n- **Uso de Instrumentos**: Instrumentos que no cumplan con los criterios de calibraci\u00f3n no deben ser utilizados.\n- **Investigaci\u00f3n de Desviaciones**: Desviaciones de los est\u00e1ndares aprobados de calibraci\u00f3n deben ser investigadas para determinar su posible impacto.\n\n### Entidades Clave\n- **Equipos y Utensilios**: Elementos utilizados en la producci\u00f3n de intermediarios y principios activos (APIs).\n- **Contaminantes**: Sustancias que pueden alterar la calidad del producto.\n- **Est\u00e1ndares de Calibraci\u00f3n**: Normas que gu\u00edan la calibraci\u00f3n de equipos cr\u00edticos.\n- **Registros de Calibraci\u00f3n**: Documentaci\u00f3n que respalda las actividades de calibraci\u00f3n realizadas. \n\nEste resumen destaca la importancia de la limpieza y calibraci\u00f3n de equipos en la producci\u00f3n farmac\u00e9utica para asegurar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: validation, computerized systems, data protection, GMP, record keeping"}}, "ce8129f0-3a0a-45b7-94c0-113b33d90687": {"node_ids": ["f5bad0c3-a3d3-414e-96aa-861f406cf9aa"], "metadata": {"page_label": "160", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 6. Documentation and records\n\n## 6.1 Documentation system and specifications\n\n6.10 All documents related to the manufacture of intermediates or APIs should be prepared, reviewed, approved and distributed according to written procedures. Such documents can be in paper or electronic form.\n\n6.11 The issuance, revision, superseding and withdrawal of all documents should be controlled with maintenance of revision histories.\n\n6.12 A procedure should be established for retaining all appropriate documents (e.g. development history reports, scale-up reports, technical transfer reports, process validation reports, training records, production records, control records and distribution records). The retention periods for these documents should be specified.\n\n6.13 All production, control and distribution records should be retained for at least one year after the expiry date of the batch. For APIs with retest dates, records should be retained for at least three years after the batch is completely distributed.\n\n6.14 Entries in records should be made indelibly in spaces provided for such entries, directly after performing the activities, and should identify the person making the entry. Corrections to entries should be dated and signed ensuring that the original entry remains readable.\n\n6.15 During the retention period, originals or copies of records should be readily available at the establishment where the activities described in these records occurred. Records that can be promptly retrieved from another location by electronic or other means are acceptable.\n\n6.16 Specifications, instructions, procedures and records can be retained either as originals or as true copies such as photocopies, microfilm, microfiche, or other accurate reproductions of the original records. Where reduction techniques such as microfilming or electronic records are used, suitable retrieval equipment and a means to produce a hard copy should be readily available.\n\n6.17 Specifications should be established and documented for raw materials, intermediates where necessary, APIs and labelling and packaging materials. In addition, specifications may be appropriate for certain other materials, such as process aids, gaskets or other materials used during the production of intermediates or APIs that could critically impact on quality. Acceptance criteria should be established and documented for in-process controls.\n\n6.18 If electronic signatures are used on documents they should be authenticated and secure.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece directrices sobre la documentaci\u00f3n y los registros relacionados con la fabricaci\u00f3n de intermediarios y principios activos (APIs). Se enfatiza la importancia de tener procedimientos escritos para la preparaci\u00f3n, revisi\u00f3n, aprobaci\u00f3n y distribuci\u00f3n de documentos. Adem\u00e1s, se especifican los requisitos para la retenci\u00f3n de registros, la autenticaci\u00f3n de firmas electr\u00f3nicas y la necesidad de mantener la integridad y disponibilidad de los documentos durante su per\u00edodo de retenci\u00f3n.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los tipos de documentos que deben ser retenidos seg\u00fan las directrices de la OMS y cu\u00e1les son los per\u00edodos de retenci\u00f3n espec\u00edficos para ellos?**\n   - Respuesta: Se deben retener documentos como informes de historia de desarrollo, informes de escalado, informes de transferencia t\u00e9cnica, informes de validaci\u00f3n de procesos, registros de capacitaci\u00f3n, registros de producci\u00f3n, registros de control y registros de distribuci\u00f3n. Los registros de producci\u00f3n, control y distribuci\u00f3n deben ser retenidos por al menos un a\u00f1o despu\u00e9s de la fecha de caducidad del lote, y para APIs con fechas de rean\u00e1lisis, los registros deben ser retenidos por al menos tres a\u00f1os despu\u00e9s de que el lote haya sido completamente distribuido.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse para realizar correcciones en los registros, seg\u00fan las directrices?**\n   - Respuesta: Las correcciones a las entradas en los registros deben ser fechadas y firmadas, asegurando que la entrada original permanezca legible. Adem\u00e1s, las entradas deben hacerse de manera indeleble en los espacios proporcionados, inmediatamente despu\u00e9s de realizar las actividades, e identificar a la persona que realiza la entrada.\n\n3. **\u00bfQu\u00e9 requisitos se establecen para las firmas electr\u00f3nicas en los documentos?**\n   - Respuesta: Si se utilizan firmas electr\u00f3nicas en los documentos, estas deben ser autenticadas y seguras, garantizando la integridad y la validez de los registros.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Validaci\u00f3n de Sistemas Computarizados**: \n   - Los sistemas computarizados relacionados con las Buenas Pr\u00e1cticas de Manufactura (GMP) deben ser validados. La profundidad y el alcance de esta validaci\u00f3n dependen de la diversidad, complejidad y criticidad de la aplicaci\u00f3n.\n\n2. **Calificaci\u00f3n de Instalaci\u00f3n y Operativa**: \n   - Se requiere demostrar la idoneidad del hardware y software mediante calificaciones adecuadas.\n\n3. **Software Comercial**: \n   - El software comercial calificado no necesita el mismo nivel de pruebas. Si un sistema no fue validado al momento de la instalaci\u00f3n, se puede realizar una validaci\u00f3n retrospectiva si hay documentaci\u00f3n adecuada.\n\n4. **Controles de Seguridad**: \n   - Los sistemas deben tener controles para prevenir accesos no autorizados y cambios en los datos. Se deben registrar todos los cambios, incluyendo la entrada anterior, el responsable y la fecha.\n\n5. **Procedimientos Escritos**: \n   - Deben existir procedimientos documentados para la operaci\u00f3n y mantenimiento de los sistemas computarizados.\n\n6. **Verificaci\u00f3n de Datos Cr\u00edticos**: \n   - Para la entrada manual de datos cr\u00edticos, se debe realizar una verificaci\u00f3n adicional de la precisi\u00f3n, ya sea por un segundo operador o por el sistema.\n\n7. **Registro de Incidentes**: \n   - Los incidentes que puedan afectar la calidad de los productos intermedios o APIs, as\u00ed como la fiabilidad de los registros o resultados de pruebas, deben ser registrados e investigados.\n\n8. **Procedimientos de Cambio**: \n   - Los cambios en el sistema deben seguir un procedimiento formal de autorizaci\u00f3n, documentaci\u00f3n y pruebas, manteniendo registros de todas las modificaciones.\n\n9. **Sistema de Respaldo**: \n   - Se debe proporcionar un sistema de respaldo para evitar la p\u00e9rdida permanente de registros en caso de fallos del sistema.\n\n10. **M\u00e9todos Adicionales de Registro**: \n    - Los datos pueden ser registrados por un segundo medio adem\u00e1s del sistema computarizado.\n\n### Entidades Clave\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normativa que regula la producci\u00f3n y control de calidad en la industria farmac\u00e9utica.\n- **Sistemas Computarizados**: Herramientas tecnol\u00f3gicas utilizadas en la gesti\u00f3n de datos y procesos en la manufactura.\n- **Software Comercial**: Programas disponibles en el mercado que pueden ser utilizados en entornos GMP.\n- **Datos Cr\u00edticos**: Informaci\u00f3n esencial que requiere un manejo cuidadoso para garantizar la calidad y la integridad de los productos. \n\nEste resumen destaca la importancia de la validaci\u00f3n, el control de acceso, la documentaci\u00f3n y la protecci\u00f3n de datos en los sistemas computarizados dentro del contexto de las GMP.", "excerpt_keywords": "Keywords: documentation, records, APIs, retention, electronic signatures"}}, "181110fb-8a95-401b-916e-a2fd07fbb8da": {"node_ids": ["7cc76db2-d4ef-4cac-9dff-0a8ae3c43a58"], "metadata": {"page_label": "161", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 6.2 Equipment cleaning and use record\n\n6.20 Records of major equipment use, cleaning, sanitization and/or sterilization and maintenance should show the date, time (if appropriate), product and batch number of each batch processed in the equipment, and the person who performed the cleaning and maintenance.\n\n6.21 If equipment is dedicated to manufacturing one intermediate or API, then individual equipment records are not necessary if batches of the intermediate or API follow in traceable sequence. In cases where dedicated equipment is employed, the records of cleaning, maintenance and use can be part of the batch record or maintained separately.\n\n# 6.3 Records of raw materials, intermediates, API labelling and packaging materials\n\n6.30 Records of raw materials, intermediates, API labelling and packaging materials should be maintained including:\n\n- the name of the manufacturer, identity and quantity of each shipment of each batch of raw materials, intermediates or labelling and packaging materials for APIs; the name of the supplier; the supplier\u2019s control number(s), if known, or other identification number; the number allocated on receipt; and the date of receipt;\n- the results of any test or examination performed and the conclusions derived from this;\n- records tracing the use of materials;\n- documentation of the examination and review of API labelling and packaging material for conformity with established specifications; and\n- the final decision regarding rejected raw materials, intermediates or API labelling and packaging materials.\n\n6.31 Master (approved) labels should be maintained for comparison to issued labels.\n\n# 6.4 Master production instructions (master production and control records)\n\n6.40 To ensure uniformity from batch to batch, master production instructions for each intermediate and API should be prepared, dated and signed by one person and independently checked, dated and signed by a person in the quality unit(s).\n\n6.41 Master production instructions should include:\n\n- the name of the intermediate or API being manufactured and an identifying document reference code, if applicable;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para el mantenimiento de registros relacionados con el uso, limpieza, sanitizaci\u00f3n, esterilizaci\u00f3n y mantenimiento de equipos en la producci\u00f3n de productos farmac\u00e9uticos, as\u00ed como la documentaci\u00f3n necesaria para materias primas, intermedios y materiales de etiquetado y empaque. Se enfatiza la importancia de mantener registros precisos y trazables para garantizar la calidad y la conformidad de los productos fabricados.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en los registros de limpieza y mantenimiento de equipos dedicados a la fabricaci\u00f3n de un intermedio o API?**\n   - Respuesta: Los registros deben incluir la fecha, hora (si es apropiado), producto y n\u00famero de lote de cada lote procesado en el equipo, as\u00ed como la persona que realiz\u00f3 la limpieza y el mantenimiento.\n\n2. **\u00bfCu\u00e1les son los elementos clave que deben documentarse en los registros de materias primas y materiales de etiquetado y empaque para APIs?**\n   - Respuesta: Los registros deben incluir el nombre del fabricante, la identidad y cantidad de cada env\u00edo, el nombre del proveedor, los n\u00fameros de control del proveedor (si se conocen), el n\u00famero asignado al recibir, la fecha de recepci\u00f3n, los resultados de pruebas realizadas, la trazabilidad de los materiales, la documentaci\u00f3n de la revisi\u00f3n de conformidad de los materiales de etiquetado y empaque, y la decisi\u00f3n final sobre materiales rechazados.\n\n3. **\u00bfQu\u00e9 pasos deben seguirse para la preparaci\u00f3n y verificaci\u00f3n de las instrucciones de producci\u00f3n maestra para intermedios y APIs?**\n   - Respuesta: Las instrucciones de producci\u00f3n maestra deben ser preparadas, fechadas y firmadas por una persona, y luego ser verificadas de manera independiente, fechadas y firmadas por una persona del(s) departamento(s) de calidad.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Documentaci\u00f3n y Registros**: La secci\u00f3n aborda la importancia de un sistema de documentaci\u00f3n adecuado para la fabricaci\u00f3n de intermediarios y principios activos (APIs).\n\n2. **Procedimientos Escritos**: Se requiere que todos los documentos sean preparados, revisados, aprobados y distribuidos de acuerdo con procedimientos escritos, ya sea en formato papel o electr\u00f3nico.\n\n3. **Control de Documentos**: Se debe mantener un control sobre la emisi\u00f3n, revisi\u00f3n, sustituci\u00f3n y retirada de documentos, incluyendo el mantenimiento de historiales de revisi\u00f3n.\n\n4. **Retenci\u00f3n de Documentos**: Se establece la necesidad de un procedimiento para la retenci\u00f3n de documentos relevantes, especificando per\u00edodos de retenci\u00f3n:\n   - Registros de producci\u00f3n, control y distribuci\u00f3n: al menos un a\u00f1o despu\u00e9s de la fecha de caducidad del lote.\n   - Registros de APIs con fechas de rean\u00e1lisis: al menos tres a\u00f1os despu\u00e9s de la distribuci\u00f3n completa del lote.\n\n5. **Integridad de Registros**: Las entradas en los registros deben ser indelibles y realizadas inmediatamente despu\u00e9s de las actividades, identificando a la persona responsable. Las correcciones deben ser fechadas y firmadas.\n\n6. **Disponibilidad de Registros**: Durante el per\u00edodo de retenci\u00f3n, los registros deben estar disponibles en el establecimiento donde se realizaron las actividades, y se aceptan registros que puedan ser recuperados electr\u00f3nicamente.\n\n7. **Especificaciones y Criterios de Aceptaci\u00f3n**: Se deben establecer y documentar especificaciones para materias primas, intermediarios, APIs y materiales de etiquetado y empaque, as\u00ed como criterios de aceptaci\u00f3n para controles en proceso.\n\n8. **Firmas Electr\u00f3nicas**: Si se utilizan firmas electr\u00f3nicas, estas deben ser autenticadas y seguras para garantizar la validez de los documentos.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Intermediarios y APIs**: Productos cuya fabricaci\u00f3n est\u00e1 regulada por las directrices.\n- **Documentos**: Incluyen informes de desarrollo, informes de escalado, informes de validaci\u00f3n, registros de producci\u00f3n, entre otros.\n- **Firmas Electr\u00f3nicas**: Elemento de seguridad en la documentaci\u00f3n electr\u00f3nica. \n\nEste resumen destaca la importancia de la documentaci\u00f3n adecuada y el cumplimiento de procedimientos para garantizar la calidad y la trazabilidad en la fabricaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: equipment cleaning, record keeping, raw materials, master production instructions, API compliance"}}, "dfcfbed1-cd49-4082-8b1d-f4198e087a6b": {"node_ids": ["4f8eee38-bcd1-46e3-9103-70bd4890c057"], "metadata": {"page_label": "162", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- a complete list of raw materials and intermediates designated by names or codes sufficiently specific to identify any special quality characteristics;\n- an accurate statement of the quantity or ratio of each raw material or intermediate to be used, including the unit of measure. Where the quantity is not fixed, the calculation for each batch size or rate of production should be included. Variations to quantities should be included where they are justified;\n- the production location and major production equipment to be used;\n- detailed production instructions, including the:\n  - sequences to be followed,\n  - ranges of process parameters to be used,\n  - sampling instructions and in-process controls with their acceptance criteria, where appropriate,\n  - time limits for completion of individual processing steps and/or the total process, where appropriate, and\n  - expected yield ranges at appropriate phases of processing or time;\n- where appropriate, special notations and precautions to be followed, or cross-references to these; and\n- the instructions for storage of the intermediate or API to assure its suitability for use, including the labelling and packaging materials and special storage conditions with time limits, where appropriate.\n\n## 6.5 Batch production records (batch production and control records)\n\n6.50 Batch production records should be prepared for each intermediate and API and should include complete information relating to the production and control of each batch. The batch production record should be checked before issuance to assure that it is the correct version and is a legible accurate reproduction of the appropriate master production instruction. If the batch production record is produced from a separate part of the master document, that document should include a reference to the current master production instruction being used.\n\n6.51 These records should be numbered with a unique batch or identification number, dated and signed when issued. In continuous production, the product code, together with the date and time, can serve as the unique identifier until the final number is allocated.\n\n6.52 Documentation of completion of each significant step in the batch production records (batch production and control records) should include:\n\n- dates and, when appropriate, times;\n- identity of major equipment (e.g., reactors, driers and mills) used;", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para la producci\u00f3n y control de materias primas e intermediarios en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de mantener registros de producci\u00f3n de lotes que incluyan informaci\u00f3n detallada sobre los materiales utilizados, las instrucciones de producci\u00f3n, el equipo, y la documentaci\u00f3n de cada paso significativo en el proceso. Adem\u00e1s, se menciona la necesidad de asegurar que los registros sean precisos y est\u00e9n actualizados, as\u00ed como la importancia de las condiciones de almacenamiento para garantizar la idoneidad de los productos intermedios o API (ingredientes farmac\u00e9uticos activos).\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en los registros de producci\u00f3n de lotes para asegurar la trazabilidad y el control de calidad?**\n   - Los registros de producci\u00f3n de lotes deben incluir una lista completa de materias primas e intermediarios, cantidades o proporciones, ubicaci\u00f3n de producci\u00f3n, instrucciones detalladas de producci\u00f3n, y documentaci\u00f3n de cada paso significativo, incluyendo fechas, tiempos y equipos utilizados.\n\n2. **\u00bfCu\u00e1les son las precauciones y notaciones especiales que deben considerarse durante el proceso de producci\u00f3n?**\n   - El documento menciona que deben incluirse notaciones y precauciones especiales donde sea apropiado, as\u00ed como referencias cruzadas a estas, aunque no se especifican ejemplos concretos en el texto.\n\n3. **\u00bfC\u00f3mo se debe manejar la documentaci\u00f3n de los registros de producci\u00f3n en caso de que se utilice una versi\u00f3n separada del documento maestro?**\n   - Si los registros de producci\u00f3n se generan a partir de una parte separada del documento maestro, este debe incluir una referencia a la instrucci\u00f3n de producci\u00f3n maestra actual que se est\u00e1 utilizando, asegurando as\u00ed que la informaci\u00f3n sea coherente y actualizada.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Registros de Limpieza y Mantenimiento de Equipos (Secci\u00f3n 6.2)**:\n   - **Requisitos de Registro**: Deben incluir la fecha, hora (si es relevante), producto y n\u00famero de lote de cada lote procesado, as\u00ed como la identificaci\u00f3n de la persona que realiz\u00f3 la limpieza y el mantenimiento.\n   - **Equipos Dedicados**: Si el equipo est\u00e1 dedicado a un solo intermedio o API, no se requieren registros individuales si los lotes son trazables. Los registros pueden formar parte del registro del lote o mantenerse por separado.\n\n2. **Registros de Materias Primas y Materiales de Etiquetado y Empaque (Secci\u00f3n 6.3)**:\n   - **Elementos Clave**: Deben incluir el nombre del fabricante, identidad y cantidad de cada env\u00edo, nombre del proveedor, n\u00fameros de control del proveedor, n\u00famero asignado al recibir, fecha de recepci\u00f3n, resultados de pruebas, trazabilidad de materiales, documentaci\u00f3n de revisi\u00f3n de conformidad y decisiones sobre materiales rechazados.\n   - **Etiquetas Maestras**: Se deben mantener etiquetas maestras aprobadas para comparaci\u00f3n con las etiquetas emitidas.\n\n3. **Instrucciones de Producci\u00f3n Maestra (Secci\u00f3n 6.4)**:\n   - **Preparaci\u00f3n y Verificaci\u00f3n**: Las instrucciones deben ser preparadas, fechadas y firmadas por una persona, y luego verificadas de manera independiente por una persona del departamento de calidad.\n   - **Contenido de las Instrucciones**: Deben incluir el nombre del intermedio o API y un c\u00f3digo de referencia del documento, si es aplicable.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Intermedios y APIs**: Productos farmac\u00e9uticos cuya producci\u00f3n est\u00e1 regulada.\n- **Equipos de Producci\u00f3n**: Herramientas utilizadas en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Materias Primas**: Materiales utilizados en la producci\u00f3n de intermedios y APIs.\n- **Proveedores**: Entidades que suministran materias primas y materiales de etiquetado y empaque.\n- **Departamento de Calidad**: Unidad responsable de la verificaci\u00f3n y control de calidad en la producci\u00f3n. \n\nEste resumen destaca la importancia de mantener registros precisos y trazables en la producci\u00f3n farmac\u00e9utica para garantizar la calidad y la conformidad de los productos.", "excerpt_keywords": "Keywords: batch production records, raw materials, production instructions, quality control, pharmaceutical manufacturing"}}, "9f0c14af-be3d-4f8c-88c1-0b7c0a45ac14": {"node_ids": ["3a7743bb-aa01-44bf-8281-5fe37fc2246b"], "metadata": {"page_label": "163", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 specific identification of each batch, including weights, measures, and batch numbers of raw materials, intermediates, or any reprocessed materials used during manufacturing;  \n\u2014 actual results recorded for critical process parameters;  \n\u2014 any sampling performed;  \n\u2014 signatures of the persons performing and directly supervising or checking each critical step in the operation;  \n\u2014 in-process and laboratory test results;  \n\u2014 actual yield at appropriate phases or times;  \n\u2014 description of packaging and label for intermediate or API;  \n\u2014 representative label of API or intermediate if made commercially available;  \n\u2014 any deviation noted, its evaluation, investigation conducted (if appropriate) or reference to that investigation if stored separately; and  \n\u2014 results of release testing.  \n\n6.53 Written procedures should be established and followed for investigating critical deviations or the failure of a batch of intermediate or API to meet specifications. The investigation should extend to other batches that may have been associated with the specific failure or deviation.\n\n## 6.6 Laboratory control records\n\n6.60 Laboratory control records should include complete data derived from all tests conducted to ensure compliance with established specifications and standards, including examinations and assays, as follows:\n\n\u2014 a description of samples received for testing, including the name of the material or its source, batch number or other distinctive code, the date the sample was taken and, where appropriate, the quantity and date the sample was received for testing;  \n\u2014 a statement of or reference to each test method used;  \n\u2014 a statement of the weight or measure of sample used for each test as described by the method;  \n\u2014 data on or cross-reference to the preparation and testing of reference standards, reagents and standard solutions;  \n\u2014 a complete record of all raw data generated during each test, in addition to graphs, charts and spectra from laboratory instrumentation, properly identified to show the specific material and batch tested;  \n\u2014 a record of all calculations performed in connection with the test, including, for example, units of measure, conversion factors and equivalency factors;  \n\u2014 a statement of the test results and how they compare with established acceptance criteria;  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para el control de calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos, espec\u00edficamente en lo que respecta a la documentaci\u00f3n y registros de laboratorio. Se enfatiza la importancia de mantener registros precisos y completos de cada lote de materiales, los resultados de pruebas, las desviaciones y las investigaciones relacionadas. Tambi\u00e9n se menciona la necesidad de procedimientos escritos para investigar cualquier desviaci\u00f3n cr\u00edtica o fallo en los lotes de productos intermedios o principios activos (API). Los registros de control de laboratorio deben incluir datos exhaustivos de todas las pruebas realizadas para asegurar el cumplimiento de las especificaciones establecidas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe incluirse en los registros de control de laboratorio para asegurar la trazabilidad de los materiales probados?**\n   - Respuesta: Los registros deben incluir una descripci\u00f3n de las muestras recibidas, el nombre del material o su fuente, el n\u00famero de lote o c\u00f3digo distintivo, la fecha en que se tom\u00f3 la muestra, y la cantidad y fecha en que se recibi\u00f3 para pruebas.\n\n2. **\u00bfCu\u00e1les son los pasos recomendados para investigar una desviaci\u00f3n cr\u00edtica en la producci\u00f3n de un lote de API?**\n   - Respuesta: Se deben establecer y seguir procedimientos escritos para investigar las desviaciones cr\u00edticas, extendiendo la investigaci\u00f3n a otros lotes que puedan estar asociados con la falla o desviaci\u00f3n espec\u00edfica.\n\n3. **\u00bfQu\u00e9 tipo de datos deben ser registrados durante las pruebas de laboratorio para garantizar la conformidad con las especificaciones establecidas?**\n   - Respuesta: Los datos deben incluir un registro completo de todos los datos brutos generados durante cada prueba, gr\u00e1ficos, tablas y espectros de la instrumentaci\u00f3n de laboratorio, as\u00ed como un registro de todos los c\u00e1lculos realizados en relaci\u00f3n con la prueba y una declaraci\u00f3n de los resultados de la prueba en comparaci\u00f3n con los criterios de aceptaci\u00f3n establecidos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Producci\u00f3n y Control de Materias Primas e Intermediarios**:\n   - Se requiere una lista completa de materias primas e intermediarios, con nombres o c\u00f3digos que identifiquen caracter\u00edsticas de calidad espec\u00edficas.\n\n2. **Documentaci\u00f3n de Cantidades**:\n   - Es necesario incluir una declaraci\u00f3n precisa de la cantidad o proporci\u00f3n de cada materia prima o intermedio, junto con la unidad de medida. Se deben documentar c\u00e1lculos para tama\u00f1os de lote o tasas de producci\u00f3n, as\u00ed como variaciones justificadas.\n\n3. **Ubicaci\u00f3n y Equipos de Producci\u00f3n**:\n   - Se debe especificar la ubicaci\u00f3n de producci\u00f3n y el equipo principal que se utilizar\u00e1 en el proceso.\n\n4. **Instrucciones de Producci\u00f3n Detalladas**:\n   - Instrucciones que incluyan secuencias de producci\u00f3n, rangos de par\u00e1metros de proceso, instrucciones de muestreo, controles en proceso, l\u00edmites de tiempo para pasos de procesamiento y rangos de rendimiento esperados.\n\n5. **Precauciones y Notaciones Especiales**:\n   - Se deben incluir notaciones y precauciones especiales, as\u00ed como referencias cruzadas a estas cuando sea apropiado.\n\n6. **Instrucciones de Almacenamiento**:\n   - Instrucciones para el almacenamiento de intermedios o API, incluyendo etiquetado, materiales de embalaje y condiciones especiales de almacenamiento.\n\n7. **Registros de Producci\u00f3n de Lotes**:\n   - Los registros deben ser preparados para cada intermedio y API, incluyendo informaci\u00f3n completa sobre la producci\u00f3n y control de cada lote. Deben ser verificados antes de su emisi\u00f3n para asegurar su precisi\u00f3n.\n\n8. **Identificaci\u00f3n y Documentaci\u00f3n**:\n   - Los registros deben tener un n\u00famero de lote \u00fanico, estar fechados y firmados al ser emitidos. En producci\u00f3n continua, el c\u00f3digo del producto junto con la fecha y hora puede servir como identificador \u00fanico.\n\n9. **Documentaci\u00f3n de Pasos Significativos**:\n   - La documentaci\u00f3n debe incluir fechas, tiempos y la identidad del equipo principal utilizado en cada paso significativo del proceso de producci\u00f3n.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece los lineamientos.\n- **API (Ingredientes Farmac\u00e9uticos Activos)**: Productos intermedios en la producci\u00f3n farmac\u00e9utica.\n- **Materias Primas e Intermediarios**: Componentes utilizados en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Registros de Producci\u00f3n**: Documentaci\u00f3n esencial para el control de calidad y trazabilidad en la producci\u00f3n.", "excerpt_keywords": "Keywords: control records, quality assurance, pharmaceutical manufacturing, laboratory testing, deviation investigation"}}, "745bff58-1987-4bfb-954b-738679cc371a": {"node_ids": ["29cf852d-eee3-4e42-9eb9-d398e0e6c0b4"], "metadata": {"page_label": "164", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 6.61 Complete records should also be maintained for:\n\n- any modifications to an established analytical method;\n- periodic calibration of laboratory instruments, apparatus, gauges and recording devices;\n- all stability testing performed on APIs; and\n- out-of-specification (OOS) investigations.\n\n## 6.7 Batch production record review\n\n6.70 Written procedures should be established and followed for the review and approval of batch production and laboratory control records, including packaging and labelling, to determine compliance of the intermediate or API with established specifications before a batch is released or distributed.\n\n6.71 Batch production and laboratory control records of critical process steps should be reviewed and approved by the quality unit(s) before an API batch is released or distributed. Production and laboratory control records of non-critical process steps can be reviewed by qualified production personnel or other units following procedures approved by the quality unit(s).\n\n6.72 All deviation, investigation and OOS reports should be reviewed as part of the batch record review before the batch is released.\n\n6.73 The quality unit(s) can delegate to the production unit the responsibility and authority for release of intermediates, except for those shipped outside the control of the manufacturing company.\n\n# 7. Materials management\n\n## 7.1 General controls\n\n7.10 There should be written procedures describing the receipt, identification, quarantine, storage, handling, sampling, testing and approval or rejection of materials.\n\n7.11 Manufacturers of intermediates and/or APIs should have a system for evaluating the suppliers of critical materials.\n\n7.12 Materials should be purchased against an agreed specification, from a supplier or suppliers approved by the quality unit(s).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Mantenimiento de Registros**: Es fundamental mantener registros completos de modificaciones en m\u00e9todos anal\u00edticos, calibraciones de instrumentos, pruebas de estabilidad de APIs y las investigaciones de resultados fuera de especificaci\u00f3n (OOS).\n\n2. **Revisi\u00f3n de Registros de Producci\u00f3n por Lotes**: Se deben establecer procedimientos escritos para la revisi\u00f3n y aprobaci\u00f3n de los registros de producci\u00f3n y control de laboratorio antes de liberar o distribuir un lote de intermediarios o APIs. Los registros de pasos cr\u00edticos deben ser revisados por la unidad de calidad, mientras que los no cr\u00edticos pueden ser revisados por personal calificado.\n\n3. **Gesti\u00f3n de Materiales**: Se requieren procedimientos escritos para la gesti\u00f3n de materiales, que incluyan su recepci\u00f3n, identificaci\u00f3n, almacenamiento y aprobaci\u00f3n. Adem\u00e1s, es esencial evaluar a los proveedores de materiales cr\u00edticos y asegurarse de que los materiales se compren de acuerdo con especificaciones acordadas.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de modificaciones deben registrarse en los m\u00e9todos anal\u00edticos seg\u00fan el documento?**\n   - El documento especifica que se deben mantener registros de cualquier modificaci\u00f3n a un m\u00e9todo anal\u00edtico establecido.\n\n2. **\u00bfQui\u00e9n es responsable de revisar los registros de producci\u00f3n de pasos cr\u00edticos y no cr\u00edticos antes de la liberaci\u00f3n de un lote de API?**\n   - Los registros de producci\u00f3n y control de laboratorio de pasos cr\u00edticos deben ser revisados y aprobados por la unidad de calidad, mientras que los de pasos no cr\u00edticos pueden ser revisados por personal de producci\u00f3n calificado o por otras unidades, siguiendo procedimientos aprobados por la unidad de calidad.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse para la gesti\u00f3n de materiales en la producci\u00f3n de intermediarios y APIs?**\n   - Deben existir procedimientos escritos que describan la recepci\u00f3n, identificaci\u00f3n, cuarentena, almacenamiento, manejo, muestreo, pruebas y aprobaci\u00f3n o rechazo de materiales, as\u00ed como un sistema para evaluar a los proveedores de materiales cr\u00edticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Documentaci\u00f3n y Registros de Calidad:**\n   - Importancia de mantener registros precisos y completos de cada lote de materiales utilizados en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n   - Inclusi\u00f3n de informaci\u00f3n sobre pesos, medidas, n\u00fameros de lote, resultados de pruebas y desviaciones.\n\n2. **Investigaci\u00f3n de Desviaciones Cr\u00edticas:**\n   - Necesidad de establecer procedimientos escritos para investigar desviaciones cr\u00edticas o fallos en lotes de productos intermedios o principios activos (API).\n   - Extensi\u00f3n de la investigaci\u00f3n a otros lotes asociados con la desviaci\u00f3n.\n\n3. **Registros de Control de Laboratorio:**\n   - Inclusi\u00f3n de datos completos de todas las pruebas realizadas para asegurar el cumplimiento de especificaciones y est\u00e1ndares.\n   - Registro de muestras, m\u00e9todos de prueba, datos brutos, c\u00e1lculos y resultados en comparaci\u00f3n con criterios de aceptaci\u00f3n.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Entidad responsable de establecer los lineamientos y est\u00e1ndares para el control de calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Productos Intermedios y API:** Tipos de productos farmac\u00e9uticos cuya calidad y conformidad deben ser monitoreadas.\n- **Lotes de Materiales:** Referencia a las cantidades espec\u00edficas de materiales utilizados en la producci\u00f3n que deben ser documentadas.\n- **Registros de Laboratorio:** Documentaci\u00f3n que incluye datos de pruebas, m\u00e9todos utilizados y resultados obtenidos.\n\nEste resumen destaca la importancia de la documentaci\u00f3n y el control de calidad en la industria farmac\u00e9utica, as\u00ed como los procedimientos necesarios para garantizar la conformidad y la trazabilidad de los productos.", "excerpt_keywords": "Keywords: quality control, batch production, analytical methods, materials management, out-of-specification"}}, "93d456ae-ce20-4c13-9bac-a33a18e1bad9": {"node_ids": ["867a6875-9ffe-4820-b84f-722732d5ea4f"], "metadata": {"page_label": "165", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 7.2 Receipt and Quarantine\n\n7.13 If the supplier of a critical material is not the manufacturer of that material, the name and address of that manufacturer should be known to the intermediate and/or API manufacturer.\n\n7.14 Changing the source of supply of critical raw materials should be done according to section 13, Change control.\n\n## Receipt and Quarantine\n\n7.20 Upon receipt and before acceptance, each container or grouping of containers of materials should be examined visually for correct labelling (including correlation between the name used by the supplier and the in-house name, if these are different), damage to containers, broken seals and evidence of tampering or contamination. Materials should be held under quarantine until they have been sampled, examined or tested as appropriate, and then released for use.\n\n7.21 Before incoming materials are mixed with existing stocks (e.g. solvents or stocks in silos), they should be identified as correct, tested, if appropriate, and released. Procedures should be available to prevent discharging incoming materials wrongly into the existing stock.\n\n7.22 If bulk deliveries are made in non-dedicated tankers, there should be assurance of no cross-contamination from the tanker. Means of providing this assurance could include one or more of the following:\n\n- certificate of cleaning;\n- testing for trace impurities;\n- audit of the supplier.\n\n7.23 Large storage containers, and their attendant manifolds, filling and discharge lines should be appropriately identified.\n\n7.24 Each container or grouping of containers (batches) of materials should be assigned and identified with a distinctive code, batch or receipt number. This number should be used in recording the disposition of each batch. A system should be in place to identify the status of each batch.\n\n# 7.3 Sampling and Testing of Incoming Production Materials\n\n7.30 At least one test to verify the identity of each batch of material should be conducted, with the exception of the materials described below in section 7.3.2. A supplier\u2019s certificate of analysis can be used in place of performing other tests, provided that the manufacturer has a system in place to evaluate suppliers.\n\n7.31 Supplier approval should include an evaluation that provides adequate evidence (e.g. past quality history) that the manufacturer can consistently", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS, en su secci\u00f3n sobre \"Recepci\u00f3n y Cuarentena\", establece directrices para la recepci\u00f3n de materiales cr\u00edticos en la producci\u00f3n. Se enfatiza la importancia de examinar visualmente los contenedores al recibirlos, asegurando que est\u00e9n correctamente etiquetados y libres de da\u00f1os o contaminaci\u00f3n. Los materiales deben ser mantenidos en cuarentena hasta que se realicen las pruebas necesarias. Adem\u00e1s, se abordan las medidas para evitar la contaminaci\u00f3n cruzada en entregas a granel y la necesidad de un sistema de identificaci\u00f3n para cada lote de materiales.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse al recibir materiales cr\u00edticos para garantizar su calidad y seguridad?**\n   - Al recibir materiales cr\u00edticos, cada contenedor debe ser examinado visualmente para verificar el etiquetado correcto, da\u00f1os, sellos rotos y evidencia de contaminaci\u00f3n. Los materiales deben mantenerse en cuarentena hasta que se realicen las pruebas adecuadas.\n\n2. **\u00bfQu\u00e9 medidas se pueden tomar para asegurar que no haya contaminaci\u00f3n cruzada en entregas a granel?**\n   - Para asegurar que no haya contaminaci\u00f3n cruzada en entregas a granel, se pueden utilizar certificados de limpieza, realizar pruebas para detectar impurezas residuales o llevar a cabo auditor\u00edas del proveedor.\n\n3. **\u00bfC\u00f3mo se debe identificar y registrar el estado de cada lote de materiales recibidos?**\n   - Cada contenedor o agrupaci\u00f3n de contenedores debe ser asignado e identificado con un c\u00f3digo distintivo, n\u00famero de lote o n\u00famero de recibo. Este n\u00famero debe ser utilizado para registrar la disposici\u00f3n de cada lote, y debe existir un sistema para identificar el estado de cada lote.", "prev_section_summary": "### Temas Clave:\n\n1. **Mantenimiento de Registros**:\n   - Importancia de mantener registros completos de modificaciones en m\u00e9todos anal\u00edticos, calibraciones de instrumentos, pruebas de estabilidad de APIs y resultados fuera de especificaci\u00f3n (OOS).\n\n2. **Revisi\u00f3n de Registros de Producci\u00f3n por Lotes**:\n   - Necesidad de establecer procedimientos escritos para la revisi\u00f3n y aprobaci\u00f3n de registros de producci\u00f3n y control de laboratorio antes de la liberaci\u00f3n de lotes.\n   - Diferenciaci\u00f3n entre registros de pasos cr\u00edticos (revisados por la unidad de calidad) y no cr\u00edticos (revisados por personal calificado).\n\n3. **Gesti\u00f3n de Materiales**:\n   - Procedimientos escritos requeridos para la gesti\u00f3n de materiales, incluyendo recepci\u00f3n, identificaci\u00f3n, almacenamiento y aprobaci\u00f3n.\n   - Evaluaci\u00f3n de proveedores de materiales cr\u00edticos y compra de materiales seg\u00fan especificaciones acordadas.\n\n### Entidades:\n\n- **Registros**: Modificaciones de m\u00e9todos anal\u00edticos, calibraciones, pruebas de estabilidad, investigaciones OOS.\n- **Unidades**: Unidad de calidad, personal de producci\u00f3n calificado.\n- **Materiales**: Intermediarios, APIs, materiales cr\u00edticos.\n- **Procedimientos**: Revisi\u00f3n y aprobaci\u00f3n de registros, gesti\u00f3n de materiales.", "excerpt_keywords": "Keywords: receipt, quarantine, contamination, supplier evaluation, batch identification"}}, "80ebe34f-e926-40c2-8655-b12e58cee011": {"node_ids": ["c9bc4427-5853-483d-9913-708c0a8c25c7"], "metadata": {"page_label": "166", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 7.32\n\nProcessing aids, hazardous or highly toxic raw materials, other special materials or materials transferred to another unit within the company\u2019s control do not need to be tested if the manufacturer\u2019s certificate of analysis is obtained, showing that these raw materials conform to established specifications. Visual examination of containers, labels and recording of batch numbers should help in establishing the identity of these materials. The lack of on-site testing for these materials should be justified and documented.\n\n# 7.33\n\nSamples should be representative of the batch of material from which they are taken. Sampling methods should specify the number of containers to be sampled, which part of the container to sample, and the amount of material to be taken from each container. The decision on the number of containers to sample and the sample size should be based upon a sampling plan that takes into consideration the criticality of the material, variability of the material, past quality history of the supplier and the quantity needed for analysis.\n\n# 7.34\n\nSampling should be conducted at defined locations and by procedures designed to prevent contamination of the material sampled and contamination of other materials.\n\n# 7.35\n\nContainers from which samples are withdrawn should be opened carefully and subsequently reclosed. They should be marked to indicate that a sample has been taken.\n\n## 7.4 Storage\n\n7.40 Materials should be handled and stored in such a manner as to prevent degradation, contamination and cross-contamination.\n\n7.41 Materials stored in fibre drums, bags or boxes should be stored off the floor and, when appropriate, suitably spaced to permit cleaning and inspection.\n\n7.42 Materials should be stored under conditions and for a period that will have no adverse affect on their quality and should normally be controlled so that the oldest stock is used first.\n\n7.43 Certain materials in suitable containers can be stored outdoors, provided identifying labels remain legible and containers are appropriately cleaned before opening and use.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Requisitos de prueba y an\u00e1lisis de materiales**: Los materiales de procesamiento, as\u00ed como los materiales peligrosos o altamente t\u00f3xicos, no necesitan ser probados si se cuenta con un certificado de an\u00e1lisis del fabricante que confirme que cumplen con las especificaciones establecidas. La identificaci\u00f3n de estos materiales se puede establecer mediante la inspecci\u00f3n visual de los envases y el registro de n\u00fameros de lote.\n\n2. **M\u00e9todos de muestreo**: El muestreo de materiales debe ser representativo del lote del cual se extraen. Los m\u00e9todos de muestreo deben detallar cu\u00e1ntos envases se muestrear\u00e1n, qu\u00e9 parte del envase se muestrear\u00e1 y la cantidad de material a tomar de cada envase. La planificaci\u00f3n del muestreo debe considerar la criticidad del material y la historia de calidad del proveedor.\n\n3. **Almacenamiento de materiales**: Los materiales deben ser manejados y almacenados de manera que se evite su degradaci\u00f3n y contaminaci\u00f3n. Deben ser almacenados en condiciones que no afecten su calidad y, en general, se debe seguir un sistema de \"primeras entradas, primeras salidas\" para su uso.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 justificaci\u00f3n se requiere si no se realiza una prueba in situ de los materiales peligrosos?**\n   - La falta de pruebas in situ debe ser justificada y documentada, y se debe contar con un certificado de an\u00e1lisis del fabricante que confirme que los materiales cumplen con las especificaciones establecidas.\n\n2. **\u00bfCu\u00e1les son los factores que deben considerarse al decidir el n\u00famero de envases a muestrear y el tama\u00f1o de la muestra?**\n   - La decisi\u00f3n debe basarse en un plan de muestreo que considere la criticidad del material, la variabilidad del material, la historia de calidad del proveedor y la cantidad necesaria para el an\u00e1lisis.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse para el almacenamiento de materiales en contenedores al aire libre?**\n   - Los materiales pueden ser almacenados al aire libre siempre que las etiquetas identificativas permanezcan legibles y los contenedores sean limpiados adecuadamente antes de abrirse y usarse.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Recepci\u00f3n de Materiales Cr\u00edticos:**\n   - Importancia de la inspecci\u00f3n visual de contenedores al recibir materiales.\n   - Verificaci\u00f3n del etiquetado correcto y la ausencia de da\u00f1os o contaminaci\u00f3n.\n   - Mantenimiento de los materiales en cuarentena hasta que se realicen las pruebas necesarias.\n\n2. **Prevenci\u00f3n de Contaminaci\u00f3n Cruzada:**\n   - Medidas a seguir para asegurar que no haya contaminaci\u00f3n cruzada en entregas a granel, como certificados de limpieza, pruebas de impurezas y auditor\u00edas de proveedores.\n\n3. **Identificaci\u00f3n y Registro de Lotes:**\n   - Asignaci\u00f3n de un c\u00f3digo distintivo, n\u00famero de lote o n\u00famero de recibo a cada contenedor o agrupaci\u00f3n de contenedores.\n   - Necesidad de un sistema para registrar y monitorear el estado de cada lote de materiales.\n\n4. **Control de Cambios:**\n   - Procedimientos para cambiar la fuente de suministro de materias primas cr\u00edticas, conforme a las directrices de control de cambios.\n\n5. **Muestreo y Pruebas:**\n   - Realizaci\u00f3n de al menos una prueba para verificar la identidad de cada lote de material.\n   - Uso de certificados de an\u00e1lisis del proveedor como alternativa a pruebas adicionales, siempre que exista un sistema de evaluaci\u00f3n de proveedores.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite las directrices.\n- **Materiales Cr\u00edticos:** Materias primas esenciales para la producci\u00f3n.\n- **Proveedores:** Entidades que suministran materiales, que pueden no ser los fabricantes.\n- **Contenedores:** Recipientes que almacenan los materiales recibidos.\n- **Lotes:** Agrupaciones de contenedores que deben ser identificadas y registradas.\n\nEste resumen destaca la importancia de los procedimientos de recepci\u00f3n y control de calidad en la gesti\u00f3n de materiales cr\u00edticos en la producci\u00f3n, as\u00ed como las medidas necesarias para garantizar la seguridad y la integridad de los productos.", "excerpt_keywords": "Keywords: sampling, storage, contamination, materials, analysis"}}, "60d8a618-1859-45ff-a741-589a8144b3e4": {"node_ids": ["3896d26c-f419-4787-aa16-c4a8de8ba24d"], "metadata": {"page_label": "167", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 7.5 Re-evaluation\n\n7.50 Materials should be re-evaluated as appropriate to determine their suitability for use (e.g. after prolonged storage or exposure to heat or humidity).\n\n# 8. Production and in-process controls\n\n## 8.1 Production operations\n\n8.10 Raw materials for manufacturing of intermediates and APIs should be weighed or measured under appropriate conditions that do not affect their suitability for use. Weighing and measuring devices should be of suitable accuracy for the intended use.\n\n8.11 If a material is subdivided for later use in production operations, the container receiving the material should be suitable and should be so identified that the following information is available:\n\n- material name and/or item code;\n- receiving or control number;\n- weight or measure of material in the new container; and\n- re-evaluation or retest date if appropriate.\n\n8.12 Critical weighing, measuring or subdividing operations should be witnessed or subjected to an equivalent control. Prior to use, production personnel should verify that the materials are those specified in the batch record for the intended intermediate or API.\n\n8.13 Other critical activities should be witnessed or subjected to an equivalent control.\n\n8.14 Actual yields should be compared with expected yields at designated steps in the production process. Expected yields with appropriate ranges should be established based on previous laboratory, pilot scale or manufacturing data. Deviations in yield associated with critical process steps should be investigated to determine their impact or potential impact on the resulting quality of affected batches.\n\n8.15 Any deviation should be documented and explained. Any critical deviation should be investigated.\n\n8.16 The processing status of major units of equipment should be indicated either on the individual units of equipment or by appropriate documentation, computer control systems or alternative means.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la re-evaluaci\u00f3n de materiales y los controles de producci\u00f3n en la fabricaci\u00f3n de intermediarios y principios activos (APIs). Se enfatiza la importancia de pesar y medir los materiales bajo condiciones adecuadas, la documentaci\u00f3n de la informaci\u00f3n relevante sobre los materiales, la verificaci\u00f3n de su idoneidad, y el control de las operaciones cr\u00edticas. Tambi\u00e9n se menciona la necesidad de comparar los rendimientos reales con los esperados y documentar cualquier desviaci\u00f3n en el proceso de producci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe estar disponible en el contenedor que recibe un material subdividido para su uso posterior en operaciones de producci\u00f3n?**\n   - La informaci\u00f3n que debe estar disponible incluye el nombre y/o c\u00f3digo del material, el n\u00famero de recepci\u00f3n o control, el peso o medida del material en el nuevo contenedor, y la fecha de re-evaluaci\u00f3n o rean\u00e1lisis si es apropiado.\n\n2. **\u00bfC\u00f3mo deben ser controladas las operaciones cr\u00edticas de pesaje, medici\u00f3n o subdivisi\u00f3n en el proceso de producci\u00f3n?**\n   - Estas operaciones deben ser presenciadas o sometidas a un control equivalente. Adem\u00e1s, el personal de producci\u00f3n debe verificar que los materiales sean los especificados en el registro de lote para el intermedio o API previsto.\n\n3. **\u00bfQu\u00e9 se debe hacer si se observa una desviaci\u00f3n en los rendimientos durante el proceso de producci\u00f3n?**\n   - Cualquier desviaci\u00f3n debe ser documentada y explicada. Las desviaciones cr\u00edticas deben ser investigadas para determinar su impacto o potencial impacto en la calidad de los lotes afectados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Requisitos de Prueba y An\u00e1lisis de Materiales**:\n   - Los materiales de procesamiento y los materiales peligrosos o altamente t\u00f3xicos no requieren pruebas si se cuenta con un certificado de an\u00e1lisis del fabricante.\n   - La identificaci\u00f3n de estos materiales se establece mediante la inspecci\u00f3n visual de envases y el registro de n\u00fameros de lote.\n   - La falta de pruebas in situ debe ser justificada y documentada.\n\n2. **M\u00e9todos de Muestreo**:\n   - Las muestras deben ser representativas del lote de material.\n   - Los m\u00e9todos de muestreo deben especificar:\n     - N\u00famero de envases a muestrear.\n     - Parte del envase a muestrear.\n     - Cantidad de material a tomar de cada envase.\n   - La planificaci\u00f3n del muestreo debe considerar:\n     - Criticidad del material.\n     - Variabilidad del material.\n     - Historia de calidad del proveedor.\n     - Cantidad necesaria para an\u00e1lisis.\n\n3. **Almacenamiento de Materiales**:\n   - Los materiales deben ser manejados y almacenados para prevenir degradaci\u00f3n y contaminaci\u00f3n.\n   - Deben ser almacenados en condiciones que no afecten su calidad, siguiendo un sistema de \"primeras entradas, primeras salidas\".\n   - Materiales en contenedores adecuados pueden ser almacenados al aire libre, siempre que las etiquetas sean legibles y los contenedores est\u00e9n limpios antes de su uso.\n\n### Entidades Clave:\n- **Materiales**: Procesamiento, peligrosos, altamente t\u00f3xicos, especiales.\n- **Documentaci\u00f3n**: Certificado de an\u00e1lisis, registro de n\u00fameros de lote.\n- **Muestreo**: M\u00e9todos, representatividad, planificaci\u00f3n.\n- **Almacenamiento**: Condiciones, limpieza, etiquetado.", "excerpt_keywords": "Keywords: re-evaluation, production controls, raw materials, critical operations, yield comparison"}}, "fc4fe7d1-e586-4723-bf5b-263abf796d0a": {"node_ids": ["e0103ddc-0001-49fb-b787-c90dad74226f"], "metadata": {"page_label": "168", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 8.2 Time limits\n\n8.20 If time limits are specified in the master production instruction (see section 6.41), these time limits should be met to ensure the quality of intermediates and APIs. Deviations should be documented and evaluated. Time limits may be inappropriate when processing to a target value (e.g. pH adjustment, hydrogenation or drying to a predetermined specification) because completion of reactions or processing steps are determined by in-process sampling and testing.\n\n8.21 Intermediates held for further processing should be stored under appropriate conditions to ensure their suitability for use.\n\n# 8.3 In-process sampling and controls\n\n8.30 Written procedures should be established to monitor the progress and control the performance of processing steps that cause variability in the quality characteristics of intermediates and APIs. In-process controls and their acceptance criteria should be defined based on the information gained during the development stage or historical data.\n\n8.31 The acceptance criteria and type and extent of testing can depend on the nature of the intermediate or API being manufactured, the reaction or process step being conducted and the degree to which the process introduces variability in the product\u2019s quality. Less stringent in-process controls may be appropriate in early processing steps, whereas tighter controls may be appropriate for later processing steps (e.g. isolation and purification steps).\n\n8.32 Critical in-process controls (and critical process monitoring), including the control points and methods, should be stated in writing and approved by the quality unit(s).\n\n8.33 In-process controls can be performed by qualified production department personnel and the process adjusted without prior quality unit(s)\u2019 approval if the adjustments are made within pre-established limits approved by the quality unit(s). All tests and results should be fully documented as part of the batch record.\n\n8.34 Written procedures should describe the sampling methods for in-process materials, intermediates and APIs. Sampling plans and procedures should be based on scientifically sound sampling practices.\n\n8.35 In-process sampling should be conducted using procedures designed to prevent contamination of the sampled material and other intermediates or", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto circundante\n\n1. **Control de Calidad en la Producci\u00f3n de Intermediarios y APIs**: El documento establece directrices sobre la importancia de cumplir con los l\u00edmites de tiempo especificados en las instrucciones de producci\u00f3n para asegurar la calidad de los intermediarios y los principios activos (APIs). Tambi\u00e9n se discute la necesidad de almacenar adecuadamente los intermediarios y de realizar controles en proceso para monitorear y ajustar la calidad del producto.\n\n2. **Procedimientos de Muestreo y Control en Proceso**: Se enfatiza la necesidad de establecer procedimientos escritos para el muestreo y control de calidad durante la producci\u00f3n. Estos procedimientos deben basarse en datos hist\u00f3ricos y deben ser aprobados por unidades de calidad. Adem\u00e1s, se menciona que los controles en proceso pueden ser realizados por personal calificado, siempre que se mantengan dentro de l\u00edmites preestablecidos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar al establecer los l\u00edmites de tiempo en las instrucciones de producci\u00f3n para intermediarios y APIs?**\n   - La respuesta a esta pregunta se puede encontrar en la secci\u00f3n 8.20, donde se menciona que los l\u00edmites de tiempo deben ser cumplidos para asegurar la calidad, y que las desviaciones deben ser documentadas y evaluadas.\n\n2. **\u00bfC\u00f3mo se determina la naturaleza y el alcance de los controles en proceso para un API espec\u00edfico?**\n   - La secci\u00f3n 8.31 proporciona informaci\u00f3n sobre c\u00f3mo los criterios de aceptaci\u00f3n y el tipo de pruebas dependen de la naturaleza del API, el paso del proceso y el grado de variabilidad introducido por el proceso.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse para el muestreo de materiales en proceso y c\u00f3mo se asegura que no haya contaminaci\u00f3n?**\n   - La secci\u00f3n 8.34 y 8.35 abordan la necesidad de tener procedimientos escritos que describan los m\u00e9todos de muestreo y c\u00f3mo estos deben ser dise\u00f1ados para prevenir la contaminaci\u00f3n del material muestreado y otros intermediarios.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### Temas Clave:\n1. **Re-evaluaci\u00f3n de Materiales**:\n   - Importancia de re-evaluar materiales para determinar su idoneidad para el uso, especialmente despu\u00e9s de almacenamiento prolongado o exposici\u00f3n a condiciones adversas (calor, humedad).\n\n2. **Controles de Producci\u00f3n**:\n   - **Pesaje y Medici\u00f3n**: Los materiales crudos deben ser pesados o medidos bajo condiciones adecuadas, utilizando dispositivos de precisi\u00f3n apropiados.\n   - **Documentaci\u00f3n de Materiales**: Los contenedores que reciben materiales subdivididos deben estar debidamente identificados y contener informaci\u00f3n relevante como nombre del material, n\u00famero de control, peso y fecha de re-evaluaci\u00f3n.\n   - **Control de Operaciones Cr\u00edticas**: Las operaciones cr\u00edticas deben ser presenciadas o controladas de manera equivalente, y el personal debe verificar la conformidad de los materiales con los registros de lote.\n   - **Comparaci\u00f3n de Rendimientos**: Se deben comparar los rendimientos reales con los esperados en etapas designadas del proceso de producci\u00f3n, investigando desviaciones cr\u00edticas.\n   - **Documentaci\u00f3n de Desviaciones**: Cualquier desviaci\u00f3n en el proceso debe ser documentada y explicada, con investigaciones para desviaciones cr\u00edticas.\n\n3. **Estado de Procesamiento de Equipos**:\n   - El estado de procesamiento de los equipos principales debe ser indicado en los propios equipos o mediante documentaci\u00f3n adecuada.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Materiales Crudos**: Sustancias utilizadas en la fabricaci\u00f3n de intermediarios y principios activos (APIs).\n- **Intermediarios y APIs**: Productos farmac\u00e9uticos en proceso de fabricaci\u00f3n.\n- **Personal de Producci\u00f3n**: Empleados responsables de verificar y controlar los materiales y procesos.\n- **Contenedores**: Recipientes utilizados para almacenar materiales subdivididos.\n- **Dispositivos de Pesaje y Medici\u00f3n**: Herramientas utilizadas para asegurar la precisi\u00f3n en la medici\u00f3n de materiales.\n\nEste resumen destaca la importancia de la re-evaluaci\u00f3n y el control riguroso en la producci\u00f3n farmac\u00e9utica para garantizar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: time limits, in-process controls, quality assurance, sampling procedures, intermediates"}}, "263bba47-3203-470f-a5a4-a5caa6beba24": {"node_ids": ["7e372e0b-bb0f-4c0f-ab44-4d243f81fdc5"], "metadata": {"page_label": "169", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Blending Batches of Intermediates or APIs\n\n8.40 For the purpose of this document, blending is defined as the process of combining materials within the same specification to produce a homogeneous intermediate or API. In-process mixing of fractions from single batches (e.g., collecting several centrifuge loads from a single crystallization batch) or combining fractions from several batches for further processing is considered to be part of the production process and is not considered to be blending.\n\n8.41 OOS batches should not be blended with other batches for the purpose of meeting specifications. Each batch incorporated into the blend should have been manufactured using an established process and should have been individually tested and found to meet appropriate specifications prior to blending.\n\n8.42 Acceptable blending operations include but are not limited to:\n\n- Blending of small batches to increase batch size;\n- Blending of tailings (i.e., relatively small quantities of isolated material) from batches of the same intermediate or API to form a single batch.\n\n8.43 Blending processes should be adequately controlled and documented and the blended batch should be tested for conformance to established specifications where appropriate.\n\n8.44 The batch record of the blending process should allow traceability back to the individual batches that make up the blend.\n\n8.45 Where physical attributes of the API are critical (e.g., APIs intended for use in solid oral dosage forms or suspensions), blending operations should be validated to show homogeneity of the combined batch. Validation should include testing of critical attributes (e.g., particle size distribution, bulk density and tap density) that may be affected by the blending process.\n\n8.46 If the blending could adversely affect stability, stability testing of the final blended batches should be performed.\n\n8.47 The expiry or retest date of the blended batch should be based on the manufacturing date of the oldest tailings or batch in the blend.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Definici\u00f3n de Blending**: El blending se refiere al proceso de combinar materiales que cumplen con las mismas especificaciones para producir un intermedio o API homog\u00e9neo. No incluye la mezcla de fracciones de un solo lote o la combinaci\u00f3n de fracciones de varios lotes para procesamiento adicional.\n\n2. **Requisitos para Lotes OOS**: Los lotes fuera de especificaci\u00f3n (OOS) no deben ser mezclados con otros lotes para cumplir con las especificaciones. Cada lote que se incorpora a la mezcla debe haber sido fabricado bajo un proceso establecido y haber sido probado individualmente.\n\n3. **Control y Documentaci\u00f3n**: Las operaciones de blending deben ser controladas y documentadas adecuadamente, y el lote mezclado debe ser probado para asegurar que cumple con las especificaciones establecidas. Adem\u00e1s, se debe permitir la trazabilidad de los lotes individuales que componen la mezcla.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben cumplirse para que un lote OOS no sea mezclado con otros lotes?**\n   - Los lotes OOS no deben ser mezclados con otros lotes para cumplir con las especificaciones. Cada lote incorporado a la mezcla debe haber sido fabricado utilizando un proceso establecido y debe haber sido probado individualmente para cumplir con las especificaciones apropiadas antes de la mezcla.\n\n2. **\u00bfQu\u00e9 tipo de pruebas se deben realizar para validar las operaciones de blending de APIs cr\u00edticos?**\n   - Las operaciones de blending deben ser validadas para demostrar la homogeneidad del lote combinado. Esto incluye pruebas de atributos cr\u00edticos como la distribuci\u00f3n del tama\u00f1o de part\u00edculas, la densidad a granel y la densidad de tapado, que pueden verse afectadas por el proceso de blending.\n\n3. **\u00bfC\u00f3mo se determina la fecha de caducidad o rean\u00e1lisis de un lote mezclado?**\n   - La fecha de caducidad o rean\u00e1lisis del lote mezclado debe basarse en la fecha de fabricaci\u00f3n del material m\u00e1s antiguo (tailings o lote) que forma parte de la mezcla.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n\n\n#### Temas Clave:\n\n1. **L\u00edmites de Tiempo en la Producci\u00f3n**:\n   - Importancia de cumplir con los l\u00edmites de tiempo especificados en las instrucciones de producci\u00f3n para garantizar la calidad de los intermediarios y APIs.\n   - Necesidad de documentar y evaluar cualquier desviaci\u00f3n de estos l\u00edmites.\n   - Consideraciones sobre la inadecuaci\u00f3n de los l\u00edmites de tiempo en procesos que requieren ajustes a valores espec\u00edficos (pH, hidrogenaci\u00f3n, secado).\n\n2. **Almacenamiento de Intermediarios**:\n   - Los intermediarios deben ser almacenados bajo condiciones adecuadas para asegurar su idoneidad para el uso posterior.\n\n3. **Muestreo y Control en Proceso**:\n   - Establecimiento de procedimientos escritos para monitorear y controlar los pasos de procesamiento que afectan la calidad de intermediarios y APIs.\n   - Definici\u00f3n de criterios de aceptaci\u00f3n y tipo de pruebas basadas en datos hist\u00f3ricos y la naturaleza del producto.\n   - Diferenciaci\u00f3n en la rigurosidad de los controles en proceso seg\u00fan la etapa del procesamiento.\n\n4. **Controles Cr\u00edticos en Proceso**:\n   - Necesidad de documentar y aprobar por parte de la unidad de calidad los controles cr\u00edticos y m\u00e9todos de monitoreo.\n\n5. **Procedimientos de Muestreo**:\n   - Descripci\u00f3n de m\u00e9todos de muestreo para materiales en proceso, intermediarios y APIs, basados en pr\u00e1cticas cient\u00edficas s\u00f3lidas.\n   - Importancia de prevenir la contaminaci\u00f3n durante el muestreo.\n\n#### Entidades:\n\n- **Intermediarios**: Sustancias qu\u00edmicas producidas durante la fabricaci\u00f3n de APIs.\n- **APIs (Principios Activos)**: Sustancias que tienen un efecto farmacol\u00f3gico y son el componente activo de un medicamento.\n- **Unidad de Calidad**: Departamento responsable de asegurar que los procesos y productos cumplan con los est\u00e1ndares de calidad.\n- **Personal Calificado**: Empleados capacitados para realizar controles en proceso y ajustes necesarios dentro de l\u00edmites preestablecidos.\n- **Documentaci\u00f3n**: Registros que deben ser mantenidos para todas las pruebas y resultados como parte del proceso de producci\u00f3n.\n\nEste resumen destaca la importancia de los l\u00edmites de tiempo, el almacenamiento adecuado, los controles en proceso y los procedimientos de muestreo para asegurar la calidad en la producci\u00f3n de intermediarios y APIs.", "excerpt_keywords": "Keywords: blending, intermediates, APIs, specifications, quality control"}}, "585aedb8-65d6-45a1-9130-ad267b5d14fb": {"node_ids": ["fa42c770-159b-402f-9b88-94824a8901d6"], "metadata": {"page_label": "170", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 8.5 Contamination control\n\n8.50 Residual materials can be carried over into successive batches of the same intermediate or API if there is adequate control. Examples include residue adhering to the wall of a micronizer, residual layer of damp crystals remaining in a centrifuge bowl after discharge and incomplete discharge of fluids or crystals from a processing vessel upon transfer of the material to the next step in the process. Such carry-over should not result in the carry-over of degradants or microbial contamination that may adversely alter the established impurity profile of the API.\n\n8.51 Production operations should be conducted in a manner that will prevent contamination of intermediates or APIs by other materials.\n\n8.52 Precautions to avoid contamination should be taken when APIs are handled after purification.\n\n# 9. Packaging and identification labelling of APIs and intermediates\n\n## 9.1 General\n\n9.10 There should be written procedures describing the receipt, identification, quarantine, sampling, examination and/or testing and release and handling of packaging and labelling materials.\n\n9.11 Packaging and labelling materials should conform to established specifications. Those that do not comply with such specifications should be rejected to prevent their use in operations for which they are unsuitable.\n\n9.12 Records should be maintained for each shipment of labels and packaging materials showing receipt, examination, or testing and whether they are accepted or rejected.\n\n## 9.2 Packaging materials\n\n9.20 Containers should provide adequate protection against deterioration or contamination of the intermediate or API that may occur during transportation and recommended storage.\n\n9.21 Containers should be clean and, where indicated by the nature of the intermediate or API, sanitized to ensure that they are suitable for their intended use. These containers should not be reactive, additive or absorptive to ensure that they do not alter the quality of the intermediate or API beyond the specified limits.\n\n9.22 If containers are reused, they should be cleaned in accordance with documented procedures and all previous labels should be removed or defaced.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en su Informe T\u00e9cnico 957 aborda el control de la contaminaci\u00f3n en la producci\u00f3n de intermediarios y principios activos (API). Se enfatiza la importancia de evitar la contaminaci\u00f3n cruzada entre lotes y de manejar adecuadamente los materiales de embalaje y etiquetado. Se establecen procedimientos escritos para la recepci\u00f3n, identificaci\u00f3n y manejo de estos materiales, as\u00ed como requisitos para la limpieza y sanitizaci\u00f3n de los contenedores utilizados para el almacenamiento y transporte de los API.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 medidas espec\u00edficas se deben tomar para evitar la contaminaci\u00f3n de los intermediarios o API durante la producci\u00f3n?**\n   - Respuesta: Las operaciones de producci\u00f3n deben llevarse a cabo de manera que se prevenga la contaminaci\u00f3n de los intermediarios o API por otros materiales. Adem\u00e1s, se deben tomar precauciones al manejar los API despu\u00e9s de la purificaci\u00f3n.\n\n2. **\u00bfCu\u00e1les son los requisitos para los materiales de embalaje y etiquetado de los API seg\u00fan el documento?**\n   - Respuesta: Los materiales de embalaje y etiquetado deben cumplir con especificaciones establecidas y aquellos que no lo hagan deben ser rechazados. Tambi\u00e9n se deben mantener registros de cada env\u00edo de materiales, mostrando su recepci\u00f3n, examen, pruebas y aceptaci\u00f3n o rechazo.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse si se reutilizan los contenedores para el almacenamiento de intermediarios o API?**\n   - Respuesta: Si los contenedores son reutilizados, deben limpiarse de acuerdo con procedimientos documentados y todas las etiquetas anteriores deben ser eliminadas o desfiguradas para evitar confusiones y asegurar la integridad del contenido.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Definici\u00f3n de Blending**:\n   - El blending se refiere a la combinaci\u00f3n de materiales que cumplen con las mismas especificaciones para crear un intermedio o API homog\u00e9neo. No incluye la mezcla de fracciones de un solo lote ni la combinaci\u00f3n de fracciones de varios lotes para procesamiento adicional.\n\n2. **Lotes Fuera de Especificaci\u00f3n (OOS)**:\n   - Los lotes OOS no deben ser mezclados con otros lotes para cumplir con las especificaciones. Cada lote en la mezcla debe haber sido fabricado bajo un proceso establecido y probado individualmente.\n\n3. **Operaciones de Blending Aceptables**:\n   - Mezcla de peque\u00f1os lotes para aumentar el tama\u00f1o del lote.\n   - Mezcla de tailings de lotes del mismo intermedio o API para formar un solo lote.\n\n4. **Control y Documentaci\u00f3n**:\n   - Las operaciones de blending deben ser controladas y documentadas adecuadamente. El lote mezclado debe ser probado para asegurar su conformidad con las especificaciones establecidas.\n\n5. **Trazabilidad**:\n   - Se debe permitir la trazabilidad de los lotes individuales que componen la mezcla.\n\n6. **Validaci\u00f3n de Blending**:\n   - Para APIs cr\u00edticos, las operaciones de blending deben ser validadas para demostrar la homogeneidad del lote combinado. Esto incluye pruebas de atributos cr\u00edticos como la distribuci\u00f3n del tama\u00f1o de part\u00edculas y densidades.\n\n7. **Pruebas de Estabilidad**:\n   - Si el blending puede afectar la estabilidad, se deben realizar pruebas de estabilidad en los lotes mezclados finales.\n\n8. **Fecha de Caducidad o Rean\u00e1lisis**:\n   - La fecha de caducidad o rean\u00e1lisis del lote mezclado debe basarse en la fecha de fabricaci\u00f3n del material m\u00e1s antiguo en la mezcla.\n\n### Entidades Clave:\n- **Blending**: Proceso de combinaci\u00f3n de materiales.\n- **Intermedios y APIs**: Productos farmac\u00e9uticos intermedios y principios activos.\n- **Lotes OOS**: Lotes fuera de especificaci\u00f3n.\n- **Tailings**: Cantidades peque\u00f1as de material aislado de lotes.\n- **Atributos Cr\u00edticos**: Caracter\u00edsticas f\u00edsicas que deben ser probadas para asegurar la calidad del producto.", "excerpt_keywords": "Keywords: contamination control, APIs, packaging materials, production operations, labeling procedures"}}, "81ba575b-2ccc-4f51-bca3-af80cc7d0881": {"node_ids": ["f1099729-2439-432b-a2c4-b80aa18f3785"], "metadata": {"page_label": "171", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9.3 Label issuance and control\n\n9.30 Access to the label storage areas should be limited to authorized personnel.\n\n9.31 Procedures should be used to reconcile the quantities of labels issued, used and returned and to evaluate discrepancies found between the number of containers labelled and the number of labels issued. Such discrepancies should be investigated and the investigation should be approved by the quality unit(s).\n\n9.32 All excess labels bearing batch numbers or other batch-related printing should be destroyed. Returned labels should be retained and stored in a manner that prevents mix-ups and provides proper identification.\n\n9.33 Obsolete and outdated labels should be destroyed.\n\n9.34 Printing devices used to print labels for packaging operations should be controlled to ensure that all imprinting conforms to the print specified in the batch production record.\n\n9.35 Printed labels issued for a batch should be carefully examined for proper identity and conformity to specifications in the master production record. The results of this examination should be documented.\n\n9.36 A printed label representative of those used should be included in the batch production record.\n\n# 9.4 Packaging and labelling operations\n\n9.40 There should be documented procedures designed to ensure that the correct packaging materials and labels are used.\n\n9.41 Labelling operations should be designed to prevent mix-ups. They should be physically or spatially separated from operations involving other intermediates or APIs.\n\n9.42 Labels used on containers of intermediates or APIs should indicate the name or identifying code, the batch number of the product and the storage conditions, when such information is critical to assure the quality of the intermediate or API.\n\n9.43 If the intermediate or API is intended to be transferred outside the control of the manufacturer\u2019s material management system, the name and address of the manufacturer, quantity of contents and special transport conditions and any special legal requirements should also be included on the label. For intermediates or APIs with an expiry date, this date should be indicated on the label and certificate of analysis. For intermediates or APIs with a retest date, the retest date should be indicated on the label and/or certificate of analysis.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl contexto se centra en las directrices de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre la emisi\u00f3n y control de etiquetas, as\u00ed como sobre las operaciones de empaquetado y etiquetado en la producci\u00f3n de intermediarios y principios activos (APIs). Se enfatiza la importancia de limitar el acceso a las \u00e1reas de almacenamiento de etiquetas, la necesidad de procedimientos documentados para reconciliar las etiquetas emitidas y utilizadas, y la destrucci\u00f3n de etiquetas obsoletas o en exceso. Tambi\u00e9n se destacan las especificaciones que deben incluirse en las etiquetas para asegurar la calidad y el cumplimiento normativo.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben implementarse para manejar las discrepancias entre las etiquetas emitidas y los contenedores etiquetados?**\n   - El contexto menciona que se deben utilizar procedimientos para reconciliar las cantidades de etiquetas emitidas, usadas y devueltas, y que cualquier discrepancia debe ser investigada y aprobada por las unidades de calidad.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n cr\u00edtica debe incluirse en las etiquetas de los intermediarios o APIs para asegurar su calidad?**\n   - Las etiquetas deben indicar el nombre o c\u00f3digo identificador, el n\u00famero de lote del producto y las condiciones de almacenamiento, cuando esta informaci\u00f3n sea cr\u00edtica para asegurar la calidad del intermediario o API.\n\n3. **\u00bfCu\u00e1les son las medidas que deben tomarse con respecto a las etiquetas que son obsoletas o que tienen informaci\u00f3n de lote?**\n   - Todas las etiquetas en exceso que contengan n\u00fameros de lote o impresi\u00f3n relacionada con el lote deben ser destruidas, y las etiquetas devueltas deben ser retenidas y almacenadas de manera que se eviten confusiones y se garantice una identificaci\u00f3n adecuada.", "prev_section_summary": "### Temas Clave:\n\n1. **Control de Contaminaci\u00f3n**:\n   - Importancia de evitar la contaminaci\u00f3n cruzada entre lotes de intermediarios y principios activos (API).\n   - Ejemplos de materiales residuales que pueden transferirse entre lotes y su impacto en el perfil de impurezas del API.\n   - Necesidad de realizar operaciones de producci\u00f3n que prevengan la contaminaci\u00f3n por otros materiales.\n   - Precauciones necesarias al manejar APIs despu\u00e9s de la purificaci\u00f3n.\n\n2. **Embalaje y Etiquetado**:\n   - Procedimientos escritos requeridos para la recepci\u00f3n, identificaci\u00f3n, cuarentena, muestreo, examen, pruebas y manejo de materiales de embalaje y etiquetado.\n   - Cumplimiento de especificaciones establecidas para materiales de embalaje y etiquetado, y rechazo de aquellos que no cumplan.\n   - Mantenimiento de registros para cada env\u00edo de materiales de embalaje y etiquetado.\n\n3. **Materiales de Embalaje**:\n   - Protecci\u00f3n adecuada de los contenedores contra la deterioraci\u00f3n o contaminaci\u00f3n durante el transporte y almacenamiento.\n   - Limpieza y sanitizaci\u00f3n de contenedores, asegurando que no alteren la calidad del API.\n   - Procedimientos documentados para la limpieza de contenedores reutilizados y eliminaci\u00f3n de etiquetas anteriores.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Intermediarios**: Sustancias qu\u00edmicas utilizadas en la producci\u00f3n de APIs.\n- **Principios Activos (API)**: Compuestos farmac\u00e9uticos que tienen un efecto terap\u00e9utico.\n- **Contaminaci\u00f3n**: Presencia no deseada de materiales que pueden afectar la calidad del producto.\n- **Contenedores**: Recipientes utilizados para el almacenamiento y transporte de intermediarios y APIs.\n- **Materiales de Embalaje y Etiquetado**: Elementos utilizados para proteger y identificar los productos farmac\u00e9uticos.\n\nEste resumen destaca la importancia del control de la contaminaci\u00f3n y el manejo adecuado de los materiales de embalaje y etiquetado en la producci\u00f3n de intermediarios y APIs, asegurando la calidad y seguridad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: etiquetas, control de calidad, intermediarios, principios activos, procedimientos documentados"}}, "e2dc0e0a-ded8-4f0a-a3d0-cc4a8b543b55": {"node_ids": ["320ce1b3-18e8-4e0b-8e9c-579c0c2bca96"], "metadata": {"page_label": "172", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9.44 \nPackaging and labelling facilities should be inspected immediately before use to ensure that all materials not needed for the next packaging operation have been removed. This examination should be documented in the batch production records, the facility log or other documentation system.\n\n# 9.45 \nPackaged and labelled intermediates or APIs should be examined to ensure that containers and packages in the batch have the correct label. This examination should be part of the packaging operation. Results of these examinations should be recorded in the batch production or control records.\n\n# 9.46 \nIntermediate or API containers that are transported outside the manufacturer\u2019s control should be sealed in a manner such that, if the seal is breached or missing, the recipient will be alerted to the possibility that the contents may have been altered.\n\n# 10. Storage and distribution\n\n## 10.1 Warehousing procedures\n\n10.10 Facilities should be available for the storage of all materials under appropriate conditions (e.g. controlled temperature and humidity when necessary). Records should be maintained of these conditions if they are critical for the maintenance of material characteristics.\n\n10.11 Unless there is an alternative system to prevent the unintentional or unauthorized use of quarantined, rejected, returned or recalled materials, separate storage areas should be assigned for their temporary storage until the decision as to their future use has been taken.\n\n## 10.2 Distribution procedures\n\n10.20 APIs and intermediates should only be released for distribution to third parties after they have been released by the quality unit(s). APIs and intermediates can be transferred under quarantine to another unit under the company\u2019s control when authorized by the quality unit(s) and if appropriate controls and documentation are in place.\n\n10.21 APIs and intermediates should be transported in a manner that does not adversely affect their quality.\n\n10.22 Special transport or storage conditions for an API or intermediate should be stated on the label.\n\n10.23 The manufacturer should ensure that the contract acceptor (contractor) for transportation of the API or intermediate knows and follows the appropriate transport and storage conditions.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 957) aborda las directrices sobre el empaquetado, etiquetado, almacenamiento y distribuci\u00f3n de intermediarios y principios activos (APIs) en la industria farmac\u00e9utica. Se enfatiza la importancia de inspeccionar las instalaciones de empaquetado antes de su uso, asegurarse de que los productos est\u00e9n correctamente etiquetados, y mantener condiciones adecuadas de almacenamiento. Tambi\u00e9n se establecen procedimientos para la distribuci\u00f3n, asegurando que los productos solo sean liberados tras la aprobaci\u00f3n de la unidad de calidad y que se sigan las condiciones de transporte y almacenamiento adecuadas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 documentaci\u00f3n se requiere para registrar la inspecci\u00f3n de las instalaciones de empaquetado antes de su uso?**\n   - La inspecci\u00f3n debe ser documentada en los registros de producci\u00f3n por lotes, el registro de la instalaci\u00f3n o en otro sistema de documentaci\u00f3n.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse si se transportan contenedores de intermediarios o APIs fuera del control del fabricante?**\n   - Los contenedores deben estar sellados de tal manera que, si el sello est\u00e1 roto o falta, el destinatario sea alertado sobre la posibilidad de que el contenido haya sido alterado.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse para que un API o intermediario sea liberado para distribuci\u00f3n a terceros?**\n   - Los APIs e intermediarios solo deben ser liberados para distribuci\u00f3n despu\u00e9s de haber sido aprobados por la(s) unidad(es) de calidad. Adem\u00e1s, pueden ser transferidos bajo cuarentena a otra unidad bajo el control de la empresa, siempre que haya controles y documentaci\u00f3n apropiados en su lugar.\n\n### Resumen de nivel superior\n\nEl documento establece directrices claras para asegurar la calidad y la integridad de los intermediarios y APIs en la industria farmac\u00e9utica, desde el empaquetado y etiquetado hasta el almacenamiento y distribuci\u00f3n. Se subraya la importancia de la documentaci\u00f3n y el cumplimiento de las condiciones de almacenamiento y transporte para prevenir la alteraci\u00f3n de los productos.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n\n\n#### Temas clave:\n1. **Control de acceso a etiquetas**: Se debe limitar el acceso a las \u00e1reas de almacenamiento de etiquetas a personal autorizado.\n2. **Reconciliaci\u00f3n de etiquetas**: Es necesario implementar procedimientos para reconciliar las cantidades de etiquetas emitidas, utilizadas y devueltas, as\u00ed como investigar discrepancias entre el n\u00famero de contenedores etiquetados y las etiquetas emitidas.\n3. **Destrucci\u00f3n de etiquetas**: Las etiquetas en exceso, obsoletas o desactualizadas deben ser destruidas. Las etiquetas devueltas deben ser almacenadas adecuadamente para evitar confusiones.\n4. **Control de dispositivos de impresi\u00f3n**: Los dispositivos utilizados para imprimir etiquetas deben ser controlados para asegurar que la impresi\u00f3n cumpla con las especificaciones del registro de producci\u00f3n.\n5. **Examen de etiquetas impresas**: Las etiquetas impresas deben ser examinadas cuidadosamente para verificar su identidad y conformidad con las especificaciones, y los resultados de esta revisi\u00f3n deben ser documentados.\n6. **Procedimientos de empaquetado y etiquetado**: Deben existir procedimientos documentados para asegurar el uso correcto de materiales de empaquetado y etiquetas, as\u00ed como medidas para prevenir confusiones durante las operaciones de etiquetado.\n7. **Informaci\u00f3n cr\u00edtica en etiquetas**: Las etiquetas de intermediarios o APIs deben incluir informaci\u00f3n esencial como el nombre o c\u00f3digo identificador, n\u00famero de lote y condiciones de almacenamiento. Si se transfieren fuera del control del fabricante, deben incluir informaci\u00f3n adicional como nombre y direcci\u00f3n del fabricante, cantidad, condiciones de transporte y requisitos legales especiales.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad que proporciona las directrices.\n- **Personal autorizado**: Individuos con permiso para acceder a las \u00e1reas de almacenamiento de etiquetas.\n- **Unidades de calidad**: Entidades responsables de aprobar las investigaciones sobre discrepancias en etiquetas.\n- **Intermediarios y principios activos (APIs)**: Productos cuya etiquetado y empaquetado deben cumplir con las regulaciones establecidas.\n- **Registro de producci\u00f3n**: Documentaci\u00f3n que especifica los detalles de la producci\u00f3n y etiquetado de los productos. \n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de etiquetas y empaquetado en la producci\u00f3n farmac\u00e9utica para asegurar la calidad y el cumplimiento normativo.", "excerpt_keywords": "Keywords: packaging, labeling, storage, distribution, quality control"}}, "2d1bf720-8100-4516-8f84-70e1ea41bb77": {"node_ids": ["a13d483f-4664-4569-b18b-a1eadf59d8d8"], "metadata": {"page_label": "173", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Laboratory controls\n\n## General controls\n\n11.10 The independent quality unit(s) should have at its disposal adequate laboratory facilities.\n\n11.11 There should be documented procedures describing sampling, testing, approval or rejection of materials and recording and storage of laboratory data. Laboratory records should be maintained in accordance with section 6.6.\n\n11.12 All specifications, sampling plans and test procedures should be scientifically sound and appropriate to ensure that raw materials, intermediates, APIs, labels and packaging materials conform to established standards of quality and/or purity. Specifications and test procedures should be consistent with those included in the registration/filing. There can be specifications in addition to those in the registration/filing. Specifications, sampling plans and test procedures, including changes to them, should be drafted by the appropriate organizational unit and reviewed and approved by the quality unit(s).\n\n11.13 Appropriate specifications should be established for APIs in accordance with accepted standards and be consistent with the manufacturing process. The specifications should include a control of the impurities (e.g. organic impurities, inorganic impurities and residual solvents). If the API has a specification for microbiological purity, appropriate action limits for total microbial counts and objectionable organisms should be established and met. If the API has a specification for endotoxins, appropriate action limits should be established and met.\n\n11.14 Laboratory controls should be followed and documented at the time of performance. Any departures from the above-described procedures should be documented and explained.\n\n11.15 Any OOS result obtained should be investigated and documented according to a procedure. This procedure should require analysis of the data, assessment of whether a significant problem exists, allocation of the tasks for corrective actions and conclusions. Any resampling and/or retesting after OOS results should be performed according to a documented procedure.\n\n11.16 Reagents and standard solutions should be prepared and labelled following written procedures. \u201cUse by\u201d dates should be applied as appropriate for analytical reagents or standard solutions.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre los controles de laboratorio en el contexto de la calidad de los productos farmac\u00e9uticos, seg\u00fan el informe t\u00e9cnico de la OMS. Se enfatiza la importancia de tener instalaciones adecuadas, procedimientos documentados para el muestreo y pruebas, y la necesidad de especificaciones cient\u00edficas para asegurar la calidad y pureza de los materiales. Tambi\u00e9n se abordan los procedimientos para manejar resultados fuera de especificaci\u00f3n (OOS) y la preparaci\u00f3n y etiquetado de reactivos y soluciones est\u00e1ndar.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse si se obtiene un resultado fuera de especificaci\u00f3n (OOS) en el laboratorio?**\n   - El texto detalla que cualquier resultado OOS debe ser investigado y documentado seg\u00fan un procedimiento que incluya el an\u00e1lisis de datos, la evaluaci\u00f3n de la existencia de un problema significativo, la asignaci\u00f3n de tareas para acciones correctivas y la conclusi\u00f3n del an\u00e1lisis. Adem\u00e1s, cualquier re-muestreo o re-prueba debe realizarse de acuerdo con un procedimiento documentado.\n\n2. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en las especificaciones para los ingredientes farmac\u00e9uticos activos (APIs)?**\n   - Las especificaciones para los APIs deben incluir el control de impurezas (como impurezas org\u00e1nicas, inorg\u00e1nicas y solventes residuales) y, si corresponde, l\u00edmites de acci\u00f3n para la pureza microbiol\u00f3gica y endotoxinas. Estas especificaciones deben ser consistentes con el proceso de fabricaci\u00f3n y con los est\u00e1ndares aceptados.\n\n3. **\u00bfQu\u00e9 requisitos existen para la documentaci\u00f3n y el almacenamiento de los datos de laboratorio?**\n   - Se requiere que existan procedimientos documentados que describan el muestreo, las pruebas, la aprobaci\u00f3n o rechazo de materiales, as\u00ed como el registro y almacenamiento de datos de laboratorio. Los registros de laboratorio deben mantenerse de acuerdo con la secci\u00f3n 6.6 del documento.", "prev_section_summary": "### Temas Clave\n\n1. **Inspecci\u00f3n de Instalaciones de Empaquetado**:\n   - Las instalaciones deben ser inspeccionadas antes de su uso para asegurar que no haya materiales innecesarios.\n   - La inspecci\u00f3n debe ser documentada en registros de producci\u00f3n por lotes o en otros sistemas de documentaci\u00f3n.\n\n2. **Etiquetado de Intermediarios y APIs**:\n   - Los productos empaquetados deben ser examinados para verificar que tienen la etiqueta correcta.\n   - Los resultados de estas inspecciones deben ser registrados.\n\n3. **Transporte de Contenedores**:\n   - Los contenedores que se transportan fuera del control del fabricante deben estar sellados para alertar sobre posibles alteraciones si el sello est\u00e1 roto o falta.\n\n4. **Almacenamiento**:\n   - Se deben mantener condiciones adecuadas de almacenamiento (temperatura y humedad controladas).\n   - Se deben llevar registros de estas condiciones si son cr\u00edticas para la calidad del material.\n\n5. **Procedimientos de Distribuci\u00f3n**:\n   - Los APIs e intermediarios solo deben ser liberados para distribuci\u00f3n tras la aprobaci\u00f3n de la unidad de calidad.\n   - Pueden ser transferidos bajo cuarentena a otra unidad bajo control de la empresa, siempre que haya controles y documentaci\u00f3n adecuados.\n   - El transporte debe realizarse de manera que no afecte la calidad del producto.\n\n6. **Condiciones Especiales de Transporte y Almacenamiento**:\n   - Las condiciones especiales deben ser indicadas en la etiqueta del producto.\n   - El contratista de transporte debe estar informado y seguir las condiciones adecuadas.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Intermediarios**: Productos intermedios en la cadena de producci\u00f3n farmac\u00e9utica.\n- **Principios Activos (APIs)**: Sustancias que proporcionan la acci\u00f3n farmacol\u00f3gica en los medicamentos.\n- **Unidad de Calidad**: Entidad responsable de la aprobaci\u00f3n de productos para distribuci\u00f3n.\n- **Contratista de Transporte**: Entidad encargada del transporte de los productos, que debe cumplir con las condiciones establecidas. \n\nEste resumen destaca la importancia de la inspecci\u00f3n, el etiquetado correcto, el almacenamiento adecuado y el cumplimiento de las normativas en la industria farmac\u00e9utica para garantizar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: laboratory controls, quality unit, specifications, active pharmaceutical ingredients, OOS results"}}, "e2eaca3a-b863-45c2-8c05-faf887e0d4be": {"node_ids": ["c41a8dc1-6f41-42b1-adb5-b804b5fe365a"], "metadata": {"page_label": "174", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11.17\n\nPrimary reference standards should be obtained as appropriate for the manufacture of APIs. The source of each primary reference standard should be documented. Records should be maintained of each primary reference standard\u2019s storage and use in accordance with the supplier\u2019s recommendations. Primary reference standards obtained from an officially recognized source are normally used without testing if stored under conditions consistent with the supplier\u2019s recommendations.\n\n11.18 Where a primary reference standard is not available from an officially recognized source, an \u201cin-house primary standard\u201d should be established. Appropriate testing should be performed to establish fully the identity and purity of the primary reference standard. Appropriate documentation of this testing should be maintained.\n\n11.19 Secondary reference standards should be appropriately prepared, identified, tested, approved and stored. The suitability of each batch of secondary reference standard should be determined prior to first use by comparing against a primary reference standard. Each batch of secondary reference standard should be periodically requalified in accordance with a written protocol.\n\n## 11.2 Testing of intermediates and APIs\n\n11.20 For each batch of intermediate and API, appropriate laboratory tests should be conducted to determine conformance to specifications.\n\n11.21 An impurity profile describing the identified and unidentified impurities present in a typical batch produced by a specific controlled production process should normally be established for each API. The impurity profile should include the identity or some qualitative analytical designation (e.g. retention time), the range of each impurity observed and classification of each identified impurity (e.g. inorganic, organic or solvent). The impurity profile is normally dependent upon the production process and origin of the API. Impurity profiles are normally not necessary for APIs of herbal or animal tissue origin. Biotechnology considerations are covered in ICH Guideline Q6B (1).\n\n11.22 The impurity profile should be compared at appropriate intervals with the impurity profile in the regulatory submission or compared with historical data in order to detect changes to the API resulting from modifications to raw materials, equipment operating parameters or the production process.\n\n11.23 Appropriate microbiological tests should be conducted on each batch of intermediate and API where microbial quality is specified.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en las normas y procedimientos relacionados con los est\u00e1ndares de referencia primarios y secundarios en la fabricaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (APIs). Se enfatiza la importancia de documentar la fuente de los est\u00e1ndares de referencia, mantener registros de su almacenamiento y uso, y realizar pruebas adecuadas para establecer la identidad y pureza de los est\u00e1ndares. Tambi\u00e9n se discute la necesidad de establecer perfiles de impurezas para cada API y realizar pruebas microbiol\u00f3gicas cuando se especifica la calidad microbiana.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 documentaci\u00f3n es necesaria para el almacenamiento y uso de los est\u00e1ndares de referencia primarios?**\n   - La documentaci\u00f3n necesaria incluye registros que mantengan informaci\u00f3n sobre la fuente de cada est\u00e1ndar de referencia primario, as\u00ed como detalles sobre su almacenamiento y uso, de acuerdo con las recomendaciones del proveedor.\n\n2. **\u00bfQu\u00e9 pasos se deben seguir si no se puede obtener un est\u00e1ndar de referencia primario de una fuente oficialmente reconocida?**\n   - En este caso, se debe establecer un \"est\u00e1ndar primario interno\", lo que implica realizar pruebas adecuadas para establecer completamente la identidad y pureza del est\u00e1ndar, y mantener la documentaci\u00f3n correspondiente de estas pruebas.\n\n3. **\u00bfC\u00f3mo se determina la idoneidad de cada lote de est\u00e1ndar de referencia secundario antes de su primer uso?**\n   - La idoneidad de cada lote de est\u00e1ndar de referencia secundario se determina compar\u00e1ndolo con un est\u00e1ndar de referencia primario. Adem\u00e1s, cada lote debe ser requalificado peri\u00f3dicamente de acuerdo con un protocolo escrito.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Controles de Laboratorio**: Se establecen directrices para asegurar la calidad y pureza de los productos farmac\u00e9uticos a trav\u00e9s de controles de laboratorio adecuados.\n\n2. **Instalaciones de Laboratorio**: Se requiere que las unidades de calidad independientes dispongan de instalaciones de laboratorio adecuadas.\n\n3. **Procedimientos Documentados**: Es esencial contar con procedimientos documentados que aborden el muestreo, pruebas, aprobaci\u00f3n o rechazo de materiales, as\u00ed como el registro y almacenamiento de datos de laboratorio.\n\n4. **Especificaciones Cient\u00edficas**: Las especificaciones, planes de muestreo y procedimientos de prueba deben ser cient\u00edficamente s\u00f3lidos y alineados con los est\u00e1ndares de calidad y pureza establecidos. Deben ser consistentes con la documentaci\u00f3n de registro.\n\n5. **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Se deben establecer especificaciones apropiadas para los APIs, incluyendo el control de impurezas y l\u00edmites de acci\u00f3n para pureza microbiol\u00f3gica y endotoxinas.\n\n6. **Resultados Fuera de Especificaci\u00f3n (OOS)**: Cualquier resultado OOS debe ser investigado y documentado, incluyendo el an\u00e1lisis de datos y la evaluaci\u00f3n de problemas significativos. Se deben seguir procedimientos documentados para re-muestreo y re-pruebas.\n\n7. **Preparaci\u00f3n de Reactivos**: Los reactivos y soluciones est\u00e1ndar deben ser preparados y etiquetados siguiendo procedimientos escritos, con fechas de \"uso hasta\" aplicadas seg\u00fan sea necesario.\n\n### Entidades Clave\n\n- **Unidades de Calidad Independientes**: Responsables de asegurar la calidad en el laboratorio.\n- **Procedimientos Documentados**: Gu\u00edas que regulan las operaciones de laboratorio.\n- **Especificaciones**: Criterios que deben cumplir los materiales y productos.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Sustancias que se utilizan en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Resultados OOS**: Resultados que no cumplen con las especificaciones establecidas.\n- **Reactivos y Soluciones Est\u00e1ndar**: Sustancias utilizadas en an\u00e1lisis y pruebas de laboratorio. \n\nEste resumen destaca la importancia de los controles de laboratorio y la documentaci\u00f3n adecuada para garantizar la calidad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: reference standards, APIs, impurity profile, microbiological tests, quality control"}}, "42f885a0-49c8-4b04-b776-18c78a204770": {"node_ids": ["87535ebe-f642-4f10-8b28-596ebd73005a"], "metadata": {"page_label": "175", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11.3 Validation of analytical procedures\n\nSee section 12.\n\n# 11.4 Certificates of analysis\n\n11.40 Authentic certificates of analysis should be issued for each batch of intermediate or API on request.\n\n11.41 Information on the name of the intermediate or API, including where appropriate its grade, the batch number and the date of release, should be provided on the certificate of analysis. For intermediates or APIs with an expiry date, the expiry date should be provided on the label and certificate of analysis. For intermediates or APIs with a retest date, the retest date should be indicated on the label and/or certificate of analysis.\n\n11.42 The certificate should list each test performed in accordance with compendial or customer requirements, including the acceptance limits and the numerical results obtained (if test results are numerical).\n\n11.43 Certificates should be dated and signed by authorized personnel from the quality unit(s) and should show the name, address and telephone number of the original manufacturer. Where the analysis has been carried out by a repacker or reprocessor, the certificate of analysis should show the name, address and telephone number of the repacker or reprocessor and a reference to the name of the original manufacturer.\n\n11.44 If new certificates are issued by or on behalf of repackers or reprocessors, agents or brokers, these certificates should show the name, address and telephone number of the laboratory that performed the analysis. They should also contain a reference to the name and address of the original manufacturer and to the original batch certificate, a copy of which should be attached.\n\n# 11.5 Stability monitoring of APIs\n\n11.50 A documented, ongoing testing programme should be designed to monitor the stability characteristics of APIs and the results should be used to confirm appropriate storage conditions and retest or expiry dates.\n\n11.51 The test procedures used in stability testing should be validated and be stability-indicating.\n\n11.52 Stability samples should be stored in containers that simulate the market container. For example, if the API is marketed in bags within fibre drums, stability samples can be packaged in bags of the same material and in smaller drums of similar or identical material composition to the drums in which the API is marketed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la validaci\u00f3n de procedimientos anal\u00edticos y la emisi\u00f3n de certificados de an\u00e1lisis para intermediarios y principios activos (API). Se enfatiza la importancia de proporcionar informaci\u00f3n detallada en los certificados, como el nombre del producto, el n\u00famero de lote, las fechas de caducidad y rean\u00e1lisis, as\u00ed como la firma de personal autorizado. Adem\u00e1s, se menciona la necesidad de un programa de monitoreo de estabilidad para los API, que debe incluir pruebas validadas y el almacenamiento de muestras en condiciones que simulen el envase comercial.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en un certificado de an\u00e1lisis para un API o intermediario?**\n   - El certificado de an\u00e1lisis debe incluir el nombre del intermediario o API, su grado (si corresponde), el n\u00famero de lote, la fecha de liberaci\u00f3n, la fecha de caducidad o rean\u00e1lisis (si aplica), y los resultados de las pruebas realizadas, incluyendo l\u00edmites de aceptaci\u00f3n y resultados num\u00e9ricos.\n\n2. **\u00bfQu\u00e9 requisitos deben cumplir los procedimientos de prueba utilizados en el monitoreo de estabilidad de los API?**\n   - Los procedimientos de prueba utilizados en el monitoreo de estabilidad deben estar validados y ser indicativos de estabilidad, asegurando que los resultados reflejen adecuadamente las caracter\u00edsticas de estabilidad del API.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n adicional debe incluirse en los certificados de an\u00e1lisis emitidos por repackers o reprocessors?**\n   - Los certificados emitidos por repackers o reprocessors deben incluir el nombre, direcci\u00f3n y n\u00famero de tel\u00e9fono del laboratorio que realiz\u00f3 el an\u00e1lisis, as\u00ed como una referencia al nombre y direcci\u00f3n del fabricante original y al certificado de lote original, que debe ser adjuntado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Est\u00e1ndares de Referencia Primarios**:\n   - Obtenci\u00f3n y documentaci\u00f3n de la fuente.\n   - Mantenimiento de registros de almacenamiento y uso seg\u00fan recomendaciones del proveedor.\n   - Uso sin pruebas si provienen de fuentes oficialmente reconocidas y se almacenan adecuadamente.\n\n2. **Est\u00e1ndares Primarios Internos**:\n   - Establecimiento de un est\u00e1ndar primario interno si no se dispone de uno reconocido.\n   - Realizaci\u00f3n de pruebas para determinar identidad y pureza.\n   - Mantenimiento de documentaci\u00f3n de las pruebas realizadas.\n\n3. **Est\u00e1ndares de Referencia Secundarios**:\n   - Preparaci\u00f3n, identificaci\u00f3n, prueba, aprobaci\u00f3n y almacenamiento adecuados.\n   - Determinaci\u00f3n de idoneidad mediante comparaci\u00f3n con un est\u00e1ndar primario antes del primer uso.\n   - Recalificaci\u00f3n peri\u00f3dica de cada lote seg\u00fan un protocolo escrito.\n\n4. **Pruebas de Intermedios y APIs**:\n   - Realizaci\u00f3n de pruebas de laboratorio para cada lote de intermedio y API para verificar conformidad con especificaciones.\n\n5. **Perfiles de Impurezas**:\n   - Establecimiento de un perfil de impurezas que incluya impurezas identificadas y no identificadas, su rango y clasificaci\u00f3n.\n   - Comparaci\u00f3n peri\u00f3dica del perfil de impurezas con datos hist\u00f3ricos o perfiles presentados en regulaciones para detectar cambios.\n\n6. **Pruebas Microbiol\u00f3gicas**:\n   - Realizaci\u00f3n de pruebas microbiol\u00f3gicas en cada lote de intermedio y API cuando se especifique calidad microbiana.\n\n### Entidades Clave\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias utilizadas en la fabricaci\u00f3n de medicamentos.\n- **Est\u00e1ndares de Referencia**: Normas utilizadas para asegurar la calidad y pureza de los productos farmac\u00e9uticos.\n- **Proveedores**: Entidades que suministran los est\u00e1ndares de referencia.\n- **Protocolos Escritos**: Documentos que establecen procedimientos para la requalificaci\u00f3n de est\u00e1ndares secundarios.\n- **Perfiles de Impurezas**: Documentaci\u00f3n que detalla las impurezas presentes en los lotes de APIs.", "excerpt_keywords": "Keywords: certificates of analysis, stability monitoring, analytical procedures, active pharmaceutical ingredients, quality assurance"}}, "2c3017e2-626e-4a3a-94c9-e7febf650b1a": {"node_ids": ["d00b4394-5c19-4bf6-a0c3-d8cd77cb2879"], "metadata": {"page_label": "176", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 11.53\n\nNormally the first three commercial production batches should be placed on the stability monitoring programme to confirm the retest or expiry date. However, where data from previous studies show that the API is expected to remain stable for at least two years, fewer than three batches can be used.\n\n## 11.54\n\nThereafter at least one batch per year of API manufactured (unless none is produced that year) should be added to the stability monitoring programme and tested at least annually to confirm the stability.\n\n## 11.55\n\nFor APIs with short shelf-lives, testing should be done more frequently. For example, for those biotechnological/biological and other APIs with shelf-lives of one year or less, stability samples should be obtained and should be tested monthly for the first three months, and at three-monthly intervals after that. When data exist that confirm that the stability of the API is not compromised, elimination of specific test intervals (e.g. nine-month testing) can be considered.\n\n## 11.56\n\nWhere appropriate, the stability storage conditions should be consistent with the WHO guidelines on stability.\n\n### 11.6 Expiry and retest dating\n\n## 11.60\n\nWhen an intermediate is intended to be transferred outside the control of the manufacturer\u2019s material management system and an expiry or retest date is assigned, supporting stability information should be available (e.g. published data and test results).\n\n## 11.61\n\nAn API expiry or retest date should be based on an evaluation of data derived from stability studies. Common practice is to use a retest date, not an expiration date.\n\n## 11.62\n\nPreliminary API expiry or retest dates can be based on pilot-scale batches if:\n\n- the pilot batches employ a method of manufacture and a procedure that simulates the final process to be used on a commercial manufacturing scale; and\n- the quality of the API represents the material to be made on a commercial scale.\n\n## 11.63\n\nA representative sample should be taken for the purpose of performing a retest.\n\n### 11.7 Reserve/retention samples\n\n## 11.70\n\nThe packaging and holding of reserve samples is for the purpose of potential future evaluation of the quality of batches of API and not for future stability testing.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece directrices sobre el monitoreo de la estabilidad de los ingredientes farmac\u00e9uticos activos (API). Se recomienda que los primeros tres lotes de producci\u00f3n comercial se incluyan en un programa de monitoreo de estabilidad para confirmar las fechas de rean\u00e1lisis o caducidad. Para APIs con vida \u00fatil corta, se sugiere realizar pruebas m\u00e1s frecuentes. Adem\u00e1s, se discuten las condiciones de almacenamiento y la importancia de la informaci\u00f3n de estabilidad al asignar fechas de caducidad o rean\u00e1lisis. Tambi\u00e9n se menciona la necesidad de muestras de reserva para la evaluaci\u00f3n futura de la calidad.\n\n### Preguntas:\n1. **\u00bfCu\u00e1ntos lotes de producci\u00f3n comercial deben incluirse inicialmente en el programa de monitoreo de estabilidad y bajo qu\u00e9 condiciones se puede reducir este n\u00famero?**\n   - Respuesta: Normalmente, se deben incluir los primeros tres lotes de producci\u00f3n comercial en el programa de monitoreo de estabilidad. Sin embargo, si los datos de estudios previos indican que el API se espera que permanezca estable durante al menos dos a\u00f1os, se puede utilizar menos de tres lotes.\n\n2. **\u00bfCon qu\u00e9 frecuencia deben realizarse las pruebas de estabilidad para APIs con vida \u00fatil corta y qu\u00e9 intervalos se sugieren despu\u00e9s de los primeros meses?**\n   - Respuesta: Para APIs con vida \u00fatil corta (un a\u00f1o o menos), se deben obtener y probar muestras de estabilidad mensualmente durante los primeros tres meses, y luego a intervalos de tres meses despu\u00e9s de eso.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse para que las fechas preliminares de caducidad o rean\u00e1lisis de un API se basen en lotes de escala piloto?**\n   - Respuesta: Las fechas preliminares de caducidad o rean\u00e1lisis pueden basarse en lotes de escala piloto si estos emplean un m\u00e9todo de fabricaci\u00f3n y un procedimiento que simulan el proceso final que se utilizar\u00e1 a escala comercial, y si la calidad del API representa el material que se fabricar\u00e1 a escala comercial.", "prev_section_summary": "### Temas clave:\n\n1. **Validaci\u00f3n de procedimientos anal\u00edticos**: Se menciona que los procedimientos anal\u00edticos deben ser validados, aunque se remite a la secci\u00f3n 12 para m\u00e1s detalles.\n\n2. **Certificados de an\u00e1lisis**: \n   - Se requiere la emisi\u00f3n de certificados aut\u00e9nticos para cada lote de intermediarios o principios activos (API) a solicitud.\n   - Los certificados deben incluir informaci\u00f3n detallada como el nombre del producto, grado, n\u00famero de lote, fecha de liberaci\u00f3n, fechas de caducidad y rean\u00e1lisis, as\u00ed como los resultados de las pruebas realizadas.\n   - Deben ser firmados y fechados por personal autorizado y contener informaci\u00f3n del fabricante original y, si aplica, del repacker o reprocessor.\n\n3. **Monitoreo de estabilidad de los API**: \n   - Se debe establecer un programa de pruebas documentado y continuo para monitorear las caracter\u00edsticas de estabilidad de los API.\n   - Los procedimientos de prueba deben ser validados y reflejar la estabilidad del producto.\n   - Las muestras de estabilidad deben almacenarse en contenedores que simulen el envase comercial.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Intermediarios y principios activos (API)**: Productos cuya calidad y estabilidad se est\u00e1n evaluando.\n- **Personal autorizado**: Individuos responsables de firmar los certificados de an\u00e1lisis.\n- **Repackers y reprocessors**: Entidades que pueden realizar an\u00e1lisis y emitir certificados en nombre del fabricante original.\n- **Laboratorios**: Entidades que realizan las pruebas de an\u00e1lisis y estabilidad.\n\nEste resumen destaca la importancia de la documentaci\u00f3n y el cumplimiento de est\u00e1ndares en la producci\u00f3n y an\u00e1lisis de intermediarios y API, as\u00ed como la necesidad de un monitoreo continuo de su estabilidad.", "excerpt_keywords": "Keywords: stability monitoring, active pharmaceutical ingredients, expiry dating, retest dates, reserve samples"}}, "2a07ad8a-43bb-4cf9-955f-92e0062ab51f": {"node_ids": ["7a381825-1f8a-4f82-835c-f71aee746826"], "metadata": {"page_label": "177", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11.71\nAppropriately identified reserve samples of each batch of API should be retained for one year after the expiry date assigned by the manufacturer to the batch, or for three years after distribution of the batch, whichever is the longer. For APIs with retest dates, similar reserve samples should be retained for three years after the batch has been completely distributed by the manufacturer.\n\n11.72 The reserve sample should be stored in the same packaging system in which the API is stored or in one that is equivalent to or more protective than the marketed packaging system. Sufficient quantities should be retained to conduct at least two full compendial analyses or, when there is no pharmacopoeial monograph, two full specification analyses.\n\n# 12. Validation\n\n## 12.1 Validation policy\n\n12.10 The company\u2019s overall policy, intentions and approach to validation, including the validation of production processes, cleaning procedures, analytical methods, in-process control test procedures, computerized systems and personnel responsible for design, review, approval and documentation of each validation phase, should be documented.\n\n12.11 The critical parameters and attributes should normally be identified during the development stage or from historical data and the ranges necessary for the reproducible operation should be defined. This should include:\n\n- defining the API in terms of its critical product attributes;\n- identifying process parameters that could affect the critical quality attributes of the API;\n- determining the range for each critical process parameter expected to be used during routine manufacturing and process control.\n\n12.12 Validation should extend to those operations determined to be critical to the quality and purity of the API.\n\n## 12.2 Validation documentation\n\n12.20 A written validation protocol should be established that specifies how validation of a particular process will be conducted. The protocol should be reviewed and approved by the quality unit(s) and other designated units.\n\n12.21 The validation protocol should specify critical process steps and acceptance criteria as well as the type of validation to be conducted (e.g. retrospective, prospective or concurrent) and the number of process runs.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la gesti\u00f3n de muestras de reserva de ingredientes farmac\u00e9uticos activos (API) y la importancia de la validaci\u00f3n en los procesos de producci\u00f3n. Se establece que las muestras de reserva deben conservarse durante un per\u00edodo espec\u00edfico, dependiendo de la fecha de caducidad o la distribuci\u00f3n. Adem\u00e1s, se detalla la pol\u00edtica de validaci\u00f3n que debe seguir una empresa, incluyendo la documentaci\u00f3n necesaria y la identificaci\u00f3n de par\u00e1metros cr\u00edticos que afectan la calidad del API.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1nto tiempo deben conservarse las muestras de reserva de un lote de API y bajo qu\u00e9 condiciones?**\n   - Las muestras de reserva de cada lote de API deben conservarse durante un a\u00f1o despu\u00e9s de la fecha de caducidad asignada por el fabricante o durante tres a\u00f1os despu\u00e9s de la distribuci\u00f3n del lote, lo que sea m\u00e1s largo. Para los API con fechas de rean\u00e1lisis, las muestras deben conservarse durante tres a\u00f1os despu\u00e9s de que el lote haya sido completamente distribuido.\n\n2. **\u00bfQu\u00e9 debe incluir un protocolo de validaci\u00f3n seg\u00fan el documento de la OMS?**\n   - Un protocolo de validaci\u00f3n debe especificar c\u00f3mo se llevar\u00e1 a cabo la validaci\u00f3n de un proceso particular, incluyendo los pasos cr\u00edticos del proceso, los criterios de aceptaci\u00f3n, el tipo de validaci\u00f3n (retrospectiva, prospectiva o concurrente) y el n\u00famero de ejecuciones del proceso. Adem\u00e1s, debe ser revisado y aprobado por las unidades de calidad y otras unidades designadas.\n\n3. **\u00bfCu\u00e1les son los par\u00e1metros cr\u00edticos que deben identificarse durante la etapa de desarrollo de un API?**\n   - Durante la etapa de desarrollo, se deben identificar los par\u00e1metros cr\u00edticos y atributos del API, que incluyen la definici\u00f3n del API en t\u00e9rminos de sus atributos cr\u00edticos del producto, la identificaci\u00f3n de par\u00e1metros de proceso que podr\u00edan afectar la calidad cr\u00edtica del API y la determinaci\u00f3n del rango para cada par\u00e1metro cr\u00edtico de proceso que se espera utilizar durante la fabricaci\u00f3n y el control del proceso.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Monitoreo de estabilidad de APIs**:\n   - Se recomienda que los primeros tres lotes de producci\u00f3n comercial se incluyan en un programa de monitoreo de estabilidad para confirmar las fechas de rean\u00e1lisis o caducidad.\n   - Si hay datos previos que indican que el API se mantendr\u00e1 estable por al menos dos a\u00f1os, se puede reducir el n\u00famero de lotes a menos de tres.\n\n2. **Frecuencia de pruebas**:\n   - Al menos un lote por a\u00f1o debe ser a\u00f1adido al programa de monitoreo de estabilidad y probado anualmente.\n   - Para APIs con vida \u00fatil corta (un a\u00f1o o menos), se deben realizar pruebas mensuales durante los primeros tres meses y luego a intervalos de tres meses.\n\n3. **Condiciones de almacenamiento**:\n   - Las condiciones de almacenamiento de estabilidad deben alinearse con las directrices de la OMS sobre estabilidad.\n\n4. **Fechas de caducidad y rean\u00e1lisis**:\n   - Las fechas de caducidad o rean\u00e1lisis deben basarse en datos de estudios de estabilidad.\n   - Se prefiere utilizar una fecha de rean\u00e1lisis en lugar de una fecha de caducidad.\n\n5. **Lotes de escala piloto**:\n   - Las fechas preliminares de caducidad o rean\u00e1lisis pueden basarse en lotes de escala piloto si simulan el proceso final de fabricaci\u00f3n y la calidad del API es representativa del material comercial.\n\n6. **Muestras de reserva**:\n   - Las muestras de reserva se utilizan para la evaluaci\u00f3n futura de la calidad de los lotes de API, no para pruebas de estabilidad.\n\n### Entidades:\n- **API (Ingrediente Farmac\u00e9utico Activo)**: Sustancia que se utiliza en la fabricaci\u00f3n de medicamentos.\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organizaci\u00f3n que proporciona directrices sobre la estabilidad de los productos farmac\u00e9uticos.\n- **Estudios de estabilidad**: Investigaciones que eval\u00faan la estabilidad de un API a lo largo del tiempo bajo condiciones espec\u00edficas.\n- **Lotes de producci\u00f3n**: Cantidades de productos fabricados en un solo ciclo de producci\u00f3n.", "excerpt_keywords": "Keywords: API, validation, reserve samples, quality control, pharmaceutical standards"}}, "34554caa-8089-4238-ac7a-f6ffd2037731": {"node_ids": ["a209e0c2-130b-4385-a9d2-8f5489fd947b"], "metadata": {"page_label": "178", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Qualification\n\n12.22 A validation report that cross-references the validation protocol should be prepared, summarizing the results obtained, commenting on any deviations observed and drawing the appropriate conclusions, including recommending changes to correct deficiencies.\n\n12.23 Any variations from the validation protocol should be documented with appropriate justification.\n\n## 12.3 Qualification\n\n12.30 Before starting process validation activities, appropriate qualification of critical equipment and ancillary systems should be completed. Qualification is usually carried out by conducting the following activities, individually or combined:\n\n- **Design qualification (DQ):** Documented verification that the proposed design of the facilities, equipment, or systems is suitable for the intended purpose;\n- **Installation qualification (IQ):** Documented verification that the equipment or systems, as installed or modified, comply with the approved design, the manufacturer\u2019s recommendations and/or user requirements;\n- **Operational qualification (OQ):** Documented verification that the equipment or systems, as installed or modified, perform as intended throughout the anticipated operating ranges;\n- **Performance qualification (PQ):** Documented verification that the equipment and ancillary systems, as connected together, can perform effectively and reproducibly based on the approved process method and specifications.\n\n## 12.4 Approaches to process validation\n\n12.40 Process validation (PV) is the documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce an intermediate or API meeting its predetermined specifications and quality attributes.\n\n12.41 There are three approaches to validation. Prospective validation is the preferred approach, but there are exceptions where the other approaches can be used. These three approaches and their applicability are outlined below.\n\n12.42 Prospective validation should normally be performed for all API processes as defined in section 12.1.3. Prospective validation performed on an API process should be completed before the commercial distribution of the FPP manufactured from that API.\n\n12.43 Concurrent validation can be conducted when data from replicate production runs are unavailable because only a limited number of API.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla los procedimientos de calificaci\u00f3n y validaci\u00f3n de procesos en la producci\u00f3n de ingredientes farmac\u00e9uticos activos (API). Se enfatiza la importancia de realizar una calificaci\u00f3n adecuada de equipos cr\u00edticos y sistemas auxiliares antes de iniciar actividades de validaci\u00f3n de procesos. Se describen cuatro tipos de calificaci\u00f3n: DQ, IQ, OQ y PQ, cada una con su prop\u00f3sito espec\u00edfico. Adem\u00e1s, se presentan tres enfoques para la validaci\u00f3n de procesos, siendo la validaci\u00f3n prospectiva la m\u00e1s recomendada, aunque se permiten excepciones.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los cuatro tipos de calificaci\u00f3n que deben realizarse antes de iniciar la validaci\u00f3n de procesos, y qu\u00e9 verifica cada uno?**\n   - Respuesta: Los cuatro tipos de calificaci\u00f3n son: \n     - **Design Qualification (DQ):** Verifica que el dise\u00f1o propuesto sea adecuado para su prop\u00f3sito.\n     - **Installation Qualification (IQ):** Verifica que el equipo o sistemas instalados cumplan con el dise\u00f1o aprobado y las recomendaciones del fabricante.\n     - **Operational Qualification (OQ):** Verifica que el equipo o sistemas funcionen como se espera dentro de los rangos operativos anticipados.\n     - **Performance Qualification (PQ):** Verifica que los equipos y sistemas conectados funcionen de manera efectiva y reproducible seg\u00fan el m\u00e9todo y especificaciones aprobadas.\n\n2. **\u00bfQu\u00e9 se debe hacer si hay variaciones del protocolo de validaci\u00f3n durante el proceso?**\n   - Respuesta: Cualquier variaci\u00f3n del protocolo de validaci\u00f3n debe ser documentada con la justificaci\u00f3n apropiada.\n\n3. **\u00bfEn qu\u00e9 situaciones se puede utilizar la validaci\u00f3n concurrente en lugar de la validaci\u00f3n prospectiva?**\n   - Respuesta: La validaci\u00f3n concurrente puede llevarse a cabo cuando no hay datos disponibles de corridas de producci\u00f3n replicadas debido a que solo se dispone de un n\u00famero limitado de API.", "prev_section_summary": "### Temas Clave:\n\n1. **Muestras de Reserva de API**:\n   - Las muestras de reserva de cada lote de Ingredientes Farmac\u00e9uticos Activos (API) deben conservarse durante un a\u00f1o despu\u00e9s de la fecha de caducidad o tres a\u00f1os despu\u00e9s de la distribuci\u00f3n, lo que sea m\u00e1s largo.\n   - Para APIs con fechas de rean\u00e1lisis, las muestras deben conservarse tres a\u00f1os despu\u00e9s de la distribuci\u00f3n completa del lote.\n   - Las muestras deben almacenarse en el mismo sistema de empaquetado que el API o en uno que ofrezca igual o mayor protecci\u00f3n.\n\n2. **Validaci\u00f3n**:\n   - La pol\u00edtica de validaci\u00f3n de la empresa debe documentar el enfoque hacia la validaci\u00f3n de procesos de producci\u00f3n, m\u00e9todos anal\u00edticos, procedimientos de limpieza, y sistemas computarizados.\n   - Se deben identificar par\u00e1metros cr\u00edticos y atributos durante la etapa de desarrollo, as\u00ed como definir los rangos necesarios para la operaci\u00f3n reproducible.\n   - La validaci\u00f3n debe abarcar operaciones cr\u00edticas para la calidad y pureza del API.\n\n3. **Documentaci\u00f3n de Validaci\u00f3n**:\n   - Se debe establecer un protocolo de validaci\u00f3n escrito que especifique c\u00f3mo se llevar\u00e1 a cabo la validaci\u00f3n de un proceso particular.\n   - El protocolo debe ser revisado y aprobado por las unidades de calidad y otras unidades designadas, e incluir pasos cr\u00edticos del proceso, criterios de aceptaci\u00f3n y el tipo de validaci\u00f3n a realizar.\n\n### Entidades:\n\n- **API (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias utilizadas en la fabricaci\u00f3n de medicamentos.\n- **Muestras de Reserva**: Muestras conservadas para an\u00e1lisis futuros.\n- **Protocolo de Validaci\u00f3n**: Documento que detalla el proceso de validaci\u00f3n.\n- **Par\u00e1metros Cr\u00edticos**: Factores que afectan la calidad del API.\n- **Unidades de Calidad**: Departamentos responsables de asegurar la calidad en la producci\u00f3n.\n\nEste resumen destaca la importancia de la gesti\u00f3n de muestras de reserva y la validaci\u00f3n en la producci\u00f3n de APIs, asegurando que se mantenga la calidad y la pureza de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: Qualification, Validation, Process Validation, Design Qualification, Performance Qualification"}}, "499749d7-8761-45c1-9276-b7fbcced6607": {"node_ids": ["cfe7a901-5c05-4c35-b6ba-acf9bd54a3eb"], "metadata": {"page_label": "179", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "batches have been produced, API batches are produced infrequently, or API batches are produced by a validated process that has been modified. Prior to the completion of concurrent validation, batches can be released and used in FPPs for commercial distribution based on thorough monitoring and testing of the API batches.\n\n12.44 An exception can be made for retrospective validation for well-established processes that have been used without significant changes to API quality due to changes in raw materials, equipment, systems, facilities or the production process. This validation approach may be used where:\n\n1. Critical quality attributes and critical process parameters have been identified.\n2. Appropriate in-process acceptance criteria and controls have been established.\n3. There have not been significant process or product failures attributable to causes other than operator error or equipment failures unrelated to equipment suitability.\n4. Impurity profiles have been established for the existing API.\n\n12.45 Batches selected for retrospective validation should be representative of all batches made during the review period, including any batches that failed to meet specifications, and should be sufficient in number to demonstrate process consistency. Retained samples can be tested to obtain data to retrospectively validate the process.\n\n## 12.5 Process validation programme\n\n12.50 The number of process runs for validation should depend on the complexity of the process or the magnitude of the process change being considered. For prospective and concurrent validation, three consecutive successful production batches should be used as a guide, but there may be situations where additional process runs are warranted to prove consistency of the process (e.g. complex API processes or API processes with prolonged completion times). Generally, for retrospective validation, data from 10 to 30 consecutive batches should be examined to assess process consistency, but fewer batches can be examined if justified.\n\n12.51 Critical process parameters should be controlled and monitored during process validation studies. Process parameters unrelated to quality, such as variables controlled to minimize energy consumption or equipment use, need not be included in the process validation.\n\n12.52 Process validation should confirm that the impurity profile for each API is within the limits specified. The impurity profile should be comparable to or better than historical data and, where applicable, the profile determined.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en la validaci\u00f3n de procesos en la producci\u00f3n de ingredientes farmac\u00e9uticos activos (API). Se discuten diferentes enfoques de validaci\u00f3n: prospectiva, concurrente y retrospectiva. La validaci\u00f3n retrospectiva se permite para procesos bien establecidos que no han sufrido cambios significativos en la calidad del API. Se establecen criterios para seleccionar lotes para la validaci\u00f3n retrospectiva, as\u00ed como la cantidad de lotes que deben ser examinados para asegurar la consistencia del proceso. Tambi\u00e9n se enfatiza la importancia de controlar y monitorear par\u00e1metros cr\u00edticos del proceso y de confirmar que el perfil de impurezas del API est\u00e9 dentro de los l\u00edmites especificados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios que deben cumplirse para considerar la validaci\u00f3n retrospectiva de un proceso de producci\u00f3n de API?**\n   - La validaci\u00f3n retrospectiva puede considerarse si se han identificado atributos cr\u00edticos de calidad y par\u00e1metros cr\u00edticos del proceso, se han establecido criterios de aceptaci\u00f3n y controles en proceso, no ha habido fallos significativos en el proceso o producto, y se han establecido perfiles de impurezas para el API existente.\n\n2. **\u00bfQu\u00e9 cantidad de lotes se recomienda examinar para la validaci\u00f3n retrospectiva y bajo qu\u00e9 condiciones se puede justificar un n\u00famero menor?**\n   - Se recomienda examinar entre 10 y 30 lotes consecutivos para la validaci\u00f3n retrospectiva, pero se puede justificar un n\u00famero menor si hay razones adecuadas que lo respalden.\n\n3. **\u00bfQu\u00e9 par\u00e1metros del proceso deben ser controlados y monitoreados durante los estudios de validaci\u00f3n del proceso?**\n   - Durante la validaci\u00f3n del proceso, deben ser controlados y monitoreados los par\u00e1metros cr\u00edticos del proceso. Los par\u00e1metros no relacionados con la calidad, como aquellos que minimizan el consumo de energ\u00eda o el uso de equipos, no necesitan ser incluidos en la validaci\u00f3n del proceso.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Calificaci\u00f3n (Qualification)**:\n   - Se refiere a la verificaci\u00f3n documentada de que los equipos cr\u00edticos y sistemas auxiliares cumplen con los requisitos necesarios antes de iniciar la validaci\u00f3n de procesos.\n   - Incluye cuatro tipos de calificaci\u00f3n:\n     - **Design Qualification (DQ)**: Verifica la adecuaci\u00f3n del dise\u00f1o propuesto.\n     - **Installation Qualification (IQ)**: Verifica que la instalaci\u00f3n cumpla con el dise\u00f1o aprobado y recomendaciones del fabricante.\n     - **Operational Qualification (OQ)**: Verifica que el equipo funcione como se espera dentro de los rangos operativos.\n     - **Performance Qualification (PQ)**: Verifica que los sistemas conectados funcionen de manera efectiva y reproducible.\n\n2. **Validaci\u00f3n de Procesos (Process Validation)**:\n   - Es la evidencia documentada de que un proceso puede operar dentro de par\u00e1metros establecidos para producir un producto intermedio o API que cumpla con especificaciones y atributos de calidad predeterminados.\n   - Se identifican tres enfoques para la validaci\u00f3n:\n     - **Validaci\u00f3n Prospectiva**: Preferida y debe completarse antes de la distribuci\u00f3n comercial del producto final.\n     - **Validaci\u00f3n Concurrente**: Se utiliza cuando no hay datos de corridas de producci\u00f3n replicadas disponibles.\n\n3. **Documentaci\u00f3n y Justificaci\u00f3n**:\n   - Se requiere un informe de validaci\u00f3n que resuma los resultados y comente sobre cualquier desviaci\u00f3n observada.\n   - Cualquier variaci\u00f3n del protocolo de validaci\u00f3n debe ser documentada con justificaci\u00f3n adecuada.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Ingredientes Farmac\u00e9uticos Activos (API)**: Sustancias que se utilizan en la producci\u00f3n de medicamentos.\n- **Proceso de Validaci\u00f3n**: Conjunto de actividades para asegurar que un proceso cumple con los est\u00e1ndares requeridos.\n\nEste resumen destaca la importancia de la calificaci\u00f3n y validaci\u00f3n en la producci\u00f3n farmac\u00e9utica, as\u00ed como los procedimientos y enfoques necesarios para garantizar la calidad y eficacia de los productos.", "excerpt_keywords": "Keywords: validaci\u00f3n de procesos, ingredientes farmac\u00e9uticos activos, calidad, par\u00e1metros cr\u00edticos, perfil de impurezas"}}, "1be8ffcc-306e-4c50-bf4a-d5d13bccd097": {"node_ids": ["613e0c61-f90c-41bc-9148-ee89351cceb9"], "metadata": {"page_label": "180", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 12.6 Periodic review of validated systems\n\n12.60 Systems and processes should be periodically evaluated to verify that they are still operating in a valid manner. Where no significant changes have been made to the system or process, and a quality review confirms that the system or process is consistently producing material meeting its specifications, there is normally no need for revalidation.\n\n# 12.7 Cleaning validation\n\n12.70 Cleaning procedures should normally be validated. In general, cleaning validation should be directed to those situations or process steps where contamination or carry-over of materials poses the greatest risk to API quality. For example, in early production it may be unnecessary to validate equipment cleaning procedures where residues are removed by subsequent purification steps.\n\n12.71 Validation of cleaning procedures should reflect actual equipment usage patterns. If various APIs or intermediates are manufactured in the same equipment and the equipment is cleaned by the same process, a representative intermediate or API can be selected for cleaning validation. This selection should be based on the solubility and difficulty of cleaning and the calculation of residue limits based on potency, toxicity and stability.\n\n12.72 The cleaning validation protocol should describe the equipment to be cleaned, procedures, materials, acceptable cleaning levels, parameters to be monitored and controlled and analytical methods. The protocol should also indicate the type of samples to be obtained and how they are collected and labelled.\n\n12.73 Sampling should include swabbing, rinsing or alternative methods (e.g. direct extraction), as appropriate, to detect both insoluble and soluble residues. The sampling methods used should be capable of quantitatively measuring levels of residues remaining on the equipment surfaces after cleaning. Swab sampling may be impractical when product contact surfaces are not easily accessible due to equipment design and/or process limitations (e.g. inner surfaces of hoses, transfer pipes, reactor tanks with small ports for handling toxic materials and small intricate equipment such as micronizers and microfluidizers).\n\n12.74 Validated analytical methods with the sensitivity to detect residues or contaminants should be used. The detection limit for each analytical method should be sufficiently sensitive to detect the established acceptable limits.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS aborda la revisi\u00f3n peri\u00f3dica de sistemas validados y la validaci\u00f3n de procedimientos de limpieza en la producci\u00f3n de ingredientes farmac\u00e9uticos activos (API). Se enfatiza la importancia de evaluar regularmente los sistemas para asegurar su validez y la necesidad de validar los procedimientos de limpieza, especialmente en situaciones donde hay un alto riesgo de contaminaci\u00f3n. Se detallan los aspectos que deben incluirse en un protocolo de validaci\u00f3n de limpieza, como la descripci\u00f3n del equipo, los procedimientos, los niveles de limpieza aceptables y los m\u00e9todos anal\u00edticos. Tambi\u00e9n se menciona la importancia de utilizar m\u00e9todos anal\u00edticos validados que sean sensibles para detectar residuos o contaminantes.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar al seleccionar un API o intermedio representativo para la validaci\u00f3n de limpieza?**\n   - La selecci\u00f3n debe basarse en la solubilidad y la dificultad de limpieza, as\u00ed como en el c\u00e1lculo de l\u00edmites de residuos considerando la potencia, toxicidad y estabilidad del material.\n\n2. **\u00bfCu\u00e1les son los m\u00e9todos de muestreo recomendados para la validaci\u00f3n de limpieza y qu\u00e9 desaf\u00edos pueden presentarse?**\n   - Los m\u00e9todos de muestreo incluyen swabbing, enjuague o m\u00e9todos alternativos como la extracci\u00f3n directa. Sin embargo, el muestreo por swabbing puede ser impr\u00e1ctico en superficies de contacto con el producto que no son f\u00e1cilmente accesibles debido al dise\u00f1o del equipo o limitaciones del proceso.\n\n3. **\u00bfQu\u00e9 elementos debe incluir un protocolo de validaci\u00f3n de limpieza?**\n   - El protocolo debe describir el equipo a limpiar, los procedimientos, los materiales, los niveles de limpieza aceptables, los par\u00e1metros a monitorear y controlar, los m\u00e9todos anal\u00edticos, as\u00ed como el tipo de muestras a obtener y c\u00f3mo se recolectan y etiquetan.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Validaci\u00f3n de Procesos:**\n   - Se discuten tres enfoques de validaci\u00f3n: prospectiva, concurrente y retrospectiva.\n   - La validaci\u00f3n retrospectiva se permite para procesos bien establecidos sin cambios significativos en la calidad del API.\n\n2. **Criterios para Validaci\u00f3n Retrospectiva:**\n   - Identificaci\u00f3n de atributos cr\u00edticos de calidad y par\u00e1metros cr\u00edticos del proceso.\n   - Establecimiento de criterios de aceptaci\u00f3n y controles en proceso.\n   - Ausencia de fallos significativos en el proceso o producto, excepto por errores de operador o fallos de equipo no relacionados con la idoneidad del equipo.\n   - Establecimiento de perfiles de impurezas para el API existente.\n\n3. **Selecci\u00f3n de Lotes para Validaci\u00f3n:**\n   - Los lotes seleccionados deben ser representativos de todos los lotes producidos durante el per\u00edodo de revisi\u00f3n.\n   - Se recomienda examinar entre 10 y 30 lotes consecutivos, aunque se puede justificar un n\u00famero menor.\n\n4. **Control y Monitoreo de Par\u00e1metros Cr\u00edticos:**\n   - Los par\u00e1metros cr\u00edticos del proceso deben ser controlados y monitoreados durante los estudios de validaci\u00f3n.\n   - Par\u00e1metros no relacionados con la calidad no necesitan ser incluidos en la validaci\u00f3n.\n\n5. **Confirmaci\u00f3n del Perfil de Impurezas:**\n   - La validaci\u00f3n del proceso debe confirmar que el perfil de impurezas del API est\u00e9 dentro de los l\u00edmites especificados y sea comparable o mejor que los datos hist\u00f3ricos.\n\n**Entidades:**\n\n- **API (Ingrediente Farmac\u00e9utico Activo):** Sustancia utilizada en la producci\u00f3n de medicamentos.\n- **FPP (Forma Farmac\u00e9utica del Producto):** Producto final que contiene el API.\n- **Par\u00e1metros Cr\u00edticos de Proceso:** Variables que afectan la calidad del producto.\n- **Perfiles de Impurezas:** Composici\u00f3n de impurezas en el API que debe ser controlada y validada.\n\nEste resumen destaca los aspectos esenciales de la validaci\u00f3n de procesos en la producci\u00f3n de API, enfatizando la importancia de criterios espec\u00edficos y el control de calidad.", "excerpt_keywords": "Keywords: validation, cleaning procedures, API quality, sampling methods, analytical methods"}}, "f56f935d-d01e-4553-bfaa-a44e5ce45602": {"node_ids": ["42aa6792-8a98-436f-8974-1cbd8f109a99"], "metadata": {"page_label": "181", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Validation of Analytical Methods\n\n12.8 **Validation of analytical methods**\n\n12.80 Analytical methods should be validated unless the method employed is included in the relevant pharmacopoeia or other recognized standard reference. The suitability of all testing methods used should nonetheless be verified under actual conditions of use and documented.\n\n12.81 Methods should be validated to include consideration of characteristics included within the ICH guidelines on validation of analytical methods. The degree of analytical validation performed should reflect the purpose of the analysis and the stage of the API production process.\n\n12.82 Appropriate qualification of analytical equipment should be considered before starting validation of analytical methods.\n\n12.83 Complete records should be maintained of any modification of a validated analytical method. Such records should include the reason for the modification and appropriate data to verify that the modification produces results that are as accurate and reliable as the established method.\n\n# Change Control\n\n13. **Change control**\n\n13.10 A formal change control system should be established to evaluate all changes that may affect the production and control of the intermediate or API.\n\n13.11 Written procedures should cover the identification, documentation, appropriate review, and approval of changes in raw materials, specifications,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a formularlas:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda la validaci\u00f3n de m\u00e9todos anal\u00edticos y el control de cambios en la producci\u00f3n de ingredientes farmac\u00e9uticos activos (API). Se enfatiza la necesidad de validar m\u00e9todos anal\u00edticos, a menos que est\u00e9n incluidos en una farmacopea reconocida, y se requiere documentaci\u00f3n rigurosa de cualquier modificaci\u00f3n a estos m\u00e9todos. Adem\u00e1s, se establece la importancia de un sistema formal de control de cambios para gestionar cualquier alteraci\u00f3n que pueda afectar la producci\u00f3n y el control de los API.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 caracter\u00edsticas deben considerarse al validar m\u00e9todos anal\u00edticos seg\u00fan las pautas de la ICH?**\n   - Esta pregunta se centra en los criterios espec\u00edficos que deben tenerse en cuenta durante la validaci\u00f3n, que no se detallan en otros documentos.\n\n2. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para las modificaciones de un m\u00e9todo anal\u00edtico validado?**\n   - Esta pregunta busca informaci\u00f3n sobre los requisitos espec\u00edficos de documentaci\u00f3n que deben cumplirse al modificar un m\u00e9todo, lo cual es crucial para mantener la integridad del proceso anal\u00edtico.\n\n3. **\u00bfCu\u00e1les son los pasos clave que deben seguirse en un sistema de control de cambios formal seg\u00fan el documento?**\n   - Esta pregunta se enfoca en los procedimientos espec\u00edficos que deben implementarse para gestionar cambios en la producci\u00f3n y control de API, lo que puede no estar claramente definido en otras fuentes. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n detallada y espec\u00edfica que se encuentra en el contexto proporcionado y que puede no estar disponible en otros documentos.", "prev_section_summary": "### Temas Clave\n\n1. **Revisi\u00f3n Peri\u00f3dica de Sistemas Validados**:\n   - Importancia de evaluar regularmente los sistemas y procesos para asegurar que operan de manera v\u00e1lida.\n   - No es necesaria la revalidaci\u00f3n si no hay cambios significativos y se confirma que el sistema produce material que cumple con las especificaciones.\n\n2. **Validaci\u00f3n de Procedimientos de Limpieza**:\n   - Necesidad de validar los procedimientos de limpieza, especialmente en situaciones de alto riesgo de contaminaci\u00f3n.\n   - La validaci\u00f3n debe reflejar los patrones de uso real del equipo.\n\n3. **Selecci\u00f3n de APIs o Intermedios para Validaci\u00f3n**:\n   - La selecci\u00f3n debe basarse en la solubilidad, dificultad de limpieza y l\u00edmites de residuos considerando potencia, toxicidad y estabilidad.\n\n4. **Protocolo de Validaci\u00f3n de Limpieza**:\n   - Debe incluir descripci\u00f3n del equipo, procedimientos, materiales, niveles de limpieza aceptables, par\u00e1metros a monitorear y m\u00e9todos anal\u00edticos.\n   - Especificaci\u00f3n de tipos de muestras y su recolecci\u00f3n y etiquetado.\n\n5. **M\u00e9todos de Muestreo**:\n   - M\u00e9todos recomendados: swabbing, enjuague y extracci\u00f3n directa.\n   - Desaf\u00edos en el muestreo, especialmente en superficies de contacto de dif\u00edcil acceso.\n\n6. **M\u00e9todos Anal\u00edticos**:\n   - Uso de m\u00e9todos anal\u00edticos validados con sensibilidad adecuada para detectar residuos o contaminantes.\n   - Importancia de establecer l\u00edmites de detecci\u00f3n que sean suficientemente sensibles.\n\n### Entidades\n\n- **Sistemas y Procesos**: Referidos a los sistemas validados en la producci\u00f3n de ingredientes farmac\u00e9uticos activos (API).\n- **API (Ingredientes Farmac\u00e9uticos Activos)**: Materiales cuya calidad debe ser protegida mediante validaci\u00f3n de limpieza.\n- **Protocolo de Validaci\u00f3n**: Documento que detalla los procedimientos y criterios para la validaci\u00f3n de limpieza.\n- **M\u00e9todos de Muestreo**: T\u00e9cnicas utilizadas para recolectar muestras y evaluar la limpieza del equipo.\n- **M\u00e9todos Anal\u00edticos**: T\u00e9cnicas utilizadas para detectar residuos o contaminantes en el equipo.", "excerpt_keywords": "Keywords: validation, analytical methods, change control, API production, documentation"}}, "803e6c34-755f-4637-88da-ccf8273bdaaf": {"node_ids": ["c3c618da-1605-47e6-80fa-e6ce94204ef4"], "metadata": {"page_label": "182", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 13.12 \nAny proposals for relevant changes to GMP should be drafted, reviewed and approved by the appropriate organizational units and reviewed and approved by the quality unit(s).\n\n13.13 \nThe potential impact of the proposed change on the quality of the intermediate or API should be evaluated. A classification procedure may help in determining the level of testing, validation and documentation needed to justify changes to a validated process. Changes can be classified (e.g. as minor or major) depending on their nature and extent and the effects these changes may have on the process. Scientific judgement should be used to determine what additional testing and validation studies are appropriate to justify a change in a validated process.\n\n13.14 \nWhen implementing approved changes, measures should be taken to ensure that all documents affected by the changes are revised.\n\n13.15 \nAfter the change has been implemented there should be an evaluation of the first batches produced or tested under the change.\n\n13.16 \nThe potential for critical changes to affect established retest or expiry dates should be evaluated. If necessary, samples of the intermediate or API produced by the modified process can be placed on an accelerated stability programme and/or can be added to the stability monitoring programme.\n\n13.17 \nManufacturers of the current dosage form should be notified of changes from established production and process control procedures that can impact the quality of the API.\n\n# 14. Rejection and reuse of materials\n\n## 14.1 Rejection\n\n14.10 \nIntermediates and APIs failing to meet established specifications should be identified as such and quarantined. These intermediates or APIs can be reprocessed or reworked as described below. The final disposition of rejected materials should be recorded.\n\n## 14.2 Reprocessing\n\n14.20 \nIntroducing an intermediate or API, including one that does not conform to standards or specifications, back into the process and reprocessing by repeating a crystallization step or other appropriate chemical or physical manipulation steps (e.g. distillation, filtration,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en las Buenas Pr\u00e1cticas de Manufactura (GMP) relacionadas con la gesti\u00f3n de cambios en la producci\u00f3n de intermediarios y principios activos (API). Se discuten los procedimientos para evaluar el impacto de los cambios propuestos en la calidad del producto, la clasificaci\u00f3n de los cambios como menores o mayores, la necesidad de revisar documentos afectados, y la evaluaci\u00f3n de lotes producidos bajo los cambios. Tambi\u00e9n se aborda el rechazo y la reutilizaci\u00f3n de materiales que no cumplen con las especificaciones, as\u00ed como el proceso de reprocesamiento de estos materiales.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se utilizan para clasificar un cambio en el proceso de producci\u00f3n como menor o mayor, y c\u00f3mo afecta esto a los requisitos de validaci\u00f3n y documentaci\u00f3n?**\n   - Esta pregunta busca detalles sobre el proceso de clasificaci\u00f3n de cambios y su impacto en la gesti\u00f3n de calidad, que no se detalla expl\u00edcitamente en otros documentos.\n\n2. **\u00bfCu\u00e1les son los pasos espec\u00edficos que deben seguirse para garantizar que todos los documentos afectados por un cambio aprobado sean revisados y actualizados?**\n   - Esta pregunta se centra en el procedimiento pr\u00e1ctico de revisi\u00f3n de documentos, que puede no estar claramente definido en otras fuentes.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar si un cambio cr\u00edtico afecta las fechas de rean\u00e1lisis o caducidad de un API, y c\u00f3mo se implementa un programa de estabilidad acelerada?**\n   - Esta pregunta busca informaci\u00f3n sobre las acciones espec\u00edficas que deben tomarse en respuesta a cambios cr\u00edticos, as\u00ed como detalles sobre la implementaci\u00f3n de programas de estabilidad, que pueden no estar disponibles en otros contextos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### Temas Clave:\n\n1. **Validaci\u00f3n de M\u00e9todos Anal\u00edticos**:\n   - La validaci\u00f3n de m\u00e9todos anal\u00edticos es esencial, salvo que el m\u00e9todo est\u00e9 en una farmacopea reconocida.\n   - Se debe verificar la idoneidad de los m\u00e9todos de prueba en condiciones reales de uso.\n   - La validaci\u00f3n debe considerar las caracter\u00edsticas de las pautas de la ICH y debe adaptarse al prop\u00f3sito del an\u00e1lisis y la etapa del proceso de producci\u00f3n del API.\n   - Es necesario calificar adecuadamente el equipo anal\u00edtico antes de iniciar la validaci\u00f3n.\n   - Se deben mantener registros completos de cualquier modificaci\u00f3n a un m\u00e9todo anal\u00edtico validado, incluyendo la raz\u00f3n de la modificaci\u00f3n y datos que respalden la precisi\u00f3n y fiabilidad de los resultados.\n\n2. **Control de Cambios**:\n   - Se debe establecer un sistema formal de control de cambios para evaluar cualquier alteraci\u00f3n que pueda afectar la producci\u00f3n y control de intermediarios o APIs.\n   - Las procedimientos escritos deben abarcar la identificaci\u00f3n, documentaci\u00f3n, revisi\u00f3n y aprobaci\u00f3n de cambios en materias primas y especificaciones.\n\n#### Entidades:\n\n- **M\u00e9todos Anal\u00edticos**: T\u00e9cnicas utilizadas para analizar la calidad y composici\u00f3n de los ingredientes farmac\u00e9uticos activos.\n- **Farmacopea**: Compendio de est\u00e1ndares de calidad para medicamentos.\n- **ICH (International Council for Harmonisation)**: Organizaci\u00f3n que establece pautas para la validaci\u00f3n de m\u00e9todos anal\u00edticos.\n- **API (Active Pharmaceutical Ingredient)**: Ingrediente farmac\u00e9utico activo utilizado en la producci\u00f3n de medicamentos.\n- **Sistema de Control de Cambios**: Proceso formal para gestionar y documentar cambios en la producci\u00f3n y control de APIs.\n\nEste resumen destaca la importancia de la validaci\u00f3n y el control de cambios en la producci\u00f3n de ingredientes farmac\u00e9uticos, asegurando la calidad y fiabilidad de los m\u00e9todos anal\u00edticos utilizados.", "excerpt_keywords": "Keywords: GMP, API, quality control, reprocessing, validation"}}, "5fbe75ba-4128-4c92-8068-9ec28dac270e": {"node_ids": ["c2d1e1e3-e988-40c3-ad61-ede9641000f3"], "metadata": {"page_label": "183", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "chromatography, milling) that are part of the established manufacturing process is generally considered acceptable. However, if such reprocessing is used for a majority of batches it should be included as part of the standard manufacturing process.\n\n14.21 Continuation of a process step after an in-process control test has shown that the step is incomplete is considered to be part of the normal process. This is not considered to be reprocessing.\n\n14.22 Introducing unreacted material back into a process and repeating a chemical reaction is considered to be reprocessing unless it is part of the established process. Such reprocessing should be preceded by careful evaluation to ensure that the quality of the intermediate or API is not adversely affected due to the potential formation of by-products and overreacted materials.\n\n## 14.3 Reworking\n\n14.30 Before a decision is taken to rework batches that do not conform to established standards or specifications, an investigation into the reason for non-conformance should be performed.\n\n14.31 Batches that have been reworked should be subjected to appropriate evaluation, testing, stability testing if warranted and documentation to show that the reworked product is of equivalent quality to that produced by the original process. Concurrent validation is often the appropriate validation approach for rework procedures. This allows a protocol to define the rework procedure, how it will be carried out and the expected results. If there is only one batch to be reworked, then a report can be written and the batch released once it is found to be acceptable.\n\n14.32 Procedures should provide for comparing the impurity profile of each reworked batch with batches manufactured by the established process. Where routine analytical methods are inadequate to characterize the reworked batch, additional methods should be used.\n\n## 14.4 Recovery of materials and solvents\n\n14.40 Recovery (e.g. from mother liquor or filtrates) of reactants, intermediates or the API is considered acceptable, provided that approved procedures exist for the recovery and the recovered materials meet specifications suitable for their intended use.\n\n14.41 Solvents can be recovered and reused in the same processes or in different processes, provided that the recovery procedures are controlled and monitored to ensure that solvents meet appropriate standards before reuse or comingling with other approved materials.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda aspectos relacionados con la fabricaci\u00f3n de productos farmac\u00e9uticos, espec\u00edficamente en lo que respecta a la reprocesamiento, reworking y recuperaci\u00f3n de materiales y solventes. Se establece que ciertas pr\u00e1cticas, como la continuaci\u00f3n de un proceso despu\u00e9s de un control de calidad o la recuperaci\u00f3n de reactantes, son aceptables bajo condiciones espec\u00edficas. Adem\u00e1s, se enfatiza la importancia de la evaluaci\u00f3n y documentaci\u00f3n adecuada para asegurar que los productos reworkeados mantengan la calidad requerida.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 condiciones deben cumplirse para que la recuperaci\u00f3n de reactantes, intermedios o APIs sea considerada aceptable?**\n   - La recuperaci\u00f3n es aceptable siempre que existan procedimientos aprobados para el proceso de recuperaci\u00f3n y que los materiales recuperados cumplan con las especificaciones adecuadas para su uso previsto.\n\n2. **\u00bfCu\u00e1l es el enfoque recomendado para validar procedimientos de reworking?**\n   - Se sugiere el uso de la validaci\u00f3n concurrente, que permite definir un protocolo para el procedimiento de reworking, incluyendo c\u00f3mo se llevar\u00e1 a cabo y los resultados esperados. Esto incluye la evaluaci\u00f3n y documentaci\u00f3n de que el producto reworkeado es de calidad equivalente al producido por el proceso original.\n\n3. **\u00bfQu\u00e9 pasos deben seguirse antes de decidir reworkear un lote que no cumple con los est\u00e1ndares establecidos?**\n   - Antes de tomar la decisi\u00f3n de reworkear, se debe realizar una investigaci\u00f3n para determinar la raz\u00f3n de la no conformidad. Adem\u00e1s, los lotes reworkeados deben ser evaluados y sometidos a pruebas adecuadas para asegurar que cumplen con los est\u00e1ndares de calidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Gesti\u00f3n de Cambios en GMP**:\n   - Propuestas de cambios en las Buenas Pr\u00e1cticas de Manufactura (GMP) deben ser redactadas, revisadas y aprobadas por unidades organizativas y unidades de calidad.\n   - Evaluaci\u00f3n del impacto de los cambios propuestos en la calidad de intermediarios y principios activos (API).\n   - Clasificaci\u00f3n de cambios como menores o mayores, basada en su naturaleza y efectos en el proceso, lo que determina los requisitos de pruebas, validaci\u00f3n y documentaci\u00f3n.\n\n2. **Documentaci\u00f3n y Revisi\u00f3n**:\n   - Asegurar que todos los documentos afectados por cambios aprobados sean revisados y actualizados.\n   - Evaluaci\u00f3n de los primeros lotes producidos o probados bajo los cambios implementados.\n\n3. **Estabilidad y Fechas de Caducidad**:\n   - Evaluaci\u00f3n del impacto de cambios cr\u00edticos en las fechas de rean\u00e1lisis o caducidad de los API.\n   - Posibilidad de colocar muestras de intermediarios o API en un programa de estabilidad acelerada o en un programa de monitoreo de estabilidad.\n\n4. **Rechazo y Reprocesamiento de Materiales**:\n   - Identificaci\u00f3n y cuarentena de intermediarios y API que no cumplen con las especificaciones.\n   - Registro de la disposici\u00f3n final de materiales rechazados.\n   - Proceso de reprocesamiento de materiales que no cumplen con los est\u00e1ndares, incluyendo pasos como cristalizaci\u00f3n, destilaci\u00f3n y filtraci\u00f3n.\n\n### Entidades Clave\n- **Organizaciones**: Unidades organizativas y unidades de calidad.\n- **Materiales**: Intermediarios y principios activos (API).\n- **Procesos**: Cambios en producci\u00f3n y control de procesos, rean\u00e1lisis, caducidad, estabilidad.\n- **Documentaci\u00f3n**: Documentos afectados por cambios, registros de disposici\u00f3n de materiales rechazados. \n\nEste resumen abarca los aspectos fundamentales de la gesti\u00f3n de cambios en GMP, el manejo de documentos, la estabilidad de productos y el tratamiento de materiales rechazados.", "excerpt_keywords": "Keywords: reprocessing, reworking, recovery, quality control, pharmaceutical manufacturing"}}, "7c651d92-d9ad-4187-915d-eac8f6283d6f": {"node_ids": ["4f05f4fc-0adc-4b6e-b1c8-92187d3e83be"], "metadata": {"page_label": "184", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 14.5 Returns\n\n14.50 Returned intermediates or APIs should be identified as such and quarantined.\n\n14.51 If the conditions under which returned intermediates or APIs have been stored or shipped before or during their return, or the condition of their containers casts doubt on their quality, the returned intermediates or APIs should be reprocessed, reworked or destroyed, as appropriate.\n\n14.52 Records of returned intermediates or APIs should be maintained. For each return, documentation should include:\n\n- name and address of the consignee;\n- intermediate or API, batch number and quantity returned;\n- reason for return; and\n- use or disposal of the returned intermediate or API.\n\n# 15. Complaints and recalls\n\n15.10 All quality-related complaints, whether received orally or in writing, should be recorded and investigated according to a written procedure.\n\n15.11 Complaint records should include:\n\n- name and address of complainant;\n- name (and, where appropriate, title) and telephone number of person submitting the complaint;\n- nature of the complaint (including name and batch number of the API);\n- date the complaint was received;\n- action initially taken (including dates and identity of person taking the action);\n- any follow-up action taken;\n- response provided to the originator of complaint (including date on which the response was sent); and\n- final decision on intermediate or API batch or lot.\n\n15.12 Records of complaints should be retained in order to evaluate trends, product-related frequencies and severity with a view to taking additional, and if appropriate, immediate corrective action.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las directrices sobre el manejo de intermediarios y principios activos (APIs) devueltos, as\u00ed como la gesti\u00f3n de quejas y retiradas de productos. Se enfatiza la importancia de identificar y poner en cuarentena los productos devueltos, as\u00ed como la necesidad de mantener registros detallados de las devoluciones y quejas para garantizar la calidad y la seguridad de los productos farmac\u00e9uticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 acciones deben tomarse si las condiciones de almacenamiento o env\u00edo de los intermediarios o APIs devueltos generan dudas sobre su calidad?**\n   - Respuesta: Si las condiciones de almacenamiento o env\u00edo de los intermediarios o APIs devueltos generan dudas sobre su calidad, estos deben ser reprocesados, retrabajados o destruidos, seg\u00fan corresponda.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la documentaci\u00f3n de cada devoluci\u00f3n de intermediarios o APIs?**\n   - Respuesta: La documentaci\u00f3n de cada devoluci\u00f3n debe incluir el nombre y direcci\u00f3n del consignatario, el nombre del intermediario o API, el n\u00famero de lote y la cantidad devuelta, la raz\u00f3n de la devoluci\u00f3n y el uso o disposici\u00f3n del intermediario o API devuelto.\n\n3. **\u00bfQu\u00e9 elementos deben registrarse en los registros de quejas relacionadas con la calidad de los productos?**\n   - Respuesta: Los registros de quejas deben incluir el nombre y direcci\u00f3n del reclamante, el nombre y n\u00famero de tel\u00e9fono de la persona que presenta la queja, la naturaleza de la queja (incluyendo el nombre y n\u00famero de lote del API), la fecha en que se recibi\u00f3 la queja, las acciones iniciales tomadas, cualquier acci\u00f3n de seguimiento, la respuesta proporcionada al reclamante y la decisi\u00f3n final sobre el lote o lote del intermediario o API.", "prev_section_summary": "### Temas Clave\n\n1. **Reprocesamiento**: Se considera aceptable la continuaci\u00f3n de ciertos pasos del proceso de fabricaci\u00f3n, como la cromatograf\u00eda y el fresado, siempre que no se utilicen de manera excesiva y se integren en el proceso est\u00e1ndar. La introducci\u00f3n de material no reaccionado y la repetici\u00f3n de reacciones qu\u00edmicas se consideran reprocesamiento, que debe ser evaluado cuidadosamente.\n\n2. **Reworking (Reprocesamiento de lotes)**: Antes de reworkear lotes que no cumplen con los est\u00e1ndares, es necesario investigar la causa de la no conformidad. Los lotes reworkeados deben ser evaluados y documentados para asegurar que su calidad sea equivalente a la del proceso original. Se recomienda la validaci\u00f3n concurrente para definir los procedimientos de reworking.\n\n3. **Recuperaci\u00f3n de materiales y solventes**: La recuperaci\u00f3n de reactantes, intermedios o APIs es aceptable si existen procedimientos aprobados y los materiales recuperados cumplen con las especificaciones necesarias. Los solventes tambi\u00e9n pueden ser recuperados y reutilizados, siempre que se controlen y monitoreen adecuadamente los procedimientos de recuperaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices sobre la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Reactantes, Intermedios, API**: Sustancias involucradas en el proceso de fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Procedimientos aprobados**: Normativas que deben seguirse para asegurar la calidad y la seguridad en el proceso de recuperaci\u00f3n y reworking.\n- **Validaci\u00f3n concurrente**: M\u00e9todo recomendado para validar procedimientos de reworking, asegurando que se cumplan los est\u00e1ndares de calidad.\n\n### Resumen\n\nEl documento de la OMS establece directrices sobre el reprocesamiento, reworking y recuperaci\u00f3n de materiales en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de seguir procedimientos aprobados y realizar evaluaciones rigurosas para garantizar que los productos reworkeados y los materiales recuperados mantengan la calidad adecuada.", "excerpt_keywords": "Keywords: returns, intermediates, APIs, complaints, quality management"}}, "77cb5145-cc16-4059-9b3e-b63880715840": {"node_ids": ["07f992cf-8567-46b0-b17f-f97f47bdbd05"], "metadata": {"page_label": "185", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "15.13 There should be a written procedure that defines the circumstances under which a recall of an intermediate or API should be considered.\n\n15.14 The recall procedure should designate who should be involved in evaluating the information, how a recall should be initiated, who should be informed about the recall and how the recalled material should be treated.\n\n15.15 In the event of a serious or potentially life-threatening situation, local, national and/or international authorities should be informed and their advice sought.\n\n## 16. Contract manufacturers (including laboratories)\n\n16.10 All contract manufacturers (including laboratories) should comply with GMP defined in this guide. Special consideration should be given to the prevention of cross-contamination and to maintaining traceability.\n\n16.11 Contract manufacturers (including laboratories) should be evaluated by the contract giver to ensure GMP compliance of the specific operations taking place at the contract sites.\n\n16.12 There should be a written and approved contract or formal agreement between the contract giver and the contract acceptor that defines in detail the GMP responsibilities, including the quality measures, of each party.\n\n16.13 The contract should permit the contract giver to audit the contract acceptor\u2019s facilities for compliance with GMP.\n\n16.14 Where subcontracting is allowed the contract acceptor should not pass to a third party any of the work entrusted to him or her under the contract without the contract giver\u2019s prior evaluation and approval of the arrangements.\n\n16.15 Manufacturing and laboratory records should be kept at the site where the activity takes place and be readily available.\n\n16.16 Changes in the process, equipment, test methods, specifications or other contractual requirements should not be made unless the contract giver is informed and approves the changes.\n\n## 17. Agents, brokers, traders, distributors, repackers and relabellers\n\n### 17.1 Applicability\n\n17.10 This section applies to any party other than the original manufacturer who may trade and/or take possession of, repack, relabel, manipulate, distribute or store an API or intermediate.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda procedimientos y regulaciones relacionados con la gesti\u00f3n de productos farmac\u00e9uticos, espec\u00edficamente en lo que respecta a la retirada de productos intermedios o de ingredientes farmac\u00e9uticos activos (API), as\u00ed como las responsabilidades de los fabricantes contratados y otros actores en la cadena de suministro. Se enfatiza la importancia de tener procedimientos escritos para las retiradas, la evaluaci\u00f3n de la conformidad con las Buenas Pr\u00e1cticas de Manufactura (GMP), y la necesidad de contratos claros que definan las responsabilidades de cada parte involucrada.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse en el procedimiento de retirada de un API o intermedio, seg\u00fan el documento?**\n   - El documento establece que debe haber un procedimiento escrito que defina las circunstancias para considerar una retirada, qui\u00e9n evaluar\u00e1 la informaci\u00f3n, c\u00f3mo se iniciar\u00e1 la retirada, qui\u00e9n ser\u00e1 informado y c\u00f3mo se tratar\u00e1 el material retirado.\n\n2. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas que deben incluirse en el contrato entre el contratante y el contratista en relaci\u00f3n con las GMP?**\n   - El contrato debe detallar las responsabilidades de GMP de cada parte, incluyendo las medidas de calidad, y debe permitir que el contratante audite las instalaciones del contratista para verificar el cumplimiento de las GMP.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse para que un contratista pueda subcontratar parte de su trabajo seg\u00fan el documento?**\n   - El contratista no puede pasar el trabajo a un tercero sin la evaluaci\u00f3n y aprobaci\u00f3n previa del contratante sobre los arreglos de subcontrataci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Devoluciones de Intermediarios y APIs**:\n   - Identificaci\u00f3n y cuarentena de productos devueltos.\n   - Evaluaci\u00f3n de las condiciones de almacenamiento y env\u00edo para determinar la calidad.\n   - Procedimientos para reprocesar, retrabajar o destruir productos devueltos si hay dudas sobre su calidad.\n   - Mantenimiento de registros detallados de las devoluciones, incluyendo informaci\u00f3n del consignatario, detalles del producto y razones de la devoluci\u00f3n.\n\n2. **Quejas y Retiradas de Productos**:\n   - Registro y an\u00e1lisis de quejas relacionadas con la calidad de los productos.\n   - Procedimientos escritos para investigar quejas, ya sean orales o escritas.\n   - Documentaci\u00f3n necesaria para los registros de quejas, que incluye informaci\u00f3n del reclamante, naturaleza de la queja, acciones tomadas y decisiones finales.\n   - Importancia de conservar registros de quejas para evaluar tendencias y tomar acciones correctivas.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Intermediarios**: Productos farmac\u00e9uticos que pueden ser devueltos.\n- **Principios Activos (APIs)**: Sustancias que pueden ser devueltas y que requieren un manejo espec\u00edfico.\n- **Consignatario**: Persona o entidad a la que se env\u00edan los productos.\n- **Reclamante**: Persona que presenta una queja sobre un producto.\n- **Registros de Quejas**: Documentaci\u00f3n que se mantiene para evaluar la calidad y seguridad de los productos. \n\nEste resumen destaca la importancia de los procedimientos adecuados para el manejo de devoluciones y quejas en el contexto de la calidad farmac\u00e9utica.", "excerpt_keywords": "Keywords: recall procedure, contract manufacturers, GMP compliance, pharmaceutical quality, intermediates"}}, "9331b45e-367f-4386-a7fe-37e5d68d27c4": {"node_ids": ["899f9f44-09a8-4e22-95d0-d250ad1ff4c2"], "metadata": {"page_label": "186", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 17.2 Traceability of distributed APIs and intermediates\n\n17.20 Agents, brokers, traders, distributors, repackers or relabellers should maintain complete traceability of the APIs and intermediates that they distribute. Documents that should be retained and available should include:\n\n- identity of original manufacturer;\n- address of original manufacturer;\n- purchase orders;\n- bills of lading (transportation documentation);\n- receipt documents;\n- name or designation of API or intermediate;\n- manufacturer\u2019s batch number;\n- transportation and distribution records;\n- all authentic certificates of analysis, including those of the original manufacturer; and\n- retest or expiry date.\n\n# 17.3 Quality management\n\n17.30 Agents, brokers, traders, distributors, repackers or relabellers should establish, document and implement an effective system of managing quality, as specified in section 2.\n\n# 17.4 Repackaging, relabelling and holding of APIs and intermediates\n\n17.40 Repackaging, relabelling and holding of APIs and intermediates should be performed under appropriate GMP controls as stipulated in this guide, to avoid mix-ups and loss of API or intermediate identity or purity.\n\n17.41 Repackaging should be conducted under appropriate environmental conditions to avoid contamination and cross-contamination.\n\n# 17.5 Stability\n\n17.50 Stability studies to justify assigned expiration or retest dates should be conducted if the API or intermediate is repackaged in a different type of container than that used by the manufacturer of the API or intermediate.\n\n# 17.6 Transfer of information\n\n17.60 Agents, brokers, distributors, repackers or relabellers should transfer all quality or regulatory information received from the manufacturer.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la trazabilidad, gesti\u00f3n de calidad, y el manejo de APIs (ingredientes farmac\u00e9uticos activos) e intermedios en la cadena de distribuci\u00f3n. Se enfatiza la importancia de mantener registros completos y precisos, realizar repacking y relabeling bajo buenas pr\u00e1cticas de manufactura (GMP), y llevar a cabo estudios de estabilidad para garantizar la calidad y seguridad de los productos farmac\u00e9uticos.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 documentos espec\u00edficos deben mantener los agentes y distribuidores para asegurar la trazabilidad de los APIs e intermedios?**\n   - Respuesta: Los agentes, brokers, traders, distribuidores, repackers o relabellers deben mantener documentos como la identidad y direcci\u00f3n del fabricante original, \u00f3rdenes de compra, documentos de transporte (bills of lading), recibos, nombre o designaci\u00f3n del API o intermedio, n\u00famero de lote del fabricante, registros de transporte y distribuci\u00f3n, certificados de an\u00e1lisis aut\u00e9nticos, y fechas de retest o expiraci\u00f3n.\n\n2. **\u00bfCu\u00e1les son las condiciones que deben cumplirse durante el repacking de APIs e intermedios para evitar problemas de calidad?**\n   - Respuesta: El repacking debe realizarse bajo controles de buenas pr\u00e1cticas de manufactura (GMP) para evitar confusiones y p\u00e9rdida de identidad o pureza del API o intermedio. Adem\u00e1s, debe llevarse a cabo en condiciones ambientales adecuadas para prevenir la contaminaci\u00f3n y la contaminaci\u00f3n cruzada.\n\n3. **\u00bfQu\u00e9 tipo de estudios se requieren si un API o intermedio se repackaged en un contenedor diferente al utilizado por el fabricante?**\n   - Respuesta: Se deben realizar estudios de estabilidad para justificar las fechas de expiraci\u00f3n o retest asignadas si el API o intermedio se repackaged en un tipo de contenedor diferente al que utiliz\u00f3 el fabricante original.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Procedimiento de Retirada de Productos**:\n   - Importancia de tener un procedimiento escrito que defina las circunstancias para considerar la retirada de un intermedio o ingrediente farmac\u00e9utico activo (API).\n   - Designaci\u00f3n de responsables para evaluar la informaci\u00f3n, iniciar la retirada, informar a las partes pertinentes y tratar el material retirado.\n   - En situaciones graves o potencialmente mortales, se debe informar a las autoridades locales, nacionales e internacionales y buscar su consejo.\n\n2. **Fabricantes Contratados**:\n   - Todos los fabricantes contratados, incluidos laboratorios, deben cumplir con las Buenas Pr\u00e1cticas de Manufactura (GMP).\n   - Evaluaci\u00f3n de los fabricantes contratados por parte del contratante para asegurar el cumplimiento de las GMP en las operaciones espec\u00edficas.\n   - Necesidad de un contrato escrito y aprobado que detalle las responsabilidades de GMP y las medidas de calidad de cada parte.\n   - Permiso para que el contratante audite las instalaciones del contratista para verificar el cumplimiento de las GMP.\n   - Restricciones sobre la subcontrataci\u00f3n, donde el contratista no puede transferir trabajo a un tercero sin la evaluaci\u00f3n y aprobaci\u00f3n del contratante.\n\n3. **Registros y Cambios**:\n   - Los registros de fabricaci\u00f3n y laboratorio deben mantenerse en el sitio de la actividad y estar f\u00e1cilmente disponibles.\n   - Cambios en procesos, equipos, m\u00e9todos de prueba, especificaciones u otros requisitos contractuales deben ser aprobados por el contratante antes de su implementaci\u00f3n.\n\n4. **Actores en la Cadena de Suministro**:\n   - Secci\u00f3n aplicable a agentes, corredores, comerciantes, distribuidores, reempaquetadores y etiquetadores que manipulan, distribuyen o almacenan un API o intermedio.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices.\n- **Contratante**: Parte que contrata a un fabricante o laboratorio.\n- **Contratista**: Parte que realiza el trabajo bajo contrato.\n- **Autoridades Locales/Nacionales/Internacionales**: Entidades a las que se debe informar en caso de situaciones graves.\n- **API (Ingrediente Farmac\u00e9utico Activo)**: Sustancia que se utiliza en la fabricaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: traceability, APIs, quality management, repackaging, stability studies"}}, "fca78862-4dc1-41eb-afe9-d452b4a2507c": {"node_ids": ["3b40347a-139f-452d-85b8-ecbafb47a6c6"], "metadata": {"page_label": "187", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 17.6\n\nThe agent, broker, trader, distributor, repacker, or relabeller who supplies the API or intermediate to the customer should provide the name of the original manufacturer of the API or intermediate and the batch number(s) supplied.\n\nThe agent should also provide the identity of the manufacturer of the original API or intermediate to regulatory authorities upon request. The original manufacturer can respond to the regulatory authority directly or through its authorized agents, depending on the legal relationship between the authorized agents and the original manufacturer of the API or intermediate. (In this context \u201cauthorized\u201d refers to authorized by the manufacturer.)\n\nThe specific guidance for certificates of analysis included in section 11.4 should be met.\n\n## 17.7 Handling of complaints and recalls\n\nAgents, brokers, traders, distributors, repackers, or relabellers should maintain records of complaints and recalls as specified in section 15 for all complaints and recalls that come to their attention.\n\nIf the situation warrants, the agents, brokers, traders, distributors, repackers, or relabellers should review the complaint with the manufacturer of the original API or intermediate to determine whether any further action, either with other customers who may have received this API or intermediate or with the regulatory authority, or both, should be initiated. The investigation into the cause for the complaint or recall should be conducted and documented by the appropriate party.\n\nWhere a complaint is referred to the original manufacturer of the API or intermediate, the record maintained by the agents, brokers, traders, distributors, repackers, or relabellers should include any response received from the original manufacturer of the API or intermediate (including date and information provided).\n\n## 17.8 Handling of returns\n\nReturns should be handled as specified in section 14.5.3. The agents, brokers, traders, distributors, repackers, or relabellers should maintain documentation of returned APIs and intermediates.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre la responsabilidad de agentes, corredores, comerciantes, distribuidores, reacondicionadores y reetiquetadores en relaci\u00f3n con la gesti\u00f3n de ingredientes farmac\u00e9uticos activos (API) o intermedios. Se enfatiza la importancia de proporcionar informaci\u00f3n sobre el fabricante original y los n\u00fameros de lote, as\u00ed como la necesidad de mantener registros de quejas y retiradas de productos. Tambi\u00e9n se menciona la obligaci\u00f3n de manejar devoluciones de acuerdo con procedimientos espec\u00edficos y de documentar adecuadamente todas las interacciones relacionadas con quejas y devoluciones.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe proporcionar un agente o distribuidor al cliente sobre el API o intermedio suministrado?**\n   - Respuesta: El agente, corredor, comerciante, distribuidor, reacondicionador o reetiquetador debe proporcionar el nombre del fabricante original del API o intermedio y los n\u00fameros de lote suministrados.\n\n2. **\u00bfC\u00f3mo deben manejarse las quejas y retiradas de productos seg\u00fan las directrices?**\n   - Respuesta: Los agentes, corredores, comerciantes, distribuidores, reacondicionadores o reetiquetadores deben mantener registros de todas las quejas y retiradas, revisar las quejas con el fabricante original si es necesario, y documentar la investigaci\u00f3n sobre la causa de la queja o retirada.\n\n3. **\u00bfQu\u00e9 documentaci\u00f3n se requiere para las devoluciones de APIs e intermedios?**\n   - Respuesta: Se debe mantener documentaci\u00f3n de las APIs e intermedios devueltos, siguiendo las especificaciones establecidas en la secci\u00f3n 14.5.3 del documento.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Trazabilidad de APIs e Intermedios**:\n   - Importancia de mantener registros completos para asegurar la trazabilidad en la distribuci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs) e intermedios.\n   - Documentos esenciales incluyen:\n     - Identidad y direcci\u00f3n del fabricante original.\n     - \u00d3rdenes de compra y documentos de transporte.\n     - Registros de distribuci\u00f3n y certificados de an\u00e1lisis.\n\n2. **Gesti\u00f3n de Calidad**:\n   - Necesidad de establecer un sistema efectivo de gesti\u00f3n de calidad por parte de agentes, distribuidores y repackers.\n   - Documentaci\u00f3n y cumplimiento de est\u00e1ndares de calidad son fundamentales.\n\n3. **Reempaquetado y Reetiquetado**:\n   - El reempaquetado y reetiquetado deben realizarse bajo buenas pr\u00e1cticas de manufactura (GMP) para evitar confusiones y mantener la pureza del producto.\n   - Condiciones ambientales adecuadas son necesarias para prevenir contaminaci\u00f3n.\n\n4. **Estudios de Estabilidad**:\n   - Se requieren estudios de estabilidad si el API o intermedio se reempaqueta en un contenedor diferente al original, para justificar las fechas de expiraci\u00f3n o retest.\n\n5. **Transferencia de Informaci\u00f3n**:\n   - Es esencial que los agentes y distribuidores transfieran toda la informaci\u00f3n de calidad y regulatoria recibida del fabricante.\n\n### Entidades Clave:\n- **Agentes, Brokers, Traders, Distribuidores, Repackers, Relabellers**: Entidades responsables de la distribuci\u00f3n y manejo de APIs e intermedios.\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias utilizadas en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Documentos de Trazabilidad**: Incluyen \u00f3rdenes de compra, certificados de an\u00e1lisis, registros de transporte, etc.\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Normativas que aseguran la calidad y seguridad en la producci\u00f3n y manejo de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: APIs, complaints, recalls, documentation, manufacturers"}}, "62140cf6-9b36-4b04-ab11-59a5ed3c989e": {"node_ids": ["fed5070f-897c-4fab-83e3-f30cc9d33501"], "metadata": {"page_label": "188", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Specific guidance for APIs manufactured by cell culture/fermentation\n\n## 18.1 General\n\n18.10 Section 18 is intended to address specific controls for APIs or intermediates manufactured by cell culture or fermentation using natural or recombinant organisms and that have not been covered adequately in the previous sections. It is not intended to be a stand-alone section. In general, the GMP principles in the other sections of this document apply. Note that the principles of fermentation for \u201cclassical\u201d processes for production of small molecules and for processes using recombinant and non-recombinant organisms for production of proteins and/or polypeptides are the same, although the degree of control will differ. Where practical, this section will address these differences. In general, the degree of control for biotechnological processes used to produce proteins and polypeptides is greater than that for classical fermentation processes.\n\n18.11 The term \u201cbiotechnological process\u201d (biotech) refers to the use of cells or organisms that have been generated or modified by recombinant DNA, hybridoma or other technology to produce APIs. The APIs produced by biotechnological processes normally consist of high molecular weight substances, such as proteins and polypeptides, for which specific guidance is given in this Section. Certain APIs of low molecular weight, such as antibiotics, amino acids, vitamins, and carbohydrates, can also be produced by recombinant DNA technology. The level of control for these types of APIs is similar to that employed for classical fermentation.\n\n18.12 The term \u201cclassical fermentation\u201d refers to processes that use microorganisms existing in nature and/or modified by conventional methods (e.g. irradiation or chemical mutagenesis) to produce APIs. APIs produced by \u201cclassical fermentation\u201d are normally low molecular weight products such as antibiotics, amino acids, vitamins, and carbohydrates.\n\n18.13 Production of APIs or intermediates from cell culture or fermentation involves biological processes such as cultivation of cells or extraction and purification of material from living organisms. Note that there may be additional process steps, such as physicochemical modification, that are part of the manufacturing process. The raw materials used (media, buffer components) may provide the potential for growth of microbiological contaminants. Depending on the source, method of preparation, and the intended use of the API or intermediate, control of bioburden, viral\n\n----\n\n2 This section has been referred to the Expert Committee on Biological Standardization for discussion and consideration. Reproduced here but currently not adopted by the aforementioned Expert Committee.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nLa secci\u00f3n 18 del documento de la OMS se centra en las directrices espec\u00edficas para la fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs) mediante cultivos celulares o fermentaci\u00f3n. Se distingue entre procesos biotecnol\u00f3gicos, que utilizan organismos modificados gen\u00e9ticamente para producir sustancias de alto peso molecular como prote\u00ednas y polip\u00e9ptidos, y la fermentaci\u00f3n cl\u00e1sica, que utiliza microorganismos naturales o modificados convencionalmente para producir productos de bajo peso molecular como antibi\u00f3ticos y amino\u00e1cidos. La secci\u00f3n tambi\u00e9n aborda la importancia del control de contaminantes microbiol\u00f3gicos y virales en estos procesos.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las diferencias clave en el control de calidad entre los procesos biotecnol\u00f3gicos y la fermentaci\u00f3n cl\u00e1sica en la producci\u00f3n de APIs?**\n   - Esta pregunta busca detalles espec\u00edficos sobre c\u00f3mo var\u00edan los niveles de control en cada tipo de proceso, lo cual no se detalla en otras secciones del documento.\n\n2. **\u00bfQu\u00e9 tipos de contaminantes microbiol\u00f3gicos y virales deben ser controlados en la producci\u00f3n de APIs a partir de cultivos celulares o fermentaci\u00f3n, y c\u00f3mo se gestionan estos riesgos?**\n   - Esta pregunta se centra en los riesgos espec\u00edficos asociados con la producci\u00f3n de APIs en estos contextos y las estrategias de mitigaci\u00f3n, que pueden no estar ampliamente cubiertas en otras partes del documento.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al seleccionar los materiales crudos (medios, componentes de tampones) para la producci\u00f3n de APIs mediante fermentaci\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n sobre la selecci\u00f3n de materiales y su impacto en el proceso de producci\u00f3n, un aspecto que puede no ser evidente en otras secciones del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Responsabilidad de los Proveedores**:\n   - Los agentes, corredores, comerciantes, distribuidores, reacondicionadores y reetiquetadores deben proporcionar informaci\u00f3n sobre el fabricante original del ingrediente farmac\u00e9utico activo (API) o intermedio, as\u00ed como los n\u00fameros de lote correspondientes.\n\n2. **Interacci\u00f3n con Autoridades Regulatorias**:\n   - Los agentes deben estar preparados para identificar al fabricante original ante las autoridades regulatorias si se solicita. La comunicaci\u00f3n puede ser directa o a trav\u00e9s de agentes autorizados.\n\n3. **Manejo de Quejas y Retiradas**:\n   - Se requiere que los proveedores mantengan registros de quejas y retiradas de productos, revisen las quejas con el fabricante original cuando sea necesario, y documenten las investigaciones sobre las causas de quejas o retiradas.\n\n4. **Documentaci\u00f3n de Respuestas**:\n   - Cualquier respuesta del fabricante original a las quejas debe ser registrada, incluyendo la fecha y la informaci\u00f3n proporcionada.\n\n5. **Manejo de Devoluciones**:\n   - Las devoluciones de APIs e intermedios deben ser gestionadas de acuerdo con procedimientos espec\u00edficos, y se debe mantener documentaci\u00f3n adecuada de los productos devueltos.\n\n### Entidades Clave\n- **Agentes, Corredores, Comerciantes, Distribuidores, Reacondicionadores, Reetiquetadores**: Entidades responsables de la gesti\u00f3n y suministro de APIs e intermedios.\n- **Fabricante Original**: Entidad que produce el API o intermedio y que debe ser identificada en la documentaci\u00f3n.\n- **Autoridades Regulatorias**: Entidades que supervisan el cumplimiento de las normativas relacionadas con la producci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos. \n\nEste resumen destaca la importancia de la transparencia y la documentaci\u00f3n en la cadena de suministro de ingredientes farmac\u00e9uticos, as\u00ed como la necesidad de una comunicaci\u00f3n efectiva entre todas las partes involucradas.", "excerpt_keywords": "Keywords: APIs, cell culture, fermentation, biotechnological processes, quality control"}}, "191e621a-f529-470c-8830-bff208608998": {"node_ids": ["5fe23a0f-b011-4ed9-9106-3c87dfdd316a"], "metadata": {"page_label": "189", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "contamination, and/or endotoxins during manufacturing and monitoring of the process at appropriate stages may be necessary.\n\n18.14 Appropriate controls should be established at all stages of manufacturing to assure intermediate and/or API quality. While this guide starts at the cell culture/fermentation step, prior steps (e.g. cell banking) should be performed under appropriate process controls. This guide covers cell culture/fermentation from the point at which a vial of the cell bank is retrieved for use in manufacturing.\n\n18.15 Appropriate equipment and environmental controls should be used to minimize the risk of contamination. The acceptance criteria for quality of the environment and the frequency of monitoring should depend on the step in production and the production conditions (open, closed or contained systems).\n\n18.16 In general, process controls should take into account:\n\n\u2014 maintenance of the working cell bank (where appropriate);\n\u2014 proper inoculation and expansion of the culture;\n\u2014 control of the critical operating parameters during fermentation/cell culture;\n\u2014 monitoring of the process for cell growth, viability (for most cell culture processes) and productivity where appropriate;\n\u2014 harvest and purification procedures that remove cells, cellular debris and media components while protecting the intermediate or API from contamination (particularly of a microbiological nature) and from loss of quality;\n\u2014 monitoring of bioburden and, where needed, endotoxin levels at appropriate stages of production; and\n\u2014 viral safety concerns as described in ICH Guideline Q5A (2).\n\n18.17 Where appropriate, the removal of media components, host cell proteins, other process-related impurities, product-related impurities and contaminants should be demonstrated.\n\n### 18.2 Cell bank maintenance and record keeping\n\n18.20 Access to cell banks should be limited to authorized personnel.\n\n18.21 Cell banks should be maintained under storage conditions designed to maintain viability and prevent contamination.\n\n18.22 Records of the use of the vials from the cell banks and storage conditions should be maintained.\n\n18.23 Where appropriate, cell banks should be periodically monitored to determine suitability for use.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Controles en la fabricaci\u00f3n de productos biol\u00f3gicos**: El documento enfatiza la importancia de establecer controles apropiados en todas las etapas de la fabricaci\u00f3n de productos biol\u00f3gicos, comenzando desde el cultivo celular y la fermentaci\u00f3n, hasta la recolecci\u00f3n y purificaci\u00f3n del producto. Se menciona la necesidad de monitorear par\u00e1metros cr\u00edticos y asegurar la calidad del ambiente de producci\u00f3n.\n\n2. **Mantenimiento y registro de bancos celulares**: Se destaca la importancia de mantener los bancos celulares en condiciones adecuadas para preservar su viabilidad y prevenir la contaminaci\u00f3n. Adem\u00e1s, se requiere un registro detallado del uso de viales y las condiciones de almacenamiento, as\u00ed como monitoreos peri\u00f3dicos para asegurar la idoneidad de los bancos celulares.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios de aceptaci\u00f3n para la calidad del ambiente en la producci\u00f3n de cultivos celulares?**\n   - El documento indica que los criterios de aceptaci\u00f3n dependen del paso en la producci\u00f3n y de las condiciones de producci\u00f3n, ya sea en sistemas abiertos, cerrados o contenidos.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir para asegurar la calidad del producto intermedio o del API durante la cosecha y purificaci\u00f3n?**\n   - Se deben implementar procedimientos que eliminen c\u00e9lulas, debris celulares y componentes del medio, protegiendo al mismo tiempo el producto intermedio o API de la contaminaci\u00f3n, especialmente de naturaleza microbiol\u00f3gica, y de la p\u00e9rdida de calidad.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar para garantizar la seguridad viral en la producci\u00f3n de productos biol\u00f3gicos?**\n   - Se deben considerar las preocupaciones de seguridad viral seg\u00fan lo descrito en la Gu\u00eda ICH Q5A, lo que implica la implementaci\u00f3n de controles y monitoreos espec\u00edficos durante el proceso de fabricaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Control de Calidad en la Producci\u00f3n de APIs**: La secci\u00f3n aborda las directrices espec\u00edficas para el control de calidad de los ingredientes farmac\u00e9uticos activos (APIs) producidos mediante cultivos celulares o fermentaci\u00f3n, destacando que no es una secci\u00f3n independiente y que se basa en principios de Buenas Pr\u00e1cticas de Manufactura (GMP) de otras secciones.\n\n2. **Diferenciaci\u00f3n entre Procesos**: Se distingue entre procesos biotecnol\u00f3gicos, que utilizan organismos modificados gen\u00e9ticamente para producir sustancias de alto peso molecular (como prote\u00ednas y polip\u00e9ptidos), y la fermentaci\u00f3n cl\u00e1sica, que utiliza microorganismos naturales o modificados convencionalmente para producir productos de bajo peso molecular (como antibi\u00f3ticos y amino\u00e1cidos).\n\n3. **Control de Contaminantes**: Se enfatiza la importancia del control de contaminantes microbiol\u00f3gicos y virales en la producci\u00f3n de APIs, dado que los materiales crudos utilizados pueden ser fuentes de contaminaci\u00f3n.\n\n4. **Materiales Crudos**: Se menciona que la selecci\u00f3n de materiales crudos (medios y componentes de tampones) es crucial, ya que pueden influir en el crecimiento de contaminantes microbiol\u00f3gicos.\n\n### Entidades\n\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias producidas mediante cultivos celulares o fermentaci\u00f3n.\n- **Procesos Biotecnol\u00f3gicos**: M\u00e9todos que utilizan organismos modificados gen\u00e9ticamente para la producci\u00f3n de APIs de alto peso molecular.\n- **Fermentaci\u00f3n Cl\u00e1sica**: Procesos que utilizan microorganismos naturales o modificados convencionalmente para la producci\u00f3n de APIs de bajo peso molecular.\n- **Contaminantes Microbiol\u00f3gicos y Virales**: Riesgos asociados con la producci\u00f3n de APIs que deben ser controlados.\n- **Materiales Crudos**: Medios y componentes utilizados en la producci\u00f3n de APIs que pueden afectar la calidad del producto final.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos m\u00e1s relevantes de la secci\u00f3n, destacando la importancia de los controles espec\u00edficos en la producci\u00f3n de APIs mediante cultivos celulares y fermentaci\u00f3n.", "excerpt_keywords": "Keywords: contamination, cell culture, process controls, bioburden, viral safety"}}, "ddd4a719-0602-4533-bf33-6ee632116b76": {"node_ids": ["5e016980-41a7-4fee-a1dd-c773067f433f"], "metadata": {"page_label": "190", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 18.3 Cell culture/fermentation\n\n18.30 Where aseptic addition of cell substrates, media, buffers, and gases is needed, closed or contained systems should be used where possible. If the inoculation of the initial vessel or subsequent transfers or additions (media, buffers) are performed in open vessels, there should be controls and procedures in place to minimize the risk of contamination.\n\n18.31 Where the quality of the API can be affected by microbial contamination, manipulations using open vessels should be performed in a biosafety cabinet or similarly controlled environment.\n\n18.32 Personnel should be appropriately gowned and take special precautions handling the cultures.\n\n18.33 Critical operating parameters (for example temperature, pH, agitation rates, addition of gases, pressure) should be monitored to ensure consistency with the established process. Cell growth, viability (for most cell culture processes), and, where appropriate, productivity should also be monitored. Critical parameters will vary from one process to another, and for classical fermentation, certain parameters (cell viability, for example) may not need to be monitored.\n\n18.34 Cell culture equipment should be cleaned and sterilized after use. As appropriate, fermentation equipment should be cleaned, and sanitized or sterilized.\n\n18.35 Culture media should be sterilized before use when appropriate to protect the quality of the API.\n\n18.36 There should be appropriate procedures in place to detect contamination and determine the course of action to be taken. This should include procedures to determine the impact of the contamination on the product and those to decontaminate the equipment and return it to a condition to be used in subsequent batches. Foreign organisms observed during fermentation processes should be identified as appropriate and the effect of their presence on product quality should be assessed, if necessary. The results of such assessments should be taken into consideration in the disposition of the material produced.\n\n18.37 Records of contamination events should be maintained.\n\n18.38 Shared (multiproduct) equipment may warrant additional testing after cleaning between product campaigns, as appropriate, to minimize the risk of cross-contamination.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre las pr\u00e1cticas de cultivo celular y fermentaci\u00f3n, enfatizando la importancia de mantener condiciones as\u00e9pticas para evitar la contaminaci\u00f3n microbiana en la producci\u00f3n de ingredientes farmac\u00e9uticos activos (API). Se destacan procedimientos para el manejo de cultivos, la monitorizaci\u00f3n de par\u00e1metros cr\u00edticos, la limpieza y esterilizaci\u00f3n de equipos, y la gesti\u00f3n de eventos de contaminaci\u00f3n. Tambi\u00e9n se menciona la necesidad de mantener registros de contaminaci\u00f3n y realizar pruebas adicionales en equipos compartidos para minimizar el riesgo de contaminaci\u00f3n cruzada.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben implementarse para minimizar el riesgo de contaminaci\u00f3n al utilizar recipientes abiertos durante la inoculaci\u00f3n o transferencias en el cultivo celular?**\n   - Respuesta: Se deben establecer controles y procedimientos espec\u00edficos para minimizar el riesgo de contaminaci\u00f3n al realizar inoculaciones o transferencias en recipientes abiertos.\n\n2. **\u00bfCu\u00e1les son los par\u00e1metros cr\u00edticos que deben ser monitoreados durante el proceso de cultivo celular y c\u00f3mo pueden variar entre diferentes procesos?**\n   - Respuesta: Los par\u00e1metros cr\u00edticos incluyen temperatura, pH, tasas de agitaci\u00f3n, adici\u00f3n de gases y presi\u00f3n. Estos par\u00e1metros pueden variar de un proceso a otro, y en algunos casos, como en la fermentaci\u00f3n cl\u00e1sica, ciertos par\u00e1metros como la viabilidad celular pueden no ser necesarios de monitorear.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse si se detecta contaminaci\u00f3n en el proceso de fermentaci\u00f3n y c\u00f3mo se eval\u00faa su impacto en la calidad del producto?**\n   - Respuesta: Deben existir procedimientos para detectar la contaminaci\u00f3n y determinar el curso de acci\u00f3n, que incluye evaluar el impacto de la contaminaci\u00f3n en el producto y desinfectar el equipo para su uso en lotes posteriores. Los organismos extra\u00f1os observados deben ser identificados y su efecto en la calidad del producto evaluado, considerando los resultados en la disposici\u00f3n del material producido.", "prev_section_summary": "### Temas Clave\n\n1. **Controles en la Fabricaci\u00f3n**: Se enfatiza la necesidad de establecer controles apropiados en todas las etapas de la fabricaci\u00f3n de productos biol\u00f3gicos, desde el cultivo celular y la fermentaci\u00f3n hasta la cosecha y purificaci\u00f3n del producto. Esto incluye la monitorizaci\u00f3n de par\u00e1metros cr\u00edticos y la calidad del ambiente de producci\u00f3n.\n\n2. **Mantenimiento de Bancos Celulares**: Se destaca la importancia de mantener los bancos celulares en condiciones adecuadas para preservar su viabilidad y prevenir la contaminaci\u00f3n. Esto implica un acceso restringido a personal autorizado y un registro detallado del uso de los viales y las condiciones de almacenamiento.\n\n3. **Monitoreo y Control de Calidad**: Se requiere un monitoreo continuo de la calidad del ambiente y de los procesos, as\u00ed como la implementaci\u00f3n de procedimientos para eliminar contaminantes y asegurar la calidad del producto intermedio o del API.\n\n4. **Seguridad Viral**: Se deben considerar las preocupaciones de seguridad viral durante la producci\u00f3n, siguiendo las directrices establecidas en la Gu\u00eda ICH Q5A.\n\n### Entidades\n\n- **Bancos Celulares**: Almacenes de c\u00e9lulas que deben ser mantenidos y monitoreados adecuadamente.\n- **API (Ingrediente Farmac\u00e9utico Activo)**: Producto intermedio cuya calidad debe ser asegurada durante la fabricaci\u00f3n.\n- **Contaminantes**: Incluyen c\u00e9lulas, debris celulares, endotoxinas y otros impurezas que deben ser eliminados durante el proceso de producci\u00f3n.\n- **Gu\u00eda ICH Q5A**: Directrices que abordan la seguridad viral en la producci\u00f3n de productos biol\u00f3gicos.\n- **Condiciones de Producci\u00f3n**: Pueden ser sistemas abiertos, cerrados o contenidos, que afectan los criterios de aceptaci\u00f3n para la calidad del ambiente.\n\nEste resumen abarca los aspectos fundamentales y las entidades relevantes mencionadas en la secci\u00f3n del documento.", "excerpt_keywords": "Keywords: cell culture, fermentation, contamination control, aseptic techniques, API quality"}}, "240e099a-de09-487c-a152-fd7136922bba": {"node_ids": ["811d1803-1a7e-49f2-a486-85492a09df7f"], "metadata": {"page_label": "191", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 18.4 Harvesting, isolation and purification\n\n18.40 Harvesting steps, either to remove cells or cellular components or to collect cellular components after disruption, should be performed in equipment and areas designed to minimize the risk of contamination.\n\n18.41 Harvest and purification procedures that remove or inactivate the producing organism, cellular debris and media components (while minimizing degradation, contamination, and loss of quality) should be adequate to ensure that the intermediate or API is recovered with consistent quality.\n\n18.42 All equipment should be properly cleaned and, as appropriate, sanitized after use. Multiple successive batching without cleaning can be used if intermediate or API quality is not compromised.\n\n18.43 If open systems are used, purification should be performed under environmental conditions appropriate for the preservation of product quality.\n\n18.44 Additional controls, such as the use of dedicated chromatography resins or additional testing, may be appropriate if equipment is to be used for multiple products.\n\n# 18.5 Viral removal/inactivation steps\n\n18.50 See the ICH Guideline Q5A (2) for more specific information.\n\n18.51 Viral removal and viral inactivation steps are critical processing steps for some processes and should be performed within their validated parameters.\n\n18.52 Appropriate precautions should be taken to prevent potential viral contamination from pre-viral to post-viral removal/inactivation steps. Therefore, open processing should be performed in areas that are separate from other processing activities and have separate air handling units.\n\n18.53 The same equipment is not normally used for different purification steps. However, if the same equipment is to be used, the equipment should be appropriately cleaned and sanitized before reuse. Appropriate precautions should be taken to prevent potential virus carry-over (e.g. through equipment or environment) from previous steps.\n\n# 19. APIs for use in clinical trials\n\n## 19.1 General\n\n19.10 Not all the controls in the previous sections of this guide are appropriate for the manufacture of a new API for investigational use during", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda los procedimientos de cosecha, aislamiento y purificaci\u00f3n de productos farmac\u00e9uticos, enfatizando la importancia de minimizar la contaminaci\u00f3n y asegurar la calidad del producto intermedio o del principio activo (API). Se detallan las medidas necesarias para la eliminaci\u00f3n o inactivaci\u00f3n de virus, subrayando la necesidad de realizar estos pasos dentro de par\u00e1metros validados y en \u00e1reas separadas para evitar la contaminaci\u00f3n cruzada. Tambi\u00e9n se menciona que no todos los controles aplicables a la fabricaci\u00f3n de APIs son pertinentes para su uso en ensayos cl\u00ednicos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las condiciones ambientales recomendadas para realizar la purificaci\u00f3n en sistemas abiertos y por qu\u00e9 son importantes?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las condiciones ambientales necesarias para preservar la calidad del producto durante la purificaci\u00f3n en sistemas abiertos, que no se detalla en otras secciones del documento.\n\n2. **\u00bfQu\u00e9 medidas adicionales se pueden implementar si se utiliza el mismo equipo para m\u00faltiples productos durante el proceso de purificaci\u00f3n?**\n   - Esta pregunta se centra en las medidas espec\u00edficas que se pueden tomar para evitar la contaminaci\u00f3n cruzada cuando se reutiliza el equipo, lo cual es un aspecto cr\u00edtico en la producci\u00f3n farmac\u00e9utica.\n\n3. **\u00bfQu\u00e9 precauciones espec\u00edficas se deben tomar para prevenir la contaminaci\u00f3n viral durante las etapas de eliminaci\u00f3n/inactivaci\u00f3n de virus?**\n   - Esta pregunta busca detalles sobre las precauciones que deben implementarse para evitar la contaminaci\u00f3n viral, lo que es crucial para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.", "prev_section_summary": "### Temas Clave\n\n1. **Condiciones Asepticas**: Importancia de utilizar sistemas cerrados o contenidos para la adici\u00f3n as\u00e9ptica de sustratos celulares, medios, tampones y gases, minimizando el riesgo de contaminaci\u00f3n.\n\n2. **Manipulaciones en Vasos Abiertos**: Cuando se utilizan recipientes abiertos, se deben realizar en entornos controlados como cabinas de bioseguridad para proteger la calidad de los ingredientes farmac\u00e9uticos activos (API).\n\n3. **Precauciones del Personal**: El personal debe estar debidamente vestido y tomar precauciones especiales al manejar cultivos celulares.\n\n4. **Monitoreo de Par\u00e1metros Cr\u00edticos**: Se deben monitorear par\u00e1metros operativos cr\u00edticos (temperatura, pH, tasas de agitaci\u00f3n, adici\u00f3n de gases, presi\u00f3n) y, cuando sea apropiado, el crecimiento celular y la viabilidad.\n\n5. **Limpieza y Esterilizaci\u00f3n de Equipos**: Equipos de cultivo celular y fermentaci\u00f3n deben ser limpiados y esterilizados despu\u00e9s de su uso.\n\n6. **Esterilizaci\u00f3n de Medios de Cultivo**: Los medios de cultivo deben ser esterilizados antes de su uso para proteger la calidad del API.\n\n7. **Detecci\u00f3n y Manejo de Contaminaci\u00f3n**: Deben existir procedimientos para detectar contaminaci\u00f3n, evaluar su impacto en el producto y desinfectar el equipo.\n\n8. **Registros de Contaminaci\u00f3n**: Es necesario mantener registros de eventos de contaminaci\u00f3n.\n\n9. **Pruebas Adicionales en Equipos Compartidos**: Equipos utilizados para m\u00faltiples productos pueden requerir pruebas adicionales despu\u00e9s de la limpieza para minimizar el riesgo de contaminaci\u00f3n cruzada.\n\n### Entidades\n\n- **API (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias cuya calidad puede verse afectada por la contaminaci\u00f3n microbiana.\n- **Cabinas de Bioseguridad**: Entornos controlados recomendados para manipulaciones en recipientes abiertos.\n- **Par\u00e1metros Cr\u00edticos**: Incluyen temperatura, pH, tasas de agitaci\u00f3n, adici\u00f3n de gases y presi\u00f3n.\n- **Equipos de Cultivo Celular y Fermentaci\u00f3n**: Equipos que deben ser limpiados y esterilizados despu\u00e9s de su uso.\n- **Contaminaci\u00f3n Microbiana**: Riesgo que se busca minimizar a trav\u00e9s de procedimientos adecuados y monitoreo.", "excerpt_keywords": "Keywords: harvesting, purification, viral inactivation, contamination control, APIs"}}, "a0be8509-024a-4e2e-8ed1-f22354761c5e": {"node_ids": ["8252b4ef-610e-4def-9377-ef6743aab7dd"], "metadata": {"page_label": "192", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "its development. Section 19 provides specific guidance unique to these circumstances.\n\n19.11 The controls used in the manufacture of APIs for use in clinical trials should be consistent with the stage of development of the pharmaceutical product incorporating the API. Process and test procedures should be flexible to allow for changes to be made as knowledge of the process increases and clinical testing of a pharmaceutical product progresses from the preclinical stages through the clinical stages. Once pharmaceutical development reaches the stage where the API is produced for use in pharmaceutical products intended for clinical trials, manufacturers should ensure that APIs are manufactured in suitable facilities using appropriate production and control procedures to ensure the quality of the API.\n\n## 19.2 Quality\n\n19.20 Appropriate GMP concepts should be applied in the production of APIs for use in clinical trials with a suitable mechanism for the approval of each batch.\n\n19.21 A quality unit(s) independent from production should be established for the approval or rejection of each batch of API for use in clinical trials.\n\n19.22 Some of the testing functions commonly performed by the quality unit(s) can be performed within other organizational units.\n\n19.23 Quality measures should include a system for testing of raw materials, packaging materials, intermediates and APIs.\n\n19.24 Process and quality problems should be evaluated.\n\n19.25 Labelling for APIs intended for use in clinical trials should be appropriately controlled and should identify the material as being for investigational use.\n\n## 19.3 Equipment and facilities\n\n19.30 During all phases of clinical development, including the use of small-scale facilities or laboratories to manufacture batches of APIs for use in clinical trials, procedures should be in place to ensure that equipment is calibrated, clean and suitable for its intended use.\n\n19.31 Procedures for the use of facilities should ensure that materials are handled in a manner that minimizes the risk of contamination and cross-contamination.\n\n## 19.4 Control of raw materials\n\n19.40 Raw materials used in production of APIs for use in clinical trials should be evaluated by testing or be received with a supplier\u2019s analysis and", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Desarrollo y Control de APIs en Ensayos Cl\u00ednicos**: El documento proporciona directrices sobre el control y la fabricaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (APIs) destinados a ensayos cl\u00ednicos, enfatizando la necesidad de que los procedimientos de producci\u00f3n y prueba sean flexibles y se adapten a las etapas de desarrollo del producto farmac\u00e9utico.\n\n2. **Calidad y Aprobaci\u00f3n de Lotes**: Se establece la importancia de aplicar conceptos de Buenas Pr\u00e1cticas de Manufactura (GMP) en la producci\u00f3n de APIs, incluyendo la creaci\u00f3n de unidades de calidad independientes para la aprobaci\u00f3n de lotes y la implementaci\u00f3n de sistemas de prueba para asegurar la calidad de los materiales utilizados.\n\n3. **Equipos y Instalaciones**: Se subraya la necesidad de que los equipos y las instalaciones utilizadas en la producci\u00f3n de APIs est\u00e9n debidamente calibrados y limpios, y que se sigan procedimientos para minimizar el riesgo de contaminaci\u00f3n durante todas las fases del desarrollo cl\u00ednico.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 flexibilidad se requiere en los procedimientos de producci\u00f3n y prueba de APIs durante las diferentes etapas de desarrollo de un producto farmac\u00e9utico?**\n   - Esta pregunta busca detalles sobre c\u00f3mo los procedimientos deben adaptarse a medida que avanza el conocimiento del proceso y se realizan pruebas cl\u00ednicas.\n\n2. **\u00bfCu\u00e1les son los requisitos espec\u00edficos para la creaci\u00f3n de una unidad de calidad independiente en la producci\u00f3n de APIs para ensayos cl\u00ednicos?**\n   - Esta pregunta se centra en la estructura y las funciones de la unidad de calidad, as\u00ed como en su papel en la aprobaci\u00f3n o rechazo de lotes de APIs.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que los materiales utilizados en la producci\u00f3n de APIs est\u00e9n libres de contaminaci\u00f3n y cumplan con los est\u00e1ndares de calidad?**\n   - Esta pregunta indaga sobre los procedimientos espec\u00edficos que deben implementarse para manejar materiales y minimizar riesgos de contaminaci\u00f3n en las instalaciones de producci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Cosecha, Aislamiento y Purificaci\u00f3n (Secci\u00f3n 18.4)**:\n   - **Objetivo**: Minimizar la contaminaci\u00f3n y asegurar la calidad del producto intermedio o del principio activo (API).\n   - **Condiciones de Equipos**: Se deben utilizar equipos y \u00e1reas dise\u00f1adas para reducir el riesgo de contaminaci\u00f3n durante la cosecha y purificaci\u00f3n.\n   - **Procedimientos**: Los procedimientos deben eliminar o inactivar organismos productores, residuos celulares y componentes del medio, manteniendo la calidad del API.\n   - **Limpieza de Equipos**: Es esencial limpiar y, cuando sea necesario, desinfectar el equipo despu\u00e9s de su uso. Se permite el uso de m\u00faltiples lotes sucesivos sin limpieza si no se compromete la calidad del API.\n   - **Sistemas Abiertos**: La purificaci\u00f3n en sistemas abiertos debe realizarse bajo condiciones ambientales que preserven la calidad del producto.\n   - **Controles Adicionales**: Se pueden implementar controles adicionales, como resinas de cromatograf\u00eda dedicadas, si se utiliza el mismo equipo para m\u00faltiples productos.\n\n2. **Eliminaci\u00f3n/Inactivaci\u00f3n Viral (Secci\u00f3n 18.5)**:\n   - **Importancia**: Los pasos de eliminaci\u00f3n e inactivaci\u00f3n viral son cr\u00edticos y deben realizarse dentro de par\u00e1metros validados.\n   - **Precauciones**: Se deben tomar precauciones para prevenir la contaminaci\u00f3n viral, realizando el procesamiento abierto en \u00e1reas separadas con unidades de manejo de aire independientes.\n   - **Uso de Equipos**: Normalmente, no se utiliza el mismo equipo para diferentes pasos de purificaci\u00f3n. Si se reutiliza, el equipo debe ser limpiado y desinfectado adecuadamente para evitar la contaminaci\u00f3n cruzada.\n\n3. **APIs para Ensayos Cl\u00ednicos (Secci\u00f3n 19.1)**:\n   - **Consideraciones**: No todos los controles mencionados anteriormente son aplicables a la fabricaci\u00f3n de nuevos APIs para uso investigacional.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Principio Activo (API)**: Sustancia activa en productos farmac\u00e9uticos.\n- **Contaminaci\u00f3n Viral**: Riesgo que se debe gestionar durante la producci\u00f3n.\n- **Equipos de Purificaci\u00f3n**: Herramientas utilizadas en los procesos de cosecha y purificaci\u00f3n.\n- **Par\u00e1metros Validados**: Normas que deben cumplirse durante los procesos cr\u00edticos. \n\nEste resumen destaca la importancia de las pr\u00e1cticas de manufactura adecuadas para garantizar la calidad y seguridad de los productos farmac\u00e9uticos, as\u00ed como las consideraciones espec\u00edficas para la producci\u00f3n de APIs destinados a ensayos cl\u00ednicos.", "excerpt_keywords": "Keywords: APIs, clinical trials, GMP, quality control, contamination"}}, "1ea24a96-2051-41b3-90c5-870d64c353fe": {"node_ids": ["4123d9cb-9b5a-4067-b84a-f6695e650218"], "metadata": {"page_label": "193", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 19.5 Production\n\n19.50 The production of APIs for use in clinical trials should be documented in laboratory notebooks, batch records or by other appropriate means. These documents should include information on the use of production materials, equipment, processing and scientific observations.\n\n19.51 Expected yields can be more variable and less defined than the expected yields used in commercial processes. Investigations into yield variations are not expected.\n\n# 19.6 Validation\n\n19.60 Process validation for the production of APIs for use in clinical trials is normally inappropriate where a single API batch is produced or where process changes during development of an API make batch replication difficult or inexact. The combination of controls, calibration and, where appropriate, equipment qualification assures quality of the API during this development phase.\n\n19.61 Process validation should be conducted in accordance with section 12 when batches are produced for commercial use, even when such batches are produced on a pilot scale or small scale.\n\n# 19.7 Changes\n\n19.70 Changes are expected during development as knowledge is gained and the production is scaled up. Every change in the production, specifications or test procedures should be adequately recorded.\n\n# 19.8 Laboratory controls\n\n19.80 While analytical methods performed to evaluate a batch of API for clinical trials may not yet be validated they should be scientifically sound.\n\n19.81 A system for retaining reserve samples of all batches should be in place. This system should ensure that a sufficient quantity of each reserve sample is retained for an appropriate length of time after approval, termination or discontinuation of an application.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la producci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (APIs) para ensayos cl\u00ednicos, destacando la importancia de la documentaci\u00f3n, la validaci\u00f3n de procesos, la gesti\u00f3n de cambios y el control de laboratorio. Se enfatiza que la producci\u00f3n debe ser registrada adecuadamente, que las variaciones en los rendimientos son esperadas y que la validaci\u00f3n de procesos es crucial para la producci\u00f3n comercial. Adem\u00e1s, se menciona la necesidad de un sistema para conservar muestras de reserva de todos los lotes producidos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para la producci\u00f3n de APIs en ensayos cl\u00ednicos y qu\u00e9 informaci\u00f3n debe incluir?**\n   - La producci\u00f3n de APIs debe ser documentada en cuadernos de laboratorio, registros de lotes u otros medios apropiados, incluyendo informaci\u00f3n sobre materiales de producci\u00f3n, equipos, procesamiento y observaciones cient\u00edficas.\n\n2. **\u00bfPor qu\u00e9 no se espera realizar investigaciones sobre las variaciones en los rendimientos de los APIs durante los ensayos cl\u00ednicos?**\n   - Se considera que los rendimientos esperados pueden ser m\u00e1s variables y menos definidos en comparaci\u00f3n con los procesos comerciales, lo que hace que las investigaciones sobre estas variaciones no sean necesarias.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse en relaci\u00f3n con los cambios en la producci\u00f3n de APIs durante el desarrollo?**\n   - Todos los cambios en la producci\u00f3n, especificaciones o procedimientos de prueba deben ser registrados adecuadamente, ya que se espera que ocurran cambios a medida que se adquiere conocimiento y se escala la producci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manufactura de APIs en Ensayos Cl\u00ednicos**:\n   - Se enfatiza la necesidad de que los controles en la fabricaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (APIs) sean coherentes con la etapa de desarrollo del producto farmac\u00e9utico. Los procedimientos de producci\u00f3n y prueba deben ser flexibles para adaptarse a los avances en el conocimiento del proceso y en las pruebas cl\u00ednicas.\n\n2. **Calidad y Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Se requiere la aplicaci\u00f3n de conceptos de GMP en la producci\u00f3n de APIs, incluyendo la creaci\u00f3n de unidades de calidad independientes que se encarguen de la aprobaci\u00f3n o rechazo de cada lote. Tambi\u00e9n se menciona la importancia de un sistema de pruebas para asegurar la calidad de los materiales utilizados.\n\n3. **Equipos e Instalaciones**:\n   - Es crucial que los equipos y las instalaciones est\u00e9n calibrados, limpios y adecuados para su uso previsto. Se deben seguir procedimientos para minimizar el riesgo de contaminaci\u00f3n y cross-contaminaci\u00f3n durante todas las fases del desarrollo cl\u00ednico.\n\n4. **Control de Materias Primas**:\n   - Las materias primas utilizadas en la producci\u00f3n de APIs deben ser evaluadas mediante pruebas o recibidas con un an\u00e1lisis del proveedor, asegurando as\u00ed su calidad y adecuaci\u00f3n para el uso en ensayos cl\u00ednicos.\n\n### Entidades Clave\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias utilizadas en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Conjunto de directrices que aseguran la calidad y seguridad en la producci\u00f3n de medicamentos.\n- **Unidades de Calidad**: Departamentos independientes responsables de la evaluaci\u00f3n de la calidad de los lotes de APIs.\n- **Contaminaci\u00f3n y Cross-Contaminaci\u00f3n**: Riesgos asociados a la manipulaci\u00f3n de materiales en la producci\u00f3n que deben ser controlados.\n\nEste resumen destaca la importancia de la calidad, el control y la flexibilidad en la producci\u00f3n de APIs para ensayos cl\u00ednicos, asegurando que se cumplan los est\u00e1ndares necesarios para la investigaci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: APIs, clinical trials, production documentation, process validation, laboratory controls"}}, "4e4e6edb-3903-4af7-91f6-9658abd6d7c0": {"node_ids": ["1f6fd653-524f-433e-a002-498183d8331b"], "metadata": {"page_label": "194", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 19.9 Documentation\n\n19.82 Expiry and retest dating as defined in section 11.6 applies to existing APIs used in clinical trials. For new APIs section 11.6 does not normally apply in early stages of clinical trials.\n\n19.90 A system should be in place to ensure that information gained during the development and the manufacture of APIs for use in clinical trials is documented and available.\n\n19.91 The development and implementation of the analytical methods used to support the release of a batch of API for use in clinical trials should be appropriately documented.\n\n19.92 A system for retaining production and control records and documents should be used. This system should ensure that records and documents are retained for an appropriate length of time after the approval, termination or discontinuation of an application.\n\n# 20. Glossary\n\n**acceptance criteria**  \nNumerical limits, ranges or other suitable measures for acceptance of test results.\n\n**active pharmaceutical ingredient (API) (or pharmaceutical substance)**  \nAny substance or mixture of substances intended to be used in the manufacture of a finished pharmaceutical product (FPP) and that, when used in the production of a pharmaceutical product, becomes an active ingredient of the pharmaceutical product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the body.\n\n**API starting material**  \nA raw material, intermediate or an API that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. An API starting material can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement or produced in-house. API starting materials normally have defined chemical properties and structure.\n\n**batch (or lot)**  \nA specific quantity of material produced in a process or series of processes so that it is expected to be homogeneous within specified limits. In the case", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la documentaci\u00f3n relacionada con los ingredientes farmac\u00e9uticos activos (API) utilizados en ensayos cl\u00ednicos. Se enfatiza la importancia de mantener registros adecuados durante el desarrollo y la fabricaci\u00f3n de APIs, as\u00ed como la necesidad de documentar los m\u00e9todos anal\u00edticos utilizados para liberar lotes de API. Tambi\u00e9n se menciona la retenci\u00f3n de registros de producci\u00f3n y control por un per\u00edodo adecuado tras la aprobaci\u00f3n o finalizaci\u00f3n de una aplicaci\u00f3n. Adem\u00e1s, se proporciona un glosario que define t\u00e9rminos clave como \"criterios de aceptaci\u00f3n\", \"ingrediente farmac\u00e9utico activo\" y \"material de partida de API\".\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 se debe documentar espec\u00edficamente durante el desarrollo y la fabricaci\u00f3n de APIs para ensayos cl\u00ednicos?**\n   - El contexto menciona que debe haber un sistema para asegurar que la informaci\u00f3n obtenida durante el desarrollo y la fabricaci\u00f3n de APIs est\u00e9 documentada y disponible. Sin embargo, no se especifican los tipos exactos de informaci\u00f3n que deben ser documentados.\n\n2. **\u00bfCu\u00e1l es la duraci\u00f3n adecuada para la retenci\u00f3n de registros y documentos relacionados con la producci\u00f3n y control de APIs?**\n   - Aunque se menciona que los registros deben ser retenidos por un \"per\u00edodo adecuado\" despu\u00e9s de la aprobaci\u00f3n o finalizaci\u00f3n de una aplicaci\u00f3n, el contexto no proporciona detalles sobre qu\u00e9 se considera un per\u00edodo adecuado.\n\n3. **\u00bfQu\u00e9 criterios se utilizan para determinar si un lote de API es homog\u00e9neo dentro de los l\u00edmites especificados?**\n   - El t\u00e9rmino \"lote\" se define en el contexto, pero no se explican los m\u00e9todos o criterios espec\u00edficos que se utilizan para evaluar la homogeneidad de un lote de material producido.\n\nEstas preguntas est\u00e1n dise\u00f1adas para profundizar en aspectos espec\u00edficos del proceso de documentaci\u00f3n y control de calidad de los APIs en ensayos cl\u00ednicos, que no se abordan de manera exhaustiva en el texto proporcionado.", "prev_section_summary": "### Temas Clave\n\n1. **Documentaci\u00f3n de Producci\u00f3n**: La producci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (APIs) para ensayos cl\u00ednicos debe ser documentada adecuadamente en cuadernos de laboratorio y registros de lotes, incluyendo detalles sobre materiales, equipos, procesos y observaciones cient\u00edficas.\n\n2. **Variabilidad en Rendimientos**: Se reconoce que los rendimientos esperados de los APIs pueden ser m\u00e1s variables en ensayos cl\u00ednicos que en procesos comerciales, y no se espera realizar investigaciones sobre estas variaciones.\n\n3. **Validaci\u00f3n de Procesos**: La validaci\u00f3n de procesos es generalmente inapropiada para lotes \u00fanicos de APIs en desarrollo, pero es esencial para la producci\u00f3n comercial. Se deben seguir las directrices establecidas en el documento para la validaci\u00f3n de lotes comerciales.\n\n4. **Gesti\u00f3n de Cambios**: Se anticipan cambios durante el desarrollo de APIs, y todos los cambios en producci\u00f3n, especificaciones o procedimientos de prueba deben ser registrados adecuadamente.\n\n5. **Controles de Laboratorio**: Aunque los m\u00e9todos anal\u00edticos para evaluar los lotes de APIs pueden no estar validados, deben ser cient\u00edficamente s\u00f3lidos. Adem\u00e1s, se debe establecer un sistema para conservar muestras de reserva de todos los lotes producidos.\n\n### Entidades\n\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias utilizadas en la producci\u00f3n de medicamentos.\n- **Ensayos Cl\u00ednicos**: Estudios realizados para evaluar la eficacia y seguridad de un medicamento.\n- **Documentaci\u00f3n**: Cuadernos de laboratorio, registros de lotes.\n- **Validaci\u00f3n de Procesos**: Proceso de asegurar que los m\u00e9todos de producci\u00f3n cumplen con los est\u00e1ndares de calidad.\n- **Muestras de Reserva**: Muestras conservadas de cada lote producido para referencia futura.", "excerpt_keywords": "Keywords: documentaci\u00f3n, ingredientes farmac\u00e9uticos activos, ensayos cl\u00ednicos, registros de producci\u00f3n, criterios de aceptaci\u00f3n"}}, "1f3f6769-307e-4ca1-9a5a-de7c5c763a9b": {"node_ids": ["62aa30e0-1d77-47ba-b2ed-eea7dae1e75e"], "metadata": {"page_label": "195", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "of continuous production, a batch may correspond to a defined fraction of the production. The batch size can be defined either by a fixed quantity or by the amount produced in a fixed time interval.\n\n**batch number (or lot number)**  \nA unique combination of numbers, letters and/or symbols that identifies a batch (or lot) and from which the production and distribution history can be determined.\n\n**bioburden**  \nThe level and type (e.g. objectionable or not) of microorganisms that can be present in raw materials, API starting materials, intermediates or APIs. Bioburden should not be considered contamination unless the levels have been exceeded or defined objectionable organisms have been detected.\n\n**calibration**  \nThe demonstration that a particular instrument or device produces results within specified limits by comparison with those produced by a reference or traceable standard over an appropriate range of measurements.\n\n**computer system**  \nA group of hardware components and associated software, designed and assembled to perform a specific function or group of functions.\n\n**computerized system**  \nA process or operation integrated with a computer system.\n\n**contamination**  \nThe undesired introduction of impurities of a chemical or microbiological nature or of foreign matter into or on to a raw material, intermediate or API during production, sampling, packaging or repackaging, storage or transport.\n\n**contract manufacturer**  \nA manufacturer performing some aspect of manufacturing on behalf of the original manufacturer.\n\n**critical**  \nDescribes a process step, process condition, test requirement or other relevant parameter or item that must be controlled within predetermined criteria to ensure that the API meets its specification.\n\n**cross-contamination**  \nContamination of a material or product with another material or product.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en su Serie de Informes T\u00e9cnicos 957 aborda conceptos clave relacionados con la producci\u00f3n de productos farmac\u00e9uticos, incluyendo definiciones de t\u00e9rminos como \"n\u00famero de lote\", \"bioburden\", \"calibraci\u00f3n\", \"sistemas computarizados\", \"contaminaci\u00f3n\", \"fabricante por contrato\", \"cr\u00edtico\" y \"contaminaci\u00f3n cruzada\". Estos t\u00e9rminos son esenciales para entender los procesos de fabricaci\u00f3n y control de calidad en la producci\u00f3n de ingredientes farmac\u00e9uticos activos (API).\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar para definir el tama\u00f1o de un lote en la producci\u00f3n continua?**\n   - Respuesta: El tama\u00f1o de un lote puede definirse ya sea por una cantidad fija o por la cantidad producida en un intervalo de tiempo fijo.\n\n2. **\u00bfC\u00f3mo se determina si el bioburden en un material es considerado contaminaci\u00f3n?**\n   - Respuesta: El bioburden no debe considerarse contaminaci\u00f3n a menos que los niveles hayan sido superados o se hayan detectado organismos objetables definidos.\n\n3. **\u00bfQu\u00e9 implica la calibraci\u00f3n de un instrumento en el contexto de la producci\u00f3n farmac\u00e9utica?**\n   - Respuesta: La calibraci\u00f3n implica demostrar que un instrumento o dispositivo produce resultados dentro de l\u00edmites especificados mediante comparaci\u00f3n con resultados producidos por un est\u00e1ndar de referencia o trazable a lo largo de un rango apropiado de mediciones.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Documentaci\u00f3n de APIs en Ensayos Cl\u00ednicos**:\n   - Se establece la necesidad de un sistema que garantice la documentaci\u00f3n y disponibilidad de la informaci\u00f3n obtenida durante el desarrollo y fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs) utilizados en ensayos cl\u00ednicos.\n\n2. **M\u00e9todos Anal\u00edticos**:\n   - Es fundamental documentar el desarrollo e implementaci\u00f3n de los m\u00e9todos anal\u00edticos que respaldan la liberaci\u00f3n de lotes de API para su uso en ensayos cl\u00ednicos.\n\n3. **Retenci\u00f3n de Registros**:\n   - Se requiere un sistema para la retenci\u00f3n de registros y documentos de producci\u00f3n y control, asegurando que se mantengan por un per\u00edodo adecuado tras la aprobaci\u00f3n, terminaci\u00f3n o discontinuaci\u00f3n de una aplicaci\u00f3n.\n\n4. **Glosario de T\u00e9rminos Clave**:\n   - **Criterios de Aceptaci\u00f3n**: L\u00edmites num\u00e9ricos o rangos para la aceptaci\u00f3n de resultados de pruebas.\n   - **Ingrediente Farmac\u00e9utico Activo (API)**: Sustancia utilizada en la fabricaci\u00f3n de un producto farmac\u00e9utico terminado que proporciona actividad farmacol\u00f3gica.\n   - **Material de Partida de API**: Materia prima o intermedio utilizado en la producci\u00f3n de un API, que se incorpora significativamente en su estructura.\n   - **Lote**: Cantidad espec\u00edfica de material producida en un proceso, esper\u00e1ndose que sea homog\u00e9nea dentro de l\u00edmites especificados.\n\nEstos temas resaltan la importancia de la documentaci\u00f3n y el control de calidad en el desarrollo y uso de APIs en ensayos cl\u00ednicos, as\u00ed como la definici\u00f3n de t\u00e9rminos clave que son esenciales para entender el proceso.", "excerpt_keywords": "Keywords: batch production, bioburden, calibration, contamination, contract manufacturer"}}, "5552ccb1-83b5-42fe-813c-b725ee407807": {"node_ids": ["d1317093-a15a-4293-841b-14532684c2e6"], "metadata": {"page_label": "196", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Deviation\n\nDeparture from an approved instruction or established standard.\n\n# Expiry Date (or Expiration Date)\n\nThe date placed on the container or labels of an API designating the time during which the API is expected to remain within established shelf-life specifications if stored under defined conditions and after which it should not be used.\n\n# Finished Pharmaceutical Product (FPP)\n\n- **ICH**: The dosage form in the final immediate packaging intended for marketing (reference Q1A (4)).\n- **WHO**: A product that has undergone all stages of production, including packaging in its final container and labelling. An FPP may contain one or more APIs.\n\n# Impurity\n\nAny component present in the intermediate or API that is not the desired entity.\n\n# Impurity Profile\n\nA description of the identified and unidentified impurities present in an API.\n\n# In-Process Control (or Process Control)\n\nChecks performed during production in order to monitor and, if appropriate, to adjust the process and/or to ensure that the intermediate or API conforms to its specifications.\n\n# Intermediate\n\nA material produced during steps of the processing of an API that undergoes further molecular change or purification before it becomes an API. Intermediates may or may not be isolated.\n\n(Note: this guide only addresses those intermediates produced after the point that the company has defined as the point at which the production of the API begins.)\n\n# Lot\n\nSee Batch.\n\n# Lot Number\n\nSee Batch number.\n\n# Manufacture\n\nAll operations of receipt of materials, production, packaging, repackaging, labelling, relabelling, quality control, release, storage and distribution of APIs and related controls.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1l es la diferencia entre un Producto Farmac\u00e9utico Terminado (FPP) seg\u00fan la ICH y la OMS?**\n   - **Respuesta:** Seg\u00fan la ICH, un Producto Farmac\u00e9utico Terminado (FPP) es la forma de dosificaci\u00f3n en el envase inmediato final destinada a la comercializaci\u00f3n. Por otro lado, la OMS define un FPP como un producto que ha pasado por todas las etapas de producci\u00f3n, incluyendo el envasado en su contenedor final y etiquetado. Adem\u00e1s, un FPP puede contener uno o m\u00e1s Ingredientes Activos (APIs).\n\n2. **\u00bfQu\u00e9 se entiende por \"Control en Proceso\" y cu\u00e1l es su prop\u00f3sito durante la producci\u00f3n de un API?**\n   - **Respuesta:** El \"Control en Proceso\" se refiere a las verificaciones realizadas durante la producci\u00f3n para monitorear y, si es apropiado, ajustar el proceso. Su prop\u00f3sito es asegurar que el intermedio o el API cumplan con sus especificaciones establecidas, garantizando as\u00ed la calidad del producto final.\n\n3. **\u00bfQu\u00e9 implica el t\u00e9rmino \"Manufactura\" en el contexto de los Ingredientes Activos (APIs)?**\n   - **Respuesta:** El t\u00e9rmino \"Manufactura\" abarca todas las operaciones relacionadas con la recepci\u00f3n de materiales, producci\u00f3n, envasado, reenvase, etiquetado, control de calidad, liberaci\u00f3n, almacenamiento y distribuci\u00f3n de APIs, as\u00ed como los controles relacionados con estos procesos.\n\n### Resumen de nivel superior:\nEl documento proporciona definiciones clave relacionadas con la producci\u00f3n y control de Ingredientes Activos (APIs) y Productos Farmac\u00e9uticos Terminados (FPP). Se abordan conceptos como desviaciones, fechas de caducidad, perfiles de impurezas, controles en proceso, intermedios y el proceso de manufactura. Estas definiciones son esenciales para entender los est\u00e1ndares y procedimientos en la industria farmac\u00e9utica, asegurando la calidad y seguridad de los productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n extra\u00edda del documento de la OMS en su Serie de Informes T\u00e9cnicos 957 se centra en definiciones y conceptos fundamentales relacionados con la producci\u00f3n de ingredientes farmac\u00e9uticos activos (API). A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n1. **Producci\u00f3n Continua**:\n   - Se define un lote como una fracci\u00f3n espec\u00edfica de la producci\u00f3n, que puede ser determinada por una cantidad fija o por el tiempo de producci\u00f3n.\n\n2. **N\u00famero de Lote**:\n   - Identificaci\u00f3n \u00fanica de un lote mediante una combinaci\u00f3n de n\u00fameros, letras y/o s\u00edmbolos, que permite rastrear la historia de producci\u00f3n y distribuci\u00f3n.\n\n3. **Bioburden**:\n   - Se refiere al nivel y tipo de microorganismos presentes en materiales crudos y APIs. No se considera contaminaci\u00f3n a menos que se superen los niveles permitidos o se detecten organismos objetables.\n\n4. **Calibraci\u00f3n**:\n   - Proceso de demostrar que un instrumento produce resultados dentro de l\u00edmites especificados, compar\u00e1ndolo con un est\u00e1ndar de referencia.\n\n5. **Sistemas Computarizados**:\n   - Incluyen tanto hardware como software dise\u00f1ados para realizar funciones espec\u00edficas, y pueden integrarse en procesos u operaciones.\n\n6. **Contaminaci\u00f3n**:\n   - Introducci\u00f3n no deseada de impurezas qu\u00edmicas o microbiol\u00f3gicas en materiales durante diversas etapas de producci\u00f3n y manejo.\n\n7. **Fabricante por Contrato**:\n   - Un fabricante que realiza parte del proceso de producci\u00f3n en nombre de otro fabricante.\n\n8. **Par\u00e1metros Cr\u00edticos**:\n   - Elementos que deben ser controlados dentro de criterios predeterminados para asegurar que el API cumpla con sus especificaciones.\n\n9. **Contaminaci\u00f3n Cruzada**:\n   - Contaminaci\u00f3n de un material o producto con otro material o producto.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que publica el documento.\n- **Ingredientes Farmac\u00e9uticos Activos (API)**: Productos cuya producci\u00f3n y control de calidad son el foco del documento.\n\nEste resumen proporciona una visi\u00f3n general de los conceptos esenciales que son fundamentales para entender los procesos de fabricaci\u00f3n y control de calidad en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: Deviation, Expiry Date, Finished Pharmaceutical Product, Impurity Profile, In-Process Control"}}, "d6f67fe0-20ec-4d01-814c-aaf494ea09ca": {"node_ids": ["5ac5f603-2b4b-4fea-ae98-10f5261707b6"], "metadata": {"page_label": "197", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Material\n\nA general term used to denote raw materials (starting materials, reagents, solvents), process aids, intermediates, APIs and packaging and labelling materials.\n\n# Mother Liquor\n\nThe residual liquid which remains after the crystallization or isolation processes. A mother liquor may contain unreacted materials, intermediates, levels of the API and/or impurities. It may be used for further processing.\n\n# Packaging Material\n\nAny material intended to protect an intermediate or API during storage and transport.\n\n# Pharmaceutical Substance\n\nSee Active pharmaceutical ingredient.\n\n# Procedure\n\nA documented description of the operations to be performed, the precautions to be taken and measures to be applied, directly or indirectly related to the manufacture of an intermediate or API.\n\n# Process Aids\n\nMaterials, excluding solvents, used as an aid in the manufacture of an intermediate or API that do not themselves participate in a chemical or biological reaction (e.g. filter aid or activated carbon).\n\n# Process Control\n\nSee In-process control.\n\n# Production\n\nAll operations involved in the preparation of an API from receipt of materials through processing and packaging of the API.\n\n# Qualification\n\nAction of proving and documenting that equipment or ancillary systems are properly installed, work correctly and actually lead to the expected results. Qualification is part of validation, but the individual qualification steps alone do not constitute process validation.\n\n# Quality Assurance (QA)\n\nThe sum total of the organized arrangements made with the object of ensuring that all APIs are of the quality required for their intended use and that quality systems are maintained.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la serie de informes t\u00e9cnicos 957 aborda definiciones y conceptos clave relacionados con la fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (API). Se describen t\u00e9rminos como \"materia prima\", \"licor madre\", \"material de embalaje\", \"procedimiento\", \"ayudas de proceso\", \"control de proceso\", \"producci\u00f3n\", \"calificaci\u00f3n\" y \"aseguramiento de calidad\". Cada t\u00e9rmino se define en el contexto de la producci\u00f3n y el manejo de sustancias farmac\u00e9uticas, destacando la importancia de la calidad y la documentaci\u00f3n en los procesos de fabricaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 se entiende por \"licor madre\" y c\u00f3mo se puede utilizar en el proceso de fabricaci\u00f3n de un API?**\n   - Respuesta: El \"licor madre\" es el l\u00edquido residual que queda despu\u00e9s de los procesos de cristalizaci\u00f3n o aislamiento. Puede contener materiales no reaccionados, intermedios, niveles del API y/o impurezas, y puede ser utilizado para un procesamiento adicional.\n\n2. **\u00bfCu\u00e1l es la diferencia entre \"calificaci\u00f3n\" y \"validaci\u00f3n\" en el contexto de la producci\u00f3n de APIs?**\n   - Respuesta: La \"calificaci\u00f3n\" se refiere a la acci\u00f3n de probar y documentar que el equipo o sistemas auxiliares est\u00e1n correctamente instalados, funcionan adecuadamente y producen los resultados esperados. Es parte del proceso de \"validaci\u00f3n\", pero los pasos individuales de calificaci\u00f3n no constituyen por s\u00ed solos la validaci\u00f3n del proceso.\n\n3. **\u00bfQu\u00e9 papel juega el \"aseguramiento de calidad\" (QA) en la producci\u00f3n de APIs seg\u00fan el documento?**\n   - Respuesta: El \"aseguramiento de calidad\" (QA) implica un conjunto organizado de arreglos destinados a garantizar que todos los APIs cumplan con la calidad requerida para su uso previsto y que se mantengan los sistemas de calidad. Esto es crucial para asegurar la eficacia y seguridad de los productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Desviaci\u00f3n (Deviation)**: Se refiere a cualquier salida de instrucciones aprobadas o est\u00e1ndares establecidos en el proceso de producci\u00f3n.\n\n2. **Fecha de Caducidad (Expiry Date)**: Es la fecha indicada en el envase o etiquetas de un Ingrediente Activo (API), que se\u00f1ala el per\u00edodo durante el cual se espera que el API mantenga sus especificaciones de vida \u00fatil bajo condiciones definidas.\n\n3. **Producto Farmac\u00e9utico Terminado (FPP)**:\n   - **Definici\u00f3n ICH**: Forma de dosificaci\u00f3n en el envase inmediato final destinada a la comercializaci\u00f3n.\n   - **Definici\u00f3n OMS**: Producto que ha completado todas las etapas de producci\u00f3n, incluyendo el envasado y etiquetado final. Puede contener uno o m\u00e1s APIs.\n\n4. **Impureza (Impurity)**: Cualquier componente presente en un intermedio o API que no es el deseado.\n\n5. **Perfil de Impurezas (Impurity Profile)**: Descripci\u00f3n de las impurezas identificadas y no identificadas presentes en un API.\n\n6. **Control en Proceso (In-Process Control)**: Verificaciones realizadas durante la producci\u00f3n para monitorear y ajustar el proceso, asegurando que el intermedio o API cumpla con sus especificaciones.\n\n7. **Intermedio (Intermediate)**: Material producido durante el procesamiento de un API que requiere cambios moleculares o purificaci\u00f3n adicional antes de convertirse en un API. Puede o no ser aislado.\n\n8. **Lote (Lot)**: T\u00e9rmino relacionado con \"Batch\", que se refiere a una cantidad espec\u00edfica de producto fabricado en un solo ciclo de producci\u00f3n.\n\n9. **N\u00famero de Lote (Lot Number)**: Identificaci\u00f3n espec\u00edfica de un lote de producci\u00f3n.\n\n10. **Manufactura (Manufacture)**: Conjunto de operaciones que incluyen la recepci\u00f3n de materiales, producci\u00f3n, envasado, etiquetado, control de calidad, liberaci\u00f3n, almacenamiento y distribuci\u00f3n de APIs, as\u00ed como los controles asociados.\n\n### Conclusi\u00f3n\nEl contenido aborda definiciones y conceptos fundamentales relacionados con la producci\u00f3n y control de APIs y FPPs, esenciales para garantizar la calidad y seguridad en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: Material, Mother Liquor, Qualification, Quality Assurance, Production"}}, "e2b2011b-e3f5-4aa7-8b98-8ea9accc5022": {"node_ids": ["9813143d-fb46-41f6-837a-8806bbc895c0"], "metadata": {"page_label": "198", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# quality control (QC)\nChecking or testing that specifications are met.\n\n# quality unit(s)\nAn organizational unit independent of production which fulfills both quality assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization.\n\n# quarantine\nThe status of materials isolated physically or by other effective means pending a decision on their subsequent approval or rejection.\n\n# raw material\nA general term used to denote starting materials, reagents and solvents intended for use in the production of intermediates or APIs.\n\n# reference standard, primary\nA substance that has been shown by an extensive set of analytical tests to be authentic material that should be of high purity. This standard can be:\n\n- obtained from an officially recognized source;\n- prepared by independent synthesis;\n- obtained from existing production material of high purity; or\n- prepared by further purification of existing production material.\n\n# reference standard, secondary\nA substance of established quality and purity, as shown by comparison to a primary reference standard, used as a reference standard for routine laboratory analysis.\n\n# reprocessing\nIntroducing an intermediate or API, including one that does not conform to standards or specifications, back into the process and repeating a crystallization step or other appropriate chemical or physical manipulation steps (e.g. distillation, filtration, chromatography or milling) that are part of the established manufacturing process. Continuation of a process step after an in-process control test has shown that the step is incomplete is considered to be part of the normal process and not to be reprocessing.\n\n# retest date\nThe date when a material should be re-examined to ensure that it is still suitable for use.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda conceptos clave relacionados con el control de calidad (QC) y la garant\u00eda de calidad (QA) en la producci\u00f3n de materiales farmac\u00e9uticos. Se definen t\u00e9rminos como \"unidad de calidad\", \"cuarentena\", \"materia prima\", \"est\u00e1ndar de referencia primario y secundario\", \"reprocesamiento\" y \"fecha de rean\u00e1lisis\". Estos t\u00e9rminos son fundamentales para asegurar que los productos farmac\u00e9uticos cumplan con las especificaciones necesarias para su uso seguro y efectivo.\n\n### Preguntas espec\u00edficas\n1. **\u00bfCu\u00e1les son las diferencias clave entre un est\u00e1ndar de referencia primario y uno secundario, y c\u00f3mo se utilizan en el an\u00e1lisis de laboratorio?**\n   - Esta pregunta busca una comparaci\u00f3n detallada que no se encuentra f\u00e1cilmente en otras fuentes, enfoc\u00e1ndose en la aplicaci\u00f3n pr\u00e1ctica de estos est\u00e1ndares en el contexto de control de calidad.\n\n2. **\u00bfQu\u00e9 procedimientos se consideran parte del \"reprocesamiento\" en la fabricaci\u00f3n de intermediarios o APIs, y c\u00f3mo se diferencia de la continuaci\u00f3n de un paso de proceso normal?**\n   - Esta pregunta se centra en la distinci\u00f3n entre reprocessing y los pasos de proceso est\u00e1ndar, lo que puede no estar claramente definido en otras fuentes.\n\n3. **\u00bfQu\u00e9 criterios se utilizan para determinar la fecha de rean\u00e1lisis de un material, y qu\u00e9 implicaciones tiene esto para su uso en la producci\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre los criterios y procesos que gu\u00edan la decisi\u00f3n de cu\u00e1ndo un material debe ser reexaminado, lo cual es crucial para la gesti\u00f3n de calidad en la producci\u00f3n farmac\u00e9utica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Material**: T\u00e9rmino general que abarca materias primas, reactivos, disolventes, ayudas de proceso, intermedios, ingredientes farmac\u00e9uticos activos (API) y materiales de embalaje y etiquetado.\n\n2. **Licor Madre**: L\u00edquido residual que queda tras los procesos de cristalizaci\u00f3n o aislamiento, que puede contener materiales no reaccionados, intermedios, niveles del API y/o impurezas. Puede ser utilizado para procesamiento adicional.\n\n3. **Material de Embalaje**: Cualquier material destinado a proteger un intermedio o API durante su almacenamiento y transporte.\n\n4. **Sustancia Farmac\u00e9utica**: Se refiere al ingrediente farmac\u00e9utico activo (API).\n\n5. **Procedimiento**: Descripci\u00f3n documentada de las operaciones a realizar, precauciones a tomar y medidas a aplicar en la fabricaci\u00f3n de un intermedio o API.\n\n6. **Ayudas de Proceso**: Materiales utilizados en la fabricaci\u00f3n de un intermedio o API que no participan en reacciones qu\u00edmicas o biol\u00f3gicas, como filtros o carb\u00f3n activado.\n\n7. **Control de Proceso**: Se refiere al control en proceso, que asegura que las operaciones se realicen de manera adecuada.\n\n8. **Producci\u00f3n**: Conjunto de operaciones involucradas en la preparaci\u00f3n de un API, desde la recepci\u00f3n de materiales hasta el procesamiento y embalaje del API.\n\n9. **Calificaci\u00f3n**: Proceso de demostrar y documentar que el equipo o sistemas auxiliares est\u00e1n correctamente instalados y funcionan adecuadamente. Es parte de la validaci\u00f3n, pero no constituye validaci\u00f3n por s\u00ed solo.\n\n10. **Aseguramiento de Calidad (QA)**: Conjunto de arreglos organizados para garantizar que todos los APIs cumplan con la calidad requerida para su uso previsto y que se mantengan los sistemas de calidad.\n\n### Entidades Clave\n- **API (Ingrediente Farmac\u00e9utico Activo)**\n- **Licor Madre**\n- **Material de Embalaje**\n- **Procedimiento**\n- **Ayudas de Proceso**\n- **Calificaci\u00f3n**\n- **Aseguramiento de Calidad (QA)**\n\nEste resumen destaca los conceptos fundamentales y las definiciones relevantes en el contexto de la fabricaci\u00f3n y manejo de ingredientes farmac\u00e9uticos activos, enfatizando la importancia de la calidad y la documentaci\u00f3n en estos procesos.", "excerpt_keywords": "Keywords: quality control, reference standard, reprocessing, raw material, quarantine"}}, "028abf06-7ac9-48e9-956f-33c159ca0673": {"node_ids": ["eb1b852f-fd7c-47de-bbf0-cbc09ae3d6df"], "metadata": {"page_label": "199", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# reworking\n\nSubjecting an intermediate or API that does not conform to standards or specifications to one or more processing steps that are different from the established manufacturing process to obtain acceptable quality intermediate or API (e.g. recrystallizing with a different solvent).\n\n# signature (signed)\n\nSee Signed.\n\n# signed (signature)\n\nThe record of the individual who performed a particular action or review. This record can be in the form of initials, full handwritten signature, personal seal or an authenticated and secure electronic signature.\n\n# solvent\n\nAn inorganic or organic liquid used as a vehicle for the preparation of solutions or suspensions in the manufacture of an intermediate or API.\n\n# specification\n\nA list of tests, references to analytical procedures and appropriate acceptance criteria that are numerical limits, ranges or other criteria for the test described. It establishes the set of criteria to which a material should conform to be considered acceptable for its intended use. \u201cConformance to specification\u201d means that the material, when tested according to the listed analytical procedures, will meet the listed acceptance criteria.\n\n# validation\n\nA documented programme that provides a high degree of assurance that a specific process, method or system will consistently produce a result meeting predetermined acceptance criteria.\n\n# validation protocol\n\nA written plan stating how validation will be conducted and defining acceptance criteria. For example, the protocol for a manufacturing process identifies processing equipment, critical process parameters and operating ranges, product characteristics, sampling, test data to be collected, number of validation runs and acceptable test results.\n\n# yield, expected\n\nThe quantity of material or the percentage of theoretical yield anticipated at any appropriate phase of production based on previous laboratory, pilot-scale or manufacturing data.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) titulado \"Technical Report Series 957\" aborda varios conceptos clave relacionados con la fabricaci\u00f3n de intermediarios y principios activos (API). Se definen t\u00e9rminos como \"reworking\", \"signature\", \"solvent\", \"specification\", \"validation\", \"validation protocol\" y \"yield, expected\". Cada uno de estos t\u00e9rminos se relaciona con los procesos de producci\u00f3n y control de calidad en la industria farmac\u00e9utica, estableciendo criterios y procedimientos para asegurar que los productos cumplan con los est\u00e1ndares requeridos.\n\n### Preguntas\n1. **\u00bfQu\u00e9 pasos se deben seguir para realizar un \"reworking\" de un intermediario o API que no cumple con las especificaciones?**\n   - Esta pregunta se centra en el proceso espec\u00edfico de reworking y los pasos que se deben seguir, que no se detallan en el contexto.\n\n2. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en un \"validation protocol\" para asegurar la calidad de un proceso de fabricaci\u00f3n?**\n   - Aunque se menciona que un validation protocol debe incluir ciertos elementos, esta pregunta busca una lista m\u00e1s detallada y espec\u00edfica de esos elementos.\n\n3. **\u00bfC\u00f3mo se determina el \"expected yield\" en un proceso de producci\u00f3n y qu\u00e9 factores pueden influir en su c\u00e1lculo?**\n   - Esta pregunta busca profundizar en el concepto de rendimiento esperado y los factores que pueden afectar su estimaci\u00f3n, lo cual no se aborda expl\u00edcitamente en el contexto.", "prev_section_summary": "La secci\u00f3n aborda conceptos fundamentales relacionados con el control de calidad (QC) y la garant\u00eda de calidad (QA) en la producci\u00f3n farmac\u00e9utica. A continuaci\u00f3n se resumen los temas clave y entidades mencionadas:\n\n1. **Control de Calidad (QC)**: Se refiere a la verificaci\u00f3n o prueba de que se cumplen las especificaciones establecidas para los productos.\n\n2. **Unidad de Calidad**: Es una unidad organizativa independiente de la producci\u00f3n que se encarga de las responsabilidades tanto de QA como de QC. Puede estar compuesta por unidades separadas o por un solo individuo o grupo, dependiendo de la estructura de la organizaci\u00f3n.\n\n3. **Cuarentena**: Estado de los materiales que han sido aislados, ya sea f\u00edsicamente o por otros medios, mientras se espera una decisi\u00f3n sobre su aprobaci\u00f3n o rechazo.\n\n4. **Materia Prima**: T\u00e9rmino general que se refiere a los materiales iniciales, reactivos y disolventes destinados a la producci\u00f3n de intermediarios o principios activos (APIs).\n\n5. **Est\u00e1ndar de Referencia Primario**: Sustancia de alta pureza que ha sido validada mediante un conjunto extenso de pruebas anal\u00edticas. Puede obtenerse de fuentes reconocidas, ser preparada por s\u00edntesis independiente, provenir de material de producci\u00f3n existente de alta pureza o ser purificada a partir de material de producci\u00f3n existente.\n\n6. **Est\u00e1ndar de Referencia Secundario**: Sustancia de calidad y pureza establecidas, comparada con un est\u00e1ndar primario, utilizada para an\u00e1lisis de laboratorio rutinarios.\n\n7. **Reprocesamiento**: Proceso de reintegrar un intermedio o API que no cumple con las especificaciones de vuelta al proceso, repitiendo pasos de manipulaci\u00f3n qu\u00edmica o f\u00edsica. La continuaci\u00f3n de un paso de proceso tras un control en proceso que indica que el paso est\u00e1 incompleto se considera parte del proceso normal, no reprocessing.\n\n8. **Fecha de Rean\u00e1lisis**: Fecha en la que un material debe ser reexaminado para asegurar que sigue siendo adecuado para su uso.\n\nEstos conceptos son esenciales para garantizar que los productos farmac\u00e9uticos sean seguros y efectivos, cumpliendo con las normativas y est\u00e1ndares de calidad establecidos.", "excerpt_keywords": "Keywords: reworking, validation, specification, solvent, yield"}}, "90b7e1ae-259a-4a9e-b777-c04b4df558a6": {"node_ids": ["91f75c63-8292-47d9-9714-7d61848ca532"], "metadata": {"page_label": "200", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# yield, theoretical\n\nThe quantity that would be produced at any appropriate phase of production, based upon the quantity of material to be used, in the absence of any loss or error in actual production.\n\n# References\n\n1. *ICH Harmonised Tripartite Guideline: Specifications: test procedures and acceptance criteria for biotechnological/biological products Q6B.* International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1999.\n\n2. *ICH Harmonised Tripartite Guideline: Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin Q5A.* International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1999.\n\n3. *ICH Harmonised Tripartite Guideline: Derivation and characterisation of cell substrates used for production of biotechnological/biological products Q5D.* International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1997.\n\n4. *ICH Harmonised Tripartite Guideline: Stability testing of new drug substances and products Q1A.* International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2003.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 957\" aborda el concepto de \"rendimiento te\u00f3rico\" en la producci\u00f3n de productos biotecnol\u00f3gicos y biol\u00f3gicos. Define el rendimiento te\u00f3rico como la cantidad que se podr\u00eda producir en cualquier fase de producci\u00f3n, asumiendo que no hay p\u00e9rdidas ni errores. Adem\u00e1s, se citan varias directrices de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) que establecen criterios y procedimientos para la evaluaci\u00f3n de productos biotecnol\u00f3gicos, incluyendo especificaciones, seguridad viral, caracterizaci\u00f3n de sustratos celulares y pruebas de estabilidad.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 se entiende por \"rendimiento te\u00f3rico\" en el contexto de la producci\u00f3n biotecnol\u00f3gica?**\n   - Respuesta: El rendimiento te\u00f3rico se refiere a la cantidad que se podr\u00eda producir en cualquier fase de producci\u00f3n, basado en la cantidad de material utilizado, sin considerar p\u00e9rdidas o errores en la producci\u00f3n real.\n\n2. **\u00bfCu\u00e1les son algunas de las directrices de la ICH mencionadas en el documento y qu\u00e9 aspectos regulan?**\n   - Respuesta: Se mencionan varias directrices de la ICH, incluyendo: \n     - Q6B: Especificaciones, procedimientos de prueba y criterios de aceptaci\u00f3n para productos biotecnol\u00f3gicos/biol\u00f3gicos.\n     - Q5A: Evaluaci\u00f3n de la seguridad viral de productos biotecnol\u00f3gicos derivados de l\u00edneas celulares de origen humano o animal.\n     - Q5D: Derivaci\u00f3n y caracterizaci\u00f3n de sustratos celulares utilizados para la producci\u00f3n de productos biotecnol\u00f3gicos/biol\u00f3gicos.\n     - Q1A: Pruebas de estabilidad de nuevas sustancias y productos farmac\u00e9uticos.\n\n3. **\u00bfQu\u00e9 implicaciones tiene el concepto de rendimiento te\u00f3rico para la industria farmac\u00e9utica y biotecnol\u00f3gica?**\n   - Respuesta: El concepto de rendimiento te\u00f3rico es crucial para la industria farmac\u00e9utica y biotecnol\u00f3gica, ya que permite establecer expectativas de producci\u00f3n y evaluar la eficiencia de los procesos. Adem\u00e1s, ayuda a identificar \u00e1reas donde se pueden producir p\u00e9rdidas o errores, lo que es fundamental para mejorar la calidad y la seguridad de los productos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n extra\u00edda del documento \"Technical Report Series 957\" de la OMS aborda varios conceptos fundamentales relacionados con la fabricaci\u00f3n de intermediarios y principios activos (API) en la industria farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n1. **Reworking**: Se refiere al proceso de someter un intermediario o API que no cumple con las especificaciones a pasos de procesamiento diferentes a los establecidos, con el fin de obtener un producto de calidad aceptable.\n\n2. **Signature (Firmado)**: Se define como el registro de la persona que realiz\u00f3 una acci\u00f3n o revisi\u00f3n espec\u00edfica, que puede presentarse en diversas formas, incluyendo iniciales, firma manuscrita, sello personal o firma electr\u00f3nica segura.\n\n3. **Solvent**: Se describe como un l\u00edquido, ya sea inorg\u00e1nico u org\u00e1nico, utilizado como veh\u00edculo para la preparaci\u00f3n de soluciones o suspensiones en la fabricaci\u00f3n de intermediarios o API.\n\n4. **Specification**: Se establece como una lista de pruebas y criterios de aceptaci\u00f3n que determinan si un material es aceptable para su uso previsto. Incluye l\u00edmites num\u00e9ricos y procedimientos anal\u00edticos.\n\n5. **Validation**: Se refiere a un programa documentado que asegura que un proceso, m\u00e9todo o sistema producir\u00e1 consistentemente resultados que cumplan con criterios de aceptaci\u00f3n predeterminados.\n\n6. **Validation Protocol**: Es un plan escrito que detalla c\u00f3mo se llevar\u00e1 a cabo la validaci\u00f3n y define los criterios de aceptaci\u00f3n, incluyendo equipos de procesamiento, par\u00e1metros cr\u00edticos, caracter\u00edsticas del producto y datos de prueba a recolectar.\n\n7. **Yield, Expected**: Se refiere a la cantidad de material o porcentaje de rendimiento te\u00f3rico anticipado en cualquier fase de producci\u00f3n, basado en datos de laboratorio, escalas piloto o fabricaci\u00f3n previa.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el documento.\n- **Intermediarios y API**: Productos farmac\u00e9uticos cuya calidad y conformidad son objeto de los procesos descritos.\n- **Criterios de aceptaci\u00f3n**: Est\u00e1ndares que los materiales deben cumplir para ser considerados aceptables.\n\nEste resumen proporciona una visi\u00f3n general de los conceptos y t\u00e9rminos clave que son esenciales para entender los procesos de producci\u00f3n y control de calidad en la industria farmac\u00e9utica seg\u00fan el documento de la OMS.", "excerpt_keywords": "Keywords: yield, theoretical, biotechnological products, ICH guidelines, production efficiency"}}, "42d97730-6d15-459c-868b-566a07ebe4cb": {"node_ids": ["c87f6cf9-bdf7-4e77-89a6-b4431cd92b4d"], "metadata": {"page_label": "201", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 1\n\n## List of references for related WHO guidelines\n\n### Distribution\n\nhttp://www.who.int/medicines/areas/quality_safety/quality_assurance/distribution/en/\n\nGood trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2003, Annex 2 (WHO Technical Report Series, No. 917).\n\nWHO pharmaceutical starting materials certification scheme (SMACS): guidelines on implementation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2003, Annex 3 (WHO Technical Report Series, No. 917).\n\nGuide to good storage practices for pharmaceuticals In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 9 (WHO Technical Report Series, No. 908).\n\n### Production\n\nhttp://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/index.html\n\nGood Manufacturing Practices for Pharmaceutical Products: Main Principles. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 4 (WHO Technical Report Series, No. 908).\n\nGood manufacturing practices: requirement for the sampling of starting materials (amendment). In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 2 (WHO Technical Report Series, No. 929).\n\nSterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 6 (WHO Technical Report Series, No. 902).\n\nInvestigational pharmaceutical products for clinical trials in humans. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations*.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es un ap\u00e9ndice del *WHO Technical Report Series 957*, que incluye una lista de referencias relacionadas con las directrices de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre la distribuci\u00f3n y producci\u00f3n de productos farmac\u00e9uticos. Se mencionan pr\u00e1cticas recomendadas para la distribuci\u00f3n y almacenamiento de materiales farmac\u00e9uticos, as\u00ed como buenas pr\u00e1cticas de manufactura. Tambi\u00e9n se incluyen enlaces a recursos en l\u00ednea y detalles sobre informes espec\u00edficos de comit\u00e9s de expertos de la OMS.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son las principales directrices de la OMS para las buenas pr\u00e1cticas de distribuci\u00f3n de materiales farmac\u00e9uticos?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las recomendaciones de la OMS en cuanto a la distribuci\u00f3n de productos farmac\u00e9uticos, que se detalla en el contexto.\n\n2. **\u00bfQu\u00e9 documentos de la OMS abordan las buenas pr\u00e1cticas de manufactura y cu\u00e1les son sus principales enfoques?**\n   - Esta pregunta se centra en identificar los informes espec\u00edficos mencionados en el contexto que tratan sobre las buenas pr\u00e1cticas de manufactura y sus enfoques clave.\n\n3. **\u00bfQu\u00e9 se entiende por el esquema de certificaci\u00f3n de materiales farmac\u00e9uticos de la OMS (SMACS) y cu\u00e1les son sus directrices de implementaci\u00f3n?**\n   - Esta pregunta busca profundizar en el esquema SMACS mencionado en el contexto, solicitando detalles sobre su prop\u00f3sito y las directrices que lo acompa\u00f1an.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Tema Clave: Rendimiento Te\u00f3rico**\n- Definici\u00f3n: El rendimiento te\u00f3rico se refiere a la cantidad de producto que se podr\u00eda generar en cualquier fase de producci\u00f3n, basado en la cantidad de material utilizado, sin considerar p\u00e9rdidas o errores en la producci\u00f3n real.\n\n**Entidades Clave:**\n1. **Organizaci\u00f3n:**\n   - **WHO (Organizaci\u00f3n Mundial de la Salud)**: Publica el documento \"Technical Report Series 957\".\n\n2. **Directrices de la ICH (Conferencia Internacional sobre Armonizaci\u00f3n):**\n   - **Q6B**: Especificaciones, procedimientos de prueba y criterios de aceptaci\u00f3n para productos biotecnol\u00f3gicos/biol\u00f3gicos.\n   - **Q5A**: Evaluaci\u00f3n de la seguridad viral de productos biotecnol\u00f3gicos derivados de l\u00edneas celulares de origen humano o animal.\n   - **Q5D**: Derivaci\u00f3n y caracterizaci\u00f3n de sustratos celulares utilizados para la producci\u00f3n de productos biotecnol\u00f3gicos/biol\u00f3gicos.\n   - **Q1A**: Pruebas de estabilidad de nuevas sustancias y productos farmac\u00e9uticos.\n\n**Implicaciones:**\n- El concepto de rendimiento te\u00f3rico es fundamental para la industria farmac\u00e9utica y biotecnol\u00f3gica, ya que permite establecer expectativas de producci\u00f3n, evaluar la eficiencia de los procesos y mejorar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: WHO, pharmaceutical guidelines, good manufacturing practices, distribution, certification scheme"}}, "173a2358-dcc0-463e-8b97-773a98ed625a": {"node_ids": ["96461032-f9e1-40f0-8590-0a42741ad196"], "metadata": {"page_label": "202", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Thirty-fourth report\n\nGeneva, World Health Organization, 1996, Annex 7 (WHO Technical Report Series, No. 863).\n\nHerbal medicinal products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 3 (WHO Technical Report Series, No. 937).\n\nWater for pharmaceutical use. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 3 (WHO Technical Report Series, No. 929).\n\nHeating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 2 (WHO Technical Report Series, No. 937).\n\nValidation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006, Annex 4 (WHO Technical Report Series, No. 937).\n\n## Quality control\n\nhttp://www.who.int/medicines/areas/quality_safety/quality_assurance/control/en/index.html\n\n*The International Pharmacopoeia (Ph. Int.)* \u2014 Fourth Edition + First Supplement. Geneva, World Health Organization, 2006.\n\nGeneral guidelines for the establishment, maintenance and distribution of chemical reference substances. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report*. Geneva, World Health Organization, 2007, Annex 3 (WHO Technical Report Series, No. 943).\n\nConsiderations for requesting analyses of drug samples. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 4 (WHO Technical Report Series, No. 902).\n\nModel certificate of analysis. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 10 (WHO Technical Report Series, No. 902).\n\n## Related regulatory standards\n\nhttp://www.who.int/medicines/areas/quality_safety/quality_assurance/regulatory_standards/en/", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que se centra en las especificaciones para preparaciones farmac\u00e9uticas. Incluye referencias a productos medicinales herbales, agua para uso farmac\u00e9utico, sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado para formas de dosificaci\u00f3n farmac\u00e9utica no est\u00e9riles, y la validaci\u00f3n de procesos. Tambi\u00e9n aborda el control de calidad y proporciona enlaces a recursos relacionados con est\u00e1ndares regulatorios y gu\u00edas sobre sustancias qu\u00edmicas de referencia.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las recomendaciones espec\u00edficas de la OMS sobre el uso de productos medicinales herbales seg\u00fan el informe mencionado?**\n   - Esta pregunta busca detalles sobre las directrices espec\u00edficas que la OMS proporciona en relaci\u00f3n con los productos herbales, que pueden no estar disponibles en otras fuentes.\n\n2. **\u00bfQu\u00e9 aspectos se consideran en la validaci\u00f3n de procesos seg\u00fan el informe de la OMS?**\n   - Esta pregunta se centra en los criterios y procedimientos que la OMS establece para la validaci\u00f3n, que son cruciales para garantizar la calidad y seguridad de los productos farmac\u00e9uticos.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n se incluye en el modelo de certificado de an\u00e1lisis mencionado en el informe?**\n   - Esta pregunta busca detalles sobre el contenido y la estructura del certificado de an\u00e1lisis, que es un documento importante en el control de calidad de los productos farmac\u00e9uticos.\n\n### Resumen de nivel superior\n\nEl informe de la OMS proporciona directrices y est\u00e1ndares para la calidad y seguridad de las preparaciones farmac\u00e9uticas, abarcando desde productos herbales hasta sistemas de control de calidad. Incluye referencias a informes anteriores y recursos en l\u00ednea que ofrecen informaci\u00f3n adicional sobre regulaciones y pr\u00e1cticas recomendadas en la industria farmac\u00e9utica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Distribuci\u00f3n de Productos Farmac\u00e9uticos:**\n   - Buenas pr\u00e1cticas de comercio y distribuci\u00f3n de materiales farmac\u00e9uticos.\n   - Esquema de certificaci\u00f3n de materiales farmac\u00e9uticos de la OMS (SMACS).\n   - Pr\u00e1cticas de almacenamiento adecuadas para productos farmac\u00e9uticos.\n\n2. **Producci\u00f3n de Productos Farmac\u00e9uticos:**\n   - Buenas pr\u00e1cticas de manufactura (BPM) para productos farmac\u00e9uticos.\n   - Requisitos para el muestreo de materiales de partida.\n   - Normativas para productos farmac\u00e9uticos est\u00e9riles.\n   - Productos farmac\u00e9uticos investigacionales para ensayos cl\u00ednicos en humanos.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Entidad responsable de la elaboraci\u00f3n de las directrices y recomendaciones.\n- **Comit\u00e9s de Expertos de la OMS:** Grupos que elaboran informes y recomendaciones sobre especificaciones para preparaciones farmac\u00e9uticas.\n- **Documentos Citados:**\n  - *WHO Technical Report Series, No. 917*\n  - *WHO Technical Report Series, No. 908*\n  - *WHO Technical Report Series, No. 929*\n  \n**Enlaces Relevantes:**\n- Recursos en l\u00ednea sobre buenas pr\u00e1cticas de distribuci\u00f3n y producci\u00f3n de productos farmac\u00e9uticos proporcionados por la OMS. \n\nEste resumen destaca la importancia de las directrices de la OMS en la regulaci\u00f3n de la distribuci\u00f3n y producci\u00f3n de productos farmac\u00e9uticos, as\u00ed como los documentos clave que respaldan estas pr\u00e1cticas.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, quality control, herbal medicinal products, validation"}}, "f2d002eb-6d82-4e34-a131-c624b4a1cf18": {"node_ids": ["518cb51f-73de-466c-8e3f-ffcf7917363d"], "metadata": {"page_label": "203", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 2 (WHO Technical Report Series, No. 953).\n\nProcedure for assessing the acceptability, in principle, of active pharmaceutical ingredients for use in pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 4 (WHO Technical Report Series, No. 953).\n\nGuidelines on active pharmaceutical ingredient master file procedure. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-second report*. Geneva, World Health Organization, 2008, Annex 4 (WHO Technical Report Series, No. 948).\n\nGuidance on variations to a prequalified product dossier. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report*. Geneva, World Health Organization, 2007, Annex 6 (WHO Technical Report Series, No. 943).\n\nWHO guidelines for sampling of pharmaceutical products and related materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 4 (WHO Technical Report Series, No. 929).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (Organizaci\u00f3n Mundial de la Salud) y se centra en las especificaciones y directrices relacionadas con los ingredientes farmac\u00e9uticos activos y los productos farmac\u00e9uticos terminados. Incluye informes de varias reuniones del Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas, donde se abordan temas como la estabilidad de los ingredientes, la aceptaci\u00f3n de ingredientes para productos farmac\u00e9uticos, procedimientos para archivos maestros de ingredientes activos y gu\u00edas sobre variaciones en los expedientes de productos prequalificados.\n\n### Preguntas espec\u00edficas\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que se utilizan para evaluar la aceptabilidad de los ingredientes farmac\u00e9uticos activos seg\u00fan el informe de 2009?**\n   - Esta pregunta busca detalles sobre los criterios de evaluaci\u00f3n que pueden no estar disponibles en otras fuentes.\n\n2. **\u00bfQu\u00e9 procedimientos se describen en el documento para la elaboraci\u00f3n y mantenimiento de un archivo maestro de ingredientes activos?**\n   - Esta pregunta se centra en los procedimientos espec\u00edficos que se deben seguir, que pueden no estar ampliamente documentados en otros lugares.\n\n3. **\u00bfQu\u00e9 recomendaciones se ofrecen en el informe de 2005 sobre el muestreo de productos farmac\u00e9uticos y materiales relacionados?**\n   - Esta pregunta busca informaci\u00f3n sobre las pr\u00e1cticas de muestreo que son cruciales para la calidad y seguridad de los productos farmac\u00e9uticos, y que pueden no ser f\u00e1cilmente accesibles en otras fuentes.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Informe T\u00e9cnico de la OMS**: El documento es parte de la Serie de Informes T\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS), espec\u00edficamente el No. 957, que aborda especificaciones para preparaciones farmac\u00e9uticas.\n\n2. **Productos Medicinales Herbales**: Se mencionan directrices sobre el uso y la regulaci\u00f3n de productos herbales en el contexto farmac\u00e9utico, referenciando el informe de la OMS de 2006.\n\n3. **Agua para Uso Farmac\u00e9utico**: Se incluyen especificaciones sobre la calidad del agua utilizada en la fabricaci\u00f3n de productos farmac\u00e9uticos, citando un informe de 2005.\n\n4. **Sistemas de HVAC**: Se abordan las recomendaciones para sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado en la producci\u00f3n de formas de dosificaci\u00f3n farmac\u00e9utica no est\u00e9riles.\n\n5. **Validaci\u00f3n de Procesos**: Se discuten los criterios y procedimientos necesarios para validar procesos en la producci\u00f3n farmac\u00e9utica, asegurando la calidad y seguridad de los productos.\n\n6. **Control de Calidad**: Se proporciona un enlace a recursos sobre control de calidad y se menciona la *Farmacopea Internacional* como referencia clave.\n\n7. **Sustancias Qu\u00edmicas de Referencia**: Se ofrecen pautas generales para el establecimiento y mantenimiento de sustancias qu\u00edmicas de referencia, as\u00ed como consideraciones para el an\u00e1lisis de muestras de medicamentos.\n\n8. **Certificado de An\u00e1lisis**: Se menciona un modelo de certificado de an\u00e1lisis que es fundamental para el control de calidad en la industria farmac\u00e9utica.\n\n9. **Est\u00e1ndares Regulatorios**: Se incluyen enlaces a recursos relacionados con est\u00e1ndares regulatorios y gu\u00edas sobre la calidad y seguridad de los productos farmac\u00e9uticos.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **WHO Technical Report Series**\n- **Productos Medicinales Herbales**\n- **Agua para Uso Farmac\u00e9utico**\n- **Sistemas de Calefacci\u00f3n, Ventilaci\u00f3n y Aire Acondicionado (HVAC)**\n- **Control de Calidad**\n- **Farmacopea Internacional (Ph. Int.)**\n- **Sustancias Qu\u00edmicas de Referencia** \n\nEste resumen destaca los temas centrales y las entidades relevantes en el contexto del informe t\u00e9cnico de la OMS sobre especificaciones para preparaciones farmac\u00e9uticas.", "excerpt_keywords": "Keywords: estabilidad, ingredientes farmac\u00e9uticos activos, muestreo, archivo maestro, directrices"}}, "e73cdffd-4dca-450d-a8eb-0c4ded11757e": {"node_ids": ["ef79f78a-8a1c-4bc4-8516-ade6a9cd1c6f"], "metadata": {"page_label": "204", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 2\n\n## General notes: additional clarifications and explanations\n\n2.1.1 The intent of this clause is that senior management of the API manufacturer has the responsibility to ensure that there is an effective quality management system in place and that all employees are made aware of their roles and responsibilities in assuring the quality of the API(s) produced.\n\n2.3 The intent of this clause is to specify the roles and responsibilities that should apply to production activities and, in particular, that these responsibilities should not be delegated to non-production personnel within the company or to any persons outside the company.\n\n5.2.1 This clause requires a written standard operating procedure (SOP) covering the maintenance of equipment. Important information to specify in this SOP should include:\n\n- who is responsible for coordinating equipment maintenance activities (usually production management or engineering management);\n- a provision that a schedule of planned preventive maintenance of equipment should be available (a useful reference is *ISPE Good Practice Guide: Maintenance. May 2009* (1));\n- a statement of the necessity to follow proper change control procedures where non-routine repairs, or modifications, replacements or other activities, are required.\n\n7.1.2 There is an expectation that suppliers of critical materials should be subject to on-site audits as part of the company\u2019s supplier qualification programme.\n\n7.2.1 There is an expectation that upon receipt and before acceptance of materials, each container or grouping of containers of materials should be examined visually for correct labelling, including correlation between the name used by the supplier and the in-house name. If these names are different, both names should be recorded and verified against a previously approved list of synonyms and checked by a scientifically qualified person.\n\n7.3.1 This clause requires that at least one test be performed to verify the identity of each batch of material received. For clarification, one test for identity may not be sufficient in the majority of cases as this is dependent on various aspects, including supplier qualification.\n\n11.7.3 For clarification, the reserve sample should be stored in a packaging system designed to give maximum protection of the API against change over time, e.g. a glass bottle with tightly fitted cap.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es un ap\u00e9ndice del Informe T\u00e9cnico de la OMS sobre la calidad de los principios activos farmac\u00e9uticos (API). Se centra en la responsabilidad de la alta direcci\u00f3n en la implementaci\u00f3n de un sistema de gesti\u00f3n de calidad efectivo, la importancia de las responsabilidades en las actividades de producci\u00f3n, y los procedimientos operativos est\u00e1ndar (SOP) necesarios para el mantenimiento de equipos y la gesti\u00f3n de materiales cr\u00edticos. Tambi\u00e9n se menciona la necesidad de auditor\u00edas a proveedores y la verificaci\u00f3n de la identidad de los materiales recibidos.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1l es la responsabilidad espec\u00edfica de la alta direcci\u00f3n en relaci\u00f3n con el sistema de gesti\u00f3n de calidad de los API?**\n   - La alta direcci\u00f3n del fabricante de API es responsable de asegurar que exista un sistema de gesti\u00f3n de calidad efectivo y que todos los empleados conozcan sus roles y responsabilidades en la garant\u00eda de calidad de los API producidos.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse al recibir materiales cr\u00edticos para asegurar su correcta identificaci\u00f3n?**\n   - Al recibir materiales, cada contenedor debe ser examinado visualmente para verificar el etiquetado correcto, asegurando que el nombre del proveedor coincida con el nombre interno. Si hay discrepancias, ambos nombres deben ser registrados y verificados contra una lista aprobada de sin\u00f3nimos por una persona calificada cient\u00edficamente.\n\n3. **\u00bfQu\u00e9 se debe incluir en un procedimiento operativo est\u00e1ndar (SOP) para el mantenimiento de equipos?**\n   - El SOP debe incluir qui\u00e9n es responsable de coordinar las actividades de mantenimiento, un cronograma de mantenimiento preventivo planificado, y la necesidad de seguir procedimientos de control de cambios adecuados para reparaciones no rutinarias o modificaciones.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Estabilidad de Ingredientes Farmac\u00e9uticos Activos y Productos Farmac\u00e9uticos Terminados**:\n   - Se aborda la importancia de realizar pruebas de estabilidad para garantizar la calidad y seguridad de los productos farmac\u00e9uticos.\n\n2. **Aceptabilidad de Ingredientes Farmac\u00e9uticos Activos**:\n   - Se describen los procedimientos para evaluar la aceptabilidad de los ingredientes activos en productos farmac\u00e9uticos, lo que es crucial para su uso seguro.\n\n3. **Archivo Maestro de Ingredientes Activos**:\n   - Se proporcionan directrices sobre c\u00f3mo elaborar y mantener un archivo maestro para ingredientes activos, que es esencial para la regulaci\u00f3n y control de calidad.\n\n4. **Variaciones en Expedientes de Productos Precalificados**:\n   - Se ofrecen orientaciones sobre c\u00f3mo manejar las variaciones en los expedientes de productos que han sido precalificados, asegurando que se mantenga la calidad.\n\n5. **Muestreo de Productos Farmac\u00e9uticos**:\n   - Se presentan directrices sobre las pr\u00e1cticas de muestreo de productos farmac\u00e9uticos y materiales relacionados, que son fundamentales para la evaluaci\u00f3n de la calidad.\n\n### Entidades Clave\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad responsable de la elaboraci\u00f3n de las directrices y especificaciones.\n- **Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas**: Grupo que elabora los informes y recomendaciones.\n- **Informes T\u00e9cnicos de la OMS**: Serie de documentos que contienen las especificaciones y directrices mencionadas.\n\n### Documentos Citados\n\n- **WHO Technical Report Series, No. 953**: Informe de 2009 que incluye temas sobre estabilidad y aceptabilidad de ingredientes.\n- **WHO Technical Report Series, No. 948**: Informe de 2008 que trata sobre el archivo maestro de ingredientes activos.\n- **WHO Technical Report Series, No. 943**: Informe de 2007 que aborda las variaciones en expedientes de productos.\n- **WHO Technical Report Series, No. 929**: Informe de 2005 que proporciona directrices sobre el muestreo de productos farmac\u00e9uticos. \n\nEste resumen destaca los aspectos fundamentales y las entidades relevantes en la secci\u00f3n del documento, proporcionando una visi\u00f3n clara de su contenido y prop\u00f3sito.", "excerpt_keywords": "Keywords: quality management, active pharmaceutical ingredients, standard operating procedures, supplier qualification, equipment maintenance"}}, "feddbbc9-1870-4c76-b611-fe4909d44af0": {"node_ids": ["b11b5e92-85a9-4c69-b5a8-d746bb2475e5"], "metadata": {"page_label": "205", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "17. Refer to WHO GTDP (2) and WHO GMP for excipients (3).\n\n18. See footnote on p. 174.\n\n## API starting material\n\nAs discussed in this document the introduction of the API starting material into the manufacturing process is where the requirements of GMP commence.\n\nThe API starting material itself needs to be proposed and justified by the manufacturer and accepted as such by assessors. This justification should be documented and be available for review by WHO GMP inspectors.\n\nThe API starting material should be fully characterized according to identity and purity. In addition, the steps prior to the step where the API starting material appears, which may involve \u201cstarting materials for synthesis\u201d, should be available in the form of a flow chart.\n\nIn general, the starting materials for synthesis should:\n\n- be a synthetic precursor one or more synthetic steps prior to the final API intermediate;\n- be a well characterized, isolated and purified substance with a fully elucidated structure;\n- have well defined specifications which include one or more specific identity tests, and tests and limits for potency, specified and unspecified impurities and total impurities.\n\n## References\n\n1. International Society for Pharmaceutical Engineering. *ISPE good practice guide: maintenance*. 2009 (http://www.ispe.org/cs/ispe_good_practice_guides_section/ispe_good_practice_guides).\n\n2. Good trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2003, Annex 2 (WHO Technical Report Series, No. 917) (http://www.who.int/medicines/areas/quality_safety/quality_assurance/distribution/en/index.html).\n\n3. WHO GMP for excipients In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report*. Geneva, World Health Organization, 1999, Annex 5 (WHO Technical Report Series, No. 885) (http://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/index.html); and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, 2nd updated ed., Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las pr\u00e1cticas de buenas manufacturas (GMP) relacionadas con los materiales de partida de los ingredientes farmac\u00e9uticos activos (API). Se enfatiza que la introducci\u00f3n del material de partida en el proceso de fabricaci\u00f3n es el punto donde comienzan los requisitos de GMP. El material de partida debe ser propuesto y justificado por el fabricante, y esta justificaci\u00f3n debe estar documentada y disponible para revisi\u00f3n. Adem\u00e1s, se requiere que el material de partida est\u00e9 completamente caracterizado en t\u00e9rminos de identidad y pureza, y que se presenten los pasos previos en un diagrama de flujo. Se establecen especificaciones claras para los materiales de partida, que incluyen pruebas de identidad y l\u00edmites para impurezas.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son los requisitos espec\u00edficos que debe cumplir un material de partida para ser aceptado como ingrediente farmac\u00e9utico activo (API) seg\u00fan las directrices de la OMS?**\n   - Esta pregunta busca detalles sobre las especificaciones y caracter\u00edsticas que un material de partida debe tener para cumplir con las normativas de la OMS.\n\n2. **\u00bfQu\u00e9 documentaci\u00f3n se requiere para justificar la aceptaci\u00f3n de un material de partida por parte de los evaluadores de la OMS?**\n   - Esta pregunta se centra en el tipo de documentaci\u00f3n que los fabricantes deben proporcionar para respaldar su propuesta de material de partida.\n\n3. **\u00bfC\u00f3mo deben presentarse los pasos previos a la introducci\u00f3n del material de partida en el proceso de fabricaci\u00f3n?**\n   - Esta pregunta indaga sobre la forma en que se deben documentar y presentar los pasos anteriores al material de partida, espec\u00edficamente en relaci\u00f3n con el uso de diagramas de flujo. \n\nEstas preguntas est\u00e1n dise\u00f1adas para obtener informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otras fuentes, ya que se centran en los requisitos y procedimientos establecidos por la OMS en el contexto de la fabricaci\u00f3n de productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Responsabilidad de la Alta Direcci\u00f3n**:\n   - La alta direcci\u00f3n de los fabricantes de principios activos farmac\u00e9uticos (API) debe garantizar un sistema de gesti\u00f3n de calidad efectivo y asegurar que todos los empleados comprendan sus roles en la calidad del producto.\n\n2. **Roles y Responsabilidades en Producci\u00f3n**:\n   - Se especifica que las responsabilidades en las actividades de producci\u00f3n no deben ser delegadas a personal no relacionado con la producci\u00f3n ni a personas externas a la empresa.\n\n3. **Procedimientos Operativos Est\u00e1ndar (SOP)**:\n   - Se requiere un SOP escrito para el mantenimiento de equipos, que debe incluir:\n     - Coordinaci\u00f3n de actividades de mantenimiento.\n     - Un cronograma de mantenimiento preventivo.\n     - Procedimientos de control de cambios para reparaciones no rutinarias.\n\n4. **Auditor\u00edas a Proveedores**:\n   - Se espera que los proveedores de materiales cr\u00edticos sean sometidos a auditor\u00edas en el sitio como parte del programa de calificaci\u00f3n de proveedores de la empresa.\n\n5. **Verificaci\u00f3n de Materiales Recibidos**:\n   - Al recibir materiales, cada contenedor debe ser examinado visualmente para verificar el etiquetado correcto. Si hay discrepancias en los nombres, deben ser registradas y verificadas.\n\n6. **Pruebas de Identidad de Materiales**:\n   - Se requiere realizar al menos una prueba para verificar la identidad de cada lote de material recibido, aunque una sola prueba puede no ser suficiente dependiendo de la calificaci\u00f3n del proveedor.\n\n7. **Almacenamiento de Muestras de Reserva**:\n   - Las muestras de reserva deben almacenarse en un sistema de embalaje que ofrezca m\u00e1xima protecci\u00f3n contra cambios a lo largo del tiempo.\n\n### Entidades Clave:\n- **API (Principios Activos Farmac\u00e9uticos)**: Sustancias utilizadas en la fabricaci\u00f3n de medicamentos.\n- **SOP (Procedimientos Operativos Est\u00e1ndar)**: Documentos que describen c\u00f3mo realizar tareas espec\u00edficas.\n- **ISPE (International Society for Pharmaceutical Engineering)**: Referencia mencionada para buenas pr\u00e1cticas en mantenimiento.\n- **Proveedores de Materiales Cr\u00edticos**: Entidades que suministran materiales esenciales para la producci\u00f3n de API.\n- **Muestras de Reserva**: Muestras de productos almacenadas para referencia futura.", "excerpt_keywords": "Keywords: API starting material, GMP, pharmaceutical manufacturing, specifications, WHO guidelines"}}, "ff13a061-005d-48a2-b0d8-bd029ee8a109": {"node_ids": ["c91287e3-67ac-46be-9fe3-47623d155594"], "metadata": {"page_label": "206", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 3\n\n## WHO good manufacturing practices for pharmaceutical products containing hazardous substances\n\n1. Introduction\n2. General\n3. Glossary\n4. Risk assessment\n5. Product protection\n6. Personal protection equipment and breathing air systems\n7. Environmental protection\n8. Facility layout\n9. Air-handling systems\n10. Air-handling units\n11. Safe change filter housings\n12. Personnel decontamination systems\n13. Effluent treatment\n14. Maintenance\n15. Qualification and validation\n\nReferences", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 957\" incluye un anexo que detalla las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para productos farmac\u00e9uticos que contienen sustancias peligrosas. Este anexo abarca una variedad de temas esenciales para garantizar la seguridad y la calidad en la producci\u00f3n de estos productos, incluyendo la evaluaci\u00f3n de riesgos, la protecci\u00f3n del producto, el equipo de protecci\u00f3n personal, la disposici\u00f3n de las instalaciones y la validaci\u00f3n de procesos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los componentes clave que se deben considerar en la evaluaci\u00f3n de riesgos para productos farmac\u00e9uticos que contienen sustancias peligrosas?**\n   - Esta pregunta se centra en el apartado de \"Evaluaci\u00f3n de riesgos\" y busca detalles sobre los factores espec\u00edficos que deben ser analizados para garantizar la seguridad en la fabricaci\u00f3n.\n\n2. **\u00bfQu\u00e9 medidas de protecci\u00f3n personal se recomiendan para el manejo de sustancias peligrosas en la fabricaci\u00f3n farmac\u00e9utica?**\n   - Esta pregunta se relaciona con el tema de \"Equipo de protecci\u00f3n personal y sistemas de aire respirable\", buscando informaci\u00f3n sobre las mejores pr\u00e1cticas y equipos necesarios para proteger a los trabajadores.\n\n3. **\u00bfQu\u00e9 aspectos se deben considerar en el dise\u00f1o de la disposici\u00f3n de las instalaciones para minimizar la exposici\u00f3n a sustancias peligrosas?**\n   - Esta pregunta se refiere al apartado de \"Disposici\u00f3n de las instalaciones\" y busca entender c\u00f3mo el dise\u00f1o f\u00edsico de las instalaciones puede influir en la seguridad y la eficacia de la producci\u00f3n. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que probablemente no se encuentre f\u00e1cilmente en otros documentos o fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Material de Partida de API**: \n   - La introducci\u00f3n del material de partida de ingredientes farmac\u00e9uticos activos (API) en el proceso de fabricaci\u00f3n marca el inicio de los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP).\n   - El material de partida debe ser propuesto y justificado por el fabricante, y esta justificaci\u00f3n debe estar documentada y disponible para revisi\u00f3n por inspectores de la OMS.\n\n2. **Caracterizaci\u00f3n**:\n   - El material de partida debe estar completamente caracterizado en t\u00e9rminos de identidad y pureza.\n   - Se requiere un diagrama de flujo que muestre los pasos previos a la introducci\u00f3n del material de partida, que pueden incluir \"materiales de partida para la s\u00edntesis\".\n\n3. **Especificaciones de Materiales de Partida**:\n   - Deben ser precursores sint\u00e9ticos en uno o m\u00e1s pasos sint\u00e9ticos antes del intermediario final del API.\n   - Deben ser sustancias bien caracterizadas, aisladas y purificadas, con una estructura completamente elucidada.\n   - Deben tener especificaciones bien definidas que incluyan pruebas de identidad y l\u00edmites para potencia, impurezas especificadas y no especificadas, y total de impurezas.\n\n4. **Referencias**:\n   - Se citan documentos y gu\u00edas relevantes de la OMS y otras organizaciones que establecen est\u00e1ndares y pr\u00e1cticas para la manufactura y distribuci\u00f3n de materiales farmac\u00e9uticos.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices de GMP.\n- **API (Ingrediente Farmac\u00e9utico Activo)**: Sustancia que se utiliza en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Conjunto de regulaciones que aseguran que los productos farmac\u00e9uticos se fabriquen de manera consistente y controlada.\n- **ISPE (International Society for Pharmaceutical Engineering)**: Organizaci\u00f3n que proporciona gu\u00edas y buenas pr\u00e1cticas en la ingenier\u00eda farmac\u00e9utica. \n\nEste resumen destaca los aspectos fundamentales relacionados con los materiales de partida en la fabricaci\u00f3n de productos farmac\u00e9uticos, as\u00ed como las normativas y requisitos establecidos por la OMS.", "excerpt_keywords": "Keywords: manufacturing practices, hazardous substances, risk assessment, personal protection, environmental protection"}}, "6cb923c9-7aec-4c3b-a13e-ef3608eef36a": {"node_ids": ["ba096cb1-0346-4383-b1a8-d3617b29d07d"], "metadata": {"page_label": "207", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 1. Introduction\n\n1.1 These guidelines set out good practices applicable to facilities handling pharmaceutical products (including active pharmaceutical ingredients (APIs)) that contain hazardous substances such as certain hormones, steroids or cytotoxins. They do not replace national legislation for protection of the environment and personnel. Other WHO guides to good manufacturing practices (GMP) and regulations need to be observed in addition to the workers\u2019 safety criteria (1\u20134).\n\n1.2 These guidelines are to be read in conjunction with other WHO GMP guidelines with respect to building finishes and general services installations, among others. See the reference list for relevant publications which serve as additional background material. The primary focus of these guidelines is on the air-conditioning and ventilation systems of the facility; however, the document also provides some guidance on personnel protection.\n\n1.3 The areas to which this document applies include all zones where the handling of products could lead to cross-contamination, exposure of personnel, or discharge to the environment. This includes research and development facilities, and the sites of API manufacturing and storage and of finished product manufacturing.\n\n1.4 Where possible products should be manufactured in closed systems.\n\n# 2. General\n\n2.1 Facilities should be designed and operated in accordance with the main GMP principles, as follows:\n\n- to ensure quality of product;\n- to protect the operators from possible harmful effects of products containing hazardous substances; and\n- to protect the environment from contamination and thereby protect the public from possible harmful effects of products containing hazardous substances.\n\n2.2 The production of certain products containing hazardous substances should generally be conducted in separate, dedicated, self-contained facilities.\n\nThese **self-contained facilities** may be in the same building as another facility but should be separated by a physical barrier and have, e.g. separate entrances, staff facilities and air-handling systems. The extent of the separation from adjacent facilities and sharing of common services should be determined by risk assessment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Objetivo de las directrices**: Las directrices establecen buenas pr\u00e1cticas para las instalaciones que manejan productos farmac\u00e9uticos que contienen sustancias peligrosas, enfatizando la importancia de la seguridad del personal y la protecci\u00f3n del medio ambiente, sin reemplazar la legislaci\u00f3n nacional.\n\n2. **\u00c1reas de aplicaci\u00f3n**: Las directrices se aplican a todas las zonas donde el manejo de productos puede causar contaminaci\u00f3n cruzada, exposici\u00f3n del personal o descarga al medio ambiente, incluyendo instalaciones de investigaci\u00f3n y desarrollo, as\u00ed como sitios de fabricaci\u00f3n y almacenamiento de ingredientes farmac\u00e9uticos activos (APIs) y productos terminados.\n\n3. **Dise\u00f1o y operaci\u00f3n de instalaciones**: Se enfatiza que las instalaciones deben ser dise\u00f1adas y operadas de acuerdo con los principios de buenas pr\u00e1cticas de manufactura (GMP), asegurando la calidad del producto y protegiendo tanto a los operadores como al medio ambiente de los efectos nocivos de las sustancias peligrosas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de instalaciones deben ser consideradas como \"autocontenidas\" seg\u00fan las directrices y qu\u00e9 caracter\u00edsticas deben tener para cumplir con esta definici\u00f3n?**\n   - Respuesta: Las instalaciones autocontenidas deben estar separadas por una barrera f\u00edsica de otras instalaciones, tener entradas y salidas separadas, as\u00ed como instalaciones para el personal y sistemas de manejo de aire independientes. La extensi\u00f3n de esta separaci\u00f3n debe ser determinada por una evaluaci\u00f3n de riesgos.\n\n2. **\u00bfCu\u00e1les son los principios clave de las buenas pr\u00e1cticas de manufactura (GMP) que deben seguir las instalaciones que manejan productos farmac\u00e9uticos peligrosos?**\n   - Respuesta: Los principios clave incluyen asegurar la calidad del producto, proteger a los operadores de los efectos nocivos de las sustancias peligrosas y proteger el medio ambiente de la contaminaci\u00f3n, lo que a su vez protege al p\u00fablico de posibles efectos perjudiciales.\n\n3. **\u00bfQu\u00e9 se recomienda en cuanto a la fabricaci\u00f3n de productos que contienen sustancias peligrosas en relaci\u00f3n con los sistemas de producci\u00f3n?**\n   - Respuesta: Se recomienda que, siempre que sea posible, los productos se fabriquen en sistemas cerrados para minimizar la exposici\u00f3n y el riesgo de contaminaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl anexo 3 del documento \"WHO - Technical Report Series 957\" se centra en las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para productos farmac\u00e9uticos que contienen sustancias peligrosas. A continuaci\u00f3n se presentan los temas clave abordados en esta secci\u00f3n:\n\n1. **Introducci\u00f3n**: Presenta el contexto y la importancia de las BPF en la fabricaci\u00f3n de productos farmac\u00e9uticos peligrosos.\n2. **General**: Proporciona principios generales que gu\u00edan las pr\u00e1cticas de fabricaci\u00f3n.\n3. **Glosario**: Define t\u00e9rminos relevantes utilizados en el documento.\n4. **Evaluaci\u00f3n de riesgos**: Detalla el proceso de identificaci\u00f3n y an\u00e1lisis de riesgos asociados con sustancias peligrosas.\n5. **Protecci\u00f3n del producto**: Describe medidas para asegurar la integridad y calidad del producto durante su fabricaci\u00f3n.\n6. **Equipo de protecci\u00f3n personal y sistemas de aire respirable**: Especifica el equipo necesario para proteger a los trabajadores que manejan sustancias peligrosas.\n7. **Protecci\u00f3n ambiental**: Aborda las pr\u00e1cticas para minimizar el impacto ambiental de la fabricaci\u00f3n.\n8. **Disposici\u00f3n de las instalaciones**: Discute el dise\u00f1o f\u00edsico de las instalaciones para mejorar la seguridad.\n9. **Sistemas de manejo de aire**: Explica la importancia de los sistemas de ventilaci\u00f3n y filtraci\u00f3n en el entorno de trabajo.\n10. **Unidades de manejo de aire**: Detalla las caracter\u00edsticas y funciones de estas unidades en la fabricaci\u00f3n.\n11. **C\u00e1maras de cambio seguro de filtros**: Describe las pr\u00e1cticas para el manejo seguro de filtros en el proceso de fabricaci\u00f3n.\n12. **Sistemas de descontaminaci\u00f3n del personal**: Proporciona directrices para la descontaminaci\u00f3n de trabajadores expuestos a sustancias peligrosas.\n13. **Tratamiento de efluentes**: Aborda la gesti\u00f3n y tratamiento de desechos generados durante la producci\u00f3n.\n14. **Mantenimiento**: Resalta la importancia del mantenimiento regular de equipos e instalaciones.\n15. **Calificaci\u00f3n y validaci\u00f3n**: Describe los procesos necesarios para asegurar que los sistemas y procesos cumplen con los est\u00e1ndares requeridos.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Productos farmac\u00e9uticos**: Categor\u00eda de productos en discusi\u00f3n.\n- **Sustancias peligrosas**: Tipo de materiales que requieren pr\u00e1cticas especiales de manejo.\n- **Buenas pr\u00e1cticas de fabricaci\u00f3n (BPF)**: Conjunto de directrices para asegurar la calidad y seguridad en la producci\u00f3n.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades clave que se abordan en el anexo, destacando la importancia de las BPF en la fabricaci\u00f3n de productos farmac\u00e9uticos que contienen sustancias peligrosas.", "excerpt_keywords": "Keywords: pharmaceutical products, hazardous substances, good manufacturing practices, air-conditioning systems, risk assessment"}}, "d9bf7809-87f5-4749-9830-37bf38e77a7a": {"node_ids": ["f11563f4-38c8-44d7-9360-538bb39e6500"], "metadata": {"page_label": "208", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 2.3\n\nIn general these manufacturing facilities should be regarded as containment facilities.\n\n## 2.4\n\nThe effective operation of a facility may require the combination of some or all of the following aspects:\n- Appropriate facility design and layout, with the emphasis on safely containing the materials being handled. Manufacturing processes using closed systems or barrier technology enhance operator and product protection;\n- Manufacturing process controls including adherence to standard operating procedures (SOPs);\n- Appropriately designed environmental control systems (ECS) or heating, ventilation and air-conditioning (HVAC);\n- Extraction systems;\n- Personal protective equipment (PPE);\n- Appropriate degowning and decontamination procedures;\n- Industrial hygiene (monitoring staff exposure levels);\n- Medical surveillance (monitoring staff exposure levels); and\n- Administrative controls.\n\n## 3. Glossary\n\nThe definitions given below apply to terms used in these guidelines. They may have a different meaning in other contexts.\n\n### action limit\n\nThe action limit is reached when the acceptance criteria of a critical parameter have been exceeded. Results outside these limits will require specified action and investigation.\n\n### active pharmaceutical ingredient (API)\n\nAny substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the body.\n\n### air-handling unit (AHU)\n\nThe air-handling unit serves to condition the air and provide the required air movement within a facility.\n\n### airlock\n\nAn enclosed space with two or more doors, which is interposed between two or more rooms, e.g. of differing classes of cleanliness, for the purpose of", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en su Informe T\u00e9cnico 957 aborda las instalaciones de fabricaci\u00f3n de productos farmac\u00e9uticos, enfatizando la importancia de considerarlas como instalaciones de contenci\u00f3n. Se describen varios aspectos clave para el funcionamiento efectivo de estas instalaciones, incluyendo el dise\u00f1o adecuado, controles de procesos, sistemas de control ambiental, y el uso de equipos de protecci\u00f3n personal. Adem\u00e1s, se proporciona un glosario de t\u00e9rminos relevantes, como \"l\u00edmite de acci\u00f3n\", \"ingrediente farmac\u00e9utico activo\" y \"unidad de tratamiento de aire\".\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los aspectos clave que deben considerarse para el dise\u00f1o y operaci\u00f3n efectiva de una instalaci\u00f3n de fabricaci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Los aspectos clave incluyen un dise\u00f1o y disposici\u00f3n adecuados de la instalaci\u00f3n, controles de procesos de fabricaci\u00f3n, sistemas de control ambiental, sistemas de extracci\u00f3n, uso de equipos de protecci\u00f3n personal, procedimientos de desvestido y descontaminaci\u00f3n, higiene industrial, vigilancia m\u00e9dica y controles administrativos.\n\n2. **\u00bfQu\u00e9 se entiende por \"l\u00edmite de acci\u00f3n\" en el contexto de las instalaciones de fabricaci\u00f3n farmac\u00e9utica?**\n   - Respuesta: El \"l\u00edmite de acci\u00f3n\" se alcanza cuando se superan los criterios de aceptaci\u00f3n de un par\u00e1metro cr\u00edtico. Los resultados que se encuentren fuera de estos l\u00edmites requerir\u00e1n acciones e investigaciones espec\u00edficas.\n\n3. **\u00bfQu\u00e9 es un \"air-handling unit\" (AHU) y cu\u00e1l es su funci\u00f3n en una instalaci\u00f3n de fabricaci\u00f3n?**\n   - Respuesta: Una \"unidad de tratamiento de aire\" (AHU) es un sistema que se encarga de acondicionar el aire y proporcionar el movimiento de aire requerido dentro de una instalaci\u00f3n, lo que es crucial para mantener las condiciones ambientales adecuadas en el proceso de fabricaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Objetivo de las Directrices**: Establecer buenas pr\u00e1cticas para instalaciones que manejan productos farmac\u00e9uticos con sustancias peligrosas, enfatizando la seguridad del personal y la protecci\u00f3n del medio ambiente, sin sustituir la legislaci\u00f3n nacional.\n\n2. **\u00c1reas de Aplicaci\u00f3n**: Las directrices son aplicables a todas las zonas donde el manejo de productos puede causar contaminaci\u00f3n cruzada, exposici\u00f3n del personal o descarga al medio ambiente, incluyendo instalaciones de investigaci\u00f3n y desarrollo, as\u00ed como sitios de fabricaci\u00f3n y almacenamiento de ingredientes farmac\u00e9uticos activos (APIs) y productos terminados.\n\n3. **Dise\u00f1o y Operaci\u00f3n de Instalaciones**: Las instalaciones deben ser dise\u00f1adas y operadas de acuerdo con los principios de buenas pr\u00e1cticas de manufactura (GMP), asegurando la calidad del producto y protegiendo a los operadores y al medio ambiente de los efectos nocivos de las sustancias peligrosas.\n\n4. **Instalaciones Autocontenidas**: Se recomienda que la producci\u00f3n de ciertos productos peligrosos se realice en instalaciones autocontenidas, que deben estar separadas por barreras f\u00edsicas y contar con entradas, instalaciones para el personal y sistemas de manejo de aire independientes.\n\n5. **Sistemas Cerrados**: Se sugiere que, siempre que sea posible, los productos se fabriquen en sistemas cerrados para minimizar la exposici\u00f3n y el riesgo de contaminaci\u00f3n.\n\n### Entidades\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Principios que deben seguir las instalaciones.\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Productos farmac\u00e9uticos que contienen sustancias peligrosas.\n- **Sustancias Peligrosas**: Hormonas, esteroides, citotoxinas y otros productos que pueden ser nocivos para la salud y el medio ambiente.\n- **Instalaciones Autocontenidas**: Espacios dise\u00f1ados para manejar productos peligrosos de manera segura y aislada.", "excerpt_keywords": "Keywords: containment facilities, active pharmaceutical ingredient, air-handling unit, manufacturing process controls, personal protective equipment"}}, "bcc4fd7f-a6b8-46c3-ab85-fd19aa2718f8": {"node_ids": ["c0726ef1-ba31-4b83-99fd-cc6e156da529"], "metadata": {"page_label": "209", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "controlling the airflow between those rooms when they need to be entered. An airlock is designed for and used by either people or goods (this can be a personnel airlock (PAL) or a material airlock (MAL)).\n\n**alert limit**  \nThe alert limit is reached when the normal operating range of a critical parameter has been exceeded, indicating that corrective measures may need to be taken to prevent the action limit being reached.\n\n**barrier technology**  \nA system designed to segregate people from the product, contain contaminants or segregate two areas, which could be a barrier isolator (BI) or a restricted access barrier system (RABS):\n\n- A BI is a unit supplied with high-efficiency particulate air (HEPA) filtered air that provides uncompromised continuous isolation of its interior from the external environment, including surrounding clean room air and personnel.\n- A RABS is a type of barrier system that reduces or eliminates interventions into the critical zone. In practice, its level of contamination control is less than that of a barrier isolator.\n\n**clean room**  \nA room or area with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation and retention of contaminants within the area.\n\n**commissioning**  \nCommissioning is the documented process of verifying that the equipment and systems are installed according to specifications, placing the equipment into active service and verifying its proper action. Commissioning takes place at the conclusion of project construction but prior to validation.\n\n**containment**  \nA process or device to contain product, dust or contaminants in one zone, preventing it from escaping to another zone.\n\n**contamination**  \nThe undesired introduction of impurities of a chemical or microbial nature, or of foreign matter, into or on to a starting material or intermediate, during production, sampling, packaging or repackaging, storage or transport.\n\n**cross-contamination**  \nContamination of a starting material, intermediate product or finished product with another starting material or material during production.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1l es la diferencia principal entre un Barrier Isolator (BI) y un Restricted Access Barrier System (RABS)?**\n   - **Respuesta:** La principal diferencia radica en el nivel de control de contaminaci\u00f3n. Un Barrier Isolator (BI) proporciona una aislamiento continuo e ininterrumpido del ambiente externo, utilizando aire filtrado de alta eficiencia (HEPA), mientras que un Restricted Access Barrier System (RABS) reduce o elimina las intervenciones en la zona cr\u00edtica, pero su nivel de control de contaminaci\u00f3n es inferior al de un BI.\n\n2. **\u00bfQu\u00e9 implica el proceso de \"commissioning\" en el contexto de la instalaci\u00f3n de equipos y sistemas?**\n   - **Respuesta:** El \"commissioning\" es el proceso documentado que verifica que los equipos y sistemas est\u00e1n instalados de acuerdo con las especificaciones, se ponen en servicio activo y se verifica su correcto funcionamiento. Este proceso se lleva a cabo al final de la construcci\u00f3n del proyecto, pero antes de la validaci\u00f3n.\n\n3. **\u00bfQu\u00e9 se entiende por \"cross-contamination\" y en qu\u00e9 etapa del proceso de producci\u00f3n puede ocurrir?**\n   - **Respuesta:** La \"cross-contamination\" se refiere a la contaminaci\u00f3n de un material inicial, producto intermedio o producto terminado con otro material durante el proceso de producci\u00f3n. Esto puede ocurrir en cualquier etapa del proceso, incluyendo la producci\u00f3n, muestreo, empaquetado o transporte.\n\n### Resumen de nivel superior del contexto circundante:\nEl contexto se centra en la gesti\u00f3n de la contaminaci\u00f3n en entornos controlados, como salas limpias, y describe tecnolog\u00edas y procesos dise\u00f1ados para prevenir la introducci\u00f3n de contaminantes. Se definen t\u00e9rminos clave como \"alert limit\", \"barrier technology\", \"clean room\", \"commissioning\", \"containment\", \"contamination\" y \"cross-contamination\", proporcionando una comprensi\u00f3n clara de las pr\u00e1cticas y sistemas necesarios para mantener la integridad de los productos en la producci\u00f3n y manipulaci\u00f3n de materiales sensibles.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS en su Informe T\u00e9cnico 957 aborda la importancia de las instalaciones de fabricaci\u00f3n farmac\u00e9utica, enfatizando que deben ser consideradas como instalaciones de contenci\u00f3n. A continuaci\u00f3n se presentan los temas clave y entidades relevantes:\n\n#### Temas Clave:\n1. **Contenci\u00f3n en Instalaciones de Fabricaci\u00f3n**: Se establece que estas instalaciones deben ser vistas como espacios de contenci\u00f3n para manejar materiales de manera segura.\n  \n2. **Aspectos para la Operaci\u00f3n Efectiva**:\n   - **Dise\u00f1o y Disposici\u00f3n de la Instalaci\u00f3n**: Enfoque en la contenci\u00f3n segura de los materiales.\n   - **Controles de Procesos de Fabricaci\u00f3n**: Cumplimiento de procedimientos operativos est\u00e1ndar (SOPs).\n   - **Sistemas de Control Ambiental**: Sistemas de control ambiental (ECS) y calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) adecuadamente dise\u00f1ados.\n   - **Sistemas de Extracci\u00f3n**: Importancia de sistemas para la extracci\u00f3n de contaminantes.\n   - **Equipos de Protecci\u00f3n Personal (PPE)**: Uso de PPE para la seguridad del personal.\n   - **Procedimientos de Desvestido y Descontaminaci\u00f3n**: Protocolos adecuados para la seguridad.\n   - **Higiene Industrial y Vigilancia M\u00e9dica**: Monitoreo de la exposici\u00f3n del personal.\n   - **Controles Administrativos**: Implementaci\u00f3n de controles administrativos para la gesti\u00f3n de riesgos.\n\n3. **Glosario de T\u00e9rminos**:\n   - **L\u00edmite de Acci\u00f3n**: Criterios que, al ser superados, requieren acciones espec\u00edficas.\n   - **Ingrediente Farmac\u00e9utico Activo (API)**: Sustancias utilizadas en la fabricaci\u00f3n de formas farmac\u00e9uticas que tienen efectos farmacol\u00f3gicos.\n   - **Unidad de Tratamiento de Aire (AHU)**: Sistema que acondiciona y mueve el aire dentro de la instalaci\u00f3n.\n   - **Airlock**: Espacio cerrado con dos o m\u00e1s puertas que separa \u00e1reas de diferentes niveles de limpieza.\n\n#### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Instalaciones de Fabricaci\u00f3n Farmac\u00e9utica**: Espacios donde se producen medicamentos.\n- **Personal de Salud**: Trabajadores que deben seguir los protocolos de seguridad y salud.\n- **Sistemas de Control Ambiental (ECS)**: Infraestructura para mantener condiciones ambientales adecuadas.\n- **Equipos de Protecci\u00f3n Personal (PPE)**: Herramientas y vestimenta para proteger al personal.\n\nEste resumen destaca la importancia de la seguridad y el control en las instalaciones de fabricaci\u00f3n farmac\u00e9utica, as\u00ed como la necesidad de seguir directrices espec\u00edficas para garantizar la protecci\u00f3n tanto de los productos como de los trabajadores.", "excerpt_keywords": "Keywords: airlock, barrier technology, clean room, commissioning, cross-contamination"}}, "e8a3be29-739f-4b9e-9a6c-838136d2f009": {"node_ids": ["a13f61d4-1159-4ada-9416-d580bdcb5b1d"], "metadata": {"page_label": "210", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# design condition\n\nDesign condition relates to the specified range or accuracy of a controlled variable used by the designer as a basis for determining the performance requirements of an engineered system.\n\n# environmental control system (ECS)\n\nEnvironmental control system, also referred to as heating, ventilation and air-conditioning (HVAC).\n\n# facility\n\nThe built environment within which the clean area installation and associated controlled environments operate together with their supporting infrastructure.\n\n# hazardous substance or product\n\nA product or substance that may present a substantial risk of injury, to health or to the environment.\n\n# heating, ventilation and air-conditioning (HVAC)\n\nHeating, ventilation and air-conditioning, also referred to as environmental control system (ECS).\n\n# high efficiency particulate air (HEPA) filter\n\nHigh efficiency particulate air filter.\n\n# ISO 14644\n\nInternational standard relating to the design, classification and testing of clean environments (5).\n\n# laminar airflow (LAF)\n\nA rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (modern standards no longer refer to laminar flow, but have adopted the term unidirectional airflow).\n\n# normal operating range\n\nThe range that the manufacturer selects as the acceptable values for a parameter during normal operations. This range must be within the operating range.\n\n# occupational exposure level (OEL)\n\nAirborne concentration of substances that will not result in adverse effects to most healthy workers, exposed for 8 hours/day, 40 hours/week.\n\n# operating range\n\nThe range of validated critical parameters within which acceptable products can be manufactured.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1l es la diferencia entre el rango de operaci\u00f3n normal y el rango de operaci\u00f3n en el contexto de un sistema de control ambiental?**\n   - Respuesta: El rango de operaci\u00f3n normal es el rango que el fabricante selecciona como valores aceptables para un par\u00e1metro durante las operaciones normales, mientras que el rango de operaci\u00f3n se refiere a los par\u00e1metros cr\u00edticos validados dentro de los cuales se pueden fabricar productos aceptables.\n\n2. **\u00bfQu\u00e9 implica el t\u00e9rmino \"flujo de aire laminar\" y c\u00f3mo ha evolucionado su definici\u00f3n en los est\u00e1ndares modernos?**\n   - Respuesta: El flujo de aire laminar se refiere a un flujo de aire rectificado sobre toda el \u00e1rea transversal de una zona limpia con una velocidad constante y l\u00edneas de corriente aproximadamente paralelas. Sin embargo, los est\u00e1ndares modernos ya no utilizan el t\u00e9rmino \"flujo laminar\" y han adoptado el t\u00e9rmino \"flujo unidireccional\".\n\n3. **\u00bfQu\u00e9 es un filtro HEPA y cu\u00e1l es su importancia en un sistema de control ambiental?**\n   - Respuesta: Un filtro HEPA (High Efficiency Particulate Air) es un tipo de filtro que captura part\u00edculas muy peque\u00f1as y es crucial en sistemas de control ambiental para mantener la calidad del aire y proteger tanto la salud humana como el medio ambiente.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona definiciones y conceptos clave relacionados con el dise\u00f1o y operaci\u00f3n de sistemas de control ambiental, espec\u00edficamente en entornos limpios. Se abordan t\u00e9rminos como condiciones de dise\u00f1o, sistemas de control ambiental (HVAC), filtros HEPA, y est\u00e1ndares internacionales como ISO 14644. Tambi\u00e9n se discuten conceptos de seguridad laboral, como el nivel de exposici\u00f3n ocupacional (OEL), y se clarifican diferencias entre rangos de operaci\u00f3n y condiciones normales de operaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Airlock**: Dispositivo dise\u00f1ado para controlar el flujo de aire entre habitaciones, utilizado para personas (PAL) o bienes (MAL).\n\n2. **Alert Limit**: Umbral que indica que un par\u00e1metro cr\u00edtico ha superado su rango operativo normal, sugiriendo la necesidad de medidas correctivas.\n\n3. **Barrier Technology**: Sistemas que segregan personas del producto y contienen contaminantes. Incluye:\n   - **Barrier Isolator (BI)**: Proporciona aislamiento continuo con aire filtrado HEPA.\n   - **Restricted Access Barrier System (RABS)**: Reduce intervenciones en la zona cr\u00edtica, con menor control de contaminaci\u00f3n que un BI.\n\n4. **Clean Room**: \u00c1rea con control ambiental para minimizar la contaminaci\u00f3n particulada y microbiana.\n\n5. **Commissioning**: Proceso documentado que verifica la instalaci\u00f3n y funcionamiento correcto de equipos y sistemas, realizado al final de la construcci\u00f3n y antes de la validaci\u00f3n.\n\n6. **Containment**: M\u00e9todos o dispositivos que evitan que productos o contaminantes escapen de una zona espec\u00edfica.\n\n7. **Contamination**: Introducci\u00f3n no deseada de impurezas qu\u00edmicas, microbianas o materia extra\u00f1a en materiales durante diversas etapas de producci\u00f3n.\n\n8. **Cross-Contamination**: Contaminaci\u00f3n de un material inicial, intermedio o terminado con otro material durante el proceso de producci\u00f3n.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que proporciona directrices sobre pr\u00e1cticas de control de contaminaci\u00f3n.\n- **HEPA (High-Efficiency Particulate Air)**: Tipo de filtro utilizado en sistemas de aislamiento para mantener la pureza del aire.\n- **Materiales Sensibles**: Productos que requieren un entorno controlado para evitar contaminaci\u00f3n.\n\nEste resumen abarca los conceptos fundamentales relacionados con la gesti\u00f3n de la contaminaci\u00f3n en entornos controlados, destacando la importancia de las tecnolog\u00edas y procesos para mantener la integridad de los productos.", "excerpt_keywords": "Keywords: design condition, environmental control system, HEPA filter, ISO 14644, occupational exposure level"}}, "64879eaf-d04a-442e-9cb1-4be5af1cc984": {"node_ids": ["9e38393f-db0f-4165-907e-8ac4c34579f7"], "metadata": {"page_label": "211", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "personal protective equipment (PPE)  \nThe necessary garments and equipment required to protect the operator in the workplace.\n\npressure cascade  \nA process whereby air flows from one area, which is maintained at a higher pressure, to another area at a lower pressure.\n\nqualification  \nThe planning, carrying out and recording of tests on equipment and a system, which forms part of the validated process, to demonstrate that it will perform as intended.\n\nstandard operating procedure (SOP)  \nAn authorized written procedure, giving instructions for performing operations, not necessarily specific to a given product or material, but of a more general nature (e.g. operation of equipment, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation.\n\nunidirectional airflow (UDAF)  \nA rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines.\n\nvalidation  \nThe documented act of proving that any procedure, process, equipment, material, activity or system actually leads to the expected results.\n\n# 4. Risk assessment\n\n4.1 Not all products containing hazardous substances are equally potent and risk assessments should be carried out to determine the potential hazards to operators and to the environment. The risk assessment should also determine which phases of the product production and control cycles, from manufacture of the API to distribution of the finished product, would fall under the requirements of these guidelines. Risk assessments applicable to the environment should include airborne contamination as well as liquid effluent contamination.\n\n4.2 Assuming that the risk assessment determines that the products or materials being handled pose a risk to the operators and/or the public and/or the environment, the guidelines to be followed for the design and operation of the facility should be as detailed in this document.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es un informe t\u00e9cnico de la OMS que aborda la seguridad en el manejo de productos que contienen sustancias peligrosas. Se definen t\u00e9rminos clave como equipo de protecci\u00f3n personal (PPE), flujo de aire unidireccional (UDAF), y procedimientos operativos est\u00e1ndar (SOP). Adem\u00e1s, se enfatiza la importancia de realizar evaluaciones de riesgo para identificar peligros potenciales para los operadores y el medio ambiente, as\u00ed como para determinar las fases de producci\u00f3n que deben cumplir con las directrices establecidas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los componentes esenciales que deben incluirse en una evaluaci\u00f3n de riesgo seg\u00fan el documento?**\n   - Esta pregunta busca detalles sobre los elementos espec\u00edficos que deben considerarse al realizar una evaluaci\u00f3n de riesgo, que no se encuentran expl\u00edcitamente en otras fuentes.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse si la evaluaci\u00f3n de riesgo indica que los productos manejados representan un riesgo para los operadores o el medio ambiente?**\n   - Esta pregunta se centra en las acciones concretas que deben tomarse en respuesta a los hallazgos de la evaluaci\u00f3n de riesgo, proporcionando informaci\u00f3n que puede no estar disponible en otros documentos.\n\n3. **\u00bfC\u00f3mo se define y qu\u00e9 importancia tiene la validaci\u00f3n en el contexto de la producci\u00f3n de productos farmac\u00e9uticos seg\u00fan el informe?**\n   - Esta pregunta busca una comprensi\u00f3n m\u00e1s profunda de la funci\u00f3n de la validaci\u00f3n en el proceso de producci\u00f3n, un aspecto cr\u00edtico que puede no estar claramente delineado en otras fuentes. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y detallada que se encuentra en el contexto del documento, lo que puede no estar disponible en otros lugares.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Condiciones de Dise\u00f1o**: Se refiere al rango o precisi\u00f3n especificada de una variable controlada que el dise\u00f1ador utiliza para determinar los requisitos de rendimiento de un sistema ingenierizado.\n\n2. **Sistema de Control Ambiental (ECS)**: Tambi\u00e9n conocido como calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC), es fundamental para mantener condiciones ambientales adecuadas en entornos controlados.\n\n3. **Instalaciones**: El entorno construido donde operan las instalaciones de \u00e1reas limpias y sus infraestructuras de soporte.\n\n4. **Sustancias o Productos Peligrosos**: Productos o sustancias que pueden representar un riesgo significativo para la salud o el medio ambiente.\n\n5. **Filtro HEPA**: Filtro de aire de alta eficiencia que captura part\u00edculas muy peque\u00f1as, esencial para mantener la calidad del aire en sistemas de control ambiental.\n\n6. **Norma ISO 14644**: Est\u00e1ndar internacional relacionado con el dise\u00f1o, clasificaci\u00f3n y prueba de entornos limpios.\n\n7. **Flujo de Aire Laminar (LAF)**: Flujo de aire rectificado en una zona limpia, que ha evolucionado en los est\u00e1ndares modernos a ser denominado \"flujo unidireccional\".\n\n8. **Rango de Operaci\u00f3n Normal**: Rango de valores aceptables seleccionados por el fabricante para un par\u00e1metro durante operaciones normales.\n\n9. **Nivel de Exposici\u00f3n Ocupacional (OEL)**: Concentraci\u00f3n de sustancias en el aire que no causar\u00e1 efectos adversos en la mayor\u00eda de los trabajadores sanos expuestos durante un tiempo determinado.\n\n10. **Rango de Operaci\u00f3n**: Rango de par\u00e1metros cr\u00edticos validados dentro del cual se pueden fabricar productos aceptables.\n\n### Entidades Clave\n- **ECS** (Sistema de Control Ambiental)\n- **HVAC** (Calefacci\u00f3n, Ventilaci\u00f3n y Aire Acondicionado)\n- **HEPA** (Filtro de Aire de Alta Eficiencia)\n- **ISO 14644** (Norma Internacional)\n- **OEL** (Nivel de Exposici\u00f3n Ocupacional)\n\nEste resumen abarca los conceptos y t\u00e9rminos esenciales relacionados con el dise\u00f1o y operaci\u00f3n de sistemas de control ambiental, as\u00ed como las normativas y est\u00e1ndares relevantes en el contexto de entornos limpios.", "excerpt_keywords": "Keywords: personal protective equipment, risk assessment, validation, standard operating procedure, unidirectional airflow"}}, "18efe620-ecfe-4da3-bed9-032a52084a73": {"node_ids": ["d31f8a17-4964-4982-a99e-d92cf0b7cdec"], "metadata": {"page_label": "212", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.3 \nThe toxicological data available, such as permissible occupational exposure levels (OEL) for the product, should be taken into account when conducting the risk assessment.\n\n4.4 The risk assessment should take into account the national or international occupational health and safety requirements for OELs in the work environment.\n\n## 5. Product protection\n\n5.1 The requirement for producing quality products, with respect to protection from contamination and cross-contamination, clean room class of air, temperature and humidity should be as for other pharmaceutical products. These requirements are covered in other WHO GMP guidelines.\n\n## 6. Personal protection equipment and breathing air systems\n\n6.1 The fundamental design principle for a facility and its production equipment is to provide product containment and operator protection. Should the facility and equipment design not provide adequate product containment, operator protection should be provided. If facility and equipment design are adequate, a spillage or non-routine incident could cause a hazardous situation, in which case PPE should be available. Unless otherwise specified in the material safety data sheet, operators should be protected from exposure with an appropriate method, such as by wearing:\n\n- flash-spun, high-density polyethylene fibre material suits or impervious washable protective suits. Integral hoods may be required depending on the respirator type used;\n- flash-spun, high-density polyethylene fibre material shoes, lower leg covers or cleanable boots;\n- suitable single-use, disposable gloves. Double gloves should be worn where direct active contact with the product cannot be avoided. Gloves should be taped or sealed on to the protective suit sleeves; and\n- respirator eye and face protection with associated breathing air systems.\n\n6.2 Where breathing air systems are used, these should be provided to supply safe breathing air to the operators to prevent them from inhaling air from within the facility. Personnel should be appropriately trained and assessed in the use of these systems before they can enter the area. The breathing air systems should comprise a protective face mask, which should form an integral part of a protective suit. The breathing air systems could be any of the systems described below:", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Evaluaci\u00f3n de riesgos y OELs**: La evaluaci\u00f3n de riesgos en el entorno laboral debe considerar los niveles de exposici\u00f3n ocupacional permisibles (OEL) y cumplir con las normativas nacionales e internacionales de salud y seguridad ocupacional.\n\n2. **Protecci\u00f3n del producto**: La producci\u00f3n de productos farmac\u00e9uticos debe seguir estrictas normas de calidad para evitar la contaminaci\u00f3n y garantizar condiciones adecuadas de aire, temperatura y humedad, aline\u00e1ndose con las directrices de Buenas Pr\u00e1cticas de Manufactura (GMP) de la OMS.\n\n3. **Equipos de protecci\u00f3n personal (EPP)**: Se deben implementar medidas de protecci\u00f3n para los operadores, incluyendo el uso de equipos de protecci\u00f3n personal adecuados y sistemas de aire respirable, especialmente en situaciones de derrames o incidentes no rutinarios.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los requisitos espec\u00edficos para el dise\u00f1o de instalaciones y equipos en relaci\u00f3n con la contenci\u00f3n del producto y la protecci\u00f3n del operador?**\n   - Esta pregunta busca detalles sobre las normas de dise\u00f1o que deben seguirse para garantizar la seguridad en la producci\u00f3n, que no se encuentran expl\u00edcitamente en otras secciones del documento.\n\n2. **\u00bfQu\u00e9 tipo de formaci\u00f3n y evaluaci\u00f3n se requiere para el personal que utiliza sistemas de aire respirable en el entorno de trabajo?**\n   - Esta pregunta se centra en los requisitos de capacitaci\u00f3n y evaluaci\u00f3n del personal, un aspecto cr\u00edtico para la seguridad que puede no estar ampliamente cubierto en otras fuentes.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse si el dise\u00f1o de la instalaci\u00f3n y el equipo no proporciona una contenci\u00f3n adecuada del producto?**\n   - Esta pregunta aborda las acciones correctivas y las medidas de protecci\u00f3n adicionales que deben implementarse en caso de que el dise\u00f1o no cumpla con los est\u00e1ndares de seguridad, un tema que puede no ser tratado en otros documentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Equipo de Protecci\u00f3n Personal (PPE)**: Se refiere a las prendas y equipos necesarios para proteger a los operadores en el lugar de trabajo.\n\n2. **Flujo de Aire Unidireccional (UDAF)**: Describe un flujo de aire rectificado en una zona limpia, caracterizado por una velocidad constante y l\u00edneas de corriente aproximadamente paralelas.\n\n3. **Procedimientos Operativos Est\u00e1ndar (SOP)**: Son procedimientos escritos autorizados que proporcionan instrucciones para realizar operaciones de manera general, no necesariamente espec\u00edficas para un producto o material.\n\n4. **Validaci\u00f3n**: Es el acto documentado de demostrar que un procedimiento, proceso, equipo, material, actividad o sistema produce los resultados esperados.\n\n5. **Evaluaci\u00f3n de Riesgo**: Se enfatiza la importancia de realizar evaluaciones de riesgo para identificar peligros potenciales para los operadores y el medio ambiente. Esto incluye la evaluaci\u00f3n de la contaminaci\u00f3n a\u00e9rea y de efluentes l\u00edquidos.\n\n6. **Fases de Producci\u00f3n**: La evaluaci\u00f3n de riesgo debe determinar qu\u00e9 fases del ciclo de producci\u00f3n y control, desde la fabricaci\u00f3n del ingrediente activo (API) hasta la distribuci\u00f3n del producto terminado, deben cumplir con las directrices establecidas.\n\n### Entidades Clave\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe t\u00e9cnico.\n- **Sustancias Peligrosas**: Productos que requieren un manejo cuidadoso debido a su potencial riesgo.\n- **Operadores**: Personas que manejan productos que contienen sustancias peligrosas.\n- **Medio Ambiente**: Consideraci\u00f3n importante en las evaluaciones de riesgo.\n\nEste resumen destaca los conceptos fundamentales y las entidades relevantes en el contexto de la seguridad en el manejo de productos peligrosos, tal como se detalla en el documento de la OMS.", "excerpt_keywords": "Keywords: risk assessment, occupational exposure levels, personal protective equipment, product protection, breathing air systems"}}, "8a781219-906d-4674-b336-0767864eabc5": {"node_ids": ["c6a9ed63-7cb6-443e-9ba2-1b281492946a"], "metadata": {"page_label": "213", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- a central air supply system which connects to the operator\u2019s face mask by means of flexible hoses and quick coupling sockets, also called an airline respirator (AR). The air connection should incorporate a one-way air system to prevent contaminated air entering the face mask during connection or disconnection. The air supply should be treated to ensure a temperature and level of humidity that are comfortable for the operator. The air source could be a high pressure fan or an air compressor. If an air compressor is used, it should be of the oil-free type or have suitable oil removal filters fitted;\n- a self-contained breathing apparatus (SCBA) or powered air purifying respirator (PAPR) that is securely attached to the operator\u2019s belt and connects to the operator\u2019s face mask. This system draws air from the room in which the operator is working and the air supply is delivered to the face mask by means of a battery-driven fan. The AR provides superior protection to the PAPR apparatus;\n- for zones with lower contamination levels, a half-mask high efficiency particulate air filter (HEPA) cartridge respirator of N95-type paper filter mask may be acceptable.\n\n6.3 The selection of the respirator type is based on the relationship between the accepted OEL and the respirator-certified protection factor (PF).\n\n6.4 The air supplies should be filtered through a final filter, which should be a HEPA filter rated as an H13 filter according to EN 1822 (European Norm). The supply of breathing air into the face mask and/or protective suit should result in the interior of the mask and suit being at a positive pressure relative to the facility environment.\n\n6.5 Central breathing air supply systems should have a 100% back-up system in the event of the main system failing. This could be in the form of a gas bottle system with at least 5 minutes supply. Changeover from the normal supply to the back-up supply should be automatic. The system should have a monitoring system and send alarm signals to a permanently manned location in the following situations:\n\n- failure of main air supply;\n- temperature out of specification (OOS);\n- humidity OOS;\n- carbon dioxide (CO2) OOS;\n- carbon monoxide (CO) OOS; and\n- sulfur dioxide (SO2) OOS.\n\n6.6 Breathing air should be filtered by means of pre-filters, coalescing filters and final filters to have the minimum air quality specifications of ISO 8573-1 3-9-1 and EN 12021:1999.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Sistemas de suministro de aire respirable**: El documento describe diferentes tipos de sistemas de suministro de aire respirable, incluyendo respiradores de aire central, aparatos de respiraci\u00f3n aut\u00f3nomos (SCBA) y respiradores de purificaci\u00f3n de aire impulsados (PAPR). Se enfatiza la importancia de la calidad del aire y la presi\u00f3n positiva en las m\u00e1scaras y trajes de protecci\u00f3n.\n\n2. **Selecci\u00f3n y filtraci\u00f3n de respiradores**: La selecci\u00f3n del tipo de respirador se basa en la relaci\u00f3n entre el l\u00edmite de exposici\u00f3n ocupacional (OEL) aceptado y el factor de protecci\u00f3n certificado del respirador. Adem\u00e1s, se requiere que el aire suministrado est\u00e9 filtrado adecuadamente para cumplir con normas espec\u00edficas de calidad del aire.\n\n3. **Sistemas de respaldo y monitoreo**: Se establece que los sistemas de suministro de aire central deben contar con un sistema de respaldo del 100% en caso de fallo del sistema principal, as\u00ed como un sistema de monitoreo que alerte sobre diversas condiciones fuera de especificaci\u00f3n, como temperatura, humedad y niveles de gases peligrosos.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de filtros se requieren para asegurar la calidad del aire en los sistemas de suministro de respiradores seg\u00fan el documento?**\n   - Respuesta: Se requieren pre-filtros, filtros coalescentes y filtros finales que cumplan con las especificaciones m\u00ednimas de calidad del aire de ISO 8573-1 3-9-1 y EN 12021:1999.\n\n2. **\u00bfCu\u00e1les son las condiciones que deben ser monitoreadas en un sistema de suministro de aire respirable y que pueden activar una alarma?**\n   - Respuesta: Las condiciones que deben ser monitoreadas incluyen la falla del suministro de aire principal, temperatura fuera de especificaci\u00f3n, humedad fuera de especificaci\u00f3n, y niveles de di\u00f3xido de carbono (CO2), mon\u00f3xido de carbono (CO) y di\u00f3xido de azufre (SO2) fuera de especificaci\u00f3n.\n\n3. **\u00bfQu\u00e9 caracter\u00edsticas debe tener un compresor de aire si se utiliza en un sistema de suministro de aire respirable?**\n   - Respuesta: Si se utiliza un compresor de aire, debe ser del tipo libre de aceite o tener filtros de eliminaci\u00f3n de aceite adecuados instalados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Evaluaci\u00f3n de Riesgos**:\n   - Importancia de considerar los niveles de exposici\u00f3n ocupacional permisibles (OEL) en la evaluaci\u00f3n de riesgos.\n   - Necesidad de cumplir con normativas nacionales e internacionales de salud y seguridad ocupacional.\n\n2. **Protecci\u00f3n del Producto**:\n   - Requisitos para la producci\u00f3n de productos farmac\u00e9uticos, incluyendo la protecci\u00f3n contra contaminaci\u00f3n y condiciones controladas de aire, temperatura y humedad.\n   - Referencia a las directrices de Buenas Pr\u00e1cticas de Manufactura (GMP) de la OMS.\n\n3. **Equipos de Protecci\u00f3n Personal (EPP)**:\n   - Dise\u00f1o de instalaciones y equipos debe garantizar la contenci\u00f3n del producto y la protecci\u00f3n del operador.\n   - Uso de EPP adecuado en caso de incidentes, incluyendo trajes, guantes y protecci\u00f3n respiratoria.\n   - Provisi\u00f3n de sistemas de aire respirable para proteger a los operadores de la inhalaci\u00f3n de aire contaminado.\n\n4. **Formaci\u00f3n y Evaluaci\u00f3n**:\n   - Requisitos de capacitaci\u00f3n y evaluaci\u00f3n para el personal que utiliza sistemas de aire respirable, asegurando su competencia antes de ingresar a \u00e1reas de riesgo.\n\n### Entidades Clave:\n- **OEL (Niveles de Exposici\u00f3n Ocupacional Permisibles)**: Indicadores cr\u00edticos en la evaluaci\u00f3n de riesgos.\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Entidad que establece directrices y est\u00e1ndares para la producci\u00f3n farmac\u00e9utica.\n- **EPP (Equipos de Protecci\u00f3n Personal)**: Elementos esenciales para la seguridad de los operadores en entornos de trabajo peligrosos.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normativas que regulan la calidad en la producci\u00f3n de productos farmac\u00e9uticos. \n\nEste resumen destaca la importancia de la seguridad en el entorno laboral, la calidad en la producci\u00f3n farmac\u00e9utica y la necesidad de formaci\u00f3n adecuada para el personal expuesto a riesgos.", "excerpt_keywords": "Keywords: respirators, air supply systems, HEPA filters, occupational exposure limits, personal protective equipment"}}, "f752a712-7916-41fe-92ff-bfda9981f116": {"node_ids": ["85a98416-33b4-4b65-a4f9-728a1c5fcd7c"], "metadata": {"page_label": "214", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "6.7 Where air is delivered through a central system the piping should not cause any contamination to be liberated into the air stream. Stainless steel piping is preferred. The final filters should be as close as possible to the operator connection points. The operator hose connection to the air supply should be a dedicated connection specific to the breathing air system (to avoid inadvertent connection to a different gas system).\n\n# 7. Environmental protection\n\n7.1 Due to the hazardous nature of the products being handled in the facility, neither the product nor its residues should be allowed to escape into the atmosphere or to be discharged directly to normal drainage systems.\n\n7.2 The external atmosphere and the public in the vicinity of the facility should be protected from possible harm from hazardous substances.\n\n7.3 If liquid effluent poses a safety or contamination risk, the effluent should be treated before being discharged to a municipal drain.\n\n7.4 Exhaust air filtration to ensure environmental protection is discussed in section 11.\n\n# 8. Facility layout\n\n8.1 The premises should be designed and constructed to prevent the ingress or egress of contaminants. In drawing up the facility design, attention should be paid to the level of containment provided by the equipment.\n\n8.2 The link between the interior and exterior of the premises should be through airlocks (PAL and/or MAL), changing rooms, pass boxes, pass-through hatches, decontamination devices, etc. These entry and exit doors for materials and personnel should have an interlock mechanism or other appropriate system to prevent the opening of more than one door at a time.\n\n8.3 The changing rooms should have an arrangement with a step-over-bench. The facilities on the exit side should incorporate showers for the operators.\n\n8.4 The premises should be laid out and designed so as to facilitate the required pressure cascades and containment.\n\n8.5 The premises (and equipment) should be appropriately designed and installed to facilitate cleaning and decontamination.\n\n8.6 The manufacturing site and buildings should be described in sufficient detail (by means of plans and written explanations) to ensure that the designation and conditions of use of all the rooms are correctly shown.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de material se prefiere para las tuber\u00edas en un sistema de aire central y por qu\u00e9?**\n   - Se prefiere el uso de tuber\u00edas de acero inoxidable en un sistema de aire central para evitar que se liberen contaminantes en la corriente de aire. Este material es menos propenso a la corrosi\u00f3n y facilita la limpieza, lo que contribuye a mantener la calidad del aire.\n\n2. **\u00bfCu\u00e1les son las medidas recomendadas para proteger el ambiente y la salud p\u00fablica en instalaciones que manejan productos peligrosos?**\n   - Las instalaciones deben asegurarse de que ni los productos ni sus residuos escapen a la atm\u00f3sfera o se descarguen en sistemas de drenaje normales. Adem\u00e1s, se deben implementar tratamientos para los efluentes l\u00edquidos que representen un riesgo de seguridad o contaminaci\u00f3n antes de ser descargados en desag\u00fces municipales. Tambi\u00e9n se debe proteger a la atm\u00f3sfera externa y al p\u00fablico circundante de sustancias peligrosas.\n\n3. **\u00bfQu\u00e9 caracter\u00edsticas deben tener las \u00e1reas de cambio y salida en las instalaciones para garantizar la seguridad y la contenci\u00f3n?**\n   - Las \u00e1reas de cambio deben contar con un banco de paso y las instalaciones de salida deben incluir duchas para los operadores. Adem\u00e1s, se deben utilizar mecanismos de interbloqueo en las puertas de entrada y salida para evitar que se abran m\u00e1s de una puerta a la vez, lo que ayuda a prevenir la entrada o salida de contaminantes.\n\n### Resumen de nivel superior del contexto:\nEl documento de la OMS proporciona directrices sobre la protecci\u00f3n ambiental y el dise\u00f1o de instalaciones que manejan productos peligrosos. Se enfatiza la importancia de evitar la contaminaci\u00f3n del aire y el agua, as\u00ed como la necesidad de un dise\u00f1o de instalaciones que prevenga la entrada y salida de contaminantes. Se destacan medidas espec\u00edficas como el uso de tuber\u00edas de acero inoxidable, la implementaci\u00f3n de duchas en \u00e1reas de cambio y la necesidad de un dise\u00f1o que facilite la limpieza y la decontaminaci\u00f3n.\n\nEstas preguntas y respuestas est\u00e1n dise\u00f1adas para abordar aspectos espec\u00edficos del contexto que pueden no ser f\u00e1cilmente accesibles en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistemas de Suministro de Aire Respirable**:\n   - **Tipos de Sistemas**:\n     - **Respirador de Aire Central (AR)**: Conexi\u00f3n a la m\u00e1scara del operador mediante mangueras flexibles y sistemas de acoplamiento r\u00e1pido. Debe tener un sistema de aire unidireccional y un suministro de aire tratado para comodidad del operador.\n     - **Aparato de Respiraci\u00f3n Aut\u00f3nomo (SCBA)**: Conectado al cintur\u00f3n del operador, utiliza aire del entorno y lo suministra a la m\u00e1scara mediante un ventilador a bater\u00eda.\n     - **Respirador de Purificaci\u00f3n de Aire Impulsado (PAPR)**: Similar al SCBA, pero proporciona una protecci\u00f3n inferior.\n     - **Mascarillas de Papel N95**: Aceptables en zonas con niveles de contaminaci\u00f3n m\u00e1s bajos.\n\n2. **Selecci\u00f3n de Respiradores**:\n   - Basada en la relaci\u00f3n entre el L\u00edmite de Exposici\u00f3n Ocupacional (OEL) y el Factor de Protecci\u00f3n (PF) certificado del respirador.\n\n3. **Filtraci\u00f3n de Aire**:\n   - El aire suministrado debe ser filtrado a trav\u00e9s de un filtro HEPA (H13) y cumplir con las especificaciones de calidad del aire de ISO 8573-1 3-9-1 y EN 12021:1999.\n\n4. **Sistemas de Respaldo y Monitoreo**:\n   - Los sistemas de aire central deben tener un sistema de respaldo del 100% en caso de fallo, como un sistema de botellas de gas con al menos 5 minutos de suministro.\n   - Monitoreo de condiciones cr\u00edticas que pueden activar alarmas: \n     - Falla del suministro de aire principal.\n     - Temperatura fuera de especificaci\u00f3n.\n     - Humedad fuera de especificaci\u00f3n.\n     - Niveles de CO2, CO y SO2 fuera de especificaci\u00f3n.\n\n5. **Requisitos para Compresores de Aire**:\n   - Si se utiliza un compresor, debe ser libre de aceite o tener filtros adecuados para la eliminaci\u00f3n de aceite.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad del documento.\n- **Normas de Calidad del Aire**: ISO 8573-1, EN 12021:1999, EN 1822.\n- **Tipos de Respiradores**: AR, SCBA, PAPR, N95.\n- **Condiciones de Monitoreo**: Temperatura, humedad, CO2, CO, SO2.", "excerpt_keywords": "Keywords: air supply system, environmental protection, facility layout, contamination prevention, hazardous substances"}}, "823a56e0-6ba7-4653-847f-58386a5ca1e7": {"node_ids": ["7cae8f59-7dc6-484f-8680-33a4ae04de95"], "metadata": {"page_label": "215", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "8.7 The flow of people and products should be clearly marked on the layouts and plans.\n\n8.8 The activities carried out in the vicinity of the site should be indicated.\n\n8.9 Plans should describe the ventilation systems, indicating inlets and outlets, in relation to other facility air inlet and outlet points.\n\n8.10 The facility should be a well-sealed structure with no air leakage through ceilings, cracks or service areas.\n\n8.11 Areas of the facility where exposed product presents a risk should be maintained at a negative air pressure relative to the environment.\n\n# 9. Air-handling systems\n\n9.1 The HVAC system should be appropriately designed, installed and maintained to ensure protection of product, personnel and the environment.\n\n9.2 The principles of airflow direction, air filtration standards, temperature, humidity and related parameters should comply with the minimum requirements as set out in Annex 2 of the fortieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, 2006 (2).\n\n9.3 Facilities and premises dealing with hazardous substances should have the following basic air-handling characteristics:\n\n- There should be no direct venting of air to the outside.\n- Air-conditioning or ventilation should result in a negative pressure relative to the outside. Air pressure differentials should be such that there is no uncontrolled flow of air between the work area and the external environment.\n- Appropriate air pressure alarm systems should be provided to warn of any pressure cascade reversal or loss of design pressure status. The appropriate design, alert and action limits should be in place. System redundancies should be in place to respond appropriately to pressure cascade failure.\n- The starting and stopping of the supply and exhaust air fan should be synchronized such that the premises remain at a negative pressure during start-up and shut-down.\n- The air pressure cascade within the facility, although negative relative to the environment, should comply with normal pharmaceutical pressure cascade requirements with regards to product protection, dust containment and personnel protection.\n- Visual indication of the status of room pressures should be provided in each room.\n- Air should be exhausted to the outside through HEPA filters and not be recirculated except to the same area, and provided that a further HEPA filtration stage is applied to the return air. Where HEPA filters are", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Informe T\u00e9cnico 957) establece directrices sobre el dise\u00f1o y mantenimiento de instalaciones que manejan productos farmac\u00e9uticos y sustancias peligrosas. Se enfatiza la importancia de un flujo de aire controlado y la presi\u00f3n negativa en \u00e1reas donde se manipulan productos expuestos a riesgos. Tambi\u00e9n se detallan los requisitos para los sistemas de manejo de aire, incluyendo la necesidad de alarmas de presi\u00f3n, sincronizaci\u00f3n de ventiladores y el uso de filtros HEPA para asegurar la calidad del aire y la protecci\u00f3n del producto, el personal y el medio ambiente.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas b\u00e1sicas que deben tener los sistemas de manejo de aire en instalaciones que tratan sustancias peligrosas seg\u00fan el informe?**\n   - Respuesta: Los sistemas deben evitar la ventilaci\u00f3n directa al exterior, mantener una presi\u00f3n negativa relativa al exterior, contar con alarmas de presi\u00f3n, sincronizar el funcionamiento de los ventiladores de suministro y extracci\u00f3n, y asegurar que el aire se expulse a trav\u00e9s de filtros HEPA sin recirculaci\u00f3n, salvo en condiciones espec\u00edficas.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para garantizar que las \u00e1reas donde hay productos expuestos mantengan una presi\u00f3n negativa?**\n   - Respuesta: Las \u00e1reas deben ser dise\u00f1adas para mantener una presi\u00f3n negativa en relaci\u00f3n con el entorno, lo que implica que no debe haber flujo de aire incontrolado entre el \u00e1rea de trabajo y el ambiente externo, y se deben implementar alarmas para detectar cualquier reversi\u00f3n de la presi\u00f3n.\n\n3. **\u00bfQu\u00e9 requisitos se establecen para la visualizaci\u00f3n del estado de la presi\u00f3n en las habitaciones de las instalaciones?**\n   - Respuesta: Se debe proporcionar una indicaci\u00f3n visual del estado de la presi\u00f3n en cada habitaci\u00f3n, lo que permite a los operadores monitorear y asegurar que las condiciones de presi\u00f3n se mantengan dentro de los l\u00edmites establecidos para la protecci\u00f3n del producto y del personal.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistemas de Aire Central**:\n   - **Material Preferido**: Tuber\u00edas de acero inoxidable para evitar la liberaci\u00f3n de contaminantes en la corriente de aire.\n   - **Filtros Finales**: Deben estar ubicados lo m\u00e1s cerca posible de los puntos de conexi\u00f3n del operador.\n\n2. **Protecci\u00f3n Ambiental**:\n   - **Manejo de Productos Peligrosos**: Prohibici\u00f3n de que productos o residuos escapen a la atm\u00f3sfera o se descarguen en sistemas de drenaje normales.\n   - **Tratamiento de Efluentes**: Los efluentes l\u00edquidos que representen un riesgo deben ser tratados antes de ser descargados en desag\u00fces municipales.\n   - **Filtraci\u00f3n de Aire de Escape**: Se menciona en la secci\u00f3n 11 para asegurar la protecci\u00f3n ambiental.\n\n3. **Dise\u00f1o de Instalaciones**:\n   - **Prevenci\u00f3n de Contaminaci\u00f3n**: Las instalaciones deben estar dise\u00f1adas para evitar la entrada y salida de contaminantes.\n   - **Accesos Controlados**: Uso de sistemas de interbloqueo en puertas de entrada y salida para evitar la apertura simult\u00e1nea de m\u00e1s de una puerta.\n   - **\u00c1reas de Cambio**: Deben incluir bancos de paso y duchas para los operadores.\n   - **Facilidad de Limpieza**: Las instalaciones y equipos deben estar dise\u00f1ados para facilitar la limpieza y decontaminaci\u00f3n.\n\n4. **Documentaci\u00f3n y Descripci\u00f3n**:\n   - **Planes y Explicaciones**: El sitio de fabricaci\u00f3n y los edificios deben ser descritos en detalle para asegurar la correcta designaci\u00f3n y condiciones de uso de todas las habitaciones.\n\n### Entidades Clave\n- **Organizaci\u00f3n**: OMS (Organizaci\u00f3n Mundial de la Salud)\n- **Documentos**: WHO - Technical Report Series 957\n- **Componentes de Instalaci\u00f3n**: Tuber\u00edas, filtros, duchas, bancos de paso, sistemas de interbloqueo.\n- **Sustancias**: Productos peligrosos, efluentes l\u00edquidos, contaminantes. \n\nEste resumen destaca los aspectos esenciales relacionados con la protecci\u00f3n ambiental y el dise\u00f1o de instalaciones que manejan productos peligrosos, enfatizando la importancia de la contenci\u00f3n y la prevenci\u00f3n de la contaminaci\u00f3n.", "excerpt_keywords": "Keywords: air-handling systems, negative pressure, hazardous substances, HEPA filters, pharmaceutical facilities"}}, "3878ce82-b8a3-4602-85b1-f142b6567da1": {"node_ids": ["5e63ac13-717d-423e-a1ac-1ef059d1f569"], "metadata": {"page_label": "216", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Figure 1\n\n## Typical airflow pattern for contaminant\n\n!Airflow Diagram\n\n- **Primary Packing**  \n  (Negative Pressure --)\n\n- **Secondary Packing**  \n  (Negative Pressure -)\n\n- **Extraction**  \n  (Negative Pressure)\n\n- **Supply Air**  \n  (Arrows indicating airflow direction)\n\n- **Extract Air**  \n  (Arrows indicating airflow direction)\n\n----\n\n- Mentioned in these guidelines, this refers to HEPA filters with a minimum rating of H13 according to EN 1822.\n- Where possible, single-pass air-handling systems with no recirculation should be provided.\n- Exhaust air or return air should be filtered through a safe-change or bag-in-bag-out filter housing. The filter housing should contain pre-filters and HEPA filters, both of which should be removable with the safe bagging system.\n- Changing rooms should be supplied with air filtered to the same standard as that for the work area they serve.\n- Airlocks, pass-through hatches, etc., should have supply and extract air to provide the necessary air pressure cascade and containment. The final, or containment perimeter, airlock or pass-through hatch bordering on an external or non-GMP area should be at a positive pressure relative to the environment, to prevent the ingress of contaminants to the facility.\n- If the facility provides insufficient containment, and operators\u2019 garments are contaminated with dust, the operators leaving the containment area should pass through a decontamination system, e.g., air showers or a mist shower system, to assist with removing or controlling dust particles on their garments. Operators should follow this route before de-gowning to use the ablutions or canteen facilities. All garments leaving the facility for laundering should be safely bagged. Appropriate means for protecting laundry staff and prevention of contamination of other garments from non-hazardous facilities should be in place.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de filtros se mencionan en las pautas y cu\u00e1l es su clasificaci\u00f3n m\u00ednima?**\n   - Las pautas mencionan filtros HEPA con una clasificaci\u00f3n m\u00ednima de H13 seg\u00fan la norma EN 1822.\n\n2. **\u00bfCu\u00e1l es la recomendaci\u00f3n sobre el manejo del aire en las \u00e1reas de trabajo y c\u00f3mo se debe tratar el aire de escape o retorno?**\n   - Se recomienda proporcionar sistemas de manejo de aire de paso \u00fanico sin recirculaci\u00f3n siempre que sea posible. El aire de escape o retorno debe ser filtrado a trav\u00e9s de un sistema de filtro de cambio seguro o de bolsa dentro de bolsa, que contenga prefiltros y filtros HEPA, ambos removibles con el sistema de envasado seguro.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar si los operadores salen de un \u00e1rea de contenci\u00f3n y sus prendas est\u00e1n contaminadas con polvo?**\n   - Si los operadores tienen prendas contaminadas con polvo al salir de un \u00e1rea de contenci\u00f3n, deben pasar por un sistema de descontaminaci\u00f3n, como duchas de aire o sistemas de duchas de niebla, para ayudar a eliminar o controlar las part\u00edculas de polvo en sus prendas. Deben seguir esta ruta antes de desvestirse para usar las instalaciones de abluci\u00f3n o el comedor.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona directrices sobre el manejo del aire en instalaciones que requieren un control estricto de contaminantes, enfatizando la importancia de utilizar filtros HEPA de alta eficiencia, sistemas de aire de paso \u00fanico y medidas de descontaminaci\u00f3n para los operadores. Se destaca la necesidad de mantener presiones negativas en \u00e1reas cr\u00edticas y asegurar que las \u00e1reas de cambio y los accesos est\u00e9n adecuadamente presurizados para prevenir la entrada de contaminantes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Flujo de Personas y Productos**:\n   - Importancia de marcar claramente el flujo de personas y productos en los planos de las instalaciones.\n\n2. **Actividades en la Vecindad**:\n   - Necesidad de indicar las actividades realizadas en las cercan\u00edas del sitio.\n\n3. **Sistemas de Ventilaci\u00f3n**:\n   - Descripci\u00f3n de los sistemas de ventilaci\u00f3n, incluyendo entradas y salidas de aire en relaci\u00f3n con otros puntos de entrada y salida de la instalaci\u00f3n.\n\n4. **Estructura Sellada**:\n   - Requerimiento de que la instalaci\u00f3n sea una estructura bien sellada, sin fugas de aire a trav\u00e9s de techos, grietas o \u00e1reas de servicio.\n\n5. **Presi\u00f3n Negativa**:\n   - Mantenimiento de presi\u00f3n negativa en \u00e1reas donde hay productos expuestos a riesgos.\n\n6. **Sistemas de Manejo de Aire (HVAC)**:\n   - Dise\u00f1o, instalaci\u00f3n y mantenimiento adecuados del sistema HVAC para proteger productos, personal y medio ambiente.\n   - Cumplimiento de est\u00e1ndares de direcci\u00f3n del flujo de aire, filtraci\u00f3n, temperatura y humedad seg\u00fan directrices de la OMS.\n\n7. **Caracter\u00edsticas B\u00e1sicas para Sustancias Peligrosas**:\n   - Prohibici\u00f3n de ventilaci\u00f3n directa al exterior.\n   - Mantenimiento de presi\u00f3n negativa en relaci\u00f3n con el exterior.\n   - Sistemas de alarma para detectar reversi\u00f3n de presi\u00f3n.\n   - Sincronizaci\u00f3n en el funcionamiento de ventiladores de suministro y extracci\u00f3n.\n   - Cumplimiento de requisitos de presi\u00f3n para protecci\u00f3n de productos y personal.\n   - Indicaci\u00f3n visual del estado de presi\u00f3n en cada habitaci\u00f3n.\n   - Uso de filtros HEPA para la expulsi\u00f3n de aire, evitando la recirculaci\u00f3n, salvo en condiciones espec\u00edficas.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices.\n- **HVAC (Calefacci\u00f3n, Ventilaci\u00f3n y Aire Acondicionado)**: Sistema cr\u00edtico para el manejo del aire en instalaciones.\n- **HEPA (Filtros de Aire de Alta Eficiencia)**: Tecnolog\u00eda de filtraci\u00f3n utilizada para asegurar la calidad del aire. \n\nEste resumen destaca la importancia de un dise\u00f1o adecuado y el mantenimiento de las instalaciones que manejan productos farmac\u00e9uticos y sustancias peligrosas, enfatizando la seguridad y la protecci\u00f3n del medio ambiente y del personal.", "excerpt_keywords": "Keywords: airflow, HEPA filters, contamination control, air-handling systems, decontamination"}}, "fce7cba5-9add-4ba1-800f-7c3c5de32806": {"node_ids": ["ac2bb7be-88be-4601-835f-81bc8f005b38"], "metadata": {"page_label": "217", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9.4\n\nIf required, appropriate measures should be taken to prevent airflow from the primary packing area (through the conveyor \u201cmouse hole\u201d) to the secondary packing area.\n\n*Note:* This could be overcome by having a pass-through chamber over the \u201cmouse hole\u201d, which is maintained at a negative pressure to both primary and secondary packing. This typical arrangement is illustrated in Figure 1. This principle can be applied to other situations where containment from two sides is required.\n\n9.5 Where possible, HEPA filters in the supply air system should be terminally mounted to provide protection against back-flow cross-contamination in the event of a failure in the supply airflow.\n\n9.6 In some cases consideration can be given to the use of biosafety cabinets, isolation systems or glove boxes as a means for containment and operator protection.\n\n9.7 There should be a system description including schematic drawings detailing the filters and their specifications, the number of air changes per hour, pressure gradients, clean room classes and related specifications. These should be available for inspection.\n\n9.8 There should be an indication of pressure gradients that are monitored by means of digital or analogue pressure indicators.\n\n9.9 Consideration should be given to providing an emergency power supply, e.g. diesel generators, to ensure that safe operation of the premises and systems can be maintained at all times.\n\n# 10. Air-handling units\n\n10.1 The air-handling units (AHUs) supplying air to the facility should conform to AHU requirements as detailed in *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials (1)* and *Supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms (2)* and the filtration should be consistent with the zone concepts and product protection required.\n\n10.2 The decision to use return air or recirculated air should be made on the basis of a risk assessment.\n\n10.3 Where a full fresh-air or single-pass system is used, an energy recovery wheel could be considered. In such cases, there should not be any potential for air leakage between the supply air and exhaust air as it passes through the wheel. The relative pressures between supply and exhaust air systems should be such that the exhaust-air system operates at a lower", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto aborda directrices sobre el manejo del aire en instalaciones farmac\u00e9uticas, enfoc\u00e1ndose en la prevenci\u00f3n de la contaminaci\u00f3n cruzada y la protecci\u00f3n del personal. Se mencionan medidas espec\u00edficas como el uso de c\u00e1maras de paso con presi\u00f3n negativa, filtros HEPA, y la importancia de un suministro de energ\u00eda de emergencia. Tambi\u00e9n se discuten los requisitos para las unidades de manejo de aire (AHUs) y la necesidad de realizar evaluaciones de riesgo al decidir entre aire de retorno o recirculado.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas se pueden implementar para evitar el flujo de aire entre las \u00e1reas de empaque primaria y secundaria, y c\u00f3mo se puede mantener la presi\u00f3n negativa en estas \u00e1reas?**\n   - Respuesta: Se pueden implementar c\u00e1maras de paso sobre el \"mouse hole\" que se mantengan a presi\u00f3n negativa respecto a ambas \u00e1reas de empaque, lo que ayuda a prevenir el flujo de aire no deseado.\n\n2. **\u00bfCu\u00e1les son las especificaciones que deben incluirse en la descripci\u00f3n del sistema de manejo de aire para su inspecci\u00f3n?**\n   - Respuesta: La descripci\u00f3n del sistema debe incluir dibujos esquem\u00e1ticos que detallen los filtros y sus especificaciones, el n\u00famero de cambios de aire por hora, los gradientes de presi\u00f3n, las clases de sala limpia y otras especificaciones relacionadas.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al decidir entre el uso de aire de retorno o aire recirculado en un sistema de manejo de aire?**\n   - Respuesta: La decisi\u00f3n debe basarse en una evaluaci\u00f3n de riesgo que considere los posibles impactos en la calidad del aire y la seguridad del producto.\n\n### Resumen de nivel superior\n\nEl documento proporciona directrices sobre el manejo del aire en instalaciones farmac\u00e9uticas, enfatizando la importancia de la prevenci\u00f3n de la contaminaci\u00f3n cruzada y la protecci\u00f3n del personal. Se sugieren medidas como el uso de filtros HEPA y sistemas de presi\u00f3n negativa, as\u00ed como la necesidad de un suministro de energ\u00eda de emergencia. Adem\u00e1s, se establecen requisitos para las unidades de manejo de aire, destacando la importancia de realizar evaluaciones de riesgo al seleccionar sistemas de aire.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Manejo del aire en instalaciones controladas**:\n   - Se enfatiza la importancia de mantener un flujo de aire adecuado para prevenir la contaminaci\u00f3n en \u00e1reas cr\u00edticas.\n\n2. **Filtros HEPA**:\n   - Se mencionan filtros HEPA con una clasificaci\u00f3n m\u00ednima de H13 seg\u00fan la norma EN 1822, que son esenciales para la filtraci\u00f3n del aire.\n\n3. **Sistemas de manejo de aire**:\n   - Se recomienda el uso de sistemas de manejo de aire de paso \u00fanico sin recirculaci\u00f3n, para asegurar la calidad del aire en las \u00e1reas de trabajo.\n\n4. **Filtraci\u00f3n del aire de escape o retorno**:\n   - El aire de escape o retorno debe ser filtrado a trav\u00e9s de sistemas de filtro de cambio seguro o de bolsa dentro de bolsa, que incluyen prefiltros y filtros HEPA.\n\n5. **\u00c1reas de cambio y presi\u00f3n del aire**:\n   - Las \u00e1reas de cambio deben recibir aire filtrado al mismo est\u00e1ndar que el \u00e1rea de trabajo. Se requiere que las esclusas de aire y los accesos tengan un flujo de aire adecuado para mantener la presi\u00f3n necesaria y evitar la entrada de contaminantes.\n\n6. **Descontaminaci\u00f3n de operadores**:\n   - Si los operadores salen de un \u00e1rea de contenci\u00f3n con prendas contaminadas, deben pasar por un sistema de descontaminaci\u00f3n (duchas de aire o de niebla) antes de desvestirse. Las prendas que salen de la instalaci\u00f3n deben ser empaquetadas de manera segura para su lavander\u00eda.\n\n7. **Protecci\u00f3n del personal de lavander\u00eda**:\n   - Se deben implementar medidas adecuadas para proteger al personal de lavander\u00eda y prevenir la contaminaci\u00f3n de otras prendas provenientes de instalaciones no peligrosas.\n\n### Entidades clave:\n- **HEPA**: Filtros de alta eficiencia.\n- **EN 1822**: Norma de clasificaci\u00f3n de filtros.\n- **Sistemas de manejo de aire**: Sistemas de filtraci\u00f3n y flujo de aire.\n- **\u00c1reas de cambio**: Espacios destinados a la vestimenta de los operadores.\n- **Sistemas de descontaminaci\u00f3n**: M\u00e9todos para eliminar contaminantes de las prendas de los operadores.", "excerpt_keywords": "Keywords: airflow management, HEPA filters, contamination prevention, air-handling units, emergency power supply"}}, "3705ed84-1765-4393-873e-6e92b272d1a3": {"node_ids": ["4d2b4ae3-d28a-452f-a7a1-fb1bc0c796d3"], "metadata": {"page_label": "218", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# \n\npressure than the supply system. (Alternatives to the energy recovery wheel, such as crossover plate heat exchangers, heat pipes and water coil heat exchangers, may be used.)\n\n10.4 Risk management principles should be applied to address the potential of cross-contamination where energy wheels are used.\n\n10.5 If return air is to be recirculated it should pass through a safe change filtration system before being introduced back into the supply AHU. The return air fan could form part of the AHU; however, the safe change filter should be a dedicated unit. With this arrangement the return air passes through two sets of HEPA filters in series, i.e. the return air filters in the safe change housing and the supply air HEPA filters. The supply air HEPA filters could either be located in the AHU or terminally located at the supply diffusers, depending on the clean room classification of the facility.\n\n10.6 The starting and stopping of the supply and exhaust air fans, and associated system ventilation fans, should be synchronized such that the premises retain their design pressure and flow relationships during start-up and shut-down. Processing should stop when the fans are not running. This fan interlock sequence should also apply if any fan should fail, to ensure that there is no airflow reversal in the system.\n\n## 11. Safe change filter housings\n\n11.1 Safe change or bag-in-bag-out filter housings should be suitably designed to provide operator protection and to prevent dust from the filters entering the atmosphere when filters are changed.\n\n**Figure 2**  \n**Safe change filter bypass arrangement**\n\n!Safe change filter bypass arrangement\n\n- **E**: Shut-off Dampers\n- **VFD**: Velocity Sensor\n- **VFD**: Variable Frequency Drive\n- **Filter Pressure Differential Gauge**\n\n- **HEPA Bag-In, Bag-Out Units**\n- **SECONDARY FILTER**\n- **HEPA FILTER**\n\n- **Filter integrity test & De-contamination by-pass duct**\n- **DOP Injection**", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en las recomendaciones para el manejo de sistemas de filtraci\u00f3n de aire en instalaciones que requieren un control estricto de la contaminaci\u00f3n, como las salas limpias. Se discuten principios de gesti\u00f3n de riesgos para evitar la contaminaci\u00f3n cruzada, la importancia de un sistema de filtraci\u00f3n seguro para el aire de retorno, y la sincronizaci\u00f3n de los ventiladores de suministro y extracci\u00f3n para mantener la presi\u00f3n y el flujo de aire adecuados. Tambi\u00e9n se menciona el dise\u00f1o de las carcasas de filtros de cambio seguro para proteger a los operadores durante el mantenimiento.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las consideraciones clave para el dise\u00f1o de un sistema de filtraci\u00f3n de aire que minimice el riesgo de contaminaci\u00f3n cruzada en instalaciones cr\u00edticas?**\n   - Respuesta: Se deben aplicar principios de gesti\u00f3n de riesgos, utilizar un sistema de filtraci\u00f3n seguro para el aire de retorno que incluya filtros HEPA en serie, y asegurar que los ventiladores de suministro y extracci\u00f3n est\u00e9n sincronizados para mantener la presi\u00f3n y el flujo de aire adecuados.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para garantizar la seguridad del operador al cambiar filtros en un sistema de filtraci\u00f3n de aire?**\n   - Respuesta: Las carcasas de los filtros deben estar dise\u00f1adas para proporcionar protecci\u00f3n al operador y evitar que el polvo de los filtros entre en la atm\u00f3sfera durante el cambio de filtros, utilizando sistemas de cambio seguro como el \"bag-in-bag-out\".\n\n3. **\u00bfC\u00f3mo se debe manejar la operaci\u00f3n de los ventiladores en un sistema de filtraci\u00f3n de aire para evitar problemas de flujo de aire?**\n   - Respuesta: Los ventiladores de suministro y extracci\u00f3n deben ser operados de manera sincronizada, y el procesamiento debe detenerse si los ventiladores no est\u00e1n funcionando. Adem\u00e1s, se debe implementar un sistema de interbloqueo para prevenir la reversi\u00f3n del flujo de aire en caso de falla de alg\u00fan ventilador.", "prev_section_summary": "### Temas Clave\n\n1. **Prevenci\u00f3n de Contaminaci\u00f3n Cruzada**: Se enfatiza la importancia de evitar el flujo de aire entre \u00e1reas de empaque primaria y secundaria mediante el uso de c\u00e1maras de paso con presi\u00f3n negativa.\n\n2. **Uso de Filtros HEPA**: Se recomienda la instalaci\u00f3n de filtros HEPA en el sistema de suministro de aire para proteger contra la contaminaci\u00f3n cruzada en caso de fallos en el flujo de aire.\n\n3. **Sistemas de Contenci\u00f3n**: Se sugiere considerar el uso de gabinetes de bioseguridad, sistemas de aislamiento o cajas de guantes para la protecci\u00f3n del operador y la contenci\u00f3n de productos.\n\n4. **Descripci\u00f3n del Sistema de Manejo de Aire**: Se requiere una descripci\u00f3n detallada del sistema que incluya dibujos esquem\u00e1ticos, especificaciones de filtros, cambios de aire por hora, gradientes de presi\u00f3n y clases de sala limpia.\n\n5. **Monitoreo de Presiones**: Es necesario contar con indicadores de presi\u00f3n digitales o anal\u00f3gicos para monitorear los gradientes de presi\u00f3n en el sistema.\n\n6. **Suministro de Energ\u00eda de Emergencia**: Se debe considerar la provisi\u00f3n de un suministro de energ\u00eda de emergencia, como generadores di\u00e9sel, para mantener la operaci\u00f3n segura de las instalaciones.\n\n7. **Unidades de Manejo de Aire (AHUs)**: Las AHUs deben cumplir con requisitos espec\u00edficos y las decisiones sobre el uso de aire de retorno o recirculado deben basarse en evaluaciones de riesgo.\n\n8. **Sistemas de Aire Fresco**: En sistemas de aire fresco o de paso \u00fanico, se debe evitar la fuga de aire entre los sistemas de suministro y escape.\n\n### Entidades\n\n- **C\u00e1maras de Paso**: Estructuras dise\u00f1adas para mantener la presi\u00f3n negativa y prevenir el flujo de aire no deseado.\n- **Filtros HEPA**: Filtros de alta eficiencia utilizados para asegurar la calidad del aire.\n- **Gabinetes de Bioseguridad**: Equipos que proporcionan un entorno seguro para el manejo de materiales peligrosos.\n- **Unidades de Manejo de Aire (AHUs)**: Equipos que regulan y distribuyen el aire en las instalaciones.\n- **Generadores Di\u00e9sel**: Fuentes de energ\u00eda de emergencia para mantener la operaci\u00f3n de los sistemas.\n\nEste resumen destaca la importancia de las medidas de control ambiental en instalaciones farmac\u00e9uticas para garantizar la seguridad y la calidad del producto.", "excerpt_keywords": "Keywords: filtration, cross-contamination, HEPA filters, air handling units, risk management"}}, "ec32098b-ec61-411d-a088-e9c5ea02c16b": {"node_ids": ["5135f2f1-0f78-41ff-8f18-fdaa6c4a9544"], "metadata": {"page_label": "219", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11.2 \nThe final filters on the safe change unit should be HEPA filters with at least an H13 classification according to EN 1822 filter standards. For dusty return, air pre-filtration may also be required to prolong the life of the HEPA filters. The pre-filtration filters should also be removable through the bag-in-bag-out method.\n\n11.3 \nFor exhaust systems where the discharge contaminant is considered particularly hazardous, two banks of HEPA filters in series should be considered to provide additional protection should the first filter fail.\n\n11.4 \nAll filter banks should be provided with pressure differential indication gauges to indicate the filter dust loading and remaining lifespan of the filters. Connection to these gauges should be copper or stainless steel and not plastic tubing, which could perish causing a contamination hazard. The tube connections on the filter casing should be provided with stopcocks, for safe removal or calibration of gauges.\n\n11.5 \nMonitoring of filters should be done at regular intervals to prevent excessive filter loading that could force dust particles through the filter media, or could cause the filters to burst, resulting in ambient contamination.\n\n11.6 \nComputer-based data monitoring systems may be installed to monitor filter condition.\n\n11.7 \nFilter pressure gauges should be marked with the clean filter resistance and the change-out filter resistance.\n\n11.8 \nInstalled filter leakage tests should be performed in accordance with ISO 14644-3. Injection ports (upstream) and access ports (downstream) should, therefore, be provided for this purpose.\n\n11.9 \nThe exhaust air fan on a safe change filter system should be located after the filters so that the filter housing is maintained at a negative pressure. This poses a difficulty when carrying out filter integrity tests, and for this reason a bypass damper system should be provided, as illustrated in Figure 2, so that air can be circulated through the HEPA filters, while the scanning ports are open. Alternatively an independent booster fan system can be used, with appropriate shut-off dampers.\n\n11.10 \nThe bypass arrangement as shown in Figure 2 also permits decontamination of the filters by means of circulation of a sanitizing agent.\n\n11.11 \nAll exhaust systems from the facility, including dust extraction systems, vacuum system exhaust, fluid bed drier exhaust and coating pan exhaust, should be passed through safe change filter housings before being exhausted to the atmosphere.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Filtraci\u00f3n y Monitoreo de Sistemas de Aire**: El documento detalla las especificaciones y requisitos para los sistemas de filtraci\u00f3n de aire en entornos donde se manejan contaminantes peligrosos. Se enfatiza la importancia de utilizar filtros HEPA de clasificaci\u00f3n H13, la necesidad de un sistema de pre-filtraci\u00f3n, y la implementaci\u00f3n de monitoreo regular para asegurar la eficacia de los filtros.\n\n2. **Pruebas de Integridad y Seguridad**: Se menciona la necesidad de realizar pruebas de integridad de los filtros y de mantener la presi\u00f3n negativa en las unidades de filtraci\u00f3n. Tambi\u00e9n se discuten los m\u00e9todos para la desinfecci\u00f3n de los filtros y la importancia de un sistema de bypass para facilitar estas pruebas.\n\n3. **Conexiones y Materiales**: El documento especifica que las conexiones a los man\u00f3metros de presi\u00f3n deben ser de cobre o acero inoxidable, evitando el uso de tuber\u00edas de pl\u00e1stico que podr\u00edan representar un riesgo de contaminaci\u00f3n. Adem\u00e1s, se requiere que todos los sistemas de extracci\u00f3n de aire pasen por filtros seguros antes de ser liberados al ambiente.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de filtros se recomienda para las unidades de cambio seguro y cu\u00e1l es su clasificaci\u00f3n m\u00ednima seg\u00fan las normas EN 1822?**\n   - Se recomienda el uso de filtros HEPA con al menos una clasificaci\u00f3n H13 seg\u00fan las normas EN 1822.\n\n2. **\u00bfCu\u00e1l es la funci\u00f3n de los man\u00f3metros de presi\u00f3n diferencial en los bancos de filtros y qu\u00e9 materiales se deben utilizar para las conexiones?**\n   - Los man\u00f3metros de presi\u00f3n diferencial indican la carga de polvo en los filtros y su vida \u00fatil restante. Las conexiones deben ser de cobre o acero inoxidable, no de pl\u00e1stico, para evitar riesgos de contaminaci\u00f3n.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar para asegurar la integridad de los filtros en un sistema de extracci\u00f3n de aire que maneja contaminantes peligrosos?**\n   - Se deben realizar pruebas de integridad de los filtros de acuerdo con la norma ISO 14644-3, y se debe mantener la presi\u00f3n negativa en la vivienda del filtro. Adem\u00e1s, se debe considerar un sistema de bypass para facilitar la circulaci\u00f3n de aire durante las pruebas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistemas de Filtraci\u00f3n de Aire**:\n   - Importancia de un dise\u00f1o adecuado para minimizar el riesgo de contaminaci\u00f3n cruzada en instalaciones cr\u00edticas, como salas limpias.\n\n2. **Gesti\u00f3n de Riesgos**:\n   - Aplicaci\u00f3n de principios de gesti\u00f3n de riesgos para abordar la potencial contaminaci\u00f3n cruzada, especialmente en sistemas que utilizan ruedas de recuperaci\u00f3n de energ\u00eda.\n\n3. **Filtraci\u00f3n de Aire de Retorno**:\n   - El aire de retorno debe pasar por un sistema de filtraci\u00f3n seguro antes de ser reintroducido en la unidad de manejo de aire (AHU). Se recomienda el uso de filtros HEPA en serie.\n\n4. **Sincronizaci\u00f3n de Ventiladores**:\n   - Los ventiladores de suministro y extracci\u00f3n deben operar de manera sincronizada para mantener la presi\u00f3n y el flujo de aire adecuados. Se debe detener el procesamiento si los ventiladores no est\u00e1n funcionando.\n\n5. **Carcasas de Filtros de Cambio Seguro**:\n   - Dise\u00f1o de carcasas de filtros (bag-in-bag-out) que protejan a los operadores y eviten la liberaci\u00f3n de polvo al ambiente durante el cambio de filtros.\n\n6. **Componentes del Sistema**:\n   - Elementos como dampers de cierre, sensores de velocidad, unidades de frecuencia variable (VFD), y medidores de presi\u00f3n diferencial de filtros son cruciales para el funcionamiento del sistema.\n\n### Entidades Clave\n- **HEPA**: Filtros de alta eficiencia para la captura de part\u00edculas.\n- **AHU**: Unidad de Manejo de Aire.\n- **DOP**: Disolvente utilizado para pruebas de integridad de filtros.\n- **VFD**: Variador de Frecuencia, utilizado para controlar la velocidad de los ventiladores.\n- **Safe Change Filter**: Sistema de filtraci\u00f3n dise\u00f1ado para facilitar el cambio de filtros de manera segura. \n\nEste resumen abarca los aspectos fundamentales del manejo de sistemas de filtraci\u00f3n de aire en entornos controlados, enfatizando la seguridad y la eficacia en la prevenci\u00f3n de la contaminaci\u00f3n.", "excerpt_keywords": "Keywords: HEPA filters, air filtration, contamination control, pressure differential gauges, safe change systems"}}, "756de20d-dd81-47ba-992a-23cf259da245": {"node_ids": ["ee79e3aa-4369-4007-9c15-3d6b13a8e622"], "metadata": {"page_label": "220", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 11.12\n\nAll exhaust points outside the building should be located as far as possible from air entry points, and exit points should be at a high level to minimize the possibility of re-entrainment of exhaust air. Dominant and seasonal wind directions should be taken into account when positioning exhaust and supply points.\n\n11.13 Where excessively dust-laden air is handled, a dust collector or bag house should be considered, with the dust collector being located in an enclosed room maintained at a negative pressure. Access control, maintenance staff, personal protection equipment (PPE) and breathing air systems should then be provided to protect the operators during removal of dust from the collector bins.\n\n11.14 Portable vacuum cleaners and portable dust collectors should be fitted with H13 HEPA filters. These types of units should be emptied and cleaned in a room which is under negative pressure relative to the environment. Personnel should be provided with suitable PPE.\n\n11.15 Records of the safe disposal of all contaminated filters and dust should be kept.\n\n# 12. Personnel decontamination systems\n\n12.1 If required, a means of preventing contaminants from leaving the facility on the garments of personnel should be provided. This could be in the form of an air shower; mist shower, water shower or appropriate device.\n\n12.2 An air shower comprises an airlock where high velocity air is supplied through air nozzles (e.g. from the sides of the airlock) in order to dislodge dust particles. Air extraction grilles (e.g. at low level) should draw the air away and return it to the filtration system. Some air showers may also incorporate a vertical unidirectional airflow section at the exit end, to flush contaminants away.\n\n*Note:* When air showers are used these should be correctly designed to effectively extract dust.\n\nAir filtration of the supply air and return or exhaust air should comply with the same filtration standards as used in the manufacturing facility. Normally the fan should be activated by opening the door as the operator enters the shower, with a timing device on the exit door interlock to allow sufficient time for the decontamination process to be effective.\n\n12.3 Flushing devices similar to air or mist showers for personnel could be used at material exits to assist with removing contaminants.\n\n12.4 Wet mist or fog decontamination systems for operators can be employed for deactivating contaminants on the operator\u2019s garments, or", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las mejores pr\u00e1cticas para la gesti\u00f3n de la calidad del aire en instalaciones que manejan aire cargado de polvo y la descontaminaci\u00f3n del personal. Se enfatiza la importancia de ubicar los puntos de escape de aire lejos de las entradas de aire, el uso de colectores de polvo en habitaciones con presi\u00f3n negativa, y la implementaci\u00f3n de sistemas de descontaminaci\u00f3n para el personal, como duchas de aire y sistemas de niebla h\u00fameda. Tambi\u00e9n se menciona la necesidad de mantener registros de la disposici\u00f3n segura de filtros y polvo contaminado.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las consideraciones clave para la ubicaci\u00f3n de los puntos de escape de aire en relaci\u00f3n con las entradas de aire en un edificio?**\n   - Esta pregunta se centra en las directrices espec\u00edficas sobre la ubicaci\u00f3n de los puntos de escape de aire y c\u00f3mo deben tener en cuenta las direcciones del viento.\n\n2. **\u00bfQu\u00e9 medidas de protecci\u00f3n deben implementarse para los operadores que manejan colectores de polvo en habitaciones de presi\u00f3n negativa?**\n   - Esta pregunta busca detalles sobre el equipo de protecci\u00f3n personal (PPE) y otros sistemas de seguridad que deben estar disponibles para los operadores durante la manipulaci\u00f3n de polvo.\n\n3. **\u00bfC\u00f3mo deben dise\u00f1arse y operar las duchas de aire para garantizar una descontaminaci\u00f3n efectiva del personal?**\n   - Esta pregunta se enfoca en los aspectos t\u00e9cnicos del dise\u00f1o y funcionamiento de las duchas de aire, incluyendo la activaci\u00f3n del ventilador y el tiempo de exposici\u00f3n necesario para una descontaminaci\u00f3n adecuada.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar disponible en otras fuentes, bas\u00e1ndose en el contenido detallado del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Filtros HEPA**:\n   - Se requiere el uso de filtros HEPA con una clasificaci\u00f3n m\u00ednima de H13 seg\u00fan las normas EN 1822.\n   - Para prolongar la vida \u00fatil de los filtros HEPA, se sugiere un sistema de pre-filtraci\u00f3n, especialmente en entornos con polvo.\n\n2. **Sistemas de Filtraci\u00f3n en Serie**:\n   - En sistemas de extracci\u00f3n donde los contaminantes son particularmente peligrosos, se recomienda utilizar dos bancos de filtros HEPA en serie para mayor protecci\u00f3n.\n\n3. **Monitoreo y Mantenimiento**:\n   - Es esencial contar con man\u00f3metros de presi\u00f3n diferencial para indicar la carga de polvo y la vida \u00fatil restante de los filtros.\n   - Se deben realizar monitoreos regulares para evitar la sobrecarga de los filtros, lo que podr\u00eda causar contaminaci\u00f3n ambiental.\n\n4. **Pruebas de Integridad**:\n   - Las pruebas de integridad de los filtros deben realizarse de acuerdo con la norma ISO 14644-3, y se deben proporcionar puertos de inyecci\u00f3n y acceso para facilitar estas pruebas.\n\n5. **Presi\u00f3n Negativa y Sistemas de Bypass**:\n   - El ventilador de extracci\u00f3n debe estar ubicado despu\u00e9s de los filtros para mantener la presi\u00f3n negativa en la vivienda del filtro.\n   - Se sugiere un sistema de compuerta de bypass para permitir la circulaci\u00f3n de aire durante las pruebas de integridad y para la desinfecci\u00f3n de los filtros.\n\n6. **Conexiones y Materiales**:\n   - Las conexiones a los man\u00f3metros deben ser de cobre o acero inoxidable, evitando el uso de tuber\u00edas de pl\u00e1stico que pueden representar un riesgo de contaminaci\u00f3n.\n\n7. **Exhaustos de Sistemas**:\n   - Todos los sistemas de extracci\u00f3n de aire, incluidos los de extracci\u00f3n de polvo y sistemas de vac\u00edo, deben pasar por alojamientos de filtros seguros antes de ser liberados al ambiente.\n\n### Entidades Clave:\n- **Filtros HEPA**: H13, pre-filtraci\u00f3n, pruebas de integridad.\n- **Normas**: EN 1822, ISO 14644-3.\n- **Materiales**: Cobre, acero inoxidable, tuber\u00edas de pl\u00e1stico (no recomendadas).\n- **Sistemas**: Sistemas de extracci\u00f3n, sistemas de bypass, ventiladores de extracci\u00f3n.", "excerpt_keywords": "Keywords: exhaust points, dust collector, HEPA filters, personnel decontamination, air filtration"}}, "881b1adf-34eb-4d4c-b671-8031a4fba642": {"node_ids": ["5332fcc5-3d42-40ad-bb6e-33a51f278875"], "metadata": {"page_label": "221", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "causing contaminants to adhere to the garments so that they are not easily liberated.\n\n12.5 Personnel should change into clean garments after having taken a shower.\n\n## 13. Effluent treatment\n\n13.1 Liquid and solid waste effluent should be handled in such a manner as not to present a risk of contamination to the product, personnel or to the environment.\n\n13.2 All effluent should be disposed of in a safe manner, and the means of disposal should be documented. Where external contractors are used for effluent disposal they should have certification authorizing them to handle and treat hazardous products.\n\n## 14. Maintenance\n\n14.1 The efficient and safe operation of a facility handling hazardous materials is reliant on regular maintenance being carried out, to ensure that all parameters remain within specified tolerances. See *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials (1)* or WHO Technical Report Series, No. 937, Annex 2, section 8.3 (2) for further details on maintenance.\n\n## 15. Qualification and validation\n\n15.1 System qualification and validation should be carried out as described in other WHO guidelines.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior del contenido:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda directrices sobre el manejo seguro de materiales peligrosos en instalaciones, enfatizando la importancia de la higiene del personal, el tratamiento adecuado de efluentes, el mantenimiento regular de las instalaciones y la calificaci\u00f3n y validaci\u00f3n de sistemas. Se destacan pr\u00e1cticas espec\u00edficas para evitar la contaminaci\u00f3n y asegurar la seguridad tanto del producto como del personal y el medio ambiente.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las recomendaciones espec\u00edficas para el cambio de vestimenta del personal en instalaciones que manejan materiales peligrosos?**\n   - Respuesta: El personal debe cambiarse a prendas limpias despu\u00e9s de haberse duchado para evitar que los contaminantes se adhieran a la ropa y no se liberen f\u00e1cilmente.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse para el tratamiento y disposici\u00f3n de efluentes en instalaciones que manejan residuos peligrosos?**\n   - Respuesta: Los efluentes l\u00edquidos y s\u00f3lidos deben manejarse de manera que no presenten riesgos de contaminaci\u00f3n. Adem\u00e1s, todos los efluentes deben ser desechados de forma segura y documentada, y los contratistas externos que se encarguen de la disposici\u00f3n deben tener certificaci\u00f3n para manejar y tratar productos peligrosos.\n\n3. **\u00bfPor qu\u00e9 es crucial el mantenimiento regular en instalaciones que manejan materiales peligrosos, seg\u00fan el documento de la OMS?**\n   - Respuesta: El mantenimiento regular es esencial para garantizar el funcionamiento eficiente y seguro de la instalaci\u00f3n, asegurando que todos los par\u00e1metros se mantengan dentro de las tolerancias especificadas. Esto ayuda a prevenir incidentes que podr\u00edan comprometer la seguridad del producto, del personal y del medio ambiente.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Ubicaci\u00f3n de Puntos de Escape de Aire**:\n   - Los puntos de escape deben estar lo m\u00e1s alejados posible de las entradas de aire.\n   - Deben situarse a una altura elevada para minimizar la recirculaci\u00f3n del aire de escape.\n   - Se deben considerar las direcciones del viento dominantes y estacionales al posicionar los puntos de escape y suministro.\n\n2. **Manejo de Aire Cargado de Polvo**:\n   - Se recomienda el uso de colectores de polvo o casas de bolsa en \u00e1reas con aire excesivamente cargado de polvo.\n   - Los colectores deben estar en habitaciones con presi\u00f3n negativa.\n   - Se deben implementar controles de acceso, personal de mantenimiento, equipo de protecci\u00f3n personal (PPE) y sistemas de aire respirable para proteger a los operadores.\n\n3. **Filtros y Equipos de Limpieza**:\n   - Los aspiradores port\u00e1tiles y colectores de polvo deben estar equipados con filtros HEPA H13.\n   - Estos equipos deben vaciarse y limpiarse en habitaciones con presi\u00f3n negativa.\n   - Es necesario mantener registros de la disposici\u00f3n segura de filtros y polvo contaminado.\n\n4. **Sistemas de Descontaminaci\u00f3n del Personal**:\n   - Se deben proporcionar medios para evitar que los contaminantes salgan de la instalaci\u00f3n en la ropa del personal, como duchas de aire, duchas de niebla o agua.\n   - Las duchas de aire deben estar dise\u00f1adas para extraer eficazmente el polvo mediante aire de alta velocidad.\n   - La filtraci\u00f3n del aire de suministro y retorno debe cumplir con los mismos est\u00e1ndares de filtraci\u00f3n que la instalaci\u00f3n de fabricaci\u00f3n.\n\n5. **Dispositivos de Flushing**:\n   - Se pueden utilizar dispositivos de flushing similares a duchas de aire o niebla en las salidas de materiales para ayudar a eliminar contaminantes.\n   - Sistemas de niebla h\u00fameda pueden ser empleados para desactivar contaminantes en la vestimenta de los operadores.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Colectores de polvo**: Equipos recomendados para manejar aire cargado de polvo.\n- **Filtros HEPA H13**: Tipo de filtro recomendado para equipos de limpieza.\n- **Equipo de Protecci\u00f3n Personal (PPE)**: Elementos necesarios para la seguridad de los operadores.\n- **Duchas de aire**: Sistemas de descontaminaci\u00f3n para el personal.\n- **Sistemas de niebla h\u00fameda**: M\u00e9todos de descontaminaci\u00f3n adicionales para operadores. \n\nEste resumen destaca las mejores pr\u00e1cticas y consideraciones para la gesti\u00f3n de la calidad del aire y la descontaminaci\u00f3n del personal en instalaciones que manejan aire contaminado.", "excerpt_keywords": "Keywords: hazardous materials, effluent treatment, personnel hygiene, maintenance, qualification and validation"}}, "4ab8e6fc-6373-4832-b6ef-cfd14228b9f4": {"node_ids": ["1794134f-2395-40d1-af06-ee4cadb7f802"], "metadata": {"page_label": "222", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, 2nd updated ed. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007.\n\n2. Supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report. Geneva, World Health Organization, 2006, Annex 2 (WHO Technical Report Series, No. 937).\n\n3. Health Canada: Laboratory biosafety guidelines, 3rd ed. Ottawa, Health Canada, 2004.\n\n4. WHO good manufacturing practices for sterile pharmaceutical products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report. Geneva, World Health Organization, 2010, Annex 4 (WHO Technical Report Series, No. 957).\n\n5. ISO: International Standard. Clean rooms and associated controlled environments. ISO 14644. Geneva, International Organization for Standardization.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento \"WHO - Technical Report Series 957\" incluye referencias a diversas gu\u00edas y est\u00e1ndares relacionados con las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) en la industria farmac\u00e9utica. Se mencionan directrices espec\u00edficas de la Organizaci\u00f3n Mundial de la Salud (OMS) y de Health Canada, as\u00ed como normas internacionales sobre salas limpias y entornos controlados. Estas referencias son cruciales para asegurar la calidad y la seguridad en la producci\u00f3n de productos farmac\u00e9uticos, tanto est\u00e9riles como no est\u00e9riles.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales diferencias entre las buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles y no est\u00e9riles seg\u00fan las gu\u00edas de la OMS?**\n   - Esta pregunta busca una comparaci\u00f3n directa entre las dos categor\u00edas de productos, que puede no estar claramente delineada en otros documentos.\n\n2. **\u00bfQu\u00e9 aspectos espec\u00edficos se abordan en las \"Supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems\" mencionadas en el documento?**\n   - Esta pregunta se centra en un tema t\u00e9cnico espec\u00edfico que puede no ser ampliamente discutido en otras fuentes.\n\n3. **\u00bfC\u00f3mo se relacionan las normas ISO 14644 sobre salas limpias con las buenas pr\u00e1cticas de fabricaci\u00f3n mencionadas en el informe de la OMS?**\n   - Esta pregunta busca una conexi\u00f3n entre est\u00e1ndares internacionales y las directrices de la OMS, lo que puede no ser evidente en otros contextos. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n detallada y espec\u00edfica que puede no estar disponible en otros documentos o fuentes.", "prev_section_summary": "### Temas Clave:\n\n1. **Higiene del Personal**: Se enfatiza la importancia de que el personal cambie a prendas limpias despu\u00e9s de ducharse para evitar la contaminaci\u00f3n.\n\n2. **Tratamiento de Efluentes**: Se establecen directrices para el manejo seguro de efluentes l\u00edquidos y s\u00f3lidos, asegurando que no representen un riesgo de contaminaci\u00f3n para productos, personal o medio ambiente. Tambi\u00e9n se requiere documentaci\u00f3n del proceso de disposici\u00f3n y certificaci\u00f3n de contratistas externos.\n\n3. **Mantenimiento de Instalaciones**: Se destaca la necesidad de realizar mantenimiento regular en instalaciones que manejan materiales peligrosos para garantizar su operaci\u00f3n eficiente y segura, manteniendo todos los par\u00e1metros dentro de tolerancias especificadas.\n\n4. **Calificaci\u00f3n y Validaci\u00f3n de Sistemas**: Se menciona que la calificaci\u00f3n y validaci\u00f3n de sistemas deben seguir las pautas establecidas por la OMS.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Materiales Peligrosos**: Tipo de sustancias que requieren manejo especial.\n- **Efluentes L\u00edquidos y S\u00f3lidos**: Residuos generados que deben ser tratados adecuadamente.\n- **Contratistas Externos**: Entidades que pueden ser contratadas para la disposici\u00f3n de efluentes, que deben estar certificadas.\n- **Instalaciones**: Lugares donde se manejan materiales peligrosos y que requieren mantenimiento regular.\n\n### Resumen:\nEl documento de la OMS proporciona directrices sobre la higiene del personal, el tratamiento seguro de efluentes, la importancia del mantenimiento regular en instalaciones que manejan materiales peligrosos y la necesidad de calificaci\u00f3n y validaci\u00f3n de sistemas. Estas pr\u00e1cticas son esenciales para prevenir la contaminaci\u00f3n y garantizar la seguridad del producto, del personal y del medio ambiente.", "excerpt_keywords": "Keywords: buenas pr\u00e1cticas de fabricaci\u00f3n, OMS, productos farmac\u00e9uticos, normas ISO, calidad y seguridad"}}, "e622c5a4-2eb3-46d4-af90-0de4edcbb3d2": {"node_ids": ["78ee4e74-ea72-4554-9dcf-c5eb9464c215"], "metadata": {"page_label": "223", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 4\n\n## WHO good manufacturing practices for sterile pharmaceutical products\n\n### Introduction\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations in its thirty-sixth report in 1999 adopted *WHO good manufacturing practices for sterile pharmaceutical products* (WHO Technical Report Series, No. 902, 2002, Annex 6) (http://whqlibdoc.who.int/trs/WHO_TRS_902.pdf); and published in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection (2007) (1).*\n\nFollowing implementation of these WHO good manufacturing practices (GMP) within the context of the WHO Prequalification Programme, a proposal for revision is being submitted to take into consideration new developments. The proposal for revision of the above-mentioned guidance is being made to bring the WHO GMP into line with International Standardization Organization standard ISO 14644-1 (2) and recent practices of the United States (3), Japan (4), the European Union (5) and the Pharmaceutical Inspection Co-operation Scheme.\n\n- New chapters on Isolator technology and Blow/fill/seal technology have been added to the document.\n- The chapter on Finishing of sterile products has been amended and provisions have been given for capping of vials.\n- The chapter entitled Manufacture of sterile preparations has been amended and provisions have been given for clean room and clean-air device monitoring.\n\nImplementation of these new practices may need to be undertaken for certain parts using a step-wise approach, especially the part relating to the provision for capping in a clean or sterile environment, as this is currently not implemented in most industries.\n\nOn the basis of the above, the following text is proposed to replace the previously published guidance.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento se centra en las Buenas Pr\u00e1cticas de Manufactura (GMP) de la OMS para productos farmac\u00e9uticos est\u00e9riles, revisadas para alinearse con est\u00e1ndares internacionales y recientes pr\u00e1cticas de varios pa\u00edses. Se han a\u00f1adido nuevos cap\u00edtulos sobre tecnolog\u00edas espec\u00edficas y se han realizado enmiendas en secciones clave, como el acabado de productos est\u00e9riles y la fabricaci\u00f3n de preparaciones est\u00e9riles. La implementaci\u00f3n de estas pr\u00e1cticas puede requerir un enfoque gradual, especialmente en lo que respecta al encapsulado en entornos limpios o est\u00e9riles.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 nuevas tecnolog\u00edas se han incorporado en la revisi\u00f3n de las Buenas Pr\u00e1cticas de Manufactura para productos farmac\u00e9uticos est\u00e9riles?**\n   - Respuesta: Se han a\u00f1adido nuevos cap\u00edtulos sobre tecnolog\u00eda de aisladores y tecnolog\u00eda de llenado/sellado.\n\n2. **\u00bfCu\u00e1les son las enmiendas realizadas en el cap\u00edtulo sobre el acabado de productos est\u00e9riles?**\n   - Respuesta: Se han realizado enmiendas para incluir disposiciones sobre el encapsulado de viales.\n\n3. **\u00bfPor qu\u00e9 se sugiere un enfoque gradual para la implementaci\u00f3n de las nuevas pr\u00e1cticas, especialmente en relaci\u00f3n con el encapsulado en un entorno limpio o est\u00e9ril?**\n   - Respuesta: Se sugiere un enfoque gradual porque actualmente esta pr\u00e1ctica no se implementa en la mayor\u00eda de las industrias.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n se centra en las referencias relacionadas con las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) en la industria farmac\u00e9utica, destacando la importancia de seguir directrices y est\u00e1ndares para garantizar la calidad y seguridad de los productos farmac\u00e9uticos. \n\n#### Temas Clave:\n1. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF)**: Se enfatiza la necesidad de seguir gu\u00edas espec\u00edficas para asegurar la calidad en la producci\u00f3n de productos farmac\u00e9uticos, tanto est\u00e9riles como no est\u00e9riles.\n2. **Normas Internacionales**: Se menciona la norma ISO 14644, que se refiere a las salas limpias y entornos controlados, cruciales para la fabricaci\u00f3n de productos farmac\u00e9uticos.\n3. **Directrices de la OMS**: Se citan varias publicaciones de la Organizaci\u00f3n Mundial de la Salud que abordan las BPF y aspectos t\u00e9cnicos relacionados con la producci\u00f3n farmac\u00e9utica.\n4. **Biosafety**: Se hace referencia a las pautas de biosalubridad de Health Canada, que son relevantes para la seguridad en laboratorios.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Publica directrices y est\u00e1ndares sobre BPF.\n- **Health Canada**: Proporciona pautas sobre biosalubridad.\n- **International Organization for Standardization (ISO)**: Establece normas internacionales, como la ISO 14644.\n\nEste resumen destaca la interconexi\u00f3n entre las directrices de la OMS, las normas internacionales y las pautas de biosalubridad, subrayando su relevancia para la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: Good Manufacturing Practices, sterile pharmaceutical products, ISO 14644, Isolator technology, clean room monitoring"}}, "56b3c7dd-5f15-40c3-9e16-68c3cb365349": {"node_ids": ["285174ca-ba4d-43e9-93fc-4b3bb33f1866"], "metadata": {"page_label": "224", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# WHO Good Manufacturing Practices for Sterile Pharmaceutical Products\n\n1. General considerations\n2. Quality control\n3. Sanitation\n4. Manufacture of sterile preparations\n5. Sterilization\n6. Terminal sterilization\n7. Aseptic processing and sterilization by filtration\n8. Isolator technology\n9. Blow/fill/seal technology\n10. Personnel\n11. Premises\n12. Equipment\n13. Finishing of sterile products\n\nReferences", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO Good Manufacturing Practices for Sterile Pharmaceutical Products\" de la OMS establece directrices y pr\u00e1cticas recomendadas para la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles. Se abordan aspectos clave como el control de calidad, la sanidad, los procesos de esterilizaci\u00f3n, el uso de tecnolog\u00eda aislante y de llenado/sellado, as\u00ed como la importancia del personal, las instalaciones y el equipo en la producci\u00f3n de estos productos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las consideraciones generales que se deben tener en cuenta al implementar buenas pr\u00e1cticas de manufactura para productos farmac\u00e9uticos est\u00e9riles?**\n   - Esta pregunta busca detalles sobre los principios fundamentales que gu\u00edan la producci\u00f3n est\u00e9ril, que pueden no estar ampliamente disponibles en otras fuentes.\n\n2. **\u00bfQu\u00e9 m\u00e9todos de esterilizaci\u00f3n se describen en el documento y cu\u00e1les son sus aplicaciones espec\u00edficas en la fabricaci\u00f3n de productos est\u00e9riles?**\n   - Esta pregunta se centra en los m\u00e9todos de esterilizaci\u00f3n mencionados, como la esterilizaci\u00f3n terminal y la filtraci\u00f3n as\u00e9ptica, y su relevancia en la industria farmac\u00e9utica.\n\n3. **\u00bfQu\u00e9 papel juega el personal en el cumplimiento de las buenas pr\u00e1cticas de manufactura para productos farmac\u00e9uticos est\u00e9riles seg\u00fan el documento de la OMS?**\n   - Esta pregunta indaga sobre la importancia del personal en el proceso de fabricaci\u00f3n, incluyendo su capacitaci\u00f3n y las pr\u00e1cticas que deben seguir para garantizar la calidad y seguridad de los productos est\u00e9riles.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Buenas Pr\u00e1cticas de Manufactura (GMP)**: El documento se centra en las GMP de la OMS para productos farmac\u00e9uticos est\u00e9riles, revisadas para alinearse con est\u00e1ndares internacionales y pr\u00e1cticas recientes.\n\n2. **Revisi\u00f3n y Actualizaci\u00f3n**: Se propone una revisi\u00f3n de las GMP para incorporar nuevos desarrollos y alinearse con la norma ISO 14644-1 y pr\u00e1cticas de pa\u00edses como Estados Unidos, Jap\u00f3n, la Uni\u00f3n Europea y el esquema de cooperaci\u00f3n de inspecci\u00f3n farmac\u00e9utica.\n\n3. **Nuevos Cap\u00edtulos**:\n   - **Tecnolog\u00eda de Aisladores**: Se ha a\u00f1adido un cap\u00edtulo sobre esta tecnolog\u00eda.\n   - **Tecnolog\u00eda de Llenado/Sellado**: Tambi\u00e9n se ha incluido un cap\u00edtulo sobre esta t\u00e9cnica.\n\n4. **Enmiendas en Cap\u00edtulos Existentes**:\n   - **Acabado de Productos Est\u00e9riles**: Se han realizado enmiendas para incluir disposiciones sobre el encapsulado de viales.\n   - **Fabricaci\u00f3n de Preparaciones Est\u00e9riles**: Se han actualizado las provisiones para el monitoreo de salas limpias y dispositivos de aire limpio.\n\n5. **Implementaci\u00f3n Gradual**: Se sugiere un enfoque gradual para la implementaci\u00f3n de las nuevas pr\u00e1cticas, especialmente en lo que respecta al encapsulado en entornos limpios o est\u00e9riles, dado que esta pr\u00e1ctica no se aplica actualmente en la mayor\u00eda de las industrias.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las GMP.\n- **ISO (Organizaci\u00f3n Internacional de Normalizaci\u00f3n)**: Est\u00e1ndar ISO 14644-1 mencionado.\n- **Pa\u00edses**: Estados Unidos, Jap\u00f3n, Uni\u00f3n Europea, que influyen en las pr\u00e1cticas de manufactura.\n- **Esquema de Cooperaci\u00f3n de Inspecci\u00f3n Farmac\u00e9utica**: Entidad que colabora en la estandarizaci\u00f3n de pr\u00e1cticas.", "excerpt_keywords": "Keywords: Good Manufacturing Practices, sterile pharmaceutical products, sterilization methods, quality control, aseptic processing"}}, "70bed42c-b350-41d4-9315-1fb51a48a49b": {"node_ids": ["78f5f09c-5840-4659-a947-bb9960fe0fed"], "metadata": {"page_label": "225", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 1. General considerations\n\n1.1 The production of sterile preparations should be carried out in clean areas, entry to which should be through airlocks for personnel and/or for equipment and materials. Clean areas should be maintained to an appropriate standard of cleanliness and supplied with air that has passed through filters of the required efficiency.\n\n1.2 The various operations of component preparation (such as those involving containers and closures), product preparation, filling and sterilization should be carried out in separate areas within the clean area. These areas are classified into four grades (see section 4).\n\nManufacturing operations are divided here into two categories:\n- first, those where the product is terminally sterilized; and\n- second, those which are conducted aseptically at some or all stages.\n\n# 2. Quality control\n\n2.1 The sterility test applied to the finished product should only be regarded as the last in a series of control measures by which sterility is assured. The test should be validated for the product(s) concerned.\n\n2.2 Samples taken for sterility testing should be representative of the whole of the batch but should, in particular, include samples taken from parts of the batch considered to be most at risk of contamination, for example:\n- for products that have been filled aseptically, samples should include containers filled at the beginning and end of the batch and after any significant interruption of work;\n- for products that have been heat sterilized in their final containers, consideration should be given to taking samples from that part of the load that is potentially the coolest.\n\n2.3 The sterility of the finished product is assured by validation of the sterilization cycle in the case of terminally sterilized products, and by \u201cmedia simulation\u201d or \u201cmedia fill\u201d runs for aseptically processed products. Batch-processing records and, in the case of aseptic processing, environmental quality records, should be examined in conjunction with the results of the sterility tests. The sterility test procedure should be validated for a given product. Pharmacopoeial methods should be used for the validation and performance of the sterility test. In those cases where parametric release has been authorized in place of sterility testing special attention should be paid to the validation and the monitoring of the entire manufacturing process.\n\n2.4 For injectable products the water for injection and the intermediate, if appropriate, and finished products should be monitored for endotoxins,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda consideraciones generales y controles de calidad en la producci\u00f3n de preparaciones est\u00e9riles. Se enfatiza la importancia de realizar estas operaciones en \u00e1reas limpias y clasificadas, as\u00ed como la necesidad de pruebas de esterilidad que validen el proceso de fabricaci\u00f3n. Se describen dos categor\u00edas de operaciones de fabricaci\u00f3n: aquellas que son esterilizadas terminalmente y aquellas que se realizan de manera as\u00e9ptica. Adem\u00e1s, se menciona la importancia de monitorear productos inyectables para endotoxinas y la validaci\u00f3n de los m\u00e9todos de prueba de esterilidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las cuatro categor\u00edas de \u00e1reas limpias mencionadas en el documento y c\u00f3mo se clasifican?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre la clasificaci\u00f3n de las \u00e1reas limpias, que no se detalla en el texto proporcionado.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir para validar el ciclo de esterilizaci\u00f3n de productos que son esterilizados terminalmente?**\n   - Esta pregunta se centra en los pasos espec\u00edficos requeridos para la validaci\u00f3n del ciclo de esterilizaci\u00f3n, que no se explican en detalle en el contexto.\n\n3. **\u00bfQu\u00e9 medidas adicionales se deben considerar en el caso de que se autorice la liberaci\u00f3n param\u00e9trica en lugar de las pruebas de esterilidad?**\n   - Esta pregunta busca informaci\u00f3n sobre las consideraciones especiales que deben tenerse en cuenta cuando se opta por la liberaci\u00f3n param\u00e9trica, un aspecto que no se aborda en profundidad en el texto.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento \"WHO Good Manufacturing Practices for Sterile Pharmaceutical Products\" de la OMS aborda una serie de temas fundamentales relacionados con la producci\u00f3n de productos farmac\u00e9uticos est\u00e9riles. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas en la secci\u00f3n:\n\n1. **Consideraciones Generales**: Principios y fundamentos que gu\u00edan la implementaci\u00f3n de buenas pr\u00e1cticas en la manufactura de productos est\u00e9riles.\n\n2. **Control de Calidad**: M\u00e9todos y procedimientos para asegurar que los productos cumplan con los est\u00e1ndares de calidad requeridos.\n\n3. **Sanidad**: Pr\u00e1cticas de limpieza y desinfecci\u00f3n necesarias para mantener un entorno de producci\u00f3n est\u00e9ril.\n\n4. **Fabricaci\u00f3n de Preparaciones Est\u00e9riles**: Proceso y t\u00e9cnicas involucradas en la producci\u00f3n de productos farmac\u00e9uticos est\u00e9riles.\n\n5. **Esterilizaci\u00f3n**: M\u00e9todos utilizados para eliminar microorganismos y asegurar la esterilidad del producto.\n\n6. **Esterilizaci\u00f3n Terminal**: Proceso de esterilizaci\u00f3n que se realiza en el producto final antes de su envasado.\n\n7. **Procesamiento Aseptico y Esterilizaci\u00f3n por Filtraci\u00f3n**: T\u00e9cnicas espec\u00edficas para mantener la esterilidad durante la producci\u00f3n.\n\n8. **Tecnolog\u00eda de Aisladores**: Uso de sistemas aislantes para proteger el proceso de fabricaci\u00f3n de contaminantes externos.\n\n9. **Tecnolog\u00eda de Llenado/Sellado**: M\u00e9todos de envasado que aseguran la esterilidad del producto final.\n\n10. **Personal**: Importancia del personal en la producci\u00f3n, incluyendo capacitaci\u00f3n y pr\u00e1cticas de trabajo.\n\n11. **Instalaciones**: Dise\u00f1o y mantenimiento de las instalaciones de producci\u00f3n para garantizar un entorno est\u00e9ril.\n\n12. **Equipo**: Herramientas y maquinaria utilizadas en la fabricaci\u00f3n de productos est\u00e9riles.\n\n13. **Finalizaci\u00f3n de Productos Est\u00e9riles**: Procesos finales que aseguran que los productos est\u00e9n listos para su distribuci\u00f3n y uso.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Productos Farmac\u00e9uticos Est\u00e9riles**: Tipo de productos que se est\u00e1n fabricando bajo estas buenas pr\u00e1cticas.\n- **M\u00e9todos de Esterilizaci\u00f3n**: Incluyen esterilizaci\u00f3n terminal y filtraci\u00f3n as\u00e9ptica.\n- **Tecnolog\u00edas**: Aisladores y sistemas de llenado/sellado.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades clave que se abordan en el documento, destacando la importancia de cada uno en el contexto de las buenas pr\u00e1cticas de manufactura para productos farmac\u00e9uticos est\u00e9riles.", "excerpt_keywords": "Keywords: sterile preparations, clean areas, quality control, sterility testing, endotoxins"}}, "30ff21c2-5e93-403e-ad74-1482cc31219f": {"node_ids": ["e3746c66-e044-4188-b48f-ce177422ac83"], "metadata": {"page_label": "226", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Sanitation\n\n3.1 The sanitation of clean areas is particularly important. They should be cleaned frequently and thoroughly in accordance with an approved written programme. Where disinfectants are used, more than one type should be employed. Monitoring should be regularly undertaken to detect contamination or the presence of an organism against which the cleaning procedure is ineffective. Interactions between different cleaning materials should be validated. Appropriate cleaning validation should be carried out to ensure disinfectant residuals can be detected and are removed by the cleaning process.\n\n3.2 Disinfectants and detergents should be monitored for microbial contamination; dilutions should be kept in previously cleaned containers and should only be stored for defined periods unless sterilized. Disinfectants and detergents used in grade A and B areas should be sterile before use.\n\n3.3 A disinfectant programme should also include a sporicidal agent since many common disinfectants are ineffective against spores. The effectiveness of cleaning and disinfectant procedures should be demonstrated.\n\n3.4 Fumigation of clean areas may be useful for reducing microbial contamination in inaccessible places.\n\n# Manufacture of sterile preparations\n\n4.1 Clean areas for the manufacture of sterile products are classified according to the required characteristics of the environment. Each manufacturing operation requires an appropriate level of environmental cleanliness in the operational state to minimize the risks of particulate or microbial contamination of the product or materials being handled.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Informe T\u00e9cnico 957) aborda la importancia de la sanidad en \u00e1reas limpias, especialmente en la fabricaci\u00f3n de productos est\u00e9riles. Se enfatiza la necesidad de un programa de limpieza aprobado, el uso de m\u00faltiples tipos de desinfectantes, la monitorizaci\u00f3n de la contaminaci\u00f3n microbiana, y la validaci\u00f3n de interacciones entre materiales de limpieza. Tambi\u00e9n se menciona la importancia de utilizar agentes esporicidas y la posible fumigaci\u00f3n de \u00e1reas limpias para reducir la contaminaci\u00f3n microbiana. Adem\u00e1s, se clasifica la limpieza de \u00e1reas seg\u00fan las caracter\u00edsticas requeridas para minimizar riesgos de contaminaci\u00f3n en la producci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de programa de limpieza se recomienda para las \u00e1reas limpias y qu\u00e9 aspectos deben ser considerados en su implementaci\u00f3n?**\n   - Respuesta: Se recomienda un programa de limpieza aprobado que incluya limpieza frecuente y exhaustiva, el uso de m\u00e1s de un tipo de desinfectante, y la monitorizaci\u00f3n regular para detectar contaminaci\u00f3n. Tambi\u00e9n se debe validar las interacciones entre diferentes materiales de limpieza y realizar una validaci\u00f3n adecuada de la limpieza.\n\n2. **\u00bfPor qu\u00e9 es importante incluir un agente esporicida en el programa de desinfecci\u00f3n y qu\u00e9 limitaciones tienen los desinfectantes comunes?**\n   - Respuesta: Es importante incluir un agente esporicida porque muchos desinfectantes comunes son ineficaces contra esporas. Esto asegura que se aborden todos los tipos de microorganismos, incluyendo aquellos que pueden ser m\u00e1s resistentes.\n\n3. **\u00bfQu\u00e9 medidas se pueden tomar para reducir la contaminaci\u00f3n microbiana en lugares de dif\u00edcil acceso dentro de las \u00e1reas limpias?**\n   - Respuesta: La fumigaci\u00f3n de \u00e1reas limpias puede ser \u00fatil para reducir la contaminaci\u00f3n microbiana en lugares de dif\u00edcil acceso, complementando as\u00ed otros m\u00e9todos de limpieza y desinfecci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Producci\u00f3n de Preparaciones Est\u00e9riles**:\n   - Debe realizarse en \u00e1reas limpias con acceso a trav\u00e9s de airlocks.\n   - Las \u00e1reas limpias deben mantener un est\u00e1ndar adecuado de limpieza y contar con aire filtrado.\n\n2. **Clasificaci\u00f3n de \u00c1reas Limpias**:\n   - Las operaciones de preparaci\u00f3n de componentes, preparaci\u00f3n de productos, llenado y esterilizaci\u00f3n deben llevarse a cabo en \u00e1reas separadas dentro de la zona limpia.\n   - Estas \u00e1reas est\u00e1n clasificadas en cuatro grados (detalles no proporcionados en el texto).\n\n3. **Categor\u00edas de Operaciones de Fabricaci\u00f3n**:\n   - **Esterilizaci\u00f3n Terminal**: Productos que son esterilizados al final del proceso.\n   - **Procesamiento Aseptico**: Productos que se manejan de manera as\u00e9ptica en alguna o todas las etapas.\n\n4. **Control de Calidad**:\n   - La prueba de esterilidad es el \u00faltimo control para asegurar la esterilidad del producto.\n   - Las muestras para pruebas de esterilidad deben ser representativas y tomar en cuenta las partes m\u00e1s vulnerables a la contaminaci\u00f3n.\n\n5. **Validaci\u00f3n de Procesos**:\n   - La esterilidad se asegura mediante la validaci\u00f3n del ciclo de esterilizaci\u00f3n para productos terminalmente esterilizados y mediante simulaciones de medios para productos procesados as\u00e9pticamente.\n   - Se deben revisar los registros de procesamiento por lotes y los registros de calidad ambiental en el caso de procesamiento as\u00e9ptico.\n\n6. **Liberaci\u00f3n Param\u00e9trica**:\n   - En casos donde se autoriza la liberaci\u00f3n param\u00e9trica en lugar de pruebas de esterilidad, se debe prestar especial atenci\u00f3n a la validaci\u00f3n y monitoreo del proceso de fabricaci\u00f3n.\n\n7. **Monitoreo de Endotoxinas**:\n   - Para productos inyectables, se debe monitorear el agua para inyecci\u00f3n y los productos intermedios y finales para endotoxinas.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad del documento.\n- **Preparaciones Est\u00e9riles**: Tipo de producto discutido.\n- **\u00c1reas Limpias**: Espacios de producci\u00f3n clasificados en grados.\n- **Esterilizaci\u00f3n Terminal y Aseptica**: Tipos de procesos de fabricaci\u00f3n.\n- **Pruebas de Esterilidad**: M\u00e9todo de control de calidad.\n- **Liberaci\u00f3n Param\u00e9trica**: Proceso alternativo a las pruebas de esterilidad.\n- **Endotoxinas**: Contaminantes a monitorear en productos inyectables.", "excerpt_keywords": "Keywords: sanitation, disinfectants, sterile preparations, microbial contamination, cleaning validation"}}, "cc264dbe-9481-47f9-bc2c-3e5061be4436": {"node_ids": ["214e2124-897d-4efd-b405-fb2a5f71cab2"], "metadata": {"page_label": "227", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.2 Detailed Information\n\nDetailed information on methods for determining the microbiological and particulate cleanliness of air, surfaces, etc., is not given in these guidelines.\n\nISO 14644-1 (2) should be used for classification of cleanliness according to concentration of airborne particles (determination of number of sample locations, calculation of sample size and evaluation of classification from the data obtained). Table 1 should also be used to define the levels to be used as the basis for monitoring clean areas for airborne particles.\n\n# 4.3 Grades of Clean Areas\n\nFor the manufacture of sterile pharmaceutical preparations, four grades of clean areas are distinguished as follows:\n\n- **Grade A**: The local zone for high-risk operations, e.g. filling and making aseptic connections. Normally such conditions are achieved by using a unidirectional airflow workstation. Unidirectional airflow systems should provide a homogeneous air speed of 0.36\u20130.54 m/s (guidance value) at a defined test position 15\u201330 cm below the terminal filter or air distributor system. The velocity at working level should not be less than 0.36 m/s. The uniformity and effectiveness of the unidirectional airflow should be demonstrated by undertaking airflow visualization tests;\n\n- **Grade B**: In aseptic preparation and filling, this is the background environment for the grade A zone;\n\n- **Grades C and D**: Clean areas for carrying out less critical stages in the manufacture of sterile products or carrying out activities during which the product is not directly exposed (i.e. aseptic connection with aseptic connectors and operations in a closed system).\n\nA unidirectional airflow and lower velocities may be used in closed isolators and glove boxes.\n\n# 4.4 Air Changes\n\nIn order to reach the B, C and D air grades the number of air changes should be appropriate for the size of the room and the equipment and personnel present in it.\n\n# 4.5 HEPA Filters\n\nHigh-efficiency particulate air (HEPA) filters should be subjected to an installed filter leakage test in accordance with ISO 14644-3 (6) at a recommended interval of every 6 months, but not exceeding 12 months. The purpose of performing regular leak tests is to ensure the filter media, filter frame and filter seal are free from leaks. The aerosol selected for HEPA leak testing should not support microbial growth and should be composed of a sufficient number or mass of particles. HEPA filter patching is allowed at the filter manufacturer and in situ operation provided that the patch sizes and procedures follow the recommendations of ISO 1822-4 (7).\n\n# 4.6 Clean Room and Clean-Air Device Classification", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona directrices sobre la clasificaci\u00f3n y los est\u00e1ndares de limpieza en \u00e1reas de fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles. Se describen cuatro grados de \u00e1reas limpias (A, B, C y D) y se especifican las condiciones necesarias para cada uno, incluyendo la velocidad del aire, el n\u00famero de cambios de aire y las pruebas de fugas para filtros HEPA. Tambi\u00e9n se menciona la importancia de utilizar normas ISO para la clasificaci\u00f3n de la limpieza del aire y la evaluaci\u00f3n de la efectividad de los sistemas de flujo de aire unidireccional.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones espec\u00edficas que deben cumplirse para que un \u00e1rea se clasifique como \"Grado A\" en la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles?**\n   - Respuesta: Un \u00e1rea se clasifica como \"Grado A\" si es la zona local para operaciones de alto riesgo, como el llenado y la realizaci\u00f3n de conexiones as\u00e9pticas. Debe utilizar un sistema de flujo de aire unidireccional que proporcione una velocidad de aire homog\u00e9nea de 0.36\u20130.54 m/s a una posici\u00f3n de prueba definida entre 15 y 30 cm por debajo del filtro terminal. La velocidad en el nivel de trabajo no debe ser inferior a 0.36 m/s, y se deben realizar pruebas de visualizaci\u00f3n del flujo de aire para demostrar la uniformidad y efectividad del sistema.\n\n2. **\u00bfQu\u00e9 intervalos se recomiendan para realizar pruebas de fugas en filtros HEPA y cu\u00e1l es el objetivo de estas pruebas?**\n   - Respuesta: Se recomienda realizar pruebas de fugas en filtros HEPA cada 6 meses, sin exceder los 12 meses. El objetivo de estas pruebas es asegurar que el medio del filtro, el marco del filtro y el sello del filtro est\u00e9n libres de fugas.\n\n3. **\u00bfC\u00f3mo se determina el n\u00famero adecuado de cambios de aire necesarios para alcanzar las clasificaciones de aire B, C y D?**\n   - Respuesta: El n\u00famero adecuado de cambios de aire se determina en funci\u00f3n del tama\u00f1o de la habitaci\u00f3n, as\u00ed como del equipo y el personal presentes en ella. Esto asegura que se mantengan las condiciones de limpieza necesarias para cada grado de aire.\n\n### Resumen de Nivel Superior\n\nEl documento establece directrices para la clasificaci\u00f3n de \u00e1reas limpias en la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles, definiendo cuatro grados de limpieza y los requisitos asociados a cada uno. Se enfatiza la importancia de mantener condiciones controladas de aire y la realizaci\u00f3n de pruebas regulares para asegurar la efectividad de los sistemas de filtraci\u00f3n y flujo de aire. Las normas ISO son fundamentales para la evaluaci\u00f3n y monitoreo de la limpieza del aire en estas \u00e1reas.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Sanidad en \u00c1reas Limpias**:\n   - Importancia de la limpieza frecuente y exhaustiva.\n   - Necesidad de un programa de limpieza aprobado.\n   - Uso de m\u00faltiples tipos de desinfectantes.\n   - Monitorizaci\u00f3n regular para detectar contaminaci\u00f3n microbiana.\n\n2. **Validaci\u00f3n de Materiales de Limpieza**:\n   - Validaci\u00f3n de interacciones entre diferentes materiales de limpieza.\n   - Validaci\u00f3n adecuada para asegurar que los residuos de desinfectantes sean detectables y eliminados.\n\n3. **Desinfectantes y Detergentes**:\n   - Monitoreo de la contaminaci\u00f3n microbiana en desinfectantes y detergentes.\n   - Almacenamiento en contenedores previamente limpios y por per\u00edodos definidos, a menos que sean esterilizados.\n   - Desinfectantes y detergentes en \u00e1reas de grado A y B deben ser est\u00e9riles antes de su uso.\n\n4. **Agentes Esporicidas**:\n   - Inclusi\u00f3n de un agente esporicida en el programa de desinfecci\u00f3n debido a la ineficacia de muchos desinfectantes comunes contra esporas.\n\n5. **Fumigaci\u00f3n**:\n   - Utilidad de la fumigaci\u00f3n en \u00e1reas limpias para reducir la contaminaci\u00f3n microbiana en lugares de dif\u00edcil acceso.\n\n6. **Fabricaci\u00f3n de Preparaciones Est\u00e9riles**:\n   - Clasificaci\u00f3n de \u00e1reas limpias seg\u00fan las caracter\u00edsticas requeridas para minimizar riesgos de contaminaci\u00f3n.\n   - Importancia de mantener un nivel adecuado de limpieza ambiental durante las operaciones de fabricaci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Desinfectantes**: Sustancias utilizadas para eliminar microorganismos.\n- **Detergentes**: Productos de limpieza que ayudan a eliminar suciedad y contaminantes.\n- **Agentes Esporicidas**: Sustancias espec\u00edficas para eliminar esporas de microorganismos.\n- **\u00c1reas Limpias**: Espacios controlados donde se fabrican productos est\u00e9riles.", "excerpt_keywords": "Keywords: clean areas, sterile pharmaceutical preparations, HEPA filters, unidirectional airflow, ISO standards"}}, "385e8c9d-5a31-41e4-883c-8a79ce4beb42": {"node_ids": ["c30242b7-66f7-4650-bed7-83618eac952d"], "metadata": {"page_label": "228", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "4.6.1 Clean rooms and clean-air devices should be classified in accordance with ISO 14644 (2, 6\u20139).\n\n4.6.1.1 Classification should be clearly differentiated from operational process environmental monitoring. The maximum permitted airborne particle concentration for each grade is given in Table 1.\n\n**Table 1**  \nMaximum permitted airborne particle concentration\n\n| Grade\\<br/>0.5 \u00b5m | Maximum permitted number of particles per m\u00b3 greater than or equal to the tabulated size\\<br/>5.0\u00b5m | Maximum permitted number of particles per m\u00b3 greater than or equal to the tabulated size\\<br/>In operation\\<br/>0.5 \u00b5m | In operation\\<br/>5.0\u00b5m | |\n| - | - | - | - | - |\n| A | 3 520 | 20 | 3 520 | 20 |\n| B | 3 520 | 29 | 352 000 | 2 900 |\n| C | 352 000 | 2 900 | 3 520 000 | 29 000 |\n| D | 3 520 000 | 29 000 | Not defined | Not defined |\n\n\n<sup>a</sup> The \"at rest\" state is the condition where the installation is complete with equipment installed and operating in a manner agreed upon by the customer and supplier, but with no personnel present.  \n<sup>b</sup> The \"in operation\" state is the condition where the installation is functioning in the defined operating mode and the specified number of personnel is present. The areas and their associated environmental control systems should be designed to achieve both the \"at rest\" and \"in operation\" states.\n\n4.6.2 For classification purposes, ISO 14644-1 (2) methodology defines both the minimum number of sample locations and the sample size based on the class limit of the largest considered particle size and the method for evaluation of the data collected. For classification of grade A zones (at rest and operational) and grade B zones (at rest), the minimum sample volume is based on the ISO 5 limit for the number of particles \u2265 0.5 \u00b5m (3520). Similarly, for classification of grade B (operational), grade C (at rest and operational), and grade D (at rest), the minimum sample volume is based on the class limits for particles \u2265 0.5 \u00b5m shown in Table 1.\n\nFor classification purposes in grade A zones, a minimum sample volume of 1 m\u00b3 should be taken per sample location. Referring to Table 1, for grade A the airborne particle classification is ISO 4.8 dictated by the limit for particles \u2265 5.0 \u00b5m. For grade B (at rest) the airborne particle classification is ISO 5 for both particle sizes considered. For grade C (at rest and in operation) the airborne particle classification is ISO 7 and ISO 8, respectively. For grade D (at rest) the airborne particle classification is ISO 8. For classification purposes ISO 14644-1 (2) methodology defines both the minimum number of sample locations and the sample size based on the class limit of the largest particle size considered and the method of evaluation of the data collected. The sample volume should be determined according to ISO 14644-1 (2) clause B.4.2. However, for lower grades.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior que puede ayudar a formular preguntas m\u00e1s relevantes:\n\n### Resumen de Nivel Superior\nEl documento se centra en la clasificaci\u00f3n de salas limpias y dispositivos de aire limpio seg\u00fan la norma ISO 14644. Se detalla la concentraci\u00f3n m\u00e1xima permitida de part\u00edculas en el aire para diferentes grados de limpieza (A, B, C y D), tanto en condiciones \"en reposo\" como \"en operaci\u00f3n\". Adem\u00e1s, se especifican los m\u00e9todos de muestreo y los vol\u00famenes m\u00ednimos requeridos para la clasificaci\u00f3n de estas \u00e1reas, as\u00ed como las diferencias entre los estados de operaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1l es la diferencia en la concentraci\u00f3n m\u00e1xima permitida de part\u00edculas de 0.5 \u00b5m entre los estados \"en reposo\" y \"en operaci\u00f3n\" para las salas limpias de grado A?**\n   - Respuesta: Para las salas limpias de grado A, la concentraci\u00f3n m\u00e1xima permitida de part\u00edculas de 0.5 \u00b5m es de 3,520 part\u00edculas por m\u00b3 tanto en estado \"en reposo\" como \"en operaci\u00f3n\".\n\n2. **\u00bfQu\u00e9 volumen m\u00ednimo de muestra se requiere para la clasificaci\u00f3n de zonas de grado A y qu\u00e9 clasificaci\u00f3n de part\u00edculas se aplica en este caso?**\n   - Respuesta: Para la clasificaci\u00f3n de zonas de grado A, se requiere un volumen m\u00ednimo de muestra de 1 m\u00b3 por ubicaci\u00f3n de muestra, y la clasificaci\u00f3n de part\u00edculas es ISO 4.8, dictada por el l\u00edmite para part\u00edculas \u2265 5.0 \u00b5m.\n\n3. **\u00bfC\u00f3mo se define el estado \"en operaci\u00f3n\" y qu\u00e9 implicaciones tiene para el dise\u00f1o de las \u00e1reas de control ambiental?**\n   - Respuesta: El estado \"en operaci\u00f3n\" se define como la condici\u00f3n en la que la instalaci\u00f3n est\u00e1 funcionando en el modo operativo definido y con el n\u00famero especificado de personal presente. Esto implica que las \u00e1reas y sus sistemas de control ambiental deben estar dise\u00f1ados para lograr tanto el estado \"en reposo\" como el \"en operaci\u00f3n\".", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Clasificaci\u00f3n de \u00c1reas Limpias**:\n   - Se definen cuatro grados de \u00e1reas limpias para la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles: **Grado A**, **Grado B**, **Grado C** y **Grado D**.\n   - Cada grado tiene requisitos espec\u00edficos relacionados con el flujo de aire, la velocidad del aire y el entorno de trabajo.\n\n2. **Grado A**:\n   - Zona local para operaciones de alto riesgo (ej. llenado y conexiones as\u00e9pticas).\n   - Requiere un sistema de flujo de aire unidireccional con velocidad de aire homog\u00e9nea de 0.36\u20130.54 m/s.\n   - Se deben realizar pruebas de visualizaci\u00f3n del flujo de aire para asegurar su efectividad.\n\n3. **Grado B**:\n   - Entorno de fondo para el Grado A durante la preparaci\u00f3n y llenado as\u00e9ptico.\n\n4. **Grados C y D**:\n   - \u00c1reas limpias para etapas menos cr\u00edticas en la fabricaci\u00f3n de productos est\u00e9riles.\n   - Actividades donde el producto no est\u00e1 directamente expuesto.\n\n5. **Cambios de Aire**:\n   - El n\u00famero de cambios de aire debe ser adecuado seg\u00fan el tama\u00f1o de la habitaci\u00f3n, el equipo y el personal presente.\n\n6. **Filtros HEPA**:\n   - Los filtros HEPA deben someterse a pruebas de fugas cada 6 meses, sin exceder 12 meses.\n   - Las pruebas aseguran que no haya fugas en el medio del filtro, el marco y el sello.\n   - Se debe utilizar un aerosol que no soporte el crecimiento microbiano para las pruebas de fugas.\n\n7. **Normas ISO**:\n   - Se menciona la importancia de las normas ISO (ISO 14644-1 y ISO 14644-3) para la clasificaci\u00f3n de la limpieza del aire y la evaluaci\u00f3n de la efectividad de los sistemas de filtraci\u00f3n.\n\n### Entidades Clave\n- **ISO 14644-1**: Norma para la clasificaci\u00f3n de limpieza seg\u00fan la concentraci\u00f3n de part\u00edculas en el aire.\n- **ISO 14644-3**: Norma para pruebas de fugas en filtros HEPA.\n- **ISO 1822-4**: Norma relacionada con el parcheo de filtros HEPA.\n- **Grados de limpieza**: A, B, C, D.\n- **Filtros HEPA**: Filtros de aire de alta eficiencia para la eliminaci\u00f3n de part\u00edculas. \n\nEste resumen destaca los aspectos fundamentales de la secci\u00f3n, incluyendo la clasificaci\u00f3n de \u00e1reas limpias, los requisitos espec\u00edficos para cada grado, la importancia de los cambios de aire y las pruebas de filtros HEPA, as\u00ed como la referencia a normas ISO relevantes.", "excerpt_keywords": "Keywords: clean rooms, ISO 14644, airborne particle concentration, classification, environmental monitoring"}}, "fa059e79-bd7a-42a8-8515-edf654539627": {"node_ids": ["2b4a7d02-975f-4c86-84a7-3773d71250d3"], "metadata": {"page_label": "229", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.6.3\n\nPortable particle counters with a short length of sample tubing should be used for classification purposes to avoid the loss of particles \u2265 5.0 \u03bcm. Isokinetic sample heads should be used in unidirectional airflow systems.\n\n# 4.6.4\n\n\"In operation\" classification may be demonstrated during normal operations, simulated operations or during media fills as worst-case simulation is required for this. ISO 14644-2 (8) provides information on testing to demonstrate continued compliance with the assigned cleanliness classification.\n\n# 4.7 Clean room and clean-air device monitoring\n\n## 4.7.1\n\nClean rooms and clean-air devices should be routinely monitored while in operation and the monitoring locations based on a formal risk analysis study and the results obtained during the classification of rooms and/or clean-air devices.\n\n## 4.7.2\n\nFor grade A zones, particle monitoring should be undertaken for the full duration of critical processing, including equipment assembly, except where justified by contaminants in the process that would damage the particle counter or present a hazard, for example, live organisms and radiological hazards. In such cases monitoring during routine equipment set-up operations should be undertaken before exposure to the risk. Monitoring during simulated operations should also be performed. The grade A zone should be monitored at a frequency and sample size such that all interventions, transient events and any system deterioration would be captured and alarms triggered if alert limits are exceeded. It is accepted that it may not always be possible to demonstrate low levels of \u2265 5.0 \u03bcm particles at the point of fill when filling is in progress, due to the generation of particles or droplets from the product itself.\n\n## 4.7.3\n\nIt is recommended that a similar system be used for grade B zones, although the sample frequency may be decreased. The importance of the particle monitoring system should be determined by the effectiveness of the segregation between the adjacent grade A and B zones. The grade B zone should be monitored at a frequency and with a sample size such that changes in levels of contamination and any deterioration of the system would be captured and alarms triggered if alert limits are exceeded.\n\n## 4.7.4\n\nAirborne particle monitoring systems may consist of independent particle counters; a network of sequentially accessed sampling points.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 957) aborda la clasificaci\u00f3n y monitoreo de salas limpias y dispositivos de aire limpio. Se enfatiza la importancia de utilizar contadores de part\u00edculas port\u00e1tiles con tuber\u00edas de muestreo cortas para evitar la p\u00e9rdida de part\u00edculas de 5.0 \u03bcm o m\u00e1s. Se establece que la clasificaci\u00f3n \"en operaci\u00f3n\" puede demostrarse durante operaciones normales, simuladas o durante llenados de medios. Adem\u00e1s, se detallan los procedimientos de monitoreo para zonas de grado A y B, destacando la necesidad de monitoreo continuo y la respuesta a eventos transitorios y deterioro del sistema.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de contadores de part\u00edculas se recomienda utilizar para la clasificaci\u00f3n en salas limpias y por qu\u00e9?**\n   - Se recomienda el uso de contadores de part\u00edculas port\u00e1tiles con una longitud corta de tuber\u00eda de muestreo para evitar la p\u00e9rdida de part\u00edculas de 5.0 \u03bcm o m\u00e1s. Adem\u00e1s, se deben utilizar cabezales de muestreo isocin\u00e9ticos en sistemas de flujo de aire unidireccional.\n\n2. **\u00bfCu\u00e1les son las condiciones bajo las cuales se puede justificar la falta de monitoreo de part\u00edculas en zonas de grado A durante el procesamiento cr\u00edtico?**\n   - El monitoreo de part\u00edculas puede no llevarse a cabo durante el procesamiento cr\u00edtico en zonas de grado A si hay contaminantes en el proceso que podr\u00edan da\u00f1ar el contador de part\u00edculas o presentar un riesgo, como organismos vivos o peligros radiol\u00f3gicos. En tales casos, se debe realizar el monitoreo durante las operaciones de configuraci\u00f3n del equipo antes de la exposici\u00f3n al riesgo.\n\n3. **\u00bfC\u00f3mo se determina la frecuencia y el tama\u00f1o de la muestra para el monitoreo en zonas de grado B?**\n   - La frecuencia y el tama\u00f1o de la muestra para el monitoreo en zonas de grado B deben ser tales que se capturen los cambios en los niveles de contaminaci\u00f3n y cualquier deterioro del sistema. La importancia del sistema de monitoreo de part\u00edculas se determina por la efectividad de la segregaci\u00f3n entre las zonas adyacentes de grado A y B.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Clasificaci\u00f3n de Salas Limpias**: \n   - Las salas limpias y dispositivos de aire limpio deben clasificarse de acuerdo con la norma ISO 14644.\n   - Se diferencian dos estados de operaci\u00f3n: \"en reposo\" y \"en operaci\u00f3n\".\n\n2. **Concentraci\u00f3n M\u00e1xima Permitida de Part\u00edculas**:\n   - Se establece una tabla (Tabla 1) que detalla la concentraci\u00f3n m\u00e1xima permitida de part\u00edculas en el aire para diferentes grados de limpieza (A, B, C y D) en ambos estados.\n   - Grado A: 3,520 part\u00edculas/m\u00b3 (0.5 \u00b5m) en ambos estados.\n   - Grado B: 3,520 part\u00edculas/m\u00b3 (0.5 \u00b5m) en reposo y 352,000 en operaci\u00f3n.\n   - Grado C y D tienen l\u00edmites m\u00e1s altos y no definidos para ciertos tama\u00f1os de part\u00edculas.\n\n3. **Definiciones de Estados**:\n   - **\"En reposo\"**: Instalaci\u00f3n completa y operativa sin personal presente.\n   - **\"En operaci\u00f3n\"**: Instalaci\u00f3n funcionando con el n\u00famero especificado de personal presente.\n\n4. **M\u00e9todos de Muestreo**:\n   - La metodolog\u00eda ISO 14644-1 define el n\u00famero m\u00ednimo de ubicaciones de muestreo y el tama\u00f1o de la muestra basado en el l\u00edmite de clase del tama\u00f1o de part\u00edcula m\u00e1s grande considerado.\n   - Para zonas de grado A, se requiere un volumen m\u00ednimo de muestra de 1 m\u00b3 por ubicaci\u00f3n de muestra.\n\n5. **Clasificaci\u00f3n de Part\u00edculas**:\n   - Grado A: ISO 4.8 (part\u00edculas \u2265 5.0 \u00b5m).\n   - Grado B: ISO 5.\n   - Grado C: ISO 7 (en reposo) y ISO 8 (en operaci\u00f3n).\n   - Grado D: ISO 8 (en reposo).\n\n### Entidades Clave\n- **Norma ISO 14644**: Est\u00e1ndar para la clasificaci\u00f3n de salas limpias.\n- **Grados de Limpieza**: A, B, C, D.\n- **Tama\u00f1os de Part\u00edculas**: 0.5 \u00b5m y 5.0 \u00b5m.\n- **Estados de Operaci\u00f3n**: \"En reposo\" y \"En operaci\u00f3n\".\n- **Volumen de Muestra**: 1 m\u00b3 para grado A. \n\nEste resumen proporciona una visi\u00f3n general de los aspectos m\u00e1s importantes relacionados con la clasificaci\u00f3n y el monitoreo de la calidad del aire en salas limpias seg\u00fan la norma ISO 14644.", "excerpt_keywords": "Keywords: clean rooms, particle monitoring, ISO 14644, contamination control, air quality"}}, "2948318f-f9ce-4779-b9ee-97f93d996255": {"node_ids": ["4c617fd8-c6e2-42d8-b9dd-5959e9ffcb22"], "metadata": {"page_label": "230", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "connected by manifold to a single particle counter; or multiple small particle counters located near monitoring points and networked to a data acquisition system. Combinations of systems can also be used. The system selected should be appropriate for the particle size considered. Where remote sampling systems are used, the length of tubing and the radii of any bends in the tubing should be considered in the context of particle losses in the tubing. The selection of the monitoring system should take account of any risk presented by the materials used in the manufacturing operation, for example, those involving live organisms or radiopharmaceuticals.\n\n4.7.5 The sizes of samples taken for monitoring purposes using automated systems will usually be a function of the sampling rate of the system used. It is not necessary for the sample volume to be the same as that used for formal classification of clean rooms and clean-air devices.\n\n4.7.6 The airborne particle conditions given in Table 1 for the \u201cat rest\u201d state should be achieved in the absence of the operating personnel after a short \u201cclean-up\u201d or \u201crecovery\u201d period of about 15\u201320 minutes (guidance value), after completion of the operations. The particulate conditions given in Table 1 for grade A \u201cin operation\u201d should be maintained in the zone immediately surrounding the product whenever the product or open container is exposed to the environment. The \u201cclean-up\u201d or \u201crecovery\u201d test should demonstrate a change in particle concentration by a factor of 100 within the prescribed time (ISO 14644-3 clause B.12) (6).\n\n4.7.7 In order to demonstrate control of the cleanliness of the various clean areas during operation, they should be monitored for airborne particles and microbial contamination. In addition to \u201cat rest\u201d and \u201cin operation\u201d classification, airborne particles should be monitored periodically \u201cin operation\u201d at critical locations. The sampling plan need not be the same as that used for classification. Locations and sample sizes should be determined based on an assessment of the process and contamination risk.\n\n4.7.8 The monitoring of grade C and D areas in operation should be performed in accordance with the principles of quality risk management. The requirements and alert/action limits will depend on the nature of the operations carried out, but the recommended \u201cclean-up period\u201d should be attained.\n\n4.7.9 Other characteristics such as temperature and relative humidity depend on the product and nature of the operations carried out. These parameters should not interfere with the defined cleanliness standard.\n\n4.7.10 Examples of operations to be carried out in the various grades are given in Table 2 (see also sections 4.14\u20134.22).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen de Nivel Superior del Contexto\n\nEl texto se centra en la monitorizaci\u00f3n de part\u00edculas en entornos controlados, como salas limpias y \u00e1reas de producci\u00f3n que manejan materiales sensibles, incluidos organismos vivos y productos farmac\u00e9uticos. Se discuten los sistemas de muestreo, la importancia de la limpieza y el control de la contaminaci\u00f3n, as\u00ed como los par\u00e1metros que deben considerarse para mantener la calidad del aire y la limpieza en estas \u00e1reas. Se mencionan las condiciones de part\u00edculas en el estado \"en reposo\" y \"en operaci\u00f3n\", as\u00ed como la necesidad de un per\u00edodo de \"limpieza\" o \"recuperaci\u00f3n\" despu\u00e9s de las operaciones. Tambi\u00e9n se hace hincapi\u00e9 en la gesti\u00f3n de riesgos de calidad y en la importancia de monitorear \u00e1reas de diferentes grados (A, C y D) para asegurar la conformidad con los est\u00e1ndares de limpieza.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 factores deben considerarse al seleccionar un sistema de monitoreo para part\u00edculas en entornos controlados?**\n   - La selecci\u00f3n del sistema debe tener en cuenta el tama\u00f1o de las part\u00edculas, la longitud y el radio de las curvas en el tubo de muestreo, as\u00ed como los riesgos asociados con los materiales utilizados en la operaci\u00f3n de fabricaci\u00f3n.\n\n2. **\u00bfCu\u00e1l es el objetivo del per\u00edodo de \"limpieza\" o \"recuperaci\u00f3n\" despu\u00e9s de las operaciones en \u00e1reas de grado A?**\n   - El objetivo es lograr las condiciones de part\u00edculas especificadas para el estado \"en reposo\" en ausencia del personal operativo, lo que implica una reducci\u00f3n en la concentraci\u00f3n de part\u00edculas por un factor de 100 dentro de un per\u00edodo de 15 a 20 minutos.\n\n3. **\u00bfC\u00f3mo se determina el tama\u00f1o y la ubicaci\u00f3n de las muestras para el monitoreo de part\u00edculas en \u00e1reas limpias?**\n   - El tama\u00f1o y la ubicaci\u00f3n de las muestras deben ser determinados en funci\u00f3n de una evaluaci\u00f3n del proceso y del riesgo de contaminaci\u00f3n, y no necesariamente deben coincidir con el plan de muestreo utilizado para la clasificaci\u00f3n formal de las \u00e1reas limpias.", "prev_section_summary": "### Temas Clave:\n\n1. **Clasificaci\u00f3n de Salas Limpias**:\n   - Uso de contadores de part\u00edculas port\u00e1tiles con tuber\u00edas de muestreo cortas para evitar la p\u00e9rdida de part\u00edculas de 5.0 \u03bcm o m\u00e1s.\n   - Implementaci\u00f3n de cabezales de muestreo isocin\u00e9ticos en sistemas de flujo de aire unidireccional.\n\n2. **Monitoreo de Salas Limpias y Dispositivos de Aire Limpio**:\n   - Monitoreo rutinario de salas limpias y dispositivos de aire limpio durante su operaci\u00f3n, basado en un an\u00e1lisis de riesgo formal.\n   - Importancia del monitoreo continuo en zonas de grado A y B, con \u00e9nfasis en la detecci\u00f3n de eventos transitorios y deterioro del sistema.\n\n3. **Condiciones de Monitoreo en Zonas de Grado A**:\n   - Monitoreo de part\u00edculas durante el procesamiento cr\u00edtico, con excepciones justificadas por contaminantes que puedan da\u00f1ar el equipo de monitoreo.\n   - Necesidad de realizar monitoreo durante operaciones simuladas y en la configuraci\u00f3n del equipo antes de la exposici\u00f3n a riesgos.\n\n4. **Monitoreo en Zonas de Grado B**:\n   - Recomendaci\u00f3n de un sistema de monitoreo similar al de grado A, con una frecuencia de muestreo que capture cambios en los niveles de contaminaci\u00f3n.\n   - Determinaci\u00f3n de la importancia del sistema de monitoreo seg\u00fan la efectividad de la segregaci\u00f3n entre zonas de grado A y B.\n\n5. **Sistemas de Monitoreo de Part\u00edculas**:\n   - Posibilidad de utilizar contadores de part\u00edculas independientes o una red de puntos de muestreo accesibles secuencialmente.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que publica el documento.\n- **ISO 14644-2**: Norma que proporciona informaci\u00f3n sobre pruebas para demostrar el cumplimiento de la clasificaci\u00f3n de limpieza.\n- **Zonas de Grado A y B**: Clasificaciones de \u00e1reas dentro de un entorno controlado que requieren diferentes niveles de monitoreo y control de part\u00edculas.\n- **Contadores de Part\u00edculas**: Dispositivos utilizados para medir la cantidad de part\u00edculas en el aire, esenciales para el monitoreo de la calidad del aire en salas limpias. \n\nEste resumen destaca la importancia de la clasificaci\u00f3n y el monitoreo en entornos controlados, as\u00ed como las pr\u00e1cticas recomendadas para garantizar la calidad del aire y la seguridad en procesos cr\u00edticos.", "excerpt_keywords": "Keywords: particle monitoring, clean rooms, contamination control, quality risk management, airborne particles"}}, "55b73b54-3677-4cc3-b7cd-c56360ac9665": {"node_ids": ["d65d8f76-7d85-4088-a3d1-60dee5029c27"], "metadata": {"page_label": "231", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Table 2\n**Examples of operations to be carried out in the various grades**\n\n| Grade | Examples of operations for terminally sterilized products(see sections 4.14\u20134.17) |\n| - | - |\n| A | Filling of products when unusually at risk |\n| C | Preparation of solutions when unusually at risk. Filling of products |\n| D | Preparation of solutions and components for subsequent filling |\n\n\n| Grade | Examples of operations for aseptic preparations(see sections 4.18\u20134.22) |\n| - | - |\n| A | Aseptic preparation and filling |\n| C | Preparation of solutions to be filtered |\n| D | Handling of components after washing |\n\n\n4.8 To control the microbiological cleanliness of the cleanliness grades A\u2013D in operation the clean areas should be monitored. Where aseptic operations are performed, monitoring should be frequent using methods such as settle plates, volumetric air and surface sampling (e.g. swabs and contact plates). Sampling methods used in operation should not interfere with zone protection. Results from monitoring should be considered when reviewing batch documentation for finished product release. Surfaces and personnel should be monitored after critical operations. Additional microbiological monitoring is also required outside production operations, e.g. after validation of systems, cleaning and sanitization.\n\n4.9 Levels of detection of microbial contamination should be established for the purpose of setting alert and action levels and for monitoring the trends in environmental cleanliness in the facility. Limits expressed in colony-forming units (CFU) for the microbiological monitoring of clean areas in operation are given in Table 3. The sampling methods and numerical values included in the table are not intended to represent specifications, but are for information only.\n\n# Table 3\n**Recommended limits for microbial contamination<sup>a</sup>**\n\n| Grade | Air sample(CFU/m) | Settle plates(diameter 90 mm)(CFU/4 hours) | Contact plates(diameter 55 mm)(CFU/plate) | Glove print(5 fingers)(CFU/glove) |\n| - | - | - | - | - |\n| A | < 1 | < 1 | < 1 | < 1 |\n| B | 10 | 5 | 5 | 5 |\n| C | 100 | 50 | 25 | \u2013 |\n| D | 200 | 100 | 50 | \u2013 |\n\n\nCFU, colony-forming units.  \n<sup>a</sup> These are average values.  \n<sup>b</sup> Individual settle plates may be exposed for less than 4 hours.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Informe T\u00e9cnico 957) aborda las operaciones en \u00e1reas limpias clasificadas en diferentes grados (A, B, C, D) para garantizar la esterilidad y la limpieza microbiol\u00f3gica en la producci\u00f3n de productos farmac\u00e9uticos. Se detallan ejemplos de operaciones para productos terminalmente esterilizados y preparaciones as\u00e9pticas, as\u00ed como los m\u00e9todos de monitoreo microbiol\u00f3gico y los l\u00edmites recomendados para la contaminaci\u00f3n microbiana en cada grado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las operaciones espec\u00edficas que se deben realizar en el grado A para productos terminalmente esterilizados y para preparaciones as\u00e9pticas?**\n   - Respuesta: En el grado A para productos terminalmente esterilizados, se debe realizar el llenado de productos cuando est\u00e1n inusualmente en riesgo. Para preparaciones as\u00e9pticas, se debe llevar a cabo la preparaci\u00f3n y el llenado as\u00e9ptico.\n\n2. **\u00bfQu\u00e9 m\u00e9todos de monitoreo microbiol\u00f3gico se recomiendan para las \u00e1reas limpias de los grados A\u2013D y con qu\u00e9 frecuencia deben realizarse?**\n   - Respuesta: Se recomienda el uso de placas de asentamiento, muestreo volum\u00e9trico de aire y muestreo de superficie (como hisopos y placas de contacto). El monitoreo debe ser frecuente, especialmente donde se realizan operaciones as\u00e9pticas.\n\n3. **\u00bfCu\u00e1les son los l\u00edmites recomendados para la contaminaci\u00f3n microbiana en el grado C seg\u00fan el muestreo de aire y las placas de asentamiento?**\n   - Respuesta: Para el grado C, los l\u00edmites recomendados son 100 CFU/m para muestras de aire y 50 CFU/4 horas para placas de asentamiento de 90 mm de di\u00e1metro.", "prev_section_summary": "### Temas Clave\n\n1. **Monitoreo de Part\u00edculas**: Se discute la importancia de seleccionar sistemas de monitoreo adecuados para part\u00edculas en entornos controlados, considerando el tama\u00f1o de las part\u00edculas y el riesgo asociado con los materiales utilizados.\n\n2. **Condiciones de Limpieza**: Se establecen condiciones espec\u00edficas para el estado \"en reposo\" y \"en operaci\u00f3n\" de las \u00e1reas limpias, as\u00ed como la necesidad de un per\u00edodo de \"limpieza\" o \"recuperaci\u00f3n\" despu\u00e9s de las operaciones.\n\n3. **Muestreo y Clasificaci\u00f3n**: Se menciona que el tama\u00f1o y la ubicaci\u00f3n de las muestras deben basarse en una evaluaci\u00f3n del proceso y el riesgo de contaminaci\u00f3n, y no necesariamente deben coincidir con los planes de muestreo para la clasificaci\u00f3n formal.\n\n4. **Gesti\u00f3n de Riesgos de Calidad**: Se enfatiza la importancia de aplicar principios de gesti\u00f3n de riesgos de calidad en el monitoreo de \u00e1reas de grado C y D.\n\n5. **Par\u00e1metros Ambientales**: Se se\u00f1ala que caracter\u00edsticas como la temperatura y la humedad relativa deben ser consideradas, pero no deben interferir con los est\u00e1ndares de limpieza definidos.\n\n### Entidades\n\n- **Sistemas de Monitoreo**: Contadores de part\u00edculas, sistemas de muestreo remoto.\n- **Condiciones de Part\u00edculas**: Estado \"en reposo\", estado \"en operaci\u00f3n\".\n- **Normas de Limpieza**: ISO 14644-3.\n- **\u00c1reas Limpias**: Grados A, C y D.\n- **Par\u00e1metros Ambientales**: Temperatura, humedad relativa.\n- **Materiales Sensibles**: Organismos vivos, productos farmac\u00e9uticos. \n\nEste resumen abarca los aspectos fundamentales del monitoreo de part\u00edculas en entornos controlados, destacando la importancia de la limpieza y el control de la contaminaci\u00f3n en la producci\u00f3n de materiales sensibles.", "excerpt_keywords": "Keywords: microbiological monitoring, aseptic preparations, terminally sterilized products, contamination limits, clean areas"}}, "075adb14-e78d-47dc-8453-6c7f60d53630": {"node_ids": ["764aec1d-ed90-4248-9d56-38663200ea64"], "metadata": {"page_label": "232", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.10\n\nAppropriate alert and action limits should be set for the results of particulate and microbiological monitoring. If the action limits are exceeded or a trend is identified in the alert levels, investigation should be initiated and the appropriate corrective actions should be taken, as prescribed in the operating procedures.\n\n# 4.11\n\nThe area grades as specified in sections 4.12 to 4.20 should be selected by the manufacturer on the basis of the nature of the process operations being performed and validation runs (e.g. aseptic media fills or others types of process simulations) are used to establish processing hold times and a maximum fill duration. The determination of an appropriate process area environment and a time limit should be based on the microbial contamination (bioburden) found.\n\n## Terminally sterilized products\n\n### 4.12\n\nComponents and most products should be prepared in at least a grade D environment to ensure low microbial bioburden and particulate counts prior to filtration and sterilization. Where the product is at unusual risk of microbial contamination (e.g. because it actively supports microbial growth, must be held for a long period before sterilization, or is necessarily processed mainly in open vessels), the preparation should generally be done in a grade C environment.\n\n### 4.13\n\nThe filling of products for terminal sterilization should generally be done in at least a grade C environment.\n\n### 4.14\n\nWhere the product is at unusual risk of contamination from the environment (e.g. because the filling operation is slow, the containers are wide-necked or are necessarily exposed for more than a few seconds before sealing), the filling should be done in a grade A zone with at least a grade C background.\n\n### 4.15\n\nThe preparation and filling of ointments, creams, suspensions and emulsions should generally be done in a grade C environment before terminal sterilization.\n\n## Aseptic preparation\n\n### 4.16\n\nComponents after washing should be handled in at least a grade D environment. The handling of sterile starting materials and components, unless subjected to sterilization or filtration through a microorganism-retaining filter later in the process, should be undertaken in a grade A environment with a grade B background.\n\n### 4.17\n\nThe preparation of solutions which are to be sterile-filtered during the process should be undertaken in a grade C environment (unless a closed system is used, in which case a Class D environment may be justifiable).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece directrices sobre los l\u00edmites de alerta y acci\u00f3n para el monitoreo de part\u00edculas y microorganismos en entornos de producci\u00f3n de productos farmac\u00e9uticos. Se especifican diferentes grados de ambientes (A, B, C, D) que deben ser seleccionados por los fabricantes seg\u00fan el tipo de operaci\u00f3n y el riesgo de contaminaci\u00f3n microbiana. Las secciones detallan las condiciones necesarias para la preparaci\u00f3n y llenado de productos que ser\u00e1n esterilizados terminalmente o preparados de manera as\u00e9ptica, enfatizando la importancia de minimizar la biocarga microbiana y las part\u00edculas en el proceso.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 criterios deben considerarse al seleccionar el grado de ambiente para la preparaci\u00f3n de productos que est\u00e1n en riesgo inusual de contaminaci\u00f3n microbiana?**\n   - Respuesta: El grado de ambiente debe seleccionarse en funci\u00f3n de factores como si el producto apoya activamente el crecimiento microbiano, si debe mantenerse durante un largo per\u00edodo antes de la esterilizaci\u00f3n, o si se procesa principalmente en recipientes abiertos. En tales casos, se recomienda generalmente un ambiente de grado C.\n\n2. **\u00bfCu\u00e1les son las implicaciones de exceder los l\u00edmites de acci\u00f3n establecidos durante el monitoreo de part\u00edculas y microorganismos?**\n   - Respuesta: Si se exceden los l\u00edmites de acci\u00f3n o se identifica una tendencia en los niveles de alerta, se debe iniciar una investigaci\u00f3n y tomar las acciones correctivas apropiadas, seg\u00fan lo prescrito en los procedimientos operativos.\n\n3. **\u00bfQu\u00e9 ambiente se recomienda para el manejo de materiales est\u00e9riles y componentes despu\u00e9s del lavado?**\n   - Respuesta: Los componentes despu\u00e9s del lavado deben ser manejados en un ambiente de al menos grado D. Sin embargo, el manejo de materiales est\u00e9riles y componentes, a menos que sean sometidos a esterilizaci\u00f3n o filtraci\u00f3n a trav\u00e9s de un filtro retentivo de microorganismos m\u00e1s adelante en el proceso, debe realizarse en un ambiente de grado A con un fondo de grado B.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Clasificaci\u00f3n de \u00e1reas limpias**: El documento clasifica las \u00e1reas limpias en grados A, B, C y D, cada uno con diferentes requisitos y operaciones espec\u00edficas para garantizar la esterilidad y la limpieza microbiol\u00f3gica.\n\n2. **Operaciones espec\u00edficas**:\n   - **Productos terminalmente esterilizados**:\n     - **Grado A**: Llenado de productos cuando est\u00e1n inusualmente en riesgo.\n     - **Grado C**: Preparaci\u00f3n de soluciones cuando est\u00e1n inusualmente en riesgo y llenado de productos.\n     - **Grado D**: Preparaci\u00f3n de soluciones y componentes para llenado posterior.\n   - **Preparaciones as\u00e9pticas**:\n     - **Grado A**: Preparaci\u00f3n y llenado as\u00e9ptico.\n     - **Grado C**: Preparaci\u00f3n de soluciones para ser filtradas.\n     - **Grado D**: Manejo de componentes despu\u00e9s del lavado.\n\n3. **Monitoreo microbiol\u00f3gico**: Se enfatiza la importancia de monitorear la limpieza microbiol\u00f3gica en las \u00e1reas limpias de los grados A\u2013D. Se deben utilizar m\u00e9todos como placas de asentamiento, muestreo volum\u00e9trico de aire y muestreo de superficie. El monitoreo debe ser frecuente, especialmente en operaciones as\u00e9pticas.\n\n4. **L\u00edmites de contaminaci\u00f3n microbiana**: Se establecen l\u00edmites recomendados para la contaminaci\u00f3n microbiana en funci\u00f3n del grado:\n   - **Grado A**: < 1 CFU/m (aire), < 1 CFU/4 horas (placas de asentamiento).\n   - **Grado B**: 10 CFU/m (aire), 5 CFU/4 horas (placas de asentamiento).\n   - **Grado C**: 100 CFU/m (aire), 50 CFU/4 horas (placas de asentamiento).\n   - **Grado D**: 200 CFU/m (aire), 100 CFU/4 horas (placas de asentamiento).\n\n5. **CFU (Unidades formadoras de colonias)**: Se utiliza como medida para establecer los l\u00edmites de contaminaci\u00f3n microbiana y se aclara que los valores son promedios y no especificaciones.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad del documento.\n- **Informe T\u00e9cnico 957**: T\u00edtulo del documento.\n- **Grados de limpieza (A, B, C, D)**: Clasificaci\u00f3n de \u00e1reas limpias.\n- **M\u00e9todos de monitoreo**: Placas de asentamiento, muestreo volum\u00e9trico de aire, muestreo de superficie.\n- **Contaminaci\u00f3n microbiana**: Medida en CFU.", "excerpt_keywords": "Keywords: microbiological monitoring, sterile environment, contamination risk, aseptic preparation, terminal sterilization"}}, "14d388f8-0a90-4a2a-9725-e179101430c6": {"node_ids": ["525e2afe-ffb8-4f05-aced-c123be20fdf2"], "metadata": {"page_label": "233", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "If not sterile-filtered (therefore an aseptic manipulation) the preparation of materials and products should be undertaken in a grade A environment with a grade B background.\n\n4.18 The handling and filling of aseptically prepared products, as well as the handling of exposed sterile equipment, should be undertaken in a grade A environment with a grade B background.\n\n4.19 The transfer of partially closed containers, as used in freeze-drying, before stoppering is completed, should be undertaken either in a grade A environment with a grade B background or in sealed transfer trays in a grade B environment.\n\n4.20 The preparation and filling of sterile ointments, creams, suspensions and emulsions should be undertaken in a grade A environment with a grade B background when the product is exposed and is not subsequently filtered.\n\n*Processing*\n\n4.21 Precautions to minimize contamination should be taken during all processing stages, including the stages before sterilization.\n\n4.22 In general, preparations containing live microorganisms should not be made, nor should containers be filled in areas used for the processing of other pharmaceutical products. However, if the manufacturer can demonstrate and validate effective containment and decontamination of the live microorganisms, the use of multiproduct facilities may be justifiable. Vaccines consisting of dead organisms or of bacterial extracts may be dispensed into containers in the same premises as other sterile pharmaceutical products, provided that the inactivation procedure has been properly validated.\n\nWhen multiproduct facilities are used to manufacture sterile preparations containing live microorganisms and other sterile pharmaceutical products, the manufacturer should demonstrate and validate the effective decontamination of the live microorganisms, in addition to precautions taken to minimize contamination.\n\n4.23 Validation of aseptic processing should include a process simulation test using a nutrient medium (media fill). Selection of the nutrient medium should be made based on dosage form of the product and selectivity, clarity, concentration and suitability for sterilization of the nutrient medium.\n\n4.24 The process simulation test should imitate as closely as possible the routine aseptic manufacturing steps except where the activity may lead to any potential microbial contamination.\n\n4.25 Process simulation tests should be performed as part of validation by running three consecutive satisfactory simulation tests. These tests should be repeated at defined intervals and after any significant modification to the process.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Entorno de Asepsia**: El documento establece que la preparaci\u00f3n y el manejo de productos y materiales que no han sido filtrados est\u00e9rilmente deben realizarse en un entorno de grado A con un fondo de grado B. Esto se aplica a la manipulaci\u00f3n de productos preparados asepticamente y equipos est\u00e9riles expuestos.\n\n2. **Contaminaci\u00f3n y Validaci\u00f3n**: Se enfatiza la importancia de minimizar la contaminaci\u00f3n durante todas las etapas de procesamiento, especialmente antes de la esterilizaci\u00f3n. Adem\u00e1s, se menciona que las instalaciones multiproducto pueden ser utilizadas bajo ciertas condiciones, siempre que se valide la contenci\u00f3n y desinfecci\u00f3n de microorganismos vivos.\n\n3. **Pruebas de Simulaci\u00f3n de Procesos**: La validaci\u00f3n del procesamiento as\u00e9ptico debe incluir pruebas de simulaci\u00f3n de procesos utilizando un medio nutritivo, y estas pruebas deben realizarse de manera regular y tras modificaciones significativas en el proceso.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 condiciones deben cumplirse para que un fabricante utilice instalaciones multiproducto para la fabricaci\u00f3n de preparaciones est\u00e9riles que contengan microorganismos vivos?**\n   - Respuesta: El fabricante debe demostrar y validar la efectiva contenci\u00f3n y desinfecci\u00f3n de los microorganismos vivos, adem\u00e1s de tomar precauciones para minimizar la contaminaci\u00f3n.\n\n2. **\u00bfCu\u00e1ntas pruebas de simulaci\u00f3n de procesos son necesarias para validar el procesamiento as\u00e9ptico y con qu\u00e9 frecuencia deben repetirse?**\n   - Respuesta: Se deben realizar tres pruebas de simulaci\u00f3n satisfactorias consecutivas como parte de la validaci\u00f3n, y estas deben repetirse a intervalos definidos y despu\u00e9s de cualquier modificaci\u00f3n significativa en el proceso.\n\n3. **\u00bfQu\u00e9 factores deben considerarse al seleccionar el medio nutritivo para las pruebas de simulaci\u00f3n de procesos?**\n   - Respuesta: La selecci\u00f3n del medio nutritivo debe basarse en la forma de dosificaci\u00f3n del producto, as\u00ed como en la selectividad, claridad, concentraci\u00f3n y adecuaci\u00f3n para la esterilizaci\u00f3n del medio nutritivo.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **L\u00edmites de alerta y acci\u00f3n**:\n   - Se deben establecer l\u00edmites apropiados para el monitoreo de part\u00edculas y microorganismos.\n   - Si se superan los l\u00edmites de acci\u00f3n o se identifican tendencias en los niveles de alerta, se debe iniciar una investigaci\u00f3n y tomar acciones correctivas.\n\n2. **Clasificaci\u00f3n de ambientes**:\n   - Los fabricantes deben seleccionar el grado de ambiente (A, B, C, D) seg\u00fan la naturaleza de las operaciones y la validaci\u00f3n de procesos.\n   - La selecci\u00f3n del ambiente debe basarse en la biocarga microbiana encontrada.\n\n3. **Productos esterilizados terminalmente**:\n   - Preparaci\u00f3n de componentes y productos en un ambiente de al menos grado D.\n   - Para productos con riesgo inusual de contaminaci\u00f3n, se recomienda un ambiente de grado C.\n   - El llenado de productos debe realizarse en un ambiente de al menos grado C, y en casos de alto riesgo, en una zona de grado A con fondo de grado C.\n\n4. **Preparaci\u00f3n as\u00e9ptica**:\n   - Manejo de componentes despu\u00e9s del lavado en un ambiente de al menos grado D.\n   - Manejo de materiales est\u00e9riles en un ambiente de grado A con fondo de grado B, a menos que se sometan a esterilizaci\u00f3n o filtraci\u00f3n.\n   - Preparaci\u00f3n de soluciones que ser\u00e1n filtradas as\u00e9pticamente en un ambiente de grado C, salvo en sistemas cerrados donde puede justificarse un ambiente de grado D.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Grados de ambiente**: A, B, C, D, que indican el nivel de control de contaminaci\u00f3n.\n- **Biocarga microbiana**: Cantidad de microorganismos presentes en un producto o ambiente.\n- **Productos farmac\u00e9uticos**: Incluyen componentes, soluciones, ung\u00fcentos, cremas, suspensiones y emulsiones que requieren esterilizaci\u00f3n o preparaci\u00f3n as\u00e9ptica.", "excerpt_keywords": "Keywords: aseptic processing, contamination control, sterile environment, validation, nutrient medium"}}, "da2e2215-2a96-4122-84cf-131a3f88baaf": {"node_ids": ["a3546723-9728-453f-8863-88322599e9ba"], "metadata": {"page_label": "234", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the heating, ventilation and air-conditioning (HVAC)-system, equipment or process. Process simulation tests should incorporate activities and interventions known to occur during normal production as well as the worst-case situation. The process simulation tests should be representative of each shift and shift changeover to address any time-related and operational features.\n\n4.26 The number of containers used for media fills should be sufficient to enable a valid evaluation. For small batches the number of containers for media fills should at least equal the size of the product batch. The target should be zero growth and the following should apply:\n\n- when filling fewer than 5000 units, no contaminated units should be detected;\n- when filling 5000\u201310 000 units:\n  - one contaminated unit should result in an investigation, including consideration of a repeat media fill,\n  - two contaminated units are considered cause for revalidation following investigation;\n- when filling more than 10 000 units:\n  - one contaminated unit should result in an investigation,\n  - two contaminated units are considered cause for revalidation following investigation.\n\n4.27 For any run size, intermittent incidents of microbial contamination may be indicative of low-level contamination that should be investigated. Investigation of gross failures should include the potential impact on the sterility assurance of batches manufactured since the last successful media fill.\n\n4.28 Care should be taken to ensure that any validation does not compromise the processes.\n\n4.29 Water sources, water-treatment equipment and treated water should be monitored regularly for chemicals, biological contamination and contamination with endotoxins to ensure that the water complies with the specifications appropriate to its use. Records should be maintained of the results of the monitoring and of any action taken (10).\n\n4.30 Activities in clean areas, especially when aseptic operations are in progress, should be kept to a minimum and the movement of personnel should be controlled and methodical, so as to avoid excessive shedding of particles and organisms due to over-vigorous activity. As far as possible, personnel should be excluded from grade A zones. The ambient temperature and humidity should not be uncomfortably high because of the nature of the garments worn and to reduce the risk of contamination liberated from the personnel.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen de nivel superior del contexto\n\nEl documento de la OMS (Informe T\u00e9cnico 957) aborda la validaci\u00f3n de procesos en la producci\u00f3n farmac\u00e9utica, centr\u00e1ndose en la importancia de las pruebas de simulaci\u00f3n de procesos, la evaluaci\u00f3n de la contaminaci\u00f3n microbiana durante los llenados de medios, y el monitoreo de fuentes de agua y equipos de tratamiento. Se establecen criterios espec\u00edficos para la aceptaci\u00f3n de unidades contaminadas en funci\u00f3n del tama\u00f1o del lote, as\u00ed como recomendaciones para minimizar la actividad en \u00e1reas limpias durante operaciones as\u00e9pticas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos para la investigaci\u00f3n de unidades contaminadas en lotes de diferentes tama\u00f1os durante los llenados de medios?**\n   - Respuesta: Para lotes de menos de 5000 unidades, no se deben detectar unidades contaminadas. Para lotes de 5000 a 10,000 unidades, una unidad contaminada requiere una investigaci\u00f3n y la consideraci\u00f3n de un llenado de medios repetido, mientras que dos unidades contaminadas son motivo para revalidaci\u00f3n. Para lotes de m\u00e1s de 10,000 unidades, una unidad contaminada tambi\u00e9n requiere investigaci\u00f3n, y dos unidades contaminadas son causa para revalidaci\u00f3n.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que la validaci\u00f3n de procesos no comprometa la producci\u00f3n?**\n   - Respuesta: Se debe tener cuidado para asegurar que cualquier validaci\u00f3n no comprometa los procesos, lo que implica realizar pruebas y simulaciones que reflejen tanto las condiciones normales de producci\u00f3n como las situaciones de peor caso, y mantener un control riguroso sobre las actividades en \u00e1reas limpias.\n\n3. **\u00bfQu\u00e9 tipo de monitoreo se recomienda para las fuentes de agua y el equipo de tratamiento de agua en el contexto de la producci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Se recomienda monitorear regularmente las fuentes de agua, el equipo de tratamiento de agua y el agua tratada para detectar contaminantes qu\u00edmicos, biol\u00f3gicos y endotoxinas, asegurando que el agua cumpla con las especificaciones adecuadas para su uso. Adem\u00e1s, se deben mantener registros de los resultados del monitoreo y de cualquier acci\u00f3n tomada.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Entorno de Asepsia**:\n   - **Grado A y Grado B**: La preparaci\u00f3n y manejo de productos no est\u00e9riles debe realizarse en un entorno de grado A con un fondo de grado B. Esto incluye la manipulaci\u00f3n de productos preparados asepticamente y equipos est\u00e9riles expuestos.\n\n2. **Manejo de Productos Asepticos**:\n   - La transferencia de contenedores parcialmente cerrados y la preparaci\u00f3n de productos est\u00e9riles (como ung\u00fcentos, cremas, suspensiones y emulsiones) tambi\u00e9n deben realizarse en un entorno de grado A con un fondo de grado B.\n\n3. **Minimizaci\u00f3n de Contaminaci\u00f3n**:\n   - Se deben tomar precauciones para minimizar la contaminaci\u00f3n en todas las etapas de procesamiento, especialmente antes de la esterilizaci\u00f3n.\n\n4. **Instalaciones Multiproducto**:\n   - Generalmente, no se deben hacer preparaciones que contengan microorganismos vivos en \u00e1reas utilizadas para otros productos farmac\u00e9uticos. Sin embargo, se permite su uso si se valida la contenci\u00f3n y desinfecci\u00f3n de los microorganismos vivos.\n\n5. **Validaci\u00f3n de Procesos Asepticos**:\n   - La validaci\u00f3n debe incluir pruebas de simulaci\u00f3n de procesos utilizando un medio nutritivo, el cual debe ser seleccionado seg\u00fan la forma de dosificaci\u00f3n del producto y su adecuaci\u00f3n para la esterilizaci\u00f3n.\n\n6. **Pruebas de Simulaci\u00f3n de Procesos**:\n   - Se requieren tres pruebas de simulaci\u00f3n satisfactorias consecutivas para validar el procesamiento as\u00e9ptico, y estas deben repetirse a intervalos definidos y tras modificaciones significativas en el proceso.\n\n### Entidades Clave:\n- **Grado A y Grado B**: Clasificaciones de ambientes para la manipulaci\u00f3n de productos est\u00e9riles.\n- **Microorganismos Vivos**: Organismos que deben ser manejados con precauciones especiales en la producci\u00f3n farmac\u00e9utica.\n- **Medio Nutritivo**: Sustancia utilizada en pruebas de simulaci\u00f3n para validar procesos as\u00e9pticos.\n- **Pruebas de Simulaci\u00f3n**: M\u00e9todos para validar la efectividad del procesamiento as\u00e9ptico. \n\nEste resumen destaca la importancia de mantener condiciones controladas y validar procesos en la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles para garantizar su seguridad y eficacia.", "excerpt_keywords": "Keywords: validation, contamination, aseptic, media fills, monitoring"}}, "13d9db7e-1432-40d7-a7e6-d2bea8551398": {"node_ids": ["98efa0eb-df2b-4fb7-b7ec-4b10d3ab866d"], "metadata": {"page_label": "235", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 4.31\nThe presence of containers and materials liable to generate fibres should be minimized in clean areas and avoided completely when aseptic work is in progress.\n\n# 4.32\nComponents, bulk-product containers and equipment should be handled after the final cleaning process in such a way as to ensure that they are not recontaminated. The stage of processing of components as well as the bulk-product containers and equipment should be properly identified.\n\n# 4.33\nThe interval between the washing and drying and the sterilization of components, bulk-product containers and equipment, as well as between sterilization and use, should be as short as possible and subject to a time-limit appropriate to the validated storage conditions.\n\n# 4.34\nThe time between the start of the preparation of a solution and its sterilization or filtration through a bacteria-retaining filter should be as short as possible. A maximum permissible time should be set for each product that takes into account its composition and the prescribed method of storage.\n\n# 4.35\nAny gas that is used to purge a solution or blanket a product should be passed through a sterilizing filter.\n\n# 4.36\nThe bioburden should be monitored before sterilization. There should be working limits on contamination immediately before sterilization, which are related to the efficiency of the method to be used. Bioburden assay should be performed on each batch for both aseptically filled products and terminally sterilized products. Where overkill sterilization parameters are set for terminally sterilized products, bioburden might be monitored only at suitable scheduled intervals. For parametric release systems, bioburden assay should be performed on each batch and considered as an in-process test. Where appropriate, the level of endotoxins should be monitored. All solutions, in particular large-volume infusion fluids, should be passed through a microorganism-retaining filter, if possible sited immediately before filling.\n\n# 4.37\nComponents, bulk-product containers, equipment, and any other articles required in a clean area where aseptic work is in progress, should be sterilized and wherever possible passed into the area through double-ended sterilizers sealed into the wall. Other procedures that prevent the introduction of contamination may be acceptable in some circumstances.\n\n# 4.38\nThe efficacy of any new processing procedure should be validated and the validation should be repeated at regular intervals thereafter or when any significant change is made in the process or equipment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Informe T\u00e9cnico 957) aborda las pr\u00e1cticas y procedimientos necesarios para mantener la asepsia en \u00e1reas limpias durante la manipulaci\u00f3n de componentes y productos. Se enfatiza la importancia de minimizar la contaminaci\u00f3n, controlar la bioburden antes de la esterilizaci\u00f3n, y asegurar que todos los procesos de limpieza y esterilizaci\u00f3n se realicen en el menor tiempo posible. Tambi\u00e9n se menciona la necesidad de validar los procedimientos de procesamiento y monitorear los niveles de endotoxinas.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las medidas espec\u00edficas que se deben tomar para evitar la recontaminaci\u00f3n de componentes y equipos despu\u00e9s de su limpieza final?**\n   - Esta pregunta se centra en las pr\u00e1cticas recomendadas para manejar componentes y equipos en un entorno limpio, lo cual no se detalla en otras secciones del documento.\n\n2. **\u00bfQu\u00e9 criterios se deben considerar al establecer un tiempo m\u00e1ximo permisible entre la preparaci\u00f3n de una soluci\u00f3n y su esterilizaci\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n sobre c\u00f3mo se determina el tiempo m\u00e1ximo permisible para la preparaci\u00f3n y esterilizaci\u00f3n de soluciones, un aspecto cr\u00edtico que puede no estar ampliamente discutido en otras fuentes.\n\n3. **\u00bfQu\u00e9 procedimientos alternativos pueden ser aceptables para prevenir la introducci\u00f3n de contaminaci\u00f3n en \u00e1reas limpias, adem\u00e1s del uso de esterilizadores de doble extremo?**\n   - Esta pregunta explora las opciones disponibles para mantener la asepsia en \u00e1reas limpias, lo que puede no estar claramente especificado en otros documentos o gu\u00edas. \n\nEstas preguntas est\u00e1n dise\u00f1adas para profundizar en aspectos espec\u00edficos del manejo de asepsia y esterilizaci\u00f3n que son cruciales para la seguridad y eficacia en entornos de producci\u00f3n farmac\u00e9utica y m\u00e9dica.", "prev_section_summary": "### Temas Clave\n\n1. **Validaci\u00f3n de Procesos**: Se enfatiza la importancia de realizar pruebas de simulaci\u00f3n de procesos que reflejen tanto las condiciones normales de producci\u00f3n como las situaciones de peor caso. Estas pruebas deben ser representativas de cada turno y los cambios de turno.\n\n2. **Contaminaci\u00f3n Microbiana en Llenados de Medios**: Se establecen criterios espec\u00edficos para la aceptaci\u00f3n de unidades contaminadas durante los llenados de medios, dependiendo del tama\u00f1o del lote. Se busca un objetivo de cero crecimiento microbiano.\n\n3. **Monitoreo de Fuentes de Agua**: Se recomienda un monitoreo regular de las fuentes de agua, el equipo de tratamiento y el agua tratada para detectar contaminantes qu\u00edmicos, biol\u00f3gicos y endotoxinas, asegurando que cumplan con las especificaciones adecuadas.\n\n4. **Control de Actividades en \u00c1reas Limpias**: Se sugiere minimizar las actividades en \u00e1reas limpias durante operaciones as\u00e9pticas y controlar el movimiento del personal para reducir la contaminaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad del documento.\n- **HVAC**: Sistema de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado mencionado en el contexto de la producci\u00f3n.\n- **Contaminaci\u00f3n Microbiana**: Problema a investigar durante los procesos de llenado.\n- **Llenados de Medios**: Proceso cr\u00edtico en la producci\u00f3n farmac\u00e9utica.\n- **Agua y Equipos de Tratamiento**: Elementos que deben ser monitoreados para asegurar la calidad del agua utilizada en la producci\u00f3n.\n- **\u00c1reas Limpias**: Espacios donde se llevan a cabo operaciones as\u00e9pticas que requieren control riguroso de actividades.", "excerpt_keywords": "Keywords: aseptic processing, sterilization, bioburden monitoring, clean areas, validation procedures"}}, "c14b61b0-2b21-4b7e-93c6-53d49185d8aa": {"node_ids": ["aa609065-3541-4da2-9599-e41eb1c9ca21"], "metadata": {"page_label": "236", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Sterilization\n\n5.1 Whenever possible products intended to be sterile should be terminally sterilized by heat in their final container. Where it is not possible to carry out terminal sterilization by heating due to the instability of a formulation or incompatibility of a pack type (necessary to the administration of the product, e.g. plastic eye-dropper bottles), a decision should be taken to use an alternative method of terminal sterilization following filtration and/or aseptic processing.\n\n5.2 Sterilization can be achieved by the use of moist or dry heat, by irradiation with ionizing radiation (noting that ultraviolet irradiation is not normally an acceptable method of sterilization), by ethylene oxide (or other suitable gaseous sterilizing agents), or by filtration with subsequent aseptic filling of sterile final containers. Each method has its advantages and disadvantages. Where possible and practicable, heat sterilization is the method of choice. In any case the sterilization process must be in accordance with the marketing and manufacturing authorizations.\n\n5.3 The microbial contamination of starting materials should be minimal and their bioburden should be monitored before sterilization. Specifications should include requirements for microbiological quality when the need for this has been indicated by monitoring.\n\n5.4 All sterilization processes should be validated. Particular attention should be paid when the adopted sterilization method is not in accordance with pharmacopoeial standards or other national standards, or when it is used for a preparation that is not a simple aqueous or oily solution, for example, colloidal suspensions.\n\n5.5 Before any sterilization process is adopted, its suitability for the product and its efficacy in achieving the desired sterilizing conditions in all parts of each type of load to be processed should be demonstrated by physical measurements and by biological indicators, where appropriate. The validity of the process should be verified at scheduled intervals, at least annually, and whenever significant modifications have been made to the equipment. Records should be kept of the results.\n\n5.6 For effective sterilization the whole of the material should be subjected to the required treatment and the process should be designed to ensure that this is achieved.\n\n5.7 Biological indicators should be considered only as an additional method of monitoring the sterilization process. They should be stored and used according to the manufacturer\u2019s instructions, and their quality checked by positive controls. If they are used, strict precautions should be taken to avoid any transfer of microbial contamination from them.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las pr\u00e1cticas de esterilizaci\u00f3n de productos destinados a ser est\u00e9riles. Se enfatiza la importancia de la esterilizaci\u00f3n terminal por calor en el envase final, aunque se reconocen alternativas cuando esto no es posible. Se describen diferentes m\u00e9todos de esterilizaci\u00f3n, como el calor h\u00famedo o seco, la irradiaci\u00f3n, el \u00f3xido de etileno y la filtraci\u00f3n, cada uno con sus ventajas y desventajas. Adem\u00e1s, se subraya la necesidad de validar todos los procesos de esterilizaci\u00f3n y de monitorear la contaminaci\u00f3n microbiana de los materiales de partida.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones que justifican el uso de m\u00e9todos alternativos de esterilizaci\u00f3n en lugar de la esterilizaci\u00f3n terminal por calor?**\n   - Respuesta: Se deben considerar m\u00e9todos alternativos cuando la formulaci\u00f3n es inestable o cuando hay incompatibilidad con el tipo de envase necesario para la administraci\u00f3n del producto, como en el caso de botellas de pl\u00e1stico para gotas oculares.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse para validar un proceso de esterilizaci\u00f3n que no cumple con los est\u00e1ndares farmacopoeiales?**\n   - Respuesta: Se debe prestar especial atenci\u00f3n a la validaci\u00f3n del proceso, demostrando su idoneidad para el producto y su eficacia en alcanzar las condiciones de esterilizaci\u00f3n deseadas en todas las partes de cada tipo de carga procesada. Esto debe incluir mediciones f\u00edsicas y, cuando sea apropiado, indicadores biol\u00f3gicos.\n\n3. **\u00bfQu\u00e9 papel juegan los indicadores biol\u00f3gicos en el monitoreo del proceso de esterilizaci\u00f3n y cu\u00e1les son las precauciones necesarias al usarlos?**\n   - Respuesta: Los indicadores biol\u00f3gicos deben considerarse como un m\u00e9todo adicional de monitoreo del proceso de esterilizaci\u00f3n. Deben ser almacenados y utilizados de acuerdo con las instrucciones del fabricante, y su calidad debe ser verificada mediante controles positivos. Es crucial tomar estrictas precauciones para evitar la transferencia de contaminaci\u00f3n microbiana desde ellos.", "prev_section_summary": "### Temas Clave:\n1. **Minimizaci\u00f3n de Contaminaci\u00f3n**: Se enfatiza la importancia de reducir la presencia de materiales que puedan generar fibras en \u00e1reas limpias, especialmente durante trabajos as\u00e9pticos.\n  \n2. **Manejo de Componentes y Equipos**: Se deben seguir pr\u00e1cticas espec\u00edficas para manejar componentes y equipos despu\u00e9s de su limpieza final, asegurando que no se recontaminen.\n\n3. **Intervalos de Tiempo Cr\u00edticos**: Se establece que el tiempo entre la limpieza, secado, esterilizaci\u00f3n y uso de componentes debe ser lo m\u00e1s corto posible, y se deben definir l\u00edmites de tiempo apropiados seg\u00fan las condiciones de almacenamiento validadas.\n\n4. **Preparaci\u00f3n y Esterilizaci\u00f3n de Soluciones**: Se debe minimizar el tiempo entre la preparaci\u00f3n de soluciones y su esterilizaci\u00f3n o filtraci\u00f3n, estableciendo un tiempo m\u00e1ximo permisible basado en la composici\u00f3n del producto.\n\n5. **Monitoreo de Bioburden**: Es crucial monitorear la bioburden antes de la esterilizaci\u00f3n, con l\u00edmites de contaminaci\u00f3n establecidos y ensayos realizados en cada lote.\n\n6. **Esterilizaci\u00f3n de Art\u00edculos**: Todos los componentes y art\u00edculos necesarios en \u00e1reas limpias deben ser esterilizados y, de ser posible, introducidos a trav\u00e9s de esterilizadores de doble extremo.\n\n7. **Validaci\u00f3n de Procedimientos**: La eficacia de nuevos procedimientos de procesamiento debe ser validada y revisada peri\u00f3dicamente, especialmente tras cambios significativos en el proceso o equipo.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Bioburden**: Concepto relacionado con la carga microbiana que debe ser monitoreada.\n- **Esterilizadores de Doble Extremo**: Equipos recomendados para la introducci\u00f3n de art\u00edculos en \u00e1reas limpias.\n- **Filtros de Retenci\u00f3n de Microorganismos**: Dispositivos utilizados para asegurar la esterilidad de soluciones.\n- **Productos Asepticamente Llenados y Esterilizados Terminalmente**: Tipos de productos que requieren monitoreo de bioburden.\n\nEste resumen proporciona una visi\u00f3n general de las pr\u00e1cticas recomendadas para mantener la asepsia y la seguridad en entornos de producci\u00f3n farmac\u00e9utica y m\u00e9dica, destacando la importancia de la validaci\u00f3n y el monitoreo continuo.", "excerpt_keywords": "Sterilization, Aseptic processing, Microbial contamination, Validation, Biological indicators"}}, "379d13a7-8c90-439d-a040-e8dcd610af0f": {"node_ids": ["68baa6bc-9c86-4d3f-afcb-c03416b6ffa1"], "metadata": {"page_label": "237", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 5.8  \nThere should be a clear means of differentiating products that have not been sterilized from those which have. Each basket, tray, or other carrier of products or components should be clearly labelled with the name of the material, its batch number and an indication of whether or not it has been sterilized. Indicators such as autoclave tape may be used where appropriate to indicate whether or not a batch (or sub-batch) has passed through a sterilization process, but they do not give a reliable indication that the batch is in fact sterile.\n\n5.9  \nValidated loading patterns should be established for all sterilization processes.\n\n5.10  \nSterilization records should be available for each sterilization run. They should be approved as part of the batch-release procedure.\n\n# 6. Terminal sterilization\n\n## Sterilization by heat\n\n6.1  \nEach heat-sterilization cycle should be recorded by means of appropriate equipment of suitable accuracy and precision, e.g. on a time/temperature chart with a suitably large scale. The temperature should be recorded by a probe situated at the coolest part of the load or loaded chamber, this point having been determined during the validation; the temperature should preferably be checked against a second independent temperature probe located at the same position. Sterilization records should be available for each sterilization run and should be approved as part of the batch release procedure. Chemical or biological indicators may also be used but should not take the place of physical controls.\n\n6.2  \nSufficient time should be allowed for the whole of the load to reach the required temperature before measurement of the sterilizing time is started. This time should be determined for each type of load to be processed.\n\n6.3  \nAfter the high-temperature phase of a heat sterilization cycle, precautions should be taken against contamination of a sterilized load during cooling. Any cooling fluid or gas in contact with the product should be sterilized.\n\n## Sterilization by moist heat\n\n6.4  \nBoth temperature and pressure should be used to monitor the process. Control instrumentation should normally be independent of monitoring instrumentation and recording charts. Where automated control and monitoring systems are used for these applications they should be validated to ensure that critical process requirements are met. System and cycle faults should be registered by the system and observed by the operator.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Diferenciaci\u00f3n de productos esterilizados y no esterilizados**: Es fundamental que los productos y componentes sean claramente etiquetados para distinguir entre aquellos que han sido esterilizados y los que no. Esto incluye informaci\u00f3n sobre el material, el n\u00famero de lote y el estado de esterilizaci\u00f3n.\n\n2. **Registros y validaci\u00f3n de procesos de esterilizaci\u00f3n**: Se requiere que existan patrones de carga validados y registros de esterilizaci\u00f3n para cada ciclo, los cuales deben ser aprobados como parte del procedimiento de liberaci\u00f3n de lotes. Esto asegura la trazabilidad y la conformidad con los est\u00e1ndares de esterilizaci\u00f3n.\n\n3. **Monitoreo de procesos de esterilizaci\u00f3n**: Tanto la esterilizaci\u00f3n por calor como por calor h\u00famedo requieren un monitoreo riguroso de temperatura y presi\u00f3n. Los sistemas de control deben ser validados y los fallos del sistema deben ser registrados y observados por el operador.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la etiqueta de los productos o componentes que han sido esterilizados?**\n   - La etiqueta debe incluir el nombre del material, el n\u00famero de lote y una indicaci\u00f3n de si ha sido esterilizado o no.\n\n2. **\u00bfCu\u00e1l es la importancia de registrar la temperatura en el ciclo de esterilizaci\u00f3n por calor?**\n   - La temperatura debe ser registrada en el punto m\u00e1s fr\u00edo de la carga para asegurar que todo el contenido haya alcanzado la temperatura requerida para la esterilizaci\u00f3n, lo que es crucial para garantizar la efectividad del proceso.\n\n3. **\u00bfQu\u00e9 precauciones deben tomarse despu\u00e9s de la fase de alta temperatura en un ciclo de esterilizaci\u00f3n por calor?**\n   - Se deben tomar precauciones para evitar la contaminaci\u00f3n de la carga esterilizada durante el enfriamiento, asegurando que cualquier fluido o gas de enfriamiento en contacto con el producto tambi\u00e9n est\u00e9 esterilizado.", "prev_section_summary": "### Temas Clave\n\n1. **Esterilizaci\u00f3n Terminal**: Se enfatiza que los productos destinados a ser est\u00e9riles deben ser esterilizados terminalmente por calor en su envase final siempre que sea posible.\n\n2. **M\u00e9todos de Esterilizaci\u00f3n**: Se describen varios m\u00e9todos de esterilizaci\u00f3n, incluyendo:\n   - Calor h\u00famedo o seco\n   - Irradiaci\u00f3n con radiaci\u00f3n ionizante\n   - \u00d3xido de etileno y otros agentes gaseosos\n   - Filtraci\u00f3n con llenado as\u00e9ptico de envases finales est\u00e9riles\n\n3. **Contaminaci\u00f3n Microbiana**: Se debe monitorear la contaminaci\u00f3n microbiana de los materiales de partida y asegurar que su bioburden sea m\u00ednimo antes de la esterilizaci\u00f3n.\n\n4. **Validaci\u00f3n de Procesos**: Todos los procesos de esterilizaci\u00f3n deben ser validados, especialmente si no cumplen con los est\u00e1ndares farmacopoeiales o se utilizan para preparaciones complejas.\n\n5. **Indicadores Biol\u00f3gicos**: Se consideran como un m\u00e9todo adicional para monitorear el proceso de esterilizaci\u00f3n, con la necesidad de seguir las instrucciones del fabricante y tomar precauciones para evitar contaminaci\u00f3n.\n\n6. **Documentaci\u00f3n y Registros**: Es importante mantener registros de los resultados de la validaci\u00f3n y monitoreo de los procesos de esterilizaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices sobre esterilizaci\u00f3n.\n- **M\u00e9todos de Esterilizaci\u00f3n**: Calor h\u00famedo, calor seco, irradiaci\u00f3n, \u00f3xido de etileno, filtraci\u00f3n.\n- **Contaminaci\u00f3n Microbiana**: Concepto relacionado con la calidad microbiol\u00f3gica de los materiales.\n- **Est\u00e1ndares Farmacopoeiales**: Normativas que regulan los m\u00e9todos de esterilizaci\u00f3n.\n- **Indicadores Biol\u00f3gicos**: Herramientas utilizadas para verificar la eficacia del proceso de esterilizaci\u00f3n.\n\nEste resumen abarca los aspectos fundamentales de la secci\u00f3n sobre esterilizaci\u00f3n, destacando la importancia de los m\u00e9todos, la validaci\u00f3n y el monitoreo en la producci\u00f3n de productos est\u00e9riles.", "excerpt_keywords": "Keywords: sterilization, heat, monitoring, validation, contamination"}}, "a11b2af6-6079-4166-9d95-bb85810e7eda": {"node_ids": ["36a59a01-03c8-47e0-8a69-1947d800e32c"], "metadata": {"page_label": "238", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The reading of the independent temperature indicator should be routinely checked against the reading on the chart recorder during the sterilization period. For sterilizers fitted with a drain at the bottom of the chamber, it may also be necessary to record the temperature at this position throughout the sterilization period. There should be regular leak tests on the chamber when a vacuum phase is part of the cycle.\n\n6.5 The items to be sterilized, other than products in sealed containers, should be wrapped in a material that allows the removal of air and the penetration of steam but prevents recontamination after sterilization. Specially designed autoclavable stainless steel containers, that allow steam to enter and air to leave, can also be used. All parts of the load should be in contact with water or saturated steam at the required temperature for the required time.\n\n6.6 Care should be taken to ensure that the steam used for sterilization is of suitable quality (chemical, microbiological and endotoxin analysis of condensate and physical examination of steam (such as dryness, superheat, and non-condensable gases)) and does not contain additives at a level that could cause contamination of the product or equipment. Steam used for sterilization should be tested regularly.\n\n*Sterilization by dry heat*\n\n6.7 Sterilization by dry heat may be suitable for non-aqueous liquids or dry-powder products.\n\nThe process used should include air circulation within the chamber and the maintenance of a positive pressure to prevent the entry of non-sterile air. If air is supplied it should be passed through a microorganism-retaining filter (e.g. a HEPA filter). Where sterilization by dry heat is also intended to remove pyrogens, challenge tests using endotoxins are required as part of the validation.\n\n*Sterilization by radiation*\n\n6.8 Sterilization by radiation is used mainly for heat-sensitive materials and products. Many pharmaceutical products and some packaging materials are radiation-sensitive, so this method is permissible only when the absence of deleterious effects on the product has been confirmed experimentally. Ultraviolet irradiation is not an acceptable method for terminal sterilization.\n\n6.9 If sterilization by radiation is done by an outside contractor, the manufacturer is responsible for ensuring that the requirements of section 6.8 are met and that the sterilization process is validated.\n\n6.10 During the sterilization procedure the radiation dose should be measured. The dosimeters used for this purpose should be independent of", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona directrices sobre los procedimientos de esterilizaci\u00f3n en el \u00e1mbito farmac\u00e9utico, centr\u00e1ndose en la importancia de verificar las lecturas de temperatura durante el proceso de esterilizaci\u00f3n, la calidad del vapor utilizado, y las condiciones necesarias para la esterilizaci\u00f3n por calor seco y radiaci\u00f3n. Se enfatiza la necesidad de pruebas regulares y validaciones para garantizar la eficacia de los m\u00e9todos de esterilizaci\u00f3n, as\u00ed como la responsabilidad del fabricante en el caso de que se utilicen contratistas externos para la esterilizaci\u00f3n por radiaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de materiales se recomienda utilizar para envolver los art\u00edculos que se van a esterilizar, y por qu\u00e9 es importante esta elecci\u00f3n?**\n   - Respuesta: Se recomienda utilizar materiales que permitan la eliminaci\u00f3n de aire y la penetraci\u00f3n de vapor, pero que eviten la recontaminaci\u00f3n despu\u00e9s de la esterilizaci\u00f3n. Esto es crucial para asegurar que los art\u00edculos est\u00e9n completamente esterilizados y no se contaminen nuevamente antes de su uso.\n\n2. **\u00bfCu\u00e1les son los requisitos espec\u00edficos para el vapor utilizado en el proceso de esterilizaci\u00f3n, y qu\u00e9 an\u00e1lisis se deben realizar para garantizar su calidad?**\n   - Respuesta: El vapor utilizado debe ser de calidad adecuada, lo que implica realizar an\u00e1lisis qu\u00edmicos, microbiol\u00f3gicos y de endotoxinas del condensado, as\u00ed como una evaluaci\u00f3n f\u00edsica del vapor (seco, sobrecalentado y gases no condensables). Esto asegura que el vapor no contenga aditivos que puedan contaminar los productos o equipos.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse si se utiliza la esterilizaci\u00f3n por radiaci\u00f3n a trav\u00e9s de un contratista externo?**\n   - Respuesta: El fabricante es responsable de asegurarse de que se cumplan los requisitos establecidos en la secci\u00f3n 6.8 del documento y de que el proceso de esterilizaci\u00f3n est\u00e9 validado. Esto incluye confirmar experimentalmente que no hay efectos perjudiciales en los productos debido a la radiaci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Diferenciaci\u00f3n de productos esterilizados y no esterilizados**:\n   - Importancia de etiquetar claramente los productos y componentes.\n   - Informaci\u00f3n requerida en las etiquetas: nombre del material, n\u00famero de lote y estado de esterilizaci\u00f3n.\n\n2. **Registros de esterilizaci\u00f3n**:\n   - Necesidad de mantener registros de cada ciclo de esterilizaci\u00f3n.\n   - Aprobaci\u00f3n de los registros como parte del procedimiento de liberaci\u00f3n de lotes.\n\n3. **Patrones de carga validados**:\n   - Establecimiento de patrones de carga para todos los procesos de esterilizaci\u00f3n.\n\n4. **Monitoreo de procesos de esterilizaci\u00f3n por calor**:\n   - Registro de ciclos de esterilizaci\u00f3n por calor mediante equipos precisos.\n   - Uso de sondas para medir la temperatura en el punto m\u00e1s fr\u00edo de la carga.\n   - Importancia de permitir tiempo suficiente para que toda la carga alcance la temperatura requerida.\n\n5. **Precauciones post-esterilizaci\u00f3n**:\n   - Medidas para evitar la contaminaci\u00f3n de la carga esterilizada durante el enfriamiento.\n   - Necesidad de esterilizar cualquier fluido o gas en contacto con el producto.\n\n6. **Esterilizaci\u00f3n por calor h\u00famedo**:\n   - Monitoreo de temperatura y presi\u00f3n durante el proceso.\n   - Validaci\u00f3n de sistemas de control y monitoreo automatizados.\n\n### Entidades clave\n- **Productos y componentes**: Elementos que requieren esterilizaci\u00f3n.\n- **Etiquetas**: Informaci\u00f3n sobre el estado de esterilizaci\u00f3n.\n- **Registros de esterilizaci\u00f3n**: Documentaci\u00f3n de cada ciclo.\n- **Patrones de carga**: Configuraciones validadas para procesos de esterilizaci\u00f3n.\n- **Equipos de monitoreo**: Herramientas para registrar temperatura y presi\u00f3n.\n- **Sondas de temperatura**: Dispositivos utilizados para medir la temperatura en el proceso de esterilizaci\u00f3n.", "excerpt_keywords": "Keywords: sterilization, steam quality, dry heat, radiation, validation"}}, "2b6fd6be-c378-446b-8131-dfa4fc25148d": {"node_ids": ["1775c8c0-042d-41d4-b0c9-96b4851574e5"], "metadata": {"page_label": "239", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "the dose rate and should provide a quantitative measurement of the dose received by the product itself. Dosimeters should be inserted in the load in sufficient number and close enough together to ensure that there is always a dosimeter in the chamber. Where plastic dosimeters are used they should be used within the time-limit of their calibration. Dosimeter absorbance should be read shortly after exposure to radiation. Radiation-sensitive colour discs may be used to differentiate between packages that have been subjected to irradiation and those that have not; they are not indicators of successful sterilization. The information obtained should constitute part of the batch record.\n\n6.11 Validation procedures should ensure that consideration is given to the effects of variations in the density of the packages.\n\n6.12 Material-handling procedures should prevent any mix-up of irradiated and non-irradiated materials. Each package should carry a radiation-sensitive indicator to show whether or not it has been subjected to radiation treatment.\n\n6.13 The total radiation dose should be administered within a predetermined period.\n\n### Sterilization by gases and fumigants\n\n6.14 Sterilization by gases and fumigants should only be used for finished products where there is no suitable alternative.\n\n6.15 Various gases and fumigants may be used for sterilization (e.g. ethylene oxide and hydrogen peroxide vapour). Ethylene oxide should be used only when no other method is practicable. During process validation it should be shown that the gas has no damaging effect on the product and that the conditions and time allowed for degassing are such as to reduce any residual gas and reaction products to defined acceptable limits for the type of product or material concerned. These limits should be incorporated in the specifications.\n\n6.16 Direct contact between gas and microorganisms is essential; precautions should therefore be taken to avoid the presence of organisms likely to be enclosed in materials such as crystals or dried protein. The nature and quantity of packaging materials can significantly affect the process.\n\n6.17 Before exposure to the gas, materials should be brought into equilibrium with the humidity and temperature required by the process. This requirement should be balanced against the need to minimize the waiting time before sterilization.\n\n6.18 Each sterilization cycle should be monitored with suitable biological indicators, using the appropriate number of test pieces distributed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Procedimientos de validaci\u00f3n y manejo de materiales**: Se enfatiza la importancia de los procedimientos de validaci\u00f3n para asegurar que las variaciones en la densidad de los paquetes se consideren adecuadamente. Adem\u00e1s, se establecen protocolos para evitar la mezcla de materiales irradiados y no irradiados, incluyendo el uso de indicadores sensibles a la radiaci\u00f3n en cada paquete.\n\n2. **M\u00e9todos de esterilizaci\u00f3n por gases y fumigantes**: Se discute el uso de gases y fumigantes, como el \u00f3xido de etileno y el vapor de per\u00f3xido de hidr\u00f3geno, para la esterilizaci\u00f3n de productos terminados. Se subraya la necesidad de validar que estos gases no da\u00f1en el producto y que se cumplan los l\u00edmites aceptables de residuos.\n\n3. **Monitoreo de ciclos de esterilizaci\u00f3n**: Se requiere que cada ciclo de esterilizaci\u00f3n sea monitoreado utilizando indicadores biol\u00f3gicos adecuados y que se distribuyan suficientes piezas de prueba para garantizar la efectividad del proceso.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que los dos\u00edmetros utilizados en la medici\u00f3n de la dosis de radiaci\u00f3n est\u00e9n correctamente posicionados y calibrados?**\n   - La respuesta se puede encontrar en la secci\u00f3n que menciona la cantidad y disposici\u00f3n de los dos\u00edmetros en la carga, as\u00ed como el tiempo l\u00edmite de calibraci\u00f3n para los dos\u00edmetros pl\u00e1sticos.\n\n2. **\u00bfCu\u00e1les son las consideraciones clave al utilizar \u00f3xido de etileno como m\u00e9todo de esterilizaci\u00f3n, y qu\u00e9 pasos se deben seguir para validar su uso?**\n   - La respuesta se puede extraer de la discusi\u00f3n sobre el uso de \u00f3xido de etileno, incluyendo la necesidad de demostrar que no causa da\u00f1o al producto y los l\u00edmites aceptables de residuos que deben ser especificados.\n\n3. **\u00bfQu\u00e9 precauciones deben tomarse para garantizar el contacto directo entre el gas de esterilizaci\u00f3n y los microorganismos?**\n   - La respuesta se puede encontrar en la secci\u00f3n que aborda la importancia del contacto directo y las precauciones necesarias para evitar la presencia de organismos encerrados en materiales que podr\u00edan interferir con el proceso de esterilizaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Verificaci\u00f3n de Temperatura**: Es fundamental comprobar regularmente la lectura del indicador de temperatura independiente contra el registrador gr\u00e1fico durante el proceso de esterilizaci\u00f3n. Esto incluye registrar la temperatura en el fondo de la c\u00e1mara si el esterilizador tiene un desag\u00fce.\n\n2. **Materiales para Envoltura**: Los art\u00edculos a esterilizar deben envolverse en materiales que permitan la eliminaci\u00f3n de aire y la penetraci\u00f3n de vapor, evitando la recontaminaci\u00f3n posterior. Se pueden utilizar contenedores de acero inoxidable autoclavables dise\u00f1ados para este prop\u00f3sito.\n\n3. **Calidad del Vapor**: El vapor utilizado para la esterilizaci\u00f3n debe ser de calidad adecuada, lo que implica realizar an\u00e1lisis qu\u00edmicos, microbiol\u00f3gicos y de endotoxinas, as\u00ed como una evaluaci\u00f3n f\u00edsica del vapor. Se debe evitar la presencia de aditivos que puedan contaminar los productos.\n\n4. **Esterilizaci\u00f3n por Calor Seco**: Este m\u00e9todo es adecuado para l\u00edquidos no acuosos o productos en polvo seco. Se requiere circulaci\u00f3n de aire y mantenimiento de presi\u00f3n positiva para prevenir la entrada de aire no est\u00e9ril. Si se busca eliminar pir\u00f3genos, se deben realizar pruebas de desaf\u00edo con endotoxinas.\n\n5. **Esterilizaci\u00f3n por Radiaci\u00f3n**: Este m\u00e9todo se utiliza principalmente para materiales y productos sensibles al calor. Es necesario confirmar experimentalmente que no hay efectos perjudiciales en los productos. La irradiaci\u00f3n ultravioleta no es aceptable para la esterilizaci\u00f3n terminal.\n\n6. **Responsabilidad del Fabricante**: Si la esterilizaci\u00f3n por radiaci\u00f3n es realizada por un contratista externo, el fabricante debe asegurarse de que se cumplan los requisitos y que el proceso est\u00e9 validado.\n\n7. **Medici\u00f3n de Dosis de Radiaci\u00f3n**: Durante el procedimiento de esterilizaci\u00f3n, se debe medir la dosis de radiaci\u00f3n utilizando dos\u00edmetros independientes.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Esterilizaci\u00f3n**: Proceso de eliminaci\u00f3n de microorganismos.\n- **Vapor**: Medio utilizado para la esterilizaci\u00f3n.\n- **Contenedores de Acero Inoxidable**: Material recomendado para envolver art\u00edculos a esterilizar.\n- **Calor Seco**: M\u00e9todo de esterilizaci\u00f3n adecuado para ciertos productos.\n- **Radiaci\u00f3n**: M\u00e9todo de esterilizaci\u00f3n utilizado para materiales sensibles al calor.\n- **Contratistas Externos**: Entidades responsables de realizar la esterilizaci\u00f3n por radiaci\u00f3n en nombre del fabricante.", "excerpt_keywords": "Keywords: sterilization, dosimeters, ethylene oxide, radiation, validation procedures"}}, "43180f24-e29b-42bf-be3a-539e29738591": {"node_ids": ["42347d41-2858-4640-b45d-6d74ea80abac"], "metadata": {"page_label": "240", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Aseptic Processing and Sterilization by Filtration\n\n7.1 The objective of aseptic processing is to maintain the sterility of a product that is assembled from components, each of which has been sterilized by one of the above methods (see sections 5 and 6).\n\n7.2 The operating conditions should be such as to prevent microbial contamination.\n\n7.3 In order to maintain the sterility of the components and the product during aseptic processing, careful attention needs to be given to:\n\n- the environment;\n- personnel;\n- critical surfaces;\n- container/closure sterilization and transfer procedures;\n- the maximum holding period of the product before filling into the final container; and\n- the sterilizing filter.\n\n7.4 Certain solutions and liquids that cannot be sterilized in the final container can be filtered through a sterile filter of nominal pore size 0.22 micron (or less), or with at least equivalent microorganism-retaining properties, into a previously sterilized container. Such filters can remove bacteria and moulds, but not all viruses or mycoplasmas. Consideration should be given to complementing the filtration process with some degree of heat treatment. Filtration alone is not considered sufficient when sterilization in the final container is possible. Of the methods currently available, steam sterilization is to be preferred.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Objetivo del Procesamiento Aseptico**: El procesamiento as\u00e9ptico tiene como objetivo mantener la esterilidad de un producto que se ensambla a partir de componentes previamente esterilizados. Esto implica un control riguroso de las condiciones operativas para prevenir la contaminaci\u00f3n microbiana.\n\n2. **Factores Cr\u00edticos en el Procesamiento Aseptico**: Para asegurar la esterilidad durante el procesamiento as\u00e9ptico, es crucial prestar atenci\u00f3n a varios factores, incluyendo el entorno, el personal, las superficies cr\u00edticas, los procedimientos de esterilizaci\u00f3n y transferencia de envases/cierres, el tiempo m\u00e1ximo de retenci\u00f3n del producto antes del llenado, y el filtro esterilizante.\n\n3. **Filtraci\u00f3n y Esterilizaci\u00f3n**: La filtraci\u00f3n a trav\u00e9s de un filtro est\u00e9ril de 0.22 micrones es una opci\u00f3n para soluciones que no pueden ser esterilizadas en su envase final. Sin embargo, esta t\u00e9cnica no es suficiente por s\u00ed sola y se recomienda complementarla con un tratamiento t\u00e9rmico. La esterilizaci\u00f3n por vapor es el m\u00e9todo preferido cuando es posible.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los componentes cr\u00edticos que deben ser controlados para mantener la esterilidad durante el procesamiento as\u00e9ptico?**\n   - Respuesta: Los componentes cr\u00edticos incluyen el entorno, el personal, las superficies cr\u00edticas, los procedimientos de esterilizaci\u00f3n y transferencia de envases/cierres, el tiempo m\u00e1ximo de retenci\u00f3n del producto antes del llenado, y el filtro esterilizante.\n\n2. **\u00bfQu\u00e9 limitaciones tienen los filtros est\u00e9riles de 0.22 micrones en t\u00e9rminos de microorganismos que pueden eliminar?**\n   - Respuesta: Los filtros est\u00e9riles de 0.22 micrones pueden eliminar bacterias y mohos, pero no son efectivos contra todos los virus o micoplasmas.\n\n3. **\u00bfPor qu\u00e9 se considera que la filtraci\u00f3n sola no es suficiente para la esterilizaci\u00f3n en el envase final?**\n   - Respuesta: La filtraci\u00f3n sola no es suficiente porque no elimina todos los tipos de microorganismos, especialmente algunos virus y micoplasmas. Se recomienda complementar la filtraci\u00f3n con alg\u00fan grado de tratamiento t\u00e9rmico, y cuando sea posible, la esterilizaci\u00f3n por vapor es preferida.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Dosimetr\u00eda y Medici\u00f3n de Radiaci\u00f3n**:\n   - Importancia de los dos\u00edmetros para medir la dosis de radiaci\u00f3n recibida por los productos.\n   - Recomendaciones sobre la cantidad y disposici\u00f3n de los dos\u00edmetros en la carga.\n   - Uso de dos\u00edmetros pl\u00e1sticos dentro de su tiempo de calibraci\u00f3n y lectura de absorbancia poco despu\u00e9s de la exposici\u00f3n.\n\n2. **Procedimientos de Validaci\u00f3n**:\n   - Necesidad de considerar las variaciones en la densidad de los paquetes durante la validaci\u00f3n.\n   - Protocolo para evitar la mezcla de materiales irradiados y no irradiados, incluyendo el uso de indicadores sensibles a la radiaci\u00f3n en cada paquete.\n\n3. **Esterilizaci\u00f3n por Gases y Fumigantes**:\n   - Uso restringido de gases y fumigantes (como \u00f3xido de etileno y vapor de per\u00f3xido de hidr\u00f3geno) solo para productos terminados sin alternativas adecuadas.\n   - Validaci\u00f3n del uso de \u00f3xido de etileno, asegurando que no cause da\u00f1o al producto y que los residuos se mantengan dentro de l\u00edmites aceptables.\n\n4. **Contacto Directo y Preparaci\u00f3n de Materiales**:\n   - Importancia del contacto directo entre el gas de esterilizaci\u00f3n y los microorganismos.\n   - Precauciones para evitar la presencia de organismos encerrados en materiales que puedan interferir con el proceso.\n   - Necesidad de equilibrar la humedad y temperatura de los materiales antes de la exposici\u00f3n al gas.\n\n5. **Monitoreo de Ciclos de Esterilizaci\u00f3n**:\n   - Cada ciclo de esterilizaci\u00f3n debe ser monitoreado con indicadores biol\u00f3gicos adecuados y un n\u00famero suficiente de piezas de prueba distribuidas.\n\n### Entidades Clave\n- **Dos\u00edmetros**: Dispositivos para medir la dosis de radiaci\u00f3n.\n- **\u00d3xido de Etileno**: Gas utilizado para la esterilizaci\u00f3n.\n- **Per\u00f3xido de Hidr\u00f3geno**: Otro gas utilizado para la esterilizaci\u00f3n.\n- **Indicadores Sensibles a la Radiaci\u00f3n**: Herramientas para identificar si un paquete ha sido irradiado.\n- **Microorganismos**: Organismos que deben ser eliminados durante el proceso de esterilizaci\u00f3n. \n\nEste resumen destaca los aspectos cr\u00edticos relacionados con la medici\u00f3n de la dosis de radiaci\u00f3n, los procedimientos de validaci\u00f3n, los m\u00e9todos de esterilizaci\u00f3n, y la importancia del monitoreo en los procesos de esterilizaci\u00f3n.", "excerpt_keywords": "Aseptic processing, Sterilization, Filtration, Microbial contamination, Steam sterilization"}}, "6ad93f16-51a1-43d2-803b-856ade15be1d": {"node_ids": ["7f6a22de-1b95-4922-b71d-e0172cbd75df"], "metadata": {"page_label": "241", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 7.5\n\nOwing to the potential additional risks of the filtration method as compared with other sterilization processes, a double-filter layer or second filtration through a further sterilized microorganism-retaining filter immediately prior to filling may be advisable. The final sterile filtration should be carried out as close as possible to the filling point.\n\n## 7.6\n\nThe fibre-shedding characteristics of filters should be minimal (virtually zero). Asbestos-containing filters should not be used under any circumstances.\n\n## 7.7\n\nThe integrity of the sterilized filter should be verified before use and should be confirmed immediately after use by an appropriate method such as a bubble point, diffusive flow or pressure hold test. The time taken to filter a known volume of bulk solution and the pressure difference to be used across the filter should be determined during validation and any significant differences from these during routine manufacturing should be noted and investigated. Results of these checks should be included in the batch record. The integrity of critical gas and air vent filters should be confirmed after use. The integrity of other filters should be confirmed at appropriate intervals. Consideration should be given to increased monitoring of filter integrity in processes that involve harsh conditions, e.g. the circulation of high-temperature air.\n\n## 7.8\n\nThe same filter should not be used for more than one working day unless such use has been validated.\n\n## 7.9\n\nThe filter should not affect the product either by removing ingredients from it or by releasing substances into it.\n\n# 8. Isolator technology\n\n## 8.1\n\nThe use of isolator technology to minimize human interventions in processing areas may result in a significant decrease in the risk of microbial contamination of aseptically manufactured products from the environment. There are many possible designs of isolators and transfer devices. The isolator and the background environment should be designed so that the required air quality for each zone can be realized. Isolators are constructed of various materials more or less prone to puncture and leakage. Transfer devices may vary from single-door to double-door designs to fully-sealed systems incorporating sterilization mechanisms.\n\n## 8.2\n\nThe transfer of materials into and out of the unit is one of the greatest potential sources of contamination. In general the area inside the isolator is the local zone for high-risk manipulations, although it is recognized that unidirectional airflow may not exist in the working zone of all isolators and transfer devices.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Filtraci\u00f3n y Esterilizaci\u00f3n**: Se discuten las mejores pr\u00e1cticas para la filtraci\u00f3n y esterilizaci\u00f3n de productos, enfatizando la importancia de la integridad de los filtros, la minimizaci\u00f3n de riesgos asociados con la filtraci\u00f3n y la necesidad de realizar pruebas de integridad antes y despu\u00e9s de su uso.\n\n2. **Tecnolog\u00eda de Aisladores**: Se aborda el uso de tecnolog\u00eda de aisladores para reducir la contaminaci\u00f3n microbiana en productos fabricados as\u00e9pticamente. Se mencionan diferentes dise\u00f1os de aisladores y dispositivos de transferencia, as\u00ed como la importancia de mantener la calidad del aire en estas \u00e1reas.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los m\u00e9todos recomendados para verificar la integridad de un filtro esterilizado antes y despu\u00e9s de su uso?**\n   - Respuesta: La integridad del filtro esterilizado debe ser verificada antes de su uso y confirmada inmediatamente despu\u00e9s mediante m\u00e9todos apropiados como la prueba de punto de burbuja, flujo difusivo o prueba de retenci\u00f3n de presi\u00f3n.\n\n2. **\u00bfQu\u00e9 caracter\u00edsticas deben tener los filtros en t\u00e9rminos de desprendimiento de fibras y qu\u00e9 materiales est\u00e1n prohibidos?**\n   - Respuesta: Las caracter\u00edsticas de desprendimiento de fibras de los filtros deben ser m\u00ednimas (pr\u00e1cticamente cero), y los filtros que contengan asbesto no deben ser utilizados bajo ninguna circunstancia.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al transferir materiales dentro y fuera de un aislador?**\n   - Respuesta: La transferencia de materiales es una de las mayores fuentes potenciales de contaminaci\u00f3n. Se reconoce que el \u00e1rea dentro del aislador es la zona local para manipulaciones de alto riesgo, y se debe tener en cuenta que el flujo de aire unidireccional puede no existir en todas las zonas de trabajo de los aisladores y dispositivos de transferencia.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Objetivo del Procesamiento Aseptico**:\n   - Mantener la esterilidad de un producto ensamblado a partir de componentes previamente esterilizados.\n\n2. **Condiciones Operativas**:\n   - Deben prevenir la contaminaci\u00f3n microbiana.\n\n3. **Factores Cr\u00edticos para Mantener la Esterilidad**:\n   - **Entorno**: Control del ambiente donde se realiza el procesamiento.\n   - **Personal**: Capacitaci\u00f3n y control de la higiene del personal involucrado.\n   - **Superficies Cr\u00edticas**: Mantenimiento de la limpieza y esterilidad de las superficies en contacto con el producto.\n   - **Procedimientos de Esterilizaci\u00f3n y Transferencia de Envases/Cierres**: M\u00e9todos adecuados para asegurar la esterilidad de los envases.\n   - **Tiempo M\u00e1ximo de Retenci\u00f3n**: Control del tiempo que el producto puede estar retenido antes de ser llenado en el envase final.\n   - **Filtro Esterilizante**: Uso de filtros adecuados para mantener la esterilidad.\n\n4. **Filtraci\u00f3n y Esterilizaci\u00f3n**:\n   - Uso de filtros est\u00e9riles de 0.22 micrones para soluciones que no pueden ser esterilizadas en el envase final.\n   - Limitaciones de los filtros: Efectivos contra bacterias y mohos, pero no contra todos los virus o micoplasmas.\n   - Recomendaci\u00f3n de complementar la filtraci\u00f3n con tratamiento t\u00e9rmico.\n   - Preferencia por la esterilizaci\u00f3n por vapor cuando es posible.\n\n### Entidades Clave\n- **Procesamiento Aseptico**\n- **Contaminaci\u00f3n Microbiana**\n- **Filtraci\u00f3n Esteril** \n- **Esterilizaci\u00f3n por Vapor**\n- **Microorganismos**: Bacterias, mohos, virus, micoplasmas. \n\nEste resumen destaca los aspectos fundamentales del procesamiento as\u00e9ptico y la esterilizaci\u00f3n por filtraci\u00f3n, as\u00ed como las consideraciones necesarias para mantener la esterilidad en productos farmac\u00e9uticos y biol\u00f3gicos.", "excerpt_keywords": "Keywords: filtration, sterilization, microbial contamination, isolator technology, air quality"}}, "f646d3cc-07fa-488f-86fe-a33eca9253dc": {"node_ids": ["e79f41df-6ff3-4acf-b03c-719013318091"], "metadata": {"page_label": "242", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 8.3 \nThe air classification required for the background environment depends on the design of the isolator and its application. It should be controlled, and for aseptic processing it should be at least grade D.\n\n8.4 \nIsolators should be introduced only after appropriate validation. Validation should take into account all critical factors of isolator technology, for example, the quality of the air inside and outside (background) the isolator, sanitization of the isolator, the transfer process and isolator integrity.\n\n8.5 \nMonitoring should be done routinely and should include frequent leak testing of the isolator and the glove/sleeve system.\n\n# 9. Blow/fill/seal technology\n\n9.1 \nBlow/fill/seal units are purpose-built machines in which, in one continuous operation, containers are formed from a thermoplastic granulate, filled and then sealed, all by the one automatic machine. Blow/fill/seal equipment used for aseptic production which is fitted with an effective grade A air shower may be installed in at least a grade C environment, provided that grade A or B clothing is used. The environment should comply with the viable and non-viable limits at rest and the viable limit only when in operation. Blow/fill/seal equipment used for the production of products which are terminally sterilized should be installed in at least a grade D environment.\n\n9.2 \nBecause of this special technology, particular attention should be paid to at least the following:\n\n- equipment design and qualification;\n- validation and reproducibility of cleaning-in-place and sterilization-in-place;\n- background clean room environment in which the equipment is located;\n- operator training and clothing; and\n- interventions in the critical zone of the equipment including any aseptic assembly prior to the commencement of filling.\n\n# 10. Personnel\n\n10.1 \nOnly the minimum number of personnel required should be present in clean areas; this is particularly important during aseptic processes. As far as possible, inspections and controls should be conducted from outside such areas.\n\n10.2 \nAll personnel (including those concerned with cleaning and maintenance) employed in such areas should receive initial and regular training in disciplines relevant to the correct manufacture of sterile products, including hygiene and the basic elements of microbiology. When outside", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Clasificaci\u00f3n del aire y validaci\u00f3n de aisladores**: La clasificaci\u00f3n del aire en el entorno de fondo de un aislador es crucial y debe ser al menos de grado D para procesos as\u00e9pticos. La introducci\u00f3n de aisladores debe estar precedida por una validaci\u00f3n adecuada que considere factores cr\u00edticos como la calidad del aire, la sanitizaci\u00f3n y la integridad del aislador.\n\n2. **Tecnolog\u00eda Blow/fill/seal**: Las unidades de tecnolog\u00eda Blow/fill/seal son m\u00e1quinas autom\u00e1ticas que forman, llenan y sellan contenedores en un solo proceso. Para la producci\u00f3n as\u00e9ptica, estas m\u00e1quinas deben estar en un entorno de al menos grado C, con ropa adecuada, y cumplir con l\u00edmites viables y no viables. La atenci\u00f3n especial debe prestarse a la validaci\u00f3n de limpieza y esterilizaci\u00f3n, as\u00ed como a la capacitaci\u00f3n del operador.\n\n3. **Personal en \u00e1reas limpias**: Es fundamental limitar el n\u00famero de personas en \u00e1reas limpias durante procesos as\u00e9pticos y realizar inspecciones desde el exterior cuando sea posible. Todo el personal debe recibir capacitaci\u00f3n regular en pr\u00e1cticas de fabricaci\u00f3n de productos est\u00e9riles, higiene y microbiolog\u00eda.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los factores cr\u00edticos que deben considerarse durante la validaci\u00f3n de un aislador en un entorno de producci\u00f3n as\u00e9ptica?**\n   - Respuesta: Los factores cr\u00edticos incluyen la calidad del aire dentro y fuera del aislador, la sanitizaci\u00f3n del aislador, el proceso de transferencia y la integridad del aislador.\n\n2. **\u00bfQu\u00e9 requisitos ambientales deben cumplirse para el equipo Blow/fill/seal utilizado en la producci\u00f3n as\u00e9ptica?**\n   - Respuesta: El equipo Blow/fill/seal debe estar instalado en un entorno de al menos grado C, siempre que se utilice ropa de grado A o B, y debe cumplir con los l\u00edmites viables y no viables en reposo y solo con el l\u00edmite viable en operaci\u00f3n.\n\n3. **\u00bfQu\u00e9 tipo de capacitaci\u00f3n deben recibir los empleados que trabajan en \u00e1reas limpias y por qu\u00e9 es importante?**\n   - Respuesta: Todos los empleados deben recibir capacitaci\u00f3n inicial y regular en disciplinas relevantes para la fabricaci\u00f3n correcta de productos est\u00e9riles, incluyendo higiene y microbiolog\u00eda, para asegurar la calidad y seguridad de los productos fabricados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### 1. Filtraci\u00f3n y Esterilizaci\u00f3n\n- **M\u00e9todos de Filtraci\u00f3n**: Se recomienda el uso de una capa de doble filtro o una segunda filtraci\u00f3n a trav\u00e9s de un filtro esterilizado que retenga microorganismos antes del llenado.\n- **Pruebas de Integridad**: Es crucial verificar la integridad de los filtros esterilizados antes y despu\u00e9s de su uso mediante pruebas como el punto de burbuja, flujo difusivo o prueba de retenci\u00f3n de presi\u00f3n.\n- **Caracter\u00edsticas de los Filtros**: Los filtros deben tener caracter\u00edsticas de desprendimiento de fibras m\u00ednimas (pr\u00e1cticamente cero) y no deben contener asbesto.\n- **Uso de Filtros**: Un filtro no debe utilizarse por m\u00e1s de un d\u00eda laboral a menos que su uso haya sido validado.\n- **Impacto en el Producto**: Los filtros no deben afectar el producto, ya sea eliminando ingredientes o liberando sustancias en \u00e9l.\n\n#### 2. Tecnolog\u00eda de Aisladores\n- **Minimizaci\u00f3n de Contaminaci\u00f3n**: La tecnolog\u00eda de aisladores se utiliza para reducir la intervenci\u00f3n humana en \u00e1reas de procesamiento, lo que disminuye el riesgo de contaminaci\u00f3n microbiana en productos fabricados as\u00e9pticamente.\n- **Dise\u00f1os de Aisladores**: Existen diversos dise\u00f1os de aisladores y dispositivos de transferencia, que deben garantizar la calidad del aire en cada zona.\n- **Transferencia de Materiales**: La transferencia de materiales dentro y fuera del aislador es una fuente significativa de contaminaci\u00f3n, y se reconoce que el flujo de aire unidireccional puede no estar presente en todas las zonas de trabajo.\n\n### Entidades Clave\n- **Filtros Esterilizados**: Dispositivos utilizados para asegurar la pureza de productos mediante la eliminaci\u00f3n de microorganismos.\n- **Aisladores**: Sistemas dise\u00f1ados para crear un ambiente controlado y minimizar la contaminaci\u00f3n durante la fabricaci\u00f3n as\u00e9ptica.\n- **Pruebas de Integridad**: M\u00e9todos utilizados para asegurar que los filtros funcionan correctamente y no comprometen la calidad del producto.\n\nEste resumen destaca la importancia de la filtraci\u00f3n y la tecnolog\u00eda de aisladores en la fabricaci\u00f3n as\u00e9ptica, as\u00ed como las mejores pr\u00e1cticas para garantizar la integridad y eficacia de los filtros utilizados en estos procesos.", "excerpt_keywords": "Keywords: air classification, isolators, blow/fill/seal technology, aseptic processing, personnel training"}}, "b1aad2e0-b19c-48e3-8761-93edc53777ef": {"node_ids": ["c35651ec-7c98-4e2c-829f-9c60234c8268"], "metadata": {"page_label": "243", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "staff who have not received such training (e.g. building or maintenance contractors) need to be brought in, particular care should be taken over their instruction and supervision.\n\n10.3 Staff who have been engaged in the processing of animal-tissue materials or of cultures of microorganisms other than those used in the current manufacturing process should not enter sterile-product areas unless rigorous and clearly defined decontamination procedures have been followed.\n\n10.4 High standards of personal hygiene and cleanliness are essential and personnel involved in the manufacture of sterile preparations should be instructed to report any conditions that may cause the shedding of abnormal numbers or types of contaminants; periodic health checks for such conditions are desirable. The action to be taken in respect of personnel who might be introducing undue microbial hazards should be decided by a designated competent person.\n\n10.5 Changing and washing should follow a written procedure designed to minimize the contamination of clean-area clothing or the carry-through of contaminants to clean areas. The clothing and its quality should be appropriate for the process and the grade of the working area. It should be worn in such a way as to protect the product from contamination.\n\n10.6 Outdoor clothing should not be brought into changing rooms leading to grade B and C rooms. For every worker in a grade A/B area, clean sterile (sterilized or adequately sanitized) protective garments should be provided at each work session. Gloves should be regularly disinfected during operations. Masks and gloves should be changed at least every working session. Operators working in grade A and B areas should wear sanitized goggles.\n\n10.7 Wrist-watches, cosmetics and jewellery should not be worn in clean areas.\n\n10.8 The clothing required for each grade is as follows:\n\n- **Grade D.** The hair and, where relevant, beard and moustache should be covered. Protective clothing and appropriate shoes or overshoes should be worn. Appropriate measures should be taken to avoid any contamination from outside the clean area.\n\n- **Grade C.** The hair and, where relevant, beard and moustache should be covered. A one-piece jumpsuit, gathered at the wrists and with a high neck, and appropriate shoes or overshoes should be worn. The clothing should shed virtually no fibres or particulate matter.\n\n- **Grades A and B.** Entry of personnel into grade A areas should be minimized. Headgear should totally enclose the hair and, where relevant, beard and moustache. A one-piece jumpsuit, gathered at the wrists and ", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl texto proporciona directrices sobre las normas de higiene y vestimenta para el personal que trabaja en \u00e1reas de productos est\u00e9riles, seg\u00fan diferentes grados de limpieza (D, C, A y B). Se enfatiza la importancia de la capacitaci\u00f3n del personal, la desinfecci\u00f3n de ropa y equipo, y la prohibici\u00f3n de ciertos objetos personales en \u00e1reas limpias. Tambi\u00e9n se menciona la necesidad de procedimientos de descontaminaci\u00f3n para el personal que ha trabajado con materiales de tejido animal o microorganismos.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 procedimientos de descontaminaci\u00f3n deben seguir los empleados que han trabajado con materiales de tejido animal antes de ingresar a \u00e1reas de productos est\u00e9riles?**\n   - La respuesta se encuentra en la secci\u00f3n 10.3, que menciona que el personal debe seguir procedimientos de descontaminaci\u00f3n rigurosos y claramente definidos.\n\n2. **\u00bfCu\u00e1les son las medidas espec\u00edficas que deben tomarse para la vestimenta del personal en \u00e1reas de grado A y B?**\n   - Seg\u00fan la secci\u00f3n 10.8, se requiere que el personal use un traje de una sola pieza que cubra completamente el cabello y, si es relevante, la barba y el bigote, y que se minimice la entrada de personal en estas \u00e1reas.\n\n3. **\u00bfQu\u00e9 tipo de controles de salud se recomiendan para el personal involucrado en la fabricaci\u00f3n de preparaciones est\u00e9riles?**\n   - La secci\u00f3n 10.4 sugiere que se deben realizar chequeos de salud peri\u00f3dicos para detectar condiciones que puedan causar la liberaci\u00f3n de contaminantes anormales.\n\n### Resumen de Nivel Superior\nEl documento establece normas estrictas para la higiene y vestimenta del personal en la fabricaci\u00f3n de productos est\u00e9riles, enfatizando la capacitaci\u00f3n adecuada, la desinfecci\u00f3n de ropa y la prohibici\u00f3n de objetos personales que puedan contaminar las \u00e1reas limpias. Se detallan los requisitos espec\u00edficos de vestimenta seg\u00fan el grado de limpieza y se subraya la importancia de la salud del personal para prevenir la introducci\u00f3n de contaminantes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Clasificaci\u00f3n del Aire y Aisladores**:\n   - **Clasificaci\u00f3n del aire**: Debe ser al menos de grado D para procesos as\u00e9pticos.\n   - **Validaci\u00f3n de aisladores**: Implica considerar la calidad del aire, la sanitizaci\u00f3n, el proceso de transferencia y la integridad del aislador.\n   - **Monitoreo**: Se debe realizar de manera rutinaria, incluyendo pruebas de fugas.\n\n2. **Tecnolog\u00eda Blow/fill/seal**:\n   - **Definici\u00f3n**: M\u00e1quinas autom\u00e1ticas que forman, llenan y sellan contenedores en un solo proceso.\n   - **Requisitos ambientales**: Deben estar en un entorno de al menos grado C con ropa de grado A o B, cumpliendo con l\u00edmites viables y no viables.\n   - **Atenci\u00f3n especial**: Dise\u00f1o y calificaci\u00f3n del equipo, validaci\u00f3n de limpieza y esterilizaci\u00f3n, entorno de sala limpia, capacitaci\u00f3n del operador e intervenciones en la zona cr\u00edtica.\n\n3. **Personal en \u00c1reas Limpias**:\n   - **Limitaci\u00f3n de personal**: Solo el n\u00famero m\u00ednimo necesario debe estar presente durante procesos as\u00e9pticos.\n   - **Capacitaci\u00f3n**: Todo el personal debe recibir formaci\u00f3n inicial y regular en fabricaci\u00f3n de productos est\u00e9riles, higiene y microbiolog\u00eda.\n\n### Entidades Clave:\n- **Aisladores**: Equipos utilizados en procesos as\u00e9pticos.\n- **Tecnolog\u00eda Blow/fill/seal**: M\u00e9todo de producci\u00f3n automatizado para envases.\n- **Grados de ambiente**: Clasificaciones que determinan la calidad del aire en \u00e1reas de producci\u00f3n (Grado A, B, C, D).\n- **Personal**: Empleados que trabajan en \u00e1reas limpias, incluyendo limpieza y mantenimiento. \n\nEste resumen destaca la importancia de la clasificaci\u00f3n del aire, la validaci\u00f3n de equipos, el entorno de producci\u00f3n y la capacitaci\u00f3n del personal en la fabricaci\u00f3n de productos est\u00e9riles.", "excerpt_keywords": "Keywords: sterile preparations, personal hygiene, decontamination procedures, clean areas, protective clothing"}}, "0fa4b35b-e261-4123-a960-feb4da553cab": {"node_ids": ["ef57c94b-381e-44e9-8d86-ef74661e97be"], "metadata": {"page_label": "244", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Premises\n\n11.1 All premises should as far as possible be designed to avoid the unnecessary entry of supervisory or control personnel. Grade A and B areas should be designed so that all operations can be observed from outside.\n\n11.2 In clean areas all exposed surfaces should be smooth, impervious and unbroken to minimize the shedding or accumulation of particles or microorganisms and to permit the repeated application of cleaning agents and disinfectants, where used.\n\n11.3 To reduce the accumulation of dust and to facilitate cleaning, there should be no uncleanable recesses and a minimum of projecting ledges, shelves, cupboards and equipment. Doors should be carefully designed to avoid uncleanable recesses; sliding doors may be undesirable for this reason. Swing doors should open to the high-pressure side and be provided with self-closers. Exceptions are permitted based on egress and site environmental, health and safety containment requirements.\n\n11.4 False ceilings should be sealed to prevent contamination from the void space above them.\n\n11.5 Pipes and ducts and other utilities should be installed so that they do not create recesses, unsealed openings and surfaces that are difficult to clean. Sanitary pipes and fittings should be used and threaded pipe connections should be avoided.\n\n11.6 Sinks and drains should be avoided wherever possible and should be excluded from grade A and B areas where aseptic operations are carried out. Where installed they should be designed, located and maintained so as to minimize the risks of microbial contamination; they should be fitted with", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proviene del \"Informe T\u00e9cnico de la OMS 957\" y se centra en las directrices para el dise\u00f1o y mantenimiento de instalaciones limpias, espec\u00edficamente en \u00e1reas clasificadas como Grado A y B. Se enfatiza la importancia de minimizar la entrada de personal no esencial, el dise\u00f1o de superficies para facilitar la limpieza y la prevenci\u00f3n de la contaminaci\u00f3n microbiana. Se abordan aspectos como la construcci\u00f3n de techos falsos, la instalaci\u00f3n de tuber\u00edas y desag\u00fces, y la necesidad de evitar recovecos que dificulten la limpieza.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que deben tener las superficies expuestas en \u00e1reas limpias para minimizar la acumulaci\u00f3n de part\u00edculas y microorganismos?**\n   - Respuesta: Las superficies expuestas en \u00e1reas limpias deben ser lisas, impermeables y sin interrupciones para minimizar la acumulaci\u00f3n de part\u00edculas y microorganismos, y permitir la aplicaci\u00f3n repetida de agentes de limpieza y desinfectantes.\n\n2. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al dise\u00f1ar puertas en \u00e1reas limpias para evitar la acumulaci\u00f3n de polvo y facilitar la limpieza?**\n   - Respuesta: Las puertas deben ser dise\u00f1adas para evitar recovecos no limpiables, preferiblemente deben ser puertas de oscilaci\u00f3n que abran hacia el lado de alta presi\u00f3n y deben estar equipadas con mecanismos de cierre autom\u00e1tico. Las puertas deslizantes pueden ser indeseables por esta raz\u00f3n.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar en relaci\u00f3n con los desag\u00fces y fregaderos en \u00e1reas de Grado A y B donde se realizan operaciones as\u00e9pticas?**\n   - Respuesta: Los fregaderos y desag\u00fces deben evitarse siempre que sea posible en \u00e1reas de Grado A y B. Si se instalan, deben ser dise\u00f1ados, ubicados y mantenidos de tal manera que minimicen los riesgos de contaminaci\u00f3n microbiana.", "prev_section_summary": "### Temas Clave\n\n1. **Capacitaci\u00f3n del Personal**: Se enfatiza la necesidad de que el personal reciba capacitaci\u00f3n adecuada, especialmente aquellos que no han sido entrenados, como contratistas de mantenimiento.\n\n2. **Procedimientos de Descontaminaci\u00f3n**: El personal que ha trabajado con materiales de tejido animal o microorganismos debe seguir procedimientos de descontaminaci\u00f3n rigurosos antes de ingresar a \u00e1reas de productos est\u00e9riles.\n\n3. **Higiene Personal**: Se requiere que el personal mantenga altos est\u00e1ndares de higiene y limpieza, reportando cualquier condici\u00f3n que pueda causar la liberaci\u00f3n de contaminantes.\n\n4. **Controles de Salud**: Se sugieren chequeos de salud peri\u00f3dicos para detectar condiciones que puedan introducir contaminantes.\n\n5. **Procedimientos de Cambio y Lavado**: Deben seguirse procedimientos escritos para minimizar la contaminaci\u00f3n de la ropa en \u00e1reas limpias.\n\n6. **Vestimenta Espec\u00edfica por Grado**: Se detallan los requisitos de vestimenta seg\u00fan el grado de limpieza (D, C, A y B), incluyendo el uso de trajes de una sola pieza y la prohibici\u00f3n de ropa exterior en \u00e1reas cr\u00edticas.\n\n7. **Prohibiciones en \u00c1reas Limpias**: Se proh\u00edbe el uso de relojes, cosm\u00e9ticos y joyer\u00eda en \u00e1reas limpias para evitar la contaminaci\u00f3n.\n\n### Entidades\n\n- **Grados de Limpieza**: D, C, A y B.\n- **Personal**: Empleados involucrados en la fabricaci\u00f3n de preparaciones est\u00e9riles, contratistas de mantenimiento.\n- **Contaminantes**: Materiales de tejido animal, microorganismos, contaminantes anormales.\n- **Equipamiento**: Ropa protectora, guantes, mascarillas, gafas sanitizadas.\n- **Procedimientos**: Descontaminaci\u00f3n, higiene personal, cambio y lavado de ropa.\n\nEste resumen destaca la importancia de la capacitaci\u00f3n, la higiene y el cumplimiento de normas espec\u00edficas para garantizar la seguridad y la calidad en la fabricaci\u00f3n de productos est\u00e9riles.", "excerpt_keywords": "Keywords: clean areas, microbial contamination, aseptic operations, facility design, hygiene standards"}}, "07ec0554-fb64-4158-b2f6-786622d47c5c": {"node_ids": ["06cb7ed4-7c2d-42d5-a9fe-9e77c0ca46ee"], "metadata": {"page_label": "245", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "effective, easily cleanable traps and with air breaks to prevent backflow. Any floor channels should be open and easily cleanable and be connected to drains outside the area in a manner that prevents the ingress of microbial contaminants.\n\n11.7 Changing rooms should be designed as airlocks and used to provide physical separation of the different stages of changing and so minimize microbial and particulate contamination of protective clothing. They should be flushed effectively with filtered air. The final stage of the changing room should, in the at-rest state, be the same grade as the area into which it leads. The use of separate changing rooms for entering and leaving clean areas is sometimes desirable. In general hand-washing facilities should be provided only in the first stage of the changing rooms.\n\nThere should not be a change of more than one grade between airlocks or passages and changing rooms, i.e. a grade D passage can lead to a grade C airlock, which leads to a grade B changing room, which leads to a grade B clean room. Changing rooms should of a sufficient size to allow for ease of changing. Changing rooms should be equipped with mirrors so that personnel can confirm the correct fit of garments before leaving the changing room.\n\n11.8 Airlock doors should not be opened simultaneously. An interlocking system and a visual and/or audible warning system should be operated to prevent the opening of more than one door at a time.\n\n11.9 A filtered air supply should be used to maintain a positive pressure and an airflow relative to surrounding areas of a lower grade under all operational conditions; it should flush the area effectively. Adjacent rooms of different grades should have a pressure differential of approximately 10\u201315 Pascals (guidance value). Particular attention should be paid to the protection of the zone of greatest risk, i.e. the immediate environment to which the product and the cleaned components in contact with it are exposed. The recommendations regarding air supplies and pressure differentials may need to be modified where it becomes necessary to contain certain materials, e.g. pathogenic, highly toxic, radioactive or live viral or bacterial materials or products. The decontamination of the facilities and the treatment of air leaving a clean area may be necessary for some operations.\n\n11.10 It should be demonstrated that airflow patterns do not present a contamination risk; for example, care should be taken to ensure that particles from a particle-generating person, operation or machine are not conveyed to a zone of higher product risk.\n\n11.11 A warning system should be operated to indicate failure in the air supply. Indicators of pressure differentials should be fitted between areas.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proviene del Informe T\u00e9cnico de la OMS (WHO - Technical Report Series 957) y se centra en las recomendaciones para el dise\u00f1o y funcionamiento de \u00e1reas limpias, espec\u00edficamente en lo que respecta a los vestuarios y sistemas de aire. Se enfatiza la importancia de mantener la separaci\u00f3n f\u00edsica entre diferentes etapas de cambio de ropa para minimizar la contaminaci\u00f3n microbiana y particulada. Se describen las caracter\u00edsticas de los vestuarios, la necesidad de un suministro de aire filtrado, la presi\u00f3n diferencial entre \u00e1reas de diferentes grados, y la implementaci\u00f3n de sistemas de advertencia para fallos en el suministro de aire.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que deben tener los vestuarios para minimizar la contaminaci\u00f3n en \u00e1reas limpias?**\n   - Esta pregunta busca detalles sobre el dise\u00f1o y las especificaciones de los vestuarios que no se encuentran f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que las puertas de los vestuarios no se abran simult\u00e1neamente y por qu\u00e9 es importante esto?**\n   - Esta pregunta se centra en el sistema de interlocking y su importancia en la prevenci\u00f3n de la contaminaci\u00f3n, un aspecto que puede no ser ampliamente discutido en otros documentos.\n\n3. **\u00bfC\u00f3mo se debe manejar el suministro de aire en \u00e1reas limpias para mantener la presi\u00f3n positiva y qu\u00e9 consideraciones especiales se deben tener en cuenta para materiales peligrosos?**\n   - Esta pregunta busca informaci\u00f3n sobre el manejo del aire en \u00e1reas limpias, especialmente en relaci\u00f3n con materiales que requieren un manejo especial, lo cual puede no estar presente en otras gu\u00edas generales. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y t\u00e9cnica que se detalla en el contexto proporcionado, y que podr\u00eda no estar disponible en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Dise\u00f1o de Instalaciones Limpias**:\n   - Las instalaciones deben evitar la entrada innecesaria de personal no esencial.\n   - Las \u00e1reas de Grado A y B deben permitir la observaci\u00f3n de todas las operaciones desde el exterior.\n\n2. **Superficies Expuestas**:\n   - Deben ser lisas, impermeables y sin interrupciones para minimizar la acumulaci\u00f3n de part\u00edculas y microorganismos.\n   - Se debe permitir la aplicaci\u00f3n repetida de agentes de limpieza y desinfectantes.\n\n3. **Dise\u00f1o de Puertas**:\n   - Las puertas deben evitar recovecos no limpiables.\n   - Preferiblemente, deben ser puertas de oscilaci\u00f3n que abran hacia el lado de alta presi\u00f3n y contar con mecanismos de cierre autom\u00e1tico.\n   - Las puertas deslizantes son indeseables por su dise\u00f1o.\n\n4. **Techos Falsos**:\n   - Deben estar sellados para prevenir la contaminaci\u00f3n desde el espacio vac\u00edo superior.\n\n5. **Instalaci\u00f3n de Tuber\u00edas y Ductos**:\n   - Deben evitar la creaci\u00f3n de recovecos, aberturas no selladas y superficies dif\u00edciles de limpiar.\n   - Se deben utilizar tuber\u00edas y accesorios sanitarios, evitando conexiones de tuber\u00edas roscadas.\n\n6. **Desag\u00fces y Fregaderos**:\n   - Deben evitarse en \u00e1reas de Grado A y B donde se realizan operaciones as\u00e9pticas.\n   - Si se instalan, deben ser dise\u00f1ados y mantenidos para minimizar el riesgo de contaminaci\u00f3n microbiana.\n\n### Entidades Clave\n- **Grado A y B**: Clasificaci\u00f3n de \u00e1reas limpias.\n- **Personal Supervisorio**: Personal que no debe ingresar innecesariamente a las \u00e1reas limpias.\n- **Agentes de Limpieza y Desinfectantes**: Sustancias utilizadas para mantener la limpieza y la asepsia.\n- **Contaminaci\u00f3n Microbiana**: Riesgo que se busca minimizar en el dise\u00f1o de las instalaciones.", "excerpt_keywords": "Keywords: \u00e1reas limpias, vestuarios, presi\u00f3n positiva, contaminaci\u00f3n microbiana, sistemas de advertencia"}}, "91809c1e-c2bd-4b92-9116-1282c1e622a8": {"node_ids": ["44709eda-106f-4441-9477-34dd8e8ffdda"], "metadata": {"page_label": "246", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Equipment\n\n12.1 A conveyor belt should not pass through a partition between a grade A or B clean area and a processing area of lower air cleanliness, unless the belt itself is continuously sterilized (e.g. in a sterilizing tunnel).\n\n12.2 Whenever possible, equipment used for processing sterile products should be chosen so that it can be effectively sterilized by steam or dry heat or other methods.\n\n12.3 As far as possible, equipment fittings and services should be designed and installed so that operations, maintenance and repairs can be carried out outside the clean area. Equipment that has to be taken apart for maintenance should be re-sterilized after complete reassembly, wherever possible.\n\n12.4 When equipment maintenance is carried out within a clean area, clean instruments and tools should be used and the area should be cleaned and disinfected again, where appropriate, before processing recommences, if the required standards of cleanliness and/or asepsis have not been maintained during the maintenance work.\n\n12.5 All equipment such as sterilizers, air-handling and filtration systems, air vent and gas filters, water treatment, generation, storage and distribution systems should be subject to validation and planned maintenance; their return to use should be approved.\n\n12.6 Water-treatment plants and distribution systems should be designed, constructed and maintained so as to ensure a reliable source of water of an appropriate quality. They should not be operated beyond their designed capacity. Consideration should be given to including a testing programme in the maintenance of a water system. Water for injection should be produced, stored and distributed in a manner which prevents the growth of microorganisms, e.g. by constant circulation at a temperature above 70\u00b0C or not more than 4\u00b0C (10).\n\n# Finishing of sterile products\n\n13.1 Containers should be closed by appropriately validated methods. Containers closed by fusion, e.g. glass or plastic ampoules, should be subject to 100% integrity testing. Samples of other containers should be checked for integrity according to appropriate procedures.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen de nivel superior del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las directrices sobre el equipo utilizado en la producci\u00f3n de productos est\u00e9riles. Se enfatiza la importancia de mantener la limpieza y la esterilidad en las \u00e1reas de procesamiento, as\u00ed como la necesidad de validar y mantener el equipo utilizado. Tambi\u00e9n se menciona la gesti\u00f3n del agua para inyecci\u00f3n, asegurando que se produzca y distribuya de manera que se evite el crecimiento de microorganismos. Adem\u00e1s, se establecen procedimientos para el cierre de contenedores de productos est\u00e9riles, destacando la necesidad de pruebas de integridad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 m\u00e9todos se recomiendan para la esterilizaci\u00f3n continua de una cinta transportadora que atraviesa una partici\u00f3n entre \u00e1reas de limpieza de diferentes grados?**\n   - Respuesta: La cinta transportadora debe ser continuamente esterilizada, por ejemplo, en un t\u00fanel de esterilizaci\u00f3n.\n\n2. **\u00bfCu\u00e1les son las consideraciones clave para el dise\u00f1o y mantenimiento de plantas de tratamiento de agua utilizadas en la producci\u00f3n de productos est\u00e9riles?**\n   - Respuesta: Las plantas de tratamiento de agua deben ser dise\u00f1adas, construidas y mantenidas para asegurar una fuente confiable de agua de calidad apropiada, no deben operar m\u00e1s all\u00e1 de su capacidad dise\u00f1ada, y se debe considerar un programa de pruebas en el mantenimiento del sistema de agua.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse para garantizar la integridad de los contenedores cerrados por fusi\u00f3n, como ampollas de vidrio o pl\u00e1stico?**\n   - Respuesta: Los contenedores cerrados por fusi\u00f3n deben someterse a pruebas de integridad al 100%, y las muestras de otros contenedores deben ser verificadas seg\u00fan procedimientos apropiados.", "prev_section_summary": "### Temas Clave\n\n1. **Dise\u00f1o de Vestuarios**: Los vestuarios deben ser dise\u00f1ados como airlocks para proporcionar separaci\u00f3n f\u00edsica entre las etapas de cambio de ropa, minimizando as\u00ed la contaminaci\u00f3n microbiana y particulada. Deben estar equipados con aire filtrado y ser de un tama\u00f1o adecuado para facilitar el cambio.\n\n2. **Sistemas de Aire**: Es esencial mantener un suministro de aire filtrado para mantener una presi\u00f3n positiva y un flujo de aire adecuado. Se recomienda una diferencia de presi\u00f3n de aproximadamente 10\u201315 Pascals entre \u00e1reas de diferentes grados.\n\n3. **Control de Contaminaci\u00f3n**: Se deben implementar sistemas que eviten la apertura simult\u00e1nea de puertas en los airlocks, utilizando sistemas de interlocking y advertencias visuales o audibles para prevenir la contaminaci\u00f3n cruzada.\n\n4. **Manejo de Materiales Peligrosos**: Las recomendaciones sobre el suministro de aire y las diferencias de presi\u00f3n pueden necesitar ajustes cuando se manejan materiales peligrosos, como pat\u00f3genos o sustancias t\u00f3xicas.\n\n5. **Patrones de Flujo de Aire**: Es crucial demostrar que los patrones de flujo de aire no representan un riesgo de contaminaci\u00f3n, asegurando que las part\u00edculas generadas no se transporten a zonas de mayor riesgo.\n\n6. **Sistemas de Advertencia**: Se deben instalar sistemas de advertencia para indicar fallos en el suministro de aire y para monitorear las diferencias de presi\u00f3n entre \u00e1reas.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las recomendaciones.\n- **Aire Filtrado**: Elemento clave para mantener la calidad del aire en \u00e1reas limpias.\n- **Vestuario/Airlock**: Espacio dise\u00f1ado para minimizar la contaminaci\u00f3n durante el cambio de ropa.\n- **Diferencia de Presi\u00f3n**: Par\u00e1metro cr\u00edtico para el control de la contaminaci\u00f3n entre \u00e1reas de diferentes grados.\n- **Materiales Peligrosos**: Sustancias que requieren manejo especial debido a su toxicidad o riesgo biol\u00f3gico.\n- **Sistema de Interlocking**: Mecanismo para prevenir la apertura simult\u00e1nea de puertas en los vestuarios. \n\nEste resumen abarca los aspectos m\u00e1s relevantes del contenido, destacando tanto los temas centrales como las entidades involucradas en el contexto de las \u00e1reas limpias y su dise\u00f1o.", "excerpt_keywords": "Keywords: sterilization, clean area, equipment maintenance, water treatment, integrity testing"}}, "4249ea8c-f6cf-435a-a15f-cb53aaa1898e": {"node_ids": ["12b433c8-61ac-42f8-8bf1-01a026c8b818"], "metadata": {"page_label": "247", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 13.2 \nThe container closure system for aseptically filled vials is not fully integral until the aluminum cap has been crimped into place on the stoppered vial. Crimping of the cap should, therefore, be performed as soon as possible after stopper insertion.\n\n# 13.3 \nAs the equipment used to crimp vial caps can generate large quantities of non-viable particulates, the equipment should be located at a separate station equipped with adequate air extraction.\n\n# 13.4 \nVial capping can be undertaken as an aseptic process using sterilized caps or as a clean process outside the aseptic core. Where this latter approach is adopted, vials should be protected by grade A conditions up to the point of leaving the aseptic processing area, and thereafter stoppered vials should be protected with a grade A air supply until the cap has been crimped.\n\n# 13.5 \nVials with missing or displaced stoppers should be rejected prior to capping. Where human intervention is required at the capping station, appropriate technology should be used to prevent direct contact with the vials and to minimize microbial contamination.\n\n# 13.6 \nRestricted access barriers and isolators may be beneficial in assuring the required conditions and minimizing direct human interventions into the capping operation.\n\n# 13.7 \nContainers sealed under vacuum should be tested for maintenance of that vacuum after an appropriate, predetermined period.\n\n# 13.8 \nFilled containers of parenteral products should be inspected individually for extraneous contamination or other defects. When inspection is carried out visually this should be done under suitable and controlled conditions of illumination and background. Operators doing the inspection should pass regular eyesight checks, using personal corrective lenses (e.g. spectacles or contact lenses) as required, and be allowed frequent breaks from inspection. Where other methods of inspection are used, the process should be validated and the performance of the equipment checked at intervals. Results should be recorded.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Cierre de viales y proceso de capping**: El sistema de cierre de los viales llenos de forma as\u00e9ptica no se considera completo hasta que la tapa de aluminio ha sido crimpada. Este proceso debe realizarse lo m\u00e1s pronto posible despu\u00e9s de insertar el tap\u00f3n, y se deben seguir estrictas medidas de control para evitar la contaminaci\u00f3n.\n\n2. **Control de contaminaci\u00f3n y condiciones de trabajo**: La maquinaria utilizada para crimpado puede generar part\u00edculas no viables, por lo que debe estar ubicada en una estaci\u00f3n separada con adecuada extracci\u00f3n de aire. Adem\u00e1s, se deben implementar barreras de acceso restringido y aisladores para minimizar la intervenci\u00f3n humana.\n\n3. **Inspecci\u00f3n de viales**: Los viales deben ser inspeccionados individualmente para detectar contaminaci\u00f3n o defectos, y esta inspecci\u00f3n debe realizarse bajo condiciones controladas. Los operadores deben tener buena visi\u00f3n y se deben registrar los resultados de las inspecciones.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1l es el procedimiento recomendado para el manejo de viales con tapones faltantes o desplazados antes del proceso de capping?**\n   - Respuesta: Los viales con tapones faltantes o desplazados deben ser rechazados antes de proceder al capping.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que el proceso de capping minimice la contaminaci\u00f3n microbiana cuando se requiere intervenci\u00f3n humana?**\n   - Respuesta: Se debe utilizar tecnolog\u00eda apropiada para prevenir el contacto directo con los viales y minimizar la contaminaci\u00f3n microbiana en el capping.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse para la inspecci\u00f3n visual de los viales llenos de productos parenterales?**\n   - Respuesta: La inspecci\u00f3n visual debe realizarse bajo condiciones adecuadas de iluminaci\u00f3n y fondo, y los operadores deben pasar chequeos regulares de visi\u00f3n, utilizando lentes correctivos si es necesario, adem\u00e1s de permitirles descansos frecuentes.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**Temas clave:**\n\n1. **Esterilizaci\u00f3n de Equipos:**\n   - Importancia de la esterilizaci\u00f3n continua de cintas transportadoras que cruzan particiones entre \u00e1reas de limpieza de diferentes grados.\n   - Preferencia por equipos que puedan ser esterilizados efectivamente mediante m\u00e9todos como vapor o calor seco.\n\n2. **Dise\u00f1o y Mantenimiento de Equipos:**\n   - Equipos deben ser dise\u00f1ados para permitir operaciones y mantenimiento fuera de \u00e1reas limpias.\n   - Re-esterilizaci\u00f3n de equipos despu\u00e9s de mantenimiento, cuando sea posible.\n\n3. **Mantenimiento en \u00c1reas Limpias:**\n   - Uso de instrumentos y herramientas limpias durante el mantenimiento.\n   - Limpieza y desinfecci\u00f3n del \u00e1rea antes de reanudar el procesamiento si no se mantienen los est\u00e1ndares de limpieza.\n\n4. **Validaci\u00f3n y Mantenimiento Planificado:**\n   - Equipos como esterilizadores y sistemas de tratamiento de agua deben ser validados y sometidos a mantenimiento planificado.\n\n5. **Calidad del Agua:**\n   - Plantas de tratamiento de agua deben asegurar una fuente confiable de agua de calidad adecuada.\n   - Prevenci\u00f3n del crecimiento de microorganismos en agua para inyecci\u00f3n mediante circulaci\u00f3n constante a temperaturas espec\u00edficas.\n\n6. **Cierre de Contenedores:**\n   - M\u00e9todos de cierre de contenedores deben ser validados.\n   - Contenedores cerrados por fusi\u00f3n deben someterse a pruebas de integridad al 100%.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite las directrices.\n- **Equipos de Procesamiento:** Incluyen cintas transportadoras, esterilizadores, sistemas de tratamiento de agua, etc.\n- **Contenedores:** Ampollas de vidrio o pl\u00e1stico y otros tipos de envases para productos est\u00e9riles.\n- **M\u00e9todos de Esterilizaci\u00f3n:** Vapor, calor seco, t\u00faneles de esterilizaci\u00f3n.\n- **Agua para Inyecci\u00f3n:** Agua tratada y distribuida para uso en productos est\u00e9riles. \n\nEste resumen destaca la importancia de la esterilidad y el mantenimiento adecuado en la producci\u00f3n de productos est\u00e9riles, as\u00ed como las pr\u00e1cticas recomendadas para garantizar la calidad y seguridad de los procesos involucrados.", "excerpt_keywords": "Keywords: aseptic processing, vial capping, contamination control, inspection procedures, sterile products"}}, "fc403379-c18d-494f-95c5-a2e56a41305f": {"node_ids": ["b6bba9e1-db1c-4fc8-8060-9437b2cd8f6d"], "metadata": {"page_label": "248", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. Good manufacturing practices for sterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 6 (WHO Technical Report Series, No. 902); and in *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.\n\n2. ISO 14644-1. *Clean rooms and associated controlled environments. Part 1: Classification of airborne particles*. Geneva, International Organization for Standardization.\n\n3. FDA Guidance for Industry. *Sterile drug products produced by aseptic processing \u2014 cGMP*. US Food and Drug Administration, 2004.\n\n4. Guidance for industry. *Sterile drug products produced by aseptic processing*. Japan, 2005.\n\n5. Manufacture of sterile medicinal products. In: *The rules governing medicinal products in the European Union Vol. 4. EU guidelines to good manufacturing practice medicinal products for human and veterinary use*. Annex 1, Brussels, 2008.\n\n6. ISO 14644-3. *Clean rooms and associated controlled environments. Part 3: Test methods*. Geneva, International Organization for Standardization.\n\n7. ISO 14644-4. *Clean rooms and associated controlled environments. Part 4: Design, construction and start-up*. Geneva, International Organization for Standardization.\n\n8. ISO 14644-2. *Clean rooms and associated controlled environments. Part 2: Monitoring for continued compliance with ISO 14644-1*. Geneva, International Organization for Standardization.\n\n9. ISO 14644-5. *Clean rooms and associated controlled environments. Part 5: Cleanroom operations*. Geneva, International Organization for Standardization.\n\n10. Good manufacturing practices for pharmaceutical products: water for pharmaceutical use. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005, Annex 3 (WHO Technical Report Series, No. 929); and in *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que se centra en las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para productos farmac\u00e9uticos est\u00e9riles. Incluye referencias a normas internacionales, gu\u00edas de la FDA y regulaciones de la Uni\u00f3n Europea sobre la producci\u00f3n y control de productos farmac\u00e9uticos est\u00e9riles. Se mencionan varias normas ISO relacionadas con salas limpias y entornos controlados, as\u00ed como directrices espec\u00edficas para la producci\u00f3n de medicamentos est\u00e9riles.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales diferencias entre las normas ISO 14644-1 y ISO 14644-2 en el contexto de las salas limpias?**\n   - Esta pregunta busca una comparaci\u00f3n espec\u00edfica entre dos normas ISO que son fundamentales para la clasificaci\u00f3n y el monitoreo de la calidad del aire en salas limpias, lo que no se detalla en el contexto.\n\n2. **\u00bfQu\u00e9 aspectos espec\u00edficos se abordan en el Anexo 1 de las directrices de la Uni\u00f3n Europea sobre la fabricaci\u00f3n de productos medicinales est\u00e9riles?**\n   - Esta pregunta se centra en el contenido del Anexo 1 mencionado en el contexto, que podr\u00eda contener detalles t\u00e9cnicos y requisitos que no est\u00e1n expl\u00edcitamente descritos en el resumen.\n\n3. **\u00bfQu\u00e9 recomendaciones espec\u00edficas proporciona la FDA en su gu\u00eda sobre productos farmac\u00e9uticos est\u00e9riles producidos mediante procesamiento as\u00e9ptico?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre las recomendaciones de la FDA, que pueden incluir pr\u00e1cticas y procedimientos espec\u00edficos que no se encuentran en el contexto proporcionado.\n\n### Resumen de Nivel Superior\n\nEl informe de la OMS proporciona un marco normativo y directrices sobre las buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles, destacando la importancia de la calidad y la seguridad en la producci\u00f3n. Se hace referencia a varias normas ISO y gu\u00edas de diferentes organismos reguladores, lo que subraya la necesidad de cumplir con est\u00e1ndares internacionales para garantizar la eficacia y seguridad de los productos farmac\u00e9uticos.\n\n### Preguntas Adicionales Basadas en el Resumen\n\n1. **\u00bfC\u00f3mo se relacionan las buenas pr\u00e1cticas de fabricaci\u00f3n de la OMS con las normas ISO y las gu\u00edas de la FDA en t\u00e9rminos de cumplimiento y regulaci\u00f3n?**\n   - Esta pregunta busca explorar la interconexi\u00f3n entre las directrices de la OMS y otros est\u00e1ndares internacionales, lo que puede proporcionar una visi\u00f3n m\u00e1s amplia de la regulaci\u00f3n en la industria farmac\u00e9utica.\n\n2. **\u00bfQu\u00e9 impacto tienen las buenas pr\u00e1cticas de fabricaci\u00f3n en la calidad de los productos farmac\u00e9uticos est\u00e9riles seg\u00fan el informe de la OMS?**\n   - Esta pregunta se centra en la relaci\u00f3n entre las BPF y la calidad del producto, lo que puede ofrecer informaci\u00f3n sobre la importancia de seguir estas directrices.\n\n3. **\u00bfCu\u00e1les son los desaf\u00edos comunes que enfrentan las empresas al implementar las buenas pr\u00e1cticas de fabricaci\u00f3n para productos est\u00e9riles?**\n   - Esta pregunta busca identificar los obst\u00e1culos que las empresas pueden encontrar al intentar cumplir con las regulaciones y est\u00e1ndares mencionados en el informe.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistema de Cierre de Viales**:\n   - El sistema de cierre de los viales llenos de forma as\u00e9ptica no se considera completo hasta que la tapa de aluminio ha sido crimpada.\n   - Se recomienda realizar el crimpado lo m\u00e1s pronto posible despu\u00e9s de insertar el tap\u00f3n.\n\n2. **Control de Contaminaci\u00f3n**:\n   - La maquinaria para crimpado puede generar part\u00edculas no viables, por lo que debe estar en una estaci\u00f3n separada con adecuada extracci\u00f3n de aire.\n   - Se deben implementar barreras de acceso restringido y aisladores para minimizar la intervenci\u00f3n humana.\n\n3. **Proceso de Capping**:\n   - El capping puede ser un proceso as\u00e9ptico con tapas esterilizadas o un proceso limpio fuera del n\u00facleo as\u00e9ptico.\n   - Los viales deben estar protegidos por condiciones de grado A hasta que se complete el crimpado.\n\n4. **Manejo de Viales Defectuosos**:\n   - Los viales con tapones faltantes o desplazados deben ser rechazados antes del capping.\n   - Se debe utilizar tecnolog\u00eda adecuada para evitar el contacto directo y minimizar la contaminaci\u00f3n microbiana.\n\n5. **Inspecci\u00f3n de Viales**:\n   - Los viales llenos de productos parenterales deben ser inspeccionados individualmente para detectar contaminaci\u00f3n o defectos.\n   - La inspecci\u00f3n visual debe realizarse bajo condiciones controladas de iluminaci\u00f3n y fondo, y los operadores deben pasar chequeos regulares de visi\u00f3n.\n\n6. **Mantenimiento de Vac\u00edo**:\n   - Los contenedores sellados al vac\u00edo deben ser probados para asegurar el mantenimiento del vac\u00edo despu\u00e9s de un per\u00edodo predeterminado.\n\n### Entidades Clave:\n- **Viales**: Contenedores utilizados para productos parenterales.\n- **Tapas de Aluminio**: Elemento crucial en el cierre de los viales.\n- **Part\u00edculas No Viables**: Contaminantes generados por el equipo de crimpado.\n- **Condiciones de Grado A**: Est\u00e1ndares de calidad del aire requeridos para la protecci\u00f3n de los viales.\n- **Tecnolog\u00eda de Capping**: Herramientas y m\u00e9todos utilizados para el proceso de crimpado.\n- **Inspecci\u00f3n Visual**: Proceso de revisi\u00f3n de viales para detectar defectos o contaminaci\u00f3n.", "excerpt_keywords": "Keywords: buenas pr\u00e1cticas de fabricaci\u00f3n, productos farmac\u00e9uticos est\u00e9riles, normas ISO, control de calidad, regulaci\u00f3n sanitaria"}}, "3298d3c9-ac4c-4fa4-8c46-580d6a02dff1": {"node_ids": ["5d561296-fb57-4aba-839a-3a31861055eb"], "metadata": {"page_label": "249", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 5\n\n## WHO good distribution practices for pharmaceutical products\n\n1. Introduction\n2. Scope of the document\n3. Glossary\n4. General principles\n5. Regulation of the distribution of pharmaceutical products\n6. Organization and management\n7. Personnel\n8. Quality system\n9. Premises, warehousing and storage\n10. Vehicles and equipment\n11. Shipment containers and container labelling\n12. Dispatch and receipt\n13. Transportation and products in transit\n14. Documentation\n15. Repackaging and relabelling\n16. Complaints\n17. Recalls\n18. Returned products\n19. Counterfeit pharmaceutical products\n20. Importation\n21. Contract activities\n22. Self-inspection\n\nReferences", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 957\" incluye un anexo que detalla las buenas pr\u00e1cticas de distribuci\u00f3n de productos farmac\u00e9uticos seg\u00fan la Organizaci\u00f3n Mundial de la Salud (OMS). Este anexo abarca una variedad de temas relacionados con la regulaci\u00f3n, organizaci\u00f3n, gesti\u00f3n, calidad, almacenamiento, transporte y manejo de productos farmac\u00e9uticos, as\u00ed como la gesti\u00f3n de quejas, retiradas del mercado y productos falsificados.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los principios generales que rigen las buenas pr\u00e1cticas de distribuci\u00f3n de productos farmac\u00e9uticos seg\u00fan la OMS?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre los principios que gu\u00edan la distribuci\u00f3n segura y efectiva de productos farmac\u00e9uticos, que se detalla en el documento.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir en caso de quejas o retiradas de productos farmac\u00e9uticos seg\u00fan las directrices de la OMS?**\n   - Esta pregunta se centra en los protocolos establecidos para manejar situaciones de quejas y retiradas, que son cruciales para la seguridad del paciente y la integridad del sistema de distribuci\u00f3n.\n\n3. **\u00bfQu\u00e9 medidas se recomiendan para prevenir la distribuci\u00f3n de productos farmac\u00e9uticos falsificados?**\n   - Esta pregunta aborda un tema cr\u00edtico en la distribuci\u00f3n de productos farmac\u00e9uticos, buscando las estrategias y pr\u00e1cticas recomendadas por la OMS para combatir la falsificaci\u00f3n en la cadena de suministro. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar f\u00e1cilmente disponible en otras fuentes, enfoc\u00e1ndose en aspectos clave de las buenas pr\u00e1cticas de distribuci\u00f3n seg\u00fan la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF):** El documento se centra en las BPF para productos farmac\u00e9uticos est\u00e9riles, destacando la importancia de seguir est\u00e1ndares internacionales para garantizar la calidad y seguridad de estos productos.\n\n2. **Normas ISO:** Se mencionan varias normas ISO relacionadas con salas limpias y entornos controlados, que son esenciales para la clasificaci\u00f3n, monitoreo y operaci\u00f3n de estos espacios en la producci\u00f3n farmac\u00e9utica.\n\n3. **Regulaciones de la FDA y la Uni\u00f3n Europea:** Se incluyen gu\u00edas y regulaciones espec\u00edficas de la FDA y la Uni\u00f3n Europea que abordan la producci\u00f3n de medicamentos est\u00e9riles, enfatizando la necesidad de cumplir con estas directrices para asegurar la calidad del producto.\n\n4. **Control de Calidad:** El informe subraya la importancia del control de calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles, lo que implica la implementaci\u00f3n de procedimientos y est\u00e1ndares rigurosos.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite directrices y recomendaciones sobre BPF.\n- **International Organization for Standardization (ISO):** Organizaci\u00f3n que establece normas internacionales, como la serie ISO 14644 relacionada con salas limpias.\n- **US Food and Drug Administration (FDA):** Agencia reguladora que proporciona gu\u00edas sobre la producci\u00f3n de productos farmac\u00e9uticos est\u00e9riles.\n- **Uni\u00f3n Europea:** Entidad que regula la fabricaci\u00f3n de productos medicinales a trav\u00e9s de directrices espec\u00edficas.\n\nEste resumen destaca la interconexi\u00f3n entre las BPF, las normas ISO y las regulaciones de diferentes organismos, enfatizando la importancia de cumplir con estos est\u00e1ndares para garantizar la eficacia y seguridad de los productos farmac\u00e9uticos est\u00e9riles.", "excerpt_keywords": "Keywords: distribution, pharmaceutical, WHO, good practices, regulations"}}, "62cf158b-f6d5-42d0-8c85-0b52011455b3": {"node_ids": ["bebe27fa-9d77-41d4-afcf-1f6f1e253e4c"], "metadata": {"page_label": "250", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nDistribution is an important activity in the integrated supply-chain management of pharmaceutical products. Various people and entities are generally responsible for the handling, storage and distribution of such products. In some cases, however, a person or entity is only involved in and responsible for certain elements of the distribution process. The objective of these guidelines is to assist in ensuring the quality and identity of pharmaceutical products during all aspects of the distribution process. These aspects include, but are not limited to, procurement, purchasing, storage, distribution, transportation, repackaging, relabelling, documentation and record-keeping practices.\n\nThe storage, sale and distribution of pharmaceutical products are often carried out by various companies, institutions and individuals. This document sets out appropriate steps to assist in fulfilling the responsibilities involved in the different aspects of the distribution process within the supply chain and to avoid the introduction of counterfeits into the marketplace via the distribution chain. The relevant sections should be considered by various participants as applicable to the particular role that they play in the distribution of pharmaceutical products.\n\nThe nature of the risks involved is likely to be similar to that for risks encountered in the manufacturing environment, e.g. mix-ups, adulteration, contamination and cross-contamination. When the distribution chain is interrupted by manufacturing steps such as repackaging and relabelling, the principles of good manufacturing practices (GMP) should be applied to these processes.\n\nCounterfeit pharmaceutical products are a real threat to public health and safety. Consequently, it is essential to protect the pharmaceutical supply chain against the penetration of such products. Weak points in the distribution processes of pharmaceutical products provide an avenue for counterfeit as well as illegally imported, stolen and substandard medicines to enter the supply chain. This is a concern in both developed and developing countries. The methods by which such products enter the supply chain have become increasingly complex and have resulted in the development of thriving secondary and grey markets throughout the world. The involvement of unauthorized entities in the distribution and sale of pharmaceutical products is a particular concern. Only a joint approach including all parties involved in the supply chain can be successful in the fight against counterfeit pharmaceutical products and, therefore, all parties active in the market should take an active part in collaborative activities.\n\nDifferent models for the distribution of pharmaceutical products are used in different countries and sometimes within the same country, for example,", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS se centra en la importancia de la distribuci\u00f3n en la gesti\u00f3n de la cadena de suministro de productos farmac\u00e9uticos. Establece directrices para asegurar la calidad e identidad de estos productos durante todo el proceso de distribuci\u00f3n, que incluye la adquisici\u00f3n, almacenamiento, transporte, y pr\u00e1cticas de documentaci\u00f3n. Se enfatiza la amenaza de los productos farmac\u00e9uticos falsificados y la necesidad de proteger la cadena de suministro contra su penetraci\u00f3n. Adem\u00e1s, se menciona que los riesgos en la distribuci\u00f3n son similares a los encontrados en la fabricaci\u00f3n, y que la colaboraci\u00f3n entre todas las partes involucradas es crucial para combatir este problema.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos que se deben seguir para evitar la introducci\u00f3n de productos farmac\u00e9uticos falsificados en la cadena de suministro?**\n   - Esta pregunta busca respuestas sobre las medidas concretas que se deben implementar en cada etapa del proceso de distribuci\u00f3n para prevenir la entrada de productos falsificados.\n\n2. **\u00bfQu\u00e9 principios de buenas pr\u00e1cticas de manufactura (GMP) deben aplicarse durante los procesos de reempaquetado y reetiquetado en la cadena de distribuci\u00f3n?**\n   - Esta pregunta se enfoca en los est\u00e1ndares espec\u00edficos de GMP que son relevantes cuando se interrumpe la cadena de distribuci\u00f3n por actividades de manufactura.\n\n3. **\u00bfQu\u00e9 modelos de distribuci\u00f3n de productos farmac\u00e9uticos se utilizan en diferentes pa\u00edses y c\u00f3mo var\u00edan dentro de un mismo pa\u00eds?**\n   - Esta pregunta busca informaci\u00f3n sobre las diferentes estrategias y estructuras de distribuci\u00f3n que se emplean globalmente y las variaciones que pueden existir en un solo pa\u00eds, lo que podr\u00eda influir en la efectividad de la lucha contra los productos falsificados.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\nEl **Anexo 5** del documento \"WHO - Technical Report Series 957\" se centra en las **buenas pr\u00e1cticas de distribuci\u00f3n de productos farmac\u00e9uticos** seg\u00fan la **Organizaci\u00f3n Mundial de la Salud (OMS)**. A continuaci\u00f3n se presentan los temas clave abordados en esta secci\u00f3n:\n\n1. **Introducci\u00f3n**: Presenta el prop\u00f3sito y la importancia de las buenas pr\u00e1cticas en la distribuci\u00f3n de productos farmac\u00e9uticos.\n2. **Alcance del documento**: Define el \u00e1mbito de aplicaci\u00f3n de las directrices.\n3. **Glosario**: Proporciona definiciones de t\u00e9rminos relevantes utilizados en el documento.\n4. **Principios generales**: Establece los fundamentos que gu\u00edan las pr\u00e1cticas de distribuci\u00f3n.\n5. **Regulaci\u00f3n de la distribuci\u00f3n**: Describe las normativas que rigen la distribuci\u00f3n de productos farmac\u00e9uticos.\n6. **Organizaci\u00f3n y gesti\u00f3n**: Aborda la estructura organizativa necesaria para una distribuci\u00f3n efectiva.\n7. **Personal**: Detalla los requisitos y responsabilidades del personal involucrado en la distribuci\u00f3n.\n8. **Sistema de calidad**: Enfatiza la importancia de un sistema de calidad en la distribuci\u00f3n.\n9. **Instalaciones, almacenamiento y almacenamiento**: Discute las condiciones necesarias para el almacenamiento adecuado de productos farmac\u00e9uticos.\n10. **Veh\u00edculos y equipos**: Especifica los requisitos para los medios de transporte y equipos utilizados.\n11. **Contenedores de env\u00edo y etiquetado**: Proporciona directrices sobre el embalaje y etiquetado de productos.\n12. **Despacho y recepci\u00f3n**: Describe los procedimientos para el manejo de productos al ser enviados y recibidos.\n13. **Transporte y productos en tr\u00e1nsito**: Aborda las consideraciones durante el transporte de productos.\n14. **Documentaci\u00f3n**: Resalta la importancia de mantener registros adecuados.\n15. **Reempaquetado y reetiquetado**: Establece directrices para estas pr\u00e1cticas.\n16. **Quejas**: Define el proceso para manejar quejas sobre productos.\n17. **Retiradas**: Describe los procedimientos a seguir en caso de retiradas de productos del mercado.\n18. **Productos devueltos**: Aborda el manejo de productos que son devueltos.\n19. **Productos farmac\u00e9uticos falsificados**: Discute las medidas para prevenir la distribuci\u00f3n de productos falsificados.\n20. **Importaci\u00f3n**: Proporciona directrices sobre la importaci\u00f3n de productos farmac\u00e9uticos.\n21. **Actividades por contrato**: Aborda las pr\u00e1cticas relacionadas con actividades subcontratadas.\n22. **Autoinspecci\u00f3n**: Enfatiza la importancia de la autoevaluaci\u00f3n en la distribuci\u00f3n.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de establecer las directrices.\n- **Productos farmac\u00e9uticos**: El foco principal del documento.\n- **Sistema de calidad**: Elemento esencial para asegurar la integridad de la distribuci\u00f3n.\n- **Personal**: Los individuos que manejan y distribuyen productos farmac\u00e9uticos.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades clave que se abordan en el anexo sobre las buenas pr\u00e1cticas de distribuci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: distribution, pharmaceutical products, counterfeit, supply chain, good manufacturing practices"}}, "529016f1-4955-4c37-a5f4-9f2405e75141": {"node_ids": ["ae05ef28-72ef-45ee-9471-89364e5d150a"], "metadata": {"page_label": "251", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "in the public and the private sector. These guidelines are intended to be applicable to all persons and outlets involved in any aspect of the distribution of pharmaceutical products from the premises of the manufacturer of the product to the person dispensing or providing pharmaceutical products directly to a patient or his or her agent. This includes all parties involved in trade and distribution of medicines, pharmaceutical manufacturers, including the manufacturers of finished products and pharmaceutical wholesalers as well as other parties such as brokers, suppliers, distributors, logistics providers, traders, transport companies and forwarding agents and their employees.\n\nThe relevant sections of these guidelines should also be considered for implementation by, among others, governments, regulatory bodies, international procurement organizations, donor agencies and certifying bodies, as well as all parties involved in any aspect of the trade and distribution of pharmaceutical products, including health care workers. The guidelines can also be used as a tool in the prevention of the distribution of counterfeit pharmaceutical products. It should, however, be noted that these are general guidelines which may be adapted to suit the prevailing situations and conditions in individual countries. National or regional guidelines may be developed to meet specific needs and situations in a particular region or country.\n\nTo maintain the original quality of pharmaceutical products, every party active in the distribution chain has to comply with the applicable legislation and regulations. Every activity in the distribution of pharmaceutical products should be carried out according to the principles of GMP, good storage practice (GSP) and good distribution practice (GDP) as applicable. These guidelines do not deal with all aspects of the standards for the storage of pharmaceuticals which are covered in the *WHO guide to good storage practices for pharmaceuticals* (1). The dispensing to patients is addressed in the WHO good pharmacy practice (GPP) guide (2). These guidelines should also be read in conjunction with other WHO guidelines (3\u20136).\n\n## 2. Scope of the document\n\nThis document lays down guidelines for the distribution of pharmaceutical products. Depending on the national and regional legislation on pharmaceuticals, these guidelines may apply equally to products for human and for veterinary use. The guidelines thus cover products for which a prescription is required by the patient, products which may be provided to a patient without a prescription, biologicals and vaccines. Although medical devices are not included in the definition of pharmaceutical products for the purposes of this document, the main principles established in this document may also be used where applicable for medical devices.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS establece directrices para la distribuci\u00f3n de productos farmac\u00e9uticos, aplicables a todos los actores involucrados en la cadena de distribuci\u00f3n, desde los fabricantes hasta los dispensadores. Estas directrices buscan asegurar la calidad de los productos farmac\u00e9uticos y prevenir la distribuci\u00f3n de productos falsificados. Se enfatiza la importancia de cumplir con la legislaci\u00f3n y regulaciones pertinentes, as\u00ed como con las buenas pr\u00e1cticas de manufactura (GMP), almacenamiento (GSP) y distribuci\u00f3n (GDP). Adem\u00e1s, se menciona que las directrices pueden adaptarse a las necesidades espec\u00edficas de diferentes pa\u00edses y regiones, y que tambi\u00e9n son relevantes para productos veterinarios y, en algunos casos, dispositivos m\u00e9dicos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 actores espec\u00edficos en la cadena de distribuci\u00f3n de productos farmac\u00e9uticos est\u00e1n incluidos en las directrices de la OMS?**\n   - Respuesta: Las directrices son aplicables a todos los actores involucrados en la distribuci\u00f3n de productos farmac\u00e9uticos, incluyendo fabricantes, mayoristas, corredores, proveedores, distribuidores, empresas de log\u00edstica, transportistas y agentes de aduanas, as\u00ed como sus empleados.\n\n2. **\u00bfC\u00f3mo pueden las directrices de la OMS ayudar en la prevenci\u00f3n de productos farmac\u00e9uticos falsificados?**\n   - Respuesta: Las directrices pueden ser utilizadas como una herramienta para prevenir la distribuci\u00f3n de productos farmac\u00e9uticos falsificados al establecer est\u00e1ndares y pr\u00e1cticas que todos los actores en la cadena de distribuci\u00f3n deben seguir, asegurando as\u00ed la calidad y autenticidad de los productos.\n\n3. **\u00bfQu\u00e9 principios deben seguir las actividades en la distribuci\u00f3n de productos farmac\u00e9uticos seg\u00fan las directrices de la OMS?**\n   - Respuesta: Todas las actividades en la distribuci\u00f3n de productos farmac\u00e9uticos deben llevarse a cabo de acuerdo con los principios de buenas pr\u00e1cticas de manufactura (GMP), buenas pr\u00e1cticas de almacenamiento (GSP) y buenas pr\u00e1cticas de distribuci\u00f3n (GDP), seg\u00fan sea aplicable.\n\n### Resumen de nivel superior\n\nEl documento de la OMS proporciona un marco de directrices para la distribuci\u00f3n de productos farmac\u00e9uticos, enfatizando la importancia de la calidad y la prevenci\u00f3n de la falsificaci\u00f3n. Las directrices son flexibles y pueden adaptarse a las condiciones locales, y son relevantes tanto para productos destinados a humanos como a animales. Se requiere que todos los actores en la cadena de distribuci\u00f3n cumplan con las regulaciones y buenas pr\u00e1cticas establecidas para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Importancia de la Distribuci\u00f3n**: La distribuci\u00f3n es fundamental en la gesti\u00f3n de la cadena de suministro de productos farmac\u00e9uticos, involucrando a diversas personas y entidades en el manejo, almacenamiento y distribuci\u00f3n.\n\n2. **Objetivo de las Directrices**: Las directrices tienen como objetivo asegurar la calidad e identidad de los productos farmac\u00e9uticos durante todo el proceso de distribuci\u00f3n, que incluye la adquisici\u00f3n, almacenamiento, transporte, reempaquetado, reetiquetado, y pr\u00e1cticas de documentaci\u00f3n.\n\n3. **Prevenci\u00f3n de Productos Falsificados**: Se enfatiza la necesidad de evitar la introducci\u00f3n de productos farmac\u00e9uticos falsificados en la cadena de suministro, destacando que los puntos d\u00e9biles en los procesos de distribuci\u00f3n pueden facilitar la entrada de medicamentos falsificados, importados ilegalmente, robados o de calidad inferior.\n\n4. **Riesgos en la Distribuci\u00f3n**: Los riesgos en la distribuci\u00f3n son similares a los encontrados en la fabricaci\u00f3n, incluyendo mezclas, adulteraci\u00f3n y contaminaci\u00f3n. Se recomienda aplicar principios de Buenas Pr\u00e1cticas de Manufactura (GMP) durante procesos de reempaquetado y reetiquetado.\n\n5. **Colaboraci\u00f3n en la Cadena de Suministro**: La lucha contra los productos farmac\u00e9uticos falsificados requiere un enfoque conjunto de todas las partes involucradas en la cadena de suministro, incluyendo empresas, instituciones y otros actores del mercado.\n\n6. **Modelos de Distribuci\u00f3n**: Existen diferentes modelos de distribuci\u00f3n de productos farmac\u00e9uticos que var\u00edan entre pa\u00edses y, a veces, dentro de un mismo pa\u00eds, lo que puede influir en la efectividad de las medidas contra los productos falsificados.\n\n### Entidades Involucradas\n- **Empresas farmac\u00e9uticas**: Responsables de la producci\u00f3n y distribuci\u00f3n de medicamentos.\n- **Instituciones de salud**: Involucradas en la regulaci\u00f3n y supervisi\u00f3n de la cadena de suministro.\n- **Distribuidores**: Actores clave en el manejo y transporte de productos farmac\u00e9uticos.\n- **Entidades no autorizadas**: Representan un riesgo al involucrarse en la distribuci\u00f3n y venta de productos farmac\u00e9uticos. \n\nEste resumen destaca la importancia de la distribuci\u00f3n en la cadena de suministro farmac\u00e9utica y la necesidad de medidas colaborativas para combatir la falsificaci\u00f3n de medicamentos.", "excerpt_keywords": "Keywords: pharmaceutical distribution, guidelines, counterfeit prevention, good distribution practice, regulatory compliance"}}, "361e471b-00c6-45a7-ba94-00c834894e78": {"node_ids": ["de23a472-dfdb-4f6f-b95e-fba4114d1a1d"], "metadata": {"page_label": "252", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The document does not specifically cover GMP aspects of finished products in bulk, distribution of labels or packaging, as these aspects are considered to be covered by other guidelines (3).\n\nThe principles for the distribution of starting materials (active pharmaceutical ingredients (APIs) and excipients) are also not covered here. These are laid down in the WHO guidance *Good trade and distribution practices for pharmaceutical starting materials* (7).\n\n## 3. Glossary\n\nThe definitions provided below apply to the words and phrases used in these guidelines. Although an effort has been made to use standard definitions as far as possible, they may have different meanings in other contexts and documents.\n\n**agreement**  \nArrangement undertaken by and legally binding on parties.\n\n**auditing**  \nAn independent and objective activity designed to add value and improve an organization\u2019s operations by helping the organization to accomplish its objectives by using a systematic, disciplined approach to evaluate and improve the effectiveness of risk management, control and governance processes.\n\n**batch**  \nA defined quantity of pharmaceutical products processed in a single process or series of processes so that it is expected to be homogeneous.\n\n**batch number**  \nA distinctive combination of numbers and/or letters which uniquely identifies a batch, for example, on the labels, its batch records and corresponding certificates of analysis.\n\n**consignment**  \nThe quantity of pharmaceutical products supplied at one time in response to a particular request or order. A consignment may comprise one or more packages or containers and may include pharmaceutical products belonging to more than one batch.\n\n**container**  \nThe material employed in the packaging of a pharmaceutical product. Containers include primary, secondary and transportation containers.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 aspectos de las Buenas Pr\u00e1cticas de Manufactura (GMP) no se abordan en el documento de la OMS?**\n   - El documento no cubre espec\u00edficamente los aspectos de GMP relacionados con los productos terminados en grandes cantidades, la distribuci\u00f3n de etiquetas o el embalaje, ya que se considera que estos aspectos est\u00e1n cubiertos por otras directrices.\n\n2. **\u00bfD\u00f3nde se encuentran los principios para la distribuci\u00f3n de materiales de partida, como los ingredientes farmac\u00e9uticos activos (APIs) y excipientes?**\n   - Los principios para la distribuci\u00f3n de materiales de partida no se abordan en este documento, sino que est\u00e1n establecidos en la gu\u00eda de la OMS titulada *Buenas pr\u00e1cticas comerciales y de distribuci\u00f3n para materiales farmac\u00e9uticos de partida*.\n\n3. **\u00bfQu\u00e9 se entiende por \"n\u00famero de lote\" seg\u00fan el documento?**\n   - El \"n\u00famero de lote\" se define como una combinaci\u00f3n distintiva de n\u00fameros y/o letras que identifica de manera \u00fanica un lote, y se utiliza en las etiquetas, los registros de lote y los certificados de an\u00e1lisis correspondientes.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento de la OMS, parte de la Serie de Informes T\u00e9cnicos 957, aborda directrices relacionadas con la distribuci\u00f3n de productos farmac\u00e9uticos, pero no se centra en los aspectos de GMP de productos terminados, etiquetas o embalaje. Tambi\u00e9n se menciona que los principios para la distribuci\u00f3n de materiales de partida est\u00e1n cubiertos en otras gu\u00edas de la OMS. Adem\u00e1s, se proporciona un glosario con definiciones clave que son relevantes para la comprensi\u00f3n de los t\u00e9rminos utilizados en las directrices.", "prev_section_summary": "### Temas Clave\n\n1. **Directrices para la Distribuci\u00f3n de Productos Farmac\u00e9uticos**: El documento establece normas aplicables a todos los actores en la cadena de distribuci\u00f3n, desde los fabricantes hasta los dispensadores, con el objetivo de asegurar la calidad de los productos farmac\u00e9uticos.\n\n2. **Prevenci\u00f3n de Productos Falsificados**: Las directrices sirven como herramienta para prevenir la distribuci\u00f3n de productos farmac\u00e9uticos falsificados, promoviendo est\u00e1ndares y pr\u00e1cticas que deben seguir todos los involucrados.\n\n3. **Cumplimiento de Normativas**: Se enfatiza la necesidad de que todos los actores en la cadena de distribuci\u00f3n cumplan con la legislaci\u00f3n y regulaciones pertinentes, as\u00ed como con las buenas pr\u00e1cticas de manufactura (GMP), almacenamiento (GSP) y distribuci\u00f3n (GDP).\n\n4. **Adaptabilidad de las Directrices**: Las directrices son generales y pueden adaptarse a las condiciones espec\u00edficas de cada pa\u00eds o regi\u00f3n, permitiendo el desarrollo de gu\u00edas nacionales o regionales.\n\n5. **Alcance de las Directrices**: Las directrices son aplicables a productos farmac\u00e9uticos para uso humano y veterinario, incluyendo medicamentos que requieren receta y aquellos que no, as\u00ed como biol\u00f3gicos y vacunas.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Actores en la Cadena de Distribuci\u00f3n**: Incluye fabricantes, mayoristas, corredores, proveedores, distribuidores, empresas de log\u00edstica, transportistas y agentes de aduanas.\n- **Reguladores y Gobiernos**: Entidades que deben considerar la implementaci\u00f3n de las directrices.\n- **Productos Farmac\u00e9uticos**: Incluye medicamentos, biol\u00f3gicos, vacunas y, en algunos casos, dispositivos m\u00e9dicos.\n- **Buenas Pr\u00e1cticas**: GMP, GSP y GDP son principios fundamentales que deben seguirse en la distribuci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: GMP, pharmaceutical distribution, WHO guidelines, active pharmaceutical ingredients, batch number"}}, "2ac17a3b-4b00-4404-8a5c-052b3cc57c02": {"node_ids": ["bbf54aab-5db8-4a1a-be62-673c5ce338c4"], "metadata": {"page_label": "253", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "Containers are referred to as primary if they are intended to be in direct contact with the product. Secondary containers are not intended to be in direct contact with the product.\n\n**contamination**  \nThe undesired introduction of impurities of a chemical or microbiological nature, or of foreign matter, into or on to a starting material, intermediate or pharmaceutical product during handling, production, sampling, packaging or repackaging, storage or transportation.\n\n**contract**  \nBusiness agreement for the supply of goods or performance of work at a specified price.\n\n**counterfeit pharmaceutical product**  \nA pharmaceutical product which is deliberately and fraudulently mislabelled with respect to identity and/or source. Counterfeiting can apply to both branded and generic products, and counterfeit pharmaceutical products may include products with the correct ingredients, with the wrong ingredients, without active ingredients, with an incorrect quantity of active ingredient or with fake packaging.\n\n**cross-contamination**  \nContamination of a starting material, intermediate product or finished pharmaceutical product with another starting material or product during production, storage and transportation.\n\n**distribution**  \nThe procuring, purchasing, holding, storing, selling, supplying, importing, exporting, or movement of pharmaceutical products, with the exception of the dispensing or providing pharmaceutical products directly to a patient or his or her agent.\n\n**expiry date**  \nThe date given on the individual container (usually on the label) of a pharmaceutical product up to and including the date on which the product is expected to remain within specifications, if stored correctly. It is established for each batch by adding the shelf-life to the date of manufacture.\n\n**first expiry/first out (FEFO)**  \nA distribution procedure that ensures that the stock with the earliest expiry date is distributed and/or used before an identical stock item with a later expiry date is distributed and/or used.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la serie de informes t\u00e9cnicos 957 aborda definiciones clave relacionadas con la manipulaci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos. Se explican conceptos como la contaminaci\u00f3n, los contratos, los productos farmac\u00e9uticos falsificados, la distribuci\u00f3n, la fecha de caducidad y el procedimiento de \"primeras fechas de caducidad primero\" (FEFO). Estas definiciones son esenciales para garantizar la calidad y seguridad de los productos farmac\u00e9uticos en todas las etapas de su ciclo de vida.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 medidas se pueden tomar para prevenir la contaminaci\u00f3n y la contaminaci\u00f3n cruzada en la producci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta busca informaci\u00f3n sobre pr\u00e1cticas espec\u00edficas que no se mencionan directamente en el texto, pero que son relevantes para el manejo seguro de productos farmac\u00e9uticos.\n\n2. **\u00bfCu\u00e1les son las implicaciones legales y de salud p\u00fablica de la distribuci\u00f3n de productos farmac\u00e9uticos falsificados?**\n   - Aunque el texto define qu\u00e9 es un producto farmac\u00e9utico falsificado, no aborda las consecuencias de su distribuci\u00f3n, lo que podr\u00eda ser crucial para entender su impacto en la salud p\u00fablica.\n\n3. **\u00bfC\u00f3mo se determina la fecha de caducidad de un producto farmac\u00e9utico y qu\u00e9 factores pueden influir en su establecimiento?**\n   - La definici\u00f3n de la fecha de caducidad se menciona, pero no se detallan los criterios o estudios que se utilizan para establecerla, lo que podr\u00eda ser un tema de inter\u00e9s para la industria farmac\u00e9utica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Aspectos de GMP No Cubiertos**:\n   - El documento no aborda los aspectos de Buenas Pr\u00e1cticas de Manufactura (GMP) relacionados con productos terminados en grandes cantidades, distribuci\u00f3n de etiquetas o embalaje, ya que se considera que est\u00e1n cubiertos por otras directrices.\n\n2. **Distribuci\u00f3n de Materiales de Partida**:\n   - Los principios para la distribuci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs) y excipientes no se tratan en este documento, sino que est\u00e1n establecidos en la gu\u00eda de la OMS sobre *Buenas pr\u00e1cticas comerciales y de distribuci\u00f3n para materiales farmac\u00e9uticos de partida*.\n\n3. **Glosario de T\u00e9rminos**:\n   - Se proporciona un glosario con definiciones clave que incluyen:\n     - **Acuerdo**: Un arreglo legalmente vinculante entre partes.\n     - **Auditor\u00eda**: Actividad independiente y objetiva para mejorar las operaciones de una organizaci\u00f3n.\n     - **Lote**: Cantidad definida de productos farmac\u00e9uticos procesados en un solo proceso.\n     - **N\u00famero de Lote**: Combinaci\u00f3n \u00fanica de n\u00fameros y/o letras que identifica un lote.\n     - **Consignaci\u00f3n**: Cantidad de productos farmac\u00e9uticos suministrados en respuesta a un pedido.\n     - **Contenedor**: Material utilizado en el embalaje de un producto farmac\u00e9utico.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite directrices sobre pr\u00e1cticas farmac\u00e9uticas.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Conjunto de directrices para asegurar la calidad en la producci\u00f3n farmac\u00e9utica.\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias que tienen un efecto farmacol\u00f3gico.\n- **Excipientes**: Sustancias inactivas que se utilizan en la formulaci\u00f3n de productos farmac\u00e9uticos. \n\nEste resumen destaca los puntos principales y las definiciones relevantes que se encuentran en la secci\u00f3n del documento de la OMS.", "excerpt_keywords": "Keywords: contamination, counterfeit pharmaceutical product, distribution, expiry date, first expiry/first out"}}, "3f901f5a-6000-48cb-865a-0fb24ffa5ec9": {"node_ids": ["38b3d38f-5320-4bd1-b750-b46e27aede6e"], "metadata": {"page_label": "254", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# forwarding agent\n\nA person or entity engaged in providing, either directly or indirectly, any service concerned with clearing and forwarding operations in any manner to any other person and includes a consignment agent.\n\n# good distribution practices (GDP)\n\nThat part of quality assurance that ensures that the quality of a pharmaceutical product is maintained by means of adequate control of the numerous activities which occur during the distribution process as well as providing a tool to secure the distribution system from counterfeits, unapproved, illegally imported, stolen, counterfeit, substandard, adulterated, and/or misbranded pharmaceutical products.\n\n# good manufacturing practices (GMP)\n\nThat part of quality assurance which ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization.\n\n# good pharmacy practice (GPP)\n\nThe practice of pharmacy aimed at providing and promoting the best use of medicines and other health care services and products, by patients and members of the public. It requires that the welfare of the patient is the pharmacist\u2019s prime concern at all times.\n\n# good storage practices (GSP)\n\nThat part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the storage thereof.\n\n# good trade and distribution practices (GTDP)\n\nThat part of quality assurance that ensures that the quality of pharmaceutical products is maintained by means of adequate control throughout the numerous activities which occur during the trade and the distribution process.\n\n# importation\n\nThe act of bringing or causing any goods to be brought into a customs territory (national territory, excluding any free zone).\n\n# intermediate product\n\nPartly processed product that must undergo further manufacturing steps before it becomes a bulk finished product.\n\n# labelling\n\nProcess of identifying a pharmaceutical product including the following information, as appropriate: name of the product; active ingredient(s),", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda diversas pr\u00e1cticas de calidad en la industria farmac\u00e9utica, incluyendo las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP), Buenas Pr\u00e1cticas de Manufactura (GMP), Buenas Pr\u00e1cticas de Farmacia (GPP), Buenas Pr\u00e1cticas de Almacenamiento (GSP) y Buenas Pr\u00e1cticas de Comercio y Distribuci\u00f3n (GTDP). Estas pr\u00e1cticas son esenciales para garantizar que los productos farmac\u00e9uticos mantengan su calidad a lo largo de todo el proceso de distribuci\u00f3n y almacenamiento, as\u00ed como para proteger a los pacientes de productos falsificados o de calidad inferior. Tambi\u00e9n se define el proceso de importaci\u00f3n y se menciona la importancia del etiquetado de productos farmac\u00e9uticos.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las principales diferencias entre las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) y las Buenas Pr\u00e1cticas de Almacenamiento (GSP) en el contexto de la calidad farmac\u00e9utica?**\n   - Esta pregunta busca aclarar las especificidades de cada pr\u00e1ctica y c\u00f3mo se complementan en el proceso de asegurar la calidad de los productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 medidas se pueden implementar para prevenir la entrada de productos farmac\u00e9uticos falsificados en el sistema de distribuci\u00f3n, seg\u00fan las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP)?**\n   - Esta pregunta se centra en las estrategias espec\u00edficas que se pueden adoptar para proteger el sistema de distribuci\u00f3n de productos no autorizados o de baja calidad.\n\n3. **\u00bfC\u00f3mo se define un \"producto intermedio\" en el contexto de la manufactura farmac\u00e9utica y qu\u00e9 pasos adicionales son necesarios para convertirlo en un producto terminado?**\n   - Esta pregunta busca profundizar en el proceso de manufactura y los requisitos que deben cumplirse para que un producto intermedio alcance su estado final como producto farmac\u00e9utico listo para el mercado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n extra\u00edda del documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la serie de informes t\u00e9cnicos 957 se centra en definiciones fundamentales relacionadas con la manipulaci\u00f3n, distribuci\u00f3n y calidad de los productos farmac\u00e9uticos. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n1. **Contenedores**:\n   - **Primarios**: Contenedores en contacto directo con el producto.\n   - **Secundarios**: Contenedores que no est\u00e1n en contacto directo con el producto.\n\n2. **Contaminaci\u00f3n**:\n   - Introducci\u00f3n no deseada de impurezas qu\u00edmicas, microbiol\u00f3gicas o materia extra\u00f1a en productos farmac\u00e9uticos durante diversas etapas como manejo, producci\u00f3n, almacenamiento y transporte.\n\n3. **Contratos**:\n   - Acuerdos comerciales para el suministro de bienes o la realizaci\u00f3n de trabajos a un precio espec\u00edfico.\n\n4. **Productos farmac\u00e9uticos falsificados**:\n   - Productos que est\u00e1n deliberadamente y fraudulentamente etiquetados incorrectamente en cuanto a identidad y/o fuente, que pueden incluir ingredientes correctos o incorrectos, o incluso carecer de ingredientes activos.\n\n5. **Contaminaci\u00f3n cruzada**:\n   - Contaminaci\u00f3n de un material inicial, producto intermedio o producto farmac\u00e9utico terminado con otro material o producto durante la producci\u00f3n, almacenamiento o transporte.\n\n6. **Distribuci\u00f3n**:\n   - Proceso de adquisici\u00f3n, almacenamiento, venta y movimiento de productos farmac\u00e9uticos, excluyendo la dispensaci\u00f3n directa a pacientes.\n\n7. **Fecha de caducidad**:\n   - Fecha en la que se espera que un producto farmac\u00e9utico mantenga sus especificaciones, determinada por la vida \u00fatil a\u00f1adida a la fecha de fabricaci\u00f3n.\n\n8. **Primeras fechas de caducidad primero (FEFO)**:\n   - Procedimiento de distribuci\u00f3n que asegura que los productos con la fecha de caducidad m\u00e1s temprana se utilicen antes que aquellos con fechas posteriores.\n\n### Conclusi\u00f3n\nEstas definiciones son esenciales para garantizar la calidad y seguridad de los productos farmac\u00e9uticos a lo largo de su ciclo de vida, desde la producci\u00f3n hasta la distribuci\u00f3n. La comprensi\u00f3n de estos t\u00e9rminos es crucial para los profesionales de la salud y la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: pharmaceutical quality assurance, good distribution practices, good manufacturing practices, importation, labeling"}}, "08f354ca-2695-416b-8137-6eb975303764": {"node_ids": ["2955a0f9-d1f2-4c51-b3dc-ba0496b3cff3"], "metadata": {"page_label": "255", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "type and amount; batch number; expiry date; special storage conditions or handling precautions; directions for use, warnings and precautions; names and addresses of the manufacturer and/or the supplier.\n\n**manufacture**  \nAll operations of purchase of materials and products, production, packaging, labelling, quality control, release, storage and distribution of pharmaceutical products, and the related controls.\n\n**marketing authorization**  \nA legal document issued by the competent medicines regulatory authority for the purpose of marketing or free distribution of a product after evaluation for safety, efficacy and quality. It must set out, inter alia, the name of the product, the pharmaceutical dosage form, the quantitative formula (including excipients) per unit dose (using INNs or national generic names where they exist), the shelf-life and storage conditions, and packaging characteristics. It specifies the information on which authorization is based (e.g. \u201cThe product(s) must conform to all the details provided in your application and as modified in subsequent correspondence\u201d). It also contains the product information approved for health professionals and the public, the sales category, the name and address of the holder of the authorization, and the period of validity of the authorization.\n\nOnce a product has been given marketing authorization, it is included on a list of authorized products \u2014 the register \u2014 and is often said to be \u201cregistered\u201d or to \u201chave registration\u201d. Market authorization may occasionally also be referred to as a \u201clicence\u201d or \u201cproduct licence\u201d.\n\n**pedigree**  \nA complete record that traces the ownership of and transactions relating to a pharmaceutical product as it is distributed through the supply chain.\n\n**pharmaceutical product**  \nAny product intended for human use, or veterinary product intended for administration to food-producing animals, presented in its finished dosage form, which is subject to control by pharmaceutical legislation in either the exporting or the importing state and includes products for which a prescription is required, products which may be sold to patients without a prescription, biologicals and vaccines. It does not, however, include medical devices.\n\n**product recall**  \nA process for withdrawing or removing a pharmaceutical product from the pharmaceutical distribution chain because of defects in the product, complaints of serious adverse reactions to the product and/or concerns.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la autorizaci\u00f3n de comercializaci\u00f3n de un producto farmac\u00e9utico?**\n   - La autorizaci\u00f3n de comercializaci\u00f3n debe incluir, entre otros aspectos, el nombre del producto, la forma farmac\u00e9utica, la f\u00f3rmula cuantitativa (incluyendo excipientes) por dosis, la vida \u00fatil y las condiciones de almacenamiento, as\u00ed como las caracter\u00edsticas del envase. Tambi\u00e9n debe especificar la informaci\u00f3n sobre la que se basa la autorizaci\u00f3n y contener la informaci\u00f3n del producto aprobada para profesionales de la salud y el p\u00fablico.\n\n2. **\u00bfCu\u00e1l es la diferencia entre un producto farmac\u00e9utico y un dispositivo m\u00e9dico seg\u00fan el contexto proporcionado?**\n   - Un producto farmac\u00e9utico se define como cualquier producto destinado para uso humano o veterinario, presentado en su forma de dosificaci\u00f3n final y sujeto a control por la legislaci\u00f3n farmac\u00e9utica. Esto incluye productos que requieren receta, productos de venta libre, biol\u00f3gicos y vacunas. En cambio, los dispositivos m\u00e9dicos no est\u00e1n incluidos en esta definici\u00f3n.\n\n3. **\u00bfQu\u00e9 implica el proceso de \"recall\" de un producto farmac\u00e9utico?**\n   - El proceso de \"recall\" implica la retirada o eliminaci\u00f3n de un producto farmac\u00e9utico de la cadena de distribuci\u00f3n debido a defectos en el producto, quejas de reacciones adversas graves o preocupaciones relacionadas con la seguridad del producto.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona definiciones y descripciones clave relacionadas con la fabricaci\u00f3n, autorizaci\u00f3n de comercializaci\u00f3n, trazabilidad y retirada de productos farmac\u00e9uticos. Se enfatiza la importancia de la regulaci\u00f3n y control en la producci\u00f3n y distribuci\u00f3n de productos destinados a la salud humana y animal, as\u00ed como los procedimientos necesarios para garantizar la seguridad y eficacia de estos productos en el mercado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) se centra en las pr\u00e1cticas de calidad en la industria farmac\u00e9utica, destacando varios conceptos fundamentales:\n\n1. **Agente de Forwarding**: Persona o entidad que proporciona servicios relacionados con las operaciones de despacho y env\u00edo de productos.\n\n2. **Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP)**: Aseguran que la calidad de los productos farmac\u00e9uticos se mantenga durante el proceso de distribuci\u00f3n, protegiendo el sistema de productos falsificados y de calidad inferior.\n\n3. **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Garantizan que los productos farmac\u00e9uticos se produzcan y controlen de acuerdo con est\u00e1ndares de calidad apropiados para su uso previsto.\n\n4. **Buenas Pr\u00e1cticas de Farmacia (GPP)**: Se enfocan en el uso \u00f3ptimo de medicamentos y servicios de salud, priorizando el bienestar del paciente.\n\n5. **Buenas Pr\u00e1cticas de Almacenamiento (GSP)**: Aseguran que la calidad de los productos farmac\u00e9uticos se mantenga durante su almacenamiento.\n\n6. **Buenas Pr\u00e1cticas de Comercio y Distribuci\u00f3n (GTDP)**: Aseguran la calidad de los productos durante las actividades de comercio y distribuci\u00f3n.\n\n7. **Importaci\u00f3n**: Acto de traer bienes a un territorio aduanero.\n\n8. **Producto Intermedio**: Producto parcialmente procesado que requiere pasos adicionales de manufactura para convertirse en un producto terminado.\n\n9. **Etiquetado**: Proceso de identificaci\u00f3n de un producto farmac\u00e9utico, que incluye informaci\u00f3n relevante como el nombre del producto y los ingredientes activos.\n\n### Conclusi\u00f3n\nEstos conceptos son esenciales para garantizar la calidad y seguridad de los productos farmac\u00e9uticos, protegiendo tanto a los consumidores como a la integridad del sistema de salud.", "excerpt_keywords": "Keywords: marketing authorization, pharmaceutical product, product recall, manufacture, pedigree"}}, "07ce91a8-97af-471f-9d7f-2cd7f299d58b": {"node_ids": ["f542bb61-6fda-45b2-a0c9-385964ced52b"], "metadata": {"page_label": "256", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "that the product is or may be counterfeit. The recall might be initiated by the manufacturer, importer, wholesaler, distributor or a responsible agency.\n\n**quality assurance**  \nA wide-ranging concept covering all matters that individually or collectively influence the quality of a product. It is the totality of the arrangements made with the object of ensuring that pharmaceutical products are of the quality required for their intended use.\n\n**quality system**  \nAn appropriate infrastructure, encompassing the organizational structure, procedures, processes and resources, and systematic actions necessary to ensure adequate confidence that a product (or services) will satisfy given requirements for quality.\n\n**quarantine**  \nThe status of pharmaceutical products isolated physically or by other effective means while a decision is awaited on their release, rejection or reprocessing.\n\n**sampling**  \nOperations designed to obtain a representative portion of a pharmaceutical product, based on an appropriate statistical procedure, for a defined purpose, e.g. acceptance of consignments or batch release.\n\n**shelf-life**  \nThe period of time during which a pharmaceutical product, if stored correctly, is expected to comply with the specification as determined by stability studies on a number of batches of the product. The shelf-life is used to establish the expiry date of each batch.\n\n**standard operating procedure (SOP)**  \nAn authorized, written procedure giving instructions for performing operations not necessarily specific to a given product but of a more general nature (e.g. equipment operation, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection).\n\n**storage**  \nThe storing of pharmaceutical products up to the point of use.\n\n**supplier**  \nA person or entity engaged in the activity of providing products and/or services.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda conceptos clave relacionados con la calidad de los productos farmac\u00e9uticos. Define t\u00e9rminos como \"aseguramiento de la calidad\", \"sistema de calidad\", \"cuarentena\", \"muestreo\", \"vida \u00fatil\", \"procedimiento operativo est\u00e1ndar (SOP)\", \"almacenamiento\" y \"proveedor\". Estos t\u00e9rminos son fundamentales para garantizar que los productos farmac\u00e9uticos cumplan con los est\u00e1ndares requeridos para su uso previsto y para manejar situaciones como el retiro de productos potencialmente falsificados.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 procedimientos se deben seguir para garantizar que un producto farmac\u00e9utico cumpla con los est\u00e1ndares de calidad requeridos?**\n   - Esta pregunta se puede responder a partir de la definici\u00f3n de \"sistema de calidad\" y \"procedimiento operativo est\u00e1ndar (SOP)\" en el contexto.\n\n2. **\u00bfCu\u00e1l es el proceso que se sigue cuando un producto farmac\u00e9utico es aislado en cuarentena?**\n   - La respuesta se puede encontrar en la definici\u00f3n de \"cuarentena\", que describe el estado de los productos farmac\u00e9uticos mientras se espera una decisi\u00f3n sobre su liberaci\u00f3n o rechazo.\n\n3. **\u00bfC\u00f3mo se determina la vida \u00fatil de un producto farmac\u00e9utico y qu\u00e9 factores influyen en su establecimiento?**\n   - La respuesta se puede derivar de la explicaci\u00f3n sobre \"vida \u00fatil\", que menciona la importancia de los estudios de estabilidad y el almacenamiento correcto para determinar el periodo en que un producto cumple con sus especificaciones.", "prev_section_summary": "La secci\u00f3n proporciona definiciones y descripciones clave relacionadas con la regulaci\u00f3n y control de productos farmac\u00e9uticos. Los temas clave incluyen:\n\n1. **Autorizaci\u00f3n de Comercializaci\u00f3n**: Documento legal emitido por la autoridad reguladora que permite la comercializaci\u00f3n de un producto tras evaluar su seguridad, eficacia y calidad. Debe incluir informaci\u00f3n como el nombre del producto, forma farmac\u00e9utica, f\u00f3rmula cuantitativa, vida \u00fatil, condiciones de almacenamiento y detalles del titular de la autorizaci\u00f3n.\n\n2. **Manufactura**: Se refiere a todas las operaciones relacionadas con la compra de materiales, producci\u00f3n, envasado, etiquetado, control de calidad, almacenamiento y distribuci\u00f3n de productos farmac\u00e9uticos.\n\n3. **Pedigr\u00ed**: Registro completo que rastrea la propiedad y las transacciones de un producto farmac\u00e9utico a lo largo de la cadena de suministro.\n\n4. **Producto Farmac\u00e9utico**: Cualquier producto destinado al uso humano o veterinario, presentado en su forma de dosificaci\u00f3n final y sujeto a la legislaci\u00f3n farmac\u00e9utica, excluyendo dispositivos m\u00e9dicos.\n\n5. **Retirada de Producto (Recall)**: Proceso de retirar un producto farmac\u00e9utico de la cadena de distribuci\u00f3n debido a defectos, quejas de reacciones adversas graves o preocupaciones de seguridad.\n\n### Entidades Clave:\n- **Autoridad Reguladora**: Entidad competente que emite la autorizaci\u00f3n de comercializaci\u00f3n.\n- **Titular de la Autorizaci\u00f3n**: Nombre y direcci\u00f3n de la entidad que posee la autorizaci\u00f3n.\n- **Productos Farmac\u00e9uticos**: Incluyen medicamentos con receta, de venta libre, biol\u00f3gicos y vacunas.\n\nEste resumen destaca la importancia de la regulaci\u00f3n en la producci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos para garantizar su seguridad y eficacia en el mercado.", "excerpt_keywords": "Keywords: quality assurance, quarantine, shelf-life, standard operating procedure, pharmaceutical products"}}, "48def0cc-4f00-4942-94c3-f22222aa35e4": {"node_ids": ["dff11a93-a5ca-4a58-b972-d7402574f00f"], "metadata": {"page_label": "257", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# General principles\n\n4.1 All parties involved in the distribution of pharmaceutical products have a responsibility to ensure that the quality of pharmaceutical products and the integrity of the distribution chain is maintained throughout the distribution process from the site of the manufacturer to the entity responsible for dispensing or providing the product to the patient or his or her agent.\n\n4.2 The principles of GDP should be included in national legislation and guidelines for the distribution of pharmaceutical products, in a country or region as applicable, as a means of establishing minimum standards.\n\n4.3 The principles of GDP are applicable both to pharmaceutical products moving forward in the distribution chain from the manufacturer to the entity responsible for dispensing or providing pharmaceutical products to the patient and to products which are moving backwards in the chain, for example, as a result of the return or recall thereof.\n\n4.4 The principles of GDP should also be adhered to in the case of pharmaceutical products which are donated.\n\n4.5 All entities involved in the distribution process should apply due diligence with adherence to the principles of GDP, for example, in procedures relating to traceability and in recognition of security risks.\n\n4.6 There should be collaboration between all parties including governments, customs agencies, law enforcement agencies, regulatory authorities, manufacturers, distributors and entities responsible for the supply of pharmaceutical products to patients to ensure the quality and safety of pharmaceutical products and prevent the exposure of patients to counterfeit pharmaceutical products.\n\n# Regulation of the distribution of pharmaceutical products\n\n5.1 National legislation should be in place to regulate the activities of persons or entities involved in the distribution of pharmaceutical products.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Responsabilidad en la distribuci\u00f3n de productos farmac\u00e9uticos**: Todas las partes involucradas en la distribuci\u00f3n de productos farmac\u00e9uticos deben garantizar la calidad de los productos y la integridad de la cadena de distribuci\u00f3n desde el fabricante hasta el paciente.\n\n2. **Principios de Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP)**: Los principios de GDP deben ser incorporados en la legislaci\u00f3n nacional y aplicarse a todos los productos farmac\u00e9uticos, independientemente de si se mueven hacia adelante o hacia atr\u00e1s en la cadena de distribuci\u00f3n.\n\n3. **Colaboraci\u00f3n y regulaci\u00f3n**: Es esencial la colaboraci\u00f3n entre diversas entidades, como gobiernos y agencias de regulaci\u00f3n, para asegurar la calidad y seguridad de los productos farmac\u00e9uticos y prevenir la exposici\u00f3n de los pacientes a productos falsificados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben tomar las entidades involucradas en la distribuci\u00f3n para asegurar la trazabilidad de los productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en las pr\u00e1cticas espec\u00edficas que deben seguir las entidades para cumplir con los principios de GDP, que no se detalla expl\u00edcitamente en el texto.\n\n2. **\u00bfC\u00f3mo se deben manejar los productos farmac\u00e9uticos que son devueltos o retirados del mercado seg\u00fan los principios de GDP?**\n   - Esta pregunta busca informaci\u00f3n sobre el manejo espec\u00edfico de productos que regresan a la cadena de distribuci\u00f3n, un aspecto que podr\u00eda no estar ampliamente cubierto en otras fuentes.\n\n3. **\u00bfQu\u00e9 papel juegan las agencias de aduanas y las fuerzas del orden en la colaboraci\u00f3n para prevenir la distribuci\u00f3n de productos farmac\u00e9uticos falsificados?**\n   - Esta pregunta se enfoca en el papel espec\u00edfico de estas entidades en la cadena de distribuci\u00f3n y c\u00f3mo contribuyen a la seguridad del suministro farmac\u00e9utico, un detalle que puede no ser evidente en otros documentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta definiciones y conceptos esenciales relacionados con la calidad de los productos farmac\u00e9uticos. A continuaci\u00f3n se resumen los temas clave y las entidades mencionadas:\n\n1. **Aseguramiento de la Calidad**: Concepto amplio que abarca todos los aspectos que influyen en la calidad de un producto farmac\u00e9utico, asegurando que cumpla con los est\u00e1ndares requeridos para su uso previsto.\n\n2. **Sistema de Calidad**: Infraestructura adecuada que incluye la estructura organizativa, procedimientos, procesos y recursos necesarios para garantizar que un producto o servicio satisfaga los requisitos de calidad.\n\n3. **Cuarentena**: Estado de los productos farmac\u00e9uticos que han sido aislados mientras se espera una decisi\u00f3n sobre su liberaci\u00f3n, rechazo o reprocesamiento.\n\n4. **Muestreo**: Operaciones dise\u00f1adas para obtener una porci\u00f3n representativa de un producto farmac\u00e9utico, utilizando procedimientos estad\u00edsticos adecuados para fines espec\u00edficos, como la aceptaci\u00f3n de consignaciones o la liberaci\u00f3n de lotes.\n\n5. **Vida \u00datil**: Per\u00edodo durante el cual un producto farmac\u00e9utico, si se almacena correctamente, se espera que cumpla con las especificaciones establecidas a partir de estudios de estabilidad.\n\n6. **Procedimiento Operativo Est\u00e1ndar (SOP)**: Procedimiento escrito autorizado que proporciona instrucciones para realizar operaciones generales, no necesariamente espec\u00edficas de un producto.\n\n7. **Almacenamiento**: Proceso de guardar productos farmac\u00e9uticos hasta el momento de su uso.\n\n8. **Proveedor**: Persona o entidad que se dedica a proporcionar productos y/o servicios.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece directrices y est\u00e1ndares para la calidad de los productos farmac\u00e9uticos.\n- **Fabricante, Importador, Mayorista, Distribuidor**: Entidades involucradas en la cadena de suministro de productos farmac\u00e9uticos, especialmente en el contexto de retiros de productos.\n\nEste resumen destaca la importancia de estos conceptos en la garant\u00eda de la calidad y seguridad de los productos farmac\u00e9uticos en el mercado.", "excerpt_keywords": "Keywords: pharmaceutical distribution, quality assurance, Good Distribution Practices, regulatory compliance, counterfeit prevention"}}, "778fb013-d3dd-4975-99f0-bf5d95dcf7e6": {"node_ids": ["a8491801-c310-498e-beec-9422bddae7d3"], "metadata": {"page_label": "258", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 5.2\n\nThe distributor or the organization to which the distributor belongs should be an entity that is appropriately authorized in terms of applicable legislation to perform the function(s) that it intends to perform. The distributor or the organization to which it belongs should be held accountable for the activities that it performs which relate to the distribution of pharmaceutical products.\n\n# 5.3\n\nOnly persons or entities which are authorized to do so and/or which hold the appropriate licence should be entitled to import or export pharmaceutical products.\n\n# 5.4\n\nDistributors or their agents may only distribute a pharmaceutical product within or to a country or territory if a marketing authorization or similar authorization has been granted, which allows the use of that pharmaceutical product in that country or territory.\n\n# 5.5\n\nHolders of an authorization to distribute pharmaceutical products should obtain their supplies of pharmaceutical products only from persons or entities which are in possession of the applicable authorization to sell or supply such products to a distributor.\n\n# 5.6\n\nDistributors or their agents should supply pharmaceutical products only to persons or entities which are themselves authorized to acquire such products either in terms of an authorization to act as a distributor or to sell or supply products directly to a patient or to his or her agent.\n\n# 5.7\n\nSome duties and responsibilities may be delegated or contracted out to suitably designated persons or entities as authorized and as necessary. Duties and responsibilities may only be delegated to entities which are suitably authorized in line with the national legislation. Duties and responsibilities should be specified in a written agreement. There should be no gaps or unexplained overlaps with regard to the application of GDP. These delegated and contracted out activities should be documented in agreements or contracts. There should be a periodic audit of such activities with regard to application of GDP.\n\n# 5.8\n\nIf a distributor or his or her agent subcontracts an activity to another entity, the person or entity to whom the activity is subcontracted must be appropriately authorized to perform the subcontracted activity and should uphold the same standards as the distributor.\n\n# 5.9\n\nThe sale of pharmaceutical products via the Internet should be limited to registered and authorized mail-order pharmacies or other authorized entities.\n\n# 6. Organization and management\n\n6.1 There should be an adequate organizational structure for each entity defined with the aid of an organizational chart. The responsibility, authority and interrelationships of all personnel should be clearly indicated.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre la distribuci\u00f3n de productos farmac\u00e9uticos, enfatizando la necesidad de que los distribuidores y las entidades relacionadas est\u00e9n debidamente autorizados y cumplan con la legislaci\u00f3n aplicable. Se detallan las responsabilidades de los distribuidores, la importancia de la autorizaci\u00f3n para la importaci\u00f3n y exportaci\u00f3n, y las condiciones bajo las cuales se pueden subcontratar actividades. Tambi\u00e9n se menciona la regulaci\u00f3n de la venta de productos farmac\u00e9uticos a trav\u00e9s de Internet y la necesidad de una estructura organizativa adecuada.\n\n### Preguntas\n1. **\u00bfQu\u00e9 requisitos deben cumplir los distribuidores para obtener y mantener su autorizaci\u00f3n para distribuir productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en los criterios espec\u00edficos que los distribuidores deben cumplir seg\u00fan la legislaci\u00f3n aplicable, lo cual no se detalla en otras fuentes.\n\n2. **\u00bfCu\u00e1les son las implicaciones de subcontratar actividades en la distribuci\u00f3n de productos farmac\u00e9uticos seg\u00fan las directrices de la OMS?**\n   - Esta pregunta aborda las responsabilidades y condiciones que deben cumplirse al subcontratar, as\u00ed como la necesidad de documentaci\u00f3n y auditor\u00eda, aspectos que pueden no estar claramente especificados en otras normativas.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse para garantizar que la venta de productos farmac\u00e9uticos por Internet se realice de manera segura y legal?**\n   - Esta pregunta se enfoca en las restricciones y regulaciones espec\u00edficas que deben seguirse para la venta en l\u00ednea, un tema que puede no estar ampliamente cubierto en otras fuentes de informaci\u00f3n sobre comercio electr\u00f3nico y productos farmac\u00e9uticos.", "prev_section_summary": "### Temas Clave\n\n1. **Responsabilidad en la Distribuci\u00f3n**: Todas las partes involucradas en la distribuci\u00f3n de productos farmac\u00e9uticos deben asegurar la calidad de los productos y la integridad de la cadena de distribuci\u00f3n desde el fabricante hasta el paciente.\n\n2. **Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP)**: Los principios de GDP deben ser incorporados en la legislaci\u00f3n nacional y aplicarse a todos los productos farmac\u00e9uticos, tanto en su movimiento hacia adelante como en el retorno o la retirada del mercado.\n\n3. **Trazabilidad y Diligencia Debida**: Las entidades deben aplicar procedimientos de trazabilidad y reconocer los riesgos de seguridad, cumpliendo con los principios de GDP.\n\n4. **Colaboraci\u00f3n Interinstitucional**: Es fundamental la colaboraci\u00f3n entre gobiernos, agencias de aduanas, fuerzas del orden, autoridades regulatorias, fabricantes y distribuidores para garantizar la calidad y seguridad de los productos farmac\u00e9uticos y prevenir la distribuci\u00f3n de productos falsificados.\n\n5. **Regulaci\u00f3n Nacional**: Se debe establecer legislaci\u00f3n nacional para regular las actividades de las personas o entidades involucradas en la distribuci\u00f3n de productos farmac\u00e9uticos.\n\n### Entidades Involucradas\n\n- **Gobiernos**: Responsables de establecer y hacer cumplir la legislaci\u00f3n relacionada con la distribuci\u00f3n de productos farmac\u00e9uticos.\n- **Agencias de Aduanas**: Colaboran en la supervisi\u00f3n y control de la entrada y salida de productos farmac\u00e9uticos.\n- **Fuerzas del Orden**: Ayudan a prevenir la distribuci\u00f3n de productos falsificados y a mantener la seguridad en la cadena de suministro.\n- **Autoridades Regulatorias**: Se encargan de la regulaci\u00f3n y supervisi\u00f3n de la calidad de los productos farmac\u00e9uticos.\n- **Fabricantes**: Producen los productos farmac\u00e9uticos y deben asegurar su calidad desde el inicio.\n- **Distribuidores**: Encargados de la distribuci\u00f3n de productos farmac\u00e9uticos a los puntos de venta o a los pacientes.\n- **Entidades de Suministro**: Proporcionan los productos farmac\u00e9uticos a los pacientes o sus agentes.", "excerpt_keywords": "Keywords: distribution, pharmaceutical products, authorization, good distribution practices, regulatory compliance"}}, "87c4514b-258b-4bcc-a239-400ffe224c5c": {"node_ids": ["c34559a4-1cd1-47e0-a6f0-b3e833b7b1ee"], "metadata": {"page_label": "259", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 6.2\n\nDuties and responsibilities should be clearly defined and understood by the individuals concerned and recorded as written job descriptions. Certain activities may require special attention, such as the supervision of performance of activities, in accordance with local legislation. At every level of the supply chain, employees should be fully informed and trained in their duties and responsibilities.\n\n## 6.3\n\nA designated person should be appointed within the organization, who has defined authority and responsibility for ensuring that a quality system is implemented and maintained.\n\n## 6.4\n\nManagerial and technical personnel must have the authority and resources needed to carry out their duties and to set up and maintain a quality system, as well as to identify and correct deviations from the established quality system (see section 8).\n\n## 6.5\n\nThe responsibilities placed on any one individual should not be so extensive as to present any risk to product quality.\n\n## 6.6\n\nThere should be arrangements in place to ensure that management and personnel are not subject to commercial, political, financial and other pressures or conflict of interest that may have an adverse effect on the quality of service provided or on the integrity of pharmaceutical products.\n\n## 6.7\n\nSafety procedures relating to all relevant aspects including the safety of personnel and property, environmental protection and product integrity, should be in place.\n\n# 7. Personnel\n\n## 7.1\n\nAll personnel involved in distribution activities should be trained and qualified in the requirements of GDP, as applicable. Training should be based on written standard operating procedures (SOPs). Personnel should receive initial and continuing training relevant to their tasks, and be assessed as applicable, in accordance with a written training programme. In addition, training of the personnel should include the topic of product security, as well as aspects of product identification, the detection of counterfeits and the avoidance of counterfeits entering the supply chain. A record of all training, which includes details of subjects covered and participants trained, should be kept.\n\n## 7.2\n\nKey personnel involved in the distribution of pharmaceutical products should have the ability and experience appropriate to their responsibility for ensuring that pharmaceutical products are distributed properly.\n\n## 7.3\n\nThere should be an adequate number of competent personnel involved in all stages of the distribution of pharmaceutical products in order to ensure that the quality of the product is maintained.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre la definici\u00f3n de deberes y responsabilidades en la cadena de suministro de productos farmac\u00e9uticos, enfatizando la importancia de la capacitaci\u00f3n del personal y la implementaci\u00f3n de un sistema de calidad. Se destaca la necesidad de designar a una persona responsable de mantener este sistema y de asegurar que el personal est\u00e9 adecuadamente entrenado y calificado para realizar sus tareas, evitando conflictos de inter\u00e9s y garantizando la seguridad en todos los aspectos relacionados con la distribuci\u00f3n de productos farmac\u00e9uticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben tomarse para garantizar que el personal involucrado en la distribuci\u00f3n de productos farmac\u00e9uticos est\u00e9 adecuadamente capacitado?**\n   - El personal debe recibir formaci\u00f3n inicial y continua basada en procedimientos operativos est\u00e1ndar (SOPs), que incluya temas de seguridad del producto, identificaci\u00f3n de productos y detecci\u00f3n de falsificaciones. Adem\u00e1s, se debe llevar un registro de toda la formaci\u00f3n recibida.\n\n2. **\u00bfCu\u00e1l es el papel de la persona designada dentro de la organizaci\u00f3n en relaci\u00f3n con el sistema de calidad?**\n   - La persona designada tiene la autoridad y responsabilidad definidas para asegurar que se implemente y mantenga un sistema de calidad dentro de la organizaci\u00f3n.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta para evitar que las responsabilidades de un individuo afecten la calidad del producto?**\n   - Las responsabilidades asignadas a un individuo no deben ser tan extensas que presenten un riesgo para la calidad del producto, y debe haber un n\u00famero adecuado de personal competente en todas las etapas de la distribuci\u00f3n para mantener la calidad del producto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS aborda varios aspectos fundamentales relacionados con la distribuci\u00f3n de productos farmac\u00e9uticos, destacando la importancia de la autorizaci\u00f3n y la responsabilidad de los distribuidores. A continuaci\u00f3n se presentan los temas clave y las entidades involucradas:\n\n#### Temas Clave:\n\n1. **Autorizaci\u00f3n de Distribuidores**:\n   - Los distribuidores deben ser entidades debidamente autorizadas seg\u00fan la legislaci\u00f3n aplicable para realizar funciones de distribuci\u00f3n de productos farmac\u00e9uticos.\n\n2. **Importaci\u00f3n y Exportaci\u00f3n**:\n   - Solo las personas o entidades autorizadas y con la licencia correspondiente pueden importar o exportar productos farmac\u00e9uticos.\n\n3. **Autorizaci\u00f3n de Comercializaci\u00f3n**:\n   - La distribuci\u00f3n de productos farmac\u00e9uticos en un pa\u00eds o territorio solo es permitida si se ha otorgado una autorizaci\u00f3n de comercializaci\u00f3n para esos productos.\n\n4. **Suministro de Productos**:\n   - Los distribuidores deben obtener sus productos \u00fanicamente de entidades que cuenten con la autorizaci\u00f3n necesaria para vender o suministrar a distribuidores.\n\n5. **Venta a Entidades Autorizadas**:\n   - Los distribuidores deben suministrar productos solo a personas o entidades que est\u00e9n autorizadas para adquirirlos.\n\n6. **Subcontrataci\u00f3n**:\n   - Las responsabilidades pueden ser delegadas o subcontratadas a entidades autorizadas, con la necesidad de documentaci\u00f3n y auditor\u00eda peri\u00f3dica para asegurar el cumplimiento de las Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP).\n\n7. **Venta en L\u00ednea**:\n   - La venta de productos farmac\u00e9uticos a trav\u00e9s de Internet debe limitarse a farmacias de correo registradas y autorizadas u otras entidades autorizadas.\n\n8. **Estructura Organizativa**:\n   - Se requiere una estructura organizativa adecuada, con claridad en las responsabilidades y relaciones de autoridad entre el personal.\n\n#### Entidades Involucradas:\n\n- **Distribuidores**: Entidades responsables de la distribuci\u00f3n de productos farmac\u00e9uticos.\n- **Agentes de Distribuci\u00f3n**: Personas o entidades que act\u00faan en nombre de los distribuidores.\n- **Entidades Autorizadas**: Organizaciones que cumplen con los requisitos legales para importar, exportar, o vender productos farmac\u00e9uticos.\n- **Farmacias de Correo**: Entidades autorizadas para la venta de productos farmac\u00e9uticos a trav\u00e9s de Internet.\n\nEste resumen destaca la necesidad de cumplir con las regulaciones y mantener est\u00e1ndares de calidad en la distribuci\u00f3n de productos farmac\u00e9uticos, as\u00ed como la importancia de la documentaci\u00f3n y la auditor\u00eda en las actividades delegadas.", "excerpt_keywords": "Keywords: quality system, training, responsibilities, pharmaceutical distribution, personnel"}}, "ed2a35bc-f311-4993-9006-47d5d82b7cdf": {"node_ids": ["b5d6d445-f94a-4c35-a99c-0eab5630d86f"], "metadata": {"page_label": "260", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 7.4\n\nNational regulations relating to the qualifications and experience of personnel should be adhered to.\n\n7.5 Personnel dealing with hazardous pharmaceutical products (such as highly active materials, radioactive materials, narcotics, and other hazardous, environmentally sensitive and/or dangerous pharmaceutical products, as well as products presenting special risks of abuse, fire or explosion) should be given specific training.\n\n7.6 Personnel involved in the distribution of pharmaceutical products should wear garments suitable for the activities that they perform. Personnel dealing with hazardous pharmaceutical products, including products containing materials that are highly active, toxic, infectious or sensitizing, should be provided with protective garments as necessary.\n\n7.7 Appropriate procedures relating to personnel hygiene, relevant to the activities to be carried out, should be established and observed. Such procedures should cover health, hygiene and clothing of personnel.\n\n7.8 Procedures and conditions of employment for employees, including contract and temporary staff, and other personnel having access to pharmaceutical products must be designed and administered to assist in minimizing the possibility of such products coming into the possession of unauthorized persons or entities.\n\n7.9 Codes of practice and punitive procedures should be in place to prevent and address situations where persons involved in the distribution of pharmaceutical products are suspected of, or found to be implicated in, any activities relating to the misappropriation, tampering, diversion or counterfeiting of any product.\n\n# 8. Quality system\n\n8.1 Within an organization, quality assurance serves as a management tool. There should be a documented quality policy describing the overall intentions and requirements of the distributor regarding quality, as formally expressed and authorized by management.\n\n8.2 The quality system should include an appropriate organizational structure, procedure, processes and resources and systematic actions necessary to ensure adequate confidence that a product or service and its documentation will satisfy given requirements for quality. The totality of these actions is described as the quality system.\n\n8.3 The quality system should include provisions to ensure that the holder of the marketing authorization, entity identified on the label (if different from the manufacturer), the appropriate national and/or international", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl contexto se centra en las regulaciones y procedimientos relacionados con el personal que maneja productos farmac\u00e9uticos, especialmente aquellos que son peligrosos o presentan riesgos especiales. Se enfatiza la importancia de la capacitaci\u00f3n, el uso de vestimenta adecuada y la higiene del personal. Adem\u00e1s, se menciona la necesidad de establecer procedimientos para prevenir el acceso no autorizado a productos farmac\u00e9uticos y para abordar situaciones de mal uso o falsificaci\u00f3n. Tambi\u00e9n se introduce el concepto de un sistema de calidad dentro de una organizaci\u00f3n, que debe incluir una pol\u00edtica de calidad documentada y una estructura organizativa adecuada para garantizar que los productos y servicios cumplan con los requisitos de calidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de formaci\u00f3n espec\u00edfica se requiere para el personal que maneja productos farmac\u00e9uticos peligrosos, y cu\u00e1les son algunos ejemplos de estos productos?**\n   - Esta pregunta busca detalles sobre la formaci\u00f3n necesaria y ejemplos concretos de productos que requieren dicha formaci\u00f3n, lo cual no se detalla en otras partes del documento.\n\n2. **\u00bfCu\u00e1les son las medidas espec\u00edficas que deben implementarse para garantizar que los productos farmac\u00e9uticos no caigan en manos no autorizadas?**\n   - Esta pregunta se centra en las condiciones y procedimientos de empleo que deben establecerse para proteger los productos farmac\u00e9uticos, proporcionando informaci\u00f3n que puede no estar disponible en otras secciones.\n\n3. **\u00bfQu\u00e9 elementos debe incluir un sistema de calidad para asegurar que los productos y servicios cumplan con los requisitos establecidos?**\n   - Esta pregunta busca una descripci\u00f3n detallada de los componentes que conforman un sistema de calidad efectivo, lo que puede no estar claramente definido en otras partes del documento.\n\n### Resumen de nivel superior\n\nEl documento establece directrices sobre la gesti\u00f3n del personal en la distribuci\u00f3n de productos farmac\u00e9uticos, enfatizando la capacitaci\u00f3n, la higiene y la prevenci\u00f3n del acceso no autorizado. Tambi\u00e9n se aborda la importancia de un sistema de calidad que garantice que los productos cumplan con los est\u00e1ndares requeridos. Estas directrices son esenciales para asegurar la seguridad y la eficacia en la distribuci\u00f3n de productos farmac\u00e9uticos, as\u00ed como para prevenir actividades ilegales o peligrosas relacionadas con estos productos.", "prev_section_summary": "### Temas Clave\n\n1. **Definici\u00f3n de Deberes y Responsabilidades**: Es fundamental que los deberes y responsabilidades de los empleados en la cadena de suministro est\u00e9n claramente definidos y documentados en descripciones de trabajo escritas.\n\n2. **Sistema de Calidad**: Se debe designar a una persona responsable de implementar y mantener un sistema de calidad dentro de la organizaci\u00f3n, asegurando que el personal tenga la autoridad y los recursos necesarios para cumplir con sus funciones.\n\n3. **Capacitaci\u00f3n del Personal**: Todo el personal involucrado en la distribuci\u00f3n de productos farmac\u00e9uticos debe recibir formaci\u00f3n inicial y continua, basada en procedimientos operativos est\u00e1ndar (SOPs), que incluya temas de seguridad del producto y detecci\u00f3n de falsificaciones.\n\n4. **Prevenci\u00f3n de Conflictos de Inter\u00e9s**: Es necesario establecer medidas para evitar que la gesti\u00f3n y el personal est\u00e9n sujetos a presiones comerciales, pol\u00edticas o financieras que puedan afectar la calidad del servicio y la integridad de los productos farmac\u00e9uticos.\n\n5. **Seguridad y Protecci\u00f3n**: Deben implementarse procedimientos de seguridad que aborden la seguridad del personal, la protecci\u00f3n ambiental y la integridad del producto.\n\n6. **Competencia del Personal**: Se debe asegurar que haya un n\u00famero adecuado de personal competente en todas las etapas de la distribuci\u00f3n para mantener la calidad del producto.\n\n### Entidades\n\n- **Organizaci\u00f3n**: Se refiere a la entidad responsable de la distribuci\u00f3n de productos farmac\u00e9uticos.\n- **Personal**: Incluye a todos los empleados involucrados en actividades de distribuci\u00f3n.\n- **Sistema de Calidad**: El marco que asegura que los productos farmac\u00e9uticos se distribuyan de acuerdo con est\u00e1ndares establecidos.\n- **Procedimientos Operativos Est\u00e1ndar (SOPs)**: Documentos que gu\u00edan la capacitaci\u00f3n y las operaciones del personal.\n- **Conflictos de Inter\u00e9s**: Situaciones que pueden comprometer la calidad del servicio o la integridad del producto.\n- **Seguridad del Producto**: Aspectos relacionados con la protecci\u00f3n y autenticidad de los productos farmac\u00e9uticos. \n\nEste resumen destaca la importancia de la claridad en las responsabilidades, la capacitaci\u00f3n adecuada del personal y la implementaci\u00f3n de un sistema de calidad robusto para garantizar la integridad de la cadena de suministro de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: pharmaceutical regulations, hazardous products, quality assurance, personnel training, distribution security"}}, "ab9e7fe5-4ca5-4666-9cd9-c37063242d91": {"node_ids": ["e6bfebe4-de76-479d-8b42-753030872fbe"], "metadata": {"page_label": "261", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Regulatory Measures for Pharmaceutical Products\n\nRegulatory bodies, as well as other relevant competent authorities, should be informed immediately in a case of confirmed or suspected counterfeiting of a pharmaceutical product. Such products should be stored in a secure, segregated area and clearly identified to prevent further distribution or sale.\n\n## Electronic Commerce\n\n8.4 Where electronic commerce (e-commerce) is used, i.e., electronic means are used for any of the distribution steps, defined procedures and adequate systems should be in place to ensure traceability and confidence in the quality of the pharmaceutical products concerned. Electronic transactions (including those conducted via the Internet), relating to the distribution of pharmaceutical products, should be performed only by authorized persons or entities.\n\n## Procurement and Release Procedures\n\n8.5 Authorized procurement and release procedures for all administrative and technical operations performed should be in place to ensure that appropriate pharmaceutical products are sourced only from approved suppliers and distributed by approved entities. The approval should come from the competent authority of the individual country where the legal entity is registered.\n\n## Inspection and Certification\n\n8.6 Inspection, auditing, and certification of compliance with a quality system (such as the applicable International Standardization Organization (ISO) series, or national or international guidelines) by external bodies is recommended. Such certification should not, however, be seen as a substitute for compliance with these GDP guidelines and the applicable principles of GMP relating to pharmaceutical products.\n\n## Integrity of Products in Transit\n\n8.7 If measures to ensure the integrity of the pharmaceutical products in transit are in place, they should be managed properly. For example, if seal control programmes for transit shipment are used, numbers should be issued in a tracked and sequential manner, the integrity of seals should be monitored and numbers verified during transit and upon receipt. Written procedures should be in place for use in situations where pharmaceutical products are suspected of being or are found to be counterfeit.\n\n## Risk Assessment\n\n8.8 Distributors should from time to time conduct risk assessments to assess potential risks to the quality and integrity of pharmaceutical products. The quality system should be developed and implemented to address any potential risks identified. The quality system should be reviewed and revised periodically to address new risks identified during a risk assessment.\n\n## Traceability of Pharmaceutical Products\n\n8.9 Regulations should foster a safe, transparent, and secure distribution system which includes product traceability throughout the supply chain. This is a shared responsibility among the parties involved. There should be...", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS aborda las medidas regulatorias para los productos farmac\u00e9uticos, enfatizando la importancia de la notificaci\u00f3n inmediata en casos de falsificaci\u00f3n, la implementaci\u00f3n de procedimientos de comercio electr\u00f3nico seguros, la necesidad de procedimientos de adquisici\u00f3n y liberaci\u00f3n autorizados, y la importancia de la inspecci\u00f3n y certificaci\u00f3n de cumplimiento con sistemas de calidad. Tambi\u00e9n se discuten las medidas para garantizar la integridad de los productos en tr\u00e1nsito, la realizaci\u00f3n de evaluaciones de riesgo y la trazabilidad de los productos a lo largo de la cadena de suministro.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben implementarse para garantizar la trazabilidad de los productos farmac\u00e9uticos en el comercio electr\u00f3nico?**\n   - El contexto menciona que deben existir procedimientos definidos y sistemas adecuados para asegurar la trazabilidad y confianza en la calidad de los productos farmac\u00e9uticos distribuidos electr\u00f3nicamente.\n\n2. **\u00bfCu\u00e1l es el papel de las autoridades competentes en la aprobaci\u00f3n de proveedores de productos farmac\u00e9uticos?**\n   - Se establece que los productos farmac\u00e9uticos deben ser adquiridos solo de proveedores aprobados, y que la aprobaci\u00f3n debe provenir de la autoridad competente del pa\u00eds donde la entidad legal est\u00e1 registrada.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse si se sospecha que un producto farmac\u00e9utico es falsificado durante el tr\u00e1nsito?**\n   - El documento indica que deben existir procedimientos escritos para manejar situaciones en las que los productos farmac\u00e9uticos son sospechosos de ser falsificados, incluyendo el monitoreo de la integridad de los sellos durante el tr\u00e1nsito y la verificaci\u00f3n de n\u00fameros al recibir los productos.", "prev_section_summary": "### Temas Clave\n\n1. **Regulaciones Nacionales**: Se enfatiza la importancia de cumplir con las regulaciones nacionales relacionadas con las calificaciones y la experiencia del personal que maneja productos farmac\u00e9uticos.\n\n2. **Capacitaci\u00f3n del Personal**: El personal que maneja productos farmac\u00e9uticos peligrosos, como materiales altamente activos, radiactivos, narc\u00f3ticos y otros productos peligrosos, debe recibir formaci\u00f3n espec\u00edfica.\n\n3. **Vestimenta y Protecci\u00f3n**: Se requiere que el personal use prendas adecuadas para sus actividades, y aquellos que manejan productos peligrosos deben contar con ropa de protecci\u00f3n adecuada.\n\n4. **Higiene del Personal**: Se deben establecer y observar procedimientos apropiados de higiene que aborden la salud, la higiene y la vestimenta del personal.\n\n5. **Prevenci\u00f3n de Acceso No Autorizado**: Se deben dise\u00f1ar y administrar procedimientos y condiciones de empleo para minimizar el riesgo de que productos farmac\u00e9uticos caigan en manos no autorizadas.\n\n6. **C\u00f3digos de Pr\u00e1ctica y Procedimientos Punitivos**: Deben existir c\u00f3digos de pr\u00e1ctica y procedimientos para prevenir y abordar situaciones de mal uso, como la malversaci\u00f3n, el sabotaje, la desviaci\u00f3n o la falsificaci\u00f3n de productos.\n\n7. **Sistema de Calidad**: Se introduce el concepto de un sistema de calidad que debe incluir una pol\u00edtica de calidad documentada, una estructura organizativa adecuada y acciones sistem\u00e1ticas para garantizar que los productos y servicios cumplan con los requisitos de calidad.\n\n### Entidades\n\n- **Personal**: Incluye empleados, personal temporal y contratistas que manejan productos farmac\u00e9uticos.\n- **Productos Farmac\u00e9uticos**: Incluye productos peligrosos como materiales altamente activos, radiactivos, narc\u00f3ticos, y otros productos que presentan riesgos especiales.\n- **Organizaci\u00f3n**: Se refiere a la entidad que distribuye productos farmac\u00e9uticos y que debe implementar un sistema de calidad.\n- **Regulaciones Nacionales**: Normativas que rigen las calificaciones y la experiencia del personal en el manejo de productos farmac\u00e9uticos.\n- **Sistema de Calidad**: Conjunto de procedimientos y pol\u00edticas que aseguran la calidad de los productos y servicios ofrecidos por la organizaci\u00f3n. \n\nEste resumen destaca la importancia de la capacitaci\u00f3n, la higiene, la prevenci\u00f3n del acceso no autorizado y la implementaci\u00f3n de un sistema de calidad en la distribuci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: regulatory measures, pharmaceutical products, electronic commerce, traceability, risk assessment"}}, "75e60126-c46a-45f3-af43-b5770ed72b0a": {"node_ids": ["97c10ad1-fbc4-4071-93a5-0459aa5dcf95"], "metadata": {"page_label": "262", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 8.10\n\nAll parties involved in the supply chain should be identifiable, depending on the type of product and on national policies and legislation.\n\n8.11 Measures should be in place to ensure that pharmaceutical products have documentation that can be used to permit traceability of the products throughout distribution channels from the manufacturer/importer to the entity responsible for selling or supplying the product to the patient or his or her agent (see also 14.2). Records including expiry dates and batch numbers may be part of a secure distribution documentation enabling traceability.\n\n8.12 Ideally there should be a procedure in place for the creation and maintenance of a pedigree for pharmaceutical products.\n\nProvision should be made for a visual and/or analytical identification of potential counterfeit products. The procedure to be followed when a suspected product is identified should include provisions for notification, as appropriate, of the holder of the marketing authorization, entity identified on the label (if different from the manufacturer), the appropriate national and/or international regulatory bodies, as well as other relevant competent authorities (see also section 19).\n\n8.13 A suitable and, to the extent possible, internationally compatible product coding, identification system should be in place and developed in collaboration with the various parties involved in the supply chain. While it is understood that a differentiated approach may be necessary for different products and regions, pedigree and/or track-and-trace technologies provide possible options to ensure traceability.\n\n# 9. Premises, warehousing and storage\n\n9.1 Good storage practices (GSP) are applicable in all circumstances where pharmaceutical products are stored and throughout the distribution process. For additional guidance relating to the general principles of storage of pharmaceutical products, refer to the *WHO guide to good storage practices for pharmaceuticals* (1).\n\n## Storage areas\n\n9.2 Precautions must be taken to prevent unauthorized persons from entering storage areas. Employees should comply with the company policies to maintain a safe, secure and efficient working environment.\n\n9.3 Storage areas should be of sufficient capacity to allow the orderly storage of the various categories of pharmaceutical products, namely commercial", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia de la trazabilidad y la identificaci\u00f3n en la cadena de suministro de productos farmac\u00e9uticos. Se enfatiza la necesidad de que todas las partes involucradas sean identificables y que existan medidas para asegurar la documentaci\u00f3n que permita rastrear los productos desde el fabricante hasta el paciente. Tambi\u00e9n se menciona la creaci\u00f3n de un \"pedigree\" para los productos farmac\u00e9uticos y la identificaci\u00f3n de productos potencialmente falsificados. Adem\u00e1s, se establecen buenas pr\u00e1cticas de almacenamiento y la importancia de mantener \u00e1reas de almacenamiento seguras y adecuadas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se sugiere para garantizar la trazabilidad de los productos farmac\u00e9uticos a lo largo de la cadena de suministro?**\n   - El contexto menciona que se deben tener registros que incluyan fechas de caducidad y n\u00fameros de lote como parte de la documentaci\u00f3n de distribuci\u00f3n segura que permita la trazabilidad.\n\n2. **\u00bfCu\u00e1les son las medidas recomendadas para la identificaci\u00f3n de productos farmac\u00e9uticos potencialmente falsificados?**\n   - Se sugiere que se debe establecer un procedimiento para la identificaci\u00f3n visual y/o anal\u00edtica de productos sospechosos, que incluya notificaciones a las autoridades competentes y al titular de la autorizaci\u00f3n de comercializaci\u00f3n.\n\n3. **\u00bfQu\u00e9 pr\u00e1cticas se deben seguir para asegurar un almacenamiento adecuado de productos farmac\u00e9uticos?**\n   - Se deben seguir las Buenas Pr\u00e1cticas de Almacenamiento (GSP), asegurando que las \u00e1reas de almacenamiento sean seguras, con acceso restringido a personas no autorizadas y con suficiente capacidad para almacenar adecuadamente las diferentes categor\u00edas de productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Notificaci\u00f3n de Falsificaci\u00f3n**: Se debe informar de inmediato a los organismos reguladores y autoridades competentes en caso de confirmaci\u00f3n o sospecha de falsificaci\u00f3n de productos farmac\u00e9uticos. Los productos sospechosos deben ser almacenados de manera segura y segregada.\n\n2. **Comercio Electr\u00f3nico**: Es esencial establecer procedimientos y sistemas adecuados para garantizar la trazabilidad y la confianza en la calidad de los productos farmac\u00e9uticos distribuidos electr\u00f3nicamente. Las transacciones electr\u00f3nicas deben ser realizadas solo por personas o entidades autorizadas.\n\n3. **Procedimientos de Adquisici\u00f3n y Liberaci\u00f3n**: Deben existir procedimientos autorizados para asegurar que los productos farmac\u00e9uticos sean adquiridos solo de proveedores aprobados, con la aprobaci\u00f3n proveniente de la autoridad competente del pa\u00eds de registro.\n\n4. **Inspecci\u00f3n y Certificaci\u00f3n**: Se recomienda la inspecci\u00f3n, auditor\u00eda y certificaci\u00f3n de cumplimiento con sistemas de calidad por parte de organismos externos. Sin embargo, esta certificaci\u00f3n no sustituye el cumplimiento de las directrices de Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) y Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n5. **Integridad de Productos en Tr\u00e1nsito**: Se deben implementar medidas para asegurar la integridad de los productos durante el tr\u00e1nsito, incluyendo programas de control de sellos y procedimientos escritos para manejar productos sospechosos de ser falsificados.\n\n6. **Evaluaci\u00f3n de Riesgos**: Los distribuidores deben realizar evaluaciones de riesgo peri\u00f3dicas para identificar y abordar riesgos potenciales a la calidad e integridad de los productos farmac\u00e9uticos. El sistema de calidad debe ser revisado y actualizado regularmente.\n\n7. **Trazabilidad de Productos Farmac\u00e9uticos**: Las regulaciones deben promover un sistema de distribuci\u00f3n seguro, transparente y seguro que incluya la trazabilidad de los productos a lo largo de la cadena de suministro, siendo una responsabilidad compartida entre todas las partes involucradas.\n\n### Entidades Clave\n- **Organismos Reguladores**: Autoridades responsables de la supervisi\u00f3n y regulaci\u00f3n de productos farmac\u00e9uticos.\n- **Proveedores Aprobados**: Entidades que han sido autorizadas para suministrar productos farmac\u00e9uticos.\n- **Entidades Autorizadas**: Personas o entidades que est\u00e1n autorizadas para realizar transacciones electr\u00f3nicas de productos farmac\u00e9uticos.\n- **Cuerpos Externos de Inspecci\u00f3n**: Organismos que realizan auditor\u00edas y certificaciones de cumplimiento con sistemas de calidad.", "excerpt_keywords": "Keywords: trazabilidad, productos farmac\u00e9uticos, almacenamiento, falsificaci\u00f3n, cadena de suministro"}}, "7847ef49-18da-4125-949f-f135eafb0765": {"node_ids": ["792110f4-aafc-4e5d-b883-afaddf8350e1"], "metadata": {"page_label": "263", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Storage and Handling of Pharmaceutical Products\n\n9.4 Storage areas should be designed or adapted to ensure appropriate and good storage conditions. In particular, they should be clean and dry and maintained within acceptable temperature limits. Pharmaceutical products should be stored off the floor and suitably spaced to permit cleaning and inspection. Pallets should be kept in a good state of cleanliness and repair.\n\n9.5 Storage areas should be clean and free from accumulated waste and vermin. Organizations in charge of distribution must ensure that premises and storage areas are cleaned regularly. There should also be a written programme for pest control. The pest control agents used should be safe and there should be no risk of contamination of pharmaceutical products. There should be appropriate procedures for the clean-up of any spillage to ensure complete removal of any risk of contamination.\n\n9.6 If sampling is performed in the storage area, it should be conducted in such a way as to prevent contamination or cross-contamination. Adequate cleaning procedures should be in place for the sampling areas.\n\n9.7 Receiving and dispatch bays should protect pharmaceutical products from the weather. Receiving areas should be designed and equipped to allow incoming containers of pharmaceutical products to be cleaned, if necessary, before storage.\n\n9.8 Where quarantine status is ensured by storage in separate areas, these areas must be clearly marked and access restricted to authorized personnel. Any system replacing physical quarantine should provide equivalent security. For example, computerized systems can be used, provided that they are validated to demonstrate security of access.\n\n9.9 Physical or other equivalent validated (e.g. electronic) segregation should be provided for the storage of rejected, expired, recalled or returned products and suspected counterfeits. The products and the areas concerned should be appropriately identified.\n\n9.10 Unless there is an appropriate alternative system to prevent the unintentional or unauthorized use of quarantined, rejected, returned, recalled or suspected counterfeit pharmaceutical products, separate storage areas should be assigned for their temporary storage until a decision as to their future has been made.\n\n9.11 Radioactive materials, narcotics and other hazardous, sensitive and/or dangerous pharmaceutical products, as well as products presenting special risks of abuse, fire or explosion (e.g. combustible or flammable liquids and solids and pressurized gases) should be stored in a dedicated area(s) that is subject to appropriate additional safety and security measures.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS sobre el almacenamiento y manejo de productos farmac\u00e9uticos establece directrices claras para garantizar condiciones adecuadas de almacenamiento. Se enfatiza la importancia de mantener \u00e1reas de almacenamiento limpias, secas y organizadas, as\u00ed como la necesidad de programas de control de plagas y procedimientos para la limpieza de derrames. Tambi\u00e9n se abordan las medidas de seguridad para productos en estado de cuarentena, rechazados o peligrosos, y se especifican las condiciones para el almacenamiento de materiales sensibles como narc\u00f3ticos y productos radiactivos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben implementarse para garantizar la limpieza y el control de plagas en las \u00e1reas de almacenamiento de productos farmac\u00e9uticos?**\n   - El contexto menciona que las \u00e1reas de almacenamiento deben estar limpias y libres de desechos y plagas, y que debe existir un programa escrito de control de plagas que utilice agentes seguros para evitar la contaminaci\u00f3n de los productos farmac\u00e9uticos.\n\n2. **\u00bfC\u00f3mo se debe manejar el almacenamiento de productos farmac\u00e9uticos que han sido rechazados, expirados o sospechosos de ser falsificados?**\n   - Se debe proporcionar una segregaci\u00f3n f\u00edsica o equivalente para estos productos, y deben ser almacenados en \u00e1reas claramente identificadas y restringidas al acceso de personal autorizado hasta que se tome una decisi\u00f3n sobre su futuro.\n\n3. **\u00bfQu\u00e9 requisitos de seguridad adicionales se deben considerar para el almacenamiento de productos farmac\u00e9uticos peligrosos, como narc\u00f3ticos o materiales radiactivos?**\n   - Estos productos deben ser almacenados en \u00e1reas dedicadas que cuenten con medidas de seguridad y protecci\u00f3n adicionales adecuadas para prevenir riesgos de abuso, incendio o explosi\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Trazabilidad en la Cadena de Suministro**:\n   - Es esencial que todas las partes involucradas en la cadena de suministro de productos farmac\u00e9uticos sean identificables.\n   - Se deben implementar medidas para asegurar que los productos farmac\u00e9uticos cuenten con documentaci\u00f3n que permita su trazabilidad desde el fabricante hasta el paciente.\n\n2. **Documentaci\u00f3n y Registros**:\n   - La documentaci\u00f3n debe incluir registros de fechas de caducidad y n\u00fameros de lote, que son cruciales para la trazabilidad.\n\n3. **Creaci\u00f3n de un \"Pedigree\"**:\n   - Se sugiere establecer un procedimiento para la creaci\u00f3n y mantenimiento de un \"pedigree\" para los productos farmac\u00e9uticos, que ayude a rastrear su origen y distribuci\u00f3n.\n\n4. **Identificaci\u00f3n de Productos Falsificados**:\n   - Se deben implementar procedimientos para la identificaci\u00f3n visual y/o anal\u00edtica de productos sospechosos de ser falsificados, incluyendo notificaciones a las autoridades competentes y al titular de la autorizaci\u00f3n de comercializaci\u00f3n.\n\n5. **Sistema de Codificaci\u00f3n y Identificaci\u00f3n**:\n   - Es necesario desarrollar un sistema de codificaci\u00f3n e identificaci\u00f3n de productos que sea compatible internacionalmente, en colaboraci\u00f3n con las partes involucradas en la cadena de suministro.\n\n6. **Buenas Pr\u00e1cticas de Almacenamiento (GSP)**:\n   - Se deben seguir las Buenas Pr\u00e1cticas de Almacenamiento en todas las circunstancias donde se almacenen productos farmac\u00e9uticos.\n   - Las \u00e1reas de almacenamiento deben ser seguras, con acceso restringido a personas no autorizadas y con suficiente capacidad para almacenar adecuadamente los productos.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que proporciona directrices sobre la trazabilidad y almacenamiento de productos farmac\u00e9uticos.\n- **Titulares de Autorizaci\u00f3n de Comercializaci\u00f3n**: Entidades responsables de la comercializaci\u00f3n de productos farmac\u00e9uticos.\n- **Autoridades Reguladoras Nacionales e Internacionales**: Cuerpos que supervisan la seguridad y eficacia de los productos farmac\u00e9uticos.\n- **Partes Involucradas en la Cadena de Suministro**: Incluyen fabricantes, importadores, distribuidores y entidades que suministran productos a los pacientes.", "excerpt_keywords": "Keywords: storage, pharmaceutical, contamination, quarantine, safety"}}, "7c30aa0a-7a23-40a8-9f6c-27b8d90fc0ef": {"node_ids": ["e7dacaa4-1fb5-473c-923a-8112abdfd803"], "metadata": {"page_label": "264", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 9.12 \nPharmaceutical products should be handled and stored in such a manner as to prevent contamination, mix-ups and cross-contamination.\n\n# 9.13 \nA system should be in place to ensure that the pharmaceutical products due to expire first are sold and/or distributed first (first expiry/first out (FEFO)). Exceptions may be permitted as appropriate, provided that adequate controls are in place to prevent the distribution of expired products.\n\n# 9.14 \nBroken or damaged items should be withdrawn from usable stock and stored separately.\n\n# 9.15 \nStorage areas should be provided with adequate lighting to enable all operations to be carried out accurately and safely.\n\n## Storage conditions and stock control\n\n# 9.16 \nStorage and handling conditions should comply with applicable national and local regulations (8).\n\n# 9.17 \nStorage conditions for pharmaceutical products should be in compliance with the recommendations of the manufacturer.\n\n# 9.18 \nFacilities should be available for the storage of all pharmaceutical products under appropriate conditions (e.g. environmentally controlled when necessary). Records should be maintained of these conditions if they are critical for the maintenance of the characteristics of the pharmaceutical product stored.\n\n# 9.19 \nRecords of temperature monitoring data should be available for review. There should be defined intervals for checking temperature. The equipment used for monitoring should be checked at suitable predetermined intervals and the results of such checks should be recorded and retained. All monitoring records should be kept for at least the shelf-life of the stored pharmaceutical product plus one year, or as required by national legislation. Temperature mapping should show uniformity of the temperature across the storage facility. It is recommended that temperature monitors be located in areas that are most likely to show fluctuations.\n\n# 9.20 \nEquipment used for monitoring of storage conditions should also be calibrated at defined intervals.\n\n# 9.21 \nPeriodic stock reconciliation should be performed by comparing the actual and recorded stocks. This should be done at defined intervals.\n\n# 9.22 \nStock discrepancies should be investigated in accordance with a specified procedure to check that there have been no inadvertent mix-ups, incorrect issues and receipts, thefts and/or misappropriations of pharmaceutical products.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl contexto se centra en las directrices de almacenamiento y manejo de productos farmac\u00e9uticos, tal como se detalla en el Informe T\u00e9cnico de la OMS. Se enfatiza la importancia de prevenir la contaminaci\u00f3n y los errores en el manejo de productos, as\u00ed como la necesidad de seguir un sistema de gesti\u00f3n de inventarios que priorice la venta de productos que est\u00e1n por expirar. Tambi\u00e9n se abordan las condiciones de almacenamiento, el monitoreo de temperatura, la calibraci\u00f3n de equipos y la reconciliaci\u00f3n peri\u00f3dica de inventarios para asegurar la integridad y seguridad de los productos farmac\u00e9uticos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para manejar productos farmac\u00e9uticos da\u00f1ados o rotos seg\u00fan el informe?**\n   - Respuesta: Los productos farmac\u00e9uticos da\u00f1ados o rotos deben ser retirados del stock utilizable y almacenados por separado.\n\n2. **\u00bfCu\u00e1les son los requisitos para el monitoreo de temperatura en las \u00e1reas de almacenamiento de productos farmac\u00e9uticos?**\n   - Respuesta: Se deben mantener registros de los datos de monitoreo de temperatura, realizar verificaciones a intervalos definidos, y conservar todos los registros de monitoreo durante al menos la vida \u00fatil del producto almacenado m\u00e1s un a\u00f1o, o seg\u00fan lo requiera la legislaci\u00f3n nacional.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse en caso de discrepancias en el inventario de productos farmac\u00e9uticos?**\n   - Respuesta: Las discrepancias en el inventario deben ser investigadas de acuerdo con un procedimiento espec\u00edfico para verificar que no haya habido errores involuntarios, problemas en la emisi\u00f3n y recepci\u00f3n, robos o apropiaciones indebidas de productos farmac\u00e9uticos.", "prev_section_summary": "### Temas Clave\n\n1. **Condiciones de Almacenamiento**: Las \u00e1reas de almacenamiento deben ser limpias, secas y mantener temperaturas adecuadas. Los productos farmac\u00e9uticos deben estar elevados del suelo y organizados para facilitar la limpieza y la inspecci\u00f3n.\n\n2. **Limpieza y Control de Plagas**: Es esencial que las \u00e1reas de almacenamiento est\u00e9n libres de desechos y plagas. Se requiere un programa escrito de control de plagas y procedimientos para la limpieza de derrames.\n\n3. **Manejo de Productos en Cuarentena**: Las \u00e1reas de cuarentena deben estar claramente marcadas y restringidas al acceso de personal autorizado. Se pueden utilizar sistemas inform\u00e1ticos validados para asegurar el acceso.\n\n4. **Almacenamiento de Productos Rechazados o Sospechosos**: Se debe proporcionar segregaci\u00f3n f\u00edsica o equivalente para productos rechazados, expirados, o sospechosos de ser falsificados, con \u00e1reas claramente identificadas.\n\n5. **Almacenamiento de Productos Peligrosos**: Los materiales radiactivos, narc\u00f3ticos y otros productos peligrosos deben almacenarse en \u00e1reas dedicadas con medidas de seguridad adicionales para prevenir riesgos.\n\n### Entidades\n\n- **Organizaciones de Distribuci\u00f3n**: Responsables de la limpieza y mantenimiento de las \u00e1reas de almacenamiento.\n- **Productos Farmac\u00e9uticos**: Incluyen medicamentos y otros productos relacionados que requieren condiciones espec\u00edficas de almacenamiento.\n- **Agentes de Control de Plagas**: Sustancias utilizadas para prevenir infestaciones que deben ser seguras y no contaminar productos.\n- **Personal Autorizado**: Individuos con permiso para acceder a \u00e1reas restringidas, especialmente en el contexto de productos en cuarentena o peligrosos.\n- **Sistemas Inform\u00e1ticos**: Herramientas que pueden ser utilizadas para asegurar el acceso a \u00e1reas de cuarentena, siempre que est\u00e9n validadas.\n\nEste resumen destaca la importancia de mantener est\u00e1ndares rigurosos en el almacenamiento y manejo de productos farmac\u00e9uticos para garantizar su integridad y seguridad.", "excerpt_keywords": "Keywords: pharmaceutical storage, contamination prevention, temperature monitoring, stock reconciliation, FEFO system"}}, "62650d87-613c-4aa5-8319-e4dcbeb91750": {"node_ids": ["c2f00f02-bfc5-4c42-a7cf-72cdf86775e2"], "metadata": {"page_label": "265", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Vehicles and equipment\n\n10.1 Vehicles and equipment used to distribute, store or handle pharmaceutical products should be suitable for their purpose and appropriately equipped to prevent exposure of the products to conditions that could affect their stability and packaging integrity, and to prevent contamination of any kind.\n\n10.2 The design and use of vehicles and equipment must aim to minimize the risk of errors and permit effective cleaning and/or maintenance to avoid contamination, build-up of dust or dirt and/or any adverse effect on the quality of the pharmaceutical products being distributed.\n\n10.3 Where feasible, consideration should be given to adding technology, such as global positioning system (GPS) electronic tracking devices and engine-kill buttons to vehicles, which would enhance the security of pharmaceutical products while in the vehicle.\n\n10.4 Dedicated vehicles and equipment should be used, where possible, when handling pharmaceutical products.\n\n10.5 Where non-dedicated vehicles and equipment are used, procedures should be in place to ensure that the quality of the pharmaceutical product will not be compromised. Appropriate cleaning should be performed, checked and recorded.\n\n10.6 Procedures should be in place to ensure that the integrity of the products is not compromised during transportation.\n\n10.7 Where third-party carriers are used, distributors should develop written agreements with carriers to ensure that appropriate measures are taken to safeguard pharmaceutical products, including maintaining appropriate documentation and records. Such agreements should be in line with national and regional regulatory requirements.\n\n10.8 Defective vehicles and equipment should not be used and should either be labelled as such or removed from service.\n\n10.9 There should be procedures in place for the operation and maintenance of all vehicles and equipment involved in the distribution process, including cleaning and safety precautions.\n\n10.10 Vehicles, containers and equipment should be kept clean and dry and free from accumulated waste. Organizations in charge of distribution must ensure that vehicles used are cleaned regularly.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las directrices sobre el uso de veh\u00edculos y equipos para la distribuci\u00f3n, almacenamiento y manejo de productos farmac\u00e9uticos. Se enfatiza la importancia de que estos veh\u00edculos y equipos sean adecuados para su prop\u00f3sito, minimizando riesgos de errores y contaminaci\u00f3n. Se sugiere el uso de tecnolog\u00eda para mejorar la seguridad, la necesidad de procedimientos de limpieza y mantenimiento, y la importancia de acuerdos escritos con transportistas de terceros. Tambi\u00e9n se menciona que los veh\u00edculos defectuosos no deben ser utilizados y que deben mantenerse limpios y secos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas espec\u00edficas deben implementarse para garantizar que los veh\u00edculos no dedicados no comprometan la calidad de los productos farmac\u00e9uticos?**\n   - Esta pregunta busca detalles sobre los procedimientos de limpieza y verificaci\u00f3n que deben seguirse cuando se utilizan veh\u00edculos que no est\u00e1n exclusivamente destinados al transporte de productos farmac\u00e9uticos.\n\n2. **\u00bfCu\u00e1les son las tecnolog\u00edas recomendadas para mejorar la seguridad de los productos farmac\u00e9uticos durante el transporte y c\u00f3mo se deben implementar?**\n   - Esta pregunta se centra en las tecnolog\u00edas mencionadas, como los dispositivos de seguimiento GPS y los botones de apagado del motor, y c\u00f3mo estas pueden ser integradas en la operaci\u00f3n de los veh\u00edculos.\n\n3. **\u00bfQu\u00e9 tipo de documentaci\u00f3n y registros deben mantenerse en los acuerdos con transportistas de terceros para asegurar la protecci\u00f3n de los productos farmac\u00e9uticos?**\n   - Esta pregunta busca informaci\u00f3n sobre los requisitos espec\u00edficos de documentaci\u00f3n y registros que deben incluirse en los acuerdos escritos con los transportistas, asegurando que se cumplan las normativas nacionales y regionales.", "prev_section_summary": "### Temas Clave\n\n1. **Manejo y Almacenamiento de Productos Farmac\u00e9uticos**: Se enfatiza la importancia de prevenir la contaminaci\u00f3n, los errores y la mezcla de productos durante su manejo y almacenamiento.\n\n2. **Sistema FEFO (First Expiry/First Out)**: Se debe implementar un sistema que garantice que los productos que est\u00e1n por expirar se vendan o distribuyan primero, con excepciones permitidas bajo controles adecuados.\n\n3. **Retiro de Productos Da\u00f1ados**: Los productos farmac\u00e9uticos da\u00f1ados o rotos deben ser retirados del stock utilizable y almacenados por separado.\n\n4. **Condiciones de Almacenamiento**: Las \u00e1reas de almacenamiento deben cumplir con regulaciones nacionales y locales, as\u00ed como con las recomendaciones del fabricante. Se deben mantener registros de las condiciones de almacenamiento.\n\n5. **Monitoreo de Temperatura**: Se requiere un registro de los datos de monitoreo de temperatura, con verificaciones a intervalos definidos y conservaci\u00f3n de registros por un per\u00edodo espec\u00edfico.\n\n6. **Calibraci\u00f3n de Equipos**: Los equipos utilizados para el monitoreo de condiciones de almacenamiento deben ser calibrados a intervalos definidos.\n\n7. **Reconciliaci\u00f3n de Inventarios**: Se debe realizar una reconciliaci\u00f3n peri\u00f3dica del inventario comparando los stocks reales con los registrados.\n\n8. **Investigaci\u00f3n de Discrepancias**: Las discrepancias en el inventario deben ser investigadas siguiendo un procedimiento espec\u00edfico para asegurar que no haya habido errores, robos o apropiaciones indebidas.\n\n### Entidades\n\n- **Productos Farmac\u00e9uticos**: Bienes que requieren manejo y almacenamiento cuidadoso.\n- **Sistema FEFO**: M\u00e9todo de gesti\u00f3n de inventarios basado en la fecha de caducidad.\n- **Regulaciones Nacionales y Locales**: Normativas que rigen el manejo y almacenamiento de productos farmac\u00e9uticos.\n- **Condiciones de Almacenamiento**: Factores ambientales que afectan la integridad de los productos.\n- **Equipos de Monitoreo**: Herramientas utilizadas para asegurar condiciones adecuadas de almacenamiento.\n- **Registros de Monitoreo**: Documentaci\u00f3n que respalda el cumplimiento de las condiciones de almacenamiento.\n- **Discrepancias de Inventario**: Diferencias entre el stock real y el registrado que requieren investigaci\u00f3n.", "excerpt_keywords": "Vehicles, pharmaceutical, distribution, contamination, equipment"}}, "c56fb46d-de57-4200-b42d-6e106d4bfe50": {"node_ids": ["48204bc4-21c4-46c3-a350-89018165b2b7"], "metadata": {"page_label": "266", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 10.11\n\nVehicles, containers and equipment should be kept free from rodents, vermin, birds and other pests. There should be written programmes and records for such pest control. The cleaning and fumigation agents used should not have any adverse effect on product quality.\n\n# 10.12\n\nEquipment chosen and used for the cleaning of vehicles should not constitute a source of contamination. Agents used for the cleaning of vehicles should be approved by management.\n\n# 10.13\n\nSpecial attention should be paid to the design, use, cleaning and maintenance of all equipment used for the handling of pharmaceutical products which are not in a protective shipping carton or case.\n\n# 10.14\n\nWhere special storage conditions (e.g. temperature and/or relative humidity), different from, or limiting, the expected environmental conditions, are required during transportation, these should be provided, checked, monitored and recorded. All monitoring records should be kept for a minimum of the shelf-life of the product distributed plus one year, or as required by national legislation. Records of monitoring data should be made available for inspection by the regulatory or other oversight body.\n\n# 10.15\n\nEquipment used for monitoring conditions, e.g. temperature and humidity, within vehicles and containers should be calibrated at regular intervals.\n\n# 10.16\n\nVehicles and containers should be of sufficient capacity to allow orderly storage of the various categories of pharmaceutical products during transportation.\n\n# 10.17\n\nWhere possible, mechanisms should be available to allow for the segregation during transit of rejected, recalled and returned pharmaceutical products as well as those suspected of being counterfeits. Such goods should be securely packaged, clearly labelled, and be accompanied by appropriate supporting documentation.\n\n# 10.18\n\nMeasures should be in place to prevent unauthorized persons from entering and/or tampering with vehicles and/or equipment, as well as to prevent the theft or misappropriation thereof.\n\n# 11. Shipment containers and container labelling\n\n## 11.1\n\nPharmaceutical products should be stored and distributed in shipment containers that have no adverse effect on the quality of the products, and that offer adequate protection from external influences, including contamination.\n\n## 11.2\n\nShipping containers should bear labels providing sufficient information on handling and storage conditions and precautions to ensure", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Control de plagas y limpieza**: Se establece la importancia de mantener veh\u00edculos, contenedores y equipos libres de plagas y de utilizar agentes de limpieza que no afecten la calidad de los productos farmac\u00e9uticos. Se requiere documentaci\u00f3n y programas escritos para el control de plagas.\n\n2. **Condiciones de almacenamiento y transporte**: Se enfatiza la necesidad de cumplir con condiciones especiales de almacenamiento durante el transporte, incluyendo el monitoreo de temperatura y humedad. Los registros de monitoreo deben ser conservados por un per\u00edodo espec\u00edfico y estar disponibles para inspecci\u00f3n.\n\n3. **Seguridad y etiquetado de contenedores**: Se requiere que los contenedores de env\u00edo sean adecuados para proteger la calidad de los productos y que contengan etiquetas con informaci\u00f3n suficiente sobre las condiciones de manejo y almacenamiento.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para el control de plagas en veh\u00edculos y contenedores de productos farmac\u00e9uticos?**\n   - La normativa exige que haya programas escritos y registros espec\u00edficos para el control de plagas, asegurando que se mantengan libres de roedores, vermin, aves y otros pestes.\n\n2. **\u00bfCu\u00e1les son las obligaciones de los responsables sobre el monitoreo de condiciones especiales durante el transporte de productos farmac\u00e9uticos?**\n   - Se requiere que se proporcionen, verifiquen, monitoreen y registren las condiciones especiales de almacenamiento, como temperatura y humedad, y que los registros se mantengan por un m\u00ednimo de la vida \u00fatil del producto m\u00e1s un a\u00f1o.\n\n3. **\u00bfQu\u00e9 medidas de seguridad deben implementarse para prevenir el acceso no autorizado a veh\u00edculos y equipos de transporte de productos farmac\u00e9uticos?**\n   - Deben establecerse medidas para evitar que personas no autorizadas ingresen o manipulen veh\u00edculos y equipos, as\u00ed como para prevenir el robo o la apropiaci\u00f3n indebida de los mismos.", "prev_section_summary": "### Temas Clave\n\n1. **Adecuaci\u00f3n de Veh\u00edculos y Equipos**: Los veh\u00edculos y equipos utilizados para la distribuci\u00f3n, almacenamiento y manejo de productos farmac\u00e9uticos deben ser apropiados para su prop\u00f3sito y estar equipados para prevenir la exposici\u00f3n a condiciones que puedan afectar la estabilidad y la integridad del empaque de los productos.\n\n2. **Minimizaci\u00f3n de Errores y Contaminaci\u00f3n**: Se debe dise\u00f1ar y utilizar veh\u00edculos y equipos que minimicen el riesgo de errores y permitan una limpieza y mantenimiento efectivos para evitar la contaminaci\u00f3n y la acumulaci\u00f3n de suciedad.\n\n3. **Tecnolog\u00eda para Seguridad**: Se recomienda la incorporaci\u00f3n de tecnolog\u00edas como dispositivos de seguimiento GPS y botones de apagado del motor para mejorar la seguridad de los productos farmac\u00e9uticos durante el transporte.\n\n4. **Uso de Veh\u00edculos Dedicados**: Siempre que sea posible, se deben utilizar veh\u00edculos y equipos dedicados para el manejo de productos farmac\u00e9uticos.\n\n5. **Procedimientos para Veh\u00edculos No Dedicados**: Cuando se utilicen veh\u00edculos no dedicados, deben existir procedimientos para asegurar que la calidad de los productos farmac\u00e9uticos no se vea comprometida, incluyendo limpieza adecuada y verificaci\u00f3n.\n\n6. **Integridad Durante el Transporte**: Se deben establecer procedimientos para garantizar que la integridad de los productos no se comprometa durante el transporte.\n\n7. **Acuerdos con Transportistas de Terceros**: Es necesario desarrollar acuerdos escritos con transportistas de terceros que incluyan medidas para salvaguardar los productos farmac\u00e9uticos y mantener la documentaci\u00f3n adecuada, cumpliendo con las normativas nacionales y regionales.\n\n8. **Mantenimiento de Veh\u00edculos y Equipos**: Los veh\u00edculos y equipos defectuosos no deben ser utilizados y deben ser etiquetados o retirados del servicio. Adem\u00e1s, deben existir procedimientos para su operaci\u00f3n y mantenimiento, incluyendo limpieza y precauciones de seguridad.\n\n9. **Limpieza y Mantenimiento**: Los veh\u00edculos, contenedores y equipos deben mantenerse limpios, secos y libres de residuos acumulados, asegurando una limpieza regular.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Productos Farmac\u00e9uticos**: Bienes que se distribuyen, almacenan y manejan.\n- **Veh\u00edculos y Equipos**: Herramientas utilizadas en la distribuci\u00f3n y manejo de productos farmac\u00e9uticos.\n- **Transportistas de Terceros**: Entidades externas que pueden ser contratadas para el transporte de productos farmac\u00e9uticos.\n- **Tecnolog\u00eda**: Dispositivos como GPS y sistemas de seguridad que se pueden implementar para mejorar la seguridad durante el transporte.", "excerpt_keywords": "Keywords: pest control, pharmaceutical transportation, equipment maintenance, monitoring conditions, shipment containers"}}, "73993a4d-3307-4d84-a223-e7b970b3891b": {"node_ids": ["62320a65-cec2-41c6-9dad-b747997468b2"], "metadata": {"page_label": "267", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "that the products are properly handled and secure at all times. The shipment container should enable identification of the container\u2019s contents and source.\n\n11.3 The need for any special transport and/or storage conditions should be stated on the shipment container label. If a pharmaceutical product is intended for transfer to areas outside the control of the manufacturer\u2019s products management system, the name and address of the manufacturer, special transport conditions and any special legal requirements, including safety symbols, should also be included on the container label.\n\n11.4 Normally, internationally and/or nationally accepted abbreviations, names or codes should be used in the labelling of shipment containers.\n\n11.5 Special care should be taken when using dry ice in shipment containers. In addition to safety issues it must be ensured that the pharmaceutical product does not come into contact with the dry ice, as it may have an adverse effect on the quality of the product.\n\n11.6 Written procedures should be available for the handling of damaged and/or broken shipment containers. Particular attention should be paid to those containing potentially toxic and hazardous products.\n\n# 12. Dispatch and receipt\n\n12.1 Pharmaceutical products should only be sold and/or distributed to persons or entities that are authorized to acquire such products in accordance with the applicable national, regional and international legislation. Written proof of such authority must be obtained prior to the distribution of products to such persons or entities.\n\n12.2 Prior to the dispatch of the pharmaceutical products, the supplier should ensure that the person or entity, e.g. the contract acceptor for transportation of the pharmaceutical products, is aware of the pharmaceutical products to be distributed and complies with the appropriate storage and transport conditions.\n\n12.3 The dispatch and transportation of pharmaceutical products should be undertaken only after the receipt of a valid delivery order or material replenishment plan, which should be documented.\n\n12.4 Written procedures for the dispatch of pharmaceutical products should be established. Such procedures should take into account the nature of the product as well as any special precautions to be observed. Pharmaceutical products under quarantine will require release for dispatch by the person responsible for quality (see 6.3).\n\n12.5 Records for the dispatch of pharmaceutical products should be prepared and should include at least the following information:", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre el manejo, transporte y despacho de productos farmac\u00e9uticos, enfatizando la importancia de la identificaci\u00f3n adecuada de los envases, el cumplimiento de las condiciones de transporte y almacenamiento, y la necesidad de procedimientos escritos para el manejo de productos da\u00f1ados. Tambi\u00e9n se menciona la importancia de asegurar que solo se distribuyan productos a entidades autorizadas y que se mantengan registros adecuados de los despachos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la etiqueta del contenedor de env\u00edo si un producto farmac\u00e9utico se transfiere a \u00e1reas fuera del control del sistema de gesti\u00f3n de productos del fabricante?**\n   - La etiqueta debe incluir el nombre y la direcci\u00f3n del fabricante, las condiciones especiales de transporte y cualquier requisito legal especial, incluidos los s\u00edmbolos de seguridad.\n\n2. **\u00bfCu\u00e1les son las precauciones espec\u00edficas que se deben tomar al utilizar hielo seco en los contenedores de env\u00edo de productos farmac\u00e9uticos?**\n   - Se debe tener especial cuidado para asegurar que el producto farmac\u00e9utico no entre en contacto con el hielo seco, ya que esto podr\u00eda afectar negativamente la calidad del producto.\n\n3. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere antes de despachar productos farmac\u00e9uticos?**\n   - Se requiere la recepci\u00f3n de una orden de entrega v\u00e1lida o un plan de reposici\u00f3n de materiales, que debe ser documentado antes de proceder con el despacho y transporte de los productos farmac\u00e9uticos.", "prev_section_summary": "### Temas Clave\n\n1. **Control de Plagas y Limpieza**: Es fundamental mantener veh\u00edculos, contenedores y equipos libres de plagas (roedores, vermin, aves, etc.). Se requiere la implementaci\u00f3n de programas escritos y registros para el control de plagas, as\u00ed como el uso de agentes de limpieza que no afecten la calidad de los productos farmac\u00e9uticos.\n\n2. **Condiciones de Almacenamiento y Transporte**: Se debe prestar especial atenci\u00f3n a las condiciones de almacenamiento durante el transporte, incluyendo temperatura y humedad. Estas condiciones deben ser verificadas, monitoreadas y registradas, y los registros deben conservarse por un m\u00ednimo de la vida \u00fatil del producto m\u00e1s un a\u00f1o.\n\n3. **Seguridad y Acceso**: Es necesario implementar medidas para prevenir el acceso no autorizado a veh\u00edculos y equipos, as\u00ed como para evitar el robo o la manipulaci\u00f3n indebida de los mismos.\n\n4. **Dise\u00f1o y Mantenimiento de Equipos**: Se debe asegurar que el dise\u00f1o, uso, limpieza y mantenimiento de los equipos utilizados para manejar productos farmac\u00e9uticos sean adecuados para evitar la contaminaci\u00f3n.\n\n5. **Etiquetado y Protecci\u00f3n de Contenedores**: Los contenedores de env\u00edo deben ser apropiados para proteger la calidad de los productos y deben llevar etiquetas que proporcionen informaci\u00f3n suficiente sobre las condiciones de manejo y almacenamiento.\n\n### Entidades\n\n- **Veh\u00edculos y Contenedores**: Elementos utilizados para el transporte de productos farmac\u00e9uticos.\n- **Agentes de Limpieza**: Sustancias utilizadas para mantener la limpieza de veh\u00edculos y equipos.\n- **Condiciones Especiales**: Requisitos espec\u00edficos de temperatura y humedad durante el transporte.\n- **Registros de Monitoreo**: Documentaci\u00f3n que debe ser mantenida para verificar el cumplimiento de las condiciones de almacenamiento.\n- **Productos Farmac\u00e9uticos**: Bienes que requieren condiciones espec\u00edficas para su manejo y transporte.\n- **Medidas de Seguridad**: Protocolos implementados para proteger los veh\u00edculos y equipos de acceso no autorizado.", "excerpt_keywords": "Keywords: pharmaceutical products, shipment containers, transport conditions, dispatch procedures, quality control"}}, "75f585ac-c459-4e7f-ad84-dcd1571dc294": {"node_ids": ["18088118-b2e8-4ece-940b-105dc7b79d66"], "metadata": {"page_label": "268", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "\u2014 date of dispatch;  \n\u2014 complete business name and address (no acronyms), type of entity responsible for the transportation, telephone number and names of contact persons;  \n\u2014 complete business name, address (no acronyms), and status of the addressee (e.g. retail pharmacy, hospital or community clinic);  \n\u2014 a description of the products including, e.g. name, dosage form and strength (if applicable);  \n\u2014 quantity of the products, i.e. number of containers and quantity per container (if applicable);  \n\u2014 applicable transport and storage conditions;  \n\u2014 a unique number to allow identification of the delivery order; and  \n\u2014 assigned batch number and expiry date (where not possible at dispatch, this information should at least be kept at receipt to facilitate traceability).  \n\n12.6 Records of dispatch should contain enough information to enable traceability of the pharmaceutical product. Such records should facilitate the recall of a batch of a product, if necessary, as well as the investigation of counterfeit or potentially counterfeit pharmaceutical products.\n\n12.7 In addition, the assigned batch number and expiry date of pharmaceutical products should be recorded at the point of receipt to facilitate traceability.\n\n12.8 Methods of transportation, including vehicles to be used, should be selected with care, and local conditions should be considered, including the climate and any seasonal variations experienced. Delivery of products requiring controlled temperatures should be in accordance with the applicable storage and transport conditions.\n\n12.9 Delivery schedules should be established and routes planned, taking local needs and conditions into account. Such schedules and plans should be realistic and systematic. Security risks should also be taken into account when planning the schedules and routes of the delivery.\n\n12.10 Care should be taken to ensure that the volume of pharmaceutical products ordered does not exceed the capacity of storage facilities at the destination.\n\n12.11 Vehicles and containers should be loaded carefully and systematically, where applicable on a first-out/last-in basis, to save time when unloading, prevent physical damage and reduce security risks. Extra care should be taken during loading and unloading of cartons to avoid damage.\n\n12.12 Pharmaceutical products should not be supplied or received after their expiry date, or so close to the expiry date that this date is likely to be reached before the products are used by the consumer.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl texto proporciona directrices sobre el manejo y transporte de productos farmac\u00e9uticos, enfatizando la importancia de la trazabilidad, la documentaci\u00f3n adecuada y las condiciones de transporte. Se detallan los elementos que deben incluirse en los registros de despacho, como la informaci\u00f3n del remitente y destinatario, la descripci\u00f3n de los productos, las condiciones de transporte y almacenamiento, as\u00ed como la gesti\u00f3n de la carga y la planificaci\u00f3n de rutas. Tambi\u00e9n se menciona la necesidad de evitar el suministro de productos que est\u00e9n cerca de su fecha de caducidad.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en los registros de despacho para garantizar la trazabilidad de los productos farmac\u00e9uticos?**\n   - Respuesta: Los registros de despacho deben incluir la fecha de despacho, el nombre y direcci\u00f3n completos del remitente y destinatario, una descripci\u00f3n de los productos, la cantidad de productos, las condiciones de transporte y almacenamiento, un n\u00famero \u00fanico para identificar el pedido, y el n\u00famero de lote y fecha de caducidad.\n\n2. **\u00bfCu\u00e1les son las consideraciones que deben tenerse en cuenta al seleccionar los m\u00e9todos de transporte para productos farmac\u00e9uticos?**\n   - Respuesta: Al seleccionar los m\u00e9todos de transporte, se deben considerar las condiciones locales, el clima, las variaciones estacionales y las condiciones de almacenamiento y transporte aplicables, especialmente para productos que requieren temperaturas controladas.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse para asegurar que los productos farmac\u00e9uticos no se suministren o reciban despu\u00e9s de su fecha de caducidad?**\n   - Respuesta: Se debe tener cuidado para no suministrar o recibir productos que est\u00e9n cerca de su fecha de caducidad, asegurando que esta fecha no se alcance antes de que los productos sean utilizados por el consumidor. Adem\u00e1s, es importante registrar la fecha de caducidad en el punto de recepci\u00f3n para facilitar la trazabilidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manejo y Seguridad de Productos Farmac\u00e9uticos**:\n   - Importancia de asegurar que los productos farmac\u00e9uticos sean manejados y asegurados adecuadamente en todo momento.\n   - Los contenedores de env\u00edo deben permitir la identificaci\u00f3n de su contenido y origen.\n\n2. **Etiquetado de Contenedores de Env\u00edo**:\n   - La etiqueta del contenedor debe incluir condiciones especiales de transporte y almacenamiento.\n   - Para productos transferidos fuera del control del fabricante, se debe incluir el nombre y direcci\u00f3n del fabricante, condiciones especiales de transporte y requisitos legales, incluidos s\u00edmbolos de seguridad.\n   - Uso de abreviaturas, nombres o c\u00f3digos aceptados internacionalmente o nacionalmente en el etiquetado.\n\n3. **Uso de Hielo Seco**:\n   - Precauciones especiales al utilizar hielo seco en contenedores de env\u00edo, asegurando que el producto no entre en contacto con el hielo seco para evitar efectos adversos en la calidad.\n\n4. **Procedimientos para Productos Da\u00f1ados**:\n   - Disponibilidad de procedimientos escritos para el manejo de contenedores de env\u00edo da\u00f1ados, con atenci\u00f3n especial a productos potencialmente t\u00f3xicos y peligrosos.\n\n5. **Despacho y Recepci\u00f3n de Productos Farmac\u00e9uticos**:\n   - Solo se deben vender o distribuir productos a entidades autorizadas, con prueba escrita de dicha autoridad.\n   - Verificaci\u00f3n de que el transportista est\u00e9 informado sobre los productos y cumpla con las condiciones de almacenamiento y transporte.\n   - Requerimiento de una orden de entrega v\u00e1lida o plan de reposici\u00f3n de materiales antes del despacho.\n   - Establecimiento de procedimientos escritos para el despacho, considerando la naturaleza del producto y precauciones especiales.\n   - Preparaci\u00f3n de registros de despacho que incluyan informaci\u00f3n relevante.\n\n### Entidades Clave\n- **Productos Farmac\u00e9uticos**: Bienes que requieren manejo y transporte cuidadoso.\n- **Fabricante**: Entidad responsable de la producci\u00f3n y etiquetado de los productos.\n- **Entidades Autorizadas**: Personas o entidades que tienen permiso legal para adquirir productos farmac\u00e9uticos.\n- **Transportistas**: Entidades encargadas del transporte de productos farmac\u00e9uticos.\n- **Autoridades Legales**: Organismos que regulan la distribuci\u00f3n y venta de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: trazabilidad, productos farmac\u00e9uticos, transporte, condiciones de almacenamiento, fecha de caducidad"}}, "9e0fa5ca-28a5-48fb-ad06-b2c1a504edd2": {"node_ids": ["bb69d4f6-37c7-49f2-aefe-686158865eae"], "metadata": {"page_label": "269", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Transportation and products in transit\n\n13.1 Products and shipment containers should be secured to prevent or provide evidence of unauthorized access. Vehicles and operators should be provided with additional security, as appropriate, to prevent theft and other misappropriation of products during transportation.\n\n13.2 Product shipments should be secured and include the appropriate documentation to facilitate identification and verification of compliance with regulatory requirements. Policies and procedures should be followed by all persons involved in the transportation, to secure pharmaceutical products.\n\n13.3 The people responsible for the transportation of pharmaceutical products should be informed about all relevant conditions for storage and transportation. These requirements should be adhered to throughout transportation and at any intermediate storage stages.\n\n13.4 Pharmaceutical products should be stored and transported in accordance with procedures such that:\n- The identity of the product is not lost.\n- The product does not contaminate and is not contaminated by other products.\n- Adequate precautions are taken against spillage, breakage, misappropriation and theft.\n- Appropriate environmental conditions are maintained, e.g. using cold chain for thermolabile products.\n\n13.5 The required storage conditions for pharmaceutical products should be maintained within acceptable limits during transportation. If a deviation has been noticed during transportation by the person or entity responsible for transportation, this should be reported to the distributor and recipient. In cases where the recipient notices the deviation, it should be reported to the distributor. Where necessary, the manufacturer of the pharmaceutical product should be contacted for information about appropriate steps to be taken.\n\n13.6 Where special conditions are required during transportation that are different from or limit the given environmental conditions (e.g. temperature and humidity) these should be provided by the manufacturer on the labels, monitored and recorded.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las mejores pr\u00e1cticas para el transporte y manejo de productos farmac\u00e9uticos. Se enfatiza la importancia de asegurar los productos y los contenedores de env\u00edo para prevenir el acceso no autorizado y el robo. Tambi\u00e9n se destacan las condiciones de almacenamiento y transporte que deben cumplirse para garantizar la integridad de los productos, as\u00ed como la necesidad de documentaci\u00f3n adecuada para verificar el cumplimiento de los requisitos regulatorios. Adem\u00e1s, se menciona la importancia de informar sobre cualquier desviaci\u00f3n en las condiciones de transporte y de seguir las instrucciones del fabricante en cuanto a condiciones especiales.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas de seguridad se deben implementar para prevenir el acceso no autorizado a los productos farmac\u00e9uticos durante el transporte?**\n   - Esta pregunta busca detalles sobre las pr\u00e1cticas espec\u00edficas de seguridad que deben seguirse, que no se encuentran f\u00e1cilmente en otros documentos.\n\n2. **\u00bfQu\u00e9 pasos deben seguir las personas responsables del transporte si se detecta una desviaci\u00f3n en las condiciones de almacenamiento durante el transporte?**\n   - Esta pregunta se centra en el protocolo a seguir en caso de problemas durante el transporte, lo cual puede no estar claramente definido en otras fuentes.\n\n3. **\u00bfC\u00f3mo deben documentarse y monitorearse las condiciones especiales de transporte que difieren de las condiciones ambientales est\u00e1ndar?**\n   - Esta pregunta busca informaci\u00f3n sobre la documentaci\u00f3n y el monitoreo de condiciones espec\u00edficas, un aspecto que puede no ser ampliamente cubierto en otros contextos relacionados con el transporte de productos farmac\u00e9uticos.", "prev_section_summary": "### Temas Clave\n\n1. **Trazabilidad de Productos Farmac\u00e9uticos**: Se enfatiza la importancia de mantener registros detallados que permitan la trazabilidad de los productos farmac\u00e9uticos, facilitando la recuperaci\u00f3n de lotes y la investigaci\u00f3n de productos falsificados.\n\n2. **Documentaci\u00f3n de Despacho**: Los registros de despacho deben incluir informaci\u00f3n esencial como la fecha de despacho, datos del remitente y destinatario, descripci\u00f3n de los productos, cantidad, condiciones de transporte y almacenamiento, y n\u00fameros de lote y fecha de caducidad.\n\n3. **Selecci\u00f3n de M\u00e9todos de Transporte**: Se deben considerar las condiciones locales, clim\u00e1ticas y estacionales al seleccionar los m\u00e9todos de transporte, especialmente para productos que requieren temperaturas controladas.\n\n4. **Planificaci\u00f3n de Rutas y Horarios de Entrega**: Es crucial establecer horarios de entrega y planificar rutas que sean realistas y sistem\u00e1ticas, teniendo en cuenta las necesidades locales y los riesgos de seguridad.\n\n5. **Manejo de Carga**: Se debe tener cuidado al cargar y descargar productos para evitar da\u00f1os y asegurar la eficiencia en el proceso.\n\n6. **Control de Fechas de Caducidad**: Se debe evitar el suministro de productos que est\u00e9n cerca de su fecha de caducidad, asegurando que no se alcancen antes de su uso por el consumidor.\n\n### Entidades\n\n- **Remitente**: Nombre y direcci\u00f3n completos, tipo de entidad responsable del transporte, n\u00famero de tel\u00e9fono y contactos.\n- **Destinatario**: Nombre y direcci\u00f3n completos, estado del destinatario (farmacia, hospital, cl\u00ednica comunitaria).\n- **Productos Farmac\u00e9uticos**: Nombre, forma de dosificaci\u00f3n, fuerza, cantidad y condiciones de transporte.\n- **Registros de Despacho**: Documentaci\u00f3n que incluye informaci\u00f3n para la trazabilidad y recuperaci\u00f3n de productos.\n- **M\u00e9todos de Transporte**: Veh\u00edculos y condiciones locales que afectan el transporte de productos.\n- **Fechas de Caducidad**: Informaci\u00f3n cr\u00edtica para asegurar la calidad y seguridad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: transportation, pharmaceutical products, security measures, storage conditions, regulatory compliance"}}, "59e0219d-b6c8-47ca-9185-a4a066a9267d": {"node_ids": ["3e20c3ae-c300-41b0-bc04-896d953147f8"], "metadata": {"page_label": "270", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 13.7 \nWritten procedures should be in place for investigating and dealing with any failure to comply with storage requirements, e.g. temperature deviations.\n\n## 13.8 \nTransportation and storage of pharmaceutical products containing hazardous substances, such as toxic, radioactive material, and other dangerous pharmaceutical products presenting special risks of abuse, fire or explosion (e.g. combustible or flammable liquids, solids and pressurized gases) should be stored in safe, dedicated and secure areas, and transported in safe, suitably designed, secured containers and vehicles. In addition, the requirements of applicable international agreements and national legislation should be met.\n\n## 13.9 \nProducts containing narcotics and other dependence-producing substances should be transported in safe and secure containers and vehicles and be stored in safe and secure areas.\n\nIn addition, applicable international agreements and national legislation should be complied with.\n\n## 13.10 \nSpillages should be cleaned up as soon as possible to prevent possible contamination, cross-contamination and hazards. Written procedures should be in place for the handling of such occurrences.\n\n## 13.11 \nPhysical or other equivalent (e.g. electronic) segregation should be provided for the storage and distribution during transit of rejected, expired, recalled or returned pharmaceutical products and suspected counterfeits. The products should be appropriately identified, securely packaged, clearly labelled and be accompanied by appropriate supporting documentation.\n\n## 13.12 \nThe interiors of vehicles and containers should remain clean and dry while pharmaceutical products are in transit.\n\n## 13.13 \nPackaging materials and shipment containers should be of suitable design to prevent damage of pharmaceutical products during transport. Seal control programmes should be in place and managed properly.\n\n## 13.14 \nDrivers of vehicles should identify themselves and present appropriate documentation to demonstrate that they are authorized to transport the load.\n\n## 13.15 \nDamage to containers and any other event or problem that occurs during transit must be recorded and reported to the relevant department, entity or authority, and investigated.\n\n## 13.16 \nPharmaceutical products in transit must be accompanied by the appropriate documentation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl contexto se centra en las directrices de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre el almacenamiento y transporte de productos farmac\u00e9uticos, especialmente aquellos que contienen sustancias peligrosas, narc\u00f3ticos y otros productos que presentan riesgos especiales. Se enfatiza la importancia de tener procedimientos escritos para manejar desviaciones de temperatura, limpieza de derrames, segregaci\u00f3n de productos rechazados o sospechosos, y la necesidad de documentaci\u00f3n adecuada durante el transporte. Tambi\u00e9n se menciona la importancia de la seguridad en el transporte y almacenamiento de estos productos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben implementarse para manejar las desviaciones de temperatura en el almacenamiento de productos farmac\u00e9uticos?**\n   - Esta pregunta busca detalles sobre las acciones espec\u00edficas que deben tomarse cuando hay un incumplimiento de los requisitos de almacenamiento, que no se detalla en otras partes del documento.\n\n2. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que deben tener los contenedores y veh\u00edculos utilizados para el transporte de productos farmac\u00e9uticos peligrosos?**\n   - Esta pregunta se enfoca en las especificaciones de seguridad y dise\u00f1o que deben cumplir los contenedores y veh\u00edculos, que pueden no estar claramente definidas en otras secciones.\n\n3. **\u00bfQu\u00e9 tipo de documentaci\u00f3n es necesaria para acompa\u00f1ar los productos farmac\u00e9uticos durante su transporte?**\n   - Esta pregunta busca informaci\u00f3n sobre los documentos espec\u00edficos que deben estar presentes durante el transporte, lo cual es crucial para el cumplimiento normativo y la trazabilidad, y puede no estar ampliamente cubierto en otras partes del texto.", "prev_section_summary": "### Temas Clave\n\n1. **Seguridad en el Transporte**: Se enfatiza la necesidad de asegurar los productos y contenedores de env\u00edo para prevenir el acceso no autorizado y el robo. Se recomienda proporcionar seguridad adicional a veh\u00edculos y operadores.\n\n2. **Documentaci\u00f3n y Cumplimiento Regulatorio**: Los env\u00edos de productos deben incluir la documentaci\u00f3n adecuada para facilitar la identificaci\u00f3n y verificaci\u00f3n del cumplimiento de los requisitos regulatorios.\n\n3. **Condiciones de Almacenamiento y Transporte**: Es crucial que las personas responsables del transporte est\u00e9n informadas sobre las condiciones relevantes de almacenamiento y transporte, y que estas se mantengan durante todo el proceso.\n\n4. **Integridad del Producto**: Se deben seguir procedimientos para asegurar que la identidad del producto no se pierda, que no haya contaminaci\u00f3n entre productos, y que se tomen precauciones adecuadas contra derrames, roturas, y robos.\n\n5. **Mantenimiento de Condiciones de Almacenamiento**: Las condiciones de almacenamiento requeridas deben mantenerse dentro de l\u00edmites aceptables durante el transporte. Cualquier desviaci\u00f3n debe ser reportada a las partes correspondientes.\n\n6. **Condiciones Especiales de Transporte**: Si se requieren condiciones especiales durante el transporte, estas deben ser proporcionadas por el fabricante, y deben ser monitoreadas y registradas.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Productos Farmac\u00e9uticos**: Bienes que est\u00e1n siendo transportados y que requieren condiciones espec\u00edficas.\n- **Distribuidores y Recipientes**: Entidades involucradas en la cadena de suministro que deben ser informadas sobre cualquier desviaci\u00f3n en las condiciones de transporte.\n- **Fabricantes**: Responsables de proporcionar informaci\u00f3n sobre condiciones especiales de transporte y etiquetado. \n\nEste resumen destaca la importancia de la seguridad, la documentaci\u00f3n, y el cumplimiento de las condiciones de transporte para garantizar la integridad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: pharmaceutical storage, hazardous substances, transportation safety, compliance procedures, documentation requirements"}}, "4ee56aff-29a9-4368-9cfd-e9d9651c5969": {"node_ids": ["eef29f94-f0ce-4455-99f0-504626af301f"], "metadata": {"page_label": "271", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Documentation\n\n14.1 Written instructions and records which document all activities relating to the distribution of pharmaceutical products, including all applicable receipts and issues (invoices) should be available. Records should be kept for seven years, unless otherwise specified in national or regional regulations.\n\n14.2 Distributors should keep records of all pharmaceutical products received. Records should contain at least the following information:\n- date;\n- name of the pharmaceutical product;\n- quantity received, or supplied; and\n- name and address of the supplier.\n\n14.3 Procedures should be established and maintained for the preparation, review, approval, use of and control of changes to all documents relating to the distribution process. Procedures must be in place for both internally generated documents and those from external sources.\n\n14.4 Documents, and in particular instructions and procedures relating to any activity that could have an impact on the quality of pharmaceutical products, should be designed, completed, reviewed and distributed with care.\n\n14.5 The title, nature and purpose of each document should be clearly stated. The contents of documents should be clear and unambiguous. Documents should be laid out in an orderly fashion and be easy to check.\n\n14.6 All documents should be completed, approved, signed (as required) and dated by an appropriate authorized person(s) and should not be changed without the necessary authorization.\n\n14.7 The nature, content and retention of documentation relating to the distribution of pharmaceutical products and any investigations conducted and action taken, should comply with national legislative requirements. Where such requirements are not in place, the documents should be retained for at least one year after the expiry date of the product concerned.\n\n14.8 The distributor must establish and maintain procedures for the identification, collection, indexing, retrieval, storage, maintenance, disposal of and access to all applicable documentation.\n\n14.9 All records must be readily retrievable, and be stored and retained using facilities that are safeguarded against unauthorized modification, damage, deterioration and/or loss of documentation.\n\n14.10 Documents should be reviewed regularly and kept up to date. When a document has been revised, a system should exist to prevent inadvertent use of the superseded version.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece directrices sobre la documentaci\u00f3n necesaria para la distribuci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de mantener registros detallados de las actividades de distribuci\u00f3n, as\u00ed como la necesidad de procedimientos claros para la gesti\u00f3n de documentos. Se especifica que los registros deben ser accesibles, seguros y actualizados, y se deben conservar durante un per\u00edodo determinado, cumpliendo con las regulaciones nacionales.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1nto tiempo deben conservarse los registros de distribuci\u00f3n de productos farmac\u00e9uticos seg\u00fan las directrices de la OMS?**\n   - Los registros deben conservarse durante siete a\u00f1os, a menos que las regulaciones nacionales o regionales indiquen un per\u00edodo diferente.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n m\u00ednima debe contener el registro de productos farmac\u00e9uticos recibidos por un distribuidor?**\n   - El registro debe incluir la fecha, el nombre del producto farmac\u00e9utico, la cantidad recibida o suministrada, y el nombre y direcci\u00f3n del proveedor.\n\n3. **\u00bfQu\u00e9 procedimientos deben establecerse para la gesti\u00f3n de documentos relacionados con la distribuci\u00f3n de productos farmac\u00e9uticos?**\n   - Se deben establecer procedimientos para la preparaci\u00f3n, revisi\u00f3n, aprobaci\u00f3n, uso y control de cambios en todos los documentos relacionados con el proceso de distribuci\u00f3n, tanto para documentos generados internamente como para aquellos de fuentes externas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Procedimientos Escritos**: Es fundamental contar con procedimientos documentados para investigar y manejar incumplimientos en los requisitos de almacenamiento, como desviaciones de temperatura.\n\n2. **Transporte y Almacenamiento de Sustancias Peligrosas**: Los productos farmac\u00e9uticos que contienen sustancias peligrosas (t\u00f3xicas, radiactivas, etc.) deben ser almacenados y transportados en \u00e1reas seguras y dedicadas, utilizando contenedores y veh\u00edculos dise\u00f1ados espec\u00edficamente para garantizar la seguridad.\n\n3. **Sustancias Narc\u00f3ticas**: Los productos que contienen narc\u00f3ticos y sustancias que generan dependencia deben ser transportados y almacenados en condiciones seguras, cumpliendo con acuerdos internacionales y legislaci\u00f3n nacional.\n\n4. **Manejo de Derrames**: Se deben establecer procedimientos para la limpieza de derrames de productos farmac\u00e9uticos para prevenir contaminaci\u00f3n y riesgos asociados.\n\n5. **Segregaci\u00f3n de Productos**: Es necesario proporcionar segregaci\u00f3n f\u00edsica o equivalente para productos rechazados, expirados, retirados o sospechosos de ser falsificados, asegurando su adecuada identificaci\u00f3n y documentaci\u00f3n.\n\n6. **Condiciones de Transporte**: Los veh\u00edculos y contenedores deben mantenerse limpios y secos durante el transporte de productos farmac\u00e9uticos.\n\n7. **Dise\u00f1o de Envases y Contenedores**: Los materiales de embalaje y los contenedores de env\u00edo deben ser adecuados para prevenir da\u00f1os a los productos durante el transporte, y se deben implementar programas de control de sellos.\n\n8. **Identificaci\u00f3n de Conductores**: Los conductores de veh\u00edculos deben identificarse y presentar la documentaci\u00f3n necesaria que demuestre su autorizaci\u00f3n para transportar la carga.\n\n9. **Registro de Incidentes**: Cualquier da\u00f1o a los contenedores o problemas ocurridos durante el transporte deben ser registrados, reportados e investigados.\n\n10. **Documentaci\u00f3n Durante el Transporte**: Los productos farmac\u00e9uticos en tr\u00e1nsito deben ir acompa\u00f1ados de la documentaci\u00f3n adecuada para asegurar el cumplimiento normativo y la trazabilidad.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de establecer las directrices.\n- **Productos Farmac\u00e9uticos**: Incluyen sustancias peligrosas, narc\u00f3ticos y otros productos con riesgos especiales.\n- **Legislaci\u00f3n Nacional e Internacional**: Normativas que deben cumplirse en el manejo y transporte de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: documentation, pharmaceutical distribution, record retention, quality control, regulatory compliance"}}, "1fa22bc9-de93-4b84-b276-e37071dfff69": {"node_ids": ["67ae15c0-56ac-44d0-ae06-4176736732e3"], "metadata": {"page_label": "272", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 14.11\n\nMechanisms should exist to allow for transfer of information, including quality or regulatory information, between a manufacturer and a customer, as well as the transfer of information to the relevant regulatory authority as required.\n\n# 14.12\n\nRecords relating to storage of pharmaceutical products should be kept and be readily available upon request in accordance with the WHO guidelines on good storage practice for pharmaceuticals (1).\n\n# 14.13\n\nPermanent records, written or electronic, should exist for each stored product indicating recommended storage conditions, any precautions to be observed and retest dates. Pharmacopoeial requirements and current national regulations concerning labels and containers should be respected at all times.\n\n# 14.14\n\nProcedures should be in place for temperature mapping, security services to prevent theft or tampering with goods at the storage facilities, destruction of unsaleable or unusable stocks and on retention of the records.\n\n# 14.15\n\nWhere the records are generated and kept in electronic form, back ups should be maintained to prevent any accidental data loss.\n\n# 15. Repackaging and relabelling\n\n15.1 Repackaging and relabelling of pharmaceutical products should be limited, as these practices may represent a risk to the safety and security of the supply chain.\n\n15.2 Where they do occur, they should only be performed by entities appropriately authorized to do so and in compliance with the applicable national, regional and international guidelines, i.e. in accordance with GMP principles.\n\n15.3 In the event of repackaging by companies other than the original manufacturer, these operations should result in at least equivalent means of identification and authentication of the products.\n\n15.4 Procedures should be in place for the secure disposal of original packaging.\n\n# 16. Complaints\n\n16.1 There should be a written procedure in place for the handling of complaints. A distinction should be made between complaints about a product or its packaging and those relating to distribution. In the case of a complaint about the quality of a product or its packaging, the original manufacturer and/or marketing authorization holder should be informed as soon as possible.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Transferencia de Informaci\u00f3n**: Se establece la importancia de mecanismos que faciliten la transferencia de informaci\u00f3n entre fabricantes, clientes y autoridades regulatorias, asegurando que se mantenga la calidad y el cumplimiento normativo.\n\n2. **Mantenimiento de Registros**: Se enfatiza la necesidad de mantener registros permanentes sobre las condiciones de almacenamiento de productos farmac\u00e9uticos, as\u00ed como la importancia de cumplir con las regulaciones nacionales y farmacop\u00e9icas.\n\n3. **Reempaquetado y Reetiquetado**: Se discuten las limitaciones y regulaciones en torno al reempaquetado y reetiquetado de productos farmac\u00e9uticos, destacando la necesidad de autorizaci\u00f3n y cumplimiento de las buenas pr\u00e1cticas de manufactura (GMP).\n\n4. **Manejo de Quejas**: Se requiere un procedimiento escrito para el manejo de quejas, diferenciando entre quejas sobre productos y quejas sobre distribuci\u00f3n, y la necesidad de informar al fabricante en caso de problemas de calidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe ser transferida entre un fabricante y un cliente, y c\u00f3mo se asegura que esta informaci\u00f3n llegue a las autoridades regulatorias?**\n   - Esta pregunta se centra en los mecanismos espec\u00edficos de transferencia de informaci\u00f3n mencionados en el contexto, que no se detalla en otras fuentes.\n\n2. **\u00bfCu\u00e1les son las recomendaciones espec\u00edficas para el mantenimiento de registros de almacenamiento de productos farmac\u00e9uticos seg\u00fan las directrices de la OMS?**\n   - Esta pregunta busca detalles sobre las pr\u00e1cticas de registro y almacenamiento que son \u00fanicas a las directrices de la OMS y que pueden no estar disponibles en otras normativas.\n\n3. **\u00bfQu\u00e9 procedimientos deben implementarse para el manejo seguro de quejas relacionadas con la calidad de un producto farmac\u00e9utico?**\n   - Esta pregunta se enfoca en los procedimientos espec\u00edficos que deben seguirse para manejar quejas, lo cual es un aspecto cr\u00edtico que puede no estar claramente definido en otras regulaciones.", "prev_section_summary": "### Temas Clave\n\n1. **Documentaci\u00f3n de Distribuci\u00f3n**: Se requiere mantener instrucciones escritas y registros que documenten todas las actividades relacionadas con la distribuci\u00f3n de productos farmac\u00e9uticos, incluyendo recibos y facturas.\n\n2. **Conservaci\u00f3n de Registros**: Los registros deben conservarse durante siete a\u00f1os, salvo que las regulaciones nacionales o regionales indiquen un per\u00edodo diferente.\n\n3. **Informaci\u00f3n M\u00ednima en Registros**: Los registros de productos farmac\u00e9uticos recibidos deben incluir la fecha, nombre del producto, cantidad recibida o suministrada, y nombre y direcci\u00f3n del proveedor.\n\n4. **Procedimientos de Gesti\u00f3n Documental**: Se deben establecer procedimientos para la preparaci\u00f3n, revisi\u00f3n, aprobaci\u00f3n y control de cambios en documentos relacionados con la distribuci\u00f3n.\n\n5. **Calidad de Documentos**: Los documentos deben ser claros, ordenados y revisados regularmente para asegurar que est\u00e9n actualizados y sean precisos.\n\n6. **Acceso y Seguridad de Documentos**: Los registros deben ser f\u00e1cilmente recuperables y almacenados en instalaciones seguras para prevenir modificaciones no autorizadas o p\u00e9rdida de documentaci\u00f3n.\n\n7. **Cumplimiento Legal**: La documentaci\u00f3n debe cumplir con los requisitos legislativos nacionales, y en ausencia de estos, los documentos deben conservarse al menos un a\u00f1o despu\u00e9s de la fecha de caducidad del producto.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad que establece las directrices sobre la documentaci\u00f3n de distribuci\u00f3n de productos farmac\u00e9uticos.\n- **Distribuidores**: Entidades responsables de mantener registros y procedimientos relacionados con la distribuci\u00f3n de productos farmac\u00e9uticos.\n- **Productos Farmac\u00e9uticos**: Bienes cuya distribuci\u00f3n y documentaci\u00f3n est\u00e1n reguladas por las directrices de la OMS.\n- **Regulaciones Nacionales/Regionales**: Normativas que pueden influir en el per\u00edodo de conservaci\u00f3n de los registros y la gesti\u00f3n documental.", "excerpt_keywords": "Keywords: pharmaceutical storage, information transfer, repackaging regulations, complaint handling, record keeping"}}, "16e57391-15ec-458a-857e-e54868b5be2e": {"node_ids": ["f8a58b5b-edef-483a-8741-9e0914e65184"], "metadata": {"page_label": "273", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 16.2 \nAll complaints and other information concerning potentially defective and potentially counterfeit pharmaceutical products should be reviewed carefully according to written procedures describing the action to be taken, including the need to consider a recall where appropriate.\n\n16.3 Any complaint concerning a material defect should be recorded and thoroughly investigated to identify the origin or reason for the complaint (e.g. repackaging procedure or original manufacturing process).\n\n16.4 If a defect relating to a pharmaceutical product is discovered or suspected, consideration should be given to whether other batches of the product should also be checked.\n\n16.5 Where necessary, appropriate follow-up action should be taken after investigation and evaluation of the complaint. There should be a system in place to ensure that the complaint, the response received from the original product manufacturer, or the results of the investigation of the complaint, are shared with all the relevant parties.\n\n16.6 Product quality problems or suspected cases of counterfeit products should be documented and the information shared with the appropriate national and/or regional regulatory authorities.\n\n# 17. Recalls\n\n17.1 There should be a system, which includes a written procedure, to effectively and promptly recall pharmaceutical products known or suspected to be defective or counterfeit, with a designated person(s) responsible for recalls. The system should comply with the guidance issued by the national or regional regulatory authority. This procedure should be checked regularly and updated as necessary.\n\n17.2 The original manufacturer and/or marketing authorization holder should be informed in the event of a recall. Where a recall is instituted by an entity other than the original manufacturer and/or marketing authorization holder, consultation with the original manufacturer and/or marketing authorization holder should, where possible, take place before the recall is instituted.\n\nInformation on a recall should be shared with the appropriate national or regional regulatory authority. If a recall of the original product is necessary because of a counterfeited product which is not easily distinguishable from the original product, the manufacturer of the original product and the relevant health authority should be informed.\n\n17.3 The effectiveness of the arrangements for recalls should be evaluated at regular intervals. All recalled pharmaceutical products should be stored in a secure, segregated area pending appropriate action.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Manejo de Quejas y Defectos**: El documento establece procedimientos claros para la revisi\u00f3n y manejo de quejas relacionadas con productos farmac\u00e9uticos potencialmente defectuosos o falsificados. Se enfatiza la importancia de investigar a fondo las quejas para identificar su origen y tomar las acciones adecuadas, incluyendo la posibilidad de un retiro del mercado.\n\n2. **Sistema de Retiro de Productos**: Se describe la necesidad de un sistema estructurado para llevar a cabo retiros de productos farmac\u00e9uticos que se sospeche sean defectuosos o falsificados. Este sistema debe incluir procedimientos escritos, designaci\u00f3n de responsables y cumplimiento con las regulaciones de las autoridades competentes.\n\n3. **Documentaci\u00f3n y Comunicaci\u00f3n**: El documento subraya la importancia de documentar problemas de calidad del producto y casos sospechosos de falsificaci\u00f3n, as\u00ed como la necesidad de compartir esta informaci\u00f3n con las autoridades regulatorias pertinentes para garantizar la seguridad p\u00fablica.\n\n### Preguntas espec\u00edficas que el contexto puede responder:\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse al recibir una queja sobre un producto farmac\u00e9utico defectuoso?**\n   - El contexto detalla que todas las quejas deben ser revisadas cuidadosamente seg\u00fan procedimientos escritos, que incluyen la necesidad de investigar a fondo la queja y considerar un retiro del producto si es apropiado.\n\n2. **\u00bfQu\u00e9 pasos deben tomarse si se descubre un defecto en un lote de productos farmac\u00e9uticos?**\n   - Se debe considerar la revisi\u00f3n de otros lotes del producto, y se deben tomar acciones de seguimiento apropiadas tras la investigaci\u00f3n de la queja, asegurando que la informaci\u00f3n se comparta con todas las partes relevantes.\n\n3. **\u00bfC\u00f3mo se debe manejar un retiro de un producto farmac\u00e9utico en caso de que se sospeche que es falsificado?**\n   - El documento establece que debe haber un sistema para realizar retiros de manera efectiva y r\u00e1pida, informando al fabricante original y a las autoridades regulatorias pertinentes, y evaluando la efectividad de los procedimientos de retiro de manera regular.", "prev_section_summary": "### Temas Clave\n\n1. **Transferencia de Informaci\u00f3n**: Se enfatiza la necesidad de establecer mecanismos para la transferencia de informaci\u00f3n entre fabricantes, clientes y autoridades regulatorias, asegurando la calidad y el cumplimiento normativo.\n\n2. **Mantenimiento de Registros**: Se requiere mantener registros permanentes sobre las condiciones de almacenamiento de productos farmac\u00e9uticos, cumpliendo con las directrices de la OMS y las regulaciones nacionales.\n\n3. **Reempaquetado y Reetiquetado**: Se discuten las limitaciones y regulaciones sobre el reempaquetado y reetiquetado de productos farmac\u00e9uticos, destacando la necesidad de autorizaci\u00f3n y cumplimiento de las buenas pr\u00e1cticas de manufactura (GMP).\n\n4. **Manejo de Quejas**: Se establece la necesidad de un procedimiento escrito para manejar quejas, diferenciando entre quejas sobre productos y distribuci\u00f3n, y la obligaci\u00f3n de informar al fabricante en caso de problemas de calidad.\n\n### Entidades\n\n- **Fabricantes**: Entidades responsables de la producci\u00f3n de productos farmac\u00e9uticos.\n- **Clientes**: Consumidores o entidades que adquieren productos farmac\u00e9uticos.\n- **Autoridades Regulatorias**: Organismos encargados de supervisar y regular la calidad y seguridad de los productos farmac\u00e9uticos.\n- **Productos Farmac\u00e9uticos**: Bienes que requieren condiciones espec\u00edficas de almacenamiento y manejo.\n- **Registros**: Documentaci\u00f3n escrita o electr\u00f3nica que detalla las condiciones de almacenamiento y otros aspectos relevantes de los productos.\n- **Entidades Autorizadas**: Organizaciones que tienen permiso para realizar actividades de reempaquetado y reetiquetado.\n- **Quejas**: Reclamos relacionados con la calidad de productos o su distribuci\u00f3n.", "excerpt_keywords": "Keywords: complaints, recalls, pharmaceutical products, counterfeit, regulatory authorities"}}, "c5983c6f-bfeb-4c57-b0d5-60c94b41cc7b": {"node_ids": ["57609d4c-495a-4ec4-a83e-57b0c61a073d"], "metadata": {"page_label": "274", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 17.4\n\nRecalled pharmaceutical products should be segregated during transit and clearly labelled as recalled products. Where segregation in transit is not possible, such goods must be securely packaged, clearly labelled, and be accompanied by appropriate documentation.\n\n# 17.5\n\nThe particular storage conditions applicable to a pharmaceutical product which is subject to recall should be maintained during storage and transit until such time as a decision has been made regarding the fate of the product in question.\n\n# 17.6\n\nAll customers and competent authorities of all countries to which a given pharmaceutical product may have been distributed should be informed promptly of any intention to recall the product because it is, or is suspected to be, defective or counterfeit.\n\n# 17.7\n\nAll records should be readily available to the designated person(s) responsible for recalls. These records should contain sufficient information on pharmaceutical products supplied to customers (including exported products).\n\n# 17.8\n\nThe progress of a recall process should be recorded and a final report issued, which includes a reconciliation between delivered and recovered quantities of products.\n\n# 17.9\n\nWhen necessary emergency recall procedures should be implemented.\n\n# 18. Returned products\n\n## 18.1\n\nA distributor should receive pharmaceutical product returns or exchanges pursuant to the terms and conditions of the agreement between the distributor and the recipient. Both distributors and recipients should be accountable for administering their returns process and ensuring that the aspects of this operation are secure and do not permit the entry of counterfeit products.\n\n## 18.2\n\nThe necessary assessment and decision regarding the disposition of such products must be made by a suitably authorized person. The nature of the product returned to the distributor, any special storage conditions required, its condition and history and the time elapsed since it was issued, should all be taken into account in this assessment. Where any doubt arises over the quality of a pharmaceutical product, it should not be considered suitable for reissue or reuse.\n\n## 18.3\n\nProvision should be made for the appropriate and safe transport of returned products in accordance with the relevant storage and other requirements.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfQu\u00e9 medidas deben tomarse durante el transporte de productos farmac\u00e9uticos que han sido retirados del mercado?**\n   - Los productos farmac\u00e9uticos retirados deben ser segregados durante el tr\u00e1nsito y etiquetados claramente como productos retirados. Si la segregaci\u00f3n no es posible, deben ser empaquetados de manera segura, etiquetados claramente y acompa\u00f1ados de la documentaci\u00f3n apropiada.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe contener la documentaci\u00f3n de los productos farmac\u00e9uticos retirados?**\n   - La documentaci\u00f3n debe incluir informaci\u00f3n suficiente sobre los productos farmac\u00e9uticos suministrados a los clientes, incluyendo productos exportados. Adem\u00e1s, todos los registros deben estar f\u00e1cilmente disponibles para las personas designadas responsables de los retiros.\n\n3. **\u00bfQu\u00e9 criterios deben considerarse al evaluar productos farmac\u00e9uticos devueltos?**\n   - La evaluaci\u00f3n de los productos devueltos debe ser realizada por una persona debidamente autorizada y debe tener en cuenta la naturaleza del producto, cualquier condici\u00f3n de almacenamiento especial requerida, su estado y historial, as\u00ed como el tiempo transcurrido desde que fue emitido. Si hay dudas sobre la calidad del producto, no debe considerarse apto para reemisi\u00f3n o reutilizaci\u00f3n.\n\n### Resumen de Nivel Superior\n\nEl contexto aborda las directrices para la gesti\u00f3n de productos farmac\u00e9uticos retirados del mercado y devueltos. Se enfatiza la importancia de la segregaci\u00f3n y etiquetado de productos retirados, la necesidad de mantener condiciones de almacenamiento adecuadas durante el transporte, y la obligaci\u00f3n de informar a las autoridades y clientes sobre los retiros. Tambi\u00e9n se menciona la responsabilidad de los distribuidores y receptores en el proceso de devoluciones, as\u00ed como la evaluaci\u00f3n cuidadosa de los productos devueltos para garantizar que no se introduzcan productos falsificados en el mercado.", "prev_section_summary": "### Temas Clave:\n\n1. **Manejo de Quejas**: Se establece la importancia de revisar y manejar quejas sobre productos farmac\u00e9uticos potencialmente defectuosos o falsificados, siguiendo procedimientos escritos que incluyan la posibilidad de un retiro del mercado.\n\n2. **Investigaci\u00f3n de Defectos**: Las quejas sobre defectos materiales deben ser registradas y analizadas a fondo para identificar su origen, considerando la revisi\u00f3n de otros lotes si se descubre o sospecha un defecto.\n\n3. **Acciones de Seguimiento**: Es necesario tomar acciones de seguimiento adecuadas tras la investigaci\u00f3n de quejas y asegurar que la informaci\u00f3n relevante se comparta con todas las partes involucradas.\n\n4. **Documentaci\u00f3n y Comunicaci\u00f3n**: Los problemas de calidad del producto y los casos sospechosos de falsificaci\u00f3n deben ser documentados y comunicados a las autoridades regulatorias pertinentes.\n\n5. **Sistema de Retiro de Productos**: Se requiere un sistema estructurado para realizar retiros de productos farmac\u00e9uticos defectuosos o falsificados, con procedimientos escritos y responsables designados.\n\n6. **Evaluaci\u00f3n de Efectividad**: La efectividad de los procedimientos de retiro debe ser evaluada regularmente, y los productos retirados deben ser almacenados de manera segura.\n\n### Entidades:\n\n- **Productos Farmac\u00e9uticos**: Incluyen aquellos que son potencialmente defectuosos o falsificados.\n- **Autoridades Regulatorias**: Nacionales y regionales que supervisan la seguridad y calidad de los productos farmac\u00e9uticos.\n- **Fabricantes Originales**: Entidades responsables de la producci\u00f3n de los productos farmac\u00e9uticos.\n- **Titulares de Autorizaci\u00f3n de Comercializaci\u00f3n**: Entidades que tienen la autorizaci\u00f3n para comercializar productos farmac\u00e9uticos.\n- **Sistema de Quejas y Retiro**: Procedimientos y protocolos establecidos para manejar quejas y realizar retiros de productos.", "excerpt_keywords": "Keywords: recall procedures, pharmaceutical products, product returns, counterfeit prevention, storage conditions"}}, "5fe8575f-324f-4b56-939e-403e837d4033": {"node_ids": ["abc7144e-c3bd-46cb-a21f-9807ce99f1f6"], "metadata": {"page_label": "275", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 18.4\n\nRejected pharmaceutical products and those returned to a distributor should be appropriately identified and handled in accordance with a procedure which involves at least:\n\n- the physical segregation of such pharmaceutical products in quarantine in a dedicated area; or\n- other equivalent (e.g. electronic) segregation.\n\nThis is to avoid confusion and prevent distribution until a decision has been taken with regard to their disposition. The particular storage conditions applicable to a pharmaceutical product which is rejected or returned should be maintained during storage and transit until such time as a decision has been made regarding the product in question.\n\n18.5 Provision should be made for the appropriate and safe transport of rejected pharmaceutical products prior to their disposal.\n\n18.6 Destruction of pharmaceutical products should be done in accordance with international, national and local requirements regarding disposal of such products, and with due consideration to protection of the environment.\n\n18.7 Records of all returned, rejected and/or destroyed pharmaceutical products should be kept for a predetermined period.\n\n# 19. Counterfeit pharmaceutical products\n\n19.1 Counterfeit pharmaceutical products found in the distribution chain should be kept apart from other pharmaceutical products to avoid any confusion. They should be clearly labelled as not for sale and national regulatory authorities and the holder of the marketing authorization for the original product should be informed immediately.\n\n19.2 The sale and distribution of a suspected counterfeit pharmaceutical product should be suspended and the national regulatory authority notified without delay.\n\n19.3 Upon confirmation of the product being counterfeit a formal decision should be taken on its disposal, ensuring that it does not re-enter the market, and the decision recorded.\n\n# 20. Importation\n\n20.1 Consideration should be given to the WHO guidelines on import procedures for pharmaceutical products (6). The following aspects should be given particular attention.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS aborda la gesti\u00f3n de productos farmac\u00e9uticos rechazados, devueltos y falsificados. Se establecen procedimientos para la identificaci\u00f3n, segregaci\u00f3n, transporte y destrucci\u00f3n de estos productos, asegurando que se manejen de acuerdo con las normativas internacionales, nacionales y locales. Tambi\u00e9n se enfatiza la importancia de mantener registros de estos productos durante un per\u00edodo determinado. En el caso de productos farmac\u00e9uticos falsificados, se deben tomar medidas inmediatas para evitar su distribuci\u00f3n y se debe notificar a las autoridades regulatorias pertinentes.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los requisitos espec\u00edficos para el almacenamiento de productos farmac\u00e9uticos rechazados o devueltos hasta que se tome una decisi\u00f3n sobre su disposici\u00f3n?**\n   - Respuesta: Los productos farmac\u00e9uticos rechazados o devueltos deben ser segregados f\u00edsicamente en un \u00e1rea dedicada en cuarentena o mediante un sistema de segregaci\u00f3n equivalente (como un sistema electr\u00f3nico). Adem\u00e1s, las condiciones de almacenamiento aplicables a estos productos deben mantenerse durante el almacenamiento y el transporte hasta que se tome una decisi\u00f3n sobre su disposici\u00f3n.\n\n2. **\u00bfQu\u00e9 pasos deben seguirse si se identifica un producto farmac\u00e9utico como falsificado en la cadena de distribuci\u00f3n?**\n   - Respuesta: Los productos farmac\u00e9uticos falsificados deben ser separados de otros productos para evitar confusiones y etiquetados claramente como no a la venta. Las autoridades regulatorias nacionales y el titular de la autorizaci\u00f3n de comercializaci\u00f3n del producto original deben ser informados de inmediato. La venta y distribuci\u00f3n del producto sospechoso deben suspenderse y la autoridad regulatoria nacional debe ser notificada sin demora.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta para el transporte seguro de productos farmac\u00e9uticos rechazados antes de su disposici\u00f3n?**\n   - Respuesta: Debe hacerse una provisi\u00f3n adecuada para el transporte seguro de los productos farmac\u00e9uticos rechazados, asegurando que se cumplan las condiciones de almacenamiento necesarias y que se sigan las normativas pertinentes para su manejo y disposici\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Retiro de Productos Farmac\u00e9uticos:**\n   - Importancia de la segregaci\u00f3n y etiquetado de productos retirados durante el transporte.\n   - Mantenimiento de condiciones de almacenamiento adecuadas hasta que se decida el destino del producto.\n\n2. **Comunicaci\u00f3n:**\n   - Notificaci\u00f3n a clientes y autoridades competentes sobre retiros de productos defectuosos o falsificados.\n\n3. **Documentaci\u00f3n y Registros:**\n   - Disponibilidad de registros para las personas responsables de los retiros, incluyendo informaci\u00f3n sobre productos suministrados.\n\n4. **Proceso de Retiro:**\n   - Registro del progreso del proceso de retiro y emisi\u00f3n de un informe final que incluya la reconciliaci\u00f3n de cantidades entregadas y recuperadas.\n\n5. **Devoluciones de Productos:**\n   - Proceso de recepci\u00f3n de devoluciones seg\u00fan acuerdos entre distribuidores y receptores.\n   - Evaluaci\u00f3n de productos devueltos por personal autorizado, considerando su estado, condiciones de almacenamiento y tiempo desde la emisi\u00f3n.\n\n6. **Transporte Seguro:**\n   - Necesidad de transporte seguro y apropiado de productos devueltos, cumpliendo con requisitos de almacenamiento.\n\n**Entidades:**\n\n- **Productos Farmac\u00e9uticos:** Incluyen aquellos que han sido retirados del mercado o devueltos.\n- **Distribuidores y Receptores:** Actores clave en el proceso de devoluci\u00f3n y gesti\u00f3n de productos.\n- **Autoridades Competentes:** Entidades que deben ser informadas sobre retiros de productos.\n- **Personal Autorizado:** Responsables de la evaluaci\u00f3n y decisi\u00f3n sobre la disposici\u00f3n de productos devueltos.\n\nEste resumen destaca la importancia de seguir procedimientos adecuados para la gesti\u00f3n de productos farmac\u00e9uticos retirados y devueltos, asegurando la seguridad y calidad en el suministro de medicamentos.", "excerpt_keywords": "Keywords: pharmaceutical products, rejection, counterfeit, disposal, regulatory authorities"}}, "f591e0df-79ae-482f-b861-d95e11f18bba": {"node_ids": ["32bc7209-77ab-4bce-8d63-d13bb100a19d"], "metadata": {"page_label": "276", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 20.2 \nThe number of ports of entry in a country for the handling of imports of pharmaceutical products should be limited by appropriate legislation. Such ports could be designated by the state.\n\n## 20.3 \nThe chosen port(s) of entry should be those most appropriately located and best equipped to handle imports of pharmaceutical products.\n\n## 20.4 \nAt the port of entry, consignments of pharmaceutical products should be stored under suitable conditions for as short a time as possible.\n\n## 20.5 \nAll reasonable steps should be taken by importers to ensure that products are not mishandled or exposed to adverse storage conditions at wharves or airports.\n\n## 20.6 \nWhere necessary, persons with pharmaceutical training should be involved with the customs procedures or should be readily contactable.\n\n## 20.7 \nThe WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce should be used to provide data regarding quality assessment of imported pharmaceutical products.\n\n## 20.8 \nCustoms, enforcement agencies and regulatory agencies responsible for supervision of pharmaceutical products should establish means for cooperation and information exchange in order to prevent importation of counterfeit pharmaceutical products.\n\n# 21. Contract activities\n\n## 21.1 \nAny activity relating to the distribution of a pharmaceutical product which is delegated to another person or entity should be performed by parties appropriately authorized for that function and in accordance with the terms of a written contract.\n\n## 21.2 \nThe contract should define the responsibilities of each party including observance of the principles of GDP and relevant warranty clauses. It should also include responsibilities of the contractor for measures to avoid the entry of counterfeit medicines into the distribution chain, such as by suitable training programmes.\n\n## 21.3 \nAll contract accepters should comply with the requirements in these guidelines.\n\n## 21.4 \nSubcontracting may be permissible, under certain conditions and subject to the written approval of the contract giver; however, the subcontractors should be authorized for the function.\n\n## 21.5 \nContract accepters should be audited periodically.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Regulaci\u00f3n de Puertos de Entrada**: El documento establece directrices sobre la cantidad y ubicaci\u00f3n de los puertos de entrada para la importaci\u00f3n de productos farmac\u00e9uticos, enfatizando la necesidad de que estos puertos est\u00e9n adecuadamente equipados y designados por el estado. Tambi\u00e9n se menciona la importancia de almacenar los productos en condiciones adecuadas y minimizar el tiempo de almacenamiento.\n\n2. **Manejo de Productos Farmac\u00e9uticos**: Se subraya la responsabilidad de los importadores para evitar el manejo inadecuado y la exposici\u00f3n a condiciones adversas de almacenamiento. Adem\u00e1s, se destaca la necesidad de involucrar a personal con formaci\u00f3n farmac\u00e9utica en los procedimientos aduaneros.\n\n3. **Actividades Contractuales**: El documento detalla las obligaciones contractuales en la distribuci\u00f3n de productos farmac\u00e9uticos, incluyendo la necesidad de contratos escritos que definan responsabilidades y medidas para prevenir la entrada de medicamentos falsificados en la cadena de distribuci\u00f3n. Tambi\u00e9n se menciona la posibilidad de subcontrataci\u00f3n bajo ciertas condiciones y la necesidad de auditor\u00edas peri\u00f3dicas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben cumplirse para la designaci\u00f3n de puertos de entrada para la importaci\u00f3n de productos farmac\u00e9uticos?**\n   - El documento especifica que los puertos de entrada deben ser limitados por legislaci\u00f3n apropiada y deben estar ubicados y equipados de manera adecuada para manejar productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 medidas deben tomar los importadores para garantizar el manejo adecuado de los productos farmac\u00e9uticos en los puertos de entrada?**\n   - Los importadores deben tomar todas las medidas razonables para asegurar que los productos no sean mal manejados ni expuestos a condiciones de almacenamiento adversas en los muelles o aeropuertos.\n\n3. **\u00bfCu\u00e1les son las responsabilidades que deben incluirse en un contrato relacionado con la distribuci\u00f3n de productos farmac\u00e9uticos?**\n   - El contrato debe definir las responsabilidades de cada parte, incluyendo la observancia de los principios de Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) y cl\u00e1usulas de garant\u00eda relevantes, as\u00ed como las responsabilidades del contratista para evitar la entrada de medicamentos falsificados en la cadena de distribuci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manejo de Productos Farmac\u00e9uticos Rechazados y Devueltos**:\n   - **Identificaci\u00f3n y Segregaci\u00f3n**: Los productos rechazados o devueltos deben ser segregados f\u00edsicamente en un \u00e1rea de cuarentena o mediante un sistema de segregaci\u00f3n equivalente para evitar confusiones y prevenir su distribuci\u00f3n.\n   - **Condiciones de Almacenamiento**: Se deben mantener las condiciones de almacenamiento adecuadas durante el almacenamiento y el transporte hasta que se tome una decisi\u00f3n sobre su disposici\u00f3n.\n   - **Transporte Seguro**: Se debe garantizar un transporte adecuado y seguro de los productos rechazados antes de su disposici\u00f3n.\n\n2. **Destrucci\u00f3n de Productos Farmac\u00e9uticos**:\n   - La destrucci\u00f3n debe realizarse de acuerdo con las normativas internacionales, nacionales y locales, considerando la protecci\u00f3n del medio ambiente.\n\n3. **Registro de Productos**:\n   - Es necesario mantener registros de todos los productos devueltos, rechazados y/o destruidos durante un per\u00edodo determinado.\n\n4. **Productos Farmac\u00e9uticos Falsificados**:\n   - **Separaci\u00f3n y Etiquetado**: Los productos falsificados deben ser separados de otros productos y etiquetados claramente como no a la venta. Se debe informar de inmediato a las autoridades regulatorias nacionales y al titular de la autorizaci\u00f3n de comercializaci\u00f3n del producto original.\n   - **Suspensi\u00f3n de Venta y Distribuci\u00f3n**: La venta y distribuci\u00f3n de productos sospechosos de ser falsificados deben suspenderse y notificar a la autoridad regulatoria nacional sin demora.\n   - **Decisi\u00f3n sobre Disposici\u00f3n**: Una vez confirmado que un producto es falsificado, se debe tomar una decisi\u00f3n formal sobre su disposici\u00f3n para asegurar que no reingrese al mercado.\n\n5. **Importaci\u00f3n de Productos Farmac\u00e9uticos**:\n   - Se deben considerar las directrices de la OMS sobre los procedimientos de importaci\u00f3n de productos farmac\u00e9uticos.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Proporciona directrices y normativas sobre el manejo de productos farmac\u00e9uticos.\n- **Autoridades Regulatorias Nacionales**: Encargadas de supervisar y regular la venta y distribuci\u00f3n de productos farmac\u00e9uticos, as\u00ed como de ser notificadas en casos de productos falsificados.", "excerpt_keywords": "Keywords: pharmaceutical products, ports of entry, contract activities, counterfeit medicines, quality assessment"}}, "da29050e-a714-4084-9010-689cfb215662": {"node_ids": ["f4a7782e-145b-4d3c-b2ca-a81af494bb73"], "metadata": {"page_label": "277", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 22. Self-inspection\n\n22.1 The quality system should include self-inspections. These should be conducted to monitor implementation and compliance with the principles of GDP and, if necessary, to trigger corrective and preventive measures.\n\n22.2 Self-inspections should be conducted in an independent and detailed way by a designated, competent person.\n\n22.3 The results of all self-inspections should be recorded. Reports should contain all observations made during the inspection and, where applicable, proposals for corrective measures. There should be an effective follow-up programme. Management should evaluate the inspection report and the records of any corrective actions taken.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl documento de la OMS, parte de la Serie de Informes T\u00e9cnicos 957, aborda la importancia de las autoinspecciones dentro de un sistema de calidad. Se enfatiza que estas autoinspecciones deben realizarse de manera independiente y detallada por una persona competente designada. Adem\u00e1s, se requiere que los resultados de las autoinspecciones se registren adecuadamente, incluyendo observaciones y propuestas de medidas correctivas, y que haya un programa de seguimiento efectivo para evaluar las acciones correctivas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben cumplir las personas designadas para llevar a cabo las autoinspecciones seg\u00fan el documento?**\n   - Esta pregunta busca informaci\u00f3n sobre las calificaciones o competencias espec\u00edficas que se requieren para realizar autoinspecciones, que no se detalla expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 tipo de medidas correctivas se pueden proponer tras una autoinspecci\u00f3n y c\u00f3mo se determina su efectividad?**\n   - Esta pregunta se centra en ejemplos concretos de medidas correctivas y en el proceso de evaluaci\u00f3n de su efectividad, que no se aborda en el contexto proporcionado.\n\n3. **\u00bfCu\u00e1l es el proceso recomendado para el seguimiento de las acciones correctivas despu\u00e9s de una autoinspecci\u00f3n?**\n   - Esta pregunta busca detalles sobre el procedimiento espec\u00edfico que debe seguirse para asegurar que las acciones correctivas se implementen y se eval\u00faen adecuadamente, informaci\u00f3n que no se encuentra en el texto.", "prev_section_summary": "### Temas Clave\n\n1. **Regulaci\u00f3n de Puertos de Entrada**:\n   - Limitaci\u00f3n de puertos de entrada para la importaci\u00f3n de productos farmac\u00e9uticos mediante legislaci\u00f3n.\n   - Selecci\u00f3n de puertos adecuadamente ubicados y equipados.\n   - Almacenamiento de productos en condiciones adecuadas y por el menor tiempo posible.\n\n2. **Manejo de Productos Farmac\u00e9uticos**:\n   - Responsabilidad de los importadores para evitar el mal manejo y condiciones adversas de almacenamiento.\n   - Involucramiento de personal con formaci\u00f3n farmac\u00e9utica en procedimientos aduaneros.\n\n3. **Prevenci\u00f3n de Medicamentos Falsificados**:\n   - Uso del Esquema de Certificaci\u00f3n de la OMS para evaluar la calidad de productos farmac\u00e9uticos importados.\n   - Cooperaci\u00f3n entre agencias aduaneras, de enforcement y reguladoras para prevenir la importaci\u00f3n de productos falsificados.\n\n4. **Actividades Contractuales**:\n   - Necesidad de contratos escritos que definan responsabilidades en la distribuci\u00f3n de productos farmac\u00e9uticos.\n   - Inclusi\u00f3n de cl\u00e1usulas sobre Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) y medidas contra medicamentos falsificados.\n   - Permisibilidad de subcontrataci\u00f3n bajo condiciones espec\u00edficas y necesidad de auditor\u00edas peri\u00f3dicas.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Referenciada en el contexto de la certificaci\u00f3n y calidad de productos farmac\u00e9uticos.\n- **Agencias Aduaneras y Reguladoras**: Encargadas de la supervisi\u00f3n y control de la importaci\u00f3n de productos farmac\u00e9uticos.\n- **Importadores**: Responsables de asegurar el manejo adecuado de los productos en los puertos de entrada.\n- **Contratistas y Subcontratistas**: Entidades involucradas en la distribuci\u00f3n de productos farmac\u00e9uticos bajo contratos espec\u00edficos. \n\nEste resumen abarca los aspectos fundamentales de la regulaci\u00f3n y manejo de productos farmac\u00e9uticos en el contexto de importaciones y actividades contractuales, destacando la importancia de la calidad y la prevenci\u00f3n de falsificaciones.", "excerpt_keywords": "Keywords: self-inspection, quality system, GDP compliance, corrective measures, management evaluation"}}, "dd5a7351-3fb6-496d-8260-d171366f8bbc": {"node_ids": ["a2170c76-e2bc-403a-8a69-fa2e43d84cda"], "metadata": {"page_label": "278", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. WHO guide to good storage practices for pharmaceuticals. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 9 (WHO Technical Report Series, No. 908).\n\n2. WHO good pharmacy practice in community and hospital pharmacy settings. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report*. Geneva, World Health Organization, 1999, Annex 7 (WHO Technical Report Series, No. 885).\n\n3. WHO good manufacturing practices. In: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Good manufacturing practices and inspection, Vol. 2, 2nd updated ed.* Geneva, World Health Organization, 2007.\n\n4. Guidelines for implementation of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth report*. Geneva, World Health Organization, 1996, Annex 10 (WHO Technical Report Series, No. 863).\n\n5. WHO pharmaceutical starting materials certification scheme (SMACS). In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2004, Annex 3 (Technical Report Series, No. 917).\n\n6. Guidelines on import procedures for pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth report*. Geneva, World Health Organization, 1996, Annex 12 (WHO Technical Report Series, No. 863).\n\n7. Good trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report*. Geneva, World Health Organization, 2004, Annex 2 (WHO Technical Report Series, No. 917).\n\n8. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report*. Geneva, World Health Organization, 2009, Annex 2 (WHO Technical Report Series, No. 953) (http://www.who.int/medicines/areas/quality_safety/quality_assurance/regulatory_standards/en/index.html).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfCu\u00e1l es el prop\u00f3sito del \"WHO pharmaceutical starting materials certification scheme (SMACS)\" mencionado en el documento?**\n   - **Respuesta:** El \"WHO pharmaceutical starting materials certification scheme (SMACS)\" tiene como objetivo establecer un sistema de certificaci\u00f3n para los materiales iniciales farmac\u00e9uticos, asegurando que estos cumplan con los est\u00e1ndares de calidad necesarios para la producci\u00f3n de medicamentos. Esto ayuda a garantizar la seguridad y eficacia de los productos farmac\u00e9uticos en el comercio internacional.\n\n2. **\u00bfQu\u00e9 documento de la OMS se refiere a las \"buenas pr\u00e1cticas de almacenamiento\" para productos farmac\u00e9uticos y en qu\u00e9 a\u00f1o fue publicado?**\n   - **Respuesta:** El documento que se refiere a las \"buenas pr\u00e1cticas de almacenamiento\" para productos farmac\u00e9uticos es la \"WHO guide to good storage practices for pharmaceuticals\", publicada en el 2003 como parte del \"Thirty-seventh report\" de la OMS.\n\n3. **\u00bfQu\u00e9 tipo de informaci\u00f3n se puede encontrar en el \"Technical Report Series, No. 953\" de la OMS?**\n   - **Respuesta:** El \"Technical Report Series, No. 953\" de la OMS incluye directrices sobre la \"Stability testing of active pharmaceutical ingredients and finished pharmaceutical products\", proporcionando criterios y m\u00e9todos para evaluar la estabilidad de los ingredientes farmac\u00e9uticos activos y los productos farmac\u00e9uticos terminados.\n\n### Resumen de Nivel Superior\n\nEl documento \"WHO - Technical Report Series 957\" incluye una serie de referencias que abordan las mejores pr\u00e1cticas y directrices de la Organizaci\u00f3n Mundial de la Salud (OMS) en relaci\u00f3n con la calidad y seguridad de los productos farmac\u00e9uticos. Estas referencias abarcan temas como el almacenamiento adecuado de medicamentos, buenas pr\u00e1cticas de farmacia, buenas pr\u00e1cticas de manufactura, y procedimientos de importaci\u00f3n y certificaci\u00f3n de materiales farmac\u00e9uticos. La informaci\u00f3n est\u00e1 destinada a asegurar que los productos farmac\u00e9uticos cumplan con los est\u00e1ndares internacionales de calidad y seguridad en el comercio global.", "prev_section_summary": "### Resumen de la Secci\u00f3n 22: Autoinspecci\u00f3n\n\nLa secci\u00f3n 22 del documento de la OMS, parte de la Serie de Informes T\u00e9cnicos 957, se centra en la importancia de las autoinspecciones dentro de un sistema de calidad. Los temas clave incluyen:\n\n1. **Incorporaci\u00f3n de Autoinspecciones**: Se establece que el sistema de calidad debe incluir autoinspecciones para monitorear la implementaci\u00f3n y el cumplimiento de los principios de Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP), as\u00ed como para activar medidas correctivas y preventivas cuando sea necesario.\n\n2. **Independencia y Competencia**: Las autoinspecciones deben ser realizadas de manera independiente y detallada por una persona designada que posea las competencias necesarias para llevar a cabo esta tarea.\n\n3. **Registro de Resultados**: Es fundamental que se registren los resultados de todas las autoinspecciones. Los informes deben incluir todas las observaciones realizadas durante la inspecci\u00f3n y, cuando sea pertinente, propuestas para medidas correctivas.\n\n4. **Programa de Seguimiento**: Debe existir un programa de seguimiento efectivo para evaluar las acciones correctivas. La gesti\u00f3n debe revisar el informe de la inspecci\u00f3n y los registros de las acciones correctivas implementadas.\n\n### Entidades Clave\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Sistema de Calidad**: Estructura que incluye las autoinspecciones como parte de su funcionamiento.\n- **Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP)**: Principios que deben cumplirse durante las autoinspecciones.\n- **Persona Designada**: Individuo competente responsable de realizar las autoinspecciones.\n- **Informes de Autoinspecci\u00f3n**: Documentos que registran las observaciones y propuestas de medidas correctivas.\n- **Programa de Seguimiento**: Proceso para evaluar la efectividad de las acciones correctivas.", "excerpt_keywords": "Keywords: WHO, pharmaceutical practices, quality assurance, good manufacturing practices, stability testing"}}, "ccf28afd-0de8-4a9e-b626-188f787f67bd": {"node_ids": ["8e920956-4282-4493-b922-31532f0a7db6"], "metadata": {"page_label": "279", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 6\n\n## Guidelines on the requalification of prequalified dossiers\n\n1. Introduction\n2. Requalification of prequalified dossiers\n\nAppendix 1  \nSummary of key product information\n\nAppendix 2  \nVariations to the product\n\n### 1. Introduction\n\nIn accordance with the provisions set out in section 12 (Maintenance of prequalification status) of the *Procedure for prequalification of pharmaceutical products*[^1], holders of WHO-prequalified products should submit a quality review 5 years from the date of prequalification of the product, or when requested to do so by WHO Prequalification (whichever date is earlier).\n\nSection 12 of the above-mentioned guidelines states that:\n\n> WHO will furthermore arrange for the products and manufacturing sites included in the list to be re-evaluated at regular intervals. If, as a result of this re-evaluation, it is found that a product and/or specified manufacturing site no longer complies with the WHO-recommended standards, such products and manufacturing sites will be removed from the list. Failure of a manufacturer or applicant to participate in the re-evaluation procedure will also lead to removal from the list.\n>\n> Re-evaluation, including re-inspections of manufacturing sites and contract research organizations (CROs), will be done at regular intervals, based on risk assessment, but at least once every 5 years.\n>\n> Re-evaluation, including re-inspections, shall also be performed:\n\n[^1]: Procedure for prequalification of pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report.* Geneva, World Health Organization, 2009, Annex 4 (WHO Technical Report Series, No. 953) (http://www.who.int/medicines/publications/pharmprep/pdf_trs953.pdf#page=145).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento proporciona directrices sobre la revalidaci\u00f3n de expedientes prequalificados por la OMS, estableciendo que los titulares de productos prequalificados deben presentar una revisi\u00f3n de calidad cada cinco a\u00f1os o cuando la OMS lo solicite. Se menciona que la OMS llevar\u00e1 a cabo reevaluaciones peri\u00f3dicas de los productos y sitios de fabricaci\u00f3n, y que la falta de participaci\u00f3n en este proceso puede resultar en la eliminaci\u00f3n de la lista de productos prequalificados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 acciones se tomar\u00e1n si un producto o sitio de fabricaci\u00f3n no cumple con los est\u00e1ndares recomendados por la OMS durante la reevaluaci\u00f3n?**\n   - Respuesta: Si se determina que un producto o sitio de fabricaci\u00f3n no cumple con los est\u00e1ndares recomendados por la OMS durante la reevaluaci\u00f3n, dicho producto y/o sitio ser\u00e1 eliminado de la lista de productos prequalificados.\n\n2. **\u00bfCon qu\u00e9 frecuencia se realizar\u00e1n las reevaluaciones de los productos y sitios de fabricaci\u00f3n seg\u00fan las directrices de la OMS?**\n   - Respuesta: Las reevaluaciones, incluidas las reinspecciones de los sitios de fabricaci\u00f3n y organizaciones de investigaci\u00f3n por contrato (CROs), se realizar\u00e1n al menos una vez cada cinco a\u00f1os, bas\u00e1ndose en una evaluaci\u00f3n de riesgos.\n\n3. **\u00bfQu\u00e9 consecuencias puede enfrentar un fabricante o solicitante que no participe en el procedimiento de reevaluaci\u00f3n?**\n   - Respuesta: La falta de participaci\u00f3n en el procedimiento de reevaluaci\u00f3n resultar\u00e1 en la eliminaci\u00f3n del fabricante o solicitante de la lista de productos prequalificados por la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nLa secci\u00f3n de referencias del documento \"WHO - Technical Report Series 957\" aborda diversas directrices y pr\u00e1cticas recomendadas por la Organizaci\u00f3n Mundial de la Salud (OMS) en relaci\u00f3n con la calidad y seguridad de los productos farmac\u00e9uticos. Los temas clave incluyen:\n\n1. **Buenas Pr\u00e1cticas de Almacenamiento**: Se menciona la gu\u00eda de la OMS sobre buenas pr\u00e1cticas de almacenamiento para asegurar la integridad de los productos farmac\u00e9uticos.\n\n2. **Buenas Pr\u00e1cticas de Farmacia**: Se hace referencia a las pr\u00e1cticas recomendadas en entornos comunitarios y hospitalarios para garantizar la correcta dispensaci\u00f3n y manejo de medicamentos.\n\n3. **Buenas Pr\u00e1cticas de Manufactura**: Se discuten las normas que deben seguirse en la producci\u00f3n de productos farmac\u00e9uticos para asegurar su calidad.\n\n4. **Certificaci\u00f3n de Productos Farmac\u00e9uticos**: Se incluyen directrices sobre la implementaci\u00f3n de esquemas de certificaci\u00f3n para productos farmac\u00e9uticos en el comercio internacional.\n\n5. **Materiales Iniciales Farmac\u00e9uticos**: Se menciona el esquema de certificaci\u00f3n de materiales iniciales farmac\u00e9uticos (SMACS) para asegurar que estos cumplan con los est\u00e1ndares de calidad.\n\n6. **Procedimientos de Importaci\u00f3n**: Se proporcionan pautas sobre los procedimientos de importaci\u00f3n de productos farmac\u00e9uticos.\n\n7. **Pr\u00e1cticas de Comercio y Distribuci\u00f3n**: Se abordan las buenas pr\u00e1cticas en el comercio y distribuci\u00f3n de materiales farmac\u00e9uticos.\n\n8. **Pruebas de Estabilidad**: Se discuten las pruebas de estabilidad para ingredientes farmac\u00e9uticos activos y productos terminados, asegurando su eficacia y seguridad a lo largo del tiempo.\n\n### Entidades Clave\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la elaboraci\u00f3n de las directrices y pr\u00e1cticas mencionadas.\n- **WHO Technical Report Series**: Serie de informes t\u00e9cnicos que compilan las recomendaciones y est\u00e1ndares de la OMS.\n- **Expert Committee on Specifications for Pharmaceutical Preparations**: Comit\u00e9 de la OMS que elabora y revisa las especificaciones y directrices para productos farmac\u00e9uticos.\n\nEste resumen destaca la importancia de seguir est\u00e1ndares internacionales para garantizar la calidad y seguridad de los productos farmac\u00e9uticos en el comercio global.", "excerpt_keywords": "Keywords: requalification, prequalified dossiers, WHO guidelines, pharmaceutical products, quality review"}}, "74445be5-ae9b-4d39-8afb-0f1e1eb9ff3b": {"node_ids": ["fb81ee37-34ee-4a0a-9458-e974f2f6995c"], "metadata": {"page_label": "280", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "- if any fraud or omissions by the applicant, manufacturer(s) of a finished pharmaceutical product (FPP) or active pharmaceutical ingredient (API), or CROs in the initial assessment procedure or during the follow-up activities, becomes evident; and\n- if WHO or any United Nations agency considers that a batch or batches of supplied prequalified pharmaceutical products are not in compliance with the specifications which were found to be applicable upon prequalification.\n\nRequalification will be applicable to multisource FPPs (generics) where the full dossiers have been submitted, assessed and prequalified by WHO. Renewal of marketing authorization for products that have been listed by WHO based on approval by a stringent regulatory agency[^2^] (SRA) remains the responsibility of the relevant SRA.\n\n## 2. Requalification of prequalified dossiers\n\nThe objective of this quality review submission is to enable WHO to requalify the product based on an assessment of the data and information submitted by the holder of a prequalified product, which includes verification of the acceptability of the product and its conformity to current norms and standards, and assessment of consistency of the quality of the prequalified FPPs, and its manufacturing process(es) over the identified period.\n\nThe holder of a prequalified product should submit the following documents electronically (in pdf format and in also in WinWord where indicated):\n\n- A covering letter, which should contain a clear statement by the responsible person submitting the quality review, indicating that the information submitted is true and correct.\n- Summary of key product information (as per Appendix 1).\n- Variations to the product (as per Appendix 2).\n- A pharmaceutical quality information form (PQIF)[^3^], completed in WinWord format. It should reflect the requirements of current prequalification guidelines and should also take into account technical and\n\n[^2^]: Stringent regulatory authority (SRA): a regulatory authority which is:\n  - a member of the International Conference on Harmonisation (ICH) (as specified on www.ich.org); or\n  - an ICH observer, being the European Free Trade Association (EFTA), as represented by Swiss Medic, Health Canada and World Health Organization (WHO) (as may be updated from time to time); or\n  - a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (as may be updated from time to time).\n\n[^3^]: Presentation of pharmaceutical quality information. In: *Guidance for submission of documentation for prequalification of multi-source (generic) finished pharmaceutical products (FPPs) used in the treatment of HIV/AIDS, malaria and tuberculosis*. Annex 8 (http://apps.who.int/prequal/info_applicants/Guidelines/GuideGenericSubmitDocFPPs_08_2005_ANNEX8.doc).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfQu\u00e9 documentos espec\u00edficos debe presentar el titular de un producto precalificado para la revalidaci\u00f3n ante la OMS?**\n   - Respuesta: El titular de un producto precalificado debe presentar los siguientes documentos electr\u00f3nicamente: una carta de presentaci\u00f3n que indique que la informaci\u00f3n es verdadera y correcta, un resumen de la informaci\u00f3n clave del producto (seg\u00fan el Ap\u00e9ndice 1), variaciones al producto (seg\u00fan el Ap\u00e9ndice 2) y un formulario de informaci\u00f3n de calidad farmac\u00e9utica (PQIF) completado en formato WinWord.\n\n2. **\u00bfCu\u00e1les son las condiciones bajo las cuales se puede llevar a cabo la revalidaci\u00f3n de un producto farmac\u00e9utico precalificado?**\n   - Respuesta: La revalidaci\u00f3n se puede llevar a cabo si se evidencia fraude u omisiones por parte del solicitante, fabricantes o CROs durante el procedimiento de evaluaci\u00f3n inicial o actividades de seguimiento, o si la OMS o alguna agencia de las Naciones Unidas considera que un lote de productos farmac\u00e9uticos precalificados no cumple con las especificaciones aplicables.\n\n3. **\u00bfQu\u00e9 responsabilidad tiene la autoridad reguladora estricta (SRA) en relaci\u00f3n con la renovaci\u00f3n de la autorizaci\u00f3n de comercializaci\u00f3n de productos listados por la OMS?**\n   - Respuesta: La renovaci\u00f3n de la autorizaci\u00f3n de comercializaci\u00f3n para productos que han sido listados por la OMS, bas\u00e1ndose en la aprobaci\u00f3n de una SRA, sigue siendo responsabilidad de la SRA relevante.\n\n### Resumen de nivel superior del contexto:\nEl documento de la OMS establece los procedimientos y requisitos para la revalidaci\u00f3n de productos farmac\u00e9uticos precalificados, especialmente aquellos que son gen\u00e9ricos. Se detalla la documentaci\u00f3n necesaria que debe presentar el titular del producto para que la OMS pueda evaluar la conformidad del producto con las normas y est\u00e1ndares actuales. Adem\u00e1s, se menciona la responsabilidad de las autoridades reguladoras estrictas en la renovaci\u00f3n de autorizaciones de comercializaci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**Temas clave:**\n\n1. **Revalidaci\u00f3n de expedientes prequalificados:** Se establecen directrices para la revalidaci\u00f3n de productos farmac\u00e9uticos que han sido prequalificados por la OMS.\n2. **Revisi\u00f3n de calidad:** Los titulares de productos prequalificados deben presentar una revisi\u00f3n de calidad cada cinco a\u00f1os o cuando la OMS lo solicite.\n3. **Reevaluaci\u00f3n peri\u00f3dica:** La OMS llevar\u00e1 a cabo reevaluaciones de productos y sitios de fabricaci\u00f3n a intervalos regulares, al menos cada cinco a\u00f1os, bas\u00e1ndose en una evaluaci\u00f3n de riesgos.\n4. **Consecuencias de no cumplir:** Si un producto o sitio de fabricaci\u00f3n no cumple con los est\u00e1ndares recomendados, ser\u00e1 eliminado de la lista de productos prequalificados. La falta de participaci\u00f3n en el proceso de reevaluaci\u00f3n tambi\u00e9n resultar\u00e1 en la eliminaci\u00f3n de la lista.\n\n**Entidades:**\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud):** Entidad responsable de la precalificaci\u00f3n y reevaluaci\u00f3n de productos farmac\u00e9uticos.\n- **Productos farmac\u00e9uticos prequalificados:** Productos que han sido evaluados y cumplen con los est\u00e1ndares de calidad establecidos por la OMS.\n- **Sitios de fabricaci\u00f3n:** Instalaciones donde se producen los productos farmac\u00e9uticos que est\u00e1n sujetos a reevaluaci\u00f3n.\n- **Organizaciones de investigaci\u00f3n por contrato (CROs):** Entidades que tambi\u00e9n pueden ser reevaluadas en el proceso de mantenimiento de la precalificaci\u00f3n.", "excerpt_keywords": "Keywords: requalification, prequalified products, pharmaceutical quality, WHO guidelines, marketing authorization"}}, "643fa042-c48f-404f-91c8-7f70d282dccf": {"node_ids": ["f13fc810-bdce-46fe-b173-9aea0bd95359"], "metadata": {"page_label": "281", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido que podr\u00eda estar relacionado:\n\n### Resumen del Contexto\nEl documento mencionado es el \"WHO - Technical Report Series 957\", que es parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica, y recomendaciones sobre pr\u00e1cticas y pol\u00edticas de salud. Sin embargo, el contenido espec\u00edfico del informe no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el informe WHO - Technical Report Series 957?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el contenido del informe, que podr\u00eda incluir recomendaciones de salud p\u00fablica o resultados de investigaciones.\n\n2. **\u00bfQu\u00e9 temas de salud p\u00fablica se abordan en la serie de informes t\u00e9cnicos de la OMS, y c\u00f3mo se relaciona el informe 957 con esos temas?**\n   - Esta pregunta se enfoca en el contexto m\u00e1s amplio de la serie de informes y c\u00f3mo el informe espec\u00edfico se integra en la discusi\u00f3n general sobre salud p\u00fablica.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas se utilizan en el informe WHO - Technical Report Series 957 para evaluar los problemas de salud tratados?**\n   - Esta pregunta indaga sobre las t\u00e9cnicas y enfoques utilizados en el informe para abordar los temas de salud, lo que podr\u00eda incluir estudios de caso, an\u00e1lisis estad\u00edsticos, o revisiones sistem\u00e1ticas.\n\nEstas preguntas est\u00e1n dise\u00f1adas para obtener informaci\u00f3n que probablemente no se encuentre f\u00e1cilmente en otros lugares, dado que se centran en el contenido espec\u00edfico del informe y su contexto dentro de la serie de la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Revalidaci\u00f3n de Productos Farmac\u00e9uticos Precalificados**:\n   - La revalidaci\u00f3n se aplica a productos farmac\u00e9uticos gen\u00e9ricos (FPPs) que han sido evaluados y precalificados por la OMS.\n   - Se puede llevar a cabo si se detectan fraudes, omisiones o si un lote no cumple con las especificaciones.\n\n2. **Documentaci\u00f3n Requerida para la Revalidaci\u00f3n**:\n   - Carta de presentaci\u00f3n que certifique la veracidad de la informaci\u00f3n.\n   - Resumen de informaci\u00f3n clave del producto (seg\u00fan el Ap\u00e9ndice 1).\n   - Variaciones al producto (seg\u00fan el Ap\u00e9ndice 2).\n   - Formulario de informaci\u00f3n de calidad farmac\u00e9utica (PQIF) en formato WinWord.\n\n3. **Responsabilidad de las Autoridades Reguladoras**:\n   - La renovaci\u00f3n de la autorizaci\u00f3n de comercializaci\u00f3n de productos listados por la OMS, basados en la aprobaci\u00f3n de una autoridad reguladora estricta (SRA), es responsabilidad de la SRA correspondiente.\n\n4. **Entidades Mencionadas**:\n   - **OMS (Organizaci\u00f3n Mundial de la Salud)**: Responsable de la evaluaci\u00f3n y revalidaci\u00f3n de productos farmac\u00e9uticos.\n   - **SRA (Autoridad Reguladora Estricta)**: Autoridades que cumplen con est\u00e1ndares internacionales y son responsables de la aprobaci\u00f3n y renovaci\u00f3n de productos farmac\u00e9uticos.\n\n5. **Normas y Est\u00e1ndares**:\n   - La revalidaci\u00f3n implica la verificaci\u00f3n de la conformidad del producto con las normas y est\u00e1ndares actuales, as\u00ed como la consistencia en la calidad y procesos de fabricaci\u00f3n.\n\nEste resumen destaca los procedimientos y requisitos clave para la revalidaci\u00f3n de productos farmac\u00e9uticos precalificados, as\u00ed como las responsabilidades de las entidades involucradas.", "excerpt_keywords": "Keywords: revalidaci\u00f3n, productos farmac\u00e9uticos, OMS, autorizaci\u00f3n de comercializaci\u00f3n, est\u00e1ndares de calidad"}}, "bee3fbbb-ae52-4458-81e9-0d7d93034934": {"node_ids": ["51f662b0-21fb-475b-85ae-6d463dcefdfb"], "metadata": {"page_label": "282", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 1\n\n## Summary of key product information\n\nThis section compares key information on the FPP at the time of prequalification and at the time of the submission for requalification. Table A1.1 should be completed by the holder of the prequalified product. Include remarks as a footnote to Table A1.1, where deemed necessary, to clarify the information provided.\n\n**Table A1.1**\n\n### Summary of key product information\n\n| Item | Prequalified dossier | Current data |\n| - | - | - |\n| Product number (e.g. HA001) | | |\n| INN, strength and pharmaceutical form | | |\n| Applicant (name, physical address and contact numbers) | | |\n| Manufacturing site(s) of FPP, with physical address (including unit and block numbers) and contact numbers (list separately if different steps are performed by different sites, e.g. packaging, quality control) | | |\n| Batch size(s) of FPP | | |\n| Product description (visual appearance) | | |\n| Primary and secondary packaging material(s) and pack size(s) | | |\n| Storage conditions of FPP | | |\n| Shelf-life of FPP | | |\n| FPP specification(s) reference number and/or versionb | | |\n| Manufacturer(s) of API(s), with physical address (including unit and block numbers) and contact numbers (list each API separately) | | |\n| Number/version of each APIMF associated with the FPP | | |\n| Storage conditions of API | | |\n| Retest period of API(s) | | |\n| API specification(s) reference number and/or version (for each API)b | | |\n| All commitments and their outcomes | | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS y se centra en la informaci\u00f3n clave sobre productos farmac\u00e9uticos precalificados. En particular, se presenta una tabla (Tabla A1.1) que debe ser completada por el titular del producto precalificado, comparando la informaci\u00f3n del expediente precalificado con los datos actuales en el momento de la revalidaci\u00f3n. La tabla incluye detalles sobre el n\u00famero de producto, la forma farmac\u00e9utica, el solicitante, los sitios de fabricaci\u00f3n, las condiciones de almacenamiento, la vida \u00fatil, y otros aspectos relevantes del producto y sus ingredientes activos.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 informaci\u00f3n espec\u00edfica debe incluirse en la secci\u00f3n de \"Compromisos y sus resultados\" de la Tabla A1.1?**\n   - Esta pregunta busca detalles sobre los compromisos que el titular del producto debe reportar y c\u00f3mo se eval\u00faan sus resultados, lo cual no se detalla expl\u00edcitamente en el contexto.\n\n2. **\u00bfCu\u00e1les son las implicaciones de no proporcionar informaci\u00f3n actualizada en la secci\u00f3n de \"Tama\u00f1o de lote(s) de FPP\" en la Tabla A1.1?**\n   - Esta pregunta indaga sobre las consecuencias que podr\u00eda tener la falta de actualizaci\u00f3n en esta secci\u00f3n, lo que podr\u00eda afectar la evaluaci\u00f3n de la calidad y la disponibilidad del producto.\n\n3. **\u00bfQu\u00e9 criterios se utilizan para determinar las \"Condiciones de almacenamiento del FPP\" y c\u00f3mo pueden variar entre diferentes productos?**\n   - Esta pregunta busca entender los factores que influyen en las condiciones de almacenamiento y c\u00f3mo estas pueden diferir seg\u00fan el tipo de producto farmac\u00e9utico, lo que no se aborda directamente en el contexto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento mencionado, \"WHO - Technical Report Series 957\", es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque el contenido espec\u00edfico no est\u00e1 disponible, se pueden inferir algunos temas clave y entidades relevantes:\n\n#### Temas Clave:\n1. **Salud P\u00fablica**: El informe probablemente aborda cuestiones relacionadas con la salud p\u00fablica, incluyendo pol\u00edticas, pr\u00e1cticas y recomendaciones para mejorar la salud global.\n2. **Investigaci\u00f3n M\u00e9dica**: Es probable que el informe incluya hallazgos de investigaciones recientes en el campo de la medicina y la salud.\n3. **Recomendaciones de Salud**: Se espera que el documento contenga recomendaciones basadas en evidencia para abordar problemas de salud espec\u00edficos.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la publicaci\u00f3n del informe, que se dedica a coordinar esfuerzos internacionales en salud p\u00fablica.\n- **Informe T\u00e9cnico**: El tipo de documento que se presenta, que forma parte de una serie m\u00e1s amplia de informes t\u00e9cnicos.\n\nEste resumen destaca la importancia del informe en el contexto de la salud p\u00fablica y la investigaci\u00f3n m\u00e9dica, aunque no se proporcionan detalles espec\u00edficos sobre su contenido.", "excerpt_keywords": "Keywords: prequalification, pharmaceutical product, WHO, manufacturing, storage conditions"}}, "d865e322-2e33-4047-9bb9-0767496ee1f4": {"node_ids": ["58a09cb7-ac05-476c-bef9-1200bd488e0e"], "metadata": {"page_label": "283", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Dado el contexto proporcionado sobre el documento \"WHO - Technical Report Series 957\", aqu\u00ed tienes tres preguntas que podr\u00edan proporcionar respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el Informe T\u00e9cnico de la OMS, Serie 957?**\n   - Esta pregunta busca obtener informaci\u00f3n detallada sobre el contenido espec\u00edfico del informe, que podr\u00eda no estar disponible en otras fuentes.\n\n2. **\u00bfQu\u00e9 temas de salud p\u00fablica se abordan en el documento y c\u00f3mo se relacionan con las pol\u00edticas actuales de la OMS?**\n   - Esta pregunta se centra en la relevancia del informe en el contexto de las pol\u00edticas de salud p\u00fablica, lo que podr\u00eda ofrecer una perspectiva \u00fanica sobre su impacto.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas se utilizaron para recopilar y analizar los datos presentados en el Informe T\u00e9cnico de la OMS, Serie 957?**\n   - Esta pregunta busca profundizar en los m\u00e9todos de investigaci\u00f3n utilizados en el informe, lo que podr\u00eda no estar ampliamente discutido en otras publicaciones.\n\n### Resumen de nivel superior del contexto circundante:\nEl \"WHO - Technical Report Series 957\" es un documento t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud que probablemente aborda temas relevantes en el \u00e1mbito de la salud p\u00fablica, incluyendo recomendaciones, hallazgos de investigaciones y metodolog\u00edas utilizadas para la recopilaci\u00f3n de datos. Este tipo de informes son cruciales para informar pol\u00edticas y pr\u00e1cticas en salud a nivel global.", "prev_section_summary": "### Resumen de temas clave y entidades\n\nLa secci\u00f3n proporcionada es un extracto del documento \"WHO - Technical Report Series 957\" y se centra en la recopilaci\u00f3n y comparaci\u00f3n de informaci\u00f3n clave sobre productos farmac\u00e9uticos precalificados. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas clave:\n1. **Precalificaci\u00f3n y Revalidaci\u00f3n**: La secci\u00f3n aborda la importancia de comparar la informaci\u00f3n del expediente precalificado con los datos actuales en el momento de la revalidaci\u00f3n del producto.\n2. **Tabla A1.1**: Se presenta una tabla que debe ser completada por el titular del producto, que incluye diversos aspectos del producto farmac\u00e9utico y sus ingredientes activos.\n3. **Informaci\u00f3n del Producto**: La tabla incluye detalles como el n\u00famero de producto, forma farmac\u00e9utica, solicitante, sitios de fabricaci\u00f3n, condiciones de almacenamiento, vida \u00fatil, especificaciones, y compromisos asociados.\n4. **Compromisos y Resultados**: Se menciona la necesidad de incluir todos los compromisos y sus resultados, lo que implica un seguimiento de las obligaciones asumidas por el titular del producto.\n\n#### Entidades:\n- **FPP (Forma Farmac\u00e9utica del Producto)**: Se refiere al producto farmac\u00e9utico que est\u00e1 siendo evaluado.\n- **INN (Nombre Com\u00fan Internacional)**: Se refiere al nombre gen\u00e9rico del medicamento.\n- **API (Ingrediente Activo Farmac\u00e9utico)**: Sustancia activa que se utiliza en la fabricaci\u00f3n del FPP.\n- **Solicitante**: Entidad o persona que presenta el expediente para la precalificaci\u00f3n o revalidaci\u00f3n del producto.\n- **Sitios de fabricaci\u00f3n**: Lugares donde se produce el FPP, que deben ser detallados con direcciones f\u00edsicas y n\u00fameros de contacto.\n\nEste resumen destaca la estructura y el prop\u00f3sito de la secci\u00f3n, as\u00ed como los elementos esenciales que deben ser considerados en el proceso de precalificaci\u00f3n y revalidaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: precalificaci\u00f3n, revalidaci\u00f3n, productos farmac\u00e9uticos, metodolog\u00eda, salud p\u00fablica"}}, "13b47a2f-455c-48f6-bc40-7effe19ec310": {"node_ids": ["f8b5b1cf-b3a3-4c9c-b5f8-0f3be0b40929"], "metadata": {"page_label": "284", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 2\n\n## Variations to the product\n\nThe holder of the prequalified product should submit a review, in tabular format, of any minor and/or major changes (including those pending) to the initially prequalified product or to the terms of the initially prequalified dossier. Table A2.1 should be completed by the holder of the prequalified product.\n\n**Table A2.1**\n\nInformation on variations to the prequalified product\n\n| Reference no. | Date of submission | Date of approval/ rejection and reference number of the letter | Date of implementation |\n| - | - | - | - |\n| **Major changes** | | | |\n| Description of the change, e.g. change in the primary packaging site of a sterile product | | | |\n| **Minor changes** | | | |\n| Description of the change according to the PQ variation guide | | | |\n\n\nAdd as many rows as necessary.\n\nNote. Requests for variations should have been submitted in accordance with WHO's Guidance on variations to a prequalified product dossier<sup>4</sup>.\n\n----\n\n<sup>4</sup> WHO Guidance on variations to a prequalified product dossier. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report. Geneva, World Health Organization, 2007, Annex 6 (WHO Technical Report Series, No. 943) (http://apps.who.int/prequal/info_general/documents/TRS943/TRS943.pdf#page=121).", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es un ap\u00e9ndice del Informe T\u00e9cnico de la OMS (WHO - Technical Report Series 957) que se centra en las variaciones de productos farmac\u00e9uticos precalificados. Se establece que el titular del producto debe presentar una revisi\u00f3n de cualquier cambio menor o mayor en un formato tabular. Se incluye una tabla (Tabla A2.1) donde se deben registrar los detalles de las variaciones, como el n\u00famero de referencia, fechas de presentaci\u00f3n y aprobaci\u00f3n, y la descripci\u00f3n de los cambios. Adem\u00e1s, se menciona que las solicitudes de variaciones deben seguir la gu\u00eda de la OMS sobre este tema.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de cambios deben ser reportados en la Tabla A2.1 y c\u00f3mo se diferencian entre s\u00ed?**\n   - La tabla debe incluir tanto cambios mayores, como un cambio en el sitio de empaquetado primario de un producto est\u00e9ril, como cambios menores, que deben describirse de acuerdo con la gu\u00eda de variaciones de la OMS.\n\n2. **\u00bfCu\u00e1l es el procedimiento que debe seguir el titular del producto para solicitar variaciones seg\u00fan la OMS?**\n   - Las solicitudes de variaciones deben ser presentadas de acuerdo con la \"Gu\u00eda de la OMS sobre variaciones a un expediente de producto precalificado\", lo que implica seguir un proceso espec\u00edfico que no se detalla en el contexto, pero que se menciona como un requisito.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n adicional se puede incluir en la Tabla A2.1 si es necesario?**\n   - Se indica que se pueden agregar tantas filas como sea necesario en la tabla para registrar m\u00faltiples variaciones, lo que sugiere que no hay un l\u00edmite en la cantidad de cambios que se pueden documentar, siempre que se sigan las pautas establecidas.", "prev_section_summary": "El documento \"WHO - Technical Report Series 957\" de la Organizaci\u00f3n Mundial de la Salud (OMS) aborda temas relevantes en el \u00e1mbito de la salud p\u00fablica. Aunque no se proporciona contenido espec\u00edfico en el extracto, se pueden inferir algunos temas clave y entidades relacionadas:\n\n1. **Hallazgos y Recomendaciones**: El informe presenta hallazgos significativos y recomendaciones que son cruciales para la salud p\u00fablica a nivel global.\n\n2. **Temas de Salud P\u00fablica**: Se abordan diversos temas de salud p\u00fablica que son relevantes para las pol\u00edticas actuales de la OMS, lo que sugiere un enfoque en la mejora de la salud a nivel mundial.\n\n3. **Metodolog\u00edas de Investigaci\u00f3n**: Se discuten las metodolog\u00edas utilizadas para la recopilaci\u00f3n y an\u00e1lisis de datos, lo que es fundamental para la validez y aplicabilidad de los hallazgos presentados.\n\nEn resumen, el informe es un recurso importante para informar pol\u00edticas y pr\u00e1cticas en salud, destacando la relevancia de la investigaci\u00f3n y las recomendaciones de la OMS en el contexto de la salud p\u00fablica global.", "excerpt_keywords": "Keywords: variations, prequalified product, WHO guidelines, pharmaceutical changes, product dossier"}}, "7d150a0a-1e0f-4615-bb63-fcf1a1be0218": {"node_ids": ["b54bb733-80a3-48d6-b143-381cd354c7ae"], "metadata": {"page_label": "285", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Annex 7\n\n## Guidelines for the preparation of a contract research organization master file\n\n### Background\n\n1. General information\n2. Quality management system of the contract research organization\n3. Personnel\n4. Ethics committee\n5. Computer systems\n6. Equipment and instruments\n7. Documentation\n8. Safety monitoring\n9. Investigational medicinal products and comparator products\n10. Pathology\n11. Bioanalytical laboratory\n12. Biostatistics\n13. Study volunteers\n14. Other information", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que pueden ser respondidas por el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 957\" incluye una secci\u00f3n titulada \"Anexo 7\", que proporciona directrices para la preparaci\u00f3n de un archivo maestro de organizaciones de investigaci\u00f3n por contrato (CRO). Este anexo abarca diversos aspectos esenciales que deben considerarse al establecer un archivo maestro, incluyendo informaci\u00f3n general, sistemas de gesti\u00f3n de calidad, personal, comit\u00e9s de \u00e9tica, sistemas inform\u00e1ticos, equipos, documentaci\u00f3n, monitoreo de seguridad, productos medicinales en investigaci\u00f3n, patolog\u00eda, laboratorios bioanal\u00edticos, bioestad\u00edstica, voluntarios de estudio y otra informaci\u00f3n relevante.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 elementos espec\u00edficos se deben incluir en la secci\u00f3n de \"Documentaci\u00f3n\" del archivo maestro de una organizaci\u00f3n de investigaci\u00f3n por contrato seg\u00fan las directrices?**\n   - Esta pregunta busca detalles sobre los tipos de documentos y registros que son necesarios para cumplir con las normativas establecidas.\n\n2. **\u00bfCu\u00e1les son los requisitos para el \"Sistema de gesti\u00f3n de calidad\" que debe tener una organizaci\u00f3n de investigaci\u00f3n por contrato, seg\u00fan el anexo?**\n   - Esta pregunta se centra en los est\u00e1ndares y procedimientos que una CRO debe implementar para asegurar la calidad en sus operaciones.\n\n3. **\u00bfQu\u00e9 consideraciones \u00e9ticas se deben tener en cuenta al establecer un \"Comit\u00e9 de \u00e9tica\" en el contexto de un archivo maestro de CRO?**\n   - Esta pregunta indaga sobre los principios y pr\u00e1cticas que deben guiar la formaci\u00f3n y funcionamiento de un comit\u00e9 de \u00e9tica en la investigaci\u00f3n cl\u00ednica. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que probablemente no se encuentre f\u00e1cilmente en otros documentos o fuentes.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Variaciones de productos farmac\u00e9uticos**: La secci\u00f3n se centra en la necesidad de reportar cambios menores y mayores en productos farmac\u00e9uticos precalificados.\n\n2. **Responsabilidad del titular del producto**: El titular del producto precalificado es responsable de presentar una revisi\u00f3n de las variaciones en un formato tabular.\n\n3. **Tabla A2.1**: Se proporciona un formato espec\u00edfico (Tabla A2.1) para documentar las variaciones, que incluye columnas para el n\u00famero de referencia, fechas de presentaci\u00f3n, aprobaci\u00f3n/rechazo y descripci\u00f3n de los cambios.\n\n4. **Tipos de cambios**:\n   - **Cambios mayores**: Ejemplo dado es el cambio en el sitio de empaquetado primario de un producto est\u00e9ril.\n   - **Cambios menores**: Deben describirse de acuerdo con la gu\u00eda de variaciones de la OMS.\n\n5. **Gu\u00eda de la OMS**: Se menciona que las solicitudes de variaciones deben seguir la \"Gu\u00eda de la OMS sobre variaciones a un expediente de producto precalificado\".\n\n6. **Flexibilidad en la documentaci\u00f3n**: Se permite agregar tantas filas como sea necesario en la tabla para registrar m\u00faltiples variaciones.\n\n### Entidades\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la gu\u00eda y regulaci\u00f3n de productos farmac\u00e9uticos.\n- **Tabla A2.1**: Herramienta para la documentaci\u00f3n de variaciones.\n- **Productos farmac\u00e9uticos precalificados**: Productos que cumplen con los est\u00e1ndares de calidad establecidos por la OMS.", "excerpt_keywords": "Keywords: contract research organization, master file, quality management, ethics committee, investigational products"}}, "c3aeecc6-fcc5-4d9b-99d2-1a438123200e": {"node_ids": ["6da9d396-97e2-470c-ac2d-c6b53d97242b"], "metadata": {"page_label": "286", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Background\n\nA contract research organization master file (CROMF) is a document prepared by the contract research organization (CRO) containing specific and factual information about the CRO and the conduct of clinical studies as well as the analyses of samples and related operations (including clinical trials, clinical data management, pharmacokinetics and statistical analysis and regulatory affairs) carried out at the named site. If only some of the operations referred to below are carried out at the site, the master file (MF) needs to be presented only for those operations.\n\nIn a case where a CRO is responsible for activities pertaining only to bioanalytical procedures, then only sections in the CROMF relating to these should be described. Other sections may be marked as \u201cnot applicable\u201d.\n\nWhere a CRO performs various activities, separate sections could be prepared for the different units, e.g. clinical pharmacology unit (CPU) and bioanalytical laboratory (BAL).\n\nA CROMF provides information on the policies, approach and general activities of a CRO. It is not trial-specific as trial-specific data are submitted in a product dossier. It serves as general information to regulators and can be used during preparation for inspections by regulatory inspectors in addition to the trial-specific data and information submitted for assessment. It also provides an overview of the organization\u2019s approach to good clinical practices (GCP), good laboratory practices (GLP) and other guidelines pertaining to its activities.\n\nA CROMF should be submitted to the national medicines regulatory authority (NMRA) where such a document is requested. It should be succinct and as far as possible not exceed 25 A4 pages (where appropriate, supportive documentation may be appended).\n\nAn updated CROMF should be submitted when requested by the NMRA, or if significant changes have been implemented by the CRO.\n\n## 1. General information\n\n1.1 Name and exact address of the CRO, including telephone, fax, 24-hour telephone numbers and e-mail address\n\n1.2 Short description of the CRO (including size, location, number of beds, layout and plan, areas for handling samples and waste)\n\n1.3 Activities as licensed/authorized by the national authority\n\n1.4 Inspections and approvals", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en un CROMF si un CRO solo realiza procedimientos bioanal\u00edticos?**\n   - Respuesta: En este caso, el CROMF debe describir \u00fanicamente las secciones relacionadas con los procedimientos bioanal\u00edticos, mientras que otras secciones pueden ser marcadas como \"no aplicable\".\n\n2. **\u00bfCu\u00e1l es la longitud m\u00e1xima recomendada para un CROMF y qu\u00e9 tipo de documentaci\u00f3n adicional puede incluirse?**\n   - Respuesta: Un CROMF debe ser sucinto y no exceder las 25 p\u00e1ginas A4. Se puede incluir documentaci\u00f3n de apoyo como ap\u00e9ndices si es apropiado.\n\n3. **\u00bfCu\u00e1ndo debe un CRO actualizar y presentar su CROMF a la autoridad reguladora nacional de medicamentos (NMRA)?**\n   - Respuesta: Un CRO debe presentar un CROMF actualizado cuando lo solicite la NMRA o si se han implementado cambios significativos en las operaciones del CRO.\n\n### Resumen de nivel superior del contexto:\nEl contexto describe el prop\u00f3sito y los requisitos de un archivo maestro de organizaci\u00f3n de investigaci\u00f3n por contrato (CROMF), que es un documento que proporciona informaci\u00f3n espec\u00edfica sobre las actividades de un CRO y su cumplimiento con las buenas pr\u00e1cticas cl\u00ednicas y de laboratorio. Se detalla la informaci\u00f3n que debe incluirse, la longitud m\u00e1xima del documento y las circunstancias bajo las cuales debe ser actualizado y presentado a las autoridades reguladoras.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\nLa secci\u00f3n \"Anexo 7\" del documento \"WHO - Technical Report Series 957\" se centra en las directrices para la preparaci\u00f3n de un archivo maestro de organizaciones de investigaci\u00f3n por contrato (CRO). Los temas clave abordados en esta secci\u00f3n incluyen:\n\n1. **Informaci\u00f3n General**: Proporciona un contexto b\u00e1sico sobre la organizaci\u00f3n y su funcionamiento.\n2. **Sistema de Gesti\u00f3n de Calidad**: Detalla los est\u00e1ndares y procedimientos necesarios para asegurar la calidad en las operaciones de la CRO.\n3. **Personal**: Describe la importancia del personal calificado y su rol en la investigaci\u00f3n.\n4. **Comit\u00e9 de \u00c9tica**: Establece las consideraciones \u00e9ticas que deben guiar la investigaci\u00f3n y la protecci\u00f3n de los participantes.\n5. **Sistemas Inform\u00e1ticos**: Aborda la infraestructura tecnol\u00f3gica necesaria para la gesti\u00f3n de datos y procesos.\n6. **Equipos e Instrumentos**: Especifica los equipos necesarios para llevar a cabo investigaciones de manera efectiva.\n7. **Documentaci\u00f3n**: Enumera los tipos de documentos y registros requeridos para cumplir con las normativas.\n8. **Monitoreo de Seguridad**: Enfatiza la importancia de la vigilancia de la seguridad de los participantes durante los estudios.\n9. **Productos Medicinales en Investigaci\u00f3n**: Incluye directrices sobre los productos utilizados en los ensayos cl\u00ednicos.\n10. **Patolog\u00eda**: Consideraciones relacionadas con el estudio de enfermedades y condiciones.\n11. **Laboratorio Bioanal\u00edtico**: Detalles sobre los laboratorios que realizan an\u00e1lisis de muestras biol\u00f3gicas.\n12. **Bioestad\u00edstica**: Importancia de la estad\u00edstica en el dise\u00f1o y an\u00e1lisis de estudios cl\u00ednicos.\n13. **Voluntarios de Estudio**: Aspectos relacionados con la selecci\u00f3n y manejo de los participantes en la investigaci\u00f3n.\n14. **Otra Informaci\u00f3n**: Cualquier otro aspecto relevante que no se haya cubierto en las secciones anteriores.\n\nEstos temas son fundamentales para establecer un archivo maestro que cumpla con los est\u00e1ndares internacionales y garantice la integridad y calidad de la investigaci\u00f3n cl\u00ednica.", "excerpt_keywords": "CROMF, CRO, clinical studies, regulatory authority, good clinical practices"}}, "301265b8-7434-48b1-bd47-b3bf6af1bebb": {"node_ids": ["250c678c-ff1d-4e6e-a99a-5e75c03e2b4a"], "metadata": {"page_label": "287", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# 1.4.1 Inspections/approvals/accreditations by any regulatory agency\n\n1.4.2 Audits of subcontractors\n\n1.5 Type of studies (and indications, where appropriate) performed on site (a list of projects conducted at this site may be provided)\n\n1.6 Provisions for insurance\n\n1.6.1 Number of employees engaged in studies, quality, storage and distribution\n\n1.7 Contract services employed\n\n1.7.1 Use of outside scientific, analytical or other technical assistance in relation to studies and analysis (e.g. clinical laboratory, bioanalytical laboratory, X-ray facilities and caterers)\n\n1.7.2 Services outsourced, e.g. contracts with tertiary care hospital for handling of medical emergencies, ambulance facility, nutrition, biomedical waste, chemical waste, caterers, pest control and pathology laboratory\n\n# 2. Quality management system of the contract research organization\n\n(Short description including, e.g. responsibilities of the quality assurance unit. A list of quality system documents can be included)\n\n2.1 Organization chart including the arrangements for quality assurance\n\n2.2 Internal audits and self inspection\n\n2.3 Corrective and preventive action plans (CAPA)\n\n# 3. Personnel\n\n(A brief description can be presented in tabular format)\n\n3.1 Qualifications, experience and responsibilities of key personnel as applicable\n\n3.1.1 project manager\n\n3.1.2 principal investigator\n\n3.1.3 analytical investigator\n\n3.1.4 biostatistician\n\n3.1.5 clinical research associates\n\n3.1.6 data manager", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior del contenido:\n\n### Resumen de Nivel Superior\nEl documento de la OMS, \"Technical Report Series 957\", aborda aspectos clave relacionados con la gesti\u00f3n de organizaciones de investigaci\u00f3n por contrato (CRO). Se enfoca en las inspecciones y aprobaciones por agencias regulatorias, auditor\u00edas de subcontratistas, tipos de estudios realizados, provisiones de seguros, servicios contratados, y el sistema de gesti\u00f3n de calidad de la CRO. Tambi\u00e9n se detalla la organizaci\u00f3n del personal clave, incluyendo sus calificaciones y responsabilidades.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 tipo de estudios se realizan en el sitio y cu\u00e1les son las indicaciones espec\u00edficas para cada uno?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre los proyectos espec\u00edficos que se llevan a cabo en la CRO, lo cual no se detalla en el resumen general.\n\n2. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas del personal clave mencionado, como el gerente de proyecto y el investigador principal?**\n   - Aunque se mencionan los roles, esta pregunta busca una descripci\u00f3n m\u00e1s profunda de las funciones y responsabilidades de cada uno, que podr\u00eda no estar disponible en otras fuentes.\n\n3. **\u00bfQu\u00e9 medidas correctivas y preventivas se implementan en la organizaci\u00f3n para abordar las no conformidades identificadas durante las auditor\u00edas internas?**\n   - Esta pregunta se centra en los planes de acci\u00f3n correctiva y preventiva (CAPA) y busca ejemplos espec\u00edficos de c\u00f3mo la CRO maneja las deficiencias, lo que podr\u00eda no estar ampliamente documentado en otros lugares.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Definici\u00f3n de CROMF**: \n   - El archivo maestro de organizaci\u00f3n de investigaci\u00f3n por contrato (CROMF) es un documento que contiene informaci\u00f3n espec\u00edfica y factual sobre un CRO y sus actividades relacionadas con estudios cl\u00ednicos, an\u00e1lisis de muestras y operaciones relacionadas.\n\n2. **Contenido del CROMF**:\n   - Debe incluir informaci\u00f3n sobre pol\u00edticas, enfoques y actividades generales del CRO, pero no es espec\u00edfico para ensayos cl\u00ednicos.\n   - Secciones espec\u00edficas deben ser presentadas dependiendo de las actividades realizadas en el sitio, como procedimientos bioanal\u00edticos o unidades de farmacolog\u00eda cl\u00ednica.\n\n3. **Requisitos de Presentaci\u00f3n**:\n   - El CROMF debe ser presentado a la autoridad reguladora nacional de medicamentos (NMRA) cuando se solicite.\n   - Debe ser conciso, no excediendo las 25 p\u00e1ginas A4, y puede incluir documentaci\u00f3n de apoyo como ap\u00e9ndices.\n\n4. **Actualizaci\u00f3n del CROMF**:\n   - Debe actualizarse y presentarse nuevamente a la NMRA si se solicitan cambios o si se implementan cambios significativos en las operaciones del CRO.\n\n5. **Informaci\u00f3n General Requerida**:\n   - Nombre y direcci\u00f3n exacta del CRO, incluyendo datos de contacto.\n   - Descripci\u00f3n breve del CRO (tama\u00f1o, ubicaci\u00f3n, capacidad, etc.).\n   - Actividades autorizadas por la autoridad nacional.\n   - Inspecciones y aprobaciones recibidas.\n\n### Entidades Clave\n- **CRO (Organizaci\u00f3n de Investigaci\u00f3n por Contrato)**: Entidad responsable de realizar estudios cl\u00ednicos y an\u00e1lisis.\n- **CROMF (Archivo Maestro de Organizaci\u00f3n de Investigaci\u00f3n por Contrato)**: Documento que detalla las operaciones y pol\u00edticas del CRO.\n- **NMRA (Autoridad Reguladora Nacional de Medicamentos)**: Entidad que solicita y revisa el CROMF.\n- **GCP (Buenas Pr\u00e1cticas Cl\u00ednicas)** y **GLP (Buenas Pr\u00e1cticas de Laboratorio)**: Normativas que gu\u00edan las operaciones del CRO.", "excerpt_keywords": "Keywords: contract research organization, quality management system, audits, personnel qualifications, regulatory inspections"}}, "24fc0c7e-d12e-4f23-94c4-75dbe325b531": {"node_ids": ["a0675d16-7c7e-4a64-9ded-59a6a2e0a84e"], "metadata": {"page_label": "288", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 3.1.7\n- monitor\n\n## 3.1.8\n- the study director(s)\n\n## 3.1.9\n- person responsible for quality assurance\n\n### 3.2 Training of personnel:\n- 3.2.1 training policy and procedure (brief description)\n- 3.2.2 training records\n\n## 4. Ethics committee\n\n### 4.1\n- Constitution and relation to CRO\n\n### 4.2\n- Procedures including review and approval of protocols\n\n## 5. Computer systems\n\n(Short description)\n\n### 5.1\n- Hardware\n\n### 5.2\n- Software (and version number) used (e.g. in the bioanalytical laboratory, in pharmacokinetic and statistical analysis) and change control procedure\n\n### 5.3\n- Data management systems (include a procedural flow chart and a brief description of query generation and resolution)\n\n### 5.4\n- Security procedures\n\n### 5.5\n- Electronic exchange of confidential information\n\n### 5.6\n- Brief description of validation programme\n\n### 5.7\n- Back-up and storage of electronic data\n\n## 6. Equipment and instruments\n\n### 6.1\n- Brief description of major equipment and instruments (a list of equipment is not required)\n\n### 6.2\n- Qualification, maintenance and calibration programme, including the temperature recording systems", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento \"WHO - Technical Report Series 957\" aborda aspectos clave relacionados con la gesti\u00f3n de estudios cl\u00ednicos, incluyendo la formaci\u00f3n del personal, la \u00e9tica en la investigaci\u00f3n, la gesti\u00f3n de sistemas inform\u00e1ticos y el uso de equipos e instrumentos. Se detallan las responsabilidades de los monitores, directores de estudio y personal de aseguramiento de calidad, as\u00ed como la importancia de los comit\u00e9s de \u00e9tica y la gesti\u00f3n de datos electr\u00f3nicos.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas del personal mencionado en la secci\u00f3n 3.1, como los monitores y los directores de estudio?**\n   - Esta pregunta busca obtener detalles sobre las funciones y responsabilidades espec\u00edficas de los monitores y directores de estudio en el contexto de la investigaci\u00f3n cl\u00ednica.\n\n2. **\u00bfQu\u00e9 procedimientos se describen para la formaci\u00f3n del personal en la secci\u00f3n 3.2, y c\u00f3mo se gestionan los registros de formaci\u00f3n?**\n   - Esta pregunta se centra en los procedimientos de formaci\u00f3n y la importancia de mantener registros adecuados, lo que es crucial para garantizar la competencia del personal involucrado en estudios cl\u00ednicos.\n\n3. **\u00bfQu\u00e9 aspectos se consideran en la secci\u00f3n 5.2 sobre el software utilizado en laboratorios bioanal\u00edticos y c\u00f3mo se gestiona el control de cambios?**\n   - Esta pregunta busca profundizar en los detalles sobre el software espec\u00edfico utilizado en el an\u00e1lisis de datos y c\u00f3mo se asegura que cualquier cambio en el software se maneje adecuadamente para mantener la integridad de los datos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Inspecciones y Aprobaciones**\n   - Inspecciones y acreditaciones por agencias regulatorias.\n   - Auditor\u00edas de subcontratistas.\n\n2. **Tipos de Estudios**\n   - Tipos de estudios realizados en el sitio, con posibles indicaciones espec\u00edficas.\n   - Provisi\u00f3n de seguros.\n\n3. **Personal y Recursos**\n   - N\u00famero de empleados involucrados en estudios, calidad, almacenamiento y distribuci\u00f3n.\n   - Servicios contratados y uso de asistencia t\u00e9cnica externa (laboratorios cl\u00ednicos, bioanal\u00edticos, etc.).\n   - Servicios subcontratados, incluyendo emergencias m\u00e9dicas y gesti\u00f3n de residuos.\n\n4. **Sistema de Gesti\u00f3n de Calidad**\n   - Descripci\u00f3n del sistema de gesti\u00f3n de calidad de la organizaci\u00f3n de investigaci\u00f3n por contrato (CRO).\n   - Organigrama y responsabilidades de la unidad de aseguramiento de calidad.\n   - Auditor\u00edas internas y autoinspecciones.\n   - Planes de acci\u00f3n correctiva y preventiva (CAPA).\n\n5. **Personal Clave**\n   - Calificaciones, experiencia y responsabilidades de personal clave, incluyendo:\n     - Gerente de proyecto.\n     - Investigador principal.\n     - Investigador anal\u00edtico.\n     - Bioestad\u00edstico.\n     - Asociados de investigaci\u00f3n cl\u00ednica.\n     - Gerente de datos.\n\nEste resumen destaca los aspectos fundamentales relacionados con la gesti\u00f3n y operaci\u00f3n de organizaciones de investigaci\u00f3n por contrato, as\u00ed como la estructura del personal y los sistemas de calidad implementados.", "excerpt_keywords": "Keywords: clinical research, quality assurance, training procedures, ethics committee, data management systems"}}, "5839449d-da40-43c8-88ef-d86b525784d2": {"node_ids": ["de7f15a5-a44f-4896-81de-c0347f8e1a12"], "metadata": {"page_label": "289", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# Documentation\n\n7.1 Briefly describe document management systems\n\n7.2 Project work flow including quality assurance and control process\n\n7.3 Preparation of protocols\n\n7.4 Preparation of informed consent forms and subject information forms\n\n7.5 Preparation of report forms\n\n7.6 Preparation of final report\n\n# Safety monitoring\n\n(Brief description)\n\nAdverse drug reaction reporting procedure\n\nProvisions made for emergencies, including protocols and equipment available\n\n# Investigational medicinal products and comparator products\n\n(Brief description)\n\n9.1 Acquisition, storage, handling, sampling and disposal\n\n9.2 Pharmacy and dispensing\n\n# Pathology\n\n10.1 Biological sample collection and storage\n\n10.2 Handling and analysis of biological samples\n\n# Bioanalytical laboratory\n\n(Brief description)\n\n11.1 Method development and validation\n\n11.2 Reference standard materials used for preparation of calibration standards and quality control samples\n\n11.3 Biological matrix storage, and handling of matrix samples\n\n11.4 Analysis of unknown samples", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a generar mejores preguntas:\n\n### Resumen de nivel superior:\nEl documento se centra en la gesti\u00f3n de la documentaci\u00f3n y los procedimientos relacionados con la investigaci\u00f3n de productos medicinales, incluyendo la preparaci\u00f3n de protocolos, consentimientos informados, y la gesti\u00f3n de muestras biol\u00f3gicas. Tambi\u00e9n aborda la monitorizaci\u00f3n de la seguridad, la gesti\u00f3n de productos investigacionales, y los procesos en laboratorios bioanal\u00edticos.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en un sistema de gesti\u00f3n de documentos para garantizar la calidad y el control en un proyecto de investigaci\u00f3n?**\n   - Esta pregunta se centra en la secci\u00f3n 7.1 sobre sistemas de gesti\u00f3n de documentos y busca detalles espec\u00edficos que no se mencionan expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir para la recolecci\u00f3n y almacenamiento de muestras biol\u00f3gicas seg\u00fan las pautas del documento?**\n   - Esta pregunta se relaciona con las secciones 10.1 y 10.2, y busca informaci\u00f3n detallada sobre las mejores pr\u00e1cticas en la manipulaci\u00f3n de muestras biol\u00f3gicas.\n\n3. **\u00bfQu\u00e9 medidas de emergencia se deben tener en cuenta en el monitoreo de seguridad de los ensayos cl\u00ednicos, y qu\u00e9 protocolos deben estar disponibles?**\n   - Esta pregunta se refiere a la secci\u00f3n sobre monitoreo de seguridad y busca informaci\u00f3n espec\u00edfica sobre los protocolos y equipos necesarios en situaciones de emergencia.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar disponible en otras fuentes, bas\u00e1ndose en el contenido del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n:\n\n1. **Responsabilidades del Personal**:\n   - **Monitores**: Encargados de supervisar el desarrollo del estudio.\n   - **Directores de Estudio**: Responsables de la planificaci\u00f3n y ejecuci\u00f3n del estudio.\n   - **Personal de Aseguramiento de Calidad**: Asegura que se cumplan los est\u00e1ndares de calidad en el estudio.\n\n2. **Formaci\u00f3n del Personal**:\n   - **Pol\u00edtica y Procedimientos de Formaci\u00f3n**: Descripci\u00f3n breve de c\u00f3mo se lleva a cabo la formaci\u00f3n del personal.\n   - **Registros de Formaci\u00f3n**: Importancia de mantener registros adecuados para garantizar la competencia del personal.\n\n3. **Comit\u00e9 de \u00c9tica**:\n   - **Constituci\u00f3n y Relaci\u00f3n con CRO**: Estructura del comit\u00e9 y su relaci\u00f3n con la organizaci\u00f3n de investigaci\u00f3n por contrato (CRO).\n   - **Procedimientos de Revisi\u00f3n y Aprobaci\u00f3n de Protocolos**: Proceso para evaluar y aprobar los protocolos de investigaci\u00f3n.\n\n4. **Sistemas Inform\u00e1ticos**:\n   - **Hardware y Software**: Descripci\u00f3n de los sistemas utilizados, incluyendo el software en laboratorios bioanal\u00edticos y procedimientos de control de cambios.\n   - **Gesti\u00f3n de Datos**: Sistemas de gesti\u00f3n de datos, incluyendo generaci\u00f3n y resoluci\u00f3n de consultas.\n   - **Procedimientos de Seguridad**: Medidas para proteger la informaci\u00f3n confidencial y asegurar la integridad de los datos.\n   - **Programa de Validaci\u00f3n**: Breve descripci\u00f3n de c\u00f3mo se valida el software y los sistemas utilizados.\n   - **Respaldo y Almacenamiento de Datos Electr\u00f3nicos**: Estrategias para asegurar la disponibilidad y seguridad de los datos.\n\n5. **Equipos e Instrumentos**:\n   - **Descripci\u00f3n de Equipos Principales**: Resumen de los equipos utilizados sin necesidad de una lista exhaustiva.\n   - **Programa de Calificaci\u00f3n, Mantenimiento y Calibraci\u00f3n**: Procedimientos para asegurar que los equipos funcionen correctamente, incluyendo sistemas de registro de temperatura.\n\nEste resumen destaca los aspectos fundamentales relacionados con la gesti\u00f3n de estudios cl\u00ednicos, la formaci\u00f3n del personal, la \u00e9tica en la investigaci\u00f3n, la gesti\u00f3n de sistemas inform\u00e1ticos y el uso de equipos e instrumentos.", "excerpt_keywords": "Keywords: document management, safety monitoring, biological samples, investigational products, quality assurance"}}, "033cce5e-e57f-4fe6-8b33-d5feedf63acd": {"node_ids": ["dc289612-2057-40b5-b38a-9dc1d87506ca"], "metadata": {"page_label": "290", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "## 11.5 Preparation and labelling of reagents\n\n## 11.6 Storage of samples\n\n## 11.7 Stability procedures\n\n## 11.8 Waste management\n\n## 12. Biostatistics\n\n### 12.1 Data processing and analysis\n\n### 12.2 Data management\n\n## 13. Study volunteers\n\n### 13.1 Procedure for recruitment\n\n### 13.2 Collecting information on volunteers (e.g. databank), while confidentiality is maintained\n\n### 13.3 Procedure for obtaining informed consent\n\n## 14. Other information\n\n### 14.1 Power supply system \u2014 uninterrupted power supply and generator availability and capacity\n\n### 14.2 Brief description of any other activities performed on site by the CRO\n\n### 14.3 Any other information which the CRO may feel it appropriate to add", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfCu\u00e1les son los procedimientos espec\u00edficos para la preparaci\u00f3n y etiquetado de reactivos seg\u00fan el documento?**\n   - **Respuesta:** El documento menciona un apartado espec\u00edfico (11.5) que trata sobre la preparaci\u00f3n y etiquetado de reactivos, aunque no se proporciona un detalle espec\u00edfico en el texto extra\u00eddo. Para obtener informaci\u00f3n precisa, ser\u00eda necesario consultar el contenido completo de esa secci\u00f3n.\n\n2. **\u00bfQu\u00e9 medidas se describen para garantizar la confidencialidad de la informaci\u00f3n de los voluntarios en el estudio?**\n   - **Respuesta:** En la secci\u00f3n 13.2, se menciona que se debe recopilar informaci\u00f3n sobre los voluntarios (por ejemplo, en una base de datos) mientras se mantiene la confidencialidad. Sin embargo, el texto no detalla las medidas espec\u00edficas que se implementan para asegurar esta confidencialidad.\n\n3. **\u00bfQu\u00e9 tipo de informaci\u00f3n adicional puede incluir el CRO en su informe seg\u00fan el documento?**\n   - **Respuesta:** En la secci\u00f3n 14.3, se indica que el CRO puede agregar cualquier otra informaci\u00f3n que considere apropiada. Esto sugiere que hay flexibilidad para incluir detalles relevantes que no se hayan abordado en las secciones anteriores del informe.\n\n### Resumen de Nivel Superior\n\nEl documento \"WHO - Technical Report Series 957\" aborda varios aspectos relacionados con la preparaci\u00f3n y manejo de reactivos, almacenamiento de muestras, procedimientos de estabilidad y gesti\u00f3n de residuos. Tambi\u00e9n se enfoca en la biostat\u00edstica, incluyendo el procesamiento y gesti\u00f3n de datos, as\u00ed como en la participaci\u00f3n de voluntarios en estudios cl\u00ednicos, destacando la importancia de la confidencialidad y el consentimiento informado. Adem\u00e1s, se menciona la infraestructura necesaria para llevar a cabo estos estudios, como el suministro de energ\u00eda y otras actividades realizadas por la organizaci\u00f3n de investigaci\u00f3n cl\u00ednica (CRO). \n\nEste resumen proporciona un contexto m\u00e1s amplio que puede ayudar a formular preguntas m\u00e1s espec\u00edficas sobre los procedimientos y regulaciones en el \u00e1mbito de la investigaci\u00f3n cl\u00ednica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Gesti\u00f3n de Documentos**:\n   - Sistemas de gesti\u00f3n de documentos (secci\u00f3n 7.1).\n   - Flujo de trabajo del proyecto, incluyendo procesos de aseguramiento y control de calidad (secci\u00f3n 7.2).\n   - Preparaci\u00f3n de protocolos, formularios de consentimiento informado, y formularios de reporte (secciones 7.3, 7.4, 7.5).\n   - Elaboraci\u00f3n del informe final (secci\u00f3n 7.6).\n\n2. **Monitoreo de Seguridad**:\n   - Procedimientos para reportar reacciones adversas a medicamentos.\n   - Provisiones para emergencias, incluyendo protocolos y equipos disponibles.\n\n3. **Productos Medicinales Investigacionales**:\n   - Adquisici\u00f3n, almacenamiento, manejo, muestreo y eliminaci\u00f3n de productos (secci\u00f3n 9.1).\n   - Farmacia y dispensaci\u00f3n de productos (secci\u00f3n 9.2).\n\n4. **Patolog\u00eda**:\n   - Recolecci\u00f3n y almacenamiento de muestras biol\u00f3gicas (secci\u00f3n 10.1).\n   - Manejo y an\u00e1lisis de muestras biol\u00f3gicas (secci\u00f3n 10.2).\n\n5. **Laboratorio Bioanal\u00edtico**:\n   - Desarrollo y validaci\u00f3n de m\u00e9todos (secci\u00f3n 11.1).\n   - Materiales de referencia para la preparaci\u00f3n de est\u00e1ndares de calibraci\u00f3n y muestras de control de calidad (secci\u00f3n 11.2).\n   - Almacenamiento y manejo de muestras biol\u00f3gicas (secci\u00f3n 11.3).\n   - An\u00e1lisis de muestras desconocidas (secci\u00f3n 11.4).\n\n### Entidades Clave:\n- **Documentos**: Protocolos, formularios de consentimiento, informes.\n- **Procedimientos**: Monitoreo de seguridad, manejo de muestras biol\u00f3gicas.\n- **Productos**: Medicamentos investigacionales, productos comparadores.\n- **Laboratorios**: Bioanal\u00edticos, manejo de muestras biol\u00f3gicas.\n\nEste resumen destaca los aspectos fundamentales del documento, proporcionando una visi\u00f3n general de los procesos y procedimientos relacionados con la investigaci\u00f3n de productos medicinales y la gesti\u00f3n de la documentaci\u00f3n asociada.", "excerpt_keywords": "Keywords: reagents, biostatistics, study volunteers, informed consent, waste management"}}, "1ca0d09a-c56a-4e41-bea4-fb6b3a8ce3ef": {"node_ids": ["e85ba49d-b17c-4409-88a9-f60f3c46b956"], "metadata": {"page_label": "291", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "# SELECTED WHO PUBLICATIONS OF RELATED INTEREST\n\n**The International Pharmacopoeia, fourth edition.**  \nVolume 1: general notices; monographs for pharmaceutical substances (A\u2013O)  \nVolume 2: monographs for pharmaceutical substances (P\u2013Z); monographs for dosage forms and radiopharmaceutical preparations; methods of analysis; reagents.  \n2006 (1500 pages), also available in CD-ROM format and online  \nFirst supplement: general notices; monographs for pharmaceutical substances; monographs for dosage forms; general and specific monographs; methods of analysis; International Chemical Reference Substances; International Infrared Reference Spectra; reagents, test solutions and volumetric solutions.  \n2008 (309 pages), also available in CD-ROM format and online  \n\n**Basic tests for drugs: pharmaceutical substances, medicinal plant materials and dosage forms**  \n1998 (94 pages)  \n\n**Basic tests for pharmaceutical dosage forms**  \n1991 (134 pages)  \n\n**Quality Assurance of Pharmaceuticals: a compendium of guidelines and related materials**  \nVolume 1: 1997 (244 pages)  \nVolume 2: good manufacturing practices and inspection.  \nSecond updated edition, 2007 (409 pages)  \nAlso available on: WHO training modules on GMP. A resource and study pack for trainers, 2007 (CD-ROM).  \n\n**WHO Expert Committee on Specifications for Pharmaceutical Preparations**  \nForty-third report.  \nWHO Technical Report Series, No. 953, 2009 (161 pages)  \n\n**International nonproprietary names (INN) for pharmaceutical substances**  \nCumulative list no. 13  \n2010 (available in CD-ROM format only)  \n\n**The selection and use of essential medicines**  \nReport of the WHO Expert Committee (including the 16th WHO Model List of Essential Medicines and the 2nd WHO Model List for Children).  \nWHO Technical Report Series, No. 958, 2010 (174 pages)  \n\n**WHO Expert Committee on Biological Standardization**  \nFifty-sixth report.  \nWHO Technical Report Series, No. 941, 2007 (340 pages)  \n\n----\n\nFurther information on these and other WHO publications can be obtained from  \nWHO Press, World Health Organization, 1211 Geneva 27, Switzerland  \n(tel. +41 22 791 3264; fax: +41 22 791 4857;  \ne-mail: bookorders@who.int; order online: http://www.who.int/bookorders)", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento presenta una lista de publicaciones seleccionadas de la Organizaci\u00f3n Mundial de la Salud (OMS) relacionadas con la farmacolog\u00eda y la calidad de los medicamentos. Incluye t\u00edtulos de la Farmacopea Internacional, pruebas b\u00e1sicas para sustancias farmac\u00e9uticas, gu\u00edas sobre aseguramiento de calidad, y reportes de comit\u00e9s expertos de la OMS. Tambi\u00e9n se proporciona informaci\u00f3n de contacto para obtener m\u00e1s detalles sobre estas publicaciones.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son los vol\u00famenes y el contenido espec\u00edfico de la cuarta edici\u00f3n de la Farmacopea Internacional?**\n   - Esta pregunta busca detalles sobre la estructura y el contenido de la Farmacopea Internacional, que se menciona en el contexto.\n\n2. **\u00bfQu\u00e9 temas se abordan en el segundo volumen de \"Quality Assurance of Pharmaceuticals\"?**\n   - Esta pregunta se centra en el contenido del segundo volumen de la publicaci\u00f3n sobre aseguramiento de calidad, que incluye buenas pr\u00e1cticas de manufactura e inspecci\u00f3n.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n se incluye en la \"Cumulative list no. 13\" de nombres no propietarios internacionales (INN) para sustancias farmac\u00e9uticas?**\n   - Esta pregunta busca aclarar el contenido espec\u00edfico de la lista acumulativa de nombres no propietarios, que es un recurso importante en la identificaci\u00f3n de sustancias farmac\u00e9uticas.\n\n### Resumen de Nivel Superior\nEl documento destaca la importancia de las publicaciones de la OMS en el \u00e1mbito farmac\u00e9utico, proporcionando gu\u00edas y est\u00e1ndares para la calidad y seguridad de los medicamentos. Incluye informaci\u00f3n sobre la Farmacopea Internacional, pruebas b\u00e1sicas para medicamentos, y reportes de comit\u00e9s expertos que ayudan a establecer normas y pr\u00e1cticas en la industria farmac\u00e9utica. Adem\u00e1s, se ofrece informaci\u00f3n de contacto para acceder a estas publicaciones, lo que facilita su consulta por parte de profesionales y organizaciones interesadas en la farmacolog\u00eda.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Preparaci\u00f3n y Etiquetado de Reactivos (Secci\u00f3n 11.5)**:\n   - Procedimientos relacionados con la preparaci\u00f3n y etiquetado de reactivos utilizados en estudios cl\u00ednicos.\n\n2. **Almacenamiento de Muestras (Secci\u00f3n 11.6)**:\n   - Directrices sobre c\u00f3mo almacenar adecuadamente las muestras para asegurar su integridad.\n\n3. **Procedimientos de Estabilidad (Secci\u00f3n 11.7)**:\n   - M\u00e9todos para evaluar y garantizar la estabilidad de los reactivos y muestras a lo largo del tiempo.\n\n4. **Gesti\u00f3n de Residuos (Secci\u00f3n 11.8)**:\n   - Estrategias para la correcta gesti\u00f3n y eliminaci\u00f3n de residuos generados durante los estudios.\n\n5. **Biostat\u00edstica (Secci\u00f3n 12)**:\n   - **Procesamiento y An\u00e1lisis de Datos (12.1)**: M\u00e9todos para analizar los datos recopilados en los estudios.\n   - **Gesti\u00f3n de Datos (12.2)**: Estrategias para manejar y almacenar datos de manera eficiente y segura.\n\n6. **Voluntarios del Estudio (Secci\u00f3n 13)**:\n   - **Procedimiento de Reclutamiento (13.1)**: M\u00e9todos para reclutar participantes para los estudios.\n   - **Recopilaci\u00f3n de Informaci\u00f3n (13.2)**: Proceso para recoger datos de los voluntarios manteniendo la confidencialidad.\n   - **Consentimiento Informado (13.3)**: Procedimientos para obtener el consentimiento de los voluntarios para participar en el estudio.\n\n7. **Otra Informaci\u00f3n (Secci\u00f3n 14)**:\n   - **Sistema de Suministro de Energ\u00eda (14.1)**: Disponibilidad y capacidad de sistemas de energ\u00eda ininterrumpida y generadores.\n   - **Actividades del CRO (14.2)**: Descripci\u00f3n breve de otras actividades realizadas por la organizaci\u00f3n de investigaci\u00f3n cl\u00ednica en el sitio.\n   - **Informaci\u00f3n Adicional (14.3)**: Oportunidad para que el CRO incluya informaci\u00f3n relevante que considere apropiada.\n\n### Entidades Clave\n- **CRO (Organizaci\u00f3n de Investigaci\u00f3n Cl\u00ednica)**: Entidad responsable de llevar a cabo estudios cl\u00ednicos.\n- **Voluntarios**: Participantes en los estudios cl\u00ednicos.\n- **Reactivos y Muestras**: Elementos utilizados en la investigaci\u00f3n que requieren manejo y almacenamiento adecuados.\n- **Datos**: Informaci\u00f3n recopilada durante los estudios que necesita ser procesada y gestionada. \n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades clave abordados en la secci\u00f3n del documento, destacando la importancia de los procedimientos y regulaciones en la investigaci\u00f3n cl\u00ednica.", "excerpt_keywords": "Keywords: WHO, pharmacopoeia, quality assurance, essential medicines, pharmaceutical standards"}}, "5687ef70-074d-416f-bcee-a5333d81db05": {"node_ids": ["c4104df8-7b79-4f14-9e1f-292e3011b482"], "metadata": {"page_label": "292", "file_name": "WHO_TRS_957_REPORTE 44.pdf", "file_path": "raw_data/WHO_TRS_957_REPORTE 44.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee on Specifications for Pharmaceutical Preparations works towards clear, independent and practical standards and guidelines for the quality assurance of medicines. Standards are developed by the Committee through worldwide consultation and an international consensus-building process. The following new guidelines were adopted and recommended for use: good practices for pharmaceutical quality control laboratories; supplementary guidelines for active pharmaceutical ingredients; good manufacturing practices for pharmaceutical products containing hazardous substances; good manufacturing practices for sterile pharmaceutical products; good distribution practices for pharmaceutical products; guidelines on the requalification of prequalified dossiers; and guidelines for the preparation of a contract research organization master file.", "parsed_text": "", "document_title": "WHO - Technical Report Series 957", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS se dedica a establecer est\u00e1ndares y directrices claras, independientes y pr\u00e1cticas para la garant\u00eda de calidad de los medicamentos. Estos est\u00e1ndares se desarrollan a trav\u00e9s de consultas a nivel mundial y un proceso de construcci\u00f3n de consenso internacional. Se han adoptado nuevas directrices que incluyen buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica, directrices suplementarias para ingredientes farmac\u00e9uticos activos, buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos que contienen sustancias peligrosas, buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles, buenas pr\u00e1cticas de distribuci\u00f3n, directrices sobre la revalidaci\u00f3n de expedientes precalificados y directrices para la preparaci\u00f3n de un archivo maestro de organizaciones de investigaci\u00f3n por contrato.\n\n### Preguntas espec\u00edficas\n1. **\u00bfCu\u00e1les son las nuevas directrices adoptadas por el Comit\u00e9 de Expertos para asegurar la calidad de los medicamentos?**\n   - Respuesta: Las nuevas directrices incluyen buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica, directrices suplementarias para ingredientes farmac\u00e9uticos activos, buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos que contienen sustancias peligrosas, buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles, buenas pr\u00e1cticas de distribuci\u00f3n, directrices sobre la revalidaci\u00f3n de expedientes precalificados y directrices para la preparaci\u00f3n de un archivo maestro de organizaciones de investigaci\u00f3n por contrato.\n\n2. **\u00bfC\u00f3mo se desarrollan los est\u00e1ndares y directrices del Comit\u00e9 de Expertos?**\n   - Respuesta: Los est\u00e1ndares se desarrollan a trav\u00e9s de consultas a nivel mundial y un proceso de construcci\u00f3n de consenso internacional.\n\n3. **\u00bfQu\u00e9 importancia tienen las buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles seg\u00fan el Comit\u00e9 de Expertos?**\n   - Respuesta: Las buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles son cruciales para garantizar la calidad y seguridad de los medicamentos que se administran a los pacientes, ya que estos productos deben cumplir con est\u00e1ndares rigurosos para prevenir la contaminaci\u00f3n y asegurar su eficacia.", "prev_section_summary": "La secci\u00f3n presenta una lista de publicaciones seleccionadas de la Organizaci\u00f3n Mundial de la Salud (OMS) que son relevantes para la farmacolog\u00eda y la calidad de los medicamentos. A continuaci\u00f3n se resumen los temas clave y entidades mencionadas:\n\n### Temas Clave:\n1. **Farmacopea Internacional**:\n   - Cuarta edici\u00f3n que incluye dos vol\u00famenes:\n     - **Volumen 1**: Avisos generales y monograf\u00edas para sustancias farmac\u00e9uticas (A\u2013O).\n     - **Volumen 2**: Monograf\u00edas para sustancias farmac\u00e9uticas (P\u2013Z), formas de dosificaci\u00f3n, preparaciones radiofarmac\u00e9uticas, m\u00e9todos de an\u00e1lisis y reactivos.\n   - Primer suplemento que abarca temas similares y se public\u00f3 en 2008.\n\n2. **Pruebas B\u00e1sicas para Medicamentos**:\n   - Publicaciones sobre pruebas para sustancias farmac\u00e9uticas, materiales de plantas medicinales y formas de dosificaci\u00f3n.\n\n3. **Aseguramiento de Calidad de los Productos Farmac\u00e9uticos**:\n   - Compendio de gu\u00edas y materiales relacionados, dividido en dos vol\u00famenes, con un enfoque en buenas pr\u00e1cticas de manufactura e inspecci\u00f3n.\n\n4. **Nombres No Propietarios Internacionales (INN)**:\n   - Lista acumulativa de nombres para sustancias farmac\u00e9uticas, disponible en formato CD-ROM.\n\n5. **Medicamentos Esenciales**:\n   - Informe sobre la selecci\u00f3n y uso de medicamentos esenciales, incluyendo listas modelo para adultos y ni\u00f1os.\n\n6. **Estandarizaci\u00f3n Biol\u00f3gica**:\n   - Reporte del Comit\u00e9 de Expertos de la OMS sobre estandarizaci\u00f3n biol\u00f3gica.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n de los documentos.\n- **WHO Press**: Proveedor de informaci\u00f3n adicional sobre las publicaciones de la OMS.\n- **Comit\u00e9s Expertos de la OMS**: Grupos que elaboran informes y gu\u00edas sobre est\u00e1ndares farmac\u00e9uticos.\n\n### Informaci\u00f3n de Contacto:\n- Se proporciona informaci\u00f3n de contacto para obtener m\u00e1s detalles sobre las publicaciones, incluyendo direcci\u00f3n, tel\u00e9fono, fax y correo electr\u00f3nico.\n\nEste resumen destaca la importancia de las publicaciones de la OMS en la regulaci\u00f3n y aseguramiento de la calidad de los medicamentos a nivel global.", "excerpt_keywords": "Keywords: pharmaceutical preparations, quality assurance, good manufacturing practices, active pharmaceutical ingredients, WHO guidelines"}}}}
\ No newline at end of file